Selegiline B-Chemical 0 0.99991715
- O 0 0.0068942723
induced O 0 0.0024584467
postural B-Disease 0 0.9725938
hypotension I-Disease 0 0.99995744
in O 0 0.0020223488
Parkinson B-Disease 0 0.9991372
' I-Disease 0 0.0007099849
s I-Disease 0 0.0003723685
disease I-Disease 0 0.022592226
: O 0 0.00025940003
a O 0 0.00020349449
longitudinal O 0 0.00023907312
study O 0 0.0001528734
on O 0 8.505701e-05
the O 0 0.00016631767
effects O 0 0.0003448563
of O 0 0.00090335036
drug O 0 0.09302197
withdrawal O 0 0.14265506
. O 0 0.0026856943

OBJECTIVES O 0 0.0035836962
: O 0 0.0019499745
The O 0 0.00083048455
United O 0 0.0012322218
Kingdom O 0 0.0031139764
Parkinson B-Disease 0 0.9851863
' I-Disease 0 0.00071797846
s I-Disease 0 0.00039869052
Disease I-Disease 0 0.0008928295
Research O 0 0.00075988204
Group O 0 0.00077570067
( O 0 0.0003222761
UKPDRG O 0 0.024125768
) O 0 0.00025600303
trial O 0 0.00013344125
found O 0 6.794652e-05
an O 0 0.000101263104
increased O 0 0.00018421475
mortality O 0 0.0014777443
in O 0 8.4083396e-05
patients O 0 0.00013387905
with O 0 0.00018331167
Parkinson B-Disease 0 0.9974255
' I-Disease 0 0.00020475373
s I-Disease 0 0.00014011943
disease I-Disease 0 0.08013448
( O 0 0.0003955699
PD B-Disease 0 0.99444556
) O 0 0.00015004342
randomized O 0 5.6242807e-05
to O 0 3.206888e-05
receive O 0 2.7850116e-05
10 O 0 5.1670442e-05
mg O 0 0.009814473
selegiline B-Chemical 1 0.9999856
per O 0 3.377019e-05
day O 0 4.309337e-05
and O 0 0.00013055463
L B-Chemical 1 0.9118756
- I-Chemical 1 0.0014507351
dopa I-Chemical 1 0.9999621
compared O 0 0.00011313649
with O 0 0.00018880951
those O 0 0.00033401194
taking O 0 0.0010214924
L B-Chemical 1 0.9502595
- I-Chemical 1 0.0070671635
dopa I-Chemical 1 0.9999163
alone O 0 0.0040061586
. O 0 0.0026904407

Recently O 0 0.002555483
, O 0 0.0016089336
we O 0 0.00046553733
found O 0 0.0004058298
that O 0 0.0002750572
therapy O 0 0.00060127344
with O 0 0.0013315007
selegiline B-Chemical 1 0.9999957
and O 0 0.0022020892
L B-Chemical 1 0.99745995
- I-Chemical 1 0.008810343
dopa I-Chemical 1 0.9999826
was O 0 0.00022092335
associated O 0 7.5256175e-05
with O 0 0.00010294208
selective O 0 0.0005332108
systolic B-Disease 0 0.9623254
orthostatic I-Disease 2 0.99996626
hypotension I-Disease 2 0.99999726
which O 0 0.00075671833
was O 0 0.000268217
abolished O 0 0.0004631551
by O 0 0.0004097854
withdrawal O 0 0.033129632
of O 0 0.0046475553
selegiline B-Chemical 1 0.99996877
. O 0 0.0036541964

This O 0 0.0038945857
unwanted O 0 0.0043826113
effect O 0 0.0009456326
on O 0 0.0005466705
postural O 0 0.018749
blood O 0 0.006278587
pressure O 0 0.004582878
was O 0 0.00037289943
not O 0 0.00020668184
the O 0 0.00022436223
result O 0 0.0002574992
of O 0 0.0005051769
underlying O 0 0.001352658
autonomic O 0 0.12491935
failure O 0 0.46173298
. O 0 0.003127874

The O 0 0.0015031535
aims O 0 0.0019364457
of O 0 0.0011104589
this O 0 0.0007472692
study O 0 0.00055350957
were O 0 0.0002562814
to O 0 0.00014406163
confirm O 0 9.4791794e-05
our O 0 0.00015730242
previous O 0 0.00010898709
findings O 0 0.00019980741
in O 0 8.356749e-05
a O 0 0.00010399434
separate O 0 5.0809773e-05
cohort O 0 0.00023171294
of O 0 0.000105201994
patients O 0 0.00011821338
and O 0 5.842589e-05
to O 0 3.757179e-05
determine O 0 1.9794952e-05
the O 0 3.5574332e-05
time O 0 2.1094209e-05
course O 0 3.1569216e-05
of O 0 5.7277914e-05
the O 0 6.743683e-05
cardiovascular O 0 0.08509366
consequences O 0 0.00011871131
of O 0 0.00016273315
stopping O 0 0.003421946
selegiline B-Chemical 1 0.99999654
in O 0 9.111239e-05
the O 0 5.2765972e-05
expectation O 0 5.4518943e-05
that O 0 3.4181805e-05
this O 0 6.276296e-05
might O 0 3.5901645e-05
shed O 0 0.000106449676
light O 0 0.00023601158
on O 0 4.127568e-05
the O 0 7.10343e-05
mechanisms O 0 0.00010673571
by O 0 0.00011223077
which O 0 0.00017085111
the O 0 0.00022454177
drug O 0 0.011256709
causes O 0 0.0030602934
orthostatic B-Disease 2 0.9998932
hypotension I-Disease 2 0.99996734
. O 0 0.0051134382

METHODS O 0 0.0016364574
: O 0 0.001320335
The O 0 0.0006516031
cardiovascular O 0 0.0228384
responses O 0 0.00064674235
to O 0 0.0003543792
standing O 0 0.0008354847
and O 0 0.00034535804
head O 0 0.0018998067
- O 0 0.0004017559
up O 0 0.00016423399
tilt O 0 0.0008986708
were O 0 0.000108373366
studied O 0 9.49092e-05
repeatedly O 0 8.913794e-05
in O 0 0.00013286
PD B-Disease 0 0.9944634
patients O 0 0.00039500298
receiving O 0 0.0010566043
selegiline B-Chemical 1 0.9999913
and O 0 0.0002934439
as O 0 0.00019102232
the O 0 0.00029930825
drug O 0 0.006158351
was O 0 0.00096255646
withdrawn O 0 0.0025641345
. O 0 0.0018484067

RESULTS O 0 0.006172048
: O 0 0.003132052
Head O 0 0.006268465
- O 0 0.0013878727
up O 0 0.0005692551
tilt O 0 0.0016125191
caused O 0 0.0005359097
systolic B-Disease 0 0.96298
orthostatic I-Disease 2 0.9999552
hypotension I-Disease 2 0.999997
which O 0 0.0010112807
was O 0 0.000211809
marked O 0 0.00018156832
in O 0 6.246579e-05
six O 0 3.386481e-05
of O 0 8.481573e-05
20 O 0 0.00013858023
PD B-Disease 0 0.9894521
patients O 0 0.00022547653
on O 0 0.00012077189
selegiline B-Chemical 1 0.9999931
, O 0 0.00018144681
one O 0 6.6037726e-05
of O 0 0.00012924045
whom O 0 0.00026192897
lost O 0 0.00024706672
consciousness O 0 0.18072405
with O 0 0.0008107983
unrecordable O 0 0.36211511
blood O 0 0.015718177
pressures O 0 0.0043534506
. O 0 0.0018769045

A O 0 0.03227783
lesser O 0 0.0071459995
degree O 0 0.0031116328
of O 0 0.004226764
orthostatic B-Disease 2 0.9994758
hypotension I-Disease 2 0.9999163
occurred O 0 0.0039548515
with O 0 0.0038003726
standing O 0 0.009381744
. O 0 0.0043406296

Orthostatic B-Disease 0 0.9972567
hypotension I-Disease 0 0.99988866
was O 0 0.0031792102
ameliorated O 0 0.04761182
4 O 0 0.00027320546
days O 0 9.2811395e-05
after O 0 7.2962794e-05
withdrawal O 0 0.0015800821
of O 0 0.00082596834
selegiline B-Chemical 1 0.9999938
and O 0 0.00035056457
totally O 0 0.00049003016
abolished O 0 0.00030765825
7 O 0 7.907641e-05
days O 0 4.7774083e-05
after O 0 7.042216e-05
discontinuation O 0 0.0019896557
of O 0 0.0005871528
the O 0 0.0009458551
drug O 0 0.031437714
. O 0 0.0023486007

Stopping O 0 0.19720097
selegiline B-Chemical 1 0.9999236
also O 0 0.0014424736
significantly O 0 0.0008841298
reduced B-Disease 0 0.00057548704
the I-Disease 0 0.00028840895
supine I-Disease 0 0.0005434311
systolic I-Disease 0 0.011522826
and I-Disease 0 0.00021587715
diastolic I-Disease 0 0.12258355
blood I-Disease 0 0.001162899
pressures I-Disease 0 0.0003476471
consistent O 0 0.00011551328
with O 0 0.0001610607
a O 0 0.00021267554
previously O 0 0.00019672624
undescribed O 0 0.0003355006
supine O 0 0.00123424
pressor O 0 0.13080962
action O 0 0.0025970133
. O 0 0.0022903394

CONCLUSION O 0 0.016262785
: O 0 0.002089157
This O 0 0.0013196837
study O 0 0.00067452114
confirms O 0 0.00034883647
our O 0 0.00036373432
previous O 0 0.00023379005
finding O 0 0.00042792014
that O 0 0.00032543024
selegiline B-Chemical 1 0.9999944
in O 0 0.0002511159
combination O 0 0.00033918128
with O 0 0.00068235747
L B-Chemical 1 0.9931463
- I-Chemical 1 0.0061721
dopa I-Chemical 1 0.999974
is O 0 0.0003096555
associated O 0 0.00021608658
with O 0 0.00048155923
selective O 0 0.009854257
orthostatic B-Disease 2 0.9998659
hypotension I-Disease 2 0.99996173
. O 0 0.0047240723

The O 0 0.0014656569
possibilities O 0 0.0011475596
that O 0 0.00062954857
these O 0 0.0010885949
cardiovascular O 0 0.38474917
findings O 0 0.000838177
might O 0 0.00017713993
be O 0 0.0001435855
the O 0 0.000111515816
result O 0 0.00010068518
of O 0 0.0001717167
non O 0 0.00024454272
- O 0 0.00027079732
selective O 0 0.00034776214
inhibition O 0 0.0005174969
of O 0 0.0009909411
monoamine O 0 0.9999753
oxidase O 0 0.999899
or O 0 0.00027509782
of O 0 0.0009127463
amphetamine B-Chemical 1 0.99999106
and O 0 0.0024060982
metamphetamine B-Chemical 0 0.9998387
are O 0 0.0010298855
discussed O 0 0.0012569878
. O 0 0.0018454021

Further O 0 0.0032125344
studies O 0 0.0017190963
on O 0 0.000810505
effects O 0 0.0011069995
of O 0 0.0013630112
irrigation O 0 0.00271792
solutions O 0 0.0031329559
on O 0 0.0011470435
rat O 0 0.0045405263
bladders O 0 0.022030262
. O 0 0.0038483506

Further O 0 0.0025567962
studies O 0 0.0012555723
on O 0 0.0004976409
the O 0 0.00046257715
effects O 0 0.0004348611
of O 0 0.00043344218
certain O 0 0.00035596234
irrigating O 0 0.0016648393
fluids O 0 0.000616863
on O 0 9.9413846e-05
the O 0 0.00016090597
rat O 0 0.00045714263
bladder O 0 0.0022073486
for O 0 0.0001782101
18 O 0 0.00023125365
hours O 0 0.00021728384
are O 0 0.0005704949
reported O 0 0.0014147304
. O 0 0.0019891965

The O 0 0.0015312895
results O 0 0.0012527927
have O 0 0.00061176636
shown O 0 0.0003492234
that O 0 0.00024488545
the O 0 0.00030863512
degradation O 0 0.00071043364
product O 0 0.0017219237
p B-Chemical 0 0.0009172623
- I-Chemical 0 0.0006197796
choloroaniline I-Chemical 0 0.024292355
is O 0 0.00015345993
not O 0 9.907769e-05
a O 0 0.00014933932
significant O 0 0.00012449229
factor O 0 0.0005013838
in O 0 0.00027338834
chlorhexidine B-Chemical 0 0.8901027
- I-Chemical 0 0.0018887942
digluconate I-Chemical 0 0.37188098
associated O 0 0.0025489572
erosive O 0 0.9978255
cystitis B-Disease 0 0.9997358
. O 0 0.0050170207

A O 0 0.012324631
high O 0 0.00185921
percentage O 0 0.00070830894
of O 0 0.0011156002
kanamycin B-Chemical 1 0.99383104
- O 0 0.0038840098
colistin B-Chemical 0 0.99949765
and O 0 0.001628994
povidone B-Chemical 0 0.999527
- I-Chemical 0 0.0057673133
iodine I-Chemical 0 0.99994314
irrigations O 0 0.026397794
were O 0 0.00012162455
associated O 0 9.000403e-05
with O 0 0.00031226734
erosive O 0 0.98755974
cystitis B-Disease 0 0.99976057
and O 0 0.00028698373
suggested O 0 0.00011243452
a O 0 0.00021693796
possible O 0 0.00022058867
complication O 0 0.004381055
with O 0 0.00063220254
human O 0 0.0010759741
usage O 0 0.0015233915
. O 0 0.001892986

Picloxydine B-Chemical 0 0.5695276
irrigations O 0 0.009556789
appeared O 0 0.0009941193
to O 0 0.0005052877
have O 0 0.00028070246
a O 0 0.00034373836
lower O 0 0.00034180513
incidence O 0 0.00052327994
of O 0 0.00067013013
erosive O 0 0.99626774
cystitis B-Disease 0 0.9998983
but O 0 0.00041370458
further O 0 0.0002293138
studies O 0 0.00011112286
would O 0 7.08249e-05
have O 0 4.829864e-05
to O 0 5.297415e-05
be O 0 5.2629228e-05
performed O 0 4.906612e-05
before O 0 3.467328e-05
it O 0 8.79321e-05
could O 0 7.442567e-05
be O 0 8.723057e-05
recommended O 0 0.000115474075
for O 0 0.00012671227
use O 0 0.00023953995
in O 0 0.00040848154
urological O 0 0.0039472245
procedures O 0 0.001402968
. O 0 0.001776926

Effects O 0 0.0032257638
of O 0 0.0039265933
tetrandrine B-Chemical 0 0.99989533
and O 0 0.002951912
fangchinoline B-Chemical 0 0.9974995
on O 0 0.00051440985
experimental O 0 0.0017752445
thrombosis B-Disease 0 0.9997062
in O 0 0.00043068724
mice O 0 0.00026893348
and O 0 0.0005220728
human O 0 0.0016010863
platelet B-Disease 2 0.9984127
aggregation I-Disease 2 0.9640741
. O 0 0.004641916

Tetrandrine B-Chemical 0 0.9995933
( O 0 0.014432271
TET B-Chemical 0 0.99521106
) O 0 0.002775519
and O 0 0.0013686618
fangchinoline B-Chemical 0 0.9987067
( O 0 0.0046206038
FAN B-Chemical 1 0.99959236
) O 0 0.00091068156
are O 0 0.00021204016
two O 0 0.00012243981
naturally O 0 0.0002977872
occurring O 0 0.00033996502
analogues O 0 0.0035801597
with O 0 0.0007169221
a O 0 0.0016986253
bisbenzylisoquinoline B-Chemical 0 0.9931083
structure O 0 0.0040332633
. O 0 0.0028033147

The O 0 0.0015055399
present O 0 0.0010330412
study O 0 0.0010286802
was O 0 0.00058231474
undertaken O 0 0.00030064787
to O 0 0.00018479882
investigate O 0 0.00010108386
the O 0 0.00014512977
effects O 0 0.00021790169
of O 0 0.0005842544
TET B-Chemical 0 0.99788266
and O 0 0.00066877337
FAN B-Chemical 1 0.99940276
on O 0 7.28656e-05
the O 0 0.000101472375
experimental O 0 0.00034631914
thrombosis B-Disease 0 0.99980396
induced O 0 0.00022607348
by O 0 0.00014996363
collagen O 0 0.02918749
plus O 0 0.00018247426
epinephrine B-Chemical 0 0.9996648
( O 0 0.0012044125
EP B-Chemical 0 0.9957897
) O 0 0.00024330037
in O 0 7.526091e-05
mice O 0 5.997234e-05
, O 0 0.00012167258
and O 0 0.00019874318
platelet B-Disease 2 0.99552035
aggregation I-Disease 2 0.80654025
and O 0 0.0008923571
blood B-Disease 2 0.5871554
coagulation I-Disease 2 0.9764192
in O 0 0.0010493561
vitro O 0 0.0024957662
. O 0 0.002147461

In O 0 0.0017825053
the O 0 0.0012980172
in O 0 0.0008624804
vivo O 0 0.0010271202
study O 0 0.00064604165
, O 0 0.00039201896
the O 0 0.00026634708
administration O 0 0.0011605081
( O 0 0.00033919828
50 O 0 0.00033636543
mg O 0 0.0074540223
/ O 0 0.00074897445
kg O 0 0.00046709512
, O 0 0.00016569479
i O 0 0.0003309588
. O 0 8.923633e-05
p O 0 0.00011385022
. O 0 6.1831466e-05
) O 0 0.00014673824
of O 0 0.00022436373
TET B-Chemical 0 0.9905522
and O 0 0.00049414067
FAN B-Chemical 1 0.99953663
in O 0 0.000109010885
mice O 0 4.8930713e-05
showed O 0 6.14498e-05
the O 0 6.523767e-05
inhibition O 0 0.00029083304
of O 0 0.0005294434
thrombosis B-Disease 0 0.9999218
by O 0 0.0001740811
55 O 0 0.00012494385
% O 0 7.4140335e-05
and O 0 6.4909334e-05
35 O 0 7.4017844e-05
% O 0 8.293421e-05
, O 0 9.8113815e-05
respectively O 0 0.0002270871
, O 0 0.00013379201
while O 0 0.00036020763
acetylsalicylic B-Chemical 0 0.99999845
acid I-Chemical 0 0.9997446
( O 0 0.0024695212
ASA B-Chemical 0 0.98714125
, O 0 0.00016608265
50 O 0 0.00021267413
mg O 0 0.0046235034
/ O 0 0.0005230517
kg O 0 0.0003488985
, O 0 0.00013660933
i O 0 0.0003089822
. O 0 8.73386e-05
p O 0 0.00012561078
. O 0 7.2923285e-05
) O 0 0.00017156746
, O 0 0.00011722724
a O 0 0.00013781618
positive O 0 0.00016305466
control O 0 0.00016465186
, O 0 0.00022839254
showed O 0 0.00022684126
only O 0 0.00034747247
30 O 0 0.00036885485
% O 0 0.0007753341
inhibition O 0 0.003038384
. O 0 0.0025105078

In O 0 0.0016426578
the O 0 0.0012038638
vitro O 0 0.0012626876
human O 0 0.0015313858
platelet B-Disease 0 0.9969976
aggregations I-Disease 0 0.027857777
induced O 0 0.00054909644
by O 0 0.00027825902
the O 0 0.00023757774
agonists O 0 0.06510339
used O 0 0.00013258451
in O 0 0.00015010998
tests O 0 0.0004949687
, O 0 0.00037598264
TET B-Chemical 0 0.9869178
and O 0 0.00075364974
FAN B-Chemical 1 0.99909294
showed O 0 0.0004244652
the O 0 0.0004950529
inhibitions O 0 0.2998078
dose O 0 0.030839944
dependently O 0 0.8991562
. O 0 0.0034595844

In O 0 0.0017306288
addition O 0 0.0010613423
, O 0 0.0014119807
neither O 0 0.0014362123
TET B-Chemical 0 0.9969789
nor O 0 0.0015243317
FAN B-Chemical 1 0.99964964
showed O 0 0.00042216806
any O 0 0.00022045389
anticoagulation O 0 0.027301485
activities O 0 0.00011614329
in O 0 6.543249e-05
the O 0 5.507924e-05
measurement O 0 3.7161746e-05
of O 0 7.480091e-05
the O 0 6.596e-05
activated O 0 0.00010345026
partial O 0 0.00053840777
thromboplastin O 0 0.97192097
time O 0 7.517684e-05
( O 0 0.00037873827
APTT O 0 0.99440306
) O 0 0.00027893286
, O 0 0.00018546451
prothrombin O 0 0.9142101
time O 0 7.12099e-05
( O 0 0.00019239768
PT O 0 0.0028376682
) O 0 0.0001815084
and O 0 0.00013364412
thrombin O 0 0.098953985
time O 0 0.00010855477
( O 0 0.00037904744
TT O 0 0.05133851
) O 0 0.00035715752
using O 0 0.00020715139
human O 0 0.00056269596
- O 0 0.00130229
citrated O 0 0.078036025
plasma O 0 0.026307967
. O 0 0.0026167824

These O 0 0.0019776383
results O 0 0.0011330674
suggest O 0 0.00044806846
that O 0 0.00048217704
antithrombosis O 0 0.012559588
of O 0 0.0015831258
TET B-Chemical 0 0.9981744
and O 0 0.0015988392
FAN B-Chemical 1 0.99961287
in O 0 0.00027572433
mice O 0 0.00011930698
may O 0 0.00011297197
be O 0 0.000101138816
mainly O 0 0.000114902905
related O 0 7.1413226e-05
to O 0 0.00015778071
the O 0 0.00038548053
antiplatelet O 0 0.5601354
aggregation O 0 0.03302144
activities O 0 0.0024600471
. O 0 0.002387509

Angioedema B-Disease 0 0.99801093
due O 0 0.0026439289
to O 0 0.0029996077
ACE B-Chemical 0 0.99922144
inhibitors I-Chemical 0 0.086551115
: O 0 0.002219605
common O 0 0.0015041456
and O 0 0.0017960541
inadequately O 0 0.012245807
diagnosed O 0 0.009861568
. O 0 0.0036008763

The O 0 0.0015136848
estimated O 0 0.0013158671
incidence O 0 0.001901959
of O 0 0.0021794909
angioedema B-Disease 0 0.9998809
during O 0 0.0007537819
angiotensin B-Chemical 1 0.999974
- I-Chemical 0 0.003463025
converting I-Chemical 0 0.03512447
enzyme I-Chemical 0 0.076460205
( I-Chemical 0 0.00086285686
ACE I-Chemical 0 0.99934846
) I-Chemical 0 0.00046543023
inhibitor I-Chemical 0 0.00074676157
treatment O 0 0.00018194158
is O 0 0.00013765306
between O 0 8.14706e-05
1 O 0 0.00012228484
and O 0 0.00015818262
7 O 0 0.00015159136
per O 0 0.00015680806
thousand O 0 0.00060762087
patients O 0 0.0014234538
. O 0 0.0018120058

This O 0 0.0037379959
potentially O 0 0.002321196
serious O 0 0.006035968
adverse O 0 0.07128656
effect O 0 0.00073111104
is O 0 0.00046131707
often O 0 0.00036287465
preceded O 0 0.0003452027
by O 0 0.0003151096
minor O 0 0.0009925994
manifestations O 0 0.0029084438
that O 0 0.00020919082
may O 0 0.00027098172
serve O 0 0.00042169326
as O 0 0.0005529054
a O 0 0.0013973156
warning O 0 0.0060302946
. O 0 0.0025644042

Cocaine B-Chemical 0 0.99964845
- O 0 0.0071519935
induced O 0 0.0028327745
mood B-Disease 0 0.9927982
disorder I-Disease 0 0.94527376
: O 0 0.00067536125
prevalence O 0 0.00032648805
rates O 0 0.00024443038
and O 0 0.00041371837
psychiatric B-Disease 2 0.99943084
symptoms O 0 0.33802867
in O 0 0.00021336366
an O 0 0.00037365395
outpatient O 0 0.0013337459
cocaine B-Chemical 1 0.9992718
- O 0 0.0010053392
dependent O 0 0.00042459168
sample O 0 0.0016757087
. O 0 0.0019705475

This O 0 0.003468038
paper O 0 0.001737169
attempts O 0 0.0011173217
to O 0 0.0004495513
examine O 0 0.00019665797
and O 0 0.00026761647
compare O 0 0.00010761727
prevalence O 0 0.00020000545
rates O 0 0.00015776446
and O 0 0.00015278305
symptom O 0 0.0003592717
patterns O 0 8.8257046e-05
of O 0 0.00023999054
DSM O 0 0.009149759
substance O 0 0.5720729
- O 0 0.0006044049
induced O 0 0.00034684793
and O 0 0.00044313545
other O 0 0.0008393223
mood B-Disease 0 0.9829301
disorders I-Disease 0 0.7105457
. O 0 0.0026163617

243 O 0 0.045706112
cocaine B-Chemical 1 0.99895835
- O 0 0.002286353
dependent O 0 0.00037249384
outpatients O 0 0.0016386339
with O 0 0.0008478112
cocaine B-Chemical 1 0.99981934
- O 0 0.0010550594
induced O 0 0.0005481777
mood B-Disease 0 0.99630535
disorder I-Disease 0 0.9805126
( O 0 0.00089887885
CIMD B-Disease 0 0.9946607
) O 0 0.00039139763
, O 0 0.00013244755
other O 0 0.00014328185
mood B-Disease 0 0.9717317
disorders I-Disease 0 0.35159352
, O 0 0.00013539291
or O 0 7.3789575e-05
no O 0 8.349246e-05
mood B-Disease 0 0.94557416
disorder I-Disease 0 0.5827968
were O 0 0.00010577901
compared O 0 5.453225e-05
on O 0 6.663457e-05
measures O 0 0.00012539225
of O 0 0.0008396718
psychiatric B-Disease 2 0.999387
symptoms O 0 0.8734603
. O 0 0.0027864417

The O 0 0.0025716017
prevalence O 0 0.0025641457
rate O 0 0.0020012807
for O 0 0.0016902995
CIMD B-Disease 0 0.9020185
was O 0 0.0017035884
12 O 0 0.0007724731
% O 0 0.0011476482
at O 0 0.001101461
baseline O 0 0.0023563718
. O 0 0.0037022508

Introduction O 0 0.0026965262
of O 0 0.0017490631
the O 0 0.0012216677
DSM O 0 0.009022104
- O 0 0.0017857465
IV O 0 0.020285647
diagnosis O 0 0.0009532601
of O 0 0.0007065891
CIMD B-Disease 0 0.982774
did O 0 0.00034599757
not O 0 0.00015544237
substantially O 0 0.00018944718
affect O 0 8.29335e-05
rates O 0 0.00016012676
of O 0 0.00026077876
the O 0 0.00036113017
other O 0 0.0009822083
depressive B-Disease 2 0.99980646
disorders I-Disease 0 0.88395345
. O 0 0.0029066699

Patients O 0 0.0024128833
with O 0 0.0020332695
CIMD B-Disease 0 0.9034961
had O 0 0.0009189708
symptom O 0 0.0018541637
severity O 0 0.0007290749
levels O 0 0.00022649765
between O 0 0.00011261821
those O 0 0.00020470198
of O 0 0.00022297329
patients O 0 0.00027797188
with O 0 0.00024050455
and O 0 0.00026575048
without O 0 0.00038653868
a O 0 0.0015453714
mood B-Disease 0 0.98885894
disorder I-Disease 0 0.95508736
. O 0 0.0028365299

These O 0 0.002286184
findings O 0 0.0018802001
suggest O 0 0.0005343168
some O 0 0.000586535
validity O 0 0.0006285318
for O 0 0.00024368457
the O 0 0.00026290573
new O 0 0.00037963726
DSM O 0 0.005766695
- O 0 0.0006793092
IV O 0 0.017679129
diagnosis O 0 0.00049655396
of O 0 0.00045434668
CIMD B-Disease 0 0.99462163
, O 0 0.00030327597
but O 0 0.00014004385
also O 0 8.850718e-05
suggest O 0 4.510813e-05
that O 0 7.5064876e-05
it O 0 0.00013218458
requires O 0 9.774029e-05
further O 0 0.0004035279
specification O 0 0.002259215
and O 0 0.0009785279
replication O 0 0.0057998695
. O 0 0.0022423284

Effect O 0 0.0029167426
of O 0 0.0038115743
fucoidan B-Chemical 0 0.99714345
treatment O 0 0.0019844244
on O 0 0.00090897107
collagenase O 0 0.31216714
- O 0 0.0022815305
induced O 0 0.0019039895
intracerebral B-Disease 0 0.99512887
hemorrhage I-Disease 2 0.9997919
in O 0 0.0024138258
rats O 0 0.004001078
. O 0 0.0026646168

Inflammatory O 0 0.016173376
cells O 0 0.0028463274
are O 0 0.0010050213
postulated O 0 0.0007102669
to O 0 0.0003924604
mediate O 0 0.00019317005
some O 0 0.00031941853
of O 0 0.00043635437
the O 0 0.0005248166
brain B-Disease 0 0.2395311
damage I-Disease 0 0.9809471
following O 0 0.0032510126
ischemic B-Disease 0 0.99996316
stroke I-Disease 0 0.99992585
. O 0 0.006771794

Intracerebral B-Disease 0 0.96698785
hemorrhage I-Disease 2 0.999705
is O 0 0.0024222326
associated O 0 0.0011213025
with O 0 0.0013230704
more O 0 0.002500093
inflammation B-Disease 0 0.98696923
than O 0 0.0043666093
ischemic B-Disease 0 0.99993956
stroke I-Disease 0 0.9999007
. O 0 0.008718304

We O 0 0.0016209318
tested O 0 0.0013324451
the O 0 0.0013328568
sulfated O 0 0.14622255
polysaccharide O 0 0.0747123
fucoidan B-Chemical 0 0.99976045
, O 0 0.0012608962
which O 0 0.00056265737
has O 0 0.00017761705
been O 0 0.00011784568
reported O 0 0.00013095685
to O 0 8.839196e-05
reduce O 0 0.00010291157
inflammatory O 0 0.15845089
brain B-Disease 0 0.8084419
damage I-Disease 0 0.9909827
, O 0 0.00025327998
in O 0 8.809509e-05
a O 0 0.00011548519
rat O 0 0.00017624833
model O 0 9.717098e-05
of O 0 0.0002120345
intracerebral B-Disease 0 0.9780929
hemorrhage I-Disease 2 0.9999064
induced O 0 0.000303567
by O 0 0.00014007243
injection O 0 0.00014317369
of O 0 0.00019118925
bacterial O 0 0.0006535034
collagenase O 0 0.019623503
into O 0 0.00013699339
the O 0 0.00038830368
caudate O 0 0.008964072
nucleus O 0 0.0011465482
. O 0 0.0016239092

Rats O 0 0.0036668987
were O 0 0.0011541047
treated O 0 0.000813921
with O 0 0.0004697814
seven O 0 0.00022956142
day O 0 0.00016525756
intravenous O 0 0.0016170501
infusion O 0 0.0005826556
of O 0 0.0005203833
fucoidan B-Chemical 0 0.99916923
( O 0 0.0004434534
30 O 0 0.00013713386
micrograms O 0 0.000935511
h O 0 0.00025641485
- O 0 0.0005516076
1 O 0 0.00033712763
) O 0 0.0006643245
or O 0 0.0007559039
vehicle O 0 0.0045182393
. O 0 0.0026903704

The O 0 0.0043199337
hematoma B-Disease 0 0.974227
was O 0 0.0026683956
assessed O 0 0.0011760881
in O 0 0.0010816617
vivo O 0 0.0017430319
by O 0 0.0016543318
magnetic O 0 0.0067414097
resonance O 0 0.025628766
imaging O 0 0.0055678836
. O 0 0.0040342403

Motor O 0 0.019161513
behavior O 0 0.002737771
, O 0 0.0015499664
passive O 0 0.0011513963
avoidance O 0 0.0015303253
, O 0 0.00067302526
and O 0 0.00044931777
skilled O 0 0.00083863473
forelimb O 0 0.004780927
function O 0 0.00031286807
were O 0 0.00022763619
tested O 0 0.00020484159
repeatedly O 0 0.00029881106
for O 0 0.00030977034
six O 0 0.0004210684
weeks O 0 0.0006087598
. O 0 0.0017133419

Fucoidan B-Chemical 0 0.9972692
- O 0 0.0057045496
treated O 0 0.001620188
rats O 0 0.00093802577
exhibited O 0 0.0004367882
evidence O 0 0.00021768596
of O 0 0.00028790784
impaired B-Disease 0 0.003558682
blood I-Disease 0 0.024247706
clotting I-Disease 0 0.82234174
and O 0 0.00038949077
hemodilution B-Disease 0 0.99250364
, O 0 0.00023184707
had O 0 0.00012683895
larger O 0 0.00026679054
hematomas B-Disease 0 0.99579656
, O 0 0.00018320754
and O 0 9.773432e-05
tended O 0 7.962258e-05
to O 0 6.241577e-05
have O 0 6.0492155e-05
less O 0 0.00014572174
inflammation B-Disease 0 0.7055965
in O 0 0.0001074443
the O 0 8.211611e-05
vicinity O 0 7.416212e-05
of O 0 0.00016401098
the O 0 0.00026193
hematoma B-Disease 0 0.9469249
after O 0 0.00017144611
three O 0 0.00028251443
days O 0 0.0005293291
. O 0 0.0014986513

They O 0 0.0030218214
showed O 0 0.0012874876
significantly O 0 0.0009635822
more O 0 0.00065124955
rapid O 0 0.0007544164
improvement O 0 0.00034432395
of O 0 0.00027156985
motor O 0 0.00059979677
function O 0 0.00015215208
in O 0 8.0277634e-05
the O 0 6.1998035e-05
first O 0 3.904797e-05
week O 0 3.677529e-05
following O 0 7.678603e-05
hemorrhage B-Disease 2 0.9967301
and O 0 0.00015190968
better O 0 0.00020261396
memory O 0 0.02197523
retention O 0 0.0005302288
in O 0 0.00017543334
the O 0 0.000237947
passive O 0 0.00058769307
avoidance O 0 0.002049489
test O 0 0.0019700357
. O 0 0.001985581

Acute O 0 0.19812508
white B-Disease 0 0.08668166
matter I-Disease 0 0.04638059
edema I-Disease 0 0.99987376
and O 0 0.0013362417
eventual O 0 0.0047182534
neuronal B-Disease 0 0.49213177
loss I-Disease 0 0.017837374
in O 0 0.00019600875
the O 0 0.00015801423
striatum O 0 0.0032211258
adjacent O 0 0.00011413653
to O 0 8.3760075e-05
the O 0 0.00017272845
hematoma B-Disease 0 0.9867291
did O 0 0.00022587868
not O 0 0.00014281072
differ O 0 0.00013367979
between O 0 0.00011769521
the O 0 0.0002979849
two O 0 0.00042598628
groups O 0 0.0010000326
. O 0 0.0016879386

Investigation O 0 0.005014027
of O 0 0.0018461638
more O 0 0.0012956203
specific O 0 0.0006807615
anti O 0 0.002894059
- O 0 0.0015522703
inflammatory O 0 0.029171256
agents O 0 0.0022661672
and O 0 0.00045561919
hemodiluting O 0 0.0066123097
agents O 0 0.0013231976
are O 0 0.00031966038
warranted O 0 0.00037088885
in O 0 0.00084779836
intracerebral B-Disease 0 0.98590356
hemorrhage I-Disease 2 0.9997023
. O 0 0.003994182

Recurarization O 0 0.022900602
in O 0 0.0063258517
the O 0 0.0062480355
recovery O 0 0.011307436
room O 0 0.014777096
. O 0 0.012177568

A O 0 0.017566841
case O 0 0.0023033624
of O 0 0.0022564568
recurarization O 0 0.023700925
in O 0 0.00098179
the O 0 0.00090277515
recovery O 0 0.0018993566
room O 0 0.0022272829
is O 0 0.0020313477
reported O 0 0.003270633
. O 0 0.0036600153

Accumulation O 0 0.00402653
of O 0 0.0026641958
atracurium B-Chemical 0 0.99702305
in O 0 0.0006867004
the O 0 0.000481641
intravenous O 0 0.0061747273
line O 0 0.00040847104
led O 0 0.00023579609
to O 0 0.0001833512
recurarization O 0 0.009794886
after O 0 9.8006094e-05
flushing O 0 0.123351924
the O 0 0.00023583499
line O 0 0.0003458333
in O 0 0.00024625048
the O 0 0.00041286164
recovery O 0 0.0014785003
room O 0 0.002628683
. O 0 0.0022483391

A O 0 0.080587946
respiratory B-Disease 0 0.6698838
arrest I-Disease 0 0.90507346
with O 0 0.004831129
severe O 0 0.24331225
desaturation B-Disease 0 0.9987005
and O 0 0.004947413
bradycardia B-Disease 0 0.99700886
occurred O 0 0.0044559166
. O 0 0.003959617

Circumstances O 0 0.017464204
leading O 0 0.0022085127
to O 0 0.0008548786
this O 0 0.000694649
event O 0 0.000899911
and O 0 0.00029446656
the O 0 0.00017944649
mechanisms O 0 0.00018621013
enabling O 0 0.00020806411
a O 0 0.00037624943
neuromuscular B-Disease 0 0.9395657
blockade I-Disease 0 0.47991246
to O 0 0.00014340406
occur O 0 7.8104924e-05
, O 0 7.87038e-05
following O 0 4.3168315e-05
the O 0 7.450428e-05
administration O 0 0.00029493152
of O 0 0.00014246459
a O 0 0.00017048528
small O 0 0.00019842546
dose O 0 0.0007745499
of O 0 0.00063583476
relaxant O 0 0.7376249
, O 0 0.00077915966
are O 0 0.00069292885
discussed O 0 0.0011907875
. O 0 0.0019078609

The O 0 0.0015763959
haemodynamic O 0 0.008206285
effects O 0 0.0010537525
of O 0 0.0013927731
propofol B-Chemical 1 0.99909675
in O 0 0.0003909882
combination O 0 0.00043697853
with O 0 0.0006706392
ephedrine B-Chemical 1 0.99993
in O 0 0.0003470418
elderly O 0 0.063281216
patients O 0 0.00048292868
( O 0 0.00048895745
ASA O 0 0.82474
groups O 0 0.0002729162
3 O 0 0.0002276946
and O 0 0.000438488
4 O 0 0.00063188176
) O 0 0.0017538927
. O 0 0.0020818885

The O 0 0.0019851283
marked O 0 0.00315974
vasodilator O 0 0.7765897
and O 0 0.0009273289
negative O 0 0.0008316681
inotropic O 0 0.4662413
effects O 0 0.00064503547
of O 0 0.0010445273
propofol B-Chemical 1 0.999166
are O 0 0.000317579
disadvantages O 0 0.00014477911
in O 0 0.00046178274
frail O 0 0.11017864
elderly O 0 0.11070754
patients O 0 0.0028774636
. O 0 0.002134815

We O 0 0.00139116
investigated O 0 0.0009250212
the O 0 0.0007034554
safety O 0 0.000704263
and O 0 0.00039395358
efficacy O 0 0.0003688014
of O 0 0.00026994178
adding O 0 0.00029152483
different O 0 0.00011702977
doses O 0 0.0010519485
of O 0 0.0006060963
ephedrine B-Chemical 1 0.9999628
to O 0 0.0004264214
propofol B-Chemical 1 0.99942505
in O 0 0.00015173193
order O 0 0.00012511053
to O 0 0.00018512864
obtund O 0 0.0016149678
the O 0 0.00066972914
hypotensive B-Disease 0 0.97973263
response O 0 0.0020961433
. O 0 0.0021825708

The O 0 0.001779488
haemodynamic O 0 0.009769842
effects O 0 0.0010975861
of O 0 0.0008659949
adding O 0 0.0008182112
15 O 0 0.00028714005
, O 0 0.00024937847
20 O 0 0.0001492586
or O 0 0.00010265399
25 O 0 0.00017096258
mg O 0 0.0018244297
of O 0 0.00032567448
ephedrine B-Chemical 1 0.9998969
to O 0 0.000112108195
200 O 0 0.00029463673
mg O 0 0.0030489375
of O 0 0.00025710324
propofol B-Chemical 1 0.9993678
were O 0 8.521118e-05
compared O 0 3.0180592e-05
to O 0 3.412643e-05
control O 0 4.549642e-05
in O 0 5.642643e-05
40 O 0 0.00012181594
ASA O 0 0.7150752
3 O 0 6.6756045e-05
/ O 0 0.00016021778
4 O 0 4.5800713e-05
patients O 0 6.2617335e-05
over O 0 3.0408912e-05
60 O 0 6.854237e-05
years O 0 7.607179e-05
presenting O 0 0.00022543248
for O 0 0.0001766464
genito O 0 0.0021795325
- O 0 0.0011485711
urinary O 0 0.091696635
surgery O 0 0.0026130937
. O 0 0.0018695724

The O 0 0.0013024425
addition O 0 0.00084813853
of O 0 0.00207024
ephedrine B-Chemical 1 0.9998578
to O 0 0.0015165082
propofol B-Chemical 1 0.9996823
appears O 0 0.0002667224
to O 0 0.00015324731
be O 0 0.00010069988
an O 0 0.00010523351
effective O 0 7.303227e-05
method O 0 0.00015009251
of O 0 0.00015768837
obtunding O 0 0.045602895
the O 0 0.00014891797
hypotensive B-Disease 0 0.9446939
response O 0 0.00013152025
to O 0 0.0001495532
propofol B-Chemical 1 0.9978441
at O 0 0.00010394298
all O 0 0.0001586197
doses O 0 0.0007262428
used O 0 0.00022500427
in O 0 0.00035302053
this O 0 0.00087423023
study O 0 0.0016688188
. O 0 0.0019018305

However O 0 0.0026363411
, O 0 0.002106594
marked O 0 0.0025251256
tachycardia B-Disease 2 0.95986515
associated O 0 0.00045790218
with O 0 0.000331429
the O 0 0.00018254474
use O 0 0.00014057352
of O 0 0.00035575218
ephedrine B-Chemical 1 0.99991393
in O 0 0.00014449596
combination O 0 0.00018671593
with O 0 0.00029172056
propofol B-Chemical 1 0.9993007
occurred O 0 8.992477e-05
in O 0 5.800364e-05
the O 0 5.6839686e-05
majority O 0 8.050839e-05
of O 0 0.00013516576
patients O 0 0.00019671909
, O 0 0.00013150733
occasionally O 0 0.00021507363
reaching O 0 0.0002326764
high O 0 0.000329885
levels O 0 0.00025903547
in O 0 0.00032470535
individual O 0 0.0005677601
patients O 0 0.0018043735
. O 0 0.0017960899

Due O 0 0.0017747933
to O 0 0.0012193315
the O 0 0.000987819
risk O 0 0.0022704764
of O 0 0.00060877204
this O 0 0.0007161439
tachycardia B-Disease 2 0.99226004
inducing O 0 0.005002522
myocardial B-Disease 0 0.9999324
ischemia I-Disease 0 0.99997973
, O 0 0.00042124832
we O 0 5.7539495e-05
would O 0 6.8571346e-05
not O 0 5.70115e-05
recommend O 0 4.9793434e-05
the O 0 5.9005964e-05
use O 0 5.8251255e-05
in O 0 7.862316e-05
elderly O 0 0.0065984926
patients O 0 0.000119122815
of O 0 8.8491906e-05
any O 0 6.161987e-05
of O 0 0.00013329604
the O 0 0.00029029176
ephedrine B-Chemical 1 0.99993885
/ O 0 0.010430233
propofol B-Chemical 1 0.9996119
/ O 0 0.0029649003
mixtures O 0 0.0041416413
studied O 0 0.002027417
. O 0 0.0019979551

Gemcitabine B-Chemical 0 0.98263043
plus O 0 0.0027229474
vinorelbine B-Chemical 0 0.99663913
in O 0 0.0022354173
nonsmall B-Disease 0 0.97931015
cell I-Disease 0 0.011413216
lung I-Disease 0 0.48150337
carcinoma I-Disease 0 0.99911565
patients O 0 0.000706418
age O 0 0.00017793573
70 O 0 0.000115133014
years O 0 7.400041e-05
or O 0 8.031852e-05
older O 0 0.000339074
or O 0 0.0001381994
patients O 0 0.00032603735
who O 0 0.0004808955
cannot O 0 0.0011423439
receive O 0 0.0007131748
cisplatin B-Chemical 0 0.99140537
. O 0 0.0027269993

Oncopaz O 0 0.06143438
Cooperative O 0 0.03754993
Group O 0 0.044182334
. O 0 0.028479412

BACKGROUND O 0 0.008063544
: O 0 0.0018821841
Although O 0 0.00058682606
the O 0 0.00059897837
prevalence O 0 0.000693773
of O 0 0.0010891695
nonsmall B-Disease 0 0.9704112
cell I-Disease 0 0.011083271
lung I-Disease 0 0.6458676
carcinoma I-Disease 0 0.99976534
( O 0 0.0028424
NSCLC B-Disease 2 0.9990715
) O 0 0.00034033522
is O 0 9.446694e-05
high O 0 0.00017717067
among O 0 0.0001533467
elderly O 0 0.021518515
patients O 0 0.00017082081
, O 0 7.620233e-05
few O 0 3.0139518e-05
data O 0 5.94266e-05
are O 0 4.702516e-05
available O 0 5.14719e-05
regarding O 0 2.659384e-05
the O 0 5.2870488e-05
efficacy O 0 0.00011067848
and O 0 0.00014398694
toxicity B-Disease 2 0.9626028
of O 0 0.0003361529
chemotherapy O 0 0.0018148412
in O 0 0.00016381891
this O 0 0.00030712053
group O 0 0.0004928965
of O 0 0.0008821733
patients O 0 0.0021424743
. O 0 0.0018346075

Recent O 0 0.0019716073
reports O 0 0.0012284109
indicate O 0 0.00041023604
that O 0 0.0002916299
single O 0 0.00034609632
agent O 0 0.0010401298
therapy O 0 0.00043038328
with O 0 0.00048571898
vinorelbine B-Chemical 0 0.9982003
( O 0 0.0009282592
VNB B-Chemical 0 0.9548318
) O 0 0.0003839973
or O 0 0.00019194033
gemcitabine B-Chemical 0 0.9960879
( O 0 0.0009128272
GEM B-Chemical 0 0.99550843
) O 0 0.00029072634
may O 0 5.9810074e-05
obtain O 0 4.3871885e-05
a O 0 7.371166e-05
response O 0 5.9848593e-05
rate O 0 7.633165e-05
of O 0 0.00010339434
20 O 0 9.4199604e-05
- O 0 0.0001254651
30 O 0 4.4050725e-05
% O 0 6.235438e-05
in O 0 6.660763e-05
elderly O 0 0.0056919865
patients O 0 0.00014355565
, O 0 8.040112e-05
with O 0 9.020345e-05
acceptable O 0 0.00014961626
toxicity B-Disease 2 0.96489656
and O 0 0.00015216107
improvement O 0 0.00015491898
in O 0 0.00013238919
symptoms O 0 0.001141689
and O 0 0.00023633493
quality O 0 0.00032949552
of O 0 0.00084393285
life O 0 0.0017617472
. O 0 0.0019154142

In O 0 0.0014869366
the O 0 0.0010724835
current O 0 0.0011433396
study O 0 0.00058494974
the O 0 0.00033437353
efficacy O 0 0.00045778457
and O 0 0.0003942258
toxicity B-Disease 2 0.97118056
of O 0 0.0002898169
the O 0 0.00012739738
combination O 0 0.00017313752
of O 0 0.00027351038
GEM B-Chemical 0 0.99062145
and O 0 0.00026565522
VNB B-Chemical 0 0.8550404
in O 0 0.000119425575
elderly O 0 0.013350813
patients O 0 0.00014898358
with O 0 0.00014498524
advanced O 0 0.0040266295
NSCLC B-Disease 2 0.9963012
or O 0 9.620089e-05
those O 0 0.00011081366
with O 0 9.294487e-05
some O 0 9.5324605e-05
contraindication O 0 0.00012116556
to O 0 0.00013214325
receiving O 0 0.00069589127
cisplatin B-Chemical 0 0.98886275
were O 0 0.0009374977
assessed O 0 0.00096638827
. O 0 0.0016875787

METHODS O 0 0.0016425577
: O 0 0.0015203513
Forty O 0 0.0013361285
- O 0 0.00094336976
nine O 0 0.0003777445
patients O 0 0.0003931893
with O 0 0.0003750837
advanced O 0 0.0035478533
NSCLC B-Disease 2 0.9941954
were O 0 0.00018817975
included O 0 9.348835e-05
, O 0 0.00011210159
38 O 0 0.00010779125
of O 0 0.000105133004
whom O 0 0.00019440101
were O 0 9.606311e-05
age O 0 0.00011376687
> O 0 0.00023711652
/ O 0 0.0003211817
= O 0 0.00011107031
70 O 0 7.459804e-05
years O 0 5.2063006e-05
and O 0 6.0751543e-05
11 O 0 6.592322e-05
were O 0 6.419178e-05
age O 0 7.670378e-05
< O 0 6.130893e-05
70 O 0 7.417711e-05
years O 0 6.303228e-05
but O 0 8.7048924e-05
who O 0 0.0001545902
had O 0 0.000114053524
some O 0 0.00015964363
contraindication O 0 0.0002555553
to O 0 0.0003262606
receiving O 0 0.0021127055
cisplatin B-Chemical 0 0.99640024
. O 0 0.0028549265

All O 0 0.002758913
patients O 0 0.0026076296
were O 0 0.0016188618
evaluable O 0 0.002116543
for O 0 0.0010906387
response O 0 0.0020431615
and O 0 0.0041042166
toxicity B-Disease 2 0.99281514
. O 0 0.007416144

Treatment O 0 0.004909974
was O 0 0.0015517755
comprised O 0 0.00090593717
of O 0 0.00120555
VNB B-Chemical 0 0.885648
, O 0 0.0006981631
25 O 0 0.0005885647
mg O 0 0.011277701
/ O 0 0.0012267401
m O 0 0.0011020225
( O 0 0.00029549527
2 O 0 0.00013392042
) O 0 0.00019554431
, O 0 0.00013177595
plus O 0 0.00013580616
GEM B-Chemical 0 0.9665832
, O 0 0.00025887697
1000 O 0 0.00044596553
mg O 0 0.0060787895
/ O 0 0.00070340774
m O 0 0.0007033321
( O 0 0.00020058278
2 O 0 9.8429984e-05
) O 0 0.0001509636
, O 0 9.601594e-05
both O 0 8.194878e-05
on O 0 7.1354065e-05
Days O 0 0.00051647384
1 O 0 0.00011977319
, O 0 0.0001496525
8 O 0 0.0001166396
, O 0 0.00016994319
and O 0 0.00017862878
15 O 0 0.00016254411
every O 0 0.00014067045
28 O 0 0.0004745902
days O 0 0.00058442703
. O 0 0.0016956733

Patients O 0 0.0024838143
received O 0 0.0010247612
a O 0 0.0008586305
minimum O 0 0.00042477524
of O 0 0.0005302944
three O 0 0.00026385166
courses O 0 0.00050463143
unless O 0 0.0006987522
progressive O 0 0.106100276
disease O 0 0.52884346
was O 0 0.0022435363
detected O 0 0.0019184722
. O 0 0.0027727187

RESULTS O 0 0.004971785
: O 0 0.0020292317
One O 0 0.0010651839
hundred O 0 0.0008912681
sixty O 0 0.00087186025
- O 0 0.00061518507
five O 0 0.00017862163
courses O 0 0.0002490508
were O 0 0.00024320431
administered O 0 0.00032645755
, O 0 0.00034708693
with O 0 0.0003694205
a O 0 0.0005276564
median O 0 0.00037571284
of O 0 0.0010724048
3 O 0 0.0012932221
. O 0 0.0021363606

6 O 0 0.007828775
courses O 0 0.00814498
per O 0 0.0059027863
patient O 0 0.012547485
. O 0 0.0145908985

The O 0 0.0017714553
overall O 0 0.0015764019
response O 0 0.0011933492
rate O 0 0.0011557577
was O 0 0.0009155919
26 O 0 0.0007932977
% O 0 0.0005533321
( O 0 0.00053846376
95 O 0 0.0004663339
% O 0 0.000323757
confidence O 0 0.00085879257
interval O 0 0.00026651472
, O 0 0.00036748702
15 O 0 0.00034043938
- O 0 0.00087827956
41 O 0 0.0012290956
% O 0 0.0013324762
) O 0 0.0025273687
. O 0 0.002661991

Two O 0 0.0022635122
patients O 0 0.0017456406
attained O 0 0.0014607753
a O 0 0.0007631788
complete O 0 0.0004616349
response O 0 0.00047568948
( O 0 0.00051972084
4 O 0 0.00020662035
% O 0 0.00025519056
) O 0 0.00029145452
and O 0 0.00018712909
11 O 0 0.00019120712
patients O 0 0.0002552645
( O 0 0.00026509355
22 O 0 0.00024519782
% O 0 0.00025334954
) O 0 0.0003598481
achieved O 0 0.00041374657
a O 0 0.00065817975
partial O 0 0.0014156887
response O 0 0.0017840975
. O 0 0.0024306744

Eastern O 0 0.0051318733
Cooperative O 0 0.0022807906
Oncology O 0 0.0015103056
Group O 0 0.0014529485
performance O 0 0.00058974023
status O 0 0.00029916622
improved O 0 0.00040276043
in O 0 0.00017779953
35 O 0 0.00016045506
% O 0 0.00012526225
of O 0 0.00012879865
those O 0 0.00015045059
patients O 0 0.00012256153
with O 0 8.0977596e-05
an O 0 7.941905e-05
initial O 0 6.918013e-05
value O 0 0.00011128806
> O 0 0.00022909613
0 O 0 7.171493e-05
, O 0 7.82247e-05
whereas O 0 7.004642e-05
relief O 0 0.00017020947
of O 0 7.0089256e-05
at O 0 3.5991252e-05
least O 0 4.2540472e-05
1 O 0 4.8214246e-05
symptom O 0 0.0001688188
without O 0 6.995177e-05
worsening O 0 0.003006096
of O 0 0.00014017518
other O 0 0.000112904025
symptoms O 0 0.001890735
was O 0 0.00011907921
noted O 0 6.975513e-05
in O 0 0.00011461226
27 O 0 0.0002742232
patients O 0 0.00034688268
( O 0 0.0004554568
55 O 0 0.00060036266
% O 0 0.0008722781
) O 0 0.0018106636
. O 0 0.0019946632

The O 0 0.001410032
median O 0 0.00074875436
time O 0 0.00049704046
to O 0 0.00059501646
progression O 0 0.0036994342
was O 0 0.00047306405
16 O 0 0.00022939361
weeks O 0 8.951615e-05
and O 0 0.00016271576
the O 0 0.00019070384
1 O 0 0.00020521047
- O 0 0.0003637573
year O 0 0.00018525383
survival O 0 0.0010493922
rate O 0 0.00059292093
was O 0 0.0008606783
33 O 0 0.0014534233
% O 0 0.001717024
. O 0 0.00223689

Toxicity B-Disease 0 0.95738584
was O 0 0.034654796
mild O 0 0.54096836
. O 0 0.02797746

Six O 0 0.0030717987
patients O 0 0.0023140889
( O 0 0.0013374856
12 O 0 0.00042154655
% O 0 0.0005154477
) O 0 0.00044995794
had O 0 0.00019779436
World O 0 0.00022497315
Health O 0 0.0001839299
Organization O 0 0.00021385247
Grade O 0 0.0028828098
3 O 0 0.00012880615
- O 0 0.0002305731
4 O 0 0.00011824934
neutropenia B-Disease 0 0.95156133
, O 0 0.00021712002
2 O 0 9.8048156e-05
patients O 0 0.00014634419
( O 0 0.0001272932
4 O 0 6.021394e-05
% O 0 8.993736e-05
) O 0 0.000132661
had O 0 0.00010459513
Grade O 0 0.0032052717
3 O 0 8.877699e-05
- O 0 0.00019669435
4 O 0 0.000115807525
thrombocytopenia B-Disease 0 0.9982609
, O 0 0.00020744192
and O 0 0.00013168715
2 O 0 9.489807e-05
patients O 0 0.00016537549
( O 0 0.00017310584
4 O 0 0.00010559175
% O 0 0.00019075206
) O 0 0.00034892993
had O 0 0.0004272242
Grade O 0 0.011285515
3 O 0 0.0011287883
neurotoxicity B-Disease 2 0.9992187
. O 0 0.0036031872

Three O 0 0.0026932175
patients O 0 0.0024211404
with O 0 0.0020976998
severe O 0 0.064154804
neutropenia B-Disease 0 0.9989649
( O 0 0.0022925462
6 O 0 0.00057166483
% O 0 0.0008578479
) O 0 0.0012923077
died O 0 0.0022559683
of O 0 0.003250246
sepsis B-Disease 2 0.9953414
. O 0 0.005437392

The O 0 0.0014938035
median O 0 0.00087425445
age O 0 0.000875016
of O 0 0.0006208648
those O 0 0.0005813631
patients O 0 0.0005519163
developing O 0 0.0016054965
Grade O 0 0.046794023
3 O 0 0.00017130836
- O 0 0.00028424547
4 O 0 0.00011978736
neutropenia B-Disease 0 0.9655805
was O 0 0.00019779945
significantly O 0 0.00014606035
higher O 0 9.4144096e-05
than O 0 3.8677885e-05
that O 0 3.632815e-05
of O 0 7.295013e-05
the O 0 6.3763255e-05
remaining O 0 0.00010981351
patients O 0 0.00016155843
( O 0 0.00012432243
75 O 0 0.00013255014
years O 0 6.851559e-05
vs O 0 8.591237e-05
. O 0 5.5802324e-05
72 O 0 0.00010273253
years O 0 0.00013544703
; O 0 0.00030168385
P O 0 0.002731047
= O 0 0.00040477156
0 O 0 0.00035095666
. O 0 0.0005258184
047 O 0 0.025755277
) O 0 0.0025279832
. O 0 0.0023530168

CONCLUSIONS O 0 0.011512989
: O 0 0.0017123747
The O 0 0.00059632317
combination O 0 0.00078323425
of O 0 0.0009953646
GEM B-Chemical 0 0.9852486
and O 0 0.00092222326
VNB B-Chemical 0 0.9433416
is O 0 0.00034391668
moderately O 0 0.0020357196
active O 0 0.00019509142
and O 0 0.00013275603
well O 0 0.00010140611
tolerated O 0 0.0006675441
except O 0 8.284087e-05
in O 0 0.00012032175
patients O 0 0.00026283358
age O 0 0.00028667663
> O 0 0.00066699146
/ O 0 0.0011296236
= O 0 0.0007510117
75 O 0 0.0010588762
years O 0 0.0010410046
. O 0 0.0016761849

This O 0 0.005973318
age O 0 0.0034578224
group O 0 0.0023145138
had O 0 0.0014985814
an O 0 0.0018234979
increased O 0 0.0030728707
risk O 0 0.02056466
of O 0 0.010042873
myelosuppression B-Disease 0 0.9998286
. O 0 0.008566495

Therefore O 0 0.0014943492
the O 0 0.0013572824
prophylactic O 0 0.0017004324
use O 0 0.00074751244
of O 0 0.0013063685
granulocyte O 0 0.99547064
- O 0 0.0029389984
colony O 0 0.088058494
stimulating O 0 0.00093158364
factor O 0 0.0012794317
should O 0 0.00016451329
be O 0 0.00020723634
considered O 0 0.00021772328
with O 0 0.00047059087
this O 0 0.0009339155
treatment O 0 0.0016697078
. O 0 0.0023289053

New O 0 0.0032080088
chemotherapy O 0 0.0039191027
combinations O 0 0.0007464073
with O 0 0.00059446174
higher O 0 0.0004464547
activity O 0 0.0003148228
and O 0 0.0003358137
lower O 0 0.0006444431
toxicity B-Disease 2 0.98495144
are O 0 0.00023151813
needed O 0 0.00013548073
for O 0 0.000185183
elderly O 0 0.015242085
patients O 0 0.0006722868
with O 0 0.00092060916
advanced O 0 0.026880318
NSCLC B-Disease 2 0.99723464
. O 0 0.0030509124

A O 0 0.032323133
selective O 0 0.023401853
dopamine B-Chemical 0 0.99980587
D4 O 0 0.99964356
receptor O 0 0.4765872
antagonist O 0 0.97773767
, O 0 0.0026206155
NRA0160 B-Chemical 1 0.9902383
: O 0 0.0010930122
a O 0 0.0010656731
preclinical O 0 0.0060951863
neuropharmacological O 0 0.56557643
profile O 0 0.0032912726
. O 0 0.00295691

NRA0160 B-Chemical 1 0.99036026
, O 0 0.0042471956
5 B-Chemical 0 0.0017268256
- I-Chemical 0 0.0025427793
[ I-Chemical 0 0.0019423679
2 I-Chemical 0 0.0006037836
- I-Chemical 0 0.00091215293
( I-Chemical 0 0.0005365471
4 I-Chemical 0 0.00026449218
- I-Chemical 0 0.00048822552
( I-Chemical 0 0.0003143744
3 I-Chemical 0 0.00016560651
- I-Chemical 0 0.0003730653
fluorobenzylidene I-Chemical 0 0.0028657047
) I-Chemical 0 0.0005718231
piperidin I-Chemical 0 0.1717636
- I-Chemical 0 0.0005794485
1 I-Chemical 0 0.00018439506
- I-Chemical 0 0.00062595826
yl I-Chemical 0 0.8765777
) I-Chemical 0 0.0012806217
ethyl I-Chemical 0 0.9998197
] I-Chemical 0 0.0020908616
- I-Chemical 0 0.00040543734
4 I-Chemical 0 0.00010279387
- I-Chemical 0 0.0002165936
( I-Chemical 0 0.00015107133
4 I-Chemical 0 9.207876e-05
- I-Chemical 0 0.00033760647
fluorophenyl I-Chemical 0 0.86403143
) I-Chemical 0 0.0007263906
thiazole I-Chemical 0 0.9383943
- I-Chemical 0 0.00057106034
2 I-Chemical 0 0.00013324393
- I-Chemical 0 0.00036240518
carboxamide I-Chemical 0 0.63334495
, O 0 0.00017549876
has O 0 6.502742e-05
a O 0 0.00010449454
high O 0 0.00017157366
affinity O 0 0.0003270507
for O 0 6.898552e-05
human O 0 0.0002037729
cloned O 0 0.0007464009
dopamine B-Chemical 0 0.9999701
D4 O 0 0.9997806
. O 0 8.7940745e-05
2 O 0 8.242365e-05
, O 0 0.00017797289
D4 O 0 0.9895356
. O 0 6.779371e-05
4 O 0 6.1907886e-05
and O 0 0.00014979726
D4 O 0 0.990218
. O 0 7.432941e-05
7 O 0 6.4012434e-05
receptors O 0 0.00034807096
, O 0 0.00010650388
with O 0 0.0001603986
Ki O 0 0.3249438
values O 0 0.00012592369
of O 0 0.0001337109
0 O 0 8.9024026e-05
. O 0 5.659683e-05
5 O 0 6.273526e-05
, O 0 0.00010016377
0 O 0 8.446834e-05
. O 0 7.051691e-05
9 O 0 9.453101e-05
and O 0 0.00014102677
2 O 0 0.00015560992
. O 0 0.00016504608
7 O 0 0.0002859132
nM O 0 0.0026489592
, O 0 0.0016341716
respectively O 0 0.0037658357
. O 0 0.0028675266

NRA0160 B-Chemical 1 0.9717995
is O 0 0.001931813
over O 0 0.00060160476
20 O 0 0.00071358925
, O 0 0.0006236174
000fold O 0 0.0019902638
more O 0 0.00036847964
potent O 0 0.00040156927
at O 0 0.00014807067
the O 0 0.0004214704
dopamine B-Chemical 0 0.9999428
D4 O 0 0.99971503
. O 0 0.00012999053
2 O 0 0.00010187609
receptor O 0 0.0005636224
compared O 0 7.015418e-05
with O 0 0.00013689126
the O 0 0.00017202253
human O 0 0.00045965606
cloned O 0 0.0020728894
dopamine B-Chemical 0 0.99988735
D2L O 0 0.9997392
receptor O 0 0.18930794
. O 0 0.002576521

NRA0160 B-Chemical 1 0.987004
has O 0 0.0018161944
negligible O 0 0.0014799767
affinity O 0 0.0016313314
for O 0 0.0003572501
the O 0 0.00035784612
human O 0 0.0005367635
cloned O 0 0.0016438187
dopamine B-Chemical 0 0.9999641
D3 O 0 0.9999734
receptor O 0 0.25194678
( O 0 0.00077677844
Ki O 0 0.7983548
= O 0 0.00030441096
39 O 0 0.00024097326
nM O 0 0.0016891572
) O 0 0.00029836182
, O 0 0.00016503161
rat O 0 0.0007651613
serotonin B-Chemical 0 0.9994148
( O 0 0.00025338624
5 B-Chemical 0 9.768344e-05
- I-Chemical 0 0.00042460783
HT I-Chemical 0 0.9910349
) O 0 0.0004050093
2A O 0 0.0003420087
receptors O 0 0.0009059656
( O 0 0.000288552
Ki O 0 0.44303352
= O 0 0.0001985428
180 O 0 0.00015464242
nM O 0 0.0011061012
) O 0 0.00024085357
and O 0 0.00016269032
rat O 0 0.0010702554
alpha1 O 0 0.99900764
adrenoceptor O 0 0.999951
( O 0 0.0015502793
Ki O 0 0.74906456
= O 0 0.0009328946
237 O 0 0.002258652
nM O 0 0.0073204804
) O 0 0.0030336527
. O 0 0.0024879728

NRA0160 B-Chemical 1 0.9891377
and O 0 0.007141017
clozapine B-Chemical 0 0.9999676
antagonized O 0 0.99445796
locomotor O 0 0.9994856
hyperactivity B-Disease 2 0.99999213
induced O 0 0.004026169
by O 0 0.0025259422
methamphetamine B-Chemical 1 0.99997807
( O 0 0.0026596643
MAP B-Chemical 0 0.43362278
) O 0 0.0013228434
in O 0 0.0008559699
mice O 0 0.001236777
. O 0 0.0022715663

NRA0160 B-Chemical 1 0.99040645
and O 0 0.007093875
clozapine B-Chemical 0 0.99996924
antagonized O 0 0.9857145
MAP B-Chemical 0 0.98209375
- O 0 0.0020277144
induced O 0 0.0005357667
stereotyped O 0 0.018687682
behavior O 0 0.00032675397
in O 0 0.00012841445
mice O 0 8.0360966e-05
, O 0 0.00011763237
although O 0 7.019742e-05
their O 0 9.391241e-05
effects O 0 0.00010331912
did O 0 0.00010676583
not O 0 7.5306634e-05
exceed O 0 8.3895655e-05
50 O 0 0.0001724426
% O 0 0.00012517102
inhibition O 0 0.00034422285
, O 0 0.00017710413
even O 0 0.00014616721
at O 0 0.000108902306
the O 0 0.00020941294
highest O 0 0.000490058
dose O 0 0.0022437475
given O 0 0.0009554624
. O 0 0.001918326

NRA0160 B-Chemical 1 0.9904218
and O 0 0.005953422
clozapine B-Chemical 0 0.9999578
significantly O 0 0.0039609377
induced O 0 0.0041194353
catalepsy B-Disease 0 0.9999889
in O 0 0.00066589424
rats O 0 0.00053783134
, O 0 0.00018281474
although O 0 8.957507e-05
their O 0 0.00010952027
effects O 0 0.00011620587
did O 0 0.00011909283
not O 0 8.338352e-05
exceed O 0 9.0987625e-05
50 O 0 0.00017201924
% O 0 0.00011294397
induction O 0 0.00012544417
even O 0 0.00014081622
at O 0 0.00010809779
the O 0 0.00020970743
highest O 0 0.00049339543
dose O 0 0.002271506
given O 0 0.0009609872
. O 0 0.0019263641

NRA0160 B-Chemical 1 0.9914062
and O 0 0.0061623566
clozapine B-Chemical 0 0.9999503
significantly O 0 0.0022269483
reversed O 0 0.0012788482
the O 0 0.00029315194
disruption O 0 0.00026267424
of O 0 0.00034054715
prepulse O 0 0.5997709
inhibition O 0 0.002031775
( O 0 0.0006102761
PPI O 0 0.011396232
) O 0 0.00038971903
in O 0 0.00021666754
rats O 0 0.00046219915
produced O 0 0.00055326277
by O 0 0.0018943073
apomorphine B-Chemical 1 0.99984133
. O 0 0.003659269

NRA0160 B-Chemical 1 0.9885576
and O 0 0.0051120264
clozapine B-Chemical 0 0.9999386
significantly O 0 0.0019873977
shortened O 0 0.0015258292
the O 0 0.0014975573
phencyclidine B-Chemical 0 0.9999989
( O 0 0.019561714
PCP B-Chemical 0 0.99986005
) O 0 0.0011953538
- O 0 0.00038601542
induced O 0 0.00017330502
prolonged O 0 0.0003380621
swimming O 0 0.0023799706
latency O 0 0.00024402053
in O 0 0.00012235752
rats O 0 0.00021344524
in O 0 0.0001639855
a O 0 0.00039686018
water O 0 0.0038018639
maze O 0 0.02252951
task O 0 0.0021835475
. O 0 0.0021955937

These O 0 0.0022191002
findings O 0 0.001895504
suggest O 0 0.0005688846
that O 0 0.0007343299
NRA0160 B-Chemical 1 0.9657379
may O 0 0.00038187572
have O 0 0.0001909737
unique O 0 0.00026544003
antipsychotic O 0 0.9798931
activities O 0 0.0001863048
without O 0 0.000117595126
the O 0 0.00013670055
liability O 0 0.0051808725
of O 0 0.00023042432
motor O 0 0.0010766719
side O 0 0.0016532519
effects O 0 0.00027815186
typical O 0 0.00032905262
of O 0 0.00069322746
classical O 0 0.0022322903
antipsychotics O 0 0.9985812
. O 0 0.0025894933

Warfarin B-Chemical 0 0.9988803
- O 0 0.006965316
induced O 0 0.0037575194
artery B-Disease 2 0.988704
calcification I-Disease 2 0.9997186
is O 0 0.0015953479
accelerated O 0 0.0040316465
by O 0 0.0011319203
growth O 0 0.008604656
and O 0 0.0049770907
vitamin B-Chemical 0 0.999948
D I-Chemical 0 0.9966229
. O 0 0.006022762

The O 0 0.0013132178
present O 0 0.00079096155
studies O 0 0.00060147856
demonstrate O 0 0.00022245222
that O 0 0.00025422743
growth O 0 0.002735469
and O 0 0.0014800866
vitamin B-Chemical 0 0.9999933
D I-Chemical 0 0.99696046
treatment O 0 0.0002225307
enhance O 0 6.0306e-05
the O 0 6.788506e-05
extent O 0 5.4283417e-05
of O 0 0.00021961094
artery B-Disease 2 0.973784
calcification I-Disease 2 0.99991906
in O 0 0.00012443308
rats O 0 9.204733e-05
given O 0 2.6089358e-05
sufficient O 0 3.7899405e-05
doses O 0 0.00044519463
of O 0 0.00033805627
Warfarin B-Chemical 0 0.99980694
to O 0 0.00010240527
inhibit O 0 0.00011232135
gamma O 0 0.94211626
- O 0 0.0012365768
carboxylation O 0 0.8528693
of O 0 0.00023430755
matrix O 0 0.0010227057
Gla O 0 0.9508307
protein O 0 0.0004819229
, O 0 0.00015421418
a O 0 0.0002681104
calcification B-Disease 0 0.99231887
inhibitor O 0 0.0015843336
known O 0 0.0001691275
to O 0 7.2188224e-05
be O 0 6.0869206e-05
expressed O 0 4.4910597e-05
by O 0 0.00010418968
smooth O 0 0.000842135
muscle O 0 0.00084433984
cells O 0 0.00019775119
and O 0 0.0001577013
macrophages O 0 0.0003164324
in O 0 0.0002655962
the O 0 0.0005460672
artery O 0 0.044554472
wall O 0 0.0067804484
. O 0 0.0023312643

The O 0 0.0014170975
first O 0 0.00081020896
series O 0 0.0009182307
of O 0 0.00057364284
experiments O 0 0.00026786333
examined O 0 0.00016769175
the O 0 0.00016137275
influence O 0 9.6184005e-05
of O 0 0.0002266255
age O 0 0.00020451374
and O 0 0.00014270892
growth O 0 0.00066344306
status O 0 0.000120970115
on O 0 0.00012384912
artery B-Disease 2 0.9455539
calcification I-Disease 2 0.9999138
in O 0 0.0018305
Warfarin B-Chemical 0 0.999858
- O 0 0.0018778408
treated O 0 0.0015600899
rats O 0 0.0025483028
. O 0 0.001983586

Treatment O 0 0.0041402234
for O 0 0.0010072566
2 O 0 0.000633451
weeks O 0 0.0002809531
with O 0 0.00078342983
Warfarin B-Chemical 0 0.9990982
caused O 0 0.0005953892
massive O 0 0.005710971
focal O 0 0.0034178344
calcification B-Disease 0 0.9943815
of I-Disease 0 0.00024631785
the I-Disease 0 0.0001386225
artery I-Disease 0 0.009018477
media O 0 0.0003556596
in O 0 0.000102712336
20 O 0 0.00011255735
- O 0 0.00016842454
day O 0 5.61584e-05
- O 0 0.00014529344
old O 0 8.044944e-05
rats O 0 0.0001016372
and O 0 6.934128e-05
less O 0 7.987688e-05
extensive O 0 0.00012325229
focal O 0 0.00088786404
calcification B-Disease 0 0.98931164
in O 0 0.00021633106
42 O 0 0.00027166208
- O 0 0.00033939446
day O 0 0.00019023458
- O 0 0.00062025647
old O 0 0.0007086766
rats O 0 0.0017072489
. O 0 0.0017995044

In O 0 0.0019958483
contrast O 0 0.0020511611
, O 0 0.0013724398
no O 0 0.000773109
artery B-Disease 2 0.9695225
calcification I-Disease 2 0.99981266
could O 0 0.00046119702
be O 0 0.00020925584
detected O 0 0.00011927467
in O 0 0.00012310629
10 O 0 0.00012933413
- O 0 0.00022497702
month O 0 6.546745e-05
- O 0 0.00017880823
old O 0 0.00010657684
adult O 0 0.00015535137
rats O 0 0.00013620143
even O 0 8.923957e-05
after O 0 4.6161058e-05
4 O 0 8.971209e-05
weeks O 0 9.030879e-05
of O 0 0.0006282625
Warfarin B-Chemical 0 0.9988819
treatment O 0 0.002301748
. O 0 0.0022861832

To O 0 0.001764568
directly O 0 0.0010049228
examine O 0 0.00041845444
the O 0 0.00043743028
importance O 0 0.0002587331
of O 0 0.00044971972
growth O 0 0.002558738
to O 0 0.000676524
Warfarin B-Chemical 0 0.9999113
- O 0 0.0009915021
induced O 0 0.0005103428
artery B-Disease 2 0.9904716
calcification I-Disease 2 0.9999269
in O 0 0.00016025658
animals O 0 6.108728e-05
of O 0 8.0907506e-05
the O 0 6.23862e-05
same O 0 4.2953627e-05
age O 0 0.00010106824
, O 0 9.2793794e-05
20 O 0 8.960505e-05
- O 0 0.00014768516
day O 0 4.9539805e-05
- O 0 0.00013152527
old O 0 6.978301e-05
rats O 0 8.777235e-05
were O 0 5.226762e-05
fed O 0 8.384751e-05
for O 0 3.56918e-05
2 O 0 3.423746e-05
weeks O 0 1.5128989e-05
either O 0 3.3047756e-05
an O 0 6.570211e-05
ad O 0 0.00019556409
libitum O 0 0.0014054845
diet O 0 0.00089018344
or O 0 6.130086e-05
a O 0 0.00010331095
6 O 0 5.272176e-05
- O 0 0.00014323978
g O 0 0.00022472662
/ O 0 0.00024480632
d O 0 0.00010666773
restricted O 0 7.201111e-05
diet O 0 0.00065860926
that O 0 9.4521005e-05
maintains O 0 0.00021431338
weight O 0 0.0013556165
but O 0 0.0005767651
prevents O 0 0.0012338925
growth O 0 0.01157183
. O 0 0.002554506

Concurrent O 0 0.0034135524
treatment O 0 0.0012047372
of O 0 0.0009000585
both O 0 0.0006434071
dietary O 0 0.024502961
groups O 0 0.00040554092
with O 0 0.00060812576
Warfarin B-Chemical 0 0.9996123
produced O 0 0.00026376566
massive O 0 0.0033652545
focal O 0 0.0022186462
calcification B-Disease 0 0.99294573
of I-Disease 0 0.00018776412
the I-Disease 0 0.0001103758
artery I-Disease 0 0.006288359
media O 0 0.00025757262
in O 0 6.725239e-05
the O 0 6.7002155e-05
ad O 0 0.00024019244
libitum O 0 0.0016762887
- O 0 0.00014506129
fed O 0 0.00012311955
rats O 0 9.865748e-05
but O 0 5.9648206e-05
no O 0 3.7085843e-05
detectable O 0 0.00012147295
artery B-Disease 2 0.9509383
calcification I-Disease 2 0.99989045
in O 0 0.00015211888
the O 0 0.00010876687
restricted O 0 0.00010749255
- O 0 0.00041698653
diet O 0 0.0040357234
, O 0 0.000388904
growth O 0 0.002993801
- O 0 0.0012124284
inhibited O 0 0.002027471
group O 0 0.0025944528
. O 0 0.002238083

Although O 0 0.0014628877
the O 0 0.0010345427
explanation O 0 0.00043706724
for O 0 0.00029493406
the O 0 0.00026039765
association O 0 0.0001575208
between O 0 0.00019234412
artery B-Disease 2 0.952669
calcification I-Disease 2 0.99990463
and O 0 0.0004257636
growth O 0 0.0017273145
status O 0 0.00012825108
cannot O 0 0.0002322845
be O 0 5.6397377e-05
determined O 0 4.3226846e-05
from O 0 3.8893744e-05
the O 0 4.793527e-05
present O 0 5.07963e-05
study O 0 0.000106524916
, O 0 8.049887e-05
there O 0 3.8495255e-05
was O 0 6.513529e-05
a O 0 5.8189522e-05
relationship O 0 2.1871992e-05
between O 0 2.9112938e-05
higher O 0 0.00011268224
serum O 0 0.085009776
phosphate B-Chemical 0 0.9901455
and O 0 0.00015986862
susceptibility O 0 0.00031637866
to O 0 0.00014459838
artery B-Disease 2 0.98307264
calcification I-Disease 2 0.9999522
, O 0 0.00020916948
with O 0 0.00010028926
30 O 0 4.6180736e-05
% O 0 5.312014e-05
higher O 0 5.621594e-05
levels O 0 6.237942e-05
of O 0 0.00015501399
serum O 0 0.14760871
phosphate B-Chemical 0 0.99485403
in O 0 0.00022166964
young O 0 0.0011643957
, O 0 0.00011080573
ad O 0 0.00026167635
libitum O 0 0.0018245287
- O 0 0.00012743153
fed O 0 9.639565e-05
rats O 0 6.6499735e-05
compared O 0 2.5808538e-05
with O 0 4.503867e-05
either O 0 4.1101124e-05
of O 0 6.5025124e-05
the O 0 5.580243e-05
groups O 0 4.584961e-05
that O 0 3.2740274e-05
was O 0 6.325748e-05
resistant O 0 8.781429e-05
to O 0 0.00016831266
Warfarin B-Chemical 0 0.99990535
- O 0 0.00045835398
induced O 0 0.00031371397
artery B-Disease 2 0.99269134
calcification I-Disease 2 0.99996495
, O 0 0.0003282949
ie O 0 0.00018795882
, O 0 8.922502e-05
the O 0 6.857101e-05
10 O 0 7.367539e-05
- O 0 0.00014052501
month O 0 4.147976e-05
- O 0 0.000122594
old O 0 7.252246e-05
rats O 0 9.440912e-05
and O 0 6.7558605e-05
the O 0 7.429427e-05
restricted O 0 9.072969e-05
- O 0 0.00037713154
diet O 0 0.0041723102
, O 0 0.0003373417
growth O 0 0.002767197
- O 0 0.0009759365
inhibited O 0 0.001603222
young O 0 0.008243253
rats O 0 0.0029379446
. O 0 0.0019750223

This O 0 0.0034363072
observation O 0 0.0012853097
suggests O 0 0.00044139658
that O 0 0.00035983868
increased O 0 0.00070014474
susceptibility O 0 0.0014375404
to O 0 0.00080427824
Warfarin B-Chemical 0 0.999905
- O 0 0.0012392948
induced O 0 0.00071100256
artery B-Disease 2 0.9934164
calcification I-Disease 2 0.99992085
could O 0 0.0002313359
be O 0 0.00012049891
related O 0 6.795507e-05
to O 0 0.00015408911
higher O 0 0.00048497503
serum O 0 0.15261325
phosphate B-Chemical 0 0.99236953
levels O 0 0.0037849287
. O 0 0.0029394843

The O 0 0.0014971814
second O 0 0.0010952558
set O 0 0.00073718996
of O 0 0.0005805707
experiments O 0 0.00028536908
examined O 0 0.0001927425
the O 0 0.00021291354
possible O 0 0.00020885143
synergy O 0 0.00078375574
between O 0 0.0004614908
vitamin B-Chemical 0 0.9999888
D I-Chemical 0 0.9984118
and O 0 0.0029809289
Warfarin B-Chemical 0 0.9998006
in O 0 0.0021568737
artery B-Disease 2 0.9904406
calcification I-Disease 2 0.999705
. O 0 0.00448841

High O 0 0.0068795052
doses O 0 0.010149665
of O 0 0.0062411116
vitamin B-Chemical 0 0.9999771
D I-Chemical 0 0.99746823
are O 0 0.00062404014
known O 0 0.00042207394
to O 0 0.00023119786
cause O 0 0.00059176475
calcification B-Disease 0 0.982862
of I-Disease 0 0.00026318838
the I-Disease 0 0.00017129513
artery I-Disease 0 0.012803604
media O 0 0.00048641578
in O 0 0.00014755582
as O 0 0.00013377721
little O 0 0.00016149666
as O 0 0.00019513123
3 O 0 0.00019332337
to O 0 0.00028190558
4 O 0 0.00042464913
days O 0 0.0005567327
. O 0 0.0016222378

High O 0 0.0055568847
doses O 0 0.0046063047
of O 0 0.001364393
the O 0 0.002312876
vitamin B-Chemical 0 0.9999913
K I-Chemical 1 0.99999106
antagonist O 0 0.9998118
Warfarin B-Chemical 0 0.99997175
are O 0 0.00028459472
also O 0 0.00012206583
known O 0 0.00014436252
to O 0 9.7690434e-05
cause O 0 0.00030601688
calcification B-Disease 0 0.97791034
of I-Disease 0 0.00016657602
the I-Disease 0 0.000114643524
artery I-Disease 0 0.0170105
media O 0 0.0004808254
, O 0 0.00012650219
but O 0 7.2469295e-05
at O 0 3.620775e-05
treatment O 0 4.9604292e-05
times O 0 2.877457e-05
of O 0 7.5097734e-05
2 O 0 5.066452e-05
weeks O 0 2.6823149e-05
or O 0 6.0021423e-05
longer O 0 6.749042e-05
yet O 0 0.0001654332
not O 0 0.00017099551
at O 0 0.0002351309
1 O 0 0.00046255835
week O 0 0.0005596018
. O 0 0.0014395164

In O 0 0.0016711408
the O 0 0.0012912349
current O 0 0.0015894974
study O 0 0.0008784993
, O 0 0.0004559355
we O 0 0.00014466222
investigated O 0 0.00016107237
the O 0 0.00016051352
synergy O 0 0.0003386085
between O 0 7.6723e-05
these O 0 0.0001552329
2 O 0 7.367181e-05
treatments O 0 0.00010190136
and O 0 6.574591e-05
found O 0 4.7393056e-05
that O 0 4.8559115e-05
concurrent O 0 0.0004655558
Warfarin B-Chemical 0 0.99991643
administration O 0 0.0016997884
dramatically O 0 0.00018640679
increased O 0 0.00013533382
the O 0 5.630227e-05
extent O 0 4.3994598e-05
of O 0 0.00017186708
calcification B-Disease 0 0.97823745
in O 0 7.210415e-05
the O 0 6.506619e-05
media O 0 0.0003306608
of O 0 0.0010968868
vitamin B-Chemical 0 0.99999726
D I-Chemical 0 0.9993069
- O 0 0.0009112708
treated O 0 0.00030194712
rats O 0 0.00024863493
at O 0 0.000117484844
3 O 0 0.00016113857
and O 0 0.0002850034
4 O 0 0.0003653515
days O 0 0.0004921015
. O 0 0.0014796652

There O 0 0.0028148552
was O 0 0.0017074229
a O 0 0.0009774427
close O 0 0.00045799057
parallel O 0 0.00036952476
between O 0 0.00015325901
the O 0 0.00017485084
effect O 0 0.00019979427
of O 0 0.0011279238
vitamin B-Chemical 0 0.9999945
D I-Chemical 0 0.9979373
dose O 0 0.0037046047
on O 0 0.00013788347
artery B-Disease 2 0.9792044
calcification I-Disease 2 0.9999212
and O 0 0.00015672331
the O 0 7.118729e-05
effect O 0 7.920274e-05
of O 0 0.0006254054
vitamin B-Chemical 0 0.9999968
D I-Chemical 0 0.99730325
dose O 0 0.0011720931
on O 0 4.100122e-05
the O 0 7.008592e-05
elevation O 0 0.003910863
of O 0 0.0002699711
serum O 0 0.45187634
calcium B-Chemical 0 0.9998416
, O 0 0.0002417771
which O 0 0.00012712713
suggests O 0 4.333796e-05
that O 0 0.00015735657
vitamin B-Chemical 0 0.99999475
D I-Chemical 0 0.99343985
may O 0 0.0001318842
induce O 0 0.00012634596
artery B-Disease 2 0.96144336
calcification I-Disease 2 0.9998073
through O 0 0.00016742731
its O 0 0.0002963538
effect O 0 0.00022684994
on O 0 0.00034494622
serum O 0 0.27125672
calcium B-Chemical 0 0.99889565
. O 0 0.003938685

Because O 0 0.0025937017
Warfarin B-Chemical 0 0.9987804
treatment O 0 0.0013950631
had O 0 0.00054170017
no O 0 0.0001855655
effect O 0 0.0001773417
on O 0 0.00010070603
the O 0 0.00015488088
elevation O 0 0.004472847
in O 0 0.00020922055
serum O 0 0.1934945
calcium B-Chemical 0 0.9996662
produced O 0 0.00043172593
by O 0 0.0011752883
vitamin B-Chemical 0 0.9999974
D I-Chemical 0 0.9985398
, O 0 0.00020387005
the O 0 8.6775995e-05
synergy O 0 0.00028505473
between O 0 0.00011098201
Warfarin B-Chemical 0 0.9999255
and O 0 0.0015099777
vitamin B-Chemical 0 0.99999726
D I-Chemical 0 0.9977513
is O 0 0.00016679442
probably O 0 0.0001453091
best O 0 0.00011256862
explained O 0 7.1249626e-05
by O 0 6.452806e-05
the O 0 6.436378e-05
hypothesis O 0 0.00012071937
that O 0 0.000118637305
Warfarin B-Chemical 0 0.9995672
inhibits O 0 8.714252e-05
the O 0 9.0191235e-05
activity O 0 9.585274e-05
of O 0 0.00021006886
matrix O 0 0.0012101589
Gla O 0 0.93541574
protein O 0 0.0008931741
as O 0 0.0004160498
a O 0 0.0013265098
calcification B-Disease 0 0.9948127
inhibitor O 0 0.03994269
. O 0 0.0028475458

High O 0 0.005584446
levels O 0 0.0016071927
of O 0 0.0015073386
matrix O 0 0.0031895707
Gla O 0 0.8911881
protein O 0 0.0011716981
are O 0 0.00026118857
found O 0 0.00012728239
at O 0 7.304285e-05
sites O 0 8.043502e-05
of O 0 0.00023584151
artery B-Disease 2 0.95636475
calcification I-Disease 2 0.9998994
in O 0 0.00016040442
rats O 0 0.0001628258
treated O 0 0.00016601535
with O 0 0.0005505111
vitamin B-Chemical 0 0.99999654
D I-Chemical 0 0.9987595
plus O 0 0.00058686745
Warfarin B-Chemical 0 0.9999534
, O 0 0.00020267654
and O 0 9.456202e-05
chemical O 0 0.0002579543
analysis O 0 6.719469e-05
showed O 0 5.2760286e-05
that O 0 3.9484814e-05
the O 0 6.48815e-05
protein O 0 0.00013377696
that O 0 6.7230074e-05
accumulated O 0 0.00012419753
was O 0 0.00017670401
indeed O 0 0.00022899894
not O 0 0.0005110757
gamma B-Chemical 0 0.9854021
- I-Chemical 0 0.007826298
carboxylated I-Chemical 0 0.9756481
. O 0 0.0035585198

These O 0 0.0020296394
observations O 0 0.0014173829
indicate O 0 0.0005084264
that O 0 0.0003935049
although O 0 0.00041781296
the O 0 0.00062434946
gamma B-Chemical 0 0.9866758
- I-Chemical 0 0.0023692527
carboxyglutamate I-Chemical 0 0.25944653
residues O 0 0.0015245221
of O 0 0.0003128156
matrix O 0 0.0012821369
Gla O 0 0.9461393
protein O 0 0.0004508475
are O 0 9.244201e-05
apparently O 0 0.00015926232
required O 0 3.1012736e-05
for O 0 4.1210158e-05
its O 0 0.00011140284
function O 0 9.009334e-05
as O 0 7.8366786e-05
a O 0 0.00024858132
calcification B-Disease 0 0.99500716
inhibitor O 0 0.0031163343
, O 0 0.00015370963
they O 0 6.535753e-05
are O 0 6.0877624e-05
not O 0 5.3325195e-05
required O 0 4.7126978e-05
for O 0 9.120993e-05
its O 0 0.00031294624
accumulation O 0 0.0006122914
at O 0 0.0005433361
calcification B-Disease 0 0.9841958
sites O 0 0.0016516406
. O 0 0.0020336844

Test O 0 0.007815068
conditions O 0 0.0016746686
influence O 0 0.00072771707
the O 0 0.0007863689
response O 0 0.0007881078
to O 0 0.0007145457
a O 0 0.0012150863
drug O 0 0.007646566
challenge O 0 0.0011581327
in O 0 0.001628341
rodents O 0 0.0045344178
. O 0 0.0033753032

These O 0 0.0022203233
studies O 0 0.0013378588
were O 0 0.00071108935
conducted O 0 0.0003866695
to O 0 0.00024099533
examine O 0 0.0001147238
the O 0 0.00017179696
differential O 0 0.00024253072
response O 0 0.00015461484
to O 0 0.000117014024
a O 0 0.0001922187
drug O 0 0.0014794539
challenge O 0 6.8571935e-05
under O 0 5.119351e-05
varied O 0 6.4891276e-05
experimental O 0 9.827945e-05
test O 0 9.717904e-05
conditions O 0 6.969223e-05
routinely O 0 5.0341987e-05
employed O 0 6.695878e-05
to O 0 6.847496e-05
study O 0 0.00015744947
drug O 0 0.0075511634
- O 0 0.0002684217
induced O 0 0.0001594597
behavioral O 0 0.0006026286
and O 0 0.00021005166
neurophysiological O 0 0.0007892148
responses O 0 0.00050974364
in O 0 0.0006785832
rodents O 0 0.002421159
. O 0 0.0019009743

Apomorphine B-Chemical 0 0.9997961
, O 0 0.0032484173
a O 0 0.0023584047
nonselective O 0 0.9738184
dopamine B-Chemical 0 0.9999193
agonist I-Chemical 0 0.9317941
, O 0 0.000511043
was O 0 0.00018904064
selected O 0 9.89793e-05
due O 0 5.8650014e-05
to O 0 7.127396e-05
its O 0 0.00015554213
biphasic O 0 0.00038066218
behavioral O 0 0.000464852
effects O 0 0.0001451911
, O 0 0.00011726592
its O 0 0.0001316555
ability O 0 8.439588e-05
to O 0 7.964088e-05
induce O 0 0.0001091285
hypothermia B-Disease 0 0.9994843
, O 0 0.00020514378
and O 0 8.700817e-05
to O 0 5.205894e-05
produce O 0 3.987783e-05
distinct O 0 4.475165e-05
changes O 0 0.000115064206
to O 0 0.00016319746
dopamine B-Chemical 0 0.99832374
turnover O 0 0.0010638945
in O 0 0.00025048747
the O 0 0.00037649967
rodent O 0 0.0010660965
brain O 0 0.006502353
. O 0 0.0020024811

From O 0 0.0017441357
such O 0 0.0008967761
experiments O 0 0.0006016989
there O 0 0.00035625548
is O 0 0.00034564675
evidence O 0 0.00018687447
that O 0 0.00012380637
characterization O 0 0.00016077039
and O 0 0.0001503112
detection O 0 0.00024235665
of O 0 0.00080216967
apomorphine B-Chemical 1 0.9999908
- O 0 0.0008607931
induced O 0 0.00017328783
activity O 0 0.000121066245
in O 0 0.000102861326
rodents O 0 0.0001765703
critically O 0 0.00014986841
depends O 0 5.8566075e-05
upon O 0 0.00010199478
the O 0 0.00023758046
test O 0 0.0004769985
conditions O 0 0.00076052675
employed O 0 0.001580943
. O 0 0.0020867197

In O 0 0.0021156229
rats O 0 0.0022060699
, O 0 0.0011802701
detection O 0 0.00097140303
of O 0 0.0020821323
apomorphine B-Chemical 1 0.9999765
- O 0 0.0034669144
induced O 0 0.0014600082
hyperactivity B-Disease 2 0.9999635
was O 0 0.0004395778
facilitated O 0 0.0001946761
by O 0 0.00013223919
a O 0 0.00013191639
period O 0 5.8482965e-05
of O 0 0.00016672858
acclimatization O 0 0.0011346503
to O 0 0.00024396005
the O 0 0.0004279654
test O 0 0.00088620244
conditions O 0 0.0015787001
. O 0 0.0020862066

Moreover O 0 0.0031079694
, O 0 0.0023213706
test O 0 0.0014099744
conditions O 0 0.0006779219
can O 0 0.00026644664
impact O 0 0.00015095109
upon O 0 0.00013929576
other O 0 0.00015958563
physiological O 0 0.00027745953
responses O 0 0.000262895
to O 0 0.00033996132
apomorphine B-Chemical 1 0.9999354
such O 0 0.00030011236
as O 0 0.00039561515
drug O 0 0.024245061
- O 0 0.0015478455
induced O 0 0.0025131004
hypothermia B-Disease 0 0.9993006
. O 0 0.0038444095

In O 0 0.001986715
mice O 0 0.0013176402
, O 0 0.0022886253
apomorphine B-Chemical 1 0.99980515
produced O 0 0.0006112444
qualitatively O 0 0.0004363816
different O 0 0.00013263432
responses O 0 0.00016541142
under O 0 8.6717024e-05
novel O 0 0.00012404176
conditions O 0 0.00011528813
when O 0 5.7466674e-05
compared O 0 5.910339e-05
to O 0 8.465598e-05
those O 0 0.0001627133
behaviors O 0 0.00030853125
elicited O 0 0.00016612318
in O 0 0.00021213884
the O 0 0.0003314192
home O 0 0.0007391332
test O 0 0.001148303
cage O 0 0.0036169689
. O 0 0.0021356328

Drug O 0 0.2629429
- O 0 0.0034477168
induced O 0 0.001117511
gross O 0 0.0011225262
activity O 0 0.00044093508
counts O 0 0.00040398672
were O 0 0.00023616754
increased O 0 0.00024973636
in O 0 0.00012237653
the O 0 0.00010504973
novel O 0 0.00014091977
exploratory O 0 0.00047809465
box O 0 0.00026571297
only O 0 0.00014677127
, O 0 0.00012206583
while O 0 8.1066915e-05
measures O 0 5.8801445e-05
of O 0 0.00020058622
stereotypic O 0 0.03364482
behavior O 0 0.00036959682
were O 0 0.00024893615
similar O 0 0.00023558126
in O 0 0.00051677873
both O 0 0.001191306
. O 0 0.0019245754

By O 0 0.002812519
contrast O 0 0.0035492056
, O 0 0.0050065913
apomorphine B-Chemical 1 0.999938
- O 0 0.0037415563
induced O 0 0.0010081494
locomotion O 0 0.010092706
was O 0 0.00045092232
more O 0 0.00040813512
prominent O 0 0.0005950876
in O 0 0.00030549048
the O 0 0.0003931232
novel O 0 0.0008095056
exploratory O 0 0.0033101533
box O 0 0.0034853646
. O 0 0.0025233077

Dopamine B-Chemical 1 0.99767786
turnover O 0 0.0064621298
ratios O 0 0.0024789174
( O 0 0.0040022866
DOPAC B-Chemical 1 0.9999882
: O 0 0.0031657773
DA B-Chemical 0 0.99965894
and O 0 0.0030431976
HVA B-Chemical 0 0.9999975
: O 0 0.0023396648
DA B-Chemical 0 0.99976903
) O 0 0.00045442156
were O 0 0.00011119302
found O 0 6.825766e-05
to O 0 6.3354564e-05
be O 0 6.507097e-05
lower O 0 9.580211e-05
in O 0 6.426522e-05
those O 0 8.552614e-05
animals O 0 4.3229444e-05
exposed O 0 5.6173234e-05
to O 0 5.429341e-05
the O 0 7.582779e-05
exploratory O 0 0.0003202296
box O 0 0.00017969134
when O 0 6.626172e-05
compared O 0 8.4295185e-05
to O 0 0.00015329248
their O 0 0.00034695677
home O 0 0.00067181315
cage O 0 0.0020386407
counterparts O 0 0.0017204505
. O 0 0.0019415737

However O 0 0.0036630123
, O 0 0.0056521394
apomorphine B-Chemical 1 0.9998951
- O 0 0.002915119
induced O 0 0.0006400299
reductions O 0 0.00056244206
in O 0 0.00041180116
striatal O 0 0.88755256
dopamine B-Chemical 0 0.9997967
turnover O 0 0.0016327392
were O 0 0.00016844222
detected O 0 9.9249395e-05
in O 0 0.00011617052
both O 0 0.00016277473
novel O 0 0.00029948354
and O 0 0.00039155997
home O 0 0.00072414224
cage O 0 0.0018974601
environments O 0 0.0017546996
. O 0 0.0020495981

The O 0 0.0014575981
implications O 0 0.0010394017
of O 0 0.0010371835
these O 0 0.00084176275
findings O 0 0.00085719506
are O 0 0.0003295166
discussed O 0 0.00023239816
with O 0 0.00023632252
particular O 0 0.00011415481
emphasis O 0 0.00016164564
upon O 0 0.0001101884
conducting O 0 0.00021011253
psychopharmacological O 0 0.005416848
challenge O 0 0.00036872478
tests O 0 0.0010692897
in O 0 0.000813272
rodents O 0 0.0027947156
. O 0 0.0021536765

Hemolysis B-Disease 0 0.99403834
of O 0 0.003258461
human O 0 0.002335456
erythrocytes O 0 0.08619575
induced O 0 0.0013745872
by O 0 0.0013748856
tamoxifen B-Chemical 1 0.9983675
is O 0 0.00043773247
related O 0 0.00016073545
to O 0 0.00025573734
disruption O 0 0.00047069587
of O 0 0.00080677564
membrane O 0 0.002087246
structure O 0 0.0022024014
. O 0 0.002402829

Tamoxifen B-Chemical 0 0.99855226
( O 0 0.013250787
TAM B-Chemical 1 0.9993674
) O 0 0.0025959774
, O 0 0.00074162136
the O 0 0.0005322248
antiestrogenic O 0 0.8382635
drug O 0 0.022450596
most O 0 0.00037337147
widely O 0 0.00012611004
prescribed O 0 0.0003088647
in O 0 6.7328234e-05
the O 0 8.419556e-05
chemotherapy O 0 0.0010109165
of O 0 0.0005694368
breast B-Disease 0 0.9992804
cancer I-Disease 0 0.99988294
, O 0 0.00025032662
induces O 0 7.0368595e-05
changes O 0 0.00011887238
in O 0 8.653678e-05
normal O 0 0.0003582366
discoid O 0 0.10401695
shape O 0 0.00022102932
of O 0 0.00042857003
erythrocytes O 0 0.17657477
and O 0 0.003996835
hemolytic B-Disease 2 0.9999876
anemia I-Disease 2 0.9999876
. O 0 0.010430507

This O 0 0.0033615283
work O 0 0.0014328366
evaluates O 0 0.000718524
the O 0 0.00050932134
effects O 0 0.00057280395
of O 0 0.0011511752
TAM B-Chemical 1 0.99956197
on O 0 0.000182376
isolated O 0 0.00019660342
human O 0 0.00036261944
erythrocytes O 0 0.057865366
, O 0 0.00017016742
attempting O 0 0.00018436833
to O 0 6.124382e-05
identify O 0 4.538159e-05
the O 0 5.2847507e-05
underlying O 0 9.4877345e-05
mechanisms O 0 0.00010550872
on O 0 9.797414e-05
TAM B-Chemical 1 0.9998963
- O 0 0.0012447129
induced O 0 0.0023637142
hemolytic B-Disease 2 0.9999989
anemia I-Disease 2 0.9999988
and O 0 0.00064524973
the O 0 0.00016441154
involvement O 0 0.00025463395
of O 0 0.00030587395
biomembranes O 0 0.37660682
in O 0 0.00022516288
its O 0 0.0005891653
cytostatic O 0 0.03929408
action O 0 0.0014496344
mechanisms O 0 0.0018988675
. O 0 0.0020619396

TAM B-Chemical 1 0.9976174
induces O 0 0.005574076
hemolysis B-Disease 0 0.9995346
of O 0 0.0052631535
erythrocytes O 0 0.18023445
as O 0 0.0012057172
a O 0 0.0013432634
function O 0 0.0013316193
of O 0 0.0022454753
concentration O 0 0.0062197833
. O 0 0.0042315833

The O 0 0.0017569093
extension O 0 0.0019021047
of O 0 0.0027608604
hemolysis B-Disease 0 0.9996425
is O 0 0.0008080493
variable O 0 0.00030685507
with O 0 0.00045411242
erythrocyte O 0 0.0749014
samples O 0 0.0003228102
, O 0 0.0002215807
but O 0 0.00014987442
12 O 0 6.89153e-05
. O 0 6.896079e-05
5 O 0 0.00010525739
microM O 0 0.14073403
TAM B-Chemical 1 0.99955326
induces O 0 0.00027128702
total O 0 0.0008011536
hemolysis B-Disease 0 0.9998827
of O 0 0.0011259795
all O 0 0.0006606643
tested O 0 0.00086015975
suspensions O 0 0.004952606
. O 0 0.0024033913

Despite O 0 0.0022266516
inducing O 0 0.0025354174
extensive O 0 0.0018995163
erythrocyte O 0 0.3123923
lysis O 0 0.042342696
, O 0 0.002434421
TAM B-Chemical 1 0.99953365
does O 0 0.00047291638
not O 0 0.0002856745
shift O 0 0.00047031062
the O 0 0.00032226133
osmotic O 0 0.0039215307
fragility O 0 0.23582909
curves O 0 0.0009610847
of O 0 0.0016529559
erythrocytes O 0 0.12783073
. O 0 0.0030209566

The O 0 0.0032278055
hemolytic B-Disease 0 0.9981394
effect O 0 0.0020079757
of O 0 0.0039961897
TAM B-Chemical 1 0.9997805
is O 0 0.00079199707
prevented O 0 0.0011522576
by O 0 0.00027663197
low O 0 0.00038915526
concentrations O 0 0.0005954541
of O 0 0.0006154105
alpha B-Chemical 0 0.99532086
- I-Chemical 0 0.03205521
tocopherol I-Chemical 0 0.99999905
( O 0 0.0051869266
alpha B-Chemical 0 0.99289304
- I-Chemical 0 0.002890216
T I-Chemical 0 0.9766153
) O 0 0.0004264226
and O 0 0.00025610166
alpha B-Chemical 0 0.9814734
- I-Chemical 0 0.017777724
tocopherol I-Chemical 0 0.9999993
acetate I-Chemical 0 0.9997737
( O 0 0.0029759237
alpha B-Chemical 0 0.99081296
- I-Chemical 0 0.0021369683
TAc I-Chemical 0 0.90660095
) O 0 0.00034471214
( O 0 0.00013594866
inactivated O 0 0.0001422234
functional O 0 0.0003529865
hydroxyl B-Chemical 0 0.9998041
) O 0 0.0004687973
indicating O 0 9.2527036e-05
that O 0 0.00017414453
TAM B-Chemical 1 0.9999174
- O 0 0.0013938758
induced O 0 0.0010321367
hemolysis B-Disease 0 0.9999639
is O 0 0.00033724718
not O 0 0.00015407
related O 0 0.00011502569
to O 0 0.0003444615
oxidative O 0 0.46336043
membrane O 0 0.005378011
damage O 0 0.4371991
. O 0 0.0026603164

This O 0 0.0042196293
was O 0 0.0019182522
further O 0 0.0013272087
evidenced O 0 0.0014248779
by O 0 0.00044578535
absence O 0 0.00022341718
of O 0 0.0006006743
oxygen B-Chemical 1 0.994712
consumption O 0 0.01637245
and O 0 0.0004047841
hemoglobin O 0 0.95803446
oxidation O 0 0.947181
both O 0 0.00018117279
determined O 0 0.000115972405
in O 0 0.00012264593
parallel O 0 0.00024692802
with O 0 0.000857557
TAM B-Chemical 1 0.9997323
- O 0 0.0038684628
induced O 0 0.0053321877
hemolysis B-Disease 0 0.9998522
. O 0 0.0052861557

Furthermore O 0 0.0030964261
, O 0 0.0023161112
it O 0 0.0011841581
was O 0 0.00073453784
observed O 0 0.00038926027
that O 0 0.0004309377
TAM B-Chemical 1 0.9994752
inhibits O 0 0.00040123105
the O 0 0.00087672606
peroxidation O 0 0.9999877
of O 0 0.000710327
human O 0 0.00052168965
erythrocytes O 0 0.11178816
induced O 0 0.00046517185
by O 0 0.0012593092
AAPH B-Chemical 0 0.9999988
, O 0 0.0007132761
thus O 0 0.00042467262
ruling O 0 0.0041927984
out O 0 0.00037384478
TAM B-Chemical 1 0.99980754
- O 0 0.0014840601
induced O 0 0.0009459299
cell O 0 0.009632057
oxidative O 0 0.9087638
stress O 0 0.15055814
. O 0 0.0029587746

Hemolysis B-Disease 0 0.99643445
caused O 0 0.004152963
by O 0 0.00350347
TAM B-Chemical 1 0.99943525
was O 0 0.00092076877
not O 0 0.00031600546
preceded O 0 0.0003129904
by O 0 0.00023880316
the O 0 0.00024581156
leakage O 0 0.054438453
of O 0 0.001225331
K B-Chemical 1 0.99989104
( O 0 0.00081392995
+ O 0 0.0005251687
) O 0 0.00019556707
from O 0 7.286226e-05
the O 0 9.32732e-05
cells O 0 0.00016009226
, O 0 0.00010263754
also O 0 7.779191e-05
excluding O 0 0.00014066348
a O 0 0.00017257845
colloid O 0 0.056227434
- O 0 0.00028700317
osmotic O 0 0.0007468505
type O 0 9.624787e-05
mechanism O 0 0.00010906672
of O 0 0.00037858574
hemolysis B-Disease 0 0.9999474
, O 0 0.0002247127
according O 0 6.1792045e-05
to O 0 7.3479845e-05
the O 0 0.00010108723
effects O 0 0.00018479797
on O 0 0.00021429213
osmotic O 0 0.006209482
fragility O 0 0.49807715
curves O 0 0.002326352
. O 0 0.0021626202

However O 0 0.0038213094
, O 0 0.0046202745
TAM B-Chemical 1 0.9978961
induces O 0 0.0010093603
release O 0 0.002244179
of O 0 0.0006730828
peripheral O 0 0.0019368717
proteins O 0 0.00032604512
of O 0 0.00031030088
membrane O 0 0.00066949555
- O 0 0.00035862633
cytoskeleton O 0 0.00043429295
and O 0 0.00019260177
cytosol O 0 0.00035203615
proteins O 0 0.00018483688
essentially O 0 0.0002104281
bound O 0 0.000253386
to O 0 0.00046602378
band O 0 0.0030044112
3 O 0 0.0011435818
. O 0 0.001813709

Either O 0 0.016393188
alpha B-Chemical 0 0.9739034
- I-Chemical 0 0.010255492
T I-Chemical 0 0.93995756
or O 0 0.0018154398
alpha B-Chemical 0 0.9754741
- I-Chemical 0 0.003108426
TAc I-Chemical 0 0.5174103
increases O 0 0.00043260833
membrane O 0 0.00081809226
packing O 0 0.0018477344
and O 0 0.00031736412
prevents O 0 0.0007013431
TAM B-Chemical 1 0.99931705
partition O 0 0.0012451636
into O 0 0.00028420592
model O 0 0.0009960058
membranes O 0 0.0038876936
. O 0 0.0022685686

These O 0 0.0019875227
effects O 0 0.0012485577
suggest O 0 0.00042920685
that O 0 0.00035651316
the O 0 0.0004122656
protection O 0 0.0009811718
from O 0 0.00067697867
hemolysis B-Disease 0 0.99996173
by O 0 0.005847581
tocopherols B-Chemical 0 0.9999974
is O 0 0.00032513286
related O 0 5.979747e-05
to O 0 8.5633874e-05
a O 0 0.00018504461
decreased O 0 0.0011120045
TAM B-Chemical 1 0.9998658
incorporation O 0 0.0009862488
in O 0 0.000106853426
condensed O 0 0.00044112315
membranes O 0 0.00030941586
and O 0 7.863351e-05
the O 0 7.945646e-05
structural O 0 0.00021632964
damage O 0 0.0139966095
of O 0 0.00024016542
the O 0 0.00026246294
erythrocyte O 0 0.06731182
membrane O 0 0.0010376193
is O 0 0.0005207631
consequently O 0 0.0011527434
avoided O 0 0.0015584417
. O 0 0.0019296986

Therefore O 0 0.002712012
, O 0 0.005262272
TAM B-Chemical 1 0.99933285
- O 0 0.0047146156
induced O 0 0.0023642327
hemolysis B-Disease 0 0.9998584
results O 0 0.0006021615
from O 0 0.00021277534
a O 0 0.00021920804
structural O 0 0.00021885114
perturbation O 0 0.00017276796
of O 0 0.00025045098
red O 0 0.0031755024
cell O 0 0.0009954302
membrane O 0 0.00046960457
, O 0 0.00012558229
leading O 0 0.0001251061
to O 0 6.256887e-05
changes O 0 8.16977e-05
in O 0 4.726753e-05
the O 0 4.413937e-05
framework O 0 4.8683283e-05
of O 0 8.9324465e-05
the O 0 0.00010235527
erythrocyte O 0 0.0308057
membrane O 0 0.00029561814
and O 0 9.241373e-05
its O 0 0.00015810781
cytoskeleton O 0 0.00032424228
caused O 0 0.00015740594
by O 0 0.00015366521
its O 0 0.00027060375
high O 0 0.00038907368
partition O 0 0.00059302297
in O 0 0.00035594637
the O 0 0.0006699992
membrane O 0 0.0025515652
. O 0 0.0019195725

These O 0 0.0024567167
defects O 0 0.0025550951
explain O 0 0.00075256923
the O 0 0.0006289027
abnormal O 0 0.002847264
erythrocyte O 0 0.0429796
shape O 0 0.00042100943
and O 0 0.0002729841
decreased O 0 0.00043179217
mechanical O 0 0.0003023931
stability O 0 0.00029790247
promoted O 0 0.0007154564
by O 0 0.0007562192
TAM B-Chemical 1 0.9997043
, O 0 0.0007127176
resulting O 0 0.000866392
in O 0 0.0025884334
hemolytic B-Disease 2 0.999985
anemia I-Disease 2 0.9999865
. O 0 0.011291336

Additionally O 0 0.002696389
, O 0 0.0019011897
since O 0 0.0007421131
membrane O 0 0.0021737928
leakage O 0 0.026926456
is O 0 0.00039764008
a O 0 0.00031269033
final O 0 0.00033451352
stage O 0 0.00062792766
of O 0 0.0005568237
cytotoxicity O 0 0.9876338
, O 0 0.00025478163
the O 0 9.844998e-05
disruption O 0 9.853347e-05
of O 0 9.256983e-05
the O 0 6.3820204e-05
structural O 0 0.00010024259
characteristics O 0 3.966649e-05
of O 0 0.00015283696
biomembranes O 0 0.581741
by O 0 0.000358177
TAM B-Chemical 1 0.9995677
may O 0 0.00010255527
contribute O 0 6.814923e-05
to O 0 7.0603855e-05
the O 0 8.915434e-05
multiple O 0 0.00013834269
mechanisms O 0 0.00019357092
of O 0 0.00035354288
its O 0 0.0009948452
anticancer O 0 0.064810224
action O 0 0.0030870496
. O 0 0.002378066

Changes O 0 0.0025603885
of O 0 0.003336688
sodium B-Chemical 0 0.99883455
and O 0 0.0034280755
ATP B-Chemical 0 0.99668807
affinities O 0 0.002155419
of O 0 0.0004846848
the O 0 0.00037730613
cardiac O 0 0.08982101
( O 0 0.0020594366
Na B-Chemical 1 0.9999585
, O 0 0.0030880724
K B-Chemical 1 0.9998708
) O 0 0.0014320716
- O 0 0.0006712896
ATPase O 0 0.0016054552
during O 0 9.2132505e-05
and O 0 0.00018199641
after O 0 0.00017555532
nitric B-Chemical 0 0.99340856
oxide I-Chemical 0 0.9771295
deficient O 0 0.006874613
hypertension B-Disease 2 0.99985313
. O 0 0.0034410798

In O 0 0.0022836395
the O 0 0.0022778884
cardiovascular O 0 0.35303777
system O 0 0.0018715033
, O 0 0.0018658362
NO B-Chemical 0 0.9914152
is O 0 0.00052696886
involved O 0 0.00022092104
in O 0 0.00021401707
the O 0 0.00021089413
regulation O 0 0.0001729567
of O 0 0.00040830075
a O 0 0.0006291784
variety O 0 0.0007620074
of O 0 0.0011846636
functions O 0 0.0018205261
. O 0 0.0024306604

Inhibition O 0 0.010398536
of O 0 0.008856776
NO B-Chemical 0 0.9912838
synthesis O 0 0.017601775
induces O 0 0.004554773
sustained O 0 0.05683151
hypertension B-Disease 2 0.9997303
. O 0 0.011111399

In O 0 0.001740576
several O 0 0.0010365997
models O 0 0.0012254694
of O 0 0.0022889804
hypertension B-Disease 2 0.9998783
, O 0 0.0011436462
elevation O 0 0.01345923
of O 0 0.0006405259
intracellular O 0 0.0014970781
sodium B-Chemical 0 0.99959093
level O 0 0.00047286568
was O 0 0.0005170152
documented O 0 0.000678299
in O 0 0.0006790926
cardiac O 0 0.063322484
tissue O 0 0.008215022
. O 0 0.002462843

To O 0 0.0017373824
assess O 0 0.0007559796
the O 0 0.0007778744
molecular O 0 0.0017629459
basis O 0 0.00050259917
of O 0 0.0005041833
disturbances O 0 0.006490874
in O 0 0.00025876472
transmembraneous O 0 0.0012255517
transport O 0 0.0005673503
of O 0 0.0007225344
Na B-Chemical 1 0.999964
+ O 0 0.0010395943
, O 0 0.00014178264
we O 0 4.4026372e-05
studied O 0 7.838906e-05
the O 0 5.6064702e-05
response O 0 7.209562e-05
of O 0 0.00017242417
cardiac O 0 0.097872585
( O 0 0.0013158281
Na B-Chemical 1 0.9999776
, O 0 0.0020386898
K B-Chemical 1 0.9999213
) O 0 0.0010564765
- O 0 0.0005548643
ATPase O 0 0.00627806
to O 0 0.00019651063
NO B-Chemical 0 0.99901986
- O 0 0.00068913517
deficient O 0 0.00054077466
hypertension B-Disease 2 0.9999633
induced O 0 0.00025111568
in O 0 0.00010865108
rats O 0 0.00018751794
by O 0 0.00017995402
NO B-Chemical 0 0.9977671
- O 0 0.0005389439
synthase O 0 0.03771562
inhibition O 0 0.00023513313
with O 0 9.8485194e-05
40 O 0 9.2624054e-05
mg O 0 0.0016038341
/ O 0 0.00031877536
kg O 0 0.00022782227
/ O 0 0.00023181854
day O 0 8.943015e-05
N B-Chemical 0 0.86547804
( I-Chemical 0 0.0004821026
G I-Chemical 0 0.9042151
) I-Chemical 0 0.00067954493
- I-Chemical 0 0.0010969993
nitro I-Chemical 0 0.99981815
- I-Chemical 0 0.0032767318
L I-Chemical 0 0.98251975
- I-Chemical 0 0.0019405753
arginine I-Chemical 0 0.92731273
methyl I-Chemical 0 0.99895597
ester I-Chemical 0 0.99821174
( O 0 0.0029939972
L B-Chemical 0 0.9931356
- I-Chemical 0 0.008575304
NAME I-Chemical 0 0.99992
) O 0 0.00072948274
for O 0 0.00023540613
4 O 0 0.0002765882
four O 0 0.00033154624
weeks O 0 0.0005253807
. O 0 0.001566501

After O 0 0.0012578717
4 O 0 0.0013115491
- O 0 0.0013867823
week O 0 0.000422088
administration O 0 0.0012984179
of O 0 0.0013742853
L B-Chemical 0 0.9896304
- I-Chemical 0 0.010112716
NAME I-Chemical 0 0.99989915
, O 0 0.00042161508
the O 0 0.00022115537
systolic O 0 0.055023976
blood O 0 0.0026339625
pressure O 0 0.0035324504
( O 0 0.00049385394
SBP O 0 0.039608173
) O 0 0.00056918355
increased O 0 0.00066723494
by O 0 0.0007376391
36 O 0 0.0010009
% O 0 0.0016006519
. O 0 0.0021535608

Two O 0 0.0019273858
weeks O 0 0.00067305285
after O 0 0.00043898905
terminating O 0 0.0011143635
the O 0 0.000588226
treatment O 0 0.00057283475
, O 0 0.0005548087
the O 0 0.00048815995
SBP O 0 0.01713302
recovered O 0 0.0005510784
to O 0 0.0006173601
control O 0 0.0010756268
value O 0 0.0022007895
. O 0 0.0028718505

When O 0 0.0017777442
activating O 0 0.0021131318
the O 0 0.0016904755
( O 0 0.0040379586
Na B-Chemical 1 0.9998361
, O 0 0.0060643614
K B-Chemical 1 0.99980074
) O 0 0.0027137797
- O 0 0.0012004394
ATPase O 0 0.0056206062
with O 0 0.00029168412
its O 0 0.0005134488
substrate O 0 0.0018622474
ATP B-Chemical 0 0.9978089
, O 0 0.00023103389
no O 0 7.068677e-05
changes O 0 0.00014783762
in O 0 0.00014131618
Km O 0 0.015389086
and O 0 0.00021337629
Vmax O 0 0.022482403
values O 0 0.00016515833
were O 0 0.0001444585
observed O 0 0.00016365403
in O 0 0.00039733338
NO B-Chemical 0 0.9936593
- O 0 0.0016127541
deficient O 0 0.0013627457
rats O 0 0.002669835
. O 0 0.0020397827

During O 0 0.0011744434
activation O 0 0.0020986043
with O 0 0.0037143575
Na B-Chemical 1 0.9998178
+ O 0 0.0035053317
, O 0 0.0006237481
the O 0 0.00040865334
Vmax O 0 0.049835525
remained O 0 0.00037049217
unchanged O 0 0.00023672936
, O 0 0.00018591776
however O 0 0.00019907756
the O 0 0.0003334717
K B-Chemical 1 0.9998524
( O 0 0.0028439064
Na B-Chemical 1 0.9999708
) O 0 0.00062727503
increased O 0 0.00026947993
by O 0 0.000144878
50 O 0 0.0002233401
% O 0 0.000124768
, O 0 0.000102564954
indicating O 0 5.908958e-05
a O 0 0.00011344361
profound O 0 0.0004164228
decrease O 0 0.00016293529
in O 0 7.798354e-05
the O 0 8.133072e-05
affinity O 0 0.00032425093
of O 0 0.00020462004
the O 0 0.00045021344
Na B-Chemical 1 0.99996996
+ O 0 0.0017344771
- O 0 0.0004367512
binding O 0 0.00019104236
site O 0 0.00020386987
in O 0 0.00044520842
NO B-Chemical 0 0.99491876
- O 0 0.0015616087
deficient O 0 0.0012980729
rats O 0 0.0025429367
. O 0 0.001975052

After O 0 0.00104362
recovery O 0 0.0024518229
from O 0 0.0017599227
hypertension B-Disease 2 0.9997111
, O 0 0.00081665016
the O 0 0.00031586632
activity O 0 0.00026419075
of O 0 0.00051785907
( O 0 0.00148144
Na B-Chemical 1 0.9999573
, O 0 0.0032832478
K B-Chemical 1 0.9999112
) O 0 0.0017119575
- O 0 0.00083173695
ATPase O 0 0.008013229
increased O 0 0.0002913467
, O 0 0.00012693164
due O 0 5.0087907e-05
to O 0 6.281806e-05
higher O 0 0.000110785564
affinity O 0 0.00036361435
of O 0 0.0001998232
the O 0 0.0003206255
ATP B-Chemical 0 0.9990283
- O 0 0.0005804302
binding O 0 0.00014362218
site O 0 0.00010260398
, O 0 0.0001256369
as O 0 8.3035506e-05
revealed O 0 8.989262e-05
from O 0 9.565561e-05
the O 0 0.00018498393
lowered O 0 0.0026513515
Km O 0 0.04128563
value O 0 0.0008061036
for O 0 0.0011082771
ATP B-Chemical 0 0.9860793
. O 0 0.0035218853

The O 0 0.0054576877
K B-Chemical 1 0.9979081
( O 0 0.012127457
Na B-Chemical 1 0.9995478
) O 0 0.0031113073
value O 0 0.0012373263
for O 0 0.0011875377
Na B-Chemical 1 0.9995685
+ O 0 0.002251796
returned O 0 0.000904371
to O 0 0.0008546232
control O 0 0.0013736212
value O 0 0.0026782227
. O 0 0.0034280398

Inhibition O 0 0.0055475095
of O 0 0.004810719
NO B-Chemical 0 0.99820197
- O 0 0.005047988
synthase O 0 0.120485276
induced O 0 0.0007061164
a O 0 0.0008240827
reversible O 0 0.4543797
hypertension B-Disease 2 0.9999746
accompanied O 0 0.0052778777
by O 0 0.0007156606
depressed B-Disease 2 0.997767
Na B-Chemical 1 0.9999889
+ O 0 0.002544357
- O 0 0.0004607906
extrusion O 0 0.0034589204
from O 0 9.426968e-05
cardiac O 0 0.005095446
cells O 0 0.00015509369
as O 0 6.30413e-05
a O 0 8.051914e-05
consequence O 0 4.975613e-05
of O 0 0.00021729691
deteriorated O 0 0.38472322
Na B-Chemical 1 0.9999831
+ O 0 0.0013462859
- O 0 0.0002570356
binding O 0 8.736401e-05
properties O 0 6.8506764e-05
of O 0 0.00015408309
the O 0 0.00023249365
( O 0 0.0009786135
Na B-Chemical 1 0.9998989
, O 0 0.003558963
K B-Chemical 1 0.99958795
) O 0 0.0036723623
- O 0 0.0032162901
ATPase O 0 0.019948425
. O 0 0.0027342776

After O 0 0.0009494496
recovery O 0 0.0017757599
of O 0 0.001110715
blood O 0 0.003163607
pressure O 0 0.0025727588
to O 0 0.00025152785
control O 0 0.00020279658
values O 0 0.00020205064
, O 0 0.00017650094
the O 0 0.00015391201
extrusion O 0 0.0058100517
of O 0 0.00078443787
Na B-Chemical 1 0.99996483
+ O 0 0.0007377079
from O 0 0.00012407891
cardiac O 0 0.009484369
cells O 0 0.00019657418
was O 0 8.962958e-05
normalized O 0 5.3442283e-05
, O 0 9.717608e-05
as O 0 6.6695466e-05
revealed O 0 7.0317205e-05
by O 0 7.8166464e-05
restoration O 0 0.00014881718
of O 0 0.00016003943
the O 0 0.0002207976
( O 0 0.00092864584
Na B-Chemical 1 0.9999286
, O 0 0.0029616994
K B-Chemical 1 0.9997043
) O 0 0.002441881
- O 0 0.0018709449
ATPase O 0 0.008594834
activity O 0 0.0017764557
. O 0 0.0023542384

Effects O 0 0.0027817835
of O 0 0.0017914514
long O 0 0.0010350317
- O 0 0.0010401173
term O 0 0.0004103268
pretreatment O 0 0.008448983
with O 0 0.0010226843
isoproterenol B-Chemical 0 0.99983215
on O 0 0.0006125873
bromocriptine B-Chemical 0 0.99997497
- O 0 0.0015059226
induced O 0 0.00083540776
tachycardia B-Disease 2 0.9889338
in O 0 0.0007546487
conscious O 0 0.005396187
rats O 0 0.0023804258
. O 0 0.0018492409

It O 0 0.0025474376
has O 0 0.00097544893
been O 0 0.0005513657
shown O 0 0.00038346392
that O 0 0.00053847453
bromocriptine B-Chemical 0 0.9999558
- O 0 0.0018173591
induced O 0 0.0007328632
tachycardia B-Disease 2 0.99515414
, O 0 0.00025155972
which O 0 0.00013808321
persisted O 0 6.506719e-05
after O 0 4.513566e-05
adrenalectomy O 0 0.16618948
, O 0 0.00016917185
is O 0 0.000113567214
( O 0 0.00014467395
i O 0 0.00023278824
) O 0 0.000113877795
mediated O 0 3.9573737e-05
by O 0 8.401871e-05
central O 0 0.00035795994
dopamine B-Chemical 0 0.9999546
D2 O 0 0.99977523
receptor O 0 0.012634881
activation O 0 0.00018248575
and O 0 0.00012187578
( O 0 0.00014496644
ii O 0 0.00021778245
) O 0 0.00014529524
reduced O 0 0.00013825897
by O 0 8.657524e-05
5 O 0 5.476384e-05
- O 0 0.00011568778
day O 0 6.017008e-05
isoproterenol B-Chemical 0 0.99911064
pretreatment O 0 0.0684131
, O 0 0.00014348968
supporting O 0 7.290827e-05
therefore O 0 7.1284296e-05
the O 0 6.132536e-05
hypothesis O 0 8.530272e-05
that O 0 4.6266916e-05
this O 0 9.858827e-05
effect O 0 8.8988374e-05
is O 0 9.1030495e-05
dependent O 0 5.527308e-05
on O 0 0.00010282288
sympathetic O 0 0.00801498
outflow O 0 0.31410164
to O 0 0.0004231754
the O 0 0.0007978282
heart O 0 0.06860192
. O 0 0.0021414827

This O 0 0.0036483677
study O 0 0.0017310559
was O 0 0.0008515801
conducted O 0 0.00039022663
to O 0 0.00022619378
examine O 0 9.7741875e-05
whether O 0 8.8543646e-05
prolonged O 0 0.0003932283
pretreatment O 0 0.023759898
with O 0 0.0008356681
isoproterenol B-Chemical 0 0.9998797
could O 0 0.00025942476
abolish O 0 0.0008119267
bromocriptine B-Chemical 0 0.9999808
- O 0 0.0011070457
induced O 0 0.0006526246
tachycardia B-Disease 2 0.9878036
in O 0 0.00063033146
conscious O 0 0.004806351
rats O 0 0.0021259978
. O 0 0.0016695568

Isoproterenol B-Chemical 0 0.9996414
pretreatment O 0 0.09019135
for O 0 0.0008049906
15 O 0 0.0004070767
days O 0 0.00020077662
caused O 0 0.00048458733
cardiac B-Disease 0 0.86380756
hypertrophy I-Disease 2 0.99988544
without O 0 0.00046886568
affecting O 0 0.00041821116
baseline O 0 0.00024277087
blood O 0 0.0018845774
pressure O 0 0.0029903955
and O 0 0.0006924512
heart O 0 0.024092875
rate O 0 0.0020101822
. O 0 0.0021514273

In O 0 0.0016075859
control O 0 0.0012442394
rats O 0 0.0014530286
, O 0 0.0010886758
intravenous O 0 0.15018933
bromocriptine B-Chemical 0 0.9999374
( O 0 0.00085049355
150 O 0 0.00043098576
microg O 0 0.0005697243
/ O 0 0.0010247862
kg O 0 0.00082186266
) O 0 0.00042021606
induced O 0 0.0004223279
significant O 0 0.0009110082
hypotension B-Disease 0 0.9996469
and O 0 0.004121175
tachycardia B-Disease 2 0.99719405
. O 0 0.0031834715

Bromocriptine B-Chemical 0 0.9994831
- O 0 0.0064061973
induced O 0 0.0027583435
hypotension B-Disease 0 0.99964976
was O 0 0.0011579032
unaffected O 0 0.001120774
by O 0 0.0005780289
isoproterenol B-Chemical 0 0.99988055
pretreatment O 0 0.34418982
, O 0 0.00035736235
while O 0 0.00024431924
tachycardia B-Disease 2 0.9871852
was O 0 0.00019394688
reversed O 0 0.0002974345
to O 0 8.6488995e-05
significant O 0 0.00015897464
bradycardia B-Disease 0 0.99163073
, O 0 0.00014406301
an O 0 9.5135816e-05
effect O 0 5.8789898e-05
that O 0 5.466408e-05
was O 0 9.700859e-05
partly O 0 0.00014978983
reduced O 0 0.00018163653
by O 0 0.00011734914
i O 0 0.00030731616
. O 0 7.679497e-05
v O 0 0.0008592345
. O 0 0.00018753385
domperidone B-Chemical 0 0.9999896
( O 0 0.00038405735
0 O 0 0.00013259386
. O 0 0.00010603906
5 O 0 0.0001742623
mg O 0 0.0023209024
/ O 0 0.0016801833
kg O 0 0.0022559478
) O 0 0.0022930696
. O 0 0.0022616412

Neither O 0 0.0036816911
cardiac O 0 0.028140636
vagal O 0 0.040753808
nor O 0 0.0013948
sympathetic O 0 0.023740172
tone O 0 0.015941916
was O 0 0.0010579005
altered O 0 0.0013358563
by O 0 0.0019864088
isoproterenol B-Chemical 0 0.9994578
pretreatment O 0 0.6821221
. O 0 0.004762359

In O 0 0.0014869537
isolated O 0 0.0011238605
perfused O 0 0.0052860756
heart O 0 0.017655699
preparations O 0 0.0008768962
from O 0 0.00049049535
isoproterenol B-Chemical 0 0.9998292
- O 0 0.0011354504
pretreated O 0 0.0013999329
rats O 0 0.00036009433
, O 0 0.00015867631
the O 0 0.0002038683
isoproterenol B-Chemical 0 0.9998573
- O 0 0.0004463281
induced O 0 0.00010253766
maximal O 0 7.506445e-05
increase O 0 5.8995727e-05
in O 0 4.949089e-05
left O 0 0.00021257577
ventricular O 0 0.47049168
systolic O 0 0.1512308
pressure O 0 0.0020625463
was O 0 8.433586e-05
significantly O 0 9.4525785e-05
reduced O 0 0.00013567311
, O 0 7.515784e-05
compared O 0 3.654922e-05
with O 0 0.000100823534
saline O 0 0.0008919826
- O 0 0.00017931957
pretreated O 0 0.0004036199
rats O 0 0.00017274688
( O 0 9.819299e-05
the O 0 7.428506e-05
EC50 O 0 0.16852708
of O 0 0.00016537013
the O 0 0.0002334172
isoproterenol B-Chemical 0 0.99991417
- O 0 0.00046614502
induced O 0 0.000106037434
increase O 0 7.541494e-05
in O 0 6.2948835e-05
left O 0 0.00028657223
ventricular O 0 0.5333594
systolic O 0 0.14347288
pressure O 0 0.0015241228
was O 0 0.00013274718
enhanced O 0 0.0001862721
approximately O 0 0.00027419967
22 O 0 0.0004905971
- O 0 0.00083461177
fold O 0 0.0014063757
) O 0 0.0021718845
. O 0 0.0021071115

These O 0 0.0019849553
results O 0 0.0011987471
show O 0 0.00057597295
that O 0 0.00036852335
15 O 0 0.00034671772
- O 0 0.00051314884
day O 0 0.00021683496
isoproterenol B-Chemical 0 0.99905556
pretreatment O 0 0.050943844
not O 0 0.00017052071
only O 0 0.00016817966
abolished O 0 0.00041054122
but O 0 0.0002626171
reversed O 0 0.010443554
bromocriptine B-Chemical 0 0.99999297
- O 0 0.00092006027
induced O 0 0.0003048364
tachycardia B-Disease 2 0.9930661
to O 0 0.00019926272
bradycardia B-Disease 0 0.99615437
, O 0 0.00013804475
an O 0 8.738134e-05
effect O 0 5.185713e-05
that O 0 4.3222888e-05
is O 0 5.3344516e-05
mainly O 0 4.9800892e-05
related O 0 2.0729525e-05
to O 0 3.9562266e-05
further O 0 0.0001286716
cardiac O 0 0.101771474
beta O 0 0.97692126
- O 0 0.0018712851
adrenoceptor O 0 0.9999517
desensitization O 0 0.04047402
rather O 0 6.7136534e-05
than O 0 5.1753534e-05
to O 0 7.833743e-05
impairment O 0 0.0070440467
of O 0 0.00024180341
autonomic O 0 0.0028654442
regulation O 0 0.00014873363
of O 0 0.00043051026
the O 0 0.0007690987
heart O 0 0.08633088
. O 0 0.0021725295

They O 0 0.0028583761
suggest O 0 0.0007526969
that O 0 0.0006416416
, O 0 0.0007289793
in O 0 0.00039707133
normal O 0 0.00067310577
conscious O 0 0.0013083902
rats O 0 0.00031866418
, O 0 0.00013164648
the O 0 8.583637e-05
central O 0 0.00018565786
tachycardia B-Disease 2 0.94488543
of O 0 0.00061069155
bromocriptine B-Chemical 0 0.9999641
appears O 0 8.898906e-05
to O 0 6.818031e-05
predominate O 0 0.0001500397
and O 0 6.40147e-05
to O 0 4.837368e-05
mask O 0 9.2462724e-05
the O 0 0.000100795565
bradycardia B-Disease 0 0.9253834
of O 0 0.0001790587
this O 0 0.00022235209
agonist O 0 0.08388554
at O 0 0.00020507688
peripheral O 0 0.047039323
dopamine B-Chemical 0 0.99987996
D2 O 0 0.9992199
receptors O 0 0.01766125
. O 0 0.002043774

A O 0 0.013193138
developmental O 0 0.0028166973
analysis O 0 0.0011464522
of O 0 0.001863196
clonidine B-Chemical 0 0.99986947
' O 0 0.00087682134
s O 0 0.00030563696
effects O 0 0.00023609844
on O 0 0.00015326543
cardiac O 0 0.0032872953
rate O 0 0.000298988
and O 0 0.0003051173
ultrasound O 0 0.0011180887
production O 0 0.00061868865
in O 0 0.00058108725
infant O 0 0.002176616
rats O 0 0.0028526601
. O 0 0.0022188723

Under O 0 0.0029688608
controlled O 0 0.0014065679
conditions O 0 0.0011575394
, O 0 0.0008292976
infant O 0 0.0008209665
rats O 0 0.0005048275
emit O 0 0.00042292755
ultrasonic O 0 0.0006391235
vocalizations O 0 0.0005227694
during O 0 6.082291e-05
extreme O 0 0.00022095114
cold O 0 0.0011881714
exposure O 0 0.00016574391
and O 0 8.1307764e-05
after O 0 3.0069068e-05
administration O 0 0.00024615214
of O 0 0.00014017665
the O 0 0.00017468634
alpha O 0 0.31390843
( O 0 0.00033905345
2 O 0 0.00017850686
) O 0 0.00062216114
adrenoceptor O 0 0.99979657
agonist O 0 0.8939327
, O 0 0.004016454
clonidine B-Chemical 0 0.9998004
. O 0 0.0031330807

Previous O 0 0.0015499074
investigations O 0 0.0016324897
have O 0 0.00058313506
determined O 0 0.00040986546
that O 0 0.00026944577
, O 0 0.00032217932
in O 0 0.00017599728
response O 0 0.00021498425
to O 0 0.00036377728
clonidine B-Chemical 0 0.99996495
, O 0 0.00043376916
ultrasound O 0 0.00086127804
production O 0 0.00021039802
increases O 0 0.00011888951
through O 0 7.606867e-05
the O 0 0.00012196973
2nd O 0 0.0003173629
- O 0 0.00025140124
week O 0 9.761119e-05
postpartum O 0 0.000292096
and O 0 0.0003618821
decreases O 0 0.0008361445
thereafter O 0 0.0011985975
. O 0 0.0018495753

Given O 0 0.0010584036
that O 0 0.0009508581
sympathetic O 0 0.0068011
neural O 0 0.0016296268
dominance O 0 0.0014904438
exhibits O 0 0.00053250056
a O 0 0.0003049934
similar O 0 0.00011374409
developmental O 0 0.00034856703
pattern O 0 0.000107589556
, O 0 0.000114410905
and O 0 7.231631e-05
given O 0 4.1983825e-05
that O 0 8.590893e-05
clonidine B-Chemical 0 0.9999287
induces O 0 0.00010399582
sympathetic O 0 0.039318822
withdrawal O 0 0.017999047
and O 0 0.00019316324
bradycardia B-Disease 0 0.98858553
, O 0 9.4678144e-05
we O 0 2.445157e-05
hypothesized O 0 2.996593e-05
that O 0 8.33306e-05
clonidine B-Chemical 0 0.99995184
' O 0 0.00016991224
s O 0 7.06578e-05
developmental O 0 0.00014328281
effects O 0 7.8753874e-05
on O 0 5.3522253e-05
cardiac O 0 0.0024828585
rate O 0 0.0001435221
and O 0 0.00015626432
ultrasound O 0 0.0006654559
production O 0 0.0003283704
would O 0 0.00028294523
mirror O 0 0.00095866295
each O 0 0.00038348383
other O 0 0.0011230791
. O 0 0.0019262881

Therefore O 0 0.0018959614
, O 0 0.0016650256
in O 0 0.0006973652
the O 0 0.00044846625
present O 0 0.0002651853
experiment O 0 0.00021590327
, O 0 0.0002147466
the O 0 0.00013200523
effects O 0 0.0001926958
of O 0 0.00070694933
clonidine B-Chemical 0 0.99998474
administration O 0 0.014898901
( O 0 0.00028145814
0 O 0 8.021824e-05
. O 0 4.4439283e-05
5 O 0 5.0915558e-05
mg O 0 0.0008441186
/ O 0 0.00032924558
kg O 0 0.00026021298
) O 0 0.00010775919
on O 0 3.8906725e-05
cardiac O 0 0.0009180598
rate O 0 9.064252e-05
and O 0 8.7735774e-05
ultrasound O 0 0.0003526031
production O 0 0.00013533587
were O 0 7.3481526e-05
examined O 0 4.726514e-05
in O 0 8.016884e-05
2 O 0 9.2560476e-05
- O 0 0.00020754918
, O 0 0.00013299727
8 O 0 9.954627e-05
- O 0 0.00021769713
, O 0 0.00013553242
15 O 0 0.00010154594
- O 0 0.00023823873
, O 0 0.0001563275
and O 0 0.00016465172
20 O 0 0.00020977565
- O 0 0.00038521693
day O 0 0.00022713581
- O 0 0.000715401
old O 0 0.00080211915
rats O 0 0.0018782698
. O 0 0.001958398

Age O 0 0.016281554
- O 0 0.0026627164
related O 0 0.0004898221
changes O 0 0.00065724796
in O 0 0.00041750574
ultrasound O 0 0.00094164425
production O 0 0.00032869016
corresponded O 0 0.00014263313
with O 0 0.00017278313
changes O 0 0.00017684323
in O 0 0.00014528
cardiovascular O 0 0.18777724
variables O 0 0.00010073955
, O 0 0.00010530499
including O 0 5.7139678e-05
baseline O 0 9.83553e-05
cardiac O 0 0.0020666157
rate O 0 0.00027444682
and O 0 0.0006741001
clonidine B-Chemical 0 0.9999348
- O 0 0.0023644676
induced O 0 0.002421387
bradycardia B-Disease 0 0.99822146
. O 0 0.0030986052

This O 0 0.0031209325
experiment O 0 0.0011096135
is O 0 0.0007647594
discussed O 0 0.00045394554
with O 0 0.00040656765
regard O 0 0.00016926075
to O 0 0.00016045278
the O 0 0.00015191939
hypothesis O 0 0.00018215441
that O 0 0.000103219376
ultrasound O 0 0.0007783326
production O 0 0.00024191455
is O 0 0.00010623854
the O 0 9.0693786e-05
acoustic O 0 0.0005338032
by O 0 0.00015955932
- O 0 0.00022103732
product O 0 0.00016668756
of O 0 9.9523866e-05
a O 0 0.00011193164
physiological O 0 0.00018510445
maneuver O 0 0.0019574112
that O 0 5.203923e-05
compensates O 0 0.00010163284
for O 0 0.00015559496
clonidine B-Chemical 0 0.99992275
' O 0 0.00029943298
s O 0 0.00015309134
detrimental O 0 0.00027082057
effects O 0 0.00034157644
on O 0 0.00039891977
cardiovascular O 0 0.6127306
function O 0 0.00257656
. O 0 0.0022998226

Recurrent O 0 0.0060812104
use O 0 0.0018095158
of O 0 0.001949699
newer O 0 0.013300889
oral B-Chemical 1 0.94793373
contraceptives I-Chemical 1 0.9994849
and O 0 0.0011718973
the O 0 0.0009349573
risk O 0 0.0052963854
of O 0 0.003367262
venous B-Disease 0 0.958963
thromboembolism I-Disease 0 0.99988425
. O 0 0.0049932925

The O 0 0.0017075218
epidemiological O 0 0.0018455092
studies O 0 0.0007717196
that O 0 0.00035697228
assessed O 0 0.00028908698
the O 0 0.00030614878
risk O 0 0.0014134686
of O 0 0.00072178623
venous B-Disease 0 0.96457434
thromboembolism I-Disease 0 0.9999939
( O 0 0.006086665
VTE B-Disease 2 0.9999052
) O 0 0.00025690376
associated O 0 7.6948614e-05
with O 0 0.00015066564
newer O 0 0.0036827717
oral B-Chemical 1 0.96411973
contraceptives I-Chemical 1 0.9999654
( O 0 0.0019202791
OC B-Chemical 0 0.9998369
) O 0 0.00031508255
did O 0 8.415254e-05
not O 0 4.700292e-05
distinguish O 0 3.1177966e-05
between O 0 2.6403985e-05
patterns O 0 4.1681476e-05
of O 0 0.00021523447
OC B-Chemical 0 0.9992524
use O 0 0.00015638594
, O 0 0.00013223075
namely O 0 0.00010934883
first O 0 8.28637e-05
- O 0 0.00023615293
time O 0 0.00010552362
users O 0 0.0006044314
, O 0 0.00045813533
repeaters O 0 0.0032396826
and O 0 0.0009954277
switchers O 0 0.0060798437
. O 0 0.0020015647

Data O 0 0.0023764207
from O 0 0.0013125539
a O 0 0.0013621781
Transnational O 0 0.0012523809
case O 0 0.0006654314
- O 0 0.00072250376
control O 0 0.0002559159
study O 0 0.00025067962
were O 0 0.00013540337
used O 0 8.4088126e-05
to O 0 7.5631215e-05
assess O 0 4.4482065e-05
the O 0 0.00011130229
risk O 0 0.0012017207
of O 0 0.00069983583
VTE B-Disease 2 0.99980325
for O 0 8.523759e-05
the O 0 8.516114e-05
latter O 0 0.00018304428
patterns O 0 5.9312744e-05
of O 0 0.00013014446
use O 0 0.00011504895
, O 0 0.00014402265
while O 0 0.00012813386
accounting O 0 0.0002654155
for O 0 0.0001807878
duration O 0 0.00022229912
of O 0 0.00083658437
use O 0 0.001343124
. O 0 0.0019478757

Over O 0 0.0021982053
the O 0 0.0012900818
period O 0 0.00076263177
1993 O 0 0.0021585166
- O 0 0.0013358764
1996 O 0 0.001044568
, O 0 0.0005976412
551 O 0 0.0036070205
cases O 0 0.0003955156
of O 0 0.0007464479
VTE B-Disease 2 0.99963295
were O 0 0.00020036584
identified O 0 0.000115512834
in O 0 0.00012975659
Germany O 0 0.00044818915
and O 0 0.00017854689
the O 0 0.00021966812
UK O 0 0.0012621983
along O 0 0.00025269965
with O 0 0.0007240001
2066 O 0 0.008747339
controls O 0 0.0023806773
. O 0 0.0020650213

Totals O 0 0.72842413
of O 0 0.0023398353
128 O 0 0.0021673949
cases O 0 0.0008830201
and O 0 0.00055933546
650 O 0 0.0021149446
controls O 0 0.00043240137
were O 0 0.00016841733
analysed O 0 0.000119128614
for O 0 9.060061e-05
repeat O 0 0.0001556819
use O 0 0.00010225138
and O 0 0.00013532775
135 O 0 0.00031617456
cases O 0 0.00018974474
and O 0 0.00020510073
622 O 0 0.0014164147
controls O 0 0.00036946492
for O 0 0.00026133232
switching O 0 0.00066228514
patterns O 0 0.0008919554
. O 0 0.0018001159

The O 0 0.0015435317
adjusted O 0 0.0010704783
rate O 0 0.0009221547
ratio O 0 0.0010527014
of O 0 0.0015139623
VTE B-Disease 2 0.9994351
for O 0 0.00027183097
repeat O 0 0.0003406053
users O 0 0.00038416736
of O 0 0.00017074932
third O 0 0.00022992396
generation O 0 0.00061748544
OC B-Chemical 0 0.9995308
was O 0 0.0002652336
0 O 0 0.000102294296
. O 0 5.8340538e-05
6 O 0 5.367794e-05
( O 0 0.00011495606
95 O 0 0.00013998257
% O 0 0.00012655891
CI O 0 0.0019238449
: O 0 0.00011644147
0 O 0 7.2212664e-05
. O 0 5.2792595e-05
3 O 0 6.4452535e-05
- O 0 0.0001420903
1 O 0 6.453778e-05
. O 0 4.5800974e-05
2 O 0 5.435842e-05
) O 0 7.992344e-05
relative O 0 4.7188674e-05
to O 0 5.5315475e-05
repeat O 0 0.00010672186
users O 0 0.00016544914
of O 0 8.1875274e-05
second O 0 8.496103e-05
generation O 0 0.00034576916
pills O 0 0.3465221
, O 0 0.0001574331
whereas O 0 0.0001142526
it O 0 0.00012370842
was O 0 0.00011675946
1 O 0 6.9932554e-05
. O 0 4.62595e-05
3 O 0 5.513568e-05
( O 0 0.00010471468
95 O 0 0.00012843318
% O 0 0.00011611914
CI O 0 0.0018013116
: O 0 0.00010762384
0 O 0 6.644631e-05
. O 0 4.7874415e-05
7 O 0 5.5596716e-05
- O 0 0.00013343808
2 O 0 5.8064245e-05
. O 0 4.1946405e-05
4 O 0 4.6668607e-05
) O 0 8.059088e-05
for O 0 4.457574e-05
switchers O 0 0.0002562521
from O 0 4.101757e-05
second O 0 4.692772e-05
to O 0 4.7688056e-05
third O 0 9.9839825e-05
generation O 0 0.00020542405
pills O 0 0.03450806
relative O 0 8.0858925e-05
to O 0 9.01982e-05
switchers O 0 0.0004956597
from O 0 9.285788e-05
third O 0 0.00018143626
to O 0 0.00019329168
second O 0 0.00042880094
generation O 0 0.0017075608
pills O 0 0.43530294
. O 0 0.0023903183

We O 0 0.001320277
conclude O 0 0.00071344676
that O 0 0.00049563794
second O 0 0.00049491663
and O 0 0.00040059316
third O 0 0.00037743294
generation O 0 0.00040945777
agents O 0 0.00093155424
are O 0 0.00014230139
associated O 0 9.407957e-05
with O 0 0.00011897729
equivalent O 0 0.000111702604
risks O 0 0.0004934375
of O 0 0.00059484236
VTE B-Disease 2 0.9998093
when O 0 5.3017102e-05
the O 0 5.712431e-05
same O 0 3.6518428e-05
agent O 0 0.00029850067
is O 0 6.2730054e-05
used O 0 3.8880135e-05
repeatedly O 0 4.2252334e-05
after O 0 1.6887529e-05
interruption O 0 6.208778e-05
periods O 0 3.245599e-05
or O 0 4.060979e-05
when O 0 4.2284253e-05
users O 0 0.00019001741
are O 0 6.4802094e-05
switched O 0 9.535042e-05
between O 0 5.7496825e-05
the O 0 0.00012304878
two O 0 0.00015342131
generations O 0 0.000501816
of O 0 0.0012672938
pills O 0 0.36450928
. O 0 0.002297019

These O 0 0.0020258664
analyses O 0 0.0010329837
suggest O 0 0.00038267733
that O 0 0.0003331101
the O 0 0.00038549266
higher O 0 0.00048591717
risk O 0 0.0015325302
observed O 0 0.00016021902
for O 0 0.000108165535
the O 0 0.00018213356
newer O 0 0.004207317
OC B-Chemical 0 0.9992561
in O 0 0.00014762983
other O 0 9.3088034e-05
studies O 0 9.013819e-05
may O 0 5.434526e-05
be O 0 4.7183723e-05
the O 0 4.4723787e-05
result O 0 4.4832293e-05
of O 0 7.177425e-05
inadequate O 0 9.259526e-05
comparisons O 0 5.4593078e-05
of O 0 0.0001707941
pill O 0 0.24383624
users O 0 0.00041487414
with O 0 0.00014551803
different O 0 9.899194e-05
patterns O 0 0.00017413723
of O 0 0.0007117239
pill O 0 0.2698829
use O 0 0.0015909653
. O 0 0.0020132326

Differential O 0 0.0026410648
effects O 0 0.0012389111
of O 0 0.0010031655
systemically O 0 0.0023462195
administered O 0 0.0017069919
ketamine B-Chemical 0 0.9999449
and O 0 0.0013407647
lidocaine B-Chemical 0 0.99971217
on O 0 0.00011120818
dynamic O 0 0.00014251772
and O 0 0.000185401
static O 0 0.0006708656
hyperalgesia B-Disease 0 0.99106836
induced O 0 0.00061332574
by O 0 0.0005955041
intradermal O 0 0.012487688
capsaicin B-Chemical 0 0.9991698
in O 0 0.0015285858
humans O 0 0.004588368
. O 0 0.0022469587

We O 0 0.0014431083
have O 0 0.000779346
examined O 0 0.0004208405
the O 0 0.00037550626
effect O 0 0.00029630496
of O 0 0.00045559133
systemic O 0 0.1071016
administration O 0 0.002214854
of O 0 0.00085535686
ketamine B-Chemical 0 0.99997926
and O 0 0.0010166412
lidocaine B-Chemical 0 0.9999033
on O 0 0.00011388779
brush O 0 0.0026801443
- O 0 0.000286166
evoked O 0 0.00048525154
( O 0 0.00013849647
dynamic O 0 0.00010983968
) O 0 0.00028091745
pain B-Disease 0 0.064938076
and O 0 0.00013806399
punctate O 0 0.0001209985
- O 0 0.00025935896
evoked O 0 0.0006471909
( O 0 0.00029854936
static O 0 0.0005706681
) O 0 0.0011761569
hyperalgesia B-Disease 0 0.9917841
induced O 0 0.001902828
by O 0 0.0029605418
capsaicin B-Chemical 0 0.9990345
. O 0 0.003808266

In O 0 0.0018875469
a O 0 0.0018551102
randomized O 0 0.0013826789
, O 0 0.0009706514
double O 0 0.0010741756
- O 0 0.001197915
blind O 0 0.008559289
, O 0 0.00044443435
placebo O 0 0.0019395172
- O 0 0.00034459354
controlled O 0 0.00014390734
, O 0 0.00018943091
crossover O 0 0.001254389
study O 0 0.00017208813
, O 0 0.00012551332
we O 0 6.30858e-05
studied O 0 0.00014121812
12 O 0 9.7084114e-05
volunteers O 0 0.00024958685
in O 0 0.00022458548
three O 0 0.00027092025
experiments O 0 0.0007958418
. O 0 0.0017124915

Capsaicin B-Chemical 1 0.99778193
100 O 0 0.0062720804
micrograms O 0 0.008144785
was O 0 0.00073907373
injected O 0 0.00032038623
intradermally O 0 0.00024856708
on O 0 0.00011456474
the O 0 0.00018328668
volar O 0 0.0025417153
forearm O 0 0.009696216
followed O 0 0.00013286229
by O 0 0.00012726008
an O 0 0.00016346517
i O 0 0.00033678339
. O 0 7.651784e-05
v O 0 0.0004152843
. O 0 5.5109977e-05
infusion O 0 0.00017567353
of O 0 0.00024266697
ketamine B-Chemical 0 0.99995077
( O 0 0.0003134189
bolus O 0 0.00050156395
0 O 0 6.67127e-05
. O 0 3.9482817e-05
1 O 0 5.4563043e-05
mg O 0 0.00087832066
kg O 0 0.00026295136
- O 0 0.00013260788
1 O 0 3.9352864e-05
over O 0 1.994442e-05
10 O 0 3.5027166e-05
min O 0 5.3644322e-05
followed O 0 4.1877058e-05
by O 0 6.139399e-05
infusion O 0 0.00013125614
of O 0 8.307233e-05
7 O 0 4.903628e-05
micrograms O 0 0.00052781584
kg O 0 0.0003186578
- O 0 0.00015955932
1 O 0 5.7229874e-05
min O 0 9.780181e-05
- O 0 0.00017280338
1 O 0 7.963063e-05
) O 0 0.00015573119
, O 0 0.00018570604
lidocaine B-Chemical 0 0.9987225
5 O 0 0.000121576544
mg O 0 0.0031147404
kg O 0 0.00047017794
- O 0 0.0002582476
1 O 0 0.000112673
or O 0 0.00014451306
saline O 0 0.0006006858
for O 0 0.00030005455
50 O 0 0.00091618707
min O 0 0.0014249749
. O 0 0.0020220445

Infusion O 0 0.014874133
started O 0 0.0024823758
15 O 0 0.001507188
min O 0 0.0016586453
after O 0 0.0009401727
injection O 0 0.0027425075
of O 0 0.0062602866
capsaicin B-Chemical 0 0.9978745
. O 0 0.008970004

The O 0 0.0013163459
following O 0 0.00076837203
were O 0 0.0006627663
measured O 0 0.00045273834
: O 0 0.0006179841
spontaneous O 0 0.0027868475
pain B-Disease 0 0.61774606
, O 0 0.00069634843
pain B-Disease 0 0.30864143
evoked O 0 0.0010990065
by O 0 0.00016387702
punctate O 0 9.940502e-05
and O 0 0.00011617673
brush O 0 0.0005579109
stimuli O 0 0.00016221538
( O 0 0.00032134796
VAS O 0 0.0030296503
) O 0 0.0002213159
, O 0 0.000120022196
and O 0 0.00010129053
areas O 0 0.00012029065
of O 0 0.0002069141
brush O 0 0.0021006167
- O 0 0.00043433747
evoked O 0 0.00076210324
and O 0 0.00032661506
punctate O 0 0.00045673235
- O 0 0.0013941667
evoked O 0 0.0133693945
hyperalgesia B-Disease 0 0.9982134
. O 0 0.0036254765

Ketamine B-Chemical 1 0.9989484
reduced O 0 0.0032627955
both O 0 0.0008946156
the O 0 0.00052755035
area O 0 0.0004342321
of O 0 0.0005073567
brush O 0 0.0032551868
- O 0 0.0005784911
evoked O 0 0.0007400484
and O 0 0.00019565063
punctate O 0 0.00016523551
- O 0 0.0004198719
evoked O 0 0.0041550105
hyperalgesia B-Disease 0 0.99792814
significantly O 0 0.0004958932
and O 0 0.0001817682
it O 0 0.00014575149
tended O 0 0.0001337359
to O 0 0.00013177481
reduce O 0 0.00020471819
brush O 0 0.003914059
- O 0 0.0015267172
evoked O 0 0.007971749
pain B-Disease 0 0.783785
. O 0 0.00294015

Lidocaine B-Chemical 0 0.9984585
reduced O 0 0.0043125455
the O 0 0.0016182516
area O 0 0.0012748397
of O 0 0.0012989646
punctate O 0 0.0012678286
- O 0 0.0028409811
evoked O 0 0.016600424
hyperalgesia B-Disease 0 0.99783945
significantly O 0 0.009355152
. O 0 0.0046498636

It O 0 0.002388961
tended O 0 0.0012289609
to O 0 0.0006903858
reduce O 0 0.00053339126
VAS O 0 0.002699164
scores O 0 0.00032001015
of O 0 0.00045617064
spontaneous O 0 0.0038858347
pain B-Disease 0 0.55649793
but O 0 0.00044231396
had O 0 0.00026082198
no O 0 0.00016812289
effect O 0 0.0003221225
on O 0 0.00047775797
evoked O 0 0.010407041
pain B-Disease 0 0.85760784
. O 0 0.0034566363

The O 0 0.0013434488
differential O 0 0.001312839
effects O 0 0.00093174604
of O 0 0.0016148792
ketamine B-Chemical 0 0.9999192
and O 0 0.0018628255
lidocaine B-Chemical 0 0.9997842
on O 0 0.00013877462
static O 0 0.00025043736
and O 0 0.00014443135
dynamic O 0 0.00020715891
hyperalgesia B-Disease 0 0.95370966
suggest O 0 4.5539742e-05
that O 0 4.672245e-05
the O 0 6.292238e-05
two O 0 4.472187e-05
types O 0 5.373264e-05
of O 0 0.0002679951
hyperalgesia B-Disease 0 0.99275714
are O 0 0.00012932502
mediated O 0 5.9030393e-05
by O 0 8.941062e-05
separate O 0 6.22643e-05
mechanisms O 0 0.00013874895
and O 0 0.00017887916
have O 0 0.00017919655
a O 0 0.0004426784
distinct O 0 0.00050353183
pharmacology O 0 0.0060708434
. O 0 0.001916397

Development O 0 0.0066765132
of O 0 0.005819937
apomorphine B-Chemical 1 0.9999094
- O 0 0.004160606
induced O 0 0.0011875683
aggressive B-Disease 0 0.040479105
behavior I-Disease 0 0.0024691585
: O 0 0.00043582075
comparison O 0 0.00020428124
of O 0 0.00032199905
adult O 0 0.00058232417
male O 0 0.001103971
and O 0 0.00050491845
female O 0 0.0019350989
Wistar O 0 0.0036888302
rats O 0 0.0019528917
. O 0 0.001774468

The O 0 0.0017754906
development O 0 0.0026069216
of O 0 0.00398859
apomorphine B-Chemical 1 0.99995553
- O 0 0.004028247
induced O 0 0.0008826883
( O 0 0.0005923454
1 O 0 0.00018622239
. O 0 9.74488e-05
0 O 0 0.000116928706
mg O 0 0.0012736564
/ O 0 0.00043255315
kg O 0 0.00031319394
s O 0 0.00012724308
. O 0 7.89411e-05
c O 0 0.00045374548
. O 0 5.0640756e-05
once O 0 4.7840556e-05
daily O 0 0.00011721249
) O 0 0.00015968138
aggressive B-Disease 0 0.0015549777
behavior I-Disease 0 0.00041890726
of O 0 0.00014588231
adult O 0 0.00022973242
male O 0 0.000385491
and O 0 9.2828835e-05
female O 0 0.00034187923
Wistar O 0 0.0003719575
rats O 0 7.279961e-05
obtained O 0 4.5510395e-05
from O 0 3.975291e-05
the O 0 5.3292963e-05
same O 0 4.922725e-05
breeder O 0 0.00042342884
was O 0 0.0001370472
studied O 0 0.00015411923
in O 0 0.00016074463
two O 0 0.00020058527
consecutive O 0 0.00047092699
sets O 0 0.0010166197
. O 0 0.0017014351

In O 0 0.0021047727
male O 0 0.0032871095
animals O 0 0.0006698945
, O 0 0.0006231896
repeated O 0 0.000414417
apomorphine B-Chemical 1 0.99992454
treatment O 0 0.00046328115
induced O 0 0.00027601628
a O 0 0.00022132203
gradual O 0 0.0002059257
development O 0 0.0002463806
of O 0 0.00023305275
aggressive B-Disease 0 0.026059952
behavior I-Disease 0 0.0011150717
as O 0 0.00011369182
evidenced O 0 0.00026223535
by O 0 8.017182e-05
the O 0 6.118989e-05
increased O 0 0.00010044909
intensity O 0 5.1916304e-05
of O 0 0.00016823098
aggressiveness B-Disease 2 0.50411016
and O 0 0.00013038071
shortened O 0 0.00017098653
latency O 0 0.00013056572
before O 0 4.1079733e-05
the O 0 0.00010150198
first O 0 0.0001360309
attack O 0 0.004156664
toward O 0 0.000623309
the O 0 0.0012514325
opponent O 0 0.06372041
. O 0 0.0025780862

In O 0 0.0029956487
female O 0 0.0052529033
rats O 0 0.002221156
, O 0 0.0012183135
only O 0 0.000862678
a O 0 0.0010398339
weak O 0 0.0018785686
tendency O 0 0.0016461874
toward O 0 0.0013576723
aggressiveness B-Disease 2 0.78875375
was O 0 0.0024173316
found O 0 0.0021947403
. O 0 0.0029617106

In O 0 0.0018618663
conclusion O 0 0.0013112555
, O 0 0.0010217086
the O 0 0.0004870932
present O 0 0.00030272856
study O 0 0.00033704934
demonstrates O 0 0.0001553019
gender O 0 0.00024575437
differences O 0 5.7387155e-05
in O 0 7.1395036e-05
the O 0 7.450079e-05
development O 0 0.00015252148
of O 0 0.0001643949
the O 0 0.0003429199
apomorphine B-Chemical 1 0.99999094
- O 0 0.00076333486
induced O 0 0.00022146261
aggressive B-Disease 0 0.040513325
behavior I-Disease 0 0.0009892432
and O 0 9.6225485e-05
indicates O 0 4.662155e-05
that O 0 4.026585e-05
the O 0 7.642407e-05
female O 0 0.00032064196
rats O 0 0.00010359211
do O 0 5.2695625e-05
not O 0 4.761022e-05
fill O 0 5.59741e-05
the O 0 6.0911887e-05
validation O 0 0.00015245256
criteria O 0 0.00013263292
for O 0 0.00011159497
use O 0 0.0001984444
in O 0 0.00030400892
this O 0 0.00079472776
method O 0 0.0022197997
. O 0 0.002045971

Intracranial B-Disease 0 0.7577496
aneurysms I-Disease 2 0.9990227
and O 0 0.009015285
cocaine B-Disease 0 0.9999243
abuse I-Disease 2 0.9974896
: O 0 0.0021370272
analysis O 0 0.0010064039
of O 0 0.0012948655
prognostic O 0 0.0028009003
indicators O 0 0.002128672
. O 0 0.0032887454

OBJECTIVE O 0 0.01985279
: O 0 0.0020306613
The O 0 0.00069496944
outcome O 0 0.0008208936
of O 0 0.0013327517
subarachnoid B-Disease 0 0.99511755
hemorrhage I-Disease 2 0.99965334
associated O 0 0.00089647534
with O 0 0.0028214976
cocaine B-Disease 0 0.99997807
abuse I-Disease 2 0.9989183
is O 0 0.0021197342
reportedly O 0 0.012317813
poor O 0 0.0068053943
. O 0 0.0026962673

However O 0 0.0027851996
, O 0 0.0018369314
no O 0 0.0006315624
study O 0 0.0006855129
in O 0 0.0003613402
the O 0 0.00031907458
literature O 0 0.00048220097
has O 0 0.00017302201
reported O 0 0.00018464842
the O 0 0.0001302788
use O 0 0.0001048122
of O 0 0.0001472094
a O 0 0.00017590904
statistical O 0 0.00021513784
model O 0 0.00013434351
to O 0 9.189595e-05
analyze O 0 7.140839e-05
the O 0 0.00013379967
variables O 0 0.00013899419
that O 0 0.00021233999
influence O 0 0.00037987513
outcome O 0 0.0015491549
. O 0 0.002074332

METHODS O 0 0.0019240663
: O 0 0.0020139164
A O 0 0.0043475986
review O 0 0.001175659
of O 0 0.0006539333
admissions O 0 0.0008653936
during O 0 0.00015668804
a O 0 0.00028922566
6 O 0 0.00012836217
- O 0 0.00021803532
year O 0 6.933414e-05
period O 0 5.086586e-05
revealed O 0 9.644623e-05
14 O 0 0.00011605239
patients O 0 0.00024350737
with O 0 0.0005643255
cocaine B-Chemical 1 0.9994759
- O 0 0.0017265248
related O 0 0.00079413725
aneurysms B-Disease 2 0.97893655
. O 0 0.0026655926

This O 0 0.0038448335
group O 0 0.0020628388
was O 0 0.0008956139
compared O 0 0.00034178884
with O 0 0.0003705261
a O 0 0.00031023906
control O 0 0.00019062131
group O 0 0.0002008785
of O 0 0.00018366157
135 O 0 0.00036381924
patients O 0 0.00021351
with O 0 0.00034214562
ruptured B-Disease 0 0.97420156
aneurysms I-Disease 2 0.9998161
and O 0 0.00032824863
no O 0 0.0001924472
history O 0 0.0008385477
of O 0 0.002185017
cocaine B-Disease 0 0.9999622
abuse I-Disease 2 0.99903995
. O 0 0.004213351

Age O 0 0.007584868
at O 0 0.001136064
presentation O 0 0.0012633204
, O 0 0.0007050033
time O 0 0.00026255005
of O 0 0.0004642068
ictus O 0 0.0027901093
after O 0 0.00017986707
intoxication O 0 0.9929778
, O 0 0.0005823333
Hunt O 0 0.00474239
and O 0 0.00021696421
Hess O 0 0.0070489706
grade O 0 0.0018605693
of O 0 0.00034177105
subarachnoid B-Disease 0 0.99784935
hemorrhage I-Disease 2 0.9998735
, O 0 0.00017787484
size O 0 0.00013550915
of O 0 0.000109974884
the O 0 0.00015771936
aneurysm B-Disease 2 0.97715604
, O 0 0.00010630522
location O 0 3.969086e-05
of O 0 9.9338795e-05
the O 0 0.00016468059
aneurysm B-Disease 2 0.98136973
, O 0 0.00015829549
and O 0 9.8786266e-05
the O 0 0.000104205574
Glasgow O 0 0.00043831396
Outcome O 0 0.00012740139
Scale O 0 0.0010160165
score O 0 0.00015587604
were O 0 0.00022048753
assessed O 0 0.00025398418
and O 0 0.0005656247
compared O 0 0.00084756286
. O 0 0.0018655546

RESULTS O 0 0.004239825
: O 0 0.0015654721
The O 0 0.0005916212
patients O 0 0.0006344618
in O 0 0.00030737623
the O 0 0.00025530078
study O 0 0.00028215293
group O 0 0.00024989783
were O 0 0.00015380919
significantly O 0 0.00022330944
younger O 0 0.000710459
than O 0 6.3178624e-05
the O 0 8.431503e-05
patients O 0 0.00011934476
in O 0 6.742795e-05
the O 0 8.2212326e-05
control O 0 0.00012882211
group O 0 0.0003053134
( O 0 0.00048307923
P O 0 0.003707774
< O 0 0.000317898
0 O 0 0.00033705786
. O 0 0.0004666763
002 O 0 0.0054857926
) O 0 0.002381153
. O 0 0.002370281

In O 0 0.0020341473
patients O 0 0.0017532904
in O 0 0.0007873144
the O 0 0.0006172819
study O 0 0.0006530246
group O 0 0.0006014087
, O 0 0.00047623433
all O 0 0.0005096336
aneurysms B-Disease 2 0.9430935
were O 0 0.00035547977
located O 0 0.00023787466
in O 0 0.00033256746
the O 0 0.00061864057
anterior O 0 0.004330536
circulation O 0 0.0049351905
. O 0 0.0025145977

The O 0 0.0014677981
majority O 0 0.0011345065
of O 0 0.0010601423
these O 0 0.0013850037
aneurysms B-Disease 2 0.9758918
were O 0 0.00035835427
smaller O 0 0.0002242568
than O 0 0.00010335116
those O 0 0.0001413829
of O 0 0.0001226636
the O 0 9.597548e-05
control O 0 0.00011452749
group O 0 0.00019915939
( O 0 0.00017907117
8 O 0 9.466226e-05
+ O 0 0.00025821064
/ O 0 0.0004664015
- O 0 0.0002488721
6 O 0 6.1939936e-05
. O 0 6.059284e-05
08 O 0 0.00040463076
mm O 0 0.00016361642
versus O 0 8.241963e-05
11 O 0 0.00012232055
+ O 0 0.00025970687
/ O 0 0.00047522626
- O 0 0.00027749577
5 O 0 9.24391e-05
. O 0 7.872362e-05
4 O 0 0.00010303725
mm O 0 0.0003354187
; O 0 0.0004426936
P O 0 0.0032093418
= O 0 0.0005184206
0 O 0 0.0004459855
. O 0 0.0006508785
05 O 0 0.0061122198
) O 0 0.0026965928
. O 0 0.0027130803

The O 0 0.0016881893
differences O 0 0.0009163635
in O 0 0.0010527937
mortality O 0 0.004133666
and O 0 0.00087036367
morbidity O 0 0.007637683
between O 0 0.00027751827
the O 0 0.0003354171
two O 0 0.0002700916
groups O 0 0.00039786342
were O 0 0.0005247073
not O 0 0.0007809794
significant O 0 0.0017347231
. O 0 0.0025288465

Hunt O 0 0.020419205
and O 0 0.0033967672
Hess O 0 0.03682199
grade O 0 0.023317603
( O 0 0.0023526284
P O 0 0.010944143
< O 0 0.00048281733
0 O 0 0.00031704872
. O 0 0.00025688665
005 O 0 0.0026236176
) O 0 0.00038701596
and O 0 0.00023452233
age O 0 0.0003086257
( O 0 0.00044117132
P O 0 0.0039869384
< O 0 0.00015268664
0 O 0 0.00010988662
. O 0 8.9354355e-05
007 O 0 0.0009733137
) O 0 0.00016910427
were O 0 7.2820854e-05
significant O 0 5.4011598e-05
predictors O 0 3.4766286e-05
of O 0 8.2602644e-05
outcome O 0 8.8363486e-05
for O 0 6.551154e-05
the O 0 0.000121108045
patients O 0 0.00029013318
with O 0 0.0006290622
cocaine B-Chemical 1 0.9996617
- O 0 0.0016550833
related O 0 0.0007191964
aneurysms B-Disease 2 0.9798126
. O 0 0.002479205

CONCLUSION O 0 0.02806658
: O 0 0.0054307436
Cocaine B-Chemical 0 0.99950993
use O 0 0.0016724508
predisposed O 0 0.07944624
aneurysmal B-Disease 0 0.9999478
rupture I-Disease 0 0.99920243
at O 0 0.00033732867
a O 0 0.00042668753
significantly O 0 0.00037925635
earlier O 0 0.00034373783
age O 0 0.0003250222
and O 0 0.0002851961
in O 0 0.00033730475
much O 0 0.0005986094
smaller O 0 0.0018234436
aneurysms B-Disease 2 0.98944104
. O 0 0.00316084

Contrary O 0 0.0018260664
to O 0 0.0013143765
the O 0 0.0009991736
published O 0 0.000964708
literature O 0 0.0010607666
, O 0 0.00059428735
this O 0 0.00047175054
group O 0 0.00049724977
did O 0 0.00040054505
reasonably O 0 0.0006628535
well O 0 0.00041168477
with O 0 0.0008581079
aggressive O 0 0.004499924
management O 0 0.002607455
. O 0 0.0026179971

Effect O 0 0.0022501242
of O 0 0.0024785602
intravenous O 0 0.23072709
nimodipine B-Chemical 0 0.9999604
on O 0 0.00077205105
blood O 0 0.0046341787
pressure O 0 0.0036391334
and O 0 0.0005479303
outcome O 0 0.0006884233
after O 0 0.0006496985
acute B-Disease 0 0.9945543
stroke I-Disease 0 0.99985397
. O 0 0.007082579

BACKGROUND O 0 0.006460131
AND O 0 0.0013065359
PURPOSE O 0 0.0016127524
: O 0 0.00075488316
The O 0 0.00044513564
Intravenous O 0 0.23423676
Nimodipine B-Chemical 0 0.99997735
West O 0 0.001027316
European O 0 0.0010888827
Stroke B-Disease 0 0.8450828
Trial O 0 0.00074766803
( O 0 0.00031017547
INWEST O 0 0.010200153
) O 0 0.00019250282
found O 0 7.115294e-05
a O 0 9.5742755e-05
correlation O 0 6.599831e-05
between O 0 0.00012902741
nimodipine B-Chemical 0 0.99999607
- O 0 0.00080530427
induced O 0 0.00017194902
reduction B-Disease 0 0.00037974314
in I-Disease 0 0.00011498423
blood I-Disease 0 0.0020104742
pressure I-Disease 0 0.004185077
( O 0 0.00031689912
BP O 0 0.51980877
) O 0 0.00022944239
and O 0 0.00012296221
an O 0 0.00020033908
unfavorable O 0 0.0010526178
outcome O 0 0.0004796553
in O 0 0.0008920318
acute B-Disease 0 0.9970229
stroke I-Disease 0 0.99990153
. O 0 0.0055152862

We O 0 0.0015305548
sought O 0 0.0016376559
to O 0 0.00070826366
confirm O 0 0.0003587356
this O 0 0.00036718065
correlation O 0 0.00018982145
with O 0 0.00024042522
and O 0 0.00016677327
without O 0 0.00011208779
adjustment O 0 7.4612064e-05
for O 0 6.437636e-05
prognostic O 0 0.00020356434
variables O 0 5.6057917e-05
and O 0 6.4859596e-05
to O 0 4.8667778e-05
investigate O 0 3.631159e-05
outcome O 0 9.478664e-05
in O 0 9.642443e-05
subgroups O 0 0.0001542726
with O 0 0.00015678027
increasing O 0 0.00025372178
levels O 0 0.0003992007
of O 0 0.0014836065
BP B-Disease 0 0.9972397
reduction I-Disease 0 0.22627662
. O 0 0.003148262

METHODS O 0 0.0014853404
: O 0 0.0012887487
Patients O 0 0.0006301933
with O 0 0.00046616615
a O 0 0.0004613857
clinical O 0 0.00080858974
diagnosis O 0 0.00080773764
of O 0 0.0013073126
ischemic B-Disease 0 0.9999882
stroke I-Disease 0 0.9999815
( O 0 0.000428236
within O 0 3.4979297e-05
24 O 0 4.4130615e-05
hours O 0 3.4206652e-05
) O 0 8.307685e-05
were O 0 4.5938148e-05
consecutively O 0 5.1686206e-05
allocated O 0 2.7193264e-05
to O 0 3.4585897e-05
receive O 0 4.0348998e-05
placebo O 0 0.00034889134
( O 0 0.00010500385
n O 0 7.1435774e-05
= O 0 0.000105016676
100 O 0 0.0002194678
) O 0 0.00016131354
, O 0 9.5944e-05
1 O 0 7.076818e-05
mg O 0 0.0009585297
/ O 0 0.0002523354
h O 0 7.525366e-05
( O 0 0.00012586257
low O 0 0.00021861444
- O 0 0.00027239887
dose O 0 0.0010617181
) O 0 0.0009266553
nimodipine B-Chemical 0 0.99999523
( O 0 0.00043613333
n O 0 0.000119245
= O 0 0.00014386699
101 O 0 0.00040697618
) O 0 0.00015109983
, O 0 8.636496e-05
or O 0 6.5186614e-05
2 O 0 7.1486604e-05
mg O 0 0.0010049687
/ O 0 0.0002748252
h O 0 8.8033616e-05
( O 0 0.00014855505
high O 0 0.00025950518
- O 0 0.00036196635
dose O 0 0.0013934299
) O 0 0.0014132113
nimodipine B-Chemical 0 0.9999869
( O 0 0.0010442616
n O 0 0.00045585178
= O 0 0.00071436726
94 O 0 0.0013083179
) O 0 0.001911398
. O 0 0.0020504782

The O 0 0.0013728039
correlation O 0 0.0007220398
between O 0 0.0004117409
average O 0 0.00040988132
BP O 0 0.12950104
change O 0 0.00031300707
during O 0 0.000116757896
the O 0 0.0001416971
first O 0 9.336264e-05
2 O 0 9.613175e-05
days O 0 5.290665e-05
and O 0 0.00010167762
the O 0 0.00011779704
outcome O 0 0.00016760592
at O 0 0.00014709897
day O 0 0.00021093813
21 O 0 0.0004488011
was O 0 0.00071106973
analyzed O 0 0.0011291308
. O 0 0.002103387

RESULTS O 0 0.0047114035
: O 0 0.0019007917
Two O 0 0.00086493324
hundred O 0 0.00075382285
sixty O 0 0.00075228716
- O 0 0.0005454867
five O 0 0.00015079125
patients O 0 0.00022655098
were O 0 0.00012750531
included O 0 8.373843e-05
in O 0 8.441278e-05
this O 0 0.00011720063
analysis O 0 0.00012370133
( O 0 0.0001657177
n O 0 9.974095e-05
= O 0 0.00012347319
92 O 0 0.00018008483
, O 0 0.00010814377
93 O 0 0.00021398505
, O 0 8.678353e-05
and O 0 6.8481226e-05
80 O 0 9.556652e-05
for O 0 6.341234e-05
placebo O 0 0.0005349625
, O 0 0.00012277301
low O 0 0.00026874125
dose O 0 0.00086333876
, O 0 0.00022486335
and O 0 0.00021501213
high O 0 0.0006339091
dose O 0 0.0026139712
, O 0 0.0010186401
respectively O 0 0.0026286745
) O 0 0.0025849605
. O 0 0.0022093912

Nimodipine B-Chemical 0 0.9998741
treatment O 0 0.0025335758
resulted O 0 0.0010191756
in O 0 0.00058532093
a O 0 0.0005896591
statistically O 0 0.0003189499
significant O 0 0.0001989195
reduction B-Disease 0 0.00036769238
in I-Disease 0 0.00018054558
systolic I-Disease 0 0.25938812
BP I-Disease 0 0.8604916
( O 0 0.00032238857
SBP O 0 0.03998802
) O 0 0.00017665482
and O 0 0.00011554568
diastolic O 0 0.32953787
BP O 0 0.7809511
( O 0 0.00028544854
DBP O 0 0.24212177
) O 0 0.00013891602
from O 0 4.9313843e-05
baseline O 0 5.161469e-05
compared O 0 4.7143563e-05
with O 0 0.00012223345
placebo O 0 0.0004043645
during O 0 7.7243356e-05
the O 0 0.00017449491
first O 0 0.00021010674
few O 0 0.0003512398
days O 0 0.00057032495
. O 0 0.0016141644

In O 0 0.0017145412
multivariate O 0 0.0017521982
analysis O 0 0.0009686282
, O 0 0.0007038343
a O 0 0.0004676841
significant O 0 0.00023507979
correlation O 0 0.00013476229
between O 0 0.0001367728
DBP B-Disease 0 0.96777433
reduction I-Disease 0 0.0122296335
and O 0 0.0002612065
worsening O 0 0.01321501
of O 0 0.00018047108
the O 0 0.00014605645
neurological O 0 0.6273622
score O 0 0.00010508509
was O 0 8.8618835e-05
found O 0 4.8835424e-05
for O 0 4.0101724e-05
the O 0 6.859914e-05
high O 0 0.00023308027
- O 0 0.0002547481
dose O 0 0.00059277297
group O 0 0.00025702603
( O 0 0.0003249782
beta O 0 0.6514367
= O 0 0.00023976319
0 O 0 0.00010342865
. O 0 8.857456e-05
49 O 0 0.00024154372
, O 0 0.0003277058
P O 0 0.0029474893
= O 0 0.00040873184
0 O 0 0.00034304676
. O 0 0.00049222744
048 O 0 0.007322269
) O 0 0.0024828918
. O 0 0.0024197772

Patients O 0 0.002416598
with O 0 0.0015270761
a O 0 0.0017319032
DBP B-Disease 0 0.95537674
reduction I-Disease 0 0.0089450665
of O 0 0.0009019141
> O 0 0.0010164493
or O 0 0.000262483
= O 0 0.000254345
20 O 0 0.00012424703
% O 0 0.00010539962
in O 0 7.1649374e-05
the O 0 8.561141e-05
high O 0 0.00025689398
- O 0 0.0002752972
dose O 0 0.00052558334
group O 0 0.00015469329
had O 0 8.064277e-05
a O 0 0.00010660835
significantly O 0 0.00012734164
increased O 0 0.00017982091
adjusted O 0 0.00012260464
OR O 0 0.0015235824
for O 0 4.0758736e-05
the O 0 6.898434e-05
compound O 0 0.008871548
outcome O 0 0.000119321194
variable O 0 0.0001002317
death B-Disease 0 0.8400859
or O 0 9.225321e-05
dependency O 0 0.00013957777
( O 0 0.00014594801
Barthel O 0 0.00011210777
Index O 0 9.2060145e-05
< O 0 6.233256e-05
60 O 0 7.1594804e-05
) O 0 0.00012480633
( O 0 0.00011521923
n O 0 9.353775e-05
/ O 0 0.00048643042
N O 0 0.7920608
= O 0 0.00018817328
25 O 0 0.00014918261
/ O 0 0.00028761374
26 O 0 0.00017233116
, O 0 0.0001742495
OR O 0 0.001276139
10 O 0 8.703083e-05
. O 0 5.8540158e-05
16 O 0 8.08543e-05
, O 0 0.000108836706
95 O 0 0.00015793968
% O 0 0.00013885854
CI O 0 0.001991791
1 O 0 7.835701e-05
. O 0 5.9192447e-05
02 O 0 0.00051738636
to O 0 7.5727556e-05
101 O 0 0.000299447
. O 0 5.7488764e-05
74 O 0 0.00015327186
) O 0 0.00015902588
and O 0 0.00016028823
death B-Disease 0 0.80600995
alone O 0 0.00021505232
( O 0 0.00021487931
n O 0 0.00012397887
/ O 0 0.0007259992
N O 0 0.9013872
= O 0 0.0002004325
9 O 0 8.505011e-05
/ O 0 0.00023787806
26 O 0 0.00016125185
, O 0 0.00017326353
OR O 0 0.0012994322
4 O 0 7.533616e-05
. O 0 6.579704e-05
336 O 0 0.0004323097
, O 0 0.00012371787
95 O 0 0.00015677308
% O 0 0.00012753668
CI O 0 0.0015373359
1 O 0 6.6335386e-05
. O 0 4.647298e-05
131 O 0 0.00016143771
16 O 0 6.99005e-05
. O 0 5.7070294e-05
619 O 0 0.0011027734
) O 0 0.0001059095
compared O 0 3.6835063e-05
with O 0 7.158613e-05
all O 0 8.205325e-05
placebo O 0 0.00053152716
patients O 0 0.00014827895
( O 0 0.00013838374
n O 0 0.00010371151
/ O 0 0.00058871624
N O 0 0.8135297
= O 0 0.00021695904
62 O 0 0.00018774784
/ O 0 0.0002803927
92 O 0 0.00024386519
and O 0 0.00015315223
14 O 0 0.00017875538
/ O 0 0.00056530075
92 O 0 0.0007564419
, O 0 0.00074266526
respectively O 0 0.0018176342
) O 0 0.0024199926
. O 0 0.0023484689

There O 0 0.003989441
was O 0 0.0024788312
no O 0 0.0010514451
correlation O 0 0.0009371807
between O 0 0.0009539347
SBP O 0 0.019198019
change O 0 0.0018615305
and O 0 0.0023433287
outcome O 0 0.003938584
. O 0 0.004553804

CONCLUSIONS O 0 0.02041596
: O 0 0.003733506
DBP O 0 0.40266716
, O 0 0.0013475015
but O 0 0.0006468286
not O 0 0.00043080773
SBP O 0 0.06270348
, O 0 0.0003935152
reduction O 0 0.0005398441
was O 0 0.00019376184
associated O 0 0.000113320995
with O 0 0.000243844
neurological O 0 0.79938567
worsening O 0 0.015369122
after O 0 3.445915e-05
the O 0 8.079379e-05
intravenous O 0 0.0019100625
administration O 0 0.0004253995
of O 0 0.00017727747
high O 0 0.00046101926
- O 0 0.00059506326
dose O 0 0.011072427
nimodipine B-Chemical 0 0.99999094
after O 0 0.0007586386
acute B-Disease 0 0.99899477
stroke I-Disease 0 0.99992704
. O 0 0.005411497

For O 0 0.0018679642
low O 0 0.003910419
- O 0 0.004117116
dose O 0 0.044092573
nimodipine B-Chemical 0 0.99997437
, O 0 0.0020892215
the O 0 0.00086863124
results O 0 0.00095839176
were O 0 0.0011089151
not O 0 0.0014836277
conclusive O 0 0.0063331546
. O 0 0.0036539428

These O 0 0.0025628887
results O 0 0.0017006156
do O 0 0.0011343436
not O 0 0.00069204555
confirm O 0 0.0004796864
or O 0 0.0005214422
exclude O 0 0.00052052713
a O 0 0.0010507941
neuroprotective O 0 0.11247783
property O 0 0.0032173805
of O 0 0.008495982
nimodipine B-Chemical 0 0.9999622
. O 0 0.0068662

Neonatal O 0 0.047934603
pyridoxine B-Chemical 1 0.9998073
responsive O 0 0.0042727543
convulsions B-Disease 0 0.99914455
due O 0 0.0022799734
to O 0 0.0035270278
isoniazid B-Chemical 1 0.99963605
therapy O 0 0.015183879
. O 0 0.005729089

A O 0 0.23471126
17 O 0 0.0055389907
- O 0 0.002314757
day O 0 0.0006157518
- O 0 0.00082373095
old O 0 0.0003445917
infant O 0 0.00044013103
on O 0 0.00021420124
isoniazid B-Chemical 1 0.9998466
therapy O 0 0.00054911635
13 O 0 0.00020116732
mg O 0 0.003296899
/ O 0 0.00041590672
kg O 0 0.00022970529
daily O 0 8.588812e-05
from O 0 5.0935807e-05
birth O 0 0.00012374937
because O 0 4.4228527e-05
of O 0 0.000115172326
maternal O 0 0.0003544482
tuberculosis B-Disease 0 0.043944508
was O 0 0.00018424778
admitted O 0 0.00022138533
after O 0 4.803604e-05
4 O 0 9.392198e-05
days O 0 0.000107548956
of O 0 0.00080351526
clonic B-Disease 0 0.9998733
fits I-Disease 0 0.68909466
. O 0 0.003335572

No O 0 0.0046668076
underlying O 0 0.00405342
infective O 0 0.0063091847
or O 0 0.0019231783
biochemical O 0 0.0050405166
cause O 0 0.0028691182
could O 0 0.0017379995
be O 0 0.002110676
found O 0 0.0028098873
. O 0 0.0040638936

The O 0 0.0019385687
fits B-Disease 0 0.0029937325
ceased O 0 0.0010537786
within O 0 0.00024765375
4 O 0 0.00023618805
hours O 0 0.00013564981
of O 0 0.0002742964
administering O 0 0.0012834362
intramuscular O 0 0.23561418
pyridoxine B-Chemical 1 0.9999933
, O 0 0.00041682614
suggesting O 0 9.1016685e-05
an O 0 0.00021077991
aetiology O 0 0.004074791
of O 0 0.0022505322
pyridoxine B-Chemical 1 0.9999963
deficiency O 0 0.9762557
secondary O 0 0.009998634
to O 0 0.001388436
isoniazid B-Chemical 1 0.99991024
medication O 0 0.20439751
. O 0 0.002450319

Ketamine B-Chemical 1 0.9992587
sedation O 0 0.1682785
for O 0 0.0007918884
the O 0 0.0006059411
reduction O 0 0.0009016319
of O 0 0.0006058935
children O 0 0.0007452317
' O 0 0.00061898556
s O 0 0.0006256206
fractures B-Disease 2 0.8379273
in O 0 0.0006531591
the O 0 0.000962307
emergency O 0 0.011821379
department O 0 0.014591915
. O 0 0.0030913518

BACKGROUND O 0 0.009504828
: O 0 0.002434308
There O 0 0.001061621
recently O 0 0.00065968034
has O 0 0.00040393005
been O 0 0.00027537937
a O 0 0.00034159518
resurgence O 0 0.00038152607
in O 0 0.00014408746
the O 0 0.00013106679
utilization O 0 0.00022482651
of O 0 0.00046630212
ketamine B-Chemical 0 0.9999608
, O 0 0.0002981784
a O 0 0.0001769451
unique O 0 0.00014053585
anesthetic O 0 0.008378746
, O 0 0.00016387561
for O 0 0.0001093848
emergency O 0 0.00045901924
- O 0 0.00038202212
department O 0 0.00041781872
procedures O 0 0.00038383552
requiring O 0 0.0007893547
sedation O 0 0.04225903
. O 0 0.0019136462

The O 0 0.0014837867
purpose O 0 0.0010883786
of O 0 0.00089441735
the O 0 0.00051662006
present O 0 0.00033401258
study O 0 0.00039190034
was O 0 0.00021180618
to O 0 9.786162e-05
examine O 0 4.832094e-05
the O 0 8.497504e-05
safety O 0 0.000119466364
and O 0 8.341049e-05
efficacy O 0 0.00012639102
of O 0 0.00025597517
ketamine B-Chemical 0 0.9999404
for O 0 0.00014249922
sedation O 0 0.016365087
in O 0 6.236538e-05
the O 0 6.093867e-05
treatment O 0 7.259899e-05
of O 0 0.00013043641
children O 0 0.0002415308
' O 0 0.00024472605
s O 0 0.0002869227
fractures B-Disease 2 0.8554694
in O 0 0.00038824152
the O 0 0.00063325366
emergency O 0 0.010071035
department O 0 0.012119952
. O 0 0.0024205807

METHODS O 0 0.0017112959
: O 0 0.0013709923
One O 0 0.000749899
hundred O 0 0.0006040915
and O 0 0.0004481178
fourteen O 0 0.0005415427
children O 0 0.0004634108
( O 0 0.0002954722
average O 0 0.0001307688
age O 0 0.0002348562
, O 0 0.00018368664
5 O 0 9.3777104e-05
. O 0 6.692368e-05
3 O 0 6.749788e-05
years O 0 7.189166e-05
; O 0 9.0166475e-05
range O 0 7.97755e-05
, O 0 8.681838e-05
twelve O 0 5.8023612e-05
months O 0 2.2237866e-05
to O 0 3.5668327e-05
ten O 0 3.578679e-05
years O 0 4.0063158e-05
and O 0 4.298014e-05
ten O 0 3.208892e-05
months O 0 2.2363918e-05
) O 0 7.7971126e-05
who O 0 7.942685e-05
underwent O 0 5.5770728e-05
closed O 0 0.00013446399
reduction O 0 0.00013425107
of O 0 8.294394e-05
an O 0 9.422825e-05
isolated O 0 0.00010046815
fracture B-Disease 0 0.7850366
or O 0 0.000151889
dislocation B-Disease 0 0.92619836
in O 0 8.87957e-05
the O 0 8.858808e-05
emergency O 0 0.0011304406
department O 0 0.0006363822
at O 0 6.3821724e-05
a O 0 0.00014916783
level O 0 0.00013956179
- O 0 0.00052536
I O 0 0.003118613
trauma B-Disease 0 0.25160414
center O 0 0.00055253156
were O 0 0.00045376213
prospectively O 0 0.0007308852
evaluated O 0 0.00093884976
. O 0 0.001771882

Ketamine B-Chemical 1 0.9998685
hydrochloride I-Chemical 0 0.9995473
was O 0 0.0017597282
administered O 0 0.00074833527
intravenously O 0 0.00054795254
( O 0 0.00031142565
at O 0 0.00010257384
a O 0 0.00016749025
dose O 0 0.0003533788
of O 0 0.00012338611
two O 0 5.328056e-05
milligrams O 0 0.00011632284
per O 0 2.5504998e-05
kilogram O 0 0.00011947662
of O 0 7.446138e-05
body O 0 0.00025390938
weight O 0 0.0005665498
) O 0 0.00015655409
in O 0 7.327223e-05
ninety O 0 0.0001758101
- O 0 0.00012194483
nine O 0 4.9415194e-05
of O 0 6.264714e-05
the O 0 6.082766e-05
patients O 0 9.995032e-05
and O 0 6.902033e-05
intramuscularly O 0 0.00013919896
( O 0 7.757338e-05
at O 0 3.2168766e-05
a O 0 7.419247e-05
dose O 0 0.00018963423
of O 0 7.5015865e-05
four O 0 3.3849246e-05
milligrams O 0 9.3634575e-05
per O 0 2.4814437e-05
kilogram O 0 0.00013520663
of O 0 0.00010491058
body O 0 0.00039211352
weight O 0 0.0008687762
) O 0 0.00033289837
in O 0 0.0002143757
the O 0 0.00035419772
other O 0 0.0006280704
fifteen O 0 0.0013287289
. O 0 0.0017674092

A O 0 0.028967587
board O 0 0.0056153857
- O 0 0.0022932768
certified O 0 0.0011197111
emergency O 0 0.0009352437
physician O 0 0.0008581512
skilled O 0 0.0004627418
in O 0 0.00016144909
airway O 0 0.0005051437
management O 0 0.00013898742
supervised O 0 0.00011639385
administration O 0 0.00031801587
of O 0 0.0001376415
the O 0 0.00013072528
anesthetic O 0 0.012258781
, O 0 0.00014329635
and O 0 0.00010189941
the O 0 0.000107397886
patients O 0 0.00017908566
were O 0 0.00013311591
monitored O 0 0.00012432112
by O 0 0.00029251125
a O 0 0.00065083103
registered O 0 0.0012766783
nurse O 0 0.003066089
. O 0 0.0020733138

Any O 0 0.0042257626
pain B-Disease 0 0.073451616
during O 0 0.00054905517
the O 0 0.00055844086
reduction O 0 0.0008879572
was O 0 0.00037960376
rated O 0 0.00029860428
by O 0 0.00016076809
the O 0 0.00013162388
orthopaedic O 0 0.0004169555
surgeon O 0 0.00023322344
treating O 0 0.00015387255
the O 0 7.637773e-05
patient O 0 7.28203e-05
according O 0 3.698914e-05
to O 0 4.706163e-05
the O 0 6.735694e-05
Children O 0 0.00014578567
' O 0 0.00011928968
s O 0 0.00010760433
Hospital O 0 0.00020456366
of O 0 0.00019673485
Eastern O 0 0.00065197365
Ontario O 0 0.0014830331
Pain B-Disease 0 0.09959793
Scale O 0 0.009438283
( O 0 0.00146863
CHEOPS O 0 0.04870303
) O 0 0.0024133585
. O 0 0.0022422962

RESULTS O 0 0.003852105
: O 0 0.00126206
The O 0 0.00038020502
average O 0 0.00023468696
time O 0 0.00016626723
from O 0 0.00020516412
intravenous O 0 0.002110234
administration O 0 0.00092940615
of O 0 0.0005516475
ketamine B-Chemical 0 0.9999279
to O 0 0.00012860364
manipulation O 0 7.7939825e-05
of O 0 0.00011990209
the O 0 0.00014719606
fracture B-Disease 0 0.84971625
or O 0 0.00021396302
dislocation B-Disease 0 0.96343476
was O 0 0.0001285475
one O 0 4.2713815e-05
minute O 0 4.4344073e-05
and O 0 6.136835e-05
thirty O 0 5.9522346e-05
- O 0 9.45329e-05
six O 0 2.816394e-05
seconds O 0 3.9645918e-05
( O 0 8.342926e-05
range O 0 6.299755e-05
, O 0 6.367399e-05
twenty O 0 3.6125082e-05
seconds O 0 2.9471305e-05
to O 0 3.4519668e-05
five O 0 2.7549875e-05
minutes O 0 3.6548456e-05
) O 0 0.00011106395
, O 0 6.675935e-05
and O 0 4.8001923e-05
the O 0 3.609471e-05
average O 0 2.3598775e-05
time O 0 2.2124275e-05
from O 0 4.1459356e-05
intramuscular O 0 0.0004122334
administration O 0 0.00022513582
to O 0 4.7060148e-05
manipulation O 0 4.8318776e-05
was O 0 5.471514e-05
four O 0 2.5157671e-05
minutes O 0 2.852931e-05
and O 0 6.8048255e-05
forty O 0 0.00010914683
- O 0 0.00011496243
two O 0 4.2718944e-05
seconds O 0 5.7496e-05
( O 0 0.00012593147
range O 0 0.00011145247
, O 0 0.00015010468
sixty O 0 0.00018031454
seconds O 0 0.00011366081
to O 0 0.0001928986
fifteen O 0 0.00038454478
minutes O 0 0.00048095282
) O 0 0.0017635099
. O 0 0.002018084

The O 0 0.0012139606
average O 0 0.0006794519
score O 0 0.0005347891
according O 0 0.00029665264
to O 0 0.00026474803
the O 0 0.00025673385
Children O 0 0.000383442
' O 0 0.00024924538
s O 0 0.00018078089
Hospital O 0 0.0002621291
of O 0 0.00019054026
Eastern O 0 0.000557812
Ontario O 0 0.0011729477
Pain B-Disease 0 0.13963635
Scale O 0 0.003290007
was O 0 0.00014023292
6 O 0 5.2644038e-05
. O 0 4.231689e-05
4 O 0 4.4650613e-05
points O 0 5.9778326e-05
( O 0 0.000109359775
range O 0 8.6991495e-05
, O 0 9.218032e-05
5 O 0 4.9492355e-05
to O 0 5.2835763e-05
10 O 0 6.796558e-05
points O 0 8.686863e-05
) O 0 0.00016783172
, O 0 0.00010614598
reflecting O 0 9.648661e-05
minimal O 0 0.00011568413
or O 0 0.00014998221
no O 0 0.0002065136
pain B-Disease 0 0.16068551
during O 0 0.00048160015
fracture B-Disease 0 0.89671135
reduction O 0 0.00959816
. O 0 0.0027588315

Adequate O 0 0.007092284
fracture B-Disease 0 0.59062225
reduction O 0 0.0045290748
was O 0 0.0016831004
obtained O 0 0.0011399905
in O 0 0.0010914452
111 O 0 0.002268697
of O 0 0.0015082519
the O 0 0.0018793348
children O 0 0.0042085377
. O 0 0.0038771403

Ninety O 0 0.004623179
- O 0 0.0026461943
nine O 0 0.0008396327
percent O 0 0.00053030957
( O 0 0.00074989867
sixty O 0 0.00061463186
- O 0 0.00047182405
eight O 0 0.00014671068
) O 0 0.0002307068
of O 0 0.00015490272
the O 0 0.00014688299
sixty O 0 0.0002348983
- O 0 0.00020200034
nine O 0 8.875313e-05
parents O 0 0.00017591339
present O 0 4.464508e-05
during O 0 3.0028432e-05
the O 0 6.1375606e-05
reduction O 0 0.00021221288
were O 0 9.664536e-05
pleased O 0 0.0006553634
with O 0 9.4413626e-05
the O 0 9.868148e-05
sedation O 0 0.01168578
and O 0 8.3565414e-05
would O 0 6.243941e-05
allow O 0 5.749776e-05
it O 0 8.539323e-05
to O 0 7.391578e-05
be O 0 8.4349536e-05
used O 0 9.4423536e-05
again O 0 0.00017455447
in O 0 0.00021266093
a O 0 0.00045856638
similar O 0 0.0004568669
situation O 0 0.0013533114
. O 0 0.0019913912

Patency O 0 0.0057602925
of O 0 0.0016510116
the O 0 0.001020618
airway O 0 0.0019408644
and O 0 0.00056432444
independent O 0 0.00031645954
respiration O 0 0.008224748
were O 0 0.00031233966
maintained O 0 0.00026915464
in O 0 0.00026944937
all O 0 0.0003574787
of O 0 0.00066023
the O 0 0.0010044551
patients O 0 0.002530163
. O 0 0.0023938527

Blood O 0 0.023303296
pressure O 0 0.014835028
and O 0 0.004212038
heart O 0 0.019137649
rate O 0 0.0039795833
remained O 0 0.004891409
stable O 0 0.0061544
. O 0 0.006248672

Minor O 0 0.036035404
side O 0 0.007873883
effects O 0 0.0015448581
included O 0 0.0014772929
nausea B-Disease 0 0.9998392
( O 0 0.0014087154
thirteen O 0 0.0007788883
patients O 0 0.0005814207
) O 0 0.0005400424
, O 0 0.0005152696
emesis B-Disease 0 0.9998801
( O 0 0.00025976828
eight O 0 5.3306532e-05
of O 0 7.757109e-05
the O 0 6.772749e-05
thirteen O 0 0.00013819228
patients O 0 0.00014827117
with O 0 0.00037344743
nausea B-Disease 0 0.9999771
) O 0 0.000900699
, O 0 0.0003589205
clumsiness B-Disease 0 0.99897456
( O 0 0.0002514127
evident O 0 8.866464e-05
as O 0 0.00017198922
ataxic B-Disease 0 0.9999709
movements I-Disease 0 0.006781605
in O 0 8.984462e-05
ten O 0 6.253486e-05
patients O 0 0.00015843274
) O 0 0.00017527482
, O 0 0.00014509614
and O 0 0.00028955206
dysphoric B-Disease 0 0.9996183
reaction I-Disease 0 0.29690656
( O 0 0.0006892586
one O 0 0.0003985537
patient O 0 0.0009704395
) O 0 0.0019227391
. O 0 0.0019588715

No O 0 0.0036185773
long O 0 0.001961207
- O 0 0.001978661
term O 0 0.0008220444
sequelae O 0 0.005030058
were O 0 0.0005175748
noted O 0 0.00026625162
, O 0 0.0003403654
and O 0 0.00025771905
no O 0 0.00019835246
patients O 0 0.0006165498
had O 0 0.0009820913
hallucinations B-Disease 0 0.9998945
or O 0 0.0029820022
nightmares O 0 0.9679961
. O 0 0.0032930698

CONCLUSIONS O 0 0.02093202
: O 0 0.0046128905
Ketamine B-Chemical 1 0.9992169
reliably O 0 0.0015957974
, O 0 0.0008434304
safely O 0 0.0006855305
, O 0 0.00028276586
and O 0 0.00017697582
quickly O 0 0.00021555155
provided O 0 0.000117413845
adequate O 0 0.0001262761
sedation O 0 0.0031081762
to O 0 6.624378e-05
effectively O 0 6.983685e-05
facilitate O 0 3.7428636e-05
the O 0 6.3359505e-05
reduction O 0 0.0001738522
of O 0 0.00013548306
children O 0 0.00020281748
' O 0 0.00016904865
s O 0 0.00017743644
fractures B-Disease 2 0.81710106
in O 0 0.00015231727
the O 0 0.00019462412
emergency O 0 0.0020495492
department O 0 0.0015730956
at O 0 0.00032892122
our O 0 0.00107619
institution O 0 0.0022392408
. O 0 0.0020075764

Ketamine B-Chemical 1 0.99889463
should O 0 0.0012075325
only O 0 0.00095636223
be O 0 0.0004418207
used O 0 0.0002555002
in O 0 0.00020409122
an O 0 0.00021581395
environment O 0 0.00015889431
such O 0 8.89045e-05
as O 0 9.923199e-05
the O 0 0.00012317451
emergency O 0 0.001924373
department O 0 0.0015735078
, O 0 0.000123099
where O 0 5.8263366e-05
proper O 0 6.755822e-05
one O 0 6.848841e-05
- O 0 0.00015777229
on O 0 4.7703023e-05
- O 0 0.00013330887
one O 0 4.1781164e-05
monitoring O 0 5.777355e-05
is O 0 5.725024e-05
used O 0 5.0240746e-05
and O 0 9.286302e-05
board O 0 0.0003418789
- O 0 0.00019906218
certified O 0 0.00016050937
physicians O 0 0.0001702619
skilled O 0 0.00016143786
in O 0 6.972022e-05
airway O 0 0.0004055504
management O 0 0.00010900008
are O 0 6.942214e-05
directly O 0 6.201075e-05
involved O 0 6.0922288e-05
in O 0 9.481087e-05
the O 0 0.00014169657
care O 0 0.00023471519
of O 0 0.00039565685
the O 0 0.00064225134
patient O 0 0.0014361823
. O 0 0.0018228395

Cyclosporine B-Chemical 0 0.9991763
and O 0 0.02131265
tacrolimus B-Chemical 0 0.99988127
- O 0 0.025156053
associated O 0 0.016717413
thrombotic B-Disease 2 0.9999162
microangiopathy I-Disease 2 0.9999846
. O 0 0.019647522

The O 0 0.001758978
development O 0 0.0026552593
of O 0 0.0056233895
thrombotic B-Disease 2 0.9999715
microangiopathy I-Disease 2 0.99999857
( O 0 0.04131619
TMA B-Disease 0 0.99842405
) O 0 0.00074390345
associated O 0 0.00017717978
with O 0 0.00019412095
the O 0 0.00016269652
use O 0 0.00019180184
of O 0 0.00076065
cyclosporine B-Chemical 1 0.9999807
has O 0 0.0005777665
been O 0 0.00047963887
well O 0 0.00066000636
documented O 0 0.0020698516
. O 0 0.002076793

Treatments O 0 0.006657175
have O 0 0.0008267956
included O 0 0.0005633407
discontinuation O 0 0.003891481
or O 0 0.00031564775
reduction O 0 0.0006487271
of O 0 0.00088807143
cyclosporine B-Chemical 1 0.99999213
dose O 0 0.008249655
with O 0 0.00021698012
or O 0 8.2807055e-05
without O 0 8.018811e-05
concurrent O 0 0.00018935326
plasma O 0 0.003364201
exchange O 0 0.0003171624
, O 0 0.0001319997
plasma O 0 0.0016712203
infusion O 0 0.00044464198
, O 0 0.00021012896
anticoagulation O 0 0.02174403
, O 0 0.00018927494
and O 0 0.0002626447
intravenous O 0 0.040636223
immunoglobulin O 0 0.97399163
G O 0 0.92932904
infusion O 0 0.007414411
. O 0 0.0023439426

However O 0 0.0027362185
, O 0 0.0017949766
for O 0 0.0007119142
recipients O 0 0.0011804012
of O 0 0.0006812382
organ O 0 0.0018602028
transplantation O 0 0.0034945519
, O 0 0.0002961013
removing O 0 0.00022662424
the O 0 0.0001765617
inciting O 0 0.001608866
agent O 0 0.0016187555
is O 0 0.0001413054
not O 0 8.5566106e-05
without O 0 8.678543e-05
the O 0 0.00010546999
attendant O 0 0.00028811075
risk O 0 0.0011310363
of O 0 0.0003637121
precipitating O 0 0.41999048
acute O 0 0.87720114
rejection O 0 0.9901328
and O 0 0.0015370578
graft O 0 0.013200205
loss O 0 0.009464831
. O 0 0.002409693

The O 0 0.0016064263
last O 0 0.000797854
decade O 0 0.0010616235
has O 0 0.00041602802
seen O 0 0.00030126504
the O 0 0.00023075739
emergence O 0 0.0003073153
of O 0 0.000737561
tacrolimus B-Chemical 0 0.9999852
as O 0 0.0002954967
a O 0 0.00024291973
potent O 0 0.0004836953
immunosuppressive O 0 0.22293489
agent O 0 0.0011191772
with O 0 0.00016152085
mechanisms O 0 0.0001235838
of O 0 0.00013195701
action O 0 0.00016659922
virtually O 0 0.00014472086
identical O 0 0.00010586478
to O 0 0.00020360551
those O 0 0.0006228761
of O 0 0.0021998985
cyclosporine B-Chemical 1 0.99995136
. O 0 0.003981444

As O 0 0.0017042105
a O 0 0.001660415
result O 0 0.00084573764
, O 0 0.00073409866
switching O 0 0.0005891996
to O 0 0.0007357859
tacrolimus B-Chemical 0 0.9999752
has O 0 0.00035751247
been O 0 0.0001669015
reported O 0 0.00016629754
to O 0 0.00010114903
be O 0 8.4420186e-05
a O 0 0.00010755285
viable O 0 0.0001196028
therapeutic O 0 0.00021880168
option O 0 0.00015108688
in O 0 9.2090166e-05
the O 0 0.00011200402
setting O 0 0.00016353143
of O 0 0.00095909234
cyclosporine B-Chemical 1 0.9999882
- O 0 0.005250392
induced O 0 0.0038493196
TMA B-Disease 0 0.9969478
. O 0 0.0034335991

With O 0 0.0021723765
the O 0 0.0012175088
more O 0 0.0009882522
widespread O 0 0.00067953515
application O 0 0.000571776
of O 0 0.0010522958
tacrolimus B-Chemical 0 0.99997175
in O 0 0.00045802508
organ O 0 0.0021192238
transplantation O 0 0.014846211
, O 0 0.001219676
tacrolimus B-Chemical 0 0.99999154
- O 0 0.0019100885
associated O 0 0.00057138375
TMA B-Disease 0 0.98294157
has O 0 0.00041394206
also O 0 0.00050498435
been O 0 0.0006944864
recognized O 0 0.001512872
. O 0 0.0020825784

However O 0 0.0026527136
, O 0 0.0018569636
literature O 0 0.001170806
regarding O 0 0.0003750213
the O 0 0.00040414135
incidence O 0 0.00054884795
of O 0 0.00029674594
the O 0 0.00024541814
recurrence O 0 0.015612847
of O 0 0.00051936135
TMA B-Disease 0 0.98383486
in O 0 0.00015907639
patients O 0 0.00014553012
exposed O 0 9.274567e-05
sequentially O 0 0.00013362398
to O 0 0.000307558
cyclosporine B-Chemical 1 0.9999858
and O 0 0.0031793464
tacrolimus B-Chemical 0 0.99997544
is O 0 0.0018271826
limited O 0 0.0017361721
. O 0 0.0020922227

We O 0 0.0018150217
report O 0 0.0019069278
a O 0 0.0011881499
case O 0 0.0006042361
of O 0 0.00055055233
a O 0 0.00049581425
living O 0 0.0007913136
donor O 0 0.0006248883
renal O 0 0.76261497
transplant O 0 0.015317599
recipient O 0 0.00046735565
who O 0 0.0003013946
developed O 0 0.00083560287
cyclosporine B-Chemical 1 0.9999969
- O 0 0.0011954438
induced O 0 0.00031667142
TMA B-Disease 0 0.98242676
that O 0 6.255539e-05
responded O 0 0.0001131312
to O 0 4.375598e-05
the O 0 6.0837872e-05
withdrawal O 0 0.0020285465
of O 0 0.0003474415
cyclosporine B-Chemical 1 0.9999919
in O 0 0.00011318244
conjunction O 0 0.000102345315
with O 0 0.00014910667
plasmapheresis O 0 0.027665649
and O 0 0.00017031175
fresh O 0 0.00051377184
frozen O 0 0.0010179097
plasma O 0 0.005819573
replacement O 0 0.0025814935
therapy O 0 0.0018340067
. O 0 0.0017409778

Introduction O 0 0.0028919587
of O 0 0.0033698524
tacrolimus B-Chemical 0 0.9998394
as O 0 0.0008013338
an O 0 0.00047210974
alternative O 0 0.00029935595
immunosuppressive O 0 0.117718935
agent O 0 0.0014453937
resulted O 0 0.00020252241
in O 0 0.00013292096
the O 0 0.00015435043
recurrence O 0 0.0137668215
of O 0 0.00045824825
TMA B-Disease 0 0.983008
and O 0 0.00019635333
the O 0 0.00013291286
subsequent O 0 0.00016652267
loss O 0 0.00063458766
of O 0 0.00048932014
the O 0 0.0008082226
renal O 0 0.97414285
allograft O 0 0.98224294
. O 0 0.0033948484

Patients O 0 0.002303586
who O 0 0.0014238483
are O 0 0.00052671373
switched O 0 0.0005724137
from O 0 0.00056653976
cyclosporine B-Chemical 1 0.9999716
to O 0 0.0012212319
tacrolimus B-Chemical 0 0.9999894
or O 0 0.00052139245
vice O 0 0.0071129575
versa O 0 0.00094832754
should O 0 5.8029313e-05
be O 0 5.6746638e-05
closely O 0 3.761305e-05
monitored O 0 3.7901464e-05
for O 0 5.266116e-05
the O 0 0.00011099768
signs O 0 0.0010518578
and O 0 0.00030507974
symptoms O 0 0.0035430149
of O 0 0.0011565859
recurrent O 0 0.1870533
TMA B-Disease 0 0.9969373
. O 0 0.0033180532

Analgesic O 0 0.9609395
effect O 0 0.001382937
of O 0 0.001479847
intravenous O 0 0.25233334
ketamine B-Chemical 0 0.9999455
in O 0 0.0011636196
cancer B-Disease 0 0.96449494
patients O 0 0.00046676266
on O 0 0.00013606747
morphine B-Chemical 0 0.9998646
therapy O 0 0.00036219106
: O 0 0.00013730697
a O 0 0.00011922646
randomized O 0 0.000114418326
, O 0 9.104881e-05
controlled O 0 8.626998e-05
, O 0 0.00012961798
double O 0 0.00026897757
- O 0 0.00038764664
blind O 0 0.004068213
, O 0 0.00027652597
crossover O 0 0.002218184
, O 0 0.0003451413
double O 0 0.0006717985
- O 0 0.0009629178
dose O 0 0.0025680326
study O 0 0.0018840699
. O 0 0.0020404002

Pain B-Disease 0 0.11102326
not O 0 0.0025238455
responsive O 0 0.0018416097
to O 0 0.0030113354
morphine B-Chemical 0 0.9988508
is O 0 0.0035890515
often O 0 0.0035835088
problematic O 0 0.004441442
. O 0 0.0046124263

Animal O 0 0.0062361984
and O 0 0.0016783318
clinical O 0 0.0017567045
studies O 0 0.00064504397
have O 0 0.00029177006
suggested O 0 0.00022888501
that O 0 0.00036528692
N B-Chemical 0 0.99279857
- I-Chemical 0 0.0032684586
methyl I-Chemical 0 0.99683857
- I-Chemical 0 0.0045333374
D I-Chemical 0 0.9538282
- I-Chemical 0 0.0040025683
aspartate I-Chemical 1 0.9999342
( O 0 0.0103242835
NMDA B-Chemical 1 0.9999982
) O 0 0.0032136466
antagonists O 0 0.73314154
, O 0 0.00015618984
such O 0 6.98899e-05
as O 0 0.00017945164
ketamine B-Chemical 0 0.9999528
, O 0 0.00018609139
may O 0 5.5846667e-05
be O 0 4.1336654e-05
effective O 0 3.4493805e-05
in O 0 4.726451e-05
improving O 0 0.00013022737
opioid O 0 0.9817617
analgesia O 0 0.5349663
in O 0 9.443029e-05
difficult O 0 0.00012441551
pain B-Disease 0 0.40909204
syndromes O 0 0.021411847
, O 0 0.0003050751
such O 0 0.0002762548
as O 0 0.0011017623
neuropathic B-Disease 0 0.99978226
pain I-Disease 0 0.99776113
. O 0 0.003356457

A O 0 0.012339459
slow O 0 0.003179047
bolus O 0 0.0033669006
of O 0 0.0012865032
subhypnotic O 0 0.99434423
doses O 0 0.0125406915
of O 0 0.0016165437
ketamine B-Chemical 0 0.9999707
( O 0 0.00065707444
0 O 0 0.00012883883
. O 0 6.526548e-05
25 O 0 0.0001327177
mg O 0 0.0014973048
/ O 0 0.00036808854
kg O 0 0.00022816227
or O 0 6.591271e-05
0 O 0 6.050201e-05
. O 0 4.1964053e-05
50 O 0 0.000115962124
mg O 0 0.0016412226
/ O 0 0.00043618277
kg O 0 0.000338731
) O 0 0.00013424979
was O 0 6.0109407e-05
given O 0 3.1051e-05
to O 0 4.9813953e-05
10 O 0 8.6832624e-05
cancer B-Disease 0 0.58903575
patients O 0 0.00019941496
whose O 0 0.00033134938
pain B-Disease 0 0.42697892
was O 0 0.0001994338
unrelieved O 0 0.022308847
by O 0 0.00022556103
morphine B-Chemical 0 0.99978095
in O 0 9.8461715e-05
a O 0 0.000120317854
randomized O 0 0.00011648312
, O 0 0.00010640745
double O 0 0.0002284729
- O 0 0.00034566337
blind O 0 0.0040135705
, O 0 0.00026067038
crossover O 0 0.0022007339
, O 0 0.0003310974
double O 0 0.00065392425
- O 0 0.0009384781
dose O 0 0.002514734
study O 0 0.0018455163
. O 0 0.0020030902

Pain B-Disease 0 0.062447477
intensity O 0 0.0010670364
on O 0 0.0005565497
a O 0 0.0006604471
0 O 0 0.00033324672
to O 0 0.00020863963
10 O 0 0.0001883686
numerical O 0 0.0005096115
scale O 0 0.00030028517
; O 0 0.0005506305
nausea B-Disease 0 0.9998869
and O 0 0.0011974678
vomiting B-Disease 0 0.99985206
, O 0 0.00126653
drowsiness O 0 0.99992883
, O 0 0.0006133173
confusion B-Disease 0 0.37945294
, O 0 0.0002045964
and O 0 0.00019840314
dry B-Disease 2 0.94211066
mouth I-Disease 2 0.8980164
, O 0 0.00015489444
using O 0 6.0199756e-05
a O 0 9.395415e-05
scale O 0 6.695808e-05
from O 0 5.0681774e-05
0 O 0 5.2389132e-05
to O 0 5.1222516e-05
3 O 0 5.1325685e-05
( O 0 7.492949e-05
not O 0 4.7762467e-05
at O 0 4.771053e-05
all O 0 9.2704984e-05
, O 0 0.0001331356
slight O 0 0.0003288102
, O 0 0.0001582389
a O 0 0.00019967258
lot O 0 0.00030824577
, O 0 0.000247518
awful O 0 0.006501543
) O 0 0.00036026738
; O 0 0.00017059162
Mini O 0 0.00024160591
- O 0 0.00021344119
Mental O 0 0.0002424246
State O 0 0.00021222341
Examination O 0 0.00010396221
( O 0 0.00019242117
MMSE O 0 0.10072126
) O 0 0.00018068164
( O 0 0.00012306699
0 O 0 7.5730306e-05
- O 0 0.0001328723
30 O 0 6.139399e-05
) O 0 0.00012315033
; O 0 7.764236e-05
and O 0 6.740314e-05
arterial O 0 0.0017217776
pressure O 0 0.0005602364
were O 0 4.990015e-05
recorded O 0 3.2660693e-05
before O 0 2.0272e-05
administration O 0 0.00015369189
of O 0 0.00013750992
drugs O 0 0.015250004
( O 0 0.00021879417
T0 O 0 0.00046187808
) O 0 0.00011374051
and O 0 4.8761012e-05
after O 0 1.965543e-05
30 O 0 3.4774843e-05
minutes O 0 3.99644e-05
( O 0 0.00015059485
T30 O 0 0.008366825
) O 0 0.00019430576
, O 0 8.990204e-05
60 O 0 6.3187304e-05
minutes O 0 4.939395e-05
( O 0 0.00015749905
T60 O 0 0.0019046384
) O 0 0.00018792514
, O 0 9.667126e-05
120 O 0 7.8137775e-05
minutes O 0 6.563322e-05
( O 0 0.00021250568
T120 O 0 0.0047450876
) O 0 0.00032836793
, O 0 0.00020380788
and O 0 0.00019736598
180 O 0 0.00029674708
minutes O 0 0.00027157037
( O 0 0.0009847002
T180 O 0 0.010941898
) O 0 0.002963553
. O 0 0.0026527594

Ketamine B-Chemical 1 0.9994111
, O 0 0.0032775823
but O 0 0.0011428435
not O 0 0.0006188997
saline O 0 0.0025604663
solution O 0 0.0026170036
, O 0 0.00036916407
significantly O 0 0.00029091872
reduced O 0 0.00032501324
the O 0 0.00024094636
pain B-Disease 0 0.08880501
intensity O 0 9.9063705e-05
in O 0 0.00010687706
almost O 0 0.00013197956
all O 0 0.00013781368
the O 0 0.00017283008
patients O 0 0.00031451922
at O 0 0.00026365728
both O 0 0.0007739202
doses O 0 0.006498125
. O 0 0.0023426742

This O 0 0.0038755934
effect O 0 0.0017104064
was O 0 0.001258652
more O 0 0.0008621423
relevant O 0 0.00046059268
in O 0 0.0005255655
patients O 0 0.0007588833
treated O 0 0.0009119435
with O 0 0.0011099819
higher O 0 0.002077558
doses O 0 0.01552119
. O 0 0.0035116917

Hallucinations B-Disease 0 0.99114406
occurred O 0 0.0017562305
in O 0 0.00095710246
4 O 0 0.000538551
patients O 0 0.000583522
, O 0 0.00037966043
and O 0 0.0002634678
an O 0 0.00036764087
unpleasant O 0 0.03082299
sensation O 0 0.16740653
( O 0 0.00048748896
" O 0 0.00027282644
empty O 0 0.0003301804
head O 0 0.0020739527
" O 0 0.0004275821
) O 0 0.00036985026
was O 0 0.00023596994
also O 0 0.00024490766
reported O 0 0.00044997316
by O 0 0.0005863849
2 O 0 0.0006954292
patients O 0 0.0017193205
. O 0 0.001987409

These O 0 0.0028116608
episodes O 0 0.003948449
reversed O 0 0.0019830726
after O 0 0.00038563838
the O 0 0.000612592
administration O 0 0.0024299326
of O 0 0.0026594817
diazepam B-Chemical 0 0.999972
1 O 0 0.0016028082
mg O 0 0.022503363
intravenously O 0 0.003033056
. O 0 0.0028312262

Significant O 0 0.0022869848
increases O 0 0.001321123
in O 0 0.0012800327
drowsiness O 0 0.9988199
were O 0 0.0005655217
reported O 0 0.0002915868
in O 0 0.00016578994
patients O 0 0.00021843192
treated O 0 0.00023542298
with O 0 0.00041389986
ketamine B-Chemical 0 0.9999534
in O 0 0.00015185583
both O 0 0.00010424662
groups O 0 7.544436e-05
and O 0 6.410786e-05
were O 0 6.279135e-05
more O 0 0.00010070151
marked O 0 0.00023368954
with O 0 0.00036657116
ketamine B-Chemical 0 0.99990416
0 O 0 0.00023332264
. O 0 0.0001486826
50 O 0 0.00048734705
mg O 0 0.005866651
/ O 0 0.0025895587
kg O 0 0.0030706571
. O 0 0.0020816745

A O 0 0.0151100345
significant O 0 0.0014733506
difference O 0 0.0006146386
in O 0 0.0007818473
MMSE O 0 0.16948505
was O 0 0.0003634317
observed O 0 0.00018239391
at O 0 0.00015665639
T30 O 0 0.00715681
in O 0 0.00018270407
patients O 0 0.00024768282
who O 0 0.00020551184
received O 0 9.495155e-05
0 O 0 0.000100234276
. O 0 8.678982e-05
50 O 0 0.00026349069
mg O 0 0.0027790652
/ O 0 0.0011252783
kg O 0 0.0013201413
of O 0 0.0019432127
ketamine B-Chemical 0 0.9996829
. O 0 0.0037595618

Ketamine B-Chemical 1 0.99881685
can O 0 0.0015705401
improve O 0 0.0014441031
morphine B-Chemical 0 0.99980074
analgesia O 0 0.92136467
in O 0 0.0004936427
difficult O 0 0.00045720997
pain B-Disease 0 0.57311785
syndromes O 0 0.03941946
, O 0 0.00058355625
such O 0 0.0004689425
as O 0 0.001616961
neuropathic B-Disease 0 0.99975353
pain I-Disease 0 0.9978625
. O 0 0.0041945586

However O 0 0.0027858089
, O 0 0.0018369849
the O 0 0.00088971626
occurrence O 0 0.0008497678
of O 0 0.0005956732
central O 0 0.00062313606
adverse O 0 0.011723611
effects O 0 0.00034546803
should O 0 0.000110158035
be O 0 0.000106930485
taken O 0 6.552747e-05
into O 0 5.567736e-05
account O 0 0.00012678684
, O 0 0.00020044798
especially O 0 0.00022099646
when O 0 0.00019904377
using O 0 0.00038394658
higher O 0 0.001134792
doses O 0 0.008590528
. O 0 0.0026344927

This O 0 0.004281222
observation O 0 0.0017827536
should O 0 0.00071868015
be O 0 0.0006694152
tested O 0 0.00051652035
in O 0 0.0004787735
studies O 0 0.0005746092
of O 0 0.0009295452
prolonged O 0 0.0055757146
ketamine B-Chemical 0 0.99987936
administration O 0 0.17636044
. O 0 0.0041787005

Paclitaxel B-Chemical 0 0.99703264
, O 0 0.006114207
cisplatin B-Chemical 0 0.9972007
, O 0 0.0015910995
and O 0 0.00095032615
gemcitabine B-Chemical 0 0.9827382
combination O 0 0.0008221399
chemotherapy O 0 0.0015646854
within O 0 7.529177e-05
a O 0 0.00019331102
multidisciplinary O 0 0.00032301006
therapeutic O 0 0.00033832018
approach O 0 0.0002528876
in O 0 0.00038822243
metastatic O 0 0.584959
nonsmall B-Disease 0 0.99318105
cell I-Disease 0 0.027719479
lung I-Disease 0 0.7786511
carcinoma I-Disease 0 0.99904794
. O 0 0.003614459

BACKGROUND O 0 0.0110762445
: O 0 0.004260514
Cisplatin B-Chemical 0 0.997773
- O 0 0.0017866197
based O 0 0.00042435576
chemotherapy O 0 0.0012004907
combinations O 0 0.00017498143
improve O 0 0.0001084299
quality O 0 0.000112368696
of O 0 0.00016038056
life O 0 0.00018439928
and O 0 0.00015715204
survival O 0 0.0009409568
in O 0 0.00023157842
advanced O 0 0.0057747844
nonsmall B-Disease 0 0.9829229
cell I-Disease 0 0.009806251
lung I-Disease 0 0.6612745
carcinoma I-Disease 0 0.9995844
( O 0 0.005483717
NSCLC B-Disease 2 0.9977366
) O 0 0.0037688676
. O 0 0.0022425416

The O 0 0.001595056
emergence O 0 0.0014945512
of O 0 0.0011061744
new O 0 0.0008833698
active O 0 0.00073027296
drugs O 0 0.004989684
might O 0 0.00017397557
translate O 0 0.00014434765
into O 0 6.216148e-05
more O 0 0.00014024857
effective O 0 0.00011672808
regimens O 0 0.00021370531
for O 0 0.00012251618
the O 0 0.00020845432
treatment O 0 0.00032842832
of O 0 0.00073485076
this O 0 0.0018792374
disease O 0 0.44167003
. O 0 0.0029640545

METHODS O 0 0.0015441565
: O 0 0.0011582893
The O 0 0.00045647906
objective O 0 0.0005713832
of O 0 0.000470203
this O 0 0.0004017657
study O 0 0.00035389594
was O 0 0.00019757045
to O 0 9.7362245e-05
determine O 0 4.9897535e-05
the O 0 8.54522e-05
feasibility O 0 8.217117e-05
, O 0 0.00011001851
response O 0 9.209552e-05
rate O 0 0.00012913081
, O 0 0.00013366426
and O 0 0.00015564094
toxicity B-Disease 2 0.96327543
of O 0 0.00026234487
a O 0 0.0004102904
paclitaxel B-Chemical 1 0.9964348
, O 0 0.00066338864
cisplatin B-Chemical 0 0.99880636
, O 0 0.00034246218
and O 0 0.0003130053
gemcitabine B-Chemical 0 0.982546
combination O 0 0.00061168475
to O 0 0.0004284273
treat O 0 0.0021880027
metastatic O 0 0.87523496
NSCLC B-Disease 2 0.998604
. O 0 0.0032052016

Thirty O 0 0.0032600267
- O 0 0.0019520071
five O 0 0.00044096675
consecutive O 0 0.00047275188
chemotherapy O 0 0.0023125217
- O 0 0.00066668517
naive O 0 0.00068313215
patients O 0 0.00029104608
with O 0 0.00025775636
Stage O 0 0.05308413
IV O 0 0.23597169
NSCLC B-Disease 2 0.9916893
and O 0 0.0001235488
an O 0 0.00011504807
Eastern O 0 0.00020580183
Cooperative O 0 0.00012839044
Oncology O 0 9.702654e-05
Group O 0 0.00014164268
performance O 0 7.091579e-05
status O 0 4.6448917e-05
of O 0 7.9967576e-05
0 O 0 7.101209e-05
- O 0 0.00012320833
2 O 0 4.338775e-05
were O 0 4.4637804e-05
treated O 0 6.717483e-05
with O 0 6.726284e-05
a O 0 8.238867e-05
combination O 0 0.00010457738
of O 0 0.00019936533
paclitaxel B-Chemical 1 0.990357
( O 0 0.00027662932
135 O 0 0.00036390632
mg O 0 0.005238064
/ O 0 0.000530256
m O 0 0.0005158173
( O 0 0.00013002376
2 O 0 5.5492364e-05
) O 0 6.9028756e-05
given O 0 2.715579e-05
intravenously O 0 6.4046086e-05
in O 0 4.9000937e-05
3 O 0 3.7292146e-05
hours O 0 2.9517034e-05
) O 0 7.3340605e-05
on O 0 3.3786426e-05
Day O 0 0.00012466704
1 O 0 7.054126e-05
, O 0 0.00013007101
cisplatin B-Chemical 0 0.9714868
( O 0 0.00017473268
120 O 0 0.00010310103
mg O 0 0.0023692867
/ O 0 0.000484908
m O 0 0.00050539704
( O 0 0.00013670238
2 O 0 5.9089303e-05
) O 0 7.297184e-05
given O 0 2.8665288e-05
intravenously O 0 6.5808956e-05
in O 0 4.8774316e-05
6 O 0 3.1532207e-05
hours O 0 2.9784927e-05
) O 0 7.455161e-05
on O 0 3.4269735e-05
Day O 0 0.000120586155
1 O 0 6.144951e-05
, O 0 8.13844e-05
and O 0 0.00012522485
gemcitabine B-Chemical 0 0.9699981
( O 0 0.00024799138
800 O 0 0.0005373114
mg O 0 0.00624052
/ O 0 0.000610492
m O 0 0.000578208
( O 0 0.00014423675
2 O 0 6.1345054e-05
) O 0 7.4759635e-05
given O 0 2.915934e-05
intravenously O 0 6.234017e-05
in O 0 4.5631117e-05
30 O 0 3.934364e-05
minutes O 0 4.0513747e-05
) O 0 0.00010492149
on O 0 5.7978374e-05
Days O 0 0.00038211502
1 O 0 0.000108360546
and O 0 0.0001401808
8 O 0 0.00014502007
, O 0 0.00022077386
every O 0 0.00014326737
4 O 0 0.00039224103
weeks O 0 0.00052265654
. O 0 0.0016008881

Although O 0 0.0013799188
responding O 0 0.0018894504
patients O 0 0.00094187044
were O 0 0.00034627784
scheduled O 0 0.00013828599
to O 0 0.000121822566
receive O 0 9.397136e-05
consolidation O 0 0.00073999417
radiotherapy O 0 0.001465659
and O 0 0.00011160284
24 O 0 5.720652e-05
patients O 0 7.929615e-05
received O 0 4.4993765e-05
preplanned O 0 0.00015104077
second O 0 7.9212026e-05
- O 0 0.00017998731
line O 0 0.00014155044
chemotherapy O 0 0.0005610682
after O 0 4.324953e-05
disease O 0 0.108992316
progression O 0 0.0126324175
, O 0 0.000105803316
the O 0 5.9058264e-05
response O 0 7.806226e-05
and O 0 0.00014109054
toxicity B-Disease 2 0.96966124
rates O 0 0.00014257806
reported O 0 0.00010653843
refer O 0 8.047369e-05
only O 0 0.000101627506
to O 0 0.00010303862
the O 0 0.000198511
chemotherapy O 0 0.001980545
regimen O 0 0.00087802776
given O 0 0.00078835385
. O 0 0.0017129887

RESULTS O 0 0.0046479153
: O 0 0.0017297659
All O 0 0.0006430951
the O 0 0.0006036342
patients O 0 0.000617884
were O 0 0.00034431543
examined O 0 0.00022632451
for O 0 0.00035836012
toxicity B-Disease 2 0.9839409
; O 0 0.00073839293
34 O 0 0.00049814215
were O 0 0.000399227
examinable O 0 0.0008953196
for O 0 0.0006265147
response O 0 0.0016084004
. O 0 0.0024641731

An O 0 0.0026609418
objective O 0 0.0018300784
response O 0 0.0011899689
was O 0 0.0008659108
observed O 0 0.00044431194
in O 0 0.0003955746
73 O 0 0.0006101514
. O 0 0.00015285445
5 O 0 0.00011657468
% O 0 0.0001334218
of O 0 0.0001418853
the O 0 0.00014540889
patients O 0 0.00024718267
( O 0 0.00020618545
95 O 0 0.00017406401
% O 0 0.000109719826
confidence O 0 0.00041904463
interval O 0 0.000121371995
[ O 0 0.00048703075
CI O 0 0.015375559
] O 0 0.0003164176
, O 0 0.00011936843
55 O 0 0.00011371578
. O 0 5.3929354e-05
6 O 0 5.3794167e-05
- O 0 0.00014855222
87 O 0 0.00018040636
. O 0 6.219896e-05
1 O 0 7.8206285e-05
% O 0 0.00011574107
) O 0 0.00016745766
, O 0 0.00010934163
including O 0 6.42803e-05
4 O 0 7.099665e-05
complete O 0 0.00010747493
responses O 0 0.00022676859
( O 0 0.0003456092
11 O 0 0.00029059692
. O 0 0.0002452979
7 O 0 0.0004016087
% O 0 0.0009783744
) O 0 0.002137131
. O 0 0.0024257912

According O 0 0.0021505018
to O 0 0.0017744747
intention O 0 0.0047907066
- O 0 0.0020473446
to O 0 0.0006913692
- O 0 0.0010792644
treat O 0 0.0005945434
, O 0 0.00027613156
the O 0 0.00014980925
overall O 0 0.0001519636
response O 0 0.00014566911
rate O 0 0.00019165795
was O 0 0.00019687542
71 O 0 0.00029412706
. O 0 7.660962e-05
4 O 0 7.826097e-05
% O 0 0.000121819205
( O 0 0.00017371796
95 O 0 0.00020639827
% O 0 0.00019283146
CI O 0 0.0028361874
, O 0 0.00018649834
53 O 0 0.00023175775
. O 0 0.00010196007
7 O 0 0.0001292879
- O 0 0.00032902815
85 O 0 0.00038610338
. O 0 0.00025539938
4 O 0 0.00041269304
% O 0 0.00096179085
) O 0 0.0020929456
. O 0 0.0023960015

After O 0 0.0011383378
154 O 0 0.00253068
courses O 0 0.00086876616
of O 0 0.0007631781
therapy O 0 0.0006802518
, O 0 0.00034396636
the O 0 0.00018238625
median O 0 0.00010207437
dose O 0 0.00038141294
intensity O 0 0.00010157461
was O 0 0.00017102942
131 O 0 0.00049545185
mg O 0 0.005631501
/ O 0 0.00066475477
m O 0 0.0006221647
( O 0 0.00016583942
2 O 0 7.636571e-05
) O 0 0.000117563075
for O 0 8.318887e-05
paclitaxel B-Chemical 1 0.9522883
( O 0 0.00028844582
97 O 0 0.0003058801
. O 0 6.231069e-05
3 O 0 6.1572166e-05
% O 0 9.6149895e-05
) O 0 0.00014191045
, O 0 0.00011193687
117 O 0 0.00032265543
mg O 0 0.0027779883
/ O 0 0.0005263601
m O 0 0.00053603057
( O 0 0.00015328912
2 O 0 7.319891e-05
) O 0 0.00011814227
for O 0 8.9044916e-05
cisplatin B-Chemical 0 0.99015766
( O 0 0.00029504628
97 O 0 0.00030899313
. O 0 6.228948e-05
3 O 0 6.215555e-05
% O 0 9.8690696e-05
) O 0 0.00014745933
, O 0 0.00011145821
and O 0 0.00014703769
1378 O 0 0.05266259
mg O 0 0.00872533
/ O 0 0.0006839728
m O 0 0.00063039997
( O 0 0.00018416296
2 O 0 9.500463e-05
) O 0 0.00016294228
for O 0 0.00014108609
gemcitabine B-Chemical 0 0.9617569
( O 0 0.00056915364
86 O 0 0.0005933416
. O 0 0.00027503856
2 O 0 0.00044829273
% O 0 0.00094941515
) O 0 0.0020412675
. O 0 0.0023059915

World O 0 0.0028797963
Health O 0 0.0016085408
Organization O 0 0.0013043799
Grade O 0 0.007168515
3 O 0 0.0005522151
- O 0 0.0007376643
4 O 0 0.0003305306
neutropenia B-Disease 0 0.9575231
and O 0 0.00089319365
thrombocytopenia B-Disease 0 0.9996941
occurred O 0 0.00029665942
in O 0 0.0001880768
39 O 0 0.00025137322
. O 0 8.197472e-05
9 O 0 9.078594e-05
% O 0 0.00011879974
and O 0 0.00013286051
11 O 0 0.0001444512
. O 0 9.679053e-05
4 O 0 0.00012172526
% O 0 0.00021751248
of O 0 0.00040728532
patients O 0 0.0009301006
, O 0 0.0012410111
respectively O 0 0.0031079182
. O 0 0.0024729536

There O 0 0.0056390655
was O 0 0.004254924
one O 0 0.0026598487
treatment O 0 0.003680369
- O 0 0.0059051313
related O 0 0.0037805336
death B-Disease 0 0.9595217
. O 0 0.009560411

Nonhematologic O 0 0.98885673
toxicities B-Disease 2 0.9930646
were O 0 0.021076515
mild O 0 0.61431766
. O 0 0.016937621

After O 0 0.001046955
a O 0 0.0014057416
median O 0 0.0005852376
follow O 0 0.0004530423
- O 0 0.00066700194
up O 0 0.00029677452
of O 0 0.0002942392
22 O 0 0.00023635048
months O 0 6.445032e-05
, O 0 0.00010331016
the O 0 8.2495586e-05
median O 0 6.419423e-05
progression O 0 0.0009556719
free O 0 0.000219683
survival O 0 0.0009581115
rate O 0 0.00015122698
was O 0 0.00011563451
7 O 0 5.2300973e-05
months O 0 3.0691775e-05
, O 0 7.3556046e-05
and O 0 7.707831e-05
the O 0 9.0241054e-05
median O 0 8.633401e-05
survival O 0 0.0006179891
time O 0 0.00016838424
was O 0 0.0004177488
16 O 0 0.0005347219
months O 0 0.00051535905
. O 0 0.0014660829

CONCLUSIONS O 0 0.011294184
: O 0 0.0016808617
The O 0 0.00058378465
combination O 0 0.00077851693
of O 0 0.0010557199
paclitaxel B-Chemical 1 0.99561656
, O 0 0.0017981903
cisplatin B-Chemical 0 0.99925417
, O 0 0.00066687923
and O 0 0.00047288008
gemcitabine B-Chemical 0 0.99234504
is O 0 0.0002360489
well O 0 0.00013834864
tolerated O 0 0.00087908254
and O 0 0.00014300845
shows O 0 9.387829e-05
high O 0 0.00034245336
activity O 0 0.00036545633
in O 0 0.00077115244
metastatic O 0 0.74404085
NSCLC B-Disease 2 0.99818426
. O 0 0.0032859347

This O 0 0.0038347032
treatment O 0 0.0016476144
merits O 0 0.001100365
further O 0 0.0010183189
comparison O 0 0.00059900666
with O 0 0.0007883339
other O 0 0.001076906
cisplatin B-Chemical 0 0.9978745
- O 0 0.0028322225
based O 0 0.0013946128
regimens O 0 0.0037844128
. O 0 0.0031380337

Serotonergic B-Chemical 0 0.94040287
antidepressants I-Chemical 0 0.99915755
and O 0 0.012853579
urinary B-Disease 0 0.48668846
incontinence I-Disease 0 0.7170841
. O 0 0.011962248

Many O 0 0.0030898328
new O 0 0.003707413
serotonergic B-Chemical 0 0.9695402
antidepressants I-Chemical 0 0.99983025
have O 0 0.0010216711
been O 0 0.00054125214
introduced O 0 0.00038917622
over O 0 0.00035706063
the O 0 0.0007865645
past O 0 0.0012718266
decade O 0 0.0027563025
. O 0 0.0030033663

Although O 0 0.0017872694
urinary B-Disease 0 0.054805357
incontinence I-Disease 0 0.25650948
is O 0 0.0006022973
listed O 0 0.00025893026
as O 0 0.00022973111
one O 0 0.00016625486
side O 0 0.0009864875
effect O 0 0.00014581655
of O 0 0.00020752661
these O 0 0.0002768148
drugs O 0 0.006447712
in O 0 0.0001196093
their O 0 0.00015165312
package O 0 0.0001815723
inserts O 0 0.0002364582
there O 0 8.226086e-05
is O 0 0.00013492019
only O 0 0.00016870614
one O 0 0.00015775558
report O 0 0.00042379744
in O 0 0.00038516885
the O 0 0.0007286633
literature O 0 0.0024335042
. O 0 0.0021046505

This O 0 0.0038349165
concerns O 0 0.0022313283
2 O 0 0.0012589145
male O 0 0.002047847
patients O 0 0.0009493573
who O 0 0.0008833295
experienced O 0 0.0009216601
incontinence B-Disease 0 0.057722766
while O 0 0.0011522383
taking O 0 0.0057679913
venlafaxine B-Chemical 0 0.9997526
. O 0 0.0040851063

In O 0 0.0015542465
the O 0 0.0010327474
present O 0 0.0005645009
paper O 0 0.0005525158
the O 0 0.0002555748
authors O 0 0.00013213241
describe O 0 0.00014531534
2 O 0 0.0001449717
female O 0 0.00038537194
patients O 0 0.00016451831
who O 0 0.0001541739
developed O 0 0.00019568179
incontinence B-Disease 0 0.054407362
secondary O 0 0.00020589544
to O 0 4.6018384e-05
the O 0 5.66745e-05
selective O 0 0.00062080886
serotonin B-Chemical 0 0.9999435
reuptake O 0 0.98686385
inhibitors O 0 0.057408042
paroxetine B-Chemical 0 0.9999962
and O 0 0.00069791067
sertraline B-Chemical 0 0.9999949
, O 0 0.00017114558
as O 0 6.403258e-05
well O 0 4.9357364e-05
as O 0 5.561877e-05
a O 0 9.77153e-05
third O 0 0.00013382136
who O 0 0.0001811284
developed O 0 0.00020691608
this O 0 0.00028530703
side O 0 0.0025778029
effect O 0 0.0005093099
on O 0 0.0009448049
venlafaxine B-Chemical 0 0.99982387
. O 0 0.0030040543

In O 0 0.0018958477
2 O 0 0.0011230268
of O 0 0.00085816963
the O 0 0.00054469064
3 O 0 0.0003137522
cases O 0 0.00028175593
the O 0 0.00019249824
patients O 0 0.0002195517
were O 0 0.00011497831
also O 0 0.000109829954
taking O 0 0.00048564162
lithium B-Chemical 0 0.9999509
carbonate I-Chemical 0 0.99947053
and O 0 0.0010440457
beta O 0 0.9859076
- O 0 0.0023803997
blockers O 0 0.996833
, O 0 0.00021164265
both O 0 0.00011203916
of O 0 0.0001526546
which O 0 0.00017622179
could O 0 0.00011718656
have O 0 0.0001241298
contributed O 0 0.00031198937
to O 0 0.00035085212
the O 0 0.0008877051
incontinence B-Disease 0 0.17835891
. O 0 0.0021885766

Animal O 0 0.005079319
studies O 0 0.0011477645
suggest O 0 0.00038640344
that O 0 0.00042440122
incontinence B-Disease 0 0.044281725
secondary O 0 0.0008938961
to O 0 0.00041818508
serotonergic B-Chemical 0 0.98786724
antidepressants I-Chemical 0 0.99997544
could O 0 0.00019306787
be O 0 0.00011102055
mediated O 0 7.287421e-05
by O 0 0.00015092648
the O 0 0.00029048443
5HT4 O 0 0.9675596
receptors O 0 0.0015512701
found O 0 0.00026061668
on O 0 0.0002779962
the O 0 0.000844339
bladder O 0 0.027423542
. O 0 0.0023182828

Further O 0 0.0032929901
research O 0 0.0020397748
is O 0 0.00090416154
needed O 0 0.0004473638
to O 0 0.00032390674
delineate O 0 0.00020505422
the O 0 0.00020383083
frequency O 0 0.00020750999
of O 0 0.00022275654
this O 0 0.00026476564
troubling O 0 0.0011892709
side O 0 0.0027304578
effect O 0 0.0002144393
and O 0 0.00022750102
how O 0 0.00019616321
best O 0 0.00049883296
to O 0 0.0005376037
treat O 0 0.0016137264
it O 0 0.0018669757
. O 0 0.0022269855

Acute O 0 0.7959739
cocaine B-Chemical 1 0.9996099
- O 0 0.0067889807
induced O 0 0.0027724323
seizures B-Disease 0 0.99979156
: O 0 0.0013032816
differential O 0 0.0008522406
sensitivity O 0 0.001355681
of O 0 0.0006177203
six O 0 0.00037916275
inbred O 0 0.0015580144
mouse O 0 0.0014358733
strains O 0 0.0017231142
. O 0 0.0024204312

Mature O 0 0.009131641
male O 0 0.004793222
and O 0 0.00124187
female O 0 0.0014372481
mice O 0 0.00024585426
from O 0 0.00019887948
six O 0 0.00012691348
inbred O 0 0.00043955282
stains O 0 0.0003158459
were O 0 0.00010888352
tested O 0 7.946935e-05
for O 0 6.950852e-05
susceptibility O 0 0.00026269577
to O 0 0.00013199112
behavioral O 0 0.0033394198
seizures B-Disease 0 0.99992085
induced O 0 0.0005613608
by O 0 0.00027004912
a O 0 0.0003169864
single O 0 0.0002981497
injection O 0 0.0006184236
of O 0 0.001973979
cocaine B-Chemical 1 0.9994155
. O 0 0.0030526125

Cocaine B-Chemical 0 0.99943095
was O 0 0.0025891832
injected O 0 0.0010701279
ip O 0 0.008671476
over O 0 0.00022336673
a O 0 0.00031681752
range O 0 0.00021569795
of O 0 0.00028216935
doses O 0 0.0017653374
( O 0 0.00033642654
50 O 0 0.00032160178
- O 0 0.00031018376
100 O 0 0.00038620882
mg O 0 0.0056589474
/ O 0 0.00070225104
kg O 0 0.0004954682
) O 0 0.00022363118
and O 0 0.0001360942
behavior O 0 0.00020812803
was O 0 0.00019284138
monitored O 0 0.00014792025
for O 0 0.00025300193
20 O 0 0.0005422079
minutes O 0 0.00072762446
. O 0 0.0017421383

Seizure B-Disease 2 0.9208369
end O 0 0.0010176789
points O 0 0.0006754948
included O 0 0.00039191774
latency O 0 0.0005343438
to O 0 0.00030315455
forelimb O 0 0.00484295
or O 0 0.0002947963
hindlimb O 0 0.05519932
clonus O 0 0.990442
, O 0 0.00026773362
latency O 0 0.0002700357
to O 0 0.00018575846
clonic O 0 0.99922633
running O 0 0.0028451488
seizure B-Disease 0 0.99795145
and O 0 0.00031470638
latency O 0 0.00044948573
to O 0 0.00039122286
jumping O 0 0.014995374
bouncing O 0 0.054481454
seizure B-Disease 0 0.99884003
. O 0 0.003386423

A O 0 0.0148582095
range O 0 0.0016729843
of O 0 0.00100957
strain O 0 0.00047500167
specific O 0 0.00031110275
sensitivities O 0 0.0007227254
was O 0 0.00037193144
documented O 0 0.00036400065
with O 0 0.00040361003
A O 0 0.026446326
/ O 0 0.0030036857
J O 0 0.6770411
and O 0 0.00035013058
SJL O 0 0.044447996
mice O 0 0.000114710456
being O 0 0.00017901277
most O 0 0.00020954396
sensitive O 0 0.00019385754
and O 0 0.00040989788
C57BL O 0 0.38939553
/ O 0 0.002343409
6J O 0 0.0056431117
most O 0 0.0011081336
resistant O 0 0.0017024153
. O 0 0.002247876

DBA O 0 0.98649305
/ O 0 0.036218558
2J O 0 0.62200195
, O 0 0.002808911
BALB O 0 0.019433277
/ O 0 0.0031971133
cByJ O 0 0.0047925985
and O 0 0.0011467137
NZW O 0 0.46302098
/ O 0 0.0019283125
LacJ O 0 0.0022100043
strains O 0 0.0006455139
exhibited O 0 0.0010145473
intermediate O 0 0.002865966
sensitivity O 0 0.00755718
. O 0 0.0035556434

EEG O 0 0.037594724
recordings O 0 0.0022574542
were O 0 0.001108973
made O 0 0.0007456942
in O 0 0.00076219835
SJL O 0 0.094636865
, O 0 0.0009807205
A O 0 0.014597866
/ O 0 0.003140714
J O 0 0.5738667
and O 0 0.0005879777
C57BL O 0 0.59127086
/ O 0 0.0018121887
6J O 0 0.0032360866
mice O 0 9.555202e-05
revealing O 0 0.00018977007
a O 0 0.0001495776
close O 0 0.000105711144
correspondence O 0 0.0002132207
between O 0 0.0001243626
electrical O 0 0.0007045845
activity O 0 0.00045400206
and O 0 0.00085134647
behavior O 0 0.0020467085
. O 0 0.0021896441

Additionally O 0 0.0025415013
, O 0 0.0018420332
levels O 0 0.0010223482
of O 0 0.0015439147
cocaine B-Chemical 1 0.99909294
determined O 0 0.0004697335
in O 0 0.00028688856
hippocampus O 0 0.008408254
and O 0 0.00026157906
cortex O 0 0.0019656867
were O 0 0.00014661768
not O 0 9.6830045e-05
different O 0 8.2629274e-05
between O 0 9.746014e-05
sensitive O 0 0.00022988362
and O 0 0.0004264279
resistant O 0 0.0008548762
strains O 0 0.0015495546
. O 0 0.0022068522

Additional O 0 0.0011141204
studies O 0 0.0011697415
of O 0 0.0009928283
these O 0 0.0008553144
murine O 0 0.0010298049
strains O 0 0.00042228357
may O 0 0.00023674448
be O 0 0.00017099599
useful O 0 0.00012524612
for O 0 9.9248355e-05
investigating O 0 0.0001372431
genetic O 0 0.00042559195
influences O 0 0.00016602626
on O 0 0.00034197327
cocaine B-Chemical 1 0.9997234
- O 0 0.0034875781
induced O 0 0.004154359
seizures B-Disease 0 0.99985707
. O 0 0.0047466727

Hypotension B-Disease 2 0.95928615
following O 0 0.00088244316
the O 0 0.0006031196
initiation O 0 0.00041011503
of O 0 0.0011990395
tizanidine B-Chemical 0 0.9999665
in O 0 0.0003717593
a O 0 0.0002968031
patient O 0 0.0001845562
treated O 0 0.00020036813
with O 0 0.00019661596
an O 0 0.0005121739
angiotensin B-Chemical 1 0.9999621
converting O 0 0.1583154
enzyme O 0 0.05399253
inhibitor O 0 0.0043326253
for O 0 0.0009074364
chronic O 0 0.93156266
hypertension B-Disease 2 0.99993134
. O 0 0.0042549307

Centrally O 0 0.016677173
acting O 0 0.0037628317
alpha O 0 0.5623305
- O 0 0.002341889
2 O 0 0.0007025151
adrenergic O 0 0.9487449
agonists O 0 0.17182034
are O 0 0.00018440315
one O 0 8.129296e-05
of O 0 0.00010597103
several O 0 6.789625e-05
pharmacologic O 0 0.00052559836
agents O 0 0.00036889335
used O 0 6.726662e-05
in O 0 6.50706e-05
the O 0 7.5311305e-05
treatment O 0 0.00011092572
of O 0 0.00036642724
spasticity B-Disease 0 0.998637
related O 0 8.820673e-05
to O 0 0.0001667165
disorders B-Disease 0 0.025212852
of I-Disease 0 0.00029865466
the I-Disease 0 0.0003099295
central I-Disease 0 0.0007420632
nervous I-Disease 0 0.017709712
system I-Disease 0 0.0019146613
. O 0 0.002028387

In O 0 0.0016303129
addition O 0 0.0008571216
to O 0 0.0007685731
their O 0 0.00072324363
effects O 0 0.00069592986
on O 0 0.0005983391
spasticity B-Disease 0 0.9989761
, O 0 0.0006481455
certain O 0 0.0004367994
adverse O 0 0.02317184
cardiorespiratory O 0 0.007979784
effects O 0 0.0006463572
have O 0 0.0005232051
been O 0 0.00078269147
reported O 0 0.0018068951
. O 0 0.0022414676

Adults O 0 0.0060924953
chronically O 0 0.0030001167
treated O 0 0.0013323004
with O 0 0.0015370474
angiotensin B-Chemical 1 0.9999373
converting O 0 0.31014472
enzyme O 0 0.10048198
inhibitors O 0 0.0020155292
may O 0 0.0001598874
have O 0 8.6915294e-05
a O 0 0.0001148015
limited O 0 7.2908966e-05
ability O 0 8.151233e-05
to O 0 6.942306e-05
respond O 0 6.348301e-05
to O 0 0.00013902229
hypotension B-Disease 0 0.9980544
when O 0 0.000111959285
the O 0 0.0001783189
sympathetic O 0 0.002814519
response O 0 0.0003022533
is O 0 0.0004143325
simultaneously O 0 0.00065469154
blocked O 0 0.0033734657
. O 0 0.002449644

The O 0 0.0013734546
authors O 0 0.0007805597
present O 0 0.00067451154
a O 0 0.0009033134
10 O 0 0.0005950864
- O 0 0.00079980993
year O 0 0.0002410353
- O 0 0.00039677505
old O 0 0.00019758608
boy O 0 0.00039342852
chronically O 0 0.0006065669
treated O 0 0.00026500155
with O 0 0.00053760834
lisinopril B-Chemical 0 0.99999225
, O 0 0.00028116422
an O 0 0.00041124664
angiotensin B-Chemical 1 0.99998415
converting O 0 0.16432635
enzyme O 0 0.05173664
inhibitor O 0 0.0013687296
, O 0 0.00010734832
to O 0 5.801216e-05
control O 0 0.00016773542
hypertension B-Disease 2 0.9999677
who O 0 0.0004084348
developed O 0 0.0003540856
hypotension B-Disease 0 0.99926275
following O 0 4.7623478e-05
the O 0 4.6225632e-05
addition O 0 4.262128e-05
of O 0 0.00038757015
tizanidine B-Chemical 0 0.9999918
, O 0 0.00025422595
an O 0 0.0003156604
alpha O 0 0.67253095
- O 0 0.00054765015
2 O 0 0.00013957218
agonist O 0 0.031122847
, O 0 0.00017124416
for O 0 0.00011580024
the O 0 0.00023207553
treatment O 0 0.0004935939
of O 0 0.0021339932
spasticity B-Disease 0 0.99921155
. O 0 0.0033554651

The O 0 0.001412848
possible O 0 0.000999445
interaction O 0 0.00073452137
of O 0 0.0016518263
tizanidine B-Chemical 0 0.99995565
and O 0 0.0006550018
other O 0 0.00036585703
antihypertensive O 0 0.76684755
agents O 0 0.00090675324
should O 0 6.423986e-05
be O 0 6.676476e-05
kept O 0 7.522855e-05
in O 0 6.430783e-05
mind O 0 0.00015074007
when O 0 4.9511335e-05
prescribing O 0 0.0003170224
therapy O 0 0.0001082294
to O 0 7.305065e-05
treat O 0 0.0002100056
either O 0 0.00037286067
hypertension B-Disease 2 0.99996173
or O 0 0.0009804197
spasticity B-Disease 0 0.9993711
in O 0 0.0005457685
such O 0 0.00058537035
patients O 0 0.0018776444
. O 0 0.0017129944

Two O 0 0.0024039357
mouse O 0 0.0019940701
lines O 0 0.0014120102
selected O 0 0.00044424972
for O 0 0.00026094637
differential O 0 0.00042473056
sensitivities O 0 0.0006733939
to O 0 0.0004943098
beta B-Chemical 0 0.9978708
- I-Chemical 0 0.009468454
carboline I-Chemical 0 0.9998079
- O 0 0.0011894424
induced O 0 0.00053389225
seizures B-Disease 0 0.99993503
are O 0 0.00013951509
also O 0 6.5478314e-05
differentially O 0 5.490733e-05
sensitive O 0 4.952824e-05
to O 0 4.7592566e-05
various O 0 7.592626e-05
pharmacological O 0 0.00058904407
effects O 0 0.00013208354
of O 0 0.00025417795
other O 0 0.0005368259
GABA B-Chemical 0 0.9999689
( O 0 0.0015637649
A O 0 0.030935792
) O 0 0.0015487463
receptor O 0 0.024787456
ligands O 0 0.01565452
. O 0 0.0026634333

Two O 0 0.0025297392
mouse O 0 0.0022819866
lines O 0 0.0018909816
were O 0 0.0005828989
selectively O 0 0.00048538635
bred O 0 0.0007697509
according O 0 0.00013072616
to O 0 0.00013021882
their O 0 0.00019518183
sensitivity O 0 0.0009381661
( O 0 0.00055178296
BS O 0 0.92897224
line O 0 0.00045139948
) O 0 0.00022593512
or O 0 9.503463e-05
resistance O 0 0.00043902337
( O 0 0.00029922096
BR O 0 0.17286693
line O 0 0.0003290297
) O 0 0.0002264944
to O 0 0.00015270208
seizures B-Disease 0 0.99986446
induced O 0 0.00031545255
by O 0 0.00013836908
a O 0 0.00014241583
single O 0 0.00010562903
i O 0 0.0002879298
. O 0 6.305223e-05
p O 0 7.5131335e-05
. O 0 3.5651014e-05
injection O 0 7.8496996e-05
of O 0 0.00026853994
methyl B-Chemical 0 0.99836797
beta I-Chemical 0 0.9996699
- I-Chemical 0 0.01149917
carboline I-Chemical 0 0.99980325
- I-Chemical 0 0.000731244
3 I-Chemical 0 0.00010814295
- I-Chemical 0 0.0003509538
carboxylate I-Chemical 0 0.84226817
( O 0 0.0007600435
beta B-Chemical 0 0.9941043
- I-Chemical 0 0.0015135456
CCM I-Chemical 0 0.9023526
) O 0 0.00033619136
, O 0 0.00011025492
an O 0 0.00010907026
inverse O 0 0.0001558863
agonist O 0 0.07646656
of O 0 0.00026266472
the O 0 0.000470039
GABA B-Chemical 0 0.9999703
( O 0 0.0011356053
A O 0 0.02943558
) O 0 0.001361514
receptor O 0 0.20011163
benzodiazepine B-Chemical 1 0.99993134
site O 0 0.0024907615
. O 0 0.0023248738

Our O 0 0.0023617754
aim O 0 0.0019036108
was O 0 0.0011571506
to O 0 0.0005208748
characterize O 0 0.0002991682
both O 0 0.00041058817
lines O 0 0.00071620237
' O 0 0.000321891
sensitivities O 0 0.00033449373
to O 0 0.00012546725
various O 0 0.00013606747
physiological O 0 0.00018781138
effects O 0 0.00014202959
of O 0 0.00018747448
other O 0 0.00015672272
ligands O 0 0.0010643627
of O 0 0.00035307184
the O 0 0.0007442374
GABA B-Chemical 0 0.9999504
( O 0 0.002139854
A O 0 0.03418714
) O 0 0.0023543325
receptor O 0 0.024313709
. O 0 0.0027824724

We O 0 0.0017576547
measured O 0 0.0026733722
diazepam B-Chemical 0 0.9999486
- O 0 0.004079316
induced O 0 0.0013680024
anxiolysis O 0 0.9968214
with O 0 0.00044605677
the O 0 0.00020165357
elevated O 0 0.00086722535
plus O 0 0.00014675461
- O 0 0.00037004706
maze O 0 0.019103695
test O 0 0.00038377388
, O 0 0.00046451404
diazepam B-Chemical 0 0.99999535
- O 0 0.0006707614
induced O 0 0.00019283587
sedation O 0 0.01665359
by O 0 6.528988e-05
recording O 0 5.0068564e-05
the O 0 5.503409e-05
vigilance O 0 0.0005433506
states O 0 0.00013044724
, O 0 0.00011989077
and O 0 0.0002922353
picrotoxin B-Chemical 0 0.9999981
- O 0 0.002929214
and O 0 0.0007313123
pentylenetetrazol B-Chemical 0 0.9999975
- O 0 0.002228021
induced O 0 0.0006456745
seizures B-Disease 0 0.99991107
after O 0 0.00013183942
i O 0 0.00071668817
. O 0 0.00023381904
p O 0 0.00042211678
. O 0 0.00043595769
injections O 0 0.0015709162
. O 0 0.0018824978

Results O 0 0.0016738956
presented O 0 0.0010243056
here O 0 0.0006524212
show O 0 0.0003314268
that O 0 0.0002135452
the O 0 0.00023319654
differential O 0 0.00032337446
sensitivities O 0 0.0004639715
of O 0 0.00047021825
BS O 0 0.9458394
and O 0 0.0003836038
BR O 0 0.39645714
lines O 0 0.0006477506
to O 0 0.00023932013
beta B-Chemical 0 0.99437827
- I-Chemical 0 0.0012870585
CCM I-Chemical 0 0.6836487
can O 0 7.545551e-05
be O 0 5.7996946e-05
extended O 0 5.961141e-05
to O 0 0.00014573259
diazepam B-Chemical 0 0.9999957
, O 0 0.0018683252
picrotoxin B-Chemical 0 0.9999987
, O 0 0.0008311773
and O 0 0.0006923661
pentylenetetrazol B-Chemical 0 0.99999714
, O 0 0.00032207152
suggesting O 0 5.3298092e-05
a O 0 9.77304e-05
genetic O 0 0.00020804408
selection O 0 8.598573e-05
of O 0 8.8829496e-05
a O 0 9.596413e-05
general O 0 8.1321334e-05
sensitivity O 0 0.00036684723
and O 0 0.000108897526
resistance O 0 0.0002481981
to O 0 7.79075e-05
several O 0 8.0949954e-05
ligands O 0 0.0006494787
of O 0 0.0002730955
the O 0 0.00061403227
GABA B-Chemical 0 0.9999472
( O 0 0.0019308947
A O 0 0.03112289
) O 0 0.0022427293
receptor O 0 0.023461023
. O 0 0.0026895236

Propylthiouracil B-Chemical 0 0.99892455
- O 0 0.006259243
induced O 0 0.0017814889
perinuclear O 0 0.0011005674
- O 0 0.0011323969
staining O 0 0.0005448236
antineutrophil O 0 0.16787308
cytoplasmic O 0 0.0008709178
autoantibody O 0 0.89761317
- O 0 0.001368134
positive O 0 0.0011873194
vasculitis B-Disease 2 0.9993088
in O 0 0.00062842574
conjunction O 0 0.0009889266
with O 0 0.0022251965
pericarditis B-Disease 0 0.9792684
. O 0 0.0036110873

OBJECTIVE O 0 0.025416119
: O 0 0.0024356442
To O 0 0.00091797666
describe O 0 0.0007519614
a O 0 0.0009785153
case O 0 0.000768957
of O 0 0.0021565782
propylthiouracil B-Chemical 0 0.99996233
- O 0 0.0076337093
induced O 0 0.0044742846
vasculitis B-Disease 2 0.9998497
manifesting O 0 0.62712705
with O 0 0.0069228387
pericarditis B-Disease 0 0.9931837
. O 0 0.0042861034

METHODS O 0 0.0015919002
: O 0 0.0012016618
We O 0 0.00040380383
present O 0 0.00031002707
the O 0 0.00028457734
first O 0 0.00016932013
case O 0 0.00020891534
report O 0 0.00027429903
of O 0 0.00021157366
a O 0 0.00024898458
woman O 0 0.0006515106
with O 0 0.00043842156
hyperthyroidism B-Disease 0 0.99996114
treated O 0 0.0006144169
with O 0 0.00059062097
propylthiouracil B-Chemical 0 0.9999796
in O 0 0.0001950929
whom O 0 0.00033733205
a O 0 0.00023958176
syndrome O 0 0.037300278
of O 0 0.0005072625
pericarditis B-Disease 0 0.98772764
, O 0 0.0015718888
fever B-Disease 0 0.99817395
, O 0 0.0012799375
and O 0 0.0019745212
glomerulonephritis B-Disease 2 0.99994576
developed O 0 0.015274477
. O 0 0.0029238681

Serologic O 0 0.02297374
testing O 0 0.00174478
and O 0 0.0012828154
immunologic O 0 0.0041291537
studies O 0 0.00077243295
were O 0 0.00049506617
done O 0 0.00037116633
, O 0 0.00045326154
and O 0 0.00042010957
a O 0 0.00073797227
pericardial O 0 0.0074035744
biopsy O 0 0.0023673896
was O 0 0.0012377528
performed O 0 0.0015149999
. O 0 0.0023878112

RESULTS O 0 0.005857289
: O 0 0.0030399587
A O 0 0.0076560397
25 O 0 0.0016317773
- O 0 0.0012876886
year O 0 0.0003745036
- O 0 0.0005390794
old O 0 0.00027673194
woman O 0 0.0005451467
with O 0 0.00038085034
Graves B-Disease 2 0.853457
' I-Disease 2 0.00075074245
disease I-Disease 2 0.63494784
had O 0 0.00022294204
a O 0 0.00040362065
febrile B-Disease 0 0.99603975
illness I-Disease 0 0.9778552
and O 0 0.00027179572
evidence O 0 0.0001469833
of O 0 0.0004302645
pericarditis B-Disease 0 0.95968
, O 0 0.00046962564
which O 0 0.00044497615
was O 0 0.00044668777
confirmed O 0 0.0005780176
by O 0 0.0009703083
biopsy O 0 0.0037029013
. O 0 0.0019833653

Serologic O 0 0.019616773
evaluation O 0 0.0014714915
revealed O 0 0.00081568264
the O 0 0.0005293349
presence O 0 0.0004166994
of O 0 0.0004913182
perinuclear O 0 0.00039970168
- O 0 0.00048974255
staining O 0 0.00027407578
antineutrophil O 0 0.15337889
cytoplasmic O 0 0.0005372013
autoantibodies O 0 0.34628215
( O 0 0.00077180023
pANCA O 0 0.022181574
) O 0 0.00061381754
against O 0 0.00046810557
myeloperoxidase O 0 0.9857368
( O 0 0.0040092953
MPO O 0 0.99463415
) O 0 0.004463559
. O 0 0.002687933

Propylthiouracil B-Chemical 0 0.99879265
therapy O 0 0.00459714
was O 0 0.0015088466
withdrawn O 0 0.0015146364
, O 0 0.000599819
and O 0 0.00035013803
she O 0 0.00021803283
was O 0 0.00021883445
treated O 0 0.00024463856
with O 0 0.00021067302
a O 0 0.00023237932
1 O 0 0.00011879657
- O 0 0.0001542726
month O 0 4.4896555e-05
course O 0 8.1605336e-05
of O 0 0.00032361443
prednisone B-Chemical 1 0.996942
, O 0 0.000534216
which O 0 0.0007378859
alleviated O 0 0.0370613
her O 0 0.0031377594
symptoms O 0 0.047554165
. O 0 0.002468881

A O 0 0.018236447
literature O 0 0.0027721294
review O 0 0.0018419869
revealed O 0 0.0005281818
no O 0 0.00021509803
prior O 0 0.00014677113
reports O 0 0.00029141398
of O 0 0.00047498467
pericarditis B-Disease 0 0.9146732
in O 0 0.00039709557
anti O 0 0.007016139
- O 0 0.0025929064
MPO O 0 0.9990281
pANCA O 0 0.21258198
- O 0 0.0006445094
positive O 0 0.0006066643
vasculitis B-Disease 2 0.99943954
associated O 0 0.00039074913
with O 0 0.00084381143
propylthio B-Chemical 0 0.7323526
- I-Chemical 0 0.0025943776
uracil I-Chemical 0 0.45662412
therapy O 0 0.0031958036
. O 0 0.0021729853

CONCLUSION O 0 0.034031566
: O 0 0.005127513
Pericarditis B-Disease 0 0.89323133
may O 0 0.0007505067
be O 0 0.0003735908
the O 0 0.00024474796
initial O 0 0.00025442283
manifestation O 0 0.001074048
of O 0 0.0005140393
drug O 0 0.06241894
- O 0 0.0008830054
induced O 0 0.00081023294
vasculitis B-Disease 2 0.99961424
attributable O 0 0.00035251252
to O 0 0.0005093366
propylthio B-Chemical 0 0.68657166
- I-Chemical 0 0.0027662327
uracil I-Chemical 0 0.46937042
therapy O 0 0.0034427287
. O 0 0.0023199422

Repeated O 0 0.0038144032
transient O 0 0.010387058
anuria B-Disease 2 0.9682196
following O 0 0.0015849116
losartan B-Chemical 1 0.9999738
administration O 0 0.012325635
in O 0 0.0004960014
a O 0 0.0005618278
patient O 0 0.00048567777
with O 0 0.0006295953
a O 0 0.0012201756
solitary O 0 0.0054206876
kidney O 0 0.8801543
. O 0 0.0034183282

We O 0 0.0017703965
report O 0 0.0017944588
the O 0 0.00091218203
case O 0 0.0006256635
of O 0 0.00060551765
a O 0 0.00054687506
70 O 0 0.00043511964
- O 0 0.00048188324
year O 0 0.0001430019
- O 0 0.00029841642
old O 0 0.00026140234
hypertensive B-Disease 2 0.99894875
man O 0 0.004126637
with O 0 0.00012561941
a O 0 0.00012576875
solitary O 0 0.00043211257
kidney O 0 0.59397364
and O 0 0.0002802377
chronic B-Disease 0 0.9058684
renal I-Disease 0 0.9991198
insufficiency I-Disease 0 0.9999223
who O 0 0.0004176558
developed O 0 0.00014587815
two O 0 5.363138e-05
episodes O 0 0.00028858552
of O 0 0.00020378105
transient O 0 0.008819741
anuria B-Disease 2 0.9945564
after O 0 0.0004979864
losartan B-Chemical 1 0.99997425
administration O 0 0.114823714
. O 0 0.00256094

He O 0 0.0061150296
was O 0 0.0021240208
hospitalized O 0 0.0029396256
for O 0 0.0005295832
a O 0 0.0012475959
myocardial B-Disease 0 0.9995752
infarction I-Disease 2 0.999985
with O 0 0.005071561
pulmonary B-Disease 0 0.9837864
edema I-Disease 0 0.99996805
, O 0 0.00073602155
treated O 0 0.0005025326
with O 0 0.00044649257
high O 0 0.0012185577
- O 0 0.0018068057
dose O 0 0.024378171
diuretics O 0 0.99954766
. O 0 0.0034597423

Due O 0 0.0031506754
to O 0 0.0030086476
severe O 0 0.020472713
systolic B-Disease 0 0.9954157
dysfunction I-Disease 0 0.9995437
losartan B-Chemical 1 0.9999763
was O 0 0.012721737
prescribed O 0 0.02582454
. O 0 0.0045862733

Surprisingly O 0 0.0024355585
, O 0 0.0015616111
the O 0 0.0006730051
first O 0 0.0003571735
dose O 0 0.0010973159
of O 0 0.00041206134
50 O 0 0.0005232779
mg O 0 0.012058026
of O 0 0.00080168893
losartan B-Chemical 1 0.99999
resulted O 0 0.00032492675
in O 0 0.00016869683
a O 0 0.0004416209
sudden O 0 0.9824523
anuria B-Disease 2 0.9988739
, O 0 0.00019884972
which O 0 8.41787e-05
lasted O 0 2.7747677e-05
eight O 0 3.090981e-05
hours O 0 3.0166606e-05
despite O 0 5.6696656e-05
high O 0 0.00025810875
- O 0 0.00045793847
dose O 0 0.0065639573
furosemide B-Chemical 0 0.9999733
and O 0 0.0028809053
amine B-Chemical 0 0.9987832
infusion O 0 0.011962595
. O 0 0.002259586

One O 0 0.0022488004
week O 0 0.0009716715
later O 0 0.00070279127
, O 0 0.0008653632
by O 0 0.0006997388
mistake O 0 0.004415088
, O 0 0.0012538646
losartan B-Chemical 1 0.99998486
was O 0 0.00069832854
prescribed O 0 0.0009889157
again O 0 0.000121353005
and O 0 7.305867e-05
after O 0 2.5157144e-05
the O 0 5.108617e-05
second O 0 6.143376e-05
dose O 0 0.0002687082
of O 0 0.00012790265
50 O 0 0.00023718935
mg O 0 0.0062549375
, O 0 0.00010525268
the O 0 7.2384e-05
patient O 0 8.77285e-05
developed O 0 0.00011549786
a O 0 0.000108569475
second O 0 8.990667e-05
episode O 0 0.00027349786
of O 0 0.0002588318
transient O 0 0.008262986
anuria B-Disease 2 0.9862797
lasting O 0 0.00058857596
10 O 0 0.00055744156
hours O 0 0.0006757031
. O 0 0.0015841253

During O 0 0.0011103473
these O 0 0.0014860901
two O 0 0.00076187524
episodes O 0 0.0020520224
, O 0 0.0008090348
his O 0 0.0008116273
blood O 0 0.0031768822
pressure O 0 0.0042729285
diminished O 0 0.0010123651
but O 0 0.00050007936
no O 0 0.00039765032
severe O 0 0.09600942
hypotension B-Disease 0 0.9998115
was O 0 0.002627847
noted O 0 0.0016001567
. O 0 0.0023110777

Ultimately O 0 0.006252629
, O 0 0.0026259217
an O 0 0.0020372113
arteriography O 0 0.014758037
showed O 0 0.00091548555
a O 0 0.0009285555
70 O 0 0.0008129187
- O 0 0.0010178699
80 O 0 0.0009501268
% O 0 0.0012604299
renal B-Disease 0 0.9824783
artery I-Disease 0 0.86626565
stenosis I-Disease 0 0.9987809
. O 0 0.0050222725

In O 0 0.0016007044
this O 0 0.0013711419
patient O 0 0.0011383551
, O 0 0.0010527421
renal B-Disease 0 0.97015095
artery I-Disease 0 0.70035076
stenosis I-Disease 0 0.9993698
combined O 0 0.0004900453
with O 0 0.00032662565
heart B-Disease 0 0.06645434
failure I-Disease 0 0.13367328
and O 0 0.0004379637
diuretic O 0 0.99970514
therapy O 0 0.0002427091
certainly O 0 0.00013082854
resulted O 0 8.440811e-05
in O 0 7.2593866e-05
a O 0 0.000103308
strong O 0 0.00010050054
activation O 0 0.00013035447
of O 0 0.00016429163
the O 0 0.00023192003
renin O 0 0.9709489
- O 0 0.002042752
angiotensin B-Chemical 1 0.99989533
system O 0 0.0011794751
( O 0 0.0015306298
RAS O 0 0.75374776
) O 0 0.0030549385
. O 0 0.0022471403

Under O 0 0.0028585545
such O 0 0.0011170247
conditions O 0 0.0013870733
, O 0 0.0020343966
angiotensin B-Chemical 1 0.99996567
II I-Chemical 1 0.90415305
receptor O 0 0.12984625
blockade O 0 0.09492149
by O 0 0.0012170868
losartan B-Chemical 1 0.9999894
probably O 0 0.00085402204
induced O 0 0.00031103395
a O 0 0.00026807233
critical O 0 0.0001813069
fall O 0 0.00068387436
in O 0 0.0004492077
glomerular O 0 0.91330194
filtration O 0 0.058114745
pressure O 0 0.025222594
. O 0 0.0021985343

This O 0 0.0035329824
case O 0 0.0013780731
report O 0 0.0010464416
highlights O 0 0.0004241875
the O 0 0.0002737791
fact O 0 0.0001317046
that O 0 0.00012839473
the O 0 0.00038245486
angiotensin B-Chemical 1 0.9999931
II I-Chemical 1 0.9620203
receptor O 0 0.5446537
antagonist O 0 0.9981079
losartan B-Chemical 1 0.9999976
can O 0 0.00015600957
cause O 0 0.00020047782
serious O 0 0.0006803484
unexpected O 0 0.00024190971
complications O 0 0.0059050755
in O 0 7.4938784e-05
patients O 0 0.00013352514
with O 0 0.00028025344
renovascular B-Disease 0 0.9999939
disease I-Disease 0 0.99600047
and O 0 0.00020062468
should O 0 4.7916215e-05
be O 0 6.268055e-05
used O 0 6.743297e-05
with O 0 0.00014728997
extreme O 0 0.00034683474
caution O 0 0.00023910028
in O 0 0.00030273665
this O 0 0.0007029078
setting O 0 0.0011372875
. O 0 0.0017806293

Calcineurin O 0 0.71471965
- O 0 0.0052866945
inhibitor O 0 0.0055988273
induced O 0 0.0031747858
pain B-Disease 0 0.96724844
syndrome O 0 0.8050994
( O 0 0.002790827
CIPS B-Disease 0 0.99680907
) O 0 0.0010127197
: O 0 0.00044068167
a O 0 0.0005419228
severe O 0 0.013257609
disabling O 0 0.6850365
complication O 0 0.02216029
after O 0 0.00035350077
organ O 0 0.0040219924
transplantation O 0 0.022423957
. O 0 0.0024921051

Bone O 0 0.036144212
pain B-Disease 0 0.22150207
after O 0 0.0007683036
transplantation O 0 0.0034721603
is O 0 0.0007094577
a O 0 0.00069698546
frequent O 0 0.00076646946
complication O 0 0.0036485514
that O 0 0.00029062404
can O 0 0.00029427515
be O 0 0.00035835686
caused O 0 0.0005848863
by O 0 0.0008607628
several O 0 0.0012174579
diseases O 0 0.16375183
. O 0 0.0031967699

Treatment O 0 0.00485937
strategies O 0 0.0016366831
depend O 0 0.0007679456
on O 0 0.00058533903
the O 0 0.0007639429
correct O 0 0.001042236
diagnosis O 0 0.0019653721
of O 0 0.001799125
the O 0 0.0027838435
pain B-Disease 0 0.7157598
. O 0 0.0047393483

Nine O 0 0.0043926304
patients O 0 0.0020099052
with O 0 0.0014460406
severe O 0 0.018177917
pain B-Disease 0 0.48745438
in O 0 0.000472476
their O 0 0.00055101194
feet O 0 0.005667452
, O 0 0.00033680344
which O 0 0.0003040655
was O 0 0.00026036214
registered O 0 0.00027563708
after O 0 0.0001369534
transplantation O 0 0.0019997298
, O 0 0.0007378475
were O 0 0.0008089908
investigated O 0 0.0011781086
. O 0 0.0021079811

Bone O 0 0.015254077
scans O 0 0.00499644
showed O 0 0.0015530997
an O 0 0.0014428927
increased O 0 0.0016758937
tracer O 0 0.0037103116
uptake O 0 0.0032707322
of O 0 0.0014585131
the O 0 0.0018094686
foot O 0 0.020753361
bones O 0 0.04228493
. O 0 0.0045537916

Magnetic O 0 0.02237779
resonance O 0 0.011553262
imaging O 0 0.0027052537
demonstrated O 0 0.0013512275
bone B-Disease 0 0.01929886
marrow I-Disease 0 0.90321827
oedema I-Disease 0 0.9996972
in O 0 0.0022867902
the O 0 0.0025374973
painful O 0 0.6983811
bones O 0 0.13995036
. O 0 0.00465557

Pain B-Disease 0 0.29188818
was O 0 0.0020668434
not O 0 0.000890522
explained O 0 0.0006931438
by O 0 0.0005330459
other O 0 0.0004844259
diseases O 0 0.10576292
causing O 0 0.0016737506
foot O 0 0.12505937
pain B-Disease 0 0.6188595
, O 0 0.00021617724
like O 0 0.00011239485
reflex B-Disease 0 0.076144114
sympathetic I-Disease 0 0.60798717
dystrophy I-Disease 0 0.99992716
, O 0 0.0015013795
polyneuropathy B-Disease 0 0.99978656
, O 0 0.000351806
Morton B-Disease 0 0.0056086904
' I-Disease 0 0.00019264218
s I-Disease 0 0.0002657388
neuralgia I-Disease 0 0.9996282
, O 0 0.0009281523
gout B-Disease 0 0.999987
, O 0 0.0017089221
osteoporosis B-Disease 0 0.9999654
, O 0 0.0011652159
avascular B-Disease 0 0.9998816
necrosis I-Disease 2 0.99998724
, O 0 0.0005856912
intermittent B-Disease 0 0.0033636587
claudication I-Disease 0 0.65586984
, O 0 0.00017650565
orthopaedic O 0 0.0007216325
foot B-Disease 0 0.010078377
deformities I-Disease 0 0.49322668
, O 0 0.00070740737
stress B-Disease 0 0.79294676
fractures I-Disease 2 0.9998016
, O 0 0.0024309475
and O 0 0.0034518368
hyperparathyroidism B-Disease 0 0.999908
. O 0 0.004127409

The O 0 0.0016195617
reduction O 0 0.002486422
of O 0 0.0032129777
cyclosporine B-Chemical 1 0.99997354
- O 0 0.003657896
or O 0 0.00074301887
tacrolimus B-Chemical 0 0.99998045
trough O 0 0.12290567
levels O 0 0.00021163316
and O 0 0.000131737
the O 0 0.000108754335
administration O 0 0.0005026893
of O 0 0.00047769604
calcium B-Chemical 0 0.99961674
channel O 0 0.7482483
blockers O 0 0.99743915
led O 0 0.0005476975
to O 0 0.0003744872
relief O 0 0.0017767628
of O 0 0.001752214
pain B-Disease 0 0.69268614
. O 0 0.0026867061

The O 0 0.002917392
Calcineurin O 0 0.37345967
- O 0 0.0033730068
inhibitor O 0 0.004928641
Induced O 0 0.051680297
Pain B-Disease 0 0.8635076
Syndrome O 0 0.37571946
( O 0 0.001314739
CIPS B-Disease 0 0.9916841
) O 0 0.0005852922
is O 0 0.00017340553
a O 0 0.00021111421
rare O 0 0.00057666126
but O 0 0.00019783569
severe O 0 0.002523969
side O 0 0.0021495284
effect O 0 0.000114842995
of O 0 0.00056992634
cyclosporine B-Chemical 1 0.999997
or O 0 0.0009550706
tacrolimus B-Chemical 0 0.9999957
and O 0 0.00025018177
is O 0 9.7905126e-05
accurately O 0 8.926733e-05
diagnosed O 0 0.00028539897
by O 0 7.612868e-05
its O 0 0.00012166689
typical O 0 8.787444e-05
presentation O 0 0.00017335312
, O 0 0.00019183931
magnetic O 0 0.0010020379
resonance O 0 0.0034796835
imaging O 0 0.0005656543
and O 0 0.0005260194
bone O 0 0.00830229
scans O 0 0.0045850673
. O 0 0.0023431992

Incorrect O 0 0.009821686
diagnosis O 0 0.002952364
of O 0 0.001254898
the O 0 0.0009552334
syndrome O 0 0.038797926
will O 0 0.0004083219
lead O 0 0.0014120034
to O 0 0.00020693701
a O 0 0.00025514435
significant O 0 0.0001643051
reduction O 0 0.00032165973
of O 0 0.00020500807
life O 0 0.0002046417
quality O 0 0.00016215075
in O 0 0.00024238761
patients O 0 0.00072386063
suffering O 0 0.054540724
from O 0 0.0015819706
CIPS B-Disease 0 0.9907802
. O 0 0.0030456376

Brain O 0 0.07570296
natriuretic O 0 0.9365021
peptide O 0 0.0037064531
is O 0 0.0013387442
a O 0 0.0010927812
predictor O 0 0.00064064015
of O 0 0.0020022772
anthracycline B-Chemical 0 0.9992649
- O 0 0.0083811665
induced O 0 0.011232342
cardiotoxicity B-Disease 0 0.99992776
. O 0 0.00827093

Anthracyclines B-Chemical 0 0.98898995
are O 0 0.0017840847
effective O 0 0.0011896663
antineoplastic O 0 0.17108215
drugs O 0 0.13037348
, O 0 0.0008707493
but O 0 0.00045366742
they O 0 0.0002845147
frequently O 0 0.0003643819
cause O 0 0.0007471264
dose O 0 0.0033747614
- O 0 0.0017775545
related O 0 0.0011588461
cardiotoxicity B-Disease 0 0.9998734
. O 0 0.00467399

The O 0 0.0029631187
cardiotoxicity B-Disease 0 0.9994678
of O 0 0.0018068143
conventional O 0 0.0012159754
anthracycline B-Chemical 0 0.9981824
therapy O 0 0.00082215876
highlights O 0 0.0002378683
a O 0 0.0002433834
need O 0 0.000104473824
to O 0 8.649238e-05
search O 0 0.00013534103
for O 0 6.7888875e-05
methods O 0 8.652241e-05
that O 0 6.5358414e-05
are O 0 8.6194406e-05
highly O 0 9.225488e-05
sensitive O 0 0.00010641943
and O 0 0.00014244694
capable O 0 0.0001648058
of O 0 0.0004068117
predicting O 0 0.00076951995
cardiac B-Disease 0 0.9549269
dysfunction I-Disease 0 0.99876595
. O 0 0.0038674434

We O 0 0.0014340319
measured O 0 0.0010441142
the O 0 0.0008913428
plasma O 0 0.0024915899
level O 0 0.0004005645
of O 0 0.0005338791
brain O 0 0.0066563548
natriuretic O 0 0.96997637
peptide O 0 0.0012704899
( O 0 0.00082744256
BNP O 0 0.9686242
) O 0 0.00031968413
to O 0 7.92845e-05
determine O 0 4.023606e-05
whether O 0 5.8655605e-05
BNP O 0 0.76826227
might O 0 6.3233e-05
serve O 0 7.6554046e-05
as O 0 5.4618227e-05
a O 0 6.978654e-05
simple O 0 7.657253e-05
diagnostic O 0 8.1440536e-05
indicator O 0 4.634923e-05
of O 0 0.00020314941
anthracycline B-Chemical 0 0.99965787
- O 0 0.0007522713
induced O 0 0.00049341586
cardiotoxicity B-Disease 0 0.9999925
in O 0 0.00017326618
patients O 0 0.00021696235
with O 0 0.0003410683
acute B-Disease 0 0.99881554
leukemia I-Disease 0 0.99999785
treated O 0 0.0021743595
with O 0 0.00038729075
a O 0 0.0008011612
daunorubicin B-Chemical 1 0.9999063
( O 0 0.003515343
DNR B-Chemical 0 0.99961877
) O 0 0.0011272555
- O 0 0.00079975545
containing O 0 0.0006087424
regimen O 0 0.0020367177
. O 0 0.0020940248

Thirteen O 0 0.0049811215
patients O 0 0.002365579
with O 0 0.0025254593
acute B-Disease 0 0.9977418
leukemia I-Disease 0 0.9999809
were O 0 0.0016246653
treated O 0 0.0010315493
with O 0 0.00082606083
a O 0 0.0019601658
DNR B-Chemical 0 0.99908197
- O 0 0.001874123
containing O 0 0.0009848394
regimen O 0 0.002903185
. O 0 0.0027086097

Cardiac O 0 0.015130587
functions O 0 0.001991213
were O 0 0.001280546
evaluated O 0 0.00090098905
with O 0 0.001246645
radionuclide O 0 0.006666894
angiography O 0 0.014659658
before O 0 0.0012225861
chemotherapies O 0 0.01211114
. O 0 0.0045967996

The O 0 0.0018622492
plasma O 0 0.0045188917
levels O 0 0.00097574363
of O 0 0.0012000152
atrial O 0 0.78486204
natriuretic O 0 0.9870029
peptide O 0 0.0023917267
( O 0 0.0017505598
ANP O 1 0.9994721
) O 0 0.0008351527
and O 0 0.0003950646
BNP O 0 0.79838806
were O 0 0.0001986729
measured O 0 0.0001196385
at O 0 0.000106049876
the O 0 0.00016935632
time O 0 0.00017122342
of O 0 0.0006282125
radionuclide O 0 0.008700162
angiography O 0 0.076245144
. O 0 0.0024902343

Three O 0 0.0027894406
patients O 0 0.0026833632
developed O 0 0.0035566213
congestive B-Disease 0 0.9974848
heart I-Disease 0 0.3734905
failure I-Disease 0 0.06121528
after O 0 0.00027244643
the O 0 0.0004385601
completion O 0 0.00043631668
of O 0 0.0014058314
chemotherapy O 0 0.0143758
. O 0 0.0031785967

Five O 0 0.003133422
patients O 0 0.0019780998
were O 0 0.0010368238
diagnosed O 0 0.001435284
as O 0 0.00045800454
having O 0 0.00062902435
subclinical O 0 0.12452971
heart B-Disease 0 0.15859687
failure I-Disease 0 0.04004098
after O 0 0.00014272211
the O 0 0.0002674206
completion O 0 0.00028815883
of O 0 0.0010475747
chemotherapy O 0 0.012256564
. O 0 0.002570292

The O 0 0.0018887448
plasma O 0 0.0053129154
levels O 0 0.0010754189
of O 0 0.0013569068
BNP O 0 0.92159283
in O 0 0.00040257696
all O 0 0.00022042908
the O 0 0.0001622788
patients O 0 0.00018575316
with O 0 0.00014374618
clinical O 0 0.0003514046
and O 0 0.00016578709
subclinical O 0 0.12667193
heart B-Disease 0 0.19912605
failure I-Disease 0 0.087936066
increased O 0 0.00020953757
above O 0 7.574677e-05
the O 0 6.3040156e-05
normal O 0 0.00016877662
limit O 0 0.00019098264
( O 0 0.000120890094
40 O 0 8.814988e-05
pg O 0 0.0019306036
/ O 0 0.00047202135
ml O 0 0.00040918036
) O 0 0.00011163104
before O 0 2.5203059e-05
the O 0 5.1122868e-05
detection O 0 8.784947e-05
of O 0 0.000118683565
clinical O 0 0.00033902336
or O 0 0.0001689995
subclinical O 0 0.111015595
heart B-Disease 0 0.1747936
failure I-Disease 0 0.16307579
by O 0 0.0008923507
radionuclide O 0 0.016746344
angiography O 0 0.08813079
. O 0 0.002002586

On O 0 0.0025805235
the O 0 0.0015813179
other O 0 0.0011173567
hand O 0 0.0017397469
, O 0 0.0015230769
BNP O 0 0.96969986
did O 0 0.0005328313
not O 0 0.00020481719
increase O 0 0.00015725518
in O 0 0.00010872073
the O 0 0.0001056395
patients O 0 0.00015184293
without O 0 0.00011487091
heart B-Disease 0 0.04522728
failure I-Disease 0 0.11563707
given O 0 0.00019689118
DNR B-Chemical 0 0.9995714
, O 0 0.00016200161
even O 0 9.034722e-05
at O 0 5.2875228e-05
more O 0 0.00012112041
than O 0 9.435638e-05
700 O 0 0.00072586886
mg O 0 0.0061192214
/ O 0 0.0012639209
m O 0 0.0015256186
( O 0 0.00083748414
2 O 0 0.000744519
) O 0 0.0018015023
. O 0 0.002071024

The O 0 0.0019585935
plasma O 0 0.0055862316
level O 0 0.0010596717
of O 0 0.0019989777
ANP O 1 0.99912244
did O 0 0.000787824
not O 0 0.0003033069
always O 0 0.0002782338
increase O 0 0.00018065526
in O 0 0.00013503681
all O 0 0.00012282711
the O 0 0.00012937337
patients O 0 0.00020818041
with O 0 0.00022562793
clinical O 0 0.00071078783
and O 0 0.00053668773
subclinical O 0 0.31186154
heart B-Disease 0 0.58384085
failure I-Disease 0 0.72916126
. O 0 0.003000575

These O 0 0.0021268611
preliminary O 0 0.0017896803
results O 0 0.0008740869
suggest O 0 0.0003760364
that O 0 0.0005384868
BNP O 0 0.93308836
may O 0 0.0003863622
be O 0 0.00022512487
useful O 0 0.00015372179
as O 0 0.0001311073
an O 0 0.00017093275
early O 0 0.00022316899
and O 0 0.00014489071
sensitive O 0 0.00013194318
indicator O 0 0.00016259759
of O 0 0.0007277847
anthracycline B-Chemical 0 0.9995735
- O 0 0.0044985977
induced O 0 0.0070434497
cardiotoxicity B-Disease 0 0.99995327
. O 0 0.0053496105

Nephrotoxicity B-Disease 0 0.99489176
of O 0 0.005691517
combined O 0 0.008128429
cephalothin B-Chemical 1 0.99942833
- O 0 0.021676779
gentamicin B-Chemical 1 0.99862874
regimen O 0 0.024184225
. O 0 0.0071279113

Two O 0 0.0021964326
patients O 0 0.0020140181
developed O 0 0.0024479958
acute B-Disease 2 0.9701956
tubular I-Disease 2 0.9993862
necrosis I-Disease 2 0.9999924
, O 0 0.0016975258
characterized O 0 0.0011617269
clinically O 0 0.002378367
by O 0 0.0003398646
acute O 0 0.8093177
oliguric B-Disease 0 0.9999647
renal I-Disease 0 0.9993224
failure I-Disease 0 0.75354207
, O 0 0.00019810033
while O 0 6.8618894e-05
they O 0 4.6673456e-05
were O 0 5.362678e-05
receiving O 0 7.182059e-05
a O 0 7.424922e-05
combination O 0 0.00012313998
of O 0 0.0004577898
cephalothin B-Chemical 1 0.99998605
sodium I-Chemical 0 0.9999821
and O 0 0.0060585123
gentamicin B-Chemical 1 0.99995303
sulfate I-Chemical 0 0.99967825
therapy O 0 0.018542506
. O 0 0.0026879057

Patients O 0 0.002588698
who O 0 0.0015748625
are O 0 0.000528752
given O 0 0.0002619747
this O 0 0.00038959403
drug O 0 0.0042449865
regimen O 0 0.000439052
should O 0 0.00010642652
be O 0 0.00012331881
observed O 0 0.00010905788
very O 0 0.00019453451
carefully O 0 0.000107537264
for O 0 0.00016243084
early O 0 0.0006508934
signs O 0 0.009993859
of O 0 0.0047889384
nephrotoxicity B-Disease 0 0.9999727
. O 0 0.0058625867

High O 0 0.0069611645
doses O 0 0.0053840238
of O 0 0.0013469401
this O 0 0.00097486266
antibiotic O 0 0.0032642996
combination O 0 0.00083359005
should O 0 0.0002731057
be O 0 0.00033542284
avoided O 0 0.00038474295
especially O 0 0.0005589177
in O 0 0.0007992168
elderly O 0 0.07133459
patients O 0 0.0033269185
. O 0 0.002495582

Patients O 0 0.003559078
with O 0 0.0034284517
renal B-Disease 0 0.9619093
insufficiency I-Disease 0 0.99267995
should O 0 0.00065631844
not O 0 0.0006094635
be O 0 0.0005572604
given O 0 0.00048546787
this O 0 0.0013094642
regimen O 0 0.0031187853
. O 0 0.0030984168

In O 0 0.002144855
vivo O 0 0.0023015267
protection O 0 0.0021833251
of O 0 0.0014613221
dna O 0 0.14837326
damage O 0 0.21342753
associated O 0 0.0004540207
apoptotic O 0 0.08063581
and O 0 0.00047266312
necrotic B-Disease 0 0.5877353
cell O 0 0.004652574
deaths O 0 0.071390234
during O 0 0.00016990819
acetaminophen B-Chemical 0 0.99999857
- O 0 0.0016926747
induced O 0 0.00092209585
nephrotoxicity B-Disease 0 0.9999989
, O 0 0.008811934
amiodarone B-Chemical 1 0.99999356
- O 0 0.0009018144
induced O 0 0.00032940228
lung B-Disease 0 0.977927
toxicity I-Disease 2 0.9999807
and O 0 0.0014253162
doxorubicin B-Chemical 1 0.99976975
- O 0 0.0013426879
induced O 0 0.00087739254
cardiotoxicity B-Disease 0 0.99999
by O 0 0.00032234736
a O 0 0.00029914794
novel O 0 0.0005077665
IH636 B-Chemical 0 0.99887127
grape I-Chemical 0 0.97584563
seed I-Chemical 0 0.059110843
proanthocyanidin I-Chemical 0 0.999801
extract I-Chemical 0 0.32464978
. O 0 0.0034689675

Grape B-Chemical 0 0.96379274
seed I-Chemical 0 0.008883893
extract I-Chemical 0 0.048346948
, O 0 0.0012102264
primarily O 0 0.00061563845
a O 0 0.00061025494
mixture O 0 0.0018525232
of O 0 0.0018545169
proanthocyanidins B-Chemical 0 0.9999683
, O 0 0.0006963259
has O 0 0.00014076868
been O 0 8.7446024e-05
shown O 0 6.198621e-05
to O 0 5.7240573e-05
modulate O 0 3.1445124e-05
a O 0 0.00012776344
wide O 0 0.00016009349
- O 0 0.00017684526
range O 0 7.60221e-05
of O 0 9.653907e-05
biological O 0 0.00011333137
, O 0 0.00013356231
pharmacological O 0 0.0009414658
and O 0 0.00017884282
toxicological O 0 0.006363184
effects O 0 0.00028687378
which O 0 0.00043793806
are O 0 0.000451322
mainly O 0 0.0010927494
cytoprotective O 0 0.41367677
. O 0 0.0025967278

This O 0 0.0033049437
study O 0 0.001417279
assessed O 0 0.0005301226
the O 0 0.00038644322
ability O 0 0.00039127824
of O 0 0.0008147753
IH636 B-Chemical 0 0.99926394
grape I-Chemical 0 0.98298967
seed I-Chemical 0 0.04135208
proanthocyanidin I-Chemical 0 0.9999553
extract I-Chemical 0 0.43340233
( O 0 0.011049804
GSPE B-Chemical 0 0.9999994
) O 0 0.0012268065
to O 0 0.0001526255
prevent O 0 0.0005190335
acetaminophen B-Chemical 0 0.9999989
( O 0 0.0036524748
AAP B-Chemical 0 0.9990138
) O 0 0.0006379277
- O 0 0.00033830968
induced O 0 0.0004569244
nephrotoxicity B-Disease 0 0.99999833
, O 0 0.006219005
amiodarone B-Chemical 1 0.9999943
( O 0 0.005335147
AMI B-Chemical 1 0.9999727
) O 0 0.00066746905
- O 0 0.0003058929
induced O 0 0.0002664926
lung B-Disease 0 0.97099394
toxicity I-Disease 2 0.9999752
, O 0 0.0005270957
and O 0 0.00037006332
doxorubicin B-Chemical 1 0.9991949
( O 0 0.002067859
DOX B-Chemical 1 0.99989295
) O 0 0.0013320029
- O 0 0.00087120576
induced O 0 0.001389522
cardiotoxicity B-Disease 0 0.9999567
in O 0 0.0014924606
mice O 0 0.001295188
. O 0 0.002036462

Experimental O 0 0.00345332
design O 0 0.0014737465
consisted O 0 0.0006853306
of O 0 0.00062198855
four O 0 0.00027552515
groups O 0 0.00029702875
: O 0 0.0002714076
control O 0 0.00020642423
( O 0 0.00030654515
vehicle O 0 0.00073423475
alone O 0 0.00034024956
) O 0 0.0006464589
, O 0 0.0008209422
GSPE B-Chemical 0 0.9999981
alone O 0 0.0010332376
, O 0 0.000490508
drug O 0 0.013153282
alone O 0 0.0005904999
and O 0 0.0020339699
GSPE B-Chemical 0 0.99999475
+ O 0 0.027631737
drug O 0 0.27181998
. O 0 0.0030365922

For O 0 0.0014097416
the O 0 0.002064698
cytoprotection O 0 0.81854016
study O 0 0.0013665368
, O 0 0.0005792704
animals O 0 0.000226835
were O 0 0.0002024174
orally O 0 0.00048428398
gavaged O 0 0.0022889737
100 O 0 0.0005206602
mg O 0 0.009171914
/ O 0 0.0011139016
Kg O 0 0.061135586
GSPE B-Chemical 0 0.9999981
for O 0 0.00019486237
7 O 0 9.284495e-05
- O 0 0.00013402979
10 O 0 4.836556e-05
days O 0 2.6149812e-05
followed O 0 4.5839337e-05
by O 0 8.429823e-05
i O 0 0.0002715455
. O 0 7.0944e-05
p O 0 8.614206e-05
. O 0 3.905333e-05
injections O 0 7.053904e-05
of O 0 7.341779e-05
organ O 0 0.00020217436
specific O 0 4.2164902e-05
three O 0 3.8875463e-05
drugs O 0 0.004686929
( O 0 0.0002669954
AAP B-Chemical 0 0.9680759
: O 0 0.0001800618
500 O 0 0.0003234741
mg O 0 0.0030350983
/ O 0 0.00035342644
Kg O 0 0.00052659475
for O 0 4.3306565e-05
24 O 0 4.3342094e-05
h O 0 6.2941464e-05
; O 0 0.00018334856
AMI B-Chemical 1 0.99923575
: O 0 0.00017127568
50 O 0 0.00018262518
mg O 0 0.0028137497
/ O 0 0.0004267541
Kg O 0 0.0008705445
/ O 0 0.00017793335
day O 0 3.4130142e-05
for O 0 3.38808e-05
four O 0 3.3937125e-05
days O 0 3.8386235e-05
; O 0 0.0001689808
DOX B-Chemical 1 0.9966425
: O 0 0.00023468696
20 O 0 0.00016441513
mg O 0 0.0023464898
/ O 0 0.0006730712
Kg O 0 0.0011692257
for O 0 0.00023806431
48 O 0 0.00037561578
h O 0 0.00068802875
) O 0 0.0018893138
. O 0 0.0021328018

Parameters O 0 0.0047431937
of O 0 0.0015428109
study O 0 0.00085533975
included O 0 0.0003810136
analysis O 0 0.00032927323
of O 0 0.000411218
serum O 0 0.016670791
chemistry O 0 0.034622002
( O 0 0.0010952579
ALT O 0 0.9992036
, O 0 0.0020699105
BUN O 0 0.9999733
and O 0 0.0019877325
CPK O 0 0.9999542
) O 0 0.00061588024
, O 0 0.00014709742
and O 0 9.840014e-05
orderly O 0 0.00023494355
fragmentation O 0 0.0006428718
of O 0 0.00013775652
genomic O 0 0.0003495089
DNA O 0 0.010973449
( O 0 0.0001820884
both O 0 0.00013118882
endonuclease O 0 0.0022481882
- O 0 0.00018640714
dependent O 0 3.574419e-05
and O 0 7.010751e-05
independent O 0 4.524267e-05
) O 0 0.000102679944
in O 0 4.1796902e-05
addition O 0 3.4418095e-05
to O 0 5.2591506e-05
microscopic O 0 0.00019354433
evaluation O 0 7.9040525e-05
of O 0 0.00017768294
damage O 0 0.08037016
and O 0 0.00020859053
/ O 0 0.00045597975
or O 0 0.00012779074
protection O 0 0.00037766676
in O 0 0.00020381158
corresponding O 0 0.00032517407
PAS O 0 0.018466048
stained O 0 0.0011233246
tissues O 0 0.0023529239
. O 0 0.0019563965

Results O 0 0.001752451
indicate O 0 0.0008988505
that O 0 0.0012648314
GSPE B-Chemical 0 0.99998903
preexposure O 0 0.010771369
prior O 0 0.00029657962
to O 0 0.0005126189
AAP B-Chemical 0 0.9977272
, O 0 0.0015739227
AMI B-Chemical 1 0.9999341
and O 0 0.0010669245
DOX B-Chemical 1 0.99989367
, O 0 0.00026289272
provided O 0 0.00010988997
near O 0 9.9883444e-05
complete O 0 7.793834e-05
protection O 0 0.00016413162
in O 0 5.5561628e-05
terms O 0 4.4240085e-05
of O 0 0.000104378814
serum O 0 0.007838077
chemistry O 0 0.005572516
changes O 0 0.00025417458
( O 0 0.00037206087
ALT O 0 0.9985605
, O 0 0.001304217
BUN O 0 0.9999732
and O 0 0.0016102684
CPK O 0 0.9999318
) O 0 0.00074783806
, O 0 0.00027505588
and O 0 0.00026641134
significantly O 0 0.00052411505
reduced O 0 0.0013536304
DNA O 0 0.03646549
fragmentation O 0 0.027129376
. O 0 0.0025889196

Histopathological O 0 0.016873192
examination O 0 0.0016182067
of O 0 0.0015275939
kidney O 0 0.5631986
, O 0 0.00096242345
heart O 0 0.026806507
and O 0 0.00039635296
lung O 0 0.0043940404
sections O 0 0.00018169872
revealed O 0 0.00012879606
moderate O 0 0.00074856065
to O 0 0.00012289787
massive O 0 0.005186159
tissue B-Disease 0 0.11680255
damage I-Disease 0 0.9237328
with O 0 0.00021662169
a O 0 0.00012869613
variety O 0 8.12942e-05
of O 0 0.00010054712
morphological O 0 0.00060881855
aberrations O 0 0.25463057
by O 0 9.100732e-05
all O 0 5.5360968e-05
the O 0 4.7690286e-05
three O 0 3.1588308e-05
drugs O 0 0.00069970347
in O 0 5.727366e-05
the O 0 6.430446e-05
absence O 0 7.445441e-05
of O 0 0.00077114074
GSPE B-Chemical 0 0.99999857
preexposure O 0 0.021447456
than O 0 0.00030306267
in O 0 0.00042143444
its O 0 0.0011355291
presence O 0 0.0014862303
. O 0 0.0021589994

GSPE B-Chemical 0 0.9999467
+ O 0 0.013323104
drug O 0 0.022252798
exposed O 0 0.0011294786
tissues O 0 0.0011023607
exhibited O 0 0.00062435836
minor O 0 0.0011030056
residual O 0 0.00076632755
damage O 0 0.07034639
or O 0 0.000582687
near O 0 0.0008141863
total O 0 0.0011178368
recovery O 0 0.003693027
. O 0 0.0026905187

Additionally O 0 0.0027061016
, O 0 0.0023937412
histopathological O 0 0.009741637
alterations O 0 0.0018169146
mirrored O 0 0.00082985556
both O 0 0.0004735448
serum O 0 0.010401449
chemistry O 0 0.005123744
changes O 0 0.00044965112
and O 0 0.00028946262
the O 0 0.0002773347
pattern O 0 0.00034191346
of O 0 0.0009616406
DNA O 0 0.019602243
fragmentation O 0 0.02213212
. O 0 0.0029677178

Interestingly O 0 0.0024019217
, O 0 0.0019159885
all O 0 0.0009252174
the O 0 0.00080293085
drugs O 0 0.014283108
, O 0 0.0005469396
such O 0 0.00023671583
as O 0 0.00030054324
, O 0 0.0005368725
AAP B-Chemical 0 0.99600947
, O 0 0.001209486
AMI B-Chemical 1 0.9999269
and O 0 0.0008717847
DOX B-Chemical 1 0.9998987
induced O 0 0.0008897518
apoptotic O 0 0.7014351
death O 0 0.99274594
in O 0 0.0001266562
addition O 0 7.0228816e-05
to O 0 0.00015102164
necrosis B-Disease 2 0.9979742
in O 0 0.00013188645
the O 0 9.116157e-05
respective O 0 0.0001000455
organs O 0 0.0005017395
which O 0 0.00019971655
was O 0 0.00019630427
very O 0 0.00032348122
effectively O 0 0.00047224003
blocked O 0 0.0027644627
by O 0 0.0052390327
GSPE B-Chemical 0 0.9999863
. O 0 0.006740352

Since O 0 0.002619574
AAP B-Chemical 0 0.9860817
, O 0 0.004872765
AMI B-Chemical 1 0.99960285
and O 0 0.0022553534
DOX B-Chemical 1 0.9996959
undergo O 0 0.0008606521
biotransformation O 0 0.9853689
and O 0 0.00027587393
are O 0 0.00013048369
known O 0 0.00013049699
to O 0 8.304192e-05
produce O 0 8.715598e-05
damaging O 0 0.0039207228
radicals O 0 0.996214
in O 0 0.00019376018
vivo O 0 0.00028260902
, O 0 0.00012324324
the O 0 9.710826e-05
protection O 0 0.0004952754
by O 0 0.0005833074
GSPE B-Chemical 0 0.99999917
may O 0 0.00021508902
be O 0 8.5709435e-05
linked O 0 6.497635e-05
to O 0 5.5651875e-05
both O 0 7.639631e-05
inhibition O 0 0.00029171916
of O 0 0.0002848662
metabolism O 0 0.040701803
and O 0 0.00022440351
/ O 0 0.0005732461
or O 0 0.00027130666
detoxification O 0 0.087033875
of O 0 0.0012213757
cytotoxic O 0 0.6917147
radicals O 0 0.99888927
. O 0 0.00421486

In O 0 0.0019512678
addition O 0 0.0011785238
, O 0 0.001409863
its O 0 0.0012716079
' O 0 0.00078668934
presumed O 0 0.00063275715
contribution O 0 0.00024396867
to O 0 0.00027054903
DNA O 0 0.007739159
repair O 0 0.00045100937
may O 0 0.00011241972
be O 0 8.655517e-05
another O 0 8.700784e-05
important O 0 5.2957737e-05
attribute O 0 0.00012911763
, O 0 0.00017759553
which O 0 0.0002042822
played O 0 0.00035525838
a O 0 0.00026030777
role O 0 0.00015313673
in O 0 0.00029372124
the O 0 0.00061753666
chemoprevention O 0 0.15000068
process O 0 0.0018748294
. O 0 0.002226925

Additionally O 0 0.0027198985
, O 0 0.0019383471
this O 0 0.0010527911
may O 0 0.000573474
have O 0 0.000313464
been O 0 0.00019893316
the O 0 0.00016967473
first O 0 0.00012387062
report O 0 0.00035205108
on O 0 0.0002742959
AMI B-Chemical 1 0.9998951
- O 0 0.0013194084
induced O 0 0.0007648738
apoptotic O 0 0.5297941
death O 0 0.9919641
in O 0 0.0006847672
the O 0 0.00085223856
lung O 0 0.088873245
tissue O 0 0.012167936
. O 0 0.0025122114

Taken O 0 0.004890485
together O 0 0.0019340032
, O 0 0.0013983207
these O 0 0.00093607674
events O 0 0.0015052691
undoubtedly O 0 0.0011208844
establish O 0 0.0007064786
GSPE B-Chemical 0 0.9999974
' O 0 0.0011385569
s O 0 0.00028832318
abundant O 0 0.00019442844
bioavailability O 0 0.8867023
, O 0 0.00019893752
and O 0 0.00011133562
the O 0 9.957969e-05
power O 0 0.00045365642
to O 0 8.589238e-05
defend O 0 0.00016161821
multiple O 0 8.3449e-05
target O 0 5.8527432e-05
organs O 0 0.00038195006
from O 0 9.9314544e-05
toxic O 0 0.12695205
assaults O 0 0.016448978
induced O 0 0.00021034466
by O 0 0.0001506632
structurally O 0 0.00021945105
diverse O 0 0.0001244282
and O 0 0.00012427215
functionally O 0 0.00016124724
different O 0 0.0001474035
entities O 0 0.0005591971
in O 0 0.00058986817
vivo O 0 0.0020486931
. O 0 0.0019672643

Antidepressant B-Chemical 0 0.99910825
- O 0 0.0066816253
induced O 0 0.0030514502
mania B-Disease 0 0.99861085
in O 0 0.0017911564
bipolar B-Disease 2 0.99712676
patients O 0 0.0013286922
: O 0 0.00070128264
identification O 0 0.00073669216
of O 0 0.0011746652
risk O 0 0.006446383
factors O 0 0.0031535071
. O 0 0.002965778

BACKGROUND O 0 0.007906656
: O 0 0.002084106
Concerns O 0 0.001354722
about O 0 0.0006398744
possible O 0 0.00042919762
risks O 0 0.00072269165
of O 0 0.00030099545
switching O 0 0.0002524824
to O 0 0.00022773173
mania B-Disease 0 0.99726844
associated O 0 0.00018365005
with O 0 0.00044358193
antidepressants B-Chemical 0 0.9998554
continue O 0 0.000114978095
to O 0 5.451021e-05
interfere O 0 4.205956e-05
with O 0 7.312454e-05
the O 0 5.9652015e-05
establishment O 0 8.659983e-05
of O 0 9.912796e-05
an O 0 0.00010300798
optimal O 0 6.2087194e-05
treatment O 0 0.0001528944
paradigm O 0 0.0003001049
for O 0 0.0005546541
bipolar B-Disease 2 0.9993259
depression I-Disease 0 0.9968952
. O 0 0.002727123

METHOD O 0 0.0052096276
: O 0 0.0015815038
The O 0 0.00051868806
response O 0 0.0005234685
of O 0 0.0005194291
44 O 0 0.0004784589
patients O 0 0.0003289535
meeting O 0 0.0002807057
DSM O 0 0.0025053835
- O 0 0.0003969016
IV O 0 0.0027976935
criteria O 0 0.00012897281
for O 0 0.00010171932
bipolar B-Disease 2 0.99732363
disorder I-Disease 0 0.6752976
to O 0 7.940042e-05
naturalistic O 0 0.00040562157
treatment O 0 8.176815e-05
was O 0 6.7473105e-05
assessed O 0 3.3773536e-05
for O 0 3.0979776e-05
at O 0 3.113278e-05
least O 0 3.6473702e-05
6 O 0 2.714279e-05
weeks O 0 1.7623857e-05
using O 0 3.658975e-05
the O 0 8.550991e-05
Montgomery O 0 0.0016855283
- O 0 0.0003675151
Asberg O 0 0.013585918
Depression O 2 0.9315496
Rating O 0 0.0017122411
Scale O 0 0.0016286139
and O 0 0.00021293442
the O 0 0.00030717906
Bech O 0 0.007983537
- O 0 0.0011269023
Rafaelson O 0 0.008801885
Mania O 0 0.67673796
Rating O 0 0.008332342
Scale O 0 0.014715016
. O 0 0.0028403495

Patients O 0 0.0022270244
who O 0 0.0014852299
experienced O 0 0.00084505975
a O 0 0.0010795246
manic B-Disease 0 0.999798
or O 0 0.00058983214
hypomanic B-Disease 0 0.9990865
switch O 0 0.00023053135
were O 0 9.6706026e-05
compared O 0 4.792988e-05
with O 0 9.2756374e-05
those O 0 0.00013000851
who O 0 0.00013451502
did O 0 7.41414e-05
not O 0 4.7581445e-05
on O 0 3.0427855e-05
several O 0 3.806e-05
variables O 0 4.165275e-05
including O 0 4.832661e-05
age O 0 0.00011799456
, O 0 0.00012948358
sex O 0 0.00028429614
, O 0 0.00011980174
diagnosis O 0 0.00026520653
( O 0 0.00017095346
DSM B-Disease 0 0.002224974
- I-Disease 0 0.00037111467
IV I-Disease 0 0.13735072
bipolar I-Disease 2 0.9999547
I I-Disease 0 0.4991266
vs O 0 0.00022067345
. O 0 0.00010880183
bipolar B-Disease 2 0.9999236
II I-Disease 0 0.78750885
) O 0 0.00026291274
, O 0 7.890219e-05
number O 0 5.0297404e-05
of O 0 7.580407e-05
previous O 0 0.00012497352
manic B-Disease 0 0.9999541
episodes O 0 0.001213712
, O 0 8.70114e-05
type O 0 6.632153e-05
of O 0 0.00014229285
antidepressant B-Chemical 1 0.999035
therapy O 0 0.0001249099
used O 0 4.9880273e-05
( O 0 0.00010555038
electroconvulsive O 0 0.017530553
therapy O 0 0.00010220421
vs O 0 7.697429e-05
. O 0 5.3675183e-05
antidepressant B-Chemical 1 0.997678
drugs O 0 0.009249966
and O 0 8.970131e-05
, O 0 7.1606686e-05
more O 0 7.966093e-05
particularly O 0 8.439201e-05
, O 0 8.6297456e-05
selective O 0 0.0007100817
serotonin B-Chemical 0 0.999943
reuptake I-Chemical 0 0.98372114
inhibitors I-Chemical 0 0.010368881
[ O 0 0.0014968629
SSRIs B-Chemical 0 0.9997657
] O 0 0.00047843633
) O 0 0.00014752599
, O 0 7.246701e-05
use O 0 4.6563116e-05
and O 0 5.3379525e-05
type O 0 6.443987e-05
of O 0 0.00014297887
mood O 0 0.95804113
stabilizers O 0 0.33317143
( O 0 0.00041327887
lithium B-Chemical 0 0.9999126
vs O 0 0.00029188945
. O 0 0.00010207262
anticonvulsants O 0 0.9955426
) O 0 0.0002284435
, O 0 8.802473e-05
and O 0 8.048206e-05
temperament O 0 0.0019419537
of O 0 9.4920964e-05
the O 0 7.335628e-05
patient O 0 8.73128e-05
, O 0 6.763029e-05
assessed O 0 3.4451856e-05
during O 0 2.6219755e-05
a O 0 9.594163e-05
normothymic O 0 0.038740892
period O 0 3.0083265e-05
using O 0 4.1976222e-05
the O 0 8.005287e-05
hyperthymia O 0 0.029738538
component O 0 9.742373e-05
of O 0 0.00016237231
the O 0 0.00018499294
Semi O 0 0.000697925
- O 0 0.00040456402
structured O 0 0.00024279262
Affective O 0 0.0012017842
Temperament O 0 0.004140837
Interview O 0 0.0027422428
. O 0 0.001986681

RESULTS O 0 0.0046397005
: O 0 0.0020554839
Switches O 0 0.002536163
to O 0 0.00091701327
hypomania B-Disease 0 0.99591196
or O 0 0.00075338007
mania B-Disease 0 0.99658257
occurred O 0 0.00024759027
in O 0 0.00015772221
27 O 0 0.0001981277
% O 0 0.000107008615
of O 0 0.00011567808
all O 0 0.0001187685
patients O 0 0.0002554992
( O 0 0.0003735144
N O 0 0.92775023
= O 0 0.0001963621
12 O 0 5.9544134e-05
) O 0 0.00014099007
( O 0 0.00010525679
and O 0 6.930519e-05
in O 0 5.7022316e-05
24 O 0 4.4105203e-05
% O 0 5.444688e-05
of O 0 6.192623e-05
the O 0 6.3621854e-05
subgroup O 0 0.00018943995
of O 0 8.880392e-05
patients O 0 0.00011389375
treated O 0 0.00013522607
with O 0 0.0003190244
SSRIs B-Chemical 0 0.9997453
[ O 0 0.00037193036
8 O 0 7.00797e-05
/ O 0 0.00024006791
33 O 0 0.00020313004
] O 0 0.00028184082
) O 0 0.00016967182
; O 0 0.00011015729
16 O 0 8.409638e-05
% O 0 0.00011891399
( O 0 0.0002494246
N O 0 0.8016339
= O 0 0.0001703803
7 O 0 6.223587e-05
) O 0 0.00012744733
experienced O 0 0.00020781034
manic B-Disease 0 0.9998964
episodes O 0 0.0015558262
, O 0 0.00016681493
and O 0 0.0001288231
11 O 0 0.00012947679
% O 0 0.00016335749
( O 0 0.00035106356
N O 0 0.7257065
= O 0 0.00031929978
5 O 0 0.00017275891
) O 0 0.00042147323
experienced O 0 0.00085600297
hypomanic B-Disease 0 0.998406
episodes O 0 0.01234811
. O 0 0.0024101269

Sex O 0 0.03334116
, O 0 0.003030652
age O 0 0.0017908546
, O 0 0.0012027274
diagnosis O 0 0.0018234765
( O 0 0.0017291525
bipolar B-Disease 2 0.9998319
I I-Disease 0 0.57683516
vs O 0 0.0006136959
. O 0 0.00028211423
bipolar B-Disease 2 0.99989986
II I-Disease 0 0.8646572
) O 0 0.00051940785
, O 0 0.00016311112
and O 0 0.00011339235
additional O 0 7.8366116e-05
treatment O 0 0.00011862089
did O 0 0.00014464057
not O 0 0.00012393393
affect O 0 0.00011392385
the O 0 0.00031025623
risk O 0 0.0020714842
of O 0 0.0010692435
switching O 0 0.0020410798
. O 0 0.002140365

The O 0 0.0017972165
incidence O 0 0.0024308548
of O 0 0.0017371393
mood O 0 0.87332153
switches O 0 0.00088897726
seemed O 0 0.0003979789
not O 0 0.00017451987
to O 0 0.00013127216
differ O 0 0.00010173513
between O 0 5.94232e-05
patients O 0 0.00014681884
receiving O 0 0.0001847703
an O 0 0.00028960922
anticonvulsant O 0 0.996296
and O 0 0.0002612237
those O 0 0.00032288162
receiving O 0 0.00045949468
no O 0 0.0004295795
mood O 0 0.94489515
stabilizer O 0 0.21459396
. O 0 0.0025091995

In O 0 0.0019158059
contrast O 0 0.002158268
, O 0 0.001851277
mood O 0 0.7938867
switches O 0 0.0008183635
were O 0 0.0002867674
less O 0 0.00020050247
frequent O 0 0.00020201114
in O 0 0.00012373782
patients O 0 0.0002349796
receiving O 0 0.000569708
lithium B-Chemical 0 0.9999207
( O 0 0.00034399485
15 O 0 7.9920625e-05
% O 0 9.873683e-05
, O 0 9.3978706e-05
4 O 0 5.9587826e-05
/ O 0 0.00019304853
26 O 0 0.00011698403
) O 0 9.8280296e-05
than O 0 3.7065904e-05
in O 0 5.1056417e-05
patients O 0 8.193269e-05
not O 0 5.6161665e-05
treated O 0 0.00014858691
with O 0 0.00035057892
lithium B-Chemical 0 0.9999436
( O 0 0.0004292412
44 O 0 0.00021665802
% O 0 0.00013579788
, O 0 0.0001391614
8 O 0 0.000109782304
/ O 0 0.00035261488
18 O 0 0.00020146852
; O 0 0.00034016877
p O 0 0.0003920676
= O 0 0.0005709423
. O 0 0.00055088877
04 O 0 0.006556977
) O 0 0.0027913752
. O 0 0.0026371188

The O 0 0.001432328
number O 0 0.0009978228
of O 0 0.00091338134
previous O 0 0.00096447096
manic B-Disease 0 0.99987876
episodes O 0 0.004306097
did O 0 0.00029191506
not O 0 0.00011533563
affect O 0 5.5330198e-05
the O 0 7.7292054e-05
probability O 0 9.600295e-05
of O 0 0.00012582728
switching O 0 0.00014991814
, O 0 0.00011825995
whereas O 0 8.1698316e-05
a O 0 0.000100275196
high O 0 0.00012940112
score O 0 5.0307e-05
on O 0 3.1785785e-05
the O 0 7.013981e-05
hyperthymia O 0 0.030434033
component O 0 5.2587893e-05
of O 0 6.161134e-05
the O 0 4.4058874e-05
Semistructured O 0 3.2348675e-05
Affective O 0 0.0001716149
Temperament O 0 0.00083382166
Interview O 0 0.00020864002
was O 0 7.315048e-05
associated O 0 5.6139175e-05
with O 0 8.8541456e-05
a O 0 0.00011415089
greater O 0 0.00012961762
risk O 0 0.00077604817
of O 0 0.00022160838
switching O 0 0.0003385686
( O 0 0.00047483682
p O 0 0.00038960128
= O 0 0.0005109724
. O 0 0.00045220918
008 O 0 0.0029779393
) O 0 0.002119936
. O 0 0.002175436

CONCLUSION O 0 0.0133621115
: O 0 0.0016737705
The O 0 0.0005483814
frequency O 0 0.00059804035
of O 0 0.00071189826
mood O 0 0.6484829
switching O 0 0.00035951086
associated O 0 0.00020717114
with O 0 0.00040240563
acute O 0 0.7093649
antidepressant B-Chemical 1 0.999894
therapy O 0 0.0005950159
may O 0 0.00018357931
be O 0 0.0002048621
reduced O 0 0.000554731
by O 0 0.0009810005
lithium B-Chemical 0 0.99972326
treatment O 0 0.0032874737
. O 0 0.0024834413

Particular O 0 0.001813677
attention O 0 0.0015726853
should O 0 0.00051173667
be O 0 0.00049136975
paid O 0 0.0004784714
to O 0 0.00024214161
patients O 0 0.000315649
with O 0 0.00026764814
a O 0 0.00058360683
hyperthymic O 0 0.99944705
temperament O 0 0.16086845
, O 0 0.00032682874
who O 0 0.00028488412
have O 0 0.00011680768
a O 0 0.00022625268
greater O 0 0.00032214183
risk O 0 0.002543302
of O 0 0.0013946021
mood O 0 0.96218735
switches O 0 0.0037805804
. O 0 0.002241507

Peritubular O 0 0.06471085
capillary O 0 0.08498866
basement O 0 0.027825508
membrane O 0 0.0019724246
reduplication O 0 0.0031868354
in O 0 0.0004731917
allografts O 0 0.009618905
and O 0 0.0003690226
native O 0 0.000604186
kidney B-Disease 0 0.85176194
disease I-Disease 0 0.36197895
: O 0 0.00030626965
a O 0 0.0002448126
clinicopathologic O 0 0.0009009555
study O 0 0.0002334368
of O 0 0.00033249139
278 O 0 0.0032371783
consecutive O 0 0.0005392388
renal O 0 0.59522384
specimens O 0 0.0017584688
. O 0 0.001891268

BACKGROUND O 0 0.008310035
: O 0 0.002067547
An O 0 0.0010852659
association O 0 0.00047572725
has O 0 0.00034946407
been O 0 0.00023153138
found O 0 0.0001982874
between O 0 0.0001854859
transplant B-Disease 0 0.92852443
glomerulopathy I-Disease 0 0.99999785
( O 0 0.014669511
TG B-Disease 2 0.9994685
) O 0 0.0004653135
and O 0 0.00017468035
reduplication O 0 0.0011447688
of O 0 0.0003470057
peritubular O 0 0.07744894
capillary O 0 0.36572552
basement O 0 0.13747491
membranes O 0 0.0029292027
( O 0 0.0013425652
PTCR O 0 0.17846912
) O 0 0.002594543
. O 0 0.0022692399

Although O 0 0.0016727723
such O 0 0.0010162141
an O 0 0.0010247354
association O 0 0.00043544875
is O 0 0.00040231395
of O 0 0.00034690666
practical O 0 0.00026197045
and O 0 0.00023058716
theoretical O 0 0.00054967246
importance O 0 0.00013203443
, O 0 0.0001939881
only O 0 0.00016899369
one O 0 0.00013626937
prospective O 0 0.0006211527
study O 0 0.00025284855
has O 0 0.00018072076
tried O 0 0.0005176614
to O 0 0.00039587964
confirm O 0 0.0005597448
it O 0 0.0015575339
. O 0 0.002048024

METHODS O 0 0.0016859389
: O 0 0.001249779
We O 0 0.00045964055
examined O 0 0.0004077517
278 O 0 0.0019716318
consecutive O 0 0.00038471216
renal O 0 0.17216942
specimens O 0 0.00030264
( O 0 0.000228794
from O 0 0.00011526022
135 O 0 0.000299457
transplants O 0 0.0008997751
and O 0 0.00016367322
143 O 0 0.0003609212
native O 0 0.00024541488
kidneys O 0 0.003729783
) O 0 0.0003153425
for O 0 0.0001750128
ultrastructural O 0 0.0011398563
evidence O 0 0.0005065505
of O 0 0.0015321763
PTCR O 0 0.3991951
. O 0 0.002527661

In O 0 0.0015086605
addition O 0 0.0008608998
to O 0 0.0010593266
renal O 0 0.80703247
allografts O 0 0.31786358
with O 0 0.0025082284
TG B-Disease 2 0.999171
, O 0 0.00032749813
we O 0 6.945147e-05
also O 0 8.735301e-05
examined O 0 6.724598e-05
grafts O 0 0.00030281456
with O 0 0.00020935423
acute O 0 0.3727435
rejection O 0 0.98638284
, O 0 0.00074527116
recurrent O 0 0.37360036
glomerulonephritis B-Disease 2 0.99999666
, O 0 0.0018663584
chronic B-Disease 0 0.9739526
allograft I-Disease 0 0.9992873
nephropathy I-Disease 2 0.9999995
and O 0 0.0005041497
stable O 0 0.0002805371
grafts O 0 0.00063128734
( O 0 0.00027917046
" O 0 0.000287131
protocol O 0 0.00038181405
biopsies O 0 0.0009482223
" O 0 0.0011771618
) O 0 0.001917291
. O 0 0.0020183437

Native O 0 0.017527072
kidney O 0 0.22947404
specimens O 0 0.0011230748
included O 0 0.00049892435
a O 0 0.00050969474
wide O 0 0.00037825224
range O 0 0.00026411217
of O 0 0.00051387615
glomerulopathies B-Disease 0 0.99934286
as O 0 0.00021636036
well O 0 0.000100646605
as O 0 9.4587e-05
cases O 0 0.00016020908
of O 0 0.00080838514
thrombotic B-Disease 2 0.99999607
microangiopathy I-Disease 2 0.99999976
, O 0 0.015454214
malignant B-Disease 0 0.99983203
hypertension I-Disease 2 0.9999988
, O 0 0.0017569895
acute O 0 0.9048475
interstitial B-Disease 0 0.9972149
nephritis I-Disease 0 0.99999857
, O 0 0.002677342
and O 0 0.0014334249
acute B-Disease 2 0.9925729
tubular I-Disease 2 0.99953556
necrosis I-Disease 2 0.99997294
. O 0 0.0069988654

RESULTS O 0 0.005137539
: O 0 0.001962671
We O 0 0.00071748905
found O 0 0.0008024502
PTCR O 0 0.031268194
in O 0 0.00038531027
14 O 0 0.00022948135
of O 0 0.00022460816
15 O 0 0.00013912201
cases O 0 0.00019632731
of O 0 0.00040083152
TG B-Disease 2 0.9974853
, O 0 0.00024044699
in O 0 0.00010064651
7 O 0 6.4087435e-05
transplant O 0 0.0006404925
biopsy O 0 0.0002574997
specimens O 0 9.8521065e-05
without O 0 0.00016762094
TG B-Disease 2 0.9948932
, O 0 0.00019733662
and O 0 0.00012196868
in O 0 0.0001043605
13 O 0 0.00012704717
of O 0 0.0001969864
143 O 0 0.00058880827
native O 0 0.0005537516
kidney O 0 0.36483213
biopsy O 0 0.0027928408
specimens O 0 0.0013528616
. O 0 0.0016735895

These O 0 0.0022646796
13 O 0 0.0013693592
included O 0 0.0006985801
cases O 0 0.0007997128
of O 0 0.0013064102
malignant B-Disease 0 0.9987509
hypertension I-Disease 2 0.99999714
, O 0 0.071445026
thrombotic B-Disease 2 0.9999964
microangiopathy I-Disease 2 0.99999976
, O 0 0.16688216
lupus B-Disease 0 0.999998
nephritis I-Disease 0 0.999998
, O 0 0.026609726
Henoch B-Disease 0 0.99988043
- I-Disease 0 0.033972107
Schonlein I-Disease 0 0.99972886
nephritis I-Disease 0 0.9999957
, O 0 0.007460509
crescentic O 0 0.9999238
glomerulonephritis B-Disease 2 0.99999666
, O 0 0.0011903963
and O 0 0.0007122701
cocaine B-Chemical 1 0.9998011
- O 0 0.0008616064
related O 0 0.00025883698
acute B-Disease 0 0.5169932
renal I-Disease 0 0.99584144
failure I-Disease 0 0.89887923
. O 0 0.0032407192

Mild O 0 0.9024183
PTCR O 0 0.4768736
in O 0 0.0012682067
allografts O 0 0.029372148
without O 0 0.0011002272
TG B-Disease 2 0.9972899
did O 0 0.00038323516
not O 0 0.00015610794
predict O 0 0.00011727061
renal B-Disease 0 0.81398255
failure I-Disease 0 0.14824277
or O 0 0.00017728761
significant O 0 0.0002711554
proteinuria B-Disease 0 0.99997866
after O 0 5.3388994e-05
follow O 0 5.8813446e-05
- O 0 0.00012077603
up O 0 6.20744e-05
periods O 0 4.674068e-05
of O 0 9.4721305e-05
between O 0 6.845556e-05
3 O 0 0.00010594011
months O 0 9.283149e-05
and O 0 0.0003082716
1 O 0 0.00050785125
year O 0 0.0007640659
. O 0 0.0016351568

CONCLUSIONS O 0 0.014423124
: O 0 0.001963764
We O 0 0.00055824604
conclude O 0 0.00037741353
that O 0 0.00034109692
in O 0 0.0004412468
transplants O 0 0.006295606
, O 0 0.0003536339
there O 0 0.00012137153
is O 0 0.00014356058
a O 0 0.00015228256
strong O 0 0.00012520039
association O 0 5.8983067e-05
between O 0 5.156362e-05
well O 0 8.43817e-05
- O 0 0.00022614848
developed O 0 0.0002849148
PTCR O 0 0.4321383
and O 0 0.00033468325
TG B-Disease 2 0.9982541
, O 0 0.00015878965
while O 0 7.045252e-05
the O 0 6.56478e-05
significance O 0 6.641108e-05
of O 0 0.00015906348
mild O 0 0.33657813
PTCR O 0 0.38989443
and O 0 0.000121329635
its O 0 0.00016666771
predictive O 0 0.00022855352
value O 0 0.00013682587
in O 0 0.00010583924
the O 0 0.0001360423
absence O 0 0.00017621373
of O 0 0.0010388256
TG B-Disease 2 0.9967326
is O 0 0.0014043621
unclear O 0 0.0014473846
. O 0 0.0022366322

PTCR O 0 0.16616717
also O 0 0.0015359137
occurs O 0 0.0008025312
in O 0 0.00057975453
certain O 0 0.0005382041
native O 0 0.0010993101
kidney B-Disease 0 0.95563465
diseases I-Disease 0 0.694017
, O 0 0.00043218007
though O 0 0.00017057388
the O 0 0.00013750796
association O 0 9.473314e-05
is O 0 0.0001377665
not O 0 0.00013167923
as O 0 0.0001592025
strong O 0 0.00028128648
as O 0 0.00027213673
that O 0 0.00038864737
for O 0 0.0011075764
TG B-Disease 2 0.995814
. O 0 0.0034647766

We O 0 0.0013639461
suggest O 0 0.0006316172
that O 0 0.0005714235
repeated O 0 0.00071946165
endothelial B-Disease 0 0.996482
injury I-Disease 0 0.9925438
, O 0 0.0009609857
including O 0 0.0003586879
immunologic B-Disease 0 0.84089065
injury I-Disease 0 0.9941697
, O 0 0.0005131828
may O 0 0.00013979248
be O 0 0.000100843834
the O 0 9.525864e-05
cause O 0 0.00014974784
of O 0 0.00014558205
this O 0 0.00019414279
lesion O 0 0.0010101666
both O 0 0.0002023954
in O 0 0.0002574138
allografts O 0 0.015749725
and O 0 0.0006746257
native O 0 0.0014904538
kidneys O 0 0.068168774
. O 0 0.0023723496

Caffeine B-Chemical 0 0.9996189
- O 0 0.008582917
induced O 0 0.0037296554
cardiac B-Disease 0 0.9789515
arrhythmia I-Disease 0 0.99988437
: O 0 0.00213565
an O 0 0.0011495794
unrecognised O 0 0.0031422428
danger O 0 0.0018869378
of O 0 0.0015886319
healthfood O 0 0.0121737495
products O 0 0.0059373025
. O 0 0.0030516118

We O 0 0.0015458056
describe O 0 0.0011545038
a O 0 0.0014436726
25 O 0 0.0013833381
- O 0 0.0011684946
year O 0 0.00033658586
- O 0 0.0005002653
old O 0 0.00024698858
woman O 0 0.00040968638
with O 0 0.00018163618
pre O 0 0.0002860266
- O 0 0.00019572415
existing O 0 0.00015384173
mitral B-Disease 0 0.020498624
valve I-Disease 0 0.0024104638
prolapse I-Disease 0 0.073513255
who O 0 0.00012603517
developed O 0 0.00012676422
intractable O 0 0.01037213
ventricular B-Disease 0 0.9869893
fibrillation I-Disease 0 0.99995077
after O 0 4.3211516e-05
consuming O 0 0.000253958
a O 0 0.000104518054
" O 0 8.8342254e-05
natural O 0 0.00013187174
energy O 0 0.0004349737
" O 0 0.00025897622
guarana O 0 0.99179137
health O 0 0.0012970731
drink O 0 0.036485415
containing O 0 0.0001325754
a O 0 0.0002550081
high O 0 0.0005149731
concentration O 0 0.0012597998
of O 0 0.0029549398
caffeine B-Chemical 0 0.99965715
. O 0 0.0035356693

This O 0 0.004144783
case O 0 0.0016133224
highlights O 0 0.0009513166
the O 0 0.00070395437
need O 0 0.00044365384
for O 0 0.00032300694
adequate O 0 0.0004135053
labelling O 0 0.000597154
and O 0 0.0004085057
regulation O 0 0.00032344757
of O 0 0.0007893427
such O 0 0.0009647571
products O 0 0.004534382
. O 0 0.0029336808

Conformationally O 0 0.08010886
restricted O 0 0.0016043665
analogs O 0 0.007546152
of O 0 0.0022574875
BD1008 B-Chemical 0 0.9991617
and O 0 0.0006813032
an O 0 0.00047328236
antisense O 0 0.0011286148
oligodeoxynucleotide B-Chemical 0 0.05220383
targeting O 0 0.0001904104
sigma1 O 0 0.5394659
receptors O 0 0.0018665182
produce O 0 0.0001760149
anti O 0 0.002610783
- O 0 0.0017750189
cocaine B-Chemical 1 0.99921286
effects O 0 0.0010219403
in O 0 0.0008396175
mice O 0 0.0010996035
. O 0 0.0019679817

Cocaine B-Chemical 0 0.9993093
' O 0 0.003130406
s O 0 0.0011318722
ability O 0 0.000609972
to O 0 0.00036307846
interact O 0 0.00015889372
with O 0 0.00035800156
sigma O 0 0.0020646174
receptors O 0 0.0011315327
suggests O 0 8.418288e-05
that O 0 9.3672534e-05
these O 0 0.00018229602
proteins O 0 0.00015473431
mediate O 0 7.366211e-05
some O 0 0.00019561463
of O 0 0.00037183712
its O 0 0.00083122466
behavioral O 0 0.0027416416
effects O 0 0.002080499
. O 0 0.0023743187

Therefore O 0 0.0017219924
, O 0 0.0014332011
three O 0 0.00043706165
novel O 0 0.000704606
sigma O 0 0.0034131957
receptor O 0 0.015131156
ligands O 0 0.0041486938
with O 0 0.0005704489
antagonist O 0 0.5823578
activity O 0 0.00018836501
were O 0 0.00011195246
evaluated O 0 7.339489e-05
in O 0 9.165878e-05
Swiss O 0 0.00075564825
Webster O 0 0.0026210744
mice O 0 7.750403e-05
: O 0 0.00024233402
BD1018 B-Chemical 0 0.9050034
( O 0 0.00061029993
3S B-Chemical 0 0.44521627
- I-Chemical 0 0.00036096098
1 I-Chemical 0 0.00011937696
- I-Chemical 0 0.00025482074
[ I-Chemical 0 0.00028018374
2 I-Chemical 0 9.885478e-05
- I-Chemical 0 0.0002000806
( I-Chemical 0 0.00013715871
3 I-Chemical 0 6.904416e-05
, I-Chemical 0 0.00010043051
4 I-Chemical 0 8.6971755e-05
- I-Chemical 0 0.00037411271
dichlorophenyl I-Chemical 0 0.98978287
) I-Chemical 0 0.001589333
ethyl I-Chemical 0 0.99986875
] I-Chemical 0 0.002301831
- I-Chemical 0 0.00038349372
1 I-Chemical 0 9.872252e-05
, I-Chemical 0 0.00011205776
4 I-Chemical 0 8.3840314e-05
- I-Chemical 0 0.00026092352
diazabicyclo I-Chemical 0 0.049355198
[ I-Chemical 0 0.00036465627
4 I-Chemical 0 6.846053e-05
. I-Chemical 0 4.8241007e-05
3 I-Chemical 0 5.128787e-05
. I-Chemical 0 4.858245e-05
0 I-Chemical 0 9.557582e-05
] I-Chemical 0 0.00046297305
nonane I-Chemical 0 0.99417865
) O 0 0.0007352627
, O 0 0.0005888055
BD1063 B-Chemical 0 0.9999813
( O 0 0.0006115638
1 B-Chemical 0 0.00015385287
- I-Chemical 0 0.0002949909
[ I-Chemical 0 0.0002990031
2 I-Chemical 0 0.00010098096
- I-Chemical 0 0.00020270205
( I-Chemical 0 0.00013796658
3 I-Chemical 0 6.9196554e-05
, I-Chemical 0 0.00010029146
4 I-Chemical 0 8.647045e-05
- I-Chemical 0 0.00036835638
dichlorophenyl I-Chemical 0 0.9890121
) I-Chemical 0 0.0014883851
ethyl I-Chemical 0 0.9998592
] I-Chemical 0 0.0021449397
- I-Chemical 0 0.00039558706
4 I-Chemical 0 0.00010625152
- I-Chemical 0 0.00033607346
methylpiperazine I-Chemical 0 0.35128212
) O 0 0.00030981965
, O 0 0.00015677427
and O 0 0.00023470129
LR132 B-Chemical 0 0.970063
( O 0 0.0011215215
1R O 0 0.9951409
, O 0 0.00050473365
2S O 0 0.8667809
- O 0 0.00062268367
( O 0 0.00028583387
+ O 0 0.0004101672
) O 0 0.00034502186
- O 0 0.00042209667
cis O 0 0.005358234
- O 0 0.0012430287
N O 0 0.981831
- O 0 0.00078058284
[ O 0 0.00046384588
2 O 0 0.00011803058
- O 0 0.00022364652
( O 0 0.0001462644
3 O 0 7.28335e-05
, O 0 0.00010628485
4 O 0 9.284088e-05
- O 0 0.00039579734
dichlorophenyl O 0 0.9884255
) O 0 0.0016326801
ethyl O 0 0.9998368
] O 0 0.0023800386
- O 0 0.00051322026
2 O 0 0.00016559135
- O 0 0.0003341247
( O 0 0.000286882
1 O 0 0.00024564384
- O 0 0.0008077083
pyrrolidinyl O 0 0.7401036
) O 0 0.003289402
cyclohexylamine O 0 0.9992642
) O 0 0.0051297145
. O 0 0.0028806373

Competition O 0 0.00426329
binding O 0 0.0018334613
assays O 0 0.0013749184
demonstrated O 0 0.00052609906
that O 0 0.00033958425
all O 0 0.00035563554
three O 0 0.00021293342
compounds O 0 0.018861169
have O 0 0.0003150633
high O 0 0.00075800234
affinities O 0 0.0016615188
for O 0 0.00083297386
sigma1 O 0 0.6702548
receptors O 0 0.020314323
. O 0 0.0028896783

The O 0 0.0014504602
three O 0 0.0008192706
compounds O 0 0.014212889
vary O 0 0.0005229723
in O 0 0.00032764114
their O 0 0.000324076
affinities O 0 0.00054932106
for O 0 0.00015738554
sigma2 O 0 0.001530952
receptors O 0 0.000879163
and O 0 0.00012497923
exhibit O 0 0.00010712827
negligible O 0 0.00016136383
affinities O 0 0.00042373585
for O 0 0.00016229087
dopamine B-Chemical 0 0.99980825
, O 0 0.00055725296
opioid O 0 0.99037397
, O 0 0.000980926
GABA B-Chemical 0 0.99996114
( O 0 0.0010016891
A O 0 0.01335462
) O 0 0.0009735641
and O 0 0.0016233966
NMDA B-Chemical 1 0.999961
receptors O 0 0.12573269
. O 0 0.003041621

In O 0 0.0019228525
behavioral O 0 0.0033656063
studies O 0 0.0012445813
, O 0 0.0009593766
pre O 0 0.0011294268
- O 0 0.0007365419
treatment O 0 0.00025135066
of O 0 0.00025464562
mice O 0 0.0001428193
with O 0 0.0004737023
BD1018 B-Chemical 0 0.9869148
, O 0 0.0013724313
BD1063 B-Chemical 0 0.9999865
, O 0 0.0005072451
or O 0 0.0002682068
LR132 B-Chemical 0 0.9380328
significantly O 0 0.00052064826
attenuated O 0 0.0036624072
cocaine B-Chemical 1 0.99993217
- O 0 0.0022814001
induced O 0 0.0018299137
convulsions B-Disease 0 0.99990153
and O 0 0.0042716055
lethality O 0 0.9080464
. O 0 0.003312372

Moreover O 0 0.00303472
, O 0 0.0021163095
post O 0 0.00088115974
- O 0 0.001368272
treatment O 0 0.0006123591
with O 0 0.0010742964
LR132 B-Chemical 0 0.98964417
prevented O 0 0.050522875
cocaine B-Chemical 1 0.9999579
- O 0 0.0020980113
induced O 0 0.0005565465
lethality O 0 0.45282972
in O 0 0.00031514326
a O 0 0.00039519454
significant O 0 0.00032385826
proportion O 0 0.0004202798
of O 0 0.0009025063
animals O 0 0.0011778605
. O 0 0.0019500256

In O 0 0.0017891811
contrast O 0 0.0015763765
to O 0 0.0007629738
the O 0 0.0005937783
protection O 0 0.00092929683
provided O 0 0.00036526515
by O 0 0.00024719775
the O 0 0.00019004366
putative O 0 0.00024412852
antagonists O 0 0.54055107
, O 0 0.00021056278
the O 0 0.00011615225
well O 0 0.00010243906
- O 0 0.0002326378
characterized O 0 0.0002787024
sigma O 0 0.0037762334
receptor O 0 0.06905865
agonist O 0 0.74603236
di B-Chemical 0 0.0029009236
- I-Chemical 0 0.00039225657
o I-Chemical 0 0.0023530782
- I-Chemical 0 0.00039209917
tolylguanidine I-Chemical 0 0.011205385
( O 0 0.0006082478
DTG B-Chemical 0 0.99990976
) O 0 0.00021760292
and O 0 6.5323264e-05
the O 0 5.3206022e-05
novel O 0 8.971585e-05
sigma O 0 0.0014602363
receptor O 0 0.054034166
agonist O 0 0.92707026
BD1031 B-Chemical 0 0.9977069
( O 0 0.00093745755
3R B-Chemical 0 0.93475986
- I-Chemical 0 0.00036998955
1 I-Chemical 0 0.0001062813
- I-Chemical 0 0.00023179136
[ I-Chemical 0 0.00025738185
2 I-Chemical 0 9.092482e-05
- I-Chemical 0 0.00018733046
( I-Chemical 0 0.0001297007
3 I-Chemical 0 6.569822e-05
, I-Chemical 0 9.637635e-05
4 I-Chemical 0 8.406335e-05
- I-Chemical 0 0.00036486526
dichlorophenyl I-Chemical 0 0.9896624
) I-Chemical 0 0.0015628033
ethyl I-Chemical 0 0.9998683
] I-Chemical 0 0.002269106
- I-Chemical 0 0.00038118122
1 I-Chemical 0 9.8674886e-05
, I-Chemical 0 0.0001125451
4 I-Chemical 0 8.4604566e-05
- I-Chemical 0 0.0002638907
diazabicyclo I-Chemical 0 0.0488349
[ I-Chemical 0 0.00037145094
4 I-Chemical 0 7.1346585e-05
. I-Chemical 0 5.1251835e-05
3 I-Chemical 0 5.553779e-05
. I-Chemical 0 5.3732845e-05
0 I-Chemical 0 0.000105087085
] I-Chemical 0 0.0004483951
nonane I-Chemical 0 0.9742813
) O 0 0.0002884593
each O 0 8.0843034e-05
worsened O 0 0.0011581806
the O 0 0.00025481806
behavioral O 0 0.002441542
toxicity B-Disease 2 0.99395025
of O 0 0.006292096
cocaine B-Chemical 1 0.9996729
. O 0 0.003417159

At O 0 0.0010670718
doses O 0 0.004185423
where O 0 0.00080073846
alone O 0 0.00077946525
, O 0 0.00053634535
they O 0 0.00022555563
produced O 0 0.00019387789
no O 0 0.000107649495
significant O 0 0.0001254407
effects O 0 0.00014845436
on O 0 0.00010200138
locomotion O 0 0.012720947
, O 0 0.00047039418
BD1018 B-Chemical 0 0.9814827
, O 0 0.0009740782
BD1063 B-Chemical 0 0.99998605
and O 0 0.0008025213
LR132 B-Chemical 0 0.9625682
significantly O 0 0.00029202612
attenuated O 0 0.0003576613
the O 0 0.00020836093
locomotor O 0 0.026729718
stimulatory O 0 0.0012529499
effects O 0 0.00093095534
of O 0 0.0035277873
cocaine B-Chemical 1 0.99967766
. O 0 0.0033725551

To O 0 0.0019976632
further O 0 0.0017107844
validate O 0 0.0008458086
the O 0 0.00061398954
hypothesis O 0 0.000534324
that O 0 0.00023995349
the O 0 0.00034546986
anti O 0 0.0029824362
- O 0 0.0017775417
cocaine B-Chemical 1 0.99947256
effects O 0 0.00025883352
of O 0 0.00017622279
the O 0 0.00010142255
novel O 0 0.00013798711
ligands O 0 0.0007376563
involved O 0 7.201359e-05
antagonism O 0 0.027199244
of O 0 0.00021864694
sigma O 0 0.0047232355
receptors O 0 0.001876891
, O 0 0.00010406517
an O 0 0.00010455365
antisense O 0 0.00048575134
oligodeoxynucleotide B-Chemical 0 0.07510178
against O 0 0.00012925302
sigma1 O 0 0.80623287
receptors O 0 0.002754338
was O 0 9.4568335e-05
also O 0 5.3759548e-05
shown O 0 4.251995e-05
to O 0 4.980227e-05
significantly O 0 0.00010671758
attenuate O 0 0.00016434302
the O 0 0.00020455763
convulsive B-Disease 2 0.9996959
and O 0 0.00033293862
locomotor O 0 0.039182752
stimulatory O 0 0.001133988
effects O 0 0.00082162616
of O 0 0.0030696734
cocaine B-Chemical 1 0.99965405
. O 0 0.0031379322

Together O 0 0.0058115614
, O 0 0.0021580954
the O 0 0.0009680552
data O 0 0.0006905822
suggests O 0 0.0002427197
that O 0 0.00022284406
functional O 0 0.00038415217
antagonism O 0 0.04068142
of O 0 0.0005023403
sigma O 0 0.005571005
receptors O 0 0.001912024
is O 0 0.00014066443
capable O 0 9.9099234e-05
of O 0 0.00018920438
attenuating O 0 0.00065227883
a O 0 0.00030945332
number O 0 0.00024143666
of O 0 0.0008253853
cocaine B-Chemical 1 0.999767
- O 0 0.0020063957
induced O 0 0.0014092185
behaviors O 0 0.005465028
. O 0 0.002327026

Ranitidine B-Chemical 0 0.9997917
- O 0 0.008801136
induced O 0 0.0035759297
acute O 0 0.8642936
interstitial B-Disease 0 0.99570024
nephritis I-Disease 0 0.9999913
in O 0 0.002732697
a O 0 0.0025598318
cadaveric O 0 0.13625096
renal O 0 0.99028087
allograft O 0 0.98559463
. O 0 0.004820906

Ranitidine B-Chemical 0 0.9996245
frequently O 0 0.0028353676
is O 0 0.0013345184
used O 0 0.000796114
for O 0 0.00077261485
preventing O 0 0.0036338985
peptic O 0 0.99791163
ulceration O 0 0.99557084
after O 0 0.00094258506
renal O 0 0.9552821
transplantation O 0 0.1457855
. O 0 0.0037419298

This O 0 0.005066232
drug O 0 0.019658592
occasionally O 0 0.0023485958
has O 0 0.0006889051
been O 0 0.0004331659
associated O 0 0.0004224072
with O 0 0.00088953896
acute O 0 0.7772666
interstitial B-Disease 0 0.9959264
nephritis I-Disease 0 0.99999464
in O 0 0.0032534732
native O 0 0.0034199122
kidneys O 0 0.16619849
. O 0 0.0029806867

There O 0 0.004124671
are O 0 0.00229269
no O 0 0.0012726827
similar O 0 0.0012620275
reports O 0 0.0023877611
with O 0 0.0035601028
renal O 0 0.95895946
transplantation O 0 0.2183758
. O 0 0.0060530854

We O 0 0.0016703836
report O 0 0.0017661058
a O 0 0.0011867236
case O 0 0.00078978663
of O 0 0.0025090396
ranitidine B-Chemical 1 0.99998784
- O 0 0.0025962822
induced O 0 0.00080451474
acute O 0 0.9071416
interstitial B-Disease 0 0.9978886
nephritis I-Disease 0 0.99999905
in O 0 0.00042951683
a O 0 0.00018594506
recipient O 0 0.00016825729
of O 0 0.000101941594
a O 0 0.00014035693
cadaveric O 0 0.0072176526
renal O 0 0.8846447
allograft O 0 0.7776021
presenting O 0 0.00084172824
with O 0 0.00026940388
acute O 0 0.40509486
allograft O 0 0.94426537
dysfunction O 0 0.7010533
within O 0 3.9613762e-05
48 O 0 5.6089564e-05
hours O 0 4.6917023e-05
of O 0 0.00014099908
exposure O 0 0.0003013214
to O 0 0.00034829465
the O 0 0.0008030851
drug O 0 0.03010816
. O 0 0.0021751132

The O 0 0.0019536826
biopsy O 0 0.002434699
specimen O 0 0.0011360899
showed O 0 0.0007827004
pathognomonic O 0 0.0015445079
features O 0 0.0006245836
, O 0 0.0005595377
including O 0 0.0004084029
eosinophilic O 0 0.60734355
infiltration O 0 0.09382442
of O 0 0.0009198113
the O 0 0.00084395526
interstitial O 0 0.020470208
compartment O 0 0.0023860275
. O 0 0.0023334448

Allograft O 0 0.011005673
function O 0 0.0019185024
improved O 0 0.0017064542
rapidly O 0 0.00093319867
and O 0 0.00052955793
returned O 0 0.00041371182
to O 0 0.00031536233
baseline O 0 0.00032131033
after O 0 0.0002471167
stopping O 0 0.0012621527
the O 0 0.0013853374
drug O 0 0.02892473
. O 0 0.0032751842

Liver B-Disease 0 0.9897682
disease I-Disease 0 0.97058004
caused O 0 0.017078249
by O 0 0.020619368
propylthiouracil B-Chemical 0 0.9994117
. O 0 0.022279007

This O 0 0.0033975309
report O 0 0.0018503853
presents O 0 0.0009415676
the O 0 0.0006320014
clinical O 0 0.0012585045
, O 0 0.00047249804
laboratory O 0 0.00047757174
, O 0 0.00022566172
and O 0 0.00015814672
light O 0 0.00041628466
and O 0 0.0001460073
electron O 0 0.0010369542
microscopic O 0 0.00025838922
observations O 0 9.2621405e-05
on O 0 3.949845e-05
a O 0 9.966053e-05
patient O 0 0.000100892416
with O 0 0.0001601292
chronic B-Disease 0 0.03312783
active I-Disease 0 0.00029057555
( I-Disease 0 0.00031757777
aggressive I-Disease 0 0.0024031627
) I-Disease 0 0.0013380754
hepatitis I-Disease 2 0.9999826
caused O 0 0.0007161078
by O 0 0.0003331628
the O 0 0.000345403
administration O 0 0.0032339569
of O 0 0.0037604838
propylthiouracil B-Chemical 0 0.9999175
. O 0 0.00455474

This O 0 0.0039495295
is O 0 0.0014541487
an O 0 0.00091794436
addition O 0 0.000378856
to O 0 0.00033750932
the O 0 0.00028382085
list O 0 0.00026491415
of O 0 0.00032552143
drugs O 0 0.003404461
that O 0 0.00011443339
must O 0 6.9391885e-05
be O 0 9.029881e-05
considered O 0 7.702709e-05
in O 0 9.935063e-05
the O 0 0.00013964338
evaluation O 0 0.00023708059
of O 0 0.00090492866
chronic O 0 0.9815663
liver B-Disease 2 0.9997696
disease I-Disease 2 0.99950993
. O 0 0.0049437922

Withdrawal B-Disease 0 0.112825155
- I-Disease 0 0.0044244127
emergent I-Disease 0 0.0023094038
rabbit I-Disease 0 0.013764467
syndrome I-Disease 0 0.5129358
during O 0 0.0006701885
dose O 0 0.0032010588
reduction O 0 0.003937922
of O 0 0.007229316
risperidone B-Chemical 0 0.99991715
. O 0 0.0053755837

Rabbit B-Disease 0 0.32876685
syndrome I-Disease 0 0.9648254
( O 0 0.006743568
RS B-Disease 0 0.9375234
) O 0 0.0018447757
is O 0 0.0006263396
a O 0 0.00072787417
rare O 0 0.0035613682
extrapyramidal O 0 0.99990547
side O 0 0.037813514
effect O 0 0.0004774263
caused O 0 0.0006172271
by O 0 0.00075405784
prolonged O 0 0.0072756815
neuroleptic O 0 0.999959
medication O 0 0.15309884
. O 0 0.002578395

Here O 0 0.002022518
we O 0 0.00084614067
present O 0 0.0007209222
a O 0 0.0008523368
case O 0 0.00051799143
of O 0 0.00071203464
withdrawal B-Disease 0 0.033910926
- I-Disease 0 0.0008869733
emergent I-Disease 0 0.0006393446
RS I-Disease 0 0.9287811
, O 0 0.00032500268
which O 0 0.00023210054
is O 0 0.0001392295
the O 0 0.00011209945
first O 0 9.363957e-05
of O 0 0.00024985854
its O 0 0.0004835076
kind O 0 0.00046828232
to O 0 0.00047971657
be O 0 0.00078020804
reported O 0 0.0017054162
. O 0 0.0021498902

The O 0 0.00249396
patient O 0 0.0026491634
developed O 0 0.003266196
RS B-Disease 0 0.43456885
during O 0 0.0010072682
dose O 0 0.004521625
reduction O 0 0.005341949
of O 0 0.009523448
risperidone B-Chemical 0 0.9999068
. O 0 0.0066736047

The O 0 0.0022396925
symptom O 0 0.0042206994
was O 0 0.0015648083
treated O 0 0.0013752221
successfully O 0 0.0013603448
with O 0 0.0037267546
trihexyphenidyl B-Chemical 1 0.9999895
anticholinergic O 0 0.99973077
therapy O 0 0.014573372
. O 0 0.003986493

The O 0 0.0015169688
underlying O 0 0.0016035165
mechanism O 0 0.0010504959
of O 0 0.0010869141
withdrawal B-Disease 0 0.024221614
- I-Disease 0 0.0009779586
emergent I-Disease 0 0.0005545299
RS I-Disease 0 0.7534519
in O 0 0.00016122556
the O 0 0.00011280115
present O 0 8.504962e-05
case O 0 0.00010290921
may O 0 7.362616e-05
have O 0 5.0684626e-05
been O 0 3.7320144e-05
related O 0 2.1499929e-05
to O 0 3.503551e-05
the O 0 4.773037e-05
pharmacological O 0 0.0004312237
profile O 0 9.461226e-05
of O 0 0.0002987355
risperidone B-Chemical 0 0.9999906
, O 0 0.00018765726
a O 0 0.00036452123
serotonin B-Chemical 0 0.9998604
- O 0 0.0019212828
dopamine B-Chemical 0 0.99992824
antagonist O 0 0.85784405
, O 0 0.00012141504
suggesting O 0 3.328421e-05
the O 0 4.577949e-05
pathophysiologic O 0 0.00013938174
influence O 0 3.2816108e-05
of O 0 0.00010176181
the O 0 0.00017071106
serotonin B-Chemical 0 0.9944872
system O 0 0.00018622096
in O 0 0.00015321372
the O 0 0.00024616293
development O 0 0.0008117143
of O 0 0.0019060242
RS B-Disease 0 0.9102954
. O 0 0.0028601927

Pharmacokinetic O 0 0.1241995
/ O 0 0.00367051
pharmacodynamic O 0 0.0060009896
assessment O 0 0.00037720634
of O 0 0.00030750316
the O 0 0.00019399179
effects O 0 0.00025407766
of O 0 0.00095080555
E4031 B-Chemical 0 0.9999956
, O 0 0.0052217855
cisapride B-Chemical 0 0.9999907
, O 0 0.0018858013
terfenadine B-Chemical 1 0.99999344
and O 0 0.00075295847
terodiline B-Chemical 0 0.99948657
on O 0 0.00011819546
monophasic O 0 0.0010890161
action O 0 0.0002442787
potential O 0 0.00024502116
duration O 0 0.00022047787
in O 0 0.0006259773
dog O 0 0.0027656264
. O 0 0.0019182255

1 O 0 0.062920205
. O 0 0.06257983

Torsades B-Disease 0 0.9967116
de I-Disease 0 0.15501633
pointes I-Disease 0 0.9998572
( O 0 0.028571675
TDP B-Disease 0 0.99963903
) O 0 0.0016253995
is O 0 0.00034469456
a O 0 0.00031790495
potentially O 0 0.0004452965
fatal O 0 0.79063976
ventricular B-Disease 2 0.99980336
tachycardia I-Disease 2 0.99990606
associated O 0 0.00018208042
with O 0 0.00013665989
increases O 0 9.932155e-05
in O 0 0.000119621385
QT O 0 0.54950637
interval O 0 7.913299e-05
and O 0 9.070815e-05
monophasic O 0 0.00051479734
action O 0 0.00016953325
potential O 0 0.00018731153
duration O 0 0.00018420037
( O 0 0.0008060745
MAPD O 0 0.080892526
) O 0 0.0023477604
. O 0 0.0020543183

TDP B-Disease 0 0.99624336
is O 0 0.0028714929
a O 0 0.002470535
side O 0 0.01570208
- O 0 0.0014295868
effect O 0 0.00036648876
that O 0 0.00022751425
has O 0 0.0001684069
led O 0 0.00020512323
to O 0 0.00015359432
withdrawal O 0 0.0019326471
of O 0 0.00017013452
several O 0 9.053989e-05
drugs O 0 0.0014720059
from O 0 7.581014e-05
the O 0 9.434154e-05
market O 0 0.00021524636
( O 0 0.00018564177
e O 0 0.00018567203
. O 0 9.716747e-05
g O 0 0.00044498296
. O 0 0.00030183286
terfenadine B-Chemical 1 0.99993753
and O 0 0.0026667234
terodiline B-Chemical 0 0.99947995
) O 0 0.00430478
. O 0 0.0024562913

2 O 0 0.058298454
. O 0 0.06073419

The O 0 0.0016661444
potential O 0 0.0014963555
of O 0 0.0016408132
compounds O 0 0.13905898
to O 0 0.00096035196
cause O 0 0.0028277389
TDP B-Disease 0 0.9994174
was O 0 0.00052673183
evaluated O 0 0.00019594916
by O 0 0.00018554037
monitoring O 0 0.00016894989
their O 0 0.0002117569
effects O 0 0.0002900707
on O 0 0.00032053012
MAPD O 0 0.0592651
in O 0 0.0010948632
dog O 0 0.0038975223
. O 0 0.0023608566

Four O 0 0.0033714396
compounds O 0 0.04763598
known O 0 0.0014189212
to O 0 0.000651737
increase O 0 0.00072657166
QT O 0 0.82042134
interval O 0 0.00031170633
and O 0 0.00028555686
cause O 0 0.00069844694
TDP B-Disease 0 0.99841404
were O 0 0.00020945947
investigated O 0 0.00015005458
: O 0 0.0005655727
terfenadine B-Chemical 1 0.99998474
, O 0 0.0015178387
terodiline B-Chemical 0 0.9998246
, O 0 0.0026412986
cisapride B-Chemical 0 0.9999387
and O 0 0.0060980413
E4031 B-Chemical 0 0.9999374
. O 0 0.0049062204

On O 0 0.0021731681
the O 0 0.0011598992
basis O 0 0.0007712737
that O 0 0.00039626478
only O 0 0.00045694964
free O 0 0.00054529484
drug O 0 0.004023028
in O 0 0.0001887089
the O 0 0.0001886785
systemic O 0 0.045378618
circulation O 0 0.0006138713
will O 0 6.93354e-05
elicit O 0 3.504243e-05
a O 0 9.955709e-05
pharmacological O 0 0.00055484835
response O 0 7.688011e-05
target O 0 5.8033576e-05
, O 0 8.8979556e-05
free O 0 0.00011252655
concentrations O 0 0.00023668782
in O 0 9.665698e-05
plasma O 0 0.001222373
were O 0 8.034258e-05
selected O 0 6.181313e-05
to O 0 5.9717466e-05
mimic O 0 7.5948556e-05
the O 0 0.00012759776
free O 0 0.00034043205
drug O 0 0.0057178875
exposures O 0 0.0019106905
in O 0 0.0011125761
man O 0 0.026178189
. O 0 0.0022677893

Infusion O 0 0.015147605
regimens O 0 0.0022627048
were O 0 0.00070491835
designed O 0 0.00040935786
that O 0 0.00022944699
rapidly O 0 0.00034725555
achieved O 0 0.00028906603
and O 0 0.00016308544
maintained O 0 0.00012650376
target O 0 9.682912e-05
- O 0 0.00020723278
free O 0 0.00012566627
concentrations O 0 0.00020953995
of O 0 0.00012447638
these O 0 0.00016659191
drugs O 0 0.004351169
in O 0 8.7100314e-05
plasma O 0 0.0011553527
and O 0 7.325379e-05
data O 0 5.6279077e-05
on O 0 2.5874882e-05
the O 0 3.7881517e-05
relationship O 0 2.242207e-05
between O 0 2.9959097e-05
free O 0 9.4913e-05
concentration O 0 0.00019146179
and O 0 0.00010348152
changes O 0 0.00013615028
in O 0 0.0001274669
MAPD O 0 0.015711479
were O 0 0.00016506512
obtained O 0 0.00020111653
for O 0 0.00027900923
these O 0 0.0010918509
compounds O 0 0.18988235
. O 0 0.0024806797

3 O 0 0.05500685
. O 0 0.05996203

These O 0 0.0019949004
data O 0 0.0012477915
indicate O 0 0.0004473681
that O 0 0.00032761428
the O 0 0.0003861615
free O 0 0.0007262138
ED50 O 0 0.8710802
in O 0 0.0003447138
plasma O 0 0.0073680365
for O 0 0.0004173995
terfenadine B-Chemical 1 0.9999938
( O 0 0.00064265035
1 O 0 0.0001238
. O 0 6.6563436e-05
9 O 0 8.7676475e-05
nM O 0 0.0009798416
) O 0 0.00032157757
, O 0 0.0002992107
terodiline B-Chemical 0 0.9995215
( O 0 0.00030678752
76 O 0 0.00030123862
nM O 0 0.0024291521
) O 0 0.00038293021
, O 0 0.00036960669
cisapride B-Chemical 0 0.99996495
( O 0 0.00032650455
11 O 0 0.00013389194
nM O 0 0.0013861266
) O 0 0.00031248233
and O 0 0.00038065706
E4031 B-Chemical 0 0.9999939
( O 0 0.0005953945
1 O 0 0.000110775
. O 0 6.0774895e-05
9 O 0 8.067715e-05
nM O 0 0.0007684347
) O 0 0.0001655285
closely O 0 5.3727515e-05
correlate O 0 6.1224026e-05
with O 0 9.9962715e-05
the O 0 0.00010469642
free O 0 0.00021457265
concentration O 0 0.00046927077
in O 0 0.0003695729
man O 0 0.007047977
causing O 0 0.0028217672
QT O 0 0.94552267
effects O 0 0.0024994868
. O 0 0.0023619237

For O 0 0.0014181134
compounds O 0 0.023629557
that O 0 0.00070897077
have O 0 0.0005172882
shown O 0 0.00053138833
TDP B-Disease 0 0.99595
in O 0 0.00024434135
the O 0 0.00019227681
clinic O 0 0.0003456293
( O 0 0.0005884363
terfenadine B-Chemical 1 0.99998987
, O 0 0.0010345692
terodiline B-Chemical 0 0.99993813
, O 0 0.0013610095
cisapride B-Chemical 0 0.99998677
) O 0 0.00033924938
there O 0 5.0690473e-05
is O 0 6.937238e-05
little O 0 6.966273e-05
differentiation O 0 0.00074623333
between O 0 3.9526665e-05
the O 0 8.19355e-05
dog O 0 0.0005237899
ED50 O 0 0.78851694
and O 0 9.602784e-05
the O 0 6.437728e-05
efficacious O 0 8.978544e-05
free O 0 0.00013424364
plasma O 0 0.0021037243
concentrations O 0 0.00040896665
in O 0 0.0001602971
man O 0 0.0058141155
( O 0 0.00022237372
< O 0 0.00011313466
10 O 0 0.000109873836
- O 0 0.00025150168
fold O 0 0.0002767222
) O 0 0.00026666923
reflecting O 0 0.00020982785
their O 0 0.00031849134
limited O 0 0.00046192695
safety O 0 0.0011815986
margins O 0 0.004069125
. O 0 0.0021182904

These O 0 0.0021287156
data O 0 0.001381089
underline O 0 0.00080668763
the O 0 0.0005429685
need O 0 0.00030022967
to O 0 0.00018893414
maximize O 0 0.000107096814
the O 0 0.00014926058
therapeutic O 0 0.00029841217
ratio O 0 0.00023217955
with O 0 0.00014750192
respect O 0 8.661701e-05
to O 0 0.00017194492
TDP B-Disease 0 0.99724555
in O 0 9.95419e-05
potential O 0 8.780499e-05
development O 0 0.00014975441
candidates O 0 8.9320805e-05
and O 0 6.451138e-05
the O 0 4.9988415e-05
importance O 0 3.6777674e-05
of O 0 8.447768e-05
using O 0 6.709499e-05
free O 0 0.0001753626
drug O 0 0.002476545
concentrations O 0 0.00046071026
in O 0 0.00027648115
pharmacokinetic O 0 0.05133962
/ O 0 0.0016489209
pharmacodynamic O 0 0.014535538
studies O 0 0.001432943
. O 0 0.0017154537

Bladder O 0 0.01249866
retention B-Disease 0 0.00465327
of I-Disease 0 0.0016679077
urine I-Disease 0 0.286639
as O 0 0.00048184444
a O 0 0.0003485539
result O 0 0.00016653571
of O 0 0.00018802368
continuous O 0 0.00013456326
intravenous O 0 0.0021254625
infusion O 0 0.000622774
of O 0 0.00072740234
fentanyl B-Chemical 0 0.9997898
: O 0 0.00079797267
2 O 0 0.00043460357
case O 0 0.00073298335
reports O 0 0.0017967869
. O 0 0.0022061875

Sedation O 0 0.010748255
has O 0 0.0011562459
been O 0 0.00060301385
commonly O 0 0.00048107113
used O 0 0.00026653812
in O 0 0.0002134019
the O 0 0.00019467667
neonate O 0 0.0004772796
to O 0 0.00011928571
decrease O 0 0.0001620407
the O 0 0.000121296194
stress O 0 0.0021075364
and O 0 0.00022836424
pain B-Disease 0 0.13605662
from O 0 6.879252e-05
the O 0 6.765221e-05
noxious O 0 0.0003372388
stimuli O 0 8.0926795e-05
and O 0 7.879392e-05
invasive O 0 0.000106677704
procedures O 0 5.5594806e-05
in O 0 4.385448e-05
the O 0 5.260324e-05
neonatal O 0 0.00015676187
intensive O 0 6.575017e-05
care O 0 7.605655e-05
unit O 0 6.335082e-05
, O 0 8.465582e-05
as O 0 6.047808e-05
well O 0 5.4115535e-05
as O 0 5.7144964e-05
to O 0 5.3232412e-05
facilitate O 0 5.0724317e-05
synchrony O 0 0.00018907219
between O 0 0.00010108963
ventilator O 0 0.0005930589
and O 0 0.00042842422
spontaneous O 0 0.0024403366
breaths O 0 0.0028777542
. O 0 0.0017662285

Fentanyl B-Chemical 0 0.9993357
, O 0 0.0031803893
an O 0 0.002652928
opioid O 0 0.99628
analgesic O 0 0.9057842
, O 0 0.0007364197
is O 0 0.00028163075
frequently O 0 0.00016924363
used O 0 0.00011647313
in O 0 0.00011408996
the O 0 0.00012294955
neonatal O 0 0.00030973108
intensive O 0 0.00013661142
care O 0 0.00014069058
unit O 0 0.000115371055
setting O 0 0.00013575384
for O 0 0.00017859848
these O 0 0.0005151169
very O 0 0.0010494787
purposes O 0 0.0013930319
. O 0 0.0020445231

Various O 0 0.0029114168
reported O 0 0.001805083
side O 0 0.0038672283
effects O 0 0.0008589939
of O 0 0.0014881747
fentanyl B-Chemical 0 0.999859
administration O 0 0.0032135337
include O 0 0.00027788256
chest B-Disease 0 0.04480205
wall I-Disease 0 0.005074314
rigidity I-Disease 0 0.98070884
, O 0 0.001140262
hypotension B-Disease 0 0.99983215
, O 0 0.00088527496
respiratory B-Disease 0 0.12771718
depression I-Disease 0 0.9944149
, O 0 0.0012702703
and O 0 0.0017056615
bradycardia B-Disease 0 0.9956536
. O 0 0.0030057847

Here O 0 0.0028072523
, O 0 0.002152834
2 O 0 0.00088848866
cases O 0 0.0006724669
of O 0 0.0006290309
urinary B-Disease 0 0.17888477
bladder I-Disease 0 0.018357113
retention I-Disease 0 0.0018085258
leading O 0 0.00029486715
to O 0 0.00016413709
renal O 0 0.7227012
pelvocalyceal O 0 0.11066548
dilatation O 0 0.3583676
mimicking O 0 0.00043244095
hydronephrosis B-Disease 0 0.9992092
as O 0 0.00013438785
a O 0 0.000112787595
result O 0 6.542651e-05
of O 0 9.985878e-05
continuous O 0 8.8982604e-05
infusion O 0 0.00040492517
of O 0 0.0006936666
fentanyl B-Chemical 0 0.9996388
are O 0 0.000980402
reported O 0 0.0015800288
. O 0 0.001789132

Fatal O 0 0.16884711
myeloencephalopathy B-Disease 0 0.90635294
due O 0 0.001031149
to O 0 0.00087728177
accidental O 0 0.08459906
intrathecal O 0 0.79306704
vincristin B-Chemical 0 0.99964523
administration O 0 0.016044406
: O 0 0.0007509864
a O 0 0.0005899806
report O 0 0.0007376967
of O 0 0.0007962181
two O 0 0.0007516135
cases O 0 0.0021192543
. O 0 0.0023423943

We O 0 0.0015763601
report O 0 0.0015160578
on O 0 0.000582655
two O 0 0.00055501104
fatal O 0 0.08649193
cases O 0 0.0005246519
of O 0 0.0004749233
accidental O 0 0.18922824
intrathecal O 0 0.829547
vincristine B-Chemical 1 0.9999014
instillation O 0 0.0025323695
in O 0 0.00016028975
a O 0 0.00018173597
5 O 0 7.464173e-05
- O 0 0.0001292189
year O 0 3.971169e-05
old O 0 6.506365e-05
girl O 0 0.00018920275
with O 0 0.0001442596
recurrent O 0 0.039404284
acute B-Disease 0 0.9991542
lymphoblastic I-Disease 0 0.99999857
leucemia I-Disease 0 0.99950683
and O 0 0.00046997718
a O 0 0.00032185233
57 O 0 0.0003402904
- O 0 0.00024073626
year O 0 0.000101593694
old O 0 0.00025062053
man O 0 0.004389879
with O 0 0.0034121678
lymphoblastic B-Disease 0 0.9999918
lymphoma I-Disease 0 0.9999114
. O 0 0.0076307687

The O 0 0.0022917173
girl O 0 0.0042299284
died O 0 0.0020226722
seven O 0 0.0005259477
days O 0 0.0002469078
, O 0 0.00037016545
the O 0 0.0003056279
man O 0 0.0013861397
four O 0 0.00012084272
weeks O 0 7.846654e-05
after O 0 0.00010791427
intrathecal O 0 0.0065991497
injection O 0 0.0010417744
of O 0 0.0028906567
vincristine B-Chemical 1 0.99915934
. O 0 0.004346173

Clinically O 0 0.008612967
, O 0 0.0021626737
the O 0 0.0010679964
onset O 0 0.0011916034
was O 0 0.0007030277
characterized O 0 0.0007170072
by O 0 0.00030792796
the O 0 0.00025285722
signs O 0 0.0015943485
of O 0 0.00040989908
opistothonus B-Disease 0 0.006291846
, I-Disease 0 0.0002801383
sensory I-Disease 0 0.00047107824
and I-Disease 0 0.00029064147
motor I-Disease 0 0.002182054
dysfunction I-Disease 0 0.6758322
and O 0 0.0014912948
ascending O 0 0.045234233
paralysis B-Disease 0 0.9984347
. O 0 0.0035061282

Histological O 0 0.008161879
and O 0 0.0018129065
immunohistochemical O 0 0.0019621763
investigations O 0 0.0014837328
( O 0 0.0016851351
HE O 0 0.9652442
- O 0 0.0030932191
LFB O 0 0.9841427
, O 0 0.0012381608
CD O 0 0.99304926
- O 0 0.0007171719
68 O 0 0.00033237063
, O 0 0.00024129213
Neurofilament O 0 0.1995084
) O 0 0.00032091263
revealed O 0 0.00017473799
degeneration B-Disease 0 0.7537971
of I-Disease 0 0.00024999076
myelin I-Disease 0 0.03346845
and I-Disease 0 0.00013550851
axons I-Disease 0 0.00019312034
as O 0 6.391942e-05
well O 0 5.5310782e-05
as O 0 8.032909e-05
pseudocystic B-Disease 0 0.019320328
transformation I-Disease 0 0.0062624346
in O 0 8.5316875e-05
areas O 0 8.4952684e-05
exposed O 0 9.459106e-05
to O 0 0.0001856933
vincristine B-Chemical 1 0.9996209
, O 0 0.00036709328
accompanied O 0 0.0006701499
by O 0 0.00020832218
secondary O 0 0.00052446715
changes O 0 0.00029377645
with O 0 0.00033661324
numerous O 0 0.0005265747
prominent O 0 0.0015572803
macrophages O 0 0.0026591239
. O 0 0.001996805

The O 0 0.0018536381
clinical O 0 0.0025418266
course O 0 0.0010470374
and O 0 0.0010249559
histopathological O 0 0.0053173425
results O 0 0.00060276134
of O 0 0.00061510125
the O 0 0.0005077905
two O 0 0.00044032832
cases O 0 0.00093635375
are O 0 0.0010164406
presented O 0 0.0018344058
. O 0 0.002862881

A O 0 0.02093794
review O 0 0.0037645334
of O 0 0.0018209005
all O 0 0.0011512778
reported O 0 0.0010743282
cases O 0 0.0009444472
in O 0 0.0006420038
the O 0 0.0007974451
literature O 0 0.0016521894
is O 0 0.0014653514
given O 0 0.0015294134
. O 0 0.002925467

A O 0 0.010780065
better O 0 0.0018235475
controlled O 0 0.00089980254
regimen O 0 0.00089882483
for O 0 0.0004867038
administering O 0 0.0027922767
vincristine B-Chemical 1 0.99920183
and O 0 0.0014968783
intrathecal O 0 0.34333318
chemotherapy O 0 0.020233897
is O 0 0.0015298781
recommended O 0 0.0021385388
. O 0 0.0025978386

Palpebral B-Disease 0 0.86074215
twitching I-Disease 0 0.8073089
in O 0 0.0034178928
a O 0 0.004251998
depressed B-Disease 2 0.7859472
adolescent O 0 0.016572105
on O 0 0.0039680176
citalopram B-Chemical 1 0.99988437
. O 0 0.008620824

Current O 0 0.0045627877
estimates O 0 0.0011701243
suggest O 0 0.00043578135
that O 0 0.00037856464
between O 0 0.00028403365
0 O 0 0.00031970246
. O 0 0.00018767014
4 O 0 0.0001583486
% O 0 0.00019407988
and O 0 0.0001716172
8 O 0 0.00012295097
. O 0 8.5517415e-05
3 O 0 8.3613486e-05
% O 0 0.00011224383
of O 0 0.0001515252
children O 0 0.00026556608
and O 0 0.00022862044
adolescents O 0 0.0006923166
are O 0 0.0002591311
affected O 0 0.00043609424
by O 0 0.0006815097
major B-Disease 2 0.0047507244
depression I-Disease 2 0.99921334
. O 0 0.0035603244

We O 0 0.0016317539
report O 0 0.0016549039
a O 0 0.0010319214
favorable O 0 0.0009795411
response O 0 0.00038537284
to O 0 0.00024899264
treatment O 0 0.0002880847
with O 0 0.00076694146
citalopram B-Chemical 1 0.9999924
by O 0 0.00033051046
a O 0 0.00023922819
15 O 0 0.00010439445
- O 0 0.00020384326
year O 0 6.742956e-05
- O 0 0.00014621236
old O 0 8.44573e-05
boy O 0 0.00018393096
with O 0 0.00010894708
major B-Disease 2 0.00055210566
depression I-Disease 2 0.99950457
who O 0 0.00037073542
exhibited O 0 0.00030155558
palpebral B-Disease 0 0.9634226
twitching I-Disease 0 0.94711447
during O 0 9.1045506e-05
his O 0 0.0001802413
first O 0 8.905221e-05
2 O 0 0.00013469164
weeks O 0 0.00011702407
of O 0 0.0005217951
treatment O 0 0.0011950942
. O 0 0.0019642238

This O 0 0.0038043023
may O 0 0.0013788679
have O 0 0.00071847474
been O 0 0.00047077975
a O 0 0.0006123243
side O 0 0.0020392374
effect O 0 0.0003667538
of O 0 0.0012767614
citalopram B-Chemical 1 0.9999914
as O 0 0.0005203201
it O 0 0.0004850985
remitted O 0 0.44500816
with O 0 0.0005003921
redistribution O 0 0.00090340804
of O 0 0.0013256685
doses O 0 0.009738242
. O 0 0.002479032

The O 0 0.0032181095
3 O 0 0.0027519593
- O 0 0.0039870786
week O 0 0.002775609
sulphasalazine B-Chemical 1 0.9996257
syndrome O 0 0.66202223
strikes O 0 0.039913815
again O 0 0.0060531334
. O 0 0.005781088

A O 0 0.025884166
34 O 0 0.0034569239
- O 0 0.002648879
year O 0 0.0007807398
- O 0 0.0010747827
old O 0 0.0005510298
lady O 0 0.0013352125
developed O 0 0.0004198544
a O 0 0.00041307087
constellation O 0 0.02067549
of O 0 0.0018695644
dermatitis B-Disease 0 0.9999635
, O 0 0.002909059
fever B-Disease 0 0.9996313
, O 0 0.0018255484
lymphadenopathy B-Disease 0 0.9992493
and O 0 0.0031561106
hepatitis B-Disease 2 0.9999956
, O 0 0.0003336523
beginning O 0 5.434577e-05
on O 0 3.89929e-05
the O 0 6.564311e-05
17th O 0 0.00011469886
day O 0 3.3693435e-05
of O 0 6.333849e-05
a O 0 8.1357015e-05
course O 0 6.422019e-05
of O 0 0.00020262516
oral O 0 0.2756276
sulphasalazine B-Chemical 1 0.9999802
for O 0 0.00037279582
sero O 0 0.011905594
- O 0 0.0011972123
negative O 0 0.00403334
rheumatoid B-Disease 0 0.99987376
arthritis I-Disease 0 0.99983466
. O 0 0.0047857943

Cervical O 0 0.014699165
and O 0 0.0021366673
inguinal O 0 0.0023982883
lymph O 0 0.005679416
node O 0 0.00089179387
biopsies O 0 0.00047709714
showed O 0 0.0001633466
the O 0 0.00012026898
features O 0 0.0001481081
of O 0 0.00027306224
severe O 0 0.053607676
necrotising O 0 0.99951994
lymphadenitis B-Disease 0 0.9940308
, O 0 0.00028376756
associated O 0 0.00011006323
with O 0 0.00022255657
erythrophagocytosis O 0 0.8884928
and O 0 0.00019819857
prominent O 0 0.0009236002
eosinophilic O 0 0.94124407
infiltrates O 0 0.7204702
, O 0 0.00013557973
without O 0 6.3046944e-05
viral O 0 0.00022079887
inclusion O 0 7.663008e-05
bodies O 0 0.00015883494
, O 0 7.656858e-05
suggestive O 0 6.658502e-05
of O 0 7.7554374e-05
an O 0 0.00013895072
adverse B-Disease 0 0.31668466
drug I-Disease 0 0.05417857
reaction I-Disease 0 0.059111018
. O 0 7.4737676e-05
A O 0 0.0012004394
week O 0 3.4264376e-05
later O 0 4.54828e-05
, O 0 0.00016412661
fulminant O 0 0.9961947
drug B-Disease 0 0.3500546
- I-Disease 0 0.0008560006
induced I-Disease 0 0.0009862817
hepatitis I-Disease 2 0.9999968
, O 0 0.00043647643
associated O 0 9.821528e-05
with O 0 0.00010227976
the O 0 6.303829e-05
presence O 0 7.081747e-05
of O 0 0.00015591574
anti O 0 0.001622706
- O 0 0.00040188443
nuclear O 0 0.0007691721
autoantibodies O 0 0.29768512
( O 0 0.00020203908
but O 0 7.603117e-05
not O 0 5.1008625e-05
with O 0 7.566433e-05
other O 0 6.881351e-05
markers O 0 0.00031056075
of O 0 0.00039346114
autoimmunity B-Disease 0 0.99973243
) O 0 0.00066891743
, O 0 0.00016069897
and O 0 0.00012555104
accompanied O 0 0.00036394762
by O 0 0.0001794958
multi B-Disease 0 0.0012949747
- I-Disease 0 0.00051186455
organ I-Disease 0 0.0015774544
failure I-Disease 0 0.16380079
and O 0 0.0012308481
sepsis B-Disease 2 0.996752
, O 0 0.002959022
supervened O 0 0.34291747
. O 0 0.0026356068

She O 0 0.0032909391
subsequently O 0 0.0017365738
died O 0 0.00157508
some O 0 0.00050360337
5 O 0 0.00022349328
weeks O 0 8.014745e-05
after O 0 5.4169028e-05
the O 0 9.707263e-05
commencement O 0 9.4893265e-05
of O 0 0.00016595332
her O 0 0.00025456358
drug O 0 0.005048414
therapy O 0 0.00021850504
. O 0 7.216167e-05
Post O 0 0.00029097253
- O 0 0.00025862877
mortem O 0 0.0044040564
examination O 0 8.227294e-05
showed O 0 5.5975648e-05
evidence O 0 5.1118917e-05
of O 0 0.00017082473
massive B-Disease 0 0.72412306
hepatocellular I-Disease 0 0.9999995
necrosis I-Disease 2 0.99999917
, O 0 0.010018842
acute O 0 0.9915251
hypersensitivity O 0 0.99997056
myocarditis B-Disease 2 0.9999994
, O 0 0.0010672295
focal O 0 0.0037378075
acute O 0 0.75597227
tubulo O 0 0.36275843
- O 0 0.0014387915
interstitial O 0 0.94956076
nephritis B-Disease 0 0.99999845
and O 0 0.0004151032
extensive O 0 0.00026470004
bone B-Disease 0 0.42893663
marrow I-Disease 0 0.97281885
necrosis I-Disease 2 0.99996245
, O 0 0.0006313656
with O 0 0.00033709366
no O 0 0.00022087281
evidence O 0 0.0004708289
of O 0 0.0019258857
malignancy B-Disease 2 0.99797696
. O 0 0.003342427

It O 0 0.0027811367
is O 0 0.0012912403
thought O 0 0.0008162654
that O 0 0.0004326133
the O 0 0.00057912606
clinico O 0 0.0047951876
- O 0 0.00073015783
pathological O 0 0.0017113383
features O 0 0.00021716683
and O 0 0.00016026132
chronology O 0 0.00051877974
of O 0 0.0001477787
this O 0 0.00014051174
case O 0 0.00012601678
bore O 0 0.00079845334
the O 0 8.900611e-05
hallmarks O 0 0.00018192461
of O 0 0.00012925794
the O 0 0.00010333539
so O 0 0.00010091838
- O 0 0.00019083027
called O 0 0.000104541985
" O 0 0.00011929992
3 O 0 6.0800117e-05
- O 0 0.00014154382
week O 0 8.5288724e-05
sulphasalazine B-Chemical 1 0.9999671
syndrome O 0 0.25676492
" O 0 0.00025838407
, O 0 0.00015279527
a O 0 0.00020149884
rare O 0 0.0007050631
, O 0 0.0002148625
but O 0 0.00020087312
often O 0 0.0003815031
fatal O 0 0.5614355
, O 0 0.0008679876
immunoallergic O 0 0.96522343
reaction O 0 0.07690903
to O 0 0.002921956
sulphasalazine B-Chemical 1 0.99990857
. O 0 0.0036035844

Intravenous O 0 0.14027393
administration O 0 0.006859508
of O 0 0.0033542486
prochlorperazine B-Chemical 0 0.99987924
by O 0 0.0006746086
15 O 0 0.0002345957
- O 0 0.00027704082
minute O 0 0.0001031743
infusion O 0 0.00023036632
versus O 0 8.665808e-05
2 O 0 7.9401325e-05
- O 0 0.000119091244
minute O 0 5.6575835e-05
bolus O 0 0.0002157364
does O 0 5.672613e-05
not O 0 4.72069e-05
affect O 0 3.2751454e-05
the O 0 6.944955e-05
incidence O 0 0.00022886034
of O 0 0.00048118716
akathisia B-Disease 0 0.9999846
: O 0 0.00042618226
a O 0 0.00031333283
prospective O 0 0.0007592863
, O 0 0.00026227257
randomized O 0 0.0003122298
, O 0 0.0003940522
controlled O 0 0.0005775292
trial O 0 0.001330261
. O 0 0.0015954633

STUDY O 0 0.004288208
OBJECTIVE O 0 0.0122567825
: O 0 0.001376826
We O 0 0.00042984966
sought O 0 0.0005856195
to O 0 0.00026443644
compare O 0 0.00010787536
the O 0 0.00014210276
rate O 0 0.00018450584
of O 0 0.0004257429
akathisia B-Disease 0 0.99995697
after O 0 6.1606406e-05
administration O 0 0.0004643965
of O 0 0.0002582151
intravenous O 0 0.25181898
prochlorperazine B-Chemical 0 0.9999709
as O 0 0.00015093829
a O 0 0.00016068641
2 O 0 8.231508e-05
- O 0 0.00012957139
minute O 0 7.467769e-05
bolus O 0 0.00033956906
or O 0 0.00014573008
15 O 0 0.00018515051
- O 0 0.00046532662
minute O 0 0.00045968677
infusion O 0 0.0020025154
. O 0 0.0018079104

METHODS O 0 0.0018140855
: O 0 0.0013831859
We O 0 0.0005172698
conducted O 0 0.00052606093
a O 0 0.0006867907
prospective O 0 0.0011678037
, O 0 0.00039319156
randomized O 0 0.00032989946
, O 0 0.00025033424
double O 0 0.0003649649
- O 0 0.00041716782
blind O 0 0.0020967457
study O 0 0.00013478928
in O 0 8.257003e-05
the O 0 0.00011325835
emergency O 0 0.0012139318
department O 0 0.0009727604
of O 0 0.000245358
a O 0 0.00033564706
central O 0 0.00049497135
- O 0 0.00076145213
city O 0 0.0009032165
teaching O 0 0.0012322218
hospital O 0 0.0023452376
. O 0 0.0019924394

Patients O 0 0.0027483054
aged O 0 0.0018512629
18 O 0 0.0006525276
years O 0 0.00038642812
or O 0 0.00026416982
older O 0 0.00069823104
treated O 0 0.00038910558
with O 0 0.00069836515
prochlorperazine B-Chemical 0 0.99996483
for O 0 0.000582405
headache B-Disease 0 0.99981576
, O 0 0.0017537344
nausea B-Disease 0 0.99995947
, O 0 0.0005547408
or O 0 0.00039937333
vomiting B-Disease 0 0.997863
were O 0 0.00043875017
eligible O 0 0.0005151488
for O 0 0.00041774163
inclusion O 0 0.0010899584
. O 0 0.0017798811

Study O 0 0.0028596176
participants O 0 0.0008701896
were O 0 0.0005298827
randomized O 0 0.00036648524
to O 0 0.00018435005
receive O 0 0.00011434068
10 O 0 0.00013033075
mg O 0 0.0016383303
of O 0 0.000408651
prochlorperazine B-Chemical 0 0.99991703
administered O 0 0.0002274403
intravenously O 0 0.00014252287
by O 0 8.028681e-05
means O 0 5.848754e-05
of O 0 9.546642e-05
2 O 0 6.555341e-05
- O 0 0.000100270125
minute O 0 4.810131e-05
push O 0 0.0002175216
( O 0 0.00010868175
bolus O 0 0.00031826278
group O 0 0.000115066505
) O 0 9.8234384e-05
or O 0 4.528782e-05
10 O 0 5.3619213e-05
mg O 0 0.00063560205
diluted O 0 0.00017081496
in O 0 6.158232e-05
50 O 0 0.000114693496
mL O 0 0.00022325665
of O 0 7.715398e-05
normal O 0 0.00018852456
saline O 0 0.0004067582
solution O 0 0.0003709951
administered O 0 7.454159e-05
by O 0 5.3957643e-05
means O 0 4.317535e-05
of O 0 8.628167e-05
intravenous O 0 0.0017782407
infusion O 0 0.00017856613
during O 0 3.60774e-05
a O 0 9.5223935e-05
15 O 0 6.445223e-05
- O 0 0.00012714654
minute O 0 7.307295e-05
period O 0 8.1793965e-05
( O 0 0.00029494925
infusion O 0 0.00079343497
group O 0 0.0009776233
) O 0 0.0018812455
. O 0 0.001990129

The O 0 0.0015206974
main O 0 0.0011989275
outcome O 0 0.0010169391
was O 0 0.00064499635
the O 0 0.0003552801
number O 0 0.0002573912
of O 0 0.00027267536
study O 0 0.0002607094
participants O 0 0.00020132256
experiencing O 0 0.0021474385
akathisia B-Disease 0 0.99992096
within O 0 0.00012855607
60 O 0 0.00022579063
minutes O 0 0.00021402708
of O 0 0.0007762715
administration O 0 0.004820394
. O 0 0.0023759797

Akathisia O 0 0.9988651
was O 0 0.0021671888
defined O 0 0.00063930865
as O 0 0.00042971224
either O 0 0.00029942958
a O 0 0.00035579133
spontaneous O 0 0.000884683
report O 0 0.000382591
of O 0 0.00045183342
restlessness O 0 0.96876985
or O 0 0.00023783882
agitation B-Disease 2 0.89304125
or O 0 0.00011112837
a O 0 0.000112491885
change O 0 7.0695074e-05
of O 0 8.909138e-05
2 O 0 4.7740337e-05
or O 0 3.8233633e-05
more O 0 6.5328e-05
in O 0 4.670329e-05
the O 0 5.9426035e-05
patient O 0 0.000106825006
- O 0 0.00020412993
reported O 0 0.0002489827
akathisia B-Disease 0 0.99997866
rating O 0 0.00020419108
scale O 0 8.194761e-05
and O 0 6.417257e-05
a O 0 7.6214106e-05
change O 0 5.6856974e-05
of O 0 7.1434544e-05
at O 0 4.305677e-05
least O 0 5.349347e-05
1 O 0 5.7538342e-05
in O 0 6.1268416e-05
the O 0 0.000108317465
investigator O 0 0.00052187475
- O 0 0.00046635792
observed O 0 0.0005063325
akathisia B-Disease 0 0.99991727
rating O 0 0.0018109832
scale O 0 0.0016470106
. O 0 0.0019814286

The O 0 0.0013985465
intensity O 0 0.0010660102
of O 0 0.002213657
headache B-Disease 0 0.99805105
and O 0 0.0031288483
nausea B-Disease 0 0.99988806
was O 0 0.0007679844
measured O 0 0.00027786611
with O 0 0.00035179895
a O 0 0.00046552822
100 O 0 0.0009110473
- O 0 0.0007322315
mm O 0 0.00095101853
visual O 0 0.007122366
analog O 0 0.0032636265
scale O 0 0.0021908926
. O 0 0.0026262703

RESULTS O 0 0.009726523
: O 0 0.0047104666
One O 0 0.0031744353
hundred O 0 0.0032692123
patients O 0 0.0037377384
were O 0 0.0038198356
enrolled O 0 0.0058929394
. O 0 0.0060045235

One O 0 0.003725041
study O 0 0.0026224088
participant O 0 0.0013921844
was O 0 0.00169252
excluded O 0 0.0014969995
after O 0 0.0009916154
protocol O 0 0.002904642
violation O 0 0.008927426
. O 0 0.005418873

Seventy O 0 0.005129381
- O 0 0.0023376057
three O 0 0.000469753
percent O 0 0.00048918935
( O 0 0.00068755914
73 O 0 0.00069805863
/ O 0 0.00080598105
99 O 0 0.0007419038
) O 0 0.00026014203
of O 0 0.0001417444
the O 0 0.00010693568
study O 0 0.00011944164
participants O 0 7.549654e-05
were O 0 8.345194e-05
treated O 0 0.0001500088
for O 0 0.00015150916
headache B-Disease 0 0.99493945
and O 0 0.00021670434
70 O 0 0.000185024
% O 0 0.00017222782
( O 0 0.00021206767
70 O 0 0.00022945991
/ O 0 0.0006526749
99 O 0 0.0010641275
) O 0 0.0008408897
for O 0 0.0010981535
nausea B-Disease 0 0.9994691
. O 0 0.0037837115

In O 0 0.0017731764
the O 0 0.0015108148
bolus O 0 0.004215376
group O 0 0.0012376409
, O 0 0.00070300204
26 O 0 0.0005197077
. O 0 0.00019102977
0 O 0 0.00018488255
% O 0 0.00021190717
( O 0 0.0002176137
13 O 0 0.0001478833
/ O 0 0.00030551545
50 O 0 0.00023339763
) O 0 0.00024467005
had O 0 0.00023441727
akathisia B-Disease 0 0.9999442
compared O 0 0.000103432
with O 0 0.00014608068
32 O 0 0.0001446672
. O 0 5.3024538e-05
7 O 0 5.181071e-05
% O 0 8.4160805e-05
( O 0 0.000107515516
16 O 0 7.969253e-05
/ O 0 0.00022211054
49 O 0 0.00014147988
) O 0 0.00010344472
in O 0 5.0352694e-05
the O 0 6.651876e-05
infusion O 0 0.00023068237
group O 0 0.00016557949
( O 0 0.00020181882
Delta O 0 0.0013851671
= O 0 0.00020559944
- O 0 0.00019462059
6 O 0 5.6032848e-05
. O 0 5.1999104e-05
7 O 0 5.928894e-05
% O 0 0.00010183511
; O 0 0.00012089932
95 O 0 0.00013709045
% O 0 0.00010107942
confidence O 0 0.0003847921
interval O 0 0.00012394575
[ O 0 0.0005085938
CI O 0 0.017819446
] O 0 0.00041524708
- O 0 0.00021521148
24 O 0 7.956452e-05
. O 0 6.856382e-05
6 O 0 7.2191935e-05
% O 0 0.0001364773
to O 0 0.000157548
11 O 0 0.00027208249
. O 0 0.0002489613
2 O 0 0.00045309713
% O 0 0.0010011948
) O 0 0.0021602756
. O 0 0.0024351797

The O 0 0.0014031308
difference O 0 0.00064909377
between O 0 0.00038833293
the O 0 0.0004369598
bolus O 0 0.0012840934
and O 0 0.00033186053
infusion O 0 0.0005380477
groups O 0 0.0001394865
in O 0 7.820538e-05
the O 0 7.00298e-05
percentage O 0 5.6770237e-05
of O 0 0.000102062404
participants O 0 8.438654e-05
who O 0 0.00015504636
saw O 0 0.0001262873
a O 0 0.000120098215
50 O 0 0.00015268038
% O 0 8.3520164e-05
reduction O 0 0.00016939185
in O 0 7.844866e-05
their O 0 0.00019021027
headache B-Disease 0 0.9754115
intensity O 0 4.1414864e-05
within O 0 1.8686804e-05
30 O 0 3.264207e-05
minutes O 0 3.3918066e-05
was O 0 8.1404745e-05
11 O 0 7.746974e-05
. O 0 4.8830858e-05
8 O 0 6.179104e-05
% O 0 0.00010051722
( O 0 0.00014984384
95 O 0 0.00018757532
% O 0 0.00018333178
CI O 0 0.0051699895
- O 0 0.00026512085
9 O 0 9.8021796e-05
. O 0 7.1638315e-05
6 O 0 7.506666e-05
% O 0 0.00014059457
to O 0 0.0001647918
33 O 0 0.00039125068
. O 0 0.0002613368
3 O 0 0.00042565528
% O 0 0.0009808532
) O 0 0.0021233077
. O 0 0.0024058735

The O 0 0.0015795737
difference O 0 0.00075710536
in O 0 0.00058432284
the O 0 0.00041173951
percentage O 0 0.0002706254
of O 0 0.00037021938
patients O 0 0.0003623076
with O 0 0.00023014349
a O 0 0.00022949006
50 O 0 0.00024664195
% O 0 0.00013189562
reduction O 0 0.00024326697
in O 0 0.000126191
their O 0 0.0004230193
nausea B-Disease 0 0.99993837
was O 0 0.00026300026
12 O 0 6.312852e-05
. O 0 5.3159667e-05
6 O 0 5.135193e-05
% O 0 9.835137e-05
( O 0 0.00014917833
95 O 0 0.00018748878
% O 0 0.0001838375
CI O 0 0.005213289
- O 0 0.00025956577
4 O 0 8.636982e-05
. O 0 7.1109935e-05
6 O 0 7.593791e-05
% O 0 0.00014370575
to O 0 0.00017090324
29 O 0 0.0004405168
. O 0 0.00027002595
8 O 0 0.00045977175
% O 0 0.0010113197
) O 0 0.0021643108
. O 0 0.0024414002

CONCLUSION O 0 0.022751786
: O 0 0.0032189325
A O 0 0.007155918
50 O 0 0.0013204211
% O 0 0.00062492513
reduction O 0 0.00059468957
in O 0 0.00022140263
the O 0 0.00019034107
incidence O 0 0.0004303749
of O 0 0.0006522363
akathisia B-Disease 0 0.99998724
when O 0 0.00037209684
prochlorperazine B-Chemical 0 0.99997413
was O 0 0.00019965811
administered O 0 0.00010878647
by O 0 6.9973656e-05
means O 0 4.998336e-05
of O 0 7.410337e-05
15 O 0 4.7764606e-05
- O 0 8.800777e-05
minute O 0 4.4190834e-05
intravenous O 0 0.00063492276
infusion O 0 0.00017175796
versus O 0 5.9180606e-05
a O 0 0.00011302154
2 O 0 8.10115e-05
- O 0 0.00015350676
minute O 0 0.00011400644
intravenous O 0 0.0018457639
push O 0 0.000916044
was O 0 0.0004537165
not O 0 0.00055044476
detected O 0 0.0010377152
. O 0 0.0018604826

The O 0 0.0014075025
efficacy O 0 0.0017306033
of O 0 0.002011857
prochlorperazine B-Chemical 0 0.99978536
in O 0 0.0004508718
the O 0 0.00024765587
treatment O 0 0.00023414698
of O 0 0.00062002894
headache B-Disease 0 0.9995939
and O 0 0.0014078865
nausea B-Disease 0 0.99997663
likewise O 0 0.007016455
did O 0 0.0001743311
not O 0 8.132893e-05
appear O 0 7.1079914e-05
to O 0 6.004152e-05
be O 0 6.354079e-05
affected O 0 8.50768e-05
by O 0 6.559613e-05
the O 0 5.924689e-05
rate O 0 8.388757e-05
of O 0 0.00014738353
administration O 0 0.000874666
, O 0 0.00016919685
although O 0 9.8076394e-05
no O 0 8.767422e-05
formal O 0 0.00024172274
statistical O 0 0.0004507386
comparisons O 0 0.00029707007
were O 0 0.0005993216
made O 0 0.0010680812
. O 0 0.0018353603

Combined O 0 0.006272922
antiretroviral O 0 0.007289509
therapy O 0 0.0020715739
causes O 0 0.0033878523
cardiomyopathy B-Disease 0 0.99990714
and O 0 0.0013860606
elevates O 0 0.008932179
plasma O 0 0.10386771
lactate B-Chemical 0 0.8549994
in O 0 0.0010224018
transgenic O 0 0.0045197555
AIDS B-Disease 2 0.9956839
mice O 0 0.0021284462
. O 0 0.0028088733

Highly O 0 0.0055796714
active O 0 0.002137792
antiretroviral O 0 0.0046718745
therapy O 0 0.0013487128
( O 0 0.0012339895
HAART O 0 0.0561109
) O 0 0.00057710387
is O 0 0.00021366292
implicated O 0 0.00014486501
in O 0 0.0004210032
cardiomyopathy B-Disease 0 0.9999784
( O 0 0.0012158076
CM B-Disease 0 0.84495306
) O 0 0.00028842216
and O 0 0.00010165493
in O 0 9.2158e-05
elevated O 0 0.0012184799
plasma O 0 0.046973478
lactate B-Chemical 0 0.9282059
( O 0 0.0009493373
LA B-Chemical 0 0.9977544
) O 0 0.0005379864
in O 0 0.00028314436
AIDS B-Disease 2 0.964992
through O 0 0.00020465339
mechanisms O 0 0.00042940406
of O 0 0.0013007895
mitochondrial B-Disease 0 0.9929864
dysfunction I-Disease 0 0.9988545
. O 0 0.0039393287

To O 0 0.0018693426
determine O 0 0.0010380091
mitochondrial O 0 0.039290108
events O 0 0.0022451573
from O 0 0.00064628763
HAART O 0 0.028481213
in O 0 0.0003146497
vivo O 0 0.0005151989
, O 0 0.00029954125
8 O 0 0.00015250228
- O 0 0.00023991414
week O 0 7.063476e-05
- O 0 0.00019730521
old O 0 0.00014746805
hemizygous O 0 0.011495333
transgenic O 0 0.0012013658
AIDS B-Disease 2 0.997401
mice O 0 0.00015470022
( O 0 0.00039575138
NL4 O 0 0.114251964
- O 0 0.00044313606
3Delta O 0 0.00993563
gag O 0 0.00369584
/ O 0 0.00072299794
pol O 0 0.047205355
; O 0 0.00046718217
TG O 2 0.9985203
) O 0 0.00037302726
and O 0 0.00013939437
wild O 0 0.00017078237
- O 0 0.00022889677
type O 0 0.00013140017
FVB O 0 0.001412594
/ O 0 0.00023651907
n O 0 4.755291e-05
littermates O 0 2.966349e-05
were O 0 3.9687682e-05
treated O 0 5.7551893e-05
with O 0 6.0132803e-05
the O 0 7.304215e-05
HAART O 0 0.005003875
combination O 0 0.00011026912
of O 0 0.0002465622
zidovudine B-Chemical 1 0.90846264
, O 0 0.00057462405
lamivudine B-Chemical 1 0.99993443
, O 0 0.00026479244
and O 0 0.00026363818
indinavir B-Chemical 0 0.9943658
or O 0 0.00012250636
vehicle O 0 0.00041798642
control O 0 0.00010139712
for O 0 8.677202e-05
10 O 0 0.00011914394
days O 0 9.449883e-05
or O 0 0.00024882104
35 O 0 0.0005221758
days O 0 0.0005481121
. O 0 0.0015508131

At O 0 0.0008358564
termination O 0 0.0011330886
of O 0 0.00089038064
the O 0 0.0005162312
experiments O 0 0.00032499462
, O 0 0.00031348135
mice O 0 0.00013807953
underwent O 0 0.00019238483
echocardiography O 0 0.00093583146
, O 0 0.00013876363
quantitation O 0 0.0002581841
of O 0 0.00010625719
abundance O 0 8.222125e-05
of O 0 0.00010227459
molecular O 0 0.00069292425
markers O 0 0.0003154357
of O 0 0.00020903948
CM B-Disease 0 0.67193025
( O 0 0.00023114673
ventricular O 0 0.26313174
mRNA O 0 0.00016729582
encoding O 0 0.000104111816
atrial O 0 0.4861905
natriuretic O 0 0.94039124
factor O 0 0.0021301482
[ O 0 0.0016522383
ANF O 1 0.99971706
] O 0 0.00052384037
and O 0 0.00018140512
sarcoplasmic O 0 0.7646474
calcium B-Chemical 0 0.99937207
ATPase O 0 0.20979795
[ O 0 0.0016688211
SERCA2 O 0 0.9741236
] O 0 0.00079038885
) O 0 0.0002695506
, O 0 0.00017734848
and O 0 0.00019915123
determination O 0 0.0006455163
of O 0 0.00089000876
plasma O 0 0.104225986
LA B-Chemical 0 0.99623823
. O 0 0.0033355053

Myocardial O 0 0.16933812
histologic O 0 0.0063971947
features O 0 0.0010860793
were O 0 0.000590245
analyzed O 0 0.00039052067
semiquantitatively O 0 0.0005748278
and O 0 0.00031941303
results O 0 0.0003239586
were O 0 0.00033811992
confirmed O 0 0.0004042001
by O 0 0.0005362856
transmission O 0 0.0009539088
electron O 0 0.008298792
microscopy O 0 0.0029309525
. O 0 0.0025684384

After O 0 0.0009982018
35 O 0 0.0011259817
days O 0 0.00044042862
in O 0 0.0005136759
the O 0 0.0007707286
TG O 2 0.9959228
+ O 0 0.0026328333
HAART O 0 0.119416595
cohort O 0 0.0011952048
, O 0 0.00032127017
left O 0 0.0007507917
ventricular O 0 0.50495934
mass O 0 0.0020325817
increased O 0 0.00073535094
160 O 0 0.001443177
% O 0 0.0006671609
by O 0 0.0010334138
echocardiography O 0 0.006668928
. O 0 0.0021867873

Molecularly O 0 0.044110056
, O 0 0.0068496596
ANF O 1 0.9975274
mRNA O 0 0.0032707602
increased O 0 0.0021240152
250 O 0 0.0021325315
% O 0 0.00088017713
and O 0 0.0009908684
SERCA2 O 0 0.75009304
mRNA O 0 0.0020471846
decreased O 0 0.002842858
57 O 0 0.0027960432
% O 0 0.0024093185
. O 0 0.002817509

Biochemically O 0 0.026867423
, O 0 0.0053360737
LA B-Chemical 0 0.9947908
was O 0 0.0021279885
elevated O 0 0.005202357
( O 0 0.0010938847
8 O 0 0.00037405497
. O 0 0.00024473353
5 O 0 0.00026057
+ O 0 0.0006707113
/ O 0 0.0011313618
- O 0 0.00082689483
2 O 0 0.00040384865
. O 0 0.0004191052
0 O 0 0.000870537
mM O 0 0.010858221
) O 0 0.004251078
. O 0 0.003693695

Pathologically O 0 0.025717663
, O 0 0.0023049584
granular O 0 0.0020467134
cytoplasmic O 0 0.000668666
changes O 0 0.00057426543
were O 0 0.00034492405
found O 0 0.00024159116
in O 0 0.0002871239
cardiac O 0 0.012552909
myocytes O 0 0.0029336486
, O 0 0.000469957
indicating O 0 0.00035251488
enlarged O 0 0.0038552058
, O 0 0.0011023408
damaged O 0 0.006187035
mitochondria O 0 0.036650795
. O 0 0.0026751116

Findings O 0 0.013120177
were O 0 0.010330874
confirmed O 0 0.011824393
ultrastructurally O 0 0.02258637
. O 0 0.015463299

No O 0 0.005917708
changes O 0 0.0042052204
were O 0 0.0028855677
found O 0 0.002285159
in O 0 0.0025157472
other O 0 0.0034356783
cohorts O 0 0.006505305
. O 0 0.0059810784

After O 0 0.0011059563
10 O 0 0.0012507561
days O 0 0.00061115855
, O 0 0.0009646965
only O 0 0.0012186541
ANF O 1 0.9992669
was O 0 0.0011088887
elevated O 0 0.003187166
, O 0 0.0004448792
and O 0 0.00026823414
only O 0 0.0002694
in O 0 0.0002743027
the O 0 0.00061469385
TG O 2 0.99713147
+ O 0 0.0040772026
HAART O 0 0.24197912
cohort O 0 0.0069057797
. O 0 0.0026957956

Results O 0 0.0018390024
show O 0 0.00090268796
that O 0 0.0006230008
cumulative O 0 0.0016384466
HAART O 0 0.08142587
caused O 0 0.0010658457
mitochondrial O 0 0.7483914
CM B-Disease 0 0.90636516
with O 0 0.0010502363
elevated O 0 0.051864833
LA B-Chemical 0 0.9992762
in O 0 0.0022009318
AIDS B-Disease 2 0.9987398
transgenic O 0 0.0045169373
mice O 0 0.0016754358
. O 0 0.0024830594

A O 0 0.012608708
Phase O 0 0.0042240554
II O 0 0.005468442
trial O 0 0.001010223
of O 0 0.00093709456
cisplatin B-Chemical 0 0.99313945
plus O 0 0.0007368261
WR B-Chemical 0 0.71131945
- I-Chemical 0 0.0018250186
2721 I-Chemical 0 0.99809283
( O 0 0.0013858704
amifostine B-Chemical 0 0.9998975
) O 0 0.00059445784
for O 0 0.00018595623
metastatic O 0 0.6900612
breast B-Disease 2 0.99921834
carcinoma I-Disease 2 0.9999342
: O 0 0.000350474
an O 0 0.00020754404
Eastern O 0 0.00037056618
Cooperative O 0 0.0002884263
Oncology O 0 0.00027738913
Group O 0 0.0005750279
Study O 0 0.00065433944
( O 0 0.0009023181
E8188 O 0 0.012481351
) O 0 0.002483975
. O 0 0.0022589744

BACKGROUND O 0 0.011020423
: O 0 0.003973725
Cisplatin B-Chemical 0 0.99640816
has O 0 0.0006531964
minimal O 0 0.000481205
antitumor O 0 0.0164555
activity O 0 0.0002958192
when O 0 0.00013158208
used O 0 0.00013960706
as O 0 0.00014016047
second O 0 0.00017000445
- O 0 0.00030560204
or O 0 0.00012919756
third O 0 0.0002729383
- O 0 0.0003811883
line O 0 0.00031688702
treatment O 0 0.0003110841
of O 0 0.0009847626
metastatic O 0 0.8971165
breast B-Disease 2 0.99919504
carcinoma I-Disease 2 0.99984086
. O 0 0.004583614

Older O 0 0.011564088
reports O 0 0.0014803762
suggest O 0 0.00045721958
an O 0 0.0005981506
objective O 0 0.0004965111
response O 0 0.0003330618
rate O 0 0.0003198817
of O 0 0.00030936184
8 O 0 0.00014667318
% O 0 0.00012374147
when O 0 6.493794e-05
60 O 0 0.000103839855
- O 0 0.00015123346
120 O 0 9.279644e-05
mg O 0 0.0010953102
/ O 0 0.0003311021
m2 O 0 0.0007218815
of O 0 0.0002841371
cisplatin B-Chemical 0 0.98972535
is O 0 0.00018159028
administered O 0 0.00016476118
every O 0 7.623576e-05
3 O 0 0.00019850835
- O 0 0.0005013611
4 O 0 0.00040262225
weeks O 0 0.0004955683
. O 0 0.001497921

Although O 0 0.001786875
a O 0 0.002077734
dose O 0 0.0052354806
- O 0 0.0013816791
response O 0 0.0004537801
effect O 0 0.0003377913
has O 0 0.00019506275
been O 0 0.00013155185
observed O 0 0.00012932846
with O 0 0.00034000137
cisplatin B-Chemical 0 0.99804735
, O 0 0.00023452278
the O 0 0.00012815732
dose O 0 0.000885902
- O 0 0.00027163667
limiting O 0 0.00034504314
toxicities B-Disease 2 0.9862726
associated O 0 0.00015005772
with O 0 0.00037652103
cisplatin B-Chemical 0 0.9990194
( O 0 0.00031401525
e O 0 0.00016611542
. O 0 5.3041786e-05
g O 0 0.00022797786
. O 0 6.7462934e-05
, O 0 0.00026204638
nephrotoxicity B-Disease 0 0.99999607
, O 0 0.0026367502
ototoxicity B-Disease 0 0.99998736
, O 0 0.00069647125
and O 0 0.0006147543
neurotoxicity B-Disease 2 0.9999708
) O 0 0.0005025987
have O 0 7.157283e-05
limited O 0 8.542662e-05
its O 0 0.00018009049
use O 0 0.00010920805
as O 0 0.00012612039
a O 0 0.00026694295
treatment O 0 0.00037779115
for O 0 0.00078715576
breast B-Disease 2 0.99732155
carcinoma I-Disease 2 0.9998017
. O 0 0.004298984

WR B-Chemical 0 0.5909913
- I-Chemical 0 0.0071893516
2721 I-Chemical 0 0.9880548
or O 0 0.002138665
amifostine B-Chemical 0 0.99967694
initially O 0 0.0016893712
was O 0 0.0005472463
developed O 0 0.00043512732
to O 0 0.00021559844
protect O 0 0.00034123907
military O 0 0.00085735926
personnel O 0 0.00039789168
in O 0 0.00019103943
the O 0 0.00025620178
event O 0 0.00081259187
of O 0 0.00085940404
nuclear O 0 0.0031234731
war O 0 0.004622793
. O 0 0.002447246

Amifostine B-Chemical 0 0.9990445
subsequently O 0 0.0029003033
was O 0 0.0011621391
shown O 0 0.00040141924
to O 0 0.00029915138
protect O 0 0.00036183797
normal O 0 0.0004851822
tissues O 0 0.00027359015
from O 0 8.981874e-05
the O 0 0.00010548216
toxic O 0 0.0085083265
effects O 0 0.00014555095
of O 0 0.00023089671
alkylating B-Chemical 0 0.67427653
agents I-Chemical 0 0.002498044
and O 0 0.00031340483
cisplatin B-Chemical 0 0.99657863
without O 0 0.00017943932
decreasing O 0 0.00023881522
the O 0 0.00017584683
antitumor O 0 0.008555863
effect O 0 0.00030304675
of O 0 0.00066718
the O 0 0.00096621696
chemotherapy O 0 0.01843298
. O 0 0.002234504

Early O 0 0.0035561565
trials O 0 0.0015354868
of O 0 0.0016993192
cisplatin B-Chemical 0 0.99706984
and O 0 0.002062346
amifostine B-Chemical 0 0.9998254
also O 0 0.0003890499
suggested O 0 0.0001307678
that O 0 9.0520036e-05
the O 0 0.00012424064
incidence O 0 0.00028094478
and O 0 0.00013561903
severity O 0 0.00039465088
of O 0 0.00044069198
cisplatin B-Chemical 0 0.9996101
- O 0 0.0014099126
induced O 0 0.0015531649
nephrotoxicity B-Disease 0 0.99999845
, O 0 0.014560708
ototoxicity B-Disease 0 0.99998415
, O 0 0.0018655201
and O 0 0.00189521
neuropathy B-Disease 0 0.99990404
were O 0 0.0017087123
reduced O 0 0.0030055684
. O 0 0.0022501466

METHODS O 0 0.0017541567
: O 0 0.0017710574
A O 0 0.0036563256
Phase O 0 0.0018575063
II O 0 0.0027620213
study O 0 0.00037464054
of O 0 0.00025619348
the O 0 0.00016968088
combination O 0 0.0002323062
of O 0 0.00038018907
cisplatin B-Chemical 0 0.9985247
plus O 0 0.0004453661
amifostine B-Chemical 0 0.9999591
was O 0 0.0002583705
conducted O 0 7.158326e-05
in O 0 6.279404e-05
patients O 0 0.00010528812
with O 0 0.000120299715
progressive O 0 0.09432174
metastatic O 0 0.9458536
breast B-Disease 2 0.9997861
carcinoma I-Disease 2 0.9999802
who O 0 0.00061058503
had O 0 8.7387845e-05
received O 0 4.756393e-05
one O 0 4.5950506e-05
, O 0 7.9305304e-05
but O 0 6.805844e-05
not O 0 5.4896755e-05
more O 0 9.517456e-05
than O 0 5.575658e-05
one O 0 7.2394e-05
, O 0 0.0001601709
chemotherapy O 0 0.001047943
regimen O 0 0.00047127722
for O 0 0.00050530356
metastatic O 0 0.5505322
disease O 0 0.631127
. O 0 0.0027890825

Patients O 0 0.0033950147
received O 0 0.002515973
amifostine B-Chemical 0 0.99893564
, O 0 0.0022515454
910 O 0 0.004606432
mg O 0 0.015824836
/ O 0 0.0016789592
m2 O 0 0.0019314609
intravenously O 0 0.0006536607
over O 0 0.0003623532
15 O 0 0.0006353835
minutes O 0 0.000981364
. O 0 0.0023081682

After O 0 0.0008125842
completion O 0 0.00070750277
of O 0 0.00092576235
the O 0 0.0010192129
amifostine B-Chemical 0 0.9996687
infusion O 0 0.0056705507
, O 0 0.00085203553
cisplatin B-Chemical 0 0.99252397
120 O 0 0.00044285142
mg O 0 0.008827607
/ O 0 0.00082110486
m2 O 0 0.0012048257
was O 0 0.00026431648
administered O 0 0.00026929346
over O 0 0.00019281158
30 O 0 0.00040488155
minutes O 0 0.00069691875
. O 0 0.0017422835

Intravenous O 0 0.23596433
hydration O 0 0.0632852
and O 0 0.0030653367
mannitol B-Chemical 0 0.9968875
was O 0 0.0013521081
administered O 0 0.00086122385
before O 0 0.00042048522
and O 0 0.0009521236
after O 0 0.0010233744
cisplatin B-Chemical 0 0.99348795
. O 0 0.0051917834

Treatment O 0 0.006298826
was O 0 0.002100767
administered O 0 0.0012657956
every O 0 0.00046131114
3 O 0 0.00062564615
weeks O 0 0.0004711034
until O 0 0.000919096
disease O 0 0.034203835
progression O 0 0.04797744
. O 0 0.0052781003

RESULTS O 0 0.0047174245
: O 0 0.002117768
Forty O 0 0.0017150937
- O 0 0.0010586214
four O 0 0.00028008973
patients O 0 0.00038939947
were O 0 0.00023798946
enrolled O 0 0.00021922686
in O 0 0.00012450475
the O 0 0.00013628173
study O 0 0.00017685385
of O 0 0.00020850761
which O 0 0.0002745756
7 O 0 0.00017323068
( O 0 0.00031077873
16 O 0 0.0002883196
% O 0 0.00045899363
) O 0 0.0008184701
were O 0 0.00096574856
ineligible O 0 0.0026770462
. O 0 0.0021962738

A O 0 0.01151136
median O 0 0.0011113548
of O 0 0.0010771777
2 O 0 0.0005234804
cycles O 0 0.00031424197
of O 0 0.0004680498
therapy O 0 0.0005599775
was O 0 0.00038580567
administered O 0 0.00037216122
to O 0 0.00031317843
the O 0 0.0004657464
37 O 0 0.0010966972
eligible O 0 0.001444006
patients O 0 0.0020967787
. O 0 0.0022014608

Six O 0 0.0025451558
partial O 0 0.0019800125
responses O 0 0.0014051407
were O 0 0.00075155485
observed O 0 0.0004365661
for O 0 0.0003292261
an O 0 0.00048661686
overall O 0 0.00045600501
response O 0 0.00050650485
rate O 0 0.00074475893
of O 0 0.0011845463
16 O 0 0.0014136138
% O 0 0.0021639396
. O 0 0.0027306003

Most O 0 0.0053988136
patients O 0 0.0033058927
( O 0 0.0021709774
57 O 0 0.0016233927
% O 0 0.0010120199
) O 0 0.0009701003
stopped O 0 0.00084834587
treatment O 0 0.0006278998
because O 0 0.0006207106
of O 0 0.0019555183
disease O 0 0.5230423
progression O 0 0.24199341
. O 0 0.0042968597

Neurologic B-Disease 0 0.988424
toxicity I-Disease 2 0.9991129
was O 0 0.004164939
reported O 0 0.0020513586
in O 0 0.0013599918
52 O 0 0.0018424339
% O 0 0.0016229332
of O 0 0.002358967
patients O 0 0.004493977
. O 0 0.004078225

Seven O 0 0.0037065868
different O 0 0.0012295744
life O 0 0.0016729365
- O 0 0.0017384283
threatening O 0 0.0025463933
toxicities B-Disease 2 0.9828555
were O 0 0.0005377887
observed O 0 0.00028669112
in O 0 0.0003154387
patients O 0 0.00054339867
while O 0 0.0005497427
receiving O 0 0.0014399155
treatment O 0 0.0017653812
. O 0 0.0024372274

CONCLUSIONS O 0 0.011270206
: O 0 0.0016673265
The O 0 0.00058032817
combination O 0 0.00077997975
of O 0 0.0010737932
cisplatin B-Chemical 0 0.99836594
and O 0 0.0016230998
amifostine B-Chemical 0 0.99988604
in O 0 0.00034591096
this O 0 0.0002633689
study O 0 0.00019702133
resulted O 0 0.00013854878
in O 0 0.00012237595
an O 0 0.00017468368
overall O 0 0.00018307604
response O 0 0.0002279255
rate O 0 0.0003868037
of O 0 0.00070485927
16 O 0 0.0009095767
% O 0 0.0015015703
. O 0 0.0020035831

Neither O 0 0.003088595
a O 0 0.0033231508
tumor B-Disease 0 0.4745872
- O 0 0.002623977
protective O 0 0.0016129446
effect O 0 0.00043145788
nor O 0 0.00037029447
reduced O 0 0.0011000213
toxicity B-Disease 2 0.9968876
to O 0 0.00025697437
normal O 0 0.00056945067
tissues O 0 0.00028634365
was O 0 9.485111e-05
observed O 0 5.4919165e-05
with O 0 7.584956e-05
the O 0 6.4518885e-05
addition O 0 6.8259156e-05
of O 0 0.0004088166
amifostine B-Chemical 0 0.99988794
to O 0 0.0007420626
cisplatin B-Chemical 0 0.9981086
in O 0 0.0006427299
this O 0 0.0011780198
trial O 0 0.0019751505
. O 0 0.001777425

Oral B-Chemical 0 0.99133766
contraceptives I-Chemical 0 0.9982004
and O 0 0.0038819977
the O 0 0.002835615
risk O 0 0.011074332
of O 0 0.007912853
myocardial B-Disease 0 0.9994655
infarction I-Disease 2 0.9999186
. O 0 0.011820131

BACKGROUND O 0 0.0076340237
: O 0 0.0018284459
An O 0 0.0008781323
association O 0 0.00034493144
between O 0 0.00021830929
the O 0 0.00024809048
use O 0 0.00022782054
of O 0 0.00057076133
oral B-Chemical 1 0.9418959
contraceptives I-Chemical 1 0.99985313
and O 0 0.00025242032
the O 0 0.00015625806
risk O 0 0.0011877426
of O 0 0.00056973164
myocardial B-Disease 0 0.9999261
infarction I-Disease 2 0.99999535
has O 0 0.00022215123
been O 0 9.495871e-05
found O 0 8.5054e-05
in O 0 0.00010044143
some O 0 0.00016274929
, O 0 0.00023070394
but O 0 0.00024558528
not O 0 0.000288836
all O 0 0.0005128701
, O 0 0.00094752014
studies O 0 0.0015383126
. O 0 0.00197634

We O 0 0.0014902068
investigated O 0 0.0010227953
this O 0 0.00085753325
association O 0 0.00040916083
, O 0 0.0004177422
according O 0 0.00015612402
to O 0 0.00014424005
the O 0 0.00014840822
type O 0 0.00018750882
of O 0 0.00042749182
progestagen B-Chemical 0 0.99983096
included O 0 0.00012636886
in O 0 0.00010476253
third O 0 0.000200265
- O 0 0.00024951497
generation O 0 0.00019738046
( O 0 0.00018049843
i O 0 0.0002536843
. O 0 5.964963e-05
e O 0 0.00013221233
. O 0 6.445924e-05
, O 0 0.00023876606
desogestrel B-Chemical 0 0.99995506
or O 0 0.0005543546
gestodene B-Chemical 0 0.9999801
) O 0 0.00030698557
and O 0 9.315242e-05
second O 0 9.80347e-05
- O 0 0.00019638083
generation O 0 0.00016421614
( O 0 0.00015662411
i O 0 0.00022269052
. O 0 5.483115e-05
e O 0 0.00012058155
. O 0 6.052285e-05
, O 0 0.00021570081
levonorgestrel B-Chemical 0 0.9998056
) O 0 0.00092595106
oral B-Chemical 1 0.9108164
contraceptives I-Chemical 1 0.9998596
, O 0 0.00015458757
the O 0 8.574998e-05
dose O 0 0.0005615414
of O 0 0.00049614283
estrogen B-Chemical 1 0.9999423
, O 0 0.00019107552
and O 0 7.774342e-05
the O 0 5.5498665e-05
presence O 0 5.639329e-05
or O 0 4.912291e-05
absence O 0 4.5623503e-05
of O 0 0.00019559357
prothrombotic O 0 0.76340693
mutations O 0 0.0022152627
METHODS O 0 8.862973e-05
: O 0 8.3319545e-05
In O 0 4.1181047e-05
a O 0 9.473387e-05
nationwide O 0 0.00020540782
, O 0 0.00012314715
population O 0 0.0002723908
- O 0 0.00019816529
based O 0 7.5871176e-05
, O 0 0.00011581835
case O 0 0.000104090475
- O 0 0.00017444634
control O 0 7.592069e-05
study O 0 0.00010072917
, O 0 6.6157925e-05
we O 0 2.7005508e-05
identified O 0 4.6805882e-05
and O 0 7.047692e-05
enrolled O 0 0.00011932097
248 O 0 0.0007267981
women O 0 0.00016989443
18 O 0 3.919048e-05
through O 0 2.8973733e-05
49 O 0 6.6809924e-05
years O 0 3.3760913e-05
of O 0 5.7796253e-05
age O 0 7.762681e-05
who O 0 9.985068e-05
had O 0 5.5973887e-05
had O 0 5.03309e-05
a O 0 7.176138e-05
first O 0 6.658451e-05
myocardial B-Disease 0 0.9996086
infarction I-Disease 2 0.9999919
between O 0 9.335436e-05
1990 O 0 0.00021807273
and O 0 6.433537e-05
1995 O 0 0.00015869447
and O 0 6.0427636e-05
925 O 0 0.00061372604
control O 0 6.2734965e-05
women O 0 0.00018279119
who O 0 8.772774e-05
had O 0 4.5136956e-05
not O 0 4.213713e-05
had O 0 6.134236e-05
a O 0 0.00020646834
myocardial B-Disease 0 0.9998029
infarction I-Disease 2 0.9999951
and O 0 0.00029881447
who O 0 0.00018150079
were O 0 5.611027e-05
matched O 0 4.119122e-05
for O 0 4.4213346e-05
age O 0 8.706147e-05
, O 0 7.2214316e-05
calendar O 0 4.336318e-05
year O 0 3.776552e-05
of O 0 7.5094875e-05
the O 0 9.4792245e-05
index O 0 0.00019697625
event O 0 0.00047345384
, O 0 0.00029098082
and O 0 0.00031969146
area O 0 0.000496749
of O 0 0.0010419402
residence O 0 0.0026159985
. O 0 0.0020512783

Subjects O 0 0.0028167618
supplied O 0 0.0021597145
information O 0 0.001036572
on O 0 0.0008476529
oral B-Chemical 0 0.23869622
- I-Chemical 0 0.0036146683
contraceptive I-Chemical 0 0.37963137
use O 0 0.0006322459
and O 0 0.00063191314
major O 0 0.0009508781
cardiovascular O 0 0.77489233
risk O 0 0.020243749
factors O 0 0.0039048344
. O 0 0.003105521

An O 0 0.002706959
analysis O 0 0.0014645784
for O 0 0.0010576337
factor O 0 0.021511087
V O 0 0.9794002
Leiden O 0 0.9996686
and O 0 0.0012447776
the O 0 0.0029471363
G20210A O 0 0.9999931
mutation O 0 0.037516322
in O 0 0.00023299475
the O 0 0.0002866813
prothrombin O 0 0.98423475
gene O 0 0.00036237406
was O 0 0.00010313919
conducted O 0 5.861339e-05
in O 0 6.80059e-05
217 O 0 0.00042682973
patients O 0 0.00011250122
and O 0 9.1668655e-05
763 O 0 0.0023348983
controls O 0 0.00014713587
RESULTS O 0 0.00020953956
: O 0 6.945968e-05
The O 0 3.5551337e-05
odds O 0 0.00011930504
ratio O 0 8.0542246e-05
for O 0 7.366808e-05
myocardial B-Disease 0 0.99960285
infarction I-Disease 2 0.9999945
among O 0 0.00046160692
women O 0 0.00044480248
who O 0 9.649193e-05
used O 0 3.5153455e-05
any O 0 3.6503418e-05
type O 0 5.5394023e-05
of O 0 8.764171e-05
combined O 0 0.00030652087
oral B-Chemical 0 0.8293753
contraceptive I-Chemical 0 0.9137137
, O 0 0.00014692135
as O 0 6.0741404e-05
compared O 0 4.4942906e-05
with O 0 0.0001651514
nonusers O 0 0.008414617
, O 0 0.0001236543
was O 0 0.000102761136
2 O 0 5.8989594e-05
. O 0 4.0278064e-05
0 O 0 5.5716187e-05
( O 0 8.870236e-05
95 O 0 8.553095e-05
percent O 0 5.0825958e-05
confidence O 0 0.00031350224
interval O 0 8.917782e-05
, O 0 0.00012377357
1 O 0 9.3892166e-05
. O 0 7.645746e-05
5 O 0 0.00010104954
to O 0 0.00016584732
2 O 0 0.0002613769
. O 0 0.0003282611
8 O 0 0.0006706863
) O 0 0.001830217
. O 0 0.0022125978

The O 0 0.0019527987
adjusted O 0 0.0016992529
odds O 0 0.0023166607
ratio O 0 0.0012119013
was O 0 0.0006668936
2 O 0 0.0003195431
. O 0 0.00017752207
5 O 0 0.00015186293
( O 0 0.00021211659
95 O 0 0.00017282712
percent O 0 8.653207e-05
confidence O 0 0.0004264259
interval O 0 0.00010444613
, O 0 0.00012286728
1 O 0 7.736254e-05
. O 0 4.7755908e-05
5 O 0 4.6651392e-05
to O 0 5.5170443e-05
4 O 0 5.5892917e-05
. O 0 4.6549445e-05
1 O 0 6.275902e-05
) O 0 0.0001123385
among O 0 9.29524e-05
women O 0 0.00021195044
who O 0 9.9051045e-05
used O 0 4.8247126e-05
second O 0 8.385677e-05
- O 0 0.00022334052
generation O 0 0.00042477442
oral B-Chemical 1 0.96134025
contraceptives I-Chemical 1 0.9999286
and O 0 0.0002382544
1 O 0 8.865009e-05
. O 0 4.6189107e-05
3 O 0 4.8677244e-05
( O 0 7.852074e-05
95 O 0 7.38642e-05
percent O 0 4.115608e-05
confidence O 0 0.0002495921
interval O 0 6.164872e-05
, O 0 7.7304285e-05
0 O 0 5.7227473e-05
. O 0 3.930872e-05
7 O 0 3.9050243e-05
to O 0 5.0512986e-05
2 O 0 5.8965634e-05
. O 0 4.5789748e-05
5 O 0 5.7428104e-05
) O 0 0.00012211078
among O 0 9.793975e-05
those O 0 0.00014504082
who O 0 0.0001837639
used O 0 0.0001314736
third O 0 0.00037475344
- O 0 0.00080179056
generation O 0 0.0018250011
oral B-Chemical 1 0.96775526
contraceptives I-Chemical 1 0.99965155
. O 0 0.0036303955

Among O 0 0.0035994467
women O 0 0.0034003286
who O 0 0.0014330918
used O 0 0.0009287104
oral B-Chemical 1 0.94901323
contraceptives I-Chemical 1 0.9998363
, O 0 0.0006131781
the O 0 0.0002887088
odds O 0 0.0006395113
ratio O 0 0.0003067951
was O 0 0.00017999676
2 O 0 9.5687625e-05
. O 0 6.0111473e-05
1 O 0 7.154785e-05
( O 0 0.00010052288
95 O 0 9.109676e-05
percent O 0 4.9587074e-05
confidence O 0 0.0002989512
interval O 0 7.390563e-05
, O 0 9.312257e-05
1 O 0 6.1269406e-05
. O 0 3.8942882e-05
5 O 0 3.9659153e-05
to O 0 4.822555e-05
3 O 0 4.9208615e-05
. O 0 3.967826e-05
0 O 0 5.510824e-05
) O 0 8.634027e-05
for O 0 4.281707e-05
those O 0 8.712598e-05
without O 0 7.568367e-05
a O 0 0.00022394313
prothrombotic O 0 0.83165956
mutation O 0 0.016045041
and O 0 0.00016939928
1 O 0 8.43172e-05
. O 0 4.738777e-05
9 O 0 5.6361678e-05
( O 0 8.343459e-05
95 O 0 7.761193e-05
percent O 0 4.2580214e-05
confidence O 0 0.0002564134
interval O 0 6.255133e-05
, O 0 7.788931e-05
0 O 0 5.7052286e-05
. O 0 3.823057e-05
6 O 0 3.2730128e-05
to O 0 4.474465e-05
5 O 0 4.8003203e-05
. O 0 4.1205323e-05
5 O 0 4.7733967e-05
) O 0 8.468643e-05
for O 0 4.301745e-05
those O 0 8.640838e-05
with O 0 8.9389985e-05
a O 0 0.00014142564
mutation O 0 0.002671519
CONCLUSIONS O 0 0.013363205
: O 0 0.0001125332
The O 0 5.0404193e-05
risk O 0 0.00048980134
of O 0 0.00032253304
myocardial B-Disease 0 0.999877
infarction I-Disease 2 0.9999949
was O 0 0.00036455426
increased O 0 0.00027319137
among O 0 0.00018483706
women O 0 0.0003799282
who O 0 0.00016327963
used O 0 0.000103255516
second O 0 0.00022360306
- O 0 0.000715617
generation O 0 0.0017321998
oral B-Chemical 1 0.9694495
contraceptives I-Chemical 1 0.999673
. O 0 0.0034369996

The O 0 0.0014903614
results O 0 0.0011985702
with O 0 0.000851771
respect O 0 0.00037158802
to O 0 0.00029850978
the O 0 0.0002477074
use O 0 0.00017954133
of O 0 0.00022915902
third O 0 0.0003152298
- O 0 0.00040794688
generation O 0 0.00057629857
oral B-Chemical 1 0.9544381
contraceptives I-Chemical 1 0.9999175
were O 0 0.00026183808
inconclusive O 0 0.0009080093
but O 0 9.780312e-05
suggested O 0 4.4382024e-05
that O 0 4.6989564e-05
the O 0 0.00010103046
risk O 0 0.0010768777
was O 0 0.00012300268
lower O 0 0.000119932054
than O 0 5.5022905e-05
the O 0 9.856758e-05
risk O 0 0.0006652184
associated O 0 0.00012048477
with O 0 0.00021220057
second O 0 0.0002760197
- O 0 0.0007923398
generation O 0 0.0018076074
oral B-Chemical 1 0.9699692
contraceptives I-Chemical 1 0.99967074
. O 0 0.003424689

The O 0 0.002002914
risk O 0 0.0051871114
of O 0 0.002631356
myocardial B-Disease 0 0.9995598
infarction I-Disease 2 0.9999746
was O 0 0.0008493188
similar O 0 0.00017503147
among O 0 0.00024521325
women O 0 0.00047285762
who O 0 0.00023432342
used O 0 0.00017856408
oral B-Chemical 1 0.8783134
contraceptives I-Chemical 1 0.999703
whether O 0 8.202016e-05
or O 0 0.00012388409
not O 0 0.00013564619
they O 0 0.00017230255
had O 0 0.00034414197
a O 0 0.0010881978
prothrombotic O 0 0.90432245
mutation O 0 0.11587068
. O 0 0.0027280776

End B-Disease 0 0.008884228
- I-Disease 0 0.004489384
stage I-Disease 0 0.005086715
renal I-Disease 0 0.9986946
disease I-Disease 0 0.9982162
( O 0 0.010411369
ESRD B-Disease 2 0.99996066
) O 0 0.00084569457
after O 0 0.000115787
orthotopic O 0 0.29004985
liver O 0 0.8615896
transplantation O 0 0.023255736
( O 0 0.0006494472
OLTX O 0 0.63171625
) O 0 0.00023676388
using O 0 0.00010401813
calcineurin O 0 0.1257899
- O 0 0.00032288252
based O 0 0.000120582234
immunotherapy O 0 0.00073207513
: O 0 0.00034385585
risk O 0 0.0012242468
of O 0 0.00043443206
development O 0 0.0008776647
and O 0 0.0008450376
treatment O 0 0.001487166
. O 0 0.0020529188

BACKGROUND O 0 0.006944522
: O 0 0.0017938303
The O 0 0.00079753005
calcineurin O 0 0.13509966
inhibitors O 0 0.06687616
cyclosporine B-Chemical 1 0.9999877
and O 0 0.006617749
tacrolimus B-Chemical 0 0.9999832
are O 0 0.00071958604
both O 0 0.00045853097
known O 0 0.00065621274
to O 0 0.0006809793
be O 0 0.0014222314
nephrotoxic B-Disease 2 0.99906677
. O 0 0.00456213

Their O 0 0.0065664514
use O 0 0.0017711897
in O 0 0.0014020103
orthotopic O 0 0.40004227
liver O 0 0.9046793
transplantation O 0 0.06880281
( O 0 0.0021251452
OLTX O 0 0.77539223
) O 0 0.0008049714
has O 0 0.00031961163
dramatically O 0 0.0006579881
improved O 0 0.0013630125
success O 0 0.0020056572
rates O 0 0.0020155483
. O 0 0.0025490085

Recently O 0 0.0031654162
, O 0 0.0025007091
however O 0 0.0014661701
, O 0 0.00079962483
we O 0 0.00025480814
have O 0 0.00022596528
had O 0 0.00020390778
an O 0 0.00019462913
increase O 0 0.0001432107
of O 0 0.00020422824
patients O 0 0.0002485408
who O 0 0.00018657501
are O 0 8.064646e-05
presenting O 0 0.00018272115
after O 0 5.0790783e-05
OLTX O 0 0.14953762
with O 0 0.00014825094
end B-Disease 0 9.1006885e-05
- I-Disease 0 0.00040597646
stage I-Disease 0 0.0012828001
renal I-Disease 0 0.9996325
disease I-Disease 0 0.99861765
( O 0 0.012870075
ESRD B-Disease 2 0.999931
) O 0 0.005868982
. O 0 0.0025368312

This O 0 0.0038662055
retrospective O 0 0.004779457
study O 0 0.0010389824
examines O 0 0.0006708759
the O 0 0.00042203185
incidence O 0 0.0006342303
and O 0 0.00026555243
treatment O 0 0.00026271705
of O 0 0.00092154596
ESRD B-Disease 2 0.99998367
and O 0 0.0010923886
chronic B-Disease 2 0.9588723
renal I-Disease 2 0.9984668
failure I-Disease 2 0.99102294
( O 0 0.0036579585
CRF B-Disease 0 0.9997422
) O 0 0.0011219003
in O 0 0.00069325685
OLTX O 0 0.5117833
patients O 0 0.0024363073
. O 0 0.0019581676

METHODS O 0 0.0015282416
: O 0 0.0013615204
Patients O 0 0.0007314824
receiving O 0 0.0006674563
an O 0 0.0006641846
OLTX O 0 0.15214853
only O 0 0.00027023017
from O 0 0.00014711426
June O 0 0.00014705338
1985 O 0 0.00020905085
through O 0 6.053814e-05
December O 0 7.8427416e-05
of O 0 0.00010766829
1994 O 0 0.00025932534
who O 0 0.00013353839
survived O 0 0.00010382549
6 O 0 4.441136e-05
months O 0 3.194846e-05
postoperatively O 0 7.2193245e-05
were O 0 0.00011444332
studied O 0 0.00020939097
( O 0 0.00036287014
n O 0 0.00037578345
= O 0 0.0008387554
834 O 0 0.0048811836
) O 0 0.002204627
. O 0 0.0021535147

Our O 0 0.0032646472
prospectively O 0 0.0026347134
collected O 0 0.001326209
database O 0 0.0023858354
was O 0 0.0014620953
the O 0 0.0011529526
source O 0 0.0013302395
of O 0 0.0024004262
information O 0 0.0034413647
. O 0 0.0046537803

Patients O 0 0.0021486674
were O 0 0.00091709767
divided O 0 0.00037137832
into O 0 0.00016387732
three O 0 0.00014452009
groups O 0 0.00022463365
: O 0 0.0002727768
Controls O 0 0.00074921147
, O 0 0.00021416589
no O 0 0.00016473682
CRF B-Disease 0 0.9996119
or O 0 0.0007575138
ESRD B-Disease 2 0.9999826
, O 0 0.00033594147
n O 0 0.00013099657
= O 0 0.00016098745
748 O 0 0.0010039528
; O 0 0.00022745873
CRF B-Disease 0 0.99819463
, O 0 0.00014695442
sustained O 0 0.0003031095
serum O 0 0.13419642
creatinine B-Chemical 1 0.9997706
> O 0 0.0009009299
2 O 0 8.658002e-05
. O 0 4.589629e-05
5 O 0 5.619322e-05
mg O 0 0.0010127429
/ O 0 0.00046346997
dl O 0 0.0024986498
, O 0 0.00018310346
n O 0 0.00013110529
= O 0 0.00017863797
41 O 0 0.0002623619
; O 0 0.00025837938
and O 0 0.00049704616
ESRD B-Disease 2 0.99987173
, O 0 0.000910678
n O 0 0.0006214559
= O 0 0.00096589123
45 O 0 0.0011049976
. O 0 0.0018173143

Groups O 0 0.005973678
were O 0 0.0010100026
compared O 0 0.0004030012
for O 0 0.00031510327
preoperative O 0 0.0006916077
laboratory O 0 0.00045076804
variables O 0 0.00017732885
, O 0 0.00024431714
diagnosis O 0 0.00037200304
, O 0 0.00017683649
postoperative O 0 0.0002756468
variables O 0 8.7629254e-05
, O 0 0.00014506544
survival O 0 0.00081313873
, O 0 0.00015852143
type O 0 0.00016255479
of O 0 0.0005657442
ESRD B-Disease 2 0.99998343
therapy O 0 0.00071577856
, O 0 0.00022326133
and O 0 0.00019883626
survival O 0 0.0009957994
from O 0 0.00028075973
onset O 0 0.0009269923
of O 0 0.0030128402
ESRD B-Disease 2 0.9998727
. O 0 0.003974778

RESULTS O 0 0.00442653
: O 0 0.0015593681
At O 0 0.00036726886
13 O 0 0.0006198499
years O 0 0.00037626195
after O 0 0.00020470198
OLTX O 0 0.15044896
, O 0 0.00030874193
the O 0 0.00018860727
incidence O 0 0.00038030997
of O 0 0.0003616286
severe O 0 0.087547325
renal B-Disease 2 0.99991274
dysfunction I-Disease 2 0.9998029
was O 0 0.0005173045
18 O 0 0.00011723215
. O 0 5.483805e-05
1 O 0 6.902118e-05
% O 0 0.00011545315
( O 0 0.00027400942
CRF B-Disease 0 0.997413
8 O 0 0.00012746667
. O 0 7.04104e-05
6 O 0 7.048465e-05
% O 0 0.00015794479
and O 0 0.00038363197
ESRD B-Disease 2 0.99987984
9 O 0 0.0004215098
. O 0 0.0002754411
5 O 0 0.00041622357
% O 0 0.00097582676
) O 0 0.0020975678
. O 0 0.0023753818

Compared O 0 0.0014123046
with O 0 0.0011510536
control O 0 0.00078384276
patients O 0 0.0010219063
, O 0 0.0010311985
CRF B-Disease 0 0.99958724
and O 0 0.0016356021
ESRD B-Disease 2 0.99997735
patients O 0 0.000522137
had O 0 0.000108443244
higher O 0 0.00011080035
preoperative O 0 0.0004500761
serum O 0 0.11379527
creatinine B-Chemical 1 0.999673
levels O 0 0.00024978112
, O 0 0.00012302544
a O 0 8.4184314e-05
greater O 0 5.6644236e-05
percentage O 0 4.117355e-05
of O 0 8.656516e-05
patients O 0 0.0001520526
with O 0 0.0003360196
hepatorenal B-Disease 0 0.9999312
syndrome I-Disease 0 0.43302593
, O 0 0.00010891643
higher O 0 6.582377e-05
percentage O 0 3.4304194e-05
requirement O 0 3.3381733e-05
for O 0 3.650196e-05
dialysis O 0 0.0003207823
in O 0 4.1796866e-05
the O 0 3.972669e-05
first O 0 2.9680414e-05
3 O 0 3.6182417e-05
months O 0 2.2616076e-05
postoperatively O 0 5.3736792e-05
, O 0 8.5942855e-05
and O 0 9.8934186e-05
a O 0 0.0001710312
higher O 0 0.00022536176
1 O 0 0.00021048912
- O 0 0.0004615368
year O 0 0.00035946514
serum O 0 0.06238227
creatinine B-Chemical 1 0.998879
. O 0 0.0036947727

Multivariate O 0 0.0028714684
stepwise O 0 0.0019801774
logistic O 0 0.0009108776
regression O 0 0.00078674214
analysis O 0 0.0003006533
using O 0 0.00018068268
preoperative O 0 0.00038483724
and O 0 0.00015805205
postoperative O 0 0.0002306494
variables O 0 5.7977435e-05
identified O 0 5.016218e-05
that O 0 4.1309147e-05
an O 0 7.931589e-05
increase O 0 6.9361e-05
of O 0 0.00014741474
serum O 0 0.11864068
creatinine B-Chemical 1 0.9993414
compared O 0 6.5831366e-05
with O 0 6.837538e-05
average O 0 3.2409745e-05
at O 0 3.753086e-05
1 O 0 4.9358303e-05
year O 0 3.6755868e-05
, O 0 6.0041573e-05
3 O 0 3.6642617e-05
months O 0 2.0396847e-05
, O 0 4.971406e-05
and O 0 4.893244e-05
4 O 0 3.1340584e-05
weeks O 0 1.7128976e-05
postoperatively O 0 3.2883054e-05
were O 0 3.7404905e-05
independent O 0 3.11945e-05
risk O 0 0.00027333337
factors O 0 7.428145e-05
for O 0 3.872704e-05
the O 0 5.4623437e-05
development O 0 0.00014618298
of O 0 0.00031025003
CRF B-Disease 0 0.9998933
or O 0 0.00052257115
ESRD B-Disease 2 0.99998724
with O 0 0.00032025704
odds O 0 0.00032993653
ratios O 0 0.0001050312
of O 0 0.00010787711
2 O 0 6.781053e-05
. O 0 4.4932964e-05
6 O 0 4.684791e-05
, O 0 9.309851e-05
2 O 0 7.74857e-05
. O 0 6.824796e-05
2 O 0 9.756484e-05
, O 0 0.00016117992
and O 0 0.00020170167
1 O 0 0.00022000706
. O 0 0.00022035575
6 O 0 0.00033046133
, O 0 0.00092907285
respectively O 0 0.0024963503
. O 0 0.0025036049

Overall O 0 0.0033287024
survival O 0 0.004106506
from O 0 0.00067956053
the O 0 0.00043777275
time O 0 0.00023426868
of O 0 0.00056432013
OLTX O 0 0.52404124
was O 0 0.0002563667
not O 0 0.00012387038
significantly O 0 0.000161982
different O 0 7.57847e-05
among O 0 0.00013773209
groups O 0 0.00011165393
, O 0 0.00011173606
but O 0 9.8723554e-05
by O 0 8.759433e-05
year O 0 5.2084215e-05
13 O 0 6.5007844e-05
, O 0 5.881457e-05
the O 0 5.3842818e-05
survival O 0 0.00029483341
of O 0 8.2485596e-05
the O 0 7.240561e-05
patients O 0 0.00014577956
who O 0 0.00021217608
had O 0 0.00029675302
ESRD B-Disease 2 0.99998426
was O 0 0.00021342795
only O 0 0.000113122245
28 O 0 7.6214106e-05
. O 0 4.056536e-05
2 O 0 4.5900666e-05
% O 0 5.7702364e-05
compared O 0 4.29045e-05
with O 0 0.00011057046
54 O 0 0.00019653895
. O 0 7.413744e-05
6 O 0 7.576353e-05
% O 0 0.00014156339
in O 0 0.0001660733
the O 0 0.00030838393
control O 0 0.00063600444
group O 0 0.001626892
. O 0 0.0020049526

Patients O 0 0.0038791515
developing O 0 0.01934145
ESRD B-Disease 2 0.99983895
had O 0 0.0013233733
a O 0 0.00075761887
6 O 0 0.00025248673
- O 0 0.00038805098
year O 0 0.00011922601
survival O 0 0.00042175176
after O 0 5.3897995e-05
onset O 0 0.00020185845
of O 0 0.00051238126
ESRD B-Disease 2 0.99997306
of O 0 0.0003475285
27 O 0 0.00019606951
% O 0 6.622148e-05
for O 0 3.45951e-05
the O 0 5.421099e-05
patients O 0 9.839348e-05
receiving O 0 0.00014316113
hemodialysis O 0 0.014588994
versus O 0 7.215148e-05
71 O 0 0.0001642816
. O 0 3.919287e-05
4 O 0 3.7558497e-05
% O 0 4.8339094e-05
for O 0 3.8671395e-05
the O 0 8.121447e-05
patients O 0 0.00024116263
developing O 0 0.0052502877
ESRD B-Disease 2 0.9999765
who O 0 0.0008978944
subsequently O 0 0.00044563963
received O 0 0.00051294785
kidney O 0 0.74034876
transplants O 0 0.18049036
. O 0 0.0021986242

CONCLUSIONS O 0 0.013883415
: O 0 0.0022587886
Patients O 0 0.0010701066
who O 0 0.00084111164
are O 0 0.00034604504
more O 0 0.00033624136
than O 0 0.00016506921
10 O 0 0.00017115522
years O 0 0.0001366819
post O 0 0.000116315736
- O 0 0.00048967736
OLTX O 0 0.32118496
have O 0 0.00033384608
CRF B-Disease 0 0.9995233
and O 0 0.0012990432
ESRD B-Disease 2 0.99992454
at O 0 0.00042310456
a O 0 0.000804328
high O 0 0.0015002289
rate O 0 0.0018404006
. O 0 0.0022148897

The O 0 0.0018930637
development O 0 0.0026850735
of O 0 0.0036565443
ESRD B-Disease 2 0.9998598
decreases O 0 0.0020921452
survival O 0 0.008782486
, O 0 0.0005382913
particularly O 0 0.00035260443
in O 0 0.00023775584
those O 0 0.00035002088
patients O 0 0.0004086218
treated O 0 0.0005399398
with O 0 0.0008097371
dialysis O 0 0.0069824206
only O 0 0.0020152347
. O 0 0.0022541885

Patients O 0 0.0028066812
who O 0 0.0023178835
develop O 0 0.002470178
ESRD B-Disease 2 0.9998312
have O 0 0.00045909558
a O 0 0.00037425896
higher O 0 0.00028547604
preoperative O 0 0.00057591527
and O 0 0.00020271521
1 O 0 0.00013586055
- O 0 0.00020748151
year O 0 8.757845e-05
serum O 0 0.012797506
creatinine B-Chemical 1 0.99852943
and O 0 0.0002770202
are O 0 0.00014560312
more O 0 0.00019259918
likely O 0 0.00015561303
to O 0 0.00029606326
have O 0 0.0007159044
hepatorenal B-Disease 0 0.9995664
syndrome I-Disease 0 0.74472183
. O 0 0.0026903525

However O 0 0.002683567
, O 0 0.0017663158
an O 0 0.001006099
increase O 0 0.0006033648
of O 0 0.00073533104
serum O 0 0.093544975
creatinine B-Chemical 1 0.99843484
at O 0 0.00020285056
various O 0 0.00017328553
times O 0 7.316457e-05
postoperatively O 0 9.63973e-05
is O 0 8.8462635e-05
more O 0 0.00012548485
predictive O 0 0.00022800003
of O 0 0.00020006113
the O 0 0.00019650166
development O 0 0.000558431
of O 0 0.001376233
CRF B-Disease 0 0.99970454
or O 0 0.004788731
ESRD B-Disease 2 0.99989545
. O 0 0.0040816045

New O 0 0.0033486101
strategies O 0 0.0015844514
for O 0 0.0009484351
long O 0 0.0009502509
- O 0 0.0012241056
term O 0 0.00068021676
immunosuppression O 0 0.49658054
may O 0 0.00048812086
be O 0 0.00034017983
needed O 0 0.00028727172
to O 0 0.00042796702
decrease O 0 0.0010088201
this O 0 0.0018995056
complication O 0 0.07757045
. O 0 0.003211173

Epileptic B-Disease 0 0.9996289
seizures I-Disease 0 0.9998254
following O 0 0.0010629265
cortical O 0 0.0019339443
application O 0 0.000682617
of O 0 0.0006982417
fibrin O 0 0.018770808
sealants O 0 0.005172528
containing O 0 0.0009771641
tranexamic B-Chemical 0 0.9988174
acid I-Chemical 0 0.9664089
in O 0 0.0021590525
rats O 0 0.0041792365
. O 0 0.0027182125

BACKGROUND O 0 0.0093122125
: O 0 0.0029919143
Fibrin O 0 0.011979381
sealants O 0 0.0075145843
( O 0 0.0018336925
FS O 0 0.025651226
) O 0 0.0007462675
derived O 0 0.00024306665
from O 0 0.00026861648
human O 0 0.00046178274
plasma O 0 0.0026003295
are O 0 0.00037507975
frequently O 0 0.0004059935
used O 0 0.000500041
in O 0 0.0009386788
neurosurgery O 0 0.0042042476
. O 0 0.0024358646

In O 0 0.0016923058
order O 0 0.00109176
to O 0 0.0008323201
increase O 0 0.00079520117
clot O 0 0.02022764
stability O 0 0.00082887127
, O 0 0.00062048
FS O 0 0.006994787
typically O 0 0.00038779117
contain O 0 0.0002349402
aprotinin O 0 0.43398413
, O 0 0.00062903634
a O 0 0.0007776094
natural O 0 0.0021741672
fibrinolysis O 0 0.9848238
inhibitor O 0 0.042817913
. O 0 0.003708863

Recently O 0 0.0026091596
, O 0 0.0019767918
synthetic O 0 0.0018100509
fibrinolysis O 0 0.906098
inhibitors O 0 0.0030576845
such O 0 0.00044579344
as O 0 0.00079046347
tranexamic B-Chemical 0 0.9994584
acid I-Chemical 0 0.9961532
( O 0 0.0043051685
tAMCA B-Chemical 1 0.9913406
) O 0 0.0006636498
have O 0 0.00015921009
been O 0 0.00015397322
considered O 0 0.00017999967
as O 0 0.0003086804
substitutes O 0 0.0010183918
for O 0 0.00090931664
aprotinin O 0 0.8285241
. O 0 0.0032419919

However O 0 0.0047633764
, O 0 0.0056449263
tAMCA B-Chemical 1 0.90271974
has O 0 0.0014981055
been O 0 0.000942995
shown O 0 0.00079350715
to O 0 0.0012356084
cause O 0 0.0071805934
epileptic B-Disease 0 0.9999423
seizures I-Disease 0 0.99997175
. O 0 0.011559772

We O 0 0.0017961422
wanted O 0 0.0022527003
to O 0 0.0010090827
study O 0 0.00089731545
whether O 0 0.00045385057
tAMCA B-Chemical 1 0.8910957
retains O 0 0.0009338862
its O 0 0.0019612852
convulsive B-Disease 2 0.9996612
action O 0 0.0009082007
if O 0 0.0002628323
incorporated O 0 0.00031912327
into O 0 0.00031831258
a O 0 0.0015558373
FS O 0 0.051325746
. O 0 0.0030680865

METHOD O 0 0.005696387
: O 0 0.0023299162
FS O 0 0.008696934
containing O 0 0.0008300027
aprotinin O 0 0.31149125
or O 0 0.00039723958
different O 0 0.00020239153
concentrations O 0 0.0006818582
of O 0 0.0007653193
tAMCA B-Chemical 1 0.98533994
( O 0 0.00045838737
0 O 0 0.00013401623
. O 0 7.535139e-05
5 O 0 7.946435e-05
- O 0 0.00017226495
47 O 0 0.00014841446
. O 0 5.2806594e-05
5 O 0 5.975689e-05
mg O 0 0.0009338799
/ O 0 0.00037285264
ml O 0 0.00041733627
) O 0 0.00015457666
were O 0 6.311408e-05
applied O 0 4.4371318e-05
to O 0 6.257567e-05
the O 0 0.00010871773
pial O 0 0.038177446
surface O 0 0.00024985734
of O 0 0.00019928816
the O 0 0.00021788153
cortex O 0 0.0025187163
of O 0 0.000784136
anaesthetized O 0 0.006958288
rats O 0 0.0021117872
. O 0 0.0017532117

The O 0 0.0014528933
response O 0 0.001215891
of O 0 0.00097153534
the O 0 0.0005590672
animals O 0 0.0003243539
was O 0 0.0002879378
evaluated O 0 0.00015977034
using O 0 0.00014469962
electroencephalography O 0 0.0013817877
and O 0 0.00014311213
by O 0 0.000104885774
monitoring O 0 8.681465e-05
the O 0 9.1911905e-05
clinical O 0 0.00022875128
behaviour O 0 0.00013716382
during O 0 6.7641966e-05
and O 0 0.00013567724
after O 0 0.00010301976
recovery O 0 0.0006354186
from O 0 0.00071957166
anaesthesia O 0 0.010373608
. O 0 0.0020505348

FINDINGS O 0 0.0060095484
: O 0 0.0026984888
FS O 0 0.014460609
containing O 0 0.0011948735
tAMCA B-Chemical 1 0.898428
caused O 0 0.0014838036
paroxysmal O 0 0.9953791
brain O 0 0.00533285
activity O 0 0.00034085542
which O 0 0.00036844736
was O 0 0.00028484987
associated O 0 0.00024262391
with O 0 0.0004736538
distinct O 0 0.0006346152
convulsive B-Disease 2 0.9994023
behaviours O 0 0.00776296
. O 0 0.0025544234

The O 0 0.0020636634
degree O 0 0.0021720766
of O 0 0.0018209161
these O 0 0.0026152844
seizures B-Disease 0 0.9995447
increased O 0 0.0024967906
with O 0 0.0011866665
increasing O 0 0.0012608562
concentration O 0 0.0032418778
of O 0 0.004995833
tAMCA B-Chemical 1 0.9884312
. O 0 0.0047871387

Thus O 0 0.0026563294
, O 0 0.0025741935
FS O 0 0.01382546
containing O 0 0.00077387335
47 O 0 0.0009280263
. O 0 0.000245956
5 O 0 0.0001911916
mg O 0 0.0023037088
/ O 0 0.0007539446
ml O 0 0.0012416756
tAMCA B-Chemical 1 0.9341642
evoked O 0 0.005880087
generalized B-Disease 0 0.6208791
seizures I-Disease 0 0.9999951
in O 0 0.0002833199
all O 0 0.000120807235
tested O 0 9.214376e-05
rats O 0 0.00018123153
( O 0 0.00013321661
n O 0 7.6253644e-05
= O 0 8.91529e-05
6 O 0 3.8149792e-05
) O 0 7.657566e-05
while O 0 4.477444e-05
the O 0 5.3637625e-05
lowest O 0 0.00010234385
concentration O 0 0.00024366922
of O 0 0.00038267914
tAMCA B-Chemical 1 0.98423994
( O 0 0.00024401031
0 O 0 6.927757e-05
. O 0 3.8752605e-05
5 O 0 4.5307694e-05
mg O 0 0.0007812786
/ O 0 0.00030200556
ml O 0 0.00034713873
) O 0 0.00012495577
only O 0 7.050749e-05
evoked O 0 0.00022592477
brief O 0 8.752945e-05
episodes O 0 0.00040373183
of O 0 0.0002277202
jerk O 0 0.39185148
- O 0 0.00038992247
correlated O 0 0.00015748102
convulsive B-Disease 2 0.9994823
potentials O 0 0.002098912
in O 0 0.00022985491
1 O 0 0.00021900787
of O 0 0.00040206953
6 O 0 0.0004375867
rats O 0 0.0014057624
. O 0 0.0017156808

In O 0 0.0022715416
contrast O 0 0.0024482463
, O 0 0.0019752232
FS O 0 0.02044122
containing O 0 0.0010353335
aprotinin O 0 0.6949453
did O 0 0.000969885
not O 0 0.0005900447
evoke O 0 0.0008409021
any O 0 0.0011724421
paroxysmal O 0 0.9863035
activity O 0 0.003067506
. O 0 0.0032930248

INTERPRETATION O 0 0.017862905
: O 0 0.00907224
Tranexamic B-Chemical 0 0.9981831
acid I-Chemical 0 0.9898415
retains O 0 0.0037031302
its O 0 0.0057304366
convulsive B-Disease 2 0.99927896
action O 0 0.0039296495
within O 0 0.0013561673
FS O 0 0.06658591
. O 0 0.004464125

Thus O 0 0.0024893284
, O 0 0.0019522059
use O 0 0.0009315854
of O 0 0.0010519089
FS O 0 0.036044475
containing O 0 0.00067201233
tAMCA B-Chemical 1 0.8928133
for O 0 0.00024231136
surgery O 0 0.00021742187
within O 0 4.9639642e-05
or O 0 8.612597e-05
close O 0 8.793948e-05
to O 0 9.720213e-05
the O 0 0.00015470569
CNS O 0 0.004881823
may O 0 0.00013116444
pose O 0 0.00016918879
a O 0 0.00026497425
substantial O 0 0.00037559
risk O 0 0.0017236178
to O 0 0.00042436933
the O 0 0.00076729676
patient O 0 0.0016222217
. O 0 0.0019894037

Sequential O 0 0.0029563308
observations O 0 0.0019672138
of O 0 0.0024305983
exencephaly B-Disease 0 0.9993519
and O 0 0.0007796907
subsequent O 0 0.00038495136
morphological O 0 0.001041194
changes O 0 0.0003204751
by O 0 0.00021740052
mouse O 0 0.0003406759
exo O 0 0.021452118
utero O 0 0.0006808658
development O 0 0.0002565073
system O 0 0.00013014756
: O 0 0.00011572451
analysis O 0 7.5142656e-05
of O 0 9.773693e-05
the O 0 9.0346184e-05
mechanism O 0 0.00013168289
of O 0 0.00023481411
transformation O 0 0.0011710308
from O 0 0.0007092126
exencephaly B-Disease 0 0.99978155
to O 0 0.00366248
anencephaly B-Disease 2 0.9994511
. O 0 0.0039984453

Anencephaly B-Disease 0 0.7134359
has O 0 0.0015156578
been O 0 0.0006737861
suggested O 0 0.00038514295
to O 0 0.00033823148
develop O 0 0.00047713678
from O 0 0.0005867545
exencephaly B-Disease 0 0.9999161
; O 0 0.0008082311
however O 0 0.0003677927
, O 0 0.00018090816
there O 0 6.990463e-05
is O 0 9.006317e-05
little O 0 7.2366114e-05
direct O 0 6.920546e-05
experimental O 0 0.00011426579
evidence O 0 6.695138e-05
to O 0 6.377803e-05
support O 0 6.712085e-05
this O 0 0.0001460048
, O 0 0.00014530412
and O 0 0.00012142801
the O 0 0.00013019324
mechanism O 0 0.00021251377
of O 0 0.00039175636
transformation O 0 0.0014667839
remains O 0 0.00069352344
unclear O 0 0.0011814272
. O 0 0.0020077704

We O 0 0.0014475534
examined O 0 0.0008343041
this O 0 0.0007969504
theory O 0 0.00082120317
using O 0 0.00037827063
the O 0 0.00040481944
exo O 0 0.022496
utero O 0 0.0010869348
development O 0 0.00035787225
system O 0 0.00013115055
that O 0 6.4923515e-05
allows O 0 7.0373964e-05
direct O 0 7.208641e-05
and O 0 7.9661535e-05
sequential O 0 0.00010052441
observations O 0 0.0001257877
of O 0 0.0001658233
mid O 0 0.00034502055
- O 0 0.0003275999
to O 0 0.00017534854
late O 0 0.0007037196
- O 0 0.0006995404
gestation O 0 0.00072737184
mouse O 0 0.0012779605
embryos O 0 0.003022176
. O 0 0.0020890974

We O 0 0.0016791933
observed O 0 0.001413198
the O 0 0.0019577267
exencephaly B-Disease 0 0.999451
induced O 0 0.0016403057
by O 0 0.00067808764
5 B-Chemical 0 0.00032100626
- I-Chemical 0 0.00069942884
azacytidine I-Chemical 0 0.7684102
at O 0 0.0001508485
embryonic O 0 0.0013853281
day O 0 8.424728e-05
13 O 0 0.00010303548
. O 0 5.8534133e-05
5 O 0 7.432891e-05
( O 0 0.00018771774
E13 O 0 0.012818245
. O 0 7.7953206e-05
5 O 0 7.528646e-05
) O 0 0.00014842805
, O 0 0.000106407344
let O 0 0.00026990726
the O 0 9.549601e-05
embryos O 0 0.00026169932
develop O 0 0.00017246364
exo O 0 0.036809377
utero O 0 0.00078429224
until O 0 8.283613e-05
E18 O 0 0.0075756568
. O 0 5.7551457e-05
5 O 0 5.5297438e-05
, O 0 8.765884e-05
and O 0 0.00010672777
re O 0 0.00047523173
- O 0 0.00021487358
observed O 0 8.191472e-05
the O 0 0.00010134609
same O 0 9.411662e-05
embryos O 0 0.00047304737
at O 0 0.0003015691
E18 O 0 0.008426816
. O 0 0.00054808654
5 O 0 0.0009081075
. O 0 0.0017290259

We O 0 0.0023246761
confirmed O 0 0.0019233302
several O 0 0.0011693081
cases O 0 0.0013888577
of O 0 0.0013744888
transformation O 0 0.003569869
from O 0 0.002382279
exencephaly B-Disease 0 0.9995639
to O 0 0.007833548
anencephaly B-Disease 2 0.9992079
. O 0 0.0069683604

However O 0 0.0029818944
, O 0 0.0020856545
in O 0 0.0009580485
many O 0 0.0006546058
cases O 0 0.00069220905
, O 0 0.00047352244
the O 0 0.00041552645
exencephalic B-Disease 2 0.9178428
brain O 0 0.00530187
tissue O 0 0.0011156369
was O 0 0.00019480869
preserved O 0 0.0003091478
with O 0 0.00016413927
more O 0 0.00019809126
or O 0 0.00014247898
less O 0 0.00021539153
reduction O 0 0.00051617244
during O 0 0.00022234065
this O 0 0.00066324713
period O 0 0.0006777533
. O 0 0.0016395076

To O 0 0.0017719781
analyze O 0 0.00093818223
the O 0 0.00091758673
transformation O 0 0.0014072827
patterns O 0 0.0003745763
, O 0 0.00037507762
we O 0 0.00014153628
classified O 0 0.0002422929
the O 0 0.00036221053
exencephaly B-Disease 0 0.99977165
by O 0 0.00028389553
size O 0 0.00023842574
and O 0 0.00010222652
shape O 0 0.00010534183
of O 0 0.00013643879
the O 0 0.00017129822
exencephalic B-Disease 2 0.90251017
tissue O 0 0.00045829586
into O 0 3.8240196e-05
several O 0 5.5409346e-05
types O 0 6.501106e-05
at O 0 0.000110594185
E13 O 0 0.021633267
. O 0 0.00014721249
5 O 0 0.00018391393
and O 0 0.00042163942
E18 O 0 0.006100225
. O 0 0.0005934734
5 O 0 0.0009773086
. O 0 0.0018468009

It O 0 0.002827454
was O 0 0.0014729901
found O 0 0.00060969696
that O 0 0.00034298858
the O 0 0.00039743222
transformation O 0 0.0010566929
of O 0 0.0007933435
exencephalic B-Disease 2 0.98551744
tissue O 0 0.0020678374
was O 0 0.00018653196
not O 0 9.322537e-05
simply O 0 0.00014095525
size O 0 0.0002385756
- O 0 0.00019605231
dependent O 0 4.7482543e-05
, O 0 0.00010218325
and O 0 8.136089e-05
all O 0 7.6615026e-05
cases O 0 0.000110839865
of O 0 0.0002599685
anencephaly B-Disease 2 0.9995535
at O 0 0.00016208072
E18 O 0 0.034042895
. O 0 4.8122736e-05
5 O 0 3.578177e-05
resulted O 0 4.6607547e-05
from O 0 5.2979758e-05
embryos O 0 0.00016425937
with O 0 9.49159e-05
a O 0 0.00011374854
large O 0 0.000110249566
amount O 0 7.3049545e-05
of O 0 0.00032526927
exencephalic B-Disease 2 0.9501988
tissue O 0 0.0019948645
at O 0 0.00038576964
E13 O 0 0.057445183
. O 0 0.0005696646
5 O 0 0.00089842116
. O 0 0.0016883003

Microscopic O 0 0.0065264646
observation O 0 0.0012807741
showed O 0 0.00069367053
the O 0 0.00048999867
configuration O 0 0.0005821882
of O 0 0.0010094432
exencephaly B-Disease 0 0.9998404
at O 0 0.00048826582
E13 O 0 0.26607642
. O 0 0.00012970477
5 O 0 9.4259165e-05
, O 0 0.00013856107
frequent O 0 0.00028156658
hemorrhaging B-Disease 0 0.9741159
and O 0 0.00027418294
detachment O 0 0.6845182
of O 0 0.00014495151
the O 0 8.06887e-05
neural O 0 0.00020688925
plate O 0 0.00051654276
from O 0 6.7973415e-05
surface O 0 0.00020448583
ectoderm O 0 0.0719372
in O 0 7.8083176e-05
the O 0 0.000121807
exencephalic B-Disease 2 0.94288474
head O 0 0.003180114
at O 0 0.00013015713
E15 O 0 0.4347449
. O 0 6.415745e-05
5 O 0 5.2613683e-05
, O 0 7.027913e-05
and O 0 6.25561e-05
multiple O 0 7.441935e-05
modes O 0 7.202402e-05
of O 0 0.00011427494
reduction O 0 0.00028025958
in O 0 0.00013154595
the O 0 0.00023806162
exencephalic B-Disease 2 0.9225547
tissue O 0 0.0016655863
at O 0 0.0003492939
E18 O 0 0.011107144
. O 0 0.0005225322
5 O 0 0.000865298
. O 0 0.0016553071

From O 0 0.001978706
observations O 0 0.0016914019
of O 0 0.0012443591
the O 0 0.0009314211
vasculature O 0 0.008479645
, O 0 0.0005310187
altered O 0 0.00033921425
distribution O 0 0.00011481201
patterns O 0 0.00012970985
of O 0 0.0002847896
vessels O 0 0.0015019844
were O 0 0.00024398098
identified O 0 0.00023999075
in O 0 0.00037816248
the O 0 0.0009004677
exencephalic B-Disease 2 0.950814
head O 0 0.043990027
. O 0 0.0031421625

These O 0 0.0022212658
findings O 0 0.0017911821
suggest O 0 0.00049324235
that O 0 0.00049506285
overgrowth O 0 0.008595704
of O 0 0.0005704391
the O 0 0.00048168414
exencephalic B-Disease 2 0.9468321
neural O 0 0.0010613822
tissue O 0 0.0007652944
causes O 0 0.00017968722
the O 0 8.89301e-05
altered O 0 9.796442e-05
distribution O 0 3.154965e-05
patterns O 0 3.8809412e-05
of O 0 0.0001049547
vessels O 0 0.0010187917
, O 0 8.67453e-05
subsequent O 0 8.0328326e-05
peripheral O 0 0.0021792243
circulatory B-Disease 0 0.7609134
failure I-Disease 0 0.9088035
and O 0 0.00022104323
/ O 0 0.0004688916
or O 0 0.00012422205
hemorrhaging B-Disease 0 0.9447883
in O 0 6.887549e-05
various O 0 6.0301973e-05
parts O 0 4.5256387e-05
of O 0 8.367243e-05
the O 0 0.00013498621
exencephalic B-Disease 2 0.97338694
head O 0 0.0053510168
, O 0 0.00013750691
leading O 0 0.00012318252
to O 0 5.7447938e-05
the O 0 5.9332324e-05
multiple O 0 7.4453565e-05
modes O 0 6.993402e-05
of O 0 0.00011774998
tissue O 0 0.00036192077
reduction O 0 0.0002690194
during O 0 8.738401e-05
transformation O 0 0.0007760874
from O 0 0.00058386335
exencephaly B-Disease 0 0.99974805
to O 0 0.0033029874
anencephaly B-Disease 2 0.99942636
. O 0 0.0038319647

99mTc B-Chemical 0 0.6188062
- I-Chemical 0 0.0075245625
glucarate I-Chemical 0 0.908169
for O 0 0.00089147955
detection O 0 0.0010549437
of O 0 0.001689729
isoproterenol B-Chemical 0 0.9997756
- O 0 0.0033731817
induced O 0 0.0025804623
myocardial B-Disease 0 0.99980587
infarction I-Disease 2 0.9999738
in O 0 0.0031294117
rats O 0 0.0043083467
. O 0 0.0024862965

Infarct B-Disease 0 0.9945622
- O 0 0.005851575
avid O 0 0.0050685033
radiopharmaceuticals O 0 0.008030501
are O 0 0.00050531805
necessary O 0 0.00022385882
for O 0 0.0002285119
rapid O 0 0.0005668576
and O 0 0.00033383147
timely O 0 0.0005042179
diagnosis O 0 0.0010129092
of O 0 0.0014187524
acute O 0 0.9957664
myocardial B-Disease 0 0.99992025
infarction I-Disease 2 0.99998665
. O 0 0.00794565

The O 0 0.0017106524
animal O 0 0.0015991224
model O 0 0.00089664967
used O 0 0.00049112743
to O 0 0.00041067626
produce O 0 0.0004923902
infarction B-Disease 2 0.999889
implies O 0 0.0003833656
artery O 0 0.084169164
ligation O 0 0.0008157685
but O 0 0.00026099815
chemical O 0 0.0006575312
induction O 0 0.00026438932
can O 0 0.00015223886
be O 0 0.00017947114
easily O 0 0.0002596905
obtained O 0 0.0004279028
with O 0 0.0015051729
isoproterenol B-Chemical 0 0.9989791
. O 0 0.0032639895

A O 0 0.020981414
new O 0 0.0043646754
infarct B-Disease 0 0.99767345
- O 0 0.0034817678
avid O 0 0.0032046563
radiopharmaceutical O 0 0.005318644
based O 0 0.00036760178
on O 0 0.0003380086
glucaric B-Chemical 0 0.99964714
acid I-Chemical 0 0.9603461
was O 0 0.00041736348
prepared O 0 0.0002190319
in O 0 0.0001751607
the O 0 0.00021017347
hospital O 0 0.00042182693
radiopharmacy O 0 0.00045677507
of O 0 0.0006727474
the O 0 0.0012300243
INCMNSZ O 0 0.1392017
. O 0 0.0024640006

99mTc B-Chemical 0 0.7237598
- I-Chemical 0 0.009406394
glucarate I-Chemical 0 0.98158294
was O 0 0.0012976336
easy O 0 0.0007617075
to O 0 0.00033254907
prepare O 0 0.00032153004
, O 0 0.00026560784
stable O 0 0.000193201
for O 0 0.00010563527
96 O 0 0.00026836974
h O 0 9.0288224e-05
and O 0 0.00010306122
was O 0 9.400756e-05
used O 0 5.8755537e-05
to O 0 6.571326e-05
study O 0 0.00010116562
its O 0 0.00015890523
biodistribution O 0 0.001635258
in O 0 9.947699e-05
rats O 0 0.00020674274
with O 0 0.00037258188
isoproterenol B-Chemical 0 0.99979323
- O 0 0.0013978765
induced O 0 0.0014129545
acute O 0 0.99790883
myocardial B-Disease 0 0.9999455
infarction I-Disease 2 0.9999896
. O 0 0.0065396796

Histological O 0 0.008171338
studies O 0 0.0014871024
demonstrated O 0 0.000642043
that O 0 0.0003923665
the O 0 0.00044301228
rats O 0 0.0005777687
developed O 0 0.0005332484
an O 0 0.000703071
infarct B-Disease 0 0.99535227
18 O 0 0.0004127102
h O 0 0.00031339645
after O 0 0.00036342547
isoproterenol B-Chemical 0 0.9987219
administration O 0 0.03852861
. O 0 0.0032056097

The O 0 0.002170866
rat O 0 0.0031474961
biodistribution O 0 0.0070125186
studies O 0 0.0010473182
showed O 0 0.000688779
a O 0 0.00079102855
rapid O 0 0.0014210002
blood O 0 0.004556321
clearance O 0 0.0048223976
via O 0 0.00078130915
the O 0 0.001495767
kidneys O 0 0.04136259
. O 0 0.0033679456

Thirty O 0 0.0020620811
minutes O 0 0.00079744426
after O 0 0.00054488494
99mTc B-Chemical 0 0.17032488
- I-Chemical 0 0.0020880934
glucarate I-Chemical 0 0.9785619
administration O 0 0.0016460206
the O 0 0.00022481215
standardised O 0 0.00017443368
heart O 0 0.0078409845
uptake O 0 0.0016980004
value O 0 0.0003318903
S O 0 0.6738618
( O 0 0.00026465763
h O 0 0.00013930706
) O 0 0.00040288296
UV O 0 0.91409016
was O 0 0.00023449282
4 O 0 7.355156e-05
. O 0 4.3886448e-05
7 O 0 4.0302966e-05
in O 0 5.8698755e-05
infarcted O 0 0.0032455348
rat O 0 0.00038848253
heart O 0 0.00785681
which O 0 0.00015125322
is O 0 8.034472e-05
six O 0 4.1504456e-05
times O 0 4.6847013e-05
more O 0 0.00014883123
than O 0 0.00014730655
in O 0 0.0003165054
normal O 0 0.0012939833
rats O 0 0.0019508019
. O 0 0.001767246

ROIs O 0 0.0026767533
drawn O 0 0.0014295944
over O 0 0.0006039551
the O 0 0.0009107509
gamma O 0 0.11597467
camera O 0 0.0018159549
images O 0 0.00068076805
showed O 0 0.00050701445
a O 0 0.00065234536
ratio O 0 0.000777216
of O 0 0.0008263808
4 O 0 0.00067373796
. O 0 0.0007583629
4 O 0 0.0013138821
. O 0 0.0024148743

The O 0 0.0014789694
high O 0 0.0014435593
image O 0 0.00081928546
quality O 0 0.00043902211
suggests O 0 0.0001863254
that O 0 0.00016561187
high O 0 0.00034453542
contrast O 0 0.00028589356
images O 0 0.0002095995
can O 0 9.2754344e-05
be O 0 8.1718885e-05
obtained O 0 8.854761e-05
in O 0 8.261682e-05
humans O 0 0.00016624789
and O 0 7.7577526e-05
the O 0 6.940532e-05
96 O 0 0.00015600512
h O 0 5.132495e-05
stability O 0 9.216977e-05
makes O 0 7.094982e-05
it O 0 7.687198e-05
an O 0 8.503342e-05
ideal O 0 7.66814e-05
agent O 0 0.00041648155
to O 0 0.00010002202
detect O 0 9.088383e-05
, O 0 0.00017251167
in O 0 0.00016666342
patients O 0 0.00039268046
, O 0 0.0004607264
early O 0 0.0020480596
cardiac B-Disease 0 0.99480504
infarction I-Disease 2 0.999985
. O 0 0.00575371

Bupropion B-Chemical 0 0.99919707
( O 0 0.039098665
Zyban B-Chemical 0 0.99320024
) O 0 0.024189487
toxicity B-Disease 2 0.988941
. O 0 0.016304314

Bupropion B-Chemical 0 0.99933237
is O 0 0.0037187748
a O 0 0.0039975494
monocyclic O 0 0.99542135
antidepressant B-Chemical 1 0.9994679
structurally O 0 0.003297623
related O 0 0.0010701168
to O 0 0.0030023723
amphetamine B-Chemical 1 0.9998627
. O 0 0.0067416904

Zyban B-Chemical 0 0.99381244
, O 0 0.0025320058
a O 0 0.0014072238
sustained O 0 0.0017469174
- O 0 0.0012616153
release O 0 0.0012740823
formulation O 0 0.003947943
of O 0 0.0029225422
bupropion B-Chemical 0 0.99999845
hydrochloride I-Chemical 0 0.999943
, O 0 0.00061146676
was O 0 0.00021430725
recently O 0 0.00011438571
released O 0 0.00018166009
in O 0 0.00018806495
Ireland O 0 0.00216747
, O 0 0.0002829374
as O 0 0.0002499424
a O 0 0.00063532346
smoking O 0 0.037612066
cessation O 0 0.0017210172
aid O 0 0.002757334
. O 0 0.002287726

In O 0 0.0015668141
the O 0 0.0010567493
initial O 0 0.0007226814
6 O 0 0.00037485707
months O 0 0.00016840432
since O 0 0.00015500306
it O 0 0.0002423867
' O 0 0.0002551207
s O 0 0.00017055584
introduction O 0 0.00013008478
, O 0 0.00020045142
12 O 0 0.00014380226
overdose B-Disease 0 0.9988494
cases O 0 0.00028976914
have O 0 9.945538e-05
been O 0 9.42588e-05
reported O 0 0.00013569937
to O 0 0.00012280744
The O 0 0.00016297711
National O 0 0.00075479044
Poisons O 0 0.048668656
Information O 0 0.0012973734
Centre O 0 0.0029603958
. O 0 0.0021992233

8 O 0 0.0053482405
patients O 0 0.0053672073
developed O 0 0.0062202364
symptoms O 0 0.024353348
of O 0 0.011190402
toxicity B-Disease 2 0.99549943
. O 0 0.012178646

Common O 0 0.005110831
features O 0 0.0022133412
included O 0 0.0019306852
tachycardia B-Disease 2 0.98539746
, O 0 0.0045268117
drowsiness O 0 0.9995851
, O 0 0.0079484545
hallucinations B-Disease 0 0.99989736
and O 0 0.013392281
convulsions B-Disease 0 0.9997013
. O 0 0.007377039

Two O 0 0.0021720456
patients O 0 0.0018711578
developed O 0 0.0018090586
severe O 0 0.037232853
cardiac B-Disease 0 0.9937914
arrhythmias I-Disease 2 0.9999851
, O 0 0.00087410776
including O 0 0.00016293157
one O 0 0.0001348776
patient O 0 0.00021330954
who O 0 0.00029631853
was O 0 0.00024060273
resuscitated O 0 0.0008227613
following O 0 0.00026752567
a O 0 0.001155083
cardiac B-Disease 2 0.88829064
arrest I-Disease 2 0.98094547
. O 0 0.003753195

All O 0 0.0058140443
patients O 0 0.0065146093
recovered O 0 0.005583027
without O 0 0.0076648593
sequelae O 0 0.06886333
. O 0 0.012948598

We O 0 0.0018341306
report O 0 0.0019447911
a O 0 0.0012259491
case O 0 0.00063774834
of O 0 0.0005913639
a O 0 0.00051079754
31 O 0 0.00037605898
year O 0 0.00012722658
old O 0 0.00015878041
female O 0 0.0003431488
who O 0 0.00011907842
required O 0 3.9627626e-05
admission O 0 0.00010758412
to O 0 5.069381e-05
the O 0 6.647437e-05
Intensive O 0 0.00037848632
Care O 0 0.00025091346
Unit O 0 0.000127662
for O 0 4.5877423e-05
ventilation O 0 0.00013906498
and O 0 6.386311e-05
full O 0 6.6338354e-05
supportive O 0 0.00016182114
therapy O 0 0.0001463319
, O 0 0.00010418302
following O 0 8.650838e-05
ingestion O 0 0.0054837326
of O 0 0.00037391126
13 O 0 0.0003877309
. O 0 0.00037050524
5g O 0 0.023381367
bupropion B-Chemical 0 0.9998043
. O 0 0.0026519494

Recurrent O 0 0.014811799
seizures B-Disease 0 0.9991009
were O 0 0.0014394526
treated O 0 0.0011340929
with O 0 0.0015046943
diazepam B-Chemical 0 0.9999783
and O 0 0.00050648715
broad O 0 0.00031630544
complex O 0 0.00035207023
tachycardia B-Disease 2 0.9666746
was O 0 0.00041558844
successfully O 0 0.00041053025
treated O 0 0.0008500743
with O 0 0.0020269002
adenosine B-Chemical 0 0.9933094
. O 0 0.0031758982

Zyban B-Chemical 0 0.9851038
caused O 0 0.0036784161
significant O 0 0.0026994643
neurological B-Disease 0 0.8115717
and I-Disease 0 0.0043819994
cardiovascular I-Disease 0 0.99915695
toxicity I-Disease 2 0.9998741
in O 0 0.017723886
overdose B-Disease 0 0.999746
. O 0 0.0065504014

The O 0 0.0018327886
potential O 0 0.0019119587
toxic O 0 0.061351847
effects O 0 0.0010789355
should O 0 0.00034019022
be O 0 0.00030692708
considered O 0 0.00020599188
when O 0 0.00019921409
prescribing O 0 0.00097514136
it O 0 0.0003623841
as O 0 0.00035866376
a O 0 0.00084102113
smoking O 0 0.046921898
cessation O 0 0.0021350028
aid O 0 0.0032838008
. O 0 0.0026486972

GLEPP1 O 0 0.6206314
receptor O 0 0.11872767
tyrosine B-Chemical 0 0.78357506
phosphatase O 0 0.5100548
( O 0 0.00440796
Ptpro O 0 0.1539641
) O 0 0.0022132231
in O 0 0.0014043153
rat O 0 0.010678
PAN B-Chemical 0 0.99956006
nephrosis B-Disease 2 0.9999044
. O 0 0.0088925585

A O 0 0.033293918
marker O 0 0.010400066
of O 0 0.010687192
acute O 0 0.89765275
podocyte O 0 0.9962598
injury O 0 0.9837193
. O 0 0.014897423

Glomerular O 0 0.41246483
epithelial O 0 0.009233252
protein O 0 0.0023692416
1 O 0 0.0009894317
( O 0 0.001248289
GLEPP1 O 0 0.18335532
) O 0 0.0007640633
is O 0 0.00028982302
a O 0 0.00043704745
podocyte O 0 0.8945824
receptor O 0 0.024599299
membrane O 0 0.00077297795
protein O 0 0.0006340988
tyrosine B-Chemical 0 0.4350706
phosphatase O 0 0.05262558
located O 0 8.3127656e-05
on O 0 4.478213e-05
the O 0 8.245956e-05
apical O 0 0.00017148828
cell O 0 0.0003927806
membrane O 0 0.00029121147
of O 0 0.00022533961
visceral O 0 0.0019625719
glomerular O 0 0.9546497
epithelial O 0 0.00859227
cell O 0 0.0017099027
and O 0 0.0007097874
foot O 0 0.0073399283
processes O 0 0.0020176184
. O 0 0.0019843508

This O 0 0.0055717397
receptor O 0 0.009005373
plays O 0 0.001021079
a O 0 0.00091817
role O 0 0.00035633057
in O 0 0.00031423895
regulating O 0 0.0001621628
the O 0 0.0002420195
structure O 0 0.0003344682
and O 0 0.00032767924
function O 0 0.00047794383
of O 0 0.0011248153
podocyte O 0 0.98259866
foot O 0 0.09262264
process O 0 0.0024362886
. O 0 0.0026034317

To O 0 0.0019900773
better O 0 0.0017556036
understand O 0 0.00084008725
the O 0 0.0005901308
utility O 0 0.00047224408
of O 0 0.00074616267
GLEPP1 O 0 0.18747026
as O 0 0.00027156365
a O 0 0.00027306197
marker O 0 0.00031238195
of O 0 0.0004513293
glomerular B-Disease 0 0.9998325
injury I-Disease 0 0.9948461
, O 0 0.00026979743
the O 0 8.415519e-05
amount O 0 4.2532116e-05
and O 0 5.7631758e-05
distribution O 0 3.4540644e-05
of O 0 0.00013373794
GLEPP1 O 0 0.17155169
protein O 0 0.00023307784
and O 0 9.3952454e-05
mRNA O 0 0.00013593832
were O 0 6.1953404e-05
examined O 0 3.998621e-05
by O 0 7.885472e-05
immunohistochemistry O 0 0.0003097352
, O 0 0.00010133681
Western O 0 0.00024497628
blot O 0 0.000284826
and O 0 0.0001560725
RNase O 0 0.27434304
protection O 0 0.0007197095
assay O 0 0.00046873002
in O 0 0.00010025512
a O 0 0.00015571428
model O 0 0.00019067586
of O 0 0.00047162193
podocyte O 0 0.9847322
injury O 0 0.6147786
in O 0 0.0007062935
the O 0 0.0009397067
rat O 0 0.003547162
. O 0 0.0020047524

Puromycin B-Chemical 0 0.9988153
aminonucleoside I-Chemical 0 0.9999523
nephrosis B-Disease 2 0.9999654
was O 0 0.002790547
induced O 0 0.0007331137
by O 0 0.00033022952
single O 0 0.0002113837
intraperitoneal O 0 0.00063856575
injection O 0 0.00021150144
of O 0 0.00031261196
puromycin B-Chemical 0 0.7006795
aminonucleoside I-Chemical 0 0.9999708
( O 0 0.003417487
PAN B-Chemical 0 0.9996867
, O 0 0.00042423766
20 O 0 0.00030066192
mg O 0 0.006682544
/ O 0 0.0025095814
100g O 0 0.6603271
BW O 0 0.13397141
) O 0 0.0029915443
. O 0 0.0024050358

Tissues O 0 0.004693458
were O 0 0.0013671278
analyzed O 0 0.0007405203
at O 0 0.00048696646
0 O 0 0.0005248499
, O 0 0.0005146624
5 O 0 0.00029141898
, O 0 0.00034432136
7 O 0 0.0001973643
, O 0 0.00025955043
11 O 0 0.00020800324
, O 0 0.000195062
21 O 0 0.00015476426
, O 0 0.00013530283
45 O 0 9.141785e-05
, O 0 9.7211196e-05
80 O 0 0.000109773304
and O 0 8.2005456e-05
126 O 0 0.00019658598
days O 0 3.0308162e-05
after O 0 3.9083923e-05
PAN B-Chemical 0 0.9956958
injection O 0 0.00017893325
so O 0 7.132999e-05
as O 0 5.0848106e-05
to O 0 4.0917243e-05
include O 0 3.566101e-05
both O 0 5.2463773e-05
the O 0 7.3873496e-05
acute O 0 0.0287886
phase O 0 0.0004703657
of O 0 0.0004331733
proteinuria B-Disease 0 0.99999285
associated O 0 0.00018393464
with O 0 0.00019612485
foot O 0 0.0019018033
process O 0 0.000103090024
effacement O 0 0.009630759
( O 0 0.00010877465
days O 0 2.7517683e-05
5 O 0 4.7754544e-05
- O 0 0.00012565487
11 O 0 7.365572e-05
) O 0 9.350279e-05
and O 0 5.9293696e-05
the O 0 7.663695e-05
chronic O 0 0.0055932705
phase O 0 0.00041989717
of O 0 0.00045822377
proteinuria B-Disease 0 0.9999906
associated O 0 0.0004239332
with O 0 0.0013565051
glomerulosclerosis B-Disease 2 0.99999535
( O 0 0.00070201885
days O 0 0.000127718
45 O 0 0.00028537938
- O 0 0.000815861
126 O 0 0.002275499
) O 0 0.0019856242
. O 0 0.0019963116

At O 0 0.0009608626
day O 0 0.0010526108
5 O 0 0.00085243786
, O 0 0.0010714082
GLEPP1 O 0 0.042039867
protein O 0 0.000880032
and O 0 0.00038986484
mRNA O 0 0.0004114531
were O 0 0.00016717655
reduced O 0 0.00018232332
from O 0 8.628577e-05
the O 0 9.6453776e-05
normal O 0 0.00023204942
range O 0 0.00013480471
( O 0 0.00020217494
265 O 0 0.0010820029
. O 0 7.2125404e-05
2 O 0 8.256823e-05
+ O 0 0.0002065069
/ O 0 0.00038110986
- O 0 0.00024340476
79 O 0 0.00016573066
. O 0 5.2047024e-05
6 O 0 4.4781358e-05
x O 0 0.00014543773
10 O 0 8.1134036e-05
( O 0 0.0001231179
6 O 0 6.13053e-05
) O 0 0.00016837943
moles O 0 0.0036642167
/ O 0 0.00038358182
glomerulus O 0 0.0019311944
and O 0 0.0001263867
100 O 0 0.00027871356
% O 0 0.00012425463
) O 0 0.0001243082
to O 0 5.67158e-05
15 O 0 5.158083e-05
% O 0 6.980331e-05
of O 0 9.864648e-05
normal O 0 0.0002824587
( O 0 0.00016777795
41 O 0 0.00017367888
. O 0 5.6297005e-05
8 O 0 6.949904e-05
+ O 0 0.00020210321
/ O 0 0.0003967885
- O 0 0.00023516273
4 O 0 6.910878e-05
. O 0 5.102755e-05
8 O 0 6.0024973e-05
x O 0 0.00016793032
10 O 0 9.625558e-05
( O 0 0.00014982167
6 O 0 8.211955e-05
) O 0 0.00023762939
moles O 0 0.004686958
/ O 0 0.0007072324
glomerulus O 0 0.004874083
, O 0 0.00038414428
p O 0 0.00030423136
< O 0 0.00029382628
0 O 0 0.00036040653
. O 0 0.00054341473
005 O 0 0.0057928627
) O 0 0.0024867414
. O 0 0.002493156

This O 0 0.0031595055
occurred O 0 0.001140865
in O 0 0.00067353353
association O 0 0.00032515728
with O 0 0.00038200262
an O 0 0.00032062977
increase O 0 0.00020796714
in O 0 0.00017267605
urinary O 0 0.016396433
protein O 0 0.0003932272
content O 0 0.00023809701
from O 0 0.00010041979
1 O 0 8.765098e-05
. O 0 5.6149773e-05
8 O 0 7.278545e-05
+ O 0 0.00021303883
/ O 0 0.0004108632
- O 0 0.0002372685
1 O 0 7.765998e-05
to O 0 7.50193e-05
99 O 0 0.0002690489
. O 0 6.2876075e-05
0 O 0 8.527613e-05
+ O 0 0.00021577117
/ O 0 0.00037970027
- O 0 0.00026139212
61 O 0 0.00022945661
mg O 0 0.0016697636
/ O 0 0.00041146722
day O 0 0.0001251814
( O 0 0.00029192364
p O 0 0.00025812944
< O 0 0.00028170084
0 O 0 0.0003598946
. O 0 0.00055393163
001 O 0 0.007492915
) O 0 0.0026167857
. O 0 0.0025979164

In O 0 0.0025011138
contrast O 0 0.0028052907
, O 0 0.0022508402
podocalyxin O 0 0.026021002
did O 0 0.0011114151
not O 0 0.0006280946
change O 0 0.00068352453
significantly O 0 0.0008398848
at O 0 0.0006259188
this O 0 0.0013217239
time O 0 0.00137191
. O 0 0.0028095732

By O 0 0.0026608924
day O 0 0.0016123719
11 O 0 0.001560656
, O 0 0.0015042687
GLEPP1 O 0 0.049308646
protein O 0 0.0012366623
and O 0 0.0006336198
mRNA O 0 0.00075229787
had O 0 0.00042652388
begun O 0 0.00053768104
to O 0 0.0004421268
return O 0 0.00080976635
towards O 0 0.0009134732
baseline O 0 0.00164718
. O 0 0.0025175102

By O 0 0.0022461165
day O 0 0.0012775077
45 O 0 0.0011662717
- O 0 0.001483971
126 O 0 0.0013629112
, O 0 0.00040800133
at O 0 0.00016306245
a O 0 0.00020201538
time O 0 8.48637e-05
when O 0 0.000115321775
glomerular O 0 0.9424335
scarring O 0 0.9230956
was O 0 0.00023957605
present O 0 0.000112164445
, O 0 0.00022703903
GLEPP1 O 0 0.23097825
was O 0 0.00012307963
absent O 0 7.506538e-05
from O 0 8.524206e-05
glomerulosclerotic O 0 0.5390219
areas O 0 9.874813e-05
although O 0 5.0237537e-05
the O 0 5.656726e-05
total O 0 0.00010461018
glomerular O 0 0.76355976
content O 0 0.00030479452
of O 0 0.00033827242
GLEPP1 O 0 0.25346997
was O 0 0.00023086525
not O 0 0.00016929627
different O 0 0.0002017882
from O 0 0.0004724282
normal O 0 0.002072706
. O 0 0.0017998915

We O 0 0.0016960261
conclude O 0 0.0011054849
that O 0 0.0011643249
GLEPP1 O 0 0.20179044
expression O 0 0.0012946343
, O 0 0.00077146303
unlike O 0 0.00045355826
podocalyxin O 0 0.05578847
, O 0 0.0007118826
reflects O 0 0.0005305993
podocyte O 0 0.97819215
injury O 0 0.8095646
induced O 0 0.0038553746
by O 0 0.0050165043
PAN B-Chemical 0 0.9992692
. O 0 0.0049472554

GLEPP1 O 0 0.18045148
expression O 0 0.0037394417
may O 0 0.0018822914
be O 0 0.0014062827
a O 0 0.0014885262
useful O 0 0.0013015256
marker O 0 0.0022869
of O 0 0.003592373
podocyte O 0 0.99100024
injury O 0 0.95196265
. O 0 0.007126471

Antithymocyte B-Chemical 0 0.60561115
globulin I-Chemical 0 0.9679119
in O 0 0.0015250259
the O 0 0.00086778536
treatment O 0 0.00082135334
of O 0 0.0018637779
D B-Chemical 0 0.99530894
- I-Chemical 0 0.05780475
penicillamine I-Chemical 1 0.99999297
- O 0 0.020302374
induced O 0 0.020292286
aplastic B-Disease 0 0.999962
anemia I-Disease 0 0.9999838
. O 0 0.014775165

A O 0 0.01330515
patient O 0 0.00162259
who O 0 0.0011430085
received O 0 0.0005679885
antithymocyte B-Chemical 0 0.9782537
globulin I-Chemical 0 0.9981639
therapy O 0 0.0021676673
for O 0 0.00074711035
aplastic B-Disease 0 0.9999802
anemia I-Disease 0 0.99999607
due O 0 0.0005323079
to O 0 0.0007390639
D B-Chemical 0 0.9955616
- I-Chemical 0 0.020386877
penicillamine I-Chemical 1 0.9999913
therapy O 0 0.003730538
is O 0 0.0012049233
described O 0 0.001412392
. O 0 0.0021387402

Bone O 0 0.015161342
marrow O 0 0.052105665
recovery O 0 0.0022757654
and O 0 0.0007761884
peripheral O 0 0.002085619
blood O 0 0.002026144
recovery O 0 0.00052155805
were O 0 0.00015114452
complete O 0 0.00010690968
1 O 0 7.204601e-05
month O 0 3.9538016e-05
and O 0 6.62016e-05
3 O 0 5.0798048e-05
months O 0 3.0318712e-05
, O 0 8.664279e-05
respectively O 0 0.00019055443
, O 0 8.20398e-05
after O 0 2.803192e-05
treatment O 0 7.742099e-05
, O 0 9.183954e-05
and O 0 9.215746e-05
blood O 0 0.0011283406
transfusion O 0 0.0008651863
or O 0 6.46441e-05
other O 0 6.374508e-05
therapies O 0 0.0001443131
were O 0 5.7473084e-05
not O 0 4.0920364e-05
necessary O 0 3.24929e-05
in O 0 5.7366262e-05
a O 0 9.910982e-05
follow O 0 5.730939e-05
- O 0 0.00013681439
up O 0 8.012192e-05
period O 0 5.521824e-05
of O 0 0.00016592356
more O 0 0.00032406705
than O 0 0.0003098935
2 O 0 0.0005511062
years O 0 0.000919774
. O 0 0.0015975869

Use O 0 0.0048795305
of O 0 0.0027257951
antithymocyte B-Chemical 0 0.9899738
globulin I-Chemical 0 0.9963084
may O 0 0.0008063721
be O 0 0.0003164529
the O 0 0.00017680987
optimal O 0 0.00011239185
treatment O 0 0.00025609872
of O 0 0.0008287378
D B-Chemical 0 0.99541086
- I-Chemical 0 0.043387335
penicillamine I-Chemical 1 0.99999547
- O 0 0.015168506
induced O 0 0.01616469
aplastic B-Disease 0 0.99996877
anemia I-Disease 0 0.9999863
. O 0 0.012574098

Metamizol B-Chemical 0 0.996653
potentiates O 0 0.096773505
morphine B-Chemical 0 0.9999374
antinociception O 0 0.9998703
but O 0 0.0022298726
not O 0 0.0013445305
constipation B-Disease 0 0.99805415
after O 0 0.0006819524
chronic O 0 0.18166026
treatment O 0 0.0033985483
. O 0 0.0032615704

This O 0 0.00314793
work O 0 0.001379283
evaluates O 0 0.00076855987
the O 0 0.00076533493
antinociceptive O 0 0.9071429
and O 0 0.0008642594
constipating B-Disease 0 0.91112
effects O 0 0.0002879567
of O 0 0.00021826163
the O 0 0.00012858635
combination O 0 0.00017602598
of O 0 0.00017240447
3 O 0 7.647765e-05
. O 0 4.716186e-05
2 O 0 5.95035e-05
mg O 0 0.0008195072
/ O 0 0.00028782059
kg O 0 0.00021309225
s O 0 8.931263e-05
. O 0 6.0895738e-05
c O 0 0.00060697773
. O 0 9.291687e-05
morphine B-Chemical 0 0.999228
with O 0 0.00024688942
177 O 0 0.0008394895
. O 0 4.711736e-05
8 O 0 4.959904e-05
mg O 0 0.000676989
/ O 0 0.00024580714
kg O 0 0.00018708715
s O 0 8.151388e-05
. O 0 5.7933714e-05
c O 0 0.0006956374
. O 0 0.00011813168
metamizol B-Chemical 0 0.99999034
in O 0 0.00015510285
acutely O 0 0.0011437888
and O 0 0.000117165764
chronically O 0 0.0005490363
treated O 0 0.00020346967
( O 0 0.00013139189
once O 0 5.4624896e-05
a O 0 0.000104186794
day O 0 6.515274e-05
for O 0 9.353614e-05
12 O 0 0.0001264706
days O 0 0.00018383504
) O 0 0.0008268538
rats O 0 0.0016635489
. O 0 0.0018893245

On O 0 0.0024240608
the O 0 0.0015209884
13th O 0 0.0020459127
day O 0 0.0006085609
, O 0 0.0008018425
antinociceptive O 0 0.63320696
effects O 0 0.00050223334
were O 0 0.00023940571
assessed O 0 0.00010899499
using O 0 8.5905405e-05
a O 0 0.00012933328
model O 0 0.00012952977
of O 0 0.00024620636
inflammatory O 0 0.29685548
nociception O 0 0.83682495
, O 0 0.0006680691
pain B-Disease 0 0.7829278
- O 0 0.00036718624
induced O 0 0.00013268251
functional O 0 0.00016755125
impairment O 0 0.054528225
model O 0 0.00017183955
, O 0 0.000115290335
and O 0 9.2218994e-05
the O 0 0.00014737682
charcoal B-Chemical 0 0.9769338
meal O 0 0.0052774176
test O 0 0.00023390733
was O 0 0.0001340014
used O 0 0.000100754725
to O 0 0.00013266872
evaluate O 0 0.00014103901
the O 0 0.0004827386
intestinal O 0 0.010119582
transit O 0 0.0055446248
. O 0 0.0020549882

Simultaneous O 0 0.003981723
administration O 0 0.0043603303
of O 0 0.0025913871
morphine B-Chemical 0 0.99987376
with O 0 0.008852993
metamizol B-Chemical 0 0.9999957
resulted O 0 0.0005035088
in O 0 0.00018358386
a O 0 0.00023551614
markedly O 0 0.0013636084
antinociceptive O 0 0.98169106
potentiation O 0 0.760348
and O 0 0.00017491986
an O 0 0.000117594
increasing O 0 8.8932735e-05
of O 0 8.209112e-05
the O 0 5.1679748e-05
duration O 0 2.5428424e-05
of O 0 6.660947e-05
action O 0 8.689483e-05
after O 0 2.7302814e-05
a O 0 0.00010601257
single O 0 0.00012159232
( O 0 0.0002596163
298 O 0 0.10805078
+ O 0 0.00040652562
/ O 0 0.0005100858
- O 0 0.00022010252
7 O 0 6.279362e-05
vs O 0 9.073021e-05
. O 0 5.8620266e-05
139 O 0 0.00020796
+ O 0 0.0002208926
/ O 0 0.00034020044
- O 0 0.00018042132
36 O 0 7.641037e-05
units O 0 7.849267e-05
area O 0 0.00013714642
( O 0 0.00036308623
ua O 0 0.97960836
) O 0 0.0005860578
; O 0 0.00033100173
P O 0 0.0036800422
< O 0 0.000111280206
0 O 0 8.547877e-05
. O 0 7.821889e-05
001 O 0 0.0015012944
) O 0 0.00012926977
and O 0 6.602608e-05
repeated O 0 5.0308292e-05
administration O 0 0.00042170673
( O 0 0.00025128646
280 O 0 0.005435165
+ O 0 0.00041172619
/ O 0 0.00053176866
- O 0 0.00026609958
17 O 0 0.00015005573
vs O 0 0.000120324046
. O 0 7.575168e-05
131 O 0 0.00033307515
+ O 0 0.00031117484
/ O 0 0.00057077466
- O 0 0.00047346056
22 O 0 0.0005022462
ua O 0 0.9387672
; O 0 0.00074570987
P O 0 0.0041241366
< O 0 0.00039566046
0 O 0 0.00042091115
. O 0 0.0006026286
001 O 0 0.0077925394
) O 0 0.0027319463
. O 0 0.0027039049

Antinociceptive O 0 0.96860605
effect O 0 0.0021233885
of O 0 0.0036409358
morphine B-Chemical 0 0.99984086
was O 0 0.0010282119
reduced O 0 0.00062634196
in O 0 0.00024967967
chronically O 0 0.000999126
treated O 0 0.00036640716
rats O 0 0.00034626148
( O 0 0.0002280457
39 O 0 0.00022044171
+ O 0 0.00029165132
/ O 0 0.00045724248
- O 0 0.00023894462
10 O 0 9.385654e-05
vs O 0 0.00011369345
. O 0 6.1601175e-05
18 O 0 8.597999e-05
+ O 0 0.00020883868
/ O 0 0.00038484455
- O 0 0.00022903935
5 O 0 7.5248136e-05
au O 0 0.00019969372
) O 0 0.0001366234
while O 0 6.675184e-05
the O 0 8.097435e-05
combination O 0 0.0002018981
- O 0 0.00034085673
induced O 0 0.00038563236
antinociception O 0 0.9998379
was O 0 0.00018542363
remained O 0 0.00010761851
similar O 0 4.0221872e-05
as O 0 5.5921813e-05
an O 0 0.00013287533
acute O 0 0.09098767
treatment O 0 0.00027322888
( O 0 0.00042630392
298 O 0 0.20952293
+ O 0 0.0005028
/ O 0 0.00059996254
- O 0 0.00027327266
7 O 0 9.302868e-05
vs O 0 0.0001526332
. O 0 0.00013105528
280 O 0 0.0023363759
+ O 0 0.00070925825
/ O 0 0.0011841841
- O 0 0.0010036047
17 O 0 0.0010156372
au O 0 0.002108365
) O 0 0.0026071128
. O 0 0.0025237615

Acute O 0 0.23517653
antinociceptive O 0 0.92555445
effects O 0 0.0013917444
of O 0 0.0008115415
the O 0 0.00042349458
combination O 0 0.00048068195
were O 0 0.00026512792
partially O 0 0.00035869543
prevented O 0 0.00076103496
by O 0 0.00024156606
3 O 0 0.00011873882
. O 0 8.285351e-05
2 O 0 0.00011645224
mg O 0 0.0015266546
/ O 0 0.0009139616
kg O 0 0.0019751086
naloxone B-Chemical 0 0.99980885
s O 0 0.0010721486
. O 0 0.00084118545
c O 0 0.005240395
. O 0 0.0024551465

( O 0 0.00990675
P O 0 0.026028752
< O 0 0.0017712935
0 O 0 0.0010949696
. O 0 0.00080882246
05 O 0 0.0063951407
) O 0 0.0008827241
, O 0 0.00040012028
suggesting O 0 0.00015976591
the O 0 0.00018638866
partial O 0 0.00032195915
involvement O 0 0.00030347295
of O 0 0.00025607232
the O 0 0.00026678012
opioidergic O 0 0.1215241
system O 0 0.00032120096
in O 0 0.0002858996
the O 0 0.0004952724
synergism O 0 0.0057617975
observed O 0 0.0016784492
. O 0 0.0024246846

In O 0 0.0015837823
independent O 0 0.0009461642
groups O 0 0.0011457321
, O 0 0.0013801856
morphine B-Chemical 0 0.9995129
inhibited O 0 0.001403852
the O 0 0.00043290516
intestinal O 0 0.007817698
transit O 0 0.0010147513
in O 0 0.0001376826
48 O 0 0.000111627414
+ O 0 0.0003006966
/ O 0 0.00050424034
- O 0 0.00025891303
4 O 0 7.313443e-05
% O 0 8.9404304e-05
and O 0 9.355434e-05
38 O 0 0.00015882403
+ O 0 0.00025825747
/ O 0 0.0004342505
- O 0 0.00021544636
4 O 0 5.571401e-05
% O 0 6.251591e-05
after O 0 3.2229567e-05
acute O 0 0.019718362
and O 0 0.0002222173
chronic O 0 0.098187335
treatment O 0 0.0002555587
, O 0 0.00020893129
respectively O 0 0.00040093696
, O 0 0.000113075
suggesting O 0 4.751062e-05
that O 0 7.58139e-05
tolerance O 0 0.011873013
did O 0 0.00017652467
not O 0 0.00013166228
develop O 0 0.00022372651
to O 0 0.00024099438
the O 0 0.00059339585
constipating B-Disease 0 0.85407984
effects O 0 0.002481408
. O 0 0.0023606801

The O 0 0.0016361395
combination O 0 0.0017383925
inhibited O 0 0.002099915
intestinal O 0 0.012308464
transit O 0 0.0017456156
similar O 0 0.00016674164
to O 0 0.00013108128
that O 0 9.572568e-05
produced O 0 0.00015659932
by O 0 0.0002915279
morphine B-Chemical 0 0.9997404
regardless O 0 5.4122247e-05
of O 0 9.252827e-05
the O 0 5.5529737e-05
time O 0 2.984091e-05
of O 0 8.205881e-05
treatment O 0 8.914193e-05
, O 0 9.2074544e-05
suggesting O 0 4.9719656e-05
that O 0 0.00015042347
metamizol B-Chemical 0 0.99999607
did O 0 0.00032539023
not O 0 0.00020099919
potentiate O 0 0.0009989653
morphine B-Chemical 0 0.999923
- O 0 0.0035202003
induced O 0 0.0037972939
constipation B-Disease 0 0.9994585
. O 0 0.003205386

These O 0 0.0021041618
findings O 0 0.0018403481
show O 0 0.0006473942
a O 0 0.00064053637
significant O 0 0.00033335027
interaction O 0 0.00023154484
between O 0 0.0002403134
morphine B-Chemical 0 0.99992144
and O 0 0.0022350682
metamizol B-Chemical 0 0.9999976
in O 0 0.0002961355
chronically O 0 0.0013211638
treated O 0 0.00026866596
rats O 0 0.0002103948
, O 0 8.9917135e-05
suggesting O 0 3.467427e-05
that O 0 4.075042e-05
this O 0 9.48097e-05
combination O 0 0.00014464553
could O 0 7.616426e-05
be O 0 7.239304e-05
useful O 0 6.831543e-05
for O 0 7.402554e-05
the O 0 0.00014700937
treatment O 0 0.00028154513
of O 0 0.0009603524
chronic B-Disease 0 0.730102
pain I-Disease 0 0.95441467
. O 0 0.0030603483

Ifosfamide B-Chemical 1 0.9983273
encephalopathy B-Disease 2 0.99939346
presenting O 0 0.105133116
with O 0 0.029560681
asterixis B-Disease 0 0.9995664
. O 0 0.016047373

CNS O 0 0.059164956
toxic O 0 0.05524491
effects O 0 0.0010943209
of O 0 0.00072668836
the O 0 0.00050024
antineoplastic O 0 0.112781525
agent O 0 0.057180602
ifosfamide B-Chemical 0 0.99991274
( O 0 0.007075226
IFX B-Chemical 0 0.99962234
) O 0 0.0004964011
are O 0 0.00012354246
frequent O 0 0.0001366294
and O 0 8.799602e-05
include O 0 6.2228624e-05
a O 0 0.00011871889
variety O 0 0.00013109103
of O 0 0.0003112205
neurological O 0 0.9978149
symptoms O 0 0.32907444
that O 0 0.00021062925
can O 0 0.00024919785
limit O 0 0.0010882673
drug O 0 0.019007346
use O 0 0.0014996821
. O 0 0.0019292764

We O 0 0.0018909744
report O 0 0.0020190445
a O 0 0.001290917
case O 0 0.0006874363
of O 0 0.00067540054
a O 0 0.0006750984
51 O 0 0.00070974074
- O 0 0.0005402569
year O 0 0.00015387489
- O 0 0.00029750913
old O 0 0.00018740103
man O 0 0.0019830312
who O 0 0.0002866611
developed O 0 0.00033113905
severe O 0 0.011275068
, O 0 0.00034049098
disabling O 0 0.49451536
negative O 0 0.00084606087
myoclonus B-Disease 0 0.9998716
of O 0 0.00022943014
the O 0 9.514462e-05
upper O 0 0.0002057275
and O 0 9.382782e-05
lower O 0 0.00017289701
extremities O 0 0.0039402135
after O 0 4.0784635e-05
the O 0 0.00011412903
infusion O 0 0.0004473723
of O 0 0.00070088205
ifosfamide B-Chemical 0 0.9983798
for O 0 0.0015717886
plasmacytoma B-Disease 0 0.9938393
. O 0 0.0032707695

He O 0 0.006525123
was O 0 0.0022544619
awake O 0 0.0022085235
, O 0 0.00085850374
revealed O 0 0.00040560222
no O 0 0.0002071271
changes O 0 0.0003055417
of O 0 0.0003255373
mental O 0 0.0015907261
status O 0 0.0001672987
and O 0 0.00013409446
at O 0 8.6897315e-05
rest O 0 0.00013953053
there O 0 9.376744e-05
were O 0 0.00016907783
no O 0 0.00016822202
further O 0 0.00059907115
motor O 0 0.004590128
symptoms O 0 0.031168833
. O 0 0.0024260795

Cranial O 0 0.022662418
magnetic O 0 0.0059791454
resonance O 0 0.0080223465
imaging O 0 0.0012424226
and O 0 0.0004779509
extensive O 0 0.00035947605
laboratory O 0 0.00040218377
studies O 0 0.00019977408
failed O 0 0.00018666005
to O 0 0.00013768207
reveal O 0 0.00014726135
structural B-Disease 0 0.00032866854
lesions I-Disease 0 0.0017421742
of I-Disease 0 0.00028387876
the I-Disease 0 0.0002820693
brain I-Disease 0 0.002271186
and O 0 0.00090917206
metabolic B-Disease 0 0.61457634
abnormalities I-Disease 0 0.80605364
. O 0 0.0028895426

An O 0 0.0030135033
electroencephalogram O 0 0.012252916
showed O 0 0.0009839466
continuous O 0 0.0005077329
, O 0 0.0005255528
generalized O 0 0.00090136257
irregular O 0 0.00057728984
slowing O 0 0.0016320599
with O 0 0.0003286839
admixed O 0 0.00075213483
periodic O 0 0.00048613673
triphasic O 0 0.06074125
waves O 0 0.0015502173
indicating O 0 0.00060933136
symptomatic O 0 0.04096162
encephalopathy B-Disease 2 0.99976116
. O 0 0.004202302

The O 0 0.0017375214
administration O 0 0.0036873133
of O 0 0.0025080866
ifosfamide B-Chemical 0 0.9988965
was O 0 0.0011732428
discontinued O 0 0.0014363055
and O 0 0.00027249474
within O 0 9.9530225e-05
12 O 0 0.00013875822
h O 0 0.00024848987
the O 0 0.00067687285
asterixis B-Disease 0 0.99975604
resolved O 0 0.004757308
completely O 0 0.0032649843
. O 0 0.0027597412

In O 0 0.0016699543
the O 0 0.0012659747
patient O 0 0.0009778426
described O 0 0.00048428995
, O 0 0.00041393394
the O 0 0.00023063378
presence O 0 0.00022549352
of O 0 0.0005465832
asterixis B-Disease 0 0.9999001
during O 0 0.000102923244
infusion O 0 0.00038745947
of O 0 0.0003163594
ifosfamide B-Chemical 0 0.99917173
, O 0 0.00017905033
normal O 0 0.00022527044
laboratory O 0 0.00013218711
findings O 0 0.000105972234
and O 0 6.062549e-05
imaging O 0 0.0001091766
studies O 0 5.118141e-05
and O 0 4.5381763e-05
the O 0 4.736984e-05
resolution O 0 0.00040231837
of O 0 0.00011594111
symptoms O 0 0.0006527997
following O 0 3.5146346e-05
the O 0 5.8293266e-05
discontinuation O 0 0.0014230263
of O 0 8.447849e-05
the O 0 7.2443654e-05
drug O 0 0.0009891555
suggest O 0 2.8625022e-05
that O 0 5.5739085e-05
negative O 0 0.0004102396
myoclonus B-Disease 0 0.9998405
is O 0 0.00023118439
associated O 0 0.00014440491
with O 0 0.0002209185
the O 0 0.0002526177
use O 0 0.00041911576
of O 0 0.0017711889
IFX B-Chemical 0 0.9960329
. O 0 0.0027509534

Antagonism O 0 0.06215887
between O 0 0.0014657952
interleukin O 0 0.30550906
3 O 0 0.0006512012
and O 0 0.00060548936
erythropoietin O 0 0.79456246
in O 0 0.00029809485
mice O 0 0.00017031224
with O 0 0.00057793444
azidothymidine B-Chemical 0 0.9992131
- O 0 0.0015470956
induced O 0 0.0013021481
anemia B-Disease 0 0.9999304
and O 0 0.00068470323
in O 0 0.0004551206
bone O 0 0.059675884
marrow O 0 0.9015941
endothelial O 0 0.97763777
cells O 0 0.004924433
. O 0 0.00261219

Azidothymidine B-Chemical 0 0.9926432
( O 0 0.011532346
AZT B-Chemical 1 0.9989581
) O 0 0.004394637
- O 0 0.0022103859
induced O 0 0.0019599355
anemia B-Disease 0 0.99989307
in O 0 0.0005233657
mice O 0 0.00016552788
can O 0 0.00011518331
be O 0 0.00011177111
reversed O 0 0.0002560975
by O 0 0.00010563165
the O 0 9.682284e-05
administration O 0 0.00053121615
of O 0 0.0004477354
IGF O 0 0.9988813
- O 0 0.0023826011
IL O 0 0.19855891
- O 0 0.0003827512
3 O 0 7.387216e-05
( O 0 9.4426774e-05
fusion O 0 9.338037e-05
protein O 0 0.00016945129
of O 0 0.00024928173
insulin O 0 0.6709477
- O 0 0.00030316148
like O 0 8.128885e-05
growth O 0 0.00093789306
factor O 0 0.0011749514
II O 0 0.019818302
( O 0 0.0005905469
IGF O 0 0.9846519
II O 0 0.032574493
) O 0 0.000672175
and O 0 0.00057614973
interleukin O 0 0.39998975
3 O 0 0.0010760132
) O 0 0.002184095
. O 0 0.0021839568

Although O 0 0.0028233011
interleukin O 0 0.35445467
3 O 0 0.0015576674
( O 0 0.0019285613
IL O 0 0.052452784
- O 0 0.001215774
3 O 0 0.0003083792
) O 0 0.00042310436
and O 0 0.0003449209
erythropoietin O 0 0.97184384
( O 0 0.0016721784
EPO O 0 0.99967384
) O 0 0.000615483
are O 0 0.00012168219
known O 0 0.000117337404
to O 0 6.752769e-05
act O 0 6.408016e-05
synergistically O 0 0.00018549299
on O 0 8.035009e-05
hematopoietic O 0 0.5511217
cell O 0 0.0050619124
proliferation O 0 0.30667558
in O 0 0.000111651374
vitro O 0 0.00017386314
, O 0 0.00010585691
injection O 0 0.00011365886
of O 0 0.00028424762
IGF O 0 0.9980877
- O 0 0.0015884792
IL O 0 0.1378394
- O 0 0.0002972987
3 O 0 6.281506e-05
and O 0 0.00012735877
EPO O 0 0.9980652
in O 0 0.00040091484
AZT B-Chemical 1 0.9996755
- O 0 0.00048274093
treated O 0 0.0001522068
mice O 0 4.7426467e-05
resulted O 0 6.888915e-05
in O 0 6.2626415e-05
a O 0 9.940531e-05
reduction O 0 0.00022267926
of O 0 0.00018007726
red O 0 0.0018307394
cells O 0 0.00014489927
and O 0 6.8413414e-05
an O 0 7.661313e-05
increase O 0 6.776611e-05
of O 0 0.00016370164
plasma O 0 0.05747882
EPO O 0 0.99959105
levels O 0 0.00015685368
as O 0 6.897657e-05
compared O 0 3.8378912e-05
to O 0 4.9028848e-05
animals O 0 5.5767054e-05
treated O 0 0.0001646131
with O 0 0.00037533374
IGF O 0 0.99757725
- O 0 0.0022624591
IL O 0 0.12639213
- O 0 0.0007161538
3 O 0 0.0002676897
or O 0 0.0005730535
EPO O 0 0.9936604
alone O 0 0.0028436058
. O 0 0.0026561497

We O 0 0.001647001
tested O 0 0.0012086176
the O 0 0.0008354608
hypothesis O 0 0.00069097424
that O 0 0.00028858552
the O 0 0.00031584225
antagonistic O 0 0.0005702347
effect O 0 0.0002982094
of O 0 0.0007631664
IL O 0 0.32953092
- O 0 0.00067687215
3 O 0 0.00013636946
and O 0 0.00024618144
EPO O 0 0.99623954
on O 0 0.000256354
erythroid O 0 0.9945024
cells O 0 0.0006369471
may O 0 0.00023022514
be O 0 0.00023816696
mediated O 0 0.0002532416
by O 0 0.00082326407
endothelial O 0 0.71436524
cells O 0 0.0036686657
. O 0 0.0025580025

Bovine O 0 0.020831048
liver O 0 0.9510424
erythroid O 0 0.9980427
cells O 0 0.0021402177
were O 0 0.0004884507
cultured O 0 0.00034427454
on O 0 0.00013101981
monolayers O 0 0.0003609417
of O 0 0.00021155611
human O 0 0.0002642734
bone O 0 0.01919914
marrow O 0 0.7800808
endothelial O 0 0.9357751
cells O 0 0.00039721295
previously O 0 0.00013968322
treated O 0 0.00027268135
with O 0 0.000548255
EPO O 0 0.99950194
and O 0 0.0013695563
IGF O 0 0.99826294
- O 0 0.0045478297
IL O 0 0.14816606
- O 0 0.0022950713
3 O 0 0.0012328569
. O 0 0.0019353192

There O 0 0.002781983
was O 0 0.0017594701
a O 0 0.0011506376
significant O 0 0.00065092754
reduction O 0 0.0010369824
of O 0 0.00089167326
thymidine B-Chemical 0 0.4845614
incorporation O 0 0.00084259495
into O 0 8.402704e-05
both O 0 0.00022938529
erythroid O 0 0.992397
and O 0 0.00042669915
endothelial O 0 0.69609493
cells O 0 0.0002763578
in O 0 9.636781e-05
cultures O 0 0.00015300086
pre O 0 0.00030550413
- O 0 0.0002789119
treated O 0 0.00026045874
with O 0 0.0005442506
IGF O 0 0.99743086
- O 0 0.0027769185
IL O 0 0.1204032
- O 0 0.0010936809
3 O 0 0.0004951077
and O 0 0.0012821923
EPO O 0 0.99510336
. O 0 0.0034470651

Endothelial O 0 0.7288853
cell O 0 0.0051951273
culture O 0 0.001385177
supernatants O 0 0.0006080617
separated O 0 0.00042930458
by O 0 0.0003068033
ultrafiltration O 0 0.0042496365
and O 0 0.00020722192
ultracentrifugation O 0 0.0007221533
from O 0 0.00010769026
cells O 0 0.00016527175
treated O 0 0.00020158188
with O 0 0.00038282562
EPO O 0 0.9996716
and O 0 0.0005376478
IL O 0 0.23576151
- O 0 0.00033501303
3 O 0 5.8995778e-05
significantly O 0 0.00010172864
reduced O 0 0.00025435834
thymidine B-Chemical 0 0.28826782
incorporation O 0 0.00044276408
into O 0 5.5732122e-05
erythroid O 0 0.98883224
cells O 0 0.00024673858
as O 0 6.414791e-05
compared O 0 3.446408e-05
to O 0 3.6903588e-05
identical O 0 3.0476584e-05
fractions O 0 6.894469e-05
obtained O 0 6.1228464e-05
from O 0 5.388643e-05
the O 0 7.689242e-05
media O 0 0.00025529566
of O 0 0.00022179418
cells O 0 0.00034639836
cultured O 0 0.0005106892
with O 0 0.0014214992
EPO O 0 0.99909294
alone O 0 0.0037041085
. O 0 0.0026720476

These O 0 0.0020838748
results O 0 0.0012155193
suggest O 0 0.00049324846
that O 0 0.0005665011
endothelial O 0 0.3309039
cells O 0 0.00077633373
treated O 0 0.00045889302
simultaneously O 0 0.00026782783
with O 0 0.0006742005
EPO O 0 0.99964833
and O 0 0.00086508115
IL O 0 0.25867683
- O 0 0.00049806735
3 O 0 9.702414e-05
have O 0 7.517124e-05
a O 0 0.00014595049
negative O 0 0.0002172596
effect O 0 0.00026331714
on O 0 0.0004142849
erythroid O 0 0.99682295
cell O 0 0.016891887
production O 0 0.0048767254
. O 0 0.0029358815

The O 0 0.0011479466
relationship O 0 0.00055560545
between O 0 0.0005347729
hippocampal O 0 0.2693803
acetylcholine B-Chemical 1 0.99987936
release O 0 0.0051851505
and O 0 0.0005068139
cholinergic O 0 0.66428655
convulsant O 0 0.9993154
sensitivity O 0 0.0031297777
in O 0 0.00022910291
withdrawal O 0 0.12910387
seizure B-Disease 0 0.999806
- O 0 0.0004943221
prone O 0 0.00012956669
and O 0 0.00018221729
withdrawal O 0 0.04853267
seizure B-Disease 0 0.9995672
- O 0 0.00075005443
resistant O 0 0.0003596031
selected O 0 0.0004680467
mouse O 0 0.0013138658
lines O 0 0.0029632652
. O 0 0.0020149997

BACKGROUND O 0 0.007953544
: O 0 0.0020077464
The O 0 0.0008429748
septo O 0 0.0056456923
- O 0 0.0012583444
hippocampal O 0 0.060432278
cholinergic O 0 0.38630465
pathway O 0 0.00036429072
has O 0 0.00013993545
been O 0 9.361619e-05
implicated O 0 7.540141e-05
in O 0 0.00013625638
epileptogenesis O 0 0.8390881
, O 0 0.00017726701
and O 0 0.000100045116
genetic O 0 0.00023402467
factors O 0 7.3437535e-05
influence O 0 2.8791555e-05
the O 0 4.712212e-05
response O 0 5.9289167e-05
to O 0 7.768442e-05
cholinergic O 0 0.20301704
agents O 0 0.0010486495
, O 0 0.00012833303
but O 0 8.243778e-05
limited O 0 6.5834385e-05
data O 0 8.446544e-05
are O 0 6.723302e-05
available O 0 8.617493e-05
on O 0 7.02317e-05
cholinergic O 0 0.041750934
involvement O 0 0.0004682756
in O 0 0.0004890258
alcohol B-Chemical 0 0.9993291
withdrawal O 0 0.31021184
severity O 0 0.0069667078
. O 0 0.0021770967

Thus O 0 0.0021566008
, O 0 0.0014970424
the O 0 0.0006336926
relationship O 0 0.0002696241
between O 0 0.00026284257
cholinergic O 0 0.040159877
activity O 0 0.0002524949
and O 0 0.00020464248
responsiveness O 0 0.00026707558
and O 0 0.0003950793
alcohol B-Chemical 0 0.9997255
withdrawal O 0 0.0961843
was O 0 0.0001894432
investigated O 0 8.3529725e-05
in O 0 8.859433e-05
a O 0 0.00015738749
genetic O 0 0.00040569308
animal O 0 0.00023381614
model O 0 0.00026383557
of O 0 0.00074586587
ethanol B-Chemical 1 0.9996014
withdrawal O 0 0.45767555
severity O 0 0.008530668
. O 0 0.0023372164

METHODS O 0 0.0016851343
: O 0 0.0019820123
Cholinergic O 0 0.051468737
convulsant O 0 0.9947078
sensitivity O 0 0.0036199684
was O 0 0.00050870416
examined O 0 0.00022526593
in O 0 0.00046739037
alcohol B-Chemical 0 0.9997522
- O 0 0.015568291
na O 0 0.9999665
ve O 0 0.56611407
Withdrawal O 0 0.7841265
Seizure B-Disease 2 0.99940574
- O 0 0.0010082052
Prone O 0 0.00781245
( O 0 0.00047989035
WSP O 0 0.38075313
) O 0 0.00039651548
and O 0 0.00028113474
- O 0 0.00059686217
Resistant O 0 0.002083063
( O 0 0.0012023677
WSR O 0 0.6160437
) O 0 0.0016083699
mice O 0 0.0012714214
. O 0 0.0022889825

Animals O 0 0.0032098147
were O 0 0.0012752017
administered O 0 0.0017806878
nicotine B-Chemical 1 0.9988105
, O 0 0.0021561165
carbachol B-Chemical 0 0.99967575
, O 0 0.000657612
or O 0 0.00037677595
neostigmine B-Chemical 0 0.99982905
via O 0 0.0001061639
timed O 0 0.00014053252
tail O 0 0.00015420197
vein O 0 0.0012908477
infusion O 0 0.00022197209
, O 0 7.636688e-05
and O 0 5.1390925e-05
the O 0 4.6576843e-05
latencies O 0 0.00012552027
to O 0 5.086319e-05
onset O 0 0.00011819478
of O 0 0.00027693994
tremor B-Disease 0 0.9998926
and O 0 0.00046318382
clonus O 0 0.9812383
were O 0 0.00015448265
recorded O 0 0.000106735504
and O 0 0.00015255624
converted O 0 0.00027757647
to O 0 0.0002917264
threshold O 0 0.00069196144
dose O 0 0.004811456
. O 0 0.0022063798

We O 0 0.0015164563
also O 0 0.0011018462
used O 0 0.0008025507
microdialysis O 0 0.0027845982
to O 0 0.00031948034
measure O 0 0.00015448206
basal O 0 0.00051539834
and O 0 0.0006038291
potassium B-Chemical 0 0.9999385
- O 0 0.0013705393
stimulated O 0 0.0005796247
acetylcholine B-Chemical 1 0.9999547
( O 0 0.0025350016
ACh B-Chemical 1 0.9999057
) O 0 0.0006199863
release O 0 0.0005470831
in O 0 0.00016087406
the O 0 0.00025325728
CA1 O 0 0.14765085
region O 0 0.0003719892
of O 0 0.000638118
the O 0 0.0010048699
hippocampus O 0 0.09829276
. O 0 0.0027625468

Potassium B-Chemical 0 0.99892247
was O 0 0.0029009513
applied O 0 0.0011084523
by O 0 0.0011823012
reverse O 0 0.0028736277
dialysis O 0 0.0036610116
twice O 0 0.00062460534
, O 0 0.0006996745
separated O 0 0.0006655462
by O 0 0.0009091911
75 O 0 0.0016441576
min O 0 0.0021341313
. O 0 0.0028819821

Hippocampal O 0 0.526641
ACh B-Chemical 1 0.99892396
also O 0 0.0017994196
was O 0 0.0010001499
measured O 0 0.00048565553
during O 0 0.00029994475
testing O 0 0.00042748894
for O 0 0.00046892534
handling O 0 0.0017741268
- O 0 0.0025578933
induced O 0 0.004586817
convulsions B-Disease 0 0.99971765
. O 0 0.006680812

RESULTS O 0 0.004800273
: O 0 0.0021442284
Sensitivity O 0 0.0041402252
to O 0 0.00064418337
several O 0 0.000550814
convulsion B-Disease 0 0.9965564
endpoints O 0 0.00093220064
induced O 0 0.00045435794
by O 0 0.0005580463
nicotine B-Chemical 1 0.999721
, O 0 0.0011038155
carbachol B-Chemical 0 0.99982184
, O 0 0.0003962759
and O 0 0.00038927142
neostigmine B-Chemical 0 0.99991953
were O 0 0.00022444333
significantly O 0 0.00020382577
greater O 0 0.0002148576
in O 0 0.00036568582
WSR O 0 0.7464977
versus O 0 0.00073514465
WSP O 0 0.39165178
mice O 0 0.0012790491
. O 0 0.002058522

In O 0 0.0020067014
microdialysis O 0 0.006150779
experiments O 0 0.0007881776
, O 0 0.00071234273
the O 0 0.00045676634
lines O 0 0.00073852495
did O 0 0.00027935207
not O 0 0.00016819425
differ O 0 0.00013325474
in O 0 0.00011296421
basal O 0 0.00026424014
release O 0 0.00053507066
of O 0 0.00048605245
ACh B-Chemical 1 0.999889
, O 0 0.00024610868
and O 0 0.00015192997
50 O 0 0.0003940456
mM O 0 0.0869109
KCl B-Chemical 0 0.9978859
increased O 0 0.0031494654
ACh B-Chemical 1 0.9998578
output O 0 0.0003668811
in O 0 0.00021779763
both O 0 0.00032553106
lines O 0 0.0009289644
of O 0 0.0009048157
mice O 0 0.001114616
. O 0 0.0020262115

However O 0 0.0027207108
, O 0 0.0018203928
the O 0 0.0008747502
increase O 0 0.00063605595
in O 0 0.00048746922
release O 0 0.0014314749
of O 0 0.0010091893
ACh B-Chemical 1 0.9998087
produced O 0 0.00028946676
by O 0 0.00015214975
the O 0 8.8531066e-05
first O 0 5.571895e-05
application O 0 0.00013869102
of O 0 0.000386467
KCl B-Chemical 0 0.99789643
was O 0 0.00043042164
2 O 0 0.00016329036
- O 0 0.00027305493
fold O 0 0.00025611042
higher O 0 0.00028404882
in O 0 0.00040384426
WSP O 0 0.5034855
versus O 0 0.0008845296
WSR O 0 0.65434325
mice O 0 0.0013285693
. O 0 0.00213996

When O 0 0.0019106215
hippocampal O 0 0.30487972
ACh B-Chemical 1 0.99961275
was O 0 0.0010085299
measured O 0 0.00030307335
during O 0 0.00013669833
testing O 0 0.00015875182
for O 0 0.00012705976
handling O 0 0.00048564185
- O 0 0.00051007123
induced O 0 0.0005325564
convulsions B-Disease 0 0.999948
, O 0 0.0006490066
extracellular O 0 0.0023590724
ACh B-Chemical 1 0.99992394
was O 0 0.0002335374
significantly O 0 0.00020489708
elevated O 0 0.001301512
( O 0 0.00025272803
192 O 0 0.00066922314
% O 0 0.00013473198
) O 0 0.00016935746
in O 0 0.00012289693
WSP O 0 0.34052277
mice O 0 8.855142e-05
, O 0 0.0001434388
but O 0 0.00014807901
was O 0 0.00022849796
nonsignificantly O 0 0.15406452
elevated O 0 0.0028210832
( O 0 0.0004141193
59 O 0 0.00037395582
% O 0 0.00032832593
) O 0 0.00055914815
in O 0 0.0006793882
WSR O 0 0.5119908
mice O 0 0.0013136031
. O 0 0.0021681655

CONCLUSIONS O 0 0.012022339
: O 0 0.0017301264
These O 0 0.00073851965
results O 0 0.0004777188
suggest O 0 0.0001814776
that O 0 0.000161388
differences O 0 0.000111744586
in O 0 0.00016921427
cholinergic O 0 0.033917207
activity O 0 0.00015405576
and O 0 0.00016909378
postsynaptic O 0 0.06383634
sensitivity O 0 0.00098832
to O 0 0.00019424685
cholinergic O 0 0.8882931
convulsants B-Disease 0 0.99995875
may O 0 0.000107594075
be O 0 5.8209724e-05
associated O 0 5.630221e-05
with O 0 0.00018431069
ethanol B-Chemical 1 0.9997056
withdrawal O 0 0.063815415
severity O 0 0.00043509458
and O 0 0.00011447094
implicate O 0 0.00010352062
cholinergic O 0 0.02966278
mechanisms O 0 0.00035517206
in O 0 0.0006036829
alcohol B-Chemical 0 0.99905175
withdrawal O 0 0.34507862
. O 0 0.0024228848

Specifically O 0 0.0029251752
, O 0 0.0032719015
WSP O 0 0.36130902
mice O 0 0.0005552695
may O 0 0.00036350897
have O 0 0.00021305832
lower O 0 0.0002849504
sensitivity O 0 0.00066636177
to O 0 0.00025184167
cholinergic O 0 0.81459355
convulsants B-Disease 0 0.9999397
compared O 0 0.00013448014
with O 0 0.00023736217
WSR O 0 0.5971544
because O 0 5.8381444e-05
of O 0 0.00017209732
postsynaptic O 0 0.281701
receptor O 0 0.026711946
desensitization O 0 0.02767183
brought O 0 0.00020384442
on O 0 7.07671e-05
by O 0 0.00013149755
higher O 0 0.00019723372
activity O 0 0.0002717338
of O 0 0.0008315369
cholinergic O 0 0.4172108
neurons O 0 0.0036939126
. O 0 0.0020410577

Capsaicin B-Chemical 1 0.99877053
- O 0 0.007128897
induced O 0 0.0029700694
muscle B-Disease 0 0.5734959
pain I-Disease 0 0.9591408
alters O 0 0.00043395732
the O 0 0.00043808584
excitability O 0 0.0054611
of O 0 0.00047526474
the O 0 0.0004333032
human O 0 0.0009924632
jaw O 0 0.19179673
- O 0 0.0024743548
stretch O 0 0.0036871678
reflex O 0 0.19135703
. O 0 0.0032988393

The O 0 0.001731682
pathophysiology O 0 0.006442041
of O 0 0.0023222342
painful O 0 0.9254286
temporomandibular B-Disease 0 0.9997731
disorders I-Disease 0 0.9972365
is O 0 0.0005028742
not O 0 0.00022344853
fully O 0 0.0002649639
understood O 0 0.00051291677
, O 0 0.00019297918
but O 0 0.00012795377
evidence O 0 7.887089e-05
suggests O 0 5.043737e-05
that O 0 0.00011292298
muscle B-Disease 0 0.16366136
pain I-Disease 0 0.9118074
modulates O 0 0.000100127
motor O 0 0.00081096595
function O 0 0.0003416546
in O 0 0.0003803498
characteristic O 0 0.0007417444
ways O 0 0.0013469066
. O 0 0.0018899235

This O 0 0.0035632926
study O 0 0.0016016818
tested O 0 0.0007324039
the O 0 0.0005032449
hypothesis O 0 0.00044136777
that O 0 0.0001896344
activation O 0 0.00033897877
of O 0 0.0005012237
nociceptive B-Disease 0 0.29970956
muscle I-Disease 0 0.16688524
afferent O 0 0.0005568922
fibers O 0 0.00024363092
would O 0 8.613895e-05
be O 0 6.303191e-05
linked O 0 5.7132755e-05
to O 0 5.12598e-05
an O 0 8.853824e-05
increased O 0 0.00016207252
excitability O 0 0.005456138
of O 0 0.00011799208
the O 0 8.958821e-05
human O 0 0.00021707201
jaw O 0 0.15094008
- O 0 0.00036879012
stretch O 0 0.00030829015
reflex O 0 0.012518467
and O 0 8.200413e-05
whether O 0 3.0801555e-05
this O 0 8.822507e-05
process O 0 8.3932144e-05
would O 0 7.717289e-05
be O 0 6.6852874e-05
sensitive O 0 7.122708e-05
to O 0 8.559558e-05
length O 0 0.00011497042
and O 0 0.00017884796
velocity O 0 0.00037880847
of O 0 0.00052209466
the O 0 0.00083455327
stretch O 0 0.0027334588
. O 0 0.0021063327

Capsaicin B-Chemical 1 0.9981439
( O 0 0.0037749773
10 O 0 0.0012837957
micro O 0 0.0032719637
g O 0 0.0022642855
) O 0 0.0007503801
was O 0 0.00027917605
injected O 0 0.00016212881
into O 0 8.056291e-05
the O 0 0.00017379817
masseter O 0 0.001553122
muscle O 0 0.00089881197
to O 0 0.00016843964
induce O 0 0.00020207067
pain B-Disease 0 0.095534876
in O 0 0.00039881255
11 O 0 0.00054560986
healthy O 0 0.0019022848
volunteers O 0 0.00197863
. O 0 0.0018514425

Short O 0 0.0030073065
- O 0 0.002371253
latency O 0 0.0013543081
reflex O 0 0.0067620664
responses O 0 0.0006578489
were O 0 0.00033898585
evoked O 0 0.00065409095
in O 0 0.00016690548
the O 0 0.00016506984
masseter O 0 0.0009497662
and O 0 0.00015605823
temporalis O 0 0.00063116645
muscles O 0 0.00030775482
by O 0 0.00010321947
a O 0 0.00013167094
stretch O 0 0.00020500239
device O 0 0.0001359041
with O 0 8.372623e-05
different O 0 4.7290934e-05
velocities O 0 0.000149915
and O 0 9.610233e-05
displacements O 0 0.00038058954
before O 0 5.8857433e-05
, O 0 0.00013657806
during O 0 8.460957e-05
, O 0 0.00021201042
and O 0 0.00023964321
after O 0 0.00020901079
the O 0 0.0009768375
pain B-Disease 0 0.4641947
. O 0 0.0026845324

The O 0 0.0013039986
normalized O 0 0.00093265466
reflex O 0 0.009590601
amplitude O 0 0.0017011872
increased O 0 0.00083887693
with O 0 0.0004445026
an O 0 0.00032191927
increase O 0 0.00018749488
in O 0 0.00012717006
velocity O 0 0.00016836192
at O 0 6.539937e-05
a O 0 0.00011572021
given O 0 6.476633e-05
displacement O 0 0.00037320523
, O 0 0.00014567147
but O 0 0.00011116917
remained O 0 0.00012845351
constant O 0 0.0001150799
with O 0 0.000119818316
different O 0 8.853571e-05
displacements O 0 0.00053544104
at O 0 0.00017826857
a O 0 0.00045730828
given O 0 0.00044235948
velocity O 0 0.0017694059
. O 0 0.0019418037

The O 0 0.0012673584
normalized O 0 0.0009161015
reflex O 0 0.01032174
amplitude O 0 0.0019262873
was O 0 0.00064809487
significantly O 0 0.00046483384
higher O 0 0.0003446576
during O 0 0.00020354298
pain B-Disease 0 0.32143748
, O 0 0.00033590285
but O 0 0.00020036813
only O 0 0.00016597229
at O 0 0.000113378075
faster O 0 0.00024272318
stretches O 0 0.00046829035
in O 0 0.00036164105
the O 0 0.0009422281
painful B-Disease 0 0.9797339
muscle I-Disease 0 0.50407904
. O 0 0.0031623815

Increased O 0 0.0033014212
sensitivity O 0 0.0029719549
of O 0 0.0010731417
the O 0 0.0006360681
fusimotor O 0 0.0024007338
system O 0 0.0004011425
during O 0 0.00022748539
acute O 0 0.51071
muscle B-Disease 0 0.8807314
pain I-Disease 0 0.9949361
could O 0 0.00025233417
be O 0 0.00015052334
one O 0 9.913325e-05
likely O 0 0.00011126664
mechanism O 0 0.0002091246
to O 0 0.00023815606
explain O 0 0.00037751373
the O 0 0.00076568907
findings O 0 0.0027472852
. O 0 0.002414972

Effects O 0 0.0030665055
of O 0 0.0021382275
5 O 0 0.001213371
- O 0 0.0022299052
HT1B O 0 0.21902996
receptor O 0 0.009657274
ligands O 0 0.0019105495
microinjected O 0 0.00036577828
into O 0 7.5726406e-05
the O 0 0.00015821082
accumbal O 0 0.38428897
shell O 0 0.00081132696
or O 0 8.537417e-05
core O 0 8.110728e-05
on O 0 6.522803e-05
the O 0 0.0002427616
cocaine B-Chemical 1 0.9997527
- O 0 0.0009959746
induced O 0 0.0008677222
locomotor B-Disease 0 0.99502593
hyperactivity I-Disease 2 0.99998605
in O 0 0.0019197655
rats O 0 0.0030527043
. O 0 0.0018675359

The O 0 0.0015448005
present O 0 0.0010653525
study O 0 0.0010576346
was O 0 0.00058640534
designed O 0 0.00033742405
to O 0 0.00019993949
examine O 0 9.445541e-05
the O 0 0.00014778505
effect O 0 0.00014578206
of O 0 0.00025465703
5 O 0 0.00015297139
- O 0 0.0004695142
HT1B O 0 0.24691759
receptor O 0 0.0077586197
ligands O 0 0.0008095761
microinjected O 0 0.00012855582
into O 0 2.5155752e-05
the O 0 4.3721735e-05
subregions O 0 7.802854e-05
of O 0 6.711317e-05
the O 0 6.2630716e-05
nucleus O 0 6.384722e-05
accumbens O 0 0.000623969
( O 0 9.579754e-05
the O 0 6.0908806e-05
shell O 0 0.00033995433
and O 0 7.368762e-05
the O 0 6.434985e-05
core O 0 8.0721635e-05
) O 0 0.00012050293
on O 0 4.940408e-05
the O 0 0.00017387839
locomotor B-Disease 0 0.97363836
hyperactivity I-Disease 2 0.9999925
induced O 0 0.00150416
by O 0 0.0012377388
cocaine B-Chemical 1 0.99964976
in O 0 0.001127928
rats O 0 0.002321936
. O 0 0.0017246405

Male O 0 0.00915509
Wistar O 0 0.004854703
rats O 0 0.0010816065
were O 0 0.0004217793
implanted O 0 0.00038038776
bilaterally O 0 0.00056362536
with O 0 0.00018881222
cannulae O 0 0.00018363305
into O 0 4.8044883e-05
the O 0 9.375438e-05
accumbens O 0 0.0007881822
shell O 0 0.00056514214
or O 0 8.0261714e-05
core O 0 8.5198335e-05
, O 0 9.177886e-05
and O 0 6.418267e-05
then O 0 4.902632e-05
were O 0 6.0844664e-05
locally O 0 0.0001422413
injected O 0 7.745925e-05
with O 0 0.00027047118
GR B-Chemical 0 0.99862194
55562 I-Chemical 0 0.9970379
( O 0 0.00020967628
an O 0 0.0001532941
antagonist O 0 0.2332434
of O 0 0.00016392923
5 O 0 7.967848e-05
- O 0 0.00026269702
HT1B O 0 0.16569062
receptors O 0 0.0015919169
) O 0 0.00022616766
or O 0 0.0001803443
CP B-Chemical 0 0.99950945
93129 I-Chemical 0 0.9998512
( O 0 0.00042069308
an O 0 0.000294196
agonist O 0 0.082741015
of O 0 0.00036256792
5 O 0 0.0002615746
- O 0 0.0009052149
HT1B O 0 0.1581552
receptors O 0 0.007052904
) O 0 0.0026000105
. O 0 0.0021735004

Given O 0 0.0011863936
alone O 0 0.0012586489
to O 0 0.00080153317
any O 0 0.00074404734
accumbal O 0 0.78553873
subregion O 0 0.0028704295
, O 0 0.0010766223
GR B-Chemical 0 0.9983376
55562 I-Chemical 0 0.99812394
( O 0 0.00053499057
0 O 0 0.00014686058
. O 0 8.173563e-05
1 O 0 9.187299e-05
- O 0 0.00014372713
10 O 0 6.893199e-05
microg O 0 0.0002065065
/ O 0 0.0006044221
side O 0 0.0037974487
) O 0 0.00033302497
or O 0 0.00023971361
CP B-Chemical 0 0.99965966
93129 I-Chemical 0 0.9998981
( O 0 0.0004366142
0 O 0 0.0001029848
. O 0 5.9701637e-05
1 O 0 7.377424e-05
- O 0 0.00012685795
10 O 0 6.821114e-05
microg O 0 0.0002327292
/ O 0 0.00073120365
side O 0 0.004041044
) O 0 0.00035728473
did O 0 0.00020359967
not O 0 0.00019346537
change O 0 0.00034094838
basal O 0 0.000993644
locomotor O 0 0.025808956
activity O 0 0.0015976871
. O 0 0.0021497482

Systemic O 0 0.73633033
cocaine B-Chemical 1 0.99912614
( O 0 0.0025389171
10 O 0 0.0008890387
mg O 0 0.009664017
/ O 0 0.0018180081
kg O 0 0.0013217025
) O 0 0.0005721661
significantly O 0 0.00038186955
increased O 0 0.00047801263
the O 0 0.0004362795
locomotor O 0 0.01309942
activity O 0 0.00068802055
of O 0 0.0014139113
rats O 0 0.0030497278
. O 0 0.002370917

GR B-Chemical 0 0.99600995
55562 I-Chemical 0 0.9960478
( O 0 0.0032940404
0 O 0 0.0009772386
. O 0 0.00047189806
1 O 0 0.00039965712
- O 0 0.00047982796
10 O 0 0.00020504132
microg O 0 0.00048698785
/ O 0 0.0011488684
side O 0 0.00545323
) O 0 0.00041829716
, O 0 0.00017076054
administered O 0 0.00017607467
intra O 0 0.0005250131
- O 0 0.00028018295
accumbens O 0 0.00085199904
shell O 0 0.00040892203
prior O 0 4.6173034e-05
to O 0 0.000126432
cocaine B-Chemical 1 0.9994778
, O 0 0.00026730358
dose O 0 0.0015498551
- O 0 0.0005873459
dependently O 0 0.25525704
attenuated O 0 0.0008007617
the O 0 0.0004376797
psychostimulant O 0 0.9956403
- O 0 0.0012628488
induced O 0 0.0015461493
locomotor B-Disease 0 0.99650025
hyperactivity I-Disease 2 0.9999746
. O 0 0.0046987426

Such O 0 0.003437493
attenuation O 0 0.0028928015
was O 0 0.0011871487
not O 0 0.0005372352
found O 0 0.000367417
in O 0 0.00026738003
animals O 0 0.00018142778
which O 0 0.0002528353
had O 0 0.00018248225
been O 0 0.00011963609
injected O 0 0.00017641665
with O 0 0.00056655676
GR B-Chemical 0 0.99601007
55562 I-Chemical 0 0.9715623
into O 0 0.00019462728
the O 0 0.00045692959
accumbens O 0 0.0041906326
core O 0 0.00137214
. O 0 0.0018953128

When O 0 0.001303793
injected O 0 0.000996696
into O 0 0.00040189136
the O 0 0.0005663262
accumbens O 0 0.0035650067
shell O 0 0.0031896723
( O 0 0.00050379446
but O 0 0.0001994893
not O 0 0.00011296421
the O 0 0.000108910295
core O 0 0.00012553236
) O 0 0.00020415407
before O 0 8.1551196e-05
cocaine B-Chemical 1 0.99969745
, O 0 0.00083943905
CP B-Chemical 0 0.99983656
93129 I-Chemical 0 0.99992347
( O 0 0.00043082185
0 O 0 9.511304e-05
. O 0 5.333094e-05
1 O 0 6.4568434e-05
- O 0 0.00010874573
10 O 0 5.369617e-05
microg O 0 0.00017468634
/ O 0 0.0005493823
side O 0 0.002883864
) O 0 0.00018359505
enhanced O 0 0.00011725127
the O 0 9.451082e-05
locomotor O 0 0.008681638
response O 0 0.00010478041
to O 0 0.00014860123
cocaine B-Chemical 1 0.99968183
; O 0 0.0001353529
the O 0 5.5060438e-05
maximum O 0 5.542837e-05
effect O 0 6.8175956e-05
being O 0 0.000107792905
observed O 0 5.71582e-05
after O 0 3.4423545e-05
10 O 0 8.5684595e-05
microg O 0 0.00032814534
/ O 0 0.0008879199
side O 0 0.0027405391
of O 0 0.0007617551
the O 0 0.0011874213
agonist O 0 0.5043635
. O 0 0.00260744

The O 0 0.0016803289
later O 0 0.0010382799
enhancement O 0 0.0016262957
was O 0 0.00080326037
attenuated O 0 0.00077019667
after O 0 0.00018756425
intra O 0 0.0010508882
- O 0 0.0005958859
accumbens O 0 0.0018527594
shell O 0 0.0011841049
treatment O 0 0.00024428006
with O 0 0.000638351
GR B-Chemical 0 0.99861634
55562 I-Chemical 0 0.99697864
( O 0 0.00058092
1 O 0 0.0002551684
microg O 0 0.00077015307
/ O 0 0.0023416437
side O 0 0.012623689
) O 0 0.0032946337
. O 0 0.0026394902

Our O 0 0.0020646458
findings O 0 0.0019411385
indicate O 0 0.00064222864
that O 0 0.00081135007
cocaine B-Chemical 1 0.9996942
induced O 0 0.0071477816
hyperlocomotion B-Disease 0 0.99999
is O 0 0.00061672373
modified O 0 0.00024261881
by O 0 0.00016465217
5 O 0 0.0001142939
- O 0 0.00034819703
HT1B O 0 0.1460968
receptor O 0 0.0051910025
ligands O 0 0.0007455399
microinjected O 0 0.00013297191
into O 0 2.884966e-05
the O 0 6.7063454e-05
accumbens O 0 0.0010379041
shell O 0 0.0009161584
, O 0 0.00011021057
but O 0 7.239504e-05
not O 0 5.035577e-05
core O 0 6.1022754e-05
, O 0 6.81781e-05
this O 0 6.686154e-05
modification O 0 8.560349e-05
consisting O 0 4.043455e-05
in O 0 4.8986873e-05
inhibitory O 0 0.00023293612
and O 0 9.316031e-05
facilitatory O 0 0.0018627082
effects O 0 0.00010573765
of O 0 0.000116933734
the O 0 8.665172e-05
5 O 0 7.011272e-05
- O 0 0.00026548607
HT1B O 0 0.28602448
receptor O 0 0.057388414
antagonist O 0 0.93401724
( O 0 0.0010416454
GR B-Chemical 0 0.9988563
55562 I-Chemical 0 0.99759966
) O 0 0.0004056834
and O 0 0.00022896336
agonist O 0 0.3411676
( O 0 0.0011804247
CP B-Chemical 0 0.9993949
93129 I-Chemical 0 0.99976724
) O 0 0.002366117
, O 0 0.0013707919
respectively O 0 0.0029600973
. O 0 0.0022682124

In O 0 0.001825319
other O 0 0.0012516564
words O 0 0.0014987753
, O 0 0.00072286156
the O 0 0.00032895853
present O 0 0.00018928575
results O 0 0.00018793014
suggest O 0 7.372066e-05
that O 0 9.484966e-05
the O 0 0.00019494338
accumbal O 0 0.7395573
shell O 0 0.002184358
5 O 0 0.00013634189
- O 0 0.0003694415
HT1B O 0 0.098718084
receptors O 0 0.0006621847
play O 0 7.0998e-05
a O 0 0.00010677724
permissive O 0 8.72675e-05
role O 0 5.7349353e-05
in O 0 8.737209e-05
the O 0 0.000117291194
behavioural O 0 0.00038531664
response O 0 0.0002489067
to O 0 0.00036002122
the O 0 0.0009868644
psychostimulant O 0 0.98476
. O 0 0.0025223503

Cocaine B-Chemical 0 0.9989141
related O 0 0.002001839
chest B-Disease 0 0.031412374
pain I-Disease 0 0.50953305
: O 0 0.001324816
are O 0 0.0005497927
we O 0 0.00034287397
seeing O 0 0.0012348302
the O 0 0.00066807104
tip O 0 0.0013520721
of O 0 0.0013970655
an O 0 0.0027893346
iceberg O 0 0.04276189
? O 0 0.009190671

The O 0 0.0031734488
recreational O 0 0.006264691
use O 0 0.0021191812
of O 0 0.003310405
cocaine B-Chemical 1 0.9984937
is O 0 0.0019568845
on O 0 0.0010816442
the O 0 0.0018989904
increase O 0 0.0032798292
. O 0 0.0043357033

The O 0 0.0021401981
emergency O 0 0.0028488946
nurse O 0 0.002071026
ought O 0 0.00095953105
to O 0 0.00045372773
be O 0 0.00033174097
familiar O 0 0.00040985606
with O 0 0.0002830356
some O 0 0.00023267683
of O 0 0.00029801868
the O 0 0.00034766004
cardiovascular O 0 0.28248194
consequences O 0 0.0010449148
of O 0 0.002304487
cocaine B-Chemical 1 0.99954647
use O 0 0.0027590967
. O 0 0.0024451588

In O 0 0.0017833284
particular O 0 0.00093463034
, O 0 0.0010153401
the O 0 0.00056711916
tendency O 0 0.000760301
of O 0 0.0008377825
cocaine B-Chemical 1 0.9993414
to O 0 0.00023017224
produce O 0 0.00015299911
chest B-Disease 0 0.01311872
pain I-Disease 0 0.3698177
ought O 0 0.00021742041
to O 0 8.2413506e-05
be O 0 6.365019e-05
in O 0 5.3698936e-05
the O 0 6.378071e-05
mind O 0 0.00015713526
of O 0 8.996902e-05
the O 0 7.5713986e-05
emergency O 0 0.00016955133
nurse O 0 0.00014791207
when O 0 4.072789e-05
faced O 0 9.871951e-05
with O 0 0.00011645424
a O 0 0.00016543793
young O 0 0.00065287034
victim O 0 0.00037751984
of O 0 0.0002211204
chest B-Disease 0 0.02194913
pain I-Disease 0 0.5436928
who O 0 0.00043154712
is O 0 0.00019805084
otherwise O 0 0.00028222453
at O 0 0.0003075536
low O 0 0.0017322478
risk O 0 0.011451019
. O 0 0.002317234

The O 0 0.0015437824
mechanism O 0 0.0014632763
of O 0 0.0015911494
chest B-Disease 0 0.015233006
pain I-Disease 0 0.23957956
related O 0 0.00029599518
to O 0 0.0005483969
cocaine B-Chemical 1 0.99934167
use O 0 0.0003692492
is O 0 0.00024330546
discussed O 0 0.00021909311
and O 0 0.0003039536
treatment O 0 0.00040768136
dilemmas O 0 0.0009592167
are O 0 0.0008973966
discussed O 0 0.001552878
. O 0 0.002401876

Finally O 0 0.0030344753
, O 0 0.0023911984
moral O 0 0.0025011732
issues O 0 0.00081426924
relating O 0 0.0003475662
to O 0 0.00035186973
the O 0 0.00031356263
testing O 0 0.00027341652
of O 0 0.00041882103
potential O 0 0.00089863944
cocaine B-Chemical 1 0.99967754
users O 0 0.0032359234
will O 0 0.0006594138
be O 0 0.0007850018
addressed O 0 0.00097062264
. O 0 0.002161684

Crossover O 0 0.007568647
comparison O 0 0.0010930216
of O 0 0.0008967914
efficacy O 0 0.00077173545
and O 0 0.00043036565
preference O 0 0.00034572024
for O 0 0.00033166257
rizatriptan B-Chemical 0 0.9998721
10 O 0 0.00029561983
mg O 0 0.0063510123
versus O 0 0.0005516969
ergotamine B-Chemical 1 0.9999802
/ O 0 0.035384938
caffeine B-Chemical 0 0.9998211
in O 0 0.0045191054
migraine B-Disease 0 0.9998241
. O 0 0.003612165

Rizatriptan B-Chemical 0 0.9993356
is O 0 0.002346874
a O 0 0.0015519453
selective O 0 0.0021640975
5 B-Chemical 0 0.0006431778
- I-Chemical 0 0.0017816434
HT I-Chemical 0 0.99225396
( O 0 0.0007974709
1B O 0 0.0005478687
/ O 0 0.0007496372
1D O 0 0.0007187585
) O 0 0.0003308456
receptor O 0 0.0028262362
agonist O 0 0.10584537
with O 0 0.0001764407
rapid O 0 0.0004972716
oral O 0 0.039364494
absorption O 0 0.47291195
and O 0 0.00012164739
early O 0 0.00015356796
onset O 0 0.00013924224
of O 0 0.0001242859
action O 0 0.00017353172
in O 0 0.00012782511
the O 0 0.00022647994
acute O 0 0.13762577
treatment O 0 0.00096802297
of O 0 0.0042702146
migraine B-Disease 0 0.9998803
. O 0 0.0035286974

This O 0 0.00300472
randomized O 0 0.0016345512
double O 0 0.0013425228
- O 0 0.0012303196
blind O 0 0.004056969
crossover O 0 0.0023597933
outpatient O 0 0.0003279252
study O 0 0.0001342649
assessed O 0 6.276901e-05
the O 0 6.971882e-05
preference O 0 7.695243e-05
for O 0 5.9140995e-05
1 O 0 0.00011370505
rizatriptan B-Chemical 0 0.99978
10 O 0 9.217645e-05
mg O 0 0.004190306
tablet O 0 0.0865936
to O 0 8.7986795e-05
2 O 0 0.00012813459
ergotamine B-Chemical 1 0.9999714
1 O 0 0.00010246376
mg O 0 0.0025320118
/ O 0 0.00072533294
caffeine B-Chemical 0 0.9995679
100 O 0 0.0006158233
mg O 0 0.015518524
tablets O 0 0.030770052
in O 0 9.583428e-05
439 O 0 0.0006075068
patients O 0 0.00012600956
treating O 0 0.00016460147
a O 0 0.00020099536
single O 0 0.00040404062
migraine B-Disease 0 0.9999101
attack O 0 0.06681271
with O 0 0.0006035915
each O 0 0.00038078486
therapy O 0 0.001653085
. O 0 0.0017795905

Of O 0 0.002670089
patients O 0 0.0017460231
expressing O 0 0.00061681133
a O 0 0.00086535496
preference O 0 0.0006607644
( O 0 0.00065195933
89 O 0 0.00065193087
. O 0 0.00016679123
1 O 0 0.00016077913
% O 0 0.0001935351
) O 0 0.00023301784
, O 0 0.00012591347
more O 0 0.000116259194
than O 0 5.3122472e-05
twice O 0 5.2300926e-05
as O 0 4.8808426e-05
many O 0 4.9817187e-05
preferred O 0 9.71519e-05
rizatriptan B-Chemical 0 0.9999466
to O 0 0.00032693252
ergotamine B-Chemical 1 0.99999535
/ O 0 0.024916
caffeine B-Chemical 0 0.99993455
( O 0 0.00034973788
69 O 0 0.00014734309
. O 0 4.7357324e-05
9 O 0 5.6831443e-05
vs O 0 7.7228986e-05
. O 0 4.722784e-05
30 O 0 5.8487814e-05
. O 0 6.0459628e-05
1 O 0 8.730255e-05
% O 0 0.00013702131
, O 0 0.00019356205
p O 0 0.0001936069
< O 0 0.00017669861
or O 0 0.00021650604
= O 0 0.00040912518
0 O 0 0.00037638878
. O 0 0.00056210416
001 O 0 0.007679184
) O 0 0.002594955
. O 0 0.0025669606

Faster O 0 0.026647545
relief O 0 0.0057181483
of O 0 0.0031551593
headache B-Disease 0 0.99628675
was O 0 0.0007953975
the O 0 0.00030952442
most O 0 0.00028341904
important O 0 9.997683e-05
reason O 0 0.00011212637
for O 0 0.000102923936
preference O 0 0.00017049635
, O 0 0.00016498644
cited O 0 0.00032565676
by O 0 0.0001359545
67 O 0 0.0002052686
. O 0 4.6878027e-05
3 O 0 4.0551473e-05
% O 0 5.148977e-05
of O 0 7.788002e-05
patients O 0 0.0001840076
preferring O 0 0.016874861
rizatriptan B-Chemical 0 0.999959
and O 0 0.00016135829
54 O 0 0.00017716544
. O 0 4.719259e-05
2 O 0 5.1534225e-05
% O 0 6.918568e-05
of O 0 0.00010987645
patients O 0 0.00021455933
who O 0 0.0003404358
preferred O 0 0.0005085391
ergotamine B-Chemical 1 0.99997437
/ O 0 0.061024506
caffeine B-Chemical 0 0.9996327
. O 0 0.0033897997

The O 0 0.002735469
co O 0 0.017403776
- O 0 0.0021339038
primary O 0 0.00070167705
endpoint O 0 0.00068173476
of O 0 0.00051852386
being O 0 0.0006998098
pain B-Disease 0 0.12726158
free O 0 0.0003665079
at O 0 0.00013752881
2 O 0 0.00013345285
h O 0 0.00013169971
was O 0 0.00018531247
also O 0 0.00019511336
in O 0 0.00028683382
favor O 0 0.00071617606
of O 0 0.0028250173
rizatriptan B-Chemical 0 0.9998357
. O 0 0.0034788128

Forty O 0 0.004459349
- O 0 0.0021039254
nine O 0 0.0005808491
percent O 0 0.00030904735
of O 0 0.0004033362
patients O 0 0.00044024602
were O 0 0.0003013492
pain B-Disease 0 0.055940647
free O 0 0.00024219033
2 O 0 8.4223895e-05
h O 0 6.563353e-05
after O 0 6.0640705e-05
rizatriptan B-Chemical 0 0.99989927
, O 0 0.00014320019
compared O 0 5.177723e-05
with O 0 8.847418e-05
24 O 0 5.124929e-05
. O 0 3.694349e-05
3 O 0 3.7174366e-05
% O 0 5.3785956e-05
treated O 0 0.00010354331
with O 0 0.0003666881
ergotamine B-Chemical 1 0.9999951
/ O 0 0.038287878
caffeine B-Chemical 0 0.99995816
( O 0 0.0005641083
p O 0 0.00013054878
< O 0 7.470005e-05
or O 0 7.0600014e-05
= O 0 0.00010847013
0 O 0 6.961678e-05
. O 0 7.315215e-05
001 O 0 0.002160985
) O 0 0.00022406488
, O 0 0.00024992615
rizatriptan B-Chemical 0 0.9996729
being O 0 0.00022474311
superior O 0 0.00020639432
within O 0 7.102008e-05
1 O 0 0.00016695417
h O 0 0.00025254212
of O 0 0.0006940216
treatment O 0 0.0014044102
. O 0 0.002174453

Headache B-Disease 2 0.655052
relief O 0 0.004286398
at O 0 0.00083402504
2 O 0 0.00056210766
h O 0 0.00040517846
was O 0 0.00040455244
75 O 0 0.00041134446
. O 0 0.00014381019
9 O 0 0.00012558396
% O 0 0.00014487718
for O 0 0.00016018967
rizatriptan B-Chemical 0 0.99987507
and O 0 0.00022205168
47 O 0 0.0002453992
. O 0 5.686495e-05
3 O 0 5.064829e-05
% O 0 7.4584386e-05
for O 0 0.00011245961
ergotamine B-Chemical 1 0.9999888
/ O 0 0.02008834
caffeine B-Chemical 0 0.9999465
( O 0 0.00057553116
p O 0 0.00013687182
< O 0 7.699845e-05
or O 0 7.086637e-05
= O 0 0.000106757885
0 O 0 6.58416e-05
. O 0 6.497561e-05
001 O 0 0.0018194554
) O 0 0.00014423043
, O 0 9.192602e-05
with O 0 0.00019104016
rizatriptan B-Chemical 0 0.99986947
being O 0 0.0001613823
superior O 0 0.00019517772
to O 0 0.00020532496
ergotamine B-Chemical 1 0.9999881
/ O 0 0.0043043382
caffeine B-Chemical 0 0.99858546
within O 0 8.047277e-05
30 O 0 0.00014105058
min O 0 0.00031004776
of O 0 0.0007124779
dosing O 0 0.0026386494
. O 0 0.0019377439

Almost O 0 0.0039770743
36 O 0 0.0012683577
% O 0 0.0007752437
of O 0 0.0005714954
patients O 0 0.0006428861
taking O 0 0.001294601
rizatriptan B-Chemical 0 0.9999269
were O 0 0.00043630652
pain B-Disease 0 0.084224515
free O 0 0.00018499735
at O 0 6.350771e-05
2 O 0 5.6880894e-05
h O 0 4.906481e-05
and O 0 6.7674024e-05
had O 0 6.8560425e-05
no O 0 5.0876482e-05
recurrence O 0 0.0031220159
or O 0 6.490939e-05
need O 0 4.300092e-05
for O 0 3.5350517e-05
additional O 0 4.128273e-05
medication O 0 0.00021
within O 0 1.8162786e-05
24 O 0 3.219387e-05
h O 0 4.025203e-05
, O 0 5.674036e-05
compared O 0 3.2290664e-05
to O 0 4.3386095e-05
20 O 0 5.6569952e-05
% O 0 5.7066976e-05
of O 0 7.643668e-05
patients O 0 0.00012629945
on O 0 0.00010367768
ergotamine B-Chemical 1 0.999992
/ O 0 0.024101462
caffeine B-Chemical 0 0.99993277
( O 0 0.0006614732
p O 0 0.00020714012
< O 0 0.00015342173
or O 0 0.00018234573
= O 0 0.0003472486
0 O 0 0.0003260781
. O 0 0.0004980011
001 O 0 0.0071860272
) O 0 0.0023927232
. O 0 0.0023911165

Rizatriptan B-Chemical 0 0.99929845
was O 0 0.0017741065
also O 0 0.0006801527
superior O 0 0.00093956065
to O 0 0.0008444855
ergotamine B-Chemical 1 0.9999833
/ O 0 0.02954241
caffeine B-Chemical 0 0.9998267
in O 0 0.00017739381
the O 0 9.71999e-05
proportions O 0 9.332383e-05
of O 0 0.00010272008
patients O 0 0.00012596727
with O 0 0.0001159295
no O 0 0.00012800025
nausea B-Disease 0 0.99999285
, O 0 0.0020095021
vomiting B-Disease 0 0.99998164
, O 0 0.0033975407
phonophobia B-Disease 0 0.99999857
or O 0 0.0012260694
photophobia B-Disease 0 0.99998343
and O 0 0.00016663419
for O 0 5.460417e-05
patients O 0 9.583026e-05
with O 0 7.1646165e-05
normal O 0 0.00013647888
function O 0 6.9317015e-05
2 O 0 3.9056613e-05
h O 0 3.4329525e-05
after O 0 2.9225013e-05
drug O 0 0.0031864475
intake O 0 0.10116033
( O 0 0.00030887002
p O 0 0.0001712014
< O 0 0.00014530329
or O 0 0.00018025575
= O 0 0.00034794532
0 O 0 0.000325353
. O 0 0.00049576507
001 O 0 0.007223231
) O 0 0.0023753243
. O 0 0.002372458

More O 0 0.007916046
patients O 0 0.0026812074
were O 0 0.0011539941
( O 0 0.0009419459
completely O 0 0.0006022749
, O 0 0.00040865116
very O 0 0.00038655175
or O 0 0.00020953317
somewhat O 0 0.0004561893
) O 0 0.00027530247
satisfied O 0 0.00015443256
2 O 0 5.875212e-05
h O 0 4.1237043e-05
after O 0 2.4116247e-05
treatment O 0 7.804811e-05
with O 0 0.00033687585
rizatriptan B-Chemical 0 0.9999721
( O 0 0.00029838315
69 O 0 0.0001444731
. O 0 4.6196106e-05
8 O 0 4.936301e-05
% O 0 7.143332e-05
) O 0 8.536579e-05
than O 0 3.2939955e-05
at O 0 3.2470074e-05
2 O 0 3.4552406e-05
h O 0 2.835658e-05
after O 0 1.820454e-05
treatment O 0 6.407485e-05
with O 0 0.00032511054
ergotamine B-Chemical 1 0.99999475
/ O 0 0.031519067
caffeine B-Chemical 0 0.99994254
( O 0 0.00040821335
38 O 0 0.00017532698
. O 0 5.913265e-05
6 O 0 5.7335685e-05
% O 0 0.000116091454
, O 0 0.00017088777
p O 0 0.00017555934
< O 0 0.00016359535
or O 0 0.00020402487
= O 0 0.0003902583
0 O 0 0.0003614489
. O 0 0.00054322655
001 O 0 0.007549331
) O 0 0.0025329778
. O 0 0.0025118052

Recurrence O 0 0.012704585
rates O 0 0.0019108469
were O 0 0.0011044008
31 O 0 0.0009163386
. O 0 0.00032064933
4 O 0 0.00023696739
% O 0 0.00029906357
with O 0 0.0005473974
rizatriptan B-Chemical 0 0.99985886
and O 0 0.0003469336
15 O 0 0.00016310973
. O 0 0.00012131691
3 O 0 0.0001436559
% O 0 0.00028285434
with O 0 0.0009482463
ergotamine B-Chemical 1 0.99995995
/ O 0 0.067477845
caffeine B-Chemical 0 0.99956816
. O 0 0.0042160405

Both O 0 0.005141645
active O 0 0.004579128
treatments O 0 0.0049022045
were O 0 0.003799699
well O 0 0.004187506
tolerated O 0 0.019167917
. O 0 0.008003615

The O 0 0.0017221906
most O 0 0.0017714099
common O 0 0.0012301626
adverse O 0 0.029312035
events O 0 0.0031354183
( O 0 0.0007995117
incidence O 0 0.0008330691
> O 0 0.0006865413
or O 0 0.00020914453
= O 0 0.00021425492
5 O 0 7.5636905e-05
% O 0 8.270968e-05
in O 0 5.860048e-05
one O 0 5.2350028e-05
group O 0 0.00010997299
) O 0 0.000115422554
after O 0 4.7366495e-05
rizatriptan B-Chemical 0 0.99994254
and O 0 0.00058027304
ergotamine B-Chemical 1 0.9999958
/ O 0 0.031395506
caffeine B-Chemical 0 0.9999509
, O 0 0.00032503708
respectively O 0 0.00040637355
, O 0 0.00013565343
were O 0 0.0001827222
dizziness B-Disease 0 0.9990885
( O 0 0.0002518304
6 O 0 4.9731178e-05
. O 0 3.8708877e-05
7 O 0 3.928837e-05
and O 0 5.9076287e-05
5 O 0 4.9417456e-05
. O 0 4.3230393e-05
3 O 0 5.2639472e-05
% O 0 9.825941e-05
) O 0 0.00020257628
, O 0 0.00031049238
nausea B-Disease 0 0.99992
( O 0 0.00037562544
4 O 0 7.94011e-05
. O 0 5.0740095e-05
2 O 0 5.5652996e-05
and O 0 7.056528e-05
8 O 0 5.8730944e-05
. O 0 4.573964e-05
5 O 0 5.37577e-05
% O 0 9.76598e-05
) O 0 0.00016890735
and O 0 0.00021913573
somnolence B-Disease 0 0.9991554
( O 0 0.00032279297
5 O 0 9.55904e-05
. O 0 7.563417e-05
5 O 0 9.350832e-05
and O 0 0.00016696357
2 O 0 0.00019734734
. O 0 0.00022373634
3 O 0 0.00039801383
% O 0 0.00095569453
) O 0 0.0021025524
. O 0 0.002406961

Severe O 0 0.07730175
ocular B-Disease 0 0.09501199
and I-Disease 0 0.0016790478
orbital I-Disease 0 0.011023938
toxicity I-Disease 2 0.9729944
after O 0 0.00033224266
intracarotid O 0 0.4325973
injection O 0 0.00066875166
of O 0 0.0009495722
carboplatin B-Chemical 0 0.9818056
for O 0 0.0011410062
recurrent O 0 0.19594005
glioblastomas B-Disease 0 0.9983342
. O 0 0.004238565

BACKGROUND O 0 0.012566273
: O 0 0.0044410806
Glioblastoma B-Disease 0 0.34358516
is O 0 0.0014997384
a O 0 0.0018514212
malignant B-Disease 0 0.94452095
tumor I-Disease 0 0.9379589
that O 0 0.0004292543
occurs O 0 0.0003570702
in O 0 0.0003752074
the O 0 0.0005695354
cerebrum O 0 0.0627625
during O 0 0.0008633663
adulthood O 0 0.021300543
. O 0 0.0026373006

With O 0 0.0019629304
current O 0 0.0017223761
treatment O 0 0.0008092182
regimens O 0 0.00075889565
including O 0 0.00024410525
combined O 0 0.00042470807
surgery O 0 0.00037552504
, O 0 0.00023690773
radiation O 0 0.0021624486
and O 0 0.00022480442
chemotherapy O 0 0.0014609915
, O 0 0.000115450945
the O 0 6.386786e-05
average O 0 4.5202003e-05
life O 0 0.000100123754
expectancy O 0 9.661273e-05
of O 0 0.000109499386
the O 0 0.00011471669
patients O 0 0.00019295211
is O 0 0.00013203896
limited O 0 0.0001483054
to O 0 0.00019221283
approximately O 0 0.00042480647
1 O 0 0.0005568157
year O 0 0.0007420364
. O 0 0.0015300296

Therefore O 0 0.0018597496
, O 0 0.0019321733
patients O 0 0.0013659089
with O 0 0.0012141225
glioblastoma B-Disease 0 0.9803491
sometimes O 0 0.0012601772
have O 0 0.0002713975
intracarotid O 0 0.35774702
injection O 0 0.00031834564
of O 0 0.00035595524
carcinostatics O 0 0.021650676
added O 0 0.00030051317
to O 0 0.00025382102
the O 0 0.00040030302
treatment O 0 0.00078595465
regimen O 0 0.0022688445
. O 0 0.0021753386

Generally O 0 0.0029217643
, O 0 0.0034180225
carboplatin B-Chemical 0 0.9707745
is O 0 0.0010806029
said O 0 0.00085762155
to O 0 0.00033545017
have O 0 0.00025258932
milder O 0 0.0219223
side O 0 0.0036005073
effects O 0 0.0003057999
than O 0 0.0002189223
cisplatin B-Chemical 0 0.997036
, O 0 0.00033862604
whose O 0 0.00045294862
ocular B-Disease 0 0.12521605
and I-Disease 0 0.00037845783
orbital I-Disease 0 0.03179695
toxicity I-Disease 2 0.9943
are O 0 0.00069918996
well O 0 0.0006595772
known O 0 0.0016994015
. O 0 0.0019593234

However O 0 0.0027798156
, O 0 0.0017856896
we O 0 0.0005632701
experienced O 0 0.00072949077
a O 0 0.0005643062
case O 0 0.00033274383
of O 0 0.00044899518
severe O 0 0.006882177
ocular B-Disease 0 0.2422331
and I-Disease 0 0.00029631343
orbital I-Disease 0 0.013572691
toxicity I-Disease 2 0.9833862
after O 0 7.685298e-05
intracarotid O 0 0.45591092
injection O 0 0.00024397938
of O 0 0.00045739635
carboplatin B-Chemical 0 0.99132794
, O 0 0.00049203925
which O 0 0.0005310891
is O 0 0.0005736719
infrequently O 0 0.0011301297
reported O 0 0.0016313492
. O 0 0.0019147889

CASE O 0 0.035015237
: O 0 0.0034758842
A O 0 0.008877109
58 O 0 0.0016923652
- O 0 0.0012515342
year O 0 0.00036938355
- O 0 0.0005584049
old O 0 0.000287395
man O 0 0.00097351783
received O 0 0.00011187006
an O 0 0.0001844195
intracarotid O 0 0.2807137
injection O 0 0.00019572396
of O 0 0.00028166836
carboplatin B-Chemical 0 0.9697127
for O 0 0.00020289158
recurrent O 0 0.025200332
glioblastomas B-Disease 0 0.9942978
in O 0 0.00038358787
his O 0 0.0006235913
left O 0 0.0012866239
temporal O 0 0.003968218
lobe O 0 0.23490514
. O 0 0.0026078604

He O 0 0.006715383
complained O 0 0.009591585
of O 0 0.002209633
pain B-Disease 0 0.34609124
and I-Disease 0 0.0009584337
visual I-Disease 0 0.2605976
disturbance I-Disease 0 0.17661616
in I-Disease 0 0.00031940604
the I-Disease 0 0.00026926448
ipsilateral I-Disease 0 0.0007513181
eye I-Disease 0 0.004055925
30 O 0 0.00020634907
h O 0 0.00021953935
after O 0 0.00019812073
the O 0 0.0006925994
injection O 0 0.0019129688
. O 0 0.002431697

Various O 0 0.00469334
ocular O 0 0.12097538
symptoms O 0 0.012067937
and O 0 0.0012479199
findings O 0 0.0014527674
caused O 0 0.001166504
by O 0 0.0018010271
carboplatin B-Chemical 0 0.9987388
toxicity B-Disease 2 0.9988545
were O 0 0.0029789486
seen O 0 0.0025710121
. O 0 0.0029983441

RESULTS O 0 0.005424123
: O 0 0.002398761
He O 0 0.0017950345
was O 0 0.0006787973
treated O 0 0.0005267339
with O 0 0.00043301436
intravenous O 0 0.005664327
administration O 0 0.001391458
of O 0 0.0007693777
corticosteroids O 1 0.999218
and O 0 0.00071463763
glycerin B-Chemical 0 0.9955397
for O 0 0.00017127258
6 O 0 0.000106871754
days O 0 8.450233e-05
after O 0 0.00013387037
the O 0 0.0005490193
injection O 0 0.0016540113
. O 0 0.0021823

Although O 0 0.0015232668
the O 0 0.0016135129
intraocular O 0 0.56949097
pressure O 0 0.01898026
elevation O 0 0.026488947
caused O 0 0.0006205155
by O 0 0.00040179212
secondary O 0 0.0016159851
acute O 0 0.65561104
angle O 0 0.12908334
- O 0 0.0011878042
closure O 0 0.023771152
glaucoma B-Disease 2 0.9999844
decreased O 0 0.0015165032
and O 0 0.0003991895
ocular B-Disease 0 0.9967237
pain I-Disease 0 0.9977906
diminished O 0 0.0020047198
, O 0 0.00042316853
inexorable O 0 0.45142648
papilledema B-Disease 0 0.9999913
and O 0 0.0033204039
exudative O 0 0.9999682
retinal B-Disease 0 0.99812084
detachment I-Disease 0 0.97339183
continued O 0 0.0003799854
for O 0 0.0002858336
3 O 0 0.0004012396
weeks O 0 0.00044151107
. O 0 0.0013386236

Finally O 0 0.0026145943
, O 0 0.0018731795
6 O 0 0.00059670064
weeks O 0 0.00028261926
later O 0 0.00031578806
, O 0 0.000629906
diffuse O 0 0.016844124
chorioretinal B-Disease 0 0.99996066
atrophy I-Disease 2 0.9999795
with O 0 0.0070962636
optic B-Disease 0 0.9980855
atrophy I-Disease 2 0.99971837
occurred O 0 0.00022369898
and O 0 0.0001539857
the O 0 0.0001715542
vision O 0 0.08223508
in O 0 0.00026791493
his O 0 0.0005478617
left O 0 0.0014824542
eye O 0 0.03405699
was O 0 0.0012515867
lost O 0 0.0019163677
. O 0 0.0021476

CONCLUSION O 0 0.012238474
: O 0 0.0016033212
When O 0 0.0004958464
performing O 0 0.00059477694
intracarotid O 0 0.17111795
injection O 0 0.0006206071
of O 0 0.0008052499
carboplatin B-Chemical 0 0.9917725
, O 0 0.00037005765
we O 0 9.895947e-05
must O 0 8.216835e-05
be O 0 0.00011734801
aware O 0 0.00013400677
of O 0 0.00023454985
its O 0 0.00046913704
potentially O 0 0.00085665943
blinding O 0 0.020795759
ocular B-Disease 0 0.9981664
toxicity I-Disease 2 0.9998499
. O 0 0.005195755

It O 0 0.0026397365
is O 0 0.001253545
recommended O 0 0.000688178
that O 0 0.00036329989
further O 0 0.0005099001
studies O 0 0.00033238396
and O 0 0.00025319547
investigations O 0 0.00027844854
are O 0 0.00013787321
undertaken O 0 0.00011511281
in O 0 0.00010852166
the O 0 0.00012314197
effort O 0 0.00017323761
to O 0 0.00012731712
minimize O 0 0.00014439943
such O 0 0.00032322196
severe O 0 0.011740566
side O 0 0.020124184
effects O 0 0.0031260164
. O 0 0.0028728081

Visual B-Disease 0 0.9822583
hallucinations I-Disease 0 0.9996605
associated O 0 0.014386304
with O 0 0.02670961
zonisamide B-Chemical 1 0.9996964
. O 0 0.015797812

Zonisamide B-Chemical 0 0.99853075
is O 0 0.0024745902
a O 0 0.0015617181
broad O 0 0.0011203928
- O 0 0.0012188653
spectrum O 0 0.001236081
antiepileptic O 0 0.99257106
drug O 0 0.014061069
used O 0 0.0002801119
to O 0 0.00026772317
treat O 0 0.0005125226
various O 0 0.0004801411
types O 0 0.0004956252
of O 0 0.002248107
seizures B-Disease 0 0.9997539
. O 0 0.0044400035

Although O 0 0.0023240747
visual B-Disease 0 0.7668648
hallucinations I-Disease 0 0.99995613
have O 0 0.0008869924
not O 0 0.00041291738
been O 0 0.00023413268
reported O 0 0.0002312049
as O 0 0.00013790083
an O 0 0.00019692969
adverse O 0 0.00597876
effect O 0 0.00011499783
of O 0 0.00016432453
this O 0 0.00018186476
agent O 0 0.0008470756
, O 0 9.1203314e-05
we O 0 2.564524e-05
describe O 0 3.470577e-05
three O 0 2.633533e-05
patients O 0 7.6344164e-05
who O 0 7.6256845e-05
experienced O 0 6.247539e-05
complex O 0 8.923549e-05
visual B-Disease 0 0.8407384
hallucinations I-Disease 0 0.999998
and O 0 0.000244776
altered O 0 0.0001946633
mental O 0 0.0010124871
status O 0 6.896849e-05
after O 0 5.035702e-05
zonisamide B-Chemical 1 0.99995506
treatment O 0 0.00018015986
was O 0 0.00016778674
begun O 0 0.00022859471
or O 0 0.000250429
its O 0 0.00096347206
dosage O 0 0.021222426
increased O 0 0.0032505533
. O 0 0.0023050858

All O 0 0.001474944
three O 0 0.0007030509
had O 0 0.0007830996
been O 0 0.0005148071
diagnosed O 0 0.0011337881
earlier O 0 0.00050794415
with O 0 0.0009394828
epilepsy B-Disease 2 0.99987745
, O 0 0.00047816802
and O 0 0.00021810288
their O 0 0.00027075756
electroencephalogram O 0 0.022065874
( O 0 0.0004749319
EEG O 0 0.023415677
) O 0 0.0006172289
findings O 0 0.0008555468
were O 0 0.00095013005
abnormal O 0 0.0059926617
. O 0 0.002445604

During O 0 0.00096825074
monitoring O 0 0.0012199478
, O 0 0.0015705625
visual B-Disease 0 0.74335855
hallucinations I-Disease 0 0.9999825
did O 0 0.00089875975
not O 0 0.00022629602
correlate O 0 0.0001391878
with O 0 0.00022093575
EEG O 0 0.056447744
readings O 0 0.00032739635
, O 0 0.00016763931
nor O 0 0.00011129496
did O 0 0.00014538088
video O 0 0.00027498615
recording O 0 0.00013865279
capture O 0 0.00018119889
any O 0 0.00016264037
of O 0 0.00032914925
the O 0 0.00043921883
described O 0 0.0007278596
events O 0 0.0040952885
. O 0 0.0022407542

None O 0 0.003274135
of O 0 0.0017601956
the O 0 0.0011285079
patients O 0 0.0011593621
had O 0 0.00075286336
experienced O 0 0.0012115833
visual B-Disease 0 0.80134976
hallucinations I-Disease 0 0.9999721
before O 0 0.0008674187
this O 0 0.0019400432
event O 0 0.006085812
. O 0 0.0031494566

The O 0 0.0017444297
only O 0 0.001406596
recent O 0 0.00083755027
change O 0 0.0005937036
in O 0 0.00039130246
their O 0 0.00039751746
treatment O 0 0.00030781465
was O 0 0.0002571778
the O 0 0.00018105727
introduction O 0 0.00018059277
or O 0 0.0002548866
increased O 0 0.0008573413
dosage O 0 0.04640941
of O 0 0.0052017006
zonisamide B-Chemical 1 0.9999174
. O 0 0.003729234

With O 0 0.0020796135
either O 0 0.0013631578
discontinuation O 0 0.010685603
or O 0 0.0006413391
decreased O 0 0.0011228855
dosage O 0 0.0054236758
of O 0 0.00036054704
the O 0 0.00025420607
drug O 0 0.0035092146
the O 0 0.00026520982
symptoms O 0 0.0024262087
disappeared O 0 0.0003900883
and O 0 0.00043716413
did O 0 0.0006724762
not O 0 0.00095500186
recur O 0 0.0042222184
. O 0 0.0022914752

Further O 0 0.0036444247
observations O 0 0.0027701713
and O 0 0.0018340015
reports O 0 0.0015557485
will O 0 0.0010076007
help O 0 0.0012007774
clarify O 0 0.00077623746
this O 0 0.0018335074
adverse O 0 0.08428886
effect O 0 0.0038651805
. O 0 0.0047124927

Until O 0 0.002804948
then O 0 0.0016751814
, O 0 0.001632562
clinicians O 0 0.0013646842
need O 0 0.0005061443
to O 0 0.00037601727
be O 0 0.00029618293
aware O 0 0.000256129
of O 0 0.00031893406
this O 0 0.00035678621
possible O 0 0.00039417145
complication O 0 0.00719214
associated O 0 0.0008597922
with O 0 0.0042245206
zonisamide B-Chemical 1 0.9999089
. O 0 0.0037225608

Anti O 0 0.14450541
- O 0 0.013199479
epileptic B-Disease 0 0.99794024
drugs O 0 0.4633244
- O 0 0.004129173
induced O 0 0.002238691
de O 0 0.0053012357
novo O 0 0.012209892
absence B-Disease 0 0.01180161
seizures I-Disease 0 0.99993443
. O 0 0.010939457

The O 0 0.0012695009
authors O 0 0.0006779639
present O 0 0.0005087427
three O 0 0.00030426006
patients O 0 0.0005115563
with O 0 0.0004227367
de O 0 0.00094498857
novo O 0 0.0017528989
absence B-Disease 0 0.0010554191
epilepsy I-Disease 2 0.99997413
after O 0 0.00017576567
administration O 0 0.0026918587
of O 0 0.00273585
carbamazepine B-Chemical 1 0.9999937
and O 0 0.011960162
vigabatrin B-Chemical 0 0.9999397
. O 0 0.003748808

Despite O 0 0.0019245481
the O 0 0.0015958141
underlying O 0 0.0024268054
diseases O 0 0.13080005
, O 0 0.0008353151
the O 0 0.00049801916
prognosis O 0 0.030408857
for O 0 0.00031218576
drug O 0 0.037945222
- O 0 0.0005652434
induced O 0 0.0002567045
de O 0 0.0007152807
novo O 0 0.0016903895
absence B-Disease 0 0.0007924349
seizure I-Disease 0 0.9999733
is O 0 0.0002739107
good O 0 0.00023206757
because O 0 6.710965e-05
it O 0 9.9605706e-05
subsides O 0 0.00013015016
rapidly O 0 0.00011191316
after O 0 4.4358963e-05
discontinuing O 0 0.0005969953
the O 0 0.00013469138
use O 0 0.00015844015
of O 0 0.0003165742
the O 0 0.00052334904
offending O 0 0.00827867
drugs O 0 0.078969
. O 0 0.0023971137

The O 0 0.00326189
gamma B-Chemical 0 0.85655427
- I-Chemical 0 0.019152282
aminobutyric I-Chemical 0 0.99972814
acid I-Chemical 0 0.994499
- O 0 0.002116552
transmitted O 0 0.00028098465
thalamocortical O 0 0.0015533364
circuitry O 0 0.00045589288
accounts O 0 0.00018654655
for O 0 8.8237095e-05
a O 0 0.00012979447
major O 0 8.6942404e-05
part O 0 7.16336e-05
of O 0 0.00011999943
the O 0 0.000117455056
underlying O 0 0.00026378225
neurophysiology O 0 0.0008917217
of O 0 0.00041327946
the O 0 0.00059754343
absence B-Disease 0 0.0032750163
epilepsy I-Disease 2 0.9999484
. O 0 0.0052367398

Because O 0 0.002366797
drug O 0 0.032600388
- O 0 0.002985827
induced O 0 0.0012402785
de O 0 0.002317482
novo O 0 0.0039782343
absence B-Disease 0 0.0021582616
seizure I-Disease 0 0.9999567
is O 0 0.0010357212
rare O 0 0.0029697714
, O 0 0.00048650717
pro O 0 0.004520432
- O 0 0.00041697995
absence O 0 0.00013515749
drugs O 0 0.005499308
can O 0 0.00014793915
only O 0 0.00022826367
be O 0 0.00021016745
considered O 0 0.00023899725
a O 0 0.0005959774
promoting O 0 0.0010518428
factor O 0 0.00644967
. O 0 0.0028450054

The O 0 0.0016374034
underlying O 0 0.002002646
epileptogenecity O 0 0.005000365
of O 0 0.0008034896
the O 0 0.00045539925
patients O 0 0.00042068688
or O 0 0.0001717619
the O 0 0.00014955662
synergistic O 0 0.00029727095
effects O 0 0.00019110942
of O 0 0.00020754343
the O 0 0.0001512
accompanying O 0 0.00044846648
drugs O 0 0.011324902
is O 0 0.00012040335
required O 0 6.0088776e-05
to O 0 9.980309e-05
trigger O 0 0.0001177702
the O 0 0.00025433896
de O 0 0.0010854779
novo O 0 0.003314164
absence B-Disease 0 0.003687117
seizure I-Disease 0 0.9998733
. O 0 0.0049749515

The O 0 0.0016002031
possibility O 0 0.0010670323
of O 0 0.0016057763
drug O 0 0.0708131
- O 0 0.001846959
induced O 0 0.0008485743
aggravation O 0 0.32985422
should O 0 0.00015284965
be O 0 0.00012609898
considered O 0 7.733061e-05
whenever O 0 7.783659e-05
an O 0 0.000108697925
unexpected O 0 0.000142756
increase O 0 0.00010595092
in O 0 0.00014263844
seizure B-Disease 0 0.9978283
frequency O 0 0.00019927109
and O 0 0.00012649134
/ O 0 0.00029908007
or O 0 8.2181126e-05
new O 0 0.00019394002
seizure B-Disease 0 0.9937056
types O 0 8.525344e-05
appear O 0 8.0361424e-05
following O 0 7.18979e-05
a O 0 0.00018677684
change O 0 0.00022241614
in O 0 0.00035919537
drug O 0 0.007604339
treatment O 0 0.0015102855
. O 0 0.002011369

By O 0 0.0021799628
understanding O 0 0.0016050976
the O 0 0.0008479624
underlying O 0 0.00087402493
mechanism O 0 0.0006266249
of O 0 0.00076683844
absence B-Disease 0 0.002191902
epilepsy I-Disease 2 0.99998844
, O 0 0.0006432404
we O 0 8.5959415e-05
can O 0 6.6783425e-05
avoid O 0 6.013602e-05
the O 0 6.9456706e-05
inappropriate O 0 0.00012803372
use O 0 7.160928e-05
of O 0 0.00019558556
anticonvulsants O 0 0.9929108
in O 0 0.00011008043
children O 0 0.00020948942
with O 0 0.0003297677
epilepsy B-Disease 2 0.99988985
and O 0 0.00030127566
prevent O 0 0.0002853688
drug O 0 0.038519762
- O 0 0.0008130911
induced O 0 0.0008395263
absence B-Disease 0 0.004732736
seizures I-Disease 0 0.99996674
. O 0 0.0053451317

Prenatal O 0 0.21212003
dexamethasone B-Chemical 0 0.99855155
programs O 0 0.009187271
hypertension B-Disease 2 0.9998733
and O 0 0.006240795
renal B-Disease 2 0.9993949
injury I-Disease 2 0.9944291
in O 0 0.0020902427
the O 0 0.0020510403
rat O 0 0.0059902417
. O 0 0.0033515792

Dexamethasone O 0 0.9981318
is O 0 0.0026513492
frequently O 0 0.0011570465
administered O 0 0.0009701919
to O 0 0.0005603705
the O 0 0.00060905825
developing O 0 0.0019547886
fetus O 0 0.0022555422
to O 0 0.00066484354
accelerate O 0 0.0014743148
pulmonary O 0 0.32592618
development O 0 0.0056137987
. O 0 0.0032344623

The O 0 0.0014761987
purpose O 0 0.0010818719
of O 0 0.00089212623
the O 0 0.0005163941
present O 0 0.00033774783
study O 0 0.0004105952
was O 0 0.00023098062
to O 0 0.00011381873
determine O 0 5.9919857e-05
if O 0 0.0001017852
prenatal O 0 0.008807987
dexamethasone B-Chemical 0 0.9997955
programmed O 0 0.031920098
a O 0 0.00034571148
progressive O 0 0.01103513
increase B-Disease 0 0.00015651902
in I-Disease 0 0.00013196697
blood I-Disease 0 0.0016457087
pressure I-Disease 0 0.0033366529
and O 0 0.00054181117
renal B-Disease 2 0.99899524
injury I-Disease 2 0.9894007
in O 0 0.0014805829
rats O 0 0.0027909875
. O 0 0.0018928543

Pregnant O 0 0.006420071
rats O 0 0.0015493719
were O 0 0.0005303172
given O 0 0.00022099246
either O 0 0.00024684682
vehicle O 0 0.00068246934
or O 0 0.00015759036
2 O 0 0.00010002565
daily O 0 0.00011518683
intraperitoneal O 0 0.00034763452
injections O 0 0.00018467272
of O 0 0.00030098343
dexamethasone B-Chemical 0 0.99949896
( O 0 0.00031266824
0 O 0 7.815425e-05
. O 0 4.297809e-05
2 O 0 5.2313888e-05
mg O 0 0.00061439467
/ O 0 0.00022962292
kg O 0 0.0001838133
body O 0 0.00022837991
weight O 0 0.00043858474
) O 0 0.00011986493
on O 0 3.7283004e-05
gestational O 0 0.00023056033
days O 0 3.2493983e-05
11 O 0 6.008706e-05
and O 0 6.2364794e-05
12 O 0 4.404468e-05
, O 0 8.35694e-05
13 O 0 7.845764e-05
and O 0 7.9198435e-05
14 O 0 7.235031e-05
, O 0 8.798461e-05
15 O 0 6.160582e-05
and O 0 9.3393e-05
16 O 0 0.000107259104
, O 0 0.00013871903
17 O 0 0.000168927
and O 0 0.00016021242
18 O 0 0.00017969511
, O 0 0.00025887083
or O 0 0.00030741637
19 O 0 0.00067389663
and O 0 0.0007786842
20 O 0 0.0013610913
. O 0 0.002027975

Offspring O 0 0.009552972
of O 0 0.001678526
rats O 0 0.0013327847
administered O 0 0.0011987654
dexamethasone B-Chemical 0 0.99329054
on O 0 0.0001953822
days O 0 9.1160524e-05
15 O 0 9.14332e-05
and O 0 0.00010151738
16 O 0 8.965274e-05
gestation O 0 0.0001207963
had O 0 8.506674e-05
a O 0 0.00010822898
20 O 0 8.473246e-05
% O 0 8.245964e-05
reduction B-Disease 2 0.00016233331
in I-Disease 2 9.041565e-05
glomerular I-Disease 2 0.7085588
number I-Disease 2 8.414475e-05
compared O 0 3.576318e-05
with O 0 5.8056383e-05
control O 0 4.8539718e-05
at O 0 3.564177e-05
6 O 0 3.089487e-05
to O 0 3.7697802e-05
9 O 0 3.9684466e-05
months O 0 2.0761674e-05
of O 0 7.088124e-05
age O 0 0.00010488988
( O 0 0.00012393181
22 O 0 0.00013048814
527 O 0 0.00094385934
+ O 0 0.0002646531
/ O 0 0.00039978453
- O 0 0.00024368595
509 O 0 0.0007374809
versus O 0 6.667461e-05
28 O 0 9.417939e-05
050 O 0 0.0018295028
+ O 0 0.00027734635
/ O 0 0.0004960317
- O 0 0.00041938075
561 O 0 0.012197304
, O 0 0.00031734354
P O 0 0.0045596464
< O 0 0.00011090055
0 O 0 8.863675e-05
. O 0 8.631129e-05
05 O 0 0.0016192195
) O 0 0.00018827844
, O 0 0.00010692579
which O 0 0.00011200295
was O 0 8.5313135e-05
comparable O 0 4.523262e-05
to O 0 4.986543e-05
the O 0 5.8714646e-05
percent O 0 5.6298617e-05
reduction O 0 0.00020131201
in O 0 0.00010996544
glomeruli O 0 0.0012856273
measured O 0 0.00011248823
at O 0 0.00010800258
3 O 0 0.00014758296
weeks O 0 0.00014025593
of O 0 0.0006311598
age O 0 0.0014209305
. O 0 0.0018814658

Six O 0 0.0036626349
- O 0 0.0030121543
to O 0 0.0009258236
9 O 0 0.000669413
- O 0 0.00068903243
month O 0 0.00016509015
old O 0 0.00020879645
rats O 0 0.00024327253
receiving O 0 0.00027992207
prenatal O 0 0.0025435002
dexamethasone B-Chemical 0 0.996977
on O 0 7.2886025e-05
days O 0 4.068406e-05
17 O 0 8.6047985e-05
and O 0 6.188645e-05
18 O 0 4.9381186e-05
of O 0 6.9332156e-05
gestation O 0 0.000107600645
had O 0 7.675089e-05
a O 0 0.000111325004
17 O 0 0.000112679874
% O 0 8.006448e-05
reduction O 0 0.00016802049
in O 0 9.3673785e-05
glomeruli O 0 0.0032620076
( O 0 0.00017809954
23 O 0 0.00016656223
380 O 0 0.0012534007
+ O 0 0.00028363094
/ O 0 0.0004966761
- O 0 0.00035973062
587 O 0 0.006745743
) O 0 0.0001467637
compared O 0 4.7903923e-05
with O 0 9.622915e-05
control O 0 0.00012371574
rats O 0 0.00034733088
( O 0 0.00045479124
P O 0 0.0029635273
< O 0 0.00033320283
0 O 0 0.00037781865
. O 0 0.0005614771
05 O 0 0.0057551195
) O 0 0.0024282937
. O 0 0.0024635482

Male O 0 0.006672827
rats O 0 0.001483805
that O 0 0.0005040212
received O 0 0.0004967764
prenatal O 0 0.0044011637
dexamethasone B-Chemical 0 0.99732375
on O 0 0.00015620799
days O 0 7.664981e-05
15 O 0 8.63546e-05
and O 0 0.00011172146
16 O 0 0.000110827175
, O 0 0.00012263037
17 O 0 0.0001267415
and O 0 9.618199e-05
18 O 0 8.149616e-05
, O 0 8.704934e-05
and O 0 7.7132645e-05
13 O 0 6.90229e-05
and O 0 5.477095e-05
14 O 0 4.0714993e-05
of O 0 5.8800044e-05
gestation O 0 9.2244416e-05
had O 0 7.734086e-05
elevated B-Disease 0 0.002019675
blood I-Disease 0 0.0015603928
pressures I-Disease 0 0.00058493693
at O 0 4.048115e-05
6 O 0 3.0209416e-05
months O 0 1.8966559e-05
of O 0 6.693708e-05
age O 0 9.6723e-05
; O 0 8.296752e-05
the O 0 6.9290254e-05
latter O 0 0.0002561275
group O 0 0.00015377221
did O 0 0.00012110054
not O 0 0.0001089665
have O 0 0.00011242305
a O 0 0.00026966984
reduction B-Disease 2 0.0008159788
in I-Disease 2 0.0006743495
glomerular I-Disease 2 0.94952196
number I-Disease 2 0.0019374248
. O 0 0.0020250508

Adult O 0 0.0043289606
rats O 0 0.0018522288
given O 0 0.0007805337
dexamethasone B-Chemical 0 0.98314244
on O 0 0.00027529092
days O 0 0.00013359531
15 O 0 0.00012980413
and O 0 0.00013581122
16 O 0 0.00011018566
of O 0 0.0001308031
gestation O 0 0.00017773514
had O 0 0.00012926977
more O 0 0.00023626306
glomeruli O 0 0.0067043616
with O 0 0.0011094289
glomerulosclerosis B-Disease 2 0.99998593
than O 0 0.00065252074
control O 0 0.000871621
rats O 0 0.0021799742
. O 0 0.0018266627

This O 0 0.0030724811
study O 0 0.0013052237
shows O 0 0.00041280972
that O 0 0.0004041787
prenatal O 0 0.008975639
dexamethasone B-Chemical 0 0.9993814
in O 0 0.00036867906
rats O 0 0.00031054445
results O 0 0.0001314761
in O 0 9.6268705e-05
a O 0 0.0001374765
reduction B-Disease 2 0.0002702969
in I-Disease 2 0.00013551665
glomerular I-Disease 2 0.9265477
number I-Disease 2 0.00027097654
, O 0 0.00053858646
glomerulosclerosis B-Disease 2 0.9999964
, O 0 0.0006141335
and O 0 0.00042071892
hypertension B-Disease 2 0.99988186
when O 0 8.919389e-05
administered O 0 0.00012995275
at O 0 8.521589e-05
specific O 0 0.0001293011
points O 0 0.00023870962
during O 0 0.00031608448
gestation O 0 0.001364829
. O 0 0.0017186693

Hypertension B-Disease 0 0.9924223
was O 0 0.0022100117
observed O 0 0.0007527023
in O 0 0.00045643814
animals O 0 0.00024209569
that O 0 0.00017553155
had O 0 0.00020959451
a O 0 0.00023308716
reduction O 0 0.00040455323
in O 0 0.00015591574
glomeruli O 0 0.003919948
as O 0 0.000101170444
well O 0 6.531935e-05
as O 0 6.1934974e-05
in O 0 5.9016038e-05
a O 0 0.000101088386
group O 0 8.780675e-05
that O 0 4.343416e-05
did O 0 7.910122e-05
not O 0 5.7863042e-05
have O 0 4.4497763e-05
a O 0 8.606456e-05
reduction B-Disease 2 0.00020720353
in I-Disease 2 0.000105812294
glomerular I-Disease 2 0.9198523
number I-Disease 2 0.0001415267
, O 0 8.815416e-05
suggesting O 0 3.2291187e-05
that O 0 3.8042726e-05
a O 0 9.434855e-05
reduction B-Disease 2 0.00022353609
in I-Disease 2 0.00011312386
glomerular I-Disease 2 0.8912196
number I-Disease 2 0.00013324368
is O 0 8.358869e-05
not O 0 7.189091e-05
the O 0 0.0001061126
sole O 0 0.0004493765
cause O 0 0.0002395299
for O 0 0.00013922207
the O 0 0.00027866257
development O 0 0.0009959927
of O 0 0.0031153297
hypertension B-Disease 2 0.99987066
. O 0 0.003564534

Kidney O 0 0.010126911
function O 0 0.0015423343
and O 0 0.00085370673
morphology O 0 0.00079278
after O 0 0.00015385229
short O 0 0.00020075327
- O 0 0.00030121248
term O 0 0.00012096597
combination O 0 0.0001949103
therapy O 0 0.00027624558
with O 0 0.00081801385
cyclosporine B-Chemical 1 0.99999845
A I-Chemical 0 0.9345064
, O 0 0.0016693725
tacrolimus B-Chemical 0 0.99998975
and O 0 0.0018126217
sirolimus B-Chemical 1 0.999874
in O 0 0.00081171
the O 0 0.0009944726
rat O 0 0.0035898057
. O 0 0.0020973654

BACKGROUND O 0 0.011151457
: O 0 0.00435438
Sirolimus B-Chemical 0 0.99323565
( O 0 0.0060900995
SRL B-Chemical 0 0.99959046
) O 0 0.00167686
may O 0 0.0005198326
supplement O 0 0.002409222
calcineurin O 0 0.3017711
inhibitors O 0 0.0033219934
in O 0 0.00070988823
clinical O 0 0.0022421489
organ O 0 0.0054308977
transplantation O 0 0.024921332
. O 0 0.0029387297

These O 0 0.0029366366
are O 0 0.0025729032
nephrotoxic B-Disease 2 0.99903655
, O 0 0.0029967085
but O 0 0.0022283325
SRL B-Chemical 0 0.9997806
seems O 0 0.0003128102
to O 0 0.0001643645
act O 0 0.000106047955
differently O 0 6.622932e-05
displaying O 0 0.0001514869
only O 0 0.00016212139
minor O 0 0.0009976623
nephrotoxic B-Disease 2 0.99973875
effects O 0 0.0007328926
, O 0 0.0003183757
although O 0 0.00016688829
this O 0 0.00027488518
question O 0 0.0003741189
is O 0 0.0004959886
still O 0 0.0008142223
open O 0 0.0024724854
. O 0 0.002003562

In O 0 0.0017546604
a O 0 0.0015042558
number O 0 0.000711612
of O 0 0.00059658237
treatment O 0 0.00041248082
protocols O 0 0.00037604285
where O 0 0.0003499265
SRL B-Chemical 0 0.99976903
was O 0 0.00031397722
combined O 0 0.00021704179
with O 0 0.00017600549
a O 0 0.00023196625
calcineurin O 0 0.19163811
inhibitor O 0 0.0011828966
indications O 0 0.00014432425
of O 0 0.00018097613
a O 0 0.00027963295
synergistic O 0 0.001317193
nephrotoxic B-Disease 2 0.99979395
effect O 0 0.0013099812
were O 0 0.0011553725
described O 0 0.0012816478
. O 0 0.0019406779

The O 0 0.0015366861
aim O 0 0.0014136503
of O 0 0.001145342
this O 0 0.0008367645
study O 0 0.0006530875
was O 0 0.00033480325
to O 0 0.00015404755
examine O 0 7.8575795e-05
further O 0 0.00020751554
the O 0 0.00019634978
renal O 0 0.6964898
function O 0 0.00027358337
, O 0 0.00012868448
including O 0 5.2482388e-05
morphological O 0 0.0002267673
analysis O 0 6.319465e-05
of O 0 7.706654e-05
the O 0 7.5839715e-05
kidneys O 0 0.002314408
of O 0 0.00018281491
male O 0 0.0010450712
Sprague O 0 0.026136877
- O 0 0.00023341787
Dawley O 0 0.00081447646
rats O 0 6.596025e-05
treated O 0 5.9867143e-05
with O 0 7.0814494e-05
either O 0 0.00021327133
cyclosporine B-Chemical 1 0.9999989
A I-Chemical 0 0.9229486
( O 0 0.0014374562
CsA B-Chemical 0 0.9999856
) O 0 0.0010012119
, O 0 0.00050620746
tacrolimus B-Chemical 0 0.9999943
( O 0 0.0023514265
FK506 B-Chemical 0 0.9999863
) O 0 0.0008874141
or O 0 0.00029364903
SRL B-Chemical 0 0.99982566
as O 0 0.00027839938
monotherapies O 0 0.0081902025
or O 0 0.0002349225
in O 0 0.00030099374
different O 0 0.00038681622
combinations O 0 0.0010282838
. O 0 0.0018818796

METHODS O 0 0.0016439673
: O 0 0.001196893
For O 0 0.00035427924
a O 0 0.0005157394
period O 0 0.00020915491
of O 0 0.0003167194
2 O 0 0.00018638403
weeks O 0 9.305856e-05
, O 0 0.00029751705
CsA B-Chemical 0 0.9997353
15 O 0 0.00020151921
mg O 0 0.0053181946
/ O 0 0.00057738833
kg O 0 0.00034579326
/ O 0 0.00024621218
day O 0 5.492367e-05
( O 0 8.836028e-05
given O 0 4.5407392e-05
orally O 0 0.00033083203
) O 0 0.00024233355
, O 0 0.00024076313
FK506 B-Chemical 0 0.99994516
3 O 0 0.00011232682
. O 0 4.8169477e-05
0 O 0 6.160829e-05
mg O 0 0.0008330922
/ O 0 0.00030310053
kg O 0 0.00022863767
/ O 0 0.00018591173
day O 0 4.31861e-05
( O 0 7.193562e-05
given O 0 3.6692025e-05
orally O 0 0.00024907384
) O 0 0.00017066224
or O 0 0.00013548254
SRL B-Chemical 0 0.9997192
0 O 0 0.00010353818
. O 0 4.5767963e-05
4 O 0 4.8853028e-05
mg O 0 0.0006916489
/ O 0 0.0002817796
kg O 0 0.00022235549
/ O 0 0.00018679467
day O 0 4.2811193e-05
( O 0 7.063887e-05
given O 0 3.246754e-05
intraperitoneally O 0 0.00011482197
) O 0 0.00012971702
was O 0 6.2041145e-05
administered O 0 5.6477464e-05
once O 0 3.1985164e-05
a O 0 5.657265e-05
day O 0 3.0197318e-05
as O 0 4.16163e-05
these O 0 8.907736e-05
doses O 0 0.00045190015
have O 0 5.4924196e-05
earlier O 0 8.7311884e-05
been O 0 5.1796338e-05
found O 0 4.8475365e-05
to O 0 4.638943e-05
achieve O 0 5.2565225e-05
a O 0 0.00012530609
significant O 0 0.00014067045
immunosuppressive O 0 0.029906953
effect O 0 0.00027176982
in O 0 0.0004790234
Sprague O 0 0.061821513
- O 0 0.0014625067
Dawley O 0 0.0073699793
rats O 0 0.0017453284
. O 0 0.0016093004

In O 0 0.0018145536
the O 0 0.0014205896
' O 0 0.0013743332
conscious O 0 0.0021112594
catheterized O 0 0.0008327156
rat O 0 0.0007589676
' O 0 0.00035587684
model O 0 0.00022967198
, O 0 0.00018077884
the O 0 0.00015228156
glomerular O 0 0.60781133
filtration O 0 0.00451996
rate O 0 0.00024037846
( O 0 0.00038574098
GFR O 0 0.997652
) O 0 0.00033983105
was O 0 0.00012265108
measured O 0 8.397753e-05
as O 0 0.00010030399
the O 0 0.00015660499
clearance O 0 0.0030263339
of O 0 0.0020197174
Cr O 0 0.99996066
( O 0 0.009070775
EDTA O 0 0.99571013
) O 0 0.006232677
. O 0 0.003065465

The O 0 0.0016407858
morphological O 0 0.00251251
analysis O 0 0.0007949133
of O 0 0.0006443417
the O 0 0.0004498833
kidneys O 0 0.0040446995
included O 0 0.00022671866
a O 0 0.0003039116
semi O 0 0.00048931857
- O 0 0.00026778493
quantitative O 0 0.00017304413
scoring O 0 0.00015479687
system O 0 8.4328785e-05
analysing O 0 6.678158e-05
the O 0 7.269236e-05
degree O 0 0.00012567405
of O 0 0.00021863027
striped O 0 0.04389965
fibrosis B-Disease 2 0.9998129
, O 0 0.0006992118
subcapsular O 0 0.931505
fibrosis B-Disease 2 0.99964845
and O 0 0.00014776828
the O 0 6.922942e-05
number O 0 6.4989115e-05
of O 0 0.00013758273
basophilic O 0 0.053031866
tubules O 0 0.00075291103
, O 0 7.576295e-05
plus O 0 3.8331254e-05
an O 0 6.539045e-05
additional O 0 3.6305326e-05
stereological O 0 8.424993e-05
analysis O 0 4.549573e-05
of O 0 5.832396e-05
the O 0 5.601083e-05
total O 0 0.000101212136
grade O 0 0.0031882504
of O 0 0.00040249233
fibrosis B-Disease 2 0.9979221
in O 0 0.00018934369
the O 0 0.00019147346
cortex O 0 0.0024998744
stained O 0 0.0005196178
with O 0 0.0011245318
Sirius O 0 0.5120079
Red O 0 0.14073315
. O 0 0.0026356468

RESULTS O 0 0.0072369426
: O 0 0.005304355
CsA B-Chemical 0 0.9994436
, O 0 0.005950911
FK506 B-Chemical 0 0.99989104
and O 0 0.0061641783
SRL B-Chemical 0 0.99973613
all O 0 0.0013759519
significantly O 0 0.0014485988
decreased O 0 0.0027576154
the O 0 0.002836867
GFR O 0 0.9975254
. O 0 0.0048614806

A O 0 0.021062257
further O 0 0.0027416209
deterioration O 0 0.017755743
was O 0 0.00087784795
seen O 0 0.00041563855
when O 0 0.00033725344
CsA B-Chemical 0 0.9999058
was O 0 0.00039559253
combined O 0 0.00023549929
with O 0 0.00019032274
either O 0 0.00028585046
FK506 B-Chemical 0 0.9999858
or O 0 0.0010896096
SRL B-Chemical 0 0.99996865
, O 0 0.00023066635
whereas O 0 9.5865355e-05
the O 0 0.00011547209
GFR O 0 0.9962649
remained O 0 0.00015214426
unchanged O 0 7.045461e-05
in O 0 4.1091367e-05
the O 0 4.6389563e-05
group O 0 7.290931e-05
treated O 0 0.000106060994
with O 0 0.00024317189
FK506 B-Chemical 0 0.9999839
plus O 0 0.00043918594
SRL B-Chemical 0 0.9999411
when O 0 7.178143e-05
compared O 0 5.468749e-05
with O 0 0.00010906579
treatment O 0 0.00010887802
with O 0 0.00015986087
any O 0 0.00014601662
of O 0 0.0003175781
the O 0 0.00045074202
single O 0 0.0009754754
substances O 0 0.07357182
. O 0 0.0022393623

The O 0 0.0032998852
morphological O 0 0.005777564
changes O 0 0.0031982255
presented O 0 0.0025750606
a O 0 0.0034576287
similar O 0 0.002570044
pattern O 0 0.004281214
. O 0 0.0063483296

The O 0 0.0019691186
semi O 0 0.003099666
- O 0 0.0017666807
quantitative O 0 0.00094260694
scoring O 0 0.0008327231
was O 0 0.00042642833
significantly O 0 0.00035754708
worst O 0 0.00048477974
in O 0 0.00012484132
the O 0 0.00011012348
group O 0 0.00014283715
treated O 0 0.00018015112
with O 0 0.00037397526
CsA B-Chemical 0 0.9999783
plus O 0 0.000852217
SRL B-Chemical 0 0.99998283
( O 0 0.0016654695
P O 0 0.025835903
< O 0 0.00010457239
0 O 0 6.957469e-05
. O 0 5.5260272e-05
001 O 0 0.00078031956
compared O 0 4.1393814e-05
with O 0 8.567299e-05
controls O 0 0.0001745613
) O 0 0.000117710464
and O 0 5.6048986e-05
the O 0 4.7918133e-05
analysis O 0 4.685461e-05
of O 0 5.925271e-05
the O 0 5.228137e-05
total O 0 8.798436e-05
grade O 0 0.003918656
of O 0 0.00032973688
fibrosis B-Disease 2 0.99876887
also O 0 0.000112734255
showed O 0 6.968219e-05
the O 0 5.1056708e-05
highest O 0 6.919998e-05
proportion O 0 5.5009114e-05
in O 0 4.1759737e-05
the O 0 4.23508e-05
same O 0 2.9663179e-05
group O 0 8.413954e-05
and O 0 7.1113864e-05
was O 0 7.9500496e-05
significantly O 0 8.939519e-05
different O 0 4.8045156e-05
from O 0 8.561207e-05
controls O 0 0.00033108634
( O 0 0.00043088678
P O 0 0.003170548
< O 0 0.00030856245
0 O 0 0.00034137798
. O 0 0.00049018924
02 O 0 0.0051948656
) O 0 0.002284598
. O 0 0.002297938

The O 0 0.0028149448
FK506 B-Chemical 0 0.99954396
plus O 0 0.0035033552
SRL B-Chemical 0 0.9997851
combination O 0 0.0017975955
showed O 0 0.0004977183
only O 0 0.0003521291
a O 0 0.000359601
marginally O 0 0.00063327013
higher O 0 0.00021593088
degree O 0 0.00027336957
of O 0 0.0005153146
fibrosis B-Disease 2 0.9990428
as O 0 0.00016646044
compared O 0 8.016059e-05
with O 0 0.0001903645
controls O 0 0.00050760194
( O 0 0.0005723742
P O 0 0.0056430534
= O 0 0.00045232472
0 O 0 0.0003738811
. O 0 0.0005503181
05 O 0 0.005708781
) O 0 0.0023811597
. O 0 0.0024153914

CONCLUSION O 0 0.017166238
: O 0 0.002250772
This O 0 0.0014545531
rat O 0 0.0012676801
study O 0 0.0005046904
demonstrated O 0 0.00023714638
a O 0 0.00032854074
synergistic O 0 0.0010010069
nephrotoxic B-Disease 2 0.9997898
effect O 0 0.00051203143
of O 0 0.0015454597
CsA B-Chemical 0 0.99998784
plus O 0 0.001183238
SRL B-Chemical 0 0.9999703
, O 0 0.00055710535
whereas O 0 0.0005363168
FK506 B-Chemical 0 0.9999703
plus O 0 0.0013822627
SRL B-Chemical 0 0.9998914
was O 0 0.0012688267
better O 0 0.0017001381
tolerated O 0 0.01180345
. O 0 0.00228758

Evaluation O 0 0.0024761928
of O 0 0.0020993932
cardiac O 0 0.092935294
troponin O 0 0.9983485
I O 0 0.042959888
and O 0 0.00095205207
T O 0 0.34873578
levels O 0 0.00032889674
as O 0 0.00020801375
markers O 0 0.00048268843
of O 0 0.0005276942
myocardial B-Disease 0 0.9999478
damage I-Disease 0 0.9955682
in O 0 0.00066152244
doxorubicin B-Chemical 1 0.99973685
- O 0 0.001593554
induced O 0 0.0012734005
cardiomyopathy B-Disease 0 0.9999907
rats O 0 0.0006608268
, O 0 0.0001292757
and O 0 8.086216e-05
their O 0 8.193581e-05
relationship O 0 4.9612147e-05
with O 0 0.00018402866
echocardiographic O 0 0.0012871019
and O 0 0.00048671075
histological O 0 0.005205996
findings O 0 0.0027706623
. O 0 0.0020918068

BACKGROUND O 0 0.00914522
: O 0 0.0033517387
Cardiac O 0 0.0407556
troponins O 0 0.98187226
I O 0 0.025771486
( O 0 0.0018004965
cTnI O 0 0.843906
) O 0 0.0011088749
and O 0 0.00063141255
T O 0 0.69263846
( O 0 0.0014085657
cTnT O 0 0.97306055
) O 0 0.0005794576
have O 0 0.000119559234
been O 0 9.106774e-05
shown O 0 7.477539e-05
to O 0 8.1068225e-05
be O 0 7.9171106e-05
highly O 0 8.4932435e-05
sensitive O 0 9.581353e-05
and O 0 0.00012714897
specific O 0 0.00013074798
markers O 0 0.0006632654
of O 0 0.0010780704
myocardial B-Disease 0 0.99972147
cell I-Disease 0 0.12395798
injury I-Disease 0 0.9845487
. O 0 0.0039464785

We O 0 0.0014422133
investigated O 0 0.0009527231
the O 0 0.0007337193
diagnostic O 0 0.00077020953
value O 0 0.0005103246
of O 0 0.0007092363
cTnI O 0 0.8556759
and O 0 0.00072029274
cTnT O 0 0.87918895
for O 0 0.00014041208
the O 0 0.00014581167
diagnosis O 0 0.00032977114
of O 0 0.0004324152
myocardial B-Disease 0 0.99995935
damage I-Disease 0 0.9913817
in O 0 0.00017076446
a O 0 0.00014327584
rat O 0 0.00017888291
model O 0 8.971603e-05
of O 0 0.00021309957
doxorubicin B-Chemical 1 0.9990982
( O 0 0.0016589833
DOX B-Chemical 1 0.9999504
) O 0 0.0009826903
- O 0 0.0004871151
induced O 0 0.0007124182
cardiomyopathy B-Disease 0 0.9999889
, O 0 0.00023096452
and O 0 7.299154e-05
we O 0 2.50481e-05
examined O 0 2.7337599e-05
the O 0 3.4615136e-05
relationship O 0 1.988611e-05
between O 0 2.8339875e-05
serial O 0 0.00016941447
cTnI O 0 0.80198354
and O 0 0.00025768927
cTnT O 0 0.8972928
with O 0 0.0001286429
the O 0 6.894554e-05
development O 0 0.00014057929
of O 0 0.00019468818
cardiac B-Disease 0 0.841493
disorders I-Disease 0 0.9238163
monitored O 0 7.138333e-05
by O 0 0.00011003069
echocardiography O 0 0.0006725339
and O 0 0.00013905278
histological O 0 0.0010544434
examinations O 0 0.00033791113
in O 0 0.00027376186
this O 0 0.0006713005
model O 0 0.0015155
. O 0 0.001885191

METHODS O 0 0.001726731
: O 0 0.001558216
Thirty O 0 0.0012027285
- O 0 0.0010148014
five O 0 0.0002893371
Wistar O 0 0.00108669
rats O 0 0.00032455032
were O 0 0.00014693958
given O 0 8.091908e-05
1 O 0 9.310703e-05
. O 0 5.9892096e-05
5 O 0 6.96903e-05
mg O 0 0.0010529471
/ O 0 0.0005380926
kg O 0 0.0009844735
DOX B-Chemical 1 0.999516
, O 0 0.00028078034
i O 0 0.00041672602
. O 0 8.946989e-05
v O 0 0.000543241
. O 0 6.383693e-05
, O 0 7.71531e-05
weekly O 0 5.6112516e-05
for O 0 4.2183685e-05
up O 0 6.4876855e-05
to O 0 5.2794814e-05
8 O 0 4.2192416e-05
weeks O 0 2.0325484e-05
for O 0 3.4323075e-05
a O 0 7.6763485e-05
total O 0 8.4090454e-05
cumulative O 0 0.00019763602
dose O 0 0.0004670911
of O 0 0.00022317003
12 O 0 0.00016406697
mg O 0 0.003847214
/ O 0 0.0017475346
kg O 0 0.0025105546
BW O 0 0.035532203
. O 0 0.0023291737

Ten O 0 0.0046473416
rats O 0 0.0030882836
received O 0 0.0016678235
saline O 0 0.0037734932
as O 0 0.0014269025
a O 0 0.0020274809
control O 0 0.002241319
group O 0 0.0042342143
. O 0 0.00458411

cTnI O 0 0.71089935
was O 0 0.0024263565
measured O 0 0.0010866512
with O 0 0.0012047235
Access O 0 0.002644647
( O 0 0.0020005552
R O 0 0.9386258
) O 0 0.0010420048
( O 0 0.00046496172
ng O 0 0.00079400407
/ O 0 0.0010790814
ml O 0 0.0010027421
) O 0 0.00030882529
and O 0 0.00014015204
a O 0 0.00018239305
research O 0 0.00020910885
immunoassay O 0 0.022152957
( O 0 0.0003370389
pg O 0 0.0087527735
/ O 0 0.0009759026
ml O 0 0.00090317265
) O 0 0.0002653884
, O 0 0.0001251579
and O 0 0.000101373436
compared O 0 8.37144e-05
with O 0 0.0003369321
cTnT O 0 0.9603931
, O 0 0.0009922984
CK O 0 0.991156
- O 0 0.0037275513
MB O 0 0.9917762
mass O 0 0.0085892165
and O 0 0.0018196581
CK O 0 0.932705
. O 0 0.0028389168

By O 0 0.0021284865
using O 0 0.0014294459
transthoracic O 0 0.0030445028
echocardiography O 0 0.0035075878
, O 0 0.0006095292
anterior O 0 0.0010169955
and O 0 0.00027849735
posterior O 0 0.00070887274
wall O 0 0.00080003665
thickness O 0 0.0013706263
, O 0 0.00028629453
LV O 0 0.9821889
diameters O 0 0.00069450267
and O 0 0.00017855284
LV O 0 0.9867474
fractional O 0 0.00153878
shortening O 0 0.0023331994
( O 0 0.00027798963
FS O 0 0.024089007
) O 0 0.00016220905
were O 0 5.872422e-05
measured O 0 4.290843e-05
in O 0 4.841462e-05
all O 0 5.5914454e-05
rats O 0 9.38177e-05
before O 0 4.229873e-05
DOX B-Chemical 1 0.998657
or O 0 0.00012368483
saline O 0 0.000668796
, O 0 8.493778e-05
and O 0 5.7836838e-05
at O 0 3.6212277e-05
weeks O 0 2.5388394e-05
6 O 0 3.5458666e-05
and O 0 6.133476e-05
9 O 0 5.9067046e-05
after O 0 4.242453e-05
treatment O 0 0.00014043205
in O 0 0.00022783008
all O 0 0.00044774756
surviving O 0 0.0027351698
rats O 0 0.002452841
. O 0 0.0019453181

Histology O 0 0.012146803
was O 0 0.0016045658
performed O 0 0.0008550553
in O 0 0.0010875906
DOX B-Chemical 1 0.9995177
- O 0 0.0013707137
rats O 0 0.0003911626
at O 0 0.00012167501
6 O 0 8.466648e-05
and O 0 9.816116e-05
9 O 0 6.7248926e-05
weeks O 0 2.9510984e-05
after O 0 3.0012628e-05
the O 0 8.34517e-05
last O 0 9.115193e-05
DOX B-Chemical 1 0.9979766
dose O 0 0.002197067
and O 0 0.00044191038
in O 0 0.00045516944
all O 0 0.0007818908
controls O 0 0.0022535094
. O 0 0.002083399

RESULTS O 0 0.0045762095
: O 0 0.0019261093
Eighteen O 0 0.0013791529
of O 0 0.00076475536
the O 0 0.0007833988
DOX B-Chemical 1 0.9990839
rats O 0 0.0010361613
died O 0 0.0007578593
prematurely O 0 0.001307711
of O 0 0.0002802118
general O 0 0.0003261707
toxicity B-Disease 2 0.9588152
during O 0 0.00014464029
the O 0 0.00025275044
9 O 0 0.00027850055
- O 0 0.0005364382
week O 0 0.0003187842
period O 0 0.0005763244
. O 0 0.0015859401

End O 0 0.009204316
- O 0 0.005031304
diastolic O 0 0.3912396
( O 0 0.0026499424
ED O 0 0.0831122
) O 0 0.0009352356
and O 0 0.00034539937
end O 0 0.00019650688
- O 0 0.0005638691
systolic O 0 0.06390488
( O 0 0.00047829706
ES O 0 0.009500622
) O 0 0.00042447433
LV O 0 0.98101246
diameters O 0 0.0009799239
/ O 0 0.000653642
BW O 0 0.032689616
significantly O 0 0.00018794986
increased O 0 0.00020609246
, O 0 0.00013824129
whereas O 0 0.00017029486
LV O 0 0.99829084
FS O 0 0.14381205
was O 0 0.00013680238
decreased O 0 0.00015021693
after O 0 2.7573165e-05
9 O 0 4.170235e-05
weeks O 0 2.1602878e-05
in O 0 5.3995016e-05
the O 0 0.00015236464
DOX B-Chemical 1 0.9994387
group O 0 0.0005655923
( O 0 0.00041193503
p O 0 0.00027928496
< O 0 0.0002778116
0 O 0 0.00034382142
. O 0 0.00052198675
001 O 0 0.0076565216
) O 0 0.0024839053
. O 0 0.0024623391

These O 0 0.004573721
parameters O 0 0.004107219
remained O 0 0.0043000123
unchanged O 0 0.0041074576
in O 0 0.0042998022
controls O 0 0.008303345
. O 0 0.007700936

Histological O 0 0.0064077815
evaluation O 0 0.0012108197
of O 0 0.0010410597
hearts O 0 0.0020227395
from O 0 0.00032889735
all O 0 0.00026174125
rats O 0 0.00031757838
given O 0 0.00018878106
DOX B-Chemical 1 0.9981047
revealed O 0 0.00028145334
significant O 0 0.00023730154
slight O 0 0.0006144889
degrees O 0 0.0018900242
of O 0 0.00080606755
perivascular O 0 0.030474514
and O 0 0.0016924525
interstitial O 0 0.9730347
fibrosis B-Disease 2 0.9999026
. O 0 0.005321392

In O 0 0.0022724788
7 O 0 0.0013241847
of O 0 0.0012267347
the O 0 0.0009100118
18 O 0 0.00077982445
rats O 0 0.0011441889
, O 0 0.0012117057
degeneration O 0 0.8794586
and O 0 0.0014383909
myocyte O 0 0.676901
vacuolisation O 0 0.48294523
were O 0 0.0015918304
found O 0 0.0017159439
. O 0 0.0024671485

Only O 0 0.002939149
five O 0 0.0009560356
of O 0 0.0010621701
the O 0 0.0007735245
controls O 0 0.00094612554
exhibited O 0 0.00066982646
evidence O 0 0.00051233947
of O 0 0.0008433122
very O 0 0.0017024745
slight O 0 0.006977461
perivascular O 0 0.5228869
fibrosis B-Disease 2 0.9993795
. O 0 0.0051272498

A O 0 0.015949981
significant O 0 0.0016416727
rise O 0 0.0016717599
in O 0 0.0011633858
cTnT O 0 0.91713023
was O 0 0.0006527708
found O 0 0.00029060105
in O 0 0.00035416122
DOX B-Chemical 1 0.9994856
rats O 0 0.00031591093
after O 0 4.6129153e-05
cumulative O 0 0.0001958158
doses O 0 0.0006713965
of O 0 0.00016666073
7 O 0 6.571565e-05
. O 0 4.095948e-05
5 O 0 3.8908358e-05
and O 0 5.1927447e-05
12 O 0 4.084134e-05
mg O 0 0.00080095365
/ O 0 0.00028272977
kg O 0 0.00018954095
in O 0 6.328294e-05
comparison O 0 6.627575e-05
with O 0 0.000121985075
baseline O 0 0.00014815795
( O 0 0.00030326992
p O 0 0.00025984534
< O 0 0.0002790273
0 O 0 0.00035545503
. O 0 0.00054918864
05 O 0 0.005715161
) O 0 0.002412679
. O 0 0.002445261

cTnT O 0 0.909462
found O 0 0.0018243697
in O 0 0.00091442064
rats O 0 0.00070427975
after O 0 0.00016634747
12 O 0 0.00018073403
mg O 0 0.0028793006
/ O 0 0.0007313116
kg O 0 0.00046237194
were O 0 0.00012823408
significantly O 0 0.00013130972
greater O 0 0.000101279526
than O 0 6.118574e-05
that O 0 6.599605e-05
found O 0 8.457521e-05
after O 0 5.051029e-05
7 O 0 9.157649e-05
. O 0 9.8020486e-05
5 O 0 0.00017073745
mg O 0 0.0027362027
/ O 0 0.0020902446
kg O 0 0.0043841596
DOX B-Chemical 1 0.9975592
. O 0 0.0035093012

Maximal O 0 0.011428785
cTnI O 0 0.8401073
( O 0 0.0032228702
pg O 0 0.015874231
/ O 0 0.0027894329
ml O 0 0.002159476
) O 0 0.0007809608
and O 0 0.00048185862
cTnT O 0 0.7857311
levels O 0 0.00027372272
were O 0 0.00017379617
significantly O 0 0.00018236294
increased O 0 0.00023848918
in O 0 0.00021750708
DOX B-Chemical 1 0.99967635
rats O 0 0.000270384
compared O 0 6.124464e-05
with O 0 0.00013059296
controls O 0 0.00030247527
( O 0 0.00025186522
p O 0 0.0001700367
= O 0 0.00017019422
0 O 0 0.0001265572
. O 0 0.00014926899
006 O 0 0.0015564515
, O 0 0.00037712776
0 O 0 0.00038112004
. O 0 0.00052772084
007 O 0 0.005318029
) O 0 0.0025333175
. O 0 0.0025213535

cTnI O 0 0.86069626
( O 0 0.0043345136
ng O 0 0.0042593046
/ O 0 0.003913303
ml O 0 0.003377253
) O 0 0.0014018688
, O 0 0.0010205226
CK O 0 0.97877365
- O 0 0.0030728185
MB O 0 0.99173224
mass O 0 0.0022169717
and O 0 0.00034136788
CK O 0 0.82608366
remained O 0 0.00028827204
unchanged O 0 0.00021522933
in O 0 0.00027082008
DOX B-Chemical 1 0.998838
rats O 0 0.0006444694
compared O 0 0.00027904383
with O 0 0.0007775001
controls O 0 0.0021406747
. O 0 0.001971208

All O 0 0.0045664734
markers O 0 0.006368061
remained O 0 0.004498942
stable O 0 0.0044888193
in O 0 0.0044996594
controls O 0 0.008539719
. O 0 0.007998151

Analysis O 0 0.0026326855
of O 0 0.0015161602
data O 0 0.0009748887
revealed O 0 0.0005597219
a O 0 0.0004994886
significant O 0 0.00024920687
correlation O 0 0.00013382059
between O 0 0.00010249484
maximal O 0 0.00027777874
cTnT O 0 0.9031357
and O 0 0.00036954752
ED O 0 0.056017783
and O 0 0.00022797349
ES O 0 0.025776826
LV O 0 0.99358964
diameters O 0 0.0011467738
/ O 0 0.0007589755
BW O 0 0.053148787
( O 0 0.00024163588
r O 0 0.00018850622
= O 0 0.00012029558
0 O 0 7.129164e-05
. O 0 5.8825008e-05
81 O 0 0.00015014302
and O 0 0.000103050705
0 O 0 0.00010113747
. O 0 9.2926966e-05
65 O 0 0.00020182227
; O 0 0.00026272982
p O 0 0.00026413787
< O 0 0.00029345372
0 O 0 0.0003742895
. O 0 0.0005687526
0001 O 0 0.0053804396
) O 0 0.0025567245
. O 0 0.0026056278

A O 0 0.015437273
significant O 0 0.0013590849
relationship O 0 0.00051283685
was O 0 0.0005812914
observed O 0 0.0002861155
between O 0 0.00017641547
maximal O 0 0.00040863268
cTnT O 0 0.8624814
and O 0 0.00022879291
the O 0 0.00011774189
extent O 0 8.3539446e-05
of O 0 0.00023897173
myocardial O 0 0.9899532
morphological O 0 0.0015188379
changes O 0 0.00021791561
, O 0 0.00013233443
and O 0 0.00010517212
between O 0 9.7125594e-05
LV O 0 0.97470593
diameters O 0 0.0014560441
/ O 0 0.0011836292
BW O 0 0.022798082
and O 0 0.00067540497
histological O 0 0.005541764
findings O 0 0.0029970107
. O 0 0.002316369

CONCLUSIONS O 0 0.012674761
: O 0 0.0021698992
Among O 0 0.0012923194
markers O 0 0.001742718
of O 0 0.0019901863
ischemic B-Disease 0 0.99994063
injury I-Disease 0 0.99551684
after O 0 0.00032237932
DOX B-Chemical 1 0.999853
in O 0 0.00030465657
rats O 0 0.00041129015
, O 0 0.0002843425
cTnT O 0 0.8220188
showed O 0 0.00012195181
the O 0 7.7684344e-05
greatest O 0 0.000114817914
ability O 0 8.928052e-05
to O 0 8.943979e-05
detect O 0 0.00013845976
myocardial B-Disease 0 0.99992216
damage I-Disease 0 0.98068583
assessed O 0 0.0001730377
by O 0 0.00019507392
echocardiographic O 0 0.0011158793
detection O 0 0.00039244903
and O 0 0.0005092053
histological O 0 0.0051086205
changes O 0 0.0018736288
. O 0 0.001929381

Although O 0 0.00169723
there O 0 0.0009871365
was O 0 0.0009857481
a O 0 0.000688263
discrepancy O 0 0.00044610052
between O 0 0.0001478771
the O 0 0.00015654469
amount O 0 0.00011017821
of O 0 0.0003519843
cTnI O 0 0.8969397
and O 0 0.000537306
cTnT O 0 0.96659374
after O 0 0.0001320017
DOX B-Chemical 1 0.99981993
, O 0 0.00023181546
probably O 0 0.00014603723
due O 0 4.7597514e-05
to O 0 5.8023114e-05
heterogeneity O 0 9.013708e-05
in O 0 6.934948e-05
cross O 0 0.00019295875
- O 0 0.0002110516
reactivities O 0 0.0015217743
of O 0 0.0001403342
mAbs O 0 0.00027492133
to O 0 7.7972094e-05
various O 0 0.00017876935
cTnI O 0 0.8853579
and O 0 0.00037798152
cTnT O 0 0.9720143
forms O 0 0.00020410038
, O 0 0.0001479895
it O 0 9.30355e-05
is O 0 5.9958325e-05
likely O 0 3.9127593e-05
that O 0 6.4988126e-05
cTnT O 0 0.78430796
in O 0 8.8567635e-05
rats O 0 0.00012437091
after O 0 4.1862568e-05
DOX B-Chemical 1 0.99940836
indicates O 0 0.00013994105
cell O 0 0.0010292717
damage O 0 0.0737112
determined O 0 8.696304e-05
by O 0 6.800422e-05
the O 0 5.5007436e-05
magnitude O 0 5.650574e-05
of O 0 0.00016485403
injury O 0 0.104781955
induced O 0 0.0002021489
and O 0 0.00013137197
that O 0 0.00011590729
cTnT O 0 0.9281025
should O 0 5.315896e-05
be O 0 5.8527545e-05
a O 0 7.700102e-05
useful O 0 5.2572952e-05
marker O 0 9.0298294e-05
for O 0 3.8921862e-05
the O 0 5.309366e-05
prediction O 0 7.488429e-05
of O 0 0.00012788778
experimentally O 0 0.00020666567
induced O 0 0.00066148775
cardiotoxicity B-Disease 0 0.99998295
and O 0 0.0005186551
possibly O 0 0.0006401184
for O 0 0.0003972046
cardioprotective O 0 0.27875334
experiments O 0 0.0012337238
. O 0 0.0018359692

Octreotide B-Chemical 0 0.99851435
- O 0 0.0068932143
induced O 0 0.0033620223
hypoxemia B-Disease 0 0.9942151
and O 0 0.004265858
pulmonary B-Disease 2 0.99852365
hypertension I-Disease 2 0.9999814
in O 0 0.0035504873
premature O 0 0.047731176
neonates O 0 0.010560813
. O 0 0.0033798555

The O 0 0.0015100598
authors O 0 0.0009629535
report O 0 0.0012936216
2 O 0 0.0006016297
cases O 0 0.0005297736
of O 0 0.00050950045
premature O 0 0.00202273
neonates O 0 0.0012603854
who O 0 0.000720451
had O 0 0.0006588428
enterocutaneous O 0 0.71785426
fistula B-Disease 0 0.73454887
complicating O 0 0.3526968
necrotizing B-Disease 0 0.9999281
enterocolitis I-Disease 0 0.9997316
. O 0 0.0071430253

Pulmonary B-Disease 0 0.8321268
hypertension I-Disease 2 0.9999033
developed O 0 0.0020457397
after O 0 0.00029875519
administration O 0 0.0011425029
of O 0 0.0004957556
a O 0 0.0007375006
somatostatin O 0 0.78288966
analogue O 0 0.007077052
, O 0 0.0007084919
octreotide B-Chemical 0 0.99196726
, O 0 0.00033675643
to O 0 0.00018352154
enhance O 0 0.00019595028
resolution O 0 0.0020445094
of O 0 0.001022622
the O 0 0.0015827611
fistula B-Disease 0 0.24027678
. O 0 0.0026831846

The O 0 0.001370294
authors O 0 0.0007245291
discuss O 0 0.00055256684
the O 0 0.00050595886
mechanism O 0 0.00044072553
of O 0 0.00037801795
the O 0 0.00024076496
occurrence O 0 0.00029820227
of O 0 0.0002342917
this O 0 0.0002698494
complication O 0 0.004775177
and O 0 0.00015271401
recommend O 0 9.213919e-05
caution O 0 8.875414e-05
of O 0 0.00014058089
its O 0 0.00023607547
use O 0 0.00014150969
in O 0 0.00018170355
high O 0 0.0007229562
- O 0 0.0011388634
risk O 0 0.0056636715
premature O 0 0.021609887
neonates O 0 0.007597808
. O 0 0.002319441

The O 0 0.0019346109
risk O 0 0.0046068425
of O 0 0.0020158226
venous B-Disease 0 0.84740937
thromboembolism I-Disease 0 0.99994564
in O 0 0.000604186
women O 0 0.0020143304
prescribed O 0 0.039970167
cyproterone B-Chemical 0 0.99999666
acetate I-Chemical 0 0.9966349
in O 0 0.00019558461
combination O 0 0.00025500887
with O 0 0.0006825991
ethinyl B-Chemical 0 0.99999154
estradiol I-Chemical 0 0.9999815
: O 0 0.0004063468
a O 0 0.00020774954
nested O 0 0.00036042556
cohort O 0 0.00046696802
analysis O 0 0.00015601642
and O 0 0.00021164064
case O 0 0.00033496923
- O 0 0.0007153695
control O 0 0.00068508903
study O 0 0.0016062963
. O 0 0.0019141135

BACKGROUND O 0 0.015455113
: O 0 0.008215256
Cyproterone B-Chemical 0 0.99992514
acetate I-Chemical 0 0.9985057
combined O 0 0.0021352973
with O 0 0.0026013881
ethinyl B-Chemical 0 0.9999856
estradiol I-Chemical 0 0.9999846
( O 0 0.0072714295
CPA B-Chemical 1 0.99989915
/ O 0 0.014457919
EE B-Chemical 0 0.9887177
) O 0 0.00039159955
is O 0 0.000119943266
licensed O 0 0.00022011198
in O 0 7.195599e-05
the O 0 8.6473425e-05
UK O 0 0.0005350558
for O 0 4.2845666e-05
the O 0 5.404932e-05
treatment O 0 5.954743e-05
of O 0 0.00011151752
women O 0 0.00034973974
with O 0 0.00025943638
acne B-Disease 0 0.99390453
and O 0 0.00068567815
hirsutism B-Disease 0 0.9994766
and O 0 0.00017169247
is O 0 8.296388e-05
also O 0 6.5651e-05
a O 0 0.00010813325
treatment O 0 0.0001002251
option O 0 0.00018628135
for O 0 0.00022789006
polycystic B-Disease 0 0.99916637
ovary I-Disease 0 0.8639156
syndrome I-Disease 0 0.72760075
( O 0 0.0031116237
PCOS B-Disease 0 0.99897444
) O 0 0.0030131883
. O 0 0.0019961123

Previous O 0 0.0015677044
studies O 0 0.0013222955
have O 0 0.0005821455
demonstrated O 0 0.00039898636
an O 0 0.00047251018
increased O 0 0.00062109885
risk O 0 0.0024139234
of O 0 0.0008591703
venous B-Disease 0 0.97349757
thromboembolism I-Disease 0 0.9999944
( O 0 0.006769927
VTE B-Disease 2 0.9999136
) O 0 0.00031293847
associated O 0 0.00011007015
with O 0 0.00034782113
CPA B-Chemical 1 0.99979335
/ O 0 0.0027540096
EE B-Chemical 0 0.82972026
compared O 0 7.021067e-05
with O 0 0.000117052434
conventional O 0 0.00016306089
combined O 0 0.0016736055
oral B-Chemical 1 0.9773876
contraceptives I-Chemical 1 0.9999597
( O 0 0.004969992
COCs O 0 0.9199483
) O 0 0.0029442273
. O 0 0.0021597967

We O 0 0.0017362399
believe O 0 0.0012077533
the O 0 0.0009489575
results O 0 0.0008018082
of O 0 0.00084756734
those O 0 0.00075503293
studies O 0 0.0005054491
may O 0 0.0003469703
have O 0 0.00030042208
been O 0 0.00034182548
affected O 0 0.0005608853
by O 0 0.00069318083
residual O 0 0.001287511
confounding O 0 0.0022124061
. O 0 0.0026675225

METHODS O 0 0.0016760605
: O 0 0.001232837
Using O 0 0.00046919024
the O 0 0.00050498656
General O 0 0.00073558785
Practice O 0 0.0010385936
Research O 0 0.0011115168
Database O 0 0.0008253598
we O 0 9.1820715e-05
conducted O 0 0.00011803642
a O 0 0.00018526672
cohort O 0 0.00038644875
analysis O 0 0.000112990936
and O 0 0.0001151809
case O 0 0.00011934317
- O 0 0.00018710412
control O 0 7.85988e-05
study O 0 9.951286e-05
nested O 0 0.00012372447
within O 0 2.3142853e-05
a O 0 8.300329e-05
population O 0 0.00014234197
of O 0 0.00012589234
women O 0 0.00028021526
aged O 0 0.00010310507
between O 0 2.699776e-05
15 O 0 3.366132e-05
and O 0 5.0651477e-05
39 O 0 8.763193e-05
years O 0 5.2183248e-05
with O 0 0.00015380948
acne B-Disease 0 0.9874821
, O 0 0.00063420524
hirsutism B-Disease 0 0.9995135
or O 0 0.00036069317
PCOS B-Disease 0 0.9990989
to O 0 7.924187e-05
estimate O 0 5.7458674e-05
the O 0 0.00010747083
risk O 0 0.0011060574
of O 0 0.00076115533
VTE B-Disease 2 0.99976295
associated O 0 0.0004487258
with O 0 0.0015923808
CPA B-Chemical 1 0.9996069
/ O 0 0.033760205
EE B-Chemical 0 0.9679346
. O 0 0.0029112408

RESULTS O 0 0.0049590818
: O 0 0.0019554112
The O 0 0.00081863924
age O 0 0.0010576516
- O 0 0.0009268037
adjusted O 0 0.00032248383
incidence O 0 0.00045338232
rate O 0 0.00024697397
ratio O 0 0.0003110805
for O 0 0.00022104492
CPA B-Chemical 1 0.99970454
/ O 0 0.0031827632
EE B-Chemical 0 0.89446324
versus O 0 0.00011523955
conventional O 0 0.00018683117
COCs O 0 0.63124204
was O 0 0.00014672156
2 O 0 7.50653e-05
. O 0 5.2434607e-05
20 O 0 9.128475e-05
[ O 0 0.00020862692
95 O 0 0.00013465593
% O 0 9.940531e-05
confidence O 0 0.00036167278
interval O 0 0.00011257335
( O 0 0.00026048155
CI O 0 0.0057036844
) O 0 0.00024674754
1 O 0 0.00011853622
. O 0 0.00010173581
35 O 0 0.00020800403
- O 0 0.0004097676
3 O 0 0.00027127692
. O 0 0.00037498912
58 O 0 0.0012505228
] O 0 0.0023583116
. O 0 0.0021984775

Using O 0 0.0014761299
as O 0 0.0010068556
the O 0 0.00063841237
reference O 0 0.0005692173
group O 0 0.00064533425
women O 0 0.00077945075
who O 0 0.00030233024
were O 0 0.00012599406
not O 0 9.6336575e-05
using O 0 0.00013200108
oral O 0 0.4846883
contraception O 0 0.58229405
, O 0 0.00017296725
had O 0 7.9750316e-05
no O 0 3.962676e-05
recent O 0 7.894532e-05
pregnancy O 0 0.0013971771
or O 0 0.00018078556
menopausal O 0 0.9931585
symptoms O 0 0.4439241
, O 0 0.00013698736
the O 0 8.125071e-05
case O 0 8.9821915e-05
- O 0 0.00014043701
control O 0 5.9518825e-05
analysis O 0 7.052141e-05
gave O 0 0.00016377565
an O 0 0.00010419157
adjusted O 0 8.696603e-05
odds O 0 0.00026933893
ratio O 0 0.00021143048
( O 0 0.00027101274
OR O 0 0.006744645
( O 0 0.00025343892
adj O 0 0.0012732563
) O 0 0.00018977786
) O 0 0.00013405176
of O 0 0.00010434459
7 O 0 6.203547e-05
. O 0 5.1334693e-05
44 O 0 0.000114957926
( O 0 0.00012753169
95 O 0 0.00014329006
% O 0 0.00012424456
CI O 0 0.0016131626
3 O 0 6.0714134e-05
. O 0 4.8356385e-05
67 O 0 0.00013903702
- O 0 0.00013801028
15 O 0 5.638845e-05
. O 0 5.7280977e-05
08 O 0 0.0005513376
) O 0 0.00014991256
for O 0 0.000108642904
CPA B-Chemical 1 0.9993668
/ O 0 0.0021869452
EE B-Chemical 0 0.8757317
use O 0 8.767589e-05
compared O 0 5.0496274e-05
with O 0 0.000108301756
an O 0 0.00024188893
OR O 0 0.013815262
( O 0 0.0002794594
adj O 0 0.0011177027
) O 0 0.00014940284
of O 0 0.000112859234
2 O 0 7.504834e-05
. O 0 5.2730917e-05
58 O 0 0.00012421957
( O 0 0.00013246824
95 O 0 0.00015172514
% O 0 0.00013560792
CI O 0 0.0017471219
1 O 0 7.7517994e-05
. O 0 5.4880584e-05
60 O 0 9.431042e-05
- O 0 0.00017944683
4 O 0 8.132056e-05
. O 0 7.713066e-05
18 O 0 0.000121152174
) O 0 0.000199605
for O 0 0.00014451651
use O 0 0.00026900478
of O 0 0.0006114854
conventional O 0 0.0014049226
COCs O 0 0.64610475
. O 0 0.0025875757

CONCLUSIONS O 0 0.014969793
: O 0 0.0021022842
We O 0 0.00063888414
have O 0 0.00044062178
demonstrated O 0 0.00033602523
an O 0 0.00043804117
increased O 0 0.0006819583
risk O 0 0.0050891456
of O 0 0.0015707338
VTE B-Disease 2 0.9998745
associated O 0 0.00016751053
with O 0 0.00014203826
the O 0 9.039151e-05
use O 0 8.437205e-05
of O 0 0.00029492
CPA B-Chemical 1 0.9998344
/ O 0 0.0037573336
EE B-Chemical 0 0.9295457
in O 0 0.00012334116
women O 0 0.00036293344
with O 0 0.00027425826
acne B-Disease 0 0.99442947
, O 0 0.0007588652
hirsutism B-Disease 0 0.99955946
or O 0 0.00044046683
PCOS B-Disease 0 0.9994087
although O 0 0.000120022894
residual O 0 0.00016525676
confounding O 0 0.00017112207
by O 0 0.0002107116
indication O 0 0.00022082479
cannot O 0 0.00090255804
be O 0 0.00059312896
excluded O 0 0.0013243903
. O 0 0.0017612801

The O 0 0.0014604428
effect O 0 0.0010678936
of O 0 0.0010262594
treatment O 0 0.000734742
with O 0 0.00096608856
gum B-Chemical 0 0.74741673
Arabic I-Chemical 0 0.011759375
on O 0 0.0004017948
gentamicin B-Chemical 1 0.9998828
nephrotoxicity B-Disease 0 0.9999968
in O 0 0.0010551095
rats O 0 0.000896771
: O 0 0.0005289985
a O 0 0.0006770141
preliminary O 0 0.0015399173
study O 0 0.0019028353
. O 0 0.0021404303

In O 0 0.0016593339
the O 0 0.0011401137
present O 0 0.000630965
work O 0 0.00054047944
we O 0 0.00019462171
assessed O 0 0.00017944135
the O 0 0.000163738
effect O 0 0.00014276226
of O 0 0.00020343084
treatment O 0 0.00014758408
of O 0 0.00017402304
rats O 0 0.00023041532
with O 0 0.00024162114
gum B-Chemical 0 0.63711554
Arabic I-Chemical 0 0.005667938
on O 0 0.000112782436
acute B-Disease 0 0.4808004
renal I-Disease 0 0.991678
failure I-Disease 0 0.45414788
induced O 0 0.0005277158
by O 0 0.00058309676
gentamicin B-Chemical 1 0.9996834
( O 0 0.0044308743
GM B-Chemical 0 0.998021
) O 0 0.013056294
nephrotoxicity B-Disease 0 0.9999659
. O 0 0.005356308

Rats O 0 0.0040034503
were O 0 0.0012985341
treated O 0 0.0009881435
with O 0 0.00063356454
the O 0 0.00047879654
vehicle O 0 0.0017283355
( O 0 0.0005211073
2 O 0 0.00020502332
mL O 0 0.00059672195
/ O 0 0.00041648993
kg O 0 0.00028999854
of O 0 0.00015692922
distilled O 0 0.0009844482
water O 0 0.0013634226
and O 0 0.00012203987
5 O 0 7.145676e-05
% O 0 0.000100155456
w O 0 0.00029016694
/ O 0 0.00055835675
v O 0 0.0020348055
cellulose O 0 0.41832194
, O 0 0.00016635477
10 O 0 7.7028344e-05
days O 0 4.3438922e-05
) O 0 0.00016318844
, O 0 0.0001849737
gum B-Chemical 0 0.48717156
Arabic I-Chemical 0 0.012650559
( O 0 0.00026444072
2 O 0 9.649267e-05
mL O 0 0.00034326658
/ O 0 0.00027042994
kg O 0 0.0001945796
of O 0 9.934865e-05
a O 0 0.000115476825
10 O 0 7.609007e-05
% O 0 9.420391e-05
w O 0 0.00024747697
/ O 0 0.00036368836
v O 0 0.0007054156
aqueous O 0 0.045973793
suspension O 0 0.00067833427
of O 0 0.0003076011
gum B-Chemical 0 0.87186813
Arabic I-Chemical 0 0.0682845
powder O 0 0.49385887
, O 0 0.00014752049
orally O 0 0.00020698218
for O 0 4.374113e-05
10 O 0 4.8755388e-05
days O 0 2.8935487e-05
) O 0 0.00010147199
, O 0 7.8422636e-05
or O 0 9.112656e-05
gum B-Chemical 0 0.37941363
Arabic I-Chemical 0 0.0048214
concomitantly O 0 0.00061805005
with O 0 0.00031928273
GM B-Chemical 0 0.995621
( O 0 0.00049611914
80mg O 0 0.8915661
/ O 0 0.00050290924
kg O 0 0.00024715863
/ O 0 0.00017987014
day O 0 4.085053e-05
intramuscularly O 0 0.000103143226
, O 0 6.0136703e-05
during O 0 2.6578273e-05
the O 0 4.462397e-05
last O 0 2.5913356e-05
six O 0 3.6359343e-05
days O 0 4.137073e-05
of O 0 0.00013810479
the O 0 0.00021121449
treatment O 0 0.0003829293
period O 0 0.00044818336
) O 0 0.0017685334
. O 0 0.0019525887

Nephrotoxicity B-Disease 0 0.9980894
was O 0 0.0024628534
assessed O 0 0.00069051347
by O 0 0.00045662766
measuring O 0 0.0002379123
the O 0 0.00022059352
concentrations O 0 0.0005064536
of O 0 0.00055087457
creatinine B-Chemical 1 0.99950325
and O 0 0.00083727227
urea B-Chemical 0 0.9994221
in O 0 0.00014569687
the O 0 0.00012185801
plasma O 0 0.0028470613
and O 0 0.00024466586
reduced O 0 0.05013323
glutathione B-Chemical 0 0.99999845
( O 0 0.06865676
GSH B-Chemical 1 0.9999989
) O 0 0.0006211533
in O 0 9.9773024e-05
the O 0 0.0001299872
kidney O 0 0.5568666
cortex O 0 0.01965911
, O 0 0.00017278774
and O 0 0.00011635789
by O 0 0.00013004299
light O 0 0.00045750142
microscopic O 0 0.00055552734
examination O 0 0.00032930463
of O 0 0.00068327895
kidney O 0 0.62632006
sections O 0 0.0021930742
. O 0 0.0018728389

The O 0 0.0013683393
results O 0 0.0010338413
indicated O 0 0.0005153153
that O 0 0.0003419661
concomitant O 0 0.0008736231
treatment O 0 0.00036982913
with O 0 0.00055478234
gum B-Chemical 0 0.8416909
Arabic I-Chemical 0 0.022246387
and O 0 0.00040475995
GM B-Chemical 0 0.98760414
significantly O 0 0.0003412664
increased O 0 0.00057541655
creatinine B-Chemical 1 0.9995766
and O 0 0.00059628044
urea B-Chemical 0 0.9993812
by O 0 0.00015334933
about O 0 0.00011987007
183 O 0 0.00073248486
and O 0 0.00011902789
239 O 0 0.0010260121
% O 0 0.000111168854
, O 0 0.00011035464
respectively O 0 0.00021695408
( O 0 9.960427e-05
compared O 0 4.0642917e-05
to O 0 7.010022e-05
432 O 0 0.0014749771
and O 0 0.00013296583
346 O 0 0.001963154
% O 0 0.000116561554
, O 0 0.00011402491
respectively O 0 0.00022196976
, O 0 8.455618e-05
in O 0 5.692772e-05
rats O 0 0.00010493029
treated O 0 0.0001210052
with O 0 0.00018934855
cellulose O 0 0.6247966
and O 0 0.00038497648
GM B-Chemical 0 0.9980956
) O 0 0.00041906422
, O 0 0.00011572231
and O 0 7.819756e-05
decreased O 0 0.00013327175
that O 0 5.0122067e-05
of O 0 0.00016200703
cortical O 0 0.057723284
GSH B-Chemical 1 0.99999845
by O 0 0.0003081379
21 O 0 0.00013365023
% O 0 9.166219e-05
( O 0 8.427758e-05
compared O 0 3.505383e-05
to O 0 5.001535e-05
27 O 0 0.000101390644
% O 0 6.0982966e-05
in O 0 4.895815e-05
the O 0 8.407361e-05
cellulose O 0 0.17312881
plus O 0 0.00014275954
GM B-Chemical 0 0.9936765
group O 0 0.00031820274
) O 0 0.00017933086
The O 0 8.440433e-05
GM B-Chemical 0 0.9815036
- O 0 0.00031723164
induced O 0 0.00014570869
proximal O 0 0.0004997684
tubular B-Disease 0 0.9935533
necrosis I-Disease 2 0.9999826
appeared O 0 0.00023722148
to O 0 7.687468e-05
be O 0 6.243608e-05
slightly O 0 0.00012475134
less O 0 9.3712384e-05
severe O 0 0.00079497695
in O 0 7.091613e-05
rats O 0 0.00010611138
given O 0 5.243656e-05
GM B-Chemical 0 0.8771383
together O 0 0.000114914525
with O 0 0.0002530519
gum B-Chemical 0 0.63199306
Arabic I-Chemical 0 0.004021527
than O 0 0.000101602614
in O 0 0.00013069414
those O 0 0.00025884662
given O 0 0.00026964262
GM B-Chemical 0 0.94652283
and O 0 0.0019670967
cellulose O 0 0.73129195
. O 0 0.0029914307

It O 0 0.0026019672
could O 0 0.0010962627
be O 0 0.000662507
inferred O 0 0.0005098629
that O 0 0.00043844158
gum B-Chemical 0 0.7258603
Arabic I-Chemical 0 0.01917274
treatment O 0 0.00043995658
has O 0 0.0001656782
induced O 0 0.00021756059
a O 0 0.00026999557
modest O 0 0.00062435184
amelioration O 0 0.06658187
of O 0 0.00022703015
some O 0 0.00011831803
of O 0 0.00013566417
the O 0 0.00012573661
histological O 0 0.0010491583
and O 0 0.00016592958
biochemical O 0 0.00061592454
indices O 0 0.0004172068
of O 0 0.0013390125
GM B-Chemical 0 0.9988611
nephrotoxicity B-Disease 0 0.99998236
. O 0 0.006324965

Further O 0 0.0030987733
work O 0 0.0018063828
is O 0 0.00088251586
warranted O 0 0.0004385883
on O 0 0.0002173516
the O 0 0.0002275097
effect O 0 0.00018113738
of O 0 0.00022103648
the O 0 0.00015190856
treatments O 0 0.00020020943
on O 0 7.931854e-05
renal O 0 0.29314196
functional O 0 0.00011108228
aspects O 0 3.629297e-05
in O 0 5.8011938e-05
models O 0 0.00010143746
of O 0 0.00026064998
chronic B-Disease 2 0.90668136
renal I-Disease 2 0.9980161
failure I-Disease 2 0.96665
, O 0 0.00029557393
and O 0 0.00012814363
on O 0 7.324967e-05
the O 0 0.0001517545
mechanism O 0 0.00030052292
( O 0 0.0005119811
s O 0 0.000550566
) O 0 0.0011053944
involved O 0 0.001079706
. O 0 0.0020955887

Increased O 0 0.0028209009
frequency O 0 0.0015938341
of O 0 0.0018626332
venous B-Disease 0 0.80502737
thromboembolism I-Disease 0 0.9999236
with O 0 0.0005067397
the O 0 0.00020324164
combination O 0 0.00023907152
of O 0 0.00036655914
docetaxel B-Chemical 1 0.9939908
and O 0 0.00050362834
thalidomide B-Chemical 1 0.9998241
in O 0 0.00023571988
patients O 0 0.00031795286
with O 0 0.00039812614
metastatic O 0 0.70662034
androgen O 0 0.9995859
- O 0 0.0014036961
independent O 0 0.00062325486
prostate B-Disease 2 0.99528027
cancer I-Disease 2 0.9993318
. O 0 0.0037481776

STUDY O 0 0.0042841537
OBJECTIVE O 0 0.011614735
: O 0 0.001324466
To O 0 0.00046544528
evaluate O 0 0.00025753945
the O 0 0.00029818152
frequency O 0 0.00033168914
of O 0 0.00063941104
venous B-Disease 0 0.93062466
thromboembolism I-Disease 0 0.99999166
( O 0 0.006759412
VTE B-Disease 2 0.99990606
) O 0 0.00031855452
in O 0 9.034825e-05
patients O 0 0.0001311757
with O 0 0.00014700124
advanced O 0 0.003707244
androgen O 0 0.9994486
- O 0 0.0003661135
independent O 0 8.839829e-05
prostate B-Disease 2 0.99535537
cancer I-Disease 2 0.9997718
who O 0 0.0003846177
were O 0 7.995629e-05
treated O 0 0.0001207652
with O 0 0.00020668145
docetaxel B-Chemical 1 0.9787739
alone O 0 0.00019567974
or O 0 0.00015713062
in O 0 0.0002143461
combination O 0 0.0006774066
with O 0 0.0021329557
thalidomide B-Chemical 1 0.99965453
. O 0 0.0035279095

DESIGN O 0 0.0045358147
: O 0 0.0031118044
Retrospective O 0 0.0050688763
analysis O 0 0.0011954107
of O 0 0.0011632141
a O 0 0.0013244641
randomized O 0 0.001389698
phase O 0 0.0026859662
II O 0 0.010390937
trial O 0 0.003925101
. O 0 0.003666207

SETTING O 0 0.006553766
: O 0 0.003644127
National O 0 0.0036926037
Institutes O 0 0.006700312
of O 0 0.0025219028
Health O 0 0.0026476292
clinical O 0 0.004467148
research O 0 0.0038733848
center O 0 0.0052793026
. O 0 0.005426537

PATIENTS O 0 0.0017623034
: O 0 0.0021139525
Seventy O 0 0.0022844502
men O 0 0.0026531478
, O 0 0.00080711127
aged O 0 0.0007503712
50 O 0 0.00062055356
- O 0 0.0005293937
80 O 0 0.00034766138
years O 0 0.00019534922
, O 0 0.00023048431
with O 0 0.00036006805
advanced O 0 0.006764671
androgen O 0 0.99917126
- O 0 0.0016568318
independent O 0 0.0007744495
prostate B-Disease 2 0.99545056
cancer I-Disease 2 0.9993012
. O 0 0.0042503793

INTERVENTION O 0 0.00243169
: O 0 0.0011114543
Each O 0 0.00031325396
patient O 0 0.00039749284
received O 0 0.00022284746
either O 0 0.00025237168
intravenous O 0 0.009564683
docetaxel B-Chemical 1 0.967188
30 O 0 0.00016385358
mg O 0 0.0029063134
/ O 0 0.00045152727
m2 O 0 0.00077791396
/ O 0 0.00022631846
week O 0 3.186184e-05
for O 0 3.3299642e-05
3 O 0 3.405179e-05
consecutive O 0 3.6485915e-05
weeks O 0 2.3048497e-05
, O 0 5.9245085e-05
followed O 0 4.666514e-05
by O 0 6.651838e-05
1 O 0 4.7712896e-05
week O 0 2.7350037e-05
off O 0 5.1973522e-05
, O 0 5.858534e-05
or O 0 3.9899056e-05
the O 0 4.5415272e-05
combination O 0 6.649713e-05
of O 0 7.6059885e-05
continuous O 0 6.8883106e-05
oral O 0 0.026137175
thalidomide B-Chemical 1 0.9998062
200 O 0 0.000693893
mg O 0 0.0012577004
every O 0 3.283533e-05
evening O 0 0.00015741255
plus O 0 8.2913255e-05
the O 0 0.00016859215
same O 0 0.0002656821
docetaxel B-Chemical 1 0.9661473
regimen O 0 0.0030488127
. O 0 0.002139449

This O 0 0.0044027227
4 O 0 0.0016184427
- O 0 0.001606931
week O 0 0.0004251895
cycle O 0 0.0006041258
was O 0 0.000296948
repeated O 0 0.00013291501
until O 0 0.0001104177
there O 0 0.000116036776
was O 0 0.0001931756
evidence O 0 0.00016284615
of O 0 0.00037057552
excessive O 0 0.007129275
toxicity B-Disease 2 0.9980995
or O 0 0.0017482084
disease O 0 0.6673354
progression O 0 0.22973879
. O 0 0.0029660647

MEASUREMENTS O 0 0.00649834
AND O 0 0.0016373822
MAIN O 0 0.0033882405
RESULTS O 0 0.0014481946
: O 0 0.00067491084
None O 0 0.00046313897
of O 0 0.00035365953
23 O 0 0.0003508424
patients O 0 0.00025735906
who O 0 0.00023171447
received O 0 0.00014939388
docetaxel B-Chemical 1 0.9669078
alone O 0 0.0003318327
developed O 0 0.0030802244
VTE B-Disease 2 0.9999471
, O 0 0.00023709577
whereas O 0 0.00010585933
9 O 0 6.0060756e-05
of O 0 8.51894e-05
47 O 0 0.000167975
patients O 0 0.00013593287
( O 0 0.0001189833
19 O 0 0.00010820018
% O 0 8.077492e-05
) O 0 0.000105239116
who O 0 9.6202086e-05
received O 0 7.37976e-05
docetaxel B-Chemical 1 0.9195829
plus O 0 0.00022230421
thalidomide B-Chemical 1 0.9999392
developed O 0 0.037140425
VTE B-Disease 2 0.99996114
( O 0 0.0008548729
p O 0 0.00033557686
= O 0 0.00032537937
0 O 0 0.0002824528
. O 0 0.00041491704
025 O 0 0.008907065
) O 0 0.002376409
. O 0 0.0022597031

CONCLUSION O 0 0.013110063
: O 0 0.0015912851
The O 0 0.00049590785
addition O 0 0.0003687745
of O 0 0.0009194954
thalidomide B-Chemical 1 0.9996345
to O 0 0.00077819277
docetaxel B-Chemical 1 0.992669
in O 0 0.00021455833
the O 0 0.00015692278
treatment O 0 0.0001892446
of O 0 0.00058038515
prostate B-Disease 2 0.99832374
cancer I-Disease 2 0.9997305
significantly O 0 0.00074385805
increases O 0 0.00033126026
the O 0 0.0003616726
frequency O 0 0.0007643469
of O 0 0.0031938567
VTE B-Disease 2 0.99944645
. O 0 0.0030301216

Clinicians O 0 0.003807477
should O 0 0.00096374843
be O 0 0.0007711242
aware O 0 0.0005374495
of O 0 0.00050215813
this O 0 0.000422313
potential O 0 0.00044995386
complication O 0 0.0031280438
when O 0 0.0002566964
adding O 0 0.0011837516
thalidomide B-Chemical 1 0.9996288
to O 0 0.0011536578
chemotherapeutic O 0 0.046274863
regimens O 0 0.0049506417
. O 0 0.0027924187

Ticlopidine B-Chemical 0 0.9990085
- O 0 0.039984934
induced O 0 0.058157366
cholestatic B-Disease 0 0.99993
hepatitis I-Disease 2 0.9999349
. O 0 0.056435693

OBJECTIVE O 0 0.024500914
: O 0 0.0022327662
To O 0 0.000884527
report O 0 0.0010970035
2 O 0 0.000492082
cases O 0 0.0005247957
of O 0 0.0013540979
ticlopidine B-Chemical 1 0.9999914
- O 0 0.0037003183
induced O 0 0.004503529
cholestatic B-Disease 0 0.9999993
hepatitis I-Disease 2 0.99999905
, O 0 0.0011658309
investigate O 0 8.925149e-05
its O 0 0.00027447904
mechanism O 0 0.00015564599
, O 0 0.000112204034
and O 0 7.079512e-05
compare O 0 2.7065815e-05
the O 0 5.1707066e-05
observed O 0 5.022216e-05
main O 0 6.477603e-05
characteristics O 0 5.4699227e-05
with O 0 0.0001443281
those O 0 0.00022846833
of O 0 0.0003142821
the O 0 0.00043761396
published O 0 0.0009791987
cases O 0 0.0018800541
. O 0 0.001992411

CASE O 0 0.035307337
SUMMARIES O 0 0.009529045
: O 0 0.0012388002
Two O 0 0.0005121793
patients O 0 0.0005281048
developed O 0 0.00059248635
prolonged O 0 0.0034837786
cholestatic B-Disease 0 0.9999975
hepatitis I-Disease 2 0.99999726
after O 0 0.00019056443
receiving O 0 0.0021040598
ticlopidine B-Chemical 1 0.999987
following O 0 8.022314e-05
percutaneous O 0 0.0001508784
coronary O 0 0.042728633
angioplasty O 0 0.010835623
, O 0 8.510674e-05
with O 0 7.7387485e-05
complete O 0 9.084327e-05
remission O 0 0.00089431345
during O 0 6.230641e-05
the O 0 0.00014057016
follow O 0 0.00016224911
- O 0 0.00050973124
up O 0 0.0005486639
period O 0 0.000630995
. O 0 0.0016172535

T O 0 0.8365305
- O 0 0.0058539603
cell O 0 0.0029696233
stimulation O 0 0.0006108534
by O 0 0.00051964703
therapeutic O 0 0.00073926215
concentration O 0 0.0010246377
of O 0 0.0018741989
ticlopidine B-Chemical 1 0.9999932
was O 0 0.0004120743
demonstrated O 0 0.0001171774
in O 0 9.704543e-05
vitro O 0 0.00015397587
in O 0 0.000101475765
the O 0 0.00013381294
patients O 0 0.0002723903
, O 0 0.00020284204
but O 0 0.0001961209
not O 0 0.0002143853
in O 0 0.0003722787
healthy O 0 0.0023753897
controls O 0 0.0022668096
. O 0 0.001941537

DISCUSSION O 0 0.0053860825
: O 0 0.007011629
Cholestatic B-Disease 0 0.9998534
hepatitis I-Disease 2 0.99997556
is O 0 0.0020379566
a O 0 0.00097521004
rare O 0 0.0016280712
complication O 0 0.003594258
of O 0 0.00025988297
the O 0 0.00024104769
antiplatelet O 0 0.8360626
agent O 0 0.09592009
ticlopidine B-Chemical 1 0.9999962
; O 0 0.00034021033
several O 0 9.406092e-05
cases O 0 0.00014395507
have O 0 8.0080055e-05
been O 0 9.433606e-05
reported O 0 0.00016426407
but O 0 0.00017334304
few O 0 0.00012072939
in O 0 0.00023531773
the O 0 0.00046704078
English O 0 0.001995136
literature O 0 0.0026588042
. O 0 0.0022304961

Our O 0 0.0021631718
patients O 0 0.0020595444
developed O 0 0.002157155
jaundice B-Disease 2 0.98442876
following O 0 0.0003498908
treatment O 0 0.00041107027
with O 0 0.001072316
ticlopidine B-Chemical 1 0.9999901
and O 0 0.00026808356
showed O 0 0.00011145459
the O 0 8.4549734e-05
clinical O 0 0.00020417433
and O 0 7.517189e-05
laboratory O 0 0.000110211615
characteristics O 0 4.862074e-05
of O 0 0.0004986283
cholestatic B-Disease 0 0.9999988
hepatitis I-Disease 2 0.9999988
, O 0 0.0010501037
which O 0 0.0002998464
resolved O 0 0.0002877591
after O 0 8.9512134e-05
discontinuation O 0 0.0039191325
of O 0 0.00056816824
the O 0 0.00087200815
drug O 0 0.029526837
. O 0 0.0021508848

Hepatitis B-Disease 0 0.99760985
may O 0 0.0016575088
develop O 0 0.00096812076
weeks O 0 0.00023278335
after O 0 0.000149346
discontinuation O 0 0.0020627584
of O 0 0.0002808079
the O 0 0.00021229811
drug O 0 0.004128722
and O 0 0.00014848847
may O 0 8.105895e-05
run O 0 0.000116245
a O 0 0.00012103405
prolonged O 0 0.00016961101
course O 0 8.9641464e-05
, O 0 0.00011442335
but O 0 0.00010013627
complete O 0 0.00012959822
remission O 0 0.004238223
was O 0 0.0001804382
observed O 0 0.00014845918
in O 0 0.00022879269
all O 0 0.0004157975
reported O 0 0.00095635763
cases O 0 0.0019465374
. O 0 0.002010261

An O 0 0.0023811404
objective O 0 0.0016387056
causality O 0 0.0013315653
assessment O 0 0.00048821306
revealed O 0 0.00031427076
that O 0 0.00019236961
the O 0 0.00029177507
adverse O 0 0.030261638
drug O 0 0.026531737
event O 0 0.0008502853
was O 0 0.00022319642
probably O 0 0.00019450596
related O 0 8.2821905e-05
to O 0 0.00016068181
the O 0 0.00028072065
use O 0 0.00051430985
of O 0 0.0027417853
ticlopidine B-Chemical 1 0.99993694
. O 0 0.0039083585

The O 0 0.002020094
mechanisms O 0 0.0021259482
of O 0 0.0022470164
this O 0 0.004864141
ticlopidine B-Chemical 1 0.9999666
- O 0 0.010366557
induced O 0 0.008664301
cholestasis B-Disease 2 0.9999713
are O 0 0.0047176033
unclear O 0 0.0030678809
. O 0 0.0038469397

Immune O 0 0.014454386
mechanisms O 0 0.0021031108
may O 0 0.00090829754
be O 0 0.00052326743
involved O 0 0.00026934867
in O 0 0.0002564711
the O 0 0.0002786041
drug O 0 0.005108661
' O 0 0.00050859695
s O 0 0.00066342123
hepatotoxicity B-Disease 0 0.99999166
, O 0 0.0005188314
as O 0 0.00015774206
suggested O 0 0.00010532185
by O 0 0.00016739158
the O 0 0.0002802046
T O 0 0.65247506
- O 0 0.00090229575
cell O 0 0.0010371301
stimulation O 0 0.0003512373
study O 0 0.00073943444
reported O 0 0.0010931748
here O 0 0.0015495754
. O 0 0.0022091505

CONCLUSIONS O 0 0.03948888
: O 0 0.011218359
Cholestatic B-Disease 0 0.99988115
hepatitis I-Disease 2 0.99997604
is O 0 0.0023142442
a O 0 0.0011570642
rare O 0 0.0021607154
adverse O 0 0.031548623
effect O 0 0.00044250285
of O 0 0.0017665378
ticlopidine B-Chemical 1 0.9999789
that O 0 0.00044276068
may O 0 0.00045066603
be O 0 0.0005938697
immune O 0 0.004117793
mediated O 0 0.00137493
. O 0 0.0025968913

Patients O 0 0.0024152305
receiving O 0 0.0015699622
the O 0 0.000846796
drug O 0 0.0039343885
should O 0 0.00022575339
be O 0 0.00019355652
monitored O 0 0.00012475182
with O 0 0.00025399533
liver O 0 0.17160706
function O 0 0.00029327665
tests O 0 0.0003316202
along O 0 0.000110636276
with O 0 0.0002321127
complete O 0 0.00035536135
blood O 0 0.0037926645
cell O 0 0.002898922
counts O 0 0.002109136
. O 0 0.0023777233

This O 0 0.0051657995
complication O 0 0.013037414
will O 0 0.0010352121
be O 0 0.00056618
observed O 0 0.00033985762
even O 0 0.00031792253
less O 0 0.0002495859
often O 0 0.00021531493
in O 0 0.00013051728
the O 0 0.00012476895
future O 0 0.00016917732
as O 0 0.0003749475
ticlopidine B-Chemical 1 0.9999869
is O 0 0.0002603748
being O 0 0.00020049082
replaced O 0 0.00014043164
by O 0 0.00016129152
the O 0 0.00022707996
newer O 0 0.0023125792
antiplatelet O 0 0.84473467
agent O 0 0.083784744
clopidogrel B-Chemical 0 0.99977523
. O 0 0.0032707914

Epithelial O 0 0.14222275
sodium B-Chemical 0 0.9990983
channel O 0 0.64535487
( O 0 0.003715088
ENaC O 0 0.9213897
) O 0 0.0015450963
subunit O 0 0.0021960728
mRNA O 0 0.0005297559
and O 0 0.0002245223
protein O 0 0.00029549192
expression O 0 0.00018560993
in O 0 0.00011815704
rats O 0 0.00020815917
with O 0 0.00026299298
puromycin B-Chemical 0 0.54979604
aminonucleoside I-Chemical 0 0.9999478
- O 0 0.005479612
induced O 0 0.007598268
nephrotic B-Disease 0 0.99998915
syndrome I-Disease 0 0.9637781
. O 0 0.0032543174

In O 0 0.0021408135
experimental O 0 0.0055320864
nephrotic B-Disease 0 0.9999492
syndrome I-Disease 0 0.7608967
, O 0 0.0012747821
urinary O 0 0.5719523
sodium B-Chemical 0 0.9999013
excretion O 0 0.9790278
is O 0 0.00037138647
decreased O 0 0.00036724945
during O 0 9.106913e-05
the O 0 0.00016183966
early O 0 0.00036454122
phase O 0 0.00074595714
of O 0 0.00079561246
the O 0 0.001346086
disease O 0 0.29089162
. O 0 0.0029193673

The O 0 0.0020686386
molecular O 0 0.004895442
mechanism O 0 0.0017594818
( O 0 0.0014515796
s O 0 0.0008917268
) O 0 0.0008667074
leading O 0 0.0006701671
to O 0 0.0006048815
salt O 0 0.9803367
retention O 0 0.0019918974
has O 0 0.0003984637
not O 0 0.00043670848
been O 0 0.0005840125
completely O 0 0.0013538044
elucidated O 0 0.002861112
. O 0 0.0025141337

The O 0 0.0019149355
rate O 0 0.0020411147
- O 0 0.0018207516
limiting O 0 0.0009409707
constituent O 0 0.0009057173
of O 0 0.0005140493
collecting O 0 0.0010531693
duct O 0 0.4758178
sodium B-Chemical 0 0.99973196
transport O 0 0.0014840256
is O 0 0.00024866645
the O 0 0.00028186393
epithelial O 0 0.010378716
sodium B-Chemical 0 0.99974555
channel O 0 0.6381294
( O 0 0.0028199162
ENaC O 0 0.87255186
) O 0 0.003725473
. O 0 0.0024677352

We O 0 0.0014591896
examined O 0 0.0008257542
the O 0 0.0007267617
abundance O 0 0.00066916645
of O 0 0.0009794962
ENaC O 0 0.8664219
subunit O 0 0.0049695987
mRNAs O 0 0.00045879307
and O 0 0.00021025645
proteins O 0 0.00020061263
in O 0 0.00020099652
puromycin B-Chemical 0 0.558789
aminonucleoside I-Chemical 0 0.99996686
( O 0 0.0070666955
PAN B-Chemical 0 0.9998524
) O 0 0.0022807764
- O 0 0.0015790489
induced O 0 0.003708475
nephrotic B-Disease 0 0.9999831
syndrome I-Disease 0 0.9513221
. O 0 0.0034079703

The O 0 0.0011516507
time O 0 0.0005918852
courses O 0 0.0006112587
of O 0 0.0007072071
urinary O 0 0.20186353
sodium B-Chemical 0 0.9998423
excretion O 0 0.98325104
, O 0 0.0006694968
plasma O 0 0.041123595
aldosterone B-Chemical 0 0.99994206
concentration O 0 0.0014422359
and O 0 0.00046336572
proteinuria B-Disease 0 0.9999876
were O 0 0.00021216391
studied O 0 0.00011573975
in O 0 9.139171e-05
male O 0 0.00064139714
Sprague O 0 0.017053677
- O 0 0.0002684368
Dawley O 0 0.0010885296
rats O 0 9.792034e-05
treated O 0 9.158863e-05
with O 0 8.98879e-05
a O 0 0.00011849281
single O 0 0.00011416527
dose O 0 0.00046558326
of O 0 0.0003188483
either O 0 0.0006624139
PAN B-Chemical 0 0.9992654
or O 0 0.0013515274
vehicle O 0 0.009027562
. O 0 0.0023967957

The O 0 0.00161389
relative O 0 0.0012123083
amounts O 0 0.0011046007
of O 0 0.001687463
alphaENaC O 0 0.5394675
, O 0 0.0013595523
betaENaC O 0 0.451252
and O 0 0.0007467929
gammaENaC O 0 0.5785738
mRNAs O 0 0.0003002909
were O 0 0.00011559558
determined O 0 7.6878205e-05
in O 0 8.218974e-05
kidneys O 0 0.0014541112
from O 0 7.354006e-05
these O 0 0.00011453054
rats O 0 0.000121901816
by O 0 7.4353375e-05
real O 0 8.9848734e-05
- O 0 0.00013478877
time O 0 4.2160034e-05
quantitative O 0 0.00021429376
TaqMan O 0 0.011057592
PCR O 0 0.015323765
, O 0 0.0001678269
and O 0 0.00011642359
the O 0 0.00011153518
amounts O 0 0.0001547613
of O 0 0.00030131132
proteins O 0 0.00044044416
by O 0 0.0005988189
Western O 0 0.0020771292
blot O 0 0.0038514903
. O 0 0.0020274518

The O 0 0.0014105975
kinetics O 0 0.0017449445
of O 0 0.0013306462
urinary O 0 0.27314255
sodium B-Chemical 0 0.999752
excretion O 0 0.949046
and O 0 0.000429073
the O 0 0.00021665121
appearance O 0 0.00047789278
of O 0 0.000630768
proteinuria B-Disease 0 0.9999765
were O 0 0.0003797176
comparable O 0 0.00017473832
with O 0 0.00036091948
those O 0 0.00063697685
reported O 0 0.00094486703
previously O 0 0.001464234
. O 0 0.0020581821

Sodium B-Chemical 0 0.9982504
retention O 0 0.0046629575
occurred O 0 0.0009931547
on O 0 0.00046988667
days O 0 0.00033445677
2 O 0 0.00041670914
, O 0 0.00048765528
3 O 0 0.00032928702
and O 0 0.00043147904
6 O 0 0.0003822861
after O 0 0.0005441526
PAN B-Chemical 0 0.9913571
injection O 0 0.004998418
. O 0 0.0037478074

A O 0 0.018663017
significant O 0 0.0018723381
up O 0 0.0014302218
- O 0 0.0012453585
regulation O 0 0.0003491572
of O 0 0.0007885296
alphaENaC O 0 0.29226634
and O 0 0.0006608658
betaENaC O 0 0.19501685
mRNA O 0 0.00031493418
abundance O 0 0.00011450608
on O 0 4.9783084e-05
days O 0 4.0185678e-05
1 O 0 6.319755e-05
and O 0 8.0088765e-05
2 O 0 7.987628e-05
preceded O 0 0.00020110865
sodium B-Chemical 0 0.99613416
retention O 0 0.0007435374
on O 0 0.00013931967
days O 0 0.00014329333
2 O 0 0.00030632486
and O 0 0.0006247117
3 O 0 0.0009508255
. O 0 0.0017733409

Conversely O 0 0.004072365
, O 0 0.0025554416
down O 0 0.0019664285
- O 0 0.0013384146
regulation O 0 0.00036403697
of O 0 0.0008707697
alphaENaC O 0 0.46476707
, O 0 0.0008823175
betaENaC O 0 0.44535676
and O 0 0.00056520815
gammaENaC O 0 0.5863319
mRNA O 0 0.00030437176
expression O 0 0.000119626624
on O 0 4.085213e-05
day O 0 3.9894567e-05
3 O 0 3.6070174e-05
occurred O 0 3.5909383e-05
in O 0 3.939755e-05
the O 0 4.433837e-05
presence O 0 5.4179873e-05
of O 0 0.000111329675
high O 0 0.00062045926
aldosterone B-Chemical 0 0.999972
concentrations O 0 0.0024799437
, O 0 0.0001857064
and O 0 0.00011109298
was O 0 9.536643e-05
followed O 0 5.6111447e-05
by O 0 7.754905e-05
a O 0 0.000116683994
return O 0 0.00015511173
of O 0 0.0003814428
sodium B-Chemical 0 0.99960595
excretion O 0 0.8772494
to O 0 0.00047287042
control O 0 0.0006676681
values O 0 0.001361199
. O 0 0.0018827432

The O 0 0.0019526295
amounts O 0 0.0018206293
of O 0 0.002507713
alphaENaC O 0 0.49996677
, O 0 0.0018881975
betaENaC O 0 0.422851
and O 0 0.0010044384
gammaENaC O 0 0.5713398
proteins O 0 0.0003855546
were O 0 0.00019599419
not O 0 0.00015016235
increased O 0 0.000341358
during O 0 0.0002626126
PAN B-Chemical 0 0.9993973
- O 0 0.0021955257
induced O 0 0.002264477
sodium B-Chemical 0 0.9995047
retention O 0 0.029775903
. O 0 0.003100709

In O 0 0.0020282625
conclusion O 0 0.0017064055
, O 0 0.0022277455
ENaC O 0 0.7238973
mRNA O 0 0.0015830097
expression O 0 0.0008062591
, O 0 0.0005362056
especially O 0 0.0006010569
alphaENaC O 0 0.45349815
, O 0 0.00031292232
is O 0 0.00013750573
increased O 0 0.00016816716
in O 0 7.885134e-05
the O 0 7.1819086e-05
very O 0 0.000115598115
early O 0 0.00012913253
phase O 0 0.0001893343
of O 0 8.869737e-05
the O 0 6.129753e-05
experimental O 0 9.2812545e-05
model O 0 0.00011005934
of O 0 0.0003503965
PAN B-Chemical 0 0.99991024
- O 0 0.0013052659
induced O 0 0.0012392806
nephrotic B-Disease 0 0.99999845
syndrome I-Disease 0 0.74502796
in O 0 0.00015058018
rats O 0 0.00020739429
, O 0 0.00010132193
but O 0 7.507525e-05
appears O 0 4.7970712e-05
to O 0 5.7351324e-05
escape O 0 0.0001928311
from O 0 6.271158e-05
the O 0 7.953106e-05
regulation O 0 7.912694e-05
by O 0 0.00026355629
aldosterone B-Chemical 0 0.99907184
after O 0 0.0002198846
day O 0 0.00040748433
3 O 0 0.0007565986
. O 0 0.0014522134

Sub O 0 0.17364621
- O 0 0.005160634
chronic O 0 0.02591586
low O 0 0.0024522452
dose O 0 0.020927718
gamma B-Chemical 0 0.98227787
- I-Chemical 0 0.011542323
vinyl I-Chemical 0 0.99631554
GABA I-Chemical 0 0.9999895
( O 0 0.0077759656
vigabatrin B-Chemical 0 0.9999871
) O 0 0.00096548727
inhibits O 0 0.00038332888
cocaine B-Chemical 1 0.9998776
- O 0 0.0008230601
induced O 0 0.00028093377
increases O 0 0.0002907612
in O 0 0.0003230297
nucleus O 0 0.0005137329
accumbens O 0 0.026048997
dopamine B-Chemical 0 0.9979924
. O 0 0.0025648666

RATIONALE O 0 0.007937897
: O 0 0.004626702
gamma B-Chemical 0 0.62597454
- I-Chemical 0 0.008239726
Vinyl I-Chemical 0 0.9270143
GABA I-Chemical 0 0.9999311
( O 0 0.011340913
GVG B-Chemical 0 0.99997854
) O 0 0.0041012326
irreversibly O 0 0.09394103
inhibits O 0 0.0030691102
GABA B-Chemical 0 0.9999311
- O 0 0.057794783
transaminase O 0 0.99967897
. O 0 0.0061916253

This O 0 0.0051410696
non O 0 0.0035627307
- O 0 0.0033204607
receptor O 0 0.004625479
mediated O 0 0.00047033076
inhibition O 0 0.0010469606
requires O 0 0.00028213736
de O 0 0.0011678871
novo O 0 0.0015637944
synthesis O 0 0.0011589343
for O 0 0.00022649614
restoration O 0 0.00061377895
of O 0 0.00081313564
functional O 0 0.0024998276
GABA B-Chemical 0 0.99987996
catabolism O 0 0.85824883
. O 0 0.0035691403

OBJECTIVES O 0 0.0031972956
: O 0 0.0016459164
Given O 0 0.00046728345
its O 0 0.0009390738
preclinical O 0 0.0016298007
success O 0 0.00072467176
for O 0 0.00026850458
treating O 0 0.0014174754
substance B-Disease 0 0.99818546
abuse I-Disease 0 0.99592113
and O 0 0.0002970743
the O 0 0.00013845552
increased O 0 0.00025854225
risk O 0 0.0009470029
of O 0 0.00018030783
visual B-Disease 2 0.05318465
field I-Disease 2 0.0003053134
defects I-Disease 2 0.017701484
( O 0 0.00081927376
VFD B-Disease 0 0.9995179
) O 0 0.00025264133
associated O 0 6.7056164e-05
with O 0 9.9057e-05
cumulative O 0 0.00021532518
lifetime O 0 0.00076346216
exposure O 0 0.00017109726
, O 0 8.150316e-05
we O 0 2.6901589e-05
explored O 0 3.8224516e-05
the O 0 4.7720132e-05
effects O 0 7.580211e-05
of O 0 0.00015425596
sub O 0 0.00083515985
- O 0 0.00038164298
chronic O 0 0.02844304
low O 0 0.00058945845
dose O 0 0.02943258
GVG B-Chemical 0 0.9999976
on O 0 0.0002891093
cocaine B-Chemical 1 0.99994135
- O 0 0.00048510637
induced O 0 0.00011896549
increases O 0 9.972716e-05
in O 0 8.440554e-05
nucleus O 0 9.1226975e-05
accumbens O 0 0.00097249803
( O 0 0.00022641514
NAcc O 0 0.0007439332
) O 0 0.00082604156
dopamine B-Chemical 0 0.99890196
( O 0 0.0024750682
DA B-Chemical 0 0.9977773
) O 0 0.0036091907
. O 0 0.0024158144

METHODS O 0 0.0017120014
: O 0 0.0013282468
Using O 0 0.0005304977
in O 0 0.0005394881
vivo O 0 0.00081317284
microdialysis O 0 0.004307086
, O 0 0.00031167158
we O 0 0.00010033536
compared O 0 0.00013468161
acute O 0 0.036080766
exposure O 0 0.0005541185
( O 0 0.0003964015
450 O 0 0.0055227294
mg O 0 0.02080279
/ O 0 0.0007417419
kg O 0 0.0004031945
) O 0 0.00013000517
to O 0 5.0691684e-05
an O 0 7.7193414e-05
identical O 0 5.3876203e-05
sub O 0 0.00043834423
- O 0 0.0003316866
chronic O 0 0.016623534
exposure O 0 0.0002927115
( O 0 0.00018392621
150 O 0 0.00017949169
mg O 0 0.0022523145
/ O 0 0.00027905844
kg O 0 0.00012520685
per O 0 1.889132e-05
day O 0 2.5656343e-05
for O 0 3.3113876e-05
3 O 0 4.1078638e-05
days O 0 3.3420718e-05
) O 0 0.00012706363
, O 0 0.00010680147
followed O 0 8.632742e-05
by O 0 0.00014696004
1 O 0 0.00014494777
- O 0 0.0002727323
or O 0 0.00017819925
3 O 0 0.00022183036
- O 0 0.0005156303
day O 0 0.00041120723
washout O 0 0.0015257914
. O 0 0.0017876693

Finally O 0 0.002474875
, O 0 0.001645798
we O 0 0.0004755972
examined O 0 0.0003733887
the O 0 0.00038728927
low O 0 0.0006125633
dose O 0 0.0011259184
of O 0 0.00036938864
150 O 0 0.0005275387
mg O 0 0.012341319
/ O 0 0.00078609545
kg O 0 0.00044648047
( O 0 0.00017352644
50 O 0 0.00019164734
mg O 0 0.001837325
/ O 0 0.00037480798
kg O 0 0.00020309343
per O 0 3.9702863e-05
day O 0 6.900868e-05
) O 0 0.00016571644
using O 0 0.00011844977
a O 0 0.00025373438
similar O 0 0.00024281416
washout O 0 0.00080619386
period O 0 0.00063039514
. O 0 0.0015877042

RESULTS O 0 0.0062091406
: O 0 0.0035901705
Sub O 0 0.041048158
- O 0 0.0034694143
chronic O 0 0.544381
GVG B-Chemical 0 0.99998605
exposure O 0 0.0017443665
inhibited O 0 0.0008444258
the O 0 0.0002292552
effect O 0 0.00018667572
of O 0 0.00058092416
cocaine B-Chemical 1 0.9997814
for O 0 0.00012515193
3 O 0 6.705182e-05
days O 0 3.2984783e-05
, O 0 7.2869625e-05
which O 0 8.568083e-05
exceeded O 0 7.478566e-05
in O 0 7.1669674e-05
magnitude O 0 7.701087e-05
and O 0 0.00010789337
duration O 0 7.738742e-05
the O 0 0.00019559654
identical O 0 0.00032414647
acute O 0 0.27783415
dose O 0 0.018699119
. O 0 0.0026482365

CONCLUSIONS O 0 0.021566806
: O 0 0.0040526744
Sub O 0 0.041645378
- O 0 0.0023789473
chronic O 0 0.01972878
low O 0 0.0018404656
dose O 0 0.07041208
GVG B-Chemical 0 0.99999356
potentiates O 0 0.004226407
and O 0 0.00027315284
extends O 0 0.00013594024
the O 0 0.00010489808
inhibition O 0 0.0004206223
of O 0 0.00073371973
cocaine B-Chemical 1 0.999948
- O 0 0.00065794674
induced O 0 0.00015242246
increases O 0 0.00015629233
in O 0 0.00023659466
dopamine B-Chemical 0 0.99972457
, O 0 0.00016309338
effectively O 0 0.000108101085
reducing O 0 0.00013743692
cumulative O 0 0.00029914314
exposures O 0 0.00063132227
and O 0 0.00027133795
the O 0 0.00038236607
risk O 0 0.0030524181
for O 0 0.0009457443
VFDS O 0 0.14142644
. O 0 0.002449847

MR O 2 0.5783385
imaging O 0 0.0025822495
with O 0 0.0009925747
quantitative O 0 0.00087995746
diffusion O 0 0.0012718055
mapping O 0 0.0003685596
of O 0 0.0011800661
tacrolimus B-Chemical 0 0.99998236
- O 0 0.0031765562
induced O 0 0.0016648059
neurotoxicity B-Disease 2 0.9998975
in O 0 0.0010190568
organ O 0 0.00580284
transplant O 0 0.09678451
patients O 0 0.0035395324
. O 0 0.0021418524

Our O 0 0.002259946
objective O 0 0.0019025747
was O 0 0.0009408089
to O 0 0.00041781593
investigate O 0 0.00024991782
brain O 0 0.0021981094
MR O 2 0.8408508
imaging O 0 0.000546737
findings O 0 0.0002861237
and O 0 0.00012646095
the O 0 8.9341236e-05
utility O 0 8.191893e-05
of O 0 0.00014638242
diffusion O 0 0.0010951541
- O 0 0.00022394699
weighted O 0 0.000105741485
( O 0 0.00022548405
DW O 0 0.48722893
) O 0 0.0001702007
imaging O 0 0.00012925154
in O 0 5.994123e-05
organ O 0 0.0002745667
transplant O 0 0.0018882367
patients O 0 0.00020707615
who O 0 0.00019152112
developed O 0 0.00032689545
neurologic O 0 0.8632774
symptoms O 0 0.01699443
during O 0 0.00046719596
tacrolimus B-Chemical 0 0.9999566
therapy O 0 0.005881707
. O 0 0.0022275245

Brain O 0 0.033370446
MR O 2 0.79847294
studies O 0 0.0015483188
, O 0 0.0009148734
including O 0 0.0004499341
DW O 0 0.42729217
imaging O 0 0.0007344423
, O 0 0.00026344068
were O 0 0.00014541666
prospectively O 0 0.00012820706
performed O 0 7.3497074e-05
in O 0 7.305818e-05
14 O 0 7.0357724e-05
organ O 0 0.00024669673
transplant O 0 0.0014770032
patients O 0 0.000321702
receiving O 0 0.00086117466
tacrolimus B-Chemical 0 0.99997914
who O 0 0.0019796481
developed O 0 0.00342788
neurologic B-Disease 0 0.99957234
complications I-Disease 0 0.98697007
. O 0 0.003507134

In O 0 0.0013745812
each O 0 0.000669463
patient O 0 0.0008733053
who O 0 0.00078753795
had O 0 0.00037439153
abnormalities O 0 0.0014318669
on O 0 0.00010632621
the O 0 0.00013071681
initial O 0 0.00020053018
MR O 2 0.9118104
study O 0 0.00028248513
, O 0 0.00016005883
a O 0 0.00015201997
follow O 0 8.238301e-05
- O 0 0.00021433952
up O 0 0.00019007464
MR O 2 0.63981
study O 0 0.00028129615
was O 0 0.0002263392
performed O 0 0.00021605197
1 O 0 0.00028786776
month O 0 0.00029933796
later O 0 0.0007195854
. O 0 0.0017232789

Apparent O 0 0.007376959
diffusion O 0 0.0061062984
coefficient O 0 0.0051359306
( O 0 0.0018873295
ADC O 0 0.1299521
) O 0 0.00078846165
values O 0 0.00027424778
on O 0 0.00012929788
the O 0 0.00016705655
initial O 0 0.00024861356
MR O 2 0.7615832
study O 0 0.00029205758
were O 0 0.00016202433
correlated O 0 0.00013267974
with O 0 0.00032293456
reversibility O 0 0.0048115314
of O 0 0.00092054735
the O 0 0.0012779959
lesions O 0 0.038933586
. O 0 0.0026283432

Of O 0 0.0024535425
the O 0 0.0014542693
14 O 0 0.0010160476
patients O 0 0.0010170246
, O 0 0.00064985454
5 O 0 0.0003201319
( O 0 0.0003854054
35 O 0 0.000234466
. O 0 0.00012308573
7 O 0 0.00010540705
% O 0 0.00015567108
) O 0 0.00020177456
had O 0 0.00013930466
white B-Disease 0 0.0022738262
matter I-Disease 0 0.0013852213
abnormalities I-Disease 0 0.1697362
, O 0 0.00022450024
1 O 0 0.00010576307
( O 0 0.00012617378
7 O 0 5.6139976e-05
. O 0 4.683558e-05
1 O 0 6.016486e-05
% O 0 8.880087e-05
) O 0 0.00014415756
had O 0 0.00015662769
putaminal B-Disease 0 0.99807656
hemorrhage I-Disease 2 0.99990726
, O 0 0.0002728509
and O 0 0.00013234605
8 O 0 8.2823884e-05
( O 0 0.00012499557
57 O 0 0.00014376441
. O 0 5.6865923e-05
1 O 0 7.2886854e-05
% O 0 0.00010718365
) O 0 0.00015573892
had O 0 0.0001116071
normal O 0 0.00024351155
findings O 0 0.00027712403
on O 0 0.00017223702
initial O 0 0.0005880766
MR O 2 0.7522747
images O 0 0.002396699
. O 0 0.002451538

Among O 0 0.0025420608
the O 0 0.0011287045
5 O 0 0.000622673
patients O 0 0.00061058387
with O 0 0.0005076586
white B-Disease 0 0.0047444794
matter I-Disease 0 0.0021281827
abnormalities I-Disease 0 0.14442238
, O 0 0.00028826352
4 O 0 0.00011246711
patients O 0 0.00016536507
( O 0 0.00014349667
80 O 0 0.00013320797
. O 0 5.6296358e-05
0 O 0 6.774402e-05
% O 0 9.379275e-05
) O 0 0.00011708759
showed O 0 6.4892076e-05
higher O 0 7.932746e-05
than O 0 4.9254482e-05
normal O 0 0.00019749888
ADC O 0 0.03333071
values O 0 6.7182766e-05
on O 0 3.2762826e-05
initial O 0 8.678221e-05
MR O 2 0.6902264
images O 0 0.00016317161
, O 0 0.00012352986
and O 0 9.464728e-05
all O 0 8.6194166e-05
showed O 0 9.237003e-05
complete O 0 0.0001218623
resolution O 0 0.00073363184
on O 0 0.00014282136
follow O 0 0.00020871406
- O 0 0.0006282279
up O 0 0.0006800956
images O 0 0.0015038134
. O 0 0.002114543

The O 0 0.0016974903
remaining O 0 0.0015467451
1 O 0 0.00094698777
patient O 0 0.0008070075
( O 0 0.00069478643
20 O 0 0.0003642805
. O 0 0.00019213406
0 O 0 0.00019233732
% O 0 0.00022779558
) O 0 0.00024838446
showed O 0 0.00013384281
lower O 0 0.00016616231
than O 0 8.95456e-05
normal O 0 0.00034523293
ADC O 0 0.08559896
value O 0 0.00016775684
and O 0 0.0001345552
showed O 0 0.00014061226
incomplete O 0 0.0003846665
resolution O 0 0.0014743992
with O 0 0.00055114925
cortical B-Disease 0 0.022400001
laminar I-Disease 0 0.018116152
necrosis I-Disease 2 0.99953127
. O 0 0.0038354977

Diffusion O 0 0.014778089
- O 0 0.0027460465
weighted O 0 0.0008915551
imaging O 0 0.0011075025
may O 0 0.00039728128
be O 0 0.0002678084
useful O 0 0.00018244138
in O 0 0.00013809453
predicting O 0 0.000113691494
the O 0 0.00012548365
outcomes O 0 0.00014466995
of O 0 0.00019144572
the O 0 0.00023061442
lesions O 0 0.007318686
of O 0 0.0019251234
tacrolimus B-Chemical 0 0.9999887
- O 0 0.008376721
induced O 0 0.006998438
neurotoxicity B-Disease 2 0.9998863
. O 0 0.0054619834

L B-Chemical 0 0.960912
- I-Chemical 0 0.010422155
arginine I-Chemical 0 0.36409748
transport O 0 0.0028531866
in O 0 0.00094974175
humans O 0 0.0015942923
with O 0 0.0017167216
cortisol B-Chemical 0 0.9872021
- O 0 0.0048520174
induced O 0 0.007092257
hypertension B-Disease 2 0.9998356
. O 0 0.0060017714

A O 0 0.035485785
deficient O 0 0.005863731
L B-Chemical 0 0.97131854
- I-Chemical 0 0.007993877
arginine I-Chemical 0 0.7993843
- O 0 0.0042159003
nitric B-Chemical 0 0.997846
oxide I-Chemical 0 0.9304433
system O 0 0.0004986071
is O 0 0.00028059332
implicated O 0 0.00021096913
in O 0 0.00045106912
cortisol B-Chemical 0 0.9605828
- O 0 0.0026468642
induced O 0 0.0046499916
hypertension B-Disease 2 0.9998654
. O 0 0.004583692

We O 0 0.0015814232
investigate O 0 0.00086064596
whether O 0 0.0006995468
abnormalities O 0 0.007385774
in O 0 0.0015647308
L B-Chemical 0 0.96188414
- I-Chemical 0 0.0038129375
arginine I-Chemical 0 0.5592042
uptake O 0 0.003902189
contribute O 0 0.00058259175
to O 0 0.00080080633
this O 0 0.0022732506
deficiency O 0 0.8162775
. O 0 0.0041465545

Eight O 0 0.0119822705
healthy O 0 0.015683446
men O 0 0.01502619
were O 0 0.006113063
recruited O 0 0.0062513105
. O 0 0.008655503

Hydrocortisone B-Chemical 0 0.999905
acetate I-Chemical 0 0.99901557
( O 0 0.0038648502
50 O 0 0.0020314811
mg O 0 0.06149981
) O 0 0.00079917075
was O 0 0.00023875537
given O 0 9.3883216e-05
orally O 0 0.00022598683
every O 0 3.5412602e-05
6 O 0 4.047478e-05
hours O 0 3.1372998e-05
for O 0 3.942743e-05
24 O 0 4.07627e-05
hours O 0 2.9789699e-05
after O 0 2.674902e-05
a O 0 9.879276e-05
5 O 0 6.600228e-05
- O 0 0.0001239408
day O 0 4.828003e-05
fixed O 0 9.770897e-05
- O 0 0.00047238858
salt O 0 0.98720306
diet O 0 0.031398058
( O 0 0.00051067804
150 O 0 0.0007347465
mmol O 0 0.2203818
/ O 0 0.0023860082
d O 0 0.0014362725
) O 0 0.0023088679
. O 0 0.0022680277

Crossover O 0 0.014977932
studies O 0 0.0036230485
were O 0 0.0024050395
performed O 0 0.001974819
2 O 0 0.001960634
weeks O 0 0.0015786121
apart O 0 0.0036604672
. O 0 0.0059075844

Thirty O 0 0.002500494
milliliters O 0 0.0013408144
of O 0 0.001090393
blood O 0 0.0025850106
was O 0 0.00048737237
obtained O 0 0.0002696205
for O 0 0.0001588581
isolation O 0 0.0002008126
of O 0 0.00028100933
peripheral O 0 0.0019090353
blood O 0 0.0035999664
mononuclear O 0 0.008382379
cells O 0 0.00031243527
after O 0 0.000108444794
each O 0 0.00018317818
treatment O 0 0.0005376591
period O 0 0.00070280675
. O 0 0.001775885

L B-Chemical 0 0.96996576
- I-Chemical 0 0.010379529
arginine I-Chemical 0 0.5439117
uptake O 0 0.007346536
was O 0 0.0007201367
assessed O 0 0.00028935252
in O 0 0.00027655892
mononuclear O 0 0.00474761
cells O 0 0.00031814023
incubated O 0 0.0001775231
with O 0 0.00059796736
L B-Chemical 0 0.9885556
- I-Chemical 0 0.002184913
arginine I-Chemical 0 0.6545015
( O 0 0.00026287013
1 O 0 7.644032e-05
to O 0 6.958983e-05
300 O 0 0.00036588986
micromol O 0 0.115925245
/ O 0 0.0017652544
L O 0 0.5591011
) O 0 0.00026789703
, O 0 0.000101609
incorporating O 0 7.468937e-05
100 O 0 0.00036425097
nmol O 0 0.1368625
/ O 0 0.0020301405
L O 0 0.7853934
[ B-Chemical 0 0.0021680447
3H I-Chemical 0 0.45269585
] I-Chemical 0 0.00055719697
- I-Chemical 0 0.00033834227
l I-Chemical 0 0.0012966149
- I-Chemical 0 0.00045439388
arginine I-Chemical 0 0.05128738
for O 0 7.9190126e-05
a O 0 0.00011616011
period O 0 4.8436927e-05
of O 0 0.00011136408
5 O 0 8.8140805e-05
minutes O 0 9.845721e-05
at O 0 0.00020978345
37 O 0 0.00095730764
degrees O 0 0.0070228367
C O 0 0.9389488
. O 0 0.0037258868

Forearm O 0 0.13941242
[ B-Chemical 0 0.015373236
3H I-Chemical 0 0.63939977
] I-Chemical 0 0.0044199284
- I-Chemical 0 0.0029023394
L I-Chemical 0 0.87971085
- I-Chemical 0 0.0021445132
arginine I-Chemical 0 0.21149422
extraction O 0 0.001074837
was O 0 0.00018815981
calculated O 0 7.185115e-05
after O 0 4.3384527e-05
infusion O 0 0.00024377288
of O 0 0.00027564444
[ B-Chemical 0 0.0013552705
3H I-Chemical 0 0.48915213
] I-Chemical 0 0.0007099416
- I-Chemical 0 0.00058240193
L I-Chemical 0 0.87599903
- I-Chemical 0 0.00056243374
arginine I-Chemical 0 0.03273329
into O 0 3.7174155e-05
the O 0 9.163003e-05
brachial O 0 0.10261958
artery O 0 0.004412511
at O 0 6.536864e-05
a O 0 0.00011267236
rate O 0 0.00010770617
of O 0 0.00017215477
100 O 0 0.00051403977
nCi O 0 0.0059854225
/ O 0 0.00058295164
min O 0 0.0003022357
for O 0 0.00029938764
80 O 0 0.00076733256
minutes O 0 0.00075389893
. O 0 0.001742884

Deep O 0 0.015220637
forearm O 0 0.025305271
venous O 0 0.024236087
samples O 0 0.0009605194
were O 0 0.0005174249
collected O 0 0.00029301978
for O 0 0.00034515793
determination O 0 0.0011400573
of O 0 0.0016002639
L B-Chemical 0 0.940133
- I-Chemical 0 0.0053382353
arginine I-Chemical 0 0.720873
extraction O 0 0.015982404
. O 0 0.0037472486

Plasma O 0 0.18001135
cortisol B-Chemical 0 0.9404672
concentrations O 0 0.0032809551
were O 0 0.0006767974
significantly O 0 0.00045880527
raised O 0 0.0003078781
during O 0 0.0001062582
the O 0 0.0001496341
active O 0 0.00020763844
phase O 0 0.00056761294
( O 0 0.00039173977
323 O 0 0.00473866
+ O 0 0.0004524946
/ O 0 0.00055853766
- O 0 0.00028205637
43 O 0 0.00018145582
to O 0 0.00013424658
1082 O 0 0.043610096
+ O 0 0.00042609006
/ O 0 0.00059547916
- O 0 0.0004285196
245 O 0 0.0023184745
mmol O 0 0.387186
/ O 0 0.0022816935
L O 0 0.45112583
, O 0 0.000730045
P O 0 0.005235962
< O 0 0.00042031994
0 O 0 0.00044425734
. O 0 0.0006375939
05 O 0 0.006103975
) O 0 0.0026529434
. O 0 0.0026727922

Systolic O 0 0.11592831
blood O 0 0.011349011
pressure O 0 0.00960062
was O 0 0.0016075554
elevated O 0 0.002497216
by O 0 0.0007572176
an O 0 0.0006843366
average O 0 0.00043805828
of O 0 0.00095213274
7 O 0 0.0009450832
mm O 0 0.0034649444
Hg O 0 0.67222893
. O 0 0.004061946

Neither O 0 0.0059318757
L B-Chemical 0 0.9542372
- I-Chemical 0 0.0063405614
arginine I-Chemical 0 0.28234014
transport O 0 0.001303315
into O 0 0.00022686634
mononuclear O 0 0.0059982063
cells O 0 0.0005395528
( O 0 0.00039974053
placebo O 0 0.0011263583
vs O 0 0.00019822012
active O 0 0.00018225692
, O 0 0.00017590215
26 O 0 0.00017531126
. O 0 7.082416e-05
3 O 0 7.8921075e-05
+ O 0 0.00022433893
/ O 0 0.00043199313
- O 0 0.0002536299
3 O 0 7.2449046e-05
. O 0 5.0094975e-05
6 O 0 4.723811e-05
vs O 0 8.6263804e-05
29 O 0 0.00012540256
. O 0 5.5743287e-05
0 O 0 8.086664e-05
+ O 0 0.0002232111
/ O 0 0.0004381709
- O 0 0.00026412858
2 O 0 8.12068e-05
. O 0 5.1422598e-05
1 O 0 5.9868853e-05
pmol O 0 0.00019924351
/ O 0 0.00022087723
10 O 0 6.214981e-05
000 O 0 7.631024e-05
cells O 0 7.186836e-05
per O 0 2.3016712e-05
5 O 0 3.3772634e-05
minutes O 0 3.4937526e-05
, O 0 9.133648e-05
respectively O 0 0.00018117366
, O 0 8.366668e-05
at O 0 4.785032e-05
an O 0 0.00014188004
l B-Chemical 0 0.0015830888
- I-Chemical 0 0.00042575732
arginine I-Chemical 0 0.10937591
concentration O 0 0.00025759128
of O 0 0.00016397393
300 O 0 0.00066970167
micromol O 0 0.26101828
/ O 0 0.0020291314
L O 0 0.6620125
) O 0 0.00031126622
nor O 0 0.00018686378
L B-Chemical 0 0.9382024
- I-Chemical 0 0.00068471953
arginine I-Chemical 0 0.15882508
extraction O 0 0.0004285584
in O 0 7.4022646e-05
the O 0 9.110405e-05
forearm O 0 0.0073886686
( O 0 0.00010075915
at O 0 3.4141212e-05
80 O 0 6.726419e-05
minutes O 0 3.3830718e-05
, O 0 8.329618e-05
placebo O 0 0.00036521343
vs O 0 9.20907e-05
active O 0 0.00010344472
, O 0 0.00011794237
1 O 0 9.926057e-05
868 O 0 0.0032135397
904 O 0 0.0026218796
+ O 0 0.00027373683
/ O 0 0.00037598962
- O 0 0.0002418917
434 O 0 0.00039501255
962 O 0 0.0015344045
vs O 0 0.00011037789
2 O 0 7.630224e-05
013 O 0 0.0005867847
910 O 0 0.00036695146
+ O 0 0.0002038895
/ O 0 0.00033543483
- O 0 0.0002634206
770 O 0 0.0026701929
619 O 0 0.0011786518
disintegrations O 0 0.00014636386
per O 0 2.1704558e-05
minute O 0 4.3271517e-05
) O 0 9.5510775e-05
was O 0 6.8177644e-05
affected O 0 8.665436e-05
by O 0 0.00011275425
cortisol B-Chemical 0 0.87426054
treatment O 0 0.00017031402
; O 0 0.00013934507
ie O 0 0.00013839813
, O 0 0.00010239628
that O 0 0.000111626476
L B-Chemical 0 0.9637678
- I-Chemical 0 0.0012188827
arginine I-Chemical 0 0.6012543
uptake O 0 0.002563085
is O 0 0.00012964307
not O 0 0.000101204314
affected O 0 0.00015989986
by O 0 0.00015319983
short O 0 0.00016633542
- O 0 0.00043913347
term O 0 0.00049728504
cortisol B-Chemical 0 0.88444006
treatment O 0 0.0018596408
. O 0 0.0020714202

We O 0 0.0014284878
conclude O 0 0.00092190166
that O 0 0.0010314691
cortisol B-Chemical 0 0.9757096
- O 0 0.0017074649
induced O 0 0.00047380783
increases B-Disease 0 0.00030652207
in I-Disease 0 0.00022576586
blood I-Disease 0 0.0019430859
pressure I-Disease 0 0.0018041502
are O 0 0.00010458027
not O 0 7.520738e-05
associated O 0 8.351834e-05
with O 0 0.00016026008
abnormalities O 0 0.001975712
in O 0 0.00015571472
the O 0 0.00024849697
l B-Chemical 0 0.0025996617
- I-Chemical 0 0.0012775267
arginine I-Chemical 0 0.34398285
transport O 0 0.0023897793
system O 0 0.0017403688
. O 0 0.0020036534

Amount O 0 0.005147136
of O 0 0.0031534666
bleeding B-Disease 0 0.9259637
and O 0 0.0018290863
hematoma B-Disease 0 0.98860043
size O 0 0.0010631979
in O 0 0.00039085402
the O 0 0.00048594497
collagenase O 0 0.18194857
- O 0 0.0012338002
induced O 0 0.0012109281
intracerebral B-Disease 0 0.9953998
hemorrhage I-Disease 2 0.99985313
rat O 0 0.00931355
model O 0 0.0027157702
. O 0 0.0024150591

The O 0 0.00254847
aggravated O 0 0.026836758
risk O 0 0.006647923
on O 0 0.00081181683
intracerebral B-Disease 0 0.9839564
hemorrhage I-Disease 2 0.99993277
( O 0 0.010358708
ICH B-Disease 0 0.9999671
) O 0 0.00070438813
with O 0 0.00028677806
drugs O 0 0.0036908083
used O 0 0.00016085533
for O 0 0.0002330192
stroke B-Disease 0 0.9920521
patients O 0 0.00063504325
should O 0 0.00018797998
be O 0 0.0003246323
estimated O 0 0.000535166
carefully O 0 0.00083331525
. O 0 0.0017356301

We O 0 0.0015237225
therefore O 0 0.0012248905
established O 0 0.0009131526
sensitive O 0 0.00048590513
quantification O 0 0.0004812989
methods O 0 0.00032633654
and O 0 0.00027529776
provided O 0 0.00026654062
a O 0 0.0004433171
rat O 0 0.002216528
ICH B-Disease 0 0.9998907
model O 0 0.00041198786
for O 0 0.00023863133
detection O 0 0.00066772033
of O 0 0.0022071525
ICH B-Disease 0 0.9999087
deterioration O 0 0.6805572
. O 0 0.0032012265

In O 0 0.00481065
ICH B-Disease 0 0.9996469
intrastriatally O 0 0.91197073
induced O 0 0.001608601
by O 0 0.000712632
0 O 0 0.00040022327
. O 0 0.0002456525
014 O 0 0.0013307577
- O 0 0.00038997506
unit O 0 0.00015608783
, O 0 0.00018074212
0 O 0 0.00012551033
. O 0 0.00010306338
070 O 0 0.0012246876
- O 0 0.00022498195
unit O 0 9.411196e-05
, O 0 0.000112521186
and O 0 9.520905e-05
0 O 0 7.744765e-05
. O 0 5.6610545e-05
350 O 0 0.00020619901
- O 0 0.00017673738
unit O 0 9.463825e-05
collagenase O 0 0.013343904
, O 0 9.65748e-05
the O 0 5.5640416e-05
amount O 0 4.239371e-05
of O 0 0.00019483746
bleeding B-Disease 0 0.94447875
was O 0 9.84574e-05
measured O 0 4.848313e-05
using O 0 4.996739e-05
a O 0 0.00015637849
hemoglobin O 0 0.77792335
assay O 0 0.0005402353
developed O 0 0.00015201142
in O 0 6.012707e-05
the O 0 5.579993e-05
present O 0 5.35773e-05
study O 0 0.00010242499
and O 0 8.8502464e-05
was O 0 9.140687e-05
compared O 0 5.5310727e-05
with O 0 0.00012333787
the O 0 0.00015829034
morphologically O 0 0.00044400097
determined O 0 0.0005556239
hematoma B-Disease 0 0.9916489
volume O 0 0.0051276633
. O 0 0.0021973609

The O 0 0.0017546612
blood O 0 0.003930002
amounts O 0 0.0010086289
and O 0 0.0010645215
hematoma B-Disease 0 0.9798527
volumes O 0 0.001085362
were O 0 0.00026943034
significantly O 0 0.00022495196
correlated O 0 0.000113124726
, O 0 0.00015920583
and O 0 0.0001349821
the O 0 0.00020909013
hematoma B-Disease 0 0.99086654
induced O 0 0.0002993385
by O 0 0.0001754904
0 O 0 0.000117159405
. O 0 8.613253e-05
014 O 0 0.0007403683
- O 0 0.00023018433
unit O 0 0.00013579061
collagenase O 0 0.0071847956
was O 0 0.00020094246
adequate O 0 0.00018692383
to O 0 0.00027295836
detect O 0 0.00063829194
ICH B-Disease 0 0.99985886
deterioration O 0 0.5502847
. O 0 0.002874229

In O 0 0.004103858
ICH B-Disease 0 0.9991968
induction O 0 0.0017383173
using O 0 0.0006790847
0 O 0 0.0005102759
. O 0 0.0003114337
014 O 0 0.0014659886
- O 0 0.00046374334
unit O 0 0.00021792289
collagenase O 0 0.039426234
, O 0 0.00038796957
heparin B-Chemical 0 0.9546911
enhanced O 0 0.00033177485
the O 0 0.0002646935
hematoma B-Disease 0 0.9952597
volume O 0 0.00068007805
3 O 0 8.692433e-05
. O 0 5.1325685e-05
4 O 0 5.6543642e-05
- O 0 0.00011794283
fold O 0 8.615997e-05
over O 0 2.5658153e-05
that O 0 3.8333117e-05
seen O 0 6.198852e-05
in O 0 7.200699e-05
control O 0 0.0001945193
ICH B-Disease 0 0.9999343
animals O 0 0.000119200995
and O 0 0.00014165955
the O 0 0.00024344977
bleeding B-Disease 0 0.87885374
7 O 0 0.00020008784
. O 0 0.00019687485
6 O 0 0.0003066439
- O 0 0.0010625094
fold O 0 0.0020351396
. O 0 0.0022674266

Data O 0 0.0019144189
suggest O 0 0.0006285126
that O 0 0.00049744104
this O 0 0.00062757457
sensitive O 0 0.0006239325
hemoglobin O 0 0.87115836
assay O 0 0.0016593783
is O 0 0.00025075226
useful O 0 0.00016451188
for O 0 0.00022945071
ICH B-Disease 0 0.9999535
detection O 0 0.00043888506
, O 0 0.00015793304
and O 0 8.422446e-05
that O 0 5.0815535e-05
a O 0 9.967336e-05
model O 0 9.088919e-05
with O 0 0.00010831478
a O 0 0.00016417795
small O 0 0.0004526931
ICH B-Disease 0 0.9999734
induced O 0 0.00021905365
with O 0 0.00016211334
a O 0 0.00016865759
low O 0 0.0003700377
- O 0 0.0003511064
dose O 0 0.0009775689
collagenase O 0 0.066992685
should O 0 4.680008e-05
be O 0 5.1627587e-05
used O 0 4.418666e-05
for O 0 4.991305e-05
evaluation O 0 8.94698e-05
of O 0 0.00020013003
drugs O 0 0.0026117545
that O 0 0.00021612574
may O 0 0.00041126355
affect O 0 0.00075218815
ICH B-Disease 0 0.9997204
. O 0 0.0030422139

Estradiol B-Chemical 0 0.9995012
reduces O 0 0.006266915
seizure B-Disease 0 0.99930346
- O 0 0.0041362853
induced O 0 0.0014336884
hippocampal B-Disease 0 0.98816
injury I-Disease 0 0.9931652
in O 0 0.00093069416
ovariectomized O 0 0.33179644
female O 0 0.0017116332
but O 0 0.0003418087
not O 0 0.00032394135
in O 0 0.00054536894
male O 0 0.0026114983
rats O 0 0.0021996535
. O 0 0.0020013247

Estrogens O 0 0.9574459
protect O 0 0.0031403648
ovariectomized O 0 0.05857663
rats O 0 0.0011937858
from O 0 0.00053769234
hippocampal B-Disease 0 0.92782634
injury I-Disease 0 0.98609006
induced O 0 0.0016498567
by O 0 0.0018708807
kainic B-Chemical 0 0.99998033
acid I-Chemical 0 0.9983897
- O 0 0.002225711
induced O 0 0.0006873321
status B-Disease 0 0.00089473976
epilepticus I-Disease 0 0.9983127
( O 0 0.002280377
SE B-Disease 0 0.09822968
) O 0 0.002967863
. O 0 0.002452469

We O 0 0.001346164
compared O 0 0.0007587387
the O 0 0.00069436996
effects O 0 0.00086844095
of O 0 0.0029246549
17beta B-Chemical 0 0.99996984
- I-Chemical 0 0.03396687
estradiol I-Chemical 0 0.9999678
in O 0 0.00039538744
adult O 0 0.00045755814
male O 0 0.0006099231
and O 0 0.00014365479
ovariectomized O 0 0.020014618
female O 0 0.00038151038
rats O 0 0.00010558269
subjected O 0 5.8098696e-05
to O 0 0.00018430525
lithium B-Chemical 0 0.99991834
- O 0 0.0110671595
pilocarpine B-Chemical 1 0.9999738
- O 0 0.003564466
induced O 0 0.0024121292
SE B-Disease 0 0.30451608
. O 0 0.0026256556

Rats O 0 0.0034277563
received O 0 0.0011061934
subcutaneous O 0 0.0019408764
injections O 0 0.0010392036
of O 0 0.0019191551
17beta B-Chemical 0 0.9999628
- I-Chemical 0 0.030482994
estradiol I-Chemical 0 0.9999784
( O 0 0.0007309942
2 O 0 0.00013390242
microg O 0 0.00029820797
/ O 0 0.0005806145
rat O 0 0.00049009395
) O 0 0.00024293642
or O 0 0.00013530116
oil O 0 0.24818775
once O 0 0.00011368672
daily O 0 0.0001720002
for O 0 0.00013268492
four O 0 0.00017959508
consecutive O 0 0.00041006715
days O 0 0.00053110474
. O 0 0.0015072827

SE B-Disease 0 0.11806454
was O 0 0.0024123508
induced O 0 0.0013068209
20 O 0 0.0007319001
h O 0 0.0004079694
following O 0 0.00025515087
the O 0 0.00030369926
second O 0 0.0003148243
injection O 0 0.00044821514
and O 0 0.0004435583
terminated O 0 0.000634532
3 O 0 0.0004848218
h O 0 0.0007184761
later O 0 0.0011700909
. O 0 0.002433503

The O 0 0.0017616777
extent O 0 0.0013677496
of O 0 0.00227915
silver B-Chemical 0 0.92475396
- O 0 0.002221251
stained O 0 0.000889751
CA3 O 0 0.6468333
and O 0 0.0007842653
CA1 O 0 0.5506547
hippocampal O 0 0.19949839
neurons O 0 0.0009341377
was O 0 0.0003262964
evaluated O 0 0.0002227217
2 O 0 0.00024018831
days O 0 0.00021348576
after O 0 0.00044927496
SE B-Disease 0 0.017135942
. O 0 0.0028610919

17beta B-Chemical 1 0.9997222
- I-Chemical 1 0.10595343
Estradiol I-Chemical 1 0.99991834
did O 0 0.0014431146
not O 0 0.00040043244
alter O 0 0.00021692284
the O 0 0.000191272
onset O 0 0.00024279517
of O 0 0.00022559975
first O 0 0.00017823986
clonus O 0 0.9742931
in O 0 0.00032839668
ovariectomized O 0 0.10229583
rats O 0 0.00047503717
but O 0 0.000299116
accelerated O 0 0.001427676
it O 0 0.00062710163
in O 0 0.0008032095
males O 0 0.0021596919
. O 0 0.0017867592

17beta B-Chemical 1 0.999617
- I-Chemical 1 0.05795485
Estradiol I-Chemical 1 0.9998722
reduced O 0 0.0028184082
the O 0 0.00094181113
argyrophilic O 0 0.15944926
neurons O 0 0.0007107262
in O 0 0.000235156
the O 0 0.00030619287
CA1 O 0 0.41652957
and O 0 0.00074017147
CA3 O 0 0.94959754
- O 0 0.0027373428
C O 0 0.9071941
sectors O 0 0.0017653897
of O 0 0.0013788108
ovariectomized O 0 0.30020404
rats O 0 0.0033750366
. O 0 0.0022309101

In O 0 0.0039383373
males O 0 0.0058466615
, O 0 0.0044780206
estradiol B-Chemical 0 0.9986084
increased O 0 0.0036001548
the O 0 0.0018422552
total O 0 0.0024565682
damage O 0 0.24321488
score O 0 0.003794726
. O 0 0.0043156343

These O 0 0.0021475551
findings O 0 0.0016741968
suggest O 0 0.00041471265
that O 0 0.00032419406
the O 0 0.0003368802
effects O 0 0.00041428156
of O 0 0.0009681484
estradiol B-Chemical 0 0.9999182
on O 0 0.00032054508
seizure B-Disease 0 0.9991621
threshold O 0 0.00029059747
and O 0 0.0002729123
damage O 0 0.06691175
may O 0 0.00012293726
be O 0 0.0001033619
altered O 0 0.00018382049
by O 0 0.00017216463
sex O 0 0.00040053454
- O 0 0.00019403509
related O 0 6.0397273e-05
differences O 0 8.433698e-05
in O 0 0.00019081189
the O 0 0.00040592844
hormonal O 0 0.0035827833
environment O 0 0.0014326553
. O 0 0.0019143714

Pseudoacromegaly B-Disease 0 0.07548517
induced O 0 0.0035739527
by O 0 0.0020019894
the O 0 0.0013834686
long O 0 0.0012846971
- O 0 0.0016759272
term O 0 0.0010651818
use O 0 0.0015215535
of O 0 0.005129887
minoxidil B-Chemical 0 0.9998747
. O 0 0.0075529474

Acromegaly B-Disease 0 0.98948544
is O 0 0.0026113172
an O 0 0.0025755924
endocrine B-Disease 0 0.9511726
disorder I-Disease 0 0.99736494
caused O 0 0.001054489
by O 0 0.0006577912
chronic O 0 0.12104146
excessive O 0 0.0071572876
growth O 0 0.016069682
hormone O 0 0.2426388
secretion O 0 0.0012921859
from O 0 0.0002617198
the O 0 0.0004502295
anterior O 0 0.004470116
pituitary O 0 0.6002875
gland O 0 0.09449522
. O 0 0.0023845148

Significant O 0 0.0037834153
disfiguring O 0 0.005442062
changes O 0 0.0013186774
occur O 0 0.0005345713
as O 0 0.00037653465
a O 0 0.00036532903
result O 0 0.00022103859
of O 0 0.0003504857
bone O 0 0.020088738
, O 0 0.00044447335
cartilage O 0 0.005045603
, O 0 0.00022052792
and O 0 0.00016344724
soft O 0 0.0011790886
tissue O 0 0.0022925679
hypertrophy B-Disease 2 0.99714524
, O 0 0.00017603235
including O 0 5.3866235e-05
the O 0 9.290101e-05
thickening O 0 0.0234338
of O 0 0.00015169084
the O 0 0.0001400854
skin O 0 0.0019588396
, O 0 0.00020214968
coarsening O 0 0.03733023
of O 0 0.00031998297
facial O 0 0.0035411587
features O 0 0.00048272894
, O 0 0.0006409886
and O 0 0.0013714723
cutis B-Disease 0 0.97893184
verticis I-Disease 0 0.97021985
gyrata I-Disease 0 0.98668796
. O 0 0.003535861

Pseudoacromegaly B-Disease 0 0.12259408
, O 0 0.002293434
on O 0 0.0007091522
the O 0 0.0007159945
other O 0 0.00057623925
hand O 0 0.0009221222
, O 0 0.0004829646
is O 0 0.0002248522
the O 0 0.00014835304
presence O 0 0.00013300565
of O 0 0.00017466139
similar O 0 0.00011032759
acromegaloid O 0 0.066305056
features O 0 0.00012046191
in O 0 6.591409e-05
the O 0 5.8805825e-05
absence O 0 4.6740497e-05
of O 0 0.00014017503
elevated O 0 0.0018364037
growth O 0 0.00923882
hormone O 0 0.29553208
or O 0 0.00031673722
insulin O 0 0.6815639
- O 0 0.00060049776
like O 0 0.00026674606
growth O 0 0.0025557347
factor O 0 0.003246292
levels O 0 0.0021068347
. O 0 0.002341872

We O 0 0.0013896477
present O 0 0.000935762
a O 0 0.0010868924
patient O 0 0.00079516787
with O 0 0.00079627446
pseudoacromegaly B-Disease 0 0.22080596
that O 0 0.00018278004
resulted O 0 0.00018009238
from O 0 0.000119816366
the O 0 0.00012690622
long O 0 0.00013391428
- O 0 0.00019973866
term O 0 0.000100208665
use O 0 0.00012166004
of O 0 0.0004349812
minoxidil B-Chemical 0 0.99996066
at O 0 0.000269131
an O 0 0.0005773999
unusually O 0 0.005162671
high O 0 0.0025335057
dose O 0 0.008976513
. O 0 0.0024856036

This O 0 0.0040098135
is O 0 0.0014971257
the O 0 0.0008099511
first O 0 0.00045066752
case O 0 0.0005373399
report O 0 0.00076466793
of O 0 0.00088394654
pseudoacromegaly B-Disease 0 0.5929052
as O 0 0.00040301777
a O 0 0.0005654541
side O 0 0.002954282
effect O 0 0.0006714928
of O 0 0.0036096263
minoxidil B-Chemical 0 0.99995613
use O 0 0.0043377415
. O 0 0.0031063745

Combined O 0 0.013861699
androgen O 0 0.99738127
blockade O 0 0.25734663
- O 0 0.0040341327
induced O 0 0.0029962712
anemia B-Disease 0 0.9998926
in O 0 0.002985032
prostate B-Disease 2 0.9989392
cancer I-Disease 2 0.99965346
patients O 0 0.00246921
without O 0 0.0010321877
bone O 0 0.058583543
involvement O 0 0.005192264
. O 0 0.0028898886

BACKGROUND O 0 0.008161698
: O 0 0.0018194062
To O 0 0.0006294418
determine O 0 0.0003214528
the O 0 0.00040417162
onset O 0 0.00044811392
and O 0 0.00023804778
extent O 0 0.0001363882
of O 0 0.00024372336
combined O 0 0.00062609004
androgen O 0 0.999482
blockade O 0 0.15620586
( O 0 0.00071101746
CAB O 0 0.09534534
) O 0 0.0004485791
- O 0 0.00037661975
induced O 0 0.00052558037
anemia B-Disease 0 0.99993896
in O 0 0.0010806235
prostate B-Disease 2 0.9989355
cancer I-Disease 2 0.9997292
patients O 0 0.0014647018
without O 0 0.000670554
bone O 0 0.048554342
involvement O 0 0.00410086
. O 0 0.002309796

PATIENTS O 0 0.0019848892
AND O 0 0.0013104716
METHODS O 0 0.0006329374
: O 0 0.00072845153
Forty O 0 0.0007213908
- O 0 0.00053381646
two O 0 0.00016708602
patients O 0 0.00024815343
with O 0 0.00024143688
biopsy O 0 0.0006613277
- O 0 0.00041445834
proven O 0 0.00050774356
prostatic B-Disease 0 0.99919516
adenocarcinoma I-Disease 0 0.9999454
[ O 0 0.00067925674
26 O 0 0.00012354573
with O 0 0.00011115581
stage O 0 0.00059134414
C O 0 0.98316526
( O 0 0.00069044466
T3N0M0 O 0 0.9851012
) O 0 0.00020999198
and O 0 8.26526e-05
16 O 0 7.1690796e-05
with O 0 0.00012154502
stage O 0 0.00077031524
D1 O 0 0.9947068
( O 0 0.000900236
T3N1M0 O 0 0.9841208
) O 0 0.00052566396
] O 0 0.00036901643
were O 0 0.000168439
included O 0 0.00018449564
in O 0 0.00031581122
this O 0 0.00079434237
study O 0 0.001592657
. O 0 0.0019438288

All O 0 0.001625463
patients O 0 0.0015166915
received O 0 0.00089833676
CAB O 0 0.067062736
[ O 0 0.0064748167
leuprolide B-Chemical 0 0.99971837
acetate I-Chemical 0 0.99962425
( O 0 0.003843285
LHRH B-Chemical 0 0.9986702
- I-Chemical 0 0.0020811597
A I-Chemical 0 0.19186264
) O 0 0.00037209256
3 O 0 8.629697e-05
. O 0 5.6464534e-05
75 O 0 0.00014399106
mg O 0 0.0015618423
, O 0 0.00011715259
intramuscularly O 0 0.00013660439
, O 0 5.625064e-05
every O 0 1.549111e-05
28 O 0 2.9431872e-05
days O 0 1.560847e-05
plus O 0 3.318741e-05
250 O 0 0.00020139437
mg O 0 0.02698167
flutamide B-Chemical 0 0.99997175
, O 0 0.00047827125
tid O 0 0.9457663
, O 0 0.00012211985
per O 0 4.6644673e-05
Os O 0 0.9325739
] O 0 0.00024252401
and O 0 6.173143e-05
were O 0 5.216061e-05
evaluated O 0 4.7454567e-05
for O 0 8.823735e-05
anemia B-Disease 0 0.9998129
by O 0 0.0001392542
physical O 0 0.00018390184
examination O 0 6.9726404e-05
and O 0 5.6225854e-05
laboratory O 0 0.00010389977
tests O 0 9.4562296e-05
at O 0 2.948927e-05
baseline O 0 4.3050408e-05
and O 0 5.3571173e-05
4 O 0 3.496989e-05
subsequent O 0 4.5004363e-05
intervals O 0 4.2946092e-05
( O 0 0.00010753265
1 O 0 7.2969546e-05
, O 0 0.00010293707
2 O 0 8.084813e-05
, O 0 0.00010840633
3 O 0 7.716546e-05
and O 0 0.00010738222
6 O 0 8.9537745e-05
months O 0 8.78943e-05
post O 0 0.00022799699
- O 0 0.001158511
CAB O 0 0.018756537
) O 0 0.0029361532
. O 0 0.0025255985

Hb O 0 0.88707775
, O 0 0.007827972
PSA O 0 0.39135844
and O 0 0.006657005
Testosterone B-Chemical 1 0.99891615
measurements O 0 0.0029280803
were O 0 0.0030712087
recorded O 0 0.0038043186
. O 0 0.005314085

Patients O 0 0.0025332454
with O 0 0.0019908056
stage O 0 0.0060626143
D2 O 0 0.9979919
- O 0 0.0019215846
3 O 0 0.0003938064
disease O 0 0.01824431
, O 0 0.00032862282
abnormal O 0 0.0019082977
hemoglobin O 0 0.59601235
level O 0 0.0001491206
or O 0 0.00016052683
renal O 0 0.74713814
and O 0 0.00026370733
liver O 0 0.5027884
function O 0 0.00017909573
tests O 0 0.00017998012
that O 0 4.4740384e-05
were O 0 6.2261635e-05
higher O 0 6.846157e-05
than O 0 4.2901884e-05
the O 0 7.314532e-05
upper O 0 0.00021993535
limits O 0 0.00031186745
were O 0 0.00017604898
excluded O 0 0.00024354429
from O 0 0.0002774558
the O 0 0.0005964879
study O 0 0.0013838073
. O 0 0.0017718296

The O 0 0.002316653
duration O 0 0.0014824846
of O 0 0.0020935605
the O 0 0.0018031526
study O 0 0.002087542
was O 0 0.0019383213
six O 0 0.0014077477
months O 0 0.0017111753
. O 0 0.0038262098

RESULTS O 0 0.0039006732
: O 0 0.001374724
The O 0 0.0005080727
mean O 0 0.0004517581
hemoglobin O 0 0.43911657
( O 0 0.0016806953
Hb O 0 0.9306127
) O 0 0.00067946065
levels O 0 0.00022113559
were O 0 0.00016703906
significantly O 0 0.00017889366
declined O 0 0.00018137244
in O 0 8.1854276e-05
all O 0 7.844739e-05
patients O 0 9.134763e-05
from O 0 4.892945e-05
baseline O 0 5.3239117e-05
of O 0 9.0606576e-05
14 O 0 6.666278e-05
. O 0 4.292038e-05
2 O 0 5.374668e-05
g O 0 0.00018161262
/ O 0 0.00028367937
dl O 0 0.001068261
to O 0 7.8235e-05
14 O 0 6.67754e-05
. O 0 4.290123e-05
0 O 0 5.9586746e-05
g O 0 0.00020948921
/ O 0 0.0003633463
dl O 0 0.002242755
, O 0 0.00015223437
13 O 0 9.859316e-05
. O 0 4.814073e-05
5 O 0 5.3421085e-05
g O 0 0.0002059799
/ O 0 0.00035914793
dl O 0 0.0021888628
, O 0 0.00015424272
13 O 0 0.000101114216
. O 0 5.0071805e-05
2 O 0 5.883959e-05
g O 0 0.00018939444
/ O 0 0.00029661527
dl O 0 0.00117258
and O 0 0.0001021891
12 O 0 4.8153863e-05
. O 0 4.3349864e-05
7 O 0 4.8270045e-05
g O 0 0.00018260184
/ O 0 0.00029163994
dl O 0 0.0010592878
at O 0 7.780141e-05
1 O 0 9.5081756e-05
, O 0 0.00011635834
2 O 0 8.458771e-05
, O 0 0.00010765505
3 O 0 7.288422e-05
and O 0 9.6007345e-05
6 O 0 7.434487e-05
months O 0 6.666901e-05
post O 0 0.00016116363
- O 0 0.0007932157
CAB O 0 0.011445169
, O 0 0.0015157971
respectively O 0 0.003327535
. O 0 0.0025723209

Severe O 0 0.03927624
and O 0 0.002245903
clinically O 0 0.0044713253
evident O 0 0.0014297019
anemia B-Disease 0 0.99971205
of O 0 0.0022714045
Hb O 0 0.97628003
< O 0 0.0003511101
11 O 0 0.00018698427
g O 0 0.00036016162
/ O 0 0.0004033556
dl O 0 0.0013270683
with O 0 0.00017439776
clinical O 0 0.00050563266
symptoms O 0 0.0019058135
was O 0 0.00013926893
detected O 0 7.928118e-05
in O 0 9.5204334e-05
6 O 0 8.087312e-05
patients O 0 0.00020666923
( O 0 0.00025569854
14 O 0 0.00020452485
. O 0 0.00021552895
3 O 0 0.0003771905
% O 0 0.0009033814
) O 0 0.0020008695
. O 0 0.0022940014

This O 0 0.008880659
CAB O 0 0.1374352
- O 0 0.006464381
induced O 0 0.006135579
anemia B-Disease 0 0.9996952
was O 0 0.009131753
normochromic O 0 0.96952313
and O 0 0.007196942
normocytic O 0 0.9824256
. O 0 0.0068195798

At O 0 0.00084399065
six O 0 0.00069946476
months O 0 0.00038971883
post O 0 0.00042605124
- O 0 0.0010701611
CAB O 0 0.011510514
, O 0 0.0004290058
patients O 0 0.00037422866
with O 0 0.0004065929
severe O 0 0.10802666
anemia B-Disease 0 0.9999633
had O 0 0.00039140455
a O 0 0.0003288036
Hb O 0 0.68590206
mean O 0 5.0836814e-05
value O 0 8.921661e-05
of O 0 0.00011753348
10 O 0 8.959548e-05
. O 0 5.9740305e-05
2 O 0 7.783168e-05
+ O 0 0.00020792629
/ O 0 0.0003872985
- O 0 0.00022355997
0 O 0 7.8366415e-05
. O 0 5.1671625e-05
1 O 0 6.534433e-05
g O 0 0.00020929836
/ O 0 0.00037700895
dl O 0 0.0038119797
( O 0 0.0003935617
X O 0 0.22504905
+ O 0 0.0005225622
/ O 0 0.00084006804
- O 0 0.0005998791
SE O 0 0.08813647
) O 0 0.00025354238
, O 0 0.0001021509
whereas O 0 6.6519904e-05
the O 0 6.0009694e-05
other O 0 6.1628736e-05
patients O 0 0.00013642188
had O 0 0.0001405699
mild O 0 0.6840161
anemia B-Disease 0 0.99996924
with O 0 0.0007155948
Hb O 0 0.88006747
mean O 0 4.398885e-05
value O 0 7.9996185e-05
of O 0 0.00011503381
13 O 0 0.00010315729
. O 0 5.480966e-05
2 O 0 7.618881e-05
+ O 0 0.0002098975
/ O 0 0.00040492634
- O 0 0.00026148057
0 O 0 0.00011256336
. O 0 9.766083e-05
17 O 0 0.00023925988
( O 0 0.00042119686
X O 0 0.054893438
+ O 0 0.0011154807
/ O 0 0.0020651526
- O 0 0.0022120525
SE O 0 0.057787728
) O 0 0.00337625
. O 0 0.0028067157

The O 0 0.0016756193
development O 0 0.0021320963
of O 0 0.0019302663
severe O 0 0.12731245
anemia B-Disease 0 0.9998286
at O 0 0.00038509065
6 O 0 0.00014755286
months O 0 6.498689e-05
post O 0 8.876227e-05
- O 0 0.00033015493
CAB O 0 0.004653414
was O 0 0.00013989703
predictable O 0 0.00013449322
by O 0 7.715295e-05
the O 0 6.805377e-05
reduction O 0 0.0001925722
of O 0 0.00020782382
Hb O 0 0.83792967
baseline O 0 8.649634e-05
value O 0 7.9754805e-05
of O 0 9.429073e-05
more O 0 0.00012140948
than O 0 5.8646998e-05
2 O 0 5.789748e-05
. O 0 3.7656908e-05
5 O 0 4.439748e-05
g O 0 0.00016914234
/ O 0 0.00025121172
dl O 0 0.0006694841
after O 0 3.516036e-05
3 O 0 5.257566e-05
months O 0 3.5129186e-05
of O 0 0.00015396529
CAB O 0 0.007330592
( O 0 0.0004314846
p O 0 0.0003249361
= O 0 0.0003771324
0 O 0 0.0003497357
. O 0 0.0004936892
01 O 0 0.0025324333
) O 0 0.0022584414
. O 0 0.0024275421

The O 0 0.0016634356
development O 0 0.0020374719
of O 0 0.0016481573
severe O 0 0.024173852
CAB O 0 0.36086237
- O 0 0.0017348148
induced O 0 0.0013619737
anemia B-Disease 0 0.99995065
in O 0 0.0015973641
prostate B-Disease 2 0.99959165
cancer I-Disease 2 0.99991226
patients O 0 0.00063278724
did O 0 0.000118611846
not O 0 6.212646e-05
correlate O 0 5.9941918e-05
with O 0 0.00014887296
T O 0 0.22032696
baseline O 0 0.000102434366
values O 0 0.00014654291
( O 0 0.0002762838
T O 0 0.2409969
< O 0 0.00013043753
3 O 0 6.383632e-05
ng O 0 0.00021837403
/ O 0 0.00036584906
ml O 0 0.00038505523
versus O 0 0.0001303382
T O 0 0.3094821
> O 0 0.0004266101
or O 0 0.00012240699
= O 0 0.00013939741
3 O 0 5.7076286e-05
ng O 0 0.0002221813
/ O 0 0.00046846265
ml O 0 0.0006132605
) O 0 0.00023146496
, O 0 0.000118828066
with O 0 0.00013467687
age O 0 0.0001398645
( O 0 0.00012692099
< O 0 7.403041e-05
76 O 0 0.000118339805
yrs O 0 6.9998954e-05
versus O 0 4.9392867e-05
> O 0 0.00015576491
or O 0 8.051768e-05
= O 0 0.00012510299
76 O 0 0.0001626835
yrs O 0 0.00011345118
) O 0 0.00012970144
, O 0 9.297076e-05
and O 0 9.9071265e-05
clinical O 0 0.0003245036
stage O 0 0.000406255
( O 0 0.00031453572
stage O 0 0.0008926117
C O 0 0.87316626
versus O 0 0.00058876193
stage O 0 0.004040123
D1 O 0 0.9926818
) O 0 0.0037727114
. O 0 0.0024338134

Severe O 0 0.045195315
and O 0 0.0022696976
clinically O 0 0.0053913314
evident O 0 0.0016307863
anemia B-Disease 0 0.99980336
was O 0 0.0007770737
easily O 0 0.00028857647
corrected O 0 0.00021149016
by O 0 0.00016883024
subcutaneous O 0 0.0005302505
injections O 0 0.00020969585
( O 0 0.0001298887
3 O 0 4.626506e-05
times O 0 3.2079617e-05
/ O 0 0.00012689835
week O 0 3.2057415e-05
for O 0 4.1350457e-05
1 O 0 5.4032207e-05
month O 0 4.0449126e-05
) O 0 0.000107818385
of O 0 0.00012425687
recombinant O 0 0.00030790886
erythropoietin O 0 0.98877627
( O 0 0.001922316
rHuEPO O 0 0.91994
- O 0 0.003310608
beta O 0 0.85618746
) O 0 0.0039415895
. O 0 0.0024842916

CONCLUSION O 0 0.013325248
: O 0 0.0016678807
Our O 0 0.00079045515
data O 0 0.0006255068
suggest O 0 0.00024821374
that O 0 0.0003967951
rHuEPO O 0 0.8511345
- O 0 0.0022394985
beta O 0 0.94227713
correctable O 0 0.24914818
CAB O 0 0.5188707
- O 0 0.00092619896
induced O 0 0.0007537287
anemia B-Disease 0 0.9999385
occurs O 0 0.00020226112
in O 0 0.000119775475
14 O 0 8.186052e-05
. O 0 4.760759e-05
3 O 0 5.1259412e-05
% O 0 8.563436e-05
of O 0 0.00023235937
prostate B-Disease 2 0.99145705
cancer I-Disease 2 0.9995074
patients O 0 0.00042872183
after O 0 7.325854e-05
6 O 0 0.00011454616
months O 0 0.00012093621
of O 0 0.000548878
therapy O 0 0.001670751
. O 0 0.001893207

Delirium B-Disease 2 0.9896208
during O 0 0.0029632752
clozapine B-Chemical 0 0.99989176
treatment O 0 0.0026643872
: O 0 0.0017836118
incidence O 0 0.0019392088
and O 0 0.0011744468
associated O 0 0.0014717844
risk O 0 0.008790493
factors O 0 0.0042191125
. O 0 0.0038141096

BACKGROUND O 0 0.010045481
: O 0 0.0029604998
Incidence O 0 0.003072646
and O 0 0.0010035229
risk O 0 0.0021902544
factors O 0 0.00067065016
for O 0 0.0005538735
delirium B-Disease 0 0.99966145
during O 0 0.0005347881
clozapine B-Chemical 0 0.99997115
treatment O 0 0.00071540684
require O 0 0.0003961473
further O 0 0.0011532403
clarification O 0 0.002634419
. O 0 0.0023696588

METHODS O 0 0.0015237601
: O 0 0.0011340653
We O 0 0.00039961556
used O 0 0.00040316957
computerized O 0 0.0009739798
pharmacy O 0 0.001232891
records O 0 0.00035312722
to O 0 0.00012611125
identify O 0 9.337698e-05
all O 0 0.00011618293
adult O 0 0.0003006318
psychiatric B-Disease 2 0.8480171
inpatients O 0 0.00080963294
treated O 0 0.0001806391
with O 0 0.00045225013
clozapine B-Chemical 0 0.9999957
( O 0 0.00047571218
1995 O 0 0.0005622569
- O 0 0.00020985646
96 O 0 0.00024847803
) O 0 0.00013378373
, O 0 7.796436e-05
reviewed O 0 0.00010060333
their O 0 7.856448e-05
medical O 0 0.00018178034
records O 0 0.00010065198
to O 0 4.4849952e-05
score O 0 5.4197855e-05
incidence O 0 0.00014875307
and O 0 9.654919e-05
severity O 0 0.00035241645
of O 0 0.0005392478
delirium B-Disease 0 0.99993014
, O 0 0.00026603567
and O 0 0.00013877713
tested O 0 0.00011870667
associations O 0 0.00013298866
with O 0 0.00032835663
potential O 0 0.00064634037
risk O 0 0.0054170433
factors O 0 0.00242315
. O 0 0.0022407947

RESULTS O 0 0.0051416596
: O 0 0.002337975
Subjects O 0 0.0012940574
( O 0 0.0010466051
n O 0 0.00057120435
= O 0 0.00059097965
139 O 0 0.00064871786
) O 0 0.00038576341
were O 0 0.00017809018
72 O 0 0.00016056832
women O 0 0.00028013482
and O 0 0.00014085394
67 O 0 0.0003008153
men O 0 0.00053465826
, O 0 0.00013805924
aged O 0 0.00016806809
40 O 0 9.8067045e-05
. O 0 5.611086e-05
8 O 0 6.958465e-05
+ O 0 0.00020141549
/ O 0 0.0003819946
- O 0 0.00020989729
12 O 0 5.0767245e-05
. O 0 4.757895e-05
1 O 0 5.8567635e-05
years O 0 5.957186e-05
, O 0 9.0299676e-05
hospitalized O 0 0.0003591532
for O 0 5.8211608e-05
24 O 0 6.0045182e-05
. O 0 4.953145e-05
9 O 0 6.728703e-05
+ O 0 0.00018668409
/ O 0 0.00037433018
- O 0 0.00023348175
23 O 0 0.00012782242
. O 0 4.2386433e-05
3 O 0 3.5849327e-05
days O 0 2.3161312e-05
, O 0 5.6676985e-05
and O 0 6.646562e-05
given O 0 9.3601106e-05
clozapine B-Chemical 0 0.99999034
, O 0 0.00019205804
gradually O 0 0.00015178692
increased O 0 0.000113053124
to O 0 4.5054905e-05
an O 0 5.4448275e-05
average O 0 3.1109597e-05
daily O 0 7.72024e-05
dose O 0 0.00023562956
of O 0 0.00016159155
282 O 0 0.0028968935
+ O 0 0.0003229894
/ O 0 0.00047604597
- O 0 0.00026788653
203 O 0 0.00093748333
mg O 0 0.005785826
( O 0 0.00015574753
3 O 0 5.597415e-05
. O 0 4.1639327e-05
45 O 0 6.3727624e-05
+ O 0 0.00018469313
/ O 0 0.00036095444
- O 0 0.00021231652
2 O 0 6.5890716e-05
. O 0 4.3153614e-05
45 O 0 6.494574e-05
mg O 0 0.0009373316
/ O 0 0.00039139166
kg O 0 0.00033807463
) O 0 0.00016311376
for O 0 7.572626e-05
18 O 0 0.00010338329
. O 0 7.9315665e-05
9 O 0 0.000122492
+ O 0 0.00034034756
/ O 0 0.00068854366
- O 0 0.0005448563
16 O 0 0.00033595812
. O 0 0.00029695028
4 O 0 0.0004567354
days O 0 0.00062157353
. O 0 0.0017920672

Delirium B-Disease 2 0.99560034
was O 0 0.0033658433
diagnosed O 0 0.0029535296
in O 0 0.00069693004
14 O 0 0.0004819919
( O 0 0.00049614656
10 O 0 0.0002558044
. O 0 0.00016021916
1 O 0 0.00016388045
% O 0 0.00020021648
incidence O 0 0.00035944956
, O 0 0.0001981247
or O 0 0.00012693091
1 O 0 0.00010237421
. O 0 5.981458e-05
48 O 0 6.574679e-05
cases O 0 0.00012077443
/ O 0 0.00032439377
person O 0 0.00019857708
- O 0 0.00021049535
years O 0 6.971111e-05
of O 0 0.00010783309
exposure O 0 0.0002607912
) O 0 0.00032825145
; O 0 0.00017877105
71 O 0 0.00024118103
. O 0 6.684714e-05
4 O 0 6.9877104e-05
% O 0 0.00010645069
of O 0 0.00016780228
cases O 0 0.0002829455
were O 0 0.00032668267
moderate O 0 0.002399334
or O 0 0.0010264424
severe O 0 0.033416223
. O 0 0.00267096

Associated O 0 0.004027215
factors O 0 0.0021150885
were O 0 0.0013371507
co O 0 0.010612303
- O 0 0.0010178708
treatment O 0 0.00028755947
with O 0 0.00022407855
other O 0 0.00015033472
centrally O 0 0.0004123914
antimuscarinic O 0 0.9083882
agents O 0 0.0009674909
, O 0 0.00015049562
poor O 0 0.00026327898
clinical O 0 0.0002989464
outcome O 0 0.00013697952
, O 0 0.00014501896
older O 0 0.0005261969
age O 0 0.00012322902
, O 0 8.589926e-05
and O 0 6.965563e-05
longer O 0 4.6042707e-05
hospitalization O 0 0.0003245305
( O 0 0.00012466194
by O 0 8.172589e-05
17 O 0 9.609793e-05
. O 0 3.5997087e-05
5 O 0 3.3361808e-05
days O 0 2.4137827e-05
, O 0 6.3918014e-05
increasing O 0 9.707374e-05
cost O 0 0.00019634583
) O 0 0.0002549605
; O 0 0.0001560682
sex O 0 0.00024587908
, O 0 0.00010646673
diagnosis O 0 0.00018567771
or O 0 8.898032e-05
medical O 0 0.000634708
co O 0 0.024630997
- O 0 0.00045877098
morbidity O 0 0.01287762
, O 0 0.0001285779
and O 0 0.00010537147
daily O 0 0.00039413688
clozapine B-Chemical 0 0.99999034
dose O 0 0.0024630865
, O 0 0.00018542435
which O 0 0.00019720983
fell O 0 0.00035784935
with O 0 0.0002965367
age O 0 0.00039009034
, O 0 0.0004891402
were O 0 0.00067138625
unrelated O 0 0.0021769954
. O 0 0.0019904212

CONCLUSIONS O 0 0.02458975
: O 0 0.005216873
Delirium B-Disease 2 0.9923977
was O 0 0.0011244231
found O 0 0.00041756028
in O 0 0.00028342553
10 O 0 0.00022565699
% O 0 0.00024985115
of O 0 0.0006139123
clozapine B-Chemical 0 0.999992
- O 0 0.0011811311
treated O 0 0.00042137422
inpatients O 0 0.0012499737
, O 0 0.00014905121
particularly O 0 0.0001414247
in O 0 0.0001238229
older O 0 0.0005157153
patients O 0 0.0001992669
exposed O 0 0.00016499715
to O 0 0.00021121408
other O 0 0.00041255265
central O 0 0.0017856403
anticholinergics O 0 0.996311
. O 0 0.0024286255

Delirium B-Disease 2 0.99520373
was O 0 0.0028044293
inconsistently O 0 0.002282536
recognized O 0 0.00079508795
clinically O 0 0.0019432295
in O 0 0.00044200668
milder O 0 0.03412807
cases O 0 0.00040915437
and O 0 0.00020305875
was O 0 0.0001532422
associated O 0 9.7744385e-05
with O 0 0.00014714735
increased O 0 0.00023681468
length O 0 0.00014755398
- O 0 0.00025959424
of O 0 0.00019178043
- O 0 0.0002685059
stay O 0 8.8644e-05
and O 0 0.0001063107
higher O 0 0.00017272367
costs O 0 0.0003579461
, O 0 0.00024087909
and O 0 0.00029734633
inferior O 0 0.0022680776
clinical O 0 0.001914888
outcome O 0 0.0016789152
. O 0 0.002009159

Neuroprotective O 0 0.76420665
action O 0 0.0044056242
of O 0 0.007706987
MPEP B-Chemical 1 0.9999914
, O 0 0.0018208564
a O 0 0.00084253395
selective O 0 0.0032565393
mGluR5 O 0 0.986074
antagonist O 0 0.95589983
, O 0 0.00041321642
in O 0 0.00037273747
methamphetamine B-Chemical 1 0.99998856
- O 0 0.0009715498
induced O 0 0.00039407623
dopaminergic O 0 0.9697641
neurotoxicity B-Disease 2 0.99997675
is O 0 0.0001904084
associated O 0 7.8720244e-05
with O 0 0.00010221277
a O 0 0.00011318018
decrease O 0 0.00014073243
in O 0 0.0001691178
dopamine B-Chemical 0 0.9996369
outflow O 0 0.65815026
and O 0 0.00019676844
inhibition O 0 0.000564226
of O 0 0.0007056967
hyperthermia B-Disease 0 0.9838299
in O 0 0.0010237391
rats O 0 0.002294985
. O 0 0.0017219122

The O 0 0.0015289228
aim O 0 0.0014037283
of O 0 0.0011350913
this O 0 0.0008249745
study O 0 0.0006373649
was O 0 0.00032162076
to O 0 0.00014220984
examine O 0 6.7451234e-05
the O 0 0.00010776053
role O 0 8.841042e-05
of O 0 0.0006823744
metabotropic O 0 0.9999677
glutamate B-Chemical 1 0.9999858
receptor O 0 0.22310452
5 O 0 0.00014092783
( O 0 0.00023956942
mGluR5 O 0 0.5798481
) O 0 0.0001820294
in O 0 6.579365e-05
the O 0 8.943842e-05
toxic O 0 0.015545684
action O 0 0.00028182252
of O 0 0.0006091784
methamphetamine B-Chemical 1 0.9999659
on O 0 0.0002701686
dopaminergic O 0 0.3803317
neurones O 0 0.002321353
in O 0 0.0006291059
rats O 0 0.0017019518
. O 0 0.0016505922

Methamphetamine B-Chemical 1 0.999376
( O 0 0.0034708192
10 O 0 0.0011797008
mg O 0 0.010823114
/ O 0 0.0019473075
kg O 0 0.001417541
sc O 0 0.002382755
) O 0 0.0004527069
, O 0 0.0001840822
administered O 0 0.00013783341
five O 0 5.731584e-05
times O 0 4.869693e-05
, O 0 9.108285e-05
reduced O 0 0.0001238756
the O 0 7.996056e-05
levels O 0 9.8220335e-05
of O 0 0.00029845574
dopamine B-Chemical 0 0.9997092
and O 0 0.00016298005
its O 0 0.00028475976
metabolites O 0 0.24670957
in O 0 0.0001209632
striatal O 0 0.195204
tissue O 0 0.0003387909
when O 0 4.9687424e-05
measured O 0 6.759766e-05
72 O 0 8.9710375e-05
h O 0 8.7447435e-05
after O 0 7.501744e-05
the O 0 0.00023965555
last O 0 0.00027749708
injection O 0 0.0013824154
. O 0 0.0019847516

A O 0 0.024848266
selective O 0 0.0074710497
antagonist O 0 0.7828191
of O 0 0.00282023
mGluR5 O 0 0.96505964
, O 0 0.0010439911
2 B-Chemical 0 0.0004464996
- I-Chemical 0 0.0010973942
methyl I-Chemical 0 0.9679896
- I-Chemical 0 0.00087900297
6 I-Chemical 0 0.00014570425
- I-Chemical 0 0.00037331218
( I-Chemical 0 0.0003557942
phenylethynyl I-Chemical 0 0.4045573
) I-Chemical 0 0.0011714236
pyridine I-Chemical 0 0.99972206
( O 0 0.0029481803
MPEP B-Chemical 1 0.99999774
; O 0 0.00038969915
5 O 0 9.012264e-05
mg O 0 0.0017091458
/ O 0 0.00043321375
kg O 0 0.00041357148
ip O 0 0.019550852
) O 0 0.00020835755
, O 0 7.1557406e-05
when O 0 3.052283e-05
administered O 0 5.157916e-05
five O 0 2.157755e-05
times O 0 1.7331313e-05
immediately O 0 2.3557333e-05
before O 0 2.1043394e-05
each O 0 4.8110025e-05
methamphetamine B-Chemical 1 0.9999136
injection O 0 0.00024968584
reversed O 0 0.00041533815
the O 0 0.00015989682
above O 0 0.0002510197
- O 0 0.00059199496
mentioned O 0 0.0007415066
methamphetamine B-Chemical 1 0.9999076
effects O 0 0.0040555666
. O 0 0.0024780722

A O 0 0.045291737
single O 0 0.0062294286
MPEP B-Chemical 1 0.9999722
( O 0 0.0025867387
5 O 0 0.00053752377
mg O 0 0.0072578355
/ O 0 0.0012553829
kg O 0 0.0009955685
ip O 0 0.02408181
) O 0 0.00033314282
injection O 0 0.00014566313
reduced O 0 0.00017961256
the O 0 0.00011021351
basal O 0 0.00026137667
extracellular O 0 0.000549463
dopamine B-Chemical 0 0.9991629
level O 0 8.000465e-05
in O 0 6.882467e-05
the O 0 8.917858e-05
striatum O 0 0.00933437
, O 0 0.00010683346
as O 0 5.9620394e-05
well O 0 5.870944e-05
as O 0 0.00012149114
dopamine B-Chemical 0 0.9993339
release O 0 0.00044247613
stimulated O 0 6.706192e-05
either O 0 9.557618e-05
by O 0 0.00023754241
methamphetamine B-Chemical 1 0.99998295
( O 0 0.00023770733
10 O 0 7.653704e-05
mg O 0 0.0016591523
/ O 0 0.00035794356
kg O 0 0.00029205089
sc O 0 0.0006666807
) O 0 0.00013883735
or O 0 6.935768e-05
by O 0 0.00012602951
intrastriatally O 0 0.28792158
administered O 0 0.00091054046
veratridine B-Chemical 0 0.9998987
( O 0 0.0014946464
100 O 0 0.002606386
microM O 0 0.44652882
) O 0 0.0038569751
. O 0 0.0024582646

Moreover O 0 0.003094469
, O 0 0.0021569692
it O 0 0.0011066155
transiently O 0 0.001251585
diminished O 0 0.001340411
the O 0 0.0010711101
methamphetamine B-Chemical 1 0.99996567
( O 0 0.00072795595
10 O 0 0.00021011895
mg O 0 0.0038306648
/ O 0 0.0007040516
kg O 0 0.0005954209
sc O 0 0.0015725371
) O 0 0.00038320976
- O 0 0.0003467696
induced O 0 0.00037601133
hyperthermia B-Disease 0 0.9627651
and O 0 0.0004999025
reduced O 0 0.00088580657
basal O 0 0.0014035798
body O 0 0.0031427569
temperature O 0 0.005318117
. O 0 0.0022934165

MPEP B-Chemical 1 0.9998982
administered O 0 0.0025453651
into O 0 0.00041906844
the O 0 0.0004704101
striatum O 0 0.0030994008
at O 0 0.00019301947
high O 0 0.0004077964
concentrations O 0 0.0007851513
( O 0 0.00040470983
500 O 0 0.0009040143
microM O 0 0.27956015
) O 0 0.00040830832
increased O 0 0.00032587667
extracellular O 0 0.0012753631
dopamine B-Chemical 0 0.99981695
levels O 0 0.00020289738
, O 0 0.00013211428
while O 0 8.990796e-05
lower O 0 0.00016577807
concentrations O 0 0.0004646137
( O 0 0.00023932286
50 O 0 0.00028189726
- O 0 0.00034126395
100 O 0 0.0005862
microM O 0 0.15253459
) O 0 0.00045389603
were O 0 0.000198984
devoid O 0 0.00016663547
of O 0 0.00044071925
any O 0 0.00058670243
effect O 0 0.0013413305
. O 0 0.0023216577

The O 0 0.001479303
results O 0 0.0011649089
of O 0 0.00094099855
this O 0 0.00063692714
study O 0 0.00042374534
suggest O 0 0.00011822296
that O 0 0.00012790888
the O 0 0.00019947486
blockade O 0 0.004112204
of O 0 0.0006630054
mGluR5 O 0 0.97974604
by O 0 0.0013391592
MPEP B-Chemical 1 0.9999974
may O 0 0.0002606711
protect O 0 0.00038670748
dopaminergic O 0 0.43410107
neurones O 0 0.0020121366
against O 0 0.0003856027
methamphetamine B-Chemical 1 0.99996924
- O 0 0.0031835681
induced O 0 0.0027726223
toxicity B-Disease 2 0.9982003
. O 0 0.0035208657

Neuroprotection O 0 0.8184523
rendered O 0 0.0053623654
by O 0 0.0046552117
MPEP B-Chemical 1 0.999982
may O 0 0.00082876824
be O 0 0.0003131336
associated O 0 0.00016876696
with O 0 0.00017304627
the O 0 0.00012358486
reduction O 0 0.0002798855
of O 0 0.00021129887
the O 0 0.00037409418
methamphetamine B-Chemical 1 0.99999046
- O 0 0.0010773682
induced O 0 0.0004749645
dopamine B-Chemical 0 0.9999169
efflux O 0 0.031686813
in O 0 7.3266296e-05
the O 0 7.170016e-05
striatum O 0 0.0013306525
due O 0 3.6722162e-05
to O 0 4.4456156e-05
the O 0 7.033512e-05
blockade O 0 0.0014464338
of O 0 0.00037726964
extrastriatal O 0 0.9896408
mGluR5 O 0 0.93292946
, O 0 0.00022564901
and O 0 0.00015729565
with O 0 0.00022999302
a O 0 0.0003949324
decrease O 0 0.00070416974
in O 0 0.0010828556
hyperthermia B-Disease 0 0.9895778
. O 0 0.0029698007

Protective O 0 0.040076174
efficacy O 0 0.0029025958
of O 0 0.0024887444
neuroactive O 0 0.80242187
steroids B-Chemical 0 0.99849427
against O 0 0.0017168174
cocaine B-Chemical 1 0.9999211
kindled O 0 0.999524
- O 0 0.014397404
seizures B-Disease 0 0.99978846
in O 0 0.0018376451
mice O 0 0.0016450022
. O 0 0.0025383278

Neuroactive O 0 0.773673
steroids B-Chemical 0 0.97436833
demonstrate O 0 0.00071150955
pharmacological O 0 0.0043701823
actions O 0 0.0010065943
that O 0 0.00024402053
have O 0 0.0001676043
relevance O 0 0.000120454446
for O 0 0.0001380116
a O 0 0.00027371594
host O 0 0.0003101518
of O 0 0.00059077964
neurological B-Disease 0 0.905537
and I-Disease 0 0.0030571376
psychiatric I-Disease 2 0.99970204
disorders I-Disease 0 0.9966402
. O 0 0.0036198

They O 0 0.003441953
offer O 0 0.0017876966
protection O 0 0.0021510893
against O 0 0.00097310427
seizures B-Disease 0 0.9996779
in O 0 0.0006136139
a O 0 0.00042473298
range O 0 0.00021688871
of O 0 0.0002056412
models O 0 0.00019428799
and O 0 0.00014565006
seem O 0 0.00010620522
to O 0 7.44124e-05
inhibit O 0 7.073634e-05
certain O 0 0.00012439996
stages O 0 0.0001767753
of O 0 0.00030188612
drug B-Disease 0 0.28325856
dependence I-Disease 0 0.0037599856
in O 0 0.0005720635
preclinical O 0 0.003913987
assessments O 0 0.0012407713
. O 0 0.0017925672

The O 0 0.001506617
present O 0 0.0010314701
study O 0 0.0010178757
was O 0 0.00056255545
designed O 0 0.00032722036
to O 0 0.00019891001
evaluate O 0 0.00010128705
two O 0 9.5992145e-05
endogenous O 0 0.00013895509
and O 0 0.000116544004
one O 0 7.340098e-05
synthetic O 0 0.00019729373
neuroactive O 0 0.37824327
steroid B-Chemical 1 0.9442408
that O 0 5.309599e-05
positively O 0 5.458933e-05
modulate O 0 2.123434e-05
the O 0 9.728651e-05
gamma B-Chemical 0 0.8565879
- I-Chemical 0 0.0035892853
aminobutyric I-Chemical 0 0.99994123
acid I-Chemical 0 0.9963909
( O 0 0.006179464
GABA B-Chemical 0 0.9999908
( O 0 0.0008764146
A O 0 0.043660447
) O 0 0.00037369924
) O 0 0.00023774811
receptor O 0 0.00089683034
against O 0 4.7988004e-05
the O 0 6.475058e-05
increase O 0 6.579779e-05
in O 0 5.9779748e-05
sensitivity O 0 0.00026159955
to O 0 6.48815e-05
the O 0 0.000111898225
convulsant O 0 0.99219745
effects O 0 0.00020942651
of O 0 0.00043953862
cocaine B-Chemical 1 0.99971956
engendered O 0 0.00029092177
by O 0 0.00011168236
repeated O 0 0.00010731201
cocaine B-Chemical 1 0.99953914
administration O 0 0.008019972
( O 0 0.0013901985
seizure B-Disease 0 0.99960274
kindling O 0 0.9962658
) O 0 0.0042528803
. O 0 0.0021433206

Allopregnanolone B-Chemical 0 0.9990212
( O 0 0.009137559
3alpha B-Chemical 0 0.9292692
- I-Chemical 0 0.021913294
hydroxy I-Chemical 0 0.99989426
- I-Chemical 0 0.020112488
5alpha I-Chemical 0 0.9711591
- I-Chemical 0 0.0030505091
pregnan I-Chemical 0 0.46552548
- I-Chemical 0 0.00064918725
20 I-Chemical 0 0.00019601324
- I-Chemical 0 0.00025335196
one I-Chemical 0 9.835343e-05
) O 0 0.00026537242
, O 0 0.00033893305
pregnanolone B-Chemical 0 0.9999713
( O 0 0.0009958588
3alpha B-Chemical 0 0.89099485
- I-Chemical 0 0.004934301
hydroxy I-Chemical 0 0.99997103
- I-Chemical 0 0.01257617
5beta I-Chemical 0 0.99824274
- I-Chemical 0 0.0013797436
pregnan I-Chemical 0 0.32855767
- I-Chemical 0 0.00032193583
20 I-Chemical 0 0.00010361078
- I-Chemical 0 0.0001496094
one I-Chemical 0 5.8436086e-05
) O 0 0.00015171024
and O 0 0.00016472237
ganaxolone B-Chemical 0 0.9984906
( O 0 0.00019386457
a O 0 0.00010225489
synthetic O 0 0.0001094926
derivative O 0 0.0013150576
of O 0 0.00071922713
allopregnanolone B-Chemical 0 0.9999988
3alpha B-Chemical 0 0.99715936
- I-Chemical 0 0.01860559
hydroxy I-Chemical 0 0.9999763
- I-Chemical 0 0.0049461173
3beta I-Chemical 0 0.77717817
- I-Chemical 0 0.0016364447
methyl I-Chemical 0 0.9930241
- I-Chemical 0 0.0019593507
5alpha I-Chemical 0 0.9098384
- I-Chemical 0 0.00096640934
pregnan I-Chemical 0 0.31148297
- I-Chemical 0 0.00031620864
20 I-Chemical 0 0.00010170274
- I-Chemical 0 0.00014890236
one I-Chemical 0 5.4492117e-05
) O 0 0.000109743574
were O 0 5.39455e-05
tested O 0 4.395304e-05
for O 0 3.719153e-05
their O 0 6.1028695e-05
ability O 0 5.5585635e-05
to O 0 4.376867e-05
suppress O 0 3.820593e-05
the O 0 6.823118e-05
expression O 0 0.0001469114
( O 0 0.00024910946
anticonvulsant O 0 0.9951267
effect O 0 0.0001443814
) O 0 0.00018519006
and O 0 8.374969e-05
development O 0 0.00021401972
( O 0 0.00020123505
antiepileptogenic O 0 0.564086
effect O 0 0.00013487722
) O 0 0.00024075028
of O 0 0.0003857972
cocaine B-Chemical 1 0.99992454
- O 0 0.0021898504
kindled O 0 0.997537
seizures B-Disease 0 0.999954
in O 0 0.00043664273
male O 0 0.0015235381
, O 0 0.00045000832
Swiss O 0 0.0023680876
- O 0 0.0013918184
Webster O 0 0.007143851
mice O 0 0.0010338333
. O 0 0.0018136183

Kindled O 0 0.9961243
seizures B-Disease 0 0.99949443
were O 0 0.0017668455
induced O 0 0.00085760193
by O 0 0.000489416
daily O 0 0.00044280902
administration O 0 0.00067222945
of O 0 0.0002952711
60 O 0 0.00025771878
mg O 0 0.0042162607
/ O 0 0.001095977
kg O 0 0.0014901201
cocaine B-Chemical 1 0.99500066
for O 0 0.00047579693
5 O 0 0.00053356774
days O 0 0.0006181378
. O 0 0.0016967461

All O 0 0.001579094
of O 0 0.0014527051
these O 0 0.0013629749
positive O 0 0.002397691
GABA B-Chemical 0 0.99994004
( O 0 0.002441112
A O 0 0.031449452
) O 0 0.00056078855
modulators O 0 0.0004237086
suppressed O 0 0.00024968633
the O 0 0.00013472197
expression O 0 0.00017655177
of O 0 0.00034331015
kindled O 0 0.9982185
seizures B-Disease 0 0.99997854
, O 0 0.00034409392
whereas O 0 0.00016348434
only O 0 0.00042569803
allopregnanolone B-Chemical 0 0.99999535
and O 0 0.0010877525
ganaxolone B-Chemical 0 0.99929976
inhibited O 0 0.00084974506
the O 0 0.00037961284
development O 0 0.00093973527
of O 0 0.0016844486
kindling O 0 0.97875893
. O 0 0.0028549614

Allopregnanolone B-Chemical 0 0.9989636
and O 0 0.009520948
pregnanolone B-Chemical 0 0.9998946
, O 0 0.0022580698
but O 0 0.0009320977
not O 0 0.00079480495
ganaxolone B-Chemical 0 0.99905473
, O 0 0.0006204939
also O 0 0.00031694834
reduced O 0 0.00063403806
cumulative O 0 0.0011486112
lethality O 0 0.4125649
associated O 0 0.0010429163
with O 0 0.002453776
kindling O 0 0.9845871
. O 0 0.0033186025

These O 0 0.0019823662
findings O 0 0.0015207264
demonstrate O 0 0.0004044904
that O 0 0.000378236
some O 0 0.00061552087
neuroactive O 0 0.6467541
steroids B-Chemical 0 0.99863416
attenuate O 0 0.0021546932
convulsant O 0 0.9994973
and O 0 0.00027693016
sensitizing O 0 0.00074168644
properties O 0 9.350209e-05
of O 0 0.00034251608
cocaine B-Chemical 1 0.9997677
and O 0 0.00015390982
add O 0 9.700323e-05
to O 0 5.8569985e-05
a O 0 9.146373e-05
growing O 0 9.677778e-05
literature O 0 0.00010885321
on O 0 3.663734e-05
their O 0 7.382075e-05
potential O 0 7.3695766e-05
use O 0 6.21113e-05
in O 0 5.848603e-05
the O 0 6.790863e-05
modulation O 0 8.849799e-05
of O 0 0.0001559443
effects O 0 0.00024965015
of O 0 0.0005847084
drugs O 0 0.040049613
of O 0 0.0021614206
abuse O 0 0.84977746
. O 0 0.0030235855

Effect O 0 0.0023398877
of O 0 0.0022283662
humoral O 0 0.05818166
modulators O 0 0.0036274232
of O 0 0.0035244718
morphine B-Chemical 0 0.99992883
- O 0 0.0023643551
induced O 0 0.00056001754
increase B-Disease 0 0.00042659708
in I-Disease 0 0.00043642026
locomotor I-Disease 0 0.021696672
activity I-Disease 0 0.0006646858
of O 0 0.0012223574
mice O 0 0.0013557572
. O 0 0.0023152607

The O 0 0.0015756261
effect O 0 0.0012238211
of O 0 0.0013757938
humoral O 0 0.047081556
modulators O 0 0.0015035112
on O 0 0.0003042737
the O 0 0.0007777228
morphine B-Chemical 0 0.9999287
- O 0 0.001261423
induced O 0 0.0003043973
increase B-Disease 0 0.0002312221
in I-Disease 0 0.00022418668
locomotor I-Disease 0 0.0153049175
activity I-Disease 0 0.00027238615
of O 0 0.0004437621
mice O 0 0.00040696433
was O 0 0.00094633515
studied O 0 0.0016641484
. O 0 0.0020476407

The O 0 0.0017512984
subcutaneous O 0 0.0029128236
administration O 0 0.0020809397
of O 0 0.00074204634
10 O 0 0.00045655324
mg O 0 0.006082075
/ O 0 0.0010097962
kg O 0 0.00076170254
of O 0 0.0007297289
morphine B-Chemical 0 0.9999535
- O 0 0.0084201805
HC1 O 0 0.99951375
produced O 0 0.00028858718
a O 0 0.00030612515
marked O 0 0.00038686048
increase B-Disease 0 0.00021594137
in I-Disease 0 0.0002606833
locomotor I-Disease 0 0.018969562
activity I-Disease 0 0.0004900149
in O 0 0.00066302967
mice O 0 0.001013628
. O 0 0.0019073588

The O 0 0.004077735
morphine B-Chemical 0 0.9994998
- O 0 0.0062014125
induced O 0 0.003379226
hyperactivity B-Disease 2 0.99989605
was O 0 0.001894275
potentiated O 0 0.07160949
by O 0 0.002523814
scopolamine B-Chemical 1 0.99999225
and O 0 0.0019528824
attenuated O 0 0.005088851
by O 0 0.004855685
physostigmine B-Chemical 0 0.9999409
. O 0 0.005215146

In O 0 0.0018050916
contrast O 0 0.001837032
, O 0 0.001269165
both O 0 0.0011831287
methscopolamine B-Chemical 0 0.9998615
and O 0 0.0038885658
neostigmine B-Chemical 0 0.99996996
, O 0 0.0006431037
which O 0 0.00026606684
do O 0 0.00012601027
not O 0 8.883679e-05
penetrate O 0 0.00011499081
the O 0 0.00010184045
blood O 0 0.001524393
- O 0 0.00029261503
brain O 0 0.001038448
barrier O 0 0.0008055438
, O 0 0.00013518831
had O 0 8.40627e-05
no O 0 5.0484094e-05
effect O 0 8.837107e-05
on O 0 0.00010019155
the O 0 0.00040050416
hyperactivity B-Disease 2 0.99986136
produced O 0 0.0012368591
by O 0 0.0027298399
morphine B-Chemical 0 0.999752
. O 0 0.0033995626

Pretreatment O 0 0.037003357
of O 0 0.001999221
mice O 0 0.0007801497
with O 0 0.0014084585
alpha B-Chemical 0 0.9651409
- I-Chemical 0 0.0031045026
methyltyrosine I-Chemical 0 0.8245303
( O 0 0.0004713644
20 O 0 0.00021121932
mg O 0 0.0032321939
/ O 0 0.0006166803
kg O 0 0.0004574932
i O 0 0.00037734315
. O 0 0.000101234145
p O 0 0.00012427405
. O 0 6.021337e-05
, O 0 8.531354e-05
one O 0 5.4447497e-05
hour O 0 6.909349e-05
) O 0 0.00014183795
, O 0 8.8006265e-05
an O 0 0.00010880691
inhibitor O 0 0.0005586229
of O 0 0.00048689664
tyrosine B-Chemical 0 0.950477
hydroxylase O 0 0.99914694
, O 0 0.0002504906
significantly O 0 0.00018344808
decreased O 0 0.00025291342
the O 0 0.00012644044
activity O 0 0.00017564741
- O 0 0.00035764306
increasing O 0 0.00031613928
effects O 0 0.00068844995
of O 0 0.0031233903
morphine B-Chemical 0 0.999782
. O 0 0.0035809884

On O 0 0.0025894
the O 0 0.0015731719
other O 0 0.0010775343
hand O 0 0.001488658
, O 0 0.001004124
pretreatment O 0 0.03607791
with O 0 0.0013777524
p B-Chemical 0 0.0012525121
- I-Chemical 0 0.0007577871
chlorophenylalamine I-Chemical 0 0.04734135
( O 0 0.00034430347
3 O 0 0.00013752999
X O 0 0.039574772
320 O 0 0.0019239673
mg O 0 0.0067878678
/ O 0 0.00055563217
kg O 0 0.00037354784
i O 0 0.00031221996
. O 0 8.3234416e-05
p O 0 0.00010584933
. O 0 5.3768417e-05
, O 0 8.088235e-05
24 O 0 5.4529497e-05
hr O 0 0.00011344015
) O 0 0.00016580241
, O 0 0.00013426055
a O 0 0.0004190934
serotonin B-Chemical 0 0.9998995
depletor O 0 0.9998043
, O 0 0.00032273974
caused O 0 0.00019209282
no O 0 0.00011594963
significant O 0 0.00020471976
change O 0 0.0002935242
in O 0 0.00045237876
the O 0 0.0013829805
hyperactivity B-Disease 2 0.9997485
. O 0 0.0034728635

The O 0 0.0017300176
study O 0 0.0013340863
suggests O 0 0.00041703376
that O 0 0.00032960172
the O 0 0.0003786437
activity O 0 0.00037662298
- O 0 0.0005096139
increasing O 0 0.00021915034
effects O 0 0.00026607874
of O 0 0.00077276584
morphine B-Chemical 0 0.9999318
are O 0 0.00017929703
mediated O 0 6.530489e-05
by O 0 9.416707e-05
the O 0 9.711892e-05
release O 0 0.00036907362
of O 0 0.000296518
catecholamines B-Chemical 0 0.99698263
from O 0 0.00029657906
adrenergic O 0 0.8651093
neurons O 0 0.0005700923
in O 0 0.00033178084
the O 0 0.0006299362
brain O 0 0.005960148
. O 0 0.0020361845

And O 0 0.0055803917
the O 0 0.0013480078
results O 0 0.00092210906
are O 0 0.00052445533
consistent O 0 0.00034148133
with O 0 0.00032769924
the O 0 0.00023129198
hypothesis O 0 0.00030801722
that O 0 0.00025039865
morphine B-Chemical 0 0.9998765
acts O 0 0.00025746092
by O 0 0.00022862304
retarding O 0 0.058196936
the O 0 0.00020208953
release O 0 0.0007311653
of O 0 0.00053863623
acetylcholine B-Chemical 1 0.9993774
at O 0 0.0001935351
some O 0 0.0003293366
central O 0 0.0008010223
cholinergic O 0 0.22275499
synapses O 0 0.009877961
. O 0 0.0022286463

It O 0 0.0028086423
is O 0 0.0012846739
also O 0 0.00066968694
suggested O 0 0.00036249432
from O 0 0.00025714393
collected O 0 0.00015395341
evidence O 0 0.00013647588
that O 0 0.00010050006
the O 0 0.00013520353
activity O 0 0.00016018921
- O 0 0.00025838186
increasing O 0 0.00012288896
effects O 0 0.00016573949
of O 0 0.0005482534
morphine B-Chemical 0 0.9999416
in O 0 0.0001397032
mice O 0 5.3111784e-05
are O 0 5.2868316e-05
mediated O 0 3.2773078e-05
by O 0 5.4244498e-05
mechanisms O 0 6.134845e-05
different O 0 3.350043e-05
from O 0 4.4339085e-05
those O 0 7.127634e-05
which O 0 6.324844e-05
mediate O 0 2.5764473e-05
the O 0 6.702139e-05
activity O 0 0.00010765484
- O 0 0.00022056869
increasing O 0 0.0001599772
effects O 0 0.00028992968
of O 0 0.0011012501
morphine B-Chemical 0 0.99981683
in O 0 0.0012391902
rats O 0 0.0024913538
. O 0 0.0017774776

Effects O 0 0.0028086624
of O 0 0.0022324007
uninephrectomy O 0 0.38140437
and O 0 0.00085563475
high O 0 0.00079278153
protein O 0 0.00067719416
feeding O 0 0.00062030077
on O 0 0.00029253995
lithium B-Chemical 0 0.9999062
- O 0 0.0018539813
induced O 0 0.0010528956
chronic B-Disease 2 0.9696481
renal I-Disease 2 0.99850595
failure I-Disease 2 0.97512096
in O 0 0.001600546
rats O 0 0.0028999888
. O 0 0.0019715773

Rats O 0 0.0047510993
with O 0 0.003532093
lithium B-Chemical 0 0.9997223
- O 0 0.004875543
induced O 0 0.002795428
nephropathy B-Disease 2 0.9999875
were O 0 0.00039472984
subjected O 0 0.00010184016
to O 0 0.00010552251
high O 0 0.00024781062
protein O 0 0.00038386902
( O 0 0.00033237983
HP O 0 0.045727443
) O 0 0.00026410285
feeding O 0 0.00024303558
, O 0 0.00019632655
uninephrectomy O 0 0.7385848
( O 0 0.0006584665
NX O 0 0.9932595
) O 0 0.00025094594
or O 0 6.845289e-05
a O 0 9.791455e-05
combination O 0 0.000108075415
of O 0 0.00012280041
these O 0 0.00015707714
, O 0 0.00010089174
in O 0 6.1334526e-05
an O 0 8.805209e-05
attempt O 0 0.0001016718
to O 0 6.873153e-05
induce O 0 8.886034e-05
glomerular O 0 0.9791014
hyperfiltration O 0 0.9998858
and O 0 0.00035813847
further O 0 0.00044027204
progression O 0 0.009778372
of O 0 0.0013616766
renal B-Disease 0 0.9865956
failure I-Disease 0 0.8221435
. O 0 0.0029516022

Newborn O 0 0.009598608
female O 0 0.005161979
Wistar O 0 0.0038671696
rats O 0 0.000822324
were O 0 0.00035075648
fed O 0 0.0005245013
a O 0 0.0006585694
lithium B-Chemical 0 0.999884
- O 0 0.00088808674
containing O 0 0.0001813579
diet O 0 0.0072709993
( O 0 0.00023197687
50 O 0 0.00028462405
mmol O 0 0.26728112
/ O 0 0.0007553185
kg O 0 0.00038634767
) O 0 0.00012482726
for O 0 4.2146206e-05
8 O 0 3.6809604e-05
weeks O 0 1.7091186e-05
and O 0 3.282869e-05
then O 0 3.2449116e-05
randomized O 0 5.496779e-05
to O 0 4.538116e-05
normal O 0 0.00022409137
diet O 0 0.003461635
, O 0 0.00017484816
HP O 0 0.058844473
diet O 0 0.007085386
( O 0 0.00015127471
40 O 0 9.823664e-05
vs O 0 0.00010262423
. O 0 5.9119004e-05
19 O 0 0.00013334802
% O 0 0.00012959055
) O 0 0.00022429551
, O 0 0.00025884117
NX O 0 0.9551707
or O 0 0.00030839685
HP O 0 0.09173577
+ O 0 0.0011999924
NX O 0 0.93251234
for O 0 0.00031342573
another O 0 0.0005617111
8 O 0 0.00054314215
weeks O 0 0.00055124436
. O 0 0.0015835282

Corresponding O 0 0.006934427
non O 0 0.004940772
- O 0 0.0073889624
lithium B-Chemical 0 0.9989673
pretreated O 0 0.019047156
groups O 0 0.0025617746
were O 0 0.0022416755
generated O 0 0.0025844763
. O 0 0.0044718347

When O 0 0.001159101
comparing O 0 0.0007670007
all O 0 0.0010778608
lithium B-Chemical 0 0.99937135
treated O 0 0.0011752426
versus O 0 0.0003411758
non O 0 0.00063145714
- O 0 0.0017222038
lithium B-Chemical 0 0.9999504
- O 0 0.0011068084
treated O 0 0.00034870766
groups O 0 0.00017411032
, O 0 0.0002382101
lithium B-Chemical 0 0.9998447
caused O 0 0.00021648995
a O 0 0.00016542278
reduction O 0 0.00025661738
in O 0 9.377799e-05
glomerular O 0 0.81349546
filtration O 0 0.005487492
rate O 0 0.0001392566
( O 0 0.00022334735
GFR O 0 0.99727136
) O 0 0.00017599024
without O 0 5.6239263e-05
significant O 0 5.2385483e-05
changes O 0 6.644776e-05
in O 0 4.9139406e-05
effective O 0 7.0906186e-05
renal O 0 0.79890954
plasma O 0 0.025818735
flow O 0 0.0013532264
( O 0 0.00013821256
as O 0 6.1747036e-05
determined O 0 6.250077e-05
by O 0 8.109938e-05
a O 0 0.00012167211
marker O 0 0.00013906445
secreted O 0 7.480312e-05
into O 0 3.8237642e-05
the O 0 9.88693e-05
proximal O 0 0.00028889166
tubules O 0 0.00118661
) O 0 0.00056361436
or O 0 0.00067078887
lithium B-Chemical 0 0.9996741
clearance O 0 0.18065798
. O 0 0.002777991

Consequently O 0 0.0029005678
, O 0 0.003904378
lithium B-Chemical 0 0.9995659
pretreatment O 0 0.23196925
caused O 0 0.0011220094
a O 0 0.0007378686
fall O 0 0.00077417505
in O 0 0.00022796959
filtration O 0 0.0017938686
fraction O 0 0.00026517545
and O 0 0.00020698397
an O 0 0.00026841374
increase O 0 0.0002863595
in O 0 0.00043099583
fractional O 0 0.011354764
Li B-Chemical 0 0.98337847
excretion O 0 0.9612475
. O 0 0.003388163

Lithium B-Chemical 0 0.9988111
also O 0 0.003054709
caused O 0 0.004112039
proteinuria B-Disease 0 0.99992883
and O 0 0.00351924
systolic O 0 0.9531989
hypertension B-Disease 2 0.9998913
in O 0 0.0010572829
absence O 0 0.00089204375
of O 0 0.005229896
glomerulosclerosis B-Disease 2 0.99996626
. O 0 0.007794663

HP O 0 0.038678613
failed O 0 0.002031897
to O 0 0.0011792391
accentuante O 0 0.007680118
progression O 0 0.009784163
of O 0 0.0011463828
renal B-Disease 0 0.96886206
failure I-Disease 0 0.36468726
and O 0 0.00028386465
in O 0 0.00011139179
fact O 0 6.40963e-05
tended O 0 8.270297e-05
to O 0 6.7859495e-05
increase O 0 0.00014047878
GFR O 0 0.996618
and O 0 0.00016575531
decrease O 0 0.00024014528
plasma O 0 0.018848306
creatinine B-Chemical 1 0.99837875
levels O 0 0.00040140355
in O 0 0.0005485943
lithium B-Chemical 0 0.99982387
pretreated O 0 0.040887956
rats O 0 0.004085453
. O 0 0.0020353033

NX O 0 0.97072774
caused O 0 0.0027774228
an O 0 0.0018459168
additive O 0 0.004281864
deterioration O 0 0.06598508
in O 0 0.0011631941
GFR O 0 0.9989542
which O 0 0.001155225
, O 0 0.00069333543
however O 0 0.00069216726
, O 0 0.000735916
was O 0 0.000961537
ameliorated O 0 0.120931536
by O 0 0.0029464776
HP O 0 0.21749388
. O 0 0.0033736415

NX O 0 0.9919849
+ O 0 0.009950388
HP O 0 0.053546038
caused O 0 0.0014601862
a O 0 0.0010376861
further O 0 0.0007351898
rise O 0 0.0006840034
in O 0 0.00040574005
blood O 0 0.0028618616
pressure O 0 0.005385571
in O 0 0.0008363987
Li B-Chemical 0 0.92873174
- O 0 0.0022564202
pretreated O 0 0.006523281
rats O 0 0.004228842
. O 0 0.002672533

The O 0 0.0015648447
results O 0 0.0013096847
indicate O 0 0.00069478934
that O 0 0.0009218534
Li B-Chemical 0 0.9768414
- O 0 0.0031547965
induced O 0 0.0035932267
nephropathy B-Disease 2 0.9999956
, O 0 0.00080692826
even O 0 0.00020682141
when O 0 8.4608124e-05
the O 0 0.00018753707
GFR O 0 0.9978369
is O 0 0.00018708181
only O 0 0.00018692973
modestly O 0 0.0037621702
reduced O 0 0.00044239932
, O 0 0.00019375111
is O 0 0.00012209296
associated O 0 0.00013488956
with O 0 0.0005021421
proteinuria B-Disease 0 0.9999722
and O 0 0.001112076
arterial O 0 0.5157152
systolic O 0 0.9592333
hypertension B-Disease 2 0.99986506
. O 0 0.0031196864

In O 0 0.0015749226
this O 0 0.0012474639
model O 0 0.0010150673
of O 0 0.0013834428
chronic B-Disease 2 0.91029346
renal I-Disease 2 0.99619186
failure I-Disease 2 0.93575704
the O 0 0.0003912488
decline O 0 0.0011739995
in O 0 0.00024184145
GFR O 0 0.9985947
is O 0 0.00015535213
not O 0 9.060078e-05
accompanied O 0 0.0002542749
by O 0 9.217698e-05
a O 0 9.1539805e-05
corresponding O 0 5.551258e-05
fall O 0 0.00015979928
in O 0 5.7727844e-05
effective O 0 8.0478145e-05
renal O 0 0.8235549
plasma O 0 0.028562656
flow O 0 0.0012516404
, O 0 0.00011300807
which O 0 9.827055e-05
may O 0 5.6136658e-05
be O 0 5.0660557e-05
the O 0 5.445845e-05
functional O 0 7.854073e-05
expression O 0 0.00010799373
of O 0 0.00014244558
the O 0 0.00016433299
formation O 0 0.00064836675
of O 0 0.0006710395
nonfiltrating O 0 0.025387613
atubular O 0 0.30959997
glomeruli O 0 0.16578192
. O 0 0.0023698637

The O 0 0.0019162965
fractional O 0 0.004892244
reabsorption O 0 0.55972254
of O 0 0.0015920353
tubular O 0 0.10301671
fluid O 0 0.0017635049
by O 0 0.00029625886
the O 0 0.00020432234
proximal O 0 0.00034284242
tubules O 0 0.0007926501
is O 0 0.00017199758
reduced O 0 0.000283352
, O 0 0.00018583483
leaving O 0 0.0002073759
the O 0 0.00011396438
distal O 0 0.00016988568
delivery O 0 0.000112409
unchanged O 0 0.00023500941
. O 0 0.00020932671
( O 0 0.00067205075
ABSTRACT O 0 0.0037705114
TRUNCATED O 0 0.003568394
AT O 0 0.006472281
250 O 0 0.0034480235
WORDS O 0 0.007019649
) O 0 0.0061910297

Treatment O 0 0.0053136894
of O 0 0.0032094335
Crohn B-Disease 0 0.8674016
' I-Disease 0 0.0013961436
s I-Disease 0 0.00090504065
disease I-Disease 0 0.048914764
with O 0 0.0011253522
fusidic B-Chemical 0 0.9991229
acid I-Chemical 0 0.97602886
: O 0 0.0005874184
an O 0 0.00032863187
antibiotic O 0 0.0013026046
with O 0 0.000371537
immunosuppressive O 0 0.043247342
properties O 0 0.00030877255
similar O 0 0.00041786232
to O 0 0.0014301485
cyclosporin B-Chemical 0 0.99992955
. O 0 0.004698883

Fusidic O 0 0.9990994
acid O 0 0.9943399
is O 0 0.002073501
an O 0 0.0014021451
antibiotic O 0 0.005894529
with O 0 0.0017349246
T O 0 0.88492626
- O 0 0.0014688573
cell O 0 0.0010378814
specific O 0 0.00022921762
immunosuppressive O 0 0.045621287
effects O 0 0.00036455496
similar O 0 0.00021970227
to O 0 0.00034491086
those O 0 0.0009317398
of O 0 0.0030026035
cyclosporin B-Chemical 0 0.9999436
. O 0 0.0052447193

Because O 0 0.0014581145
of O 0 0.0014988283
the O 0 0.0008151124
need O 0 0.00043692664
for O 0 0.000261082
the O 0 0.00025319573
development O 0 0.00033943087
of O 0 0.00023246773
new O 0 0.00021125878
treatments O 0 0.00024423888
for O 0 0.00015731456
Crohn B-Disease 0 0.9150933
' I-Disease 0 0.00028342038
s I-Disease 0 0.00019992309
disease I-Disease 0 0.037008815
, O 0 0.00014742318
a O 0 0.00013395771
pilot O 0 0.00022329985
study O 0 0.00010626427
was O 0 6.889323e-05
undertaken O 0 4.263551e-05
to O 0 3.4943023e-05
estimate O 0 3.2024356e-05
the O 0 5.8888872e-05
pharmacodynamics O 0 0.016468236
and O 0 7.677739e-05
tolerability O 0 0.00095484185
of O 0 0.00023953676
fusidic B-Chemical 0 0.99874014
acid I-Chemical 0 0.9585277
treatment O 0 0.00028677096
in O 0 0.00019569654
chronic O 0 0.0703104
active O 0 0.00040851466
, O 0 0.00035894223
therapy O 0 0.0005806676
- O 0 0.00074895815
resistant O 0 0.0008698024
patients O 0 0.0021909904
. O 0 0.0019280537

Eight O 0 0.010006606
Crohn B-Disease 0 0.75140965
' I-Disease 0 0.0045651295
s I-Disease 0 0.0035402756
disease I-Disease 0 0.03809996
patients O 0 0.0037994934
were O 0 0.0028929405
included O 0 0.0034369747
. O 0 0.0049974974

Fusidic B-Chemical 0 0.9992182
acid I-Chemical 0 0.9956548
was O 0 0.0021244718
administered O 0 0.0010424504
orally O 0 0.0013479757
in O 0 0.0002690686
a O 0 0.0002861095
dose O 0 0.0006663837
of O 0 0.0002777594
500 O 0 0.00089478225
mg O 0 0.030338744
t O 0 0.00038744585
. O 0 7.340834e-05
d O 0 0.00011853814
. O 0 5.837827e-05
s O 0 8.8405955e-05
. O 0 5.7504833e-05
and O 0 8.5083135e-05
the O 0 0.000100216115
treatment O 0 0.00013720672
was O 0 0.00017309083
planned O 0 0.00018818979
to O 0 0.00018840739
last O 0 0.00017904898
8 O 0 0.00043354678
weeks O 0 0.0005143437
. O 0 0.0015551167

The O 0 0.0030675568
disease O 0 0.03755934
activity O 0 0.0015397341
was O 0 0.0010731407
primarily O 0 0.0007211764
measured O 0 0.000544456
by O 0 0.0005908577
a O 0 0.0007075125
modified O 0 0.00066690566
individual O 0 0.00077279843
grading O 0 0.0024912546
score O 0 0.001890125
. O 0 0.002856375

Five O 0 0.0030274892
of O 0 0.0018371346
8 O 0 0.00096582115
patients O 0 0.0009839719
( O 0 0.0007381422
63 O 0 0.0005719303
% O 0 0.00034716722
) O 0 0.00032395677
improved O 0 0.00029461004
during O 0 0.00013842768
fusidic B-Chemical 0 0.996521
acid I-Chemical 0 0.9572059
treatment O 0 0.00040912518
: O 0 0.00021688333
3 O 0 7.015499e-05
at O 0 5.1215386e-05
two O 0 5.6847595e-05
weeks O 0 4.8929687e-05
and O 0 0.00012873272
2 O 0 0.00013934691
after O 0 0.00012463007
four O 0 0.00031432707
weeks O 0 0.00052229204
. O 0 0.0015626082

There O 0 0.0024743478
were O 0 0.0013598214
no O 0 0.0006326299
serious O 0 0.0022130874
clinical O 0 0.0021891876
side O 0 0.0057378965
effects O 0 0.0006162599
, O 0 0.00045365034
but O 0 0.00031071654
dose O 0 0.0011169226
reduction O 0 0.0006439212
was O 0 0.0001848235
required O 0 7.802267e-05
in O 0 0.00013290778
two O 0 0.00013358817
patients O 0 0.00034219847
because O 0 0.00036826142
of O 0 0.0023874748
nausea B-Disease 0 0.99979526
. O 0 0.0039506946

Biochemically O 0 0.015308899
, O 0 0.00222815
an O 0 0.0012362296
increase O 0 0.0007883887
in O 0 0.00071636273
alkaline O 0 0.21416089
phosphatases O 0 0.05661343
was O 0 0.00038115398
noted O 0 0.00012422218
in O 0 0.00011807075
5 O 0 7.769376e-05
of O 0 0.00012015802
8 O 0 8.723348e-05
cases O 0 0.00013362781
( O 0 0.00015684261
63 O 0 0.00017659992
% O 0 0.00013152628
) O 0 0.00016514541
, O 0 9.442416e-05
and O 0 7.2107454e-05
the O 0 6.5155036e-05
greatest O 0 0.00012212894
increases O 0 9.6174925e-05
were O 0 8.317895e-05
seen O 0 6.6413675e-05
in O 0 7.009641e-05
those O 0 0.00013994372
who O 0 0.00019453341
had O 0 0.0001402836
elevated O 0 0.0007882467
levels O 0 0.00024287296
prior O 0 0.0002027703
to O 0 0.0005139746
treatment O 0 0.0012905039
. O 0 0.0019390631

All O 0 0.0024232098
reversed O 0 0.0032691516
to O 0 0.0013858678
pre O 0 0.002266428
- O 0 0.0015780847
treatment O 0 0.0006571928
levels O 0 0.00059017463
after O 0 0.00036389937
cessation O 0 0.001202488
of O 0 0.0017244738
treatment O 0 0.0027406488
. O 0 0.003441904

The O 0 0.0014653988
results O 0 0.0011512116
of O 0 0.0009403103
this O 0 0.0006882105
pilot O 0 0.00090716884
study O 0 0.00035439563
suggest O 0 0.00011564046
that O 0 0.00023254311
fusidic B-Chemical 0 0.99920803
acid I-Chemical 0 0.9785427
may O 0 0.00022413579
be O 0 0.00010783751
of O 0 0.00011415318
benefit O 0 8.204903e-05
in O 0 6.2090396e-05
selected O 0 9.116018e-05
chronic O 0 0.01612076
active O 0 0.00039222123
Crohn B-Disease 0 0.95947003
' I-Disease 0 0.00022141974
s I-Disease 0 0.00015428098
disease I-Disease 0 0.01567497
patients O 0 0.00019846825
in O 0 0.0001199929
whom O 0 0.0002929522
conventional O 0 0.00024424866
treatment O 0 0.0004021109
is O 0 0.0007800534
ineffective O 0 0.004978255
. O 0 0.00232893

Because O 0 0.0015010193
there O 0 0.00091145054
seems O 0 0.00070712325
to O 0 0.0005296105
exist O 0 0.0003119864
a O 0 0.0003661793
scientific O 0 0.00049759774
rationale O 0 0.00025649508
for O 0 0.000109776345
the O 0 0.00011956824
use O 0 0.000109528424
of O 0 0.00030074132
fusidic B-Chemical 0 0.99870086
acid I-Chemical 0 0.9205211
at O 0 0.00010253033
the O 0 0.00011795585
cytokine O 0 0.0014539928
level O 0 8.330699e-05
in O 0 0.00014543385
inflammatory B-Disease 0 0.8079401
bowel I-Disease 0 0.8353376
disease I-Disease 0 0.92787015
, O 0 0.00014548378
we O 0 3.4973757e-05
suggest O 0 2.6075999e-05
that O 0 3.888874e-05
the O 0 6.0373728e-05
role O 0 4.8873906e-05
of O 0 0.00013010674
this O 0 0.00018515087
treatment O 0 0.00019854224
should O 0 0.00015051945
be O 0 0.00031146986
further O 0 0.0007563982
investigated O 0 0.0011169476
. O 0 0.0019760355

Changes O 0 0.0031623996
in O 0 0.0028649946
depressive B-Disease 2 0.99717903
status O 0 0.0012412877
associated O 0 0.0009553249
with O 0 0.0018497803
topical O 0 0.93746316
beta O 0 0.99104553
- O 0 0.020842826
blockers O 0 0.9977418
. O 0 0.005827568

Depression B-Disease 2 0.97937655
and O 0 0.0041071493
sexual B-Disease 0 0.4565081
dysfunction I-Disease 0 0.9872678
have O 0 0.00058098533
been O 0 0.00026334927
related O 0 0.00013444349
to O 0 0.00022516439
side O 0 0.0013833507
effects O 0 0.00045695968
of O 0 0.0011410991
topical O 0 0.9625089
beta O 0 0.993509
- O 0 0.018005282
blockers O 0 0.9979785
. O 0 0.004159823

We O 0 0.0013869625
performed O 0 0.0010090768
a O 0 0.0009558065
preliminary O 0 0.00092232774
study O 0 0.00048069755
in O 0 0.00021636182
order O 0 0.0001447896
to O 0 0.00011584287
determine O 0 5.748635e-05
any O 0 7.593784e-05
difference O 0 4.580779e-05
between O 0 4.3064574e-05
a O 0 0.00011175853
non O 0 0.00016688829
selective O 0 0.0014176137
beta O 0 0.9677229
- O 0 0.0016270408
blocker O 0 0.9876984
( O 0 0.0017224465
timolol B-Chemical 0 0.99999356
) O 0 0.00036696388
and O 0 0.0001027192
a O 0 0.0001608078
selective O 0 0.0011032062
beta O 0 0.9287009
- O 0 0.001385914
blocker O 0 0.97693163
( O 0 0.0021787237
betaxolol B-Chemical 0 0.9999931
) O 0 0.00083732844
regarding O 0 0.00028902554
CNS O 0 0.033968743
side O 0 0.008748753
effects O 0 0.0025226404
. O 0 0.0026378313

Eight O 0 0.008999647
glaucomatous B-Disease 0 0.99974066
patients O 0 0.0023357405
chronically O 0 0.0024030644
treated O 0 0.00081511587
with O 0 0.0011633072
timolol B-Chemical 0 0.999985
0 O 0 0.0002762137
. O 0 8.910081e-05
5 O 0 7.397994e-05
% O 0 0.00011221505
/ O 0 0.0003318166
12h O 0 0.0012143325
, O 0 0.00016975711
suffering O 0 0.006305957
from O 0 0.00016009547
depression B-Disease 0 0.9647091
diagnosed O 0 0.00084442913
through O 0 0.00013707504
DMS O 0 0.9953062
- O 0 0.0008684789
III O 0 0.021906232
- O 0 0.00081139494
R O 0 0.7996769
criteria O 0 0.00027432412
, O 0 0.00019942105
were O 0 0.00016894907
included O 0 0.00018383541
in O 0 0.00031540048
the O 0 0.00064051565
study O 0 0.001494081
. O 0 0.0019065284

During O 0 0.0010459846
the O 0 0.0011734886
six O 0 0.0006150268
- O 0 0.00086825475
month O 0 0.0002166907
follow O 0 0.00018239634
up O 0 0.00029428245
, O 0 0.0004610836
depression B-Disease 0 0.84610736
was O 0 0.00025245064
quantified O 0 0.00015035392
through O 0 9.896268e-05
the O 0 0.00017781174
Beck O 0 0.004987977
and O 0 0.00034736696
Zung O 0 0.015831862
- O 0 0.0007361931
Conde O 0 0.0039232075
scales O 0 0.00022168063
every O 0 0.00015135536
two O 0 0.0003790487
months O 0 0.00057519285
. O 0 0.001638637

In O 0 0.0019865427
a O 0 0.002008383
double O 0 0.0019487306
blind O 0 0.009730249
cross O 0 0.0010191363
- O 0 0.00053051533
over O 0 9.577589e-05
study O 0 0.00015404902
with O 0 0.00012792315
control O 0 0.00011184052
group O 0 0.00014615731
, O 0 8.7557084e-05
the O 0 6.614683e-05
patients O 0 0.00010844603
under O 0 9.081685e-05
timolol B-Chemical 0 0.99998474
treatment O 0 0.00011262864
presented O 0 7.546385e-05
higher O 0 0.00018429909
depression B-Disease 0 0.89693433
values O 0 8.362647e-05
measured O 0 4.6815887e-05
through O 0 4.255557e-05
the O 0 8.344876e-05
Beck O 0 0.002406439
and O 0 0.00010247011
the O 0 0.00014670046
Zung O 0 0.01526434
- O 0 0.0004739435
Conde O 0 0.0081384545
scales O 0 0.00015430126
( O 0 0.00026298597
p O 0 0.0001812789
< O 0 0.00015836462
0 O 0 0.00017037625
. O 0 0.00021547225
001 O 0 0.002717168
vs O 0 0.00063642586
control O 0 0.0008807166
) O 0 0.0022767943
. O 0 0.0023992632

These O 0 0.002019402
results O 0 0.0012309091
suggest O 0 0.00056756573
that O 0 0.0009946926
betaxolol B-Chemical 0 0.9999826
could O 0 0.0006007293
be O 0 0.0002727921
less O 0 0.00023007065
of O 0 0.00032696556
a O 0 0.00076536305
depression B-Disease 0 0.99349135
- O 0 0.0011079405
inducer O 0 0.0046585537
than O 0 0.00060627644
timolol B-Chemical 0 0.99997234
in O 0 0.0011773154
predisposed O 0 0.040599555
patients O 0 0.003236603
. O 0 0.0020710821

Protection O 0 0.004992393
against O 0 0.0026896517
amphetamine B-Chemical 1 0.9999584
- O 0 0.006103151
induced O 0 0.0022131894
neurotoxicity B-Disease 2 0.99991333
toward O 0 0.0012158655
striatal O 0 0.98404044
dopamine B-Chemical 0 0.99988914
neurons O 0 0.00058961695
in O 0 0.00014857727
rodents O 0 0.00033668402
by O 0 0.00038060808
LY274614 B-Chemical 0 0.9999027
, O 0 0.0004461765
an O 0 0.00067636924
excitatory O 0 0.82073176
amino B-Chemical 0 0.9977157
acid I-Chemical 0 0.99942076
antagonist O 0 0.9964259
. O 0 0.004361032

LY274614 B-Chemical 0 0.99950683
, O 0 0.007226429
3SR B-Chemical 0 0.24955937
, I-Chemical 0 0.0024779825
4aRS I-Chemical 0 0.007979319
, I-Chemical 0 0.0015528944
6SR I-Chemical 0 0.5939693
, I-Chemical 0 0.0009504478
8aRS I-Chemical 0 0.0051784203
- I-Chemical 0 0.00075311126
6 I-Chemical 0 0.00017750278
- I-Chemical 0 0.00048169444
[ I-Chemical 0 0.00076184364
phosphonomethyl I-Chemical 0 0.8456564
] I-Chemical 0 0.0010048298
decahydr I-Chemical 0 0.008695241
oisoquinoline I-Chemical 0 0.020825839
- I-Chemical 0 0.00047664216
3 I-Chemical 0 0.00012624938
- I-Chemical 0 0.0005354293
carboxylic I-Chemical 0 0.9976821
acid I-Chemical 0 0.9726811
, O 0 0.0003134894
has O 0 8.029891e-05
been O 0 5.7345256e-05
described O 0 5.353695e-05
as O 0 5.951315e-05
a O 0 0.000107509164
potent O 0 0.00031526585
antagonist O 0 0.43205896
of O 0 0.00023842549
the O 0 0.00030877106
N B-Chemical 0 0.99502206
- I-Chemical 0 0.0018644131
methyl I-Chemical 0 0.9952697
- I-Chemical 0 0.0027580683
D I-Chemical 0 0.9284284
- I-Chemical 0 0.0030626857
aspartate I-Chemical 1 0.9999145
( O 0 0.008152362
NMDA B-Chemical 1 0.9999951
) O 0 0.0025492338
subtype O 0 0.014769628
of O 0 0.0023892575
glutamate B-Chemical 1 0.99976534
receptor O 0 0.37663162
. O 0 0.0029235485

Here O 0 0.0021354011
its O 0 0.0019622995
ability O 0 0.00095825945
to O 0 0.0005735362
antagonize O 0 0.00070208404
the O 0 0.00033035295
prolonged O 0 0.0005200938
depletion O 0 0.0006791211
of O 0 0.00066087715
dopamine B-Chemical 0 0.9996728
in O 0 0.00014924465
the O 0 0.00013196772
striatum O 0 0.011118448
by O 0 0.00036378318
amphetamine B-Chemical 1 0.9999907
in O 0 0.0012135779
iprindole B-Chemical 0 0.99999595
- O 0 0.0014469181
treated O 0 0.0006890058
rats O 0 0.0008619438
is O 0 0.00077886565
reported O 0 0.0015517797
. O 0 0.001906739

A O 0 0.017918115
single O 0 0.0020504997
18 O 0 0.0011026921
. O 0 0.0005220135
4 O 0 0.0004167693
mg O 0 0.0036996345
/ O 0 0.0012413225
kg O 0 0.0009733945
( O 0 0.0004119661
i O 0 0.0005287222
. O 0 0.00016100235
p O 0 0.00018757908
. O 0 9.5476986e-05
) O 0 0.00019451263
dose O 0 0.0004085645
of O 0 0.00024843347
( O 0 0.0003086092
+ O 0 0.00042373425
/ O 0 0.0008000993
- O 0 0.00048456283
) O 0 0.00039410876
- O 0 0.0010691753
amphetamine B-Chemical 1 0.9999968
hemisulfate O 0 0.99996424
, O 0 0.00019725705
given O 0 4.008303e-05
to O 0 4.6613237e-05
rats O 0 9.768503e-05
pretreated O 0 0.00042942556
with O 0 0.00053297996
iprindole B-Chemical 0 0.99999714
, O 0 0.00019798061
resulted O 0 8.763277e-05
in O 0 7.478324e-05
persistent O 0 0.00042015564
depletion O 0 0.0004537143
of O 0 0.00050663523
dopamine B-Chemical 0 0.9995727
in O 0 0.00017344538
the O 0 0.00020529715
striatum O 0 0.004456103
1 O 0 0.00028534324
week O 0 0.00025231493
later O 0 0.0006073886
. O 0 0.0015061492

This O 0 0.0033569932
prolonged O 0 0.0023665698
depletion O 0 0.0021224935
of O 0 0.0017921455
dopamine B-Chemical 0 0.99945134
in O 0 0.00039189996
the O 0 0.00029020567
striatum O 0 0.017121991
was O 0 0.00036293155
antagonized O 0 0.27930647
by O 0 0.0010110331
dizocilpine B-Chemical 0 0.99999654
( O 0 0.0037590568
MK B-Chemical 0 0.99660885
- I-Chemical 0 0.0014116928
801 I-Chemical 0 0.26762727
, O 0 0.00013921224
a O 0 0.00013160279
non O 0 0.00016660303
- O 0 0.00025678377
competitive O 0 0.004113307
antagonist O 0 0.8010432
of O 0 0.0019362922
NMDA B-Chemical 1 0.99999857
receptors O 0 0.054345846
) O 0 0.00028854646
or O 0 0.00010441924
by O 0 0.00029407037
LY274614 B-Chemical 0 0.999951
( O 0 0.0003725297
a O 0 0.0002856786
competitive O 0 0.008165983
antagonist O 0 0.84169996
of O 0 0.0045856093
NMDA B-Chemical 1 0.9999889
receptors O 0 0.17724173
) O 0 0.0035315827
. O 0 0.0021239037

The O 0 0.0018951982
protective O 0 0.0030188502
effect O 0 0.0012370569
of O 0 0.0032482478
LY274614 B-Chemical 0 0.99993813
was O 0 0.0015296901
dose O 0 0.0048984233
- O 0 0.000614585
dependent O 0 0.00011253974
, O 0 0.00018974725
being O 0 0.00014794
maximum O 0 9.646867e-05
at O 0 8.1607985e-05
10 O 0 0.00013036405
- O 0 0.0002748404
40 O 0 0.00024849508
mgkg O 0 0.21161443
( O 0 0.00049097504
i O 0 0.0007401951
. O 0 0.00034575237
p O 0 0.0006483621
. O 0 0.00068719394
) O 0 0.002153865
. O 0 0.0024280376

A O 0 0.014950567
10 O 0 0.00190573
mg O 0 0.012824727
/ O 0 0.0022737288
kg O 0 0.0014649662
dose O 0 0.0017638492
of O 0 0.0012213103
LY274614 B-Chemical 0 0.9999442
was O 0 0.00037928493
effective O 0 0.00012170472
in O 0 0.00011069854
antagonizing O 0 0.00048185818
the O 0 0.000112466674
depletion O 0 0.00034580578
of O 0 0.0004230062
dopamine B-Chemical 0 0.9997614
in O 0 0.00010889815
the O 0 0.000101549034
striatum O 0 0.00845516
, O 0 7.937013e-05
when O 0 3.0228173e-05
given O 0 3.0648134e-05
as O 0 4.4456538e-05
long O 0 4.8297996e-05
as O 0 4.3706514e-05
8 O 0 3.2588294e-05
hr O 0 4.627508e-05
prior O 0 3.0078761e-05
to O 0 0.00012168162
amphetamine B-Chemical 1 0.999987
but O 0 0.00016835296
not O 0 6.779611e-05
when O 0 4.6099376e-05
given O 0 5.357812e-05
24 O 0 8.218966e-05
hr O 0 0.00017670334
prior O 0 0.00019397736
to O 0 0.0009083754
amphetamine B-Chemical 1 0.9999083
. O 0 0.003312268

Depletion O 0 0.0061381184
of O 0 0.003555795
dopamine B-Chemical 0 0.9988636
in O 0 0.0007507181
the O 0 0.00049836177
striatum O 0 0.010549534
was O 0 0.00030805715
also O 0 0.00021337405
antagonized O 0 0.19950138
when O 0 0.0003183884
LY274614 B-Chemical 0 0.99997056
was O 0 0.00017463107
given O 0 3.676667e-05
after O 0 2.0108107e-05
the O 0 4.7833986e-05
injection O 0 9.5630705e-05
of O 0 0.00043067842
amphetamine B-Chemical 1 0.9999975
; O 0 0.0017912356
LY274614 B-Chemical 0 0.99996483
protected O 0 0.00020293218
when O 0 3.8085745e-05
given O 0 3.1577736e-05
up O 0 5.244206e-05
to O 0 4.499312e-05
4 O 0 3.7383044e-05
hr O 0 5.3947868e-05
after O 0 2.4431365e-05
but O 0 6.303739e-05
not O 0 5.258298e-05
when O 0 4.4396715e-05
given O 0 5.4351163e-05
8 O 0 7.657063e-05
or O 0 9.825107e-05
24 O 0 0.00014030395
hr O 0 0.0003613476
after O 0 0.0004696735
amphetamine B-Chemical 1 0.9998646
. O 0 0.0032476997

The O 0 0.0016493918
prolonged O 0 0.0020559486
depletion O 0 0.0020279381
of O 0 0.0018382978
dopamine B-Chemical 0 0.9994772
in O 0 0.00041716103
the O 0 0.00028641796
striatum O 0 0.0068262042
in O 0 0.0001392558
mice O 0 7.525804e-05
, O 0 9.2163886e-05
given O 0 4.4212673e-05
multiple O 0 9.214903e-05
injections O 0 0.00015856468
of O 0 0.00038183536
methamphetamine B-Chemical 1 0.9999839
, O 0 0.00028503462
was O 0 0.00013795291
also O 0 0.00013402173
antagonized O 0 0.25870278
dose O 0 0.010672465
- O 0 0.0012441191
dependently O 0 0.42870906
and O 0 0.0005873319
completely O 0 0.0010702095
by O 0 0.0022210875
LY274614 B-Chemical 0 0.99971384
. O 0 0.0033644293

The O 0 0.001582309
data O 0 0.0013186686
strengthen O 0 0.0008005316
the O 0 0.0005107839
evidence O 0 0.0002981545
that O 0 0.00021062884
the O 0 0.00036714895
neurotoxic B-Disease 0 0.98871094
effect O 0 0.00033864702
of O 0 0.0011393869
amphetamine B-Chemical 1 0.9999949
and O 0 0.00021797483
related O 0 5.2734536e-05
compounds O 0 0.051476058
toward O 0 0.00017226479
nigrostriatal O 0 0.97590816
dopamine B-Chemical 0 0.9998646
neurons O 0 0.00032323305
involves O 0 0.00011443535
NMDA B-Chemical 1 0.99999654
receptors O 0 0.0048025977
and O 0 0.00010379332
that O 0 0.00011309776
LY274614 B-Chemical 0 0.9999633
is O 0 0.00018391991
an O 0 0.0006205681
NMDA B-Chemical 1 0.9999981
receptor O 0 0.4424953
antagonist O 0 0.8650164
with O 0 0.00024212153
long O 0 0.00013107303
- O 0 0.00018314464
lasting O 0 9.896136e-05
in O 0 0.00013552984
vivo O 0 0.0003572665
effects O 0 0.00048543545
in O 0 0.0007306387
rats O 0 0.0021543857
. O 0 0.0018375182

Ketoconazole B-Chemical 0 0.99911803
- O 0 0.03046134
induced O 0 0.021868533
neurologic B-Disease 0 0.9973838
sequelae I-Disease 0 0.98367834
. O 0 0.019131334

A O 0 0.02889183
77 O 0 0.0068667326
- O 0 0.003637516
y O 0 0.0030174342
- O 0 0.0010976284
old O 0 0.00042973907
patient O 0 0.00036597496
developed O 0 0.00071427267
weakness B-Disease 0 0.97400135
of I-Disease 0 0.00097472797
extremities I-Disease 0 0.913207
, O 0 0.0010761768
legs B-Disease 0 0.98595977
paralysis I-Disease 0 0.9999789
, O 0 0.0020915843
dysarthria B-Disease 0 0.9999249
and O 0 0.0011232332
tremor B-Disease 0 0.99989986
1 O 0 8.546769e-05
h O 0 3.831028e-05
after O 0 2.2380495e-05
ingestion O 0 0.0010116932
of O 0 0.00012985713
200 O 0 0.0005633367
mg O 0 0.20549901
ketoconazole B-Chemical 1 0.9999918
for O 0 0.00013987649
the O 0 0.00012843452
first O 0 0.00010021106
time O 0 0.00013768798
in O 0 0.00035916266
his O 0 0.001081297
life O 0 0.0016974492
. O 0 0.0019711412

All O 0 0.005588597
complaints O 0 0.014061339
faded O 0 0.0071860817
away O 0 0.0028377252
within O 0 0.0014880932
24 O 0 0.0027558317
h O 0 0.004513881
. O 0 0.0067104804

Few O 0 0.0024211705
days O 0 0.0007562331
later O 0 0.0005610465
, O 0 0.00056680635
the O 0 0.00032219067
patient O 0 0.00026476238
used O 0 0.0001496037
another O 0 0.00021110494
200 O 0 0.0008078762
mg O 0 0.49366274
ketoconazole B-Chemical 1 0.9999981
tablet O 0 0.95516527
, O 0 0.00021875539
and O 0 7.5111784e-05
within O 0 2.278915e-05
an O 0 6.241976e-05
hour O 0 4.412161e-05
experienced O 0 7.599174e-05
a O 0 8.389597e-05
similar O 0 5.1587427e-05
clinical O 0 0.00024394561
picture O 0 0.00018296382
, O 0 0.00015602104
which O 0 0.00019223116
resolved O 0 0.00033448415
again O 0 0.0002697002
spontaneously O 0 0.0006614975
within O 0 0.00022619896
hours O 0 0.0006021477
. O 0 0.0015080853

Laboratory O 0 0.010103068
evaluations O 0 0.0024961245
, O 0 0.0022515173
including O 0 0.0013358103
head O 0 0.0062603313
CT O 0 0.034251556
scan O 0 0.004741683
, O 0 0.0023362427
were O 0 0.0022625087
normal O 0 0.0048772315
. O 0 0.004188397

This O 0 0.0037283732
case O 0 0.0013954525
illustrates O 0 0.00065992365
the O 0 0.00053791277
need O 0 0.0003229287
for O 0 0.00021757303
close O 0 0.00024437445
vigilance O 0 0.0012521758
in O 0 0.0003057684
adverse B-Disease 0 0.31318364
drug I-Disease 0 0.0724435
reactions I-Disease 0 0.028506082
, O 0 0.000502319
particularly O 0 0.00051309256
in O 0 0.0005426841
the O 0 0.0010894538
elderly O 0 0.09883415
. O 0 0.0024864336

Development O 0 0.0054481295
of O 0 0.004485224
levodopa B-Chemical 0 0.99988425
- O 0 0.003976727
induced O 0 0.0019383506
dyskinesias B-Disease 0 0.99991715
in O 0 0.0010320686
parkinsonian B-Disease 2 0.9997241
monkeys O 0 0.00012888257
may O 0 6.993389e-05
depend O 0 4.10589e-05
upon O 0 4.3805707e-05
rate O 0 8.7342516e-05
of O 0 0.00014025472
symptom O 0 0.00052037765
onset O 0 0.00022665015
and O 0 0.00019664073
/ O 0 0.00044986166
or O 0 0.00019364472
duration O 0 0.00020616617
of O 0 0.0009186889
symptoms O 0 0.014556112
. O 0 0.0022142637

Levodopa B-Chemical 0 0.9996308
- O 0 0.007893686
induced O 0 0.004454939
dyskinesias B-Disease 0 0.9998981
( O 0 0.0052870633
LIDs B-Disease 0 0.9990151
) O 0 0.0006962104
present O 0 0.00015357559
a O 0 0.00018632665
major O 0 0.00012023274
problem O 0 0.00014459866
for O 0 7.5850425e-05
the O 0 0.000101419166
long O 0 0.00011005378
- O 0 0.00016215183
term O 0 8.214007e-05
management O 0 0.00013327479
of O 0 0.00031720134
Parkinson B-Disease 0 0.99748516
' I-Disease 0 0.0004673053
s I-Disease 0 0.00037212577
disease I-Disease 0 0.10084074
( O 0 0.0015110536
PD B-Disease 0 0.9945827
) O 0 0.002073947
patients O 0 0.0022971488
. O 0 0.0021461248

Due O 0 0.0018037553
to O 0 0.0011465946
the O 0 0.000774683
interdependence O 0 0.0006517246
of O 0 0.00072710944
risk O 0 0.0021471689
factors O 0 0.00042511572
in O 0 0.00024185206
clinical O 0 0.00079398596
populations O 0 0.0003717822
, O 0 0.00019599196
it O 0 0.00013627861
is O 0 8.971979e-05
difficult O 0 5.955595e-05
to O 0 5.6143344e-05
independently O 0 4.611776e-05
examine O 0 3.4393815e-05
factors O 0 9.684805e-05
that O 0 7.349476e-05
may O 0 9.442299e-05
influence O 0 9.276522e-05
the O 0 0.00024908074
development O 0 0.00085711014
of O 0 0.0022060343
LIDs B-Disease 0 0.99843985
. O 0 0.0030834782

Using O 0 0.0012592658
macaque O 0 0.00070094987
monkeys O 0 0.0005115947
with O 0 0.00049487985
different O 0 0.00025915477
types O 0 0.00025922104
of O 0 0.0014480808
MPTP B-Chemical 0 0.9999964
- O 0 0.005182183
induced O 0 0.0023623742
parkinsonism B-Disease 2 0.9999924
, O 0 0.00030032042
the O 0 0.00010003271
current O 0 0.00016891668
study O 0 9.074077e-05
evaluated O 0 4.957662e-05
the O 0 5.7134337e-05
degree O 0 8.748256e-05
to O 0 4.9583294e-05
which O 0 7.218849e-05
rate O 0 6.747285e-05
of O 0 0.000108531276
symptom O 0 0.0007430443
progression O 0 0.0076476363
, O 0 0.00014971345
symptom O 0 0.00066632027
severity O 0 0.00030136676
, O 0 8.6583e-05
and O 0 5.6126646e-05
response O 0 5.1255844e-05
to O 0 4.2739066e-05
and O 0 5.1043367e-05
duration O 0 3.116257e-05
of O 0 0.00021201103
levodopa B-Chemical 0 0.9999633
therapy O 0 0.0002746801
may O 0 8.6868975e-05
be O 0 8.128451e-05
involved O 0 7.1530725e-05
in O 0 0.00012442382
the O 0 0.00022372203
development O 0 0.0007763019
of O 0 0.0020394498
LIDs B-Disease 0 0.99833006
. O 0 0.0030096495

Monkeys O 0 0.008214315
with O 0 0.0027545844
acute O 0 0.16850981
( O 0 0.0013281855
short O 0 0.00046545794
- O 0 0.0007541404
term O 0 0.00041761025
) O 0 0.0018732882
MPTP B-Chemical 0 0.9999918
exposure O 0 0.00084434304
, O 0 0.00021402258
rapid O 0 0.00035973114
symptom O 0 0.000533631
onset O 0 0.000117379925
and O 0 6.1712126e-05
short O 0 4.226897e-05
symptom O 0 0.00013506357
duration O 0 1.769425e-05
prior O 0 1.6882519e-05
to O 0 2.684073e-05
initiation O 0 3.514028e-05
of O 0 0.00018395252
levodopa B-Chemical 0 0.9999716
therapy O 0 0.00036827652
developed O 0 0.0008239414
dyskinesia B-Disease 0 0.9999893
between O 0 7.268738e-05
11 O 0 7.65331e-05
and O 0 5.9684444e-05
24 O 0 4.8648846e-05
days O 0 4.354701e-05
of O 0 0.00019486832
daily O 0 0.0009356599
levodopa B-Chemical 0 0.9998429
administration O 0 0.02290374
. O 0 0.0023878475

In O 0 0.0019171986
contrast O 0 0.0018572817
, O 0 0.0010356461
monkeys O 0 0.00040651285
with O 0 0.00046463983
long O 0 0.00038009646
- O 0 0.0006517339
term O 0 0.00058536336
MPTP B-Chemical 0 0.9999937
exposure O 0 0.0008573789
, O 0 0.00022993996
slow O 0 0.00054810895
symptom O 0 0.0008045791
progression O 0 0.0027333964
and O 0 0.000116849464
/ O 0 0.00022102195
or O 0 4.904236e-05
long O 0 5.021847e-05
symptom O 0 0.00013063631
duration O 0 1.687172e-05
prior O 0 1.6141199e-05
to O 0 2.589861e-05
initiation O 0 3.389101e-05
of O 0 0.00018005562
levodopa B-Chemical 0 0.9999697
therapy O 0 0.00018135477
were O 0 5.847343e-05
more O 0 6.884095e-05
resistant O 0 7.224897e-05
to O 0 7.665668e-05
developing O 0 0.0024244736
LIDs B-Disease 0 0.99947387
( O 0 0.0002619752
e O 0 0.00014446636
. O 0 5.060334e-05
g O 0 0.00021237238
. O 0 6.536963e-05
, O 0 0.00023108588
dyskinesia B-Disease 0 0.9999789
developed O 0 0.00026134425
no O 0 6.47012e-05
sooner O 0 0.00019673468
than O 0 5.90309e-05
146 O 0 0.00020012334
days O 0 4.908151e-05
of O 0 0.00025430718
chronic O 0 0.53996503
levodopa B-Chemical 0 0.9999703
administration O 0 0.07570858
) O 0 0.0034736583
. O 0 0.0020930038

All O 0 0.0014991515
animals O 0 0.00082953705
were O 0 0.0005929266
similarly O 0 0.00043359963
symptomatic O 0 0.000771093
at O 0 0.00013113228
the O 0 0.0001227661
start O 0 8.563575e-05
of O 0 0.0003988247
levodopa B-Chemical 0 0.999951
treatment O 0 0.00027756984
and O 0 0.00017012624
had O 0 0.0001314162
similar O 0 9.692205e-05
therapeutic O 0 0.0003470284
responses O 0 0.00035624008
to O 0 0.0004053832
the O 0 0.0009160431
drug O 0 0.03411251
. O 0 0.002409464

These O 0 0.0020302827
data O 0 0.0012308015
suggest O 0 0.00040775246
distinct O 0 0.00029411665
differences O 0 0.0001725041
in O 0 0.00018505732
the O 0 0.00016442421
propensity O 0 0.00027916676
to O 0 0.00014367096
develop O 0 0.00033764433
LIDs B-Disease 0 0.99542314
in O 0 9.765812e-05
monkeys O 0 4.4031327e-05
with O 0 5.6661636e-05
different O 0 2.8943714e-05
rates O 0 4.5007153e-05
of O 0 7.6974226e-05
symptom O 0 0.0003793497
progression O 0 0.0012694546
or O 0 5.340906e-05
symptom O 0 0.00014820318
durations O 0 2.4770294e-05
prior O 0 2.3705985e-05
to O 0 8.405581e-05
levodopa B-Chemical 0 0.99991703
and O 0 8.541122e-05
demonstrate O 0 2.737832e-05
the O 0 5.209723e-05
value O 0 6.651997e-05
of O 0 8.9406436e-05
these O 0 0.00011304666
models O 0 0.0001071017
for O 0 7.518961e-05
further O 0 0.00017465139
studying O 0 0.00021270919
the O 0 0.0003067647
pathophysiology O 0 0.0051590237
of O 0 0.0024590807
LIDs B-Disease 0 0.99850535
. O 0 0.0029322235

A O 0 0.039754525
diet O 0 0.021075474
promoting O 0 0.0024217626
sugar B-Disease 0 0.9307958
dependency I-Disease 0 0.003957478
causes O 0 0.0011250362
behavioral B-Disease 0 0.0028640737
cross I-Disease 0 0.0010226994
- I-Disease 0 0.0007298496
sensitization I-Disease 0 0.0018456901
to O 0 0.00025833503
a O 0 0.00045459057
low O 0 0.00094810803
dose O 0 0.004292677
of O 0 0.0049409918
amphetamine B-Chemical 1 0.99995804
. O 0 0.004714904

Previous O 0 0.0014900948
research O 0 0.0013800628
in O 0 0.00065522786
this O 0 0.0005821416
laboratory O 0 0.0006861174
has O 0 0.0001861869
shown O 0 0.00011295064
that O 0 9.237267e-05
a O 0 0.00021082978
diet O 0 0.0020862443
of O 0 0.0001911867
intermittent O 0 0.0008679566
excessive O 0 0.0032811672
sugar O 0 0.4660614
consumption O 0 0.0029917262
produces O 0 0.00010012738
a O 0 0.00012483417
state O 0 0.000109288994
with O 0 0.00013496973
neurochemical O 0 0.00393323
and O 0 0.00015373791
behavioral O 0 0.0004543291
similarities O 0 0.00019206041
to O 0 0.00039800908
drug B-Disease 0 0.26650652
dependency I-Disease 0 0.008840696
. O 0 0.0024972267

The O 0 0.0014128105
present O 0 0.0009099078
study O 0 0.00079214276
examined O 0 0.00031426596
whether O 0 0.00020277205
female O 0 0.00081323413
rats O 0 0.00024602682
on O 0 7.4372736e-05
various O 0 0.00011979786
regimens O 0 0.00019586866
of O 0 0.00021402749
sugar O 0 0.05241093
access O 0 0.000107714695
would O 0 7.542055e-05
show O 0 6.357631e-05
behavioral B-Disease 0 0.00039165685
cross I-Disease 0 0.00029236736
- I-Disease 0 0.00030404347
sensitization I-Disease 0 0.0010362201
to O 0 0.0001520278
a O 0 0.00030647672
low O 0 0.0007103643
dose O 0 0.003430753
of O 0 0.0041824067
amphetamine B-Chemical 1 0.99996245
. O 0 0.004092829

After O 0 0.0010942334
a O 0 0.0015300282
30 O 0 0.0008272814
- O 0 0.00090099167
min O 0 0.00041594668
baseline O 0 0.00021671983
measure O 0 0.000108256136
of O 0 0.00026258634
locomotor O 0 0.010903186
activity O 0 0.00020245965
( O 0 0.00019341518
day O 0 7.1796225e-05
0 O 0 9.495753e-05
) O 0 0.0001528715
, O 0 8.94101e-05
animals O 0 5.1474795e-05
were O 0 5.5083598e-05
maintained O 0 5.2390573e-05
on O 0 3.6743917e-05
a O 0 0.00011566716
cyclic O 0 0.0012167391
diet O 0 0.0020822017
of O 0 0.000118494056
12 O 0 4.9743605e-05
- O 0 0.00010860768
h O 0 4.7096153e-05
deprivation O 0 0.00012965468
followed O 0 5.56306e-05
by O 0 7.2690425e-05
12 O 0 4.276072e-05
- O 0 9.890928e-05
h O 0 4.1363233e-05
access O 0 4.7177517e-05
to O 0 4.568411e-05
10 O 0 5.874545e-05
% O 0 0.00010777768
sucrose B-Chemical 0 0.71847695
solution O 0 0.0015030695
and O 0 0.00014131605
chow O 0 0.0115389675
pellets O 0 0.0004185819
( O 0 8.815155e-05
12 O 0 2.6880281e-05
h O 0 3.2661068e-05
access O 0 3.762356e-05
starting O 0 3.4718283e-05
4 O 0 3.6392474e-05
h O 0 3.5778496e-05
after O 0 2.4972805e-05
onset O 0 9.252501e-05
of O 0 0.00011422505
the O 0 0.00011858901
dark O 0 0.0002621141
period O 0 0.00011190803
) O 0 0.00032141598
for O 0 0.00027705455
21 O 0 0.00061083416
days O 0 0.0005842778
. O 0 0.0016393656

Locomotor O 0 0.023370957
activity O 0 0.0015356914
was O 0 0.00094874605
measured O 0 0.0004525261
again O 0 0.0003613815
for O 0 0.0001820195
30 O 0 0.00014727312
min O 0 0.00017180647
at O 0 9.451307e-05
the O 0 0.00011262025
beginning O 0 8.776725e-05
of O 0 0.00017411265
days O 0 9.508965e-05
1 O 0 0.00016387859
and O 0 0.0002475586
21 O 0 0.0003869951
of O 0 0.00079774385
sugar O 0 0.057343427
access O 0 0.0021761316
. O 0 0.0024331436

Beginning O 0 0.0038715967
on O 0 0.0011488536
day O 0 0.0009351657
22 O 0 0.0010527141
, O 0 0.000770542
all O 0 0.0004944839
rats O 0 0.0005908211
were O 0 0.00034841787
maintained O 0 0.00033106393
on O 0 0.00031521113
ad O 0 0.0014951989
libitum O 0 0.0071741748
chow O 0 0.019411068
. O 0 0.0025832742

Nine O 0 0.0032397646
days O 0 0.0007122287
later O 0 0.00059793884
locomotor O 0 0.0064136493
activity O 0 0.00044128846
was O 0 0.0003150273
measured O 0 0.0001590703
in O 0 0.00013052126
response O 0 0.00013336187
to O 0 0.00010588487
a O 0 0.00015164704
single O 0 0.00011431483
low O 0 0.0002498149
dose O 0 0.0009141972
of O 0 0.00085508876
amphetamine B-Chemical 1 0.9999938
( O 0 0.00056180154
0 O 0 0.00014451995
. O 0 0.00010729102
5 O 0 0.00017391786
mg O 0 0.0023974571
/ O 0 0.0016851061
kg O 0 0.0022459778
) O 0 0.002277945
. O 0 0.0022453046

The O 0 0.0013996895
animals O 0 0.0007833246
that O 0 0.0004879071
had O 0 0.00052300916
experienced O 0 0.00060208054
cyclic O 0 0.011740859
sucrose B-Chemical 0 0.9634094
and O 0 0.00038603376
chow O 0 0.02077125
were O 0 0.00014904214
hyperactive B-Disease 0 0.013708212
in O 0 6.919266e-05
response O 0 8.121981e-05
to O 0 0.00013587337
amphetamine B-Chemical 1 0.9999881
compared O 0 6.6787754e-05
with O 0 7.45777e-05
four O 0 3.0523996e-05
control O 0 5.225496e-05
groups O 0 6.0130278e-05
( O 0 7.1531336e-05
ad O 0 0.00012829769
libitum O 0 0.00048658688
10 O 0 4.8325273e-05
% O 0 7.6673496e-05
sucrose B-Chemical 0 0.4318366
and O 0 0.00010776351
chow O 0 0.0062905876
followed O 0 6.3198575e-05
by O 0 0.00016863248
amphetamine B-Chemical 1 0.9999913
injection O 0 0.00028388255
, O 0 0.00013684179
cyclic O 0 0.0013473429
chow O 0 0.010166374
followed O 0 5.9983548e-05
by O 0 0.00015594474
amphetamine B-Chemical 1 0.9999887
injection O 0 0.00020201982
, O 0 8.728398e-05
ad O 0 0.00017559499
libitum O 0 0.0010968549
chow O 0 0.0039493213
with O 0 0.000227748
amphetamine B-Chemical 1 0.9999896
, O 0 0.00017251282
or O 0 8.1025326e-05
cyclic O 0 0.00072354724
10 O 0 8.1595535e-05
% O 0 0.00012901684
sucrose B-Chemical 0 0.5405509
and O 0 0.00019740305
chow O 0 0.006521486
with O 0 0.00024613523
a O 0 0.0004298476
saline O 0 0.0018300584
injection O 0 0.0011124458
) O 0 0.0020556347
. O 0 0.0019286134

These O 0 0.0020081927
results O 0 0.001139605
suggest O 0 0.00042374455
that O 0 0.00037534232
a O 0 0.0006123345
diet O 0 0.0028647739
comprised O 0 0.00022881212
of O 0 0.000229977
alternating O 0 0.00035731538
deprivation O 0 0.0003078502
and O 0 0.000112160385
access O 0 7.8821795e-05
to O 0 6.9194444e-05
a O 0 0.00017614351
sugar O 0 0.097074755
solution O 0 0.0014780936
and O 0 0.00013109729
chow O 0 0.009231604
produces O 0 0.00012518319
bingeing O 0 0.8846085
on O 0 6.54106e-05
sugar O 0 0.018379193
that O 0 4.740065e-05
leads O 0 6.143745e-05
to O 0 5.102273e-05
a O 0 7.54532e-05
long O 0 4.6431516e-05
lasting O 0 4.424519e-05
state O 0 6.537512e-05
of O 0 7.833489e-05
increased O 0 0.0001498987
sensitivity O 0 0.00079607917
to O 0 0.00029219486
amphetamine B-Chemical 1 0.99999523
, O 0 0.00027142797
possibly O 0 0.00018981296
due O 0 5.10966e-05
to O 0 6.6186956e-05
a O 0 0.00012079665
lasting O 0 0.00011490072
alteration O 0 0.0003006413
in O 0 0.00026590255
the O 0 0.00070146046
dopamine B-Chemical 0 0.9983925
system O 0 0.0022220025
. O 0 0.0020269328

Reversible O 0 0.72935194
dilated B-Disease 0 0.9982388
cardiomyopathy I-Disease 0 0.9999368
related O 0 0.0022357758
to O 0 0.003820888
amphotericin B-Chemical 0 0.9994849
B I-Chemical 0 0.96917367
therapy O 0 0.01583876
. O 0 0.0065067634

We O 0 0.001252221
describe O 0 0.0008735224
a O 0 0.00097343756
patient O 0 0.0007096528
who O 0 0.0007447845
developed O 0 0.0013345509
dilated B-Disease 0 0.9996069
cardiomyopathy I-Disease 0 0.9999974
and O 0 0.000791572
clinical O 0 0.0045263795
congestive O 0 0.9988772
heart B-Disease 0 0.24124709
failure I-Disease 0 0.027967826
after O 0 3.1026582e-05
2 O 0 3.7002334e-05
months O 0 1.6337473e-05
of O 0 5.3611795e-05
therapy O 0 0.00012327275
with O 0 0.00037933377
amphotericin B-Chemical 0 0.999923
B I-Chemical 0 0.98781514
( O 0 0.0030536838
AmB B-Chemical 1 0.9998
) O 0 0.0016608277
for O 0 0.0008644846
disseminated O 0 0.823277
coccidioidomycosis B-Disease 0 0.9993273
. O 0 0.0045040273

His O 0 0.006316142
echocardiographic O 0 0.0073638516
abnormalities O 0 0.007794081
and O 0 0.001122937
heart B-Disease 0 0.03964343
failure I-Disease 0 0.078590885
resolved O 0 0.0011467214
after O 0 0.0003587026
posaconazole B-Chemical 0 0.9998147
was O 0 0.0015028899
substituted O 0 0.006499159
for O 0 0.0019156637
AmB B-Chemical 1 0.99906915
. O 0 0.0050792033

It O 0 0.0030754926
is O 0 0.0013940816
important O 0 0.0005902709
to O 0 0.00058430457
recognize O 0 0.0003690159
the O 0 0.0005254333
rare O 0 0.0013168595
and O 0 0.000558477
potentially O 0 0.0010326569
reversible O 0 0.2417412
toxicity B-Disease 2 0.9986016
of O 0 0.012552236
AmB B-Chemical 1 0.9995517
. O 0 0.00525549

NO B-Chemical 0 0.996718
- O 0 0.0084231915
induced O 0 0.0054302877
migraine B-Disease 0 0.9998926
attack O 0 0.40704566
: O 0 0.0007689515
strong O 0 0.00033796683
increase O 0 0.00021533544
in O 0 0.00020486738
plasma O 0 0.015840588
calcitonin B-Chemical 0 0.8268787
gene I-Chemical 0 0.00066187495
- I-Chemical 0 0.00025246845
related I-Chemical 0 5.386084e-05
peptide I-Chemical 0 0.00028899522
( O 0 0.00046271627
CGRP B-Chemical 1 0.99722725
) O 0 0.00031105088
concentration O 0 0.00024735503
and O 0 0.0001291537
negative O 0 0.00018381646
correlation O 0 0.00015361102
with O 0 0.0006297616
platelet O 0 0.987265
serotonin B-Chemical 0 0.9996401
release O 0 0.012769199
. O 0 0.0024426011

The O 0 0.0014857065
aim O 0 0.0013302318
of O 0 0.0010129585
the O 0 0.00057321216
present O 0 0.00036766366
study O 0 0.0004319
was O 0 0.00023661
to O 0 0.0001132117
investigate O 0 6.538198e-05
changes O 0 0.00012912243
in O 0 8.75793e-05
the O 0 0.00012184581
plasma O 0 0.009995568
calcitonin B-Chemical 0 0.78691673
gene I-Chemical 0 0.0005313331
- I-Chemical 0 0.00020153268
related I-Chemical 0 4.0898594e-05
peptide I-Chemical 0 0.0002215699
( O 0 0.00034683276
CGRP B-Chemical 1 0.9966961
) O 0 0.00022255997
concentration O 0 0.00021666258
and O 0 0.00018728261
platelet O 0 0.9834947
serotonin B-Chemical 0 0.9999037
( O 0 0.00028442926
5 B-Chemical 0 7.818496e-05
- I-Chemical 0 0.00019240391
hydroxytriptamine I-Chemical 0 0.0014619762
, O 0 0.00013907703
5 B-Chemical 0 9.0116446e-05
- I-Chemical 0 0.0004052791
HT I-Chemical 0 0.9843242
) O 0 0.00018092644
content O 0 8.668626e-05
during O 0 2.9387387e-05
the O 0 6.425315e-05
immediate O 0 0.0003261141
headache B-Disease 0 0.9951651
and O 0 0.00015696828
the O 0 0.0001337313
delayed O 0 0.0010186625
genuine O 0 0.0016725846
migraine B-Disease 0 0.9999567
attack O 0 0.42191118
provoked O 0 0.03930069
by O 0 0.004397698
nitroglycerin B-Chemical 0 0.9999223
. O 0 0.0034158179

Fifteen O 0 0.00490112
female O 0 0.009488448
migraineurs B-Disease 0 0.98263204
( I-Disease 0 0.0018937393
without I-Disease 0 0.0016954086
aura I-Disease 0 0.99993455
) I-Disease 0 0.0011431408
and O 0 0.0003306819
eight O 0 0.00021220924
controls O 0 0.000512961
participated O 0 0.0006761192
in O 0 0.00050738116
the O 0 0.0008989559
study O 0 0.0019291368
. O 0 0.002336334

Sublingual O 0 0.94572645
nitroglycerin B-Chemical 0 0.9998041
( O 0 0.0042963107
0 O 0 0.0013327332
. O 0 0.00080875034
5 O 0 0.0008971991
mg O 0 0.0078173755
) O 0 0.002478282
was O 0 0.0022554274
administered O 0 0.0035994945
. O 0 0.0042561344

Blood O 0 0.011317136
was O 0 0.0014706735
collected O 0 0.0005115172
from O 0 0.0004095415
the O 0 0.00040765395
antecubital O 0 0.0018017207
vein O 0 0.0014241887
four O 0 9.216625e-05
times O 0 6.0345807e-05
: O 0 9.873994e-05
60 O 0 6.592189e-05
min O 0 6.847503e-05
before O 0 2.8587374e-05
and O 0 5.1637733e-05
after O 0 2.7487544e-05
the O 0 0.00014186988
nitroglycerin B-Chemical 0 0.99996805
application O 0 0.00023958221
, O 0 0.00011113685
and O 0 6.535592e-05
60 O 0 4.855499e-05
and O 0 4.1091327e-05
120 O 0 3.9302307e-05
min O 0 4.2163574e-05
after O 0 1.6310247e-05
the O 0 3.4853467e-05
beginning O 0 3.088344e-05
of O 0 0.00010079105
the O 0 0.00024986494
migraine B-Disease 0 0.99996173
attack O 0 0.11938851
( O 0 0.00020046023
mean O 0 6.4679116e-05
344 O 0 0.00075734453
and O 0 0.00014725278
404 O 0 0.0007269363
min O 0 0.0002463907
; O 0 0.00031871462
12 O 0 0.00026254152
subjects O 0 0.00082099845
) O 0 0.0016799506
. O 0 0.0019547727

In O 0 0.0016653261
those O 0 0.0015960451
subjects O 0 0.0012420375
who O 0 0.0009625875
had O 0 0.0005144469
no O 0 0.00049520447
migraine B-Disease 0 0.9999324
attack O 0 0.42567512
( O 0 0.00066317787
11 O 0 0.0002486503
subjects O 0 0.0002653889
) O 0 0.00025307768
a O 0 0.00019945926
similar O 0 0.00013424274
time O 0 0.00017043928
schedule O 0 0.00043880678
was O 0 0.000790451
used O 0 0.0012118071
. O 0 0.0021775982

Plasma O 0 0.47038397
CGRP B-Chemical 1 0.99696916
concentration O 0 0.004217222
increased O 0 0.002017531
significantly O 0 0.0017325002
( O 0 0.0015849177
P O 0 0.0127662765
< O 0 0.00030231292
0 O 0 0.00019043982
. O 0 0.00013216832
01 O 0 0.00043748433
) O 0 0.00017062757
during O 0 6.2060906e-05
the O 0 0.00023389395
migraine B-Disease 0 0.9998981
attack O 0 0.04694596
and O 0 0.000153599
returned O 0 0.000105462845
to O 0 7.7247554e-05
baseline O 0 7.6714525e-05
after O 0 5.0409046e-05
the O 0 0.0001511164
cessation O 0 0.0003728489
of O 0 0.00068565924
the O 0 0.0018417167
migraine B-Disease 0 0.99978715
. O 0 0.0034009072

In O 0 0.0017810921
addition O 0 0.0010228407
, O 0 0.001097067
both O 0 0.00056869735
change O 0 0.00044713402
and O 0 0.00034611794
peak O 0 0.00038502476
, O 0 0.0002534544
showed O 0 0.00014924664
significant O 0 0.000112943315
positive O 0 0.0001341148
correlations O 0 0.000111922345
with O 0 0.0009905475
migraine B-Disease 0 0.99999774
headache B-Disease 0 0.99997854
intensity O 0 0.0004366762
( O 0 0.0008432467
P O 0 0.0058630477
< O 0 0.0003514848
0 O 0 0.0003738022
. O 0 0.00053790456
001 O 0 0.0077584293
) O 0 0.0025067637
. O 0 0.0024866338

However O 0 0.0027651687
, O 0 0.0026757403
plasma O 0 0.05157426
CGRP B-Chemical 1 0.9981311
concentrations O 0 0.0021796343
failed O 0 0.0005003754
to O 0 0.00022098952
change O 0 0.0001733275
during O 0 9.288348e-05
immediate O 0 0.00056292076
headache B-Disease 0 0.995647
and O 0 0.0002313211
in O 0 0.00013581471
the O 0 0.00016331077
subjects O 0 0.0002929265
with O 0 0.00042401065
no O 0 0.0007566769
migraine B-Disease 0 0.9998635
attack O 0 0.6593941
. O 0 0.0033655597

Basal O 0 0.02369534
CGRP B-Chemical 1 0.99468994
concentration O 0 0.003460278
was O 0 0.0009814402
significantly O 0 0.0006237749
higher O 0 0.00045332912
and O 0 0.00046717213
platelet O 0 0.80114967
5 B-Chemical 0 0.00032085052
- I-Chemical 0 0.0009027911
HT I-Chemical 0 0.97958654
content O 0 0.00032313104
tended O 0 0.00013621988
to O 0 9.125159e-05
be O 0 8.851081e-05
lower O 0 0.00013248732
in O 0 0.00011704026
subjects O 0 0.00023065602
who O 0 0.00035262192
experienced O 0 0.0005480324
a O 0 0.0021557864
migraine B-Disease 0 0.9998913
attack O 0 0.66437113
. O 0 0.003227825

Platelet O 0 0.9659412
serotonin B-Chemical 0 0.99854314
content O 0 0.00268734
decreased O 0 0.0021687516
significantly O 0 0.0014347661
( O 0 0.001384227
P O 0 0.010821699
< O 0 0.00027302525
0 O 0 0.00017008309
. O 0 0.00011702865
01 O 0 0.0004041169
) O 0 0.00017293937
after O 0 6.837043e-05
nitroglycerin B-Chemical 0 0.99988973
in O 0 0.00012715867
subjects O 0 0.00013742487
with O 0 0.00012702415
no O 0 0.00014167778
migraine B-Disease 0 0.99997306
attack O 0 0.24309541
but O 0 0.00017690565
no O 0 5.5624925e-05
consistent O 0 8.3234016e-05
change O 0 0.00010782373
was O 0 0.000118673495
observed O 0 9.9936326e-05
in O 0 0.00016428945
patients O 0 0.00053234556
with O 0 0.0016127594
migraine B-Disease 0 0.9999031
attack O 0 0.63934004
. O 0 0.0029696277

In O 0 0.0019172892
conclusion O 0 0.001352988
, O 0 0.0010361578
the O 0 0.00047049485
fact O 0 0.00024174234
that O 0 0.0002706551
plasma O 0 0.045904014
CGRP B-Chemical 1 0.9989643
concentration O 0 0.0006884512
correlates O 0 0.0001236062
with O 0 0.00011630398
the O 0 6.494327e-05
timing O 0 4.175492e-05
and O 0 8.161125e-05
severity O 0 0.00022213891
of O 0 0.00020826916
a O 0 0.0021194092
migraine B-Disease 0 0.9999988
headache B-Disease 0 0.9999821
suggests O 0 0.000113334725
a O 0 0.00016601472
direct O 0 0.000104833875
relationship O 0 9.654901e-05
between O 0 0.00027926685
CGRP B-Chemical 1 0.996772
and O 0 0.0037767855
migraine B-Disease 0 0.9998258
. O 0 0.0034112625

In O 0 0.0019161124
contrast O 0 0.0023198624
, O 0 0.0024692924
serotonin B-Chemical 0 0.9990852
release O 0 0.0033551846
from O 0 0.00041375094
platelets O 0 0.024490604
does O 0 0.00022232837
not O 0 0.0002102805
provoke O 0 0.0023013866
migraine B-Disease 0 0.9999703
, O 0 0.00035294797
it O 0 0.0001347294
may O 0 6.7703266e-05
even O 0 8.273208e-05
counteract O 0 0.00011303911
the O 0 0.00021169189
headache B-Disease 0 0.9957321
and O 0 0.00019044036
the O 0 0.00018885414
concomitant O 0 0.002497248
CGRP B-Chemical 1 0.9982476
release O 0 0.0019855127
in O 0 0.0004384815
this O 0 0.0008680927
model O 0 0.0017299536
. O 0 0.0020191425

Hyperbaric O 0 0.73597324
oxygen B-Chemical 1 0.977123
therapy O 0 0.0015277177
for O 0 0.00046478838
control O 0 0.00046209566
of O 0 0.0008016973
intractable O 0 0.14023891
cyclophosphamide B-Chemical 0 0.9998012
- O 0 0.006297671
induced O 0 0.0063573117
hemorrhagic B-Disease 2 0.9998184
cystitis I-Disease 0 0.999866
. O 0 0.007447174

We O 0 0.0017896992
report O 0 0.0018540033
a O 0 0.0011886662
case O 0 0.0006763171
of O 0 0.0009066857
intractable O 0 0.16524552
hemorrhagic B-Disease 2 0.9998467
cystitis I-Disease 0 0.999869
due O 0 0.00032593697
to O 0 0.0003898816
cyclophosphamide B-Chemical 0 0.9991246
therapy O 0 0.0009326502
for O 0 0.00051236636
Wegener B-Disease 0 0.19613221
' I-Disease 0 0.0013642507
s I-Disease 0 0.0015150462
granulomatosis I-Disease 0 0.41569582
. O 0 0.0029656328

Conservative O 0 0.12116785
treatment O 0 0.0018963685
, O 0 0.0010797138
including O 0 0.00042703442
bladder O 0 0.0031993263
irrigation O 0 0.00078255864
with O 0 0.00022640952
physiological O 0 0.00029216925
saline O 0 0.0005869369
and O 0 0.0001361016
instillation O 0 0.0004977871
of O 0 0.0016080262
prostaglandin B-Chemical 0 0.9999982
F2 I-Chemical 0 0.9993067
alpha I-Chemical 0 0.9863533
, O 0 0.00040585245
failed O 0 0.00030436914
to O 0 0.00029340613
totally O 0 0.0013593147
control O 0 0.0017252637
hemorrhage B-Disease 2 0.9993618
. O 0 0.0032992405

We O 0 0.001429326
then O 0 0.0010266282
used O 0 0.0010054656
hyperbaric O 0 0.14072467
oxygen B-Chemical 1 0.9480197
at O 0 0.00025743686
an O 0 0.0002794778
absolute O 0 0.00037678314
pressure O 0 0.0014657045
of O 0 0.0002737838
2 O 0 0.00018354849
atm O 0 0.076170266
, O 0 0.00017390757
5 O 0 7.321099e-05
days O 0 4.6728244e-05
a O 0 0.00012514812
week O 0 8.184061e-05
for O 0 0.00014548433
8 O 0 0.00025276106
consecutive O 0 0.0004398295
weeks O 0 0.0005423646
. O 0 0.0015956622

The O 0 0.0030574852
bleeding B-Disease 0 0.8237541
ceased O 0 0.00183347
completely O 0 0.0009847701
by O 0 0.00047454677
the O 0 0.00026933584
end O 0 0.0001449569
of O 0 0.00025766913
treatment O 0 0.0002168449
and O 0 0.00019287525
the O 0 0.00017960246
patient O 0 0.00023289547
remained O 0 0.00033888116
free O 0 0.00057607674
of O 0 0.0012900652
hematuria B-Disease 0 0.9992331
thereafter O 0 0.0022230642
. O 0 0.0021874802

No O 0 0.005411667
side O 0 0.010221566
effect O 0 0.0019171359
was O 0 0.0014626086
noted O 0 0.0006617419
during O 0 0.00047689443
the O 0 0.00076812354
course O 0 0.0009880436
of O 0 0.0021258248
therapy O 0 0.004550797
. O 0 0.003935551

In O 0 0.0021165602
future O 0 0.0016203993
, O 0 0.0011171789
this O 0 0.0006436236
form O 0 0.00041049113
of O 0 0.0004538203
therapy O 0 0.00042650357
can O 0 0.0001435447
offer O 0 0.00015526518
a O 0 0.00016321054
safe O 0 0.00013664295
alternative O 0 7.3749405e-05
in O 0 7.958226e-05
the O 0 9.644007e-05
treatment O 0 0.00015645931
of O 0 0.00058402336
cyclophosphamide B-Chemical 0 0.99976045
- O 0 0.0034211038
induced O 0 0.0044849985
hemorrhagic B-Disease 2 0.99986434
cystitis I-Disease 0 0.99989223
. O 0 0.0059862854

Acute B-Disease 0 0.9754682
psychosis I-Disease 0 0.99955875
due O 0 0.0011946526
to O 0 0.00077935605
treatment O 0 0.0008365939
with O 0 0.0019372386
phenytoin B-Chemical 1 0.9999765
in O 0 0.001411432
a O 0 0.0023622958
nonepileptic O 0 0.990879
patient O 0 0.0031110323
. O 0 0.0026680375

The O 0 0.0015297929
development O 0 0.001833977
of O 0 0.0015685936
psychosis B-Disease 0 0.99226356
related O 0 0.0002653737
to O 0 0.00038325327
antiepileptic O 0 0.9931792
drug O 0 0.031746153
treatment O 0 0.00021838654
is O 0 0.00012228276
usually O 0 0.00011335441
attributed O 0 5.828615e-05
to O 0 5.6317465e-05
the O 0 6.164767e-05
interaction O 0 5.5843375e-05
between O 0 4.7876107e-05
the O 0 0.00014629312
epileptic B-Disease 0 0.99771297
brain O 0 0.003291967
substratum O 0 0.001416603
and O 0 0.0003191427
the O 0 0.0005986482
antiepileptic O 0 0.99036777
drugs O 0 0.10022333
. O 0 0.002214104

The O 0 0.0016005466
case O 0 0.0011315786
of O 0 0.0009885483
a O 0 0.0010297215
nonepileptic O 0 0.9146058
patient O 0 0.00054852286
who O 0 0.0004304395
developed O 0 0.00053898385
psychosis B-Disease 0 0.99843735
following O 0 0.0004124492
phenytoin B-Chemical 1 0.9999912
treatment O 0 0.0004828987
for O 0 0.00035566246
trigeminal B-Disease 0 0.043843806
neuralgia I-Disease 0 0.9992268
is O 0 0.0012325412
described O 0 0.0013643139
. O 0 0.0020522256

This O 0 0.0032856143
case O 0 0.001124534
suggests O 0 0.00039568738
that O 0 0.00035265222
the O 0 0.0008839878
psychotic B-Disease 0 0.9999882
symptoms I-Disease 0 0.5689746
that O 0 0.00012934043
occur O 0 8.79836e-05
following O 0 0.00012590965
phenytoin B-Chemical 1 0.9999932
treatment O 0 0.00018830504
in O 0 9.560891e-05
some O 0 0.00016785125
epileptic B-Disease 0 0.99936813
patients O 0 0.0002589461
may O 0 6.2670864e-05
be O 0 5.2253166e-05
the O 0 5.1906805e-05
direct O 0 5.77235e-05
result O 0 8.4262225e-05
of O 0 0.00022343147
medication O 0 0.002202431
, O 0 0.00037740578
unrelated O 0 0.0010260699
to O 0 0.0012574347
seizures B-Disease 0 0.99976736
. O 0 0.0035627563

Risks O 0 0.010956599
of O 0 0.0032328458
the O 0 0.0023976886
consumption O 0 0.007342649
of O 0 0.003766344
beverages O 0 0.87861484
containing O 0 0.0054044696
quinine B-Chemical 0 0.99892515
. O 0 0.00839193

Although O 0 0.0016377792
the O 0 0.0013867902
United O 0 0.0014185423
States O 0 0.0016449945
Food O 0 0.004153945
and O 0 0.0005779609
Drug O 0 0.050978888
Administration O 0 0.0027379105
banned O 0 0.00090628245
its O 0 0.00025546
use O 0 9.8275996e-05
for O 0 9.527808e-05
nocturnal B-Disease 0 0.25069645
leg I-Disease 0 0.7490001
cramps I-Disease 0 0.9999291
due O 0 8.3677216e-05
to O 0 6.27495e-05
lack O 0 6.0106828e-05
of O 0 8.5085485e-05
safety O 0 0.00011008641
and O 0 8.662049e-05
efficacy O 0 0.00019017435
, O 0 0.00029264175
quinine B-Chemical 0 0.9993861
is O 0 0.00017196067
widely O 0 8.797588e-05
available O 0 0.00011854084
in O 0 0.00013738383
beverages O 0 0.26500726
including O 0 0.00014461452
tonic O 0 0.0064651063
water O 0 0.0093891835
and O 0 0.0011754759
bitter O 0 0.9246172
lemon O 0 0.99760497
. O 0 0.0035551938

Numerous O 0 0.0025330356
anecdotal O 0 0.0029143638
reports O 0 0.0009225866
suggest O 0 0.00026404214
that O 0 0.0002477036
products O 0 0.00078749144
containing O 0 0.00036926067
quinine B-Chemical 0 0.9993224
may O 0 0.00021678949
produce O 0 0.00019826322
neurological B-Disease 0 0.9992065
complications I-Disease 0 0.9374244
, O 0 0.00030990771
including O 0 0.00012348591
confusion B-Disease 0 0.2234695
, O 0 0.0001747325
altered O 0 0.00020558394
mental O 0 0.0019017165
status O 0 0.0001608302
, O 0 0.00033221667
seizures B-Disease 0 0.99991953
, O 0 0.00052208646
and O 0 0.00055606506
coma B-Disease 0 0.9990614
, O 0 0.00046953966
particularly O 0 0.00045969948
in O 0 0.00053451705
older O 0 0.003289005
women O 0 0.0037064778
. O 0 0.0018503274

Psychologists O 0 0.004398922
need O 0 0.0012218283
to O 0 0.00085253984
inquire O 0 0.0013117365
about O 0 0.0005993887
consumption O 0 0.0034463
of O 0 0.0013818456
quinine B-Chemical 0 0.99979633
- O 0 0.0014138009
containing O 0 0.0003745024
beverages O 0 0.5736458
as O 0 0.00025230626
part O 0 0.0002007012
of O 0 0.0003917123
an O 0 0.0006536918
evaluation O 0 0.0007787403
process O 0 0.0014674866
. O 0 0.0021614486

Transient O 0 0.20974772
platypnea B-Disease 0 0.5994661
- I-Disease 0 0.0077409856
orthodeoxia I-Disease 0 0.9244544
- I-Disease 0 0.0017605142
like I-Disease 0 0.00042665377
syndrome I-Disease 0 0.03043464
induced O 0 0.00054725783
by O 0 0.0011142932
propafenone B-Chemical 0 0.99999666
overdose B-Disease 0 0.99995124
in O 0 0.0003474622
a O 0 0.00038114854
young O 0 0.0012397775
woman O 0 0.0008059377
with O 0 0.0005430008
Ebstein B-Disease 0 0.020158643
' I-Disease 0 0.00087672775
s I-Disease 0 0.0010643622
anomaly I-Disease 0 0.031012362
. O 0 0.002591725

In O 0 0.0017209781
this O 0 0.0013907519
report O 0 0.0010233676
we O 0 0.00028936358
describe O 0 0.00028091183
the O 0 0.00028239246
case O 0 0.00023354676
of O 0 0.00028017012
a O 0 0.0003223575
37 O 0 0.00048060494
- O 0 0.00032731518
year O 0 8.874094e-05
- O 0 0.00017047163
old O 0 0.000101175654
white O 0 0.00043704765
woman O 0 0.00027978836
with O 0 0.00014985412
Ebstein B-Disease 0 0.0106492555
' I-Disease 0 0.00012512878
s I-Disease 0 0.000107257976
anomaly I-Disease 0 0.007073095
, O 0 0.00013814247
who O 0 0.00015153646
developed O 0 0.00014402623
a O 0 0.00016781714
rare O 0 0.000980821
syndrome O 0 0.08167157
called O 0 0.00025865174
platypnea B-Disease 0 0.33703706
- I-Disease 0 0.00087229896
orthodeoxia I-Disease 0 0.8504112
, O 0 0.00017269154
characterized O 0 0.0002420135
by O 0 0.000116101866
massive O 0 0.0017795227
right O 0 0.0010044919
- O 0 0.00024895705
to O 0 8.443387e-05
- O 0 0.00017903224
left O 0 0.00026668957
interatrial O 0 0.0009057619
shunting O 0 0.0041327197
with O 0 0.00022420892
transient O 0 0.001840801
profound O 0 0.0059109177
hypoxia B-Disease 2 0.9844171
and O 0 0.0035969845
cyanosis B-Disease 0 0.9968746
. O 0 0.0030813725

This O 0 0.0037376373
shunt O 0 0.004033328
of O 0 0.001209661
blood O 0 0.0022207417
via O 0 0.00032875
a O 0 0.0006026303
patent B-Disease 0 0.036086563
foramen I-Disease 0 0.16475745
ovale I-Disease 0 0.48553705
occurred O 0 0.00014483959
in O 0 9.602491e-05
the O 0 8.1891834e-05
presence O 0 8.205607e-05
of O 0 0.000118603035
a O 0 0.00014562103
normal O 0 0.00033808802
pulmonary O 0 0.11536226
artery O 0 0.09181538
pressure O 0 0.0054619056
, O 0 0.0001642144
and O 0 0.0001263679
was O 0 0.00013832055
probably O 0 0.00020333233
precipitated O 0 0.0006866506
by O 0 0.0005126354
a O 0 0.0033526658
propafenone B-Chemical 0 0.99998605
overdose B-Disease 0 0.99989665
. O 0 0.0040705316

This O 0 0.0044490937
drug O 0 0.020072276
caused O 0 0.0025917557
biventricular B-Disease 0 0.97993124
dysfunction I-Disease 0 0.9988493
, O 0 0.00074979436
due O 0 0.00015879376
to O 0 0.0001433566
its O 0 0.00025716453
negative O 0 0.0003035068
inotropic O 0 0.64827746
effect O 0 0.00026134125
, O 0 0.00030871693
and O 0 0.00042607784
hypotension B-Disease 0 0.99975175
, O 0 0.0003181657
due O 0 0.00011957532
to O 0 0.00018127664
its O 0 0.0005798656
peripheral O 0 0.006018251
vasodilatory O 0 0.70395446
effect O 0 0.0018769992
. O 0 0.0023240314

These O 0 0.0023332094
effects O 0 0.001870181
gave O 0 0.0022235117
rise O 0 0.0010016776
to O 0 0.0004007268
an O 0 0.00037858772
increase O 0 0.0002234353
in O 0 0.00014310722
the O 0 0.00013411339
right O 0 0.00058352423
atrial O 0 0.23768562
pressure O 0 0.0024316576
and O 0 0.000114116076
a O 0 0.00011531881
decrease O 0 0.0001036946
in O 0 5.8942813e-05
the O 0 6.299623e-05
left O 0 0.00016640729
one O 0 4.6465797e-05
with O 0 7.7321834e-05
a O 0 9.7039134e-05
consequent O 0 0.00016241628
stretching O 0 0.0003797761
of O 0 0.00011652044
the O 0 0.00014694294
foramen O 0 0.050270796
ovale O 0 0.04933115
and O 0 9.65051e-05
the O 0 8.040803e-05
creation O 0 0.00014007991
of O 0 0.00021040605
massive O 0 0.003128927
right O 0 0.0017797006
- O 0 0.00066944957
to O 0 0.00037419653
- O 0 0.0010737174
left O 0 0.0027288117
shunting O 0 0.104464434
. O 0 0.0023891884

In O 0 0.0019319922
our O 0 0.0016942902
case O 0 0.0009408022
this O 0 0.0009028397
interatrial O 0 0.0034158567
shunt O 0 0.0021163174
was O 0 0.0004079039
very O 0 0.00039243329
accurately O 0 0.00027680025
detected O 0 0.0002557154
at O 0 0.00032517093
bubble O 0 0.004213887
contrast O 0 0.0022618158
echocardiography O 0 0.016352842
. O 0 0.0026980233

Noxious O 0 0.09773106
chemical O 0 0.00358964
stimulation O 0 0.0008436128
of O 0 0.000901475
rat O 0 0.0014480725
facial O 0 0.0076946896
mucosa O 0 0.012594196
increases O 0 0.00031956012
intracranial O 0 0.16792147
blood O 0 0.0029448671
flow O 0 0.0005679376
through O 0 7.789332e-05
a O 0 0.00017003556
trigemino O 0 0.0026996029
- O 0 0.00050003646
parasympathetic O 0 0.30023235
reflex O 0 0.15492398
- O 0 0.00052687194
- O 0 0.00022039338
an O 0 0.00011964785
experimental O 0 0.00014049807
model O 0 0.00016447001
for O 0 0.00020272603
vascular B-Disease 0 0.9375117
dysfunctions I-Disease 0 0.97459227
in O 0 0.00093916815
cluster B-Disease 0 0.003073058
headache I-Disease 0 0.9984591
. O 0 0.0028990621

Cluster B-Disease 0 0.85361075
headache I-Disease 0 0.9993261
is O 0 0.0023052874
characterized O 0 0.0016862844
by O 0 0.0006491922
typical O 0 0.00055057724
autonomic O 0 0.011132135
dysfunctions O 0 0.056539435
including O 0 0.00037654577
facial O 0 0.0047334093
and O 0 0.0011376402
intracranial B-Disease 0 0.9545741
vascular I-Disease 0 0.80602145
disturbances I-Disease 0 0.8563885
. O 0 0.003402399

Both O 0 0.0024080263
the O 0 0.0016013407
trigeminal O 0 0.002776715
and O 0 0.00086235296
the O 0 0.0007087498
cranial O 0 0.0078045754
parasympathetic O 0 0.113707446
systems O 0 0.00046548343
may O 0 0.0002792381
be O 0 0.0002485119
involved O 0 0.00020273299
in O 0 0.00030915256
mediating O 0 0.00037169695
these O 0 0.0016893245
dysfunctions O 0 0.37157878
. O 0 0.0031660257

An O 0 0.0026715267
experimental O 0 0.0018352303
model O 0 0.0012156884
was O 0 0.00079613226
developed O 0 0.0006238261
in O 0 0.00029256783
the O 0 0.00022674204
rat O 0 0.00033818535
to O 0 9.683485e-05
measure O 0 4.9437822e-05
changes O 0 0.0001340814
in O 0 0.00016485185
lacrimation O 0 0.9819042
and O 0 0.00022608705
intracranial O 0 0.13052267
blood O 0 0.0017740018
flow O 0 0.0004582299
following O 0 9.9640565e-05
noxious O 0 0.0007132167
chemical O 0 0.00060339185
stimulation O 0 0.00028597697
of O 0 0.0009481975
facial O 0 0.07738832
mucosa O 0 0.21838214
. O 0 0.0025714

Blood O 0 0.01467795
flow O 0 0.004523873
was O 0 0.0010417774
monitored O 0 0.00040887078
in O 0 0.00044098694
arteries O 0 0.0056197704
of O 0 0.0003220341
the O 0 0.00020926083
exposed O 0 0.00025600864
cranial O 0 0.004474973
dura O 0 0.0058794348
mater O 0 0.023850882
and O 0 0.00022027448
the O 0 0.00020618622
parietal O 0 0.006072259
cortex O 0 0.0031544063
using O 0 0.0004826424
laser O 0 0.0029845824
Doppler O 0 0.03455091
flowmetry O 0 0.0060198084
. O 0 0.0023254403

Capsaicin B-Chemical 1 0.9981974
( O 0 0.0047373427
0 O 0 0.0015172795
. O 0 0.0008395239
01 O 0 0.0020191101
- O 0 0.000859578
1 O 0 0.00030615518
mm O 0 0.00045664445
) O 0 0.00029615243
applied O 0 0.00012082291
to O 0 0.00016558013
oral O 0 0.002567515
or O 0 0.0001918748
nasal O 0 0.0011149076
mucosa O 0 0.0064849076
induced O 0 0.0001795663
increases B-Disease 0 0.0001619406
in I-Disease 0 0.00016966615
dural I-Disease 0 0.03824804
and I-Disease 0 0.00018536532
cortical I-Disease 0 0.001048765
blood I-Disease 0 0.0031231705
flow I-Disease 0 0.0016329538
and O 0 0.0007775968
provoked O 0 0.016714443
lacrimation O 0 0.99826485
. O 0 0.003367851

These O 0 0.0023146216
responses O 0 0.0018934852
were O 0 0.0010510203
blocked O 0 0.0013790532
by O 0 0.0008042284
systemic O 0 0.08116881
pre O 0 0.0012408502
- O 0 0.0007141276
administration O 0 0.0014072793
of O 0 0.002847401
hexamethonium B-Chemical 0 0.99999905
chloride I-Chemical 0 0.99999297
( O 0 0.0021343164
20 O 0 0.00056548644
mg O 0 0.011340791
/ O 0 0.0024106528
kg O 0 0.0026099114
) O 0 0.002425731
. O 0 0.0023230785

The O 0 0.0017134723
evoked O 0 0.0032542804
increases B-Disease 0 0.0010204201
in I-Disease 0 0.0008102097
dural I-Disease 0 0.08212751
blood I-Disease 0 0.0039411774
flow I-Disease 0 0.0012334953
were O 0 0.00019138951
also O 0 0.00013219568
abolished O 0 0.00030348363
by O 0 0.00022453473
topical O 0 0.33267653
pre O 0 0.00060558
- O 0 0.0003250216
administration O 0 0.0006467318
of O 0 0.0006463621
atropine B-Chemical 0 0.9999858
( O 0 0.0004223001
1 O 0 9.3836046e-05
mm O 0 0.00019434022
) O 0 0.00017242877
and O 0 0.00014804387
[ O 0 0.00050809816
Lys1 O 0 0.0037281322
, O 0 0.00027096982
Pro2 O 0 0.015673378
, O 0 0.00017565762
5 O 0 9.764574e-05
, O 0 0.00019688348
Arg3 O 0 0.15940565
, O 0 0.00019883568
4 O 0 0.00010612818
, O 0 0.00021570596
Tyr6 O 0 0.33990112
] O 0 0.00087810133
- O 0 0.0005609193
VIP O 0 0.46242127
( O 0 0.00021863196
0 O 0 8.7180175e-05
. O 0 5.6483605e-05
1 O 0 7.162827e-05
mm O 0 0.0001763228
) O 0 0.00017473601
, O 0 0.00012447224
a O 0 0.00019355946
vasoactive O 0 0.002177497
intestinal O 0 0.003927906
polypeptide O 0 0.0036309357
( O 0 0.0005409943
VIP O 0 0.7793595
) O 0 0.0006565245
antagonist O 0 0.2936294
, O 0 0.0002599353
onto O 0 0.00018103309
the O 0 0.0003154733
exposed O 0 0.000698073
dura O 0 0.01954284
mater O 0 0.3051347
. O 0 0.0028795772

We O 0 0.0014131495
conclude O 0 0.00081562233
that O 0 0.000650463
noxious O 0 0.0020540564
stimulation O 0 0.0004117415
of O 0 0.00061409315
facial O 0 0.009952522
mucosa O 0 0.017429363
increases O 0 0.00032707438
intracranial O 0 0.22103179
blood O 0 0.0047737746
flow O 0 0.0012992641
and O 0 0.00038600696
lacrimation O 0 0.9696415
via O 0 0.00022307364
a O 0 0.0005623341
trigemino O 0 0.0069442424
- O 0 0.0020256757
parasympathetic O 0 0.3045766
reflex O 0 0.17905025
. O 0 0.0027051289

The O 0 0.0020784105
blood O 0 0.005457279
flow O 0 0.0031122183
responses O 0 0.0010231901
seem O 0 0.00060703914
to O 0 0.00036762265
be O 0 0.00027032732
mediated O 0 0.00016410407
by O 0 0.00023363119
the O 0 0.0002460782
release O 0 0.0009769194
of O 0 0.0010088797
acetylcholine B-Chemical 1 0.999775
and O 0 0.0010071022
VIP O 0 0.28687096
within O 0 0.00029407206
the O 0 0.00096969877
meninges O 0 0.013241824
. O 0 0.0025182446

Similar O 0 0.002473744
mechanisms O 0 0.0023796288
may O 0 0.0013015444
be O 0 0.000895972
involved O 0 0.0005611433
in O 0 0.00061537157
the O 0 0.0007589166
pathogenesis O 0 0.0019168721
of O 0 0.0020546566
cluster B-Disease 0 0.005561696
headache I-Disease 0 0.99824595
. O 0 0.005130768

Organophosphate B-Chemical 0 0.9994667
- O 0 0.012748368
induced O 0 0.006464277
convulsions B-Disease 0 0.9993542
and O 0 0.0035015629
prevention O 0 0.0039942204
of O 0 0.005326116
neuropathological B-Disease 0 0.99639386
damages I-Disease 0 0.9936885
. O 0 0.0074185384

Such O 0 0.012433172
organophosphorus B-Chemical 0 0.99991465
( O 0 0.016981019
OP B-Chemical 0 0.99962544
) O 0 0.0032806215
compounds O 0 0.4864031
as O 0 0.0015769056
diisopropylfluorophosphate B-Chemical 0 0.9999701
( O 0 0.030964702
DFP B-Chemical 0 0.9999827
) O 0 0.0027721794
, O 0 0.00083015295
sarin B-Chemical 0 0.99992156
and O 0 0.0010527541
soman B-Chemical 0 0.9998752
are O 0 0.00019990213
potent O 0 0.00030106492
inhibitors O 0 0.00073782884
of O 0 0.00038350085
acetylcholinesterases O 0 0.2995818
( O 0 0.00058226864
AChEs O 0 0.12127777
) O 0 0.0004924869
and O 0 0.0004458593
butyrylcholinesterases O 0 0.2550383
( O 0 0.0014929892
BChEs O 0 0.061767787
) O 0 0.0029444024
. O 0 0.002358956

The O 0 0.0027148174
acute O 0 0.48352972
toxicity B-Disease 2 0.99792683
of O 0 0.004530627
OPs B-Chemical 0 0.981937
is O 0 0.00042181206
the O 0 0.00020034538
result O 0 0.00013860414
of O 0 0.00019458683
their O 0 0.00022738695
irreversible O 0 0.029822472
binding O 0 0.00019819535
with O 0 0.00024713035
AChEs O 0 0.035278633
in O 0 7.674555e-05
the O 0 7.251721e-05
central O 0 0.00013561308
nervous O 0 0.0036692058
system O 0 0.00019438026
( O 0 0.00029212385
CNS O 0 0.028456502
) O 0 0.00032371288
, O 0 0.000191345
which O 0 0.00033204793
elevates O 0 0.019094279
acetylcholine B-Chemical 1 0.99990225
( O 0 0.0036474492
ACh B-Chemical 1 0.9995339
) O 0 0.002162637
levels O 0 0.001760055
. O 0 0.002284625

The O 0 0.0018773226
protective O 0 0.0028429274
action O 0 0.0013596985
of O 0 0.0008722462
subcutaneously O 0 0.0006567514
( O 0 0.00070411194
SC O 0 0.010038636
) O 0 0.00041219924
administered O 0 0.0002870237
antidotes O 0 0.100393705
or O 0 0.00012076106
their O 0 0.00013009383
combinations O 0 0.00011348797
in O 0 0.00027205652
DFP B-Chemical 0 0.99996495
( O 0 0.00040888286
2 O 0 7.955033e-05
. O 0 4.167575e-05
0 O 0 5.667925e-05
mg O 0 0.0007337525
/ O 0 0.00031218486
kg O 0 0.00038176528
BW O 0 0.05469753
) O 0 0.00041983795
intoxication O 0 0.984968
was O 0 0.00020380536
studied O 0 0.00013032068
in O 0 9.1090755e-05
9 O 0 9.18327e-05
- O 0 0.00017686313
10 O 0 9.770943e-05
- O 0 0.00019318222
weeks O 0 6.240476e-05
- O 0 0.00028244578
old O 0 0.000342796
Han O 0 0.36741957
- O 0 0.0010224364
Wistar O 0 0.0029365984
male O 0 0.0023698774
rats O 0 0.0017877945
. O 0 0.0017047363

The O 0 0.0016759095
rats O 0 0.0020114025
received O 0 0.0012225593
AChE O 0 0.9478171
reactivator O 0 0.97767913
pralidoxime B-Chemical 0 0.99979275
- I-Chemical 0 0.0027382437
2 I-Chemical 0 0.00034296451
- I-Chemical 0 0.0010920995
chloride I-Chemical 0 0.9998691
( O 0 0.0020379296
2PAM B-Chemical 0 0.9972363
) O 0 0.0004864635
( O 0 0.00015925351
30 O 0 6.1219296e-05
. O 0 4.5161843e-05
0 O 0 6.145584e-05
mg O 0 0.0007091423
/ O 0 0.00031027367
kg O 0 0.00035467278
BW O 0 0.025546879
) O 0 0.00025354335
, O 0 0.00025651415
anticonvulsant O 0 0.9998324
diazepam B-Chemical 0 0.9999975
( O 0 0.00042670686
2 O 0 6.9301226e-05
. O 0 3.6780482e-05
0 O 0 5.2331256e-05
mg O 0 0.00068132364
/ O 0 0.00030994404
kg O 0 0.00037508836
BW O 0 0.033372696
) O 0 0.00025391614
, O 0 0.00016891734
A O 0 0.0034934294
( O 0 0.00019540827
1 O 0 9.973211e-05
) O 0 0.00021102322
- O 0 0.00042173892
adenosine B-Chemical 0 0.9932934
receptor O 0 0.143361
agonist O 0 0.9384442
N B-Chemical 0 0.99390393
( I-Chemical 0 0.00023715633
6 I-Chemical 0 6.4294836e-05
) I-Chemical 0 0.00019447591
- I-Chemical 0 0.0005008512
cyclopentyl I-Chemical 0 0.99924505
adenosine I-Chemical 0 0.99958986
( O 0 0.0016735371
CPA B-Chemical 1 0.9998797
) O 0 0.0005444789
( O 0 0.00016674449
2 O 0 5.916988e-05
. O 0 3.6295183e-05
0 O 0 5.185367e-05
mg O 0 0.00064664654
/ O 0 0.0002895482
kg O 0 0.0003504269
BW O 0 0.038283892
) O 0 0.00029751364
, O 0 0.00037117483
NMDA B-Chemical 1 0.99999595
- O 0 0.0023886838
receptor O 0 0.13415441
antagonist O 0 0.99741936
dizocilpine B-Chemical 0 0.9999995
maleate I-Chemical 0 0.99999964
( O 0 0.0023733003
+ O 0 0.0011952934
- O 0 0.0048595476
MK801 O 0 0.99999964
hydrogen O 0 0.999997
maleate O 0 0.99999964
) O 0 0.0022066557
( O 0 0.00019490399
2 O 0 5.5092954e-05
. O 0 3.212946e-05
0 O 0 4.643435e-05
mg O 0 0.00060643133
/ O 0 0.0002671087
kg O 0 0.00029426225
BW O 0 0.014482127
) O 0 0.00011420011
or O 0 4.037917e-05
their O 0 5.2185038e-05
combinations O 0 4.5285273e-05
with O 0 0.00013232596
cholinolytic O 0 0.9965126
drug O 0 0.76680523
atropine B-Chemical 0 0.9999987
sulfate I-Chemical 0 0.99985945
( O 0 0.00050120504
50 O 0 0.00017278841
. O 0 4.0772928e-05
0 O 0 5.295627e-05
mg O 0 0.0007468015
/ O 0 0.00029363058
kg O 0 0.0003127139
BW O 0 0.011502357
) O 0 0.000116243886
immediately O 0 4.0864208e-05
or O 0 4.6562007e-05
30 O 0 4.3543856e-05
min O 0 6.7681634e-05
after O 0 3.7557067e-05
the O 0 0.00011030551
single O 0 0.00022031942
SC O 0 0.0035294353
injection O 0 0.00084490073
of O 0 0.0029536167
DFP B-Chemical 0 0.9997079
. O 0 0.004289804

The O 0 0.0013171115
control O 0 0.0010848277
rats O 0 0.0014160959
received O 0 0.0013161133
atropine B-Chemical 0 0.9999889
sulfate I-Chemical 0 0.9997378
, O 0 0.001046328
but O 0 0.00028745257
also O 0 0.0001789143
saline O 0 0.0010748381
and O 0 0.000256213
olive O 0 0.837116
oil O 0 0.91087407
instead O 0 0.00021132447
of O 0 0.0002781171
other O 0 0.0003252993
antidotes O 0 0.6798938
and O 0 0.0022568123
DFP B-Chemical 0 0.9998988
, O 0 0.0031718325
respectively O 0 0.004800766
. O 0 0.0025044002

All O 0 0.001886803
rats O 0 0.0017362349
were O 0 0.000762731
terminated O 0 0.00059902406
either O 0 0.00037048617
24 O 0 0.00024593863
h O 0 0.0002277265
or O 0 0.00021134259
3 O 0 0.00017332552
weeks O 0 0.000114129994
after O 0 0.0001837688
the O 0 0.0010024556
DFP B-Chemical 0 0.9994586
injection O 0 0.006248586
. O 0 0.003665871

The O 0 0.0016625487
rats O 0 0.0019523416
treated O 0 0.0016781145
with O 0 0.0030441005
DFP B-Chemical 0 0.99994504
- O 0 0.032084104
atropine B-Chemical 0 0.99996877
showed O 0 0.0013095469
severe O 0 0.033627152
typical O 0 0.0015874713
OP B-Chemical 0 0.9998056
- O 0 0.0029010177
induced O 0 0.002442427
toxicity B-Disease 2 0.9989254
signs O 0 0.40438464
. O 0 0.0034692246

When O 0 0.0030388634
CPA B-Chemical 1 0.9989134
, O 0 0.0065370467
diazepam B-Chemical 0 0.9999746
or O 0 0.0020895146
2PAM B-Chemical 0 0.9939149
was O 0 0.000314168
given O 0 8.7455526e-05
immediately O 0 9.181213e-05
after O 0 0.000103659484
DFP B-Chemical 0 0.99996424
- O 0 0.009785599
atropine B-Chemical 0 0.99998367
, O 0 0.0003334857
these O 0 0.00021767349
treatments O 0 0.00024195768
prevented O 0 0.0005453889
, O 0 0.00019076276
delayed O 0 0.0005802963
or O 0 0.00010881948
shortened O 0 0.00020872243
the O 0 0.00012240875
occurrence O 0 0.0002491223
of O 0 0.00035547063
serious O 0 0.0047609126
signs O 0 0.036880467
of O 0 0.0045672865
poisoning B-Disease 2 0.9997943
. O 0 0.004515958

Atropine B-Chemical 0 0.9998987
- O 0 0.231394
MK801 B-Chemical 0 0.99998283
did O 0 0.0024512724
not O 0 0.0007076625
offer O 0 0.00057230645
any O 0 0.00040011265
additional O 0 0.00042636247
protection O 0 0.0018341098
against O 0 0.0020038995
DFP B-Chemical 0 0.999907
toxicity B-Disease 2 0.99952996
. O 0 0.007165563

In O 0 0.0019229109
conclusion O 0 0.0017425107
, O 0 0.0030366832
CPA B-Chemical 1 0.99957806
, O 0 0.004683396
diazepam B-Chemical 0 0.9999889
and O 0 0.0018719798
2PAM B-Chemical 0 0.9929081
in O 0 0.00020559807
combination O 0 0.00028027082
with O 0 0.0005675242
atropine B-Chemical 0 0.9999802
prevented O 0 0.0015472304
the O 0 0.00013436453
occurrence O 0 0.00017034521
of O 0 0.00015601478
serious O 0 0.0016532338
signs O 0 0.008058507
of O 0 0.0006821904
poisoning B-Disease 2 0.99992514
and O 0 0.000250845
thus O 0 0.00018492079
reduced O 0 0.00029774493
the O 0 0.00031926812
toxicity B-Disease 2 0.99551743
of O 0 0.004446965
DFP B-Chemical 0 0.9999155
in O 0 0.0018374493
rat O 0 0.005360931
. O 0 0.0021562232

A O 0 0.7086377
pyridoxine B-Chemical 1 0.99985373
- O 0 0.0064401035
dependent O 0 0.0014391381
behavioral B-Disease 0 0.18738423
disorder I-Disease 0 0.99789006
unmasked O 0 0.3412871
by O 0 0.008211689
isoniazid B-Chemical 1 0.9996594
. O 0 0.007242267

A O 0 0.029693004
3 O 0 0.0020638364
- O 0 0.0022041984
year O 0 0.00068808784
- O 0 0.0009256869
old O 0 0.0004494212
girl O 0 0.0008882254
had O 0 0.00031207502
behavioral B-Disease 0 0.034193717
deterioration I-Disease 0 0.7450268
, O 0 0.00035550044
with O 0 0.0005341157
hyperkinesis B-Disease 0 0.99941146
, O 0 0.00072970666
irritability B-Disease 0 0.9995009
, O 0 0.00027703473
and O 0 0.00019000727
sleeping B-Disease 0 0.023919623
difficulties I-Disease 0 0.0007559227
after O 0 5.3031217e-05
the O 0 0.00013892342
therapeutic O 0 0.00051726954
administration O 0 0.0028216895
of O 0 0.0035008276
isoniazid B-Chemical 1 0.9998336
. O 0 0.0038507879

The O 0 0.001566481
administration O 0 0.0025343206
of O 0 0.0011542883
pharmacologic O 0 0.0044799126
doses O 0 0.010832408
of O 0 0.0072701527
pyridoxine B-Chemical 1 0.999998
hydrochloride I-Chemical 0 0.99990046
led O 0 0.0011634496
to O 0 0.00042249658
a O 0 0.00070070947
disappearance O 0 0.0024761115
of O 0 0.0017825679
symptoms O 0 0.038618717
. O 0 0.0027778058

After O 0 0.0013251776
discontinuing O 0 0.034424644
isoniazid B-Chemical 1 0.9996991
therapy O 0 0.0018080702
a O 0 0.000598464
similar O 0 0.00019804177
pattern O 0 0.0001824339
of O 0 0.00027188778
behavior O 0 0.00033927718
was O 0 0.00024513286
noted O 0 0.00014470072
that O 0 0.00019751942
was O 0 0.00045340825
controlled O 0 0.0006589919
by O 0 0.0022557203
pyridoxine B-Chemical 1 0.99991834
. O 0 0.004391309

A O 0 0.035887655
placebo O 0 0.009987478
had O 0 0.0011643288
no O 0 0.0005270487
effect O 0 0.0007345658
, O 0 0.0011455705
but O 0 0.0020365743
niacinamide B-Chemical 0 0.99995196
was O 0 0.0015040059
as O 0 0.00068596454
effective O 0 0.0009821398
as O 0 0.0029728098
pyridoxine B-Chemical 1 0.99991953
. O 0 0.00564273

Periodic O 0 0.0047677048
withdrawal O 0 0.017994689
of O 0 0.006008529
pyridoxine B-Chemical 1 0.99993753
was O 0 0.0016176099
associated O 0 0.0006620264
with O 0 0.0007592276
return O 0 0.0009097669
of O 0 0.0012139434
the O 0 0.0022124923
hyperkinesis B-Disease 0 0.99652904
. O 0 0.00423372

The O 0 0.0018636113
level O 0 0.0015613098
of O 0 0.0029561608
pyridoxal B-Chemical 0 0.9996712
in O 0 0.0009937093
the O 0 0.00065327424
blood O 0 0.0028634747
was O 0 0.00044349782
normal O 0 0.0004434304
during O 0 0.00016242
the O 0 0.00031097824
periods O 0 0.00039196856
of O 0 0.0013168098
relapse O 0 0.357918
. O 0 0.0032040745

Metabolic O 0 0.0195527
studies O 0 0.0018192676
suggested O 0 0.0008538101
a O 0 0.0009818518
block O 0 0.0007674247
in O 0 0.0006091452
the O 0 0.0009772545
kynurenine B-Chemical 0 0.9994715
pathway O 0 0.0015918866
of O 0 0.0034747748
tryptophan B-Chemical 0 0.99858826
metabolism O 0 0.7283756
. O 0 0.003989151

The O 0 0.0018658566
patient O 0 0.0016559812
has O 0 0.0006952603
been O 0 0.00039745157
followed O 0 0.00026212385
for O 0 0.00018421159
six O 0 0.00012961576
years O 0 0.00013929523
and O 0 0.00012351642
has O 0 7.604241e-05
required O 0 6.5353546e-05
pharmacologic O 0 0.0010098019
doses O 0 0.0024710523
of O 0 0.0015773195
pyridoxine B-Chemical 1 0.99998415
to O 0 0.0005624772
control O 0 0.0006443374
her O 0 0.0013670112
behavior O 0 0.0020776787
. O 0 0.0021130564

Recurrent O 0 0.008526042
excitation O 0 0.026395377
in O 0 0.001243102
the O 0 0.0009952039
dentate O 0 0.051805947
gyrus O 0 0.32012418
of O 0 0.0009207209
a O 0 0.00073686126
murine O 0 0.0009912574
model O 0 0.00064964435
of O 0 0.0009897168
temporal B-Disease 0 0.035278115
lobe I-Disease 0 0.9179296
epilepsy I-Disease 2 0.9999198
. O 0 0.0061349804

Similar O 0 0.0016873297
to O 0 0.0012700936
rats O 0 0.0015265485
, O 0 0.0011682609
systemic O 0 0.5806624
pilocarpine B-Chemical 1 0.9999726
injection O 0 0.0010814797
causes O 0 0.0006517768
status B-Disease 0 0.00046663318
epilepticus I-Disease 0 0.99761236
( O 0 0.00063636154
SE B-Disease 0 0.07894643
) O 0 0.00018999458
and O 0 7.6004784e-05
the O 0 6.692674e-05
eventual O 0 0.00024868728
development O 0 0.00016258983
of O 0 0.00015667178
spontaneous O 0 0.00402226
seizures B-Disease 0 0.9999385
and O 0 0.00029810535
mossy O 0 0.04030335
fiber O 0 0.0014711173
sprouting O 0 0.6080524
in O 0 0.00019210548
C57BL O 0 0.44645965
/ O 0 0.00041060086
6 O 0 5.013344e-05
and O 0 8.637468e-05
CD1 O 0 0.002080615
mice O 0 5.974521e-05
, O 0 8.943194e-05
but O 0 6.727599e-05
the O 0 5.55094e-05
physiological O 0 9.389718e-05
correlates O 0 5.9530405e-05
of O 0 0.000108846674
these O 0 0.00016028273
events O 0 0.0004240775
have O 0 0.00010251801
not O 0 0.00014291589
been O 0 0.00019050032
identified O 0 0.00029805533
in O 0 0.000517417
mice O 0 0.00089454826
. O 0 0.0017797515

Population O 0 0.004432696
responses O 0 0.0019296913
in O 0 0.0011031728
granule O 0 0.005992639
cells O 0 0.0007864109
of O 0 0.00043559755
the O 0 0.00033347486
dentate O 0 0.04925568
gyrus O 0 0.27889627
were O 0 0.00017883637
examined O 0 7.165901e-05
in O 0 8.2571445e-05
transverse O 0 0.00020374222
slices O 0 0.00023243693
of O 0 0.00010200946
the O 0 8.6315566e-05
ventral O 0 0.00019997513
hippocampus O 0 0.008369579
from O 0 0.0003234624
pilocarpine B-Chemical 1 0.9999739
- O 0 0.0010474928
treated O 0 0.0005491174
and O 0 0.0004957433
untreated O 0 0.001171419
mice O 0 0.001027732
. O 0 0.001865345

In O 0 0.0057355734
Mg B-Chemical 0 0.9996865
( O 0 0.0036721113
2 O 0 0.0010241679
+ O 0 0.001494179
) O 0 0.00090046175
- O 0 0.00059590547
free O 0 0.00038264118
bathing O 0 0.0011510168
medium O 0 0.0009289635
containing O 0 0.0003893291
bicuculline B-Chemical 1 0.9999896
, O 0 0.00040213525
conditions O 0 0.00015867752
designed O 0 8.80877e-05
to O 0 6.775591e-05
increase O 0 9.6977514e-05
excitability O 0 0.0046261116
in O 0 7.036403e-05
the O 0 7.074309e-05
slices O 0 0.00034228823
, O 0 8.9826455e-05
electrical O 0 0.00017652955
stimulation O 0 4.378754e-05
of O 0 8.270937e-05
the O 0 8.075836e-05
hilus O 0 0.0011341262
resulted O 0 7.604719e-05
in O 0 5.7877056e-05
a O 0 7.7195335e-05
single O 0 5.7128123e-05
population O 0 0.00010738355
spike O 0 0.000113111455
in O 0 7.08976e-05
granule O 0 0.004145425
cells O 0 0.0001302609
from O 0 4.974925e-05
control O 0 6.0504033e-05
mice O 0 5.861177e-05
and O 0 0.0002637239
pilocarpine B-Chemical 1 0.9999863
- O 0 0.00074868475
treated O 0 0.00022704077
mice O 0 8.8809255e-05
that O 0 0.000125051
did O 0 0.00030300635
not O 0 0.00042897082
experience O 0 0.0014449209
SE B-Disease 0 0.10620308
. O 0 0.0024250364

In O 0 0.0029309704
SE B-Disease 0 0.095304415
survivors O 0 0.0032715218
, O 0 0.0008380489
similar O 0 0.00027438876
stimulation O 0 0.0002286686
resulted O 0 0.00023605723
in O 0 0.00017375177
a O 0 0.00021552034
population O 0 0.00027451018
spike O 0 0.00024088644
followed O 0 9.774867e-05
, O 0 0.00010477492
at O 0 5.1591458e-05
a O 0 9.786237e-05
variable O 0 5.8970127e-05
latency O 0 0.0001590867
, O 0 0.00010211321
by O 0 8.5811334e-05
negative O 0 0.00016951497
DC O 0 0.013142869
shifts O 0 0.00020531206
and O 0 8.520549e-05
repetitive O 0 0.00010402091
afterdischarges O 0 0.23867615
of O 0 0.00014635954
3 O 0 6.592038e-05
- O 0 0.000101270634
60 O 0 4.9198945e-05
s O 0 5.372147e-05
duration O 0 3.5521785e-05
, O 0 8.791097e-05
which O 0 0.0001214111
were O 0 0.00013421393
blocked O 0 0.0004830113
by O 0 0.0007703641
ionotropic O 0 0.9993174
glutamate B-Chemical 1 0.99993575
receptor O 0 0.76048136
antagonists O 0 0.9641649
. O 0 0.002860723

Focal O 0 0.016200295
glutamate B-Chemical 1 0.998711
photostimulation O 0 0.003702842
of O 0 0.0008847471
the O 0 0.00054443575
granule O 0 0.017511196
cell O 0 0.0016440204
layer O 0 0.0006961241
at O 0 0.00010574441
sites O 0 0.00010051108
distant O 0 0.00038987753
from O 0 6.4620544e-05
the O 0 6.878793e-05
recording O 0 9.245657e-05
pipette O 0 0.0010337869
resulted O 0 8.3606705e-05
in O 0 7.239829e-05
population O 0 0.0001501373
responses O 0 0.000101624304
of O 0 0.00012847775
1 O 0 8.113458e-05
- O 0 0.00010702739
30 O 0 3.8086902e-05
s O 0 4.8080998e-05
duration O 0 2.8825103e-05
in O 0 5.7915375e-05
slices O 0 0.00026216108
from O 0 0.0001424885
SE B-Disease 0 0.016377188
survivors O 0 0.00068993296
but O 0 0.00032098548
not O 0 0.00035893283
other O 0 0.00066058873
groups O 0 0.0011578088
. O 0 0.0017266218

These O 0 0.0021385972
data O 0 0.0013644618
support O 0 0.00064959814
the O 0 0.00057454355
hypothesis O 0 0.0006049945
that O 0 0.000397447
SE B-Disease 0 0.19428068
- O 0 0.0006994168
induced O 0 0.0003657699
mossy O 0 0.05287536
fiber O 0 0.0022540146
sprouting O 0 0.5280512
and O 0 0.00015603354
synaptic O 0 0.00047649088
reorganization O 0 0.00013627432
are O 0 4.6398676e-05
relevant O 0 2.8465798e-05
characteristics O 0 2.8409067e-05
of O 0 0.00011859511
seizure B-Disease 0 0.99550253
development O 0 0.00030106035
in O 0 8.5344705e-05
these O 0 0.00013305793
murine O 0 0.00027724693
strains O 0 0.00013035981
, O 0 0.00013423148
resembling O 0 0.00013949754
rat O 0 0.00026232935
models O 0 0.00016660352
of O 0 0.0002447013
human O 0 0.00048280394
temporal B-Disease 0 0.01880179
lobe I-Disease 0 0.8860584
epilepsy I-Disease 2 0.9999368
. O 0 0.004454895

Urinary B-Disease 0 0.88725084
bladder I-Disease 0 0.96042156
cancer I-Disease 0 0.9989858
in O 0 0.0021029105
Wegener B-Disease 0 0.18563874
' I-Disease 0 0.0010311696
s I-Disease 0 0.0007627862
granulomatosis I-Disease 0 0.12210163
: O 0 0.00068155484
risks O 0 0.0009189998
and O 0 0.00046690524
relation O 0 0.00038644322
to O 0 0.0013252874
cyclophosphamide B-Chemical 0 0.99837214
. O 0 0.0044127796

OBJECTIVE O 0 0.024315009
: O 0 0.0022370173
To O 0 0.00078002445
assess O 0 0.00039597304
and O 0 0.00044499477
characterise O 0 0.0003005596
the O 0 0.000335835
risk O 0 0.0016883952
of O 0 0.00078476995
bladder B-Disease 0 0.97737795
cancer I-Disease 0 0.99977595
, O 0 0.0003665072
and O 0 0.00013579697
its O 0 0.0001469924
relation O 0 4.803059e-05
to O 0 0.00014354443
cyclophosphamide B-Chemical 0 0.99842703
, O 0 0.00028221915
in O 0 0.00017676553
patients O 0 0.00035568536
with O 0 0.0005653274
Wegener B-Disease 0 0.14062914
' I-Disease 0 0.0011235997
s I-Disease 0 0.0013066789
granulomatosis I-Disease 0 0.39984965
. O 0 0.002674364

METHODS O 0 0.0016771754
: O 0 0.0013283518
In O 0 0.0005168782
the O 0 0.00050709856
population O 0 0.000634116
based O 0 0.00030374675
, O 0 0.0003348444
nationwide O 0 0.00044291522
Swedish O 0 0.00066315854
Inpatient O 0 0.00078236335
Register O 0 0.00020023213
a O 0 0.00017477432
cohort O 0 0.00032605443
of O 0 0.00021699398
1065 O 0 0.076927945
patients O 0 0.00022250904
with O 0 0.00023948494
Wegener B-Disease 0 0.05276029
' I-Disease 0 0.00029399918
s I-Disease 0 0.00028462676
granulomatosis I-Disease 0 0.18813083
, O 0 0.00045271078
1969 O 0 0.0012581085
- O 0 0.00067228015
95 O 0 0.00060217304
, O 0 0.0005769251
was O 0 0.0008507108
identified O 0 0.0012726112
. O 0 0.0021076528

Through O 0 0.003146365
linkage O 0 0.0043751984
with O 0 0.0011694157
the O 0 0.0008097807
Swedish O 0 0.0024977291
Cancer B-Disease 0 0.14840804
Register O 0 0.00066280505
, O 0 0.0003420077
all O 0 0.00020693721
subjects O 0 0.00021044897
in O 0 0.00013424082
this O 0 0.0002294798
cohort O 0 0.00089966966
diagnosed O 0 0.0011119541
with O 0 0.00077836186
bladder B-Disease 0 0.9104699
cancer I-Disease 0 0.99899787
were O 0 0.0014308931
identified O 0 0.0013503201
. O 0 0.0018730547

Nested O 0 0.0063995784
within O 0 0.00069738115
the O 0 0.0009919938
cohort O 0 0.0020183194
, O 0 0.00057454687
a O 0 0.00041433092
matched O 0 0.00023226014
case O 0 0.00024035989
- O 0 0.00032650612
control O 0 0.00012673631
study O 0 0.00014619424
was O 0 9.232044e-05
performed O 0 5.2125557e-05
to O 0 4.4269374e-05
estimate O 0 3.6819434e-05
the O 0 4.7616486e-05
association O 0 3.835846e-05
between O 0 6.2224e-05
cyclophosphamide B-Chemical 0 0.9986284
and O 0 0.0004825233
bladder B-Disease 0 0.96495163
cancer I-Disease 0 0.99959284
using O 0 0.00022127284
odds O 0 0.0006313915
ratios O 0 0.00030023398
( O 0 0.000365204
ORs O 0 0.000715011
) O 0 0.00043345478
as O 0 0.0003786675
relative O 0 0.0007549234
risk O 0 0.0073466226
. O 0 0.0023643237

In O 0 0.0016650979
the O 0 0.001330861
cohort O 0 0.0016816461
the O 0 0.00054681645
cumulative O 0 0.00086634984
risk O 0 0.002470756
of O 0 0.0008247017
bladder B-Disease 0 0.9365618
cancer I-Disease 0 0.99900144
after O 0 0.0001326906
Wegener B-Disease 0 0.12973951
' I-Disease 0 0.00024957827
s I-Disease 0 0.00019014065
granulomatosis I-Disease 0 0.1275576
, O 0 0.00012854899
and O 0 7.3607975e-05
the O 0 5.76644e-05
relative O 0 5.8345824e-05
prevalence O 0 8.501355e-05
of O 0 9.752708e-05
a O 0 0.00013894304
history O 0 0.00020003426
of O 0 0.00023511519
bladder B-Disease 0 0.8984307
cancer I-Disease 0 0.99833554
at O 0 6.134494e-05
the O 0 5.4855678e-05
time O 0 3.1320233e-05
of O 0 9.255572e-05
diagnosis O 0 0.00021786906
of O 0 0.0002426739
Wegener B-Disease 0 0.091705374
' I-Disease 0 0.00032416685
s I-Disease 0 0.00031236382
granulomatosis I-Disease 0 0.14519434
, O 0 0.0004385726
were O 0 0.000405602
also O 0 0.00058465166
estimated O 0 0.001221478
. O 0 0.0019798148

RESULTS O 0 0.0039635203
: O 0 0.0013725255
The O 0 0.00047211762
median O 0 0.00032025366
cumulative O 0 0.0005702765
doses O 0 0.0016395928
of O 0 0.00079517846
cyclophosphamide B-Chemical 0 0.9996449
among O 0 0.00065529894
cases O 0 0.00037802407
( O 0 0.00026445586
n O 0 0.00012944407
= O 0 0.00014635982
11 O 0 9.936057e-05
) O 0 0.00012965011
and O 0 9.360423e-05
controls O 0 0.00019543881
( O 0 0.00015720149
n O 0 9.8710654e-05
= O 0 0.00012776052
25 O 0 0.00014429247
) O 0 0.00017028122
were O 0 0.00012773371
113 O 0 0.00037809592
g O 0 0.00035750566
and O 0 0.00024817474
25 O 0 0.00048244695
g O 0 0.0010999897
, O 0 0.0011155275
respectively O 0 0.0026624836
. O 0 0.0023666685

The O 0 0.0021510292
risk O 0 0.005728225
of O 0 0.0024243237
bladder B-Disease 0 0.9179327
cancer I-Disease 0 0.99839586
doubled O 0 0.0006139533
for O 0 0.00013710799
every O 0 5.1917046e-05
10 O 0 9.2564536e-05
g O 0 0.00021606144
increment O 0 0.00015525984
in O 0 0.00020488046
cyclophosphamide B-Chemical 0 0.9995608
( O 0 0.0010333085
OR O 0 0.023285434
= O 0 0.00020236624
2 O 0 7.978492e-05
. O 0 5.5286466e-05
0 O 0 7.3852505e-05
, O 0 0.00010802257
95 O 0 0.00013917134
% O 0 0.00010408501
confidence O 0 0.00036932618
interval O 0 0.00011359407
( O 0 0.0002538428
CI O 0 0.004402681
) O 0 0.00022141046
0 O 0 0.00011033937
. O 0 9.200512e-05
8 O 0 0.000121580015
to O 0 0.00017813926
4 O 0 0.00026030827
. O 0 0.00035738264
9 O 0 0.00076554174
) O 0 0.0019496693
. O 0 0.0023485913

Treatment O 0 0.0037817333
duration O 0 0.00077973976
longer O 0 0.00050808804
than O 0 0.00037185624
1 O 0 0.00031635817
year O 0 0.0001930064
was O 0 0.00020774835
associated O 0 0.00014521589
with O 0 0.00020278714
an O 0 0.0002684122
eightfold O 0 0.001345872
increased O 0 0.0006720901
risk O 0 0.012424428
( O 0 0.00067624904
OR O 0 0.013011901
= O 0 0.00019956352
7 O 0 7.676597e-05
. O 0 6.633823e-05
7 O 0 7.8859084e-05
, O 0 0.00014804216
95 O 0 0.00023102156
% O 0 0.00022968995
CI O 0 0.0019879418
0 O 0 0.00018267812
. O 0 0.00016880126
9 O 0 0.00026908788
to O 0 0.00045247827
69 O 0 0.0012839582
) O 0 0.0020839144
. O 0 0.0023121238

The O 0 0.0017627731
absolute O 0 0.0024909817
risk O 0 0.0045547104
for O 0 0.0009272913
bladder B-Disease 0 0.8887655
cancer I-Disease 0 0.9985398
in O 0 0.00034983974
the O 0 0.00022192851
cohort O 0 0.00048746387
reached O 0 0.00013579709
10 O 0 9.660058e-05
% O 0 9.489852e-05
16 O 0 6.819046e-05
years O 0 4.5670477e-05
after O 0 2.5915728e-05
diagnosis O 0 0.00013476537
of O 0 0.00016632845
Wegener B-Disease 0 0.069763064
' I-Disease 0 0.00019397296
s I-Disease 0 0.00015813284
granulomatosis I-Disease 0 0.1311735
, O 0 0.00012342306
and O 0 8.2363855e-05
a O 0 0.000116142626
history O 0 0.00017545072
of O 0 0.00023859061
bladder B-Disease 0 0.9500488
cancer I-Disease 0 0.999813
was O 0 0.00037171858
( O 0 0.00019529743
non O 0 0.00017346306
- O 0 0.00022448205
significantly O 0 0.0001558872
) O 0 0.00012538425
twice O 0 4.854772e-05
as O 0 5.055535e-05
common O 0 6.4444794e-05
as O 0 4.9055638e-05
expected O 0 4.305562e-05
at O 0 3.906991e-05
the O 0 6.0229788e-05
time O 0 4.8945592e-05
of O 0 0.0001622454
diagnosis O 0 0.000445516
of O 0 0.0005971865
Wegener B-Disease 0 0.18389495
' I-Disease 0 0.0011436124
s I-Disease 0 0.0013000526
granulomatosis I-Disease 0 0.41781697
. O 0 0.0026432362

CONCLUSION O 0 0.014555837
: O 0 0.0017231748
The O 0 0.00055185554
results O 0 0.0005333359
indicate O 0 0.0002872931
a O 0 0.0004888906
dose O 0 0.0015616133
- O 0 0.0004160423
response O 0 0.000129211
relationship O 0 6.287301e-05
between O 0 9.671045e-05
cyclophosphamide B-Chemical 0 0.9973922
and O 0 0.00018281805
the O 0 0.00013587637
risk O 0 0.0011590538
of O 0 0.00040944648
bladder B-Disease 0 0.97520566
cancer I-Disease 0 0.99979407
, O 0 0.00022188787
high O 0 0.0002209914
cumulative O 0 0.00020708524
risks O 0 0.00024187674
in O 0 5.12865e-05
the O 0 5.023059e-05
entire O 0 5.5470675e-05
cohort O 0 0.00032403492
, O 0 8.586618e-05
and O 0 6.501893e-05
also O 0 5.557042e-05
the O 0 6.0065002e-05
possibility O 0 5.4529395e-05
of O 0 0.00015375346
risk O 0 0.0008074844
factors O 0 0.00018604279
operating O 0 0.0001895106
even O 0 0.00018638368
before O 0 0.00017150873
Wegener B-Disease 0 0.048797075
' I-Disease 0 0.0009830841
s I-Disease 0 0.0012234069
granulomatosis I-Disease 0 0.3818322
. O 0 0.0026083183

Differential O 0 0.0032445537
modulation O 0 0.0016409399
by O 0 0.0018640031
estrogen B-Chemical 1 0.9990023
of O 0 0.0025393106
alpha2 O 0 0.99491924
- O 0 0.0031264117
adrenergic O 0 0.98356307
and O 0 0.00083590625
I1 O 0 0.9736703
- O 0 0.0023946636
imidazoline B-Chemical 0 0.9999113
receptor O 0 0.11508187
- O 0 0.00077843684
mediated O 0 0.00032109843
hypotension B-Disease 0 0.99950254
in O 0 0.00096776756
female O 0 0.0036123353
rats O 0 0.0021949722
. O 0 0.0018012793

We O 0 0.0015388101
have O 0 0.00090820156
recently O 0 0.000576891
shown O 0 0.00039203116
that O 0 0.00041230494
estrogen B-Chemical 1 0.9986829
negatively O 0 0.00025119347
modulates O 0 6.612462e-05
the O 0 0.00015160583
hypotensive B-Disease 0 0.9388352
effect O 0 0.00015862394
of O 0 0.00067229546
clonidine B-Chemical 0 0.9999858
( O 0 0.00044248978
mixed O 0 0.0010714327
alpha2 O 0 0.9958121
- O 0 0.00085556105
/ O 0 0.0016561443
I1 O 0 0.9639168
- O 0 0.00062295323
receptor O 0 0.01821692
agonist O 0 0.44624075
) O 0 0.00022404862
in O 0 8.19605e-05
female O 0 0.0002850493
rats O 0 0.0001084205
and O 0 6.8174595e-05
implicates O 0 6.852329e-05
the O 0 0.000118563104
cardiovascular O 0 0.26221833
autonomic O 0 0.007584524
control O 0 0.00022683998
in O 0 0.00028610567
this O 0 0.0006544639
interaction O 0 0.0010579681
. O 0 0.0018206259

The O 0 0.0014476563
present O 0 0.0009448176
study O 0 0.00082932005
investigated O 0 0.00036054445
whether O 0 0.00016957121
this O 0 0.00030053666
effect O 0 0.000271901
of O 0 0.0007678674
estrogen B-Chemical 1 0.9997321
involves O 0 0.00014947736
interaction O 0 0.0001621155
with O 0 0.0005121737
alpha2 O 0 0.987301
- O 0 0.00076657324
and O 0 0.00031178183
/ O 0 0.00094846624
or O 0 0.00063130964
I1 O 0 0.8081811
- O 0 0.0026121442
receptors O 0 0.0064665796
. O 0 0.0023720877

Changes O 0 0.0024686933
evoked O 0 0.0038171476
by O 0 0.001038093
a O 0 0.00072653353
single O 0 0.00041957048
intraperitoneal O 0 0.0010089797
injection O 0 0.00039648017
of O 0 0.0008476158
rilmenidine B-Chemical 0 0.9999913
( O 0 0.0005183121
600 O 0 0.0005202165
microg O 0 0.0002856963
/ O 0 0.00053420936
kg O 0 0.00037940085
) O 0 0.0001681447
or O 0 0.000120537865
alpha B-Chemical 0 0.93313146
- I-Chemical 0 0.0047279317
methyldopa I-Chemical 0 0.9999988
( O 0 0.00045704373
100 O 0 0.00042112262
mg O 0 0.0064179082
/ O 0 0.0005238014
kg O 0 0.0003631266
) O 0 0.0001627499
, O 0 0.00011002859
selective O 0 0.00070910656
I1 O 0 0.9072633
- O 0 0.00034670482
and O 0 0.00021125114
alpha2 O 0 0.9894701
- O 0 0.00092861394
receptor O 0 0.038336575
agonists O 0 0.4313951
, O 0 0.00019510982
respectively O 0 0.00027026932
, O 0 8.3023704e-05
in O 0 6.0486847e-05
blood O 0 0.00068060786
pressure O 0 0.0010054036
, O 0 8.7559754e-05
hemodynamic O 0 0.0005838174
variability O 0 7.1284565e-05
, O 0 7.349743e-05
and O 0 7.1241004e-05
locomotor O 0 0.003872272
activity O 0 6.207322e-05
were O 0 5.431168e-05
assessed O 0 3.630027e-05
in O 0 5.5762273e-05
radiotelemetered O 0 0.0012699122
sham O 0 6.929065e-05
- O 0 0.00015900891
operated O 0 0.0001930294
and O 0 0.0001237764
ovariectomized O 0 0.06948712
( O 0 0.0003529182
Ovx O 0 0.55726373
) O 0 0.0003432705
Sprague O 0 0.010110582
- O 0 0.00028431645
Dawley O 0 0.0012829694
female O 0 0.00023781412
rats O 0 9.5971096e-05
with O 0 8.0270285e-05
or O 0 7.451472e-05
without O 0 0.00011146522
12 O 0 0.000119778444
- O 0 0.00041054748
wk O 0 0.0003650314
estrogen B-Chemical 1 0.998696
replacement O 0 0.009490212
. O 0 0.0022099274

Three O 0 0.0017287681
time O 0 0.00071438635
domain O 0 0.0005608751
indexes O 0 0.00058662443
of O 0 0.00045921642
hemodynamic O 0 0.0018219651
variability O 0 0.00023615475
were O 0 0.000147917
employed O 0 0.00012726565
: O 0 0.00011402383
the O 0 6.286066e-05
standard O 0 5.404973e-05
deviation O 0 0.000103401835
of O 0 6.671627e-05
mean O 0 3.8262813e-05
arterial O 0 0.004324499
pressure O 0 0.0010710958
as O 0 5.8835154e-05
a O 0 6.159148e-05
measure O 0 2.158463e-05
of O 0 7.138333e-05
blood O 0 0.0005623217
pressure O 0 0.00050953036
variability O 0 5.2008574e-05
and O 0 4.1935808e-05
the O 0 3.590678e-05
standard O 0 3.8203783e-05
deviation O 0 0.00011418628
of O 0 0.000119643744
beat O 0 0.00063929893
- O 0 0.00022857815
to O 0 8.043908e-05
- O 0 0.00018114099
beat O 0 0.00020759706
intervals O 0 4.653418e-05
( O 0 0.00013057866
SDRR O 0 0.007584222
) O 0 0.00010534103
and O 0 5.116047e-05
the O 0 4.8515696e-05
root O 0 0.00016550483
mean O 0 3.0363937e-05
square O 0 0.000102663
of O 0 7.0684146e-05
successive O 0 5.5298016e-05
differences O 0 4.0934065e-05
in O 0 0.00014997662
R O 0 0.96184963
- O 0 0.00061955815
wave O 0 0.0015509895
- O 0 0.00039342119
to O 0 0.00016789557
- O 0 0.00091635564
R O 0 0.9352433
- O 0 0.00041498392
wave O 0 0.0004065566
intervals O 0 7.110912e-05
as O 0 9.0201815e-05
measures O 0 9.06121e-05
of O 0 0.0003347033
heart O 0 0.009421602
rate O 0 0.0009260173
variability O 0 0.0013394398
. O 0 0.0018268959

In O 0 0.0018639785
sham O 0 0.0013990427
- O 0 0.0017552861
operated O 0 0.0012446743
rats O 0 0.00085158256
, O 0 0.00084133167
rilmenidine B-Chemical 0 0.9999801
or O 0 0.0007150494
alpha B-Chemical 0 0.98939484
- I-Chemical 0 0.00784713
methyldopa I-Chemical 0 0.9999981
elicited O 0 0.00024226909
similar O 0 0.00013274972
hypotension B-Disease 0 0.9984623
that O 0 5.6332552e-05
lasted O 0 2.8324797e-05
at O 0 3.1830772e-05
least O 0 4.0218994e-05
5 O 0 3.871438e-05
h O 0 4.5123703e-05
and O 0 6.865843e-05
was O 0 7.593118e-05
associated O 0 5.8632344e-05
with O 0 8.8917805e-05
reductions O 0 0.00011478913
in O 0 7.4097574e-05
standard O 0 8.598155e-05
deviation O 0 0.00023173966
of O 0 0.00025184263
mean O 0 0.00026789293
arterial O 0 0.03824734
pressure O 0 0.017870316
. O 0 0.0021137313

SDRR O 0 0.07878751
was O 0 0.004412763
reduced O 0 0.0038402264
only O 0 0.0031840012
by O 0 0.004594919
alpha B-Chemical 0 0.9735522
- I-Chemical 0 0.088063225
methyldopa I-Chemical 0 0.9999633
. O 0 0.013210011

Ovx O 0 0.60151535
significantly O 0 0.0021549081
enhanced O 0 0.0012586477
the O 0 0.0008574111
hypotensive B-Disease 0 0.9493638
response O 0 0.00057972857
to O 0 0.000539293
alpha B-Chemical 0 0.9893828
- I-Chemical 0 0.026602468
methyldopa I-Chemical 0 0.99999857
, O 0 0.00059372117
in O 0 0.00017396329
contrast O 0 0.00025705717
to O 0 0.00014749715
no O 0 0.00013688239
effect O 0 0.00033445994
on O 0 0.0008588703
rilmenidine B-Chemical 0 0.9999844
hypotension B-Disease 0 0.99989104
. O 0 0.004525

The O 0 0.0018571448
enhanced O 0 0.003205948
alpha B-Chemical 0 0.9750821
- I-Chemical 0 0.04935003
methyldopa I-Chemical 0 0.9999981
hypotension B-Disease 0 0.9999695
in O 0 0.0019421295
Ovx O 0 0.9424321
rats O 0 0.00049162627
was O 0 0.00016478928
paralleled O 0 0.00016216682
with O 0 0.00014669976
further O 0 0.00019676657
reduction O 0 0.00044019843
in O 0 0.00023020098
SDRR O 0 0.019907625
and O 0 0.00025320295
a B-Disease 0 0.0004411778
reduced I-Disease 0 0.0010556104
locomotor I-Disease 0 0.09990292
activity I-Disease 0 0.0017677961
. O 0 0.002205602

Estrogen O 0 0.9995067
replacement O 0 0.03541042
( O 0 0.008108532
17beta B-Chemical 0 0.9998877
- I-Chemical 0 0.017705888
estradiol I-Chemical 0 0.99994147
subcutaneous O 0 0.004545026
pellet O 0 0.00055282505
, O 0 0.00023916454
14 O 0 0.00011543423
. O 0 6.4604894e-05
2 O 0 6.2766194e-05
microg O 0 0.00015796829
/ O 0 0.00027070285
day O 0 5.9719405e-05
, O 0 7.851571e-05
12 O 0 3.548792e-05
wk O 0 3.619736e-05
) O 0 0.0001062116
of O 0 0.00013943996
Ovx O 0 0.33219725
rats O 0 0.00013654993
restored O 0 9.554219e-05
the O 0 6.5916865e-05
hemodynamic O 0 0.00075523
and O 0 9.1878595e-05
locomotor O 0 0.0040946854
effects O 0 0.00012348591
of O 0 0.0003518484
alpha B-Chemical 0 0.98434883
- I-Chemical 0 0.009804122
methyldopa I-Chemical 0 0.9999976
to O 0 0.00043163582
sham O 0 0.0003797506
- O 0 0.0009150233
operated O 0 0.0015151859
levels O 0 0.0015208306
. O 0 0.0021014141

These O 0 0.002059506
findings O 0 0.0017359243
suggest O 0 0.0005265719
that O 0 0.0007780097
estrogen B-Chemical 1 0.99962485
downregulates O 0 0.0021413106
alpha2 O 0 0.9985292
- O 0 0.001445817
but O 0 0.00027839592
not O 0 0.0002858151
I1 O 0 0.9621096
- O 0 0.00082116824
receptor O 0 0.010592354
- O 0 0.00032931936
mediated O 0 0.00010299471
hypotension B-Disease 0 0.9993813
and O 0 0.00012373533
highlight O 0 4.2295098e-05
a O 0 7.561989e-05
role O 0 3.1693737e-05
for O 0 3.8684448e-05
the O 0 6.94944e-05
cardiac O 0 0.0033619232
autonomic O 0 0.0027959128
control O 0 0.000109175875
in O 0 0.00019102523
alpha B-Chemical 0 0.95808643
- I-Chemical 0 0.018001474
methyldopa I-Chemical 0 0.9999981
- O 0 0.030025886
estrogen B-Chemical 1 0.999691
interaction O 0 0.0022212658
. O 0 0.002197106

Severe O 0 0.049200773
reversible O 0 0.016686793
left B-Disease 0 0.0033444862
ventricular I-Disease 0 0.68801445
systolic I-Disease 0 0.19568889
and I-Disease 0 0.0008552647
diastolic I-Disease 0 0.9883078
dysfunction I-Disease 0 0.980923
due O 0 0.0003139036
to O 0 0.00042645962
accidental O 0 0.15423723
iatrogenic O 0 0.78635937
epinephrine B-Chemical 0 0.99984276
overdose B-Disease 0 0.9998777
. O 0 0.004486218

Catecholamine B-Chemical 0 0.9970867
- O 0 0.0068826624
induced O 0 0.004073003
cardiomyopathy B-Disease 0 0.9998528
due O 0 0.00052506156
to O 0 0.0004505337
chronic O 0 0.045971457
excess O 0 0.0010682915
of O 0 0.0003740749
endogenous O 0 0.0006005015
catecholamines B-Chemical 0 0.99928194
has O 0 0.00016710325
been O 0 0.00011095016
recognized O 0 0.00014176847
for O 0 0.00013610952
decades O 0 0.0002500427
as O 0 0.00025040176
a O 0 0.0006411001
clinical O 0 0.0022324105
phenomenon O 0 0.005008107
. O 0 0.0022424958

In O 0 0.0021288535
contrast O 0 0.0021164727
, O 0 0.0013837755
reports O 0 0.001041376
of O 0 0.0018624301
myocardial B-Disease 0 0.99987555
dysfunction I-Disease 0 0.9990086
due O 0 0.0005326724
to O 0 0.0006580734
acute O 0 0.77799946
iatrogenic O 0 0.9054537
overdose B-Disease 0 0.99991703
are O 0 0.0029418054
rare O 0 0.010025503
. O 0 0.0026971956

A O 0 0.021675456
35 O 0 0.0027545162
- O 0 0.0023778668
year O 0 0.00069905794
- O 0 0.000918787
old O 0 0.00046203396
woman O 0 0.00083846145
whose O 0 0.0006791315
cervix O 0 0.034312546
uteri O 0 0.0027605365
was O 0 0.00013692492
inadvertently O 0 0.00017427892
injected O 0 6.564906e-05
with O 0 7.708132e-05
8 O 0 5.0114562e-05
mg O 0 0.00066695135
of O 0 0.00017138693
epinephrine B-Chemical 0 0.99708456
developed O 0 0.0006693514
myocardial B-Disease 0 0.99912196
stunning I-Disease 0 0.39289638
that O 0 8.1142396e-05
was O 0 0.000109873836
characterized O 0 0.00018555982
by O 0 9.6050746e-05
severe O 0 0.0017893619
hemodynamic O 0 0.0064250063
compromise O 0 0.0002737919
, O 0 0.00013049463
profound O 0 0.0007881393
, O 0 0.00018370416
albeit O 0 0.0006078618
transient O 0 0.0012948008
, O 0 9.968477e-05
left B-Disease 0 0.00026018624
ventricular I-Disease 0 0.45685458
systolic I-Disease 0 0.09498997
and I-Disease 0 0.00016492873
diastolic I-Disease 0 0.9934916
dysfunction I-Disease 0 0.9944976
, O 0 0.00020411027
and O 0 0.00010850572
only O 0 0.00013718578
modestly O 0 0.0017845586
elevated O 0 0.0015439139
biochemical O 0 0.0014371228
markers O 0 0.0011925481
of O 0 0.0019692108
myocardial B-Disease 0 0.9999224
necrosis I-Disease 2 0.999936
. O 0 0.0060364776

Our O 0 0.002423882
case O 0 0.0013723648
illustrates O 0 0.000669302
the O 0 0.00061346754
serious O 0 0.001419351
consequences O 0 0.0005396861
of O 0 0.00049776526
medical O 0 0.0010835191
errors O 0 0.0007856457
that O 0 0.00012489954
can O 0 0.00010585953
be O 0 0.00010333637
avoided O 0 0.00010288134
through O 0 9.432058e-05
improved O 0 0.00036217066
medication O 0 0.0013722575
labeling O 0 0.00051023555
and O 0 0.00056138006
staff O 0 0.001576107
supervision O 0 0.003036498
. O 0 0.0020236657

Cardioprotective O 0 0.31728733
effect O 0 0.0020269349
of O 0 0.0027587132
tincture B-Chemical 0 0.9907025
of I-Chemical 0 0.0025506648
Crataegus I-Chemical 0 0.9866642
on O 0 0.0008213847
isoproterenol B-Chemical 0 0.99983394
- O 0 0.002739606
induced O 0 0.002099859
myocardial B-Disease 0 0.9998111
infarction I-Disease 2 0.9999752
in O 0 0.002825993
rats O 0 0.0039815307
. O 0 0.0023306643

Tincture B-Chemical 0 0.972637
of I-Chemical 0 0.005591797
Crataegus I-Chemical 0 0.9906929
( O 0 0.0063141133
TCR B-Chemical 0 0.98874915
) O 0 0.0017523591
, O 0 0.000598038
an O 0 0.0007667471
alcoholic B-Chemical 0 0.9994942
extract I-Chemical 0 0.0071054786
of I-Chemical 0 0.00033871422
the I-Chemical 0 0.00027221948
berries I-Chemical 0 0.87652683
of I-Chemical 0 0.0006206869
hawthorn I-Chemical 0 0.9882057
( O 0 0.0012109879
Crataegus B-Chemical 0 0.9972435
oxycantha I-Chemical 0 0.9745273
) O 0 0.0006504807
, O 0 0.00020593984
is O 0 0.00014148904
used O 0 0.00013772212
in O 0 0.00025265868
herbal O 0 0.10781451
and O 0 0.00091629016
homeopathic O 0 0.030262696
medicine O 0 0.008489576
. O 0 0.0024935033

The O 0 0.0015696805
present O 0 0.0010940228
study O 0 0.0011133766
was O 0 0.00064677134
done O 0 0.00031562938
to O 0 0.00021477323
investigate O 0 0.00012832679
the O 0 0.0002094357
protective O 0 0.00062434416
effect O 0 0.00024901994
of O 0 0.00069996394
TCR B-Chemical 0 0.97742665
on O 0 0.00018293121
experimentally O 0 0.00043470427
induced O 0 0.001244445
myocardial B-Disease 0 0.9998441
infarction I-Disease 2 0.99998105
in O 0 0.0023972644
rats O 0 0.003484161
. O 0 0.002022137

Pretreatment O 0 0.12378596
of O 0 0.005411328
TCR B-Chemical 0 0.96875393
, O 0 0.0012381219
at O 0 0.00039321333
a O 0 0.0005167067
dose O 0 0.0010710103
of O 0 0.00036258728
0 O 0 0.00018905272
. O 0 9.558347e-05
5 O 0 9.0450834e-05
mL O 0 0.00034944608
/ O 0 0.00027257582
100 O 0 0.0002274752
g O 0 0.00026161328
bodyweight O 0 0.00072676304
per O 0 2.7592787e-05
day O 0 3.662302e-05
, O 0 6.16409e-05
orally O 0 0.000120532575
for O 0 3.813302e-05
30 O 0 3.8180147e-05
days O 0 2.541143e-05
, O 0 6.446827e-05
prevented O 0 0.00015525895
the O 0 7.367342e-05
increase O 0 8.953809e-05
in O 0 0.00015206331
lipid O 0 0.9646684
peroxidation O 0 0.9999949
and O 0 0.00017213146
activity O 0 7.390986e-05
of O 0 0.00011593714
marker O 0 0.0002024863
enzymes O 0 0.0007576859
observed O 0 6.93995e-05
in O 0 0.000149725
isoproterenol B-Chemical 0 0.999892
- O 0 0.00049571175
induced O 0 0.00013805187
rats O 0 0.00018598887
( O 0 0.00010936842
85 O 0 0.00013718814
mg O 0 0.0026289145
kg O 0 0.00037168793
( O 0 0.00018155895
- O 0 0.00019230304
1 O 0 7.815886e-05
) O 0 0.00012495494
s O 0 9.2964285e-05
. O 0 7.1192655e-05
c O 0 0.00046883748
. O 0 5.680446e-05
for O 0 5.599524e-05
2 O 0 5.970078e-05
days O 0 3.5324403e-05
at O 0 5.9951868e-05
an O 0 0.00015848833
interval O 0 0.00015699492
of O 0 0.0002960593
24 O 0 0.0003559328
h O 0 0.00068553933
) O 0 0.0019277041
. O 0 0.0021324402

TCR B-Chemical 0 0.9436955
prevented O 0 0.0067640683
the O 0 0.003078064
isoproterenol B-Chemical 0 0.9997769
- O 0 0.0029521133
induced O 0 0.0006282509
decrease O 0 0.0006136473
in O 0 0.00048753727
antioxidant O 0 0.9985631
enzymes O 0 0.0066123474
in O 0 0.00012305642
the O 0 0.00012207538
heart O 0 0.00953298
and O 0 0.00011828059
increased O 0 0.00014469436
the O 0 8.478411e-05
rate O 0 0.00013390383
of O 0 0.00048092924
ADP B-Chemical 0 0.99976176
- O 0 0.0006519637
stimulated O 0 0.00028979426
oxygen B-Chemical 1 0.9904158
uptake O 0 0.0032919813
and O 0 0.00044844998
respiratory O 0 0.007104563
coupling O 0 0.0019029513
ratio O 0 0.002249971
. O 0 0.001960244

TCR B-Chemical 0 0.8589318
protected O 0 0.0034959435
against O 0 0.0014423623
pathological O 0 0.0075735804
changes O 0 0.0015186685
induced O 0 0.0014381546
by O 0 0.0019083977
isoproterenol B-Chemical 0 0.99925894
in O 0 0.0020419639
rat O 0 0.006234431
heart O 0 0.21552703
. O 0 0.0036397043

The O 0 0.0014399949
results O 0 0.0011429448
show O 0 0.0006090169
that O 0 0.0004951858
pretreatment O 0 0.02446948
with O 0 0.0017342021
TCR B-Chemical 0 0.98431396
may O 0 0.00032313872
be O 0 0.00018154459
useful O 0 0.00012758291
in O 0 0.00012690827
preventing O 0 0.0002447979
the O 0 0.00025493666
damage O 0 0.074340425
induced O 0 0.0005771151
by O 0 0.0008320517
isoproterenol B-Chemical 0 0.99960643
in O 0 0.0009844792
rat O 0 0.0037278964
heart O 0 0.16202231
. O 0 0.0023399221

Treatment O 0 0.0044150255
of O 0 0.0025105653
tinnitus B-Disease 2 0.9851613
by O 0 0.0013449341
intratympanic O 0 0.8890909
instillation O 0 0.0028466226
of O 0 0.0021424303
lignocaine B-Chemical 0 0.9999571
( O 0 0.003724082
lidocaine B-Chemical 0 0.9998729
) O 0 0.00061633595
2 O 0 0.00015273935
per O 0 8.767682e-05
cent O 0 0.0002241328
through O 0 0.000325003
ventilation O 0 0.0014355015
tubes O 0 0.0024853
. O 0 0.0020976686

Idiopathic B-Disease 0 0.5622576
subjective I-Disease 0 0.010532067
tinnitus I-Disease 2 0.9993679
( O 0 0.0068977536
IST B-Disease 0 0.8215493
) O 0 0.0013638311
is O 0 0.00046881914
one O 0 0.00029002532
of O 0 0.00044859172
the O 0 0.000482809
most O 0 0.0010888852
obscure O 0 0.0034867295
otological O 0 0.1419862
pathologies O 0 0.21702574
. O 0 0.003601359

This O 0 0.0033312344
paper O 0 0.0016155934
presents O 0 0.00081983436
the O 0 0.0004582207
results O 0 0.00036629397
of O 0 0.0004375525
treating O 0 0.0010026982
IST B-Disease 0 0.5358909
by O 0 0.00027889194
intratympanic O 0 0.78150004
instillation O 0 0.0010906585
of O 0 0.001034934
lignocaine B-Chemical 0 0.9999746
( O 0 0.0021951497
lidocaine B-Chemical 0 0.99992394
) O 0 0.00031212537
2 O 0 5.6530273e-05
per O 0 2.5660063e-05
cent O 0 5.5690904e-05
through O 0 6.140769e-05
a O 0 0.00019567936
grommet O 0 0.007550432
, O 0 0.00024098589
for O 0 0.0001709652
five O 0 0.00022018881
weekly O 0 0.00054325396
courses O 0 0.0011004914
. O 0 0.00176305

Fifty O 0 0.006169293
- O 0 0.0023651426
two O 0 0.00059848337
patients O 0 0.0008453396
suffering O 0 0.0055795712
from O 0 0.00031853415
intractable O 0 0.014448762
tinnitus B-Disease 2 0.9944284
entered O 0 0.0002666695
this O 0 0.000192185
therapeutic O 0 0.00038551562
trial O 0 0.00027327106
, O 0 0.00017712743
but O 0 0.00015776989
only O 0 0.00018599276
nine O 0 0.00021610843
finished O 0 0.00031592566
all O 0 0.00034439124
five O 0 0.0004017485
courses O 0 0.0011582705
. O 0 0.0018401799

In O 0 0.0017218776
one O 0 0.0010690327
patient O 0 0.0010513645
, O 0 0.00077126716
the O 0 0.0006567952
tinnitus B-Disease 2 0.9921489
was O 0 0.00056390074
almost O 0 0.0002848526
completely O 0 0.00035689014
abolished O 0 0.0006097604
, O 0 0.00024302864
but O 0 0.00013444245
in O 0 7.880519e-05
all O 0 6.967721e-05
the O 0 6.840017e-05
nine O 0 8.324108e-05
patients O 0 0.00013577197
the O 0 0.00019027086
decompensated O 0 0.9992736
tinnitus B-Disease 2 0.99943906
changed O 0 0.00053167006
to O 0 0.00034054127
a O 0 0.0008098068
compensated O 0 0.004585868
one O 0 0.0012407084
. O 0 0.001958777

We O 0 0.0013515764
suggest O 0 0.000639828
this O 0 0.00075007946
mode O 0 0.0006073046
of O 0 0.00048402598
treatment O 0 0.00030085945
for O 0 0.00016557571
patients O 0 0.00021894254
that O 0 9.154723e-05
were O 0 0.00011761284
previously O 0 9.997054e-05
treated O 0 0.00018537328
by O 0 0.00017125675
drugs O 0 0.00920897
, O 0 0.00021495554
acupuncture O 0 0.0004201076
and O 0 0.00020014873
biofeedback O 0 0.00067641697
, O 0 0.0003436759
with O 0 0.000548057
disappointing O 0 0.002252564
results O 0 0.0016108573
. O 0 0.0021669907

Patients O 0 0.0025264334
should O 0 0.0008131508
be O 0 0.00072723074
warned O 0 0.0010987609
about O 0 0.00037394837
the O 0 0.00031808385
side O 0 0.0015131445
effects O 0 0.00031707136
of O 0 0.0008960987
vertigo B-Disease 0 0.9999578
and O 0 0.0026502914
vomiting B-Disease 0 0.99987435
, O 0 0.0002989373
which O 0 0.00016898644
subsides O 0 0.000154638
gradually O 0 0.00011978119
with O 0 6.3447485e-05
every O 0 1.9139901e-05
new O 0 7.0572205e-05
instillation O 0 0.0002307233
, O 0 9.041979e-05
and O 0 5.8749712e-05
that O 0 4.3213575e-05
the O 0 0.00011548981
tinnitus B-Disease 2 0.99239326
may O 0 0.000101104095
not O 0 8.62111e-05
disappear O 0 0.00017942445
but O 0 9.436717e-05
will O 0 6.553828e-05
be O 0 7.8547324e-05
alleviated O 0 0.0015349363
, O 0 0.00012002083
enabling O 0 0.000110297726
them O 0 0.00014595731
to O 0 6.109915e-05
cope O 0 0.00014626633
more O 0 0.00013183667
easily O 0 0.0001004852
with O 0 0.00011568159
the O 0 0.00015538796
disease O 0 0.032837722
and O 0 0.0002459663
lead O 0 0.0012361459
a O 0 0.00042110254
more O 0 0.00061986345
normal O 0 0.0015731618
life O 0 0.0017465
. O 0 0.0018953478

The O 0 0.0027053682
alpha3 O 0 0.93214554
and O 0 0.0037661057
beta4 O 0 0.99923515
nicotinic O 0 0.99996996
acetylcholine B-Chemical 1 0.9999765
receptor O 0 0.2907357
subunits O 0 0.0018842681
are O 0 0.00015211989
necessary O 0 8.33286e-05
for O 0 0.00018929767
nicotine B-Chemical 1 0.9994112
- O 0 0.0011018824
induced O 0 0.0009831033
seizures B-Disease 0 0.9999554
and O 0 0.003683192
hypolocomotion B-Disease 0 0.9999186
in O 0 0.0013154411
mice O 0 0.0011629547
. O 0 0.0018861296

Binding O 0 0.002629142
of O 0 0.0026061705
nicotine B-Chemical 1 0.99788624
to O 0 0.0025737993
nicotinic O 0 0.99994385
acetylcholine B-Chemical 1 0.99997354
receptors O 0 0.13459681
( O 0 0.0014192773
nAChRs O 0 0.91811657
) O 0 0.0002652705
elicits O 0 7.955905e-05
a O 0 0.00013376244
series O 0 0.00014076331
of O 0 0.00015567863
dose O 0 0.00088911114
- O 0 0.00020039488
dependent O 0 3.9225626e-05
behaviors O 0 0.00017897795
that O 0 4.881903e-05
go O 0 9.6905416e-05
from O 0 5.1037478e-05
altered O 0 0.00011489501
exploration O 0 0.00019225867
, O 0 0.00018032022
sedation O 0 0.024771513
, O 0 0.00020554257
and O 0 0.00033491975
tremors B-Disease 2 0.9993679
, O 0 0.0006366923
to O 0 0.0006640668
seizures B-Disease 0 0.99987006
and O 0 0.004420063
death B-Disease 0 0.9930911
. O 0 0.0032942067

nAChRs O 0 0.8862464
are O 0 0.0031388423
pentameric O 0 0.013144198
ion O 0 0.14454876
channels O 0 0.005446399
usually O 0 0.00081978017
composed O 0 0.0005739912
of O 0 0.0011151566
alpha O 0 0.347178
and O 0 0.0025586719
beta O 0 0.8999147
subunits O 0 0.016788105
. O 0 0.004078558

A O 0 0.015265113
gene O 0 0.0025462504
cluster O 0 0.0012633059
comprises O 0 0.00068860286
the O 0 0.00097310194
alpha3 O 0 0.98746455
, O 0 0.0019064995
alpha5 O 0 0.9992712
and O 0 0.0016508154
beta4 O 0 0.9979175
subunits O 0 0.004557989
, O 0 0.0004218965
which O 0 0.000467019
coassemble O 0 0.0018233913
to O 0 0.0002993585
form O 0 0.0004578348
functional O 0 0.001024731
receptors O 0 0.00543796
. O 0 0.0022547634

We O 0 0.0014060951
examined O 0 0.0007745034
the O 0 0.00061025174
role O 0 0.0003324445
of O 0 0.0005227943
the O 0 0.0006402031
beta4 O 0 0.99337536
subunits O 0 0.005135721
in O 0 0.000546438
nicotine B-Chemical 1 0.99982387
- O 0 0.001072879
induced O 0 0.0005556843
seizures B-Disease 0 0.9999732
and O 0 0.00134953
hypolocomotion B-Disease 0 0.9999821
in O 0 0.000566785
beta4 O 0 0.99873585
homozygous O 0 0.02764636
null O 0 0.00032578848
( O 0 0.0006419469
beta4 O 0 0.9979533
- O 0 0.0009195813
/ O 0 0.0008865724
- O 0 0.00039297948
) O 0 0.0002602785
and O 0 0.00028592028
alpha3 O 0 0.98726904
heterozygous O 0 0.014652662
( O 0 0.0006829281
+ O 0 0.0008975086
/ O 0 0.0016400372
- O 0 0.0013528396
) O 0 0.001313588
mice O 0 0.0011716578
. O 0 0.0021704198

beta4 O 0 0.9934041
- O 0 0.009173865
/ O 0 0.00557351
- O 0 0.0016413649
mice O 0 0.0003468025
were O 0 0.00029280476
less O 0 0.00020894581
sensitive O 0 0.00014338108
to O 0 0.00010802823
the O 0 0.000102261416
effects O 0 0.00014466871
of O 0 0.00034985575
nicotine B-Chemical 1 0.9983883
both O 0 0.00013578233
at O 0 6.336259e-05
low O 0 0.00026897603
doses O 0 0.0011368131
, O 0 0.000114549766
measured O 0 6.515603e-05
as O 0 6.715741e-05
decreased O 0 0.00017923703
exploration O 0 0.0001459224
in O 0 6.1004837e-05
an O 0 9.498905e-05
open O 0 0.00015570952
field O 0 0.0001174443
, O 0 8.6528686e-05
and O 0 6.5235494e-05
at O 0 4.6948266e-05
high O 0 0.00020969546
doses O 0 0.0008693906
, O 0 0.00012933859
measured O 0 8.903175e-05
as O 0 0.00012032438
sensitivity O 0 0.00082665845
to O 0 0.0004985359
nicotine B-Chemical 1 0.99955887
- O 0 0.0029435838
induced O 0 0.003639075
seizures B-Disease 0 0.99987125
. O 0 0.0042128866

Using O 0 0.0016246901
in O 0 0.0012492858
situ O 0 0.0012590518
hybridization O 0 0.00058295997
probes O 0 0.00034950202
for O 0 0.00018124415
the O 0 0.0003410904
alpha3 O 0 0.98244894
and O 0 0.0008841807
alpha5 O 0 0.9996817
subunits O 0 0.003592718
, O 0 0.000153207
we O 0 4.592729e-05
showed O 0 8.802498e-05
that O 0 0.000118033044
alpha5 O 0 0.99890995
mRNA O 0 0.0003749995
levels O 0 0.000109287634
are O 0 7.540868e-05
unchanged O 0 9.6711185e-05
, O 0 0.000109182845
whereas O 0 0.00016964336
alpha3 O 0 0.9796052
mRNA O 0 0.00025465753
levels O 0 8.733077e-05
are O 0 5.8794158e-05
selectively O 0 7.6293945e-05
decreased O 0 0.0001491206
in O 0 5.6640565e-05
the O 0 7.9937534e-05
mitral O 0 0.0055740704
cell O 0 0.00031856028
layer O 0 0.00022252009
of O 0 8.425001e-05
the O 0 7.433324e-05
olfactory O 0 0.00051565625
bulb O 0 0.016486805
, O 0 8.515432e-05
and O 0 5.705098e-05
the O 0 5.7907146e-05
inferior O 0 0.00034003006
and O 0 7.4656185e-05
the O 0 7.445342e-05
superior O 0 0.00019434614
colliculus O 0 0.0006834026
of O 0 0.0006081626
beta4 O 0 0.9952996
- O 0 0.002088977
/ O 0 0.0024342567
- O 0 0.0018397614
brains O 0 0.004544638
. O 0 0.0022352876

alpha3 O 0 0.9900956
+ O 0 0.0085703395
/ O 0 0.005380473
- O 0 0.0015660684
mice O 0 0.00033505898
were O 0 0.0002945311
partially O 0 0.0003145255
resistant O 0 0.00030680126
to O 0 0.0003832816
nicotine B-Chemical 1 0.9996631
- O 0 0.0012112857
induced O 0 0.00066079054
seizures B-Disease 0 0.9999087
when O 0 0.00017793827
compared O 0 0.00014107209
to O 0 0.0002218115
wild O 0 0.00047638052
- O 0 0.0008373524
type O 0 0.0007857816
littermates O 0 0.0010197734
. O 0 0.0018816072

mRNA O 0 0.0032363846
levels O 0 0.0013257659
for O 0 0.00077369314
the O 0 0.0011463331
alpha5 O 0 0.9923113
and O 0 0.00075234874
the O 0 0.0007111605
beta4 O 0 0.98896897
subunits O 0 0.0020468459
were O 0 0.00028767242
unchanged O 0 0.00031674537
in O 0 0.00046657133
alpha3 O 0 0.9835101
+ O 0 0.0022105542
/ O 0 0.002814341
- O 0 0.0021307364
brains O 0 0.0049885996
. O 0 0.0025219352

Together O 0 0.0055333623
, O 0 0.0021002996
these O 0 0.001082723
results O 0 0.00056612055
suggest O 0 0.00021696939
that O 0 0.00023654569
the O 0 0.00046702783
beta4 O 0 0.9760434
and O 0 0.00038513468
the O 0 0.00040793832
alpha3 O 0 0.9899294
subunits O 0 0.00142247
are O 0 0.00015921022
mediators O 0 0.00036294624
of O 0 0.00066057174
nicotine B-Chemical 1 0.9996958
- O 0 0.0016268503
induced O 0 0.0016380373
seizures B-Disease 0 0.999944
and O 0 0.010727635
hypolocomotion B-Disease 0 0.99989223
. O 0 0.003936381

The O 0 0.0021054838
effects O 0 0.002390939
of O 0 0.0037754816
sevoflurane B-Chemical 1 0.99905735
on O 0 0.0030686113
lidocaine B-Chemical 0 0.9997211
- O 0 0.010607737
induced O 0 0.009746408
convulsions B-Disease 0 0.9996903
. O 0 0.00907746

The O 0 0.0014299178
influence O 0 0.00090356724
of O 0 0.0019413807
sevoflurane B-Chemical 1 0.9992275
on O 0 0.0013551661
lidocaine B-Chemical 0 0.9998729
- O 0 0.0037674878
induced O 0 0.0022547354
convulsions B-Disease 0 0.9998635
was O 0 0.0018186175
studied O 0 0.0011724707
in O 0 0.0011164423
cats O 0 0.0029558712
. O 0 0.0026176237

The O 0 0.0030888228
convulsive B-Disease 2 0.9953223
threshold O 0 0.0015954023
( O 0 0.0011155445
mean O 0 0.00036149012
+ O 0 0.0010765485
/ O 0 0.0016019386
- O 0 0.0011537217
SD O 0 0.004577546
) O 0 0.0005348509
was O 0 0.00029473339
41 O 0 0.0003624183
. O 0 0.00013604671
4 O 0 0.00016078571
+ O 0 0.00044527612
/ O 0 0.00082920864
- O 0 0.0006235021
6 O 0 0.00027310828
. O 0 0.00035994468
5 O 0 0.00070669415
mg O 0 0.0069498313
. O 0 0.0027265497

l O 0 0.009726271
( O 0 0.003710802
- O 0 0.0023462668
1 O 0 0.00077452627
) O 0 0.00087528955
with O 0 0.0008314933
lidocaine B-Chemical 0 0.9996358
infusion O 0 0.002391624
( O 0 0.00040201854
6 O 0 0.00012088272
mg O 0 0.0017281296
. O 0 0.00011988792
kg O 0 0.00041572016
( O 0 0.00025710033
- O 0 0.00027514977
1 O 0 0.000111610076
) O 0 0.00016005729
. O 0 6.423257e-05
min O 0 0.00014369066
( O 0 0.00022515988
- O 0 0.00027149558
1 O 0 0.000121097764
) O 0 0.00021954543
) O 0 0.00019564318
, O 0 0.00012209936
increasing O 0 0.00013048158
significantly O 0 0.00016739382
to O 0 0.00010940754
66 O 0 0.00021041931
. O 0 8.21986e-05
6 O 0 9.128692e-05
+ O 0 0.00031885013
/ O 0 0.00065711956
- O 0 0.0005282643
10 O 0 0.00032669512
. O 0 0.000363002
9 O 0 0.0007675461
mg O 0 0.0069814227
. O 0 0.0025109714

l O 0 0.011082598
( O 0 0.004412113
- O 0 0.0028947336
1 O 0 0.00094028335
) O 0 0.0008257597
when O 0 0.00026429884
the O 0 0.00029877058
end O 0 0.00021170019
- O 0 0.0005414245
tidal O 0 0.0026297148
concentration O 0 0.00073893607
of O 0 0.0010166294
sevoflurane B-Chemical 1 0.9997062
was O 0 0.00078481954
0 O 0 0.0004165719
. O 0 0.00039299464
8 O 0 0.0006842011
% O 0 0.0015071083
. O 0 0.0022214605

However O 0 0.0029091614
, O 0 0.0019904096
the O 0 0.0010278289
threshold O 0 0.00084869313
( O 0 0.0009901102
61 O 0 0.0007167462
. O 0 0.00024125235
6 O 0 0.00018276036
+ O 0 0.0004799947
/ O 0 0.000763453
- O 0 0.00041951428
8 O 0 0.00012256738
. O 0 7.995675e-05
7 O 0 8.540129e-05
mg O 0 0.0011213147
. O 0 0.0001028167
l O 0 0.0004408176
( O 0 0.00026212534
- O 0 0.00028248754
1 O 0 0.00011120448
) O 0 0.00017663158
) O 0 0.00012773943
during O 0 4.226768e-05
1 O 0 6.391686e-05
. O 0 4.351787e-05
6 O 0 4.424692e-05
% O 0 0.00012590556
sevoflurane B-Chemical 1 0.99796486
was O 0 0.00013795792
not O 0 6.623197e-05
significant O 0 6.113144e-05
from O 0 4.41299e-05
that O 0 4.0339644e-05
during O 0 3.799802e-05
0 O 0 6.839266e-05
. O 0 5.74647e-05
8 O 0 8.7032655e-05
% O 0 0.0002400569
sevoflurane B-Chemical 1 0.99792695
, O 0 0.00045536924
indicating O 0 0.00029863845
a O 0 0.0008128401
celling O 0 0.0031804012
effect O 0 0.0016712458
. O 0 0.0025249238

There O 0 0.0030059628
was O 0 0.0018386442
no O 0 0.0006913728
significant O 0 0.0006333409
difference O 0 0.00030786515
in O 0 0.00036388653
the O 0 0.00055125536
convulsive B-Disease 2 0.9985997
threshold O 0 0.0007135957
between O 0 0.00065740896
sevoflurane B-Chemical 1 0.99953187
and O 0 0.006843913
enflurane B-Chemical 1 0.9998344
. O 0 0.004609984

The O 0 0.0015934348
rise O 0 0.001731425
in O 0 0.0008964182
blood O 0 0.0030661498
pressure O 0 0.0035239055
became O 0 0.0005181543
less O 0 0.00025947372
marked O 0 0.0002921378
when O 0 8.045819e-05
higher O 0 0.00013506564
concentrations O 0 0.00033202354
of O 0 0.00040229995
sevoflurane B-Chemical 1 0.9999267
or O 0 0.00051469775
enflurane B-Chemical 1 0.99998367
were O 0 0.000114800074
administered O 0 7.159412e-05
and O 0 5.0692117e-05
the O 0 5.2319876e-05
blood O 0 0.0005639438
pressure O 0 0.0009570769
at O 0 8.372111e-05
convulsions B-Disease 0 0.9998281
decreased O 0 0.0008074975
significantly O 0 0.00020723772
in O 0 8.059657e-05
1 O 0 5.9142803e-05
. O 0 3.6229376e-05
6 O 0 3.8885883e-05
% O 0 0.0001233767
sevoflurane B-Chemical 1 0.9986609
, O 0 0.00017313752
and O 0 0.00010644825
in O 0 8.93145e-05
0 O 0 8.614059e-05
. O 0 6.5312306e-05
8 O 0 8.457006e-05
% O 0 0.000137216
and O 0 0.00017598068
1 O 0 0.00020077566
. O 0 0.00021159423
6 O 0 0.00035871164
% O 0 0.0013862281
enflurane B-Chemical 1 0.9992361
. O 0 0.003629954

However O 0 0.0028451502
, O 0 0.001926069
there O 0 0.0006718612
was O 0 0.000670323
no O 0 0.00025770723
significant O 0 0.00025742996
difference O 0 0.00011817045
in O 0 0.00015265068
the O 0 0.00028678903
lidocaine B-Chemical 0 0.9996767
concentrations O 0 0.0007033008
measured O 0 0.000121757526
when O 0 8.0779995e-05
the O 0 0.00016269994
systolic O 0 0.05335119
blood O 0 0.0027652516
pressure O 0 0.0028415245
became O 0 0.000705499
70 O 0 0.00082545256
mmHg O 0 0.0022814416
. O 0 0.0017141837

Apamin B-Chemical 0 0.99908066
, O 0 0.003300911
a O 0 0.0017459646
selective O 0 0.0038107815
blocker O 0 0.9658491
of O 0 0.0026886233
calcium B-Chemical 0 0.99973494
- O 0 0.0016191517
dependent O 0 0.00027381876
potassium B-Chemical 0 0.9999789
channels O 0 0.10575442
, O 0 0.00022633745
was O 0 0.00011777401
administered O 0 0.00012065355
intracerebroventricularly O 0 0.01063885
in O 0 7.1598355e-05
rats O 0 0.000105873056
anesthetized O 0 0.00017886928
with O 0 7.285267e-05
0 O 0 5.2852847e-05
. O 0 3.7559e-05
8 O 0 5.0169598e-05
% O 0 0.00011757811
sevoflurane B-Chemical 1 0.98923826
to O 0 9.336006e-05
investigate O 0 5.6698387e-05
the O 0 0.00011557828
mechanism O 0 0.00019072494
of O 0 0.00036526006
the O 0 0.0007246704
anticonvulsive O 0 0.9986702
effects O 0 0.0036116983
. O 0 0.0026929227

Apamin B-Chemical 0 0.9991548
( O 0 0.0044762017
10 O 0 0.0013309207
ng O 0 0.0026342862
) O 0 0.0012575453
had O 0 0.00043407793
a O 0 0.00040366003
tendency O 0 0.0003964189
to O 0 0.00016904784
decrease O 0 0.00025922598
the O 0 0.00028299994
convulsive B-Disease 2 0.99964285
threshold O 0 0.00028561757
( O 0 0.00025230434
21 O 0 0.000117555894
. O 0 5.7996505e-05
6 O 0 5.763033e-05
+ O 0 0.0002034939
/ O 0 0.00042357246
- O 0 0.00026542688
2 O 0 8.3097846e-05
. O 0 5.3389813e-05
2 O 0 5.783028e-05
to O 0 6.6007444e-05
19 O 0 0.00012977021
. O 0 5.9780596e-05
9 O 0 7.996155e-05
+ O 0 0.00021737107
/ O 0 0.00042973147
- O 0 0.00025758392
2 O 0 7.927739e-05
. O 0 5.185713e-05
5 O 0 6.38499e-05
mg O 0 0.0008911182
. O 0 8.818788e-05
l O 0 0.00040103373
( O 0 0.00025830622
- O 0 0.00030412377
1 O 0 0.00014086791
) O 0 0.0002632476
) O 0 0.00025476754
but O 0 0.00019018578
this O 0 0.00027962655
was O 0 0.00036013825
not O 0 0.0004175971
statistically O 0 0.000837455
significant O 0 0.0014593856
. O 0 0.002119107

It O 0 0.0025408403
is O 0 0.0011817073
suggested O 0 0.00058621785
that O 0 0.0006179632
sevoflurane B-Chemical 1 0.9991381
reduces O 0 0.0005106414
the O 0 0.00050821976
convulsive B-Disease 2 0.9995751
effect O 0 0.0003501821
of O 0 0.0012442529
lidocaine B-Chemical 0 0.9999747
toxicity B-Disease 2 0.99964774
but O 0 0.00047637871
carries O 0 0.00030255024
some O 0 0.0002648765
risk O 0 0.0012186529
due O 0 0.00021508677
to O 0 0.0004921899
circulatory O 0 0.17671885
depression B-Disease 0 0.991793
. O 0 0.0028149995

Cardiac B-Disease 0 0.9025999
toxicity I-Disease 2 0.99891853
observed O 0 0.0011151971
in O 0 0.0005123018
association O 0 0.00024799377
with O 0 0.00036926192
high O 0 0.0007012438
- O 0 0.0007487715
dose O 0 0.004419625
cyclophosphamide B-Chemical 0 0.99969923
- O 0 0.0009046402
based O 0 0.00027615472
chemotherapy O 0 0.002542008
for O 0 0.0006150672
metastatic O 0 0.85721684
breast B-Disease 0 0.99891376
cancer I-Disease 0 0.9995474
. O 0 0.0046865935

INTRODUCTION O 0 0.007334785
: O 0 0.0041875695
Cyclophosphamide B-Chemical 0 0.9913517
is O 0 0.0010893558
an O 0 0.0009965284
alkylating O 0 0.5972768
agent O 0 0.002974215
given O 0 0.00023968639
frequently O 0 0.00024638316
as O 0 0.00018361167
a O 0 0.00023737371
component O 0 0.00020350321
of O 0 0.0003568327
many O 0 0.00040089228
conditioning O 0 0.0010300688
regimens O 0 0.0024113478
. O 0 0.0021207207

In O 0 0.0023112604
high O 0 0.0030287534
doses O 0 0.007513919
, O 0 0.0016464666
its O 0 0.0028113397
nonhematological O 0 0.9990884
dose O 0 0.035933997
- O 0 0.0025353355
limiting O 0 0.0037773636
toxicity B-Disease 2 0.99870086
is O 0 0.011093336
cardiomyopathy B-Disease 0 0.9998965
. O 0 0.0051189326

STUDY O 0 0.003759919
DESIGN O 0 0.0017573126
: O 0 0.0010638216
We O 0 0.0004269891
combined O 0 0.0009034498
paclitaxel B-Chemical 1 0.98282754
, O 0 0.0014424695
melphalan B-Chemical 1 0.99966145
and O 0 0.00050934486
high O 0 0.000719914
- O 0 0.0005662167
dose O 0 0.0032868357
cyclophosphamide B-Chemical 0 0.99983215
, O 0 0.001056538
thiotepa B-Chemical 0 0.9998454
, O 0 0.00033408203
and O 0 0.00022678591
carboplatin B-Chemical 0 0.97147954
in O 0 0.0001076421
a O 0 0.00013827029
triple O 0 0.00027040465
sequential O 0 0.00011249661
high O 0 0.00024552416
- O 0 0.00022668863
dose O 0 0.00037490999
regimen O 0 0.00018056073
for O 0 0.00011279104
patients O 0 0.00037020916
with O 0 0.00072888756
metastatic O 0 0.83935285
breast B-Disease 0 0.99893576
cancer I-Disease 0 0.9995788
. O 0 0.0040766606

Analysis O 0 0.002934218
was O 0 0.0012997343
performed O 0 0.0005890816
on O 0 0.0003506
61 O 0 0.0006365409
women O 0 0.0006197583
with O 0 0.00030590227
chemotherapy O 0 0.0021328044
- O 0 0.00037464485
responsive O 0 0.0001391297
metastatic O 0 0.54988974
breast B-Disease 0 0.9988908
cancer I-Disease 0 0.99980205
receiving O 0 0.00067400513
96 O 0 0.00041778383
- O 0 0.00015194115
h O 0 7.173476e-05
infusional O 0 0.18102822
cyclophosphamide B-Chemical 0 0.99837327
as O 0 8.8396766e-05
part O 0 4.723883e-05
of O 0 8.269453e-05
a O 0 0.00010572697
triple O 0 0.00022634566
sequential O 0 9.18857e-05
high O 0 0.00021639791
- O 0 0.0001893206
dose O 0 0.00030585213
regimen O 0 0.00010021468
to O 0 3.7300288e-05
assess O 0 1.7520912e-05
association O 0 2.335532e-05
between O 0 2.2191642e-05
presence O 0 4.5828496e-05
of O 0 0.00012903934
peritransplant O 0 0.19070575
congestive B-Disease 0 0.9996983
heart I-Disease 0 0.6550771
failure I-Disease 0 0.6679902
( O 0 0.0015925809
CHF B-Disease 2 0.9999603
) O 0 0.00020247644
and O 0 4.8910835e-05
the O 0 3.5266945e-05
following O 0 2.9752648e-05
pretreatment O 0 0.00082116283
characteristics O 0 3.2269236e-05
: O 0 5.5734145e-05
presence O 0 4.364271e-05
of O 0 0.000108305576
electrocardiogram O 0 0.026311815
( O 0 0.00017900032
EKG O 0 0.028782107
) O 0 0.00019440842
abnormalities O 0 0.00250617
, O 0 0.0001414251
age O 0 0.00015138049
, O 0 0.00025347035
hypertension B-Disease 2 0.9999428
, O 0 0.00013637246
prior O 0 4.50412e-05
cardiac O 0 0.01616639
history O 0 0.000387452
, O 0 0.00020570021
smoking O 0 0.14328644
, O 0 0.0005518074
diabetes B-Disease 0 0.9999033
mellitus I-Disease 0 0.9979995
, O 0 0.00013398606
prior O 0 3.674248e-05
use O 0 6.793693e-05
of O 0 0.00021800643
anthracyclines B-Chemical 0 0.9977952
, O 0 0.00029859287
and O 0 0.00026361257
left O 0 0.0011310308
- O 0 0.0012100021
sided O 0 0.085098654
chest O 0 0.032239705
irradiation O 0 0.019561904
. O 0 0.0027511364

RESULTS O 0 0.0049817073
: O 0 0.001992235
Six O 0 0.0009943002
of O 0 0.00090557465
61 O 0 0.0010750653
women O 0 0.0010712448
( O 0 0.00042177885
10 O 0 0.00020741702
% O 0 0.00022513088
) O 0 0.00024382213
developed O 0 0.00023070657
clinically O 0 0.0010064864
reversible O 0 0.026669595
grade O 0 0.015760327
3 O 0 0.00014199589
CHF B-Disease 2 0.9990044
following O 0 0.00010475074
infusional O 0 0.37259188
cyclophosphamide B-Chemical 0 0.9988194
with O 0 0.00019265302
a O 0 0.00012360772
median O 0 4.523266e-05
percent O 0 6.2767154e-05
decline O 0 0.00029754624
in O 0 0.00015032582
ejection O 0 0.048692103
fraction O 0 0.00041129816
of O 0 0.00067862164
31 O 0 0.0011523959
% O 0 0.001261745
. O 0 0.0016869877

Incidence O 0 0.006039794
of O 0 0.00229546
transient O 0 0.021311346
cyclophosphamide B-Chemical 0 0.9996271
- O 0 0.0022768464
related O 0 0.00034384948
cardiac B-Disease 0 0.9521387
toxicity I-Disease 2 0.9999336
( O 0 0.001090165
10 O 0 0.00025161295
% O 0 0.00026727197
) O 0 0.00029871133
is O 0 0.00017383398
comparable O 0 0.00015117264
to O 0 0.0002381238
previous O 0 0.00044824934
recorded O 0 0.00082186336
literature O 0 0.0026521133
. O 0 0.0024216599

Older O 0 0.019056847
age O 0 0.002088298
was O 0 0.000942321
significantly O 0 0.0005785937
correlated O 0 0.00025881254
with O 0 0.00037853897
the O 0 0.0005521014
CHF B-Disease 2 0.99986696
development O 0 0.0009832073
; O 0 0.00021221995
with O 0 0.000121419784
median O 0 5.2723568e-05
ages O 0 8.335006e-05
for O 0 3.8450566e-05
the O 0 5.1722396e-05
entire O 0 4.9136077e-05
group O 0 8.929687e-05
and O 0 7.2050134e-05
for O 0 6.9795984e-05
patients O 0 0.00025374212
developing O 0 0.0034111172
CHF B-Disease 2 0.9998559
of O 0 0.00043450002
45 O 0 0.00022924732
and O 0 0.00032228744
59 O 0 0.00066635414
, O 0 0.0008637036
respectively O 0 0.0022542528
. O 0 0.0020562587

No O 0 0.0046587395
association O 0 0.0020156328
was O 0 0.0022035188
found O 0 0.0014310804
with O 0 0.0017347124
other O 0 0.0019319297
pretreatment O 0 0.03267674
characteristics O 0 0.0028964805
. O 0 0.004577613

CONCLUSIONS O 0 0.018036146
: O 0 0.0024255523
As O 0 0.00066751166
a O 0 0.00074670924
result O 0 0.0004048482
of O 0 0.00045566174
these O 0 0.00046901454
findings O 0 0.00062749744
, O 0 0.00036127664
oncologists O 0 0.0004962156
should O 0 8.905221e-05
carefully O 0 9.429036e-05
monitor O 0 0.00013801949
fluid O 0 0.00060100644
balance O 0 0.0005783957
in O 0 0.000509921
older O 0 0.0024734864
patients O 0 0.0022142278
. O 0 0.0020443578

Routine O 0 0.0032726228
EKG O 0 0.008769578
monitoring O 0 0.0009577925
during O 0 0.00065305573
infusional O 0 0.37495065
cyclophosphamide B-Chemical 0 0.9988418
did O 0 0.0013444364
not O 0 0.00086085586
predict O 0 0.0011778179
CHF B-Disease 2 0.9994504
development O 0 0.0083976295
. O 0 0.0036401886

Tremor B-Disease 0 0.9266423
side O 0 0.012235095
effects O 0 0.0023183245
of O 0 0.003670048
salbutamol B-Chemical 0 0.99961746
, O 0 0.0019175609
quantified O 0 0.001042102
by O 0 0.0009558685
a O 0 0.0014374384
laser O 0 0.0041625462
pointer O 0 0.0047415397
technique O 0 0.0037704257
. O 0 0.0032641818

OBJECTIVE O 0 0.021623893
: O 0 0.0021582188
To O 0 0.000941285
study O 0 0.0017073075
tremor B-Disease 0 0.9993438
side O 0 0.01315382
effects O 0 0.0006064169
of O 0 0.0010401362
salbutamol B-Chemical 0 0.99983597
an O 0 0.0005964419
easily O 0 0.00024640758
applicable O 0 0.0001353729
, O 0 0.0001870235
quick O 0 0.0006357475
and O 0 0.00027883583
low O 0 0.00082978094
- O 0 0.0011277953
priced O 0 0.011631518
method O 0 0.0011616244
is O 0 0.00096244086
needed O 0 0.0012550534
. O 0 0.0022610377

A O 0 0.016311934
new O 0 0.0026056562
method O 0 0.0019915143
using O 0 0.0008993972
a O 0 0.0012073393
commercially O 0 0.003081633
available O 0 0.0010797853
, O 0 0.0009872575
pen O 0 0.0034080576
- O 0 0.0010804377
shaped O 0 0.0009623364
laser O 0 0.0026885336
pointer O 0 0.0029036794
was O 0 0.0016425849
developed O 0 0.0032289666
. O 0 0.0029753663

Aim O 0 0.016164554
of O 0 0.0021367935
the O 0 0.0011419676
study O 0 0.0009010856
was O 0 0.0004895345
to O 0 0.00024049927
determine O 0 0.00013635529
sensitivity O 0 0.00084767235
, O 0 0.00030380354
reproducibility O 0 0.00044786537
, O 0 0.00020813895
reference O 0 0.0001625593
values O 0 0.00017463474
and O 0 0.00019282741
the O 0 0.00024228226
agreement O 0 0.00083267223
with O 0 0.00070176396
a O 0 0.0013383675
questionnaire O 0 0.0015497641
. O 0 0.0022108634

METHODS O 0 0.0032593855
: O 0 0.004119516
Tremor B-Disease 0 0.31863177
was O 0 0.0018268399
measured O 0 0.0011305872
using O 0 0.0011583649
a O 0 0.002132974
laser O 0 0.0054502315
pointer O 0 0.0062773726
technique O 0 0.005286101
. O 0 0.0045232135

To O 0 0.0016677061
determine O 0 0.0007809098
sensitivity O 0 0.0017305252
we O 0 0.00040534575
assessed O 0 0.00057552295
tremor B-Disease 0 0.99880874
in O 0 0.00033645413
44 O 0 0.0003165235
patients O 0 0.00024816644
with O 0 0.00036555322
obstructive B-Disease 0 0.9937464
lung I-Disease 0 0.38237554
disease I-Disease 0 0.75794
after O 0 7.119693e-05
administration O 0 0.000484109
of O 0 0.00026737698
cumulative O 0 0.0006726999
doses O 0 0.003783674
of O 0 0.002956283
salbutamol B-Chemical 0 0.9996761
. O 0 0.0033553883

Subjects O 0 0.0025602595
were O 0 0.0010714051
asked O 0 0.0006631839
to O 0 0.00043240056
aim O 0 0.0004283491
at O 0 0.0002402992
the O 0 0.00026507283
centre O 0 0.0003005705
of O 0 0.00025475683
a O 0 0.00024437165
target O 0 0.00013977502
, O 0 0.00022120369
subdivided O 0 0.00022352376
in O 0 0.00016283497
concentric O 0 0.0021858905
circles O 0 0.00055366504
, O 0 0.0003279008
from O 0 0.0002949245
5 O 0 0.0004330296
m O 0 0.0015619464
distance O 0 0.0013307552
. O 0 0.0020798885

The O 0 0.00222417
circle O 0 0.003099663
in O 0 0.0009909476
which O 0 0.00082739297
the O 0 0.0005429066
participant O 0 0.0003853121
succeeded O 0 0.0019589816
to O 0 0.00037347293
aim O 0 0.00051112875
was O 0 0.0005823597
recorded O 0 0.00054417073
in O 0 0.00078331534
millimetres O 0 0.0019918643
radius O 0 0.007634272
. O 0 0.0031180677

In O 0 0.0016810881
another O 0 0.001354281
series O 0 0.0009966063
of O 0 0.00061911717
measurements O 0 0.00031767893
, O 0 0.00031847678
reproducibility O 0 0.00036199353
and O 0 0.00016245469
reference O 0 0.000127566
values O 0 0.00011384718
of O 0 0.00015164197
the O 0 0.00023783428
tremor B-Disease 0 0.9997677
was O 0 0.00018293993
assessed O 0 5.6389257e-05
in O 0 5.696389e-05
65 O 0 8.235364e-05
healthy O 0 0.00019502426
subjects O 0 6.564379e-05
in O 0 3.7318576e-05
three O 0 2.3801987e-05
sessions O 0 3.3628687e-05
, O 0 5.7795594e-05
at O 0 4.1835152e-05
9 O 0 5.854206e-05
a O 0 0.000102827784
. O 0 6.719681e-05
m O 0 0.0003345971
. O 0 6.962222e-05
, O 0 0.00011726022
4 O 0 8.284253e-05
p O 0 0.0001010453
. O 0 6.426289e-05
m O 0 0.00027424045
. O 0 6.5563036e-05
and O 0 0.00010023055
9 O 0 8.802045e-05
a O 0 0.00015147318
. O 0 0.00010670955
m O 0 0.0004832487
. O 0 0.00013573753
, O 0 0.0002800243
respectively O 0 0.00057018414
, O 0 0.0004213278
1 O 0 0.00036311205
week O 0 0.0003464309
later O 0 0.00079813
. O 0 0.0018667715

Postural O 0 0.561055
tremor B-Disease 0 0.9987978
was O 0 0.0013994024
measured O 0 0.0004500929
with O 0 0.00035156377
the O 0 0.00023993792
arm O 0 0.0003590882
horizontally O 0 0.00038115197
outstretched O 0 0.011834698
rest O 0 0.00037199416
tremor B-Disease 0 0.999119
with O 0 0.00019540975
the O 0 0.00010268287
arm O 0 0.00016622568
supported O 0 0.00014415165
by O 0 9.900874e-05
an O 0 0.00018933664
armrest O 0 0.01632235
and O 0 0.00013452451
finally O 0 0.00077597424
tremor B-Disease 0 0.9997968
was O 0 0.00015530708
measured O 0 6.234505e-05
after O 0 3.844514e-05
holding O 0 0.0003176571
a O 0 0.00021429948
2 O 0 0.00015099427
- O 0 0.00033181187
kg O 0 0.00049744983
weight O 0 0.0010153867
until O 0 0.00048794923
exhaustion O 0 0.006947863
. O 0 0.0022232598

Inter O 0 0.010869688
- O 0 0.004082589
observer O 0 0.0024203337
variability O 0 0.0009677777
was O 0 0.00074204773
measured O 0 0.00045222335
in O 0 0.0004304543
a O 0 0.0005948994
series O 0 0.0006674263
of O 0 0.00072846195
10 O 0 0.0007915813
healthy O 0 0.0030655377
subjects O 0 0.0025250965
. O 0 0.0026336971

Tremor B-Disease 0 0.8687168
was O 0 0.0038137187
measured O 0 0.0019125539
simultaneously O 0 0.0017137105
by O 0 0.0017715463
two O 0 0.0013145661
independent O 0 0.0017472983
observers O 0 0.005313362
. O 0 0.0050527155

RESULTS O 0 0.005635877
: O 0 0.0038978206
Salbutamol B-Chemical 0 0.99919957
significantly O 0 0.0019329708
increased O 0 0.0026173163
tremor B-Disease 0 0.9997831
severity O 0 0.0023912385
in O 0 0.0003457326
patients O 0 0.00040244803
in O 0 0.00025475878
a O 0 0.0005201208
dose O 0 0.002107204
- O 0 0.0010592383
dependent O 0 0.00057764427
way O 0 0.0016867722
. O 0 0.002422878

Within O 0 0.0011204606
healthy O 0 0.0039731245
adults O 0 0.0020542871
no O 0 0.0005303579
age O 0 0.0008130101
- O 0 0.00072608056
dependency O 0 0.0003624658
could O 0 0.00020648133
be O 0 0.00017555783
found O 0 0.00016514919
( O 0 0.00026844678
b O 0 0.0004071873
= O 0 0.0001846389
0 O 0 9.92531e-05
. O 0 8.454006e-05
262 O 0 0.000523234
mm O 0 0.0002953632
/ O 0 0.00044314578
year O 0 0.00016792168
; O 0 0.0004008812
P O 0 0.0030595777
= O 0 0.00042614163
0 O 0 0.0003262659
. O 0 0.00038694756
72 O 0 0.0009163233
) O 0 0.0021288453
. O 0 0.0024102426

There O 0 0.0025971504
was O 0 0.0015241192
no O 0 0.0005403825
agreement O 0 0.0008837689
between O 0 0.00023109117
the O 0 0.0002693071
questionnaire O 0 0.00027689082
and O 0 0.0004932847
tremor B-Disease 0 0.9998179
severity O 0 0.0027240897
( O 0 0.00045160454
r O 0 0.0003012619
= O 0 0.00018808468
0 O 0 0.00012289858
. O 0 0.00013400204
093 O 0 0.0014441133
; O 0 0.00047771065
P O 0 0.0030879418
= O 0 0.00046564007
0 O 0 0.0003674242
. O 0 0.00046138372
53 O 0 0.0014341064
) O 0 0.0022801503
. O 0 0.002504454

Postural O 0 0.58667356
tremor B-Disease 0 0.99895954
showed O 0 0.0014195895
no O 0 0.00042973497
significant O 0 0.00035595507
difference O 0 0.00014432934
between O 0 0.00010219758
the O 0 0.00013000207
first O 0 9.7122254e-05
and O 0 0.00016719216
third O 0 0.00026216384
session O 0 0.000258685
( O 0 0.000591052
P O 0 0.0047879657
= O 0 0.0005217619
0 O 0 0.00041215934
. O 0 0.0005466106
07 O 0 0.0030475408
) O 0 0.00256532
. O 0 0.0026410648

Support O 0 0.0032699555
of O 0 0.001534899
the O 0 0.0009999049
arm O 0 0.0014601597
decreased O 0 0.0036548558
tremor B-Disease 0 0.99977595
severity O 0 0.0052502276
, O 0 0.00090947445
exhaustion O 0 0.009715714
increased O 0 0.0035953922
tremor B-Disease 0 0.99981254
severity O 0 0.011454556
significantly O 0 0.0038334574
. O 0 0.0027845085

A O 0 0.016857173
good O 0 0.002845253
agreement O 0 0.0024063839
was O 0 0.00083712384
found O 0 0.0003543196
between O 0 0.00017209338
two O 0 0.00013860877
independent O 0 0.00012908009
observers O 0 0.00036335964
( O 0 0.00031481468
interclass O 0 0.0006718336
correlation O 0 0.00022655184
coefficient O 0 0.0011964326
0 O 0 0.0004510584
. O 0 0.00046873317
72 O 0 0.0010512633
) O 0 0.002334705
. O 0 0.0025480276

DISCUSSION O 0 0.0035464072
: O 0 0.0020022127
Quantifying O 0 0.0017311928
tremor B-Disease 0 0.997341
by O 0 0.0007997814
using O 0 0.00034000768
an O 0 0.00045116676
inexpensive O 0 0.0021288535
laser O 0 0.0015334288
pointer O 0 0.0008274599
is O 0 0.00018736834
, O 0 0.00014315432
with O 0 0.00011541199
the O 0 9.195714e-05
exception O 0 8.517998e-05
of O 0 0.0001578078
children O 0 0.00028386034
( O 0 0.00020319919
< O 0 0.00011189652
12 O 0 6.9838454e-05
years O 0 0.00011146044
) O 0 0.0002023429
a O 0 0.00022995925
sensitive O 0 0.00027336174
and O 0 0.0004975935
reproducible O 0 0.001181436
method O 0 0.0024023156
. O 0 0.0022570707

Safety O 0 0.006500569
and O 0 0.0020524792
adverse O 0 0.009572112
effects O 0 0.0010672652
associated O 0 0.0007324653
with O 0 0.0015631366
raloxifene B-Chemical 0 0.99966645
: O 0 0.0008628363
multiple O 0 0.0005220578
outcomes O 0 0.0006385152
of O 0 0.0016032968
raloxifene B-Chemical 0 0.9993783
evaluation O 0 0.003031084
. O 0 0.002765433

OBJECTIVE O 0 0.024052925
: O 0 0.0020991815
To O 0 0.0006873545
examine O 0 0.0003407855
the O 0 0.00042216646
effect O 0 0.00039357744
of O 0 0.0009147374
raloxifene B-Chemical 0 0.99956375
on O 0 0.00016342106
major O 0 0.00020164378
adverse O 0 0.00982864
events O 0 0.00046159048
that O 0 8.876684e-05
occur O 0 0.00011033391
with O 0 0.0004111316
postmenopausal O 0 0.9835401
estrogen B-Chemical 1 0.9998505
therapy O 0 0.001849468
or O 0 0.0012833531
tamoxifen B-Chemical 1 0.998102
. O 0 0.002754617

METHODS O 0 0.0016827302
: O 0 0.0011976234
The O 0 0.00047718585
Multiple O 0 0.000660051
Outcomes O 0 0.00046629435
of O 0 0.0006972037
Raloxifene B-Chemical 1 0.99958175
Evaluation O 0 0.0005547109
, O 0 0.00029766143
a O 0 0.00031203817
multicenter O 0 0.007207593
, O 0 0.00018821777
randomized O 0 0.00016729646
, O 0 0.00013775915
double O 0 0.00023706455
- O 0 0.00030911923
blind O 0 0.0022230844
trial O 0 0.00019497071
, O 0 0.00014873433
enrolled O 0 0.0001678759
7 O 0 0.00011141357
, O 0 0.00026964725
705 O 0 0.0042378893
postmenopausal O 0 0.7620106
women O 0 0.002266262
with O 0 0.0021754554
osteoporosis B-Disease 0 0.9995926
. O 0 0.0034073035

Women O 0 0.0035367615
were O 0 0.0008686978
randomly O 0 0.00027471725
assigned O 0 0.0003407855
to O 0 0.0004639896
raloxifene B-Chemical 0 0.997764
60 O 0 0.00049295946
mg O 0 0.0068403464
/ O 0 0.0006794047
d O 0 0.00022946054
or O 0 0.00015021864
120 O 0 0.000246692
mg O 0 0.003071917
/ O 0 0.0010210609
d O 0 0.0006673498
or O 0 0.0008640819
placebo O 0 0.0054652398
. O 0 0.0022689106

Outcomes O 0 0.002891915
included O 0 0.0022309197
venous B-Disease 0 0.7821459
thromboembolism I-Disease 0 0.99993205
, O 0 0.0065236217
cataracts B-Disease 2 0.9999291
, O 0 0.0035920148
gallbladder B-Disease 2 0.99625105
disease I-Disease 2 0.9925829
, O 0 0.0013050373
and O 0 0.0014059431
endometrial B-Disease 0 0.9913931
hyperplasia I-Disease 0 0.99903405
or I-Disease 0 0.0034556375
cancer I-Disease 0 0.9793306
. O 0 0.0033907676

RESULTS O 0 0.0043730717
: O 0 0.0014936918
During O 0 0.00034983057
a O 0 0.0005425543
mean O 0 0.0002355653
follow O 0 0.00024546028
- O 0 0.00043970122
up O 0 0.00021734413
of O 0 0.00025314046
3 O 0 0.00013460794
. O 0 8.429357e-05
3 O 0 8.3991225e-05
years O 0 0.00010010351
, O 0 0.00021807608
raloxifene B-Chemical 0 0.9993647
was O 0 0.00019293555
associated O 0 8.384631e-05
with O 0 0.00010785315
an O 0 0.00012152253
increased O 0 0.0002220485
risk O 0 0.0012102753
for O 0 0.00013941043
venous B-Disease 0 0.9033793
thromboembolism I-Disease 0 0.9999893
( O 0 0.00026935793
relative O 0 0.00012795509
risk O 0 0.0031847034
[ O 0 0.0011703462
RR O 0 0.22162181
] O 0 0.0003868894
2 O 0 8.08876e-05
. O 0 5.4389482e-05
1 O 0 7.282266e-05
; O 0 0.00010394555
95 O 0 0.00012346565
% O 0 9.655675e-05
confidence O 0 0.00036833851
interval O 0 0.00012664944
[ O 0 0.00050082017
CI O 0 0.011091909
] O 0 0.00036018805
1 O 0 0.00011970708
. O 0 0.000102242804
2 O 0 0.0001644722
- O 0 0.00038091224
3 O 0 0.00026126954
. O 0 0.00034486008
8 O 0 0.0006968306
) O 0 0.001890861
. O 0 0.0022871536

The O 0 0.002115897
excess O 0 0.0031635542
event O 0 0.0023122597
rate O 0 0.001122792
was O 0 0.0007463337
1 O 0 0.00034526933
. O 0 0.00017089167
8 O 0 0.0001278312
per O 0 6.8336405e-05
1 O 0 0.000113413225
, O 0 0.00014549155
000 O 0 0.000207453
woman O 0 0.0005440416
- O 0 0.00032021277
years O 0 0.00011923419
( O 0 0.00016579674
95 O 0 0.00018652396
% O 0 0.00016568089
CI O 0 0.0048285876
- O 0 0.00021574258
0 O 0 7.951445e-05
. O 0 5.5529526e-05
5 O 0 6.6184046e-05
- O 0 0.00015250215
4 O 0 6.24097e-05
. O 0 5.3844356e-05
1 O 0 7.500785e-05
) O 0 0.00013073202
, O 0 8.841e-05
and O 0 7.348748e-05
the O 0 6.8589005e-05
number O 0 6.533186e-05
needed O 0 5.1903982e-05
to O 0 7.2486364e-05
treat O 0 0.00016699954
to O 0 9.257689e-05
cause O 0 0.00018520665
1 O 0 8.597416e-05
event O 0 0.00022255424
was O 0 0.00012653295
170 O 0 0.00030677347
( O 0 0.00015866889
95 O 0 0.00016160619
% O 0 0.00014383339
CI O 0 0.002556407
100 O 0 0.00041200942
- O 0 0.00044046956
582 O 0 0.0028775923
) O 0 0.00026511273
over O 0 0.000104194645
3 O 0 0.00019389435
. O 0 0.00025074076
3 O 0 0.00047496677
years O 0 0.00093687355
. O 0 0.0017235473

Risk O 0 0.0048968988
in O 0 0.0014175834
the O 0 0.0015869373
raloxifene B-Chemical 0 0.9994012
group O 0 0.0012974307
was O 0 0.00038945925
higher O 0 0.0002356635
than O 0 9.936739e-05
in O 0 9.732215e-05
the O 0 0.000114841576
placebo O 0 0.00064219715
group O 0 0.00010351825
for O 0 4.761113e-05
the O 0 6.370777e-05
first O 0 4.9332048e-05
2 O 0 7.030024e-05
years O 0 6.725303e-05
, O 0 8.9342764e-05
but O 0 9.079217e-05
decreased O 0 0.00018134562
to O 0 6.803561e-05
about O 0 7.301082e-05
the O 0 6.880742e-05
same O 0 4.424017e-05
rate O 0 0.0001029683
as O 0 9.8785225e-05
in O 0 0.00012490872
the O 0 0.00023883961
placebo O 0 0.0016770939
group O 0 0.00073170825
thereafter O 0 0.0009826332
. O 0 0.0016518877

Raloxifene B-Chemical 1 0.99903524
did O 0 0.0028285591
not O 0 0.0010947296
increase O 0 0.0009932219
risk O 0 0.005978057
for O 0 0.0010300154
cataracts B-Disease 2 0.9999666
( O 0 0.0029642025
RR O 0 0.19562066
0 O 0 0.00018817114
. O 0 9.781151e-05
9 O 0 0.00010715892
; O 0 0.00014581057
95 O 0 0.00017706495
% O 0 0.0001531918
CI O 0 0.0016920277
0 O 0 9.03679e-05
. O 0 6.2970576e-05
8 O 0 7.8528894e-05
- O 0 0.00016750749
1 O 0 7.829127e-05
. O 0 5.880324e-05
1 O 0 8.3046194e-05
) O 0 0.00016916668
, O 0 0.00021191787
gallbladder B-Disease 2 0.9552572
disease I-Disease 2 0.9891473
( O 0 0.0008985295
RR O 0 0.07693191
1 O 0 9.9539815e-05
. O 0 5.5730266e-05
0 O 0 7.380541e-05
; O 0 0.00010949207
95 O 0 0.0001394341
% O 0 0.00012487227
CI O 0 0.0014575348
0 O 0 7.7885e-05
. O 0 5.4815464e-05
7 O 0 6.396233e-05
- O 0 0.00015306946
1 O 0 7.3411065e-05
. O 0 5.6236477e-05
3 O 0 7.3052746e-05
) O 0 0.000178248
, O 0 0.00024495856
endometrial B-Disease 0 0.96459365
hyperplasia I-Disease 0 0.9993505
( O 0 0.0009700116
RR O 0 0.103248775
1 O 0 9.65247e-05
. O 0 5.3974734e-05
3 O 0 6.072479e-05
; O 0 9.7852106e-05
95 O 0 0.00012902422
% O 0 0.000117479685
CI O 0 0.0014513279
0 O 0 7.428053e-05
. O 0 5.221237e-05
4 O 0 6.251859e-05
- O 0 0.00013648461
5 O 0 5.8904036e-05
. O 0 5.3721313e-05
1 O 0 7.6768825e-05
) O 0 0.0001450079
, O 0 0.00013042273
or O 0 0.00022210735
endometrial B-Disease 2 0.9996132
cancer I-Disease 2 0.999848
( O 0 0.0011320604
RR O 0 0.0880768
0 O 0 0.0001059102
. O 0 6.3266896e-05
9 O 0 8.042314e-05
; O 0 0.0001237554
95 O 0 0.00016619814
% O 0 0.00016162869
CI O 0 0.0016275895
0 O 0 0.00012206816
. O 0 0.000107122236
3 O 0 0.000157531
- O 0 0.00039228008
2 O 0 0.00028932633
. O 0 0.00035480096
7 O 0 0.0006592548
) O 0 0.0019292496
. O 0 0.002349188

CONCLUSION O 0 0.03496872
: O 0 0.0052652583
Raloxifene B-Chemical 1 0.9992461
was O 0 0.0012196387
associated O 0 0.00042966346
with O 0 0.00038338627
an O 0 0.0003464051
increased O 0 0.00049189955
risk O 0 0.002238838
for O 0 0.00026975322
venous B-Disease 0 0.9587282
thromboembolism I-Disease 0 0.999992
, O 0 0.00035285298
but O 0 0.00013870897
there O 0 5.8239646e-05
was O 0 9.43508e-05
no O 0 5.2063057e-05
increased O 0 0.00023161419
risk O 0 0.0025307282
for O 0 0.0002870891
cataracts B-Disease 2 0.99998546
, O 0 0.0014488669
gallbladder B-Disease 2 0.99756086
disease I-Disease 2 0.9965789
, O 0 0.0015877117
endometrial B-Disease 0 0.99616396
hyperplasia I-Disease 0 0.99927014
, O 0 0.0011346332
or O 0 0.0013639409
endometrial B-Disease 2 0.9993641
cancer I-Disease 2 0.9993451
. O 0 0.0035893347

LEVEL O 0 0.06729099
OF O 0 0.049518444
EVIDENCE O 0 0.0639895
: O 0 0.037538342
I O 0 0.07927779

Optimization O 0 0.015316779
of O 0 0.019139256
levodopa B-Chemical 0 0.99900657
therapy O 0 0.035044186
. O 0 0.01678062

While O 0 0.0018884437
there O 0 0.0009147779
is O 0 0.0007270998
no O 0 0.00029214338
single O 0 0.00027500762
correct O 0 0.0002100068
starting O 0 0.0001408694
dose O 0 0.00074821763
for O 0 0.00025099047
levodopa B-Chemical 0 0.9999727
therapy O 0 0.00057152973
, O 0 0.00015696842
many O 0 8.563298e-05
individuals O 0 0.00013822824
can O 0 4.6976886e-05
be O 0 4.4368186e-05
started O 0 4.0425755e-05
on O 0 2.7202757e-05
either O 0 4.8029855e-05
the O 0 6.097971e-05
25 O 0 0.00010751777
/ O 0 0.00020661404
100 O 0 0.00016301796
or O 0 6.066048e-05
controlled O 0 8.5135e-05
- O 0 0.00019282814
release O 0 0.00032897358
formula O 0 0.00048151086
, O 0 7.056393e-05
following O 0 3.3015745e-05
the O 0 4.729044e-05
general O 0 5.8215664e-05
rule O 0 0.00012723435
not O 0 4.4964385e-05
to O 0 4.151396e-05
attempt O 0 8.455635e-05
to O 0 8.116445e-05
titrate O 0 0.0014072732
carbidopa B-Chemical 0 0.99999785
- O 0 0.00631534
levodopa B-Chemical 0 0.99996483
to O 0 8.886855e-05
the O 0 6.875408e-05
point O 0 6.1168765e-05
of O 0 0.00013946761
" O 0 0.0002138162
normality O 0 0.001260826
, O 0 0.0002354701
" O 0 0.00025352303
which O 0 0.00028711182
can O 0 0.0002695822
lead O 0 0.0025140976
to O 0 0.0012188734
toxicity B-Disease 2 0.99453235
. O 0 0.0033357844

The O 0 0.0019256436
physician O 0 0.0024737618
should O 0 0.00043871359
also O 0 0.00035649075
determine O 0 0.00015545495
the O 0 0.00019125851
proper O 0 0.00015086487
use O 0 0.00012694109
of O 0 0.00015507387
any O 0 0.00011713069
adjunctive O 0 0.0008843948
medications O 0 0.0032302036
; O 0 0.00012742594
such O 0 5.92417e-05
combined O 0 0.00015170242
therapy O 0 0.00016813734
has O 0 7.9904465e-05
become O 0 0.00010303176
the O 0 0.00011707844
standard O 0 0.00015907228
approach O 0 0.0003324201
to O 0 0.0005259422
treatment O 0 0.0013544507
. O 0 0.0020422246

Following O 0 0.0012969607
the O 0 0.0008955132
initial O 0 0.0005669608
period O 0 0.0003037103
of O 0 0.0004759847
therapy O 0 0.0004926381
, O 0 0.0002606082
emerging O 0 0.0001580923
difficulties O 0 0.00027634806
require O 0 7.007095e-05
a O 0 0.0001304797
reassessment O 0 0.00020725216
of O 0 0.00011736918
therapeutic O 0 0.00020936542
approaches O 0 0.00013137185
, O 0 0.00010800094
such O 0 5.9989496e-05
as O 0 9.550604e-05
dosage O 0 0.0013573722
adjustment O 0 8.449138e-05
or O 0 9.721955e-05
introduction O 0 0.00013690768
of O 0 0.00041451244
a O 0 0.0017374502
dopamine B-Chemical 0 0.9996946
agonist O 0 0.87195617
. O 0 0.0026434723

Other O 0 0.0031439012
possible O 0 0.0016752142
adverse O 0 0.0248886
effects O 0 0.0016748903
- O 0 0.0018456603
- O 0 0.0006916869
such O 0 0.00018536214
as O 0 0.00031356505
gastrointestinal B-Disease 0 0.9954059
disorders I-Disease 0 0.99434704
, O 0 0.00087032304
orthostatic B-Disease 2 0.99995804
hypotension I-Disease 2 0.9999969
, O 0 0.005434953
levodopa B-Chemical 0 0.99999154
- O 0 0.00068970356
induced O 0 0.00030121536
psychosis B-Disease 0 0.99967384
, O 0 0.00025622864
sleep B-Disease 0 0.44453564
disturbances I-Disease 0 0.49781182
or O 0 0.000147852
parasomnias B-Disease 0 0.7182797
, O 0 0.00011328288
or O 0 8.008678e-05
drug O 0 0.0018939972
interactions O 0 0.00020016573
- O 0 0.00032765052
- O 0 0.00020395835
also O 0 9.483121e-05
require O 0 7.2137096e-05
carefully O 0 9.750346e-05
monitored O 0 0.00016062052
individual O 0 0.00039326563
treatment O 0 0.001063205
. O 0 0.0017948773

Nonpharmacologic O 0 0.0034760628
concerns O 0 0.0016969378
can O 0 0.0007210152
help O 0 0.0008068076
the O 0 0.00072645704
Parkinson B-Disease 0 0.992796
' I-Disease 0 0.00064589106
s I-Disease 0 0.00035726037
disease I-Disease 0 0.010827791
patient O 0 0.00015260615
achieve O 0 7.138326e-05
and O 0 7.131217e-05
maintain O 0 4.519183e-05
optimal O 0 4.0846207e-05
functioning O 0 0.00014133748
, O 0 9.3060786e-05
including O 0 5.050446e-05
daily O 0 0.00012484453
exercise O 0 0.00019905345
, O 0 0.00011426339
physical O 0 0.00023753154
therapy O 0 0.00022323665
, O 0 0.00018623266
and O 0 0.00020029706
involvement O 0 0.00041521856
with O 0 0.00048536903
support O 0 0.00059478544
groups O 0 0.0011379701
. O 0 0.0016900114

Long O 0 0.006549467
term O 0 0.0023077808
audiological O 0 0.0047158482
evaluation O 0 0.0016475916
of O 0 0.0032749507
beta B-Disease 0 0.9921665
- I-Disease 0 0.017691422
thalassemic I-Disease 0 0.9993691
patients O 0 0.015091043
. O 0 0.0051089916

OBJECTIVE O 0 0.020989377
: O 0 0.001920065
The O 0 0.00061433663
objective O 0 0.0007088755
of O 0 0.0005443338
this O 0 0.00044404774
study O 0 0.00037831243
was O 0 0.00020928557
to O 0 0.00010807923
identify O 0 8.747947e-05
the O 0 0.00011202165
incidence O 0 0.00022812485
and O 0 8.712183e-05
to O 0 5.5162604e-05
monitor O 0 4.5505272e-05
the O 0 7.707948e-05
progression O 0 0.0014940909
of O 0 0.00025558643
hearing B-Disease 0 0.9764637
loss I-Disease 0 0.0019054797
in O 0 0.00014563758
children O 0 0.00022864353
and O 0 0.00015827117
young O 0 0.0010475357
adults O 0 0.0006213901
with O 0 0.0007744687
beta B-Disease 0 0.9967393
- I-Disease 0 0.01839115
thalassemia I-Disease 0 0.9999751
major O 0 0.0042939982
. O 0 0.0026896961

METHODS O 0 0.0017816724
: O 0 0.0014274883
One O 0 0.0007827549
hundred O 0 0.0006147385
and O 0 0.00042573194
four O 0 0.00024849744
( O 0 0.00042993922
104 O 0 0.0005343204
) O 0 0.0004020496
patients O 0 0.00028736377
aged O 0 0.0002791902
6 O 0 8.9777306e-05
- O 0 0.00018429839
35 O 0 0.00010606524
years O 0 8.242207e-05
( O 0 0.000103604354
mean O 0 5.4552846e-05
17 O 0 0.00015500085
, O 0 0.00015732642
2 O 0 0.00012781829
years O 0 0.00015521677
) O 0 0.00031414072
participated O 0 0.00045611954
in O 0 0.00040167398
the O 0 0.00077005685
study O 0 0.0017249556
. O 0 0.002121831

All O 0 0.0018430136
patients O 0 0.0015372173
were O 0 0.0006676993
on O 0 0.00030322885
a O 0 0.00046628856
regular O 0 0.0004304467
transfusion O 0 0.0038806759
- O 0 0.0009632509
chelation O 0 0.5157423
program O 0 0.00022330666
maintaining O 0 0.00015917457
a O 0 0.00015549557
mean O 0 8.199795e-05
hemoglobin O 0 0.18180913
level O 0 0.00016787382
of O 0 0.00028650832
9 O 0 0.00020211922
. O 0 0.00016902464
5 O 0 0.0002855895
gr O 0 0.0018878344
/ O 0 0.0025045779
dl O 0 0.012484307
. O 0 0.002746816

Subjects O 0 0.0024258776
were O 0 0.0013910837
receiving O 0 0.0030635097
desferrioxamine B-Chemical 0 0.99995625
( O 0 0.022988623
DFO B-Chemical 1 0.99998736
) O 0 0.0056785354
chelation O 0 0.9146135
treatment O 0 0.00026501116
with O 0 0.00015591885
a O 0 0.000111660534
mean O 0 4.0177285e-05
daily O 0 9.855152e-05
dose O 0 0.00026211535
of O 0 0.00013586858
50 O 0 0.00021771829
- O 0 0.00017369761
60 O 0 8.231437e-05
mg O 0 0.0017135751
/ O 0 0.00040774938
kg O 0 0.0002883515
, O 0 0.00010218412
5 O 0 5.7857364e-05
- O 0 0.000102447266
6 O 0 2.7031638e-05
days O 0 1.8095618e-05
a O 0 4.3915374e-05
week O 0 2.0592019e-05
during O 0 1.881862e-05
the O 0 3.5037418e-05
first O 0 2.8465554e-05
six O 0 3.0027517e-05
years O 0 4.05265e-05
of O 0 6.346213e-05
the O 0 7.3755386e-05
study O 0 0.000118897435
, O 0 9.758457e-05
which O 0 0.00010996418
was O 0 8.1873004e-05
then O 0 5.200069e-05
reduced O 0 0.00012536428
to O 0 7.4755924e-05
40 O 0 0.00011429226
- O 0 0.00017857226
50 O 0 0.00018314237
mg O 0 0.002302637
/ O 0 0.00044908485
kg O 0 0.00027789158
for O 0 0.00010238788
the O 0 0.00016957153
following O 0 0.00022149517
eight O 0 0.0004326356
years O 0 0.0009174869
. O 0 0.001553739

Patients O 0 0.004423781
were O 0 0.0024870927
followed O 0 0.0016744455
for O 0 0.0016128556
8 O 0 0.002013861
- O 0 0.003424031
14 O 0 0.0026703605
years O 0 0.0034986488
. O 0 0.0048608114

RESULTS O 0 0.0053565516
: O 0 0.002266221
Overall O 0 0.0014781286
, O 0 0.00089668034
21 O 0 0.00046808555
out O 0 0.0002506576
of O 0 0.00034686032
104 O 0 0.0005879962
patients O 0 0.00038168448
( O 0 0.00025858294
20 O 0 0.00014194565
. O 0 7.802311e-05
2 O 0 7.908169e-05
% O 0 9.8873454e-05
) O 0 0.00011206951
presented O 0 6.660445e-05
with O 0 0.000108909786
high O 0 0.00027228828
frequency O 0 0.0005389017
sensorineural B-Disease 2 0.9999933
hearing I-Disease 2 0.9999286
loss I-Disease 2 0.9342612
( O 0 0.040590454
SNHL B-Disease 0 0.99999714
) O 0 0.0023866503
, O 0 0.00041962028
either O 0 0.00042046834
unilateral O 0 0.016117182
or O 0 0.0010826245
bilateral O 0 0.029873505
. O 0 0.0024834767

No O 0 0.006260613
ototoxic B-Disease 0 0.99335724
factor O 0 0.009942077
, O 0 0.0015455657
other O 0 0.00077569333
than O 0 0.00089535577
DFO B-Chemical 1 0.9999641
, O 0 0.0011670131
was O 0 0.00043303662
present O 0 0.0002334586
in O 0 0.0002813213
any O 0 0.00032116025
of O 0 0.00068167376
the O 0 0.0010239244
patients O 0 0.002612686
. O 0 0.002370432

Patients O 0 0.0028123562
with O 0 0.0032483216
SNHL B-Disease 0 0.9998753
presented O 0 0.0008227873
with O 0 0.000522897
relatively O 0 0.00049825344
lower O 0 0.0005260309
serum O 0 0.1445783
ferritin O 0 0.9990428
levels O 0 0.00027668523
than O 0 9.310535e-05
those O 0 0.00014812632
with O 0 0.0001583367
normal O 0 0.0007220212
hearing O 0 0.98705405
, O 0 0.00043973394
however O 0 0.00031042608
, O 0 0.00019099392
no O 0 0.00011033854
statistically O 0 0.00021340007
significant O 0 0.0002587057
difference O 0 0.00025058922
was O 0 0.0006992972
observed O 0 0.0010845972
. O 0 0.0019588752

Subjects O 0 0.0040654703
with O 0 0.0046135536
SNHL B-Disease 0 0.99982566
were O 0 0.001625412
submitted O 0 0.0011015596
to O 0 0.0013240145
DFO B-Chemical 1 0.99989295
reduction O 0 0.0072116135
or O 0 0.0015914964
temporary O 0 0.010729563
withdrawal O 0 0.1498448
. O 0 0.0036881068

Following O 0 0.001853937
intervention O 0 0.0015437683
, O 0 0.0011122153
7 O 0 0.00043755834
out O 0 0.0003103151
of O 0 0.00040764012
21 O 0 0.00032974506
affected O 0 0.00030620192
patients O 0 0.00029072494
recovered O 0 0.00019857727
, O 0 0.00021898329
10 O 0 0.00015395795
remained O 0 0.00024593627
stable O 0 0.00030595416
and O 0 0.00035370674
4 O 0 0.00037717557
demonstrated O 0 0.00079294405
aggravation O 0 0.3387216
. O 0 0.0031203155

CONCLUSION O 0 0.015292986
: O 0 0.001934482
The O 0 0.0006806075
findings O 0 0.0010073521
are O 0 0.00048513705
indicative O 0 0.00041830234
of O 0 0.0011934867
DFO B-Chemical 1 0.99995995
' O 0 0.0009203649
s O 0 0.00029510114
contributing O 0 0.00025697704
role O 0 0.00013232863
in O 0 0.00018724902
the O 0 0.00026215834
development O 0 0.0007293171
of O 0 0.0015400947
hearing B-Disease 0 0.99719113
impairment I-Disease 0 0.96643704
. O 0 0.0044424455

Regular O 0 0.005548993
audiologic O 0 0.008255962
evaluation O 0 0.000882156
is O 0 0.00048296276
imperative O 0 0.00029816446
in O 0 0.00030218385
all O 0 0.00040047304
thalassemic B-Disease 0 0.9964078
patients O 0 0.00045718887
so O 0 9.984687e-05
that O 0 6.420892e-05
early O 0 0.00015757204
changes O 0 0.0001333671
may O 0 6.9196816e-05
be O 0 6.355873e-05
recognized O 0 7.346163e-05
and O 0 8.093421e-05
treatment O 0 8.2712526e-05
may O 0 6.5708875e-05
be O 0 7.0303926e-05
judiciously O 0 0.00013103467
adjusted O 0 6.334755e-05
in O 0 6.206008e-05
order O 0 7.48246e-05
to O 0 0.00010801104
prevent O 0 0.00019568963
or O 0 0.00035707717
reverse O 0 0.012202959
hearing B-Disease 0 0.9981743
impairment I-Disease 0 0.9674787
. O 0 0.0038820917

Individual O 0 0.002195671
differences O 0 0.0008146833
in O 0 0.0010734893
renal O 0 0.8187005
ACE O 0 0.9988613
activity O 0 0.00054031354
in O 0 0.00029499762
healthy O 0 0.00070151355
rats O 0 0.00022915618
predict O 0 9.621758e-05
susceptibility O 0 0.00045580423
to O 0 0.00042052247
adriamycin B-Chemical 0 0.99956113
- O 0 0.003034902
induced O 0 0.0032898244
renal B-Disease 0 0.99968696
damage I-Disease 0 0.9982632
. O 0 0.0047724815

BACKGROUND O 0 0.009728099
: O 0 0.0025013098
In O 0 0.0010471317
man O 0 0.0043059494
, O 0 0.00062195415
differences O 0 0.00022554856
in O 0 0.00047813795
angiotensin B-Chemical 1 0.99993765
- O 0 0.0022576435
converting O 0 0.02952211
enzyme O 0 0.08689159
( O 0 0.0009868174
ACE O 0 0.9994816
) O 0 0.00042331975
levels O 0 0.00013666287
, O 0 0.000115728486
related O 0 5.0708604e-05
to O 0 0.00015814883
ACE O 0 0.9987658
( O 0 0.0005020065
I O 0 0.003582089
/ O 0 0.001408093
D O 0 0.64711565
) O 0 0.000586509
genotype O 0 0.0009670892
, O 0 0.00026702162
are O 0 0.000211373
associated O 0 0.00030677931
with O 0 0.00095349725
renal O 0 0.97025216
prognosis O 0 0.70626396
. O 0 0.0031311368

This O 0 0.0029780972
raises O 0 0.0008275081
the O 0 0.00077805924
hypothesis O 0 0.00061218865
that O 0 0.00024339616
individual O 0 0.0002203837
differences O 0 0.00012745074
in O 0 0.00025157147
renal O 0 0.9316212
ACE O 0 0.999529
activity O 0 0.00028343932
are O 0 0.0001562843
involved O 0 0.00011730842
in O 0 0.00023791549
renal O 0 0.66050774
susceptibility O 0 0.0019642932
to O 0 0.00096524163
inflicted O 0 0.34519467
damage O 0 0.8369126
. O 0 0.0036317518

Therefore O 0 0.00199008
, O 0 0.0016882198
we O 0 0.0005258011
studied O 0 0.00059672253
the O 0 0.00034316108
predictive O 0 0.0004864909
effect O 0 0.0002726959
of O 0 0.0006077338
renal O 0 0.98906285
ACE O 0 0.9997632
activity O 0 0.00018975703
for O 0 7.712389e-05
the O 0 0.000104036386
severity O 0 0.00034201422
of O 0 0.0004281815
renal B-Disease 0 0.9997118
damage I-Disease 0 0.9927751
induced O 0 0.0004396381
by O 0 0.00017905665
a O 0 0.00018204364
single O 0 0.00014231484
injection O 0 0.00024641745
of O 0 0.00066359545
adriamycin B-Chemical 0 0.9988691
in O 0 0.0011916034
rats O 0 0.0026472288
. O 0 0.0018698971

METHODS O 0 0.002064129
: O 0 0.0022166397
Renal O 0 0.012346167
ACE O 0 0.9890183
activity O 0 0.0011351455
( O 0 0.0012616189
Hip B-Chemical 0 0.009888768
- I-Chemical 0 0.0013091698
His I-Chemical 0 0.0020376428
- I-Chemical 0 0.0016704925
Leu I-Chemical 0 0.97962564
cleavage O 0 0.0008183234
by O 0 0.00023923299
cortical O 0 0.0013103941
homogenates O 0 0.002610726
) O 0 0.0003211881
was O 0 0.00013511446
determined O 0 0.00010487587
by O 0 0.00018311848
renal O 0 0.59249777
biopsy O 0 0.0007426663
in O 0 0.0001832327
27 O 0 0.00035253842
adult O 0 0.0005001523
male O 0 0.0014201291
Wistar O 0 0.0026555918
rats O 0 0.0015750142
. O 0 0.0015308922

After O 0 0.0010086764
1 O 0 0.0009732823
week O 0 0.000445419
of O 0 0.0006149811
recovery O 0 0.0012592096
, O 0 0.0012642918
proteinuria B-Disease 0 0.9999629
was O 0 0.00078621757
induced O 0 0.00044969484
by O 0 0.00057090033
adriamycin B-Chemical 0 0.99985015
[ O 0 0.0014553664
1 O 0 0.00011296982
. O 0 5.3637414e-05
5 O 0 5.7561392e-05
mg O 0 0.000786007
/ O 0 0.00029339548
kg O 0 0.00021706043
intravenously O 0 0.00013120259
( O 0 0.00014629563
i O 0 0.00023068786
. O 0 7.468018e-05
v O 0 0.0004889413
. O 0 7.78792e-05
) O 0 0.00015797718
n O 0 9.0278845e-05
= O 0 0.00011309291
18 O 0 7.720276e-05
; O 0 0.00010627137
controls O 0 0.00016291386
, O 0 0.0001522232
saline O 0 0.00056388084
i O 0 0.00037029022
. O 0 0.00013958802
v O 0 0.0007554473
. O 0 0.00020922969
n O 0 0.00035547878
= O 0 0.0006789338
9 O 0 0.0008137108
] O 0 0.0021898064
. O 0 0.002186679

Proteinuria B-Disease 2 0.9985006
was O 0 0.0063299355
measured O 0 0.0029794772
every O 0 0.0017396037
2 O 0 0.0031255574
weeks O 0 0.0029901876
. O 0 0.006429293

After O 0 0.0012553643
12 O 0 0.0010397856
weeks O 0 0.00064694707
, O 0 0.0010063071
rats O 0 0.00095871143
were O 0 0.00057758915
sacrificed O 0 0.00046258926
and O 0 0.0007835721
their O 0 0.0012536962
kidneys O 0 0.010292142
harvested O 0 0.0019704113
. O 0 0.0032906155

RESULTS O 0 0.0051768264
: O 0 0.0019400729
As O 0 0.0005953089
anticipated O 0 0.0006574365
, O 0 0.0010372358
adriamycin B-Chemical 0 0.9982316
elicited O 0 0.0022619436
nephrotic B-Disease 0 0.9999908
range O 0 0.0051033907
proteinuria B-Disease 0 0.99999225
, O 0 0.0022522502
renal B-Disease 0 0.9982615
interstitial I-Disease 0 0.42505696
damage I-Disease 0 0.95767605
and O 0 0.0014035399
mild O 0 0.8560776
focal B-Disease 0 0.9374125
glomerulosclerosis I-Disease 2 0.99999535
. O 0 0.009285096

Baseline O 0 0.004368944
renal O 0 0.8196625
ACE O 0 0.99722314
positively O 0 0.00076942315
correlated O 0 0.00028004992
with O 0 0.00026195694
the O 0 0.00015911508
relative O 0 0.00012834172
rise O 0 0.00025292527
in O 0 0.000253882
proteinuria B-Disease 0 0.9999769
after O 0 0.00015896039
adriamycin B-Chemical 0 0.9997787
( O 0 0.0005603625
r O 0 0.000261282
= O 0 0.00012773859
0 O 0 6.867074e-05
. O 0 5.6841203e-05
62 O 0 0.00015394238
, O 0 0.00018413922
P O 0 0.0020900378
< O 0 0.00010702739
0 O 0 8.449927e-05
. O 0 7.263735e-05
01 O 0 0.00033161577
) O 0 0.00017496674
, O 0 0.00015189407
renal O 0 0.45688567
interstitial O 0 0.061921783
alpha O 0 0.7818876
- O 0 0.0005270839
smooth O 0 0.0011668807
muscle O 0 0.0008531067
actin O 0 0.00054014876
( O 0 0.00018768928
r O 0 0.00015220795
= O 0 0.00010008338
0 O 0 6.237858e-05
. O 0 5.527772e-05
49 O 0 0.0001468813
, O 0 0.0001803228
P O 0 0.0020592804
< O 0 0.00010975488
0 O 0 9.159727e-05
. O 0 8.96077e-05
05 O 0 0.0013990467
) O 0 0.00019204231
, O 0 0.00013433468
interstitial O 0 0.0015517517
macrophage O 0 0.009118389
influx O 0 0.17809129
( O 0 0.0003121215
r O 0 0.00020616263
= O 0 0.00011706025
0 O 0 6.626387e-05
. O 0 5.4760032e-05
56 O 0 0.00012233338
, O 0 0.00018433158
P O 0 0.002091593
< O 0 0.00011208598
0 O 0 9.304863e-05
. O 0 9.1084934e-05
05 O 0 0.0013472891
) O 0 0.00019411245
, O 0 0.00014326806
interstitial O 0 0.0023313086
collagen O 0 0.13816728
III O 0 0.02178433
( O 0 0.00025473454
r O 0 0.00019188835
= O 0 0.00011843485
0 O 0 6.967681e-05
. O 0 5.9592654e-05
53 O 0 0.00016489839
, O 0 0.0001920736
P O 0 0.0021965257
< O 0 0.00011106713
0 O 0 9.1466085e-05
. O 0 8.842096e-05
05 O 0 0.0013160838
) O 0 0.00019179836
, O 0 0.00016167725
glomerular O 0 0.85207546
alpha O 0 0.59371805
- O 0 0.0004868356
smooth O 0 0.0010526273
muscle O 0 0.000857709
actin O 0 0.0005569917
( O 0 0.00019793794
r O 0 0.00015922646
= O 0 0.000103595565
0 O 0 6.3490035e-05
. O 0 5.551274e-05
74 O 0 0.00016586424
, O 0 0.0001878646
P O 0 0.0021188103
< O 0 0.00010994406
0 O 0 8.632561e-05
. O 0 7.2780036e-05
01 O 0 0.00030395735
) O 0 0.00015278478
and O 0 0.00013706263
glomerular O 0 0.78042316
desmin O 0 0.065575056
( O 0 0.00032653072
r O 0 0.00022404245
= O 0 0.00014643729
0 O 0 9.437609e-05
. O 0 8.6968605e-05
48 O 0 0.00013726456
, O 0 0.0003399192
P O 0 0.00241669
< O 0 0.0003939138
0 O 0 0.00044682642
. O 0 0.0006579631
05 O 0 0.0062413183
) O 0 0.0027255553
. O 0 0.00273821

Baseline O 0 0.0047130384
renal O 0 0.8931801
ACE O 0 0.99852884
did O 0 0.0011789202
not O 0 0.00043334076
correlate O 0 0.00031288122
with O 0 0.0006027435
focal B-Disease 0 0.36852962
glomerulosclerosis I-Disease 2 0.9999987
( O 0 0.0036719402
r O 0 0.0007106523
= O 0 0.0003435929
0 O 0 0.00022111787
. O 0 0.00023726081
22 O 0 0.00061260426
, O 0 0.0012358066
NS O 0 0.17142749
) O 0 0.003170144
. O 0 0.0028195435

In O 0 0.0026296123
controls O 0 0.0029012372
, O 0 0.0014576341
no O 0 0.00060182274
predictive O 0 0.0011644047
values O 0 0.0008088221
for O 0 0.0007318582
renal O 0 0.58810544
parameters O 0 0.0017651216
were O 0 0.0015294789
observed O 0 0.0019182614
. O 0 0.0030705286

CONCLUSION O 0 0.013285696
: O 0 0.0018291615
Individual O 0 0.0008251836
differences O 0 0.00033910674
in O 0 0.0005006355
renal O 0 0.7737886
ACE O 0 0.99854845
activity O 0 0.00024549422
predict O 0 9.002721e-05
the O 0 0.00013475663
severity O 0 0.00040052173
of O 0 0.00051071827
adriamycin B-Chemical 0 0.99984324
- O 0 0.0015211477
induced O 0 0.0009089572
renal B-Disease 0 0.9997929
damage I-Disease 0 0.99179244
in O 0 0.0004219774
this O 0 0.00054834073
outbred O 0 0.0016167115
rat O 0 0.0014083505
strain O 0 0.0009986549
. O 0 0.0017486555

This O 0 0.0032991688
supports O 0 0.0011262354
the O 0 0.00072433683
assumption O 0 0.0004865118
that O 0 0.00024834537
differences O 0 0.00017296444
in O 0 0.00031994728
renal O 0 0.9438684
ACE O 0 0.99962306
activity O 0 0.00036555057
predispose O 0 0.00038532584
to O 0 0.00014315255
a O 0 0.00022290145
less O 0 0.00022080098
favourable O 0 0.00048206793
course O 0 0.0003505609
of O 0 0.0013809772
renal B-Disease 0 0.99927694
damage I-Disease 0 0.9968928
. O 0 0.0043135555

Recurrent O 0 0.022619836
acute O 0 0.8296228
interstitial B-Disease 0 0.99255544
nephritis I-Disease 0 0.999966
induced O 0 0.030967172
by O 0 0.012438221
azithromycin B-Chemical 0 0.9989318
. O 0 0.009170506

A O 0 0.02615438
14 O 0 0.0024535868
- O 0 0.002511172
year O 0 0.0007899785
- O 0 0.0010977623
old O 0 0.00054992293
girl O 0 0.0009867431
is O 0 0.00029057055
reported O 0 0.0002793598
with O 0 0.00035794577
recurrent O 0 0.012113732
, O 0 0.0009802796
azithromycin B-Chemical 0 0.99971825
- O 0 0.0017021754
induced O 0 0.0008378368
, O 0 0.0013643788
acute O 0 0.9171136
interstitial B-Disease 0 0.9982494
nephritis I-Disease 0 0.9999913
. O 0 0.0096138455

The O 0 0.0015247602
second O 0 0.0012983104
episode O 0 0.0019533574
was O 0 0.0008232649
more O 0 0.00072844315
severe O 0 0.0023335146
than O 0 0.00017195706
the O 0 0.00015751824
first O 0 0.00010669998
; O 0 0.00017458877
and O 0 0.00011315861
although O 0 7.808638e-05
both O 0 8.534585e-05
were O 0 8.171514e-05
treated O 0 0.000114494615
with O 0 0.00012522856
intensive O 0 0.00019981238
corticosteroid O 0 0.99153686
therapy O 0 0.00054506224
, O 0 0.00039071054
renal O 0 0.6891499
function O 0 0.00077896327
remained O 0 0.0013218095
impaired O 0 0.0057845693
. O 0 0.002191172

Although O 0 0.0016376645
most O 0 0.0017398852
cases O 0 0.0010382048
of O 0 0.0007914324
antibiotic O 0 0.0030147645
induced O 0 0.0010683881
acute O 0 0.90011823
interstitial B-Disease 0 0.9980854
nephritis I-Disease 0 0.9999989
are O 0 0.0013681796
benign O 0 0.054402776
and O 0 0.00021393181
self O 0 0.00063736795
- O 0 0.00028207467
limited O 0 0.00010796026
, O 0 0.00012277979
some O 0 0.00011070096
patients O 0 0.00016393531
are O 0 0.000104442246
at O 0 0.0001092819
risk O 0 0.0009279091
for O 0 0.0003337783
permanent O 0 0.01765804
renal B-Disease 2 0.9995326
injury I-Disease 2 0.99813193
. O 0 0.0044161114

Spironolactone B-Chemical 0 0.99967015
- O 0 0.008047324
induced O 0 0.0033021825
renal B-Disease 0 0.99346054
insufficiency I-Disease 0 0.9991959
and O 0 0.0039191027
hyperkalemia B-Disease 2 0.9999629
in O 0 0.0010236504
patients O 0 0.0011358606
with O 0 0.0012634522
heart B-Disease 0 0.25569916
failure I-Disease 0 0.6026111
. O 0 0.0033982832

BACKGROUND O 0 0.008392338
: O 0 0.0023243986
A O 0 0.0038196617
previous O 0 0.0004646976
randomized O 0 0.0003848976
controlled O 0 0.00019364659
trial O 0 0.00016627865
evaluating O 0 6.196907e-05
the O 0 8.7257526e-05
use O 0 8.829593e-05
of O 0 0.00029959806
spironolactone B-Chemical 1 0.99999
in O 0 0.00025841017
heart B-Disease 0 0.14648686
failure I-Disease 0 0.17215629
patients O 0 0.00025738333
reported O 0 0.000103226266
a O 0 0.00011770441
low O 0 0.00027405957
risk O 0 0.0022611893
of O 0 0.00085785944
hyperkalemia B-Disease 2 0.99999404
( O 0 0.0006299795
2 O 0 0.00011340371
% O 0 0.00013620793
) O 0 0.0002166998
and O 0 0.00027198603
renal B-Disease 0 0.9725604
insufficiency I-Disease 0 0.99792504
( O 0 0.0010967443
0 O 0 0.00054675963
% O 0 0.0009606361
) O 0 0.0019185579
. O 0 0.0020771136

Because O 0 0.0013535226
treatments O 0 0.0016895384
for O 0 0.00080782763
heart B-Disease 0 0.05143194
failure I-Disease 0 0.08984785
have O 0 0.00026137667
changed O 0 0.00017698006
since O 0 6.979438e-05
the O 0 9.059767e-05
benefits O 0 9.665448e-05
of O 0 0.00037128467
spironolactone B-Chemical 1 0.9999913
were O 0 0.00026524978
reported O 0 0.0001538203
, O 0 0.000100308855
the O 0 7.460637e-05
prevalence O 0 0.00010018851
of O 0 0.00012554445
these O 0 0.00023098523
complications O 0 0.004777711
may O 0 0.00013231524
differ O 0 0.00013231586
in O 0 0.00017929601
current O 0 0.00062073016
clinical O 0 0.0016394531
practice O 0 0.0015496654
. O 0 0.0017862897

We O 0 0.0015008821
therefore O 0 0.001222196
sought O 0 0.001118033
to O 0 0.00046081826
determine O 0 0.00019419576
the O 0 0.00026335078
prevalence O 0 0.0002759163
and O 0 0.00018040654
clinical O 0 0.00031841273
associations O 0 0.00010150789
of O 0 0.00044427763
hyperkalemia B-Disease 2 0.9999864
and O 0 0.0010131208
renal B-Disease 0 0.9966719
insufficiency I-Disease 0 0.99845684
in O 0 0.0002907468
heart B-Disease 0 0.09751091
failure I-Disease 0 0.14164726
patients O 0 0.00065481197
treated O 0 0.0008369671
with O 0 0.0028552099
spironolactone B-Chemical 1 0.99995327
. O 0 0.0034101866

METHODS O 0 0.0016899229
: O 0 0.0012981464
We O 0 0.00046321642
performed O 0 0.00043284637
a O 0 0.00047359552
case O 0 0.00027497043
control O 0 0.00022153357
study O 0 0.00023531348
of O 0 0.00027911775
heart B-Disease 0 0.056984082
failure I-Disease 0 0.13692577
patients O 0 0.0004272222
treated O 0 0.00034755943
with O 0 0.00075532857
spironolactone B-Chemical 1 0.99998
in O 0 0.0004733383
our O 0 0.00077056524
clinical O 0 0.0020926772
practice O 0 0.0016495459
. O 0 0.0018312488

Cases O 0 0.005367457
were O 0 0.0013622586
patients O 0 0.0011598527
who O 0 0.001115891
developed O 0 0.0023626261
hyperkalemia B-Disease 2 0.99998116
( O 0 0.020007102
K B-Chemical 1 0.9998641
( O 0 0.0012118799
+ O 0 0.0008016324
) O 0 0.00037966948
> O 0 0.00032601712
5 O 0 8.7319444e-05
. O 0 6.614102e-05
0 O 0 0.00011227081
mEq O 0 0.09326325
/ O 0 0.00089843187
L O 0 0.33448178
) O 0 0.0002887746
or O 0 0.00016929675
renal B-Disease 0 0.9835656
insufficiency I-Disease 0 0.9996019
( O 0 0.0033173128
Cr B-Chemical 0 0.99998546
> O 0 0.00097419793
or O 0 0.00013169768
= O 0 0.00013607317
2 O 0 5.5039964e-05
. O 0 3.7185288e-05
5 O 0 4.8642076e-05
mg O 0 0.0009499653
/ O 0 0.00050116784
dL O 0 0.0014805136
) O 0 0.00021853522
, O 0 0.000102302976
and O 0 7.519147e-05
they O 0 5.6560788e-05
were O 0 6.4533226e-05
compared O 0 4.3686105e-05
to O 0 6.226235e-05
2 O 0 6.3989726e-05
randomly O 0 4.4852564e-05
selected O 0 0.00014210383
controls O 0 0.00039978873
per O 0 0.00027170352
case O 0 0.0011041
. O 0 0.0018253487

Clinical O 0 0.0052068015
characteristics O 0 0.0011390634
, O 0 0.0014621288
medications O 0 0.0045111887
, O 0 0.0006346487
and O 0 0.00041799978
serum O 0 0.0051091826
chemistries O 0 0.0037723638
at O 0 0.00015516498
baseline O 0 0.00015537876
and O 0 0.00016910765
follow O 0 0.00012187486
- O 0 0.00026681522
up O 0 0.00017165729
time O 0 0.00013981009
periods O 0 0.00025259078
were O 0 0.0005514304
compared O 0 0.0008198215
. O 0 0.0019001856

RESULTS O 0 0.004846352
: O 0 0.0021720654
Sixty O 0 0.0017934155
- O 0 0.0011263605
seven O 0 0.0003697591
of O 0 0.0005607413
926 O 0 0.09697625
patients O 0 0.0006273294
( O 0 0.00032958068
7 O 0 0.00011289907
. O 0 7.908245e-05
2 O 0 8.138456e-05
% O 0 9.87824e-05
) O 0 0.00010260916
required O 0 4.3779855e-05
discontinuation O 0 0.0018227563
of O 0 0.00037472002
spironolactone B-Chemical 1 0.9999881
due O 0 0.00011913373
to O 0 0.00025391878
hyperkalemia B-Disease 2 0.9999877
( O 0 0.00047705485
n O 0 0.00012232953
= O 0 0.00013441514
33 O 0 0.00015130184
) O 0 0.00016568389
or O 0 0.00014854145
renal B-Disease 0 0.75860023
failure I-Disease 0 0.22359158
( O 0 0.00066317123
n O 0 0.00038115706
= O 0 0.0006291323
34 O 0 0.00097540714
) O 0 0.0017709613
. O 0 0.001972392

Patients O 0 0.0026243152
who O 0 0.0022011066
developed O 0 0.0029022098
hyperkalemia B-Disease 2 0.99991524
were O 0 0.001026037
older O 0 0.0013467388
and O 0 0.00021140587
more O 0 0.00018500334
likely O 0 8.565771e-05
to O 0 0.00010771316
have O 0 0.00015879967
diabetes B-Disease 0 0.99828845
, O 0 0.00016679108
had O 0 6.995697e-05
higher O 0 7.60419e-05
baseline O 0 8.0138736e-05
serum O 0 0.103660956
potassium B-Chemical 0 0.9999757
levels O 0 0.00017318824
and O 0 9.670787e-05
lower O 0 0.00013676574
baseline O 0 0.00016624725
potassium B-Chemical 0 0.9999696
supplement O 0 0.017387148
doses O 0 0.003838175
, O 0 0.00013533664
and O 0 8.160013e-05
were O 0 6.108483e-05
more O 0 6.8449626e-05
likely O 0 3.7045334e-05
to O 0 4.45029e-05
be O 0 5.080929e-05
treated O 0 0.00011757989
with O 0 0.00025620862
beta O 0 0.9335998
- O 0 0.0012015261
blockers O 0 0.98797554
than O 0 0.00015485018
controls O 0 0.00041007908
( O 0 0.00036151402
n O 0 0.00031663125
= O 0 0.00063887436
134 O 0 0.0016890141
) O 0 0.0018708274
. O 0 0.0019613963

Patients O 0 0.002398227
who O 0 0.001850765
developed O 0 0.0018576876
renal B-Disease 0 0.9747781
insufficiency I-Disease 0 0.99741936
had O 0 0.00043327612
lower O 0 0.00024703043
baseline O 0 0.000109049455
body O 0 0.00029631823
weight O 0 0.00039430283
and O 0 8.5103165e-05
higher O 0 9.02229e-05
baseline O 0 8.9641726e-05
serum O 0 0.044330053
creatinine B-Chemical 1 0.9994147
, O 0 0.00014857457
required O 0 3.768504e-05
higher O 0 9.724162e-05
doses O 0 0.00046780583
of O 0 0.000172882
loop O 0 0.00039942094
diuretics O 0 0.99977905
, O 0 0.00018918833
and O 0 9.42918e-05
were O 0 6.9155394e-05
more O 0 7.836732e-05
likely O 0 4.5123787e-05
to O 0 5.606508e-05
be O 0 6.94826e-05
treated O 0 0.00018340154
with O 0 0.00076242856
thiazide B-Chemical 0 0.99999285
diuretics O 0 0.99989283
than O 0 0.0008686743
controls O 0 0.002471518
. O 0 0.0017715472

CONCLUSIONS O 0 0.025480097
: O 0 0.0062128194
Spironolactone B-Chemical 0 0.9997849
- O 0 0.0039443513
induced O 0 0.0021749374
hyperkalemia B-Disease 2 0.99997044
and O 0 0.002485859
renal B-Disease 0 0.99756587
insufficiency I-Disease 0 0.99880815
are O 0 0.00023552669
more O 0 0.00018498323
common O 0 0.00013357581
in O 0 0.00010589709
our O 0 0.00020091391
clinical O 0 0.0005074254
experience O 0 0.00035849542
than O 0 0.0003070134
reported O 0 0.0008663912
previously O 0 0.0014253272
. O 0 0.00200684

This O 0 0.0038545798
difference O 0 0.0011196662
is O 0 0.0009692975
explained O 0 0.0006716698
by O 0 0.0005480026
patient O 0 0.0005797175
comorbidities O 0 0.0025115067
and O 0 0.0003218131
more O 0 0.00038939092
frequent O 0 0.00046077522
use O 0 0.00036435048
of O 0 0.0010224476
beta O 0 0.9264915
- O 0 0.008593586
blockers O 0 0.99705964
. O 0 0.0040577585

Acute O 0 0.6950344
reserpine B-Chemical 1 0.99993134
and O 0 0.007960879
subchronic O 0 0.99995816
haloperidol B-Chemical 1 0.99999785
treatments O 0 0.00238215
change O 0 0.0004935104
synaptosomal O 0 0.39649153
brain O 0 0.03152187
glutamate B-Chemical 1 0.9998487
uptake O 0 0.0043532522
and O 0 0.00027737702
elicit O 0 0.00023905672
orofacial B-Disease 0 0.9830421
dyskinesia I-Disease 0 0.9999943
in O 0 0.0018142582
rats O 0 0.002845667
. O 0 0.0019093307

Reserpine B-Chemical 1 0.9997372
- O 0 0.009249852
and O 0 0.0040651676
haloperidol B-Chemical 1 0.9999901
- O 0 0.0038452551
induced O 0 0.0014655594
orofacial B-Disease 0 0.9967589
dyskinesia I-Disease 0 0.99999833
are O 0 0.00028139164
putative O 0 0.00010265527
animal O 0 0.00013053222
models O 0 0.00013441194
of O 0 0.0006542213
tardive B-Disease 0 0.99999726
dyskinesia I-Disease 0 0.9999987
( O 0 0.005998388
TD B-Disease 0 0.9999006
) O 0 0.00035594348
whose O 0 0.00025154077
pathophysiology O 0 0.0014547108
has O 0 7.2737574e-05
been O 0 5.50365e-05
related O 0 4.0015006e-05
to O 0 9.09806e-05
free O 0 0.0002929483
radical O 0 0.10125004
generation O 0 0.0007720635
and O 0 0.000882629
oxidative O 0 0.68761414
stress O 0 0.06602842
. O 0 0.0025926682

In O 0 0.0016424123
the O 0 0.0011509456
present O 0 0.00069757225
study O 0 0.0007314929
, O 0 0.00042292677
the O 0 0.00022320129
authors O 0 0.00015170415
induced O 0 0.0005944425
orofacial B-Disease 0 0.9953263
dyskinesia I-Disease 0 0.99999905
by O 0 0.0014883108
acute O 0 0.9661664
reserpine B-Chemical 1 0.9999962
and O 0 0.005635946
subchronic O 0 0.9999876
haloperidol B-Chemical 1 0.99999845
administration O 0 0.04681261
to O 0 0.0009257331
rats O 0 0.0022322205
. O 0 0.0017136829

Reserpine B-Chemical 1 0.999559
injection O 0 0.0037125545
( O 0 0.0014686021
one O 0 0.00043909636
dose O 0 0.0011588158
of O 0 0.00043992174
1 O 0 0.0002639694
mg O 0 0.0037361002
/ O 0 0.00069540273
kg O 0 0.00044641705
s O 0 0.00016790454
. O 0 0.000104523635
c O 0 0.0007481491
. O 0 7.86545e-05
) O 0 0.00010451108
every O 0 2.3499155e-05
other O 0 4.5200453e-05
day O 0 3.649002e-05
for O 0 3.8935825e-05
3 O 0 3.8591774e-05
days O 0 2.3065253e-05
caused O 0 6.011881e-05
a O 0 0.000100078214
significant O 0 7.4811396e-05
increase O 0 8.7213426e-05
in O 0 0.00013235261
vacuous O 0 0.8851286
chewing O 0 0.5375823
, O 0 0.00025198748
tongue O 0 0.0049387002
protrusion O 0 0.0017111786
and O 0 9.052694e-05
duration O 0 4.3462955e-05
of O 0 0.00016138476
facial O 0 0.0078846095
twitching O 0 0.29068175
, O 0 0.00031146035
compared O 0 0.00016255867
to O 0 0.00028186018
the O 0 0.000560434
control O 0 0.0011637438
. O 0 0.001958232

Haloperidol B-Chemical 1 0.99992275
administration O 0 0.04320236
( O 0 0.0016075968
one O 0 0.00041520473
dose O 0 0.0010001336
of O 0 0.00034592365
12 O 0 0.00015042677
mg O 0 0.0031550515
/ O 0 0.0005584533
kg O 0 0.00027878987
once O 0 6.1274084e-05
a O 0 9.434073e-05
week O 0 4.5528104e-05
s O 0 8.94733e-05
. O 0 7.264989e-05
c O 0 0.0006422523
. O 0 7.2449046e-05
) O 0 0.00012049879
for O 0 4.9101553e-05
4 O 0 4.3427866e-05
weeks O 0 2.2111242e-05
caused O 0 5.4673776e-05
an O 0 8.7879635e-05
increase O 0 9.024803e-05
in O 0 0.00013295775
vacuous O 0 0.87065583
chewing O 0 0.5173649
, O 0 0.00025254043
tongue O 0 0.0046949508
protrusion O 0 0.0016482302
and O 0 8.783305e-05
duration O 0 4.088023e-05
of O 0 0.00014160472
facial O 0 0.0037314724
twitching O 0 0.104547784
observed O 0 0.00018127421
in O 0 0.00018327776
four O 0 0.00018849508
weekly O 0 0.000460865
evaluations O 0 0.00084347004
. O 0 0.0016069862

After O 0 0.0009747596
the O 0 0.0011831456
treatments O 0 0.0011995718
and O 0 0.0007056362
behavioral O 0 0.0016221621
observation O 0 0.00068412535
, O 0 0.001110725
glutamate B-Chemical 1 0.99973077
uptake O 0 0.007305534
by O 0 0.00036719747
segments O 0 0.00033232282
of O 0 0.00034533747
the O 0 0.00042071252
brain O 0 0.003077075
was O 0 0.0011180126
analyzed O 0 0.001346979
. O 0 0.0022172409

A O 0 0.05183989
decreased O 0 0.0118164
glutamate B-Chemical 1 0.9996069
uptake O 0 0.025898606
was O 0 0.00065026473
observed O 0 0.00023200562
in O 0 0.00016069345
the O 0 0.00014485176
subcortical O 0 0.008093095
parts O 0 0.00010214457
of O 0 0.00011355378
animals O 0 7.115756e-05
treated O 0 0.00017983875
with O 0 0.0004981701
reserpine B-Chemical 1 0.99999166
and O 0 0.003627244
haloperidol B-Chemical 1 0.9999975
, O 0 0.0004976137
compared O 0 0.000175701
to O 0 0.0002822393
the O 0 0.0005488887
control O 0 0.0011355155
. O 0 0.0019152097

Importantly O 0 0.0022497354
, O 0 0.002087849
a O 0 0.0014003934
decrease O 0 0.0012059313
in O 0 0.0011296787
glutamate B-Chemical 1 0.999673
uptake O 0 0.005261361
correlates O 0 0.00023877746
negatively O 0 0.00023382729
with O 0 0.00023025589
an O 0 0.0002307616
increase O 0 0.00018913527
in O 0 0.00018612528
the O 0 0.0002758463
incidence O 0 0.0009675002
of O 0 0.0017079846
orofacial B-Disease 0 0.98352665
diskinesia I-Disease 0 0.9985123
. O 0 0.0037404438

These O 0 0.0019843734
results O 0 0.0011653256
indicate O 0 0.00048133993
that O 0 0.00036311362
early O 0 0.000611391
changes O 0 0.0005730977
in O 0 0.00061743887
glutamate B-Chemical 1 0.999782
transport O 0 0.001277012
may O 0 0.00013947798
be O 0 8.763628e-05
related O 0 4.3234228e-05
to O 0 7.1732095e-05
the O 0 0.00010131487
development O 0 0.0002547277
of O 0 0.0004281172
vacuous O 0 0.9043168
chewing O 0 0.4828278
movements O 0 0.0015207763
in O 0 0.00083238515
rats O 0 0.0021506862
. O 0 0.0019303564

Ceftriaxone B-Chemical 0 0.97416097
- O 0 0.0066590267
associated O 0 0.0028758966
biliary B-Disease 0 0.9968844
pseudolithiasis I-Disease 2 0.9993808
in O 0 0.0020132123
paediatric O 0 0.0024280883
surgical O 0 0.0022502977
patients O 0 0.003320824
. O 0 0.0031518165

It O 0 0.0030923383
is O 0 0.001566067
well O 0 0.00086083583
known O 0 0.00093374745
that O 0 0.00069752504
ceftriaxone B-Chemical 0 0.997262
leads O 0 0.001091805
to O 0 0.0009849177
pseudolithiasis B-Disease 2 0.9810668
in O 0 0.0010413775
some O 0 0.0014536787
patients O 0 0.0029966116
. O 0 0.0025795053

Clinical O 0 0.0059575066
and O 0 0.0015012223
experimental O 0 0.0010386469
studies O 0 0.0005465811
also O 0 0.0002897909
suggest O 0 0.00011932916
that O 0 0.00012997331
situations O 0 0.00020490294
causing O 0 0.00094772276
gallbladder B-Disease 0 0.9962843
dysfunction I-Disease 0 0.99934274
, O 0 0.0003532422
such O 0 9.9293524e-05
as O 0 0.00014829365
fasting O 0 0.045858596
, O 0 0.00015064696
may O 0 8.3421306e-05
have O 0 7.158429e-05
a O 0 0.000121457306
role O 0 7.8536534e-05
for O 0 0.00012687694
the O 0 0.00026863802
development O 0 0.00086084474
of O 0 0.0019945132
pseudolithiasis B-Disease 2 0.9950572
. O 0 0.0030703915

In O 0 0.001758042
this O 0 0.0014995736
study O 0 0.0011033808
, O 0 0.0005935916
we O 0 0.00020401533
prospectively O 0 0.0003122423
evaluated O 0 0.00015746358
the O 0 0.00015882766
incidence O 0 0.00028913718
and O 0 0.0001229954
clinical O 0 0.00019924979
importance O 0 5.2205898e-05
of O 0 0.00016185909
pseudolithiasis B-Disease 2 0.9380755
in O 0 7.865705e-05
paediatric O 0 9.861818e-05
surgical O 0 6.885546e-05
patients O 0 9.506843e-05
receiving O 0 0.00021045477
ceftriaxone B-Chemical 0 0.99851173
treatment O 0 0.00019924028
, O 0 0.00013697064
who O 0 0.00014868457
often O 0 9.881755e-05
had O 0 8.00599e-05
to O 0 7.302725e-05
fast O 0 0.00020931753
in O 0 0.00011217022
the O 0 0.00015591335
post O 0 0.0001800129
- O 0 0.0006040299
operative O 0 0.0008475221
period O 0 0.0006365132
. O 0 0.0015766842

Fifty O 0 0.005459482
children O 0 0.0022835373
who O 0 0.0013091468
were O 0 0.0005960669
given O 0 0.00044746406
ceftriaxone B-Chemical 0 0.9884701
were O 0 0.0006462064
evaluated O 0 0.00042671422
by O 0 0.00062612613
serial O 0 0.0014195192
abdominal O 0 0.0120078605
sonograms O 0 0.02361047
. O 0 0.0031383857

Of O 0 0.0043337853
those O 0 0.003426165
, O 0 0.0024729595
13 O 0 0.001723721
( O 0 0.0016957984
26 O 0 0.0014902407
% O 0 0.0013959217
) O 0 0.0019312523
developed O 0 0.0030535704
biliary O 0 0.88243943
pathology O 0 0.09520141
. O 0 0.0049926816

Comparison O 0 0.0013582878
of O 0 0.0011850704
the O 0 0.0007325441
patients O 0 0.00065371086
with O 0 0.0003873214
or O 0 0.0002393708
without O 0 0.00031231376
pseudolithiasis B-Disease 2 0.974702
revealed O 0 0.00018645798
no O 0 7.073034e-05
significant O 0 8.709018e-05
difference O 0 4.261084e-05
with O 0 8.3606865e-05
respect O 0 5.7413265e-05
to O 0 8.9319095e-05
age O 0 0.00015999963
, O 0 0.00015807888
sex O 0 0.000268349
, O 0 9.600469e-05
duration O 0 4.5209246e-05
of O 0 0.00012672761
the O 0 0.00015171457
treatment O 0 0.00023910597
and O 0 0.00040668182
starvation O 0 0.0021495628
variables O 0 0.0011106404
. O 0 0.0018498974

After O 0 0.00113547
cessation O 0 0.0015910169
of O 0 0.0011025812
the O 0 0.00076048874
treatment O 0 0.0008041081
, O 0 0.0010702494
pseudolithiasis B-Disease 2 0.9630251
resolved O 0 0.0011703639
spontaneously O 0 0.0009797978
within O 0 0.00018914032
a O 0 0.00059272157
short O 0 0.0006089078
period O 0 0.00079161715
. O 0 0.0019205139

The O 0 0.0030288282
incidence O 0 0.004629041
of O 0 0.0039414605
pseudolithiasis B-Disease 2 0.9781296
is O 0 0.0020702141
not O 0 0.0014449456
affected O 0 0.0022479019
by O 0 0.003123809
fasting O 0 0.28282958
. O 0 0.0047489237

Coronary B-Disease 0 0.53282654
aneurysm I-Disease 2 0.9936413
after O 0 0.0009779764
implantation O 0 0.0014728415
of O 0 0.0014260616
a O 0 0.0025166534
paclitaxel B-Chemical 1 0.99316376
- O 0 0.006417936
eluting O 0 0.031760097
stent O 0 0.012978752
. O 0 0.004283076

Formation O 0 0.0074887034
of O 0 0.002662129
coronary B-Disease 0 0.4307939
aneurysm I-Disease 2 0.99304044
is O 0 0.00073088665
a O 0 0.00056828954
rare O 0 0.001122914
complication O 0 0.003406808
of O 0 0.00034614035
stenting O 0 0.0037183333
with O 0 0.000279253
bare O 0 0.005585145
metal O 0 0.10495942
stents O 0 0.0014031496
, O 0 0.00012269718
but O 0 7.187589e-05
based O 0 4.4963657e-05
on O 0 3.322243e-05
experimental O 0 9.093427e-05
studies O 0 0.000107849235
drug O 0 0.0064139357
- O 0 0.00030061093
eluting O 0 0.0018672192
stents O 0 0.00042830827
may O 0 5.1881067e-05
induce O 0 4.711309e-05
toxic O 0 0.008879329
effects O 0 8.695169e-05
on O 0 3.675552e-05
the O 0 6.658895e-05
vessel O 0 0.0010440631
wall O 0 0.0003190974
with O 0 8.9593e-05
incomplete O 0 0.00019953537
stent O 0 0.00038087196
apposition O 0 0.0006044619
, O 0 0.00020707556
aneurysm B-Disease 2 0.9591145
formation O 0 0.00049467274
and O 0 0.00010419773
with O 0 0.00010142275
the O 0 8.591212e-05
potential O 0 0.0001310533
of O 0 0.00032829118
stent O 0 0.0049164556
thrombosis B-Disease 0 0.99964094
or O 0 0.0012898527
vessel B-Disease 0 0.82193375
rupture I-Disease 0 0.9978897
. O 0 0.0036091201

We O 0 0.0015834076
present O 0 0.0011343985
a O 0 0.001463802
43 O 0 0.0014951619
- O 0 0.0011384364
year O 0 0.0003318242
- O 0 0.0005335736
old O 0 0.00029812043
man O 0 0.0017226612
who O 0 0.0002591326
developed O 0 0.00019316196
a O 0 0.00023647424
coronary B-Disease 0 0.29102087
aneurysm I-Disease 2 0.98036903
in O 0 8.648462e-05
the O 0 7.258389e-05
right O 0 0.0003303624
coronary O 0 0.046480287
artery O 0 0.0054544066
6 O 0 4.731791e-05
months O 0 2.5613317e-05
after O 0 3.4176945e-05
receiving O 0 0.00019223594
a O 0 0.00047583305
paclitaxel B-Chemical 1 0.98568463
- O 0 0.0024922236
eluting O 0 0.0200009
stent O 0 0.0071485774
. O 0 0.0022157962

The O 0 0.0019575888
patient O 0 0.0018929464
was O 0 0.0014101826
asymptomatic O 0 0.0029911643
and O 0 0.0007266294
the O 0 0.0008781465
aneurysm B-Disease 2 0.98557055
was O 0 0.00074031646
detected O 0 0.00038170177
in O 0 0.00045441333
a O 0 0.0008445338
routine O 0 0.00096866646
control O 0 0.0015347778
. O 0 0.0024926055

Angiography O 0 0.009043478
and O 0 0.0017280566
intracoronary O 0 0.050379083
ultrasound O 0 0.002082594
demonstrated O 0 0.00034576096
lack O 0 0.000261078
of O 0 0.00026360553
contact O 0 0.00022639659
between O 0 9.9574e-05
stent O 0 0.0004657009
and O 0 0.00015538026
vessel O 0 0.0017895834
wall O 0 0.00058132986
in O 0 0.000107137465
a O 0 0.00014428134
15 O 0 8.018635e-05
- O 0 0.00015336456
mm O 0 0.00013876178
long O 0 7.6861856e-05
segment O 0 0.00012795607
with O 0 0.000118718664
maximal O 0 0.00022421448
aneurysm B-Disease 2 0.9578645
diameter O 0 0.001070492
of O 0 0.00035845887
6 O 0 0.00021564326
. O 0 0.0002717211
0 O 0 0.000568516
mm O 0 0.0018800856
. O 0 0.0020120717

The O 0 0.0026375526
patient O 0 0.0026444078
was O 0 0.0019064051
successfully O 0 0.0015118553
treated O 0 0.0017517619
with O 0 0.0017597325
a O 0 0.0026623835
graft O 0 0.010562273
stent O 0 0.012989409
. O 0 0.004506861

Causes O 0 0.010744575
of O 0 0.005357274
acute O 0 0.98103714
thrombotic B-Disease 2 0.9999751
microangiopathy I-Disease 2 0.99999607
in O 0 0.0030217955
patients O 0 0.0025826301
receiving O 0 0.0030192279
kidney O 0 0.8683641
transplantation O 0 0.12837355
. O 0 0.0035272625

OBJECTIVES O 0 0.005492735
: O 0 0.007905829
Thrombotic B-Disease 0 0.9993488
microangiopathy I-Disease 0 0.99998975
is O 0 0.0019942722
a O 0 0.0009902011
well O 0 0.0004535809
- O 0 0.0006564667
known O 0 0.00036379966
problem O 0 0.0003822174
in O 0 0.0003081882
patients O 0 0.0005485859
following O 0 0.00056334963
renal O 0 0.8993689
transplantation O 0 0.087996975
. O 0 0.0028615708

In O 0 0.0033184856
postrenal O 0 0.84731525
transplantation O 0 0.076510884
, O 0 0.010014308
thrombotic B-Disease 2 0.9999769
microangiopathy I-Disease 2 0.99999774
is O 0 0.0013459245
often O 0 0.0005673018
a O 0 0.0005471527
reflection O 0 0.0010659514
of O 0 0.0034013125
hemolytic B-Disease 0 0.99998176
uremic I-Disease 0 0.99998474
syndrome I-Disease 0 0.9980584
. O 0 0.004603962

We O 0 0.0016286606
aimed O 0 0.0016639456
to O 0 0.0007966799
determine O 0 0.0003480968
the O 0 0.0004720861
causes O 0 0.00076837244
of O 0 0.0031335175
thrombotic B-Disease 2 0.99999154
microangiopathy I-Disease 2 0.9999993
in O 0 0.0005899104
a O 0 0.0003253735
population O 0 0.00033737597
of O 0 0.0003117628
renal O 0 0.8230717
transplantation O 0 0.0059300344
recipients O 0 0.00090685644
and O 0 0.00031503686
discuss O 0 0.00030275455
the O 0 0.00069329113
literature O 0 0.0023165364
. O 0 0.0020776798

MATERIALS O 0 0.001990296
AND O 0 0.0013872979
METHODS O 0 0.0006830163
: O 0 0.0006777016
We O 0 0.00028563148
investigated O 0 0.0002818169
the O 0 0.00030193012
causes O 0 0.00052177033
of O 0 0.0021670018
thrombotic B-Disease 2 0.99999213
microangiopathy I-Disease 2 0.9999993
during O 0 0.00022720752
a O 0 0.0003180447
1 O 0 0.00012038027
- O 0 0.00015362655
year O 0 4.336351e-05
period O 0 3.1714815e-05
, O 0 6.4429856e-05
from O 0 5.1670097e-05
June O 0 6.957456e-05
2003 O 0 9.399456e-05
to O 0 5.6565805e-05
June O 0 7.843594e-05
2004 O 0 0.00013079139
, O 0 7.78118e-05
at O 0 4.9945716e-05
the O 0 0.00010928159
King O 0 0.0018785094
Fahad O 0 0.0013854905
National O 0 0.00022650241
Guard O 0 0.00029021534
Hospital O 0 0.00018149526
in O 0 8.315301e-05
Riyadh O 0 0.00016278963
, O 0 0.00012461451
Saudi O 0 0.0001858481
Arabia O 0 0.00012510717
, O 0 9.746832e-05
by O 0 7.400563e-05
reviewing O 0 0.00011911487
the O 0 6.524657e-05
slides O 0 0.00013136858
of O 0 9.3138115e-05
all O 0 8.9926565e-05
transplant O 0 0.0016437256
biopsies O 0 0.0003363071
( O 0 0.00016161575
n O 0 0.000101701386
= O 0 0.00014351336
25 O 0 0.00017485267
) O 0 0.00021061841
performed O 0 0.00015597699
during O 0 0.00018062978
this O 0 0.0006631807
interval O 0 0.0010219626
. O 0 0.001667749

Pre O 0 0.010957139
- O 0 0.005460266
and O 0 0.0026125617
posttransplant O 0 0.011969408
crossmatching O 0 0.0053442162
was O 0 0.0019797648
done O 0 0.0014852202
when O 0 0.0015821703
possible O 0 0.0033567967
. O 0 0.004810611

RESULTS O 0 0.007482231
: O 0 0.0035266092
Five O 0 0.0026378313
cases O 0 0.0027668036
of O 0 0.0062602954
thrombotic B-Disease 2 0.99991405
microangiopathy I-Disease 2 0.99998975
were O 0 0.007882966
found O 0 0.0039265878
. O 0 0.0042836987

Three O 0 0.0020929081
of O 0 0.001569762
these O 0 0.0011651958
cases O 0 0.0007233332
were O 0 0.00033186877
from O 0 0.00018476378
the O 0 0.00017665618
25 O 0 0.00023409119
transplantations O 0 0.0008077503
performed O 0 0.00011437109
at O 0 0.00010993945
King O 0 0.0023808018
Fahad O 0 0.0017286588
National O 0 0.00027691905
Guard O 0 0.00036581713
Hospital O 0 0.00022718542
, O 0 9.517964e-05
while O 0 6.605945e-05
the O 0 6.772852e-05
other O 0 6.717655e-05
2 O 0 6.555997e-05
transplantations O 0 0.00060442503
had O 0 7.8704776e-05
been O 0 5.2783438e-05
performed O 0 6.466395e-05
abroad O 0 0.0001692041
and O 0 0.00010050984
were O 0 0.00010276917
referred O 0 0.00014334827
to O 0 0.0001357352
us O 0 0.00041353368
for O 0 0.00024366852
follow O 0 0.0003515812
- O 0 0.0011598422
up O 0 0.0014116068
. O 0 0.0020560198

Three O 0 0.0023785469
cases O 0 0.0016062778
were O 0 0.0007473724
related O 0 0.00034979006
to O 0 0.00084077835
cyclosporine B-Chemical 1 0.99996984
, O 0 0.0010003577
and O 0 0.00039404503
1 O 0 0.00021074094
case O 0 0.00019426983
was O 0 0.00022754788
secondary O 0 0.00046516716
to O 0 0.00027725645
both O 0 0.00092819997
cyclosporine B-Chemical 1 0.9999788
and O 0 0.011025924
tacrolimus B-Chemical 0 0.9999584
. O 0 0.0049655805

The O 0 0.00179844
fifth O 0 0.0022249932
case O 0 0.00089311536
had O 0 0.0006072923
features O 0 0.0006341469
of O 0 0.0022068447
thrombotic B-Disease 2 0.9999857
microangiopathy I-Disease 2 0.9999987
related O 0 0.00022485801
to O 0 0.00021968091
an O 0 0.00084715243
antiphospholipid B-Disease 0 0.9999492
syndrome I-Disease 0 0.20925818
in O 0 0.00018482949
a O 0 0.00027091042
patient O 0 0.00034390995
with O 0 0.0011380039
systemic B-Disease 0 0.99864393
lupus I-Disease 0 0.9999964
erythematosus I-Disease 0 0.9999924
. O 0 0.008951863

CONCLUSIONS O 0 0.014974955
: O 0 0.002131136
In O 0 0.00071479846
the O 0 0.00068801345
literature O 0 0.00088720024
, O 0 0.0005010869
the O 0 0.0003154327
most O 0 0.0005381169
- O 0 0.0005336768
frequent O 0 0.00027369137
cause O 0 0.0003252649
of O 0 0.0010667498
hemolytic B-Disease 0 0.9999962
uremic I-Disease 0 0.9999974
syndrome I-Disease 0 0.98306054
in O 0 0.00015305149
patients O 0 0.00013788242
following O 0 7.4136864e-05
renal O 0 0.60261333
transplantation O 0 0.0028418407
is O 0 0.00019723899
recurrence O 0 0.0067178896
of O 0 0.00042833848
the O 0 0.0012298333
hemolytic B-Disease 0 0.99998367
uremic I-Disease 0 0.99998665
syndrome I-Disease 0 0.9975648
. O 0 0.0036329823

Other O 0 0.0034604426
causes O 0 0.002054725
include O 0 0.0010158006
drug O 0 0.017640267
- O 0 0.0010607439
related O 0 0.00023835052
( O 0 0.0011072188
cyclosporine B-Chemical 1 0.9999844
, O 0 0.0036438913
tacrolimus B-Chemical 0 0.9999944
) O 0 0.006578628
toxicity B-Disease 2 0.99910295
, O 0 0.0009268523
procoagulant O 0 0.61733216
status O 0 0.00030350767
, O 0 0.0003052965
and O 0 0.00033829984
antibody O 0 0.0018502955
- O 0 0.0011865845
mediated O 0 0.00084681856
rejection O 0 0.95533144
. O 0 0.0037232826

We O 0 0.0016973207
found O 0 0.0011126482
that O 0 0.0006314856
the O 0 0.0007182881
most O 0 0.0010678413
- O 0 0.0010264828
frequent O 0 0.00051918265
cause O 0 0.0006079922
of O 0 0.0023626168
thrombotic B-Disease 2 0.9999943
microangiopathy I-Disease 2 0.9999995
was O 0 0.0017649285
drug O 0 0.012669071
related O 0 0.00012282653
, O 0 0.00028033552
secondary O 0 0.0007262459
mainly O 0 0.0007239765
to O 0 0.0014677646
cyclosporine B-Chemical 1 0.99994147
. O 0 0.0040046535

In O 0 0.0016685001
the O 0 0.0012666616
current O 0 0.0014855524
study O 0 0.0008217287
, O 0 0.00046022693
the O 0 0.00027025308
frequency O 0 0.0003610272
of O 0 0.0017138494
thrombotic B-Disease 2 0.9999937
microangiopathy I-Disease 2 0.9999995
was O 0 0.0006773033
similar O 0 8.094471e-05
to O 0 7.318027e-05
the O 0 8.007005e-05
percentage O 0 7.807208e-05
reported O 0 0.00013410942
in O 0 0.00012245195
the O 0 0.00018929082
literature O 0 0.0005377398
( O 0 0.0005641928
20 O 0 0.0005674008
% O 0 0.0010105448
) O 0 0.0020405634
. O 0 0.0021725884

Comparison O 0 0.0015158247
of O 0 0.0015744249
developmental O 0 0.0030628927
toxicity B-Disease 2 0.9775318
of O 0 0.0010086768
selective O 0 0.0015215577
and O 0 0.00035899217
non O 0 0.0004297599
- O 0 0.000561816
selective O 0 0.0027523716
cyclooxygenase O 0 0.9999391
- O 0 0.00065187836
2 O 0 9.349459e-05
inhibitors O 0 0.00029820827
in O 0 0.00015200331
CRL O 0 0.18902618
: O 0 0.000280027
( O 0 0.00030805275
WI O 0 0.0013163509
) O 0 0.0004292146
WUBR O 0 0.016794667
Wistar O 0 0.0013703809
rats O 0 0.00041547435
- O 0 0.0006514517
- O 0 0.0016877506
DFU B-Chemical 1 0.9999635
and O 0 0.003856521
piroxicam B-Chemical 0 0.99995303
study O 0 0.00470191
. O 0 0.0024876287

BACKGROUND O 0 0.012493294
: O 0 0.005754059
Cyclooxygenase O 0 0.9992304
( O 0 0.006039299
COX O 0 0.9997385
) O 0 0.0015673775
inhibitors O 0 0.0013067861
are O 0 0.00026953005
one O 0 0.00015040985
of O 0 0.00021578556
the O 0 0.00019323529
most O 0 0.0003345365
often O 0 0.00040753564
ingested O 0 0.0031022266
drugs O 0 0.009447617
during O 0 0.0005997396
pregnancy O 0 0.007910648
. O 0 0.0022318976

Unlike O 0 0.0018312408
general O 0 0.002276866
toxicity B-Disease 2 0.98075
data O 0 0.0014466266
, O 0 0.00082034
their O 0 0.0006326359
prenatal O 0 0.002963158
toxic O 0 0.11081615
effects O 0 0.00058387115
were O 0 0.00039090394
not O 0 0.00033880852
extensively O 0 0.00048722883
studied O 0 0.00085051695
before O 0 0.00078603096
. O 0 0.0021052032

The O 0 0.0014794848
aim O 0 0.0013252842
of O 0 0.0010118121
the O 0 0.00056981604
experiment O 0 0.0003437138
was O 0 0.0002986806
to O 0 0.00014409077
evaluate O 0 7.870448e-05
the O 0 0.00013656609
developmental O 0 0.00070826936
toxicity B-Disease 2 0.98421836
of O 0 0.00027444446
the O 0 0.00013991089
non O 0 0.00022531943
- O 0 0.00028762032
selective O 0 0.0007525911
( O 0 0.000681935
piroxicam B-Chemical 0 0.99999225
) O 0 0.00044304697
and O 0 0.00013806345
selective O 0 0.0010001614
( O 0 0.0010638037
DFU B-Chemical 1 0.9999919
; O 0 0.00027768128
5 B-Chemical 0 7.6921686e-05
, I-Chemical 0 0.00010165997
5 I-Chemical 0 8.296815e-05
- I-Chemical 0 0.00038257896
dimethyl I-Chemical 0 0.99648523
- I-Chemical 0 0.0005869066
3 I-Chemical 0 0.00010952738
- I-Chemical 0 0.00022832502
( I-Chemical 0 0.00015680148
3 I-Chemical 0 9.59839e-05
- I-Chemical 0 0.00035411867
fluorophenyl I-Chemical 0 0.8348704
) I-Chemical 0 0.0004292745
- I-Chemical 0 0.00029058746
4 I-Chemical 0 9.553391e-05
- I-Chemical 0 0.00021417977
( I-Chemical 0 0.00016018278
4 I-Chemical 0 0.00010362274
- I-Chemical 0 0.00043762298
methylsulphonyl I-Chemical 0 0.9797473
) I-Chemical 0 0.0012633638
phenyl I-Chemical 0 0.9982181
- I-Chemical 0 0.00074287417
2 I-Chemical 0 0.00016458138
( I-Chemical 0 0.000347345
5H I-Chemical 0 0.004384942
) I-Chemical 0 0.0003538821
- I-Chemical 0 0.00048348
furanon I-Chemical 0 0.00477067
) O 0 0.0015280712
COX O 0 0.99972993
- O 0 0.0017665479
2 O 0 0.0007625943
inhibitors O 0 0.0035276953
. O 0 0.0024756098

METHODS O 0 0.0018300252
: O 0 0.0018831699
Drugs O 0 0.0061921864
were O 0 0.0005882036
separately O 0 0.0002600508
, O 0 0.00031698673
orally O 0 0.00042709368
once O 0 0.000118219585
daily O 0 0.0001845956
dosed O 0 0.00043306226
to O 0 0.00011016549
pregnant O 0 0.0004986854
rats O 0 0.00012370064
from O 0 5.8158726e-05
day O 0 5.1357074e-05
8 O 0 6.500245e-05
to O 0 9.000395e-05
21 O 0 0.00018410377
( O 0 0.00035177413
GD1 O 0 0.006918199
= O 0 0.00061750633
plug O 0 0.0012725978
day O 0 0.00063534384
) O 0 0.001915445
. O 0 0.0021682729

Doses O 0 0.017624851
were O 0 0.001453399
set O 0 0.0007791017
at O 0 0.0004423633
0 O 0 0.00044270794
. O 0 0.0002648813
3 O 0 0.0002193021
, O 0 0.00025055438
3 O 0 0.00013640005
. O 0 9.1445065e-05
0 O 0 9.435656e-05
and O 0 0.00010071986
30 O 0 8.77459e-05
. O 0 9.791175e-05
0mg O 0 0.5650594
/ O 0 0.00048780715
kg O 0 0.00033099105
for O 0 0.00014768573
piroxicam B-Chemical 0 0.9999783
and O 0 0.0002463249
0 O 0 0.000107472566
. O 0 6.262904e-05
2 O 0 7.268433e-05
, O 0 9.815612e-05
2 O 0 7.040833e-05
. O 0 5.4171815e-05
0 O 0 7.285059e-05
and O 0 0.00010819431
20 O 0 0.00015699373
. O 0 0.00018991834
0mg O 0 0.58219695
/ O 0 0.0015758435
kg O 0 0.0017203751
for O 0 0.0015275009
DFU B-Chemical 1 0.99981564
. O 0 0.004138726

Fetuses O 0 0.0076194108
were O 0 0.0019942515
delivered O 0 0.0010999485
on O 0 0.0013108199
GD O 0 0.3019096
21 O 0 0.0017904507
and O 0 0.0015405099
routinely O 0 0.0017197898
examined O 0 0.0022614219
. O 0 0.004127021

Comprehensive O 0 0.009694943
clinical O 0 0.006297638
and O 0 0.0031546047
developmental O 0 0.0040868446
measurements O 0 0.0024694707
were O 0 0.0032962426
done O 0 0.004268686
. O 0 0.0060766004

The O 0 0.0014097382
pooled O 0 0.0010583532
statistical O 0 0.0010127346
analysis O 0 0.00048288377
for O 0 0.00035655175
ventricular B-Disease 0 0.55557394
septal I-Disease 0 0.013427737
( I-Disease 0 0.00079548656
VSD I-Disease 0 0.6975805
) I-Disease 0 0.0003281779
and I-Disease 0 0.00015918503
midline I-Disease 0 0.00057008356
( I-Disease 0 0.00041429675
MD I-Disease 0 0.95860666
) I-Disease 0 0.0003286654
defects I-Disease 0 0.00038034527
was O 0 9.733661e-05
performed O 0 5.406777e-05
for O 0 4.7506586e-05
rat O 0 0.00017104344
fetuses O 0 0.00020334066
exposed O 0 8.556603e-05
to O 0 0.00018180911
piroxicam B-Chemical 0 0.99999225
, O 0 0.00027333832
selective O 0 0.0004887972
and O 0 0.0001194331
non O 0 0.00019342847
- O 0 0.00033019172
selective O 0 0.0028164347
COX O 0 0.99996233
- O 0 0.0004983031
2 O 0 8.546679e-05
inhibitor O 0 0.00026084686
based O 0 0.00010304236
on O 0 9.921743e-05
present O 0 0.000200604
and O 0 0.0004852765
historic O 0 0.0020999487
data O 0 0.001715018
. O 0 0.0021009743

RESULTS O 0 0.0049378094
: O 0 0.0023411668
Maternal O 0 0.0032536758
toxicity B-Disease 2 0.9935464
, O 0 0.0019319757
intrauterine B-Disease 0 0.5582178
growth I-Disease 0 0.82228166
retardation I-Disease 0 0.99981683
, O 0 0.0006811162
and O 0 0.00019573685
increase B-Disease 0 0.00011861015
of I-Disease 0 0.00013649931
external I-Disease 0 0.00015299064
and I-Disease 0 0.00012422241
skeletal I-Disease 0 0.0008428576
variations I-Disease 0 7.6324584e-05
were O 0 6.976557e-05
found O 0 5.3388947e-05
in O 0 6.139692e-05
rats O 0 0.00011994406
treated O 0 0.0001300859
with O 0 0.00013402096
the O 0 0.00014639526
highest O 0 0.00034379205
dose O 0 0.0027737655
of O 0 0.004211087
piroxicam B-Chemical 0 0.9999542
. O 0 0.0042121867

Decrease O 0 0.006894011
of O 0 0.0020902466
fetal O 0 0.0060508223
length O 0 0.0006984067
was O 0 0.00043906938
the O 0 0.00024924253
only O 0 0.00026475178
signs O 0 0.0012563212
of O 0 0.00031978203
the O 0 0.0005927904
DFU B-Chemical 1 0.999992
developmental O 0 0.0137543455
toxicity B-Disease 2 0.9974511
observed O 0 0.00017250344
in O 0 0.00011762205
pups O 0 0.00017815524
exposed O 0 0.00012344446
to O 0 0.00014014897
the O 0 0.00024612958
highest O 0 0.0007153415
compound O 0 0.1813654
dose O 0 0.0139992945
. O 0 0.002557375

Lack O 0 0.0049037393
of O 0 0.004768501
teratogenicity O 0 0.99935085
was O 0 0.0017511883
found O 0 0.00080696895
in O 0 0.0013583163
piroxicam B-Chemical 0 0.999977
and O 0 0.016212763
DFU B-Chemical 1 0.9999782
- O 0 0.004355299
exposed O 0 0.0016454111
groups O 0 0.0020366423
. O 0 0.0026147868

Prenatal O 0 0.016671518
exposure O 0 0.00220033
to O 0 0.0009889558
non O 0 0.0011732271
- O 0 0.001296132
selective O 0 0.0033742546
COX O 0 0.99988985
inhibitors O 0 0.0022478288
increases O 0 0.00022455056
the O 0 0.00017697363
risk O 0 0.0011930838
of O 0 0.000389992
VSD O 0 0.87196505
and O 0 0.00027493265
MD O 0 0.90983224
when O 0 5.666315e-05
compared O 0 4.5220586e-05
to O 0 6.0350238e-05
historic O 0 0.00024227994
control O 0 9.4371135e-05
but O 0 0.000110769186
not O 0 0.00010766757
with O 0 0.00027378747
selective O 0 0.004971625
COX O 0 0.99989426
- O 0 0.0016947631
2 O 0 0.0006362455
inhibitors O 0 0.0032585675
. O 0 0.0021347343

CONCLUSION O 0 0.01660818
: O 0 0.0021424622
Both O 0 0.0010057061
selective O 0 0.0015344693
and O 0 0.00064242946
non O 0 0.00072915433
- O 0 0.0009671647
selective O 0 0.004539759
COX O 0 0.9999472
- O 0 0.00087146653
2 O 0 0.00012359087
inhibitors O 0 0.00037007668
were O 0 0.00014776771
toxic O 0 0.009009455
for O 0 9.333318e-05
rats O 0 0.00019292763
fetuses O 0 0.000254898
when O 0 7.462473e-05
administered O 0 0.00017538898
in O 0 0.00019516509
the O 0 0.0003380324
highest O 0 0.0009350543
dose O 0 0.00602758
. O 0 0.0022954303

Unlike O 0 0.0061689476
DFU B-Chemical 1 0.9998766
, O 0 0.013763094
piroxicam B-Chemical 0 0.99993575
was O 0 0.0021564385
also O 0 0.000899614
highly O 0 0.0010373555
toxic O 0 0.072838694
to O 0 0.0011785215
the O 0 0.0018128754
dams O 0 0.009411327
. O 0 0.0033099614

Prenatal O 0 0.01545018
exposure O 0 0.0022276856
to O 0 0.0012015147
selective O 0 0.011533818
COX O 0 0.99991715
- O 0 0.0019248172
2 O 0 0.00023888926
inhibitors O 0 0.0005092662
does O 0 0.00013888754
not O 0 0.00010108868
increase O 0 0.00010068615
the O 0 0.00010598093
risk O 0 0.000518776
of O 0 0.00017722844
ventricular B-Disease 0 0.70542026
septal I-Disease 0 0.0024125827
and I-Disease 0 0.00013035447
midline I-Disease 0 0.0043573086
defects I-Disease 0 0.0057565747
in O 0 9.654487e-05
rat O 0 0.00017699794
when O 0 4.264486e-05
compared O 0 4.747403e-05
to O 0 8.132102e-05
non O 0 0.00021368838
- O 0 0.0003534428
selective O 0 0.0008295591
drugs O 0 0.0077126385
and O 0 0.00053278456
historic O 0 0.0018532358
control O 0 0.001308855
. O 0 0.0019460262

Lone O 0 0.028614061
atrial B-Disease 0 0.93445873
fibrillation I-Disease 0 0.9995353
associated O 0 0.0030354059
with O 0 0.006450046
creatine B-Chemical 1 0.99976903
monohydrate O 0 0.99976355
supplementation O 0 0.9935387
. O 0 0.007923145

Atrial B-Disease 0 0.96640843
fibrillation I-Disease 0 0.99986744
in O 0 0.0023986627
young O 0 0.004237965
patients O 0 0.0010574411
without O 0 0.0006676446
structural O 0 0.0017140115
heart B-Disease 0 0.21392421
disease I-Disease 0 0.44284382
is O 0 0.00260508
rare O 0 0.009286053
. O 0 0.003397954

Therefore O 0 0.0019493735
, O 0 0.0017298234
when O 0 0.00069727417
the O 0 0.0010874558
arrhythmia B-Disease 0 0.9939267
is O 0 0.0004940762
present O 0 0.00021386267
in O 0 0.00019671797
this O 0 0.00027981907
population O 0 0.000606017
, O 0 0.00038063386
reversible O 0 0.012210662
causes O 0 0.0004920627
must O 0 0.00016924475
be O 0 0.00027527596
identified O 0 0.0003839147
and O 0 0.00080164464
resolved O 0 0.0024960295
. O 0 0.002272617

Thyroid B-Disease 0 0.9800576
disorders I-Disease 0 0.98108864
, O 0 0.0029273983
illicit O 0 0.7059907
drug O 0 0.04094389
or O 0 0.00058187864
stimulant O 0 0.559647
use O 0 0.0003229333
, O 0 0.00032919037
and O 0 0.00046434978
acute B-Disease 0 0.98715556
alcohol I-Disease 0 0.9999578
intoxication I-Disease 0 0.9999362
are O 0 0.0009421827
among O 0 0.00071720424
these O 0 0.0011683977
causes O 0 0.0026297248
. O 0 0.0023560245

We O 0 0.0017580788
report O 0 0.0017766983
the O 0 0.0009017388
case O 0 0.00061780325
of O 0 0.0005980494
a O 0 0.0005258459
30 O 0 0.00027594154
- O 0 0.0004526853
year O 0 0.00014517007
- O 0 0.00029378207
old O 0 0.0002194797
Caucasian O 0 0.013906523
man O 0 0.0032000719
who O 0 0.00021025243
came O 0 0.000115037095
to O 0 6.0372e-05
the O 0 8.611711e-05
emergency O 0 0.0009346321
department O 0 0.0008305938
in O 0 0.00017968345
atrial B-Disease 0 0.826892
fibrillation I-Disease 0 0.9998716
with O 0 0.0005534627
rapid O 0 0.0016520761
ventricular O 0 0.7107664
response O 0 0.0015809287
. O 0 0.0018201398

His O 0 0.009319812
medical O 0 0.005975988
history O 0 0.0028573708
was O 0 0.0012685849
unremarkable O 0 0.0031155755
, O 0 0.0005451607
except O 0 0.00024270538
for O 0 0.00026216506
minor O 0 0.0015444072
fractures B-Disease 2 0.9287109
of O 0 0.00089649245
the O 0 0.00089310255
fingers O 0 0.013705518
and O 0 0.0020312949
foot O 0 0.033803113
. O 0 0.0031489774

Thyroid O 0 0.4519419
- O 0 0.004348146
stimulating O 0 0.0026129046
hormone O 0 0.39125517
, O 0 0.0022385465
magnesium B-Chemical 1 0.99983037
, O 0 0.0010674482
and O 0 0.0008635057
potassium B-Chemical 0 0.9999174
levels O 0 0.0002810918
were O 0 0.000106636304
within O 0 3.3452347e-05
normal O 0 0.00016295037
limits O 0 0.00024637987
, O 0 0.00016695767
urine O 0 0.064450465
drug O 0 0.011150962
screen O 0 0.00032588225
was O 0 0.00017465655
negative O 0 0.00026448007
, O 0 0.00032011358
and O 0 0.0005474388
alcohol B-Chemical 0 0.9978892
use O 0 0.00095177087
was O 0 0.0013518204
denied O 0 0.004170161
. O 0 0.0022776045

However O 0 0.0026565492
, O 0 0.0016846843
when O 0 0.00058683474
the O 0 0.0006035149
patient O 0 0.0005549841
was O 0 0.00036834777
questioned O 0 0.00029361545
about O 0 0.0001872417
use O 0 0.00014919598
of O 0 0.0002736883
herbal O 0 0.32576495
products O 0 0.0011378803
and O 0 0.00031157618
supplements O 0 0.20318346
, O 0 0.00020830847
the O 0 0.0001457198
use O 0 0.00018127768
of O 0 0.0007820965
creatine B-Chemical 1 0.9998827
monohydrate O 0 0.9997718
was O 0 0.0027227404
revealed O 0 0.001851906
. O 0 0.0021107886

The O 0 0.0016915743
patient O 0 0.0015478823
was O 0 0.0009827578
admitted O 0 0.00088074926
to O 0 0.0002901227
the O 0 0.0002704923
hospital O 0 0.0004340012
, O 0 0.00024219033
anticoagulated O 0 0.0009103795
with O 0 0.00021088768
unfractionated O 0 0.13362224
heparin B-Chemical 0 0.9933094
, O 0 0.00016634096
and O 0 7.783977e-05
given O 0 5.4499244e-05
intravenous O 0 0.034628306
diltiazem B-Chemical 1 0.9999901
for O 0 7.124705e-05
rate O 0 7.735414e-05
control O 0 6.924091e-05
and O 0 0.00012524743
intravenous O 0 0.041881245
amiodarone B-Chemical 1 0.9998934
for O 0 0.00016880497
rate O 0 0.00027524843
and O 0 0.00037809578
rhythm O 0 0.0020662171
control O 0 0.0010356017
. O 0 0.0016771132

When O 0 0.0016166377
discharged O 0 0.0025199726
less O 0 0.0008828935
than O 0 0.00036448683
24 O 0 0.0002357181
hours O 0 0.00013808373
later O 0 0.00013439322
, O 0 0.00020099881
he O 0 0.00015470819
was O 0 0.00017319764
receiving O 0 0.0007546487
metoprolol B-Chemical 1 0.9999976
and O 0 0.0014652091
aspirin B-Chemical 0 0.99997115
, O 0 0.00022939993
with O 0 0.00013200121
follow O 0 6.124207e-05
- O 0 0.00013280695
up O 0 7.231665e-05
plans O 0 0.00013176704
for O 0 8.693113e-05
echocardiography O 0 0.00076575106
and O 0 0.00015893705
nuclear O 0 0.0004158946
imaging O 0 0.00043914496
to O 0 0.0003010704
assess O 0 0.0003700054
perfusion O 0 0.011594925
. O 0 0.0021607277

Exogenous O 0 0.37036347
creatine B-Chemical 1 0.99893934
is O 0 0.0024559477
used O 0 0.0011559576
by O 0 0.0011172041
athletes O 0 0.001881894
to O 0 0.0005863028
theoretically O 0 0.00087212696
improve O 0 0.0008175564
exercise O 0 0.0023602375
performance O 0 0.0030061319
. O 0 0.00323881

Vegetarians O 0 0.14308722
may O 0 0.0014351719
also O 0 0.000925824
take O 0 0.00068149995
creatine B-Chemical 1 0.99781525
to O 0 0.0004469853
replace O 0 0.00029528633
what O 0 0.0003089701
they O 0 0.00014029432
are O 0 0.00012000961
not O 0 0.00011453054
consuming O 0 0.00035739766
from O 0 0.00016224927
meat O 0 0.0068955524
, O 0 0.00034911808
fish O 0 0.0031045736
, O 0 0.0003464562
and O 0 0.00032823143
other O 0 0.0004262812
animal O 0 0.001211371
products O 0 0.0034785778
. O 0 0.0022030575

Previous O 0 0.0023205667
anecdotal O 0 0.0042604003
reports O 0 0.0017598656
have O 0 0.0008862768
linked O 0 0.001222287
creatine B-Chemical 1 0.9983005
to O 0 0.00088348764
the O 0 0.0008692606
development O 0 0.0018879996
of O 0 0.0037145622
arrhythmia B-Disease 0 0.99869066
. O 0 0.0048412587

Clinicians O 0 0.0034413447
must O 0 0.0008663259
be O 0 0.0007375993
diligent O 0 0.00077991653
when O 0 0.00024943057
interviewing O 0 0.0005445801
patients O 0 0.0002667247
about O 0 0.0001535047
their O 0 0.00019114073
drug O 0 0.0024802962
therapy O 0 0.00018558638
histories O 0 0.00012367775
and O 0 7.451124e-05
include O 0 5.1805036e-05
questions O 0 8.476689e-05
about O 0 8.8530636e-05
their O 0 0.00012433984
use O 0 0.000108835666
of O 0 0.00025876323
herbal O 0 0.20235008
products O 0 0.0015875931
and O 0 0.0008405677
dietary O 0 0.17294121
supplements O 0 0.6884032
. O 0 0.0028221456

In O 0 0.0019467572
addition O 0 0.0011941048
, O 0 0.0013867437
it O 0 0.00069761544
is O 0 0.00033545884
important O 0 0.00014310448
to O 0 0.00018618387
report O 0 0.00036069367
adverse O 0 0.0081635965
effects O 0 0.00019758796
associated O 0 0.00011711304
with O 0 0.00015401405
frequently O 0 0.00012472566
consumed O 0 0.0011603555
supplements O 0 0.125483
and O 0 0.00016530012
herbal O 0 0.15671794
products O 0 0.00037161986
to O 0 7.8888865e-05
the O 0 0.00011431766
Food O 0 0.0017242908
and O 0 0.00020397158
Drug O 0 0.028167577
Administration O 0 0.0014430906
and O 0 0.0003189523
in O 0 0.0003593356
the O 0 0.0006712263
literature O 0 0.0021574732
. O 0 0.002027804

Seizures B-Disease 0 0.9950418
induced O 0 0.0041378904
by O 0 0.0023510822
the O 0 0.002778572
cocaine B-Chemical 1 0.99971503
metabolite O 0 0.99905425
benzoylecgonine B-Chemical 1 0.9999869
in O 0 0.004658368
rats O 0 0.0054069334
. O 0 0.0035127748

The O 0 0.002004782
half O 0 0.0015802839
- O 0 0.0020812806
life O 0 0.0011014884
( O 0 0.0008383408
t1 O 0 0.00059214444
/ O 0 0.0008096506
2 O 0 0.00024862876
) O 0 0.0003379549
of O 0 0.00040047133
cocaine B-Chemical 1 0.9990362
is O 0 0.00020922889
relatively O 0 0.00020488222
short O 0 0.00010064152
, O 0 0.00012392615
but O 0 8.9141686e-05
some O 0 6.942002e-05
of O 0 8.47205e-05
the O 0 6.508531e-05
consequences O 0 0.000102066195
of O 0 0.00013389208
its O 0 0.0002191771
use O 0 9.2200884e-05
, O 0 9.974105e-05
such O 0 6.886511e-05
as O 0 0.0001897348
seizures B-Disease 0 0.99992955
and O 0 0.0009620045
strokes B-Disease 0 0.9979265
, O 0 0.00034100848
can O 0 0.00013080896
occur O 0 0.00013750902
hours O 0 0.0001499529
after O 0 0.00023865614
exposure O 0 0.0014758293
. O 0 0.0020227192

This O 0 0.0039332546
led O 0 0.0021414615
us O 0 0.0020216387
to O 0 0.0005610823
hypothesize O 0 0.00032327554
that O 0 0.00027493315
a O 0 0.00064876355
metabolite O 0 0.80781406
of O 0 0.0013069609
cocaine B-Chemical 1 0.99974793
may O 0 0.00023311963
be O 0 0.00013672088
responsible O 0 0.00011168971
for O 0 0.000119694065
some O 0 0.00023060763
of O 0 0.0004538011
those O 0 0.00092530466
delayed O 0 0.005598684
sequelae O 0 0.118127346
. O 0 0.0030790707

We O 0 0.001509525
evaluated O 0 0.000995297
the O 0 0.0006899928
potential O 0 0.00052758306
of O 0 0.00046147936
the O 0 0.0002973957
major O 0 0.0003414187
metabolite O 0 0.6714756
of O 0 0.0013803834
cocaine B-Chemical 1 0.99992514
, O 0 0.005831871
benzoylecgonine B-Chemical 1 0.9999982
( O 0 0.0049688937
BE B-Chemical 0 0.9572463
) O 0 0.000852578
, O 0 0.00054566504
to O 0 0.0006514682
cause O 0 0.0035002555
seizures B-Disease 0 0.99975103
. O 0 0.0045830742

Two O 0 0.0020277076
separate O 0 0.0012057602
equimolar O 0 0.058956217
doses O 0 0.00952433
( O 0 0.0010425171
0 O 0 0.00035817872
. O 0 0.00018281979
2 O 0 0.0001496856
and O 0 0.00015194186
0 O 0 0.00012615336
. O 0 8.494256e-05
4 O 0 9.446982e-05
mumol O 0 0.0023423166
) O 0 0.00022053423
of O 0 0.00015090648
either O 0 0.00023476328
cocaine B-Chemical 1 0.9995565
or O 0 0.00032433038
BE B-Chemical 0 0.6501409
were O 0 0.00013561256
injected O 0 0.00013359213
ventricularly O 0 0.00076019997
in O 0 0.0002648177
unanesthetized O 0 0.0018849641
juvenile O 0 0.013804878
rats O 0 0.0020558096
. O 0 0.0017273559

Treated O 0 0.014866177
rats O 0 0.001982382
were O 0 0.0006722243
then O 0 0.00034259673
evaluated O 0 0.0002824046
for O 0 0.00023237664
incidence O 0 0.00061160134
, O 0 0.00028497702
latency O 0 0.00038471198
, O 0 0.00022777668
and O 0 0.00024769676
seizure B-Disease 0 0.9945663
pattern O 0 0.00013417196
or O 0 0.0001022002
for O 0 0.000103938415
locomotor O 0 0.0070660026
activity O 0 0.00019181191
in O 0 0.00022563589
animals O 0 0.00034078
without O 0 0.0011946515
seizures B-Disease 0 0.9997321
. O 0 0.003591571

BE B-Chemical 0 0.95783305
- O 0 0.0071516475
Induced O 0 0.025823785
seizures B-Disease 0 0.999446
occurred O 0 0.00072169997
more O 0 0.00053345895
frequently O 0 0.00025354215
and O 0 0.00020099306
had O 0 0.00014567147
significantly O 0 0.00014966862
longer O 0 6.1868515e-05
latencies O 0 0.00024275975
than O 0 8.6011394e-05
those O 0 0.00018326518
induced O 0 0.00024253858
by O 0 0.0003485157
equimolar O 0 0.066745706
amounts O 0 0.00091855146
of O 0 0.0033945788
cocaine B-Chemical 1 0.9996321
. O 0 0.0033894721

Whereas O 0 0.0052367896
cocaine B-Chemical 1 0.9993856
- O 0 0.005145158
induced O 0 0.0021869235
seizures B-Disease 0 0.9998442
were O 0 0.0006329212
best O 0 0.00038873145
characterized O 0 0.00044566617
as O 0 0.00014213244
brief O 0 0.00015707008
, O 0 0.000182235
generalized O 0 0.00073861046
, O 0 0.00017054999
and O 0 0.00013021597
tonic O 0 0.0025963455
and O 0 0.00011643547
resulted O 0 0.00012568437
in O 0 0.00021212468
death B-Disease 0 0.97879136
, O 0 0.00021346948
those O 0 0.00015860339
induced O 0 0.00014813196
by O 0 0.00021305303
BE B-Chemical 0 0.8277086
were O 0 0.00011299244
prolonged O 0 0.00016717146
, O 0 9.2012924e-05
often O 0 8.274549e-05
multiple O 0 9.1614296e-05
and O 0 8.9306064e-05
mixed O 0 0.00021797587
in O 0 0.00012386306
type O 0 0.00019005509
, O 0 0.00021148009
and O 0 0.00022592112
rarely O 0 0.00036477952
resulted O 0 0.00063388096
in O 0 0.0013340418
death B-Disease 0 0.9800863
. O 0 0.0031378337

Electrical O 0 0.0062014363
recordings O 0 0.0015219735
from O 0 0.00068105746
the O 0 0.00058267615
hippocampus O 0 0.0042536254
showed O 0 0.00036142927
a O 0 0.0003325735
rhythmic O 0 0.0005578509
progression O 0 0.0019582356
in O 0 0.00020322342
EEG O 0 0.0199055
frequency O 0 0.00021926113
and O 0 0.0002296028
voltage O 0 0.0015720174
with O 0 0.00055567507
clinical O 0 0.0031275593
seizure B-Disease 0 0.9984413
expression O 0 0.0035767285
. O 0 0.0024313708

BE B-Chemical 0 0.94132656
- O 0 0.0045471517
Injected O 0 0.0028440075
rats O 0 0.00082683924
that O 0 0.0002743804
did O 0 0.00033148902
not O 0 0.00022467585
have O 0 0.00024284981
seizures B-Disease 0 0.99981266
had O 0 0.00029150175
significantly O 0 0.00022620153
more O 0 0.00022864007
locomotor O 0 0.020004643
activity O 0 0.00015770551
than O 0 0.0001858233
cocaine B-Chemical 1 0.9996613
- O 0 0.00059521984
injected O 0 0.00024778437
animals O 0 0.00033673344
without O 0 0.001123038
seizures B-Disease 0 0.9997111
. O 0 0.0033702895

The O 0 0.0018100825
finding O 0 0.0021422233
that O 0 0.0013501664
cocaine B-Chemical 1 0.99967504
- O 0 0.0032422105
and O 0 0.0010467436
BE B-Chemical 0 0.97130615
- O 0 0.0009994768
induced O 0 0.00063037896
seizures B-Disease 0 0.9999229
differ O 0 0.00023070636
in O 0 9.134746e-05
several O 0 6.201063e-05
respects O 0 0.00011284654
suggests O 0 3.4387653e-05
more O 0 8.0467864e-05
than O 0 3.863726e-05
one O 0 3.8939612e-05
mechanism O 0 8.209598e-05
for O 0 0.00011934727
cocaine B-Chemical 1 0.99989855
- O 0 0.00072206114
induced O 0 0.00040146592
seizures B-Disease 0 0.99993575
and O 0 0.00017516622
emphasizes O 0 9.741462e-05
the O 0 8.3015475e-05
importance O 0 7.109266e-05
of O 0 0.00024438722
a O 0 0.0009587808
cocaine B-Chemical 1 0.9998499
metabolite O 0 0.9871471
, O 0 0.0036557277
BE B-Chemical 0 0.90568006
. O 0 0.002613176

The O 0 0.0018820391
selective O 0 0.0031308269
5 O 0 0.0011406456
- O 0 0.0024303175
HT6 O 0 0.83623224
receptor O 0 0.08680157
antagonist O 0 0.9620548
Ro4368554 B-Chemical 1 0.9406928
restores O 0 0.0003721916
memory O 0 0.07909924
performance O 0 0.00032813568
in O 0 0.00015031922
cholinergic O 0 0.0754626
and O 0 0.00019375778
serotonergic O 0 0.027209945
models O 0 0.00020133716
of O 0 0.00041747987
memory B-Disease 0 0.98099697
deficiency I-Disease 0 0.99664223
in O 0 0.0009253478
the O 0 0.0010723457
rat O 0 0.0039536534
. O 0 0.0020652097

Antagonists O 0 0.041203797
at O 0 0.0021904942
serotonin B-Chemical 0 0.9974031
type O 0 0.0012697653
6 O 0 0.00043074673
( O 0 0.00056972343
5 B-Chemical 0 0.00032577603
- I-Chemical 0 0.0010483015
HT I-Chemical 0 0.9814431
( O 0 0.0005316566
6 O 0 0.00015852538
) O 0 0.0003299589
) O 0 0.00031017253
receptors O 0 0.0005345652
show O 0 0.000108501896
activity O 0 0.00013983808
in O 0 0.00015506322
models O 0 0.00025888812
of O 0 0.0004144427
learning O 0 0.0013034026
and O 0 0.0012342868
memory O 0 0.33347198
. O 0 0.0031679675

Although O 0 0.0015833096
the O 0 0.001254616
underlying O 0 0.0013154385
mechanism O 0 0.0010079411
( O 0 0.00088701013
s O 0 0.0005351099
) O 0 0.0005196644
are O 0 0.00019610074
not O 0 0.00015471497
well O 0 0.00015236494
understood O 0 0.00040195533
, O 0 0.00016967571
these O 0 0.00015640086
effects O 0 0.00013784655
may O 0 9.063293e-05
involve O 0 7.4056254e-05
an O 0 0.00015078981
increase O 0 0.00019350668
in O 0 0.00047017503
acetylcholine B-Chemical 1 0.9998425
( O 0 0.0033327609
ACh B-Chemical 1 0.9995689
) O 0 0.0022397616
levels O 0 0.0018015226
. O 0 0.0023135869

The O 0 0.0014317564
present O 0 0.00094317255
study O 0 0.00088490214
sought O 0 0.00073136983
to O 0 0.00031422518
characterize O 0 0.0001778019
the O 0 0.00029083694
cognitive O 0 0.13259874
- O 0 0.000432059
enhancing O 0 0.00014975185
effects O 0 0.00015500438
of O 0 0.0001821082
the O 0 0.00014041102
5 B-Chemical 0 0.00011812627
- I-Chemical 0 0.000531324
HT I-Chemical 0 0.9906549
( O 0 0.0002478855
6 O 0 7.358959e-05
) O 0 0.00024623144
antagonist O 0 0.65750617
Ro4368554 B-Chemical 1 0.95919544
( O 0 0.0003413718
3 B-Chemical 0 0.00012288954
- I-Chemical 0 0.0004703254
benzenesulfonyl I-Chemical 0 0.95909816
- I-Chemical 0 0.00059719017
7 I-Chemical 0 0.000103377584
- I-Chemical 0 0.00023451964
( I-Chemical 0 0.00015824988
4 I-Chemical 0 9.613458e-05
- I-Chemical 0 0.00038998306
methyl I-Chemical 0 0.96383023
- I-Chemical 0 0.0014755868
piperazin I-Chemical 0 0.850405
- I-Chemical 0 0.00063549675
1 I-Chemical 0 0.00016207932
- I-Chemical 0 0.00055842486
yl I-Chemical 0 0.85407764
) I-Chemical 0 0.0009808851
1H I-Chemical 0 0.4641628
- I-Chemical 0 0.00057053583
indole I-Chemical 0 0.9143238
) O 0 0.00025201007
in O 0 7.5398326e-05
a O 0 0.00010230883
rat O 0 0.00014693916
object O 0 0.00010255576
recognition O 0 6.836111e-05
task O 0 8.260233e-05
employing O 0 6.563791e-05
a O 0 0.00016135059
cholinergic O 0 0.45717335
( O 0 0.00082038884
scopolamine B-Chemical 1 0.99999833
pretreatment O 0 0.4560253
) O 0 0.00033131053
and O 0 9.597548e-05
a O 0 0.00018975703
serotonergic O 0 0.28780115
- O 0 0.00044511486
( O 0 0.00036670105
tryptophan B-Chemical 0 0.997787
( O 0 0.0014492265
TRP B-Chemical 0 0.99991274
) O 0 0.00048162445
depletion O 0 0.00058609387
) O 0 0.00023099911
deficient O 0 0.0001300384
model O 0 0.00013092838
, O 0 0.00010155494
and O 0 6.9472066e-05
compared O 0 4.048864e-05
its O 0 9.4799485e-05
pattern O 0 4.9807495e-05
of O 0 8.763862e-05
action O 0 0.00012304726
with O 0 0.00010642136
that O 0 8.0130325e-05
of O 0 0.00022963322
the O 0 0.00044506753
acetylcholinesterase O 0 0.99835014
inhibitor O 0 0.29806313
metrifonate B-Chemical 0 0.99986875
. O 0 0.0036114

Initial O 0 0.0029351246
testing O 0 0.0012826638
in O 0 0.000758339
a O 0 0.00068812526
time O 0 0.00029821254
- O 0 0.0005119553
dependent O 0 0.0001452098
forgetting O 0 0.008364263
task O 0 0.00026402308
employing O 0 0.0001443752
a O 0 0.00017432694
24 O 0 8.616293e-05
- O 0 0.00014377045
h O 0 5.2834705e-05
delay O 0 7.724866e-05
between O 0 3.2415002e-05
training O 0 4.6714205e-05
and O 0 5.8511698e-05
testing O 0 5.1752104e-05
showed O 0 5.726782e-05
that O 0 7.578564e-05
metrifonate B-Chemical 0 0.9998472
improved O 0 0.0003512107
object O 0 0.00018779185
recognition O 0 0.00011477259
( O 0 0.00010310408
at O 0 3.784715e-05
10 O 0 4.876566e-05
and O 0 5.651539e-05
30 O 0 5.700019e-05
mg O 0 0.0012909379
/ O 0 0.00045988048
kg O 0 0.00041247086
, O 0 0.00019793531
p O 0 0.00016105764
. O 0 0.00010073542
o O 0 0.0009584182
. O 0 0.00016102492
) O 0 0.00038485427
, O 0 0.0003721996
whereas O 0 0.0006199828
Ro4368554 B-Chemical 1 0.7376369
was O 0 0.0015816492
inactive O 0 0.0039872034
. O 0 0.0024710947

Both O 0 0.0038109932
, O 0 0.003914482
Ro4368554 B-Chemical 1 0.80162203
( O 0 0.0016192795
3 O 0 0.00044497912
and O 0 0.00036447152
10 O 0 0.00031636664
mg O 0 0.004350235
/ O 0 0.0010118233
kg O 0 0.0006530545
, O 0 0.0002083019
intraperitoneally O 0 0.00027033145
( O 0 0.0002613597
i O 0 0.00038046096
. O 0 0.00010394288
p O 0 0.00013346339
. O 0 7.33539e-05
) O 0 0.00018059657
) O 0 0.00017749803
and O 0 0.00018961071
metrifonate B-Chemical 0 0.999808
( O 0 0.00025832342
10 O 0 0.000100824975
mg O 0 0.0024424247
/ O 0 0.00052634184
kg O 0 0.00041979871
, O 0 0.00017152935
p O 0 0.00012407727
. O 0 6.421456e-05
o O 0 0.0006641542
. O 0 7.118532e-05
, O 0 0.0001263215
respectively O 0 0.0003109062
) O 0 0.00019918274
reversed O 0 0.0005183262
memory B-Disease 0 0.97912097
deficits I-Disease 0 0.9839189
induced O 0 0.0005291801
by O 0 0.0007506336
scopolamine B-Chemical 1 0.99999905
and O 0 0.003094934
TRP B-Chemical 0 0.9999459
depletion O 0 0.0013590526
( O 0 0.00018948149
10 O 0 8.192675e-05
mg O 0 0.0023614203
/ O 0 0.00044749386
kg O 0 0.00032123312
, O 0 0.00012817467
i O 0 0.0002887603
. O 0 7.9044294e-05
p O 0 0.00010519577
. O 0 5.4906282e-05
, O 0 9.173205e-05
and O 0 9.2637485e-05
3 O 0 8.283897e-05
mg O 0 0.0014973162
/ O 0 0.0005632459
kg O 0 0.0005230575
, O 0 0.00027529986
p O 0 0.00024617653
. O 0 0.00017782429
o O 0 0.001405245
. O 0 0.00034582554
, O 0 0.00083027285
respectively O 0 0.002160707
) O 0 0.002684434
. O 0 0.002500274

In O 0 0.0019608065
conclusion O 0 0.0015716748
, O 0 0.0015623041
although O 0 0.0009965954
Ro4368554 B-Chemical 1 0.83358544
did O 0 0.0005300541
not O 0 0.00021272014
improve O 0 0.00013575748
a O 0 0.00018551313
time O 0 7.9925034e-05
- O 0 0.00018783395
related O 0 5.4045915e-05
retention O 0 0.007198217
deficit O 0 0.802059
, O 0 0.00022378686
it O 0 0.00012351242
reversed O 0 0.0002990573
a O 0 0.00018913095
cholinergic O 0 0.11231758
and O 0 0.00010177462
a O 0 0.00017397622
serotonergic O 0 0.4088253
memory B-Disease 0 0.98850787
deficit I-Disease 0 0.9603094
, O 0 0.00018255659
suggesting O 0 3.8528055e-05
that O 0 3.682414e-05
both O 0 5.82722e-05
mechanisms O 0 7.754631e-05
may O 0 4.721271e-05
be O 0 4.1093364e-05
involved O 0 2.7753871e-05
in O 0 3.6905698e-05
the O 0 4.4251476e-05
facilitation O 0 0.000245626
of O 0 0.000100632205
object O 0 0.0002512955
memory O 0 0.1911079
by O 0 0.0003335553
Ro4368554 B-Chemical 1 0.9179924
and O 0 0.00020357755
, O 0 0.00016202958
possibly O 0 0.0002596717
, O 0 0.00014465905
other O 0 0.000117391675
5 B-Chemical 0 0.00013844813
- I-Chemical 0 0.0006197547
HT I-Chemical 0 0.97653764
( O 0 0.0005116908
6 O 0 0.00025136842
) O 0 0.0008027401
receptor O 0 0.011557419
antagonists O 0 0.70189816
. O 0 0.00291338

Evaluation O 0 0.0028491793
of O 0 0.0018633157
the O 0 0.001350547
anticocaine O 0 0.0049559325
monoclonal O 0 0.004779838
antibody O 0 0.0065131346
GNC92H2 B-Chemical 1 0.8898709
as O 0 0.00068625214
an O 0 0.00085730123
immunotherapy O 0 0.0035377769
for O 0 0.002184992
cocaine B-Disease 1 0.9999703
overdose I-Disease 0 0.9999696
. O 0 0.007524321

The O 0 0.002453204
illicit O 0 0.19510213
use O 0 0.001183588
of O 0 0.0016174553
cocaine B-Chemical 1 0.99921477
continues O 0 0.0005188158
in O 0 0.0002764561
epidemic O 0 0.00048379583
proportions O 0 0.0002482019
and O 0 0.00021786657
treatment O 0 0.00030472802
for O 0 0.0006420264
cocaine B-Disease 1 0.99998415
overdose I-Disease 0 0.99998224
remains O 0 0.0025074207
elusive O 0 0.0033502243
. O 0 0.0021875072

Current O 0 0.007258519
protein O 0 0.003506601
- O 0 0.0020146593
based O 0 0.0006206846
technology O 0 0.000801072
offers O 0 0.00039977042
a O 0 0.00037988415
new O 0 0.00030103448
therapeutic O 0 0.00043169258
venue O 0 0.0003046197
by O 0 0.00016748002
which O 0 0.00018206237
antibodies O 0 0.00025564205
bind O 0 4.3277952e-05
the O 0 0.00010214584
drug O 0 0.0012951609
in O 0 9.9228404e-05
the O 0 0.0001226015
blood O 0 0.0009295417
stream O 0 0.00041171737
, O 0 0.00033689162
inactivating O 0 0.0013711668
its O 0 0.0013446867
toxic O 0 0.22828104
effects O 0 0.0030279069
. O 0 0.0026230372

The O 0 0.0016708431
therapeutic O 0 0.001983152
potential O 0 0.0009628724
of O 0 0.0008387566
the O 0 0.00062699773
anticocaine O 0 0.0040263697
antibody O 0 0.0055817305
GNC92H2 B-Chemical 1 0.94446707
was O 0 0.00046318228
examined O 0 0.00017996912
using O 0 0.00020649076
a O 0 0.0004108981
model O 0 0.00065812987
of O 0 0.0033490031
cocaine B-Disease 1 0.9999763
overdose I-Disease 0 0.99997425
. O 0 0.006505573

Swiss O 0 0.009215159
albino O 0 0.005373998
mice O 0 0.00049939344
prepared O 0 0.00044513648
with O 0 0.00045013055
intrajugular O 0 0.024342507
catheters O 0 0.00050293846
were O 0 0.00013509154
tested O 0 9.7066986e-05
in O 0 0.0001043042
photocell O 0 0.0011546715
cages O 0 0.00017788706
after O 0 2.9439308e-05
administration O 0 0.00018089988
of O 0 0.000117418764
93 O 0 0.0003410732
mg O 0 0.0039429297
/ O 0 0.00047926686
kg O 0 0.0003786738
( O 0 0.00022037448
LD50 O 0 0.75280184
) O 0 0.0002612922
of O 0 0.00027469682
cocaine B-Chemical 1 0.9996731
and O 0 0.00030679101
GNC92H2 B-Chemical 1 0.8344813
infusions O 0 0.0005240654
ranging O 0 0.00014784439
from O 0 8.5761436e-05
30 O 0 9.627265e-05
to O 0 0.00017246415
190 O 0 0.0014605625
mg O 0 0.0071818572
/ O 0 0.002612502
kg O 0 0.0030384446
. O 0 0.002049105

GNC92H2 B-Chemical 1 0.7117954
was O 0 0.0019078318
delivered O 0 0.00057457364
30 O 0 0.00047584588
min O 0 0.0005160659
before O 0 0.0002282197
, O 0 0.00042571532
concomitantly O 0 0.0007054903
or O 0 0.00029419546
3 O 0 0.00023701164
min O 0 0.0003930561
after O 0 0.0003980855
cocaine B-Chemical 1 0.9970438
treatment O 0 0.0029195258
. O 0 0.0028928334

Significant O 0 0.002901892
blockade O 0 0.010841813
of O 0 0.0037322715
cocaine B-Chemical 1 0.9998764
toxicity B-Disease 2 0.99953485
was O 0 0.00066294783
observed O 0 0.00017149908
with O 0 0.00016013361
the O 0 0.000108257576
higher O 0 0.00014541471
dose O 0 0.00061590964
of O 0 0.00035254244
GNC92H2 B-Chemical 1 0.95633554
( O 0 0.00033062926
190 O 0 0.0011281118
mg O 0 0.006757165
/ O 0 0.00055976777
kg O 0 0.00039305928
) O 0 0.00016111185
, O 0 8.574525e-05
where O 0 6.963856e-05
premorbid O 0 0.05389203
behaviors O 0 0.0002883669
were O 0 7.629772e-05
reduced O 0 0.00010889254
up O 0 7.5698386e-05
to O 0 6.3575164e-05
40 O 0 0.00010192254
% O 0 0.00012606231
, O 0 0.00021526443
seizures B-Disease 0 0.99962413
up O 0 0.0002192674
to O 0 0.00015087266
77 O 0 0.0005443359
% O 0 0.00027540486
and O 0 0.00045572556
death B-Disease 0 0.85048574
by O 0 0.00087447395
72 O 0 0.0010037926
% O 0 0.001530697
. O 0 0.0019635484

Importantly O 0 0.0035714982
, O 0 0.0055239163
GNC92H2 B-Chemical 1 0.9416394
prevented O 0 0.027760029
death B-Disease 0 0.9894627
even O 0 0.0023396814
post O 0 0.0013249328
- O 0 0.005139104
cocaine B-Chemical 1 0.9990865
injection O 0 0.007003288
. O 0 0.004111136

The O 0 0.0016469862
results O 0 0.0012534573
support O 0 0.00067025854
the O 0 0.0005061858
important O 0 0.000272738
potential O 0 0.00046797423
of O 0 0.00084394927
GNC92H2 B-Chemical 1 0.8397985
as O 0 0.00041025772
a O 0 0.00047336356
therapeutic O 0 0.0008221853
tool O 0 0.0009501173
against O 0 0.001514368
cocaine B-Disease 1 0.9999746
overdose I-Disease 0 0.9999738
. O 0 0.0069049825

Electrocardiographic O 0 0.09809447
evidence O 0 0.0020889472
of O 0 0.0034346106
myocardial B-Disease 0 0.9995753
injury I-Disease 0 0.99111396
in O 0 0.0027576748
psychiatrically O 0 0.9741931
hospitalized O 0 0.47126508
cocaine B-Chemical 1 0.9998266
abusers O 0 0.99457437
. O 0 0.004041627

The O 0 0.0020385135
electrocardiograms O 0 0.01294021
( O 0 0.0022015444
ECG O 0 0.06770471
) O 0 0.0010565409
of O 0 0.0006667887
99 O 0 0.0031651815
cocaine B-Chemical 1 0.99971884
- O 0 0.0020098821
abusing O 0 0.19391567
patients O 0 0.00029550315
were O 0 0.00010792188
compared O 0 6.157956e-05
with O 0 0.00011375559
the O 0 0.00014741164
ECGs O 0 0.0011263185
of O 0 0.00038883748
50 O 0 0.0012648301
schizophrenic B-Disease 2 0.99935883
controls O 0 0.0039597508
. O 0 0.0021495894

Eleven O 0 0.0040048347
of O 0 0.0016513531
the O 0 0.0016218433
cocaine B-Chemical 1 0.9996612
abusers O 0 0.95353395
and O 0 0.00039629912
none O 0 0.00018626482
of O 0 0.00016020144
the O 0 0.000115224495
controls O 0 0.00020576242
had O 0 0.0001236437
ECG O 0 0.028023355
evidence O 0 6.747967e-05
of O 0 0.00012310546
significant O 0 0.00022062592
myocardial B-Disease 0 0.99994636
injury I-Disease 0 0.98789096
defined O 0 0.0001780761
as O 0 0.00029956462
myocardial B-Disease 0 0.99988127
infarction I-Disease 2 0.9999958
, O 0 0.003973932
ischemia B-Disease 0 0.99988914
, O 0 0.00072241353
and O 0 0.00055518403
bundle B-Disease 0 0.006245514
branch I-Disease 0 0.0024325089
block I-Disease 0 0.0032312141
. O 0 0.0022821843

Behavioral O 0 0.0070392215
effects O 0 0.0027916539
of O 0 0.0037276754
urotensin B-Chemical 0 0.9939507
- I-Chemical 0 0.0050830888
II I-Chemical 0 0.031135686
centrally O 0 0.002072058
administered O 0 0.001521478
in O 0 0.0014534884
mice O 0 0.0019437429
. O 0 0.0032948484

Urotensin B-Chemical 0 0.76680857
- I-Chemical 0 0.009163494
II I-Chemical 0 0.19096322
( O 0 0.004921637
U B-Chemical 0 0.9361753
- I-Chemical 0 0.0038116032
II I-Chemical 0 0.19142513
) O 0 0.0014383626
receptors O 0 0.0018766597
are O 0 0.00029603188
widely O 0 0.00019914229
distributed O 0 0.0001416752
in O 0 0.00022050059
the O 0 0.00036009023
central O 0 0.00089601765
nervous O 0 0.014074341
system O 0 0.0023946022
. O 0 0.002518598

Intracerebroventricular O 0 0.8660602
( O 0 0.0043980614
i O 0 0.002948552
. O 0 0.0009018308
c O 0 0.0029774522
. O 0 0.00046738057
v O 0 0.0016395437
. O 0 0.00026938567
) O 0 0.0003848517
injection O 0 0.00028213012
of O 0 0.00064785033
U B-Chemical 0 0.9456207
- I-Chemical 0 0.0013534783
II I-Chemical 0 0.15961647
causes O 0 0.0016911511
hypertension B-Disease 2 0.99997556
and O 0 0.0007445055
bradycardia B-Disease 0 0.99421895
and O 0 0.00027980065
stimulates O 0 0.00020146718
prolactin O 0 0.92482716
and O 0 0.0014052104
thyrotropin O 0 0.998376
secretion O 0 0.01707155
. O 0 0.002478343

However O 0 0.0028102866
, O 0 0.0018547889
the O 0 0.00091675826
behavioral O 0 0.0014170847
effects O 0 0.00059449667
of O 0 0.0006002629
centrally O 0 0.0009499105
administered O 0 0.001269935
U B-Chemical 0 0.91446424
- I-Chemical 0 0.0018014471
II I-Chemical 0 0.027475085
have O 0 0.00039720233
received O 0 0.0004665869
little O 0 0.00087727676
attention O 0 0.0026039763
. O 0 0.0024676835

In O 0 0.0017064151
the O 0 0.0012250305
present O 0 0.00076865254
study O 0 0.0008458722
, O 0 0.00048515116
we O 0 0.00015994441
tested O 0 0.00019174497
the O 0 0.0001707534
effects O 0 0.00021810726
of O 0 0.0003280584
i O 0 0.00072156964
. O 0 0.00013332182
c O 0 0.0011567159
. O 0 9.972945e-05
v O 0 0.00056683924
. O 0 7.6674376e-05
injections O 0 0.00016508526
of O 0 0.00035754757
U B-Chemical 0 0.899413
- I-Chemical 0 0.00074544264
II I-Chemical 0 0.015893081
on O 0 8.687494e-05
behavioral O 0 0.0007150195
, O 0 0.0002484247
metabolic O 0 0.0036077846
, O 0 0.0002603981
and O 0 0.00028606618
endocrine O 0 0.0117090875
responses O 0 0.0005599914
in O 0 0.0006208704
mice O 0 0.00097124436
. O 0 0.0018556912

Administration O 0 0.0069801034
of O 0 0.0019158481
graded O 0 0.0020603843
doses O 0 0.004890116
of O 0 0.0022478611
U B-Chemical 0 0.9793879
- I-Chemical 0 0.0029773547
II I-Chemical 0 0.2152744
( O 0 0.00060207397
1 O 0 0.00021525724
- O 0 0.00028461046
10 O 0 0.000116173185
, O 0 0.00012801735
000 O 0 0.00013834256
ng O 0 0.0003739906
/ O 0 0.0005766948
mouse O 0 0.00030277242
) O 0 0.00027242381
provoked O 0 0.0007753378
: O 0 0.00023989308
( O 0 0.00018289946
1 O 0 8.725087e-05
) O 0 0.00012654092
a O 0 0.000120363045
dose O 0 0.0005360987
- O 0 0.0001798084
dependent O 0 3.9081202e-05
reduction O 0 0.00018557365
in O 0 6.2460196e-05
the O 0 5.914912e-05
number O 0 6.0470466e-05
of O 0 0.000107978274
head O 0 0.0010391483
dips O 0 0.0012583116
in O 0 7.316924e-05
the O 0 0.00010709069
hole O 0 0.01505487
- O 0 0.000316913
board O 0 0.00037584986
test O 0 0.00020496546
; O 0 0.00014348175
( O 0 0.00013752002
2 O 0 7.14524e-05
) O 0 0.000112558315
a O 0 0.00011078747
dose O 0 0.00051326794
- O 0 0.00017132502
dependent O 0 3.632496e-05
reduction O 0 0.0001775175
in O 0 5.716583e-05
the O 0 5.2107764e-05
number O 0 4.9118367e-05
of O 0 7.2832525e-05
entries O 0 0.00019923592
in O 0 4.8746184e-05
the O 0 5.819984e-05
white O 0 0.00040796475
chamber O 0 0.0003349239
in O 0 6.088732e-05
the O 0 8.9298315e-05
black O 0 0.00088955427
- O 0 0.00023868207
and O 0 0.00011299848
- O 0 0.00021420614
white O 0 0.0005463134
compartment O 0 0.0001239064
test O 0 0.00012817969
, O 0 7.708808e-05
and O 0 5.9106886e-05
in O 0 4.525255e-05
the O 0 4.7491554e-05
number O 0 4.8138987e-05
of O 0 7.275617e-05
entries O 0 0.00019165703
in O 0 4.388486e-05
the O 0 4.2723917e-05
central O 0 6.779365e-05
platform O 0 0.00011894405
and O 0 6.456955e-05
open O 0 0.00012885775
arms O 0 0.00012776308
in O 0 4.2196963e-05
the O 0 5.0201954e-05
plus O 0 5.9776612e-05
- O 0 0.00022044044
maze O 0 0.012673151
test O 0 0.00024219541
; O 0 0.00013020926
and O 0 0.00010960615
( O 0 0.00014410561
3 O 0 6.4596024e-05
) O 0 0.000112073154
a O 0 0.00011236291
dose O 0 0.0005305788
- O 0 0.00016926817
dependent O 0 3.3320215e-05
increase O 0 6.10486e-05
in O 0 4.7776724e-05
the O 0 4.581792e-05
duration O 0 2.8472125e-05
of O 0 0.00011749123
immobility O 0 0.19921634
in O 0 8.988962e-05
the O 0 0.00010963981
forced O 0 0.0012810951
- O 0 0.00042983613
swimming O 0 0.0025251072
test O 0 0.00031104643
and O 0 0.00029745747
tail O 0 0.000685918
suspension O 0 0.0021666312
test O 0 0.0018279587
. O 0 0.001930667

Intracerebroventricular O 0 0.6938397
injection O 0 0.0033719651
of O 0 0.0038860708
U B-Chemical 0 0.96547925
- I-Chemical 0 0.0028896085
II I-Chemical 0 0.032573856
also O 0 0.00032366626
caused O 0 0.00027909543
an O 0 0.0002506055
increase O 0 0.00015868388
in O 0 0.00012595693
: O 0 0.00016854118
food O 0 0.00065956777
intake O 0 0.01524046
at O 0 6.2576866e-05
doses O 0 0.00042785364
of O 0 0.00014312429
100 O 0 0.0003070643
and O 0 0.00010319734
1 O 0 6.743509e-05
, O 0 7.069258e-05
000 O 0 8.272056e-05
ng O 0 0.00023799557
/ O 0 0.0003629475
mouse O 0 0.00016606998
, O 0 0.000116281575
water O 0 0.001892323
intake O 0 0.013851239
at O 0 5.3008458e-05
doses O 0 0.00038886472
of O 0 0.00015064309
100 O 0 0.00044453266
- O 0 0.00021570247
10 O 0 6.900559e-05
, O 0 7.823306e-05
000 O 0 8.918887e-05
ng O 0 0.00025979403
/ O 0 0.00039078397
mouse O 0 0.00016763277
, O 0 9.444424e-05
and O 0 7.427699e-05
horizontal O 0 0.00016902368
locomotion O 0 0.00067989924
activity O 0 7.457471e-05
at O 0 5.7055055e-05
a O 0 0.00014212227
dose O 0 0.00042583683
of O 0 0.00022600924
10 O 0 0.00019373045
, O 0 0.00028334875
000 O 0 0.00042265048
ng O 0 0.001394148
/ O 0 0.002727299
mouse O 0 0.0027113277
. O 0 0.0023183876

Whatever O 0 0.006924544
was O 0 0.0019554326
the O 0 0.0010356274
dose O 0 0.002423159
, O 0 0.00055453915
the O 0 0.00028585157
central O 0 0.00035541272
administration O 0 0.001230213
of O 0 0.0010069928
U B-Chemical 0 0.9804929
- I-Chemical 0 0.0014064864
II I-Chemical 0 0.08245449
had O 0 0.00012636188
no O 0 4.669363e-05
effect O 0 6.0648563e-05
on O 0 4.8333663e-05
body O 0 0.00045018725
temperature O 0 0.0009518892
, O 0 0.0002393507
nociception O 0 0.326751
, O 0 0.00058927195
apomorphine B-Chemical 1 0.99998593
- O 0 0.000534391
induced O 0 0.00021346967
penile B-Disease 0 0.13408977
erection I-Disease 0 0.5235266
and O 0 0.00017821437
climbing O 0 0.000894865
behavior O 0 0.0001869882
, O 0 0.00015278814
and O 0 0.00017408872
stress O 0 0.0032139735
- O 0 0.0006252427
induced O 0 0.0006402672
plasma O 0 0.12206489
corticosterone B-Chemical 1 0.99931633
level O 0 0.0020184338
. O 0 0.0022966922

Taken O 0 0.0049079903
together O 0 0.001908276
, O 0 0.0012819665
the O 0 0.00059148675
present O 0 0.0003523872
study O 0 0.00035020313
demonstrates O 0 0.00013316733
that O 0 0.00010335076
the O 0 0.00012622013
central O 0 0.00017373518
injection O 0 0.0002007548
of O 0 0.0005179524
U B-Chemical 0 0.9504011
- I-Chemical 0 0.0007969091
II I-Chemical 0 0.022853857
at O 0 8.2698636e-05
doses O 0 0.00070286635
of O 0 0.00019822881
1 O 0 0.00011261885
- O 0 0.00017072733
10 O 0 7.034309e-05
, O 0 8.451201e-05
000 O 0 9.837294e-05
ng O 0 0.00027749763
/ O 0 0.00039862367
mouse O 0 0.00019073987
induces O 0 0.00013671853
anxiogenic O 0 0.98002255
- O 0 0.0007323438
and O 0 0.00038008665
depressant O 0 0.9894366
- O 0 0.0007345455
like O 0 0.00023378246
effects O 0 0.0005680048
in O 0 0.0008078857
mouse O 0 0.0023711517
. O 0 0.0020728775

These O 0 0.0024932222
data O 0 0.0017294759
suggest O 0 0.00075594464
that O 0 0.0012120774
U B-Chemical 0 0.93490124
- I-Chemical 0 0.0031671664
II I-Chemical 0 0.04296502
may O 0 0.000390201
be O 0 0.00025900512
involved O 0 0.00016894264
in O 0 0.00020698119
some O 0 0.00026828275
aspects O 0 0.00026802835
of O 0 0.0016540745
psychiatric B-Disease 2 0.99955815
disorders I-Disease 0 0.99646384
. O 0 0.0039398824

Learning O 0 0.012954695
of O 0 0.0040949695
rats O 0 0.004093175
under O 0 0.002939381
amnesia B-Disease 0 0.9954839
caused O 0 0.0061332216
by O 0 0.0076905508
pentobarbital B-Chemical 0 0.9991672
. O 0 0.008399388

Dissociated O 0 0.0066335825
learning O 0 0.0025506236
of O 0 0.0011775279
rats O 0 0.00082811696
in O 0 0.00030831396
the O 0 0.00024029323
normal O 0 0.0003869254
state O 0 0.00019424685
and O 0 0.00012473446
the O 0 0.000103659884
state O 0 0.00014745722
of O 0 0.0002777255
amnesia B-Disease 0 0.99829704
produced O 0 0.00023188486
by O 0 0.00033128873
pentobarbital B-Chemical 0 0.9997805
( O 0 0.00028131116
15 O 0 9.364743e-05
mg O 0 0.0017509275
/ O 0 0.00056144723
kg O 0 0.0005280688
, O 0 0.00034301734
ip O 0 0.020085309
) O 0 0.00071856816
was O 0 0.00053624803
carried O 0 0.00067546614
out O 0 0.0010656406
. O 0 0.0020116216

Rats O 0 0.004638342
were O 0 0.0015656301
trained O 0 0.000986455
to O 0 0.00060833537
approach O 0 0.00063374266
a O 0 0.00081849494
shelf O 0 0.0015191226
where O 0 0.00040786093
they O 0 0.00047142326
received O 0 0.00065808283
food O 0 0.0027297721
reinforcement O 0 0.0029715083
. O 0 0.0028051455

In O 0 0.002152144
Group O 0 0.0038598105
1 O 0 0.0008000451
the O 0 0.0005292078
rats O 0 0.0005624617
were O 0 0.00025410578
trained O 0 0.00017668886
under O 0 9.289065e-05
the O 0 9.4717245e-05
influence O 0 6.8656074e-05
of O 0 0.00030445505
pentobarbital B-Chemical 0 0.99947757
to O 0 0.00015527895
run O 0 0.0001492882
to O 0 8.120184e-05
the O 0 9.123724e-05
same O 0 7.844492e-05
shelf O 0 0.0005229593
as O 0 0.00016968412
in O 0 0.00022072732
the O 0 0.00039951404
normal O 0 0.0013930398
state O 0 0.0017485246
. O 0 0.0020158878

In O 0 0.0022455535
Group O 0 0.003980502
2 O 0 0.000833992
the O 0 0.00059611996
rats O 0 0.0006672267
were O 0 0.00033982244
trained O 0 0.00027253656
to O 0 0.00019224493
approach O 0 0.00024398194
different O 0 0.00021801598
shelves O 0 0.0016014903
in O 0 0.00039305832
different O 0 0.0004696001
drug O 0 0.009292969
states O 0 0.0025956647
. O 0 0.002489391

It O 0 0.0032467074
was O 0 0.0018562742
shown O 0 0.0008727587
that O 0 0.0008957317
memory B-Disease 0 0.74334747
dissociation I-Disease 0 0.16612415
occurred O 0 0.0012449465
in O 0 0.0010760301
both O 0 0.0015721779
groups O 0 0.002211377
. O 0 0.0029806532

Differences O 0 0.0013454886
in O 0 0.00092189026
the O 0 0.00062085735
parameters O 0 0.00052723114
of O 0 0.00041613056
training O 0 0.00022452381
under O 0 0.00014181995
the O 0 0.00013768705
influence O 0 9.7749326e-05
of O 0 0.00039839954
pentobarbital B-Chemical 0 0.9993808
between O 0 0.00022079467
Groups O 0 0.0011084735
1 O 0 0.0002106196
and O 0 0.00028939283
2 O 0 0.00035608487
were O 0 0.0006274186
revealed O 0 0.0012173489
. O 0 0.0020150554

These O 0 0.002226465
findings O 0 0.001901338
show O 0 0.000634194
that O 0 0.00040413195
the O 0 0.00050258095
brain O 0 0.0030474537
- O 0 0.0007292996
dissociated O 0 0.00036072137
state O 0 0.0002592312
induced O 0 0.00027410506
by O 0 0.0003815979
pentobarbital B-Chemical 0 0.9996668
is O 0 0.00019266276
formed O 0 0.00015187032
with O 0 0.00011709865
the O 0 9.56566e-05
participation O 0 0.0001467956
of O 0 0.00015870549
the O 0 0.00015815336
mechanisms O 0 0.00025350004
of O 0 0.00044468863
information O 0 0.0007100276
perception O 0 0.0026942138
. O 0 0.0022169268

The O 0 0.0015087281
effects O 0 0.001341172
of O 0 0.0010956947
short O 0 0.00062510144
- O 0 0.0009554505
term O 0 0.00057611975
raloxifene B-Chemical 0 0.99953055
therapy O 0 0.00062105857
on O 0 0.00020543367
fibrinolysis O 0 0.9554487
markers O 0 0.0019765643
: O 0 0.0010276908
TAFI O 0 0.99958485
, O 0 0.0009991275
tPA O 0 0.108854555
, O 0 0.0005941009
and O 0 0.0007226305
PAI O 0 0.0074076233
- O 0 0.0019324393
1 O 0 0.0015093065
. O 0 0.0022632084

BACKGROUND O 0 0.0087631885
: O 0 0.0026885055
Markers O 0 0.0054908176
of O 0 0.0017773133
fibrinolysis O 0 0.96288675
, O 0 0.0014025779
thrombin O 0 0.77711135
- O 0 0.0016102468
activatable O 0 0.01795262
fibrinolysis O 0 0.98954284
inhibitor O 0 0.02316874
( O 0 0.0020782226
TAFI O 0 0.9998241
) O 0 0.0007561759
, O 0 0.00023953196
tissue O 0 0.0008478864
- O 0 0.00034472038
type O 0 0.00020808616
plasminogen O 0 0.053303402
activator O 0 0.00029851092
( O 0 0.00036530985
tPA O 0 0.067270264
) O 0 0.00024205369
, O 0 0.00012120231
and O 0 0.00013641409
plasminogen O 0 0.02250821
activator O 0 0.00022463172
inhibitor O 0 0.0014313814
- O 0 0.0004228469
1 O 0 0.00010943029
( O 0 0.00018553666
PAI O 0 0.0018259726
- O 0 0.00023754127
1 O 0 8.195956e-05
) O 0 0.00011172466
levels O 0 6.9632246e-05
were O 0 7.0078495e-05
studied O 0 6.571652e-05
for O 0 3.8007514e-05
the O 0 5.1829393e-05
evaluation O 0 5.593088e-05
of O 0 8.799602e-05
short O 0 7.272724e-05
- O 0 0.00014071178
term O 0 7.127315e-05
effects O 0 0.00014317177
of O 0 0.000533527
raloxifene B-Chemical 0 0.99985075
administration O 0 0.013096263
in O 0 0.001156646
postmenopausal O 0 0.9594064
women O 0 0.0057272045
. O 0 0.0018109927

METHODS O 0 0.0016408861
: O 0 0.0014411912
Thirty O 0 0.0011509982
- O 0 0.0011250259
nine O 0 0.0006345387
postmenopausal O 0 0.42796686
women O 0 0.0011572228
with O 0 0.00070076884
osteopenia B-Disease 0 0.99994576
or O 0 0.0010903495
osteoporosis B-Disease 0 0.9998914
were O 0 0.00024568883
included O 0 0.000111491165
in O 0 0.00012509584
this O 0 0.00024608077
prospective O 0 0.00084673264
, O 0 0.00036097868
controlled O 0 0.00042908982
clinical O 0 0.0016280217
study O 0 0.0015865171
. O 0 0.0018954013

Twenty O 0 0.0039414093
- O 0 0.0022677071
five O 0 0.0005504574
women O 0 0.0009406499
were O 0 0.00033509664
given O 0 0.0003021565
raloxifene B-Chemical 0 0.9998073
hydrochloride I-Chemical 0 0.99858606
( O 0 0.00047567653
60 O 0 0.00016912718
mg O 0 0.0019515732
/ O 0 0.00034110702
day O 0 8.120897e-05
) O 0 0.00017959885
plus O 0 0.00016314267
calcium B-Chemical 0 0.9942304
( O 0 0.00066562626
500 O 0 0.0011175836
mg O 0 0.0087299505
/ O 0 0.0015788272
day O 0 0.0006789742
) O 0 0.0019446838
. O 0 0.0020872331

Age O 0 0.017462706
- O 0 0.0035878157
matched O 0 0.0011572278
controls O 0 0.0015515345
( O 0 0.0011184154
n O 0 0.00061224756
= O 0 0.00064727763
14 O 0 0.0004204894
) O 0 0.00063713326
were O 0 0.00047885493
given O 0 0.0005268699
only O 0 0.0019462928
calcium B-Chemical 0 0.99361986
. O 0 0.004820311

Plasma O 0 0.7391626
TAFI O 0 0.998845
, O 0 0.004954072
tPA O 0 0.18780102
, O 0 0.001134972
and O 0 0.0007560516
PAI O 0 0.007055476
- O 0 0.0006626759
1 O 0 0.0001846072
antigen O 0 0.0004381663
levels O 0 0.00014797246
were O 0 0.000105295345
measured O 0 6.646778e-05
at O 0 5.2209034e-05
baseline O 0 6.698197e-05
and O 0 7.077196e-05
after O 0 3.2822496e-05
3 O 0 5.2044194e-05
months O 0 3.2561147e-05
of O 0 0.00011017916
treatment O 0 0.00017632383
by O 0 0.0003262261
commercially O 0 0.0024910057
available O 0 0.0015590474
ELISA O 0 0.7199391
kits O 0 0.14753738
. O 0 0.0030399775

Variations O 0 0.004666985
of O 0 0.0028909303
individuals O 0 0.0024101175
were O 0 0.0014152329
assessed O 0 0.001065222
by O 0 0.0015814881
Wilcoxon O 0 0.0037206407
' O 0 0.0024029936
s O 0 0.0025137607
test O 0 0.0040099085
. O 0 0.0045486325

Relationship O 0 0.0021268448
between O 0 0.001295362
those O 0 0.001712864
markers O 0 0.002009137
and O 0 0.0010831403
demographic O 0 0.00096439826
characteristics O 0 0.0008625514
were O 0 0.0016309414
investigated O 0 0.0023550629
. O 0 0.0039629717

RESULTS O 0 0.0041575884
: O 0 0.0015551673
Three O 0 0.0006572229
months O 0 0.00029252458
of O 0 0.00078104966
raloxifene B-Chemical 0 0.9993943
treatment O 0 0.0005638094
was O 0 0.00027269172
associated O 0 0.00013516897
with O 0 0.00017024908
a O 0 0.00016560304
significant O 0 9.6215204e-05
decrease O 0 0.000115585106
in O 0 7.131904e-05
the O 0 0.00011012474
plasma O 0 0.03394556
TAFI O 0 0.99977595
antigen O 0 0.0037043833
concentrations O 0 0.0009093981
( O 0 0.0002177698
16 O 0 9.372704e-05
% O 0 9.560572e-05
change O 0 0.00011401796
, O 0 0.00022113262
P O 0 0.0045148046
< O 0 0.0001085438
0 O 0 8.355075e-05
. O 0 7.045931e-05
01 O 0 0.00035657472
) O 0 0.00016495389
, O 0 9.988068e-05
and O 0 8.4612315e-05
a O 0 0.00011097503
significant O 0 8.0917154e-05
increase O 0 9.274753e-05
in O 0 0.00012654562
tPA O 0 0.038056348
antigen O 0 0.0008945209
concentrations O 0 0.0006270187
( O 0 0.00024952498
25 O 0 0.00020105974
% O 0 0.00016307985
change O 0 0.00020476973
, O 0 0.00041278335
P O 0 0.0038036413
< O 0 0.0003712097
0 O 0 0.0004061611
. O 0 0.0005916238
05 O 0 0.0059706466
) O 0 0.0025028917
. O 0 0.002526322

A O 0 0.015678404
significant O 0 0.001411557
correlation O 0 0.00063793495
was O 0 0.0005677963
found O 0 0.0002783596
between O 0 0.000171663
baseline O 0 0.00035975804
TAFI O 0 0.9985576
antigen O 0 0.0022704082
concentrations O 0 0.0006796873
and O 0 0.00014733944
the O 0 9.4740186e-05
duration O 0 5.640201e-05
of O 0 0.00030038913
amenorrhea B-Disease 0 0.9834781
( O 0 0.00070328877
P O 0 0.0071449904
< O 0 0.00014778209
0 O 0 0.00012318263
. O 0 0.00013152126
05 O 0 0.0015622163
; O 0 0.00029554655
r O 0 0.0003615699
= O 0 0.0003602765
0 O 0 0.00032601244
. O 0 0.0004335955
33 O 0 0.0013351744
) O 0 0.0022488507
. O 0 0.0025076615

CONCLUSION O 0 0.017199462
: O 0 0.0019729687
We O 0 0.00054089894
suggest O 0 0.00027711582
that O 0 0.00026168933
the O 0 0.0003170315
increased O 0 0.000545677
risk O 0 0.0022872372
of O 0 0.00074228185
venous B-Disease 0 0.93938655
thromboembolism I-Disease 0 0.9999831
due O 0 0.00013377606
to O 0 0.00022288617
raloxifene B-Chemical 0 0.99981064
treatment O 0 0.00020411865
may O 0 8.157835e-05
be O 0 6.133289e-05
related O 0 3.556436e-05
to O 0 8.079556e-05
increased O 0 0.0003494123
tPA O 0 0.07040399
levels O 0 0.0002817793
, O 0 0.00035482258
but O 0 0.00044056991
not O 0 0.0008393335
TAFI O 0 0.99849594
levels O 0 0.0029661919
. O 0 0.0026985835

Valproate B-Chemical 1 0.9991615
- O 0 0.044307392
induced O 0 0.035712287
encephalopathy B-Disease 2 0.9989373
. O 0 0.027784957

Valproate B-Chemical 1 0.999821
- O 0 0.012232306
induced O 0 0.0054739527
encephalopathy B-Disease 2 0.99981385
is O 0 0.0013644932
a O 0 0.0010030088
rare O 0 0.0028922558
syndrome O 0 0.042728536
that O 0 0.0001821089
may O 0 0.00018390692
manifest O 0 0.0004739417
in O 0 0.00021710843
otherwise O 0 0.0004376505
normal O 0 0.0020514815
epileptic B-Disease 0 0.9991217
individuals O 0 0.003989602
. O 0 0.0021579168

It O 0 0.0024407497
may O 0 0.0010706742
even O 0 0.0007709828
present O 0 0.00042115958
in O 0 0.00041342076
patients O 0 0.0005414024
who O 0 0.00045683925
have O 0 0.00020147332
tolerated O 0 0.001148755
this O 0 0.0003647378
medicine O 0 0.0010365128
well O 0 0.00030927488
in O 0 0.00042910743
the O 0 0.00072994275
past O 0 0.0012402795
. O 0 0.0021018062

It O 0 0.00420498
is O 0 0.0024577263
usually O 0 0.002053099
but O 0 0.0014536468
not O 0 0.0010325684
necessarily O 0 0.0014347839
associated O 0 0.0017767247
with O 0 0.0056044213
hyperammonemia B-Disease 0 0.99984384
. O 0 0.008454169

The O 0 0.0020542587
EEG O 0 0.014409107
shows O 0 0.0007793753
characteristic O 0 0.0009443739
triphasic O 0 0.019586574
waves O 0 0.0017940352
in O 0 0.00054130226
most O 0 0.0008445241
patients O 0 0.0009345004
with O 0 0.0009998317
this O 0 0.0019607123
complication O 0 0.063046336
. O 0 0.0033080932

A O 0 0.020970922
case O 0 0.003354902
of O 0 0.006334496
valproate B-Chemical 0 0.99992085
- O 0 0.01310437
induced O 0 0.007673953
encephalopathy B-Disease 2 0.9997967
is O 0 0.005153586
presented O 0 0.004176141
. O 0 0.0045474325

The O 0 0.0025999595
problems O 0 0.0036964335
in O 0 0.0017396145
diagnosing O 0 0.002293011
this O 0 0.0014829193
condition O 0 0.0021961306
are O 0 0.0014437984
subsequently O 0 0.0020904695
discussed O 0 0.0030083705
. O 0 0.004069539

Recurrent O 0 0.051062305
dysphonia B-Disease 0 0.9752195
and O 0 0.036212835
acitretin B-Chemical 0 0.9992428
. O 0 0.025894752

We O 0 0.0017847652
report O 0 0.001783061
the O 0 0.0009159837
case O 0 0.00064413936
of O 0 0.0006602719
a O 0 0.000775159
woman O 0 0.0020379443
complaining O 0 0.005918589
of O 0 0.0007531813
dysphonia B-Disease 0 0.9419741
while O 0 0.00041899516
she O 0 0.00032001807
was O 0 0.00048555783
treated O 0 0.0011935591
by O 0 0.0027843413
acitretin B-Chemical 0 0.9998764
. O 0 0.0046847896

Her O 0 0.0065256176
symptoms O 0 0.00783939
totally O 0 0.002051496
regressed O 0 0.0011993032
after O 0 0.00030291852
drug O 0 0.006577796
withdrawal O 0 0.0065448866
and O 0 0.0005513182
reappeared O 0 0.0009647783
when O 0 0.00078413973
acitretin B-Chemical 0 0.9998708
was O 0 0.002943512
reintroduced O 0 0.0036864758
. O 0 0.0026555625

To O 0 0.0025284304
our O 0 0.0026958776
knowledge O 0 0.0025049208
, O 0 0.0012845747
this O 0 0.00079571136
is O 0 0.00050739973
the O 0 0.00035616802
first O 0 0.00027134625
case O 0 0.0005607519
of O 0 0.002390248
acitretin B-Chemical 0 0.999959
- O 0 0.008012585
induced O 0 0.005759023
dysphonia B-Disease 0 0.99527776
. O 0 0.0045848885

This O 0 0.003943496
effect O 0 0.0016456431
may O 0 0.0009385818
be O 0 0.00053173286
related O 0 0.00021928141
to O 0 0.000262796
the O 0 0.00028904565
pharmacological O 0 0.0015456629
effect O 0 0.0002932255
of O 0 0.0004499547
this O 0 0.0006170442
drug O 0 0.011491432
on O 0 0.00069841003
mucous O 0 0.06554579
membranes O 0 0.006714067
. O 0 0.002579397

Nitro B-Chemical 0 0.65174264
- I-Chemical 0 0.01426431
L I-Chemical 0 0.9499379
- I-Chemical 0 0.008965249
arginine I-Chemical 0 0.94113505
methyl I-Chemical 0 0.99836737
ester I-Chemical 0 0.9948272
: O 0 0.0014598512
a O 0 0.00081715314
potential O 0 0.0008033185
protector O 0 0.012641366
against O 0 0.0015176306
gentamicin B-Chemical 1 0.9997807
ototoxicity B-Disease 0 0.99994946
. O 0 0.009742745

The O 0 0.0034358972
nitric B-Chemical 0 0.98987484
oxide I-Chemical 0 0.9662601
( O 0 0.0042610844
NO B-Chemical 0 0.99745184
) O 0 0.002089843
inhibitor O 0 0.023497563
nitro B-Chemical 0 0.9998857
- I-Chemical 0 0.011465667
L I-Chemical 0 0.9909209
- I-Chemical 0 0.0032784173
arginine I-Chemical 0 0.9486954
methyl I-Chemical 0 0.99929106
ester I-Chemical 0 0.99887806
( O 0 0.0037588798
L B-Chemical 0 0.99703217
- I-Chemical 0 0.015809678
NAME I-Chemical 0 0.9999732
) O 0 0.0004989404
may O 0 7.749028e-05
act O 0 6.467949e-05
as O 0 6.367436e-05
an O 0 0.00010947142
otoprotectant O 0 0.0015266677
against O 0 6.029921e-05
high B-Disease 0 0.0002989957
- I-Disease 0 0.00025575908
frequency I-Disease 0 0.00016253605
hearing I-Disease 0 0.9688122
loss I-Disease 0 0.002517331
caused O 0 0.00025246412
by O 0 0.00029658698
gentamicin B-Chemical 1 0.9997727
, O 0 0.00029427628
but O 0 0.000115222516
further O 0 0.00011677349
studies O 0 7.054402e-05
are O 0 4.2750566e-05
needed O 0 3.134746e-05
to O 0 3.7360598e-05
confirm O 0 3.4392273e-05
this O 0 8.7918685e-05
. O 0 6.9608344e-05
Aminoglycoside B-Chemical 0 0.8125413
antibiotics O 0 0.0071412064
are O 0 9.024975e-05
still O 0 7.6962104e-05
widely O 0 6.222584e-05
used O 0 6.3450934e-05
by O 0 0.00010321141
virtue O 0 0.00025921708
of O 0 0.00019793115
their O 0 0.0002594742
efficacy O 0 0.00042091755
and O 0 0.0005183885
low O 0 0.001639147
cost O 0 0.002336803
. O 0 0.0021005392

Their O 0 0.034549877
ototoxicity B-Disease 0 0.99952364
is O 0 0.0020370667
a O 0 0.0013118151
serious O 0 0.0030685384
health O 0 0.001553787
problem O 0 0.00054084015
and O 0 0.00031514475
, O 0 0.00023722125
as O 0 0.00014532573
their O 0 0.0002594104
ototoxic B-Disease 0 0.9664038
mechanism O 0 0.0001848741
involves O 0 6.521858e-05
the O 0 8.99041e-05
production O 0 0.00019211024
of O 0 0.00039881727
NO B-Chemical 0 0.9984003
, O 0 0.0001597781
we O 0 3.7895392e-05
need O 0 4.5146382e-05
to O 0 4.1246447e-05
assess O 0 2.4099001e-05
the O 0 5.373315e-05
use O 0 6.28192e-05
of O 0 0.00018781926
NO B-Chemical 0 0.9939872
inhibitors O 0 0.0007346254
for O 0 7.105856e-05
the O 0 9.5725045e-05
prevention O 0 0.0002183253
of O 0 0.0004460072
aminoglycoside B-Chemical 0 0.9942198
- O 0 0.0024362076
induced O 0 0.0040524765
sensorineural B-Disease 2 0.9999896
hearing I-Disease 2 0.9998827
loss I-Disease 2 0.9575327
. O 0 0.005219631

In O 0 0.001746771
this O 0 0.001395875
experimental O 0 0.0011535193
study O 0 0.0006624808
we O 0 0.00022592218
used O 0 0.00026764788
30 O 0 0.00029681556
Sprague O 0 0.010611912
- O 0 0.00065252325
Dawley O 0 0.0022881506
rats O 0 0.00022510879
, O 0 0.00013118044
27 O 0 0.00013285772
of O 0 0.00011569516
which O 0 0.00017348408
had O 0 0.00024309027
gentamicin B-Chemical 1 0.99493694
instilled O 0 0.003290343
into O 0 0.00019409007
the O 0 0.0005286018
middle O 0 0.0022555313
ear O 0 0.011158294
. O 0 0.002748823

The O 0 0.0032636453
otoprotectant O 0 0.12552814
L B-Chemical 0 0.9873885
- I-Chemical 0 0.01711976
NAME I-Chemical 0 0.9996635
was O 0 0.0013872853
administered O 0 0.0010579117
topically O 0 0.027748812
to O 0 0.00057046465
12 O 0 0.0004635926
/ O 0 0.0015196451
27 O 0 0.0014748443
animals O 0 0.0013725184
. O 0 0.00243033

Its O 0 0.017360235
effect O 0 0.0017684425
was O 0 0.0011387889
determined O 0 0.0005027425
in O 0 0.00031621286
terms O 0 0.00019628256
of O 0 0.0002668292
attenuation O 0 0.00055561896
of O 0 0.00063295435
hearing B-Disease 0 0.99230677
loss I-Disease 0 0.007941059
, O 0 0.00030455517
measured O 0 0.00013005812
by O 0 0.00014171252
shifts O 0 0.00020658373
in O 0 0.000115688774
the O 0 0.00015300493
auditory O 0 0.00058341917
brainstem O 0 0.0026965928
response O 0 0.0007596728
threshold O 0 0.0013885576
. O 0 0.0020673156

L B-Chemical 0 0.98355603
- I-Chemical 0 0.024113005
NAME I-Chemical 0 0.9995994
reduced O 0 0.008961368
gentamicin B-Chemical 1 0.99972695
- O 0 0.0041461135
induced O 0 0.0011014852
hearing B-Disease 0 0.9892687
loss I-Disease 0 0.0034883171
in O 0 0.00021230943
the O 0 0.00016222932
high O 0 0.0004082328
- O 0 0.00031232447
frequency O 0 0.0001439802
range O 0 0.00014491612
, O 0 0.0001596368
but O 0 0.0001504711
gave O 0 0.00029518385
no O 0 8.318927e-05
protection O 0 0.00032989224
in O 0 0.00015599336
the O 0 0.00021605114
middle O 0 0.0006702495
or O 0 0.00044131075
low O 0 0.001605258
frequencies O 0 0.0021640111
. O 0 0.002274222

Safety O 0 0.0046833116
profile O 0 0.0014313665
of O 0 0.0011494358
a O 0 0.0015946394
nicotine B-Chemical 1 0.99950993
lozenge O 0 0.98968935
compared O 0 0.00018178069
with O 0 0.00016161636
that O 0 9.269243e-05
of O 0 0.0003669546
nicotine B-Chemical 1 0.99972063
gum O 0 0.40074793
in O 0 0.00013401445
adult O 0 0.0002676328
smokers O 0 0.00061037386
with O 0 8.06863e-05
underlying O 0 0.00013031633
medical O 0 0.00028773828
conditions O 0 0.00010786919
: O 0 0.00010410784
a O 0 0.00010431067
12 O 0 5.2658495e-05
- O 0 0.00013309738
week O 0 4.985007e-05
, O 0 0.00012191483
randomized O 0 0.00017852492
, O 0 0.00025470732
open O 0 0.00061982265
- O 0 0.000970007
label O 0 0.002067056
study O 0 0.0016910882
. O 0 0.0019823473

BACKGROUND O 0 0.011522473
: O 0 0.005690864
Nicotine B-Chemical 0 0.9998166
polacrilex O 0 0.9932847
lozenges O 0 0.91156274
deliver O 0 0.00026128473
25 O 0 0.0003551119
% O 0 0.00019405397
to O 0 0.000120451456
27 O 0 0.00020165165
% O 0 0.00013718945
more O 0 0.0002489385
nicotine B-Chemical 1 0.98858553
compared O 0 9.591793e-05
with O 0 0.00014096398
equivalent O 0 0.000165431
doses O 0 0.0013653043
of O 0 0.0012455337
nicotine B-Chemical 1 0.99978966
polacrilex O 0 0.99423665
gum O 0 0.645185
. O 0 0.0025461754

The O 0 0.001914714
increased O 0 0.003134651
nicotine B-Chemical 1 0.9949791
exposure O 0 0.0012157833
from O 0 0.0004136048
the O 0 0.00049911434
lozenge O 0 0.9006074
has O 0 0.00017477134
raised O 0 0.00020437631
questions O 0 0.00015836704
about O 0 0.00012615407
the O 0 0.00012004818
relative O 0 0.00012770864
safety O 0 0.00023794948
of O 0 0.00031953212
the O 0 0.0005878696
lozenge O 0 0.94679165
and O 0 0.0017675187
gum O 0 0.26948282
. O 0 0.0027725878

OBJECTIVE O 0 0.020613253
: O 0 0.0018819296
The O 0 0.0005987898
objective O 0 0.0006862541
of O 0 0.00052054925
this O 0 0.00041949714
study O 0 0.0003533414
was O 0 0.0001913676
to O 0 9.309496e-05
compare O 0 4.313514e-05
the O 0 7.064945e-05
safety O 0 9.5028925e-05
profiles O 0 6.126637e-05
of O 0 8.6251304e-05
the O 0 7.7616445e-05
4 O 0 6.423777e-05
- O 0 0.00018825423
mg O 0 0.02407268
nicotine B-Chemical 1 0.99981767
lozenge O 0 0.9930072
and O 0 0.00014523594
4 O 0 6.7789384e-05
- O 0 0.00018368225
mg O 0 0.015766053
nicotine B-Chemical 1 0.9994295
gum O 0 0.24951154
in O 0 0.0001734988
smokers O 0 0.0008940247
with O 0 0.00017220697
selected O 0 0.00023172221
label O 0 0.0011620772
- O 0 0.00086079276
restricted O 0 0.0007669064
diseases O 0 0.094116054
. O 0 0.0024627775

METHODS O 0 0.0018364132
: O 0 0.0015753334
This O 0 0.001234976
was O 0 0.00073364796
a O 0 0.0007186069
multicenter O 0 0.007086436
, O 0 0.00037750776
randomized O 0 0.00029301978
, O 0 0.00021039
open O 0 0.0003396299
- O 0 0.00031191652
label O 0 0.0003613304
study O 0 0.000109300454
in O 0 7.4881216e-05
adult O 0 0.0002010287
smokers O 0 0.0007259252
with O 0 0.00015003598
heart B-Disease 0 0.14182496
disease I-Disease 0 0.53754723
, O 0 0.0004960886
hypertension B-Disease 2 0.99992454
not O 0 0.000113082555
controlled O 0 9.0060945e-05
by O 0 0.00012615781
medication O 0 0.0009703093
, O 0 0.00020302684
and O 0 0.00026352008
/ O 0 0.0010810292
or O 0 0.0010603786
diabetes B-Disease 0 0.9995648
mellitus I-Disease 0 0.9990595
. O 0 0.0031627272

Patients O 0 0.0021799246
were O 0 0.0010744511
randomized O 0 0.0007636895
in O 0 0.00043283257
a O 0 0.000487898
1 O 0 0.00028102324
: O 0 0.0002706205
1 O 0 0.00014081542
ratio O 0 0.00016216883
to O 0 9.2961716e-05
receive O 0 6.76299e-05
the O 0 9.0813126e-05
4 O 0 8.655889e-05
- O 0 0.00025199782
mg O 0 0.023486793
nicotine B-Chemical 1 0.99974126
lozenge O 0 0.9902924
or O 0 0.00024603246
4 O 0 0.00020927301
- O 0 0.00068445917
mg O 0 0.05407344
nicotine B-Chemical 1 0.9992126
gum O 0 0.708497
. O 0 0.0029061418

Safety O 0 0.005087219
assessments O 0 0.0012086822
were O 0 0.0007020985
made O 0 0.00040250018
at O 0 0.0002448628
baseline O 0 0.00025272803
and O 0 0.00024449517
at O 0 0.00016154026
2 O 0 0.00017983172
, O 0 0.0002039253
4 O 0 0.00012387476
, O 0 0.00015615484
6 O 0 8.365344e-05
, O 0 0.00012277522
and O 0 0.000102156366
12 O 0 5.7678484e-05
weeks O 0 3.9401533e-05
after O 0 4.7723544e-05
the O 0 0.00013686295
start O 0 0.0001737632
of O 0 0.0006281895
product O 0 0.0018863424
use O 0 0.001687472
. O 0 0.0022827117

RESULTS O 0 0.0043302807
: O 0 0.0018002273
Nine O 0 0.0013367465
hundred O 0 0.0005319574
one O 0 0.00025768095
patients O 0 0.00029118845
were O 0 0.00016498707
randomized O 0 0.00014938191
to O 0 9.551105e-05
treatment O 0 0.0001312614
, O 0 0.00018059176
447 O 0 0.0018712184
who O 0 0.00014315732
received O 0 5.97431e-05
the O 0 0.00011379247
lozenge O 0 0.8387536
and O 0 0.00016469425
454 O 0 0.001307155
who O 0 0.00018355619
received O 0 9.393945e-05
the O 0 0.00019405193
gum O 0 0.038421668
( O 0 0.00056817965
safety O 0 0.0007569326
population O 0 0.0015594184
) O 0 0.0022062317
. O 0 0.002088521

The O 0 0.0026022987
majority O 0 0.0024729595
were O 0 0.0021707646
women O 0 0.0031989524
( O 0 0.0018298607
52 O 0 0.0015944653
. O 0 0.0009616754
7 O 0 0.0011997136
% O 0 0.0024024313
) O 0 0.004420378
. O 0 0.004558982

Patients O 0 0.002652068
' O 0 0.0016479148
mean O 0 0.0005813592
age O 0 0.0008337053
was O 0 0.00057391496
53 O 0 0.0005532456
. O 0 0.0001828027
9 O 0 0.00015508954
years O 0 0.0001178776
, O 0 0.000110242094
their O 0 9.300871e-05
mean O 0 5.259868e-05
weight O 0 0.00046404317
was O 0 0.00020243322
193 O 0 0.0010181536
. O 0 6.6623004e-05
9 O 0 7.147829e-05
pounds O 0 0.00013572085
, O 0 8.3045954e-05
and O 0 7.549618e-05
they O 0 7.592271e-05
smoked O 0 0.00048101883
a O 0 7.365642e-05
mean O 0 3.567737e-05
of O 0 0.00010831704
25 O 0 0.00016290936
. O 0 7.526063e-05
2 O 0 0.000101845406
cigarettes O 0 0.00040075032
per O 0 7.425857e-05
day O 0 0.00015388032
at O 0 0.00032219497
baseline O 0 0.00091712945
. O 0 0.001732096

Five O 0 0.0031767148
hundred O 0 0.0017045374
fifty O 0 0.0012583995
- O 0 0.0009170972
three O 0 0.00022943714
patients O 0 0.0004055071
, O 0 0.00030801722
264 O 0 0.0008005454
taking O 0 0.00024829048
the O 0 0.00018500721
lozenge O 0 0.8184418
and O 0 0.00017683615
289 O 0 0.00094129174
taking O 0 0.00015836129
the O 0 0.000113782924
gum O 0 0.03419734
, O 0 0.00010850862
used O 0 5.517923e-05
the O 0 6.9351736e-05
study O 0 9.216485e-05
product O 0 0.00015576668
for O 0 6.265795e-05
> O 0 0.00023013473
or O 0 8.28867e-05
= O 0 9.2990806e-05
4 O 0 3.0714407e-05
days O 0 1.589303e-05
per O 0 1.4850272e-05
week O 0 1.9390127e-05
during O 0 2.2786217e-05
the O 0 5.060773e-05
first O 0 5.3627802e-05
2 O 0 8.596621e-05
weeks O 0 7.152261e-05
( O 0 0.00029837718
evaluable O 0 0.0008975386
population O 0 0.0013465373
) O 0 0.0021560793
. O 0 0.0021145511

The O 0 0.0027336068
nicotine B-Chemical 1 0.9985707
lozenge O 0 0.9951167
and O 0 0.0023396371
nicotine B-Chemical 1 0.9995509
gum O 0 0.45412922
were O 0 0.00031960494
equally O 0 0.00024896345
well O 0 0.00016249018
tolerated O 0 0.0011660442
, O 0 0.00020178108
despite O 0 0.0001533865
increased O 0 0.0007160665
nicotine B-Chemical 1 0.9977174
exposure O 0 0.00082978833
from O 0 0.00053188036
the O 0 0.001303315
lozenge O 0 0.95592207
. O 0 0.0025179416

The O 0 0.0018225012
incidence O 0 0.0022501284
of O 0 0.0013061364
adverse O 0 0.023757834
events O 0 0.0017282546
in O 0 0.00030325833
the O 0 0.00022738414
2 O 0 0.0001491873
groups O 0 0.00011526681
was O 0 8.7350934e-05
similar O 0 4.240883e-05
during O 0 3.2159653e-05
the O 0 5.2132218e-05
first O 0 3.8441845e-05
2 O 0 4.3490985e-05
weeks O 0 2.0851103e-05
of O 0 6.6453336e-05
product O 0 0.00016928578
use O 0 7.319975e-05
( O 0 9.770356e-05
evaluation O 0 6.7237575e-05
population O 0 0.00017094107
: O 0 0.00011329141
55 O 0 9.722465e-05
. O 0 4.2927342e-05
3 O 0 5.002284e-05
% O 0 0.00011337483
lozenge O 0 0.6668609
, O 0 0.00013909389
54 O 0 0.00016003211
. O 0 4.7876063e-05
7 O 0 5.0423423e-05
% O 0 0.000113253926
gum O 0 0.032568734
) O 0 0.0002520442
, O 0 0.00011221613
as O 0 6.6538625e-05
well O 0 4.9784983e-05
as O 0 4.343056e-05
during O 0 2.4010022e-05
the O 0 4.2157622e-05
entire O 0 4.384143e-05
study O 0 8.6858294e-05
( O 0 9.8440316e-05
safety O 0 0.00010600489
population O 0 0.00018258634
: O 0 0.00013327887
63 O 0 0.00014983784
. O 0 5.648689e-05
8 O 0 6.59683e-05
% O 0 9.9306395e-05
and O 0 0.00012367232
58 O 0 0.00021962686
. O 0 0.00012203033
6 O 0 0.00015390776
% O 0 0.00036780562
, O 0 0.00070229586
respectively O 0 0.0019303866
) O 0 0.0025979634
. O 0 0.0024769055

Stratification O 0 0.014696887
of O 0 0.0021814688
patients O 0 0.0017142906
by O 0 0.0010056851
sex O 0 0.0015381697
, O 0 0.0005273633
age O 0 0.00034436138
, O 0 0.00019542986
extent O 0 0.000104364684
of O 0 0.0002056549
concurrent O 0 0.00050167163
smoking O 0 0.08937824
, O 0 0.00014147015
extent O 0 6.343648e-05
of O 0 0.00013021992
product O 0 0.00027232227
use O 0 8.694158e-05
, O 0 9.515042e-05
and O 0 8.255626e-05
severity O 0 0.00018743481
of O 0 0.00013763415
adverse O 0 0.013442191
events O 0 0.0004757008
revealed O 0 8.582468e-05
no O 0 5.7050165e-05
clinically O 0 0.00038603894
significant O 0 9.73914e-05
differences O 0 5.9178798e-05
between O 0 9.589753e-05
the O 0 0.00039220048
lozenge O 0 0.922941
and O 0 0.0015317658
gum O 0 0.25280535
. O 0 0.0025317182

The O 0 0.0016334606
most O 0 0.0016314541
common O 0 0.0010994981
adverse O 0 0.015707182
events O 0 0.0029371404
were O 0 0.0011737065
nausea B-Disease 0 0.9998925
( O 0 0.00091504125
17 O 0 0.0003413559
. O 0 0.0001109727
2 O 0 0.000104551254
% O 0 0.0001241104
and O 0 0.00012197229
16 O 0 0.0001192401
. O 0 7.6445715e-05
1 O 0 9.306229e-05
% O 0 0.00012778075
; O 0 0.00015186914
95 O 0 0.000195333
% O 0 0.00018012672
CI O 0 0.0054144543
, O 0 0.00018658656
- O 0 0.0002349281
3 O 0 6.793668e-05
. O 0 4.6291894e-05
7 O 0 4.3557644e-05
to O 0 5.1839528e-05
6 O 0 4.5990833e-05
. O 0 4.7676007e-05
0 O 0 7.790965e-05
) O 0 0.00018224666
, O 0 0.0002171691
hiccups B-Disease 2 0.9007652
( O 0 0.0002616467
10 O 0 9.544393e-05
. O 0 5.752309e-05
7 O 0 5.5923843e-05
% O 0 8.413881e-05
and O 0 8.7693115e-05
6 O 0 5.718503e-05
. O 0 5.353062e-05
6 O 0 5.4181113e-05
% O 0 0.00010351242
; O 0 0.00013064554
95 O 0 0.00017111098
% O 0 0.00015285314
CI O 0 0.0026277243
, O 0 0.00011489809
0 O 0 7.1430186e-05
. O 0 4.5652097e-05
5 O 0 4.464644e-05
to O 0 5.3312026e-05
7 O 0 5.3981425e-05
. O 0 4.9382885e-05
8 O 0 6.630629e-05
) O 0 0.00014208678
, O 0 0.0001286721
and O 0 0.00025460948
headache B-Disease 0 0.99767333
( O 0 0.0003115364
8 O 0 8.4896084e-05
. O 0 5.3507756e-05
7 O 0 5.4648972e-05
% O 0 8.533494e-05
and O 0 9.383319e-05
9 O 0 8.181776e-05
. O 0 6.0936232e-05
9 O 0 7.875492e-05
% O 0 0.00011845338
; O 0 0.0001554846
95 O 0 0.00023729565
% O 0 0.00031113124
Cl O 0 0.99964046
, O 0 0.00039637153
- O 0 0.00035915733
5 O 0 0.00010858665
. O 0 9.388769e-05
0 O 0 0.00013269164
to O 0 0.0001890134
2 O 0 0.00028424684
. O 0 0.0003446231
6 O 0 0.0005866779
) O 0 0.0018713919
. O 0 0.0023167217

Serious O 0 0.018242216
adverse O 0 0.053208657
events O 0 0.004155829
were O 0 0.00094444584
reported O 0 0.0006417081
in O 0 0.0004093335
11 O 0 0.00036313318
and O 0 0.00031327872
13 O 0 0.00032607344
patients O 0 0.00038044283
in O 0 0.0003241817
the O 0 0.00049703225
respective O 0 0.0008436651
groups O 0 0.001490654
. O 0 0.0022473051

Fewer O 0 0.0068161804
than O 0 0.0011151748
6 O 0 0.00059344026
% O 0 0.0005546697
of O 0 0.00045027607
patients O 0 0.0003901917
in O 0 0.00018151048
either O 0 0.00016640143
group O 0 0.00020567726
were O 0 0.00010753306
considered O 0 6.767919e-05
by O 0 8.325347e-05
the O 0 8.415261e-05
investigator O 0 0.00023075608
to O 0 7.1362985e-05
have O 0 6.136794e-05
a O 0 0.00014080199
worsening O 0 0.0032356002
of O 0 0.00017893361
their O 0 0.00017757893
overall O 0 0.0002568095
disease O 0 0.02967239
condition O 0 0.0005183455
during O 0 0.00022332606
the O 0 0.00061466964
study O 0 0.0014214354
. O 0 0.0017983372

The O 0 0.001684268
majority O 0 0.0013812928
of O 0 0.0013498744
patients O 0 0.0013038979
( O 0 0.00088853104
> O 0 0.0008284628
60 O 0 0.0003452372
% O 0 0.0003281044
) O 0 0.0003352363
experienced O 0 0.00020937259
no O 0 0.00011224555
change O 0 0.00018719208
in O 0 0.00021187261
their O 0 0.0004479877
disease O 0 0.031387523
status O 0 0.00049041543
from O 0 0.00062353833
baseline O 0 0.0012095274
. O 0 0.0019822482

CONCLUSION O 0 0.015161342
: O 0 0.0019013654
The O 0 0.0006663117
4 O 0 0.00057853846
- O 0 0.0010155222
mg O 0 0.051793233
nicotine B-Chemical 1 0.9997086
lozenge O 0 0.9954556
and O 0 0.00033463855
4 O 0 0.00013328498
- O 0 0.0002912212
mg O 0 0.024070583
nicotine B-Chemical 1 0.999548
gum O 0 0.25023127
had O 0 0.00010287231
comparable O 0 4.839638e-05
safety O 0 7.956467e-05
profiles O 0 5.6096407e-05
in O 0 6.232477e-05
these O 0 0.0001265898
patients O 0 0.00018687607
with O 0 0.00024237766
label O 0 0.0009545362
- O 0 0.00050723634
restricted O 0 0.00032830745
medical O 0 0.0016890535
conditions O 0 0.0015092747
. O 0 0.0018963098

Pharmacological O 0 0.1407885
modulation O 0 0.0020544708
of O 0 0.0026575916
pain B-Disease 0 0.68101805
- O 0 0.0011698178
related O 0 0.00018505414
brain O 0 0.00084362726
activity O 0 0.00018584989
during O 0 0.00010299304
normal O 0 0.0003234849
and O 0 0.00021515199
central O 0 0.00039224158
sensitization O 0 0.002877289
states O 0 0.00087461097
in O 0 0.0008461827
humans O 0 0.0029806301
. O 0 0.0021802895

Abnormal O 0 0.003336837
processing O 0 0.0008638901
of O 0 0.00086460524
somatosensory O 0 0.0013282006
inputs O 0 0.0005100293
in O 0 0.00024218712
the O 0 0.00019454212
central O 0 0.0002766027
nervous O 0 0.0035524042
system O 0 0.000222692
( O 0 0.00020901776
central O 0 0.00020464287
sensitization O 0 0.003232646
) O 0 0.00024918217
is O 0 7.8086756e-05
the O 0 6.151982e-05
mechanism O 0 7.229928e-05
accounting O 0 0.00010755183
for O 0 4.8631126e-05
the O 0 7.58727e-05
enhanced O 0 0.00024546168
pain B-Disease 0 0.3529999
sensitivity O 0 0.00072137883
in O 0 0.00010764601
the O 0 0.00013114868
skin O 0 0.0016016703
surrounding O 0 0.00028863177
tissue B-Disease 0 0.09628599
injury I-Disease 0 0.9886674
( O 0 0.0028377816
secondary B-Disease 2 0.6594386
hyperalgesia I-Disease 2 0.99988544
) O 0 0.0076363464
. O 0 0.002604037

Secondary B-Disease 0 0.091968276
hyperalgesia I-Disease 0 0.998422
shares O 0 0.0023312531
clinical O 0 0.0017197806
characteristics O 0 0.00040647353
with O 0 0.0009289338
neurogenic B-Disease 0 0.97993416
hyperalgesia I-Disease 0 0.9998447
in O 0 0.00089907495
patients O 0 0.0014746715
with O 0 0.0032554436
neuropathic B-Disease 0 0.99983084
pain I-Disease 0 0.9982419
. O 0 0.0042590857

Abnormal O 0 0.004518632
brain O 0 0.0030896598
responses O 0 0.0009176903
to O 0 0.00042206107
somatosensory O 0 0.0009036159
stimuli O 0 0.00032541782
have O 0 0.00016067631
been O 0 0.00011684445
found O 0 0.00010590294
in O 0 0.00011537413
patients O 0 0.0002501126
with O 0 0.00042610776
hyperalgesia B-Disease 0 0.9955461
as O 0 0.00015223626
well O 0 8.2812825e-05
as O 0 7.8601275e-05
in O 0 8.508403e-05
normal O 0 0.00023420058
subjects O 0 0.00016151962
during O 0 0.00010115269
experimental O 0 0.00039555525
central O 0 0.00097445876
sensitization O 0 0.01138179
. O 0 0.0022453407

The O 0 0.001522462
aim O 0 0.0013967395
of O 0 0.0011269668
this O 0 0.00081970904
study O 0 0.00063754176
was O 0 0.0003236163
to O 0 0.0001452505
assess O 0 6.46785e-05
the O 0 0.00010063422
effects O 0 0.00016763611
of O 0 0.0006800253
gabapentin B-Chemical 0 0.99997497
, O 0 0.00025250696
a O 0 0.00017484301
drug O 0 0.0027485106
effective O 0 8.9531255e-05
in O 0 0.00028374023
neuropathic B-Disease 0 0.99996495
pain I-Disease 0 0.9985085
patients O 0 0.0003841791
, O 0 8.680067e-05
on O 0 3.4128938e-05
brain O 0 0.00024429243
processing O 0 5.1028474e-05
of O 0 0.0001185553
nociceptive O 0 0.0005481432
information O 0 0.000101087135
in O 0 0.00011335332
normal O 0 0.000311937
and O 0 0.00024743023
central O 0 0.0005771564
sensitization O 0 0.005748886
states O 0 0.0022123766
. O 0 0.0019359539

Using O 0 0.0015095054
functional O 0 0.0014664208
magnetic O 0 0.0030076841
resonance O 0 0.005995457
imaging O 0 0.0010300432
( O 0 0.0005238254
fMRI O 0 0.00052781485
) O 0 0.0003255879
in O 0 0.00014394081
normal O 0 0.00030035022
volunteers O 0 0.00022934747
, O 0 0.00010069287
we O 0 4.4261735e-05
studied O 0 0.00012072721
the O 0 0.00024090252
gabapentin B-Chemical 0 0.99996674
- O 0 0.0004102511
induced O 0 0.00010213123
modulation O 0 7.824545e-05
of O 0 0.000111110036
brain O 0 0.0006322737
activity O 0 6.6438384e-05
in O 0 4.9442067e-05
response O 0 5.8692767e-05
to O 0 5.9527454e-05
nociceptive O 0 0.00043157986
mechanical O 0 9.7847995e-05
stimulation O 0 5.2603842e-05
of O 0 0.00012910755
normal O 0 0.000475427
skin O 0 0.00554188
and O 0 0.0005989462
capsaicin B-Chemical 0 0.9996605
- O 0 0.0021423243
induced O 0 0.0018331463
secondary B-Disease 2 0.79393077
hyperalgesia I-Disease 2 0.99986327
. O 0 0.0046423175

The O 0 0.0018059165
dose O 0 0.00493182
of O 0 0.0035757688
gabapentin B-Chemical 0 0.999882
was O 0 0.0012253189
1 O 0 0.00039863717
, O 0 0.00036183695
800 O 0 0.00080377376
mg O 0 0.0026410823
per O 0 0.00016063554
os O 0 0.0038086725
, O 0 0.0004048566
in O 0 0.0003549779
a O 0 0.00073355745
single O 0 0.0010405554
administration O 0 0.0060653873
. O 0 0.0027298033

We O 0 0.0016347427
found O 0 0.0011246148
that O 0 0.00072660245
( O 0 0.0011340539
i O 0 0.001594356
) O 0 0.0017088441
gabapentin B-Chemical 0 0.99980134
reduced O 0 0.0005281889
the O 0 0.00015699492
activations O 0 0.00028089143
in O 0 9.889164e-05
the O 0 0.0001031992
bilateral O 0 0.0010917615
operculoinsular O 0 0.0008931179
cortex O 0 0.0026012396
, O 0 9.3238166e-05
independently O 0 3.9941733e-05
of O 0 6.444553e-05
the O 0 4.9856346e-05
presence O 0 5.2902058e-05
of O 0 9.0779446e-05
central O 0 0.0001562652
sensitization O 0 0.0043282066
; O 0 0.00016669299
( O 0 0.0001385316
ii O 0 0.00027550885
) O 0 0.00041625416
gabapentin B-Chemical 0 0.99985874
reduced O 0 0.00021033343
the O 0 7.142869e-05
activation O 0 9.58065e-05
in O 0 5.823848e-05
the O 0 6.9878966e-05
brainstem O 0 0.0011232713
, O 0 7.906917e-05
only O 0 5.3501837e-05
during O 0 2.6670363e-05
central O 0 0.00010137635
sensitization O 0 0.00210166
; O 0 0.00015117017
( O 0 0.00013806767
iii O 0 0.00038676424
) O 0 0.00042869017
gabapentin B-Chemical 0 0.9998627
suppressed O 0 0.0002404227
stimulus O 0 0.00015534413
- O 0 0.00021079197
induced O 0 0.00010018422
deactivations O 0 0.0010466749
, O 0 8.559182e-05
only O 0 5.7544545e-05
during O 0 2.8370268e-05
central O 0 0.000103787876
sensitization O 0 0.0014309712
; O 0 0.000109638866
this O 0 8.873679e-05
effect O 0 8.405421e-05
was O 0 0.00010782681
more O 0 0.00011234717
robust O 0 7.5285876e-05
than O 0 7.6982e-05
the O 0 0.0001296117
effect O 0 0.00019783266
on O 0 0.00027872395
brain O 0 0.0040658023
activation O 0 0.0025285506
. O 0 0.0023215052

The O 0 0.0019458807
observed O 0 0.0017442253
drug O 0 0.02673828
- O 0 0.0018462103
induced O 0 0.00065410405
effects O 0 0.0005487462
were O 0 0.0003282918
not O 0 0.00019285997
due O 0 0.00013561567
to O 0 0.00016631861
changes O 0 0.0002595593
in O 0 0.00021761993
the O 0 0.00029679207
baseline O 0 0.0004330519
fMRI O 0 0.001320755
signal O 0 0.0012095614
. O 0 0.0022718387

These O 0 0.0019248768
findings O 0 0.0016949502
indicate O 0 0.00057213526
that O 0 0.0007558707
gabapentin B-Chemical 0 0.9998766
has O 0 0.00035045596
a O 0 0.00035902415
measurable O 0 0.0005078599
antinociceptive O 0 0.9223439
effect O 0 0.00019650576
and O 0 0.00015313864
a O 0 0.00016718611
stronger O 0 0.00025495855
antihyperalgesic O 0 0.92345154
effect O 0 0.00012602578
most O 0 0.00017240217
evident O 0 6.0871294e-05
in O 0 4.86675e-05
the O 0 5.3104042e-05
brain O 0 0.00040404583
areas O 0 7.8997575e-05
undergoing O 0 9.127935e-05
deactivation O 0 0.00041338545
, O 0 7.7449055e-05
thus O 0 6.6328306e-05
supporting O 0 4.8302787e-05
the O 0 4.7161364e-05
concept O 0 6.9005524e-05
that O 0 0.00010237831
gabapentin B-Chemical 0 0.999938
is O 0 0.00010830579
more O 0 9.8734294e-05
effective O 0 5.503639e-05
in O 0 6.167731e-05
modulating O 0 6.465606e-05
nociceptive O 0 0.0006289363
transmission O 0 0.00015354014
when O 0 0.000109996916
central O 0 0.0003954398
sensitization O 0 0.0034431969
is O 0 0.00078105455
present O 0 0.0010237605
. O 0 0.0018564536

Investigation O 0 0.0061455206
of O 0 0.0029487
mitochondrial O 0 0.1178497
involvement O 0 0.0013981061
in O 0 0.00051050505
the O 0 0.00039310986
experimental O 0 0.000517044
model O 0 0.000605115
of O 0 0.0014646831
epilepsy B-Disease 2 0.9998093
induced O 0 0.0045131035
by O 0 0.005927163
pilocarpine B-Chemical 1 0.99991083
. O 0 0.0051019522

Mitochondrial B-Disease 0 0.9895908
abnormalities I-Disease 0 0.37203777
have O 0 0.0008661824
been O 0 0.00040666535
associated O 0 0.00026756624
with O 0 0.0002387021
several O 0 0.000111745336
aspects O 0 8.133933e-05
of O 0 0.0002843219
epileptogenesis O 0 0.90956426
, O 0 0.00022565483
such O 0 8.207977e-05
as O 0 9.843383e-05
energy O 0 0.00034351734
generation O 0 0.00016872899
, O 0 0.000105166495
control O 0 8.907014e-05
of O 0 0.00023203657
cell O 0 0.00469073
death B-Disease 0 0.99131036
, O 0 0.00048451254
neurotransmitter O 0 0.22556177
synthesis O 0 0.0013466245
, O 0 0.00020893886
and O 0 0.00019089141
free O 0 0.0004732084
radical O 0 0.35348803
( O 0 0.0012386558
FR O 0 0.13128255
) O 0 0.0015799212
production O 0 0.0023188035
. O 0 0.0023963181

Increased O 0 0.0037804926
production O 0 0.0024802948
of O 0 0.0018647843
FRs O 0 0.015267148
may O 0 0.0006807044
cause O 0 0.0013467066
mtDNA O 0 0.22945486
damage O 0 0.1468601
leading O 0 0.000477019
to O 0 0.00016832277
decreased O 0 0.00035155486
activities O 0 0.00018402164
of O 0 0.00030973935
oxidative O 0 0.3969912
phosphorylation O 0 0.0011076924
complexes O 0 0.00041154824
containing O 0 0.00032669917
mtDNA O 0 0.06532248
- O 0 0.0010621182
encoded O 0 0.0007763518
subunits O 0 0.0040907627
. O 0 0.0022919562

In O 0 0.0018754168
this O 0 0.0016530959
study O 0 0.0012595538
, O 0 0.00067593943
we O 0 0.0002106935
investigated O 0 0.00020470764
whether O 0 0.0001083744
increased O 0 0.00030949345
generation O 0 0.000306119
of O 0 0.0003047254
FR O 0 0.09041367
during O 0 7.298117e-05
status B-Disease 0 0.00017624968
epilepticus I-Disease 0 0.96639365
would O 0 9.191979e-05
be O 0 5.0904928e-05
sufficient O 0 3.673747e-05
to O 0 4.7944184e-05
provoke O 0 0.00016682368
abnormalities O 0 0.0037345027
in O 0 0.000112734255
mtDNA O 0 0.019045187
and O 0 6.751244e-05
in O 0 4.5270463e-05
the O 0 4.8862352e-05
expression O 0 7.3963594e-05
and O 0 6.209063e-05
activity O 0 7.7081684e-05
of O 0 0.000387037
cytochrome O 0 0.99989307
c O 0 0.4132253
oxidase O 0 0.9999565
( O 0 0.0012095926
CCO O 0 0.9580599
) O 0 0.00022947368
, O 0 8.348179e-05
complex O 0 8.0820064e-05
IV O 0 0.0019249748
of O 0 9.5136355e-05
the O 0 9.4370596e-05
respiratory O 0 0.0069947774
chain O 0 0.004772916
, O 0 0.0001349898
in O 0 7.006112e-05
the O 0 9.386442e-05
chronic O 0 0.008951338
phase O 0 0.0003461247
of O 0 0.00019141579
the O 0 0.0002918115
pilocarpine B-Chemical 1 0.99993145
model O 0 0.00045315895
of O 0 0.0005868054
temporal B-Disease 0 0.038919505
lobe I-Disease 0 0.91470355
epilepsy I-Disease 2 0.9999422
. O 0 0.0044539915

DNA O 0 0.015719814
analysis O 0 0.0015418468
revealed O 0 0.000908211
low O 0 0.0009864612
amounts O 0 0.00048052962
of O 0 0.00049332186
a O 0 0.0004412609
4 O 0 0.00016741647
. O 0 9.82639e-05
8 O 0 9.856552e-05
kb O 0 0.00032502192
mtDNA O 0 0.015593145
deletion O 0 0.00046655975
but O 0 0.00014706208
with O 0 0.00011388225
no O 0 4.6182588e-05
differences O 0 3.572575e-05
in O 0 5.9629492e-05
frequency O 0 8.581559e-05
or O 0 6.763674e-05
quantity O 0 7.5982905e-05
in O 0 9.1847585e-05
the O 0 0.00012457163
control O 0 0.00019457458
and O 0 0.000363821
experimental O 0 0.0008704325
groups O 0 0.0011319149
. O 0 0.001695073

We O 0 0.001638989
did O 0 0.001438797
not O 0 0.0007602514
find O 0 0.0005921117
abnormalities O 0 0.0030909185
in O 0 0.00027969692
the O 0 0.00020102542
expression O 0 0.00019568384
and O 0 0.0001185343
distribution O 0 5.6827324e-05
of O 0 0.00014105892
an O 0 0.0002796649
mtDNA O 0 0.100717455
- O 0 0.00028338283
encoded O 0 9.189157e-05
subunit O 0 0.00095958007
of O 0 0.00044628643
CCO O 0 0.9865311
( O 0 0.000751572
CCO O 0 0.97042996
- O 0 0.00062160456
I O 0 0.0025263412
) O 0 0.00016037338
or O 0 5.8785183e-05
a O 0 8.640237e-05
relative O 0 6.739376e-05
decrease O 0 0.00014500001
in O 0 0.0001720445
CCO O 0 0.9554242
- O 0 0.00043433456
I O 0 0.00072242727
when O 0 4.242303e-05
compared O 0 4.5054432e-05
with O 0 0.00010935884
nuclear O 0 0.00041747515
- O 0 0.00023990222
encoded O 0 0.000110224435
subunits O 0 0.0009380508
( O 0 0.0005287585
CCO O 0 0.9038893
- O 0 0.00094395014
IV O 0 0.026600305
and O 0 0.00090662617
SDH O 0 0.9964265
- O 0 0.005037939
fp O 0 0.5028778
) O 0 0.0033300312
. O 0 0.002444489

No O 0 0.005723424
abnormality O 0 0.015212382
in O 0 0.0031586736
CCO O 0 0.63250214
activity O 0 0.0018480371
was O 0 0.0017581173
observed O 0 0.0014176299
through O 0 0.0018859593
histochemistry O 0 0.008999061
. O 0 0.0040803873

Although O 0 0.0015022275
evidences O 0 0.0016067711
of O 0 0.0018322688
mitochondrial B-Disease 0 0.97154546
abnormalities I-Disease 0 0.6761875
were O 0 0.00042994536
found O 0 0.00018071801
in O 0 0.00013671385
previously O 0 0.00012399223
published O 0 0.00014223182
studies O 0 0.00012348144
, O 0 0.00010684232
our O 0 0.000111059504
results O 0 8.94791e-05
do O 0 7.1526905e-05
not O 0 5.2376596e-05
suggest O 0 2.6256788e-05
that O 0 4.304926e-05
the O 0 9.450189e-05
FRs O 0 0.0048705037
, O 0 7.845749e-05
generated O 0 3.5173874e-05
during O 0 3.0217974e-05
the O 0 8.3891566e-05
acute O 0 0.059458036
phase O 0 0.0005550875
, O 0 0.00010103575
determined O 0 5.02156e-05
important O 0 3.891296e-05
abnormalities O 0 0.0028612916
in O 0 0.0001401931
mtDNA O 0 0.03824574
, O 0 0.000114092785
in O 0 7.8084224e-05
expression O 0 0.00015557953
of O 0 0.0003928119
CCO O 0 0.9665108
- O 0 0.00093934365
I O 0 0.0025241526
, O 0 0.00035248025
and O 0 0.00040457715
in O 0 0.0006872844
CCO O 0 0.661153
activity O 0 0.001806479
. O 0 0.0022538023

Adverse O 0 0.0057200245
effect O 0 0.0012306366
of O 0 0.0011424408
the O 0 0.0011462333
calcium B-Chemical 0 0.99886924
channel O 0 0.8653069
blocker O 0 0.99963844
nitrendipine B-Chemical 1 0.999998
on O 0 0.0014689881
nephrosclerosis B-Disease 0 0.9999944
in O 0 0.0008324673
rats O 0 0.0011487155
with O 0 0.0023824708
renovascular B-Disease 0 0.99998045
hypertension I-Disease 2 0.99998724
. O 0 0.006411663

The O 0 0.0015932984
effect O 0 0.0012128188
of O 0 0.0011666206
a O 0 0.0009121087
6 O 0 0.00032302353
- O 0 0.00041619
week O 0 9.575883e-05
treatment O 0 0.00011034927
with O 0 0.00013385456
the O 0 0.0001964539
calcium B-Chemical 0 0.9991085
channel O 0 0.8067521
blocker O 0 0.99956673
nitrendipine B-Chemical 1 0.99999905
or O 0 0.00019628687
the O 0 0.00021765978
angiotensin B-Chemical 1 0.9999777
converting O 0 0.09014953
enzyme O 0 0.05126466
inhibitor O 0 0.018065287
enalapril B-Chemical 1 0.9999949
on O 0 7.634038e-05
blood O 0 0.00255515
pressure O 0 0.0056993426
, O 0 0.000308391
albuminuria B-Disease 2 0.9999888
, O 0 0.0004168855
renal O 0 0.9550632
hemodynamics O 0 0.7169937
, O 0 0.000111654575
and O 0 6.2429106e-05
morphology O 0 0.000119083415
of O 0 7.7276876e-05
the O 0 9.016424e-05
nonclipped O 0 0.23981138
kidney O 0 0.771756
was O 0 0.00014591502
studied O 0 8.682707e-05
in O 0 5.9976683e-05
rats O 0 0.00011187497
with O 0 0.000108472406
two O 0 9.520487e-05
- O 0 0.0003997489
kidney O 0 0.34343356
, O 0 0.00041293903
one O 0 0.00036567607
clip O 0 0.01692754
renovascular B-Disease 0 0.9999808
hypertension I-Disease 2 0.9999871
. O 0 0.0056701633

Six O 0 0.001926718
weeks O 0 0.00056256645
after O 0 0.0003489737
clipping O 0 0.0012261232
of O 0 0.00047879698
one O 0 0.00032846807
renal O 0 0.7570896
artery O 0 0.26713312
, O 0 0.0008214038
hypertensive B-Disease 2 0.999451
rats O 0 0.0005491677
( O 0 0.00026679234
178 O 0 0.00078175555
+ O 0 0.00030016902
/ O 0 0.00041515782
- O 0 0.00020244226
4 O 0 6.398662e-05
mm O 0 0.00021657377
Hg O 0 0.4570364
) O 0 0.00012989501
were O 0 4.0249342e-05
randomly O 0 1.4942471e-05
assigned O 0 2.434951e-05
to O 0 2.7568116e-05
three O 0 2.1845995e-05
groups O 0 4.6041434e-05
: O 0 7.097926e-05
untreated O 0 0.00023591437
hypertensive B-Disease 2 0.9989152
controls O 0 0.00033729544
( O 0 0.00013226325
n O 0 6.992409e-05
= O 0 8.7831206e-05
8 O 0 5.5208286e-05
) O 0 0.0001415661
, O 0 0.00023690547
enalapril B-Chemical 1 0.99999166
- O 0 0.00065352017
treated O 0 0.00026114797
( O 0 0.00018849294
n O 0 9.6644435e-05
= O 0 0.000116190684
8 O 0 6.838386e-05
) O 0 0.00013955914
, O 0 0.00013255367
or O 0 0.0002834266
nitrendipine B-Chemical 1 0.99999523
- O 0 0.0012231919
treated O 0 0.0005575494
( O 0 0.00049137353
n O 0 0.00036164725
= O 0 0.0006181974
10 O 0 0.00072981056
) O 0 0.0018864843
. O 0 0.0021385306

Sham O 0 0.052126765
- O 0 0.003713812
operated O 0 0.0018842727
rats O 0 0.00094005855
served O 0 0.0007230362
as O 0 0.00045349682
normotensive O 0 0.549953
controls O 0 0.00063306774
( O 0 0.0003732942
128 O 0 0.0005212379
+ O 0 0.00051387615
/ O 0 0.0007085185
- O 0 0.00039550543
3 O 0 0.0001615957
mm O 0 0.0005442921
Hg O 0 0.3041742
, O 0 0.0005256622
n O 0 0.00045863717
= O 0 0.0007457333
8 O 0 0.000766314
) O 0 0.0019644017
. O 0 0.0023030327

After O 0 0.0009680257
6 O 0 0.0007219221
weeks O 0 0.00034182874
of O 0 0.0005470039
treatment O 0 0.00050170644
, O 0 0.00061811635
renal O 0 0.8265056
hemodynamics O 0 0.7819778
( O 0 0.0005076942
glomerular O 0 0.6388425
filtration O 0 0.0024380428
rate O 0 0.0001647362
and O 0 0.00017038581
renal O 0 0.655654
plasma O 0 0.013167687
flow O 0 0.00124304
) O 0 0.00024079274
were O 0 0.00012355563
measured O 0 0.00012640236
in O 0 0.00019761303
the O 0 0.00038416352
anesthetized O 0 0.002013311
rats O 0 0.0018262854
. O 0 0.0017429173

Renal O 0 0.02697107
tissue O 0 0.0051808776
was O 0 0.0015233104
obtained O 0 0.0008906407
for O 0 0.0006488322
determination O 0 0.0015335141
of O 0 0.0015143834
glomerular O 0 0.92084664
size O 0 0.0035002623
and O 0 0.0035736167
sclerosis O 0 0.97499883
. O 0 0.004431526

Enalapril B-Chemical 0 0.9998006
but O 0 0.006119001
not O 0 0.0048973914
nitrendipine B-Chemical 1 0.9999486
reduced O 0 0.00957001
blood O 0 0.05420568
pressure O 0 0.039775625
significantly O 0 0.005782985
. O 0 0.0048439656

After O 0 0.0010356166
6 O 0 0.00078549114
weeks O 0 0.00038433075
of O 0 0.0006349276
therapy O 0 0.0007405472
, O 0 0.00064892217
glomerular O 0 0.7030088
filtration O 0 0.006950483
rate O 0 0.0003920691
was O 0 0.00025654177
not O 0 0.00017190937
different O 0 0.00016676661
among O 0 0.00034052413
the O 0 0.00047616308
studied O 0 0.0010157209
groups O 0 0.0013403147
. O 0 0.0020252801

Renal O 0 0.026233524
plasma O 0 0.012428167
flow O 0 0.003911761
increased O 0 0.0012905286
, O 0 0.00076925487
but O 0 0.00062653056
albumin O 0 0.95843637
excretion O 0 0.96768737
and O 0 0.0019848193
glomerulosclerosis B-Disease 2 0.999992
did O 0 0.00069509796
not O 0 0.00025340944
change O 0 0.00031925747
after O 0 0.0003594252
enalapril B-Chemical 1 0.9999418
treatment O 0 0.003288686
. O 0 0.0026215059

In O 0 0.0018942838
contrast O 0 0.0018676567
, O 0 0.0011383301
in O 0 0.0006351534
the O 0 0.0012408774
nitrendipine B-Chemical 1 0.9999951
- O 0 0.0025497952
treated O 0 0.0007112117
group O 0 0.0010120247
albuminuria B-Disease 2 0.99997973
increased O 0 0.0006208301
from O 0 0.00011381982
12 O 0 5.7229434e-05
. O 0 5.1234092e-05
8 O 0 6.518786e-05
+ O 0 0.00018703402
/ O 0 0.00035023468
- O 0 0.0001995034
2 O 0 6.182227e-05
progressively O 0 8.955423e-05
to O 0 7.7472396e-05
163 O 0 0.0005082575
+ O 0 0.00025821806
/ O 0 0.0003723302
- O 0 0.00018282467
55 O 0 8.5575826e-05
compared O 0 4.4127966e-05
with O 0 0.000100209334
19 O 0 0.00013591058
. O 0 5.60846e-05
2 O 0 7.473325e-05
+ O 0 0.00020048908
/ O 0 0.00037784604
- O 0 0.00024253651
9 O 0 0.00010631942
mg O 0 0.0011216705
/ O 0 0.00032546438
24 O 0 0.00010498023
hr O 0 0.0001873753
in O 0 0.00023041025
the O 0 0.00061943295
hypertensive B-Disease 2 0.9982607
controls O 0 0.0035917999
. O 0 0.002108586

Furthermore O 0 0.0034400043
, O 0 0.00497951
glomerulosclerosis B-Disease 2 0.9999256
index O 0 0.0027601027
was O 0 0.0006769239
significantly O 0 0.00041544528
increased O 0 0.00034709804
in O 0 0.00019800365
the O 0 0.00050012086
nitrendipine B-Chemical 1 0.9999981
- O 0 0.0011833203
treated O 0 0.00024252031
group O 0 0.00012458516
compared O 0 4.3238884e-05
with O 0 8.788483e-05
the O 0 0.00014666327
hypertensive B-Disease 2 0.9993487
controls O 0 0.00041127217
( O 0 0.00014071661
0 O 0 6.3949716e-05
. O 0 4.731191e-05
38 O 0 0.00011475826
+ O 0 0.00020635969
/ O 0 0.00037428932
- O 0 0.00021833238
0 O 0 7.908682e-05
. O 0 5.2943647e-05
1 O 0 6.1174775e-05
versus O 0 6.269609e-05
0 O 0 8.8284396e-05
. O 0 8.608114e-05
13 O 0 0.00017066875
+ O 0 0.00039657293
/ O 0 0.0007837995
- O 0 0.00067476934
0 O 0 0.00044088523
. O 0 0.00058033457
04 O 0 0.0065571596
) O 0 0.0028505938
. O 0 0.0027064646

In O 0 0.0017604352
addition O 0 0.0010644676
, O 0 0.0015066642
glomerular O 0 0.69848734
size O 0 0.0011672198
was O 0 0.00038251866
higher O 0 0.00025727786
in O 0 0.00019668105
the O 0 0.00050792575
nitrendipine B-Chemical 1 0.9999976
- O 0 0.001581059
treated O 0 0.0004188442
group O 0 0.000289469
( O 0 0.00018970059
14 O 0 8.664146e-05
. O 0 5.844857e-05
9 O 0 7.794986e-05
+ O 0 0.00020655851
/ O 0 0.00038381483
- O 0 0.00022696568
0 O 0 8.120479e-05
. O 0 5.540274e-05
17 O 0 9.8511126e-05
10 O 0 8.111137e-05
( O 0 0.00015228809
- O 0 0.00018547228
3 O 0 7.278184e-05
) O 0 0.00014328951
mm2 O 0 0.00017617323
) O 0 0.00014241651
but O 0 7.906043e-05
lower O 0 9.532915e-05
in O 0 7.3651856e-05
the O 0 0.00021946193
enalapril B-Chemical 1 0.9999958
- O 0 0.00079710694
treated O 0 0.00028089466
group O 0 0.0002241166
( O 0 0.00016396736
11 O 0 8.69618e-05
. O 0 4.7005207e-05
5 O 0 5.749014e-05
+ O 0 0.00018204782
/ O 0 0.00034846473
- O 0 0.00020585445
0 O 0 7.179993e-05
. O 0 4.5786473e-05
15 O 0 4.9739905e-05
10 O 0 7.2006034e-05
( O 0 0.00014276254
- O 0 0.00017729911
3 O 0 7.01289e-05
) O 0 0.00013172683
mm2 O 0 0.00014645878
) O 0 0.000103154045
compared O 0 3.7889033e-05
with O 0 7.926598e-05
the O 0 0.00013917772
hypertensive B-Disease 2 0.99915457
controls O 0 0.0004154005
( O 0 0.00013912466
12 O 0 4.3982644e-05
. O 0 4.590294e-05
1 O 0 6.8088964e-05
+ O 0 0.00018417928
/ O 0 0.00035496673
- O 0 0.0002196428
0 O 0 8.3409526e-05
. O 0 6.0408503e-05
17 O 0 0.00011218413
10 O 0 9.8506054e-05
( O 0 0.00019219633
- O 0 0.00024843702
3 O 0 0.000119858414
) O 0 0.00025738234
mm2 O 0 0.00036681397
) O 0 0.00040156525
. O 0 0.00024291559
( O 0 0.00072805415
ABSTRACT O 0 0.0038760833
TRUNCATED O 0 0.0039488077
AT O 0 0.007110237
250 O 0 0.0038502524
WORDS O 0 0.007798543
) O 0 0.006778432

Ketoconazole B-Chemical 0 0.9995704
induced O 0 0.028587025
torsades B-Disease 0 0.99972993
de I-Disease 0 0.1465407
pointes I-Disease 0 0.999587
without O 0 0.0010478073
concomitant O 0 0.0015831447
use O 0 0.00043066626
of O 0 0.0008059739
QT O 0 0.86203605
interval O 0 0.00059818797
- O 0 0.0010504865
prolonging O 0 0.001559123
drug O 0 0.022998279
. O 0 0.002677669

Ketoconazole B-Chemical 0 0.9995522
is O 0 0.002628263
not O 0 0.0010227424
known O 0 0.000857298
to O 0 0.0004598892
be O 0 0.00043428628
proarrhythmic O 0 0.4848817
without O 0 0.000358375
concomitant O 0 0.00075852114
use O 0 0.00027084892
of O 0 0.0005741494
QT O 0 0.82104695
interval O 0 0.00047965755
- O 0 0.00088967767
prolonging O 0 0.0013999963
drugs O 0 0.028468678
. O 0 0.002478058

We O 0 0.0016234398
report O 0 0.0016531196
a O 0 0.0011591855
woman O 0 0.0013324306
with O 0 0.00062276743
coronary B-Disease 0 0.17983091
artery I-Disease 0 0.26053077
disease I-Disease 0 0.2813054
who O 0 0.00042312132
developed O 0 0.00023416575
a O 0 0.00018829157
markedly O 0 0.000540653
prolonged B-Disease 0 0.0019463819
QT I-Disease 0 0.91944027
interval I-Disease 0 0.00022961394
and O 0 0.00028221833
torsades B-Disease 0 0.9996431
de I-Disease 0 0.020256678
pointes I-Disease 0 0.9998746
( O 0 0.0030258663
TdP B-Disease 2 0.999928
) O 0 0.00029241169
after O 0 5.5297012e-05
taking O 0 0.0006483055
ketoconazole B-Chemical 1 0.99998045
for O 0 0.00024694615
treatment O 0 0.00038743755
of O 0 0.0009388493
fungal B-Disease 0 0.2583053
infection I-Disease 0 0.8670817
. O 0 0.003761359

Her O 0 0.010823297
QT O 0 0.72683036
interval O 0 0.0014155039
returned O 0 0.0009735641
to O 0 0.0007404018
normal O 0 0.0012152265
upon O 0 0.00080681674
withdrawal O 0 0.022673499
of O 0 0.0085763745
ketoconazole B-Chemical 1 0.99993813
. O 0 0.007899216

Genetic O 0 0.010991618
study O 0 0.0020868776
did O 0 0.0011513107
not O 0 0.00060690835
find O 0 0.0004563111
any O 0 0.00039083237
mutation O 0 0.00279887
in O 0 0.0003311842
her O 0 0.0003972951
genes O 0 0.00029400873
that O 0 0.00016755667
encode O 0 0.00024285397
cardiac O 0 0.12971328
IKr O 0 0.99971277
channel O 0 0.35774082
proteins O 0 0.002867824
. O 0 0.002367859

We O 0 0.0016862391
postulate O 0 0.0016414726
that O 0 0.00074107136
by O 0 0.0007789562
virtue O 0 0.0010190246
of O 0 0.0004640575
its O 0 0.00043056754
direct O 0 0.00017366199
blocking O 0 0.00034190534
action O 0 0.00033894132
on O 0 0.00020805837
IKr O 0 0.99991643
, O 0 0.002224119
ketoconazole B-Chemical 1 0.99999404
alone O 0 0.00040228845
may O 0 0.0001827574
prolong O 0 0.0002958437
QT O 0 0.5980664
interval O 0 0.00030340033
and O 0 0.00048430884
induce O 0 0.0009423649
TdP B-Disease 2 0.999188
. O 0 0.0031466195

This O 0 0.0035743555
calls O 0 0.00209077
for O 0 0.0007280715
attention O 0 0.0009811663
when O 0 0.00072139327
ketoconazole B-Chemical 1 0.999984
is O 0 0.0005419946
administered O 0 0.00034669522
to O 0 0.00018320263
patients O 0 0.00028281816
with O 0 0.00026050588
risk O 0 0.0010240317
factors O 0 0.00027907334
for O 0 0.00022210459
acquired O 0 0.0008595801
long B-Disease 0 0.002492015
QT I-Disease 0 0.9872722
syndrome I-Disease 0 0.8337672
. O 0 0.002760162

Cerebral B-Disease 0 0.9699542
vasculitis I-Disease 2 0.9993742
following O 0 0.0018387878
oral O 0 0.43194568
methylphenidate B-Chemical 1 0.9999305
intake O 0 0.48709148
in O 0 0.0005128632
an O 0 0.00061091944
adult O 0 0.00085094915
: O 0 0.0007199181
a O 0 0.00095031026
case O 0 0.0012819432
report O 0 0.0033138522
. O 0 0.0028524257

Methylphenidate B-Chemical 0 0.9986817
is O 0 0.0039909873
structurally O 0 0.003150277
and O 0 0.0017715243
functionally O 0 0.0016483339
similar O 0 0.0014946486
to O 0 0.0037340487
amphetamine B-Chemical 1 0.9998272
. O 0 0.008270092

Cerebral B-Disease 0 0.9833597
vasculitis I-Disease 2 0.9996264
associated O 0 0.0021009461
with O 0 0.006604571
amphetamine B-Disease 1 0.9999981
abuse I-Disease 0 0.99956995
is O 0 0.0006365181
well O 0 0.00020962988
documented O 0 0.00029538656
, O 0 0.0001636712
and O 0 0.00012159672
in O 0 0.000120408054
rare O 0 0.0010844034
cases O 0 0.0019574212
ischaemic B-Disease 0 0.9999964
stroke I-Disease 0 0.99998415
has O 0 0.00023671401
been O 0 0.000112772424
reported O 0 0.00015741044
after O 0 0.00012893972
methylphenidate B-Chemical 1 0.999882
intake O 0 0.2666249
in O 0 0.00080368837
children O 0 0.0020993473
. O 0 0.0018359527

We O 0 0.0017582162
report O 0 0.0017686749
the O 0 0.00089915213
case O 0 0.00062228035
of O 0 0.0006260778
a O 0 0.0006334885
63 O 0 0.0007079502
- O 0 0.00052155904
year O 0 0.0001459167
- O 0 0.00026997703
old O 0 0.00015076839
female O 0 0.0004079731
who O 0 0.0001729102
was O 0 9.9566685e-05
treated O 0 0.00015351584
with O 0 0.00032088906
methylphenidate B-Chemical 1 0.99991775
due O 0 0.00010343407
to O 0 0.00022271066
hyperactivity B-Disease 2 0.99992144
and O 0 0.00043376733
suffered O 0 0.003205113
from O 0 0.00041596734
multiple O 0 0.0027844051
ischaemic B-Disease 0 0.9999739
strokes I-Disease 0 0.9998864
. O 0 0.0047889515

We O 0 0.001515336
consider O 0 0.0010140613
drug O 0 0.016322695
- O 0 0.0021105
induced O 0 0.0015874895
cerebral B-Disease 0 0.99948406
vasculitis I-Disease 2 0.99997616
as O 0 0.00048551202
the O 0 0.00019666473
most O 0 0.00021790522
likely O 0 8.861604e-05
cause O 0 0.00018092335
of O 0 0.0003029997
recurrent O 0 0.43111
ischaemic B-Disease 0 0.9999981
strokes I-Disease 0 0.99998176
in O 0 0.00019589104
the O 0 8.205646e-05
absence O 0 4.8769012e-05
of O 0 0.00010774562
any O 0 8.5072745e-05
pathological O 0 0.0010323805
findings O 0 0.00021286137
during O 0 7.574576e-05
the O 0 0.00018500017
diagnostic O 0 0.0004707793
work O 0 0.00065570447
- O 0 0.0013376614
up O 0 0.0014975321
. O 0 0.0020859642

We O 0 0.0013831212
conclude O 0 0.0009152989
that O 0 0.0011891656
methylphenidate B-Chemical 1 0.9998215
mediated O 0 0.0012351195
vasculitis B-Disease 2 0.99961203
should O 0 0.00018416242
be O 0 0.00013190217
considered O 0 8.127032e-05
in O 0 9.512384e-05
patients O 0 0.00017564003
with O 0 0.00029690756
neurological O 0 0.99830127
symptoms O 0 0.56646
and O 0 0.00029700523
a O 0 0.00038164482
history O 0 0.00066546124
of O 0 0.0012502952
methylphenidate B-Chemical 1 0.9998497
therapy O 0 0.00392075
. O 0 0.0020256042

This O 0 0.0038902983
potential O 0 0.002489513
side O 0 0.021515107
- O 0 0.002192024
effect O 0 0.0006957999
, O 0 0.0006492633
though O 0 0.00037088478
very O 0 0.00059967156
rare O 0 0.0012315718
, O 0 0.00024718125
represents O 0 0.00012482013
one O 0 8.530223e-05
more O 0 0.0001422032
reason O 0 8.5285974e-05
to O 0 9.316955e-05
be O 0 0.00010032598
very O 0 0.00018634937
restrictive O 0 0.0002821936
in O 0 0.00016784163
the O 0 0.00024885547
use O 0 0.00042504622
of O 0 0.0018256439
methylphenidate B-Chemical 1 0.99974746
. O 0 0.0029744839

MDMA B-Chemical 0 0.99997485
polydrug O 0 0.9996093
users O 0 0.0057957387
show O 0 0.0005046822
process O 0 0.00044759526
- O 0 0.00048784737
specific O 0 0.00015560917
central O 0 0.0003392093
executive O 0 0.045872763
impairments O 0 0.025440263
coupled O 0 0.00027874703
with O 0 0.00026374933
impaired B-Disease 0 0.0007491579
social I-Disease 0 0.0009749073
and I-Disease 0 0.00047726324
emotional I-Disease 0 0.0037436846
judgement I-Disease 0 0.0037928391
processes I-Disease 0 0.0023278953
. O 0 0.0021824092

In O 0 0.0017972712
recent O 0 0.0013111895
years O 0 0.0008796457
working O 0 0.0016216263
memory B-Disease 0 0.95637566
deficits I-Disease 0 0.96742076
have O 0 0.00029840137
been O 0 0.00015438016
reported O 0 0.00016780931
in O 0 0.00013671214
users O 0 0.000555656
of O 0 0.0009463653
MDMA B-Chemical 0 0.9999988
( O 0 0.0006968443
3 B-Chemical 0 0.00014379827
, I-Chemical 0 0.00020287513
4 I-Chemical 0 0.00020693504
- I-Chemical 0 0.0012046455
methylenedioxymethamphetamine I-Chemical 0 0.99994993
, O 0 0.003947315
ecstasy B-Chemical 1 0.9998128
) O 0 0.0045254556
. O 0 0.002412541

The O 0 0.0016029335
current O 0 0.0019179062
study O 0 0.00096192013
aimed O 0 0.00070397306
to O 0 0.00032081263
assess O 0 0.00012780512
the O 0 0.00015736617
impact O 0 0.00012052569
of O 0 0.00086819025
MDMA B-Chemical 0 0.9999982
use O 0 0.00018064753
on O 0 4.7388945e-05
three O 0 3.0052011e-05
separate O 0 3.467748e-05
central O 0 9.064494e-05
executive O 0 0.006474391
processes O 0 0.00016241039
( O 0 0.000114762304
set O 0 6.938044e-05
shifting O 0 0.00014225622
, O 0 0.000101551166
inhibition O 0 0.0002390394
and O 0 0.00013461371
memory O 0 0.06372767
updating O 0 0.00048363485
) O 0 0.00023223777
and O 0 9.0511145e-05
also O 0 7.5737094e-05
on O 0 6.098925e-05
" O 0 0.00015790864
prefrontal O 0 0.0014374903
" O 0 0.00019828475
mediated O 0 0.00010849403
social O 0 0.0005647889
and O 0 0.00040208755
emotional O 0 0.0033111381
judgement O 0 0.003630418
processes O 0 0.0022836872
. O 0 0.0021468233

Fifteen O 0 0.007820299
polydrug O 0 0.999218
ecstasy B-Chemical 1 0.999869
users O 0 0.003164532
and O 0 0.00044074128
15 O 0 0.00029786956
polydrug O 0 0.9934476
non O 0 0.00057320565
- O 0 0.0010016504
ecstasy B-Chemical 1 0.999879
user O 0 0.00024239617
controls O 0 0.00015716972
completed O 0 5.9058882e-05
a O 0 7.741214e-05
general O 0 8.168562e-05
drug O 0 0.0012484839
use O 0 7.361443e-05
questionnaire O 0 7.15325e-05
, O 0 8.2785264e-05
the O 0 8.735676e-05
Brixton O 0 0.0016875401
Spatial O 0 0.0003268487
Anticipation O 0 0.00071184395
task O 0 0.0001380699
( O 0 0.00011436891
set O 0 7.4325726e-05
shifting O 0 0.00017366001
) O 0 0.00017335924
, O 0 0.000116800446
Backward O 0 0.0018585655
Digit O 0 0.9851483
Span O 0 0.89840126
procedure O 0 0.00013149316
( O 0 0.0001508807
memory O 0 0.013543043
updating O 0 0.00035975326
) O 0 0.00022879007
, O 0 0.000105542436
Inhibition O 0 0.00017512914
of O 0 0.00016742668
Return O 0 0.00069421047
( O 0 0.00017330238
inhibition O 0 0.00038830945
) O 0 0.00022072207
, O 0 9.834405e-05
an O 0 0.00010928461
emotional O 0 0.0007094814
intelligence O 0 0.0026425172
scale O 0 0.00014445037
, O 0 0.00012172109
the O 0 0.00011752899
Tromso O 0 0.0010326697
Social O 0 0.0005383095
Intelligence O 0 0.00076294976
Scale O 0 0.0017190096
and O 0 0.00018922077
the O 0 0.0002780299
Dysexecutive O 0 0.013664186
Questionnaire O 0 0.00084131415
( O 0 0.0013559089
DEX O 0 0.97647756
) O 0 0.0035706686
. O 0 0.0024822045

Compared O 0 0.0020949794
with O 0 0.00469193
MDMA B-Chemical 0 0.9999871
- O 0 0.0032807244
free O 0 0.0013783954
polydrug O 0 0.99915874
controls O 0 0.0013443513
, O 0 0.0010581153
MDMA B-Chemical 0 0.99999917
polydrug O 0 0.9999486
users O 0 0.0014453903
showed O 0 0.00013685889
impairments O 0 0.0058292984
in O 0 7.431865e-05
set O 0 6.999234e-05
shifting O 0 0.0001319925
and O 0 0.00011217194
memory O 0 0.031864196
updating O 0 0.00039046482
, O 0 0.00017297913
and O 0 0.000121638805
also O 0 0.00011671038
in O 0 0.00014241692
social O 0 0.0005431996
and O 0 0.00037934806
emotional O 0 0.0031752475
judgement O 0 0.0035139301
processes O 0 0.0022155307
. O 0 0.0020863076

The O 0 0.0020033985
latter O 0 0.0027594233
two O 0 0.0010511917
deficits O 0 0.013581293
remained O 0 0.0009884523
significant O 0 0.00044171518
after O 0 0.00018615989
controlling O 0 0.00030817377
for O 0 0.0004485915
other O 0 0.00090830185
drug O 0 0.018671917
use O 0 0.0023631386
. O 0 0.002862514

These O 0 0.0024049445
data O 0 0.0017354747
lend O 0 0.0015626515
further O 0 0.00083031715
support O 0 0.00035889036
to O 0 0.0002834739
the O 0 0.00025869266
proposal O 0 0.00055239204
that O 0 0.00015900344
cognitive O 0 0.044542897
processes O 0 0.0002427498
mediated O 0 7.958075e-05
by O 0 0.00010900101
the O 0 0.00011065718
prefrontal O 0 0.0026196889
cortex O 0 0.0021416938
may O 0 0.000150938
be O 0 0.00016784675
impaired O 0 0.0006558489
by O 0 0.00058072346
recreational O 0 0.025587115
ecstasy B-Chemical 1 0.9997478
use O 0 0.0022526179
. O 0 0.0021100352

Phase O 0 0.006703593
II O 0 0.0072024227
study O 0 0.0011670103
of O 0 0.0009260639
the O 0 0.0011158079
amsacrine B-Chemical 0 0.9998504
analogue O 0 0.17203255
CI B-Chemical 0 0.4265882
- I-Chemical 0 0.0014485082
921 I-Chemical 0 0.06625015
( O 0 0.0008710846
NSC B-Chemical 0 0.9970427
343499 I-Chemical 0 0.6246868
) O 0 0.00051036227
in O 0 0.00023454515
non B-Disease 2 0.00045958642
- I-Disease 2 0.00073538185
small I-Disease 2 0.0008710954
cell I-Disease 2 0.006808099
lung I-Disease 2 0.9816807
cancer I-Disease 2 0.999474
. O 0 0.005069636

CI B-Chemical 0 0.2152241
- I-Chemical 0 0.0066821384
921 I-Chemical 0 0.057141926
( O 0 0.003504957
NSC B-Chemical 0 0.99627113
343499 I-Chemical 0 0.73784345
; O 0 0.001093766
9 B-Chemical 0 0.0004611355
- I-Chemical 0 0.0007795792
[ I-Chemical 0 0.0008331978
[ I-Chemical 0 0.000633576
2 I-Chemical 0 0.00022925256
- I-Chemical 0 0.0007291641
methoxy I-Chemical 0 0.99843854
- I-Chemical 0 0.0009068854
4 I-Chemical 0 0.00016398268
- I-Chemical 0 0.00037276134
[ I-Chemical 0 0.00047393423
( I-Chemical 0 0.00040040433
methylsulphonyl I-Chemical 0 0.977809
) I-Chemical 0 0.000764677
amino I-Chemical 0 0.76055
] I-Chemical 0 0.005329843
phenyl I-Chemical 0 0.99957114
] I-Chemical 0 0.003602172
amino I-Chemical 0 0.8521037
] I-Chemical 0 0.0023508475
- I-Chemical 0 0.001120341
N I-Chemical 0 0.9584731
, I-Chemical 0 0.00022770173
5 I-Chemical 0 0.00011946215
- I-Chemical 0 0.0004930797
dimethyl I-Chemical 0 0.9969643
- I-Chemical 0 0.0005734745
4 I-Chemical 0 0.0001087114
- I-Chemical 0 0.00025437144
acridinecarboxamide I-Chemical 0 0.002792947
) O 0 0.00021297626
is O 0 0.00010805955
a O 0 0.00020956676
topoisomerase O 0 0.6570763
II O 0 0.012678796
poison O 0 0.015583302
with O 0 0.00030957698
high O 0 0.0005842948
experimental O 0 0.0008051421
antitumour O 0 0.19632445
activity O 0 0.0019920391
. O 0 0.0023550077

It O 0 0.0026152795
was O 0 0.0013899057
administered O 0 0.0008636448
by O 0 0.0004686798
15 O 0 0.00023329128
min O 0 0.0002696863
infusion O 0 0.0003283322
to O 0 0.000119835
16 O 0 0.000115901545
evaluable O 0 0.00023232681
patients O 0 0.00012970193
with O 0 0.000121131496
non B-Disease 2 0.0001797006
- I-Disease 2 0.00023693348
small I-Disease 2 0.00019446979
cell I-Disease 2 0.002293347
lung I-Disease 2 0.9855671
cancer I-Disease 2 0.9999515
( O 0 0.005130092
NSCLC B-Disease 2 0.9996319
) O 0 0.00041389075
( O 0 0.00012113681
7 O 0 3.589692e-05
with O 0 4.740291e-05
no O 0 2.6183847e-05
prior O 0 2.7019807e-05
treatment O 0 6.728061e-05
, O 0 7.723974e-05
9 O 0 4.678897e-05
patients O 0 6.603666e-05
in O 0 5.358864e-05
relapse O 0 0.0063037826
following O 0 5.1520274e-05
surgery O 0 0.00011833462
/ O 0 0.00026717567
radiotherapy O 0 0.0013403535
) O 0 0.00011379616
at O 0 3.7372673e-05
a O 0 9.506299e-05
dose O 0 0.0004321249
( O 0 0.00018228125
648 O 0 0.0054819253
mg O 0 0.0029835848
/ O 0 0.0002749266
m2 O 0 0.0003734357
divided O 0 3.6256577e-05
over O 0 2.0797366e-05
3 O 0 2.90843e-05
days O 0 1.965288e-05
, O 0 4.2527332e-05
repeated O 0 2.6677382e-05
every O 0 2.3649354e-05
3 O 0 5.215151e-05
weeks O 0 4.498613e-05
) O 0 0.00017043065
determined O 0 0.00016796363
by O 0 0.00036211335
phase O 0 0.0013817014
I O 0 0.0055066934
trial O 0 0.0021771174
. O 0 0.0021207754

Patients O 0 0.002434544
had O 0 0.001122616
a O 0 0.00081352243
median O 0 0.0003425611
performance O 0 0.0005283557
status O 0 0.00030091344
of O 0 0.00038990055
1 O 0 0.00027796155
( O 0 0.00038830147
WHO O 0 0.0006358135
) O 0 0.00042464325
, O 0 0.00027635807
and O 0 0.000250671
median O 0 0.00020389202
age O 0 0.00044267057
of O 0 0.00075022096
61 O 0 0.00154909
years O 0 0.001273626
. O 0 0.0019450039

The O 0 0.0021794662
histology O 0 0.00790643
comprised O 0 0.0030131137
squamous B-Disease 0 0.9988105
carcinoma I-Disease 0 0.9997943
( O 0 0.001754763
11 O 0 0.00053227047
) O 0 0.0006154205
, O 0 0.00059114525
adenocarcinoma B-Disease 0 0.9867372
( O 0 0.00044642788
1 O 0 0.00015597863
) O 0 0.00020868282
, O 0 0.00013721391
mixed O 0 0.00034617932
histology O 0 0.0072416514
( O 0 0.00025547485
2 O 0 0.000111918496
) O 0 0.00018640714
, O 0 0.00015710005
bronchio B-Disease 0 0.0011057294
- I-Disease 0 0.00043549706
alveolar I-Disease 0 0.017758122
carcinoma I-Disease 0 0.9984806
( O 0 0.00040645932
1 O 0 0.000121018355
) O 0 0.00016726728
and O 0 0.00013399297
large O 0 0.0002926072
cell O 0 0.0023730586
undifferentiated B-Disease 0 0.85073227
carcinoma I-Disease 0 0.9998331
( O 0 0.0020271593
1 O 0 0.0009299793
) O 0 0.0018716699
. O 0 0.0019707484

Neutropenia B-Disease 0 0.9969837
grade O 0 0.026616704
greater O 0 0.0010864012
than O 0 0.0004027666
or O 0 0.00028198137
equal O 0 0.0002124433
to O 0 0.00019468076
3 O 0 0.00013751688
was O 0 0.00013710091
seen O 0 9.572632e-05
in O 0 8.422832e-05
15 O 0 7.274978e-05
patients O 0 0.00014334089
, O 0 0.00013734272
infections B-Disease 0 0.006703314
with O 0 0.00016966794
recovery O 0 0.00033042635
in O 0 0.000113149974
3 O 0 8.708113e-05
, O 0 0.00013390409
and O 0 0.0002001619
grand O 0 0.0030209422
mal O 0 0.9973826
seizures B-Disease 0 0.9999708
in O 0 0.0010206962
1 O 0 0.00076101755
patient O 0 0.0013046619
. O 0 0.0017832716

Grade O 0 0.020354314
less O 0 0.0015606812
than O 0 0.0005858732
or O 0 0.0003912842
equal O 0 0.00028675812
to O 0 0.0002971412
2 O 0 0.00039927056
nausea B-Disease 0 0.99978405
and O 0 0.00088053365
vomiting B-Disease 0 0.99869555
occurred O 0 0.00018392358
in O 0 0.0001162695
66 O 0 0.00017059651
% O 0 9.880822e-05
courses O 0 0.000104037776
and O 0 0.00021399444
phlebitis B-Disease 0 0.9948108
in O 0 0.00015678072
the O 0 0.0001634605
infusion O 0 0.0004967675
arm O 0 0.0004816162
in O 0 0.0004473056
37 O 0 0.0012893478
% O 0 0.0014859332
. O 0 0.0019404608

1 O 0 0.0028281424
patient O 0 0.002221365
with O 0 0.0028287033
squamous B-Disease 0 0.97719145
cell I-Disease 0 0.027910171
carcinoma I-Disease 0 0.9985115
achieved O 0 0.0009797772
a O 0 0.0005392475
partial O 0 0.0005704201
response O 0 0.0004349768
lasting O 0 0.0005553915
5 O 0 0.0006293958
months O 0 0.00069731
. O 0 0.0018670114

Further O 0 0.0027975237
testing O 0 0.0013895563
in O 0 0.00084000884
this O 0 0.00074226764
and O 0 0.00060383545
other O 0 0.00052180013
tumour B-Disease 0 0.15581729
types O 0 0.00025025927
using O 0 0.0002245024
multiple O 0 0.00036080077
daily O 0 0.0005188146
schedules O 0 0.0005950967
is O 0 0.00082531886
warranted O 0 0.0012915258
. O 0 0.0022519545

Pharmacokinetics O 0 0.68111485
of O 0 0.011951973
desipramine B-Chemical 0 0.9999932
HCl I-Chemical 0 0.99986005
when O 0 0.001351366
administered O 0 0.0024904204
with O 0 0.008588513
cinacalcet B-Chemical 1 0.99997973
HCl I-Chemical 0 0.99985874
. O 0 0.008595297

OBJECTIVE O 0 0.032205664
: O 0 0.002403738
In O 0 0.0007787911
vitro O 0 0.0009153717
work O 0 0.0006036846
has O 0 0.00026897655
demonstrated O 0 0.00022713862
that O 0 0.00034712235
cinacalcet B-Chemical 1 0.9999677
is O 0 0.0003477545
a O 0 0.00025968906
strong O 0 0.00025961033
inhibitor O 0 0.002121498
of O 0 0.002335956
cytochrome O 0 0.9999548
P450 O 0 0.9999931
isoenzyme O 0 0.9993268
( O 0 0.02893113
CYP O 0 0.9999863
) O 0 0.048731823
2D6 O 0 0.99990237
. O 0 0.0043122387

The O 0 0.00152068
purpose O 0 0.0011419593
of O 0 0.0009963803
this O 0 0.0007417854
study O 0 0.000585804
was O 0 0.00029935307
to O 0 0.00013603205
evaluate O 0 6.988403e-05
the O 0 0.000104082435
effect O 0 0.00012388716
of O 0 0.00056331034
cinacalcet B-Chemical 1 0.9999851
on O 0 0.00035686753
CYP2D6 O 0 0.99996495
activity O 0 0.00019740757
, O 0 0.00017427343
using O 0 0.00019965143
desipramine B-Chemical 0 0.99999464
as O 0 0.00021380516
a O 0 0.00021966205
probe O 0 0.0001802432
substrate O 0 0.0005021845
, O 0 0.00035381952
in O 0 0.0004000539
healthy O 0 0.002368446
subjects O 0 0.0017639382
. O 0 0.0018302656

METHODS O 0 0.0014855327
: O 0 0.0013659688
Seventeen O 0 0.0014523462
subjects O 0 0.0006557363
who O 0 0.00050843006
were O 0 0.00030257736
genotyped O 0 0.0018758845
as O 0 0.00035681922
CYP2D6 O 0 0.9998431
extensive O 0 0.00040336922
metabolizers O 0 0.9929889
were O 0 0.00010203155
enrolled O 0 7.432063e-05
in O 0 4.223005e-05
this O 0 6.760507e-05
randomized O 0 9.448189e-05
, O 0 8.511762e-05
open O 0 0.0001937393
- O 0 0.00021440699
label O 0 0.00034083036
, O 0 0.00010415838
crossover O 0 0.0006540162
study O 0 6.765105e-05
to O 0 3.85199e-05
receive O 0 2.9298906e-05
a O 0 5.83219e-05
single O 0 6.2954e-05
oral O 0 0.0016152665
dose O 0 0.0005385746
of O 0 0.000567777
desipramine B-Chemical 0 0.9999987
( O 0 0.00037520597
50 O 0 0.00022444013
mg O 0 0.004550853
) O 0 0.000108756925
on O 0 2.6839321e-05
two O 0 2.8825214e-05
separate O 0 3.113934e-05
occasions O 0 6.2721796e-05
, O 0 5.4631146e-05
once O 0 3.2547392e-05
alone O 0 5.302828e-05
and O 0 5.1699815e-05
once O 0 3.0015604e-05
after O 0 2.0157855e-05
multiple O 0 7.883533e-05
doses O 0 0.0006182498
of O 0 0.00053346576
cinacalcet B-Chemical 1 0.9999777
( O 0 0.00036363341
90 O 0 0.00017287362
mg O 0 0.0013499592
for O 0 0.00019062095
7 O 0 0.00026125857
days O 0 0.0003258997
) O 0 0.0014590367
. O 0 0.001848331

Blood O 0 0.010391888
samples O 0 0.0018786399
were O 0 0.0010994173
obtained O 0 0.0009884754
predose O 0 0.005271968
and O 0 0.0008093123
up O 0 0.0007460133
to O 0 0.00067832327
72 O 0 0.00097139925
h O 0 0.0013427172
postdose O 0 0.004123381
. O 0 0.0032446755

RESULTS O 0 0.006986244
: O 0 0.0033957488
Fourteen O 0 0.0029192634
subjects O 0 0.001847005
completed O 0 0.0013552526
both O 0 0.0016408367
treatment O 0 0.0028186617
arms O 0 0.007053512
. O 0 0.005016162

Relative O 0 0.0029920407
to O 0 0.0024583826
desipramine B-Chemical 0 0.9999597
alone O 0 0.0013573495
, O 0 0.0005609182
mean O 0 0.00020436948
AUC O 0 0.0019621388
and O 0 0.00048845814
C O 0 0.96934086
( O 0 0.0006130844
max O 0 0.008060733
) O 0 0.0003427937
of O 0 0.0005270131
desipramine B-Chemical 0 0.9999964
increased O 0 0.000857727
3 O 0 0.000119816366
. O 0 6.513616e-05
6 O 0 6.181909e-05
- O 0 0.00016311795
and O 0 0.000109809735
1 O 0 9.69949e-05
. O 0 7.449617e-05
8 O 0 0.00010351647
- O 0 0.0002382301
fold O 0 0.00027042942
when O 0 0.00024149285
coadministered O 0 0.1357925
with O 0 0.0044687046
cinacalcet B-Chemical 1 0.9999057
. O 0 0.0040616607

The O 0 0.0029527275
t O 0 0.0041481303
( O 0 0.0018808927
1 O 0 0.00088144856
/ O 0 0.0013911081
2 O 0 0.0004311296
, O 0 0.00043692748
z O 0 0.0008104244
) O 0 0.00046174295
of O 0 0.00063172396
desipramine B-Chemical 0 0.9999939
was O 0 0.00030392263
longer O 0 7.225338e-05
when O 0 0.00012400512
desipramine B-Chemical 0 0.9999958
was O 0 0.00041361744
coadministered O 0 0.1823203
with O 0 0.00094069366
cinacalcet B-Chemical 1 0.9999852
( O 0 0.00042460987
21 O 0 0.00013232963
. O 0 6.582917e-05
0 O 0 9.0103385e-05
versus O 0 0.00012108968
43 O 0 0.00031264918
. O 0 0.00023135994
3 O 0 0.00043850744
hs O 0 0.0047374815
) O 0 0.0023948024
. O 0 0.0023535842

The O 0 0.003707024
t O 0 0.0055547403
( O 0 0.0035933668
max O 0 0.011798012
) O 0 0.0024926509
was O 0 0.0012723445
similar O 0 0.00077368977
between O 0 0.00084538636
the O 0 0.0018358706
regimens O 0 0.0046564625
. O 0 0.004433328

Fewer O 0 0.0060910685
subjects O 0 0.0016608624
reported O 0 0.0009049415
adverse O 0 0.007136549
events O 0 0.0008914821
following O 0 0.00015751705
treatment O 0 0.00021823207
with O 0 0.0005868054
desipramine B-Chemical 0 0.99999654
alone O 0 0.00023068853
than O 0 5.8412348e-05
when O 0 5.144854e-05
receiving O 0 0.0005197392
desipramine B-Chemical 0 0.9999982
with O 0 0.002784556
cinacalcet B-Chemical 1 0.9999907
( O 0 0.00030798788
33 O 0 0.00012729452
versus O 0 5.220943e-05
86 O 0 0.0001412883
% O 0 9.503372e-05
) O 0 0.000120009034
, O 0 6.7541216e-05
the O 0 5.432567e-05
most O 0 9.804441e-05
frequent O 0 9.2826354e-05
of O 0 9.42102e-05
which O 0 0.00017196247
( O 0 0.0004513416
nausea B-Disease 0 0.9999602
and O 0 0.0008900639
headache B-Disease 0 0.9996636
) O 0 0.0003014837
have O 0 5.3057367e-05
been O 0 4.6069763e-05
reported O 0 6.507178e-05
for O 0 4.9941616e-05
patients O 0 0.00012657291
treated O 0 0.0001604494
with O 0 0.00023940913
either O 0 0.0008267624
desipramine B-Chemical 0 0.9999939
or O 0 0.005552905
cinacalcet B-Chemical 1 0.9999273
. O 0 0.0035370253

CONCLUSION O 0 0.017402748
: O 0 0.0024492422
This O 0 0.0016274869
study O 0 0.00090706773
demonstrates O 0 0.0004663632
that O 0 0.0007611539
cinacalcet B-Chemical 1 0.9999
is O 0 0.0009309376
a O 0 0.0008355766
strong O 0 0.0010309619
inhibitor O 0 0.009119094
of O 0 0.009033784
CYP2D6 O 0 0.99975103
. O 0 0.004609327

These O 0 0.0019243702
data O 0 0.0011382401
suggest O 0 0.00034724895
that O 0 0.00026837457
during O 0 0.0001827567
concomitant O 0 0.00060732785
treatment O 0 0.00032272004
with O 0 0.00088586647
cinacalcet B-Chemical 1 0.99998224
, O 0 0.00042443848
dose O 0 0.00085292256
adjustment O 0 8.885729e-05
may O 0 6.30312e-05
be O 0 4.8852195e-05
necessary O 0 3.1260202e-05
for O 0 5.0206163e-05
drugs O 0 0.00078728213
that O 0 4.741661e-05
demonstrate O 0 3.732879e-05
a O 0 0.00011716622
narrow O 0 0.00021415668
therapeutic O 0 0.00027932995
index O 0 0.0002750517
and O 0 0.00030046076
are O 0 0.00052608
metabolized O 0 0.5214842
by O 0 0.0028580937
CYP2D6 O 0 0.9996393
. O 0 0.0029218697

Case O 0 0.011330893
report O 0 0.0062747556
: O 0 0.006106273
acute O 0 0.5424146
unintentional O 0 0.9671714
carbachol B-Chemical 0 0.99978036
intoxication O 0 0.9995383
. O 0 0.012658999

INTRODUCTION O 0 0.00625645
: O 0 0.003219989
Intoxications O 0 0.161242
with O 0 0.002488843
carbachol B-Chemical 0 0.99921024
, O 0 0.0013686552
a O 0 0.001653798
muscarinic O 0 0.99786526
cholinergic O 0 0.907916
receptor O 0 0.1697049
agonist O 0 0.65159893
are O 0 0.0017447734
rare O 0 0.0063142153
. O 0 0.0026818246

We O 0 0.0022479724
report O 0 0.0022724376
an O 0 0.00138812
interesting O 0 0.00061551
case O 0 0.0008067237
investigating O 0 0.0007723822
a O 0 0.0013124702
( O 0 0.0014553359
near O 0 0.0017476326
) O 0 0.004112954
fatal O 0 0.9697123
poisoning B-Disease 2 0.999772
. O 0 0.008323883

METHODS O 0 0.0019805997
: O 0 0.0016316598
The O 0 0.00079378474
son O 0 0.0019885756
of O 0 0.00065054576
an O 0 0.00062938535
84 O 0 0.00077361154
- O 0 0.0006058941
year O 0 0.00018028548
- O 0 0.00032389592
old O 0 0.00017899126
male O 0 0.00039189085
discovered O 0 0.00015126044
a O 0 0.00013947027
newspaper O 0 0.0001747265
report O 0 0.00018058125
stating O 0 0.00021347111
clinical O 0 0.00030071783
success O 0 0.00023261584
with O 0 0.00017489068
plant O 0 0.0008103317
extracts O 0 0.00073530467
in O 0 0.00061850407
Alzheimer B-Disease 0 0.9999099
' I-Disease 0 0.001843913
s I-Disease 0 0.0013508868
disease I-Disease 0 0.105745114
. O 0 0.0026327607

The O 0 0.0017597509
mode O 0 0.0016215058
of O 0 0.0012516165
action O 0 0.0012977379
was O 0 0.0007306304
said O 0 0.00060862757
to O 0 0.00023523718
be O 0 0.00015425039
comparable O 0 9.1116555e-05
to O 0 8.5151645e-05
that O 0 7.185321e-05
of O 0 0.00014061655
the O 0 0.00012952408
synthetic O 0 0.00027822636
compound O 0 0.107339464
' O 0 0.0006722153
carbamylcholin B-Chemical 0 0.2057995
' O 0 0.0005414562
; O 0 0.00035120719
that O 0 0.00027986817
is O 0 0.00073233125
, O 0 0.001882153
carbachol B-Chemical 0 0.9982881
. O 0 0.0036215617

He O 0 0.006069629
bought O 0 0.0041835946
25 O 0 0.0015894453
g O 0 0.0019647025
of O 0 0.0012369622
carbachol B-Chemical 0 0.9991345
as O 0 0.0005612674
pure O 0 0.0020026756
substance O 0 0.41939792
in O 0 0.00022504288
a O 0 0.00030990943
pharmacy O 0 0.0017738205
, O 0 0.00018710252
and O 0 0.00014206997
the O 0 0.00016603307
father O 0 0.000734979
was O 0 0.00021124953
administered O 0 0.00029818807
400 O 0 0.00079100067
to O 0 0.00042843033
500 O 0 0.0021938777
mg O 0 0.02155988
. O 0 0.0023677622

Carbachol B-Chemical 0 0.9991642
concentrations O 0 0.005977309
in O 0 0.001220085
serum O 0 0.013497907
and O 0 0.0007269301
urine O 0 0.023546016
on O 0 0.00015462088
day O 0 0.00011957178
1 O 0 0.000111075395
and O 0 0.000109446366
2 O 0 8.494085e-05
of O 0 0.00012957276
hospital O 0 0.00022981195
admission O 0 0.0002458275
were O 0 0.00017214954
analysed O 0 0.00023071912
by O 0 0.00055213354
HPLC O 0 0.931195
- O 0 0.0021996014
mass O 0 0.009943894
spectrometry O 0 0.3046055
. O 0 0.0025358156

RESULTS O 0 0.0046717143
: O 0 0.0020669107
Minutes O 0 0.0038467003
after O 0 0.000409776
oral O 0 0.0045697065
administration O 0 0.0017069993
, O 0 0.00036980497
the O 0 0.00022323921
patient O 0 0.0003115688
developed O 0 0.0011182219
nausea B-Disease 0 0.99994576
, O 0 0.0015919139
sweating O 0 0.999014
and O 0 0.0014391134
hypotension B-Disease 0 0.99977463
, O 0 0.0009298034
and O 0 0.0007217667
finally O 0 0.0019498996
collapsed O 0 0.0034761834
. O 0 0.002322546

Bradycardia B-Disease 0 0.9897746
, O 0 0.0074571846
cholinergic O 0 0.48314703
symptoms O 0 0.044235006
and O 0 0.0055831173
asystole B-Disease 0 0.97911775
occurred O 0 0.0062256134
. O 0 0.0061179083

Initial O 0 0.0025362135
cardiopulmonary O 0 0.0016772598
resuscitation O 0 0.00091651804
and O 0 0.000435491
immediate O 0 0.0004613065
treatment O 0 0.000342865
with O 0 0.00078493886
adrenaline B-Chemical 1 0.999918
( O 0 0.0018917396
epinephrine B-Chemical 0 0.99930227
) O 0 0.000987727
, O 0 0.0007598045
atropine B-Chemical 0 0.99993515
and O 0 0.0029219503
furosemide B-Chemical 0 0.9999471
was O 0 0.0022165396
successful O 0 0.0019866922
. O 0 0.0021801733

On O 0 0.0029024277
hospital O 0 0.002803884
admission O 0 0.001829724
, O 0 0.0009959205
blood O 0 0.0022981982
pressure O 0 0.0021874185
of O 0 0.00041990858
the O 0 0.00032624067
intubated O 0 0.00082142896
, O 0 0.0003934518
bradyarrhythmic O 0 0.02404536
patient O 0 0.00038970882
was O 0 0.0004077855
100 O 0 0.00088432146
/ O 0 0.0014018313
65 O 0 0.0011444472
mmHg O 0 0.002679048
. O 0 0.002072771

Further O 0 0.0030089053
signs O 0 0.008966134
were O 0 0.0025171607
hyperhidrosis B-Disease 0 0.998679
, O 0 0.0038564259
hypersalivation B-Disease 0 0.9999025
, O 0 0.0020624315
bronchorrhoea B-Disease 0 0.66708463
, O 0 0.0004340425
and O 0 0.00037640615
severe O 0 0.111320406
miosis B-Disease 0 0.99998164
; O 0 0.00043496914
the O 0 0.00021532745
electrocardiographic O 0 0.079079665
finding O 0 0.00049058074
was O 0 0.0004016309
atrio B-Disease 0 0.003706721
- I-Disease 0 0.0013025766
ventricular I-Disease 0 0.71637416
dissociation I-Disease 0 0.016710086
. O 0 0.0023389205

High O 0 0.00687432
doses O 0 0.008652468
of O 0 0.0038153476
atropine B-Chemical 0 0.99992955
( O 0 0.0013981395
up O 0 0.00036758935
to O 0 0.0002055667
50 O 0 0.00033739398
mg O 0 0.0014336993
per O 0 6.17319e-05
24 O 0 8.2550825e-05
hours O 0 8.4657026e-05
) O 0 0.0002963259
, O 0 0.0004623785
adrenaline B-Chemical 1 0.9996087
and O 0 0.0012965532
dopamine B-Chemical 0 0.99888617
were O 0 0.0009668956
necessary O 0 0.0008766393
. O 0 0.0019060767

The O 0 0.0036162725
patient O 0 0.0038567518
was O 0 0.0032147437
extubated O 0 0.00282093
1 O 0 0.0020874755
week O 0 0.0017699398
later O 0 0.0030437994
. O 0 0.0056830067

However O 0 0.0047612493
, O 0 0.0045700497
increased O 0 0.0058667287
dyspnoea B-Disease 0 0.9460129
and O 0 0.0072920932
bronchospasm B-Disease 0 0.9989802
necessitated O 0 0.01346673
reintubation O 0 0.2963788
. O 0 0.005523777

Respiratory B-Disease 0 0.84464425
insufficiency I-Disease 0 0.99855727
was O 0 0.0027782524
further O 0 0.0018564342
worsened O 0 0.0073088096
by O 0 0.0009958384
Proteus B-Disease 0 0.02885001
mirabilis I-Disease 0 0.0056137987
infection I-Disease 0 0.15415056
and O 0 0.0022617446
severe O 0 0.33641964
bronchoconstriction O 0 0.9989949
. O 0 0.0052320794

One O 0 0.0021446724
week O 0 0.0008944967
later O 0 0.0006041428
, O 0 0.0006466027
the O 0 0.00041104926
patient O 0 0.00040950128
was O 0 0.00029562745
again O 0 0.00022807177
extubated O 0 0.00019396777
and O 0 0.00013852605
3 O 0 8.885407e-05
days O 0 5.7297315e-05
later O 0 9.54312e-05
was O 0 0.00019289473
transferred O 0 0.00025859944
to O 0 0.00030727868
a O 0 0.0007971358
peripheral O 0 0.0045218947
ward O 0 0.0019489299
. O 0 0.0022056797

On O 0 0.0024815071
the O 0 0.0013221105
next O 0 0.0006147036
day O 0 0.00065596256
he O 0 0.00085995655
died O 0 0.0012727124
, O 0 0.0006340629
probably O 0 0.00062896323
as O 0 0.00039662456
a O 0 0.0005538386
result O 0 0.0005267092
of O 0 0.0013312978
heart B-Disease 0 0.33205834
failure I-Disease 0 0.7005564
. O 0 0.0037284316

Serum O 0 0.06755879
samples O 0 0.0015580583
from O 0 0.00065113354
the O 0 0.00043002507
first O 0 0.00022830283
and O 0 0.00025107115
second O 0 0.00017728457
days O 0 8.5217034e-05
contained O 0 0.000107722204
3 O 0 0.00010963239
. O 0 8.023354e-05
6 O 0 7.1773495e-05
and O 0 0.00011594012
1 O 0 0.0001109818
. O 0 9.142605e-05
9 O 0 0.00014876584
mg O 0 0.0018279133
/ O 0 0.0012029884
l O 0 0.0027860312
carbachol B-Chemical 0 0.9987349
, O 0 0.0023846533
respectively O 0 0.0040961965
. O 0 0.002606612

The O 0 0.0017667363
corresponding O 0 0.001473045
urine O 0 0.01355345
concentrations O 0 0.0021685448
amounted O 0 0.0016030923
to O 0 0.0008420451
374 O 0 0.0050871274
and O 0 0.0010599333
554 O 0 0.00725576
mg O 0 0.023887783
/ O 0 0.0047129085
l O 0 0.005270843
. O 0 0.0032214245

CONCLUSION O 0 0.017370341
: O 0 0.0021885908
This O 0 0.0013451409
case O 0 0.0005789473
started O 0 0.00043406448
with O 0 0.0004077268
a O 0 0.0003833603
media O 0 0.000678904
report O 0 0.00038705804
in O 0 0.00015775287
a O 0 0.00019764941
popular O 0 0.0002446612
newspaper O 0 0.00024400192
, O 0 0.00012826097
initiated O 0 9.79026e-05
by O 0 0.00011938162
published O 0 0.0001522139
, O 0 0.00016457416
peer O 0 0.0015389208
- O 0 0.0002919718
reviewed O 0 0.00016623584
research O 0 9.752318e-05
on O 0 6.209027e-05
herbals O 0 0.17409962
, O 0 0.00014664227
and O 0 8.85087e-05
involved O 0 5.62516e-05
human O 0 0.00016144615
failure O 0 0.019761564
in O 0 0.00011730428
a O 0 0.00017494237
case O 0 0.00015396676
history O 0 0.00033117345
, O 0 0.00020320831
medical O 0 0.00049758994
examination O 0 0.0002598842
and O 0 0.00036508252
clinical O 0 0.0013829647
treatment O 0 0.0013035049
. O 0 0.0018970283

For O 0 0.0011576925
the O 0 0.0010636566
first O 0 0.0005271813
time O 0 0.0003825234
, O 0 0.0004769198
an O 0 0.00039709578
analytical O 0 0.001215657
method O 0 0.00034978407
for O 0 0.00011488735
the O 0 0.00013695196
determination O 0 0.00041463476
of O 0 0.00045856286
carbachol B-Chemical 0 0.99945754
in O 0 0.00033817827
plasma O 0 0.0061417497
and O 0 0.00045890175
urine O 0 0.078518055
has O 0 0.0005056016
been O 0 0.0006909262
developed O 0 0.0020953184
. O 0 0.002138368

The O 0 0.0018077759
analysed O 0 0.0022394143
carbachol B-Chemical 0 0.9974017
concentration O 0 0.0020026565
exceeded O 0 0.0004870342
the O 0 0.00032197725
supposed O 0 0.0004651893
serum O 0 0.005402788
level O 0 0.00016633383
resulting O 0 0.00017676939
from O 0 0.00012063537
a O 0 0.00019473846
therapeutic O 0 0.0003679315
dose O 0 0.0008628116
by O 0 0.00024404239
a O 0 0.00035291855
factor O 0 0.0009202447
of O 0 0.00068648375
130 O 0 0.001331332
to O 0 0.000961267
260 O 0 0.013852778
. O 0 0.0023692742

Especially O 0 0.004401945
in O 0 0.0015213434
old O 0 0.0012038109
patients O 0 0.00095387525
, O 0 0.0005649934
intensivists O 0 0.0006243459
should O 0 0.00012024982
consider O 0 0.00014843172
intoxications O 0 0.99336785
( O 0 0.0005892765
with O 0 0.00050255994
cholinergics O 0 0.7589795
) O 0 0.00044948573
as O 0 0.0001800503
a O 0 0.0003218281
cause O 0 0.0005357831
of O 0 0.0011627765
acute B-Disease 0 0.98999375
cardiovascular I-Disease 0 0.9978283
failure I-Disease 0 0.99316627
. O 0 0.0041132784

Pharmacological O 0 0.13168822
evidence O 0 0.0014759162
for O 0 0.00072322774
the O 0 0.00059105846
potential O 0 0.0005727889
of O 0 0.0009017629
Daucus O 0 0.11989867
carota O 0 0.14933948
in O 0 0.00041079198
the O 0 0.00040124595
management O 0 0.0006244857
of O 0 0.0012734211
cognitive B-Disease 0 0.5876087
dysfunctions I-Disease 0 0.8025423
. O 0 0.0037941744

The O 0 0.0015296451
present O 0 0.001043905
study O 0 0.0010151119
was O 0 0.0005640991
aimed O 0 0.0004384397
at O 0 0.0001852063
investigating O 0 0.00016541505
the O 0 0.00014628476
effects O 0 0.0001837243
of O 0 0.00037288468
Daucus O 0 0.24882737
carota O 0 0.500059
seeds O 0 0.0021810555
on O 0 7.813509e-05
cognitive O 0 0.017621353
functions O 0 0.00012106636
, O 0 0.00011173073
total O 0 0.00014315869
serum O 0 0.14578699
cholesterol B-Chemical 0 0.9999112
levels O 0 0.00038400918
and O 0 0.00033343738
brain O 0 0.017101549
cholinesterase O 0 0.9991009
activity O 0 0.0006178934
in O 0 0.000671021
mice O 0 0.0009496047
. O 0 0.0017822235

The O 0 0.0020105774
ethanolic O 0 0.52911496
extract B-Chemical 0 0.007010062
of I-Chemical 0 0.0018132378
Daucus I-Chemical 0 0.32938287
carota I-Chemical 0 0.71651524
seeds I-Chemical 0 0.02438267
( O 0 0.0010694503
DCE B-Chemical 0 0.96407837
) O 0 0.0004616747
was O 0 0.00015167003
administered O 0 0.00013107967
orally O 0 0.00025036474
in O 0 7.1512106e-05
three O 0 4.4147117e-05
doses O 0 0.00055837026
( O 0 0.000175382
100 O 0 0.00026506092
, O 0 0.00012264207
200 O 0 0.00023630088
, O 0 0.000119783814
400 O 0 0.0003470775
mg O 0 0.0025542604
/ O 0 0.00044698615
kg O 0 0.000300941
) O 0 0.000113667644
for O 0 4.226655e-05
seven O 0 4.4846573e-05
successive O 0 4.431254e-05
days O 0 2.9561039e-05
to O 0 5.5273293e-05
different O 0 6.7402754e-05
groups O 0 0.00012889966
of O 0 0.00026941262
young O 0 0.0013135993
and O 0 0.000548531
aged O 0 0.0011354581
mice O 0 0.0009286056
. O 0 0.001793781

Elevated O 0 0.009930439
plus O 0 0.0015409471
maze O 0 0.0084350435
and O 0 0.00075541815
passive O 0 0.0006188261
avoidance O 0 0.00072907243
apparatus O 0 0.0003298834
served O 0 0.00035102654
as O 0 0.0001811626
the O 0 0.00019835719
exteroceptive O 0 0.002064799
behavioral O 0 0.0010118376
models O 0 0.0004473753
for O 0 0.0004128378
testing O 0 0.0009168858
memory O 0 0.1600972
. O 0 0.003120194

Diazepam B-Chemical 0 0.9999169
- O 0 0.021187324
, O 0 0.00660333
scopolamine B-Chemical 1 0.9999851
- O 0 0.0050508576
and O 0 0.0009161286
ageing O 0 0.048666425
- O 0 0.0011315148
induced O 0 0.0008405144
amnesia B-Disease 0 0.9990735
served O 0 0.00087644916
as O 0 0.00030119094
the O 0 0.0003679796
interoceptive O 0 0.0028556308
behavioral O 0 0.003124103
models O 0 0.002212701
. O 0 0.0023066609

DCE B-Chemical 0 0.93503517
( O 0 0.0037095146
200 O 0 0.00276593
, O 0 0.0012650766
400 O 0 0.0022345115
mg O 0 0.014703266
/ O 0 0.0018793734
kg O 0 0.0013147434
, O 0 0.00046899662
p O 0 0.00029771682
. O 0 0.00014118836
o O 0 0.0010210946
. O 0 0.00012290689
) O 0 0.00020114258
showed O 0 0.00010750711
significant O 0 0.000101570346
improvement O 0 0.00012827676
in O 0 0.00011906092
memory O 0 0.0123391105
scores O 0 0.0002120533
of O 0 0.00040266602
young O 0 0.0018118091
and O 0 0.0006024012
aged O 0 0.0011986077
mice O 0 0.0009522054
. O 0 0.0018261158

The O 0 0.0013582903
extent O 0 0.000883899
of O 0 0.0010559512
memory O 0 0.019624904
improvement O 0 0.00078984833
evoked O 0 0.0020783136
by O 0 0.000603642
DCE B-Chemical 0 0.9518935
was O 0 0.00031262924
23 O 0 0.0002023537
% O 0 9.376905e-05
at O 0 4.6735862e-05
the O 0 6.995851e-05
dose O 0 0.00024762444
of O 0 0.00013571372
200 O 0 0.0003815741
mg O 0 0.0061991005
/ O 0 0.0004553157
kg O 0 0.00023167889
and O 0 7.3356554e-05
35 O 0 6.369271e-05
% O 0 5.1206494e-05
at O 0 3.0538293e-05
the O 0 5.3176253e-05
dose O 0 0.00021688559
of O 0 0.00014113991
400 O 0 0.00056218455
mg O 0 0.0050698696
/ O 0 0.00051955396
kg O 0 0.00032327525
in O 0 0.00012330261
young O 0 0.000437375
mice O 0 0.000111478825
using O 0 0.00018832729
elevated O 0 0.0014253698
plus O 0 0.00077128113
maze O 0 0.076344945
. O 0 0.0024623862

Similarly O 0 0.0030675435
, O 0 0.001886383
significant O 0 0.0008210376
improvements O 0 0.0005074859
in O 0 0.00042437072
memory O 0 0.011033279
scores O 0 0.00030555043
were O 0 0.00022304452
observed O 0 0.00015696694
using O 0 0.00016003226
passive O 0 0.00032600286
avoidance O 0 0.00070204167
apparatus O 0 0.00048889156
and O 0 0.0006381624
aged O 0 0.0013043451
mice O 0 0.0010922815
. O 0 0.0020674735

Furthermore O 0 0.0030322892
, O 0 0.0032144105
DCE B-Chemical 0 0.92060834
reversed O 0 0.003143169
the O 0 0.0012463775
amnesia B-Disease 0 0.9989411
induced O 0 0.0012720984
by O 0 0.0015107228
scopolamine B-Chemical 1 0.999997
( O 0 0.0008503019
0 O 0 0.00013734469
. O 0 6.5954395e-05
4 O 0 6.995697e-05
mg O 0 0.0009840196
/ O 0 0.00040826845
kg O 0 0.00034290456
, O 0 0.00014493948
i O 0 0.00030266822
. O 0 8.647375e-05
p O 0 0.00011491738
. O 0 6.580463e-05
) O 0 0.00017808001
and O 0 0.00026918613
diazepam B-Chemical 0 0.9999871
( O 0 0.00040021446
1 O 0 0.00013498479
mg O 0 0.0019468637
/ O 0 0.000611282
kg O 0 0.0005357968
, O 0 0.00030762106
i O 0 0.0006564329
. O 0 0.00032639655
p O 0 0.0006236706
. O 0 0.0006652787
) O 0 0.0020996672
. O 0 0.002373307

Daucus B-Chemical 0 0.6333125
carota I-Chemical 0 0.6151458
extract I-Chemical 0 0.057850353
( O 0 0.0018045264
200 O 0 0.0015068394
, O 0 0.00063961645
400 O 0 0.0013212702
mg O 0 0.010347461
/ O 0 0.0012649857
kg O 0 0.0008933188
, O 0 0.00032510338
p O 0 0.00021446812
. O 0 0.00010512779
o O 0 0.0008862616
. O 0 9.98362e-05
) O 0 0.0001693224
reduced O 0 0.00015758556
significantly O 0 0.00014062888
the O 0 0.00010778756
brain O 0 0.0024987664
acetylcholinesterase O 0 0.99374783
activity O 0 0.00021064693
and O 0 0.00034555464
cholesterol B-Chemical 0 0.9997305
levels O 0 0.00040403946
in O 0 0.00033308184
young O 0 0.001758233
and O 0 0.00056092726
aged O 0 0.0011301802
mice O 0 0.0009056316
. O 0 0.0017570517

The O 0 0.0014049507
extent O 0 0.0008897383
of O 0 0.00090719736
inhibition O 0 0.0011371629
of O 0 0.00074622454
brain O 0 0.013357575
cholinesterase O 0 0.9992836
activity O 0 0.0003448142
evoked O 0 0.0012144487
by O 0 0.00025897103
DCE B-Chemical 0 0.8000752
at O 0 7.008438e-05
the O 0 8.243676e-05
dose O 0 0.00028799707
of O 0 0.00015751254
400 O 0 0.0005880102
mg O 0 0.005474215
/ O 0 0.0005274485
kg O 0 0.00032391972
was O 0 0.000121714234
22 O 0 0.000121613775
% O 0 0.0001076301
in O 0 0.00011528022
young O 0 0.00057669287
and O 0 0.00022509182
19 O 0 0.00035379827
% O 0 0.00031484204
in O 0 0.0003991081
aged O 0 0.0010432682
mice O 0 0.0009690509
. O 0 0.0019031243

There O 0 0.0028272143
was O 0 0.0017759873
a O 0 0.001124751
remarkable O 0 0.000902853
reduction O 0 0.000961627
in O 0 0.00036378906
total O 0 0.0006057067
cholesterol B-Chemical 0 0.9997949
level O 0 0.00030217692
as O 0 0.00018702082
well O 0 0.00012041161
, O 0 0.00012380531
to O 0 6.792871e-05
the O 0 6.9379115e-05
extent O 0 5.7603953e-05
of O 0 0.00012798927
23 O 0 0.00015981054
% O 0 9.531806e-05
in O 0 8.422736e-05
young O 0 0.00042533566
and O 0 0.000103545
21 O 0 9.682395e-05
% O 0 8.774047e-05
in O 0 7.9801815e-05
aged O 0 0.00015346636
animals O 0 8.261477e-05
with O 0 0.00017112143
this O 0 0.0003450265
dose O 0 0.0019730004
of O 0 0.0021347282
DCE B-Chemical 0 0.97300774
. O 0 0.0029362373

Therefore O 0 0.002383145
, O 0 0.0032811468
DCE B-Chemical 0 0.7913602
may O 0 0.00088269345
prove O 0 0.00066759373
to O 0 0.00033604875
be O 0 0.00023789325
a O 0 0.00024341544
useful O 0 0.00015183931
remedy O 0 0.0003486797
for O 0 8.179623e-05
the O 0 9.1063914e-05
management O 0 0.00010882041
of O 0 0.0001747285
cognitive B-Disease 0 0.19789192
dysfunctions I-Disease 0 0.09436134
on O 0 4.9606042e-05
account O 0 5.926622e-05
of O 0 9.0223584e-05
its O 0 0.00014902849
multifarious O 0 0.00022869084
beneficial O 0 0.00012392743
effects O 0 9.397261e-05
such O 0 6.121818e-05
as O 0 8.444402e-05
, O 0 0.00011457425
memory O 0 0.016905053
improving O 0 0.00016424214
property O 0 0.00033922572
, O 0 0.00041341365
cholesterol B-Chemical 0 0.99981564
lowering O 0 0.060097206
property O 0 0.0010958106
and O 0 0.0011043508
anticholinesterase O 0 0.99878234
activity O 0 0.0023784856
. O 0 0.0023064723

Valproic B-Chemical 0 0.999874
acid I-Chemical 0 0.9987081
induced O 0 0.060750924
encephalopathy B-Disease 2 0.99995637
- O 0 0.016400086
- O 0 0.0013419611
19 O 0 0.00040324143
new O 0 0.00023678737
cases O 0 0.00019764357
in O 0 0.00013187501
Germany O 0 0.00039738297
from O 0 0.000108829125
1994 O 0 0.00029159235
to O 0 9.821959e-05
2003 O 0 0.0002420089
- O 0 0.00028627078
- O 0 0.00020666567
a O 0 0.00015606597
side O 0 0.0009447563
effect O 0 0.00010919784
associated O 0 0.00014408253
to O 0 0.00035233397
VPA B-Chemical 1 0.9999901
- O 0 0.0011345457
therapy O 0 0.00031096608
not O 0 0.00019043183
only O 0 0.0003460744
in O 0 0.00049746636
young O 0 0.003310595
children O 0 0.0023508563
. O 0 0.0019861744

Valproic B-Chemical 0 0.99987483
acid I-Chemical 0 0.99901295
( O 0 0.053739212
VPA B-Chemical 1 0.9999651
) O 0 0.0030652785
is O 0 0.0005402116
a O 0 0.0004678602
broad O 0 0.0004131977
- O 0 0.00054442394
spectrum O 0 0.00070863566
antiepileptic O 0 0.9931004
drug O 0 0.019364905
and O 0 0.0003265192
is O 0 0.0002932937
usually O 0 0.0004525317
well O 0 0.0005144704
- O 0 0.0016733402
tolerated O 0 0.0074751913
. O 0 0.0023394478

Rare O 0 0.059569187
serious O 0 0.010755538
complications O 0 0.026594749
may O 0 0.00063547736
occur O 0 0.00030976854
in O 0 0.00023791639
some O 0 0.00023859448
patients O 0 0.0003323605
, O 0 0.00023845551
including O 0 0.00024342148
haemorrhagic O 0 0.99994266
pancreatitis B-Disease 0 0.9999974
, O 0 0.0014110316
bone B-Disease 0 0.8198563
marrow I-Disease 0 0.9986754
suppression I-Disease 0 0.8728401
, O 0 0.004158634
VPA B-Chemical 1 0.99999523
- O 0 0.0028487998
induced O 0 0.0021241163
hepatotoxicity B-Disease 0 0.99999774
and O 0 0.019568997
VPA B-Chemical 1 0.99998975
- O 0 0.008269897
induced O 0 0.006118514
encephalopathy B-Disease 2 0.9998903
. O 0 0.004980634

The O 0 0.0014845188
typical O 0 0.0013733087
signs O 0 0.0056465915
of O 0 0.0035508145
VPA B-Chemical 1 0.9999795
- O 0 0.005282258
induced O 0 0.0019173347
encephalopathy B-Disease 2 0.9999548
are O 0 0.00063259975
impaired B-Disease 0 0.13824058
consciousness I-Disease 0 0.9957249
, O 0 0.0003258804
sometimes O 0 0.00034099453
marked O 0 0.00031834262
EEG O 0 0.05577059
background O 0 0.00015879315
slowing O 0 0.0015849252
, O 0 0.0001802719
increased O 0 0.00043082124
seizure B-Disease 0 0.9987104
frequency O 0 0.00037555024
, O 0 0.0002752508
with O 0 0.00033775056
or O 0 0.00045448396
without O 0 0.0016068767
hyperammonemia B-Disease 0 0.9999014
. O 0 0.0042381063

There O 0 0.0028633522
is O 0 0.001602793
still O 0 0.0008518594
no O 0 0.00037070835
proof O 0 0.00036812556
of O 0 0.00037477812
causative O 0 0.00039380227
effect O 0 0.0002512644
of O 0 0.0009989899
VPA B-Chemical 1 0.9999893
in O 0 0.00035384466
patients O 0 0.00049115135
with O 0 0.0008034759
encephalopathy B-Disease 2 0.9999691
, O 0 0.00042997467
but O 0 0.0001577908
only O 0 0.0001189302
of O 0 0.0001380549
an O 0 0.00015523899
association O 0 9.342008e-05
with O 0 0.00021158697
an O 0 0.0003201319
assumed O 0 0.00033605163
causal O 0 0.00091448607
relation O 0 0.0007412893
. O 0 0.0018683341

We O 0 0.001626525
report O 0 0.0018581501
19 O 0 0.0013880883
patients O 0 0.001050612
with O 0 0.0016461789
VPA B-Chemical 1 0.9999783
- O 0 0.002889688
associated O 0 0.00066224154
encephalopathy B-Disease 2 0.9999145
in O 0 0.0003398084
Germany O 0 0.00062373007
from O 0 9.120558e-05
the O 0 9.901979e-05
years O 0 8.8941386e-05
1994 O 0 0.00020311959
to O 0 8.124196e-05
2003 O 0 0.00017647738
, O 0 0.00012627983
none O 0 0.0001290636
of O 0 0.00022634005
whom O 0 0.0005284169
had O 0 0.00033147604
been O 0 0.00037110725
published O 0 0.00080781226
previously O 0 0.0013057112
. O 0 0.001921581

Cerebral B-Disease 0 0.98331904
haemorrhage I-Disease 0 0.9996019
induced O 0 0.004256115
by O 0 0.003434521
warfarin B-Chemical 1 0.99962425
- O 0 0.0013429039
the O 0 0.0003536639
influence O 0 0.00023984254
of O 0 0.00072624383
drug O 0 0.029372964
- O 0 0.0021637978
drug O 0 0.015855314
interactions O 0 0.002688636
. O 0 0.0028047655

PURPOSE O 0 0.0048438576
: O 0 0.0017019808
To O 0 0.0006281024
evaluate O 0 0.00036116678
the O 0 0.00043520678
frequency O 0 0.00047384365
, O 0 0.00041566708
severity O 0 0.0006423894
and O 0 0.00029589955
preventability O 0 0.016714772
of O 0 0.0012498214
warfarin B-Chemical 1 0.99993813
- O 0 0.00072085386
induced O 0 0.0003830023
cerebral B-Disease 0 0.99963593
haemorrhages I-Disease 0 0.99997926
due O 0 0.00010370329
to O 0 0.00018149319
warfarin B-Chemical 1 0.99983335
and O 0 0.00047451293
warfarin B-Chemical 1 0.99987674
- O 0 0.0003740314
drug O 0 0.001540331
interactions O 0 9.182571e-05
in O 0 7.297421e-05
patients O 0 0.00013472144
living O 0 0.00023144356
in O 0 8.9348985e-05
the O 0 0.0001353018
county O 0 0.00055548816
of O 0 0.00043238985
Osterg O 0 0.008996671
tland O 0 0.016120676
, O 0 0.001448511
Sweden O 0 0.003805192
. O 0 0.0020898927

METHODS O 0 0.0015198317
: O 0 0.0011936915
All O 0 0.00051554467
patients O 0 0.0005680166
with O 0 0.00042105195
a O 0 0.000545267
diagnosed O 0 0.0024440447
cerebral B-Disease 0 0.9981034
haemorrhage I-Disease 0 0.99994504
at O 0 0.00014492025
three O 0 6.4227606e-05
hospitals O 0 0.000120942204
during O 0 5.0464027e-05
the O 0 0.00010095169
period O 0 9.498145e-05
2000 O 0 0.00036151658
- O 0 0.00053841964
2002 O 0 0.0007650749
were O 0 0.0006826261
identified O 0 0.0011028742
. O 0 0.0018843209

Medical O 0 0.0037442127
records O 0 0.0018480654
were O 0 0.0007246297
studied O 0 0.0004829908
retrospectively O 0 0.00029010943
to O 0 0.00017027343
evaluate O 0 0.0001027825
whether O 0 0.00015109724
warfarin B-Chemical 1 0.9996412
and O 0 0.0010304498
warfarin B-Chemical 1 0.9998803
- O 0 0.00082830794
drug O 0 0.0036182934
interactions O 0 0.000221492
could O 0 0.00015394944
have O 0 0.0001710069
caused O 0 0.00042461476
the O 0 0.0011036278
cerebral B-Disease 0 0.9991155
haemorrhage I-Disease 0 0.99992657
. O 0 0.0047355345

The O 0 0.0020505462
proportion O 0 0.001535247
of O 0 0.0014883518
possibly O 0 0.0018380142
avoidable O 0 0.0029750934
cases O 0 0.00081507664
due O 0 0.00037022188
to O 0 0.00052038307
drug O 0 0.0065674465
interactions O 0 0.0011340702
was O 0 0.001381916
estimated O 0 0.0019148143
. O 0 0.0027746877

RESULTS O 0 0.0048836744
: O 0 0.0022237042
Among O 0 0.0016751599
593 O 0 0.012133525
patients O 0 0.00089318265
with O 0 0.0009347106
cerebral B-Disease 0 0.99875927
haemorrhage I-Disease 0 0.9999702
, O 0 0.00081926904
59 O 0 0.0004623252
( O 0 0.0002492164
10 O 0 0.00013714471
% O 0 0.00017751311
) O 0 0.00021887096
were O 0 0.00013242921
assessed O 0 0.000110738554
as O 0 0.00014761844
related O 0 0.00015214889
to O 0 0.00060338946
warfarin B-Chemical 1 0.9988092
treatment O 0 0.0022930163
. O 0 0.0023586638

This O 0 0.0036362545
imply O 0 0.001060982
an O 0 0.0014911622
incidence O 0 0.0017868024
of O 0 0.0010119254
1 O 0 0.000553683
. O 0 0.00031884282
7 O 0 0.00031404817
/ O 0 0.00086182967
100 O 0 0.00092357036
, O 0 0.00070150587
000 O 0 0.0008902874
treatment O 0 0.0011623789
years O 0 0.0017200786
. O 0 0.0025165454

Of O 0 0.002657249
the O 0 0.0016580005
59 O 0 0.0017712427
cases O 0 0.0010497661
, O 0 0.0007427453
26 O 0 0.0006308813
( O 0 0.0004724372
44 O 0 0.00037017127
% O 0 0.00027482884
) O 0 0.0003037937
had O 0 0.00016823644
a O 0 0.0003045857
fatal O 0 0.21146323
outcome O 0 0.0002637805
, O 0 0.00014293035
compared O 0 6.231247e-05
to O 0 8.978767e-05
136 O 0 0.00044109437
( O 0 0.00014908462
25 O 0 0.00013339915
% O 0 0.00011001442
) O 0 0.0001310112
among O 0 8.246365e-05
the O 0 8.975788e-05
non O 0 0.00024023686
- O 0 0.00086278364
warfarin B-Chemical 1 0.99967515
patients O 0 0.0006253819
( O 0 0.0003816439
p O 0 0.0002639571
< O 0 0.00026537018
0 O 0 0.00032430413
. O 0 0.00046246446
01 O 0 0.0024208273
) O 0 0.0021583377
. O 0 0.0023277104

A O 0 0.42270732
warfarin B-Chemical 1 0.9994079
- O 0 0.0044558635
drug O 0 0.009294891
interaction O 0 0.0004136626
could O 0 0.0002332517
have O 0 0.00013735963
contributed O 0 0.00022224401
to O 0 0.0001424529
the O 0 0.0002694216
haemorrhage B-Disease 0 0.9983688
in O 0 0.00015644022
24 O 0 9.030466e-05
( O 0 0.00013742513
41 O 0 0.00015329526
% O 0 9.137506e-05
) O 0 0.00010220148
of O 0 9.0536516e-05
the O 0 0.00016753079
warfarin B-Chemical 1 0.99951696
patients O 0 0.0002021788
and O 0 7.8631034e-05
in O 0 5.8119196e-05
7 O 0 4.037086e-05
of O 0 7.460516e-05
these O 0 0.00012359406
( O 0 0.000119182696
12 O 0 4.5850527e-05
% O 0 9.199976e-05
) O 0 0.00014439048
the O 0 0.00016924994
bleeding B-Disease 0 0.9492713
complication O 0 0.0088915825
was O 0 0.00024027374
considered O 0 0.00016644587
being O 0 0.00033108256
possible O 0 0.00034730858
to O 0 0.0005732141
avoid O 0 0.0011926424
. O 0 0.0019824083

CONCLUSIONS O 0 0.028439391
: O 0 0.0065173474
Warfarin B-Chemical 0 0.9991072
- O 0 0.0030649402
induced O 0 0.0017682775
cerebral B-Disease 0 0.9990934
haemorrhages I-Disease 0 0.99993384
are O 0 0.00047268995
a O 0 0.00030082194
major O 0 0.00020623971
clinical O 0 0.00052578526
problem O 0 0.00034735425
with O 0 0.00040450483
a O 0 0.0006731039
high O 0 0.0017651878
fatality O 0 0.31403464
rate O 0 0.0025559657
. O 0 0.002467165

Almost O 0 0.004393844
half O 0 0.001245415
of O 0 0.0011927009
the O 0 0.0008372759
cases O 0 0.00079965795
was O 0 0.00047585904
related O 0 0.00021442703
to O 0 0.00041112318
a O 0 0.0015551983
warfarin B-Chemical 1 0.99959
- O 0 0.0029250472
drug O 0 0.020248985
interaction O 0 0.0019747636
. O 0 0.0027408258

A O 0 0.01433641
significant O 0 0.0014408221
proportion O 0 0.0009297278
of O 0 0.0017859226
warfarin B-Chemical 1 0.9997204
- O 0 0.0011082592
related O 0 0.00020895898
cerebral B-Disease 0 0.9983651
haemorrhages I-Disease 0 0.99995697
might O 0 0.00015335811
have O 0 9.196862e-05
been O 0 7.182875e-05
prevented O 0 0.00020657033
if O 0 5.4542492e-05
greater O 0 8.874027e-05
caution O 0 7.322628e-05
had O 0 6.760952e-05
been O 0 4.1860934e-05
taken O 0 3.3977707e-05
when O 0 5.089017e-05
prescribing O 0 0.0004925278
drugs O 0 0.0023121324
known O 0 0.00022586879
to O 0 0.00018548344
interact O 0 0.00019505159
with O 0 0.0015742524
warfarin B-Chemical 1 0.9992099
. O 0 0.002560381

Antipsychotic O 0 0.9946591
- O 0 0.003822709
like O 0 0.0008259329
profile O 0 0.0010558799
of O 0 0.0022525375
thioperamide B-Chemical 0 0.9999701
, O 0 0.0013053506
a O 0 0.00090226135
selective O 0 0.005114382
H3 O 0 0.606856
- O 0 0.0017483198
receptor O 0 0.031358857
antagonist O 0 0.74728423
in O 0 0.0012061324
mice O 0 0.001333859
. O 0 0.002242418

Experimental O 0 0.004631652
and O 0 0.0017357937
clinical O 0 0.0018380502
evidence O 0 0.00057289813
points O 0 0.00039750952
to O 0 0.00027771865
a O 0 0.0002994327
role O 0 0.00013974078
of O 0 0.00026230284
central O 0 0.00040507092
histaminergic O 0 0.038457446
system O 0 0.00028294983
in O 0 0.00022993732
the O 0 0.0003601551
pathogenesis O 0 0.0013968631
of O 0 0.0026490956
schizophrenia B-Disease 2 0.99964464
. O 0 0.0036922528

The O 0 0.0015205924
present O 0 0.0010433958
study O 0 0.001034318
was O 0 0.0005769075
designed O 0 0.00034458796
to O 0 0.00023187026
study O 0 0.00022764293
the O 0 0.00014649944
effect O 0 0.0001738701
of O 0 0.0010967932
histamine B-Chemical 1 0.9999838
H O 0 0.9999577
( O 0 0.00063582236
3 O 0 0.00012231938
) O 0 0.00022924648
- O 0 0.0002732414
receptor O 0 0.0020214329
ligands O 0 0.0013302248
on O 0 0.00015126377
neuroleptic O 0 0.9999908
- O 0 0.0010735906
induced O 0 0.0010338781
catalepsy B-Disease 0 0.99999785
, O 0 0.004030188
apomorphine B-Chemical 1 0.9999931
- O 0 0.0006067591
induced O 0 0.00016823324
climbing O 0 0.0011288492
behavior O 0 0.00023360467
and O 0 0.0004111585
amphetamine B-Chemical 1 0.999992
- O 0 0.0009729855
induced O 0 0.00041905663
locomotor O 0 0.055404734
activities O 0 0.0005286426
in O 0 0.00058941945
mice O 0 0.0009050545
. O 0 0.0017459564

Catalepsy B-Disease 0 0.9990049
was O 0 0.0029568088
induced O 0 0.0018104385
by O 0 0.0025065348
haloperidol B-Chemical 1 0.99999034
( O 0 0.0014526526
2 O 0 0.00031242424
mg O 0 0.004786235
/ O 0 0.0009246635
kg O 0 0.0007662132
p O 0 0.00020516959
. O 0 9.963962e-05
o O 0 0.00083968224
. O 0 0.00010697342
) O 0 0.0002181343
, O 0 0.00015933644
while O 0 0.0002793907
apomorphine B-Chemical 1 0.9999794
( O 0 0.00038063203
1 O 0 8.3638515e-05
. O 0 4.3689935e-05
5 O 0 4.9979168e-05
mg O 0 0.00070172217
/ O 0 0.00028293766
kg O 0 0.00022260792
s O 0 9.7793614e-05
. O 0 6.762526e-05
c O 0 0.00057069253
. O 0 7.0621696e-05
) O 0 0.00017195953
and O 0 0.00022864617
amphetamine B-Chemical 1 0.9999882
( O 0 0.00032054723
2 O 0 8.5332904e-05
mg O 0 0.001170045
/ O 0 0.00031342756
kg O 0 0.00023050363
s O 0 0.00010024088
. O 0 7.129775e-05
c O 0 0.000600946
. O 0 7.1888164e-05
) O 0 0.00013029222
were O 0 6.819507e-05
used O 0 5.4661577e-05
for O 0 6.217298e-05
studying O 0 0.00014666354
climbing O 0 0.000763026
behavior O 0 0.0002614741
and O 0 0.0003001498
locomotor O 0 0.022157496
activities O 0 0.0007301421
, O 0 0.0011703633
respectively O 0 0.0029320004
. O 0 0.0022270202

( B-Chemical 0 0.011230896
R I-Chemical 0 0.94796646
) I-Chemical 0 0.004704622
- I-Chemical 0 0.0037111717
alpha I-Chemical 0 0.5945589
- I-Chemical 0 0.00462095
methylhistamine I-Chemical 0 0.99878806
( O 0 0.0045171846
RAMH B-Chemical 1 0.9999397
) O 0 0.0010372503
( O 0 0.0002880418
5 O 0 9.747929e-05
microg O 0 0.00024890318
i O 0 0.00041800615
. O 0 0.00011329691
c O 0 0.0008876357
. O 0 9.807509e-05
v O 0 0.0006271136
. O 0 9.189332e-05
) O 0 0.00022477911
and O 0 0.00033545546
thioperamide B-Chemical 0 0.9999912
( O 0 0.0023489357
THP B-Chemical 1 0.9999565
) O 0 0.0005654541
( O 0 0.00015711354
15 O 0 7.060951e-05
mg O 0 0.0011776512
/ O 0 0.00038984942
kg O 0 0.00033483098
i O 0 0.0003216036
. O 0 9.800273e-05
p O 0 0.00014295707
. O 0 8.913752e-05
) O 0 0.00020365753
, O 0 0.00014634669
per O 0 7.580776e-05
se O 0 0.00032558324
did O 0 0.0004085096
not O 0 0.0006534125
cause O 0 0.005147741
catalepsy B-Disease 0 0.9999403
. O 0 0.004551667

Administration O 0 0.012220951
of O 0 0.0051610135
THP B-Chemical 1 0.9996019
( O 0 0.0025322116
3 O 0 0.00055091345
. O 0 0.0003040626
75 O 0 0.00046722247
, O 0 0.00029526773
7 O 0 0.00014092098
. O 0 9.439165e-05
5 O 0 8.044568e-05
and O 0 9.621997e-05
15 O 0 8.761188e-05
mg O 0 0.0012988929
/ O 0 0.0004639626
kg O 0 0.00038397187
i O 0 0.0003348364
. O 0 8.989947e-05
p O 0 0.00011580465
. O 0 5.956743e-05
) O 0 0.00011204195
1 O 0 4.5593628e-05
h O 0 3.6876892e-05
prior O 0 3.21294e-05
to O 0 0.00012343528
haloperidol B-Chemical 1 0.99999344
resulted O 0 0.00016955021
in O 0 9.510616e-05
a O 0 0.00015735507
dose O 0 0.00074799586
- O 0 0.00018157248
dependent O 0 3.7612765e-05
increase O 0 8.406247e-05
in O 0 0.000100024125
the O 0 0.00026811552
catalepsy B-Disease 0 0.9999808
times O 0 0.00017774716
( O 0 0.0005008775
P O 0 0.0032532038
< O 0 0.00031568873
0 O 0 0.00035851658
. O 0 0.0005356534
05 O 0 0.005649283
) O 0 0.0023538196
. O 0 0.0023933551

However O 0 0.0025580805
, O 0 0.002200785
pretreatment O 0 0.0270138
with O 0 0.0037829338
RAMH B-Chemical 1 0.9999219
significantly O 0 0.0013761681
reversed O 0 0.0009090833
such O 0 0.0001524937
an O 0 0.00020652464
effect O 0 0.00016963106
of O 0 0.0006119125
THP B-Chemical 1 0.99992824
( O 0 0.00048143123
15 O 0 0.0001439168
mg O 0 0.002525255
/ O 0 0.0007221303
kg O 0 0.0006559576
i O 0 0.0006851798
. O 0 0.00033023584
p O 0 0.0006281359
. O 0 0.00067381054
) O 0 0.0021268367
. O 0 0.002408065

RAMH B-Chemical 1 0.99873024
per O 0 0.0010679772
se O 0 0.0014372112
showed O 0 0.0005785371
significant O 0 0.00039445903
reduction O 0 0.00066190585
in O 0 0.00027018637
locomotor O 0 0.015027517
time O 0 9.163745e-05
, O 0 0.00012562612
distance O 0 9.0450914e-05
traveled O 0 0.00016071828
and O 0 6.538509e-05
average O 0 4.7198217e-05
speed O 0 0.00019075078
but O 0 0.00026240788
THP B-Chemical 1 0.9998971
( O 0 0.00026815003
15 O 0 7.727186e-05
mg O 0 0.0015849199
/ O 0 0.0004016435
kg O 0 0.00032262685
i O 0 0.00030071067
. O 0 8.4306754e-05
p O 0 0.000114461654
. O 0 6.296559e-05
) O 0 0.00011979649
per O 0 4.1485695e-05
se O 0 0.00016139739
had O 0 0.00012373958
no O 0 9.87374e-05
effect O 0 0.0001917817
on O 0 0.00024994643
these O 0 0.00087194704
parameters O 0 0.0016150846
. O 0 0.0020393946

On O 0 0.007277914
amphetamine B-Chemical 1 0.99991584
- O 0 0.008185788
induced O 0 0.003768388
hyperactivity B-Disease 2 0.99994266
, O 0 0.0051713362
THP B-Chemical 1 0.9999418
( O 0 0.0010100093
3 O 0 0.00016415978
. O 0 8.998902e-05
75 O 0 0.00015905713
and O 0 0.00010452543
7 O 0 6.659162e-05
. O 0 5.1734434e-05
5 O 0 6.205593e-05
mg O 0 0.0009087039
/ O 0 0.00038688924
kg O 0 0.0003390903
i O 0 0.00031000786
. O 0 8.548318e-05
p O 0 0.00011388519
. O 0 6.2399886e-05
) O 0 0.00013871891
reduced O 0 0.00018571809
locomotor O 0 0.008832273
time O 0 5.8310336e-05
, O 0 9.5465235e-05
distance O 0 8.2006394e-05
traveled O 0 0.00016656223
and O 0 8.468182e-05
average O 0 7.780349e-05
speed O 0 0.0003559875
( O 0 0.0005410799
P O 0 0.003728449
< O 0 0.00036635197
0 O 0 0.00040426388
. O 0 0.00059168186
05 O 0 0.006022115
) O 0 0.0025096866
. O 0 0.0025294602

Pretreatment O 0 0.18276362
with O 0 0.0077350517
RAMH B-Chemical 1 0.99979347
( O 0 0.0017520137
5 O 0 0.00039295907
microg O 0 0.00073218025
i O 0 0.00091142574
. O 0 0.00024327902
c O 0 0.0015095895
. O 0 0.00017460609
v O 0 0.00096938614
. O 0 0.00013010499
) O 0 0.00020440789
could O 0 8.4041225e-05
partially O 0 0.00016396673
reverse O 0 0.000458081
such O 0 7.0797e-05
effects O 0 0.00014867847
of O 0 0.0005198165
THP B-Chemical 1 0.99995506
( O 0 0.00043824542
3 O 0 8.635657e-05
. O 0 6.0265353e-05
75 O 0 0.00016807226
mg O 0 0.0015280405
/ O 0 0.0005966435
kg O 0 0.0005773153
i O 0 0.0006287834
. O 0 0.0003067173
p O 0 0.00059156993
. O 0 0.00063998596
) O 0 0.0020410526
. O 0 0.00232238

Climbing O 0 0.013624883
behavior O 0 0.002800879
induced O 0 0.0022026382
by O 0 0.0027571346
apomorphine B-Chemical 1 0.99990904
was O 0 0.0013706705
reduced O 0 0.00095729483
in O 0 0.0004849769
animals O 0 0.00048139223
treated O 0 0.0013637708
with O 0 0.0035165793
THP B-Chemical 1 0.9994823
. O 0 0.005398275

Such O 0 0.004167585
an O 0 0.002551894
effect O 0 0.0017203751
was O 0 0.0017140451
, O 0 0.0013127888
however O 0 0.0011298315
, O 0 0.0009782158
reversed O 0 0.0016310478
in O 0 0.0008062565
presence O 0 0.001299566
of O 0 0.0054971497
RAMH B-Chemical 1 0.99962115
. O 0 0.0055817803

THP B-Chemical 1 0.99823403
exhibited O 0 0.0029751996
an O 0 0.0027988595
antipsychotic O 0 0.9984927
- O 0 0.0012736382
like O 0 0.00021404483
profile O 0 0.0002777578
by O 0 0.0002918794
potentiating O 0 0.19084883
haloperidol B-Chemical 1 0.99999905
- O 0 0.006199056
induced O 0 0.0019475439
catalepsy B-Disease 0 0.99999654
, O 0 0.00060244655
reducing O 0 0.0011435415
amphetamine B-Chemical 1 0.9999975
- O 0 0.001422619
induced O 0 0.00054731074
hyperactivity B-Disease 2 0.9999701
and O 0 0.00041491052
reducing O 0 0.0013954273
apomorphine B-Chemical 1 0.9999876
- O 0 0.0015135781
induced O 0 0.00066266017
climbing O 0 0.0039037648
in O 0 0.0006806066
mice O 0 0.0009616553
. O 0 0.0017961697

Such O 0 0.0029539901
effects O 0 0.0018625718
of O 0 0.002615028
THP B-Chemical 1 0.9996282
were O 0 0.0011740207
reversed O 0 0.0018920476
by O 0 0.0009880605
RAMH B-Chemical 1 0.99986875
indicating O 0 0.00023485172
the O 0 0.00020302122
involvement O 0 0.00042981812
of O 0 0.0013610758
histamine B-Chemical 1 0.99996185
H O 0 0.99984777
( O 0 0.0012544248
3 O 0 0.0004631202
) O 0 0.0010537063
- O 0 0.001806778
receptors O 0 0.0056047933
. O 0 0.002608219

Findings O 0 0.002174805
suggest O 0 0.0007890125
a O 0 0.0010652569
potential O 0 0.00084383145
for O 0 0.00096016855
H O 0 0.99914384
( O 0 0.0010658306
3 O 0 0.00031314883
) O 0 0.0005344045
- O 0 0.0006143688
receptor O 0 0.005189481
antagonists O 0 0.26503074
in O 0 0.00019246188
improving O 0 0.00020772773
the O 0 0.00024059492
refractory O 0 0.0013978133
cases O 0 0.00084188307
of O 0 0.0021029406
schizophrenia B-Disease 2 0.9996319
. O 0 0.0033062163

Cauda B-Disease 0 0.28271112
equina I-Disease 0 0.009811225
syndrome I-Disease 0 0.08939857
after O 0 0.0006857837
epidural O 0 0.052973717
steroid B-Chemical 1 0.9808337
injection O 0 0.0015323989
: O 0 0.0012248829
a O 0 0.0013625349
case O 0 0.0016742527
report O 0 0.0039428174
. O 0 0.0033787182

OBJECTIVE O 0 0.017816309
: O 0 0.0018473582
Conventional O 0 0.0011019553
treatment O 0 0.00050642545
methods O 0 0.0003858706
of O 0 0.000553674
lumbusacral O 0 0.08613663
radiculopathy B-Disease 0 0.9997404
are O 0 0.0002536021
physical O 0 0.00032396294
therapy O 0 0.0002226816
, O 0 0.00020271423
epidural O 0 0.029538073
steroid B-Chemical 1 0.98275846
injections O 0 0.000361441
, O 0 0.00022665101
oral O 0 0.011350312
medications O 0 0.0037120252
, O 0 0.0002980593
and O 0 0.00035279745
spinal O 0 0.0019952822
manipulative O 0 0.002816424
therapy O 0 0.0023054685
. O 0 0.0020600746

Cauda B-Disease 0 0.46931428
equina I-Disease 0 0.01845845
syndrome I-Disease 0 0.27436024
is O 0 0.0018533221
a O 0 0.0018714312
rare O 0 0.0039191903
complication O 0 0.013482501
of O 0 0.0030280824
epidural O 0 0.13047935
anesthesia O 0 0.08096033
. O 0 0.00400743

The O 0 0.001567083
following O 0 0.00095995725
case O 0 0.0008749544
is O 0 0.0005969213
a O 0 0.0005551235
report O 0 0.00056152564
of O 0 0.00059469865
cauda B-Disease 0 0.020787517
equina I-Disease 0 0.003038111
syndrome I-Disease 0 0.18070266
possibly O 0 0.00037868158
caused O 0 0.00021587305
by O 0 0.00023500314
epidural O 0 0.003293986
injection O 0 0.00039868368
of O 0 0.0013373091
triamcinolone B-Chemical 0 0.9999455
and O 0 0.006296277
bupivacaine B-Chemical 1 0.9998266
. O 0 0.0037054145

CLINICAL O 0 0.0051875124
FEATURES O 0 0.0034632639
: O 0 0.0021022405
A O 0 0.006288788
50 O 0 0.001459683
- O 0 0.0010852767
year O 0 0.00030803483
- O 0 0.0004669573
old O 0 0.00023810883
woman O 0 0.00041384104
with O 0 0.00018392112
low B-Disease 0 0.0003213449
back I-Disease 0 0.00028245224
and I-Disease 0 0.00015842836
right I-Disease 0 0.0008885098
leg I-Disease 0 0.006489056
pain I-Disease 0 0.1796642
was O 0 0.00021784454
scheduled O 0 0.000112879476
for O 0 0.00022733017
epidural O 0 0.032145362
steroid B-Chemical 1 0.97740984
injection O 0 0.002761399
. O 0 0.002215345

INTERVENTION O 0 0.0034987156
AND O 0 0.0013606228
OUTCOME O 0 0.0016276094
: O 0 0.00094890915
An O 0 0.0007094966
18 O 0 0.00052376045
- O 0 0.0006562809
gauge O 0 0.00043882398
Touhy O 0 0.0007662665
needle O 0 0.00034943045
was O 0 0.00017857975
inserted O 0 8.865491e-05
until O 0 6.608529e-05
loss O 0 0.0002524499
of O 0 0.00018287
resistance O 0 0.0003662744
occurred O 0 0.0001486239
at O 0 0.00014163645
the O 0 0.0003296247
L4 O 0 0.0031637526
- O 0 0.0011033345
5 O 0 0.00063659175
level O 0 0.0011827175
. O 0 0.0022358748

Spread O 0 0.0038093498
of O 0 0.0016280696
the O 0 0.0009910988
contrast O 0 0.0015306912
medium O 0 0.0022594496
within O 0 0.00021333112
the O 0 0.00042292374
epidural O 0 0.0033884272
space O 0 0.00035595096
was O 0 0.00042744988
determined O 0 0.00042363914
by O 0 0.00079097744
radiographic O 0 0.003957681
imaging O 0 0.003684613
. O 0 0.0027578976

After O 0 0.0010904704
verifying O 0 0.0014260962
the O 0 0.0011666868
epidural O 0 0.0056290184
space O 0 0.0008072559
, O 0 0.0016200569
bupivacaine B-Chemical 1 0.9998368
and O 0 0.008498138
triamcinolone B-Chemical 1 0.9999863
diacetate I-Chemical 1 0.99945277
were O 0 0.0023153904
injected O 0 0.0021833428
. O 0 0.0028433125

After O 0 0.0013454631
the O 0 0.0017733838
injection O 0 0.0017696912
, O 0 0.0012950142
there O 0 0.0006079452
was O 0 0.00086533016
a O 0 0.0010063838
reduction O 0 0.0021486448
in O 0 0.001830892
radicular O 0 0.83250546
symptoms O 0 0.10316375
. O 0 0.0041570826

Three O 0 0.0023568033
hours O 0 0.0010703269
later O 0 0.00085564377
, O 0 0.0010181415
she O 0 0.00072901545
complained O 0 0.0033353718
of O 0 0.0011762358
perineal O 0 0.016219556
numbness B-Disease 0 0.98748267
and O 0 0.0016564911
lower B-Disease 0 0.0076414184
extremity I-Disease 0 0.68473893
weakness I-Disease 0 0.997269
. O 0 0.005071847

The O 0 0.0021979557
neurologic O 0 0.18920308
evaluation O 0 0.0010683057
revealed O 0 0.00071831513
loss B-Disease 0 0.0024142312
of I-Disease 0 0.0008330525
sensation I-Disease 0 0.16628174
in O 0 0.00027690086
the O 0 0.00025355833
saddle O 0 0.0012534154
area O 0 0.00022367512
and O 0 0.00021649942
medial O 0 0.0006576931
aspect O 0 0.00023187601
of O 0 0.0005373776
her O 0 0.001202796
right O 0 0.004252143
leg O 0 0.013697104
. O 0 0.0027524629

There O 0 0.004067019
was O 0 0.002764448
a O 0 0.0019801417
decrease O 0 0.0015007041
in O 0 0.0009265062
the O 0 0.0009673394
perception O 0 0.002030672
of O 0 0.00293484
pinprick O 0 0.27879676
test O 0 0.005142865
. O 0 0.0041446416

Deep O 0 0.020285858
- O 0 0.0059520733
tendon O 0 0.014407142
reflexes O 0 0.050092675
were O 0 0.001331285
decreased O 0 0.0016189173
especially O 0 0.0010235709
in O 0 0.00090069213
the O 0 0.0013418784
right O 0 0.0059258644
leg O 0 0.017969003
. O 0 0.004166462

She O 0 0.013658222
was O 0 0.008373925
unable O 0 0.0072239526
to O 0 0.010266538
urinate O 0 0.03506922
. O 0 0.013521026

The O 0 0.002010148
patient O 0 0.0018984952
' O 0 0.0015573833
s O 0 0.0011471409
symptoms O 0 0.0034547464
improved O 0 0.0011810152
slightly O 0 0.00081210694
over O 0 0.0002800705
the O 0 0.0004467738
next O 0 0.00038971234
few O 0 0.0006754842
hours O 0 0.0011741796
. O 0 0.0026132576

She O 0 0.0038234682
had O 0 0.0015778781
a O 0 0.0011627222
gradual O 0 0.00093856483
return O 0 0.00066471205
of O 0 0.00054617913
motor O 0 0.0011101157
function O 0 0.00044277337
and O 0 0.0003906055
ability O 0 0.00049369724
of O 0 0.0011060212
feeling O 0 0.026551124
Foley O 0 0.009203998
catheter O 0 0.0023285332
. O 0 0.0021165977

All O 0 0.0017985206
of O 0 0.0016086547
the O 0 0.0012017069
symptoms O 0 0.004379217
were O 0 0.00068908004
completely O 0 0.0006244971
resolved O 0 0.00065055786
over O 0 0.00023502106
the O 0 0.000394
next O 0 0.00036447917
8 O 0 0.00074010063
hours O 0 0.0010327229
. O 0 0.0024189914

CONCLUSION O 0 0.017644258
: O 0 0.002976079
Complications O 0 0.002335827
associated O 0 0.0010056591
with O 0 0.0015557478
epidural O 0 0.107726164
steroid B-Chemical 1 0.99080604
injections O 0 0.0033303068
are O 0 0.00206815
rare O 0 0.007363985
. O 0 0.0036605734

Clinical O 0 0.005316788
examination O 0 0.0013207624
and O 0 0.0007787236
continued O 0 0.0005949572
vigilance O 0 0.0020929032
for O 0 0.00046738726
neurologic B-Disease 0 0.9954513
deterioration I-Disease 0 0.69065017
after O 0 0.00027473614
epidural O 0 0.11353231
steroid B-Chemical 1 0.9876501
injections O 0 0.0012429683
is O 0 0.0008247398
important O 0 0.000889598
. O 0 0.0021108445

High O 0 0.012168227
- O 0 0.0061376295
dose O 0 0.018916838
testosterone B-Chemical 0 0.9992818
is O 0 0.0015716418
associated O 0 0.0010475382
with O 0 0.0025332142
atherosclerosis B-Disease 2 0.99978596
in O 0 0.004065
postmenopausal O 0 0.97918075
women O 0 0.009605002
. O 0 0.0029485067

OBJECTIVES O 0 0.003648052
: O 0 0.0020215807
To O 0 0.00086571614
study O 0 0.00086669705
the O 0 0.00054703513
long O 0 0.00045907457
- O 0 0.0005287903
term O 0 0.00020604747
effects O 0 0.00029186354
of O 0 0.0006407812
androgen O 0 0.99763274
treatment O 0 0.00053359516
on O 0 0.00043739754
atherosclerosis B-Disease 2 0.9998323
in O 0 0.002230874
postmenopausal O 0 0.9732896
women O 0 0.006852079
. O 0 0.0021233275

METHODS O 0 0.0017827131
: O 0 0.0014775433
In O 0 0.00062027824
a O 0 0.0008490769
population O 0 0.0010211131
- O 0 0.00063881715
based O 0 0.00022263086
study O 0 0.0002609603
in O 0 0.00019406212
513 O 0 0.0014796425
naturally O 0 0.000567479
postmenopausal O 0 0.8088175
women O 0 0.00061758666
aged O 0 0.00022444547
54 O 0 0.00019889332
- O 0 0.0001726932
67 O 0 0.00015145744
years O 0 5.719173e-05
, O 0 5.492933e-05
we O 0 2.7093038e-05
studied O 0 5.9443493e-05
the O 0 4.7799924e-05
association O 0 3.5745517e-05
between O 0 4.1445597e-05
self O 0 0.00038449894
- O 0 0.00022062592
reported O 0 8.481184e-05
intramuscularly O 0 0.00012258573
administered O 0 8.745594e-05
high O 0 0.0002413941
- O 0 0.0003267384
dose O 0 0.006410484
estrogen B-Chemical 1 0.99997354
- O 0 0.00428627
testosterone B-Chemical 0 0.9999496
therapy O 0 0.00084929663
( O 0 0.0006947668
estradiol B-Chemical 0 0.9999392
- I-Chemical 0 0.0010462357
and I-Chemical 0 0.0006098482
testosterone I-Chemical 0 0.9999341
esters I-Chemical 0 0.9967734
) O 0 0.0016113989
and O 0 0.0011741145
aortic O 0 0.5859889
atherosclerosis B-Disease 2 0.99972695
. O 0 0.0037238172

Aortic O 0 0.3685697
atherosclerosis B-Disease 2 0.9993123
was O 0 0.0023995806
diagnosed O 0 0.0019705046
by O 0 0.00047872987
radiographic O 0 0.0009544206
detection O 0 0.00032452028
of O 0 0.00032318896
calcified O 0 0.007424854
deposits O 0 0.0070440196
in O 0 0.00012786142
the O 0 0.00014195513
abdominal O 0 0.0025881983
aorta O 0 0.027264208
, O 0 0.00017890595
which O 0 0.00016492084
have O 0 9.860642e-05
been O 0 0.0001087226
shown O 0 0.00012774931
to O 0 0.00022826671
reflect O 0 0.0004368294
intima O 0 0.8590319
atherosclerosis B-Disease 2 0.9997855
. O 0 0.004132834

Hormone O 0 0.53568715
therapy O 0 0.0047836597
users O 0 0.0040447563
were O 0 0.0015293806
compared O 0 0.001103806
with O 0 0.0021943958
never O 0 0.0038232703
users O 0 0.0075218566
. O 0 0.004656922

RESULTS O 0 0.005261768
: O 0 0.002762297
Intramuscular O 0 0.016055634
hormone O 0 0.053385492
therapy O 0 0.0009144368
use O 0 0.00035161484
for O 0 0.00022184895
1 O 0 0.00021200012
year O 0 0.00014379073
or O 0 0.00016913506
longer O 0 0.00016782658
was O 0 0.00036877184
reported O 0 0.00052315445
by O 0 0.0007648709
25 O 0 0.0015655921
women O 0 0.0035981406
. O 0 0.002227391

In O 0 0.0016334762
almost O 0 0.0011378424
half O 0 0.0006121782
of O 0 0.0006816997
these O 0 0.000789214
women O 0 0.0019696758
severe O 0 0.043101497
atherosclerosis B-Disease 2 0.9999125
of O 0 0.00048051128
the O 0 0.0002110792
aorta O 0 0.021405011
was O 0 0.0001277905
present O 0 7.849564e-05
( O 0 0.0001524024
n O 0 9.477399e-05
= O 0 0.00012216084
11 O 0 9.06662e-05
) O 0 0.00012551788
, O 0 7.823478e-05
while O 0 6.3040214e-05
in O 0 7.353291e-05
women O 0 0.0002212541
without O 0 9.306531e-05
hormone O 0 0.04495262
use O 0 0.00012322913
severe O 0 0.019079562
atherosclerosis B-Disease 2 0.9999428
of O 0 0.00023698839
the O 0 0.00011524527
aorta O 0 0.0153125925
was O 0 7.480876e-05
present O 0 4.1487045e-05
in O 0 5.1406463e-05
less O 0 6.6355686e-05
than O 0 4.873159e-05
20 O 0 8.3877254e-05
% O 0 0.000119502125
( O 0 0.00022106538
OR O 0 0.0019623814
3 O 0 7.0274305e-05
. O 0 5.1669755e-05
1 O 0 6.9824484e-05
; O 0 0.00010546134
95 O 0 0.00014566006
% O 0 0.00014105732
CI O 0 0.0030822195
, O 0 0.00012745596
1 O 0 7.9351514e-05
. O 0 5.5313685e-05
1 O 0 7.700139e-05
- O 0 0.00014854797
8 O 0 6.1127765e-05
. O 0 4.648406e-05
5 O 0 5.0955536e-05
, O 0 7.772518e-05
adjusted O 0 6.502965e-05
for O 0 6.7554865e-05
age O 0 0.00013616092
, O 0 0.00012318039
years O 0 8.4043146e-05
since O 0 7.571933e-05
menopause O 0 0.01933455
, O 0 0.00033981027
smoking O 0 0.032842357
, O 0 0.00030173216
and O 0 0.00031036127
body O 0 0.0012852778
mass O 0 0.0031842194
index O 0 0.0015001448
) O 0 0.0022381118
. O 0 0.0021189838

The O 0 0.0014503588
association O 0 0.00077299663
remained O 0 0.00076630845
after O 0 0.0002172099
additional O 0 0.00024130156
adjustment O 0 0.0002484259
for O 0 0.0003897844
diabetes B-Disease 0 0.9994862
, O 0 0.0013263563
cholesterol B-Chemical 0 0.9998313
level O 0 0.00029404013
, O 0 0.00033507272
systolic O 0 0.123713024
blood O 0 0.004471158
pressure O 0 0.0046963547
, O 0 0.0005455938
or O 0 0.00075779896
alcohol B-Chemical 0 0.9965753
use O 0 0.0022431286
. O 0 0.0022889695

No O 0 0.003706601
association O 0 0.0014750859
was O 0 0.0015035126
found O 0 0.0008705789
for O 0 0.0007961399
hormone O 0 0.04311086
use O 0 0.00082509476
less O 0 0.0008886995
than O 0 0.00078290334
1 O 0 0.0011998793
year O 0 0.0014960064
. O 0 0.0027400788

CONCLUSION O 0 0.013899104
: O 0 0.0016745459
Our O 0 0.00075640326
results O 0 0.00053230283
suggest O 0 0.00021068046
that O 0 0.00022785115
high O 0 0.00071023806
- O 0 0.0008204612
dose O 0 0.006518999
testosterone B-Chemical 0 0.9999088
therapy O 0 0.00042429828
may O 0 9.218471e-05
adversely O 0 0.00030877872
affect O 0 9.825435e-05
atherosclerosis B-Disease 2 0.9999088
in O 0 0.0003101356
postmenopausal O 0 0.8917306
women O 0 0.00032730706
and O 0 6.380936e-05
indicate O 0 3.7084574e-05
that O 0 8.3841755e-05
androgen O 0 0.9971359
replacement O 0 0.0007810173
in O 0 0.00012385195
these O 0 0.00025098716
women O 0 0.0005009787
may O 0 0.00020605297
not O 0 0.00035952817
be O 0 0.00066394085
harmless O 0 0.0031646115
. O 0 0.0019455447

Optimising O 0 0.0071284985
stroke B-Disease 0 0.9684406
prevention O 0 0.0041259783
in O 0 0.0018894126
non O 0 0.0025475929
- O 0 0.0039033156
valvular O 0 0.32730338
atrial B-Disease 0 0.99045956
fibrillation I-Disease 0 0.9997316
. O 0 0.006406816

Atrial B-Disease 0 0.9770583
fibrillation I-Disease 0 0.99983716
is O 0 0.0030256405
associated O 0 0.0015111616
with O 0 0.0016897725
substantial O 0 0.002316144
morbidity O 0 0.093677886
and O 0 0.0036717488
mortality O 0 0.06652966
. O 0 0.004615439

Pooled O 0 0.0037754995
data O 0 0.001047172
from O 0 0.000491855
trials O 0 0.00038774253
comparing O 0 0.00020464403
antithrombotic O 0 0.052175004
treatment O 0 0.00021863237
with O 0 0.00023586422
placebo O 0 0.00093170564
have O 0 6.578134e-05
shown O 0 5.962938e-05
that O 0 9.9957375e-05
warfarin B-Chemical 1 0.99907327
reduces O 0 0.00012187509
the O 0 0.00013377849
risk O 0 0.0015221967
of O 0 0.00043442086
stroke B-Disease 0 0.99788505
by O 0 0.0002028757
62 O 0 0.00021104737
% O 0 9.703737e-05
, O 0 8.778666e-05
and O 0 8.701605e-05
that O 0 0.00013428766
aspirin B-Chemical 0 0.99987173
alone O 0 0.00028725338
reduces O 0 0.00025120834
the O 0 0.00037794458
risk O 0 0.0029665271
by O 0 0.00071864243
22 O 0 0.0011151704
% O 0 0.0014000463
. O 0 0.0018351434

Overall O 0 0.004025719
, O 0 0.002159291
in O 0 0.0010634612
high O 0 0.0016690784
- O 0 0.0017081138
risk O 0 0.003857569
patients O 0 0.0008522503
, O 0 0.0006826587
warfarin B-Chemical 1 0.99939466
is O 0 0.0001888738
superior O 0 0.00028093407
to O 0 0.00021775195
aspirin B-Chemical 0 0.9999068
in O 0 0.00022203474
preventing O 0 0.0007979673
strokes B-Disease 0 0.9981725
, O 0 0.0002896186
with O 0 0.00019489398
a O 0 0.0002181085
relative O 0 0.00020302163
risk O 0 0.0016094283
reduction O 0 0.001063214
of O 0 0.0008596202
36 O 0 0.0009841603
% O 0 0.0014444042
. O 0 0.0018735388

Ximelagatran B-Chemical 0 0.9967822
, O 0 0.0027114006
an O 0 0.0016342992
oral O 0 0.013195795
direct O 0 0.0013630878
thrombin O 0 0.8863527
inhibitor O 0 0.13156763
, O 0 0.0006250056
was O 0 0.00025446725
found O 0 0.0001128361
to O 0 8.732111e-05
be O 0 7.188721e-05
as O 0 5.7232493e-05
efficient O 0 6.20014e-05
as O 0 0.00029571343
vitamin B-Chemical 0 0.99999726
K I-Chemical 1 0.99999547
antagonist O 0 0.9952238
drugs O 0 0.084579
in O 0 7.692638e-05
the O 0 6.346062e-05
prevention O 0 0.00012237571
of O 0 0.00022523008
embolic B-Disease 0 0.9887582
events I-Disease 0 0.20069124
, O 0 0.00025106204
but O 0 0.00014296443
has O 0 6.8099485e-05
been O 0 5.986657e-05
recently O 0 6.605844e-05
withdrawn O 0 0.00016619972
because O 0 8.355712e-05
of O 0 0.0002953984
abnormal B-Disease 0 0.052184112
liver I-Disease 0 0.87215495
function I-Disease 0 0.004286912
tests O 0 0.0038642006
. O 0 0.0019437807

The O 0 0.003111887
ACTIVE O 0 0.029543938
- O 0 0.004295458
W O 0 0.18006779
( O 0 0.0014217807
Atrial B-Disease 0 0.26405844
Fibrillation I-Disease 0 0.11395155
Clopidogrel B-Chemical 0 0.99958867
Trial O 0 0.0007858932
with O 0 0.00032738197
Irbesartan B-Chemical 0 0.9996729
for O 0 0.000102804064
Prevention O 0 0.00011262282
of O 0 0.00014337439
Vascular O 0 0.051056538
Events O 0 0.0009546775
) O 0 0.00015874955
study O 0 8.322084e-05
has O 0 4.083051e-05
demonstrated O 0 4.4023014e-05
that O 0 7.6711745e-05
warfarin B-Chemical 1 0.99887246
is O 0 7.689506e-05
superior O 0 0.0001126831
to O 0 6.947378e-05
platelet O 0 0.627235
therapy O 0 0.0003367455
( O 0 0.0003969597
clopidogrel B-Chemical 0 0.9998363
plus O 0 0.0003413705
aspirin B-Chemical 0 0.99994946
) O 0 0.00048605195
in O 0 0.0001723249
the O 0 0.00026618916
prevention O 0 0.0011346948
af O 0 0.31491438
embolic B-Disease 0 0.9962463
events I-Disease 0 0.4435075
. O 0 0.003100712

Idraparinux B-Chemical 0 0.8319224
, O 0 0.003673926
a O 0 0.0034238133
Factor O 0 0.88685906
Xa O 0 0.99357915
inhibitor O 0 0.010928196
, O 0 0.0009808622
is O 0 0.00046021116
being O 0 0.000417839
evaluated O 0 0.0002515156
in O 0 0.00030567747
patients O 0 0.0006261032
with O 0 0.0012295076
atrial B-Disease 0 0.96727276
fibrillation I-Disease 0 0.99979705
. O 0 0.0037646235

Angiotensin B-Chemical 0 0.9995716
- O 0 0.0075613232
converting O 0 0.014171212
enzyme O 0 0.018116135
inhibitors O 0 0.0038681342
and O 0 0.0016658731
angiotensin B-Chemical 1 0.9999893
II I-Chemical 1 0.9530573
receptor O 0 0.14597838
- O 0 0.00067200785
blocking O 0 0.000515911
drugs O 0 0.008891075
hold O 0 0.00023831618
promise O 0 0.00019892158
in O 0 0.0002369425
atrial B-Disease 0 0.75604886
fibrillation I-Disease 0 0.9998031
through O 0 0.0007551239
cardiac B-Disease 0 0.74761456
remodelling I-Disease 0 0.16670829
. O 0 0.0025197635

Preliminary O 0 0.0032687215
studies O 0 0.0013616476
suggest O 0 0.0005296574
that O 0 0.0007804229
statins B-Chemical 0 0.9981925
could O 0 0.00042930953
interfere O 0 0.00023656238
with O 0 0.00033599575
the O 0 0.0003172903
risk O 0 0.0016765433
of O 0 0.00057347777
recurrence O 0 0.0133281695
after O 0 0.0003067407
electrical O 0 0.003539411
cardioversion O 0 0.008617046
. O 0 0.002126535

Finally O 0 0.0022694836
, O 0 0.0016676949
percutaneous O 0 0.00088730594
methods O 0 0.00046461544
for O 0 0.00023755757
the O 0 0.00022483057
exclusion O 0 0.00026807055
of O 0 0.00024120518
left O 0 0.0007255151
atrial O 0 0.38392177
appendage O 0 0.00513015
are O 0 0.00013367062
under O 0 0.00010271391
investigation O 0 0.00024309536
in O 0 0.00023141551
high O 0 0.00089929724
- O 0 0.001482702
risk O 0 0.0068326765
patients O 0 0.0030050315
. O 0 0.0021855107

Anti O 0 0.13094646
- O 0 0.006874796
oxidant O 0 0.85349715
effects O 0 0.0015504631
of O 0 0.0028801744
atorvastatin B-Chemical 0 0.99996793
in O 0 0.0029755926
dexamethasone B-Chemical 0 0.99986017
- O 0 0.0044642924
induced O 0 0.0028298397
hypertension B-Disease 2 0.9999261
in O 0 0.0012030825
the O 0 0.0012731645
rat O 0 0.0042176265
. O 0 0.0023806193

1 O 0 0.062920205
. O 0 0.06257983

Dexamethasone B-Chemical 0 0.9992581
( O 0 0.015833337
Dex B-Chemical 1 0.99898523
) O 0 0.0054805432
- O 0 0.002378805
induced O 0 0.0020354495
hypertension B-Disease 2 0.9999343
is O 0 0.00065270043
characterized O 0 0.0007772582
by O 0 0.00034872393
endothelial O 0 0.80380803
dysfunction O 0 0.6725709
associated O 0 0.00017912818
with O 0 0.000386066
nitric B-Chemical 0 0.99908674
oxide I-Chemical 0 0.9867163
( O 0 0.00087974203
NO B-Chemical 0 0.9985122
) O 0 0.0007428043
deficiency O 0 0.31976712
and O 0 0.00037474273
increased O 0 0.0028619121
superoxide B-Chemical 1 0.99997723
( O 0 0.0067466856
O2 B-Chemical 0 0.9998092
- I-Chemical 0 0.002997659
) O 0 0.0015976279
production O 0 0.0023710036
. O 0 0.0024182792

Atorvastatin B-Chemical 0 0.999498
( O 0 0.0116012525
Ato B-Chemical 1 0.9868542
) O 0 0.0017947237
possesses O 0 0.00047853554
pleiotropic O 0 0.0006295534
properties O 0 0.00019689005
that O 0 0.00014301624
have O 0 0.000120967576
been O 0 9.8006654e-05
reported O 0 0.000114266775
to O 0 7.7673896e-05
improve O 0 8.76779e-05
endothelial O 0 0.1366591
function O 0 0.00012023251
through O 0 5.408922e-05
increased O 0 0.00011998031
availability O 0 0.00011544984
of O 0 0.0002439512
NO B-Chemical 0 0.9954171
and O 0 0.00024973205
reduced O 0 0.0010645812
O2 B-Chemical 0 0.99991155
- I-Chemical 0 0.0006661344
production O 0 0.0002861155
in O 0 0.00018447507
various O 0 0.00030280967
forms O 0 0.00053119846
of O 0 0.0024785295
hypertension B-Disease 2 0.9998411
. O 0 0.003442588

In O 0 0.0016708004
the O 0 0.0011945809
present O 0 0.0007452928
study O 0 0.0008149698
, O 0 0.00045904785
we O 0 0.00014731527
investigated O 0 0.00015243338
whether O 0 9.273444e-05
50 O 0 0.00036791578
mg O 0 0.009298386
/ O 0 0.00060534285
kg O 0 0.0002563601
per O 0 3.8025642e-05
day O 0 6.055564e-05
, O 0 0.00013694334
p O 0 0.00012778977
. O 0 7.617298e-05
o O 0 0.0007859554
. O 0 9.781329e-05
, O 0 0.00022428074
Ato B-Chemical 1 0.862084
could O 0 0.00010980639
prevent O 0 0.00017590921
endothelial O 0 0.9241084
NO B-Chemical 0 0.9997682
synthase O 0 0.7502688
( O 0 0.00044966183
eNOS O 0 0.09469597
) O 0 0.00019642709
downregulation O 0 0.00017777002
and O 0 7.980744e-05
the O 0 7.117351e-05
increase O 0 0.00010006695
in O 0 0.00019719571
O2 B-Chemical 0 0.9998343
- I-Chemical 0 0.0005010336
in O 0 0.00016505268
Sprague O 0 0.020268217
- O 0 0.0004042402
Dawley O 0 0.0024215241
( O 0 0.00023221498
SD O 0 0.0012209673
) O 0 0.0002555226
rats O 0 0.00025384617
, O 0 0.00023357706
thereby O 0 0.0003316964
reducing O 0 0.00075433514
blood O 0 0.010746725
pressure O 0 0.020497404
. O 0 0.0023027118

2 O 0 0.058298454
. O 0 0.06073419

Male O 0 0.012390562
SD O 0 0.010601708
rats O 0 0.0019014166
( O 0 0.0010949528
n O 0 0.0004945646
= O 0 0.0004096778
30 O 0 0.00020096623
) O 0 0.00029706696
were O 0 0.00015622021
treated O 0 0.00023500583
with O 0 0.00038639957
Ato B-Chemical 1 0.98049325
( O 0 0.00030526423
50 O 0 0.00024351108
mg O 0 0.0027785285
/ O 0 0.0003486315
kg O 0 0.00015601047
per O 0 2.4456049e-05
day O 0 3.5218687e-05
in O 0 6.76043e-05
drinking O 0 0.004174605
water O 0 0.003085585
) O 0 0.00024092408
or O 0 0.00013844801
tap O 0 0.0010075438
water O 0 0.0014869423
for O 0 0.00029116374
15 O 0 0.00042564003
days O 0 0.0005289466
. O 0 0.0015060189

Dexamethasone B-Chemical 0 0.9986426
( O 0 0.003562526
10 O 0 0.001048805
microg O 0 0.0014296909
/ O 0 0.0015370242
kg O 0 0.0007236455
per O 0 0.0001104636
day O 0 0.0001242423
, O 0 0.00018491076
s O 0 0.00018199747
. O 0 0.00012334046
c O 0 0.0009171226
. O 0 9.957494e-05
) O 0 0.00016978802
or O 0 8.996465e-05
saline O 0 0.00042558787
was O 0 8.182977e-05
started O 0 5.2147632e-05
after O 0 2.4598898e-05
4 O 0 3.7085774e-05
days O 0 2.7023054e-05
in O 0 9.709678e-05
Ato B-Chemical 1 0.97051805
- O 0 0.00034861857
treated O 0 0.00017855386
and O 0 0.00012853857
non O 0 0.00021118426
- O 0 0.00025122944
treated O 0 0.00018199573
rats O 0 0.00019356482
and O 0 0.00012094025
continued O 0 0.00014416565
for O 0 0.00016905672
11 O 0 0.00034491284
- O 0 0.0006285102
13 O 0 0.0005936654
days O 0 0.00056360575
. O 0 0.0015876158

Systolic O 0 0.100896135
blood O 0 0.0100109335
pressure O 0 0.009955398
( O 0 0.001965869
SBP O 0 0.07113975
) O 0 0.0010116402
was O 0 0.0003746856
measured O 0 0.0002018804
on O 0 0.00013818858
alternate O 0 0.00023817173
days O 0 0.00012568028
using O 0 0.00021056217
the O 0 0.00038550608
tail O 0 0.0009650173
- O 0 0.0015124875
cuff O 0 0.0037544328
method O 0 0.0029542611
. O 0 0.002654217

Endothelial O 0 0.4199391
function O 0 0.0021107441
was O 0 0.0012314322
assessed O 0 0.000648622
by O 0 0.0011868
acetylcholine B-Chemical 1 0.9997769
- O 0 0.0017477283
induced O 0 0.001065115
vasorelaxation O 0 0.99989176
and O 0 0.0030135007
phenylephrine B-Chemical 0 0.9999689
- O 0 0.0017997682
induced O 0 0.0009875773
vasoconstriction O 0 0.9976568
in O 0 0.0011120304
aortic O 0 0.08666482
segments O 0 0.0020257244
. O 0 0.0019796751

Vascular O 0 0.3194329
eNOS O 0 0.1317571
mRNA O 0 0.002631734
was O 0 0.0011044787
assessed O 0 0.00052236
by O 0 0.00058759504
semi O 0 0.001107137
- O 0 0.0008409531
quantitative O 0 0.00077111827
reverse O 0 0.0024120985
transcription O 0 0.0015347442
- O 0 0.0019779266
polymerase O 0 0.06037723
chain O 0 0.035147656
reaction O 0 0.07569728
. O 0 0.003841131

3 O 0 0.05500685
. O 0 0.05996203

In O 0 0.0018907556
rats O 0 0.0020885526
treated O 0 0.0015765273
with O 0 0.0016678807
Dex B-Chemical 1 0.9985862
alone O 0 0.0009605355
, O 0 0.0006382028
SBP O 0 0.10520915
was O 0 0.0002548613
increased O 0 0.00024062567
from O 0 0.00014174804
109 O 0 0.00046668676
+ O 0 0.0003771319
/ O 0 0.0005450049
- O 0 0.00025782004
2 O 0 7.767931e-05
to O 0 8.3435545e-05
133 O 0 0.000441389
+ O 0 0.00030714073
/ O 0 0.00044262753
- O 0 0.00021012416
2 O 0 6.6233675e-05
mmHg O 0 0.00012965221
on O 0 4.7042195e-05
Days O 0 0.00025506064
4 O 0 5.8086396e-05
and O 0 7.8056226e-05
Day O 0 0.00016348744
14 O 0 0.00010927784
, O 0 0.00018865708
respectively O 0 0.00050463266
( O 0 0.0005526048
P O 0 0.0033626135
< O 0 0.00038148207
0 O 0 0.00041403677
. O 0 0.0005960697
001 O 0 0.007988259
) O 0 0.0026949467
. O 0 0.0026572468

In O 0 0.002375516
the O 0 0.0029960845
Ato B-Chemical 1 0.98883724
+ O 0 0.0075636054
Dex B-Chemical 1 0.998451
group O 0 0.0015524242
, O 0 0.0006677375
SBP O 0 0.05833015
was O 0 0.00029730608
increased O 0 0.00028256833
from O 0 0.0001764651
113 O 0 0.00081565627
+ O 0 0.00042516517
/ O 0 0.00058441394
- O 0 0.00027290368
2 O 0 8.1941434e-05
to O 0 8.653694e-05
119 O 0 0.00034524463
+ O 0 0.0002878126
/ O 0 0.000424624
- O 0 0.00020532105
2 O 0 6.4188054e-05
mmHg O 0 0.00012548508
on O 0 4.3971148e-05
Days O 0 0.00024819528
4 O 0 5.025627e-05
to O 0 5.426737e-05
14 O 0 7.294638e-05
, O 0 0.0001217515
respectively O 0 0.0003481149
( O 0 0.00032311102
P O 0 0.0035259523
< O 0 0.00010912528
0 O 0 8.7311295e-05
. O 0 8.505677e-05
001 O 0 0.0033344913
) O 0 0.00020988067
, O 0 0.000121240344
but O 0 0.000105098916
was O 0 9.708485e-05
significantly O 0 0.00010874562
lower O 0 0.00010239755
than O 0 5.4699067e-05
SBP O 0 0.0070420722
in O 0 5.996719e-05
the O 0 6.80129e-05
group O 0 0.00011285558
treated O 0 0.00017833912
with O 0 0.00039035594
Dex B-Chemical 1 0.9989016
alone O 0 0.00075376744
( O 0 0.00096702005
P O 0 0.008541238
< O 0 0.0003664052
0 O 0 0.00038492715
. O 0 0.0005555255
05 O 0 0.005843962
) O 0 0.0023809657
. O 0 0.0024090894

Endothelial O 0 0.7190922
- O 0 0.0032819004
dependent O 0 0.00068543776
relaxation O 0 0.0059747943
and O 0 0.00086134695
eNOS O 0 0.043726817
mRNA O 0 0.0005121886
expression O 0 0.00022830196
were O 0 0.000117947304
greater O 0 0.00010348321
in O 0 0.00010139451
the O 0 0.00020804684
Dex B-Chemical 1 0.9992418
+ O 0 0.0027531881
Ato B-Chemical 1 0.99068284
group O 0 0.00020145142
than O 0 5.2810523e-05
in O 0 6.7722576e-05
the O 0 0.00013487773
Dex B-Chemical 1 0.99547595
only O 0 0.00028528692
group O 0 0.0003463827
( O 0 0.00037764042
P O 0 0.004544653
< O 0 0.00012195077
0 O 0 0.00010100629
. O 0 0.00010308029
05 O 0 0.001353283
and O 0 0.00025973562
P O 0 0.0022794344
< O 0 0.00022506157
0 O 0 0.0002225307
. O 0 0.00028329343
0001 O 0 0.0027308138
, O 0 0.0009205868
respectively O 0 0.0020539255
) O 0 0.002762741
. O 0 0.0027144249

Aortic O 0 0.5320429
superoxide B-Chemical 1 0.9995646
production O 0 0.0030072236
was O 0 0.0009067903
lower O 0 0.00056536304
in O 0 0.00031117632
the O 0 0.00047588992
Dex B-Chemical 1 0.9993148
+ O 0 0.0042024693
Ato B-Chemical 1 0.9908546
group O 0 0.00026422628
compared O 0 6.295442e-05
with O 0 9.465342e-05
the O 0 8.6684275e-05
group O 0 0.00013677812
treated O 0 0.00020761289
with O 0 0.00043529805
Dex B-Chemical 1 0.9989998
alone O 0 0.00080065563
( O 0 0.0010023572
P O 0 0.00864604
< O 0 0.00036409963
0 O 0 0.00037491857
. O 0 0.00052763685
0001 O 0 0.005374727
) O 0 0.0023482542
. O 0 0.0023972027

4 O 0 0.05549409
. O 0 0.060457766

Treatment O 0 0.005944551
with O 0 0.003287564
Ato B-Chemical 1 0.9666795
improved O 0 0.0033280284
endothelial O 0 0.6178695
function O 0 0.00094963907
, O 0 0.0007056819
reduced O 0 0.0024301612
superoxide B-Chemical 1 0.9999583
production O 0 0.0009984648
and O 0 0.00028551355
reduced O 0 0.00056582125
SBP O 0 0.2333915
in O 0 0.00055058906
Dex B-Chemical 1 0.9988927
- O 0 0.0017877179
treated O 0 0.0015608728
SD O 0 0.012254578
rats O 0 0.0028355832
. O 0 0.002138327

Severe O 0 0.4415349
citrate B-Chemical 0 0.9778365
toxicity B-Disease 2 0.9973502
complicating O 0 0.063014485
volunteer O 0 0.012991818
apheresis O 0 0.18891375
platelet O 0 0.97984856
donation O 0 0.07500535
. O 0 0.0056359326

We O 0 0.0019059186
report O 0 0.0020409557
a O 0 0.0013632058
case O 0 0.0008155167
of O 0 0.0011372571
severe O 0 0.057850737
citrate B-Chemical 0 0.98680204
toxicity B-Disease 2 0.9970306
during O 0 0.00029073237
volunteer O 0 0.0010768243
donor O 0 0.0010115062
apheresis O 0 0.023167744
platelet O 0 0.8719529
collection O 0 0.0032681061
. O 0 0.0025815007

The O 0 0.0021010581
donor O 0 0.0025458096
was O 0 0.0013259407
a O 0 0.0010287019
40 O 0 0.0008387107
- O 0 0.0009483077
year O 0 0.00031849832
- O 0 0.0005653931
old O 0 0.0003412301
female O 0 0.00073181116
, O 0 0.00025717582
first O 0 0.00016740465
- O 0 0.00043784827
time O 0 0.00025011282
apheresis O 0 0.0073897946
platelet O 0 0.83604515
donor O 0 0.0053482964
. O 0 0.0027859982

Past O 0 0.012343789
medical O 0 0.0062320093
history O 0 0.0026712855
was O 0 0.001126677
remarkable O 0 0.0011889061
for O 0 0.0012495023
hypertension B-Disease 2 0.99992824
, O 0 0.008564486
hyperlipidemia B-Disease 0 0.99996376
, O 0 0.0038782395
and O 0 0.0032177486
depression B-Disease 0 0.98680186
. O 0 0.0038625342

Reported O 0 0.0047366866
medications O 0 0.01373303
included O 0 0.0033073572
bumetanide B-Chemical 0 0.9999298
, O 0 0.01486983
pravastatin B-Chemical 0 0.9999418
, O 0 0.0065370435
and O 0 0.008021086
paroxetine B-Chemical 0 0.99991894
. O 0 0.0072308737

Thirty O 0 0.0021070754
minutes O 0 0.00074095454
from O 0 0.00052496576
the O 0 0.00038118212
start O 0 0.00020953036
of O 0 0.00032438943
the O 0 0.00023907017
procedure O 0 0.00020824216
, O 0 0.0002011031
the O 0 0.00014682724
donor O 0 0.00029713864
noted O 0 0.00018205857
tingling O 0 0.22896905
around O 0 0.00017690362
the O 0 0.0002975088
mouth O 0 0.020831857
, O 0 0.00059632596
hands O 0 0.0018770081
, O 0 0.0009475848
and O 0 0.0014647172
feet O 0 0.02223405
. O 0 0.002792921

She O 0 0.0030311833
then O 0 0.001235815
very O 0 0.001448736
rapidly O 0 0.0012295065
developed O 0 0.001525023
acute O 0 0.16551013
onset O 0 0.0013605277
of O 0 0.0011518992
severe O 0 0.02573092
facial O 0 0.068059444
and O 0 0.0029361031
extremity O 0 0.79352677
tetany B-Disease 0 0.9995877
. O 0 0.0055128336

Empirical O 0 0.002855722
treatment O 0 0.0012910091
with O 0 0.0013030313
intravenous O 0 0.23113067
calcium B-Chemical 0 0.9997588
gluconate I-Chemical 0 0.98665386
was O 0 0.0005463832
initiated O 0 0.00024246323
, O 0 0.00024295309
and O 0 0.00025470514
muscle B-Disease 0 0.08487308
contractions I-Disease 0 0.5582025
slowly O 0 0.00055128225
subsided O 0 0.00034412998
over O 0 7.257642e-05
approximately O 0 0.00017381524
10 O 0 0.00020657506
to O 0 0.00027937553
15 O 0 0.0004315017
minutes O 0 0.00070280035
. O 0 0.0017545976

The O 0 0.001704058
events O 0 0.0028211125
are O 0 0.00078529207
consistent O 0 0.0004978611
with O 0 0.0005145619
a O 0 0.0005857788
severe O 0 0.0039626504
reaction O 0 0.006596005
to O 0 0.00048952573
calcium B-Chemical 0 0.9997961
chelation O 0 0.99629056
by O 0 0.0020975003
sodium B-Chemical 0 0.9999875
citrate I-Chemical 0 0.9998023
anticoagulant O 0 0.9682009
resulting O 0 0.00043174776
in O 0 0.00042361533
symptomatic O 0 0.013244664
systemic O 0 0.9146673
hypocalcemia B-Disease 0 0.99991345
. O 0 0.004184235

Upon O 0 0.0024005098
additional O 0 0.0012937234
retrospective O 0 0.0034455652
analysis O 0 0.0008100049
, O 0 0.0006284545
it O 0 0.00037643508
was O 0 0.00026591241
noted O 0 0.00014105409
that O 0 0.00026868895
bumetanide B-Chemical 0 0.99998343
is O 0 0.00042263174
a O 0 0.00045079814
loop B-Chemical 0 0.0014635448
diuretic I-Chemical 0 0.99984634
that O 0 0.00031330623
may O 0 0.00041065182
cause O 0 0.0012918961
significant O 0 0.0026483547
hypocalcemia B-Disease 0 0.99987507
. O 0 0.0044251904

We O 0 0.0013839646
conclude O 0 0.0007742595
that O 0 0.00057399884
careful O 0 0.0006969167
screening O 0 0.0005914919
for O 0 0.0002556869
medications O 0 0.0018105676
and O 0 0.00017311443
underlying O 0 0.0002136277
conditions O 0 0.00021680642
predisposing O 0 0.0014057268
to O 0 0.00028051596
hypocalcemia B-Disease 0 0.9999485
is O 0 0.00021866863
recommended O 0 0.00011750793
to O 0 8.484905e-05
help O 0 0.0001625012
prevent O 0 0.00018074506
severe O 0 0.0035911717
reactions O 0 0.0018742685
due O 0 0.00026334272
to O 0 0.00070683344
citrate B-Chemical 0 0.97677165
toxicity B-Disease 2 0.9988979
. O 0 0.003763736

Laboratory O 0 0.0055920193
measurement O 0 0.00091346755
of O 0 0.0010836772
pre O 0 0.0013353447
- O 0 0.00091688713
procedure O 0 0.00041360717
serum O 0 0.0591506
calcium B-Chemical 0 0.9986091
levels O 0 0.00039634222
in O 0 0.00020092867
selected O 0 0.00019013377
donors O 0 0.00040269617
may O 0 0.00015996178
identify O 0 0.00019114731
cases O 0 0.00041032367
requiring O 0 0.0005272072
heightened O 0 0.0035343561
vigilance O 0 0.01635759
. O 0 0.0022862048

The O 0 0.00184148
case O 0 0.0012562829
also O 0 0.00072352344
illustrates O 0 0.00039579265
the O 0 0.00032291762
importance O 0 0.00018716337
of O 0 0.00026802145
maintaining O 0 0.0002386789
preparedness O 0 0.00028555145
for O 0 0.00016159448
managing O 0 0.00066600053
rare O 0 0.0010935487
but O 0 0.00027927166
serious O 0 0.001393073
reactions O 0 0.001529862
in O 0 0.00027440992
volunteer O 0 0.0012546817
apheresis O 0 0.01159682
blood O 0 0.011764258
donors O 0 0.004257662
. O 0 0.0021582034

Sirolimus B-Chemical 0 0.9918459
- O 0 0.011983751
associated O 0 0.006576425
proteinuria B-Disease 0 0.9997987
and O 0 0.019516496
renal B-Disease 2 0.99918133
dysfunction I-Disease 2 0.998966
. O 0 0.011246942

Sirolimus B-Chemical 0 0.97939724
is O 0 0.0019273593
a O 0 0.0011867875
novel O 0 0.0009822841
immunosuppressant O 0 0.70987743
with O 0 0.0007603275
potent O 0 0.0013224869
antiproliferative O 0 0.4780422
actions O 0 0.0008627964
through O 0 0.00011667255
its O 0 0.00019719741
ability O 0 0.000110548644
to O 0 8.4840394e-05
inhibit O 0 7.766308e-05
the O 0 0.00014870768
raptor O 0 0.0038607698
- O 0 0.0002961225
containing O 0 9.394913e-05
mammalian O 0 0.0001157201
target O 0 0.00012203592
of O 0 0.00041612677
rapamycin B-Chemical 0 0.74965113
protein O 0 0.0046146885
kinase O 0 0.04884548
. O 0 0.0027344546

Sirolimus B-Chemical 0 0.9590923
represents O 0 0.0016034197
a O 0 0.0010517285
major O 0 0.0005631662
therapeutic O 0 0.00087993854
advance O 0 0.00056559313
in O 0 0.00022766921
the O 0 0.00019726946
prevention O 0 0.0003296897
of O 0 0.0004644046
acute O 0 0.6329326
renal O 0 0.99562645
allograft O 0 0.9927901
rejection O 0 0.9968465
and O 0 0.0029868248
chronic O 0 0.99151176
allograft O 0 0.99953413
nephropathy B-Disease 2 0.9999957
. O 0 0.007327532

Its O 0 0.011139255
role O 0 0.0010950029
in O 0 0.0008231053
the O 0 0.0006599086
therapy O 0 0.0009463383
of O 0 0.0019062655
glomerulonephritis B-Disease 2 0.99997544
, O 0 0.004344729
autoimmunity B-Disease 0 0.9997002
, O 0 0.0014564146
cystic B-Disease 0 0.937907
renal I-Disease 0 0.99826765
diseases I-Disease 0 0.98160905
and O 0 0.001888778
renal B-Disease 0 0.99979645
cancer I-Disease 0 0.99961805
is O 0 0.0010061202
under O 0 0.0006996168
investigation O 0 0.0020339263
. O 0 0.0019958883

Because O 0 0.0024051093
sirolimus B-Chemical 1 0.99850035
does O 0 0.0011496526
not O 0 0.00051921455
share O 0 0.0004455394
the O 0 0.00044014637
vasomotor O 0 0.8761026
renal O 0 0.9468607
adverse O 0 0.104362555
effects O 0 0.0002581804
exhibited O 0 0.00024395654
by O 0 0.00020998876
calcineurin O 0 0.53088087
inhibitors O 0 0.0047564236
, O 0 0.00024766012
it O 0 0.00014636178
has O 0 7.8815705e-05
been O 0 7.502402e-05
designated O 0 0.00010017437
a O 0 0.00021289608
' O 0 0.00031042518
non O 0 0.0005264287
- O 0 0.0014515311
nephrotoxic B-Disease 2 0.99962914
drug O 0 0.54012334
' O 0 0.0037052876
. O 0 0.0023726881

However O 0 0.0027197148
, O 0 0.0020357447
clinical O 0 0.001928362
reports O 0 0.00077167666
suggest O 0 0.00024308052
that O 0 0.00024599914
, O 0 0.0003021804
under O 0 0.00014986428
some O 0 0.0001860293
circumstances O 0 0.0002755162
, O 0 0.00046259255
sirolimus B-Chemical 1 0.9998491
is O 0 0.00028298944
associated O 0 0.00021541514
with O 0 0.0008450924
proteinuria B-Disease 0 0.9999856
and O 0 0.0038154507
acute B-Disease 0 0.99772316
renal I-Disease 2 0.9999112
dysfunction I-Disease 2 0.99987984
. O 0 0.0055866344

A O 0 0.022708781
common O 0 0.0029518113
risk O 0 0.0077236486
factor O 0 0.0024956758
appears O 0 0.0005359376
to O 0 0.00038436044
be O 0 0.0002844949
presence O 0 0.000274264
of O 0 0.00047463187
pre O 0 0.0010168044
- O 0 0.0010352466
existing O 0 0.0014842404
chronic B-Disease 0 0.9801308
renal I-Disease 0 0.99981946
damage I-Disease 0 0.99951315
. O 0 0.0059983903

The O 0 0.0015280668
mechanisms O 0 0.0017156963
of O 0 0.0024670241
sirolimus B-Chemical 1 0.99978966
- O 0 0.003730974
associated O 0 0.0010608981
proteinuria B-Disease 0 0.9999788
are O 0 0.0006747668
multifactorial O 0 0.005535277
and O 0 0.00020791795
may O 0 0.00010307576
be O 0 7.850628e-05
due O 0 4.9345035e-05
to O 0 6.505e-05
an O 0 0.00010950575
increase O 0 0.00010587699
in O 0 0.00014131308
glomerular O 0 0.88057053
capillary O 0 0.15019901
pressure O 0 0.002179496
following O 0 0.00022936452
calcineurin O 0 0.31184292
inhibitor O 0 0.016483536
withdrawal O 0 0.17716208
. O 0 0.0024421643

It O 0 0.0028240653
has O 0 0.0010739425
also O 0 0.00071375346
been O 0 0.00041498351
suggested O 0 0.00027693703
that O 0 0.0003345974
sirolimus B-Chemical 1 0.9997323
directly O 0 0.00031464762
causes O 0 0.00037355605
increased O 0 0.00073084765
glomerular O 0 0.9964588
permeability O 0 0.9770463
/ O 0 0.005240624
injury O 0 0.36402333
, O 0 0.00030081705
but O 0 0.00016423994
evidence O 0 0.000108815
for O 0 0.00010944219
this O 0 0.00024903845
mechanism O 0 0.00038194875
is O 0 0.0005249951
currently O 0 0.0011207254
inconclusive O 0 0.009110098
. O 0 0.0023404073

The O 0 0.00279506
acute B-Disease 0 0.9375883
renal I-Disease 2 0.99948466
dysfunction I-Disease 2 0.9997484
associated O 0 0.001147308
with O 0 0.0018807602
sirolimus B-Chemical 1 0.99995184
( O 0 0.0005750268
such O 0 0.00010456641
as O 0 0.000100621466
in O 0 9.3122835e-05
delayed O 0 0.00045967315
graft O 0 0.0008382353
function O 0 0.00021534716
) O 0 0.00019744897
may O 0 6.315719e-05
be O 0 5.288501e-05
due O 0 3.50108e-05
to O 0 5.007754e-05
suppression O 0 0.00014865606
of O 0 0.00016726904
compensatory O 0 0.00093613204
renal O 0 0.97144395
cell O 0 0.010192078
proliferation O 0 0.38303775
and O 0 0.0004749215
survival O 0 0.0039000206
/ O 0 0.0017280853
repair O 0 0.0014224998
processes O 0 0.0016737154
. O 0 0.001870544

Although O 0 0.0016059796
these O 0 0.0017640212
adverse O 0 0.0095280735
effects O 0 0.000764868
occur O 0 0.00032521595
in O 0 0.00024963063
some O 0 0.0002514475
patients O 0 0.0003402452
, O 0 0.00018903486
their O 0 0.00016311811
occurrence O 0 0.00020121741
could O 0 8.5922526e-05
be O 0 7.3012634e-05
minimised O 0 7.729899e-05
by O 0 7.391197e-05
knowledge O 0 0.00010111991
of O 0 7.940913e-05
the O 0 6.326985e-05
molecular O 0 0.00039060833
effects O 0 0.000105319436
of O 0 0.00026128348
sirolimus B-Chemical 1 0.9998895
on O 0 6.688884e-05
the O 0 0.00012908132
kidney O 0 0.5811483
, O 0 0.00011791155
the O 0 6.0268052e-05
use O 0 5.352674e-05
of O 0 0.00015827903
sirolimus B-Chemical 1 0.99982953
in O 0 7.9899895e-05
appropriate O 0 4.3011176e-05
patient O 0 8.055477e-05
populations O 0 9.048293e-05
, O 0 5.2596173e-05
close O 0 3.5316018e-05
monitoring O 0 5.2897973e-05
of O 0 0.00019952755
proteinuria B-Disease 0 0.99998975
and O 0 0.00036873884
renal O 0 0.8529461
function O 0 0.00017957934
, O 0 9.00716e-05
use O 0 5.5940265e-05
of O 0 0.00021372753
angiotensin B-Chemical 1 0.9999795
- O 0 0.00073918083
converting O 0 0.005269446
enzyme O 0 0.0065873186
inhibitors O 0 0.00065453316
or O 0 0.00021771
angiotensin B-Chemical 1 0.9999944
II I-Chemical 1 0.87057966
receptor O 0 0.21385978
blockers O 0 0.99859744
if O 0 0.00029387645
proteinuria B-Disease 0 0.9999845
occurs O 0 0.0003464747
and O 0 0.0003768997
withdrawal O 0 0.0047616675
if O 0 0.00045693223
needed O 0 0.00093287195
. O 0 0.0017569028

Further O 0 0.00292458
long O 0 0.00164095
- O 0 0.0014147292
term O 0 0.00045540772
analysis O 0 0.00037591756
of O 0 0.00051005365
renal O 0 0.755988
allograft O 0 0.68952566
studies O 0 0.00033184976
using O 0 0.00019715025
sirolimus B-Chemical 1 0.9997793
as O 0 0.0002052279
de O 0 0.00048542136
novo O 0 0.0010639244
immunosuppression O 0 0.42784756
along O 0 7.587819e-05
with O 0 0.00012775601
clinical O 0 0.0002713023
and O 0 0.000100611
laboratory O 0 0.00015877014
studies O 0 9.767935e-05
will O 0 9.520261e-05
refine O 0 0.00037649876
these O 0 0.00025522363
issues O 0 0.00030170166
in O 0 0.00036281618
the O 0 0.0006543563
future O 0 0.0013924801
. O 0 0.0020373287

Proteinuria B-Disease 2 0.99864215
after O 0 0.0017179938
conversion O 0 0.005132309
to O 0 0.0020866075
sirolimus B-Chemical 1 0.99929655
in O 0 0.002966578
renal O 0 0.9609008
transplant O 0 0.33347318
recipients O 0 0.020342903
. O 0 0.004232681

Sirolimus B-Chemical 0 0.99573094
( O 0 0.018317008
SRL B-Chemical 0 0.9993399
) O 0 0.004650424
is O 0 0.0015041084
a O 0 0.0014721474
new O 0 0.0014663467
, O 0 0.0015823857
potent O 0 0.0039669704
immunosuppressive O 0 0.68103635
agent O 0 0.058182042
. O 0 0.0057851784

More O 0 0.008366746
recently O 0 0.0022180828
, O 0 0.0035769192
proteinuria B-Disease 0 0.99991393
has O 0 0.0008489212
been O 0 0.00035488297
reported O 0 0.000312648
as O 0 0.00016993006
a O 0 0.00018126333
consequence O 0 0.00010475433
of O 0 0.00044704945
sirolimus B-Chemical 1 0.9999436
therapy O 0 0.00088810356
, O 0 0.00025477144
although O 0 0.00015301544
the O 0 0.00020320385
mechanism O 0 0.0003477107
has O 0 0.00036792416
remained O 0 0.0009422124
unclear O 0 0.0012045216
. O 0 0.0020844273

We O 0 0.0012792585
retrospectively O 0 0.0010029993
examined O 0 0.0004467623
the O 0 0.00042405448
records O 0 0.00053480035
of O 0 0.00037730217
25 O 0 0.0004996822
renal O 0 0.59305215
transplant O 0 0.033682086
patients O 0 0.0005112145
, O 0 0.00020305258
who O 0 0.00021007867
developed O 0 0.00018936986
or O 0 0.00012482287
displayed O 0 0.00022308642
increased O 0 0.0013272566
proteinuria B-Disease 0 0.9999807
after O 0 0.0008733069
SRL B-Chemical 0 0.99981266
conversion O 0 0.054945152
. O 0 0.0026830288

The O 0 0.0018747599
patient O 0 0.0020311892
cohort O 0 0.0028920632
( O 0 0.0010982382
14 O 0 0.00053406996
men O 0 0.0012850937
, O 0 0.00035875454
11 O 0 0.00027071574
women O 0 0.0005169718
) O 0 0.00024700997
was O 0 0.00013505894
treated O 0 0.0002025116
with O 0 0.00041070243
SRL B-Chemical 0 0.99991393
as O 0 0.0002011938
conversion O 0 0.0011923187
therapy O 0 0.00017935585
, O 0 8.7817636e-05
due O 0 4.4094264e-05
to O 0 9.971518e-05
chronic B-Disease 0 0.80271435
allograft I-Disease 0 0.9992461
nephropathy I-Disease 2 0.99999976
( O 0 0.01780756
CAN B-Disease 0 0.9995541
) O 0 0.00046222162
( O 0 0.00015801046
n O 0 8.2320505e-05
= O 0 0.00010015337
15 O 0 7.1994225e-05
) O 0 0.00028785077
neoplasia B-Disease 0 0.9765984
( O 0 0.0002099111
n O 0 9.5251366e-05
= O 0 0.000109927074
8 O 0 6.964746e-05
) O 0 0.00015908654
; O 0 0.00018192946
Kaposi B-Disease 0 0.113846
' I-Disease 0 0.00020689478
s I-Disease 0 0.00019656426
sarcoma I-Disease 0 0.84755594
, O 0 0.0001921161
Four O 0 0.00020756222
skin B-Disease 0 0.44285727
cancers I-Disease 0 0.9976826
, O 0 0.00023010575
One O 0 0.00016170976
intestinal B-Disease 0 0.54362
tumors I-Disease 0 0.9864932
, O 0 0.0002113845
One O 0 0.0001580156
renal B-Disease 0 0.98665255
cell I-Disease 0 0.0057954113
carsinom I-Disease 0 0.19999973
) O 0 0.00036532935
or O 0 0.00024279492
BK O 0 0.9991246
virus O 0 0.34636903
nephropathy B-Disease 2 0.9999964
( O 0 0.0016505828
n O 0 0.00046983943
= O 0 0.00066023634
2 O 0 0.0006532904
) O 0 0.0016762295
. O 0 0.0019801173

SRL B-Chemical 0 0.99844813
was O 0 0.0025618162
started O 0 0.0009830873
at O 0 0.00046587051
a O 0 0.000494645
mean O 0 0.00020542563
of O 0 0.00041556926
78 O 0 0.00072619197
+ O 0 0.0007185822
/ O 0 0.00093610125
- O 0 0.00048676739
42 O 0 0.00025869734
( O 0 0.00022585543
15 O 0 0.00012366548
to O 0 0.00017655919
163 O 0 0.0008195891
) O 0 0.00042485422
months O 0 0.00018486385
after O 0 0.00033185957
transplantation O 0 0.004756877
. O 0 0.002437376

Mean O 0 0.0014139235
follow O 0 0.0011099834
- O 0 0.0014476314
up O 0 0.00070836535
on O 0 0.0005697056
SRL B-Chemical 0 0.9993814
therapy O 0 0.0012126028
was O 0 0.0004918846
20 O 0 0.00035395636
+ O 0 0.00064981054
/ O 0 0.00090889627
- O 0 0.0004922355
12 O 0 0.00016379391
( O 0 0.00030350534
6 O 0 0.00017875213
to O 0 0.00031443438
43 O 0 0.0008546961
) O 0 0.001172589
months O 0 0.00078579277
. O 0 0.00200623

Proteinuria B-Disease 2 0.9991831
increased O 0 0.003341341
from O 0 0.0010334423
0 O 0 0.00070493645
. O 0 0.00042742462
445 O 0 0.0022369877
( O 0 0.0004235037
0 O 0 0.00018618742
to O 0 0.00015133934
1 O 0 0.00014187097
. O 0 9.040083e-05
5 O 0 9.390157e-05
) O 0 0.00018044715
g O 0 0.00028644304
/ O 0 0.00028773115
d O 0 0.00011586651
before O 0 4.4541146e-05
conversion O 0 0.0003147769
to O 0 8.483352e-05
3 O 0 6.768745e-05
. O 0 4.9128812e-05
2 O 0 6.223082e-05
g O 0 0.000211174
/ O 0 0.00036080182
dL O 0 0.00084635353
( O 0 0.00016450262
0 O 0 7.90985e-05
. O 0 5.3232056e-05
2 O 0 5.642987e-05
to O 0 5.9713937e-05
12 O 0 5.938508e-05
) O 0 0.00013269782
after O 0 6.2788706e-05
conversion O 0 0.00087530207
( O 0 0.00060486473
P O 0 0.0048265005
= O 0 0.0004852201
0 O 0 0.00039874014
. O 0 0.0005744357
001 O 0 0.0077576907
) O 0 0.002621799
. O 0 0.0025946763

Before O 0 0.0028179644
conversion O 0 0.0050083473
8 O 0 0.0011710286
( O 0 0.001091792
32 O 0 0.0007357478
% O 0 0.0005556623
) O 0 0.0005626608
patients O 0 0.00039098947
had O 0 0.0002749345
no O 0 0.00029162518
proteinuria B-Disease 0 0.9999746
, O 0 0.00073516736
whereas O 0 0.0003466989
afterwards O 0 0.00052418356
all O 0 0.0003839151
patients O 0 0.0010007961
had O 0 0.0019243831
proteinuria B-Disease 0 0.9999206
. O 0 0.0044402317

In O 0 0.0019486999
28 O 0 0.0014145944
% O 0 0.0010038534
of O 0 0.0009054219
patients O 0 0.0019313432
proteinuria B-Disease 0 0.9999517
remained O 0 0.0015800828
unchanged O 0 0.0005533952
, O 0 0.0003467294
whereas O 0 0.00024158126
it O 0 0.00025301278
increased O 0 0.00040346442
in O 0 0.0003129743
68 O 0 0.00058920373
% O 0 0.00052544835
of O 0 0.0009754679
patients O 0 0.0023076863
. O 0 0.0021836984

In O 0 0.0029900228
40 O 0 0.0028877843
% O 0 0.0021246113
it O 0 0.0014464229
increased O 0 0.0016405946
by O 0 0.0012600877
more O 0 0.0015601494
than O 0 0.0012949851
100 O 0 0.00395981
% O 0 0.0036734445
. O 0 0.0040680086

Twenty O 0 0.0040535643
- O 0 0.0021907694
eight O 0 0.00051790295
percent O 0 0.00041098465
of O 0 0.00057332637
patients O 0 0.00064828206
showed O 0 0.00050211174
increased O 0 0.0018149301
proteinuria B-Disease 0 0.99996233
to O 0 0.0014356177
the O 0 0.002580185
nephrotic B-Disease 0 0.9999503
range O 0 0.0047063436
. O 0 0.0029366545

Biopsies O 0 0.0037587548
performed O 0 0.0011155647
in O 0 0.00070984964
five O 0 0.00037061615
patients O 0 0.00049219694
revealed O 0 0.00030056018
new O 0 0.00037787488
pathological O 0 0.0018388516
changes O 0 0.00045152087
: O 0 0.0005212816
One O 0 0.0009502196
membranoproliferative B-Disease 0 0.99999213
glomerulopathy I-Disease 0 0.99999607
and O 0 0.021022854
interstitial B-Disease 0 0.9965753
nephritis I-Disease 0 0.99998784
. O 0 0.008250307

These O 0 0.0046460293
patients O 0 0.0041453526
showed O 0 0.0027822752
persistently O 0 0.0069530043
good O 0 0.0050744773
graft O 0 0.010638289
function O 0 0.006030423
. O 0 0.0061462075

Serum O 0 0.67254
creatinine B-Chemical 1 0.99731016
values O 0 0.0016922428
did O 0 0.00083345507
not O 0 0.00041866137
change O 0 0.0003953631
significantly O 0 0.0004951412
: O 0 0.00037197748
1 O 0 0.00017666696
. O 0 0.000112799964
98 O 0 0.00046893177
+ O 0 0.00037630426
/ O 0 0.0005341677
- O 0 0.0002666141
0 O 0 8.643096e-05
. O 0 5.3083582e-05
8 O 0 6.1600644e-05
mg O 0 0.0007964434
/ O 0 0.00034472512
dL O 0 0.00063301617
before O 0 6.981336e-05
SRL B-Chemical 0 0.999577
therapy O 0 0.00026022043
and O 0 0.00012074263
2 O 0 7.7259414e-05
. O 0 5.4285592e-05
53 O 0 0.00014774318
+ O 0 0.00023433706
/ O 0 0.00043312993
- O 0 0.000239902
1 O 0 7.588977e-05
. O 0 4.862125e-05
9 O 0 6.5939435e-05
mg O 0 0.0008059001
/ O 0 0.00033187037
dL O 0 0.00039786132
at O 0 5.4225882e-05
last O 0 4.1599556e-05
follow O 0 7.6340526e-05
- O 0 0.00025099958
up O 0 0.00025182945
( O 0 0.0006177447
P O 0 0.00549942
= O 0 0.000635849
. O 0 0.00043624765
14 O 0 0.0008527555
) O 0 0.0020493572
. O 0 0.0023600254

Five O 0 0.003996479
grafts O 0 0.0034641575
were O 0 0.0013391426
lost O 0 0.0011037214
and O 0 0.0008585152
the O 0 0.0008211808
patients O 0 0.0011724505
returned O 0 0.0012288099
to O 0 0.0016412883
dialysis O 0 0.01231006
. O 0 0.0037954217

Five O 0 0.0051014055
patients O 0 0.003955933
displayed O 0 0.0037020114
CAN B-Disease 0 0.9734125
and O 0 0.0051127495
Kaposi B-Disease 0 0.79796433
' I-Disease 0 0.0051934314
s I-Disease 0 0.005097434
sarcoma I-Disease 0 0.9577323
. O 0 0.006968727

Mean O 0 0.0012758868
urinary O 0 0.0063983104
protein O 0 0.0012628296
of O 0 0.0007580695
patients O 0 0.0006241954
who O 0 0.00038110532
returned O 0 0.0001942676
to O 0 0.00016624725
dialysis O 0 0.0013319624
was O 0 0.00019198864
1 O 0 9.794629e-05
. O 0 6.2321385e-05
26 O 0 0.00012301323
( O 0 0.000119731165
0 O 0 6.9047725e-05
. O 0 4.8011716e-05
5 O 0 4.80567e-05
to O 0 5.783215e-05
3 O 0 5.8968162e-05
. O 0 4.761059e-05
5 O 0 5.7171066e-05
) O 0 0.00012321585
g O 0 0.00021438878
/ O 0 0.00023147532
d O 0 9.462201e-05
before O 0 3.567737e-05
and O 0 8.35474e-05
4 O 0 6.242726e-05
. O 0 4.9669277e-05
7 O 0 5.5220084e-05
( O 0 9.5931195e-05
3 O 0 5.0948976e-05
to O 0 5.6223387e-05
12 O 0 5.6009925e-05
) O 0 0.00014636401
g O 0 0.00025901204
/ O 0 0.00029802948
d O 0 0.00015108846
after O 0 7.9973826e-05
conversion O 0 0.0011255912
( O 0 0.0007984887
P O 0 0.0073267133
= O 0 0.0007916356
. O 0 0.0006066221
01 O 0 0.0029074687
) O 0 0.0024058963
. O 0 0.0025055488

Mean O 0 0.0015904686
serum O 0 0.024881233
creatinine B-Chemical 1 0.99349546
level O 0 0.00077334774
before O 0 0.00030723063
conversion O 0 0.0015923323
was O 0 0.00037101354
2 O 0 0.00016952904
. O 0 9.989334e-05
21 O 0 0.0001471245
mg O 0 0.0017559477
/ O 0 0.0006007494
dL O 0 0.001000919
and O 0 0.00015383468
thereafter O 0 0.0001171039
, O 0 0.00012532438
4 O 0 7.486007e-05
. O 0 6.843605e-05
93 O 0 0.00028503133
mg O 0 0.0022278563
/ O 0 0.000923371
dL O 0 0.0027180442
( O 0 0.00085856835
P O 0 0.006351485
= O 0 0.0007924206
. O 0 0.00064205896
02 O 0 0.006263646
) O 0 0.002594089
. O 0 0.0025381502

Heavy O 0 0.9505329
proteinuria B-Disease 0 0.99982494
was O 0 0.0023313153
common O 0 0.00069431745
after O 0 0.00020025505
the O 0 0.00030414434
use O 0 0.00030505122
of O 0 0.00078245054
SRL B-Chemical 0 0.99970585
as O 0 0.0005092631
rescue O 0 0.00078838726
therapy O 0 0.0007576794
for O 0 0.00068057375
renal O 0 0.9363317
transplantation O 0 0.114481725
. O 0 0.0029968652

Therefore O 0 0.002237226
, O 0 0.0023952718
conversion O 0 0.002861088
should O 0 0.000427434
be O 0 0.000361908
considered O 0 0.00022726167
for O 0 0.000211422
patients O 0 0.00040198446
who O 0 0.00036303472
have O 0 0.00016053388
not O 0 0.00022939993
developed O 0 0.0007899774
advanced O 0 0.02065681
CAN B-Disease 0 0.9988481
and O 0 0.0065035643
proteinuria B-Disease 0 0.99995077
. O 0 0.005227862

The O 0 0.0018502726
possibility O 0 0.001199076
of O 0 0.0014493045
de O 0 0.0023430465
novo O 0 0.0038532123
glomerular O 0 0.9578021
pathology O 0 0.017029602
under O 0 0.00057452574
SRL B-Chemical 0 0.99971956
treatment O 0 0.0003802759
requires O 0 0.00017329297
further O 0 0.00049001444
investigation O 0 0.000828458
by O 0 0.0010688859
renal O 0 0.94346356
biopsy O 0 0.011346834
. O 0 0.0024684775

Long O 0 0.007700156
- O 0 0.0025350293
term O 0 0.0007567457
follow O 0 0.0004395453
- O 0 0.0006103686
up O 0 0.00030451137
of O 0 0.00061577454
ifosfamide B-Chemical 0 0.9997942
renal B-Disease 0 0.9999136
toxicity I-Disease 2 0.99997246
in O 0 0.00039238727
children O 0 0.00033132252
treated O 0 0.00024489177
for O 0 0.00016899289
malignant B-Disease 0 0.96396816
mesenchymal I-Disease 0 0.9811122
tumors I-Disease 0 0.99951077
: O 0 0.00031195994
an O 0 0.00019151054
International O 0 0.00017383398
Society O 0 0.00019748663
of O 0 0.0002721393
Pediatric O 0 0.00041624898
Oncology O 0 0.0008909098
report O 0 0.0015618348
. O 0 0.0018054087

The O 0 0.0021207652
renal O 0 0.12522481
function O 0 0.0010480847
of O 0 0.000715334
74 O 0 0.00069136254
children O 0 0.00046677934
with O 0 0.0004776487
malignant B-Disease 0 0.92670524
mesenchymal I-Disease 0 0.95960677
tumors I-Disease 0 0.99895144
in O 0 0.00012929123
complete O 0 0.00011160029
remission O 0 0.0035643375
and O 0 8.0639e-05
who O 0 9.065237e-05
have O 0 2.9477938e-05
received O 0 2.7097532e-05
the O 0 3.573284e-05
same O 0 4.038868e-05
ifosfamide B-Chemical 0 0.99448806
chemotherapy O 0 0.0022281373
protocol O 0 0.00013737322
( O 0 9.828414e-05
International O 0 6.173408e-05
Society O 0 5.8535585e-05
of O 0 6.213055e-05
Pediatric O 0 6.4011525e-05
Oncology O 0 0.00013729467
Malignant B-Disease 0 0.0015571453
Mesenchymal I-Disease 0 0.0015516999
Tumor I-Disease 0 0.624652
Study O 0 0.00019442399
84 O 0 0.000119721815
[ O 0 0.00013669208
SIOP O 0 0.00017591356
MMT O 0 0.025291402
84 O 0 0.0002142349
] O 0 0.00023528743
) O 0 0.00013409101
were O 0 8.197582e-05
studied O 0 9.7993194e-05
1 O 0 7.12972e-05
year O 0 5.324897e-05
after O 0 4.7616304e-05
the O 0 0.00014593868
completion O 0 0.0001993467
of O 0 0.0007226546
treatment O 0 0.0014878318
. O 0 0.0021704857

Total O 0 0.002299141
cumulative O 0 0.002186498
doses O 0 0.003598906
were O 0 0.0005572583
36 O 0 0.00031049532
or O 0 0.00018041462
60 O 0 0.0001809437
g O 0 0.00036116008
/ O 0 0.00037035038
m2 O 0 0.00076750346
of O 0 0.00035737976
ifosfamide B-Chemical 0 0.998393
( O 0 0.00022706113
six O 0 4.5594064e-05
or O 0 5.144761e-05
10 O 0 5.044459e-05
cycles O 0 4.601874e-05
of O 0 0.00020267462
ifosfamide B-Chemical 0 0.9989311
, I-Chemical 0 0.000812552
vincristine I-Chemical 1 0.999551
, I-Chemical 0 0.0005633008
and I-Chemical 0 0.000628615
dactinomycin I-Chemical 0 0.96323055
[ O 0 0.015316491
IVA B-Chemical 0 0.9998671
] O 0 0.0064525697
) O 0 0.0029658615
. O 0 0.0023651381

None O 0 0.00542187
of O 0 0.0036187905
them O 0 0.003898713
had O 0 0.002728394
received O 0 0.003370533
cisplatin B-Chemical 0 0.99612856
chemotherapy O 0 0.24439074
. O 0 0.0075428025

Ages O 0 0.004967711
ranged O 0 0.0015447682
from O 0 0.00086147664
4 O 0 0.0005248805
months O 0 0.00023439447
to O 0 0.00030678752
17 O 0 0.0004494733
years O 0 0.00029431493
; O 0 0.00033589872
58 O 0 0.00037862564
patients O 0 0.0003850882
were O 0 0.00035780808
males O 0 0.00060366595
and O 0 0.00056485715
42 O 0 0.0010606161
females O 0 0.0017688012
. O 0 0.0020168053

The O 0 0.0023547357
most O 0 0.002479598
common O 0 0.0016049234
primary O 0 0.0015595119
tumor B-Disease 0 0.091222934
site O 0 0.0010164527
was O 0 0.0010839403
the O 0 0.0011196818
head O 0 0.0062573566
and O 0 0.0030300785
neck O 0 0.06553393
. O 0 0.0044988366

Renal O 0 0.0160742
function O 0 0.001819471
was O 0 0.00096808566
investigated O 0 0.00042280383
by O 0 0.0003396894
measuring O 0 0.00022627918
plasma O 0 0.00153238
and O 0 0.00026926037
urinary O 0 0.12192647
electrolytes O 0 0.9758035
, O 0 0.0011003708
glucosuria B-Disease 0 0.9999827
, O 0 0.0025496532
proteinuria B-Disease 0 0.9999963
, O 0 0.0035977096
aminoaciduria B-Disease 0 0.99999475
, O 0 0.00064999366
urinary O 0 0.34680322
pH O 0 0.05183724
, O 0 0.0002439754
osmolarity O 0 0.65483654
, O 0 0.00037993782
creatinine B-Chemical 1 0.9990736
clearance O 0 0.042598043
, O 0 0.0004261727
phosphate B-Chemical 0 0.98644036
tubular O 0 0.7746894
reabsorption O 0 0.9917605
, O 0 0.0007413339
beta O 0 0.73969734
2 O 0 0.0003797931
microglobulinuria O 0 0.07455625
, O 0 0.0007757222
and O 0 0.0012525443
lysozymuria O 0 0.8560738
. O 0 0.0026885876

Fifty O 0 0.0068551037
- O 0 0.0027098092
eight O 0 0.00070287776
patients O 0 0.0009324832
( O 0 0.0007006968
78 O 0 0.0006279018
% O 0 0.00034182335
) O 0 0.00033353717
had O 0 0.00018512264
normal O 0 0.0005138473
renal O 0 0.7594578
tests O 0 0.00079003425
, O 0 0.00018904894
whereas O 0 0.00013845711
16 O 0 0.00014066214
patients O 0 0.0002198393
( O 0 0.00023619637
22 O 0 0.00024166258
% O 0 0.0002884018
) O 0 0.0005485289
had O 0 0.000824785
renal B-Disease 0 0.99764484
abnormalities I-Disease 0 0.94885653
. O 0 0.0033814746

Two O 0 0.0021444305
subsets O 0 0.001719176
of O 0 0.0010903416
patients O 0 0.00081483903
were O 0 0.00033099134
identified O 0 0.00017259146
from O 0 0.00012972223
this O 0 0.00016656653
latter O 0 0.00037273823
group O 0 0.00018844512
: O 0 0.00011043381
the O 0 5.941828e-05
first O 0 3.8645587e-05
included O 0 5.1379848e-05
four O 0 4.6920693e-05
patients O 0 0.00012790802
( O 0 0.00010381806
5 O 0 4.3163538e-05
% O 0 5.0299037e-05
of O 0 5.4904296e-05
the O 0 5.077373e-05
total O 0 7.7998266e-05
population O 0 0.00024270029
) O 0 0.00016019808
who O 0 0.00011144864
developed O 0 0.000107640466
major O 0 0.0001099189
toxicity B-Disease 2 0.9725566
resulting O 0 0.00018130189
in O 0 0.00014886573
Fanconi B-Disease 0 0.75403655
' I-Disease 0 0.00021504062
s I-Disease 0 0.00015870143
syndrome I-Disease 0 0.07664186
( O 0 0.00046029143
TDFS B-Disease 0 0.97309136
) O 0 0.00029299856
; O 0 9.6600954e-05
and O 0 5.595158e-05
the O 0 4.7217392e-05
second O 0 5.089857e-05
group O 0 6.612854e-05
included O 0 3.8022994e-05
five O 0 3.3112738e-05
patients O 0 8.93564e-05
with O 0 0.00012657302
elevated O 0 0.0028623778
beta O 0 0.84630996
2 O 0 0.00026113726
microglobulinuria O 0 0.06289318
and O 0 0.00045642312
low O 0 0.0021490105
phosphate B-Chemical 0 0.9942644
reabsorption O 0 0.9944899
. O 0 0.0034371417

The O 0 0.002085581
remaining O 0 0.0019775236
seven O 0 0.0013294055
patients O 0 0.0016045766
had O 0 0.0012539552
isolated O 0 0.0016401899
beta O 0 0.6680557
2 O 0 0.0030962345
microglobulinuria O 0 0.2995011
. O 0 0.004960301

Severe O 0 0.42603967
toxicity B-Disease 2 0.9949532
was O 0 0.0013969742
correlated O 0 0.00038472298
with O 0 0.00036531544
the O 0 0.0002214394
higher O 0 0.00022331903
cumulative O 0 0.00030127796
dose O 0 0.00051912275
of O 0 0.00015551127
60 O 0 0.000106523796
g O 0 0.00024133101
/ O 0 0.00025992538
m2 O 0 0.00065138395
of O 0 0.00029535926
ifosfamide B-Chemical 0 0.9990883
, O 0 0.00024324561
a O 0 0.00026008155
younger O 0 0.002259912
age O 0 0.00016698935
( O 0 0.00012368742
less O 0 8.319395e-05
than O 0 5.8855072e-05
2 O 0 6.592818e-05
1 O 0 6.539332e-05
/ O 0 0.00018837505
2 O 0 7.213909e-05
years O 0 7.365164e-05
old O 0 0.000117282245
) O 0 0.00019250152
, O 0 0.00015208231
and O 0 0.00015826726
a O 0 0.0002652897
predominance O 0 0.00045397368
of O 0 0.00063475064
vesicoprostatic O 0 0.007279378
tumor B-Disease 0 0.4944292
involvement O 0 0.0047701625
. O 0 0.0025091278

This O 0 0.004026289
low O 0 0.0026742036
percentage O 0 0.0010498967
( O 0 0.001106017
5 O 0 0.00043499607
% O 0 0.00049252075
) O 0 0.00053007965
of O 0 0.0005253192
TDFS O 0 0.8055955
must O 0 0.00010295298
be O 0 9.752746e-05
evaluated O 0 7.181664e-05
with O 0 8.754707e-05
respect O 0 5.000424e-05
to O 0 5.5816006e-05
the O 0 6.992869e-05
efficacy O 0 0.00013610562
of O 0 0.00027565862
ifosfamide B-Chemical 0 0.99786735
in O 0 0.00015312943
the O 0 0.00014274266
treatment O 0 0.0002062053
of O 0 0.0006028739
mesenchymal B-Disease 0 0.895546
tumors I-Disease 0 0.9922889
in O 0 0.0012082717
children O 0 0.0026288056
. O 0 0.0019819925

Progressive O 0 0.46780786
myopathy B-Disease 2 0.99853575
with O 0 0.0024429287
up O 0 0.0012043242
- O 0 0.0009480665
regulation O 0 0.00026738105
of O 0 0.0005569907
MHC O 0 0.01147381
- O 0 0.0013431534
I O 0 0.0026356645
associated O 0 0.000604882
with O 0 0.0017497719
statin B-Chemical 1 0.9979571
therapy O 0 0.005643602
. O 0 0.0029024389

Statins B-Chemical 0 0.9982734
can O 0 0.0022982769
cause O 0 0.0025456545
a O 0 0.0033175524
necrotizing O 0 0.9995881
myopathy B-Disease 2 0.99994314
and O 0 0.003507641
hyperCKaemia B-Disease 0 0.8929422
which O 0 0.00061559066
is O 0 0.00033851358
reversible O 0 0.0033911816
on O 0 0.00019683302
cessation O 0 0.00048753427
of O 0 0.0006622296
the O 0 0.0010618394
drug O 0 0.032858014
. O 0 0.0025862677

What O 0 0.008203902
is O 0 0.0018771243
less O 0 0.001163807
well O 0 0.00064954185
known O 0 0.00069083564
is O 0 0.00039396712
a O 0 0.0004164673
phenomenon O 0 0.00088775327
whereby O 0 0.00043101472
statins B-Chemical 0 0.9995016
may O 0 0.00018921861
induce O 0 0.00012907406
a O 0 0.00083865237
myopathy B-Disease 2 0.9998524
, O 0 0.00032869613
which O 0 0.00018551067
persists O 0 9.279141e-05
or O 0 9.864807e-05
may O 0 0.000107342385
progress O 0 0.00022903475
after O 0 0.00010626125
stopping O 0 0.0006994978
the O 0 0.0007976943
drug O 0 0.020456605
. O 0 0.0021847354

We O 0 0.0025801198
investigated O 0 0.002115316
the O 0 0.0023188675
muscle O 0 0.007482554
pathology O 0 0.006996182
in O 0 0.0016409828
8 O 0 0.0014121835
such O 0 0.0017234791
cases O 0 0.00410138
. O 0 0.0043589845

All O 0 0.002679303
had O 0 0.002823289
myofibre O 0 0.17341088
necrosis B-Disease 2 0.9975454
but O 0 0.0018444976
only O 0 0.0010930644
3 O 0 0.00068934733
had O 0 0.0009016332
an O 0 0.0019348981
inflammatory O 0 0.22496134
infiltrate O 0 0.36671928
. O 0 0.0045427354

In O 0 0.0020078458
all O 0 0.001477843
cases O 0 0.0010859768
there O 0 0.00045843745
was O 0 0.0006553327
diffuse O 0 0.0016800986
or O 0 0.00037841487
multifocal O 0 0.124680325
up O 0 0.00031372378
- O 0 0.0002716737
regulation O 0 7.300742e-05
of O 0 0.00020116022
MHC O 0 0.011568749
- O 0 0.00063016266
I O 0 0.0015993523
expression O 0 0.00027506347
even O 0 0.00027451906
in O 0 0.0003064785
non O 0 0.00081656064
- O 0 0.0018109902
necrotic B-Disease 0 0.36690167
fibres O 0 0.009532241
. O 0 0.0024663366

Progressive O 0 0.016780572
improvement O 0 0.0016268442
occurred O 0 0.00071605283
in O 0 0.0004557512
7 O 0 0.000246716
cases O 0 0.00021102403
after O 0 7.283621e-05
commencement O 0 0.00014617795
of O 0 0.0005015193
prednisolone B-Chemical 0 0.999918
and O 0 0.0019722756
methotrexate B-Chemical 0 0.9998933
, O 0 0.0006053293
and O 0 0.00034600118
in O 0 0.0003226979
one O 0 0.00039739016
case O 0 0.00093724224
spontaneously O 0 0.004394983
. O 0 0.0022005788

These O 0 0.0021119118
observations O 0 0.0014971494
suggest O 0 0.0005511256
that O 0 0.0007896677
statins B-Chemical 0 0.99819297
may O 0 0.00037736312
initiate O 0 0.00016414632
an O 0 0.00036876975
immune O 0 0.014247136
- O 0 0.00079468224
mediated O 0 0.00022342615
myopathy B-Disease 2 0.9995334
that O 0 0.00011160349
persists O 0 7.0874004e-05
after O 0 3.685559e-05
withdrawal O 0 0.00094563665
of O 0 0.00014358276
the O 0 0.00014034731
drug O 0 0.002054023
and O 0 0.00018890099
responds O 0 0.00023174452
to O 0 0.00039999324
immunosuppressive O 0 0.21000591
therapy O 0 0.0031731261
. O 0 0.0021168757

The O 0 0.0016009171
mechanism O 0 0.0014812441
of O 0 0.0014319577
this O 0 0.002275536
myopathy B-Disease 2 0.99963737
is O 0 0.00077539246
uncertain O 0 0.0004897327
but O 0 0.00023887468
may O 0 0.00010349515
involve O 0 6.811533e-05
the O 0 8.639643e-05
induction O 0 0.00014411715
by O 0 0.00023406216
statins B-Chemical 0 0.99809235
of O 0 0.0001863682
an O 0 0.0001736466
endoplasmic O 0 0.0042946017
reticulum O 0 0.00109303
stress O 0 0.00047038274
response O 0 6.959474e-05
with O 0 8.2278595e-05
associated O 0 6.4502274e-05
up O 0 8.920385e-05
- O 0 0.00012164936
regulation O 0 3.982451e-05
of O 0 0.00013063358
MHC O 0 0.00880797
- O 0 0.00045894593
I O 0 0.0011910229
expression O 0 0.00021636533
and O 0 0.00021423328
antigen O 0 0.0009812672
presentation O 0 0.00068678346
by O 0 0.0008782913
muscle O 0 0.006176753
fibres O 0 0.005370864
. O 0 0.002139742

Use O 0 0.005148516
of O 0 0.0023936818
chromosome O 0 0.006091387
substitution O 0 0.008038349
strains O 0 0.00070937286
to O 0 0.00048044077
identify O 0 0.00060542417
seizure B-Disease 0 0.99734336
susceptibility O 0 0.004027241
loci O 0 0.0035903733
in O 0 0.0011553013
mice O 0 0.0015237528
. O 0 0.0026383894

Seizure B-Disease 2 0.9768188
susceptibility O 0 0.009655413
varies O 0 0.0037138353
among O 0 0.0035382241
inbred O 0 0.0061953384
mouse O 0 0.004791989
strains O 0 0.0048003877
. O 0 0.005791001

Chromosome O 0 0.06587087
substitution O 0 0.020983275
strains O 0 0.0018848861
( O 0 0.0024945245
CSS O 0 0.8245341
) O 0 0.0012608406
, O 0 0.00041549694
in O 0 0.00021030132
which O 0 0.0002263694
a O 0 0.0002025112
single O 0 0.00014499243
chromosome O 0 0.00058274006
from O 0 8.0159974e-05
one O 0 6.833295e-05
inbred O 0 0.00024351224
strain O 0 8.185896e-05
( O 0 0.0001536699
donor O 0 0.0002372934
) O 0 0.00018154424
has O 0 5.4794033e-05
been O 0 4.5187433e-05
transferred O 0 6.0329465e-05
onto O 0 4.487918e-05
a O 0 8.137866e-05
second O 0 6.507197e-05
strain O 0 7.029307e-05
( O 0 0.00013242329
host O 0 0.00012372422
) O 0 0.00013018852
by O 0 6.9180925e-05
repeated O 0 5.1826133e-05
backcrossing O 0 0.0005684806
, O 0 0.00010338685
may O 0 5.6032954e-05
be O 0 4.8961047e-05
used O 0 3.946102e-05
to O 0 4.337203e-05
identify O 0 4.9575676e-05
quantitative O 0 0.00018430612
trait O 0 0.0013644478
loci O 0 0.0007470826
( O 0 0.0002606537
QTLs O 0 0.0037145868
) O 0 0.00023225039
that O 0 0.00011926738
contribute O 0 0.00021579358
to O 0 0.0005476878
seizure B-Disease 0 0.9980338
susceptibility O 0 0.0080696065
. O 0 0.0026224237

QTLs O 0 0.014254971
for O 0 0.0012698004
susceptibility O 0 0.0025594204
to O 0 0.0016826662
pilocarpine B-Chemical 1 0.9999685
- O 0 0.0050695883
induced O 0 0.0017830483
seizures B-Disease 0 0.9999515
, O 0 0.0004980137
a O 0 0.0002030665
model O 0 0.0001248993
of O 0 0.00015018957
temporal B-Disease 0 0.0052881544
lobe I-Disease 0 0.8155878
epilepsy I-Disease 2 0.9999913
, O 0 0.00034205432
have O 0 6.947392e-05
not O 0 6.748469e-05
been O 0 6.267827e-05
reported O 0 0.00010842503
, O 0 0.000117527874
and O 0 0.00016173907
CSS O 0 0.473985
have O 0 7.4020034e-05
not O 0 7.6175005e-05
previously O 0 8.738117e-05
been O 0 7.161522e-05
used O 0 8.1641774e-05
to O 0 0.00011719907
localize O 0 0.000117629235
seizure B-Disease 0 0.9938013
susceptibility O 0 0.0034702485
genes O 0 0.0027169976
. O 0 0.002033695

We O 0 0.0018138902
report O 0 0.0022885294
QTLs O 0 0.00786302
identified O 0 0.00069700304
using O 0 0.00052081083
a O 0 0.0009921589
B6 O 0 0.5456063
( O 0 0.0006476645
host O 0 0.000415507
) O 0 0.00043634686
x O 0 0.0007227348
A O 0 0.011117447
/ O 0 0.0021258492
J O 0 0.5852792
( O 0 0.00032536325
donor O 0 0.0003945158
) O 0 0.00043479292
CSS O 0 0.27969307
panel O 0 0.0001616774
to O 0 6.178574e-05
localize O 0 2.6148316e-05
genes O 0 0.00010258235
involved O 0 5.957805e-05
in O 0 0.00010455674
susceptibility O 0 0.00048291992
to O 0 0.0005448948
pilocarpine B-Chemical 1 0.9999701
- O 0 0.0046202308
induced O 0 0.0045343186
seizures B-Disease 0 0.9998797
. O 0 0.0043963017

Three O 0 0.0025719444
hundred O 0 0.001795209
fifty O 0 0.0013964144
- O 0 0.0010904674
five O 0 0.00032173886
adult O 0 0.0007192289
male O 0 0.0021228793
CSS O 0 0.41487572
mice O 0 0.00020363773
, O 0 0.00028461238
58 O 0 0.00042301626
B6 O 0 0.19916429
, O 0 0.000212204
and O 0 0.00016064075
39 O 0 0.000281739
A O 0 0.0034947228
/ O 0 0.0011011484
J O 0 0.20639195
were O 0 0.00013056335
tested O 0 9.565878e-05
for O 0 0.000102718026
susceptibility O 0 0.000585598
to O 0 0.0006189464
pilocarpine B-Chemical 1 0.9999697
- O 0 0.005012388
induced O 0 0.004796321
seizures B-Disease 0 0.99987817
. O 0 0.004534876

Highest O 0 0.011842642
stage O 0 0.003173334
reached O 0 0.0012338427
and O 0 0.0007828026
latency O 0 0.00077249995
to O 0 0.00035226444
each O 0 0.00022453367
stage O 0 0.00066747284
were O 0 0.0003946648
recorded O 0 0.00040907154
for O 0 0.0005108874
all O 0 0.001007897
mice O 0 0.0014335738
. O 0 0.0026093929

B6 O 0 0.34553474
mice O 0 0.0012378383
were O 0 0.0008643701
resistant O 0 0.00073136215
to O 0 0.0007226793
seizures B-Disease 0 0.99961627
and O 0 0.0005289798
slower O 0 0.00038834423
to O 0 0.00018334437
reach O 0 0.00016497419
stages O 0 0.00022973264
compared O 0 0.00017741494
to O 0 0.0004080859
A O 0 0.010253924
/ O 0 0.0050416333
J O 0 0.3145196
mice O 0 0.0017673032
. O 0 0.0026770486

The O 0 0.0026726932
CSS O 0 0.18163212
for O 0 0.0012529823
Chromosomes O 0 0.020890018
10 O 0 0.0005330106
and O 0 0.00037215947
18 O 0 0.00024316026
progressed O 0 0.00030688752
to O 0 0.0001467777
the O 0 0.00017064823
most O 0 0.00038236278
severe O 0 0.0036554327
stages O 0 0.0004013779
, O 0 0.00028682782
diverging O 0 0.00047395818
dramatically O 0 0.00035957756
from O 0 0.0003113232
the O 0 0.00071807246
B6 O 0 0.44661826
phenotype O 0 0.005659809
. O 0 0.0027086881

Latencies O 0 0.017469678
to O 0 0.0020178305
stages O 0 0.001675995
were O 0 0.0008899346
also O 0 0.0006565543
significantly O 0 0.0008088474
shorter O 0 0.00057944935
for O 0 0.00073733967
CSS10 O 0 0.0650398
and O 0 0.0018888094
CSS18 O 0 0.07416753
mice O 0 0.0022346815
. O 0 0.0032697034

CSS O 0 0.29307756
mapping O 0 0.0018316453
suggests O 0 0.001209872
seizure B-Disease 0 0.98980576
susceptibility O 0 0.0034539436
loci O 0 0.0022287501
on O 0 0.00046838724
mouse O 0 0.0012479086
Chromosomes O 0 0.02423715
10 O 0 0.00092600845
and O 0 0.0013202934
18 O 0 0.0019028183
. O 0 0.0026503229

This O 0 0.003352776
approach O 0 0.0014113056
provides O 0 0.00073680026
a O 0 0.00068600435
framework O 0 0.00038203833
for O 0 0.00025644177
identifying O 0 0.00032322932
potentially O 0 0.00030135582
novel O 0 0.0002584486
homologous O 0 0.0001807037
candidate O 0 0.00028417935
genes O 0 0.00030313115
for O 0 0.00020718182
human O 0 0.00059715693
temporal B-Disease 0 0.01878259
lobe I-Disease 0 0.8944676
epilepsy I-Disease 2 0.9999299
. O 0 0.0051770085

In O 0 0.0017072333
vitro O 0 0.0014431867
characterization O 0 0.00083666533
of O 0 0.00093469804
parasympathetic O 0 0.080186635
and O 0 0.00048351756
sympathetic O 0 0.004154359
responses O 0 0.0004329945
in O 0 0.0004819243
cyclophosphamide B-Chemical 0 0.9996717
- O 0 0.0020707794
induced O 0 0.0015411107
cystitis B-Disease 0 0.9996215
in O 0 0.0011537019
the O 0 0.0012156819
rat O 0 0.0042244485
. O 0 0.0022811226

In O 0 0.0035152696
cyclophosphamide B-Chemical 0 0.9989298
- O 0 0.005600976
induced O 0 0.0023501967
cystitis B-Disease 0 0.9993382
in O 0 0.0005668187
the O 0 0.00031667866
rat O 0 0.00070396374
, O 0 0.0003147004
detrusor O 0 0.36085695
function O 0 0.00019019975
is O 0 0.00011941829
impaired O 0 0.00032675927
and O 0 0.00011146086
the O 0 9.648275e-05
expression O 0 0.00014317902
and O 0 0.0001420197
effects O 0 0.0002686874
of O 0 0.0009876207
muscarinic O 0 0.9965413
receptors O 0 0.012485066
altered O 0 0.0027592774
. O 0 0.0020416812

Whether O 0 0.0018889318
or O 0 0.0013280141
not O 0 0.00086836977
the O 0 0.00081537885
neuronal O 0 0.0037765417
transmission O 0 0.00072110805
may O 0 0.00038770813
be O 0 0.00037723346
affected O 0 0.00057962915
by O 0 0.000956828
cystitis B-Disease 0 0.9992118
was O 0 0.0017436956
presently O 0 0.0026122634
investigated O 0 0.0017124709
. O 0 0.002500607

Responses O 0 0.0024185574
of O 0 0.0014981577
urinary O 0 0.009431353
strip O 0 0.0013678368
preparations O 0 0.0005234176
from O 0 0.00019840921
control O 0 0.00020779036
and O 0 0.00037722336
cyclophosphamide B-Chemical 0 0.9996748
- O 0 0.00089150673
pretreated O 0 0.0010082301
rats O 0 0.00020752364
to O 0 6.6791064e-05
electrical O 0 0.00022441807
field O 0 8.7239714e-05
stimulation O 0 5.0406114e-05
and O 0 7.84521e-05
to O 0 8.490742e-05
agonists O 0 0.051105008
were O 0 7.8835474e-05
assessed O 0 3.9421302e-05
in O 0 4.2235773e-05
the O 0 4.611543e-05
absence O 0 3.9013656e-05
and O 0 7.2150724e-05
presence O 0 9.666601e-05
of O 0 0.00036923095
muscarinic O 0 0.9956955
, O 0 0.0005795882
adrenergic O 0 0.94993436
and O 0 0.00061496993
purinergic O 0 0.2300798
receptor O 0 0.09475824
antagonists O 0 0.8084933
. O 0 0.0023087426

Generally O 0 0.0027401429
, O 0 0.003958935
atropine B-Chemical 0 0.99982125
reduced O 0 0.0054883086
contractions O 0 0.363798
, O 0 0.0006463141
but O 0 0.00028039995
in O 0 0.00015286522
contrast O 0 0.00024195168
to O 0 0.00014593548
controls O 0 0.00035971898
, O 0 0.00015071851
it O 0 9.632188e-05
also O 0 7.191299e-05
reduced O 0 0.00014572966
responses O 0 0.0001098994
to O 0 6.8586254e-05
low O 0 0.00019164826
electrical O 0 0.0003351165
field O 0 0.00011062204
stimulation O 0 6.600631e-05
intensity O 0 8.606662e-05
( O 0 0.00020378825
1 O 0 0.00012737152
- O 0 0.00024718267
5 O 0 0.00015010152
Hz O 0 0.0011346558
) O 0 0.0005061882
in O 0 0.00046554732
inflamed O 0 0.0026040622
preparations O 0 0.0022566735
. O 0 0.0021699055

In O 0 0.001761702
both O 0 0.0013057012
types O 0 0.0007785414
, O 0 0.0012020024
purinoceptor O 0 0.84415925
desensitization O 0 0.12674305
with O 0 0.0010128833
alpha B-Chemical 0 0.792357
, I-Chemical 0 0.00095301226
beta I-Chemical 0 0.97156996
- I-Chemical 0 0.0029062126
methylene I-Chemical 0 0.99378455
adenosine I-Chemical 0 0.99959344
- I-Chemical 0 0.00068175164
5 I-Chemical 0 9.731333e-05
' I-Chemical 0 0.00018458221
- I-Chemical 0 0.00032438635
triphosphate I-Chemical 0 0.036377892
( O 0 0.0003759959
alpha B-Chemical 0 0.41369295
, I-Chemical 0 0.0005630804
beta I-Chemical 0 0.97816133
- I-Chemical 0 0.0061626886
meATP I-Chemical 0 0.99961084
) O 0 0.00036834163
caused O 0 0.00013196218
further O 0 0.00015036394
reductions O 0 0.00015589761
at O 0 8.98735e-05
low O 0 0.00033865237
frequencies O 0 0.00035602495
( O 0 0.00044822006
< O 0 0.0004032991
10 O 0 0.0005803074
Hz O 0 0.0039492347
) O 0 0.0025134066
. O 0 0.002410022

The O 0 0.0028484154
muscarinic O 0 0.99549097
receptor O 0 0.33867052
antagonists O 0 0.99654275
atropine B-Chemical 0 0.9999802
, O 0 0.0015434539
4 B-Chemical 0 0.0003352162
- I-Chemical 0 0.00062105735
diphenylacetoxy I-Chemical 0 0.011292672
- I-Chemical 0 0.0016612103
N I-Chemical 0 0.987789
- I-Chemical 0 0.001438599
methylpiperidine I-Chemical 0 0.91143805
( O 0 0.00034701364
4 B-Chemical 0 0.0001226677
- I-Chemical 0 0.0003570731
DAMP I-Chemical 0 0.6317681
) O 0 0.00041710935
( O 0 0.00027878562
' O 0 0.00038246886
M O 0 0.46148804
( O 0 0.00030418436
1 O 0 0.0001352101
) O 0 0.00024986922
/ O 0 0.0007496164
M O 0 0.41509414
( O 0 0.0002899023
3 O 0 0.000112281625
) O 0 0.0002349861
/ O 0 0.0007215187
M O 0 0.42305586
( O 0 0.00027271252
5 O 0 0.00010262423
) O 0 0.00020337423
- O 0 0.0002161179
selective O 0 0.0003814748
' O 0 0.0002504999
) O 0 0.0003166841
, O 0 0.00042201314
methoctramine B-Chemical 0 0.9999902
( O 0 0.0007737104
' O 0 0.0005233186
M O 0 0.6671708
( O 0 0.00028333635
2 O 0 0.0001083278
) O 0 0.00018320544
- O 0 0.00019176927
selective O 0 0.0003291775
' O 0 0.0002073567
) O 0 0.0002477612
and O 0 0.00037055998
pirenzepine B-Chemical 0 0.9999963
( O 0 0.000732018
' O 0 0.0005124674
M O 0 0.7093229
( O 0 0.0002832178
1 O 0 0.00011087603
) O 0 0.00018693863
- O 0 0.00019780983
selective O 0 0.00035980472
' O 0 0.00021001721
) O 0 0.00021966959
antagonized O 0 0.024382822
the O 0 0.00010802206
tonic O 0 0.0010978522
component O 0 5.621224e-05
of O 0 7.575544e-05
the O 0 6.0592723e-05
electrical O 0 0.00021777084
field O 0 9.542892e-05
stimulation O 0 6.8821784e-05
- O 0 0.00020022505
evoked O 0 0.0005166964
contractile O 0 0.0066193235
response O 0 0.00013542958
more O 0 0.00022859994
potently O 0 0.00074710354
than O 0 0.00018025146
the O 0 0.00035794047
phasic O 0 0.002450484
component O 0 0.0011098419
. O 0 0.0017510799

4 B-Chemical 0 0.0032068714
- I-Chemical 0 0.0041475906
DAMP I-Chemical 0 0.30356243
inhibited O 0 0.0015707435
the O 0 0.0007042361
tonic O 0 0.014586169
contractions O 0 0.03283487
in O 0 0.00029112626
controls O 0 0.0004094297
more O 0 0.00040307498
potently O 0 0.002115963
than O 0 0.00088330335
methoctramine B-Chemical 0 0.99997306
and O 0 0.022182276
pirenzepine B-Chemical 0 0.99996984
. O 0 0.004821844

In O 0 0.0020634083
inflamed O 0 0.0037300612
preparations O 0 0.0015076976
, O 0 0.00082107674
the O 0 0.00076168287
muscarinic O 0 0.9975044
receptor O 0 0.06313738
antagonism O 0 0.08339684
on O 0 8.160394e-05
the O 0 9.286709e-05
phasic O 0 0.00039992886
component O 0 5.901075e-05
of O 0 7.920999e-05
the O 0 6.361542e-05
electrical O 0 0.00021760416
field O 0 9.4629766e-05
stimulation O 0 6.58659e-05
- O 0 0.00019919357
evoked O 0 0.00062487216
contraction O 0 0.013353961
was O 0 0.000113656264
decreased O 0 0.00018605946
and O 0 0.00010075954
the O 0 0.00024248494
pirenzepine B-Chemical 0 0.9999969
and O 0 0.00022228555
4 B-Chemical 0 8.330246e-05
- I-Chemical 0 0.00024576587
DAMP I-Chemical 0 0.6293189
antagonism O 0 0.028007457
on O 0 4.802793e-05
the O 0 8.264259e-05
tonic O 0 0.0012618233
component O 0 0.00010824839
was O 0 0.00013483132
much O 0 0.00010596294
less O 0 0.00014557122
efficient O 0 0.00016031283
than O 0 0.0002487378
in O 0 0.00056903483
controls O 0 0.0020322874
. O 0 0.0019345888

In O 0 0.0016961156
contrast O 0 0.0015896163
to O 0 0.0009587251
controls O 0 0.0018489398
, O 0 0.0021631618
methoctramine B-Chemical 0 0.9999809
increased O 0 0.0055150036
- O 0 0.0017432842
- O 0 0.00050300895
instead O 0 0.00017323597
of O 0 0.00029179096
decreased O 0 0.0009204754
- O 0 0.0006763976
- O 0 0.00036120057
the O 0 0.00019546902
tonic O 0 0.0020314616
responses O 0 0.00038317867
at O 0 0.00033135852
high O 0 0.0014075582
frequencies O 0 0.0019842074
. O 0 0.0022375134

While O 0 0.002198781
contractions O 0 0.032091156
to O 0 0.001757222
carbachol B-Chemical 0 0.9994336
and O 0 0.002240055
ATP B-Chemical 0 0.9961941
were O 0 0.00031777043
the O 0 0.00014081971
same O 0 7.2033436e-05
in O 0 0.00011177345
inflamed O 0 0.0004537282
and O 0 9.746814e-05
in O 0 6.6712324e-05
control O 0 7.3031435e-05
strips O 0 0.00015514456
when O 0 3.2335163e-05
related O 0 2.483418e-05
to O 0 4.5471264e-05
a O 0 0.000101046164
reference O 0 0.00020271019
potassium B-Chemical 0 0.99992466
response O 0 0.0003542703
, O 0 0.0005705631
isoprenaline B-Chemical 0 0.999918
- O 0 0.000766509
induced O 0 0.0004463019
relaxations O 0 0.9779523
were O 0 0.00028550293
smaller O 0 0.00031489637
in O 0 0.00042685823
inflamed O 0 0.0027724102
strips O 0 0.0031276108
. O 0 0.0018832682

Thus O 0 0.0031385468
, O 0 0.002964672
in O 0 0.002178188
cystitis B-Disease 0 0.9950015
substantial O 0 0.0014220468
changes O 0 0.0008397631
of O 0 0.0006532058
the O 0 0.0005674287
efferent O 0 0.0016430129
functional O 0 0.0009064387
responses O 0 0.0014063255
occur O 0 0.0016602222
. O 0 0.0026592035

While O 0 0.003766652
postjunctional O 0 0.9955706
beta O 0 0.98490465
- O 0 0.012610156
adrenoceptor O 0 0.99987996
- O 0 0.0021632821
mediated O 0 0.000380689
relaxations O 0 0.9853698
are O 0 0.0002783535
reduced O 0 0.00033954965
, O 0 0.00019226728
effects O 0 0.00019857065
by O 0 0.0003181681
prejunctional O 0 0.9227049
inhibitory O 0 0.019242242
muscarinic O 0 0.9989685
receptors O 0 0.006004706
may O 0 0.0005037551
be O 0 0.00067744596
increased O 0 0.0019531762
. O 0 0.0020877318

Direct O 0 0.0035761257
inhibition O 0 0.002876709
of O 0 0.0019861592
cardiac O 0 0.19352031
hyperpolarization O 0 0.9635956
- O 0 0.0018026275
activated O 0 0.000784706
cyclic B-Chemical 0 0.22873239
nucleotide I-Chemical 0 0.7647827
- O 0 0.0011664563
gated O 0 0.0017687037
pacemaker O 0 0.0028796182
channels O 0 0.0047038025
by O 0 0.0021890483
clonidine B-Chemical 0 0.9996896
. O 0 0.003630525

BACKGROUND O 0 0.00801024
: O 0 0.0020502673
Inhibition O 0 0.0013913091
of O 0 0.00091173983
cardiac O 0 0.0138121955
sympathetic O 0 0.02743432
tone O 0 0.0058677406
represents O 0 0.00016215847
an O 0 0.00013008316
important O 0 5.008795e-05
strategy O 0 9.104776e-05
for O 0 6.2887164e-05
treatment O 0 0.00010361206
of O 0 0.00026905682
cardiovascular B-Disease 0 0.93995756
disease I-Disease 0 0.5635294
, O 0 0.00021742292
including O 0 0.00012365983
arrhythmia B-Disease 0 0.99665916
, O 0 0.0003272331
coronary B-Disease 0 0.26607758
heart I-Disease 0 0.21760531
disease I-Disease 0 0.24446821
, O 0 0.0004045781
and O 0 0.000478813
chronic O 0 0.17807476
heart B-Disease 0 0.50525904
failure I-Disease 0 0.67770284
. O 0 0.0027759336

Activation O 0 0.0035348327
of O 0 0.002540033
presynaptic O 0 0.26141387
alpha2 O 0 0.99543506
- O 0 0.006490735
adrenoceptors O 0 0.9961469
is O 0 0.00035158105
the O 0 0.0001891297
most O 0 0.0002414157
widely O 0 0.00010628768
accepted O 0 0.00017222059
mechanism O 0 8.550756e-05
of O 0 8.868849e-05
action O 0 0.00010195919
of O 0 9.5841955e-05
the O 0 0.0001027193
antisympathetic O 0 0.11351878
drug O 0 0.37781402
clonidine B-Chemical 0 0.99998856
; O 0 0.00028032615
however O 0 0.00014163714
, O 0 8.129002e-05
other O 0 4.8045982e-05
target O 0 4.436869e-05
proteins O 0 8.2145634e-05
have O 0 4.7082638e-05
been O 0 4.5948487e-05
postulated O 0 6.882611e-05
to O 0 5.4962653e-05
contribute O 0 5.8588183e-05
to O 0 7.701321e-05
the O 0 0.00011341764
in O 0 0.00015052693
vivo O 0 0.00045563738
actions O 0 0.0013799386
of O 0 0.003306801
clonidine B-Chemical 0 0.99986994
. O 0 0.0034172884

METHODS O 0 0.001797882
AND O 0 0.0010421228
RESULTS O 0 0.0014522639
: O 0 0.0007342649
To O 0 0.0003754783
test O 0 0.0005100162
whether O 0 0.00024685485
clonidine B-Chemical 0 0.999778
elicits O 0 0.00022858554
pharmacological O 0 0.0017472384
effects O 0 0.00015326236
independent O 0 7.681182e-05
of O 0 0.00039033566
alpha2 O 0 0.99691856
- O 0 0.0029928216
adrenoceptors O 0 0.997291
, O 0 0.00012916849
we O 0 3.4304554e-05
have O 0 3.6838155e-05
generated O 0 3.4270783e-05
mice O 0 3.8331764e-05
with O 0 7.4928634e-05
a O 0 8.327911e-05
targeted O 0 4.6331505e-05
deletion O 0 0.00018788716
of O 0 0.00012428199
all O 0 0.00010885456
3 O 0 0.000115936025
alpha2 O 0 0.93511134
- O 0 0.0013136506
adrenoceptor O 0 0.9999136
subtypes O 0 0.0019539553
( O 0 0.00048459193
alpha2ABC O 0 0.0029345024
- O 0 0.0010732888
/ O 0 0.0020002192
- O 0 0.0019751291
) O 0 0.00235332
. O 0 0.0022492702

Alpha2ABC O 0 0.04735649
- O 0 0.005597978
/ O 0 0.0039895335
- O 0 0.0013363033
mice O 0 0.00029470472
were O 0 0.00026089663
completely O 0 0.00023165326
unresponsive O 0 0.00019979503
to O 0 0.00010988096
the O 0 0.00014309098
analgesic O 0 0.0928394
and O 0 0.00017638285
hypnotic O 0 0.8633916
effects O 0 0.00017946771
of O 0 0.00061764027
clonidine B-Chemical 0 0.99998784
; O 0 0.0003002071
however O 0 0.00019882014
, O 0 0.00027468245
clonidine B-Chemical 0 0.99996245
significantly O 0 0.0003269833
lowered O 0 0.0019220344
heart O 0 0.018510949
rate O 0 0.00013735321
in O 0 0.00011780389
alpha2ABC O 0 0.0023676148
- O 0 0.00043260914
/ O 0 0.00059118465
- O 0 0.00028452202
mice O 0 0.000110350426
by O 0 0.00019879664
up O 0 0.00027067392
to O 0 0.00037854965
150 O 0 0.0011376804
bpm O 0 0.002634812
. O 0 0.0019790225

Clonidine B-Chemical 0 0.9998708
- O 0 0.0072300523
induced O 0 0.0021948218
bradycardia B-Disease 0 0.9881898
in O 0 0.0007621566
conscious O 0 0.0043132086
alpha2ABC O 0 0.012467401
- O 0 0.0009209097
/ O 0 0.00093875715
- O 0 0.000352425
mice O 0 9.438662e-05
was O 0 0.00014277043
32 O 0 0.00014526308
. O 0 6.2424166e-05
3 O 0 6.232911e-05
% O 0 8.804142e-05
( O 0 0.000100072684
10 O 0 6.276003e-05
microg O 0 0.00018714623
/ O 0 0.00047599582
kg O 0 0.0004106512
) O 0 0.00018015044
and O 0 0.000103447
26 O 0 0.0001298107
. O 0 5.209241e-05
6 O 0 4.5709952e-05
% O 0 8.116545e-05
( O 0 0.00010658782
100 O 0 0.00016741773
microg O 0 0.00025114467
/ O 0 0.0005615588
kg O 0 0.00041384716
) O 0 0.0001753997
of O 0 0.0001263867
the O 0 0.00012458266
effect O 0 0.0001705952
in O 0 0.00027150955
wild O 0 0.00053952675
- O 0 0.0009334378
type O 0 0.0008433106
mice O 0 0.0010660152
. O 0 0.001972105

A O 0 0.012765905
similar O 0 0.0013305442
bradycardic O 0 0.977102
effect O 0 0.0010269157
of O 0 0.0023249316
clonidine B-Chemical 0 0.99996126
was O 0 0.0005410549
observed O 0 0.0001469264
in O 0 0.000102041675
isolated O 0 9.501207e-05
spontaneously O 0 0.0003429961
beating O 0 0.00050712464
right O 0 0.0004621555
atria O 0 0.0043067425
from O 0 0.00011844186
alpha2ABC O 0 0.0013749191
- O 0 0.00033118704
knockout O 0 0.0003378219
and O 0 0.0002928095
wild O 0 0.00046505188
- O 0 0.00080567435
type O 0 0.0007648687
mice O 0 0.0010055528
. O 0 0.00190174

Clonidine B-Chemical 0 0.9997434
inhibited O 0 0.0041821525
the O 0 0.0010292291
native O 0 0.0009639045
pacemaker O 0 0.0018324378
current O 0 0.00089898077
( O 0 0.0006618964
I O 0 0.0029437193
( O 0 0.00039923118
f O 0 0.0005315727
) O 0 0.00032000864
) O 0 0.00017563801
in O 0 7.28617e-05
isolated O 0 8.588771e-05
sinoatrial O 0 0.00909719
node O 0 0.000234325
pacemaker O 0 0.00035453588
cells O 0 0.000105440224
and O 0 7.515334e-05
the O 0 9.914252e-05
I O 0 0.0015255195
( O 0 0.00018994077
f O 0 0.0003333887
) O 0 0.00022638707
- O 0 0.0001835037
generating O 0 0.000110129986
hyperpolarization O 0 0.69252807
- O 0 0.00036340032
activated O 0 0.00020424557
cyclic B-Chemical 0 0.16329281
nucleotide I-Chemical 0 0.79425454
- O 0 0.00054071
gated O 0 0.0010982392
( O 0 0.00042735637
HCN O 0 0.9507443
) O 0 0.00033655536
2 O 0 0.00012410307
and O 0 0.00024492678
HCN4 O 0 0.90055734
channels O 0 0.0024099327
in O 0 0.00032110026
transfected O 0 0.00064261415
HEK293 O 0 0.088416435
cells O 0 0.0030276377
. O 0 0.0024320323

As O 0 0.0017780189
a O 0 0.0016183872
consequence O 0 0.00071037957
of O 0 0.0009623454
blocking O 0 0.0018750464
I O 0 0.016613856
( O 0 0.00080802204
f O 0 0.000962916
) O 0 0.0006332886
, O 0 0.0005305773
clonidine B-Chemical 0 0.9999198
reduced O 0 0.000446589
the O 0 0.00013223251
slope O 0 0.00037462896
of O 0 9.857069e-05
the O 0 9.7365766e-05
diastolic O 0 0.37012118
depolarization O 0 0.067785904
and O 0 7.921603e-05
the O 0 5.0653798e-05
frequency O 0 5.6577235e-05
of O 0 7.7498706e-05
pacemaker O 0 0.00026619143
potentials O 0 0.0002633036
in O 0 7.318327e-05
sinoatrial O 0 0.011213716
node O 0 0.00019800365
cells O 0 0.00012310252
from O 0 8.005555e-05
wild O 0 0.00015912115
- O 0 0.00025793977
type O 0 0.00019886374
and O 0 0.00030618501
alpha2ABC O 0 0.003346197
- O 0 0.0009894619
knockout O 0 0.0013303098
mice O 0 0.0010796234
. O 0 0.0018690795

CONCLUSIONS O 0 0.012456673
: O 0 0.0019549413
Direct O 0 0.0012298328
inhibition O 0 0.0011553086
of O 0 0.0008538463
cardiac O 0 0.10752883
HCN O 0 0.9926238
pacemaker O 0 0.003917867
channels O 0 0.0010615209
contributes O 0 6.771948e-05
to O 0 6.63032e-05
the O 0 9.707133e-05
bradycardic O 0 0.9640439
effects O 0 0.00020519462
of O 0 0.0007179545
clonidine B-Chemical 0 0.9999871
gene O 0 0.0013343118
- O 0 0.00024365369
targeted O 0 4.666434e-05
mice O 0 4.1928684e-05
in O 0 6.144975e-05
vivo O 0 0.00015360309
, O 0 0.000101277976
and O 0 9.046274e-05
thus O 0 0.00017097498
, O 0 0.00036368836
clonidine B-Chemical 0 0.9999701
- O 0 0.00038642925
like O 0 7.488992e-05
drugs O 0 0.0011695113
represent O 0 7.383617e-05
novel O 0 0.00011397644
structures O 0 0.00013319375
for O 0 0.00014549932
future O 0 0.00048629087
HCN O 0 0.962475
channel O 0 0.19217314
inhibitors O 0 0.014949066
. O 0 0.0026225692

Granulomatous B-Disease 0 0.5701203
hepatitis I-Disease 2 0.99978524
due O 0 0.0017503868
to O 0 0.0011245946
combination B-Chemical 0 0.001525399
of I-Chemical 0 0.0025295862
amoxicillin I-Chemical 0 0.9991978
and I-Chemical 0 0.009077241
clavulanic I-Chemical 0 0.9998703
acid I-Chemical 0 0.9973085
. O 0 0.00850724

We O 0 0.0016466695
report O 0 0.0016250018
the O 0 0.000802514
case O 0 0.00052504434
of O 0 0.0004860603
a O 0 0.00043722457
patient O 0 0.0003632966
with O 0 0.00064681325
amoxicillin B-Chemical 0 0.9997217
- I-Chemical 0 0.011899565
clavulanic I-Chemical 0 0.9999759
acid I-Chemical 0 0.9985536
- O 0 0.004453184
induced O 0 0.0026582351
hepatitis B-Disease 2 0.9999882
with O 0 0.0049195006
histologic O 0 0.11131257
multiple O 0 0.0028508704
granulomas B-Disease 0 0.8181717
. O 0 0.0028923438

This O 0 0.0036367485
type O 0 0.0017151011
of O 0 0.0013047141
lesion O 0 0.0030244037
broadens O 0 0.0014454238
the O 0 0.00038787397
spectrum O 0 0.0005887291
of O 0 0.00079292513
liver B-Disease 0 0.999137
injury I-Disease 0 0.98509985
due O 0 0.00014226665
to O 0 0.000112406
this O 0 0.00018200665
drug O 0 0.0058905715
combination O 0 0.00026553014
, O 0 0.00017666881
mainly O 0 0.00018258479
represented O 0 0.00021688931
by O 0 0.00032966994
a O 0 0.0011163685
benign O 0 0.8490812
cholestatic B-Disease 0 0.999997
syndrome I-Disease 0 0.99916434
. O 0 0.004470625

The O 0 0.0022209657
association O 0 0.0015100929
of O 0 0.0026511597
granulomas B-Disease 0 0.38611263
and O 0 0.003662706
eosinophilia B-Disease 0 0.99846244
favor O 0 0.0035298516
an O 0 0.0042162845
immunoallergic O 0 0.9742097
mechanism O 0 0.0056724814
. O 0 0.004182252

As O 0 0.0027952802
penicillin B-Chemical 1 0.9993656
derivatives O 0 0.23828319
and O 0 0.002261596
amoxicillin B-Chemical 0 0.9991678
alone O 0 0.00084834715
are O 0 0.00030309474
known O 0 0.00024750008
to O 0 0.00011122866
induce O 0 6.8620335e-05
such O 0 6.4313535e-05
types O 0 5.8316844e-05
of O 0 0.00014955577
lesions O 0 0.0043973457
, O 0 0.0001290535
the O 0 0.00013264103
amoxicillin B-Chemical 0 0.9941202
component O 0 0.0001272278
, O 0 0.00011224726
with O 0 9.53426e-05
or O 0 5.9344547e-05
without O 0 6.553246e-05
a O 0 0.00011746469
potentiating O 0 0.0010727614
effect O 0 0.00016216635
of O 0 0.0009852354
clavulanic B-Chemical 0 0.99998236
acid I-Chemical 0 0.9945431
, O 0 0.0005630243
might O 0 0.0001838361
have O 0 0.00023033185
a O 0 0.0004966742
major O 0 0.0006292372
role O 0 0.0009231357
. O 0 0.0019648972

Dobutamine B-Chemical 0 0.9951828
stress O 0 0.030166574
echocardiography O 0 0.009626111
: O 0 0.0007516823
a O 0 0.00038037088
sensitive O 0 0.00019148386
indicator O 0 0.00013132337
of O 0 0.00020378863
diminished O 0 0.0006174477
myocardial O 0 0.9905061
function O 0 0.0002780917
in O 0 0.00017352229
asymptomatic O 0 0.023098
doxorubicin B-Chemical 1 0.9991042
- O 0 0.0007265644
treated O 0 0.00030710237
long O 0 0.00020376864
- O 0 0.00033131492
term O 0 0.00024010405
survivors O 0 0.001017
of O 0 0.0012291658
childhood O 0 0.7751017
cancer B-Disease 0 0.995226
. O 0 0.0036194217

Doxorubicin B-Chemical 0 0.9974443
is O 0 0.0020931412
an O 0 0.0012292723
effective O 0 0.00080431206
anticancer O 0 0.0659547
chemotherapeutic O 0 0.037608575
agent O 0 0.0051643047
known O 0 0.0008545585
to O 0 0.0005001764
cause O 0 0.0014173357
acute O 0 0.64651364
and O 0 0.0035380842
chronic O 0 0.9805012
cardiomyopathy B-Disease 0 0.99995506
. O 0 0.0054953145

To O 0 0.0019854824
develop O 0 0.0016370338
a O 0 0.0010513745
more O 0 0.00067015504
sensitive O 0 0.00041109454
echocardiographic O 0 0.0018376068
screening O 0 0.00045258176
test O 0 0.00028541748
for O 0 0.00015708567
cardiac B-Disease 0 0.6983271
damage I-Disease 0 0.90541
due O 0 0.00010999449
to O 0 0.00016557271
doxorubicin B-Chemical 1 0.9968665
, O 0 0.00020821494
a O 0 0.00017021954
cohort O 0 0.00038011203
study O 0 8.41881e-05
was O 0 5.5728295e-05
performed O 0 4.021447e-05
using O 0 6.204789e-05
dobutamine B-Chemical 1 0.9949685
infusion O 0 0.0002558537
to O 0 5.47758e-05
differentiate O 0 8.875566e-05
asymptomatic O 0 0.0006160188
long O 0 7.311485e-05
- O 0 0.00011406167
term O 0 5.919279e-05
survivors O 0 0.00021948159
of O 0 0.00019563833
childhood O 0 0.4140538
cancer B-Disease 0 0.9828378
treated O 0 0.00048458594
with O 0 0.00041787783
doxorubicin B-Chemical 1 0.9917331
from O 0 0.0002915957
healthy O 0 0.0013398787
control O 0 0.0006076504
subjects O 0 0.0015124774
. O 0 0.0016037271

Echocardiographic O 0 0.015355922
data O 0 0.0012778443
from O 0 0.0005721571
the O 0 0.00042638648
experimental O 0 0.00045267452
group O 0 0.000356293
of O 0 0.00027655734
21 O 0 0.00021450226
patients O 0 0.00020778282
( O 0 0.00014790022
mean O 0 5.665472e-05
age O 0 0.00012418047
16 O 0 0.00011036106
+ O 0 0.00027129764
/ O 0 0.0004894506
- O 0 0.0002440159
5 O 0 6.903791e-05
years O 0 7.2133655e-05
) O 0 0.0001118242
treated O 0 0.00010681797
from O 0 7.233494e-05
1 O 0 6.8197805e-05
. O 0 4.092786e-05
6 O 0 3.422695e-05
to O 0 4.6198307e-05
14 O 0 5.6443107e-05
. O 0 4.122234e-05
3 O 0 4.569744e-05
years O 0 5.0367915e-05
( O 0 7.32487e-05
median O 0 3.5892535e-05
5 O 0 4.6376288e-05
. O 0 4.0703893e-05
3 O 0 4.5656932e-05
) O 0 6.92497e-05
before O 0 2.2126214e-05
this O 0 6.0545994e-05
study O 0 7.491292e-05
with O 0 8.017909e-05
27 O 0 0.00011025072
to O 0 7.209762e-05
532 O 0 0.033728972
mg O 0 0.0060785934
/ O 0 0.0003255236
m2 O 0 0.00057260774
of O 0 0.00017003152
doxorubicin B-Chemical 1 0.9882848
( O 0 0.00014385958
mean O 0 4.02073e-05
196 O 0 0.00041819605
) O 0 9.724403e-05
were O 0 4.185271e-05
compared O 0 2.6315194e-05
with O 0 6.0834624e-05
echocardiographic O 0 0.0003224488
data O 0 7.18724e-05
from O 0 5.61996e-05
12 O 0 5.3287775e-05
normal O 0 0.00021475663
age O 0 0.00020146447
- O 0 0.00031378752
matched O 0 0.00024565883
control O 0 0.0005452075
subjects O 0 0.0014863322
. O 0 0.0017206125

Graded O 0 0.012759511
dobutamine B-Chemical 1 0.99745494
infusions O 0 0.0048821983
of O 0 0.0009940662
0 O 0 0.00048417406
. O 0 0.00024780305
5 O 0 0.00020702521
, O 0 0.00026329482
2 O 0 0.00016471985
. O 0 0.00010979875
5 O 0 0.00010621291
, O 0 0.0001394994
5 O 0 8.703531e-05
and O 0 0.000110465815
10 O 0 0.000119876015
micrograms O 0 0.0007094566
/ O 0 0.00052898336
kg O 0 0.0003730834
per O 0 0.00011249714
min O 0 0.00037625697
were O 0 0.0006230483
administered O 0 0.0013865979
. O 0 0.0020258452

Echocardiographic O 0 0.032488257
Doppler O 0 0.008241
studies O 0 0.00084797817
were O 0 0.00042381018
performed O 0 0.00023990222
before O 0 0.00013197956
infusion O 0 0.00037539066
and O 0 0.0001655367
after O 0 6.9348156e-05
15 O 0 0.000108161206
min O 0 0.00018265599
of O 0 0.0002791827
infusion O 0 0.0005887202
at O 0 0.00031847833
each O 0 0.0004253778
rate O 0 0.0015031549
. O 0 0.0022749363

Dobutamine B-Chemical 0 0.9907732
infusion O 0 0.00298249
at O 0 0.0005722664
10 O 0 0.000471804
micrograms O 0 0.0016943291
/ O 0 0.00081177853
kg O 0 0.00038752455
per O 0 6.365056e-05
min O 0 0.00013587534
was O 0 0.00013075247
discontinued O 0 0.00023033537
after O 0 3.6785816e-05
six O 0 4.745746e-05
studies O 0 9.132777e-05
secondary O 0 0.00022967703
to O 0 0.00010605938
a O 0 0.00020139494
50 O 0 0.0002793534
% O 0 0.00021049473
incidence O 0 0.00037975222
rate O 0 0.00034371065
of O 0 0.00079467177
adverse O 0 0.21118267
symptoms O 0 0.06558049
. O 0 0.002512338

The O 0 0.0015138692
most O 0 0.0012848072
important O 0 0.00046739128
findings O 0 0.00083061546
were O 0 0.00032552826
that O 0 0.0001519736
compared O 0 0.000118959244
with O 0 0.00016223395
values O 0 0.00013020266
in O 0 9.271931e-05
control O 0 0.000110388
subjects O 0 0.00016172534
, O 0 9.4697476e-05
end O 0 4.7302932e-05
- O 0 0.00015662411
systolic O 0 0.008831017
left O 0 0.0002969684
ventricular O 0 0.2361415
posterior O 0 0.0004257691
wall O 0 0.0002462615
dimension O 0 8.5209875e-05
and O 0 4.371131e-05
percent O 0 2.7362114e-05
of O 0 5.259211e-05
left O 0 0.00017783107
ventricular O 0 0.18001519
posterior O 0 0.00049869274
wall O 0 0.00058616645
thickening O 0 0.09315591
in O 0 0.00014394273
doxorubicin B-Chemical 1 0.9975303
- O 0 0.0003838057
treated O 0 0.00015875333
patients O 0 0.0001209157
were O 0 5.6082135e-05
decreased O 0 9.527971e-05
at O 0 3.2689393e-05
baseline O 0 4.568089e-05
study O 0 6.5058564e-05
and O 0 5.9434537e-05
these O 0 9.269844e-05
findings O 0 0.00015148964
were O 0 8.725968e-05
more O 0 0.00012238097
clearly O 0 0.00011901564
delineated O 0 0.00033640585
with O 0 0.00069199206
dobutamine B-Chemical 1 0.99728024
stimulation O 0 0.0014445658
. O 0 0.0020339806

End O 0 0.006907605
- O 0 0.0030408895
systolic O 0 0.014434537
left O 0 0.0017376554
ventricular O 0 0.28364024
posterior O 0 0.0012811205
wall O 0 0.00068848993
dimension O 0 0.00022476519
at O 0 7.759572e-05
baseline O 0 7.804789e-05
for O 0 6.7911154e-05
the O 0 0.0001641529
doxorubicin B-Chemical 1 0.99701536
- O 0 0.0006425064
treated O 0 0.0002827551
group O 0 0.00021964216
was O 0 0.00014758551
11 O 0 0.0001232584
+ O 0 0.00026303134
/ O 0 0.00049951323
- O 0 0.0002560067
1 O 0 7.626005e-05
. O 0 4.524116e-05
9 O 0 5.166384e-05
mm O 0 0.0001080475
versus O 0 6.29997e-05
13 O 0 8.886796e-05
. O 0 5.5695684e-05
1 O 0 7.945707e-05
+ O 0 0.00021716185
/ O 0 0.00043540556
- O 0 0.00025578932
1 O 0 7.9284204e-05
. O 0 4.604692e-05
5 O 0 4.5654535e-05
mm O 0 9.55791e-05
for O 0 5.203382e-05
control O 0 0.00010220488
subjects O 0 0.0002189248
( O 0 0.00024542215
p O 0 0.00017197395
less O 0 0.00018746054
than O 0 0.00020191832
0 O 0 0.00035968196
. O 0 0.0004932076
01 O 0 0.0025851005
) O 0 0.0022189186
. O 0 0.0023457217

End O 0 0.00700748
- O 0 0.0031023782
systolic O 0 0.0147774285
left O 0 0.0018042258
ventricular O 0 0.30334413
posterior O 0 0.0014093206
wall O 0 0.00078516034
dimension O 0 0.00026663064
at O 0 9.5494746e-05
the O 0 0.000117641226
5 O 0 9.002026e-05
- O 0 0.00017619962
micrograms O 0 0.00053063827
/ O 0 0.00027032912
kg O 0 0.00012680535
per O 0 2.1278027e-05
min O 0 8.314113e-05
dobutamine B-Chemical 1 0.9753553
infusion O 0 0.0001843286
for O 0 4.5012726e-05
the O 0 0.0001085349
doxorubicin B-Chemical 1 0.99600226
- O 0 0.00046016945
treated O 0 0.00021622262
group O 0 0.00016937278
was O 0 0.00010708957
14 O 0 6.799553e-05
. O 0 4.7508536e-05
1 O 0 6.914254e-05
+ O 0 0.00019347625
/ O 0 0.00039554958
- O 0 0.00023016852
2 O 0 6.8671856e-05
. O 0 4.212166e-05
4 O 0 4.3801407e-05
mm O 0 0.00010242772
versus O 0 6.306312e-05
19 O 0 0.000119295604
. O 0 5.4122764e-05
3 O 0 6.6218265e-05
+ O 0 0.00019910505
/ O 0 0.0004022894
- O 0 0.00024140648
2 O 0 7.138115e-05
. O 0 4.183595e-05
6 O 0 3.4762274e-05
mm O 0 7.9424346e-05
for O 0 4.249717e-05
control O 0 8.204558e-05
subjects O 0 0.00017524893
( O 0 0.00018057038
p O 0 0.00010477371
less O 0 9.3831666e-05
than O 0 8.034579e-05
0 O 0 0.00011898205
. O 0 0.00012235763
01 O 0 0.0006146653
) O 0 0.0003624912
. O 0 0.00022653499
( O 0 0.00068684266
ABSTRACT O 0 0.0035696763
TRUNCATED O 0 0.0037710238
AT O 0 0.0068740207
250 O 0 0.003804418
WORDS O 0 0.0077530933
) O 0 0.0067675556

Influence O 0 0.0076316064
of O 0 0.008148777
smoking B-Chemical 0 0.042166382
on O 0 0.004887274
developing O 0 0.017238898
cochlea O 0 0.041569285
. O 0 0.009982391

Does O 0 0.0050670537
smoking B-Chemical 0 0.01744206
during O 0 0.0006846961
pregnancy O 0 0.0018435059
affect O 0 0.00025094763
the O 0 0.00030501114
amplitudes O 0 0.00074590876
of O 0 0.0005586721
transient O 0 0.0053580003
evoked O 0 0.01476543
otoacoustic O 0 0.9866834
emissions O 0 0.086758666
in O 0 0.0015227812
newborns O 0 0.0061127497
? O 0 0.0055979327

OBJECTIVE O 0 0.03090715
: O 0 0.0037453424
Maternal O 0 0.00396224
tobacco O 0 0.014577823
smoking B-Chemical 0 0.07759945
has O 0 0.0007535434
negative O 0 0.00090198376
effects O 0 0.0010193003
on O 0 0.00094618136
fetal O 0 0.026296988
growth O 0 0.028259352
. O 0 0.0045489995

The O 0 0.0013903691
influence O 0 0.00081337505
of O 0 0.0012819761
smoking B-Chemical 0 0.011760938
during O 0 0.00027045672
pregnancy O 0 0.0012002569
on O 0 0.00013032851
the O 0 0.00018895359
developing O 0 0.00094603363
cochlea O 0 0.0020472647
has O 0 0.00010131893
not O 0 8.803093e-05
been O 0 7.146247e-05
estimated O 0 0.000102898906
, O 0 0.00014431916
although O 0 0.00014004545
smoking B-Chemical 0 0.023502316
has O 0 8.946349e-05
been O 0 7.474095e-05
positively O 0 0.00011194712
associated O 0 0.00015246755
with O 0 0.0004625963
hearing B-Disease 0 0.9819639
loss I-Disease 0 0.012765278
in O 0 0.0013359033
adults O 0 0.00439236
. O 0 0.0020405708

The O 0 0.0015241301
objective O 0 0.0014976149
of O 0 0.0010205294
this O 0 0.00074727705
study O 0 0.00059379754
was O 0 0.00030860977
to O 0 0.00014034705
determine O 0 6.670704e-05
the O 0 0.00010425536
effects O 0 0.00013954689
of O 0 0.00022063137
maternal O 0 0.000605565
smoking B-Chemical 0 0.034305803
on O 0 8.3042076e-05
transient O 0 0.002014369
evoked O 0 0.005563935
otoacoustic O 0 0.98474485
emissions O 0 0.083048716
( O 0 0.00057248434
TEOAEs O 0 0.013929462
) O 0 0.0005224048
of O 0 0.00060983276
healthy O 0 0.003077177
neonates O 0 0.003937185
. O 0 0.0021153612

METHODS O 0 0.001748806
: O 0 0.0015052545
This O 0 0.0011821903
study O 0 0.00074872124
was O 0 0.00045545938
undertaken O 0 0.00027029176
as O 0 0.00019461577
part O 0 0.00013666405
of O 0 0.00022114023
neonatal O 0 0.0005443754
screening O 0 0.00033487953
for O 0 0.00018298338
hearing B-Disease 0 0.9871946
impairment I-Disease 0 0.5454683
and O 0 0.00029650415
involved O 0 0.00014487123
both O 0 0.00028755178
ears O 0 0.004821714
of O 0 0.0008889739
200 O 0 0.002500645
newborns O 0 0.0043150526
. O 0 0.0021917403

Newborns O 0 0.007476734
whose O 0 0.002159449
mothers O 0 0.0015431099
reported O 0 0.0009651286
smoking B-Chemical 0 0.016662173
during O 0 0.00020796277
pregnancy O 0 0.0020928103
( O 0 0.00032075326
n O 0 0.00014833691
= O 0 0.00016680792
200 O 0 0.0003209068
ears O 0 0.0035404605
) O 0 0.00021370001
were O 0 7.521154e-05
compared O 0 4.0364426e-05
to O 0 4.934141e-05
a O 0 8.0338126e-05
control O 0 6.846778e-05
group O 0 9.972926e-05
of O 0 0.00012013131
newborns O 0 0.00040313226
( O 0 0.00016276604
n O 0 9.204698e-05
= O 0 0.00012998433
200 O 0 0.00029671707
ears O 0 0.003813976
) O 0 0.00031084276
, O 0 0.00018920653
whose O 0 0.00030309276
mothers O 0 0.00040456944
were O 0 0.00036434614
non O 0 0.00082953944
- O 0 0.00190787
smokers O 0 0.007638384
. O 0 0.0020464405

Exposure O 0 0.0064545935
to O 0 0.0019487046
tobacco O 0 0.0066143028
was O 0 0.0010464799
characterized O 0 0.0010405069
as O 0 0.0004009028
low O 0 0.0007558687
( O 0 0.00044061046
< O 0 0.00018179456
5 O 0 0.00010455455
cigarettes O 0 0.00036969004
per O 0 3.505403e-05
day O 0 4.985454e-05
, O 0 9.155553e-05
n O 0 8.343785e-05
= O 0 0.00011629266
88 O 0 0.00023032284
ears O 0 0.0031907626
) O 0 0.00026745757
, O 0 0.00015818443
moderate O 0 0.0011651779
( O 0 0.00017858332
5 O 0 6.306305e-05
< O 0 6.9093025e-05
or O 0 6.881423e-05
= O 0 0.0001193286
cigarettes O 0 0.0002739543
per O 0 2.2776418e-05
day O 0 3.5068206e-05
< O 0 5.6595047e-05
10 O 0 5.6743767e-05
, O 0 8.502871e-05
n O 0 7.718533e-05
= O 0 0.00010401505
76 O 0 0.00014220712
) O 0 0.00011915007
or O 0 6.634962e-05
high O 0 0.0002023925
( O 0 0.00018186631
> O 0 0.00023743279
or O 0 0.000103140264
= O 0 0.00014047073
10 O 0 9.140173e-05
cigarettes O 0 0.00037158906
per O 0 4.8750553e-05
day O 0 9.4183066e-05
, O 0 0.00024065388
n O 0 0.00030842307
= O 0 0.00060039276
36 O 0 0.0008148743
) O 0 0.001820984
. O 0 0.0020852177

RESULTS O 0 0.004620327
: O 0 0.0017325975
In O 0 0.00062329293
exposed O 0 0.000655028
neonates O 0 0.0011844762
, O 0 0.0004931888
TEOAEs O 0 0.0026604026
mean O 0 0.000101579164
response O 0 0.00016707009
( O 0 0.00018061102
across O 0 5.4481934e-05
frequency O 0 0.00011735674
) O 0 0.00013080174
and O 0 6.044833e-05
mean O 0 3.4120574e-05
amplitude O 0 0.00015723404
at O 0 8.5580396e-05
4000Hz O 0 0.1482443
was O 0 0.00017957727
significantly O 0 0.00018842338
lower O 0 0.00018896603
than O 0 0.000110549176
in O 0 0.000194657
non O 0 0.0004880504
- O 0 0.00081822125
exposed O 0 0.0008740636
neonates O 0 0.0044388613
. O 0 0.0022402916

Comparisons O 0 0.001778208
between O 0 0.0011027671
exposed O 0 0.0014008998
newborns O 0 0.0028032523
' O 0 0.0016277118
subgroups O 0 0.001167966
revealed O 0 0.0008361667
no O 0 0.0007946444
significant O 0 0.0014614369
differences O 0 0.0015441241
. O 0 0.0032633597

However O 0 0.002763514
, O 0 0.0018452089
by O 0 0.0008282717
comparing O 0 0.00030860066
each O 0 0.00021428845
subgroup O 0 0.00061438757
to O 0 0.00018221729
control O 0 0.00020097733
group O 0 0.0002692755
, O 0 0.00015532397
we O 0 6.258672e-05
found O 0 0.000102787984
statistically O 0 0.00011061202
significant O 0 8.8424e-05
decreases B-Disease 0 0.00012318087
of I-Disease 0 0.0001879409
TEOAEs I-Disease 0 0.009847772
amplitudes I-Disease 0 0.00047561032
at O 0 0.00015434778
4000Hz O 0 0.045274697
for O 0 0.0002181738
all O 0 0.00035077683
three O 0 0.0003486556
groups O 0 0.0009819621
. O 0 0.0016603643

Mean O 0 0.0015249648
TEOAEs O 0 0.006313724
responses O 0 0.0010660413
of O 0 0.00069930515
highly O 0 0.00041560165
exposed O 0 0.00038335813
newborns O 0 0.00080931996
were O 0 0.0002175295
also O 0 0.0001674388
significantly O 0 0.00026179315
lower O 0 0.0002531993
in O 0 0.00016793833
comparison O 0 0.00017551714
to O 0 0.00022679151
our O 0 0.000548313
control O 0 0.00080581795
group O 0 0.0018883124
. O 0 0.0021360128

CONCLUSION O 0 0.01992807
: O 0 0.002369422
In O 0 0.00086972123
utero O 0 0.001938074
, O 0 0.0007052389
exposure O 0 0.0006376049
to O 0 0.00044013775
tobacco O 0 0.018915031
smoking B-Chemical 0 0.11159545
seems O 0 0.00018773852
to O 0 0.00015707519
have O 0 0.00012151813
a O 0 0.00020294901
small O 0 0.0002066708
impact O 0 0.00014758437
on O 0 0.00029952437
outer O 0 0.005164393
hair O 0 0.5463922
cells O 0 0.003990781
. O 0 0.0027466149

These O 0 0.0024160268
effects O 0 0.0017758901
seem O 0 0.0011319461
to O 0 0.0006210328
be O 0 0.00042626905
equally O 0 0.0004102859
true O 0 0.00032459173
for O 0 0.00016237386
all O 0 0.00018915458
exposed O 0 0.0002295264
newborns O 0 0.0006764124
, O 0 0.00022647496
regardless O 0 0.00010005839
of O 0 0.0002960903
the O 0 0.00034596422
degree O 0 0.0007249867
of O 0 0.0011963431
exposure O 0 0.0030026007
. O 0 0.0026949828

Further O 0 0.0027152281
studies O 0 0.0015014897
are O 0 0.00071113
needed O 0 0.00039507664
in O 0 0.0003060744
order O 0 0.0002117238
to O 0 0.00017596994
establish O 0 0.00012867234
a O 0 0.00018870026
potential O 0 0.00014367151
negative O 0 0.00018393989
effect O 0 0.0001363891
of O 0 0.00026113875
maternal O 0 0.0007047521
smoking B-Chemical 0 0.022849422
on O 0 0.00010842649
the O 0 0.00021284533
neonate O 0 0.00095155777
' O 0 0.00065991236
s O 0 0.0009183162
hearing O 0 0.99465406
acuity O 0 0.999201
. O 0 0.004724549

Simvastatin B-Chemical 0 0.9997665
- O 0 0.007216313
induced O 0 0.0021843768
bilateral O 0 0.015567027
leg O 0 0.020208647
compartment B-Disease 0 0.0070263157
syndrome I-Disease 0 0.9255098
and O 0 0.0022231413
myonecrosis B-Disease 0 0.99947625
associated O 0 0.0020760975
with O 0 0.0058705956
hypothyroidism B-Disease 0 0.9998084
. O 0 0.0048908656

A O 0 0.026544103
54 O 0 0.0040177624
- O 0 0.0023445662
year O 0 0.0006503087
- O 0 0.00090670737
old O 0 0.0005561742
hypothyroid B-Disease 2 0.9382313
male O 0 0.001523235
taking O 0 0.00069176627
thyroxine B-Chemical 1 0.9998203
and O 0 0.0005991545
simvastatin B-Chemical 1 0.9999608
presented O 0 0.00027206226
with O 0 0.00036078654
bilateral O 0 0.014835774
leg O 0 0.016015964
compartment B-Disease 0 0.0060082553
syndrome I-Disease 0 0.9414074
and O 0 0.0034165191
myonecrosis B-Disease 0 0.99948347
. O 0 0.0035960758

Urgent O 0 0.0059615322
fasciotomies O 0 0.0062582963
were O 0 0.00074145675
performed O 0 0.00040473219
and O 0 0.00034254693
the O 0 0.0002578097
patient O 0 0.0002376339
made O 0 0.00015651782
an O 0 0.00019060532
uneventful O 0 0.0001946839
recovery O 0 0.00032525157
with O 0 0.00028319214
the O 0 0.00038946187
withdrawal O 0 0.013771925
of O 0 0.0038117103
simvastatin B-Chemical 1 0.9999112
. O 0 0.004886815

It O 0 0.0028048053
is O 0 0.0012567197
likely O 0 0.0005437699
that O 0 0.00039199658
this O 0 0.00060825585
complication O 0 0.005492631
will O 0 0.0002611181
be O 0 0.00016258906
seen O 0 0.000121106896
more O 0 0.00015116153
often O 0 0.00012839044
with O 0 0.00012072697
the O 0 9.821116e-05
increased O 0 0.00020814211
worldwide O 0 0.00046442988
use O 0 8.257854e-05
of O 0 0.00011438429
this O 0 0.00015960299
drug O 0 0.003485762
and O 0 0.00015874743
its O 0 0.00029194425
approval O 0 0.0003347911
for O 0 0.00021541535
all O 0 0.00073253614
arteriopathic B-Disease 0 0.9975915
patients O 0 0.0032463833
. O 0 0.0019864854

Neuroinflammation B-Disease 0 0.6162751
and O 0 0.0021601748
behavioral B-Disease 0 0.019025084
abnormalities I-Disease 0 0.1017384
after O 0 0.00029431834
neonatal O 0 0.0024641214
terbutaline B-Chemical 0 0.9998729
treatment O 0 0.0006371214
in O 0 0.00034689676
rats O 0 0.00054820586
: O 0 0.00047251603
implications O 0 0.000525403
for O 0 0.0010400693
autism B-Disease 0 0.9612197
. O 0 0.0032801565

Autism B-Disease 0 0.92854536
is O 0 0.0021460904
a O 0 0.0023750938
neurodevelopmental B-Disease 0 0.99719596
disorder I-Disease 0 0.99850035
presenting O 0 0.0016840043
before O 0 0.00013055028
3 O 0 0.00012616515
years O 0 9.8885415e-05
of O 0 0.00013760582
age O 0 0.0001610306
with O 0 0.00019311887
deficits B-Disease 0 0.020329446
in I-Disease 0 0.00016562006
communication I-Disease 0 0.00032770517
and I-Disease 0 0.000217549
social I-Disease 0 0.0007564408
skills I-Disease 0 0.0009353813
and O 0 0.00066819106
repetitive B-Disease 0 0.0031322145
behaviors I-Disease 0 0.04110078
. O 0 0.0026186572

In O 0 0.0016974404
addition O 0 0.00091568317
to O 0 0.00086013554
genetic O 0 0.0015330695
influences O 0 0.00038913707
, O 0 0.0004491551
recent O 0 0.00024840317
studies O 0 0.00018077814
suggest O 0 6.630964e-05
that O 0 0.00010282151
prenatal O 0 0.0013255298
drug O 0 0.0064052925
or O 0 0.0001635623
chemical O 0 0.0006806662
exposures O 0 0.0008677355
are O 0 0.0003202833
risk O 0 0.0016602806
factors O 0 0.0007640375
for O 0 0.0010181075
autism B-Disease 0 0.9788943
. O 0 0.0028688905

Terbutaline B-Chemical 0 0.99891436
, O 0 0.0033465084
a O 0 0.0029595147
beta2 O 0 0.9960871
- O 0 0.007797459
adrenoceptor O 0 0.9999269
agonist O 0 0.79943234
used O 0 0.00026278145
to O 0 0.0002409528
arrest O 0 0.23931894
preterm B-Disease 0 0.9303109
labor I-Disease 0 0.4945633
, O 0 0.0002998904
has O 0 9.443488e-05
been O 0 7.263042e-05
associated O 0 8.238215e-05
with O 0 0.00014072198
increased O 0 0.0002696128
concordance O 0 0.000548958
for O 0 0.00029585385
autism B-Disease 0 0.9527252
in O 0 0.0009694462
dizygotic O 0 0.16314846
twins O 0 0.083507575
. O 0 0.0025930847

We O 0 0.0015304872
studied O 0 0.0012498432
the O 0 0.0006863718
effects O 0 0.00070708344
of O 0 0.0013245378
terbutaline B-Chemical 0 0.9998758
on O 0 0.0003603938
microglial O 0 0.032503318
activation O 0 0.00035844176
in O 0 0.00014277588
different O 0 8.87897e-05
brain O 0 0.00061888795
regions O 0 0.00013836341
and O 0 0.00016110124
behavioral O 0 0.0005807489
outcomes O 0 0.00035361302
in O 0 0.00045559678
developing O 0 0.0030304415
rats O 0 0.0028438221
. O 0 0.0020209039

Newborn O 0 0.0063778507
rats O 0 0.0018401169
were O 0 0.00075883564
given O 0 0.00053919194
terbutaline B-Chemical 0 0.99970764
( O 0 0.0007999895
10 O 0 0.00027314216
mg O 0 0.004798889
/ O 0 0.00079315563
kg O 0 0.00052060816
) O 0 0.00019022987
daily O 0 9.8946446e-05
on O 0 4.3633976e-05
postnatal O 0 0.00011672686
days O 0 4.4325683e-05
( O 0 0.00016483644
PN O 0 0.008459695
) O 0 0.00017963414
2 O 0 5.791366e-05
to O 0 5.016223e-05
5 O 0 4.9090268e-05
or O 0 7.085367e-05
PN O 0 0.0020719268
11 O 0 7.642224e-05
to O 0 5.07207e-05
14 O 0 5.1436666e-05
and O 0 5.5254473e-05
examined O 0 4.0350496e-05
24 O 0 4.3557393e-05
h O 0 4.483871e-05
after O 0 2.94513e-05
the O 0 7.443689e-05
last O 0 6.223516e-05
dose O 0 0.000492647
and O 0 0.0003339301
at O 0 0.00042587708
PN O 0 0.011209043
30 O 0 0.0011257286
. O 0 0.0018374738

Immunohistochemical O 0 0.0035677429
studies O 0 0.0011984052
showed O 0 0.0005844889
that O 0 0.00032226904
administration O 0 0.0013200708
of O 0 0.00094482297
terbutaline B-Chemical 0 0.99992573
on O 0 0.0002595539
PN O 0 0.050725948
2 O 0 0.000107705666
to O 0 6.927176e-05
5 O 0 5.320618e-05
produced O 0 6.0567538e-05
a O 0 9.048224e-05
robust O 0 5.647886e-05
increase O 0 8.6428896e-05
in O 0 9.191208e-05
microglial O 0 0.005632543
activation O 0 0.00015002898
on O 0 5.7944926e-05
PN O 0 0.0030391149
30 O 0 4.5518595e-05
in O 0 4.751316e-05
the O 0 7.722817e-05
cerebral O 0 0.18591714
cortex O 0 0.007655138
, O 0 0.00015857996
as O 0 8.751302e-05
well O 0 7.9052435e-05
as O 0 0.00010287614
in O 0 0.00015595247
cerebellar O 0 0.040567495
and O 0 0.0006114973
cerebrocortical O 0 0.80472213
white O 0 0.009601686
matter O 0 0.00622973
. O 0 0.0021008193

None O 0 0.0031328755
of O 0 0.001617975
these O 0 0.0010589059
effects O 0 0.00071059825
occurred O 0 0.0004259118
in O 0 0.0003132892
animals O 0 0.00023906218
given O 0 0.00030636368
terbutaline B-Chemical 0 0.9996056
on O 0 0.0005328486
PN O 0 0.024000004
11 O 0 0.00077186927
to O 0 0.0007955339
14 O 0 0.0014185461
. O 0 0.0021839424

In O 0 0.001834171
behavioral O 0 0.0038728698
tests O 0 0.002083299
, O 0 0.0006606668
animals O 0 0.0002777615
treated O 0 0.00042454916
with O 0 0.000609147
terbutaline B-Chemical 0 0.9999087
on O 0 0.00020809469
PN O 0 0.037772965
2 O 0 9.112429e-05
to O 0 5.950231e-05
5 O 0 4.7253794e-05
showed O 0 5.114852e-05
consistent O 0 5.1451436e-05
patterns O 0 4.87216e-05
of O 0 0.0001773363
hyper O 0 0.44325817
- O 0 0.00035238452
reactivity O 0 0.00030622818
to O 0 7.450264e-05
novelty O 0 0.0009981941
and O 0 8.3416686e-05
aversive O 0 0.0003852658
stimuli O 0 7.2535244e-05
when O 0 4.0568146e-05
assessed O 0 4.5563203e-05
in O 0 5.3522763e-05
a O 0 8.7012486e-05
novel O 0 9.594474e-05
open O 0 0.00019092545
field O 0 0.00015262407
, O 0 0.00012036512
as O 0 8.048497e-05
well O 0 7.259379e-05
as O 0 8.417854e-05
in O 0 9.640291e-05
the O 0 0.00015662993
acoustic O 0 0.0012215466
startle O 0 0.41079047
response O 0 0.0011435252
test O 0 0.0019966671
. O 0 0.0019599157

Our O 0 0.0019450745
findings O 0 0.0017936561
indicate O 0 0.00059030124
that O 0 0.0007265627
beta2 O 0 0.9964785
- O 0 0.008283525
adrenoceptor O 0 0.9999527
overstimulation O 0 0.92997366
during O 0 0.00010330918
an O 0 0.0001348731
early O 0 0.00011316185
critical O 0 4.9553797e-05
period O 0 3.2268006e-05
results O 0 6.564849e-05
in O 0 7.805697e-05
microglial O 0 0.0045847143
activation O 0 0.0001598604
associated O 0 8.762675e-05
with O 0 0.00014809892
innate O 0 0.00097362633
neuroinflammatory O 0 0.8211316
pathways O 0 0.00018293993
and O 0 0.0001385007
behavioral B-Disease 0 0.030206712
abnormalities I-Disease 0 0.44447687
, O 0 0.00019322275
similar O 0 8.939851e-05
to O 0 0.00014626468
those O 0 0.0003371899
described O 0 0.0003909505
in O 0 0.00095262006
autism B-Disease 0 0.9647719
. O 0 0.00271088

This O 0 0.0037986615
study O 0 0.0017104367
provides O 0 0.00076349446
a O 0 0.00081400236
useful O 0 0.00044303216
animal O 0 0.00046392632
model O 0 0.00030438017
for O 0 0.00017884352
understanding O 0 0.00026927012
the O 0 0.00027555038
neuropathological O 0 0.04180319
processes O 0 0.0006581869
underlying O 0 0.0015107286
autism B-Disease 0 0.99797183
spectrum I-Disease 0 0.008137715
disorders I-Disease 0 0.9431813
. O 0 0.0030867106

Upregulation O 0 0.004584201
of O 0 0.0018337291
brain O 0 0.003317951
expression O 0 0.001042093
of O 0 0.0014426041
P O 0 0.08986704
- O 0 0.0010324228
glycoprotein O 0 0.01576583
in O 0 0.00055975444
MRP2 O 0 0.9995153
- O 0 0.00092861045
deficient O 0 0.0005149394
TR O 0 0.89782107
( O 0 0.00047794747
- O 0 0.00038236132
) O 0 0.00020052122
rats O 0 0.00016946843
resembles O 0 0.00013101993
seizure B-Disease 0 0.99877626
- O 0 0.0004361167
induced O 0 0.00014940952
up O 0 0.00013375707
- O 0 0.0001561261
regulation O 0 4.519381e-05
of O 0 0.00010963929
this O 0 0.00019830442
drug O 0 0.018367473
efflux O 0 0.0302561
transporter O 0 0.0044585974
in O 0 0.0003844139
normal O 0 0.0012952498
rats O 0 0.001775039
. O 0 0.0016749831

PURPOSE O 0 0.004745844
: O 0 0.0018067884
The O 0 0.0007551817
multidrug O 0 0.0023963363
resistance O 0 0.0013473736
protein O 0 0.00091015926
2 O 0 0.00040300316
( O 0 0.00074246497
MRP2 O 0 0.9954483
) O 0 0.0004869953
is O 0 0.00015481179
a O 0 0.00021910315
drug O 0 0.011684977
efflux O 0 0.033452637
transporter O 0 0.0020204063
that O 0 5.8749654e-05
is O 0 6.0997332e-05
expressed O 0 3.083632e-05
predominantly O 0 4.2687014e-05
at O 0 3.1064443e-05
the O 0 5.301751e-05
apical O 0 0.00010123376
domain O 0 6.113226e-05
of O 0 0.00015044141
hepatocytes O 0 0.023845041
but O 0 0.00011680457
seems O 0 4.758544e-05
also O 0 5.3104446e-05
to O 0 4.745755e-05
be O 0 3.9981784e-05
expressed O 0 2.3754686e-05
at O 0 2.606926e-05
the O 0 4.6554593e-05
apical O 0 8.983348e-05
membrane O 0 0.00013865253
of O 0 0.0001018525
brain O 0 0.0013902409
capillary O 0 0.24114567
endothelial O 0 0.6177612
cells O 0 0.00015829639
that O 0 5.4796543e-05
form O 0 8.070131e-05
the O 0 0.00012631415
blood O 0 0.0017314719
- O 0 0.0004679044
brain O 0 0.0019627532
barrier O 0 0.0028904944
( O 0 0.0015707893
BBB O 0 0.96402884
) O 0 0.0030815923
. O 0 0.0022897425

MRP2 O 0 0.99362826
is O 0 0.0021437572
absent O 0 0.0009460714
in O 0 0.00058867806
the O 0 0.0005252991
transport O 0 0.0012253177
- O 0 0.0007584565
deficient O 0 0.0004759747
( O 0 0.000758399
TR O 0 0.76693153
( O 0 0.0006311316
- O 0 0.0005728926
) O 0 0.0003595678
) O 0 0.00028361473
Wistar O 0 0.0007043549
rat O 0 0.0002481371
mutant O 0 0.00010262423
, O 0 9.431833e-05
so O 0 5.0521805e-05
that O 0 4.0328414e-05
this O 0 8.646847e-05
rat O 0 0.00017854212
strain O 0 5.655443e-05
was O 0 7.457151e-05
very O 0 9.35688e-05
helpful O 0 6.181454e-05
in O 0 4.330537e-05
defining O 0 4.4894197e-05
substrates O 0 9.517973e-05
of O 0 0.00020300284
MRP2 O 0 0.9957788
by O 0 8.474693e-05
comparing O 0 3.3233933e-05
tissue O 0 0.0001920714
concentrations O 0 0.00015014374
or O 0 4.7571462e-05
functional O 0 5.7718047e-05
activities O 0 6.1612045e-05
of O 0 0.00012422395
compounds O 0 0.17111537
in O 0 0.00027881245
MRP2 O 0 0.9995203
- O 0 0.00036146975
deficient O 0 0.00013088108
rats O 0 0.00015001223
with O 0 0.00011595207
those O 0 0.00015283143
in O 0 0.00013868889
transport O 0 0.0004820608
- O 0 0.00044252776
competent O 0 0.00033999473
Wistar O 0 0.0026878973
rats O 0 0.0016394375
. O 0 0.0015498314

By O 0 0.0020925994
using O 0 0.0011039284
this O 0 0.0008499702
strategy O 0 0.000614616
to O 0 0.00036568794
study O 0 0.00033604857
the O 0 0.00021525477
involvement O 0 0.00032903
of O 0 0.0004631699
MRP2 O 0 0.9959955
in O 0 0.00012759643
brain O 0 0.0004398593
access O 0 7.554226e-05
of O 0 0.00016175388
antiepileptic O 0 0.9890035
drugs O 0 0.040050786
( O 0 0.00034695645
AEDs O 0 0.23287258
) O 0 0.00018684899
, O 0 7.688069e-05
we O 0 3.2767854e-05
recently O 0 5.5782803e-05
reported O 0 0.00010100822
that O 0 0.00015889584
phenytoin B-Chemical 1 0.9999949
is O 0 0.00027427814
a O 0 0.00025425435
substrate O 0 0.0004371339
for O 0 0.0002809247
MRP2 O 0 0.9891009
in O 0 0.0006219335
the O 0 0.0012483055
BBB O 0 0.9665099
. O 0 0.0026712292

However O 0 0.0028600402
, O 0 0.0018964306
one O 0 0.0007205884
drawback O 0 0.00063466694
of O 0 0.0005284064
such O 0 0.00025592934
studies O 0 0.0002893382
in O 0 0.00020141856
genetically O 0 0.00031572123
deficient O 0 0.00022330646
rats O 0 0.00023440542
is O 0 9.05209e-05
the O 0 6.5810775e-05
fact O 0 4.4311524e-05
that O 0 5.3137977e-05
compensatory O 0 0.00022559652
changes O 0 0.00015889478
with O 0 0.00016721114
upregulation O 0 0.0003027101
of O 0 0.0003416284
other O 0 0.00038739227
transporters O 0 0.0023935689
can O 0 0.00049744226
occur O 0 0.00088163425
. O 0 0.0016110996

This O 0 0.0035329086
prompted O 0 0.002103285
us O 0 0.0020583752
to O 0 0.00061277044
study O 0 0.0005025335
the O 0 0.00031343353
brain O 0 0.0012468584
expression O 0 0.0004035748
of O 0 0.00072544353
P O 0 0.10513981
- O 0 0.0007819341
glycoprotein O 0 0.050651956
( O 0 0.00080374343
Pgp O 0 0.9860599
) O 0 0.00034597958
, O 0 0.00011244042
a O 0 9.98502e-05
major O 0 9.568469e-05
drug O 0 0.008828467
efflux O 0 0.025376815
transporter O 0 0.0022213918
in O 0 6.908914e-05
many O 0 6.321166e-05
tissues O 0 0.00015201548
, O 0 7.445427e-05
including O 0 4.4693774e-05
the O 0 0.00012763242
BBB O 0 0.976528
, O 0 0.00017205022
in O 0 0.00015775273
TR O 0 0.7060821
( O 0 0.0003188681
- O 0 0.0002825907
) O 0 0.00015251624
rats O 0 0.00011436685
compared O 0 5.979975e-05
with O 0 0.00019647094
nonmutant O 0 0.4029399
( O 0 0.00038728223
wild O 0 0.00031117632
- O 0 0.00051090517
type O 0 0.0004665171
) O 0 0.00090748485
Wistar O 0 0.0031395196
rats O 0 0.0018769705
. O 0 0.0017551858

METHODS O 0 0.0015442211
: O 0 0.0011790578
The O 0 0.0004928293
expression O 0 0.0006322963
of O 0 0.000941861
MRP2 O 0 0.9959006
and O 0 0.00082297705
Pgp O 0 0.91948664
in O 0 0.00021207069
brain O 0 0.0009875707
and O 0 0.00020376903
liver O 0 0.199532
sections O 0 0.00016397455
of O 0 0.00028253061
TR O 0 0.8159305
( O 0 0.0003465799
- O 0 0.00028944304
) O 0 0.00014854499
rats O 0 0.0001057059
and O 0 7.317336e-05
normal O 0 0.00018681907
Wistar O 0 0.00043452566
rats O 0 9.513164e-05
was O 0 5.6880843e-05
determined O 0 4.6784604e-05
with O 0 9.547161e-05
immunohistochemistry O 0 0.00037233793
, O 0 9.5351694e-05
by O 0 6.962899e-05
using O 0 5.1161154e-05
a O 0 9.413745e-05
novel O 0 0.000100558624
, O 0 9.556396e-05
highly O 0 8.887898e-05
selective O 0 0.00048800293
monoclonal O 0 0.0027250075
MRP2 O 0 0.997969
antibody O 0 0.0008134093
and O 0 0.00015567284
the O 0 0.00018493719
monoclonal O 0 0.0023624776
Pgp O 0 0.9683317
antibody O 0 0.005644839
C219 O 0 0.15131995
, O 0 0.0015734934
respectively O 0 0.0031140684
. O 0 0.0022850218

RESULTS O 0 0.0044657085
: O 0 0.0019395467
Immunofluorescence O 0 0.001527725
staining O 0 0.0006339752
with O 0 0.00048238004
the O 0 0.00057081383
MRP2 O 0 0.99734926
antibody O 0 0.0018358896
was O 0 0.0002589846
found O 0 0.00011718935
to O 0 0.00010616866
label O 0 0.00036600098
a O 0 0.00012864327
high O 0 0.00016238671
number O 0 7.5745185e-05
of O 0 0.00010190475
microvessels O 0 0.00096848793
throughout O 0 2.5365767e-05
the O 0 4.929386e-05
brain O 0 0.00031582962
in O 0 6.824152e-05
normal O 0 0.00023527395
Wistar O 0 0.0006320868
rats O 0 0.00013016556
, O 0 7.8788886e-05
whereas O 0 6.454295e-05
such O 0 5.6973724e-05
labeling O 0 0.00015490582
was O 0 0.00012391077
absent O 0 0.00014496534
in O 0 0.00027904435
TR O 0 0.57099944
( O 0 0.0009210128
- O 0 0.0011837701
) O 0 0.0013043315
rats O 0 0.0020361014
. O 0 0.0019889683

TR O 0 0.89256185
( O 0 0.0057396535
- O 0 0.0034968671
) O 0 0.001500239
rats O 0 0.00078911247
exhibited O 0 0.00047997318
a O 0 0.00041629537
significant O 0 0.00024961805
up O 0 0.00024538586
- O 0 0.00028521457
regulation O 0 8.549573e-05
of O 0 0.00027482756
Pgp O 0 0.8759498
in O 0 0.00016116208
brain O 0 0.0017788063
capillary O 0 0.24588236
endothelial O 0 0.6921423
cells O 0 0.00030573984
compared O 0 0.00011184703
with O 0 0.00027787674
wild O 0 0.0004461046
- O 0 0.0008007513
type O 0 0.0008201993
controls O 0 0.0021859654
. O 0 0.0019583867

No O 0 0.0035869463
such O 0 0.0014689378
obvious O 0 0.0012909109
upregulation O 0 0.0017374553
of O 0 0.0022981067
Pgp O 0 0.9712327
was O 0 0.0012418801
observed O 0 0.0008037251
in O 0 0.0012339213
liver O 0 0.6034502
sections O 0 0.0036645613
. O 0 0.00318616

A O 0 0.012900504
comparable O 0 0.0012621093
overexpression O 0 0.0012953274
of O 0 0.0014120382
Pgp O 0 0.933544
in O 0 0.00040980452
the O 0 0.00042765893
BBB O 0 0.96285266
was O 0 0.0002438703
obtained O 0 0.00016847464
after O 0 0.000121271805
pilocarpine B-Chemical 1 0.9999765
- O 0 0.0014550118
induced O 0 0.0008574859
seizures B-Disease 0 0.999943
in O 0 0.00052348996
wild O 0 0.0005503015
- O 0 0.0007285189
type O 0 0.00065012963
Wistar O 0 0.0035791118
rats O 0 0.0018583251
. O 0 0.0016866408

Experiments O 0 0.0024189786
with O 0 0.0016671773
systemic O 0 0.033026233
administration O 0 0.002321997
of O 0 0.0006200599
the O 0 0.0005557836
Pgp O 0 0.9878683
substrate O 0 0.006768126
phenobarbital B-Chemical 0 0.9999975
and O 0 0.0002848252
the O 0 0.00013546676
selective O 0 0.00092829997
Pgp O 0 0.98286027
inhibitor O 0 0.013283758
tariquidar B-Chemical 0 0.9999591
in O 0 0.00037561922
TR O 0 0.8949761
( O 0 0.00035052598
- O 0 0.0002936367
) O 0 0.00016270507
rats O 0 0.00013771582
substantiated O 0 0.00028097822
that O 0 9.4079754e-05
Pgp O 0 0.9140816
is O 0 0.00010076338
functional O 0 8.53303e-05
and O 0 7.221535e-05
compensates O 0 7.6048644e-05
for O 0 6.281518e-05
the O 0 0.00010291088
lack O 0 0.00015756994
of O 0 0.00048686998
MRP2 O 0 0.9922099
in O 0 0.00064704573
the O 0 0.0012865682
BBB O 0 0.9703249
. O 0 0.0026902528

CONCLUSIONS O 0 0.012667544
: O 0 0.001870637
The O 0 0.0006569705
data O 0 0.00076035573
on O 0 0.0005433956
TR O 0 0.5988393
( O 0 0.0011618464
- O 0 0.0008733119
) O 0 0.00040614817
rats O 0 0.00023772546
indicate O 0 8.4412946e-05
that O 0 0.00012845069
Pgp O 0 0.7372156
plays O 0 8.746946e-05
an O 0 0.000100646605
important O 0 4.3361277e-05
role O 0 5.0847142e-05
in O 0 7.781357e-05
the O 0 0.000109235865
compensation O 0 0.0005226937
of O 0 0.00078283687
MRP2 O 0 0.9995158
deficiency O 0 0.78439325
in O 0 0.0007966134
the O 0 0.0015160628
BBB O 0 0.9817594
. O 0 0.002808334

Because O 0 0.0014856579
such O 0 0.001044791
a O 0 0.001141641
compensatory O 0 0.0012151523
mechanism O 0 0.00058616203
most O 0 0.00049829594
likely O 0 0.00017424584
occurs O 0 0.00013736016
to O 0 0.00012338234
reduce O 0 0.0001217933
injury B-Disease 0 0.03466143
to I-Disease 0 0.000106684216
the I-Disease 0 9.651863e-05
brain I-Disease 0 0.0006662538
from O 0 0.000104768515
cytotoxic O 0 0.12969331
compounds O 0 0.40359774
, O 0 0.00013037698
the O 0 6.1287996e-05
present O 0 4.801955e-05
data O 0 7.423322e-05
substantiate O 0 7.769968e-05
the O 0 6.505974e-05
concept O 0 9.404199e-05
that O 0 0.00012250987
MRP2 O 0 0.99380684
performs O 0 0.00025123352
a O 0 0.00029369217
protective O 0 0.0005686873
role O 0 0.0002180029
in O 0 0.00048324987
the O 0 0.0012754336
BBB O 0 0.97741574
. O 0 0.0028668833

Furthermore O 0 0.0025904924
, O 0 0.0017676918
our O 0 0.0010661869
data O 0 0.0006820896
suggest O 0 0.00025997346
that O 0 0.0004204888
TR O 0 0.8513023
( O 0 0.0010139656
- O 0 0.0007613273
) O 0 0.00034422023
rats O 0 0.00020246467
are O 0 8.2763494e-05
an O 0 8.0741185e-05
interesting O 0 3.713252e-05
tool O 0 9.5144074e-05
to O 0 6.0105394e-05
study O 0 7.740506e-05
consequences O 0 8.6312524e-05
of O 0 0.000110509965
overexpression O 0 0.00017776633
of O 0 0.00028043843
Pgp O 0 0.9532746
in O 0 8.6894e-05
the O 0 0.00010696557
BBB O 0 0.8343904
on O 0 3.738914e-05
access O 0 5.1396808e-05
of O 0 8.926851e-05
drugs O 0 0.0013086168
in O 0 5.865863e-05
the O 0 6.782832e-05
brain O 0 0.00065999036
, O 0 8.8644e-05
without O 0 5.5995028e-05
the O 0 5.771348e-05
need O 0 4.954997e-05
of O 0 0.00011370429
inducing O 0 0.00055599934
seizures B-Disease 0 0.9999523
or O 0 0.00026640398
other O 0 0.0003059008
Pgp O 0 0.97657734
- O 0 0.0004073542
enhancing O 0 0.00023899543
events O 0 0.0007370137
for O 0 0.00029384563
this O 0 0.00078005187
purpose O 0 0.0013139048
. O 0 0.0021044943

Role O 0 0.004363194
of O 0 0.00914087
xanthine B-Chemical 0 0.9999676
oxidase O 0 0.99986553
in O 0 0.0069067087
dexamethasone B-Chemical 0 0.99976987
- O 0 0.0072273836
induced O 0 0.0049851737
hypertension B-Disease 2 0.99989474
in O 0 0.0028159851
rats O 0 0.004511006
. O 0 0.0028765392

1 O 0 0.062920205
. O 0 0.06257983

Glucocorticoid O 0 0.9874885
- O 0 0.007224202
induced O 0 0.0051486646
hypertension B-Disease 2 0.9999192
( O 0 0.006723314
GC O 0 0.9102633
- O 0 0.00467173
HT B-Disease 0 0.9973285
) O 0 0.0006733092
in O 0 0.00019579862
the O 0 0.00019434985
rat O 0 0.00041615855
is O 0 0.00018685024
associated O 0 0.00020489181
with O 0 0.00064646197
nitric B-Chemical 0 0.9987431
oxide I-Chemical 0 0.98934525
- O 0 0.0033153237
redox O 0 0.0791938
imbalance O 0 0.013848922
. O 0 0.0023017214

2 O 0 0.058298454
. O 0 0.06073419

We O 0 0.0017272613
studied O 0 0.0014663187
the O 0 0.00084502186
role O 0 0.00062212796
of O 0 0.003797153
xanthine B-Chemical 0 0.9999958
oxidase O 0 0.99998677
( O 0 0.21264665
XO O 0 0.99999523
) O 0 0.0018781681
, O 0 0.00027450363
which O 0 0.00019434799
is O 0 0.000107844295
implicated O 0 5.7603844e-05
in O 0 6.6645436e-05
the O 0 7.417944e-05
production O 0 0.00015196056
of O 0 0.00021731805
reactive O 0 0.036100846
oxygen O 1 0.99749446
species O 0 0.0002988375
, O 0 0.00015478815
in O 0 0.0001976185
dexamethasone B-Chemical 0 0.9994905
- O 0 0.0012837399
induced O 0 0.0016373207
hypertension B-Disease 2 0.9999831
( O 0 0.008463471
dex B-Chemical 0 0.9995184
- O 0 0.012880943
HT B-Disease 0 0.99729913
) O 0 0.004196858
. O 0 0.002462562

3 O 0 0.05500685
. O 0 0.05996203

Thirty O 0 0.004467748
male O 0 0.006753748
Sprague O 0 0.041765217
- O 0 0.0020281554
Dawley O 0 0.0037767142
rats O 0 0.00035906542
were O 0 0.00012830918
divided O 0 5.8095924e-05
randomly O 0 2.6349573e-05
into O 0 2.5644726e-05
four O 0 3.4545323e-05
treatment O 0 6.775603e-05
groups O 0 8.108794e-05
: O 0 0.000121551275
saline O 0 0.0007081841
, O 0 0.00026318815
dexamethasone B-Chemical 0 0.9995602
( O 0 0.0014368211
dex B-Chemical 0 0.999387
) O 0 0.0007856962
, O 0 0.000474559
allopurinol B-Chemical 0 0.99998426
plus O 0 0.0002873013
saline O 0 0.0025361166
, O 0 0.00039638416
and O 0 0.0008742152
allopurinol B-Chemical 0 0.9999726
plus O 0 0.0038320373
dex B-Chemical 0 0.9987305
. O 0 0.0039033473

4 O 0 0.05549409
. O 0 0.060457766

Systolic O 0 0.08149526
blood O 0 0.008234758
pressures O 0 0.003883672
( O 0 0.0019160359
SBP O 0 0.040870495
) O 0 0.0012358692
and O 0 0.0006826716
bodyweights O 0 0.003956181
were O 0 0.00042748856
recorded O 0 0.00037719536
each O 0 0.00034352834
alternate O 0 0.0010975616
day O 0 0.0013350409
. O 0 0.0025611045

Thymus O 0 0.050820272
weight O 0 0.0066910884
was O 0 0.0012859753
used O 0 0.0005518061
as O 0 0.00041743988
a O 0 0.00045863586
marker O 0 0.00047804406
of O 0 0.00045886502
glucocorticoid O 0 0.5349781
activity O 0 0.00031654944
, O 0 0.0003041281
and O 0 0.00033000828
serum O 0 0.10030609
urate B-Chemical 0 0.9991196
to O 0 0.00092239236
assess O 0 0.00077166304
XO O 0 0.9999105
inhibition O 0 0.03556098
. O 0 0.0034351202

5 O 0 0.055621844
. O 0 0.061102226

Dex B-Chemical 1 0.9954295
increased B-Disease 0 0.033687916
SBP I-Disease 0 0.9675655
( O 0 0.0026704164
110 O 0 0.0022169836
+ O 0 0.0015196892
/ O 0 0.0016657081
- O 0 0.00082285824
2 O 0 0.00027670345
- O 0 0.00046532194
126 O 0 0.00074379356
+ O 0 0.0004971308
/ O 0 0.0006483241
- O 0 0.00032791457
3 O 0 0.0001113936
mmHg O 0 0.00036852196
; O 0 0.00027347176
P O 0 0.002118615
< O 0 0.00012721057
0 O 0 0.00010161085
. O 0 9.701118e-05
001 O 0 0.0019157422
) O 0 0.00019236428
and O 0 0.00012045616
decreased B-Disease 0 0.00032470658
thymus I-Disease 0 0.0025753495
( I-Disease 0 0.00054642593
P I-Disease 0 0.005363721
< I-Disease 0 0.00012883563
0 I-Disease 0 0.00010099444
. I-Disease 0 9.954646e-05
001 I-Disease 0 0.00201306
) I-Disease 0 0.00024110149
and I-Disease 0 0.00021045278
bodyweights I-Disease 0 0.0067734616
( O 0 0.00054758496
P O 0 0.0030705172
" O 0 0.00043645984
< O 0 0.0003748989
0 O 0 0.00042315258
. O 0 0.00057728845
01 O 0 0.0028458484
) O 0 0.0025177177
. O 0 0.0026753065

Allopurinol B-Chemical 0 0.99975985
decreased O 0 0.012333462
serum O 0 0.45637065
urate B-Chemical 0 0.9987913
from O 0 0.0009190496
76 O 0 0.001191374
+ O 0 0.0009164328
/ O 0 0.0009875369
- O 0 0.0003988563
5 O 0 0.00010172534
to O 0 9.3218085e-05
30 O 0 0.000103795195
+ O 0 0.0002887493
/ O 0 0.00047532775
- O 0 0.0002794781
3 O 0 0.00010753173
micromol O 0 0.024282293
/ O 0 0.0013573592
L O 0 0.55316794
( O 0 0.00055740017
P O 0 0.004822895
< O 0 0.00012236253
0 O 0 9.2451715e-05
. O 0 8.440022e-05
001 O 0 0.0017262766
) O 0 0.00014882612
in O 0 7.8244855e-05
saline O 0 0.00028550104
and O 0 7.845464e-05
from O 0 6.922355e-05
84 O 0 0.00016746437
+ O 0 0.00023728503
/ O 0 0.00039063068
- O 0 0.00021004485
13 O 0 8.2345316e-05
to O 0 6.267559e-05
28 O 0 8.96007e-05
+ O 0 0.00020880841
/ O 0 0.00037179815
- O 0 0.00022626584
2 O 0 9.399286e-05
micromol O 0 0.02170251
/ O 0 0.0010127332
L O 0 0.34254518
in O 0 0.0003335811
dex B-Chemical 0 0.99851173
- O 0 0.00084354525
treated O 0 0.00056922575
( O 0 0.0006621866
P O 0 0.005351793
< O 0 0.00027723925
0 O 0 0.00026371863
. O 0 0.0003187122
01 O 0 0.0015572906
) O 0 0.0012446697
groups O 0 0.0013127602
. O 0 0.002132704

6 O 0 0.05100751
. O 0 0.05934413

Allopurinol B-Chemical 0 0.9995504
did O 0 0.0077958205
not O 0 0.0044402233
prevent O 0 0.007576151
dex B-Chemical 0 0.9979844
- O 0 0.04646627
HT B-Disease 0 0.99426055
. O 0 0.010357329

This O 0 0.0039194007
, O 0 0.0016912766
together O 0 0.000791049
with O 0 0.00060134847
our O 0 0.00047353012
previous O 0 0.00027259556
findings O 0 0.00048644454
that O 0 0.00032820762
allopurinol B-Chemical 0 0.9999902
failed O 0 0.00047121834
to O 0 0.00015765498
prevent O 0 0.0002867863
adrenocorticotrophic O 0 0.9932421
hormone O 0 0.540421
induced O 0 0.0011050532
hypertension B-Disease 2 0.9999846
, O 0 0.00024959043
suggests O 0 5.7373425e-05
that O 0 0.00017559985
XO O 0 0.9999906
activity O 0 0.00018371729
is O 0 9.295968e-05
not O 0 6.224454e-05
a O 0 8.7238135e-05
major O 0 6.872576e-05
determinant O 0 5.9039907e-05
of O 0 0.00035413538
GC O 0 0.5866898
- O 0 0.0018137436
HT B-Disease 0 0.98168725
in O 0 0.0005875139
the O 0 0.00087611144
rat O 0 0.0032852024
. O 0 0.0020548461

Side O 0 0.039581627
effects O 0 0.0015441256
of O 0 0.0011730673
postoperative O 0 0.0014731261
administration O 0 0.0019416116
of O 0 0.0012039009
methylprednisolone B-Chemical 0 0.9997874
and O 0 0.000773057
gentamicin B-Chemical 1 0.99688905
into O 0 0.00013161672
the O 0 0.0002294857
posterior O 0 0.0012962172
sub O 0 0.0013457309
- O 0 0.0010801613
Tenon O 0 0.014577666
' O 0 0.00093440234
s O 0 0.00088170316
space O 0 0.0013085584
. O 0 0.0021834748

PURPOSE O 0 0.0049296
: O 0 0.001727993
To O 0 0.000635352
assess O 0 0.00032632626
the O 0 0.0003953226
incidence O 0 0.00057025405
of O 0 0.00039545924
postoperative O 0 0.0011229845
emetic O 0 0.6028923
side O 0 0.0030639875
effects O 0 0.0001367506
after O 0 3.575895e-05
the O 0 7.7545716e-05
administration O 0 0.000451116
of O 0 0.00039236576
methylprednisolone B-Chemical 0 0.99986196
and O 0 0.00029972976
gentamicin B-Chemical 1 0.99648947
into O 0 4.4712575e-05
the O 0 8.171373e-05
posterior O 0 0.0005781675
sub O 0 0.0005604388
- O 0 0.00032920012
Tenon O 0 0.0066749733
' O 0 0.00013066523
s O 0 7.7957e-05
space O 0 6.0157636e-05
at O 0 5.8124682e-05
the O 0 0.00010069738
end O 0 0.00010297399
of O 0 0.0003708335
routine O 0 0.0008880105
cataract B-Disease 2 0.9985875
surgery O 0 0.0037263648
. O 0 0.0020644374

SETTING O 0 0.04152197
: O 0 0.032273103
St O 0 0.052543294
. O 0 0.029450553

Luke O 0 0.027687537
' O 0 0.0076752175
s O 0 0.0059017627
Hospital O 0 0.008002465
, O 0 0.0063855
Gwardamangia O 0 0.017736781
, O 0 0.008524488
Malta O 0 0.021689905
. O 0 0.0096424455

METHODS O 0 0.0020797125
: O 0 0.002270732
A O 0 0.005718327
double O 0 0.0016519661
- O 0 0.0016150137
blind O 0 0.005556703
double O 0 0.00076842215
- O 0 0.00058901706
armed O 0 0.00077405333
prospective O 0 0.0004526892
study O 0 0.00011372456
comprised O 0 7.861716e-05
40 O 0 8.415181e-05
patients O 0 9.9987126e-05
who O 0 9.6011834e-05
had O 0 5.6845915e-05
uneventful O 0 8.830081e-05
sutureless O 0 0.0005590525
phacoemulsification O 0 0.09404404
under O 0 7.585824e-05
sub O 0 0.00040970923
- O 0 0.00029867946
Tenon O 0 0.0066380682
' O 0 0.00013954821
s O 0 9.6742726e-05
local O 0 0.00018096874
infiltration O 0 0.004510777
of O 0 0.0002816753
3 O 0 0.00019120566
mL O 0 0.0007875916
of O 0 0.0007860681
plain O 0 0.07534995
lignocaine B-Chemical 0 0.999423
. O 0 0.0032942987

At O 0 0.00089465856
the O 0 0.000996867
end O 0 0.00051258126
of O 0 0.0006291587
the O 0 0.00042826417
procedure O 0 0.00037027468
, O 0 0.00044713993
Group O 0 0.0016471321
A O 0 0.0056285756
( O 0 0.0003386719
n O 0 0.00015692458
= O 0 0.00015540203
20 O 0 0.00010599488
) O 0 0.00014275817
had O 0 7.899238e-05
20 O 0 9.279733e-05
mg O 0 0.0014589542
/ O 0 0.0003070936
0 O 0 7.1042574e-05
. O 0 4.1538744e-05
5 O 0 4.523999e-05
mL O 0 0.00020912441
of O 0 0.00018113012
methylprednisolone B-Chemical 0 0.9988385
and O 0 0.00014356892
10 O 0 9.010992e-05
mg O 0 0.0020780207
/ O 0 0.00029883522
0 O 0 6.359971e-05
. O 0 3.672633e-05
5 O 0 3.961607e-05
mL O 0 0.00016456035
of O 0 0.000110519766
gentamicin B-Chemical 1 0.9789122
injected O 0 8.7886336e-05
into O 0 2.8878812e-05
the O 0 6.1882616e-05
posterior O 0 0.0004244476
sub O 0 0.00046223972
- O 0 0.00027461487
Tenon O 0 0.0053699617
' O 0 0.000100309524
s O 0 5.8817826e-05
space O 0 4.7237572e-05
and O 0 8.540593e-05
Group O 0 0.00059845834
B O 0 0.025953988
( O 0 0.00017614452
n O 0 8.745561e-05
= O 0 9.8421915e-05
20 O 0 7.348909e-05
) O 0 0.000105720115
had O 0 5.4599688e-05
the O 0 4.808265e-05
same O 0 3.273665e-05
combination O 0 7.878528e-05
injected O 0 6.616607e-05
into O 0 4.0470302e-05
the O 0 0.00011614993
anterior O 0 0.0009765364
sub O 0 0.0008951921
- O 0 0.0008138453
Tenon O 0 0.011764857
' O 0 0.0007785614
s O 0 0.00075586146
space O 0 0.0011566685
. O 0 0.0019687423

Postoperatively O 0 0.005492839
, O 0 0.0019195124
all O 0 0.0009087229
patients O 0 0.000763077
were O 0 0.0003626483
assessed O 0 0.00021011253
for O 0 0.00021967881
symptoms O 0 0.0031962593
of O 0 0.0018852969
nausea B-Disease 0 0.9999825
, I-Disease 0 0.008490476
vomiting I-Disease 0 0.99990046
, O 0 0.0027621707
and O 0 0.003187446
headache B-Disease 0 0.99850094
. O 0 0.003900664

A O 0 0.0933558
chi O 0 0.06733016
- O 0 0.0038870014
square O 0 0.0024358577
test O 0 0.0011825636
was O 0 0.0005834384
used O 0 0.0003331987
to O 0 0.00029031222
assess O 0 0.000182787
the O 0 0.00036727134
statistical O 0 0.00079463504
significance O 0 0.0006853646
of O 0 0.0013113267
results O 0 0.0023173313
. O 0 0.0030722562

RESULTS O 0 0.0038299377
: O 0 0.0014675872
Sixty O 0 0.00093236234
percent O 0 0.00033507717
in O 0 0.00033513023
Group O 0 0.0010899256
A O 0 0.0023020238
developed O 0 0.0004769885
postoperative B-Disease 0 0.0053615132
emetic I-Disease 0 0.9105053
symptoms I-Disease 0 0.56997883
, O 0 0.0009859125
headache B-Disease 0 0.9993242
, O 0 0.0002833812
or O 0 0.00012193961
both O 0 0.00014905975
; O 0 0.00016859037
1 O 0 9.9532976e-05
patient O 0 0.00013995254
in O 0 0.00020591156
Group O 0 0.0013399074
B O 0 0.023287078
developed O 0 0.0022712369
symptoms O 0 0.036385816
. O 0 0.0025925029

CONCLUSIONS O 0 0.01088663
: O 0 0.0015653766
The O 0 0.00056814606
administration O 0 0.001543811
of O 0 0.0012294909
methylprednisolone B-Chemical 0 0.9997093
and O 0 0.0008856538
gentamicin B-Chemical 1 0.9986929
in O 0 0.0002466652
the O 0 0.0001692643
posterior O 0 0.0009134184
sub O 0 0.00079079194
- O 0 0.000407151
Tenon O 0 0.01029682
' O 0 0.00014269285
s O 0 8.1186976e-05
space O 0 5.81858e-05
was O 0 6.6245804e-05
related O 0 2.9221808e-05
to O 0 5.2392574e-05
a O 0 9.786452e-05
high O 0 0.00017297766
incidence O 0 0.00021783914
of O 0 0.00017059634
side O 0 0.00167218
effects O 0 0.0002688063
including O 0 0.00041232636
nausea B-Disease 0 0.9999888
, I-Disease 0 0.0054524103
vomiting I-Disease 0 0.9999201
, O 0 0.0019940985
and O 0 0.0024587065
headache B-Disease 0 0.998565
. O 0 0.0032199915

All O 0 0.004848731
adverse O 0 0.019110732
effects O 0 0.004871579
were O 0 0.0044328435
self O 0 0.008928743
- O 0 0.007676859
limiting O 0 0.009166309
. O 0 0.0078116823

Assessment O 0 0.0026631774
of O 0 0.0017931575
a O 0 0.0013763307
new O 0 0.0010642188
non O 0 0.00097254815
- O 0 0.00086419383
invasive O 0 0.00043568583
index O 0 0.00029433123
of O 0 0.00026710643
cardiac O 0 0.0038787997
performance O 0 0.00025228554
for O 0 0.00010950492
detection O 0 0.00025243955
of O 0 0.00062266586
dobutamine B-Chemical 1 0.999602
- O 0 0.0017168459
induced O 0 0.0021712913
myocardial B-Disease 0 0.9996667
ischemia I-Disease 0 0.9998635
. O 0 0.004924892

BACKGROUND O 0 0.00966786
: O 0 0.0030179191
Electrocardiography O 0 0.008832436
has O 0 0.0006214624
a O 0 0.00062354904
very O 0 0.0006031782
low O 0 0.0006817809
sensitivity O 0 0.0010764797
in O 0 0.00034830993
detecting O 0 0.0006483908
dobutamine B-Chemical 1 0.9995448
- O 0 0.0022854286
induced O 0 0.0027291467
myocardial B-Disease 0 0.99964046
ischemia I-Disease 0 0.99985147
. O 0 0.0055724108

OBJECTIVES O 0 0.0033737253
: O 0 0.0017641134
To O 0 0.0006634506
assess O 0 0.00033938832
the O 0 0.00038944645
added O 0 0.00042849345
diagnostic O 0 0.00045640464
value O 0 0.00026409127
of O 0 0.0002377223
a O 0 0.00022719019
new O 0 0.00021253506
cardiac O 0 0.005262205
performance O 0 0.00030406608
index O 0 0.0002696462
( O 0 0.0003106555
dP O 0 0.0020562853
/ O 0 0.0004841293
dtejc O 0 0.0021480722
) O 0 0.00015720344
measurement O 0 4.6887373e-05
, O 0 6.598692e-05
based O 0 4.522464e-05
on O 0 4.8629365e-05
brachial O 0 0.09207328
artery O 0 0.01825771
flow O 0 0.0006300246
changes O 0 0.00012907875
, O 0 8.765407e-05
as O 0 4.9357644e-05
compared O 0 3.203682e-05
to O 0 3.979065e-05
standard O 0 4.727939e-05
12 O 0 4.2228323e-05
- O 0 0.0001461696
lead O 0 0.0008875368
ECG O 0 0.12552576
, O 0 8.96118e-05
for O 0 4.6477147e-05
detecting O 0 0.0001230346
dobutamine B-Chemical 1 0.99939895
- O 0 0.00037798873
induced O 0 0.00027915504
myocardial B-Disease 0 0.99974686
ischemia I-Disease 0 0.9999622
, O 0 0.00028245954
using O 0 0.00012611655
Tc99m B-Chemical 0 0.91866904
- I-Chemical 0 0.00060382765
Sestamibi I-Chemical 0 0.9418073
single O 0 0.00015794631
- O 0 0.00024544908
photon O 0 0.011094645
emission O 0 0.023091452
computed O 0 0.000106475054
tomography O 0 0.0011285685
as O 0 5.5255372e-05
the O 0 6.505173e-05
gold O 0 0.0062917266
standard O 0 6.2420535e-05
of O 0 9.385601e-05
comparison O 0 6.6998706e-05
to O 0 6.31773e-05
assess O 0 4.223702e-05
the O 0 0.00010422894
presence O 0 0.00016797581
or O 0 0.00024331565
absence O 0 0.0003959789
of O 0 0.0026179585
ischemia B-Disease 0 0.99962413
. O 0 0.003991122

METHODS O 0 0.0016462713
: O 0 0.0012357014
The O 0 0.0005088005
study O 0 0.00055605656
group O 0 0.0004086292
comprised O 0 0.00027531298
40 O 0 0.0002885869
patients O 0 0.0003399412
undergoing O 0 0.00045280487
Sestamibi B-Chemical 0 0.6632425
- O 0 0.0011794362
SPECT O 0 0.74759185
/ O 0 0.003184439
dobutamine B-Chemical 1 0.9980387
stress O 0 0.023960534
test O 0 0.0028413595
. O 0 0.0024175756

Simultaneous O 0 0.003450633
measurements O 0 0.0011065113
of O 0 0.0013489446
ECG O 0 0.041809414
and O 0 0.0009949872
brachial O 0 0.3154078
artery O 0 0.18611395
dP O 0 0.007553154
/ O 0 0.0010881003
dtejc O 0 0.0018007787
were O 0 0.00024442966
performed O 0 0.0001934602
at O 0 0.00022009035
each O 0 0.00038359282
dobutamine B-Chemical 1 0.98401386
level O 0 0.0019122807
. O 0 0.002651241

In O 0 0.0021225146
19 O 0 0.001831791
of O 0 0.0009459835
the O 0 0.0005827456
40 O 0 0.0005620779
patients O 0 0.0005938796
perfusion O 0 0.005037442
defects O 0 0.0010526829
compatible O 0 0.0005087417
with O 0 0.0009821681
ischemia B-Disease 0 0.99935704
were O 0 0.0007258709
detected O 0 0.00053231703
on O 0 0.00082840264
SPECT O 0 0.65425944
. O 0 0.003029417

The O 0 0.0018620703
increase O 0 0.001551561
in O 0 0.0013069435
dP O 0 0.0060679177
/ O 0 0.00137856
dtejc O 0 0.0016864544
during O 0 0.00013543863
infusion O 0 0.00038962354
of O 0 0.0003427653
dobutamine B-Chemical 1 0.997542
in O 0 0.00013863071
this O 0 0.00014960913
group O 0 0.0001744698
was O 0 0.00013502572
severely O 0 0.0011001256
impaired O 0 0.0005886093
as O 0 0.000113574795
compared O 0 7.591018e-05
to O 0 0.000119623204
the O 0 0.000228897
non O 0 0.0007133787
- O 0 0.0021866101
ischemic O 0 0.99898726
group O 0 0.004051451
. O 0 0.0023144623

dP O 0 0.023327107
/ O 0 0.004801855
dtejc O 0 0.005796195
outcome O 0 0.0008763369
was O 0 0.00051468745
combined O 0 0.00037806635
with O 0 0.00028660204
the O 0 0.00026185258
ECG O 0 0.06989418
results O 0 0.0002223487
, O 0 0.0002039819
giving O 0 0.00030134115
an O 0 0.0003480882
ECG O 0 0.34671232
- O 0 0.00039642683
enhanced O 0 0.00026533427
value O 0 0.0002477546
, O 0 0.00023774766
and O 0 0.00021967881
compared O 0 0.00020802645
to O 0 0.00051061454
ECG O 0 0.12189112
alone O 0 0.0020046628
. O 0 0.0024756403

RESULTS O 0 0.004476962
: O 0 0.0016761731
The O 0 0.0006646753
sensitivity O 0 0.001549928
improved O 0 0.00096400466
dramatically O 0 0.0005685998
from O 0 0.00026522376
16 O 0 0.00022828371
% O 0 0.00018578395
to O 0 0.000129135
79 O 0 0.0002592203
% O 0 0.00014441744
, O 0 0.00011682963
positive O 0 0.0001197048
predictive O 0 0.00022436907
value O 0 0.00013256731
increased O 0 0.00016422757
from O 0 7.909933e-05
60 O 0 8.2208164e-05
% O 0 7.571355e-05
to O 0 5.8607748e-05
68 O 0 0.0001191561
% O 0 7.2725576e-05
and O 0 6.1708946e-05
negative O 0 9.2023016e-05
predictive O 0 0.00017284756
value O 0 0.00010482049
from O 0 7.657727e-05
54 O 0 0.00015877256
% O 0 8.714409e-05
to O 0 7.1926086e-05
78 O 0 0.00020045698
% O 0 0.00011684211
, O 0 0.000117531126
and O 0 0.00011974681
specificity O 0 0.00037899366
decreased O 0 0.0003709113
from O 0 0.00017054233
90 O 0 0.00023823782
% O 0 0.00031979784
to O 0 0.0004109132
67 O 0 0.0013469977
% O 0 0.0014839169
. O 0 0.0019786854

CONCLUSIONS O 0 0.013466933
: O 0 0.0020406623
If O 0 0.00079418806
ECG O 0 0.043074004
alone O 0 0.00068113476
is O 0 0.0003817253
used O 0 0.00021934688
for O 0 0.00017440644
specificity O 0 0.00061551115
, O 0 0.00020764497
the O 0 0.00013016122
combination O 0 0.00021418631
with O 0 0.00031141643
dP O 0 0.0041490993
/ O 0 0.0004579991
dtejc O 0 0.0012803241
improved O 0 0.00017590249
the O 0 7.302969e-05
sensitivity O 0 0.0002661176
of O 0 0.000116095114
the O 0 9.552389e-05
test O 0 0.00014032483
and O 0 8.217133e-05
could O 0 5.755217e-05
be O 0 5.845286e-05
a O 0 9.7063654e-05
cost O 0 0.00013297166
- O 0 0.00015550446
savings O 0 0.00019948665
alternative O 0 4.4049717e-05
to O 0 5.265915e-05
cardiac O 0 0.0015404439
imaging O 0 0.00014948705
or O 0 5.6490928e-05
perfusion O 0 0.0012196226
studies O 0 6.529723e-05
to O 0 5.4647302e-05
detect O 0 9.181292e-05
myocardial B-Disease 0 0.99932575
ischemia I-Disease 0 0.99995077
, O 0 0.00040473085
especially O 0 0.00021611874
in O 0 0.00017374712
patients O 0 0.00030346023
unable O 0 0.00031309904
to O 0 0.0006550533
exercise O 0 0.0027443783
. O 0 0.001974135

Cocaine B-Chemical 0 0.99954706
- O 0 0.008924314
induced O 0 0.004715658
myocardial B-Disease 0 0.9994462
infarction I-Disease 2 0.9999522
: O 0 0.0026021432
clinical O 0 0.0020193348
observations O 0 0.0010735067
and O 0 0.0011461027
pathogenetic O 0 0.0044007334
considerations O 0 0.0023440134
. O 0 0.0032243412

Clinical O 0 0.0057093627
and O 0 0.0014658483
experimental O 0 0.0011007856
data O 0 0.00074297114
published O 0 0.0005392537
to O 0 0.00030841277
date O 0 0.00021818129
suggest O 0 8.589467e-05
several O 0 9.839058e-05
possible O 0 0.00011742056
mechanisms O 0 0.0001812058
by O 0 0.00019356611
which O 0 0.0004791449
cocaine B-Chemical 1 0.9994197
may O 0 0.00022870589
result O 0 0.00027137887
in O 0 0.00058949663
acute B-Disease 0 0.9912676
myocardial I-Disease 0 0.9999231
infarction I-Disease 2 0.9999881
. O 0 0.0067175208

In O 0 0.0019133623
individuals O 0 0.0018786812
with O 0 0.0011650447
preexisting O 0 0.0028115124
, O 0 0.0006914061
high O 0 0.00079451577
- O 0 0.0006712531
grade O 0 0.0034987435
coronary O 0 0.083797716
arterial O 0 0.06700837
narrowing O 0 0.005984867
, O 0 0.00035882334
acute B-Disease 0 0.9729417
myocardial I-Disease 0 0.9999703
infarction I-Disease 2 0.99999845
may O 0 0.00016371677
result O 0 7.086894e-05
from O 0 4.7090045e-05
an O 0 6.976964e-05
increase O 0 6.787244e-05
in O 0 0.000112342765
myocardial O 0 0.99753237
oxygen B-Chemical 1 0.9968156
demand O 0 0.0002382728
associated O 0 0.00010150808
with O 0 0.00038396966
cocaine B-Chemical 1 0.99985814
- O 0 0.0005191762
induced O 0 0.0001895097
increase O 0 0.00018886298
in O 0 0.00020590429
rate O 0 0.00042662575
- O 0 0.0009948906
pressure O 0 0.006135111
product O 0 0.002870836
. O 0 0.002019504

In O 0 0.0017577844
other O 0 0.0011888393
individuals O 0 0.001034061
with O 0 0.0005432058
no O 0 0.00026869358
underlying O 0 0.0011366032
atherosclerotic B-Disease 2 0.99991655
obstruction I-Disease 0 0.99332255
, O 0 0.0006933936
coronary B-Disease 0 0.2369376
occlusion I-Disease 0 0.040413696
may O 0 0.00013390677
be O 0 0.00010507688
due O 0 9.0583155e-05
to O 0 0.00025716453
spasm B-Disease 2 0.99783057
, O 0 0.0011936476
thrombus B-Disease 0 0.998755
, O 0 0.0010907749
or O 0 0.0008224666
both O 0 0.0015473726
. O 0 0.0021975196

With O 0 0.0024362353
regard O 0 0.0011755729
to O 0 0.0016100599
spasm B-Disease 2 0.9943792
, O 0 0.0008499462
the O 0 0.0003872472
clinical O 0 0.0007543243
findings O 0 0.0004926346
are O 0 0.00020997094
largely O 0 0.00026544384
circumstantial O 0 0.00066809333
, O 0 0.00018883366
and O 0 0.0001297837
the O 0 0.00012832595
locus O 0 0.00028275457
of O 0 0.0005980939
cocaine B-Chemical 1 0.999826
- O 0 0.001567732
induced O 0 0.0012501546
vasoconstriction O 0 0.9980447
remains O 0 0.0013219682
speculative O 0 0.0041700187
. O 0 0.0023073414

Although O 0 0.001498333
certain O 0 0.0012382871
clinical O 0 0.0016363717
and O 0 0.00055961043
experimental O 0 0.00047368318
findings O 0 0.00044889396
support O 0 0.00016608376
the O 0 0.00017487234
hypothesis O 0 0.00023182739
that O 0 0.00017721798
spasm B-Disease 2 0.9912635
involves O 0 9.4707575e-05
the O 0 0.00012327368
epicardial O 0 0.0008291767
, O 0 0.0001812184
medium O 0 0.0006489176
- O 0 0.00034789313
size O 0 0.00032370083
vessels O 0 0.0019279473
, O 0 0.00023438709
other O 0 0.00020253593
data O 0 0.00035988208
suggest O 0 0.00036074268
intramural O 0 0.016058225
vasoconstriction O 0 0.9968671
. O 0 0.003126661

Diffuse O 0 0.025052467
intramural O 0 0.042285796
vasoconstriction O 0 0.99567115
is O 0 0.0011741023
not O 0 0.00052006304
consistent O 0 0.0004352035
with O 0 0.00050447107
reports O 0 0.00060909503
of O 0 0.0008525618
segmental O 0 0.013330177
, O 0 0.0014979906
discrete O 0 0.0022085065
infarction B-Disease 2 0.9998104
. O 0 0.0047756867

Whereas O 0 0.0021940824
certain O 0 0.0013050184
in O 0 0.00075636944
vivo O 0 0.000750073
data O 0 0.00037725558
suggest O 0 0.00012165284
that O 0 0.00012927101
these O 0 0.0002345617
effects O 0 0.00027873644
are O 0 0.00033354163
alpha O 0 0.5998961
- O 0 0.00058712205
mediated O 0 0.00011903924
, O 0 0.00018817328
other O 0 0.00013059023
in O 0 0.00014349393
vitro O 0 0.00028562386
data O 0 0.00029198686
suggest O 0 0.00020881319
the O 0 0.0006310088
opposite O 0 0.0017958326
. O 0 0.0022238735

The O 0 0.001893779
finding O 0 0.002436233
of O 0 0.002927173
cocaine B-Chemical 1 0.99969864
- O 0 0.0027641417
induced O 0 0.0010071107
vasoconstriction O 0 0.9972326
in O 0 0.00029734292
segments O 0 0.0002335383
of O 0 0.00020362201
( O 0 0.00024328945
noninnervated O 0 0.0008112194
) O 0 0.0001771222
human O 0 0.00013812035
umbilical O 0 0.0019505842
artery O 0 0.0041135238
suggests O 0 3.6904363e-05
that O 0 3.944815e-05
the O 0 5.5559405e-05
presence O 0 5.988193e-05
or O 0 5.0300667e-05
absence O 0 3.9403112e-05
of O 0 9.633051e-05
intact O 0 0.00011192298
innervation O 0 0.00043838914
is O 0 5.77962e-05
not O 0 4.098742e-05
sufficient O 0 3.620834e-05
to O 0 4.229365e-05
explain O 0 4.516671e-05
the O 0 6.0642324e-05
discrepant O 0 0.00017752546
data O 0 8.651523e-05
involving O 0 7.865825e-05
the O 0 9.452768e-05
possibility O 0 0.000117040705
of O 0 0.00048877904
alpha O 0 0.4918118
- O 0 0.0012675074
mediated O 0 0.00056025083
effects O 0 0.0020370008
. O 0 0.0024410903

Finally O 0 0.0026341255
, O 0 0.0018625789
the O 0 0.00085331604
contribution O 0 0.00055552623
of O 0 0.00067626644
a O 0 0.0006344516
primary O 0 0.00059376296
, O 0 0.00089897815
thrombotic B-Disease 0 0.99733895
effect O 0 0.0005012032
of O 0 0.0014146738
cocaine B-Chemical 1 0.99975115
has O 0 0.00050246913
not O 0 0.00051029073
been O 0 0.00072074257
excluded O 0 0.0016603463
. O 0 0.0020867027

Proteomic O 0 0.008746755
analysis O 0 0.0016562672
of O 0 0.0015167268
striatal O 0 0.15792647
proteins O 0 0.0007072297
in O 0 0.00033654505
the O 0 0.0002917239
rat O 0 0.0005718659
model O 0 0.00040466548
of O 0 0.001013866
L B-Chemical 0 0.985802
- I-Chemical 0 0.016044097
DOPA I-Chemical 0 0.9999753
- O 0 0.0076048872
induced O 0 0.008446681
dyskinesia B-Disease 0 0.99994373
. O 0 0.0044330284

L B-Chemical 0 0.98529226
- I-Chemical 0 0.035662334
DOPA I-Chemical 0 0.9999138
- O 0 0.0074183308
induced O 0 0.004972696
dyskinesia B-Disease 0 0.99998796
( O 0 0.0077315536
LID B-Disease 0 0.9998355
) O 0 0.00075187854
is O 0 0.00016879561
among O 0 0.00012249609
the O 0 9.785173e-05
motor O 0 0.00047834302
complications O 0 0.0011923619
that O 0 5.3822794e-05
arise O 0 5.3532152e-05
in O 0 0.00011295226
Parkinson B-Disease 0 0.9942924
' I-Disease 0 0.00022258861
s I-Disease 0 0.00016476041
disease I-Disease 0 0.09154442
( O 0 0.0005355939
PD B-Disease 0 0.99703974
) O 0 0.00026051732
patients O 0 0.000110350746
after O 0 3.668975e-05
a O 0 0.00013521475
prolonged O 0 0.00027965024
treatment O 0 0.00030678164
with O 0 0.0011097784
L B-Chemical 0 0.97602016
- I-Chemical 0 0.018281324
DOPA I-Chemical 0 0.99991214
. O 0 0.0044814805

To O 0 0.0018812877
this O 0 0.0014797609
day O 0 0.0007637209
, O 0 0.0007091762
transcriptome O 0 0.00065962056
analysis O 0 0.0003426673
has O 0 0.00017774547
been O 0 0.00012275475
performed O 0 0.000109613466
in O 0 0.00010807439
a O 0 0.0001587397
rat O 0 0.00026095632
model O 0 0.00015929392
of O 0 0.0004221697
LID B-Disease 0 0.9998716
[ O 0 0.0014664513
Neurobiol O 0 0.030341556
. O 0 9.984668e-05
Dis O 0 0.0015217998
. O 0 7.2477655e-05
, O 0 0.0001130694
17 O 0 0.00014061399
( O 0 0.00014885636
2004 O 0 0.00022579794
) O 0 0.0002071269
, O 0 0.00017397225
219 O 0 0.0008703405
] O 0 0.00026311007
but O 0 9.839583e-05
information O 0 9.2481074e-05
regarding O 0 8.258665e-05
the O 0 0.0001928241
proteome O 0 0.0006223868
is O 0 0.00045424534
still O 0 0.0006908363
lacking O 0 0.0011881851
. O 0 0.0020809795

In O 0 0.0016568366
the O 0 0.001178726
present O 0 0.00073146715
study O 0 0.00079368305
, O 0 0.00044498924
we O 0 0.0001434012
investigated O 0 0.00015421933
the O 0 0.00014333104
changes O 0 0.00015482477
occurring O 0 0.00010870166
at O 0 5.7471716e-05
the O 0 7.594588e-05
protein O 0 0.00013814008
level O 0 6.253284e-05
in O 0 8.186271e-05
striatal O 0 0.08643424
samples O 0 7.90033e-05
obtained O 0 5.43747e-05
from O 0 4.348285e-05
the O 0 6.604094e-05
unilaterally O 0 0.0009165402
6 B-Chemical 0 5.9379418e-05
- I-Chemical 0 0.00021830865
hydroxydopamine I-Chemical 0 0.3691946
- O 0 0.00027365016
lesion O 0 0.0005116888
rat O 0 0.00017438762
model O 0 8.6904605e-05
of O 0 0.00020027244
PD B-Disease 0 0.9962949
treated O 0 0.00018909218
with O 0 0.00014567758
saline O 0 0.0011526243
, O 0 0.00023042389
L B-Chemical 0 0.96783674
- I-Chemical 0 0.0023453317
DOPA I-Chemical 0 0.9999924
or O 0 0.00044628835
bromocriptine B-Chemical 0 0.9999497
using O 0 9.142745e-05
two O 0 5.9710404e-05
- O 0 0.00012736702
dimensional O 0 0.00010163303
difference O 0 6.108868e-05
gel O 0 0.001068608
electrophoresis O 0 0.0030132341
and O 0 0.00033541324
mass O 0 0.003195841
spectrometry O 0 0.2941675
( O 0 0.0020610532
MS O 2 0.98673266
) O 0 0.0032208734
. O 0 0.0022859199

Rats O 0 0.0042231013
treated O 0 0.002283585
with O 0 0.0024797372
L B-Chemical 0 0.98186696
- I-Chemical 0 0.008823186
DOPA I-Chemical 0 0.99995327
were O 0 0.0004375736
allocated O 0 0.00013378411
to O 0 0.00010860852
two O 0 8.294663e-05
groups O 0 9.496804e-05
based O 0 8.0641774e-05
on O 0 7.638778e-05
the O 0 0.00014668198
presence O 0 0.00021968865
or O 0 0.00030272166
absence O 0 0.0004706492
of O 0 0.0028863184
LID B-Disease 0 0.9993728
. O 0 0.0038192514

Among O 0 0.0027812314
the O 0 0.0012807125
2000 O 0 0.001206045
spots O 0 0.0008722017
compared O 0 0.00026164396
for O 0 0.00021049313
statistical O 0 0.00036474716
difference O 0 0.00012061133
, O 0 0.000176734
67 O 0 0.0002282345
spots O 0 0.00022707367
were O 0 9.9458885e-05
significantly O 0 0.00010924003
changed O 0 7.8149846e-05
in O 0 6.1180785e-05
abundance O 0 7.4538104e-05
and O 0 6.955229e-05
identified O 0 5.7587808e-05
using O 0 6.0275757e-05
matrix O 0 0.00029246492
- O 0 0.0002577492
assisted O 0 0.00023589819
laser O 0 0.0009311301
desorption O 0 0.79150033
/ O 0 0.0011467726
ionization O 0 0.18119356
time O 0 5.8241254e-05
- O 0 0.00015650634
of O 0 0.00013004646
- O 0 0.00027275126
flight O 0 0.00053019536
MS O 2 0.98703545
, O 0 0.0001497407
atmospheric O 0 0.036178518
pressure O 0 0.0023078467
matrix O 0 0.00038212628
- O 0 0.00024207353
assisted O 0 0.00021139419
laser O 0 0.0007526471
desorption O 0 0.7022463
/ O 0 0.0011363865
ionization O 0 0.3122271
and O 0 0.0002617323
HPLC O 0 0.867978
coupled O 0 0.0002602155
tandem O 0 0.0008325374
MS O 2 0.9873661
( O 0 0.0006642288
LC O 0 0.31244215
/ O 0 0.0038636697
MS O 2 0.99657565
/ O 0 0.0104763
MS O 2 0.99464875
) O 0 0.003882444
. O 0 0.0025482012

Out O 0 0.0055383076
of O 0 0.0016833488
these O 0 0.0012076221
67 O 0 0.0012112176
proteins O 0 0.0007159013
, O 0 0.0008599135
LID B-Disease 0 0.9992362
significantly O 0 0.0004849091
changed O 0 0.00017535524
the O 0 0.000115721865
expression O 0 0.00012057638
level O 0 6.926899e-05
of O 0 0.00010780174
five O 0 5.474724e-05
proteins O 0 0.00013974917
: O 0 0.00026283207
alphabeta O 0 0.8698723
- O 0 0.00071230467
crystalin O 0 0.010871412
, O 0 0.00035818163
gamma O 0 0.88955945
- O 0 0.0010784905
enolase O 0 0.035097983
, O 0 0.00040745386
guanidoacetate O 0 0.7844652
methyltransferase O 0 0.15608628
, O 0 0.00025549557
vinculin O 0 0.005594082
, O 0 0.00026398478
and O 0 0.00030567747
proteasome O 0 0.46821344
alpha O 0 0.7844139
- O 0 0.0019005584
2 O 0 0.00081207056
subunit O 0 0.0046368013
. O 0 0.0023736965

Complementary O 0 0.0028161646
techniques O 0 0.0014086497
such O 0 0.0006479124
as O 0 0.0005539711
western O 0 0.00074981106
immunoblotting O 0 0.00044084698
and O 0 0.0002599482
immunohistochemistry O 0 0.0004631717
were O 0 0.00011197957
performed O 0 6.8221285e-05
to O 0 5.8495294e-05
investigate O 0 4.134265e-05
the O 0 8.038289e-05
validity O 0 0.00015978343
of O 0 0.0001433581
the O 0 0.00012979038
data O 0 0.00016883327
obtained O 0 0.00019478399
using O 0 0.00022251542
the O 0 0.0004132749
proteomic O 0 0.0014660213
approach O 0 0.0015035026
. O 0 0.0020066956

In O 0 0.0021648072
conclusion O 0 0.0015997102
, O 0 0.0013380895
this O 0 0.0008179102
study O 0 0.0005941916
provides O 0 0.0002834266
new O 0 0.00032732173
insights O 0 0.00024851854
into O 0 0.00011102393
the O 0 0.0002180981
protein O 0 0.00048900687
changes O 0 0.0005987664
occurring O 0 0.0009246076
in O 0 0.0016952987
LID B-Disease 0 0.9987342
. O 0 0.0038654485

Cardiac O 0 0.01825093
Angiography O 0 0.0066379863
in O 0 0.001065324
Renally O 0 0.008050434
Impaired O 0 0.0028887154
Patients O 0 0.00053740444
( O 0 0.00048073466
CARE O 0 0.0013714123
) O 0 0.0003292698
study O 0 0.0001767426
: O 0 0.0001438545
a O 0 0.0001336403
randomized O 0 0.00013763626
double O 0 0.0001928745
- O 0 0.0002366576
blind O 0 0.0013210656
trial O 0 0.00011770901
of O 0 0.00011245447
contrast O 0 0.0002923802
- O 0 0.0004604709
induced O 0 0.0007437666
nephropathy B-Disease 2 0.9999957
in O 0 0.0004374205
patients O 0 0.0005833146
with O 0 0.00082824717
chronic B-Disease 0 0.94264644
kidney I-Disease 0 0.9965108
disease I-Disease 0 0.9897597
. O 0 0.0031617666

BACKGROUND O 0 0.008816674
: O 0 0.0021749889
No O 0 0.00095161225
direct O 0 0.00045827052
comparisons O 0 0.00025714393
exist O 0 0.0001555445
of O 0 0.00019734979
the O 0 0.0001954146
renal O 0 0.53142804
tolerability O 0 0.0046184617
of O 0 0.00015216252
the O 0 9.835343e-05
low O 0 0.00026446368
- O 0 0.00027717315
osmolality O 0 0.28145367
contrast B-Chemical 0 0.001136439
medium I-Chemical 0 0.048573244
iopamidol B-Chemical 1 0.9996749
with O 0 0.00016434943
that O 0 5.13774e-05
of O 0 0.00010557281
the O 0 0.00013192846
iso O 0 0.8703934
- O 0 0.00045015846
osmolality O 0 0.32972547
contrast B-Chemical 0 0.0012932307
medium I-Chemical 0 0.03496205
iodixanol B-Chemical 1 0.9992879
in O 0 0.00046871413
high O 0 0.0014148557
- O 0 0.001652147
risk O 0 0.0074571557
patients O 0 0.0028552169
. O 0 0.0020352625

METHODS O 0 0.0018893427
AND O 0 0.0010746649
RESULTS O 0 0.0014378573
: O 0 0.00067101454
The O 0 0.0002780988
present O 0 0.0002581969
study O 0 0.00034102637
is O 0 0.00023487188
a O 0 0.0003301996
multicenter O 0 0.0096474
, O 0 0.00020209051
randomized O 0 0.00017279942
, O 0 0.00012353127
double O 0 0.00019323455
- O 0 0.00021109528
blind O 0 0.0008823082
comparison O 0 5.4779823e-05
of O 0 0.000143189
iopamidol B-Chemical 1 0.99895084
and O 0 0.00025552287
iodixanol B-Chemical 1 0.9983171
in O 0 0.00011651355
patients O 0 0.00015647245
with O 0 0.00020733674
chronic B-Disease 0 0.85213184
kidney I-Disease 0 0.99359185
disease I-Disease 0 0.96999276
( O 0 0.00018061808
estimated O 0 8.709973e-05
glomerular O 0 0.7283051
filtration O 0 0.0033876414
rate O 0 0.000104858875
, O 0 7.6259166e-05
20 O 0 5.401778e-05
to O 0 4.9161008e-05
59 O 0 0.00010964808
mL O 0 0.00026250246
/ O 0 0.00019729316
min O 0 0.000117663105
) O 0 0.00015227574
who O 0 0.00013492173
underwent O 0 0.000121489866
cardiac O 0 0.002352455
angiography O 0 0.0063374443
or O 0 0.00024306985
percutaneous O 0 0.0006014328
coronary O 0 0.015360652
interventions O 0 0.0011218811
. O 0 0.0017179609

Serum O 0 0.74159443
creatinine B-Chemical 1 0.9986688
( O 0 0.006004842
SCr O 0 0.96648073
) O 0 0.0012669547
levels O 0 0.00035800805
and O 0 0.00025976013
estimated O 0 0.00024337087
glomerular O 0 0.6046353
filtration O 0 0.0033417854
rate O 0 0.00016992829
were O 0 9.2649585e-05
assessed O 0 5.287896e-05
at O 0 4.8845344e-05
baseline O 0 7.556885e-05
and O 0 0.00010232396
2 O 0 8.1779224e-05
to O 0 8.244871e-05
5 O 0 8.733402e-05
days O 0 7.8329285e-05
after O 0 0.00014371918
receiving O 0 0.0009935579
medications O 0 0.008635396
. O 0 0.0020277319

The O 0 0.0014914902
primary O 0 0.0012116791
outcome O 0 0.0009601118
was O 0 0.0006427287
a O 0 0.0005751013
postdose O 0 0.0012361623
SCr O 0 0.6880329
increase O 0 0.0003501
> O 0 0.0005610829
or O 0 0.00018436972
= O 0 0.00020556865
0 O 0 9.748171e-05
. O 0 6.646334e-05
5 O 0 8.016395e-05
mg O 0 0.001198739
/ O 0 0.00057685806
dL O 0 0.0011960748
( O 0 0.00024126477
44 O 0 0.00019451838
. O 0 0.000100688834
2 O 0 0.00015876953
micromol O 0 0.010149498
/ O 0 0.0017647856
L O 0 0.11981602
) O 0 0.0008947197
over O 0 0.00045123923
baseline O 0 0.0012254623
. O 0 0.002130037

Secondary O 0 0.0036648961
outcomes O 0 0.0014670254
were O 0 0.0007915542
a O 0 0.00074049714
postdose O 0 0.0014230411
SCr O 0 0.61054456
increase O 0 0.00042567617
> O 0 0.00065961113
or O 0 0.00021778973
= O 0 0.00025130154
25 O 0 0.00019114804
% O 0 0.00013341963
, O 0 0.0001080983
a O 0 0.000114503026
postdose O 0 0.00017675526
estimated O 0 8.50932e-05
glomerular O 0 0.4412482
filtration O 0 0.0020013968
rate O 0 0.00011151731
decrease O 0 0.000116748786
of O 0 0.00014521436
> O 0 0.0002900726
or O 0 0.00010923034
= O 0 0.00015514989
25 O 0 0.00014320087
% O 0 0.00011594433
, O 0 0.000110048946
and O 0 9.624337e-05
the O 0 9.983668e-05
mean O 0 8.858909e-05
peak O 0 0.0003068764
change O 0 0.0004882833
in O 0 0.0009947617
SCr O 0 0.9532534
. O 0 0.0029663902

In O 0 0.0025689565
414 O 0 0.010003016
patients O 0 0.0016635837
, O 0 0.00079681
contrast O 0 0.0005937489
volume O 0 0.00084710756
, O 0 0.00034268782
presence O 0 0.00026759531
of O 0 0.001129216
diabetes B-Disease 0 0.9999225
mellitus I-Disease 0 0.9994154
, O 0 0.00031643812
use O 0 0.000119253295
of O 0 0.0004304875
N B-Chemical 0 0.999571
- I-Chemical 0 0.0032924584
acetylcysteine I-Chemical 0 0.99995613
, O 0 0.00014224199
mean O 0 3.929429e-05
baseline O 0 9.220906e-05
SCr O 0 0.7885404
, O 0 0.00012658293
and O 0 7.98181e-05
estimated O 0 9.9760175e-05
glomerular O 0 0.66191703
filtration O 0 0.0026024848
rate O 0 0.00014392353
were O 0 0.00010750445
comparable O 0 9.5923875e-05
in O 0 0.00017423986
the O 0 0.0003236669
2 O 0 0.0004940573
groups O 0 0.0008970073
. O 0 0.0016004904

SCr O 0 0.83008766
increases O 0 0.002678158
> O 0 0.0029807664
or O 0 0.00087642967
= O 0 0.00076599704
0 O 0 0.0003214436
. O 0 0.00018153904
5 O 0 0.0001695515
mg O 0 0.0019788453
/ O 0 0.0007213692
dL O 0 0.0009747447
occurred O 0 0.00012896961
in O 0 0.000114527706
4 O 0 8.200092e-05
. O 0 5.9038444e-05
4 O 0 6.1668245e-05
% O 0 8.9675144e-05
( O 0 9.993289e-05
9 O 0 5.406792e-05
of O 0 8.869948e-05
204 O 0 0.0003737954
patients O 0 0.00013973545
) O 0 0.00011843
after O 0 4.5133642e-05
iopamidol B-Chemical 1 0.9953773
and O 0 0.00016824012
6 O 0 5.7858848e-05
. O 0 4.4412544e-05
7 O 0 4.5509307e-05
% O 0 7.123427e-05
( O 0 8.1216254e-05
14 O 0 4.6003028e-05
of O 0 7.749021e-05
210 O 0 0.0002903778
patients O 0 0.00013464464
) O 0 0.000114446484
after O 0 4.532805e-05
iodixanol B-Chemical 1 0.9977176
( O 0 0.0007665747
P O 0 0.01934454
= O 0 0.00014837341
0 O 0 7.0357724e-05
. O 0 5.388504e-05
39 O 0 0.00013458137
) O 0 0.00013846741
, O 0 8.3983694e-05
whereas O 0 6.524788e-05
rates O 0 7.54312e-05
of O 0 0.00015967117
SCr O 0 0.8729512
increases O 0 0.00017809885
> O 0 0.00032828428
or O 0 0.00010076877
= O 0 0.0001306241
25 O 0 0.00011267837
% O 0 8.763394e-05
were O 0 7.527971e-05
9 O 0 5.932242e-05
. O 0 4.3918684e-05
8 O 0 5.2295687e-05
% O 0 7.47689e-05
and O 0 7.729899e-05
12 O 0 5.3361204e-05
. O 0 5.8088113e-05
4 O 0 7.288373e-05
% O 0 0.00013098684
, O 0 0.00020173242
respectively O 0 0.00056959863
( O 0 0.0006078572
P O 0 0.0048763175
= O 0 0.0004524079
0 O 0 0.00033907575
. O 0 0.00041443005
44 O 0 0.0012208207
) O 0 0.002131292
. O 0 0.0023637724

In O 0 0.0020125993
patients O 0 0.0023750914
with O 0 0.002736533
diabetes B-Disease 0 0.99889934
, O 0 0.0016934404
SCr O 0 0.95554006
increases O 0 0.0005369838
> O 0 0.00073781406
or O 0 0.0002038353
= O 0 0.00021228737
0 O 0 9.49896e-05
. O 0 6.1343366e-05
5 O 0 7.029642e-05
mg O 0 0.001075842
/ O 0 0.0004675709
dL O 0 0.00081607455
were O 0 0.00010824519
5 O 0 6.3151645e-05
. O 0 4.9521772e-05
1 O 0 6.143388e-05
% O 0 8.096323e-05
( O 0 8.976755e-05
4 O 0 4.2659507e-05
of O 0 7.0601825e-05
78 O 0 0.00014523236
patients O 0 0.000121714584
) O 0 0.0001312827
with O 0 0.00017732057
iopamidol B-Chemical 1 0.9983517
and O 0 0.00018875334
13 O 0 0.000106039966
. O 0 4.4985783e-05
0 O 0 5.421228e-05
% O 0 7.027819e-05
( O 0 7.222017e-05
12 O 0 2.9047294e-05
of O 0 6.2428866e-05
92 O 0 0.0001522316
patients O 0 0.0001176041
) O 0 0.00012833452
with O 0 0.00018328721
iodixanol B-Chemical 1 0.999212
( O 0 0.00088180054
P O 0 0.022882141
= O 0 0.00014857882
0 O 0 6.972487e-05
. O 0 5.1701587e-05
11 O 0 8.45865e-05
) O 0 0.00012803408
, O 0 9.617887e-05
whereas O 0 0.00012221305
SCr O 0 0.7665682
increases O 0 0.00017420812
> O 0 0.00032083556
or O 0 0.000102063575
= O 0 0.00013078464
25 O 0 0.000110530935
% O 0 8.404411e-05
were O 0 7.069993e-05
10 O 0 6.329984e-05
. O 0 4.7886333e-05
3 O 0 5.2928048e-05
% O 0 7.6472475e-05
and O 0 8.085075e-05
15 O 0 6.8790556e-05
. O 0 6.313527e-05
2 O 0 8.438332e-05
% O 0 0.00013668674
, O 0 0.00020670787
respectively O 0 0.00057708955
( O 0 0.00060870365
P O 0 0.0047028945
= O 0 0.00045003963
0 O 0 0.0003386164
. O 0 0.00041628073
37 O 0 0.0014124634
) O 0 0.0022568926
. O 0 0.0024320253

Mean O 0 0.0013967342
post O 0 0.0011709265
- O 0 0.0023397643
SCr O 0 0.5472288
increases O 0 0.0006178145
were O 0 0.00034586826
significantly O 0 0.00029282208
less O 0 0.00022530914
with O 0 0.00046821006
iopamidol B-Chemical 1 0.9995049
( O 0 0.00043213746
all O 0 0.00014490976
patients O 0 0.00018274032
: O 0 0.00012846712
0 O 0 7.363753e-05
. O 0 5.2510713e-05
07 O 0 0.00022212557
versus O 0 5.361185e-05
0 O 0 5.5399832e-05
. O 0 3.873768e-05
12 O 0 4.1690895e-05
mg O 0 0.00088432815
/ O 0 0.00045712135
dL O 0 0.0009935702
, O 0 0.00012983508
6 O 0 5.0774797e-05
. O 0 4.1833395e-05
2 O 0 4.59265e-05
versus O 0 4.5231496e-05
10 O 0 5.8965747e-05
. O 0 4.7187325e-05
6 O 0 5.504175e-05
micromol O 0 0.008910289
/ O 0 0.0010743974
L O 0 0.50675803
, O 0 0.00042914262
P O 0 0.0121354805
= O 0 0.0001619389
0 O 0 8.04978e-05
. O 0 6.747883e-05
03 O 0 0.00056717324
; O 0 0.00011859172
patients O 0 0.00013716146
with O 0 0.0002602083
diabetes B-Disease 0 0.99778605
: O 0 0.00021015022
0 O 0 7.463384e-05
. O 0 4.706333e-05
07 O 0 0.00020201481
versus O 0 4.8597976e-05
0 O 0 5.26046e-05
. O 0 3.974893e-05
16 O 0 6.828924e-05
mg O 0 0.0011227106
/ O 0 0.0004955003
dL O 0 0.0010363527
, O 0 0.00013436965
6 O 0 5.3598043e-05
. O 0 4.535961e-05
2 O 0 5.1643343e-05
versus O 0 5.3501837e-05
14 O 0 6.9678266e-05
. O 0 6.178332e-05
1 O 0 0.000106209984
micromol O 0 0.0118985735
/ O 0 0.001507109
L O 0 0.37829387
, O 0 0.0007793765
P O 0 0.007999202
= O 0 0.00055082
0 O 0 0.0004252357
. O 0 0.0005581505
01 O 0 0.0027481082
) O 0 0.0024251516
. O 0 0.0025863154

CONCLUSIONS O 0 0.012599658
: O 0 0.0017967306
The O 0 0.00058273337
rate O 0 0.0006506701
of O 0 0.0006529929
contrast O 0 0.0009878963
- O 0 0.0013879626
induced O 0 0.0019937484
nephropathy B-Disease 2 0.9999958
, O 0 0.0006072294
defined O 0 0.00011513224
by O 0 0.0001030293
multiple O 0 9.089153e-05
end O 0 4.5378732e-05
points O 0 7.531554e-05
, O 0 9.5398274e-05
is O 0 6.534033e-05
not O 0 5.3798987e-05
statistically O 0 4.8956892e-05
different O 0 2.2982145e-05
after O 0 1.5185595e-05
the O 0 4.3722357e-05
intraarterial O 0 0.0017349131
administration O 0 0.0003068214
of O 0 0.00022851779
iopamidol B-Chemical 1 0.99951005
or O 0 0.0002318159
iodixanol B-Chemical 1 0.99874866
to O 0 0.00015127081
high O 0 0.0005225169
- O 0 0.0004977726
risk O 0 0.0017317728
patients O 0 0.00029292985
, O 0 0.00018046798
with O 0 0.00023420146
or O 0 0.00031241024
without O 0 0.0012256596
diabetes B-Disease 0 0.99971
mellitus I-Disease 0 0.9992785
. O 0 0.0031574054

Any O 0 0.003210909
true O 0 0.0017271363
difference O 0 0.00056427123
between O 0 0.0003768503
the O 0 0.0004977742
agents O 0 0.0015472973
is O 0 0.0004503692
small O 0 0.00044190136
and O 0 0.00031256158
not O 0 0.0002511128
likely O 0 0.00024911138
to O 0 0.00036930977
be O 0 0.00058147695
clinically O 0 0.0029406669
significant O 0 0.0018917477
. O 0 0.002409995

A O 0 0.018991003
novel O 0 0.003336869
compound O 0 0.20225866
, O 0 0.0025942344
maltolyl B-Chemical 1 0.36465797
p I-Chemical 1 0.001834781
- I-Chemical 1 0.0027969477
coumarate I-Chemical 1 0.99597484
, O 0 0.0006674926
attenuates O 0 0.0027723983
cognitive B-Disease 2 0.9953844
deficits I-Disease 2 0.9817463
and O 0 0.00030885794
shows O 0 0.00010134049
neuroprotective O 0 0.021412099
effects O 0 0.00021788196
in O 0 0.00015826272
vitro O 0 0.00031775134
and O 0 0.00028980753
in O 0 0.00038963096
vivo O 0 0.0026083502
dementia B-Disease 0 0.9996954
models O 0 0.0041146926
. O 0 0.0024184792

To O 0 0.0021355231
develop O 0 0.0018186294
a O 0 0.0012144719
novel O 0 0.00079563924
and O 0 0.00051500025
effective O 0 0.00034931168
drug O 0 0.0035253023
that O 0 0.00014895077
could O 0 0.00011398775
enhance O 0 9.022531e-05
cognitive O 0 0.05091494
function O 0 0.0002557349
and O 0 0.00025766718
neuroprotection O 0 0.6061857
, O 0 0.00015670358
we O 0 4.8638267e-05
newly O 0 0.00024468332
synthesized O 0 0.0005258923
maltolyl B-Chemical 1 0.27669704
p I-Chemical 1 0.0003729467
- I-Chemical 1 0.000730418
coumarate I-Chemical 1 0.986801
by O 0 0.000203991
the O 0 0.0002451029
esterification O 0 0.9953603
of O 0 0.0027029684
maltol B-Chemical 0 0.9999894
and O 0 0.0020566932
p B-Chemical 0 0.0013010771
- I-Chemical 0 0.004586377
coumaric I-Chemical 0 0.99973804
acid I-Chemical 0 0.9943903
. O 0 0.004950259

In O 0 0.0016464015
the O 0 0.0011708469
present O 0 0.00072868064
study O 0 0.0007974618
, O 0 0.00045869226
we O 0 0.00015457047
investigated O 0 0.00018756281
whether O 0 0.0001505812
maltolyl B-Chemical 1 0.27213398
p I-Chemical 1 0.0006673046
- I-Chemical 1 0.0011151205
coumarate I-Chemical 1 0.98870647
could O 0 0.000113329326
improve O 0 8.6066364e-05
cognitive B-Disease 0 0.06312705
decline I-Disease 0 0.0012688182
in O 0 0.00035284756
scopolamine B-Chemical 1 0.9999982
- O 0 0.00059189985
injected O 0 8.86813e-05
rats O 0 0.00012507413
and O 0 8.4662766e-05
in O 0 0.00013614976
amyloid B-Chemical 0 0.99443555
beta I-Chemical 0 0.9584929
peptide I-Chemical 0 0.0007949967
( I-Chemical 0 0.00032575987
1 I-Chemical 0 0.00016672397
- I-Chemical 0 0.00032877448
42 I-Chemical 0 0.00032250106
) I-Chemical 0 0.0005294327
- O 0 0.00077708194
infused O 0 0.0015425003
rats O 0 0.0021767488
. O 0 0.0020237947

Maltolyl B-Chemical 0 0.34905878
p I-Chemical 0 0.005553392
- I-Chemical 0 0.006495829
coumarate I-Chemical 0 0.9880818
was O 0 0.0010013083
found O 0 0.00035606144
to O 0 0.00026322147
attenuate O 0 0.0007290773
cognitive B-Disease 2 0.9883393
deficits I-Disease 2 0.9696147
in O 0 0.00021574361
both O 0 0.00013566068
rat O 0 0.00023686257
models O 0 9.013278e-05
using O 0 5.190007e-05
passive O 0 0.00010190233
avoidance O 0 0.00025714934
test O 0 0.00013513134
and O 0 7.101893e-05
to O 0 5.7732304e-05
reduce O 0 7.386181e-05
apoptotic O 0 0.092754185
cell O 0 0.010324089
death O 0 0.9785729
observed O 0 9.702395e-05
in O 0 6.2182415e-05
the O 0 6.814787e-05
hippocampus O 0 0.0024345974
of O 0 0.00014652865
the O 0 0.00020646243
amyloid B-Chemical 0 0.99753845
beta I-Chemical 0 0.97178644
peptide I-Chemical 0 0.00086054346
( I-Chemical 0 0.00033530788
1 I-Chemical 0 0.00016831764
- I-Chemical 0 0.0003308875
42 I-Chemical 0 0.00032338063
) I-Chemical 0 0.0005301052
- O 0 0.0007771538
infused O 0 0.0015420691
rats O 0 0.0021740515
. O 0 0.0020201164

We O 0 0.001544886
also O 0 0.0010864111
examined O 0 0.00063502876
the O 0 0.0007218595
neuroprotective O 0 0.029424472
effects O 0 0.0007662227
of O 0 0.0012023179
maltolyl B-Chemical 1 0.5270366
p I-Chemical 1 0.0009910662
- I-Chemical 1 0.0014799823
coumarate I-Chemical 1 0.98382264
in O 0 0.00035144447
vitro O 0 0.0006450926
using O 0 0.00072386063
SH O 0 0.9986387
- O 0 0.0074342503
SY5Y O 0 0.9983553
cells O 0 0.0050850813
. O 0 0.0029606123

Cells O 0 0.004199561
were O 0 0.0015392577
pretreated O 0 0.0027415545
with O 0 0.0016097059
maltolyl B-Chemical 1 0.33487207
p I-Chemical 1 0.0014635468
- I-Chemical 1 0.0021546932
coumarate I-Chemical 1 0.9901337
, O 0 0.00032252044
before O 0 7.465163e-05
exposed O 0 0.00015082375
to O 0 0.00024248006
amyloid B-Chemical 0 0.9973385
beta I-Chemical 0 0.9792586
peptide I-Chemical 0 0.0011418398
( I-Chemical 0 0.00039963957
1 I-Chemical 0 0.00018354709
- I-Chemical 0 0.00033736936
42 I-Chemical 0 0.0003161694
) I-Chemical 0 0.0005488798
, O 0 0.0008849676
glutamate B-Chemical 1 0.9993067
or O 0 0.0036057692
H2O2 B-Chemical 0 0.9995384
. O 0 0.0047673266

We O 0 0.0017118289
found O 0 0.0012827847
that O 0 0.0010387964
maltolyl B-Chemical 1 0.21225542
p I-Chemical 1 0.0018622227
- I-Chemical 1 0.0026361886
coumarate I-Chemical 1 0.9933037
significantly O 0 0.00096075324
decreased O 0 0.0015159739
apoptotic O 0 0.3651302
cell O 0 0.02991729
death O 0 0.9929496
and O 0 0.00035167573
reduced O 0 0.0006352091
reactive O 0 0.073996596
oxygen O 1 0.99839467
species O 0 0.0005859149
, O 0 0.00050260546
cytochrome O 0 0.9991768
c O 0 0.010195596
release O 0 0.001372581
, O 0 0.00041913337
and O 0 0.0005216833
caspase O 0 0.047351997
3 O 0 0.00072233775
activation O 0 0.0017846947
. O 0 0.0022346133

Taking O 0 0.0023173103
these O 0 0.0016111486
in O 0 0.00082292367
vitro O 0 0.0007880845
and O 0 0.00046274447
in O 0 0.00027573382
vivo O 0 0.00036851884
results O 0 0.00021784496
together O 0 0.00019512321
, O 0 0.00018701315
our O 0 0.00018090573
study O 0 0.00014291618
suggests O 0 5.2994204e-05
that O 0 0.00010610116
maltolyl B-Chemical 1 0.20568466
p I-Chemical 1 0.0004374432
- I-Chemical 1 0.0009549859
coumarate I-Chemical 1 0.99299896
is O 0 0.00014797105
a O 0 0.00011404536
potentially O 0 9.637718e-05
effective O 0 6.356564e-05
candidate O 0 0.0001367261
against O 0 0.00012558444
Alzheimer B-Disease 0 0.99997425
' I-Disease 0 0.0003688861
s I-Disease 0 0.00016785268
disease I-Disease 0 0.011715918
that O 0 7.589875e-05
is O 0 0.00010416126
characterized O 0 0.00020337307
by O 0 0.00010925283
wide O 0 0.00015051056
spread O 0 0.00031238224
neuronal B-Disease 0 0.8253191
death I-Disease 0 0.9997818
and O 0 0.00059078075
progressive O 0 0.06335862
decline B-Disease 0 0.002402206
of I-Disease 0 0.0008789367
cognitive I-Disease 0 0.26520765
function I-Disease 0 0.002258495
. O 0 0.0020697864

Attenuation O 0 0.013497692
of O 0 0.0069678687
methamphetamine B-Chemical 1 0.9999131
- O 0 0.0050796466
induced O 0 0.0019139288
nigrostriatal O 0 0.99140936
dopaminergic O 0 0.9897663
neurotoxicity B-Disease 2 0.9999176
in O 0 0.0007744034
mice O 0 0.00046809224
by O 0 0.001151313
lipopolysaccharide B-Chemical 0 0.9933426
pretreatment O 0 0.5959339
. O 0 0.0039501446

Immunological O 0 0.045896433
activation O 0 0.0027676127
has O 0 0.0009825331
been O 0 0.0005250794
proposed O 0 0.00041787405
to O 0 0.00030989648
play O 0 0.00022961372
a O 0 0.000324144
role O 0 0.00020809131
in O 0 0.0006541858
methamphetamine B-Chemical 1 0.99996674
- O 0 0.0024996197
induced O 0 0.0016093457
dopaminergic B-Disease 0 0.9843188
terminal I-Disease 0 0.02137443
damage I-Disease 0 0.93300325
. O 0 0.003524589

In O 0 0.0019575686
this O 0 0.0017183764
study O 0 0.0012860107
, O 0 0.0006846132
we O 0 0.00021407891
examined O 0 0.00018396464
the O 0 0.00019629381
roles O 0 0.00014981182
of O 0 0.00044681528
lipopolysaccharide B-Chemical 0 0.99527365
, O 0 0.00047141832
a O 0 0.00041251798
pro O 0 0.00875918
- O 0 0.00063462486
inflammatory O 0 0.03468276
and O 0 0.00026220034
inflammatory O 0 0.074995436
factor O 0 0.0012802705
, O 0 0.00015870715
treatment O 0 8.7267836e-05
in O 0 7.125235e-05
modulating O 0 7.5938566e-05
the O 0 0.00031893468
methamphetamine B-Chemical 1 0.999979
- O 0 0.0015449845
induced O 0 0.0013252349
nigrostriatal O 0 0.998587
dopamine B-Chemical 0 0.9999329
neurotoxicity B-Disease 2 0.99991
. O 0 0.0041245054

Lipopolysaccharide B-Chemical 0 0.99283326
pretreatment O 0 0.12062271
did O 0 0.0013162105
not O 0 0.00044905444
affect O 0 0.00019978933
the O 0 0.00024120312
basal O 0 0.0004186582
body O 0 0.0007239207
temperature O 0 0.0011472085
or O 0 0.0004775549
methamphetamine B-Chemical 1 0.9999664
- O 0 0.0009632243
elicited O 0 0.00037798585
hyperthermia B-Disease 0 0.91033673
three O 0 0.00027245472
days O 0 0.00032423082
later O 0 0.0007793557
. O 0 0.0017769716

Such O 0 0.004338992
systemic O 0 0.27699214
lipopolysaccharide B-Chemical 0 0.9936778
treatment O 0 0.0022289963
mitigated O 0 0.107419506
methamphetamine B-Chemical 1 0.99998784
- O 0 0.002469626
induced O 0 0.0006385505
striatal O 0 0.97458786
dopamine B-Chemical 0 0.99989784
and O 0 0.00026169058
3 B-Chemical 0 9.928377e-05
, I-Chemical 0 0.00012876981
4 I-Chemical 0 0.000119517405
- I-Chemical 0 0.0008748644
dihydroxyphenylacetic I-Chemical 0 0.99999416
acid I-Chemical 0 0.9757934
depletions O 0 0.13841279
in O 0 0.00024247776
a O 0 0.0004265678
dose O 0 0.0017065412
- O 0 0.00083880906
dependent O 0 0.00045933152
manner O 0 0.0014259665
. O 0 0.0020516044

As O 0 0.0015292722
the O 0 0.0012559766
most O 0 0.0012827574
potent O 0 0.0017239853
dose O 0 0.0045785583
( O 0 0.00076565193
1 O 0 0.00028986722
mg O 0 0.0042631263
/ O 0 0.00084372406
kg O 0 0.000601203
) O 0 0.00024256378
of O 0 0.00022282875
lipopolysaccharide B-Chemical 0 0.9679386
was O 0 0.00018007537
administered O 0 0.00010443946
two O 0 4.1672494e-05
weeks O 0 2.3172512e-05
, O 0 4.780804e-05
one O 0 2.7224323e-05
day O 0 2.237565e-05
before O 0 1.5529675e-05
or O 0 2.6941821e-05
after O 0 1.7659879e-05
the O 0 8.8753884e-05
methamphetamine B-Chemical 1 0.9999652
dosing O 0 0.00083769957
regimen O 0 0.00026855353
, O 0 0.00031234056
methamphetamine B-Chemical 1 0.99998724
- O 0 0.0005524579
induced O 0 0.00024563444
striatal O 0 0.9543782
dopamine B-Chemical 0 0.9998622
and O 0 0.00017716257
3 B-Chemical 0 8.264977e-05
, I-Chemical 0 0.00012655093
4 I-Chemical 0 0.00013533136
- I-Chemical 0 0.0009918489
dihydroxyphenylacetic I-Chemical 0 0.99998796
acid I-Chemical 0 0.97196543
depletions O 0 0.24743529
remained O 0 0.0016041152
unaltered O 0 0.0020439695
. O 0 0.001990455

Moreover O 0 0.0030666252
, O 0 0.0029216667
systemic O 0 0.37127793
lipopolysaccharide B-Chemical 0 0.9982344
pretreatment O 0 0.5046342
( O 0 0.0011016006
1 O 0 0.00029447244
mg O 0 0.004701094
/ O 0 0.0007905553
kg O 0 0.000545897
) O 0 0.0002119975
attenuated O 0 0.00025395947
local O 0 0.0005109349
methamphetamine B-Chemical 1 0.9999852
infusion O 0 0.0026822276
- O 0 0.0003175345
produced O 0 0.00016835006
dopamine B-Chemical 0 0.9996006
and O 0 0.00014564757
3 B-Chemical 0 6.449299e-05
, I-Chemical 0 8.7715525e-05
4 I-Chemical 0 8.17839e-05
- I-Chemical 0 0.00064669095
dihydroxyphenylacetic I-Chemical 0 0.99999607
acid I-Chemical 0 0.9692765
depletions O 0 0.08633075
in O 0 9.185985e-05
the O 0 9.7484124e-05
striatum O 0 0.009687196
, O 0 9.5650954e-05
indicating O 0 3.9429084e-05
that O 0 3.697256e-05
the O 0 6.5772685e-05
protective O 0 0.00025467356
effect O 0 0.00010496081
of O 0 0.00037762924
lipopolysaccharide B-Chemical 0 0.99654156
is O 0 0.00017657486
less O 0 9.36895e-05
likely O 0 4.942585e-05
due O 0 4.2609176e-05
to O 0 6.493454e-05
interrupted O 0 0.00013933708
peripheral O 0 0.0005021194
distribution O 0 9.741165e-05
or O 0 0.00026213555
metabolism O 0 0.02769153
of O 0 0.0026102045
methamphetamine B-Chemical 1 0.99990106
. O 0 0.0032610435

We O 0 0.0015553551
concluded O 0 0.001037906
a O 0 0.0008639798
critical O 0 0.00035984363
time O 0 0.0002113555
window O 0 0.00029886118
for O 0 0.00023616978
systemic O 0 0.22833987
lipopolysaccharide B-Chemical 0 0.9977926
pretreatment O 0 0.15040503
in O 0 0.00021488177
exerting O 0 0.0004914618
effective O 0 0.00014034222
protection O 0 0.000624871
against O 0 0.00036600148
methamphetamine B-Chemical 1 0.9999882
- O 0 0.0025200264
induced O 0 0.0016738381
nigrostriatal O 0 0.9988287
dopamine B-Chemical 0 0.99993455
neurotoxicity B-Disease 2 0.9999101
. O 0 0.0042255744

Acute O 0 0.8293116
myocarditis B-Disease 2 0.99937195
associated O 0 0.013208992
with O 0 0.029336333
clozapine B-Chemical 0 0.9998559
. O 0 0.01623587

OBJECTIVE O 0 0.04058975
: O 0 0.0034265378
A O 0 0.0074776183
case O 0 0.00089209137
of O 0 0.0013561809
acute O 0 0.9074797
myocarditis B-Disease 2 0.99997234
associated O 0 0.0005219785
with O 0 0.0002626001
the O 0 0.00012031154
commencement O 0 0.00010818688
of O 0 0.00047231247
clozapine B-Chemical 0 0.99999344
is O 0 0.0002333676
described O 0 0.00010127199
, O 0 0.00011104986
highlighting O 0 8.196066e-05
the O 0 0.000117886375
onset O 0 0.00023509546
, O 0 0.00019931555
course O 0 0.00016861253
and O 0 0.0002698206
possible O 0 0.00038141385
contributing O 0 0.0010033417
factors O 0 0.001993216
. O 0 0.0022071514

There O 0 0.0031004879
is O 0 0.0017847652
an O 0 0.0013453759
urgent O 0 0.0010646087
need O 0 0.00043312227
to O 0 0.0003082969
raise O 0 0.00031323815
awareness O 0 0.00054393534
about O 0 0.00028963957
this O 0 0.00038760394
potentially O 0 0.00084649713
fatal O 0 0.78537494
complication O 0 0.16051206
of O 0 0.005336326
clozapine B-Chemical 0 0.9999739
use O 0 0.003311445
. O 0 0.0025170005

RESULTS O 0 0.0057688984
: O 0 0.0029721712
A O 0 0.007039952
20 O 0 0.0011871533
- O 0 0.0012322675
year O 0 0.00037258046
- O 0 0.00054857496
old O 0 0.00028502126
male O 0 0.0006754971
with O 0 0.00042473094
schizophrenia B-Disease 2 0.9997656
developed O 0 0.0006557026
a O 0 0.0005208877
sudden O 0 0.7944436
onset O 0 0.00062306604
of O 0 0.0008257593
myocarditis B-Disease 2 0.9999093
after O 0 0.00019811922
commencement O 0 0.00050936546
of O 0 0.0025256046
clozapine B-Chemical 0 0.999954
. O 0 0.003591078

The O 0 0.0032826583
patient O 0 0.0031630246
recovered O 0 0.0024856178
with O 0 0.002834855
intensive O 0 0.0032056528
medical O 0 0.006839691
support O 0 0.004086243
. O 0 0.005742991

The O 0 0.0020182973
symptoms O 0 0.0051418985
occurred O 0 0.0008149031
around O 0 0.0005071353
2 O 0 0.00031750937
weeks O 0 0.0001297899
after O 0 0.00012627334
starting O 0 0.00042991646
clozapine B-Chemical 0 0.99993074
in O 0 0.0008052276
an O 0 0.0011494545
inpatient O 0 0.002370245
setting O 0 0.001603906
. O 0 0.0022855385

Possible O 0 0.0042421413
contributing O 0 0.002175848
factors O 0 0.0014183335
may O 0 0.0007094263
have O 0 0.00044986937
been O 0 0.00041515802
concomitant O 0 0.0021393765
antidepressant B-Chemical 1 0.9990564
use O 0 0.0006177683
and O 0 0.00063232484
unaccustomed O 0 0.001491403
physical O 0 0.0018024164
activity O 0 0.0018405215
. O 0 0.0026245448

CONCLUSIONS O 0 0.031565454
: O 0 0.0060726907
Myocarditis B-Disease 0 0.9794102
is O 0 0.001166714
an O 0 0.00079597987
increasingly O 0 0.00065124955
recognized O 0 0.00060621696
complication O 0 0.004060693
associated O 0 0.0003722968
with O 0 0.00046273848
the O 0 0.00046691168
use O 0 0.0006939919
of O 0 0.002961854
clozapine B-Chemical 0 0.9999424
. O 0 0.00450981

It O 0 0.0041535287
can O 0 0.002076801
be O 0 0.0020439178
fatal O 0 0.07470919
if O 0 0.00085344125
not O 0 0.0008831194
recognized O 0 0.0011816883
and O 0 0.00142481
treated O 0 0.0028086356
early O 0 0.0053112274
. O 0 0.0042301053

Considering O 0 0.001247836
that O 0 0.0015287983
clozapine B-Chemical 0 0.99991596
remains O 0 0.0006754564
the O 0 0.00043331782
gold O 0 0.038073257
standard O 0 0.0001674468
in O 0 0.00012228555
treatment O 0 0.000120080935
of O 0 0.00018305126
resistant O 0 0.0004319989
psychosis B-Disease 0 0.9997311
, O 0 0.00022747715
there O 0 6.0026407e-05
is O 0 7.662584e-05
an O 0 9.365547e-05
urgent O 0 0.00012337505
need O 0 5.1662606e-05
to O 0 5.0694292e-05
raise O 0 7.049365e-05
awareness O 0 0.00023796492
among O 0 0.00015307208
medical O 0 0.00039939635
and O 0 0.00013474817
paramedical O 0 0.00061494764
staff O 0 0.00018890892
involved O 0 6.975759e-05
in O 0 0.00010265517
the O 0 0.00014817886
care O 0 0.00024375058
of O 0 0.00042625726
these O 0 0.0009569688
patients O 0 0.0020239854
. O 0 0.0018341569

There O 0 0.0027273668
are O 0 0.0013184375
also O 0 0.0007359525
implications O 0 0.0005504975
for O 0 0.00042247167
recommendations O 0 0.0006737521
and O 0 0.0004515755
regulations O 0 0.0007186369
regarding O 0 0.00028261036
the O 0 0.0005215237
use O 0 0.0008152976
of O 0 0.0032469945
clozapine B-Chemical 0 0.99993396
. O 0 0.005092464

Severe O 0 0.68939865
rhabdomyolysis B-Disease 0 0.99978846
and O 0 0.004926432
acute B-Disease 0 0.88141793
renal I-Disease 0 0.99521554
failure I-Disease 0 0.62452394
secondary O 0 0.0016825269
to O 0 0.0002173659
concomitant O 0 0.0005477687
use O 0 0.00018941212
of O 0 0.0007087282
simvastatin B-Chemical 1 0.99998355
, O 0 0.0049567954
amiodarone B-Chemical 1 0.9999645
, O 0 0.0016793677
and O 0 0.0019998013
atazanavir B-Chemical 0 0.994787
. O 0 0.002941769

OBJECTIVE O 0 0.02841733
: O 0 0.0023789054
To O 0 0.00093949086
report O 0 0.0011572636
a O 0 0.0007580604
case O 0 0.00040436123
of O 0 0.00042094057
a O 0 0.00044398868
severe O 0 0.001900873
interaction O 0 0.00018168191
between O 0 0.0002022507
simvastatin B-Chemical 1 0.99998975
, O 0 0.0033167922
amiodarone B-Chemical 1 0.9999863
, O 0 0.00039063403
and O 0 0.00028479204
atazanavir B-Chemical 0 0.9764995
resulting O 0 0.0002879298
in O 0 0.00043934467
rhabdomyolysis B-Disease 0 0.9999505
and O 0 0.0018011112
acute B-Disease 0 0.9121385
renal I-Disease 0 0.9982942
failure I-Disease 0 0.9323546
. O 0 0.0032904774

BACKGROUND O 0 0.010868602
: O 0 0.0033980184
A O 0 0.007973505
72 O 0 0.0010945023
- O 0 0.001193911
year O 0 0.00035771495
- O 0 0.0005323156
old O 0 0.00028574938
white O 0 0.0010456607
man O 0 0.00160771
with O 0 0.00018819644
underlying O 0 0.00029984323
human B-Disease 0 0.0018859735
immunodeficiency I-Disease 0 0.9997271
virus I-Disease 0 0.14950438
, O 0 0.00036236594
atrial B-Disease 0 0.93757486
fibrillation I-Disease 0 0.9999682
, O 0 0.00024474986
coronary B-Disease 0 0.22170192
artery I-Disease 0 0.18202014
disease I-Disease 0 0.18268192
, O 0 0.0001570593
and O 0 0.00019588956
hyperlipidemia B-Disease 0 0.99996436
presented O 0 0.00014002835
with O 0 0.0001852494
generalized O 0 0.0051287827
pain B-Disease 0 0.8313803
, O 0 0.0004358015
fatigue B-Disease 0 0.8324537
, O 0 0.00021748882
and O 0 0.00017669157
dark O 0 0.0005997936
orange O 0 0.2140206
urine O 0 0.057779726
for O 0 0.00034809147
3 O 0 0.000437913
days O 0 0.00051103253
. O 0 0.0014741716

The O 0 0.001620481
patient O 0 0.001404548
was O 0 0.0008579755
taking O 0 0.000679874
80 O 0 0.00066776236
mg O 0 0.06911544
simvastatin B-Chemical 1 0.9999422
at O 0 0.00031154175
bedtime O 0 0.13510647
( O 0 0.00019804102
initiated O 0 8.772774e-05
27 O 0 0.00011431625
days O 0 3.3493816e-05
earlier O 0 0.00010432876
) O 0 0.00021745295
; O 0 0.00022010987
amiodarone B-Chemical 1 0.9997861
at O 0 6.555141e-05
a O 0 0.000107323765
dose O 0 0.00027390756
of O 0 0.000124131
400 O 0 0.0004201845
mg O 0 0.002001037
daily O 0 8.820538e-05
for O 0 3.577573e-05
7 O 0 2.982782e-05
days O 0 1.8368486e-05
, O 0 4.0582192e-05
then O 0 3.6635836e-05
200 O 0 0.00015990247
mg O 0 0.0016054453
daily O 0 0.0001247309
( O 0 8.773846e-05
initiated O 0 5.4860702e-05
19 O 0 7.832801e-05
days O 0 2.4632323e-05
earlier O 0 8.312844e-05
) O 0 0.00014250928
; O 0 8.377462e-05
and O 0 7.534686e-05
400 O 0 0.00033665082
mg O 0 0.016282715
atazanavir B-Chemical 0 0.984625
daily O 0 0.00022201188
( O 0 0.00012962897
initiated O 0 8.134399e-05
at O 0 8.027687e-05
least O 0 0.00013304701
2 O 0 0.00021306968
years O 0 0.00031214053
previously O 0 0.0006589175
) O 0 0.0017985512
. O 0 0.0019642576

Laboratory O 0 0.007014159
evaluation O 0 0.0015256332
revealed O 0 0.0010707674
66 O 0 0.0013060425
, O 0 0.0010125297
680 O 0 0.04291125
U O 0 0.45739666
/ O 0 0.0038576457
L O 0 0.9150734
creatine B-Chemical 1 0.9998338
kinase O 0 0.018517338
, O 0 0.0003113256
93 O 0 0.00048283386
mg O 0 0.0039283563
/ O 0 0.0006461097
dL O 0 0.0031395499
blood B-Chemical 1 0.40035915
urea I-Chemical 1 0.9999826
nitrogen I-Chemical 1 0.9999788
, O 0 0.0003497909
4 O 0 7.262072e-05
. O 0 4.2372532e-05
6 O 0 4.2781277e-05
mg O 0 0.0006679628
/ O 0 0.000425077
dL O 0 0.0025605152
creatinine B-Chemical 1 0.9978669
, O 0 0.00054805644
1579 O 0 0.2477325
U O 0 0.31922758
/ O 0 0.0020951391
L O 0 0.9044867
aspartate B-Chemical 1 0.9999083
aminotransferase O 0 0.9985727
, O 0 0.00061027525
and O 0 0.00050622295
738 O 0 0.07285085
U O 0 0.34391746
/ O 0 0.0045640273
L O 0 0.82424
alanine B-Chemical 1 0.99832267
aminotransferase O 0 0.998718
. O 0 0.0043515866

Simvastatin B-Chemical 0 0.9998293
, O 0 0.014235078
amiodarone B-Chemical 1 0.99988544
, O 0 0.0015195799
and O 0 0.000497723
the O 0 0.00029669557
patient O 0 0.00027280356
' O 0 0.0002562665
s O 0 0.00019917535
human B-Disease 0 0.00083827286
immunodeficiency I-Disease 0 0.99923646
virus I-Disease 0 0.14828798
medications O 0 0.009409585
were O 0 9.244598e-05
all O 0 6.8785565e-05
temporarily O 0 0.00028587176
discontinued O 0 0.00027324737
and O 0 6.595207e-05
the O 0 6.345941e-05
patient O 0 8.204042e-05
was O 0 7.7496195e-05
given O 0 6.0074795e-05
forced O 0 0.0010761084
alkaline O 0 0.32311854
diuresis O 0 0.99732995
and O 0 0.00044882376
started O 0 0.00040922404
on O 0 0.00049442105
dialysis O 0 0.007187371
. O 0 0.002001464

Nine O 0 0.0032674477
days O 0 0.0006811444
later O 0 0.00047152306
the O 0 0.00047014427
patient O 0 0.00047583232
' O 0 0.0005027314
s O 0 0.0005357524
creatine B-Chemical 1 0.9991009
kinase O 0 0.006417157
had O 0 0.00029390026
dropped O 0 0.0006705997
to O 0 0.00025608015
1695 O 0 0.18151629
U O 0 0.39813787
/ O 0 0.0017167019
L O 0 0.4672758
and O 0 0.00046000147
creatinine B-Chemical 1 0.9982849
was O 0 0.000395581
3 O 0 0.00016560461
. O 0 0.00015332479
3 O 0 0.00027516155
mg O 0 0.0035656416
/ O 0 0.0028144617
dL O 0 0.00718798
. O 0 0.0026531753

The O 0 0.0017201753
patient O 0 0.0015680724
was O 0 0.0010070369
discharged O 0 0.0010565973
and O 0 0.0003835873
continued O 0 0.00031345294
outpatient O 0 0.0004685261
dialysis O 0 0.0007655629
for O 0 0.00013706641
1 O 0 0.00013262143
month O 0 8.793563e-05
until O 0 0.00012909868
his O 0 0.0005438352
renal O 0 0.37529933
function O 0 0.001236207
recovered O 0 0.0016916983
. O 0 0.0022458923

DISCUSSION O 0 0.0035599538
: O 0 0.0018117608
The O 0 0.00086664385
risk O 0 0.0036491028
of O 0 0.0022594281
rhabdomyolysis B-Disease 0 0.9999131
is O 0 0.00076799473
increased O 0 0.00051706785
in O 0 0.00017908258
the O 0 0.00013705922
presence O 0 0.00014224525
of O 0 0.0002476143
concomitant O 0 0.0009518846
drugs O 0 0.008045189
that O 0 0.00028976914
inhibit O 0 0.0008942214
simvastatin B-Chemical 1 0.9999641
metabolism O 0 0.9048334
. O 0 0.003247539

Simvastatin B-Chemical 0 0.999209
is O 0 0.025181944
metabolized O 0 0.95448065
by O 0 0.030120522
CYP3A4 O 0 0.9994772
. O 0 0.019900082

Amiodarone B-Chemical 1 0.99914944
and O 0 0.008980037
atazanavir B-Chemical 0 0.9941749
are O 0 0.0040770806
recognized O 0 0.0071672318
CYP3A4 O 0 0.9998235
inhibitors O 0 0.14994471
. O 0 0.008077434

CONCLUSIONS O 0 0.012840105
: O 0 0.0025261417
Pharmacokinetic O 0 0.016401924
differences O 0 0.00047028146
in O 0 0.0007323372
statins B-Chemical 0 0.9954196
are O 0 0.000325658
an O 0 0.00021623849
important O 0 8.822944e-05
consideration O 0 0.00010020541
for O 0 0.00010191243
assessing O 0 0.00011230144
the O 0 0.00022281517
risk O 0 0.0011595412
of O 0 0.0004934987
potential O 0 0.0007787491
drug O 0 0.020690646
interactions O 0 0.0021788315
. O 0 0.0022697884

In O 0 0.0016822458
patients O 0 0.0013742534
requiring O 0 0.0005809372
the O 0 0.00039700582
concurrent O 0 0.00042269262
use O 0 0.00025537648
of O 0 0.00063222065
statins B-Chemical 0 0.99978846
and O 0 0.0023039454
CYP3A4 O 0 0.99999547
inhibitors O 0 0.037104733
, O 0 0.0012585962
pravastatin B-Chemical 0 0.9999945
, O 0 0.003139881
fluvastatin B-Chemical 0 0.99999464
, O 0 0.0004697033
and O 0 0.00036199944
rosuvastatin B-Chemical 0 0.99996746
carry O 0 0.000121608326
the O 0 7.75594e-05
lowest O 0 0.00014083124
risk O 0 0.00053385866
of O 0 0.00012667154
drug O 0 0.0045375912
interactions O 0 0.00016012233
; O 0 0.00027093472
atorvastatin B-Chemical 0 0.99997437
carries O 0 0.00042613942
moderate O 0 0.015293667
risk O 0 0.0065769046
, O 0 0.0001632326
whereas O 0 0.00025254837
simvastatin B-Chemical 1 0.9999906
and O 0 0.001114676
lovastatin B-Chemical 1 0.9999864
have O 0 0.000104366765
the O 0 8.5580716e-05
highest O 0 0.00016057215
risk O 0 0.0011756567
and O 0 0.00010374563
should O 0 4.1983745e-05
be O 0 6.2708525e-05
avoided O 0 7.777397e-05
in O 0 9.9921366e-05
patients O 0 0.0002604895
taking O 0 0.00057900243
concomitant O 0 0.010667633
CYP3A4 O 0 0.9999614
inhibitors O 0 0.054056294
. O 0 0.0025686116

Interaction O 0 0.0047889473
between O 0 0.0029416292
warfarin B-Chemical 1 0.99807525
and O 0 0.0050477535
levofloxacin B-Chemical 1 0.99880123
: O 0 0.005086857
case O 0 0.0035885775
series O 0 0.005901751
. O 0 0.0051336167

Warfarin B-Chemical 0 0.998159
is O 0 0.0020887672
the O 0 0.0010002385
most O 0 0.00093363714
widely O 0 0.00044503977
used O 0 0.00043611234
oral O 0 0.050573897
anticoagulant O 0 0.8008222
and O 0 0.00043822578
is O 0 0.00029625915
indicated O 0 0.00022055082
for O 0 0.0002678878
many O 0 0.00049273536
clinical O 0 0.001772334
conditions O 0 0.0018923843
. O 0 0.0023172244

Levofloxacin B-Chemical 0 0.9961547
, O 0 0.0036892197
a O 0 0.0030488565
fluoroquinolone B-Chemical 0 0.9974124
, O 0 0.0011765481
is O 0 0.0003798514
one O 0 0.00016449227
of O 0 0.0001923577
the O 0 0.00013426745
most O 0 0.00019278734
commonly O 0 0.00017193214
prescribed O 0 0.00070277095
antibiotics O 0 0.0020952038
in O 0 9.635568e-05
clinical O 0 0.00029562943
practice O 0 0.000117211144
and O 0 8.957217e-05
is O 0 7.641699e-05
effective O 0 6.5257394e-05
against O 0 8.5814114e-05
Gram O 0 0.0050001442
- O 0 0.00040433713
positive O 0 0.00026753359
, O 0 0.00029361097
Gram O 0 0.00491976
- O 0 0.0005511677
negative O 0 0.00045537468
, O 0 0.0004884113
and O 0 0.00062672043
atypical O 0 0.0038626331
bacteria O 0 0.0036382952
. O 0 0.0022144734

While O 0 0.0019352084
small O 0 0.0017506434
prospective O 0 0.0019372015
studies O 0 0.0005299657
have O 0 0.00022297564
not O 0 0.00018026934
revealed O 0 0.00016071675
any O 0 0.0001227284
significant O 0 0.00016417247
drug O 0 0.0109003885
- O 0 0.00034248177
drug O 0 0.0015131128
interaction O 0 7.539027e-05
between O 0 8.507802e-05
warfarin B-Chemical 1 0.99969256
and O 0 0.00034045984
levofloxacin B-Chemical 1 0.99970657
, O 0 0.00016882943
several O 0 5.257586e-05
case O 0 6.2213374e-05
reports O 0 7.856321e-05
have O 0 4.0022445e-05
indicated O 0 4.2983906e-05
that O 0 7.599826e-05
levofloxacin B-Chemical 1 0.9987839
may O 0 0.000122994
significantly O 0 0.00018229913
potentiate O 0 0.00018406815
the O 0 0.00023437614
anticoagulation O 0 0.042884488
effect O 0 0.00045548432
of O 0 0.0025348098
warfarin B-Chemical 1 0.9995202
. O 0 0.00268678

We O 0 0.001767978
report O 0 0.0018600966
3 O 0 0.000757629
cases O 0 0.00066227943
of O 0 0.0006640076
serious O 0 0.009004923
bleeding B-Disease 0 0.99571
complications O 0 0.035130393
that O 0 0.00015484604
appear O 0 0.00013568137
to O 0 9.240033e-05
be O 0 7.8591605e-05
the O 0 7.381315e-05
result O 0 7.694127e-05
of O 0 0.00012396953
the O 0 0.0001228393
interaction O 0 0.00016060768
between O 0 0.0002860825
warfarin B-Chemical 1 0.9994579
and O 0 0.0024728547
levofloxacin B-Chemical 1 0.9993061
. O 0 0.0035646392

Physicians O 0 0.0033658044
should O 0 0.00087996334
be O 0 0.0007078791
aware O 0 0.0004837801
of O 0 0.00044045007
this O 0 0.00033182892
potential O 0 0.00026161276
interaction O 0 0.00018089333
and O 0 0.00018726262
use O 0 0.00012762548
caution O 0 0.000109610955
when O 0 0.000104667066
prescribing O 0 0.0013864657
levofloxacin B-Chemical 1 0.99737227
to O 0 0.00046449678
patients O 0 0.0012731277
taking O 0 0.003681736
warfarin B-Chemical 1 0.99915934
. O 0 0.0027094213

Mutations O 0 0.0059882263
associated O 0 0.0016207078
with O 0 0.0031861658
lamivudine B-Chemical 1 0.99980074
- O 0 0.0023417394
resistance O 0 0.001219325
in O 0 0.0003764356
therapy O 0 0.00096333853
- O 0 0.0036935548
na B-Chemical 0 0.9999745
ve O 0 0.98555017
hepatitis B-Disease 2 0.9999995
B I-Disease 2 0.99983764
virus I-Disease 0 0.29913008
( I-Disease 0 0.0019567404
HBV I-Disease 0 0.99656653
) I-Disease 0 0.00037918298
infected I-Disease 0 9.798983e-05
patients O 0 0.00014694098
with O 0 0.00011358465
and O 0 0.000110651476
without O 0 0.00016879175
HIV B-Disease 0 0.3495544
co I-Disease 0 0.09156578
- I-Disease 0 0.0004749876
infection I-Disease 0 0.0013622039
: O 0 9.752755e-05
implications O 0 5.2308307e-05
for O 0 5.8383277e-05
antiretroviral O 0 0.00045881426
therapy O 0 0.00013120384
in O 0 0.00014923268
HBV B-Disease 0 0.96716934
and I-Disease 0 0.00057080836
HIV I-Disease 0 0.54215395
co I-Disease 0 0.11110263
- I-Disease 0 0.0008167155
infected I-Disease 0 0.00038174522
South O 0 0.0009991442
African O 0 0.0027194228
patients O 0 0.002232058
. O 0 0.001964282

This O 0 0.003628044
was O 0 0.0014988966
an O 0 0.00093574414
exploratory O 0 0.0012322476
study O 0 0.00045698104
to O 0 0.0002444933
investigate O 0 0.0002592796
lamivudine B-Chemical 1 0.9999075
- O 0 0.0022419293
resistant O 0 0.0037979996
hepatitis B-Disease 2 0.9999995
B I-Disease 2 0.9998448
virus O 0 0.35943598
( O 0 0.0022209764
HBV O 0 0.9968997
) O 0 0.00035154147
strains O 0 9.854484e-05
in O 0 8.597187e-05
selected O 0 0.0002473345
lamivudine B-Chemical 1 0.9999535
- O 0 0.013167722
na B-Chemical 0 0.9999858
ve O 0 0.77616996
HBV O 0 0.9987703
carriers O 0 0.0065931003
with O 0 0.00016041513
and O 0 0.00010485517
without O 0 0.000119555705
human B-Disease 0 0.0015761647
immunodeficiency I-Disease 0 0.99980325
virus I-Disease 0 0.36248955
( I-Disease 0 0.0010548685
HIV I-Disease 0 0.4630766
) I-Disease 0 0.00077058026
co I-Disease 0 0.028380306
- I-Disease 0 0.00070906506
infection I-Disease 0 0.0029478688
in O 0 0.00044929935
South O 0 0.0010169094
African O 0 0.002702182
patients O 0 0.0022114443
. O 0 0.0019633353

Thirty O 0 0.004150948
- O 0 0.0033762143
five O 0 0.0013402833
lamivudine B-Chemical 1 0.999683
- O 0 0.029766196
na B-Chemical 0 0.9999356
ve O 0 0.8799672
HBV B-Disease 0 0.99984515
infected I-Disease 0 0.0022188027
patients O 0 0.0004988363
with O 0 0.00022097876
or O 0 0.0001336176
without O 0 0.00022643719
HIV B-Disease 0 0.41542888
co I-Disease 0 0.12383905
- I-Disease 0 0.0005953083
infection I-Disease 0 0.0021365983
were O 0 0.00011327207
studied O 0 0.00010738714
: O 0 0.00010536505
15 O 0 7.800957e-05
chronic O 0 0.11244334
HBV B-Disease 0 0.998782
mono I-Disease 0 0.68455356
- I-Disease 0 0.00041371284
infected I-Disease 0 0.000100494595
patients O 0 0.00017802906
and O 0 0.00014928322
20 O 0 0.00027571488
HBV B-Disease 0 0.98312575
- I-Disease 0 0.002058336
HIV I-Disease 0 0.4559892
co I-Disease 0 0.11187095
- I-Disease 0 0.0014014522
infected I-Disease 0 0.0008107712
patients O 0 0.0023876978
. O 0 0.0020852357

The O 0 0.0018945253
latter O 0 0.0028455104
group O 0 0.0015459219
was O 0 0.00083396415
further O 0 0.0007641795
sub O 0 0.0013615438
- O 0 0.0005340831
divided O 0 0.00012323748
into O 0 7.1018185e-05
13 O 0 0.00018938251
occult O 0 0.026191698
HBV O 0 0.9977175
( O 0 0.0025778664
HBsAg B-Chemical 0 0.99987316
- O 0 0.0009855059
negative O 0 0.00036470164
) O 0 0.0003016329
and O 0 0.00015289176
7 O 0 0.00013041253
overt O 0 0.03922343
HBV O 0 0.99685043
( O 0 0.002683976
HBsAg B-Chemical 0 0.99970144
- O 0 0.0019742025
positive O 0 0.0012860954
) O 0 0.0018169078
patients O 0 0.0024707867
. O 0 0.0022331127

HBsAg B-Chemical 0 0.997801
, O 0 0.0061955084
anti O 0 0.01437022
- O 0 0.0093714325
HBs O 0 0.9970324
, O 0 0.0019513683
anti O 0 0.0083028395
- O 0 0.002947335
HBc O 0 0.8754869
, O 0 0.0005772719
and O 0 0.00036732384
anti O 0 0.0027891053
- O 0 0.0011777668
HIV O 0 0.120935805
1 O 0 0.00015031263
/ O 0 0.00029695933
2 O 0 6.8489324e-05
were O 0 5.813893e-05
determined O 0 4.8851816e-05
as O 0 4.822187e-05
part O 0 4.2218533e-05
of O 0 8.3053725e-05
routine O 0 8.757871e-05
diagnosis O 0 0.00018121755
using O 0 9.9004676e-05
Axsym O 0 0.0158631
assays O 0 0.0003123766
( O 0 0.00037234506
Abbott O 0 0.041166343
Laboratories O 0 0.0031108875
, O 0 0.0004264747
North O 0 0.0005586413
Chicago O 0 0.0021213281
, O 0 0.0012395025
IL O 0 0.027318347
) O 0 0.0032625597
. O 0 0.0026664494

Serum O 0 0.0756723
samples O 0 0.002168605
were O 0 0.0012454754
PCR O 0 0.0049352515
amplified O 0 0.0006564835
with O 0 0.0008809524
HBV O 0 0.99065924
reverse O 0 0.058795303
transcriptase O 0 0.82347417
( O 0 0.0010943402
RT O 0 0.010690111
) O 0 0.00043411084
primers O 0 0.0004175551
, O 0 0.00016054581
followed O 0 7.841979e-05
by O 0 8.467585e-05
direct O 0 7.2150244e-05
sequencing O 0 0.00022072459
across O 0 3.7704707e-05
the O 0 0.00011384153
tyrosine B-Chemical 0 0.5408518
- O 0 0.0030788893
methionine B-Chemical 0 0.9998864
- O 0 0.00902155
aspartate B-Chemical 1 0.99995565
- O 0 0.015816327
aspartate B-Chemical 1 0.9999546
( O 0 0.0036041185
YMDD O 0 0.9996426
) O 0 0.0003751688
motif O 0 0.00012722476
of O 0 0.000101718935
the O 0 7.939746e-05
major O 0 9.893475e-05
catalytic O 0 0.001245575
region O 0 0.000100553734
in O 0 0.000103937826
the O 0 0.00021227967
C O 0 0.83677524
domain O 0 0.00022755438
of O 0 0.0004251145
the O 0 0.0007629159
HBV O 0 0.9930824
RT O 0 0.13246681
enzyme O 0 0.19470024
. O 0 0.0031385168

HBV O 0 0.9589989
viral O 0 0.0074680047
load O 0 0.0025460299
was O 0 0.0008979803
performed O 0 0.00050672935
with O 0 0.000985767
Amplicor O 0 0.76339585
HBV O 0 0.9975783
Monitor O 0 0.021996353
test O 0 0.001174335
v2 O 0 0.00859706
. O 0 0.0001823819
0 O 0 0.00021359837
( O 0 0.0004284634
Roche O 0 0.0026850484
Diagnostics O 0 0.0035945554
, O 0 0.0011462811
Penzberg O 0 0.11119695
, O 0 0.0017538595
Germany O 0 0.0048812167
) O 0 0.0036060712
. O 0 0.0030582019

HBV O 0 0.9983851
lamivudine B-Chemical 1 0.99980944
- O 0 0.0047764345
resistant O 0 0.00093365717
strains O 0 0.00051801157
were O 0 0.00029860542
detected O 0 0.00015695272
in O 0 0.0001391061
3 O 0 9.260957e-05
of O 0 0.00013351547
15 O 0 0.00011543995
mono O 0 0.020901617
- O 0 0.00035883853
infected O 0 0.00024930335
chronic O 0 0.9962333
hepatitis B-Disease 2 0.99999976
B I-Disease 2 0.9999416
patients O 0 0.0011531503
and O 0 0.00015737518
10 O 0 9.5796626e-05
of O 0 0.0001667386
20 O 0 0.0002918549
HBV B-Disease 0 0.9823111
- I-Disease 0 0.0021138017
HIV I-Disease 0 0.4561283
co I-Disease 0 0.11389952
- I-Disease 0 0.0014431743
infected I-Disease 0 0.0008323054
patients O 0 0.0024370353
. O 0 0.0021233703

To O 0 0.0018991729
the O 0 0.0013727321
best O 0 0.0011830848
of O 0 0.0008930226
our O 0 0.00080358423
knowledge O 0 0.00080000237
, O 0 0.0003383892
this O 0 0.00019628854
constitutes O 0 0.00010851958
the O 0 9.716283e-05
first O 0 6.5826534e-05
report O 0 0.00021321785
of O 0 0.00054710556
HBV O 0 0.9997931
lamivudine B-Chemical 1 0.9999852
- O 0 0.0008571069
resistant O 0 0.00015959705
strains O 0 0.0001223238
in O 0 0.00012853892
therapy O 0 0.00046983515
- O 0 0.0018956801
na B-Chemical 0 0.999961
ve O 0 0.7994669
HBV B-Disease 0 0.9993517
- I-Disease 0 0.004988112
HIV I-Disease 0 0.6057001
co I-Disease 0 0.13150543
- I-Disease 0 0.0014680253
infected I-Disease 0 0.00084059936
patients O 0 0.0024233942
. O 0 0.0021397583

The O 0 0.002949853
HBV O 0 0.90825355
viral O 0 0.005575562
loads O 0 0.0025872001
for O 0 0.0008282697
mono O 0 0.31479582
- O 0 0.0010616513
infected O 0 0.00027837153
and O 0 0.0003591796
co O 0 0.0191977
- O 0 0.00039023146
infected O 0 0.0001048028
patients O 0 0.00013362576
ranged O 0 7.942223e-05
from O 0 6.612803e-05
3 O 0 5.544709e-05
. O 0 4.2377138e-05
32 O 0 8.750518e-05
x O 0 0.0001751993
10 O 0 8.683643e-05
( O 0 0.0001324589
2 O 0 7.646956e-05
) O 0 0.00011672195
to O 0 6.495888e-05
3 O 0 5.9978054e-05
. O 0 4.80414e-05
82 O 0 0.00013105292
x O 0 0.00018819016
10 O 0 8.836213e-05
( O 0 0.00012627298
7 O 0 6.511139e-05
) O 0 0.00012248161
and O 0 9.0298636e-05
< O 0 9.228674e-05
200 O 0 0.0001711614
to O 0 7.680391e-05
4 O 0 6.5112195e-05
. O 0 5.1715888e-05
40 O 0 9.003485e-05
x O 0 0.00021616921
10 O 0 0.00012425677
( O 0 0.00019906332
3 O 0 0.00013236394
) O 0 0.0002756607
copies O 0 0.00029179011
/ O 0 0.0009337608
ml O 0 0.001611266
, O 0 0.0013622267
respectively O 0 0.0031020138
. O 0 0.0025815447

It O 0 0.0027029314
remains O 0 0.0011680351
to O 0 0.0007781031
be O 0 0.00049142435
seen O 0 0.00028361418
whether O 0 0.00012779879
such O 0 0.00017270654
pre O 0 0.00048992765
- O 0 0.0003571977
existing O 0 0.0002224276
antiviral O 0 0.0024837812
mutations O 0 0.002427109
could O 0 9.662361e-05
result O 0 8.0080514e-05
in O 0 6.848926e-05
widespread O 0 9.449018e-05
emergence O 0 0.00010031211
of O 0 0.00020185344
HBV O 0 0.9633103
resistant O 0 0.00016171808
strains O 0 0.00011612911
when O 0 0.00011745426
lamivudine B-Chemical 1 0.999907
- O 0 0.00031081194
containing O 0 5.8033907e-05
highly O 0 7.346283e-05
active O 0 0.00012803773
antiretroviral O 0 0.00091926026
( O 0 0.00016923653
ARV O 0 0.0027752076
) O 0 0.00014435138
treatment O 0 9.702377e-05
( O 0 0.0001975469
HAART O 0 0.014704416
) O 0 0.00014610882
regimens O 0 0.00010623277
become O 0 6.1034283e-05
widely O 0 4.195605e-05
applied O 0 3.9763374e-05
in O 0 7.5859825e-05
South O 0 0.00018116069
Africa O 0 0.00013242707
, O 0 9.040264e-05
as O 0 6.2834166e-05
this O 0 8.917288e-05
is O 0 6.696325e-05
likely O 0 4.0922707e-05
to O 0 4.549061e-05
have O 0 3.5466714e-05
potential O 0 4.885932e-05
implications O 0 5.098717e-05
in O 0 5.8876856e-05
the O 0 7.719033e-05
management O 0 0.00014841204
of O 0 0.00049295987
HBV B-Disease 0 0.9973851
- I-Disease 0 0.003774562
HIV I-Disease 0 0.64498985
co I-Disease 0 0.16574723
- I-Disease 0 0.001467318
infected I-Disease 0 0.0008103468
patients O 0 0.0023980127
. O 0 0.002056948

Rabbit B-Disease 0 0.24993059
syndrome I-Disease 0 0.9285944
, O 0 0.004888975
antidepressant B-Chemical 1 0.99874073
use O 0 0.0012658546
, O 0 0.000974845
and O 0 0.0008922325
cerebral O 0 0.29805538
perfusion O 0 0.13124742
SPECT O 0 0.84633744
scan O 0 0.005526685
findings O 0 0.004775023
. O 0 0.0037249916

The O 0 0.0027754784
rabbit B-Disease 0 0.01870272
syndrome I-Disease 0 0.70735645
is O 0 0.0012258686
an O 0 0.0016136081
extrapyramidal O 0 0.99983037
side O 0 0.02890798
effect O 0 0.0005468063
associated O 0 0.00055515626
with O 0 0.0014394219
chronic O 0 0.92169726
neuroleptic O 0 0.9999715
therapy O 0 0.01026849
. O 0 0.0028751623

Its O 0 0.016648516
occurrence O 0 0.0021903731
in O 0 0.00085080886
a O 0 0.0007393372
patient O 0 0.00049352075
being O 0 0.00040700624
treated O 0 0.0004661535
with O 0 0.00094581494
imipramine B-Chemical 0 0.9999937
is O 0 0.0003179483
described O 0 0.000112438596
, O 0 0.00010381618
representing O 0 6.2757885e-05
the O 0 6.675567e-05
first O 0 5.1417053e-05
reported O 0 0.00010771727
case O 0 0.00010103874
of O 0 0.00017070163
this O 0 0.0003212683
syndrome O 0 0.032246083
in O 0 0.00026555118
conjunction O 0 0.00057998113
with O 0 0.001979614
antidepressants B-Chemical 0 0.9996088
. O 0 0.002660782

Repeated O 0 0.0033632014
cerebral O 0 0.09225937
perfusion O 0 0.039912667
SPECT O 0 0.69382304
scans O 0 0.001348248
revealed O 0 0.0003225484
decreased B-Disease 0 0.00048165114
basal I-Disease 0 0.00043890934
ganglia I-Disease 0 0.0008300557
perfusion I-Disease 0 0.0028168983
while O 0 0.000114726856
the O 0 0.00011026944
movement B-Disease 0 0.0003199232
disorder I-Disease 0 0.50232184
was O 0 0.00013371267
present O 0 7.32598e-05
, O 0 0.000104828585
and O 0 8.301928e-05
a O 0 0.00010641678
return O 0 0.0001028576
to O 0 7.8077144e-05
normal O 0 0.00027385194
perfusion O 0 0.0021359557
when O 0 0.00013499869
the O 0 0.0003572532
rabbit B-Disease 0 0.021018108
syndrome I-Disease 0 0.8924055
resolved O 0 0.004480134
. O 0 0.0022219846

Estrogen O 0 0.99920076
prevents O 0 0.010035413
cholesteryl B-Chemical 0 0.99977905
ester I-Chemical 0 0.9991934
accumulation O 0 0.0041479534
in O 0 0.00068612857
macrophages O 0 0.0008939463
induced O 0 0.00055786147
by O 0 0.000479611
the O 0 0.000616854
HIV O 0 0.29004785
protease O 0 0.04584613
inhibitor O 0 0.19206795
ritonavir B-Chemical 0 0.9994271
. O 0 0.0050672316

Individuals O 0 0.0054353913
with O 0 0.0027794389
HIV O 0 0.058785208
can O 0 0.0005878174
now O 0 0.00047539297
live O 0 0.00047417238
long O 0 0.00025705225
lives O 0 0.0007078217
with O 0 0.0002822116
drug O 0 0.004609445
therapy O 0 0.00021048672
that O 0 9.440652e-05
often O 0 0.00017704301
includes O 0 0.00015149746
protease O 0 0.0015486504
inhibitors O 0 0.0014218889
such O 0 0.0004983133
as O 0 0.0013512808
ritonavir B-Chemical 0 0.9975527
. O 0 0.0032396966

Many O 0 0.003294637
patients O 0 0.0028578762
, O 0 0.0016485221
however O 0 0.001077822
, O 0 0.0007022598
develop O 0 0.00051710365
negative O 0 0.00053884776
long O 0 0.00040107305
- O 0 0.00053471164
term O 0 0.00030673982
side O 0 0.0019807466
effects O 0 0.000519661
such O 0 0.0005132931
as O 0 0.001270228
premature B-Disease 0 0.91040456
atherosclerosis I-Disease 2 0.99996185
. O 0 0.006747939

We O 0 0.0014729566
have O 0 0.00086846156
previously O 0 0.0005820595
demonstrated O 0 0.00036924603
that O 0 0.0003851455
ritonavir B-Chemical 0 0.9964277
treatment O 0 0.00048518638
increases O 0 0.0006744267
atherosclerotic B-Disease 2 0.99994814
lesion I-Disease 0 0.588784
formation O 0 0.001588551
in O 0 0.00017303554
male O 0 0.00044829253
mice O 0 6.1281564e-05
to O 0 7.7377306e-05
a O 0 0.00013563507
greater O 0 0.00013591732
extent O 0 0.00013853781
than O 0 0.00020151095
in O 0 0.00043157057
female O 0 0.0018804776
mice O 0 0.0009797022
. O 0 0.0018090017

Furthermore O 0 0.0028152904
, O 0 0.0022716594
peripheral O 0 0.004339451
blood O 0 0.0055964864
monocytes O 0 0.004905499
isolated O 0 0.0004380126
from O 0 0.0005231482
ritonavir B-Chemical 0 0.9986261
- O 0 0.0009958808
treated O 0 0.00049648865
females O 0 0.0004575049
had O 0 0.00036761354
less O 0 0.001045468
cholesteryl B-Chemical 0 0.9998282
ester I-Chemical 0 0.9993067
accumulation O 0 0.035865564
. O 0 0.0037561452

In O 0 0.0016810057
the O 0 0.0012003175
present O 0 0.00074896665
study O 0 0.00081882346
, O 0 0.00046789143
we O 0 0.00015456398
have O 0 0.00013694778
investigated O 0 0.00011695502
the O 0 0.00012960797
molecular O 0 0.0006830393
mechanisms O 0 0.0001674599
by O 0 0.00012169415
which O 0 0.00016977589
female O 0 0.0005913723
hormones O 0 0.004708482
influence O 0 9.469946e-05
cholesterol B-Chemical 0 0.9999236
metabolism O 0 0.20057398
in O 0 0.00010956321
macrophages O 0 0.00016719599
in O 0 7.557376e-05
response O 0 9.797637e-05
to O 0 0.00011822927
the O 0 0.0002696097
HIV O 0 0.16711657
protease O 0 0.027134513
inhibitor O 0 0.12639086
ritonavir B-Chemical 0 0.99939406
. O 0 0.003937935

We O 0 0.0016371491
have O 0 0.00092959305
utilized O 0 0.0006334999
the O 0 0.0006173236
human O 0 0.0008174735
monocyte O 0 0.10018094
cell O 0 0.004416883
line O 0 0.0011722635
, O 0 0.001041071
THP O 1 0.99992204
- O 0 0.0014106957
1 O 0 0.00020685137
as O 0 0.0001641964
a O 0 0.00024745197
model O 0 0.00026221434
to O 0 0.0002441788
address O 0 0.0002350511
this O 0 0.0008752629
question O 0 0.0017640591
. O 0 0.0023970571

Briefly O 0 0.0022028836
, O 0 0.0021200082
cells O 0 0.00143859
were O 0 0.00067954813
differentiated O 0 0.0006218197
for O 0 0.00018339016
72 O 0 0.00016980503
h O 0 0.00012686508
with O 0 0.0001860174
100 O 0 0.00057912304
nM O 0 0.009089854
PMA O 0 0.93832934
to O 0 0.00015891707
obtain O 0 9.2881615e-05
a O 0 0.00021645549
macrophage O 0 0.0045837946
- O 0 0.00031413592
like O 0 6.605719e-05
phenotype O 0 0.00023429927
in O 0 6.375097e-05
the O 0 5.816416e-05
presence O 0 6.0933446e-05
or O 0 5.1964253e-05
absence O 0 4.421992e-05
of O 0 0.00013724415
1 O 0 0.00013016284
nM O 0 0.061599575
17beta B-Chemical 0 0.9999925
- I-Chemical 0 0.03746084
estradiol I-Chemical 0 0.99999523
( O 0 0.0099364
E2 B-Chemical 0 0.9999665
) O 0 0.00070532557
, O 0 0.00018396412
100 O 0 0.00055978243
nM O 0 0.033882085
progesterone B-Chemical 1 0.9999436
or O 0 0.0002842146
vehicle O 0 0.0013748589
( O 0 0.00033338423
0 O 0 0.00019380268
. O 0 0.00020927262
01 O 0 0.0011341642
% O 0 0.00094765564
ethanol B-Chemical 1 0.9951515
) O 0 0.0041264696
. O 0 0.0026926054

Cells O 0 0.0039410465
were O 0 0.0011917691
then O 0 0.00060477713
treated O 0 0.00066414464
with O 0 0.00041613908
30 O 0 0.00023669077
ng O 0 0.00071791274
/ O 0 0.0011293053
ml O 0 0.0022049241
ritonavir B-Chemical 0 0.99669063
or O 0 0.00021898872
vehicle O 0 0.00060731976
in O 0 0.00011535125
the O 0 0.00010842193
presence O 0 0.00013745711
of O 0 0.00029374368
aggregated O 0 0.0006897193
LDL O 0 0.9996749
for O 0 0.00063214655
24 O 0 0.00070757826
h O 0 0.0011402762
. O 0 0.0019520909

Cell O 0 0.026590677
extracts O 0 0.0041520167
were O 0 0.0012694406
harvested O 0 0.00065943896
, O 0 0.0009021032
and O 0 0.0008238848
lipid O 0 0.089745626
or O 0 0.0006623558
total O 0 0.00088509533
RNA O 0 0.0050546746
was O 0 0.001648337
isolated O 0 0.0019107233
. O 0 0.0028721439

E2 B-Chemical 0 0.9978544
decreased O 0 0.0048868386
the O 0 0.0014782919
accumulation O 0 0.0020021077
of O 0 0.0031647272
cholesteryl B-Chemical 0 0.9998865
esters I-Chemical 0 0.99946076
in O 0 0.0010803867
macrophages O 0 0.0015575724
following O 0 0.0010229747
ritonavir B-Chemical 0 0.99828184
treatment O 0 0.0038837788
. O 0 0.0032546748

Ritonavir B-Chemical 0 0.99833727
increased O 0 0.0028043974
the O 0 0.001003568
expression O 0 0.0007497114
of O 0 0.00069475954
the O 0 0.00087533053
scavenger O 0 0.9985342
receptor O 0 0.31637996
, O 0 0.0012483132
CD36 O 0 0.8602471
mRNA O 0 0.0007743742
, O 0 0.00028626804
responsible O 0 0.00018193676
for O 0 0.00019931326
the O 0 0.0004284487
uptake O 0 0.0034260985
of O 0 0.0038098404
LDL O 0 0.99968994
. O 0 0.0051624877

Additionally O 0 0.0028320232
, O 0 0.003289183
ritonavir B-Chemical 0 0.99372584
treatment O 0 0.00094671705
selectively O 0 0.0005917506
increased O 0 0.00047364522
the O 0 0.00020642344
relative O 0 0.00015497276
levels O 0 0.00018954456
of O 0 0.00044014698
PPARgamma O 0 0.93038416
mRNA O 0 0.00069110666
, O 0 0.00018770414
a O 0 0.00016323915
transcription O 0 0.00020261241
factor O 0 0.0003593777
responsible O 0 9.913287e-05
for O 0 8.395376e-05
the O 0 0.00012800869
regulation O 0 0.00013428357
of O 0 0.0005993661
CD36 O 0 0.6503023
mRNA O 0 0.002192223
expression O 0 0.002317998
. O 0 0.00218415

Treatment O 0 0.0093472265
with O 0 0.0070118685
E2 B-Chemical 0 0.9995383
, O 0 0.0024579042
however O 0 0.0011761328
, O 0 0.00061683985
failed O 0 0.00044040786
to O 0 0.0002838
prevent O 0 0.00029450358
these O 0 0.00039920167
increases O 0 0.00035086315
at O 0 0.0003065559
the O 0 0.0005845095
mRNA O 0 0.0014624586
level O 0 0.0015597215
. O 0 0.0025098443

E2 B-Chemical 0 0.9987797
did O 0 0.0047586043
, O 0 0.0023380304
however O 0 0.0014076183
, O 0 0.00089114753
significantly O 0 0.00070312025
suppress O 0 0.0004823067
CD36 O 0 0.6707302
protein O 0 0.0009899031
levels O 0 0.000463097
as O 0 0.0003913771
measured O 0 0.00045673584
by O 0 0.00085157
fluorescent O 0 0.0030058427
immunocytochemistry O 0 0.0045894873
. O 0 0.0024951298

This O 0 0.0034376418
data O 0 0.0016218525
suggests O 0 0.0006263517
that O 0 0.00081306987
E2 B-Chemical 0 0.99931145
modifies O 0 0.00056354614
the O 0 0.00030079207
expression O 0 0.00030931644
of O 0 0.00040296165
CD36 O 0 0.48840553
at O 0 8.394832e-05
the O 0 8.223749e-05
level O 0 6.215259e-05
of O 0 0.000113028334
protein O 0 0.00020607143
expression O 0 0.00015517652
in O 0 0.000119080796
monocyte O 0 0.056831703
- O 0 0.00024442663
derived O 0 5.5197233e-05
macrophages O 0 0.00013687272
resulting O 0 0.00010207437
in O 0 0.00011417931
reduced O 0 0.0008053677
cholesteryl B-Chemical 0 0.999948
ester I-Chemical 0 0.99934083
accumulation O 0 0.0022889716
following O 0 0.0007022283
ritonavir B-Chemical 0 0.9985189
treatment O 0 0.0025889406
. O 0 0.002268534

Acute O 0 0.92318994
hepatitis B-Disease 2 0.99984217
attack O 0 0.4068552
after O 0 0.0019297098
exposure O 0 0.004594221
to O 0 0.00488382
telithromycin B-Chemical 1 0.9958949
. O 0 0.008617854

INTRODUCTION O 0 0.01145537
: O 0 0.0067411694
Antibiotic O 0 0.03741797
- O 0 0.006934007
associated O 0 0.005992363
hepatotoxicity B-Disease 0 0.99990654
is O 0 0.01069788
rare O 0 0.02738882
. O 0 0.0069101634

With O 0 0.002571581
widespread O 0 0.0016655512
use O 0 0.0008115991
of O 0 0.0007856573
antimicrobial O 0 0.002041051
agents O 0 0.0030647044
, O 0 0.0005933354
however O 0 0.0005671646
, O 0 0.0007326614
hepatic B-Disease 0 0.99973387
injury I-Disease 0 0.9931526
occurs O 0 0.00025918175
frequently O 0 0.00016362625
, O 0 0.00013319984
and O 0 0.00011039063
among O 0 0.00016975339
adverse B-Disease 0 0.25837138
drug I-Disease 0 0.0505055
reactions I-Disease 0 0.027717719
, O 0 0.00033598056
idiosyncratic O 0 0.0095828045
reactions O 0 0.0018822576
are O 0 0.00032263363
the O 0 0.00043105372
most O 0 0.0013105853
serious O 0 0.011428785
. O 0 0.002540178

CASE O 0 0.026232671
SUMMARY O 0 0.0042008734
: O 0 0.0021706491
A O 0 0.005870478
25 O 0 0.0012562076
- O 0 0.0010454062
year O 0 0.00031476878
- O 0 0.0004961267
old O 0 0.00026129445
male O 0 0.0005839866
patient O 0 0.0001777209
, O 0 0.00013402161
with O 0 0.00011248899
a O 0 0.00012814875
height O 0 0.00020669919
of O 0 0.0001171746
175 O 0 0.00027540015
cm O 0 0.00012519084
and O 0 5.9342456e-05
weight O 0 0.00019967886
of O 0 8.2067265e-05
72 O 0 6.585284e-05
kg O 0 0.0001216053
presented O 0 5.3629385e-05
to O 0 7.618169e-05
Marmara O 0 0.008604973
University O 0 0.00026066514
Hospital O 0 0.00021554394
Emergency O 0 0.00030053323
Department O 0 0.00024602376
, O 0 0.00014299373
Istanbul O 0 0.0007259581
, O 0 0.00015408352
Turkey O 0 0.0004505221
, O 0 0.00010116968
with O 0 8.3385356e-05
5 O 0 4.386331e-05
days O 0 2.9359322e-05
' O 0 0.00010438041
history O 0 0.00019767428
of O 0 0.0003846177
jaundice B-Disease 2 0.99928457
, O 0 0.0016381409
malaise O 0 0.9997131
, O 0 0.00392493
nausea B-Disease 0 0.9999368
, O 0 0.0021368058
and O 0 0.0025950118
vomiting B-Disease 0 0.9990501
. O 0 0.0034355936

He O 0 0.0047096997
had O 0 0.0013577704
been O 0 0.00073317933
prescribed O 0 0.0027296448
telithromycin B-Chemical 1 0.9877957
400 O 0 0.0032673518
mg O 0 0.02168334
/ O 0 0.0009664228
d O 0 0.00036486227
PO O 0 0.11488776
to O 0 0.00013778872
treat O 0 0.00021545889
an O 0 0.0002046649
upper B-Disease 0 0.00044700387
respiratory I-Disease 0 0.0044708923
tract I-Disease 0 0.0012391814
infection I-Disease 0 0.0034168747
7 O 0 0.0002805537
days O 0 0.00025115017
prior O 0 0.0006017051
. O 0 0.0017150724

Admission O 0 0.0048684594
laboratory O 0 0.002251048
tests O 0 0.0015034791
were O 0 0.00051422353
as O 0 0.00032012365
follows O 0 0.00033904746
: O 0 0.0006141212
alanine B-Chemical 1 0.9737584
aminotransferase O 0 0.9953753
, O 0 0.000627307
67 O 0 0.0010740192
U O 0 0.34996927
/ O 0 0.0017212415
L O 0 0.42670944
( O 0 0.00023039556
reference O 0 0.00012456378
range O 0 0.00012332799
, O 0 0.00013224698
10 O 0 0.000110279645
- O 0 0.000242146
37 O 0 0.0003844449
U O 0 0.1288892
/ O 0 0.0013688209
L O 0 0.5805635
) O 0 0.0005321785
; O 0 0.00042370133
aspartate B-Chemical 1 0.99973124
aminotransferase O 0 0.9973475
, O 0 0.00047183235
98 O 0 0.0025632274
U O 0 0.38350776
/ O 0 0.0016476794
L O 0 0.4965601
( O 0 0.00025269436
10 O 0 0.00011876102
- O 0 0.00022456277
40 O 0 0.00019146198
U O 0 0.080552764
/ O 0 0.0013037726
L O 0 0.5822533
) O 0 0.00047944227
; O 0 0.0002737363
alkaline O 0 0.07634424
phosphatase O 0 0.20820946
, O 0 0.0005666345
513 O 0 0.032833703
U O 0 0.45929927
/ O 0 0.0017350055
L O 0 0.450522
( O 0 0.00025320414
0 O 0 0.00011958923
- O 0 0.00025930483
270 O 0 0.0015803153
U O 0 0.17288151
/ O 0 0.0014093408
L O 0 0.57957643
) O 0 0.00048203045
; O 0 0.000308234
gamma O 0 0.7363954
- O 0 0.0015976067
glutamyltransferase O 0 0.9981845
, O 0 0.0003599426
32 O 0 0.00042223508
U O 0 0.22242215
/ O 0 0.0014960762
L O 0 0.48015705
( O 0 0.00027911062
7 O 0 0.000102045946
- O 0 0.00024014893
49 O 0 0.00030009318
U O 0 0.07962225
/ O 0 0.0012953884
L O 0 0.5485707
) O 0 0.0004816396
; O 0 0.0002862473
amylase O 0 0.4212912
, O 0 0.00026566157
46 O 0 0.00037114634
U O 0 0.15834163
/ O 0 0.0012839993
L O 0 0.39753082
( O 0 0.0002518477
0 O 0 0.000119615215
- O 0 0.00025694078
220 O 0 0.0012313066
U O 0 0.19350109
/ O 0 0.0013837451
L O 0 0.5510193
) O 0 0.00033674084
; O 0 0.00015639355
total O 0 0.00023541735
bilirubin B-Chemical 1 0.9999517
, O 0 0.00029844462
20 O 0 0.00011560628
. O 0 5.3144362e-05
1 O 0 6.84619e-05
mg O 0 0.001128232
/ O 0 0.00047201998
dL O 0 0.0010316944
( O 0 0.00016072288
0 O 0 7.756643e-05
. O 0 5.5107663e-05
2 O 0 7.1180904e-05
- O 0 0.00013623586
1 O 0 5.914946e-05
. O 0 4.2068707e-05
0 O 0 6.458112e-05
mg O 0 0.0009796176
/ O 0 0.0004866586
dL O 0 0.0013082343
) O 0 0.0002345286
; O 0 0.00013398351
direct O 0 0.00016210746
bilirubin B-Chemical 1 0.9999404
, O 0 0.00028554216
14 O 0 9.004807e-05
. O 0 4.777495e-05
8 O 0 5.9166327e-05
mg O 0 0.0010732291
/ O 0 0.00046293065
dL O 0 0.0010062439
( O 0 0.00016217642
0 O 0 8.4873005e-05
- O 0 0.00014052071
0 O 0 6.0734277e-05
. O 0 4.377685e-05
3 O 0 5.4978485e-05
mg O 0 0.00086085463
/ O 0 0.00046284244
dL O 0 0.0013016148
) O 0 0.00023611374
; O 0 0.00013230716
and O 0 0.00014135649
albumin O 0 0.86162794
, O 0 0.00020222022
4 O 0 6.992843e-05
. O 0 4.668788e-05
7 O 0 5.616445e-05
mg O 0 0.0010202859
/ O 0 0.0005213723
dL O 0 0.001265546
( O 0 0.00020422088
3 O 0 8.4527805e-05
. O 0 6.880099e-05
5 O 0 8.956337e-05
- O 0 0.00020500006
5 O 0 0.000109174944
. O 0 0.0001221323
4 O 0 0.00021248359
mg O 0 0.0026920994
/ O 0 0.0021560355
dL O 0 0.0058709746
) O 0 0.0029204672
. O 0 0.002599642

No O 0 0.0070506064
toxin O 0 0.14107691
, O 0 0.0063454243
alcohol B-Chemical 0 0.9980927
, O 0 0.0022962051
or O 0 0.001096109
other O 0 0.001258043
drugs O 0 0.022562776
were O 0 0.0020932793
reported O 0 0.003225808
. O 0 0.003578765

The O 0 0.0017333003
patient O 0 0.0016894997
had O 0 0.0010807471
suffered O 0 0.0023807394
a O 0 0.0005952896
previous O 0 0.0003188216
episode O 0 0.0007066186
of O 0 0.00049768155
" O 0 0.0010234192
acute O 0 0.9993975
hepatitis B-Disease 2 0.9999993
of O 0 0.0057525453
unknown O 0 0.0014654744
origin O 0 0.000406116
, O 0 0.0002388526
" O 0 0.00018500052
that O 0 0.00011191359
occurred O 0 0.00020563787
after O 0 0.0002381002
telithromycin B-Chemical 1 0.9609243
usage O 0 0.0022149065
. O 0 0.0022356727

Both O 0 0.0061638164
incidents O 0 0.007863668
occurred O 0 0.0034564494
within O 0 0.0020480151
a O 0 0.0055748587
year O 0 0.0051662163
. O 0 0.0073857317

DISCUSSION O 0 0.0039323913
: O 0 0.002738702
Telithromycin B-Chemical 0 0.48357412
is O 0 0.00075477816
the O 0 0.00036176466
first O 0 0.00018632415
of O 0 0.0002780262
the O 0 0.00025259174
ketolide O 0 0.0078040725
antibacterials O 0 0.16574036
to O 0 0.00019924485
receive O 0 0.00015237191
US O 0 0.0019946482
Food O 0 0.00237006
and O 0 0.00028350632
Drug O 0 0.023930104
Administration O 0 0.0018547006
approval O 0 0.00057772023
for O 0 0.0003779246
clinical O 0 0.0015864167
use O 0 0.0014089574
. O 0 0.002055924

It O 0 0.0032753213
has O 0 0.0013548938
been O 0 0.000803082
associated O 0 0.0006288095
with O 0 0.0007306519
infrequent O 0 0.001103695
and O 0 0.00064420904
usually O 0 0.0010611771
reversible O 0 0.17159511
severe O 0 0.4944329
hepatic B-Disease 0 0.99977773
dysfunction I-Disease 0 0.9995073
. O 0 0.0059667737

Based O 0 0.0031507143
on O 0 0.0009579635
a O 0 0.0010408944
score O 0 0.0005067313
of O 0 0.00046041716
8 O 0 0.00021131884
on O 0 0.00011897377
the O 0 0.00022161409
Naranjo O 0 0.03879997
adverse B-Disease 0 0.3339841
drug I-Disease 0 0.036986265
reaction I-Disease 0 0.021709045
probability O 0 0.00020840146
scale O 0 0.00016115609
, O 0 0.00019270372
telithromycin B-Chemical 1 0.98058575
was O 0 0.00014837088
the O 0 8.863632e-05
probable O 0 0.00031590217
cause O 0 0.00020543112
of O 0 0.0005744477
acute O 0 0.9997303
hepatitis B-Disease 2 0.99999964
in O 0 0.000473652
this O 0 0.00025539182
patient O 0 0.00016394672
, O 0 0.00011196441
and O 0 0.00010555088
pathological O 0 0.0011456175
findings O 0 0.00029126645
suggested O 0 0.00016968428
drug O 0 0.02031155
- O 0 0.0010981964
induced O 0 0.0022191533
toxic B-Disease 0 0.9993166
hepatitis I-Disease 2 0.99999464
. O 0 0.014623802

Recurrence O 0 0.024242027
of O 0 0.007447654
hepatitis B-Disease 2 0.9999474
attack O 0 0.54815644
might O 0 0.0005164281
have O 0 0.0002729102
been O 0 0.00016160772
avoided O 0 0.00012542373
if O 0 6.5315544e-05
the O 0 8.190433e-05
initial O 0 0.00011122749
incident O 0 0.0014483022
had O 0 0.00012387593
been O 0 6.41254e-05
communicated O 0 8.608795e-05
to O 0 5.3551557e-05
the O 0 7.4437594e-05
attending O 0 0.00016897242
physician O 0 0.00032898076
who O 0 0.00026511578
prescribed O 0 0.0011206544
telithromycin B-Chemical 1 0.9281175
the O 0 0.0004015756
second O 0 0.0005415113
time O 0 0.00066500955
. O 0 0.0015651934

CONCLUSION O 0 0.018875606
: O 0 0.0021553698
Here O 0 0.0008777688
we O 0 0.00046280888
report O 0 0.00078810484
a O 0 0.0006079844
case O 0 0.00044494245
of O 0 0.0012905458
acute O 0 0.9995969
hepatitis B-Disease 2 0.9999989
probably O 0 0.0052167666
associated O 0 0.0003780835
with O 0 0.00038417598
the O 0 0.00036134225
administration O 0 0.0023303574
of O 0 0.0021920518
telithromycin B-Chemical 1 0.9971921
. O 0 0.0032233451

A O 0 0.015876608
study O 0 0.0016601209
on O 0 0.0005477144
the O 0 0.0004947232
effect O 0 0.0003552152
of O 0 0.0003615835
the O 0 0.00021783457
duration O 0 0.00011569869
of O 0 0.00031445862
subcutaneous O 0 0.0022052054
heparin B-Chemical 0 0.97643286
injection O 0 0.0007377336
on O 0 0.0005459517
bruising B-Disease 0 0.99764985
and O 0 0.0030993773
pain B-Disease 0 0.796578
. O 0 0.0031488605

AIM O 0 0.19651929
: O 0 0.0026494332
This O 0 0.0016435978
study O 0 0.000865218
was O 0 0.0004601405
carried O 0 0.0002420135
out O 0 0.00014409132
to O 0 0.00010918847
determine O 0 5.4267162e-05
the O 0 8.584513e-05
effect O 0 8.047507e-05
of O 0 0.00011914917
injection O 0 0.00010572173
duration O 0 4.257128e-05
on O 0 8.001182e-05
bruising B-Disease 0 0.9960473
and O 0 0.0002714474
pain B-Disease 0 0.097273156
following O 0 6.289046e-05
the O 0 8.894257e-05
administration O 0 0.00032970606
of O 0 0.00017436252
the O 0 0.00019188927
subcutaneous O 0 0.0008627997
injection O 0 0.0005660132
of O 0 0.0016058665
heparin B-Chemical 0 0.99176216
. O 0 0.0029312256

BACKGROUND O 0 0.0074958443
: O 0 0.0016593861
Although O 0 0.00046656645
different O 0 0.00030148687
methods O 0 0.00031380908
to O 0 0.00025105747
prevent O 0 0.00046509493
bruising B-Disease 0 0.9980223
and O 0 0.00051841664
pain B-Disease 0 0.13390593
following O 0 7.6369935e-05
the O 0 8.966095e-05
subcutaneous O 0 0.0002695542
injection O 0 0.0001010586
of O 0 0.00020488477
heparin B-Chemical 0 0.9819373
have O 0 8.035284e-05
been O 0 5.5895478e-05
widely O 0 5.085771e-05
studied O 0 7.3912255e-05
and O 0 6.53462e-05
described O 0 5.446422e-05
, O 0 6.8705725e-05
the O 0 5.0745126e-05
effect O 0 5.1956125e-05
of O 0 8.761655e-05
injection O 0 7.6310396e-05
duration O 0 2.7242786e-05
on O 0 3.130217e-05
the O 0 6.705885e-05
occurrence O 0 0.00018864451
of O 0 0.00051095785
bruising B-Disease 0 0.9990802
and O 0 0.00093889853
pain B-Disease 0 0.5339084
is O 0 0.00063503115
little O 0 0.00078767
documented O 0 0.0023054248
. O 0 0.002034848

DESIGN O 0 0.0035558427
: O 0 0.0022490614
This O 0 0.0017124214
study O 0 0.0010547533
was O 0 0.0006494444
designed O 0 0.0004557586
as O 0 0.0003452723
within O 0 0.0001838289
- O 0 0.0006212373
subject O 0 0.00030940995
, O 0 0.0006270133
quasi O 0 0.0017147092
- O 0 0.0013924921
experimental O 0 0.0015123318
research O 0 0.0023714495
. O 0 0.0027118034

METHOD O 0 0.005457064
: O 0 0.001694979
The O 0 0.00058933935
sample O 0 0.0006467806
for O 0 0.00028877682
the O 0 0.00027637152
study O 0 0.0002538169
consisted O 0 0.00015565964
of O 0 0.00022579686
50 O 0 0.0003186894
patients O 0 0.0002527081
to O 0 0.00018368383
whom O 0 0.00070267345
subcutaneous O 0 0.0034307789
heparin B-Chemical 0 0.9801319
was O 0 0.0013870365
administered O 0 0.0019415433
. O 0 0.0021354519

Heparin B-Chemical 1 0.9899014
was O 0 0.0019807569
injected O 0 0.00071699487
over O 0 0.00026269205
10 O 0 0.00025447842
seconds O 0 0.00015777591
on O 0 0.000114250855
the O 0 0.0001820018
right O 0 0.00063438993
abdominal O 0 0.0013378754
site O 0 0.0001435009
and O 0 0.00013758076
30 O 0 9.5214506e-05
seconds O 0 9.428604e-05
on O 0 0.00011538184
the O 0 0.00030412493
left O 0 0.0013736881
abdominal O 0 0.0057719517
site O 0 0.0016151484
. O 0 0.002374269

Injections O 0 0.0064278645
areas O 0 0.0015737249
were O 0 0.0007993463
assessed O 0 0.00038385365
for O 0 0.00025845526
the O 0 0.00027495835
presence O 0 0.00030632544
of O 0 0.00076717185
bruising B-Disease 0 0.99407476
at O 0 0.00020579006
48 O 0 0.00015673199
and O 0 0.0001657041
72 O 0 0.00016311687
hours O 0 0.000120377175
after O 0 0.00014934402
each O 0 0.00035174025
injection O 0 0.0015745476
. O 0 0.0022669605

Dimensions O 0 0.004401239
of O 0 0.001978562
the O 0 0.001729099
bruising B-Disease 0 0.9742664
on O 0 0.00045854083
the O 0 0.0006222332
heparin B-Chemical 0 0.93331623
applied O 0 0.0002990282
areas O 0 0.00032743718
were O 0 0.00023565562
measured O 0 0.0002069658
using O 0 0.0002697722
transparent O 0 0.0010162152
millimetric O 0 0.0023136442
measuring O 0 0.00092046225
paper O 0 0.0026291697
. O 0 0.002558026

The O 0 0.0018976948
visual O 0 0.0075906785
analog O 0 0.0031843008
scale O 0 0.0011955667
( O 0 0.0013743908
VAS O 0 0.0059277806
) O 0 0.00063235173
was O 0 0.0002505606
used O 0 0.0001326347
to O 0 0.00011892714
measure O 0 8.779855e-05
pain B-Disease 0 0.031074671
intensity O 0 0.00010574038
and O 0 0.00014918446
a O 0 0.00023402912
stop O 0 0.00087136606
- O 0 0.00042964664
watch O 0 0.0002694848
was O 0 0.00014787681
used O 0 0.000105746636
to O 0 0.00013320085
time O 0 0.00015004628
the O 0 0.00047733556
pain B-Disease 0 0.096498094
period O 0 0.00085411646
. O 0 0.0018036779

Data O 0 0.0027395927
were O 0 0.0015782417
analysed O 0 0.001089221
using O 0 0.0009286481
chi O 0 0.010484895
- O 0 0.0014359978
square O 0 0.0011948472
test O 0 0.00081410946
, O 0 0.0007823805
Mann O 0 0.0077835633
- O 0 0.0017736068
Whitney O 0 0.20970091
U O 0 0.28938273
, O 0 0.0006975852
Wilcoxon O 0 0.0015680805
signed O 0 0.0010931497
ranks O 0 0.001910987
tests O 0 0.001269038
and O 0 0.00095747533
correlation O 0 0.0012834704
. O 0 0.002415442

RESULTS O 0 0.004381833
: O 0 0.0015695378
The O 0 0.0005710285
percentage O 0 0.0005277847
of O 0 0.0011685871
bruising B-Disease 0 0.99556905
occurrence O 0 0.0010924294
was O 0 0.00038391398
64 O 0 0.00028718685
% O 0 0.00014250711
with O 0 0.00011233485
the O 0 8.760527e-05
injection O 0 0.00010029615
of O 0 0.00010171563
10 O 0 6.2479914e-05
seconds O 0 4.420803e-05
duration O 0 3.8673017e-05
and O 0 9.0611495e-05
42 O 0 0.0001289792
% O 0 0.000117859614
in O 0 0.00011084082
the O 0 0.00017110788
30 O 0 0.00022261386
- O 0 0.00059586007
second O 0 0.0006430267
injection O 0 0.0017596537
. O 0 0.0021799721

It O 0 0.0028816424
was O 0 0.0014719435
determined O 0 0.00064869365
that O 0 0.00036239202
the O 0 0.00038612564
size O 0 0.0004978867
of O 0 0.00044369904
the O 0 0.0006319062
bruising B-Disease 0 0.9975782
was O 0 0.00043891062
smaller O 0 0.0002674461
in O 0 0.00019956542
the O 0 0.00025098116
30 O 0 0.00029314356
- O 0 0.00072540273
second O 0 0.0007512304
injection O 0 0.0019818745
. O 0 0.002407156

Pain B-Disease 0 0.067455724
intensity O 0 0.0011824764
and O 0 0.0012445173
pain B-Disease 0 0.05255911
period O 0 0.00026496718
were O 0 0.0002835863
statistically O 0 0.00021134604
significantly O 0 0.00021833321
lower O 0 0.00018304812
for O 0 8.756544e-05
the O 0 0.00011235863
30 O 0 9.6150536e-05
- O 0 0.00018204711
second O 0 9.290996e-05
injection O 0 0.00013249982
than O 0 8.333401e-05
for O 0 0.000106570944
the O 0 0.00020393463
10 O 0 0.00028706226
- O 0 0.00066021114
second O 0 0.00068165036
injection O 0 0.0018328286
. O 0 0.0022175312

CONCLUSIONS O 0 0.018885624
: O 0 0.0026061458
It O 0 0.0009825049
was O 0 0.00057835743
determined O 0 0.00028018907
that O 0 0.00017114426
injection O 0 0.00022638236
duration O 0 9.0182286e-05
had O 0 0.00012014553
an O 0 0.00013467546
effect O 0 0.000119402124
on O 0 0.00014701554
bruising B-Disease 0 0.9976972
and O 0 0.0004168605
pain B-Disease 0 0.11424972
following O 0 0.000120674034
the O 0 0.00020368549
subcutaneous O 0 0.0010017433
administration O 0 0.0018488314
of O 0 0.0019924415
heparin B-Chemical 0 0.9937723
. O 0 0.003130784

This O 0 0.005565284
study O 0 0.0026880954
should O 0 0.000987231
be O 0 0.0009452592
repeated O 0 0.0006353713
on O 0 0.00077753747
a O 0 0.0017933932
larger O 0 0.0023558887
sample O 0 0.0039791865
. O 0 0.0044170776

RELEVANCE O 0 0.0064523807
TO O 0 0.0068297284
CLINICAL O 0 0.0014941883
PRACTICE O 0 0.00039696574
: O 0 0.0004977662
When O 0 0.00022544945
administering O 0 0.0007894453
subcutaneous O 0 0.0027709035
heparin B-Chemical 0 0.99306595
injections O 0 0.00085436634
, O 0 0.0002769653
it O 0 0.0001647896
is O 0 0.00010389363
important O 0 5.8675356e-05
to O 0 9.4740106e-05
extend O 0 0.00010141269
the O 0 0.00013933337
duration O 0 0.00012674053
of O 0 0.00043454184
the O 0 0.00071404234
injection O 0 0.0018878129
. O 0 0.002184067

Acute B-Disease 0 0.86084753
liver I-Disease 0 0.9419939
failure I-Disease 0 0.7390305
in O 0 0.00072558457
two O 0 0.0002793326
patients O 0 0.00033646182
with O 0 0.00026527228
regular O 0 0.00039420606
alcohol B-Chemical 0 0.9985055
consumption O 0 0.0567896
ingesting O 0 0.6539449
paracetamol B-Chemical 0 0.99996305
at O 0 0.00061758014
therapeutic O 0 0.0028682163
dosage O 0 0.054976296
. O 0 0.0023846258

BACKGROUND O 0 0.008014556
: O 0 0.0018049988
The O 0 0.00057289755
possible O 0 0.00046603708
role O 0 0.000310649
of O 0 0.0007621221
alcohol B-Chemical 0 0.9971987
in O 0 0.00024606672
the O 0 0.00016018799
development O 0 0.0003406809
of O 0 0.00068613444
hepatotoxicity B-Disease 0 0.9999956
associated O 0 0.00021357066
with O 0 0.00016672858
therapeutic O 0 0.00031953485
doses O 0 0.0018405864
of O 0 0.0014085397
paracetamol B-Chemical 0 0.99999547
( O 0 0.016471596
acetaminophen B-Chemical 0 0.9999963
) O 0 0.0016879082
is O 0 0.00061122555
currently O 0 0.0010319165
debated O 0 0.0026196875
. O 0 0.0019269035

CASE O 0 0.016750379
REPORT O 0 0.002348567
: O 0 0.0010565551
We O 0 0.0003450291
describe O 0 0.0003143768
2 O 0 0.00028310413
patients O 0 0.00031185494
who O 0 0.00026229283
were O 0 0.00012787338
regular O 0 0.00012434447
consumers O 0 0.0006920798
of O 0 0.00031591725
alcohol B-Chemical 0 0.999
and O 0 0.00022666657
who O 0 0.0002583493
developed O 0 0.00032978342
liver B-Disease 0 0.8607772
failure I-Disease 0 0.09784823
within O 0 3.6596695e-05
3 O 0 5.3290925e-05
- O 0 8.344136e-05
5 O 0 2.399878e-05
days O 0 1.3485752e-05
after O 0 1.5222453e-05
hospitalization O 0 0.00011636966
and O 0 7.2653136e-05
stopping O 0 0.0005090963
alcohol B-Chemical 0 0.9993543
consumption O 0 0.0069788042
while O 0 0.000104146566
being O 0 0.00013707987
treated O 0 0.00016279584
with O 0 0.00018759303
4 O 0 0.00017669828
g O 0 0.0014559618
paracetamol B-Chemical 0 0.9998946
/ O 0 0.003152542
day O 0 0.0009283521
. O 0 0.001673592

A O 0 0.42031452
paracetamol B-Chemical 0 0.99987006
serum O 0 0.1311206
level O 0 0.0007616807
obtained O 0 0.0005184023
in O 0 0.00030228874
one O 0 0.00018672876
of O 0 0.0002834566
these O 0 0.0003673888
patients O 0 0.00039813074
was O 0 0.00026141826
not O 0 0.00022258372
in O 0 0.0003244454
the O 0 0.00063533353
toxic O 0 0.121056855
range O 0 0.0023803986
. O 0 0.0024718787

Possible O 0 0.0051092673
risk O 0 0.0054108193
factors O 0 0.0010990074
for O 0 0.00042837748
the O 0 0.0003902622
development O 0 0.000688158
of O 0 0.0012615626
hepatotoxicity B-Disease 0 0.9999932
in O 0 0.00044561923
patients O 0 0.00033370865
treated O 0 0.00022811287
with O 0 0.0002050937
therapeutic O 0 0.000557551
doses O 0 0.0032662477
of O 0 0.0021520536
paracetamol B-Chemical 0 0.9999639
are O 0 0.0014104377
discussed O 0 0.0015281047
. O 0 0.0020857698

CONCLUSION O 0 0.017106744
: O 0 0.002148108
In O 0 0.0007754291
patients O 0 0.00091592356
with O 0 0.0007158881
risk O 0 0.002523471
factors O 0 0.000577042
, O 0 0.00037229716
e O 0 0.0003356143
. O 0 0.000107131535
g O 0 0.0003008741
. O 0 6.877875e-05
regular O 0 0.00010555229
consumption O 0 0.0008051302
of O 0 0.0003942478
alcohol B-Chemical 0 0.9996551
, O 0 0.00063613267
liver B-Disease 0 0.9219924
failure I-Disease 0 0.23272069
is O 0 0.00018496875
possible O 0 0.00011506958
when O 0 0.00011557133
therapeutic O 0 0.00060599745
doses O 0 0.002615966
are O 0 0.0009167861
ingested O 0 0.008505791
. O 0 0.0020943217

We O 0 0.001154612
propose O 0 0.00067649304
that O 0 0.00061919424
the O 0 0.0013117278
paracetamol B-Chemical 0 0.99995565
dose O 0 0.006053074
should O 0 0.00013843812
not O 0 0.00013099283
exceed O 0 0.000116111834
2 O 0 9.0649264e-05
g O 0 0.00022172208
/ O 0 0.00019572639
day O 0 4.452013e-05
in O 0 5.024553e-05
such O 0 4.5743e-05
patients O 0 9.746944e-05
and O 0 6.1971376e-05
that O 0 5.0676794e-05
their O 0 0.00014873348
liver O 0 0.31997842
function O 0 0.00014648253
should O 0 4.1448166e-05
be O 0 5.215996e-05
monitored O 0 4.1682986e-05
closely O 0 5.864398e-05
while O 0 0.00011777424
being O 0 0.00029029918
treated O 0 0.0007256634
with O 0 0.002831322
paracetamol B-Chemical 0 0.99992526
. O 0 0.003478505

Associations O 0 0.0018532859
between O 0 0.00077057147
use O 0 0.0007449009
of O 0 0.0012684749
benzodiazepines B-Chemical 1 0.9996723
or O 0 0.00034245744
related O 0 0.00013755729
drugs O 0 0.004238211
and O 0 0.0002117034
health O 0 0.0004772241
, O 0 0.000168226
physical O 0 0.00024693037
abilities O 0 0.0007443456
and O 0 0.00015615886
cognitive O 0 0.049296793
function O 0 0.00018950427
: O 0 0.00015970148
a O 0 0.000155726
non O 0 0.0001914724
- O 0 0.00025193466
randomised O 0 0.00019942218
clinical O 0 0.00036249688
study O 0 0.00027893207
in O 0 0.0003371771
the O 0 0.00078721007
elderly O 0 0.0648753
. O 0 0.002113313

OBJECTIVE O 0 0.021775266
: O 0 0.0019381421
To O 0 0.00064467837
describe O 0 0.0004446204
associations O 0 0.00028876745
between O 0 0.00017609801
the O 0 0.00020443343
use O 0 0.00018487973
of O 0 0.00045882785
benzodiazepines B-Chemical 1 0.9998336
or O 0 0.00014099867
related O 0 6.955499e-05
drugs O 0 0.012443229
( O 0 0.0006017487
BZDs B-Chemical 0 0.99985754
/ O 0 0.0010336796
RDs O 0 0.00147331
) O 0 0.00017468468
and O 0 0.00010218335
health O 0 0.00028635564
, O 0 0.00013068404
functional O 0 0.0001315797
abilities O 0 0.00066148204
and O 0 0.00023364212
cognitive O 0 0.03623346
function O 0 0.00042452972
in O 0 0.0004448756
the O 0 0.00092599075
elderly O 0 0.099791706
. O 0 0.0021541251

METHODS O 0 0.0019082441
: O 0 0.0020038271
A O 0 0.0043893387
non O 0 0.0010004538
- O 0 0.0008714321
randomised O 0 0.00043739358
clinical O 0 0.0004690829
study O 0 0.00021617478
of O 0 0.00021029734
patients O 0 0.00026513299
aged O 0 0.00028010522
> O 0 0.00028107228
or O 0 0.000110485096
= O 0 0.0001466694
65 O 0 0.00011071184
years O 0 7.498153e-05
admitted O 0 0.00017830785
to O 0 0.00012776649
acute O 0 0.04009612
hospital O 0 0.00055341335
wards O 0 0.00031898057
during O 0 0.00018822892
1 O 0 0.0004316383
month O 0 0.0005591871
. O 0 0.0014483096

164 O 0 0.0072912998
patients O 0 0.002367923
( O 0 0.0012539278
mean O 0 0.00040870707
age O 0 0.00068672677
+ O 0 0.0008970773
/ O 0 0.0009993479
- O 0 0.00043363008
standard O 0 0.00017283701
deviation O 0 0.0005047279
[ O 0 0.0007577022
SD O 0 0.003829759
] O 0 0.00049760134
81 O 0 0.00030042353
. O 0 8.925413e-05
6 O 0 8.594581e-05
+ O 0 0.00028042853
/ O 0 0.00053897925
- O 0 0.00035378884
6 O 0 0.000117401185
. O 0 0.00012402248
8 O 0 0.00018517028
years O 0 0.00028454914
) O 0 0.0006475435
were O 0 0.00084491604
admitted O 0 0.0026892344
. O 0 0.0021912071

Of O 0 0.0027691992
these O 0 0.00195966
, O 0 0.0011731717
nearly O 0 0.0007591723
half O 0 0.0004334794
( O 0 0.0005478374
n O 0 0.0002855144
= O 0 0.00028698044
78 O 0 0.00031351479
) O 0 0.00022753466
had O 0 0.00012784483
used O 0 0.00019037121
BZDs B-Chemical 0 0.99973994
/ O 0 0.000782951
RDs O 0 0.0005918603
before O 0 4.0672156e-05
admission O 0 0.00014686618
, O 0 9.894815e-05
and O 0 8.3581195e-05
the O 0 9.168885e-05
remainder O 0 0.00018425303
( O 0 0.00018885921
n O 0 0.0001311448
= O 0 0.00019416353
86 O 0 0.0003187201
) O 0 0.0003453358
were O 0 0.0003254414
non O 0 0.0007355066
- O 0 0.0016187987
users O 0 0.0034578752
. O 0 0.00223831

Cognitive O 0 0.038791366
ability O 0 0.0023765406
was O 0 0.0016223553
assessed O 0 0.00075868744
by O 0 0.0007193859
the O 0 0.00063939154
Mini O 0 0.0012278856
- O 0 0.0011122846
Mental O 0 0.0012523988
State O 0 0.001204851
Examination O 0 0.0008126519
( O 0 0.001638654
MMSE O 0 0.09173521
) O 0 0.0032956097
. O 0 0.0030400227

Patients O 0 0.0024051415
scoring O 0 0.0020845614
> O 0 0.0018650867
or O 0 0.0006314691
= O 0 0.00061057217
20 O 0 0.00038946036
MMSE O 0 0.0139311915
sum O 0 0.00016313614
points O 0 0.0001330224
were O 0 0.0001455118
interviewed O 0 0.00028498028
( O 0 0.00018532731
n O 0 0.00011003048
= O 0 0.00013390766
79 O 0 0.00016108158
) O 0 0.00012851588
and O 0 7.662123e-05
questioned O 0 0.00010150876
regarding O 0 5.4581415e-05
symptoms O 0 0.000852405
and O 0 0.0001019484
functional O 0 0.000110157715
abilities O 0 0.00037508836
during O 0 6.0095714e-05
the O 0 0.00011270931
week O 0 8.958172e-05
prior O 0 0.00014923667
to O 0 0.00046786913
admission O 0 0.0019634173
. O 0 0.0018512593

Data O 0 0.0020797106
on O 0 0.00090633554
use O 0 0.0009212124
of O 0 0.0016823427
BZDs B-Chemical 0 0.9996517
/ O 0 0.0022628554
RDs O 0 0.0011948084
before O 0 8.808929e-05
admission O 0 0.00023299386
, O 0 0.00015550505
current O 0 0.0002817309
medications O 0 0.0012627982
and O 0 0.00014044585
discharge O 0 0.00021972237
diagnoses O 0 0.00030210317
were O 0 0.00015083712
collected O 0 0.00014143226
from O 0 0.00031305634
medical O 0 0.0016089396
records O 0 0.0020273996
. O 0 0.0018689814

Health O 0 0.0033891243
, O 0 0.0019228103
physical O 0 0.0015380005
abilities O 0 0.0024245612
and O 0 0.0006133456
cognitive O 0 0.028533496
function O 0 0.0003143019
were O 0 0.00015964806
compared O 0 8.70525e-05
between O 0 0.00012578662
BZD O 0 0.9994916
/ O 0 0.0034046003
RD O 0 0.9969598
users O 0 0.00081280957
and O 0 0.00015579848
non O 0 0.0002432493
- O 0 0.00035564895
users O 0 0.00039267467
, O 0 0.00014004303
and O 0 0.00011646357
adjustments O 0 0.00012626553
were O 0 0.00015744947
made O 0 0.00018038986
for O 0 0.00025789032
confounding O 0 0.000634065
variables O 0 0.0009376665
. O 0 0.0018293061

The O 0 0.0015034139
residual O 0 0.0016185767
serum O 0 0.009960427
concentrations O 0 0.0034665647
of O 0 0.0055388645
oxazepam B-Chemical 0 0.9999974
, O 0 0.022290617
temazepam B-Chemical 0 0.9999951
and O 0 0.0074855317
zopiclone B-Chemical 0 0.9999764
were O 0 0.0019386386
analysed O 0 0.0018115626
. O 0 0.0024598783

RESULTS O 0 0.0045135017
: O 0 0.0016346376
The O 0 0.00059907715
mean O 0 0.00044765515
+ O 0 0.0011826835
/ O 0 0.0014534302
- O 0 0.00084436516
SD O 0 0.0013748346
duration O 0 0.0001288983
of O 0 0.00051768526
BZD O 0 0.99971753
/ O 0 0.004915798
RD O 0 0.9935561
use O 0 0.00020966868
was O 0 0.0001850642
7 O 0 0.000105827625
+ O 0 0.0002990051
/ O 0 0.00053970155
- O 0 0.0003307226
7 O 0 0.00012245569
years O 0 0.00015077846
( O 0 0.00026497652
range O 0 0.0003054683
1 O 0 0.00042827168
- O 0 0.0010632484
31 O 0 0.0014938796
) O 0 0.0022494232
. O 0 0.002413065

Two O 0 0.0020996018
or O 0 0.0013021369
three O 0 0.0009808379
BZDs B-Chemical 0 0.9990138
/ O 0 0.002630085
RDs O 0 0.0019311539
were O 0 0.0002743414
concomitantly O 0 0.00040539075
taken O 0 0.00012624227
by O 0 0.00018693472
26 O 0 0.00023685038
% O 0 0.00019304485
of O 0 0.0002905304
users O 0 0.0008366912
( O 0 0.0004987864
n O 0 0.00040231127
= O 0 0.00069132895
20 O 0 0.0008917081
) O 0 0.0020689887
. O 0 0.0023043181

Long O 0 0.008081531
- O 0 0.0026253099
term O 0 0.0007663074
use O 0 0.000506884
of O 0 0.000497018
these O 0 0.00056146696
drugs O 0 0.010293001
was O 0 0.00026611707
associated O 0 0.00014334526
with O 0 0.0002391495
female O 0 0.00085183827
sex O 0 0.0002866075
and O 0 8.341971e-05
use O 0 5.9113085e-05
of O 0 8.620222e-05
a O 0 9.664536e-05
higher O 0 8.634784e-05
number O 0 6.622281e-05
of O 0 0.00011034317
drugs O 0 0.0022604386
with O 0 9.373938e-05
effects O 0 8.532436e-05
on O 0 5.1351686e-05
the O 0 0.00012896112
CNS O 0 0.030487476
, O 0 0.0001757848
which O 0 0.00016910007
tended O 0 0.0001398997
to O 0 0.00012062893
be O 0 0.00014228403
related O 0 0.00013565343
to O 0 0.0004880783
diagnosed O 0 0.011297934
dementia B-Disease 0 0.99959105
. O 0 0.0033101658

After O 0 0.0009121334
adjustment O 0 0.00080185325
for O 0 0.0005026658
these O 0 0.00055197306
variables O 0 0.00027266055
as O 0 0.00025199013
confounders O 0 0.00023111542
, O 0 0.00021075744
use O 0 0.00015712732
of O 0 0.0005147944
BZDs B-Chemical 0 0.9999033
/ O 0 0.0014835111
RDs O 0 0.0012386327
was O 0 0.000106855965
not O 0 6.806805e-05
associated O 0 8.034318e-05
with O 0 0.00016567724
cognitive O 0 0.033009257
function O 0 0.00024723454
as O 0 0.00019184829
measured O 0 0.00024106885
by O 0 0.0004896046
the O 0 0.0010267533
MMSE O 0 0.3738981
. O 0 0.002244937

However O 0 0.0026777936
, O 0 0.001922458
use O 0 0.0010385757
of O 0 0.0019197875
BZDs B-Chemical 0 0.9997545
/ O 0 0.0031931095
RDs O 0 0.002215326
was O 0 0.0002182302
associated O 0 0.00014081542
with O 0 0.0004103839
dizziness B-Disease 0 0.9995629
, O 0 0.00023595756
inability B-Disease 0 0.00027595626
to I-Disease 0 9.300463e-05
sleep I-Disease 0 0.0063144728
after O 0 3.070114e-05
awaking O 0 0.002449727
at O 0 3.859811e-05
night O 0 0.00014666437
and O 0 9.83599e-05
tiredness B-Disease 0 0.3293961
in O 0 6.152809e-05
the O 0 5.8925612e-05
mornings O 0 0.0003708954
during O 0 1.8893697e-05
the O 0 2.970179e-05
week O 0 1.622647e-05
prior O 0 1.6065487e-05
to O 0 3.315875e-05
admission O 0 8.3597064e-05
and O 0 5.783651e-05
with O 0 9.504759e-05
stronger O 0 0.00038791078
depressive B-Disease 2 0.9999927
symptoms I-Disease 0 0.40862986
measured O 0 0.00010068019
at O 0 6.628688e-05
the O 0 0.00010147664
beginning O 0 0.00010355259
of O 0 0.00030267227
the O 0 0.0004610353
hospital O 0 0.0012652496
stay O 0 0.0011170385
. O 0 0.0016397794

Use O 0 0.0060635423
of O 0 0.004399705
BZDs B-Chemical 0 0.99947244
/ O 0 0.0049881455
RDs O 0 0.002946601
tended O 0 0.00035490043
to O 0 0.00020488966
be O 0 0.00015304273
associated O 0 0.000120364886
with O 0 0.00016099589
a O 0 0.00016394703
reduced O 0 0.00017972854
ability O 0 0.00011857566
to O 0 0.00010419673
walk O 0 0.00029131895
and O 0 8.4167135e-05
shorter O 0 6.576592e-05
night O 0 0.00020275619
- O 0 0.00013073925
time O 0 4.3399876e-05
sleep O 0 0.00042984472
during O 0 4.750116e-05
the O 0 9.468447e-05
week O 0 8.234264e-05
prior O 0 0.0001427914
to O 0 0.00045563173
admission O 0 0.0019012167
. O 0 0.0018488412

A O 0 0.011604141
higher O 0 0.0014514136
residual O 0 0.0010795606
serum O 0 0.009465967
concentration O 0 0.0017329504
of O 0 0.0021197782
temazepam B-Chemical 0 0.9999956
correlated O 0 0.00024778012
with O 0 0.00023563721
a O 0 0.00023738209
lower O 0 0.00034322342
MMSE O 0 0.095138654
sum O 0 0.000112008616
score O 0 9.3600924e-05
after O 0 6.667773e-05
adjustment O 0 0.00016102292
for O 0 0.00026878662
confounding O 0 0.0006712675
variables O 0 0.0009797951
. O 0 0.0018847461

CONCLUSIONS O 0 0.016868826
: O 0 0.0029479377
Long O 0 0.0031872962
- O 0 0.0012494333
term O 0 0.0004194025
use O 0 0.00031494707
and O 0 0.00028016503
concomitant O 0 0.0004915667
use O 0 0.00014941636
of O 0 0.00016432312
more O 0 0.00017316593
than O 0 8.824644e-05
one O 0 0.00014994074
BZD O 0 0.9995358
/ O 0 0.0022497205
RD O 0 0.9827476
were O 0 0.0001241781
common O 0 0.00010297143
in O 0 0.0001156366
elderly O 0 0.009675177
patients O 0 0.00038470724
hospitalised O 0 0.0038275986
because O 0 0.00022650973
of O 0 0.0009857969
acute O 0 0.79254705
illnesses O 0 0.76764154
. O 0 0.003330025

Long O 0 0.00865728
- O 0 0.00284376
term O 0 0.0008604529
use O 0 0.0005893038
was O 0 0.00042288622
associated O 0 0.00022019864
with O 0 0.00025788616
daytime O 0 0.0008529932
and O 0 0.00017206992
night O 0 0.00035643723
- O 0 0.00018985764
time O 0 5.0897837e-05
symptoms O 0 0.00049104576
indicative O 0 7.32584e-05
of O 0 0.000121545825
poorer O 0 0.00022247212
health O 0 0.0002813546
and O 0 0.000108371394
potentially O 0 0.00014519664
caused O 0 0.00014680848
by O 0 0.00014495123
the O 0 0.0001716663
adverse O 0 0.004957289
effects O 0 0.000392937
of O 0 0.0007075132
these O 0 0.0015555063
drugs O 0 0.073595256
. O 0 0.0022799496

Acute O 0 0.16658147
vocal B-Disease 0 0.027256133
fold I-Disease 0 0.0110483775
palsy I-Disease 0 0.9991523
after O 0 0.002656961
acute O 0 0.9932039
disulfiram B-Chemical 0 0.99998426
intoxication O 0 0.999754
. O 0 0.012166702

Acute O 0 0.553341
peripheral B-Disease 2 0.96217495
neuropathy I-Disease 2 0.9999573
caused O 0 0.0025686326
by O 0 0.001096737
a O 0 0.0042021777
disulfiram B-Chemical 0 0.9999975
overdose B-Disease 0 0.9999782
is O 0 0.00056643906
very O 0 0.00045234023
rare O 0 0.00075902947
and O 0 0.0001462365
there O 0 7.023531e-05
is O 0 9.975484e-05
no O 0 6.992303e-05
report O 0 0.00020651557
of O 0 0.00022471636
it O 0 0.00023529012
leading O 0 0.00042436365
to O 0 0.00043930905
vocal B-Disease 0 0.0110965865
fold I-Disease 0 0.0062199775
palsy I-Disease 0 0.9997236
. O 0 0.0044207806

A O 0 0.029932296
49 O 0 0.00412077
- O 0 0.0025980473
year O 0 0.0007501524
- O 0 0.0010235143
old O 0 0.00050178304
woman O 0 0.0007844238
was O 0 0.00022200553
transferred O 0 0.00015213701
to O 0 9.5938514e-05
our O 0 0.00014859074
department O 0 0.00019690114
because O 0 7.765836e-05
of O 0 0.000383106
quadriparesis B-Disease 0 0.9993311
, O 0 0.0010463678
lancinating O 0 0.9442823
pain B-Disease 0 0.8308237
, O 0 0.00031690695
sensory B-Disease 0 0.006830104
loss I-Disease 0 0.02169825
, O 0 0.00037665525
and O 0 0.0004589844
paresthesia B-Disease 0 0.9825957
of O 0 0.000669145
the O 0 0.0006605126
distal O 0 0.0018631376
limbs O 0 0.057667572
. O 0 0.0023689193

One O 0 0.0022207797
month O 0 0.0009796914
previously O 0 0.00085006416
, O 0 0.00072347454
she O 0 0.00034777357
had O 0 0.00024578438
taken O 0 0.00012014197
a O 0 0.00018267026
single O 0 0.00013305286
high O 0 0.0002431677
dose O 0 0.0008532867
of O 0 0.0008158789
disulfiram B-Chemical 0 0.99999464
( O 0 0.00048296803
130 O 0 0.0004028464
tablets O 0 0.011889516
of O 0 0.00022971557
ALCOHOL B-Chemical 0 0.044145398
STOP O 0 0.008357256
TAB O 0 0.25294048
, O 0 0.00029079837
Shin O 0 0.03508507
- O 0 0.00086467736
Poong O 0 0.8934102
Pharm O 0 0.8687998
. O 0 0.00018705633
Co O 0 0.8496674
. O 0 0.00013956433
, O 0 0.0003006992
Ansan O 0 0.11366296
, O 0 0.00037728905
Korea O 0 0.0010538208
) O 0 0.00045054077
in O 0 0.000361828
a O 0 0.0010495296
suicide O 0 0.35133496
attempt O 0 0.003402533
. O 0 0.0027232347

She O 0 0.01331603
was O 0 0.008637511
not O 0 0.007274631
an O 0 0.015982473
alcoholic O 0 0.997326
. O 0 0.018733962

For O 0 0.0011486927
the O 0 0.0010411533
first O 0 0.00049562426
few O 0 0.00029485507
days O 0 0.00018485344
after O 0 0.00015664368
ingestion O 0 0.015872078
, O 0 0.00039599722
she O 0 0.00018153332
was O 0 0.00018022534
in O 0 0.00012344022
a O 0 0.00021500148
confused O 0 0.0004186502
state O 0 0.00017060236
and O 0 0.00015375375
had O 0 0.00020894902
mild O 0 0.052324764
to O 0 0.00042083988
moderate O 0 0.15605363
ataxia B-Disease 0 0.99997914
and O 0 0.023240332
giddiness B-Disease 0 0.9998635
. O 0 0.0042333277

She O 0 0.004079666
noticed O 0 0.0030866796
hoarseness B-Disease 2 0.8240903
and O 0 0.0012460024
distally O 0 0.0012629151
accentuated O 0 0.0016727478
motor O 0 0.0012339731
and O 0 0.00032762304
sensory O 0 0.00085657695
dysfunction O 0 0.23125523
after O 0 9.8160686e-05
she O 0 0.00016010036
had O 0 0.00018857454
recovered O 0 0.00024324398
from O 0 0.00033488145
this O 0 0.00084449106
state O 0 0.0017610168
. O 0 0.0020388823

A O 0 0.028942036
nerve O 0 0.015168934
conduction O 0 0.0063555073
study O 0 0.0015364345
was O 0 0.0008991478
consistent O 0 0.0006679259
with O 0 0.0010841283
severe O 0 0.017416816
sensorimotor O 0 0.26252794
axonal O 0 0.74030256
polyneuropathy B-Disease 0 0.9996455
. O 0 0.005781951

Laryngeal O 0 0.017937846
electromyography O 0 0.02746691
( O 0 0.0041185278
thyroarytenoid O 0 0.005106018
muscle O 0 0.0065792636
) O 0 0.0024726773
showed O 0 0.0016288543
ample O 0 0.0033611627
denervation O 0 0.63966334
potentials O 0 0.02052265
. O 0 0.005168996

Laryngoscopy O 0 0.013361476
revealed O 0 0.002983338
asymmetric O 0 0.0039806566
vocal O 0 0.008102302
fold O 0 0.0031454228
movements O 0 0.0033295187
during O 0 0.0019909951
phonation O 0 0.012288378
. O 0 0.00538945

Her O 0 0.007170246
vocal O 0 0.0073634204
change O 0 0.0016429517
and O 0 0.0015625906
weakness O 0 0.42053986
began O 0 0.0005978882
to O 0 0.00033520052
improve O 0 0.0002721811
spontaneously O 0 0.0007101514
about O 0 0.00032947923
3 O 0 0.0002675866
weeks O 0 0.00020175109
after O 0 0.00035443652
transfer O 0 0.0018297624
. O 0 0.0024620043

This O 0 0.0041459347
was O 0 0.0018061057
a O 0 0.0011466192
case O 0 0.0006894633
of O 0 0.0011014421
acute O 0 0.85473573
palsy B-Disease 0 0.9999255
of O 0 0.0007421813
the O 0 0.00029394342
recurrent O 0 0.010453261
laryngeal O 0 0.07534235
nerve O 0 0.010391355
and O 0 0.00014883677
superimposed O 0 0.00035298214
severe O 0 0.011762046
acute O 0 0.53056014
sensorimotor O 0 0.33185145
axonal O 0 0.5890564
polyneuropathy B-Disease 0 0.99987924
caused O 0 0.0004658676
by O 0 0.0002752623
high O 0 0.0008543525
- O 0 0.0013272591
dose O 0 0.07653206
disulfiram B-Chemical 0 0.9999901
intoxication O 0 0.9997793
. O 0 0.004609966

Encephalopathy B-Disease 0 0.9756364
induced O 0 0.006757047
by O 0 0.006817946
levetiracetam B-Chemical 0 0.9996779
added O 0 0.0064177234
to O 0 0.0072369217
valproate B-Chemical 0 0.9998037
. O 0 0.010726982

BACKGROUND O 0 0.008918192
: O 0 0.002055347
We O 0 0.00065991806
report O 0 0.0007561723
on O 0 0.0003052898
the O 0 0.000399982
manifestation O 0 0.0011875938
of O 0 0.0005807948
a O 0 0.001678674
levetiracetam B-Chemical 0 0.99997044
( O 0 0.0038280783
LEV B-Chemical 0 0.99958795
) O 0 0.0022727684
- O 0 0.002088316
induced O 0 0.0037783824
encephalopathy B-Disease 2 0.99980253
. O 0 0.0057695615

FINDINGS O 0 0.0065076565
: O 0 0.0029839496
A O 0 0.007645766
28 O 0 0.0010290381
- O 0 0.0010662306
year O 0 0.0003244269
- O 0 0.00051778444
old O 0 0.0003067006
man O 0 0.0034233187
suffering O 0 0.050768886
from O 0 0.0003795765
idiopathic B-Disease 0 0.9996741
epilepsy I-Disease 2 0.99999666
with O 0 0.0020254366
generalized O 0 0.8090835
seizures B-Disease 0 0.9999976
was O 0 0.00037393766
treated O 0 0.0002185321
with O 0 0.00029961034
LEV B-Chemical 0 0.99945
( O 0 0.00021219974
3000 O 0 0.00039578284
mg O 0 0.0029129828
) O 0 0.00014387755
added O 0 0.00011329379
to O 0 0.000234875
valproate B-Chemical 0 0.99998486
( O 0 0.004409456
VPA B-Chemical 1 0.9999831
) O 0 0.0015237847
( O 0 0.0007383173
2000 O 0 0.0011179019
mg O 0 0.012288187
) O 0 0.0025227799
. O 0 0.0022381502

Frequency O 0 0.003640434
of O 0 0.0018556365
generalized O 0 0.0045498335
tonic B-Disease 0 0.20753801
- I-Disease 0 0.011519351
clonic I-Disease 0 0.9999752
seizures I-Disease 0 0.99999297
increased O 0 0.0018018237
from O 0 0.00019887228
one O 0 9.8713674e-05
per O 0 5.3687872e-05
6 O 0 6.999575e-05
months O 0 5.7935482e-05
to O 0 0.0001306976
two O 0 0.00018802495
per O 0 0.00024655563
month O 0 0.00060674496
. O 0 0.0015791798

Neuropsychological O 0 0.027373351
testing O 0 0.0016032938
showed O 0 0.0010834819
impaired B-Disease 0 0.0019630538
word I-Disease 0 0.0031796182
fluency I-Disease 0 0.88565195
, I-Disease 0 0.0017665598
psychomotor I-Disease 0 0.97156346
speed I-Disease 0 0.0017673016
and I-Disease 0 0.0010587486
working I-Disease 0 0.0030222062
memory I-Disease 0 0.36221308
. O 0 0.0039378433

The O 0 0.0016635543
interictal O 0 0.08101572
electroencephalogram O 0 0.05474298
( O 0 0.0015598551
EEG O 0 0.061709177
) O 0 0.0007664746
showed O 0 0.0002823265
a O 0 0.0003197689
generalized O 0 0.00086754933
slowing O 0 0.0017036557
to O 0 0.00011822679
5 O 0 5.9973372e-05
per O 0 2.9434734e-05
second O 0 7.0954484e-05
theta O 0 0.0014947561
rhythms O 0 0.0003685032
with O 0 0.00018621777
bilateral O 0 0.001796385
generalized O 0 0.0017814084
high O 0 0.0011802315
- O 0 0.0011574737
amplitude O 0 0.0021409092
discharges O 0 0.010263878
. O 0 0.0021427965

OUTCOME O 0 0.0032536092
: O 0 0.0014235935
Following O 0 0.00060241896
discontinuation O 0 0.004388041
of O 0 0.0012351442
LEV B-Chemical 0 0.9989072
, O 0 0.00075906096
EEG O 0 0.0467342
and O 0 0.00040676014
neuropsychological O 0 0.014185589
findings O 0 0.00057300896
improved O 0 0.0007682421
and O 0 0.0008026497
seizure B-Disease 0 0.99784195
frequency O 0 0.0020827944
decreased O 0 0.005290621
. O 0 0.0028897405

Norepinephrine B-Chemical 0 0.99824464
signaling O 0 0.002411658
through O 0 0.0014521409
beta O 0 0.88713384
- O 0 0.0048024384
adrenergic O 0 0.98906714
receptors O 0 0.0032239212
is O 0 0.00025842298
critical O 0 0.00015287353
for O 0 0.0001645067
expression O 0 0.00038684707
of O 0 0.0010607429
cocaine B-Chemical 1 0.99976987
- O 0 0.00307705
induced O 0 0.0026692913
anxiety B-Disease 0 0.9793888
. O 0 0.0033615844

BACKGROUND O 0 0.0152295865
: O 0 0.0064482004
Cocaine B-Chemical 0 0.9995216
is O 0 0.0013966211
a O 0 0.0010032915
widely O 0 0.0006595011
abused O 0 0.42186052
psychostimulant O 0 0.9784146
that O 0 0.00027192428
has O 0 0.00022679778
both O 0 0.00032179928
rewarding O 0 0.0019788756
and O 0 0.00065108825
aversive O 0 0.0041493126
properties O 0 0.0014082332
. O 0 0.0022886926

While O 0 0.0016271115
the O 0 0.0011280233
mechanisms O 0 0.0010946286
underlying O 0 0.0018912931
cocaine B-Chemical 1 0.9994235
' O 0 0.00082627963
s O 0 0.00033437705
rewarding O 0 0.0009805468
effects O 0 0.00021661406
have O 0 0.00011271942
been O 0 9.741518e-05
studied O 0 0.00013884914
extensively O 0 9.845862e-05
, O 0 0.00011906876
less O 0 0.00011059219
attention O 0 0.00017792638
has O 0 6.898434e-05
been O 0 6.293828e-05
paid O 0 9.347087e-05
to O 0 5.1815805e-05
the O 0 7.802267e-05
unpleasant O 0 0.0028383257
behavioral O 0 0.0008349891
states O 0 0.00023366435
induced O 0 0.0002641006
by O 0 0.0005145447
cocaine B-Chemical 1 0.9996357
, O 0 0.0005969122
such O 0 0.00040548138
as O 0 0.000971236
anxiety B-Disease 0 0.8776921
. O 0 0.002537641

METHODS O 0 0.0016936114
: O 0 0.0013768984
In O 0 0.00055242254
this O 0 0.00062467356
study O 0 0.0005473893
, O 0 0.000313897
we O 0 0.00010567757
evaluated O 0 0.00011920384
the O 0 0.0001248563
performance O 0 0.00024212661
of O 0 0.00061143766
dopamine B-Chemical 0 0.99995565
beta O 0 0.9973597
- O 0 0.006553201
hydroxylase O 0 0.99675864
knockout O 0 0.0010099404
( O 0 0.0005535215
Dbh O 0 0.23762517
- O 0 0.00044533875
/ O 0 0.00061409717
- O 0 0.00031426415
) O 0 0.0001499865
mice O 0 5.282886e-05
, O 0 8.50979e-05
which O 0 0.00010944313
lack O 0 0.0001889208
norepinephrine B-Chemical 1 0.9998265
( O 0 0.00067281973
NE B-Chemical 0 0.99700767
) O 0 0.00026505915
, O 0 8.585128e-05
in O 0 5.1072293e-05
the O 0 5.8654598e-05
elevated O 0 0.00031613116
plus O 0 7.998359e-05
maze O 0 0.032993387
( O 0 0.00036989662
EPM O 0 0.74385136
) O 0 0.00017199545
to O 0 4.9979597e-05
examine O 0 2.733533e-05
the O 0 5.4764314e-05
contribution O 0 6.157563e-05
of O 0 0.00020105648
noradrenergic O 0 0.15126428
signaling O 0 0.00025132476
to O 0 0.00042002968
cocaine B-Chemical 1 0.9997209
- O 0 0.0021470932
induced O 0 0.0020832503
anxiety B-Disease 0 0.97492063
. O 0 0.0029084948

RESULTS O 0 0.0047524543
: O 0 0.0017290415
We O 0 0.00056964013
found O 0 0.0005189249
that O 0 0.0005565667
cocaine B-Chemical 1 0.99956864
dose O 0 0.036758415
- O 0 0.0019396058
dependently O 0 0.66293204
increased O 0 0.0019353458
anxiety B-Disease 0 0.9843589
- O 0 0.0004629148
like O 0 6.97119e-05
behavior O 0 0.00012380377
in O 0 8.152702e-05
control O 0 0.00012900602
( O 0 0.00033756692
Dbh O 0 0.15768042
+ O 0 0.0005116616
/ O 0 0.00078094885
- O 0 0.0003888078
) O 0 0.00019246317
mice O 0 7.239049e-05
, O 0 0.00012061996
as O 0 8.92623e-05
measured O 0 9.791716e-05
by O 0 0.000147562
a O 0 0.00022946141
decrease O 0 0.0003038603
in O 0 0.0002918883
open O 0 0.00081098906
arm O 0 0.0012980816
exploration O 0 0.0023314017
. O 0 0.0021473404

The O 0 0.003874721
Dbh O 0 0.32301807
- O 0 0.0038246398
/ O 0 0.0028908206
- O 0 0.0009872867
mice O 0 0.00022214527
had O 0 0.0002137656
normal O 0 0.00027531612
baseline O 0 0.000111630296
performance O 0 0.00015714321
in O 0 0.000102049846
the O 0 0.00016035426
EPM O 0 0.5714948
but O 0 0.00016299961
were O 0 0.00010559337
completely O 0 0.00012292976
resistant O 0 0.00012817222
to O 0 0.00012230806
the O 0 0.00024717796
anxiogenic O 0 0.8488291
effects O 0 0.0010319429
of O 0 0.0033483063
cocaine B-Chemical 1 0.9996308
. O 0 0.0033153614

Cocaine B-Chemical 0 0.9996731
- O 0 0.007975705
induced O 0 0.0025944368
anxiety B-Disease 0 0.90578234
was O 0 0.0008265253
also O 0 0.00037935874
attenuated O 0 0.000934398
in O 0 0.0005293581
Dbh O 0 0.44068363
+ O 0 0.0008262446
/ O 0 0.0007403518
- O 0 0.00021605671
mice O 0 4.8792226e-05
following O 0 5.4047774e-05
administration O 0 0.00046598728
of O 0 0.0006982444
disulfiram B-Chemical 0 0.9999945
, O 0 0.00052385085
a O 0 0.0009832128
dopamine B-Chemical 0 0.9999318
beta O 0 0.9917263
- O 0 0.0045785387
hydroxylase O 0 0.9966426
( O 0 0.0017838784
DBH O 0 0.9669126
) O 0 0.001767278
inhibitor O 0 0.0059236293
. O 0 0.0026625392

In O 0 0.0013886767
experiments O 0 0.00082596403
using O 0 0.0006020103
specific O 0 0.00063397764
adrenergic O 0 0.9917875
antagonists O 0 0.8843029
, O 0 0.00036123153
we O 0 7.9292215e-05
found O 0 8.5710904e-05
that O 0 7.151729e-05
pretreatment O 0 0.0037568551
with O 0 0.00019210803
the O 0 0.00021087965
beta O 0 0.95396477
- O 0 0.0015478869
adrenergic O 0 0.99463826
receptor O 0 0.19697271
antagonist O 0 0.99423605
propranolol B-Chemical 1 0.99999857
blocked O 0 0.06329287
cocaine B-Chemical 1 0.9999815
- O 0 0.0009985178
induced O 0 0.00030792298
anxiety B-Disease 0 0.95904595
- O 0 0.00029749775
like O 0 5.3672007e-05
behavior O 0 0.00013745671
in O 0 0.0001374512
Dbh O 0 0.17205545
+ O 0 0.00038571117
/ O 0 0.00052782247
- O 0 0.00023433371
and O 0 0.00010790242
wild O 0 0.00014645557
- O 0 0.00020676579
type O 0 0.00013553255
C57BL6 O 0 0.003054937
/ O 0 0.00084002875
J O 0 0.18435757
mice O 0 6.062931e-05
, O 0 8.103352e-05
while O 0 6.366076e-05
the O 0 0.00010541027
alpha O 0 0.23959813
( O 0 0.00020058984
1 O 0 8.388797e-05
) O 0 0.00021294621
antagonist O 0 0.83594245
prazosin B-Chemical 1 0.9999969
and O 0 0.00023692445
the O 0 0.00017543384
alpha O 0 0.3162025
( O 0 0.00027952867
2 O 0 0.0001359308
) O 0 0.00042078516
antagonist O 0 0.9120033
yohimbine B-Chemical 1 0.9999945
had O 0 0.0011326115
no O 0 0.00056543166
effect O 0 0.0013271645
. O 0 0.0021800117

CONCLUSIONS O 0 0.011575529
: O 0 0.0017223548
These O 0 0.00074702356
results O 0 0.00052166864
indicate O 0 0.00025176007
that O 0 0.00027187634
noradrenergic O 0 0.064001404
signaling O 0 0.0003124871
via O 0 0.00022815705
beta O 0 0.89855945
- O 0 0.0019620284
adrenergic O 0 0.98785037
receptors O 0 0.0017102478
is O 0 0.00011992473
required O 0 7.038993e-05
for O 0 0.00020098731
cocaine B-Chemical 1 0.99973816
- O 0 0.0011227663
induced O 0 0.0008083685
anxiety B-Disease 0 0.8975061
in O 0 0.0009188894
mice O 0 0.0010882568
. O 0 0.0018970988

Hypothalamic O 0 0.08264194
prolactin O 0 0.96278423
receptor O 0 0.054705348
messenger O 0 0.008815675
ribonucleic B-Chemical 0 0.97180825
acid I-Chemical 0 0.99761105
levels O 0 0.00087598624
, O 0 0.00062090706
prolactin O 0 0.8999871
signaling O 0 0.0002804943
, O 0 0.00021871702
and O 0 0.00025403794
hyperprolactinemic B-Disease 0 0.9939002
inhibition O 0 0.00040354868
of O 0 0.00022425638
pulsatile O 0 0.0017581834
luteinizing O 0 0.8666116
hormone O 0 0.1633328
secretion O 0 0.0011282074
are O 0 0.00022521181
dependent O 0 0.00021304045
on O 0 0.0006574234
estradiol B-Chemical 0 0.99945325
. O 0 0.0033298223

Hyperprolactinemia B-Disease 0 0.99609715
can O 0 0.005387135
reduce O 0 0.004631705
fertility O 0 0.028729208
and O 0 0.009581008
libido O 0 0.9176104
. O 0 0.010345939

Although O 0 0.001682583
central O 0 0.0023075214
prolactin O 0 0.71209747
actions O 0 0.002209585
are O 0 0.00048810642
thought O 0 0.00035560978
to O 0 0.00021791561
contribute O 0 0.00017603437
to O 0 0.00018751883
this O 0 0.00029208598
, O 0 0.00029888796
the O 0 0.0002693086
mechanisms O 0 0.00045974902
are O 0 0.0005743798
poorly O 0 0.0015651279
understood O 0 0.0032629473
. O 0 0.0023655545

We O 0 0.0012786239
first O 0 0.0007474006
tested O 0 0.0007092106
whether O 0 0.00048072156
chronic O 0 0.749696
hyperprolactinemia B-Disease 0 0.9999795
inhibited O 0 0.0020437527
two O 0 0.00018502523
neuroendocrine O 0 0.0014039475
parameters O 0 0.00010590031
necessary O 0 4.5832432e-05
for O 0 6.494482e-05
female O 0 0.00039053985
fertility O 0 0.0017950928
: O 0 0.00014795158
pulsatile O 0 0.00066230155
LH O 0 0.93405867
secretion O 0 0.0009009976
and O 0 0.0002087487
the O 0 0.00040846286
estrogen B-Chemical 1 0.9997656
- O 0 0.0016269728
induced O 0 0.0017326351
LH O 0 0.99332833
surge O 0 0.20874995
. O 0 0.002856564

Chronic O 0 0.59378994
hyperprolactinemia B-Disease 0 0.99983597
induced O 0 0.0020597826
by O 0 0.0008184018
the O 0 0.00092566793
dopamine B-Chemical 0 0.99991465
antagonist O 0 0.99921334
sulpiride B-Chemical 0 0.99999857
caused O 0 0.0005713756
a O 0 0.00024876863
40 O 0 0.00012722053
% O 0 0.00010365298
reduction O 0 0.00036709593
LH O 0 0.9477519
pulse O 0 0.000221015
frequency O 0 0.00010722096
in O 0 9.4215415e-05
ovariectomized O 0 0.033416968
rats O 0 0.0002003452
, O 0 9.8616765e-05
but O 0 7.731298e-05
only O 0 7.672886e-05
in O 0 6.358432e-05
the O 0 7.5223164e-05
presence O 0 0.00011241296
of O 0 0.00030738534
chronic O 0 0.07938023
low O 0 0.0011748503
levels O 0 0.00083556067
of O 0 0.003437813
estradiol B-Chemical 0 0.9998067
. O 0 0.0039782603

Sulpiride B-Chemical 0 0.99981374
did O 0 0.002443638
not O 0 0.0007021008
affect O 0 0.00027963772
the O 0 0.0002761521
magnitude O 0 0.00021923812
of O 0 0.00037737394
a O 0 0.0008859239
steroid B-Chemical 1 0.99717796
- O 0 0.00092883344
induced O 0 0.0005099273
LH O 0 0.99413514
surge O 0 0.011182924
or O 0 0.00011135994
the O 0 9.132968e-05
percentage O 0 8.3392595e-05
of O 0 0.00022374338
GnRH O 0 0.026990341
neurons O 0 0.00038591417
activated O 0 0.0002728691
during O 0 0.00024293018
the O 0 0.000782844
surge O 0 0.01946373
. O 0 0.0023690993

Estradiol B-Chemical 0 0.9994338
is O 0 0.0025535948
known O 0 0.0012127933
to O 0 0.00045323017
influence O 0 0.00022208304
expression O 0 0.00029682403
of O 0 0.00023654028
the O 0 0.00014896129
long O 0 0.00011623391
form O 0 0.00010521545
of O 0 0.0002646317
prolactin O 0 0.9769437
receptors O 0 0.015765978
( O 0 0.0010435117
PRL O 0 0.99992037
- O 0 0.0028298262
R O 0 0.94574213
) O 0 0.00029497794
and O 0 0.000119299235
components O 0 0.0001089848
of O 0 0.00035256543
prolactin O 0 0.8222867
' O 0 0.0006278328
s O 0 0.00046969723
signaling O 0 0.00073852803
pathway O 0 0.0014442316
. O 0 0.0021109532

To O 0 0.0022020421
test O 0 0.0019628373
the O 0 0.0008917693
hypothesis O 0 0.00090320496
that O 0 0.00067690574
estrogen B-Chemical 1 0.9997907
increases O 0 0.0029270896
PRL O 0 0.9999559
- O 0 0.006989718
R O 0 0.95065486
expression O 0 0.0002787545
and O 0 0.00015406574
sensitivity O 0 0.00059377716
to O 0 0.00017619962
prolactin O 0 0.90782785
, O 0 0.00012279257
we O 0 3.2787768e-05
next O 0 3.2297066e-05
demonstrated O 0 6.313948e-05
that O 0 0.00012776333
estradiol B-Chemical 0 0.9998895
greatly O 0 0.00401772
augments O 0 0.002343788
prolactin O 0 0.9947955
- O 0 0.0015250935
induced O 0 0.001092627
STAT5 O 0 0.17293249
activation O 0 0.003765829
. O 0 0.0025487076

Lastly O 0 0.003060366
, O 0 0.0019602769
we O 0 0.00073010975
measured O 0 0.0014281803
PRL O 0 0.99961853
- O 0 0.00633437
R O 0 0.90995693
and O 0 0.00050040643
suppressor O 0 0.0020415871
of O 0 0.00041659948
cytokine O 0 0.0071217385
signaling O 0 0.0003414625
( O 0 0.0005076532
SOCS O 0 0.033053912
- O 0 0.00035525992
1 O 0 9.542883e-05
and O 0 0.00011556814
- O 0 0.00019828098
3 O 0 7.0194605e-05
and O 0 0.00012558312
CIS O 0 0.099776946
, O 0 0.000112203496
which O 0 7.85776e-05
reflect O 0 3.424337e-05
the O 0 5.0793737e-05
level O 0 5.4519358e-05
of O 0 0.00017556568
prolactin O 0 0.8603254
signaling O 0 0.00021115004
) O 0 0.00021934813
mRNAs O 0 0.00014048064
in O 0 0.00010535961
response O 0 0.00020865118
to O 0 0.000642499
sulpiride B-Chemical 0 0.9999913
and O 0 0.006616709
estradiol B-Chemical 0 0.99979836
. O 0 0.0038375822

Sulpiride B-Chemical 0 0.9997974
induced O 0 0.0045950147
only O 0 0.0027475643
SOCS O 0 0.09647241
- O 0 0.0012189617
1 O 0 0.00026135647
in O 0 0.00016533653
the O 0 0.0001655885
medial O 0 0.00054178125
preoptic O 0 0.00051718566
area O 0 0.0001499147
, O 0 0.00012587168
where O 0 9.6269534e-05
GnRH O 0 0.012990681
neurons O 0 0.00022482243
are O 0 7.256209e-05
regulated O 0 3.731427e-05
, O 0 8.535415e-05
but O 0 7.061671e-05
in O 0 5.258965e-05
the O 0 6.030657e-05
arcuate O 0 0.00015401229
nucleus O 0 5.4124775e-05
and O 0 0.000105349165
choroid O 0 0.3949766
plexus O 0 0.011912631
, O 0 0.00040956336
PRL O 0 0.9999101
- O 0 0.002951733
R O 0 0.97772664
, O 0 0.00049164647
SOCS O 0 0.049043894
- O 0 0.00039571227
3 O 0 0.00010659961
, O 0 0.0001607664
and O 0 0.00023623467
CIS O 0 0.10260632
mRNA O 0 0.0005211828
levels O 0 0.0003769791
were O 0 0.00047065996
also O 0 0.00070020877
induced O 0 0.0019277454
. O 0 0.0024001123

Estradiol B-Chemical 0 0.99866295
enhanced O 0 0.004749719
these O 0 0.002459344
effects O 0 0.0018553273
on O 0 0.0013786171
SOCS O 0 0.03604477
- O 0 0.0030867236
3 O 0 0.0015062196
and O 0 0.0028988475
CIS O 0 0.29465848
. O 0 0.0053910655

Interestingly O 0 0.0032131851
, O 0 0.0045286315
estradiol B-Chemical 0 0.999188
also O 0 0.0018099189
induced O 0 0.0045930417
PRL O 0 0.99990773
- O 0 0.025714548
R O 0 0.99010766
, O 0 0.0013270304
SOCS O 0 0.070970416
- O 0 0.0008459537
3 O 0 0.00024877954
, O 0 0.00036678987
and O 0 0.0005237824
CIS O 0 0.11041474
mRNA O 0 0.0012134342
levels O 0 0.0010509494
independently O 0 0.0013317835
. O 0 0.0023275742

These O 0 0.0020615817
data O 0 0.0013543828
show O 0 0.0006095257
that O 0 0.00048136376
GnRH O 0 0.024357876
pulse O 0 0.00073675666
frequency O 0 0.0003779743
is O 0 0.0002594235
inhibited O 0 0.0005664612
by O 0 0.0005568925
chronic O 0 0.86432415
hyperprolactinemia B-Disease 0 0.99998903
in O 0 0.0006706392
a O 0 0.001455092
steroid B-Chemical 1 0.9924769
- O 0 0.0011769958
dependent O 0 0.00048133993
manner O 0 0.0014148355
. O 0 0.002014415

They O 0 0.0028889077
also O 0 0.0011349682
provide O 0 0.0007225546
evidence O 0 0.00061085424
for O 0 0.0007438857
estradiol B-Chemical 0 0.9998523
- O 0 0.001172427
dependent O 0 0.00013870289
and O 0 0.00022331327
brain O 0 0.0012052951
region O 0 0.00017034424
- O 0 0.00019518871
specific O 0 6.158361e-05
regulation O 0 7.1850736e-05
of O 0 0.000451814
PRL O 0 0.9999089
- O 0 0.0026691316
R O 0 0.8800531
expression O 0 0.00037051004
and O 0 0.00027024635
signaling O 0 0.00035387097
responses O 0 0.00072020077
by O 0 0.0014028696
prolactin O 0 0.95192516
. O 0 0.002889567

Clonidine B-Chemical 0 0.9996408
for O 0 0.0032612123
attention B-Disease 0 0.004010787
- I-Disease 0 0.0040289364
deficit I-Disease 0 0.07128675
/ I-Disease 0 0.01685444
hyperactivity I-Disease 2 0.99987435
disorder I-Disease 0 0.99317366
: O 0 0.005609946
II O 0 0.025891837
. O 0 0.0039042837

ECG O 0 0.09919639
changes O 0 0.007189086
and O 0 0.006362536
adverse O 0 0.049832094
events O 0 0.0142518375
analysis O 0 0.008526342
. O 0 0.008779723

OBJECTIVE O 0 0.0207012
: O 0 0.0018733704
To O 0 0.00060148607
examine O 0 0.0002877089
the O 0 0.00034658253
safety O 0 0.00038842566
and O 0 0.0002690607
tolerability O 0 0.0024897216
of O 0 0.00063910824
clonidine B-Chemical 0 0.99995387
used O 0 0.00015295156
alone O 0 0.0001312574
or O 0 0.0001017954
with O 0 0.00033780382
methylphenidate B-Chemical 1 0.9999424
in O 0 0.00013361302
children O 0 0.00018560303
with O 0 0.0001567683
attention B-Disease 0 0.00033597928
- I-Disease 0 0.00053321465
deficit I-Disease 0 0.074055135
/ I-Disease 0 0.010564127
hyperactivity I-Disease 2 0.9999763
disorder I-Disease 0 0.9968382
( O 0 0.005778183
ADHD B-Disease 0 0.9997311
) O 0 0.0039831237
. O 0 0.0022267003

METHOD O 0 0.0062943976
: O 0 0.0021248134
In O 0 0.00077902456
a O 0 0.00091267325
16 O 0 0.0005900824
- O 0 0.00065438345
week O 0 0.00020916769
multicenter O 0 0.0030419796
, O 0 0.00028828828
double O 0 0.00037761344
- O 0 0.00040653642
blind O 0 0.00243728
trial O 0 0.00017380265
, O 0 0.00010632763
122 O 0 0.00023274295
children O 0 0.00013312316
with O 0 0.00019777232
ADHD B-Disease 0 0.99961746
were O 0 5.7118537e-05
randomly O 0 1.6410851e-05
assigned O 0 3.38164e-05
to O 0 8.494256e-05
clonidine B-Chemical 0 0.99993205
( O 0 0.0002252526
n O 0 8.608779e-05
= O 0 0.00010489187
31 O 0 0.00011806726
) O 0 0.0001482996
, O 0 0.00018647789
methylphenidate B-Chemical 1 0.99986947
( O 0 0.00020623952
n O 0 8.432203e-05
= O 0 0.00010228405
29 O 0 0.00013632771
) O 0 0.00015085697
, O 0 0.0001912691
clonidine B-Chemical 0 0.99993086
and O 0 0.0005134659
methylphenidate B-Chemical 1 0.9999552
( O 0 0.00026461403
n O 0 9.975513e-05
= O 0 0.00012095605
32 O 0 0.0001345607
) O 0 0.00016731561
, O 0 0.00012943851
or O 0 0.00014532809
placebo O 0 0.0009948086
( O 0 0.00036364378
n O 0 0.00031825522
= O 0 0.000564329
30 O 0 0.0006105403
) O 0 0.0017698656
. O 0 0.0020666835

Doses O 0 0.016099816
were O 0 0.0012868133
flexibly O 0 0.0007230713
titrated O 0 0.00081543904
up O 0 0.00040906217
to O 0 0.00025708563
0 O 0 0.00021178758
. O 0 0.00011774392
6 O 0 9.3378585e-05
mg O 0 0.0009706056
/ O 0 0.00028862324
day O 0 6.939956e-05
for O 0 0.00011256647
clonidine B-Chemical 0 0.9998319
and O 0 0.00014854076
60 O 0 0.00010349623
mg O 0 0.0011751429
/ O 0 0.00022958791
day O 0 5.6773486e-05
for O 0 0.00011638287
methylphenidate B-Chemical 1 0.9998035
( O 0 0.0002643825
both O 0 0.00015884644
with O 0 0.00027128056
divided O 0 0.0002961584
dosing O 0 0.0015624014
) O 0 0.0019304594
. O 0 0.0019361564

Groups O 0 0.0061664344
were O 0 0.0011016594
compared O 0 0.0004654313
regarding O 0 0.00036081523
adverse O 0 0.005480241
events O 0 0.0010927394
and O 0 0.00026230482
changes O 0 0.0002082374
from O 0 0.00011413935
baseline O 0 0.000103356775
to O 0 9.572121e-05
week O 0 7.323466e-05
16 O 0 0.00012484644
in O 0 0.00018327708
electrocardiograms O 0 0.0022609616
and O 0 0.0005438109
vital O 0 0.0017157672
signs O 0 0.01078179
. O 0 0.0025857745

RESULTS O 0 0.004540188
: O 0 0.0017542795
There O 0 0.00074709614
were O 0 0.0005028982
more O 0 0.00044326935
incidents O 0 0.00069403055
of O 0 0.0004502619
bradycardia B-Disease 0 0.97496504
in O 0 0.00018984609
subjects O 0 0.00017997669
treated O 0 0.00017519544
with O 0 0.00033781398
clonidine B-Chemical 0 0.9999645
compared O 0 6.937594e-05
with O 0 9.121532e-05
those O 0 8.246051e-05
not O 0 5.1625128e-05
treated O 0 0.00014031613
with O 0 0.00043785162
clonidine B-Chemical 0 0.99998474
( O 0 0.0003547296
17 O 0 0.00013136545
. O 0 4.0463554e-05
5 O 0 4.014454e-05
% O 0 5.9686037e-05
versus O 0 4.9874707e-05
3 O 0 5.2344585e-05
. O 0 4.4379107e-05
4 O 0 5.5445238e-05
% O 0 0.00010259938
; O 0 0.0001496756
p O 0 0.00013907743
= O 0 0.00014986513
. O 0 8.507177e-05
02 O 0 0.0018755865
) O 0 0.00021270839
, O 0 0.0001182789
but O 0 9.0028756e-05
no O 0 4.8009977e-05
other O 0 7.00073e-05
significant O 0 8.4050436e-05
group O 0 9.765794e-05
differences O 0 4.582177e-05
regarding O 0 8.168063e-05
electrocardiogram O 0 0.003399559
and O 0 0.0003073613
other O 0 0.0005170142
cardiovascular O 0 0.50583094
outcomes O 0 0.002246175
. O 0 0.0020343622

There O 0 0.0026190733
were O 0 0.0013831345
no O 0 0.0005888807
suggestions O 0 0.0007921246
of O 0 0.00061040604
interactions O 0 0.000566197
between O 0 0.00049739575
clonidine B-Chemical 0 0.9998939
and O 0 0.0021312707
methylphenidate B-Chemical 1 0.9998338
regarding O 0 0.00089808524
cardiovascular O 0 0.74861735
outcomes O 0 0.0031589544
. O 0 0.0026146476

Moderate O 0 0.065123916
or O 0 0.0019209334
severe O 0 0.008059449
adverse O 0 0.06290492
events O 0 0.0018983261
were O 0 0.00028446264
more O 0 0.00022391943
common O 0 0.00014970702
in O 0 0.00011024304
subjects O 0 0.00016053113
on O 0 0.00011825385
clonidine B-Chemical 0 0.9999511
( O 0 0.00037332214
79 O 0 0.00021758817
. O 0 5.4520297e-05
4 O 0 5.0523446e-05
% O 0 6.9595335e-05
versus O 0 6.019465e-05
49 O 0 0.0001275621
. O 0 5.6390603e-05
2 O 0 7.084733e-05
% O 0 0.0001141362
; O 0 0.00016152576
p O 0 0.00014600827
= O 0 0.00015378029
. O 0 8.556709e-05
0006 O 0 0.0011584526
) O 0 0.00018240209
but O 0 9.558092e-05
not O 0 7.583986e-05
associated O 0 9.05045e-05
with O 0 0.00014582768
higher O 0 0.00018128182
rates O 0 0.0001998
of O 0 0.00034116357
early O 0 0.00083386723
study O 0 0.001216235
withdrawal O 0 0.049144424
. O 0 0.0022608668

Drowsiness B-Disease 0 0.97366345
was O 0 0.002445304
common O 0 0.0012905322
on O 0 0.0010167233
clonidine B-Chemical 0 0.9998753
, O 0 0.0012345408
but O 0 0.0005627968
generally O 0 0.0004871872
resolved O 0 0.00068107824
by O 0 0.0004271307
6 O 0 0.0002794613
to O 0 0.0004195619
8 O 0 0.00063223747
weeks O 0 0.0006964888
. O 0 0.0019528982

CONCLUSIONS O 0 0.029921766
: O 0 0.0068053775
Clonidine B-Chemical 0 0.99986863
, O 0 0.0013394271
used O 0 0.00042822128
alone O 0 0.0003888744
or O 0 0.00030849333
with O 0 0.00087175396
methylphenidate B-Chemical 1 0.99993885
, O 0 0.00037799447
appears O 0 0.00014485036
safe O 0 0.00023956006
and O 0 0.00018431053
well O 0 0.00021162933
tolerated O 0 0.0018487021
in O 0 0.0007815593
childhood O 0 0.79905295
ADHD B-Disease 0 0.9997882
. O 0 0.004118256

Physicians O 0 0.0037963018
prescribing O 0 0.009934467
clonidine B-Chemical 0 0.99957997
should O 0 0.000379422
monitor O 0 0.00026123368
for O 0 0.00027830253
bradycardia B-Disease 0 0.9579249
and O 0 0.00040466082
advise O 0 0.0011091818
patients O 0 0.00024521607
about O 0 0.00015009982
the O 0 0.0001717339
high O 0 0.00039105638
likelihood O 0 0.00048722277
of O 0 0.0006880082
initial O 0 0.0016148702
drowsiness B-Disease 0 0.99950314
. O 0 0.003556155

Renal B-Disease 0 0.80035734
Fanconi I-Disease 2 0.9985447
syndrome I-Disease 2 0.9978188
and O 0 0.0043237233
myopathy B-Disease 2 0.99927586
after O 0 0.0004378558
liver O 0 0.6941426
transplantation O 0 0.01611071
: O 0 0.0009322512
drug O 0 0.017391361
- O 0 0.0010477594
related O 0 0.0005447914
mitochondrial B-Disease 0 0.5682122
cytopathy I-Disease 0 0.9970247
? O 0 0.010701589

Advances O 0 0.003684627
in O 0 0.001218902
the O 0 0.00076884055
field O 0 0.0007216683
of O 0 0.0005566574
transplantation O 0 0.001351028
provide O 0 0.00019828003
a O 0 0.00020732824
better O 0 0.00016325316
quality O 0 0.000103164086
of O 0 0.00014300205
life O 0 0.0001446377
and O 0 9.028555e-05
allow O 0 6.452523e-05
more O 0 0.00012799048
favorable O 0 0.00024908432
conditions O 0 0.00014138236
for O 0 0.00012083063
growth O 0 0.00097591366
and O 0 0.00036645186
development O 0 0.0008034219
in O 0 0.00077877915
children O 0 0.0022686583
. O 0 0.0020627566

However O 0 0.0027830587
, O 0 0.0018781304
combinations O 0 0.0008457127
of O 0 0.00075388816
different O 0 0.00037074907
therapeutic O 0 0.0007690713
regimens O 0 0.00055164145
require O 0 0.00020718023
consideration O 0 0.00025960887
of O 0 0.0005637976
potential O 0 0.0010544463
adverse O 0 0.16560246
reactions O 0 0.023905396
. O 0 0.0033334089

We O 0 0.0016412524
describe O 0 0.0012156361
a O 0 0.0014235852
15 O 0 0.00080872106
- O 0 0.001218296
yr O 0 0.00054925453
- O 0 0.0005838978
old O 0 0.00032306914
girl O 0 0.00075043016
who O 0 0.00040605018
had O 0 0.00027681215
orthotopic O 0 0.44958425
liver O 0 0.82039356
transplantation O 0 0.0038359966
because O 0 0.00021138349
of O 0 0.0005874044
Wilson B-Disease 0 0.045026112
' I-Disease 0 0.0011098598
s I-Disease 0 0.0011843329
disease I-Disease 0 0.08800356
. O 0 0.002632465

Tacrolimus B-Chemical 1 0.9994491
, O 0 0.01707692
MMF B-Chemical 0 0.99981385
, O 0 0.0036871454
and O 0 0.0024307878
steroids B-Chemical 0 0.9860015
were O 0 0.001278028
given O 0 0.00084646523
as O 0 0.0018260028
immunosuppressant O 0 0.9012027
. O 0 0.0049269265

Lamivudine B-Chemical 1 0.99826163
was O 0 0.0026587863
added O 0 0.0013161878
because O 0 0.0006427826
of O 0 0.0010468134
de O 0 0.0038817544
nova O 0 0.7415575
hepatitis B-Disease 2 0.99999905
B I-Disease 2 0.9995809
infection I-Disease 0 0.6949324
during O 0 0.00048225568
her O 0 0.0010819728
follow O 0 0.0005729445
- O 0 0.0016244279
up O 0 0.0018294054
. O 0 0.0025314868

Three O 0 0.0021013382
yr O 0 0.0012091865
after O 0 0.00037937495
transplantation O 0 0.0015822676
she O 0 0.0004510584
developed O 0 0.0011789808
renal B-Disease 0 0.9993673
Fanconi I-Disease 2 0.9999176
syndrome I-Disease 2 0.99945384
with O 0 0.0011810671
severe O 0 0.13727178
metabolic B-Disease 2 0.9923723
acidosis I-Disease 2 0.9999913
, O 0 0.009778131
hypophosphatemia B-Disease 0 0.9999925
, O 0 0.008226203
glycosuria B-Disease 2 0.9999654
, O 0 0.0024598225
and O 0 0.0031466344
aminoaciduria B-Disease 0 0.9999435
. O 0 0.005170826

Although O 0 0.0036166473
tacrolimus B-Chemical 0 0.999835
was O 0 0.0026635092
suspected O 0 0.0023355358
to O 0 0.00042697423
be O 0 0.00025851416
the O 0 0.000200844
cause O 0 0.00025501786
of O 0 0.00021290318
late O 0 0.00034487224
post O 0 9.8311975e-05
- O 0 0.0003286629
transplant O 0 0.024059696
renal O 0 0.9962639
acidosis B-Disease 2 0.9999237
and O 0 0.00029397226
was O 0 0.00014176495
replaced O 0 0.000121930876
by O 0 0.00027851755
sirolimus B-Chemical 1 0.999951
, O 0 0.0012681559
acidosis B-Disease 2 0.9997271
, O 0 0.0005673397
and O 0 0.0004892743
electrolyte O 0 0.66105384
imbalance O 0 0.010391874
got O 0 0.0021905757
worse O 0 0.0033865888
. O 0 0.0020427383

Proximal O 0 0.027269151
muscle B-Disease 0 0.043624245
weakness I-Disease 0 0.7858541
has O 0 0.0015719988
developed O 0 0.0016339367
during O 0 0.0007845927
her O 0 0.0017734935
follow O 0 0.0011251733
- O 0 0.0027788547
up O 0 0.0030147315
. O 0 0.0039287345

Fanconi B-Disease 2 0.9974832
syndrome I-Disease 2 0.9786164
, O 0 0.0021576374
as O 0 0.00077482377
well O 0 0.0005420302
as O 0 0.00092606747
myopathy B-Disease 2 0.9997123
, O 0 0.000628799
is O 0 0.00020164339
well O 0 0.00010625527
recognized O 0 0.00011854265
in O 0 0.00010667068
patients O 0 0.00020963968
with O 0 0.00035934435
mitochondrial B-Disease 0 0.9917048
disorders I-Disease 0 0.9834695
and O 0 0.0003440188
caused O 0 0.0003500144
by O 0 0.00041070598
depletion O 0 0.0015367065
of O 0 0.0021123034
mtDNA O 0 0.25020462
. O 0 0.0024320416

We O 0 0.0013302054
suggest O 0 0.0006009661
that O 0 0.0005021354
our O 0 0.0007034497
patient O 0 0.00054421736
' O 0 0.0004911932
s O 0 0.0004523217
tubular B-Disease 0 0.94510955
dysfunction I-Disease 0 0.99919873
and O 0 0.002129907
myopathy B-Disease 2 0.99985635
may O 0 0.0001567139
have O 0 6.6947425e-05
resulted O 0 8.9576526e-05
from O 0 0.00014084573
mitochondrial B-Disease 0 0.98295814
dysfunction I-Disease 0 0.9958943
which O 0 0.00033367236
is O 0 0.00013165952
triggered O 0 0.00015692489
by O 0 0.00042486045
tacrolimus B-Chemical 0 0.9999771
and O 0 0.0006712493
augmented O 0 0.0020266515
by O 0 0.002571443
lamivudine B-Chemical 1 0.99972993
. O 0 0.0034947244

Higher O 0 0.006430701
optical O 0 0.005802892
density O 0 0.0019588803
of O 0 0.0008680107
an O 0 0.000735755
antigen O 0 0.002029541
assay O 0 0.0012523916
predicts O 0 0.0005589803
thrombosis B-Disease 0 0.99976903
in O 0 0.0003784912
patients O 0 0.0005424752
with O 0 0.0008453599
heparin B-Chemical 0 0.99673104
- O 0 0.0034287337
induced O 0 0.0048036827
thrombocytopenia B-Disease 0 0.99978393
. O 0 0.004841539

OBJECTIVES O 0 0.003296025
: O 0 0.0017563106
To O 0 0.00071124925
correlate O 0 0.0005934909
optical O 0 0.0019178092
density O 0 0.0008148755
and O 0 0.00027241107
percent O 0 0.00014397403
inhibition O 0 0.00037966043
of O 0 0.00023465877
a O 0 0.00021881504
two O 0 9.7562996e-05
- O 0 0.00025861448
step O 0 0.0002654479
heparin B-Chemical 0 0.9970336
- O 0 0.0009013583
induced O 0 0.000783244
thrombocytopenia B-Disease 0 0.999972
( O 0 0.004829825
HIT B-Disease 2 0.9996778
) O 0 0.00040352118
antigen O 0 0.0008542874
assay O 0 0.00059599517
with O 0 0.00053585815
thrombosis B-Disease 0 0.99993396
; O 0 0.00020876779
the O 0 9.3227325e-05
assay O 0 0.0001985072
utilizes O 0 5.3291642e-05
reaction O 0 0.00064814894
inhibition O 0 0.00031178034
characteristics O 0 8.4796644e-05
of O 0 0.00022531899
a O 0 0.00044994013
high O 0 0.0018355298
heparin B-Chemical 0 0.99362755
concentration O 0 0.008001405
. O 0 0.002729253

PATIENTS O 0 0.0018629628
AND O 0 0.0012321338
METHODS O 0 0.00058832386
: O 0 0.0006438181
Patients O 0 0.000364356
with O 0 0.00029788347
more O 0 0.0002883515
than O 0 0.0001469247
50 O 0 0.0002588817
% O 0 0.00015391686
decrease O 0 0.00015636387
in O 0 0.00014323405
platelet O 0 0.66633654
count O 0 0.0011260416
or O 0 0.00036015475
thrombocytopenia B-Disease 0 0.99988616
( O 0 0.00043978673
< O 0 0.000119142125
150 O 0 0.00015521204
x O 0 0.00021578844
10 O 0 8.981157e-05
( O 0 0.00012858868
9 O 0 7.986036e-05
) O 0 0.0001627496
/ O 0 0.00044878465
L O 0 0.15803164
) O 0 0.00014818707
after O 0 2.7903445e-05
exposure O 0 0.00011460701
to O 0 0.00013889535
heparin B-Chemical 0 0.99256164
, O 0 0.00023483201
who O 0 0.00020068626
had O 0 7.9947065e-05
a O 0 9.68486e-05
positive O 0 0.000102581864
two O 0 5.934511e-05
- O 0 0.00014676175
step O 0 0.00010102487
antigen O 0 0.00074897875
assay O 0 0.0006541231
[ O 0 0.00038018162
optical O 0 0.0010221828
density O 0 0.0006039048
( O 0 0.00034857003
OD O 0 0.5435499
) O 0 0.00029758795
> O 0 0.00024791717
0 O 0 7.085597e-05
. O 0 4.1753126e-05
4 O 0 4.0848932e-05
and O 0 6.0962968e-05
> O 0 0.00014441759
50 O 0 0.000112569905
inhibition O 0 0.0001848732
with O 0 0.00011879521
high O 0 0.00021045821
concentration O 0 0.00036490333
of O 0 0.0005550177
heparin B-Chemical 0 0.9979931
] O 0 0.00083939475
were O 0 0.00019176031
included O 0 0.00018559275
in O 0 0.00030722126
the O 0 0.00061944354
study O 0 0.00144551
. O 0 0.0018446872

RESULTS O 0 0.0043117763
: O 0 0.0017762529
Forty O 0 0.0012274659
of O 0 0.0008081444
94 O 0 0.0015215621
HIT B-Disease 2 0.98741686
patients O 0 0.00087699847
had O 0 0.00059199776
thrombosis B-Disease 0 0.9993375
at O 0 0.00020203445
diagnosis O 0 0.0005067874
; O 0 0.00022581451
54 O 0 0.00025424318
/ O 0 0.00035008797
94 O 0 0.0002723794
had O 0 0.00019795078
isolated O 0 0.00031709886
- O 0 0.0015020057
HIT B-Disease 2 0.99518764
without O 0 0.0035679534
thrombosis B-Disease 0 0.99958783
. O 0 0.0035207656

Eight O 0 0.002783944
of O 0 0.0014269556
the O 0 0.0008577768
isolated O 0 0.0008234273
- O 0 0.0025195926
HIT B-Disease 2 0.9969183
patients O 0 0.0009980737
developed O 0 0.0011058557
thrombosis B-Disease 0 0.99944144
within O 0 5.585839e-05
the O 0 7.253276e-05
next O 0 3.990073e-05
30 O 0 6.487766e-05
d O 0 0.00012586989
; O 0 0.00011954226
thus O 0 0.00012487322
, O 0 0.00011365648
a O 0 0.000110734865
total O 0 9.7222604e-05
of O 0 0.0001385719
48 O 0 0.000108325
patients O 0 0.00024921473
had O 0 0.000370215
thrombosis B-Disease 0 0.9982663
at O 0 0.00033958897
day O 0 0.00041255777
30 O 0 0.0007753149
. O 0 0.0015317556

At O 0 0.0011127744
diagnosis O 0 0.0022684182
there O 0 0.00063512044
was O 0 0.0006423759
no O 0 0.00025518227
significant O 0 0.00026630872
difference O 0 0.0001343945
in O 0 0.00021943389
OD O 0 0.22850232
between O 0 0.00023099844
HIT B-Disease 2 0.99784493
patients O 0 0.0006123328
with O 0 0.00068109774
thrombosis B-Disease 0 0.99981505
and O 0 0.00035701555
those O 0 0.00037399077
with O 0 0.00045079534
isolated O 0 0.0007374447
- O 0 0.003591462
HIT B-Disease 2 0.9958406
. O 0 0.0031515318

However O 0 0.0031872566
, O 0 0.0031685687
OD O 0 0.36886615
was O 0 0.0010506359
significantly O 0 0.00062467984
higher O 0 0.00037746315
in O 0 0.00021855834
all O 0 0.00019793096
patients O 0 0.00030570372
with O 0 0.00053843553
thrombosis B-Disease 0 0.99988794
( O 0 0.00041710553
n O 0 0.00013222368
= O 0 0.00012819667
48 O 0 6.65265e-05
, O 0 9.745587e-05
1 O 0 7.066865e-05
. O 0 5.3423733e-05
34 O 0 0.000116932504
+ O 0 0.00022462678
/ O 0 0.00039354406
- O 0 0.00022917958
0 O 0 8.392734e-05
. O 0 6.1462815e-05
89 O 0 0.00019787927
) O 0 0.000143192
, O 0 8.190347e-05
including O 0 4.7067242e-05
isolated O 0 9.823805e-05
- O 0 0.0005096188
HIT B-Disease 2 0.9958163
patients O 0 0.00024718075
who O 0 0.00013102006
later O 0 4.8467045e-05
developed O 0 0.0002642127
thrombosis B-Disease 0 0.9991974
within O 0 3.105047e-05
30 O 0 4.7958867e-05
d O 0 8.920376e-05
( O 0 0.0001064176
n O 0 7.637802e-05
= O 0 0.00010213902
8 O 0 5.924757e-05
, O 0 8.5221254e-05
1 O 0 6.411183e-05
. O 0 4.9359245e-05
84 O 0 0.00013124588
+ O 0 0.00021032018
/ O 0 0.00036205622
- O 0 0.00020481582
0 O 0 7.20491e-05
. O 0 4.9783797e-05
64 O 0 0.00010699075
) O 0 0.000103855404
as O 0 4.853828e-05
compared O 0 3.5727317e-05
to O 0 5.1759158e-05
isolated O 0 9.635384e-05
- O 0 0.00058524654
HIT B-Disease 2 0.99786144
patients O 0 0.0003078637
who O 0 0.00016005516
did O 0 8.553536e-05
not O 0 7.8747784e-05
develop O 0 0.00033671563
thrombosis B-Disease 0 0.9999206
( O 0 0.0002708748
0 O 0 7.8371944e-05
. O 0 5.1624535e-05
96 O 0 0.00019953497
+ O 0 0.00022401508
/ O 0 0.0003762609
- O 0 0.00021757468
0 O 0 8.406808e-05
. O 0 6.608756e-05
75 O 0 0.00019143878
; O 0 0.00023521071
P O 0 0.0020926371
= O 0 0.00017911932
0 O 0 0.00011312171
. O 0 0.00011835583
011 O 0 0.001429239
and O 0 0.00038627637
P O 0 0.003700598
= O 0 0.0004731003
0 O 0 0.00038707445
. O 0 0.00052876986
008 O 0 0.0030549904
) O 0 0.0024573118
. O 0 0.00255801

The O 0 0.00256205
Receiver O 0 0.026124056
Operative O 0 0.0036497496
Characteristic O 0 0.0027200896
Curve O 0 0.09748586
showed O 0 0.00049869565
that O 0 0.00035880142
OD O 0 0.4862785
> O 0 0.0009457438
1 O 0 0.00017998114
. O 0 8.8872366e-05
27 O 0 0.000136089
in O 0 7.4809686e-05
the O 0 8.7067194e-05
isolated O 0 0.00013384076
- O 0 0.00070695876
HIT B-Disease 2 0.9968624
group O 0 0.00026507128
had O 0 0.000111551766
a O 0 0.00014065557
significantly O 0 0.00016300693
higher O 0 0.0001762611
chance O 0 0.00047231745
of O 0 0.00041998562
developing O 0 0.013489383
thrombosis B-Disease 0 0.9998172
by O 0 0.00074115756
day O 0 0.0004744796
30 O 0 0.0008227575
. O 0 0.0015564694

None O 0 0.0037982678
of O 0 0.0021720808
these O 0 0.001720172
groups O 0 0.0010379327
showed O 0 0.00077153917
significant O 0 0.0007040308
difference O 0 0.000479573
in O 0 0.00078891893
percent O 0 0.0011606627
inhibition O 0 0.0053553986
. O 0 0.004060792

Multivariate O 0 0.003949986
analysis O 0 0.0017419021
showed O 0 0.0011658353
a O 0 0.0011382933
2 O 0 0.00058900635
. O 0 0.00035959276
8 O 0 0.00036376202
- O 0 0.0006490567
fold O 0 0.0005967973
increased O 0 0.00089095224
risk O 0 0.005136355
of O 0 0.0024995557
thrombosis B-Disease 0 0.9997118
in O 0 0.001896938
females O 0 0.002974758
. O 0 0.0023408516

Similarly O 0 0.0056142034
, O 0 0.006880711
thrombotic B-Disease 0 0.9976889
risk O 0 0.019282883
increased O 0 0.00247467
with O 0 0.0017206518
age O 0 0.0016792526
and O 0 0.0018779732
OD O 0 0.4006816
values O 0 0.0038342008
. O 0 0.00401394

CONCLUSION O 0 0.01836399
: O 0 0.0027389105
Higher O 0 0.004434384
OD O 0 0.30940887
is O 0 0.0006420962
associated O 0 0.0003303391
with O 0 0.00035869816
significant O 0 0.00026653
risk O 0 0.0010879106
of O 0 0.00025284564
subsequent O 0 0.000347887
thrombosis B-Disease 0 0.99986506
in O 0 0.00015907866
patients O 0 0.00016296949
with O 0 0.00012252541
isolated O 0 0.00014739647
- O 0 0.0008221619
HIT B-Disease 2 0.997203
; O 0 0.00020813775
percent O 0 9.9832585e-05
inhibition O 0 0.0005078938
, O 0 0.00032454164
however O 0 0.00040956493
, O 0 0.0004305948
was O 0 0.0004889698
not O 0 0.0006294274
predictive O 0 0.0027699105
. O 0 0.0024141003

Thalidomide B-Chemical 0 0.9982545
has O 0 0.0016157288
limited O 0 0.0009115088
single O 0 0.00073858513
- O 0 0.00083567126
agent O 0 0.00086994
activity O 0 0.00023123401
in O 0 0.00020205641
relapsed O 0 0.008022468
or O 0 0.00015048041
refractory O 0 0.00089725805
indolent O 0 0.00347601
non B-Disease 0 0.00032089886
- I-Disease 0 0.00059351575
Hodgkin I-Disease 0 0.8868517
lymphomas I-Disease 0 0.96553373
: O 0 0.0002214318
a O 0 0.00015521883
phase O 0 0.0003231175
II O 0 0.0013352914
trial O 0 0.00015731365
of O 0 0.00017240463
the O 0 0.00027483254
Cancer B-Disease 0 0.110839404
and O 0 0.0009253469
Leukemia B-Disease 0 0.99425185
Group O 0 0.019326393
B O 0 0.16859886
. O 0 0.0028248737

Thalidomide B-Chemical 0 0.99796593
is O 0 0.0020844084
an O 0 0.0013759021
immunomodulatory O 0 0.0057427953
agent O 0 0.0029165996
with O 0 0.00052575994
demonstrated O 0 0.00023248301
activity O 0 0.00021798501
in O 0 0.00021569918
multiple B-Disease 0 0.00052420195
myeloma I-Disease 0 0.9968054
, O 0 0.00096180884
mantle B-Disease 0 0.620976
cell I-Disease 0 0.021846374
lymphoma I-Disease 0 0.9993212
and O 0 0.0044427365
lymphoplasmacytic B-Disease 0 0.99967396
lymphoma I-Disease 0 0.9997521
. O 0 0.005678789

Its O 0 0.020091504
activity O 0 0.002155299
is O 0 0.0012710678
believed O 0 0.0009732424
to O 0 0.00047600607
be O 0 0.0002927093
due O 0 0.00015325725
modulation O 0 0.0001910737
of O 0 0.00025871585
the O 0 0.00027167602
tumour B-Disease 0 0.32140815
milieu O 0 0.00026082198
, O 0 0.0002210485
including O 0 0.0001273482
downregulation O 0 0.000545063
of O 0 0.00073363184
angiogenesis O 0 0.9135881
and O 0 0.001480014
inflammatory O 0 0.3404932
cytokines O 0 0.18370093
. O 0 0.0031937442

Between O 0 0.0035276178
July O 0 0.001765534
2001 O 0 0.0014758853
and O 0 0.00068020384
April O 0 0.00054620416
2004 O 0 0.00057486724
, O 0 0.00027035928
24 O 0 0.00012722974
patients O 0 0.00016771654
with O 0 0.00016998274
relapsed O 0 0.0063185063
/ O 0 0.0005247489
refractory O 0 0.00096639415
indolent O 0 0.019985655
lymphomas B-Disease 0 0.9382633
received O 0 0.00016269545
thalidomide B-Chemical 1 0.99969745
200 O 0 0.0006348048
mg O 0 0.003646709
daily O 0 9.167819e-05
with O 0 7.09576e-05
escalation O 0 0.00039323056
by O 0 6.710978e-05
100 O 0 0.00019337465
mg O 0 0.001344145
daily O 0 6.985691e-05
every O 0 1.8518182e-05
1 O 0 4.700902e-05
- O 0 8.940021e-05
2 O 0 3.620675e-05
weeks O 0 2.0931891e-05
as O 0 5.734711e-05
tolerated O 0 0.0004599142
, O 0 0.0001118112
up O 0 9.753081e-05
to O 0 8.760603e-05
a O 0 0.00015527983
maximum O 0 0.00015929696
of O 0 0.0003948966
800 O 0 0.0019322664
mg O 0 0.016015377
daily O 0 0.001989082
. O 0 0.0018653593

Patients O 0 0.002598574
had O 0 0.0012396098
received O 0 0.0006278139
a O 0 0.0006311728
median O 0 0.00028847932
of O 0 0.00047784223
2 O 0 0.00033192072
( O 0 0.00042141796
range O 0 0.00032801836
, O 0 0.0004068761
1 O 0 0.00032609832
- O 0 0.000569292
4 O 0 0.00032497945
) O 0 0.0006341402
prior O 0 0.0005213994
regimens O 0 0.0022139668
. O 0 0.002563381

Of O 0 0.0019441766
24 O 0 0.000931426
evaluable O 0 0.0014822248
patients O 0 0.0006928117
, O 0 0.00035837124
two O 0 0.00014155002
achieved O 0 0.00020339535
a O 0 0.00018035565
complete O 0 0.00015761712
remission O 0 0.002950425
and O 0 0.00010271695
one O 0 5.3707736e-05
achieved O 0 9.6008436e-05
a O 0 0.0001011992
partial O 0 0.00019648384
remission O 0 0.0020910276
for O 0 4.6176334e-05
an O 0 7.302335e-05
overall O 0 6.5015396e-05
response O 0 6.224863e-05
rate O 0 8.1258695e-05
of O 0 0.0001044783
12 O 0 4.8965903e-05
. O 0 4.556694e-05
5 O 0 5.3557073e-05
% O 0 9.132811e-05
( O 0 0.00012594853
95 O 0 0.00012987928
% O 0 9.3112896e-05
confidence O 0 0.00033182546
interval O 0 8.771319e-05
: O 0 0.0001310243
2 O 0 8.956943e-05
. O 0 7.7865094e-05
6 O 0 9.958254e-05
- O 0 0.00029223584
32 O 0 0.00030933914
. O 0 0.00024185714
4 O 0 0.00040043623
% O 0 0.0009429586
) O 0 0.0020598234
. O 0 0.002362347

Eleven O 0 0.013152488
patients O 0 0.007204073
progressed O 0 0.0071729617
during O 0 0.004167742
therapy O 0 0.0103223445
. O 0 0.009737327

Grade O 0 0.033103496
3 O 0 0.0017845103
- O 0 0.0017077007
4 O 0 0.00054579345
adverse O 0 0.002732457
effects O 0 0.0005674133
included O 0 0.00066347665
myelosuppression B-Disease 0 0.9999409
, O 0 0.0019296381
fatigue B-Disease 0 0.9731002
, O 0 0.0012423404
somnolence B-Disease 0 0.99982077
/ O 0 0.01894365
depressed B-Disease 2 0.99971527
mood I-Disease 0 0.9998468
, O 0 0.004530868
neuropathy B-Disease 0 0.9999187
and O 0 0.0048564957
dyspnea B-Disease 0 0.99042916
. O 0 0.0032275042

Of O 0 0.0041793357
concern O 0 0.0032269706
was O 0 0.0019197783
the O 0 0.0012969027
occurrence O 0 0.001824816
of O 0 0.0020795048
four O 0 0.0022062107
thromboembolic B-Disease 0 0.99934846
events O 0 0.035031464
. O 0 0.0051796925

Our O 0 0.00214122
results O 0 0.0013986009
failed O 0 0.0010264018
to O 0 0.0004976068
demonstrate O 0 0.00020209783
an O 0 0.00026512536
important O 0 0.00010472277
response O 0 0.00015269757
rate O 0 0.00014868288
to O 0 9.793265e-05
single O 0 0.0001335217
agent O 0 0.0020048793
thalidomide B-Chemical 1 0.99986815
in O 0 0.00029884634
indolent O 0 0.0652866
lymphomas B-Disease 0 0.9647977
and O 0 0.00014144818
contrast O 0 0.00015766927
with O 0 0.000103855404
the O 0 6.663863e-05
higher O 0 8.345655e-05
activity O 0 6.748752e-05
level O 0 6.167801e-05
reported O 0 9.847505e-05
with O 0 9.9347606e-05
the O 0 8.700974e-05
second O 0 0.00011637554
generation O 0 0.00031984175
immunomodulatory O 0 0.0060218805
agent O 0 0.009814098
, O 0 0.0030269239
lenalidomide B-Chemical 0 0.9991429
. O 0 0.0036079492

Sex O 0 0.010842427
differences O 0 0.0009634115
in O 0 0.0017190506
NMDA B-Chemical 1 0.99996734
antagonist O 0 0.96421677
enhancement O 0 0.0023055188
of O 0 0.0018122153
morphine B-Chemical 0 0.99997175
antihyperalgesia O 0 0.9855467
in O 0 0.0002397417
a O 0 0.00039042428
capsaicin B-Chemical 0 0.99807215
model O 0 0.00020440106
of O 0 0.00021421349
persistent O 0 0.003778537
pain B-Disease 0 0.5996578
: O 0 0.00020567451
comparisons O 0 7.491635e-05
to O 0 8.929278e-05
two O 0 0.000106582025
models O 0 0.00032077986
of O 0 0.0009471141
acute B-Disease 0 0.8365945
pain I-Disease 0 0.95814496
. O 0 0.0032244362

In O 0 0.0029871229
acute B-Disease 0 0.52991974
pain I-Disease 0 0.8106128
models O 0 0.002233663
, O 0 0.0023698988
N B-Chemical 0 0.9955279
- I-Chemical 0 0.004690425
methyl I-Chemical 0 0.9963864
- I-Chemical 0 0.004983991
D I-Chemical 0 0.9477809
- I-Chemical 0 0.004289426
aspartate I-Chemical 1 0.9999219
( O 0 0.009331909
NMDA B-Chemical 1 0.9999976
) O 0 0.0015405694
antagonists O 0 0.21869087
enhance O 0 6.168583e-05
the O 0 0.00011360946
antinociceptive O 0 0.71667117
effects O 0 0.00021004405
of O 0 0.00057745486
morphine B-Chemical 0 0.99991536
to O 0 0.0001600918
a O 0 0.00017634632
greater O 0 0.00014185772
extent O 0 0.0001382306
in O 0 0.00026285034
males O 0 0.0006117792
than O 0 0.00044499413
females O 0 0.0014515062
. O 0 0.0016290202

The O 0 0.0015299588
purpose O 0 0.0011468307
of O 0 0.0009956141
this O 0 0.00073847466
investigation O 0 0.00076484244
was O 0 0.0003423507
to O 0 0.00016060584
extend O 0 0.00012115484
these O 0 0.00017363568
findings O 0 0.00021926845
to O 0 0.00010077924
a O 0 0.00020159186
persistent O 0 0.0024262916
pain B-Disease 0 0.5663477
model O 0 0.00018949957
which O 0 0.00014738817
could O 0 6.3229025e-05
be O 0 5.6467445e-05
distinguished O 0 7.0592265e-05
from O 0 7.674101e-05
acute B-Disease 0 0.20843986
pain I-Disease 0 0.40833074
models O 0 0.000106929154
on O 0 3.2844033e-05
the O 0 4.7168338e-05
basis O 0 5.3807402e-05
of O 0 7.98727e-05
the O 0 8.6537846e-05
nociceptive O 0 0.0007287803
fibers O 0 0.00017789789
activated O 0 0.00012844751
, O 0 0.00016413943
neurochemical O 0 0.014270795
substrates O 0 0.00021498854
, O 0 0.00013917134
and O 0 0.00011191146
duration O 0 7.835783e-05
of O 0 0.00025298336
the O 0 0.0004105866
nociceptive O 0 0.0030427608
stimulus O 0 0.0015515774
. O 0 0.0020694626

To O 0 0.0019170811
this O 0 0.0015522778
end O 0 0.0008412299
, O 0 0.0013213513
persistent O 0 0.01318576
hyperalgesia B-Disease 0 0.9988838
was O 0 0.00073551503
induced O 0 0.00036176931
by O 0 0.00024047979
administration O 0 0.0009932875
of O 0 0.0005561562
capsaicin B-Chemical 0 0.99938405
in O 0 0.00014394314
the O 0 9.167661e-05
tail O 0 0.0001230801
of O 0 0.000109513065
gonadally O 0 0.00035366692
intact O 0 0.00010979801
F344 O 0 0.029318064
rats O 0 0.00011676168
, O 0 5.562503e-05
following O 0 3.157566e-05
which O 0 6.813221e-05
the O 0 6.260629e-05
tail O 0 0.00011251882
was O 0 7.649114e-05
immersed O 0 0.0001188079
in O 0 6.295551e-05
a O 0 0.00013806767
mildly O 0 0.07038876
noxious O 0 0.0018348065
thermal O 0 0.0010891447
stimulus O 0 0.00016904011
, O 0 0.00018928396
and O 0 0.00019346057
tail O 0 0.00042676344
- O 0 0.00061428867
withdrawal O 0 0.004533471
latencies O 0 0.0017943257
measured O 0 0.001159897
. O 0 0.00188301

For O 0 0.0012857107
comparison O 0 0.001259945
, O 0 0.0011344544
tests O 0 0.0010193381
were O 0 0.00035103408
conducted O 0 0.00022345853
in O 0 0.00019854242
two O 0 0.00018832693
acute B-Disease 0 0.30669513
pain I-Disease 0 0.7000036
models O 0 0.00038327114
, O 0 0.00021929834
the O 0 0.00019074805
hotplate O 0 0.04203276
and O 0 0.00025199808
warm O 0 0.0021084896
water O 0 0.0043336535
tail O 0 0.00082470756
- O 0 0.0010636182
withdrawal O 0 0.007796116
procedures O 0 0.0015619016
. O 0 0.0018884633

In O 0 0.0023549553
males O 0 0.0026729424
, O 0 0.0010494202
the O 0 0.0006200788
non O 0 0.0008393839
- O 0 0.0013169151
competitive O 0 0.14536901
NMDA B-Chemical 1 0.99999785
antagonist O 0 0.9997713
dextromethorphan B-Chemical 0 0.9999988
enhanced O 0 0.00076799764
the O 0 0.00023124968
antihyperalgesic O 0 0.8539438
effect O 0 9.69655e-05
of O 0 0.00013137485
low O 0 0.00020931753
to O 0 8.430176e-05
moderate O 0 0.001595799
doses O 0 0.0018092885
of O 0 0.00054907246
morphine B-Chemical 0 0.99993336
in O 0 0.00017997857
a O 0 0.00025812577
dose O 0 0.0012780093
- O 0 0.0004047596
and O 0 0.0002048697
time O 0 0.00016927496
- O 0 0.0005561376
dependent O 0 0.00037764205
manner O 0 0.0012476351
. O 0 0.0019050628

Across O 0 0.0022126997
the O 0 0.0013547802
doses O 0 0.0034619556
and O 0 0.0008554449
pretreatment O 0 0.0056302994
times O 0 0.00026405425
examined O 0 0.0002667715
, O 0 0.00042141275
enhancement O 0 0.00077263324
was O 0 0.0004762121
not O 0 0.00038913373
observed O 0 0.00054630457
in O 0 0.0009696475
females O 0 0.0023675335
. O 0 0.0022979116

Enhancement O 0 0.006393571
of O 0 0.005006962
morphine B-Chemical 0 0.9999094
antinociception O 0 0.9999207
by O 0 0.0079834005
dextromethorphan B-Chemical 0 0.99999547
was O 0 0.00061277876
seen O 0 0.00016067967
in O 0 0.00010390235
both O 0 0.00011390189
males O 0 0.00018330608
and O 0 8.085106e-05
females O 0 9.831873e-05
in O 0 5.813438e-05
the O 0 0.00011209838
acute B-Disease 0 0.41446778
pain I-Disease 0 0.7600603
models O 0 0.00024920522
, O 0 0.00012621471
with O 0 9.81825e-05
the O 0 7.297205e-05
magnitude O 0 6.9199654e-05
of O 0 0.00012813925
this O 0 0.00017028512
effect O 0 0.00019765958
being O 0 0.00041792827
greater O 0 0.0005156828
in O 0 0.0008103194
males O 0 0.0022551955
. O 0 0.0017762256

These O 0 0.0022515496
findings O 0 0.0019228791
demonstrate O 0 0.0006195339
a O 0 0.00122994
sexually O 0 0.005135078
- O 0 0.00096904906
dimorphic O 0 0.0003789972
interaction O 0 0.0001719746
between O 0 0.00022989349
NMDA B-Chemical 1 0.9999963
antagonists O 0 0.9876643
and O 0 0.00085784186
morphine B-Chemical 0 0.9999305
in O 0 0.00014788033
a O 0 0.00018531653
persistent O 0 0.0020258327
pain B-Disease 0 0.4275223
model O 0 0.00013648564
that O 0 6.36346e-05
can O 0 5.909758e-05
be O 0 6.649847e-05
distinguished O 0 8.318633e-05
from O 0 7.388026e-05
those O 0 0.00015187712
observed O 0 0.00015424156
in O 0 0.00036154367
acute B-Disease 0 0.5935899
pain I-Disease 0 0.887771
models O 0 0.0035142344
. O 0 0.0023898564

Development O 0 0.005341475
of O 0 0.0034583877
proteinuria B-Disease 0 0.9997118
after O 0 0.00043832435
switch O 0 0.00058281835
to O 0 0.000582605
sirolimus B-Chemical 1 0.9998547
- O 0 0.0011466487
based O 0 0.00029601692
immunosuppression O 0 0.49540457
in O 0 0.00030180239
long O 0 0.0002989373
- O 0 0.00047773705
term O 0 0.0003959121
cardiac O 0 0.023153612
transplant O 0 0.056840915
patients O 0 0.0031177062
. O 0 0.0020277798

Calcineurin O 0 0.7205599
- O 0 0.0055216975
inhibitor O 0 0.0051331786
therapy O 0 0.0017469507
can O 0 0.0006141646
lead O 0 0.0026894799
to O 0 0.0008608416
renal B-Disease 2 0.9991616
dysfunction I-Disease 2 0.99883
in O 0 0.0013068096
heart O 0 0.20297082
transplantation O 0 0.037789784
patients O 0 0.0035346246
. O 0 0.0022336484

The O 0 0.0018047104
novel O 0 0.0022164604
immunosuppressive O 0 0.23057197
( O 0 0.0023050748
IS O 0 0.05785235
) O 0 0.0013932255
drug O 0 0.048410147
sirolmus B-Chemical 0 0.70548517
( O 0 0.0011089065
Srl B-Chemical 0 0.16419256
) O 0 0.00042627775
lacks O 0 0.00016855341
nephrotoxic B-Disease 2 0.9991855
effects O 0 0.0006942674
; O 0 0.00034110472
however O 0 0.0002915276
, O 0 0.0004135098
proteinuria B-Disease 0 0.99998355
associated O 0 0.00034915505
with O 0 0.00052086933
Srl B-Chemical 0 0.1048298
has O 0 0.00014929903
been O 0 0.00015436544
reported O 0 0.00028319756
following O 0 0.0004056981
renal O 0 0.9009365
transplantation O 0 0.08443725
. O 0 0.002469136

In O 0 0.0027388013
cardiac O 0 0.019354591
transplantation O 0 0.0075370227
, O 0 0.0011691204
the O 0 0.00064358074
incidence O 0 0.0012483103
of O 0 0.0015951972
proteinuria B-Disease 0 0.9999659
associated O 0 0.0015545143
with O 0 0.0021987958
Srl B-Chemical 0 0.2691065
is O 0 0.0017039946
unknown O 0 0.003622639
. O 0 0.0029041092

In O 0 0.0018895763
this O 0 0.0016670774
study O 0 0.0013128201
, O 0 0.00082226057
long O 0 0.00048002577
- O 0 0.00056087004
term O 0 0.00024633756
cardiac O 0 0.006168059
transplant O 0 0.00551333
patients O 0 0.000278851
were O 0 0.00011860246
switched O 0 0.00017955486
from O 0 0.00026010437
cyclosporine B-Chemical 1 0.9999702
to O 0 0.00079721137
Srl B-Chemical 0 0.2432101
- O 0 0.0013256231
based O 0 0.0010520072
IS O 0 0.02893212
. O 0 0.0027175609

Concomitant O 0 0.0077037783
IS O 0 0.014366182
consisted O 0 0.0020112176
of O 0 0.0064879004
mycophenolate B-Chemical 0 0.99998665
mofetil I-Chemical 0 0.99999094
+ O 0 0.086803675
/ O 0 0.019104114
- O 0 0.010587298
steroids B-Chemical 0 0.9956483
. O 0 0.006009913

Proteinuria O 2 0.9993881
increased O 0 0.0037160693
significantly O 0 0.001358575
from O 0 0.00047524978
a O 0 0.00044207365
median O 0 0.00016999863
of O 0 0.00026673207
0 O 0 0.00017713723
. O 0 0.00010370567
13 O 0 0.00013324813
g O 0 0.0002845638
/ O 0 0.00027139593
day O 0 7.5460615e-05
( O 0 0.00012951258
range O 0 9.818419e-05
0 O 0 9.8672725e-05
- O 0 0.00017386976
5 O 0 6.427877e-05
. O 0 5.2625375e-05
7 O 0 5.998709e-05
) O 0 0.00014210153
preswitch O 0 0.0010215412
to O 0 8.014561e-05
0 O 0 7.398799e-05
. O 0 5.019707e-05
23 O 0 0.00010283935
g O 0 0.00019364695
/ O 0 0.00020499594
day O 0 6.0720908e-05
( O 0 0.00012183082
0 O 0 8.677062e-05
- O 0 0.00016331763
9 O 0 7.119082e-05
. O 0 5.49022e-05
88 O 0 0.00015824144
) O 0 0.000111040434
at O 0 4.894858e-05
24 O 0 6.237526e-05
months O 0 5.2662064e-05
postswitch O 0 0.00072983425
( O 0 0.0003388198
p O 0 0.0002935035
= O 0 0.0003588741
0 O 0 0.0003400848
. O 0 0.0005051933
0024 O 0 0.0068272003
) O 0 0.0024998325
. O 0 0.0024472254

Before O 0 0.0021457279
the O 0 0.0016044703
switch O 0 0.0013424653
, O 0 0.0010730159
11 O 0 0.00058627035
. O 0 0.0002486463
5 O 0 0.00017719701
% O 0 0.00019030258
of O 0 0.00019917116
patients O 0 0.00024222568
had O 0 0.00015320846
high O 0 0.00040049464
- O 0 0.000660657
grade O 0 0.14666088
proteinuria B-Disease 0 0.9999944
( O 0 0.00089491694
> O 0 0.00042054072
1 O 0 8.018826e-05
. O 0 4.4270222e-05
0 O 0 5.7557827e-05
g O 0 0.00017232951
/ O 0 0.00020776261
day O 0 6.551416e-05
) O 0 0.00015053051
; O 0 9.797227e-05
this O 0 9.519016e-05
increased O 0 0.00015810422
to O 0 0.00010122951
22 O 0 0.00014494722
. O 0 6.719238e-05
9 O 0 8.844003e-05
% O 0 0.00015168577
postswitch O 0 0.0012411163
( O 0 0.00039348254
p O 0 0.00031358897
= O 0 0.0003705688
0 O 0 0.00034652997
. O 0 0.0005153148
006 O 0 0.005418441
) O 0 0.0023884543
. O 0 0.002406597

ACE B-Chemical 0 0.99842924
inhibitor I-Chemical 0 0.11620824
and O 0 0.005470374
angiotensin B-Chemical 1 0.9999107
- I-Chemical 0 0.0068640998
releasing I-Chemical 0 0.006108084
blocker I-Chemical 0 0.9942247
( O 0 0.005985043
ARB B-Chemical 0 0.9999666
) O 0 0.0021086342
therapy O 0 0.0013906684
reduced O 0 0.004091696
proteinuria B-Disease 0 0.99994934
development O 0 0.022203492
. O 0 0.0037420574

Patients O 0 0.0025835002
without O 0 0.0021641345
proteinuria B-Disease 0 0.99983287
had O 0 0.0012679097
increased O 0 0.0012316796
renal O 0 0.8161114
function O 0 0.0005349913
( O 0 0.00028425036
median O 0 8.20046e-05
42 O 0 0.00013400728
. O 0 6.319164e-05
5 O 0 6.600504e-05
vs O 0 0.00010001955
. O 0 6.166042e-05
64 O 0 0.00012495779
. O 0 6.3209365e-05
1 O 0 8.1784216e-05
, O 0 0.00012687816
p O 0 0.00012081807
= O 0 0.00010783802
0 O 0 6.369313e-05
. O 0 4.9873946e-05
25 O 0 0.00011537501
) O 0 0.0001383125
, O 0 8.7226486e-05
whereas O 0 7.932111e-05
patients O 0 0.00013102056
who O 0 0.0001280231
developed O 0 0.00013423956
high O 0 0.00031735504
- O 0 0.00044262857
grade O 0 0.08155132
proteinuria B-Disease 0 0.99999404
showed O 0 0.00033605035
decreased O 0 0.0047828653
renal O 0 0.880538
function O 0 0.00027091274
at O 0 3.75691e-05
the O 0 4.267676e-05
end O 0 2.6021424e-05
of O 0 7.034256e-05
follow O 0 4.872638e-05
- O 0 0.000128984
up O 0 7.8371726e-05
( O 0 0.000100859994
median O 0 4.5177952e-05
39 O 0 0.00011364718
. O 0 4.8915223e-05
6 O 0 4.9070983e-05
vs O 0 9.3101524e-05
. O 0 6.7482375e-05
29 O 0 0.00017030703
. O 0 8.597597e-05
2 O 0 0.000122089
, O 0 0.00022391963
p O 0 0.0002653029
= O 0 0.0003243387
0 O 0 0.00029746033
. O 0 0.00041119332
125 O 0 0.002103438
) O 0 0.0023772097
. O 0 0.0024527886

Thus O 0 0.0029778031
, O 0 0.004327539
proteinuria B-Disease 0 0.9997863
may O 0 0.00094358594
develop O 0 0.0006368597
in O 0 0.00035541202
cardiac O 0 0.010163535
transplant O 0 0.0068867276
patients O 0 0.00022964658
after O 0 4.2706317e-05
switch O 0 0.000107313135
to O 0 0.00012850019
Srl B-Chemical 0 0.043172054
, O 0 0.0001479352
which O 0 0.00012685286
may O 0 7.333795e-05
have O 0 5.9733302e-05
an O 0 0.00013035472
adverse O 0 0.0027725748
effect O 0 0.00013247506
on O 0 0.00013180009
renal O 0 0.60009193
function O 0 0.00046869673
in O 0 0.00040530053
these O 0 0.0009636873
patients O 0 0.0019709151
. O 0 0.0017855162

Srl B-Chemical 0 0.060260985
should O 0 0.001036816
be O 0 0.0007502982
used O 0 0.00053035916
with O 0 0.0010566748
ACEi B-Chemical 0 0.99983156
/ O 0 0.03411549
ARB B-Chemical 0 0.99997616
therapy O 0 0.00087067386
and O 0 0.0002457263
patients O 0 0.00022626796
monitored O 0 0.00011835989
for O 0 0.000267918
proteinuria B-Disease 0 0.9999559
and O 0 0.0012322172
increased O 0 0.0044409945
renal B-Disease 2 0.99968684
dysfunction I-Disease 2 0.9994555
. O 0 0.0045858985

Ginsenoside B-Chemical 0 0.9997985
Rg1 I-Chemical 1 0.99990606
restores O 0 0.0030143687
the O 0 0.0014517079
impairment B-Disease 0 0.4144434
of I-Disease 0 0.0008467545
learning I-Disease 0 0.0028050346
induced O 0 0.00069230935
by O 0 0.00079724827
chronic O 0 0.81796193
morphine B-Chemical 0 0.9999434
administration O 0 0.03209594
in O 0 0.0012515426
rats O 0 0.002718763
. O 0 0.0020652774

Rg1 B-Chemical 1 0.99936646
, O 0 0.0042797932
as O 0 0.0016808424
a O 0 0.0024557023
ginsenoside B-Chemical 0 0.99981433
extracted O 0 0.0008026115
from O 0 0.0006761405
Panax O 0 0.19920138
ginseng O 0 0.7251852
, O 0 0.00072405837
could O 0 0.000401402
ameliorate O 0 0.002277804
spatial O 0 0.002999026
learning B-Disease 0 0.14304961
impairment I-Disease 0 0.99185735
. O 0 0.0046792366

Previous O 0 0.001525293
studies O 0 0.0013170292
have O 0 0.00061293016
demonstrated O 0 0.00048086068
that O 0 0.0006159919
Rg1 B-Chemical 1 0.99990106
might O 0 0.00030578388
be O 0 0.00020434374
a O 0 0.00020064323
useful O 0 0.00012625613
agent O 0 0.00044184658
for O 0 9.082803e-05
the O 0 0.000118247655
prevention O 0 0.00020578751
and O 0 0.00013715624
treatment O 0 0.00013150745
of O 0 0.00019973483
the O 0 0.0002480127
adverse O 0 0.015963053
effects O 0 0.00091414584
of O 0 0.0038284136
morphine B-Chemical 0 0.9997974
. O 0 0.0037391644

The O 0 0.0015292816
aim O 0 0.001405846
of O 0 0.0011375638
this O 0 0.0008310465
study O 0 0.0006494308
was O 0 0.00033167837
to O 0 0.00015133055
investigate O 0 8.328999e-05
the O 0 0.00012572366
effect O 0 0.00014960143
of O 0 0.00062159327
Rg1 B-Chemical 1 0.999974
on O 0 0.00015221362
learning B-Disease 0 0.04960716
impairment I-Disease 0 0.9846021
by O 0 0.0006161879
chronic O 0 0.8522995
morphine B-Chemical 0 0.9999778
administration O 0 0.0050803074
and O 0 0.00016872254
the O 0 0.00012765166
mechanism O 0 0.00017331561
responsible O 0 0.00018031265
for O 0 0.0002483949
this O 0 0.0007346512
effect O 0 0.0013388263
. O 0 0.0021982559

Male O 0 0.0072716284
rats O 0 0.0017184517
were O 0 0.0006112634
subcutaneously O 0 0.00038915008
injected O 0 0.00032746157
with O 0 0.00065845484
morphine B-Chemical 0 0.99983025
( O 0 0.0005108624
10 O 0 0.00016836192
mg O 0 0.0033497612
/ O 0 0.0005953628
kg O 0 0.0003905432
) O 0 0.00013737113
twice O 0 5.0352694e-05
a O 0 6.576165e-05
day O 0 3.0840878e-05
at O 0 2.6754786e-05
12 O 0 2.2067277e-05
hour O 0 2.4597302e-05
intervals O 0 2.2264689e-05
for O 0 2.8446177e-05
10 O 0 4.185638e-05
days O 0 2.9055356e-05
, O 0 9.3345465e-05
and O 0 0.00021867717
Rg1 B-Chemical 1 0.9999633
( O 0 0.00028102673
30 O 0 7.865001e-05
mg O 0 0.0024226347
/ O 0 0.0004754238
kg O 0 0.00036023732
) O 0 0.00014145815
was O 0 6.66014e-05
intraperitoneally O 0 7.728226e-05
injected O 0 5.6341578e-05
2 O 0 3.5565172e-05
hours O 0 1.8858884e-05
after O 0 1.5413409e-05
the O 0 3.8814112e-05
second O 0 5.4130556e-05
injection O 0 0.00010979508
of O 0 0.00030743866
morphine B-Chemical 0 0.99970824
once O 0 0.00013133224
a O 0 0.00019594877
day O 0 0.00012351041
for O 0 0.00020833232
10 O 0 0.00043492185
days O 0 0.00053658773
. O 0 0.0015395831

Spatial O 0 0.006214374
learning O 0 0.003948421
capacity O 0 0.0027850112
was O 0 0.0015285208
assessed O 0 0.00084539194
in O 0 0.0008826328
the O 0 0.0012417914
Morris O 0 0.007819436
water O 0 0.016236914
maze O 0 0.09210444
. O 0 0.0044967313

The O 0 0.0014598998
results O 0 0.0011742299
showed O 0 0.0007060599
that O 0 0.0003828038
rats O 0 0.00065315125
treated O 0 0.0006254054
with O 0 0.0012225022
Morphine B-Chemical 0 0.99997747
/ O 0 0.060874213
Rg1 B-Chemical 1 0.9999788
decreased O 0 0.0015663548
escape O 0 0.0008282377
latency O 0 0.0002601356
and O 0 0.00010888176
increased O 0 0.00014277289
the O 0 8.205951e-05
time O 0 5.0523253e-05
spent O 0 7.967096e-05
in O 0 0.0001150823
platform O 0 0.00042038903
quadrant O 0 0.0010086587
and O 0 0.00045682947
entering O 0 0.0009283946
frequency O 0 0.001490077
. O 0 0.002001835

By O 0 0.0019821255
implantation O 0 0.0014453708
of O 0 0.0009402028
electrodes O 0 0.00094515336
and O 0 0.00041612142
electrophysiological O 0 0.001006709
recording O 0 0.00022849362
in O 0 0.0001579746
vivo O 0 0.0002612653
, O 0 0.00014350405
the O 0 9.08418e-05
results O 0 0.00010367927
showed O 0 0.00011143132
that O 0 0.00015991893
Rg1 B-Chemical 1 0.999974
restored O 0 0.00051127427
the O 0 0.00013059533
long O 0 0.000110047484
- O 0 0.00016781667
term O 0 9.528335e-05
potentiation O 0 0.38787255
( O 0 0.0005746125
LTP O 0 0.9985869
) O 0 0.00045956695
impaired O 0 0.0007885488
by O 0 0.00033086643
morphine B-Chemical 0 0.99977
in O 0 0.00016523805
both O 0 0.00015477427
freely O 0 0.00023444521
moving O 0 0.00039201355
and O 0 0.00049081864
anaesthetised O 0 0.0067320126
rats O 0 0.0018000656
. O 0 0.0016290405

The O 0 0.0014290728
electrophysiological O 0 0.0027228903
recording O 0 0.0007605493
in O 0 0.00043492144
vitro O 0 0.00047302098
showed O 0 0.0003177068
that O 0 0.00034825617
Rg1 B-Chemical 1 0.9999554
restored O 0 0.00089417456
the O 0 0.00032061266
LTP O 0 0.9947844
in O 0 0.0001469512
slices O 0 0.00034183654
from O 0 5.5817498e-05
the O 0 5.889303e-05
rats O 0 0.00010647648
treated O 0 0.00014059429
with O 0 0.0003602899
morphine B-Chemical 0 0.999956
, O 0 0.00021651141
but O 0 8.8888475e-05
not O 0 5.72111e-05
changed O 0 9.755155e-05
LTP O 0 0.97551507
in O 0 7.0295544e-05
the O 0 5.234793e-05
slices O 0 0.0001753763
from O 0 4.7112775e-05
normal O 0 0.00018519147
saline O 0 0.00061822386
- O 0 0.00017786042
or O 0 0.0001366539
morphine B-Chemical 0 0.9999474
/ O 0 0.03730833
Rg1 B-Chemical 1 0.9999926
- O 0 0.0010057712
treated O 0 0.00023961328
rats O 0 0.00019383317
; O 0 8.480667e-05
this O 0 7.277545e-05
restoration O 0 0.00014186015
could O 0 6.46949e-05
be O 0 7.105422e-05
inhibited O 0 0.00023978583
by O 0 0.00037310174
N B-Chemical 0 0.9954354
- I-Chemical 0 0.0021288577
methyl I-Chemical 0 0.9955224
- I-Chemical 0 0.0028702356
D I-Chemical 0 0.9234223
- I-Chemical 0 0.0030815687
aspartate I-Chemical 1 0.99990475
( O 0 0.009283881
NMDA B-Chemical 1 0.9999945
) O 0 0.005971634
receptor O 0 0.43388247
antagonist O 0 0.9981989
MK801 B-Chemical 0 0.99999046
. O 0 0.006263705

We O 0 0.0015053232
conclude O 0 0.0010401887
that O 0 0.0013767659
Rg1 B-Chemical 1 0.99979573
may O 0 0.000690046
significantly O 0 0.000473355
improve O 0 0.00015505937
the O 0 0.00013111005
spatial O 0 0.00024960877
learning O 0 0.0003268811
capacity O 0 0.00029321792
impaired O 0 0.0007831123
by O 0 0.00027933635
chonic O 0 0.18825372
morphine B-Chemical 0 0.9999404
administration O 0 0.0021024684
and O 0 0.00016502074
restore O 0 0.00016194477
the O 0 0.0004841342
morphine B-Chemical 0 0.9998524
- O 0 0.0027596317
inhibited O 0 0.0057603116
LTP O 0 0.99876094
. O 0 0.003934921

This O 0 0.008852006
effect O 0 0.0063353037
is O 0 0.01162988
NMDA B-Chemical 1 0.9997986
receptor O 0 0.29126754
dependent O 0 0.0065455656
. O 0 0.0091113765

Synthesis O 0 0.01686655
of O 0 0.006131949
N B-Chemical 0 0.9897737
- I-Chemical 0 0.007335372
pyrimidinyl I-Chemical 0 0.9559529
- I-Chemical 0 0.0023850412
2 I-Chemical 0 0.0005847218
- I-Chemical 0 0.000950581
phenoxyacetamides I-Chemical 0 0.0039153523
as O 0 0.001102159
adenosine B-Chemical 0 0.99899584
A2A O 0 0.99952126
receptor O 0 0.55772007
antagonists O 0 0.940065
. O 0 0.0037188404

A O 0 0.01661808
series O 0 0.0031038236
of O 0 0.0036683623
N B-Chemical 0 0.990176
- I-Chemical 0 0.0054918807
pyrimidinyl I-Chemical 0 0.96188974
- I-Chemical 0 0.0017838563
2 I-Chemical 0 0.0004095374
- I-Chemical 0 0.0008543818
phenoxyacetamide I-Chemical 0 0.24862798
adenosine B-Chemical 0 0.998492
A O 0 0.094763
( O 0 0.00086122216
2A O 0 0.00091787387
) O 0 0.0010741133
antagonists O 0 0.22469176
is O 0 0.0013258442
described O 0 0.0015775642
. O 0 0.0024179434

SAR O 0 0.27874485
studies O 0 0.0019928152
led O 0 0.00130035
to O 0 0.000802034
compound O 0 0.014587443
14 O 0 0.00034284242
with O 0 0.0002927467
excellent O 0 0.0006458889
potency O 0 0.058610532
( O 0 0.0015569794
K O 1 0.9996816
( O 0 0.0006244506
i O 0 0.000703141
) O 0 0.0003409121
= O 0 0.00016958546
0 O 0 8.6648164e-05
. O 0 6.4315245e-05
4 O 0 8.1034916e-05
nM O 0 0.0009027489
) O 0 0.00030489336
, O 0 0.00019038082
selectivity O 0 0.00226337
( O 0 0.00038189176
A O 0 0.0067921057
( O 0 0.00024032762
1 O 0 0.00011362029
) O 0 0.0002004654
/ O 0 0.00046374553
A O 0 0.0049510505
( O 0 0.0002696241
2A O 0 0.00028966388
) O 0 0.00020558081
> O 0 0.00027419312
100 O 0 0.00035831038
) O 0 0.00020642107
, O 0 0.00010727834
and O 0 9.5292984e-05
efficacy O 0 0.00017642691
( O 0 0.00022678201
MED O 0 0.041981984
10 O 0 0.00010284701
mg O 0 0.0025393036
/ O 0 0.0005349585
kg O 0 0.00046723985
p O 0 0.00012642874
. O 0 6.330292e-05
o O 0 0.00060356787
. O 0 6.7872956e-05
) O 0 0.000116677984
in O 0 6.280476e-05
the O 0 0.00010492098
rat O 0 0.0019058253
haloperidol B-Chemical 1 0.99999785
- O 0 0.0014086918
induced O 0 0.00094230886
catalepsy B-Disease 0 0.9999862
model O 0 0.00063753355
for O 0 0.0004180197
Parkinson B-Disease 0 0.9973145
' I-Disease 0 0.0012754402
s I-Disease 0 0.0011691237
disease I-Disease 0 0.072522014
. O 0 0.0025494143

Evidence O 0 0.0034101994
for O 0 0.0010848101
an O 0 0.0011685297
involvement O 0 0.0012166498
of O 0 0.0016926182
D1 O 0 0.99592173
and O 0 0.0020597333
D2 O 0 0.9997483
dopamine B-Chemical 0 0.99990964
receptors O 0 0.0030800283
in O 0 0.00019322736
mediating O 0 0.00019154797
nicotine B-Chemical 1 0.99929106
- O 0 0.0014905276
induced O 0 0.0014893628
hyperactivity B-Disease 2 0.9999014
in O 0 0.0016077635
rats O 0 0.0030488654
. O 0 0.0019860032

Previous O 0 0.0014897981
studies O 0 0.0012289037
have O 0 0.0004960785
suggested O 0 0.00026853764
that O 0 0.00017448142
repeated O 0 0.00013106929
exposure O 0 0.0002576883
of O 0 0.000238117
rats O 0 0.00022704531
to O 0 8.6896565e-05
the O 0 0.00010551868
drug O 0 0.001948662
or O 0 7.427911e-05
to O 0 5.9542832e-05
the O 0 6.728819e-05
experimental O 0 0.000103437524
environment O 0 9.352686e-05
is O 0 7.473404e-05
necessary O 0 4.9795908e-05
to O 0 0.00010275417
observe O 0 0.00017493939
nicotine B-Chemical 1 0.9987049
- O 0 0.0010896479
induced O 0 0.0008418361
locomotor O 0 0.1346428
stimulation O 0 0.0013852121
. O 0 0.0020714065

In O 0 0.001585858
the O 0 0.0010717431
present O 0 0.0006034577
study O 0 0.0005471806
the O 0 0.00027734684
role O 0 0.00014704833
of O 0 0.00024471837
habituation O 0 0.0010782321
to O 0 0.00011999588
the O 0 0.00010077087
experimental O 0 0.00011962845
environment O 0 8.987753e-05
on O 0 5.1668965e-05
the O 0 0.00012096147
stimulant O 0 0.1572184
effect O 0 0.00018044113
of O 0 0.00062582875
nicotine B-Chemical 1 0.99889874
in O 0 0.00044241978
rats O 0 0.00077974645
was O 0 0.000687513
examined O 0 0.00082009187
. O 0 0.0017443134

In O 0 0.0017427214
addition O 0 0.0009695496
, O 0 0.0009854955
the O 0 0.00048468338
role O 0 0.00029635805
of O 0 0.0009425176
dopamine B-Chemical 0 0.99981123
receptors O 0 0.0034391477
in O 0 0.00016189646
mediating O 0 0.00012857128
nicotine B-Chemical 1 0.9996118
- O 0 0.00059228676
induced O 0 0.0002011261
locomotor O 0 0.057134245
stimulation O 0 8.257878e-05
was O 0 9.116636e-05
investigated O 0 4.8719226e-05
by O 0 4.981415e-05
examining O 0 2.8314642e-05
the O 0 4.524241e-05
effects O 0 7.394765e-05
of O 0 0.00016668536
selective O 0 0.0036247582
D1 O 0 0.9981945
and O 0 0.0006797729
D2 O 0 0.99984396
dopamine B-Chemical 0 0.99994445
receptor O 0 0.083633594
antagonists O 0 0.3086646
on O 0 0.00012350593
activity O 0 0.00026050812
induced O 0 0.0007177243
by O 0 0.0017702018
nicotine B-Chemical 1 0.9987093
. O 0 0.0029677008

Locomotor O 0 0.023363376
activity O 0 0.0019425814
was O 0 0.0013667906
assessed O 0 0.00070550106
in O 0 0.000759211
male O 0 0.0027512382
Sprague O 0 0.032065243
- O 0 0.0013124575
Dawley O 0 0.004020986
rats O 0 0.00061610044
tested O 0 0.00047458478
in O 0 0.0007811699
photocell O 0 0.010455757
cages O 0 0.0043819356
. O 0 0.0026512886

Nicotine B-Chemical 0 0.99954504
( O 0 0.004190774
1 O 0 0.0010935206
. O 0 0.0004986909
0 O 0 0.00047950266
mg O 0 0.004200993
/ O 0 0.0013148711
kg O 0 0.0010046135
) O 0 0.00037198653
caused O 0 0.00019107334
a O 0 0.0002090335
significant O 0 0.00012116107
increase B-Disease 0 0.00010919878
in I-Disease 0 0.000108627886
locomotor I-Disease 0 0.013304387
activity I-Disease 0 8.6901455e-05
in O 0 6.443557e-05
rats O 0 8.291223e-05
that O 0 3.44794e-05
were O 0 4.7380316e-05
habituated O 0 6.215093e-05
to O 0 3.715916e-05
the O 0 5.5102042e-05
test O 0 9.615008e-05
environment O 0 8.4144354e-05
, O 0 9.78326e-05
but O 0 8.674587e-05
had O 0 7.09735e-05
only O 0 8.163951e-05
a O 0 0.00011953439
weak O 0 0.00029962178
and O 0 0.000118687305
delayed O 0 0.0011780513
stimulant O 0 0.53859025
action O 0 0.00019736278
in O 0 8.172776e-05
rats O 0 0.0001104871
that O 0 5.921673e-05
were O 0 0.00010746365
unfamiliar O 0 0.0002845185
with O 0 0.00026162202
the O 0 0.00037292976
test O 0 0.0007758836
environment O 0 0.0012707035
. O 0 0.0018410509

The O 0 0.002061781
stimulant O 0 0.22881484
action O 0 0.0018622297
of O 0 0.001974458
nicotine B-Chemical 1 0.99935704
was O 0 0.0006109101
blocked O 0 0.00053784053
by O 0 0.00017018546
the O 0 0.0001368234
central O 0 0.00051908963
nicotinic O 0 0.99995244
antagonist O 0 0.99850297
mecamylamine B-Chemical 0 0.99999845
but O 0 0.00028236932
not O 0 6.827113e-05
by O 0 6.103801e-05
the O 0 7.7777455e-05
peripheral O 0 0.014146274
nicotinic O 0 0.99997234
blocker O 0 0.99983025
hexamethonium B-Chemical 0 0.9999988
, O 0 0.00037973444
indicating O 0 6.170618e-05
that O 0 4.7355385e-05
the O 0 7.3183975e-05
response O 0 0.00010100407
is O 0 0.00011901722
probably O 0 0.000188816
mediated O 0 0.0001298528
by O 0 0.0003611735
central O 0 0.0015525793
nicotinic O 0 0.99945515
receptors O 0 0.029400289
. O 0 0.0022746094

Nicotine B-Chemical 0 0.99969006
- O 0 0.007813239
induced O 0 0.0036876425
hyperactivity B-Disease 2 0.99985576
was O 0 0.0010803137
blocked O 0 0.00085609633
by O 0 0.00026955982
the O 0 0.00022696545
selective O 0 0.003699877
D1 O 0 0.9996605
antagonist O 0 0.9991014
SCH B-Chemical 0 0.9999981
23390 I-Chemical 0 0.99999464
, O 0 0.00027742275
the O 0 0.00012368636
selective O 0 0.0017813873
D2 O 0 0.9997025
antagonist O 0 0.9939579
raclopride B-Chemical 0 0.9999962
and O 0 0.00039929757
the O 0 0.00042822596
D1 O 0 0.9951852
/ O 0 0.0112185385
D2 O 0 0.99956304
antagonist O 0 0.9981194
fluphenazine B-Chemical 0 0.9999851
. O 0 0.0037825452

Pretreatment O 0 0.043906577
with O 0 0.0021539265
the O 0 0.0021611617
D2 O 0 0.999183
agonist O 0 0.9873302
PHNO B-Chemical 0 0.9999567
enhanced O 0 0.00520684
nicotine B-Chemical 1 0.99988675
- O 0 0.001557264
induced O 0 0.00079253985
hyperactivity B-Disease 2 0.99997234
, O 0 0.00036600305
whereas O 0 0.0001868791
the O 0 0.00037839217
D1 O 0 0.99941885
agonist O 0 0.99682
SKF B-Chemical 0 0.99999714
38393 I-Chemical 0 0.9999964
had O 0 0.0009862159
no O 0 0.0004958932
effect O 0 0.0011730382
. O 0 0.002011685

The O 0 0.0014085438
results O 0 0.0011315424
indicate O 0 0.000558245
that O 0 0.00064225716
acute O 0 0.7452775
nicotine B-Chemical 1 0.9997665
injection O 0 0.00084386277
induces O 0 0.00022488716
a O 0 0.00043522049
pronounced O 0 0.0010607141
hyperactivity B-Disease 2 0.99993515
in O 0 0.00026896043
rats O 0 0.000307624
habituated O 0 0.00025796925
to O 0 0.00019980152
the O 0 0.00038353264
test O 0 0.000823793
environment O 0 0.00137886
. O 0 0.0020088302

The O 0 0.001775214
effect O 0 0.0013173028
appears O 0 0.00080028677
to O 0 0.00058366195
be O 0 0.00037324242
mediated O 0 0.00020304424
by O 0 0.00029203252
central O 0 0.00069776137
nicotine B-Chemical 1 0.99961394
receptors O 0 0.0071896547
, O 0 0.00019952889
possibly O 0 0.00018681213
located O 0 6.725515e-05
on O 0 6.295544e-05
dopaminergic O 0 0.118129455
neurons O 0 0.000315203
, O 0 0.00011336608
and O 0 7.509086e-05
also O 0 5.6860663e-05
requires O 0 3.5653666e-05
the O 0 7.146166e-05
activation O 0 0.00013996242
of O 0 0.00023835643
both O 0 0.0004896364
D1 O 0 0.9955987
and O 0 0.0018257326
D2 O 0 0.9995664
dopamine B-Chemical 0 0.99976426
receptors O 0 0.026618348
. O 0 0.0022594412

Central O 0 0.0060762777
retinal B-Disease 0 0.37003985
vein I-Disease 0 0.020023583
occlusion I-Disease 0 0.029342173
associated O 0 0.0013450404
with O 0 0.0034725612
clomiphene B-Chemical 0 0.99975127
- O 0 0.0049138623
induced O 0 0.003973291
ovulation O 0 0.7450494
. O 0 0.004464445

OBJECTIVE O 0 0.029153962
: O 0 0.002566448
To O 0 0.0010285744
report O 0 0.0012265227
a O 0 0.0007855903
case O 0 0.0004174403
of O 0 0.00043805203
central O 0 0.0006224011
retinal B-Disease 0 0.7583221
vein I-Disease 0 0.024909692
occlusion I-Disease 0 0.028330896
associated O 0 0.0003179474
with O 0 0.0016447484
clomiphene B-Chemical 0 0.9999801
citrate I-Chemical 0 0.9993223
( O 0 0.006728628
CC B-Chemical 0 0.96632093
) O 0 0.0039695865
. O 0 0.0025764448

DESIGN O 0 0.020781644
: O 0 0.017581439
Case O 0 0.02547795
study O 0 0.019100677
. O 0 0.018978069

SETTING O 0 0.008207582
: O 0 0.0051675793
Ophthalmology O 0 0.008852379
clinic O 0 0.0034505283
of O 0 0.0029024193
an O 0 0.0038965875
academic O 0 0.0072027636
hospital O 0 0.008286303
. O 0 0.0059681423

PATIENT O 0 0.0049863416
( O 0 0.0049293474
S O 0 0.43886894
) O 0 0.0024976518
: O 0 0.0013961517
A O 0 0.0051600444
36 O 0 0.00064335443
- O 0 0.00073847745
year O 0 0.00023734478
- O 0 0.00041043322
old O 0 0.00023623399
woman O 0 0.00042193307
referred O 0 0.00020193259
from O 0 0.00014986441
the O 0 0.00031031805
infertility B-Disease 0 0.78047603
clinic O 0 0.0007905433
for O 0 0.00069587247
blurred B-Disease 0 0.9759149
vision I-Disease 0 0.99685466
. O 0 0.0043016057

INTERVENTION O 0 0.0065033794
( O 0 0.0060540233
S O 0 0.2960017
) O 0 0.003482375
: O 0 0.002252263
Ophthalmic O 0 0.0047299177
examination O 0 0.0014563451
after O 0 0.0011534523
CC B-Chemical 0 0.6470797
therapy O 0 0.0065334057
. O 0 0.0048330803

MAIN O 0 0.011729971
OUTCOME O 0 0.0041807187
MEASURE O 0 0.0039040851
( O 0 0.0024150466
S O 0 0.1455289
) O 0 0.0013205506
: O 0 0.0007399768
Central O 0 0.00070432544
retinal B-Disease 0 0.23685166
vein I-Disease 0 0.007615496
occlusion I-Disease 0 0.008746644
after O 0 0.00024187213
ovulation O 0 0.04671765
induction O 0 0.001190808
with O 0 0.0028751392
CC B-Chemical 0 0.93811077
. O 0 0.003553988

RESULT O 0 0.012890691
( O 0 0.005626366
S O 0 0.5278494
) O 0 0.0026045796
: O 0 0.0014238918
A O 0 0.0051501105
36 O 0 0.00063537376
- O 0 0.0007113686
year O 0 0.00022540151
- O 0 0.00038632096
old O 0 0.00023782205
Chinese O 0 0.0016598911
woman O 0 0.00049321866
developed O 0 0.0002488208
central O 0 0.00033014268
retinal B-Disease 0 0.6930927
vein I-Disease 0 0.010929072
occlusion I-Disease 0 0.004561861
after O 0 8.479729e-05
eight O 0 0.00017403564
courses O 0 0.00043525323
of O 0 0.0014654043
CC B-Chemical 0 0.88134927
. O 0 0.002925409

A O 0 0.012927079
search O 0 0.0018802395
of O 0 0.001058061
the O 0 0.0005748525
literature O 0 0.0005802852
on O 0 0.00021881169
the O 0 0.00054405874
thromboembolic B-Disease 0 0.9998764
complications O 0 0.20851703
of O 0 0.0009752678
CC B-Chemical 0 0.96325153
does O 0 0.00011405733
not O 0 6.9593276e-05
include O 0 5.2017156e-05
this O 0 0.000117824784
severe O 0 0.0037336973
ophthalmic O 0 0.31693798
complication O 0 0.029457396
, O 0 0.00017036828
although O 0 0.00011807267
mild O 0 0.15562855
visual B-Disease 0 0.6340285
disturbance I-Disease 0 0.4612432
after O 0 0.00017577439
CC B-Chemical 0 0.9738766
intake O 0 0.23442288
is O 0 0.00059224607
not O 0 0.00074111833
uncommon O 0 0.0044320147
. O 0 0.0021141756

CONCLUSION O 0 0.04741846
( O 0 0.00648069
S O 0 0.63715476
) O 0 0.002300539
: O 0 0.0009649934
This O 0 0.00076438044
is O 0 0.00033603708
the O 0 0.00021567736
first O 0 0.0001377086
reported O 0 0.00021163336
case O 0 0.00016174925
of O 0 0.00022366784
central O 0 0.0004171447
retinal B-Disease 0 0.8023181
vein I-Disease 0 0.022552123
occlusion I-Disease 0 0.0124862185
after O 0 0.00014637447
treatment O 0 0.0005187847
with O 0 0.0017756271
CC B-Chemical 0 0.9181444
. O 0 0.0029341255

Extra O 0 0.0067903274
caution O 0 0.0013176015
is O 0 0.00081994926
warranted O 0 0.0004697006
in O 0 0.00042036854
treating O 0 0.0012376634
infertility B-Disease 0 0.95015275
patients O 0 0.00068893953
with O 0 0.00058846833
CC B-Chemical 0 0.96835035
, O 0 0.00023297919
and O 0 0.00014043512
patients O 0 0.00014742572
should O 0 4.2897424e-05
be O 0 6.1950566e-05
well O 0 6.724726e-05
informed O 0 0.00028858552
of O 0 0.00012422477
this O 0 0.0001842903
side O 0 0.0011766742
effect O 0 0.00016055546
before O 0 0.000121049045
commencement O 0 0.00032168336
of O 0 0.000878293
therapy O 0 0.0022659365
. O 0 0.0020745858

Acute O 0 0.13996068
bronchodilating O 0 0.94744396
effects O 0 0.0017782543
of O 0 0.0035102824
ipratropium B-Chemical 0 0.9999703
bromide I-Chemical 0 0.99994075
and O 0 0.0054482073
theophylline B-Chemical 0 0.99996483
in O 0 0.0015930465
chronic B-Disease 0 0.8172005
obstructive I-Disease 0 0.99789953
pulmonary I-Disease 0 0.9774329
disease I-Disease 0 0.85937434
. O 0 0.0034725233

The O 0 0.0018256084
bronchodilator O 0 0.021994188
effects O 0 0.000974644
of O 0 0.0006933626
a O 0 0.00047848327
single O 0 0.00028447024
dose O 0 0.0010238669
of O 0 0.00094290567
ipratropium B-Chemical 0 0.99998665
bromide I-Chemical 0 0.99996996
aerosol O 0 0.070715524
( O 0 0.00031605642
36 O 0 0.0001027729
micrograms O 0 0.00072469306
) O 0 0.00013759834
and O 0 6.282022e-05
short O 0 5.52559e-05
- O 0 0.00014998564
acting O 0 0.00025571953
theophylline B-Chemical 0 0.9999852
tablets O 0 0.5530506
( O 0 0.00018364319
dose O 0 0.00031549405
titrated O 0 0.00012938201
to O 0 4.684527e-05
produce O 0 4.3516706e-05
serum O 0 0.0027257353
levels O 0 9.5394265e-05
of O 0 0.00012834798
10 O 0 8.293666e-05
- O 0 0.00013446565
20 O 0 6.659886e-05
micrograms O 0 0.00059541437
/ O 0 0.0004475502
mL O 0 0.00062774756
) O 0 0.00013331014
were O 0 5.435319e-05
compared O 0 3.3168966e-05
in O 0 5.0401693e-05
a O 0 0.000104277045
double O 0 0.00022094545
- O 0 0.00030162977
blind O 0 0.0055199875
, O 0 0.00014275694
placebo O 0 0.0006870597
- O 0 0.0001337012
controlled O 0 6.499693e-05
crossover O 0 0.00053900236
study O 0 7.631913e-05
in O 0 5.629722e-05
21 O 0 7.260037e-05
patients O 0 9.7824945e-05
with O 0 0.00012136042
stable O 0 0.00022975214
, O 0 0.00040226214
chronic B-Disease 0 0.3398438
obstructive I-Disease 0 0.9948756
pulmonary I-Disease 0 0.9622233
disease I-Disease 0 0.8110018
. O 0 0.002802411

Mean O 0 0.0012431252
peak O 0 0.0015764243
forced O 0 0.0026342608
expiratory O 0 0.006233959
volume O 0 0.00096122205
in O 0 0.00031445175
1 O 0 0.00020077087
second O 0 0.00019015244
( O 0 0.00033250853
FEV1 O 0 0.0067726597
) O 0 0.00020359832
increases O 0 8.461579e-05
over O 0 3.8549442e-05
baseline O 0 5.637092e-05
and O 0 6.22443e-05
the O 0 5.7312176e-05
proportion O 0 6.0441987e-05
of O 0 9.3296694e-05
patients O 0 0.00011979855
attaining O 0 0.0003636147
at O 0 4.3776057e-05
least O 0 4.8053767e-05
a O 0 8.574001e-05
15 O 0 4.547027e-05
% O 0 5.571454e-05
increase O 0 4.8064216e-05
in O 0 4.9200262e-05
the O 0 7.887886e-05
FEV1 O 0 0.0122503415
( O 0 0.000152478
responders O 0 0.00036045926
) O 0 0.00014018532
were O 0 7.678662e-05
31 O 0 9.79167e-05
% O 0 6.6342654e-05
and O 0 6.116923e-05
90 O 0 7.151415e-05
% O 0 9.254469e-05
, O 0 0.000110490786
respectively O 0 0.00022794741
, O 0 0.00011512949
for O 0 0.00011526044
ipratropium B-Chemical 0 0.9994037
and O 0 0.00020711603
17 O 0 0.00017564741
% O 0 0.0001151809
and O 0 0.00012253417
50 O 0 0.0002502755
% O 0 0.00023178008
, O 0 0.000317602
respectively O 0 0.00072009856
, O 0 0.00067281205
for O 0 0.0010756114
theophylline B-Chemical 0 0.9997515
. O 0 0.0038014122

The O 0 0.0014155983
average O 0 0.0010156651
FEV1 O 0 0.006793342
increases O 0 0.00056243537
during O 0 0.00023942557
the O 0 0.00029159235
6 O 0 0.00016665929
- O 0 0.00025144845
hour O 0 9.0429436e-05
observation O 0 0.000103205006
period O 0 5.8657733e-05
were O 0 9.753127e-05
18 O 0 9.2402624e-05
% O 0 0.000119894314
for O 0 0.0001593928
ipratropium B-Chemical 0 0.9984267
and O 0 0.00041502583
8 O 0 0.00029519937
% O 0 0.0004975515
for O 0 0.0008995205
theophylline B-Chemical 0 0.99967265
. O 0 0.0037492213

The O 0 0.0011762024
mean O 0 0.0005759913
duration O 0 0.0004226001
of O 0 0.0006585794
action O 0 0.00081945054
was O 0 0.00048674352
3 O 0 0.00019356611
. O 0 0.00010864456
8 O 0 8.967874e-05
hours O 0 7.1669674e-05
with O 0 0.00027434088
ipratropium B-Chemical 0 0.99920386
and O 0 0.0003306731
2 O 0 0.00016941737
. O 0 0.000121031044
4 O 0 0.00015466895
hours O 0 0.00022397004
with O 0 0.0012397227
theophylline B-Chemical 0 0.99963796
. O 0 0.0036899208

While O 0 0.0025120848
side O 0 0.007139493
effects O 0 0.0015558382
were O 0 0.0010088384
rare O 0 0.0017339126
, O 0 0.0005249214
those O 0 0.00036572228
experienced O 0 0.00029624673
after O 0 0.00014837115
theophylline B-Chemical 0 0.99989676
use O 0 0.0003011947
did O 0 0.00024401846
involve O 0 0.00016513612
the O 0 0.00033896908
cardiovascular B-Disease 0 0.38438645
and I-Disease 0 0.0011193383
gastrointestinal I-Disease 0 0.5590372
systems I-Disease 0 0.0020805022
. O 0 0.0021313508

These O 0 0.0019059896
results O 0 0.0012027799
show O 0 0.0006754143
that O 0 0.00072935974
ipratropium B-Chemical 0 0.9995276
is O 0 0.0005102808
a O 0 0.0003358883
more O 0 0.00027391384
potent O 0 0.0005300668
bronchodilator O 0 0.10689157
than O 0 0.0001607339
oral O 0 0.10621801
theophylline B-Chemical 0 0.9999585
in O 0 0.00031529198
patients O 0 0.00045709475
with O 0 0.00065111485
chronic B-Disease 0 0.8283601
airflow I-Disease 0 0.86184937
obstruction I-Disease 0 0.9671262
. O 0 0.0030032634

Methamphetamine B-Chemical 1 0.99963963
- O 0 0.009814904
induced O 0 0.00446754
neurotoxicity B-Disease 2 0.99980813
and O 0 0.002001801
microglial O 0 0.08456755
activation O 0 0.0008300898
are O 0 0.0003393209
not O 0 0.00026786485
mediated O 0 0.00028419343
by O 0 0.0008366506
fractalkine O 0 0.89615524
receptor O 0 0.07330327
signaling O 0 0.0027924876
. O 0 0.0026712343

Methamphetamine B-Chemical 1 0.9996087
( O 0 0.017269786
METH B-Chemical 0 0.9999211
) O 0 0.0057331272
damages O 0 0.66225916
dopamine B-Chemical 0 0.9998833
( O 0 0.0031586345
DA B-Chemical 0 0.99966824
) O 0 0.0010019906
nerve O 0 0.0053950353
endings O 0 0.0017590221
by O 0 0.00014958858
a O 0 0.0001389914
process O 0 9.010244e-05
that O 0 6.741509e-05
has O 0 6.652587e-05
been O 0 5.6955527e-05
linked O 0 7.070775e-05
to O 0 8.255933e-05
microglial O 0 0.010944175
activation O 0 0.00021090153
but O 0 0.00010556205
the O 0 6.580714e-05
signaling O 0 6.86731e-05
pathways O 0 6.8181354e-05
that O 0 4.144876e-05
mediate O 0 3.293468e-05
this O 0 0.00010662511
response O 0 0.0001427489
have O 0 0.00014260391
not O 0 0.0002473175
yet O 0 0.0005354686
been O 0 0.0006204202
delineated O 0 0.0017688652
. O 0 0.0018315816

Cardona O 0 0.10953227
et O 0 0.035875775
al O 0 0.041334193
. O 0 0.032082528

[ O 0 0.011074756
Nat O 0 0.012174751
. O 0 0.0017058745
Neurosci O 0 0.019787954
. O 0 0.0005997859
9 O 0 0.00046464507
( O 0 0.00056017766
2006 O 0 0.0006251236
) O 0 0.0005929509
, O 0 0.00046117156
917 O 0 0.047321707
] O 0 0.00048500646
recently O 0 0.00010298804
identified O 0 9.697973e-05
the O 0 0.00014015887
microglial O 0 0.033155654
- O 0 0.00039451147
specific O 0 0.00013731065
fractalkine O 0 0.9446121
receptor O 0 0.17339516
( O 0 0.00091310637
CX3CR1 O 0 0.98704356
) O 0 0.0002652144
as O 0 6.9804104e-05
an O 0 8.237586e-05
important O 0 5.1111267e-05
mediator O 0 0.00025836285
of O 0 0.0015737667
MPTP B-Chemical 0 0.9999975
- O 0 0.0025750836
induced O 0 0.0013388711
neurodegeneration B-Disease 0 0.99971336
of O 0 0.0074575017
DA B-Chemical 0 0.99948573
neurons O 0 0.005813755
. O 0 0.0022623518

Because O 0 0.0017279537
the O 0 0.0023960501
CNS B-Disease 0 0.8253363
damage I-Disease 0 0.92758423
caused O 0 0.0018758132
by O 0 0.0024159623
METH B-Chemical 0 0.9999902
and O 0 0.01188466
MPTP B-Chemical 0 0.99999654
is O 0 0.00034007512
highly O 0 0.00014094342
selective O 0 0.00029152288
for O 0 7.141806e-05
the O 0 0.00017326404
DA B-Chemical 0 0.9992901
neuronal O 0 0.0048432075
system O 0 0.00011015709
in O 0 6.800007e-05
mouse O 0 0.0001158358
models O 0 0.00012297147
of O 0 0.00039786988
neurotoxicity B-Disease 2 0.9999578
, O 0 0.00019127346
we O 0 3.4386667e-05
hypothesized O 0 3.364386e-05
that O 0 5.218584e-05
the O 0 0.00015329364
CX3CR1 O 0 0.91248554
plays O 0 8.034594e-05
a O 0 0.00012932008
role O 0 7.589644e-05
in O 0 0.00032649803
METH B-Chemical 0 0.9999883
- O 0 0.0017100371
induced O 0 0.0013408541
neurotoxicity B-Disease 2 0.99993145
and O 0 0.002017454
microglial O 0 0.26451167
activation O 0 0.003742665
. O 0 0.0024259076

Mice O 0 0.001593227
in O 0 0.0012019114
which O 0 0.0011594893
the O 0 0.0011976685
CX3CR1 O 0 0.942767
gene O 0 0.0012390066
has O 0 0.0002516888
been O 0 0.00016191947
deleted O 0 0.00022550943
and O 0 0.00015396765
replaced O 0 0.00013530967
with O 0 0.00016254486
a O 0 0.00017499378
cDNA O 0 0.00017941931
encoding O 0 0.00010325915
enhanced O 0 0.00022033896
green O 0 0.0014445619
fluorescent O 0 0.00063725194
protein O 0 0.00035721145
( O 0 0.00021139681
eGFP O 0 0.0003215328
) O 0 0.00015332407
were O 0 8.214298e-05
treated O 0 0.00016168726
with O 0 0.0004062025
METH B-Chemical 0 0.9999633
and O 0 0.00032466176
examined O 0 0.00021255208
for O 0 0.0004943065
striatal O 0 0.96177804
neurotoxicity B-Disease 2 0.9998622
. O 0 0.0041349265

METH B-Chemical 0 0.99975115
depleted O 0 0.0112311235
DA B-Chemical 0 0.99949193
, O 0 0.0017928777
caused O 0 0.0009657075
microglial O 0 0.059245616
activation O 0 0.00073981215
, O 0 0.00032448285
and O 0 0.00018092127
increased O 0 0.00027169182
body O 0 0.00082494854
temperature O 0 0.0012035422
in O 0 0.00026137667
CX3CR1 O 0 0.9694931
knockout O 0 0.00028842656
mice O 0 5.214032e-05
to O 0 4.7909085e-05
the O 0 4.665028e-05
same O 0 2.7219961e-05
extent O 0 3.7945443e-05
and O 0 5.3565756e-05
over O 0 2.4973848e-05
the O 0 4.2685344e-05
same O 0 3.04242e-05
time O 0 3.7198908e-05
course O 0 7.5156626e-05
seen O 0 0.00012578243
in O 0 0.00018294116
wild O 0 0.00039848365
- O 0 0.00077255146
type O 0 0.0008154597
controls O 0 0.002198693
. O 0 0.0019598354

The O 0 0.0015833201
effects O 0 0.0018088571
of O 0 0.0036356188
METH B-Chemical 0 0.99995184
in O 0 0.0026935055
CX3CR1 O 0 0.98842037
knockout O 0 0.00082446676
mice O 0 0.00015987031
were O 0 0.00015790954
not O 0 0.0001356334
gender O 0 0.00031005868
- O 0 0.00023290236
dependent O 0 7.388308e-05
and O 0 0.00016456067
did O 0 0.00019851782
not O 0 0.00018421229
extend O 0 0.00022603832
beyond O 0 0.00033668758
the O 0 0.00085631787
striatum O 0 0.047010407
. O 0 0.0024594082

Striatal O 0 0.89706385
microglia O 0 0.009040326
expressing O 0 0.00084490556
eGFP O 0 0.0011965705
constitutively O 0 0.00035702868
show O 0 0.00023571786
morphological O 0 0.00069917657
changes O 0 0.0003395686
after O 0 0.00019680223
METH B-Chemical 0 0.9998741
that O 0 0.00034264836
are O 0 0.00038960553
characteristic O 0 0.00052156055
of O 0 0.0010001222
activation O 0 0.0024091767
. O 0 0.0025481961

This O 0 0.0032964635
response O 0 0.0016088953
was O 0 0.0009668053
restricted O 0 0.0003790012
to O 0 0.0003136224
the O 0 0.00032344263
striatum O 0 0.0045097545
and O 0 0.00024633287
contrasted O 0 0.00034373166
sharply O 0 0.0005073925
with O 0 0.00020059291
unresponsive O 0 0.0002991565
eGFP O 0 0.0007046665
- O 0 0.00034357863
microglia O 0 0.0008100245
in O 0 9.083721e-05
surrounding O 0 0.00010230951
brain O 0 0.0005685615
areas O 0 0.0001281567
that O 0 9.927061e-05
are O 0 0.00017618937
not O 0 0.0002765837
damaged O 0 0.0025555706
by O 0 0.0022465438
METH B-Chemical 0 0.99989164
. O 0 0.0036505281

We O 0 0.001438775
conclude O 0 0.0008490231
from O 0 0.00073352
these O 0 0.0007847004
studies O 0 0.0005540995
that O 0 0.00045024365
CX3CR1 O 0 0.90088475
signaling O 0 0.00037597204
does O 0 0.00022765856
not O 0 0.00021864673
modulate O 0 0.00022586297
METH B-Chemical 0 0.9999838
neurotoxicity B-Disease 2 0.9999573
or O 0 0.0020034246
microglial O 0 0.2753092
activation O 0 0.0041032736
. O 0 0.0026802449

Furthermore O 0 0.0030993123
, O 0 0.0022228686
it O 0 0.0010358648
appears O 0 0.0005109822
that O 0 0.00046170267
striatal O 0 0.6094056
- O 0 0.0009264921
resident O 0 0.0003415989
microglia O 0 0.0010771147
respond O 0 0.00010373781
to O 0 0.00021202155
METH B-Chemical 0 0.9999765
with O 0 0.00023905968
an O 0 0.00014134868
activation O 0 0.00014168088
cascade O 0 0.00014592255
and O 0 7.999489e-05
then O 0 5.6918445e-05
return O 0 9.264862e-05
to O 0 6.7903e-05
a O 0 0.00013555853
surveying O 0 0.0002911926
state O 0 0.00017980547
without O 0 0.00020335542
undergoing O 0 0.0005405536
apoptosis O 0 0.31185782
or O 0 0.0009620314
migration O 0 0.006567216
. O 0 0.0022354024

Nicotine B-Chemical 0 0.9993999
- O 0 0.010280467
induced O 0 0.005480881
nystagmus B-Disease 0 0.99623483
correlates O 0 0.0028552427
with O 0 0.0038011088
midpontine O 0 0.1474229
activation O 0 0.006448549
. O 0 0.0053289

The O 0 0.0028762151
pathomechanism O 0 0.06880794
of O 0 0.0050857905
nicotine B-Chemical 1 0.99933237
- O 0 0.0053585363
induced O 0 0.003769097
nystagmus B-Disease 0 0.9997116
( O 0 0.008537038
NIN B-Disease 0 0.97257555
) O 0 0.0028808233
is O 0 0.0019441711
unknown O 0 0.0039560436
. O 0 0.003535992

The O 0 0.0016563664
aim O 0 0.0015469438
of O 0 0.00127399
this O 0 0.00095336547
study O 0 0.00076067966
was O 0 0.00042595906
to O 0 0.0002278464
delineate O 0 0.00018742784
brain O 0 0.0008789
structures O 0 0.00025099338
that O 0 0.00018591581
are O 0 0.00028137254
involved O 0 0.00031570438
in O 0 0.0008010597
NIN B-Disease 0 0.76961195
generation O 0 0.0034043577
. O 0 0.0027626783

Eight O 0 0.002727774
healthy O 0 0.0028773192
volunteers O 0 0.0017366533
inhaled O 0 0.45894733
nicotine B-Chemical 1 0.99913555
in O 0 0.00042272583
darkness O 0 0.0020021684
during O 0 7.271288e-05
a O 0 0.00012868398
functional O 0 0.000119321994
magnetic O 0 0.00061187544
resonance O 0 0.0023578496
imaging O 0 0.00023348488
( O 0 0.00013791319
fMRI O 0 0.00019718446
) O 0 0.00014647206
experiment O 0 8.459828e-05
; O 0 0.00017392715
eye O 0 0.0017298218
movements O 0 0.00034856703
were O 0 0.00019704107
registered O 0 0.00030719314
using O 0 0.00031336062
video O 0 0.0014578908
- O 0 0.002045136
oculography O 0 0.06255172
. O 0 0.0025597322

NIN B-Disease 0 0.6573231
correlated O 0 0.0014309973
with O 0 0.0016065774
blood O 0 0.013975027
oxygen B-Chemical 1 0.9831565
level O 0 0.00056475174
- O 0 0.0005910872
dependent O 0 0.00013511433
( O 0 0.0002961654
BOLD O 0 0.0008765983
) O 0 0.0002807771
activity O 0 0.00013443912
levels O 0 0.00015230855
in O 0 0.00015306886
a O 0 0.00029417445
midpontine O 0 0.0069452454
site O 0 0.0001787968
in O 0 0.00020168799
the O 0 0.0003146227
posterior O 0 0.0014635983
basis O 0 0.0009206684
pontis O 0 0.0015482147
. O 0 0.0018975321

NIN B-Disease 0 0.9606752
- O 0 0.0051214644
induced O 0 0.001827502
midpontine O 0 0.022042518
activation O 0 0.0007674131
may O 0 0.00027015363
correspond O 0 0.00013390637
to O 0 0.00012268196
activation O 0 0.00015996148
of O 0 0.00014538699
the O 0 0.00011128986
dorsomedial O 0 0.00039686437
pontine O 0 0.0008919826
nuclei O 0 0.00012751637
and O 0 6.380639e-05
the O 0 5.698057e-05
nucleus O 0 5.4504697e-05
reticularis O 0 0.00011191487
tegmenti O 0 2.7530254e-05
pontis O 0 4.733944e-05
, O 0 5.56815e-05
structures O 0 5.7900517e-05
known O 0 7.538848e-05
to O 0 5.5377965e-05
participate O 0 5.606588e-05
in O 0 5.4851018e-05
the O 0 6.65868e-05
generation O 0 0.00012234201
of O 0 0.00016971162
multidirectional O 0 0.0012888629
saccades O 0 0.0039051552
and O 0 0.0003364102
smooth O 0 0.0018978665
pursuit O 0 0.0025676151
eye O 0 0.03489978
movements O 0 0.0033482206
. O 0 0.0021036481

Acute O 0 0.035934296
effects O 0 0.0028271258
of O 0 0.0045132963
N B-Chemical 0 0.99444807
- I-Chemical 0 0.0028708924
( I-Chemical 0 0.00086780154
2 I-Chemical 0 0.00035185192
- I-Chemical 0 0.0006022149
propylpentanoyl I-Chemical 0 0.0040044733
) I-Chemical 0 0.00074122753
urea I-Chemical 0 0.9937109
on O 0 0.0001475084
hippocampal O 0 0.42990816
amino B-Chemical 0 0.9969156
acid I-Chemical 0 0.99917513
neurotransmitters O 0 0.42136616
in O 0 0.0008087138
pilocarpine B-Chemical 1 0.9999852
- O 0 0.0020235423
induced O 0 0.0011789466
seizure B-Disease 0 0.9993749
in O 0 0.0013327211
rats O 0 0.00264808
. O 0 0.0018746102

The O 0 0.0014005543
present O 0 0.0009059147
study O 0 0.00080341654
aimed O 0 0.0006258108
to O 0 0.00030945832
investigate O 0 0.00017382966
the O 0 0.00038196828
anticonvulsant O 0 0.9973308
activity O 0 0.00027386367
as O 0 0.00013532142
well O 0 8.165283e-05
as O 0 6.694372e-05
the O 0 5.88139e-05
effects O 0 6.83943e-05
on O 0 3.5475405e-05
the O 0 5.2233638e-05
level O 0 4.6695008e-05
of O 0 0.0001294637
hippocampal O 0 0.56871426
amino B-Chemical 0 0.9983487
acid I-Chemical 0 0.99959224
neurotransmitters O 0 0.6657087
( O 0 0.0013865234
glutamate B-Chemical 1 0.99994373
, O 0 0.0010554082
aspartate B-Chemical 1 0.99994123
, O 0 0.0015068924
glycine B-Chemical 0 0.9998938
and O 0 0.0018249995
GABA B-Chemical 0 0.99998987
) O 0 0.00065760885
of O 0 0.00054170785
N B-Chemical 0 0.9931752
- I-Chemical 0 0.0005765711
( I-Chemical 0 0.00018940419
2 I-Chemical 0 8.968832e-05
- I-Chemical 0 0.00021460188
propylpentanoyl I-Chemical 0 0.0036892672
) I-Chemical 0 0.0006704338
urea I-Chemical 0 0.9996892
( O 0 0.00092797977
VPU B-Chemical 0 0.9891567
) O 0 0.00026043737
in O 0 7.54879e-05
comparison O 0 6.476676e-05
to O 0 7.119897e-05
its O 0 0.00020018803
parent O 0 0.00037210074
compound O 0 0.13205262
, O 0 0.0013074882
valproic B-Chemical 0 0.9999852
acid I-Chemical 0 0.9972228
( O 0 0.018490497
VPA B-Chemical 1 0.9999509
) O 0 0.007404142
. O 0 0.002863167

VPU B-Chemical 0 0.97530603
was O 0 0.0024333796
more O 0 0.0014311036
potent O 0 0.0018844338
than O 0 0.00094936497
VPA B-Chemical 1 0.9999571
, O 0 0.0006379398
exhibiting O 0 0.0003558273
the O 0 0.00013440463
median O 0 6.6317545e-05
effective O 0 9.699378e-05
dose O 0 0.0009393941
( O 0 0.00039614862
ED O 0 0.08681819
( O 0 0.00023816242
50 O 0 0.00023607323
) O 0 0.00019692743
) O 0 0.0001288693
of O 0 0.00010236289
49 O 0 0.00016633351
mg O 0 0.0020083217
/ O 0 0.00035393424
kg O 0 0.00020696169
in O 0 6.4064276e-05
protecting O 0 0.0002508297
rats O 0 0.00017965144
against O 0 0.00012496459
pilocarpine B-Chemical 1 0.9999912
- O 0 0.0009954248
induced O 0 0.00035710182
seizure B-Disease 0 0.99942064
whereas O 0 0.00013784379
the O 0 7.397825e-05
corresponding O 0 6.562715e-05
value O 0 0.0001263708
for O 0 0.00020277571
VPA B-Chemical 1 0.9999566
was O 0 0.0008144776
322 O 0 0.0042319978
mg O 0 0.020069223
/ O 0 0.002950352
kg O 0 0.003125018
. O 0 0.0020044756

In O 0 0.0018291458
vivo O 0 0.002046137
microdialysis O 0 0.004677234
demonstrated O 0 0.00036405568
that O 0 0.0001933396
an O 0 0.00028664657
intraperitoneal O 0 0.0011757945
administration O 0 0.0018648267
of O 0 0.000977111
pilocarpine B-Chemical 1 0.99998736
induced O 0 0.00041149586
a O 0 0.00019574095
pronounced O 0 0.00013949953
increment O 0 0.00011116281
of O 0 0.00016408543
hippocampal O 0 0.7809668
glutamate B-Chemical 1 0.99997306
and O 0 0.0009840089
aspartate B-Chemical 1 0.9998944
whereas O 0 0.00017962215
no O 0 5.7643894e-05
significant O 0 8.420391e-05
change O 0 9.182474e-05
was O 0 9.3928706e-05
observed O 0 6.39893e-05
on O 0 5.6729e-05
the O 0 0.00012324759
level O 0 0.00019491292
of O 0 0.0011041379
glycine B-Chemical 0 0.99956745
and O 0 0.009591725
GABA B-Chemical 0 0.99985635
. O 0 0.0041620443

Pretreatment O 0 0.060599167
with O 0 0.0024042833
either O 0 0.0019146649
VPU B-Chemical 0 0.9876993
( O 0 0.0010647075
50 O 0 0.00056928274
and O 0 0.0002928388
100 O 0 0.0006215584
mg O 0 0.008181021
/ O 0 0.0008747564
kg O 0 0.0006249737
) O 0 0.00028509743
or O 0 0.00023235248
VPA B-Chemical 1 0.9999759
( O 0 0.00037790858
300 O 0 0.00034784203
and O 0 0.000109960405
600 O 0 0.0004896825
mg O 0 0.0034842286
/ O 0 0.0004689182
kg O 0 0.0003438339
) O 0 0.00016078357
completely O 0 0.0001635531
abolished O 0 0.0011946708
pilocarpine B-Chemical 1 0.9999896
- O 0 0.0010066436
evoked O 0 0.0008452743
increases O 0 0.0002314837
in O 0 0.0002849034
extracellular O 0 0.0025598549
glutamate B-Chemical 1 0.9997646
and O 0 0.0048593585
aspartate B-Chemical 1 0.99965227
. O 0 0.004033048

In O 0 0.0018218645
addition O 0 0.0010912406
, O 0 0.001303528
a O 0 0.0009793153
statistically O 0 0.0005598534
significant O 0 0.00036324814
reduction O 0 0.00069956115
was O 0 0.00024023572
also O 0 0.00012075231
observed O 0 8.3675935e-05
on O 0 4.9784176e-05
the O 0 7.659625e-05
level O 0 8.534503e-05
of O 0 0.0005357152
GABA B-Chemical 0 0.99998796
and O 0 0.0014800697
glycine B-Chemical 0 0.9998275
but O 0 0.00028074151
less O 0 0.00013557223
than O 0 7.4356496e-05
a O 0 0.0001598389
drastic O 0 0.0005022467
reduction O 0 0.0008465133
of O 0 0.001316376
glutamate B-Chemical 1 0.9998548
and O 0 0.0030963144
aspartate B-Chemical 1 0.9996302
level O 0 0.0024952032
. O 0 0.0025743956

Based O 0 0.0029804572
on O 0 0.0009015146
the O 0 0.00086546916
finding O 0 0.0010169549
that O 0 0.00061797583
VPU B-Chemical 0 0.995612
and O 0 0.0021264623
VPA B-Chemical 1 0.9999825
could O 0 0.0002798591
protect O 0 0.00023368909
the O 0 0.00012236557
animals O 0 8.8784356e-05
against O 0 0.00015156825
pilocarpine B-Chemical 1 0.9999919
- O 0 0.0016937339
induced O 0 0.0005627475
seizure B-Disease 0 0.9998287
it O 0 0.0002110663
is O 0 6.853394e-05
suggested O 0 3.0953906e-05
that O 0 2.9344821e-05
the O 0 4.7142395e-05
reduction O 0 0.00014915018
of O 0 0.00013344634
inhibitory O 0 0.0045975503
amino B-Chemical 0 0.9983962
acid I-Chemical 0 0.99956304
neurotransmitters O 0 0.2861198
was O 0 0.00017140002
comparatively O 0 0.00040693197
minor O 0 0.0003473612
and O 0 0.00010682837
offset O 0 0.00021876518
by O 0 0.00012876195
a O 0 0.00018624688
pronounced O 0 0.0003021052
reduction O 0 0.00086361804
of O 0 0.0015656316
glutamate B-Chemical 1 0.99982953
and O 0 0.0055517177
aspartate B-Chemical 1 0.99968076
. O 0 0.00401032

Therefore O 0 0.002182487
, O 0 0.002512128
like O 0 0.0018622156
VPA B-Chemical 1 0.99991727
, O 0 0.001227329
the O 0 0.00045105218
finding O 0 0.0005677557
that O 0 0.00029259382
VPU B-Chemical 0 0.98773926
could O 0 0.00019873827
drastically O 0 0.00078532984
reduce O 0 0.00029605476
pilocarpine B-Chemical 1 0.9999918
- O 0 0.0008722
induced O 0 0.00015836053
increases O 0 0.00015196635
in O 0 0.00024381888
glutamate B-Chemical 1 0.99992156
and O 0 0.0006183877
aspartate B-Chemical 1 0.99976677
should O 0 5.4239274e-05
account O 0 6.479826e-05
, O 0 6.4653344e-05
at O 0 3.366835e-05
least O 0 4.407417e-05
partly O 0 0.00012431198
, O 0 7.317937e-05
for O 0 4.7036858e-05
its O 0 0.00025276563
anticonvulsant O 0 0.99350077
activity O 0 0.00011220756
observed O 0 0.00010327462
in O 0 0.00027390654
pilocarpine B-Chemical 1 0.9999869
- O 0 0.0013202161
induced O 0 0.00070351333
seizure B-Disease 0 0.9992742
in O 0 0.0005596184
experimental O 0 0.00091601
animals O 0 0.0009744787
. O 0 0.0016556304

Some O 0 0.0031565756
other O 0 0.0015180475
mechanism O 0 0.0012520523
than O 0 0.0006595207
those O 0 0.00086092605
being O 0 0.00077000255
reported O 0 0.00062312256
herein O 0 0.0007980128
should O 0 0.00039390402
be O 0 0.0006487527
further O 0 0.0012764547
investigated O 0 0.0017398684
. O 0 0.002862598

Protective O 0 0.03505233
effect O 0 0.0020590299
of O 0 0.0038492738
verapamil B-Chemical 0 0.99993265
on O 0 0.00214736
gastric B-Disease 0 0.9985953
hemorrhagic I-Disease 2 0.9999808
ulcers B-Disease 0 0.9998739
in O 0 0.0022297665
severe O 0 0.25145182
atherosclerotic B-Disease 2 0.99900705
rats O 0 0.008123018
. O 0 0.0029660221

Studies O 0 0.003949662
concerning O 0 0.0011861409
with O 0 0.0012236964
pathogenesis O 0 0.0019420895
of O 0 0.0018793931
gastric B-Disease 0 0.99557316
hemorrhage I-Disease 2 0.99997663
and O 0 0.0019026623
mucosal O 0 0.49172214
ulceration O 0 0.9945556
produced O 0 0.0004640856
in O 0 0.0005728889
atherosclerotic B-Disease 2 0.9947431
rats O 0 0.0015038004
are O 0 0.0007782232
lacking O 0 0.0011140195
. O 0 0.0019946215

The O 0 0.0015825116
aim O 0 0.0014682622
of O 0 0.0011994895
this O 0 0.0008735508
study O 0 0.0006521191
is O 0 0.00030099202
to O 0 0.00015622766
examine O 0 7.34708e-05
the O 0 0.00011352131
role O 0 8.431857e-05
of O 0 0.00035359414
gastric O 0 0.57080775
acid O 0 0.9591896
back O 0 0.0011495673
- O 0 0.00043699477
diffusion O 0 0.0015677185
, O 0 0.00027074307
mast O 0 0.33667633
cell O 0 0.016360583
histamine B-Chemical 1 0.9999436
release O 0 0.006328472
, O 0 0.00039663853
lipid O 0 0.96257234
peroxide O 0 0.9999621
( O 0 0.011322643
LPO O 0 0.99999785
) O 0 0.00044529245
generation O 0 0.00016152332
and O 0 0.00012362706
mucosal O 0 0.016070655
microvascular O 0 0.7566977
permeability O 0 0.44241285
in O 0 8.746737e-05
modulating O 0 0.00010285093
gastric B-Disease 0 0.990294
hemorrhage I-Disease 2 0.99999297
and O 0 0.0008614258
ulcer B-Disease 0 0.9918494
in O 0 9.638186e-05
rats O 0 0.00015963572
with O 0 0.0002628759
atherosclerosis B-Disease 2 0.9998996
induced O 0 0.0003387704
by O 0 0.00031425635
coadministration O 0 0.9744648
of O 0 0.007861302
vitamin B-Chemical 0 0.99999475
D2 I-Chemical 0 0.9999403
and O 0 0.007128063
cholesterol B-Chemical 0 0.9997125
. O 0 0.0038113461

Additionally O 0 0.002914389
, O 0 0.002114353
the O 0 0.0011285106
protective O 0 0.0018456427
effect O 0 0.00077862374
of O 0 0.0021329639
verapamil B-Chemical 0 0.999956
on O 0 0.00066023
this O 0 0.0018769375
ulcer B-Disease 0 0.9928814
model O 0 0.001509875
was O 0 0.0014653108
evaluated O 0 0.0016317042
. O 0 0.0026390385

Male O 0 0.010257485
Wistar O 0 0.005799936
rats O 0 0.0012135301
were O 0 0.000426704
challenged O 0 0.00026988023
intragastrically O 0 0.0013176692
once O 0 0.00013435633
daily O 0 0.0001585789
for O 0 7.2659095e-05
9 O 0 6.584041e-05
days O 0 3.458392e-05
with O 0 8.482389e-05
1 O 0 6.678852e-05
. O 0 4.340542e-05
0 O 0 5.7568308e-05
ml O 0 0.00018344946
/ O 0 0.00023529821
kg O 0 0.00022566666
of O 0 0.00021780551
corn O 0 0.97228324
oil O 0 0.9805013
containing O 0 0.0011387955
vitamin B-Chemical 0 0.9999964
D2 I-Chemical 0 0.9999614
and O 0 0.0020245768
cholesterol B-Chemical 0 0.9997795
to O 0 0.0010173842
induce O 0 0.0014572748
atherosclerosis B-Disease 2 0.9997913
. O 0 0.0040827477

Control O 0 0.0073326817
rats O 0 0.0062362934
received O 0 0.0051817745
corn O 0 0.9634101
oil O 0 0.9735623
only O 0 0.012180791
. O 0 0.009259207

After O 0 0.001624281
gastric O 0 0.029815447
surgery O 0 0.0017357672
, O 0 0.0008883524
rat O 0 0.0011482288
stomachs O 0 0.0026683472
were O 0 0.00027798963
irrigated O 0 0.0009814828
for O 0 0.00010780955
3 O 0 8.3731335e-05
h O 0 7.579178e-05
with O 0 0.00010378827
either O 0 0.0001176566
simulated O 0 0.00021057102
gastric O 0 0.17266749
juice O 0 0.9821599
or O 0 0.00062502467
normal O 0 0.002240108
saline O 0 0.0056029945
. O 0 0.0019671204

Gastric O 0 0.14975476
acid O 0 0.85363567
back O 0 0.004786184
- O 0 0.0023505008
diffusion O 0 0.0039566737
, O 0 0.0012760338
mucosal O 0 0.47896814
LPO O 0 0.99999213
generation O 0 0.0028372556
, O 0 0.0011010896
histamine B-Chemical 1 0.99982965
concentration O 0 0.0015170166
, O 0 0.0004432273
microvascular O 0 0.8647178
permeability O 0 0.8352664
, O 0 0.00041540604
luminal B-Chemical 0 0.11089886
hemoglobin O 0 0.8007957
content O 0 0.00064354175
and O 0 0.0006355912
ulcer B-Disease 0 0.9708231
areas O 0 0.00067439704
were O 0 0.0006946572
determined O 0 0.0010753932
. O 0 0.0018720975

Elevated O 0 0.056444183
atherosclerotic B-Disease 2 0.98678964
parameters O 0 0.0017899496
, O 0 0.0008053857
such O 0 0.0003209157
as O 0 0.00039977825
serum O 0 0.10619271
calcium B-Chemical 0 0.99951065
, O 0 0.00054641085
total O 0 0.000541735
cholesterol B-Chemical 0 0.9998933
and O 0 0.00041416977
low O 0 0.00071774726
- O 0 0.00049785874
density O 0 0.0011227246
lipoprotein O 0 0.9987198
concentration O 0 0.0010247051
were O 0 0.00027880396
obtained O 0 0.0003349494
in O 0 0.0006336376
atherosclerotic B-Disease 2 0.9921125
rats O 0 0.0038629982
. O 0 0.0020860771

Severe O 0 0.48326758
gastric O 0 0.89719766
ulcers B-Disease 0 0.9987949
accompanied O 0 0.0029878032
with O 0 0.0008486802
increased O 0 0.0014384214
ulcerogenic O 0 0.99852234
factors O 0 0.00067170436
, O 0 0.00029196232
including O 0 0.00016977508
gastric O 0 0.41533425
acid O 0 0.9330805
back O 0 0.00091884914
- O 0 0.00040279308
diffusion O 0 0.0019284649
, O 0 0.00043418654
histamine B-Chemical 1 0.99989605
release O 0 0.00796882
, O 0 0.0007625173
LPO O 0 0.9999951
generation O 0 0.0005186193
and O 0 0.00023986652
luminal B-Chemical 0 0.122046016
hemoglobin O 0 0.7659423
content O 0 0.00032100044
were O 0 0.00014621376
also O 0 0.00014023039
observed O 0 0.00018629806
in O 0 0.0003209549
these O 0 0.0008836746
rats O 0 0.0020181395
. O 0 0.001802758

Moreover O 0 0.0028853926
, O 0 0.0018891232
a O 0 0.0010927916
positive O 0 0.0006693571
correlation O 0 0.00036506064
of O 0 0.0009600798
histamine B-Chemical 1 0.99975616
to O 0 0.0010218531
gastric B-Disease 0 0.9977696
hemorrhage I-Disease 2 0.9999863
and O 0 0.00069049804
to O 0 0.00047093397
ulcer B-Disease 0 0.9910403
was O 0 0.00033260556
found O 0 0.00021044957
in O 0 0.0003130602
those O 0 0.001115825
atherosclerotic B-Disease 2 0.9941507
rats O 0 0.004223779
. O 0 0.002176666

This O 0 0.00961786
hemorrhagic B-Disease 2 0.9990214
ulcer B-Disease 0 0.99765766
and O 0 0.0011933623
various O 0 0.0009458425
ulcerogenic O 0 0.99249285
parameters O 0 0.0005376704
were O 0 0.00032022744
dose O 0 0.0015975746
- O 0 0.0009987402
dependently O 0 0.47962108
ameliorated O 0 0.23685247
by O 0 0.000740066
daily O 0 0.0018141234
intragastric O 0 0.95713896
verapamil B-Chemical 0 0.99991417
. O 0 0.0039128866

Atherosclerosis B-Disease 0 0.9690616
could O 0 0.001841282
produce O 0 0.0015131918
gastric B-Disease 0 0.990646
hemorrhagic I-Disease 2 0.9999635
ulcer B-Disease 0 0.9994973
via O 0 0.00037290566
aggravation O 0 0.32587537
of O 0 0.0009956919
gastric O 0 0.7644741
acid O 0 0.96642447
back O 0 0.0012136786
- O 0 0.000492989
diffusion O 0 0.003102833
, O 0 0.0006491266
LPO O 0 0.99999523
generation O 0 0.0010329039
, O 0 0.00053804176
histamine B-Chemical 1 0.9998467
release O 0 0.0014592145
and O 0 0.00022166625
microvascular O 0 0.7369353
permeability O 0 0.3862457
that O 0 9.784846e-05
could O 0 0.00010880888
be O 0 0.00016117269
ameliorated O 0 0.02941232
by O 0 0.0011393619
verapamil B-Chemical 0 0.9999442
in O 0 0.001378465
rats O 0 0.0026753328
. O 0 0.0018769143

Lamivudine B-Chemical 1 0.99720037
for O 0 0.0013636162
the O 0 0.00098989
prevention O 0 0.0014250624
of O 0 0.0048793177
hepatitis B-Disease 2 0.9999981
B I-Disease 2 0.99961793
virus O 0 0.20059486
reactivation O 0 0.17748465
in O 0 0.0026150593
hepatitis B-Chemical 2 0.99999714
- I-Chemical 0 0.022634307
B I-Chemical 0 0.43577164
surface I-Chemical 0 0.00063119654
antigen I-Chemical 0 0.0034871688
( O 0 0.00086788833
HBSAG B-Chemical 0 0.99635786
) O 0 0.0008652778
seropositive O 0 0.009778818
cancer B-Disease 0 0.8744383
patients O 0 0.00075444405
undergoing O 0 0.00073413056
cytotoxic O 0 0.17452452
chemotherapy O 0 0.05719022
. O 0 0.0024370214

Hepatitis B-Disease 0 0.9997553
B I-Disease 0 0.9944929
virus O 0 0.19163421
( O 0 0.0077742143
HBV O 0 0.99690646
) O 0 0.002102428
is O 0 0.00047729275
one O 0 0.00023099824
of O 0 0.00029398265
the O 0 0.0002310471
major O 0 0.00026725009
causes O 0 0.0005955529
of O 0 0.0014403185
chronic O 0 0.9912409
liver B-Disease 2 0.99982953
disease I-Disease 2 0.99963653
worldwide O 0 0.20174508
. O 0 0.0035612634

Cancer B-Disease 0 0.1875491
patients O 0 0.0027057182
who O 0 0.0015901614
are O 0 0.00069658214
chronic O 0 0.039007884
carriers O 0 0.004464034
of O 0 0.0007693784
HBV O 0 0.98596835
have O 0 0.00015995842
a O 0 0.00021046221
higher O 0 0.00031758353
hepatic B-Disease 0 0.99931204
complication I-Disease 0 0.58266485
rate O 0 0.00015923801
while O 0 9.329313e-05
receiving O 0 0.00020219325
cytotoxic O 0 0.078809105
chemotherapy O 0 0.010671928
( O 0 0.00035518032
CT O 0 0.045355476
) O 0 0.00023907633
and O 0 0.00011335819
this O 0 0.0001434615
has O 0 0.00010103055
mainly O 0 0.00017236451
been O 0 0.00015435455
attributed O 0 0.0002201657
to O 0 0.00058241794
HBV O 0 0.9801048
reactivation O 0 0.1556519
. O 0 0.003287236

In O 0 0.0017276215
this O 0 0.0015864319
study O 0 0.001481539
, O 0 0.0014307941
cancer B-Disease 0 0.851398
patients O 0 0.00084697996
who O 0 0.00041397853
have O 0 0.00012867995
solid O 0 0.0026517627
and O 0 0.00035330348
hematological B-Disease 0 0.99975413
malignancies I-Disease 2 0.99995077
with O 0 0.0020816487
chronic O 0 0.92024183
HBV B-Disease 0 0.9999728
infection I-Disease 0 0.763574
received O 0 9.621374e-05
the O 0 8.719405e-05
antiviral O 0 0.0037112706
agent O 0 0.01809479
lamivudine B-Chemical 1 0.9999051
prior O 0 4.7390888e-05
and O 0 6.5975604e-05
during O 0 3.4114393e-05
CT O 0 0.0024354034
compared O 0 4.038002e-05
with O 0 7.9197074e-05
historical O 0 0.00028902086
control O 0 0.00010830703
group O 0 0.00018752064
who O 0 0.00024327576
did O 0 0.00023298986
not O 0 0.00034493767
receive O 0 0.0007140828
lamivudine B-Chemical 1 0.9992576
. O 0 0.0028133057

The O 0 0.0013902242
objectives O 0 0.0011731046
were O 0 0.00072690094
to O 0 0.00037182934
assess O 0 0.00016887579
the O 0 0.00023239748
efficacy O 0 0.00038110767
of O 0 0.0007141304
lamivudine B-Chemical 1 0.9998172
in O 0 0.00023169657
reducing O 0 0.00021096089
the O 0 0.00016423964
incidence O 0 0.0004282313
of O 0 0.0005000274
HBV O 0 0.99617106
reactivation O 0 0.037822135
, O 0 0.00035587768
and O 0 0.00025094717
diminishing O 0 0.0008850168
morbidity O 0 0.03907461
and O 0 0.0005845674
mortality O 0 0.0051889988
during O 0 0.0006324177
CT O 0 0.03518929
. O 0 0.0023659437

Two O 0 0.00424618
groups O 0 0.0029701144
were O 0 0.0021691644
compared O 0 0.0015753921
in O 0 0.0022574444
this O 0 0.0037578335
study O 0 0.005865619
. O 0 0.00613633

The O 0 0.0019184191
prophylactic O 0 0.004032516
lamivudin B-Chemical 0 0.8134947
group O 0 0.00092137925
consisted O 0 0.00036323012
of O 0 0.00041509367
37 O 0 0.0005804595
patients O 0 0.00043162
who O 0 0.00043867884
received O 0 0.00034271824
prophylactic O 0 0.0035424028
lamivudine B-Chemical 1 0.999699
treatment O 0 0.003836126
. O 0 0.0029841377

The O 0 0.0015884056
historical O 0 0.0026472267
controls O 0 0.0011110583
consisted O 0 0.0004434399
of O 0 0.0004335046
50 O 0 0.00045131214
consecutive O 0 0.00024636742
patients O 0 0.00033432417
who O 0 0.0003562859
underwent O 0 0.0003080037
CT O 0 0.0050787795
without O 0 0.00068883447
prophylactic O 0 0.008926937
lamivudine B-Chemical 1 0.9996456
. O 0 0.004089392

They O 0 0.0040072324
were O 0 0.0017050932
followed O 0 0.000923397
up O 0 0.00084883213
during O 0 0.00044391316
and O 0 0.0006450306
for O 0 0.0005181148
8 O 0 0.00057578465
weeks O 0 0.00043888213
after O 0 0.0007986405
CT O 0 0.016232047
. O 0 0.0042377803

The O 0 0.0029838893
outcomes O 0 0.0029780127
were O 0 0.0021601378
compared O 0 0.001433754
for O 0 0.001819653
both O 0 0.0031614946
groups O 0 0.0043672
. O 0 0.0056193704

Of O 0 0.002285811
our O 0 0.0015952247
control O 0 0.0010332464
group O 0 0.0011167204
( O 0 0.0008366015
n O 0 0.0004373611
= O 0 0.00045616156
50 O 0 0.00048463262
) O 0 0.00045262746
, O 0 0.00028132828
21 O 0 0.00024377172
patients O 0 0.00031572906
( O 0 0.00033277966
42 O 0 0.00032895288
% O 0 0.0003849695
) O 0 0.0006295189
were O 0 0.00071743806
established O 0 0.0027979107
hepatitis B-Disease 2 0.9998976
. O 0 0.0064806263

Twelve O 0 0.0068249633
( O 0 0.0031133962
24 O 0 0.001249081
% O 0 0.0013390739
) O 0 0.0012098247
of O 0 0.00085075933
them O 0 0.001122538
were O 0 0.0007295064
evaluated O 0 0.0007826642
as O 0 0.0015802236
severe O 0 0.37756574
hepatitis B-Disease 2 0.9999449
. O 0 0.011675147

In O 0 0.0014418919
the O 0 0.0013306589
prophylactic O 0 0.0056104194
lamivudine B-Chemical 1 0.9998344
group O 0 0.004187595
severe O 0 0.53930694
hepatitis B-Disease 2 0.99999344
were O 0 0.0007268344
observed O 0 0.00017113218
only O 0 0.00016851354
in O 0 0.00011681314
1 O 0 9.616823e-05
patient O 0 0.00012654635
( O 0 0.00015228635
2 O 0 7.692895e-05
. O 0 5.416045e-05
7 O 0 5.991294e-05
% O 0 0.00010070497
) O 0 0.00013855883
of O 0 0.00014055327
37 O 0 0.00030068026
patients O 0 0.00031010987
( O 0 0.00033449405
p O 0 0.0002684145
< O 0 0.00027648354
0 O 0 0.0003401881
. O 0 0.000507364
006 O 0 0.005439709
) O 0 0.002363579
. O 0 0.0023802365

Comparison O 0 0.0013306804
of O 0 0.0010805473
the O 0 0.00063026
mean O 0 0.00040418605
ALT O 0 0.9481054
values O 0 0.00045585286
revealed O 0 0.00023452727
significantly O 0 0.00022259114
higher O 0 0.00016588622
mean O 0 0.000110340006
alanine B-Chemical 1 0.9849437
aminotransferase O 0 0.9987619
( O 0 0.0015699465
ALT O 0 0.9993795
) O 0 0.00037351617
values O 0 9.0368245e-05
in O 0 5.2992233e-05
the O 0 5.03106e-05
control O 0 5.5170025e-05
group O 0 7.109218e-05
than O 0 3.405705e-05
the O 0 6.9738446e-05
prophylactic O 0 0.0008454395
lamivudine B-Chemical 1 0.9998834
group O 0 0.00039881218
; O 0 0.00020464209
154 O 0 0.0005193861
: O 0 0.00018886136
64 O 0 0.00023554444
( O 0 0.00026252502
p O 0 0.00021709643
< O 0 0.00022677769
0 O 0 0.00027188388
. O 0 0.00035982972
32 O 0 0.0010667731
) O 0 0.0020179166
. O 0 0.0022683244

Our O 0 0.0020933892
study O 0 0.0013143979
suggests O 0 0.00040521473
that O 0 0.0004091975
prophylactic O 0 0.0037737924
lamivudine B-Chemical 1 0.99987316
significantly O 0 0.0007770882
decreases O 0 0.0003119305
the O 0 0.00018300187
incidence O 0 0.0004075675
of O 0 0.0004098116
HBV O 0 0.99262613
reactivation O 0 0.011177862
and O 0 0.00019144389
overall O 0 0.00021820086
morbidity O 0 0.034785014
in O 0 0.00030697766
cancer B-Disease 0 0.910083
patients O 0 0.00027703977
during O 0 8.101652e-05
and O 0 0.00018401566
after O 0 0.00017762772
immunosuppressive O 0 0.1104369
therapy O 0 0.0028516294
. O 0 0.0020647577

Further O 0 0.0026768234
studies O 0 0.0014671484
are O 0 0.00068115315
needed O 0 0.0003616438
to O 0 0.00025798724
determine O 0 0.00011972969
the O 0 0.00017156942
most O 0 0.00024222638
appropriate O 0 0.00014902154
nucleoside B-Chemical 0 0.1615594
or O 0 0.00020989268
nucleotide B-Chemical 0 0.08040599
analogue O 0 0.0008787245
for O 0 7.687864e-05
antiviral O 0 0.0008747793
prophylaxis O 0 0.00019770498
during O 0 4.8917696e-05
CT O 0 0.0038660415
and O 0 7.795983e-05
the O 0 5.3053725e-05
optimal O 0 3.6310797e-05
duration O 0 4.4086442e-05
of O 0 0.00014046273
administration O 0 0.00042676585
after O 0 0.000110501955
completion O 0 0.00026081633
of O 0 0.0011387228
CT O 0 0.0610259
. O 0 0.0025410675

Recovery O 0 0.007319747
of O 0 0.004344098
tacrolimus B-Chemical 0 0.9999231
- O 0 0.00386931
associated O 0 0.0011057926
brachial B-Disease 0 0.99896514
neuritis I-Disease 0 0.9999702
after O 0 0.00016814886
conversion O 0 0.0012224435
to O 0 0.00018549085
everolimus B-Chemical 0 0.99180436
in O 0 0.00015019887
a O 0 0.00020287144
pediatric O 0 0.00061107846
renal O 0 0.8512879
transplant O 0 0.04345108
recipient O 0 0.0009386149
- O 0 0.0004943517
- O 0 0.00026295515
case O 0 0.00013823838
report O 0 0.0002702871
and O 0 0.00024337343
review O 0 0.00051921036
of O 0 0.0005152539
the O 0 0.0007669751
literature O 0 0.0024456566
. O 0 0.0020624755

TAC B-Chemical 0 0.987905
has O 0 0.0017724902
been O 0 0.0008129498
shown O 0 0.00046125246
to O 0 0.00037457864
be O 0 0.00029310753
a O 0 0.0003525359
potent O 0 0.00075391226
immunosuppressive O 0 0.21652552
agent O 0 0.0025617979
for O 0 0.00034829864
solid O 0 0.01230836
organ O 0 0.0035458244
transplantation O 0 0.008615613
in O 0 0.0011584322
pediatrics O 0 0.0057105245
. O 0 0.0022593152

Neurotoxicity B-Disease 0 0.99655616
is O 0 0.005849162
a O 0 0.0045477217
potentially O 0 0.0046701026
serious O 0 0.02114536
toxic O 0 0.59535956
effect O 0 0.007915986
. O 0 0.0077971644

It O 0 0.0033953097
is O 0 0.0020893875
characterized O 0 0.0028807067
by O 0 0.0028065476
encephalopathy B-Disease 2 0.99986124
, O 0 0.009818213
headaches B-Disease 0 0.9998307
, O 0 0.004944618
seizures B-Disease 0 0.99990225
, O 0 0.002288564
or O 0 0.0018946471
neurological B-Disease 0 0.998882
deficits I-Disease 0 0.9955207
. O 0 0.005230362

Here O 0 0.002793885
, O 0 0.0018780438
we O 0 0.00056015817
describe O 0 0.0005410815
an O 0 0.0007119037
eight O 0 0.00041118174
- O 0 0.0008335606
and O 0 0.00042450643
- O 0 0.0006333617
a O 0 0.0004041044
- O 0 0.000455225
half O 0 0.00016374425
- O 0 0.0003890073
yr O 0 0.00018322816
- O 0 0.0002508376
old O 0 0.00018591456
male O 0 0.00072771707
renal O 0 0.5082404
transplant O 0 0.009544394
recipient O 0 0.00084095146
with O 0 0.00077812973
right O 0 0.00473197
BN O 0 0.85858905
. O 0 0.0024718444

MRI O 0 0.034670345
demonstrated O 0 0.0014186106
hyperintense O 0 0.007900023
T2 O 0 0.0026014366
signals O 0 0.00035107395
in O 0 0.0002946252
the O 0 0.00032221156
cervical O 0 0.0037567022
cord O 0 0.0022071176
and O 0 0.00025324643
right O 0 0.0011111875
brachial O 0 0.5554284
plexus O 0 0.0068635824
roots O 0 0.00084250426
indicative O 0 0.00013938731
of O 0 0.0002670443
both O 0 0.0005394912
myelitis B-Disease 0 0.9997975
and O 0 0.0011711221
right O 0 0.013441287
brachial B-Disease 0 0.9974311
plexitis I-Disease 0 0.95487505
. O 0 0.003176102

Symptoms O 0 0.0054684863
persisted O 0 0.00084172626
for O 0 0.00043932075
three O 0 0.0002197628
months O 0 0.00014701189
despite O 0 0.00025351555
TAC B-Chemical 0 0.9681871
dose O 0 0.0020064588
reduction O 0 0.00082538096
, O 0 0.0002440964
administration O 0 0.0007085019
of O 0 0.00040114459
IVIG O 0 0.96817017
and O 0 0.00019470486
four O 0 0.00010660012
doses O 0 0.0009374669
of O 0 0.0008893305
methylprednisolone B-Chemical 0 0.99963915
pulse O 0 0.0039263284
therapy O 0 0.0028651962
. O 0 0.0020513993

Improvement O 0 0.0056402828
and O 0 0.0015908031
eventually O 0 0.00157417
full O 0 0.0005768099
recovery O 0 0.0007778102
only O 0 0.00034818592
occurred O 0 0.00021965243
after O 0 0.0001409855
TAC B-Chemical 0 0.96476847
was O 0 0.000333213
completely O 0 0.00033937293
discontinued O 0 0.0009061581
and O 0 0.00029092093
successfully O 0 0.00042083728
replaced O 0 0.00063245744
by O 0 0.0015496504
everolimus B-Chemical 0 0.998102
. O 0 0.0036679893

Omitting O 0 0.018968735
fentanyl B-Chemical 0 0.99954337
reduces O 0 0.004147717
nausea B-Disease 0 0.99991024
and O 0 0.0046997857
vomiting B-Disease 0 0.99970067
, O 0 0.0007043059
without O 0 0.00032362522
increasing O 0 0.000636233
pain B-Disease 0 0.4582251
, O 0 0.00037834526
after O 0 0.00018527555
sevoflurane B-Chemical 1 0.99675214
for O 0 0.0004868444
day O 0 0.00060289685
surgery O 0 0.0016604576
. O 0 0.0018338969

BACKGROUND O 0 0.0076026637
AND O 0 0.0016921511
OBJECTIVE O 0 0.0064569428
: O 0 0.00088142935
Despite O 0 0.00028642887
advantages O 0 0.00014938533
of O 0 0.00026658128
induction O 0 0.00023161597
and O 0 0.00017398519
maintenance O 0 0.00020187655
of O 0 0.00020677054
anaesthesia O 0 0.0026282868
with O 0 0.0004133663
sevoflurane B-Chemical 1 0.99973243
, O 0 0.0004811537
postoperative B-Disease 0 0.003320769
nausea I-Disease 0 0.999915
and I-Disease 0 0.0018394303
vomiting I-Disease 0 0.999161
occurs O 0 0.0011680074
frequently O 0 0.00169901
. O 0 0.0019294876

Fentanyl B-Chemical 0 0.999321
is O 0 0.0023261795
a O 0 0.0013309427
commonly O 0 0.00072162156
used O 0 0.00041796765
supplement O 0 0.0011618442
that O 0 0.00019200383
may O 0 0.00016753655
contribute O 0 0.00013590073
to O 0 0.0001510575
this O 0 0.000262518
, O 0 0.0002770894
although O 0 0.00019817115
it O 0 0.0002645358
may O 0 0.00025614558
also O 0 0.00046347242
improve O 0 0.0008751578
analgesia O 0 0.6479847
. O 0 0.002510224

METHODS O 0 0.0017472043
: O 0 0.0015381281
This O 0 0.0013207122
double O 0 0.0012016601
- O 0 0.0011410813
blind O 0 0.0028249358
study O 0 0.00025203315
examined O 0 9.930214e-05
the O 0 0.00012173385
incidence O 0 0.00024004937
and O 0 0.00010854038
severity O 0 0.00021286706
of O 0 0.00015661634
postoperative B-Disease 0 0.0016705698
nausea I-Disease 0 0.99996424
and I-Disease 0 0.00071651704
vomiting I-Disease 0 0.9997801
and O 0 0.00036819716
pain B-Disease 0 0.23685811
in O 0 6.6237975e-05
the O 0 4.7470952e-05
first O 0 2.9361227e-05
24 O 0 3.395134e-05
h O 0 4.0746687e-05
after O 0 4.404837e-05
sevoflurane B-Chemical 1 0.9982085
anaesthesia O 0 0.0046869805
in O 0 0.0001664138
216 O 0 0.000690044
adult O 0 0.00031049148
day O 0 0.00021774655
surgery O 0 0.0006723185
patients O 0 0.0013138101
. O 0 0.0015987982

Patients O 0 0.00179042
were O 0 0.0007046648
randomly O 0 0.00021350816
allocated O 0 0.00020301618
to O 0 0.0001719551
either O 0 0.00016156981
receive O 0 0.00010153781
or O 0 9.324938e-05
not O 0 8.953698e-05
receive O 0 6.9007496e-05
1 O 0 8.631474e-05
1 O 0 0.00012666418
fentanyl B-Chemical 0 0.9991103
, O 0 0.00015296483
while O 0 8.341255e-05
a O 0 0.000116546675
third O 0 0.00013603621
group O 0 0.00016746564
received O 0 0.00016826275
dexamethasone B-Chemical 0 0.9914795
in O 0 0.0003093492
addition O 0 0.00037630857
to O 0 0.0013904427
fentanyl B-Chemical 0 0.9996433
. O 0 0.0031130237

RESULTS O 0 0.0044832593
: O 0 0.002105462
Omission O 0 0.004588686
of O 0 0.002038076
fentanyl B-Chemical 0 0.9997403
did O 0 0.00057160755
not O 0 0.00018319268
reduce O 0 9.706135e-05
the O 0 0.0001013543
overall O 0 0.000117303614
incidence O 0 0.00019906448
of O 0 0.00017769514
postoperative B-Disease 0 0.0023689372
nausea I-Disease 0 0.9999733
and I-Disease 0 0.001300507
vomiting I-Disease 0 0.99987936
, O 0 0.00027433984
but O 0 0.00011140963
did O 0 7.482053e-05
reduce O 0 3.882326e-05
the O 0 6.347091e-05
incidence O 0 0.00019193903
of O 0 0.00029572274
vomiting B-Disease 0 0.99952316
and O 0 0.00017982401
/ O 0 0.0003479306
or O 0 6.9543596e-05
moderate O 0 0.0007914275
to O 0 0.00010826015
severe O 0 0.04721997
nausea B-Disease 0 0.99995565
prior O 0 4.8261347e-05
to O 0 5.169858e-05
discharge O 0 7.8373734e-05
from O 0 3.953002e-05
20 O 0 5.0665487e-05
% O 0 5.2723975e-05
and O 0 5.1183797e-05
17 O 0 6.9365626e-05
% O 0 6.030266e-05
with O 0 0.00015534087
fentanyl B-Chemical 0 0.99989355
and O 0 0.0006129798
fentanyl B-Chemical 0 0.99997675
- O 0 0.0033539406
dexamethasone B-Chemical 0 0.99971
, O 0 0.00038372722
respectively O 0 0.00048492788
, O 0 0.00014408637
to O 0 9.954987e-05
5 O 0 0.00010552231
% O 0 0.00020583245
( O 0 0.00042763122
P O 0 0.0034370043
= O 0 0.00043824414
0 O 0 0.00036576623
. O 0 0.0005171963
013 O 0 0.0045465776
) O 0 0.0023868242
. O 0 0.0024169567

Antiemetic O 0 0.31505343
requirements O 0 0.0013076463
were O 0 0.00089724193
reduced O 0 0.0008037201
from O 0 0.0003790153
24 O 0 0.00027772575
% O 0 0.0003156102
and O 0 0.0002665818
31 O 0 0.0003350954
% O 0 0.00022247488
to O 0 0.00017154358
7 O 0 0.00018078882
% O 0 0.000334906
( O 0 0.0006525242
P O 0 0.0045201615
= O 0 0.00062626187
0 O 0 0.00050459563
. O 0 0.00068294496
0012 O 0 0.005542043
) O 0 0.002913488
. O 0 0.0028702342

Dexamethasone B-Chemical 0 0.99868995
had O 0 0.0021821547
no O 0 0.0006470426
significant O 0 0.000523762
effect O 0 0.00033941245
on O 0 0.0001990007
the O 0 0.00027682033
incidence O 0 0.00053713867
or O 0 0.00023548739
severity O 0 0.0006415531
of O 0 0.00063808943
postoperative B-Disease 0 0.007539948
nausea I-Disease 0 0.99989045
and I-Disease 0 0.006380486
vomiting I-Disease 0 0.9994067
. O 0 0.003982552

Combining O 0 0.0016640706
the O 0 0.0012122055
two O 0 0.0009796404
fentanyl B-Chemical 0 0.99938655
groups O 0 0.0005343403
revealed O 0 0.00023566236
further O 0 0.0002402694
significant O 0 0.00012477764
benefits O 0 8.0138045e-05
from O 0 6.031543e-05
the O 0 6.787037e-05
avoidance O 0 0.0002050458
of O 0 0.00022622742
opioids O 0 0.8293675
, O 0 0.000103230996
reducing O 0 0.00011160806
postoperative B-Disease 0 0.0013136576
nausea I-Disease 0 0.99996126
and I-Disease 0 0.0005740695
vomiting I-Disease 0 0.9997986
and O 0 0.0005469074
nausea B-Disease 0 0.9999305
prior O 0 4.8568654e-05
to O 0 5.4630364e-05
discharge O 0 8.657309e-05
from O 0 4.636815e-05
35 O 0 6.465026e-05
% O 0 6.704518e-05
and O 0 7.009414e-05
33 O 0 0.00010984042
% O 0 7.15686e-05
to O 0 5.6784804e-05
22 O 0 9.7217504e-05
% O 0 8.395905e-05
and O 0 9.10495e-05
19 O 0 0.00015060157
% O 0 0.00013410277
( O 0 0.00025610017
P O 0 0.0033056505
= O 0 0.00013457764
0 O 0 7.310363e-05
. O 0 6.810156e-05
049 O 0 0.0055480646
and O 0 0.00021059511
P O 0 0.00430513
= O 0 0.00013838004
0 O 0 7.5633085e-05
. O 0 7.044876e-05
035 O 0 0.001136263
) O 0 0.0001923841
, O 0 0.00012753632
respectively O 0 0.00025495514
, O 0 0.00013412899
while O 0 0.00019706416
nausea B-Disease 0 0.99985707
in O 0 0.00010789656
the O 0 6.545534e-05
first O 0 3.866417e-05
24 O 0 4.4506676e-05
h O 0 5.3809865e-05
was O 0 8.11615e-05
decreased O 0 0.00015444582
from O 0 7.658624e-05
42 O 0 0.00011717818
% O 0 9.650786e-05
to O 0 8.9073365e-05
27 O 0 0.00022819793
% O 0 0.00022381761
( O 0 0.0004372539
P O 0 0.0035727199
= O 0 0.0004289559
0 O 0 0.00036024352
. O 0 0.0005334995
034 O 0 0.011032247
) O 0 0.0025607052
. O 0 0.0024705073

Pain B-Disease 0 0.27709252
severity O 0 0.004331424
and O 0 0.001737576
analgesic O 0 0.09107663
requirements O 0 0.0006054415
were O 0 0.0005567128
unaffected O 0 0.00077636837
by O 0 0.0005080519
the O 0 0.00057742454
omission O 0 0.002329985
of O 0 0.0038700802
fentanyl B-Chemical 0 0.99960834
. O 0 0.0044593066

Fentanyl B-Chemical 0 0.99916184
did O 0 0.0018831
reduce O 0 0.00063463993
minor O 0 0.0012002918
intraoperative O 0 0.0010198171
movement O 0 0.00056728953
but O 0 0.00028335524
had O 0 0.00020179457
no O 0 0.00017926574
sevoflurane B-Chemical 1 0.99983144
- O 0 0.00077216286
sparing O 0 0.001093709
effect O 0 0.00014054471
and O 0 0.00017373204
increased O 0 0.0004746472
respiratory B-Disease 0 0.16759445
depression I-Disease 0 0.9982151
, O 0 0.0019873173
hypotension B-Disease 0 0.9998085
and O 0 0.0035351622
bradycardia B-Disease 0 0.99815065
. O 0 0.0028748384

CONCLUSION O 0 0.01617869
: O 0 0.0020691406
As O 0 0.0008752696
fentanyl B-Chemical 0 0.9992607
exacerbated O 0 0.0059984536
postoperative B-Disease 0 0.012096657
nausea I-Disease 0 0.99994814
and I-Disease 0 0.0012606723
vomiting I-Disease 0 0.99931455
without O 0 0.00016491204
an O 0 0.00013277224
improvement O 0 0.00010915974
in O 0 9.512683e-05
postoperative B-Disease 0 0.014046427
pain I-Disease 0 0.94442505
and O 0 0.00011044412
also O 0 7.1447765e-05
had O 0 9.1636575e-05
adverse O 0 0.010101219
cardiorespiratory O 0 0.00983459
effects O 0 0.00017584817
, O 0 0.00013792017
it O 0 8.40927e-05
appears O 0 4.791041e-05
to O 0 5.193106e-05
be O 0 5.2723673e-05
an O 0 8.422454e-05
unnecessary O 0 0.0001436415
and O 0 8.666775e-05
possibly O 0 0.00016875296
detrimental O 0 0.0002498378
supplement O 0 0.0010656172
to O 0 0.00031608625
sevoflurane B-Chemical 1 0.9989801
in O 0 0.00047466668
day O 0 0.00046490628
surgery O 0 0.0013737928
. O 0 0.0015457554

Valvular B-Disease 0 0.19050306
heart I-Disease 0 0.23464082
disease I-Disease 0 0.6225393
in O 0 0.0009994697
patients O 0 0.000954709
with O 0 0.0009921712
Parkinson B-Disease 0 0.9958181
' I-Disease 0 0.0009532719
s I-Disease 0 0.0006697777
disease I-Disease 0 0.03035901
treated O 0 0.0017705465
with O 0 0.004508466
pergolide B-Chemical 0 0.9998814
. O 0 0.004599759

Course O 0 0.013567216
following O 0 0.0070644603
treatment O 0 0.010903501
modifications O 0 0.017694993
. O 0 0.01627111

Valvular B-Disease 0 0.11774041
heart I-Disease 0 0.093932986
abnormalities I-Disease 0 0.103294015
have O 0 0.00054052577
been O 0 0.0002989763
reported O 0 0.00028509687
in O 0 0.00020000507
patients O 0 0.0002935228
with O 0 0.00039599402
Parkinson B-Disease 0 0.99752945
' I-Disease 0 0.00044646364
s I-Disease 0 0.00031702907
disease I-Disease 0 0.098687515
( O 0 0.00096105854
PD B-Disease 0 0.9951651
) O 0 0.00082678767
treated O 0 0.0009854331
with O 0 0.0030134404
pergolide B-Chemical 0 0.99988544
. O 0 0.00372995

However O 0 0.0026737866
, O 0 0.0018353078
the O 0 0.00097096304
incidence O 0 0.0012848654
and O 0 0.0005254183
severity O 0 0.0006824885
of O 0 0.00030682023
these O 0 0.00031159754
abnormalities O 0 0.0023731713
vary O 0 9.4041265e-05
from O 0 6.791912e-05
study O 0 8.819377e-05
to O 0 5.975393e-05
study O 0 8.772992e-05
and O 0 7.003667e-05
their O 0 7.696328e-05
course O 0 5.6804347e-05
after O 0 4.3440497e-05
drug O 0 0.0033878668
withdrawal O 0 0.0043603797
has O 0 0.00016776579
not O 0 0.0002112773
been O 0 0.00028899245
systematically O 0 0.00048039242
assessed O 0 0.00090134883
. O 0 0.0017393386

OBJECTIVES O 0 0.003227012
: O 0 0.0016563695
To O 0 0.0006181296
estimate O 0 0.0004246392
the O 0 0.000390898
frequency O 0 0.00036969202
and O 0 0.00029267024
severity O 0 0.0005155057
of O 0 0.00039382649
valvular B-Disease 0 0.5825267
heart I-Disease 0 0.22648497
abnormality I-Disease 0 0.1984263
and O 0 0.00014484761
its O 0 0.00015573492
possible O 0 7.8726625e-05
reversibility O 0 0.001582196
after O 0 4.8833e-05
drug O 0 0.0054274094
withdrawal O 0 0.004493595
in O 0 0.00017417641
a O 0 0.00032154875
case O 0 0.00036875063
- O 0 0.00075049384
control O 0 0.00070090446
study O 0 0.0016302303
. O 0 0.0019309095

METHODS O 0 0.0016684469
: O 0 0.0015166845
All O 0 0.0009166874
PD B-Disease 0 0.8717671
patients O 0 0.0006791771
in O 0 0.00027122675
the O 0 0.00024380845
Amiens O 0 0.0010578317
area O 0 0.00018628313
treated O 0 0.00027254515
with O 0 0.0005950698
pergolide B-Chemical 0 0.9999801
were O 0 0.00024912326
invited O 0 0.0002407094
to O 0 0.000100886835
attend O 0 0.0001385176
a O 0 0.00020982308
cardiologic O 0 0.00085090334
assessment O 0 0.00021432052
including O 0 0.0003214972
transthoracic O 0 0.00265688
echocardiography O 0 0.0062381015
. O 0 0.0017829895

Thirty O 0 0.010464246
PD B-Disease 0 0.9785297
patients O 0 0.005360476
participated O 0 0.004644261
in O 0 0.002552223
the O 0 0.003336415
study O 0 0.005498142
. O 0 0.005866901

A O 0 0.0126647055
second O 0 0.0018071859
echocardiography O 0 0.0046031745
was O 0 0.0007113171
performed O 0 0.00036693236
( O 0 0.0003669065
median O 0 0.00012719796
interval O 0 0.00014137375
: O 0 0.00016746804
13 O 0 0.00011618315
months O 0 5.014539e-05
) O 0 0.00014333324
after O 0 8.692102e-05
pergolide B-Chemical 0 0.9999522
withdrawal O 0 0.04865648
( O 0 0.0004523139
n O 0 0.00025270352
= O 0 0.00037411542
10 O 0 0.0004054628
patients O 0 0.0011001413
) O 0 0.0019871385
. O 0 0.0021464955

Controls O 0 0.0077583925
were O 0 0.0019019644
age O 0 0.0015513847
- O 0 0.0014014802
and O 0 0.00067274284
sex O 0 0.0011822523
- O 0 0.0005778844
matched O 0 0.0002314548
non O 0 0.00048323305
- O 0 0.0011327566
PD B-Disease 0 0.9940096
patients O 0 0.00052946154
referred O 0 0.0003431289
to O 0 0.0002815913
the O 0 0.00051343604
cardiology O 0 0.0021189314
department O 0 0.0025436284
. O 0 0.0020968097

RESULTS O 0 0.004296295
: O 0 0.0016031594
Compared O 0 0.00059106556
to O 0 0.0005395799
controls O 0 0.0008426672
, O 0 0.0008413843
aortic B-Disease 0 0.9631322
regurgitation I-Disease 0 0.9996296
( O 0 0.0014941009
OR O 0 0.014163642
: O 0 0.0002660471
3 O 0 0.0001080916
. O 0 7.4894924e-05
1 O 0 9.143669e-05
; O 0 0.00012468357
95 O 0 0.00014843399
% O 0 0.00012124289
IC O 0 0.0023701265
: O 0 0.00017160246
1 O 0 9.1232374e-05
. O 0 6.120209e-05
1 O 0 8.189628e-05
- O 0 0.00015049476
8 O 0 6.153032e-05
. O 0 4.678781e-05
8 O 0 5.6401146e-05
) O 0 0.00011239185
and O 0 0.0001382583
mitral B-Disease 2 0.79023427
regurgitation I-Disease 2 0.9990638
( O 0 0.00062568503
OR O 0 0.0059027527
: O 0 0.00014296306
10 O 0 7.946382e-05
. O 0 5.3099127e-05
7 O 0 5.659845e-05
; O 0 9.58777e-05
95 O 0 0.0001211918
% O 0 0.000101835394
IC O 0 0.0021654416
: O 0 0.00015185308
2 O 0 7.861147e-05
. O 0 5.4888176e-05
1 O 0 7.611423e-05
- O 0 0.0001583489
53 O 0 0.00015107263
) O 0 0.00012683726
were O 0 7.1630726e-05
more O 0 0.00010895414
frequent O 0 0.00016988488
in O 0 0.00020273357
PD B-Disease 0 0.99167424
patients O 0 0.000593675
( O 0 0.0005836622
tricuspid O 0 0.029194485
: O 0 0.0013938136
NS O 0 0.32116762
) O 0 0.002539708
. O 0 0.0021953594

The O 0 0.0017977733
number O 0 0.0013284581
of O 0 0.0012516523
affected O 0 0.0012214048
valves O 0 0.0032971827
( O 0 0.00070124416
n O 0 0.00033542
= O 0 0.00031882344
2 O 0 0.00015008649
. O 0 0.00010275604
4 O 0 0.00011182782
+ O 0 0.0002898719
/ O 0 0.0004980137
- O 0 0.0002964564
0 O 0 0.00010468144
. O 0 6.58168e-05
7 O 0 6.325706e-05
) O 0 0.00010564917
and O 0 6.211207e-05
the O 0 5.904334e-05
sum O 0 7.078181e-05
of O 0 0.00021484736
regurgitation O 0 0.92054427
grades O 0 0.0030648324
( O 0 0.0001981381
n O 0 9.737896e-05
= O 0 0.000113798436
2 O 0 6.072919e-05
. O 0 4.737155e-05
8 O 0 6.525179e-05
+ O 0 0.00019667279
/ O 0 0.00040328104
- O 0 0.00025845453
1 O 0 9.223676e-05
. O 0 7.167036e-05
09 O 0 0.0004824971
) O 0 0.00015775995
were O 0 8.827976e-05
higher O 0 0.00013216984
( O 0 0.00020498267
p O 0 0.00013358651
= O 0 0.00011917587
0 O 0 7.474679e-05
. O 0 6.79565e-05
008 O 0 0.000381381
and O 0 0.00013341747
p O 0 0.00014041825
= O 0 0.00013157367
0 O 0 9.079555e-05
. O 0 9.568425e-05
006 O 0 0.0012505464
, O 0 0.00022168994
respectively O 0 0.00041606784
) O 0 0.00034331964
in O 0 0.000281768
the O 0 0.0008462285
pergolide B-Chemical 0 0.99988294
group O 0 0.0033812837
. O 0 0.00233759

Severity O 0 0.0040390976
of O 0 0.003390893
regurgitation O 0 0.84670997
was O 0 0.0012027044
not O 0 0.00060566457
correlated O 0 0.0005908968
with O 0 0.0019688678
pergolide B-Chemical 0 0.9998946
cumulative O 0 0.008288886
dose O 0 0.018594833
. O 0 0.0037891062

A O 0 0.013287271
restrictive O 0 0.0019353126
pattern O 0 0.00075783185
of O 0 0.0014009192
valvular B-Disease 0 0.98285484
regurgitation I-Disease 0 0.99956053
, O 0 0.0005684932
suggestive O 0 0.00024795218
of O 0 0.00016863651
the O 0 0.00010445928
role O 0 7.440019e-05
of O 0 0.0005349115
pergolide B-Chemical 0 0.9999902
, O 0 0.000309022
was O 0 0.00012632186
observed O 0 6.7670604e-05
in O 0 6.755293e-05
12 O 0 4.776219e-05
/ O 0 0.00017472783
30 O 0 6.6465494e-05
( O 0 0.00011852265
40 O 0 0.00010530839
% O 0 0.00013404025
) O 0 0.00019421759
patients O 0 0.0001712208
including O 0 0.000116774376
two O 0 0.0001789097
with O 0 0.0006155065
heart B-Disease 0 0.118880086
failure I-Disease 0 0.48927572
. O 0 0.0027995978

Pergolide B-Chemical 0 0.9995901
was O 0 0.0025920775
discontinued O 0 0.0023739755
in O 0 0.00045958618
10 O 0 0.0003087149
patients O 0 0.0003247394
with O 0 0.00037341326
valvular B-Disease 0 0.5757476
heart I-Disease 0 0.52790415
disease I-Disease 0 0.90106076
, O 0 0.00019680934
resulting O 0 0.00010812005
in O 0 7.7113305e-05
a O 0 0.00013202701
lower O 0 0.0003070222
regurgitation O 0 0.9474507
grade O 0 0.03547719
( O 0 0.000313742
p O 0 0.00013594737
= O 0 0.00010813872
0 O 0 6.262719e-05
. O 0 5.130905e-05
01 O 0 0.00020775014
) O 0 7.8626756e-05
at O 0 2.926852e-05
the O 0 4.2141663e-05
second O 0 5.7479992e-05
transthoracic O 0 0.00029466816
echocardiography O 0 0.0004128437
and O 0 5.4139233e-05
the O 0 4.7163838e-05
two O 0 3.730285e-05
patients O 0 8.638473e-05
with O 0 0.000116106625
heart B-Disease 0 0.015125435
failure I-Disease 0 0.017864216
returned O 0 0.00015800112
to O 0 0.00012642212
nearly O 0 0.00026732832
normal O 0 0.00072298106
clinical O 0 0.0013906353
examination O 0 0.0012964987
. O 0 0.0016147047

This O 0 0.0033144632
study O 0 0.0013876046
supports O 0 0.0005763338
the O 0 0.00043041262
high O 0 0.0004928438
frequency O 0 0.00027416673
of O 0 0.00028616464
restrictive O 0 0.00090528175
valve B-Disease 0 0.5326871
regurgitation I-Disease 0 0.9989642
in O 0 0.00033352032
PD B-Disease 0 0.998577
patients O 0 0.00022017874
treated O 0 0.00016806008
with O 0 0.00036241487
pergolide B-Chemical 0 0.99998677
and O 0 0.00012990604
reveals O 0 6.674071e-05
that O 0 4.0175408e-05
a O 0 9.019683e-05
significant O 0 6.629548e-05
improvement O 0 8.80956e-05
is O 0 6.0245762e-05
usual O 0 5.897789e-05
when O 0 3.3893437e-05
the O 0 6.33609e-05
treatment O 0 8.5759886e-05
is O 0 9.487518e-05
converted O 0 0.00015626804
to O 0 0.00013685536
non O 0 0.00048154462
- O 0 0.0022281266
ergot O 0 0.99991333
dopamine B-Chemical 0 0.9998826
agonists O 0 0.85971886
. O 0 0.0025906072

Adriamycin B-Chemical 0 0.99862075
- O 0 0.006883004
induced O 0 0.0023043796
autophagic O 0 0.047195345
cardiomyocyte O 0 0.98208207
death B-Disease 0 0.9939964
plays O 0 0.00040630283
a O 0 0.00045071196
pathogenic O 0 0.00037448326
role O 0 0.00014049941
in O 0 0.00020267985
a O 0 0.00035288627
rat O 0 0.0006509877
model O 0 0.00049222907
of O 0 0.0010239921
heart B-Disease 0 0.26551154
failure I-Disease 0 0.63069624
. O 0 0.0031749366

BACKGROUND O 0 0.00759706
: O 0 0.0017404765
The O 0 0.00059258484
mechanisms O 0 0.0007242136
underlying O 0 0.0010106988
heart B-Disease 0 0.07366304
failure I-Disease 0 0.14366248
induced O 0 0.0008513031
by O 0 0.00079458306
adriamycin B-Chemical 0 0.9993845
are O 0 0.0004657244
very O 0 0.00060759246
complicated O 0 0.0009908075
and O 0 0.00061045034
still O 0 0.0008619644
unclear O 0 0.0013461323
. O 0 0.0022582503

The O 0 0.0015271016
aim O 0 0.0014038406
of O 0 0.001139275
this O 0 0.00084018084
study O 0 0.00067157316
was O 0 0.0003513321
to O 0 0.00016413412
investigate O 0 8.983305e-05
whether O 0 9.037713e-05
autophagy O 0 0.017552594
was O 0 0.00016606602
involved O 0 5.802483e-05
in O 0 6.594842e-05
the O 0 8.197816e-05
progression O 0 0.0016477352
of O 0 0.00021706684
heart B-Disease 0 0.11227039
failure I-Disease 0 0.142049
induced O 0 0.00031552624
by O 0 0.00036593623
adriamycin B-Chemical 0 0.9997987
, O 0 0.00023133899
so O 0 7.109808e-05
that O 0 4.7826463e-05
we O 0 4.1349078e-05
can O 0 5.794377e-05
develop O 0 0.000115159804
a O 0 0.00015354074
novel O 0 0.00016943997
treatment O 0 0.00018686555
strategy O 0 0.00031530642
for O 0 0.0004490168
heart B-Disease 0 0.20478311
failure I-Disease 0 0.6043631
. O 0 0.0028193318

METHODS O 0 0.0020629053
: O 0 0.0019895846
3 B-Chemical 0 0.0010892929
- I-Chemical 0 0.0019753943
methyladenine I-Chemical 0 0.15140676
( O 0 0.0023294773
3MA B-Chemical 0 0.9986313
) O 0 0.0013108323
, O 0 0.00034647255
a O 0 0.0002359054
specific O 0 0.00011915179
inhibitor O 0 0.0006682271
on O 0 0.00011638398
autophagy O 0 0.02211986
was O 0 0.00017314842
used O 0 8.4000996e-05
in O 0 9.804348e-05
a O 0 0.00021680126
heart B-Disease 0 0.03508003
failure I-Disease 0 0.050826043
model O 0 0.0002917431
of O 0 0.00033627215
rats O 0 0.0005435622
induced O 0 0.0007068304
by O 0 0.0016791439
adriamycin B-Chemical 0 0.9990362
. O 0 0.0035046923

Neonatal O 0 0.006779203
cardiomyocytes O 0 0.0066454266
were O 0 0.00087643496
isolated O 0 0.00048962655
from O 0 0.00047549288
Sprague O 0 0.018019486
- O 0 0.0008187383
Dawley O 0 0.0026879916
rat O 0 0.0003385906
hearts O 0 0.00044631105
and O 0 6.358674e-05
randomly O 0 2.1973285e-05
divided O 0 2.9631992e-05
into O 0 2.2726514e-05
controls O 0 0.000105658335
, O 0 9.7925185e-05
an O 0 0.000248515
adriamycin B-Chemical 0 0.9997508
- O 0 0.00070588465
treated O 0 0.00028014046
group O 0 0.00020525511
, O 0 0.00013174555
and O 0 0.00013393167
a O 0 0.00038209916
3MA B-Chemical 0 0.99771476
plus O 0 0.00073720014
adriamycin B-Chemical 0 0.99980336
- O 0 0.002990819
treated O 0 0.0020661238
group O 0 0.0022927874
. O 0 0.0020929172

We O 0 0.0013894704
then O 0 0.0009023194
examined O 0 0.00055855233
the O 0 0.000584889
morphology O 0 0.0010403096
, O 0 0.00046764442
expression O 0 0.0003709661
of O 0 0.00049577426
beclin O 0 0.69347507
1 O 0 0.00021238375
gene O 0 0.00033639494
, O 0 0.00024245605
mitochondrial O 0 0.23704354
permeability O 0 0.7725754
transition O 0 0.006541378
( O 0 0.0011125566
MPT O 0 0.99990714
) O 0 0.00056950963
, O 0 0.00024624154
and O 0 0.00047733512
Na O 1 0.9999361
+ O 0 0.0032654407
- O 0 0.002857467
K B-Chemical 1 0.9995548
+ O 0 0.0021458413
ATPase O 0 0.008156888
activity O 0 0.00062822335
in O 0 0.00086420914
vivo O 0 0.002737637
. O 0 0.0023566654

We O 0 0.0017801394
also O 0 0.0014547289
assessed O 0 0.0011501532
cell O 0 0.003574153
viability O 0 0.06054716
, O 0 0.0010893325
mitochondrial O 0 0.14355129
membrane O 0 0.0007507631
potential O 0 0.00023906378
changes O 0 0.00024386773
and O 0 0.0001897773
counted O 0 0.00016951043
autophagic O 0 0.0012550224
vacuoles O 0 0.0006559657
in O 0 0.0004669511
cultured O 0 0.001232074
cardiomyocytes O 0 0.018531425
. O 0 0.0025378885

In O 0 0.0018647043
addition O 0 0.0010546814
, O 0 0.0010396844
we O 0 0.00032701826
analyzed O 0 0.00034132792
the O 0 0.0002930374
expression O 0 0.0003239824
of O 0 0.0003771069
autophagy O 0 0.025582846
associated O 0 0.0002507025
gene O 0 0.0006203114
, O 0 0.00032155577
beclin O 0 0.53747493
1 O 0 0.0001434366
using O 0 0.00011492625
RT O 0 0.0017020005
- O 0 0.0004563616
PCR O 0 0.004151236
and O 0 0.00024212708
Western O 0 0.0006106688
blotting O 0 0.0008484335
in O 0 0.00028421782
an O 0 0.00055895234
animal O 0 0.0010515583
model O 0 0.0016951326
. O 0 0.0020146451

RESULTS O 0 0.0072659412
: O 0 0.00448184
3MA B-Chemical 0 0.97521645
significantly O 0 0.0021761192
improved O 0 0.0022691814
cardiac O 0 0.014011884
function O 0 0.0011906311
and O 0 0.0013022604
reduced O 0 0.0048629893
mitochondrial O 0 0.9957266
injury O 0 0.996971
. O 0 0.006415035

Furthermore O 0 0.003298256
, O 0 0.0036422957
adriamycin B-Chemical 0 0.99751115
induced O 0 0.0013345592
the O 0 0.00055569626
formation O 0 0.00095529406
of O 0 0.00043047537
autophagic O 0 0.0031864992
vacuoles O 0 0.0006101063
, O 0 0.00023587907
and O 0 0.0002783731
3MA B-Chemical 0 0.9959408
strongly O 0 0.00026353818
downregulated O 0 0.00015993677
the O 0 8.175029e-05
expression O 0 0.000113361
of O 0 0.00018288378
beclin O 0 0.68424344
1 O 0 0.00010903
in O 0 0.00013821071
adriamycin B-Chemical 0 0.9994524
- O 0 0.00048033707
induced O 0 0.00019199323
failing O 0 0.0016119757
heart O 0 0.034625463
and O 0 0.00018273335
inhibited O 0 0.00032410966
the O 0 0.00022974337
formation O 0 0.0008017225
of O 0 0.0007165765
autophagic O 0 0.0074323467
vacuoles O 0 0.0029082843
. O 0 0.0019498327

CONCLUSION O 0 0.026623454
: O 0 0.00416499
Autophagic O 0 0.07012927
cardiomyocyte O 0 0.8918477
death B-Disease 0 0.957726
plays O 0 0.00036874975
an O 0 0.00029472494
important O 0 0.00010379777
role O 0 9.7829805e-05
in O 0 0.00012250636
the O 0 0.00014193672
pathogenesis O 0 0.0003841921
of O 0 0.0003347196
heart B-Disease 0 0.10612842
failure I-Disease 0 0.12732014
in O 0 0.0003342588
rats O 0 0.00058562536
induced O 0 0.0007372701
by O 0 0.001714262
adriamycin B-Chemical 0 0.99902487
. O 0 0.003562248

Mitochondrial O 0 0.90097684
injury O 0 0.2047476
may O 0 0.0011745631
be O 0 0.0005640532
involved O 0 0.0002729417
in O 0 0.00025367923
the O 0 0.00026401752
progression O 0 0.0024927633
of O 0 0.000497694
heart B-Disease 0 0.1230541
failure I-Disease 0 0.16537331
caused O 0 0.0005651034
by O 0 0.00061342504
adriamycin B-Chemical 0 0.9986222
via O 0 0.00033740126
the O 0 0.00058414973
autophagy O 0 0.035322588
pathway O 0 0.0018840679
. O 0 0.0021671597

mToR O 0 0.019016346
inhibitors O 0 0.012547355
- O 0 0.004935355
induced O 0 0.003843953
proteinuria B-Disease 0 0.99993265
: O 0 0.0024954597
mechanisms O 0 0.001182554
, O 0 0.0010152424
significance O 0 0.00083300075
, O 0 0.0011813944
and O 0 0.0015304346
management O 0 0.0029140315
. O 0 0.0033558605

Massive O 0 0.014554061
urinary O 0 0.07293012
protein O 0 0.02510164
excretion O 0 0.9943686
has O 0 0.00047742724
been O 0 0.00019708446
observed O 0 0.00012494576
after O 0 5.912938e-05
conversion O 0 0.00043566234
from O 0 0.00011777199
calcineurin O 0 0.1293948
inhibitors O 0 0.000710819
to O 0 7.9416466e-05
mammalian O 0 6.378022e-05
target O 0 4.7015517e-05
of O 0 0.00014770616
rapamycin B-Chemical 0 0.84908265
( O 0 0.0004831195
mToR O 0 0.0037917418
) O 0 0.00024376334
inhibitors O 0 0.0005364213
, O 0 0.00016348744
especially O 0 0.00027165146
sirolimus B-Chemical 1 0.99990785
, O 0 0.00025146236
in O 0 0.00015662053
renal O 0 0.71636385
transplant O 0 0.020536628
recipients O 0 0.0014234307
with O 0 0.00095590495
chronic B-Disease 0 0.9666257
allograft I-Disease 0 0.9993216
nephropathy I-Disease 2 0.9999956
. O 0 0.006293271

Because O 0 0.003348844
proteinuria B-Disease 0 0.9996934
is O 0 0.0016698366
a O 0 0.00082350883
major O 0 0.00041151274
predictive O 0 0.00068388216
factor O 0 0.00091438374
of O 0 0.00038668347
poor O 0 0.0007216171
transplantation O 0 0.0019259994
outcome O 0 0.00023863293
, O 0 0.00014498454
many O 0 7.8834346e-05
studies O 0 8.241256e-05
focused O 0 5.707013e-05
on O 0 5.785604e-05
this O 0 0.00017993583
adverse O 0 0.009201585
event O 0 0.00055038964
during O 0 0.00015138424
the O 0 0.0003513244
past O 0 0.00057431695
years O 0 0.0010125827
. O 0 0.0016569251

Whether O 0 0.0035811597
proteinuria B-Disease 0 0.9997695
was O 0 0.001829379
due O 0 0.0004885088
to O 0 0.00061717717
sirolimus B-Chemical 1 0.99973935
or O 0 0.00034444875
only O 0 0.00021617951
a O 0 0.00016211582
consequence O 0 7.060547e-05
of O 0 0.00017853003
calcineurin O 0 0.33922258
inhibitors O 0 0.0024667305
withdrawal O 0 0.008799988
remained O 0 0.00014378909
unsolved O 0 0.00013022564
until O 0 3.1231742e-05
high O 0 0.00012722294
range O 0 0.00018027259
proteinuria B-Disease 0 0.9999864
has O 0 8.690593e-05
been O 0 4.097249e-05
observed O 0 3.763892e-05
during O 0 3.8882765e-05
sirolimus B-Chemical 1 0.9997037
therapy O 0 0.0001971386
in O 0 9.2750444e-05
islet O 0 0.09221616
transplantation O 0 0.0012868979
and O 0 0.000112911126
in O 0 0.000101108824
patients O 0 0.000219976
who O 0 0.00033704404
received O 0 0.0003967633
sirolimus B-Chemical 1 0.9997056
de O 0 0.0072961748
novo O 0 0.011739687
. O 0 0.002417925

Podocyte O 0 0.8884735
injury O 0 0.28852266
and O 0 0.0017308276
focal O 0 0.011503843
segmental O 0 0.5426053
glomerulosclerosis B-Disease 2 0.9999962
have O 0 0.0004786779
been O 0 0.0001418757
related O 0 6.357389e-05
to O 0 0.00011037263
mToR O 0 0.0008586023
inhibition O 0 0.0003695528
in O 0 0.000120551784
some O 0 0.00014267204
patients O 0 0.00023468296
, O 0 0.00014173696
but O 0 0.00011228537
the O 0 0.0001042483
pathways O 0 0.0001506895
underlying O 0 0.0002972117
these O 0 0.00051342766
lesions O 0 0.00548715
remain O 0 0.00081488286
hypothetic O 0 0.0043200743
. O 0 0.002043566

We O 0 0.001563881
discuss O 0 0.0010366036
herein O 0 0.001170365
the O 0 0.00067019905
possible O 0 0.00047199204
mechanisms O 0 0.00050924724
and O 0 0.0003742151
the O 0 0.00031377855
significance O 0 0.00032420305
of O 0 0.0006005078
mToR O 0 0.008933539
blockade O 0 0.09086732
- O 0 0.0033519904
induced O 0 0.005805944
proteinuria B-Disease 0 0.9999536
. O 0 0.0065564797

Neuropsychiatric O 0 0.101092264
side O 0 0.011252473
effects O 0 0.002461112
after O 0 0.0010705359
the O 0 0.0018683376
use O 0 0.0024578061
of O 0 0.006119057
mefloquine B-Chemical 0 0.9983504
. O 0 0.008525899

This O 0 0.0036266926
study O 0 0.0019377732
describes O 0 0.0022327197
neuropsychiatric O 0 0.97981185
side O 0 0.009352868
effects O 0 0.000693238
in O 0 0.0004288645
patients O 0 0.0004786907
after O 0 0.00020486406
treatment O 0 0.0007092579
with O 0 0.002653415
mefloquine B-Chemical 0 0.9989267
. O 0 0.004075571

Reactions O 0 0.005367581
consisted O 0 0.0012599898
mainly O 0 0.0011390634
of O 0 0.0018836466
seizures B-Disease 0 0.99984765
, O 0 0.0027524238
acute O 0 0.95866716
psychoses B-Disease 0 0.9999497
, O 0 0.0031513674
anxiety B-Disease 0 0.99986017
neurosis I-Disease 0 0.9998816
, O 0 0.00040429816
and O 0 0.00016968558
major O 0 0.00017094563
disturbances B-Disease 0 0.0036072396
of I-Disease 0 0.00048404123
sleep I-Disease 0 0.011241051
- I-Disease 0 0.0009947716
wake I-Disease 0 0.0013192478
rhythm I-Disease 0 0.004709604
. O 0 0.0019022305

Side O 0 0.06164146
effects O 0 0.0017162854
occurred O 0 0.00074573257
after O 0 0.00026564384
both O 0 0.00036176102
therapeutic O 0 0.0006426393
and O 0 0.0003801775
prophylactic O 0 0.0010248144
intake O 0 0.07441725
and O 0 0.0002800737
were O 0 0.00022388253
graded O 0 0.0004255816
from O 0 0.0003000889
moderate O 0 0.0024535297
to O 0 0.0010358673
severe O 0 0.033328205
. O 0 0.002827501

In O 0 0.0020372355
a O 0 0.0020864767
risk O 0 0.0032762522
analysis O 0 0.0006859108
of O 0 0.0009344403
neuropsychiatric O 0 0.98902637
side O 0 0.012869403
effects O 0 0.00041682392
in O 0 0.00028152068
Germany O 0 0.0012441486
, O 0 0.00023105944
it O 0 0.00013860216
is O 0 8.785701e-05
estimated O 0 6.854931e-05
that O 0 5.2245694e-05
one O 0 5.9136262e-05
of O 0 0.00011925647
8 O 0 8.702493e-05
, O 0 0.00013609628
000 O 0 0.00030900814
mefloquine B-Chemical 0 0.9959836
users O 0 0.0010406169
suffers O 0 0.0010898194
from O 0 0.00038573382
such O 0 0.00059842516
reactions O 0 0.005356562
. O 0 0.0021968025

The O 0 0.0017418134
incidence O 0 0.0019348855
calculation O 0 0.00067872094
revealed O 0 0.00041357384
that O 0 0.00021530263
one O 0 0.0001773708
of O 0 0.00028220945
215 O 0 0.0014297508
therapeutic O 0 0.0004782528
users O 0 0.0005927693
had O 0 0.00015152548
reactions O 0 0.00078357616
, O 0 0.00011831938
compared O 0 4.930768e-05
with O 0 8.100285e-05
one O 0 4.9076272e-05
of O 0 9.7334385e-05
13 O 0 8.0588805e-05
, O 0 6.333015e-05
000 O 0 6.186261e-05
in O 0 4.341697e-05
the O 0 5.8222548e-05
prophylaxis O 0 0.00015791466
group O 0 0.00011386063
, O 0 8.284197e-05
making O 0 9.037204e-05
the O 0 8.288133e-05
risk O 0 0.0006076064
of O 0 0.00021614345
neuropsychiatric O 0 0.9852704
reactions O 0 0.0016236625
after O 0 5.762824e-05
mefloquine B-Chemical 0 0.99641883
treatment O 0 0.00011717695
60 O 0 8.649626e-05
times O 0 5.699649e-05
higher O 0 0.00016247561
than O 0 0.0001761319
after O 0 0.00025993132
prophylaxis O 0 0.0019395744
. O 0 0.0017919255

Therefore O 0 0.00195695
, O 0 0.0017071317
certain O 0 0.0008132225
limitations O 0 0.0005200908
for O 0 0.00049235014
malaria B-Disease 0 0.058363985
prophylaxis O 0 0.0011072662
and O 0 0.00043935538
treatment O 0 0.00051988935
with O 0 0.0014014281
mefloquine B-Chemical 0 0.9990244
are O 0 0.0014592757
recommended O 0 0.0019654918
. O 0 0.0023796922

Prenatal O 0 0.01672646
protein O 0 0.0026742571
deprivation O 0 0.0021596453
alters O 0 0.0011134149
dopamine B-Chemical 0 0.9995603
- O 0 0.0012563092
mediated O 0 0.00025180954
behaviors O 0 0.00086899305
and O 0 0.00050610304
dopaminergic O 0 0.2566591
and O 0 0.0010451176
glutamatergic O 0 0.8301363
receptor O 0 0.039526384
binding O 0 0.0025160501
. O 0 0.0025737283

Epidemiological O 0 0.00574322
evidence O 0 0.0014620674
indicates O 0 0.00082377176
that O 0 0.0006021751
prenatal O 0 0.0033589848
nutritional O 0 0.0034142388
deprivation O 0 0.000996921
may O 0 0.00035978705
increase O 0 0.00044126826
the O 0 0.00063684967
risk O 0 0.005406482
of O 0 0.0037115845
schizophrenia B-Disease 2 0.99967194
. O 0 0.0041899444

The O 0 0.0015920573
goal O 0 0.0016577359
of O 0 0.0011922461
these O 0 0.0009244684
studies O 0 0.0005770873
was O 0 0.00037938438
to O 0 0.00019960671
use O 0 0.00016309074
an O 0 0.0001908832
animal O 0 0.00019028662
model O 0 0.00011649334
to O 0 6.229702e-05
examine O 0 3.1372223e-05
the O 0 5.9890725e-05
effects O 0 8.717328e-05
of O 0 0.0001481704
prenatal O 0 0.00093889225
protein O 0 0.0002264942
deprivation O 0 0.00021857483
on O 0 5.497136e-05
behaviors O 0 0.00032946005
and O 0 0.00017408177
receptor O 0 0.0018630433
binding O 0 0.00021194274
with O 0 0.00028633574
relevance O 0 0.00029097614
to O 0 0.00095140183
schizophrenia B-Disease 2 0.9994468
. O 0 0.0028912767

We O 0 0.001562197
report O 0 0.0015554472
that O 0 0.00074235885
prenatally O 0 0.020766597
protein O 0 0.0011027408
deprived O 0 0.00094069773
( O 0 0.0011520359
PD O 0 0.99861395
) O 0 0.00058690493
female O 0 0.0005495232
rats O 0 0.0001617218
showed O 0 8.065068e-05
an O 0 0.00010515436
increased O 0 0.00019366469
stereotypic O 0 0.036886767
response O 0 0.00014169494
to O 0 0.00019947486
apomorphine B-Chemical 1 0.9999702
and O 0 0.00017914135
an O 0 0.00015920096
increased O 0 0.00027515762
locomotor O 0 0.02205567
response O 0 0.00026428318
to O 0 0.0005306787
amphetamine B-Chemical 1 0.9999685
in O 0 0.0016758409
adulthood O 0 0.067839146
. O 0 0.002065241

These O 0 0.003933615
differences O 0 0.0019533825
were O 0 0.0021899713
not O 0 0.001855656
observed O 0 0.0022334866
during O 0 0.0027562734
puberty O 0 0.13095115
. O 0 0.0073541966

No O 0 0.0028740978
changes O 0 0.0021440315
in O 0 0.0026251962
haloperidol B-Chemical 1 0.99998605
- O 0 0.0061633782
induced O 0 0.0031564976
catalepsy B-Disease 0 0.99998915
or O 0 0.0018036558
MK B-Chemical 0 0.9975284
- I-Chemical 0 0.003055903
801 I-Chemical 0 0.4934886
- O 0 0.00060677185
induced O 0 0.0003615609
locomotion O 0 0.0035540052
were O 0 0.00037844808
seen O 0 0.0004593293
following O 0 0.0008771314
PD O 0 0.990949
. O 0 0.0029044787

In O 0 0.0018885372
addition O 0 0.0013124902
, O 0 0.0026654024
PD O 0 0.9966419
female O 0 0.00335035
rats O 0 0.00066687446
showed O 0 0.00029068085
increased O 0 0.0004571209
( O 0 0.00038617896
3 O 0 0.00018395639
) O 0 0.0006783989
H B-Chemical 0 0.99929273
- O 0 0.0016803369
MK B-Chemical 0 0.9859547
- I-Chemical 0 0.001117295
801 I-Chemical 0 0.08886305
binding O 0 0.0001320017
in O 0 8.757662e-05
the O 0 0.00011320739
striatum O 0 0.0049828845
and O 0 0.00020844696
hippocampus O 0 0.017369121
, O 0 0.00028129749
but O 0 0.00022697628
not O 0 0.00023246706
in O 0 0.0003658548
the O 0 0.0007562793
cortex O 0 0.015699979
. O 0 0.0023696178

PD O 0 0.9944332
female O 0 0.006688744
rats O 0 0.0014288048
also O 0 0.0005699805
showed O 0 0.00047296716
increased O 0 0.00069464237
( O 0 0.0005690446
3 O 0 0.00025934412
) O 0 0.00089313276
H B-Chemical 0 0.9993938
- O 0 0.0041260645
haloperidol B-Chemical 1 0.99999344
binding O 0 0.00046004314
and O 0 0.00032942017
decreased O 0 0.0019701407
dopamine B-Chemical 0 0.9997948
transporter O 0 0.02072493
binding O 0 0.0006113199
in O 0 0.00083301077
striatum O 0 0.037655983
. O 0 0.0023111692

No O 0 0.0032251226
statistically O 0 0.001426444
significant O 0 0.00072859286
changes O 0 0.0005902118
in O 0 0.00033913893
behavior O 0 0.00041083168
or O 0 0.00027383756
receptor O 0 0.002541846
binding O 0 0.00020530695
were O 0 0.00013455082
found O 0 0.0001021702
in O 0 0.00017442406
PD O 0 0.9961515
males O 0 0.00026391985
with O 0 8.943228e-05
the O 0 6.962143e-05
exception O 0 6.7598114e-05
of O 0 0.00012626624
increased O 0 0.00028189135
( O 0 0.00026243617
3 O 0 0.0001408013
) O 0 0.0006010927
H B-Chemical 0 0.99893683
- O 0 0.00196223
MK B-Chemical 0 0.97843504
- I-Chemical 0 0.0019227206
801 I-Chemical 0 0.123216406
binding O 0 0.0006725562
in O 0 0.00085690647
cortex O 0 0.015241506
. O 0 0.0024675005

This O 0 0.0038441499
animal O 0 0.002080048
model O 0 0.0011009014
may O 0 0.0005374767
be O 0 0.00033410938
useful O 0 0.00020922215
to O 0 0.00014237157
explore O 0 9.740124e-05
the O 0 0.00012202462
mechanisms O 0 0.00015235011
by O 0 0.00013133576
which O 0 0.00020741584
prenatal O 0 0.006641414
nutritional B-Disease 0 0.58695614
deficiency I-Disease 0 0.9915399
enhances O 0 0.00020017313
risk O 0 0.006301106
for O 0 0.00017061897
schizophrenia B-Disease 2 0.9999043
in O 0 0.00014442226
humans O 0 0.00023101321
and O 0 7.3406234e-05
may O 0 4.3952707e-05
also O 0 4.636656e-05
have O 0 3.246187e-05
implications O 0 3.9134757e-05
for O 0 4.274759e-05
developmental O 0 0.00018539872
processes O 0 0.0001221718
leading O 0 0.00013615651
to O 0 9.391652e-05
differential O 0 0.00025787164
sensitivity O 0 0.0007424452
to O 0 0.00034576227
drugs O 0 0.017543903
of O 0 0.001855292
abuse O 0 0.8028341
. O 0 0.0029125009

Adverse O 0 0.008170685
effects O 0 0.0027782419
of O 0 0.003429004
topical O 0 0.88412064
papaverine B-Chemical 0 0.999559
on O 0 0.0015479517
auditory O 0 0.004988656
nerve O 0 0.023362119
function O 0 0.004432681
. O 0 0.004381588

BACKGROUND O 0 0.01192094
: O 0 0.00555206
Papaverine B-Chemical 0 0.99940455
hydrochloride I-Chemical 0 0.99951065
is O 0 0.0011122858
a O 0 0.0006467061
direct O 0 0.0003535026
- O 0 0.000546676
acting O 0 0.0004473587
vasodilator O 0 0.72678167
used O 0 0.00020916808
to O 0 0.00022594784
manage O 0 0.0010074562
vasospasm B-Disease 2 0.999889
during O 0 0.000291234
various O 0 0.00059814606
neurosurgical O 0 0.0016702048
operations O 0 0.0015744197
. O 0 0.0018794467

Transient O 0 0.112721086
cranial B-Disease 0 0.45169213
nerve I-Disease 0 0.2647917
dysfunction I-Disease 0 0.98509085
has O 0 0.0008046493
been O 0 0.00039771813
described O 0 0.00029070248
in O 0 0.0002838333
a O 0 0.00040028375
few O 0 0.00024083062
cases O 0 0.0006108353
with O 0 0.0013888883
topical O 0 0.974126
papaverine B-Chemical 0 0.99981314
. O 0 0.004787791

This O 0 0.0035832296
study O 0 0.0015791784
supports O 0 0.00069895474
previous O 0 0.0005202899
reports O 0 0.0005196265
and O 0 0.00031466348
provides O 0 0.00019242737
neurophysiological O 0 0.00058695633
evidence O 0 0.00016621365
of O 0 0.00023334243
an O 0 0.0003316401
adverse O 0 0.0071244296
effect O 0 0.00025655082
on O 0 0.00022782662
the O 0 0.000529865
auditory O 0 0.0029862495
nerve O 0 0.04013748
. O 0 0.0027477748

METHODS O 0 0.0017578277
: O 0 0.0013243468
We O 0 0.0004775219
conducted O 0 0.00045822593
a O 0 0.00055172533
retrospective O 0 0.0012360864
review O 0 0.00041479687
of O 0 0.00018507654
70 O 0 0.00013585355
consecutive O 0 0.00010720267
microvascular O 0 0.05834406
decompression O 0 0.0006336364
operations O 0 0.00011398459
and O 0 8.7818305e-05
studied O 0 0.000105280276
those O 0 0.00013331167
patients O 0 0.00017455085
who O 0 0.00023074486
received O 0 0.00023674381
topical O 0 0.8525046
papaverine B-Chemical 0 0.99990153
for O 0 0.0029483193
vasospasm B-Disease 2 0.99993205
. O 0 0.0039433795

Topical O 0 0.99462247
papaverine B-Chemical 0 0.99975866
was O 0 0.0021808883
used O 0 0.0006407388
as O 0 0.00041240008
a O 0 0.00037086714
direct O 0 0.000213601
therapeutic O 0 0.0004360263
action O 0 0.00036472248
to O 0 0.000256191
manage O 0 0.00143149
vasospasm B-Disease 2 0.9999615
in O 0 0.00039571323
a O 0 0.0004151097
total O 0 0.00039635014
of O 0 0.0007373607
11 O 0 0.0009530018
patients O 0 0.0018131395
. O 0 0.001954692

The O 0 0.0012853789
timing O 0 0.00087410025
of O 0 0.00176005
papaverine B-Chemical 0 0.9994319
application O 0 0.0008617928
and O 0 0.00036100743
ongoing O 0 0.0002784758
operative O 0 0.0004092997
events O 0 0.0006861143
was O 0 0.00023639106
reviewed O 0 0.00025521978
relative O 0 0.00015392949
to O 0 0.00018490566
changes O 0 0.00035323732
in O 0 0.00040607728
neurophysiological O 0 0.0019560673
recordings O 0 0.0018110676
. O 0 0.0020414735

Brainstem O 0 0.005727981
auditory O 0 0.0023880124
evoked O 0 0.0031366528
potentials O 0 0.003272844
( O 0 0.0011608199
BAEPs O 0 0.031359624
) O 0 0.00065180287
were O 0 0.00022982665
routinely O 0 0.00014930185
used O 0 0.00012702026
to O 0 0.00013672166
monitor O 0 0.00016277845
cochlear O 0 0.0015708504
nerve O 0 0.002472943
function O 0 0.0003769897
during O 0 0.00027093934
these O 0 0.0009137017
operations O 0 0.0016560853
. O 0 0.0019814651

FINDINGS O 0 0.005752166
: O 0 0.0023763618
A O 0 0.0038769392
temporal O 0 0.0012054874
relationship O 0 0.00029154596
was O 0 0.00036438747
found O 0 0.00020860622
between O 0 0.00018146583
topical O 0 0.7448306
papaverine B-Chemical 0 0.99993277
and O 0 0.0006148474
BAEP O 0 0.35013607
changes O 0 0.00034324176
leading O 0 0.0003675058
to O 0 0.00027302213
complete O 0 0.00048601258
waveform O 0 0.0013141774
loss O 0 0.0040531964
. O 0 0.0023782502

The O 0 0.0012098432
average O 0 0.00071584136
temporal O 0 0.0014416786
delay O 0 0.0009691064
between O 0 0.0005515124
papaverine B-Chemical 0 0.9996661
and O 0 0.00046167622
the O 0 0.00023991917
onset O 0 0.00028210535
of O 0 0.00025903326
an O 0 0.00038689072
adverse O 0 0.051304437
BAEP O 0 0.40566754
change O 0 0.0005380066
was O 0 0.0006154689
5 O 0 0.00057299074
min O 0 0.0013845762
. O 0 0.0021367322

In O 0 0.0018734221
10 O 0 0.0013306633
of O 0 0.001115392
11 O 0 0.0007723586
patients O 0 0.00065918255
, O 0 0.0005457477
BAEP O 0 0.11307434
waves O 0 0.0016862449
II O 0 0.009986738
/ O 0 0.001780309
III O 0 0.023953296
- O 0 0.001027362
V O 0 0.15027335
completely O 0 0.0002414005
disappeared O 0 0.00015229521
within O 0 6.0580827e-05
2 O 0 0.00011284956
to O 0 0.0001392753
25 O 0 0.00031995247
min O 0 0.00047504078
after O 0 0.00060147065
papaverine B-Chemical 0 0.9987093
. O 0 0.003366667

Eight O 0 0.0028259647
of O 0 0.0014912275
these O 0 0.0010484759
10 O 0 0.000615276
patients O 0 0.0005778279
had O 0 0.00031631836
complete O 0 0.0002794016
loss O 0 0.0006254925
of O 0 0.0004855192
BAEP O 0 0.08234326
waveforms O 0 0.00053576723
within O 0 0.00023927883
10 O 0 0.0006869759
min O 0 0.0016002404
. O 0 0.0024349794

One O 0 0.0024296714
patient O 0 0.0016393345
showed O 0 0.0008451053
no O 0 0.00040968324
recovery O 0 0.0007941949
of O 0 0.0004769576
later O 0 0.00026017978
waves O 0 0.0009064733
and O 0 0.00038547593
a O 0 0.0006187396
delayed O 0 0.0034371058
profound O 0 0.15313888
sensorineural B-Disease 2 0.9999876
hearing I-Disease 2 0.99986196
loss I-Disease 2 0.9612519
. O 0 0.0061699417

The O 0 0.001201443
average O 0 0.00068285293
recovery O 0 0.0009328848
time O 0 0.00030546045
of O 0 0.00050003856
BAEP O 0 0.046033975
waveforms O 0 0.00045312912
to O 0 0.00027042915
pre O 0 0.0007268722
- O 0 0.0011690947
papaverine B-Chemical 0 0.9993718
baseline O 0 0.0004633589
values O 0 0.0005292845
was O 0 0.00074569136
39 O 0 0.0012470649
min O 0 0.0016916903
. O 0 0.0024055506

CONCLUSIONS O 0 0.017101588
: O 0 0.003803898
Topical O 0 0.9724811
papaverine B-Chemical 0 0.9997254
for O 0 0.0005019766
the O 0 0.00033728738
treatment O 0 0.00031669915
of O 0 0.00089272065
vasospasm B-Disease 2 0.9999808
was O 0 0.00037565807
associated O 0 0.00011557486
with O 0 0.00012768527
the O 0 8.768952e-05
onset O 0 0.00012977244
of O 0 0.00012531315
a O 0 0.00016034096
transient O 0 0.0012183713
disturbance O 0 0.0019956147
in O 0 9.0231755e-05
neurophysiological O 0 0.00029184294
function O 0 0.00011773672
of O 0 0.00015680955
the O 0 0.00018541269
ascending O 0 0.0009783108
auditory O 0 0.0010109647
brainstem O 0 0.005439115
pathway O 0 0.0014386516
. O 0 0.0018779696

The O 0 0.0012917067
complete O 0 0.0010262448
disappearance O 0 0.0016438711
of O 0 0.0008113014
BAEP O 0 0.115846545
waveforms O 0 0.00052358076
with O 0 0.00029626762
a O 0 0.00024446205
consistent O 0 0.0001496846
temporal O 0 0.00048399848
delay O 0 0.000250557
suggests O 0 8.18955e-05
a O 0 0.00018078089
possible O 0 0.00015725564
adverse B-Disease 0 0.0048071356
effect I-Disease 0 0.00020047878
on I-Disease 0 0.00017346207
the I-Disease 0 0.00038913262
proximal I-Disease 0 0.0011802461
eighth I-Disease 0 0.004930713
nerve I-Disease 0 0.025787007
. O 0 0.0026470907

Recommendations O 0 0.0026253785
to O 0 0.001471689
avoid O 0 0.0011082592
potential O 0 0.0015009522
cranial B-Disease 0 0.103239134
nerve I-Disease 0 0.05598616
deficits I-Disease 0 0.7670785
from O 0 0.0023615416
papaverine B-Chemical 0 0.9995963
are O 0 0.0023421962
provided O 0 0.0027245535
. O 0 0.003201704

Simvastatin B-Chemical 0 0.99990964
- I-Chemical 0 0.1980954
ezetimibe I-Chemical 0 0.99994266
- O 0 0.00900751
induced O 0 0.0032555487
hepatic B-Disease 0 0.9885367
failure I-Disease 0 0.7382001
necessitating O 0 0.0057484447
liver O 0 0.9504313
transplantation O 0 0.15847008
. O 0 0.0038868263

Abstract O 0 0.015234343
Serum O 0 0.5507073
aminotransferase O 0 0.99072695
elevations O 0 0.1247861
are O 0 0.00055960077
a O 0 0.00041504405
commonly O 0 0.0002735839
known O 0 0.00029509186
adverse O 0 0.0063389153
effect O 0 0.00016502138
of O 0 0.00028779314
3 O 0 0.00017810361
- O 0 0.00086850836
hydroxy O 0 0.999908
- O 0 0.0011558897
3 O 0 0.00018145876
- O 0 0.00085559895
methylglutaryl O 0 0.99247724
coenzyme O 0 0.9999844
A O 0 0.79832935
reductase O 0 0.99970514
inhibitor O 0 0.027298398
( O 0 0.0021330207
statin B-Chemical 1 0.9979074
) O 0 0.0022171745
therapy O 0 0.0024728088
. O 0 0.0021487223

However O 0 0.0032900588
, O 0 0.004038062
hepatotoxic B-Disease 0 0.99961346
events O 0 0.006040393
have O 0 0.00040036865
not O 0 0.00026065297
been O 0 0.00016834766
widely O 0 0.00013112191
published O 0 0.00017807781
with O 0 0.00036607514
ezetimibe B-Chemical 0 0.99991405
or O 0 0.00020763982
the O 0 0.00020236411
combination O 0 0.0006502808
agent O 0 0.10809107
simvastatin B-Chemical 1 0.99999416
- I-Chemical 0 0.32798928
ezetimibe I-Chemical 0 0.9999702
. O 0 0.0056246454

We O 0 0.0015366598
describe O 0 0.0011096062
a O 0 0.0012781292
70 O 0 0.0010229269
- O 0 0.001034758
year O 0 0.00031425996
- O 0 0.00050959346
old O 0 0.0003284634
Hispanic O 0 0.021759633
woman O 0 0.00077908835
who O 0 0.0003325136
developed O 0 0.00069294637
fulminant B-Disease 2 0.99993217
hepatic I-Disease 2 0.9993292
failure I-Disease 2 0.9670081
necessitating O 0 0.00061350927
liver O 0 0.7732878
transplantation O 0 0.0015579669
10 O 0 4.4677192e-05
weeks O 0 1.3338761e-05
after O 0 1.42455065e-05
conversion O 0 0.00017254686
from O 0 8.433457e-05
simvastatin B-Chemical 1 0.9999461
40 O 0 0.00017824206
mg O 0 0.0033109211
/ O 0 0.00022432054
day O 0 4.305357e-05
to O 0 0.00010089876
simvastatin B-Chemical 1 0.9999411
10 I-Chemical 0 0.00022993251
mg I-Chemical 0 0.026872642
- I-Chemical 0 0.0012176735
ezetimibe I-Chemical 0 0.9998827
40 I-Chemical 0 0.0007242754
mg I-Chemical 0 0.01120992
/ O 0 0.0019239436
day O 0 0.00087937363
. O 0 0.0016983585

The O 0 0.0017120697
patient O 0 0.0015621367
' O 0 0.0012466611
s O 0 0.0009355409
lipid O 0 0.102809116
panel O 0 0.0006455791
had O 0 0.00025769247
been O 0 0.00013071344
maintained O 0 0.00015740594
with O 0 0.00037134896
simvastatin B-Chemical 1 0.99995196
for O 0 0.00015616303
18 O 0 9.863162e-05
months O 0 3.3101307e-05
before O 0 3.761782e-05
the O 0 0.000115559
conversion O 0 0.0005884762
without O 0 0.00028921684
evidence O 0 0.0005386588
of O 0 0.0032010134
hepatotoxicity B-Disease 0 0.9999746
. O 0 0.005057193

A O 0 0.016023584
routine O 0 0.0018172303
laboratory O 0 0.0017072618
work O 0 0.0009618788
- O 0 0.0008729613
up O 0 0.00034550868
10 O 0 0.00021883383
weeks O 0 9.698751e-05
after O 0 0.0001025315
conversion O 0 0.0006918631
revealed O 0 0.0004079391
elevated O 0 0.004087788
serum O 0 0.34299415
aminotransferase O 0 0.99775106
levels O 0 0.0042616674
. O 0 0.0032264013

Simvastatinezetimibe B-Chemical 0 0.27092242
and O 0 0.0038624755
escitalopram B-Chemical 0 0.9997824
( O 0 0.0015511757
which O 0 0.0005816342
she O 0 0.00027969235
was O 0 0.0002625543
taking O 0 0.00029965377
for O 0 0.0001965991
depression B-Disease 0 0.9721788
) O 0 0.0004164943
were O 0 0.00016085012
discontinued O 0 0.0004952016
, O 0 0.00014758775
and O 0 0.00011853565
other O 0 0.00011314588
potential O 0 0.00019634621
causes O 0 0.0005069618
of O 0 0.0018725138
hepatotoxicity B-Disease 0 0.9999888
were O 0 0.0021479046
excluded O 0 0.002133244
. O 0 0.0019841008

A O 0 0.024021113
repeat O 0 0.0025428734
work O 0 0.0014487292
- O 0 0.0012144904
up O 0 0.00044815388
revealed O 0 0.00030367757
further O 0 0.00041263815
elevations O 0 0.0083684875
in O 0 0.00035978
aminotransferase O 0 0.974078
levels O 0 0.00030764856
, O 0 0.00023201865
and O 0 0.0002122987
liver O 0 0.5286002
biopsy O 0 0.00060252525
revealed O 0 9.914337e-05
evidence O 0 8.3575695e-05
of O 0 0.00020557572
moderate O 0 0.0038389934
- O 0 0.00055983226
to O 0 0.00028259098
- O 0 0.001060253
severe O 0 0.063669994
drug B-Disease 0 0.9821369
toxicity I-Disease 2 0.99981004
. O 0 0.004583705

She O 0 0.0049756574
underwent O 0 0.0028360526
liver O 0 0.14986742
transplantation O 0 0.006117186
with O 0 0.0013753518
an O 0 0.0013489698
uneventful O 0 0.0015832086
postoperative O 0 0.0027548806
course O 0 0.002180524
. O 0 0.00334102

Her O 0 0.008909202
aminotransferase O 0 0.81736493
levels O 0 0.0010426834
returned O 0 0.00059836137
to O 0 0.00035743872
normal O 0 0.0005246519
by O 0 0.00024281393
postoperative O 0 0.00035930393
day O 0 0.00010630786
23 O 0 0.0001916916
, O 0 0.00014959999
and O 0 0.00014886333
her O 0 0.000224429
2 O 0 0.00012131968
- O 0 0.00019986171
year O 0 7.8461526e-05
follow O 0 8.803613e-05
- O 0 0.00025126798
up O 0 0.00020854516
showed O 0 0.00029811557
no O 0 0.00042889456
adverse O 0 0.0580408
events O 0 0.007865044
. O 0 0.0025962808

Ezetimibe B-Chemical 0 0.9983724
undergoes O 0 0.0021895543
extensive O 0 0.0025393846
glucuronidation O 0 0.99971634
by O 0 0.002830844
uridine B-Chemical 0 0.9995326
diphosphate I-Chemical 0 0.99450976
glucoronosyltransferases O 0 0.32149374
( O 0 0.0019947696
UGT O 0 0.9996896
) O 0 0.00033525552
in O 0 9.491572e-05
the O 0 0.00010769909
intestine O 0 0.00079629617
and O 0 0.00017276715
liver O 0 0.4650317
and O 0 0.00013241242
may O 0 6.017685e-05
have O 0 4.3276053e-05
inhibited O 0 0.00014463521
the O 0 0.00018891685
glucuronidation O 0 0.9999368
of O 0 0.0063807406
simvastatin B-Chemical 1 0.9999995
hydroxy I-Chemical 0 0.9999976
acid I-Chemical 0 0.9996996
, O 0 0.00036090604
resulting O 0 0.00017028983
in O 0 0.00014440698
increased O 0 0.0008447479
simvastatin B-Chemical 1 0.9999709
exposure O 0 0.0016226557
and O 0 0.0009602535
subsequent O 0 0.0029705777
hepatotoxicity B-Disease 0 0.99997795
. O 0 0.0046426035

To O 0 0.002221735
our O 0 0.0023425529
knowledge O 0 0.0021677671
, O 0 0.0010225149
this O 0 0.0005914913
is O 0 0.00033291834
the O 0 0.00019824601
first O 0 0.00011435071
case O 0 0.00016539282
report O 0 0.00034942178
of O 0 0.0011596119
simvastatin B-Chemical 1 0.9999981
- I-Chemical 0 0.17708978
ezetimibe I-Chemical 0 0.99999726
- O 0 0.0033852146
induced O 0 0.0006884637
liver B-Disease 0 0.9533427
failure I-Disease 0 0.2208921
that O 0 0.00022968359
resulted O 0 0.00043048934
in O 0 0.0006569233
liver O 0 0.8525704
transplantation O 0 0.10272956
. O 0 0.0024389361

We O 0 0.0015567124
postulate O 0 0.0014167022
that O 0 0.0005829706
the O 0 0.00053387805
mechanism O 0 0.00047506776
of O 0 0.00048528603
the O 0 0.00050619256
simvastatinezetimibe B-Chemical 0 0.7308012
- O 0 0.0013638642
induced O 0 0.001353863
hepatotoxicity B-Disease 0 0.9999968
is O 0 0.00036595194
the O 0 0.0001745277
increased O 0 0.0007719587
simvastatin B-Chemical 1 0.99998057
exposure O 0 0.0013204557
by O 0 0.000926771
ezetimibe B-Chemical 0 0.99995804
inhibition O 0 0.014110833
of O 0 0.007250494
UGT O 0 0.9997154
enzymes O 0 0.08432786
. O 0 0.0025055525

Clinicians O 0 0.0032849838
should O 0 0.0007824737
be O 0 0.00060400803
aware O 0 0.00042141296
of O 0 0.0004912651
potential O 0 0.00096625567
hepatotoxicity B-Disease 0 0.99999416
with O 0 0.031870343
simvastatin B-Chemical 1 0.99999857
- I-Chemical 0 0.095648
ezetimibe I-Chemical 0 0.9999943
especially O 0 0.00043911126
in O 0 0.00016163301
elderly O 0 0.033624638
patients O 0 0.00014470694
and O 0 5.8232814e-05
should O 0 2.2431097e-05
carefully O 0 2.5185254e-05
monitor O 0 4.3161228e-05
serum O 0 0.0061763395
aminotransferase O 0 0.9420146
levels O 0 0.000120064105
when O 0 5.9329323e-05
starting O 0 9.254989e-05
therapy O 0 0.00025734998
and O 0 0.0002978616
titrating O 0 0.0015837528
the O 0 0.0009062885
dosage O 0 0.03181034
. O 0 0.002170433

Massive O 0 0.14595953
proteinuria B-Disease 0 0.9998159
and O 0 0.0037205846
acute B-Disease 0 0.7241187
renal I-Disease 0 0.98510724
failure I-Disease 0 0.34111512
after O 0 0.00021010655
oral O 0 0.3287431
bisphosphonate B-Chemical 0 0.99991643
( O 0 0.0026505673
alendronate B-Chemical 0 0.9998839
) O 0 0.0006071236
administration O 0 0.0006571224
in O 0 0.00014315241
a O 0 0.00022747325
patient O 0 0.00024828952
with O 0 0.00045785392
focal B-Disease 0 0.019886617
segmental I-Disease 0 0.73633176
glomerulosclerosis I-Disease 2 0.9999902
. O 0 0.006579048

A O 0 0.027361067
61 O 0 0.0041577932
- O 0 0.0024587451
year O 0 0.00069659494
- O 0 0.00090960617
old O 0 0.00048284582
Japanese O 0 0.0028980647
man O 0 0.0071349414
with O 0 0.001433696
nephrotic B-Disease 0 0.9999939
syndrome I-Disease 0 0.3612942
due O 0 9.1005146e-05
to O 0 0.000103844504
focal B-Disease 0 0.002714327
segmental I-Disease 0 0.3349891
glomerulosclerosis I-Disease 2 0.99999857
was O 0 0.00048303686
initially O 0 0.00026065795
responding O 0 0.00036974924
well O 0 0.00021990514
to O 0 0.0004880832
steroid B-Chemical 1 0.97228855
therapy O 0 0.002923051
. O 0 0.0019660178

The O 0 0.0014219161
amount O 0 0.00078498945
of O 0 0.00092712085
daily O 0 0.00091115455
urinary O 0 0.01290167
protein O 0 0.00090519636
decreased O 0 0.00074328727
from O 0 0.00023969234
15 O 0 0.00018110077
. O 0 0.00014075176
6 O 0 0.0001381899
to O 0 0.00022397088
2 O 0 0.00032885658
. O 0 0.0003925519
8 O 0 0.0007640586
g O 0 0.002547292
. O 0 0.0025284833

Within O 0 0.00077800115
14 O 0 0.0007825471
days O 0 0.0003272537
of O 0 0.00047777302
the O 0 0.00051047
oral O 0 0.1599187
bisphosphonate B-Chemical 0 0.9998838
( O 0 0.010374617
alendronate B-Chemical 0 0.9999912
sodium I-Chemical 0 0.99999213
) O 0 0.0026118064
administration O 0 0.0016347802
, O 0 0.00013565783
the O 0 6.291608e-05
amount O 0 3.663311e-05
of O 0 8.035836e-05
daily O 0 0.0001170925
urinary O 0 0.008053112
protein O 0 0.00022754159
increased O 0 0.00017126605
rapidly O 0 0.00014000804
up O 0 8.428296e-05
to O 0 6.664868e-05
12 O 0 5.368511e-05
. O 0 6.116182e-05
8 O 0 9.517257e-05
g O 0 0.00034844625
with O 0 0.0005013723
acute B-Disease 0 0.5042744
renal I-Disease 0 0.9958538
failure I-Disease 0 0.9084455
. O 0 0.0034037624

After O 0 0.0011233038
discontinuing O 0 0.004400357
the O 0 0.001334929
oral O 0 0.17588402
alendronate B-Chemical 0 0.9996184
, O 0 0.00060117344
the O 0 0.00022586514
patient O 0 0.00017512382
underwent O 0 0.000102431724
six O 0 4.9641156e-05
cycles O 0 5.821261e-05
of O 0 0.00015565193
hemodialysis O 0 0.0056046764
and O 0 0.00017165483
four O 0 0.00011668789
cycles O 0 0.00020059005
of O 0 0.0011159312
LDL O 0 0.9997008
apheresis O 0 0.37629613
. O 0 0.0035353836

Urinary O 0 0.033625487
volume O 0 0.002882395
and O 0 0.0012611866
serum O 0 0.07401242
creatinine B-Chemical 1 0.9983936
levels O 0 0.00051292946
recovered O 0 0.00025127686
to O 0 0.00014986527
the O 0 0.0001477225
normal O 0 0.00029758114
range O 0 0.00014505023
, O 0 0.00014090567
with O 0 0.0001695641
urinary O 0 0.012908169
protein O 0 0.00050011463
disappearing O 0 0.0006351715
completely O 0 0.00029559052
within O 0 0.00015402345
40 O 0 0.0005065524
days O 0 0.00052624603
. O 0 0.0014974858

This O 0 0.0033986582
report O 0 0.0016899864
demonstrates O 0 0.00051070366
that O 0 0.00032975295
not O 0 0.00033717792
only O 0 0.0004488591
intravenous O 0 0.015722169
, O 0 0.00034255165
but O 0 0.00022194585
also O 0 0.0002524564
oral O 0 0.22601713
bisphosphonates B-Chemical 0 0.9998746
can O 0 0.0003975296
aggravate O 0 0.14264332
proteinuria B-Disease 0 0.9999894
and O 0 0.0030908408
acute B-Disease 0 0.93617666
renal I-Disease 0 0.9983815
failure I-Disease 0 0.93338186
. O 0 0.0033752136

Serum O 0 0.46348864
- O 0 0.0057699876
and O 0 0.0022280493
glucocorticoid O 0 0.6567447
- O 0 0.001805132
inducible O 0 0.0014678583
kinase O 0 0.0031858452
1 O 0 0.00043311878
in O 0 0.0005477695
doxorubicin B-Chemical 1 0.9950588
- O 0 0.0036321327
induced O 0 0.0070958436
nephrotic B-Disease 0 0.99998176
syndrome I-Disease 0 0.96930647
. O 0 0.004178679

Doxorubicin B-Chemical 0 0.9990446
- O 0 0.009121413
induced O 0 0.0049995584
nephropathy B-Disease 2 0.9999591
leads O 0 0.0010375363
to O 0 0.0005737897
epithelial O 0 0.03047698
sodium B-Chemical 0 0.9998859
channel O 0 0.77720714
( O 0 0.0014236063
ENaC O 0 0.9267432
) O 0 0.000627229
- O 0 0.00031443196
dependent O 0 0.000119116004
volume B-Disease 0 0.0018230096
retention I-Disease 0 0.0076241135
and O 0 0.0016132502
renal O 0 0.99543
fibrosis B-Disease 2 0.9996045
. O 0 0.004242109

The O 0 0.0031704667
aldosterone B-Chemical 0 0.99932003
- O 0 0.0035799828
sensitive O 0 0.0009173393
serum O 0 0.053244416
- O 0 0.0014403583
and O 0 0.0005469329
glucocorticoid O 0 0.7402598
- O 0 0.0006445865
inducible O 0 0.00076391886
kinase O 0 0.012733878
SGK1 O 0 0.92296773
has O 0 0.00011436816
been O 0 6.162739e-05
shown O 0 4.4113865e-05
to O 0 4.424249e-05
participate O 0 4.381661e-05
in O 0 4.1264502e-05
the O 0 4.6179106e-05
stimulation O 0 4.988531e-05
of O 0 0.00018157576
ENaC O 0 0.66513366
and O 0 0.0001144479
to O 0 7.239007e-05
mediate O 0 6.23617e-05
renal O 0 0.9472168
fibrosis B-Disease 2 0.999549
following O 0 0.00051302236
mineralocorticoid O 0 0.9995561
and O 0 0.001681241
salt O 0 0.99255085
excess O 0 0.011934147
. O 0 0.0023685968

The O 0 0.0015731008
present O 0 0.0010809479
study O 0 0.0010670121
was O 0 0.0006059405
performed O 0 0.00030169188
to O 0 0.0002112316
elucidate O 0 0.00013225341
the O 0 0.00015136172
role O 0 0.000106449275
of O 0 0.0003032936
SGK1 O 0 0.5560054
in O 0 0.00016108711
the O 0 0.00015143074
volume B-Disease 0 0.0015467611
retention I-Disease 0 0.0069532506
and O 0 0.0008110661
fibrosis B-Disease 2 0.99914443
during O 0 0.0012942336
nephrotic B-Disease 0 0.9999827
syndrome I-Disease 0 0.91930836
. O 0 0.0029020356

To O 0 0.0020236715
this O 0 0.001656425
end O 0 0.00094589574
, O 0 0.001687304
doxorubicin B-Chemical 1 0.99438924
( O 0 0.00095707417
15 O 0 0.00023549212
mug O 0 0.0003320397
/ O 0 0.0006714567
g O 0 0.0005844393
body O 0 0.00062803173
wt O 0 0.00037025101
) O 0 0.00024264984
was O 0 9.598281e-05
injected O 0 6.691589e-05
intravenously O 0 9.109666e-05
into O 0 3.703432e-05
gene O 0 0.00018955396
- O 0 0.00015407104
targeted O 0 4.9172824e-05
mice O 0 5.3072446e-05
lacking O 0 0.00010065006
SGK1 O 0 0.8369784
( O 0 0.0003847204
sgk1 O 0 0.051813703
( O 0 0.00037768672
- O 0 0.00036044946
/ O 0 0.0006135906
- O 0 0.0003731478
) O 0 0.00023784651
) O 0 0.0001669376
and O 0 0.0001008597
their O 0 0.00013967523
wild O 0 0.00017120043
- O 0 0.00023427761
type O 0 0.00013262927
littermates O 0 0.00010957126
( O 0 0.00027757965
sgk1 O 0 0.008640909
( O 0 0.0005731403
+ O 0 0.0008066076
/ O 0 0.0015740336
+ O 0 0.0016650279
) O 0 0.0019449217
) O 0 0.0026164986
. O 0 0.0025344577

Doxorubicin B-Chemical 0 0.9977666
treatment O 0 0.0020181471
resulted O 0 0.0010544372
in O 0 0.0009785598
heavy O 0 0.789809
proteinuria B-Disease 0 0.9999877
( O 0 0.001669007
> O 0 0.000716345
100 O 0 0.00054419664
mg O 0 0.0042482708
protein O 0 0.00041216816
/ O 0 0.0008670316
mg O 0 0.046204917
crea O 0 0.4285989
) O 0 0.00024108218
in O 0 7.820501e-05
15 O 0 6.225694e-05
/ O 0 0.00018208042
44 O 0 0.00011028553
of O 0 0.0001317492
sgk1 O 0 0.014190038
( O 0 0.0002856535
+ O 0 0.00032160667
/ O 0 0.00048817164
+ O 0 0.00032094968
) O 0 0.00016939378
and O 0 8.6860775e-05
15 O 0 6.281123e-05
/ O 0 0.0001827473
44 O 0 0.0001100754
of O 0 0.00013468316
sgk1 O 0 0.021634772
( O 0 0.00034884998
- O 0 0.00035590262
/ O 0 0.00058472605
- O 0 0.00030199863
) O 0 0.00013315796
mice O 0 4.458939e-05
leading O 0 0.00011388974
to O 0 0.000113324466
severe O 0 0.074810766
nephrotic B-Disease 0 0.9999975
syndrome I-Disease 0 0.7707732
with O 0 0.00089519593
ascites B-Disease 0 0.9994735
, O 0 0.0010781917
lipidemia B-Disease 0 0.9998299
, O 0 0.00047269827
and O 0 0.0005286653
hypoalbuminemia B-Disease 0 0.99980396
in O 0 0.0006918681
both O 0 0.0009665825
genotypes O 0 0.0047030724
. O 0 0.002043694

Plasma O 0 0.29814723
aldosterone B-Chemical 0 0.99934465
levels O 0 0.0016940709
increased O 0 0.001622431
in O 0 0.001328501
nephrotic B-Disease 0 0.9999653
mice O 0 0.00024646937
of O 0 0.00026706516
both O 0 0.00020526802
genotypes O 0 0.0008049031
and O 0 0.00014805912
was O 0 0.00012645444
followed O 0 7.6364326e-05
by O 0 0.00011221356
increased O 0 0.00031087265
SGK1 O 0 0.7693641
protein O 0 0.00044594193
expression O 0 0.000236807
in O 0 0.00018863929
sgk1 O 0 0.03176997
( O 0 0.0005847714
+ O 0 0.0007666181
/ O 0 0.0014053255
+ O 0 0.0013145881
) O 0 0.0013155525
mice O 0 0.0011609514
. O 0 0.0021488187

Urinary O 0 0.5520441
sodium B-Chemical 0 0.9990658
excretion O 0 0.9123274
reached O 0 0.0015479295
signficantly O 0 0.07371821
lower O 0 0.0005259567
values O 0 0.00028613844
in O 0 0.00024951188
sgk1 O 0 0.02709237
( O 0 0.0005429988
+ O 0 0.00057405257
/ O 0 0.000828106
+ O 0 0.0005150167
) O 0 0.00024375266
mice O 0 8.652671e-05
( O 0 0.0001561078
15 O 0 8.217227e-05
+ O 0 0.0002290282
/ O 0 0.000384448
- O 0 0.00021529134
5 O 0 7.629547e-05
mumol O 0 0.0036086868
/ O 0 0.0006782192
mg O 0 0.028269855
crea O 0 0.36273557
) O 0 0.00022517682
than O 0 6.200401e-05
in O 0 0.000100785284
sgk1 O 0 0.02211697
( O 0 0.0003685239
- O 0 0.00038422615
/ O 0 0.00065024494
- O 0 0.0003478367
) O 0 0.00016955407
mice O 0 6.4264794e-05
( O 0 0.00012734407
35 O 0 9.979452e-05
+ O 0 0.00021293401
/ O 0 0.00035590687
- O 0 0.0001926534
5 O 0 6.616436e-05
mumol O 0 0.0035018958
/ O 0 0.0006269905
mg O 0 0.03109571
crea O 0 0.46255577
) O 0 0.00024165312
and O 0 8.99528e-05
was O 0 7.683752e-05
associated O 0 5.2385734e-05
with O 0 8.136903e-05
a O 0 9.322413e-05
significantly O 0 9.289543e-05
higher O 0 8.340332e-05
body O 0 0.0002637209
weight B-Disease 0 0.0004548693
gain I-Disease 0 0.00030576548
in O 0 0.00010527797
sgk1 O 0 0.030717181
( O 0 0.00026472707
+ O 0 0.00029460413
/ O 0 0.00045517573
+ O 0 0.00027970705
) O 0 0.00014044852
compared O 0 5.1852683e-05
with O 0 0.00014108932
sgk1 O 0 0.035830684
( O 0 0.00037972812
- O 0 0.00038211062
/ O 0 0.0006520998
- O 0 0.00035556042
) O 0 0.00018282467
mice O 0 7.387731e-05
( O 0 0.0001685068
+ O 0 0.0001968056
6 O 0 5.578966e-05
. O 0 5.1313455e-05
6 O 0 5.479388e-05
+ O 0 0.00018845986
/ O 0 0.0003669474
- O 0 0.00023090179
0 O 0 8.5953514e-05
. O 0 5.8438764e-05
7 O 0 6.356085e-05
vs O 0 0.00010792672
. O 0 7.595805e-05
+ O 0 0.00020625207
4 O 0 9.089751e-05
. O 0 8.308898e-05
1 O 0 0.00012664798
+ O 0 0.00033152537
/ O 0 0.0006283099
- O 0 0.00047927647
0 O 0 0.00026131337
. O 0 0.0002688063
8 O 0 0.00048214127
g O 0 0.0016740456
) O 0 0.0023412034
. O 0 0.002505152

During O 0 0.00087759027
the O 0 0.000960406
course O 0 0.0008404892
of O 0 0.002383196
nephrotic B-Disease 0 0.99998164
syndrome I-Disease 0 0.87906647
, O 0 0.0009869534
serum O 0 0.420167
urea B-Chemical 0 0.9998568
concentrations O 0 0.0020896879
increased O 0 0.00044286955
significantly O 0 0.00024675697
faster O 0 0.00015213701
in O 0 0.00013388466
sgk1 O 0 0.046732508
( O 0 0.00040948592
- O 0 0.0004045185
/ O 0 0.000674932
- O 0 0.00033316534
) O 0 0.00014522074
mice O 0 4.666274e-05
than O 0 4.9381375e-05
in O 0 8.632635e-05
sgk1 O 0 0.016061872
( O 0 0.00028162054
+ O 0 0.00033093645
/ O 0 0.0005341091
+ O 0 0.00033135567
) O 0 0.00015033917
mice O 0 5.0009054e-05
leading O 0 0.00014507596
to O 0 0.0001765181
uremia B-Disease 0 0.99994886
and O 0 0.00018088538
a O 0 0.00012672097
reduced O 0 0.00014247464
median O 0 5.278001e-05
survival O 0 0.00058457465
in O 0 0.000119374796
sgk1 O 0 0.05353459
( O 0 0.00039406779
- O 0 0.00038985148
/ O 0 0.0006522142
- O 0 0.0003393063
) O 0 0.00016710005
mice O 0 6.4867265e-05
( O 0 0.00013476485
29 O 0 0.0001481314
vs O 0 9.1810994e-05
. O 0 4.5561203e-05
40 O 0 6.445991e-05
days O 0 3.911521e-05
in O 0 0.00010502279
sgk1 O 0 0.0060798554
( O 0 0.00047292295
+ O 0 0.00065838895
/ O 0 0.0011970219
+ O 0 0.0010805884
) O 0 0.0010041695
mice O 0 0.00081867084
) O 0 0.002335616
. O 0 0.002358624

In O 0 0.0022062443
conclusion O 0 0.001777574
, O 0 0.001778168
gene O 0 0.001956557
- O 0 0.0010943282
targeted O 0 0.0002479786
mice O 0 0.000180242
lacking O 0 0.00021232944
SGK1 O 0 0.60632026
showed O 0 0.00024893708
blunted O 0 0.004596983
volume B-Disease 0 0.009493019
retention I-Disease 0 0.020661306
, O 0 0.00023331953
yet O 0 0.00014448081
were O 0 8.3261555e-05
not O 0 7.066513e-05
protected O 0 0.00015589657
against O 0 0.00015891343
renal O 0 0.9816721
fibrosis B-Disease 2 0.9995552
during O 0 0.00034856802
experimental O 0 0.0036122957
nephrotic B-Disease 0 0.9999825
syndrome I-Disease 0 0.9122133
. O 0 0.002788144

Severe O 0 0.59099936
thrombocytopenia B-Disease 0 0.9995204
and O 0 0.0077635325
haemolytic B-Disease 0 0.9998666
anaemia I-Disease 0 0.9999783
associated O 0 0.0016575496
with O 0 0.0021979045
ciprofloxacin B-Chemical 1 0.9998965
: O 0 0.00091359724
a O 0 0.000504757
case O 0 0.0004018875
report O 0 0.0008594433
with O 0 0.0012720247
fatal O 0 0.71109825
outcome O 0 0.0034675256
. O 0 0.0026344613

Haematological O 0 0.9353661
adverse O 0 0.122552596
reactions O 0 0.0060576685
associated O 0 0.00093727704
with O 0 0.001215158
fatal O 0 0.36073494
outcome O 0 0.0007090691
are O 0 0.00037371457
rare O 0 0.00077755086
during O 0 0.00022269286
treatment O 0 0.00060273946
with O 0 0.002057077
ciprofloxacin B-Chemical 1 0.99937564
. O 0 0.0043425653

A O 0 0.016013812
30 O 0 0.0017461975
- O 0 0.0017668741
year O 0 0.0005125553
old O 0 0.0006338943
Caucasian O 0 0.0087527735
man O 0 0.0025772504
reported O 0 0.00025761462
with O 0 0.000293358
abdominal B-Disease 0 0.020764966
pain I-Disease 0 0.632655
and O 0 0.0004246232
jaundice B-Disease 2 0.9946498
after O 0 5.2457468e-05
3 O 0 6.6934335e-05
- O 0 0.00010194441
day O 0 3.6204092e-05
administration O 0 0.00018685736
of O 0 0.00018345471
oral O 0 0.07026669
ciprofloxacin B-Chemical 1 0.9997104
for O 0 0.00016999764
a O 0 0.00028138116
suspect O 0 0.00047651952
of O 0 0.0005082469
urinary B-Disease 0 0.14634629
tract I-Disease 0 0.0050543
infection I-Disease 0 0.052577067
. O 0 0.0024507232

Clinical O 0 0.0056076907
evaluations O 0 0.0013824055
suggested O 0 0.00077922345
an O 0 0.0008852918
initial O 0 0.00077634695
diagnosis O 0 0.0017926609
of O 0 0.0018013091
severe O 0 0.38364738
thrombocytopenia B-Disease 0 0.9998925
and O 0 0.03411722
haemolysis B-Disease 0 0.9999001
. O 0 0.008175242

The O 0 0.0019665062
patient O 0 0.0019013543
progressively O 0 0.0018424919
developed O 0 0.0029285732
petechiae B-Disease 0 0.92208093
and O 0 0.0028577403
purpura B-Disease 0 0.99908197
on O 0 0.0008671819
thorax O 0 0.008211541
and O 0 0.0013668576
lower O 0 0.0028068305
limbs O 0 0.07454336
. O 0 0.0035660416

Despite O 0 0.0020034888
pharmacological O 0 0.0065627005
and O 0 0.0011072367
supportive O 0 0.0009995736
interventions O 0 0.00041562426
, O 0 0.0003676789
laboratory O 0 0.00037422794
parameters O 0 0.0002844808
worsened O 0 0.0019720392
and O 0 0.00020288384
the O 0 0.00018082642
patient O 0 0.000254768
died O 0 0.0004624583
17 O 0 0.00030514927
hours O 0 0.00019106932
after O 0 0.00029788885
admission O 0 0.001879538
. O 0 0.0019812994

An O 0 0.0040272432
accurate O 0 0.0029904665
autopsy O 0 0.007837839
revealed O 0 0.0014228155
most O 0 0.0018001529
organs O 0 0.0038931763
with O 0 0.0024467036
diffuse O 0 0.054471992
petechial O 0 0.97912025
haemorrhages B-Disease 0 0.999318
. O 0 0.0058344183

No O 0 0.0059011914
signs O 0 0.009606933
of O 0 0.0044460176
bone B-Disease 0 0.40100577
marrow I-Disease 0 0.9522729
depression I-Disease 0 0.9988098
were O 0 0.004853897
found O 0 0.0040353974
. O 0 0.0048976303

No O 0 0.005785206
thrombi B-Disease 2 0.94552726
or O 0 0.0019902315
signs O 0 0.008526849
of O 0 0.0034859856
microangiopathies B-Disease 0 0.9996985
were O 0 0.0012514591
observed O 0 0.0007810813
in O 0 0.0011714045
arterial O 0 0.09307954
vessels O 0 0.023024999
. O 0 0.0034856994

Blood O 0 0.016464014
and O 0 0.003044818
urine O 0 0.031960625
cultures O 0 0.0017149608
did O 0 0.0011558094
not O 0 0.0008150176
show O 0 0.00077359093
any O 0 0.0011204932
bacterial O 0 0.004223783
growth O 0 0.016392943
. O 0 0.004775254

This O 0 0.0032654016
case O 0 0.0012958964
report O 0 0.0010390012
shows O 0 0.00032062485
that O 0 0.00038305233
ciprofloxacin B-Chemical 1 0.99945086
may O 0 0.0003889628
precipitate O 0 0.0070134383
life O 0 0.00052694074
- O 0 0.00053548085
threatening O 0 0.0024158694
thrombocytopenia B-Disease 0 0.9999348
and O 0 0.0022051486
haemolytic B-Disease 0 0.99998474
anaemia I-Disease 0 0.99999726
, O 0 0.0007027223
even O 0 0.00015339
in O 0 6.9974456e-05
the O 0 6.480222e-05
early O 0 0.00012165516
phases O 0 0.0001530067
of O 0 0.00013433391
treatment O 0 0.00013661037
and O 0 0.00016618085
without O 0 0.00021397608
apparent O 0 0.00047392774
previous O 0 0.0007759945
exposures O 0 0.0046045077
. O 0 0.0022097037

Alpha B-Chemical 0 0.35981405
- I-Chemical 0 0.023894643
lipoic I-Chemical 0 0.99987566
acid I-Chemical 0 0.9922801
prevents O 0 0.007222342
mitochondrial B-Disease 0 0.99866843
damage I-Disease 0 0.9967781
and O 0 0.0032861112
neurotoxicity B-Disease 2 0.99988496
in O 0 0.0010908507
experimental O 0 0.0022772534
chemotherapy O 0 0.33332387
neuropathy B-Disease 0 0.9998455
. O 0 0.0051437407

The O 0 0.00169052
study O 0 0.0015308384
investigates O 0 0.0013409831
if O 0 0.00083340966
alpha B-Chemical 1 0.88228166
- I-Chemical 1 0.021892466
lipoic I-Chemical 1 0.99998486
acid I-Chemical 1 0.99678814
is O 0 0.00075095997
neuroprotective O 0 0.16509153
against O 0 0.00017324551
chemotherapy O 0 0.014163515
induced O 0 0.0013000106
neurotoxicity B-Disease 2 0.9999857
, O 0 0.0006535669
if O 0 0.00018734224
mitochondrial B-Disease 0 0.9926105
damage I-Disease 0 0.949032
plays O 0 8.5297674e-05
a O 0 9.78243e-05
critical O 0 4.7179856e-05
role O 0 4.801346e-05
in O 0 0.00013944699
toxic B-Disease 0 0.9465582
neurodegenerative I-Disease 0 0.9989207
cascade I-Disease 0 0.0031351445
, O 0 0.0001708612
and O 0 8.946852e-05
if O 0 5.8758284e-05
neuroprotective O 0 0.009656088
effects O 0 0.00018316491
of O 0 0.000508182
alpha B-Chemical 1 0.9338214
- I-Chemical 1 0.010223514
lipoic I-Chemical 1 0.99998164
acid I-Chemical 1 0.9468287
depend O 0 0.00029511467
on O 0 0.00038946778
mitochondria O 0 0.010007158
protection O 0 0.004592398
. O 0 0.0023359004

We O 0 0.0015169731
used O 0 0.0010496926
an O 0 0.00095642917
in O 0 0.000508149
vitro O 0 0.00047818353
model O 0 0.00033954642
of O 0 0.00038110188
chemotherapy O 0 0.0033223662
induced O 0 0.0007814168
peripheral B-Disease 2 0.97034687
neuropathy I-Disease 2 0.9999958
that O 0 0.00015457135
closely O 0 6.138989e-05
mimic O 0 5.132226e-05
the O 0 5.9197755e-05
in O 0 5.6493733e-05
vivo O 0 0.00012620266
condition O 0 0.00016468218
by O 0 7.601754e-05
exposing O 0 0.00016056816
primary O 0 7.406388e-05
cultures O 0 7.476555e-05
of O 0 8.8341156e-05
dorsal O 0 0.00018602255
root O 0 0.0011217602
ganglion O 0 0.14937492
( O 0 0.0002576888
DRG O 0 0.005852643
) O 0 0.00015650739
sensory O 0 0.00017583542
neurons O 0 0.00015482152
to O 0 9.878636e-05
paclitaxel B-Chemical 1 0.98009974
and O 0 0.0004528756
cisplatin B-Chemical 0 0.99885523
, O 0 0.00023418493
two O 0 7.635129e-05
widely O 0 8.107449e-05
used O 0 8.853917e-05
and O 0 0.00014445493
highly O 0 0.000213037
effective O 0 0.00038607317
chemotherapeutic O 0 0.012988762
drugs O 0 0.11916272
. O 0 0.0025244108

This O 0 0.0026828474
approach O 0 0.0010502877
allowed O 0 0.00071998325
investigating O 0 0.0004177207
the O 0 0.00034792128
efficacy O 0 0.00047821546
of O 0 0.00072371
alpha B-Chemical 1 0.9331553
- I-Chemical 1 0.015271521
lipoic I-Chemical 1 0.99999
acid I-Chemical 1 0.9901917
in O 0 0.00032139244
preventing O 0 0.00074259343
axonal B-Disease 0 0.91211665
damage I-Disease 0 0.9932688
and O 0 0.00051901885
apoptosis O 0 0.65045
and O 0 0.000112164664
the O 0 6.251269e-05
function O 0 7.390154e-05
and O 0 7.212664e-05
ultrastructural O 0 0.00038299576
morphology O 0 0.00019199193
of O 0 0.0001181452
mitochondria O 0 0.0008102113
after O 0 2.6684049e-05
exposure O 0 0.000107232314
to O 0 0.000109765875
toxic O 0 0.07738723
agents O 0 0.002285759
and O 0 0.00068232755
alpha B-Chemical 1 0.8821278
- I-Chemical 1 0.020329894
lipoic I-Chemical 1 0.99995506
acid I-Chemical 1 0.9960145
. O 0 0.0044647204

Our O 0 0.0018299242
results O 0 0.0010845853
demonstrate O 0 0.00040414673
that O 0 0.00039007346
both O 0 0.0006924387
cisplatin B-Chemical 0 0.9978265
and O 0 0.0011123556
paclitaxel B-Chemical 1 0.9977519
cause O 0 0.0010996514
early O 0 0.0016419181
mitochondrial B-Disease 0 0.99737346
impairment I-Disease 0 0.98250824
with O 0 0.00037728887
loss O 0 0.0005885297
of O 0 0.00018215805
membrane O 0 0.00028029436
potential O 0 0.00011552286
and O 0 0.00012317629
induction O 0 0.00017796474
of O 0 0.00032721346
autophagic O 0 0.002691485
vacuoles O 0 0.00095729023
in O 0 0.00070910587
neurons O 0 0.0022599373
. O 0 0.001904247

Alpha B-Chemical 0 0.3700744
- I-Chemical 0 0.021481985
lipoic I-Chemical 0 0.9998864
acid I-Chemical 0 0.9823899
exerts O 0 0.0014457632
neuroprotective O 0 0.26456356
effects O 0 0.0005225464
against O 0 0.00021775195
chemotherapy O 0 0.011678515
induced O 0 0.0010090334
neurotoxicity B-Disease 2 0.9999665
in O 0 0.0002810187
sensory O 0 0.00060851965
neurons O 0 0.00031969877
: O 0 0.00013275705
it O 0 9.084735e-05
rescues O 0 0.00046488788
the O 0 0.00022717328
mitochondrial B-Disease 0 0.9965718
toxicity I-Disease 2 0.9999528
and O 0 0.00018040481
induces O 0 5.5310516e-05
the O 0 7.499311e-05
expression O 0 0.00012927002
of O 0 0.00031123654
frataxin O 0 0.99927956
, O 0 0.00017433858
an O 0 0.00012096839
essential O 0 0.00011313509
mitochondrial O 0 0.11319546
protein O 0 0.0003703624
with O 0 0.0002978017
anti O 0 0.0028361117
- O 0 0.0011991205
oxidant O 0 0.9444478
and O 0 0.0007059739
chaperone O 0 0.0017355607
properties O 0 0.0010448028
. O 0 0.0017522288

In O 0 0.0021592334
conclusion O 0 0.0026748397
mitochondrial B-Disease 0 0.9960393
toxicity I-Disease 2 0.9998216
is O 0 0.0010471446
an O 0 0.00054606464
early O 0 0.0004568552
common O 0 0.000267554
event O 0 0.0004550449
both O 0 0.00021503858
in O 0 0.00031312145
paclitaxel B-Chemical 1 0.98686755
and O 0 0.0016630507
cisplatin B-Chemical 0 0.99938166
induced O 0 0.025468687
neurotoxicity B-Disease 2 0.99991727
. O 0 0.0062122983

Alpha B-Chemical 0 0.38777408
- I-Chemical 0 0.02410587
lipoic I-Chemical 0 0.9998802
acid I-Chemical 0 0.9809186
protects O 0 0.002276385
sensory O 0 0.0018738342
neurons O 0 0.0006816559
through O 0 0.00017892644
its O 0 0.00046964223
anti O 0 0.0024281184
- O 0 0.0011535009
oxidant O 0 0.9792644
and O 0 0.00038829094
mitochondrial O 0 0.12523247
regulatory O 0 0.00019503507
functions O 0 0.0001651196
, O 0 0.00019094747
possibly O 0 0.0003018133
inducing O 0 0.0003751479
the O 0 0.00033913038
expression O 0 0.0007603608
of O 0 0.0022576656
frataxin O 0 0.9987961
. O 0 0.0034273362

These O 0 0.0021300793
findings O 0 0.0017955985
suggest O 0 0.0005473697
that O 0 0.00075940497
alpha B-Chemical 1 0.8859724
- I-Chemical 1 0.021279078
lipoic I-Chemical 1 0.9999819
acid I-Chemical 1 0.9859627
might O 0 0.00019253018
reduce O 0 0.00011526197
the O 0 0.00014534681
risk O 0 0.00073267467
of O 0 0.00018576023
developing O 0 0.0013227615
peripheral B-Disease 0 0.14123014
nerve I-Disease 0 0.14256331
toxicity I-Disease 2 0.9996321
in O 0 0.00015503455
patients O 0 0.00017870376
undergoing O 0 0.00014527944
chemotherapy O 0 0.0006310907
and O 0 0.00013568967
encourage O 0 0.0002080401
further O 0 0.0004146415
confirmatory O 0 0.006605291
clinical O 0 0.0020407059
trials O 0 0.0013333191
. O 0 0.00163008

Toxicity B-Disease 0 0.75593764
in O 0 0.001128731
rhesus O 0 0.00038513544
monkeys O 0 0.0002660988
following O 0 0.00020596497
administration O 0 0.000657345
of O 0 0.00030363153
the O 0 0.00022443433
8 B-Chemical 0 0.00017931516
- I-Chemical 0 0.00042016385
aminoquinoline I-Chemical 0 0.22200258
8 B-Chemical 0 0.00019508322
- I-Chemical 0 0.00038843916
[ I-Chemical 0 0.00039049576
( I-Chemical 0 0.00019116262
4 I-Chemical 0 0.000103658305
- I-Chemical 0 0.00030080182
amino I-Chemical 0 0.16408956
- I-Chemical 0 0.00063171674
l I-Chemical 0 0.00095649116
- I-Chemical 0 0.00067859876
methylbutyl I-Chemical 0 0.33643645
) I-Chemical 0 0.0006341124
amino I-Chemical 0 0.66123474
] I-Chemical 0 0.0011258916
- I-Chemical 0 0.00034175883
5 I-Chemical 0 0.00010035756
- I-Chemical 0 0.00023842232
( I-Chemical 0 0.00019370145
l I-Chemical 0 0.0005299951
- I-Chemical 0 0.0005150033
hexyloxy I-Chemical 0 0.4511229
) I-Chemical 0 0.0004905258
- I-Chemical 0 0.00034258398
6 I-Chemical 0 0.00011788985
- I-Chemical 0 0.00057471823
methoxy I-Chemical 0 0.9975696
- I-Chemical 0 0.0010091469
4 I-Chemical 0 0.0002841883
- I-Chemical 0 0.0008088798
methylquinoline I-Chemical 0 0.03358428
( O 0 0.0024092817
WR242511 B-Chemical 1 0.9928464
) O 0 0.0043689795
. O 0 0.0028702249

INTRODUCTION O 0 0.005878884
: O 0 0.0022765798
Many O 0 0.0011913422
substances O 0 0.0057750335
that O 0 0.0005338022
form O 0 0.0009970807
methemoglobin O 0 0.9998907
( O 0 0.0017669615
MHb O 0 0.4939408
) O 0 0.0006718836
effectively O 0 0.0005125007
counter O 0 0.008302509
cyanide O 0 0.99992585
( O 0 0.0059913383
CN O 0 0.98473537
) O 0 0.005690637
toxicity B-Disease 2 0.99505144
. O 0 0.004091146

Although O 0 0.0021225277
MHb O 0 0.24232891
formers O 0 0.57207537
are O 0 0.0006294778
generally O 0 0.00034482163
applied O 0 0.00018244138
as O 0 0.00019374944
treatments O 0 0.00031371636
for O 0 0.00025847967
CN O 0 0.99806136
poisoning B-Disease 2 0.9999722
, O 0 0.00068323954
it O 0 0.00019963564
has O 0 7.272218e-05
been O 0 5.172733e-05
proposed O 0 5.747983e-05
that O 0 5.2718642e-05
a O 0 0.00012601797
stable O 0 0.00014461603
, O 0 0.00012802845
long O 0 0.000115467126
- O 0 0.0002194272
acting O 0 0.00022311173
MHb O 0 0.20397158
former O 0 0.0009539174
could O 0 0.00014205859
serve O 0 0.00021264958
as O 0 0.0002964606
a O 0 0.0010211422
CN O 0 0.92170566
pretreatment O 0 0.29327053
. O 0 0.003190905

Using O 0 0.0016385885
this O 0 0.0014849359
rationale O 0 0.0014214002
, O 0 0.0009484739
the O 0 0.00056428416
8 B-Chemical 0 0.00044927478
- I-Chemical 0 0.0010845766
aminoquinoline I-Chemical 0 0.887523
WR242511 B-Chemical 1 0.9994056
, O 0 0.00046192209
a O 0 0.00026749502
potent O 0 0.00033857973
long O 0 0.00015683049
- O 0 0.00020858813
lasting O 0 0.00010298666
MHb O 0 0.13882397
former O 0 0.00069231394
in O 0 8.735226e-05
rodents O 0 0.00016885131
and O 0 0.000112636255
beagle O 0 0.00095610524
dogs O 0 0.00017097253
, O 0 0.00010033976
was O 0 8.219805e-05
studied O 0 7.1393544e-05
in O 0 4.777331e-05
the O 0 4.931497e-05
rhesus O 0 3.6725734e-05
monkey O 0 9.8757824e-05
for O 0 7.066332e-05
advanced O 0 0.000529612
development O 0 0.0003175448
as O 0 0.00019989983
a O 0 0.00042541124
potential O 0 0.0008782051
CN O 0 0.9598783
pretreatment O 0 0.3624886
. O 0 0.0030693964

METHODS O 0 0.0016590545
: O 0 0.0013384209
In O 0 0.0005393657
this O 0 0.00065501616
study O 0 0.0007510486
, O 0 0.00084580784
WR242511 B-Chemical 1 0.99278635
was O 0 0.00035712073
administered O 0 0.0002450048
intravenously O 0 0.00030930084
( O 0 0.0003542549
IV O 0 0.015167651
) O 0 0.00021260943
in O 0 8.8004585e-05
2 O 0 7.730746e-05
female O 0 0.00020909692
and O 0 7.180102e-05
4 O 0 4.698867e-05
male O 0 0.0001096349
rhesus O 0 2.334875e-05
monkeys O 0 2.812588e-05
in O 0 4.617074e-05
doses O 0 0.00028599662
of O 0 0.00012248207
3 O 0 6.124073e-05
. O 0 3.8652703e-05
5 O 0 4.0942385e-05
and O 0 6.714704e-05
/ O 0 0.00019704351
or O 0 6.384923e-05
7 O 0 4.6734123e-05
. O 0 3.7272912e-05
0 O 0 5.7419453e-05
mg O 0 0.00089008216
/ O 0 0.00036079562
kg O 0 0.00028959653
; O 0 0.00010223236
a O 0 9.248292e-05
single O 0 8.2855964e-05
male O 0 0.00023086679
also O 0 7.2534065e-05
received O 0 0.00011306659
WR242511 B-Chemical 1 0.9913856
orally O 0 0.0013092776
( O 0 0.00037902125
PO O 0 0.31290025
) O 0 0.00022324857
at O 0 8.709841e-05
7 O 0 0.00010716137
. O 0 0.00012291523
0 O 0 0.0002666784
mg O 0 0.0031659189
/ O 0 0.0023770647
kg O 0 0.003146338
. O 0 0.0022451659

Health O 0 0.004120625
status O 0 0.0022079789
and O 0 0.0022621728
MHb O 0 0.056711078
levels O 0 0.0014434287
were O 0 0.0011208764
monitored O 0 0.0008515377
following O 0 0.001298031
exposure O 0 0.0039796284
. O 0 0.004541483

RESULTS O 0 0.00422268
: O 0 0.0015057421
The O 0 0.0005466035
selected O 0 0.00058297726
doses O 0 0.0023448677
of O 0 0.0013178599
WR242511 B-Chemical 1 0.99874806
, O 0 0.00047823682
which O 0 0.00026334022
produced O 0 0.00020437708
significant O 0 0.0004476313
methemoglobinemia B-Disease 0 0.9999857
in O 0 0.00034347054
beagle O 0 0.0030959256
dogs O 0 0.00015583697
in O 0 6.1670304e-05
earlier O 0 8.02637e-05
studies O 0 7.620451e-05
conducted O 0 6.6595305e-05
elsewhere O 0 8.550854e-05
, O 0 8.123097e-05
produced O 0 6.936966e-05
very O 0 0.00014901272
little O 0 0.00012291041
MHb O 0 0.2652899
( O 0 0.00013966658
mean O 0 4.7397214e-05
< O 0 9.2716306e-05
2 O 0 7.7375975e-05
. O 0 6.7440495e-05
0 O 0 0.00010770659
% O 0 0.00018581178
) O 0 0.00027752036
in O 0 0.00021801141
the O 0 0.0003536855
rhesus O 0 0.00046324363
monkey O 0 0.0016491532
. O 0 0.0019267695

Furthermore O 0 0.0029606137
, O 0 0.0027201986
transient O 0 0.019101964
hemoglobinuria B-Disease 0 0.9995895
was O 0 0.00085961417
noted O 0 0.00018922637
approximately O 0 0.00017347366
60 O 0 0.00010879353
minutes O 0 5.928329e-05
postinjection O 0 0.00013018976
of O 0 0.00027504223
WR242511 B-Chemical 1 0.99582905
( O 0 0.00032846056
3 O 0 8.35412e-05
. O 0 5.0692746e-05
5 O 0 4.8142294e-05
or O 0 5.466262e-05
7 O 0 4.8153637e-05
. O 0 4.1313324e-05
0 O 0 6.3745436e-05
mg O 0 0.00096718874
/ O 0 0.0004163859
kg O 0 0.00038937456
) O 0 0.0001845618
, O 0 0.00010502248
and O 0 9.696569e-05
2 O 0 9.041048e-05
lethalities O 0 0.4303412
occurred O 0 0.00010545611
( O 0 0.00012984153
one O 0 7.095428e-05
IV O 0 0.0030125096
and O 0 0.00010249123
one O 0 9.5455856e-05
PO O 0 0.23698026
) O 0 0.00016395954
following O 0 6.0455535e-05
the O 0 9.914252e-05
7 O 0 8.421482e-05
. O 0 8.7832035e-05
0 O 0 0.00017538066
mg O 0 0.002212779
/ O 0 0.0014686916
kg O 0 0.0019893833
dose O 0 0.004221974
. O 0 0.0023742577

Myoglobinuria B-Disease 0 0.9936899
was O 0 0.0026103607
also O 0 0.00096082874
observed O 0 0.0005685355
following O 0 0.00038063276
the O 0 0.0004558177
7 O 0 0.00032799432
. O 0 0.00028206228
0 O 0 0.0004468988
mg O 0 0.0044950033
/ O 0 0.0025557652
kg O 0 0.0032051862
dose O 0 0.006108316
. O 0 0.0033436504

Histopathology O 0 0.010828199
analyses O 0 0.0012381962
in O 0 0.0006755395
the O 0 0.00046615128
2 O 0 0.0002659299
animals O 0 0.00014937493
that O 0 0.00013320644
died O 0 0.00040930498
revealed O 0 0.00023182429
liver B-Disease 0 0.6359635
and I-Disease 0 0.0005222176
kidney I-Disease 0 0.9820561
toxicity I-Disease 2 0.99956363
, O 0 0.0002767499
with O 0 0.00014963653
greater O 0 0.0001378091
severity O 0 0.000329326
in O 0 0.00012810135
the O 0 0.00019843549
orally O 0 0.0012137305
- O 0 0.0008634128
treated O 0 0.0011328188
animal O 0 0.0023736795
. O 0 0.002113511

CONCLUSIONS O 0 0.013245526
: O 0 0.0020777856
These O 0 0.0009766602
data O 0 0.0007500974
demonstrate O 0 0.00032612283
direct O 0 0.0004363949
and O 0 0.00054847146
/ O 0 0.0011135675
or O 0 0.00046400598
indirect O 0 0.0015505465
drug O 0 0.062940404
- O 0 0.0024489937
induced O 0 0.003310537
toxicity B-Disease 2 0.99788755
. O 0 0.004748768

It O 0 0.0027992413
is O 0 0.0013449219
concluded O 0 0.00080816256
that O 0 0.0008251926
WR242511 B-Chemical 1 0.99423873
should O 0 0.00027153982
not O 0 0.00024536598
be O 0 0.00018810637
pursued O 0 0.00032470998
as O 0 0.00012813263
a O 0 0.00019587837
pretreatment O 0 0.009798014
for O 0 0.00024341824
CN O 0 0.9981882
poisoning B-Disease 2 0.99995756
unless O 0 0.00021980096
the O 0 0.00015528219
anti O 0 0.0016358582
- O 0 0.00055134733
CN O 0 0.6573262
characteristics O 0 4.9608978e-05
of O 0 0.00010109638
this O 0 0.00015919915
compound O 0 0.02382947
can O 0 8.25232e-05
be O 0 8.0166086e-05
successfully O 0 0.00010447323
dissociated O 0 0.00016061531
from O 0 0.00013746654
those O 0 0.00031413144
producing O 0 0.0005698699
undesirable O 0 0.02888781
toxicity B-Disease 2 0.9980848
. O 0 0.0035348798

Repetitive O 0 0.0039052593
transcranial O 0 0.0030226603
magnetic O 0 0.002401894
stimulation O 0 0.0006681474
for O 0 0.00094474456
levodopa B-Chemical 0 0.99991465
- O 0 0.002522902
induced O 0 0.0018003336
dyskinesias B-Disease 0 0.99986815
in O 0 0.0016898247
Parkinson B-Disease 0 0.9982096
' I-Disease 0 0.0020922888
s I-Disease 0 0.0017663209
disease I-Disease 0 0.08201035
. O 0 0.003363269

In O 0 0.0020669934
a O 0 0.0024778715
placebo O 0 0.008432104
- O 0 0.0015656018
controlled O 0 0.0005218364
, O 0 0.00046463718
single O 0 0.0003518979
- O 0 0.00050990685
blinded O 0 0.00030158402
, O 0 0.00020676146
crossover O 0 0.001244567
study O 0 0.00016076917
, O 0 9.929485e-05
we O 0 3.8977356e-05
assessed O 0 5.005061e-05
the O 0 6.290869e-05
effect O 0 7.1788694e-05
of O 0 0.00014232488
" O 0 0.00012123665
real O 0 8.236055e-05
" O 0 8.855049e-05
repetitive O 0 7.325057e-05
transcranial O 0 0.00022518799
magnetic O 0 0.0003194301
stimulation O 0 6.389156e-05
( O 0 0.00014509795
rTMS O 0 0.0010175167
) O 0 0.00014398694
versus O 0 5.65719e-05
" O 0 8.302323e-05
sham O 0 4.992519e-05
" O 0 9.5486364e-05
rTMS O 0 0.00075643754
( O 0 0.00015184324
placebo O 0 0.00046545526
) O 0 8.98711e-05
on O 0 3.192897e-05
peak O 0 0.00011382155
dose O 0 0.0017517171
dyskinesias B-Disease 0 0.9999019
in O 0 0.00015220085
patients O 0 0.00021081851
with O 0 0.00030599293
Parkinson B-Disease 0 0.9966035
' I-Disease 0 0.000496532
s I-Disease 0 0.0004362556
disease I-Disease 0 0.10578078
( O 0 0.002113711
PD B-Disease 0 0.9942258
) O 0 0.0034185962
. O 0 0.0024014872

Ten O 0 0.00302958
patients O 0 0.0017752986
with O 0 0.0015939978
PD B-Disease 0 0.9893428
and O 0 0.00071436795
prominent O 0 0.002281509
dyskinesias B-Disease 0 0.99991274
had O 0 0.00050040596
rTMS O 0 0.004308608
( O 0 0.00026017978
1 O 0 0.00010098549
, O 0 0.000110677414
800 O 0 0.00026910714
pulses O 0 0.00015886054
; O 0 0.00012821305
1 O 0 7.8526944e-05
Hz O 0 0.00039523497
rate O 0 9.627723e-05
) O 0 9.124402e-05
delivered O 0 2.6291013e-05
over O 0 2.2444146e-05
the O 0 4.7395002e-05
motor O 0 0.00024063552
cortex O 0 0.00075750443
for O 0 4.396159e-05
4 O 0 3.2440545e-05
consecutive O 0 2.9480243e-05
days O 0 1.7945877e-05
twice O 0 3.287898e-05
, O 0 4.550796e-05
once O 0 2.6344573e-05
real O 0 4.1103438e-05
stimuli O 0 5.4390675e-05
and O 0 5.3901076e-05
once O 0 3.1284682e-05
sham O 0 3.2412067e-05
stimulation O 0 3.6549256e-05
were O 0 5.2664524e-05
used O 0 4.4224853e-05
; O 0 6.250124e-05
evaluations O 0 3.904931e-05
were O 0 4.3093984e-05
done O 0 3.2195407e-05
at O 0 2.7619504e-05
the O 0 4.6784247e-05
baseline O 0 5.03023e-05
and O 0 6.264869e-05
1 O 0 4.3462704e-05
day O 0 2.7791244e-05
after O 0 2.174718e-05
the O 0 5.447404e-05
end O 0 4.6913534e-05
of O 0 0.000116509116
each O 0 8.032181e-05
of O 0 0.00026058962
the O 0 0.0003890544
treatment O 0 0.0007766215
series O 0 0.0021172927
. O 0 0.0021008402

Direct O 0 0.0030169794
comparison O 0 0.0010102706
between O 0 0.0004508744
sham O 0 0.00037470524
and O 0 0.00033033753
real O 0 0.00030274186
rTMS O 0 0.0014758544
effects O 0 0.00028314732
showed O 0 0.00020494552
no O 0 0.00011226257
significant O 0 0.00015757144
difference O 0 0.00010024528
in O 0 0.00019824733
clinician O 0 0.0007830302
- O 0 0.0009745014
assessed O 0 0.0009773001
dyskinesia B-Disease 0 0.9999418
severity O 0 0.011926941
. O 0 0.0026265676

However O 0 0.0024550064
, O 0 0.0016169854
comparison O 0 0.0006464361
with O 0 0.0005092332
the O 0 0.00032493853
baseline O 0 0.0002449985
showed O 0 0.00022281305
small O 0 0.00025817007
but O 0 0.00018534994
significant O 0 0.00014939073
reduction O 0 0.0004996648
in O 0 0.000413844
dyskinesia B-Disease 0 0.9999877
severity O 0 0.00062468956
following O 0 0.000107574495
real O 0 0.00022491912
rTMS O 0 0.0018173263
but O 0 0.00045507247
not O 0 0.00071076816
placebo O 0 0.0054387827
. O 0 0.0018798771

The O 0 0.0032672118
major O 0 0.0031855511
effect O 0 0.0032190091
was O 0 0.0042268406
on O 0 0.004344291
dystonia B-Disease 2 0.9995772
subscore O 0 0.021116447
. O 0 0.0074438197

Similarly O 0 0.0028834064
, O 0 0.0017680334
in O 0 0.0008271218
patient O 0 0.0007415161
diaries O 0 0.00072994904
, O 0 0.00036809786
although O 0 0.00017390806
both O 0 0.0001629701
treatments O 0 0.00022206311
caused O 0 0.00014861682
reduction O 0 0.0003406725
in O 0 0.00012871479
subjective O 0 0.0009230342
dyskinesia B-Disease 0 0.9999862
scores O 0 7.366822e-05
during O 0 2.4201143e-05
the O 0 3.7028418e-05
days O 0 1.962196e-05
of O 0 5.8587524e-05
intervention O 0 6.2032756e-05
, O 0 7.357611e-05
the O 0 6.086549e-05
effect O 0 7.1919836e-05
was O 0 9.605368e-05
sustained O 0 0.00015801769
for O 0 5.2449264e-05
3 O 0 4.028283e-05
days O 0 2.1036994e-05
after O 0 2.2654305e-05
the O 0 6.5186614e-05
intervention O 0 8.685514e-05
for O 0 0.00010501978
the O 0 0.00021878582
real O 0 0.00048622015
rTMS O 0 0.004622863
only O 0 0.0016987829
. O 0 0.002088358

Following O 0 0.0020536515
rTMS O 0 0.008255682
, O 0 0.001390948
no O 0 0.00054494356
side O 0 0.0029821552
effects O 0 0.00055510015
and O 0 0.0003717467
no O 0 0.00018898837
adverse O 0 0.0054759188
effects O 0 0.00024528365
on O 0 0.00012142975
motor O 0 0.0007485749
function O 0 0.00035425593
and O 0 0.0006434467
PD B-Disease 0 0.9978149
symptoms O 0 0.017175904
were O 0 0.0008894051
noted O 0 0.0010542786
. O 0 0.0018592485

The O 0 0.0015023993
results O 0 0.0011080913
suggest O 0 0.00043624788
the O 0 0.00045370654
existence O 0 0.00033592337
of O 0 0.00032276005
residual O 0 0.0002874761
beneficial O 0 0.00034950124
clinical O 0 0.0005423972
aftereffects O 0 0.0012452404
of O 0 0.00016095892
consecutive O 0 8.914313e-05
daily O 0 0.000106053514
applications O 0 6.9979666e-05
of O 0 0.00013579425
low O 0 0.0003472809
- O 0 0.00031643512
frequency O 0 0.00021144337
rTMS O 0 0.0019012918
on O 0 0.00037346312
dyskinesias B-Disease 0 0.99980086
in O 0 0.002335347
PD B-Disease 0 0.99701905
. O 0 0.0028436275

The O 0 0.0025620135
effects O 0 0.002589725
may O 0 0.0016909617
be O 0 0.0012798423
further O 0 0.0012967198
exploited O 0 0.0012690949
for O 0 0.00088430627
potential O 0 0.0016074727
therapeutic O 0 0.0037986992
uses O 0 0.0030894056
. O 0 0.004397494

Intracavernous O 0 0.42363077
epinephrine B-Chemical 0 0.9961506
: O 0 0.0020240538
a O 0 0.000979005
minimally O 0 0.00071410486
invasive O 0 0.00068890076
treatment O 0 0.00043661962
for O 0 0.0005018622
priapism B-Disease 0 0.9900399
in O 0 0.00071974454
the O 0 0.0009776858
emergency O 0 0.012555972
department O 0 0.014460392
. O 0 0.0029791344

Priapism B-Disease 0 0.92077994
is O 0 0.0019585832
the O 0 0.0010539783
prolonged O 0 0.0013884988
erection O 0 0.0063205785
of O 0 0.0006435789
the O 0 0.00047658128
penis O 0 0.0012333079
in O 0 0.00028874155
the O 0 0.00031205718
absence O 0 0.00034805897
of O 0 0.0011420028
sexual O 0 0.020562759
arousal O 0 0.09802519
. O 0 0.0030931334

A O 0 0.021085324
45 O 0 0.0024353073
- O 0 0.0024685876
year O 0 0.0007630442
- O 0 0.0010974602
old O 0 0.00058950396
man O 0 0.0027366779
, O 0 0.000297907
an O 0 0.0002631751
admitted O 0 0.00054467923
frequent O 0 0.0005065992
cocaine B-Chemical 1 0.9996531
user O 0 0.00029160207
, O 0 0.000103766295
presented O 0 6.0840426e-05
to O 0 5.5335684e-05
the O 0 7.780416e-05
Emergency O 0 0.0003854225
Department O 0 0.00032383634
( O 0 0.00021586029
ED O 0 0.016118044
) O 0 0.00011851745
on O 0 3.2201457e-05
two O 0 3.384282e-05
separate O 0 3.6553403e-05
occasions O 0 7.402886e-05
with O 0 9.283327e-05
a O 0 0.00017132878
history O 0 0.00032457506
of O 0 0.00051891844
priapism B-Disease 0 0.9962125
after O 0 0.00044067053
cocaine B-Chemical 1 0.99929214
use O 0 0.0020296366
. O 0 0.0019943444

The O 0 0.0015512479
management O 0 0.0013745165
options O 0 0.0010606081
in O 0 0.00060199766
the O 0 0.0006415463
ED O 0 0.07193646
, O 0 0.00045361443
as O 0 0.00022795482
exemplified O 0 0.000336607
by O 0 0.00014523015
four O 0 6.3988016e-05
individual O 0 8.159756e-05
case O 0 0.00010133334
reports O 0 0.00014708002
, O 0 0.00011123555
in O 0 6.1688705e-05
particular O 0 4.0904055e-05
the O 0 6.5444474e-05
use O 0 5.874842e-05
of O 0 8.954321e-05
a O 0 0.00010953365
minimally O 0 0.00011209325
invasive O 0 0.00014586117
method O 0 0.00015253384
of O 0 0.00019563534
intracorporal O 0 0.005796986
epinephrine B-Chemical 0 0.9967019
instillation O 0 0.0020216424
, O 0 0.0006736471
are O 0 0.00066042505
discussed O 0 0.0011619017
. O 0 0.0018786973

Prophylactic O 0 0.009765221
use O 0 0.001783555
of O 0 0.0026586142
lamivudine B-Chemical 1 0.999534
with O 0 0.0024100244
chronic O 0 0.49724075
immunosuppressive O 0 0.8087822
therapy O 0 0.0029209862
for O 0 0.0016998386
rheumatologic B-Disease 0 0.9985946
disorders I-Disease 0 0.9965836
. O 0 0.004742104

The O 0 0.0014718489
objective O 0 0.00143829
of O 0 0.0009679907
this O 0 0.00070490595
study O 0 0.00056719757
was O 0 0.0003118939
to O 0 0.00017062447
report O 0 0.00024962562
our O 0 0.00018304304
experience O 0 0.00013530593
concerning O 0 5.6731704e-05
the O 0 6.331917e-05
effectiveness O 0 4.6997273e-05
of O 0 7.9172685e-05
the O 0 6.9518326e-05
prophylactic O 0 0.00020177745
administration O 0 0.0006062118
of O 0 0.00060561177
lamivudine B-Chemical 1 0.9999713
in O 0 0.0029673085
hepatitis B-Chemical 2 0.99999964
B I-Chemical 2 0.99971753
virus I-Chemical 0 0.05597697
surface I-Chemical 0 0.0008943462
antigen I-Chemical 0 0.008795223
( O 0 0.0012387431
HBs B-Chemical 0 0.99979025
Ag I-Chemical 0 0.76745075
) O 0 0.00069498003
positive O 0 0.0004473086
patients O 0 0.0007817716
with O 0 0.001665414
rheumatologic B-Disease 0 0.99844605
disease I-Disease 0 0.99268407
. O 0 0.003628444

From O 0 0.002340931
June O 0 0.0018666773
2004 O 0 0.0015011193
to O 0 0.00062844495
October O 0 0.0005894837
2006 O 0 0.00073723914
, O 0 0.00050910265
11 O 0 0.00052479765
HBs B-Chemical 0 0.99615026
Ag I-Chemical 0 0.22508186
positive O 0 0.00046855694
patients O 0 0.00046839347
with O 0 0.0007181003
rheumatologic B-Disease 0 0.9993357
diseases I-Disease 0 0.99120855
, O 0 0.00032353267
who O 0 0.00018387711
were O 0 5.964024e-05
on O 0 3.143484e-05
both O 0 7.5032534e-05
immunosuppressive O 0 0.019730423
and O 0 0.00018760895
prophylactic O 0 0.0020000925
lamivudine B-Chemical 1 0.9998735
therapies O 0 0.0013243575
, O 0 0.00044250663
were O 0 0.00042245473
retrospectively O 0 0.0005731452
assessed O 0 0.0008704599
. O 0 0.0017236014

Liver O 0 0.3753992
function O 0 0.002833051
tests O 0 0.0045191874
, O 0 0.004802256
hepatitis B-Disease 2 0.9999945
B I-Disease 2 0.99935466
virus O 0 0.2950766
( O 0 0.003403536
HBV O 0 0.9982913
) O 0 0.0015331856
serologic O 0 0.050855126
markers O 0 0.0009918761
, O 0 0.00025587465
and O 0 0.00029714828
HBV O 0 0.9890815
DNA O 0 0.029773816
levels O 0 0.00012968363
of O 0 0.00013274592
the O 0 9.212205e-05
patients O 0 0.00010674567
during O 0 3.782463e-05
follow O 0 5.452872e-05
- O 0 0.00014673446
up O 0 9.529117e-05
were O 0 0.00010590436
obtained O 0 0.00014148891
from O 0 0.00019648252
hospital O 0 0.000589441
file O 0 0.0004629986
records O 0 0.0017185974
. O 0 0.0018099474

Eleven O 0 0.006081752
patients O 0 0.0023706902
( O 0 0.0013358422
six O 0 0.00044357686
male O 0 0.00128099
) O 0 0.0004974697
with O 0 0.0002508266
median O 0 0.00013085599
age O 0 0.00019933094
47 O 0 0.00024994166
years O 0 0.00011041317
( O 0 0.00013460498
range O 0 0.00010842255
27 O 0 0.0001998194
- O 0 0.0002240356
73 O 0 0.00022925957
) O 0 0.00014814496
, O 0 8.509425e-05
median O 0 5.1238934e-05
disease O 0 0.0025415688
duration O 0 3.8297967e-05
50 O 0 0.00010390423
months O 0 2.917817e-05
( O 0 7.8661855e-05
range O 0 6.996678e-05
9 O 0 7.141071e-05
- O 0 0.00016745128
178 O 0 0.0004249192
) O 0 0.00011090162
and O 0 5.501535e-05
median O 0 3.1742074e-05
follow O 0 3.6385183e-05
- O 0 8.681102e-05
up O 0 4.4877124e-05
period O 0 2.5760788e-05
of O 0 7.735716e-05
patients O 0 0.00012515597
13 O 0 7.89475e-05
. O 0 4.0413768e-05
8 O 0 4.3538043e-05
months O 0 2.8195356e-05
( O 0 8.504185e-05
range O 0 8.341001e-05
5 O 0 8.420311e-05
- O 0 0.00021567736
27 O 0 0.00022542602
) O 0 0.00023554152
were O 0 0.00018768839
enrolled O 0 0.00028470435
in O 0 0.0003105045
this O 0 0.0007964593
study O 0 0.0016199211
. O 0 0.001982295

Lamivudine B-Chemical 1 0.99868983
therapy O 0 0.0039997483
was O 0 0.0013050913
started O 0 0.0007350175
3 O 0 0.00044827478
- O 0 0.0005215665
7 O 0 0.00014980267
days O 0 8.268042e-05
prior O 0 9.825725e-05
to O 0 0.00022689837
immunosuppressive O 0 0.033401936
therapy O 0 0.000856222
in O 0 0.00060960295
all O 0 0.0010086645
patients O 0 0.002434176
. O 0 0.0023182142

Baseline O 0 0.003656313
, O 0 0.002521735
liver O 0 0.109837614
function O 0 0.001043828
tests O 0 0.0010533073
were O 0 0.00032348523
elevated O 0 0.0007650596
in O 0 0.00016268552
two O 0 0.00010082584
patients O 0 0.00019562975
( O 0 0.00015999856
fourth O 0 0.00018410025
patient O 0 0.0001355562
: O 0 0.00021379007
ALT O 0 0.98417455
: O 0 0.00028480915
122 O 0 0.000603397
IU O 0 0.0056475983
/ O 0 0.00044471704
l O 0 0.00041943073
, O 0 0.00021650315
AST O 0 0.9833413
: O 0 0.00025802315
111 O 0 0.0005295476
IU O 0 0.0050290986
/ O 0 0.00039950013
l O 0 0.00029953266
, O 0 9.9389574e-05
tenth O 0 0.00013945496
patient O 0 0.000102872895
: O 0 0.00017287163
ALT O 0 0.98063433
: O 0 0.0003219926
294 O 0 0.0032568364
IU O 0 0.007791846
/ O 0 0.0004520945
l O 0 0.0004085182
, O 0 0.0002091577
AST O 0 0.98379105
: O 0 0.0002884997
274 O 0 0.0056023095
IU O 0 0.012917986
/ O 0 0.00048685557
l O 0 0.00033944525
, O 0 9.971024e-05
with O 0 8.4663494e-05
minimal O 0 8.411538e-05
changes O 0 0.00013936007
in O 0 0.00011896344
the O 0 0.00021827433
liver O 0 0.45504394
biopsy O 0 0.0015312714
in O 0 0.00046085162
both O 0 0.0008863815
) O 0 0.002098942
. O 0 0.0019663451

Shortly O 0 0.004109385
after O 0 0.00071317074
treatment O 0 0.00081093656
their O 0 0.0006468422
tests O 0 0.0005813019
normalized O 0 0.00017010434
and O 0 0.00018961108
during O 0 8.716779e-05
follow O 0 9.6315445e-05
- O 0 0.00018682903
up O 0 8.816249e-05
period O 0 4.6478075e-05
none O 0 8.4219e-05
of O 0 0.00012406637
the O 0 0.0001379679
patients O 0 0.0002778071
had O 0 0.00029812782
abnormal B-Disease 0 0.03793773
liver I-Disease 0 0.8638646
function I-Disease 0 0.0045889295
tests O 0 0.0041366667
. O 0 0.0020612264

In O 0 0.00200886
four O 0 0.0013038061
patients O 0 0.0027364162
HBV O 0 0.9796799
DNA O 0 0.04412328
levels O 0 0.000789214
were O 0 0.0005265135
higher O 0 0.0005165541
than O 0 0.00039349945
normal O 0 0.0010249136
at O 0 0.0007368985
baseline O 0 0.0015906239
. O 0 0.002533201

Two O 0 0.0028972724
of O 0 0.0022245676
these O 0 0.001667679
normalized O 0 0.0010018159
and O 0 0.0014096695
the O 0 0.0015002728
others O 0 0.0029988491
increased O 0 0.0034801832
later O 0 0.0028576886
. O 0 0.004383269

In O 0 0.001696416
three O 0 0.0008107242
additional O 0 0.0008142553
patients O 0 0.0013353314
, O 0 0.001393633
HBV O 0 0.9852011
DNA O 0 0.05104078
levels O 0 0.0006001376
were O 0 0.00042815928
increased O 0 0.00055372674
during O 0 0.00030883582
follow O 0 0.0005003921
- O 0 0.0015316579
up O 0 0.0018369314
. O 0 0.0025966961

None O 0 0.0036425656
of O 0 0.0020188987
the O 0 0.0013422181
patients O 0 0.0013910095
had O 0 0.00085751526
significant O 0 0.0008213506
clinical O 0 0.0022958117
sings O 0 0.0069938703
of O 0 0.0025921972
HBV O 0 0.98330367
activation O 0 0.007764627
. O 0 0.0045255763

Lamivudine B-Chemical 1 0.99833375
was O 0 0.003229998
well O 0 0.0014333698
tolerated O 0 0.0047979373
and O 0 0.0010585276
was O 0 0.00090961915
continued O 0 0.0008397975
in O 0 0.0009865825
all O 0 0.0015555864
patients O 0 0.003366499
. O 0 0.0032599464

Prophylactic O 0 0.010047704
administration O 0 0.0051408256
of O 0 0.0026563217
lamivudine B-Chemical 1 0.999721
in O 0 0.0005656643
patients O 0 0.00048774946
who O 0 0.00026676338
required O 0 9.248513e-05
immunosuppressive O 0 0.08581621
therapy O 0 0.00028115723
seems O 0 8.537971e-05
to O 0 8.734018e-05
be O 0 8.905715e-05
safe O 0 0.00014681969
, O 0 0.00011779704
well O 0 9.6583084e-05
tolerated O 0 0.0006688763
and O 0 0.00015762344
effective O 0 0.0001809865
in O 0 0.0003295502
preventing O 0 0.001868405
HBV O 0 0.99518967
reactivation O 0 0.27426958
. O 0 0.0035130787

Effect O 0 0.002379889
of O 0 0.0029735772
green B-Chemical 1 0.275409
tea I-Chemical 1 0.99985516
and O 0 0.015010391
vitamin B-Chemical 0 0.9999919
E I-Chemical 0 0.999851
combination O 0 0.0018000056
in O 0 0.0008017951
isoproterenol B-Chemical 0 0.9998153
induced O 0 0.0056879614
myocardial B-Disease 0 0.99990237
infarction I-Disease 2 0.9999821
in O 0 0.002595671
rats O 0 0.0036250614
. O 0 0.0021011862

The O 0 0.0015064175
present O 0 0.0010369943
study O 0 0.0010347773
was O 0 0.0005811343
aimed O 0 0.00046612503
to O 0 0.00022421918
investigate O 0 0.00010898625
the O 0 0.00014090809
combined O 0 0.0001798523
effects O 0 0.00018405323
of O 0 0.0004578651
green B-Chemical 1 0.554329
tea I-Chemical 1 0.9999876
and O 0 0.010665343
vitamin B-Chemical 0 0.99999833
E I-Chemical 0 0.9999373
on O 0 0.0001076916
heart O 0 0.03828578
weight O 0 0.0011174644
, O 0 0.00011378532
body O 0 0.00030367498
weight O 0 0.00059480127
, O 0 0.00013519966
serum O 0 0.011755166
marker O 0 0.000425566
enzymes O 0 0.0046388814
, O 0 0.00031615523
lipid O 0 0.97984445
peroxidation O 0 0.99999666
, O 0 0.00035501493
endogenous O 0 0.00033234275
antioxidants O 0 0.99931884
and O 0 0.00016890444
membrane O 0 0.0002657312
bound O 0 8.127466e-05
ATPases O 0 0.004601696
in O 0 0.00015422287
isoproterenol B-Chemical 0 0.9998055
( O 0 0.00080107653
ISO B-Chemical 0 0.95762235
) O 0 0.00060712936
- O 0 0.0004827151
induced O 0 0.0007547429
myocardial B-Disease 0 0.99977845
infarction I-Disease 2 0.9999783
in O 0 0.0020105173
rats O 0 0.0030784984
. O 0 0.0018691719

Adult O 0 0.00622407
male O 0 0.005486687
albino O 0 0.006037387
rats O 0 0.0010555952
, O 0 0.0004941854
treated O 0 0.00046238885
with O 0 0.0005271236
ISO B-Chemical 0 0.9268114
( O 0 0.0004524472
200 O 0 0.0005363507
mg O 0 0.0075200913
/ O 0 0.00067855144
kg O 0 0.00040120192
, O 0 0.00014108824
s O 0 0.0001238359
. O 0 8.552231e-05
c O 0 0.0007169372
. O 0 7.59141e-05
) O 0 0.00012278566
for O 0 4.987271e-05
2 O 0 4.54414e-05
days O 0 2.1597769e-05
at O 0 2.9756848e-05
an O 0 6.5312495e-05
interval O 0 4.879069e-05
of O 0 6.789315e-05
24 O 0 4.4211196e-05
h O 0 4.879167e-05
caused O 0 8.5332984e-05
a O 0 0.00015825473
significant O 0 0.00016611446
( O 0 0.00036545584
P O 0 0.0072385524
< O 0 0.00010247422
0 O 0 7.7752906e-05
. O 0 6.953836e-05
05 O 0 0.0011801706
) O 0 0.00014314735
elevation O 0 0.00072218437
of O 0 0.00014870257
heart O 0 0.01502998
weight O 0 0.0011739301
, O 0 0.00015767573
serum O 0 0.012072328
marker O 0 0.00040642044
enzymes O 0 0.0033986452
, O 0 0.0002775074
lipid O 0 0.9690888
peroxidation O 0 0.9999968
and O 0 0.002410715
Ca B-Chemical 1 0.9999776
+ O 0 0.0009110841
2 O 0 0.00010647831
ATPase O 0 0.0012081894
level O 0 5.6957102e-05
whereas O 0 6.940718e-05
there O 0 4.539293e-05
was O 0 9.049665e-05
a O 0 0.00012603504
significant O 0 0.00014050155
( O 0 0.00032276867
P O 0 0.0059922133
< O 0 0.00010180898
0 O 0 7.9986494e-05
. O 0 7.3657124e-05
05 O 0 0.0011866863
) O 0 0.00012913156
decrease O 0 8.679752e-05
in O 0 6.6668574e-05
body O 0 0.00026873793
weight O 0 0.00056278927
, O 0 0.00014985555
endogenous O 0 0.0003218812
antioxidants O 0 0.99979454
, O 0 0.0017834626
Na B-Chemical 1 0.9999751
+ O 0 0.002698212
/ O 0 0.006795845
K B-Chemical 1 0.9997906
+ O 0 0.0019107886
ATPase O 0 0.042139567
and O 0 0.001127725
Mg B-Chemical 0 0.9999447
+ O 0 0.002286986
2 O 0 0.0006678447
ATPase O 0 0.005194757
levels O 0 0.0017526594
. O 0 0.0023107314

Administration O 0 0.010037071
of O 0 0.0036820162
green B-Chemical 1 0.32199436
tea I-Chemical 1 0.9997869
( O 0 0.0019404442
100 O 0 0.0016221621
mg O 0 0.022366017
/ O 0 0.0012496308
kg O 0 0.00070800056
/ O 0 0.00048270662
day O 0 0.00011823242
, O 0 0.00020662094
p O 0 0.00016208272
. O 0 8.6017295e-05
o O 0 0.00074923283
. O 0 9.4967865e-05
) O 0 0.00023997451
and O 0 0.000416151
vitamin B-Chemical 0 0.9999943
E I-Chemical 0 0.9999298
( O 0 0.0004991736
100 O 0 0.00049180764
mg O 0 0.00735403
/ O 0 0.0005245849
kg O 0 0.00031641911
/ O 0 0.00025826163
day O 0 6.3951054e-05
, O 0 0.000130373
p O 0 0.00011070149
. O 0 6.125282e-05
o O 0 0.0006162129
. O 0 6.418493e-05
) O 0 0.00010002966
together O 0 4.832444e-05
for O 0 3.4587418e-05
30 O 0 3.3437198e-05
consecutive O 0 3.4139455e-05
days O 0 2.0369243e-05
and O 0 4.2453667e-05
challenged O 0 5.161302e-05
with O 0 0.00014654403
ISO B-Chemical 0 0.60915864
on O 0 4.2205695e-05
the O 0 5.476938e-05
day O 0 3.9808867e-05
29th O 0 0.00015748762
and O 0 7.575111e-05
30th O 0 0.00016682241
, O 0 8.3447325e-05
showed O 0 7.468096e-05
a O 0 0.00013023186
significant O 0 0.00014362314
( O 0 0.00032740633
P O 0 0.00598775
< O 0 0.000103327104
0 O 0 8.071271e-05
. O 0 7.3671035e-05
05 O 0 0.0012534143
) O 0 0.00013046029
decrease O 0 9.029124e-05
in O 0 7.461498e-05
heart O 0 0.0046652225
weight O 0 0.000899752
, O 0 0.0001543438
serum O 0 0.011395104
marker O 0 0.00042426615
enzymes O 0 0.0039333417
, O 0 0.0003199671
lipid O 0 0.9819735
peroxidation O 0 0.9999976
, O 0 0.0035510575
Ca B-Chemical 1 0.9999776
+ O 0 0.0009877849
2 O 0 0.00011223955
ATPase O 0 0.0015347662
and O 0 7.696754e-05
a O 0 8.955329e-05
significant O 0 5.780336e-05
increase O 0 5.4832348e-05
in O 0 4.7347432e-05
the O 0 5.681161e-05
body O 0 0.0002708952
weight O 0 0.00059447053
, O 0 0.00013161171
endogenous O 0 0.0002944845
antioxidants O 0 0.9998338
, O 0 0.0016157959
Na B-Chemical 1 0.999982
+ O 0 0.0024118873
/ O 0 0.0068435925
K B-Chemical 1 0.9998758
+ O 0 0.0014865785
ATPase O 0 0.04651108
and O 0 0.00057837856
Mg B-Chemical 0 0.999987
+ O 0 0.0008490422
2 O 0 9.540881e-05
ATPase O 0 0.0007252921
when O 0 3.1800035e-05
compared O 0 3.510742e-05
with O 0 0.00011045791
ISO B-Chemical 0 0.7369455
treated O 0 0.00021832738
group O 0 0.00016958691
and O 0 0.00018882121
green B-Chemical 1 0.21025537
tea I-Chemical 1 0.99997437
or O 0 0.0036988158
vitamin B-Chemical 0 0.99999595
E I-Chemical 0 0.99986184
alone O 0 0.0014758994
treated O 0 0.0023191716
groups O 0 0.0015340473
. O 0 0.0018609413

These O 0 0.002194427
findings O 0 0.0018634729
indicate O 0 0.00058093993
the O 0 0.0005631348
synergistic O 0 0.0010054392
protective O 0 0.0013704135
effect O 0 0.00038226365
of O 0 0.0009916797
green B-Chemical 1 0.7003082
tea I-Chemical 1 0.9999832
and O 0 0.016786637
vitamin B-Chemical 0 0.9999974
E I-Chemical 0 0.9999124
during O 0 0.00028604025
ISO B-Chemical 0 0.9574658
induced O 0 0.0022121568
myocardial B-Disease 0 0.9998808
infarction I-Disease 2 0.999982
in O 0 0.002238919
rats O 0 0.0032898975
. O 0 0.0019358561

Irreversible O 0 0.4145858
damage O 0 0.09972233
to O 0 0.0012940278
the O 0 0.0010112288
medullary O 0 0.022578552
interstitium O 0 0.0019593595
in O 0 0.00043156068
experimental O 0 0.0010854413
analgesic O 0 0.9645423
nephropathy B-Disease 2 0.99998724
in O 0 0.0027283432
F344 O 0 0.5500199
rats O 0 0.0033757298
. O 0 0.0022276922

Renal B-Disease 0 0.6379706
papillary I-Disease 0 0.98745453
necrosis I-Disease 2 0.9999397
( O 0 0.0134441275
RPN B-Disease 2 0.998771
) O 0 0.0011056724
and O 0 0.00029541415
a O 0 0.00026962848
decreased O 0 0.00041430682
urinary O 0 0.02282087
concentrating O 0 0.0025296572
ability O 0 0.00013742354
developed O 0 0.00013744767
during O 0 3.6622983e-05
continuous O 0 4.723595e-05
long O 0 6.669102e-05
- O 0 0.0001088257
term O 0 5.575663e-05
treatment O 0 8.78446e-05
with O 0 0.00033629267
aspirin B-Chemical 0 0.9999529
and O 0 0.0011249674
paracetamol B-Chemical 0 0.9999777
in O 0 0.0005478115
female O 0 0.0025723088
Fischer O 0 0.0059822747
344 O 0 0.005172361
rats O 0 0.0015401228
. O 0 0.001464234

Renal O 0 0.013035512
structure O 0 0.0017524309
and O 0 0.0009808092
concentrating O 0 0.002354794
ability O 0 0.00046419044
were O 0 0.00026186905
examined O 0 0.00010888589
after O 0 5.6110108e-05
a O 0 0.00013009185
recovery O 0 0.00017473
period O 0 4.3980835e-05
of O 0 8.888322e-05
up O 0 8.152779e-05
to O 0 6.328825e-05
18 O 0 5.85568e-05
weeks O 0 2.5080633e-05
, O 0 5.7331195e-05
when O 0 3.9012913e-05
no O 0 6.467048e-05
analgesics O 0 0.11493622
were O 0 7.941177e-05
given O 0 4.2536092e-05
, O 0 6.978574e-05
to O 0 4.5866662e-05
investigate O 0 3.3416545e-05
whether O 0 4.469441e-05
the O 0 0.00020096372
analgesic O 0 0.4141696
- O 0 0.00060964125
induced O 0 0.00042625968
changes O 0 0.0007656876
were O 0 0.0009588265
reversible O 0 0.046525467
. O 0 0.0023331083

There O 0 0.002907201
was O 0 0.0017285659
no O 0 0.00060078426
evidence O 0 0.00050521694
of O 0 0.00056117005
repair O 0 0.0005970323
to O 0 0.00020027492
the O 0 0.00021704966
damaged O 0 0.0013541746
medullary O 0 0.14057216
interstitial O 0 0.024219856
matrix O 0 0.0008216661
, O 0 0.00017660666
or O 0 0.00011072737
proliferation O 0 0.026312595
of O 0 0.00013969601
remaining O 0 0.00014337753
undamaged O 0 0.0005250646
type O 0 0.00011201919
1 O 0 8.3622006e-05
medullary O 0 0.0074716154
interstitial O 0 0.001967935
cells O 0 0.00012533584
after O 0 3.0700845e-05
the O 0 7.350822e-05
recovery O 0 0.0001848087
period O 0 8.900136e-05
following O 0 0.00023829826
analgesic O 0 0.10846129
treatment O 0 0.001463581
. O 0 0.0018884139

The O 0 0.0014535242
recovery O 0 0.0018499221
of O 0 0.0011505514
urinary O 0 0.021324376
concentrating O 0 0.0051416205
ability O 0 0.0004377329
was O 0 0.00024227718
related O 0 6.86096e-05
to O 0 8.455844e-05
the O 0 8.719854e-05
length O 0 8.336262e-05
of O 0 0.00018361642
analgesic O 0 0.17345057
treatment O 0 0.00013542546
and O 0 9.9679535e-05
the O 0 8.1581e-05
extent O 0 7.259954e-05
of O 0 0.00015708836
the O 0 0.0001730334
resulting O 0 0.00037756847
inner O 0 0.008021929
medullary O 0 0.2891645
structural O 0 0.003515126
damage O 0 0.4321625
. O 0 0.002672017

During O 0 0.0009411609
the O 0 0.0010241694
early O 0 0.0010525836
stages O 0 0.00076998275
of O 0 0.0007824155
analgesic O 0 0.4030494
treatment O 0 0.00039359884
, O 0 0.00021270433
the O 0 0.000113280395
changes O 0 0.00012783826
in O 0 9.113185e-05
urinary O 0 0.008874031
concentrating O 0 0.0020316744
ability O 0 0.00013871586
were O 0 0.00013690717
reversible O 0 0.008287443
, O 0 0.00011855982
but O 0 6.621271e-05
after O 0 2.528274e-05
prolonged O 0 0.00020187617
analgesic O 0 0.12093159
treatment O 0 0.00011268503
, O 0 0.00010159728
maximum O 0 0.00010781285
urinary O 0 0.014697812
concentrating O 0 0.0028193558
ability O 0 0.00032260007
failed O 0 0.00055187446
to O 0 0.00061958755
recover O 0 0.0017534421
. O 0 0.0019716676

This O 0 0.0029959904
study O 0 0.0012414876
shows O 0 0.000379024
that O 0 0.00031825367
prolonged O 0 0.00096334214
analgesic O 0 0.33307773
treatment O 0 0.00036002448
in O 0 0.00025992934
Fischer O 0 0.0043398757
344 O 0 0.0023869642
rats O 0 0.00019149006
causes O 0 0.00018259435
progressive O 0 0.013682733
and O 0 0.0002535854
irreversible O 0 0.17458338
damage O 0 0.15609874
to O 0 0.00010397273
the O 0 0.00010906089
interstitial O 0 0.0020400605
matrix O 0 0.0004047318
and O 0 0.00015402374
type O 0 0.00017805504
1 O 0 0.00016060995
interstitial O 0 0.0016766844
cells O 0 0.00057655293
leading O 0 0.001046126
to O 0 0.0014266267
RPN B-Disease 2 0.9949255
. O 0 0.0029264144

The O 0 0.0016238759
associated O 0 0.0013154523
urinary O 0 0.021552216
concentrating O 0 0.01080284
defect O 0 0.0014673355
is O 0 0.00049836864
reversible O 0 0.005995775
only O 0 0.00023646407
during O 0 8.275481e-05
the O 0 0.00012635271
early O 0 0.00023312963
stages O 0 0.00021358879
of O 0 0.0002692154
structural O 0 0.00063066435
damage O 0 0.046340987
to O 0 0.00045582076
the O 0 0.00080406526
inner O 0 0.015238357
medulla O 0 0.15963617
. O 0 0.0027064541

Testosterone B-Chemical 1 0.99955803
- O 0 0.0061052185
dependent O 0 0.0013653302
hypertension B-Disease 2 0.9996001
and O 0 0.000850603
upregulation O 0 0.00064657297
of O 0 0.0006156355
intrarenal O 0 0.77471876
angiotensinogen O 0 0.99752074
in O 0 0.0010520048
Dahl O 0 0.96078485
salt B-Chemical 0 0.9961488
- O 0 0.0018375646
sensitive O 0 0.001042913
rats O 0 0.0026207203
. O 0 0.0022205368

Blood O 0 0.018898042
pressure O 0 0.015120939
( O 0 0.0035535384
BP O 0 0.6787389
) O 0 0.0017007418
is O 0 0.0006649005
more O 0 0.0010080514
salt B-Chemical 0 0.9523328
sensitive O 0 0.00057553174
in O 0 0.00052647904
men O 0 0.0016037992
than O 0 0.00038623868
in O 0 0.00085567805
premenopausal O 0 0.1774384
women O 0 0.0049794056
. O 0 0.0023094786

In O 0 0.0037562381
Dahl O 0 0.955188
salt B-Chemical 0 0.9978275
- O 0 0.0027907488
sensitive O 0 0.00067091285
rats O 0 0.0011576981
( O 0 0.0011431071
DS O 0 0.94230753
) O 0 0.00074701814
, O 0 0.00032020148
high O 0 0.000685054
- O 0 0.0013299355
salt B-Chemical 0 0.99725777
( O 0 0.0009414425
HS O 0 0.48032725
) O 0 0.00054815994
diet O 0 0.0024964393
increases O 0 0.00029568383
BP O 0 0.43897966
more O 0 0.00041204068
in O 0 0.0003475159
males O 0 0.00070697156
than O 0 0.00050236715
females O 0 0.001568946
. O 0 0.0017610219

In O 0 0.0017140368
contrast O 0 0.0014472082
to O 0 0.0007425485
the O 0 0.0007577496
systemic O 0 0.25293434
renin O 0 0.9955012
- O 0 0.0050496645
angiotensin B-Chemical 1 0.9999491
system O 0 0.0005534397
, O 0 0.00023654435
which O 0 0.00017855848
is O 0 0.00010549575
suppressed O 0 0.00014680582
in O 0 7.803509e-05
response O 0 8.922238e-05
to O 0 0.00010220664
HS O 0 0.0832575
in O 0 0.00014088821
male O 0 0.0012982733
DS O 0 0.85060287
, O 0 0.00019572004
intrarenal O 0 0.6525551
angiotensinogen O 0 0.99538296
expression O 0 0.00024771586
is O 0 0.00010454677
increased O 0 0.00016908781
, O 0 0.00012104846
and O 0 0.00012094129
intrarenal O 0 0.07624817
levels O 0 0.00020074102
of O 0 0.00054371526
ANG O 0 0.99924845
II O 0 0.029403018
are O 0 0.00047236605
not O 0 0.00059831905
suppressed O 0 0.0022600535
. O 0 0.002340933

In O 0 0.0018631003
this O 0 0.0016443491
study O 0 0.0012924388
, O 0 0.0007745027
the O 0 0.00045968677
hypothesis O 0 0.00054720644
was O 0 0.00030972576
tested O 0 0.00016278
that O 0 0.000106601954
there O 0 9.166088e-05
is O 0 0.0001367681
a O 0 0.00022254512
sexual O 0 0.0023813695
dimorphism O 0 0.000955518
in O 0 0.00018863658
HS O 0 0.39399692
- O 0 0.00029474573
induced O 0 0.0001103859
upregulation O 0 0.0001608848
of O 0 0.00019447684
intrarenal O 0 0.8087064
angiotensinogen O 0 0.9960168
mediated O 0 0.00010574229
by O 0 0.00025494784
testosterone B-Chemical 0 0.99969923
that O 0 0.0001012048
also O 0 0.00012251548
causes O 0 0.00021575349
increases O 0 0.00022815139
in O 0 0.00035743666
BP O 0 0.7838848
and O 0 0.00147712
renal B-Disease 2 0.9993741
injury I-Disease 2 0.99761
. O 0 0.0042475625

On O 0 0.0029796497
a O 0 0.0026890964
low O 0 0.0036377073
- O 0 0.0049430695
salt B-Chemical 0 0.9961022
( O 0 0.0021867184
LS O 0 0.048446503
) O 0 0.0010351501
diet O 0 0.0070731426
, O 0 0.00044750966
male O 0 0.0019203201
DS O 0 0.79165494
had O 0 0.00019839974
higher O 0 0.00017526095
levels O 0 0.00017116418
of O 0 0.00037464575
intrarenal O 0 0.8022768
angiotensinogen O 0 0.9966383
mRNA O 0 0.0014495585
than O 0 0.00065044255
females O 0 0.0017266406
. O 0 0.0017322609

HS O 0 0.43337312
diet O 0 0.014062443
for O 0 0.00078554277
4 O 0 0.00042302374
wk O 0 0.00023184795
increased O 0 0.0004832501
renal O 0 0.38863304
cortical O 0 0.0067713954
angiotensinogen O 0 0.9957925
mRNA O 0 0.00056769786
and O 0 0.0001680559
protein O 0 0.00023912216
only O 0 0.00016689625
in O 0 0.00018878485
male O 0 0.0022932529
DS O 0 0.90128195
, O 0 0.00036303594
which O 0 0.00040913592
was O 0 0.0004885785
prevented O 0 0.0016720727
by O 0 0.0014733052
castration O 0 0.086132705
. O 0 0.0025469735

Ovariectomy O 0 0.84863013
of O 0 0.0037457747
female O 0 0.009991303
DS O 0 0.8945365
had O 0 0.0006228607
no O 0 0.00023322922
effect O 0 0.0002650349
on O 0 0.00025552872
intrarenal O 0 0.60059905
angiotensinogen O 0 0.9936573
expression O 0 0.0007909532
on O 0 0.00039730797
either O 0 0.0010837814
diet O 0 0.016657712
. O 0 0.0026623087

Radiotelemetric O 0 0.025682034
BP O 0 0.50610197
was O 0 0.001668705
similar O 0 0.0006255711
between O 0 0.0005015396
males O 0 0.0009967596
and O 0 0.00069172634
castrated O 0 0.0063009155
rats O 0 0.0010811476
on O 0 0.00075711147
LS O 0 0.014169196
diet O 0 0.021708095
. O 0 0.0035312185

HS O 0 0.49205583
diet O 0 0.017930908
for O 0 0.0008641734
4 O 0 0.00047022835
wk O 0 0.0002472951
caused O 0 0.00035047636
a O 0 0.00045022398
progressive O 0 0.006304129
increase O 0 0.0002782553
in O 0 0.0002429707
BP O 0 0.68968326
, O 0 0.00017845618
protein O 0 0.0002193067
and O 0 0.00017140231
albumin O 0 0.96139383
excretion O 0 0.89282113
, O 0 0.00023577138
and O 0 0.00024761667
glomerular B-Disease 2 0.9998342
sclerosis I-Disease 2 0.9997906
in O 0 0.00027600076
male O 0 0.0022974988
DS O 0 0.85605866
rats O 0 0.0003409999
, O 0 0.00019841905
which O 0 0.00025656426
were O 0 0.00030910448
attenuated O 0 0.0009527616
by O 0 0.001194894
castration O 0 0.057823267
. O 0 0.0023805208

Testosterone B-Chemical 1 0.99946064
replacement O 0 0.008078979
in O 0 0.0014854788
castrated O 0 0.082138345
DS O 0 0.9140491
rats O 0 0.000849839
increased O 0 0.0008776844
BP O 0 0.9182477
, O 0 0.0009977944
renal B-Disease 2 0.99962556
injury I-Disease 2 0.995948
, O 0 0.0004760868
and O 0 0.0001979287
upregulation O 0 0.00029265293
of O 0 0.00042120912
renal O 0 0.9659275
angiotensinogen O 0 0.9976674
associated O 0 0.00060013926
with O 0 0.0012075312
HS O 0 0.58281857
diet O 0 0.06388764
. O 0 0.0024070356

Testosterone B-Chemical 1 0.9989058
contributes O 0 0.0013009085
to O 0 0.0007143959
the O 0 0.00050842954
development O 0 0.0007604057
of O 0 0.001207215
hypertension B-Disease 2 0.999951
and O 0 0.0015328425
renal B-Disease 2 0.99976593
injury I-Disease 2 0.99487126
in O 0 0.00041703356
male O 0 0.0045318226
DS O 0 0.9010161
rats O 0 0.00019813697
on O 0 6.749048e-05
HS O 0 0.120980434
diet O 0 0.0030697144
possibly O 0 0.00018202698
through O 0 6.541017e-05
upregulation O 0 0.00014623147
of O 0 0.00016024453
the O 0 0.00022029254
intrarenal O 0 0.69612795
renin O 0 0.99193865
- O 0 0.004429528
angiotensin B-Chemical 1 0.9998029
system O 0 0.003080305
. O 0 0.0021685155

Explicit O 0 0.0065981015
episodic O 0 0.25335863
memory O 0 0.0664503
for O 0 0.0006352354
sensory O 0 0.0012978183
- O 0 0.0006403313
discriminative O 0 0.00056233833
components O 0 0.00017953842
of O 0 0.00065194204
capsaicin B-Chemical 0 0.9997638
- O 0 0.0014943306
induced O 0 0.0007160447
pain B-Disease 0 0.5900126
: O 0 0.0005020576
immediate O 0 0.0006139498
and O 0 0.0006151218
delayed O 0 0.0032202671
ratings O 0 0.002177215
. O 0 0.0021643487

Pain B-Disease 0 0.4401428
memory O 0 0.077435024
is O 0 0.0012745424
thought O 0 0.00072970975
to O 0 0.0003868205
affect O 0 0.00021993998
future O 0 0.00043986307
pain B-Disease 0 0.183463
sensitivity O 0 0.00137476
and O 0 0.00030268295
thus O 0 0.00028692736
contribute O 0 0.00021240844
to O 0 0.00034976072
clinical O 0 0.0021510914
pain B-Disease 0 0.3416964
conditions O 0 0.0025257883
. O 0 0.0024480703

Systematic O 0 0.003143344
investigations O 0 0.0018249367
of O 0 0.00107405
the O 0 0.00063999754
human O 0 0.0005591748
capacity O 0 0.0005610894
to O 0 0.00028534597
remember O 0 0.00063013774
sensory O 0 0.0005510505
features O 0 0.0003212622
of O 0 0.00046283758
experimental O 0 0.0010497316
pain B-Disease 0 0.3539932
are O 0 0.0011796964
sparse O 0 0.0021282826
. O 0 0.002325239

In O 0 0.0015402003
order O 0 0.0009240456
to O 0 0.000591855
address O 0 0.0002753224
long O 0 0.00042339042
- O 0 0.0005978771
term O 0 0.00034373134
pain B-Disease 0 0.3724788
memory O 0 0.18939465
, O 0 0.00025054388
nine O 0 0.00013251157
healthy O 0 0.00041539496
male O 0 0.00031615252
volunteers O 0 0.000109531655
received O 0 4.450655e-05
intradermal O 0 0.00019352014
injections O 0 7.3298375e-05
of O 0 6.003448e-05
three O 0 3.0148747e-05
doses O 0 0.00040714478
of O 0 0.00033979025
capsaicin B-Chemical 0 0.9997702
( O 0 0.0003619739
0 O 0 9.782943e-05
. O 0 7.286872e-05
05 O 0 0.0012853697
, O 0 9.145518e-05
1 O 0 5.2592906e-05
and O 0 5.4215125e-05
20 O 0 5.8443555e-05
microg O 0 0.00014351103
, O 0 9.954588e-05
separated O 0 7.6601435e-05
by O 0 6.526884e-05
15 O 0 4.771822e-05
min O 0 0.000103400445
breaks O 0 0.0008049142
) O 0 0.00014812307
, O 0 6.2682935e-05
each O 0 2.2748629e-05
given O 0 2.4832498e-05
three O 0 2.0955258e-05
times O 0 2.4549285e-05
in O 0 4.464066e-05
a O 0 7.9870944e-05
balanced O 0 0.00011591205
design O 0 8.389789e-05
across O 0 3.5509656e-05
three O 0 4.024278e-05
sessions O 0 6.301604e-05
at O 0 9.483302e-05
one O 0 0.0001831939
week O 0 0.00026194946
intervals O 0 0.0005426231
. O 0 0.0013819746

Pain B-Disease 0 0.1642776
rating O 0 0.002087545
was O 0 0.0009127623
performed O 0 0.00042595217
using O 0 0.0002918677
a O 0 0.00038933713
computerized O 0 0.000894726
visual O 0 0.0037742085
analogue O 0 0.0016877563
scale O 0 0.00027519226
( O 0 0.0002538111
0 O 0 0.00013800607
- O 0 0.00023660029
100 O 0 0.0002798228
) O 0 0.0001801154
digitized O 0 0.0002470399
at O 0 7.365017e-05
1 O 0 8.6557564e-05
/ O 0 0.0002092293
s O 0 9.684039e-05
, O 0 8.803042e-05
either O 0 6.5383596e-05
immediately O 0 5.9334074e-05
online O 0 0.000106755244
or O 0 7.184279e-05
one O 0 6.293348e-05
hour O 0 7.360573e-05
or O 0 0.000106037136
one O 0 0.00012789229
day O 0 0.0001701835
after O 0 0.00024828385
injection O 0 0.0013383508
. O 0 0.0019469535

Subjects O 0 0.0043463376
also O 0 0.0026637905
recalled O 0 0.0052970387
their O 0 0.0033994461
pains B-Disease 0 0.28309733
one O 0 0.0018987346
week O 0 0.001547458
later O 0 0.0024479004
. O 0 0.004417311

Capsaicin B-Chemical 1 0.997729
injection O 0 0.0027483278
reliably O 0 0.0011639057
induced O 0 0.00078730384
a O 0 0.0007885364
dose O 0 0.0029794031
- O 0 0.0007694055
dependent O 0 0.00021888138
flare O 0 0.9182787
( O 0 0.0007017593
p O 0 0.00023553276
< O 0 0.0001394543
0 O 0 0.00011679008
. O 0 0.0001143904
001 O 0 0.0021562108
) O 0 0.00021645158
without O 0 0.00011622638
any O 0 0.000112847076
difference O 0 8.872875e-05
within O 0 9.1540416e-05
or O 0 0.0002718766
across O 0 0.00033955486
sessions O 0 0.00075520907
. O 0 0.0016225654

The O 0 0.0028105956
strong O 0 0.0040435353
burning O 0 0.36307037
pain B-Disease 0 0.6403102
decayed O 0 0.006119831
exponentially O 0 0.0013784755
within O 0 0.00049574807
a O 0 0.0012712035
few O 0 0.00097086595
minutes O 0 0.0015602309
. O 0 0.0032336847

Subjects O 0 0.0023470279
were O 0 0.00090777234
able O 0 0.00046764754
to O 0 0.00039016714
reliably O 0 0.00038213065
discriminate O 0 0.00028272276
pain B-Disease 0 0.035572
magnitude O 0 0.00013845711
and O 0 0.00011371719
duration O 0 5.440323e-05
across O 0 7.784772e-05
capsaicin B-Chemical 0 0.99825925
doses O 0 0.0075634057
( O 0 0.0002635992
both O 0 0.00014867976
p O 0 0.00012988162
< O 0 8.5613705e-05
0 O 0 7.6856646e-05
. O 0 7.656077e-05
001 O 0 0.0027862007
) O 0 0.00016251851
, O 0 7.525244e-05
regardless O 0 2.8642933e-05
of O 0 6.5581924e-05
whether O 0 2.99078e-05
first O 0 4.8709746e-05
- O 0 0.0001211367
time O 0 3.342225e-05
ratings O 0 8.206984e-05
were O 0 6.469515e-05
requested O 0 9.442425e-05
immediately O 0 5.4985823e-05
, O 0 7.8902034e-05
after O 0 3.3206274e-05
one O 0 6.44126e-05
hour O 0 8.8018605e-05
or O 0 0.00013898252
after O 0 0.00013873426
one O 0 0.00039439663
day O 0 0.0007190346
. O 0 0.0016111165

Pain B-Disease 0 0.14004964
recall O 0 0.0026941192
after O 0 0.00042173732
one O 0 0.00038354268
week O 0 0.00023671311
was O 0 0.0002680787
similarly O 0 0.00020084708
precise O 0 0.00018825047
( O 0 0.00026375483
magnitude O 0 0.00016258983
: O 0 0.00029161404
p O 0 0.00020059406
< O 0 0.00014157502
0 O 0 0.000120820485
. O 0 0.000105838124
01 O 0 0.00039058732
, O 0 0.00016217765
duration O 0 0.00010292217
: O 0 0.0003134679
p O 0 0.0003115756
< O 0 0.00033348822
0 O 0 0.00041849655
. O 0 0.00063817215
05 O 0 0.006132556
) O 0 0.002699454
. O 0 0.0027126197

Correlation O 0 0.0014719751
with O 0 0.0012380688
rating O 0 0.0009169001
recall O 0 0.00083241996
after O 0 0.00014777645
one O 0 0.00015926642
week O 0 0.00010498614
was O 0 0.0001360244
best O 0 0.00012973398
when O 0 6.399162e-05
first O 0 6.771276e-05
- O 0 0.00015195142
time O 0 4.073333e-05
ratings O 0 9.3915005e-05
were O 0 7.038665e-05
requested O 0 0.00010415392
as O 0 6.247753e-05
late O 0 0.00014197733
as O 0 5.2151165e-05
one O 0 3.4326087e-05
day O 0 2.9125937e-05
after O 0 2.3682755e-05
injection O 0 0.00012916628
( O 0 0.00036280925
R O 0 0.91705096
( O 0 0.0002705434
2 O 0 0.000103503044
) O 0 0.0001645144
= O 0 0.00010971941
0 O 0 6.4593245e-05
. O 0 5.3019532e-05
79 O 0 0.00013866616
) O 0 0.00011598159
indicating O 0 4.918206e-05
that O 0 5.3541546e-05
both O 0 9.819655e-05
rating O 0 0.0001466466
retrievals O 0 0.00019075624
utilized O 0 0.00016340299
similar O 0 0.00027792522
memory O 0 0.055080373
traces O 0 0.005786026
. O 0 0.0024403238

These O 0 0.002236365
results O 0 0.0014051956
indicate O 0 0.00066274445
a O 0 0.0008358366
reliable O 0 0.00062535173
memory O 0 0.010150312
for O 0 0.00030294163
magnitude O 0 0.00027626113
and O 0 0.00030176726
duration O 0 0.0001977182
of O 0 0.00056372344
experimentally O 0 0.001070646
induced O 0 0.0027675473
pain B-Disease 0 0.8632695
. O 0 0.0036506094

The O 0 0.001579461
data O 0 0.0013590214
further O 0 0.000895419
suggest O 0 0.00026352308
that O 0 0.00023176792
the O 0 0.0002732122
consolidation O 0 0.001386483
of O 0 0.0003139724
this O 0 0.00031501887
memory O 0 0.09756156
is O 0 0.00016718866
an O 0 0.000129127
important O 0 6.517567e-05
interim O 0 0.0009026978
stage O 0 0.00046193815
, O 0 0.0001839013
and O 0 0.00014532656
may O 0 0.00011937502
take O 0 0.00010514975
up O 0 0.0002226659
to O 0 0.0002959385
one O 0 0.00047755355
day O 0 0.0008116466
. O 0 0.0017535242

Severe O 0 0.027701879
and O 0 0.0017351015
long O 0 0.0009754824
lasting O 0 0.0013208631
cholestasis B-Disease 2 0.99995744
after O 0 0.00027637073
high O 0 0.0010098191
- O 0 0.00079805014
dose O 0 0.002655243
co B-Chemical 0 0.4249779
- I-Chemical 0 0.0008616499
trimoxazole I-Chemical 0 0.04732226
treatment O 0 0.00016597593
for O 0 0.00017846689
Pneumocystis B-Disease 0 0.9980653
pneumonia I-Disease 0 0.99995077
in O 0 0.0011304796
HIV B-Disease 2 0.9700485
- I-Disease 2 0.0007059577
infected I-Disease 2 0.00032777488
patients O 0 0.00051596214
- O 0 0.0005324539
- O 0 0.00037849825
a O 0 0.00030574683
report O 0 0.0004680701
of O 0 0.00056337134
two O 0 0.0005644805
cases O 0 0.001714409
. O 0 0.0019381571

Pneumocystis B-Disease 0 0.99672914
pneumonia I-Disease 0 0.9996505
( O 0 0.037308984
PCP B-Disease 0 0.9995097
) O 0 0.002613903
, O 0 0.0006133415
a O 0 0.00041626682
common O 0 0.00031686286
opportunistic B-Disease 0 0.0032281226
infection I-Disease 0 0.022485053
in O 0 0.0005571463
HIV B-Disease 2 0.94929045
- I-Disease 2 0.00077131495
infected I-Disease 2 0.000297869
individuals O 0 0.0003341183
, O 0 0.00015974976
is O 0 0.00010310094
generally O 0 0.0001219232
treated O 0 0.00018532855
with O 0 0.00020226209
high O 0 0.00053010293
doses O 0 0.0025444317
of O 0 0.0012467928
co B-Chemical 0 0.6369172
- I-Chemical 0 0.0049185506
trimoxazole I-Chemical 0 0.3417001
. O 0 0.0025611094

However O 0 0.0043260227
, O 0 0.0035957613
treatment O 0 0.0022037074
is O 0 0.0017834437
often O 0 0.001670673
limited O 0 0.0015949119
by O 0 0.0022769123
adverse O 0 0.06399347
effects O 0 0.005489508
. O 0 0.005261985

Here O 0 0.0027078395
, O 0 0.0018787724
we O 0 0.0005988234
report O 0 0.0008439425
two O 0 0.00033374008
cases O 0 0.00039236445
of O 0 0.00043059254
severely O 0 0.021539921
immunocompromised O 0 0.96258086
HIV B-Disease 2 0.98463064
- I-Disease 2 0.0007206999
infected I-Disease 2 0.00021670619
patients O 0 0.0002095895
who O 0 0.00018370312
developed O 0 0.00026056153
severe O 0 0.086883895
intrahepatic B-Disease 0 0.9999634
cholestasis I-Disease 2 0.9999999
, O 0 0.0009127854
and O 0 0.00011946523
in O 0 5.7234407e-05
one O 0 4.289922e-05
patient O 0 8.8480854e-05
lesions O 0 0.0011006828
mimicking O 0 0.00019255989
liver B-Disease 0 0.7861224
abscess I-Disease 0 0.4535759
formation O 0 0.00043824187
on O 0 5.9555663e-05
radiologic O 0 0.00084555714
exams O 0 0.00029216005
, O 0 0.00012636984
during O 0 9.2998074e-05
co B-Chemical 0 0.053405147
- I-Chemical 0 0.0008656056
trimoxazole I-Chemical 0 0.043998774
treatment O 0 0.0006801494
for O 0 0.0010998611
PCP B-Disease 0 0.9979837
. O 0 0.0032260825

Whereas O 0 0.0024509253
patient O 0 0.001729076
1 O 0 0.0008825907
showed O 0 0.0006645708
lesions O 0 0.0025391125
of O 0 0.00046160762
up O 0 0.00030289716
to O 0 0.00018924044
1 O 0 0.00015599633
cm O 0 0.00022190246
readily O 0 0.000110915775
detectable O 0 7.812281e-05
on O 0 5.4688113e-05
magnetic O 0 0.00047280666
resonance O 0 0.001474934
imaging O 0 0.00015323724
under O 0 6.390637e-05
prolonged O 0 0.00025285457
co B-Chemical 0 0.097942956
- I-Chemical 0 0.00050682767
trimoxazole I-Chemical 0 0.029232154
treatment O 0 0.00014942948
, O 0 0.00014297791
therapy O 0 0.00016594969
of O 0 0.00020043996
patient O 0 0.00025301208
2 O 0 0.00021664791
was O 0 0.00037333101
switched O 0 0.0008019808
early O 0 0.0020030777
. O 0 0.0020876783

Bradykinin B-Chemical 0 0.99944097
receptors O 0 0.051057134
antagonists O 0 0.711533
and O 0 0.001622309
nitric B-Chemical 0 0.997721
oxide I-Chemical 0 0.97961867
synthase O 0 0.34529066
inhibitors O 0 0.0015193138
in O 0 0.00033884746
vincristine B-Chemical 1 0.9995276
and O 0 0.0010456055
streptozotocin B-Chemical 0 0.9999912
induced O 0 0.0031602597
hyperalgesia B-Disease 0 0.99908125
in O 0 0.00036341575
chemotherapy O 0 0.013641852
and O 0 0.0018762766
diabetic B-Disease 2 0.9999913
neuropathy I-Disease 0 0.99999416
rat O 0 0.04225159
model O 0 0.0026792877
. O 0 0.0020462829

PURPOSE O 0 0.0049935128
: O 0 0.001696533
The O 0 0.00055010646
influence O 0 0.00035673482
of O 0 0.0005452052
an O 0 0.0006035641
irreversible O 0 0.03042219
inhibitor O 0 0.002151925
of O 0 0.00053465413
constitutive O 0 0.0011955394
NO B-Chemical 0 0.9995559
synthase O 0 0.7952462
( O 0 0.000827624
L O 0 0.6948495
- O 0 0.00077857927
NOArg O 0 0.11282605
; O 0 0.00018262083
1 O 0 7.320087e-05
. O 0 4.404283e-05
0 O 0 6.389912e-05
mg O 0 0.0008650973
/ O 0 0.00038443884
kg O 0 0.00041474975
ip O 0 0.018351883
) O 0 0.00024037343
, O 0 9.848726e-05
a O 0 9.607217e-05
relatively O 0 0.00012516636
selective O 0 0.00028465714
inhibitor O 0 0.00040085174
of O 0 0.00018101117
inducible O 0 0.0013906884
NO B-Chemical 0 0.9995408
synthase O 0 0.7294196
( O 0 0.0005828392
L O 0 0.6535213
- O 0 0.00064667145
NIL O 0 0.11637802
; O 0 0.000170755
1 O 0 6.779048e-05
. O 0 4.0225863e-05
0 O 0 5.8485137e-05
mg O 0 0.00081061985
/ O 0 0.00034974836
kg O 0 0.00035930154
ip O 0 0.0117307445
) O 0 0.00018235616
and O 0 7.3933545e-05
a O 0 8.4449166e-05
relatively O 0 9.165528e-05
specific O 0 5.2309406e-05
inhibitor O 0 0.00037705587
of O 0 0.00023817107
neuronal O 0 0.06369836
NO B-Chemical 0 0.9997029
synthase O 0 0.6599975
( O 0 0.00024073763
7 O 0 7.360362e-05
- O 0 0.00022402899
NI O 0 0.031276774
; O 0 0.00012982072
0 O 0 6.545246e-05
. O 0 4.3067615e-05
1 O 0 5.854876e-05
mg O 0 0.00077293883
/ O 0 0.000338315
kg O 0 0.00035489432
ip O 0 0.013862018
) O 0 0.00019731422
, O 0 8.236118e-05
on O 0 4.8652513e-05
antihyperalgesic O 0 0.41336483
action O 0 0.00014639109
of O 0 0.00013732426
selective O 0 0.0008354644
antagonists O 0 0.5491147
of O 0 0.00051954156
B2 O 0 0.99343336
and O 0 0.00051252625
B1 O 0 0.9985727
receptors O 0 0.010658634
: O 0 0.0004346011
D O 0 0.814518
- O 0 0.0013259327
Arg O 0 0.9862664
- O 0 0.0014817774
[ O 0 0.0014763569
Hyp3 O 0 0.9726839
, O 0 0.00036625747
Thi5 O 0 0.48385817
, O 0 0.00028145761
D O 0 0.4226281
- O 0 0.0004226491
Tic7 O 0 0.002807442
, O 0 0.00033382222
Oic8 O 0 0.9965959
] O 0 0.0018547773
bradykinin B-Chemical 1 0.99991727
( O 0 0.00076537434
HOE B-Chemical 0 0.99987936
140 I-Chemical 0 0.0015477255
; O 0 0.00011977204
70 O 0 9.9532976e-05
nmol O 0 0.012500201
/ O 0 0.0004075123
kg O 0 0.0003178668
ip O 0 0.006524572
) O 0 0.00016988454
or O 0 7.9890146e-05
des B-Chemical 0 0.00026541497
Arg10 I-Chemical 0 0.98214865
HOE I-Chemical 0 0.9999502
140 I-Chemical 0 0.0026321094
( O 0 0.00015091928
70 O 0 0.000104851366
nmol O 0 0.017104818
/ O 0 0.0004547977
kg O 0 0.00038109624
ip O 0 0.019914722
) O 0 0.00026249894
respectively O 0 0.00023027958
, O 0 8.394319e-05
in O 0 5.5993958e-05
model O 0 0.00010182394
of O 0 0.00038298825
diabetic B-Disease 2 0.99992967
( I-Disease 0 0.0022722797
streptozotocin I-Disease 0 0.99999356
- I-Disease 0 0.0008836223
induced I-Disease 0 0.00022328348
) I-Disease 0 0.00025671622
and I-Disease 0 0.00017680768
toxic I-Disease 0 0.26172432
( I-Disease 0 0.0011791465
vincristine I-Disease 1 0.9997546
- I-Disease 0 0.0015497125
induced I-Disease 0 0.001068234
) I-Disease 0 0.0037988992
neuropathy I-Disease 0 0.9998913
was O 0 0.0020417017
investigated O 0 0.0014488479
. O 0 0.0021124966

METHODS O 0 0.0014726297
: O 0 0.0011075115
The O 0 0.00044910068
changes O 0 0.000577446
in O 0 0.0004985135
pain B-Disease 0 0.055632394
thresholds O 0 0.00040380363
were O 0 0.00018354307
determined O 0 0.00011289864
using O 0 9.065617e-05
mechanical O 0 0.00016983626
stimuli O 0 0.00020443225
- O 0 0.00040043244
- O 0 0.00021399769
the O 0 8.512501e-05
modification O 0 0.00013076032
of O 0 0.00012791558
the O 0 0.00014765601
classic O 0 0.0031565966
paw O 0 0.5312222
withdrawal O 0 0.027272582
test O 0 0.00040547983
described O 0 0.00028289098
by O 0 0.00061685365
Randall O 0 0.0053404686
- O 0 0.0027890028
Selitto O 0 0.35640505
. O 0 0.0026585157

RESULTS O 0 0.0043847254
: O 0 0.0015547719
The O 0 0.0005406791
results O 0 0.0005243166
of O 0 0.0004954112
this O 0 0.00038603085
paper O 0 0.00033682145
confirm O 0 0.00011825149
that O 0 0.000110447916
inhibition O 0 0.00057193864
of O 0 0.0009858176
bradykinin B-Chemical 1 0.9999684
receptors O 0 0.008963079
and O 0 0.00021173205
inducible O 0 0.0013935652
NO B-Chemical 0 0.99923325
synthase O 0 0.3611301
but O 0 0.0001776599
not O 0 0.00014722176
neuronal O 0 0.011720372
NO B-Chemical 0 0.9982224
synthase O 0 0.3618555
activity O 0 0.0005960168
reduces O 0 0.0024781737
diabetic B-Disease 2 0.9999784
hyperalgesia I-Disease 0 0.9999144
. O 0 0.004856777

Pretreatment O 0 0.10514138
with O 0 0.0048385398
L O 0 0.79989886
- O 0 0.0035769055
NOArg O 0 0.15775214
and O 0 0.001221143
L O 0 0.74574316
- O 0 0.0015978456
NIL O 0 0.09399499
but O 0 0.00029753576
not O 0 0.00016792616
7 O 0 0.00013317393
- O 0 0.00036356703
NI O 0 0.030881675
, O 0 0.00017221025
significantly O 0 0.00017153703
increases O 0 0.00018474915
antihyperalgesic O 0 0.7397944
activity O 0 0.0001864507
both O 0 0.00035629843
HOE B-Chemical 0 0.99982053
140 I-Chemical 0 0.0027283821
and O 0 0.00045682467
des B-Chemical 0 0.0012316181
Arg10 I-Chemical 0 0.98158294
HOE I-Chemical 0 0.9997938
140 I-Chemical 0 0.028986158
. O 0 0.0026563848

It O 0 0.0028712212
was O 0 0.0014944444
also O 0 0.0007032436
shown O 0 0.00038356756
that O 0 0.00025791003
both O 0 0.00030080843
products O 0 0.0005821801
of O 0 0.00033584094
inducible O 0 0.0016823065
NO B-Chemical 0 0.99921644
synthase O 0 0.43267202
and O 0 0.00028534187
neuronal O 0 0.02287062
NO B-Chemical 0 0.99904245
synthase O 0 0.23385587
activation O 0 0.0001896494
as O 0 8.626455e-05
well O 0 8.321584e-05
as O 0 0.00018037611
bradykinin B-Chemical 1 0.999706
are O 0 0.00017895919
involved O 0 0.0001241343
in O 0 0.00033138503
hyperalgesia B-Disease 0 0.9868569
produced O 0 0.0009282977
by O 0 0.0021409928
vincristine B-Chemical 1 0.99911314
. O 0 0.003666742

Moreover O 0 0.0039720167
, O 0 0.004359151
L O 0 0.6212638
- O 0 0.0036257762
NOArg O 0 0.088189505
and O 0 0.0007146914
7 O 0 0.0003589821
- O 0 0.00073225
NI O 0 0.028375365
but O 0 0.0002983462
not O 0 0.00027740293
L O 0 0.4878782
- O 0 0.0006624865
NIL O 0 0.031485055
intensify O 0 0.00030877226
antihyperalgesic O 0 0.77361447
activity O 0 0.00016640681
of O 0 0.0004623935
HOE B-Chemical 0 0.9999174
140 I-Chemical 0 0.0024947429
or O 0 0.00017620198
des B-Chemical 0 0.00032291823
- I-Chemical 0 0.00044401432
Arg10HOE I-Chemical 0 0.001988707
140 I-Chemical 0 0.00079691637
in O 0 0.00083207106
toxic B-Disease 0 0.99504447
neuropathy I-Disease 0 0.9999745
. O 0 0.0058714864

CONCLUSIONS O 0 0.011738603
: O 0 0.0018046965
Results O 0 0.00071398646
of O 0 0.00065119436
these O 0 0.0005050939
studies O 0 0.0003063362
suggest O 0 0.00012879152
that O 0 0.0002592376
B1 O 0 0.9955592
and O 0 0.0010613367
B2 O 0 0.99591476
receptors O 0 0.0033579692
are O 0 0.00011503688
engaged O 0 9.642535e-05
in O 0 7.4451e-05
transmission O 0 0.00010099137
of O 0 0.00014249027
nociceptive O 0 0.0007077374
stimuli O 0 0.0001590544
in O 0 0.00018472483
both O 0 0.0005380969
diabetic B-Disease 2 0.9997552
and I-Disease 0 0.003262364
toxic I-Disease 0 0.99910295
neuropathy I-Disease 0 0.9999846
. O 0 0.0063247667

In O 0 0.0050684456
streptozotocin B-Chemical 0 0.9998559
- O 0 0.010246313
induced O 0 0.00392149
hyperalgesia B-Disease 0 0.9983595
, O 0 0.0011491337
inducible O 0 0.003325296
NO B-Chemical 0 0.99922836
synthase O 0 0.21876673
participates O 0 0.00011928627
in O 0 0.000118964694
pronociceptive O 0 0.0041169287
activity O 0 0.00012587373
of O 0 0.00044935872
bradykinin B-Chemical 1 0.99995196
, O 0 0.00026303812
whereas O 0 0.00014015031
in O 0 0.00022488889
vincristine B-Chemical 1 0.99981254
- O 0 0.0013739597
induced O 0 0.0013710957
hyperalgesia B-Disease 0 0.9999099
bradykinin B-Chemical 1 0.9999727
seemed O 0 0.00047534815
to O 0 0.00016799949
activate O 0 0.00013666066
neuronal O 0 0.02519703
NO B-Chemical 0 0.998168
synthase O 0 0.5624564
pathway O 0 0.0018435759
. O 0 0.0019541208

Therefore O 0 0.0017613674
, O 0 0.0017386351
concomitant O 0 0.0017327237
administration O 0 0.0017668692
of O 0 0.0005404804
small O 0 0.00044597063
doses O 0 0.0019558682
of O 0 0.0010146324
bradykinin B-Chemical 1 0.99997437
receptor O 0 0.42306277
antagonists O 0 0.9011379
and O 0 0.000492098
NO B-Chemical 0 0.99921453
synthase O 0 0.442166
inhibitors O 0 0.00073123287
can O 0 5.4584852e-05
be O 0 4.728408e-05
effective O 0 4.4526198e-05
in O 0 7.1516675e-05
alleviation O 0 0.0015939691
of O 0 0.0015746654
neuropathic B-Disease 0 0.9999701
pain I-Disease 0 0.99861574
, O 0 0.000567117
even O 0 0.0004135857
in O 0 0.00045497206
hospital O 0 0.00127688
care O 0 0.0014589375
. O 0 0.001689606

Confusion B-Disease 0 0.15076706
, O 0 0.0022270915
a O 0 0.0011394888
rather O 0 0.00062047614
serious O 0 0.0032044763
adverse O 0 0.5686915
drug O 0 0.11682263
reaction O 0 0.14523976
with O 0 0.0022772278
valproic B-Chemical 0 0.9999913
acid I-Chemical 0 0.99040633
: O 0 0.0006197654
a O 0 0.0003665691
review O 0 0.00043659194
of O 0 0.00032904322
the O 0 0.00042169384
French O 0 0.0020821185
Pharmacovigilance O 0 0.007666985
database O 0 0.0033587834
. O 0 0.002330221

INTRODUCTION O 0 0.0077036335
: O 0 0.0038977691
Confusion B-Disease 0 0.01766365
is O 0 0.0010258455
an O 0 0.0011215082
adverse O 0 0.23765378
drug O 0 0.04690644
reaction O 0 0.024806064
frequently O 0 0.00063176465
observed O 0 0.00062577176
with O 0 0.0026880992
valproic B-Chemical 0 0.9999523
acid I-Chemical 0 0.9951816
. O 0 0.005563403

Some O 0 0.0028810808
case O 0 0.0014375863
reports O 0 0.0011285106
are O 0 0.00057454413
published O 0 0.00044995727
in O 0 0.00026459308
the O 0 0.00024126892
literature O 0 0.00038175323
but O 0 0.00018506791
no O 0 8.283234e-05
systematic O 0 0.00014706489
study O 0 0.00014621919
from O 0 9.486015e-05
a O 0 0.00017157562
sample O 0 0.00022728746
of O 0 0.00033293673
patients O 0 0.0005633877
has O 0 0.00039751575
been O 0 0.0006407361
published O 0 0.0015430541
. O 0 0.0019813462

We O 0 0.0014611015
performed O 0 0.0010687117
this O 0 0.0009201602
study O 0 0.00067679194
in O 0 0.00032660508
order O 0 0.00022243778
to O 0 0.0001831684
describe O 0 0.00014937978
the O 0 0.00016056755
main O 0 0.00015722998
characteristics O 0 0.00012245265
of O 0 0.00031225898
this O 0 0.00069632725
adverse O 0 0.67094004
drug O 0 0.25290146
reaction O 0 0.35936072
. O 0 0.0033057763

METHODS O 0 0.0016942822
: O 0 0.0012632074
Using O 0 0.0004975935
the O 0 0.00057190686
French O 0 0.0014170456
Pharmacovigilance O 0 0.0032627797
database O 0 0.00080083235
, O 0 0.00028005178
we O 0 9.4160256e-05
selected O 0 0.00013314754
the O 0 0.00014804499
cases O 0 0.0002099101
of O 0 0.00031910653
confusion B-Disease 0 0.14776188
reported O 0 0.0003478543
since O 0 0.00018732529
1985 O 0 0.001158233
with O 0 0.001523792
valproic B-Chemical 0 0.99994576
acid I-Chemical 0 0.9900333
. O 0 0.00411254

RESULTS O 0 0.005138036
: O 0 0.0024289058
272 O 0 0.0038933908
cases O 0 0.0009374959
of O 0 0.0008310307
confusion B-Disease 0 0.056720432
were O 0 0.0004045133
reported O 0 0.00037661724
with O 0 0.00085044047
valproic B-Chemical 0 0.9999795
acid I-Chemical 0 0.98445743
: O 0 0.0012308223
153 O 0 0.0036603056
women O 0 0.001333187
and O 0 0.00077025214
119 O 0 0.002679464
men O 0 0.0046432163
. O 0 0.0020010425

Confusion B-Disease 0 0.05425422
mostly O 0 0.0016865949
occurred O 0 0.00061749306
during O 0 0.000253452
the O 0 0.00025596152
two O 0 0.00013314767
first O 0 0.0001018723
weeks O 0 7.917481e-05
following O 0 0.00021288855
valproic B-Chemical 0 0.9999685
acid I-Chemical 0 0.97637784
exposure O 0 0.0018030618
( O 0 0.0008167583
39 O 0 0.0006154408
. O 0 0.00029710517
7 O 0 0.00043400575
% O 0 0.0010058427
) O 0 0.0021578264
. O 0 0.0024272453

It O 0 0.0036613108
was O 0 0.0022985076
" O 0 0.0016638783
serious O 0 0.0025402047
" O 0 0.0007462167
for O 0 0.00028081838
almost O 0 0.00032440617
2 O 0 0.0002129716
/ O 0 0.00038384268
3 O 0 9.543138e-05
of O 0 0.00012151581
the O 0 0.0001254114
patients O 0 0.00022314728
( O 0 0.0001883485
62 O 0 0.00016952434
. O 0 5.9743328e-05
5 O 0 6.104895e-05
% O 0 9.712688e-05
) O 0 0.00012679638
and O 0 8.139442e-05
its O 0 0.00013881801
outcome O 0 0.00011605626
favourable O 0 0.00019576482
in O 0 9.034791e-05
most O 0 0.00017310519
of O 0 0.00020234848
the O 0 0.00023155787
cases O 0 0.00045236456
( O 0 0.00060820545
82 O 0 0.0010959349
% O 0 0.001045876
) O 0 0.002021857
. O 0 0.0021174136

The O 0 0.001782032
occurrence O 0 0.0019440638
of O 0 0.0014815996
this O 0 0.0019993163
ADR O 0 0.99966323
was O 0 0.00093197165
more O 0 0.0005533538
frequent O 0 0.00044467082
in O 0 0.00024829284
patients O 0 0.0003699328
aged O 0 0.00037929742
between O 0 0.00017172063
61 O 0 0.0005155177
and O 0 0.00051679794
80 O 0 0.0011016835
years O 0 0.0011814131
. O 0 0.0018489591

CONCLUSION O 0 0.017125562
: O 0 0.0021516383
This O 0 0.0012901293
work O 0 0.00061236025
shows O 0 0.00023472458
that O 0 0.00027699908
confusion B-Disease 0 0.1856547
with O 0 0.0021595932
valproic B-Chemical 0 0.99999285
acid I-Chemical 0 0.99465275
is O 0 0.00045462762
a O 0 0.0003822001
serious O 0 0.0015522188
, O 0 0.00021179627
rather O 0 0.00014051549
frequent O 0 0.00035513105
but O 0 0.00037228756
reversible O 0 0.07029796
adverse O 0 0.85037076
drug O 0 0.27077213
reaction O 0 0.31609455
. O 0 0.0028840986

It O 0 0.002578036
occurs O 0 0.0011868299
especially O 0 0.0010033374
in O 0 0.00070118974
older O 0 0.0016311939
patients O 0 0.0005019921
and O 0 0.00024109022
during O 0 0.0001123656
the O 0 0.00016808444
first O 0 0.00014201728
two O 0 0.00018515898
weeks O 0 0.00020079306
of O 0 0.0007849591
treatment O 0 0.0016443235
. O 0 0.0024954719

Reversible O 0 0.02956826
inferior B-Disease 0 0.015768345
colliculus I-Disease 0 0.005795969
lesion I-Disease 0 0.017993571
in O 0 0.0012632543
metronidazole B-Chemical 0 0.9996118
- O 0 0.002153901
induced O 0 0.0012134936
encephalopathy B-Disease 2 0.9999356
: O 0 0.0007276183
magnetic O 0 0.0018355384
resonance O 0 0.0039182617
findings O 0 0.00019279394
on O 0 7.2845025e-05
diffusion O 0 0.00068848405
- O 0 0.00022753987
weighted O 0 0.00012281377
and O 0 0.00018241095
fluid O 0 0.000606379
attenuated O 0 0.0006947191
inversion O 0 0.0027695678
recovery O 0 0.0019025094
imaging O 0 0.0027418165
. O 0 0.0020022467

OBJECTIVE O 0 0.0270817
: O 0 0.002479192
This O 0 0.0014441629
is O 0 0.0005688428
to O 0 0.0003018982
present O 0 0.00023946667
reversible O 0 0.0038200424
inferior B-Disease 0 0.019196458
colliculus I-Disease 0 0.0027687328
lesions I-Disease 0 0.101373926
in O 0 0.0004265247
metronidazole B-Chemical 0 0.9997999
- O 0 0.0012965451
induced O 0 0.0009289232
encephalopathy B-Disease 2 0.9999721
, O 0 0.00031153875
to O 0 7.7814686e-05
focus O 0 5.464105e-05
on O 0 3.6020232e-05
the O 0 7.119762e-05
diffusion O 0 0.000579964
- O 0 0.00013968695
weighted O 0 6.9207104e-05
imaging O 0 0.00021032139
( O 0 0.0002058295
DWI O 0 0.74557835
) O 0 0.00022357682
and O 0 0.00012095236
fluid O 0 0.00034952874
attenuated O 0 0.00033160945
inversion O 0 0.0013234925
recovery O 0 0.00083024555
( O 0 0.0007988452
FLAIR O 0 0.7861965
) O 0 0.001810828
imaging O 0 0.0026643
. O 0 0.0022129451

MATERIALS O 0 0.0019283033
AND O 0 0.0013160863
METHODS O 0 0.0006447318
: O 0 0.0006540636
From O 0 0.0003880182
November O 0 0.0004153706
2005 O 0 0.0004054628
to O 0 0.00021006847
September O 0 0.00023774043
2007 O 0 0.00034017593
, O 0 0.00020913736
8 O 0 0.000121575154
patients O 0 0.0001821933
( O 0 0.00016337338
5 O 0 8.4193955e-05
men O 0 0.00029387028
and O 0 9.015049e-05
3 O 0 7.117303e-05
women O 0 0.00021614922
) O 0 0.00012424822
were O 0 7.870868e-05
diagnosed O 0 0.00023501636
as O 0 8.677311e-05
having O 0 0.00033799265
metronidazole B-Chemical 0 0.9996966
- O 0 0.0009100908
induced O 0 0.0008219413
encephalopathy B-Disease 2 0.9999709
( O 0 0.00073822204
age O 0 0.0002434897
range O 0 0.00020698909
; O 0 0.00029515516
43 O 0 0.00044973494
- O 0 0.00062035996
78 O 0 0.0008767504
years O 0 0.0007009452
) O 0 0.0016523721
. O 0 0.0019271051

They O 0 0.0031734311
had O 0 0.0014000402
been O 0 0.00080495485
taking O 0 0.0018044972
metronidazole B-Chemical 0 0.998541
( O 0 0.000802194
total O 0 0.00039964527
dosage O 0 0.010118102
, O 0 0.00026079768
45 O 0 0.00013850123
- O 0 0.00019203845
120 O 0 0.000102701866
g O 0 0.00025927686
; O 0 0.00010215451
duration O 0 3.9369796e-05
, O 0 7.1365226e-05
30 O 0 4.204617e-05
days O 0 2.7916009e-05
to O 0 5.2045583e-05
2 O 0 6.18743e-05
months O 0 3.9524555e-05
) O 0 0.00012739701
to O 0 0.000100574645
treat O 0 0.00025790607
the O 0 0.0002594307
infection B-Disease 0 0.0026215932
in O 0 0.00054740236
various O 0 0.0011230349
organs O 0 0.0074117575
. O 0 0.0022876847

Initial O 0 0.0029592954
brain O 0 0.0040020305
magnetic O 0 0.0036581012
resonance O 0 0.006612417
imaging O 0 0.0011382755
( O 0 0.000738702
MRI O 0 0.031337164
) O 0 0.00041476917
were O 0 0.00014091052
obtained O 0 0.00010411935
after O 0 4.6070905e-05
the O 0 0.0001085171
hospitalization O 0 0.0003660872
, O 0 0.00014119886
including O 0 0.00010414964
DWI O 0 0.8903979
( O 0 0.00024037457
8 O 0 8.848946e-05
/ O 0 0.00024243847
8 O 0 8.0010745e-05
) O 0 0.0001291456
, O 0 8.2925115e-05
apparent O 0 0.000102314785
diffusion O 0 0.000672391
coefficient O 0 0.00089046085
( O 0 0.0002746709
ADC O 0 0.15227321
) O 0 0.0002162989
map O 0 0.00011205263
( O 0 0.0001517415
4 O 0 7.419968e-05
/ O 0 0.0002209777
8 O 0 8.439925e-05
) O 0 0.00015801993
, O 0 0.00015276819
FLAIR O 0 0.6911475
( O 0 0.00024751067
7 O 0 9.301279e-05
/ O 0 0.00026873432
8 O 0 0.00010317784
) O 0 0.00017985557
, O 0 0.00013733932
and O 0 0.00015775273
T2 O 0 0.0012207127
- O 0 0.00028521675
weighted O 0 0.0001683587
image O 0 0.00033604266
( O 0 0.00047771362
8 O 0 0.00037878574
/ O 0 0.0011842292
8 O 0 0.0008574177
) O 0 0.0020713857
. O 0 0.002365998

Follow O 0 0.0082495
- O 0 0.0026311884
up O 0 0.0010869513
MRIs O 0 0.0026155568
were O 0 0.00041194743
performed O 0 0.00022954062
on O 0 0.00014085112
5 O 0 0.00014017492
patients O 0 0.00016624725
from O 0 0.00010051837
third O 0 0.00014704371
to O 0 0.000111206806
14th O 0 0.00025636744
days O 0 5.8632235e-05
after O 0 7.932783e-05
discontinuation O 0 0.0033678673
of O 0 0.0012906317
metronidazole B-Chemical 0 0.9992512
administration O 0 0.052107636
. O 0 0.0029719917

Findings O 0 0.0019029964
of O 0 0.0012019898
initial O 0 0.0006885086
and O 0 0.0005610719
follow O 0 0.00028312707
- O 0 0.00041893922
up O 0 0.00021083861
MRIs O 0 0.00091539347
were O 0 0.00012688854
retrospectively O 0 0.00010210863
evaluated O 0 8.236463e-05
by O 0 0.00010787095
2 O 0 8.8823566e-05
neuroradiologists O 0 0.00030532767
by O 0 8.869365e-05
consensus O 0 6.964241e-05
, O 0 8.909112e-05
to O 0 5.101193e-05
analyze O 0 3.3215398e-05
the O 0 5.32766e-05
presence O 0 6.0466948e-05
of O 0 0.000101837926
abnormal O 0 0.00048673977
signal O 0 5.462875e-05
intensities O 0 5.8781377e-05
, O 0 9.5166215e-05
their O 0 9.429216e-05
locations O 0 6.442206e-05
, O 0 9.9790916e-05
and O 0 8.524482e-05
signal O 0 7.7771816e-05
changes O 0 0.00015551217
on O 0 0.00011935455
follow O 0 0.00019800516
- O 0 0.00061750604
up O 0 0.00069012796
images O 0 0.0015320166
. O 0 0.0021570327

RESULTS O 0 0.003948335
: O 0 0.001524065
Initial O 0 0.0011034581
MRIs O 0 0.002669731
showed O 0 0.0004580301
abnormal O 0 0.00092903513
high O 0 0.0003073188
signal O 0 0.00010755777
intensities O 0 8.769546e-05
on O 0 9.344771e-05
DWI O 0 0.640825
and O 0 0.00025212925
FLAIR O 0 0.9182254
( O 0 0.00026928418
or O 0 0.00011784455
T2 O 0 0.0010376743
- O 0 0.00016580369
weighted O 0 7.074512e-05
image O 0 0.00011215151
) O 0 0.000115809176
at O 0 4.4245568e-05
the O 0 7.856336e-05
dentate O 0 0.0036512946
nucleus O 0 9.975142e-05
( O 0 0.000122033816
8 O 0 6.510176e-05
/ O 0 0.00018398935
8 O 0 6.972427e-05
) O 0 0.00011609833
, O 0 9.0209905e-05
inferior O 0 0.0004712615
colliculus O 0 0.00055118394
( O 0 0.0001565905
6 O 0 6.024185e-05
/ O 0 0.00020110271
8 O 0 7.915246e-05
) O 0 0.00013918064
, O 0 0.00011307619
corpus O 0 0.00055263116
callosum O 0 0.08355375
( O 0 0.00020541155
2 O 0 9.073021e-05
/ O 0 0.0002361196
8 O 0 8.818839e-05
) O 0 0.0001679726
, O 0 0.00015551943
pons O 0 0.020834494
( O 0 0.00021491868
2 O 0 9.751127e-05
/ O 0 0.00025439516
8 O 0 9.564046e-05
) O 0 0.00017797526
, O 0 0.00015637968
medulla O 0 0.0040489044
( O 0 0.00021796943
1 O 0 9.9953366e-05
/ O 0 0.0002516955
8 O 0 9.044514e-05
) O 0 0.0001548227
, O 0 0.00011405091
and O 0 0.00012997728
bilateral O 0 0.0015282508
cerebral O 0 0.4727852
white O 0 0.0030011851
matter O 0 0.0015699816
( O 0 0.0005177598
1 O 0 0.0003686276
/ O 0 0.0010706318
8 O 0 0.00077084906
) O 0 0.0018925103
. O 0 0.0021856388

High O 0 0.007680539
- O 0 0.0024161707
signal O 0 0.00063091115
intensity O 0 0.000510524
lesions O 0 0.0025649066
on O 0 0.00032209486
DWI O 0 0.7697057
tended O 0 0.00027803573
to O 0 0.00014000457
show O 0 9.386425e-05
low O 0 0.0001566047
signal O 0 6.4233e-05
intensity O 0 5.8617694e-05
on O 0 6.5747096e-05
ADC O 0 0.054325804
map O 0 0.00015043179
( O 0 0.00018137279
3 O 0 7.991216e-05
/ O 0 0.0002493162
4 O 0 8.087989e-05
) O 0 0.00015131611
, O 0 0.000101390644
but O 0 8.425651e-05
in O 0 6.1980834e-05
one O 0 5.223423e-05
patient O 0 8.5900894e-05
, O 0 7.343508e-05
high O 0 9.1576316e-05
signal O 0 4.0280564e-05
intensity O 0 4.1952288e-05
was O 0 6.586018e-05
shown O 0 3.960768e-05
at O 0 4.2785807e-05
bilateral O 0 0.000612655
dentate O 0 0.015611403
nuclei O 0 0.00016206123
on O 0 5.1999898e-05
not O 0 9.99125e-05
only O 0 0.0002617737
DWI O 0 0.73837703
but O 0 0.0004775622
also O 0 0.000635157
ADC O 0 0.15969998
map O 0 0.0018494009
. O 0 0.002259284

All O 0 0.001798238
the O 0 0.0014774624
lesions O 0 0.0036202574
in O 0 0.00074389635
dentate O 0 0.008831934
, O 0 0.000593556
inferior O 0 0.0017587485
colliculus O 0 0.001604876
, O 0 0.00042761612
pons O 0 0.03839298
, O 0 0.00025492403
and O 0 0.00017694104
medullas O 0 0.0012249046
had O 0 0.000119326774
been O 0 6.701053e-05
resolved O 0 0.00012722769
completely O 0 8.800123e-05
on O 0 3.8354945e-05
follow O 0 4.506522e-05
- O 0 0.00010925283
up O 0 7.135434e-05
MRIs O 0 0.0006432839
in O 0 6.891431e-05
5 O 0 5.8595335e-05
patients O 0 0.00011646291
, O 0 0.00010245966
but O 0 9.423616e-05
in O 0 7.961392e-05
1 O 0 7.497509e-05
patient O 0 9.8301476e-05
of O 0 0.00016439977
them O 0 0.0003479697
, O 0 0.00033501908
corpus O 0 0.0015431849
callosal B-Disease 0 0.120590135
lesion I-Disease 0 0.08252773
persisted O 0 0.0014887232
. O 0 0.0020890315

CONCLUSIONS O 0 0.012106761
: O 0 0.002615904
Reversible O 0 0.014490922
inferior B-Disease 0 0.013783614
colliculus I-Disease 0 0.0048399586
lesions I-Disease 0 0.037454594
could O 0 0.0003109631
be O 0 0.0001884189
considered O 0 0.0001152178
as O 0 0.00010751213
the O 0 0.000108491644
characteristic O 0 0.00014727004
for O 0 0.00019028934
metronidazole B-Chemical 0 0.99971455
- O 0 0.0012644159
induced O 0 0.0009828953
encephalopathy B-Disease 2 0.9999449
, O 0 0.0003754382
next O 0 0.00010263853
to O 0 0.00018407518
the O 0 0.0003530281
dentate O 0 0.019639498
nucleus O 0 0.0008351523
involvement O 0 0.002110927
. O 0 0.002090225

Clinically O 0 0.008234871
significant O 0 0.0030486335
proteinuria B-Disease 0 0.9997073
following O 0 0.00071631494
the O 0 0.0006023771
administration O 0 0.0018779427
of O 0 0.0013525577
sirolimus B-Chemical 1 0.99980325
to O 0 0.0014669975
renal O 0 0.97379774
transplant O 0 0.32303524
recipients O 0 0.016012274
. O 0 0.0028879698

BACKGROUND O 0 0.010030499
: O 0 0.0032723804
Sirolimus B-Chemical 0 0.9284876
is O 0 0.00078646856
the O 0 0.0004346106
latest O 0 0.0007356587
immunosuppressive O 0 0.13079593
agent O 0 0.0018516928
used O 0 0.00018564195
to O 0 0.00014987527
prevent O 0 0.00022806568
rejection O 0 0.8952951
, O 0 0.00029828504
and O 0 0.00012881326
may O 0 7.507139e-05
have O 0 6.6865374e-05
less O 0 0.00020827394
nephrotoxicity B-Disease 0 0.9999902
than O 0 0.00023533811
calcineurin O 0 0.6568427
inhibitor O 0 0.016845949
( O 0 0.0015904397
CNI O 0 0.999806
) O 0 0.0012478549
- O 0 0.0008451504
based O 0 0.000653174
regimens O 0 0.0020731052
. O 0 0.0020542813

To O 0 0.0024744538
date O 0 0.0017100044
there O 0 0.0007411268
has O 0 0.0005466721
been O 0 0.00033257637
little O 0 0.0002955939
documentation O 0 0.00039314473
of O 0 0.0003725929
clinically O 0 0.001971193
significant O 0 0.00065267866
proteinuria B-Disease 0 0.99997306
linked O 0 0.0004803645
with O 0 0.00038543332
the O 0 0.00034616346
use O 0 0.00050810614
of O 0 0.0018803469
sirolimus B-Chemical 1 0.9997174
. O 0 0.00386391

We O 0 0.001623351
have O 0 0.0009424009
encountered O 0 0.00077267294
several O 0 0.000514153
patients O 0 0.00076181797
who O 0 0.0006728223
developed O 0 0.00069806137
substantial O 0 0.001294749
proteinuria B-Disease 0 0.99996865
associated O 0 0.0015615269
with O 0 0.003229102
sirolimus B-Chemical 1 0.999821
use O 0 0.00339933
. O 0 0.0027967005

In O 0 0.0016082199
each O 0 0.00079048646
patient O 0 0.00094590656
, O 0 0.0005914949
the O 0 0.0002910397
close O 0 0.00019325335
temporal O 0 0.00040197794
association O 0 9.650795e-05
between O 0 6.1235e-05
the O 0 7.727511e-05
commencement O 0 7.748725e-05
of O 0 0.00022901093
sirolimus B-Chemical 1 0.999912
therapy O 0 0.0005503857
and O 0 0.00039348516
proteinuria B-Disease 0 0.9999908
implicated O 0 0.0004029419
sirolimus B-Chemical 1 0.9999386
as O 0 0.00016490404
the O 0 0.00012163742
most O 0 0.00021243012
likely O 0 0.00016010982
etiology O 0 0.0015697979
of O 0 0.00080673146
the O 0 0.001898609
proteinuria B-Disease 0 0.9999443
. O 0 0.0042919153

METHODS O 0 0.0016150012
: O 0 0.0012147543
We O 0 0.00042272118
analyzed O 0 0.00037881677
the O 0 0.00033918794
clinical O 0 0.0005998888
and O 0 0.00024594614
laboratory O 0 0.00026632828
information O 0 0.00013321229
available O 0 0.00013424314
for O 0 7.329404e-05
all O 0 9.8915785e-05
119 O 0 0.00023834597
patients O 0 0.000102878395
transplanted O 0 0.00025600204
at O 0 4.1960688e-05
the O 0 7.5120086e-05
Washington O 0 0.0004704128
Hospital O 0 0.00019708897
Center O 0 0.00015039492
between O 0 4.7424164e-05
1999 O 0 0.00016166907
- O 0 0.00013734968
2003 O 0 0.00010235615
for O 0 6.365323e-05
whom O 0 0.00043579357
sirolimus B-Chemical 1 0.9997793
was O 0 0.00020776855
a O 0 0.00015609052
component O 0 0.0001306094
of O 0 0.00029366667
their O 0 0.0006178475
immunosuppressant O 0 0.8913289
regimen O 0 0.0037548929
. O 0 0.0021163055

In O 0 0.0018613065
these O 0 0.001835037
patients O 0 0.0013149794
, O 0 0.00062664284
the O 0 0.00032193432
magnitude O 0 0.0002706822
of O 0 0.00078384497
proteinuria B-Disease 0 0.99997807
was O 0 0.0004017324
assessed O 0 8.3939995e-05
on O 0 5.0785642e-05
morning O 0 0.00025913602
urine O 0 0.008311097
samples O 0 0.000101808306
by O 0 8.31053e-05
turbidometric O 0 0.003560113
measurement O 0 4.49724e-05
or O 0 5.1804145e-05
random O 0 0.00011108631
urine O 0 0.024350313
protein O 0 0.00031633556
: O 0 0.00026355174
creatinine B-Chemical 1 0.9962767
ratios O 0 0.00025019012
, O 0 0.00011152879
an O 0 0.0001002361
estimate O 0 6.957105e-05
of O 0 0.000178432
grams O 0 0.00051947765
of O 0 0.00092417334
proteinuria B-Disease 0 0.999964
/ O 0 0.006684557
day O 0 0.0010565318
. O 0 0.0017565605

Laboratory O 0 0.007838863
results O 0 0.0016656765
were O 0 0.0009598145
compared O 0 0.00044335535
between O 0 0.0003082355
prior O 0 0.0002790632
, O 0 0.0004838299
during O 0 0.00027480788
and O 0 0.0006068103
following O 0 0.00096169976
sirolimus B-Chemical 1 0.99946135
use O 0 0.0037975388
. O 0 0.003456561

RESULTS O 0 0.0049040653
: O 0 0.002199641
Twenty O 0 0.0015066097
- O 0 0.001120087
eight O 0 0.0003447069
patients O 0 0.00052369805
( O 0 0.00038672594
24 O 0 0.00017051518
% O 0 0.00022922154
) O 0 0.00026724755
developed O 0 0.00027328046
increased O 0 0.0007428256
proteinuria B-Disease 0 0.99997544
from O 0 0.00021857233
baseline O 0 0.00012621519
during O 0 8.4432664e-05
their O 0 0.00022151203
post O 0 0.00022919313
- O 0 0.0008114131
transplantation O 0 0.003554238
course O 0 0.0014318996
. O 0 0.0021239158

In O 0 0.0019277565
21 O 0 0.0014987699
patients O 0 0.0009460633
an O 0 0.0005847084
alternative O 0 0.00036095493
cause O 0 0.0006247006
of O 0 0.0011125804
proteinuria B-Disease 0 0.9999844
was O 0 0.0005318074
either O 0 0.00016449885
obvious O 0 0.00012693902
or O 0 0.00012382939
insufficient O 0 0.00020332806
data O 0 0.0002680171
was O 0 0.0003227797
available O 0 0.00041558823
to O 0 0.0004917327
be O 0 0.00088455563
conclusive O 0 0.0036695949
. O 0 0.0022422748

In O 0 0.0018474426
7 O 0 0.0010044025
of O 0 0.0008571779
the O 0 0.0005648815
28 O 0 0.00044480394
patients O 0 0.00038192543
there O 0 0.00014959615
was O 0 0.0001929823
a O 0 0.00016190774
striking O 0 0.000120777186
temporal O 0 0.0002840534
association O 0 5.8242254e-05
between O 0 4.026424e-05
the O 0 5.8454032e-05
initiation O 0 6.388791e-05
of O 0 0.0002604242
sirolimus B-Chemical 1 0.9998646
and O 0 0.00021116291
the O 0 0.00015689377
development O 0 0.00047699804
of O 0 0.0015592937
nephrotic B-Disease 0 0.9999889
- O 0 0.0054761786
range O 0 0.0029011997
proteinuria B-Disease 0 0.99994004
. O 0 0.00425331

Proteinuria B-Disease 2 0.99899036
correlated O 0 0.0013373863
most O 0 0.0011825428
strongly O 0 0.00083518133
with O 0 0.0011086309
sirolimus B-Chemical 1 0.9998128
therapy O 0 0.00077435724
when O 0 0.0001588569
compared O 0 0.00013323058
to O 0 0.00016502122
other O 0 0.00021179586
demographic O 0 0.00028955785
and O 0 0.00049492694
clinical O 0 0.0015196784
variables O 0 0.0011454844
. O 0 0.0020536918

In O 0 0.0018362358
most O 0 0.00196209
patients O 0 0.001461448
, O 0 0.00091357547
discontinuation O 0 0.011300245
of O 0 0.0011658097
sirolimus B-Chemical 1 0.99985385
resulted O 0 0.00053132605
in O 0 0.000275382
a O 0 0.0003624007
decrease O 0 0.00040641634
, O 0 0.0003189569
but O 0 0.00027227166
not O 0 0.0002996446
resolution O 0 0.003504912
, O 0 0.0011518646
of O 0 0.003490141
proteinuria B-Disease 0 0.9999418
. O 0 0.0052650357

CONCLUSIONS O 0 0.019282307
: O 0 0.003586227
Sirolimus B-Chemical 0 0.9294656
induces O 0 0.00083025824
or O 0 0.0007372202
aggravates O 0 0.04022993
pre O 0 0.0017137293
- O 0 0.0008715355
existing O 0 0.0007745123
proteinuria B-Disease 0 0.999964
in O 0 0.00034178278
an O 0 0.00030593347
unpredictable O 0 0.0005256039
subset O 0 0.0003662275
of O 0 0.00074486
renal O 0 0.96362996
allograft O 0 0.9710896
recipients O 0 0.029909015
. O 0 0.0026146898

Proteinuria B-Disease 2 0.9992706
may O 0 0.002422615
improve O 0 0.0012808033
, O 0 0.0012096
but O 0 0.00071359915
does O 0 0.00047205004
not O 0 0.0004103518
resolve O 0 0.00046391427
, O 0 0.00066656223
when O 0 0.0006876915
sirolimus B-Chemical 1 0.9995809
is O 0 0.0025488238
withdrawn O 0 0.005428428
. O 0 0.002926046

Components O 0 0.0045673256
of O 0 0.003999486
lemon O 0 0.94437903
essential O 0 0.0027566482
oil O 0 0.9792251
attenuate O 0 0.024196513
dementia B-Disease 0 0.99981254
induced O 0 0.007421081
by O 0 0.009409793
scopolamine B-Chemical 1 0.9999672
. O 0 0.007708869

The O 0 0.0026242177
anti O 0 0.008220405
- O 0 0.0072401837
dementia B-Disease 0 0.9986779
effects O 0 0.0009552434
of O 0 0.00078301673
s B-Chemical 0 0.0011330028
- I-Chemical 0 0.0017994334
limonene I-Chemical 0 0.9999304
and O 0 0.000504334
s B-Chemical 0 0.00037464718
- I-Chemical 0 0.0014466501
perillyl I-Chemical 0 0.9998951
alcohol I-Chemical 0 0.9999666
were O 0 0.00020770871
observed O 0 6.645074e-05
using O 0 4.742796e-05
the O 0 5.9914826e-05
passive O 0 0.00011353192
avoidance O 0 0.00036081544
test O 0 0.0002791332
( O 0 0.00029916334
PA O 0 0.11551187
) O 0 0.0002181183
and O 0 9.646931e-05
the O 0 9.677678e-05
open O 0 0.00019925511
field O 0 0.00023832824
habituation O 0 0.0019259067
test O 0 0.00083220506
( O 0 0.0014710656
OFH O 0 0.52333385
) O 0 0.003041835
. O 0 0.0024105082

These O 0 0.003918824
lemon O 0 0.92698735
essential O 0 0.0018367514
oils O 0 0.97298807
showed O 0 0.00068874453
strong O 0 0.00037951642
ability O 0 0.00023210804
to O 0 0.00014980925
improve O 0 0.00015360632
memory B-Disease 0 0.8643597
impaired I-Disease 0 0.20806158
by O 0 0.0015226172
scopolamine B-Chemical 1 0.9999988
; O 0 0.000559203
however O 0 0.00020383685
, O 0 0.00012787314
s B-Chemical 0 0.00014458761
- I-Chemical 0 0.0007720731
perillyl I-Chemical 0 0.9999106
alcohol I-Chemical 0 0.999985
relieved O 0 0.022574682
the O 0 0.0001406871
deficit B-Disease 0 0.006833624
of I-Disease 0 0.00012188879
associative I-Disease 0 0.0017884934
memory I-Disease 0 0.19349176
in O 0 0.00020120513
PA O 0 0.25206414
only O 0 0.00016853926
, O 0 0.00012140033
and O 0 8.7371845e-05
did O 0 8.8528104e-05
not O 0 6.8168156e-05
improve O 0 7.353683e-05
non O 0 0.0001856708
- O 0 0.0002999024
associative O 0 0.0015082519
memory O 0 0.121886745
significantly O 0 0.0013493282
in O 0 0.0014013842
OFH O 0 0.6578574
. O 0 0.002482952

Analysis O 0 0.0027458977
of O 0 0.002015577
neurotransmitter O 0 0.08866766
concentration O 0 0.0013839798
in O 0 0.0003811983
some O 0 0.00027629695
brain O 0 0.0008978414
regions O 0 0.00012705672
on O 0 5.802422e-05
the O 0 8.711169e-05
test O 0 0.000109359775
day O 0 4.3906708e-05
showed O 0 6.249373e-05
that O 0 8.220416e-05
dopamine B-Chemical 0 0.9992192
concentration O 0 0.00028614388
of O 0 0.000110208566
the O 0 8.362376e-05
vehicle O 0 0.00095817633
/ O 0 0.0044984743
scopolamine B-Chemical 1 0.99999833
group O 0 0.00047176154
was O 0 0.00010801845
significantly O 0 0.000102773876
lower O 0 8.242483e-05
than O 0 2.9358427e-05
that O 0 3.0528365e-05
of O 0 7.342094e-05
the O 0 7.463156e-05
vehicle O 0 0.00062467897
/ O 0 0.000508064
vehicle O 0 0.00074408075
group O 0 0.00018270896
, O 0 0.00010321446
but O 0 8.136399e-05
this O 0 0.00010872799
phenomenon O 0 0.00043734023
was O 0 0.000102531696
reversed O 0 0.00019384576
when O 0 5.6967965e-05
s B-Chemical 0 0.00025078334
- I-Chemical 0 0.0006585691
limonene I-Chemical 0 0.99995446
or O 0 0.00018379086
s B-Chemical 0 0.00020392335
- I-Chemical 0 0.0009492894
perillyl I-Chemical 0 0.99986637
alcohol I-Chemical 0 0.9999509
were O 0 0.00019401105
administered O 0 0.000121413424
before O 0 6.022399e-05
the O 0 0.00017471034
injection O 0 0.0005177006
of O 0 0.0025637832
scopolamine B-Chemical 1 0.9999764
. O 0 0.004160748

Simultaneously O 0 0.0052354163
, O 0 0.0018927114
we O 0 0.00051963766
found O 0 0.00043510017
that O 0 0.0002701475
these O 0 0.00043759964
two O 0 0.00027207885
lemon O 0 0.941246
essential O 0 0.00034322342
oil O 0 0.8308148
components O 0 0.00015189032
could O 0 0.000121685334
inhibit O 0 0.00015777138
acetylcholinesterase O 0 0.9911555
activity O 0 0.00022772541
in O 0 0.00017765007
vitro O 0 0.00035284422
using O 0 0.0003193533
the O 0 0.0008367399
Ellman O 0 0.6831825
method O 0 0.0035096651
. O 0 0.0024520804

Attentional O 0 0.009250883
modulation O 0 0.0016327905
of O 0 0.0014742721
perceived O 0 0.00175145
pain B-Disease 0 0.17245248
intensity O 0 0.0006378541
in O 0 0.0012250808
capsaicin B-Chemical 0 0.9994742
- O 0 0.0045670155
induced O 0 0.0035599929
secondary O 2 0.83719087
hyperalgesia B-Disease 2 0.9998259
. O 0 0.0067379107

Perceived O 0 0.011472651
pain B-Disease 0 0.10205639
intensity O 0 0.0027909717
is O 0 0.002831552
modulated O 0 0.0019082977
by O 0 0.004034711
attention O 0 0.0070357197
. O 0 0.006482929

However O 0 0.0031558224
, O 0 0.0023299253
it O 0 0.0011535457
is O 0 0.0006085208
not O 0 0.0003386703
known O 0 0.0003119748
that O 0 0.0001445537
how O 0 0.00018592467
pain B-Disease 0 0.07828849
intensity O 0 0.00012561533
ratings O 0 0.000204605
are O 0 0.00012302496
affected O 0 0.00016414022
by O 0 0.00015775951
attention O 0 0.000321818
in O 0 0.0004328014
capsaicin B-Chemical 0 0.9996468
- O 0 0.0025247121
induced O 0 0.0021497514
secondary O 2 0.82857686
hyperalgesia B-Disease 2 0.9998684
. O 0 0.004994814

Here O 0 0.0018241344
we O 0 0.0007473895
show O 0 0.0005571088
that O 0 0.00042195362
perceived O 0 0.00092110835
pain B-Disease 0 0.19519171
intensity O 0 0.00025120212
in O 0 0.00036271175
secondary O 2 0.28880814
hyperalgesia B-Disease 2 0.999948
is O 0 0.0004022551
decreased O 0 0.0004276516
when O 0 8.2191546e-05
attention O 0 0.00019312275
is O 0 0.00012001465
distracted O 0 0.00079315447
away O 0 8.676499e-05
from O 0 7.255344e-05
the O 0 0.00014557941
painful O 0 0.17797214
pinprick O 0 0.028180828
stimulus O 0 0.0002542119
with O 0 0.00038968652
a O 0 0.00072085386
visual O 0 0.009160724
task O 0 0.002379611
. O 0 0.0021927187

Furthermore O 0 0.003151727
, O 0 0.0023815504
it O 0 0.0012171499
was O 0 0.00071275834
found O 0 0.00029547897
that O 0 0.00016255496
the O 0 0.000162037
magnitude O 0 0.00011507858
of O 0 0.0001629244
attentional O 0 0.0021576437
modulation O 0 0.00018080986
in O 0 0.00021327866
secondary O 2 0.2766355
hyperalgesia B-Disease 2 0.99995303
is O 0 0.00023818965
very O 0 0.00016490245
similar O 0 5.0042876e-05
to O 0 5.8343434e-05
that O 0 7.500613e-05
of O 0 0.0004676239
capsaicin B-Chemical 0 0.99974066
- O 0 0.0012744773
untreated O 0 0.00074221735
, O 0 0.0005235504
control O 0 0.000669771
condition O 0 0.0024895368
. O 0 0.0020455099

Our O 0 0.0024685394
findings O 0 0.0026288119
, O 0 0.0012445113
showing O 0 0.00058606314
no O 0 0.00024166948
interaction O 0 0.00024595833
between O 0 0.00022865094
capsaicin B-Chemical 0 0.9986833
treatment O 0 0.00029228625
and O 0 0.00014988797
attentional O 0 0.0018842941
modulation O 0 0.000104369654
suggest O 0 4.28156e-05
that O 0 0.00012503097
capsaicin B-Chemical 0 0.9998332
- O 0 0.0010430287
induced O 0 0.00045125923
secondary O 2 0.6087674
hyperalgesia B-Disease 2 0.9999645
and O 0 0.00029740925
attention O 0 0.00017908856
might O 0 5.8505837e-05
affect O 0 6.920058e-05
mechanical O 0 0.00033575433
pain B-Disease 0 0.04305491
through O 0 0.00025628242
independent O 0 0.00035579776
mechanisms O 0 0.0012321243
. O 0 0.0017567436

Cardioprotective O 0 0.41702682
effect O 0 0.0028711695
of O 0 0.01713338
salvianolic B-Chemical 1 0.999997
acid I-Chemical 1 0.99984
A I-Chemical 1 0.9543214
on O 0 0.0010672732
isoproterenol B-Chemical 0 0.999892
- O 0 0.003449597
induced O 0 0.0023716583
myocardial B-Disease 0 0.999833
infarction I-Disease 2 0.99997675
in O 0 0.0028372903
rats O 0 0.0039686775
. O 0 0.0023031544

The O 0 0.0015355664
present O 0 0.0010528674
study O 0 0.0010361281
was O 0 0.0005686846
designed O 0 0.00032634338
to O 0 0.00019738838
evaluate O 0 0.00010703596
the O 0 0.00019476505
cardioprotective O 0 0.084295906
potential O 0 0.0003919252
of O 0 0.005503495
salvianolic B-Chemical 1 0.99999964
acid I-Chemical 1 0.9999424
A I-Chemical 1 0.94794554
on O 0 0.00039932196
isoproterenol B-Chemical 0 0.9999298
- O 0 0.001830527
induced O 0 0.0014241682
myocardial B-Disease 0 0.999863
infarction I-Disease 2 0.99998164
in O 0 0.0021341455
rats O 0 0.0031589805
. O 0 0.0018876357

Hemodynamic O 0 0.024614666
parameters O 0 0.0021266383
and O 0 0.0015911018
lead O 0 0.0046723215
II O 0 0.010777478
electrocardiograph O 0 0.01251792
were O 0 0.00064023247
monitored O 0 0.00043711104
and O 0 0.0007580532
recorded O 0 0.0010604453
continuously O 0 0.0019557078
. O 0 0.0028663517

Cardiac O 0 0.028273296
marker O 0 0.0034445417
enzymes O 0 0.0054599866
and O 0 0.0012648591
antioxidative O 0 0.91324127
parameters O 0 0.0008283277
in O 0 0.00051907275
serum O 0 0.011447878
and O 0 0.0008779408
heart O 0 0.049615927
tissues O 0 0.0017370468
were O 0 0.000999216
measured O 0 0.0013484654
. O 0 0.0022795703

Assay O 0 0.012092521
for O 0 0.0018057387
mitochondrial O 0 0.090138935
respiratory O 0 0.007252059
function O 0 0.00084147725
and O 0 0.0006446587
histopathological O 0 0.0070722587
examination O 0 0.0004547306
of O 0 0.0005985244
heart O 0 0.025261428
tissues O 0 0.0013943651
were O 0 0.0008654679
performed O 0 0.0012059152
. O 0 0.002014898

Isoproterenol B-Chemical 0 0.9997775
- O 0 0.006738948
treated O 0 0.0016517059
rats O 0 0.0010112417
showed O 0 0.00038890587
significant O 0 0.00023588199
increases O 0 0.00017978578
in O 0 0.00012435406
the O 0 0.000111438436
levels O 0 0.00013523137
of O 0 0.00043687652
lactate B-Chemical 0 0.9851666
dehydrogenase O 0 0.9915131
, O 0 0.0010727432
aspartate B-Chemical 1 0.99997485
transaminase O 0 0.99998784
, O 0 0.00327065
creatine B-Chemical 1 0.9999647
kinase O 0 0.17603804
and O 0 0.0034572806
malondialdehyde B-Chemical 1 0.99999976
and O 0 0.0003061272
significant O 0 9.40185e-05
decreases O 0 9.1178095e-05
in O 0 5.7476318e-05
the O 0 6.801524e-05
activities O 0 0.00013986141
of O 0 0.0015478639
superoxide B-Chemical 1 0.9999974
dismutase O 0 0.99999964
, O 0 0.027361669
catalase O 0 0.9999665
and O 0 0.009894686
glutathione B-Chemical 0 0.99999166
peroxidase O 0 0.99794346
in O 0 0.0006524672
serum O 0 0.07162346
and O 0 0.0015159234
heart O 0 0.22714832
. O 0 0.0024449565

These O 0 0.0023845478
rats O 0 0.0017928419
also O 0 0.0007356938
showed O 0 0.0005233413
declines O 0 0.0006214885
in O 0 0.00023372943
left O 0 0.0005906665
ventricular O 0 0.56343615
systolic O 0 0.19921136
pressure O 0 0.0022447212
, O 0 0.00010734198
maximum O 0 6.09378e-05
and O 0 5.546972e-05
minimum O 0 3.571015e-05
rate O 0 5.8862373e-05
of O 0 7.516329e-05
developed O 0 0.00012178447
left O 0 0.00038204217
ventricular O 0 0.67018914
pressure O 0 0.0038646352
, O 0 0.000101254525
and O 0 7.838614e-05
elevation O 0 0.0010957364
of O 0 0.00013347255
left O 0 0.0004560354
ventricular O 0 0.356661
end O 0 9.270905e-05
- O 0 0.00033321045
diastolic O 0 0.13564503
pressure O 0 0.0028837807
and O 0 0.0005369001
ST O 0 0.1354926
- O 0 0.0017305004
segment O 0 0.002167324
. O 0 0.0020115585

In O 0 0.0017043629
addition O 0 0.0010990896
, O 0 0.0018132911
mitochondrial O 0 0.61170167
respiratory B-Disease 0 0.9484067
dysfunction I-Disease 0 0.9993868
characterized O 0 0.0034646513
by O 0 0.00031425635
decreased O 0 0.0005397123
respiratory O 0 0.004194973
control O 0 0.00016799664
ratio O 0 0.0003224906
and O 0 0.00040337638
ADP B-Chemical 0 0.9997137
/ O 0 0.0054604737
O O 0 0.9855972
was O 0 0.00026148857
observed O 0 0.00017210306
in O 0 0.00038436646
isoproterenol B-Chemical 0 0.99966204
- O 0 0.0019674124
treated O 0 0.0016645588
rats O 0 0.0026995568
. O 0 0.0019921835

Administration O 0 0.018141963
of O 0 0.017882055
salvianolic B-Chemical 1 0.999995
acid I-Chemical 1 0.999765
A I-Chemical 1 0.83972305
for O 0 0.00038114365
a O 0 0.00031166148
period O 0 8.4213876e-05
of O 0 0.00014100835
8 O 0 7.2671086e-05
days O 0 3.8886552e-05
significantly O 0 0.00013191866
attenuated O 0 0.00083323615
isoproterenol B-Chemical 0 0.99993753
- O 0 0.0009314309
induced O 0 0.00038055782
cardiac B-Disease 0 0.96829045
dysfunction I-Disease 0 0.999356
and O 0 0.0016284636
myocardial B-Disease 0 0.99997413
injury I-Disease 0 0.9958883
and O 0 0.00067706354
improved O 0 0.0015908685
mitochondrial O 0 0.38437083
respiratory O 0 0.04802684
function O 0 0.0024025522
. O 0 0.0020839223

The O 0 0.0019498002
protective O 0 0.002972191
role O 0 0.0010227468
of O 0 0.0074307327
salvianolic B-Chemical 1 0.9999981
acid I-Chemical 1 0.9999007
A I-Chemical 1 0.97193265
against O 0 0.0010696276
isoproterenol B-Chemical 0 0.9999573
- O 0 0.0032323324
induced O 0 0.0014880032
myocardial B-Disease 0 0.99997044
damage I-Disease 0 0.997101
was O 0 0.00061805564
further O 0 0.00045140163
confirmed O 0 0.00043501888
by O 0 0.00063932757
histopathological O 0 0.02536662
examination O 0 0.0017865057
. O 0 0.0019179975

The O 0 0.0014265281
results O 0 0.0011236465
of O 0 0.00093057496
our O 0 0.0007401465
study O 0 0.00050229835
suggest O 0 0.00019482651
that O 0 0.00073195406
salvianolic B-Chemical 1 0.9999993
acid I-Chemical 1 0.99995065
A I-Chemical 1 0.98912024
possessing O 0 0.010123443
antioxidant O 0 0.99941695
activity O 0 0.00028333368
has O 0 0.00010484106
a O 0 0.00016438284
significant O 0 0.00012496638
protective O 0 0.00042588028
effect O 0 0.00018709485
against O 0 0.00034838993
isoproterenol B-Chemical 0 0.99990404
- O 0 0.0034151461
induced O 0 0.003615216
myocardial B-Disease 0 0.99985194
infarction I-Disease 2 0.9999716
. O 0 0.0053385594

Long O 0 0.009609443
- O 0 0.0040534255
term O 0 0.0024760265
glutamate B-Chemical 1 0.9996451
supplementation O 0 0.8041573
failed O 0 0.0010611827
to O 0 0.0004942005
protect O 0 0.0006883466
against O 0 0.000636509
peripheral B-Disease 0 0.8442457
neurotoxicity I-Disease 2 0.99997985
of O 0 0.041462936
paclitaxel B-Chemical 1 0.99890375
. O 0 0.0048618154

Toxic O 0 0.9316202
peripheral B-Disease 2 0.96981984
neuropathy I-Disease 2 0.99995625
is O 0 0.001431713
still O 0 0.00051554054
a O 0 0.00040312283
significant O 0 0.00020366219
limiting O 0 0.00029989242
factor O 0 0.00043164572
for O 0 0.000108743334
chemotherapy O 0 0.0014156104
with O 0 0.00036135226
paclitaxel B-Chemical 1 0.99830973
( O 0 0.0013343374
PAC B-Chemical 0 0.99741507
) O 0 0.00048729524
, O 0 0.00017312547
although O 0 0.00018476289
glutamate B-Chemical 1 0.99970955
and O 0 0.00016004754
its O 0 0.0001596823
closely O 0 5.688556e-05
related O 0 6.893627e-05
amino B-Chemical 0 0.97379994
acid I-Chemical 0 0.9995135
glutamine B-Chemical 0 0.99987733
were O 0 0.000528279
claimed O 0 0.0005676454
to O 0 0.0004184832
ameliorate O 0 0.0609658
PAC B-Chemical 0 0.99929965
neurotoxicity B-Disease 2 0.99991536
. O 0 0.0048809294

This O 0 0.0034146167
pilot O 0 0.0024485898
trial O 0 0.0010504028
aimed O 0 0.00066058116
to O 0 0.00030581155
evaluate O 0 0.00014128601
the O 0 0.00017545557
role O 0 0.00012842008
of O 0 0.0007018028
glutamate B-Chemical 1 0.9999503
supplementation O 0 0.89450425
for O 0 0.00019415538
preventing O 0 0.0010641464
PAC B-Chemical 0 0.99886477
- O 0 0.0006900572
induced O 0 0.00038077956
peripheral B-Disease 2 0.94511646
neuropathy I-Disease 2 0.9999968
in O 0 0.0001822524
a O 0 0.00014811882
randomized O 0 0.00012342821
, O 0 0.00010409831
placebo O 0 0.00063582807
- O 0 0.00016405339
controlled O 0 8.3768544e-05
, O 0 0.00011953473
double O 0 0.00022179396
- O 0 0.00024802546
blinded O 0 0.00018760108
clinical O 0 0.00036525034
and O 0 0.00028636766
electro O 0 0.0034055423
- O 0 0.0008672791
diagnostic O 0 0.0010220342
study O 0 0.0015035706
. O 0 0.0018381587

Forty O 0 0.0045815
- O 0 0.0026020368
three O 0 0.0008175179
ovarian B-Disease 0 0.9746576
cancer I-Disease 0 0.9989434
patients O 0 0.0011188682
were O 0 0.0002347163
available O 0 0.00014782436
for O 0 6.733716e-05
analysis O 0 6.747304e-05
following O 0 4.0708393e-05
six O 0 3.084241e-05
cycles O 0 3.1962663e-05
of O 0 6.361305e-05
the O 0 6.369222e-05
same O 0 6.248981e-05
PAC B-Chemical 0 0.9592337
- O 0 0.00021200659
containing O 0 5.7477417e-05
regimen O 0 0.00012675492
: O 0 9.458277e-05
23 O 0 9.3484785e-05
had O 0 5.466679e-05
been O 0 4.498836e-05
supplemented O 0 0.0002020067
by O 0 0.00019952413
glutamate B-Chemical 1 0.99964726
all O 0 9.026592e-05
along O 0 3.5981986e-05
the O 0 4.674763e-05
treatment O 0 4.72678e-05
period O 0 2.5055197e-05
, O 0 4.906682e-05
at O 0 2.9180981e-05
a O 0 6.6946464e-05
daily O 0 7.4161624e-05
dose O 0 0.00015232484
of O 0 5.760774e-05
three O 0 2.1108495e-05
times O 0 2.5103556e-05
500 O 0 0.00017888207
mg O 0 0.0028126582
( O 0 0.00018881637
group O 0 0.00028415714
G O 0 0.8492067
) O 0 0.00028257238
, O 0 0.00011410237
and O 0 8.836264e-05
20 O 0 8.5549145e-05
had O 0 8.772298e-05
received O 0 8.961265e-05
a O 0 0.00026092053
placebo O 0 0.0016992141
( O 0 0.0006165098
group O 0 0.001124526
P O 0 0.013098987
) O 0 0.0025631092
. O 0 0.002329309

Patients O 0 0.0024324672
were O 0 0.0011900231
evaluated O 0 0.000729096
by O 0 0.00084735174
neurological O 0 0.25200573
examinations O 0 0.00090424856
, O 0 0.00043882354
questionnaires O 0 0.00032225673
and O 0 0.0003259932
sensory O 0 0.0009120482
- O 0 0.00087844033
motor O 0 0.0022377775
nerve O 0 0.011407515
conduction O 0 0.006446044
studies O 0 0.0021674144
. O 0 0.0022720087

There O 0 0.0026782688
was O 0 0.0016071331
no O 0 0.0005614475
significant O 0 0.00048385528
difference O 0 0.00019801913
in O 0 0.00018043355
the O 0 0.00015349827
frequency O 0 0.00016534347
of O 0 0.0002130173
signs O 0 0.0016046086
or O 0 0.00012592356
symptoms O 0 0.0009859129
between O 0 4.0081537e-05
the O 0 5.5675875e-05
two O 0 4.244861e-05
groups O 0 7.045951e-05
although O 0 0.0001052592
neurotoxicity B-Disease 2 0.99992955
symptoms O 0 0.018214777
presented O 0 9.793789e-05
mostly O 0 0.00013322169
with O 0 0.00011776907
lower O 0 0.0001449298
scores O 0 0.00010937197
of O 0 0.00023972732
severity O 0 0.00078894565
in O 0 0.00054805964
group O 0 0.0018167667
G O 0 0.70942056
. O 0 0.0026926333

However O 0 0.0025801184
, O 0 0.001672798
this O 0 0.0008320754
difference O 0 0.00032700892
reached O 0 0.00038394346
statistical O 0 0.00047823772
significance O 0 0.00022490475
only O 0 0.00019112143
with O 0 0.0001741314
regard O 0 8.9619745e-05
to O 0 0.00013827781
reported O 0 0.00041359378
pain B-Disease 0 0.76769704
sensation O 0 0.36716712
( O 0 0.0012042428
P O 0 0.011656245
= O 0 0.0005131209
0 O 0 0.00039180415
. O 0 0.00053723954
011 O 0 0.0060129426
) O 0 0.0025944249
. O 0 0.002522679

Also O 0 0.0022834744
the O 0 0.0011675312
frequency O 0 0.00089894386
of O 0 0.0008560691
abnormal O 0 0.004671142
electro O 0 0.014139738
- O 0 0.0006450889
diagnostic O 0 0.00027399245
findings O 0 0.00024710962
showed O 0 0.00010626437
similarity O 0 8.215747e-05
between O 0 4.7215635e-05
the O 0 7.464565e-05
two O 0 6.367685e-05
groups O 0 0.0001152145
( O 0 0.00024828975
G O 0 0.5238951
: O 0 0.0001914961
7 O 0 8.061732e-05
/ O 0 0.00024983232
23 O 0 0.00015808326
= O 0 0.00011125985
30 O 0 6.184893e-05
. O 0 5.9277525e-05
4 O 0 7.561514e-05
% O 0 0.00014826538
; O 0 0.0002629975
P O 0 0.0020108274
: O 0 0.0002317032
6 O 0 0.00013275907
/ O 0 0.0004335976
20 O 0 0.00030495503
= O 0 0.00046657398
30 O 0 0.00044002384
% O 0 0.0010444894
) O 0 0.002198323
. O 0 0.0024791404

This O 0 0.0037578694
pilot O 0 0.0026746294
study O 0 0.00094904157
leads O 0 0.00046702145
to O 0 0.0002912409
the O 0 0.00024002967
conclusion O 0 0.00022487623
that O 0 0.00032403675
glutamate B-Chemical 1 0.99993265
supplementation O 0 0.75547576
at O 0 0.000103352344
the O 0 9.418774e-05
chosen O 0 9.51997e-05
regimen O 0 0.00015920507
fails O 0 0.000116630836
to O 0 0.00012180444
protect O 0 0.000266245
against O 0 0.00032468152
peripheral B-Disease 0 0.84255284
neurotoxicity I-Disease 2 0.99998546
of O 0 0.042213652
PAC B-Chemical 0 0.9974999
. O 0 0.0032844434

Development O 0 0.0043671047
of O 0 0.0027291828
ocular B-Disease 0 0.9625172
myasthenia I-Disease 0 0.9995913
during O 0 0.0008083728
pegylated B-Chemical 0 0.99830985
interferon I-Chemical 0 0.9999294
and O 0 0.002719265
ribavirin B-Chemical 0 0.999668
treatment O 0 0.0015280215
for O 0 0.0015296886
chronic B-Disease 0 0.9993268
hepatitis I-Disease 2 0.9999981
C I-Disease 0 0.9999503
. O 0 0.0127916755

A O 0 0.025539795
63 O 0 0.0039567337
- O 0 0.0024146663
year O 0 0.000667291
- O 0 0.0008575929
old O 0 0.00041634598
male O 0 0.00092259806
experienced O 0 0.0005695731
sudden O 0 0.9629224
diplopia B-Disease 0 0.9995024
after O 0 6.34104e-05
9 O 0 5.6733053e-05
weeks O 0 2.0311536e-05
of O 0 5.6083576e-05
administration O 0 0.00023399657
of O 0 0.00025167415
pegylated B-Chemical 0 0.9981674
interferon I-Chemical 0 0.9999857
( I-Chemical 0 0.0073654796
IFN I-Chemical 0 0.9999639
) I-Chemical 0 0.0018704302
alpha I-Chemical 0 0.78133124
- I-Chemical 0 0.0004990695
2b I-Chemical 0 0.00019385351
and O 0 0.00017957007
ribavirin B-Chemical 0 0.99656457
for O 0 0.0005674723
chronic B-Disease 0 0.9993242
hepatitis I-Disease 2 0.9999995
C I-Disease 0 0.9999893
( O 0 0.100245655
CHC B-Disease 0 0.9990835
) O 0 0.0065416815
. O 0 0.0027580194

Ophthalmologic O 0 0.1425321
examinations O 0 0.00224312
showed O 0 0.0011784734
ptosis B-Disease 0 0.667285
on I-Disease 0 0.00025604843
the I-Disease 0 0.00027223869
right I-Disease 0 0.0007183843
upper I-Disease 0 0.0006542665
lid I-Disease 0 0.004216779
and O 0 0.0001709466
restricted B-Disease 0 0.000112251655
right I-Disease 0 0.00058486365
eye I-Disease 0 0.0054018917
movement I-Disease 0 0.0003586882
without O 0 0.00021941192
any O 0 0.0002757527
other O 0 0.0006270584
neurological O 0 0.90606236
signs O 0 0.10380472
. O 0 0.0028332395

A O 0 0.015352938
brain O 0 0.004944524
imaging O 0 0.002131159
study O 0 0.00093707355
and O 0 0.0006134503
repetitive O 0 0.0006467436
nerve O 0 0.0032732112
stimulation O 0 0.00051928114
test O 0 0.0008593049
indicated O 0 0.00066238735
no O 0 0.0010662072
abnormality O 0 0.047700662
. O 0 0.0034396742

The O 0 0.0035407767
acetylcholine B-Chemical 1 0.99940693
receptor O 0 0.06699216
antibody O 0 0.003839442
titer O 0 0.0038595854
and O 0 0.00040806085
response O 0 0.0003096348
to O 0 0.00032799464
acetylcholinesterase O 0 0.9963535
inhibitors O 0 0.0029243936
were O 0 0.00020421366
negative O 0 0.00021435566
, O 0 0.00015011441
and O 0 0.00010510894
the O 0 9.686143e-05
results O 0 0.0001352177
of O 0 0.00029260188
thyroid O 0 0.18405728
function O 0 0.00053881336
tests O 0 0.0010164377
were O 0 0.00071274483
normal O 0 0.0022054529
. O 0 0.0018064118

The O 0 0.0015771781
patient O 0 0.0014065184
' O 0 0.0010981131
s O 0 0.0008308486
ophthalmological O 0 0.041796558
symptoms O 0 0.004260508
improved O 0 0.000536521
rapidly O 0 0.00024522518
3 O 0 7.63617e-05
weeks O 0 3.0372712e-05
after O 0 3.2552234e-05
discontinuation O 0 0.00076201826
of O 0 0.00029696812
pegylated B-Chemical 0 0.96743786
IFN I-Chemical 0 0.9999505
alpha I-Chemical 0 0.9816705
- I-Chemical 0 0.0023807772
2b I-Chemical 0 0.0010020693
and O 0 0.0013188304
ribavirin B-Chemical 0 0.99760336
. O 0 0.0035590203

The O 0 0.0024926804
ocular B-Disease 0 0.95001054
myasthenia I-Disease 0 0.9993765
associated O 0 0.0008194837
with O 0 0.0004943687
combination O 0 0.00038386555
therapy O 0 0.00030121938
of O 0 0.00037410614
pegylated B-Chemical 0 0.9827187
IFN I-Chemical 0 0.99997747
alpha I-Chemical 0 0.9903706
- I-Chemical 0 0.001134
2b I-Chemical 0 0.00025028933
and O 0 0.00017347399
ribavirin B-Chemical 0 0.9973701
for O 0 0.00023120976
CHC B-Disease 0 0.99724007
is O 0 0.00017579318
very O 0 0.00020272564
rarely O 0 0.00013503242
reported O 0 0.00015094737
; O 0 0.000111564754
therefore O 0 8.3819374e-05
, O 0 7.050293e-05
we O 0 2.7372316e-05
present O 0 4.3454205e-05
this O 0 8.6347674e-05
case O 0 7.997917e-05
with O 0 0.00010995256
a O 0 0.00013958816
review O 0 0.00018094612
of O 0 0.000117692856
the O 0 0.00011607397
various O 0 0.0002211092
eye O 0 0.023358678
complications O 0 0.037722223
of O 0 0.0017461427
IFN B-Chemical 0 0.99955064
therapy O 0 0.0066504804
. O 0 0.002432

Learning B-Disease 0 0.010310728
and I-Disease 0 0.0026639071
memory I-Disease 0 0.87671113
deficits I-Disease 0 0.9596593
in O 0 0.0025948798
ecstasy B-Chemical 1 0.99993646
users O 0 0.002647443
and O 0 0.0003066094
their O 0 0.00024396167
neural O 0 0.00035697245
correlates O 0 0.00016093176
during O 0 0.0001326237
a O 0 0.0004063218
face O 0 0.00067976833
- O 0 0.0010852881
learning O 0 0.0019739855
task O 0 0.002537467
. O 0 0.0025520932

It O 0 0.0028010309
has O 0 0.0010948267
been O 0 0.000609888
consistently O 0 0.00049140985
shown O 0 0.00033971816
that O 0 0.0004775713
ecstasy B-Chemical 1 0.99988794
users O 0 0.001811066
display O 0 0.00031549615
impairments B-Disease 0 0.0070091435
in I-Disease 0 0.0002825379
learning I-Disease 0 0.0008104379
and I-Disease 0 0.0006929992
memory I-Disease 0 0.13646097
performance O 0 0.003930676
. O 0 0.0026419214

In O 0 0.0016695998
addition O 0 0.0009493871
, O 0 0.0010602252
working O 0 0.0011067657
memory O 0 0.021061199
processing O 0 0.00036071087
in O 0 0.0007209441
ecstasy B-Chemical 1 0.99996686
users O 0 0.0023355817
has O 0 0.00011197466
been O 0 7.021274e-05
shown O 0 5.3732227e-05
to O 0 5.5957076e-05
be O 0 5.2833646e-05
associated O 0 5.0183906e-05
with O 0 8.251471e-05
neural O 0 0.00019651513
alterations O 0 0.0002484837
in O 0 7.060391e-05
hippocampal O 0 0.026471864
and O 0 0.00012666841
/ O 0 0.00023872852
or O 0 5.6795525e-05
cortical O 0 0.00030595096
regions O 0 7.8436766e-05
as O 0 6.174804e-05
measured O 0 6.574566e-05
by O 0 0.00010113496
functional O 0 0.0001621911
magnetic O 0 0.0010594437
resonance O 0 0.0045675854
imaging O 0 0.00071753527
( O 0 0.0007030017
fMRI O 0 0.0015641721
) O 0 0.0020217889
. O 0 0.002135469

Using O 0 0.001556414
functional O 0 0.0014355805
imaging O 0 0.0015124206
and O 0 0.0007122335
a O 0 0.0006761908
face O 0 0.0006469673
- O 0 0.0006272122
learning O 0 0.00053715584
task O 0 0.00034049456
, O 0 0.00018475231
we O 0 6.3449e-05
investigated O 0 8.707506e-05
neural O 0 0.00021702814
correlates O 0 8.353634e-05
of O 0 0.00013203619
encoding O 0 0.00011004559
and O 0 0.00012379681
recalling O 0 0.0006193102
face O 0 0.00021589137
- O 0 0.00020266807
name O 0 8.217352e-05
associations O 0 4.1553165e-05
in O 0 5.293729e-05
20 O 0 7.089111e-05
recreational O 0 0.0004721212
drug O 0 0.001881636
users O 0 0.00023936988
whose O 0 0.00013152239
predominant O 0 0.0001321595
drug O 0 0.0028939915
use O 0 0.00019285685
was O 0 0.00048252373
ecstasy B-Chemical 1 0.99972206
and O 0 0.0006120988
20 O 0 0.00067401543
controls O 0 0.001630825
. O 0 0.001704144

To O 0 0.0015946794
address O 0 0.0006600491
the O 0 0.0006961573
potential O 0 0.00054954883
confounding O 0 0.0003997118
effects O 0 0.00033744882
of O 0 0.00039180604
the O 0 0.00044487984
cannabis B-Chemical 0 0.99951124
use O 0 0.00018187222
of O 0 0.00020906341
the O 0 0.00030071035
ecstasy B-Chemical 1 0.999946
using O 0 0.00013529457
group O 0 0.00015613562
, O 0 8.438074e-05
a O 0 7.575977e-05
second O 0 5.329723e-05
analysis O 0 5.4447864e-05
included O 0 4.4239958e-05
14 O 0 4.9076036e-05
previously O 0 6.0775186e-05
tested O 0 0.00013836869
cannabis B-Chemical 0 0.9997918
users O 0 0.0017690826
( O 0 0.00031804806
Nestor O 0 0.008885152
, O 0 0.00027504485
L O 0 0.26229236
. O 0 9.831892e-05
, O 0 0.00017766362
Roberts O 0 0.0019486472
, O 0 0.00030394635
G O 0 0.6745902
. O 0 0.000104210056
, O 0 0.00018651683
Garavan O 0 0.08458352
, O 0 0.0005360868
H O 0 0.99903035
. O 0 0.00013597564
, O 0 0.00023576934
Hester O 0 0.0082552135
, O 0 0.00038637288
R O 0 0.9009169
. O 0 0.000101029495
, O 0 0.00012329592
2008 O 0 0.00017945677
. O 0 5.324104e-05
Deficits B-Disease 0 0.0003483352
in I-Disease 0 5.4123175e-05
learning I-Disease 0 0.00013970507
and I-Disease 0 8.698967e-05
memory I-Disease 0 0.021307848
: O 0 0.00021139458
parahippocampal O 0 0.700061
hyperactivity B-Disease 2 0.9999739
and O 0 0.0003960646
frontocortical O 0 0.9630621
hypoactivity O 0 0.99939156
in O 0 0.0003550811
cannabis B-Chemical 0 0.99977165
users O 0 0.00077403634
. O 0 0.000106093066
Neuroimage O 0 0.0011445334
40 O 0 0.0002927972
, O 0 0.00053711765
1328 O 0 0.015365565
- O 0 0.0019351745
1339 O 0 0.35003072
) O 0 0.0028887566
. O 0 0.0023825364

Ecstasy B-Chemical 0 0.99925524
users O 0 0.005432124
performed O 0 0.00094455516
significantly O 0 0.0008670296
worse O 0 0.0008100045
in O 0 0.00028442327
learning O 0 0.000540397
and O 0 0.0003245967
memory O 0 0.019161353
compared O 0 0.00020758777
to O 0 0.00028675975
controls O 0 0.00087617245
and O 0 0.0012811706
cannabis B-Chemical 0 0.9993975
users O 0 0.01221155
. O 0 0.0026507892

A O 0 0.0130289
conjunction O 0 0.0015618379
analysis O 0 0.000857955
of O 0 0.0006420888
the O 0 0.00035973405
encode O 0 0.00017090063
and O 0 0.00020102985
recall O 0 0.00039976204
phases O 0 0.00022634307
of O 0 0.00014075203
the O 0 0.00010534695
task O 0 0.00019090617
revealed O 0 0.00030902788
ecstasy B-Chemical 1 0.9999713
- O 0 0.0004994486
specific O 0 0.00011437054
hyperactivity B-Disease 2 0.9998965
in O 0 0.00011857192
bilateral O 0 0.0014965613
frontal O 0 0.019398386
regions O 0 9.292838e-05
, O 0 7.883428e-05
left O 0 0.00015401581
temporal O 0 0.0002776847
, O 0 0.000121447
right O 0 0.00034528153
parietal O 0 0.01024761
, O 0 0.0001798818
bilateral O 0 0.0008788279
temporal O 0 0.0006489967
, O 0 0.00025934118
and O 0 0.0002810972
bilateral O 0 0.0037920196
occipital O 0 0.3543061
brain O 0 0.0103491405
regions O 0 0.0016242223
. O 0 0.0019109461

Ecstasy B-Chemical 0 0.9994678
- O 0 0.0057265535
specific O 0 0.0013305391
hypoactivity O 0 0.9935002
was O 0 0.0006993919
evident O 0 0.00024200197
in O 0 0.00016486977
the O 0 0.00015265825
right O 0 0.00039804043
dorsal O 0 0.00032180143
anterior O 0 0.0012099491
cingulated O 0 0.6921954
cortex O 0 0.009163175
( O 0 0.0005113529
ACC O 0 0.013925322
) O 0 0.0004326944
and O 0 0.00030874455
left O 0 0.0009958674
posterior O 0 0.0040893606
cingulated O 0 0.895286
cortex O 0 0.04625677
. O 0 0.002913127

In O 0 0.0020213327
both O 0 0.0027162174
ecstasy B-Chemical 1 0.9997261
and O 0 0.0026220821
cannabis B-Chemical 0 0.9995883
groups O 0 0.0005177208
brain O 0 0.0012000643
activation O 0 0.0002990849
was O 0 0.00017709128
decreased O 0 0.00021873703
in O 0 7.962182e-05
the O 0 8.0007696e-05
right O 0 0.00026173727
medial O 0 0.0004978336
frontal O 0 0.012830469
gyrus O 0 0.17218795
, O 0 0.00018248524
left O 0 0.00037530743
parahippocampal O 0 0.1389526
gyrus O 0 0.19695593
, O 0 0.00023922842
left O 0 0.0004012299
dorsal O 0 0.00044740218
cingulate O 0 0.45904723
gyrus O 0 0.35935554
, O 0 0.00069795124
and O 0 0.0007041509
left O 0 0.0025066086
caudate O 0 0.04787717
. O 0 0.0026524602

These O 0 0.0026775429
results O 0 0.0024738463
elucidated O 0 0.005956392
ecstasy B-Chemical 1 0.9998381
- O 0 0.0022422974
related O 0 0.00031676164
deficits O 0 0.048487686
, O 0 0.00040633
only O 0 0.00024894896
some O 0 0.00020021132
of O 0 0.00024419185
which O 0 0.00025467525
might O 0 0.00014383296
be O 0 0.00021142521
attributed O 0 0.00026949457
to O 0 0.00071573973
cannabis B-Chemical 0 0.9988176
use O 0 0.0023858354
. O 0 0.0024026851

These O 0 0.0068557505
ecstasy B-Chemical 1 0.999564
- O 0 0.0031045885
specific O 0 0.00051418145
effects O 0 0.0005553802
may O 0 0.0003026137
be O 0 0.00018309578
related O 0 7.7948745e-05
to O 0 0.000103801736
the O 0 0.00011940872
vulnerability O 0 0.0005091672
of O 0 0.00024118403
isocortical O 0 0.24899618
and O 0 0.00020249962
allocortical O 0 0.0034171797
regions O 0 0.0001384323
to O 0 0.00013307644
the O 0 0.00029959262
neurotoxic B-Disease 0 0.9753779
effects O 0 0.0015376447
of O 0 0.0054544224
ecstasy B-Chemical 1 0.99985516
. O 0 0.0037161696

Disulfiram B-Chemical 0 0.9997887
- O 0 0.006573806
like O 0 0.001249106
syndrome O 0 0.07523454
after O 0 0.0006327782
hydrogen B-Chemical 0 0.99993
cyanamide I-Chemical 0 0.9999844
professional O 0 0.0044718008
skin O 0 0.01351664
exposure O 0 0.0006143139
: O 0 0.0003819608
two O 0 0.00019339194
case O 0 0.00036726412
reports O 0 0.0007466573
in O 0 0.0010236397
France O 0 0.0075063594
. O 0 0.0025391637

Hydrogen B-Chemical 0 0.9985759
cyanamide I-Chemical 0 0.9998584
is O 0 0.002674056
a O 0 0.0015225918
plant O 0 0.0029242602
growth O 0 0.0019337141
regulator O 0 0.00019818173
used O 0 0.00022769805
in O 0 0.00027368462
agriculture O 0 0.0040103616
to O 0 0.00025076684
induce O 0 0.00023997085
bud O 0 0.004594066
break O 0 0.0008926517
in O 0 0.0007195384
fruit O 0 0.0781276
trees O 0 0.0041180467
. O 0 0.002777909

Contact O 0 0.019882705
with O 0 0.0019578713
the O 0 0.0012054461
skin O 0 0.0034386017
can O 0 0.0003175693
result O 0 0.00023001735
in O 0 0.00019391302
percutaneous O 0 0.00028309823
absorption O 0 0.083663896
of O 0 0.00020539215
the O 0 0.00016841429
substance O 0 0.1580982
that O 0 0.000118882024
inhibits O 0 0.00038851585
aldehyde B-Chemical 0 0.9999914
dehydrogenase O 0 0.9949233
and O 0 0.0002470227
can O 0 0.00010609478
induce O 0 0.00021218153
acetaldehyde B-Chemical 0 0.9999924
syndrome O 0 0.49497944
in O 0 0.00028630163
case O 0 0.000375959
of O 0 0.0011577869
alcohol B-Chemical 0 0.9987538
use O 0 0.00222116
. O 0 0.0021147835

The O 0 0.0015368924
purpose O 0 0.0011615045
of O 0 0.0010291389
this O 0 0.0007856169
report O 0 0.00077305594
is O 0 0.00030291508
to O 0 0.00016137044
describe O 0 0.00012533322
two O 0 0.0001010085
cases O 0 0.00016136844
of O 0 0.00023745454
a O 0 0.001129267
disulfiram B-Chemical 0 0.99999547
- O 0 0.0011373524
like O 0 0.00015787009
syndrome O 0 0.012422498
following O 0 0.00012596355
occupational O 0 0.00050049514
exposure O 0 0.000726795
to O 0 0.0014108446
hydrogen B-Chemical 0 0.99992764
cyanamide I-Chemical 0 0.99996793
. O 0 0.00644547

The O 0 0.0016434414
first O 0 0.00096850266
case O 0 0.0008657553
involved O 0 0.00051980454
a O 0 0.0007943348
59 O 0 0.0008546908
- O 0 0.00068352383
year O 0 0.00020283625
- O 0 0.00037016015
old O 0 0.00022297542
man O 0 0.0017357126
who O 0 0.00025823037
used O 0 0.00013160806
Dormex B-Chemical 0 0.1630124
, O 0 0.00017055226
which O 0 0.00019398367
contains O 0 0.00020379621
hydrogen B-Chemical 0 0.99998724
cyanamide I-Chemical 0 0.9999962
, O 0 0.00049252075
without O 0 0.0001294358
protection O 0 0.00025136504
after O 0 4.1447493e-05
consuming O 0 0.00026510516
a O 0 0.00013403705
large O 0 0.00013139953
amount O 0 9.046446e-05
of O 0 0.0004197835
alcohol B-Chemical 0 0.99570197
during O 0 0.00034449404
a O 0 0.0012863108
meal O 0 0.0072321473
. O 0 0.002092924

In O 0 0.0018607953
less O 0 0.0014051916
than O 0 0.00059042335
1 O 0 0.0003890477
hour O 0 0.00020968087
after O 0 0.00010610359
the O 0 0.00022083384
ingestion O 0 0.013232681
of O 0 0.0009803553
alcohol B-Chemical 0 0.9997521
, O 0 0.00044513604
he O 0 0.00020838297
developed O 0 0.0005790162
malaise O 0 0.99840826
with O 0 0.0006469501
flushing B-Disease 0 0.45997286
of I-Disease 0 0.00024545047
the I-Disease 0 0.00018124311
face I-Disease 0 0.00036947776
, O 0 0.00062294496
tachycardia B-Disease 2 0.98587495
, O 0 0.001133135
and O 0 0.001658279
dyspnea B-Disease 0 0.9645972
. O 0 0.0029518506

Manifestations O 0 0.012226488
regressed O 0 0.0050846715
spontaneously O 0 0.004109779
under O 0 0.0014782258
surveillance O 0 0.0015578052
in O 0 0.0017587402
the O 0 0.002630873
hospital O 0 0.0060520777
. O 0 0.004918105

The O 0 0.0017731932
second O 0 0.0013954724
case O 0 0.00095660007
occurred O 0 0.0006333985
in O 0 0.0005095464
a O 0 0.00064481137
55 O 0 0.0006110205
- O 0 0.0006283305
year O 0 0.00022084943
- O 0 0.00043011503
old O 0 0.00029718818
farmer O 0 0.0011902415
following O 0 0.00031604405
cutaneous O 0 0.008783483
contact O 0 0.0011173679
with O 0 0.002021219
Dormex B-Chemical 0 0.49683276
. O 0 0.0030678269

Five O 0 0.002388486
hours O 0 0.0007459746
after O 0 0.0003947692
exposure O 0 0.00087139016
, O 0 0.00069366064
he O 0 0.0005609519
developed O 0 0.002629507
disulfiram B-Chemical 0 0.99999416
- O 0 0.0018763312
like O 0 0.00019913127
syndrome O 0 0.06637046
with O 0 0.00040449458
flushing B-Disease 0 0.7459103
, O 0 0.00038110366
tachycardia B-Disease 2 0.9736692
, O 0 0.00018819554
and O 0 0.00018825011
arterial B-Disease 0 0.89407325
hypotension I-Disease 0 0.99995184
after O 0 0.00011803125
consuming O 0 0.0005556433
three O 0 0.00019384908
glasses O 0 0.0079217935
of O 0 0.0018781689
wine O 0 0.95795316
. O 0 0.0028159209

The O 0 0.0018781814
patient O 0 0.001600325
recovered O 0 0.001056064
spontaneously O 0 0.001642894
in O 0 0.0005433151
3 O 0 0.0003261474
hours O 0 0.00021962122
under O 0 0.0003023046
surveillance O 0 0.0004687937
in O 0 0.0006831123
the O 0 0.0012457828
hospital O 0 0.003434278
. O 0 0.0028999504

These O 0 0.002367189
cases O 0 0.0014325681
confirm O 0 0.00051313726
the O 0 0.00043314003
necessity O 0 0.00041262872
of O 0 0.00043757146
avoiding O 0 0.0008385517
alcohol B-Chemical 0 0.99964976
consumption O 0 0.021161046
as O 0 0.00013985622
recommended O 0 9.815612e-05
in O 0 6.5825094e-05
the O 0 6.572236e-05
instructions O 0 7.286685e-05
for O 0 5.3866952e-05
use O 0 8.008731e-05
of O 0 0.00018669834
Dormex B-Chemical 0 0.06313408
and O 0 0.00019147985
of O 0 0.00027843472
preventing O 0 0.0006758151
cutaneous O 0 0.023728145
contact O 0 0.00072915823
during O 0 0.0004688321
use O 0 0.0012740295
. O 0 0.0019358966

Sulpiride B-Chemical 0 0.99960357
- O 0 0.040259786
induced O 0 0.05255627
tardive B-Disease 0 0.99987864
dystonia I-Disease 2 0.99982786
. O 0 0.026267713

Sulpiride B-Chemical 0 0.99978095
is O 0 0.0029921674
a O 0 0.0023217462
selective O 0 0.011624909
D2 O 0 0.998978
- O 0 0.002930196
receptor O 0 0.024263157
antagonist O 0 0.7717284
with O 0 0.0016032753
antipsychotic O 0 0.99836415
and O 0 0.0015782311
antidepressant B-Chemical 1 0.9983834
properties O 0 0.0017354729
. O 0 0.0023860151

Although O 0 0.0015846036
initially O 0 0.0014680512
thought O 0 0.00087409193
to O 0 0.0004701223
be O 0 0.0003063298
free O 0 0.0003652566
of O 0 0.00057088723
extrapyramidal O 0 0.9999049
side O 0 0.04770675
effects O 0 0.0006966139
, O 0 0.0017915724
sulpiride B-Chemical 0 0.9999987
- O 0 0.002975383
induced O 0 0.0026268961
tardive B-Disease 0 0.99999774
dyskinesia I-Disease 0 0.999998
and O 0 0.0048013697
parkinsonism B-Disease 2 0.99997747
have O 0 0.00042300092
been O 0 0.00039731272
reported O 0 0.00082823064
occasionally O 0 0.0023216887
. O 0 0.0018928635

We O 0 0.0018410945
studied O 0 0.0017474063
a O 0 0.0014277316
37 O 0 0.001672021
- O 0 0.0011676758
year O 0 0.00033581225
- O 0 0.0005317813
old O 0 0.00030006026
man O 0 0.0017837017
who O 0 0.00029124174
developed O 0 0.00026665657
persistent O 0 0.0018963513
segmental O 0 0.2574278
dystonia B-Disease 2 0.9999751
within O 0 6.7748806e-05
2 O 0 7.898808e-05
months O 0 4.146489e-05
after O 0 6.809584e-05
starting O 0 0.0004401688
sulpiride B-Chemical 0 0.9999727
therapy O 0 0.0055253333
. O 0 0.0023254303

We O 0 0.0018298808
could O 0 0.0012120993
not O 0 0.00083523674
find O 0 0.00058817945
any O 0 0.0004174878
previous O 0 0.00042641893
reports O 0 0.0007637914
of O 0 0.0031551956
sulpiride B-Chemical 0 0.9999958
- O 0 0.016187707
induced O 0 0.026753357
tardive B-Disease 0 0.9999883
dystonia I-Disease 2 0.99997234
. O 0 0.0077351537

Comparative O 0 0.0041694622
cognitive O 0 0.023151642
and O 0 0.0010745013
subjective O 0 0.0012320175
side O 0 0.0024508701
effects O 0 0.00042659423
of O 0 0.00043609424
immediate O 0 0.000788234
- O 0 0.0009811266
release O 0 0.0050241905
oxycodone B-Chemical 1 0.9999074
in O 0 0.00029168467
healthy O 0 0.0011894046
middle O 0 0.0008357112
- O 0 0.00065067905
aged O 0 0.00064661476
and O 0 0.00062437926
older O 0 0.0032530618
adults O 0 0.0035351268
. O 0 0.0021468583

This O 0 0.0031038385
study O 0 0.0012969583
measured O 0 0.0005591204
the O 0 0.00041785213
objective O 0 0.0004391018
and O 0 0.00030532855
subjective O 0 0.00053689705
neurocognitive O 0 0.0615696
effects O 0 0.00022949795
of O 0 0.00021898578
a O 0 0.00019058606
single O 0 0.00011712232
10 O 0 9.703589e-05
- O 0 0.00019817323
mg O 0 0.0015357975
dose O 0 0.00036713373
of O 0 0.00013357121
immediate O 0 0.0003137217
- O 0 0.00045313904
release O 0 0.0033603006
oxycodone B-Chemical 1 0.999943
in O 0 0.00013483403
healthy O 0 0.0006614364
, O 0 0.00013291565
older O 0 0.0004921664
( O 0 0.00014873518
> O 0 0.00020385842
65 O 0 0.00011662605
years O 0 7.4504984e-05
) O 0 0.00012398597
, O 0 9.17408e-05
and O 0 0.00010204488
middle O 0 0.0003685845
- O 0 0.00027834764
aged O 0 0.00019175885
( O 0 0.00010463692
35 O 0 6.1318045e-05
to O 0 5.0058967e-05
55 O 0 9.128762e-05
years O 0 6.592089e-05
) O 0 0.000121235265
adults O 0 0.0001769355
who O 0 0.00012866793
were O 0 7.728145e-05
not O 0 9.1214446e-05
suffering O 0 0.006899194
from O 0 0.00016921654
chronic O 0 0.019939749
or O 0 0.00029063757
significant O 0 0.000511743
daily O 0 0.0015247428
pain B-Disease 0 0.4932046
. O 0 0.002234472

Seventy O 0 0.004769655
- O 0 0.0022033302
one O 0 0.0005248327
participants O 0 0.00037740488
completed O 0 0.0002695845
2 O 0 0.00015856528
separate O 0 9.154767e-05
study O 0 0.00012364087
days O 0 5.1273833e-05
and O 0 9.524664e-05
were O 0 0.000109815606
blind O 0 0.00097031705
to O 0 9.575316e-05
medication O 0 0.0008610085
condition O 0 0.00031063356
( O 0 0.00025675076
placebo O 0 0.0008277589
, O 0 0.00021681572
10 O 0 0.00024079734
- O 0 0.00090946397
mg O 0 0.1725971
oxycodone B-Chemical 1 0.9998292
) O 0 0.0039201193
. O 0 0.002278951

Plasma O 0 0.63041556
oxycodone B-Chemical 1 0.99963427
concentration O 0 0.0030087908
peaked O 0 0.0009423785
between O 0 0.0002260267
60 O 0 0.00021567408
and O 0 0.00014488545
90 O 0 0.00011799625
minutes O 0 8.708013e-05
postdose O 0 0.0004053442
( O 0 0.00034169923
P O 0 0.0030050555
< O 0 0.0001630318
. O 0 0.00010210756
01 O 0 0.00040519162
) O 0 0.0001745049
and O 0 0.00011430284
pupil O 0 0.0008463862
size O 0 0.00019763848
, O 0 0.00010015833
an O 0 8.39885e-05
indication O 0 4.095862e-05
of O 0 6.818122e-05
physiological O 0 9.7552576e-05
effects O 0 7.351307e-05
of O 0 0.0001033824
the O 0 0.00010452423
medication O 0 0.00092891435
, O 0 8.6751505e-05
peaked O 0 9.3644216e-05
at O 0 3.680676e-05
approximately O 0 5.8461555e-05
90 O 0 5.258007e-05
to O 0 4.375698e-05
120 O 0 6.3498024e-05
minutes O 0 6.546545e-05
postdose O 0 0.0003901519
( O 0 0.00042996526
P O 0 0.0027580867
< O 0 0.000506769
. O 0 0.00055315124
01 O 0 0.002741668
) O 0 0.0023222123
. O 0 0.0024429697

Significant O 0 0.0028384712
declines B-Disease 0 0.0022739042
in I-Disease 0 0.00080361025
simple I-Disease 0 0.0007585312
and I-Disease 0 0.00047783495
sustained I-Disease 0 0.0007185143
attention I-Disease 0 0.0005166969
, I-Disease 0 0.00027315074
working I-Disease 0 0.00054077024
memory I-Disease 0 0.17108414
, I-Disease 0 0.00024545606
and I-Disease 0 0.0001554978
verbal I-Disease 0 0.0044812737
memory I-Disease 0 0.08258557
were O 0 9.56121e-05
observed O 0 4.497815e-05
at O 0 3.0833937e-05
1 O 0 3.2585962e-05
hour O 0 2.8212544e-05
postdose O 0 8.2926694e-05
compared O 0 2.3076778e-05
to O 0 3.137644e-05
baseline O 0 3.7233083e-05
for O 0 3.6507667e-05
both O 0 6.984065e-05
age O 0 9.5219046e-05
groups O 0 6.4321874e-05
with O 0 8.600696e-05
a O 0 0.00013418155
trend O 0 0.0001456673
toward O 0 8.406046e-05
return O 0 0.00012772762
to O 0 9.8872326e-05
baseline O 0 0.00013803976
by O 0 0.00021685234
5 O 0 0.0002253336
hours O 0 0.00033522485
postdose O 0 0.0017945076
. O 0 0.0016104954

For O 0 0.0011551148
almost O 0 0.0012553103
all O 0 0.0009006758
cognitive O 0 0.016551547
measures O 0 0.00028749477
, O 0 0.00032707746
there O 0 0.00012939508
were O 0 0.00015672467
no O 0 0.00010064084
medication O 0 0.0010417367
by O 0 0.0001721968
age O 0 0.00019094766
- O 0 0.00019538257
interaction O 0 7.182683e-05
effects O 0 0.00013942452
, O 0 0.00013078428
which O 0 0.00011714153
indicates O 0 5.6022745e-05
that O 0 4.7247573e-05
the O 0 7.7562436e-05
2 O 0 6.603111e-05
age O 0 8.301642e-05
groups O 0 6.327902e-05
exhibited O 0 8.748098e-05
similar O 0 7.018336e-05
responses O 0 0.00016845635
to O 0 0.00018845483
the O 0 0.00040417275
medication O 0 0.003321291
challenge O 0 0.0011702881
. O 0 0.0019452872

This O 0 0.0034112707
study O 0 0.0013820252
suggests O 0 0.0003856847
that O 0 0.00029054398
for O 0 0.00028914737
healthy O 0 0.0014426647
older O 0 0.0014530302
adults O 0 0.000616544
who O 0 0.0002431976
are O 0 8.800241e-05
not O 0 9.100957e-05
suffering O 0 0.0107682
from O 0 0.00013984341
chronic B-Disease 0 0.28943855
pain I-Disease 0 0.78394777
, O 0 0.00019726157
neurocognitive O 0 0.100204155
and O 0 9.999103e-05
pharmacodynamic O 0 0.0025836085
changes O 0 7.0819224e-05
in O 0 4.1483006e-05
response O 0 5.0688443e-05
to O 0 4.907978e-05
a O 0 9.6002586e-05
10 O 0 7.060553e-05
- O 0 0.00016054887
mg O 0 0.0013375494
dose O 0 0.00032455713
of O 0 0.00012271471
immediate O 0 0.00030528428
- O 0 0.00046142176
release O 0 0.0038168936
oxycodone B-Chemical 1 0.99992883
are O 0 9.091528e-05
similar O 0 4.4687167e-05
to O 0 6.5867716e-05
those O 0 0.00012793204
observed O 0 0.00011247097
for O 0 0.000175559
middle O 0 0.0010869638
- O 0 0.0012050931
aged O 0 0.0016694743
adults O 0 0.0029964603
. O 0 0.0019968704

PERSPECTIVE O 0 0.0057822857
: O 0 0.0018471103
Study O 0 0.0012771421
findings O 0 0.0007848552
indicate O 0 0.0002489943
that O 0 0.00021640823
the O 0 0.00034551165
metabolism O 0 0.033242855
, O 0 0.00037014126
neurocognitive O 0 0.121914536
effects O 0 0.00025693464
, O 0 0.00017131113
and O 0 0.000114386254
physical O 0 0.00024500643
side O 0 0.00089571625
effects O 0 0.00013061738
of O 0 0.0002971899
oral O 0 0.39434248
oxycodone B-Chemical 1 0.99995375
are O 0 0.000102663
similar O 0 4.867075e-05
for O 0 7.269451e-05
healthy O 0 0.00057491276
middle O 0 0.0006063458
- O 0 0.0005322578
aged O 0 0.0005601082
and O 0 0.0005537521
older O 0 0.0030397854
adults O 0 0.0032959399
. O 0 0.0019873374

Therefore O 0 0.0019185726
, O 0 0.0018280527
clinicians O 0 0.001245374
should O 0 0.000280779
not O 0 0.0002551088
avoid O 0 0.0002407714
prescribing O 0 0.0014469615
oral O 0 0.045386493
opioids O 0 0.8784282
to O 0 0.00018815103
older O 0 0.00069199735
adults O 0 0.0002179069
based O 0 5.7948742e-05
on O 0 4.0888728e-05
the O 0 7.505277e-05
belief O 0 0.00021580345
that O 0 7.769494e-05
older O 0 0.0006503806
adults O 0 0.00025199927
are O 0 6.698752e-05
at O 0 5.0553714e-05
higher O 0 0.00014228416
risk O 0 0.00074837945
for O 0 0.00014356304
side O 0 0.0019382399
effects O 0 0.0004666621
than O 0 0.0004933717
younger O 0 0.0076354574
adults O 0 0.0041266913
. O 0 0.0020798312

The O 0 0.004169585
glycine B-Chemical 0 0.99861217
transporter O 0 0.1940009
- O 0 0.0022109349
1 O 0 0.00056671957
inhibitor O 0 0.0030444476
SSR103800 B-Chemical 0 0.9920536
displays O 0 0.00035917122
a O 0 0.00033455243
selective O 0 0.0005577536
and O 0 0.00018494231
specific O 0 0.00018614568
antipsychotic O 0 0.99674207
- O 0 0.00039877457
like O 0 0.00010486367
profile O 0 0.00019220257
in O 0 0.00019793246
normal O 0 0.00060947594
and O 0 0.0005214909
transgenic O 0 0.0014086216
mice O 0 0.0011156455
. O 0 0.0019868664

Schizophrenia B-Disease 0 0.8975275
has O 0 0.001983054
been O 0 0.0010550132
initially O 0 0.0011299489
associated O 0 0.0008432668
with O 0 0.001506604
dysfunction O 0 0.7751219
in O 0 0.003448761
dopamine B-Chemical 0 0.99966574
neurotransmission O 0 0.9350738
. O 0 0.004029788

However O 0 0.0024874418
, O 0 0.0015923838
the O 0 0.00074062985
observation O 0 0.00051501533
that O 0 0.000355266
antagonists O 0 0.26525548
of O 0 0.00061077654
the O 0 0.0009302027
glutamate B-Chemical 1 0.99997306
N B-Chemical 0 0.9997428
- I-Chemical 0 0.007673488
methyl I-Chemical 0 0.9978381
- I-Chemical 0 0.004002304
D I-Chemical 0 0.9513358
- I-Chemical 0 0.0033852502
aspartate I-Chemical 1 0.99993825
( O 0 0.008118098
NMDA B-Chemical 1 0.9999982
) O 0 0.0013091686
receptor O 0 0.008375764
produce O 0 0.00013717271
schizophrenic B-Disease 2 0.9999207
- O 0 0.00037053792
like O 0 6.7860274e-05
symptoms O 0 0.0014673355
in O 0 8.42611e-05
humans O 0 0.00018509297
has O 0 4.7599053e-05
led O 0 7.281072e-05
to O 0 5.3936248e-05
the O 0 6.362458e-05
idea O 0 9.968705e-05
of O 0 0.00012181084
a O 0 0.00016871709
dysfunctioning O 0 0.0015444903
of O 0 0.00016866272
the O 0 0.00018240992
glutamatergic O 0 0.27832034
system O 0 0.00027339277
via O 0 0.00023404296
its O 0 0.0024690174
NMDA B-Chemical 1 0.99997234
receptor O 0 0.49139524
. O 0 0.0029814325

As O 0 0.0019267714
a O 0 0.0019940028
result O 0 0.0010742598
, O 0 0.0008917336
there O 0 0.00033444466
is O 0 0.00035246176
a O 0 0.0003178904
growing O 0 0.00023849963
interest O 0 0.00010900372
in O 0 8.576037e-05
the O 0 7.804618e-05
development O 0 0.00013630927
of O 0 0.00012350123
pharmacological O 0 0.0014757806
agents O 0 0.00043381253
with O 0 0.00010897919
potential O 0 0.00014252138
antipsychotic O 0 0.97528774
properties O 0 4.370948e-05
that O 0 3.148957e-05
enhance O 0 2.9722107e-05
the O 0 4.9785554e-05
activity O 0 5.7327754e-05
of O 0 0.00010287466
the O 0 0.00012533036
glutamatergic O 0 0.2826969
system O 0 0.00012634668
via O 0 6.449502e-05
a O 0 0.00014349543
modulation O 0 0.00016475239
of O 0 0.00043299762
the O 0 0.0013321361
NMDA B-Chemical 1 0.9999752
receptor O 0 0.5763431
. O 0 0.0031352919

Among O 0 0.0036031238
them O 0 0.0032567608
are O 0 0.0022307744
glycine B-Chemical 0 0.99931717
transporter O 0 0.21344021
- O 0 0.0012992132
1 O 0 0.0003266185
( O 0 0.0005660434
GlyT1 O 0 0.9924508
) O 0 0.00045826004
inhibitors O 0 0.0005511671
such O 0 0.00012395806
as O 0 0.00023805484
SSR103800 B-Chemical 0 0.9928485
, O 0 0.00018180495
which O 0 0.0001211129
indirectly O 0 0.00014413585
enhance O 0 0.00015374816
NMDA B-Chemical 1 0.99999714
receptor O 0 0.07262837
function O 0 0.00017573805
by O 0 9.529942e-05
increasing O 0 0.00013314931
the O 0 0.0002443861
glycine B-Chemical 0 0.99971265
( O 0 0.00037478312
a O 0 0.00027235164
co O 0 0.03305443
- O 0 0.00052795856
agonist O 0 0.08538858
for O 0 0.00010736092
the O 0 0.00041965907
NMDA B-Chemical 1 0.999995
receptor O 0 0.20929173
) O 0 0.00058074837
levels O 0 0.00030980606
in O 0 0.0004006539
the O 0 0.00079995516
synapse O 0 0.0068588736
. O 0 0.0023292766

This O 0 0.0033137533
study O 0 0.0014106836
aimed O 0 0.0009276324
at O 0 0.00037209084
investigating O 0 0.0003141006
the O 0 0.00029867233
potential O 0 0.0005192965
antipsychotic O 0 0.99847573
- O 0 0.0005030461
like O 0 8.5609616e-05
properties O 0 9.576896e-05
of O 0 0.00035582628
SSR103800 B-Chemical 0 0.99732226
, O 0 0.00021455382
with O 0 0.00012661153
a O 0 9.678185e-05
particular O 0 3.646299e-05
focus O 0 4.46221e-05
on O 0 3.356893e-05
models O 0 9.843468e-05
of O 0 0.00031161896
hyperactivity B-Disease 2 0.99996376
, O 0 0.00017489401
involving O 0 7.161543e-05
either O 0 7.96411e-05
drug O 0 0.0018832254
challenge O 0 7.328971e-05
( O 0 0.00014031678
ie O 0 0.00016979611
, O 0 0.00025854225
amphetamine B-Chemical 1 0.9999918
and O 0 0.00057039125
MK B-Chemical 0 0.99472153
- I-Chemical 0 0.0013077148
801 I-Chemical 0 0.42440712
) O 0 0.00022235782
or O 0 7.5967975e-05
transgenic O 0 0.00017011359
mice O 0 6.3344414e-05
( O 0 0.00014649525
ie O 0 0.00020524688
, O 0 0.00041605596
NMDA B-Chemical 1 0.9999951
Nr1 O 0 0.84488523
( O 0 0.0004928016
neo O 0 0.004023582
- O 0 0.0005046331
/ O 0 0.00071973493
- O 0 0.0004493947
) O 0 0.0003417769
and O 0 0.00039643972
DAT O 0 0.9910507
( O 0 0.00085107406
- O 0 0.0009902144
/ O 0 0.0017843676
- O 0 0.0016993781
) O 0 0.001914825
) O 0 0.002603596
. O 0 0.0025518925

Results O 0 0.0021937757
showed O 0 0.0015180504
that O 0 0.0012221158
SSR103800 B-Chemical 0 0.9941706
( O 0 0.0013256699
10 O 0 0.00045331274
- O 0 0.00050569297
30 O 0 0.00019598224
mg O 0 0.0031371522
/ O 0 0.0008744509
kg O 0 0.00076497364
p O 0 0.00020584994
. O 0 9.883848e-05
o O 0 0.00084214465
. O 0 0.00010595729
) O 0 0.00024144979
blocked O 0 0.0008302827
hyperactivity B-Disease 2 0.9999583
induced O 0 0.00035195428
by O 0 0.00013129544
the O 0 0.00010054722
non O 0 0.0002053234
- O 0 0.00042057657
competitive O 0 0.11708853
NMDA B-Chemical 1 0.9999988
receptor O 0 0.71936655
antagonist O 0 0.97734106
, O 0 0.0005499337
MK B-Chemical 0 0.98990834
- I-Chemical 0 0.0007017252
801 I-Chemical 0 0.0869843
and O 0 9.038832e-05
partially O 0 0.00014313193
reversed O 0 0.0004412782
spontaneous O 0 0.008196751
hyperactivity B-Disease 2 0.9999745
of O 0 0.007882358
NMDA B-Chemical 1 0.9999981
Nr1 O 0 0.93800765
( O 0 0.00080771063
neo O 0 0.0067150905
- O 0 0.0009980614
/ O 0 0.0015923217
- O 0 0.0012927282
) O 0 0.0012537165
mice O 0 0.001125572
. O 0 0.0021054016

In O 0 0.0020805062
contrast O 0 0.0025418678
, O 0 0.0023398332
SSR103800 B-Chemical 0 0.98368734
failed O 0 0.0008068887
to O 0 0.00037153272
affect O 0 0.0002887157
hyperactivity B-Disease 2 0.9998971
induced O 0 0.0008165011
by O 0 0.00076682813
amphetamine B-Chemical 1 0.9999931
or O 0 0.00017070147
naturally O 0 0.00020306108
observed O 0 8.820488e-05
in O 0 0.00017968791
dopamine B-Chemical 0 0.9998851
transporter O 0 0.081203125
( O 0 0.00051865366
DAT O 0 0.995503
( O 0 0.00037213534
- O 0 0.00037188284
/ O 0 0.00067096093
- O 0 0.00042926677
) O 0 0.00027807552
) O 0 0.00019029988
knockout O 0 0.00017305039
mice O 0 7.8285e-05
( O 0 0.00014478076
10 O 0 9.218032e-05
- O 0 0.0001665011
30 O 0 9.403786e-05
mg O 0 0.0015928539
/ O 0 0.00071400584
kg O 0 0.0007584235
p O 0 0.0003781428
. O 0 0.00031713545
o O 0 0.0023642674
. O 0 0.0008207717
) O 0 0.0023042923
. O 0 0.0024249535

Importantly O 0 0.0019247899
, O 0 0.0016638933
both O 0 0.0008693981
classical O 0 0.0011765256
( O 0 0.0026907236
haloperidol B-Chemical 1 0.9999918
) O 0 0.0011468808
and O 0 0.00029139454
atypical O 0 0.0014470787
( O 0 0.0007556281
olanzapine B-Chemical 1 0.99998796
, O 0 0.0009128794
clozapine B-Chemical 0 0.99999404
and O 0 0.00089827564
aripiprazole B-Chemical 0 0.99998033
) O 0 0.000776784
antipsychotics O 0 0.99015874
were O 0 0.00011247236
effective O 0 7.928685e-05
in O 0 0.00010615286
all O 0 0.00015397057
these O 0 0.0003197311
models O 0 0.0006247632
of O 0 0.0021523305
hyperactivity B-Disease 2 0.99980205
. O 0 0.0036122613

However O 0 0.0027749857
, O 0 0.0018376644
unlike O 0 0.00072850497
these O 0 0.0009525084
latter O 0 0.001784816
, O 0 0.0010839207
SSR103800 B-Chemical 0 0.99425703
did O 0 0.00043421055
not O 0 0.00022009182
produce O 0 0.000291101
catalepsy B-Disease 0 0.99998784
( O 0 0.00037106764
retention O 0 0.00024414039
on O 0 5.0643266e-05
the O 0 9.841177e-05
bar O 0 0.0011612091
test O 0 0.0002370225
) O 0 0.00017743355
up O 0 0.00010360011
to O 0 9.7877106e-05
30 O 0 0.0001358993
mg O 0 0.0026447952
/ O 0 0.001115314
kg O 0 0.0012190336
p O 0 0.0007101118
. O 0 0.00071110023
o O 0 0.005326197
. O 0 0.0025605138

Together O 0 0.004138873
these O 0 0.0017973823
findings O 0 0.0013471723
show O 0 0.00043638537
that O 0 0.0003222862
the O 0 0.00063600444
GlyT1 O 0 0.9986964
inhibitor O 0 0.020130077
, O 0 0.0011525172
SSR103800 B-Chemical 0 0.9981793
, O 0 0.00035634942
produces O 0 0.00032203348
antipsychotic O 0 0.9986625
- O 0 0.0003497944
like O 0 6.200129e-05
effects O 0 0.00011988722
, O 0 0.00010914661
which O 0 0.00010293138
differ O 0 5.3253945e-05
from O 0 4.0406907e-05
those O 0 6.627196e-05
observed O 0 4.5791585e-05
with O 0 9.408308e-05
compounds O 0 0.01701677
primarily O 0 7.357317e-05
targeting O 0 2.9379236e-05
the O 0 8.228284e-05
dopaminergic O 0 0.10678675
system O 0 0.00012796254
, O 0 0.00010393941
and O 0 8.4125415e-05
has O 0 5.6487e-05
a O 0 0.00012053579
reduced O 0 0.00031021456
side O 0 0.008821613
- O 0 0.00029178397
effect O 0 9.734933e-05
potential O 0 0.00013873307
as O 0 0.000120559256
compared O 0 0.000107030755
with O 0 0.0002750488
these O 0 0.00059018953
latter O 0 0.0024582199
drugs O 0 0.06519101
. O 0 0.0022500867

Pyrrolidine B-Chemical 0 0.99865687
dithiocarbamate I-Chemical 0 0.99921715
protects O 0 0.003814974
the O 0 0.0011877678
piriform O 0 0.007038779
cortex O 0 0.0045285546
in O 0 0.00058041635
the O 0 0.0010353216
pilocarpine B-Chemical 1 0.99991894
status B-Disease 0 0.002997982
epilepticus I-Disease 0 0.9972487
model O 0 0.0038038143
. O 0 0.0029485165

Pyrrolidine B-Chemical 0 0.99920505
dithiocarbamate I-Chemical 0 0.999816
( O 0 0.12890138
PDTC B-Chemical 1 0.99998367
) O 0 0.0046405024
has O 0 0.0003909112
a O 0 0.000366269
dual O 0 0.00035959535
mechanism O 0 0.0002028343
of O 0 0.00020329356
action O 0 0.00025362844
as O 0 0.00014692331
an O 0 0.000346013
antioxidant O 0 0.9917175
and O 0 0.00019152075
an O 0 0.00018956373
inhibitor O 0 0.00063154375
of O 0 0.00023050189
the O 0 0.00019967735
transcription O 0 0.00052084704
factor O 0 0.0027968623
kappa O 0 0.18607509
- O 0 0.004393143
beta O 0 0.8476131
. O 0 0.0032308025

Both O 0 0.003169186
, O 0 0.0021824983
production O 0 0.0016093225
of O 0 0.0013888275
reactive O 0 0.039764266
oxygen B-Chemical 1 0.99594516
species O 0 0.000665637
as O 0 0.00019671835
well O 0 0.000120813806
as O 0 0.00010988515
activation O 0 0.00018271069
of O 0 0.00037398437
NF O 0 0.92428744
- O 0 0.0004759557
kappaB O 0 0.0013118201
have O 0 7.3850955e-05
been O 0 5.2574655e-05
implicated O 0 4.629631e-05
in O 0 8.789271e-05
severe O 0 0.005948503
neuronal B-Disease 0 0.7403414
damage I-Disease 0 0.9583533
in O 0 0.00012702268
different O 0 6.4588756e-05
sub O 0 0.00037530763
- O 0 0.00016540922
regions O 0 6.26717e-05
of O 0 9.066767e-05
the O 0 0.00010356731
hippocampus O 0 0.005936397
as O 0 0.00013181855
well O 0 0.0001150325
as O 0 0.00015007333
in O 0 0.000201698
the O 0 0.00036072
surrounding O 0 0.00081110117
cortices O 0 0.1365233
. O 0 0.0023305546

The O 0 0.0016417813
effect O 0 0.0014839286
of O 0 0.0029886984
PDTC B-Chemical 1 0.9999589
on O 0 0.0008288812
status B-Disease 0 0.0011976503
epilepticus I-Disease 0 0.997863
- O 0 0.00089339796
associated O 0 0.00020226787
cell O 0 0.000653255
loss O 0 0.00040455803
in O 0 9.6122036e-05
the O 0 9.789335e-05
hippocampus O 0 0.0033674238
and O 0 0.00013945617
piriform O 0 0.0023487527
cortex O 0 0.001840736
was O 0 0.000131245
evaluated O 0 8.1422055e-05
in O 0 0.000102471684
the O 0 0.00016468877
rat O 0 0.0006777327
fractionated O 0 0.0018316662
pilocarpine B-Chemical 1 0.9998995
model O 0 0.0038324345
. O 0 0.0023514626

Treatment O 0 0.004311088
with O 0 0.001661045
150 O 0 0.0019008223
mg O 0 0.022540214
/ O 0 0.002678559
kg O 0 0.003718386
PDTC B-Chemical 1 0.9999609
before O 0 0.00016079308
and O 0 0.0001797323
following O 0 0.00011500836
status B-Disease 0 0.00024165105
epilepticus I-Disease 0 0.97229296
significantly O 0 0.00031859646
increased O 0 0.00031151978
the O 0 0.00023856922
mortality O 0 0.0021141698
rate O 0 0.00041547592
to O 0 0.0004830175
100 O 0 0.0018395897
% O 0 0.0016968539
. O 0 0.0020706889

Administration O 0 0.007076412
of O 0 0.0019012891
50 O 0 0.0019158564
mg O 0 0.03030912
/ O 0 0.0033279047
kg O 0 0.006906954
PDTC B-Chemical 1 0.99998415
( O 0 0.0016051893
low O 0 0.0011649915
- O 0 0.0007619714
dose O 0 0.0015805141
) O 0 0.0003036712
did O 0 0.00011750086
not O 0 6.796084e-05
exert O 0 5.396969e-05
major O 0 5.978755e-05
effects O 0 7.990431e-05
on O 0 4.5081724e-05
the O 0 7.932821e-05
development O 0 0.00017742171
of O 0 0.00017609583
a O 0 0.00027183926
status B-Disease 0 0.0002970307
epilepticus I-Disease 0 0.9786427
or O 0 0.00033376875
the O 0 0.0005053412
mortality O 0 0.005797797
rate O 0 0.0017095845
. O 0 0.0019621667

In O 0 0.0023560086
vehicle O 0 0.0067674527
- O 0 0.0026082958
treated O 0 0.0012179498
rats O 0 0.0010539283
, O 0 0.00055113144
status B-Disease 0 0.00045272373
epilepticus I-Disease 0 0.97675407
caused O 0 0.00041064632
pronounced O 0 0.00071502116
neuronal B-Disease 0 0.57595384
damage I-Disease 0 0.90369844
in O 0 0.00015848878
the O 0 0.00013326488
piriform O 0 0.0018485817
cortex O 0 0.0013712685
comprising O 0 0.00017735524
both O 0 0.00027782135
pyramidal O 0 0.06780167
cells O 0 0.0011124623
and O 0 0.0012822669
interneurons O 0 0.0143387
. O 0 0.0024262706

Low O 0 0.02074213
- O 0 0.0056285756
dose O 0 0.03318809
PDTC B-Chemical 1 0.99995685
treatment O 0 0.001726938
almost O 0 0.0006881016
completely O 0 0.00060770713
protected O 0 0.00056416256
from O 0 0.00037655458
lesions O 0 0.0030871492
in O 0 0.00046702943
the O 0 0.00073666894
piriform O 0 0.014405897
cortex O 0 0.023662472
. O 0 0.0029552968

A O 0 0.018505493
significant O 0 0.0017111998
decrease O 0 0.0012505822
in O 0 0.00065085187
neuronal O 0 0.0025584726
density O 0 0.0006875778
of O 0 0.0002839383
the O 0 0.00020456678
hippocampal O 0 0.097944595
hilar O 0 0.5908408
formation O 0 0.0012636863
was O 0 0.00015429787
identified O 0 8.274802e-05
in O 0 0.00010170071
vehicle O 0 0.0009825713
- O 0 0.000528532
and O 0 0.0005517535
PDTC B-Chemical 1 0.99999464
- O 0 0.001982197
treated O 0 0.0005356126
rats O 0 0.00048790875
following O 0 0.00033026136
status B-Disease 0 0.00101928
epilepticus I-Disease 0 0.9923868
. O 0 0.0024397867

In O 0 0.002111997
conclusion O 0 0.001604814
, O 0 0.0015132524
the O 0 0.0011747456
NF O 0 0.79357517
- O 0 0.0013425306
kappaB O 0 0.0035394346
inhibitor O 0 0.0036737167
and O 0 0.0010960507
antioxidant O 0 0.9998148
PDTC B-Chemical 1 0.99999654
protected O 0 0.0012095481
the O 0 0.00024774089
piriform O 0 0.012690106
cortex O 0 0.00925997
, O 0 0.00021564613
whereas O 0 0.00015144487
it O 0 0.00016356511
did O 0 0.00018262936
not O 0 0.00018905055
affect O 0 0.00024843204
hilar O 0 0.5741852
neuronal B-Disease 0 0.79743445
loss I-Disease 0 0.33950073
. O 0 0.0030909642

These O 0 0.0021369378
data O 0 0.0013380552
might O 0 0.00052377395
indicate O 0 0.00030469985
that O 0 0.00024173586
the O 0 0.00028275696
generation O 0 0.00040536388
of O 0 0.000462351
reactive O 0 0.036289047
oxygen B-Chemical 1 0.9963522
species O 0 0.0003054721
and O 0 0.000124913
activation O 0 0.00017160345
of O 0 0.00033171944
NF O 0 0.9113971
- O 0 0.0003939303
kappaB O 0 0.000929531
plays O 0 6.4104854e-05
a O 0 9.425314e-05
more O 0 8.6730746e-05
central O 0 8.267948e-05
role O 0 4.4858127e-05
in O 0 0.00013027036
seizure B-Disease 0 0.999305
- O 0 0.00052448467
associated O 0 0.00015541285
neuronal B-Disease 0 0.4758455
damage I-Disease 0 0.8782547
in O 0 0.00010412809
the O 0 8.281369e-05
temporal O 0 0.00039258707
cortex O 0 0.002157389
as O 0 0.00013986809
compared O 0 0.00011473539
to O 0 0.00021553165
the O 0 0.0005010518
hippocampal O 0 0.24760899
hilus O 0 0.08936492
. O 0 0.0024921957

However O 0 0.0028191977
, O 0 0.0019365066
future O 0 0.0009957422
investigations O 0 0.0008497386
are O 0 0.00032936898
necessary O 0 0.00015072382
to O 0 0.00014375646
exactly O 0 0.00010255028
analyze O 0 7.172006e-05
the O 0 0.00011010951
biochemical O 0 0.00036704118
mechanisms O 0 0.00016819635
by O 0 0.00017255823
which O 0 0.0005397345
PDTC B-Chemical 1 0.9999914
exerted O 0 0.0015449191
its O 0 0.00061262824
beneficial O 0 0.00036216652
effects O 0 0.0003025197
in O 0 0.00031498374
the O 0 0.000556408
piriform O 0 0.019955158
cortex O 0 0.029103486
. O 0 0.0024323747

Anaesthetists O 0 0.012371008
' O 0 0.0031627724
nightmare O 0 0.006177964
: O 0 0.0020712644
masseter B-Disease 0 0.4020937
spasm I-Disease 2 0.99941885
after O 0 0.0002714342
induction O 0 0.00046343092
in O 0 0.000358725
an O 0 0.00066656765
undiagnosed O 0 0.008770378
case O 0 0.0009095052
of O 0 0.004167269
myotonia B-Disease 0 0.9998336
congenita I-Disease 0 0.887286
. O 0 0.0039040912

We O 0 0.001627914
report O 0 0.0017867439
an O 0 0.0014463264
undiagnosed O 0 0.006289778
case O 0 0.00067080744
of O 0 0.002246433
myotonia B-Disease 0 0.9999285
congenita I-Disease 0 0.43495157
in O 0 0.0002540089
a O 0 0.00023328216
24 O 0 0.00010475943
- O 0 0.00020072875
year O 0 6.517051e-05
- O 0 0.00013468946
old O 0 7.350276e-05
previously O 0 6.9384674e-05
healthy O 0 0.0004512911
primigravida O 0 0.0007152086
, O 0 0.00010193936
who O 0 0.00011082147
developed O 0 0.000108165645
life O 0 0.00013111753
threatening O 0 0.00072260835
masseter B-Disease 0 0.6624159
spasm I-Disease 2 0.9998778
following O 0 6.725239e-05
a O 0 8.643681e-05
standard O 0 5.5110137e-05
dose O 0 0.00027101065
of O 0 0.00023731103
intravenous O 0 0.12121468
suxamethonium B-Chemical 0 0.99962854
for O 0 0.00027524395
induction O 0 0.0005981857
of O 0 0.0013644471
anaesthesia O 0 0.037381448
. O 0 0.0020376989

Neither O 0 0.002274432
the O 0 0.001434101
patient O 0 0.0010624495
nor O 0 0.00057938776
the O 0 0.00048297658
anaesthetist O 0 0.00085480115
was O 0 0.00030002967
aware O 0 0.00019507614
of O 0 0.00024032418
the O 0 0.00020835616
diagnosis O 0 0.00035417086
before O 0 9.5286174e-05
this O 0 0.00027742248
potentially O 0 0.00061452517
lethal O 0 0.008966583
complication O 0 0.09056664
occurred O 0 0.0020675382
. O 0 0.0023071659

Twin O 0 0.010082625
preterm O 0 0.010268364
neonates O 0 0.0027967426
with O 0 0.0016034037
cardiac B-Disease 0 0.8867611
toxicity I-Disease 2 0.9996136
related O 0 0.00041657072
to O 0 0.0007494578
lopinavir B-Chemical 0 0.9902312
/ I-Chemical 0 0.016162181
ritonavir I-Chemical 0 0.99965334
therapy O 0 0.0080813635
. O 0 0.003169242

We O 0 0.0016312305
report O 0 0.00206531
twin O 0 0.007510361
neonates O 0 0.0018913003
who O 0 0.00072297617
were O 0 0.0002873416
born O 0 0.0003634778
prematurely O 0 0.00066683954
at O 0 8.915272e-05
32 O 0 0.00011987785
weeks O 0 3.6297748e-05
of O 0 9.3461065e-05
gestation O 0 0.00014236831
to O 0 0.0001045671
a O 0 0.00023430555
mother O 0 0.0007616407
with O 0 0.00051910715
human B-Disease 0 0.005701032
immunodeficiency I-Disease 0 0.9997013
virus I-Disease 0 0.5533759
infection I-Disease 0 0.32346725
. O 0 0.0033883725

One O 0 0.0020628467
of O 0 0.0014914037
the O 0 0.0009957895
twins O 0 0.0042054
developed O 0 0.00063296314
complete O 0 0.0003650495
heart B-Disease 0 0.008539525
block I-Disease 0 0.0003534967
and O 0 0.00047339336
dilated B-Disease 0 0.9994438
cardiomyopathy I-Disease 0 0.99999666
related O 0 8.7705324e-05
to O 0 0.00014695064
lopinavir B-Chemical 0 0.96902496
/ I-Chemical 0 0.0041106753
ritonavir I-Chemical 0 0.9998348
therapy O 0 0.0004101066
, O 0 0.00013217538
a O 0 0.00013214274
boosted O 0 0.00018086609
protease O 0 0.0034152598
- O 0 0.00039780486
inhibitor O 0 0.0011599191
agent O 0 0.0017255864
, O 0 0.00020248997
while O 0 0.00013132174
the O 0 0.00015803275
other O 0 0.0002434122
twin O 0 0.0122662075
developed O 0 0.0022273997
mild O 0 0.9024997
bradycardia B-Disease 0 0.99916697
. O 0 0.003336133

We O 0 0.0016396146
recommend O 0 0.0010864928
caution O 0 0.0006931194
in O 0 0.00047070257
the O 0 0.00036926032
use O 0 0.00032030832
of O 0 0.00067811646
lopinavir B-Chemical 0 0.9887002
/ I-Chemical 0 0.008833304
ritonavir I-Chemical 0 0.9995819
in O 0 0.00046290064
the O 0 0.00042025116
immediate O 0 0.00091568584
neonatal O 0 0.002086794
period O 0 0.00088958105
. O 0 0.0019347123

When O 0 0.0019227262
drugs O 0 0.010281021
disappear O 0 0.0014765544
from O 0 0.00052679837
the O 0 0.00044653326
patient O 0 0.00043768345
: O 0 0.00039421435
elimination O 0 0.00046395732
of O 0 0.0005998408
intravenous O 0 0.018299969
medication O 0 0.0067458777
by O 0 0.001591847
hemodiafiltration O 0 0.123610616
. O 0 0.002788487

Twenty O 0 0.0037932536
- O 0 0.0019397424
three O 0 0.00035516222
hours O 0 0.00025500933
after O 0 0.00018108283
heart O 0 0.0058086473
transplantation O 0 0.00323473
, O 0 0.00035815925
life O 0 0.00034723504
- O 0 0.0003921988
threatening O 0 0.0007284609
acute O 0 0.31977993
right B-Disease 0 0.04697182
heart I-Disease 0 0.4275879
failure I-Disease 0 0.8424576
was O 0 0.00027498248
diagnosed O 0 0.00038885808
in O 0 6.741715e-05
a O 0 9.936436e-05
patient O 0 8.5766005e-05
requiring O 0 8.6713466e-05
continuous O 0 0.00012021233
venovenous O 0 0.0010421446
hemodiafiltration O 0 0.017383272
( O 0 0.0010668326
CVVHDF O 0 0.14647433
) O 0 0.0021903797
. O 0 0.0019984657

Increasing O 0 0.0032012754
doses O 0 0.007011981
of O 0 0.002846038
catecholamines B-Chemical 0 0.9993318
, O 0 0.0025010281
sedatives O 0 0.9526024
, O 0 0.000510203
and O 0 0.00035723922
muscle O 0 0.0033458474
relaxants O 0 0.26455322
administered O 0 0.00020189656
through O 0 0.000110289424
a O 0 0.0002201821
central O 0 0.0003669154
venous O 0 0.010314787
catheter O 0 0.00063809793
were O 0 0.00070433813
ineffective O 0 0.0030647658
. O 0 0.002215931

However O 0 0.0028034025
, O 0 0.0019942874
a O 0 0.0013732107
bolus O 0 0.002868169
of O 0 0.001265226
epinephrine B-Chemical 0 0.9910193
injected O 0 0.0004060123
through O 0 0.00019303325
an O 0 0.00026123092
alternative O 0 0.0002276577
catheter O 0 0.00049640826
provoked O 0 0.0020318872
a O 0 0.0023972301
hypertensive B-Disease 2 0.9993716
crisis O 0 0.4505325
. O 0 0.0033132222

Thus O 0 0.0025866649
, O 0 0.001986473
interference O 0 0.001204401
with O 0 0.0007806642
the O 0 0.00051422557
central O 0 0.00073035195
venous O 0 0.02749947
infusion O 0 0.0008628042
by O 0 0.00035530407
the O 0 0.0003757936
dialysis O 0 0.002005842
catheter O 0 0.00097252673
was O 0 0.0011768478
suspected O 0 0.004513429
. O 0 0.0025680768

The O 0 0.002054422
catheters O 0 0.0026527315
were O 0 0.001086967
changed O 0 0.00085564295
, O 0 0.0007952686
and O 0 0.00072680536
hemodynamics O 0 0.0664873
stabilized O 0 0.0013294314
at O 0 0.00057872984
lower O 0 0.0020802487
catecholamine B-Chemical 0 0.99870133
doses O 0 0.049360108
. O 0 0.0037056096

When O 0 0.0012365957
the O 0 0.0010179603
effects O 0 0.0009009256
of O 0 0.0010876942
IV O 0 0.056679837
drugs O 0 0.012544159
are O 0 0.00021534531
inadequate O 0 0.00019208237
in O 0 0.000125816
patients O 0 0.00021489694
receiving O 0 0.00034238547
CVVHDF O 0 0.11527836
, O 0 0.0001017853
interference O 0 9.865043e-05
with O 0 8.935171e-05
adjacent O 0 7.592163e-05
catheters O 0 0.000120694516
resulting O 0 6.157633e-05
in O 0 5.5173445e-05
elimination O 0 0.00011841985
of O 0 0.00012560753
the O 0 0.00015087755
drug O 0 0.0039341105
by O 0 0.0003842468
CVVHDF O 0 0.070067644
should O 0 0.0002824878
be O 0 0.00063245295
suspected O 0 0.0032640393
. O 0 0.0020104186

Less O 0 0.033832315
frequent O 0 0.0076950784
lithium B-Chemical 0 0.9991861
administration O 0 0.017696485
and O 0 0.0027041717
lower O 0 0.0035183611
urine O 0 0.20007566
volume O 0 0.008704963
. O 0 0.004980488

OBJECTIVE O 0 0.025205575
: O 0 0.0024723148
This O 0 0.0016072586
study O 0 0.0008706328
was O 0 0.00045589937
designed O 0 0.00026294435
to O 0 0.00015637133
determine O 0 6.927705e-05
whether O 0 6.163127e-05
patients O 0 0.00014034289
maintained O 0 8.1488695e-05
on O 0 4.3652868e-05
a O 0 0.00010244131
regimen O 0 0.00015023268
of O 0 0.00024293504
lithium B-Chemical 0 0.99986506
on O 0 7.395132e-05
a O 0 0.00013207195
once O 0 5.9247122e-05
- O 0 0.00012156796
per O 0 2.4825704e-05
- O 0 8.011015e-05
day O 0 2.6879845e-05
schedule O 0 4.1205676e-05
have O 0 3.4806926e-05
lower O 0 8.996705e-05
urine O 0 0.0066113514
volumes O 0 0.00017477582
than O 0 5.5198074e-05
do O 0 8.792682e-05
patients O 0 0.0001563934
receiving O 0 0.00020346616
multiple O 0 0.00025711674
doses O 0 0.0009825985
per O 0 0.00024296212
day O 0 0.0006027101
. O 0 0.0013788902

METHOD O 0 0.0065576537
: O 0 0.002398243
This O 0 0.0016931179
was O 0 0.00090152235
a O 0 0.00072379515
cross O 0 0.0007945222
- O 0 0.00065825006
sectional O 0 0.00069480424
study O 0 0.00021683496
of O 0 0.00018373234
85 O 0 0.00022822013
patients O 0 0.00014792956
from O 0 9.4412186e-05
a O 0 0.00030820933
lithium B-Chemical 0 0.9997688
clinic O 0 0.0005075949
who O 0 0.00030260131
received O 0 0.0001706492
different O 0 0.00023330684
dose O 0 0.0017408394
schedules O 0 0.0015078252
. O 0 0.0018133516

Patients O 0 0.0023524782
were O 0 0.0011805812
admitted O 0 0.0010948412
to O 0 0.00037279085
the O 0 0.00030713517
hospital O 0 0.0003445876
for O 0 0.00011851394
measurement O 0 0.00010661099
of O 0 0.00036774308
lithium B-Chemical 0 0.9998412
level O 0 0.00027674885
, O 0 0.00045726117
creatinine B-Chemical 1 0.998949
clearance O 0 0.03261168
, O 0 0.00040842046
urine O 0 0.043981105
volume O 0 0.0007230533
, O 0 0.00039253675
and O 0 0.0004488897
maximum O 0 0.0008698554
osmolality O 0 0.45975348
. O 0 0.0026310747

RESULTS O 0 0.0048829117
: O 0 0.0019598783
Multiple O 0 0.0013547647
daily O 0 0.0010185742
doses O 0 0.0022463952
of O 0 0.0012352372
lithium B-Chemical 0 0.999686
were O 0 0.00062474026
associated O 0 0.0003938706
with O 0 0.0005955683
higher O 0 0.001057164
urine O 0 0.15006459
volumes O 0 0.004282214
. O 0 0.00266298

The O 0 0.0015032608
dosing O 0 0.0020705312
schedule O 0 0.0008245799
, O 0 0.0005308523
duration O 0 0.00020537843
of O 0 0.00062873453
lithium B-Chemical 0 0.99985397
treatment O 0 0.0005047093
, O 0 0.00022119272
and O 0 0.00012988348
daily O 0 0.00016222373
dose O 0 0.0005055896
of O 0 0.0003917112
lithium B-Chemical 0 0.9999106
did O 0 0.00021110696
not O 0 8.843429e-05
affect O 0 6.2161365e-05
maximum O 0 0.00017984357
osmolality O 0 0.24859269
or O 0 0.00085581216
creatinine B-Chemical 1 0.9988381
clearance O 0 0.14982739
. O 0 0.002684152

CONCLUSIONS O 0 0.014768526
: O 0 0.0027210694
Urine O 0 0.013558309
volume O 0 0.0015498484
can O 0 0.00039467364
be O 0 0.0002930156
reduced O 0 0.00038444472
by O 0 0.0002819717
giving O 0 0.0008421952
lithium B-Chemical 0 0.99974805
once O 0 0.00015593819
daily O 0 0.00020029859
and O 0 0.00014487178
/ O 0 0.00034484031
or O 0 0.00012173513
by O 0 0.00017934934
lowering O 0 0.0013359834
the O 0 0.00025704957
total O 0 0.0004488619
daily O 0 0.0010627325
dose O 0 0.004374274
. O 0 0.002113688

Lithium B-Chemical 0 0.9995746
- O 0 0.009966132
induced O 0 0.0035497518
polyuria B-Disease 0 0.9979055
seems O 0 0.0006612678
to O 0 0.00036255983
be O 0 0.00022485135
related O 0 0.000116291776
to O 0 0.00023314674
extrarenal O 0 0.28963855
as O 0 0.0003250876
well O 0 0.00026086354
as O 0 0.00035596505
to O 0 0.000598168
renal O 0 0.8218439
effects O 0 0.0035671801
. O 0 0.0029109851

Antibacterial O 0 0.014049914
medication O 0 0.0064092395
use O 0 0.0008806536
during O 0 0.00042051965
pregnancy O 0 0.0021397115
and O 0 0.00054185616
risk O 0 0.0016890158
of O 0 0.0004984347
birth B-Disease 0 0.0009890943
defects I-Disease 0 0.0014155295
: O 0 0.0006360117
National O 0 0.0010089575
Birth B-Disease 0 0.005354931
Defects I-Disease 0 0.0046097166
Prevention O 0 0.0018689433
Study O 0 0.0029791652
. O 0 0.0024105613

OBJECTIVE O 0 0.024727039
: O 0 0.0023414164
To O 0 0.0008342114
estimate O 0 0.00056639104
the O 0 0.000507644
association O 0 0.00030985745
between O 0 0.0002972154
antibacterial O 0 0.0040893336
medications O 0 0.00794281
and O 0 0.00072759954
selected O 0 0.0008821116
birth B-Disease 0 0.003033878
defects I-Disease 0 0.007197044
. O 0 0.0032385236

DESIGN O 0 0.0052247727
, O 0 0.003147074
SETTING O 0 0.0021582597
, O 0 0.0010074504
AND O 0 0.00050406123
PARTICIPANTS O 0 0.0006059371
: O 0 0.00047139812
Population O 0 0.0007887081
- O 0 0.00048450512
based O 0 0.00019780907
, O 0 0.00025350804
multisite O 0 0.00046934592
, O 0 0.00021149499
case O 0 0.00014654557
- O 0 0.00019498689
control O 0 7.7292054e-05
study O 0 9.4403185e-05
of O 0 0.00012388574
women O 0 0.00033078532
who O 0 0.00015226385
had O 0 0.00010018153
pregnancies O 0 0.0033259506
affected O 0 0.00012499306
by O 0 7.638975e-05
1 O 0 4.478708e-05
of O 0 5.4750944e-05
more O 0 6.583815e-05
than O 0 3.0857587e-05
30 O 0 3.2322583e-05
eligible O 0 5.6705147e-05
major O 0 4.3163825e-05
birth B-Disease 0 0.00014485036
defects I-Disease 0 0.00020938797
identified O 0 5.178647e-05
via O 0 3.626837e-05
birth B-Disease 0 0.00014208407
defect I-Disease 0 0.0001085616
surveillance O 0 5.123277e-05
programs O 0 6.935015e-05
in O 0 5.7356847e-05
10 O 0 5.93248e-05
states O 0 0.0001063322
( O 0 0.0001091539
n O 0 6.893613e-05
= O 0 8.7339016e-05
13 O 0 6.969914e-05
155 O 0 0.00020185595
) O 0 9.5992145e-05
and O 0 5.306779e-05
control O 0 5.63563e-05
women O 0 0.00010735795
randomly O 0 1.894093e-05
selected O 0 3.955514e-05
from O 0 4.204312e-05
the O 0 5.577695e-05
same O 0 4.8349237e-05
geographical O 0 0.00012700791
regions O 0 0.00017336484
( O 0 0.00034898313
n O 0 0.0003687079
= O 0 0.0008334891
4941 O 0 0.003890688
) O 0 0.0020963745
. O 0 0.0021327895

MAIN O 0 0.010330331
EXPOSURE O 0 0.004309402
: O 0 0.0014197362
Reported O 0 0.0008745852
maternal O 0 0.00073911244
use O 0 0.0003600859
of O 0 0.0005292956
antibacterials O 0 0.34690046
( O 0 0.00042827823
1 O 0 0.00011816661
month O 0 5.3945758e-05
before O 0 4.8386322e-05
pregnancy O 0 0.00033031107
through O 0 7.88442e-05
the O 0 0.00010455933
end O 0 8.6288564e-05
of O 0 0.00023202087
the O 0 0.00031303632
first O 0 0.0004729563
trimester O 0 0.05139249
) O 0 0.0029895795
. O 0 0.002430293

MAIN O 0 0.010321954
OUTCOME O 0 0.003458608
MEASURE O 0 0.0028750845
: O 0 0.0013702608
Odds O 0 0.0014308392
ratios O 0 0.00067213405
( O 0 0.0006567896
ORs O 0 0.0007932018
) O 0 0.00030434155
measuring O 0 0.00011494642
the O 0 0.00011357783
association O 0 7.5598124e-05
between O 0 7.405992e-05
antibacterial O 0 0.0009663008
use O 0 0.00013548821
and O 0 0.00013850599
selected O 0 0.00015181674
birth B-Disease 0 0.00045974815
defects I-Disease 0 0.0007121378
adjusted O 0 0.00026533328
for O 0 0.00030589642
potential O 0 0.00083708676
confounders O 0 0.0015203513
. O 0 0.0019654806

RESULTS O 0 0.004767963
: O 0 0.0017858748
The O 0 0.000691612
reported O 0 0.0007189808
use O 0 0.00047104098
of O 0 0.00063451385
antibacterials O 0 0.13772218
increased O 0 0.0006467979
during O 0 0.00020431317
pregnancy O 0 0.0022156222
, O 0 0.00037017022
peaking O 0 0.00086564024
during O 0 0.00019096478
the O 0 0.00041848337
third O 0 0.0008899027
month O 0 0.0008427347
. O 0 0.0018590983

Sulfonamides B-Chemical 0 0.97201896
were O 0 0.0019018531
associated O 0 0.0010288811
with O 0 0.001819613
anencephaly B-Disease 2 0.9991517
( O 0 0.0014642898
adjusted O 0 0.000673399
OR O 0 0.041352686
[ O 0 0.0020889041
AOR O 0 0.20089778
] O 0 0.00071034906
= O 0 0.00021945125
3 O 0 9.1135495e-05
. O 0 6.919253e-05
4 O 0 7.785856e-05
; O 0 0.00012048408
95 O 0 0.00013777899
% O 0 0.00010396955
confidence O 0 0.00037463056
interval O 0 0.00012123341
[ O 0 0.00049393985
CI O 0 0.018425457
] O 0 0.00035366495
, O 0 0.00012685105
1 O 0 7.865878e-05
. O 0 5.3693147e-05
3 O 0 6.511294e-05
- O 0 0.00013916193
8 O 0 5.9642178e-05
. O 0 4.7834397e-05
8 O 0 6.1184866e-05
) O 0 0.00012604489
, O 0 0.00012175382
hypoplastic B-Disease 0 0.06891507
left I-Disease 0 0.00075173745
heart I-Disease 0 0.17701851
syndrome I-Disease 0 0.3503259
( O 0 0.0006005647
AOR O 0 0.0905559
= O 0 0.0001483143
3 O 0 5.8079968e-05
. O 0 4.66043e-05
2 O 0 6.305524e-05
; O 0 0.0001006157
95 O 0 0.00014030287
% O 0 0.00013785665
CI O 0 0.0027875847
, O 0 0.00012512795
1 O 0 7.760667e-05
. O 0 5.3943237e-05
3 O 0 6.587475e-05
- O 0 0.00013911139
7 O 0 5.5249056e-05
. O 0 4.815175e-05
6 O 0 4.9971444e-05
) O 0 0.000121134035
, O 0 0.00011570068
coarctation B-Disease 0 0.027287576
of I-Disease 0 0.000124084
the I-Disease 0 0.00013122748
aorta I-Disease 0 0.046602856
( O 0 0.0004530043
AOR O 0 0.06243955
= O 0 0.00016079615
2 O 0 6.929811e-05
. O 0 4.9665014e-05
7 O 0 5.792344e-05
; O 0 0.000105401225
95 O 0 0.00014782691
% O 0 0.00014516244
CI O 0 0.0029637178
, O 0 0.00013022614
1 O 0 8.034533e-05
. O 0 5.565899e-05
3 O 0 6.751237e-05
- O 0 0.00014147542
5 O 0 5.974555e-05
. O 0 5.2283816e-05
6 O 0 5.607914e-05
) O 0 0.00014267095
, O 0 0.00015302449
choanal B-Disease 0 0.023175098
atresia I-Disease 0 0.3632707
( O 0 0.00082585687
AOR O 0 0.14472519
= O 0 0.0001810837
8 O 0 6.775681e-05
. O 0 5.0582068e-05
0 O 0 7.160545e-05
; O 0 0.00011252655
95 O 0 0.00015104077
% O 0 0.00014506571
CI O 0 0.0026340804
, O 0 0.00012722926
2 O 0 7.473475e-05
. O 0 5.2559462e-05
7 O 0 6.135945e-05
- O 0 0.00014992787
23 O 0 0.000118338794
. O 0 5.307103e-05
5 O 0 6.0509457e-05
) O 0 0.0001277872
, O 0 0.000117848824
transverse B-Disease 0 0.0011010016
limb I-Disease 0 0.16546904
deficiency I-Disease 0 0.9854778
( O 0 0.0012328833
AOR O 0 0.23121887
= O 0 0.0001956137
2 O 0 7.447344e-05
. O 0 5.0710445e-05
5 O 0 6.072218e-05
; O 0 0.00010835631
95 O 0 0.00014954864
% O 0 0.00014484042
CI O 0 0.0027557397
, O 0 0.00012479919
1 O 0 7.540818e-05
. O 0 5.206534e-05
0 O 0 7.5567485e-05
- O 0 0.00014879563
5 O 0 6.059053e-05
. O 0 5.2972937e-05
9 O 0 7.074699e-05
) O 0 0.00012686424
, O 0 0.00010217701
and O 0 0.0001502834
diaphragmatic B-Disease 0 0.56159127
hernia I-Disease 0 0.8946801
( O 0 0.0009514966
AOR O 0 0.19300419
= O 0 0.00019492202
2 O 0 7.720145e-05
. O 0 5.5060438e-05
4 O 0 6.790934e-05
; O 0 0.00012147364
95 O 0 0.00017232294
% O 0 0.0001797023
CI O 0 0.0028522315
, O 0 0.00018834884
1 O 0 0.00013288915
. O 0 0.00011369226
1 O 0 0.00018448087
- O 0 0.00039783664
5 O 0 0.0002683761
. O 0 0.00036258798
4 O 0 0.0006820684
) O 0 0.0019328917
. O 0 0.0023431345

Nitrofurantoins B-Chemical 0 0.26123446
were O 0 0.0016915038
associated O 0 0.0009563814
with O 0 0.0017025854
anophthalmia B-Disease 0 0.9995216
or O 0 0.0024836962
microphthalmos B-Disease 0 0.9999187
( O 0 0.004446047
AOR O 0 0.40551284
= O 0 0.0003220341
3 O 0 0.00010395716
. O 0 7.3104595e-05
7 O 0 7.850478e-05
; O 0 0.0001348074
95 O 0 0.00017930388
% O 0 0.00017097335
CI O 0 0.0032806867
, O 0 0.0001456184
1 O 0 8.802138e-05
. O 0 5.9391252e-05
1 O 0 7.7517994e-05
- O 0 0.00013542443
12 O 0 4.6188532e-05
. O 0 4.951766e-05
2 O 0 6.601443e-05
) O 0 0.00012861971
, O 0 0.00012383117
hypoplastic B-Disease 0 0.0689846
left I-Disease 0 0.0007602839
heart I-Disease 0 0.17740992
syndrome I-Disease 0 0.34943336
( O 0 0.00060229906
AOR O 0 0.08583039
= O 0 0.0001471207
4 O 0 5.7452373e-05
. O 0 4.7281555e-05
2 O 0 6.416174e-05
; O 0 0.000102835336
95 O 0 0.00014363055
% O 0 0.0001417536
CI O 0 0.002765725
, O 0 0.00012939348
1 O 0 8.094756e-05
. O 0 5.7155157e-05
9 O 0 7.830889e-05
- O 0 0.00015857829
9 O 0 7.1621165e-05
. O 0 5.421947e-05
1 O 0 7.307149e-05
) O 0 0.00013335387
, O 0 0.00013613937
atrial B-Disease 0 0.46741125
septal I-Disease 0 0.0036777083
defects I-Disease 0 0.0063506546
( O 0 0.0005888795
AOR O 0 0.09928372
= O 0 0.0001752379
1 O 0 7.621003e-05
. O 0 5.322439e-05
9 O 0 7.081403e-05
; O 0 0.00010963824
95 O 0 0.00015069438
% O 0 0.00014618284
CI O 0 0.0030033418
, O 0 0.00013073126
1 O 0 8.096424e-05
. O 0 5.6312845e-05
1 O 0 7.791678e-05
- O 0 0.0001500752
3 O 0 6.020154e-05
. O 0 4.9046706e-05
4 O 0 5.930862e-05
) O 0 0.00011943036
, O 0 9.668389e-05
and O 0 0.000125955
cleft B-Disease 0 0.0024652435
lip I-Disease 0 0.0049990723
with O 0 0.00035195463
cleft B-Disease 0 0.045073703
palate I-Disease 0 0.2399182
( O 0 0.0010239576
AOR O 0 0.25258547
= O 0 0.00022294119
2 O 0 8.591778e-05
. O 0 6.0995528e-05
1 O 0 8.421034e-05
; O 0 0.00013092214
95 O 0 0.00018103309
% O 0 0.00018463291
CI O 0 0.0028653354
, O 0 0.00018932132
1 O 0 0.0001333076
. O 0 0.00011499235
2 O 0 0.00018219957
- O 0 0.00041780874
3 O 0 0.0002855539
. O 0 0.00037725002
9 O 0 0.00079046574
) O 0 0.00199051
. O 0 0.0023883565

Other O 0 0.003200764
antibacterial O 0 0.0064588706
agents O 0 0.0026826719
that O 0 0.00043903152
showed O 0 0.0003795776
associations O 0 0.00023336738
included O 0 0.00036007733
erythromycins B-Chemical 0 0.99785906
( O 0 0.00055612065
2 O 0 0.00016640109
defects O 0 0.0006658803
) O 0 0.00040132113
, O 0 0.00033677457
penicillins B-Chemical 0 0.9947025
( O 0 0.00039941847
1 O 0 0.00012576995
defect O 0 0.00027992422
) O 0 0.00030291796
, O 0 0.00028822944
cephalosporins B-Chemical 1 0.9942662
( O 0 0.00038516594
1 O 0 0.00014157339
defect O 0 0.0003196887
) O 0 0.000327406
, O 0 0.00026484093
and O 0 0.00041780935
quinolones B-Chemical 0 0.9633834
( O 0 0.0010498937
1 O 0 0.0006389937
defect O 0 0.0017158213
) O 0 0.0025335588
. O 0 0.0024313754

CONCLUSIONS O 0 0.016150637
: O 0 0.003023718
Reassuringly O 0 0.004106123
, O 0 0.0019560189
penicillins B-Chemical 0 0.9962836
, O 0 0.0024614376
erythromycins B-Chemical 0 0.99886763
, O 0 0.0008461423
and O 0 0.00065499183
cephalosporins B-Chemical 1 0.9983192
, O 0 0.0003893618
although O 0 0.00013463359
used O 0 0.00010668829
commonly O 0 0.00016019563
by O 0 0.00017572747
pregnant O 0 0.0015654222
women O 0 0.00048214677
, O 0 0.00014039496
were O 0 0.00010938397
not O 0 0.00010842751
associated O 0 0.00016985604
with O 0 0.00034154585
many O 0 0.0004752113
birth B-Disease 0 0.0020180475
defects I-Disease 0 0.0054943217
. O 0 0.002361799

Sulfonamides B-Chemical 0 0.987655
and O 0 0.0035511993
nitrofurantoins B-Chemical 0 0.34860042
were O 0 0.0008383543
associated O 0 0.00041914292
with O 0 0.00041329858
several O 0 0.00026532618
birth B-Disease 0 0.0008283979
defects I-Disease 0 0.0012718429
, O 0 0.0004134609
indicating O 0 0.0002355478
a O 0 0.0004163051
need O 0 0.00032518955
for O 0 0.00041497778
additional O 0 0.0007828586
scrutiny O 0 0.0045012636
. O 0 0.00247367

Differential O 0 0.0028154536
impact O 0 0.00085390406
of O 0 0.0011646671
immune O 0 0.00512617
escape O 0 0.003177666
mutations O 0 0.038452208
G145R O 0 0.988992
and O 0 0.0006548651
P120T O 0 0.046784315
on O 0 9.192908e-05
the O 0 0.00012277979
replication O 0 0.00075593777
of O 0 0.00072482566
lamivudine B-Chemical 1 0.9999622
- O 0 0.0019120349
resistant O 0 0.0029256814
hepatitis B-Chemical 2 0.9999994
B I-Chemical 2 0.9996371
virus I-Chemical 0 0.07220376
e I-Chemical 0 0.0007378134
antigen I-Chemical 0 0.0026548642
- O 0 0.0006126942
positive O 0 0.00042201916
and O 0 0.00048823157
- O 0 0.0009074204
negative O 0 0.0011275079
strains O 0 0.0016337842
. O 0 0.0021884972

Immune O 0 0.015019036
escape O 0 0.0035937289
variants O 0 0.0016256254
of O 0 0.0012317606
the O 0 0.0025408983
hepatitis B-Disease 2 0.99999714
B I-Disease 2 0.99961734
virus O 0 0.37044156
( O 0 0.0032243505
HBV O 0 0.99681026
) O 0 0.00050055195
represent O 0 9.991707e-05
an O 0 0.00011977273
emerging O 0 9.736428e-05
clinical O 0 0.0003007617
challenge O 0 9.527426e-05
, O 0 0.00011461729
because O 0 5.5995188e-05
they O 0 6.5844746e-05
can O 0 5.3500815e-05
be O 0 5.8606405e-05
associated O 0 6.329737e-05
with O 0 0.00011806456
vaccine O 0 0.00020906521
escape O 0 0.00090454926
, O 0 0.00044802122
HBV O 0 0.9920596
reactivation O 0 0.030819342
, O 0 0.00043501845
and O 0 0.00036870874
failure O 0 0.033702593
of O 0 0.00088492956
diagnostic O 0 0.0015437669
tests O 0 0.002840899
. O 0 0.0019545634

Recent O 0 0.0023313775
data O 0 0.0014980941
suggest O 0 0.0005331041
a O 0 0.0007028872
preferential O 0 0.0005153553
selection O 0 0.0004427662
of O 0 0.00042711772
immune O 0 0.0029790604
escape O 0 0.00083027553
mutants O 0 0.00019541683
in O 0 0.00012885258
distinct O 0 0.000101434554
peripheral O 0 0.00093373546
blood O 0 0.0019341938
leukocyte O 0 0.006987429
compartments O 0 0.00020377367
of O 0 0.00044720434
infected O 0 0.0006535863
individuals O 0 0.0020810093
. O 0 0.0020833076

We O 0 0.0014140892
therefore O 0 0.0010622224
systematically O 0 0.00059167284
analyzed O 0 0.00041121745
the O 0 0.00029601582
functional O 0 0.00022972259
impact O 0 0.00011265163
of O 0 0.00020644964
the O 0 0.00015697171
most O 0 0.00024975085
prevalent O 0 0.00021531944
immune O 0 0.0024473532
escape O 0 0.00081665756
variants O 0 0.00037168403
, O 0 0.00014455027
the O 0 0.0001264337
sG145R O 0 0.015459343
and O 0 0.00013020504
sP120T O 0 0.00047519413
mutants O 0 9.238465e-05
, O 0 7.3703224e-05
on O 0 3.0679545e-05
the O 0 5.281662e-05
viral O 0 0.00023979384
replication O 0 0.00052786624
efficacy O 0 0.00014466154
and O 0 0.000100175894
antiviral O 0 0.0014930817
drug O 0 0.008916612
susceptibility O 0 0.0002835304
of O 0 0.00012166387
common O 0 0.000106845684
treatment O 0 0.000108719694
- O 0 0.00015119727
associated O 0 5.2184045e-05
mutants O 0 6.8471636e-05
with O 0 0.000102592625
resistance O 0 0.00036876588
to O 0 0.00024389982
lamivudine B-Chemical 1 0.99993515
( O 0 0.0014995292
LAM B-Chemical 0 0.99757
) O 0 0.0006206757
and O 0 0.00035431588
/ O 0 0.0011524814
or O 0 0.0009767592
HBeAg B-Chemical 0 0.9997845
negativity O 0 0.57090217
. O 0 0.0033686052

Replication O 0 0.009814255
- O 0 0.003255193
competent O 0 0.0011285186
HBV O 0 0.87506104
strains O 0 0.0007566311
with O 0 0.0006855103
sG145R O 0 0.028249208
or O 0 0.000259768
sP120T O 0 0.0011419404
and O 0 0.0003540939
LAM B-Chemical 0 0.99033386
resistance O 0 0.0012506095
( O 0 0.00046840307
rtM204I O 0 0.92008334
or O 0 0.00026678367
rtL180M O 0 0.9960039
/ O 0 0.0028239123
rtM204V O 0 0.81466407
) O 0 0.00023555296
were O 0 6.614128e-05
generated O 0 3.9906212e-05
on O 0 4.7188496e-05
an O 0 0.00029527082
HBeAg B-Chemical 0 0.99995875
- O 0 0.00058736885
positive O 0 0.00017063196
and O 0 0.00014388784
an O 0 0.00044662497
HBeAg B-Chemical 0 0.9999683
- O 0 0.0005170773
negative O 0 0.00015749573
background O 0 0.00015890766
with O 0 0.00034737808
precore O 0 0.9361406
( O 0 0.0007278416
PC O 0 0.51323843
) O 0 0.0003474099
and O 0 0.00016169697
basal O 0 0.00026898066
core O 0 0.00019444237
promoter O 0 0.00039302933
( O 0 0.00086090225
BCP O 0 0.27013496
) O 0 0.0018529209
mutants O 0 0.001885314
. O 0 0.002529205

The O 0 0.0025656207
sG145R O 0 0.03600044
mutation O 0 0.007986347
strongly O 0 0.0015112091
reduced O 0 0.003738386
HBsAg B-Chemical 0 0.999652
levels O 0 0.00074887206
and O 0 0.00038827595
was O 0 0.00020754879
able O 0 9.5773066e-05
to O 0 9.4637435e-05
fully O 0 0.0001023264
restore O 0 6.815339e-05
the O 0 7.724151e-05
impaired O 0 0.0003315592
replication O 0 0.0010015555
of O 0 0.0005079568
LAM B-Chemical 0 0.99922943
- O 0 0.00056380295
resistant O 0 0.0002772062
HBV O 0 0.97217923
mutants O 0 0.00013654941
to O 0 7.107083e-05
the O 0 7.4189986e-05
levels O 0 8.906734e-05
of O 0 0.0001652711
wild O 0 0.00021439063
- O 0 0.00033579255
type O 0 0.000281682
HBV O 0 0.985508
, O 0 0.00029289717
and O 0 0.00026846107
PC O 0 0.25907326
or O 0 0.00028239246
BCP O 0 0.38696414
mutations O 0 0.0033441144
further O 0 0.0005765082
enhanced O 0 0.0009327644
viral O 0 0.005142626
replication O 0 0.015181861
. O 0 0.0027662695

Although O 0 0.0017409879
the O 0 0.001617811
sP120T O 0 0.004374579
substitution O 0 0.009867553
also O 0 0.0007897211
impaired O 0 0.014822908
HBsAg B-Chemical 0 0.99987686
secretion O 0 0.04770966
, O 0 0.0005288161
it O 0 0.00023514971
did O 0 0.00016600997
not O 0 9.897853e-05
enhance O 0 7.8062105e-05
the O 0 0.00015791286
replication O 0 0.0010721127
of O 0 0.0010185058
LAM B-Chemical 0 0.997869
- O 0 0.0017135262
resistant O 0 0.0012098863
clones O 0 0.002825035
. O 0 0.0024776596

However O 0 0.0026620354
, O 0 0.0017735257
the O 0 0.000911527
concomitant O 0 0.0013414249
occurrence O 0 0.00092436717
of O 0 0.001392301
HBeAg B-Chemical 0 0.99994504
negativity O 0 0.6006942
( O 0 0.001568822
PC O 0 0.6969224
/ O 0 0.0031385918
BCP O 0 0.7725499
) O 0 0.00058578496
, O 0 0.00022865116
sP120T O 0 0.0007902308
, O 0 0.00018468997
and O 0 0.00022509524
LAM B-Chemical 0 0.98290724
resistance O 0 0.00048135826
resulted O 0 0.00011525758
in O 0 7.928359e-05
the O 0 7.6671306e-05
restoration O 0 0.00015851765
of O 0 0.00016100096
replication O 0 0.00062773586
to O 0 0.00013218963
levels O 0 0.0002112451
of O 0 0.00043107738
wild O 0 0.0006836698
- O 0 0.0013457976
type O 0 0.001740195
HBV O 0 0.9832676
. O 0 0.0034446283

In O 0 0.0017881272
all O 0 0.0012279943
clones O 0 0.001133774
with O 0 0.00063565775
combined O 0 0.00064620085
immune O 0 0.0040667756
escape O 0 0.0015360006
and O 0 0.00058998633
LAM B-Chemical 0 0.9961366
resistance O 0 0.0016231091
mutations O 0 0.0037112776
, O 0 0.00018843308
the O 0 0.00015867932
nucleotide B-Chemical 0 0.17215346
analogues O 0 0.22772889
adefovir B-Chemical 0 0.9999546
and O 0 0.00052634586
tenofovir B-Chemical 0 0.99394834
remained O 0 0.00026958014
effective O 0 0.00010914454
in O 0 0.00012489632
suppressing O 0 0.0003014205
viral O 0 0.0016254475
replication O 0 0.0033052799
in O 0 0.0008217702
vitro O 0 0.0026056129
. O 0 0.0022228751

These O 0 0.0022220493
findings O 0 0.0018818437
reveal O 0 0.0007719356
the O 0 0.0004951634
differential O 0 0.00047025675
impact O 0 0.00017753967
of O 0 0.00033637346
immune O 0 0.0028188091
escape O 0 0.00083945546
variants O 0 0.00027649934
on O 0 6.2885236e-05
the O 0 9.617355e-05
replication O 0 0.00047588762
and O 0 0.0001271063
drug O 0 0.0024683857
susceptibility O 0 0.00025198702
of O 0 0.00013799634
complex O 0 0.00019063751
HBV O 0 0.98022914
mutants O 0 0.00019546697
, O 0 0.00012231948
supporting O 0 7.2944575e-05
the O 0 6.154165e-05
need O 0 4.261486e-05
of O 0 6.2393934e-05
close O 0 4.4126155e-05
surveillance O 0 4.8406815e-05
and O 0 6.410211e-05
treatment O 0 6.4958636e-05
adjustment O 0 5.128229e-05
in O 0 5.9045364e-05
response O 0 7.781521e-05
to O 0 7.7018354e-05
the O 0 0.000106400345
selection O 0 0.00019256138
of O 0 0.00028256106
distinct O 0 0.00027681532
mutational O 0 0.0024526638
patterns O 0 0.0009081573
. O 0 0.0017174211

Hemolytic B-Disease 0 0.9945761
anemia I-Disease 0 0.99981195
associated O 0 0.0038363538
with O 0 0.00253141
the O 0 0.0018513703
use O 0 0.0021795158
of O 0 0.006160155
omeprazole B-Chemical 1 0.9995851
. O 0 0.0075075673

Omeprazole B-Chemical 0 0.9994618
is O 0 0.0018495347
the O 0 0.00077819946
first O 0 0.00041690262
drug O 0 0.003292297
designed O 0 0.00033199345
to O 0 0.00019955209
block O 0 0.0002032296
the O 0 0.00013938679
final O 0 0.0001973146
step O 0 0.0001951491
in O 0 0.00016046777
the O 0 0.00023725853
acid O 0 0.30367726
secretory O 0 0.000441381
process O 0 0.00020333118
within O 0 0.00012819667
the O 0 0.0004941289
parietal O 0 0.049242668
cell O 0 0.0066246744
. O 0 0.0026222402

It O 0 0.0028864227
has O 0 0.0011376461
been O 0 0.00063302123
shown O 0 0.00038069297
to O 0 0.00030612602
be O 0 0.00022942225
extremely O 0 0.00038690233
effective O 0 0.00013859873
in O 0 0.000113152244
the O 0 0.000111962494
treatment O 0 0.00016110478
of O 0 0.00084592507
peptic B-Disease 0 0.9999056
ulcer I-Disease 0 0.99978715
disease I-Disease 0 0.9737693
, O 0 0.0008061597
reflux B-Disease 0 0.99210066
esophagitis I-Disease 0 0.9997323
, O 0 0.00037225068
and O 0 0.0002787242
the O 0 0.0004521794
Zollinger B-Disease 0 0.039608978
- I-Disease 0 0.0014540504
Ellison I-Disease 0 0.0034501709
syndrome I-Disease 0 0.061400164
. O 0 0.002239392

Although O 0 0.0015432466
clinical O 0 0.0024228918
experience O 0 0.0013552215
with O 0 0.0019313422
omeprazole B-Chemical 1 0.9998807
is O 0 0.0005489453
still O 0 0.00027454362
limited O 0 0.00020620649
, O 0 0.00017413689
many O 0 9.409205e-05
controlled O 0 9.479577e-05
studies O 0 9.6035175e-05
have O 0 6.2559804e-05
established O 0 0.00010628414
the O 0 9.682367e-05
short O 0 0.00011113748
- O 0 0.00024198124
term O 0 0.00016867077
safety O 0 0.00033253452
of O 0 0.0004873231
this O 0 0.0011059906
drug O 0 0.03696908
. O 0 0.0022964124

We O 0 0.0017044084
report O 0 0.0016455193
the O 0 0.0007773323
first O 0 0.00040935166
case O 0 0.0004269669
of O 0 0.00045611194
a O 0 0.00045424578
serious O 0 0.0012393703
short O 0 0.00021697227
- O 0 0.00032827083
term O 0 0.0001564841
adverse O 0 0.010944866
reaction O 0 0.0016323179
with O 0 0.00018863352
the O 0 0.00013966004
use O 0 0.00017164173
of O 0 0.0008540522
omeprazole B-Chemical 1 0.99995196
: O 0 0.02156714
hemolytic B-Disease 2 0.9999888
anemia I-Disease 2 0.99998796
. O 0 0.010774503

The O 0 0.0018310866
patient O 0 0.0020638257
developed O 0 0.003321861
weakness O 0 0.96326417
, O 0 0.003306295
lethargy B-Disease 0 0.99936277
, O 0 0.0009454591
and O 0 0.0005898766
shortness B-Disease 0 0.75632644
of I-Disease 0 0.000564189
breath I-Disease 0 0.18101679
2 O 0 0.000104503306
days O 0 4.5309636e-05
after O 0 5.0607057e-05
starting O 0 0.00015671404
therapy O 0 0.0006458259
with O 0 0.0020091
omeprazole B-Chemical 1 0.9996747
. O 0 0.003338201

Two O 0 0.0016527103
weeks O 0 0.0005108234
after O 0 0.00026598823
the O 0 0.0003370444
initiation O 0 0.000247972
of O 0 0.00039894486
therapy O 0 0.00049846456
, O 0 0.0003282183
her O 0 0.00043752493
hematocrit O 0 0.32546452
had O 0 0.00019654156
decreased O 0 0.00029924235
from O 0 0.00010384847
44 O 0 0.00015799134
. O 0 5.5045322e-05
1 O 0 5.9606973e-05
% O 0 6.820411e-05
to O 0 5.7719317e-05
20 O 0 8.229814e-05
. O 0 5.231898e-05
4 O 0 5.590299e-05
% O 0 8.375288e-05
, O 0 8.984582e-05
and O 0 8.30942e-05
she O 0 6.536988e-05
had O 0 7.624855e-05
a O 0 0.00011009102
positive O 0 0.00015799058
direct O 0 0.00026559873
Coombs O 0 0.9906138
antiglobulin O 0 0.99868006
test O 0 0.0006845565
and O 0 0.00031531544
an O 0 0.00059099076
elevated O 0 0.00811946
indirect O 0 0.022521993
bilirubin B-Chemical 1 0.9998878
. O 0 0.004997673

After O 0 0.0010346363
she O 0 0.0012373423
discontinued O 0 0.00258366
the O 0 0.0014763463
omeprazole B-Chemical 1 0.9998487
, O 0 0.0011598008
her O 0 0.0011106869
hemoglobin O 0 0.7247176
and O 0 0.0007889625
hematocrit O 0 0.31151217
gradually O 0 0.0009403129
returned O 0 0.000689925
to O 0 0.0008460702
normal O 0 0.0031001759
. O 0 0.0024043657

The O 0 0.0016683111
mechanism O 0 0.0015525187
by O 0 0.0011603899
which O 0 0.0017369707
omeprazole B-Chemical 1 0.9998084
caused O 0 0.0006349969
the O 0 0.00030828454
patient O 0 0.00030866248
' O 0 0.00038893498
s O 0 0.0007390639
hemolytic B-Disease 2 0.9999958
anemia I-Disease 2 0.999998
is O 0 0.0009801545
uncertain O 0 0.0004412952
, O 0 0.00023532467
but O 0 0.00017024745
physicians O 0 0.00025193466
should O 0 6.5564534e-05
be O 0 0.00010967192
alerted O 0 0.00031058566
to O 0 0.0001552091
this O 0 0.0003179759
possible O 0 0.00049940107
adverse O 0 0.05010227
effect O 0 0.0018441884
. O 0 0.0025158753

Phenylephrine B-Chemical 0 0.99942786
but O 0 0.0030775797
not O 0 0.0017977416
ephedrine B-Chemical 1 0.9994947
reduces B-Disease 0 0.00097110274
frontal I-Disease 0 0.05693751
lobe I-Disease 0 0.0959955
oxygenation I-Disease 0 0.03672557
following O 0 0.00051913713
anesthesia O 0 0.015292123
- O 0 0.0017754347
induced O 0 0.0029333697
hypotension B-Disease 0 0.9995383
. O 0 0.004565219

BACKGROUND O 0 0.009468896
: O 0 0.0030849313
Vasopressor O 0 0.010056963
agents O 0 0.0029518225
are O 0 0.0006565161
used O 0 0.00045309585
to O 0 0.00047817486
correct O 0 0.0009345952
anesthesia O 0 0.021183258
- O 0 0.0026205338
induced O 0 0.004169363
hypotension B-Disease 0 0.99956995
. O 0 0.0055989656

We O 0 0.0012207545
describe O 0 0.0007907829
the O 0 0.0006516805
effect O 0 0.00054820586
of O 0 0.0012670513
phenylephrine B-Chemical 0 0.9999254
and O 0 0.0013573761
ephedrine B-Chemical 1 0.99988174
on O 0 0.00016648887
frontal O 0 0.029307468
lobe O 0 0.1386975
oxygenation O 0 0.21319275
( O 0 0.00065878563
S O 0 0.68091834
( O 0 0.0004511123
c O 0 0.0026141724
) O 0 0.0007112398
O O 0 0.96680284
( O 0 0.00042119707
2 O 0 0.00017572279
) O 0 0.0002893528
) O 0 0.00027767837
following O 0 0.00022898216
anesthesia O 0 0.0065764184
- O 0 0.0013964775
induced O 0 0.00257117
hypotension B-Disease 0 0.99958426
. O 0 0.0041219443

METHODS O 0 0.0015282516
: O 0 0.0011504709
Following O 0 0.00044470685
induction O 0 0.0005348177
of O 0 0.00065186684
anesthesia O 0 0.009707615
by O 0 0.0008364115
fentanyl B-Chemical 0 0.9998807
( O 0 0.0004811397
0 O 0 0.00012559055
. O 0 6.523792e-05
15 O 0 7.32061e-05
mg O 0 0.0013565542
kg O 0 0.00042858106
( O 0 0.0002280981
- O 0 0.00023904874
1 O 0 9.823758e-05
) O 0 0.00017110052
) O 0 0.00016886048
and O 0 0.00019083117
propofol B-Chemical 1 0.9993024
( O 0 0.0002588365
2 O 0 7.082051e-05
. O 0 4.1998082e-05
0 O 0 6.247288e-05
mg O 0 0.0011307854
kg O 0 0.00036606324
( O 0 0.00020369889
- O 0 0.00022591851
1 O 0 9.476495e-05
) O 0 0.00016718754
) O 0 0.00014392927
, O 0 8.850769e-05
13 O 0 7.43032e-05
patients O 0 0.00010132251
received O 0 0.00011143355
phenylephrine B-Chemical 0 0.9999151
( O 0 0.0002218921
0 O 0 6.493819e-05
. O 0 3.8197155e-05
1 O 0 5.1251733e-05
mg O 0 0.00076725
iv O 0 0.0003124174
) O 0 0.00011552188
and O 0 5.4354434e-05
12 O 0 3.13587e-05
patients O 0 7.826709e-05
received O 0 9.2660455e-05
ephedrine B-Chemical 1 0.9998679
( O 0 0.0001979859
10 O 0 8.520825e-05
mg O 0 0.0020134116
iv O 0 0.00043065334
) O 0 0.00014182644
to O 0 6.196854e-05
restore O 0 7.81132e-05
mean O 0 9.175488e-05
arterial O 0 0.0063970312
pressure O 0 0.0054579806
( O 0 0.0011932891
MAP O 0 0.17600802
) O 0 0.0028600427
. O 0 0.002249012

Heart O 0 0.009094301
rate O 0 0.002951023
( O 0 0.0031232787
HR O 0 0.059990793
) O 0 0.0015849664
, O 0 0.0009098159
MAP O 0 0.2436673
, O 0 0.0011037098
stroke B-Disease 0 0.9898907
volume O 0 0.0017147681
( O 0 0.00060458604
SV O 0 0.07110727
) O 0 0.0004088421
, O 0 0.00019941058
cardiac O 0 0.0039591733
output O 0 0.00025748543
( O 0 0.00046220815
CO O 0 0.9984781
) O 0 0.00033633498
, O 0 0.0001190322
and O 0 0.000105987594
frontal O 0 0.0067552263
lobe O 0 0.068362996
oxygenation O 0 0.14679387
( O 0 0.00057790853
S O 0 0.6145206
( O 0 0.00046945465
c O 0 0.0025924265
) O 0 0.0008331914
O O 0 0.95228314
( O 0 0.00063763594
2 O 0 0.00033836547
) O 0 0.00065694674
) O 0 0.00082905666
were O 0 0.00090331474
registered O 0 0.0020083217
. O 0 0.0023094434

RESULTS O 0 0.005123996
: O 0 0.0021458084
Induction O 0 0.0015463607
of O 0 0.0011165008
anesthesia O 0 0.007055562
was O 0 0.00050032296
followed O 0 0.00022739172
by O 0 0.00022901005
a B-Disease 0 0.00025194086
decrease I-Disease 0 0.00025833183
in I-Disease 0 0.00021240012
MAP I-Disease 0 0.32962438
, I-Disease 0 0.00044326493
HR I-Disease 0 0.06786625
, I-Disease 0 0.00024069953
SV I-Disease 0 0.030539416
, I-Disease 0 0.00019236613
and I-Disease 0 0.0002195762
CO I-Disease 0 0.99723417
concomitant O 0 0.00061265245
with O 0 0.00016303724
an O 0 0.00020450495
elevation O 0 0.010809665
in O 0 0.00036054052
S O 0 0.80263984
( O 0 0.0007380384
c O 0 0.0044326414
) O 0 0.0014341486
O O 0 0.9479532
( O 0 0.0014850462
2 O 0 0.0010056022
) O 0 0.0022010272
. O 0 0.0023797443

After O 0 0.0011574687
administration O 0 0.0037638936
of O 0 0.0032136831
phenylephrine B-Chemical 0 0.9998697
, O 0 0.0018916207
MAP O 0 0.41526124
increased O 0 0.0011279056
( O 0 0.00060867576
51 O 0 0.00045775008
+ O 0 0.0005036768
/ O 0 0.0006333484
- O 0 0.00027830253
12 O 0 6.823001e-05
to O 0 9.2651535e-05
81 O 0 0.0002740878
+ O 0 0.00030754597
/ O 0 0.00047796205
- O 0 0.0002783699
13 O 0 0.00014379347
mmHg O 0 0.00038473634
; O 0 0.00027301587
P O 0 0.0020346874
< O 0 0.0001413015
0 O 0 0.00011973048
. O 0 0.000123703
001 O 0 0.0015376961
; O 0 0.0002205277
mean O 0 0.0001456894
+ O 0 0.00066384283
/ O 0 0.0015118689
- O 0 0.0017910525
SD O 0 0.007456619
) O 0 0.0030579201
. O 0 0.002724634

However O 0 0.0034069954
, O 0 0.002531576
a O 0 0.0016589296
14 O 0 0.00087564613
% O 0 0.00074469077
( O 0 0.0005542136
from O 0 0.000270131
70 O 0 0.00037405032
+ O 0 0.00064045214
/ O 0 0.000883667
- O 0 0.0004300968
8 O 0 0.0001231064
% O 0 0.00012433261
to O 0 9.312106e-05
60 O 0 0.00013549675
+ O 0 0.0003114651
/ O 0 0.0005237645
- O 0 0.00028254677
7 O 0 8.186972e-05
% O 0 0.000120688754
) O 0 0.00016382516
reduction O 0 0.0002703013
in O 0 0.00021294336
S O 0 0.75338537
( O 0 0.0004366741
c O 0 0.003335929
) O 0 0.00066353794
O O 0 0.98044753
( O 0 0.00035593534
2 O 0 0.00013629447
) O 0 0.00025033255
( O 0 0.0002857731
P O 0 0.0025170483
< O 0 0.0001134831
0 O 0 8.983776e-05
. O 0 8.2662766e-05
05 O 0 0.0011939893
) O 0 0.00013546136
followed O 0 5.461271e-05
with O 0 7.894878e-05
no O 0 4.752485e-05
change O 0 9.689968e-05
in O 0 0.00017286371
CO O 0 0.9990361
( O 0 0.00030621476
3 O 0 7.599435e-05
. O 0 5.1298677e-05
7 O 0 6.0329814e-05
+ O 0 0.00019952851
/ O 0 0.00042421298
- O 0 0.00026499547
1 O 0 8.6292355e-05
. O 0 5.3865413e-05
1 O 0 6.0083104e-05
to O 0 6.2895735e-05
3 O 0 6.668415e-05
. O 0 5.7498524e-05
4 O 0 7.494493e-05
+ O 0 0.00021940794
/ O 0 0.00041299214
- O 0 0.000267582
0 O 0 0.00010969306
. O 0 8.352837e-05
9 O 0 0.000114652605
l O 0 0.00032717604
min O 0 0.00032453483
( O 0 0.0005826
- O 0 0.00087751844
1 O 0 0.00069172436
) O 0 0.0015829817
) O 0 0.0024944828
. O 0 0.0026661148

The O 0 0.0017537184
administration O 0 0.0040805424
of O 0 0.0028460675
ephedrine B-Chemical 1 0.9997968
led O 0 0.00096741907
to O 0 0.00034286795
a O 0 0.0003202091
similar O 0 0.0001370438
increase O 0 0.00029908208
in O 0 0.00022726016
MAP O 0 0.81230164
( O 0 0.00039822332
53 O 0 0.00032498752
+ O 0 0.00035620132
/ O 0 0.0005132926
- O 0 0.00024680633
9 O 0 7.645286e-05
to O 0 7.5418175e-05
79 O 0 0.00019920117
+ O 0 0.00025778808
/ O 0 0.00041282095
- O 0 0.00022677421
8 O 0 8.385973e-05
mmHg O 0 0.0002978156
; O 0 0.00022163287
P O 0 0.0019523416
< O 0 0.000107222084
0 O 0 8.856628e-05
. O 0 8.8040586e-05
001 O 0 0.0024234508
) O 0 0.00021237724
, O 0 0.00014713504
restored O 0 0.00043143463
CO O 0 0.99910295
( O 0 0.00034883432
3 O 0 8.7149085e-05
. O 0 5.9678412e-05
2 O 0 7.832846e-05
+ O 0 0.00021548291
/ O 0 0.00043654675
- O 0 0.00026884582
1 O 0 8.6635024e-05
. O 0 5.311791e-05
2 O 0 5.4955523e-05
to O 0 5.6106255e-05
5 O 0 5.7525507e-05
. O 0 5.17834e-05
0 O 0 7.973655e-05
+ O 0 0.00022472597
/ O 0 0.00043844534
- O 0 0.0002596861
1 O 0 8.363668e-05
. O 0 5.1750427e-05
3 O 0 5.6622852e-05
l O 0 0.00017380745
min O 0 0.00014372877
( O 0 0.00022179418
- O 0 0.0002694676
1 O 0 0.00012675214
) O 0 0.00023303473
) O 0 0.00022036815
, O 0 0.00016099989
and O 0 0.00018903794
preserved O 0 0.0010552995
S O 0 0.7148285
( O 0 0.0008144811
c O 0 0.0042126747
) O 0 0.0015518994
O O 0 0.9409818
( O 0 0.0016162605
2 O 0 0.0010966657
) O 0 0.0023684686
. O 0 0.0025414398

CONCLUSIONS O 0 0.0116490405
: O 0 0.0016684937
The O 0 0.00057184114
utilization O 0 0.00074178324
of O 0 0.00095515663
phenylephrine B-Chemical 0 0.9997894
to O 0 0.00037627108
correct O 0 0.00058690045
hypotension B-Disease 0 0.99972874
induced O 0 0.00053217495
by O 0 0.0002841306
anesthesia O 0 0.0075324713
has O 0 7.419289e-05
a O 0 9.598903e-05
negative O 0 9.005743e-05
impact O 0 4.9307026e-05
on O 0 9.120419e-05
S O 0 0.75963396
( O 0 0.00039931014
c O 0 0.00364903
) O 0 0.0005993122
O O 0 0.9804243
( O 0 0.00026602778
2 O 0 9.0604066e-05
) O 0 0.00013422163
while O 0 0.00012587085
ephedrine B-Chemical 1 0.9993999
maintains O 0 0.00016382281
frontal O 0 0.027334442
lobe O 0 0.056913637
oxygenation O 0 0.015141184
potentially O 0 0.00016984144
related O 0 7.095604e-05
to O 0 0.00014398144
an O 0 0.00034069864
increase O 0 0.0005404593
in O 0 0.001235961
CO O 0 0.99649256
. O 0 0.0030684657

Prolonged O 0 0.004544852
elevation O 0 0.009857407
of O 0 0.0017561301
plasma O 0 0.09424928
argatroban B-Chemical 0 0.9991732
in O 0 0.0003892586
a O 0 0.0003882656
cardiac O 0 0.008690408
transplant O 0 0.0052422746
patient O 0 0.000187183
with O 0 0.00014306631
a O 0 0.00018316491
suspected O 0 0.0006398213
history O 0 0.00037400963
of O 0 0.0004980025
heparin B-Chemical 0 0.99725515
- O 0 0.0015586821
induced O 0 0.0017802048
thrombocytopenia B-Disease 0 0.9998908
with O 0 0.027416905
thrombosis B-Disease 0 0.99982446
. O 0 0.0036258586

BACKGROUND O 0 0.007997851
: O 0 0.0024020565
Direct O 0 0.0031523502
thrombin O 0 0.46482787
inhibitors O 0 0.025015283
( O 0 0.0010802678
DTIs O 0 0.0030387682
) O 0 0.00033624616
provide O 0 9.9709e-05
an O 0 0.00011387801
alternative O 0 7.623452e-05
method O 0 0.00015496716
of O 0 0.00017547364
anticoagulation O 0 0.022029757
for O 0 5.9938033e-05
patients O 0 0.000107925785
with O 0 8.444925e-05
a O 0 0.00012009237
history O 0 0.00019224694
of O 0 0.00026586803
heparin B-Chemical 0 0.9979304
- O 0 0.00077865896
induced O 0 0.00066967047
thrombocytopenia B-Disease 0 0.9999734
( O 0 0.004256066
HIT B-Disease 2 0.99967027
) O 0 0.0004267494
or O 0 0.00019486758
HIT B-Disease 2 0.99732286
with O 0 0.0009659528
thrombosis B-Disease 0 0.99994755
( O 0 0.0013048346
HITT B-Disease 0 0.997687
) O 0 0.00038402417
undergoing O 0 0.0002408143
cardiopulmonary O 0 0.00040076027
bypass O 0 0.00046221633
( O 0 0.00079216616
CPB O 0 0.0072981026
) O 0 0.0021211286
. O 0 0.0020603293

In O 0 0.0016837206
the O 0 0.0011751284
following O 0 0.00070741406
report O 0 0.001160113
, O 0 0.0006894253
a O 0 0.00057710573
65 O 0 0.0004971822
- O 0 0.00045156816
year O 0 0.00013324685
- O 0 0.00023931943
old O 0 0.00013952161
critically B-Disease 0 0.0013632514
ill I-Disease 0 0.66064644
patient O 0 0.00015637431
with O 0 0.00011510172
a O 0 0.00014418615
suspected O 0 0.00052591786
history O 0 0.00026906477
of O 0 0.00033869225
HITT B-Disease 0 0.99879384
was O 0 0.00018676618
administered O 0 0.00028233268
argatroban B-Chemical 0 0.9971354
for O 0 0.0001430071
anticoagulation O 0 0.008541398
on O 0 9.735658e-05
bypass O 0 0.00023778169
during O 0 0.00020613923
heart O 0 0.010569701
transplantation O 0 0.012144756
. O 0 0.0020598706

The O 0 0.0016274321
patient O 0 0.001294511
required O 0 0.0005797004
massive O 0 0.0031627393
transfusion O 0 0.0032151146
support O 0 0.00033667005
( O 0 0.00036630605
55 O 0 0.00019668123
units O 0 0.00012186649
of O 0 0.00019217766
red O 0 0.0014878849
blood O 0 0.002078737
cells O 0 0.00024003218
, O 0 0.0001184701
42 O 0 8.951828e-05
units O 0 5.9192e-05
of O 0 9.667135e-05
fresh O 0 0.00033578117
- O 0 0.00022135835
frozen O 0 0.00037279227
plasma O 0 0.0012384362
, O 0 8.5411055e-05
40 O 0 5.8477053e-05
units O 0 5.0719245e-05
of O 0 0.00011141059
cryoprecipitate O 0 0.1738377
, O 0 9.61963e-05
40 O 0 6.319008e-05
units O 0 5.3982196e-05
of O 0 0.0001124819
platelets O 0 0.019215975
, O 0 0.00010771727
and O 0 6.4624124e-05
three O 0 3.2962358e-05
doses O 0 0.0002612892
of O 0 0.00013458509
recombinant O 0 0.00033124446
Factor O 0 0.9598464
VIIa O 0 0.99098176
) O 0 0.00042832986
for O 0 0.00014694798
severe O 0 0.0018547374
intraoperative B-Disease 0 0.0011325052
and I-Disease 0 0.00068643864
postoperative I-Disease 0 0.004694558
bleeding I-Disease 0 0.96785104
. O 0 0.0023500235

STUDY O 0 0.0049997177
DESIGN O 0 0.00243312
AND O 0 0.0010056469
METHODS O 0 0.0005211977
: O 0 0.00065464544
Plasma O 0 0.0018793109
samples O 0 0.0002720524
from O 0 0.00013990435
before O 0 6.869616e-05
and O 0 0.00010564473
after O 0 5.3739557e-05
CPB O 0 0.0010538438
were O 0 8.3381456e-05
analyzed O 0 6.359008e-05
postoperatively O 0 6.749563e-05
for O 0 8.825014e-05
argatroban B-Chemical 0 0.99458706
concentration O 0 0.0003414844
using O 0 9.55216e-05
a O 0 0.00016670887
modified O 0 0.00018895036
ecarin O 0 0.010178637
clotting O 0 0.025802454
time O 0 0.00019167003
( O 0 0.00066162075
ECT O 0 0.14381826
) O 0 0.0016005253
assay O 0 0.0033126255
. O 0 0.0023046623

RESULTS O 0 0.0046515567
: O 0 0.0018603908
Unexpectedly O 0 0.0011371976
high O 0 0.00095403515
concentrations O 0 0.001218913
of O 0 0.0010809606
argatroban B-Chemical 0 0.9990363
were O 0 0.00024988066
measured O 0 0.00011348787
in O 0 9.9898396e-05
these O 0 0.0001461201
samples O 0 0.00014144872
( O 0 0.00015932397
range O 0 0.000109996065
, O 0 0.00011967843
0 O 0 8.8223045e-05
- O 0 0.00014735405
32 O 0 9.703126e-05
microg O 0 0.00021040566
/ O 0 0.00058353896
mL O 0 0.0009409285
) O 0 0.00019714705
, O 0 8.8415814e-05
and O 0 6.6292254e-05
a O 0 9.156757e-05
prolonged O 0 0.00020652701
plasma O 0 0.017300809
argatroban B-Chemical 0 0.9983845
half O 0 9.2500035e-05
life O 0 0.0001727408
( O 0 0.00019029061
t O 0 0.00021062884
( O 0 0.00012933019
1 O 0 7.596247e-05
/ O 0 0.00021984642
2 O 0 8.009579e-05
) O 0 0.0001366152
) O 0 0.00011635313
of O 0 0.00010950816
514 O 0 0.0008763636
minutes O 0 4.8584396e-05
was O 0 8.1579834e-05
observed O 0 6.5749984e-05
( O 0 0.000110846
published O 0 9.46758e-05
elimination O 0 0.0002591316
t O 0 0.000293183
( O 0 0.00015284325
1 O 0 8.606177e-05
/ O 0 0.00024920263
2 O 0 8.9148736e-05
) O 0 0.00014076359
is O 0 9.425368e-05
39 O 0 0.00015398674
- O 0 0.00015271605
51 O 0 0.00010285093
minutes O 0 5.420794e-05
[ O 0 0.00019427223
< O 0 8.896251e-05
or O 0 9.009221e-05
= O 0 0.00015111627
181 O 0 0.00029937536
minutes O 0 9.881247e-05
with O 0 0.000450295
hepatic B-Disease 0 0.99899215
impairment I-Disease 0 0.9966762
] O 0 0.0072998474
) O 0 0.0029836218
. O 0 0.0022242141

CONCLUSIONS O 0 0.00949318
: O 0 0.0014787876
Correlation O 0 0.0005239946
of O 0 0.00073589635
plasma O 0 0.01650364
argatroban B-Chemical 0 0.99853134
concentration O 0 0.00084382354
versus O 0 0.00015539402
the O 0 0.00012952581
patient O 0 0.00013561903
' O 0 0.00013954955
s O 0 0.00011449876
coagulation O 0 0.008953452
variables O 0 5.708946e-05
and O 0 6.7492154e-05
clinical O 0 0.00013689126
course O 0 4.2383686e-05
suggest O 0 2.143413e-05
that O 0 3.4407793e-05
prolonged O 0 0.00012716945
elevated O 0 0.0004457456
levels O 0 8.879113e-05
of O 0 0.0001891847
plasma O 0 0.069369175
argatroban B-Chemical 0 0.9993913
may O 0 9.119514e-05
have O 0 5.6976878e-05
contributed O 0 0.000112953654
to O 0 8.6610075e-05
the O 0 0.00013869761
patient O 0 0.0002463188
' O 0 0.00042119206
s O 0 0.0005154371
extended O 0 0.0012334565
coagulopathy B-Disease 2 0.99944896
. O 0 0.0037973586

Because O 0 0.0015795211
DTIs O 0 0.005047972
do O 0 0.00092600315
not O 0 0.0005090027
have O 0 0.00032577667
reversal O 0 0.0006721052
agents O 0 0.001183002
, O 0 0.00027584052
surgical O 0 0.00019913696
teams O 0 0.00014147785
and O 0 0.00013734942
transfusion O 0 0.0007805059
services O 0 0.00014481308
should O 0 4.0163915e-05
remain O 0 5.3900563e-05
aware O 0 5.761703e-05
of O 0 8.4437255e-05
the O 0 6.836482e-05
possibility O 0 5.7895824e-05
of O 0 0.00015237714
massive O 0 0.0018941738
transfusion O 0 0.002090413
events O 0 0.0005367712
during O 0 0.00012384534
anticoagulation O 0 0.014736414
with O 0 0.0004567694
these O 0 0.00095998
agents O 0 0.004395681
. O 0 0.0020648364

This O 0 0.00357935
is O 0 0.0012729942
the O 0 0.0006506264
first O 0 0.00034152187
report O 0 0.0004750816
to O 0 0.00022483272
measure O 0 0.00014368411
plasma O 0 0.018121472
argatroban B-Chemical 0 0.9992236
concentration O 0 0.00069856417
in O 0 0.00015738704
the O 0 0.00012677051
context O 0 8.174787e-05
of O 0 0.00040396053
CPB O 0 0.009466807
and O 0 0.00076568034
extended O 0 0.0016048424
coagulopathy B-Disease 2 0.99959666
. O 0 0.0041769287

The O 0 0.0013184675
effects O 0 0.0011227343
of O 0 0.00090300955
the O 0 0.0006843451
adjunctive O 0 0.009356999
bupropion B-Chemical 0 0.999956
on O 0 0.0002672241
male O 0 0.0030005174
sexual B-Disease 0 0.44835067
dysfunction I-Disease 0 0.9927683
induced O 0 0.0003199232
by O 0 0.0001363748
a O 0 0.00016363748
selective B-Chemical 0 0.0012149138
serotonin I-Chemical 0 0.9997775
reuptake I-Chemical 0 0.96726704
inhibitor I-Chemical 0 0.0006597589
: O 0 0.00014402196
a O 0 0.00014240836
double O 0 0.00025534775
- O 0 0.0003572079
blind O 0 0.0076330444
placebo O 0 0.001486659
- O 0 0.00031216402
controlled O 0 0.00020475274
and O 0 0.00035384856
randomized O 0 0.0006683647
study O 0 0.0011157703
. O 0 0.0015504785

OBJECTIVE O 0 0.021618621
: O 0 0.0019403353
To O 0 0.00063613965
determine O 0 0.00030487828
the O 0 0.00035840226
safety O 0 0.000388667
and O 0 0.00022569268
efficacy O 0 0.00024477972
of O 0 0.00029493097
adjunctive O 0 0.012795251
bupropion B-Chemical 0 0.9999869
sustained O 0 0.0021275047
- O 0 0.00063913385
release O 0 0.00087803823
( O 0 0.0002931251
SR O 0 0.07722193
) O 0 0.00015153878
on O 0 5.33608e-05
male O 0 0.00069605187
sexual B-Disease 0 0.28912988
dysfunction I-Disease 0 0.99719715
( O 0 0.00063797995
SD B-Disease 0 0.008351434
) O 0 0.0001507786
induced O 0 8.296546e-05
by O 0 7.123176e-05
a O 0 0.00010776844
selective B-Chemical 0 0.0007969331
serotonin I-Chemical 0 0.9997359
reuptake I-Chemical 0 0.97293043
inhibitor I-Chemical 0 0.0012946565
( O 0 0.00055543624
SSRI B-Chemical 0 0.9999666
) O 0 0.0003030341
, O 0 0.00011189918
as O 0 9.2506925e-05
SD B-Disease 0 0.0010339185
is O 0 7.4962576e-05
a O 0 0.00010056179
common O 0 0.000121889025
side O 0 0.0022490367
- O 0 0.0001905648
effect O 0 7.593148e-05
of O 0 0.00029264344
SSRIs B-Chemical 0 0.99922836
and O 0 0.00010253659
the O 0 7.609283e-05
most O 0 0.00013384945
effective O 0 0.00010278544
treatments O 0 0.00024061005
have O 0 0.00015758496
yet O 0 0.0003079902
to O 0 0.00033375985
be O 0 0.0005657495
determined O 0 0.0010158501
. O 0 0.0018290778

PATIENTS O 0 0.0019735827
AND O 0 0.0012572859
METHODS O 0 0.0005691401
: O 0 0.00049667514
The O 0 0.00022056869
randomized O 0 0.00025603303
sample O 0 0.00022093787
consisted O 0 0.00014980654
of O 0 0.00026655893
234 O 0 0.0035907556
euthymic O 0 0.85427666
men O 0 0.0014652286
who O 0 0.00026104765
were O 0 0.000155554
receiving O 0 0.00024200244
some O 0 0.00026960098
type O 0 0.0005311098
of O 0 0.002037823
SSRI B-Chemical 0 0.9997863
. O 0 0.003038904

The O 0 0.001820417
men O 0 0.002627547
were O 0 0.00047311117
randomly O 0 0.00014831558
assigned O 0 0.00020065508
to O 0 0.00036624025
bupropion B-Chemical 0 0.9999633
SR O 0 0.5555067
( O 0 0.0002885938
150 O 0 0.00021474701
mg O 0 0.0010884637
twice O 0 7.889413e-05
daily O 0 0.00012582992
, O 0 0.00011788413
117 O 0 0.00030536117
) O 0 0.00014168439
or O 0 8.302576e-05
placebo O 0 0.00050268904
( O 0 0.00012584
twice O 0 8.249732e-05
daily O 0 0.00017360869
, O 0 0.00022059814
117 O 0 0.0005702594
) O 0 0.00035145637
for O 0 0.00024790867
12 O 0 0.00035595673
weeks O 0 0.0004942679
. O 0 0.001483541

Efficacy O 0 0.0047885
was O 0 0.0015531591
evaluated O 0 0.00065953605
using O 0 0.00041948794
the O 0 0.00039645028
Clinical O 0 0.00092135026
Global O 0 0.0006723403
Impression O 0 0.0012108693
- O 0 0.0005428658
Sexual O 0 0.0009792495
Function O 0 0.00066478044
( O 0 0.00036848828
CGI O 0 0.019821279
- O 0 0.00042291527
SF O 0 0.0038913204
; O 0 0.00014242901
the O 0 7.3474446e-05
primary O 0 8.690344e-05
outcome O 0 9.356281e-05
measure O 0 4.6931073e-05
) O 0 0.00014817831
, O 0 8.325022e-05
the O 0 6.584098e-05
International O 0 8.13111e-05
Index O 0 8.3531e-05
of O 0 7.371531e-05
Erectile O 0 9.411913e-05
Function O 0 0.00023970264
( O 0 0.00014841615
IIEF O 0 0.00031800836
) O 0 0.00014781815
, O 0 0.00011750288
Arizona O 0 0.00043869266
Sexual O 0 0.0006317119
Experience O 0 0.0006696098
Scale O 0 0.0031212603
( O 0 0.00032903286
ASEX O 0 0.28934225
) O 0 0.00019263814
, O 0 9.741183e-05
and O 0 8.996499e-05
Erectile B-Disease 0 0.0002495642
Dysfunction I-Disease 0 0.0009745195
Inventory O 0 0.00045766195
of O 0 0.0001344563
Treatment O 0 0.00038343595
Satisfaction O 0 0.0004434287
( O 0 0.00032247155
EDITS O 0 0.003064093
) O 0 0.00036022445
( O 0 0.00030505558
secondary O 0 0.0005832412
outcome O 0 0.0005243914
measures O 0 0.0005594562
) O 0 0.0020080674
. O 0 0.002125303

Participants O 0 0.0030821078
were O 0 0.0023093896
followed O 0 0.0016558171
biweekly O 0 0.0023867257
during O 0 0.0014068077
study O 0 0.0028009443
period O 0 0.0024999932
. O 0 0.0049462416

RESULTS O 0 0.004214407
: O 0 0.0014250543
After O 0 0.00032116025
12 O 0 0.0002781073
weeks O 0 0.00015891554
of O 0 0.00028758138
treatment O 0 0.00025336453
, O 0 0.00021191848
the O 0 0.00013066847
mean O 0 8.039093e-05
( O 0 0.00020471819
sd O 0 0.0002165011
) O 0 0.00015029428
scores O 0 7.4120326e-05
for O 0 9.1095535e-05
CGI O 0 0.038580745
- O 0 0.00036290026
SF O 0 0.00505978
were O 0 0.00011551769
significantly O 0 0.00014434241
lower O 0 0.000163694
, O 0 0.00012830088
i O 0 0.00024998025
. O 0 5.7108082e-05
e O 0 0.00011137524
. O 0 4.3147073e-05
better O 0 8.9951085e-05
, O 0 7.612534e-05
in O 0 5.643741e-05
patients O 0 0.00010512478
on O 0 8.4039704e-05
bupropion B-Chemical 0 0.999985
SR O 0 0.3949955
, O 0 0.00011107688
at O 0 4.951766e-05
2 O 0 5.8374928e-05
. O 0 4.1337287e-05
4 O 0 5.05881e-05
( O 0 9.565442e-05
1 O 0 6.1806e-05
. O 0 4.8407925e-05
2 O 0 6.5985405e-05
) O 0 0.000116572126
, O 0 7.312155e-05
than O 0 4.0570503e-05
in O 0 5.2300926e-05
the O 0 7.876244e-05
placebo O 0 0.0005970954
group O 0 0.00012467179
, O 0 9.289109e-05
at O 0 5.6469493e-05
3 O 0 6.655037e-05
. O 0 5.5244047e-05
9 O 0 7.822843e-05
( O 0 0.00013621728
1 O 0 9.436466e-05
. O 0 8.4279025e-05
1 O 0 0.00014166764
) O 0 0.00033831838
( O 0 0.0005051885
P O 0 0.0034614522
= O 0 0.00052534393
0 O 0 0.00043333994
. O 0 0.0005798029
01 O 0 0.002831129
) O 0 0.0024999743
. O 0 0.0026587206

Men O 0 0.01384176
who O 0 0.0023978252
received O 0 0.0014962144
bupropion B-Chemical 0 0.9999157
had O 0 0.00061097654
a O 0 0.00038367164
significant O 0 0.00018499594
increase O 0 0.00013355087
in O 0 9.264313e-05
the O 0 8.458247e-05
total O 0 0.00011767163
IIEF O 0 0.00037397654
score O 0 9.0953276e-05
( O 0 0.0001453695
54 O 0 0.00015322656
. O 0 5.1582214e-05
4 O 0 5.3079435e-05
% O 0 8.2896346e-05
vs O 0 9.6243464e-05
1 O 0 7.048317e-05
. O 0 5.3612304e-05
2 O 0 7.2297065e-05
% O 0 0.00012643152
; O 0 0.00022036796
P O 0 0.0029116576
= O 0 0.0001644333
0 O 0 9.592369e-05
. O 0 9.41802e-05
003 O 0 0.0013129596
) O 0 0.00020957155
, O 0 0.00012640007
and O 0 0.0001064046
in O 0 9.328726e-05
the O 0 0.00010501447
five O 0 8.0934675e-05
different O 0 0.00011272339
domains O 0 0.00018830126
of O 0 0.00052074675
the O 0 0.0009847953
IIEF O 0 0.0042997086
. O 0 0.0020698803

Total O 0 0.0032907468
ASEX O 0 0.24860261
scores O 0 0.00091071305
were O 0 0.0006337611
significantly O 0 0.00062280183
lower O 0 0.0005783279
, O 0 0.00041512793
i O 0 0.0005845176
. O 0 0.00014044235
e O 0 0.0002216316
. O 0 8.24491e-05
better O 0 0.00015342583
, O 0 0.0001392676
among O 0 0.00014291276
men O 0 0.00052383007
who O 0 0.00016367588
received O 0 0.00012921926
bupropion B-Chemical 0 0.9999666
than O 0 8.4025516e-05
placebo O 0 0.0006372544
, O 0 7.650748e-05
at O 0 4.1986706e-05
15 O 0 4.9459795e-05
. O 0 4.1753046e-05
5 O 0 5.042217e-05
( O 0 9.474056e-05
4 O 0 5.2976073e-05
. O 0 4.6813784e-05
3 O 0 5.9942944e-05
) O 0 0.00012576551
vs O 0 0.00010324201
21 O 0 9.305351e-05
. O 0 5.8751e-05
5 O 0 7.0802205e-05
( O 0 0.00013213797
4 O 0 8.1716076e-05
. O 0 8.0353835e-05
7 O 0 0.00011522987
) O 0 0.00032186336
( O 0 0.00048621272
P O 0 0.0032867626
= O 0 0.00049036025
0 O 0 0.00040053474
. O 0 0.0005486706
002 O 0 0.0057170913
) O 0 0.0026828002
. O 0 0.0026524717

The O 0 0.0023155382
EDITS O 0 0.00754176
scores O 0 0.0009673563
were O 0 0.00072806835
67 O 0 0.00084004
. O 0 0.00028245978
4 O 0 0.00022292526
( O 0 0.00029030087
10 O 0 0.00016847979
. O 0 0.000111637324
2 O 0 0.00011095609
) O 0 0.0001490501
for O 0 7.8186225e-05
the O 0 0.00023092995
bupropion B-Chemical 0 0.999951
and O 0 0.00019835777
36 O 0 0.00011974874
. O 0 6.171689e-05
3 O 0 6.7098896e-05
( O 0 0.00011672597
11 O 0 8.411201e-05
. O 0 5.1508876e-05
7 O 0 5.536583e-05
) O 0 9.74674e-05
for O 0 5.426147e-05
the O 0 0.00011369942
placebo O 0 0.0008573086
group O 0 0.00031136564
( O 0 0.0005213147
P O 0 0.004995833
= O 0 0.00046693796
0 O 0 0.00038347088
. O 0 0.0005537262
001 O 0 0.007828116
) O 0 0.002546834
. O 0 0.0025183752

The O 0 0.0025846162
ASEX O 0 0.1748255
score O 0 0.0011873092
and O 0 0.0012731974
CGI O 0 0.05127061
- O 0 0.001423931
SF O 0 0.0047960156
score O 0 0.0003486109
were O 0 0.00031538372
correlated O 0 0.00029578223
( O 0 0.00085573585
P O 0 0.0056807064
= O 0 0.00070306065
0 O 0 0.00055181
. O 0 0.00074163347
003 O 0 0.0062882337
) O 0 0.0030350378
. O 0 0.002996945

In O 0 0.0016130212
linear O 0 0.0014481621
regression O 0 0.0013469375
analyses O 0 0.0005924849
the O 0 0.0006263768
CGI O 0 0.08360567
- O 0 0.0009479956
SF O 0 0.0066896123
score O 0 0.00020257571
was O 0 0.00017684542
not O 0 0.00011643458
affected O 0 0.0001694959
significantly O 0 0.0001670462
by O 0 9.5041425e-05
the O 0 7.377621e-05
duration O 0 4.603726e-05
of O 0 0.0001753905
SD B-Disease 0 0.0019951912
, O 0 0.00018381121
type O 0 0.00021364864
of O 0 0.00065117946
SSRI B-Chemical 0 0.9998696
used O 0 0.00060189667
and O 0 0.0009843919
age O 0 0.0017375024
. O 0 0.0019871574

CONCLUSIONS O 0 0.029516352
: O 0 0.0066251075
Bupropion B-Chemical 0 0.99942636
is O 0 0.0011004981
an O 0 0.0007022651
effective O 0 0.00042102547
treatment O 0 0.00045200015
for O 0 0.00042623832
male O 0 0.0023730712
SD B-Disease 0 0.004477829
induced O 0 0.001349724
by O 0 0.0027896368
SSRIs B-Chemical 0 0.998809
. O 0 0.0036265615

These O 0 0.0023490463
results O 0 0.0014761158
provide O 0 0.0009010663
empirical O 0 0.0010802663
support O 0 0.00051431987
for O 0 0.0004105709
conducting O 0 0.0005035554
a O 0 0.00070027687
further O 0 0.00090851734
study O 0 0.0012963148
of O 0 0.0040992773
bupropion B-Chemical 0 0.99987435
. O 0 0.0043365494

Prevention O 0 0.0030810442
of O 0 0.002876337
seizures B-Disease 0 0.9987251
and O 0 0.0009380303
reorganization O 0 0.0006907376
of O 0 0.000454868
hippocampal O 0 0.024625294
functions O 0 0.00027686497
by O 0 0.00020049806
transplantation O 0 0.0008703579
of O 0 0.00026398603
bone O 0 0.020053877
marrow O 0 0.42153072
cells O 0 0.00038753008
in O 0 0.00015078348
the O 0 0.00021504637
acute O 0 0.06893711
phase O 0 0.0012392257
of O 0 0.0009780356
experimental O 0 0.0033870507
epilepsy B-Disease 2 0.99977106
. O 0 0.0037846444

In O 0 0.0019481836
this O 0 0.001710734
study O 0 0.0012834326
, O 0 0.00068761193
we O 0 0.00021950083
investigated O 0 0.00022379564
the O 0 0.00020603373
therapeutic O 0 0.00033889248
potential O 0 0.00019498708
of O 0 0.00028535683
bone O 0 0.029249568
marrow O 0 0.76728255
mononuclear O 0 0.28161877
cells O 0 0.00059842976
( O 0 0.0003574249
BMCs O 0 0.026684476
) O 0 0.00022566946
in O 0 8.3933104e-05
a O 0 0.00013017276
model O 0 0.00016283916
of O 0 0.00045883787
epilepsy B-Disease 2 0.9998659
induced O 0 0.001120196
by O 0 0.0014251167
pilocarpine B-Chemical 1 0.99994934
in O 0 0.0014439098
rats O 0 0.002735958
. O 0 0.0018321135

BMCs O 0 0.015816001
obtained O 0 0.001616513
from O 0 0.00101356
green O 0 0.002540258
fluorescent O 0 0.001744873
protein O 0 0.0011116042
( O 0 0.0007997624
GFP O 0 0.0024238047
) O 0 0.0004843324
transgenic O 0 0.00030512284
mice O 0 8.7094915e-05
or O 0 9.272338e-05
rats O 0 0.00014724351
were O 0 8.218074e-05
transplanted O 0 0.00029553697
intravenously O 0 9.610058e-05
after O 0 3.6713795e-05
induction O 0 0.00013020291
of O 0 0.00028425577
status B-Disease 0 0.0005037224
epilepticus I-Disease 0 0.9968208
( O 0 0.0018169146
SE B-Disease 0 0.08372792
) O 0 0.0026568575
. O 0 0.0022277874

Spontaneous B-Disease 0 0.019393133
recurrent I-Disease 0 0.17699908
seizures I-Disease 0 0.9999052
( O 0 0.0066666286
SRS B-Disease 0 0.7360069
) O 0 0.0010220581
were O 0 0.00032888356
monitored O 0 0.00019977636
using O 0 0.00027696847
Racine O 0 0.00088769407
' O 0 0.0005956432
s O 0 0.00077109045
seizure B-Disease 0 0.9928048
severity O 0 0.0047804504
scale O 0 0.002576854
. O 0 0.0028745637

All O 0 0.0015615537
of O 0 0.0012932097
the O 0 0.0007599124
rats O 0 0.0007135746
in O 0 0.00030942916
the O 0 0.00029732028
saline O 0 0.0016138401
- O 0 0.00046070496
treated O 0 0.00040612143
epileptic B-Disease 0 0.9982121
control O 0 0.00020357347
group O 0 0.00021390793
developed O 0 0.0003502138
SRS B-Disease 0 0.5910763
, O 0 0.00014609643
whereas O 0 8.283929e-05
none O 0 7.477518e-05
of O 0 0.000106317595
the O 0 0.00015250097
BMC O 0 0.9853672
- O 0 0.0004953527
treated O 0 0.00038561245
epileptic B-Disease 0 0.9994905
animals O 0 0.00011469252
had O 0 0.00017217692
seizures B-Disease 0 0.9998087
in O 0 8.3738196e-05
the O 0 5.3644937e-05
short O 0 4.24238e-05
term O 0 5.98398e-05
( O 0 7.991879e-05
15 O 0 3.4292385e-05
days O 0 2.3463035e-05
after O 0 3.2873428e-05
transplantation O 0 0.0007240194
) O 0 0.00027611
, O 0 0.00016955133
regardless O 0 0.00010053811
of O 0 0.00040376614
the O 0 0.00076501595
BMC O 0 0.8577055
source O 0 0.0019695836
. O 0 0.0024467853

Over O 0 0.0021657217
the O 0 0.0013386899
long O 0 0.0010090676
- O 0 0.0011579158
term O 0 0.0005162971
chronic O 0 0.030880628
phase O 0 0.0011239514
( O 0 0.00028604025
120 O 0 0.00011663906
days O 0 4.453503e-05
after O 0 4.2480962e-05
transplantation O 0 0.000800727
) O 0 0.00025627654
, O 0 0.000116324605
only O 0 0.000100178
25 O 0 0.0001261009
% O 0 9.0503905e-05
of O 0 0.00018413081
BMC O 0 0.97836375
- O 0 0.00048811294
treated O 0 0.0003859996
epileptic B-Disease 0 0.9994935
animals O 0 0.00013405253
had O 0 0.00025397982
seizures B-Disease 0 0.9999522
, O 0 0.00024347531
but O 0 0.00010576025
with O 0 9.6050004e-05
a O 0 0.0001041845
lower O 0 0.00010581895
frequency O 0 8.3044135e-05
and O 0 6.950639e-05
duration O 0 3.8435097e-05
compared O 0 5.8769103e-05
to O 0 0.00011588585
the O 0 0.0003118737
epileptic B-Disease 0 0.99778265
control O 0 0.001039217
group O 0 0.0018135536
. O 0 0.0018256822

The O 0 0.0017082015
density O 0 0.0022002817
of O 0 0.0012642153
hippocampal O 0 0.03108531
neurons O 0 0.0011902852
in O 0 0.00033072513
the O 0 0.00026422148
brains O 0 0.00063389004
of O 0 0.00026326568
animals O 0 0.0001740509
treated O 0 0.00037622664
with O 0 0.0005432708
BMCs O 0 0.04064815
was O 0 0.0009286096
markedly O 0 0.0030816307
preserved O 0 0.0050813067
. O 0 0.0025208942

At O 0 0.0012139364
hippocampal O 0 0.0144475475
Schaeffer O 0 0.0087422095
collateral O 0 0.07458101
- O 0 0.0033231634
CA1 O 0 0.67187
synapses O 0 0.0071420926
, O 0 0.00047310395
long O 0 0.0002655823
- O 0 0.0003412277
term O 0 0.00016879207
potentiation O 0 0.17197673
was O 0 0.00026428397
preserved O 0 0.0005146237
in O 0 0.00025493567
BMC O 0 0.9716755
- O 0 0.0006424929
transplanted O 0 0.0013897457
rats O 0 0.000332563
compared O 0 0.0001750118
to O 0 0.00047022925
epileptic B-Disease 0 0.9985209
controls O 0 0.0042256885
. O 0 0.0021403683

The O 0 0.002277041
donor O 0 0.0030828493
- O 0 0.0021172825
derived O 0 0.0007246538
GFP O 0 0.0037116476
( O 0 0.0010979752
+ O 0 0.0011173212
) O 0 0.0006129196
cells O 0 0.0003902985
were O 0 0.00021634964
rarely O 0 0.00019268315
found O 0 0.0001412188
in O 0 0.00014033179
the O 0 0.00018362481
brains O 0 0.00071810646
of O 0 0.00058180717
transplanted O 0 0.020478172
epileptic B-Disease 0 0.9994572
rats O 0 0.004921918
. O 0 0.002148839

In O 0 0.0018839417
conclusion O 0 0.0014074744
, O 0 0.0012434663
treatment O 0 0.00072599197
with O 0 0.00074762217
BMCs O 0 0.023463178
can O 0 0.00018096718
prevent O 0 0.00014531825
the O 0 0.00013107379
development O 0 0.00026945272
of O 0 0.00039716443
chronic O 0 0.75541043
seizures B-Disease 0 0.99998283
, O 0 0.00044226882
reduce O 0 0.0001508764
neuronal B-Disease 0 0.5136046
loss I-Disease 0 0.04989265
, O 0 0.00018935633
and O 0 9.079841e-05
influence O 0 4.797721e-05
the O 0 9.206945e-05
reorganization O 0 0.00021217628
of O 0 0.0002452528
the O 0 0.0003351165
hippocampal O 0 0.14434154
neuronal O 0 0.01947255
network O 0 0.0015696498
. O 0 0.001981599

Normalizing O 0 0.0036486383
effects O 0 0.0022219445
of O 0 0.0032201263
modafinil B-Chemical 0 0.9996785
on O 0 0.0010185015
sleep O 0 0.010846918
in O 0 0.00147647
chronic O 0 0.703523
cocaine B-Chemical 1 0.9997303
users O 0 0.03134546
. O 0 0.0037996217

OBJECTIVE O 0 0.022140723
: O 0 0.0019787315
The O 0 0.00060312275
purpose O 0 0.0005198571
of O 0 0.00048996176
the O 0 0.00030639904
present O 0 0.00021642225
study O 0 0.00028643323
was O 0 0.00016504308
to O 0 8.0313155e-05
determine O 0 4.0035084e-05
the O 0 6.850056e-05
effect O 0 7.088212e-05
of O 0 0.00014025981
morning O 0 0.00053187937
- O 0 0.00028516835
dosed O 0 0.0019346586
modafinil B-Chemical 0 0.9999057
on O 0 7.157522e-05
sleep O 0 0.001184887
and O 0 0.00013671072
daytime B-Disease 0 0.017775146
sleepiness I-Disease 0 0.7608656
in O 0 0.00042725573
chronic O 0 0.48243022
cocaine B-Chemical 1 0.99977
users O 0 0.01238214
. O 0 0.00204866

METHOD O 0 0.00569332
: O 0 0.002451998
Twenty O 0 0.0025661993
cocaine B-Chemical 1 0.9984434
- O 0 0.0009581955
dependent O 0 0.00013387827
participants O 0 0.00012435406
were O 0 8.0903264e-05
randomly O 0 2.9937051e-05
assigned O 0 4.517227e-05
to O 0 5.9004335e-05
receive O 0 9.5649404e-05
modafinil B-Chemical 0 0.9999149
, O 0 0.00021101238
400 O 0 0.0005873504
mg O 0 0.011563064
( O 0 0.00044484466
N O 0 0.94423467
= O 0 0.00019025961
10 O 0 8.7051085e-05
) O 0 0.0001390252
, O 0 8.940635e-05
or O 0 8.739859e-05
placebo O 0 0.0010071059
( O 0 0.00032496083
N O 0 0.89918274
= O 0 0.00016694986
10 O 0 6.7667694e-05
) O 0 7.580429e-05
every O 0 1.977578e-05
morning O 0 0.00010102217
at O 0 4.09832e-05
7 O 0 4.682504e-05
: O 0 7.2602656e-05
30 O 0 5.0378963e-05
a O 0 0.00010139567
. O 0 6.329586e-05
m O 0 0.00024287157
. O 0 4.685229e-05
for O 0 4.597233e-05
16 O 0 5.8514936e-05
days O 0 3.1535423e-05
in O 0 6.497797e-05
an O 0 0.0001513275
inpatient O 0 0.00040381745
, O 0 0.000256086
double O 0 0.00050102646
- O 0 0.0007379758
blind O 0 0.00494627
randomized O 0 0.00089207356
trial O 0 0.0013074651
. O 0 0.0015302423

Participants O 0 0.0011307062
underwent O 0 0.0008129203
polysomnographic O 0 0.0019232549
sleep O 0 0.0018150925
recordings O 0 0.0003160522
on O 0 0.00012578699
days O 0 9.0679176e-05
1 O 0 0.00011846943
to O 0 0.00011211654
3 O 0 0.000108369844
, O 0 0.00013287761
7 O 0 7.598834e-05
to O 0 8.505206e-05
9 O 0 9.314078e-05
, O 0 0.00011128201
and O 0 9.9017234e-05
14 O 0 7.642968e-05
to O 0 7.360117e-05
16 O 0 9.764871e-05
( O 0 0.00011968825
first O 0 6.366647e-05
, O 0 0.00012807033
second O 0 0.00012568844
, O 0 0.00016610972
and O 0 0.000157932
third O 0 0.0002301953
weeks O 0 0.00013552234
of O 0 0.0006254967
abstinence O 0 0.048115343
) O 0 0.0025302034
. O 0 0.0021494546

The O 0 0.0018400713
Multiple O 0 0.002259819
Sleep O 0 0.0038063345
Latency O 0 0.00267173
Test O 0 0.0016682849
was O 0 0.00036530118
performed O 0 0.00020332147
at O 0 0.0001536935
11 O 0 0.0001948605
: O 0 0.00017883313
30 O 0 0.00010651577
a O 0 0.00018280289
. O 0 0.000113206945
m O 0 0.00043548792
. O 0 9.6749376e-05
, O 0 0.0001454921
2 O 0 0.00010767517
: O 0 0.00019145303
00 O 0 0.0010266821
p O 0 0.00014408925
. O 0 7.741421e-05
m O 0 0.00031184603
. O 0 7.4292926e-05
, O 0 0.000110987094
and O 0 0.00010198583
4 O 0 7.3241084e-05
: O 0 0.00010936435
30 O 0 8.433714e-05
p O 0 0.00011480993
. O 0 7.319947e-05
m O 0 0.00026614525
. O 0 6.5813096e-05
on O 0 6.330407e-05
days O 0 7.5180425e-05
2 O 0 0.00015673992
, O 0 0.00028374646
8 O 0 0.0002994884
, O 0 0.00057502405
and O 0 0.0008724943
15 O 0 0.0012198954
. O 0 0.0021129802

For O 0 0.0010599291
comparison O 0 0.00090877194
of O 0 0.00090255885
sleep O 0 0.0030191187
architecture O 0 0.00055594736
variables O 0 0.00020624719
, O 0 0.000201534
12 O 0 8.227954e-05
healthy O 0 0.00023890108
comparison O 0 7.016703e-05
participants O 0 6.229619e-05
underwent O 0 6.395813e-05
a O 0 7.920954e-05
single O 0 6.516778e-05
night O 0 0.00012367303
of O 0 7.927951e-05
experimental O 0 0.000103316466
polysomnography O 0 0.00016204348
that O 0 5.9296297e-05
followed O 0 8.968507e-05
1 O 0 0.00012671323
night O 0 0.00033938573
of O 0 0.00045392496
accommodation O 0 0.0028719187
polysomnography O 0 0.0027155883
. O 0 0.0015950281

RESULTS O 0 0.005111668
: O 0 0.002561581
Progressive O 0 0.009875192
abstinence O 0 0.014014849
from O 0 0.00088900776
cocaine B-Chemical 1 0.9990907
was O 0 0.00047460018
associated O 0 0.00021448568
with O 0 0.00031169446
worsening O 0 0.00495529
of O 0 0.00030339422
all O 0 0.00022405077
measured O 0 0.0002798596
polysomnographic O 0 0.002915248
sleep O 0 0.0050692563
outcomes O 0 0.0015227572
. O 0 0.001873686

Compared O 0 0.0015247413
with O 0 0.0016020896
placebo O 0 0.005998115
, O 0 0.0014034978
modafinil B-Chemical 0 0.9998486
decreased O 0 0.0010996881
nighttime O 0 0.0015843879
sleep O 0 0.002279736
latency O 0 0.0002340037
and O 0 0.00012617042
increased O 0 0.00021577942
slow O 0 0.0006076362
- O 0 0.00030180725
wave O 0 0.0005103197
sleep O 0 0.001410619
time O 0 9.797824e-05
in O 0 0.0002904836
cocaine B-Chemical 1 0.9986319
- O 0 0.0009266893
dependent O 0 0.0004085573
participants O 0 0.00107584
. O 0 0.0017494088

The O 0 0.0014581812
effect O 0 0.0012571184
of O 0 0.002283934
modafinil B-Chemical 0 0.99986017
interacted O 0 0.00049308233
with O 0 0.0003685905
the O 0 0.00024278731
abstinence O 0 0.0044350955
week O 0 6.780063e-05
and O 0 9.033205e-05
was O 0 8.2803745e-05
associated O 0 5.4223347e-05
with O 0 6.821856e-05
longer O 0 3.0235036e-05
total O 0 5.94155e-05
sleep O 0 0.0005160679
time O 0 2.8004668e-05
and O 0 5.024113e-05
shorter O 0 6.0080067e-05
REM O 0 0.44054496
sleep O 0 0.001108622
latency O 0 0.00013724036
in O 0 8.072841e-05
the O 0 0.00011285665
third O 0 0.00021952805
week O 0 0.00018194663
of O 0 0.00074429344
abstinence O 0 0.032126613
. O 0 0.001981156

Comparison O 0 0.0015894799
of O 0 0.0016542753
slow O 0 0.0026969956
- O 0 0.0014683309
wave O 0 0.0014900806
sleep O 0 0.002511571
time O 0 0.00014210411
, O 0 0.00017097026
total O 0 0.00013838954
sleep O 0 0.0010090113
time O 0 5.729627e-05
, O 0 9.038014e-05
and O 0 8.247954e-05
sleep O 0 0.0009101202
latency O 0 0.00017178156
in O 0 0.00015082663
cocaine B-Chemical 1 0.99964213
- O 0 0.00023829349
dependent O 0 3.318118e-05
and O 0 7.061119e-05
healthy O 0 0.00022697174
participants O 0 4.48642e-05
revealed O 0 4.7134166e-05
a O 0 6.977536e-05
normalizing O 0 0.000113872804
effect O 0 9.919274e-05
of O 0 0.00055591244
modafinil B-Chemical 0 0.9999771
in O 0 0.00083402224
cocaine B-Chemical 1 0.9997508
- O 0 0.0010373193
dependent O 0 0.00037585435
participants O 0 0.0009915492
. O 0 0.0016102118

Modafinil B-Chemical 0 0.999148
was O 0 0.0021590304
associated O 0 0.00070953683
with O 0 0.0005615328
increased O 0 0.00056858646
daytime O 0 0.001710089
sleep O 0 0.003633859
latency O 0 0.00035829723
, O 0 0.00017330288
as O 0 9.411465e-05
measured O 0 7.79767e-05
by O 0 8.6973414e-05
the O 0 8.150782e-05
Multiple O 0 0.00018065906
Sleep O 0 0.00068287767
Latency O 0 0.0005911762
Test O 0 0.00046220687
, O 0 0.00010958505
and O 0 9.527591e-05
a O 0 0.00013154656
nearly O 0 0.00015169867
significant O 0 0.00014803454
decrease O 0 0.00024487567
in O 0 0.0002628278
subjective O 0 0.0010603302
daytime B-Disease 0 0.1646552
sleepiness I-Disease 0 0.94102126
. O 0 0.0022726278

CONCLUSIONS O 0 0.0151212225
: O 0 0.0028132277
Morning O 0 0.008495222
- O 0 0.0019401688
dosed O 0 0.005003571
modafinil B-Chemical 0 0.9997713
promotes O 0 0.00025036378
nocturnal O 0 0.0055754213
sleep O 0 0.0038829457
, O 0 0.00019128495
normalizes O 0 0.0008905831
sleep O 0 0.002000763
architecture O 0 0.00020677982
, O 0 0.00012313247
and O 0 9.984096e-05
decreases O 0 0.00018033104
daytime B-Disease 0 0.026464406
sleepiness I-Disease 0 0.7983854
in O 0 0.00046077167
abstinent O 0 0.66430444
cocaine B-Chemical 1 0.99946386
users O 0 0.006999117
. O 0 0.0019329755

These O 0 0.0028020141
effects O 0 0.0020698574
may O 0 0.0011466602
be O 0 0.0007307495
relevant O 0 0.00044817396
in O 0 0.0004838
the O 0 0.00054321694
treatment O 0 0.0008099914
of O 0 0.0022796136
cocaine B-Chemical 1 0.9993393
dependence O 0 0.011556026
. O 0 0.003919613

Safety O 0 0.0064148162
of O 0 0.0029560078
transesophageal O 0 0.049486294
echocardiography O 0 0.005278353
in O 0 0.0007898374
adults O 0 0.00128831
: O 0 0.00074252207
study O 0 0.0006484483
in O 0 0.00060684583
a O 0 0.0012372696
multidisciplinary O 0 0.0028847184
hospital O 0 0.0038552862
. O 0 0.00284773

BACKGROUND O 0 0.011713613
: O 0 0.0038453336
TEE O 0 0.03221567
is O 0 0.00091667863
a O 0 0.000832098
semi O 0 0.0011637748
- O 0 0.00070701743
invasive O 0 0.00036341124
tool O 0 0.00024948598
broadly O 0 0.00010853562
used O 0 9.594053e-05
and O 0 0.00011756117
its O 0 0.00018094441
utilization O 0 0.0001534121
associated O 0 9.915878e-05
to O 0 0.00016339005
sedatives O 0 0.87196213
drugs O 0 0.0046053603
might O 0 9.07534e-05
to O 0 0.00012289951
affect O 0 0.00012192773
the O 0 0.0003176426
procedure O 0 0.0006002165
safety O 0 0.0016019531
. O 0 0.001801148

OBJECTIVE O 0 0.023816563
: O 0 0.0020840138
to O 0 0.0006899803
analyze O 0 0.00032352528
aspects O 0 0.00024169669
of O 0 0.0005269744
TEE O 0 0.021891637
safety O 0 0.00030644084
associated O 0 0.00013358715
to O 0 0.00010307891
the O 0 0.000105774576
use O 0 0.00010185366
of O 0 0.00026795504
Midazolan B-Chemical 0 0.86874366
( O 0 0.00072957034
MZ B-Chemical 1 0.9938076
) O 0 0.0004995944
and O 0 0.00047764936
Flumazenil B-Chemical 0 0.9999945
( O 0 0.0016379864
FL B-Chemical 0 0.93263274
) O 0 0.0002523693
and O 0 8.356374e-05
the O 0 6.146991e-05
influence O 0 4.071239e-05
of O 0 0.00010412114
the O 0 0.000108985216
clinical O 0 0.00028773936
variables O 0 0.0001154274
on O 0 0.00014128696
the O 0 0.00038469257
event O 0 0.001588374
rate O 0 0.00169692
. O 0 0.0021184152

METHOD O 0 0.005871225
: O 0 0.0022755405
prospective O 0 0.0019386534
study O 0 0.0006986058
with O 0 0.00052223005
137 O 0 0.0008690891
patients O 0 0.00029988098
that O 0 0.00015278596
underwent O 0 0.00028837653
TEE O 0 0.018117039
with O 0 0.00054061034
MZ B-Chemical 1 0.93127275
associated O 0 0.0004850293
to O 0 0.0006316521
moderate O 0 0.016053926
sedation O 0 0.3215542
. O 0 0.002512502

We O 0 0.0014232153
analyzed O 0 0.0009589681
the O 0 0.0006324852
following O 0 0.00039369866
events O 0 0.001212217
: O 0 0.0005538197
complications O 0 0.0018669864
related O 0 9.493871e-05
with O 0 0.00017453535
the O 0 0.0001999288
topical O 0 0.38562238
anesthesia O 0 0.03464185
, O 0 0.00029509806
with O 0 0.0004711117
MZ B-Chemical 1 0.968194
use O 0 0.00029932024
and O 0 0.00033123975
with O 0 0.00050809624
the O 0 0.0007196992
procedure O 0 0.0012735643
. O 0 0.001941608

Uni O 0 0.76293254
- O 0 0.003951449
and O 0 0.0010324721
multivariate O 0 0.00082349236
analyses O 0 0.00041943073
were O 0 0.00027242044
used O 0 0.00016798526
to O 0 0.00015486123
test O 0 0.0001820301
the O 0 8.660784e-05
influence O 0 4.9719703e-05
of O 0 0.00010537761
the O 0 9.1119866e-05
clinical O 0 0.00025193748
variables O 0 7.5972464e-05
: O 0 0.00014469272
age O 0 0.00014407016
, O 0 0.00015833775
sex O 0 0.00044123334
, O 0 0.00029143508
stroke B-Disease 0 0.99866605
, O 0 0.0013247813
myocardiopathy B-Disease 0 0.9999678
( O 0 0.0015467956
MP B-Disease 0 0.99364096
) O 0 0.00029340386
, O 0 8.285335e-05
duration O 0 2.973634e-05
of O 0 7.477168e-05
the O 0 8.359044e-05
test O 0 0.0001670991
, O 0 0.00022963497
mitral B-Disease 2 0.86748487
regurgitation I-Disease 2 0.9990068
( O 0 0.00093161647
MR B-Disease 2 0.9240642
) O 0 0.00056676497
and O 0 0.00039032858
the O 0 0.0007724565
MZ B-Chemical 1 0.9650445
dose O 0 0.013438365
. O 0 0.0028908066

RESULTS O 0 0.005266005
: O 0 0.0021397613
All O 0 0.00092959177
patients O 0 0.0011711221
( O 0 0.0009782695
65 O 0 0.000728573
+ O 0 0.0009307905
/ O 0 0.0011677481
- O 0 0.0006502111
16 O 0 0.0002981616
yrs O 0 0.00031456538
; O 0 0.00029888484
58 O 0 0.00036237025
% O 0 0.00035770476
males O 0 0.00056714134
) O 0 0.0005758527
finished O 0 0.000646514
the O 0 0.00085447833
examination O 0 0.0017807261
. O 0 0.0023247853

The O 0 0.0013209858
mean O 0 0.00080760755
doses O 0 0.0031881474
of O 0 0.001865235
MZ B-Chemical 1 0.9943989
and O 0 0.0015685562
FL B-Chemical 0 0.92132914
were O 0 0.00039941407
4 O 0 0.00016509945
. O 0 0.000107755906
3 O 0 0.000115666495
+ O 0 0.00030780525
/ O 0 0.0005592364
- O 0 0.0003280925
1 O 0 0.00010516931
. O 0 6.481322e-05
9 O 0 8.0521815e-05
mg O 0 0.0007353559
and O 0 0.000120324155
0 O 0 9.566006e-05
. O 0 7.100762e-05
28 O 0 0.00011483369
+ O 0 0.00028159024
/ O 0 0.0005210467
- O 0 0.00036080767
0 O 0 0.00017410866
. O 0 0.00016772599
2 O 0 0.00030640865
mg O 0 0.0033715197
, O 0 0.0013026453
respectively O 0 0.0030030776
. O 0 0.002553277

The O 0 0.0013433606
duration O 0 0.0006828138
of O 0 0.00079065026
the O 0 0.00048228275
examination O 0 0.00034670217
and O 0 0.00020719052
the O 0 0.0001356224
mean O 0 8.7749504e-05
ejection O 0 0.02611522
fraction O 0 0.00027515553
( O 0 0.00036509088
EF O 0 0.4362519
) O 0 0.00029256253
were O 0 0.00010992781
16 O 0 8.727799e-05
. O 0 5.598072e-05
4 O 0 6.877639e-05
+ O 0 0.00020633057
/ O 0 0.00040232894
- O 0 0.00023771232
6 O 0 6.083874e-05
. O 0 5.058115e-05
1 O 0 5.512317e-05
minutes O 0 4.8230977e-05
and O 0 0.000108835666
60 O 0 0.0001602558
+ O 0 0.0004074999
/ O 0 0.00080870494
- O 0 0.0006549188
9 O 0 0.0003922119
% O 0 0.0006596787
, O 0 0.0011678259
respectively O 0 0.002899921
. O 0 0.0026298699

Mild O 0 0.9477731
hypoxia B-Disease 2 0.9793728
( O 0 0.0059635583
SO2 O 0 0.9960508
< O 0 0.00083376875
90 O 0 0.00044991824
% O 0 0.00039934405
) O 0 0.00037617446
was O 0 0.00017987288
the O 0 0.00012735525
most O 0 0.00019423943
common O 0 0.00016360285
event O 0 0.00044205427
( O 0 0.00020618485
11 O 0 0.000116595584
patients O 0 0.00017078595
) O 0 0.00018615936
; O 0 0.00011113377
3 O 0 6.022738e-05
patients O 0 0.000113019494
( O 0 0.00011209667
2 O 0 5.8648842e-05
% O 0 7.512224e-05
) O 0 9.5447576e-05
presented O 0 6.857939e-05
transient O 0 0.0011428642
hypoxia B-Disease 2 0.6890709
due O 0 5.5935787e-05
to O 0 6.108599e-05
upper O 0 0.00022436671
airway B-Disease 0 0.0011764655
obstruction I-Disease 0 0.05615855
by O 0 8.852608e-05
probe O 0 6.289496e-05
introduction O 0 5.8160167e-05
and O 0 8.919679e-05
8 O 0 7.148224e-05
( O 0 0.00011096582
5 O 0 5.958322e-05
. O 0 5.4474975e-05
8 O 0 7.233666e-05
% O 0 0.00012028113
) O 0 0.0001682711
due O 0 9.815929e-05
to O 0 0.000226527
hypoxia B-Disease 2 0.67012066
caused O 0 0.001135297
by O 0 0.001698221
MZ B-Chemical 1 0.9855913
use O 0 0.0025052165
. O 0 0.0025472194

Transient O 0 0.4304315
hypotension B-Disease 0 0.9993686
( O 0 0.0063115535
SAP O 0 0.88384795
< O 0 0.0013199709
90mmHg O 0 0.014630813
) O 0 0.0006965479
occurred O 0 0.00027115358
in O 0 0.0002569506
1 O 0 0.00024491933
patient O 0 0.00032937084
( O 0 0.00044902108
0 O 0 0.00033208495
. O 0 0.00034278166
7 O 0 0.0005348937
% O 0 0.001251855
) O 0 0.0026160507
. O 0 0.002916698

The O 0 0.0014543439
multivariate O 0 0.0014770606
analysis O 0 0.00080377416
showed O 0 0.0005282115
that O 0 0.0003994383
severe O 0 0.021839933
MR B-Disease 2 0.9941075
, O 0 0.0012718188
MP B-Disease 0 0.991267
( O 0 0.0007831914
EF O 0 0.3896157
< O 0 0.00018509896
45 O 0 0.00010802803
% O 0 0.00012302263
) O 0 0.00013975077
and O 0 8.550511e-05
high O 0 0.0001920055
doses O 0 0.000846848
of O 0 0.0004591087
MZ B-Chemical 1 0.9975473
( O 0 0.0004782134
> O 0 0.00086203346
5mg O 0 0.7055436
) O 0 0.00022083426
were O 0 8.353737e-05
associated O 0 7.7309596e-05
with O 0 0.00016080274
events O 0 0.00073702
( O 0 0.00036634604
p O 0 0.00026350073
< O 0 0.00026730308
0 O 0 0.00033393424
. O 0 0.00051083294
001 O 0 0.0075273765
) O 0 0.0024485597
. O 0 0.002434623

The O 0 0.0027988844
EF O 0 0.32020026
was O 0 0.0016279519
40 O 0 0.00096550706
% O 0 0.0006420249
, O 0 0.00039747692
in O 0 0.00021218254
the O 0 0.00019977636
group O 0 0.0002731028
with O 0 0.00035858227
MP B-Disease 0 0.95741075
and O 0 0.00022021146
44 O 0 0.00018601191
% O 0 8.826024e-05
in O 0 5.5749933e-05
the O 0 6.6678615e-05
group O 0 0.00010935832
with O 0 0.00015099053
severe O 0 0.013066886
MR B-Disease 2 0.98454213
and O 0 0.00019168244
it O 0 0.000116635165
can O 0 5.6246776e-05
be O 0 6.1348685e-05
a O 0 9.988687e-05
factor O 0 0.00025258693
associated O 0 9.666831e-05
with O 0 0.00015813796
clinical O 0 0.00041178445
events O 0 0.00049804477
in O 0 0.00019355079
the O 0 0.00028385466
last O 0 0.00029321935
group O 0 0.0012465803
. O 0 0.0017750197

CONCLUSION O 0 0.020746019
: O 0 0.0038752567
TEE O 0 0.01985509
with O 0 0.0016561506
sedation O 0 0.013315203
presents O 0 0.001009549
a O 0 0.0010593635
low O 0 0.001369581
rate O 0 0.0012874729
of O 0 0.0021508194
events O 0 0.0076730163
. O 0 0.0036702137

There O 0 0.002771212
were O 0 0.0016205444
no O 0 0.0008317255
severe O 0 0.0042972756
events O 0 0.0022739365
and O 0 0.0005865912
there O 0 0.00029543275
was O 0 0.00039599172
no O 0 0.00022120452
need O 0 0.00028655722
to O 0 0.00034654088
interrupt O 0 0.0005281705
the O 0 0.00096023304
examinations O 0 0.002459406
. O 0 0.0023665165

Effect O 0 0.0018113245
of O 0 0.0013131027
direct O 0 0.0008273579
intracoronary O 0 0.087519996
administration O 0 0.0026992462
of O 0 0.001299597
methylergonovine B-Chemical 0 0.9995716
in O 0 0.00038679963
patients O 0 0.00040601034
with O 0 0.00033850208
and O 0 0.00042356682
without O 0 0.0008485371
variant B-Disease 2 0.19279851
angina I-Disease 2 0.99992204
. O 0 0.004956732

The O 0 0.0012256672
effects O 0 0.0010922612
of O 0 0.0011073549
intracoronary O 0 0.11670046
administration O 0 0.0026810798
of O 0 0.001163879
methylergonovine B-Chemical 0 0.9996902
were O 0 0.00024171468
studied O 0 0.00013254583
in O 0 7.308347e-05
21 O 0 7.4444615e-05
patients O 0 8.678668e-05
with O 0 0.000127713
variant B-Disease 2 0.036093567
angina I-Disease 2 0.99998534
and O 0 0.00017150694
22 O 0 0.000101078644
patients O 0 7.428705e-05
with O 0 7.522223e-05
atypical O 0 0.0006078421
chest B-Disease 0 0.007572861
pain I-Disease 0 0.20621027
and O 0 0.0001040213
in O 0 8.111517e-05
others O 0 0.000255405
without O 0 0.00039236725
angina B-Disease 0 0.99995434
pectoris I-Disease 0 0.9999217
( O 0 0.0007163962
control O 0 0.000469177
group O 0 0.001020301
) O 0 0.0018425786
. O 0 0.0018686489

Methylergonovine B-Chemical 0 0.7996379
was O 0 0.0020163667
administered O 0 0.001001922
continuously O 0 0.00050388207
at O 0 0.0002717952
a O 0 0.0003438717
rate O 0 0.00026818583
of O 0 0.00027894482
10 O 0 0.00022114906
micrograms O 0 0.0012213239
/ O 0 0.0006742152
min O 0 0.00035313953
up O 0 0.00038228993
to O 0 0.00048245638
50 O 0 0.0014075675
micrograms O 0 0.007813072
. O 0 0.0028227537

In O 0 0.0015867868
all O 0 0.001146563
patients O 0 0.0010113154
with O 0 0.00094546494
variant B-Disease 2 0.11015258
angina I-Disease 2 0.99997663
, O 0 0.0022349472
coronary B-Disease 2 0.99840647
spasm I-Disease 2 0.9999639
was O 0 0.0004422343
provoked O 0 0.00057708786
at O 0 6.4577245e-05
a O 0 9.138377e-05
mean O 0 4.021401e-05
dose O 0 0.0002472939
of O 0 0.00014725306
28 O 0 0.00013066
+ O 0 0.00028137016
/ O 0 0.00046121943
- O 0 0.00025380237
13 O 0 0.0001253442
micrograms O 0 0.0006151648
( O 0 0.00021308758
mean O 0 0.0001197323
+ O 0 0.0005819724
/ O 0 0.0014055982
- O 0 0.0016128349
SD O 0 0.007288008
) O 0 0.0027381056
. O 0 0.002430402

In O 0 0.001807578
the O 0 0.0013350397
control O 0 0.0010747898
group O 0 0.001312134
neither O 0 0.0015681231
ischemic O 0 0.99928063
ST O 0 0.6629471
change O 0 0.00090618746
nor O 0 0.0007506075
localized O 0 0.0009571251
spasm B-Disease 2 0.99506795
occurred O 0 0.0030456376
. O 0 0.0030727133

The O 0 0.0017402496
basal O 0 0.0022139046
tone O 0 0.004386304
of O 0 0.0007328081
the O 0 0.00045149503
right O 0 0.001215143
coronary O 0 0.13350476
artery O 0 0.05126374
was O 0 0.00033664136
significantly O 0 0.0002720856
lower O 0 0.0002188455
than O 0 0.000100814315
that O 0 0.00011731794
of O 0 0.00027449997
the O 0 0.0003739947
left O 0 0.0018583987
coronary O 0 0.3665139
artery O 0 0.18558946
. O 0 0.0027223804

The O 0 0.0014887616
percentage O 0 0.0010212054
of O 0 0.0014175328
vasoconstriction O 0 0.9668811
of O 0 0.00066135626
the O 0 0.00033216254
right O 0 0.0010224428
coronary O 0 0.15538466
artery O 0 0.04866187
was O 0 0.00026002398
significantly O 0 0.00020695991
higher O 0 0.00015892676
than O 0 8.6841224e-05
that O 0 0.0001038049
of O 0 0.0002496392
the O 0 0.00034619684
left O 0 0.0017706022
coronary O 0 0.36343542
artery O 0 0.18193255
. O 0 0.0026358927

These O 0 0.0019036344
results O 0 0.0011233891
suggest O 0 0.0004927123
that O 0 0.0007689189
spasm B-Disease 2 0.9989359
provocation O 0 0.24566695
tests O 0 0.0014662071
, O 0 0.00027994503
which O 0 0.00019046653
use O 0 0.00010426034
an O 0 0.00016525944
intracoronary O 0 0.034611512
injection O 0 0.00012408223
of O 0 0.000103474325
a O 0 9.829538e-05
relatively O 0 0.00011651888
low O 0 0.00018956084
dose O 0 0.000666891
of O 0 0.00047637828
methylergonovine B-Chemical 0 0.99988055
, O 0 0.00015607386
have O 0 4.468998e-05
a O 0 7.104921e-05
high O 0 0.00012094405
sensitivity O 0 0.00036766613
in O 0 0.00011735585
variant B-Disease 2 0.0713721
angina I-Disease 2 0.99998844
and O 0 0.00016519644
the O 0 0.00011674399
vasoreactivity O 0 0.9389405
of O 0 0.000101281934
the O 0 6.761997e-05
right O 0 0.0003584556
coronary O 0 0.07963242
artery O 0 0.011590729
may O 0 7.691413e-05
be O 0 6.2311876e-05
greater O 0 7.210264e-05
than O 0 5.58975e-05
that O 0 7.685137e-05
of O 0 0.00019957758
the O 0 0.00026371513
other O 0 0.000528847
coronary O 0 0.34620762
arteries O 0 0.38518527
. O 0 0.002384694

Oral O 0 0.3132054
manifestations O 0 0.021292608
of O 0 0.0037212877
" O 0 0.005380363
meth B-Disease 2 0.99957436
mouth I-Disease 2 0.9535644
" O 0 0.0023546685
: O 0 0.0015437868
a O 0 0.0017161112
case O 0 0.0020735848
report O 0 0.0046564178
. O 0 0.0040004775

AIM O 0 0.16000816
: O 0 0.0020793977
The O 0 0.0006102883
aim O 0 0.0006371226
of O 0 0.00054883334
the O 0 0.00035024388
documentation O 0 0.00038424975
of O 0 0.0002720241
this O 0 0.0002565242
clinical O 0 0.00056078105
case O 0 0.00015774221
is O 0 0.000115025905
to O 0 8.057321e-05
make O 0 8.264031e-05
clinicians O 0 0.00017957727
aware O 0 9.963772e-05
of O 0 0.00022779817
" O 0 0.00061135244
meth B-Disease 2 0.9999366
mouth I-Disease 2 0.9481312
" O 0 0.00024335185
and O 0 0.000118401105
the O 0 0.0001245714
medical O 0 0.0004536804
risks O 0 0.0004460298
associated O 0 0.000193034
with O 0 0.0003487698
this O 0 0.00063788943
serious O 0 0.0069127227
condition O 0 0.0041822954
. O 0 0.0022746162

BACKGROUND O 0 0.012871281
: O 0 0.005327397
Methamphetamine B-Chemical 1 0.9994543
is O 0 0.0010635625
a O 0 0.0007565201
very O 0 0.0009603775
addictive O 0 0.34273776
, O 0 0.00035326293
powerful O 0 0.00044663987
stimulant O 0 0.166592
that O 0 8.408372e-05
increases O 0 0.00012895546
wakefulness O 0 0.009406443
and O 0 8.788852e-05
physical O 0 0.00014401249
activity O 0 7.212602e-05
and O 0 7.450968e-05
can O 0 3.856239e-05
produce O 0 3.303206e-05
other O 0 4.4354943e-05
effects O 0 6.765627e-05
such O 0 5.5712946e-05
as O 0 0.00013737754
cardiac B-Disease 0 0.9664969
dysrhythmias I-Disease 0 0.99999356
, O 0 0.0045959526
hypertension B-Disease 2 0.99998534
, O 0 0.0023248186
hallucinations B-Disease 0 0.99996936
, O 0 0.0010265794
and O 0 0.0010055145
violent B-Disease 0 0.94657916
behavior I-Disease 0 0.015011336
. O 0 0.0025155963

Dental O 0 0.0077184755
patients O 0 0.00508816
abusing O 0 0.89873534
methamphetamine B-Chemical 1 0.9999182
can O 0 0.00041321048
present O 0 0.00021246678
with O 0 0.00028565378
poor O 0 0.00077561726
oral O 0 0.019500762
hygiene O 0 0.0010206676
, O 0 0.0006390611
xerostomia B-Disease 0 0.9997085
, O 0 0.00062406453
rampant O 0 0.019542921
caries B-Disease 0 0.992242
( O 0 0.0007893066
" O 0 0.0008667653
meth B-Disease 2 0.9999019
mouth I-Disease 2 0.96422535
" O 0 0.00069966115
) O 0 0.0005091366
, O 0 0.00037216442
and O 0 0.0004794318
excessive O 0 0.003801246
tooth B-Disease 0 0.058584623
wear I-Disease 0 0.061053514
. O 0 0.0029136736

Oral O 0 0.09312437
rehabilitation O 0 0.0037373782
of O 0 0.002390871
patients O 0 0.0025398254
using O 0 0.0021786627
methamphetamine B-Chemical 1 0.9996904
can O 0 0.001961752
be O 0 0.001928575
challenging O 0 0.0028688645
. O 0 0.0035338118

CASE O 0 0.02859975
DESCRIPTION O 0 0.005657611
: O 0 0.0020391897
A O 0 0.004334139
30 O 0 0.0006106159
- O 0 0.00082938455
year O 0 0.0002735998
- O 0 0.00045492352
old O 0 0.00029219876
Caucasian O 0 0.0036886097
woman O 0 0.0003859208
presented O 0 0.000121223005
with O 0 0.00020158783
dental O 0 0.00097366254
pain B-Disease 0 0.6299866
, O 0 0.00050378777
bad B-Disease 0 0.44580248
breath I-Disease 0 0.9227429
, O 0 0.00038703257
and O 0 0.0003101592
self O 0 0.0011106393
- O 0 0.0008534087
reported O 0 0.0007986961
poor O 0 0.0030072096
esthetics O 0 0.06829861
. O 0 0.0028975853

A O 0 0.012039807
comprehensive O 0 0.0016114909
examination O 0 0.00093966944
including O 0 0.0004543445
her O 0 0.00073165813
medical O 0 0.0011032089
history O 0 0.00053765444
, O 0 0.00027184212
panoramic O 0 0.0057736104
radiograph O 0 0.0027872012
, O 0 0.0001683186
and O 0 0.0001118387
intraoral O 0 0.00022943276
examination O 0 0.000113713075
revealed O 0 0.00010690897
19 O 0 0.000247434
carious B-Disease 0 0.34553203
lesions I-Disease 0 0.4251507
, O 0 0.00024982585
which O 0 0.0001978436
is O 0 0.00012831017
not O 0 0.00011111396
very O 0 0.00022646222
common O 0 0.00022165444
for O 0 0.00021614427
a O 0 0.00069229753
healthy O 0 0.0028084675
adult O 0 0.0024423946
. O 0 0.0019736378

She O 0 0.0035759194
reported O 0 0.0017944622
her O 0 0.0013417937
use O 0 0.0006168357
of O 0 0.0011424299
methamphetamine B-Chemical 1 0.99992144
for O 0 0.0002494498
five O 0 0.00010827936
years O 0 0.000102668295
and O 0 9.371193e-05
had O 0 8.272466e-05
not O 0 6.9782145e-05
experienced O 0 0.00010033498
any O 0 6.550261e-05
major O 0 0.00012250355
carious B-Disease 0 0.27234885
episodes I-Disease 0 0.0088651525
before O 0 8.458327e-05
she O 0 0.00014403557
started O 0 0.00021844858
using O 0 0.00032280252
the O 0 0.00077590917
drug O 0 0.021130102
. O 0 0.0022763177

SUMMARY O 0 0.0047103055
: O 0 0.0017595633
The O 0 0.0006640276
patient O 0 0.00072473317
' O 0 0.0006308002
s O 0 0.00042452363
medical O 0 0.00060617423
and O 0 0.0002211379
dental O 0 0.00032142122
histories O 0 0.00015931409
along O 0 6.579176e-05
with O 0 0.00011515255
radiographic O 0 0.00045531915
and O 0 0.00010968939
clinical O 0 0.00026401904
findings O 0 0.0002101959
lead O 0 0.0006512501
to O 0 7.899938e-05
a O 0 0.00013845408
diagnosis O 0 0.00022339933
of O 0 0.00019008806
" O 0 0.00050814945
meth B-Disease 2 0.99994934
mouth I-Disease 2 0.95192504
. O 0 7.138687e-05
" O 0 6.9559035e-05
Although O 0 2.5191765e-05
three O 0 1.9772311e-05
different O 0 2.7337519e-05
dental O 0 0.00011107073
treatment O 0 6.754044e-05
modalities O 0 0.00012890935
( O 0 8.8167864e-05
either O 0 5.0212006e-05
conventional O 0 6.198763e-05
or O 0 6.184232e-05
implant O 0 0.00020931472
- O 0 0.0002412749
supported O 0 0.00019616431
) O 0 0.0001689766
have O 0 4.8161255e-05
been O 0 4.4106167e-05
offered O 0 6.951515e-05
to O 0 4.573829e-05
the O 0 5.8173984e-05
patient O 0 6.73247e-05
since O 0 3.7061694e-05
August O 0 7.633398e-05
2007 O 0 0.00013541926
, O 0 9.289631e-05
the O 0 9.341295e-05
patient O 0 0.00014314968
has O 0 0.0001114243
yet O 0 0.00018020747
to O 0 0.00015824838
initiate O 0 0.0001909371
any O 0 0.00049991254
treatment O 0 0.0012615649
. O 0 0.0019813406

CLINICAL O 0 0.0051202155
SIGNIFICANCE O 0 0.0029739535
: O 0 0.0011857304
This O 0 0.0008809063
clinical O 0 0.0008799079
case O 0 0.00033569784
showing O 0 0.00035735502
oral O 0 0.010657649
manifestations O 0 0.011127811
of O 0 0.0011073295
meth B-Disease 2 0.99995923
mouth I-Disease 2 0.9650323
was O 0 0.00019122734
presented O 0 8.828162e-05
to O 0 7.7630284e-05
help O 0 0.00013936684
dental O 0 0.0002761339
practitioners O 0 0.00024270585
recognize O 0 5.9636604e-05
and O 0 0.00012782888
manage O 0 0.00027658924
patients O 0 0.00033427696
who O 0 0.0003792311
may O 0 0.00030467426
be O 0 0.0007019142
abusing O 0 0.85133845
methamphetamines B-Chemical 0 0.9998741
. O 0 0.003420429

Dental O 0 0.007161968
practitioners O 0 0.0031652148
also O 0 0.0009890425
may O 0 0.00059116544
be O 0 0.00039613977
skeptical O 0 0.0005651244
about O 0 0.00022451609
the O 0 0.0001746409
reliability O 0 0.00022934967
of O 0 0.00023848737
appointment O 0 0.00054126664
keeping O 0 0.00023008292
by O 0 0.00013303559
these O 0 0.0001897165
patients O 0 0.00021689055
, O 0 0.00012801857
as O 0 8.4693675e-05
they O 0 8.18084e-05
frequently O 0 0.00012779367
miss O 0 0.00039611312
their O 0 0.00027448346
appointments O 0 0.00097473315
without O 0 0.00032698023
reasonable O 0 0.0004732544
justification O 0 0.0016008547
. O 0 0.0019254016

Antituberculosis B-Chemical 0 0.8978404
therapy O 0 0.005597983
- O 0 0.0033815615
induced O 0 0.0021023161
acute B-Disease 2 0.9844705
liver I-Disease 2 0.99614453
failure I-Disease 2 0.97782683
: O 0 0.00076780515
magnitude O 0 0.00023984027
, O 0 0.00026640398
profile O 0 0.0002923766
, O 0 0.0003727155
prognosis O 0 0.019778354
, O 0 0.00039964984
and O 0 0.0003165736
predictors O 0 0.00028909137
of O 0 0.0009357553
outcome O 0 0.0019189543
. O 0 0.002318294

Antituberculosis B-Chemical 0 0.86090285
therapy O 0 0.005117343
( O 0 0.0030865918
ATT O 0 0.027982028
) O 0 0.0016766295
- O 0 0.0010441133
associated O 0 0.0005357116
acute B-Disease 2 0.9467629
liver I-Disease 2 0.9952609
failure I-Disease 2 0.9910308
( O 0 0.0023081726
ATT O 0 0.16143106
- O 0 0.0025636542
ALF B-Disease 2 0.999949
) O 0 0.0005983071
is O 0 0.00015570092
the O 0 0.00015836931
commonest O 0 0.0016284434
drug O 0 0.058525387
- O 0 0.00100633
induced O 0 0.0013012318
ALF B-Disease 2 0.9998945
in O 0 0.0013989372
South O 0 0.0021100442
Asia O 0 0.00328762
. O 0 0.0021925524

Prospective O 0 0.015581657
studies O 0 0.0037094338
on O 0 0.0026950506
ATT O 0 0.04323221
- O 0 0.01179287
ALF B-Disease 2 0.9986339
are O 0 0.0054320158
lacking O 0 0.004753219
. O 0 0.006318106

The O 0 0.0014828868
current O 0 0.0017842231
study O 0 0.0009973324
prospectively O 0 0.0006486912
evaluated O 0 0.00029640328
the O 0 0.00025801797
magnitude O 0 0.00022808112
, O 0 0.00028467312
clinical O 0 0.00048353808
course O 0 0.00018389395
, O 0 0.00022126232
outcome O 0 0.0002157938
, O 0 0.00021591524
and O 0 0.00020493596
prognostic O 0 0.0005274722
factors O 0 0.00048175346
in O 0 0.0006655006
ATT O 0 0.054420512
- O 0 0.006094442
ALF B-Disease 2 0.9995499
. O 0 0.004670327

From O 0 0.0019735636
January O 0 0.0012149492
1986 O 0 0.0018554599
to O 0 0.0005194609
January O 0 0.00037437567
2009 O 0 0.0006766045
, O 0 0.0004455623
1223 O 0 0.006869244
consecutive O 0 0.00039599798
ALF B-Disease 2 0.9998635
patients O 0 0.00046831378
were O 0 0.00013406914
evaluated O 0 9.923294e-05
: O 0 0.00018472412
ATT O 0 0.002021627
alone O 0 0.00015332508
was O 0 0.0001403382
the O 0 0.00011362756
cause O 0 0.0001901885
in O 0 0.00012533108
70 O 0 0.0001846551
( O 0 0.00021671176
5 O 0 0.00012863922
. O 0 0.00014107236
7 O 0 0.00022315132
% O 0 0.0005306231
) O 0 0.0011505334
patients O 0 0.0019754863
. O 0 0.0022457403

Another O 0 0.004191491
15 O 0 0.0020902886
( O 0 0.0020691787
1 O 0 0.00093529763
. O 0 0.00054415566
2 O 0 0.00048438043
% O 0 0.00058895675
) O 0 0.0007047
had O 0 0.00051398616
ATT O 0 0.0042697927
and O 0 0.00085967424
simultaneous O 0 0.0076103513
hepatitis B-Disease 2 0.9999877
virus I-Disease 0 0.74983054
infection I-Disease 0 0.9428354
. O 0 0.006000825

In O 0 0.0025227629
44 O 0 0.0027512226
( O 0 0.0018346764
62 O 0 0.001206999
. O 0 0.0004317525
8 O 0 0.00033722274
% O 0 0.00040786248
) O 0 0.0004906635
patients O 0 0.00039855068
, O 0 0.0003494351
ATT O 0 0.0030536114
was O 0 0.00029011883
prescribed O 0 0.0006063643
empirically O 0 0.00032439656
without O 0 0.00025597177
definitive O 0 0.0004692886
evidence O 0 0.0005045302
of O 0 0.0014331145
tuberculosis B-Disease 0 0.22126824
. O 0 0.0029096538

ATT O 0 0.16068706
- O 0 0.011343866
ALF B-Disease 2 0.99937195
patients O 0 0.0026976445
were O 0 0.0009152325
younger O 0 0.0027792754
( O 0 0.000529053
32 O 0 0.00033798476
. O 0 0.00015599573
87 O 0 0.0004413019
[ O 0 0.00052233756
+ O 0 0.00042966468
/ O 0 0.00063586724
- O 0 0.00031773042
15 O 0 9.848886e-05
. O 0 7.918206e-05
8 O 0 0.000102647726
] O 0 0.00025745502
years O 0 0.000116762574
) O 0 0.00019543584
, O 0 0.00015125121
and O 0 0.00015924561
49 O 0 0.00025142613
( O 0 0.00020769109
70 O 0 0.00018802799
% O 0 0.00023259077
) O 0 0.0003416748
of O 0 0.00041522726
them O 0 0.00097161095
were O 0 0.0010261822
women O 0 0.003028212
. O 0 0.001994071

Most O 0 0.003943286
had O 0 0.0018611205
hyperacute O 0 0.35269225
presentation O 0 0.0015008778
; O 0 0.0006763158
the O 0 0.00037221337
median O 0 0.00044110697
icterus B-Disease 0 0.9998276
encephalopathy B-Disease 2 0.9999651
interval O 0 0.0005382357
was O 0 0.00026251248
4 O 0 0.00011780872
. O 0 9.373776e-05
5 O 0 0.000121738034
( O 0 0.0002540159
0 O 0 0.00023896123
- O 0 0.0005282065
30 O 0 0.00041545054
) O 0 0.0009975511
days O 0 0.00077364995
. O 0 0.002037662

The O 0 0.001465932
median O 0 0.0008032386
duration O 0 0.00055302965
of O 0 0.001036736
ATT O 0 0.00834852
before O 0 0.0005947463
ALF B-Disease 2 0.99964964
was O 0 0.00085352745
30 O 0 0.00038490788
( O 0 0.0005709169
7 O 0 0.00037772165
- O 0 0.0008973531
350 O 0 0.0014391656
) O 0 0.0015162685
days O 0 0.0010191896
. O 0 0.002460527

At O 0 0.0009963211
presentation O 0 0.0020891768
, O 0 0.0018764097
advanced O 0 0.010792791
encephalopathy B-Disease 2 0.9998247
and O 0 0.00205081
cerebral B-Disease 0 0.98594683
edema I-Disease 0 0.9999156
were O 0 0.00032500364
present O 0 0.000118921474
in O 0 0.00012851907
51 O 0 0.00021711506
( O 0 0.00017145315
76 O 0 0.00020710714
% O 0 0.00014350747
) O 0 0.00018191386
and O 0 0.00013655762
29 O 0 0.0002583572
( O 0 0.00021618839
41 O 0 0.0002505878
. O 0 0.00010758104
4 O 0 0.00014029686
% O 0 0.0002808403
) O 0 0.00054344354
patients O 0 0.0008109103
, O 0 0.0011920155
respectively O 0 0.0029682878
. O 0 0.002508486

Gastrointestinal B-Disease 0 0.73319507
bleed I-Disease 0 0.870125
, O 0 0.0043692775
seizures B-Disease 0 0.9997341
, O 0 0.001971006
infection B-Disease 0 0.015766842
, O 0 0.000592
and O 0 0.00047425515
acute B-Disease 0 0.58067286
renal I-Disease 0 0.9933189
failure I-Disease 0 0.5247605
were O 0 0.00022016236
documented O 0 0.00016623552
in O 0 8.273429e-05
seven O 0 7.958932e-05
( O 0 0.00012279222
10 O 0 8.029263e-05
% O 0 0.00012152739
) O 0 0.00017104442
, O 0 0.00010868694
five O 0 6.058036e-05
( O 0 0.00013374559
7 O 0 6.323192e-05
. O 0 5.5574874e-05
1 O 0 7.550562e-05
% O 0 0.000115532675
) O 0 0.00017377347
, O 0 0.00012934869
26 O 0 0.00015964791
( O 0 0.00014916924
37 O 0 0.00018037524
. O 0 6.9480615e-05
1 O 0 8.590508e-05
% O 0 0.00012761149
) O 0 0.00019107206
, O 0 0.0001405364
and O 0 0.00014015232
seven O 0 0.0001376998
( O 0 0.00023355724
10 O 0 0.00018724706
% O 0 0.0003291709
) O 0 0.0005986043
patients O 0 0.0008570439
, O 0 0.0012084541
respectively O 0 0.0030055726
. O 0 0.0024867945

Compared O 0 0.0026665865
with O 0 0.009777116
hepatitis B-Disease 2 0.99999213
E I-Disease 0 0.9999411
virus O 0 0.43955705
( O 0 0.0040065576
HEV O 0 0.94883645
) O 0 0.0008995513
and O 0 0.0003033405
non O 0 0.00043095392
- O 0 0.00065355917
A O 0 0.009220445
non O 0 0.0005789958
- O 0 0.0017634252
E O 0 0.9983802
- O 0 0.0010275483
induced O 0 0.0009446528
ALF B-Disease 2 0.9999863
, O 0 0.0009865644
ATT O 0 0.1271685
- O 0 0.0013868818
ALF B-Disease 2 0.9999548
patients O 0 0.00034473516
had O 0 7.961832e-05
nearly O 0 7.435139e-05
similar O 0 4.077452e-05
presentations O 0 9.67514e-05
except O 0 5.303319e-05
for O 0 6.99587e-05
older O 0 0.00044881477
age O 0 0.00015339967
and O 0 0.00014721656
less O 0 0.00026576087
elevation O 0 0.014335851
of O 0 0.001629498
liver O 0 0.9675473
enzymes O 0 0.0892013
. O 0 0.0025009592

The O 0 0.0019551383
mortality O 0 0.0050568236
rate O 0 0.0011746336
among O 0 0.0007973866
patients O 0 0.00071707374
with O 0 0.0006955611
ATT O 0 0.09325572
- O 0 0.0027091685
ALF B-Disease 2 0.99991786
was O 0 0.0005012299
high O 0 0.00051833806
( O 0 0.0002884535
67 O 0 0.0002611211
. O 0 7.344657e-05
1 O 0 8.0631165e-05
% O 0 0.00010090799
, O 0 0.00011247054
n O 0 9.9658726e-05
= O 0 0.0001362126
47 O 0 0.00019436171
) O 0 0.00016720811
, O 0 0.00010542976
and O 0 9.53406e-05
only O 0 0.00012429182
23 O 0 0.00018521107
( O 0 0.00015157678
32 O 0 0.00013357161
. O 0 6.703488e-05
9 O 0 8.682616e-05
% O 0 0.00013610095
) O 0 0.00021311479
patients O 0 0.00021518524
recovered O 0 0.0002428894
with O 0 0.0005482453
medical O 0 0.0021993543
treatment O 0 0.001495599
. O 0 0.0020619575

In O 0 0.0016791214
multivariate O 0 0.0016544956
analysis O 0 0.0008672291
, O 0 0.00054865814
three O 0 0.00016286835
factors O 0 0.0002341358
independently O 0 0.0001254437
predicted O 0 0.00016214796
mortality O 0 0.0022816542
: O 0 0.00036278646
serum O 0 0.30580503
bilirubin B-Chemical 1 0.9999863
( O 0 0.0009710898
> O 0 0.0004953376
or O 0 0.00012211113
= O 0 0.00013593509
10 O 0 6.567342e-05
. O 0 4.526161e-05
8 O 0 5.8484693e-05
mg O 0 0.0010012158
/ O 0 0.0004965417
dL O 0 0.0015128736
) O 0 0.0002695434
, O 0 0.00020599444
prothrombin O 0 0.9077757
time O 0 7.8148056e-05
( O 0 0.00020911384
PT O 0 0.0037520076
) O 0 0.00021496885
prolongation O 0 0.0005803871
( O 0 0.0001817949
> O 0 0.00021847482
or O 0 9.2256465e-05
= O 0 0.00012157156
26 O 0 0.00010166279
seconds O 0 6.695279e-05
) O 0 0.00016203546
, O 0 0.00013311948
and O 0 0.00017807745
grade O 0 0.003797036
III O 0 0.0071542007
/ O 0 0.0018626073
IV O 0 0.20673484
encephalopathy B-Disease 2 0.9997261
at O 0 0.0009832849
presentation O 0 0.0024878795
. O 0 0.002268002

CONCLUSION O 0 0.029370027
: O 0 0.004475857
ATT O 0 0.043033678
- O 0 0.005671787
ALF B-Disease 2 0.999508
constituted O 0 0.0018252548
5 O 0 0.00036891972
. O 0 0.00019327691
7 O 0 0.00015347208
% O 0 0.00021599451
of O 0 0.0004254871
ALF B-Disease 2 0.999762
at O 0 0.00019110431
our O 0 0.00028592243
center O 0 0.00027909543
and O 0 0.00024480492
had O 0 0.00028928634
a O 0 0.00052458287
high O 0 0.0013176429
mortality O 0 0.013914307
rate O 0 0.0022339583
. O 0 0.0023234165

Because O 0 0.0016764601
the O 0 0.0017950431
mortality O 0 0.005738408
rate O 0 0.0011108477
is O 0 0.0006402239
so O 0 0.00039852297
high O 0 0.0005892919
, O 0 0.0003189043
determining O 0 0.00017132485
which O 0 0.0002925271
factors O 0 0.00033450586
are O 0 0.00025420074
predictors O 0 0.00021566625
is O 0 0.00047773158
less O 0 0.0007642916
important O 0 0.0009921578
. O 0 0.0023308252

A O 0 0.014304178
high O 0 0.0022885401
proportion O 0 0.0009273743
of O 0 0.0008727762
patients O 0 0.0008656361
had O 0 0.000545093
consumed O 0 0.0024734535
ATT O 0 0.007288084
empirically O 0 0.0006970612
, O 0 0.00045896822
which O 0 0.00048628252
could O 0 0.00041402024
have O 0 0.00050564186
been O 0 0.0008600401
prevented O 0 0.0043959497
. O 0 0.0029647818

Design O 0 0.008607642
and O 0 0.0016254552
analysis O 0 0.00085619435
of O 0 0.0007445964
the O 0 0.00063390034
HYPREN O 0 0.12898785
- O 0 0.00068744936
trial O 0 0.0002597012
: O 0 0.00015971703
safety O 0 0.00015497263
of O 0 0.00033832676
enalapril B-Chemical 1 0.9999933
and O 0 0.0010914068
prazosin B-Chemical 1 0.9999968
in O 0 0.00012796107
the O 0 6.6262735e-05
initial O 0 6.660045e-05
treatment O 0 9.344762e-05
phase O 0 0.00025878026
of O 0 0.00023441548
patients O 0 0.00044710247
with O 0 0.0009095975
congestive B-Disease 0 0.99918205
heart I-Disease 0 0.7386392
failure I-Disease 0 0.7257934
. O 0 0.0025236006

Since O 0 0.0011502557
the O 0 0.0010013641
introduction O 0 0.00068181247
of O 0 0.0014442344
angiotensin B-Chemical 1 0.99991775
converting I-Chemical 0 0.3758392
enzyme I-Chemical 0 0.25680974
( I-Chemical 0 0.0015002289
ACE I-Chemical 0 0.9993938
) I-Chemical 0 0.00043232908
inhibitors I-Chemical 0 0.00031235666
into O 0 3.718706e-05
the O 0 6.528615e-05
adjunctive O 0 0.00021273861
treatment O 0 6.5810964e-05
of O 0 0.00010354252
patients O 0 0.00016006417
with O 0 0.00027954814
congestive B-Disease 0 0.99884605
heart I-Disease 0 0.46039963
failure I-Disease 0 0.2443413
, O 0 0.00015485326
cases O 0 0.00010757111
of O 0 0.00016597181
severe O 0 0.054667324
hypotension B-Disease 0 0.9999409
, O 0 0.00021052183
especially O 0 8.3677376e-05
on O 0 3.2032232e-05
the O 0 4.6766756e-05
first O 0 3.557688e-05
day O 0 4.6869758e-05
of O 0 0.00012721894
treatment O 0 0.00018527308
, O 0 0.0002744047
have O 0 0.00023488619
occasionally O 0 0.0007676668
been O 0 0.00063795503
reported O 0 0.0015131948
. O 0 0.0018887509

To O 0 0.0016764746
assess O 0 0.0007093793
the O 0 0.00068244524
safety O 0 0.0006604553
of O 0 0.0005182526
the O 0 0.0006306148
ACE B-Chemical 0 0.99984825
inhibitor I-Chemical 0 0.705892
enalapril B-Chemical 1 0.9999964
a O 0 0.0014365228
multicenter O 0 0.07104006
, O 0 0.00017676469
randomized O 0 0.00018219712
, O 0 0.00027821658
prazosin B-Chemical 1 0.99999654
- O 0 0.00046691613
controlled O 0 7.803174e-05
trial O 0 9.2442715e-05
was O 0 5.227723e-05
designed O 0 3.894734e-05
that O 0 3.175555e-05
compared O 0 3.3409753e-05
the O 0 5.8234036e-05
incidence O 0 0.00015591455
and O 0 8.406014e-05
severity O 0 0.00021895049
of O 0 0.00018753528
symptomatic O 0 0.008088854
hypotension B-Disease 0 0.9993325
on O 0 9.279609e-05
the O 0 0.000120663455
first O 0 0.0001103358
day O 0 0.00018133993
of O 0 0.0005980161
treatment O 0 0.0012535529
. O 0 0.0019205256

Trial O 0 0.007170246
medication O 0 0.0069927415
was O 0 0.0014236111
2 O 0 0.00064364326
. O 0 0.00037420867
5 O 0 0.000404609
mg O 0 0.024795698
enalapril B-Chemical 1 0.9999504
or O 0 0.00083496055
0 O 0 0.00061289273
. O 0 0.0005913661
5 O 0 0.0013354301
prazosin B-Chemical 1 0.99982977
. O 0 0.0048740185

Subjects O 0 0.0031180722
were O 0 0.001941597
1210 O 0 0.05634212
inpatients O 0 0.0019819385
with O 0 0.0005693389
New O 0 0.0005165812
York O 0 0.00087482267
Heart O 0 0.0009402663
Association O 0 0.0002653965
( O 0 0.0004052304
NYHA O 0 0.0022430357
) O 0 0.0004545611
functional O 0 0.00038775642
class O 0 0.00076098094
II O 0 0.004232701
and O 0 0.0016775954
III O 0 0.012853289
. O 0 0.0030390064

Patients O 0 0.0021798208
who O 0 0.0016205027
received O 0 0.0010363557
enalapril B-Chemical 1 0.9999522
experienced O 0 0.0011512241
clinically O 0 0.0022936305
and O 0 0.00026274336
statistically O 0 0.00016229118
significantly O 0 0.0001682406
less O 0 0.00017684576
symptomatic O 0 0.012312233
hypotension B-Disease 0 0.9999032
( O 0 0.00040324565
5 O 0 7.672147e-05
. O 0 4.922575e-05
2 O 0 5.625053e-05
% O 0 7.6321456e-05
) O 0 9.1387e-05
than O 0 3.8687842e-05
the O 0 6.494711e-05
patients O 0 0.00013479854
who O 0 0.00020087925
received O 0 0.00024290169
prazosin B-Chemical 1 0.99999297
( O 0 0.00061093725
12 O 0 0.00016737227
. O 0 0.00020552517
9 O 0 0.00039001726
% O 0 0.0008400271
) O 0 0.0018789654
. O 0 0.0021584856

All O 0 0.014181562
patients O 0 0.018289758
recovered O 0 0.01815867
. O 0 0.02198461

It O 0 0.0024595968
was O 0 0.0011659286
concluded O 0 0.00049789954
that O 0 0.00033235416
treatment O 0 0.00046002428
with O 0 0.0011298411
enalapril B-Chemical 1 0.9999912
was O 0 0.00057394314
well O 0 0.00018255727
tolerated O 0 0.0018110641
and O 0 0.00016873848
it O 0 0.00015281
is O 0 0.00012283318
, O 0 0.00012274689
therefore O 0 0.000116729745
, O 0 0.000116903175
unreasonable O 0 0.00021347232
to O 0 6.0043636e-05
restrict O 0 4.3984233e-05
the O 0 6.120588e-05
initiation O 0 6.1436454e-05
of O 0 0.00015137586
treatment O 0 0.00023254177
with O 0 0.0010169763
enalapril B-Chemical 1 0.9999778
to O 0 0.0014864553
inpatients O 0 0.011072657
. O 0 0.0019054743

Central B-Disease 0 0.0034515117
nervous I-Disease 0 0.0074578617
system I-Disease 0 0.0013228119
complications I-Disease 0 0.0038269423
during O 0 0.00029287426
treatment O 0 0.00044727259
of O 0 0.0012084013
acute B-Disease 0 0.99897087
lymphoblastic I-Disease 0 0.99999726
leukemia I-Disease 0 0.99999535
in O 0 0.002464512
a O 0 0.0013873415
single O 0 0.000959682
pediatric O 0 0.0027841716
institution O 0 0.0026100208
. O 0 0.0022286656

Central B-Disease 0 0.0039659864
nervous I-Disease 0 0.009729293
system I-Disease 0 0.0016863854
( I-Disease 0 0.0016582711
CNS I-Disease 0 0.021491505
) I-Disease 0 0.00095675274
complications I-Disease 0 0.0019948853
during O 0 0.00011919917
treatment O 0 0.00018070819
of O 0 0.00037789182
childhood O 0 0.735382
acute B-Disease 0 0.9997999
lymphoblastic I-Disease 0 0.99999917
leukemia I-Disease 0 0.99999905
( O 0 0.29580414
ALL B-Disease 0 0.99992955
) O 0 0.0012477612
remain O 0 0.0003049527
a O 0 0.0004541704
challenging O 0 0.000549776
clinical O 0 0.0017044992
problem O 0 0.0020609647
. O 0 0.0022352405

Outcome O 0 0.0018836161
improvement O 0 0.0011668523
with O 0 0.0007585797
more O 0 0.0006414057
intensive O 0 0.00046478023
chemotherapy O 0 0.0021966398
has O 0 0.00023743462
significantly O 0 0.00032073492
increased O 0 0.00037035692
the O 0 0.0002611923
incidence O 0 0.0005922596
and O 0 0.0003595225
severity O 0 0.0009933931
of O 0 0.0010786467
adverse O 0 0.19850697
events O 0 0.009836462
. O 0 0.0026259595

This O 0 0.003124875
study O 0 0.0013533114
analyzed O 0 0.0006143618
the O 0 0.0004803389
incidence O 0 0.00076857675
of O 0 0.00078776316
neurological B-Disease 0 0.99877363
complications I-Disease 0 0.9112321
during O 0 0.0002816031
ALL B-Disease 0 0.9997335
treatment O 0 0.00028420158
in O 0 0.00011988014
a O 0 0.00015337479
single O 0 0.00011944768
pediatric O 0 0.00031591213
institution O 0 0.00018275513
, O 0 0.000106396285
focusing O 0 0.00010717221
on O 0 7.261144e-05
clinical O 0 0.0004088895
, O 0 0.00025715915
radiological O 0 0.0009879414
, O 0 0.0003967475
and O 0 0.0005163665
electrophysiological O 0 0.0029617161
findings O 0 0.002652262
. O 0 0.0022111295

Exclusion O 0 0.008495415
criteria O 0 0.0014842163
included O 0 0.0009391471
CNS O 0 0.099499084
leukemic B-Disease 0 0.9983467
infiltration I-Disease 0 0.20246519
at O 0 0.0003002168
diagnosis O 0 0.0007449094
, O 0 0.00025597957
therapy O 0 0.00028905616
- O 0 0.00027054004
related O 0 9.353855e-05
peripheral B-Disease 2 0.80627984
neuropathy I-Disease 2 0.9999963
, O 0 0.0006736153
late O 0 0.0009814674
- O 0 0.000587487
onset O 0 0.0008730973
encephalopathy B-Disease 2 0.99992573
, O 0 0.00042237394
or O 0 0.00020029019
long O 0 0.0002727708
- O 0 0.0005618543
term O 0 0.0006756249
neurocognitive B-Disease 0 0.9616581
defects I-Disease 0 0.21176507
. O 0 0.0030444649

During O 0 0.0013295421
a O 0 0.0020311407
9 O 0 0.0011201608
- O 0 0.0011131454
year O 0 0.00030171778
period O 0 0.00016388217
, O 0 0.00020253516
we O 0 8.118279e-05
retrospectively O 0 0.00011774122
collected O 0 8.455224e-05
27 O 0 0.00024819173
neurological O 0 0.2513143
events O 0 0.0010401887
( O 0 0.00025453008
11 O 0 0.00012634632
% O 0 0.00011884224
) O 0 0.00013447809
in O 0 6.863892e-05
as O 0 6.715755e-05
many O 0 6.949188e-05
patients O 0 0.00012668277
, O 0 8.692881e-05
from O 0 7.045662e-05
253 O 0 0.0005151336
children O 0 0.00015003227
enrolled O 0 0.00012702426
in O 0 0.00011567774
the O 0 0.0003333439
ALL B-Disease 0 0.99938786
front O 0 0.0039622625
- O 0 0.001572871
line O 0 0.0014486988
protocol O 0 0.0017712901
. O 0 0.0020684868

CNS O 0 0.042034112
complications O 0 0.011291454
included O 0 0.0010269049
posterior O 0 0.003534789
reversible O 0 0.2292705
leukoencephalopathy B-Disease 2 0.99958247
syndrome O 0 0.8043063
( O 0 0.000698699
n O 0 0.00021132367
= O 0 0.000195679
10 O 0 0.00012799854
) O 0 0.00025885698
, O 0 0.00028039914
stroke B-Disease 0 0.98575366
( O 0 0.00033604974
n O 0 0.00012558085
= O 0 0.00012413194
5 O 0 6.301226e-05
) O 0 0.000117066615
, O 0 9.379302e-05
temporal B-Disease 0 0.0010514872
lobe I-Disease 0 0.4824019
epilepsy I-Disease 2 0.9999863
( O 0 0.0005235945
n O 0 0.00012345577
= O 0 0.000118562086
2 O 0 6.415892e-05
) O 0 0.00010905361
, O 0 7.9186735e-05
high O 0 0.00017703592
- O 0 0.000267655
dose O 0 0.003980585
methotrexate B-Chemical 0 0.99996364
toxicity B-Disease 2 0.9996456
( O 0 0.00045835305
n O 0 0.00011083078
= O 0 0.000112283764
2 O 0 6.2200204e-05
) O 0 0.00011391461
, O 0 9.7881304e-05
syndrome O 0 0.0018256874
of O 0 0.00012039554
inappropriate B-Disease 0 0.000436849
antidiuretic I-Disease 0 0.936157
hormone I-Disease 0 0.17853272
secretion I-Disease 0 0.0010734147
( O 0 0.00016927044
n O 0 8.848828e-05
= O 0 0.0001119089
1 O 0 7.4654476e-05
) O 0 0.00013571398
, O 0 0.00010399255
and O 0 0.00010703168
other O 0 0.0001373037
unclassified O 0 0.001529964
events O 0 0.0009155963
( O 0 0.00043210885
n O 0 0.00034005046
= O 0 0.0005822293
7 O 0 0.00058109616
) O 0 0.0016809001
. O 0 0.0020315582

In O 0 0.0019899264
conclusion O 0 0.0015914654
, O 0 0.0018066019
CNS O 0 0.053086445
complications O 0 0.017098632
are O 0 0.000371565
frequent O 0 0.00033121736
events O 0 0.00061421865
during O 0 0.00017157546
ALL B-Disease 0 0.999482
therapy O 0 0.0006571928
, O 0 0.00019308849
and O 0 0.0001094975
require O 0 5.532877e-05
rapid O 0 0.00021094558
detection O 0 0.00017141047
and O 0 0.00014674566
prompt O 0 0.0004861154
treatment O 0 0.00023753334
to O 0 0.00029599067
limit O 0 0.0014578367
permanent O 0 0.0181924
damage O 0 0.6234886
. O 0 0.0029444247

Cocaine B-Chemical 0 0.99939454
causes O 0 0.0044365907
memory B-Disease 0 0.13081267
and I-Disease 0 0.0009492008
learning I-Disease 0 0.0015003677
impairments I-Disease 0 0.03758794
in O 0 0.00029773754
rats O 0 0.00035479013
: O 0 0.00019755859
involvement O 0 0.00018020472
of O 0 0.00017342901
nuclear O 0 0.0004989647
factor O 0 0.001144772
kappa O 0 0.12540035
B O 0 0.2167291
and O 0 0.00039641702
oxidative O 0 0.61663246
stress O 0 0.013852862
, O 0 0.00042879887
and O 0 0.00040696762
prevention O 0 0.0011859179
by O 0 0.0024507898
topiramate B-Chemical 0 0.99993825
. O 0 0.0034522468

Different O 0 0.002115584
mechanisms O 0 0.0015096557
have O 0 0.0006339906
been O 0 0.0003836535
suggested O 0 0.00028610023
for O 0 0.00041480083
cocaine B-Chemical 1 0.99987304
toxicity B-Disease 2 0.9989981
including O 0 0.00017357955
an O 0 0.00019816983
increase O 0 0.0001359137
in O 0 0.0001509141
oxidative O 0 0.48234206
stress O 0 0.0066890605
but O 0 0.000115392184
the O 0 6.20789e-05
association O 0 4.0569113e-05
between O 0 5.0254348e-05
oxidative O 0 0.13373603
status O 0 7.677593e-05
in O 0 5.8585287e-05
the O 0 7.756546e-05
brain O 0 0.0010529667
and O 0 0.00034086435
cocaine B-Chemical 1 0.99969745
induced O 0 0.0006387255
- O 0 0.0006778263
behaviour O 0 0.00048845186
is O 0 0.0005158888
poorly O 0 0.0013742907
understood O 0 0.0027944644
. O 0 0.0019536177

Nuclear O 0 0.012867805
factor O 0 0.0077911164
kappa O 0 0.15895593
B O 0 0.41564855
( O 0 0.0021776399
NFkappaB O 0 0.023568759
) O 0 0.0009698461
is O 0 0.0002837816
a O 0 0.00024402238
sensor O 0 0.00014232325
of O 0 0.00031962994
oxidative O 0 0.46906334
stress O 0 0.0055120126
and O 0 0.00014061293
participates O 0 6.614468e-05
in O 0 9.1989845e-05
memory O 0 0.029824171
formation O 0 0.00047273186
that O 0 7.572973e-05
could O 0 7.5048265e-05
be O 0 7.182546e-05
involved O 0 6.7004774e-05
in O 0 0.00017745217
drug O 0 0.6753538
toxicity B-Disease 2 0.99978083
and O 0 0.0016120211
addiction O 0 0.5304615
mechanisms O 0 0.0021152142
. O 0 0.0019782938

Therefore O 0 0.0023945027
NFkappaB O 0 0.010419749
activity O 0 0.0017145339
, O 0 0.0017589994
oxidative O 0 0.53407276
stress O 0 0.019611344
, O 0 0.00077998533
neuronal O 0 0.026152616
nitric B-Chemical 0 0.9993799
oxide I-Chemical 0 0.9937682
synthase O 0 0.6689103
( O 0 0.0004757992
nNOS O 0 0.013605174
) O 0 0.0001765134
activity O 0 7.448324e-05
, O 0 7.8719044e-05
spatial O 0 0.00014904016
learning O 0 0.00025100174
and O 0 0.00012308186
memory O 0 0.052361432
as O 0 8.594122e-05
well O 0 4.9916005e-05
as O 0 4.3291246e-05
the O 0 4.5122237e-05
effect O 0 6.3921485e-05
of O 0 0.000487905
topiramate B-Chemical 0 0.9999957
, O 0 0.00018129496
a O 0 0.00010290057
previously O 0 5.1399064e-05
proposed O 0 5.5624925e-05
therapy O 0 0.00011472555
for O 0 0.00012528995
cocaine B-Disease 1 0.99999285
addiction I-Disease 0 0.9974878
, O 0 0.0001861299
were O 0 7.07068e-05
evaluated O 0 4.5307563e-05
in O 0 5.0326384e-05
an O 0 8.584628e-05
experimental O 0 0.00011864986
model O 0 0.00016594415
of O 0 0.0005009209
cocaine B-Chemical 1 0.99968076
administration O 0 0.0061043627
in O 0 0.0008319664
rats O 0 0.0020884057
. O 0 0.0016949743

NFkappaB O 0 0.013585127
activity O 0 0.0017556737
was O 0 0.001106566
decreased O 0 0.0009025748
in O 0 0.00031647942
the O 0 0.0002602837
frontal O 0 0.0056866943
cortex O 0 0.005772559
of O 0 0.00074443605
cocaine B-Chemical 1 0.99984324
treated O 0 0.00067661295
rats O 0 0.00031790737
, O 0 0.00012444126
as O 0 7.642997e-05
well O 0 8.68737e-05
as O 0 0.00028612616
GSH B-Chemical 1 0.9999976
concentration O 0 0.007538981
and O 0 0.0023435426
glutathione B-Chemical 0 0.9999956
peroxidase O 0 0.9964754
activity O 0 0.0001532729
in O 0 8.444305e-05
the O 0 0.00010483148
hippocampus O 0 0.018427858
, O 0 0.00018550748
whereas O 0 0.00016502562
nNOS O 0 0.0048300563
activity O 0 0.00014636651
in O 0 0.00016629737
the O 0 0.00029973488
hippocampus O 0 0.023343774
was O 0 0.0010808551
increased O 0 0.0024580748
. O 0 0.0022039192

Memory O 0 0.028572032
retrieval O 0 0.0016834465
of O 0 0.0010251622
experiences O 0 0.00095448614
acquired O 0 0.0005827284
prior O 0 0.00018568055
to O 0 0.00038170378
cocaine B-Chemical 1 0.9996816
administration O 0 0.004559603
was O 0 0.0002551419
impaired O 0 0.0004607054
and O 0 0.00012318509
negatively O 0 0.00011063765
correlated O 0 8.586913e-05
with O 0 0.00018970927
NFkappaB O 0 0.0022664992
activity O 0 0.00022496459
in O 0 0.00025367248
the O 0 0.00046678315
frontal O 0 0.056388408
cortex O 0 0.045625784
. O 0 0.0024726535

In O 0 0.0020807935
contrast O 0 0.002014394
, O 0 0.0012133907
learning O 0 0.0011411275
of O 0 0.00061414053
new O 0 0.00048541324
tasks O 0 0.00048073026
was O 0 0.00024682612
enhanced O 0 0.00024056029
and O 0 0.00015116326
correlated O 0 8.6872285e-05
with O 0 0.00013362143
the O 0 0.0001072407
increase O 0 0.00012451259
of O 0 0.00024487378
nNOS O 0 0.0101337405
activity O 0 0.00015882296
and O 0 0.00018354377
the O 0 0.00023863521
decrease O 0 0.00072773994
of O 0 0.003981077
glutathione B-Chemical 0 0.9999585
peroxidase O 0 0.99883145
. O 0 0.0040587303

These O 0 0.002190686
results O 0 0.0013392192
provide O 0 0.00076469226
evidence O 0 0.00051840825
for O 0 0.0003411057
a O 0 0.00042277944
possible O 0 0.00024350248
mechanistic O 0 0.00041294354
role O 0 0.00013578414
of O 0 0.00039346903
oxidative O 0 0.6323675
and O 0 0.0005499026
nitrosative O 0 0.98680264
stress O 0 0.013443867
and O 0 0.00027569436
NFkappaB O 0 0.0035585708
in O 0 0.00017603471
the O 0 0.00021798669
alterations O 0 0.0009315342
induced O 0 0.0008455104
by O 0 0.0020028148
cocaine B-Chemical 1 0.9994294
. O 0 0.0032314723

Topiramate B-Chemical 0 0.9997731
prevented O 0 0.008535961
all O 0 0.001471476
the O 0 0.00095461385
alterations O 0 0.0018018443
observed O 0 0.0006881947
, O 0 0.0008625353
showing O 0 0.00085632317
novel O 0 0.0015491373
neuroprotective O 0 0.14600621
properties O 0 0.0025736159
. O 0 0.003492352

Efficacy O 0 0.003528374
and O 0 0.0012614315
safety O 0 0.0010746793
of O 0 0.001267819
asenapine B-Chemical 1 0.9998479
in O 0 0.00040143795
a O 0 0.00046036864
placebo O 0 0.0030024466
- O 0 0.0005194084
and O 0 0.0005001697
haloperidol B-Chemical 1 0.99999654
- O 0 0.0006030284
controlled O 0 0.00010944678
trial O 0 0.0001250937
in O 0 9.152794e-05
patients O 0 0.0002008691
with O 0 0.00034701763
acute O 0 0.46500334
exacerbation O 0 0.8127924
of O 0 0.0071440674
schizophrenia B-Disease 2 0.9998248
. O 0 0.003392658

Asenapine B-Chemical 0 0.99778783
is O 0 0.002146365
approved O 0 0.0013481348
by O 0 0.0006320544
the O 0 0.00047095524
Food O 0 0.0028995033
and O 0 0.0003670917
Drugs O 0 0.013402701
Administration O 0 0.0013243145
in O 0 0.00015579164
adults O 0 0.00026613486
for O 0 8.641596e-05
acute O 0 0.03480834
treatment O 0 0.00015363503
of O 0 0.00032063553
schizophrenia B-Disease 2 0.99986446
or O 0 0.0001205812
of O 0 0.00030332283
manic B-Disease 0 0.9999497
or O 0 8.591179e-05
mixed O 0 0.00019926004
episodes O 0 0.00037591485
associated O 0 9.3069655e-05
with O 0 0.0005017848
bipolar B-Disease 2 0.99999094
I I-Disease 0 0.909862
disorder I-Disease 0 0.98794377
with O 0 0.00035521097
or O 0 0.0002636281
without O 0 0.0007238904
psychotic B-Disease 0 0.9997974
features O 0 0.002571242
. O 0 0.001970871

In O 0 0.0021830425
a O 0 0.0023114285
double O 0 0.0022821494
- O 0 0.0020976418
blind O 0 0.005411061
6 O 0 0.00025593225
- O 0 0.0003380094
week O 0 9.167154e-05
trial O 0 0.00016863956
, O 0 0.0001592295
458 O 0 0.0009726245
patients O 0 0.0001694143
with O 0 0.0001913645
acute O 0 0.48625663
schizophrenia B-Disease 2 0.99990463
were O 0 7.938543e-05
randomly O 0 1.606866e-05
assigned O 0 2.47896e-05
to O 0 2.8520497e-05
fixed O 0 4.198791e-05
- O 0 0.00011097735
dose O 0 0.00020004896
treatment O 0 7.037571e-05
with O 0 0.00018515
asenapine B-Chemical 1 0.9999268
at O 0 4.2809315e-05
5 O 0 3.663615e-05
mg O 0 0.00039010466
twice O 0 4.0408333e-05
daily O 0 9.01412e-05
( O 0 0.00015068921
BID O 0 0.83154666
) O 0 0.00024682164
, O 0 0.00016583594
asenapine B-Chemical 1 0.99980086
at O 0 4.783595e-05
10 O 0 6.549792e-05
mg O 0 0.005410958
BID O 0 0.9159597
, O 0 0.0001845882
placebo O 0 0.0007774961
, O 0 0.00010462515
or O 0 0.00015023412
haloperidol B-Chemical 1 0.99999225
at O 0 9.1042726e-05
4 O 0 9.139397e-05
mg O 0 0.0052773817
BID O 0 0.85653555
( O 0 0.00030803715
to O 0 0.00016906108
verify O 0 0.00019254083
assay O 0 0.0013212684
sensitivity O 0 0.0041589737
) O 0 0.0029515584
. O 0 0.002295329

With O 0 0.0019681614
last O 0 0.0006776442
observations O 0 0.0009730115
carried O 0 0.0007333153
forward O 0 0.0024811116
( O 0 0.0010587748
LOCF O 0 0.0132909985
) O 0 0.00039780638
, O 0 0.00015940027
mean O 0 6.894298e-05
Positive O 0 0.00030716154
and O 0 0.00014487193
Negative O 0 0.0012493548
Syndrome O 0 0.02844262
Scale O 0 0.0012867643
total O 0 7.527971e-05
score O 0 4.7658275e-05
reductions O 0 6.411672e-05
from O 0 3.795496e-05
baseline O 0 3.670956e-05
to O 0 3.742714e-05
endpoint O 0 7.403084e-05
were O 0 4.3606018e-05
significantly O 0 5.448214e-05
greater O 0 5.4951124e-05
with O 0 0.00015114307
asenapine B-Chemical 1 0.9998934
at O 0 4.8808655e-05
5 O 0 5.4446045e-05
mg O 0 0.0059148027
BID O 0 0.95057666
( O 0 0.00030210003
- O 0 0.00020685927
16 O 0 7.219724e-05
. O 0 4.184385e-05
2 O 0 5.456315e-05
) O 0 0.00012343434
and O 0 0.00022176625
haloperidol B-Chemical 1 0.9999964
( O 0 0.0005159612
- O 0 0.00023315387
15 O 0 5.779763e-05
. O 0 4.313436e-05
4 O 0 4.77914e-05
) O 0 9.01988e-05
than O 0 5.548528e-05
placebo O 0 0.0005880346
( O 0 0.00017746146
- O 0 0.00019219742
10 O 0 7.886841e-05
. O 0 5.4790165e-05
7 O 0 5.9328588e-05
; O 0 0.000103642495
both O 0 0.00014218895
P O 0 0.0030327674
< O 0 0.00011064187
0 O 0 9.050261e-05
. O 0 8.746028e-05
05 O 0 0.0016781217
) O 0 0.00018685807
; O 0 9.5916e-05
using O 0 5.063158e-05
mixed O 0 0.0001202738
model O 0 7.33951e-05
for O 0 3.81071e-05
repeated O 0 3.2223605e-05
measures O 0 4.086265e-05
( O 0 0.0001722155
MMRM O 0 0.008014947
) O 0 0.00015912646
, O 0 7.258438e-05
changes O 0 6.152539e-05
at O 0 3.095007e-05
day O 0 2.9864223e-05
42 O 0 5.0808994e-05
were O 0 3.9945964e-05
significantly O 0 5.254032e-05
greater O 0 5.65376e-05
with O 0 0.0001610776
asenapine B-Chemical 1 0.99989784
at O 0 4.7633563e-05
5 O 0 3.782452e-05
and O 0 4.8862585e-05
10 O 0 6.301058e-05
mg O 0 0.006576481
BID O 0 0.95746887
( O 0 0.00035140206
- O 0 0.00024173586
21 O 0 8.99276e-05
. O 0 4.5149096e-05
3 O 0 4.9151728e-05
and O 0 8.523946e-05
- O 0 0.00018263633
19 O 0 0.00012280943
. O 0 4.824036e-05
4 O 0 5.1940817e-05
, O 0 9.037118e-05
respectively O 0 0.00023420191
) O 0 0.00020706886
and O 0 0.00031363618
haloperidol B-Chemical 1 0.99999714
( O 0 0.0005734313
- O 0 0.00024820238
20 O 0 8.3274026e-05
. O 0 4.642045e-05
0 O 0 6.0765506e-05
) O 0 0.00010459344
than O 0 6.368414e-05
placebo O 0 0.0006515743
( O 0 0.00020452036
- O 0 0.0002289271
14 O 0 9.816191e-05
. O 0 7.503575e-05
6 O 0 8.544356e-05
; O 0 0.000191295
all O 0 0.00027239783
P O 0 0.0026571052
< O 0 0.00038305053
0 O 0 0.00043035208
. O 0 0.0006306305
05 O 0 0.0061519104
) O 0 0.0026323951
. O 0 0.0026466497

On O 0 0.0023612261
the O 0 0.0014927377
Positive O 0 0.0021461248
and O 0 0.0009250803
Negative O 0 0.0036833612
Syndrome O 0 0.06022687
Scale O 0 0.0043102526
positive O 0 0.000357819
subscale O 0 0.00034167644
, O 0 0.0001648127
all O 0 0.00010008462
treatments O 0 0.00012518605
were O 0 6.628859e-05
superior O 0 9.467056e-05
to O 0 5.5432283e-05
placebo O 0 0.0002941237
with O 0 9.8429045e-05
LOCF O 0 0.002870113
and O 0 0.0001036338
MMRM O 0 0.0103115495
; O 0 0.00017632147
asenapine B-Chemical 1 0.9996506
at O 0 4.762275e-05
5 O 0 4.946805e-05
mg O 0 0.0021216979
BID O 0 0.73153347
was O 0 9.6741154e-05
superior O 0 0.00010705904
to O 0 5.2440762e-05
placebo O 0 0.00021474168
on O 0 2.5129235e-05
the O 0 4.4994493e-05
negative O 0 8.960659e-05
subscale O 0 0.00012750251
with O 0 0.00014632744
MMRM O 0 0.0040793447
and O 0 7.1765964e-05
on O 0 3.9399165e-05
the O 0 7.1977134e-05
general O 0 0.0001355151
psychopathology O 0 0.13118322
subscale O 0 0.00037770648
with O 0 0.00047542516
LOCF O 0 0.011313849
and O 0 0.0010027373
MMRM O 0 0.023680778
. O 0 0.002120735

Treatment O 0 0.007140774
- O 0 0.0026864507
related O 0 0.00061498984
adverse O 0 0.011470921
events O 0 0.002801793
( O 0 0.0010408033
AEs O 0 0.022437276
) O 0 0.0004167983
occurred O 0 0.00015019144
in O 0 0.00013962758
44 O 0 0.0001976833
% O 0 0.00013200108
and O 0 0.00011727061
52 O 0 0.00017013436
% O 0 0.00012749473
, O 0 0.00012532629
57 O 0 0.00017791452
% O 0 0.00010780009
, O 0 9.662444e-05
and O 0 8.6103144e-05
41 O 0 0.00013032329
% O 0 6.316874e-05
of O 0 7.580313e-05
the O 0 0.00012476396
asenapine B-Chemical 1 0.9998573
at O 0 5.3002193e-05
5 O 0 4.2163294e-05
and O 0 5.365164e-05
10 O 0 6.957695e-05
mg O 0 0.005601222
BID O 0 0.9687396
, O 0 0.0010452737
haloperidol B-Chemical 1 0.99999607
, O 0 0.00046579746
and O 0 0.00032919322
placebo O 0 0.0018237212
groups O 0 0.0004300587
, O 0 0.0008601241
respectively O 0 0.0024151797
. O 0 0.0021102962

Extrapyramidal B-Disease 0 0.9990988
symptoms I-Disease 0 0.6656681
reported O 0 0.0017795872
as O 0 0.0008417298
AEs O 0 0.009411745
occurred O 0 0.0002876143
in O 0 0.0002075365
15 O 0 0.00014396744
% O 0 0.00016980503
and O 0 0.00014898642
18 O 0 0.00012787533
% O 0 0.00013977595
, O 0 0.00013866351
34 O 0 0.00015301238
% O 0 0.00012159567
, O 0 0.000105856096
and O 0 8.4627165e-05
10 O 0 6.5171385e-05
% O 0 6.640354e-05
of O 0 8.1297614e-05
the O 0 0.0001344999
asenapine B-Chemical 1 0.99986196
at O 0 5.6203564e-05
5 O 0 4.4116056e-05
and O 0 5.5558976e-05
10 O 0 7.153598e-05
mg O 0 0.0057443036
BID O 0 0.9692812
, O 0 0.0010595779
haloperidol B-Chemical 1 0.99999607
, O 0 0.00047036706
and O 0 0.00033163792
placebo O 0 0.0018350142
groups O 0 0.00043229116
, O 0 0.00086357247
respectively O 0 0.0024220794
. O 0 0.0021159926

Across O 0 0.002760056
all O 0 0.0015670575
groups O 0 0.001054009
, O 0 0.0007163668
no O 0 0.00030149464
more O 0 0.0004564573
than O 0 0.00022340867
5 O 0 0.00018372778
% O 0 0.00021600461
of O 0 0.00026204737
patients O 0 0.00038615486
had O 0 0.00033099356
clinically O 0 0.001434251
significant O 0 0.00065306353
weight O 0 0.0032510555
change O 0 0.0018293853
. O 0 0.002260228

Post O 0 0.00550731
hoc O 0 0.0040203845
analyses O 0 0.0007139392
indicated O 0 0.00033493474
that O 0 0.0002249086
efficacy O 0 0.00037712435
was O 0 0.00020735413
similar O 0 0.0001022863
with O 0 0.00037932617
asenapine B-Chemical 1 0.99997175
and O 0 0.0011066846
haloperidol B-Chemical 1 0.9999975
; O 0 0.00027059962
greater O 0 0.00011462002
contrasts O 0 0.00015551603
were O 0 0.00010701535
seen O 0 0.00010813016
in O 0 0.0001681556
AEs O 0 0.009165243
, O 0 0.000451712
especially O 0 0.0013999809
extrapyramidal B-Disease 0 0.999977
symptoms I-Disease 0 0.969342
. O 0 0.0033725486

Salvage O 0 0.005150531
therapy O 0 0.0020811202
with O 0 0.0017218366
nelarabine B-Chemical 0 0.86032903
, O 0 0.001607032
etoposide B-Chemical 0 0.9989454
, O 0 0.00068582
and O 0 0.00047767328
cyclophosphamide B-Chemical 0 0.99872893
in O 0 0.00035285798
relapsed O 0 0.047123846
/ O 0 0.00090874464
refractory O 0 0.0014432732
paediatric O 0 0.0009342489
T B-Disease 0 0.7573126
- I-Disease 0 0.0019117474
cell I-Disease 0 0.059235733
lymphoblastic I-Disease 0 0.99999
leukaemia I-Disease 0 0.99998295
and I-Disease 0 0.07461726
lymphoma I-Disease 0 0.9986792
. O 0 0.0045932266

A O 0 0.01427274
combination O 0 0.0019898668
of O 0 0.0011866807
5 O 0 0.00052781135
d O 0 0.0005643869
of O 0 0.0006791881
nelarabine B-Chemical 0 0.8283539
( O 0 0.0009471704
AraG B-Chemical 0 0.2557231
) O 0 0.0003543115
with O 0 0.00014800603
5 O 0 7.740801e-05
d O 0 0.00011377392
of O 0 0.00021972152
etoposide B-Chemical 0 0.99903464
( O 0 0.00082654424
VP B-Chemical 0 0.8739985
) O 0 0.00030493815
and O 0 0.00020326645
cyclophosphamide B-Chemical 0 0.99949217
( O 0 0.00072412525
CPM B-Chemical 0 0.9803051
) O 0 0.00021357088
and O 0 8.41352e-05
prophylactic O 0 0.00024377591
intrathecal O 0 0.034586243
chemotherapy O 0 0.0016962318
was O 0 8.275544e-05
used O 0 4.6497276e-05
as O 0 5.7361336e-05
salvage O 0 0.00021955212
therapy O 0 8.1422055e-05
in O 0 4.7331945e-05
seven O 0 4.517059e-05
children O 0 8.6718836e-05
with O 0 9.18243e-05
refractory O 0 0.0005088399
or O 0 0.00018373094
relapsed O 0 0.22679996
T B-Disease 0 0.91564226
- I-Disease 0 0.002383093
cell I-Disease 0 0.027958622
leukaemia I-Disease 0 0.9999188
or I-Disease 0 0.0063803783
lymphoma I-Disease 0 0.9975789
. O 0 0.0037484379

The O 0 0.0017372171
most O 0 0.0017943102
common O 0 0.001185177
side O 0 0.0033109179
effects O 0 0.0005391895
attributable O 0 0.00025788788
to O 0 0.00021579544
the O 0 0.00025674954
AraG B-Chemical 0 0.07168367
included O 0 0.00018698836
Grade O 0 0.0054764845
2 O 0 0.00010488907
and O 0 0.0001001354
3 O 0 8.18279e-05
sensory O 0 0.00025413727
and O 0 0.0003070892
motor O 0 0.33172977
neuropathy B-Disease 0 0.9999844
and O 0 0.0034776325
musculoskeletal B-Disease 0 0.4004914
pain I-Disease 0 0.89434785
. O 0 0.0029242367

Haematological B-Disease 0 0.99875665
toxicity I-Disease 2 0.99948066
was O 0 0.0016632502
greater O 0 0.0005599588
for O 0 0.00024884313
the O 0 0.00024009582
combination O 0 0.00032467625
than O 0 0.00018083314
AraG B-Chemical 0 0.1733602
alone O 0 0.0002244579
, O 0 0.00014889357
although O 0 6.751849e-05
median O 0 3.640202e-05
time O 0 3.281085e-05
to O 0 6.6983564e-05
neutrophil O 0 0.0047158436
and O 0 0.00022331966
platelet O 0 0.73985296
recovery O 0 0.0007085097
was O 0 0.0002074121
consistent O 0 0.00017566382
with O 0 0.0003200013
other O 0 0.00046317454
salvage O 0 0.0025930724
therapies O 0 0.0028790513
. O 0 0.0020732603

All O 0 0.0017700226
patients O 0 0.0015478487
had O 0 0.00068142754
some O 0 0.00039861113
response O 0 0.00030688636
to O 0 0.00019540788
the O 0 0.00017425582
combined O 0 0.00024015488
therapy O 0 0.00021341289
and O 0 0.00010469202
five O 0 4.575893e-05
of O 0 8.2051374e-05
the O 0 6.782857e-05
seven O 0 5.1844076e-05
went O 0 7.687483e-05
into O 0 2.231043e-05
complete O 0 5.933136e-05
remission O 0 0.00065225305
after O 0 2.6257138e-05
one O 0 4.4351687e-05
or O 0 5.844523e-05
two O 0 5.8944162e-05
courses O 0 0.00012304046
of O 0 0.00034171925
AraG B-Chemical 0 0.25703612
/ O 0 0.0040757065
VP B-Chemical 0 0.87386996
/ O 0 0.007920361
CPM B-Chemical 0 0.9574171
. O 0 0.0031152293

Our O 0 0.0022062252
experience O 0 0.0015508255
supports O 0 0.0006450164
the O 0 0.0004879548
safety O 0 0.0004985915
of O 0 0.00041318554
giving O 0 0.0008088914
AraG B-Chemical 0 0.17384401
as O 0 0.00018254666
salvage O 0 0.00041915372
therapy O 0 0.000121132885
in O 0 6.41741e-05
synchrony O 0 0.00016399362
with O 0 0.00022845525
etoposide B-Chemical 0 0.9990246
and O 0 0.00062089815
cyclophosphamide B-Chemical 0 0.9998273
, O 0 0.00048812738
although O 0 0.00040567687
neurological B-Disease 0 0.9996543
toxicity I-Disease 2 0.9998994
must O 0 0.00028704177
be O 0 0.0003372279
closely O 0 0.00036947388
monitored O 0 0.00068632344
. O 0 0.0015397267

Effect O 0 0.0024660737
of O 0 0.0029267275
adriamycin B-Chemical 0 0.99714893
combined O 0 0.0015426149
with O 0 0.0007321698
whole O 0 0.00064067193
body O 0 0.0022461999
hyperthermia B-Disease 0 0.9410574
on O 0 0.00046623792
tumor B-Disease 0 0.17949635
and O 0 0.0010683221
normal O 0 0.0025167253
tissues O 0 0.0031191797
. O 0 0.0023638871

Thermal O 0 0.011934331
enhancement O 0 0.0032356188
of O 0 0.003053051
Adriamycin B-Chemical 0 0.99953115
- O 0 0.0020313922
mediated O 0 0.00028770123
antitumor O 0 0.016305927
activity O 0 0.0002607193
and O 0 0.00021625849
normal O 0 0.00047188546
tissue O 0 0.0011866604
toxicities B-Disease 2 0.972391
by O 0 0.00015097857
whole O 0 0.00015549557
body O 0 0.0008559936
hyperthermia B-Disease 0 0.93734115
were O 0 0.0001792037
compared O 0 0.00010048003
using O 0 0.00017128632
a O 0 0.00055837265
F344 O 0 0.07934356
rat O 0 0.001871759
model O 0 0.0016776067
. O 0 0.001919539

Antitumor O 0 0.052125126
activity O 0 0.0028113802
was O 0 0.0020982
studied O 0 0.0014556934
using O 0 0.00097265834
a O 0 0.0017970145
tumor B-Disease 0 0.23596826
growth O 0 0.012003924
delay O 0 0.0046068425
assay O 0 0.008617406
. O 0 0.0042526154

Acute O 0 0.05009202
normal O 0 0.004072373
tissue O 0 0.006889308
toxicities B-Disease 2 0.99453026
( O 0 0.001395523
i O 0 0.00095450925
. O 0 0.00021207858
e O 0 0.00033958783
. O 0 0.00015361716
, O 0 0.00040997643
leukopenia B-Disease 0 0.9998654
and O 0 0.0016056646
thrombocytopenia B-Disease 0 0.9999409
) O 0 0.00057157007
and O 0 0.00012610319
late O 0 0.00023305386
normal O 0 0.00032413565
tissue O 0 0.0011552107
toxicities B-Disease 2 0.992871
( O 0 0.00028762963
i O 0 0.00028121166
. O 0 5.635464e-05
e O 0 0.00011465621
. O 0 5.259647e-05
, O 0 0.00013202737
myocardial B-Disease 0 0.9801555
and I-Disease 0 0.00052798854
kidney I-Disease 0 0.99955493
injury I-Disease 0 0.99732614
) O 0 0.0005166979
were O 0 0.00010096959
evaluated O 0 6.635454e-05
by O 0 9.0955094e-05
functional O 0 0.00013140768
/ O 0 0.00034942478
physiological O 0 0.0002748215
assays O 0 0.0003259749
and O 0 0.0003105726
by O 0 0.0004977726
morphological O 0 0.0020013826
techniques O 0 0.0016607723
. O 0 0.0019659954

Whole O 0 0.007005434
body O 0 0.006808576
hyperthermia B-Disease 0 0.91710347
( O 0 0.0011448779
120 O 0 0.00042792872
min O 0 0.0003487362
at O 0 0.0001916532
41 O 0 0.00035065715
. O 0 0.00012352361
5 O 0 0.00013273225
degrees O 0 0.0016086517
C O 0 0.962499
) O 0 0.0004613496
enhanced O 0 0.00032071688
both O 0 0.0004542408
Adriamycin B-Chemical 0 0.9997743
- O 0 0.0007658252
mediated O 0 0.00015137543
antitumor O 0 0.020593498
activity O 0 0.00040351736
and O 0 0.000685939
toxic O 0 0.40521112
side O 0 0.049970202
effects O 0 0.003357205
. O 0 0.0028424298

The O 0 0.0020991175
thermal O 0 0.0040862784
enhancement O 0 0.0020135387
ratio O 0 0.0011767941
calculated O 0 0.000509542
for O 0 0.00052597624
antitumor O 0 0.01635499
activity O 0 0.0010435147
was O 0 0.0012009254
1 O 0 0.0009014235
. O 0 0.00087160437
6 O 0 0.0013080057
. O 0 0.0025920626

Thermal O 0 0.012190285
enhancement O 0 0.0026080392
ratios O 0 0.001243284
estimated O 0 0.00062256004
for O 0 0.0004211642
" O 0 0.00072643976
acute O 0 0.1191179
" O 0 0.00075123896
hematological O 0 0.8165859
changes O 0 0.00037270447
were O 0 0.00016761788
1 O 0 9.823008e-05
. O 0 5.9290247e-05
3 O 0 6.138064e-05
, O 0 8.4205356e-05
whereas O 0 7.6407385e-05
those O 0 9.94182e-05
estimated O 0 7.5556025e-05
for O 0 6.6977176e-05
" O 0 0.00014032403
late O 0 0.00028719724
" O 0 0.00021499756
damage O 0 0.040092368
( O 0 0.00013078927
based O 0 4.7667912e-05
on O 0 3.7917445e-05
morphological O 0 0.0003358377
cardiac B-Disease 0 0.008650335
and I-Disease 0 0.00027144016
renal I-Disease 0 0.99925584
lesions I-Disease 0 0.85425144
) O 0 0.00030894866
varied O 0 0.000100421516
between O 0 6.393887e-05
2 O 0 9.6755e-05
. O 0 8.8468034e-05
4 O 0 0.0001282605
and O 0 0.00024752886
4 O 0 0.00031353004
. O 0 0.00044818508
3 O 0 0.0009031361
. O 0 0.0017975732

Thus O 0 0.0023587854
, O 0 0.0017530475
while O 0 0.000801422
whole O 0 0.00080845994
body O 0 0.002575886
hyperthermia B-Disease 0 0.9662023
enhances O 0 0.0007714024
Adriamycin B-Chemical 0 0.99988806
- O 0 0.0011123387
mediated O 0 0.00012593484
antitumor O 0 0.03292968
effect O 0 0.00019829231
, O 0 0.00021628714
normal O 0 0.00056687056
tissue O 0 0.002542448
toxicity B-Disease 2 0.99515164
is O 0 0.00015500822
also O 0 9.3719886e-05
increased O 0 0.00019891096
, O 0 0.00010688337
and O 0 6.836743e-05
the O 0 5.7422298e-05
potential O 0 7.421963e-05
therapeutic O 0 0.0001802102
gain O 0 0.00026826563
of O 0 0.00014484498
the O 0 0.00013208404
combined O 0 0.0002743796
modality O 0 0.00043067674
treatment O 0 0.00057712314
is O 0 0.0010812258
eroded O 0 0.0071494873
. O 0 0.0021750964

Permeability O 0 0.064029954
, O 0 0.002434947
ultrastructural O 0 0.0033560742
changes O 0 0.001051901
, O 0 0.000600258
and O 0 0.0003007267
distribution O 0 0.0001319052
of O 0 0.00022047787
novel O 0 0.00021802161
proteins O 0 0.00019184974
in O 0 0.00013096134
the O 0 0.00018384887
glomerular O 0 0.7758511
barrier O 0 0.0011560881
in O 0 0.0002385774
early O 0 0.00083339785
puromycin B-Chemical 0 0.85444945
aminonucleoside I-Chemical 0 0.99995935
nephrosis B-Disease 2 0.999966
. O 0 0.006589376

BACKGROUND O 0 0.011495397
/ O 0 0.0065123877
AIMS O 0 0.013187931
: O 0 0.0016117233
It O 0 0.00071222807
is O 0 0.00046681333
still O 0 0.0003503658
unclear O 0 0.00025987232
what O 0 0.00040988676
happens O 0 0.00032425713
in O 0 0.0002618401
the O 0 0.00036832286
glomerulus O 0 0.006828112
when O 0 0.00085638603
proteinuria B-Disease 0 0.9999267
starts O 0 0.0065723234
. O 0 0.003116414

Using O 0 0.0023101685
puromycin B-Chemical 0 0.56759685
aminonucleoside I-Chemical 0 0.9998994
nephrosis B-Disease 2 0.9999814
( O 0 0.06254133
PAN O 0 0.99986935
) O 0 0.0016498553
rats O 0 0.00046990503
, O 0 0.00016975177
we O 0 5.9451544e-05
studied O 0 0.00011322952
early O 0 0.00016673653
ultrastructural O 0 0.0007591003
and O 0 0.00016773846
permeability O 0 0.19260523
changes O 0 0.00011961476
in O 0 4.912689e-05
relation O 0 2.3819246e-05
to O 0 3.992928e-05
the O 0 5.1867668e-05
expression O 0 7.9685844e-05
of O 0 0.000103757506
the O 0 0.00014033768
podocyte O 0 0.9489693
- O 0 0.0003786664
associated O 0 8.851983e-05
molecules O 0 0.00025496754
nephrin O 0 0.9856446
, O 0 0.00028868573
a O 0 0.00030333904
- O 0 0.0005354773
actinin O 0 0.29981568
, O 0 0.0002467612
dendrin O 0 0.0102763735
, O 0 0.00014685554
and O 0 0.00011826976
plekhh2 O 0 0.0009793163
, O 0 8.956892e-05
the O 0 5.4338412e-05
last O 0 2.6898126e-05
two O 0 4.2716176e-05
of O 0 0.000105249055
which O 0 0.00016284133
were O 0 0.00015456589
only O 0 0.0002074178
recently O 0 0.00025638455
discovered O 0 0.000634032
in O 0 0.00085552473
podocytes O 0 0.39018673
. O 0 0.002485968

METHODS O 0 0.0019942457
: O 0 0.0015821289
Using O 0 0.00074527925
immune O 0 0.0031334516
stainings O 0 0.001321559
, O 0 0.00061893073
semiquantitative O 0 0.000619809
measurement O 0 0.00026337086
was O 0 0.00034943843
performed O 0 0.00028898145
under O 0 0.00035817325
the O 0 0.00070962886
electron O 0 0.0057151997
microscope O 0 0.0026570507
. O 0 0.0027748763

Permeability O 0 0.04748286
was O 0 0.002798408
assessed O 0 0.0012925152
using O 0 0.0010978674
isolated O 0 0.0014465206
kidney O 0 0.41034395
perfusion O 0 0.08799264
with O 0 0.0034646378
tracers O 0 0.008699319
. O 0 0.0040308465

Possible O 0 0.0074112103
effects O 0 0.0047140894
of O 0 0.006866037
ACE O 0 0.99592966
inhibition O 0 0.014072132
were O 0 0.0053005926
tested O 0 0.005495119
. O 0 0.006984643

RESULTS O 0 0.0052573495
: O 0 0.0020205267
By O 0 0.0009451065
day O 0 0.0006340638
2 O 0 0.0005180857
, O 0 0.0004882335
some O 0 0.00038974965
patchy O 0 0.001176765
foot O 0 0.003039268
process O 0 0.0004539856
effacement O 0 0.017359965
, O 0 0.0005267379
but O 0 0.0005120021
no O 0 0.00068878423
proteinuria B-Disease 0 0.9999455
, O 0 0.0031716288
appeared O 0 0.0025913364
. O 0 0.0026653265

The O 0 0.0019021218
amount O 0 0.001271898
of O 0 0.0021996265
nephrin O 0 0.9177565
was O 0 0.0014309931
reduced O 0 0.001098729
in O 0 0.00055127277
both O 0 0.0006240509
diseased O 0 0.0020348423
and O 0 0.0009475165
normal O 0 0.0022263655
areas O 0 0.0022695207
. O 0 0.0026924566

The O 0 0.0020253556
other O 0 0.0015189897
proteins O 0 0.0013209801
showed O 0 0.000824631
few O 0 0.00042839258
changes O 0 0.00069972646
, O 0 0.0006132147
which O 0 0.0005772816
were O 0 0.00048257437
limited O 0 0.0005202839
to O 0 0.0007293997
diseased O 0 0.0032728873
areas O 0 0.002306209
. O 0 0.0027183003

By O 0 0.0022437552
day O 0 0.0012645465
4 O 0 0.0008806041
, O 0 0.00092214503
foot O 0 0.0022229797
process O 0 0.00050058967
effacement O 0 0.005082009
was O 0 0.00029619253
complete O 0 0.00022087386
and O 0 0.00040830713
proteinuria B-Disease 0 0.9999639
appeared O 0 0.0003322452
in O 0 0.0001527191
parallel O 0 0.0001862419
with O 0 0.00026760757
signs O 0 0.001704983
of O 0 0.00057475775
size O 0 0.0011818976
barrier O 0 0.0062876195
damage O 0 0.39352638
. O 0 0.002869657

Nephrin O 0 0.02005093
decreased O 0 0.004227732
further O 0 0.0020676444
, O 0 0.0011879213
while O 0 0.0007228122
dendrin O 0 0.0066093914
and O 0 0.00058074674
plekhh2 O 0 0.002464445
also O 0 0.00034410213
decreased O 0 0.0008315559
but O 0 0.00048598612
a O 0 0.0007668538
- O 0 0.001332263
actinin O 0 0.16059586
remained O 0 0.0019756216
unchanged O 0 0.0021592213
. O 0 0.002352462

ACE O 0 0.9933849
inhibition O 0 0.011575855
had O 0 0.0038313856
no O 0 0.0022487855
significant O 0 0.0032596088
protective O 0 0.008598773
effect O 0 0.0062614027
. O 0 0.0075058616

CONCLUSIONS O 0 0.022476047
: O 0 0.004612921
PAN O 0 0.995634
glomeruli O 0 0.012538544
already O 0 0.0006200797
showed O 0 0.00045935847
significant O 0 0.0003809967
pathology O 0 0.0017426736
by O 0 0.000271596
day O 0 0.0001540311
4 O 0 0.0001668539
, O 0 0.00026265395
despite O 0 0.00031201256
relatively O 0 0.0015448328
mild O 0 0.9280496
proteinuria B-Disease 0 0.99996185
. O 0 0.006046402

This O 0 0.0046773604
was O 0 0.0021247931
preceded O 0 0.0013803947
by O 0 0.0010635413
altered O 0 0.0015424209
nephrin O 0 0.9561726
expression O 0 0.0011886695
, O 0 0.00053001073
supporting O 0 0.00033964386
its O 0 0.00050231756
pivotal O 0 0.00042175155
role O 0 0.00035441015
in O 0 0.00084387726
podocyte O 0 0.9396052
morphology O 0 0.008674189
. O 0 0.00300396

The O 0 0.0017296949
novel O 0 0.0017062252
proteins O 0 0.0014689057
dendrin O 0 0.0068917032
and O 0 0.0008015182
plekhh2 O 0 0.0031076712
were O 0 0.00032449554
both O 0 0.00023819828
reduced O 0 0.00042357048
, O 0 0.00024060476
suggesting O 0 9.846895e-05
roles O 0 0.000118856515
in O 0 0.0003022821
PAN O 0 0.99942493
, O 0 0.0005115879
whereas O 0 0.0003415372
a O 0 0.00068775285
- O 0 0.0012716189
actinin O 0 0.20420349
was O 0 0.0013935135
unchanged O 0 0.001795686
. O 0 0.002137119

A O 0 0.01658469
novel O 0 0.0024732887
, O 0 0.0015438927
multiple O 0 0.00097255455
symptom O 0 0.0016829929
model O 0 0.0007310343
of O 0 0.0015918564
obsessive B-Disease 0 0.99978083
- I-Disease 0 0.008648886
compulsive I-Disease 0 0.9995024
- I-Disease 0 0.0014463855
like I-Disease 0 0.00041470455
behaviors I-Disease 0 0.0013459886
in O 0 0.00083351054
animals O 0 0.0012476387
. O 0 0.0021589333

BACKGROUND O 0 0.008506262
: O 0 0.0022592829
Current O 0 0.002022601
animal O 0 0.0008801654
models O 0 0.0006319794
of O 0 0.0011770542
obsessive B-Disease 0 0.9997478
- I-Disease 0 0.0062693316
compulsive I-Disease 0 0.99983084
disorder I-Disease 0 0.993386
( O 0 0.0021905173
OCD B-Disease 2 0.9999777
) O 0 0.0003229718
typically O 0 0.00011888974
involve O 0 8.590057e-05
acute O 0 0.07905001
, O 0 0.0002546879
drug O 0 0.021258472
- O 0 0.0002684718
induced O 0 0.00014927953
symptom O 0 0.0011708234
provocation O 0 0.0062273596
or O 0 0.000105610285
a O 0 0.00017868809
genetic O 0 0.00044920002
association O 0 0.00015253792
with O 0 0.00079831143
stereotypies O 0 0.99960047
or O 0 0.0020182012
anxiety B-Disease 0 0.9673953
. O 0 0.0026808148

None O 0 0.003581354
of O 0 0.0019678448
these O 0 0.0014410147
current O 0 0.00135934
models O 0 0.0008913139
demonstrate O 0 0.00051614706
multiple O 0 0.0022836719
OCD B-Disease 2 0.9998746
- O 0 0.0035586532
like O 0 0.0015210711
behaviors O 0 0.0059743915
. O 0 0.0035243158

METHODS O 0 0.0015288957
: O 0 0.0013760173
Neonatal O 0 0.0013364898
rats O 0 0.0006379228
were O 0 0.000273741
treated O 0 0.00024309628
with O 0 0.00019374724
the O 0 0.00027775406
tricyclic O 0 0.9998628
antidepressant B-Chemical 1 0.99997663
clomipramine B-Chemical 0 0.99999774
or O 0 0.0001736163
vehicle O 0 0.0003646429
between O 0 4.1000443e-05
days O 0 2.9862114e-05
9 O 0 4.7397352e-05
and O 0 5.909167e-05
16 O 0 6.186137e-05
twice O 0 6.339021e-05
daily O 0 0.00012826882
and O 0 0.00016413457
behaviorally O 0 0.0010503388
tested O 0 0.0004379804
in O 0 0.00082843355
adulthood O 0 0.02554867
. O 0 0.0021766971

RESULTS O 0 0.0054187444
: O 0 0.0036679653
Clomipramine B-Chemical 0 0.9995622
exposure O 0 0.0014517751
in O 0 0.0005032607
immature O 0 0.0011272009
rats O 0 0.00035037045
produced O 0 0.00015226181
significant O 0 0.00012886364
behavioral O 0 0.00040000642
and O 0 0.000109912515
biochemical O 0 0.00028967162
changes O 0 8.45083e-05
that O 0 4.3472406e-05
include O 0 5.2134208e-05
enhanced O 0 0.00020259194
anxiety B-Disease 0 0.862402
( O 0 0.0001934639
elevated O 0 0.00040687766
plus O 0 7.143679e-05
maze O 0 0.010948718
and O 0 0.00018506756
marble O 0 0.012280381
burying O 0 0.3233331
) O 0 0.0003291998
, O 0 0.00013904973
behavioral B-Disease 0 0.015154152
inflexibility I-Disease 0 0.45605063
( O 0 0.00028827673
perseveration O 0 0.6280584
in O 0 6.443913e-05
the O 0 5.669655e-05
spontaneous O 0 0.00027728497
alternation O 0 0.00037459077
task O 0 9.443632e-05
and O 0 6.911154e-05
impaired O 0 0.00027996878
reversal O 0 0.00026590863
learning O 0 0.00046954612
) O 0 0.00021882985
, O 0 0.00010624199
working O 0 0.00044659773
memory B-Disease 2 0.9874414
impairment I-Disease 2 0.99469674
( O 0 0.00051299523
e O 0 0.00021604166
. O 0 6.5254906e-05
g O 0 0.00026060228
. O 0 6.829171e-05
, O 0 0.00012937954
win O 0 0.00021338198
- O 0 0.0002271811
shift O 0 0.00022906641
paradigm O 0 0.0002191907
) O 0 0.00039418347
, O 0 0.000424916
hoarding B-Disease 0 0.92617166
, O 0 0.0006632335
and O 0 0.0009390022
corticostriatal B-Disease 0 0.96649563
dysfunction I-Disease 0 0.998198
. O 0 0.0037849613

Dopamine B-Chemical 1 0.9995728
D2 O 0 0.9984394
receptors O 0 0.008144053
were O 0 0.00069477875
elevated O 0 0.0011688995
in O 0 0.00025939927
the O 0 0.00024830797
striatum O 0 0.011825814
, O 0 0.0002849966
whereas O 0 0.0003589287
serotonin B-Chemical 0 0.99972624
2C O 0 0.00069786917
, O 0 0.00013849199
but O 0 0.00011788985
not O 0 0.00017230453
serotonin B-Chemical 0 0.9994518
1A O 0 0.00042305276
, O 0 0.00016631275
receptors O 0 0.0005276177
were O 0 0.00013811521
elevated O 0 0.0005021665
in O 0 0.00017878215
the O 0 0.0002927093
orbital O 0 0.005050549
frontal O 0 0.1217972
cortex O 0 0.05374466
. O 0 0.0025589275

CONCLUSIONS O 0 0.016043669
: O 0 0.0024324663
This O 0 0.0014986501
is O 0 0.0006096596
the O 0 0.0003440731
first O 0 0.00019052862
demonstration O 0 0.00026223736
of O 0 0.00027436757
multiple O 0 0.0003026215
symptoms O 0 0.0019274537
consistent O 0 0.00018348306
with O 0 0.0003065054
an O 0 0.0010494267
OCD B-Disease 2 0.99997056
- O 0 0.0009405648
like O 0 0.00026216081
profile O 0 0.0005243441
in O 0 0.0006232282
animals O 0 0.0010244708
. O 0 0.0018651852

Moreover O 0 0.0029214877
, O 0 0.002060806
these O 0 0.0013541816
behaviors O 0 0.0017222005
are O 0 0.0005189983
accompanied O 0 0.0007733629
by O 0 0.00032217347
biochemical O 0 0.00071552617
changes O 0 0.00024566584
in O 0 0.0001550162
brain O 0 0.0007626132
regions O 0 0.00016261371
previously O 0 0.00015400318
identified O 0 0.00017171916
as O 0 0.00023529079
relevant O 0 0.0003666332
to O 0 0.0012642136
OCD B-Disease 2 0.9997892
. O 0 0.0034135135

This O 0 0.0029751116
novel O 0 0.00149528
model O 0 0.0011429539
of O 0 0.0018312556
OCD B-Disease 2 0.9998752
demonstrates O 0 0.00030508268
that O 0 0.00019566293
drug O 0 0.00365603
exposure O 0 0.00022619161
during O 0 6.0389673e-05
a O 0 0.00011395296
sensitive O 0 7.150883e-05
period O 0 4.2143874e-05
can O 0 5.905072e-05
program O 0 0.00018349056
disease O 0 0.127885
- O 0 0.00026309254
like O 0 5.8653648e-05
systems O 0 9.738303e-05
permanently O 0 0.00035593755
, O 0 0.00010061302
which O 0 9.22679e-05
could O 0 4.801135e-05
have O 0 3.3979617e-05
implications O 0 4.059821e-05
for O 0 4.4737055e-05
current O 0 0.00014181092
and O 0 8.2998464e-05
future O 0 8.1750215e-05
therapeutic O 0 0.0001673212
strategies O 0 0.00010734976
for O 0 0.00010185657
this O 0 0.00025456454
and O 0 0.00038865287
other O 0 0.00096143037
psychiatric B-Disease 2 0.999619
disorders I-Disease 0 0.9956766
. O 0 0.0031290906

Elevation O 0 0.03351712
of O 0 0.0063875276
ADAM10 O 0 0.9852834
, O 0 0.0044661574
ADAM17 O 0 0.95931387
, O 0 0.002742925
MMP O 0 0.98650545
- O 0 0.001354482
2 O 0 0.00025988618
and O 0 0.00035665138
MMP O 0 0.8918263
- O 0 0.00046876533
9 O 0 9.7841e-05
expression O 0 0.00011155496
with O 0 0.00014008913
media O 0 0.00073421095
degeneration O 0 0.96596164
features O 0 0.00069845194
CaCl2 B-Chemical 0 0.99943405
- O 0 0.0007833384
induced O 0 0.0003760031
thoracic B-Disease 0 0.10154796
aortic I-Disease 0 0.52433836
aneurysm I-Disease 2 0.99881625
in O 0 0.00048745738
a O 0 0.0008350179
rat O 0 0.0018364541
model O 0 0.0018066294
. O 0 0.0020798903

PURPOSE O 0 0.005238422
: O 0 0.0021108747
This O 0 0.0014990068
study O 0 0.0008629473
was O 0 0.00047286524
designed O 0 0.00028718272
to O 0 0.00019054499
establish O 0 0.00013859979
a O 0 0.00020810639
rat O 0 0.000262506
model O 0 0.00012834344
of O 0 0.00019479846
thoracic B-Disease 0 0.03535651
aortic I-Disease 0 0.51519614
aneurysm I-Disease 2 0.9998123
( O 0 0.00084274675
TAA B-Disease 0 0.9678986
) O 0 0.00038073183
by O 0 0.0002803927
calcium B-Chemical 0 0.9998503
chloride I-Chemical 0 0.99998605
( O 0 0.0066508274
CaCl B-Chemical 0 0.9998103
( I-Chemical 0 0.000599325
2 I-Chemical 0 0.0001304389
) I-Chemical 0 0.00021543936
) O 0 0.00019827037
- O 0 0.00019170897
induced O 0 0.00019351074
arterial B-Disease 0 0.9347603
injury I-Disease 0 0.9611355
and O 0 0.00016942866
to O 0 6.292501e-05
explore O 0 3.9100738e-05
the O 0 5.3943644e-05
potential O 0 5.934002e-05
role O 0 4.0366584e-05
of O 0 0.000121500525
a O 0 0.00026431977
disintegrin O 0 0.17873454
and O 0 0.00031772407
metalloproteinase O 0 0.44747686
( O 0 0.00072113995
ADAM O 0 0.8389858
) O 0 0.00033606318
, O 0 0.00016094832
matrix O 0 0.00057924475
metalloproteinases O 0 0.36887026
( O 0 0.0005118047
MMPs O 0 0.32464138
) O 0 0.00023505156
and O 0 0.00010075262
their O 0 0.0001189022
endogenous O 0 0.00017593874
inhibitors O 0 0.0013007809
( O 0 0.00067038176
TIMPs O 0 0.24131809
) O 0 0.0007638743
in O 0 0.0007090742
TAA B-Disease 0 0.8514902
formation O 0 0.007399854
. O 0 0.002624647

METHODS O 0 0.0019066699
: O 0 0.0018443932
Thoracic O 0 0.002715055
aorta O 0 0.0048228875
of O 0 0.00093416555
male O 0 0.0024592467
Sprague O 0 0.029842526
- O 0 0.0008522145
Dawley O 0 0.002498568
rats O 0 0.00022493477
was O 0 0.000112278954
exposed O 0 8.906794e-05
to O 0 9.002747e-05
0 O 0 0.00011395687
. O 0 0.00013219568
5M O 0 0.69352174
CaCl B-Chemical 0 0.9989926
( I-Chemical 0 0.0005572344
2 I-Chemical 0 0.00016511866
) I-Chemical 0 0.0002239662
or O 0 0.0001611962
normal O 0 0.0006162678
saline O 0 0.0022403619
( O 0 0.0014431777
NaCl B-Chemical 0 0.97513336
) O 0 0.004674542
. O 0 0.0028768114

After O 0 0.0012597896
12weeks O 0 0.0027918639
, O 0 0.001031886
animals O 0 0.0004340446
were O 0 0.00035838215
euthanized O 0 0.00027848833
, O 0 0.0003544975
and O 0 0.000497018
CaCl B-Chemical 0 0.998809
( I-Chemical 0 0.0007835026
2 I-Chemical 0 0.00021080926
) I-Chemical 0 0.00032091478
- O 0 0.00030695746
treated O 0 0.0003127193
, O 0 0.00047745343
CaCl B-Chemical 0 0.9993625
( I-Chemical 0 0.00060905877
2 I-Chemical 0 0.0001461286
) I-Chemical 0 0.0002249395
- O 0 0.00020577165
untreated O 0 0.00019495974
( O 0 0.00015281016
n O 0 8.389285e-05
= O 0 9.262794e-05
12 O 0 4.254019e-05
) O 0 0.000115912495
and O 0 0.0001353
NaCl B-Chemical 0 0.9812511
- O 0 0.00043176426
treated O 0 0.0002521771
aortic O 0 0.022231596
segments O 0 0.00018363848
( O 0 0.00014189506
n O 0 8.443823e-05
= O 0 9.941972e-05
12 O 0 4.9963724e-05
) O 0 0.00011268891
were O 0 7.618809e-05
collected O 0 6.700363e-05
for O 0 0.00012837184
histological O 0 0.0011954881
and O 0 0.000501989
molecular O 0 0.002825962
assessments O 0 0.0012782611
. O 0 0.0018686845

MMP O 0 0.971162
- O 0 0.011188249
TIMP O 0 0.73596346
and O 0 0.0021474303
ADAM O 0 0.47911432
mRNAs O 0 0.0008784546
were O 0 0.00043437537
semi O 0 0.00068253704
- O 0 0.00042843726
quantitatively O 0 0.00024050249
analyzed O 0 0.00017552183
and O 0 0.00021390263
protein O 0 0.00038455817
expressions O 0 0.00036733955
were O 0 0.00040801612
determined O 0 0.0005008732
by O 0 0.0010441651
immunohistochemistry O 0 0.004476342
. O 0 0.0022844262

RESULTS O 0 0.0045107524
: O 0 0.0016449036
Despite O 0 0.00057389715
similar O 0 0.00037697592
external O 0 0.0005793845
diameters O 0 0.001569259
among O 0 0.0009868353
CaCl B-Chemical 0 0.999393
( I-Chemical 0 0.0010661884
2 I-Chemical 0 0.00025435182
) I-Chemical 0 0.0003705688
- O 0 0.0003192389
treated O 0 0.000248578
, O 0 0.00021173367
non O 0 0.00036471133
- O 0 0.0011724121
CaCl B-Chemical 0 0.999443
( I-Chemical 0 0.00056269276
2 I-Chemical 0 0.00013122697
) I-Chemical 0 0.00020261279
- O 0 0.00018433106
treated O 0 0.00016308732
and O 0 0.00023252115
NaCl B-Chemical 0 0.99689376
- O 0 0.00062199985
treated O 0 0.00023596094
segments O 0 0.00018442249
, O 0 0.0001343904
aneurymal O 0 0.0018170236
alteration O 0 0.0002768602
( O 0 0.00016677137
n O 0 8.596319e-05
= O 0 9.646785e-05
6 O 0 4.106986e-05
, O 0 7.5048905e-05
50 O 0 0.00013277402
% O 0 0.00011894348
) O 0 0.00016462707
, O 0 0.00011939597
media O 0 0.0005604965
degeneration O 0 0.91627324
with O 0 0.00016776867
regional O 0 0.00015362112
disruption O 0 0.00012524636
, O 0 0.00010696842
fragmentation O 0 0.00058329845
of O 0 0.00013550102
elastic O 0 0.00035786506
fiber O 0 0.00049478404
, O 0 0.00011509777
and O 0 8.9755056e-05
increased O 0 0.00021834654
collagen O 0 0.050782412
deposition O 0 0.0018938043
( O 0 0.00020013937
n O 0 8.447108e-05
= O 0 8.8556735e-05
12 O 0 3.823859e-05
, O 0 8.049611e-05
100 O 0 0.00019419428
% O 0 0.00011966634
) O 0 0.00014128601
were O 0 8.421179e-05
demonstrated O 0 9.134781e-05
in O 0 0.00022735224
CaCl B-Chemical 0 0.9982047
( I-Chemical 0 0.0007754058
2 I-Chemical 0 0.000306717
) I-Chemical 0 0.00059376186
- O 0 0.00082061294
treated O 0 0.001202119
segments O 0 0.0019895819
. O 0 0.002207517

MMP O 0 0.96602273
- O 0 0.0068433983
2 O 0 0.0018146174
, O 0 0.002197737
MMP O 0 0.88794386
- O 0 0.0020104935
9 O 0 0.0005509576
, O 0 0.0007662227
ADAM O 0 0.5677449
- O 0 0.00071729184
10 O 0 0.00022555115
and O 0 0.00035030165
ADAM O 0 0.66996896
- O 0 0.0004860955
17 O 0 0.00017459877
mRNA O 0 0.00015617642
levels O 0 9.423984e-05
were O 0 9.018917e-05
increased O 0 0.0001730027
in O 0 0.00022142798
CaCl B-Chemical 0 0.9993476
( I-Chemical 0 0.0004915555
2 I-Chemical 0 0.00012140752
) I-Chemical 0 0.00019430817
- O 0 0.00017854842
treated O 0 0.00015132218
segments O 0 0.00017093583
( O 0 0.00015239426
all O 0 0.000111880516
p O 0 0.000113793234
< O 0 8.206609e-05
0 O 0 7.307846e-05
. O 0 6.418034e-05
01 O 0 0.0003147775
) O 0 0.00013992384
, O 0 7.828395e-05
with O 0 7.2024304e-05
trends O 0 6.497096e-05
of O 0 0.00011936695
elevation O 0 0.0099391965
in O 0 0.00032498254
CaCl B-Chemical 0 0.9996729
( I-Chemical 0 0.0005429884
2 I-Chemical 0 0.00012329685
) I-Chemical 0 0.00019590842
- O 0 0.00018310589
untreated O 0 0.0001760033
segments O 0 0.0001522981
, O 0 0.00012019469
as O 0 9.476866e-05
compared O 0 0.0001038053
with O 0 0.00047227152
NaCl B-Chemical 0 0.9929711
- O 0 0.0021654374
treated O 0 0.0017904404
segments O 0 0.0022238607
. O 0 0.0021378286

Immunohistochemistry O 0 0.0052009406
displayed O 0 0.0014809944
significantly O 0 0.0011307175
increased O 0 0.00088181405
expressions O 0 0.0006428764
of O 0 0.0012607685
MMP O 0 0.9875973
- O 0 0.0013588358
2 O 0 0.00027609788
, O 0 0.00043318898
MMP O 0 0.9108255
- O 0 0.0006561102
9 O 0 0.00017477215
, O 0 0.00029449348
ADAM O 0 0.5115585
- O 0 0.00038255096
10 O 0 0.00012770377
and O 0 0.00023041926
ADAM O 0 0.65533274
- O 0 0.000437909
17 O 0 0.00019639637
( O 0 0.00015843198
all O 0 0.00011636356
p O 0 0.00012030924
< O 0 8.915213e-05
0 O 0 7.921037e-05
. O 0 6.9822214e-05
01 O 0 0.00029844776
) O 0 0.00014216971
in O 0 9.949445e-05
intima O 0 0.03159404
and O 0 0.00014974356
media O 0 0.00043491024
for O 0 0.00026600802
CaCl B-Chemical 0 0.9991466
( I-Chemical 0 0.0009186416
2 I-Chemical 0 0.00033260364
) I-Chemical 0 0.0006250535
- O 0 0.0008506146
treated O 0 0.0012345656
segments O 0 0.0020312346
. O 0 0.00225165

TIMP O 0 0.6734272
mRNA O 0 0.0030864598
and O 0 0.0014069524
tissue O 0 0.001904739
levels O 0 0.0006182445
did O 0 0.000534473
not O 0 0.00036346147
differ O 0 0.0003342706
obviously O 0 0.0008653202
among O 0 0.00039719138
the O 0 0.00038504862
three O 0 0.00039601856
aortic O 0 0.01469284
segments O 0 0.0021114012
. O 0 0.0022833133

CONCLUSION O 0 0.016803
: O 0 0.0022721265
This O 0 0.0014633336
study O 0 0.0007922764
establishes O 0 0.0005592118
a O 0 0.00080734433
TAA B-Disease 0 0.8083483
model O 0 0.0005035073
by O 0 0.0005212409
periarterial O 0 0.7872897
CaCl B-Chemical 0 0.99978095
( I-Chemical 0 0.00070556893
2 I-Chemical 0 0.00013845606
) I-Chemical 0 0.00015683153
exposure O 0 0.00012998769
in O 0 9.505376e-05
rats O 0 0.00017205007
, O 0 9.528926e-05
and O 0 6.960735e-05
demonstrates O 0 4.617629e-05
a O 0 9.991526e-05
significant O 0 8.523109e-05
elevation O 0 0.0020960246
of O 0 0.00016128353
expression O 0 0.00019396406
of O 0 0.00042249355
MMP O 0 0.99007636
- O 0 0.00058201014
2 O 0 0.000121402416
, O 0 0.00023190852
MMP O 0 0.90794724
- O 0 0.00046830953
9 O 0 0.00013918383
, O 0 0.0002658232
ADAM10 O 0 0.8542912
and O 0 0.00044785024
ADAM17 O 0 0.5684546
in O 0 0.00023495677
the O 0 0.0002723597
pathogenesis O 0 0.00081686885
of O 0 0.001018414
vascular O 0 0.2503833
remodeling O 0 0.0075147054
. O 0 0.0024455774

Suxamethonium B-Chemical 1 0.96636504
induced O 0 0.00338497
prolonged O 0 0.0047995155
apnea B-Disease 0 0.87960297
in O 0 0.00084278284
a O 0 0.0009107257
patient O 0 0.0008874395
receiving O 0 0.0016821024
electroconvulsive O 0 0.28817528
therapy O 0 0.003570368
. O 0 0.0028337932

Suxamethonium B-Chemical 1 0.9715812
causes O 0 0.002883493
prolonged O 0 0.0032828173
apnea B-Disease 0 0.869099
in O 0 0.000490101
patients O 0 0.00045036792
in O 0 0.00027803017
whom O 0 0.0013865437
pseudocholinesterase O 0 0.9989373
enzyme O 0 0.07587437
gets O 0 0.00085348426
deactivated O 0 0.0040014996
by O 0 0.0012777474
organophosphorus B-Chemical 0 0.9999865
( I-Chemical 0 0.01269506
OP I-Chemical 0 0.9996567
) I-Chemical 0 0.005412287
poisons I-Chemical 0 0.5417881
. O 0 0.0031860024

Here O 0 0.0027313954
, O 0 0.0018682681
we O 0 0.00054879696
present O 0 0.00048244672
a O 0 0.0005757194
similar O 0 0.00028298647
incident O 0 0.0015479848
in O 0 0.00022599027
a O 0 0.00032335942
severely O 0 0.006289687
depressed B-Disease 2 0.83734614
patient O 0 0.0002813162
who O 0 0.00025864533
received O 0 0.00016015013
electroconvulsive O 0 0.072403215
therapy O 0 0.00070738577
( O 0 0.0010342846
ECT O 0 0.29899618
) O 0 0.0024546536
. O 0 0.0020925875

Prolonged O 0 0.008061816
apnea B-Disease 0 0.8038088
in O 0 0.0009864001
our O 0 0.00079833274
case O 0 0.00048348715
ensued O 0 0.0009768067
because O 0 0.00014656706
the O 0 0.0001476832
information O 0 0.00015975129
about O 0 0.0002966031
suicidal O 0 0.9912248
attempt O 0 0.00075782463
by O 0 0.0009144551
OP B-Chemical 0 0.9999646
compound I-Chemical 0 0.93057865
was O 0 0.00054279924
concealed O 0 0.00070776977
from O 0 0.00024918097
the O 0 0.00044555424
treating O 0 0.001366661
team O 0 0.0017158751
. O 0 0.0020849868

Curcumin B-Chemical 0 0.99951065
ameliorates O 0 0.9303107
cognitive B-Disease 0 0.95904696
dysfunction I-Disease 0 0.9701479
and O 0 0.0018967376
oxidative O 0 0.8843213
damage O 0 0.5944201
in O 0 0.0013503734
phenobarbitone B-Chemical 0 0.9999938
and O 0 0.0077543342
carbamazepine B-Chemical 1 0.9999912
administered O 0 0.004118614
rats O 0 0.003620137
. O 0 0.0022228751

The O 0 0.0023050003
antiepileptic O 0 0.99000543
drugs O 0 0.23480438
, O 0 0.0033135184
phenobarbitone B-Chemical 0 0.99999
and O 0 0.01045256
carbamazepine B-Chemical 1 0.99999607
are O 0 0.00048517386
well O 0 0.00018062291
known O 0 0.00023556822
to O 0 0.00018292302
cause O 0 0.0005208982
cognitive B-Disease 0 0.33410105
impairment I-Disease 0 0.3233204
on O 0 0.0006166473
chronic O 0 0.25362104
use O 0 0.0021511407
. O 0 0.0022777067

The O 0 0.0018069226
increase O 0 0.0014028917
in O 0 0.00094958255
free O 0 0.0012784145
radical O 0 0.16536152
generation O 0 0.0010229431
has O 0 0.00025780036
been O 0 0.00015402846
implicated O 0 0.00010339206
as O 0 0.000102985774
one O 0 6.986684e-05
of O 0 0.00010446845
the O 0 7.6532e-05
important O 0 5.2466024e-05
mechanisms O 0 0.00013954288
of O 0 0.00028474428
cognitive B-Disease 0 0.26528096
impairment I-Disease 0 0.38592723
by O 0 0.0016201478
antiepileptic O 0 0.99804795
drugs O 0 0.20624712
. O 0 0.0023437992

Curcumin B-Chemical 0 0.99932575
has O 0 0.0029440788
shown O 0 0.0021184527
antioxidant O 0 0.9970696
, O 0 0.0020081403
anti O 0 0.006471054
- O 0 0.002502375
inflammatory O 0 0.076652996
and O 0 0.0014110651
neuro O 0 0.06293632
- O 0 0.0021547177
protective O 0 0.0032105974
properties O 0 0.0019091588
. O 0 0.0029590589

Therefore O 0 0.0018392168
, O 0 0.0016016322
the O 0 0.0007629716
present O 0 0.0004742633
study O 0 0.0005331295
was O 0 0.00030987224
carried O 0 0.00016852928
out O 0 0.00010182812
to O 0 8.040006e-05
investigate O 0 4.674696e-05
the O 0 7.5501724e-05
effect O 0 8.453393e-05
of O 0 0.00027464548
chronic O 0 0.61801356
curcumin B-Chemical 1 0.999984
administration O 0 0.031333026
on O 0 0.00024110402
phenobarbitone B-Chemical 0 0.9999988
- O 0 0.0035949755
and O 0 0.00091653544
carbamazepine B-Chemical 1 0.99999845
- O 0 0.00096668565
induced O 0 0.00031069963
cognitive B-Disease 0 0.53812087
impairment I-Disease 0 0.43649897
and O 0 0.00064422813
oxidative O 0 0.6803206
stress O 0 0.014458325
in O 0 0.00083507434
rats O 0 0.0020348616
. O 0 0.001675696

Pharmacokinetic O 0 0.049795676
interactions O 0 0.001955909
of O 0 0.0023735599
curcumin B-Chemical 1 0.9996345
with O 0 0.01054206
phenobarbitone B-Chemical 0 0.9999925
and O 0 0.020091882
carbamazepine B-Chemical 1 0.9999889
were O 0 0.0018372665
also O 0 0.0013736816
studied O 0 0.0024841195
. O 0 0.002728054

Vehicle O 0 0.07944479
/ O 0 0.0060113147
drugs O 0 0.009849349
were O 0 0.00088180567
administered O 0 0.0007133621
daily O 0 0.0006474806
for O 0 0.00045066603
21days O 0 0.0055926824
to O 0 0.0007581042
male O 0 0.0031219115
Wistar O 0 0.005236906
rats O 0 0.0027348914
. O 0 0.0023775988

Passive O 0 0.005713763
avoidance O 0 0.0026489592
paradigm O 0 0.0011215253
and O 0 0.000792737
elevated O 0 0.0016138802
plus O 0 0.00046174336
maze O 0 0.015451457
test O 0 0.0006023329
were O 0 0.00030027376
used O 0 0.00025590396
to O 0 0.00033017597
assess O 0 0.00034911843
cognitive O 0 0.04391734
function O 0 0.0027306865
. O 0 0.0028654824

At O 0 0.0008274252
the O 0 0.0009102546
end O 0 0.0004617795
of O 0 0.0005800851
study O 0 0.00042279152
period O 0 0.0001733523
, O 0 0.00038141347
serum O 0 0.2085826
phenobarbitone B-Chemical 0 0.9999975
and O 0 0.012898636
carbamazepine B-Chemical 1 0.9999981
, O 0 0.00057234196
whole O 0 0.0004575097
brain O 0 0.24822617
malondialdehyde B-Chemical 1 0.9999994
and O 0 0.0018887707
reduced O 0 0.095824845
glutathione B-Chemical 0 0.99998474
levels O 0 0.0013563132
were O 0 0.0009403224
estimated O 0 0.0012940562
. O 0 0.0018872843

The O 0 0.0014952843
administration O 0 0.003448892
of O 0 0.0030156248
phenobarbitone B-Chemical 0 0.99998796
and O 0 0.010008731
carbamazepine B-Chemical 1 0.9999957
for O 0 0.00051263813
21days O 0 0.04502768
caused O 0 0.00024373546
a O 0 0.0002562653
significant O 0 0.00019359436
impairment B-Disease 0 0.32735604
of I-Disease 0 0.0002601981
learning I-Disease 0 0.0016808952
and I-Disease 0 0.00022193084
memory I-Disease 0 0.08603594
as O 0 0.0001833823
well O 0 0.00014727525
as O 0 0.0001936525
an O 0 0.00043995256
increased O 0 0.0014571534
oxidative O 0 0.8313715
stress O 0 0.10473156
. O 0 0.002707497

Concomitant O 0 0.019377861
curcumin B-Chemical 1 0.9995377
administration O 0 0.020696165
prevented O 0 0.0029910777
the O 0 0.00075697654
cognitive B-Disease 0 0.50897086
impairment I-Disease 0 0.32198966
and O 0 0.00037028015
decreased O 0 0.0005224048
the O 0 0.00021057182
increased O 0 0.0005877278
oxidative O 0 0.64373016
stress O 0 0.0076594204
induced O 0 0.00045698276
by O 0 0.0004467199
these O 0 0.0012772346
antiepileptic O 0 0.99614304
drugs O 0 0.15620705
. O 0 0.002378307

Curcumin B-Chemical 0 0.9996519
co O 0 0.6270211
- O 0 0.005139494
administration O 0 0.003793958
did O 0 0.0007005765
not O 0 0.00033882918
cause O 0 0.00040032173
any O 0 0.00015777741
significant O 0 0.00014271926
alteration O 0 0.00020807146
in O 0 9.5452946e-05
the O 0 0.000112446745
serum O 0 0.0056828186
concentrations O 0 0.0005533604
of O 0 0.00033699744
both O 0 0.00068457046
phenobarbitone B-Chemical 0 0.9999926
as O 0 0.0006437997
well O 0 0.00056529074
as O 0 0.0017145785
carbamazepine B-Chemical 1 0.99996555
. O 0 0.0037332329

These O 0 0.0019443878
results O 0 0.0012367277
show O 0 0.00069495157
that O 0 0.00073434814
curcumin B-Chemical 1 0.99975485
has O 0 0.00047581329
beneficial O 0 0.00047312587
effect O 0 0.00018717014
in O 0 0.00014381706
mitigating O 0 0.00039075583
the O 0 0.00015677084
deterioration B-Disease 0 0.008714004
of I-Disease 0 0.00021300389
cognitive I-Disease 0 0.10607146
functions I-Disease 0 0.00014297586
and O 0 0.00017712136
oxidative O 0 0.6141437
damage O 0 0.14764065
in O 0 8.272246e-05
rats O 0 0.00011221003
treated O 0 0.000121516045
with O 0 0.00033314087
phenobarbitone B-Chemical 0 0.99999774
and O 0 0.0019995444
carbamazepine B-Chemical 1 0.9999974
without O 0 0.00028237607
significantly O 0 0.00031950622
altering O 0 0.00038663778
their O 0 0.00056526973
serum O 0 0.055148628
concentrations O 0 0.0063836
. O 0 0.002511406

The O 0 0.0015927
findings O 0 0.0017768312
suggest O 0 0.0005606653
that O 0 0.00080498215
curcumin B-Chemical 1 0.9997274
can O 0 0.00045362284
be O 0 0.00023653872
considered O 0 0.00012790655
as O 0 0.00011094223
a O 0 0.00012799245
potential O 0 0.00010261122
safe O 0 0.00013264368
and O 0 7.808713e-05
effective O 0 6.859129e-05
adjuvant O 0 0.0006975592
to O 0 0.00018517135
phenobarbitone B-Chemical 0 0.9999975
and O 0 0.0022013918
carbamazepine B-Chemical 1 0.99999833
therapy O 0 0.00043511443
in O 0 0.000112559384
preventing O 0 0.0003021023
cognitive B-Disease 0 0.3379332
impairment I-Disease 0 0.17569178
associated O 0 0.00035222716
with O 0 0.00059449184
these O 0 0.0012825106
drugs O 0 0.05305996
. O 0 0.002025129

Can O 0 0.024300449
angiogenesis O 0 0.5726641
be O 0 0.0013238051
a O 0 0.00083992473
target O 0 0.00039507457
of O 0 0.0005691867
treatment O 0 0.0005623013
for O 0 0.0007366261
ribavirin B-Chemical 0 0.99943084
associated O 0 0.032960396
hemolytic B-Disease 2 0.99998856
anemia I-Disease 2 0.99998796
? O 0 0.38019243

BACKGROUND O 0 0.009228473
/ O 0 0.0051149568
AIMS O 0 0.010001
: O 0 0.0013070164
Recently O 0 0.00080789643
ribavirin B-Chemical 0 0.9976909
has O 0 0.00039128214
been O 0 0.00019800819
found O 0 0.00014414436
to O 0 0.00011961385
inhibit O 0 0.00014102772
angiogenesis O 0 0.7444058
and O 0 0.00018114204
a O 0 0.00014501011
number O 0 8.612137e-05
of O 0 0.00016512338
angiogenesis O 0 0.7147643
inhibitors O 0 0.00080798473
such O 0 8.068777e-05
as O 0 0.00016164134
sunitinib B-Chemical 0 0.9984143
and O 0 0.0004989523
sorafenib B-Chemical 0 0.99969447
have O 0 0.0001695515
been O 0 0.0001380008
found O 0 0.00017418388
to O 0 0.00030983734
cause O 0 0.0019623553
acute O 0 0.97639036
hemolysis B-Disease 0 0.99993074
. O 0 0.0059333635

We O 0 0.0015813616
aimed O 0 0.0016653307
to O 0 0.0007901408
investigate O 0 0.0003531686
whether O 0 0.00022600278
there O 0 0.00021418775
is O 0 0.00022555563
a O 0 0.0001910094
relation O 0 7.1063914e-05
between O 0 0.000106519125
hemoglobin O 0 0.76995677
, O 0 0.0005376286
haptoglobin O 0 0.97689885
and O 0 0.00043986537
angiogenesis O 0 0.9085553
soluble O 0 0.0022532535
markers O 0 0.0005218534
which O 0 0.00017084427
are O 0 0.000112384994
modifiable O 0 0.000455571
and O 0 0.00013260069
can O 0 9.1779824e-05
help O 0 0.00019847884
in O 0 0.0002029117
developing O 0 0.0010501358
strategies O 0 0.00068266736
against O 0 0.0014766922
anemia B-Disease 0 0.9998023
. O 0 0.004941423

METHODS O 0 0.0015689206
: O 0 0.0014159731
Fourteen O 0 0.0011826431
patients O 0 0.00064399454
chronically B-Disease 0 0.00091747305
infected I-Disease 0 0.00037133234
with I-Disease 0 0.0022854046
hepatitis I-Disease 2 0.99999905
C I-Disease 0 0.9999751
virus I-Disease 0 0.07342207
were O 0 0.00029358995
treated O 0 0.00032412668
by O 0 0.00036471238
pegylated B-Chemical 0 0.99757
interferon I-Chemical 0 0.99996686
alpha I-Chemical 0 0.97579056
2a I-Chemical 0 0.0019200204
and O 0 0.0016745363
ribavirin B-Chemical 0 0.99847275
. O 0 0.0036255487

Serum O 0 0.56127536
hemoglobin O 0 0.93830854
, O 0 0.0038863628
haptoglobin O 0 0.95754844
and O 0 0.0014149244
angiogenesis O 0 0.80831045
markers O 0 0.0013810212
of O 0 0.0005827844
vascular O 0 0.30261764
endothelial O 0 0.87708557
growth O 0 0.00911253
factor O 0 0.0015339319
and O 0 0.00036648227
angiopoetin O 0 0.06534257
- O 0 0.00043273764
2 O 0 0.000101849386
were O 0 0.00010238749
investigated O 0 9.946818e-05
before O 0 9.932032e-05
and O 0 0.00029446936
after O 0 0.00031249368
therapy O 0 0.0017352096
. O 0 0.0020198268

RESULTS O 0 0.005189319
: O 0 0.001918284
We O 0 0.0006363801
observed O 0 0.0005550875
a O 0 0.00064759597
significant O 0 0.00041429733
decrease O 0 0.00049399375
in O 0 0.00042501237
haptoglobin O 0 0.8681871
levels O 0 0.00029783775
at O 0 0.00014120317
the O 0 0.00017031662
end O 0 0.0001296903
of O 0 0.00032418108
the O 0 0.00042088682
treatment O 0 0.00070822047
period O 0 0.00080696394
. O 0 0.0019258638

Hemoglobin O 0 0.9901806
levels O 0 0.00414088
also O 0 0.0028379706
decreased O 0 0.0049513555
but O 0 0.0036998366
insignificantly O 0 0.052110247
by O 0 0.0038774714
treatment O 0 0.0047552767
. O 0 0.00556506

In O 0 0.0016942547
contrast O 0 0.0015252806
with O 0 0.00094144285
the O 0 0.0006230536
literature O 0 0.0008792995
, O 0 0.000526873
serum O 0 0.0073816148
levels O 0 0.00030983263
of O 0 0.000476569
angiogenesis O 0 0.85554975
factors O 0 0.00034255686
did O 0 0.00015873031
not O 0 9.20792e-05
change O 0 0.00011073729
significantly O 0 0.00019796248
by O 0 0.00029933508
pegylated B-Chemical 0 0.9938584
interferon I-Chemical 0 0.9999273
and O 0 0.003926578
ribavirin B-Chemical 0 0.9996246
therapy O 0 0.009852912
. O 0 0.0027646334

We O 0 0.0018305427
found O 0 0.0012327172
no O 0 0.00062832725
correlation O 0 0.0005475711
of O 0 0.0010492706
angiogenesis O 0 0.77102715
soluble O 0 0.0041355784
markers O 0 0.001429968
with O 0 0.0006087317
either O 0 0.00079156406
hemoglobin O 0 0.88362247
or O 0 0.0026021344
haptoglobin O 0 0.98520386
. O 0 0.0041525643

CONCLUSION O 0 0.01863472
: O 0 0.0023945246
This O 0 0.0014635962
is O 0 0.0005956647
the O 0 0.00034076814
first O 0 0.00019392838
study O 0 0.00025531175
in O 0 0.00014457438
the O 0 0.00013272768
literature O 0 0.00019113345
investigating O 0 9.3363975e-05
a O 0 0.000119764285
link O 0 5.863279e-05
between O 0 6.480531e-05
angiogenesis O 0 0.6194155
soluble O 0 0.0014692764
markers O 0 0.00061169645
and O 0 0.00023861244
ribavirin B-Chemical 0 0.9993826
induced O 0 0.0017171368
anemia B-Disease 0 0.99997735
in O 0 0.00029121508
patients O 0 0.00053806516
with O 0 0.0030573413
hepatitis B-Disease 2 0.99999964
C I-Disease 0 0.99997234
and O 0 0.0004906502
we O 0 0.000108930246
could O 0 0.00015217646
not O 0 0.00021180013
find O 0 0.00030179316
any O 0 0.0004630604
relation O 0 0.00065880734
. O 0 0.0017722448

Future O 0 0.0024737862
research O 0 0.0016303865
with O 0 0.00095932354
larger O 0 0.0006911228
number O 0 0.00039924664
of O 0 0.0004351676
patients O 0 0.00040526633
is O 0 0.00017521417
needed O 0 0.00010309995
to O 0 0.0001015075
find O 0 9.260868e-05
out O 0 8.603518e-05
modifiable O 0 0.00041343764
factors O 0 0.00013626562
that O 0 7.497781e-05
will O 0 8.361149e-05
improve O 0 8.2176346e-05
the O 0 0.00013916883
safety O 0 0.00032604916
of O 0 0.00078397756
ribavirin B-Chemical 0 0.9983708
therapy O 0 0.0057104267
. O 0 0.002556006

Reduction O 0 0.004371897
in O 0 0.0015038147
injection O 0 0.0017660806
pain B-Disease 0 0.25321606
using O 0 0.00076942093
buffered O 0 0.01505545
lidocaine B-Chemical 0 0.9994887
as O 0 0.00043547817
a O 0 0.000427513
local O 0 0.00053034857
anesthetic O 0 0.0050182277
before O 0 0.0004034656
cardiac O 0 0.018585403
catheterization O 0 0.005404382
. O 0 0.0021220774

Previous O 0 0.0014496895
reports O 0 0.0013760737
have O 0 0.00054787163
suggested O 0 0.00034424532
that O 0 0.0003546615
pain B-Disease 0 0.17313585
associated O 0 0.0002286771
with O 0 0.00021213804
the O 0 0.00013839772
injection O 0 0.00020140513
of O 0 0.0005090755
lidocaine B-Chemical 0 0.9998217
is O 0 0.00017654622
related O 0 6.294338e-05
to O 0 0.000118082346
the O 0 0.00023287503
acidic O 0 0.0051234956
pH O 0 0.006659597
of O 0 0.0008204065
the O 0 0.0010652174
solution O 0 0.009777655
. O 0 0.0026291057

To O 0 0.0017415009
determine O 0 0.0007274823
if O 0 0.0005310372
the O 0 0.00045061484
addition O 0 0.0002531535
of O 0 0.0004075712
a O 0 0.0004416632
buffering O 0 0.0030761596
solution O 0 0.0012935126
to O 0 0.00010725829
adjust O 0 6.276284e-05
the O 0 0.00011590984
pH O 0 0.002556565
of O 0 0.00032184404
lidocaine B-Chemical 0 0.9993766
into O 0 3.717575e-05
the O 0 5.5778866e-05
physiologic O 0 0.00015196243
range O 0 6.8866684e-05
would O 0 5.6966117e-05
reduce O 0 6.5344015e-05
pain B-Disease 0 0.06724554
during O 0 4.166776e-05
injection O 0 9.633106e-05
, O 0 7.090869e-05
we O 0 2.854594e-05
performed O 0 4.862658e-05
a O 0 9.298468e-05
blinded O 0 0.00011101356
randomized O 0 9.4625706e-05
study O 0 0.000103709724
in O 0 0.00011763372
patients O 0 0.00029550513
undergoing O 0 0.00050936575
cardiac O 0 0.018293587
catheterization O 0 0.0042905295
. O 0 0.0015586526

Twenty O 0 0.0030405167
patients O 0 0.0014540621
were O 0 0.0005846115
asked O 0 0.0003480955
to O 0 0.00021843481
quantify O 0 0.0001322456
the O 0 0.00018183996
severity O 0 0.00042190513
of O 0 0.00031660195
pain B-Disease 0 0.10153984
after O 0 4.412119e-05
receiving O 0 0.00014301391
standard O 0 0.00012346306
lidocaine B-Chemical 0 0.9992493
in O 0 9.979567e-05
one O 0 6.6119195e-05
femoral O 0 0.0008726116
area O 0 0.00012279784
and O 0 0.00016534899
buffered O 0 0.0050848112
lidocaine B-Chemical 0 0.99898213
in O 0 0.0002511978
the O 0 0.0002981861
opposite O 0 0.0007060121
femoral O 0 0.008467661
area O 0 0.0017981835
. O 0 0.00209096

The O 0 0.0012388239
mean O 0 0.00085203553
pain B-Disease 0 0.043011893
score O 0 0.00051911385
for O 0 0.00040713995
buffered O 0 0.013896758
lidocaine B-Chemical 0 0.99982846
was O 0 0.0004161821
significantly O 0 0.00023632862
lower O 0 0.00014218489
than O 0 4.5801058e-05
the O 0 4.571675e-05
mean O 0 2.5740355e-05
score O 0 3.9426377e-05
for O 0 4.4463486e-05
standard O 0 0.00013673093
lidocaine B-Chemical 0 0.9998542
( O 0 0.00032147267
2 O 0 8.32106e-05
. O 0 5.0192284e-05
7 O 0 5.8978338e-05
+ O 0 0.00019481276
/ O 0 0.00040871135
- O 0 0.00025154388
1 O 0 8.2864884e-05
. O 0 5.400995e-05
9 O 0 6.749254e-05
vs O 0 9.4437855e-05
. O 0 5.749765e-05
3 O 0 6.256696e-05
. O 0 5.6640238e-05
8 O 0 7.960937e-05
+ O 0 0.00023717668
/ O 0 0.0004831527
- O 0 0.0003282502
2 O 0 0.00012601473
. O 0 0.00010359586
2 O 0 0.00015900617
, O 0 0.00036053947
P O 0 0.0031816608
= O 0 0.0005043316
0 O 0 0.0004275542
. O 0 0.0005964822
03 O 0 0.004404913
) O 0 0.002612127
. O 0 0.0026527466

The O 0 0.002119726
pH O 0 0.0071784616
adjustment O 0 0.0007197714
of O 0 0.0007595852
standard O 0 0.00076608907
lidocaine B-Chemical 0 0.99961394
can O 0 0.0002694396
be O 0 0.00016139323
accomplished O 0 0.00017632265
easily O 0 0.00010171952
in O 0 6.0259546e-05
the O 0 6.724328e-05
catheterization O 0 0.00021122395
laboratory O 0 9.020827e-05
before O 0 2.3609107e-05
injection O 0 6.434077e-05
and O 0 6.224026e-05
results O 0 6.622755e-05
in O 0 6.2295054e-05
a O 0 0.00010442471
reduction O 0 0.00021413302
of O 0 0.00015621544
the O 0 0.00018300799
pain B-Disease 0 0.10862338
occurring O 0 0.00018772634
during O 0 0.00010456721
the O 0 0.00030688578
infiltration O 0 0.02157022
of O 0 0.0014606729
tissues O 0 0.00331844
. O 0 0.0020137222

Effect O 0 0.0030790619
of O 0 0.004066579
L B-Chemical 0 0.73261213
- I-Chemical 0 0.0058487128
alpha I-Chemical 0 0.813475
- I-Chemical 0 0.010788551
glyceryl I-Chemical 0 0.9997886
- I-Chemical 0 0.00337842
phosphorylcholine I-Chemical 0 0.036480457
on O 0 0.0007870436
amnesia B-Disease 0 0.998922
caused O 0 0.0032926854
by O 0 0.0060080416
scopolamine B-Chemical 1 0.9999708
. O 0 0.00632858

The O 0 0.0015471206
present O 0 0.0010513068
study O 0 0.0010308797
was O 0 0.00059060124
carried O 0 0.00032118842
out O 0 0.00020216008
to O 0 0.00018351244
test O 0 0.00021892355
the O 0 0.00012052764
effects O 0 0.00017929036
of O 0 0.0004917655
L B-Chemical 0 0.8892325
- I-Chemical 0 0.0015591381
alpha I-Chemical 0 0.83947515
- I-Chemical 0 0.0018118453
glycerylphosphorylcholine I-Chemical 0 0.92100465
( O 0 0.00068036624
L B-Chemical 0 0.7058635
- I-Chemical 0 0.0009982896
alpha I-Chemical 0 0.737477
- I-Chemical 0 0.0017306487
GFC I-Chemical 0 0.9935148
) O 0 0.00034361304
on O 0 0.00011947981
memory B-Disease 2 0.90906954
impairment I-Disease 2 0.97778815
induced O 0 0.0014808575
by O 0 0.0024127972
scopolamine B-Chemical 1 0.99999154
in O 0 0.0032613196
man O 0 0.11640918
. O 0 0.0024169926

Thirty O 0 0.0038715329
- O 0 0.0025223119
two O 0 0.0007078207
healthy O 0 0.0016784086
young O 0 0.0015324719
volunteers O 0 0.00049122295
were O 0 0.00019279268
randomly O 0 8.714551e-05
allocated O 0 0.00013883351
to O 0 0.00021645446
four O 0 0.00027227867
different O 0 0.00051876565
groups O 0 0.001254592
. O 0 0.0020654514

They O 0 0.0029658729
were O 0 0.0010906013
given O 0 0.0004432514
a O 0 0.0004964536
ten O 0 0.000213064
day O 0 0.00017324719
pretreatment O 0 0.0016691928
with O 0 0.00029843865
either O 0 0.00036801223
L B-Chemical 0 0.8325613
- I-Chemical 0 0.001422472
alpha I-Chemical 0 0.8132234
- I-Chemical 0 0.0017450325
GFC I-Chemical 0 0.9932285
or O 0 0.00022485392
placebo O 0 0.00236097
, O 0 0.00021836821
p O 0 0.00015039778
. O 0 7.494907e-05
o O 0 0.0007724498
. O 0 7.1249015e-05
, O 0 9.111969e-05
and O 0 6.598818e-05
on O 0 3.7431244e-05
the O 0 6.766583e-05
eleventh O 0 0.00024303418
day O 0 5.8883146e-05
either O 0 0.0002036583
scopolamine B-Chemical 1 0.9999919
or O 0 0.00049772963
placebo O 0 0.0032836976
, O 0 0.00050195906
i O 0 0.0011542217
. O 0 0.0006646278
m O 0 0.0030861076
. O 0 0.0020716116

Before O 0 0.0025539973
and O 0 0.001983302
0 O 0 0.0012157247
. O 0 0.00064673525
5 O 0 0.00049183064
, O 0 0.0005662442
1 O 0 0.00036496544
, O 0 0.0003789024
2 O 0 0.00023375217
, O 0 0.00025226298
3 O 0 0.00014355456
, O 0 0.0001639905
and O 0 0.00012466454
6 O 0 6.24269e-05
h O 0 6.0906597e-05
after O 0 3.6697904e-05
injection O 0 0.000104024686
the O 0 0.00011288507
subjects O 0 0.00016667297
were O 0 0.0001264132
given O 0 0.00011153433
attention O 0 0.0003581012
and O 0 0.00050210266
mnemonic O 0 0.0046649436
tests O 0 0.0032594241
. O 0 0.0021232883

The O 0 0.00159447
findings O 0 0.001750985
of O 0 0.0009950906
this O 0 0.0006631984
study O 0 0.00046281374
indicate O 0 0.00015004526
that O 0 0.00014059871
the O 0 0.00022767985
drug O 0 0.005905907
is O 0 0.00015431142
able O 0 9.35655e-05
to O 0 0.000120521545
antagonize O 0 0.0003907493
impairment B-Disease 0 0.07139187
of I-Disease 0 0.0003142159
attention I-Disease 0 0.00036936326
and I-Disease 0 0.00030282614
memory I-Disease 0 0.112762354
induced O 0 0.0015515523
by O 0 0.0040592314
scopolamine B-Chemical 1 0.9999807
. O 0 0.0047032046

Safety O 0 0.016767375
of O 0 0.010592144
capecitabine B-Chemical 1 0.9923034
: O 0 0.009983042
a O 0 0.0093703745
review O 0 0.014124824
. O 0 0.0095394775

IMPORTANCE O 0 0.008999179
OF O 0 0.004613856
THE O 0 0.002603871
FIELD O 0 0.008004978
: O 0 0.0015676604
Fluoropyrimidines B-Chemical 0 0.36409608
, O 0 0.0005763128
in O 0 0.0002455586
particular O 0 0.00014848635
5 B-Chemical 0 0.00019769273
- I-Chemical 0 0.00069795625
fluorouracil I-Chemical 0 0.9956988
( O 0 0.00038328578
5 B-Chemical 0 0.00013744216
- I-Chemical 0 0.00041301007
FU I-Chemical 0 0.14333571
) O 0 0.00027630408
, O 0 0.00011960121
have O 0 5.5275454e-05
been O 0 4.7567562e-05
the O 0 5.872243e-05
mainstay O 0 0.0001222902
of O 0 8.854348e-05
treatment O 0 7.080626e-05
for O 0 5.097181e-05
several O 0 7.2962306e-05
solid O 0 0.011082566
tumors B-Disease 0 0.48378322
, O 0 0.00017914783
including O 0 0.00011393622
colorectal B-Disease 0 0.9055212
, I-Disease 0 0.00032132075
breast I-Disease 0 0.1660967
and I-Disease 0 0.00021961263
head I-Disease 0 0.0017640423
and I-Disease 0 0.00036471031
neck I-Disease 0 0.10443459
cancers I-Disease 0 0.8950852
, O 0 0.00042370052
for O 0 0.00029611232
> O 0 0.0010312747
40 O 0 0.00083670317
years O 0 0.0010652945
. O 0 0.0016935959

AREAS O 0 0.006855056
COVERED O 0 0.007279423
IN O 0 0.008173471
THIS O 0 0.006131925
REVIEW O 0 0.004219379
: O 0 0.0007956256
This O 0 0.0005497259
article O 0 0.00036579216
reviews O 0 0.00038146044
the O 0 0.00021263295
pharmacology O 0 0.0011121457
and O 0 0.00017059375
efficacy O 0 0.000236037
of O 0 0.0004130073
capecitabine B-Chemical 1 0.99525684
with O 0 0.00039362776
a O 0 0.00033553303
special O 0 0.00023858948
emphasis O 0 0.000310607
on O 0 0.00030600463
its O 0 0.0012750479
safety O 0 0.002212463
. O 0 0.002127373

WHAT O 0 0.00789888
THE O 0 0.0046855076
READER O 0 0.10985904
WILL O 0 0.023010245
GAIN O 0 0.022092646
: O 0 0.0007961892
The O 0 0.0003225939
reader O 0 0.0019421459
will O 0 0.0002318073
gain O 0 0.00037715907
better O 0 0.00017820859
insight O 0 0.00011368987
into O 0 3.825238e-05
the O 0 6.733055e-05
safety O 0 0.00011838292
of O 0 0.00020864917
capecitabine B-Chemical 1 0.9865246
in O 0 0.000110218025
special O 0 9.171823e-05
populations O 0 0.00011311577
such O 0 5.241411e-05
as O 0 8.0652375e-05
patients O 0 0.00015165369
with O 0 0.00018111874
advanced O 0 0.0012148016
age O 0 0.0003433812
, O 0 0.00043760543
renal B-Disease 0 0.8638103
and I-Disease 0 0.0015491814
kidney I-Disease 0 0.96953267
disease I-Disease 0 0.8066884
. O 0 0.0027606424

We O 0 0.0018372079
also O 0 0.0012708767
explore O 0 0.0007809548
different O 0 0.00063438603
dosing O 0 0.001351937
and O 0 0.0008042108
schedules O 0 0.0010275196
of O 0 0.0021013012
capecitabine B-Chemical 1 0.99777967
administration O 0 0.057313394
. O 0 0.0046311333

TAKE O 0 0.026866063
HOME O 0 0.018804427
MESSAGE O 0 0.0131065585
: O 0 0.0023611968
Capecitabine B-Chemical 0 0.96987176
is O 0 0.0005944357
an O 0 0.0005982159
oral O 0 0.01955163
prodrug O 0 0.1775906
of O 0 0.0003822713
5 B-Chemical 0 0.00016489273
- I-Chemical 0 0.00041144036
FU I-Chemical 0 0.063650146
and O 0 0.00014706516
was O 0 0.000120260265
developed O 0 0.00012870252
to O 0 6.635391e-05
fulfill O 0 6.682432e-05
the O 0 6.272144e-05
need O 0 4.718449e-05
for O 0 4.3202166e-05
a O 0 8.820875e-05
more O 0 0.00010379936
convenient O 0 0.00011876284
therapy O 0 0.00012198286
and O 0 8.7281485e-05
provide O 0 8.069008e-05
an O 0 0.00017740228
improved O 0 0.0003820897
safety O 0 0.0004685507
/ O 0 0.0010235796
efficacy O 0 0.0009690509
profile O 0 0.0016787698
. O 0 0.0020548776

It O 0 0.002461583
has O 0 0.0009188346
shown O 0 0.0004963608
promising O 0 0.00051092077
results O 0 0.00037053137
alone O 0 0.0003027084
or O 0 0.00018525773
in O 0 0.00014487634
combination O 0 0.00018639701
with O 0 0.00014827965
other O 0 0.00011437294
chemotherapeutic O 0 0.0023984094
agents O 0 0.0010454307
in O 0 0.00024998072
colorectal B-Disease 0 0.9547557
, I-Disease 0 0.00042696382
breast I-Disease 0 0.3493428
, I-Disease 0 0.00034902224
pancreaticobiliary I-Disease 0 0.55437225
, I-Disease 0 0.0003260333
gastric I-Disease 0 0.06472033
, I-Disease 0 0.00033203812
renal I-Disease 0 0.79120433
cell I-Disease 0 0.0017365359
and I-Disease 0 0.00046535436
head I-Disease 0 0.0038162067
and I-Disease 0 0.0013181317
neck I-Disease 0 0.20648281
cancers I-Disease 0 0.960613
. O 0 0.0031673398

The O 0 0.001669053
most O 0 0.0017005783
commonly O 0 0.0010358505
reported O 0 0.00080538116
toxic O 0 0.039072588
effects O 0 0.0005171448
of O 0 0.0009031111
capecitabine B-Chemical 1 0.9993641
are O 0 0.00078645546
diarrhea B-Disease 0 0.9990891
, O 0 0.003391651
nausea B-Disease 0 0.9999933
, O 0 0.0049041277
vomiting B-Disease 0 0.99995697
, O 0 0.0015871223
stomatitis B-Disease 2 0.9961132
and O 0 0.00075439125
hand B-Disease 2 0.00167941
- I-Disease 2 0.002867802
foot I-Disease 2 0.07587605
syndrome I-Disease 2 0.3853044
. O 0 0.002838949

Capecitabine B-Chemical 0 0.99438137
has O 0 0.0017151778
a O 0 0.001336257
well O 0 0.00066859595
- O 0 0.00084554503
established O 0 0.00038609508
safety O 0 0.00033594162
profile O 0 0.00023757954
and O 0 0.00017169394
can O 0 8.993805e-05
be O 0 8.094533e-05
given O 0 5.9117538e-05
safely O 0 0.00014130905
to O 0 7.8632904e-05
patients O 0 0.00015943688
with O 0 0.00019054099
advanced O 0 0.0011686394
age O 0 0.00035383186
, O 0 0.00044788353
hepatic B-Disease 0 0.87838286
and I-Disease 0 0.0015021947
renal I-Disease 0 0.988482
dysfunctions I-Disease 0 0.88188505
. O 0 0.0028444089

Levodopa B-Chemical 0 0.99962497
- O 0 0.0069134035
induced O 0 0.0031069354
dyskinesias B-Disease 0 0.9997009
in O 0 0.0007323962
patients O 0 0.00064367696
with O 0 0.0006217556
Parkinson B-Disease 0 0.9968683
' I-Disease 0 0.000500545
s I-Disease 0 0.00030431314
disease I-Disease 0 0.01451273
: O 0 0.0003075483
filling O 0 0.0007008924
the O 0 0.0003033682
bench O 0 0.0024686814
- O 0 0.0007069043
to O 0 0.0004868467
- O 0 0.0013639266
bedside O 0 0.0033066627
gap O 0 0.0023557465
. O 0 0.0023581793

Levodopa B-Chemical 0 0.99922025
is O 0 0.002128598
the O 0 0.0009783716
most O 0 0.00089730433
effective O 0 0.0005361519
drug O 0 0.0034253625
for O 0 0.00028473532
the O 0 0.00033310786
treatment O 0 0.00044546716
of O 0 0.0011683501
Parkinson B-Disease 0 0.9981567
' I-Disease 0 0.0021740163
s I-Disease 0 0.0018009576
disease I-Disease 0 0.10864143
. O 0 0.0033626452

However O 0 0.0028744545
, O 0 0.0019711948
the O 0 0.0010236313
long O 0 0.0007759113
- O 0 0.0008247064
term O 0 0.00029023527
use O 0 0.00022628004
of O 0 0.00030745217
this O 0 0.00061248016
dopamine B-Chemical 0 0.9997837
precursor O 0 0.0054402966
is O 0 0.00027065742
complicated O 0 0.00044923343
by O 0 0.00023756867
highly O 0 0.00034361894
disabling O 0 0.15986763
fluctuations O 0 0.0011988854
and O 0 0.0021671173
dyskinesias B-Disease 0 0.9996551
. O 0 0.0032189572

Although O 0 0.0017161727
preclinical O 0 0.0036814373
and O 0 0.00090667716
clinical O 0 0.0010616513
findings O 0 0.0005343973
suggest O 0 0.00013222368
pulsatile O 0 0.0003965841
stimulation O 0 0.00012667748
of O 0 0.00030180122
striatal O 0 0.7941256
postsynaptic O 0 0.6132179
receptors O 0 0.001863975
as O 0 8.7694374e-05
a O 0 8.6135165e-05
key O 0 4.9511284e-05
mechanism O 0 0.000108476546
underlying O 0 0.0005978591
levodopa B-Chemical 0 0.9999846
- O 0 0.0010265202
induced O 0 0.0008234151
dyskinesias B-Disease 0 0.9999522
, O 0 0.00046133882
their O 0 0.00037849968
pathogenesis O 0 0.00079811714
is O 0 0.0004827616
still O 0 0.000692477
unclear O 0 0.0011390863
. O 0 0.0019964238

In O 0 0.0021914784
recent O 0 0.001690359
years O 0 0.001053892
, O 0 0.0006696108
evidence O 0 0.00031339913
from O 0 0.00022897014
animal O 0 0.0002915454
models O 0 0.00023852944
of O 0 0.0004294372
Parkinson B-Disease 0 0.9981298
' I-Disease 0 0.00038931763
s I-Disease 0 0.00021631933
disease I-Disease 0 0.017605266
has O 0 6.7024404e-05
provided O 0 5.551242e-05
important O 0 2.8965695e-05
information O 0 5.077567e-05
to O 0 4.491167e-05
understand O 0 4.6657442e-05
the O 0 5.461479e-05
effect O 0 5.83717e-05
of O 0 0.00011054538
specific O 0 7.969382e-05
receptor O 0 0.0028243577
and O 0 0.00011305291
post O 0 6.5258144e-05
- O 0 0.00023260807
receptor O 0 0.0010594457
molecular O 0 0.00060929713
mechanisms O 0 0.00013338795
underlying O 0 0.00018672306
the O 0 0.00017330272
development O 0 0.0005381331
of O 0 0.0015641013
dyskinetic B-Disease 0 0.99994266
movements I-Disease 0 0.15794219
. O 0 0.002660828

Recent O 0 0.0025303639
preclinical O 0 0.0041033477
and O 0 0.0010171313
clinical O 0 0.0011620673
data O 0 0.00044072553
from O 0 0.00023964161
promising O 0 0.00031736866
lines O 0 0.00044400647
of O 0 0.00019839065
research O 0 0.0001434853
focus O 0 7.434735e-05
on O 0 4.4755918e-05
the O 0 6.539494e-05
differential O 0 0.00010121445
role O 0 3.881726e-05
of O 0 0.000105802
presynaptic O 0 0.0030119938
versus O 0 7.217817e-05
postsynaptic O 0 0.021447284
mechanisms O 0 0.00016507898
, O 0 0.00026094387
dopamine B-Chemical 0 0.99987876
receptor O 0 0.053723063
subtypes O 0 0.000761521
, O 0 0.00020377776
ionotropic O 0 0.98933804
and O 0 0.00066187116
metabotropic O 0 0.9999734
glutamate B-Chemical 1 0.9999852
receptors O 0 0.020601075
, O 0 0.00013825869
and O 0 9.305732e-05
non O 0 0.00016080857
- O 0 0.00027718823
dopaminergic O 0 0.17921722
neurotransmitter O 0 0.0285414
systems O 0 7.710338e-05
in O 0 6.098285e-05
the O 0 9.717367e-05
pathophysiology O 0 0.0015473181
of O 0 0.0009868578
levodopa B-Chemical 0 0.99996567
- O 0 0.0028944705
induced O 0 0.00378462
dyskinesias B-Disease 0 0.9998307
. O 0 0.0033755405

Effects O 0 0.002705196
of O 0 0.0023654555
pallidal O 0 0.51015294
neurotensin B-Chemical 0 0.9914206
on O 0 0.0012187689
haloperidol B-Chemical 1 0.9999938
- O 0 0.004278491
induced O 0 0.0040117144
parkinsonian B-Disease 2 0.9999962
catalepsy I-Disease 0 0.99999833
: O 0 0.001739327
behavioral O 0 0.0017878729
and O 0 0.00066485873
electrophysiological O 0 0.0028193346
studies O 0 0.0015632333
. O 0 0.0019158999

OBJECTIVE O 0 0.023947403
: O 0 0.003174804
The O 0 0.001569724
globus O 0 0.07963716
pallidus O 0 0.43312162
plays O 0 0.00087321294
a O 0 0.0009128342
critical O 0 0.00057407765
role O 0 0.00057557726
in O 0 0.00093159603
movement O 0 0.001962316
regulation O 0 0.0017104897
. O 0 0.0032524525

Previous O 0 0.0014630584
studies O 0 0.0011983647
have O 0 0.000500814
indicated O 0 0.00029750913
that O 0 0.00022463
the O 0 0.00035794268
globus O 0 0.12885436
pallidus O 0 0.45969152
receives O 0 0.00016284584
neurotensinergic O 0 0.000399027
innervation O 0 0.00034715928
from O 0 7.2832525e-05
the O 0 9.946619e-05
striatum O 0 0.0035922811
, O 0 0.00013094886
and O 0 0.00011900611
systemic O 0 0.020872619
administration O 0 0.0006495728
of O 0 0.00023651523
a O 0 0.00049183745
neurotensin B-Chemical 0 0.9702575
analog O 0 0.0008206946
could O 0 0.00021869823
produce O 0 0.0003464527
antiparkinsonian O 0 0.92194825
effects O 0 0.0021153514
. O 0 0.002224643

The O 0 0.0015079516
present O 0 0.0009945068
study O 0 0.00089471415
aimed O 0 0.00069857645
to O 0 0.00033209
investigate O 0 0.00016376331
the O 0 0.0002021227
effects O 0 0.00025533125
of O 0 0.00049433904
pallidal O 0 0.8112609
neurotensin B-Chemical 0 0.9946977
on O 0 0.0005451031
haloperidol B-Chemical 1 0.99999547
- O 0 0.0033703086
induced O 0 0.0036305268
parkinsonian B-Disease 2 0.9999765
symptoms I-Disease 0 0.9520781
. O 0 0.0032168406

METHODS O 0 0.001782125
: O 0 0.001546773
Behavioral O 0 0.0016105076
experiments O 0 0.00047376353
and O 0 0.00048864883
electrophysiological O 0 0.0011141023
recordings O 0 0.00045131598
were O 0 0.00031006194
performed O 0 0.00028173038
in O 0 0.00036019835
the O 0 0.0005441402
present O 0 0.0008329131
study O 0 0.0021913648
. O 0 0.0025999458

RESULTS O 0 0.004589313
: O 0 0.0020672115
Bilateral O 0 0.0026719
infusions O 0 0.0017642353
of O 0 0.0008499564
neurotensin B-Chemical 0 0.6762933
into O 0 0.00013105478
the O 0 0.00024112494
globus O 0 0.17481971
pallidus O 0 0.93386257
reversed O 0 0.021097118
haloperidol B-Chemical 1 0.99999726
- O 0 0.003561013
induced O 0 0.004231156
parkinsonian B-Disease 2 0.99999535
catalepsy I-Disease 0 0.99999666
in O 0 0.0027880971
rats O 0 0.0032445271
. O 0 0.001973427

Electrophysiological O 0 0.011988749
recordings O 0 0.001592546
showed O 0 0.0006920578
that O 0 0.00037391714
microinjection O 0 0.0010481597
of O 0 0.00083833357
neurotensin B-Chemical 0 0.9709485
induced O 0 0.0005409108
excitation O 0 0.1300868
of O 0 0.00049378286
pallidal O 0 0.33066118
neurons O 0 0.00032172285
in O 0 0.00010194792
the O 0 0.000110764435
presence O 0 0.00017708352
of O 0 0.0006596118
systemic O 0 0.9553567
haloperidol B-Chemical 1 0.99999344
administration O 0 0.18268444
. O 0 0.002789462

The O 0 0.0029626724
neurotensin B-Chemical 0 0.9551942
type I-Chemical 0 0.0021426321
- I-Chemical 0 0.0018066854
1 I-Chemical 0 0.00065139047
receptor I-Chemical 0 0.020864867
antagonist I-Chemical 0 0.9913771
SR48692 B-Chemical 0 0.9999877
blocked O 0 0.0020513847
both O 0 0.00024440332
the O 0 0.00016322236
behavioral O 0 0.0004845478
and O 0 0.00015629696
the O 0 0.00017068796
electrophysiological O 0 0.000869263
effects O 0 0.000446734
induced O 0 0.0009965517
by O 0 0.0021535084
neurotensin B-Chemical 0 0.9860487
. O 0 0.0029969905

CONCLUSION O 0 0.014263719
: O 0 0.0022793498
Activation O 0 0.0016461837
of O 0 0.0014106183
pallidal O 0 0.6801541
neurotensin B-Chemical 0 0.99531317
receptors O 0 0.003451709
may O 0 0.00027654629
be O 0 0.00020396827
involved O 0 0.000168171
in O 0 0.00038416975
neurotensin B-Chemical 0 0.9588027
- O 0 0.0012266675
induced O 0 0.0013399529
antiparkinsonian O 0 0.98691756
effects O 0 0.0032609717
. O 0 0.0028508215

Carmofur B-Chemical 0 0.94883096
- O 0 0.013573944
induced O 0 0.0097120805
organic B-Disease 0 0.9914841
mental I-Disease 0 0.5646182
disorders I-Disease 0 0.98538554
. O 0 0.0110554425

Organic B-Disease 0 0.9645025
mental I-Disease 0 0.111100376
disorder I-Disease 0 0.98836833
was O 0 0.001028989
observed O 0 0.00037473775
in O 0 0.00029431272
a O 0 0.00041194077
29 O 0 0.0005467448
- O 0 0.00041898174
year O 0 0.00012540231
- O 0 0.00024141018
old O 0 0.0001300157
female O 0 0.00024532553
in O 0 6.166654e-05
the O 0 6.385805e-05
prognostic O 0 0.00013183491
period O 0 3.1995536e-05
after O 0 2.8727161e-05
the O 0 8.8097106e-05
onset O 0 0.00025026358
of O 0 0.00068125484
carmofur B-Chemical 0 0.997068
- O 0 0.0027248543
induced O 0 0.003355379
leukoencephalopathy B-Disease 2 0.99940467
. O 0 0.004850761

Symptoms O 0 0.007280991
such O 0 0.0013224176
as O 0 0.0014768575
euphoria O 0 0.98361385
, O 0 0.0009471831
emotional O 0 0.0031803604
lability O 0 0.046510108
and O 0 0.00040903172
puerile O 0 0.001896753
attitude O 0 0.0006496161
noted O 0 7.706316e-05
in O 0 6.867631e-05
the O 0 6.972846e-05
patient O 0 8.8365596e-05
were O 0 8.1153856e-05
diagnosed O 0 0.00025483654
as O 0 0.00010285603
organic B-Disease 0 0.9910978
personality I-Disease 0 0.97371167
syndrome I-Disease 0 0.44765374
according O 0 4.5570676e-05
to O 0 4.3140077e-05
the O 0 5.307918e-05
criteria O 0 7.563849e-05
defined O 0 5.8954047e-05
in O 0 9.8496086e-05
the O 0 0.00020572337
DSM O 0 0.003932136
- O 0 0.0012471005
III O 0 0.016464584
- O 0 0.0038063487
R O 0 0.84339166
. O 0 0.0032962302

It O 0 0.004366719
is O 0 0.0025921206
referred O 0 0.0021153633
to O 0 0.0014669948
as O 0 0.0015772802
a O 0 0.0028656756
frontal B-Disease 0 0.53307694
lobe I-Disease 0 0.746368
syndrome I-Disease 0 0.9419448
. O 0 0.006468032

Brain O 0 0.01941218
CT O 0 0.020468203
revealed O 0 0.0011072439
a O 0 0.0009709853
periventricular O 0 0.0029458252
low O 0 0.00068789313
density O 0 0.0005676734
area O 0 0.00019142966
in O 0 0.00010954033
the O 0 0.00011677939
frontal O 0 0.0051829447
white O 0 0.0010231979
matter O 0 0.0005235194
and O 0 0.00013811585
moderate O 0 0.0011636508
dilatation O 0 0.038043734
of O 0 0.00013257755
the O 0 0.00010406666
lateral O 0 0.0004657266
ventricles O 0 0.0013584651
especially O 0 0.0001525209
at O 0 0.00012987098
the O 0 0.00032079333
bilateral O 0 0.0054108044
anterior O 0 0.013012881
horns O 0 0.0415244
. O 0 0.0022944119

Consequently O 0 0.0032180855
, O 0 0.0042625046
carmofur B-Chemical 0 0.9956676
- O 0 0.0038111398
induced O 0 0.0017540138
leukoencephalopathy B-Disease 2 0.997203
may O 0 0.00065491727
uncommonly O 0 0.004400167
result O 0 0.000244251
in O 0 0.00030390898
organic B-Disease 0 0.99379843
personality I-Disease 0 0.98332787
syndrome I-Disease 0 0.6584357
in O 0 0.00035249873
the O 0 0.00041486663
residual O 0 0.00089660607
state O 0 0.0018394943
. O 0 0.0020808973

It O 0 0.00336054
may O 0 0.001603164
be O 0 0.0010383916
attributed O 0 0.00063281227
to O 0 0.0005783119
the O 0 0.0006530085
structural B-Disease 0 0.0013216226
damage I-Disease 0 0.03146559
to I-Disease 0 0.00087288924
the I-Disease 0 0.0013048757
frontal I-Disease 0 0.14327744
lobe I-Disease 0 0.3564382
. O 0 0.004132017

Butyrylcholinesterase O 0 0.11599268
gene O 0 0.0033125612
mutations O 0 0.0035486526
in O 0 0.0007121988
patients O 0 0.0006441581
with O 0 0.00046819192
prolonged O 0 0.0010272946
apnea B-Disease 0 0.7566911
after O 0 0.0002734827
succinylcholine B-Chemical 1 0.9983941
for O 0 0.00076328206
electroconvulsive O 0 0.43540323
therapy O 0 0.0027383089
. O 0 0.0021413818

BACKGROUND O 0 0.0070440224
: O 0 0.0018768205
patients O 0 0.0010652888
undergoing O 0 0.0007577055
electroconvulsive O 0 0.05672729
therapy O 0 0.00069895276
( O 0 0.0005449945
ECT O 0 0.113198
) O 0 0.00032353023
often O 0 0.00019213076
receive O 0 0.00016517061
succinylcholine B-Chemical 1 0.99480116
as O 0 0.00019490789
part O 0 0.0001528011
of O 0 0.00031918078
the O 0 0.000503564
anesthetic O 0 0.015386717
procedure O 0 0.0014830887
. O 0 0.001962455

The O 0 0.0014002336
duration O 0 0.00074245967
of O 0 0.0009353613
action O 0 0.000877684
may O 0 0.00037724336
be O 0 0.00025211702
prolonged O 0 0.00032197387
in O 0 0.0001565908
patients O 0 0.0001799288
with O 0 0.00013501775
genetic O 0 0.00035890646
variants O 0 0.00018197091
of O 0 0.00014426124
the O 0 0.00019162908
butyrylcholinesterase O 0 0.9877331
enzyme O 0 0.11598271
( O 0 0.0006262109
BChE O 0 0.99732983
) O 0 0.0003928057
, O 0 0.00011268375
the O 0 7.774934e-05
most O 0 0.00013606396
common O 0 0.00012689883
being O 0 0.0002015717
the O 0 0.00032462768
K O 1 0.99948186
- O 0 0.0008303899
and O 0 0.00033490633
the O 0 0.00050013466
A O 0 0.0114397
- O 0 0.0019649973
variants O 0 0.0028792212
. O 0 0.0024529777

The O 0 0.0015632899
aim O 0 0.0014409304
of O 0 0.0011622749
the O 0 0.0007364591
study O 0 0.00063868565
was O 0 0.00034664004
to O 0 0.00016221586
assess O 0 7.520423e-05
the O 0 0.00012050776
clinical O 0 0.00027869336
significance O 0 9.809397e-05
of O 0 0.00012596823
genetic O 0 0.00039814212
variants O 0 0.00023872919
in O 0 0.00014837341
butyrylcholinesterase O 0 0.9520547
gene O 0 0.0008006865
( O 0 0.0005362557
BCHE O 0 0.99911636
) O 0 0.00025225742
in O 0 7.651529e-05
patients O 0 0.000110837536
with O 0 9.2615395e-05
a O 0 0.00012554685
suspected O 0 0.0003042798
prolonged O 0 0.00014933005
duration O 0 4.552589e-05
of O 0 0.00013016358
action O 0 0.00027638022
of O 0 0.00069957646
succinylcholine B-Chemical 1 0.99932706
after O 0 0.0005995299
ECT O 0 0.5427679
. O 0 0.002096263

METHODS O 0 0.0017552342
: O 0 0.0014105493
a O 0 0.0008433556
total O 0 0.00052972813
of O 0 0.00052917196
13 O 0 0.00037922058
patients O 0 0.00031391648
were O 0 0.0001663094
referred O 0 0.00015931576
to O 0 0.00010807294
the O 0 0.0001591172
Danish O 0 0.0009752221
Cholinesterase O 0 0.9796107
Research O 0 0.0009753365
Unit O 0 0.0003596883
after O 0 0.000112259455
ECT O 0 0.00718268
during O 0 0.00024959567
38 O 0 0.0007371472
months O 0 0.00053945056
. O 0 0.0014762621

We O 0 0.0015324609
determined O 0 0.0011872415
the O 0 0.0011675012
BChE O 0 0.92537206
activity O 0 0.00062259973
and O 0 0.0004447522
the O 0 0.0005124713
BCHE O 0 0.9986498
genotype O 0 0.0014362979
using O 0 0.00012784934
molecular O 0 0.0008503153
genetic O 0 0.00047471872
methods O 0 0.000110090295
, O 0 8.6602224e-05
the O 0 5.666412e-05
duration O 0 3.5140984e-05
of O 0 0.0001630004
apnea B-Disease 0 0.8007598
, O 0 9.867206e-05
time O 0 3.284087e-05
to O 0 4.5717537e-05
sufficient O 0 5.5851087e-05
spontaneous O 0 0.0003944854
ventilation O 0 0.00026323102
and O 0 0.0001130695
whether O 0 9.3110764e-05
neuromuscular O 0 0.012215875
monitoring O 0 0.00046331433
was O 0 0.00070637086
used O 0 0.0009948295
. O 0 0.0017816195

The O 0 0.0015028814
duration O 0 0.00091909076
of O 0 0.0017781663
apnea B-Disease 0 0.781103
was O 0 0.0007813426
compared O 0 0.00031344188
with O 0 0.00046247593
published O 0 0.0005161367
data O 0 0.000535827
on O 0 0.00047891063
normal O 0 0.0020086763
subjects O 0 0.0024888027
. O 0 0.0025563852

RESULTS O 0 0.0050763055
: O 0 0.0020612178
in O 0 0.0009631971
11 O 0 0.0007933389
patients O 0 0.00071183854
, O 0 0.0005174288
mutations O 0 0.0013384119
were O 0 0.0002511882
found O 0 0.00015265489
in O 0 0.00015339936
the O 0 0.00029604178
BCHE O 0 0.9985428
gene O 0 0.0008590135
, O 0 0.00032137462
the O 0 0.0004920304
K O 1 0.99961555
- O 0 0.0011795806
variant O 0 0.00074120384
being O 0 0.0005352487
the O 0 0.0004974465
most O 0 0.001296676
frequent O 0 0.0025744713
. O 0 0.0021972104

The O 0 0.0014150896
duration O 0 0.0008474252
of O 0 0.0016561853
apnea B-Disease 0 0.84681374
was O 0 0.0007580145
5 O 0 0.00028827507
- O 0 0.00035165742
15 O 0 0.00011490346
min O 0 0.00015498135
compared O 0 0.00010042286
with O 0 0.00019902535
3 O 0 0.00015319545
- O 0 0.00027698322
5 O 0 0.00011974726
. O 0 0.00010989521
3 O 0 0.00013662054
min O 0 0.00026926704
from O 0 0.000357633
the O 0 0.0007906985
literature O 0 0.0025118575
. O 0 0.0024848355

Severe O 0 0.2894097
distress O 0 0.08304723
was O 0 0.0016532697
noted O 0 0.0005823164
in O 0 0.00050292886
the O 0 0.0004909014
recovery O 0 0.0010350868
phase O 0 0.0013171147
in O 0 0.0007980783
two O 0 0.000913505
patients O 0 0.00269285
. O 0 0.0028138687

Neuromuscular O 0 0.017076375
monitoring O 0 0.0035003384
was O 0 0.0028516946
used O 0 0.0020535735
in O 0 0.002343344
two O 0 0.0025451945
patients O 0 0.0059938263
. O 0 0.00599631

CONCLUSION O 0 0.016185824
: O 0 0.002132361
eleven O 0 0.0010176547
of O 0 0.0007248215
13 O 0 0.0004807326
patients O 0 0.00035965416
with O 0 0.00022576586
a O 0 0.00019905118
prolonged O 0 0.0001857397
duration O 0 4.8781432e-05
of O 0 9.634126e-05
action O 0 0.00014712157
of O 0 0.00030360025
succinylcholine B-Chemical 1 0.99983764
had O 0 0.00023892638
mutations O 0 0.0040196707
in O 0 0.00027113236
BCHE O 0 0.99961036
, O 0 0.0001754991
indicating O 0 5.466679e-05
that O 0 4.821066e-05
this O 0 0.00010147363
is O 0 8.0195605e-05
the O 0 7.248298e-05
possible O 0 7.391233e-05
reason O 0 7.555069e-05
for O 0 8.9741276e-05
a O 0 0.00022139294
prolonged O 0 0.0003856682
period O 0 0.00023299696
of O 0 0.0011564195
apnea B-Disease 0 0.89468646
. O 0 0.0022773566

We O 0 0.0019760118
recommend O 0 0.0014983044
objective O 0 0.0020648069
neuromuscular O 0 0.012597766
monitoring O 0 0.001060356
during O 0 0.0006332892
the O 0 0.0011546931
first O 0 0.001648887
ECT O 0 0.36624593
. O 0 0.0046994

Perhexiline B-Chemical 0 0.9995072
maleate I-Chemical 0 0.9999304
and O 0 0.050848573
peripheral B-Disease 2 0.9851569
neuropathy I-Disease 2 0.9998267
. O 0 0.021647787

Peripheral B-Disease 0 0.99046373
neuropathy I-Disease 0 0.9998939
has O 0 0.0014177354
been O 0 0.00050341187
noted O 0 0.00025712457
as O 0 0.00022869388
a O 0 0.0002861005
complication O 0 0.001486725
of O 0 0.0002302034
therapy O 0 0.0003180353
with O 0 0.0013132829
perhexiline B-Chemical 0 0.9999994
maleate I-Chemical 0 0.99999976
, O 0 0.00065461424
a O 0 0.0002582183
drug O 0 0.003885071
widely O 0 5.941737e-05
used O 0 4.9899867e-05
in O 0 7.6822434e-05
France O 0 0.0007081398
( O 0 0.00011201834
and O 0 6.196369e-05
in O 0 5.3770826e-05
clinical O 0 0.00014914208
trials O 0 6.2260624e-05
in O 0 4.9832342e-05
the O 0 6.955215e-05
United O 0 0.00014673319
States O 0 0.00027868702
) O 0 0.00013798632
for O 0 6.187099e-05
the O 0 0.00010990171
prophylactic O 0 0.00033215302
treatment O 0 0.0003425781
of O 0 0.0020184028
angina B-Disease 0 0.99991035
pectoris I-Disease 0 0.99985003
. O 0 0.0033997626

In O 0 0.0016319467
24 O 0 0.0009826134
patients O 0 0.0009233785
with O 0 0.00058600504
this O 0 0.0005894489
complication O 0 0.007221303
, O 0 0.0003250173
the O 0 0.0001781379
marked O 0 0.00032273203
slowing O 0 0.0010416579
of O 0 0.00019954564
motor O 0 0.00090332795
nerve O 0 0.0030008103
conduction O 0 0.0006971679
velocity O 0 0.0001546542
and O 0 8.467528e-05
the O 0 9.212724e-05
electromyographic O 0 0.00067792874
changes O 0 0.00016363843
imply O 0 9.974723e-05
mainly O 0 0.00038695938
a O 0 0.0016081478
demyelinating B-Disease 0 0.9994879
disorder I-Disease 0 0.9993274
. O 0 0.0040032864

Improvement O 0 0.010646629
was O 0 0.0036939303
noted O 0 0.0019491944
with O 0 0.0025335199
cessation O 0 0.0035600585
of O 0 0.0042918213
therapy O 0 0.007679983
. O 0 0.0061896928

In O 0 0.0021271724
a O 0 0.0018382978
few O 0 0.0006543604
cases O 0 0.0006760106
the O 0 0.00037926034
presence O 0 0.00032409639
of O 0 0.00043526565
active O 0 0.0006281742
denervation O 0 0.7495529
signified O 0 0.005096534
a O 0 0.0004730677
poor O 0 0.0011687152
prognosis O 0 0.08970426
, O 0 0.00044615884
with O 0 0.000457392
only O 0 0.000651998
slight O 0 0.0022205126
improvement O 0 0.0022736508
. O 0 0.0021950263

The O 0 0.0015877738
underlying O 0 0.0017496912
mechanism O 0 0.0012279055
causing O 0 0.0017496536
the O 0 0.0019277583
neuropathy B-Disease 0 0.9999095
is O 0 0.0006106607
not O 0 0.0002596893
yet O 0 0.0002694938
fully O 0 0.00019329334
known O 0 0.00021478366
, O 0 0.00015460805
although O 0 8.929099e-05
some O 0 0.00010052336
evidence O 0 8.61419e-05
indicates O 0 7.911796e-05
that O 0 8.519769e-05
it O 0 0.00015652379
may O 0 0.0001372295
be O 0 0.00018542558
a O 0 0.00046309526
lipid O 0 0.16523205
storage O 0 0.0022446616
process O 0 0.0015640759
. O 0 0.0019929686

A O 0 0.02304815
phase O 0 0.006392832
I O 0 0.00877331
study O 0 0.0018548523
of O 0 0.0016117095
4 B-Chemical 0 0.0011025455
' I-Chemical 0 0.0017746757
- I-Chemical 0 0.0021872376
0 I-Chemical 0 0.0015758843
- I-Chemical 0 0.0036799805
tetrahydropyranyladriamycin I-Chemical 0 0.051669266
. O 0 0.0051667974

Clinical O 0 0.027678892
pharmacology O 0 0.035709098
and O 0 0.01672367
pharmacokinetics O 0 0.61567247
. O 0 0.018908763

A O 0 0.0156169655
Phase O 0 0.005014251
I O 0 0.0049607903
study O 0 0.00088519277
of O 0 0.000822183
intravenous O 0 0.020009656
( O 0 0.0009838603
IV O 0 0.030522436
) O 0 0.0004971388
bolus O 0 0.0008225133
4 B-Chemical 0 0.000133723
' I-Chemical 0 0.00021013057
- I-Chemical 0 0.00024524506
0 I-Chemical 0 0.00011551041
- I-Chemical 0 0.0002622321
tetrahydropyranyladriamycin I-Chemical 0 0.016788464
( O 0 0.00043121778
Pirarubicin B-Chemical 0 0.9290822
) O 0 0.0002814517
was O 0 0.000101363774
done O 0 6.1421226e-05
in O 0 6.7434e-05
55 O 0 0.000100654855
patients O 0 0.00010112213
in O 0 7.494586e-05
good O 0 0.00018398112
performance O 0 0.00023678692
status O 0 0.0002229835
with O 0 0.00057452277
refractory O 0 0.0089137675
tumors B-Disease 0 0.73016006
. O 0 0.00246855

Twenty O 0 0.0039390684
- O 0 0.002173291
six O 0 0.0004515196
had O 0 0.00037905882
minimal O 0 0.00025959424
prior O 0 0.00016496098
therapy O 0 0.00040822267
( O 0 0.0003451265
good O 0 0.0004793724
risk O 0 0.0031030152
) O 0 0.0003806781
, O 0 0.0001578397
23 O 0 0.00014132926
had O 0 6.935861e-05
extensive O 0 6.829979e-05
prior O 0 4.1241372e-05
therapy O 0 0.00014689166
( O 0 0.00016398205
poor O 0 0.00044000812
risk O 0 0.0023253718
) O 0 0.00027468818
, O 0 0.00012335775
and O 0 9.826887e-05
six O 0 6.714006e-05
had O 0 0.00017241512
renal B-Disease 0 0.4864832
and I-Disease 0 0.0004456394
/ I-Disease 0 0.0013063665
or I-Disease 0 0.0009117181
hepatic I-Disease 0 0.9993905
dysfunction I-Disease 0 0.99917763
. O 0 0.0041605206

A O 0 0.010680761
total O 0 0.0015123549
of O 0 0.0012162303
167 O 0 0.0013046041
courses O 0 0.0004558459
at O 0 0.0002682088
doses O 0 0.0009879962
of O 0 0.000334562
15 O 0 0.00017245114
to O 0 0.00017084068
70 O 0 0.0003073616
mg O 0 0.0031519246
/ O 0 0.0011907642
m2 O 0 0.0023901009
were O 0 0.0009647149
evaluable O 0 0.0027112847
. O 0 0.001991194

Maximum O 0 0.0042247977
tolerated O 0 0.007161561
dose O 0 0.0035009836
in O 0 0.00072013563
good O 0 0.0011825677
- O 0 0.0011522878
risk O 0 0.0020435483
patients O 0 0.00037313963
was O 0 0.00017996861
70 O 0 0.0001662704
mg O 0 0.002741861
/ O 0 0.0005396035
m2 O 0 0.0011226283
, O 0 0.00015411337
and O 0 0.00011288647
in O 0 0.00011510271
poor O 0 0.0004991973
- O 0 0.00045932623
risk O 0 0.0013730444
patients O 0 0.00037574937
, O 0 0.0002960141
60 O 0 0.00035427976
mg O 0 0.0051333783
/ O 0 0.0024567773
m2 O 0 0.006650084
. O 0 0.0022614424

The O 0 0.0027157408
dose O 0 0.00828615
- O 0 0.0034183506
limiting O 0 0.0024430193
toxic O 0 0.13785937
effect O 0 0.0013876198
was O 0 0.0018344659
transient O 0 0.04095126
noncumulative O 0 0.94294906
granulocytopenia B-Disease 0 0.9998198
. O 0 0.006986171

Granulocyte O 0 0.88268375
nadir O 0 0.005162904
was O 0 0.0015566414
on O 0 0.00058133685
day O 0 0.0005410327
14 O 0 0.00059826317
( O 0 0.0007944847
range O 0 0.00067773135
, O 0 0.0009155432
4 O 0 0.00078073016
- O 0 0.0017722548
22 O 0 0.0020484934
) O 0 0.0033151186
. O 0 0.0033944482

Less O 0 0.022108216
frequent O 0 0.0028606742
toxic O 0 0.07437394
effects O 0 0.0012372225
included O 0 0.0012426967
thrombocytopenia B-Disease 0 0.9999019
, O 0 0.008905562
anemia B-Disease 0 0.99997485
, O 0 0.010709751
nausea B-Disease 0 0.9999788
, O 0 0.0030264822
mild O 0 0.98341125
alopecia B-Disease 0 0.99998057
, O 0 0.007862455
phlebitis B-Disease 0 0.99976283
, O 0 0.0024463267
and O 0 0.0037083286
mucositis B-Disease 2 0.9998336
. O 0 0.0046604285

Myelosuppression B-Disease 0 0.9981694
was O 0 0.004451802
more O 0 0.0027137615
in O 0 0.0018778427
patients O 0 0.0028185837
with O 0 0.004483551
hepatic B-Disease 0 0.9990388
dysfunction I-Disease 0 0.99897003
. O 0 0.008735184

Pharmacokinetic O 0 0.04857082
analyses O 0 0.0012471
in O 0 0.0006850408
21 O 0 0.0005340649
patients O 0 0.00046365624
revealed O 0 0.00040511182
Pirarubicin B-Chemical 0 0.94195324
plasma O 0 0.06773201
T O 0 0.6902282
1 O 0 0.00024151841
/ O 0 0.00049678166
2 O 0 0.00016719998
alpha O 0 0.085595116
( O 0 0.0003563248
+ O 0 0.00043350045
/ O 0 0.0007638606
- O 0 0.000586015
SE O 0 0.04429863
) O 0 0.00024602402
of O 0 0.00015722758
2 O 0 9.359646e-05
. O 0 5.8332862e-05
5 O 0 6.827426e-05
+ O 0 0.00020381139
/ O 0 0.00036514207
- O 0 0.00020765766
0 O 0 7.101344e-05
. O 0 4.4736116e-05
85 O 0 8.6488086e-05
minutes O 0 5.0975068e-05
, O 0 0.00017575461
T O 0 0.527503
beta O 0 0.8100375
1 O 0 0.000157034
/ O 0 0.0002798439
2 O 0 6.8445974e-05
of O 0 9.646305e-05
25 O 0 0.00013121184
. O 0 5.845944e-05
6 O 0 5.7041565e-05
+ O 0 0.00019647954
/ O 0 0.00038542194
- O 0 0.00022045727
6 O 0 5.238918e-05
. O 0 4.1387302e-05
5 O 0 4.0275914e-05
minutes O 0 4.1415256e-05
, O 0 0.000103131126
and O 0 0.00015563708
T O 0 0.14435726
1 O 0 0.00014059052
/ O 0 0.0003317144
2 O 0 0.00011854332
gamma O 0 0.047587726
of O 0 0.00023900864
23 O 0 0.00024169369
. O 0 9.050364e-05
6 O 0 9.8438904e-05
+ O 0 0.0003366797
/ O 0 0.00068696734
- O 0 0.0005332617
7 O 0 0.00025559132
. O 0 0.00028616682
6 O 0 0.0004111571
hours O 0 0.00073844544
. O 0 0.0019081334

The O 0 0.0017437688
area O 0 0.0013529705
under O 0 0.00068683835
the O 0 0.00067857606
curve O 0 0.001062938
was O 0 0.0007791337
537 O 0 0.010451091
+ O 0 0.0010140584
/ O 0 0.0010956227
- O 0 0.00054125785
149 O 0 0.00060308364
ng O 0 0.0004952488
/ O 0 0.0005761481
ml O 0 0.00045720758
x O 0 0.00025924822
hours O 0 5.330699e-05
, O 0 8.169177e-05
volume O 0 0.00012727827
of O 0 8.9772686e-05
distribution O 0 5.494562e-05
( O 0 0.00018059897
Vd O 0 0.004620654
) O 0 0.00028982302
3504 O 0 0.023700591
+ O 0 0.00032154078
/ O 0 0.00046200954
- O 0 0.0003144083
644 O 0 0.0026516616
l O 0 0.00035100602
/ O 0 0.00031487236
m2 O 0 0.0006207195
, O 0 9.870087e-05
and O 0 7.080058e-05
total O 0 9.6415606e-05
clearance O 0 0.0022443477
( O 0 0.0003681347
ClT O 0 0.35596037
) O 0 0.0002574594
was O 0 0.00015719925
204 O 0 0.0005279472
+ O 0 0.00026133232
39 O 0 0.00019864656
. O 0 9.620621e-05
3 O 0 0.00012879459
l O 0 0.0004212284
/ O 0 0.00061769935
hour O 0 0.0004191737
/ O 0 0.0018286809
m2 O 0 0.005248385
. O 0 0.0024272765

Adriamycinol B-Chemical 0 0.7946745
, O 0 0.0051095095
doxorubicin B-Chemical 1 0.9978726
, O 0 0.0031929216
adriamycinone B-Chemical 0 0.8118975
, O 0 0.00081908045
and O 0 0.00048105483
tetrahydropyranyladriamycinol B-Chemical 0 0.12687035
were O 0 0.00020215083
the O 0 0.00016100694
metabolites O 0 0.11641184
detected O 0 8.701572e-05
in O 0 8.9169655e-05
plasma O 0 0.00096633524
and O 0 7.935409e-05
the O 0 5.63462e-05
amount O 0 4.3020158e-05
of O 0 0.00019448742
doxorubicin B-Chemical 1 0.9965134
was O 0 0.0001918997
less O 0 0.00010110564
than O 0 5.460708e-05
or O 0 6.3302075e-05
equal O 0 7.2899784e-05
to O 0 9.750932e-05
10 O 0 0.00012591253
% O 0 0.00017578664
of O 0 0.00026495155
the O 0 0.00039691807
total O 0 0.0010386974
metabolites O 0 0.60503095
. O 0 0.002509098

Urinary O 0 0.12163693
excretion O 0 0.56896013
of O 0 0.002439074
Pirarubicin B-Chemical 0 0.9033804
in O 0 0.00042628672
the O 0 0.00023710458
first O 0 0.0001285486
24 O 0 0.0001235495
hours O 0 9.484179e-05
was O 0 0.00016726187
less O 0 0.00017254605
than O 0 0.00013998272
or O 0 0.00020435604
equal O 0 0.00029544573
to O 0 0.00050700235
10 O 0 0.00087685726
% O 0 0.0017203605
. O 0 0.0022989179

Activity O 0 0.0054032546
was O 0 0.0023451382
noted O 0 0.0011678349
in O 0 0.0015249925
mesothelioma B-Disease 0 0.13773811
, O 0 0.0028053012
leiomyosarcoma B-Disease 0 0.91432846
, O 0 0.0014265383
and O 0 0.0013303028
basal B-Disease 0 0.006399326
cell I-Disease 0 0.018640235
carcinoma I-Disease 0 0.9985489
. O 0 0.0050950297

The O 0 0.0014280524
recommended O 0 0.0009870506
starting O 0 0.000573983
dose O 0 0.0013283544
for O 0 0.00034814698
Phase O 0 0.0011580631
II O 0 0.0023265823
trials O 0 0.00023860653
is O 0 0.00016409122
60 O 0 0.00017039264
mg O 0 0.00176784
/ O 0 0.0006278947
m2 O 0 0.0016388911
IV O 0 0.004908838
bolus O 0 0.000780179
every O 0 0.0001647417
3 O 0 0.00039724435
weeks O 0 0.00049959007
. O 0 0.0015228288

Ocular B-Disease 0 0.053779528
and I-Disease 0 0.002504355
auditory I-Disease 0 0.0044840337
toxicity I-Disease 2 0.98812777
in O 0 0.0030441585
hemodialyzed O 0 0.9990584
patients O 0 0.00754543
receiving O 0 0.01796626
desferrioxamine B-Chemical 0 0.9998745
. O 0 0.007794685

During O 0 0.001164966
an O 0 0.001666438
18 O 0 0.0009606078
- O 0 0.0008074794
month O 0 0.0001700719
period O 0 0.00011031288
of O 0 0.0001938415
study O 0 0.00023562777
41 O 0 0.0005342119
hemodialyzed O 0 0.99705017
patients O 0 0.00061240635
receiving O 0 0.0013678174
desferrioxamine B-Chemical 0 0.9999902
( O 0 0.0005416563
10 O 0 0.000114208495
- O 0 0.00016085502
40 O 0 9.043712e-05
mg O 0 0.0012456753
/ O 0 0.00034177155
kg O 0 0.00031921573
BW O 0 0.009916595
/ O 0 0.00022841735
3 O 0 4.0090064e-05
times O 0 2.537259e-05
weekly O 0 5.3965876e-05
) O 0 8.146928e-05
for O 0 3.8061342e-05
the O 0 5.176484e-05
first O 0 3.900242e-05
time O 0 4.1552372e-05
were O 0 7.433083e-05
monitored O 0 6.2940984e-05
for O 0 0.00010469073
detection O 0 0.00032231264
of O 0 0.00072157546
audiovisual B-Disease 0 0.047778428
toxicity I-Disease 2 0.9997434
. O 0 0.004636233

6 O 0 0.0019742795
patients O 0 0.0016774884
presented O 0 0.0010692354
clinical O 0 0.002139064
symptoms O 0 0.0041128327
of O 0 0.0011908511
visual B-Disease 0 0.006479834
or I-Disease 0 0.001336481
auditory I-Disease 0 0.007918694
toxicity I-Disease 2 0.99650335
. O 0 0.0053051044

Moreover O 0 0.0027714018
, O 0 0.0018995254
detailed O 0 0.000954709
ophthalmologic O 0 0.009143012
and O 0 0.0007325598
audiologic O 0 0.00390921
studies O 0 0.00045752717
disclosed O 0 0.00074437645
abnormalities O 0 0.003178805
in O 0 0.00032093405
7 O 0 0.0002798495
more O 0 0.0007136501
asymptomatic O 0 0.006018188
patients O 0 0.0026725251
. O 0 0.0023357624

Visual B-Disease 0 0.98043835
toxicity I-Disease 2 0.99921525
was O 0 0.002441679
of O 0 0.0016355756
retinal O 0 0.75883675
origin O 0 0.00071963656
and O 0 0.00035399006
was O 0 0.00027317836
characterized O 0 0.0003826505
by O 0 0.00020827333
a O 0 0.0005944556
tritan O 0 0.999739
- O 0 0.0010642649
type O 0 0.00032335788
dyschromatopsy B-Disease 0 0.22855343
, O 0 0.00017681492
sometimes O 0 0.00022157139
associated O 0 8.396145e-05
with O 0 0.00012040737
a B-Disease 0 0.00015077487
loss I-Disease 0 0.0003694119
of I-Disease 0 0.0003041513
visual I-Disease 0 0.07380751
acuity I-Disease 0 0.99890673
and O 0 0.0036171663
pigmentary B-Disease 0 0.9999081
retinal I-Disease 0 0.99864715
deposits I-Disease 0 0.9639724
. O 0 0.003289766

Auditory B-Disease 0 0.5559772
toxicity I-Disease 2 0.9991708
was O 0 0.0025389919
characterized O 0 0.0016438897
by O 0 0.0005717379
a O 0 0.0005219927
mid O 0 0.0006407061
- O 0 0.0004711052
to O 0 0.00016512668
high O 0 0.00045600848
- O 0 0.00047157268
frequency O 0 0.00040192736
neurosensorial B-Disease 0 0.9987173
hearing I-Disease 0 0.9989484
loss I-Disease 0 0.09646397
and O 0 0.00031467786
the O 0 0.0002289247
lesion O 0 0.0013627594
was O 0 0.00029578054
of O 0 0.0003959038
the O 0 0.0005793845
cochlear O 0 0.006637159
type O 0 0.0019975759
. O 0 0.002189073

Desferrioxamine B-Chemical 0 0.9995714
withdrawal O 0 0.09280104
resulted O 0 0.0010713653
in O 0 0.0004852617
a O 0 0.0003785069
complete O 0 0.00021621436
recovery O 0 0.00034215965
of O 0 0.00021639501
visual O 0 0.0018960184
function O 0 0.00016843418
in O 0 9.454697e-05
1 O 0 6.567781e-05
patient O 0 6.5096545e-05
and O 0 5.8993362e-05
partial O 0 0.0001159869
recovery O 0 0.0001883643
in O 0 7.404404e-05
3 O 0 5.3643147e-05
, O 0 6.586388e-05
and O 0 5.7986006e-05
a O 0 7.5608645e-05
complete O 0 6.714051e-05
reversal O 0 0.00018205788
of O 0 0.00020815917
hearing B-Disease 0 0.9716509
loss I-Disease 0 0.0019090798
in O 0 0.00014290976
3 O 0 8.60598e-05
patients O 0 0.00014164268
and O 0 0.00014233071
partial O 0 0.00038617363
recovery O 0 0.0007679617
in O 0 0.00062514795
3 O 0 0.00088020397
. O 0 0.0015387168

This O 0 0.0054236036
toxicity B-Disease 2 0.97577083
appeared O 0 0.001146213
in O 0 0.0005466901
patients O 0 0.0005074586
receiving O 0 0.0003275568
the O 0 0.00015762147
higher O 0 0.0002140189
doses O 0 0.0015393748
of O 0 0.0007908602
desferrioxamine B-Chemical 0 0.99998915
or O 0 0.0002397952
coincided O 0 0.00022732715
with O 0 0.00012165818
the O 0 8.46978e-05
normalization O 0 0.00014625868
of O 0 0.00041506466
ferritin O 0 0.99808747
or O 0 0.0011376445
aluminium B-Chemical 0 0.99883145
serum O 0 0.5458234
levels O 0 0.0033547985
. O 0 0.0027110334

The O 0 0.0014856727
data O 0 0.0012424634
indicate O 0 0.0005006932
that O 0 0.0004910366
audiovisual B-Disease 0 0.009159706
toxicity I-Disease 2 0.99976164
is O 0 0.0005988933
not O 0 0.0002421728
an O 0 0.00030597896
infrequent O 0 0.0006759037
complication O 0 0.0074346084
in O 0 0.0005482498
hemodialyzed O 0 0.99928313
patients O 0 0.0029896463
receiving O 0 0.008566082
desferrioxamine B-Chemical 0 0.99991596
. O 0 0.004656767

Periodical O 0 0.0029256826
audiovisual O 0 0.0018455321
monitoring O 0 0.0007911677
should O 0 0.0002985243
be O 0 0.00025321115
performed O 0 0.00019027341
on O 0 0.00018935777
hemodialyzed O 0 0.9936154
patients O 0 0.0004276571
receiving O 0 0.00022879837
the O 0 0.00012213568
drug O 0 0.0015407761
in O 0 8.2950115e-05
order O 0 7.2995994e-05
to O 0 8.621455e-05
detect O 0 0.00010052883
adverse O 0 0.0049301307
effects O 0 0.00035021483
as O 0 0.00034365492
early O 0 0.0008174739
as O 0 0.00074998866
possible O 0 0.0013161898
. O 0 0.0020821146

Serial O 0 0.009200994
epilepsy B-Disease 2 0.9979335
caused O 0 0.002691732
by O 0 0.0029754315
levodopa B-Chemical 0 0.9999801
/ I-Chemical 0 0.19101465
carbidopa I-Chemical 0 0.99999523
administration O 0 0.011418247
in O 0 0.00044710122
two O 0 0.00031311336
patients O 0 0.0006978279
on O 0 0.0006970549
hemodialysis O 0 0.14474313
. O 0 0.0026796293

Two O 0 0.0019492917
patients O 0 0.0013645944
with O 0 0.0006765614
similar O 0 0.00030181732
clinical O 0 0.0006225956
features O 0 0.00026411444
are O 0 0.00014809749
presented O 0 0.00012701396
: O 0 0.00015459876
both O 0 0.00011054813
patients O 0 0.00019797984
had O 0 0.00019007792
chronic B-Disease 2 0.773695
renal I-Disease 2 0.9957415
failure I-Disease 2 0.93724835
, O 0 0.00018445273
on O 0 5.3266336e-05
hemodialysis O 0 0.011770397
for O 0 4.99764e-05
many O 0 5.801802e-05
years O 0 5.3038802e-05
but O 0 5.3544914e-05
recently O 0 3.8964943e-05
begun O 0 6.54063e-05
on O 0 3.5141114e-05
a O 0 0.00010616593
high O 0 0.0002686201
- O 0 0.0002827586
flux O 0 0.00087696005
dialyzer O 0 0.028748548
; O 0 9.9599914e-05
both O 0 5.6034074e-05
had O 0 5.4641256e-05
been O 0 4.0652805e-05
receiving O 0 0.000110566456
a O 0 0.00036569734
carbidopa B-Chemical 0 0.9999988
/ I-Chemical 0 0.042679127
levodopa I-Chemical 0 0.99999475
preparation O 0 0.0002365757
; O 0 0.000101959486
and O 0 5.5597033e-05
both O 0 5.2266423e-05
had O 0 5.030383e-05
the O 0 5.0955437e-05
onset O 0 0.00011784613
of O 0 0.0003540083
hallucinosis B-Disease 0 0.99998164
and O 0 0.00041419646
recurrent O 0 0.11728955
seizures B-Disease 0 0.9999653
, O 0 0.00039850533
which O 0 0.00028454128
were O 0 0.0002661397
refractory O 0 0.0013808103
to O 0 0.000913129
anticonvulsants O 0 0.996403
. O 0 0.0023278266

The O 0 0.0013625284
first O 0 0.0008432162
patient O 0 0.0010191153
died O 0 0.001134551
without O 0 0.00042364118
a O 0 0.0005512271
diagnosis O 0 0.0007633788
; O 0 0.00023585162
the O 0 0.00012004303
second O 0 0.00011979216
patient O 0 0.00014410946
had O 0 0.00010693211
a O 0 0.00012926977
dramatic O 0 0.00017951462
recovery O 0 0.00022900397
following O 0 9.5407e-05
the O 0 0.00020150692
administration O 0 0.0020006676
of O 0 0.0041309814
vitamin B-Chemical 0 0.99997795
B6 I-Chemical 0 0.99836
. O 0 0.004218391

Neither O 0 0.0028130165
patient O 0 0.0020090693
was O 0 0.0010884512
considered O 0 0.00047399392
to O 0 0.00038109638
have O 0 0.00027788707
a O 0 0.00051826966
renal O 0 0.6055436
state O 0 0.00053832313
sufficiently O 0 0.00053861004
severe O 0 0.002245905
enough O 0 0.0003821977
to O 0 0.0002985667
explain O 0 0.00042249696
their O 0 0.0009282008
presentation O 0 0.0021471176
. O 0 0.002384135

Randomized O 0 0.0064395913
, O 0 0.0030064948
double O 0 0.002559148
- O 0 0.0024985273
blind O 0 0.005452852
trial O 0 0.0013450888
of O 0 0.0023247367
mazindol B-Chemical 0 0.99991214
in O 0 0.008834703
Duchenne B-Disease 0 0.9997775
dystrophy I-Disease 0 0.9998846
. O 0 0.008671848

There O 0 0.0028413704
is O 0 0.0015848723
evidence O 0 0.000793846
that O 0 0.00059847423
growth O 0 0.00501864
hormone O 0 0.12341309
may O 0 0.00031276012
be O 0 0.00017800056
related O 0 8.5123706e-05
to O 0 0.0001396064
the O 0 0.00022907996
progression O 0 0.0043284167
of O 0 0.0013049154
weakness B-Disease 0 0.97806644
in O 0 0.0044132695
Duchenne B-Disease 0 0.99985635
dystrophy I-Disease 0 0.9999244
. O 0 0.0064490894

We O 0 0.0016017864
conducted O 0 0.0012296917
a O 0 0.0010949242
12 O 0 0.00043784123
- O 0 0.00057998754
month O 0 0.00013999072
controlled O 0 0.00016834043
trial O 0 0.0002487895
of O 0 0.0004818821
mazindol B-Chemical 0 0.9999707
, O 0 0.00032780954
a O 0 0.00019469892
putative O 0 0.00013524748
growth O 0 0.0021675806
hormone O 0 0.19938302
secretion O 0 0.0018175115
inhibitor O 0 0.0015924354
, O 0 0.00027603892
in O 0 0.0002162156
83 O 0 0.00065636466
boys O 0 0.0014297446
with O 0 0.0020531106
Duchenne B-Disease 0 0.99978715
dystrophy I-Disease 0 0.99991345
. O 0 0.005713826

Muscle O 0 0.039608736
strength O 0 0.0043537663
, O 0 0.003650183
contractures O 0 0.9952272
, O 0 0.000925571
functional O 0 0.00038668627
ability O 0 0.0002849292
and O 0 0.0002841872
pulmonary O 0 0.022889253
function O 0 0.00020905942
were O 0 0.00010620482
tested O 0 6.7571425e-05
at O 0 5.0187115e-05
baseline O 0 7.4142736e-05
, O 0 9.3008886e-05
and O 0 7.449575e-05
6 O 0 3.660954e-05
and O 0 4.4995824e-05
12 O 0 2.4771969e-05
months O 0 1.5353024e-05
after O 0 1.7139531e-05
treatment O 0 6.6373155e-05
with O 0 0.00029778408
mazindol B-Chemical 0 0.99997485
( O 0 0.00038492694
3 O 0 0.00012863088
mg O 0 0.0020295524
/ O 0 0.00069078564
d O 0 0.00043845768
) O 0 0.0006484903
or O 0 0.0007341267
placebo O 0 0.004950924
. O 0 0.0020382216

The O 0 0.0019349146
study O 0 0.0017395497
was O 0 0.0009608879
designed O 0 0.00057873176
to O 0 0.00038837813
have O 0 0.00024450914
a O 0 0.0003402564
power O 0 0.00086094165
of O 0 0.00023850874
greater O 0 0.00017344406
than O 0 9.115358e-05
0 O 0 8.6654196e-05
. O 0 4.7794638e-05
90 O 0 5.9139194e-05
to O 0 5.0826056e-05
detect O 0 4.641903e-05
a O 0 0.00011340695
slowing O 0 0.00064173463
to O 0 8.058519e-05
25 O 0 0.00011964385
% O 0 7.085705e-05
of O 0 7.068327e-05
the O 0 5.643698e-05
expected O 0 4.8645135e-05
rate O 0 7.989136e-05
of O 0 0.00014328433
progression O 0 0.0048197033
of O 0 0.00048410325
weakness B-Disease 0 0.88876617
at O 0 0.00025720257
P O 0 0.0043971073
less O 0 0.00027043096
than O 0 0.00026223934
0 O 0 0.0004798867
. O 0 0.00073800684
05 O 0 0.0074088746
. O 0 0.0022427721

Mazindol B-Chemical 0 0.99837
did O 0 0.00310922
not O 0 0.0012677055
benefit O 0 0.0010147833
strength O 0 0.00095961563
at O 0 0.0004577977
any O 0 0.0005039201
point O 0 0.0005843809
in O 0 0.00082804833
the O 0 0.0013668811
study O 0 0.0027177625
. O 0 0.003127779

Side O 0 0.053454556
effects O 0 0.0016645762
attributable O 0 0.0008484441
to O 0 0.0010681245
mazindol B-Chemical 0 0.99991226
included O 0 0.0006936077
decreased B-Disease 0 0.047489163
appetite I-Disease 0 0.99911493
( O 0 0.0006719572
36 O 0 0.00020792669
% O 0 0.00019223007
) O 0 0.00025559132
, O 0 0.00023601766
dry B-Disease 2 0.8566002
mouth I-Disease 2 0.90142673
( O 0 0.00032198892
10 O 0 0.000117329226
% O 0 0.00013994239
) O 0 0.00017040776
, O 0 0.000106505206
behavioral O 0 0.0003050789
change O 0 0.00012050661
( O 0 0.00014948777
22 O 0 0.000118459255
% O 0 0.00010750721
) O 0 0.00014278405
, O 0 0.00010267632
and O 0 0.00015916744
gastrointestinal B-Disease 0 0.9912717
symptoms I-Disease 0 0.5672686
( O 0 0.0002597668
18 O 0 9.762441e-05
% O 0 0.0001183485
) O 0 0.00021764317
; O 0 0.00030810508
mazindol B-Chemical 0 0.9999597
dosage O 0 0.033757575
was O 0 0.00024346137
reduced O 0 0.00031753661
in O 0 0.00023713168
43 O 0 0.00046676243
% O 0 0.0004328016
of O 0 0.000842627
patients O 0 0.0020678323
. O 0 0.0019662096

The O 0 0.0014829758
effect O 0 0.0012850111
of O 0 0.0023596764
mazindol B-Chemical 0 0.9999124
on O 0 0.0008366975
GH O 0 0.98880285
secretion O 0 0.0030702807
was O 0 0.0002606873
estimated O 0 0.00012912466
indirectly O 0 0.00013990715
by O 0 9.2037764e-05
comparing O 0 4.598417e-05
the O 0 0.00010824777
postabsorptive O 0 0.15406169
IGF O 0 0.9959162
- O 0 0.00065340503
I O 0 0.0010355337
levels O 0 8.3303974e-05
obtained O 0 8.1350656e-05
following O 0 5.922836e-05
3 O 0 6.7624875e-05
, O 0 8.8732224e-05
6 O 0 4.8454018e-05
, O 0 8.15687e-05
9 O 0 5.926125e-05
, O 0 6.959832e-05
and O 0 5.70016e-05
12 O 0 3.043215e-05
months O 0 2.0480562e-05
in O 0 4.659732e-05
the O 0 0.00013846689
mazindol B-Chemical 0 0.999949
treated O 0 0.00036822824
to O 0 0.00014085192
those O 0 0.00023339296
in O 0 0.00020100169
the O 0 0.0004000644
placebo O 0 0.0030317986
groups O 0 0.0010412029
. O 0 0.0016337407

Although O 0 0.0035209095
mazindol B-Chemical 0 0.9998698
- O 0 0.0040731225
treated O 0 0.0011052544
patients O 0 0.0006188169
gained O 0 0.00038918626
less O 0 0.0002002839
weight O 0 0.00067742844
and O 0 0.00016322827
height O 0 0.00033007938
than O 0 9.409474e-05
placebo O 0 0.0012744779
- O 0 0.00026237188
treated O 0 0.00021728156
patients O 0 0.00023404475
, O 0 0.00012113912
no O 0 5.989781e-05
significant O 0 9.9504505e-05
effect O 0 0.00013107379
on O 0 0.00018896333
IGF O 0 0.9951513
- O 0 0.001903714
I O 0 0.0038238007
levels O 0 0.00069109775
was O 0 0.0010384223
observed O 0 0.0013101208
. O 0 0.002178496

Mazindol B-Chemical 0 0.9985505
doses O 0 0.014266314
not O 0 0.0013908459
slow O 0 0.002222839
the O 0 0.001030622
progression O 0 0.008968931
of O 0 0.0027968013
weakness B-Disease 0 0.9782085
in O 0 0.0070113298
Duchenne B-Disease 0 0.99978644
dystrophy I-Disease 0 0.9998952
. O 0 0.008748431

Facilitation O 0 0.005748191
of O 0 0.0018620685
memory O 0 0.014786824
retrieval O 0 0.0010463637
by O 0 0.00061062345
pre O 0 0.0009786623
- O 0 0.0008892492
test O 0 0.0008247178
morphine B-Chemical 0 0.9997842
and O 0 0.00028987162
its O 0 0.000273269
state O 0 0.00013999495
dependency O 0 0.00011924966
in O 0 8.0215344e-05
the O 0 9.0299676e-05
step O 0 0.000151066
- O 0 0.0002070712
through O 0 7.3801755e-05
type O 0 0.00012949605
passive O 0 0.00020800524
avoidance O 0 0.00050544715
learning O 0 0.0008563656
test O 0 0.0006642681
in O 0 0.0006278265
mice O 0 0.0010028492
. O 0 0.0019132238

Amnesia B-Disease 0 0.80813885
produced O 0 0.002246514
by O 0 0.0026817939
scopolamine B-Chemical 1 0.9999794
and O 0 0.002094219
cycloheximide B-Chemical 1 0.9990709
were O 0 0.0006370661
reversed O 0 0.0010668474
by O 0 0.0004065372
morphine B-Chemical 0 0.9996686
given O 0 6.7858266e-05
30 O 0 4.5645396e-05
min O 0 5.4331576e-05
before O 0 2.3537194e-05
the O 0 5.50196e-05
test O 0 0.0001051284
trial O 0 0.00012093263
( O 0 0.00012939174
pre O 0 0.00022704422
- O 0 0.00026406004
test O 0 0.0001932163
) O 0 0.00017534521
, O 0 9.78159e-05
and O 0 9.594785e-05
pre O 0 0.00025781413
- O 0 0.00029749918
test O 0 0.00032065116
morphine B-Chemical 0 0.99956757
also O 0 9.0259906e-05
facilitated O 0 7.667613e-05
the O 0 6.790558e-05
memory O 0 0.009451429
retrieval O 0 0.00013185915
in O 0 6.200613e-05
the O 0 6.397246e-05
animals O 0 7.1062226e-05
administered O 0 0.00029104884
naloxone B-Chemical 0 0.9998417
during O 0 0.00016620591
the O 0 0.0003219303
training O 0 0.0005193227
trial O 0 0.0013369495
. O 0 0.0015632244

Similarly O 0 0.0030247732
, O 0 0.002215519
pre O 0 0.0024048944
- O 0 0.0021093648
test O 0 0.0020939761
scopolamine B-Chemical 1 0.9999858
partially O 0 0.0016662746
reversed O 0 0.0022213461
the O 0 0.001098929
scopolamine B-Chemical 1 0.9999987
- O 0 0.0050717434
induced O 0 0.0010335324
amnesia B-Disease 0 0.999905
, O 0 0.00034052637
but O 0 0.00012846576
not O 0 8.123213e-05
significantly O 0 0.00016296637
; O 0 0.00011430011
and O 0 9.409492e-05
pre O 0 0.00024025016
- O 0 0.00026255232
test O 0 0.00023215165
cycloheximide B-Chemical 1 0.985379
failed O 0 0.0003073062
to O 0 0.00017972528
reverse O 0 0.0017919289
the O 0 0.0005938819
cycloheximide B-Chemical 1 0.99914527
- O 0 0.0051213307
induced O 0 0.004903032
amnesia B-Disease 0 0.99965346
. O 0 0.0041386117

These O 0 0.0020010942
results O 0 0.0011223066
suggest O 0 0.00040119272
that O 0 0.00032221738
the O 0 0.0003381148
facilitation O 0 0.0010139124
of O 0 0.0003923723
memory O 0 0.044909295
retrieval O 0 0.00038895835
by O 0 0.00021332644
pre O 0 0.00044777084
- O 0 0.0004410893
test O 0 0.00044657514
morphine B-Chemical 0 0.9997063
might O 0 7.404291e-05
be O 0 5.9105587e-05
the O 0 5.091347e-05
direct O 0 5.4383727e-05
action O 0 0.00014003235
of O 0 0.0003434632
morphine B-Chemical 0 0.9997652
rather O 0 0.00017557105
than O 0 0.00014048816
a O 0 0.00030733988
state O 0 0.00037343334
dependent O 0 0.0003477694
effect O 0 0.001232047
. O 0 0.0021335525

Naloxone B-Chemical 0 0.99941516
reverses O 0 0.020415334
the O 0 0.004055197
antihypertensive O 0 0.8111949
effect O 0 0.0035738647
of O 0 0.011023292
clonidine B-Chemical 0 0.9997465
. O 0 0.009375335

In O 0 0.0020531183
unanesthetized O 0 0.0039580795
, O 0 0.0015148195
spontaneously O 0 0.0038807364
hypertensive B-Disease 2 0.99825424
rats O 0 0.000605623
the O 0 0.00018510003
decrease O 0 0.000187731
in O 0 0.000121375924
blood O 0 0.0009685977
pressure O 0 0.001210687
and O 0 0.000119396194
heart O 0 0.0023943218
rate O 0 9.118026e-05
produced O 0 7.290173e-05
by O 0 0.00012511601
intravenous O 0 0.113543876
clonidine B-Chemical 0 0.99997795
, O 0 0.00015612952
5 O 0 4.2228763e-05
to O 0 3.799679e-05
20 O 0 5.7294306e-05
micrograms O 0 0.0004997277
/ O 0 0.0004011425
kg O 0 0.00030258487
, O 0 0.000110240624
was O 0 9.509618e-05
inhibited O 0 0.00018305247
or O 0 0.000117631134
reversed O 0 0.00055319
by O 0 0.000268521
nalozone B-Chemical 0 0.40500438
, O 0 0.00022019049
0 O 0 0.000113440794
. O 0 8.1008795e-05
2 O 0 0.0001045366
to O 0 0.00015078593
2 O 0 0.00028637724
mg O 0 0.0035828417
/ O 0 0.00245929
kg O 0 0.003203794
. O 0 0.0022408243

The O 0 0.0023055114
hypotensive B-Disease 0 0.8561421
effect O 0 0.0010441163
of O 0 0.000956725
100 O 0 0.0016358622
mg O 0 0.027377719
/ O 0 0.0018202697
kg O 0 0.0021427732
alpha B-Chemical 0 0.95779634
- I-Chemical 0 0.007259478
methyldopa I-Chemical 0 0.9999964
was O 0 0.0006804035
also O 0 0.00034554247
partially O 0 0.00083014584
reversed O 0 0.0033874481
by O 0 0.0034073824
naloxone B-Chemical 0 0.99988747
. O 0 0.0042497297

Naloxone B-Chemical 0 0.9996835
alone O 0 0.0034225704
did O 0 0.0014936847
not O 0 0.0006524712
affect O 0 0.00036350553
either O 0 0.0005938389
blood O 0 0.003960049
pressure O 0 0.0058755176
or O 0 0.0011052438
heart O 0 0.04249965
rate O 0 0.0030180872
. O 0 0.0030159818

In O 0 0.0017722633
brain O 0 0.0031908175
membranes O 0 0.0018472526
from O 0 0.00054656947
spontaneously O 0 0.0025853196
hypertensive B-Disease 2 0.9993794
rats O 0 0.00321317
clonidine B-Chemical 0 0.99996185
, O 0 0.00042260293
10 O 0 0.00018009375
( O 0 0.00025436902
- O 0 0.00025738776
8 O 0 9.370979e-05
) O 0 0.0001409328
to O 0 7.941631e-05
10 O 0 0.000107966334
( O 0 0.00019647356
- O 0 0.00024036883
5 O 0 0.00010245116
) O 0 0.0003306088
M O 0 0.25716627
, O 0 0.00016132844
did O 0 0.00010500235
not O 0 6.759998e-05
influence O 0 5.8234535e-05
stereoselective O 0 0.05405121
binding O 0 0.00013500357
of O 0 0.00027925515
[ B-Chemical 0 0.0015762534
3H I-Chemical 0 0.60839874
] I-Chemical 0 0.00075294054
- I-Chemical 0 0.00080941187
naloxone I-Chemical 0 0.99997294
( O 0 0.00035822927
8 O 0 9.630754e-05
nM O 0 0.0013166356
) O 0 0.0002627103
, O 0 0.00015571695
and O 0 0.00029714432
naloxone B-Chemical 0 0.99997616
, O 0 0.00029732593
10 O 0 0.00012457602
( O 0 0.00018853626
- O 0 0.00019771574
8 O 0 7.167582e-05
) O 0 0.000112631744
to O 0 6.498608e-05
10 O 0 9.1593596e-05
( O 0 0.00017405821
- O 0 0.0002220991
4 O 0 9.2934584e-05
) O 0 0.0002848662
M O 0 0.20527284
, O 0 0.00014407757
did O 0 9.96021e-05
not O 0 7.528789e-05
influence O 0 0.00010350936
clonidine B-Chemical 0 0.9999734
- O 0 0.00087473355
suppressible O 0 0.016764287
binding O 0 0.00017751429
of O 0 0.0003579285
[ B-Chemical 0 0.0016589864
3H I-Chemical 0 0.39255673
] I-Chemical 0 0.00086050853
- I-Chemical 0 0.0008989259
dihydroergocryptine I-Chemical 0 0.98701
( O 0 0.00083355507
1 O 0 0.00058362377
nM O 0 0.0049933586
) O 0 0.002917708
. O 0 0.0025369085

These O 0 0.0021386691
findings O 0 0.0017458643
indicate O 0 0.00050065736
that O 0 0.00036912004
in O 0 0.0004361092
spontaneously O 0 0.0022715773
hypertensive B-Disease 2 0.9985372
rats O 0 0.000335495
the O 0 0.000102878395
effects O 0 0.000108514
of O 0 0.00015844755
central O 0 0.00032206075
alpha O 0 0.5556261
- O 0 0.0011949713
adrenoceptor O 0 0.99967647
stimulation O 0 0.00017004757
involve O 0 0.00014590097
activation O 0 0.0004097424
of O 0 0.001233241
opiate O 0 0.99807274
receptors O 0 0.02421392
. O 0 0.002220655

As O 0 0.0030409503
naloxone B-Chemical 0 0.9997955
and O 0 0.0053543113
clonidine B-Chemical 0 0.9999205
do O 0 0.00065387716
not O 0 0.00024971156
appear O 0 0.00016003165
to O 0 9.469585e-05
interact O 0 4.4442462e-05
with O 0 0.00010094957
the O 0 8.374034e-05
same O 0 6.0320377e-05
receptor O 0 0.0015603928
site O 0 8.645412e-05
, O 0 8.752853e-05
the O 0 5.9525977e-05
observed O 0 5.559062e-05
functional O 0 0.00010533138
antagonism O 0 0.015494169
suggests O 0 3.8710208e-05
the O 0 6.522871e-05
release O 0 0.00020172684
of O 0 7.820114e-05
an O 0 9.281148e-05
endogenous O 0 0.0001750405
opiate O 0 0.99400747
by O 0 0.0003146416
clonidine B-Chemical 0 0.9999765
or O 0 0.0002496673
alpha B-Chemical 0 0.9855693
- I-Chemical 0 0.006581948
methyldopa I-Chemical 0 0.9999988
and O 0 0.00016414805
the O 0 6.687914e-05
possible O 0 4.7725593e-05
role O 0 3.616086e-05
of O 0 0.000101452344
the O 0 0.00014970817
opiate O 0 0.94828564
in O 0 0.00011111904
the O 0 0.00010971072
central O 0 0.00018981495
control O 0 0.00022889787
of O 0 0.0006749041
sympathetic O 0 0.04892663
tone O 0 0.04291054
. O 0 0.0022256032

Neurotoxicity B-Disease 0 0.9978529
of O 0 0.008119991
halogenated B-Chemical 0 0.9989755
hydroxyquinolines I-Chemical 0 0.996342
: O 0 0.001614515
clinical O 0 0.001298465
analysis O 0 0.0005304082
of O 0 0.0006743219
cases O 0 0.0008672014
reported O 0 0.0009973496
outside O 0 0.001095676
Japan O 0 0.008257371
. O 0 0.0030132488

An O 0 0.002784545
analysis O 0 0.0013993083
is O 0 0.0008175471
presented O 0 0.0005255122
of O 0 0.0006352932
220 O 0 0.0016920399
cases O 0 0.00037006577
of O 0 0.00031133599
possible O 0 0.00032891807
neurotoxic B-Disease 0 0.995577
reactions O 0 0.012954671
to O 0 0.00057068904
halogenated B-Chemical 0 0.9995944
hydroxyquinolines I-Chemical 0 0.996479
reported O 0 0.000744002
from O 0 0.00043887776
outside O 0 0.00065584196
Japan O 0 0.005368992
. O 0 0.0021074312

In O 0 0.0017364747
80 O 0 0.0018768543
cases O 0 0.0009314549
insufficient O 0 0.0005587427
information O 0 0.00042710366
was O 0 0.00036159452
available O 0 0.00023383688
for O 0 0.000116976
adequate O 0 0.00015186914
comment O 0 0.0004334007
and O 0 0.00013445194
in O 0 0.00010204352
29 O 0 0.00015066104
a O 0 9.1762144e-05
relationship O 0 3.9620638e-05
to O 0 7.389167e-05
the O 0 0.00012952642
administration O 0 0.0010314775
of O 0 0.0012521351
clioquinol B-Chemical 0 0.9999453
could O 0 0.0008184193
be O 0 0.00082628714
excluded O 0 0.0016131918
. O 0 0.0019440841

Of O 0 0.0024786557
the O 0 0.0014882582
remainder O 0 0.0014369956
, O 0 0.00083433697
a O 0 0.0005578775
relationship O 0 0.00023696377
to O 0 0.0006012958
clioquinol B-Chemical 0 0.9999392
was O 0 0.0006050602
considered O 0 0.00021089413
probable O 0 0.000566594
in O 0 0.0002031436
42 O 0 0.00026243768
and O 0 0.00024033169
possible O 0 0.00030964543
in O 0 0.0005237794
69 O 0 0.0011973559
cases O 0 0.0017398238
. O 0 0.0020450172

In O 0 0.0015658463
six O 0 0.00072563026
of O 0 0.0008048195
the O 0 0.0005584318
probable O 0 0.0010252967
cases O 0 0.0004270218
the O 0 0.0003580335
neurological B-Disease 0 0.9938234
disturbance I-Disease 0 0.28575742
consisted O 0 0.00013935966
of O 0 0.00017824971
an O 0 0.00030760578
acute O 0 0.645699
reversible O 0 0.8432083
encephalopathy B-Disease 2 0.999979
usually O 0 0.00027259893
related O 0 3.5702724e-05
to O 0 4.989249e-05
the O 0 7.16474e-05
ingestion O 0 0.0034819152
of O 0 0.00013100707
a O 0 0.00014438276
high O 0 0.00026307374
dose O 0 0.0009561044
of O 0 0.00071552076
clioquinol B-Chemical 0 0.99992824
over O 0 0.00020459095
a O 0 0.000480901
short O 0 0.00044444454
period O 0 0.00056961656
. O 0 0.0014574737

The O 0 0.0020290734
most O 0 0.0022605504
common O 0 0.0016196789
manifestation O 0 0.0038720972
, O 0 0.00082335976
observed O 0 0.00038889196
in O 0 0.00032378634
15 O 0 0.00025166143
further O 0 0.00044820216
cases O 0 0.00056445977
, O 0 0.00058286
was O 0 0.00071060436
isolated O 0 0.001222883
optic B-Disease 0 0.9909195
atrophy I-Disease 2 0.99941754
. O 0 0.0047978074

This O 0 0.0042128987
was O 0 0.001892833
most O 0 0.0012651664
frequently O 0 0.0006129243
found O 0 0.00038507866
in O 0 0.00031465507
children O 0 0.00043425322
, O 0 0.0002173603
many O 0 0.000119598124
of O 0 0.00019225794
whom O 0 0.00035140393
had O 0 0.00017991046
received O 0 0.0002459682
clioquinol B-Chemical 0 0.9999323
as O 0 0.00034778268
treatment O 0 0.00040847826
for O 0 0.0006825708
acrodermatitis B-Disease 0 0.97745854
enteropathica I-Disease 0 0.99971706
. O 0 0.0048822733

In O 0 0.0016684406
the O 0 0.0012521065
remaining O 0 0.0011055578
cases O 0 0.0008926033
, O 0 0.00055037555
a O 0 0.00044357262
combination O 0 0.00054012355
of O 0 0.0013616708
myelopathy B-Disease 0 0.9999484
, O 0 0.00086807733
visual B-Disease 0 0.6592795
disturbance I-Disease 0 0.6301635
, O 0 0.0004323348
and O 0 0.00045921816
peripheral B-Disease 2 0.87011844
neuropathy I-Disease 2 0.99999154
was O 0 0.00075124827
the O 0 0.000359081
most O 0 0.0007665199
common O 0 0.001152505
manifestation O 0 0.007226623
. O 0 0.002292184

Isolated O 0 0.015236654
myelopathy B-Disease 0 0.999316
or O 0 0.0036454187
peripheral B-Disease 2 0.95650303
neuropathy I-Disease 2 0.9999807
, O 0 0.0014737758
or O 0 0.00042962638
these O 0 0.0006087546
manifestations O 0 0.003750135
occurring O 0 0.0005228751
together O 0 0.00055623864
, O 0 0.0008647832
were O 0 0.0010565661
infrequent O 0 0.00330123
. O 0 0.00253446

The O 0 0.0016681857
onset O 0 0.0017699635
of O 0 0.0012504719
all O 0 0.0009149257
manifestations O 0 0.009443736
( O 0 0.0008282527
except O 0 0.00040519546
toxic O 0 0.8363976
encephalopathy B-Disease 2 0.9999728
) O 0 0.0019523045
was O 0 0.00040146898
usually O 0 0.0005761467
subacute O 0 0.9043188
, O 0 0.00044065664
with O 0 0.00037445207
subsequent O 0 0.00044972703
partial O 0 0.0014415605
recovery O 0 0.003043384
. O 0 0.0021614311

Older O 0 0.018805696
subjects O 0 0.0035339007
tended O 0 0.0020775157
to O 0 0.0015763823
display O 0 0.0018180046
more O 0 0.0032950633
side O 0 0.01456465
effects O 0 0.006966748
. O 0 0.0070126285

The O 0 0.001679985
full O 0 0.0017336592
syndrome O 0 0.026462218
of O 0 0.0020214594
subacute O 0 0.9895844
myelo B-Disease 0 0.86067665
- I-Disease 0 0.023770798
optic I-Disease 0 0.9999145
neuropathy I-Disease 0 0.9999969
was O 0 0.00074013806
more O 0 0.00028651682
frequent O 0 0.00022119102
in O 0 0.00013016333
women O 0 0.0004229544
, O 0 0.0001229246
but O 0 9.559843e-05
they O 0 6.646315e-05
tended O 0 8.476576e-05
to O 0 7.1330054e-05
have O 0 6.391466e-05
taken O 0 6.597095e-05
greater O 0 0.00015190015
quantities O 0 0.00028040793
of O 0 0.0005273789
the O 0 0.00089204544
drug O 0 0.030523194
. O 0 0.0022718452

Prazosin B-Chemical 0 0.99967694
- O 0 0.026096115
induced O 0 0.014590103
stress B-Disease 0 0.878326
incontinence I-Disease 0 0.9896332
. O 0 0.015381886

A O 0 0.015413375
case O 0 0.0015805081
of O 0 0.001245845
genuine O 0 0.0014695898
stress B-Disease 0 0.38599178
incontinence I-Disease 0 0.94637626
due O 0 0.00033579353
to O 0 0.00064975483
prazosin B-Chemical 1 0.9999937
, O 0 0.0006083069
a O 0 0.00037544177
common O 0 0.0004495817
antihypertensive O 0 0.8263699
drug O 0 0.024621468
, O 0 0.0007904119
is O 0 0.0008530127
presented O 0 0.0014307008
. O 0 0.0022271643

Prazosin B-Chemical 0 0.9997961
exerts O 0 0.0023716975
its O 0 0.0026044208
antihypertensive O 0 0.71573615
effects O 0 0.0007025392
through O 0 0.0004343983
vasodilatation O 0 0.99411994
caused O 0 0.00042712767
by O 0 0.00026456558
selective O 0 0.00077609037
blockade O 0 0.0044978247
of O 0 0.00059880514
postsynaptic O 0 0.64209324
alpha O 0 0.84500337
- O 0 0.0017676448
1 O 0 0.0007859666
adrenergic O 0 0.9043046
receptors O 0 0.008997406
. O 0 0.0022834907

As O 0 0.0019501072
an O 0 0.0029963236
alpha O 0 0.7161921
- O 0 0.0066667837
blocker O 0 0.98186284
, O 0 0.0010118054
it O 0 0.0003882917
also O 0 0.00022195156
exerts O 0 0.00020360899
a O 0 0.00030752778
significant O 0 0.00028292093
relaxant O 0 0.2323174
effect O 0 0.00020176223
on O 0 0.0001577386
the O 0 0.00038765423
bladder O 0 0.019659698
neck O 0 0.02697595
and O 0 0.0014809521
urethra O 0 0.0076435404
. O 0 0.0021818504

The O 0 0.0017352715
patient O 0 0.0015509304
' O 0 0.0011554648
s O 0 0.0007109908
clinical O 0 0.0008526024
course O 0 0.00030844565
is O 0 0.000231995
described O 0 0.00013269657
and O 0 0.00011752765
correlated O 0 6.676374e-05
with O 0 8.983742e-05
initial O 0 8.953006e-05
urodynamic O 0 0.00048498847
studies O 0 8.784587e-05
while O 0 8.522004e-05
on O 0 0.00011820898
prazosin B-Chemical 1 0.9999896
and O 0 0.00027730453
subsequent O 0 0.000203523
studies O 0 0.0002824428
while O 0 0.0004511775
taking O 0 0.0032371723
verapamil B-Chemical 0 0.999869
. O 0 0.0035216156

Her O 0 0.011333389
incontinence B-Disease 0 0.09925907
resolved O 0 0.003463621
with O 0 0.0018901108
the O 0 0.0015570505
change O 0 0.0018892509
of O 0 0.0033324887
medication O 0 0.021202592
. O 0 0.00505966

The O 0 0.0015477851
restoration O 0 0.0017516136
of O 0 0.001281475
continence O 0 0.0030268936
was O 0 0.00070933095
accompanied O 0 0.00087600213
by O 0 0.00032808998
a O 0 0.00027941304
substantial O 0 0.0001984868
rise O 0 0.00020202096
in O 0 9.28856e-05
maximum O 0 0.000101030935
urethral O 0 0.00035773066
pressure O 0 0.00079096685
, O 0 0.0001122113
maximum O 0 0.000102778875
urethral O 0 0.00044790746
closure O 0 0.00075109553
pressure O 0 0.0015554545
, O 0 0.00027201453
and O 0 0.00029326096
functional O 0 0.00050296844
urethral O 0 0.001703732
length O 0 0.0010790089
. O 0 0.0017380938

Patients O 0 0.002051222
who O 0 0.0011798481
present O 0 0.00043568207
with O 0 0.0005997393
stress B-Disease 0 0.23934208
incontinence I-Disease 0 0.9580702
while O 0 0.00035022886
taking O 0 0.0011968885
prazosin B-Chemical 1 0.9999938
should O 0 6.5858985e-05
change O 0 7.307936e-05
their O 0 0.0001124669
antihypertensive O 0 0.3655006
medication O 0 0.0004301007
before O 0 2.4480669e-05
considering O 0 4.986315e-05
surgery O 0 9.295108e-05
, O 0 6.427613e-05
because O 0 4.083857e-05
their O 0 0.000116066665
incontinence B-Disease 0 0.017271746
may O 0 6.447442e-05
resolve O 0 7.31329e-05
spontaneously O 0 0.00026412326
with O 0 0.00013974984
a O 0 0.00019988535
change O 0 0.00022431198
in O 0 0.0003621494
drug O 0 0.009200238
therapy O 0 0.002192761
. O 0 0.0019140545

Myocardial B-Disease 0 0.99328387
infarction I-Disease 2 0.9998294
following O 0 0.0035374942
sublingual O 0 0.65179235
administration O 0 0.013503853
of O 0 0.018567797
isosorbide B-Chemical 0 0.9999862
dinitrate I-Chemical 0 0.99995124
. O 0 0.009298897

A O 0 0.027709238
78 O 0 0.004704466
- O 0 0.002551934
year O 0 0.00069440244
- O 0 0.0008351125
old O 0 0.00036324604
with O 0 0.00036631635
healed O 0 0.0020105767
septal O 0 0.017426705
necrosis B-Disease 2 0.99946576
suffered O 0 0.017131472
a O 0 0.00045573188
recurrent O 0 0.06021831
myocardial B-Disease 0 0.99991524
infarction I-Disease 2 0.99999166
of O 0 0.00031809777
the O 0 0.00010540564
anterior O 0 0.00046470403
wall O 0 0.00021001742
following O 0 4.12882e-05
the O 0 7.510261e-05
administration O 0 0.00048715074
of O 0 0.0012872516
isosorbide B-Chemical 0 0.99999833
dinitrate I-Chemical 0 0.99999034
5 O 0 0.0008145902
mg O 0 0.07985048
sublingually O 0 0.8495626
. O 0 0.0021442182

After O 0 0.001062319
detailing O 0 0.0014495654
the O 0 0.0007737568
course O 0 0.0005308846
of O 0 0.0006234142
events O 0 0.0012393384
, O 0 0.00029593823
we O 0 8.579154e-05
discuss O 0 8.192151e-05
the O 0 8.813426e-05
role O 0 5.4533917e-05
of O 0 0.00013729323
paradoxical O 0 0.005662952
coronary O 2 0.9977196
spasm B-Disease 2 0.99998295
and O 0 0.0012340695
hypotension B-Disease 0 0.9999454
- O 0 0.00062694924
mediated O 0 0.00010700412
myocardial B-Disease 0 0.99955255
ischemia I-Disease 0 0.99992704
occurring O 0 0.00014886062
downstream O 0 4.629013e-05
to O 0 4.995767e-05
significant O 0 8.651656e-05
coronary B-Disease 0 0.42713487
arterial I-Disease 0 0.28950006
stenosis I-Disease 0 0.9974981
in O 0 0.00013887284
the O 0 0.00016110892
pathophysiology O 0 0.001826488
of O 0 0.00081069395
acute B-Disease 0 0.97526574
coronary I-Disease 0 0.98869634
insufficiency I-Disease 0 0.9995852
. O 0 0.0037060622

Comparison O 0 0.0015156406
of O 0 0.0013445561
the O 0 0.00088374614
respiratory O 0 0.003085889
effects O 0 0.00065028545
of O 0 0.00065191963
i O 0 0.0009918214
. O 0 0.00020051145
v O 0 0.00083407306
. O 0 0.00012464718
infusions O 0 0.0004775467
of O 0 0.0004350826
morphine B-Chemical 0 0.9996499
and O 0 0.0004277672
regional O 0 0.00083123654
analgesia O 0 0.4826088
by O 0 0.00091718545
extradural O 0 0.08237987
block O 0 0.002196065
. O 0 0.0023247853

The O 0 0.0015534231
incidence O 0 0.0018120953
of O 0 0.0010052703
postoperative O 0 0.0016585585
respiratory O 0 0.044546932
apnoea B-Disease 0 0.9898544
was O 0 0.0002903734
compared O 0 7.763984e-05
between O 0 5.1144616e-05
five O 0 4.777513e-05
patients O 0 0.00010840923
receiving O 0 0.00010791817
a O 0 8.8273024e-05
continuous O 0 5.602344e-05
i O 0 0.00020634868
. O 0 5.501834e-05
v O 0 0.0003481645
. O 0 4.600575e-05
infusion O 0 0.00015896859
of O 0 0.00021528886
morphine B-Chemical 0 0.99983597
( O 0 0.00015147463
mean O 0 3.455155e-05
73 O 0 0.000114993665
. O 0 3.3837303e-05
6 O 0 3.4055753e-05
mg O 0 0.0007183659
) O 0 0.000103013284
and O 0 5.0883566e-05
five O 0 2.9474733e-05
patients O 0 6.723411e-05
receiving O 0 6.699187e-05
a O 0 5.9549588e-05
continuous O 0 4.5165376e-05
extradural O 0 0.0043785893
infusion O 0 0.00018568656
of O 0 8.855834e-05
0 O 0 5.5477663e-05
. O 0 3.5545778e-05
25 O 0 8.79274e-05
% O 0 0.0001337702
bupivacaine B-Chemical 1 0.9996555
( O 0 0.0001354208
mean O 0 4.1915817e-05
192 O 0 0.00045649556
mg O 0 0.003096653
) O 0 0.00015858705
in O 0 6.758026e-05
the O 0 7.8771154e-05
24 O 0 7.412344e-05
- O 0 0.0001388678
h O 0 7.534895e-05
period O 0 6.728113e-05
following O 0 0.00015816814
upper O 0 0.0009299837
abdominal O 0 0.005960306
surgery O 0 0.002071286
. O 0 0.0018758837

Monitoring O 0 0.00216201
consisted O 0 0.0010576546
of O 0 0.0011099635
airflow O 0 0.011118946
detection O 0 0.0007856641
by O 0 0.00045628677
a O 0 0.0006712263
carbon B-Chemical 0 0.93789774
dioxide I-Chemical 0 0.9963039
analyser O 0 0.080983914
, O 0 0.00027016498
chest O 0 0.001313064
wall O 0 0.00050243613
movement O 0 0.00017183709
detected O 0 7.258826e-05
by O 0 0.000105075065
pneumatic O 0 0.00049974106
capsules O 0 0.00079328415
, O 0 9.729959e-05
and O 0 7.418807e-05
continuous O 0 7.226469e-05
electrocardiograph O 0 0.001344172
recorded O 0 0.000110893474
with O 0 0.00019665722
a O 0 0.000446178
Holter O 0 0.010106025
ambulatory O 0 0.00088216277
monitor O 0 0.00076372013
. O 0 0.0015530466

Both O 0 0.0050429823
obstructive B-Disease 0 0.92956406
( I-Disease 0 0.0049471003
P I-Disease 0 0.01407155
less I-Disease 0 0.00061734236
than I-Disease 0 0.00030761637
0 I-Disease 0 0.00031273626
. I-Disease 0 0.00023713552
05 I-Disease 0 0.0022874863
) I-Disease 0 0.00028321892
and I-Disease 0 0.00016138906
central I-Disease 0 0.0003590074
apnoea I-Disease 0 0.97461027
( O 0 0.00057705573
P O 0 0.00307118
less O 0 0.00011811838
than O 0 7.506373e-05
0 O 0 9.649838e-05
. O 0 8.761773e-05
05 O 0 0.0013197315
) O 0 0.00014007885
occurred O 0 6.610552e-05
more O 0 0.00010829969
frequently O 0 9.2456125e-05
in O 0 0.0001004875
patients O 0 0.00021717967
who O 0 0.00030272396
had O 0 0.0003011801
a O 0 0.0011517423
morphine B-Chemical 0 0.99973017
infusion O 0 0.013112623
. O 0 0.002234897

There O 0 0.0028195595
was O 0 0.0017094543
also O 0 0.0008154705
a O 0 0.00078710733
higher O 0 0.0006024965
incidence O 0 0.0009248736
of O 0 0.0010823857
tachyarrhythmias B-Disease 0 0.9998758
( O 0 0.0019694415
P O 0 0.014527856
less O 0 0.00015733513
than O 0 8.724471e-05
0 O 0 0.000103483304
. O 0 8.737943e-05
05 O 0 0.0012951929
) O 0 0.00014746313
and O 0 0.000112868496
ventricular B-Disease 0 0.759702
ectopic I-Disease 0 0.002405798
beats I-Disease 0 0.17736948
( O 0 0.00039690066
P O 0 0.0020706407
less O 0 9.765896e-05
than O 0 6.902105e-05
0 O 0 9.8006276e-05
. O 0 0.000102261816
05 O 0 0.0013953886
) O 0 0.00022326475
in O 0 0.00016084171
the O 0 0.0004052304
morphine B-Chemical 0 0.99947625
infusion O 0 0.0048949705
group O 0 0.002032572
. O 0 0.0019897872

Effects O 0 0.003355821
of O 0 0.0036398354
aminophylline B-Chemical 0 0.999691
on O 0 0.0006034822
the O 0 0.00043528664
threshold O 0 0.000296667
for O 0 0.00023972527
initiating O 0 0.0006357148
ventricular B-Disease 0 0.9740496
fibrillation I-Disease 0 0.999859
during O 0 0.0006981461
respiratory B-Disease 0 0.062057354
failure I-Disease 0 0.61317044
. O 0 0.003328655

Cardiac B-Disease 0 0.9363622
arrhythmias I-Disease 2 0.9997228
have O 0 0.0016653213
frequently O 0 0.00090692507
been O 0 0.0005312486
reported O 0 0.0005553792
in O 0 0.00043695647
association O 0 0.00043372964
with O 0 0.0012535218
respiratory B-Disease 0 0.091034584
failure I-Disease 0 0.77257603
. O 0 0.0043071024

The O 0 0.0015908275
possible O 0 0.00113687
additive O 0 0.0016039548
role O 0 0.0003867355
of O 0 0.00052740244
pharmacologic O 0 0.0023112406
agents O 0 0.001474833
in O 0 0.00027593368
precipitating O 0 0.2399092
cardiac B-Disease 0 0.9577005
disturbances I-Disease 0 0.87978745
in O 0 0.00018604189
patients O 0 0.00022199536
with O 0 0.0002190764
respiratory B-Disease 0 0.017823612
failure I-Disease 0 0.17949572
has O 0 0.00026448435
only O 0 0.00036816203
recently O 0 0.0003934679
been O 0 0.0005447592
emphasized O 0 0.0009361553
. O 0 0.0018278011

The O 0 0.00136072
effects O 0 0.0013660638
of O 0 0.0019081479
aminophylline B-Chemical 0 0.9998109
on O 0 0.0003292996
the O 0 0.00041449646
ventricular B-Disease 0 0.97120756
fibrillation I-Disease 0 0.99992335
threshold O 0 0.00017602179
during O 0 7.357036e-05
normal O 0 0.0006314787
acid O 0 0.7705566
- O 0 0.00042831257
base O 0 0.00023519683
conditions O 0 0.00010906568
and O 0 7.967651e-05
during O 0 4.9160073e-05
respiratory B-Disease 0 0.0026195403
failure I-Disease 0 0.043275505
were O 0 0.00017479397
studied O 0 0.00016054351
in O 0 0.0001605648
anesthetized O 0 0.00081361854
open O 0 0.0008351833
chest O 0 0.006126369
dogs O 0 0.0022178413
. O 0 0.0018655033

The O 0 0.0021343445
ventricular B-Disease 0 0.94467336
fibrillation I-Disease 0 0.9997272
threshold O 0 0.00085837196
was O 0 0.00046844973
measured O 0 0.00021661096
by O 0 0.00021323492
passing O 0 0.0003081021
a O 0 0.00020055524
gated O 0 0.00041332177
train O 0 0.00010609216
of O 0 9.829679e-05
12 O 0 3.9426715e-05
constant O 0 6.257704e-05
current O 0 9.5952324e-05
pulses O 0 7.6725344e-05
through O 0 4.0157254e-05
the O 0 7.479522e-05
ventricular O 0 0.22585803
myocardium O 0 0.013039216
during O 0 4.9147322e-05
the O 0 8.065676e-05
vulnerable O 0 0.00013833768
period O 0 7.3959076e-05
of O 0 0.0002409967
the O 0 0.00045127945
cardiac O 0 0.029998653
cycle O 0 0.0025321587
. O 0 0.0019628776

During O 0 0.00086916785
the O 0 0.0010377206
infusion O 0 0.0017211745
of O 0 0.0016122827
aminophylline B-Chemical 0 0.99992716
, O 0 0.0006489281
the O 0 0.0003744417
ventricular B-Disease 0 0.9812794
fibrillation I-Disease 0 0.9999523
threshold O 0 0.00023536012
was O 0 0.00015815184
reduced O 0 0.0001659794
by O 0 8.022329e-05
30 O 0 4.300974e-05
to O 0 3.8649163e-05
40 O 0 4.6339414e-05
percent O 0 3.0528598e-05
of O 0 5.5252e-05
the O 0 4.973687e-05
control O 0 5.5685006e-05
when O 0 5.2219693e-05
pH O 0 0.0013982754
and O 0 7.890286e-05
partial O 0 0.00013698686
pressures O 0 0.0002727172
of O 0 0.00022293058
oxygen B-Chemical 1 0.99534637
( O 0 0.00073196844
PO2 B-Chemical 0 0.9997104
) O 0 0.00032913667
and O 0 0.00020137093
carbon B-Chemical 0 0.91184276
dioxide I-Chemical 0 0.993937
( O 0 0.00061463536
CO2 B-Chemical 0 0.8595317
) O 0 0.00030557316
were O 0 0.00014245439
kept O 0 0.0001740529
within O 0 0.0001408874
normal O 0 0.00095138926
limits O 0 0.002372194
. O 0 0.0019948531

When O 0 0.0019733477
respiratory B-Disease 0 0.015154593
failure I-Disease 0 0.10768983
was O 0 0.0010582061
produced O 0 0.00056292425
by O 0 0.0007552354
hypoventilation B-Disease 0 0.9939452
( O 0 0.0009786042
pH O 0 0.0062195174
7 O 0 0.00016286434
. O 0 0.00012393866
05 O 0 0.00103452
to O 0 9.797227e-05
7 O 0 7.632189e-05
. O 0 6.366045e-05
25 O 0 0.00014287748
; O 0 0.00016189893
PC02 O 0 0.004693988
70 O 0 9.636294e-05
to O 0 6.506514e-05
100 O 0 0.00020943451
mm O 0 0.00031377675
Hg O 0 0.61671895
: O 0 0.00022392049
P02 O 0 0.012239834
20 O 0 7.1650466e-05
to O 0 4.797419e-05
40 O 0 7.6303404e-05
mm O 0 0.00023222891
Hg O 0 0.6587813
) O 0 0.00019718107
, O 0 9.257636e-05
infusion O 0 0.00019580573
of O 0 0.00024158356
aminophylline B-Chemical 0 0.99996424
resulted O 0 0.00014865692
in O 0 7.349308e-05
an O 0 8.622179e-05
even O 0 6.533404e-05
greater O 0 6.52554e-05
decrease O 0 0.00010163875
in O 0 0.00010585912
ventricular B-Disease 0 0.95756006
fibrillation I-Disease 0 0.99991906
threshold O 0 0.00011701481
to O 0 7.7413766e-05
60 O 0 8.5275155e-05
percent O 0 8.2305756e-05
of O 0 0.00019710475
the O 0 0.00029273945
control O 0 0.00053962495
level O 0 0.0010650367
. O 0 0.0019552174

These O 0 0.0018999793
experiments O 0 0.00088178634
suggest O 0 0.00040448518
that O 0 0.00036332014
although O 0 0.00032242417
many O 0 0.00022817659
factors O 0 0.00026159207
may O 0 0.00012219184
contribute O 0 8.515026e-05
to O 0 7.707646e-05
the O 0 8.1430444e-05
increased O 0 0.00015241579
incidence O 0 0.00022126969
of O 0 0.00026411068
ventricular B-Disease 0 0.999686
arrhythmias I-Disease 2 0.9999931
in O 0 0.00026572766
respiratory B-Disease 0 0.03569821
failure I-Disease 0 0.15662903
, O 0 0.00018206584
pharmacologic O 0 0.0011540597
agents O 0 0.0007748799
, O 0 0.00019698376
particularly O 0 0.0005683175
aminophylline B-Chemical 0 0.99997044
, O 0 0.00043208993
may O 0 0.00019616057
play O 0 0.00020443517
a O 0 0.00050725474
significant O 0 0.00064043445
role O 0 0.00088335585
. O 0 0.0019447079

Pentoxifylline B-Chemical 0 0.9995472
( O 0 0.01460367
Trental B-Chemical 0 0.99886227
) O 0 0.0018292023
does O 0 0.00045329827
not O 0 0.00032369714
inhibit O 0 0.00044696828
dipyridamole B-Chemical 0 0.9999443
- O 0 0.0010967473
induced O 0 0.00045526013
coronary O 0 0.6951086
hyperemia B-Disease 2 0.99789846
: O 0 0.00020614022
implications O 0 0.0001129219
for O 0 0.00021078192
dipyridamole B-Chemical 0 0.9999368
- O 0 0.0031009598
thallium B-Chemical 0 0.9993999
- O 0 0.0019689428
201 O 0 0.005799408
myocardial O 0 0.98892844
imaging O 0 0.0046267873
. O 0 0.002223575

Dipyridamole B-Chemical 0 0.9996387
- O 0 0.019396879
thallium B-Chemical 0 0.99890876
- O 0 0.0028979352
201 O 0 0.0020773357
imaging O 0 0.0006735036
is O 0 0.00023930417
often O 0 0.00019372047
performed O 0 0.00013596733
in O 0 0.00013695823
patients O 0 0.0001746224
unable O 0 0.00012097601
to O 0 0.00016208459
exercise O 0 0.0003704353
because O 0 0.00019955324
of O 0 0.00069587666
peripheral B-Disease 0 0.1591443
vascular I-Disease 0 0.8421459
disease I-Disease 0 0.95323074
. O 0 0.003348182

Many O 0 0.0019760071
of O 0 0.001400613
these O 0 0.0010459372
patients O 0 0.00079857506
are O 0 0.00044746578
taking O 0 0.0014386503
pentoxifylline B-Chemical 1 0.99994206
( O 0 0.003740758
Trental B-Chemical 0 0.9994911
) O 0 0.0007573384
, O 0 0.0003047928
a O 0 0.0006319465
methylxanthine B-Chemical 0 0.9999019
derivative O 0 0.016162401
which O 0 0.0004627495
may O 0 0.00028610186
improve O 0 0.0004188999
intermittent B-Disease 0 0.005129802
claudication I-Disease 0 0.7929224
. O 0 0.0023018266

Whether O 0 0.0031633046
pentoxifylline B-Chemical 1 0.99961555
inhibits O 0 0.0034741126
dipyridamole B-Chemical 0 0.99995327
- O 0 0.002777259
induced O 0 0.0008217028
coronary O 0 0.78586555
hyperemia B-Disease 2 0.998599
like O 0 0.00016177856
other O 0 0.00023919191
methylxanthines B-Chemical 0 0.9999136
such O 0 0.00012844359
as O 0 0.00022148163
theophylline B-Chemical 0 0.9999597
and O 0 0.00015085164
should O 0 3.7260044e-05
be O 0 4.7121714e-05
stopped O 0 7.813673e-05
prior O 0 4.2553216e-05
to O 0 0.00017298013
dipyridamole B-Chemical 0 0.9999523
- O 0 0.0029264658
thallium B-Chemical 0 0.9995535
- O 0 0.0012100147
201 O 0 0.0017519472
imaging O 0 0.0009036921
is O 0 0.00078149413
unknown O 0 0.0019908869
. O 0 0.0020208815

Therefore O 0 0.001877301
, O 0 0.0015785913
we O 0 0.00049442856
studied O 0 0.00061455043
the O 0 0.00045887727
hyperemic O 0 0.056280445
response O 0 0.0002973197
to O 0 0.00033079102
dipyridamole B-Chemical 0 0.9998913
in O 0 0.00019038319
seven O 0 0.00010471927
open O 0 0.00023315543
- O 0 0.00023388729
chest O 0 0.0008545601
anesthetized O 0 0.00031863895
dogs O 0 8.079263e-05
after O 0 2.220536e-05
pretreatment O 0 0.001036978
with O 0 0.00013927146
either O 0 0.00027112025
pentoxifylline B-Chemical 1 0.99997246
( O 0 0.00036801453
0 O 0 9.020585e-05
, O 0 9.242642e-05
7 O 0 4.895451e-05
. O 0 3.9262453e-05
5 O 0 4.2770956e-05
, O 0 6.162833e-05
or O 0 4.956074e-05
15 O 0 5.5140987e-05
mg O 0 0.0009851425
/ O 0 0.00033452056
kg O 0 0.00026896555
i O 0 0.00024019864
. O 0 6.942227e-05
v O 0 0.00047708992
. O 0 7.2758114e-05
) O 0 0.00016663037
or O 0 0.00016659765
theophylline B-Chemical 0 0.9999362
( O 0 0.00034990747
3 O 0 0.000116146395
mg O 0 0.0016067291
/ O 0 0.0005986419
kg O 0 0.00057153736
i O 0 0.00063147984
. O 0 0.0003250002
v O 0 0.001969314
. O 0 0.0007979589
) O 0 0.002247085
. O 0 0.002386412

Baseline O 0 0.0032383972
circumflex O 0 0.017570814
coronary O 0 0.04320892
blood O 0 0.005485093
flows O 0 0.00226557
did O 0 0.00063987495
not O 0 0.00043912698
differ O 0 0.00043495628
significantly O 0 0.0006713453
among O 0 0.0008127336
treatment O 0 0.001207449
groups O 0 0.0017957336
. O 0 0.0025435812

Dipyridamole B-Chemical 0 0.9992519
significantly O 0 0.0026940063
increased O 0 0.0018053872
coronary O 0 0.109221235
blood O 0 0.0043091564
flow O 0 0.0010480399
before O 0 0.00010388729
and O 0 0.00014577594
after O 0 6.0867984e-05
7 O 0 8.4329426e-05
. O 0 6.216711e-05
5 O 0 5.7205536e-05
or O 0 6.0482693e-05
15 O 0 6.2526036e-05
mm O 0 0.00016312992
/ O 0 0.00029589506
kg O 0 0.00028458278
i O 0 0.00027111094
. O 0 9.321328e-05
v O 0 0.0007903505
. O 0 0.00020080915
pentoxifylline B-Chemical 1 0.99988365
( O 0 0.00063044496
p O 0 0.00022276846
less O 0 0.00019766674
than O 0 0.00019332686
0 O 0 0.00033446884
. O 0 0.00046812053
002 O 0 0.0059405877
) O 0 0.0023967945
. O 0 0.0023592284

Neither O 0 0.002366018
dose O 0 0.0055329106
of O 0 0.0030861956
pentoxifylline B-Chemical 1 0.9998779
significantly O 0 0.0015756965
decreased O 0 0.0013497036
the O 0 0.0008885505
dipyridamole B-Chemical 0 0.99997544
- O 0 0.001790119
induced O 0 0.0007835493
hyperemia B-Disease 2 0.99916756
, O 0 0.0001827349
while O 0 7.971404e-05
peak O 0 0.00014010261
coronary O 0 0.033736087
blood O 0 0.0015320166
flow O 0 0.0004906141
was O 0 9.136383e-05
significantly O 0 0.00010233478
lower O 0 0.000121155295
after O 0 7.3538096e-05
theophylline B-Chemical 0 0.99995136
( O 0 0.0005625729
p O 0 0.00019477842
less O 0 0.00018276542
than O 0 0.00018690762
0 O 0 0.00033212706
. O 0 0.0004584287
01 O 0 0.0024580373
) O 0 0.0021132545
. O 0 0.0022473224

We O 0 0.0014946751
conclude O 0 0.00092447014
that O 0 0.00089035404
pentoxyifylline B-Chemical 0 0.121282704
does O 0 0.00055566285
not O 0 0.00038974
inhibit O 0 0.00055534893
dipyridamole B-Chemical 0 0.99994624
- O 0 0.0014784763
induced O 0 0.00072598713
coronary O 0 0.77625126
hyperemia B-Disease 2 0.9977202
even O 0 0.00056262844
at O 0 0.00039546887
high O 0 0.0017181605
doses O 0 0.008313388
. O 0 0.0025231733

Cause O 0 0.018448643
of O 0 0.004285269
death B-Disease 0 0.91716695
among O 0 0.0013051231
patients O 0 0.00093881873
with O 0 0.00089862966
Parkinson B-Disease 0 0.9977354
' I-Disease 0 0.0007097932
s I-Disease 0 0.00043375406
disease I-Disease 0 0.03208145
: O 0 0.00041102857
a O 0 0.00041178544
rare O 0 0.0011590492
mortality O 0 0.0028215824
due O 0 0.00036570817
to O 0 0.0009739678
cerebral B-Disease 0 0.99871826
haemorrhage I-Disease 0 0.9999068
. O 0 0.004841015

Causes O 0 0.012077468
of O 0 0.004931923
death B-Disease 0 0.9652415
, O 0 0.0012101554
with O 0 0.0005242659
special O 0 0.00027247344
reference O 0 0.0002482642
to O 0 0.0002860678
cerebral B-Disease 0 0.99867
haemorrhage I-Disease 0 0.99998033
, O 0 0.0003532624
among O 0 0.00014046392
240 O 0 0.00019941363
patients O 0 0.00011300203
with O 0 0.000113876056
pathologically O 0 0.019174261
verified O 0 0.00019378217
Parkinson B-Disease 0 0.9967899
' I-Disease 0 0.00019596318
s I-Disease 0 0.000120469376
disease I-Disease 0 0.007037206
were O 0 7.520029e-05
investigated O 0 4.7050362e-05
using O 0 4.7127698e-05
the O 0 7.665639e-05
Annuals O 0 0.0003860879
of O 0 9.798216e-05
the O 0 0.00011795181
Pathological O 0 0.0072671585
Autopsy O 0 0.029705482
Cases O 0 0.00065867015
in O 0 0.00017430518
Japan O 0 0.0008510148
from O 0 0.00028452883
1981 O 0 0.0010278857
to O 0 0.0006694136
1985 O 0 0.0028214292
. O 0 0.0018599887

The O 0 0.0019744318
leading O 0 0.0022519417
causes O 0 0.0018099593
of O 0 0.0022271262
death B-Disease 0 0.98470414
were O 0 0.0014371865
pneumonia B-Disease 0 0.997445
and O 0 0.00327738
bronchitis B-Disease 0 0.99987197
( O 0 0.0009896457
44 O 0 0.00033820228
. O 0 9.087654e-05
1 O 0 9.727473e-05
% O 0 0.00013547594
) O 0 0.00021745129
, O 0 0.00022854566
malignant O 0 0.29980212
neoplasms B-Disease 0 0.89450794
( O 0 0.00036259388
11 O 0 0.00012154408
. O 0 5.4376982e-05
6 O 0 4.9285733e-05
% O 0 9.8993456e-05
) O 0 0.00016733522
, O 0 0.00016471828
heart B-Disease 0 0.069005445
diseases I-Disease 0 0.2403015
( O 0 0.0002780713
4 O 0 7.492092e-05
. O 0 5.1406856e-05
1 O 0 6.5780594e-05
% O 0 9.999627e-05
) O 0 0.00016949493
, O 0 0.00019416983
cerebral B-Disease 0 0.92627466
infarction I-Disease 2 0.9999877
( O 0 0.00056161283
3 O 0 9.682118e-05
. O 0 5.944848e-05
7 O 0 6.593158e-05
% O 0 0.00012565176
) O 0 0.000226527
and O 0 0.0002821734
septicaemia B-Disease 0 0.9441425
( O 0 0.00062863657
3 O 0 0.00024752508
. O 0 0.00024731894
3 O 0 0.00041081366
% O 0 0.0009572
) O 0 0.0020886124
. O 0 0.0023814654

Cerebral B-Disease 0 0.9847077
haemorrhage I-Disease 0 0.99961025
was O 0 0.0019036471
the O 0 0.0007697902
11th O 0 0.0012164377
most O 0 0.0006034442
frequent O 0 0.0005339533
cause O 0 0.00054247887
of O 0 0.0008201966
death B-Disease 0 0.9876801
, O 0 0.00029161348
accounting O 0 0.00023458341
for O 0 8.044683e-05
only O 0 0.00012248768
0 O 0 7.956883e-05
. O 0 4.598627e-05
8 O 0 4.7801383e-05
% O 0 6.63185e-05
of O 0 0.00011702084
deaths B-Disease 0 0.004591265
among O 0 0.00011108376
the O 0 9.325454e-05
patients O 0 0.0001774498
, O 0 0.000108266766
whereas O 0 8.958283e-05
it O 0 9.051745e-05
was O 0 7.5475305e-05
the O 0 6.231859e-05
5th O 0 0.000104102684
most O 0 0.00011564752
common O 0 0.00011646113
cause O 0 0.00020888186
of O 0 0.0003838862
death B-Disease 0 0.9653032
among O 0 0.0002701261
the O 0 0.0002006874
Japanese O 0 0.0016050533
general O 0 0.00033564403
population O 0 0.00076371286
in O 0 0.00075194373
1985 O 0 0.0032492203
. O 0 0.0017618956

The O 0 0.0017594569
low O 0 0.0022412115
incidence O 0 0.002009777
of O 0 0.0018503466
cerebral B-Disease 0 0.9991315
haemorrhage I-Disease 0 0.99996626
as O 0 0.00061770144
a O 0 0.00044842696
cause O 0 0.00039605593
of O 0 0.0005052092
death B-Disease 0 0.9655746
in O 0 0.0001656267
patients O 0 0.00020540685
with O 0 0.00024133884
Parkinson B-Disease 0 0.99803394
' I-Disease 0 0.00021562784
s I-Disease 0 0.00011804993
disease I-Disease 0 0.004146927
may O 0 4.320818e-05
reflect O 0 2.7554026e-05
the O 0 6.149348e-05
hypotensive B-Disease 0 0.7989695
effect O 0 8.688728e-05
of O 0 0.00035746832
levodopa B-Chemical 0 0.9999769
and O 0 0.00016146479
a O 0 0.00021769815
hypotensive B-Disease 0 0.94959795
mechanism O 0 0.0001134264
due O 0 5.107083e-05
to O 0 8.692798e-05
reduced O 0 0.0005856619
noradrenaline B-Chemical 1 0.9997725
levels O 0 0.00028645177
in O 0 0.0002872501
the O 0 0.00073475734
parkinsonian B-Disease 2 0.99963975
brain O 0 0.040946517
. O 0 0.0022502302

Possible O 0 0.008255596
intramuscular O 0 0.15554489
midazolam B-Chemical 0 0.9998667
- O 0 0.005659221
associated O 0 0.0021581736
cardiorespiratory B-Disease 0 0.8068658
arrest I-Disease 0 0.9709907
and O 0 0.0079593435
death B-Disease 0 0.9929404
. O 0 0.006262607

Midazolam B-Chemical 0 0.99990404
hydrochloride I-Chemical 0 0.9993104
is O 0 0.0026633525
commonly O 0 0.0013215684
used O 0 0.00073879346
for O 0 0.000664783
dental O 0 0.0017025919
or O 0 0.0011472044
endoscopic O 0 0.0025498632
procedures O 0 0.002355968
. O 0 0.0030277646

Although O 0 0.001420428
generally O 0 0.0010996897
consisted O 0 0.00062960736
safe O 0 0.00056546164
when O 0 0.00020236606
given O 0 0.00016559497
intramuscularly O 0 0.00045309323
, O 0 0.00029882076
intravenous O 0 0.005799018
administration O 0 0.0011653446
is O 0 0.0002162589
known O 0 0.00023835505
to O 0 0.00019636417
cause O 0 0.00053517724
respiratory B-Disease 0 0.019402562
and I-Disease 0 0.0020727864
cardiovascular I-Disease 0 0.9994393
depression I-Disease 0 0.99973565
. O 0 0.0040182774

This O 0 0.003471809
report O 0 0.001850012
describes O 0 0.001053326
the O 0 0.00047879014
first O 0 0.00025066955
published O 0 0.0003331101
case O 0 0.00024563164
of O 0 0.00045705115
cardiorespiratory B-Disease 0 0.80917877
arrest I-Disease 0 0.96624494
and O 0 0.000920471
death B-Disease 0 0.9695286
associated O 0 0.00027399583
with O 0 0.00040476653
intramuscular O 0 0.004218241
administration O 0 0.003489569
of O 0 0.0037163957
midazolam B-Chemical 0 0.99991405
. O 0 0.0033666492

Information O 0 0.0032795893
regarding O 0 0.002300478
midazolam B-Chemical 0 0.9997397
use O 0 0.0013666338
is O 0 0.00077710865
reviewed O 0 0.000781279
to O 0 0.00039628326
provide O 0 0.0004257066
recommendation O 0 0.0011040968
for O 0 0.0006377654
safe O 0 0.0019601292
administration O 0 0.007122156
. O 0 0.0031397587

Myasthenia B-Disease 0 0.9931063
gravis I-Disease 0 0.9985266
presenting O 0 0.012171712
as O 0 0.0036595108
weakness O 0 0.82888174
after O 0 0.0021569189
magnesium B-Chemical 1 0.99942553
administration O 0 0.20428921
. O 0 0.006685918

We O 0 0.0015594125
studied O 0 0.0013931447
a O 0 0.0009790139
patient O 0 0.0005840671
with O 0 0.00034947274
no O 0 0.00013311478
prior O 0 0.00010112637
history O 0 0.0002901144
of O 0 0.00035896155
neuromuscular B-Disease 0 0.98322195
disease I-Disease 0 0.98042977
who O 0 0.0004249986
became O 0 0.00019167477
virtually O 0 0.00021973558
quadriplegic B-Disease 0 0.8593214
after O 0 9.4412724e-05
parenteral O 0 0.109095395
magnesium B-Chemical 1 0.9998642
administration O 0 0.035618372
for O 0 0.0019741086
preeclampsia B-Disease 0 0.99990594
. O 0 0.0039843568

The O 0 0.0024716875
serum O 0 0.20448752
magnesium B-Chemical 1 0.99963105
concentration O 0 0.00704465
was O 0 0.0010498306
3 O 0 0.00035179226
. O 0 0.00022818879
0 O 0 0.00034162233
mEq O 0 0.19235317
/ O 0 0.0021344745
L O 0 0.23639525
, O 0 0.0005410252
which O 0 0.000513714
is O 0 0.00048361043
usually O 0 0.0007533051
well O 0 0.0009147535
tolerated O 0 0.007702284
. O 0 0.0025522425

The O 0 0.004254561
magnesium B-Chemical 1 0.99842465
was O 0 0.0027065622
stopped O 0 0.0019850933
and O 0 0.0009737033
she O 0 0.0006277607
recovered O 0 0.0005919024
over O 0 0.00041810615
a O 0 0.0010309505
few O 0 0.0008133782
days O 0 0.0011143454
. O 0 0.0026948315

While O 0 0.0024393804
she O 0 0.0017683449
was O 0 0.0014930477
weak O 0 0.0020584594
, O 0 0.0008449225
2 O 0 0.00040783585
- O 0 0.0005995384
Hz O 0 0.0011660419
repetitive O 0 0.00016774533
stimulation O 0 0.00010193119
revealed O 0 0.00011467317
a O 0 0.00015187262
decrement O 0 0.00043136516
without O 0 9.2644645e-05
significant O 0 8.1898936e-05
facilitation O 0 0.0003727407
at O 0 5.502301e-05
rapid O 0 0.00018577847
rates O 0 8.871514e-05
or O 0 6.687908e-05
after O 0 4.7369478e-05
exercise O 0 0.0002833018
, O 0 0.00023673478
suggesting O 0 0.00026225782
postsynaptic B-Disease 0 0.8736231
neuromuscular I-Disease 0 0.9927246
blockade I-Disease 0 0.99156415
. O 0 0.0036298092

After O 0 0.0012133776
her O 0 0.0019632364
strength O 0 0.0013441823
returned O 0 0.0007874239
, O 0 0.0005889587
repetitive O 0 0.0003637766
stimulation O 0 0.00025750656
was O 0 0.0003438216
normal O 0 0.000565277
, O 0 0.00025955413
but O 0 0.00019329866
single O 0 0.00019123555
fiber O 0 0.00074449065
EMG O 0 0.004272133
revealed O 0 0.0002538849
increased O 0 0.00055165385
jitter O 0 0.0027772274
and O 0 0.0010353453
blocking O 0 0.0035833302
. O 0 0.002618504

Her O 0 0.029530918
acetylcholine B-Chemical 1 0.99907863
receptor O 0 0.074082084
antibody O 0 0.007578077
level O 0 0.0024813097
was O 0 0.0032902807
markedly O 0 0.00845951
elevated O 0 0.031941477
. O 0 0.006801959

Although O 0 0.0028123024
paralysis B-Disease 0 0.9905228
after O 0 0.0010078008
magnesium B-Chemical 1 0.99979705
administration O 0 0.017017918
has O 0 0.00027965236
been O 0 0.00013357429
described O 0 9.3481845e-05
in O 0 9.1159316e-05
patients O 0 0.00013600626
with O 0 0.00014436885
known O 0 0.00056821
myasthenia B-Disease 0 0.9998802
gravis I-Disease 0 0.999209
, O 0 0.00026157108
it O 0 0.00011448262
has O 0 5.219201e-05
not O 0 5.829104e-05
previously O 0 6.826033e-05
been O 0 5.5563116e-05
reported O 0 7.895902e-05
to O 0 5.879898e-05
be O 0 5.6219207e-05
the O 0 5.9717695e-05
initial O 0 8.637468e-05
or O 0 0.00012636984
only O 0 0.00026778568
manifestation O 0 0.0014374821
of O 0 0.00078691693
the O 0 0.0012717934
disease O 0 0.31120032
. O 0 0.002575521

Patients O 0 0.0026884926
who O 0 0.0017764625
are O 0 0.00070598937
unusually O 0 0.001606475
sensitive O 0 0.00031873406
to O 0 0.00021511833
the O 0 0.00023573876
neuromuscular O 0 0.021157123
effects O 0 0.00029986582
of O 0 0.0007504219
magnesium B-Chemical 1 0.9998996
should O 0 0.000112337424
be O 0 0.00011542454
suspected O 0 0.00032634893
of O 0 0.00015996698
having O 0 0.0001726489
an O 0 0.00020865157
underlying O 0 0.00049906335
disorder B-Disease 0 0.5082455
of I-Disease 0 0.0009968631
neuromuscular I-Disease 0 0.16955611
transmission I-Disease 0 0.0020090626
. O 0 0.00195239

No O 0 0.0033989453
enhancement O 0 0.0035006292
by O 0 0.0030881194
phenobarbital B-Chemical 0 0.99997807
of O 0 0.0020665457
the O 0 0.0011288213
hepatocarcinogenicity O 0 0.9997253
of O 0 0.0015596702
a O 0 0.0025945555
choline B-Chemical 1 0.9998394
- O 0 0.0012749067
devoid O 0 0.00029920044
diet O 0 0.003940036
in O 0 0.0005592537
the O 0 0.00094714377
rat O 0 0.003562563
. O 0 0.0023192798

An O 0 0.0023808924
experiment O 0 0.0010743047
was O 0 0.0008353099
performed O 0 0.00041642736
to O 0 0.00031139803
test O 0 0.00028682835
whether O 0 8.522142e-05
inclusion O 0 0.00018167325
of O 0 0.0006803523
phenobarbital B-Chemical 0 0.99999774
in O 0 0.00051172695
a O 0 0.0012876041
choline B-Chemical 1 0.99990606
- O 0 0.00066939986
devoid O 0 0.00010941693
diet O 0 0.002283492
would O 0 0.00013894064
increase O 0 0.00019224052
the O 0 0.00038279317
hepatocarcinogenicity O 0 0.9993098
of O 0 0.0012536512
the O 0 0.0012185877
diet O 0 0.029281983
. O 0 0.0022324391

Groups O 0 0.007433194
of O 0 0.0019853257
5 O 0 0.0009816553
- O 0 0.001059684
week O 0 0.00029709356
old O 0 0.00044079614
male O 0 0.0012891933
Fischer O 0 0.003981455
- O 0 0.0005794396
344 O 0 0.0013551884
rats O 0 0.00017397456
were O 0 8.371345e-05
fed O 0 0.0001227641
for O 0 5.6109413e-05
7 O 0 5.9002985e-05
- O 0 0.00011876509
25 O 0 8.6608095e-05
months O 0 3.5634563e-05
semipurified O 0 0.0034905176
choline B-Chemical 1 0.9997793
- O 0 0.0003810975
devoid O 0 6.8270354e-05
or O 0 0.00020851118
choline B-Chemical 1 0.99987376
- O 0 0.00073286775
supplemented O 0 0.0007838372
diets O 0 0.016644908
, O 0 0.00015448796
containing O 0 9.840539e-05
or O 0 0.000121843026
not O 0 0.00016438065
0 O 0 0.00022360326
. O 0 0.00028389934
06 O 0 0.002611866
% O 0 0.0019117419
phenobarbital B-Chemical 0 0.9999471
. O 0 0.004223462

No O 0 0.0047924262
hepatic O 0 0.9177323
preneoplastic O 0 0.9672418
nodules O 0 0.40625647
or O 0 0.0022826598
hepatocellular B-Disease 0 0.99999297
carcinomas I-Disease 0 0.9974318
developed O 0 0.00067345746
in O 0 0.00014504747
rats O 0 0.00016030947
fed O 0 0.00016191545
the O 0 0.0001160722
plain O 0 0.037458256
choline B-Chemical 1 0.9999051
- O 0 0.00070174795
supplemented O 0 0.0006721549
diet O 0 0.012186828
, O 0 0.0001245013
while O 0 8.05308e-05
one O 0 8.461409e-05
preneoplastic O 0 0.6998215
nodule O 0 0.09508431
and O 0 0.00016219002
one O 0 0.00022140602
hepatocellular B-Disease 0 0.9999981
carcinoma I-Disease 0 0.99997497
developed O 0 0.0005075565
in O 0 9.066586e-05
two O 0 5.2895597e-05
rats O 0 0.00011652155
fed O 0 0.00014888334
the O 0 0.000111093934
same O 0 0.00013704694
diet O 0 0.0039151623
containing O 0 0.0013640202
phenobarbital B-Chemical 0 0.99997914
. O 0 0.004308821

The O 0 0.0019538307
incidence O 0 0.0026862512
of O 0 0.0019861725
preneoplastic O 0 0.8313606
nodules O 0 0.09747966
and O 0 0.00065927306
of O 0 0.0019685004
hepatocellular B-Disease 0 0.9999957
carcinomas I-Disease 0 0.9984694
was O 0 0.00037668258
10 O 0 0.00011806951
% O 0 0.00010632043
and O 0 9.569876e-05
37 O 0 0.00019488727
% O 0 0.00012383283
, O 0 0.00013270036
respectively O 0 0.00025607573
, O 0 9.9712895e-05
in O 0 6.3973435e-05
rats O 0 0.000102727434
fed O 0 0.00012758085
the O 0 0.00010340233
plain O 0 0.036671005
choline B-Chemical 1 0.99988985
- O 0 0.0004930415
devoid O 0 7.8767844e-05
diet O 0 0.0048001185
, O 0 0.00012413264
and O 0 9.758551e-05
17 O 0 0.00011389864
% O 0 7.588152e-05
and O 0 6.644479e-05
30 O 0 5.4198274e-05
% O 0 8.1307684e-05
, O 0 7.978485e-05
in O 0 6.502265e-05
rats O 0 0.00012829744
fed O 0 0.0002164301
the O 0 0.0003316556
phenobarbital B-Chemical 0 0.9999974
- O 0 0.0018253434
containing O 0 0.0006017964
choline B-Chemical 1 0.99967206
- O 0 0.0019032448
devoid O 0 0.0007597586
diet O 0 0.017276771
. O 0 0.002262327

The O 0 0.0018554335
results O 0 0.0018414223
evinced O 0 0.006170202
no O 0 0.00054348906
enhancement O 0 0.00096344633
of O 0 0.00066714885
the O 0 0.0006942181
hepatocarcinogenicity O 0 0.99961996
of O 0 0.0011773951
the O 0 0.0011129567
choline B-Chemical 1 0.9997918
- O 0 0.0014954074
devoid O 0 0.00044722206
diet O 0 0.024334973
by O 0 0.0034493639
phenobarbital B-Chemical 0 0.99997723
. O 0 0.0052024215

Sporadic O 0 0.08169666
neoplastic O 0 0.18442607
lesions O 0 0.014081517
were O 0 0.00071141747
observed O 0 0.00034546325
in O 0 0.0002929614
organs O 0 0.00079627417
other O 0 0.00016500251
than O 0 0.00010557403
the O 0 0.00016530028
liver O 0 0.22732434
of O 0 0.00022881539
some O 0 0.00012935758
of O 0 0.0001488104
the O 0 0.000117389885
animals O 0 0.00010056677
, O 0 0.0001410109
irrespective O 0 8.952682e-05
of O 0 0.00031991708
the O 0 0.0005375451
diet O 0 0.010481907
fed O 0 0.0029776078
. O 0 0.002153781

On O 0 0.0023393177
two O 0 0.0012200117
paradoxical O 0 0.004943105
side O 0 0.011856868
- O 0 0.0012262693
effects O 0 0.00054756826
of O 0 0.0012202256
prednisolone B-Chemical 0 0.9998939
in O 0 0.0004519467
rats O 0 0.0004892071
, O 0 0.00025600253
ribosomal O 0 0.0010191693
RNA O 0 0.0061597987
biosyntheses O 0 0.056172624
, O 0 0.00035650757
and O 0 0.00028555145
a O 0 0.0004338715
mechanism O 0 0.0005506426
of O 0 0.001095077
action O 0 0.0027076993
. O 0 0.0024898304

Liver B-Disease 0 0.9902726
enlargement I-Disease 0 0.754062
and O 0 0.0027960485
muscle B-Disease 0 0.19914404
wastage I-Disease 0 0.13130206
occurred O 0 0.0004344385
in O 0 0.00031606093
Wistar O 0 0.0010219499
rats O 0 0.0002357707
following O 0 0.0001176308
the O 0 0.00022080562
subcutaneous O 0 0.0010306794
administration O 0 0.0023320827
of O 0 0.0031190815
prednisolone B-Chemical 0 0.99973375
. O 0 0.00398949

In O 0 0.0019819536
the O 0 0.0018184598
liver O 0 0.16761011
both O 0 0.00070890784
the O 0 0.00040840564
content O 0 0.0004377999
of O 0 0.00034308175
RNA O 0 0.0018824188
and O 0 0.00019179049
the O 0 0.00014898075
biosynthesis O 0 0.0009706971
of O 0 0.00019658523
ribosomal O 0 0.0009145779
RNA O 0 0.0021128405
increased O 0 0.00021848376
while O 0 8.827361e-05
both O 0 7.6592885e-05
the O 0 8.047553e-05
RNA O 0 0.00072748616
content O 0 0.0001667712
and O 0 0.000121674195
ribosomal O 0 0.0006961357
RNA O 0 0.0027123117
biosynthesis O 0 0.0021444845
were O 0 0.00018778935
reduced O 0 0.0003175233
in O 0 0.00028119556
the O 0 0.0005674052
gastrocnemius O 0 0.007072526
muscle O 0 0.0059109116
. O 0 0.002005098

It O 0 0.0027562587
is O 0 0.001252345
suggested O 0 0.0005516686
that O 0 0.00038218132
the O 0 0.00049065694
drug O 0 0.006928559
acted O 0 0.0009304162
in O 0 0.00022993557
a O 0 0.00028647963
selective O 0 0.00066903443
and O 0 0.00022474868
tissue O 0 0.0008718827
- O 0 0.00023763618
specific O 0 5.9711714e-05
manner O 0 6.664232e-05
to O 0 5.2678137e-05
enhance O 0 4.801016e-05
ribosomal O 0 0.00047354365
RNA O 0 0.0014469587
synthesis O 0 0.0006593848
in O 0 0.000109717526
the O 0 0.00015548785
liver O 0 0.45946553
and O 0 0.00027435448
depress O 0 0.0016290948
such O 0 0.0001916269
synthesis O 0 0.0012075185
in O 0 0.00046082708
the O 0 0.0008907595
muscle O 0 0.0063147475
. O 0 0.0020736335

This O 0 0.003744081
view O 0 0.001902982
supports O 0 0.0008657788
the O 0 0.00067349087
contention O 0 0.0007689005
that O 0 0.00028413683
the O 0 0.00043963664
liver O 0 0.5059081
and O 0 0.00052856305
muscle O 0 0.0015129916
are O 0 0.0001815761
independent O 0 0.00012917613
sites O 0 0.00026902428
of O 0 0.0011639711
prednisolone B-Chemical 0 0.9996692
action O 0 0.0064580995
. O 0 0.0030239224

Differential O 0 0.0034236962
effects O 0 0.0020483404
of O 0 0.0031806373
gamma B-Chemical 0 0.9955655
- I-Chemical 0 0.060496673
hexachlorocyclohexane I-Chemical 0 0.9999893
( O 0 0.037750553
lindane B-Chemical 1 0.9999782
) O 0 0.0022652175
on O 0 0.00050854444
pharmacologically O 0 0.6438146
- O 0 0.0029183128
induced O 0 0.004077799
seizures B-Disease 0 0.99979717
. O 0 0.005396595

Gamma B-Chemical 0 0.6591434
- I-Chemical 0 0.029968493
hexachlorocyclohexane I-Chemical 0 0.9999521
( O 0 0.013836769
gamma B-Chemical 1 0.9981964
- I-Chemical 1 0.036498208
HCH I-Chemical 1 0.99994445
) O 0 0.001477245
, O 0 0.0002701534
the O 0 0.00014663416
active O 0 0.00019822127
ingredient O 0 0.02203816
of O 0 0.00021750812
the O 0 0.0002729373
insecticide O 0 0.97840035
lindane B-Chemical 1 0.9999963
, O 0 0.0005293975
has O 0 7.7562356e-05
been O 0 4.8982343e-05
shown O 0 3.9342587e-05
to O 0 4.9270788e-05
decrease O 0 0.00016057905
seizure B-Disease 0 0.9965996
threshold O 0 0.00011998638
to O 0 0.00013077044
pentylenetrazol O 0 0.9213303
( O 0 0.0017323385
PTZ B-Chemical 0 0.9999987
) O 0 0.0004385455
3 O 0 4.527262e-05
h O 0 3.1411735e-05
after O 0 1.8354058e-05
exposure O 0 8.985473e-05
to O 0 0.00013290525
gamma B-Chemical 1 0.9950722
- I-Chemical 1 0.0063648704
HCH I-Chemical 1 0.99996936
and O 0 0.00026381772
conversely O 0 0.0013529749
increase O 0 9.180258e-05
threshold O 0 0.00010087567
to O 0 0.00027229942
PTZ B-Chemical 0 0.99999905
- O 0 0.0015748012
induced O 0 0.00044069954
seizures B-Disease 0 0.9999219
24 O 0 7.693379e-05
h O 0 4.323534e-05
after O 0 2.4249357e-05
exposure O 0 0.00012203208
to O 0 0.00019003081
gamma B-Chemical 1 0.99340254
- I-Chemical 1 0.00891739
HCH I-Chemical 1 0.9999473
( O 0 0.0013916926
Vohland O 0 0.010437045
et O 0 0.00052307145
al O 0 0.0006970177
. O 0 0.0005052872
1981 O 0 0.0022801482
) O 0 0.0021242592
. O 0 0.0022122758

In O 0 0.001809832
this O 0 0.0015784168
study O 0 0.0012111485
, O 0 0.0007083453
the O 0 0.00041078648
severity O 0 0.0006423771
of O 0 0.0002834736
response O 0 0.0002105668
to O 0 0.00016897032
other O 0 0.00029112794
seizure B-Disease 0 0.9996489
- O 0 0.00078981067
inducing O 0 0.00036336278
agents O 0 0.0012246496
was O 0 0.00014824019
tested O 0 8.0448364e-05
in O 0 6.8724716e-05
mice O 0 4.797309e-05
1 O 0 4.9940474e-05
and O 0 4.7668684e-05
24 O 0 3.2944325e-05
h O 0 3.3012253e-05
after O 0 2.2600445e-05
intraperitoneal O 0 0.0002466953
administration O 0 0.00033757946
of O 0 0.00017008261
80 O 0 0.0002845342
mg O 0 0.0055663586
/ O 0 0.0012940302
kg O 0 0.0021460392
gamma B-Chemical 1 0.9767594
- I-Chemical 1 0.010663239
HCH I-Chemical 1 0.999595
. O 0 0.004130797

One O 0 0.0017260432
hour O 0 0.0008136616
after O 0 0.00032990106
the O 0 0.00048656185
administration O 0 0.0015012244
of O 0 0.0012767876
gamma B-Chemical 1 0.9980179
- I-Chemical 1 0.020954773
HCH I-Chemical 1 0.9999541
, O 0 0.00037816697
the O 0 0.00013038605
activity O 0 0.00012505028
of O 0 0.00037617123
seizure B-Disease 0 0.99974877
- O 0 0.00073070766
inducing O 0 0.00033479588
agents O 0 0.0012417146
was O 0 0.00015800564
increased O 0 0.00019224583
, O 0 9.282529e-05
regardless O 0 3.0222353e-05
of O 0 8.9714405e-05
their O 0 0.00010081374
mechanism O 0 0.000103119426
, O 0 9.102181e-05
while O 0 6.1628154e-05
24 O 0 4.6369034e-05
h O 0 5.5479777e-05
after O 0 5.9029324e-05
gamma B-Chemical 1 0.9621336
- I-Chemical 1 0.0030238503
HCH I-Chemical 1 0.999874
a O 0 0.0006854658
differential O 0 0.00067224354
response O 0 0.0005579109
was O 0 0.00088156783
observed O 0 0.0011597782
. O 0 0.001999477

Seizure B-Disease 2 0.95479107
activity O 0 0.0016559599
due O 0 0.0008315392
to O 0 0.0014535942
PTZ B-Chemical 0 0.9999908
and O 0 0.014038064
picrotoxin B-Chemical 0 0.999998
( O 0 0.038640447
PTX B-Chemical 0 0.9999356
) O 0 0.0011649983
was O 0 0.00023389862
significantly O 0 0.00023396131
decreased O 0 0.00047045475
; O 0 0.00020177821
however O 0 0.0001874557
, O 0 0.00021018107
seizure B-Disease 0 0.99548256
activity O 0 0.00012042011
due O 0 5.4479337e-05
to O 0 7.8859535e-05
3 B-Chemical 0 9.400621e-05
- I-Chemical 0 0.0004648458
mercaptopropionic I-Chemical 0 0.9968496
acid I-Chemical 0 0.9921421
( O 0 0.004184243
MPA B-Chemical 0 0.9999825
) O 0 0.0011791746
, O 0 0.00065572007
bicuculline B-Chemical 1 0.99999475
( O 0 0.0069296607
BCC B-Chemical 0 0.999856
) O 0 0.00078435126
, O 0 0.00032500766
methyl B-Chemical 0 0.9285831
6 I-Chemical 0 9.0441856e-05
, I-Chemical 0 0.000121966936
7 I-Chemical 0 9.057996e-05
- I-Chemical 0 0.00044912423
dimethoxy I-Chemical 0 0.99730384
- I-Chemical 0 0.00054952636
4 I-Chemical 0 0.00011976497
- I-Chemical 0 0.0005523584
ethyl I-Chemical 0 0.99967694
- I-Chemical 0 0.0022661132
B I-Chemical 0 0.567074
- I-Chemical 0 0.0016445043
carboline I-Chemical 0 0.99576974
- I-Chemical 0 0.0005665465
3 I-Chemical 0 0.00010762261
- I-Chemical 0 0.00035784903
carboxylate I-Chemical 0 0.88257307
( O 0 0.0016211724
DMCM B-Chemical 0 0.99999845
) O 0 0.0008069091
, O 0 0.00020988748
or O 0 0.00029585892
strychnine B-Chemical 0 0.9999931
( O 0 0.0031581752
STR B-Chemical 0 0.9975666
) O 0 0.000508773
was O 0 0.00021542274
not O 0 0.00018019509
different O 0 0.000213023
from O 0 0.00045982745
control O 0 0.0010970744
. O 0 0.0019333427

In O 0 0.002047812
vitro O 0 0.0025001478
, O 0 0.0027441802
gamma B-Chemical 1 0.9930442
- I-Chemical 1 0.026606996
HCH I-Chemical 1 0.9999515
, O 0 0.0057916213
pentylenetetrazol B-Chemical 0 0.9999958
and O 0 0.009785535
picrotoxin B-Chemical 0 0.99999785
were O 0 0.00036782597
shown O 0 8.296815e-05
to O 0 8.148761e-05
inhibit O 0 0.00015624853
3H B-Chemical 1 0.954953
- I-Chemical 1 0.0011274961
TBOB I-Chemical 1 0.9960407
binding O 0 0.00014267082
in O 0 7.523558e-05
mouse O 0 0.00010534636
whole O 0 9.1774054e-05
brain O 0 0.00059832365
, O 0 0.00010710681
with O 0 0.0001457312
IC50 O 0 0.22131118
values O 0 0.00014332423
of O 0 0.00015535376
4 O 0 7.968228e-05
. O 0 5.7630823e-05
6 O 0 6.0537855e-05
, O 0 0.00013371382
404 O 0 0.0006285339
and O 0 0.00016911393
9 O 0 0.00015505937
. O 0 0.00015161131
4 O 0 0.00028495147
microM O 0 0.019129636
, O 0 0.001644152
respectively O 0 0.0035715813
. O 0 0.0026631914

MPA B-Chemical 0 0.9994696
, O 0 0.012764331
BCC B-Chemical 0 0.9989122
, O 0 0.009088073
DMCM B-Chemical 0 0.9999914
, O 0 0.0018868193
and O 0 0.0009126454
STR B-Chemical 0 0.986842
showed O 0 0.0002609954
no O 0 0.00011050933
inhibition O 0 0.00057317724
of O 0 0.001138463
3H B-Chemical 1 0.98758906
- I-Chemical 1 0.0025314195
TBOB I-Chemical 1 0.99928206
( O 0 0.0006406554
t B-Chemical 0 0.0006877476
- I-Chemical 0 0.0010786447
butyl I-Chemical 0 0.9998975
bicyclo I-Chemical 0 0.99834895
- I-Chemical 0 0.0018765025
orthobenzoate I-Chemical 0 0.23788199
) O 0 0.00031556684
binding O 0 0.00016291588
at O 0 0.00014146732
concentrations O 0 0.00060782646
of O 0 0.00079189596
100 O 0 0.002367549
micron O 0 0.007962612
. O 0 0.0023824617

The O 0 0.0016190775
pharmacological O 0 0.004378731
challenge O 0 0.0007287703
data O 0 0.00056288106
suggest O 0 0.00018959408
that O 0 0.00023505827
tolerance O 0 0.011830673
may O 0 0.00016693633
occur O 0 0.00010878441
to O 0 0.00014912587
seizure B-Disease 0 0.99552613
activity O 0 0.00019342256
induced O 0 0.00027773212
by O 0 0.00061969564
PTZ B-Chemical 0 0.9999987
and O 0 0.001232615
PTX B-Chemical 0 0.9997359
24 O 0 8.470442e-05
h O 0 5.9218197e-05
after O 0 4.8496448e-05
gamma B-Chemical 1 0.98597187
- I-Chemical 1 0.005732203
HCH I-Chemical 1 0.9999666
, O 0 0.00021271974
since O 0 4.2934793e-05
the O 0 5.7352147e-05
response O 0 6.476726e-05
to O 0 6.201607e-05
only O 0 0.00010059939
these O 0 0.00017268215
two O 0 0.00016062634
seizure B-Disease 0 0.9984957
- O 0 0.0009401266
inducing O 0 0.00086689
agents O 0 0.003161723
is O 0 0.0011363357
decreased O 0 0.0037755014
. O 0 0.0023914943

The O 0 0.0016208868
in O 0 0.0011346573
vitro O 0 0.00097647455
data O 0 0.0005774042
suggest O 0 0.00018665507
that O 0 0.00017648445
the O 0 0.00019318296
site O 0 0.00013006582
responsible O 0 0.00010467905
for O 0 7.950816e-05
the O 0 0.000103349084
decrease O 0 0.00016673081
in O 0 0.00015287106
seizure B-Disease 0 0.99461997
activity O 0 0.00011935978
24 O 0 5.3574135e-05
h O 0 5.2253068e-05
after O 0 4.780471e-05
gamma B-Chemical 1 0.9713949
- I-Chemical 1 0.002703159
HCH I-Chemical 1 0.9999231
may O 0 0.00015913573
be O 0 0.00012370583
the O 0 0.00029186328
GABA B-Chemical 0 0.9999684
- O 0 0.0017514133
A O 0 0.03967385
receptor O 0 0.033362985
- O 0 0.0013039719
linked O 0 0.0013198522
chloride O 0 0.9996815
channel O 0 0.6543095
. O 0 0.0032029352

Tolerance O 0 0.026852481
and O 0 0.002074257
antiviral O 0 0.0038770516
effect O 0 0.00094475725
of O 0 0.0017241759
ribavirin B-Chemical 0 0.9989115
in O 0 0.0010482816
patients O 0 0.0014125104
with O 0 0.0017713374
Argentine B-Disease 0 0.3736152
hemorrhagic I-Disease 2 0.999798
fever I-Disease 0 0.99977154
. O 0 0.007566355

Tolerance O 0 0.025574397
and O 0 0.0017238541
antiviral O 0 0.0033370543
effect O 0 0.0007082623
of O 0 0.0014076438
ribavirin B-Chemical 0 0.9995377
was O 0 0.00067806477
studied O 0 0.00028579708
in O 0 0.00013125439
6 O 0 7.086381e-05
patients O 0 0.00012865849
with O 0 0.00019463693
Argentine B-Disease 0 0.06395466
hemorrhagic I-Disease 2 0.9999387
fever I-Disease 0 0.99997556
( O 0 0.017126229
AHF B-Disease 0 0.9999782
) O 0 0.00054429576
of O 0 0.00020110386
more O 0 0.0002204314
than O 0 0.0001310138
8 O 0 0.00016086837
days O 0 0.00015323065
of O 0 0.0006189355
evolution O 0 0.0014210118
. O 0 0.002019404

Administration O 0 0.009673944
of O 0 0.0032817612
ribavirin B-Chemical 0 0.99783945
resulted O 0 0.001125406
in O 0 0.00056698837
a O 0 0.0006506571
neutralization O 0 0.014672309
of O 0 0.0011058304
viremia B-Disease 0 0.9680439
and O 0 0.0005200117
a O 0 0.0005175309
drop O 0 0.001344012
of O 0 0.00068154646
endogenous O 0 0.0017852342
interferon O 0 0.99920875
titers O 0 0.07671787
. O 0 0.003487871

The O 0 0.002903242
average O 0 0.0021428617
time O 0 0.0023036143
of O 0 0.0056461394
death B-Disease 0 0.9479904
was O 0 0.007890883
delayed O 0 0.022399358
. O 0 0.007973196

A O 0 0.117808655
reversible O 0 0.6134734
anemia B-Disease 0 0.9995453
was O 0 0.0032738582
the O 0 0.0015393896
only O 0 0.0018729174
adverse O 0 0.047037438
effect O 0 0.0024908371
observed O 0 0.0034208633
. O 0 0.004506585

From O 0 0.0019158444
these O 0 0.001619315
results O 0 0.0009799629
, O 0 0.0006582233
we O 0 0.00020639983
conclude O 0 0.00019625411
that O 0 0.000292668
ribavirin B-Chemical 0 0.99897575
has O 0 0.00022317193
an O 0 0.00026453708
antiviral O 0 0.0016236764
effect O 0 0.00014661068
in O 0 0.00014545854
advanced O 0 0.0011375888
cases O 0 0.000243084
of O 0 0.00070377253
AHF B-Disease 0 0.9999838
, O 0 0.00029590438
and O 0 0.00014338053
that O 0 0.00017669743
anemia B-Disease 0 0.99994326
, O 0 0.000262526
the O 0 0.00011579761
only O 0 0.0001496057
secondary O 0 0.0005999254
reaction O 0 0.0031454125
observed O 0 0.00024818207
, O 0 0.0003340387
can O 0 0.00025378497
be O 0 0.00041324142
easily O 0 0.0007950663
managed O 0 0.002010213
. O 0 0.001940349

The O 0 0.0016526812
possible O 0 0.0012268253
beneficial O 0 0.001256332
effect O 0 0.00071093184
of O 0 0.0012217655
ribavirin B-Chemical 0 0.99710673
during O 0 0.0002514144
the O 0 0.00026929317
initial O 0 0.00028655177
days O 0 0.00025491748
of O 0 0.0014387612
AHF B-Disease 0 0.9997857
is O 0 0.0022985481
discussed O 0 0.002306673
. O 0 0.0028754168

Is O 0 0.010430882
the O 0 0.0050007687
treatment O 0 0.0052870964
of O 0 0.00862247
scabies B-Disease 0 0.76350814
hazardous O 0 0.09372641
? O 0 0.021503717

Treatment O 0 0.005952931
for O 0 0.00198922
scabies B-Disease 0 0.35025835
is O 0 0.00089335535
usually O 0 0.0005836689
initiated O 0 0.00034925758
by O 0 0.00027654206
general O 0 0.00024447558
practitioners O 0 0.0005651507
; O 0 0.00019640948
most O 0 0.00020389535
consider O 0 0.00016051505
lindane B-Chemical 1 0.9999865
( O 0 0.0073463973
gamma B-Chemical 0 0.999843
benzene I-Chemical 0 0.9999989
hexachloride I-Chemical 0 0.99999845
) O 0 0.0028116473
the O 0 0.00040000433
treatment O 0 0.0004738536
of O 0 0.00095312664
choice O 0 0.0014764884
. O 0 0.0020570906

Lindane B-Chemical 0 0.9996964
is O 0 0.0027697945
also O 0 0.001074298
widely O 0 0.00054668536
used O 0 0.00034942228
as O 0 0.00029041548
an O 0 0.00038072458
agricultural O 0 0.0029574444
and O 0 0.00037481598
industrial O 0 0.0153795015
pesticide O 0 0.9641337
, O 0 0.0003484112
and O 0 0.000158092
as O 0 9.7834374e-05
a O 0 0.00012435207
result O 0 8.7889865e-05
the O 0 0.00012448683
toxic O 0 0.022552187
profile O 0 0.00021234687
of O 0 0.000255902
this O 0 0.0004917284
insecticide O 0 0.41771233
is O 0 0.00064218737
well O 0 0.0007069992
understood O 0 0.0030473233
. O 0 0.0021051893

Evidence O 0 0.0046129036
is O 0 0.0017402562
accumulating O 0 0.0015529476
that O 0 0.001157687
lindane B-Chemical 1 0.9999373
can O 0 0.00062901655
be O 0 0.00039640887
toxic B-Disease 0 0.026927263
to I-Disease 0 0.00016784963
the I-Disease 0 0.00014690035
central I-Disease 0 0.00023182231
nervous I-Disease 0 0.0034607123
system I-Disease 0 0.00020326566
and O 0 0.00017134151
may O 0 0.00014145963
be O 0 0.00017818599
associated O 0 0.0003229521
with O 0 0.0021004563
aplastic B-Disease 0 0.99993014
anaemia I-Disease 0 0.99996173
. O 0 0.008407141

Preparations O 0 0.007783714
containing O 0 0.0028311792
lindane B-Chemical 1 0.99977523
continue O 0 0.0013579371
to O 0 0.00054416887
be O 0 0.0003599443
sold O 0 0.0006444599
over O 0 9.932572e-05
the O 0 0.00016197226
counter O 0 0.0005477082
and O 0 0.00017555029
may O 0 0.00012127608
represent O 0 0.00013090891
a O 0 0.00028385007
hazard O 0 0.0012132613
to O 0 0.00033824745
poorly O 0 0.0011812565
informed O 0 0.002962406
patients O 0 0.0022085316
. O 0 0.0019630634

This O 0 0.0037297546
literature O 0 0.0023883258
review O 0 0.0014950408
suggests O 0 0.00028750574
that O 0 0.00022543417
general O 0 0.00028647034
practitioners O 0 0.00051622035
should O 0 0.000107360815
prescribe O 0 0.0007016948
scabicides O 0 0.059465587
with O 0 0.00017994818
increased O 0 0.0001980886
caution O 0 7.835013e-05
for O 0 5.383542e-05
certain O 0 8.4008614e-05
at O 0 7.6310534e-05
- O 0 0.00030834426
risk O 0 0.001001898
groups O 0 0.00012725302
, O 0 0.00011700477
and O 0 0.000109223256
give O 0 0.00014967717
adequate O 0 0.00018213426
warnings O 0 0.0009083343
regarding O 0 0.0002835301
potential O 0 0.001257782
toxicity B-Disease 2 0.99393636
. O 0 0.00318759

Mouse O 0 0.009370817
strain O 0 0.001862391
- O 0 0.0017281462
dependent O 0 0.00041284767
effect O 0 0.0005828739
of O 0 0.0013885918
amantadine B-Chemical 1 0.999683
on O 0 0.0006075088
motility O 0 0.0136390915
and O 0 0.0010879708
brain O 0 0.03624545
biogenic O 0 0.9941825
amines B-Chemical 0 0.9988527
. O 0 0.0042966353

The O 0 0.001412883
effect O 0 0.0013093349
of O 0 0.0035158123
amantadine B-Chemical 1 0.9999738
hydrochloride I-Chemical 0 0.999905
, O 0 0.0012452145
injected O 0 0.00042445445
i O 0 0.0008543264
. O 0 0.00016042202
p O 0 0.0001561511
. O 0 6.2121544e-05
in O 0 6.395465e-05
6 O 0 4.0251376e-05
increments O 0 7.41438e-05
of O 0 0.00010089078
100 O 0 0.00029178426
mg O 0 0.003644262
/ O 0 0.00035101117
kg O 0 0.00014502132
each O 0 2.4360685e-05
over O 0 2.2123979e-05
30 O 0 3.60145e-05
hr O 0 6.895974e-05
, O 0 6.628663e-05
on O 0 3.716841e-05
mouse O 0 0.00012833941
motility O 0 0.0011293235
and O 0 6.9224865e-05
whole O 0 7.4611635e-05
brain O 0 0.00033175776
content O 0 9.945689e-05
of O 0 9.501524e-05
selected O 0 0.00013886423
biogenic O 0 0.96625507
amines B-Chemical 0 0.9984712
and O 0 0.00014527848
major O 0 0.00013918994
metabolites O 0 0.28406394
was O 0 0.00017646914
studied O 0 0.00015935011
in O 0 0.00014239395
4 O 0 0.00015543657
strains O 0 0.0002855939
of O 0 0.0006819265
mice O 0 0.0009830367
. O 0 0.0018904491

These O 0 0.002625938
were O 0 0.001563805
the O 0 0.0012409756
albino O 0 0.0064710663
Sprague O 0 0.04616993
- O 0 0.0014466253
Dawley O 0 0.0059836134
ICR O 0 0.003026721
and O 0 0.00033555753
BALB O 0 0.01438454
/ O 0 0.0016964532
C O 0 0.9279573
, O 0 0.0002822649
the O 0 0.00022061034
black O 0 0.0017551908
C57BL O 0 0.34804797
/ O 0 0.0005464424
6 O 0 8.7121996e-05
and O 0 0.00013486846
the O 0 0.00023745727
brown O 0 0.0033408774
CDF O 0 0.2357949
- O 0 0.0013438149
I O 0 0.0033308542
mouse O 0 0.0014115509
strains O 0 0.0016275056
. O 0 0.0022322086

Amantadine B-Chemical 0 0.9977939
treatment O 0 0.0029765673
produced O 0 0.0016821447
a O 0 0.0017501501
biphasic O 0 0.0029013543
effect O 0 0.0012448931
on O 0 0.001193106
mouse O 0 0.0038037277
motility O 0 0.0374782
. O 0 0.0045110555

The O 0 0.0011476657
initial O 0 0.00094984676
dose O 0 0.0027090732
of O 0 0.0018886952
amantadine B-Chemical 1 0.99992776
depressed B-Disease 2 0.995333
locomotor O 0 0.37020835
activity O 0 0.00024136232
in O 0 0.00013677591
all O 0 0.000113348455
mouse O 0 0.00014480134
strains O 0 9.912267e-05
studied O 0 0.00011492418
with O 0 0.00013283735
the O 0 0.00018589027
BALB O 0 0.034313977
/ O 0 0.0017056275
C O 0 0.8413053
mice O 0 0.0002145577
being O 0 0.0004030777
the O 0 0.00040853105
most O 0 0.0010321544
sensitive O 0 0.0014685728
. O 0 0.0022079162

Subsequent O 0 0.0038344264
amantadine B-Chemical 1 0.99902296
treatments O 0 0.0018803254
produced O 0 0.0005677773
enhancement O 0 0.00079551945
of O 0 0.0005013179
motility O 0 0.0038930285
from O 0 0.00011965401
corresponding O 0 8.4480744e-05
control O 0 9.455094e-05
in O 0 8.698055e-05
all O 0 8.913726e-05
mouse O 0 0.00012620026
strains O 0 9.1149755e-05
with O 0 0.00012450297
the O 0 0.00017286686
BALB O 0 0.027058728
/ O 0 0.0015447079
C O 0 0.8198584
mice O 0 0.00020133043
being O 0 0.00037145024
the O 0 0.00036248253
least O 0 0.00049862853
sensitive O 0 0.0013003325
. O 0 0.0021152808

The O 0 0.0019724662
locomotor O 0 0.016291149
activity O 0 0.0010006949
was O 0 0.0006776706
decreased O 0 0.00061326986
from O 0 0.00020211576
corresponding O 0 0.0001553764
controls O 0 0.00025617052
in O 0 0.00011291091
all O 0 0.00010383886
strains O 0 0.00011417539
studied O 0 0.00014703615
, O 0 0.00011342674
except O 0 5.7079873e-05
for O 0 5.674274e-05
the O 0 0.00010485207
ICR O 0 0.001622407
mice O 0 5.4894033e-05
, O 0 6.833093e-05
during O 0 2.9095343e-05
an O 0 7.810522e-05
overnight O 0 0.00011567808
drug O 0 0.0024815095
- O 0 0.0001759555
free O 0 9.999379e-05
period O 0 4.350625e-05
following O 0 7.449888e-05
the O 0 0.0002072563
fourth O 0 0.0012509342
amantadine B-Chemical 1 0.99945027
treatment O 0 0.002679102
. O 0 0.0023499515

Readministration O 0 0.1276355
of O 0 0.00513819
amantadine B-Chemical 1 0.9996711
, O 0 0.0011904644
after O 0 0.00022183203
a O 0 0.00054993184
drug O 0 0.0148152495
- O 0 0.0004729856
free O 0 0.00018858102
overnight O 0 0.0001255302
period O 0 5.2369152e-05
, O 0 9.607713e-05
increased O 0 0.00015642846
motility O 0 0.0015417889
from O 0 5.9154423e-05
respective O 0 6.550942e-05
saline O 0 0.00025973562
control O 0 5.312916e-05
in O 0 4.964305e-05
all O 0 5.2390624e-05
strains O 0 5.839408e-05
with O 0 7.619026e-05
exception O 0 6.259937e-05
of O 0 0.00011268439
the O 0 0.00015421654
BALB O 0 0.03799954
/ O 0 0.0014234756
C O 0 0.83836615
mice O 0 0.00012850326
where O 0 0.00016438158
suppression B-Disease 0 0.001219515
of I-Disease 0 0.0010058904
motility I-Disease 0 0.17549485
occurred O 0 0.0017694723
. O 0 0.002062732

Treatment O 0 0.005579336
with O 0 0.0033440923
amantadine B-Chemical 1 0.9995797
did O 0 0.0009459768
not O 0 0.00030472307
alter O 0 0.00018312337
whole O 0 0.00027380834
brain O 0 0.0064406954
dopamine B-Chemical 0 0.9997497
levels O 0 0.00024523243
but O 0 0.00015462782
decreased O 0 0.00022689273
the O 0 8.672595e-05
amounts O 0 9.007348e-05
of O 0 0.00014598752
3 B-Chemical 0 7.979345e-05
, I-Chemical 0 0.000113218826
4 I-Chemical 0 0.0001026213
- I-Chemical 0 0.00080015865
dihydroxyphenylacetic I-Chemical 0 0.99999523
acid I-Chemical 0 0.90106726
in O 0 0.00017152657
the O 0 0.00019072714
BALB O 0 0.031415578
/ O 0 0.0013768144
C O 0 0.7844938
mice O 0 0.00015331514
compared O 0 0.00016640936
to O 0 0.00034037756
saline O 0 0.001989632
control O 0 0.0012041515
. O 0 0.0019474698

Conversely O 0 0.0032994086
, O 0 0.0022448408
brain O 0 0.010672994
normetanephrine B-Chemical 0 0.99990964
concentration O 0 0.003046211
was O 0 0.00047425856
increased O 0 0.0003460404
from O 0 0.00017354678
saline O 0 0.0006152722
control O 0 0.0001721761
by O 0 0.0003436733
amantadine B-Chemical 1 0.99944896
in O 0 0.00038808127
the O 0 0.0005523702
BALB O 0 0.060301922
/ O 0 0.004447206
C O 0 0.86615515
mice O 0 0.0017580957
. O 0 0.0025640978

The O 0 0.0015983247
results O 0 0.0012658257
suggest O 0 0.00054576126
a O 0 0.00080098404
strain O 0 0.0004611817
- O 0 0.00055750296
dependent O 0 0.00011793439
effect O 0 0.0001923953
of O 0 0.0005992396
amantadine B-Chemical 1 0.9998872
on O 0 0.00015083973
motility O 0 0.00761265
and O 0 0.00011959379
indicate O 0 4.985511e-05
a O 0 0.000100960155
differential O 0 0.00013507415
response O 0 9.4379146e-05
to O 0 9.13971e-05
the O 0 0.00015974048
acute O 0 0.046765093
and O 0 0.00028113284
multiple O 0 0.00040129354
dose O 0 0.0018202922
regimens O 0 0.0012574644
used O 0 0.0011682104
. O 0 0.0019741594

The O 0 0.0029626905
BALB O 0 0.058634542
/ O 0 0.0096539045
C O 0 0.9432892
mouse O 0 0.0013442169
was O 0 0.0005283273
the O 0 0.00027637914
most O 0 0.0003209613
sensitive O 0 0.00017337296
strain O 0 0.00013858035
and O 0 0.000151703
could O 0 9.299763e-05
serve O 0 0.00010219767
as O 0 7.62394e-05
the O 0 6.968731e-05
strain O 0 6.0659906e-05
of O 0 9.96823e-05
choice O 0 8.00738e-05
for O 0 6.549743e-05
evaluating O 0 7.454557e-05
the O 0 0.00018698676
side O 0 0.00183887
effects O 0 0.0007790913
of O 0 0.0032916071
amantadine B-Chemical 1 0.99975234
. O 0 0.004127436

The O 0 0.001594476
biochemical O 0 0.0024786263
results O 0 0.00093861006
of O 0 0.0009911592
brain O 0 0.008061472
biogenic O 0 0.9943889
amines B-Chemical 0 0.999521
of O 0 0.0013087278
BALB O 0 0.23233496
/ O 0 0.0033168127
C O 0 0.9625195
mouse O 0 0.0002559874
strain O 0 7.798852e-05
suggest O 0 3.9425773e-05
a O 0 0.00011137428
probable O 0 0.00023548874
decrease O 0 0.00013666326
of O 0 0.0002378311
catecholamine B-Chemical 0 0.998973
turnover O 0 0.00071141304
rate O 0 0.000103066915
and O 0 8.657837e-05
/ O 0 0.00024128752
or O 0 8.440996e-05
metabolism O 0 0.02400006
by O 0 0.0003359155
monoamine O 0 0.999966
oxidase O 0 0.999892
and O 0 0.00014931952
a O 0 0.00010038474
resulting O 0 7.784802e-05
increase O 0 9.0789756e-05
in O 0 0.00016002922
O O 0 0.9929034
- O 0 0.0004931933
methylation O 0 0.0019586603
of O 0 0.000256431
norepinephrine B-Chemical 1 0.9993223
which O 0 0.00011927251
may O 0 4.376491e-05
account O 0 4.2107e-05
for O 0 3.9703544e-05
a O 0 0.00013483917
behavioral B-Disease 0 0.06247064
depression I-Disease 0 0.99952936
caused O 0 0.00036939236
by O 0 0.00045802988
amantadine B-Chemical 1 0.99981195
in O 0 0.00031943555
the O 0 0.00045572905
BALB O 0 0.06807187
/ O 0 0.0039714947
C O 0 0.87199223
mice O 0 0.0015394497
. O 0 0.002286357

Chloroacetaldehyde B-Chemical 0 0.9910488
and O 0 0.0023320718
its O 0 0.001562345
contribution O 0 0.00068018894
to O 0 0.0007906646
urotoxicity O 0 0.9972651
during O 0 0.0003529766
treatment O 0 0.00058709376
with O 0 0.0013819233
cyclophosphamide B-Chemical 0 0.99949205
or O 0 0.004709175
ifosfamide B-Chemical 0 0.99925774
. O 0 0.004873824

An O 0 0.007770192
experimental O 0 0.0065650446
study O 0 0.006069036
/ O 0 0.008579091
short O 0 0.0048214463
communication O 0 0.010005954
. O 0 0.008430518

Based O 0 0.0030303206
on O 0 0.0010202903
clinical O 0 0.0019776572
data O 0 0.00093876343
, O 0 0.0006663415
indicating O 0 0.00031867574
that O 0 0.00044107944
chloroacetaldehyde B-Chemical 0 0.99995184
( O 0 0.004388243
CAA B-Chemical 0 0.9921034
) O 0 0.0004699404
is O 0 0.00010614316
an O 0 9.2878254e-05
important O 0 5.518218e-05
metabolite O 0 0.29589906
of O 0 0.00029472748
oxazaphosphorine O 0 0.9109872
cytostatics O 0 0.9099428
, O 0 0.00016253309
an O 0 0.000112455
experimental O 0 0.00011980061
study O 0 9.880747e-05
was O 0 6.94228e-05
carried O 0 4.9539285e-05
out O 0 4.0843246e-05
in O 0 4.632784e-05
order O 0 4.624803e-05
to O 0 4.852592e-05
elucidate O 0 3.8853632e-05
the O 0 6.4492495e-05
role O 0 5.8050733e-05
of O 0 0.0002574732
CAA B-Chemical 0 0.83799314
in O 0 0.00018354149
the O 0 0.00021440617
development O 0 0.00068182644
of O 0 0.0019485257
hemorrhagic B-Disease 2 0.99976546
cystitis I-Disease 0 0.9998623
. O 0 0.0053342925

The O 0 0.0016053132
data O 0 0.0013364924
demonstrate O 0 0.00053296034
that O 0 0.00066819834
CAA B-Chemical 0 0.668854
after O 0 0.00027321637
i O 0 0.00092783
. O 0 0.00026853688
v O 0 0.001175589
. O 0 0.00019900865
administration O 0 0.0006532332
does O 0 0.00025652663
not O 0 0.00027368515
contribute O 0 0.00036886064
to O 0 0.0008498968
bladder B-Disease 0 0.7780715
damage I-Disease 0 0.98618525
. O 0 0.0040092575

When O 0 0.0016346524
instilled O 0 0.0032888707
directly O 0 0.0006357671
into O 0 0.0002698265
the O 0 0.00043613
bladder O 0 0.007749532
, O 0 0.0006785586
CAA B-Chemical 0 0.909403
exerts O 0 0.0005198477
urotoxic O 0 0.9890838
effects O 0 0.00061446725
, O 0 0.00035260056
it O 0 0.00022759213
is O 0 0.00018528278
, O 0 0.0002027678
however O 0 0.00022825539
, O 0 0.00020750525
susceptible O 0 0.0002353949
to O 0 0.00036756188
detoxification O 0 0.3057811
with O 0 0.0035703904
mesna B-Chemical 0 0.9995691
. O 0 0.003255583

Source O 0 0.011275596
of O 0 0.003931211
pain B-Disease 0 0.30600393
and O 0 0.0017098188
primitive O 0 0.006445995
dysfunction O 0 0.8521467
in O 0 0.0024432717
migraine B-Disease 0 0.99985504
: O 0 0.0015444432
an O 0 0.0011069683
identical O 0 0.00086053356
site O 0 0.0019375316
? O 0 0.0054510916

Twenty O 0 0.0034216924
common O 0 0.002752565
migraine B-Disease 0 0.9995189
patients O 0 0.001153436
received O 0 0.00028446803
a O 0 0.00029737243
one O 0 0.0001952507
sided O 0 0.06189033
frontotemporal O 0 0.9944214
application O 0 0.00031167665
of O 0 0.000692808
nitroglycerin B-Chemical 0 0.9999887
( O 0 0.00029807494
10 O 0 8.2292965e-05
patients O 0 0.00012225546
) O 0 0.000116608266
or O 0 8.027802e-05
placebo O 0 0.0015889413
ointment O 0 0.793706
( O 0 0.00023451584
10 O 0 0.000120915
patients O 0 0.00023116962
) O 0 0.000258742
in O 0 0.00019670298
a O 0 0.0004798085
double O 0 0.0011331744
blind O 0 0.015088281
study O 0 0.0018517791
. O 0 0.0019432019

Early O 0 0.005762043
onset O 0 0.008202918
migraine B-Disease 0 0.9998142
attacks O 0 0.6830041
were O 0 0.0007129377
induced O 0 0.00054521736
by O 0 0.0007360072
nitroglycerin B-Chemical 0 0.9999608
in O 0 0.00020682259
seven O 0 8.919619e-05
out O 0 6.173649e-05
of O 0 0.00010770906
10 O 0 8.930751e-05
patients O 0 0.00012725934
versus O 0 7.511493e-05
no O 0 7.8178324e-05
patient O 0 0.00017031321
in O 0 0.0001996994
the O 0 0.00041411316
placebo O 0 0.003193703
group O 0 0.0015234222
. O 0 0.0018626677

Subsequently O 0 0.0027032436
20 O 0 0.0033705651
migraine B-Disease 0 0.99958795
patients O 0 0.0021603617
, O 0 0.0006881901
who O 0 0.0004897796
developed O 0 0.00030994727
an O 0 0.00022419865
early O 0 0.0002721297
onset O 0 0.00032582387
attack O 0 0.023994474
with O 0 0.00072473736
frontotemporal O 0 0.9999325
nitroglycerin B-Chemical 0 0.9999949
, O 0 0.00021875791
received O 0 6.100972e-05
the O 0 7.635915e-05
drug O 0 0.001107109
in O 0 7.770102e-05
a O 0 0.00011596466
second O 0 0.00010326861
induction O 0 0.00019012507
test O 0 0.00025967867
at O 0 0.00017739246
other O 0 0.00040469712
body O 0 0.0020952218
areas O 0 0.0016281706
. O 0 0.0019431778

No O 0 0.0077608596
early O 0 0.008267152
onset O 0 0.016472492
migraine B-Disease 0 0.9991736
was O 0 0.009553302
observed O 0 0.006849643
. O 0 0.008375637

Thus O 0 0.0025300977
the O 0 0.003952166
migraine B-Disease 0 0.99975616
- O 0 0.002731772
inducing O 0 0.000855081
effect O 0 0.0004433955
of O 0 0.0015934805
nitroglycerin B-Chemical 0 0.9999808
seems O 0 0.0001787046
to O 0 8.53828e-05
depend O 0 4.2123953e-05
on O 0 3.5780304e-05
direct O 0 4.8197784e-05
stimulation O 0 4.539228e-05
of O 0 8.912307e-05
the O 0 8.5138076e-05
habitual O 0 0.0006353023
site O 0 7.2993695e-05
of O 0 0.00024047337
pain B-Disease 0 0.46790737
, O 0 0.00012757549
suggesting O 0 3.929459e-05
that O 0 4.769802e-05
the O 0 0.00013349
frontotemporal O 0 0.9936522
region O 0 0.000108389075
is O 0 6.870009e-05
of O 0 6.996578e-05
crucial O 0 4.340298e-05
importance O 0 5.2079446e-05
in O 0 8.601828e-05
the O 0 0.00012843612
development O 0 0.00036649394
of O 0 0.0006145159
a O 0 0.0028373364
migraine B-Disease 0 0.9998921
crisis O 0 0.68505245
. O 0 0.003244168

This O 0 0.004918453
is O 0 0.002010077
not O 0 0.0011113023
consistent O 0 0.00094193814
with O 0 0.0010690916
a O 0 0.0014169809
CNS O 0 0.023163551
origin O 0 0.0017273419
of O 0 0.0044651655
migraine B-Disease 0 0.99985266
attack O 0 0.7702463
. O 0 0.005123394

Hypersensitivity B-Disease 0 0.5927762
to O 0 0.0039281487
carbamazepine B-Chemical 1 0.9999695
presenting O 0 0.0055922153
with O 0 0.0011065305
a O 0 0.0013430843
leukemoid B-Disease 0 0.6266141
reaction I-Disease 0 0.06771047
, O 0 0.0021309848
eosinophilia B-Disease 0 0.99975985
, O 0 0.0035457232
erythroderma B-Disease 0 0.99853265
, O 0 0.001432478
and O 0 0.0014818318
renal B-Disease 0 0.98072505
failure I-Disease 0 0.81260616
. O 0 0.003585198

We O 0 0.0014871716
report O 0 0.0015166221
a O 0 0.00097589236
patient O 0 0.000610208
in O 0 0.00040106007
whom O 0 0.0010622866
hypersensitivity B-Disease 0 0.49843475
to O 0 0.000630796
carbamazepine B-Chemical 1 0.9999962
presented O 0 0.0003152352
with O 0 0.0003625163
generalized O 0 0.021286188
erythroderma B-Disease 0 0.9991191
, O 0 0.0003905888
a O 0 0.00040291672
severe O 0 0.044541936
leukemoid B-Disease 0 0.8063967
reaction I-Disease 0 0.07902741
, O 0 0.0011888031
eosinophilia B-Disease 0 0.9998037
, O 0 0.0023519772
hyponatremia B-Disease 2 0.99995255
, O 0 0.0013117247
and O 0 0.0011870922
renal B-Disease 0 0.978963
failure I-Disease 0 0.77815694
. O 0 0.0030088455

This O 0 0.0044238036
is O 0 0.0017149893
the O 0 0.0009692642
first O 0 0.00059067097
report O 0 0.00093994127
of O 0 0.0007174747
such O 0 0.00045541898
an O 0 0.000835337
unusual O 0 0.0014780415
reaction O 0 0.0152208805
to O 0 0.003834257
carbamazepine B-Chemical 1 0.9999653
. O 0 0.0060515744

Fluoxetine B-Chemical 0 0.9997335
- O 0 0.0129937995
induced O 0 0.0075939405
akathisia B-Disease 0 0.99986875
: O 0 0.0039228313
clinical O 0 0.003546013
and O 0 0.0018756846
theoretical O 0 0.0048429724
implications O 0 0.0034246952
. O 0 0.004387316

Five O 0 0.0026950184
patients O 0 0.0019219064
receiving O 0 0.0024304234
fluoxetine B-Chemical 1 0.9998871
for O 0 0.00037201776
the O 0 0.0002777557
treatment O 0 0.00029489805
of O 0 0.0010256832
obsessive B-Disease 0 0.9999753
compulsive I-Disease 0 0.9999511
disorder I-Disease 0 0.9980592
or O 0 0.00050329964
major B-Disease 2 0.0031549556
depression I-Disease 2 0.9996755
developed O 0 0.043580707
akathisia B-Disease 0 0.99995255
. O 0 0.004268609

The O 0 0.0017203555
typical O 0 0.0026036531
fluoxetine B-Chemical 1 0.99993706
- O 0 0.0030247145
induced O 0 0.00082725496
symptoms O 0 0.011316325
of O 0 0.0009746937
restlessness O 0 0.9774954
, O 0 0.0002822649
constant O 0 0.00021189626
pacing O 0 0.0014764069
, O 0 0.00019094475
purposeless O 0 0.13271558
movements O 0 0.00021183223
of O 0 0.00010469343
the O 0 0.00010569028
feet O 0 0.0024943538
and O 0 0.00019838066
legs O 0 0.009041369
, O 0 0.00012233104
and O 0 0.00010417199
marked O 0 0.00032589314
anxiety B-Disease 0 0.5185187
were O 0 9.0847774e-05
indistinguishable O 0 4.605158e-05
from O 0 7.721801e-05
those O 0 0.00020055467
of O 0 0.0007186103
neuroleptic O 0 0.99997294
- O 0 0.0029464106
induced O 0 0.0042974427
akathisia B-Disease 0 0.99994624
. O 0 0.003957136

Three O 0 0.0019575648
patients O 0 0.0016204887
who O 0 0.0011387555
had O 0 0.0006177506
experienced O 0 0.0015445057
neuroleptic O 0 0.99998176
- O 0 0.0021079117
induced O 0 0.0010182065
akathisia B-Disease 0 0.9999845
in O 0 0.00018421703
the O 0 9.324635e-05
past O 0 5.8224603e-05
reported O 0 6.2642655e-05
that O 0 3.8550876e-05
the O 0 7.486179e-05
symptoms O 0 0.0018521334
of O 0 0.0005891063
fluoxetine B-Chemical 1 0.9999957
- O 0 0.0013120502
induced O 0 0.00081675174
akathisia B-Disease 0 0.9999852
were O 0 0.0002791806
identical O 0 0.00013963926
, O 0 0.00031299875
although O 0 0.00038117304
somewhat O 0 0.0018838546
milder O 0 0.20412947
. O 0 0.0025640235

Akathisia B-Disease 0 0.99851376
appeared O 0 0.0022777747
to O 0 0.00095798646
be O 0 0.0005379774
a O 0 0.0004706377
common O 0 0.00036258227
side O 0 0.0015684994
effect O 0 0.00022374956
of O 0 0.0007288362
fluoxetine B-Chemical 1 0.9999888
and O 0 0.00026433938
generally O 0 0.00013922817
responded O 0 0.00014533543
well O 0 5.02647e-05
to O 0 4.651599e-05
treatment O 0 5.946561e-05
with O 0 9.143661e-05
the O 0 0.00014582739
beta O 0 0.907551
- O 0 0.0015029
adrenergic O 0 0.99753076
antagonist O 0 0.9962817
propranolol B-Chemical 1 0.9999968
, O 0 0.0006611097
dose O 0 0.0017969032
reduction O 0 0.0013519472
, O 0 0.0006261446
or O 0 0.0006362736
both O 0 0.001337073
. O 0 0.0019478366

The O 0 0.0012257636
authors O 0 0.00066690374
suggest O 0 0.0004386751
that O 0 0.0008214719
fluoxetine B-Chemical 1 0.9999778
- O 0 0.0042063026
induced O 0 0.002047789
akathisia B-Disease 0 0.99998486
may O 0 0.0003079453
be O 0 0.00013846054
caused O 0 0.00013165222
by O 0 0.00013067121
serotonergically O 0 0.0033737863
mediated O 0 5.2084117e-05
inhibition O 0 0.00025293345
of O 0 0.00023395015
dopaminergic O 0 0.66882986
neurotransmission O 0 0.3723141
and O 0 6.183902e-05
that O 0 3.092582e-05
the O 0 5.5220713e-05
pathophysiology O 0 0.0009783598
of O 0 0.00040911074
fluoxetine B-Chemical 1 0.99999547
- O 0 0.0007483181
induced O 0 0.00048112866
akathisia B-Disease 0 0.9999927
and O 0 0.0010943292
tricyclic O 0 0.999956
antidepressant B-Chemical 1 0.9999218
- O 0 0.0006114394
induced O 0 0.00032127168
" O 0 0.00070122053
jitteriness O 0 0.98688346
" O 0 0.00058210606
may O 0 0.0003511526
be O 0 0.00050579227
identical O 0 0.0007365496
. O 0 0.0016877715

Effect O 0 0.0025894023
of O 0 0.0025490108
converting O 0 0.014047676
enzyme O 0 0.013391097
inhibition O 0 0.0015654289
on O 0 0.000332603
the O 0 0.00038961612
course O 0 0.00043188504
of O 0 0.0014242323
adriamycin B-Chemical 0 0.9996495
- O 0 0.008612639
induced O 0 0.014138031
nephropathy B-Disease 2 0.9999769
. O 0 0.007612786

The O 0 0.0015273978
effect O 0 0.0011130732
of O 0 0.0010541471
the O 0 0.0007885322
converting O 0 0.010705012
enzyme O 0 0.04100495
inhibitor O 0 0.009775655
( O 0 0.0017537809
CEI O 0 0.9985884
) O 0 0.0029462224
enalapril B-Chemical 1 0.9999881
was O 0 0.00036924393
assessed O 0 0.00012245102
in O 0 0.0001575001
Munich O 0 0.0010728515
- O 0 0.00044446805
Wistar O 0 0.0008923184
rats O 0 0.00029315698
with O 0 0.00036247377
established O 0 0.001497115
adriamycin B-Chemical 0 0.9997451
nephrosis B-Disease 2 0.999946
. O 0 0.005755295

Rats O 0 0.0036547428
were O 0 0.0010631623
given O 0 0.0004317761
a O 0 0.000519804
single O 0 0.0003566296
dose O 0 0.0010564448
of O 0 0.00064936484
adriamycin B-Chemical 0 0.99941087
and O 0 0.00027082628
one O 0 7.919737e-05
month O 0 3.7591464e-05
later O 0 3.2831573e-05
divided O 0 3.200604e-05
into O 0 1.9942194e-05
four O 0 2.8718641e-05
groups O 0 4.6591013e-05
matched O 0 5.1297502e-05
for O 0 0.00010751675
albuminuria B-Disease 2 0.9999751
, O 0 0.00037635918
blood O 0 0.003008931
pressure O 0 0.0027096842
, O 0 0.00026109297
and O 0 0.0003311728
plasma O 0 0.009919616
albumin O 0 0.9662991
concentration O 0 0.0067222826
. O 0 0.002595424

Groups O 0 0.008270014
1 O 0 0.001548015
and O 0 0.001007438
3 O 0 0.00057334115
remained O 0 0.0006368324
untreated O 0 0.00068999146
while O 0 0.00045157937
groups O 0 0.0004078407
2 O 0 0.00032794863
and O 0 0.0004619516
4 O 0 0.00057760486
received O 0 0.0014612307
enalapril B-Chemical 1 0.99984217
. O 0 0.004682667

Groups O 0 0.009113341
1 O 0 0.002012634
and O 0 0.0014130527
2 O 0 0.0009523795
underwent O 0 0.0008734326
micropuncture O 0 0.0018370574
studies O 0 0.0008163082
after O 0 0.0004928157
10 O 0 0.0011366344
days O 0 0.0012703895
. O 0 0.0030738583

These O 0 0.0022252651
short O 0 0.0012438074
- O 0 0.0013601545
term O 0 0.00045110483
studies O 0 0.00037621084
showed O 0 0.00026664283
that O 0 0.0002952666
enalapril B-Chemical 1 0.9999845
reduced O 0 0.0011572317
arterial O 0 0.16655031
blood O 0 0.00816047
pressure O 0 0.0056359246
( O 0 0.00027824257
101 O 0 0.0006369004
+ O 0 0.00030404722
/ O 0 0.0004514068
- O 0 0.00023455857
2 O 0 7.895405e-05
vs O 0 9.708078e-05
. O 0 6.1138555e-05
124 O 0 0.00026087053
+ O 0 0.00024939034
/ O 0 0.00039267165
- O 0 0.00020656876
3 O 0 6.8547604e-05
mm O 0 0.00023195497
Hg O 0 0.44575635
, O 0 0.00014655782
group O 0 0.00013356919
2 O 0 7.315446e-05
vs O 0 9.5352785e-05
. O 0 5.6514582e-05
1 O 0 8.067415e-05
, O 0 0.00015347105
P O 0 0.0014628919
less O 0 9.3363175e-05
than O 0 6.437459e-05
0 O 0 8.5662694e-05
. O 0 7.858756e-05
05 O 0 0.0012138144
) O 0 0.0001445435
and O 0 0.00010928096
glomerular O 0 0.67348534
capillary O 0 0.13009371
pressure O 0 0.0036207358
( O 0 0.00019006271
54 O 0 0.00020459018
+ O 0 0.00024716096
/ O 0 0.0004167592
- O 0 0.00023085687
1 O 0 8.2408944e-05
vs O 0 9.719193e-05
. O 0 5.902195e-05
61 O 0 0.00015143404
+ O 0 0.00022116063
/ O 0 0.00037863178
- O 0 0.0002169216
2 O 0 8.226667e-05
mm O 0 0.00028217043
Hg O 0 0.71154165
, O 0 0.0003130578
P O 0 0.0033532875
less O 0 9.644871e-05
than O 0 6.150321e-05
0 O 0 8.011069e-05
. O 0 7.2425355e-05
05 O 0 0.0011931458
) O 0 0.00012843196
without O 0 7.89548e-05
reducing O 0 0.0003076885
albuminuria B-Disease 2 0.9999889
( O 0 0.0009085511
617 O 0 0.016219327
+ O 0 0.00035970044
/ O 0 0.0004437105
- O 0 0.00021845129
50 O 0 0.00016719248
vs O 0 0.00012511731
. O 0 7.833751e-05
570 O 0 0.02639727
+ O 0 0.00036737495
/ O 0 0.00045102055
- O 0 0.00021948492
47 O 0 0.00018558213
mg O 0 0.0014356518
/ O 0 0.00024717607
day O 0 5.4774024e-05
) O 0 0.0001242385
or O 0 0.00010989322
GFR O 0 0.9964774
( O 0 0.00026671196
1 O 0 9.665826e-05
. O 0 7.4992975e-05
03 O 0 0.0007036995
+ O 0 0.00026557723
/ O 0 0.00041375388
- O 0 0.00023763979
0 O 0 9.363752e-05
. O 0 7.825291e-05
04 O 0 0.0009949551
vs O 0 0.00015665415
. O 0 7.710212e-05
1 O 0 9.374296e-05
. O 0 9.0787325e-05
04 O 0 0.001283127
+ O 0 0.00041482435
/ O 0 0.00060478406
- O 0 0.00036313562
0 O 0 0.00016201196
. O 0 0.00014325397
11 O 0 0.0002658683
ml O 0 0.0007522054
/ O 0 0.0012493071
min O 0 0.0012871296
) O 0 0.0025614945
. O 0 0.0025737209

Groups O 0 0.0074307676
3 O 0 0.0012034589
and O 0 0.0008340366
4 O 0 0.0004417017
were O 0 0.00033154624
studied O 0 0.00025873212
at O 0 0.00012679977
four O 0 9.294682e-05
and O 0 0.00011167512
at O 0 6.585955e-05
six O 0 4.8119706e-05
months O 0 2.9515179e-05
to O 0 4.2410047e-05
assess O 0 2.7170245e-05
the O 0 5.599524e-05
effect O 0 8.057052e-05
of O 0 0.00039836363
enalapril B-Chemical 1 0.99999094
on O 0 0.00014288619
progression O 0 0.013588073
of O 0 0.0008702219
renal B-Disease 2 0.99971455
injury I-Disease 2 0.99792093
in O 0 0.004271261
adriamycin B-Chemical 0 0.99990237
nephrosis B-Disease 2 0.9999629
. O 0 0.006049288

Chronic O 0 0.5042142
enalapril B-Chemical 1 0.9999367
treatment O 0 0.0023430365
reduced O 0 0.0017802235
blood O 0 0.0058222003
pressure O 0 0.004516914
without O 0 0.0005619616
reducing O 0 0.0015968675
albuminuria B-Disease 2 0.9999505
in O 0 0.0014835318
group O 0 0.0016289335
4 O 0 0.0013022163
. O 0 0.0020910148

Untreated O 0 0.02375341
group O 0 0.00219355
3 O 0 0.0006964685
rats O 0 0.00066967396
exhibited O 0 0.00045164008
a O 0 0.00047353146
progressive O 0 0.0061395206
reduction O 0 0.0009958457
in O 0 0.00039071613
GFR O 0 0.9991654
( O 0 0.00038288184
0 O 0 0.00011474535
. O 0 6.8724454e-05
35 O 0 0.000109894376
+ O 0 0.00024153013
/ O 0 0.00041134979
- O 0 0.00023826872
0 O 0 8.754941e-05
. O 0 6.561039e-05
08 O 0 0.00046028572
ml O 0 0.00023466595
/ O 0 0.00018968324
min O 0 8.577124e-05
at O 0 4.9572885e-05
4 O 0 5.1805724e-05
months O 0 3.0600735e-05
, O 0 7.529062e-05
0 O 0 6.892661e-05
. O 0 5.9975424e-05
27 O 0 0.00015681089
+ O 0 0.0002504058
/ O 0 0.0004268106
- O 0 0.00025748104
0 O 0 0.000104249106
. O 0 8.707632e-05
07 O 0 0.0004084278
ml O 0 0.00035668147
/ O 0 0.00036507382
min O 0 0.00023403784
at O 0 0.00020642778
6 O 0 0.00028791552
months O 0 0.0003722528
) O 0 0.0016135274
. O 0 0.002110941

Enalapril B-Chemical 0 0.9998981
treatment O 0 0.0038019267
blunted O 0 0.026732326
but O 0 0.0009471221
did O 0 0.0004695316
not O 0 0.00022600839
prevent O 0 0.00020194471
reduction O 0 0.0005122628
in O 0 0.0002555548
GFR O 0 0.9979134
in O 0 0.00018185488
group O 0 0.0001806031
4 O 0 7.724939e-05
( O 0 0.00011216916
0 O 0 6.9000715e-05
. O 0 5.502207e-05
86 O 0 0.00016499794
+ O 0 0.00024125006
/ O 0 0.00039830833
- O 0 0.00021363625
0 O 0 7.081679e-05
. O 0 4.291395e-05
15 O 0 4.6261004e-05
ml O 0 0.00015270237
/ O 0 0.00015731981
min O 0 7.823545e-05
at O 0 4.6500023e-05
4 O 0 4.90115e-05
months O 0 2.8748458e-05
, O 0 7.06712e-05
0 O 0 6.394294e-05
. O 0 5.4386837e-05
69 O 0 0.00012585368
+ O 0 0.00021060453
/ O 0 0.00036657942
- O 0 0.0002088558
0 O 0 7.312259e-05
. O 0 4.771781e-05
13 O 0 6.85497e-05
ml O 0 0.00016205492
/ O 0 0.0001605354
min O 0 7.7911805e-05
at O 0 4.5683937e-05
6 O 0 4.186117e-05
months O 0 3.0440277e-05
, O 0 8.70803e-05
both O 0 0.00014627876
P O 0 0.0020870045
less O 0 0.00012558971
than O 0 9.328423e-05
0 O 0 0.00013286278
. O 0 0.00014427307
05 O 0 0.0017217416
vs O 0 0.00030656063
. O 0 0.00023730268
group O 0 0.0005638647
3 O 0 0.000686489
) O 0 0.0018568345
. O 0 0.0022033846

Reduction O 0 0.005065462
in O 0 0.0022274037
GFR O 0 0.9939948
was O 0 0.0009912645
associated O 0 0.00035685764
with O 0 0.00030182625
the O 0 0.00019967962
development O 0 0.00035010566
of O 0 0.0005539648
glomerular B-Disease 2 0.9998858
sclerosis I-Disease 2 0.99982685
in O 0 0.00019665367
both O 0 0.00012826882
treated O 0 0.00019910792
and O 0 0.00015348992
untreated O 0 0.0003319523
rats O 0 0.00037302476
. O 0 0.00019703148
( O 0 0.0006129453
ABSTRACT O 0 0.0034454914
TRUNCATED O 0 0.0033114688
AT O 0 0.006099718
250 O 0 0.0032778129
WORDS O 0 0.006726544
) O 0 0.0059677404

Clotiazepam B-Chemical 0 0.9241988
- O 0 0.023249565
induced O 0 0.02429096
acute O 0 0.9978638
hepatitis B-Disease 2 0.99994206
. O 0 0.055449482

We O 0 0.0016035769
report O 0 0.0015763163
the O 0 0.0007748577
case O 0 0.00050560664
of O 0 0.0004739273
a O 0 0.00042921602
patient O 0 0.00034054386
who O 0 0.00043360319
developed O 0 0.0009547127
acute O 0 0.99951565
hepatitis B-Disease 2 0.9999995
with O 0 0.018393096
extensive B-Disease 0 0.14302325
hepatocellular I-Disease 0 0.9999995
necrosis I-Disease 2 0.9999988
, O 0 0.0006291251
7 O 0 5.568607e-05
months O 0 1.7677841e-05
after O 0 1.5715037e-05
the O 0 4.459955e-05
onset O 0 9.471372e-05
of O 0 0.00014255386
administration O 0 0.001023507
of O 0 0.0013121782
clotiazepam B-Chemical 0 0.9999783
, O 0 0.00096208334
a O 0 0.0017715609
thienodiazepine B-Chemical 0 0.9973469
derivative O 0 0.0824357
. O 0 0.0027289623

Clotiazepam B-Chemical 0 0.8497999
withdrawal O 0 0.04041666
was O 0 0.004142727
followed O 0 0.0024243996
by O 0 0.0031865928
prompt O 0 0.007818567
recovery O 0 0.009808895
. O 0 0.0069289454

The O 0 0.0016084311
administration O 0 0.002844846
of O 0 0.0012648585
several O 0 0.000994793
benzodiazepines B-Chemical 1 0.9998479
, O 0 0.0007132565
chemically O 0 0.0013770302
related O 0 0.00011529341
to O 0 0.0003576782
clotiazepam B-Chemical 0 0.9999827
, O 0 0.00029109017
did O 0 0.00012807643
not O 0 6.978893e-05
interfere O 0 5.5637553e-05
with O 0 0.00011840968
recovery O 0 0.00029029176
and O 0 0.00013676978
did O 0 0.00014349433
not O 0 0.00012023595
induce O 0 0.00013514837
any O 0 0.00034318643
relapse O 0 0.38045168
of O 0 0.0062552905
hepatitis B-Disease 2 0.9999614
. O 0 0.0067869127

This O 0 0.0029999472
observation O 0 0.0012165179
shows O 0 0.00052655366
that O 0 0.0007813575
clotiazepam B-Chemical 0 0.99994624
can O 0 0.00042562015
induce O 0 0.00044986958
acute O 0 0.99964094
hepatitis B-Disease 2 0.9999994
and O 0 0.0013063106
suggests O 0 9.1775975e-05
that O 0 7.787757e-05
there O 0 6.5716966e-05
is O 0 0.000101428064
no O 0 8.7255525e-05
cross O 0 0.00091739255
hepatotoxicity B-Disease 0 0.99999404
between O 0 0.0007404562
clotiazepam B-Chemical 0 0.9999633
and O 0 0.00094751205
several O 0 0.0011218138
benzodiazepines B-Chemical 1 0.9995708
. O 0 0.002585811

5 B-Chemical 0 0.0039607235
- I-Chemical 0 0.0058140527
azacytidine I-Chemical 0 0.82474285
potentiates O 0 0.0036739802
initiation B-Disease 0 0.0011283999
induced I-Disease 0 0.001630045
by I-Disease 0 0.0017746531
carcinogens I-Disease 0 0.7700145
in O 0 0.0017689123
rat O 0 0.007283211
liver O 0 0.91769695
. O 0 0.004318586

To O 0 0.0022537722
test O 0 0.0019588002
the O 0 0.0008789376
validity O 0 0.0009232351
of O 0 0.0005730297
the O 0 0.00036713827
hypothesis O 0 0.00040606663
that O 0 0.0002396503
hypomethylation O 0 0.19874822
of O 0 0.00038289465
DNA O 0 0.006244182
plays O 0 7.7230754e-05
an O 0 9.326094e-05
important O 0 3.6507216e-05
role O 0 3.8842813e-05
in O 0 5.229279e-05
the O 0 5.4220814e-05
initiation B-Disease 0 5.7034995e-05
of I-Disease 0 0.0002065215
carcinogenic I-Disease 0 0.97067106
process I-Disease 0 0.00018722759
, O 0 0.00015115693
5 B-Chemical 0 8.328125e-05
- I-Chemical 0 0.00032192937
azacytidine I-Chemical 0 0.93245494
( O 0 0.00027853748
5 B-Chemical 0 9.90263e-05
- I-Chemical 0 0.00034145548
AzC I-Chemical 0 0.39958823
) O 0 0.00026357535
( O 0 0.0001288548
10 O 0 7.899185e-05
mg O 0 0.0015357047
/ O 0 0.0004523846
kg O 0 0.00037043175
) O 0 0.00016095
, O 0 8.445819e-05
an O 0 9.824142e-05
inhibitor O 0 0.000433138
of O 0 0.00027241575
DNA O 0 0.060702793
methylation O 0 0.00904385
, O 0 0.00011716935
was O 0 6.9728136e-05
given O 0 3.1134918e-05
to O 0 4.0694733e-05
rats O 0 6.214003e-05
during O 0 2.1229218e-05
the O 0 4.225717e-05
phase O 0 0.00012664968
of O 0 0.00010535229
repair O 0 0.00020236759
synthesis O 0 0.00040590952
induced O 0 0.00011536027
by O 0 8.31378e-05
the O 0 7.3461844e-05
three O 0 5.9030393e-05
carcinogens O 0 0.6761933
, O 0 0.00044417346
benzo B-Chemical 0 0.99953866
[ I-Chemical 0 0.000964147
a I-Chemical 0 0.00031600244
] I-Chemical 0 0.0006074807
- I-Chemical 0 0.00044269318
pyrene I-Chemical 0 0.94992507
( O 0 0.00020110501
200 O 0 0.00027002
mg O 0 0.0031295696
/ O 0 0.00049605034
kg O 0 0.0004216448
) O 0 0.00024772153
, O 0 0.00027444446
N B-Chemical 0 0.97689974
- I-Chemical 0 0.0013699566
methyl I-Chemical 0 0.99381787
- I-Chemical 0 0.003646846
N I-Chemical 0 0.9942737
- I-Chemical 0 0.001091276
nitrosourea I-Chemical 0 0.98567605
( O 0 0.00022513904
60 O 0 0.000102149635
mg O 0 0.0019609344
/ O 0 0.000434931
kg O 0 0.00035111493
) O 0 0.00016309773
and O 0 9.701081e-05
1 B-Chemical 0 8.258933e-05
, I-Chemical 0 0.00011177207
2 I-Chemical 0 0.00010237822
- I-Chemical 0 0.00033747873
dimethylhydrazine I-Chemical 0 0.8927932
( O 0 0.0002501276
1 B-Chemical 0 0.0001008597
, I-Chemical 0 0.00012790899
2 I-Chemical 0 0.00011643691
- I-Chemical 0 0.00034828734
DMH I-Chemical 0 0.39798105
) O 0 0.00040419164
( O 0 0.00032739292
100 O 0 0.00068631273
mg O 0 0.006642755
/ O 0 0.0022719796
kg O 0 0.0025860118
) O 0 0.0024169176
. O 0 0.0023205203

The O 0 0.0016971946
initiated O 0 0.0015495105
hepatocytes O 0 0.008286204
in O 0 0.0006538062
the O 0 0.0005738348
liver O 0 0.36350825
were O 0 0.00030589907
assayed O 0 0.00017805929
as O 0 0.00013301529
the O 0 0.00020546715
gamma O 0 0.87317836
- O 0 0.0030746623
glutamyltransferase O 0 0.9996332
( O 0 0.0012437747
gamma O 0 0.9604786
- O 0 0.0018717074
GT O 0 0.8432844
) O 0 0.00021282076
positive O 0 9.1682035e-05
foci O 0 5.5044795e-05
formed O 0 7.886946e-05
following O 0 4.4397733e-05
a O 0 0.00010622305
2 O 0 5.907358e-05
- O 0 8.154918e-05
week O 0 2.0775817e-05
selection O 0 4.857977e-05
regimen O 0 6.6860266e-05
consisting O 0 4.367706e-05
of O 0 0.00012528278
dietary O 0 0.010000103
0 O 0 0.000100704296
. O 0 7.156586e-05
02 O 0 0.0011339524
% O 0 0.000121327656
2 B-Chemical 0 0.00010164844
- I-Chemical 0 0.00031500868
acetylaminofluorene I-Chemical 0 0.86563575
coupled O 0 0.00023074949
with O 0 0.00027773477
a O 0 0.0006100627
necrogenic O 0 0.9420051
dose O 0 0.01899631
of O 0 0.008901981
CCl4 B-Chemical 0 0.9999794
. O 0 0.0053578992

The O 0 0.0013962707
results O 0 0.0010830361
obtained O 0 0.0007472457
indicate O 0 0.00031729875
that O 0 0.00025234016
with O 0 0.0003450487
all O 0 0.00023523133
three O 0 0.00013697692
carcinogens O 0 0.44279346
, O 0 0.00024228595
administration O 0 0.00061090925
of O 0 0.00022084269
5 B-Chemical 0 0.000111880094
- I-Chemical 0 0.00028458712
AzC I-Chemical 0 0.063564874
during O 0 4.8665086e-05
repair O 0 0.00016554238
synthesis O 0 0.00031819908
increased O 0 0.0001501476
the O 0 8.9514615e-05
incidence O 0 0.00019146946
of O 0 0.00012169207
initiated O 0 0.0001272807
hepatocytes O 0 0.0285474
, O 0 0.000114784416
for O 0 5.1457915e-05
example O 0 6.543449e-05
10 O 0 7.320911e-05
- O 0 0.00012047569
20 O 0 5.4085096e-05
foci O 0 5.3626216e-05
/ O 0 0.00020432196
cm2 O 0 0.0001647692
in O 0 6.6180764e-05
5 B-Chemical 0 6.6749424e-05
- I-Chemical 0 0.0002448768
AzC I-Chemical 0 0.32284206
and O 0 0.0002638464
carcinogen O 0 0.96570396
- O 0 0.00033482298
treated O 0 0.00014175304
rats O 0 0.000118787175
compared O 0 4.269829e-05
with O 0 9.3668954e-05
3 O 0 6.382397e-05
- O 0 0.0001150891
5 O 0 4.3924338e-05
foci O 0 6.1030438e-05
/ O 0 0.00024013885
cm2 O 0 0.0002169243
in O 0 0.000110051886
rats O 0 0.00025158084
treated O 0 0.0004015645
with O 0 0.00083842187
carcinogen O 0 0.9133805
only O 0 0.0023121017
. O 0 0.0021044912

Administration O 0 0.011423836
of O 0 0.004039566
[ B-Chemical 0 0.010092773
3H I-Chemical 0 0.7074583
] I-Chemical 0 0.0025553058
- I-Chemical 0 0.0009548172
5 I-Chemical 0 0.00028775388
- I-Chemical 0 0.00048096676
azadeoxycytidine I-Chemical 0 0.0016450492
during O 0 8.661354e-05
the O 0 0.00013407541
repair O 0 0.00028898174
synthesis O 0 0.00061926886
induced O 0 0.00022245981
by O 0 0.00017858349
1 B-Chemical 0 0.00011281728
, I-Chemical 0 0.00012474564
2 I-Chemical 0 9.2487426e-05
- I-Chemical 0 0.0002266117
DMH I-Chemical 0 0.17886911
further O 0 0.00013535391
showed O 0 7.1104514e-05
that O 0 5.23698e-05
0 O 0 7.187069e-05
. O 0 6.05221e-05
019 O 0 0.00069708144
mol O 0 0.07552903
% O 0 0.00013880809
of O 0 0.00023040918
cytosine B-Chemical 0 0.8945456
residues O 0 0.0009328276
in O 0 0.0001275458
DNA O 0 0.007156999
were O 0 0.00012322032
substituted O 0 0.0005743196
by O 0 0.00010299403
the O 0 0.00011761565
analogue O 0 0.00088996976
, O 0 0.00012101028
indicating O 0 5.9641206e-05
that O 0 6.822337e-05
incorporation O 0 0.0003470148
of O 0 0.00020968106
5 B-Chemical 0 0.00015888705
- I-Chemical 0 0.00048750892
AzC I-Chemical 0 0.07916754
occurs O 0 0.00026650683
during O 0 0.0002686188
repair O 0 0.0012380016
synthesis O 0 0.0044747777
. O 0 0.0022264735

In O 0 0.0017265576
the O 0 0.0011649006
absence O 0 0.0006197811
of O 0 0.0008970692
the O 0 0.0009227945
carcinogen O 0 0.972651
, O 0 0.00066062086
5 B-Chemical 0 0.00023771751
- I-Chemical 0 0.0005017438
AzC I-Chemical 0 0.061083738
given O 0 6.3652624e-05
after O 0 3.2587144e-05
a O 0 8.478306e-05
two O 0 4.8534206e-05
thirds O 0 0.0001174051
partial O 0 0.00029022282
hepatectomy O 0 0.93626994
, O 0 0.00012601774
when O 0 4.987209e-05
its O 0 0.00016812995
incorporation O 0 0.0002569376
should O 0 3.6493464e-05
be O 0 5.1664625e-05
maximum O 0 6.724373e-05
, O 0 9.7935554e-05
failed O 0 0.00010881698
to O 0 9.3267874e-05
induce O 0 0.00010288065
any O 0 0.00026538662
gamma O 0 0.7990759
- O 0 0.0025572826
GT O 0 0.6004514
positive O 0 0.0014729481
foci O 0 0.001465327
. O 0 0.0021364274

The O 0 0.0016617529
results O 0 0.0013135711
suggest O 0 0.0005845179
that O 0 0.0007101933
hypomethylation O 0 0.0994973
of O 0 0.00090006023
DNA O 0 0.006752213
per O 0 0.00016385513
se O 0 0.00042111095
may O 0 0.00022486657
not O 0 0.00025099097
be O 0 0.00027722365
sufficient O 0 0.00031770862
for O 0 0.0005514756
initiation O 0 0.0012572992
. O 0 0.00238128

Perhaps O 0 0.0025447418
two O 0 0.0010855751
events O 0 0.0017347548
might O 0 0.00042118004
be O 0 0.0003148207
necessary O 0 0.00015321781
for O 0 0.00015028483
initiation O 0 0.00016099542
, O 0 0.0001973592
the O 0 0.00012547264
first O 0 8.6565655e-05
caused O 0 0.00017567018
by O 0 0.00018674978
the O 0 0.00025009402
carcinogen O 0 0.8518442
and O 0 0.00023269016
a O 0 0.00025818852
second O 0 0.00023901663
involving O 0 0.00046498986
hypomethylation O 0 0.16047788
of O 0 0.0017049684
DNA O 0 0.041664016
. O 0 0.0024923284

Antihypertensive O 0 0.98708296
drugs O 0 0.17213953
and O 0 0.0074591395
depression B-Disease 0 0.9713108
: O 0 0.00629965
a O 0 0.006576455
reappraisal O 0 0.026119398
. O 0 0.0074577346

Eighty O 0 0.0041479054
- O 0 0.0025362666
nine O 0 0.0008177384
new O 0 0.00083358603
referral O 0 0.0015779128
hypertensive B-Disease 2 0.99610656
out O 0 0.0003347732
- O 0 0.00046868203
patients O 0 0.00021557642
and O 0 0.00012931552
46 O 0 0.00013430047
new O 0 0.00011662661
referral O 0 0.00021001401
non O 0 0.00017414354
- O 0 0.0004103557
hypertensive B-Disease 2 0.9980527
chronically O 0 0.0010685947
physically O 0 0.00036638582
ill O 0 0.017990686
out O 0 6.919187e-05
- O 0 0.00015209928
patients O 0 9.192488e-05
completed O 0 6.004112e-05
a O 0 0.00015292647
mood O 0 0.5604113
rating O 0 0.00012986528
scale O 0 8.631334e-05
at O 0 6.282285e-05
regular O 0 0.000119676835
intervals O 0 0.00010242518
for O 0 0.000191476
one O 0 0.00041442216
year O 0 0.0007694272
. O 0 0.0015838991

The O 0 0.0015738253
results O 0 0.0013256029
showed O 0 0.0008982379
a O 0 0.00080438476
high O 0 0.00084575935
prevalence O 0 0.00057241664
of O 0 0.00072530593
depression B-Disease 0 0.97092414
in O 0 0.00020123352
both O 0 0.0001545398
groups O 0 0.000121868
of O 0 0.00016131291
patients O 0 0.00024078677
, O 0 0.00016038989
with O 0 0.00016853203
no O 0 0.00012498602
preponderance O 0 0.00072801777
in O 0 0.00029900708
the O 0 0.0007569462
hypertensive B-Disease 2 0.99914706
group O 0 0.0026161862
. O 0 0.0019345337

Hypertensive B-Disease 0 0.99557734
patients O 0 0.0028221833
with O 0 0.0017094185
psychiatric B-Disease 2 0.90532094
histories O 0 0.0007862235
had O 0 0.00029962207
a O 0 0.0002849042
higher O 0 0.00026678416
prevalence O 0 0.00031949527
of O 0 0.000547845
depression B-Disease 0 0.9363147
than O 0 0.0002920286
the O 0 0.00045238677
comparison O 0 0.00069997925
patients O 0 0.0019735121
. O 0 0.0019971556

This O 0 0.004180584
was O 0 0.0017910167
accounted O 0 0.0008903379
for O 0 0.00045877055
by O 0 0.00044903136
a O 0 0.0004062916
significant O 0 0.00023256063
number O 0 0.0001871605
of O 0 0.00034639324
depressions B-Disease 0 0.9234668
occurring O 0 0.00032509872
in O 0 0.00043921318
methyl B-Chemical 0 0.99979275
dopa I-Chemical 0 0.99998987
treated O 0 0.0017442793
patients O 0 0.00089789013
with O 0 0.0011023371
psychiatric B-Disease 2 0.97069675
histories O 0 0.0027370537
. O 0 0.001913823

Chronic B-Disease 0 0.46178305
active I-Disease 0 0.013198479
hepatitis I-Disease 2 0.99993944
associated O 0 0.006355115
with O 0 0.057513848
diclofenac B-Chemical 1 0.999995
sodium I-Chemical 0 0.99993443
therapy O 0 0.10243922
. O 0 0.006217508

Diclofenac B-Chemical 0 0.99990726
sodium I-Chemical 0 0.999887
( O 0 0.029031105
Voltarol B-Chemical 0 0.9995776
, O 0 0.0035999336
Geigy O 0 0.98532176
Pharmaceuticals O 0 0.1251949
) O 0 0.0008003181
is O 0 0.00027152404
a O 0 0.00032602646
non O 0 0.00044540095
- O 0 0.0008541018
steroidal O 0 0.75472033
anti O 0 0.0053663673
- O 0 0.0013152574
inflammatory O 0 0.11005159
derivative O 0 0.034771893
of O 0 0.0055723893
phenylacetic B-Chemical 1 0.99991846
acid I-Chemical 1 0.99894565
. O 0 0.005471791

Although O 0 0.0016344253
generally O 0 0.0014544781
well O 0 0.00094618317
- O 0 0.0015076034
tolerated O 0 0.002963881
, O 0 0.0005125213
asymptomatic O 0 0.002794265
abnormalities B-Disease 0 0.00622739
of I-Disease 0 0.00041582956
liver I-Disease 0 0.58665276
function I-Disease 0 0.0002347521
have O 0 7.895375e-05
been O 0 6.4261796e-05
recorded O 0 7.5836244e-05
and O 0 0.000111591355
, O 0 0.0001350887
less O 0 0.00015268518
commonly O 0 0.00027842674
, O 0 0.00047359688
severe O 0 0.20824623
hepatitis B-Disease 2 0.99998844
induced O 0 0.021672236
by O 0 0.018694796
diclofenac B-Chemical 1 0.99998057
. O 0 0.005061009

The O 0 0.001480522
patient O 0 0.0012700658
described O 0 0.0006876319
developed O 0 0.0012998278
chronic B-Disease 0 0.7263579
active I-Disease 0 0.004321946
hepatitis I-Disease 2 0.99999344
after O 0 0.00011191092
six O 0 6.340847e-05
months O 0 3.3830656e-05
therapy O 0 0.00012170971
with O 0 0.00063197064
diclofenac B-Chemical 1 0.99999964
sodium I-Chemical 0 0.9999908
which O 0 0.00054553966
progressed O 0 0.00029521764
despite O 0 5.98398e-05
the O 0 7.82209e-05
withdrawal O 0 0.0011359932
of O 0 0.0001368384
the O 0 0.00014364492
drug O 0 0.006040109
, O 0 0.0002234777
a O 0 0.00028293522
finding O 0 0.000472123
not O 0 0.00038894388
previously O 0 0.0007566383
reported O 0 0.0017319262
. O 0 0.0020082253

Arterial O 0 0.6080559
hypertension B-Disease 2 0.99929976
as O 0 0.0024757183
a O 0 0.0022170574
complication O 0 0.009176483
of O 0 0.0023309563
prolonged O 0 0.017578531
ketoconazole B-Chemical 1 0.9999609
treatment O 0 0.009853396
. O 0 0.0049954588

Two O 0 0.0020261807
of O 0 0.0015170837
14 O 0 0.00086558005
patients O 0 0.0008364075
with O 0 0.0008694022
Cushing B-Disease 0 0.95451367
' I-Disease 0 0.0005874293
s I-Disease 0 0.00036288088
syndrome I-Disease 0 0.009972218
treated O 0 0.0002589819
on O 0 8.5576474e-05
a O 0 0.00018174342
long O 0 0.00014048173
- O 0 0.00020666055
term O 0 0.00011251389
basis O 0 0.0002021867
with O 0 0.0008926717
ketoconazole B-Chemical 1 0.9999858
developed O 0 0.0056186244
sustained O 0 0.0727252
hypertension B-Disease 2 0.9999155
. O 0 0.0041435515

In O 0 0.0015651309
both O 0 0.0011409421
cases O 0 0.0009387482
normal O 0 0.0009981213
plasma O 0 0.0024796496
and O 0 0.00033169577
urinary O 0 0.014619997
free O 0 0.00055184733
cortisol B-Chemical 0 0.91244465
levels O 0 0.00017042807
had O 0 9.9756464e-05
been O 0 5.349633e-05
achieved O 0 0.00010563013
following O 0 0.0001339028
ketoconazole B-Chemical 1 0.9999964
therapy O 0 0.00053196354
, O 0 0.000120857934
yet O 0 7.353052e-05
continuous O 0 3.885778e-05
blood O 0 0.0003612512
pressure O 0 0.0004606072
monitoring O 0 6.995417e-05
demonstrated O 0 0.00012530848
hypertension B-Disease 2 0.99993896
31 O 0 0.00028061253
( O 0 0.00012402957
patient O 0 8.3824e-05
1 O 0 6.405976e-05
) O 0 9.825238e-05
and O 0 7.114806e-05
52 O 0 0.00010510714
weeks O 0 4.5199162e-05
( O 0 0.00015209349
patient O 0 0.00018369628
2 O 0 0.00020423993
) O 0 0.000399614
after O 0 0.00027619925
treatment O 0 0.001161041
. O 0 0.0020482915

In O 0 0.0022426976
patient O 0 0.001968553
1 O 0 0.001107452
, O 0 0.0010006598
plasma O 0 0.0027095773
levels O 0 0.0006973456
of O 0 0.0017320911
deoxycorticosterone B-Chemical 0 0.9999769
and O 0 0.0016096269
11 B-Chemical 0 0.0009309607
- I-Chemical 0 0.0017201966
deoxycortisol I-Chemical 0 0.96464247
were O 0 0.0016608813
elevated O 0 0.008011053
. O 0 0.0030370525

In O 0 0.002103541
patient O 0 0.0018401853
2 O 0 0.000885534
, O 0 0.00064783986
in O 0 0.00031132798
addition O 0 0.00017914835
to O 0 0.00018920221
an O 0 0.00022930483
increase O 0 0.00016763947
in O 0 0.00015317166
both O 0 0.00036136433
deoxycorticosterone B-Chemical 0 0.9999939
and O 0 0.0004557512
11 B-Chemical 0 0.0002070803
- I-Chemical 0 0.00036962272
deoxycortisol I-Chemical 0 0.9620912
levels O 0 0.00014428627
, O 0 0.00015464654
plasma O 0 0.00875577
aldosterone B-Chemical 0 0.99989843
values O 0 0.00017865808
were O 0 0.00010349219
raised O 0 0.00014485368
, O 0 0.00013397355
with O 0 0.00014987442
a O 0 0.00022857684
concomitant O 0 0.00058585085
suppression O 0 0.0007994188
of O 0 0.0012066518
renin O 0 0.9689275
levels O 0 0.0023790267
. O 0 0.0022381833

Our O 0 0.0021804734
findings O 0 0.0020116188
show O 0 0.0006467818
that O 0 0.00040872168
long O 0 0.00045533048
- O 0 0.00051753584
term O 0 0.00017656188
treatment O 0 0.0001629754
with O 0 0.00017377993
high O 0 0.00034673387
doses O 0 0.0023806659
of O 0 0.0013266867
ketoconazole B-Chemical 1 0.99999666
may O 0 0.00021372222
induce O 0 0.00012508655
enzyme O 0 0.013073923
blockade O 0 0.0089755915
leading O 0 0.00052927417
to O 0 0.00048283502
mineralocorticoid O 0 0.9994655
- O 0 0.0018038325
related O 0 0.000785691
hypertension B-Disease 2 0.99971956
. O 0 0.0028671233

Effects O 0 0.0025622633
of O 0 0.0015302409
an O 0 0.0011314686
inhibitor O 0 0.0025301678
of O 0 0.0019362357
angiotensin B-Chemical 1 0.99996245
converting O 0 0.49610898
enzyme O 0 0.34467405
( O 0 0.0022397437
Captopril B-Chemical 0 0.99998796
) O 0 0.000514844
on O 0 9.7064665e-05
pulmonary B-Disease 0 0.038762193
and I-Disease 0 0.00034785664
renal I-Disease 0 0.9779008
insufficiency I-Disease 0 0.99200445
due O 0 0.00016014492
to O 0 0.00027496097
intravascular B-Disease 0 0.9030029
coagulation I-Disease 0 0.9755229
in O 0 0.00066877145
the O 0 0.00088570156
rat O 0 0.0031262052
. O 0 0.001986496

Induction O 0 0.0038263917
of O 0 0.0027201446
intravascular B-Disease 0 0.8571152
coagulation I-Disease 0 0.9617387
and O 0 0.0007667098
inhibition O 0 0.0011151492
of O 0 0.0008284757
fibrinolysis O 0 0.96462625
by O 0 0.00022569354
injection O 0 0.00017289404
of O 0 0.00024970347
thrombin O 0 0.66301304
and O 0 0.0005771303
tranexamic B-Chemical 0 0.9995894
acid I-Chemical 0 0.9936168
( O 0 0.0023656848
AMCA B-Chemical 0 0.99927837
) O 0 0.00030652207
in O 0 7.1992436e-05
the O 0 7.011233e-05
rat O 0 0.00015522388
gives O 0 8.2816456e-05
rise O 0 0.00010489778
to O 0 7.213648e-05
pulmonary B-Disease 0 0.042439293
and I-Disease 0 0.00025097662
renal I-Disease 0 0.9853585
insufficiency I-Disease 0 0.99543226
resembling O 0 0.00016176792
that O 0 6.2958505e-05
occurring O 0 0.00011498983
after O 0 7.701417e-05
trauma B-Disease 0 0.22174469
or O 0 0.000670004
sepsis B-Disease 2 0.9938776
in O 0 0.0018796856
man O 0 0.064747326
. O 0 0.0023104304

Injection O 0 0.012891273
of O 0 0.005743111
Captopril B-Chemical 0 0.9999362
( O 0 0.0024577242
1 O 0 0.0006236191
mg O 0 0.008253138
/ O 0 0.0013809404
kg O 0 0.00095573824
) O 0 0.0003559739
, O 0 0.00016470681
an O 0 0.00015937594
inhibitor O 0 0.00059762044
of O 0 0.00059008016
angiotensin B-Chemical 1 0.9999808
converting O 0 0.29765713
enzyme O 0 0.17817956
( O 0 0.0009073106
ACE O 0 0.99960357
) O 0 0.00040701884
, O 0 0.00012982542
reduced O 0 0.00017222717
both O 0 0.00015593687
pulmonary B-Disease 0 0.087036714
and I-Disease 0 0.00044455385
renal I-Disease 0 0.98760694
insufficiency I-Disease 0 0.995893
in O 0 0.0004236997
this O 0 0.0006446918
rat O 0 0.0017481752
model O 0 0.0016245487
. O 0 0.0018485605

The O 0 0.0020056844
lung O 0 0.005661779
weights O 0 0.0011596916
were O 0 0.0006393352
lower O 0 0.0005879878
and O 0 0.0005241688
PaO2 O 0 0.3628441
was O 0 0.00033284756
improved O 0 0.00034929422
in O 0 0.00016160002
rats O 0 0.00023013866
given O 0 0.0001231987
this O 0 0.00037752162
enzyme O 0 0.0102177225
- O 0 0.0013187621
blocking O 0 0.0025013373
agent O 0 0.014308957
. O 0 0.0031056863

The O 0 0.0017443533
contents O 0 0.0029241599
of O 0 0.0015101834
albumin O 0 0.8177775
in O 0 0.00055996893
the O 0 0.00035722696
lungs O 0 0.0007741581
were O 0 0.00019767653
not O 0 0.00012841041
changed O 0 0.00015411027
, O 0 0.00015339351
indicating O 0 9.365216e-05
that O 0 0.00018651132
Captopril B-Chemical 0 0.999979
did O 0 0.0003073519
not O 0 0.00014259941
influence O 0 0.00011788435
the O 0 0.0003287704
extravasation O 0 0.015016461
of O 0 0.0012642876
protein O 0 0.003224084
. O 0 0.0023353593

Renal B-Disease 0 0.7595162
damage I-Disease 0 0.8657562
as O 0 0.0014023961
reflected O 0 0.0007235
by O 0 0.00047864456
an O 0 0.0004007941
increase O 0 0.0002917186
in O 0 0.00031627223
serum O 0 0.1694277
urea B-Chemical 0 0.9996648
and O 0 0.00048651086
in O 0 0.00033184758
kidney O 0 0.5967117
weight O 0 0.0047059846
was O 0 0.00069852785
prevented O 0 0.0027668406
by O 0 0.0034503771
Captopril B-Chemical 0 0.9999298
. O 0 0.004289157

The O 0 0.0014916819
amount O 0 0.00087248936
of O 0 0.0011662374
fibrin O 0 0.0066352766
in O 0 0.0004897152
the O 0 0.00040706465
kidneys O 0 0.009262625
was O 0 0.00028244336
also O 0 0.0001560435
considerably O 0 0.00023282088
lower O 0 0.00018681177
than O 0 7.947071e-05
in O 0 9.4116804e-05
animals O 0 9.228111e-05
which O 0 0.00020316547
received O 0 0.00025956874
thrombin O 0 0.45503503
and O 0 0.0015456039
AMCA B-Chemical 0 0.9944746
alone O 0 0.0030506575
. O 0 0.0027123268

It O 0 0.002747144
is O 0 0.0012255155
suggested O 0 0.0005143216
that O 0 0.00032042593
the O 0 0.00032622454
effects O 0 0.0004024856
of O 0 0.001050672
Captopril B-Chemical 0 0.9999813
on O 0 0.00017585621
the O 0 0.00017697515
lungs O 0 0.0004730196
may O 0 8.957003e-05
be O 0 6.437219e-05
attributable O 0 4.5568635e-05
to O 0 5.9640864e-05
a O 0 0.00015250678
vasodilatory O 0 0.30302465
effect O 0 8.514344e-05
due O 0 4.662786e-05
to O 0 5.8182748e-05
a O 0 0.000103254235
reduction O 0 0.00019274178
in O 0 6.1848514e-05
the O 0 6.434298e-05
circulating O 0 0.0003069431
level O 0 6.5844244e-05
of O 0 0.00023001143
Angiotension B-Chemical 0 0.8122882
II I-Chemical 0 0.08184254
and O 0 0.00010510032
an O 0 0.00011550623
increase O 0 0.00012747808
in O 0 0.00032276497
prostacyclin B-Chemical 0 0.99998856
( O 0 0.00043587582
secondary O 0 0.0004160958
to O 0 0.00014226652
an O 0 0.0002796148
increase O 0 0.00039704598
in O 0 0.00099879
bradykinin B-Chemical 1 0.9997327
) O 0 0.004837559
. O 0 0.0023567819

Captopril B-Chemical 0 0.99977535
may O 0 0.0028078265
, O 0 0.0015801874
by O 0 0.00068247266
the O 0 0.00037445294
same O 0 0.0001906764
mechanism O 0 0.00030062807
, O 0 0.00022714036
reduce O 0 0.0001009077
the O 0 0.00011406733
increase O 0 0.00011176279
in O 0 0.00012131528
glomerular O 0 0.8215011
filtration O 0 0.005680583
that O 0 7.610965e-05
is O 0 8.215214e-05
known O 0 8.384287e-05
to O 0 4.6174617e-05
occur O 0 3.2632575e-05
after O 0 1.7899885e-05
an O 0 6.29764e-05
injection O 0 8.52302e-05
of O 0 0.00017424385
thrombin O 0 0.5134636
, O 0 0.000119756056
thereby O 0 8.4158564e-05
diminishing O 0 0.00016425326
the O 0 7.2537114e-05
aggregation O 0 0.0016847181
of O 0 0.00016786934
fibrin O 0 0.013648654
monomers O 0 0.00031785772
in O 0 6.0923852e-05
the O 0 7.438118e-05
glomeruli O 0 0.002514599
, O 0 9.122802e-05
with O 0 7.3242765e-05
the O 0 5.3301705e-05
result O 0 4.7607227e-05
that O 0 4.4762743e-05
less O 0 0.000108926826
fibrin O 0 0.0044806274
will O 0 8.4690786e-05
be O 0 7.779154e-05
deposited O 0 0.0002335481
and O 0 0.000119610675
thus O 0 0.00020100092
less O 0 0.00041999784
kidney B-Disease 0 0.99684745
damage I-Disease 0 0.9797696
will O 0 0.0007215727
be O 0 0.0007135753
produced O 0 0.00122395
. O 0 0.0019484485

Stroke B-Disease 0 0.72487587
associated O 0 0.008695193
with O 0 0.013170475
cocaine B-Chemical 1 0.9972941
use O 0 0.014057538
. O 0 0.01137345

We O 0 0.0011838642
describe O 0 0.0008031463
eight O 0 0.0005357765
patients O 0 0.0006600092
in O 0 0.00043390444
whom O 0 0.0016282403
cocaine B-Chemical 1 0.99958485
use O 0 0.0003084045
was O 0 0.00018624404
related O 0 7.608891e-05
to O 0 0.0002042259
stroke B-Disease 0 0.9832197
and O 0 0.00035957652
review O 0 0.0005605638
39 O 0 0.0003793535
cases O 0 0.00032496022
from O 0 0.00031757719
the O 0 0.0006796738
literature O 0 0.0022289285
. O 0 0.0021137435

Among O 0 0.0028763094
these O 0 0.001641618
47 O 0 0.0013828395
patients O 0 0.00063614873
the O 0 0.0003229589
mean O 0 0.000193731
( O 0 0.00046127665
+ O 0 0.0006522602
/ O 0 0.0010978387
- O 0 0.0007812458
SD O 0 0.0044830916
) O 0 0.00035948106
age O 0 0.00018813739
was O 0 0.00014609963
32 O 0 0.00015102263
. O 0 6.776121e-05
5 O 0 7.7415985e-05
+ O 0 0.00023469189
/ O 0 0.0004342776
- O 0 0.00024546683
12 O 0 6.515454e-05
. O 0 6.4033375e-05
1 O 0 8.377158e-05
years O 0 9.258422e-05
; O 0 0.00014185689
76 O 0 0.00022717676
% O 0 0.00019024729
( O 0 0.00025647282
34 O 0 0.0002987085
/ O 0 0.00061537157
45 O 0 0.00038230413
) O 0 0.00079252484
were O 0 0.0009820014
men O 0 0.00386597
. O 0 0.002112371

Stroke B-Disease 0 0.85619193
followed O 0 0.003176337
cocaine B-Chemical 1 0.99840206
use O 0 0.0011759571
by O 0 0.0008356618
inhalation O 0 0.012935489
, O 0 0.0007028195
intranasal O 0 0.0014377218
, O 0 0.0007086377
intravenous O 0 0.0117848385
, O 0 0.0007467868
and O 0 0.0008484554
intramuscular O 0 0.0061885715
routes O 0 0.0026021725
. O 0 0.0023241884

Intracranial B-Disease 0 0.59966075
aneurysms I-Disease 2 0.9985877
or O 0 0.0019474735
arteriovenous B-Disease 0 0.13410768
malformations I-Disease 0 0.9711259
were O 0 0.0003573009
present O 0 0.00014830129
in O 0 0.00013195664
17 O 0 0.00013754863
of O 0 0.00011262251
32 O 0 0.00012621195
patients O 0 0.00011845022
studied O 0 0.00012954407
angiographically O 0 0.2062852
or O 0 8.4773514e-05
at O 0 8.135872e-05
autopsy O 0 0.0063687917
; O 0 0.00045156386
cerebral B-Disease 0 0.99872273
vasculitis I-Disease 2 0.9999751
was O 0 0.0004900928
present O 0 0.00022249439
in O 0 0.00033276604
two O 0 0.00044614458
patients O 0 0.0015806599
. O 0 0.0017625624

Cerebral B-Disease 0 0.9898144
infarction I-Disease 2 0.9999101
occurred O 0 0.0015281629
in O 0 0.0006920373
10 O 0 0.000471359
patients O 0 0.0005391753
( O 0 0.00041460159
22 O 0 0.0002919314
% O 0 0.00025076084
) O 0 0.00032383204
, O 0 0.00029008702
intracerebral B-Disease 0 0.8924482
hemorrhage I-Disease 2 0.9997893
in O 0 0.00023427137
22 O 0 0.00021445239
( O 0 0.00017630818
49 O 0 0.0001777141
% O 0 0.0001407115
) O 0 0.0001958453
, O 0 0.00015987991
and O 0 0.00027882974
subarachnoid B-Disease 0 0.99095505
hemorrhage I-Disease 2 0.99962986
in O 0 0.00039174518
13 O 0 0.00040867785
( O 0 0.00056340755
29 O 0 0.00091358065
% O 0 0.0010460863
) O 0 0.002095505
. O 0 0.0022789412

These O 0 0.0021723306
data O 0 0.0014679268
indicate O 0 0.00059457676
that O 0 0.00052648084
( O 0 0.00081152405
1 O 0 0.0003534315
) O 0 0.0003603445
the O 0 0.00017453618
apparent O 0 0.00023666436
incidence O 0 0.00045140597
of O 0 0.0004585301
stroke B-Disease 0 0.9927308
related O 0 8.594441e-05
to O 0 0.00019715815
cocaine B-Chemical 1 0.999705
use O 0 0.00014672033
is O 0 0.00010359744
increasing O 0 0.00015549082
; O 0 0.00016165766
( O 0 0.00015019703
2 O 0 8.86807e-05
) O 0 0.00029962463
cocaine B-Chemical 1 0.9995834
- O 0 0.00047416295
associated O 0 0.00016353486
stroke B-Disease 0 0.98643386
occurs O 0 8.167868e-05
primarily O 0 9.446442e-05
in O 0 8.7832035e-05
young O 0 0.0008811514
adults O 0 0.00039416054
; O 0 0.00013333277
( O 0 0.00012843269
3 O 0 6.720879e-05
) O 0 0.00019987696
stroke B-Disease 0 0.90411884
may O 0 5.8283986e-05
follow O 0 3.066574e-05
any O 0 3.459494e-05
route O 0 6.412345e-05
of O 0 0.00017308851
cocaine B-Chemical 1 0.9998233
administration O 0 0.005520189
; O 0 0.00019437545
( O 0 0.00013706392
4 O 0 6.397429e-05
) O 0 0.00019443959
stroke B-Disease 0 0.94254035
after O 0 6.515212e-05
cocaine B-Chemical 1 0.9993413
use O 0 9.201679e-05
is O 0 5.720772e-05
frequently O 0 4.1977702e-05
associated O 0 4.273288e-05
with O 0 0.00012755212
intracranial B-Disease 0 0.98826116
aneurysms I-Disease 2 0.99991333
and O 0 0.00037563243
arteriovenous B-Disease 0 0.19241454
malformations I-Disease 0 0.9958882
; O 0 0.00023540904
and O 0 0.00012058994
( O 0 0.00013214035
5 O 0 5.96395e-05
) O 0 0.0001279778
in O 0 0.00013619805
cocaine B-Chemical 1 0.99975115
- O 0 0.00058697263
associated O 0 0.00021470607
stroke B-Disease 0 0.9955338
, O 0 0.00015595724
the O 0 8.198989e-05
frequency O 0 0.000114516784
of O 0 0.00029583977
intracranial B-Disease 0 0.9958384
hemorrhage I-Disease 2 0.9999664
exceeds O 0 0.00028881239
that O 0 0.00026944448
of O 0 0.0012859729
cerebral B-Disease 0 0.9901562
infarction I-Disease 2 0.9999403
. O 0 0.0043039816

A O 0 0.011449577
randomized O 0 0.001983521
comparison O 0 0.0011364915
of O 0 0.0026956724
labetalol B-Chemical 0 0.99998224
and O 0 0.011478408
nitroprusside B-Chemical 0 0.9999808
for O 0 0.0025918223
induced O 0 0.0077413414
hypotension B-Disease 0 0.99965036
. O 0 0.0060732597

In O 0 0.0015583794
a O 0 0.0014499658
randomized O 0 0.0010641402
study O 0 0.00090162375
, O 0 0.001510287
labetalol B-Chemical 0 0.9999945
- O 0 0.0026721188
induced O 0 0.0010438965
hypotension B-Disease 0 0.9999449
and O 0 0.008525439
nitroprusside B-Chemical 0 0.9999989
- O 0 0.00215947
induced O 0 0.00045200836
hypotension B-Disease 0 0.99981016
were O 0 0.00012983807
compared O 0 4.1794116e-05
in O 0 5.304037e-05
20 O 0 7.01301e-05
patients O 0 0.000112557886
( O 0 9.786844e-05
10 O 0 5.521229e-05
in O 0 5.5412514e-05
each O 0 4.6792808e-05
group O 0 0.00015179807
) O 0 0.00018747109
scheduled O 0 9.32636e-05
for O 0 0.00015217863
major O 0 0.00040046216
orthopedic O 0 0.0021022714
procedures O 0 0.0013566485
. O 0 0.0018167398

Each O 0 0.0012031627
patient O 0 0.0013311267
was O 0 0.00069575745
subjected O 0 0.0002716833
to O 0 0.00024037433
an O 0 0.00024363
identical O 0 0.00013814088
anesthetic O 0 0.0034144642
protocol O 0 0.00021290075
and O 0 0.00012427228
similar O 0 9.001494e-05
drug O 0 0.006286267
- O 0 0.00024320246
induced O 0 9.845703e-05
reductions B-Disease 0 0.00010733258
in I-Disease 0 5.4353863e-05
mean I-Disease 0 3.9674855e-05
arterial I-Disease 0 0.0037968536
blood I-Disease 0 0.0017262971
pressure I-Disease 0 0.0033358159
( O 0 0.00038815013
BP O 0 0.57722956
) O 0 0.000400011
( O 0 0.00028173576
50 O 0 0.0003211673
to O 0 0.0002903402
55 O 0 0.0006619986
mmHg O 0 0.0017989043
) O 0 0.0019781026
. O 0 0.002083529

Nitroprusside O 0 0.99957925
infusion O 0 0.007929408
was O 0 0.0011887306
associated O 0 0.0004907287
with O 0 0.00049553165
a O 0 0.00049723365
significant O 0 0.00035852648
( O 0 0.00044152958
p O 0 0.00018810423
less O 0 0.000129054
than O 0 8.801768e-05
0 O 0 0.00011299083
. O 0 9.874822e-05
05 O 0 0.0016708623
) O 0 0.00015119181
increase B-Disease 0 7.489285e-05
in I-Disease 0 7.7102864e-05
heart I-Disease 0 0.001958543
rate I-Disease 0 0.00010272105
and I-Disease 0 9.328147e-05
cardiac I-Disease 0 0.0027384548
output I-Disease 0 0.00014051094
; O 0 0.0001770403
rebound O 0 0.05182275
hypertension B-Disease 2 0.99996364
was O 0 0.00017521482
observed O 0 6.50513e-05
in O 0 6.1025432e-05
three O 0 4.5640478e-05
patients O 0 0.00013852962
after O 0 0.000101652215
discontinuation O 0 0.01409394
of O 0 0.0034519746
nitroprusside B-Chemical 0 0.9999732
. O 0 0.0042216294

Labetalol B-Chemical 0 0.99978334
administration O 0 0.024848348
was O 0 0.0019647381
not O 0 0.0008619734
associated O 0 0.00073542946
with O 0 0.00087754766
any O 0 0.0007336906
of O 0 0.0012859753
these O 0 0.0021638917
findings O 0 0.0048972955
. O 0 0.003770304

Arterial O 0 0.43904144
PO2 B-Chemical 0 0.99325985
decreased O 0 0.01001549
in O 0 0.0047263075
both O 0 0.005319108
groups O 0 0.00645572
. O 0 0.0077984403

It O 0 0.0038291733
was O 0 0.0022580891
concluded O 0 0.0014337772
that O 0 0.0019345527
labetalol B-Chemical 0 0.9999232
offers O 0 0.0022556065
advantages O 0 0.0011285772
over O 0 0.0020902886
nitroprusside B-Chemical 0 0.9998735
. O 0 0.0076140976

Sodium B-Chemical 0 0.99791986
status O 0 0.0027866606
influences O 0 0.0020885088
chronic O 0 0.8537808
amphotericin B-Chemical 0 0.9999043
B I-Chemical 0 0.9987295
nephrotoxicity B-Disease 0 0.99998534
in O 0 0.008733954
rats O 0 0.008788616
. O 0 0.0041808337

The O 0 0.0023898284
nephrotoxic B-Disease 2 0.9931293
potential O 0 0.001981118
of O 0 0.004009657
amphotericin B-Chemical 0 0.99991536
B I-Chemical 0 0.98908794
( O 0 0.0010103744
5 O 0 0.00022264167
mg O 0 0.0035545896
/ O 0 0.000518956
kg O 0 0.00022094294
per O 0 2.993568e-05
day O 0 3.4384244e-05
intraperitoneally O 0 7.2482355e-05
for O 0 4.6891353e-05
3 O 0 4.6281217e-05
weeks O 0 2.8071274e-05
) O 0 9.404907e-05
has O 0 4.4296143e-05
been O 0 4.6976573e-05
investigated O 0 6.4264976e-05
in O 0 0.00015606062
salt O 0 0.9971878
- O 0 0.00055987824
depleted O 0 0.0002065065
, O 0 0.00021154944
normal O 0 0.00076293375
- O 0 0.0009049916
salt O 0 0.9916204
, O 0 0.0005049252
and O 0 0.0006285488
salt O 0 0.991396
- O 0 0.0014632464
loaded O 0 0.00094048405
rats O 0 0.0023456505
. O 0 0.0020046476

In O 0 0.0036425688
salt O 0 0.99407345
- O 0 0.0031332907
depleted O 0 0.0009748525
rats O 0 0.0013084324
, O 0 0.0012118258
amphotericin B-Chemical 0 0.99986386
B I-Chemical 0 0.97177356
decreased O 0 0.0065927473
creatinine B-Chemical 1 0.99970514
clearance O 0 0.0260354
linearly O 0 0.00024457395
with O 0 0.00015788124
time O 0 6.7058085e-05
, O 0 0.0001266904
with O 0 0.00014029471
an O 0 0.0002078046
85 O 0 0.00031180828
% O 0 0.000237032
reduction O 0 0.0005659091
by O 0 0.0004735951
week O 0 0.0004002452
3 O 0 0.0008140978
. O 0 0.0015694092

In O 0 0.0019261423
contrast O 0 0.0019477634
, O 0 0.001192932
in O 0 0.00064015685
normal O 0 0.0014657825
- O 0 0.0015542242
salt O 0 0.9918812
rats O 0 0.0014419477
creatinine B-Chemical 1 0.9993131
clearance O 0 0.037993256
was O 0 0.00025552922
decreased O 0 0.00035363133
but O 0 0.00013234717
to O 0 8.183024e-05
a O 0 0.00015103877
lesser O 0 0.0002792666
extent O 0 4.585066e-05
at O 0 3.7761412e-05
week O 0 3.050281e-05
2 O 0 3.9981212e-05
and O 0 5.296819e-05
3 O 0 4.468964e-05
, O 0 6.4076004e-05
and O 0 7.276686e-05
in O 0 0.00012088641
salt O 0 0.9914859
- O 0 0.00026461226
loaded O 0 8.7671375e-05
rats O 0 0.00025813733
creatinine B-Chemical 1 0.9975923
clearance O 0 0.0077044573
did O 0 0.000105647254
not O 0 5.6961013e-05
change O 0 6.0823662e-05
for O 0 4.576159e-05
2 O 0 4.9465267e-05
weeks O 0 2.71956e-05
and O 0 7.786287e-05
was O 0 0.00012356778
decreased O 0 0.00028471116
by O 0 0.00021146113
43 O 0 0.00031658233
% O 0 0.00023832185
at O 0 0.00022620801
week O 0 0.00033657267
3 O 0 0.0007461281
. O 0 0.0015177398

All O 0 0.001665346
rats O 0 0.0015582638
in O 0 0.00079019234
the O 0 0.0010541712
sodium B-Chemical 0 0.99946886
- O 0 0.0015704317
depleted O 0 0.00039807527
group O 0 0.0003646158
had O 0 0.00020140686
histopathological O 0 0.0031664665
evidence O 0 9.0846224e-05
of O 0 0.00014026396
patchy O 0 0.0006601193
tubular O 0 0.15469633
cytoplasmic O 0 0.00033216632
degeneration O 0 0.9457448
in O 0 0.00010299766
tubules O 0 0.00034118508
that O 0 4.6431425e-05
was O 0 6.791368e-05
not O 0 4.6827587e-05
observed O 0 4.907351e-05
in O 0 6.0309678e-05
any O 0 7.696857e-05
normal O 0 0.00048773485
- O 0 0.0007533144
salt O 0 0.99134773
or O 0 0.00077144353
salt O 0 0.99608886
- O 0 0.0016893148
loaded O 0 0.0010171288
rat O 0 0.003703505
. O 0 0.0021070584

Concentrations O 0 0.026522325
of O 0 0.0053927274
amphotericin B-Chemical 0 0.9997212
B I-Chemical 0 0.9393698
in O 0 0.00093637296
plasma O 0 0.006472624
were O 0 0.00028680183
not O 0 0.00015549452
significantly O 0 0.00018514683
different O 0 8.1520644e-05
among O 0 0.00010868715
the O 0 8.274108e-05
three O 0 5.1012274e-05
groups O 0 8.5361964e-05
at O 0 7.1258735e-05
any O 0 0.00010976451
time O 0 0.00011513543
during O 0 0.00019008662
the O 0 0.0005999251
study O 0 0.0014802838
. O 0 0.0019262633

However O 0 0.0026002477
, O 0 0.0016228033
at O 0 0.00057434995
the O 0 0.00045664338
end O 0 0.00024119622
of O 0 0.0003550546
3 O 0 0.00018056453
weeks O 0 9.836074e-05
, O 0 0.00038989927
amphotericin B-Chemical 0 0.9997894
B I-Chemical 0 0.89406776
levels O 0 0.0002494843
in O 0 0.00012587266
the O 0 0.00012785179
kidneys O 0 0.012288341
and O 0 0.00020118516
liver O 0 0.5401375
were O 0 0.00011506596
significantly O 0 0.000109429246
higher O 0 0.00010632175
in O 0 0.0001431131
salt O 0 0.9969416
- O 0 0.00035716366
depleted O 0 0.00011501528
and O 0 0.00011228591
normal O 0 0.0005124085
- O 0 0.0004978782
salt O 0 0.9879579
rats O 0 0.0001828414
than O 0 4.367469e-05
those O 0 9.6684074e-05
in O 0 0.00011567643
salt O 0 0.99352264
- O 0 0.00027997894
loaded O 0 8.461393e-05
rats O 0 0.00013818621
, O 0 8.074565e-05
with O 0 0.00010482948
plasma O 0 0.0024361103
/ O 0 0.000555922
kidney O 0 0.30191034
ratios O 0 0.0001611501
of O 0 0.00012029857
21 O 0 9.2134615e-05
, O 0 8.0323414e-05
14 O 0 5.69083e-05
, O 0 7.0732436e-05
and O 0 6.888961e-05
8 O 0 5.761472e-05
in O 0 0.000110957466
salt O 0 0.9902974
- O 0 0.00042047916
depleted O 0 0.00017420332
, O 0 0.00018183928
normal O 0 0.00065605453
- O 0 0.00078306
salt O 0 0.99281716
, O 0 0.00037267857
and O 0 0.0004346937
salt O 0 0.9933281
- O 0 0.00079405564
loaded O 0 0.00041545968
rats O 0 0.00097048946
, O 0 0.0010775251
respectively O 0 0.0026147894
. O 0 0.002155623

In O 0 0.0017814889
conclusion O 0 0.0012469806
, O 0 0.0010152251
reductions O 0 0.0006967214
in O 0 0.00056786963
creatinine B-Chemical 1 0.99657047
clearance O 0 0.025239853
and O 0 0.0006374408
renal O 0 0.9956247
amphotericin B-Chemical 0 0.9999763
B I-Chemical 0 0.9712781
accumulation O 0 0.00063208473
after O 0 7.4580545e-05
chronic O 0 0.6979213
amphotericin B-Chemical 0 0.9999809
B I-Chemical 0 0.9883958
administration O 0 0.004502593
were O 0 0.00014417818
enhanced O 0 0.00020166069
by O 0 0.0002593597
salt O 0 0.99482334
depletion O 0 0.0010561001
and O 0 0.00024173681
attenuated O 0 0.0007269422
by O 0 0.00060963165
sodium B-Chemical 0 0.9992592
loading O 0 0.0014397034
in O 0 0.0008818679
rats O 0 0.0021956638
. O 0 0.0018168712

Flestolol B-Chemical 1 0.93648005
: O 0 0.0034682984
an O 0 0.0021992957
ultra O 0 0.045441583
- O 0 0.0018776176
short O 0 0.0006265652
- O 0 0.0011650115
acting O 0 0.0013522021
beta O 0 0.8677091
- O 0 0.0041399873
adrenergic O 0 0.9633013
blocking O 0 0.0056896284
agent O 0 0.01992675
. O 0 0.0038027633

Flestolol B-Chemical 1 0.9836553
( O 0 0.0065378766
ACC B-Chemical 0 0.1772996
- I-Chemical 0 0.004007378
9089 I-Chemical 0 0.015090703
) O 0 0.0010670049
is O 0 0.0004208168
a O 0 0.00057466875
nonselective O 0 0.48061615
, O 0 0.00049344363
competitive O 0 0.0037722473
, O 0 0.00034677028
ultra O 0 0.0592195
- O 0 0.00037998252
short O 0 0.00010975111
- O 0 0.0002556252
acting O 0 0.00030845508
beta O 0 0.89113873
- O 0 0.0010959964
adrenergic O 0 0.95194006
blocking O 0 0.0006912914
agent O 0 0.0015283631
, O 0 0.00023136743
without O 0 0.00017660043
any O 0 0.00022611098
intrinsic O 0 0.00062440394
sympathomimetic O 0 0.8934908
activity O 0 0.0016404383
. O 0 0.0020287705

Flestolol B-Chemical 1 0.97899127
is O 0 0.003997283
metabolized O 0 0.65773576
by O 0 0.0015585709
plasma O 0 0.05792716
esterases O 0 0.6583267
and O 0 0.00048116333
has O 0 0.00018696803
an O 0 0.00022844718
elimination O 0 0.00032718197
half O 0 0.00016481821
- O 0 0.00031949495
life O 0 0.00020478184
of O 0 0.00022357404
approximately O 0 0.00027619844
6 O 0 0.00020283663
. O 0 0.00024169855
5 O 0 0.00040240237
minutes O 0 0.00070957025
. O 0 0.0018185837

This O 0 0.0040160036
agent O 0 0.005412588
was O 0 0.001166489
well O 0 0.00053168525
tolerated O 0 0.001768877
in O 0 0.00028565706
healthy O 0 0.00073169614
volunteers O 0 0.00026623206
at O 0 0.00010052364
doses O 0 0.0005123876
up O 0 0.00016175635
to O 0 0.00015277838
100 O 0 0.000524288
micrograms O 0 0.0023166507
/ O 0 0.0015182024
kg O 0 0.0014495503
/ O 0 0.0018232212
min O 0 0.0017181097
. O 0 0.0022744474

In O 0 0.0019193524
long O 0 0.0014324724
- O 0 0.0013677255
term O 0 0.00049241324
infusion O 0 0.00089478906
studies O 0 0.00037954628
, O 0 0.00041292407
flestolol B-Chemical 0 0.9299582
was O 0 0.00023369714
well O 0 0.00010448178
tolerated O 0 0.00044436153
at O 0 5.3508982e-05
the O 0 8.489479e-05
effective O 0 0.00013906577
beta O 0 0.8783422
- O 0 0.00046431637
blocking O 0 0.000361665
dose O 0 0.0012165443
( O 0 0.00017494938
5 O 0 6.3467094e-05
micrograms O 0 0.0005022381
/ O 0 0.00037711428
kg O 0 0.0003039823
/ O 0 0.00029496162
min O 0 0.00017798613
) O 0 0.00022065894
for O 0 0.00013069886
up O 0 0.00025181458
to O 0 0.00031773376
seven O 0 0.00051330606
days O 0 0.0006352932
. O 0 0.0017208247

Flestolol B-Chemical 1 0.9626122
blood O 0 0.011088284
concentrations O 0 0.0024115306
increased O 0 0.0009599663
linearly O 0 0.00052222505
with O 0 0.0003593142
increasing O 0 0.0003096685
dose O 0 0.00091761106
and O 0 0.00016440777
good O 0 0.00019409892
correlation O 0 6.819683e-05
exists O 0 5.8856986e-05
between O 0 5.095699e-05
blood O 0 0.0005934244
concentrations O 0 0.00033830016
of O 0 0.00040446667
flestolol B-Chemical 0 0.984194
and O 0 0.00086671277
beta O 0 0.9311626
- O 0 0.004257042
adrenergic O 0 0.9842562
blockade O 0 0.1547558
. O 0 0.00264774

Flestolol B-Chemical 1 0.9072657
produced O 0 0.0025016465
a O 0 0.0022204055
dose O 0 0.0049976823
- O 0 0.0013214312
dependent O 0 0.00034885795
attenuation O 0 0.0013927454
of O 0 0.0024436028
isoproterenol B-Chemical 0 0.99979824
- O 0 0.0059861466
induced O 0 0.004750394
tachycardia B-Disease 2 0.99787664
. O 0 0.004215444

Electrophysiologic O 0 0.075324126
and O 0 0.0016365101
hemodynamic O 0 0.0037477894
effects O 0 0.0008140439
of O 0 0.001061533
flestolol B-Chemical 0 0.96417636
are O 0 0.00038635006
similar O 0 0.00018927925
to O 0 0.00023720608
those O 0 0.00041192718
of O 0 0.000602378
other O 0 0.0011086405
beta O 0 0.96994656
blockers O 0 0.99884737
. O 0 0.004606352

In O 0 0.0015998046
contrast O 0 0.0014961218
with O 0 0.0011028124
other O 0 0.0010678199
beta O 0 0.9810253
blockers O 0 0.99965954
, O 0 0.002108284
flestolol B-Chemical 0 0.9978278
- O 0 0.0008170821
induced O 0 0.00021667789
effects O 0 0.00024006034
reverse O 0 0.0014781794
rapidly O 0 0.00026604783
( O 0 0.00010947653
within O 0 2.2306558e-05
30 O 0 3.6443213e-05
minutes O 0 3.6396916e-05
) O 0 9.098919e-05
following O 0 5.66846e-05
discontinuation O 0 0.0009366566
because O 0 8.427219e-05
of O 0 0.00018822102
its O 0 0.00032403955
short O 0 0.00024331518
half O 0 0.00037370707
- O 0 0.0011835097
life O 0 0.0016720671
. O 0 0.0020013247

Flestolol B-Chemical 1 0.9195209
effectively O 0 0.0030017162
reduced O 0 0.002729911
heart O 0 0.017571721
rate O 0 0.0011200423
in O 0 0.00075104507
patients O 0 0.0011550587
with O 0 0.002064746
supraventricular B-Disease 0 0.9991443
tachyarrhythmia I-Disease 0 0.99980944
. O 0 0.005814673

In O 0 0.0016565622
patients O 0 0.0016727659
with O 0 0.0015611107
unstable B-Disease 0 0.6997931
angina I-Disease 0 0.9999691
, O 0 0.0019341818
flestolol B-Chemical 0 0.9935309
infusion O 0 0.0016250049
was O 0 0.0002556062
found O 0 0.00012770451
to O 0 0.00011602196
be O 0 0.000121484074
safe O 0 0.0001853464
and O 0 0.00015028955
effective O 0 0.00016361299
in O 0 0.0002611654
controlling O 0 0.0005008958
chest B-Disease 0 0.044010006
pain I-Disease 0 0.7846814
. O 0 0.0030270505

It O 0 0.0026855157
is O 0 0.0012471748
concluded O 0 0.0007123278
that O 0 0.0006824882
flestolol B-Chemical 0 0.97426504
is O 0 0.00061863346
a O 0 0.0005170827
potent O 0 0.00076106185
, O 0 0.00034126444
well O 0 0.00020686974
- O 0 0.0005125085
tolerated O 0 0.0017392839
, O 0 0.00027395794
ultra O 0 0.053134996
- O 0 0.0004207627
short O 0 0.00014703558
- O 0 0.00036622066
acting O 0 0.0005157536
beta O 0 0.836301
- O 0 0.0022585553
adrenergic O 0 0.94558275
blocking O 0 0.0036159926
agent O 0 0.012570072
. O 0 0.002698507

Use O 0 0.0056382953
of O 0 0.0029794117
flestolol B-Chemical 0 0.8902592
in O 0 0.0010021055
the O 0 0.0006077934
critical O 0 0.0004650284
care O 0 0.00058660965
setting O 0 0.0004556274
is O 0 0.0005852147
currently O 0 0.0009163622
undergoing O 0 0.0014150579
investigation O 0 0.0025263964
. O 0 0.0025938742

Immunohistochemical O 0 0.005403137
, O 0 0.0022289327
electron O 0 0.0037082108
microscopic O 0 0.0012312704
and O 0 0.00044237252
morphometric O 0 0.0006711261
studies O 0 0.0003481111
of O 0 0.0007948308
estrogen B-Chemical 1 0.999835
- O 0 0.0010174242
induced O 0 0.00045729868
rat O 0 0.0021715125
prolactinomas B-Disease 0 0.99878997
after O 0 0.00047462372
bromocriptine B-Chemical 0 0.9998344
treatment O 0 0.0026522293
. O 0 0.0023093598

To O 0 0.0016105152
clarify O 0 0.00083884975
the O 0 0.00072609575
effects O 0 0.000751991
of O 0 0.0015425177
bromocriptine B-Chemical 0 0.99993515
on O 0 0.0006291203
prolactinoma B-Disease 2 0.9998685
cells O 0 0.0006235241
in O 0 0.00016117023
vivo O 0 0.00027587605
, O 0 0.00015413275
immunohistochemical O 0 0.00028458113
, O 0 0.00010994385
ultrastructural O 0 0.0003423982
and O 0 7.738808e-05
morphometrical O 0 0.0002286309
analyses O 0 5.013229e-05
were O 0 4.530687e-05
applied O 0 4.088015e-05
to O 0 0.00012842548
estrogen B-Chemical 1 0.9999018
- O 0 0.000458562
induced O 0 0.00018509597
rat O 0 0.0018796972
prolactinoma B-Disease 2 0.9999075
cells O 0 0.0002600379
1 O 0 5.4480846e-05
h O 0 3.969355e-05
and O 0 4.807178e-05
6 O 0 2.5702677e-05
h O 0 2.8063618e-05
after O 0 1.907183e-05
injection O 0 7.9566096e-05
of O 0 0.00030717088
bromocriptine B-Chemical 0 0.99996066
( O 0 0.00031615797
3 O 0 0.00010571568
mg O 0 0.0013382679
/ O 0 0.0004942957
kg O 0 0.0004380675
of O 0 0.0003850866
body O 0 0.0015922306
weight O 0 0.0043021073
) O 0 0.002539207
. O 0 0.0021428557

One O 0 0.0027146782
h O 0 0.0015694683
after O 0 0.00072974246
treatment O 0 0.0012872767
, O 0 0.0017560716
serum O 0 0.07565442
prolactin O 0 0.9749221
levels O 0 0.0027116733
decreased O 0 0.0064294427
markedly O 0 0.015225855
. O 0 0.0048919055

Electron O 0 0.007059886
microscopy O 0 0.0020117003
disclosed O 0 0.0014221219
many O 0 0.0005328674
secretory O 0 0.0007865233
granules O 0 0.00074982643
, O 0 0.0003515663
slightly O 0 0.00038560183
distorted O 0 0.0005268521
rough O 0 0.00042327464
endoplasmic O 0 0.004440001
reticulum O 0 0.0017063908
, O 0 0.0001531293
and O 0 0.00012207887
partially O 0 0.00026600342
dilated O 0 0.106817864
Golgi O 0 0.00039649205
cisternae O 0 0.0004643232
in O 0 0.0002539844
the O 0 0.0006850133
prolactinoma B-Disease 2 0.99912447
cells O 0 0.003472657
. O 0 0.0024150442

Morphometric O 0 0.009301999
analysis O 0 0.0013102132
revealed O 0 0.0006485002
that O 0 0.00031966253
the O 0 0.00031946477
volume O 0 0.0005170792
density O 0 0.0004995853
of O 0 0.00029715535
secretory O 0 0.00042674088
granules O 0 0.00043002464
increased O 0 0.00033629106
, O 0 0.00019428057
while O 0 0.00012086577
the O 0 0.00012815242
volume O 0 0.00031195872
density O 0 0.00043708412
of O 0 0.0003825513
cytoplasmic O 0 0.0005352132
microtubules O 0 0.0032236592
decreased O 0 0.003812447
. O 0 0.0022875997

These O 0 0.002006984
findings O 0 0.0015811445
suggest O 0 0.00041738575
that O 0 0.00041692986
lowered O 0 0.0038575358
serum O 0 0.18682551
prolactin O 0 0.97554123
levels O 0 0.00028879335
in O 0 0.00012351041
the O 0 9.215729e-05
early O 0 0.00015010424
phase O 0 0.00031866904
of O 0 0.0004245787
bromocriptine B-Chemical 0 0.99997187
treatment O 0 0.00016858973
may O 0 6.0448212e-05
result O 0 5.4253294e-05
from O 0 4.831873e-05
an O 0 9.1700575e-05
impaired O 0 0.00037591485
secretion O 0 0.0007011256
of O 0 0.00026221332
prolactin O 0 0.804259
due O 0 8.3915336e-05
to O 0 0.000104765815
decreasing O 0 0.00022769849
numbers O 0 0.00025759105
of O 0 0.0004182493
cytoplasmic O 0 0.0007085652
microtubules O 0 0.004638534
. O 0 0.0019308084

At O 0 0.0009676772
6 O 0 0.000821616
h O 0 0.0006223563
after O 0 0.00029122955
injection O 0 0.00060428475
, O 0 0.0006464004
serum O 0 0.03718667
prolactin O 0 0.94995093
levels O 0 0.00043614666
were O 0 0.00026175025
still O 0 0.00023028838
considerably O 0 0.00038866937
lower O 0 0.00044826668
than O 0 0.00035025875
in O 0 0.00071574654
controls O 0 0.0023207467
. O 0 0.0022227925

The O 0 0.0033032824
prolactinoma B-Disease 2 0.9975351
cells O 0 0.0016373222
at O 0 0.00039974166
this O 0 0.00036779302
time O 0 0.00016893861
were O 0 0.00020034022
well O 0 0.00015465905
granulated O 0 0.00064122357
, O 0 0.00018469524
with O 0 0.00019670805
vesiculated O 0 0.00094546314
rough O 0 0.0003150624
endoplasmic O 0 0.0022661823
reticulum O 0 0.0012666753
and O 0 0.00026451034
markedly O 0 0.0011834229
dilated O 0 0.2978529
Golgi O 0 0.0016298611
cisternae O 0 0.0026785005
. O 0 0.0017734286

Electron O 0 0.0066595655
microscopical O 0 0.0038459343
immunohistochemistry O 0 0.0019199828
revealed O 0 0.0005374915
positive O 0 0.00052268995
reaction O 0 0.0021511037
products O 0 0.0006633223
noted O 0 0.00010827771
on O 0 7.029883e-05
the O 0 0.00010959665
secretory O 0 0.00022953078
granules O 0 0.0002677306
, O 0 0.00014368411
Golgi O 0 0.00020832755
cisternae O 0 0.00027468163
, O 0 0.00010525969
and O 0 0.000110924666
endoplasmic O 0 0.0011604893
reticulum O 0 0.0007256955
of O 0 0.00015948388
the O 0 0.00018705704
untreated O 0 0.0006196762
rat O 0 0.0030207841
prolactinoma B-Disease 2 0.99952865
cells O 0 0.0036291333
. O 0 0.0023017128

However O 0 0.0026501135
, O 0 0.0018089984
only O 0 0.0009700855
secretory O 0 0.0010508413
granules O 0 0.0008299553
showed O 0 0.00029567847
the O 0 0.00021923103
positive O 0 0.00028020618
reaction O 0 0.0017241052
products O 0 0.000592296
for O 0 0.00014461782
prolactin O 0 0.6682443
6 O 0 7.2435636e-05
h O 0 7.350486e-05
after O 0 7.757893e-05
bromocriptine B-Chemical 0 0.99964905
treatment O 0 0.00035452234
of O 0 0.00058478536
the O 0 0.0010722568
adenoma B-Disease 0 0.998393
cells O 0 0.0043040263
. O 0 0.0024317745

An O 0 0.0028439735
increase O 0 0.001362967
in O 0 0.00072451564
the O 0 0.00048679867
volume O 0 0.0007005328
density O 0 0.00061582687
of O 0 0.00033907092
secretory O 0 0.00044138668
granules O 0 0.0003955865
and O 0 0.00015600586
a O 0 0.00016430761
decrease O 0 0.00014178792
in O 0 7.17059e-05
the O 0 6.436685e-05
volume O 0 0.00014076491
densities O 0 0.000105023384
of O 0 8.544845e-05
rough O 0 0.00017039165
endoplasmic O 0 0.0019363122
reticulum O 0 0.0006573695
and O 0 6.275979e-05
microtubules O 0 0.00024287596
was O 0 6.436213e-05
determined O 0 4.179152e-05
by O 0 5.2106425e-05
morphometric O 0 0.00014533752
analysis O 0 6.471928e-05
, O 0 6.7485336e-05
suggesting O 0 3.4576202e-05
that O 0 7.75435e-05
bromocriptine B-Chemical 0 0.99991727
inhibits O 0 9.807331e-05
protein O 0 0.0003087752
synthesis O 0 0.00079327764
as O 0 8.438268e-05
well O 0 6.471169e-05
as O 0 7.619622e-05
bringing O 0 0.00020480255
about O 0 0.00012120567
a O 0 0.0002408575
disturbance O 0 0.0018333059
of O 0 0.00045338014
the O 0 0.00073797227
prolactin O 0 0.9612765
secretion O 0 0.014927496
. O 0 0.0023747955

Sulfasalazine B-Chemical 0 0.9980894
- O 0 0.045390293
induced O 0 0.09654688
lupus B-Disease 0 0.99988484
erythematosus I-Disease 0 0.9998221
. O 0 0.03511091

Pneumonitis B-Disease 0 0.9514135
, O 0 0.002961567
bilateral O 0 0.0066751787
pleural B-Disease 0 0.03278117
effusions I-Disease 0 0.080588326
, O 0 0.0005997393
echocardiographic O 0 0.0013148222
evidence O 0 0.00016038866
of O 0 0.00028017306
cardiac B-Disease 0 0.07570739
tamponade I-Disease 0 0.46113196
, O 0 0.00018994966
and O 0 0.00011419652
positive O 0 0.00018590092
autoantibodies O 0 0.084874146
developed O 0 0.00024437607
in O 0 9.7265736e-05
a O 0 0.00016281167
43 O 0 0.00022420057
- O 0 0.0002003173
year O 0 6.262958e-05
- O 0 0.0001623779
old O 0 0.000116915995
man O 0 0.0013859022
, O 0 0.00012427049
who O 0 0.00014645724
was O 0 8.6235355e-05
receiving O 0 0.00011178965
long O 0 8.388685e-05
- O 0 0.00018335364
term O 0 0.00021548457
sulfasalazine B-Chemical 0 0.9999422
therapy O 0 0.00066244474
for O 0 0.00047986893
chronic O 0 0.97761106
ulcerative B-Disease 0 0.9999939
colitis I-Disease 0 0.9999889
. O 0 0.008845699

After O 0 0.0009487026
cessation O 0 0.0013372749
of O 0 0.0010477265
the O 0 0.001200302
sulfasalazine B-Chemical 0 0.99987507
and O 0 0.0004644046
completion O 0 0.00014701877
of O 0 0.00022041943
a O 0 0.00021039863
six O 0 7.968683e-05
- O 0 0.00015819845
week O 0 3.8977952e-05
course O 0 6.04353e-05
of O 0 0.00021543608
corticosteroids O 1 0.9953727
, O 0 0.00018392691
these O 0 0.00015208943
problems O 0 0.00025067385
resolved O 0 0.00015191955
over O 0 4.0929615e-05
a O 0 9.74674e-05
period O 0 5.205899e-05
of O 0 0.00014110896
four O 0 0.00012175822
to O 0 0.00023844687
six O 0 0.00033038825
months O 0 0.00051092467
. O 0 0.0014723184

It O 0 0.0025730992
is O 0 0.0011397441
suggested O 0 0.00048451786
that O 0 0.00031891002
the O 0 0.00038002344
patient O 0 0.000515217
had O 0 0.00088762306
sulfasalazine B-Chemical 0 0.9999778
- O 0 0.0027655736
induced O 0 0.0019580976
lupus B-Disease 0 0.9999875
, O 0 0.00046000892
which O 0 0.0002557644
manifested O 0 0.0018431154
with O 0 0.00076425594
serositis B-Disease 0 0.9998976
and O 0 0.00039806162
pulmonary O 0 0.31113538
parenchymal O 0 0.44752622
involvement O 0 0.00037416586
in O 0 0.0001291302
the O 0 0.00014174926
absence O 0 0.00016962492
of O 0 0.00069216656
joint O 0 0.040698633
symptoms O 0 0.06621953
. O 0 0.0024338006

Physicians O 0 0.003311412
who O 0 0.0021969718
use O 0 0.0015216395
sulfasalazine B-Chemical 0 0.9997677
to O 0 0.0006121093
treat O 0 0.000704467
patients O 0 0.00044830516
with O 0 0.00044124766
inflammatory B-Disease 0 0.8386555
bowel I-Disease 0 0.7741835
disease I-Disease 0 0.8092691
should O 0 7.474694e-05
be O 0 7.326693e-05
aware O 0 6.92011e-05
of O 0 0.00011294343
the O 0 0.0001376839
signs O 0 0.0024516364
of O 0 0.0015384123
sulfasalazine B-Chemical 0 0.99998057
- O 0 0.0064912704
induced O 0 0.016613606
lupus B-Disease 0 0.9999932
syndrome I-Disease 0 0.99876654
. O 0 0.004545758

Chronic O 0 0.64233005
carbamazepine B-Chemical 1 0.9999695
treatment O 0 0.0018452721
in O 0 0.00055296865
the O 0 0.0003821496
rat O 0 0.00074251957
: O 0 0.00036444637
efficacy O 0 0.00043043972
, O 0 0.00048728107
toxicity B-Disease 2 0.99321645
, O 0 0.00033992474
and O 0 0.00016576116
effect O 0 0.00013811718
on O 0 0.00013500408
plasma O 0 0.003231093
and O 0 0.0006147068
tissue O 0 0.009162845
folate B-Chemical 0 0.99945885
concentrations O 0 0.012755307
. O 0 0.0029299601

Folate B-Chemical 1 0.9997948
depletion O 0 0.007222814
has O 0 0.0010428559
often O 0 0.0007567068
been O 0 0.0003585614
a O 0 0.00039841983
problem O 0 0.00037549192
in O 0 0.0003468481
chronic O 0 0.25285
antiepileptic O 0 0.99909866
drug O 0 0.17213748
( O 0 0.0015914228
AED O 0 0.6910486
) O 0 0.0019340512
therapy O 0 0.002442714
. O 0 0.002380248

Carbamazepine B-Chemical 0 0.99991333
( O 0 0.077458374
CBZ B-Chemical 0 0.99998784
) O 0 0.0048478562
, O 0 0.00095585705
a O 0 0.0006295552
commonly O 0 0.00047338792
used O 0 0.00043991857
AED O 0 0.6586638
, O 0 0.0005139692
has O 0 0.00023410546
been O 0 0.00020751929
implicated O 0 0.00020709707
in O 0 0.0003210041
some O 0 0.00059823954
clinical O 0 0.0020403827
studies O 0 0.0018504328
. O 0 0.0022324263

A O 0 0.0223491
rat O 0 0.0034989119
model O 0 0.0013507842
was O 0 0.0007984366
developed O 0 0.0005530975
to O 0 0.00021867154
examine O 0 9.516821e-05
the O 0 0.00014243566
effects O 0 0.00020379467
of O 0 0.0005310355
chronic O 0 0.9159429
CBZ B-Chemical 0 0.99999917
treatment O 0 0.0007961178
on O 0 0.00031214466
folate B-Chemical 0 0.99959654
concentrations O 0 0.0021120082
in O 0 0.00060205226
the O 0 0.0009340188
rat O 0 0.003616204
. O 0 0.002120525

In O 0 0.0016674392
the O 0 0.0011657814
course O 0 0.0007820459
of O 0 0.00085144467
developing O 0 0.001615642
this O 0 0.00049960054
model O 0 0.0004267091
, O 0 0.0002881943
a O 0 0.00023965463
common O 0 0.00019864656
vehicle O 0 0.0010708327
, O 0 0.00036582237
propylene B-Chemical 0 0.99824834
glycol I-Chemical 0 0.86160254
, O 0 0.00029932024
by O 0 0.00011875615
itself O 0 0.00010680962
in O 0 8.148349e-05
high O 0 0.00027312106
doses O 0 0.0017360151
, O 0 0.000161715
was O 0 0.00010787311
found O 0 6.1510495e-05
to O 0 5.9875532e-05
exhibit O 0 9.1459275e-05
protective O 0 0.00026194798
properties O 0 7.966435e-05
against O 0 0.00010480549
induced O 0 0.00064580736
seizures B-Disease 0 0.9999292
and O 0 0.00079812395
inhibited O 0 0.001744849
weight B-Disease 0 0.010342414
gain I-Disease 0 0.0063009276
. O 0 0.0023047174

Seizures B-Disease 0 0.9965676
induced O 0 0.003999482
by O 0 0.0031193427
hexafluorodiethyl B-Chemical 0 0.99728
ether I-Chemical 0 0.99976987
( O 0 0.005618722
HFDE B-Chemical 0 0.9814202
) O 0 0.0007540348
were O 0 0.0001865942
also O 0 0.00012480085
found O 0 0.00010219758
to O 0 8.878783e-05
be O 0 7.912098e-05
a O 0 9.774048e-05
more O 0 9.318626e-05
sensitive O 0 5.8266585e-05
measure O 0 3.2545406e-05
of O 0 0.000110288056
protection O 0 0.0004549521
by O 0 0.0005526422
CBZ B-Chemical 0 0.9999989
than O 0 0.00039177915
seizures B-Disease 0 0.9999268
induced O 0 0.0005677439
by O 0 0.00038299814
maximal O 0 0.00095359713
electroshock O 0 0.9999089
( O 0 0.0069078575
MES O 0 0.9955676
) O 0 0.004948631
. O 0 0.0026728811

Oral O 0 0.16546115
administration O 0 0.007524608
of O 0 0.0049377107
CBZ B-Chemical 0 0.99999046
as O 0 0.00082830794
an O 0 0.00059447536
aqueous O 0 0.066577375
suspension O 0 0.000649618
every O 0 4.9785078e-05
8 O 0 6.215864e-05
h O 0 5.2000043e-05
at O 0 4.465981e-05
a O 0 9.950185e-05
dose O 0 0.00028849667
of O 0 0.00015917941
250 O 0 0.00035260746
mg O 0 0.003893419
/ O 0 0.00045144252
kg O 0 0.00025436562
was O 0 7.932565e-05
continuously O 0 6.760714e-05
protective O 0 0.00024763698
against O 0 0.00011019344
HFDE B-Chemical 0 0.9808951
- O 0 0.0006069552
induced O 0 0.00040302545
seizures B-Disease 0 0.99995613
and O 0 0.00024387795
was O 0 0.00012678381
minimally O 0 0.00013753655
toxic O 0 0.02455214
as O 0 7.975199e-05
measured O 0 6.510176e-05
by O 0 9.126595e-05
weight B-Disease 0 0.00041819425
gain I-Disease 0 0.00029661186
over O 0 7.317574e-05
8 O 0 0.00012289624
weeks O 0 0.000112341826
of O 0 0.0005046798
treatment O 0 0.001169488
. O 0 0.0019479683

The O 0 0.003832913
CBZ B-Chemical 0 0.9999373
levels O 0 0.0014743261
measured O 0 0.000652374
in O 0 0.0004993858
plasma O 0 0.0026935658
and O 0 0.0003436392
brain O 0 0.0010797416
of O 0 0.0002725376
these O 0 0.00025538672
animals O 0 0.00013773367
, O 0 0.0001932268
however O 0 0.00021424021
, O 0 0.00018711551
were O 0 0.0001492142
below O 0 0.00015973866
those O 0 0.00032344757
normally O 0 0.00035738008
considered O 0 0.00064485654
protective O 0 0.0038575856
. O 0 0.002450263

This O 0 0.0029906768
treatment O 0 0.0016234956
with O 0 0.003161923
CBZ B-Chemical 0 0.99999213
had O 0 0.00078022364
no O 0 0.00018662482
apparent O 0 0.0003095212
adverse O 0 0.012496401
effect O 0 0.00019430724
on O 0 0.00017304446
folate B-Chemical 0 0.99980193
concentrations O 0 0.00101456
in O 0 0.0001252761
the O 0 0.00011988894
rat O 0 0.00038252832
, O 0 0.00013171528
and O 0 0.00010518405
, O 0 0.00010016615
indeed O 0 8.819966e-05
, O 0 0.00011193505
the O 0 0.00017009414
folate B-Chemical 0 0.9996315
concentration O 0 0.00053617574
increased O 0 0.00026796144
in O 0 0.00012500785
liver O 0 0.2630621
after O 0 2.7253544e-05
6 O 0 2.6422773e-05
weeks O 0 1.59921e-05
of O 0 5.3368025e-05
treatment O 0 6.786895e-05
and O 0 8.816753e-05
in O 0 0.00010080239
plasma O 0 0.00087168615
at O 0 0.00010841987
8 O 0 0.00013856147
weeks O 0 0.00011758817
of O 0 0.00051550195
treatment O 0 0.0011766606
. O 0 0.0019459502

Dipyridamole B-Chemical 0 0.99880564
- O 0 0.025473196
induced O 0 0.020927645
myocardial B-Disease 0 0.99823195
ischemia I-Disease 0 0.999303
. O 0 0.02122092

Angina B-Disease 0 0.97841096
and O 0 0.0034126085
ischemic O 0 0.9971265
electrocardiographic O 0 0.39331514
changes O 0 0.00054135174
occurred O 0 0.00018690691
after O 0 7.711213e-05
administration O 0 0.00044327718
of O 0 0.00034123322
oral O 0 0.18082525
dipyridamole B-Chemical 0 0.99994326
in O 0 0.00020488887
four O 0 0.00010428579
patients O 0 0.00026583968
awaiting O 0 0.0011782667
urgent O 0 0.0009831146
myocardial O 0 0.9951218
revascularization O 0 0.0609921
procedures O 0 0.0015016553
. O 0 0.0017064771

To O 0 0.002152824
our O 0 0.0022690282
knowledge O 0 0.002106794
, O 0 0.0010042469
this O 0 0.0006057604
has O 0 0.00027861315
not O 0 0.00021824372
previously O 0 0.00018914393
been O 0 0.00012181281
reported O 0 0.000143304
as O 0 9.3775845e-05
a O 0 0.00014744006
side O 0 0.0007102739
effect O 0 7.3501e-05
of O 0 0.0001493611
preoperative O 0 0.0021916328
dipyridamole B-Chemical 0 0.9999759
therapy O 0 0.0004426309
, O 0 0.0001537294
although O 0 0.00018718958
dipyridamole B-Chemical 0 0.9999771
- O 0 0.00065546046
induced O 0 0.00042286143
myocardial B-Disease 0 0.9998919
ischemia I-Disease 0 0.99997544
has O 0 0.00014953667
been O 0 6.2682935e-05
demonstrated O 0 5.0915365e-05
to O 0 5.3134783e-05
occur O 0 5.088056e-05
in O 0 6.341494e-05
animals O 0 7.074726e-05
and O 0 0.00012661757
humans O 0 0.0003282189
with O 0 0.00046122298
coronary B-Disease 0 0.3190046
artery I-Disease 0 0.32963967
disease I-Disease 0 0.39803103
. O 0 0.0025760208

Epicardial O 0 0.004615106
coronary O 0 0.016555957
collateral O 0 0.011798662
vessels O 0 0.004495366
were O 0 0.00043072164
demonstrated O 0 0.00021998923
in O 0 0.00018525083
all O 0 0.00015960801
four O 0 0.00010160435
patients O 0 0.00022052287
; O 0 0.00017288218
a O 0 0.0002249693
coronary O 0 0.05743723
" O 0 0.0003874796
steal O 0 0.016200554
" O 0 0.00021665514
phenomenon O 0 0.00032843676
may O 0 7.439934e-05
be O 0 6.352916e-05
the O 0 6.5290384e-05
mechanism O 0 9.842801e-05
of O 0 0.00018591492
the O 0 0.0004501428
dipyridamole B-Chemical 0 0.99994445
- O 0 0.0022558523
induced O 0 0.0022334761
ischemia B-Disease 0 0.99971217
observed O 0 0.002926128
. O 0 0.0025602838

Inhibition O 0 0.0050962367
of O 0 0.002958229
sympathoadrenal O 0 0.016032727
activity O 0 0.0015628538
by O 0 0.0018392535
atrial O 0 0.7492179
natriuretic O 0 0.9721443
factor O 0 0.007146077
in O 0 0.0023610787
dogs O 0 0.0046134815
. O 0 0.003618046

In O 0 0.0017586012
six O 0 0.00096479384
conscious O 0 0.0027928436
, O 0 0.0008441484
trained O 0 0.0005278657
dogs O 0 0.00048105235
, O 0 0.0002322566
maintained O 0 0.00013732334
on O 0 7.550129e-05
a O 0 0.00018903973
normal O 0 0.0008664523
sodium B-Chemical 0 0.9998067
intake O 0 0.43408662
of O 0 0.00022207732
2 O 0 7.5416945e-05
to O 0 6.137069e-05
4 O 0 7.749412e-05
mEq O 0 0.069701955
/ O 0 0.00036035822
kg O 0 0.00023847145
/ O 0 0.00018785206
day O 0 4.5587803e-05
, O 0 8.22844e-05
sympathetic O 0 0.00090235384
activity O 0 7.8616256e-05
was O 0 7.952007e-05
assessed O 0 4.2659754e-05
as O 0 4.6960893e-05
the O 0 5.7619887e-05
release O 0 0.00018400795
rate O 0 8.213013e-05
of O 0 0.00021261796
norepinephrine B-Chemical 1 0.9996123
and O 0 0.0001979772
epinephrine B-Chemical 0 0.9799111
during O 0 3.8740043e-05
15 O 0 4.6802175e-05
- O 0 9.20591e-05
minute O 0 4.836501e-05
i O 0 0.00016128937
. O 0 6.012592e-05
v O 0 0.0003509153
. O 0 6.70315e-05
infusions O 0 0.00025592395
of O 0 0.00018707414
human O 0 0.00041702145
alpha O 0 0.3452323
- O 0 0.00178332
atrial O 0 0.7993911
natriuretic O 0 0.96146387
factor O 0 0.009455109
. O 0 0.0026628873

Mean O 0 0.0016217158
arterial O 0 0.012107404
pressure O 0 0.008360521
( O 0 0.0012101037
as O 0 0.0004179605
a O 0 0.00036841835
percentage O 0 0.00018480727
of O 0 0.0002578321
control O 0 0.0002463747
+ O 0 0.000574318
/ O 0 0.00075212546
- O 0 0.00034493144
SEM O 0 0.00024688026
) O 0 0.00011757619
during O 0 3.485104e-05
randomized O 0 8.079556e-05
infusions O 0 0.00017390624
of O 0 0.00010238652
0 O 0 8.341844e-05
. O 0 6.846856e-05
03 O 0 0.00061553105
, O 0 0.000107394
0 O 0 7.378747e-05
. O 0 5.2881278e-05
1 O 0 6.5460954e-05
, O 0 8.6492706e-05
0 O 0 7.060897e-05
. O 0 5.34537e-05
3 O 0 5.8544178e-05
, O 0 8.376215e-05
or O 0 6.992815e-05
1 O 0 6.70416e-05
. O 0 4.4589346e-05
0 O 0 6.215378e-05
microgram O 0 0.0008432881
/ O 0 0.0003514999
kg O 0 0.00025858515
/ O 0 0.00022688364
min O 0 0.00012133958
was O 0 0.00013167533
99 O 0 0.00038497572
+ O 0 0.00029925292
/ O 0 0.0004993949
- O 0 0.00027538542
1 O 0 9.637644e-05
, O 0 0.0001229818
95 O 0 0.00018346381
+ O 0 0.00023712467
/ O 0 0.00045372904
- O 0 0.0002831106
1 O 0 0.00010441007
( O 0 0.0001550857
p O 0 9.177895e-05
less O 0 7.805719e-05
than O 0 6.3194835e-05
0 O 0 9.143504e-05
. O 0 9.1343274e-05
05 O 0 0.0017168426
) O 0 0.000205722
, O 0 0.0001401292
93 O 0 0.00034607886
+ O 0 0.00031971338
/ O 0 0.00054036145
- O 0 0.00030687288
1 O 0 0.00010909273
( O 0 0.00016039738
p O 0 9.445523e-05
less O 0 7.979025e-05
than O 0 6.346328e-05
0 O 0 8.757128e-05
. O 0 7.6650686e-05
01 O 0 0.000386188
) O 0 0.00017566029
, O 0 0.00010980618
or O 0 9.204681e-05
79 O 0 0.00022572002
+ O 0 0.00028636167
/ O 0 0.0004773747
- O 0 0.0002516499
6 O 0 6.431034e-05
% O 0 0.00011054875
( O 0 0.00015162215
p O 0 8.844492e-05
less O 0 7.3271956e-05
than O 0 5.7314963e-05
0 O 0 8.148473e-05
. O 0 8.051476e-05
001 O 0 0.004115181
) O 0 0.0002140975
, O 0 0.00013846319
respectively O 0 0.0002767
, O 0 0.00011856231
but O 0 9.496043e-05
no O 0 6.652809e-05
tachycardia B-Disease 2 0.89986855
and O 0 9.1261776e-05
no O 0 3.6822734e-05
augmentation O 0 0.00014894098
of O 0 0.00010589284
the O 0 0.0001746657
norepinephrine B-Chemical 1 0.99971825
release O 0 0.000600397
rate O 0 0.00011137534
( O 0 0.0001003234
up O 0 5.9793307e-05
to O 0 5.1746672e-05
0 O 0 5.5822555e-05
. O 0 3.8043487e-05
3 O 0 4.4631208e-05
microgram O 0 0.000694418
/ O 0 0.0003002228
kg O 0 0.00022832307
/ O 0 0.0002125851
min O 0 0.000116859825
) O 0 0.00013881351
were O 0 7.155399e-05
observed O 0 6.4294836e-05
, O 0 9.202319e-05
which O 0 0.00010372179
is O 0 7.535585e-05
in O 0 6.223599e-05
contrast O 0 0.0001267611
to O 0 9.349504e-05
comparable O 0 0.00016084309
hypotension B-Disease 0 0.99947673
induced O 0 0.0008064518
by O 0 0.0015221649
hydralazine B-Chemical 0 0.9999889
or O 0 0.0063429475
nitroglycerin B-Chemical 0 0.9999312
. O 0 0.0033854272

The O 0 0.0019717934
release O 0 0.0032495167
rate O 0 0.0013050528
of O 0 0.0017869701
epinephrine B-Chemical 0 0.9987361
( O 0 0.0010705354
control O 0 0.00037996858
, O 0 0.000340043
6 O 0 0.00013216316
. O 0 0.00010518897
7 O 0 0.00010974797
+ O 0 0.00030501376
/ O 0 0.0005281692
- O 0 0.00030201365
0 O 0 0.0001010719
. O 0 5.971291e-05
6 O 0 4.845254e-05
ng O 0 0.00019510592
/ O 0 0.0003506822
kg O 0 0.00028454425
/ O 0 0.00024186383
min O 0 0.000119852935
) O 0 0.000118546704
declined O 0 7.68042e-05
immediately O 0 3.1511827e-05
during O 0 2.6045307e-05
infusions O 0 0.00014190396
of O 0 0.00012282254
atrial O 0 0.49688506
natriuretic O 0 0.90564436
factor O 0 0.00046163602
to O 0 6.7201865e-05
a O 0 7.788842e-05
minimum O 0 4.5183468e-05
of O 0 0.00011429903
49 O 0 0.00019587782
+ O 0 0.00025770502
/ O 0 0.00043481906
- O 0 0.00019825906
5 O 0 5.267211e-05
% O 0 6.3971e-05
of O 0 8.1424856e-05
control O 0 0.000102449885
( O 0 0.00017957983
p O 0 8.78493e-05
less O 0 7.0345915e-05
than O 0 5.399656e-05
0 O 0 7.5512675e-05
. O 0 7.085327e-05
001 O 0 0.0018308798
) O 0 0.00011448926
during O 0 3.536819e-05
0 O 0 5.7426787e-05
. O 0 4.322178e-05
1 O 0 5.8308615e-05
microgram O 0 0.0007305367
/ O 0 0.00031867877
kg O 0 0.00023110904
/ O 0 0.00018984824
min O 0 9.04004e-05
and O 0 7.725315e-05
to O 0 7.3744064e-05
63 O 0 0.00018009341
+ O 0 0.00025577343
/ O 0 0.00044068188
- O 0 0.00022941569
5 O 0 6.879338e-05
% O 0 9.744361e-05
( O 0 0.0001140695
0 O 0 6.5557346e-05
. O 0 4.495298e-05
1 O 0 4.8955866e-05
greater O 0 6.51197e-05
than O 0 6.186379e-05
p O 0 8.001807e-05
greater O 0 7.253822e-05
than O 0 6.020762e-05
0 O 0 8.5868145e-05
. O 0 8.182025e-05
05 O 0 0.0014657896
) O 0 0.00015519104
or O 0 8.6795786e-05
95 O 0 0.00017869132
+ O 0 0.00022051529
/ O 0 0.0004025069
- O 0 0.00024536456
13 O 0 0.00010657715
% O 0 0.00010004884
( O 0 0.00010686493
not O 0 6.927123e-05
significant O 0 9.514489e-05
) O 0 0.00012518559
during O 0 4.1191335e-05
0 O 0 6.9748945e-05
. O 0 5.273464e-05
3 O 0 5.8969348e-05
or O 0 7.588442e-05
1 O 0 9.1456226e-05
. O 0 8.1199214e-05
0 O 0 0.00014507415
microgram O 0 0.0017554732
/ O 0 0.0011557611
kg O 0 0.0012721105
/ O 0 0.0017184125
min O 0 0.0016896077
. O 0 0.0022725998

Steady O 0 0.02787019
state O 0 0.00206843
arterial O 0 0.011484512
plasma O 0 0.0041859713
concentrations O 0 0.0010693718
of O 0 0.00069523905
atrial O 0 0.7493486
natriuretic O 0 0.970394
factor O 0 0.0014851056
were O 0 0.00024117368
39 O 0 0.0002757012
+ O 0 0.00032039144
/ O 0 0.0004650918
- O 0 0.00024313039
10 O 0 0.00010088972
pg O 0 0.0016780968
/ O 0 0.0005167999
ml O 0 0.0004932913
( O 0 0.00017134869
n O 0 8.888356e-05
= O 0 9.4566174e-05
6 O 0 3.8878465e-05
) O 0 6.808493e-05
during O 0 2.8254115e-05
infusions O 0 0.00014653773
of O 0 0.00010161791
saline O 0 0.00045479427
and O 0 0.00012147736
284 O 0 0.00077850797
+ O 0 0.00026779232
/ O 0 0.00038252576
- O 0 0.00018105727
24 O 0 6.287068e-05
pg O 0 0.0012452737
/ O 0 0.00042418548
ml O 0 0.0004235664
( O 0 0.00015813315
n O 0 8.811593e-05
= O 0 0.000103744045
6 O 0 5.0659975e-05
) O 0 0.00012245908
and O 0 0.00012704499
1520 O 0 0.009862909
+ O 0 0.00034456863
/ O 0 0.00047975685
- O 0 0.00026669263
300 O 0 0.00035586447
pg O 0 0.0030256854
/ O 0 0.00055335695
ml O 0 0.00048632815
( O 0 0.00016874347
n O 0 9.151101e-05
= O 0 0.00010667831
9 O 0 6.0648163e-05
) O 0 8.57181e-05
during O 0 3.440057e-05
0 O 0 6.425659e-05
. O 0 5.9077072e-05
03 O 0 0.0004022156
and O 0 8.3261715e-05
0 O 0 6.760862e-05
. O 0 4.7313762e-05
1 O 0 6.175981e-05
microgram O 0 0.00071547984
/ O 0 0.0003120477
kg O 0 0.0002268698
/ O 0 0.00019359564
min O 0 0.00011001495
infusions O 0 0.00025100246
of O 0 0.00014534348
the O 0 0.00016636048
factor O 0 0.0007643987
. O 0 0.00025339203
( O 0 0.00073976186
ABSTRACT O 0 0.0040178653
TRUNCATED O 0 0.003586592
AT O 0 0.006450357
250 O 0 0.0034083785
WORDS O 0 0.00693777
) O 0 0.006116966

Inhibition O 0 0.003999486
of O 0 0.0023772933
immunoreactive O 0 0.0036558423
corticotropin O 0 0.9994748
- O 0 0.0027049358
releasing O 0 0.0013122277
factor O 0 0.0011234198
secretion O 0 0.0009154097
into O 0 0.000100081365
the O 0 0.0002145939
hypophysial O 0 0.013777815
- O 0 0.00050857477
portal O 0 0.0065098
circulation O 0 0.0010029332
by O 0 0.00047453956
delayed O 0 0.0031000136
glucocorticoid O 0 0.7539709
feedback O 0 0.0032115332
. O 0 0.0023362082

Nitroprusside B-Chemical 0 0.99970067
- O 0 0.00690056
induced O 0 0.0028721713
hypotension B-Disease 0 0.99966025
evokes O 0 0.022723584
ACTH O 0 0.99991095
secretion O 0 0.0082094725
which O 0 0.0004015
is O 0 0.00016131984
primarily O 0 0.00012673643
mediated O 0 6.855009e-05
by O 0 0.00010074234
enhanced O 0 0.00016620637
secretion O 0 0.00059810246
of O 0 0.00021352728
immunoreactive O 0 0.0006162649
corticotropin O 0 0.99985445
- O 0 0.0007344517
releasing O 0 0.0005487705
factor O 0 0.0010573575
( O 0 0.00047136753
irCRF O 0 0.051985566
) O 0 0.00022166205
into O 0 7.2617884e-05
the O 0 0.00023354965
hypophysial O 0 0.009536501
- O 0 0.0010447943
portal O 0 0.02164283
circulation O 0 0.004700788
. O 0 0.0021305983

Portal O 0 0.065679476
plasma O 0 0.009451859
concentrations O 0 0.0022255967
of O 0 0.001016754
neither O 0 0.0010759436
arginine B-Chemical 0 0.6290131
vasopressin I-Chemical 1 0.99946326
nor O 0 0.0008565538
oxytocin B-Chemical 0 0.9582832
are O 0 0.0003204745
significantly O 0 0.0003759538
altered O 0 0.00048779388
in O 0 0.0004226007
this O 0 0.00086862047
paradigm O 0 0.0017356557
. O 0 0.0021663362

Application O 0 0.0034641512
of O 0 0.0018849163
a O 0 0.0013863234
delayed O 0 0.0019100396
feedback O 0 0.00068392657
signal O 0 0.00031977898
, O 0 0.0003275593
in O 0 0.00016698251
the O 0 0.00014085622
form O 0 0.00011836463
of O 0 0.00016593718
a O 0 0.00019454454
2 O 0 9.806723e-05
- O 0 0.00014801817
h O 0 7.89006e-05
systemic O 0 0.08550589
corticosterone B-Chemical 1 0.9996351
infusion O 0 0.00074369786
in O 0 0.00013562136
urethane B-Chemical 0 0.87790436
- O 0 0.00024510434
anesthetized O 0 0.00020750207
rats O 0 7.2450566e-05
with O 0 6.151343e-05
pharmacological O 0 0.00073575747
blockade O 0 0.0023429294
of O 0 0.00024101646
glucocorticoid O 0 0.83752394
synthesis O 0 0.0027185278
, O 0 0.00012353822
is O 0 5.8635585e-05
without O 0 4.354352e-05
effect O 0 3.9778923e-05
on O 0 2.6959427e-05
the O 0 4.971174e-05
resting O 0 0.00010919784
secretion O 0 0.00033089193
of O 0 0.00022028791
arginine B-Chemical 0 0.32113796
vasopressin I-Chemical 1 0.9985166
and O 0 0.00026801354
oxytocin B-Chemical 0 0.750486
at O 0 9.8652694e-05
any O 0 0.00020378533
corticosterone B-Chemical 1 0.99565494
feedback O 0 0.001030271
dose O 0 0.0034381442
tested O 0 0.0014629645
. O 0 0.0021111267

Resting O 0 0.013135801
irCRF O 0 0.062367953
levels O 0 0.0011472146
are O 0 0.00057723775
suppressed O 0 0.00055087195
only O 0 0.00030046736
at O 0 0.0001371765
the O 0 0.00016259572
highest O 0 0.0003336361
corticosterone B-Chemical 1 0.9993954
infusion O 0 0.0009379797
rate O 0 0.0001850582
, O 0 0.0001299385
which O 0 0.00011429031
resulted O 0 0.00010847055
in O 0 0.0001498987
systemic O 0 0.260008
corticosterone B-Chemical 1 0.9992594
levels O 0 0.00027499686
of O 0 0.00032926444
40 O 0 0.00040605039
micrograms O 0 0.0035568397
/ O 0 0.003376699
dl O 0 0.020726101
. O 0 0.0024342835

Suppression O 0 0.004600305
of O 0 0.0030148218
irCRF O 0 0.17311923
secretion O 0 0.0026406215
in O 0 0.00042788402
response O 0 0.00044312805
to O 0 0.0008412865
nitroprusside B-Chemical 0 0.99999666
- O 0 0.0033413835
induced O 0 0.00089742825
hypotension B-Disease 0 0.99988925
is O 0 0.0002348815
observed O 0 9.0346184e-05
and O 0 8.0120626e-05
occurs O 0 5.1854066e-05
at O 0 4.7513204e-05
a O 0 0.00015546117
plasma O 0 0.00838648
corticosterone B-Chemical 1 0.9985891
level O 0 0.00013625079
between O 0 9.057564e-05
8 O 0 0.00013808321
- O 0 0.000291594
12 O 0 0.00018861552
micrograms O 0 0.0020588327
/ O 0 0.0029271117
dl O 0 0.016281867
. O 0 0.0025617164

These O 0 0.0022200719
studies O 0 0.0012877195
provide O 0 0.0006911438
further O 0 0.0007012863
evidence O 0 0.00033853293
for O 0 0.00021989507
a O 0 0.0002816117
strong O 0 0.00020736027
central O 0 0.00017700925
component O 0 0.00010892412
of O 0 0.00015353164
the O 0 0.00012790022
delayed O 0 0.00051664124
feedback O 0 0.0002103896
process O 0 0.00015034476
which O 0 0.00020669997
is O 0 0.00015352096
mediated O 0 0.00011179798
by O 0 0.00023313875
modulation O 0 0.0003728372
of O 0 0.0011940644
irCRF O 0 0.43518838
release O 0 0.0074170567
. O 0 0.00245091

Noradrenergic O 0 0.030203564
involvement O 0 0.0049661454
in O 0 0.004174171
catalepsy B-Disease 0 0.99988234
induced O 0 0.004044584
by O 0 0.0025965106
delta B-Chemical 0 0.20143428
9 I-Chemical 0 0.0020951787
- I-Chemical 0 0.005892118
tetrahydrocannabinol I-Chemical 0 0.99950266
. O 0 0.0058352756

In O 0 0.0016341528
order O 0 0.0010024145
to O 0 0.0006556994
elucidate O 0 0.0003510793
the O 0 0.0003110642
role O 0 0.00017179566
of O 0 0.00026587007
the O 0 0.00022422773
catecholaminergic O 0 0.0044345404
system O 0 0.0001426998
in O 0 9.459674e-05
the O 0 0.00014487606
cataleptogenic O 0 0.9971257
effect O 0 0.0001418776
of O 0 0.00030976353
delta B-Chemical 0 0.22644413
9 I-Chemical 0 0.00015045705
- I-Chemical 0 0.0006667486
tetrahydrocannabinol I-Chemical 0 0.99997973
( O 0 0.003842113
THC B-Chemical 0 0.9999981
) O 0 0.00053534
, O 0 9.0979986e-05
the O 0 5.2367304e-05
effect O 0 5.2725183e-05
of O 0 0.00012311674
pretreatment O 0 0.011323695
with O 0 0.00019746367
6 B-Chemical 0 6.8131754e-05
- I-Chemical 0 0.000251968
hydroxydopamine I-Chemical 0 0.39595783
( O 0 0.00018096942
6 B-Chemical 0 5.8866583e-05
- I-Chemical 0 0.00024690237
OHDA I-Chemical 0 0.85346437
) O 0 0.00016611115
or O 0 6.831856e-05
with O 0 0.00028470627
desipramine B-Chemical 0 0.99999654
and O 0 0.00023386854
6 B-Chemical 0 7.880429e-05
- I-Chemical 0 0.00028340393
OHDA I-Chemical 0 0.7333347
and O 0 0.00015638742
lesions O 0 0.0011177368
of O 0 0.00014132292
the O 0 0.00012656434
locus O 0 0.00026388414
coeruleus O 0 0.0015026747
were O 0 0.00023833867
investigated O 0 0.00026842963
in O 0 0.0005531044
rats O 0 0.0017244123
. O 0 0.0017961586

The O 0 0.0025387283
cataleptogenic O 0 0.99626344
effect O 0 0.0015770701
of O 0 0.004243841
THC B-Chemical 0 0.99999106
was O 0 0.001106944
significantly O 0 0.00046125113
reduced O 0 0.00036241347
in O 0 0.00014492884
rats O 0 0.00020720158
treated O 0 0.00017643027
with O 0 0.00015564242
6 B-Chemical 0 7.7198645e-05
- I-Chemical 0 0.00030184205
OHDA I-Chemical 0 0.8000804
and O 0 0.000102451944
in O 0 6.390186e-05
rats O 0 0.000101684695
with O 0 9.1386915e-05
lesions O 0 0.00081133115
of O 0 8.802557e-05
the O 0 6.8422414e-05
locus O 0 0.00013923163
coeruleus O 0 0.00091055135
but O 0 6.4273925e-05
not O 0 4.0445884e-05
in O 0 4.2600885e-05
rats O 0 8.240517e-05
treated O 0 0.000112608766
with O 0 0.00034453376
desipramine B-Chemical 0 0.9999975
and O 0 0.00028319567
6 B-Chemical 0 9.818157e-05
- I-Chemical 0 0.0004109678
OHDA I-Chemical 0 0.85683227
, O 0 0.00021675475
as O 0 0.00013798289
compared O 0 0.0001357611
with O 0 0.00036582845
control O 0 0.00063925324
rats O 0 0.0019737966
. O 0 0.0018199144

On O 0 0.0023125417
the O 0 0.0013287934
contrary O 0 0.0011089508
, O 0 0.00089914177
the O 0 0.0006900389
cataleptogenic O 0 0.998774
effect O 0 0.0005087767
of O 0 0.0021291329
haloperidol B-Chemical 1 0.99999833
was O 0 0.000498088
significantly O 0 0.00021270453
reduced O 0 0.00018231949
in O 0 7.493206e-05
rats O 0 0.00011923419
treated O 0 0.00013656908
with O 0 0.0003829109
desipramine B-Chemical 0 0.9999982
and O 0 0.00026033708
6 B-Chemical 0 7.2906594e-05
- I-Chemical 0 0.00030380525
OHDA I-Chemical 0 0.8757404
but O 0 9.7043754e-05
not O 0 5.3077507e-05
in O 0 5.3301806e-05
rats O 0 0.00010030083
treated O 0 0.00010702433
with O 0 0.00011390537
6 B-Chemical 0 6.490402e-05
- I-Chemical 0 0.00027542113
OHDA I-Chemical 0 0.730501
or O 0 9.6845564e-05
in O 0 9.313421e-05
rats O 0 0.00017796677
with O 0 0.00020488653
lesions O 0 0.0018196374
of O 0 0.00038831664
the O 0 0.0004973555
locus O 0 0.0014001235
coeruleus O 0 0.013381702
. O 0 0.0020403515

These O 0 0.0019253396
results O 0 0.0011549268
indicate O 0 0.00052217033
that O 0 0.00051664567
noradrenergic O 0 0.20347746
neurons O 0 0.000730707
have O 0 0.00015225107
an O 0 0.00014498662
important O 0 6.013853e-05
role O 0 6.143686e-05
in O 0 8.41206e-05
the O 0 0.000113364345
manifestation O 0 0.0010214004
of O 0 0.00092126906
catalepsy B-Disease 0 0.99999535
induced O 0 0.0009806962
by O 0 0.0010639816
THC B-Chemical 0 0.999998
, O 0 0.00036779253
whereas O 0 0.00018419493
dopaminergic O 0 0.17613894
neurons O 0 0.00023534978
are O 0 8.263809e-05
important O 0 7.517827e-05
in O 0 0.00038583844
catalepsy B-Disease 0 0.9999708
induced O 0 0.002471955
by O 0 0.004510981
haloperidol B-Chemical 1 0.99998057
. O 0 0.003821037

Reversibility O 0 0.037420608
of O 0 0.006511317
captopril B-Chemical 1 0.999946
- O 0 0.0053826934
induced O 0 0.0017675085
renal B-Disease 0 0.99456537
insufficiency I-Disease 0 0.99724543
after O 0 0.00014934472
prolonged O 0 0.00043040977
use O 0 0.00017410351
in O 0 0.00016017271
an O 0 0.0002772675
unusual O 0 0.0004836526
case O 0 0.0005291806
of O 0 0.002781139
renovascular B-Disease 0 0.9999858
hypertension I-Disease 2 0.9999901
. O 0 0.007241537

We O 0 0.0017510075
report O 0 0.0018631216
a O 0 0.0012087657
case O 0 0.00069344847
of O 0 0.0009844388
severe O 0 0.11196678
hypertension B-Disease 2 0.99994195
with O 0 0.00049375795
an O 0 0.0002823182
occluded O 0 0.0012005314
renal O 0 0.8621242
artery O 0 0.04421545
to O 0 0.00010172727
a O 0 0.00015547793
solitary O 0 0.0006147736
kidney O 0 0.69817173
, O 0 0.00020788387
who O 0 0.00021686574
developed O 0 0.00032091202
sudden B-Disease 0 0.8480386
deterioration I-Disease 0 0.07039575
of I-Disease 0 0.0003552853
renal I-Disease 0 0.7309192
function I-Disease 0 0.00022134947
following O 0 0.00014776997
treatment O 0 0.00040133332
with O 0 0.001972377
captopril B-Chemical 1 0.99991906
. O 0 0.003277003

His O 0 0.009661142
renal O 0 0.46011427
function O 0 0.0014504504
remained O 0 0.0009928704
impaired O 0 0.0013338106
but O 0 0.00033907866
stable O 0 0.00020832874
during O 0 7.386251e-05
2 O 0 8.700119e-05
years O 0 7.018088e-05
' O 0 9.642968e-05
treatment O 0 9.0796675e-05
with O 0 0.00029011385
captopril B-Chemical 1 0.9999831
but O 0 0.00019475073
returned O 0 9.891286e-05
to O 0 8.383903e-05
pre O 0 0.0002595665
- O 0 0.0002155193
treatment O 0 9.79011e-05
levels O 0 0.00011373585
soon O 0 0.00012796388
after O 0 7.4964795e-05
cessation O 0 0.0003204452
of O 0 0.0005072499
the O 0 0.0008777868
drug O 0 0.033853196
. O 0 0.0022217415

This O 0 0.00326961
indicates O 0 0.0012946207
reversibility O 0 0.012275361
in O 0 0.0017624242
captopril B-Chemical 1 0.9999769
- O 0 0.0030776248
induced O 0 0.00085406186
renal B-Disease 0 0.9812872
failure I-Disease 0 0.3429856
even O 0 0.00020621806
after O 0 4.1442436e-05
its O 0 0.00016341047
prolonged O 0 0.0001908512
use O 0 7.417888e-05
and O 0 7.055283e-05
suggests O 0 3.2938075e-05
that O 0 5.0776343e-05
no O 0 7.891039e-05
organic O 0 0.86381423
damage O 0 0.16540904
occurs O 0 0.00012425058
to O 0 0.00014951643
glomerular O 0 0.9270099
arterioles O 0 0.10665598
following O 0 0.00032269975
chronic O 0 0.4108869
ACE O 0 0.9993674
inhibition O 0 0.01279771
. O 0 0.002603262

HMG O 0 0.99146676
CoA O 1 0.9988003
reductase O 0 0.9977785
inhibitors O 0 0.3405548
. O 0 0.023740774

Current O 0 0.038233347
clinical O 0 0.034583647
experience O 0 0.028334305
. O 0 0.024679812

Lovastatin B-Chemical 0 0.9996407
and O 0 0.00845915
simvastatin B-Chemical 1 0.9998983
are O 0 0.001098821
the O 0 0.0005083365
2 O 0 0.00028817888
best O 0 0.000385455
- O 0 0.00045619148
known O 0 0.00021886136
members O 0 0.00013984062
of O 0 0.00013030974
the O 0 0.000102239974
class O 0 0.00016078418
of O 0 0.00030563347
hypolipidaemic O 0 0.9986527
agents O 0 0.0046533514
known O 0 0.00076089636
as O 0 0.0010293439
HMG O 0 0.9972398
CoA O 1 0.99994147
reductase O 0 0.9997589
inhibitors O 0 0.093031965
. O 0 0.0029407816

Clinical O 0 0.0056895204
experience O 0 0.0020556836
with O 0 0.0020703443
lovastatin B-Chemical 1 0.999752
includes O 0 0.000439989
over O 0 0.00017003785
5000 O 0 0.0006489129
patients O 0 0.00026929166
, O 0 0.00017277242
700 O 0 0.00038592302
of O 0 0.00014916612
whom O 0 0.00022016256
have O 0 5.976692e-05
been O 0 5.2813444e-05
treated O 0 0.0001001971
for O 0 5.3946893e-05
2 O 0 5.742882e-05
years O 0 4.4183627e-05
or O 0 4.3264747e-05
more O 0 9.520043e-05
, O 0 8.26206e-05
and O 0 6.817622e-05
experience O 0 0.000103573926
with O 0 0.00022916647
simvastatin B-Chemical 1 0.99996614
includes O 0 7.8591e-05
over O 0 3.8476795e-05
3500 O 0 0.00046732803
patients O 0 0.00010598952
, O 0 7.1177514e-05
of O 0 9.177939e-05
whom O 0 0.0001902471
350 O 0 0.00021423084
have O 0 6.118102e-05
been O 0 6.731937e-05
treated O 0 0.00014115122
for O 0 0.000112946225
18 O 0 0.00017604243
months O 0 0.00012956571
or O 0 0.0004021004
more O 0 0.0014346226
. O 0 0.0019854268

Lovastatin B-Chemical 0 0.9994684
has O 0 0.0030006715
been O 0 0.0015556129
marketed O 0 0.00536581
in O 0 0.0007090759
the O 0 0.0006102211
United O 0 0.0008223844
States O 0 0.00096286135
for O 0 0.0004207783
over O 0 0.00038715804
6 O 0 0.000623785
months O 0 0.0007990858
. O 0 0.00216555

Both O 0 0.0023154048
agents O 0 0.0032647315
show O 0 0.0006960737
substantial O 0 0.00068761915
clinical O 0 0.0011564239
efficacy O 0 0.0005862916
, O 0 0.00029754144
with O 0 0.0001968024
reductions O 0 0.00019705477
in O 0 0.000118714815
total O 0 0.00023387211
cholesterol B-Chemical 0 0.999627
of O 0 0.00022417214
over O 0 4.5244607e-05
30 O 0 5.7520843e-05
% O 0 8.244919e-05
and O 0 0.00010365
in O 0 0.00025030653
LDL O 0 0.9999552
- O 0 0.004197318
cholesterol B-Chemical 0 0.9998012
of O 0 0.0006512436
40 O 0 0.00036097868
% O 0 0.00033600855
in O 0 0.00039153828
clinical O 0 0.0015558057
studies O 0 0.00155925
. O 0 0.0019722495

Modest O 0 0.15615669
increases O 0 0.0028405706
in O 0 0.0033375982
HDL O 0 0.99980694
- O 0 0.014474234
cholesterol B-Chemical 0 0.999602
levels O 0 0.00093184726
of O 0 0.0007025168
about O 0 0.00052046665
10 O 0 0.00048399137
% O 0 0.00059718103
are O 0 0.0006079762
also O 0 0.0009873083
reported O 0 0.002340964
. O 0 0.002803339

Clinical O 0 0.0059125344
tolerability O 0 0.0069696573
of O 0 0.001171255
both O 0 0.0007172029
agents O 0 0.0019093815
has O 0 0.00029840902
been O 0 0.00019917154
good O 0 0.0003573874
, O 0 0.00020401164
with O 0 0.00016103091
fewer O 0 0.00011654833
than O 0 7.137897e-05
3 O 0 6.3635016e-05
% O 0 7.57675e-05
of O 0 0.00010122893
patients O 0 0.00014318994
withdrawn O 0 0.00018231079
from O 0 8.245044e-05
treatment O 0 0.00011426405
because O 0 0.0001245854
of O 0 0.00039175467
clinical O 0 0.0018607979
adverse O 0 0.102440804
experiences O 0 0.0045374017
. O 0 0.002496723

Ophthalmological O 0 0.010230876
examinations O 0 0.0016034388
in O 0 0.0005903986
over O 0 0.00027908638
1100 O 0 0.001440648
patients O 0 0.00039347148
treated O 0 0.0002923501
with O 0 0.00019252594
one O 0 9.234941e-05
or O 0 8.533885e-05
the O 0 9.139841e-05
other O 0 9.471607e-05
agent O 0 0.00050545175
have O 0 6.976837e-05
revealed O 0 7.053063e-05
no O 0 4.153819e-05
evidence O 0 5.5074193e-05
of O 0 9.446298e-05
significant O 0 7.556611e-05
short O 0 6.3444284e-05
term O 0 0.000100733305
( O 0 0.00015278581
up O 0 0.000120799064
to O 0 0.00013586068
2 O 0 0.00019042385
years O 0 0.0002863098
) O 0 0.0008350723
cataractogenic O 0 0.673597
potential O 0 0.0026062324
. O 0 0.0025203237

One O 0 0.0024732256
to O 0 0.0013636512
2 O 0 0.0008365541
% O 0 0.00063162914
of O 0 0.00049744936
patients O 0 0.00044743888
have O 0 0.00019447182
elevations O 0 0.0030233443
of O 0 0.00044844215
serum O 0 0.26859087
transaminases O 0 0.9996542
to O 0 0.0002373753
greater O 0 0.00017541109
than O 0 8.503139e-05
3 O 0 7.1575356e-05
times O 0 5.658787e-05
the O 0 0.00014324444
upper O 0 0.00046273784
limit O 0 0.00078844465
of O 0 0.0011337019
normal O 0 0.003612723
. O 0 0.0021876008

These O 0 0.0030418322
episodes O 0 0.0045433654
are O 0 0.0015909955
asymptomatic O 0 0.0043856585
and O 0 0.0011527993
reversible O 0 0.008050285
when O 0 0.00078542373
therapy O 0 0.0018198417
is O 0 0.0019408026
discontinued O 0 0.008144045
. O 0 0.0034148977

Minor O 0 0.042407773
elevations O 0 0.024477934
of O 0 0.004177449
creatine B-Chemical 1 0.9994537
kinase O 0 0.02000241
levels O 0 0.0008344062
are O 0 0.00045946817
reported O 0 0.0004194871
in O 0 0.00031008114
about O 0 0.00038632096
5 O 0 0.0003835833
% O 0 0.00064807513
of O 0 0.0011956224
patients O 0 0.0027460465
. O 0 0.002586377

Myopathy B-Disease 0 0.98779094
, O 0 0.0025704035
associated O 0 0.0008540668
in O 0 0.0005586809
some O 0 0.00047155312
cases O 0 0.0005806123
with O 0 0.00126058
myoglobinuria B-Disease 0 0.99997663
, O 0 0.00059637515
and O 0 0.0001861134
in O 0 0.00010525839
2 O 0 7.27219e-05
cases O 0 8.707714e-05
with O 0 0.00012108853
transient O 0 0.0053932085
renal B-Disease 0 0.98697424
failure I-Disease 0 0.60440373
, O 0 0.00022276164
has O 0 5.909984e-05
been O 0 4.51071e-05
rarely O 0 6.617401e-05
reported O 0 0.00010088568
with O 0 0.0003337525
lovastatin B-Chemical 1 0.99998486
, O 0 0.0002413545
especially O 0 0.00010975676
in O 0 7.084753e-05
patients O 0 0.0001234851
concomitantly O 0 0.00029839796
treated O 0 0.00027129299
with O 0 0.0008603405
cyclosporin B-Chemical 0 0.99999416
, O 0 0.012002159
gemfibrozil B-Chemical 0 0.9999931
or O 0 0.01850376
niacin B-Chemical 0 0.999977
. O 0 0.0043147923

Lovastatin B-Chemical 0 0.9996562
and O 0 0.008555122
simvastatin B-Chemical 1 0.99990153
are O 0 0.0010007275
both O 0 0.0004203846
effective O 0 0.00026373522
and O 0 0.00026922955
well O 0 0.00020328426
- O 0 0.00044800626
tolerated O 0 0.0011147022
agents O 0 0.00062929187
for O 0 0.00016654523
lowering O 0 0.0048940787
elevated O 0 0.0025747248
levels O 0 0.0005405984
of O 0 0.0013657697
serum O 0 0.71825117
cholesterol B-Chemical 0 0.9998104
. O 0 0.005424211

As O 0 0.0017623183
wider O 0 0.0017686447
use O 0 0.0008098211
confirms O 0 0.0005455818
their O 0 0.00050611293
safety O 0 0.00047811854
profile O 0 0.0003441346
, O 0 0.00024512442
they O 0 0.00012618894
will O 0 0.00011676692
gain O 0 0.00026938412
increasing O 0 0.00012966532
importance O 0 6.901677e-05
in O 0 8.7832035e-05
the O 0 0.00010485167
therapeutic O 0 0.00027150515
approach O 0 0.0002495823
to O 0 0.00049175613
hypercholesterolaemia B-Disease 0 0.9999379
and O 0 0.0011281199
its O 0 0.0017486113
consequences O 0 0.0025885971
. O 0 0.0023247635

Hepatic O 0 0.29243827
reactions O 0 0.008886511
associated O 0 0.0023553788
with O 0 0.005056621
ketoconazole B-Chemical 1 0.99993837
in O 0 0.0025138666
the O 0 0.0021470513
United O 0 0.0038310287
Kingdom O 0 0.01012436
. O 0 0.0045679086

Ketoconazole B-Chemical 0 0.9992655
was O 0 0.004537755
introduced O 0 0.0016224995
in O 0 0.0015580532
the O 0 0.0016521983
United O 0 0.0026886694
Kingdom O 0 0.0056200735
in O 0 0.0029755277
1981 O 0 0.008522912
. O 0 0.004740156

By O 0 0.0023898317
November O 0 0.0018242516
1984 O 0 0.0020157525
the O 0 0.0006827143
Committee O 0 0.001160224
on O 0 0.00025178384
Safety O 0 0.00076196523
of O 0 0.00036569388
Medicines O 0 0.0013154323
had O 0 0.00016872448
received O 0 0.00010092743
82 O 0 0.00017938868
reports O 0 0.00011881017
of O 0 0.00016624582
possible O 0 0.00028560724
hepatotoxicity B-Disease 0 0.9999933
associated O 0 0.00028359416
with O 0 0.00025744666
the O 0 0.00023573518
drug O 0 0.005721619
, O 0 0.0003897597
including O 0 0.00032124599
five O 0 0.0005708731
deaths B-Disease 0 0.020472957
. O 0 0.0021643518

An O 0 0.0025578775
analysis O 0 0.0012484648
of O 0 0.00093561446
the O 0 0.0005731499
75 O 0 0.0006653728
cases O 0 0.00031830743
that O 0 0.00015223597
had O 0 0.00017639494
been O 0 0.00010217243
adequately O 0 0.00011750288
followed O 0 6.584523e-05
up O 0 7.97831e-05
suggested O 0 5.2660256e-05
that O 0 5.928035e-05
16 O 0 8.842518e-05
, O 0 8.702153e-05
including O 0 5.1415733e-05
three O 0 5.9358867e-05
deaths B-Disease 0 0.0039015363
, O 0 0.00013535004
were O 0 9.156059e-05
probably O 0 0.00011068882
related O 0 5.2738458e-05
to O 0 0.00011396568
treatment O 0 0.00021465243
with O 0 0.0004559109
the O 0 0.0008247064
drug O 0 0.028995972
. O 0 0.0021804743

Of O 0 0.0024497607
the O 0 0.001470665
remainder O 0 0.001413412
, O 0 0.0008139542
48 O 0 0.00034818175
were O 0 0.00027779065
possibly O 0 0.00028981417
related O 0 9.242457e-05
to O 0 0.00013803002
treatment O 0 0.00017715445
, O 0 0.00016970742
five O 0 7.49062e-05
were O 0 0.00010221843
unlikely O 0 7.941359e-05
to O 0 0.0001166096
be O 0 0.0001427895
so O 0 0.00016170036
, O 0 0.00025208024
and O 0 0.0002959842
six O 0 0.0002995201
were O 0 0.0008418365
unclassifiable O 0 0.011431712
. O 0 0.0023871523

The O 0 0.0014035745
mean O 0 0.0007803887
age O 0 0.0009429048
of O 0 0.00069199107
patients O 0 0.0005697691
in O 0 0.00026086505
the O 0 0.0002250845
16 O 0 0.0002080084
probable O 0 0.00048514793
cases O 0 0.00025172334
was O 0 0.00018953752
57 O 0 0.00023401264
. O 0 7.88918e-05
9 O 0 9.55523e-05
, O 0 0.00016362408
with O 0 0.00048130297
hepatotoxicity B-Disease 0 0.99998665
being O 0 0.00086910155
more O 0 0.0005636552
common O 0 0.0006282892
in O 0 0.0008203955
women O 0 0.0032219808
. O 0 0.0018583597

The O 0 0.0012892485
average O 0 0.00071976514
duration O 0 0.00047451517
of O 0 0.0006631719
treatment O 0 0.00044051636
before O 0 0.00020324512
the O 0 0.00036510587
onset O 0 0.00074343075
of O 0 0.0014828742
jaundice B-Disease 2 0.9979321
was O 0 0.0017514033
61 O 0 0.0017063536
days O 0 0.00086232746
. O 0 0.0020596453

None O 0 0.00325614
of O 0 0.0017484331
these O 0 0.0012098985
well O 0 0.0005919038
validated O 0 0.0005580524
cases O 0 0.00039777125
occurred O 0 0.00019056734
within O 0 8.695302e-05
the O 0 0.00017064236
first O 0 0.00015159714
10 O 0 0.00023761851
days O 0 0.00019506033
after O 0 0.0003313863
treatment O 0 0.0014332202
. O 0 0.002489378

The O 0 0.0014450214
results O 0 0.0012447028
of O 0 0.00136342
serum O 0 0.03833203
liver O 0 0.7023879
function O 0 0.0009078735
tests O 0 0.0012987982
suggested O 0 0.00058096927
hepatocellular B-Disease 0 0.99999535
injury I-Disease 0 0.997696
in O 0 0.0003588517
10 O 0 0.00017779344
( O 0 0.0002154215
63 O 0 0.0002256944
% O 0 0.0001755016
) O 0 0.00024109184
; O 0 0.00016976245
the O 0 0.0001514934
rest O 0 0.00023879793
showed O 0 0.00029629195
a O 0 0.0006119877
mixed O 0 0.0014865416
pattern O 0 0.0014153246
. O 0 0.0022136024

In O 0 0.0020909817
contrast O 0 0.0020220445
, O 0 0.0011439436
the O 0 0.00055856165
results O 0 0.00046124254
of O 0 0.0005437616
histological O 0 0.002366967
examination O 0 0.0003172437
of O 0 0.0003169417
the O 0 0.00034089357
liver O 0 0.36249942
often O 0 0.0005799618
showed O 0 0.00047539664
evidence O 0 0.00069107075
of O 0 0.0037629942
cholestasis B-Disease 2 0.9999683
. O 0 0.0060706534

The O 0 0.0016018868
characteristics O 0 0.000917912
of O 0 0.0010586982
the O 0 0.0007212035
48 O 0 0.0005191915
patients O 0 0.00060825754
in O 0 0.0003958504
the O 0 0.00044930814
possible O 0 0.0005840843
cases O 0 0.0010503768
were O 0 0.0010796872
similar O 0 0.0013244849
. O 0 0.0025851128

Allergic O 0 0.86101764
manifestations O 0 0.029753134
such O 0 0.0024805416
as O 0 0.0034808859
rash B-Disease 0 0.99357224
and O 0 0.006294732
eosinophilia B-Disease 0 0.9987676
were O 0 0.0054049464
rare O 0 0.015127886
. O 0 0.0049337135

Hepatitis B-Disease 0 0.9983734
was O 0 0.0030241436
usually O 0 0.0016100745
reversible O 0 0.009460424
when O 0 0.000356319
treatment O 0 0.00040527058
was O 0 0.000324658
stopped O 0 0.00037578234
, O 0 0.00018778972
with O 0 0.00013238325
the O 0 9.120236e-05
results O 0 0.00010042295
of O 0 0.00019146854
liver O 0 0.477561
function O 0 0.00022734555
tests O 0 0.00028840013
returning O 0 0.000117228024
to O 0 6.550542e-05
normal O 0 0.00013850903
after O 0 3.2613756e-05
an O 0 9.99588e-05
average O 0 7.987277e-05
of O 0 0.00023526164
3 O 0 0.00020708858
. O 0 0.00023201577
1 O 0 0.000437056
months O 0 0.00049946195
. O 0 0.0014812978

In O 0 0.0015417896
two O 0 0.0007847011
of O 0 0.00075214123
the O 0 0.00046050645
three O 0 0.0002442929
deaths B-Disease 0 0.0034127415
probably O 0 0.0003250185
associated O 0 0.00018848538
with O 0 0.00077317416
ketoconazole B-Chemical 1 0.9999957
treatment O 0 0.00030065133
the O 0 0.00015679536
drug O 0 0.007083773
had O 0 9.688351e-05
been O 0 4.6223427e-05
continued O 0 4.787547e-05
after O 0 2.3670065e-05
the O 0 6.613434e-05
onset O 0 0.00016741102
of O 0 0.00039908677
jaundice B-Disease 2 0.9970432
and O 0 0.00040744708
other O 0 0.0004185819
symptoms O 0 0.021824103
of O 0 0.0045317826
hepatitis B-Disease 2 0.99995935
. O 0 0.006202735

Clinical O 0 0.0053790947
and O 0 0.0014127538
biochemical O 0 0.0015746122
monitoring O 0 0.0004376013
at O 0 0.00021069872
regular O 0 0.00019303527
intervals O 0 9.417158e-05
for O 0 8.925668e-05
evidence O 0 0.00013308405
of O 0 0.00066329323
hepatitis B-Disease 2 0.9999901
is O 0 0.00043409015
advised O 0 0.0003342349
during O 0 3.9998486e-05
long O 0 5.928397e-05
term O 0 6.953557e-05
treatment O 0 0.00011966406
with O 0 0.0005391226
ketoconazole B-Chemical 1 0.9999907
to O 0 0.00028291417
prevent O 0 0.0003015372
possible O 0 0.0004867892
serious O 0 0.06405803
hepatic B-Disease 0 0.9997539
injury I-Disease 0 0.9986803
. O 0 0.004795342

Glyburide B-Chemical 0 0.9980818
- O 0 0.046710797
induced O 0 0.04591729
hepatitis B-Disease 2 0.99952257
. O 0 0.038571924

Drug O 0 0.4352778
- O 0 0.006875098
induced O 0 0.006152333
hepatotoxicity B-Disease 0 0.9999801
, O 0 0.0024737476
although O 0 0.0006249043
common O 0 0.0005699521
, O 0 0.0004614745
has O 0 0.00023366569
been O 0 0.00022558619
reported O 0 0.0003492075
only O 0 0.0004844303
infrequently O 0 0.0010849414
with O 0 0.0025971183
sulfonylureas B-Chemical 0 0.9995946
. O 0 0.0037506465

For O 0 0.0028612944
glyburide B-Chemical 0 0.9995927
, O 0 0.0022886035
a O 0 0.0011852763
second O 0 0.0007784523
- O 0 0.00133069
generation O 0 0.002054027
sulfonylurea B-Chemical 0 0.9999281
, O 0 0.0006652504
only O 0 0.0003088933
two O 0 0.00016972101
brief O 0 0.00030931408
reports O 0 0.0006785117
of O 0 0.002342359
hepatotoxicity B-Disease 0 0.9999758
exist O 0 0.0028906995
. O 0 0.0025903531

Two O 0 0.0020645387
patients O 0 0.001594224
with O 0 0.0010550151
type B-Disease 0 0.0011721434
II I-Disease 0 0.18471788
diabetes I-Disease 0 0.9997925
mellitus I-Disease 0 0.9990221
developed O 0 0.0016897643
an O 0 0.0020943198
acute B-Disease 0 0.99983394
hepatitis I-Disease 2 0.99999964
- I-Disease 0 0.0201764
like I-Disease 0 0.00028004806
syndrome I-Disease 0 0.035001907
soon O 0 0.00014584964
after O 0 6.460219e-05
initiation O 0 0.00019105438
of O 0 0.0011427499
glyburide B-Chemical 0 0.99985194
therapy O 0 0.005306549
. O 0 0.0023168537

There O 0 0.002781081
was O 0 0.0017866623
no O 0 0.00076434185
serologic O 0 0.0058161695
evidence O 0 0.00047093284
of O 0 0.0006852999
viral B-Disease 0 0.12757531
infection I-Disease 0 0.7677995
, O 0 0.0005589201
and O 0 0.0002587277
a O 0 0.00035130864
liver O 0 0.5842312
biopsy O 0 0.0006413885
sample O 0 0.00016265649
showed O 0 9.5637086e-05
a O 0 0.00014866117
histologic O 0 0.0008624425
pattern O 0 9.142605e-05
consistent O 0 0.00014235325
with O 0 0.00036764718
drug B-Disease 0 0.03439299
- I-Disease 0 0.0018088053
induced I-Disease 0 0.004247494
hepatitis I-Disease 2 0.999961
. O 0 0.0069464655

Both O 0 0.0020633845
patients O 0 0.0013216635
recovered O 0 0.00061259314
quickly O 0 0.00058567384
after O 0 0.00016457385
stopping O 0 0.001414989
glyburide B-Chemical 0 0.9999287
therapy O 0 0.00062928104
and O 0 0.00019172594
have O 0 9.4033734e-05
remained O 0 0.0001450945
well O 0 8.027626e-05
for O 0 7.632218e-05
a O 0 0.00016140353
follow O 0 9.707337e-05
- O 0 0.00023460713
up O 0 0.00016411518
period O 0 0.00013467262
of O 0 0.00044672162
1 O 0 0.0006055433
year O 0 0.00083787285
. O 0 0.0017254024

Glyburide B-Chemical 0 0.9986707
can O 0 0.0019996224
produce O 0 0.0012294855
an O 0 0.0034008876
acute B-Disease 0 0.9992914
hepatitis I-Disease 2 0.99999726
- I-Disease 0 0.034800924
like I-Disease 0 0.0011954937
illness I-Disease 0 0.24724126
in O 0 0.0012232163
some O 0 0.0017529249
persons O 0 0.0039961217
. O 0 0.0028449947

Intracranial O 0 0.01763646
pressure O 0 0.01038955
increases O 0 0.0026491408
during O 0 0.0023549865
alfentanil B-Chemical 0 0.9995616
- O 0 0.008752232
induced O 0 0.0068125688
rigidity B-Disease 0 0.9038366
. O 0 0.007577894

Intracranial O 0 0.01774559
pressure O 0 0.019274553
( O 0 0.0039656176
ICP O 0 0.89791965
) O 0 0.0016251698
was O 0 0.000585998
measured O 0 0.00038076815
during O 0 0.00044123043
alfentanil B-Chemical 0 0.99982834
- O 0 0.0022553566
induced O 0 0.0014589285
rigidity B-Disease 0 0.677771
in O 0 0.0016744726
rats O 0 0.0033649316
. O 0 0.002564564

Ten O 0 0.0033831466
rats O 0 0.0020584927
had O 0 0.0010905358
arterial O 0 0.007113173
, O 0 0.000714029
central O 0 0.0007409171
venous O 0 0.083835796
( O 0 0.001005128
CVP O 0 0.8841074
) O 0 0.0006001542
, O 0 0.00032967876
and O 0 0.00038894796
subdural O 0 0.74977446
cannulae O 0 0.0007751723
inserted O 0 0.0003341817
under O 0 0.00068171363
halothane B-Chemical 0 0.9992737
anesthesia O 0 0.20395927
. O 0 0.0029176222

The O 0 0.0015751933
animals O 0 0.001010287
were O 0 0.00079659285
mechanically O 0 0.0011227791
ventilated O 0 0.00070501916
to O 0 0.0001993906
achieve O 0 0.00017913946
normocarbia O 0 0.0016103911
( O 0 0.0004976632
PCO2 O 0 0.74246174
= O 0 0.00027457273
42 O 0 0.00020019051
+ O 0 0.00033217616
/ O 0 0.0005241608
- O 0 0.0003083598
1 O 0 0.0001285475
mmHg O 0 0.00029862594
, O 0 0.00018336973
mean O 0 0.00014047863
+ O 0 0.0006870237
/ O 0 0.0017028725
- O 0 0.0021172385
SE O 0 0.0641376
) O 0 0.0034160744
. O 0 0.0028057124

Following O 0 0.0019387733
instrumentation O 0 0.005521546
, O 0 0.002451312
halothane B-Chemical 0 0.999534
was O 0 0.001082476
discontinued O 0 0.0020463099
and O 0 0.00070512254
alfentanil B-Chemical 0 0.9999194
( O 0 0.0006836063
125 O 0 0.0012569855
mu O 0 0.041475512
/ O 0 0.00065827474
kg O 0 0.00043593958
) O 0 0.00020104172
administered O 0 0.00015342965
iv O 0 0.00030552945
during O 0 0.00010059421
emergence O 0 0.00031780553
from O 0 0.0006411202
halothane B-Chemical 0 0.99952257
anesthesia O 0 0.2480009
. O 0 0.0025679816

In O 0 0.0015745979
the O 0 0.0010625649
five O 0 0.0004767376
rats O 0 0.00058039697
that O 0 0.00026654828
developed O 0 0.0007440899
somatic B-Disease 0 0.068755515
rigidity I-Disease 0 0.9965552
, O 0 0.0009069493
ICP O 0 0.96064085
and O 0 0.0003714798
CVP O 0 0.87948465
increased O 0 0.00020780321
significantly O 0 0.00013056361
above O 0 8.4295905e-05
baseline O 0 9.124455e-05
( O 0 0.00021951257
delta O 0 0.13453126
ICP O 0 0.9323737
7 O 0 9.051175e-05
. O 0 5.568129e-05
5 O 0 6.515566e-05
+ O 0 0.00020782759
/ O 0 0.0004104727
- O 0 0.00023765046
1 O 0 7.5181575e-05
. O 0 4.6811376e-05
0 O 0 6.3758634e-05
mmHg O 0 0.00019739647
, O 0 0.00016946292
delta O 0 0.05235395
CVP O 0 0.8266721
5 O 0 0.00010650177
. O 0 7.8918514e-05
9 O 0 0.00011456386
+ O 0 0.00031619595
/ O 0 0.00064491224
- O 0 0.00049470575
1 O 0 0.00025115782
. O 0 0.0002423368
3 O 0 0.00041657605
mmHg O 0 0.0016467447
) O 0 0.0021588216
. O 0 0.0023730304

These O 0 0.002207399
variables O 0 0.0010989971
returned O 0 0.0009863682
to O 0 0.0007081915
baseline O 0 0.00067369855
when O 0 0.0006577584
rigidity B-Disease 0 0.21501772
was O 0 0.0015192225
abolished O 0 0.0031515188
with O 0 0.006024741
metocurine B-Chemical 0 0.9995565
. O 0 0.0056773727

In O 0 0.0017620181
five O 0 0.00088560476
rats O 0 0.0010136786
that O 0 0.00041105336
did O 0 0.0004916305
not O 0 0.00030303176
become O 0 0.00032184928
rigid O 0 0.0005520349
, O 0 0.00049572537
ICP O 0 0.85648346
and O 0 0.0006027421
CVP O 0 0.82648355
did O 0 0.0003504949
not O 0 0.000288155
change O 0 0.0005035554
following O 0 0.0009983554
alfentanil B-Chemical 0 0.99953294
. O 0 0.0035698595

These O 0 0.0020919384
observations O 0 0.0014562121
suggest O 0 0.00050591375
that O 0 0.0005834653
rigidity B-Disease 0 0.18223503
should O 0 0.00024467867
be O 0 0.00022966956
prevented O 0 0.00056379085
when O 0 0.0002765104
alfentanil B-Chemical 0 0.99996114
, O 0 0.00040797095
and O 0 0.00019005944
, O 0 0.00016028073
presumably O 0 0.00026642476
, O 0 0.00015913663
other O 0 0.00018270529
opiates O 0 0.9889902
, O 0 0.00015239208
are O 0 6.445905e-05
used O 0 4.8224403e-05
in O 0 5.8691705e-05
the O 0 8.866549e-05
anesthetic O 0 0.0019297318
management O 0 0.00017911266
of O 0 0.00027967477
patients O 0 0.000540473
with O 0 0.0009477648
ICP O 0 0.9415873
problems O 0 0.006023639
. O 0 0.0023333551

Verapamil B-Chemical 0 0.9998072
withdrawal O 0 0.16481164
as O 0 0.0012442505
a O 0 0.000825136
possible O 0 0.0004270267
cause O 0 0.0005931377
of O 0 0.0009538434
myocardial B-Disease 0 0.9998216
infarction I-Disease 2 0.99998856
in O 0 0.0005627486
a O 0 0.00092481286
hypertensive B-Disease 2 0.9996499
woman O 0 0.0012506454
with O 0 0.0003064653
a O 0 0.0004559172
normal O 0 0.0013455484
coronary O 0 0.34001613
angiogram O 0 0.56112564
. O 0 0.002411169

Verapamil B-Chemical 0 0.9995541
is O 0 0.003477338
an O 0 0.00202712
effective O 0 0.001194655
and O 0 0.0012457228
relatively O 0 0.0018061675
- O 0 0.002364697
safe O 0 0.0030456895
antihypertensive O 0 0.8958743
drug O 0 0.11331946
. O 0 0.004227824

Serious O 0 0.017109968
adverse O 0 0.037395723
effects O 0 0.0017091385
are O 0 0.0008399829
uncommon O 0 0.0011830933
and O 0 0.00036887696
mainly O 0 0.0002761355
have O 0 0.00011749986
been O 0 7.376256e-05
related O 0 3.9709073e-05
to O 0 6.522809e-05
the O 0 0.000116790194
depression B-Disease 0 0.81125766
of O 0 0.00021316276
cardiac O 0 0.055077456
contractility O 0 0.49038965
and O 0 0.00014415344
conduction O 0 0.00074117346
, O 0 9.4902585e-05
especially O 0 6.715978e-05
when O 0 4.0190815e-05
the O 0 8.511859e-05
drug O 0 0.0015107054
is O 0 0.00012643827
combined O 0 0.00024775648
with O 0 0.00054697046
beta O 0 0.8428283
- O 0 0.0015726404
blocking O 0 0.0024431997
agents O 0 0.009775249
. O 0 0.002516036

We O 0 0.0017196136
report O 0 0.001803065
a O 0 0.0011177325
case O 0 0.0005732012
in O 0 0.00042693448
which O 0 0.000911006
myocardial B-Disease 0 0.9997297
infarction I-Disease 2 0.9999864
coincided O 0 0.00080236344
with O 0 0.00018501164
the O 0 8.073203e-05
introduction O 0 6.580946e-05
of O 0 0.00026499346
captopril B-Chemical 1 0.9999832
and O 0 0.0001587974
the O 0 0.0001014388
withdrawal O 0 0.004079395
of O 0 0.00047792058
verapamil B-Chemical 0 0.99998367
in O 0 0.00017655599
a O 0 0.00021042468
previously O 0 0.00019344027
asymptomatic O 0 0.004294577
woman O 0 0.0015224216
with O 0 0.0011617783
severe O 0 0.42704198
hypertension B-Disease 2 0.99991786
. O 0 0.0037046047

Possible O 0 0.0033509363
mechanisms O 0 0.0014235786
that O 0 0.0006208124
involve O 0 0.00055185496
a O 0 0.0017151835
verapamil B-Chemical 0 0.99997234
- O 0 0.0012236043
related O 0 0.000109856446
increase O 0 0.00016397238
in O 0 0.00017800294
platelet O 0 0.5775274
and O 0 0.00023477693
/ O 0 0.00045181572
or O 0 0.00015110329
vascular O 0 0.12646191
alpha O 0 0.5005539
2 O 0 0.00021949288
- O 0 0.0006243771
adrenoreceptor O 0 0.9994893
affinity O 0 0.0017138035
for O 0 0.00046910348
catecholamines B-Chemical 0 0.995188
are O 0 0.0009373744
discussed O 0 0.0012956965
. O 0 0.0019511656

Haemolytic B-Disease 0 0.2524993
- I-Disease 0 0.013952769
uraemic I-Disease 0 0.99679404
syndrome I-Disease 0 0.1261769
after O 0 0.0009708724
treatment O 0 0.0020595852
with O 0 0.004926333
metronidazole B-Chemical 0 0.99825674
. O 0 0.0070475964

This O 0 0.003424402
paper O 0 0.0016781017
describes O 0 0.0010541797
the O 0 0.0005365569
clinical O 0 0.0007513528
features O 0 0.0003062206
of O 0 0.0002578741
six O 0 0.000112108195
children O 0 0.00024619835
who O 0 0.00021958919
developed O 0 0.00022932517
the O 0 0.00025815456
haemolytic B-Disease 0 0.9921415
- I-Disease 0 0.0055480436
uraemic I-Disease 0 0.99973184
syndrome I-Disease 0 0.14633302
after O 0 0.00013629498
treatment O 0 0.00046345696
with O 0 0.0017453964
metronidazole B-Chemical 0 0.9986701
. O 0 0.0030220512

These O 0 0.002565557
children O 0 0.0022313583
were O 0 0.0010170597
older O 0 0.0015122311
and O 0 0.00042496543
were O 0 0.00026008525
more O 0 0.00022810744
likely O 0 0.00011015415
to O 0 0.000102933736
have O 0 7.760852e-05
undergone O 0 9.16461e-05
recent O 0 0.0001460311
bowel O 0 0.012550675
surgery O 0 0.00018758535
than O 0 7.6556025e-05
are O 0 0.0001083898
other O 0 0.0001377476
children O 0 0.00033352253
with O 0 0.00041857155
this O 0 0.000871313
condition O 0 0.0027490386
. O 0 0.0020583225

While O 0 0.0017309405
the O 0 0.001284417
involvement O 0 0.0013199049
of O 0 0.0014464944
metronidazole B-Chemical 0 0.9985435
in O 0 0.00039782643
the O 0 0.0002635967
aetiology O 0 0.0013529363
of O 0 0.0002576021
the O 0 0.0002812406
haemolytic B-Disease 0 0.9953904
- I-Disease 0 0.011192487
uraemic I-Disease 0 0.9999033
syndrome I-Disease 0 0.49802107
is O 0 0.00012887939
not O 0 7.3033036e-05
established O 0 0.00010829887
firmly O 0 9.407383e-05
, O 0 6.770333e-05
the O 0 4.7942038e-05
action O 0 7.641948e-05
of O 0 8.012146e-05
this O 0 0.00010458995
drug O 0 0.0027552026
in O 0 7.443972e-05
sensitizing O 0 0.0006839968
tissues O 0 0.0003171956
to O 0 0.00013298016
oxidation O 0 0.976385
injury O 0 0.34918284
and O 0 0.000123688
the O 0 7.226496e-05
reported O 0 7.7113014e-05
evidence O 0 5.234773e-05
of O 0 0.0001490248
oxidation O 0 0.7602001
changes O 0 0.00011698782
in O 0 5.8858554e-05
the O 0 0.0001062965
haemolytic B-Disease 0 0.9864225
- I-Disease 0 0.003654797
uraemic I-Disease 0 0.99981016
syndrome I-Disease 0 0.1458296
suggest O 0 3.3301167e-05
a O 0 6.830605e-05
possible O 0 4.0600302e-05
link O 0 3.736238e-05
between O 0 5.6608762e-05
metronidazole B-Chemical 0 0.9958916
treatment O 0 0.00013410367
and O 0 0.000107005144
some O 0 0.00011296874
cases O 0 0.00015625598
of O 0 0.00021642762
the O 0 0.00041180724
haemolytic B-Disease 0 0.9932326
- I-Disease 0 0.018060435
uraemic I-Disease 0 0.99970347
syndrome I-Disease 0 0.8398415
. O 0 0.0028034616

Adverse O 0 0.008015792
cardiac O 0 0.007687531
effects O 0 0.00089708634
during O 0 0.00033213655
induction O 0 0.00053434895
chemotherapy O 0 0.0026270845
treatment O 0 0.00043022205
with O 0 0.0006484112
cis B-Chemical 0 0.105376385
- I-Chemical 0 0.0016885117
platin I-Chemical 0 0.8471643
and O 0 0.0008065915
5 B-Chemical 0 0.0006909048
- I-Chemical 0 0.0027261788
fluorouracil I-Chemical 0 0.99257565
. O 0 0.0033817189

Survival O 0 0.0075051514
for O 0 0.001182224
patients O 0 0.0011721563
with O 0 0.00080842443
advanced O 0 0.0020947163
head B-Disease 0 0.0028948998
and I-Disease 0 0.0006553314
neck I-Disease 0 0.10589816
carcinoma I-Disease 0 0.9968761
and O 0 0.0009772494
esophageal B-Disease 0 0.98429954
carcinoma I-Disease 0 0.99984264
is O 0 0.00029480364
poor O 0 0.00045565172
with O 0 0.00028409754
radiotherapy O 0 0.0026403216
and O 0 0.00042413638
/ O 0 0.0011969922
or O 0 0.00076233275
surgery O 0 0.0018536608
. O 0 0.0018227977

Obviously O 0 0.0059035867
, O 0 0.003556363
there O 0 0.0015176941
is O 0 0.0016909111
a O 0 0.00168151
need O 0 0.0011502452
for O 0 0.0011784779
effective O 0 0.002334826
chemotherapy O 0 0.022181295
. O 0 0.005315925

In O 0 0.0016787042
the O 0 0.0012075232
present O 0 0.00078972935
study O 0 0.0010416812
, O 0 0.0009773914
cis B-Chemical 0 0.07597769
- I-Chemical 0 0.0019513996
platin I-Chemical 0 0.9021211
( O 0 0.0004967277
80 O 0 0.00030613772
- O 0 0.00024402796
120 O 0 0.0001298903
mg O 0 0.002143076
/ O 0 0.00052817725
m2BSA O 0 0.0013636935
) O 0 0.00019869242
and O 0 9.818859e-05
5 B-Chemical 0 7.656522e-05
- I-Chemical 0 0.00023260053
FU I-Chemical 0 0.035635542
( O 0 0.00015142439
1000 O 0 0.00021982046
mg O 0 0.0017532918
/ O 0 0.00032895725
m2BSA O 0 0.00059207785
daily O 0 9.4108545e-05
as O 0 4.5081295e-05
a O 0 6.020372e-05
continuous O 0 3.743035e-05
infusion O 0 9.841487e-05
during O 0 2.60248e-05
5 O 0 3.4493703e-05
days O 0 2.6586233e-05
) O 0 8.3428946e-05
were O 0 5.3275737e-05
given O 0 4.001867e-05
to O 0 7.0727576e-05
76 O 0 0.00018787353
patients O 0 0.00017395963
before O 0 0.000119466364
radiotherapy O 0 0.0020625433
and O 0 0.0008273858
surgery O 0 0.0018026567
. O 0 0.0017569109

The O 0 0.001597701
aim O 0 0.0014793002
of O 0 0.0012027193
the O 0 0.0007701897
study O 0 0.0006771629
was O 0 0.00037761612
to O 0 0.00018592254
clarify O 0 0.00012191553
the O 0 0.00018618014
incidence O 0 0.00039580112
and O 0 0.00020066064
severity O 0 0.0004326954
of O 0 0.00033255573
adverse O 0 0.04957866
cardiac O 0 0.025989251
effects O 0 0.00046547654
to O 0 0.00041064885
this O 0 0.0009274256
treatment O 0 0.00155834
. O 0 0.002099775

Before O 0 0.0018889776
treatment O 0 0.0013735349
all O 0 0.00088164944
patients O 0 0.00080314785
had O 0 0.00040208027
a O 0 0.00042846237
cardiac O 0 0.0033898477
evaluation O 0 0.00020221212
and O 0 0.00015114842
during O 0 8.0606565e-05
treatment O 0 0.00016537783
serial O 0 0.00044290232
ECG O 0 0.03795008
recordings O 0 0.0006538211
were O 0 0.0007087897
performed O 0 0.0011033366
. O 0 0.0019416581

In O 0 0.0017800344
the O 0 0.0014891741
pre O 0 0.0020879188
- O 0 0.0013378486
treatment O 0 0.0004772782
evaluation O 0 0.00038502348
, O 0 0.00040602256
signs O 0 0.0017582496
of O 0 0.00062191597
cardiovascular B-Disease 0 0.9233937
disease I-Disease 0 0.38583425
were O 0 0.00023564148
found O 0 0.00014065034
in O 0 0.00016344257
33 O 0 0.00034630293
patients O 0 0.0004398018
( O 0 0.00058074394
43 O 0 0.00088285946
% O 0 0.0010589653
) O 0 0.0020950362
. O 0 0.0022437784

During O 0 0.0012441616
treatment O 0 0.0016338945
, O 0 0.0015715199
adverse O 0 0.022807255
cardiac O 0 0.018174948
effects O 0 0.0006702591
were O 0 0.00037570173
observed O 0 0.00024109184
in O 0 0.0002632117
14 O 0 0.0003013297
patients O 0 0.00056003616
( O 0 0.0007129717
18 O 0 0.0006882737
% O 0 0.001207315
) O 0 0.0024219123
. O 0 0.0026223361

The O 0 0.0014277847
mean O 0 0.00079282845
age O 0 0.0009474245
of O 0 0.00069097755
these O 0 0.00069411955
patients O 0 0.0005974347
was O 0 0.0002880226
the O 0 0.00016651077
same O 0 9.9676596e-05
as O 0 0.00013383834
for O 0 0.00011705913
the O 0 0.00018093697
entire O 0 0.00021845858
group O 0 0.00050202943
, O 0 0.00069546734
64 O 0 0.0011842212
years O 0 0.0012029139
. O 0 0.0018798135

The O 0 0.0018804892
incidence O 0 0.0029827964
of O 0 0.003274025
cardiotoxicity B-Disease 0 0.999941
was O 0 0.0010112874
not O 0 0.00027201272
higher O 0 0.00024828716
in O 0 0.00015352256
patients O 0 0.00019515467
with O 0 0.00016570363
signs O 0 0.0013537265
of O 0 0.0003604991
cardiovascular B-Disease 0 0.928005
disease I-Disease 0 0.29584202
than O 0 8.364705e-05
in O 0 8.253729e-05
those O 0 0.00011728001
without O 0 9.1681155e-05
in O 0 0.00011282373
the O 0 0.0001861155
pre O 0 0.000576875
- O 0 0.00070133514
treatment O 0 0.0006718352
evaluation O 0 0.0012916991
. O 0 0.0019809185

The O 0 0.0016163329
most O 0 0.0016320297
common O 0 0.0010744771
signs O 0 0.0036646954
of O 0 0.0017302436
cardiotoxicity B-Disease 0 0.9999596
were O 0 0.0010744213
chest B-Disease 0 0.047506716
pain I-Disease 0 0.73646104
, O 0 0.0007853946
ST O 0 0.42486867
- O 0 0.001277397
T O 0 0.24671043
wave O 0 0.0017753027
changes O 0 0.0007202162
and O 0 0.0010893127
atrial B-Disease 0 0.94399697
fibrillation I-Disease 0 0.99975175
. O 0 0.0036468145

This O 0 0.0038827388
was O 0 0.0016625014
followed O 0 0.0007841487
by O 0 0.0010043541
ventricular B-Disease 0 0.9574067
fibrillation I-Disease 0 0.99986625
in O 0 0.00048471344
one O 0 0.00027381562
patient O 0 0.00048387417
and O 0 0.0009454452
sudden B-Disease 0 0.9992217
death I-Disease 0 0.99968207
in O 0 0.0021395332
another O 0 0.002961992
. O 0 0.0026239506

It O 0 0.0026958073
is O 0 0.0012101554
concluded O 0 0.0006200399
that O 0 0.0004195819
patients O 0 0.0005387882
on O 0 0.00019813773
5 B-Chemical 0 0.0002256247
- I-Chemical 0 0.0005440385
FU I-Chemical 0 0.051902432
treatment O 0 0.00016087621
should O 0 6.013567e-05
be O 0 6.481884e-05
under O 0 4.8485304e-05
close O 0 6.0046386e-05
supervision O 0 0.00016714659
and O 0 6.3036605e-05
that O 0 4.20724e-05
the O 0 6.479771e-05
treatment O 0 6.913264e-05
should O 0 3.6222948e-05
be O 0 6.315574e-05
discontinued O 0 0.0002345581
if O 0 9.008732e-05
chest B-Disease 0 0.0055126552
pain I-Disease 0 0.41192725
or O 0 0.0006157886
tachyarrhythmia B-Disease 0 0.996161
is O 0 0.0011041095
observed O 0 0.0012034114
. O 0 0.0018420675

Death B-Disease 0 0.29171076
from O 0 0.003883552
chemotherapy O 0 0.009905824
in O 0 0.0035402921
gestational B-Disease 0 0.01856241
trophoblastic I-Disease 0 0.9437498
disease I-Disease 0 0.79284114
. O 0 0.008230499

Multiple O 0 0.00444496
cytotoxic O 0 0.1237967
drug O 0 0.07283491
administration O 0 0.004176886
is O 0 0.0004873003
the O 0 0.00027262646
generally O 0 0.00026092972
accepted O 0 0.0003665217
treatment O 0 0.00016060918
of O 0 0.00021450697
patients O 0 0.00025996828
with O 0 0.0002124534
a O 0 0.00031138465
high O 0 0.00072156655
- O 0 0.0009044601
risk O 0 0.0032937103
stage O 0 0.0019278629
of O 0 0.0029645124
choriocarcinoma B-Disease 0 0.99912184
. O 0 0.003505973

Based O 0 0.003058952
on O 0 0.0009146459
this O 0 0.00087970006
principle O 0 0.00069041905
a O 0 0.00078349287
27 O 0 0.0007941085
- O 0 0.0005640145
year O 0 0.00015302915
old O 0 0.00021303618
woman O 0 0.00046806587
, O 0 0.00016333399
classified O 0 0.00011379507
as O 0 8.376622e-05
being O 0 0.00010782568
in O 0 6.803061e-05
the O 0 8.563167e-05
high O 0 0.00031416258
- O 0 0.00039205863
risk O 0 0.001300247
group O 0 0.00021827787
( O 0 0.00018778183
Goldstein O 0 0.0014225919
and O 0 0.00012689871
Berkowitz O 0 0.002156051
score O 0 9.6155214e-05
: O 0 0.00014753612
11 O 0 0.00012848218
) O 0 0.00018661343
, O 0 0.00014681184
was O 0 0.00015915635
treated O 0 0.00025854426
with O 0 0.00036234403
multiple O 0 0.000796259
cytotoxic O 0 0.29973862
drugs O 0 0.28312883
. O 0 0.0027357528

The O 0 0.0015870173
multiple O 0 0.001440228
drug O 0 0.004617122
schema O 0 0.0012572657
consisted O 0 0.00040662097
of O 0 0.00054865546
: O 0 0.0008563427
Etoposide B-Chemical 0 0.9994272
16 O 0 0.00036463002
. O 0 0.00016217795
213 O 0 0.0013969776
, O 0 0.00044633064
Methotrexate B-Chemical 0 0.99652725
, O 0 0.00080628454
Cyclophosphamide B-Chemical 0 0.99922407
, O 0 0.0009849962
Actomycin B-Chemical 0 0.8255295
- I-Chemical 0 0.00286036
D I-Chemical 0 0.90075
, O 0 0.0013193393
and O 0 0.0021053257
Cisplatin B-Chemical 0 0.9988385
. O 0 0.0039036751

On O 0 0.0021755118
the O 0 0.0010920413
first O 0 0.0004947303
day O 0 0.00036622732
of O 0 0.0003976384
the O 0 0.00028346656
schedule O 0 0.00028476407
, O 0 0.00028088316
moderate O 0 0.0009555225
high O 0 0.0004678542
doses O 0 0.0019473382
of O 0 0.0009465142
Methotrexate B-Chemical 0 0.99956244
, O 0 0.0013192074
Etoposide B-Chemical 0 0.9998093
and O 0 0.0016643449
Cyclophosphamide B-Chemical 0 0.9987865
were O 0 0.0011751127
administered O 0 0.0017274602
. O 0 0.0019465821

Within O 0 0.0008445824
8 O 0 0.0007846861
hours O 0 0.0003286447
after O 0 0.00016622602
initiation O 0 0.00020474981
of O 0 0.00029720008
therapy O 0 0.0002897252
the O 0 0.00016545372
patient O 0 0.00018507832
died O 0 0.00025601912
with O 0 0.00012475658
a O 0 0.00013337091
clinical O 0 0.00023671718
picture O 0 0.00013840711
resembling O 0 0.00013935808
massive O 0 0.0038412462
pulmonary B-Disease 0 0.9806045
obstruction I-Disease 0 0.9257811
due O 0 8.8458415e-05
to O 0 0.00011187027
choriocarcinomic O 0 0.0025989374
tissue O 0 0.00068659754
plugs O 0 0.0005274422
, O 0 0.00017690008
probably O 0 0.00021653579
originating O 0 0.0001838652
from O 0 0.0003097098
the O 0 0.000731589
uterus O 0 0.005151767
. O 0 0.0019039478

Formation O 0 0.007702743
of O 0 0.0018973011
these O 0 0.0013867744
plugs O 0 0.001785246
was O 0 0.0005505182
probably O 0 0.00038952904
due O 0 0.00015219794
to O 0 0.00016377955
extensive O 0 0.0002942005
tumor B-Disease 0 0.60350794
necrosis B-Disease 2 0.9991091
at O 0 0.000117361444
the O 0 9.041013e-05
level O 0 6.015098e-05
of O 0 9.522158e-05
the O 0 8.549769e-05
walls O 0 0.00055051397
of O 0 9.339656e-05
the O 0 6.8873254e-05
major O 0 9.6691445e-05
uterine O 0 0.006719067
veins O 0 0.01813889
, O 0 9.835831e-05
which O 0 8.204731e-05
resulted O 0 6.5007465e-05
in O 0 5.71168e-05
an O 0 8.851359e-05
open O 0 0.00014076976
exchange O 0 0.0001442658
of O 0 0.00012137916
tumor B-Disease 0 0.093358114
plugs O 0 0.0003291141
to O 0 5.5731325e-05
the O 0 8.161118e-05
vascular O 0 0.017686417
spaces O 0 0.00020262979
; O 0 0.00010127759
decrease O 0 9.5427735e-05
in O 0 8.301326e-05
tumor B-Disease 0 0.081205726
tissue O 0 0.0005969958
coherence O 0 0.0010655075
secondary O 0 0.00028604953
to O 0 8.114178e-05
chemotherapy O 0 0.0006616498
may O 0 6.571728e-05
have O 0 5.473847e-05
further O 0 0.00011168269
contributed O 0 0.00015711025
to O 0 0.000118229495
the O 0 0.00019643534
formation O 0 0.0008634202
of O 0 0.0011387337
tumor B-Disease 0 0.8671495
emboli O 0 0.97882724
. O 0 0.0030992534

In O 0 0.0017714957
view O 0 0.0015017041
of O 0 0.00093321374
the O 0 0.0004768369
close O 0 0.0002688871
time O 0 0.00012864634
association O 0 9.72624e-05
between O 0 6.777413e-05
the O 0 7.94058e-05
start O 0 5.2655734e-05
of O 0 0.000148915
chemotherapy O 0 0.0010551267
and O 0 0.00012074009
the O 0 0.0001329676
acute O 0 0.08817567
onset O 0 0.00032154078
of O 0 0.00034235022
massive O 0 0.1563946
embolism B-Disease 0 0.99994624
other O 0 0.00016463773
explanations O 0 8.8167864e-05
, O 0 0.000111427486
such O 0 7.1180366e-05
as O 0 0.0001379683
spontaneous O 0 0.003703574
necrosis B-Disease 2 0.9993086
, O 0 0.00041823892
must O 0 0.00012670115
be O 0 0.00021121044
considered O 0 0.00027369297
less O 0 0.000658367
likely O 0 0.0010526568
. O 0 0.0019667703

Patients O 0 0.0021260593
with O 0 0.0013839132
large O 0 0.001483637
pelvic B-Disease 0 0.12753887
tumor I-Disease 0 0.95242405
loads O 0 0.0015749758
are O 0 0.00028849585
, O 0 0.00018845609
according O 0 7.584862e-05
to O 0 8.5449676e-05
existing O 0 0.00014676104
classifications O 0 0.00016470949
, O 0 0.00012626033
at O 0 8.009304e-05
high O 0 0.00034072076
risk O 0 0.0013264726
to O 0 0.00019269067
die O 0 0.0005681382
and O 0 0.0002455476
to O 0 0.00026994385
develop O 0 0.00072550087
drug O 0 0.027576521
resistance O 0 0.00500369
. O 0 0.002410215

Notwithstanding O 0 0.0023540321
these O 0 0.0015643121
facts O 0 0.0017760686
our O 0 0.0007487248
findings O 0 0.00061059056
suggest O 0 0.00013273934
that O 0 0.00013614236
these O 0 0.00024981753
patients O 0 0.00019541198
might O 0 6.1159895e-05
benefit O 0 7.822396e-05
from O 0 5.9721853e-05
relatively O 0 0.00016235544
mild O 0 0.024232531
initial O 0 0.00010957366
treatment O 0 0.00013101082
, O 0 0.00011706337
especially O 0 0.00010477301
true O 0 0.00011765245
for O 0 6.962182e-05
patients O 0 0.00015102609
not O 0 0.00010133285
previously O 0 0.00014330374
exposed O 0 0.00021890372
to O 0 0.00032965452
this O 0 0.0010303564
drug O 0 0.04445637
. O 0 0.0021959979

Close O 0 0.0076254625
observation O 0 0.0013003598
of O 0 0.0008574025
the O 0 0.00045820503
response O 0 0.000376083
status O 0 0.00024629437
both O 0 0.00022440137
clinically O 0 0.00087635906
and O 0 0.00022554879
with O 0 0.00044395632
beta O 0 0.95656574
- O 0 0.0011246514
hCG O 0 0.4768774
values O 0 0.00012283014
may O 0 5.759763e-05
indicate O 0 3.272816e-05
whether O 0 2.6908514e-05
and O 0 5.9741848e-05
when O 0 4.1095285e-05
more O 0 0.00012625517
agressive O 0 0.0010617878
combination O 0 0.00024374151
chemotherapy O 0 0.0011205418
should O 0 6.5494925e-05
be O 0 0.00010512719
started O 0 0.00015686445
. O 0 0.00018050153
( O 0 0.00061033224
ABSTRACT O 0 0.0035791083
TRUNCATED O 0 0.0033424555
AT O 0 0.0061220936
250 O 0 0.0032370891
WORDS O 0 0.006587524
) O 0 0.0058513256

Pulmonary O 0 0.011113966
shunt O 0 0.0057656127
and O 0 0.0015869032
cardiovascular O 0 0.10962346
responses O 0 0.0010873439
to O 0 0.0008164742
CPAP O 0 0.29803044
during O 0 0.0010203185
nitroprusside B-Chemical 0 0.99998045
- O 0 0.007653522
induced O 0 0.0058924984
hypotension B-Disease 0 0.9996383
. O 0 0.00543576

The O 0 0.001460385
effects O 0 0.001235289
of O 0 0.00092510803
continuous O 0 0.00044257668
positive O 0 0.0005546961
airway O 0 0.0020190352
pressure O 0 0.0092107635
( O 0 0.0006982008
CPAP O 0 0.23170038
) O 0 0.00025249922
on O 0 7.478837e-05
cardiovascular O 0 0.028320057
dynamics O 0 0.00011737634
and O 0 0.00013835286
pulmonary O 0 0.04674418
shunt O 0 0.0015692031
( O 0 0.00018871595
QS O 0 0.002090569
/ O 0 0.0008080752
QT O 0 0.87502104
) O 0 0.00016731114
were O 0 5.6943627e-05
investigated O 0 3.8475217e-05
in O 0 4.0512743e-05
12 O 0 2.6241069e-05
dogs O 0 4.8286438e-05
before O 0 1.8449857e-05
and O 0 5.1390925e-05
during O 0 6.925161e-05
sodium B-Chemical 1 0.9999865
nitroprusside I-Chemical 1 0.99999964
infusion O 0 0.0012017036
that O 0 5.5971108e-05
decreased O 0 0.00013211984
mean O 0 4.6191268e-05
arterial O 0 0.003984474
blood O 0 0.001469135
pressure O 0 0.0016850486
40 O 0 0.00025107953
- O 0 0.0003940351
50 O 0 0.00042158214
per O 0 0.00026435754
cent O 0 0.0009307266
. O 0 0.001583952

Before O 0 0.005436371
nitroprusside B-Chemical 0 0.99991786
infusion O 0 0.0082466835
, O 0 0.0010512779
5 O 0 0.00043011195
cm O 0 0.0011418978
H2O B-Chemical 1 0.99587655
CPAP O 0 0.55165195
significantly O 0 0.0007282044
, O 0 0.0005609032
P O 0 0.006497417
less O 0 0.00017997908
than O 0 0.000114256414
. O 0 0.00011524614
05 O 0 0.0016902672
, O 0 0.00012065988
decreased O 0 0.00023039753
arterial O 0 0.01854974
blood O 0 0.0032067013
pressure O 0 0.0036201647
, O 0 0.00013985248
but O 0 9.303674e-05
did O 0 8.241382e-05
not O 0 5.9343583e-05
significantly O 0 9.805133e-05
alter O 0 6.424917e-05
heart O 0 0.003830905
rate O 0 0.00013244413
, O 0 0.00013258678
cardiac O 0 0.0028855377
output O 0 0.00016518352
, O 0 0.00020418991
systemic O 0 0.0820467
vascular O 0 0.1367535
resistance O 0 0.001081974
, O 0 0.0004130311
or O 0 0.000457049
QS O 0 0.008366976
/ O 0 0.0053196303
QT O 0 0.8985477
. O 0 0.0026004952

Ten O 0 0.003552938
cm O 0 0.004366984
H2O B-Chemical 1 0.99363554
CPAP O 0 0.4007384
before O 0 0.0006795973
nitroprusside B-Chemical 0 0.99998105
infusion O 0 0.0021040565
produced O 0 0.00024155731
a O 0 0.00022699531
further O 0 0.00018172139
decrease B-Disease 0 0.0001541526
in I-Disease 0 0.00010338645
arterial I-Disease 0 0.013091604
blood I-Disease 0 0.0019047165
pressure I-Disease 0 0.0014206322
and O 0 0.000104422026
significantly O 0 0.00013442758
increased O 0 0.00020216106
heart O 0 0.008888511
rate O 0 0.00015639147
and O 0 0.00015457519
decreased B-Disease 0 0.0010386781
cardiac I-Disease 0 0.016256645
output I-Disease 0 0.0007072823
and O 0 0.00055823755
QS O 0 0.0095262015
/ O 0 0.005150966
QT O 0 0.8974232
. O 0 0.0024581687

Nitroprusside B-Chemical 0 0.99945897
caused O 0 0.0026939067
significant O 0 0.0009548508
decreases B-Disease 0 0.0006390391
in I-Disease 0 0.00038345315
arterial I-Disease 0 0.013851803
blood I-Disease 0 0.0027273707
pressure I-Disease 0 0.0022504337
and O 0 0.00024304021
systemic O 0 0.084619224
vascular O 0 0.11692806
resistance O 0 0.00054255745
and O 0 0.00011435463
increases O 0 9.819514e-05
in O 0 0.00010032598
heart O 0 0.010519012
rate O 0 0.00017470085
, O 0 0.0001426338
but O 0 0.000107705666
did O 0 0.00010579393
not O 0 9.199028e-05
change O 0 0.0001551826
cardiac O 0 0.00291826
output O 0 0.00032998782
or O 0 0.00042443402
QS O 0 0.008178258
/ O 0 0.005091754
QT O 0 0.89630306
. O 0 0.0024718777

Five O 0 0.0036123372
cm O 0 0.0050023887
H2O B-Chemical 1 0.9944588
CPAP O 0 0.47954795
during O 0 0.0009493753
nitroprusside B-Chemical 0 0.999979
did O 0 0.00080045307
not O 0 0.00026610517
further O 0 0.0002873972
alter O 0 0.00014937934
any O 0 0.00014986513
of O 0 0.00025367536
the O 0 0.0002761305
above O 0 0.00045100422
- O 0 0.0008627844
mentioned O 0 0.0007501059
variables O 0 0.0011893682
. O 0 0.0020977797

However O 0 0.0029111425
, O 0 0.0021048107
10 O 0 0.0012447353
cm O 0 0.0026013993
H2O B-Chemical 1 0.993273
CPAP O 0 0.3100386
decreased O 0 0.0013224392
arterial O 0 0.043283068
blood O 0 0.0051127737
pressure O 0 0.004319546
, O 0 0.0004657244
cardiac O 0 0.0051311236
output O 0 0.00047432046
, O 0 0.0005283991
and O 0 0.00069070334
QS O 0 0.008853839
/ O 0 0.0060963053
QT O 0 0.90344083
. O 0 0.0030564782

These O 0 0.0018914478
data O 0 0.0012647362
indicate O 0 0.00057032984
that O 0 0.00085661816
nitroprusside B-Chemical 0 0.9999825
infusion O 0 0.0024399164
rates O 0 0.00022795872
that O 0 9.357379e-05
decrease O 0 0.0001283711
mean O 0 5.979097e-05
arterial O 0 0.004700489
blood O 0 0.0015822289
pressure O 0 0.0013494722
by O 0 0.00011437229
40 O 0 0.00011340122
- O 0 0.0001414568
50 O 0 8.959975e-05
per O 0 2.7494678e-05
cent O 0 5.720008e-05
do O 0 6.722629e-05
not O 0 7.6119744e-05
change O 0 0.00013952373
cardiac O 0 0.0022192884
output O 0 0.00032178886
or O 0 0.000422284
QS O 0 0.007853889
/ O 0 0.00506578
QT O 0 0.89472675
. O 0 0.0024885328

During O 0 0.002161711
nitroprusside B-Chemical 0 0.9998975
infusion O 0 0.0052005653
low O 0 0.0012413178
levels O 0 0.0004505513
of O 0 0.00061387016
CPAP O 0 0.22802642
do O 0 0.00019548187
not O 0 0.00012380413
markedly O 0 0.00037895495
alter O 0 0.00012222296
cardiovascular O 0 0.19587663
dynamics O 0 0.00015663831
, O 0 0.00013876682
but O 0 9.4773e-05
high O 0 0.00014612067
levels O 0 9.4596646e-05
of O 0 0.00022313897
CPAP O 0 0.36768103
( O 0 0.00016932789
10 O 0 9.2153954e-05
cm O 0 0.00038708036
H2O B-Chemical 1 0.9941315
) O 0 0.00028834376
, O 0 0.00011747386
while O 0 8.8364664e-05
decreasing O 0 0.00018856394
QS O 0 0.0054972013
/ O 0 0.0012459345
QT O 0 0.87213546
, O 0 0.00013582234
produce O 0 6.2642896e-05
marked O 0 0.00017505333
decreases B-Disease 0 0.00014069515
in I-Disease 0 0.00013635491
arterial I-Disease 0 0.013094573
blood I-Disease 0 0.0026825848
pressure I-Disease 0 0.002958538
and I-Disease 0 0.0005746782
cardiac I-Disease 0 0.015552917
output I-Disease 0 0.001687736
. O 0 0.0018846797

Systolic O 0 0.071806274
pressure O 0 0.0069562914
variation O 0 0.0011227438
is O 0 0.0005490015
greater O 0 0.00041463357
during O 0 0.00029016222
hemorrhage B-Disease 2 0.9957325
than O 0 0.0002473977
during O 0 0.00031880793
sodium B-Chemical 1 0.9999838
nitroprusside I-Chemical 1 0.9999994
- O 0 0.009636195
induced O 0 0.0016134775
hypotension B-Disease 0 0.9997229
in O 0 0.0010293645
ventilated O 0 0.0043173353
dogs O 0 0.002304407
. O 0 0.0019250609

The O 0 0.0017976989
systolic O 0 0.027843224
pressure O 0 0.0066033704
variation O 0 0.0012692962
( O 0 0.0014800231
SPV O 0 0.4675861
) O 0 0.00086444634
, O 0 0.00033909193
which O 0 0.00025826387
is O 0 0.00014959772
the O 0 0.00010369608
difference O 0 4.9294e-05
between O 0 4.0072788e-05
the O 0 6.063434e-05
maximal O 0 7.290834e-05
and O 0 6.630673e-05
minimal O 0 5.9249887e-05
values O 0 6.654947e-05
of O 0 7.569968e-05
the O 0 7.819741e-05
systolic O 0 0.044716645
blood O 0 0.0018963658
pressure O 0 0.0025574723
( O 0 0.00018731474
SBP O 0 0.028721457
) O 0 0.000108954344
after O 0 2.2484784e-05
one O 0 4.285571e-05
positive O 0 0.00011770104
- O 0 0.00025165878
pressure O 0 0.0036683553
breath O 0 0.04266856
, O 0 0.00015696154
was O 0 0.000119958255
studied O 0 0.00011918963
in O 0 0.00011559085
ventilated O 0 0.0004878176
dogs O 0 0.00030456562
subjected O 0 0.00026270177
to O 0 0.0008955029
hypotension B-Disease 0 0.99918765
. O 0 0.0030716236

Mean O 0 0.0015828543
arterial O 0 0.010657467
pressure O 0 0.0064759823
was O 0 0.00092228205
decreased O 0 0.0008073289
to O 0 0.00030764157
50 O 0 0.00046831177
mm O 0 0.0006184292
Hg O 0 0.2684443
for O 0 8.695964e-05
30 O 0 5.9649057e-05
minutes O 0 4.3420034e-05
either O 0 8.9062065e-05
by O 0 0.00024425844
hemorrhage B-Disease 2 0.9997992
( O 0 0.0014186037
HEM B-Disease 0 0.9998573
, O 0 0.00025765438
n O 0 0.000115628776
= O 0 0.000111341986
7 O 0 5.0659783e-05
) O 0 8.708445e-05
or O 0 4.566786e-05
by O 0 5.516208e-05
continuous O 0 4.792636e-05
infusion O 0 0.00021321887
of O 0 0.00055403775
sodium B-Chemical 1 0.99999046
nitroprusside I-Chemical 1 0.99999964
( O 0 0.0146363415
SNP B-Chemical 1 0.99267113
, O 0 0.00061127567
n O 0 0.00041913777
= O 0 0.0006359784
7 O 0 0.00060595095
) O 0 0.0017306437
. O 0 0.0020866115

During O 0 0.0023473897
HEM B-Disease 0 0.99862766
- O 0 0.003982737
induced O 0 0.0018846323
hypotension B-Disease 0 0.99944216
the O 0 0.00074192113
cardiac O 0 0.0236376
output O 0 0.0003146659
was O 0 0.00019500733
significantly O 0 0.00018049947
lower O 0 0.0001745921
and O 0 0.00015932899
systemic O 0 0.09162396
vascular O 0 0.12680447
resistance O 0 0.0005057392
higher O 0 0.0001481441
compared O 0 7.3451825e-05
with O 0 0.00013472479
that O 0 0.0001284818
in O 0 0.00027333753
the O 0 0.00073275925
SNP B-Chemical 1 0.9664679
group O 0 0.0028573328
. O 0 0.0022343881

The O 0 0.0025506562
systemic O 0 0.029070226
, O 0 0.0016261782
central O 0 0.0013169955
venous O 0 0.05015855
, O 0 0.0007572435
pulmonary O 0 0.08845467
capillary O 0 0.38104597
wedge O 0 0.5990233
pressures O 0 0.0011009601
, O 0 0.00023640906
and O 0 0.00019338015
heart O 0 0.00598109
rates O 0 0.0002149785
, O 0 0.00018767301
were O 0 0.0001357259
similar O 0 0.000108798304
in O 0 0.00019402953
the O 0 0.0003304922
two O 0 0.0004546759
groups O 0 0.0010458694
. O 0 0.0017562738

Analysis O 0 0.0027303589
of O 0 0.0015412994
the O 0 0.0009703434
respiratory O 0 0.0033578228
changes O 0 0.00059262157
in O 0 0.00027957826
the O 0 0.00025811736
arterial O 0 0.006081256
pressure O 0 0.0017662771
waveform O 0 0.00034987277
enabled O 0 0.0003576969
differentiation O 0 0.0014898833
between O 0 0.00020207453
the O 0 0.00041190538
two O 0 0.00052892294
groups O 0 0.0011658208
. O 0 0.0019011952

The O 0 0.0025999907
SPV O 0 0.13464953
during O 0 0.0013202304
hypotension B-Disease 0 0.9985911
was O 0 0.0011346547
15 O 0 0.00037335954
. O 0 0.00022006728
7 O 0 0.00019481889
+ O 0 0.0004747604
/ O 0 0.0007506137
- O 0 0.00039149952
6 O 0 9.021704e-05
. O 0 6.772542e-05
7 O 0 6.639265e-05
mm O 0 0.00021109167
Hg O 0 0.15742283
in O 0 0.00010927732
the O 0 0.000216775
HEM B-Disease 0 0.99978036
group O 0 0.00029741632
, O 0 0.0001147098
compared O 0 5.5217555e-05
with O 0 0.00011436423
9 O 0 7.843161e-05
. O 0 5.4374912e-05
1 O 0 7.759535e-05
+ O 0 0.00021307376
/ O 0 0.00041927779
- O 0 0.00023923481
2 O 0 7.090775e-05
. O 0 4.4925724e-05
0 O 0 5.996227e-05
mm O 0 0.00018550696
Hg O 0 0.1386002
in O 0 0.00010651171
the O 0 0.0002048244
SNP B-Chemical 1 0.97617257
group O 0 0.00051809166
( O 0 0.0004916
P O 0 0.0027124428
less O 0 0.00023639263
than O 0 0.00021810684
0 O 0 0.0003730987
. O 0 0.0005247604
02 O 0 0.005978734
) O 0 0.0023899954
. O 0 0.002354433

The O 0 0.0027541562
delta O 0 0.05533485
down O 0 0.002267335
, O 0 0.0011021704
which O 0 0.000669308
is O 0 0.00033526414
the O 0 0.00019445662
measure O 0 8.6375505e-05
of O 0 0.00017796474
decrease O 0 0.00019329424
of O 0 0.00021109004
SBP O 0 0.01888129
after O 0 4.285988e-05
a O 0 0.00013402263
mechanical O 0 0.0002555565
breath O 0 0.041917805
, O 0 0.00015317896
was O 0 0.00010974829
20 O 0 8.512298e-05
. O 0 5.219534e-05
3 O 0 6.306185e-05
+ O 0 0.00018866375
/ O 0 0.00038159225
- O 0 0.00023057398
8 O 0 6.946451e-05
. O 0 4.710262e-05
4 O 0 4.806981e-05
and O 0 6.8009016e-05
10 O 0 7.1764865e-05
. O 0 5.7990925e-05
1 O 0 8.167962e-05
+ O 0 0.0002181946
/ O 0 0.00042479104
- O 0 0.00024382191
3 O 0 6.645372e-05
. O 0 4.454323e-05
8 O 0 5.0580813e-05
mm O 0 0.00015922207
Hg O 0 0.1211679
in O 0 8.7439264e-05
the O 0 0.00018600357
HEM B-Disease 0 0.99980396
and O 0 0.00048716099
SNP B-Chemical 1 0.9919338
groups O 0 0.00019129463
, O 0 0.00014986999
respectively O 0 0.00027742088
, O 0 0.00013520675
during O 0 0.00010515947
hypotension B-Disease 0 0.9997485
( O 0 0.00096594315
P O 0 0.00442021
less O 0 0.0002305498
than O 0 0.00020409239
0 O 0 0.0003485082
. O 0 0.0004932285
02 O 0 0.005708749
) O 0 0.0022933774
. O 0 0.0022753498

It O 0 0.002799939
is O 0 0.0012627303
concluded O 0 0.0006361915
that O 0 0.00039568948
increases O 0 0.00042576992
in O 0 0.00030835046
the O 0 0.00034585292
SPV O 0 0.17879209
and O 0 0.00021580367
the O 0 0.00020219824
delta O 0 0.0245559
down O 0 0.00023843799
are O 0 9.2250135e-05
characteristic O 0 8.8872024e-05
of O 0 0.00012872032
a O 0 0.0002625831
hypotensive B-Disease 0 0.96797645
state O 0 0.00020980665
due O 0 8.521337e-05
to O 0 0.00012116742
a O 0 0.00024720625
predominant O 0 0.00032531234
decrease O 0 0.0007215724
in O 0 0.0009688589
preload O 0 0.36708146
. O 0 0.0023477739

They O 0 0.0037384613
are O 0 0.0014438933
thus O 0 0.0010412218
more O 0 0.00072554447
important O 0 0.00031953305
during O 0 0.00031678492
absolute O 0 0.0013012865
hypovolemia B-Disease 0 0.99677366
than O 0 0.00069289556
during O 0 0.0006867775
deliberate O 0 0.023209423
hypotension B-Disease 0 0.99960345
. O 0 0.005017745

Ventricular B-Disease 0 0.98607314
tachyarrhythmias I-Disease 0 0.9995419
during O 0 0.0007169822
cesarean O 0 0.00072728103
section O 0 0.0002967805
after O 0 0.0002452645
ritodrine B-Chemical 0 0.99863464
therapy O 0 0.000990173
: O 0 0.0006933962
interaction O 0 0.0006268973
with O 0 0.0020021943
anesthetics O 0 0.9729901
. O 0 0.003562001

This O 0 0.0028739034
case O 0 0.0009784339
illustrates O 0 0.00042278346
that O 0 0.00029649932
patients O 0 0.00051834877
receiving O 0 0.0009012114
ritodrine B-Chemical 0 0.99972254
for O 0 0.00027088588
preterm B-Disease 0 0.7145677
labor I-Disease 0 0.14972891
may O 0 0.00014101372
risk O 0 0.00060173345
interactions O 0 8.174608e-05
between O 0 3.0925676e-05
the O 0 4.6958477e-05
residual O 0 9.395595e-05
betamimetic O 0 0.017176257
effects O 0 0.00012168417
of O 0 0.0003522641
ritodrine B-Chemical 0 0.99978
and O 0 0.00013798343
the O 0 9.540519e-05
effects O 0 0.000159493
of O 0 0.0003948176
anesthetics O 0 0.8225169
during O 0 0.00030424874
cesarean O 0 0.0010145241
section O 0 0.0009718941
. O 0 0.0016310393

Such O 0 0.0033478162
interactions O 0 0.0016465269
may O 0 0.0007926671
result O 0 0.0005658137
in O 0 0.0005413693
serious O 0 0.0070829755
cardiovascular B-Disease 0 0.99907446
complications I-Disease 0 0.8958419
even O 0 0.00035721264
after O 0 9.063128e-05
cessation O 0 0.000254838
of O 0 0.00028519394
an O 0 0.00048418675
infusion O 0 0.001526111
of O 0 0.0023993202
ritodrine B-Chemical 0 0.99949086
. O 0 0.0032297326

Preoperative O 0 0.005161824
assessment O 0 0.0013746317
should O 0 0.00061392196
focus O 0 0.0006613239
on O 0 0.00058325956
cardiovascular O 0 0.19438483
status O 0 0.00095157773
and O 0 0.0013932203
serum O 0 0.45946956
potassium B-Chemical 0 0.99979526
level O 0 0.0050876485
. O 0 0.004421675

Delaying O 0 0.0052656955
induction O 0 0.002928303
of O 0 0.0028381161
anesthesia O 0 0.008991422
should O 0 0.0009187598
be O 0 0.0010785646
considered O 0 0.0010671341
whenever O 0 0.0016921583
possible O 0 0.002892796
. O 0 0.0042227404

Careful O 0 0.0035811425
fluid O 0 0.0038508284
administration O 0 0.002977152
and O 0 0.0009152264
cautious O 0 0.0010565822
use O 0 0.00041340815
of O 0 0.00049568666
titrated O 0 0.000943559
doses O 0 0.0035589393
of O 0 0.0024648327
ephedrine B-Chemical 1 0.99985886
are O 0 0.0023884429
advised O 0 0.0052745943
. O 0 0.0026454483

After O 0 0.0009278577
delivery O 0 0.00088790053
of O 0 0.00095384434
the O 0 0.00068428187
infant O 0 0.0011522993
, O 0 0.00044611818
there O 0 0.00015090388
should O 0 9.8013006e-05
be O 0 0.000106723695
no O 0 6.668217e-05
contraindication O 0 9.664222e-05
to O 0 6.0446942e-05
the O 0 6.695029e-05
use O 0 5.9081696e-05
of O 0 0.00010045819
an O 0 0.00021332136
alpha O 0 0.60293967
- O 0 0.00094041956
adrenergic O 0 0.9755879
vasopressor O 0 0.20410912
such O 0 8.032082e-05
as O 0 0.00016277458
phenylephrine B-Chemical 0 0.9998128
to O 0 0.0001837716
treat O 0 0.0006405382
hypotensive B-Disease 0 0.9896025
patients O 0 0.0011367217
with O 0 0.0015899416
tachycardia B-Disease 2 0.9936081
. O 0 0.002313042

Verapamil B-Chemical 0 0.9995016
- O 0 0.034549255
induced O 0 0.046788245
carbamazepine B-Chemical 1 0.9999558
neurotoxicity B-Disease 2 0.99980587
. O 0 0.02612368

A O 0 0.033905942
report O 0 0.010464311
of O 0 0.008521159
two O 0 0.0066549424
cases O 0 0.012199988
. O 0 0.011572834

Two O 0 0.0017833234
patients O 0 0.0013414724
with O 0 0.0008823806
signs O 0 0.003899528
of O 0 0.0027772645
carbamazepine B-Chemical 1 0.99999785
neurotoxicity B-Disease 2 0.9999728
after O 0 0.00010432469
combined O 0 0.000213634
treatment O 0 0.00014181793
with O 0 0.0003863025
verapamil B-Chemical 0 0.99998343
showed O 0 0.00014937963
complete O 0 8.6781874e-05
recovery O 0 0.00015679373
after O 0 4.3918768e-05
discontinuation O 0 0.0016198393
of O 0 0.00025576222
the O 0 0.00046224124
calcium B-Chemical 0 0.9969518
entry O 0 0.0065812957
blocker O 0 0.9833182
. O 0 0.0030430183

Use O 0 0.0047352547
of O 0 0.0030815601
verapamil B-Chemical 0 0.9998534
in O 0 0.00087516446
combination O 0 0.00093911233
with O 0 0.001681806
carbamazepine B-Chemical 1 0.99999416
should O 0 0.00013468739
either O 0 0.00012451436
be O 0 8.18891e-05
avoided O 0 6.9015005e-05
or O 0 6.349741e-05
prescribed O 0 0.00024090552
only O 0 6.1500104e-05
with O 0 5.529269e-05
appropriate O 0 2.9399469e-05
adjustment O 0 3.440943e-05
of O 0 8.36299e-05
the O 0 0.00021033343
carbamazepine B-Chemical 1 0.9999975
dose O 0 0.005764609
( O 0 0.00017471467
usually O 0 0.00010329046
reduction O 0 0.00020827433
of O 0 0.00017343364
the O 0 0.00038045718
carbamazepine B-Chemical 1 0.9999943
dose O 0 0.0040921373
by O 0 0.00040255007
one O 0 0.0003557722
half O 0 0.00061865884
) O 0 0.0018661835
. O 0 0.0018989985

Paracetamol B-Chemical 0 0.9998399
- O 0 0.010276513
associated O 0 0.0030933234
coma B-Disease 0 0.99879694
, O 0 0.0035588886
metabolic B-Disease 2 0.96624047
acidosis I-Disease 2 0.99994457
, O 0 0.0038856757
renal B-Disease 0 0.9710911
and I-Disease 0 0.003173114
hepatic I-Disease 0 0.99059194
failure I-Disease 0 0.8339533
. O 0 0.004175063

A O 0 0.016144987
case O 0 0.0017711872
of O 0 0.0023008261
metabolic B-Disease 2 0.9513468
acidosis I-Disease 2 0.99995685
, O 0 0.0032091497
acute B-Disease 0 0.8524168
renal I-Disease 0 0.9956189
failure I-Disease 0 0.6632788
and I-Disease 0 0.00073823467
hepatic I-Disease 0 0.97397906
failure I-Disease 0 0.33525154
following O 0 0.00068582984
paracetamol B-Chemical 0 0.9999796
ingestion O 0 0.4239144
is O 0 0.0011024505
presented O 0 0.0014141136
. O 0 0.0019949386

The O 0 0.0033144383
diagnostic O 0 0.0040510525
difficulty O 0 0.003860865
at O 0 0.0021328898
presentation O 0 0.0038681286
is O 0 0.004128687
highlighted O 0 0.0052493215
. O 0 0.006839906

Continuous O 0 0.0048686415
arteriovenous O 0 0.035117093
haemofiltration O 0 0.1262325
proved O 0 0.001653584
a O 0 0.0008695132
valuable O 0 0.00052673835
means O 0 0.00039040917
of O 0 0.0005061173
maintaining O 0 0.00070902443
fluid O 0 0.0020820233
and O 0 0.0013454835
electrolyte O 0 0.5864811
balance O 0 0.006036718
. O 0 0.0031945095

The O 0 0.013315177
patient O 0 0.017183214
recovered O 0 0.018989377
. O 0 0.022897668

Sexual B-Disease 0 0.24644716
dysfunction I-Disease 0 0.9783278
among O 0 0.0069513656
patients O 0 0.007630914
with O 0 0.010008458
arthritis B-Disease 0 0.99487793
. O 0 0.00991668

The O 0 0.0013194599
relationship O 0 0.0007520384
of O 0 0.0019476151
arthritis B-Disease 0 0.9910234
and O 0 0.0014440859
sexual B-Disease 0 0.6238998
dysfunction I-Disease 0 0.9958203
was O 0 0.00037006784
investigated O 0 0.00012509667
among O 0 0.00014573454
169 O 0 0.00047688803
patients O 0 0.00017051469
with O 0 0.00041227308
rheumatoid B-Disease 0 0.9999567
arthritis I-Disease 0 0.99997807
, O 0 0.001073019
osteoarthritis B-Disease 0 0.9947826
and O 0 0.00040999107
spondyloarthropathy B-Disease 0 0.99522346
, O 0 0.00017377928
130 O 0 0.00019601475
of O 0 0.00013395298
whom O 0 0.00025169313
were O 0 0.00014222287
pair O 0 0.00018947138
- O 0 0.00035719175
matched O 0 0.00026544053
to O 0 0.0005079599
controls O 0 0.00186215
. O 0 0.0018911093

Assessments O 0 0.0020509174
of O 0 0.0018303617
marital O 0 0.0024958136
happiness O 0 0.013142381
and O 0 0.0013531033
depressed B-Disease 2 0.99909973
mood I-Disease 0 0.9994429
were O 0 0.0003212123
also O 0 0.00014538171
made O 0 0.000115571
using O 0 0.00010467825
the O 0 0.00020486698
CES O 0 0.15738827
- O 0 0.00070330384
D O 0 0.10182448
and O 0 0.00023217202
the O 0 0.0002671013
Azrin O 0 0.0035432035
Marital O 0 0.0049307435
Happiness O 0 0.013292868
Scale O 0 0.011026797
( O 0 0.001604368
AMHS O 0 0.08509898
) O 0 0.0027147245
. O 0 0.0023238987

Sexual B-Disease 0 0.18902206
dysfunctions I-Disease 0 0.8466861
were O 0 0.0012809534
found O 0 0.0005266405
to O 0 0.00033322573
be O 0 0.00023834163
common O 0 0.00022214401
among O 0 0.00021377417
patients O 0 0.00022842694
and O 0 0.00014926885
controls O 0 0.00024198725
, O 0 0.000117042044
the O 0 8.125459e-05
majority O 0 0.00010248068
in O 0 8.7139364e-05
both O 0 0.00011298016
groups O 0 0.0001258963
reporting O 0 0.00022101332
one O 0 0.00018074541
or O 0 0.0003612713
more O 0 0.0013634864
dysfunctions O 0 0.36115077
. O 0 0.0025721057

Impotence B-Disease 2 0.4769484
was O 0 0.0018534819
more O 0 0.0010685715
common O 0 0.00067372585
among O 0 0.0005401822
male O 0 0.0010729976
patients O 0 0.00029806103
than O 0 0.000113117174
controls O 0 0.0002509228
and O 0 0.00014835106
was O 0 0.00013561826
found O 0 8.443017e-05
to O 0 8.072318e-05
be O 0 8.24723e-05
associated O 0 9.664102e-05
with O 0 0.00024499407
co O 0 0.023018751
- O 0 0.0006131825
morbidity O 0 0.008062799
and O 0 0.00025859918
the O 0 0.00029435454
taking O 0 0.0008069045
of O 0 0.002020021
methotrexate B-Chemical 0 0.999476
. O 0 0.0033198849

Depressed B-Disease 0 0.99792767
mood I-Disease 0 0.9980965
was O 0 0.00165924
more O 0 0.0008409193
common O 0 0.00051575754
among O 0 0.00040332772
patients O 0 0.0003664868
and O 0 0.00021361995
was O 0 0.00017874039
associated O 0 0.00012426195
with O 0 0.00018750702
certain O 0 0.00022097075
sexual O 0 0.002034116
difficulties O 0 0.00071165746
, O 0 0.00036314168
but O 0 0.00036436488
not O 0 0.00048903277
with O 0 0.0017012067
impotence B-Disease 0 0.9024644
. O 0 0.0026825976

Marital O 0 0.09037577
unhappiness O 0 0.6697192
, O 0 0.0018589967
as O 0 0.00070743356
indicated O 0 0.00041850854
by O 0 0.0005277615
AMHS O 0 0.046269637
scores O 0 0.00025330632
, O 0 0.00022595451
was O 0 0.00014839039
not O 0 9.853009e-05
associated O 0 0.00012496387
with O 0 0.0004957991
arthritis B-Disease 0 0.9957879
but O 0 0.0002355496
was O 0 0.00013549584
associated O 0 0.00010455475
with O 0 0.00030309302
sexual B-Disease 0 0.53309715
dysfunction I-Disease 0 0.99771535
, O 0 0.00073549186
sexual O 0 0.007751413
dissatisfaction O 0 0.005788967
and O 0 0.0006423943
being O 0 0.001311328
female O 0 0.0039843605
. O 0 0.0018290987

Does O 0 0.0151005015
paracetamol B-Chemical 0 0.9997273
cause O 0 0.02172191
urothelial B-Disease 0 0.99809796
cancer I-Disease 0 0.99905807
or O 0 0.0067540933
renal B-Disease 2 0.99919933
papillary I-Disease 2 0.99877805
necrosis I-Disease 2 0.999928
? O 0 0.059095927

The O 0 0.0020543125
risk O 0 0.00442208
of O 0 0.0015228908
developing O 0 0.007148703
renal B-Disease 2 0.9991197
papillary I-Disease 2 0.9989666
necrosis I-Disease 2 0.99999166
or O 0 0.0013941015
cancer B-Disease 0 0.92882377
of I-Disease 0 0.00025628877
the I-Disease 0 0.00017420332
renal I-Disease 0 0.84197265
pelvis I-Disease 0 0.071982026
, I-Disease 0 0.00016265959
ureter I-Disease 0 0.0010911115
or I-Disease 0 7.137326e-05
bladder I-Disease 0 0.0011921074
associated O 0 5.433396e-05
with O 0 8.588926e-05
consumption O 0 0.0005529209
of O 0 0.000105124076
either O 0 0.0002859639
phenacetin B-Chemical 1 0.99999905
or O 0 0.0006982942
paracetamol B-Chemical 0 0.9999906
was O 0 0.00011944153
calculated O 0 3.8057242e-05
from O 0 4.3176628e-05
data O 0 7.008865e-05
acquired O 0 0.0001263644
by O 0 0.00010618791
questionnaire O 0 0.00010962016
from O 0 0.00015134958
381 O 0 0.0012671502
cases O 0 0.0004327645
and O 0 0.00063191494
808 O 0 0.039890405
controls O 0 0.002562841
. O 0 0.00195453

The O 0 0.0020787804
risk O 0 0.0051411814
of O 0 0.002389145
renal B-Disease 2 0.99807465
papillary I-Disease 2 0.99845004
necrosis I-Disease 2 0.99998605
was O 0 0.0009842808
increased O 0 0.00041886454
nearly O 0 0.00025540424
20 O 0 0.00017709399
- O 0 0.00024509543
fold O 0 0.00017673284
by O 0 0.0001285475
consumption O 0 0.0020862382
of O 0 0.0010370866
phenacetin B-Chemical 1 0.9999988
, O 0 0.00029747223
which O 0 0.00013265481
also O 0 7.529076e-05
increased O 0 0.00014785412
the O 0 0.000111534435
risk O 0 0.000874778
for O 0 0.00011214445
cancer B-Disease 0 0.71354336
of I-Disease 0 0.00017422391
the I-Disease 0 0.00015787236
renal I-Disease 0 0.85069686
pelvis I-Disease 0 0.06362406
and I-Disease 0 0.00027238255
bladder I-Disease 0 0.0056851525
but O 0 0.00026401653
not O 0 0.0002841138
for O 0 0.0005713745
ureteric B-Disease 0 0.96832734
cancer I-Disease 0 0.9993144
. O 0 0.003691483

By O 0 0.0025960957
contrast O 0 0.0023543683
, O 0 0.0012488907
we O 0 0.00037459383
were O 0 0.00035997832
unable O 0 0.0002326094
to O 0 0.00021049494
substantiate O 0 0.00024478533
an O 0 0.00023802667
increased O 0 0.0003757603
risk O 0 0.0024361243
from O 0 0.00027842517
paracetamol B-Chemical 0 0.9999887
consumption O 0 0.013053953
for O 0 0.0001380653
renal B-Disease 2 0.9988642
papillary I-Disease 2 0.9979843
necrosis I-Disease 2 0.9999945
or O 0 0.00017165941
any O 0 6.620766e-05
of O 0 0.000118197815
these O 0 0.00029551247
cancers B-Disease 0 0.8059955
although O 0 8.731105e-05
there O 0 5.2316183e-05
was O 0 0.00010339039
a O 0 0.00013875768
suggestion O 0 0.00038549613
of O 0 0.00015033572
an O 0 0.00017535406
association O 0 0.0001257185
with O 0 0.0004911736
cancer B-Disease 0 0.8061391
of I-Disease 0 0.0009372941
the I-Disease 0 0.0010947229
ureter I-Disease 0 0.026836
. O 0 0.0020535013

Dapsone B-Chemical 0 0.99878114
- O 0 0.005488054
associated O 0 0.001559218
Heinz O 0 0.39598066
body O 0 0.17740265
hemolytic B-Disease 2 0.9999926
anemia I-Disease 2 0.99999404
in O 0 0.0013524661
a O 0 0.00096923474
Cambodian O 0 0.0126137445
woman O 0 0.00217544
with O 0 0.0013200431
hemoglobin O 0 0.9903619
E O 0 0.99770206
trait O 0 0.1023866
. O 0 0.0031933526

A O 0 0.021696305
Cambodian O 0 0.011542868
woman O 0 0.0034622485
with O 0 0.0016004614
hemoglobin O 0 0.9849113
E O 0 0.99898225
trait O 0 0.046587266
( O 0 0.0009091945
AE O 0 0.5264664
) O 0 0.00050815433
and O 0 0.0002955339
leprosy B-Disease 0 0.7716725
developed O 0 0.0003210672
a O 0 0.00029134116
Heinz O 0 0.31338808
body O 0 0.0846204
hemolytic B-Disease 2 0.99999857
anemia I-Disease 2 0.9999987
while O 0 0.00052131846
taking O 0 0.00028175564
a O 0 0.00013277908
dose O 0 0.00055229326
of O 0 0.00048975024
dapsone B-Chemical 0 0.99995995
( O 0 0.0003310412
50 O 0 0.0002474012
mg O 0 0.004201452
/ O 0 0.00035690513
day O 0 7.506666e-05
) O 0 0.00015118935
not O 0 9.843412e-05
usually O 0 0.00019685326
associated O 0 0.00025119924
with O 0 0.00073888496
clinical O 0 0.008753754
hemolysis B-Disease 0 0.9997416
. O 0 0.004093904

Her O 0 0.008145378
red O 0 0.009070817
blood O 0 0.007946715
cells O 0 0.0018304435
( O 0 0.0013022387
RBCs O 0 0.010004603
) O 0 0.00071288506
had O 0 0.00025250044
increased O 0 0.00028733443
incubated O 0 0.00021359937
Heinz O 0 0.07295759
body O 0 0.001240419
formation O 0 0.0009801807
, O 0 0.0002824065
decreased O 0 0.0010743907
reduced O 0 0.12500466
glutathione B-Chemical 0 0.99999774
( O 0 0.11972627
GSH B-Chemical 1 0.99999774
) O 0 0.0022403512
, O 0 0.0005673487
and O 0 0.0006876725
decreased O 0 0.009668034
GSH B-Chemical 1 0.9999716
stability O 0 0.008201064
. O 0 0.0031739706

The O 0 0.0035338101
pentose B-Chemical 0 0.6949615
phosphate I-Chemical 0 0.99422693
shunt O 0 0.0053275772
activity O 0 0.0005562463
of O 0 0.0006045834
the O 0 0.0008333851
dapsone B-Chemical 0 0.9999131
- O 0 0.0012359899
exposed O 0 0.00044174766
AE O 0 0.692071
RBCs O 0 0.020981679
was O 0 0.0003386774
increased O 0 0.00039486366
compared O 0 0.00023776489
to O 0 0.00046034015
normal O 0 0.0021649213
RBCs O 0 0.018020902
. O 0 0.002626746

Although O 0 0.0016550205
the O 0 0.0017219463
AE O 0 0.2645565
RBCs O 0 0.00719501
from O 0 0.0003602289
an O 0 0.000306765
individual O 0 0.00017791486
not O 0 0.0001884791
taking O 0 0.00078066794
dapsone B-Chemical 0 0.9998605
had O 0 0.00023864431
increased O 0 0.00023155787
incubated O 0 0.00014879082
Heinz O 0 0.09140038
body O 0 0.001028542
formation O 0 0.0008634515
, O 0 0.00027055034
the O 0 0.00055260793
GSH B-Chemical 1 0.9999943
content O 0 0.0018639038
and O 0 0.0017116169
GSH B-Chemical 1 0.99998665
stability O 0 0.0018070808
were O 0 0.001063132
normal O 0 0.002739744
. O 0 0.0019426949

The O 0 0.0035809712
pentose B-Chemical 0 0.71556264
phosphate I-Chemical 0 0.9948754
shunt O 0 0.005519341
activity O 0 0.00052660855
of O 0 0.00046001858
the O 0 0.00034380666
non O 0 0.0006794277
- O 0 0.0021756885
dapsone B-Chemical 0 0.99992466
- O 0 0.0009496034
exposed O 0 0.00034816118
AE O 0 0.66056323
RBCs O 0 0.019186543
was O 0 0.00031237927
decreased O 0 0.00046944883
compared O 0 0.00022016067
to O 0 0.00042977178
normal O 0 0.0020609552
RBCs O 0 0.017239805
. O 0 0.0025342624

Thus O 0 0.002814507
, O 0 0.0030762618
AE O 0 0.41009006
RBCs O 0 0.016197953
appear O 0 0.0005743303
to O 0 0.00029984352
have O 0 0.00017596592
an O 0 0.00023105416
increased O 0 0.00032527145
sensitivity O 0 0.0010187504
to O 0 0.00025624427
oxidant O 0 0.9877265
stress O 0 0.013829159
both O 0 0.00013724244
in O 0 7.792555e-05
vitro O 0 0.00012806765
and O 0 8.654023e-05
in O 0 7.094732e-05
vivo O 0 0.00017918389
, O 0 0.0001207682
since O 0 8.4615065e-05
dapsone B-Chemical 0 0.99987113
does O 0 0.0001384331
not O 0 0.00015652379
cause O 0 0.0023987563
hemolytic B-Disease 2 0.9999982
anemia I-Disease 2 0.9999976
at O 0 0.00022617565
this O 0 0.0002774484
dose O 0 0.0009627839
in O 0 0.00034256044
hematologically O 0 0.61834717
normal O 0 0.002112643
individuals O 0 0.0019613332
. O 0 0.0017431364

Given O 0 0.0013661719
the O 0 0.001772886
influx O 0 0.02002985
of O 0 0.0014789017
Southeast O 0 0.0025134664
Asians O 0 0.0072311307
into O 0 0.00012508976
the O 0 0.00018127318
United O 0 0.00028940802
States O 0 0.0005290424
, O 0 0.00032349722
oxidant O 0 0.9761396
medications O 0 0.007855358
should O 0 4.8563095e-05
be O 0 5.351276e-05
used O 0 4.873047e-05
with O 0 9.314007e-05
caution O 0 7.848338e-05
, O 0 9.206507e-05
especially O 0 7.869307e-05
if O 0 4.7883597e-05
an O 0 0.00013410776
infection B-Disease 0 0.0019928433
is O 0 9.738944e-05
present O 0 6.721456e-05
, O 0 9.5714095e-05
in O 0 7.0094204e-05
individuals O 0 0.00013513959
of O 0 0.00015922813
ethnic O 0 0.0008972782
backgrounds O 0 0.00014338751
that O 0 7.433175e-05
have O 0 8.5836706e-05
an O 0 0.00018346943
increased O 0 0.00038881524
prevalence O 0 0.0005435173
of O 0 0.0015490678
hemoglobin O 0 0.9955937
E O 0 0.9978047
. O 0 0.0037043006

Severe O 0 0.046104796
complications O 0 0.016536178
of O 0 0.0019579895
antianginal O 0 0.9769388
drug O 0 0.05024432
therapy O 0 0.00056228106
in O 0 0.00018838943
a O 0 0.00020497561
patient O 0 0.0001376205
identified O 0 8.3677376e-05
as O 0 7.7771445e-05
a O 0 0.00013081009
poor O 0 0.0005766959
metabolizer O 0 0.98216635
of O 0 0.000691609
metoprolol B-Chemical 1 0.99999726
, O 0 0.002011991
propafenone B-Chemical 0 0.99999225
, O 0 0.0029827736
diltiazem B-Chemical 1 0.9999875
, O 0 0.0019217399
and O 0 0.0027033542
sparteine B-Chemical 0 0.9997609
. O 0 0.0033181875

A O 0 0.027062938
47 O 0 0.004391192
- O 0 0.0025065765
year O 0 0.0006798837
- O 0 0.0008347043
old O 0 0.00036584644
patient O 0 0.0003225589
suffering O 0 0.0027241493
from O 0 0.00020238613
coronary B-Disease 0 0.11376152
artery I-Disease 0 0.1642301
disease I-Disease 0 0.14727774
was O 0 0.00023843959
admitted O 0 0.0002843425
to O 0 0.00011668811
the O 0 0.00020015807
CCU O 0 0.0020034765
in O 0 0.00040712187
shock B-Disease 0 0.6344574
with O 0 0.0024083194
III O 0 0.026012052
. O 0 0.0023850412

AV B-Disease 0 0.89100313
block I-Disease 0 0.010577084
, O 0 0.0040359073
severe O 0 0.124058194
hypotension B-Disease 0 0.99968255
, O 0 0.0023366527
and O 0 0.0012850385
impairment B-Disease 0 0.067652695
of I-Disease 0 0.0023366227
ventricular I-Disease 0 0.88595533
function I-Disease 0 0.0037502686
. O 0 0.0031299684

One O 0 0.0016805121
week O 0 0.00062135933
prior O 0 0.00033231202
to O 0 0.00036846718
admission O 0 0.00048480654
a O 0 0.00031067655
therapy O 0 0.00023446289
with O 0 0.00014966734
standard O 0 0.00010780452
doses O 0 0.00081379147
of O 0 0.0008093247
metoprolol B-Chemical 1 0.99999833
( O 0 0.00059323246
100 O 0 0.0006089566
mg O 0 0.019886246
t O 0 0.0002909811
. O 0 5.8861136e-05
i O 0 0.00019105329
. O 0 5.3196898e-05
d O 0 8.8749905e-05
. O 0 4.1547617e-05
and O 0 5.692202e-05
then O 0 5.9197755e-05
100 O 0 0.00027137497
mg O 0 0.004177249
b O 0 0.0004083357
. O 0 9.1065136e-05
i O 0 0.00028857178
. O 0 0.00011070973
d O 0 0.00023386587
. O 0 0.0001826776
) O 0 0.0004772464
had O 0 0.00047766734
been O 0 0.00065554696
initiated O 0 0.0013625271
. O 0 0.0021954796

Two O 0 0.0015308965
days O 0 0.0005835301
before O 0 0.0004451011
admission O 0 0.0020431732
diltiazem B-Chemical 1 0.99996245
( O 0 0.001059681
60 O 0 0.0004060016
mg O 0 0.006539283
b O 0 0.0006790587
. O 0 0.00015478786
i O 0 0.0003946516
. O 0 0.00014103229
d O 0 0.00025858392
. O 0 0.00017778478
) O 0 0.00041741962
was O 0 0.00042235648
prescribed O 0 0.0012125323
in O 0 0.00066559954
addition O 0 0.0011481335
. O 0 0.0023785355

Analyses O 0 0.0019559956
of O 0 0.0014222314
a O 0 0.0011025319
blood O 0 0.0021287105
sample O 0 0.0005646473
revealed O 0 0.0002948199
unusually O 0 0.0015280318
high O 0 0.00054174976
plasma O 0 0.004421629
concentrations O 0 0.00079313223
of O 0 0.0012629209
metoprolol B-Chemical 1 0.99999833
( O 0 0.00038466926
greater O 0 0.00011334359
than O 0 6.589097e-05
3000 O 0 0.00025904857
ng O 0 0.00032306576
/ O 0 0.0005098155
ml O 0 0.0005703543
) O 0 0.0002919629
and O 0 0.000392661
diltiazem B-Chemical 1 0.99998343
( O 0 0.0009870402
526 O 0 0.0063760197
ng O 0 0.0015120569
/ O 0 0.002490702
ml O 0 0.0033969854
) O 0 0.0026098778
. O 0 0.0023115342

The O 0 0.0018306558
patient O 0 0.0014254865
recovered O 0 0.00076091604
within O 0 0.00029702618
1 O 0 0.00037877003
week O 0 0.00022391153
following O 0 0.0003242271
discontinuation O 0 0.00409607
of O 0 0.001745654
antianginal O 0 0.9581745
therapy O 0 0.0051907664
. O 0 0.0033246265

Three O 0 0.0018231422
months O 0 0.0005873935
later O 0 0.00043080506
the O 0 0.0004449505
patient O 0 0.00042498444
was O 0 0.00027762513
exposed O 0 0.00017695135
to O 0 0.00012582776
a O 0 0.00015655663
single O 0 0.000113440794
dose O 0 0.000524278
of O 0 0.00067959283
metoprolol B-Chemical 1 0.9999989
, O 0 0.0033163605
diltiazem B-Chemical 1 0.99999845
, O 0 0.0033415183
propafenone B-Chemical 0 0.99999654
( O 0 0.0002758474
since O 0 4.2389423e-05
he O 0 6.1028226e-05
had O 0 5.0062306e-05
received O 0 3.7119673e-05
this O 0 7.406388e-05
drug O 0 0.0013003356
in O 0 5.583597e-05
the O 0 6.206724e-05
past O 0 6.747324e-05
) O 0 0.00015911447
, O 0 0.00012150654
and O 0 0.00027925326
sparteine B-Chemical 0 0.99997294
( O 0 0.00023843096
as O 0 6.50616e-05
a O 0 7.7904224e-05
probe O 0 5.830906e-05
for O 0 6.261106e-05
the O 0 0.00033434771
debrisoquine B-Chemical 0 0.9999975
/ O 0 0.014897929
sparteine B-Chemical 0 0.9999603
type O 0 0.00043749073
polymorphism O 0 0.01649481
of O 0 0.0005777426
oxidative O 0 0.74183035
drug O 0 0.23702884
metabolism O 0 0.27152115
) O 0 0.0026668885
. O 0 0.0019863406

It O 0 0.0030297497
was O 0 0.0016599022
found O 0 0.00074035814
that O 0 0.0004556674
he O 0 0.0005304198
was O 0 0.000368024
a O 0 0.00035621884
poor O 0 0.001149497
metabolizer O 0 0.9706322
of O 0 0.00020912797
all O 0 0.00011730585
four O 0 7.762096e-05
drugs O 0 0.0022387935
, O 0 0.00013741778
indicating O 0 6.8782356e-05
that O 0 7.7213816e-05
their O 0 0.0002170329
metabolism O 0 0.008639843
is O 0 0.00015685607
under O 0 0.00012302803
the O 0 0.0001952548
same O 0 0.00022306514
genetic O 0 0.0013855539
control O 0 0.0012650584
. O 0 0.002013763

Therefore O 0 0.0019175629
, O 0 0.0018440253
patients O 0 0.000977356
belonging O 0 0.00033212296
to O 0 0.00028873552
the O 0 0.00029660563
poor O 0 0.00086470204
- O 0 0.001042396
metabolizer O 0 0.9732633
phenotype O 0 0.00056054327
of O 0 0.0006141493
sparteine B-Chemical 0 0.9999826
/ O 0 0.10045601
debrisoquine B-Chemical 0 0.99999857
polymorphism O 0 0.13687253
in O 0 0.00014469906
drug O 0 0.015775312
metabolism O 0 0.0344119
, O 0 0.00011036895
which O 0 9.277477e-05
constitutes O 0 6.179941e-05
6 O 0 4.3309126e-05
. O 0 3.5917605e-05
4 O 0 3.692697e-05
% O 0 4.8226746e-05
of O 0 5.913637e-05
the O 0 6.4856504e-05
German O 0 0.00017531207
population O 0 0.00018853859
, O 0 8.589066e-05
may O 0 5.3044063e-05
experience O 0 0.00012619629
adverse B-Disease 0 0.17168027
drug I-Disease 0 0.020982796
reactions I-Disease 0 0.004114391
when O 0 4.8419373e-05
treated O 0 0.000111288915
with O 0 9.34928e-05
standard O 0 7.9280726e-05
doses O 0 0.00045212256
of O 0 0.00017309825
one O 0 0.00012527968
of O 0 0.00030246403
these O 0 0.00069093704
drugs O 0 0.023273304
alone O 0 0.001763991
. O 0 0.0021135504

Moreover O 0 0.0027173024
, O 0 0.0019024985
the O 0 0.0012084696
coadministration O 0 0.70516247
of O 0 0.0008191203
these O 0 0.0005176742
frequently O 0 0.00025673385
used O 0 0.0002078264
drugs O 0 0.005295964
is O 0 0.00017186839
expected O 0 0.0001111059
to O 0 0.000116246105
be O 0 0.0001224077
especially O 0 0.00017676655
harmful O 0 0.001017052
in O 0 0.00021242972
this O 0 0.00040883195
subgroup O 0 0.0013547654
of O 0 0.0010683668
patients O 0 0.002382753
. O 0 0.001954718

Clinical O 0 0.00808654
experiences O 0 0.0035773236
in O 0 0.0014740195
an O 0 0.0015110371
open O 0 0.0016448416
and O 0 0.0010804175
a O 0 0.0015052647
double O 0 0.002315721
- O 0 0.00312001
blind O 0 0.02089757
trial O 0 0.003589978
. O 0 0.0031034078

A O 0 0.009947457
total O 0 0.0013004619
of O 0 0.0010589759
sixty O 0 0.00088476815
patients O 0 0.00049505907
were O 0 0.00029388655
trated O 0 0.003228672
with O 0 0.00065337657
bromperidol B-Chemical 0 0.9999925
first O 0 0.000105311396
in O 0 9.485039e-05
open O 0 0.00017254389
conditions O 0 0.00012511088
( O 0 0.00013274098
20 O 0 9.224459e-05
patients O 0 0.00015692158
) O 0 0.00014280596
, O 0 7.195661e-05
then O 0 4.409805e-05
on O 0 3.711507e-05
a O 0 0.000101041056
double O 0 0.00017900167
blind O 0 0.0015624224
basis O 0 9.818868e-05
( O 0 0.000119628225
40 O 0 9.502919e-05
patients O 0 0.00015869325
) O 0 0.0002182225
with O 0 0.00046218638
haloperidol B-Chemical 1 0.9999875
as O 0 0.00042398012
the O 0 0.00047093013
reference O 0 0.0010770463
substance O 0 0.48076922
. O 0 0.0024251866

The O 0 0.001699002
open O 0 0.0017520054
study O 0 0.00073257624
lasted O 0 0.0002801244
for O 0 0.00023720699
four O 0 0.00016070141
weeks O 0 0.00010576741
; O 0 0.00020190928
the O 0 0.00017540739
drug O 0 0.0028271743
was O 0 0.00023089122
administrated O 0 0.00055093976
in O 0 0.0001451198
the O 0 0.00015729971
form O 0 0.0001929466
of O 0 0.00041799957
1 O 0 0.00053857616
mg O 0 0.020693483
tablets O 0 0.17257434
. O 0 0.0025083572

The O 0 0.0015906292
daily O 0 0.0017284966
dose O 0 0.0027896236
( O 0 0.00076034776
initial O 0 0.0003760846
dose O 0 0.0016234276
: O 0 0.00040474566
1 O 0 0.00018692331
mg O 0 0.0019007237
; O 0 0.00013791372
mean O 0 4.778224e-05
dose O 0 0.00020975404
at O 0 4.898318e-05
the O 0 5.8559483e-05
end O 0 3.544247e-05
of O 0 8.172815e-05
the O 0 8.224988e-05
trial O 0 0.00013507917
: O 0 0.00010542193
4 O 0 5.4483753e-05
. O 0 4.654896e-05
47 O 0 0.00016312215
mg O 0 0.0021299862
) O 0 0.00021757303
was O 0 0.00012664282
always O 0 0.00014549543
administered O 0 0.00019477081
in O 0 0.0002107739
one O 0 0.00028728214
single O 0 0.00072520366
dose O 0 0.0039929366
. O 0 0.0021463335

Nineteen O 0 0.0060114544
patients O 0 0.0017370664
finished O 0 0.0010622765
the O 0 0.00062840956
trial O 0 0.00069935113
, O 0 0.0004182397
and O 0 0.00027224183
in O 0 0.00019701042
18 O 0 0.00015989925
cases O 0 0.00015863938
the O 0 0.0001287391
therapeutic O 0 0.00029549244
result O 0 0.00018353346
was O 0 0.00023006013
considered O 0 0.00018788985
very O 0 0.00048331963
good O 0 0.00086947676
to O 0 0.00077944255
good O 0 0.002709348
. O 0 0.0023794272

These O 0 0.0046839737
results O 0 0.003799867
were O 0 0.0032075197
confirmed O 0 0.0030615737
by O 0 0.0034874554
statistical O 0 0.005691614
analysis O 0 0.00575366
. O 0 0.006629169

Nine O 0 0.004078213
patients O 0 0.0017512509
exhibited O 0 0.0011890783
mild O 0 0.036659174
to O 0 0.0005649821
moderate O 0 0.03498966
extrapyramidal B-Disease 0 0.9999844
concomitant I-Disease 0 0.059110355
symptoms I-Disease 0 0.47350514
; O 0 0.0003883953
no O 0 0.00015080333
other O 0 0.0002774135
side O 0 0.0025328696
effects O 0 0.0007908142
were O 0 0.000966449
observed O 0 0.0013178687
. O 0 0.0022022924

The O 0 0.0014262327
results O 0 0.001106352
of O 0 0.0008720962
detailed O 0 0.0004445547
laboratory O 0 0.00067374564
tests O 0 0.0005157644
and O 0 0.00018829138
evaluations O 0 0.00012170228
of O 0 0.0001447849
various O 0 0.00012722999
quantitative O 0 0.00018633217
and O 0 0.00010665675
qualitative O 0 0.00022922592
tolerability O 0 0.0010410184
parameters O 0 0.00014953667
were O 0 0.00012762414
not O 0 0.00013317342
indicative O 0 0.00022592218
of O 0 0.0006821293
toxic O 0 0.16411449
effects O 0 0.003032642
. O 0 0.0026721063

In O 0 0.0016121523
the O 0 0.0012661229
double O 0 0.0014535866
blind O 0 0.006078115
study O 0 0.0006743784
with O 0 0.0012835223
haloperidol B-Chemical 1 0.99999547
, O 0 0.000567897
both O 0 0.0002542381
substances O 0 0.028999366
were O 0 0.00012896309
found O 0 7.050232e-05
to O 0 6.0507205e-05
be O 0 5.31007e-05
highly O 0 5.0478226e-05
effective O 0 4.351239e-05
in O 0 4.8514397e-05
the O 0 5.8612328e-05
treatment O 0 8.868342e-05
of O 0 0.0003515921
psychotic B-Disease 0 0.99996996
syndromes I-Disease 0 0.027586684
belonging I-Disease 0 8.8876775e-05
predominantly I-Disease 0 0.00014369341
to I-Disease 0 0.00019351517
the I-Disease 0 0.0005656182
schizophrenia I-Disease 2 0.9995047
group I-Disease 0 0.0026627495
. O 0 0.0018888201

Certain O 0 0.0044178646
clues O 0 0.0023828119
, O 0 0.0013391012
including O 0 0.00048784786
the O 0 0.00048025826
onset O 0 0.0005661362
of O 0 0.00048638709
action O 0 0.00063657144
, O 0 0.00037223683
seem O 0 0.00021626095
to O 0 0.00015373732
be O 0 0.00014258595
indicative O 0 0.00014065597
of O 0 0.00024638764
the O 0 0.0003052901
superiority O 0 0.00069977157
of O 0 0.0031375147
bromperidol B-Chemical 0 0.99996996
. O 0 0.0040876525

No O 0 0.0029703812
differences O 0 0.0009931367
were O 0 0.00091865176
observed O 0 0.00057385315
with O 0 0.0005846939
respect O 0 0.00038318982
to O 0 0.00051685056
side O 0 0.0029233731
effects O 0 0.00095328013
and O 0 0.0011127723
general O 0 0.0018656427
tolerability O 0 0.028995568
. O 0 0.0033050631

Prolonged O 0 0.032236915
cholestasis B-Disease 2 0.9998834
after O 0 0.005775461
troleandomycin B-Chemical 0 0.9999864
- O 0 0.037289806
induced O 0 0.018149193
acute O 0 0.9994522
hepatitis B-Disease 2 0.99998784
. O 0 0.035457365

We O 0 0.0016724395
report O 0 0.0016588521
the O 0 0.0008253896
case O 0 0.00054629415
of O 0 0.00050818245
a O 0 0.00044917964
patient O 0 0.0003291734
in O 0 0.0002929768
whom O 0 0.0052875928
troleandomycin B-Chemical 0 0.9999987
- O 0 0.006460086
induced O 0 0.0025496555
hepatitis B-Disease 2 0.9999919
was O 0 0.0010809931
followed O 0 0.00032399013
by O 0 0.000625036
prolonged O 0 0.009044121
anicteric O 0 0.99987364
cholestasis B-Disease 2 0.9999887
. O 0 0.008492724

Jaundice B-Disease 0 0.78823656
occurred O 0 0.0012558713
after O 0 0.00045838827
administration O 0 0.0023841453
of O 0 0.0025109737
troleandomycin B-Chemical 0 0.9999933
for O 0 0.0005134539
7 O 0 0.00022404564
days O 0 0.00013046552
and O 0 0.0002930578
was O 0 0.0004549261
associated O 0 0.00067808025
with O 0 0.002824049
hypereosinophilia B-Disease 0 0.99950457
. O 0 0.0046730405

Jaundice B-Disease 0 0.81557316
disappeared O 0 0.0015081225
within O 0 0.00038352807
3 O 0 0.00037106016
months O 0 0.0001645445
but O 0 0.00024554736
was O 0 0.00020582284
followed O 0 0.00012644767
by O 0 0.00018915946
prolonged O 0 0.0013186033
anicteric O 0 0.99994564
cholestasis B-Disease 2 0.9999987
marked O 0 0.020762911
by O 0 0.00084574
pruritus B-Disease 0 0.9997272
and O 0 0.00023350226
high O 0 0.00028828252
levels O 0 0.00018003503
of O 0 0.00040916103
alkaline O 0 0.30731323
phosphatase O 0 0.41565102
and O 0 0.0015325216
gammaglutamyltransferase O 0 0.5359656
activities O 0 0.002618016
. O 0 0.0023435114

Finally O 0 0.0030671472
, O 0 0.0040841284
pruritus B-Disease 0 0.99590486
disappeared O 0 0.0009348357
within O 0 0.00023044914
19 O 0 0.0004275014
months O 0 0.000113241935
, O 0 0.0002078692
and O 0 0.00022527152
liver O 0 0.24568728
tests O 0 0.0004235067
returned O 0 0.00012564936
to O 0 9.920334e-05
normal O 0 0.0002433124
27 O 0 0.00015751449
months O 0 4.4375043e-05
after O 0 5.6197558e-05
the O 0 0.00021737107
onset O 0 0.0008085223
of O 0 0.003270353
hepatitis B-Disease 2 0.9999473
. O 0 0.0066058137

This O 0 0.0033262165
observation O 0 0.0013064356
demonstrates O 0 0.0006055183
that O 0 0.0005686672
prolonged O 0 0.00423296
cholestasis B-Disease 2 0.9999844
can O 0 0.0009299479
follow O 0 0.00095020165
troleandomycin B-Chemical 0 0.9999951
- O 0 0.008135914
induced O 0 0.006400087
acute O 0 0.99962056
hepatitis B-Disease 2 0.9999939
. O 0 0.020849727

Serial O 0 0.003948293
studies O 0 0.0017258608
of O 0 0.0017588548
auditory B-Disease 0 0.05055503
neurotoxicity I-Disease 2 0.999928
in O 0 0.0019038918
patients O 0 0.0027310082
receiving O 0 0.0068127527
deferoxamine B-Chemical 0 0.9998896
therapy O 0 0.02011548
. O 0 0.004242758

Visual B-Disease 0 0.05987932
and I-Disease 0 0.0024662227
auditory I-Disease 0 0.13284764
neurotoxicity I-Disease 2 0.99995947
was O 0 0.0014687405
previously O 0 0.00037605307
documented O 0 0.00030786457
in O 0 0.00013260776
42 O 0 0.00013118131
of O 0 0.00012265412
89 O 0 0.0002245512
patients O 0 0.00012270173
with O 0 0.00012761209
transfusion O 0 0.0016754727
- O 0 0.00023941325
dependent O 0 8.494823e-05
anemia B-Disease 0 0.9999205
who O 0 0.00049482554
were O 0 0.00013439091
receiving O 0 0.00046142834
iron B-Chemical 0 0.99987423
chelation O 0 0.9657047
therapy O 0 0.00048681884
with O 0 0.0003823047
daily O 0 0.0008981147
subcutaneous O 0 0.015599264
deferoxamine B-Chemical 0 0.99985015
. O 0 0.003760384

Twenty O 0 0.0039511714
- O 0 0.0022617986
two O 0 0.0005503577
patients O 0 0.0005691135
in O 0 0.00027166103
the O 0 0.000222938
affected O 0 0.0002453012
group O 0 0.00021137543
had O 0 0.00012977491
abnormal B-Disease 0 0.001136339
audiograms I-Disease 0 0.118764445
with I-Disease 0 0.00025705225
deficits I-Disease 0 0.058857363
mostly I-Disease 0 0.0001664733
in I-Disease 0 6.367388e-05
the I-Disease 0 5.9685128e-05
high I-Disease 0 0.0001249516
frequency I-Disease 0 8.350017e-05
range I-Disease 0 7.207349e-05
of I-Disease 0 9.837425e-05
4 I-Disease 0 5.4833552e-05
, I-Disease 0 6.63032e-05
000 I-Disease 0 7.244227e-05
to I-Disease 0 5.319436e-05
8 I-Disease 0 5.120083e-05
, I-Disease 0 6.739742e-05
000 I-Disease 0 9.641431e-05
Hz I-Disease 0 0.0004419454
and O 0 8.255933e-05
in O 0 7.395372e-05
the O 0 0.00012090486
hearing O 0 0.73887247
threshold O 0 0.00021190959
levels O 0 0.0002076636
of O 0 0.00029421397
30 O 0 0.00023214234
to O 0 0.00039359246
100 O 0 0.0017167707
decibels O 0 0.0075848536
. O 0 0.0022727079

When O 0 0.0025962219
deferoxamine B-Chemical 0 0.9996495
therapy O 0 0.0032192266
was O 0 0.00091566355
discontinued O 0 0.0012054053
and O 0 0.00025086247
serial O 0 0.0002412935
studies O 0 0.00015045576
were O 0 0.00010235546
performed O 0 8.109367e-05
, O 0 0.00012439807
audiograms O 0 0.010416027
in O 0 8.759784e-05
seven O 0 7.001585e-05
cases O 0 9.750234e-05
reverted O 0 0.00029616148
to O 0 6.386238e-05
normal O 0 0.0001578501
or O 0 5.1224175e-05
near O 0 6.7297486e-05
normal O 0 9.4098155e-05
within O 0 1.691985e-05
two O 0 2.5451034e-05
to O 0 3.2605232e-05
three O 0 2.392823e-05
weeks O 0 2.3997269e-05
, O 0 6.4559325e-05
and O 0 6.944769e-05
nine O 0 7.827484e-05
of O 0 0.00012229488
13 O 0 0.00013439848
patients O 0 0.00020020865
with O 0 0.0003155807
symptoms O 0 0.004155745
became O 0 0.0014564159
asymptomatic O 0 0.015877606
. O 0 0.002003938

Audiograms O 0 0.011738746
from O 0 0.001134551
15 O 0 0.00068031077
patients O 0 0.0006582164
remained O 0 0.00053161074
abnormal O 0 0.0012175298
and O 0 0.00027858978
four O 0 0.00014003209
patients O 0 0.00024334813
required O 0 0.00016621144
hearing O 0 0.81196237
aids O 0 0.0012422788
because O 0 0.0004173627
of O 0 0.0015020961
permanent B-Disease 0 0.5917858
disability I-Disease 0 0.97149086
. O 0 0.0036497805

Since O 0 0.0013411962
18 O 0 0.00107179
of O 0 0.00077196566
the O 0 0.00048894976
22 O 0 0.00045014775
patients O 0 0.00032006353
were O 0 0.00017051322
initially O 0 0.0002478659
receiving O 0 0.0007346453
deferoxamine B-Chemical 0 0.9999734
doses O 0 0.017019873
in O 0 0.00015469904
excess O 0 0.00033760408
of O 0 0.00011900316
the O 0 7.0872724e-05
commonly O 0 7.453469e-05
recommended O 0 6.4783446e-05
50 O 0 0.00013397458
mg O 0 0.0023329966
/ O 0 0.00027713753
kg O 0 0.00013422278
per O 0 2.1437158e-05
dose O 0 0.00018967493
, O 0 8.220981e-05
therapy O 0 9.6411924e-05
was O 0 7.19702e-05
restarted O 0 0.00012836375
with O 0 8.816619e-05
lower O 0 0.00014254163
doses O 0 0.0006869445
, O 0 9.573144e-05
usually O 0 9.474426e-05
50 O 0 0.00015482506
mg O 0 0.0027127254
/ O 0 0.0002885751
kg O 0 0.0001358494
per O 0 2.07886e-05
dose O 0 0.00014106013
or O 0 4.507046e-05
less O 0 5.2847205e-05
depending O 0 4.1102263e-05
on O 0 2.6912929e-05
the O 0 4.5464894e-05
degree O 0 7.4293566e-05
of O 0 0.00010419951
auditory B-Disease 0 0.015554947
abnormality I-Disease 0 0.652173
, O 0 0.00016368806
and O 0 8.512184e-05
with O 0 8.689532e-05
the O 0 6.7295114e-05
exception O 0 6.339232e-05
of O 0 0.00010626671
two O 0 7.3536554e-05
cases O 0 0.00015584497
no O 0 0.00012624673
further O 0 0.00071825896
toxicity B-Disease 2 0.994294
was O 0 0.0015886765
demonstrated O 0 0.0013838473
. O 0 0.00199051

Auditory O 0 0.011707864
deterioration O 0 0.013842645
and O 0 0.0011412444
improvement O 0 0.0007518463
, O 0 0.00042222362
demonstrated O 0 0.00017268858
serially O 0 0.00013809754
in O 0 0.000102613565
individual O 0 9.4410025e-05
patients O 0 0.00014931893
receiving O 0 0.00013760805
and O 0 8.390925e-05
not O 0 9.352686e-05
receiving O 0 0.0006906363
deferoxamine B-Chemical 0 0.9999862
, O 0 0.00062707416
respectively O 0 0.0006932291
, O 0 0.0001349099
provided O 0 9.862034e-05
convincing O 0 0.00016651569
evidence O 0 6.284532e-05
for O 0 6.0036768e-05
a O 0 0.00017699743
cause O 0 0.0002949498
- O 0 0.000326452
and O 0 0.0001364033
- O 0 0.00017982126
effect O 0 7.519276e-05
relation O 0 6.542837e-05
between O 0 0.00018672911
deferoxamine B-Chemical 0 0.999946
administration O 0 0.10570627
and O 0 0.0051860805
ototoxicity B-Disease 0 0.99990463
. O 0 0.004752863

Based O 0 0.0031271635
on O 0 0.0010135479
these O 0 0.001203846
data O 0 0.00088623544
, O 0 0.0006208082
a O 0 0.0004516323
plan O 0 0.0004368761
of O 0 0.00034814829
management O 0 0.00031468386
was O 0 0.00022762055
developed O 0 0.00021367798
that O 0 0.00010206561
allows O 0 0.00013388926
effective O 0 0.00017363651
yet O 0 0.00031542458
safe O 0 0.0005407948
administration O 0 0.0026110634
of O 0 0.0036161423
deferoxamine B-Chemical 0 0.99990416
. O 0 0.00538597

A O 0 0.017418573
dose O 0 0.004926913
of O 0 0.0016067812
50 O 0 0.001779539
mg O 0 0.030689713
/ O 0 0.0020923843
kg O 0 0.00111964
is O 0 0.00033220812
recommended O 0 0.00029259044
in O 0 0.0002941663
those O 0 0.00053371215
without O 0 0.00079763203
audiogram O 0 0.34027773
abnormalities O 0 0.17228387
. O 0 0.0032113332

With O 0 0.0044539073
mild O 0 0.6931383
toxicity B-Disease 2 0.9982845
, O 0 0.0015234438
a O 0 0.00071981206
reduction O 0 0.00069810264
to O 0 0.00018543673
30 O 0 0.000114956936
or O 0 9.89289e-05
40 O 0 0.00013813666
mg O 0 0.0018199024
/ O 0 0.0003786249
kg O 0 0.00019630352
per O 0 3.130748e-05
dose O 0 0.00017433226
should O 0 3.3909793e-05
result O 0 5.394447e-05
in O 0 6.0086488e-05
a O 0 9.9964716e-05
reversal O 0 0.00016203792
of O 0 0.00010716128
the O 0 9.65457e-05
abnormal O 0 0.0006180315
results O 0 0.00013185728
to O 0 0.00012556936
normal O 0 0.00031208544
within O 0 0.000118547156
four O 0 0.000284525
weeks O 0 0.00045737717
. O 0 0.0013877683

Moderate O 0 0.0708884
abnormalities O 0 0.008701461
require O 0 0.0006131492
a O 0 0.0007558891
reduction O 0 0.0010950477
of O 0 0.0012264748
deferoxamine B-Chemical 0 0.9999378
to O 0 0.0004982753
25 O 0 0.0005763452
mg O 0 0.009034549
/ O 0 0.00073953415
kg O 0 0.0004138884
per O 0 0.00010500356
dose O 0 0.00061751134
with O 0 0.0005456572
careful O 0 0.0010154379
monitoring O 0 0.0014401678
. O 0 0.0020243688

In O 0 0.0016907308
those O 0 0.0015099734
with O 0 0.0011049486
symptoms O 0 0.0052891853
of O 0 0.0011213928
hearing B-Disease 0 0.98263794
loss I-Disease 0 0.0056986944
, O 0 0.00038635998
the O 0 0.00020174877
drug O 0 0.0030437012
should O 0 5.658668e-05
be O 0 6.410712e-05
stopped O 0 9.528217e-05
for O 0 4.487704e-05
four O 0 3.6357265e-05
weeks O 0 2.488237e-05
, O 0 5.8747188e-05
and O 0 5.1150568e-05
when O 0 3.435753e-05
the O 0 7.794057e-05
audiogram O 0 0.04154644
is O 0 8.91149e-05
stable O 0 9.95607e-05
or O 0 6.8305e-05
improved O 0 0.00020329318
, O 0 0.00010825861
therapy O 0 0.00010317351
should O 0 3.4806762e-05
be O 0 5.302712e-05
restarted O 0 0.00010962727
at O 0 4.6819277e-05
10 O 0 6.754508e-05
to O 0 8.320981e-05
25 O 0 0.00022386052
mg O 0 0.0023864394
/ O 0 0.00086139044
kg O 0 0.00077895774
per O 0 0.00032531234
dose O 0 0.0025708876
. O 0 0.0020069822

Serial O 0 0.0044965036
audiograms O 0 0.019859014
should O 0 0.0005392522
be O 0 0.00036664493
performed O 0 0.00019573871
every O 0 7.626615e-05
six O 0 7.937135e-05
months O 0 5.1292805e-05
in O 0 7.940792e-05
those O 0 0.000117183656
without O 0 9.088339e-05
problems O 0 0.0002465728
and O 0 0.00010069133
more O 0 0.00011933064
frequently O 0 7.4808544e-05
in O 0 6.8718495e-05
young O 0 0.00035692027
patients O 0 9.32613e-05
with O 0 8.363605e-05
normal O 0 0.00028872833
serum O 0 0.05489952
ferritin O 0 0.99797887
values O 0 0.00023708037
and O 0 0.00015805748
in O 0 0.0001517519
those O 0 0.00031460077
with O 0 0.0005830639
auditory B-Disease 0 0.079838425
dysfunction I-Disease 0 0.9976858
. O 0 0.003487863

Lidocaine B-Chemical 0 0.998487
- O 0 0.02274719
induced O 0 0.016494779
cardiac B-Disease 0 0.984744
asystole I-Disease 0 0.99881977
. O 0 0.017906155

Intravenous O 0 0.15881743
administration O 0 0.0048501627
of O 0 0.0011826082
a O 0 0.000754744
single O 0 0.00042744886
50 O 0 0.00056342315
- O 0 0.00050374115
mg O 0 0.0032573878
bolus O 0 0.0010028826
of O 0 0.00044691542
lidocaine B-Chemical 0 0.99976915
in O 0 0.00016382422
a O 0 0.00019942751
67 O 0 0.00030720836
- O 0 0.00021868448
year O 0 6.685657e-05
- O 0 0.0001609471
old O 0 0.0001034757
man O 0 0.0006098854
resulted O 0 8.176035e-05
in O 0 8.2634e-05
profound O 0 0.0012434319
depression B-Disease 0 0.96149814
of O 0 0.00015395941
the O 0 8.0153106e-05
activity O 0 7.80633e-05
of O 0 0.00013004374
the O 0 0.00016393517
sinoatrial O 0 0.019335924
and O 0 0.00037049694
atrioventricular O 0 0.013623615
nodal O 0 0.004365604
pacemakers O 0 0.0046198005
. O 0 0.0014706902

The O 0 0.0016512304
patient O 0 0.001473531
had O 0 0.00074314314
no O 0 0.00031348073
apparent O 0 0.00039874375
associated O 0 0.00023776853
conditions O 0 0.00026392538
which O 0 0.00022444974
might O 0 0.00010399096
have O 0 0.000121031735
predisposed O 0 0.0019442618
him O 0 0.00047751667
to O 0 6.720962e-05
the O 0 7.133897e-05
development O 0 0.00017838401
of O 0 0.00036198445
bradyarrhythmias B-Disease 0 0.9997657
; O 0 0.0002736974
and O 0 0.00013399028
, O 0 0.00012389317
thus O 0 0.00013143974
, O 0 0.00011162137
this O 0 0.00011657279
probably O 0 0.00017915844
represented O 0 0.00016374596
a O 0 0.00030088413
true O 0 0.00054046675
idiosyncrasy O 0 0.088463135
to O 0 0.0016373862
lidocaine B-Chemical 0 0.99949384
. O 0 0.0031851756

Flurbiprofen B-Chemical 0 0.99912626
in O 0 0.0032598253
the O 0 0.0021517577
treatment O 0 0.0023396239
of O 0 0.0052442895
juvenile B-Disease 0 0.9846615
rheumatoid I-Disease 0 0.9998159
arthritis I-Disease 0 0.9998648
. O 0 0.011721058

Thirty O 0 0.0032819035
- O 0 0.0020539472
four O 0 0.00047179367
patients O 0 0.0006580935
with O 0 0.0008161667
juvenile B-Disease 0 0.93150264
rheumatoid I-Disease 0 0.9999634
arthritis I-Disease 0 0.9999881
, O 0 0.0006809763
who O 0 0.00030504368
were O 0 0.000102048776
treated O 0 0.00015885053
with O 0 0.00036585133
flurbiprofen B-Chemical 0 0.99999166
at O 0 7.423173e-05
a O 0 9.058687e-05
maximum O 0 6.2813386e-05
dose O 0 0.00027331564
of O 0 0.00010986315
4 O 0 6.256541e-05
mg O 0 0.0014404606
/ O 0 0.00033383653
kg O 0 0.0002319125
/ O 0 0.00019071368
day O 0 4.3377575e-05
, O 0 7.468994e-05
had O 0 6.7337736e-05
statistically O 0 6.538296e-05
significant O 0 5.291255e-05
decreases O 0 6.9424124e-05
from O 0 5.0195253e-05
baseline O 0 5.7020035e-05
in O 0 7.286295e-05
6 O 0 7.869674e-05
arthritis B-Disease 0 0.5900323
indices O 0 0.00013833161
after O 0 5.646023e-05
12 O 0 9.703395e-05
weeks O 0 0.00011551206
of O 0 0.0005195332
treatment O 0 0.001198844
. O 0 0.0019938129

Improvements O 0 0.0021142524
were O 0 0.0011890025
seen O 0 0.00061889325
in O 0 0.00038236863
the O 0 0.00029872727
number O 0 0.00025476754
of O 0 0.00044266635
tender B-Disease 0 0.034310218
joints I-Disease 0 0.21800299
, O 0 0.00022893911
the O 0 0.00013569575
severity O 0 0.00037124773
of O 0 0.00037831458
swelling B-Disease 0 0.95512044
and O 0 0.00058329455
tenderness B-Disease 0 0.94362336
, O 0 0.00014350378
the O 0 6.3518375e-05
time O 0 3.432167e-05
of O 0 9.482019e-05
walk O 0 0.00026430032
50 O 0 0.00018727368
feet O 0 0.0010627392
, O 0 8.376519e-05
the O 0 5.3357493e-05
duration O 0 3.2959975e-05
of O 0 0.000118344324
morning B-Disease 0 0.003588828
stiffness I-Disease 0 0.21670334
and O 0 0.00019005907
the O 0 0.00019159728
circumference O 0 0.0009406615
of O 0 0.0003585217
the O 0 0.00053495
left O 0 0.002764139
knee O 0 0.070635684
. O 0 0.0025829303

The O 0 0.0017544172
most O 0 0.0017423797
frequently O 0 0.00085029093
observed O 0 0.0006133125
side O 0 0.002820442
effect O 0 0.00041237686
was O 0 0.00048028072
fecal B-Disease 0 0.094709836
occult I-Disease 0 0.120308205
blood I-Disease 0 0.13325872
( O 0 0.00031170988
25 O 0 0.00017402436
% O 0 0.00010648216
of O 0 0.00014191709
patients O 0 0.00026959684
) O 0 0.00026558407
; O 0 0.00014953139
however O 0 0.0001461969
, O 0 0.0001100755
there O 0 5.355309e-05
was O 0 8.875803e-05
no O 0 4.4631037e-05
other O 0 6.562252e-05
evidence O 0 7.84768e-05
of O 0 0.0002252348
gastrointestinal B-Disease 0 0.673662
( I-Disease 0 0.00064560835
GI I-Disease 0 0.4861001
) I-Disease 0 0.00090220466
bleeding I-Disease 0 0.8346339
in O 0 0.00044217738
these O 0 0.0009636952
patients O 0 0.001922071
. O 0 0.0018153155

One O 0 0.0024334951
patient O 0 0.0017667529
was O 0 0.0012200065
prematurely O 0 0.0026597348
discontinued O 0 0.0013886661
from O 0 0.000293623
the O 0 0.00028705545
study O 0 0.00035803436
for O 0 0.00033090235
severe O 0 0.046013553
headache B-Disease 0 0.9992512
and O 0 0.002341797
abdominal B-Disease 0 0.14430726
pain I-Disease 0 0.81481504
. O 0 0.0032295065

Most O 0 0.0055420483
side O 0 0.008970801
effects O 0 0.0022218577
were O 0 0.001773627
mild O 0 0.041027103
and O 0 0.00091041514
related O 0 0.00045716617
to O 0 0.00079900585
the O 0 0.0015225817
GI O 0 0.24327217
tract O 0 0.007311445
. O 0 0.0035877624

Hyperkalemia B-Disease 0 0.9971112
associated O 0 0.009438448
with O 0 0.018355714
sulindac B-Chemical 1 0.99984455
therapy O 0 0.045680534
. O 0 0.011217623

Hyperkalemia B-Disease 0 0.99899596
has O 0 0.0018467823
recently O 0 0.00081594696
been O 0 0.00045069176
recognized O 0 0.0003900128
as O 0 0.00026538334
a O 0 0.00035716654
complication O 0 0.0031447187
of O 0 0.0009047183
nonsteroidal O 0 0.9999635
antiinflammatory O 0 0.99109054
agents O 0 0.028734172
( O 0 0.0026333393
NSAID O 0 0.9999752
) O 0 0.0012244128
such O 0 0.00054879615
as O 0 0.001692586
indomethacin B-Chemical 0 0.9998864
. O 0 0.0043807183

Several O 0 0.0022494765
recent O 0 0.0013462591
studies O 0 0.0008706009
have O 0 0.00040064604
stressed O 0 0.0004952571
the O 0 0.0003706151
renal O 0 0.52506095
sparing O 0 0.0029641502
features O 0 0.00035225216
of O 0 0.0010344776
sulindac B-Chemical 1 0.9999945
, O 0 0.00039667747
owing O 0 0.00016611574
to O 0 0.00010271969
its O 0 0.00018700048
lack O 0 0.00012469452
of O 0 0.0001986678
interference O 0 0.0004447632
with O 0 0.001137319
renal O 0 0.9984535
prostacyclin B-Chemical 0 0.9999782
synthesis O 0 0.17867707
. O 0 0.002823434

We O 0 0.0013254504
describe O 0 0.00092473533
4 O 0 0.0006558982
patients O 0 0.00062983
in O 0 0.00043041614
whom O 0 0.0016205389
hyperkalemia B-Disease 2 0.9999418
ranging O 0 0.000841363
from O 0 0.00018054697
6 O 0 8.691239e-05
. O 0 6.446434e-05
1 O 0 6.78604e-05
to O 0 6.564624e-05
6 O 0 5.675238e-05
. O 0 5.8866975e-05
9 O 0 0.00010172262
mEq O 0 0.04415188
/ O 0 0.00043313034
l O 0 0.00030650038
developed O 0 0.00013773997
within O 0 4.2339125e-05
3 O 0 7.088895e-05
to O 0 8.4738844e-05
8 O 0 0.00010826274
days O 0 0.00011795136
of O 0 0.00090178085
sulindac B-Chemical 1 0.99995947
administration O 0 0.12624516
. O 0 0.0031861889

In O 0 0.0017065956
all O 0 0.0011268144
of O 0 0.0009722646
them O 0 0.0011146129
normal O 0 0.001538588
serum O 0 0.31006482
potassium B-Chemical 0 0.9999318
levels O 0 0.00049691193
reached O 0 0.0002410245
within O 0 7.568597e-05
2 O 0 0.000119711076
to O 0 0.000119099655
4 O 0 0.0001284926
days O 0 0.0001271509
of O 0 0.00058832974
stopping O 0 0.007426148
sulindac B-Chemical 1 0.99994123
. O 0 0.00485958

As O 0 0.0013855748
no O 0 0.0007784034
other O 0 0.0008046164
medications O 0 0.0036022593
known O 0 0.00044488237
to O 0 0.00021872806
effect O 0 0.0002982512
serum O 0 0.5132514
potassium B-Chemical 0 0.9999826
had O 0 0.00042377508
been O 0 9.439616e-05
given O 0 5.8664336e-05
concomitantly O 0 0.00029543275
, O 0 9.171649e-05
this O 0 7.4476855e-05
course O 0 5.481149e-05
of O 0 0.00010565955
events O 0 0.00037410847
is O 0 9.0530746e-05
suggestive O 0 0.000107707
of O 0 0.0001396325
a O 0 0.00021738726
cause O 0 0.0003311242
- O 0 0.00035077782
and O 0 0.00015388781
- O 0 0.00021300185
effect O 0 0.00010326033
relationship O 0 0.0001073729
between O 0 0.00036400658
sulindac B-Chemical 1 0.99998176
and O 0 0.010953355
hyperkalemia B-Disease 2 0.99996245
. O 0 0.0046806806

These O 0 0.0019691752
observations O 0 0.0013258833
indicate O 0 0.00044905808
that O 0 0.00032821327
initial O 0 0.00042828723
hopes O 0 0.001784331
that O 0 0.00061542756
sulindac B-Chemical 1 0.99999094
may O 0 0.00029692193
not O 0 0.00014202755
be O 0 8.8539426e-05
associated O 0 7.048679e-05
with O 0 0.00010195832
the O 0 0.0001135683
adverse O 0 0.02021087
renal O 0 0.7347563
effects O 0 0.00025612387
of O 0 0.00033628414
other O 0 0.00056385505
NSAID O 0 0.9999726
are O 0 0.0004601449
probably O 0 0.00062002183
not O 0 0.0006820869
justified O 0 0.0025221931
. O 0 0.001909458

Drug O 0 0.201544
- O 0 0.0073885075
induced O 0 0.0047556916
arterial O 0 0.51473844
spasm B-Disease 2 0.9986266
relieved O 0 0.16918178
by O 0 0.009923199
lidocaine B-Chemical 0 0.99915266
. O 0 0.008574502

Case O 0 0.066510186
report O 0 0.04968347
. O 0 0.040404446

Following O 0 0.0015061265
major O 0 0.0015162136
intracranial O 0 0.053177364
surgery O 0 0.0010379744
in O 0 0.00039885723
a O 0 0.0004474649
35 O 0 0.00034966104
- O 0 0.0004383762
year O 0 0.00014313056
- O 0 0.00029848985
old O 0 0.00021329794
man O 0 0.004096673
, O 0 0.000662222
sodium B-Chemical 0 0.9999703
pentothal I-Chemical 0 0.99951434
was O 0 0.00031775862
intravenously O 0 0.00023337248
infused O 0 0.0003881681
to O 0 0.00024127513
minimize O 0 0.00049256586
cerebral B-Disease 0 0.998478
ischaemia I-Disease 0 0.9999521
. O 0 0.005175572

Intense O 0 0.013180208
vasospasm B-Disease 2 0.9996107
with O 0 0.00461201
threatened O 0 0.03810831
gangrene B-Disease 0 0.9949503
arose O 0 0.00064920215
in O 0 0.00036430272
the O 0 0.0003467256
arm O 0 0.000541247
used O 0 0.00037450812
for O 0 0.00048820834
the O 0 0.0010937185
infusion O 0 0.0043997434
. O 0 0.0028193293

Since O 0 0.0013469234
the O 0 0.0014588491
cranial O 0 0.004890931
condition O 0 0.0011944876
precluded O 0 0.00059919286
use O 0 0.00027168822
of O 0 0.00025991915
more O 0 0.00024670048
usual O 0 0.00018633358
methods O 0 0.00018018855
, O 0 0.00033110086
lidocaine B-Chemical 0 0.9996326
was O 0 0.00017589895
given O 0 6.5936416e-05
intra O 0 0.00036581172
- O 0 0.00022202608
arterially O 0 0.00062984566
, O 0 0.0001129261
with O 0 0.00012053568
careful O 0 0.00020134138
cardiovascular O 0 0.16929242
monitoring O 0 0.00022538303
, O 0 0.00024214646
to O 0 0.00022953974
counteract O 0 0.0006370398
the O 0 0.0019272557
vasospasm B-Disease 2 0.9998889
. O 0 0.0039459844

The O 0 0.006117343
treatment O 0 0.0069218064
was O 0 0.007420182
rapidly O 0 0.008821367
successful O 0 0.010651014
. O 0 0.011024613

Regional O 0 0.0022310473
localization O 0 0.0007725496
of O 0 0.0010066178
the O 0 0.0008694106
antagonism O 0 0.100019485
of O 0 0.0036413681
amphetamine B-Chemical 1 0.9999908
- O 0 0.004439413
induced O 0 0.0019246599
hyperactivity B-Disease 2 0.9999285
by O 0 0.0020821271
intracerebral O 0 0.98982424
calcitonin B-Chemical 0 0.9701735
injections O 0 0.0045771073
. O 0 0.0024194783

Calcitonin B-Chemical 0 0.8604414
receptors O 0 0.008620046
are O 0 0.0009885149
found O 0 0.0005163636
in O 0 0.00036280788
the O 0 0.00033569735
brain O 0 0.0015354627
, O 0 0.00034863333
and O 0 0.00029926834
intracerebral O 0 0.4894489
infusions O 0 0.001670417
of O 0 0.00058033457
calcitonin B-Chemical 0 0.37656263
can O 0 0.00028310413
produce O 0 0.00033308342
behavioral O 0 0.0019895458
effects O 0 0.0019711147
. O 0 0.002423717

Among O 0 0.0027651042
these O 0 0.0015482922
behavioral O 0 0.0019633118
effects O 0 0.0007290564
are O 0 0.0003901413
decreases O 0 0.0003547993
in O 0 0.00026613535
food O 0 0.001520082
intake O 0 0.05779018
and O 0 0.00025584246
decreases O 0 0.00037687938
in O 0 0.0006601454
amphetamine B-Chemical 1 0.9999876
- O 0 0.0022435447
induced O 0 0.0011472413
locomotor O 0 0.1703839
activity O 0 0.0018693764
. O 0 0.0022383246

In O 0 0.0015984131
previous O 0 0.0009571626
experiments O 0 0.0005427437
we O 0 0.00027151447
found O 0 0.00025926056
that O 0 0.00017027667
decreases O 0 0.0002711006
in O 0 0.00020686597
food O 0 0.0015765927
intake O 0 0.08497522
were O 0 0.00013792425
induced O 0 0.000118174394
by O 0 9.413432e-05
local O 0 0.0001338257
administration O 0 0.00046004646
of O 0 0.00023529955
calcitonin B-Chemical 0 0.1886984
into O 0 4.3955304e-05
several O 0 6.780361e-05
hypothalamic O 0 0.0004263633
sites O 0 9.8873265e-05
and O 0 0.00013593522
into O 0 0.00010031297
the O 0 0.00031417847
nucleus O 0 0.000592318
accumbens O 0 0.006040054
. O 0 0.0018994388

In O 0 0.0014030689
the O 0 0.0009217304
present O 0 0.000545487
experiment O 0 0.0005646919
calcitonin B-Chemical 0 0.44893524
decreased O 0 0.0013517578
locomotor O 0 0.046656772
activity O 0 0.0002006878
when O 0 9.8886354e-05
locally O 0 0.00029465888
injected O 0 9.5246374e-05
into O 0 4.2460877e-05
the O 0 7.7307086e-05
same O 0 6.1717066e-05
sites O 0 0.00010663559
where O 0 0.00015052248
it O 0 0.00030545198
decreases O 0 0.00070475443
food O 0 0.005299494
intake O 0 0.22641721
. O 0 0.0024249442

The O 0 0.0016995684
areas O 0 0.0014741479
where O 0 0.0009991318
calcitonin B-Chemical 0 0.3030799
is O 0 0.0005344472
most O 0 0.0004280491
effective O 0 0.00020068015
in O 0 0.00017319764
decreasing O 0 0.00030167494
locomotor O 0 0.021111647
activity O 0 0.0001229233
are O 0 7.4008734e-05
located O 0 4.6891262e-05
in O 0 5.163931e-05
the O 0 6.420942e-05
hypothalamus O 0 0.00025832123
and O 0 7.525301e-05
nucleus O 0 6.307557e-05
accumbens O 0 0.0005879396
, O 0 7.134672e-05
suggesting O 0 2.8456841e-05
that O 0 3.3496788e-05
these O 0 7.89536e-05
areas O 0 6.691985e-05
are O 0 4.4155076e-05
the O 0 4.0424675e-05
major O 0 4.2786785e-05
sites O 0 4.0638653e-05
of O 0 7.5393946e-05
action O 0 0.00012960772
of O 0 0.0002301097
calcitonin B-Chemical 0 0.5456144
in O 0 0.00019720926
inhibiting O 0 0.0011981033
amphetamine B-Chemical 1 0.9999938
- O 0 0.0022037348
induced O 0 0.0010024213
locomotor O 0 0.17653687
activity O 0 0.001650872
. O 0 0.0019968573

The O 0 0.001887986
hematologic O 0 0.16690037
effects O 0 0.0012199589
of O 0 0.0015299347
cefonicid B-Chemical 0 0.99584097
and O 0 0.0013639136
cefazedone B-Chemical 1 0.99929774
in O 0 0.00032053282
the O 0 0.00023524705
dog O 0 0.0005294585
: O 0 0.00019879987
a O 0 0.00016478363
potential O 0 0.00015686893
model O 0 0.00026994306
of O 0 0.00087016966
cephalosporin B-Chemical 0 0.9996979
hematotoxicity B-Disease 0 0.99998057
in O 0 0.004260269
man O 0 0.15210572
. O 0 0.002739558

Cephalosporin B-Chemical 0 0.945785
antibiotics O 0 0.06348656
cause O 0 0.0021342398
a O 0 0.000983463
variety O 0 0.00062658906
of O 0 0.00086739927
hematologic B-Disease 0 0.9989347
disturbances I-Disease 0 0.9368387
in O 0 0.00048715543
man O 0 0.007916413
, O 0 0.00022100109
the O 0 0.00016607378
pathogeneses O 0 0.0009494965
and O 0 0.00017360669
hematopathology O 0 0.0003137959
of O 0 0.00026736732
which O 0 0.00039101465
remain O 0 0.00043390752
poorly O 0 0.0013097373
characterized O 0 0.0024858697
. O 0 0.001972529

There O 0 0.0031049245
is O 0 0.0018185368
a O 0 0.001310378
need O 0 0.0005949742
for O 0 0.00039340492
a O 0 0.0005551396
well O 0 0.0003261443
- O 0 0.00045988636
defined O 0 0.00013625756
animal O 0 0.00022574348
model O 0 0.00018282833
in O 0 0.00014707245
which O 0 0.000260493
these O 0 0.00059630326
blood B-Disease 0 0.5823959
dyscrasias I-Disease 0 0.9987332
can O 0 0.00072834466
be O 0 0.00088242843
studied O 0 0.001626982
. O 0 0.002048584

In O 0 0.0018348012
four O 0 0.0014173506
subacute O 0 0.93198997
toxicity B-Disease 2 0.9966402
studies O 0 0.00076904893
, O 0 0.00032275912
the O 0 0.00018642705
intravenous O 0 0.002571478
administration O 0 0.0006810711
of O 0 0.00035120954
cefonicid B-Chemical 0 0.9937039
or O 0 0.00029722843
cefazedone B-Chemical 1 0.99946755
to O 0 0.00018583641
beagle O 0 0.0019353935
dogs O 0 0.00015180343
caused O 0 9.580723e-05
a O 0 0.00015891313
dose O 0 0.0007923949
- O 0 0.00018623019
dependent O 0 4.1106105e-05
incidence O 0 0.00029092704
of O 0 0.0006617731
anemia B-Disease 0 0.9999809
, O 0 0.0014799809
neutropenia B-Disease 0 0.9996507
, O 0 0.00044769852
and O 0 0.00040702682
thrombocytopenia B-Disease 0 0.9996885
after O 0 8.92144e-05
1 O 0 0.00015663532
- O 0 0.00026346077
3 O 0 0.00013483249
months O 0 0.00012423484
of O 0 0.0005209801
treatment O 0 0.0011878952
. O 0 0.0019822558

A O 0 0.15821815
nonregenerative O 0 0.7763287
anemia B-Disease 0 0.99974054
was O 0 0.0013219556
the O 0 0.000418658
most O 0 0.00041570904
compromising O 0 0.00053436885
of O 0 0.00028355038
the O 0 0.00032160914
cytopenias B-Disease 0 0.9997099
and O 0 0.00023782272
occurred O 0 9.065022e-05
in O 0 6.694526e-05
approximately O 0 8.7618304e-05
50 O 0 0.00013208052
% O 0 7.2378614e-05
of O 0 8.7134125e-05
dogs O 0 0.00013286469
receiving O 0 0.00015635582
400 O 0 0.00035892066
- O 0 0.00016602896
500 O 0 0.00022845373
mg O 0 0.0017667817
/ O 0 0.00038866475
kg O 0 0.00047067343
cefonicid B-Chemical 0 0.85639006
or O 0 0.00021312598
540 O 0 0.035120483
- O 0 0.00063004246
840 O 0 0.0035242606
mg O 0 0.008703539
/ O 0 0.0022217075
kg O 0 0.003832924
cefazedone B-Chemical 1 0.9952114
. O 0 0.003083981

All O 0 0.001601623
three O 0 0.0010644424
cytopenias B-Disease 0 0.9957794
were O 0 0.0008958806
completely O 0 0.00064988557
reversible O 0 0.0035000339
following O 0 0.00015704402
cessation O 0 0.0002361365
of O 0 0.00019621465
treatment O 0 0.00016121003
; O 0 0.00011620931
the O 0 5.7047117e-05
time O 0 2.7531803e-05
required O 0 2.5661386e-05
for O 0 3.6574955e-05
recovery O 0 0.00012623999
of O 0 9.5453586e-05
the O 0 0.00011290908
erythron O 0 0.7817741
( O 0 0.00016070633
approximately O 0 8.464524e-05
1 O 0 5.443291e-05
month O 0 3.343462e-05
) O 0 9.2553775e-05
was O 0 6.326327e-05
considerably O 0 7.388624e-05
longer O 0 2.9022238e-05
than O 0 2.8710017e-05
that O 0 3.4158144e-05
of O 0 8.74708e-05
the O 0 0.00011448992
granulocytes O 0 0.058008745
and O 0 0.00025113556
platelets O 0 0.0635928
( O 0 0.00024021442
hours O 0 8.512054e-05
to O 0 0.00015201519
a O 0 0.00033462036
few O 0 0.00026177717
days O 0 0.00039323358
) O 0 0.0016816108
. O 0 0.0020005875

Upon O 0 0.002621164
rechallenge O 0 0.006525698
with O 0 0.0012807642
either O 0 0.001067797
cephalosporin B-Chemical 0 0.99690044
, O 0 0.0007228405
the O 0 0.0005736193
hematologic B-Disease 0 0.99963236
syndrome I-Disease 0 0.98579794
was O 0 0.00032608153
reproduced O 0 0.00020996794
in O 0 8.121966e-05
most O 0 0.00014565882
dogs O 0 0.00014550127
tested O 0 9.7810866e-05
; O 0 0.00021177466
cefonicid B-Chemical 0 0.9813706
( O 0 0.00022991629
but O 0 0.00011796395
not O 0 0.00016698251
cefazedone B-Chemical 1 0.9997614
) O 0 0.00059280795
- O 0 0.00025837345
treated O 0 0.0001560627
dogs O 0 0.00014304106
showed O 0 7.442531e-05
a O 0 9.9745426e-05
substantially O 0 0.00011085953
reduced O 0 0.00013883787
induction O 0 0.00010064296
period O 0 4.1873864e-05
( O 0 0.000100652745
15 O 0 5.6457644e-05
+ O 0 0.00018275843
/ O 0 0.00033658554
- O 0 0.00016911379
5 O 0 4.407854e-05
days O 0 2.7895303e-05
) O 0 7.7607045e-05
compared O 0 3.2125023e-05
to O 0 3.939109e-05
that O 0 3.8015925e-05
of O 0 7.686765e-05
the O 0 5.832196e-05
first O 0 4.047088e-05
exposure O 0 0.00010807366
to O 0 7.9539706e-05
the O 0 0.00013230514
drug O 0 0.00631616
( O 0 0.0002985075
61 O 0 0.00034033522
+ O 0 0.00043713622
/ O 0 0.0007527496
- O 0 0.0005463991
24 O 0 0.000331896
days O 0 0.00039466142
) O 0 0.001644617
. O 0 0.0020306741

This O 0 0.0038242
observation O 0 0.0016257238
, O 0 0.0009923971
along O 0 0.0003803823
with O 0 0.00039920243
the O 0 0.00026322476
rapid O 0 0.00043148667
rate O 0 0.00022765574
of O 0 0.00023918416
decline O 0 0.00065969187
in O 0 0.00016401599
red O 0 0.0015233438
cell O 0 0.0005597539
mass O 0 0.0005701429
parameters O 0 0.000113557464
of O 0 0.00013290906
affected O 0 0.00016797421
dogs O 0 0.00017840034
, O 0 8.416457e-05
suggests O 0 3.0353223e-05
that O 0 4.9460174e-05
a O 0 0.00024172758
hemolytic B-Disease 0 0.99975055
component O 0 0.00015890964
complicated O 0 0.0003544936
the O 0 0.00013896689
red O 0 0.0028498282
cell O 0 0.00059520564
production O 0 0.00019103543
problem O 0 0.00013750495
and O 0 8.196425e-05
that O 0 5.849641e-05
multiple O 0 0.00014091186
toxicologic O 0 0.001944197
mechanisms O 0 0.00020418933
contributed O 0 0.00034867803
to O 0 0.00038520407
the O 0 0.0012924492
cytopenia B-Disease 0 0.9997938
. O 0 0.004137763

We O 0 0.0012461547
conclude O 0 0.000666386
that O 0 0.00046367748
the O 0 0.00048075913
administration O 0 0.0010362471
of O 0 0.00037682982
high O 0 0.000496473
doses O 0 0.001607978
of O 0 0.00048767953
cefonicid B-Chemical 0 0.99686736
or O 0 0.00036842012
cefazedone B-Chemical 1 0.9995777
to O 0 0.00015711955
dogs O 0 0.00018513233
can O 0 5.775224e-05
induce O 0 9.073004e-05
hematotoxicity B-Disease 0 0.9999733
similar O 0 7.314615e-05
to O 0 6.915889e-05
the O 0 0.00014382556
cephalosporin B-Chemical 0 0.99744654
- O 0 0.00046573507
induced O 0 0.0002703142
blood B-Disease 0 0.8005939
dyscrasias I-Disease 0 0.99934417
described O 0 0.0001298799
in O 0 0.00011612811
man O 0 0.0014711553
and O 0 8.7850305e-05
thus O 0 9.007366e-05
provides O 0 5.6633384e-05
a O 0 0.00010193158
useful O 0 6.680432e-05
model O 0 9.219156e-05
for O 0 7.212794e-05
studying O 0 0.00013789453
the O 0 0.00015478669
mechanisms O 0 0.00028140558
of O 0 0.0005843201
these O 0 0.0015999617
disorders O 0 0.41454893
. O 0 0.0024242774

Cerebral O 0 0.052168116
blood O 0 0.008059286
flow O 0 0.003509545
and O 0 0.0009610335
metabolism O 0 0.009023596
during O 0 0.00038578254
isoflurane B-Chemical 1 0.99870586
- O 0 0.0012674774
induced O 0 0.0007144381
hypotension B-Disease 0 0.9997327
in O 0 0.0002927573
patients O 0 0.00023566395
subjected O 0 0.000109747554
to O 0 0.00019271749
surgery O 0 0.00043414894
for O 0 0.0005713271
cerebral B-Disease 0 0.99711037
aneurysms I-Disease 2 0.9996216
. O 0 0.0039169365

Cerebral O 0 0.044545796
blood O 0 0.007179756
flow O 0 0.003092869
and O 0 0.0008909353
cerebral O 0 0.09755488
metabolic O 0 0.003940257
rate O 0 0.000333919
for O 0 0.0002080943
oxygen B-Chemical 1 0.9084983
were O 0 0.00013891944
measured O 0 7.993944e-05
during O 0 7.869825e-05
isoflurane B-Chemical 1 0.99810106
- O 0 0.00056279515
induced O 0 0.00034913106
hypotension B-Disease 0 0.9997645
in O 0 0.00014083902
10 O 0 7.739672e-05
patients O 0 8.2138664e-05
subjected O 0 4.573393e-05
to O 0 8.407851e-05
craniotomy O 0 0.0008993311
for O 0 0.00013599043
clipping O 0 0.0010384915
of O 0 0.0005198571
a O 0 0.0016575418
cerebral B-Disease 0 0.99847704
aneurysm I-Disease 2 0.99971217
. O 0 0.0042676246

Flow O 0 0.05020454
and O 0 0.002503686
metabolism O 0 0.012977214
were O 0 0.00069079484
measured O 0 0.00038269535
5 O 0 0.0002809188
- O 0 0.0003782886
13 O 0 0.00013655098
days O 0 5.029937e-05
after O 0 4.5806388e-05
the O 0 0.0002168453
subarachnoid B-Disease 0 0.9998379
haemorrhage I-Disease 0 0.9999745
by O 0 0.00024963968
a O 0 0.00016444961
modification O 0 0.00013461961
of O 0 0.000102120124
the O 0 8.435684e-05
classical O 0 0.00016979595
Kety O 0 0.0044269995
- O 0 0.00024124222
Schmidt O 0 0.00075416995
technique O 0 0.00012342106
using O 0 9.901781e-05
xenon B-Chemical 0 0.95995235
- O 0 0.00044521925
133 O 0 0.0004545884
i O 0 0.00024944267
. O 0 6.027742e-05
v O 0 0.00042950988
. O 0 6.5849636e-05
Anaesthesia O 0 0.0032072468
was O 0 7.266727e-05
maintained O 0 5.4297703e-05
with O 0 6.649149e-05
an O 0 9.7203985e-05
inspired O 0 0.0007844163
isoflurane B-Chemical 1 0.9986707
concentration O 0 0.0004702698
of O 0 0.00016079537
0 O 0 7.565083e-05
. O 0 4.264767e-05
75 O 0 9.908525e-05
% O 0 7.269305e-05
( O 0 7.551749e-05
plus O 0 4.6461366e-05
67 O 0 0.00014581042
% O 0 0.00012585944
nitrous B-Chemical 0 0.9952018
oxide I-Chemical 0 0.9401471
in O 0 0.00024383051
oxygen B-Chemical 1 0.9938259
) O 0 0.0002330965
, O 0 6.92567e-05
during O 0 2.8688257e-05
which O 0 0.00010220684
CBF O 0 0.38500902
and O 0 0.00018654921
CMRO2 O 0 0.99238116
were O 0 0.00011827371
34 O 0 0.00010389076
. O 0 4.6335084e-05
3 O 0 5.6224944e-05
+ O 0 0.00017271707
/ O 0 0.00036481084
- O 0 0.0002265067
2 O 0 7.011433e-05
. O 0 4.4926364e-05
1 O 0 5.550983e-05
ml O 0 0.00016641426
/ O 0 0.00020095243
100 O 0 0.00019108683
g O 0 0.00023649947
min O 0 0.00014180334
- O 0 0.00019160312
1 O 0 6.938097e-05
and O 0 7.8059275e-05
2 O 0 6.5040134e-05
. O 0 5.0556315e-05
32 O 0 0.00011538073
+ O 0 0.00021878874
/ O 0 0.0003805912
- O 0 0.0002121437
0 O 0 7.211351e-05
. O 0 4.601751e-05
16 O 0 6.300217e-05
ml O 0 0.00018094578
/ O 0 0.0002065599
100 O 0 0.00018921502
g O 0 0.00022285321
min O 0 0.00012725158
- O 0 0.00015765618
1 O 0 5.6771645e-05
at O 0 5.7468704e-05
PaCO2 O 0 0.043399777
4 O 0 7.366064e-05
. O 0 5.5258217e-05
1 O 0 7.8474404e-05
+ O 0 0.00020518951
/ O 0 0.0003920356
- O 0 0.0002529971
0 O 0 0.000101858604
. O 0 7.6522076e-05
1 O 0 0.00010900516
kPa O 0 0.00047157425
( O 0 0.00021166324
mean O 0 0.0001309381
+ O 0 0.00060459325
/ O 0 0.001292099
- O 0 0.001328534
SEM O 0 0.002153372
) O 0 0.002747528
. O 0 0.0026277457

Controlled O 0 0.0047012744
hypotension B-Disease 0 0.9938479
to O 0 0.0010376074
an O 0 0.0007006787
average O 0 0.0003571088
MAP O 0 0.04397538
of O 0 0.0005384134
50 O 0 0.00061016815
- O 0 0.0004294749
55 O 0 0.00022266145
mm O 0 0.0004398184
Hg B-Chemical 0 0.6375106
was O 0 0.00016747075
induced O 0 0.00012919806
by O 0 9.609234e-05
increasing O 0 9.830653e-05
the O 0 8.4426705e-05
dose O 0 0.000511486
of O 0 0.00036654656
isoflurane B-Chemical 1 0.99961936
, O 0 0.00018855225
and O 0 7.769983e-05
maintained O 0 5.930613e-05
at O 0 3.7695034e-05
an O 0 8.5964166e-05
inspired O 0 0.0002988529
concentration O 0 0.00027858498
of O 0 0.00019462022
2 O 0 0.00010612808
. O 0 7.3487194e-05
2 O 0 0.00011132351
+ O 0 0.00031923645
/ O 0 0.00065646984
- O 0 0.0005310643
0 O 0 0.00031274045
. O 0 0.0003494118
2 O 0 0.0006405657
% O 0 0.0014234185
. O 0 0.0021178308

This O 0 0.0035327675
resulted O 0 0.0014832696
in O 0 0.00089836336
a O 0 0.0008468755
significant O 0 0.00048999634
decrease O 0 0.00056227244
in O 0 0.00048685927
CMRO2 O 0 0.99832803
( O 0 0.0004833807
to O 0 0.00016025947
1 O 0 0.00013107016
. O 0 8.758714e-05
73 O 0 0.00024435532
+ O 0 0.0002997006
/ O 0 0.00047474046
- O 0 0.00025500523
0 O 0 8.74753e-05
. O 0 5.6611243e-05
16 O 0 7.778813e-05
ml O 0 0.0002204724
/ O 0 0.00025968757
100 O 0 0.0002537794
g O 0 0.00032500425
min O 0 0.00022185277
- O 0 0.00035184354
1 O 0 0.00018058141
) O 0 0.00032406737
, O 0 0.00031567004
while O 0 0.00046763863
CBF O 0 0.35206392
was O 0 0.0013631353
unchanged O 0 0.001874503
. O 0 0.0023395082

After O 0 0.001001855
the O 0 0.0012458866
clipping O 0 0.0022909313
of O 0 0.0008217315
the O 0 0.000810979
aneurysm B-Disease 2 0.9847269
the O 0 0.0009307088
isoflurane B-Chemical 1 0.99915373
concentration O 0 0.0021267857
was O 0 0.00049740425
reduced O 0 0.0005591588
to O 0 0.00035212358
0 O 0 0.00041043028
. O 0 0.00043911062
75 O 0 0.0012576674
% O 0 0.0016805894
. O 0 0.0022793717

There O 0 0.0029457323
was O 0 0.0018900172
a O 0 0.0012432389
significant O 0 0.0006601004
increase O 0 0.000503599
in O 0 0.00049366476
CBF O 0 0.74806577
, O 0 0.0005352984
although O 0 0.00035583408
CMRO2 O 0 0.9962025
was O 0 0.0003314811
unchanged O 0 0.00022141024
, O 0 0.00018842843
compared O 0 0.00012237979
with O 0 0.0003236703
pre O 0 0.00094224286
- O 0 0.001693971
hypotensive B-Disease 0 0.9768737
values O 0 0.0024564934
. O 0 0.0024341738

These O 0 0.0026115952
changes O 0 0.0018100955
might O 0 0.00078851904
offer O 0 0.000901786
protection O 0 0.0011932474
to O 0 0.00051349076
brain O 0 0.0019847516
tissue O 0 0.0009805512
during O 0 0.00022330774
periods O 0 0.00032614463
of O 0 0.00087718735
induced O 0 0.003085251
hypotension B-Disease 0 0.99960655
. O 0 0.0049521457

Triazolam B-Chemical 0 0.9998273
- O 0 0.005974148
induced O 0 0.0014127836
brief O 0 0.0009240043
episodes O 0 0.0020860832
of O 0 0.000941936
secondary O 0 0.0040919874
mania B-Disease 0 0.99916446
in O 0 0.0009827127
a O 0 0.001925212
depressed B-Disease 2 0.8548636
patient O 0 0.00323207
. O 0 0.0027528715

Large O 0 0.0051515475
doses O 0 0.0071911314
of O 0 0.0041381363
triazolam B-Chemical 0 0.9999875
repeatedly O 0 0.0008905886
induced O 0 0.00045194026
brief O 0 0.00034181573
episodes O 0 0.0012361665
of O 0 0.00074802217
mania B-Disease 0 0.9988427
in O 0 0.00052887347
a O 0 0.0012446452
depressed B-Disease 2 0.9497844
elderly O 0 0.5416995
woman O 0 0.01057944
. O 0 0.00241709

Features O 0 0.007326367
of O 0 0.0037379889
organic B-Disease 0 0.98047286
mental I-Disease 0 0.23256433
disorder I-Disease 0 0.9981371
( O 0 0.006763175
delirium B-Disease 0 0.9997204
) O 0 0.0021006784
were O 0 0.00089360395
not O 0 0.00096355006
present O 0 0.0016044497
. O 0 0.0029229228

Manic B-Disease 0 0.99550384
excitement O 0 0.023184681
was O 0 0.0018057757
coincident O 0 0.0010254855
with O 0 0.0007122518
the O 0 0.00048188484
duration O 0 0.0003144086
of O 0 0.0007711967
action O 0 0.0018179466
of O 0 0.007216521
triazolam B-Chemical 0 0.99998
. O 0 0.0062653315

The O 0 0.0016415179
possible O 0 0.0011219768
contribution O 0 0.00076356105
of O 0 0.00093570043
the O 0 0.00092224864
triazolo B-Chemical 0 0.8800133
group O 0 0.00070749165
to O 0 0.00031549856
changes O 0 0.0004595641
in O 0 0.00046097068
affective O 0 0.03947223
status O 0 0.0008030568
is O 0 0.0011353825
discussed O 0 0.0017963989
. O 0 0.0026723791

The O 0 0.0015560737
correlation O 0 0.0010472415
between O 0 0.0010549538
neurotoxic B-Disease 0 0.997647
esterase O 0 0.9340591
inhibition O 0 0.008545744
and O 0 0.003331231
mipafox B-Chemical 0 0.99996257
- O 0 0.0067682345
induced O 0 0.0049494156
neuropathic B-Disease 0 0.99990845
damage I-Disease 0 0.9941664
in O 0 0.0020400507
rats O 0 0.0035511153
. O 0 0.0023353605

The O 0 0.0014069846
correlation O 0 0.0009822531
between O 0 0.0011468471
neuropathic B-Disease 0 0.99954695
damage I-Disease 0 0.96692723
and O 0 0.00064776454
inhibition O 0 0.0012345456
of O 0 0.0012569017
neurotoxic B-Disease 0 0.9998386
esterase O 0 0.989239
or O 0 0.0010114156
neuropathy B-Disease 0 0.9999697
target O 0 0.0002843574
enzyme O 0 0.116998866
( O 0 0.00083158835
NTE O 0 0.9977944
) O 0 0.00032421228
was O 0 8.955577e-05
examined O 0 4.2177046e-05
in O 0 5.7800335e-05
rats O 0 0.00011424041
acutely O 0 0.00041636446
exposed O 0 9.776546e-05
to O 0 0.00018297342
Mipafox B-Chemical 0 0.9998853
( O 0 0.0014994021
N B-Chemical 0 0.9873039
, I-Chemical 0 0.00066160754
N I-Chemical 0 0.96853125
' I-Chemical 0 0.00055996125
- I-Chemical 0 0.00066067436
diisopropylphosphorodiamidofluoridate I-Chemical 0 0.006921682
) O 0 0.00066986703
, O 0 0.0005814867
a O 0 0.0018262803
neurotoxic B-Disease 0 0.99948585
organophosphate B-Chemical 0 0.99996626
. O 0 0.0059345337

Brain O 0 0.014404766
and O 0 0.0024115841
spinal O 0 0.0057959664
cord O 0 0.03814563
NTE O 0 0.98739177
activities O 0 0.00063162675
were O 0 0.00027517625
measured O 0 0.0001652924
in O 0 0.00019057788
Long O 0 0.00093114615
- O 0 0.00053477084
Evans O 0 0.052268
male O 0 0.0005640556
rats O 0 0.0001442981
1 O 0 5.6507415e-05
hr O 0 6.887706e-05
post O 0 4.5384706e-05
- O 0 0.00012086496
exposure O 0 9.264658e-05
to O 0 6.496978e-05
various O 0 0.00012087257
dosages O 0 0.009417939
of O 0 0.00063859625
Mipafox B-Chemical 0 0.99992144
( O 0 0.000786267
ip O 0 0.07612245
, O 0 0.00027505693
1 O 0 0.00015909306
- O 0 0.00027823754
15 O 0 0.00019236613
mg O 0 0.0027875074
/ O 0 0.001728565
kg O 0 0.0022296857
) O 0 0.0022367642
. O 0 0.0022030177

These O 0 0.0019523267
data O 0 0.0012837872
were O 0 0.00065055786
correlated O 0 0.0003369504
with O 0 0.0004891022
histologically O 0 0.0029564602
scored O 0 0.0007592761
cervical O 0 0.06540066
cord B-Disease 0 0.6957682
damage I-Disease 0 0.9597361
in O 0 0.00018633217
a O 0 0.00014398969
separate O 0 5.1690447e-05
group O 0 8.6005486e-05
of O 0 8.512282e-05
similarly O 0 9.7083466e-05
dosed O 0 0.00043584884
rats O 0 0.0001385546
sampled O 0 7.033961e-05
14 O 0 0.0001009156
- O 0 0.00019900656
21 O 0 0.00014346834
days O 0 0.000105095605
post O 0 0.00025509886
- O 0 0.001047657
exposure O 0 0.0020038234
. O 0 0.0024494075

Those O 0 0.0055021457
dosages O 0 0.042476248
( O 0 0.0014623683
greater O 0 0.0005779841
than O 0 0.0002644912
or O 0 0.00019873373
equal O 0 0.00015215963
to O 0 0.0001443383
10 O 0 0.00015944372
mg O 0 0.0042581074
/ O 0 0.0007051391
kg O 0 0.00044167647
) O 0 0.00014203176
that O 0 5.1761974e-05
inhibited O 0 0.0001749781
mean O 0 8.155898e-05
NTE O 0 0.96503186
activity O 0 0.000108869295
in O 0 7.318628e-05
the O 0 8.5492306e-05
spinal O 0 0.00060287735
cord O 0 0.0011460781
greater O 0 9.2817856e-05
than O 0 4.448329e-05
or O 0 4.5180022e-05
equal O 0 4.6713536e-05
to O 0 5.9614253e-05
73 O 0 0.00015890054
% O 0 6.891661e-05
and O 0 6.141355e-05
brain O 0 0.0003423628
greater O 0 6.960583e-05
than O 0 3.7890044e-05
or O 0 4.0061284e-05
equal O 0 4.1971096e-05
to O 0 5.2042957e-05
67 O 0 0.00012315878
% O 0 5.4321525e-05
of O 0 5.724341e-05
control O 0 5.4078697e-05
values O 0 7.302238e-05
produced O 0 9.780592e-05
severe O 0 0.0032415355
( O 0 0.00015285563
greater O 0 7.6193246e-05
than O 0 4.318713e-05
or O 0 4.7598238e-05
equal O 0 5.3254043e-05
to O 0 7.3507596e-05
3 O 0 8.336803e-05
) O 0 0.00021303822
cervical O 0 0.003212874
cord O 0 0.0036008526
pathology O 0 0.0020252531
in O 0 0.00019996292
85 O 0 0.00035750636
% O 0 0.00027032578
of O 0 0.0004307574
the O 0 0.0007059456
rats O 0 0.0019800605
. O 0 0.0018600737

In O 0 0.0019054109
contrast O 0 0.0020571954
, O 0 0.0016062702
dosages O 0 0.037532244
of O 0 0.0024978372
Mipafox B-Chemical 0 0.9998535
( O 0 0.00091645296
less O 0 0.00024184698
than O 0 0.00010048683
or O 0 8.564816e-05
equal O 0 7.524074e-05
to O 0 8.018635e-05
5 O 0 7.646933e-05
mg O 0 0.0019016215
/ O 0 0.00047580374
kg O 0 0.00034781732
) O 0 0.00013425005
which O 0 8.64116e-05
inhibited O 0 0.00015999305
mean O 0 7.3357885e-05
NTE O 0 0.9631579
activity O 0 0.000116880314
in O 0 0.00010067194
spinal O 0 0.00079793454
cord O 0 0.0016830685
less O 0 9.895627e-05
than O 0 4.5585628e-05
or O 0 4.6545007e-05
equal O 0 4.824225e-05
to O 0 6.1278646e-05
61 O 0 0.00013056882
% O 0 7.098568e-05
and O 0 6.70893e-05
brain O 0 0.00041900994
less O 0 7.720115e-05
than O 0 4.0774095e-05
or O 0 4.339859e-05
equal O 0 4.46968e-05
to O 0 5.1924722e-05
60 O 0 6.259615e-05
% O 0 5.940797e-05
produced O 0 5.1981602e-05
this O 0 9.019261e-05
degree O 0 0.00015838198
of O 0 0.00032130358
cord B-Disease 0 0.59726197
damage I-Disease 0 0.95924914
in O 0 0.00025012283
only O 0 0.00025437484
9 O 0 0.00018227412
% O 0 0.00024237952
of O 0 0.00039868482
the O 0 0.00061898085
animals O 0 0.0010116661
. O 0 0.0018281762

These O 0 0.0021454492
data O 0 0.0013733217
indicate O 0 0.0004983321
that O 0 0.0003530816
a O 0 0.00041887313
critical O 0 0.00021610926
percentage O 0 0.00021857877
of O 0 0.0005494472
NTE O 0 0.99205583
inhibition O 0 0.0009650693
in O 0 0.00016663768
brain O 0 0.001089233
and O 0 0.00014375894
spinal O 0 0.000590501
cord O 0 0.00082251447
sampled O 0 5.5430908e-05
shortly O 0 8.7587316e-05
after O 0 4.8898477e-05
Mipafox B-Chemical 0 0.9989774
exposure O 0 0.00029498077
can O 0 9.1366084e-05
predict O 0 0.00015567004
neuropathic B-Disease 0 0.9998369
damage I-Disease 0 0.9435112
in O 0 0.0002719165
rats O 0 0.00034558066
several O 0 0.00021211295
weeks O 0 0.00022129796
later O 0 0.00061233685
. O 0 0.001516187

Allergic B-Disease 0 0.9892831
reaction I-Disease 0 0.20642664
to O 0 0.0043341555
5 B-Chemical 0 0.0036055811
- I-Chemical 0 0.008595216
fluorouracil I-Chemical 0 0.9933782
infusion O 0 0.021725869
. O 0 0.008142077

An O 0 0.006508135
allergic B-Disease 2 0.9991379
reaction I-Disease 2 0.39613524
consisting O 0 0.0013001801
of O 0 0.008632997
angioneurotic B-Disease 0 0.9999913
edema I-Disease 0 0.9999944
secondary O 0 0.006748575
to O 0 0.0001609342
continuous O 0 9.24125e-05
infusion O 0 0.00027494627
5 B-Chemical 0 8.426295e-05
- I-Chemical 0 0.00028601024
fluorouracil I-Chemical 0 0.9700818
occurred O 0 7.520939e-05
in O 0 5.937449e-05
a O 0 9.03026e-05
patient O 0 8.3693885e-05
with O 0 0.00012863554
recurrent O 0 0.009755948
carcinoma B-Disease 0 0.9877415
of I-Disease 0 0.0001677922
the I-Disease 0 0.0001218579
oral I-Disease 0 0.015707513
cavity I-Disease 0 0.00081105786
, O 0 0.0006303657
cirrhosis B-Disease 0 0.9999944
, O 0 0.00056916935
and O 0 0.00049097976
cisplatin B-Chemical 0 0.9989397
- O 0 0.0010873853
induced O 0 0.000712596
impaired B-Disease 0 0.07812123
renal I-Disease 0 0.9912072
function I-Disease 0 0.011393783
. O 0 0.0025057197

This O 0 0.004428678
reaction O 0 0.0050033904
occurred O 0 0.0009446762
during O 0 0.00044156404
the O 0 0.00058332545
sixth O 0 0.0014044222
and O 0 0.00057637546
seventh O 0 0.0010768212
courses O 0 0.00065997837
of O 0 0.0013914832
infusional O 0 0.58873975
chemotherapy O 0 0.050530773
. O 0 0.003730797

Oral O 0 0.93999875
diphenhydramine B-Chemical 0 0.9999733
and O 0 0.0055520223
prednisone B-Chemical 1 0.9990133
were O 0 0.00081299624
ineffective O 0 0.001153042
in O 0 0.00032183208
preventing O 0 0.00045814845
the O 0 0.00041433645
recurrence O 0 0.014950567
of O 0 0.0009775638
the O 0 0.0019067952
allergic B-Disease 2 0.9998672
reaction I-Disease 2 0.97714794
. O 0 0.005472824

Discontinuance O 0 0.011458481
of O 0 0.0016533791
effective O 0 0.00087742263
chemotherapy O 0 0.0027419261
in O 0 0.00036146285
this O 0 0.00030803512
patient O 0 0.00022297031
during O 0 0.000103028804
partial O 0 0.0004113535
remission O 0 0.0050743837
resulted O 0 0.00043754352
in O 0 0.0007166205
fatal O 0 0.8741945
disease O 0 0.82670647
progression O 0 0.319174
. O 0 0.003219413

Myasthenia B-Disease 0 0.99370813
gravis I-Disease 0 0.99862003
caused O 0 0.004211647
by O 0 0.004358368
penicillamine B-Chemical 1 0.99994767
and O 0 0.0035915985
chloroquine B-Chemical 1 0.99724823
therapy O 0 0.004029847
for O 0 0.002762548
rheumatoid B-Disease 0 0.99977964
arthritis I-Disease 0 0.99976426
. O 0 0.00706011

We O 0 0.0015636814
have O 0 0.0009014355
described O 0 0.0005720976
a O 0 0.00056541146
unique O 0 0.00037151447
patient O 0 0.0003802554
who O 0 0.00039842326
had O 0 0.00021258814
reversible O 0 0.0047134967
and O 0 0.00020645928
dose O 0 0.00094179314
- O 0 0.00027765852
related O 0 9.2690665e-05
myasthenia B-Disease 0 0.9991198
gravis I-Disease 0 0.9943357
after O 0 0.00014656161
penicillamine B-Chemical 1 0.9999814
and O 0 0.0007374121
chloroquine B-Chemical 1 0.9931258
therapy O 0 0.0012989454
for O 0 0.0011727299
rheumatoid B-Disease 0 0.99985075
arthritis I-Disease 0 0.9998171
. O 0 0.004512251

Although O 0 0.0035704123
acetylcholine B-Chemical 1 0.9994893
receptor O 0 0.06613573
antibodies O 0 0.0022757265
were O 0 0.0005345308
not O 0 0.00029697263
detectable O 0 0.000273138
, O 0 0.000243379
the O 0 0.00015155927
time O 0 9.6074924e-05
course O 0 0.00015800474
was O 0 0.00023457623
consistent O 0 0.00026194646
with O 0 0.00055215834
an O 0 0.0014527907
autoimmune O 0 0.97023916
process O 0 0.0030166842
. O 0 0.0027250694

On O 0 0.0022795298
the O 0 0.0012747037
mechanisms O 0 0.0010118015
of O 0 0.00074863335
the O 0 0.00047054334
development O 0 0.00064549304
of O 0 0.0005562219
tolerance O 0 0.01961648
to O 0 0.00027396396
the O 0 0.00038245285
muscular B-Disease 0 0.19951612
rigidity I-Disease 0 0.5633332
produced O 0 0.00053522317
by O 0 0.0009840648
morphine B-Chemical 0 0.9996555
in O 0 0.0013246111
rats O 0 0.0026250689
. O 0 0.0019949728

The O 0 0.0017670844
development O 0 0.002059018
of O 0 0.0015179566
tolerance O 0 0.013572181
to O 0 0.0006035005
the O 0 0.000690679
muscular B-Disease 0 0.19630565
rigidity I-Disease 0 0.56407595
produced O 0 0.00058590336
by O 0 0.00093524327
morphine B-Chemical 0 0.9997898
was O 0 0.00093000766
studied O 0 0.0007620001
in O 0 0.0008278251
rats O 0 0.0022636114
. O 0 0.0021082738

Saline O 0 0.8129942
- O 0 0.0037145284
pretreated O 0 0.0026624938
controls O 0 0.00091494055
given O 0 0.00024069448
a O 0 0.00035761198
test O 0 0.00033894068
dose O 0 0.0008851303
of O 0 0.0007063248
morphine B-Chemical 0 0.9999336
( O 0 0.00040065273
20 O 0 0.00014303069
mg O 0 0.002839404
/ O 0 0.00047307872
kg O 0 0.0003480747
i O 0 0.0003045494
. O 0 8.129451e-05
p O 0 0.00010940942
. O 0 5.9923284e-05
) O 0 0.00013054516
showed O 0 8.523645e-05
a O 0 0.00014438249
pronounced O 0 0.0002750632
rigidity B-Disease 0 0.18062697
recorded O 0 0.0001609385
as O 0 0.00016152207
tonic O 0 0.0017010431
activity O 0 0.0002794317
in O 0 0.00037667432
the O 0 0.00079110474
electromyogram O 0 0.027302505
. O 0 0.0022410324

Rats O 0 0.00379533
treated O 0 0.0015354487
for O 0 0.0005751402
11 O 0 0.0004499543
days O 0 0.00018531796
with O 0 0.00051227014
morphine B-Chemical 0 0.99964607
and O 0 0.00034362348
withdrawn O 0 0.0003486368
for O 0 9.421721e-05
36 O 0 0.000118456766
- O 0 0.00015017382
40 O 0 6.962315e-05
h O 0 4.883882e-05
showed O 0 5.1816445e-05
differences O 0 2.7981307e-05
in O 0 4.305053e-05
the O 0 5.351725e-05
development O 0 0.0001295257
of O 0 0.00015945347
tolerance O 0 0.026074413
: O 0 0.000118790915
about O 0 5.8485137e-05
half O 0 3.9711766e-05
of O 0 6.5843364e-05
the O 0 5.259883e-05
animals O 0 4.1875184e-05
showed O 0 5.9220456e-05
a O 0 0.00012101362
rigidity B-Disease 0 0.07131684
after O 0 2.415574e-05
the O 0 5.5318484e-05
test O 0 9.9290875e-05
dose O 0 0.00035289148
of O 0 0.00031157827
morphine B-Chemical 0 0.999908
that O 0 8.738601e-05
was O 0 9.5024574e-05
not O 0 5.5969398e-05
significantly O 0 9.5742755e-05
less O 0 6.703367e-05
than O 0 4.046911e-05
in O 0 5.232257e-05
the O 0 7.108744e-05
controls O 0 0.00016781058
and O 0 0.00013740925
were O 0 0.00025016384
akinetic B-Disease 2 0.94629604
( O 0 0.00085454097
A O 0 0.006911315
group O 0 0.0013781603
) O 0 0.0022065633
. O 0 0.0021024162

The O 0 0.0017386168
other O 0 0.0012730791
rats O 0 0.0012926892
showed O 0 0.00057943416
a O 0 0.0005173741
strong O 0 0.00038584028
decrease O 0 0.00034351117
in O 0 0.0001826508
the O 0 0.00021350673
rigidity B-Disease 0 0.20714968
and O 0 0.00015499833
the O 0 9.8651086e-05
occurrence O 0 0.00016128599
of O 0 0.00021021233
stereotyped O 0 0.04630881
( O 0 0.0005316031
S O 0 0.8583507
) O 0 0.0004218933
licking O 0 0.021255568
and O 0 0.00013612068
/ O 0 0.00035392225
or O 0 0.000118171796
gnawing O 0 0.35127932
in O 0 6.438631e-05
presence O 0 6.440806e-05
of O 0 0.00017187593
akinetic B-Disease 2 0.98114645
or O 0 0.0003056084
hyperkinetic B-Disease 0 0.999866
( O 0 0.0012863918
K O 1 0.99975485
) O 0 0.00034931485
behaviour O 0 0.00020813437
( O 0 0.00024814278
AS O 0 0.058268026
/ O 0 0.0015016805
KS O 0 0.84043914
group O 0 0.00040610923
) O 0 0.00032327927
, O 0 0.00021034546
suggesting O 0 0.0001557226
signs O 0 0.0019672005
of O 0 0.000970226
dopaminergic O 0 0.4582973
activation O 0 0.0031352965
. O 0 0.0024387795

The O 0 0.0029616007
rigidity B-Disease 0 0.22233729
was O 0 0.001843076
considerably O 0 0.0012277436
decreased O 0 0.0011680863
in O 0 0.00044490272
both O 0 0.00037753806
groups O 0 0.00028839958
after O 0 0.00015183439
20 O 0 0.00036997985
days O 0 0.00033107813
' O 0 0.0011763261
treatment O 0 0.0018152482
. O 0 0.002835405

In O 0 0.001845179
a O 0 0.0016170348
further O 0 0.0010729649
series O 0 0.0007437673
of O 0 0.000521075
experiments O 0 0.00036120485
, O 0 0.0010536761
haloperidol B-Chemical 1 0.99999464
( O 0 0.0007168616
0 O 0 0.00014816869
. O 0 7.518028e-05
2 O 0 8.469376e-05
mg O 0 0.0010467098
/ O 0 0.00040470756
kg O 0 0.0003481124
i O 0 0.00031587263
. O 0 8.701016e-05
p O 0 0.00011586806
. O 0 6.188503e-05
) O 0 0.00012994991
was O 0 7.262072e-05
used O 0 4.5984518e-05
in O 0 4.767719e-05
order O 0 4.5781886e-05
to O 0 5.1629213e-05
block O 0 8.308453e-05
the O 0 9.3381255e-05
dopaminergic O 0 0.077786565
activation O 0 0.00014382364
and O 0 7.511959e-05
to O 0 4.620598e-05
estimate O 0 3.817953e-05
the O 0 5.2158615e-05
real O 0 6.5708125e-05
degree O 0 0.00010085508
of O 0 0.00011345681
the O 0 0.00012104246
tolerance O 0 0.007916649
to O 0 0.00012827004
the O 0 0.00021570925
rigidity B-Disease 0 0.25218955
without O 0 0.00038605643
any O 0 0.0005062082
dopaminergic O 0 0.23970136
interference O 0 0.0030751843
. O 0 0.0021880944

Haloperidol B-Chemical 1 0.9997818
enhanced O 0 0.007098142
the O 0 0.0037036794
rigidity B-Disease 0 0.34710363
in O 0 0.0024146216
the O 0 0.0027977575
A O 0 0.019473925
group O 0 0.0057012076
. O 0 0.0053910455

However O 0 0.0028438114
, O 0 0.001878504
the O 0 0.0008700859
level O 0 0.00054224365
in O 0 0.0004564051
the O 0 0.0005215982
AS O 0 0.13723664
/ O 0 0.0033663707
KS O 0 0.8183735
group O 0 0.00045293738
remained O 0 0.00032479392
considerably O 0 0.00032860463
lower O 0 0.00030596412
than O 0 0.00018849794
in O 0 0.00031930493
the O 0 0.00064255844
A O 0 0.009676018
group O 0 0.0024257726
. O 0 0.0024488063

The O 0 0.0015516307
results O 0 0.001235816
suggest O 0 0.00055635127
that O 0 0.0007271032
rigidity B-Disease 0 0.57133347
, O 0 0.0008282046
which O 0 0.00048100232
is O 0 0.00022804482
assumed O 0 0.00013687847
to O 0 0.000113979055
be O 0 8.507835e-05
due O 0 4.8953905e-05
to O 0 5.8648224e-05
an O 0 9.624438e-05
action O 0 0.00015480381
of O 0 0.000347171
morphine B-Chemical 0 0.99989605
in O 0 0.00014159607
the O 0 0.00013303738
striatum O 0 0.020953948
, O 0 0.0001378313
can O 0 6.309079e-05
be O 0 9.177195e-05
antagonized O 0 0.026062483
by O 0 0.00012511542
another O 0 0.000115091294
process O 0 0.00010428251
leading O 0 0.00019454547
to O 0 0.00016772965
dopaminergic O 0 0.078165665
activation O 0 0.0004493735
in O 0 0.0004098733
the O 0 0.00080409925
striatum O 0 0.047468886
. O 0 0.0021879799

Nevertheless O 0 0.003674467
, O 0 0.0026953572
there O 0 0.0010323442
occurs O 0 0.00097039895
some O 0 0.0010245646
real O 0 0.0013104567
tolerance O 0 0.014476424
to O 0 0.0012938348
this O 0 0.002061208
effect O 0 0.0029992254
. O 0 0.0042219507

The O 0 0.0014978219
rapid O 0 0.0020538247
alternations O 0 0.0025227007
of O 0 0.0012134429
rigidity B-Disease 0 0.2710531
and O 0 0.00044793778
the O 0 0.00027463608
signs O 0 0.0014858538
of O 0 0.00035473632
dopaminergic O 0 0.1904817
activation O 0 0.00023032569
observed O 0 8.792557e-05
in O 0 6.7433095e-05
the O 0 6.111996e-05
animals O 0 4.579521e-05
of O 0 8.543313e-05
the O 0 0.00011598192
AS O 0 0.13419439
/ O 0 0.001807913
KS O 0 0.8409344
group O 0 0.00016206448
might O 0 4.6453435e-05
be O 0 5.141014e-05
due O 0 3.516257e-05
to O 0 5.2444462e-05
rapid O 0 0.00017641815
shifts O 0 0.00015630396
in O 0 7.928057e-05
the O 0 0.000100308185
predominance O 0 0.00022595494
of O 0 0.00028345984
various O 0 0.00072063575
DA O 0 0.99933213
- O 0 0.0019383674
innervated O 0 0.0018899866
structures O 0 0.0014619046
. O 0 0.0018657038

A O 0 0.019820163
case O 0 0.0031556499
of O 0 0.003625943
massive O 0 0.075490244
rhabdomyolysis B-Disease 0 0.999859
following O 0 0.011948751
molindone B-Chemical 0 0.9999869
administration O 0 0.50767404
. O 0 0.0066961423

Rhabdomyolysis B-Disease 0 0.9964461
is O 0 0.0026574943
a O 0 0.0016052214
potentially O 0 0.0012906736
lethal O 0 0.007850478
syndrome O 0 0.16444552
that O 0 0.00067493395
psychiatric B-Disease 2 0.97348446
patients O 0 0.0011613623
seem O 0 0.0006602565
predisposed O 0 0.00411633
to O 0 0.0009668661
develop O 0 0.002226766
. O 0 0.0025644614

The O 0 0.0017848075
clinical O 0 0.0033074343
signs O 0 0.0054320414
and O 0 0.0011114479
symptoms O 0 0.0055891145
, O 0 0.00048745435
typical O 0 0.0002857731
laboratory O 0 0.000411488
features O 0 0.00028145037
, O 0 0.00029548348
and O 0 0.00033798814
complications O 0 0.009353535
of O 0 0.0016663522
rhabdomyolysis B-Disease 0 0.99991727
are O 0 0.0017436093
presented O 0 0.0018223798
. O 0 0.0023406108

The O 0 0.0016404821
case O 0 0.0012093569
of O 0 0.0011751927
a O 0 0.0016853213
schizophrenic B-Disease 2 0.99959713
patient O 0 0.00073201454
is O 0 0.00026149632
reported O 0 0.0001843158
to O 0 0.00011057816
illustrate O 0 0.000119029246
massive O 0 0.022036385
rhabdomyolysis B-Disease 0 0.99997175
and O 0 0.00043385167
subsequent O 0 0.00033715522
acute B-Disease 0 0.60109913
renal I-Disease 0 0.99217683
failure I-Disease 0 0.67402434
following O 0 0.0015788926
molindone B-Chemical 0 0.9999943
administration O 0 0.14133623
. O 0 0.0025996482

Physicians O 0 0.004919512
who O 0 0.0043209074
prescribe O 0 0.014340737
molindone B-Chemical 0 0.9999659
should O 0 0.0010333518
be O 0 0.0008461701
aware O 0 0.0008438508
of O 0 0.0013237168
this O 0 0.0022268742
reaction O 0 0.023285678
. O 0 0.0043647005

Compression B-Disease 0 0.25062516
neuropathy I-Disease 0 0.9987919
of I-Disease 0 0.0021270227
the I-Disease 0 0.0010670933
radial I-Disease 0 0.0031874175
nerve I-Disease 0 0.005497686
due O 0 0.00053337065
to O 0 0.0013809549
pentazocine B-Chemical 1 0.99998105
- O 0 0.005950087
induced O 0 0.004109693
fibrous B-Disease 0 0.9610062
myopathy I-Disease 2 0.9999188
. O 0 0.006951767

Fibrous B-Disease 0 0.5640643
myopathy I-Disease 2 0.99973685
is O 0 0.0025095912
a O 0 0.0014578111
common O 0 0.00085393747
, O 0 0.0006552235
well O 0 0.00038490456
- O 0 0.00065414055
known O 0 0.00044699127
side O 0 0.001915147
effect O 0 0.00033938797
of O 0 0.000674788
repeated O 0 0.0009196356
pentazocine B-Chemical 1 0.99995863
injection O 0 0.0065967175
. O 0 0.0029634796

However O 0 0.003112892
, O 0 0.003635223
compression B-Disease 0 0.6559111
neuropathy I-Disease 0 0.99994123
due O 0 0.00068626716
to O 0 0.0005514378
fibrotic O 0 0.1973829
muscle O 0 0.0074234027
affected O 0 0.0005837737
by O 0 0.001027563
pentazocine B-Chemical 1 0.99999607
- O 0 0.003356122
induced O 0 0.0015690281
myopathy B-Disease 2 0.99984574
has O 0 0.00035940978
not O 0 0.00032442846
previously O 0 0.0004761213
been O 0 0.0006459616
reported O 0 0.0015539979
. O 0 0.0019757648

In O 0 0.0020929617
a O 0 0.0021710992
37 O 0 0.0023489378
- O 0 0.0015747367
year O 0 0.00043837348
- O 0 0.0006140469
old O 0 0.00030140785
woman O 0 0.0005567452
with O 0 0.00032009004
documented O 0 0.0015907488
pentazocine B-Chemical 1 0.9999963
- O 0 0.0012039744
induced O 0 0.00039231696
fibrous B-Disease 0 0.7847125
myopathy I-Disease 2 0.9999852
of O 0 0.0006668612
triceps O 0 0.16263829
and O 0 0.00015511899
deltoid O 0 0.09676049
muscles O 0 0.00028307905
bilaterally O 0 0.00028831247
and O 0 6.158003e-05
a O 0 6.934459e-05
three O 0 2.9774645e-05
- O 0 9.187439e-05
week O 0 2.494486e-05
history O 0 6.687863e-05
of O 0 7.041652e-05
right O 0 0.00042147707
wrist O 0 0.021730857
drop O 0 0.0008692232
, O 0 0.00013560636
electrodiagnostic O 0 0.005701148
examination O 0 8.191526e-05
showed O 0 6.815314e-05
a O 0 0.00013097622
severe O 0 0.0012337896
but O 0 9.63928e-05
partial O 0 0.0001599865
lesion O 0 0.00041347512
of O 0 8.015653e-05
the O 0 6.413984e-05
right O 0 0.00027335057
radial O 0 0.00076751655
nerve O 0 0.0016421456
distal O 0 0.00012326581
to O 0 5.4505166e-05
the O 0 6.927903e-05
branches O 0 0.00018531653
to O 0 7.705942e-05
the O 0 0.00014676678
triceps O 0 0.038415603
, O 0 0.0001791333
in O 0 0.000121718884
addition O 0 0.00014323978
to O 0 0.00031347296
the O 0 0.0009145553
fibrous B-Disease 0 0.8099088
myopathy I-Disease 2 0.9999162
. O 0 0.005047547

Surgery O 0 0.005262307
revealed O 0 0.0012714989
the O 0 0.0009303063
right O 0 0.0017234373
radial O 0 0.002678284
nerve O 0 0.004216797
to O 0 0.00035304792
be O 0 0.0002788587
severely O 0 0.0012605056
compressed O 0 0.00043133448
by O 0 0.00020138956
the O 0 0.0001859456
densely O 0 0.00028866561
fibrotic O 0 0.012294914
lateral O 0 0.0016109938
head O 0 0.002373447
of O 0 0.0009164237
the O 0 0.0013821272
triceps O 0 0.18261567
. O 0 0.0026960596

Decompression O 0 0.012047166
and O 0 0.0027038893
neurolysis O 0 0.013321775
were O 0 0.000808886
performed O 0 0.0005111166
with O 0 0.00058169954
good O 0 0.0008109188
subsequent O 0 0.0006474914
recovery O 0 0.0015003977
of O 0 0.0016755284
function O 0 0.002695644
. O 0 0.0031170775

Recurrent O 0 0.0167352
reversible O 0 0.16826673
acute B-Disease 0 0.87643206
renal I-Disease 0 0.9938484
failure I-Disease 0 0.8771446
from O 0 0.0078062434
amphotericin B-Chemical 0 0.9976465
. O 0 0.009485382

A O 0 0.01720544
patient O 0 0.0022591108
with O 0 0.0030693933
cryptogenic O 0 0.99962425
cirrhosis B-Disease 0 0.9999933
and O 0 0.0039585195
disseminated O 0 0.90946066
sporotrichosis B-Disease 0 0.9991098
developed O 0 0.003139466
acute B-Disease 0 0.8830993
renal I-Disease 0 0.9936401
failure I-Disease 0 0.15320794
immediately O 0 6.819332e-05
following O 0 4.5449375e-05
the O 0 7.6082746e-05
administration O 0 0.0004761463
of O 0 0.000603834
amphotericin B-Chemical 0 0.99988365
B I-Chemical 0 0.7790904
on O 0 0.0002341287
four O 0 0.00026034054
separate O 0 0.00043500497
occasions O 0 0.001286491
. O 0 0.0016840637

The O 0 0.001874082
abruptness O 0 0.0039652106
of O 0 0.0013112368
the O 0 0.0010142004
renal B-Disease 0 0.8660494
failure I-Disease 0 0.24543822
and O 0 0.00046400202
its O 0 0.00046318182
reversibility O 0 0.002372915
within O 0 4.4758992e-05
days O 0 3.7983347e-05
suggests O 0 3.7429563e-05
that O 0 5.633868e-05
there O 0 6.6439716e-05
was O 0 0.0001272745
a O 0 0.00014980124
functional O 0 0.00014592726
component O 0 0.00016780291
to O 0 0.0002808858
the O 0 0.00086710975
renal B-Disease 2 0.9993268
dysfunction I-Disease 2 0.99929
. O 0 0.0043032886

We O 0 0.0013510706
propose O 0 0.00092424377
that O 0 0.00121895
amphotericin B-Chemical 0 0.9977685
, O 0 0.0011642034
in O 0 0.00037409275
the O 0 0.0002480084
setting O 0 0.00016150359
of O 0 0.00019974587
reduced O 0 0.0002605111
effective O 0 0.00014588774
arterial O 0 0.021238722
volume O 0 0.0004761329
, O 0 0.00014044423
may O 0 6.8208734e-05
activate O 0 4.6805035e-05
tubuloglomerular O 0 0.045930117
feedback O 0 0.00027919177
, O 0 0.00018867778
thereby O 0 0.00020304405
contributing O 0 0.00036191734
to O 0 0.00046367172
acute B-Disease 0 0.66986346
renal I-Disease 0 0.997224
failure I-Disease 0 0.9251207
. O 0 0.0034350024

Cerebral B-Disease 0 0.98908514
infarction I-Disease 2 0.99987197
with O 0 0.0038172307
a O 0 0.0022068277
single O 0 0.0016175893
oral O 0 0.019218981
dose O 0 0.009821573
of O 0 0.0098371925
phenylpropanolamine B-Chemical 0 0.999948
. O 0 0.0075788335

Phenylpropanolamine B-Chemical 0 0.9990872
( O 0 0.012107878
PPA B-Chemical 1 0.99844813
) O 0 0.0023933607
, O 0 0.0007018166
a O 0 0.00048013765
synthetic O 0 0.0005348289
sympathomimetic O 0 0.89794666
that O 0 0.00016978591
is O 0 0.00015852386
structurally O 0 0.0001996048
similar O 0 8.12065e-05
to O 0 0.00022377321
amphetamine B-Chemical 1 0.9999926
, O 0 0.0003053297
is O 0 0.00010339256
available O 0 7.908215e-05
over O 0 3.0928473e-05
the O 0 6.662618e-05
counter O 0 0.000332287
in O 0 0.00015822425
anorectics O 0 0.73591036
, O 0 0.00028888174
nasal O 0 0.0011370471
congestants O 0 0.0042319414
, O 0 0.00045157853
and O 0 0.0005524592
cold O 0 0.0067985686
preparations O 0 0.002588388
. O 0 0.0020921712

Its O 0 0.016788537
prolonged O 0 0.0027843467
use O 0 0.001135204
or O 0 0.0008772572
overuse O 0 0.02870846
has O 0 0.00030807508
been O 0 0.00018269224
associated O 0 0.00018342759
with O 0 0.0005337529
seizures B-Disease 0 0.999938
, O 0 0.0010254283
intracerebral B-Disease 0 0.9946985
hemorrhage I-Disease 2 0.9999598
, O 0 0.0016014521
neuropsychiatric B-Disease 0 0.9999198
symptoms I-Disease 0 0.78434974
, O 0 0.0006402123
and O 0 0.0009111615
nonhemorrhagic O 0 0.99901307
cerebral B-Disease 0 0.9978873
infarction I-Disease 2 0.99994636
. O 0 0.004677327

We O 0 0.0017105571
report O 0 0.0017025919
the O 0 0.00086277706
case O 0 0.0005936623
of O 0 0.0006037361
a O 0 0.0006645704
young O 0 0.0024216634
woman O 0 0.0012591135
who O 0 0.00047195653
suffered O 0 0.0015880013
a O 0 0.00048277908
cerebral B-Disease 0 0.96979564
infarction I-Disease 2 0.99997425
after O 0 0.00010030474
taking O 0 0.0002745329
a O 0 0.00023181921
single O 0 0.00027276142
oral O 0 0.008214276
dose O 0 0.0031104146
of O 0 0.0029678533
PPA B-Chemical 1 0.99870336
. O 0 0.003236157

Remission O 0 0.06614344
induction O 0 0.002522079
of O 0 0.0036228176
meningeal B-Disease 0 0.9980738
leukemia I-Disease 0 0.999964
with O 0 0.0038148328
high O 0 0.0033892612
- O 0 0.002406819
dose O 0 0.009669275
intravenous O 0 0.6920914
methotrexate B-Chemical 0 0.99960023
. O 0 0.0049699317

Twenty O 0 0.0027352322
children O 0 0.0018229506
with O 0 0.001913588
acute B-Disease 0 0.9972832
lymphoblastic I-Disease 0 0.99999535
leukemia I-Disease 0 0.99999654
who O 0 0.034879226
developed O 0 0.005829226
meningeal B-Disease 0 0.9994392
disease I-Disease 0 0.9931251
were O 0 0.00021253404
treated O 0 0.0001555488
with O 0 0.00010366542
a O 0 0.00011063554
high O 0 0.00020377523
- O 0 0.00019981863
dose O 0 0.00065082265
intravenous O 0 0.1142962
methotrexate B-Chemical 0 0.99986374
regimen O 0 0.00019469262
that O 0 4.5777393e-05
was O 0 6.0980754e-05
designed O 0 4.0932075e-05
to O 0 3.2015072e-05
achieve O 0 3.0054964e-05
and O 0 4.558815e-05
maintain O 0 5.743391e-05
CSF O 0 0.53822047
methotrexate B-Chemical 0 0.999754
concentrations O 0 0.00055643433
of O 0 0.0001870085
10 O 0 0.000115019546
( O 0 0.0001844137
- O 0 0.0002013291
5 O 0 8.133219e-05
) O 0 0.0002236184
mol O 0 0.17745477
/ O 0 0.0012504524
L O 0 0.12633382
without O 0 0.00014069543
the O 0 0.00013078103
need O 0 0.00012513736
for O 0 0.00017273636
concomitant O 0 0.0014291947
intrathecal O 0 0.21322967
dosing O 0 0.005481772
. O 0 0.002062288

The O 0 0.003104544
methotrexate B-Chemical 0 0.99861825
was O 0 0.001511427
administered O 0 0.00080082426
as O 0 0.00035520436
a O 0 0.00032882462
loading O 0 0.00033196213
dose O 0 0.00084134087
of O 0 0.00024749723
6 O 0 8.589885e-05
, O 0 0.000106640065
000 O 0 0.00013071681
mg O 0 0.001489372
/ O 0 0.00032799618
m2 O 0 0.00043897712
for O 0 4.89943e-05
a O 0 6.845426e-05
period O 0 2.5213922e-05
of O 0 5.4017164e-05
one O 0 3.531521e-05
hour O 0 3.7375845e-05
followed O 0 4.1928208e-05
by O 0 6.004547e-05
an O 0 9.484939e-05
infusion O 0 0.00020316236
of O 0 0.00012246457
1 O 0 8.0916e-05
, O 0 0.000101417136
200 O 0 0.00025853043
mg O 0 0.0021880087
/ O 0 0.0005618248
m2 O 0 0.001170719
/ O 0 0.000528287
h O 0 0.00022235421
for O 0 0.00029708334
23 O 0 0.0007886806
hours O 0 0.00071330735
. O 0 0.0016967164

Leucovorin B-Chemical 0 0.99771404
rescue O 0 0.0040415195
was O 0 0.0010442656
initiated O 0 0.00044557848
12 O 0 0.00017448375
hours O 0 9.8166216e-05
after O 0 5.680592e-05
the O 0 9.159499e-05
end O 0 5.645845e-05
of O 0 0.00011169291
the O 0 9.8969096e-05
infusion O 0 0.0002331532
with O 0 9.9966244e-05
a O 0 9.5715004e-05
loading O 0 0.00010757295
dose O 0 0.0002982947
of O 0 0.00012314632
200 O 0 0.00032186368
mg O 0 0.004080199
/ O 0 0.00034563884
m2 O 0 0.00052381464
followed O 0 4.876715e-05
by O 0 5.315105e-05
12 O 0 3.2721702e-05
mg O 0 0.00058125256
/ O 0 0.00017150168
m2 O 0 0.00018981367
every O 0 1.3519102e-05
three O 0 1.5241132e-05
hours O 0 1.739606e-05
for O 0 2.4892624e-05
six O 0 2.6649617e-05
doses O 0 0.00018316806
and O 0 4.5343568e-05
then O 0 2.626147e-05
every O 0 1.1924624e-05
six O 0 1.5977648e-05
hours O 0 1.5943173e-05
until O 0 1.8753608e-05
the O 0 5.5658726e-05
plasma O 0 0.009903617
methotrexate B-Chemical 0 0.9996723
level O 0 0.00010484427
decreased O 0 0.0002660004
to O 0 8.187691e-05
less O 0 0.00010848793
than O 0 8.5188585e-05
1 O 0 0.00014265421
X O 0 0.029556178
10 O 0 0.00019264275
( O 0 0.00034505574
- O 0 0.00046679398
7 O 0 0.00029127506
) O 0 0.0009183589
mol O 0 0.24177667
/ O 0 0.007974969
L O 0 0.40361008
. O 0 0.0035289624

The O 0 0.0012174845
mean O 0 0.00067594845
steady O 0 0.0009918177
- O 0 0.0010300461
state O 0 0.0004996362
plasma O 0 0.0020191888
and O 0 0.0004584492
CSF O 0 0.72356695
methotrexate B-Chemical 0 0.9998136
concentrations O 0 0.0012330478
achieved O 0 0.00033270827
were O 0 0.00015486316
1 O 0 9.582368e-05
. O 0 6.5511784e-05
1 O 0 0.00010590939
X O 0 0.01463203
10 O 0 0.00013008864
( O 0 0.00020912878
- O 0 0.00023852375
3 O 0 9.916237e-05
) O 0 0.0002408561
mol O 0 0.17406918
/ O 0 0.0014698291
L O 0 0.28066632
and O 0 0.00018473751
3 O 0 9.444119e-05
. O 0 7.0624184e-05
6 O 0 8.722574e-05
X O 0 0.0071448484
10 O 0 0.00016805623
( O 0 0.00028989045
- O 0 0.0003635114
5 O 0 0.00020301426
) O 0 0.0005936906
mol O 0 0.19960953
/ O 0 0.0045369887
L O 0 0.38246793
, O 0 0.0020965463
respectively O 0 0.003982427
. O 0 0.0028762985

All O 0 0.0016142059
20 O 0 0.0013143509
patients O 0 0.0009814327
responded O 0 0.0007266384
to O 0 0.0003250563
this O 0 0.00037300927
regimen O 0 0.0005255618
, O 0 0.00029157154
16 O 0 0.00018922295
/ O 0 0.00037972975
20 O 0 0.00014561368
( O 0 0.00016122249
80 O 0 0.00015892372
% O 0 0.0001271195
) O 0 0.0001395006
achieved O 0 0.00011017726
a O 0 0.00012419066
complete O 0 0.00013825606
remission O 0 0.005590392
, O 0 0.00016719918
and O 0 0.00013748869
20 O 0 0.0001447351
% O 0 0.00017323332
obtained O 0 0.00022749386
a O 0 0.00052161614
partial O 0 0.0016487404
remission O 0 0.05657101
. O 0 0.0022522113

The O 0 0.0015800146
most O 0 0.0016471627
common O 0 0.0012473145
toxicities B-Disease 2 0.90638494
encountered O 0 0.0006114248
were O 0 0.00038903952
transient O 0 0.0027379182
serum O 0 0.38591903
transaminase O 0 0.9999455
and O 0 0.0032021047
bilirubin B-Chemical 1 0.9999821
elevations O 0 0.87357676
, O 0 0.0026747317
neutropenia B-Disease 0 0.99946934
, O 0 0.0027561567
and O 0 0.0043008397
mucositis B-Disease 2 0.99986887
. O 0 0.0047760424

One O 0 0.0025666603
patient O 0 0.0019389855
had O 0 0.0013686225
focal O 0 0.004375651
seizures B-Disease 0 0.99977344
and O 0 0.003414969
transient B-Disease 0 0.93417555
hemiparesis I-Disease 0 0.9999527
but O 0 0.0028188748
recovered O 0 0.0017930202
completely O 0 0.0032845966
. O 0 0.003052392

High O 0 0.007933842
- O 0 0.0033430466
dose O 0 0.005792714
intravenous O 0 0.35272563
methotrexate B-Chemical 0 0.9997769
is O 0 0.0004860696
an O 0 0.000279566
effective O 0 0.0001361861
treatment O 0 0.00012268103
for O 0 7.099692e-05
the O 0 8.3729414e-05
induction O 0 0.00011329541
of O 0 0.0001839718
remission O 0 0.00365561
after O 0 8.2414605e-05
meningeal O 0 0.35102454
relapse O 0 0.551473
in O 0 0.0011818829
acute B-Disease 0 0.9989324
lymphoblastic I-Disease 0 0.99999285
leukemia I-Disease 0 0.9999864
. O 0 0.017768137

Interaction O 0 0.0072741457
of O 0 0.010506467
cyclosporin B-Chemical 0 0.9999188
A I-Chemical 0 0.73276967
with O 0 0.007599347
antineoplastic O 0 0.5650785
agents O 0 0.05076558
. O 0 0.008049064

A O 0 0.013423569
synergistic O 0 0.0025014065
effect O 0 0.0010867217
of O 0 0.0019510014
etoposide B-Chemical 0 0.99962604
and O 0 0.009059663
cyclosporin B-Chemical 0 0.99999833
A I-Chemical 0 0.9483204
was O 0 0.00042676262
observed O 0 0.00013632058
in O 0 0.00011340446
a O 0 0.00017480997
patient O 0 0.00018251917
with O 0 0.00036567502
acute B-Disease 0 0.7639774
T I-Disease 0 0.99091
- I-Disease 0 0.033266883
lymphocytic I-Disease 0 0.9999391
leukemia I-Disease 0 0.9999676
in O 0 0.006875053
relapse O 0 0.9175169
. O 0 0.003305566

The O 0 0.0015399688
concomitant O 0 0.002260329
administration O 0 0.0029122918
of O 0 0.0017010544
etoposide B-Chemical 0 0.9995573
and O 0 0.0054113553
cyclosporin B-Chemical 0 0.99999785
A I-Chemical 0 0.8267323
resulted O 0 0.00032517558
in O 0 0.00016690261
eradication O 0 0.00026272383
of O 0 0.00024509104
hitherto O 0 0.0013255827
refractory O 0 0.011533845
leukemic B-Disease 0 0.99937075
infiltration I-Disease 0 0.5162083
of O 0 0.0020215798
bone O 0 0.29174602
marrow O 0 0.9118233
. O 0 0.0034512265

Severe O 0 0.09474416
side O 0 0.009536563
effects O 0 0.0011567214
in O 0 0.0005430888
terms O 0 0.0003068343
of O 0 0.00048155832
mental O 0 0.007981823
confusion B-Disease 0 0.4791177
and O 0 0.0005623727
progressive O 0 0.64768714
hyperbilirubinemia B-Disease 0 0.9999883
, O 0 0.0007187331
however O 0 0.00027033017
, O 0 0.00011369768
point O 0 5.5303874e-05
to O 0 5.300416e-05
an O 0 8.550487e-05
enhancement O 0 0.00015530322
not O 0 6.70838e-05
only O 0 8.7367676e-05
of O 0 0.00014671528
antineoplastic O 0 0.019630969
effects O 0 0.0001990379
but O 0 0.00016902336
also O 0 0.00016266704
of O 0 0.00049872405
toxicity B-Disease 2 0.99067515
in O 0 0.00068634475
normal O 0 0.0022399526
tissues O 0 0.0025687024
. O 0 0.0017771915

This O 0 0.0034990548
report O 0 0.0017541649
demonstrates O 0 0.00053695537
for O 0 0.00032414153
the O 0 0.0002494779
first O 0 0.00011960566
time O 0 7.5556745e-05
that O 0 7.235017e-05
the O 0 0.00010349456
pharmacodynamic O 0 0.0014682232
properties O 0 9.376923e-05
of O 0 0.0006128659
cyclosporin B-Chemical 0 0.9999987
A I-Chemical 0 0.8018878
may O 0 0.00013004498
not O 0 8.851359e-05
be O 0 6.430728e-05
confined O 0 4.7503916e-05
strictly O 0 5.61996e-05
to O 0 7.00264e-05
suppression O 0 0.00023830347
of O 0 0.0003443479
normal O 0 0.0018971293
T O 0 0.7078924
- O 0 0.0018822969
cell O 0 0.0031132589
functions O 0 0.0018195716
. O 0 0.0022850044

Incidence O 0 0.0070868423
of O 0 0.0028630088
neoplasms B-Disease 0 0.24691749
in O 0 0.00085704314
patients O 0 0.0010287205
with O 0 0.0017151559
rheumatoid B-Disease 0 0.99986255
arthritis I-Disease 0 0.99983597
exposed O 0 0.0007016483
to O 0 0.00038515872
different O 0 0.00036700984
treatment O 0 0.0008999939
regimens O 0 0.0025686387
. O 0 0.0024175986

Immunosuppressive O 0 0.75126225
drugs O 0 0.06494277
have O 0 0.00081965874
been O 0 0.00037864546
used O 0 0.0002309317
during O 0 0.00011877371
the O 0 0.0001399783
last O 0 6.542576e-05
30 O 0 9.461506e-05
years O 0 9.393802e-05
in O 0 9.246396e-05
treatment O 0 0.000132397
of O 0 0.0002642182
patients O 0 0.000533875
with O 0 0.0009817563
severe O 0 0.580137
rheumatoid B-Disease 0 0.9999255
arthritis I-Disease 0 0.9998696
. O 0 0.005135181

The O 0 0.0017801031
drugs O 0 0.0073956316
commonly O 0 0.00090629974
used O 0 0.0005017496
are O 0 0.0005649805
cyclophosphamide B-Chemical 0 0.9987841
and O 0 0.0014664708
chlorambucil B-Chemical 0 0.99994195
( O 0 0.0012324555
alkylating B-Chemical 0 0.81853867
agents I-Chemical 0 0.009916428
) O 0 0.00077157817
, O 0 0.00063000957
azathioprine B-Chemical 0 0.9999789
( O 0 0.0017839599
purine B-Chemical 0 0.9953597
analogue O 0 0.009864791
) O 0 0.00042494273
, O 0 0.00024184052
and O 0 0.00048667457
methotrexate B-Chemical 0 0.9998721
( O 0 0.0049471385
folic B-Chemical 0 0.9999449
acid I-Chemical 0 0.99685645
analogue O 0 0.18912764
) O 0 0.0046170824
. O 0 0.0026893495

There O 0 0.0026088418
is O 0 0.0013843396
evidence O 0 0.0006245599
that O 0 0.00036447952
all O 0 0.00035487773
four O 0 0.00022138742
immunosuppressive O 0 0.08966302
drugs O 0 0.030873016
can O 0 0.00018090573
reduce O 0 0.00025634738
synovitis B-Disease 0 0.9984999
, O 0 0.0004534458
but O 0 0.00030992096
disease O 0 0.036315322
activity O 0 0.00015329584
almost O 0 0.00016561092
always O 0 0.0002238018
recurs O 0 0.00045906822
after O 0 0.00012793424
therapy O 0 0.0005740071
is O 0 0.0007682571
stopped O 0 0.0022510826
. O 0 0.0020809576

Since O 0 0.0018078707
adverse O 0 0.029867923
reactions O 0 0.006096415
are O 0 0.0008584244
frequent O 0 0.0007228384
, O 0 0.000381768
less O 0 0.00022322855
than O 0 0.00011252504
50 O 0 0.0001735564
percent O 0 7.848563e-05
of O 0 0.00014615202
patients O 0 0.00017690903
are O 0 7.582337e-05
able O 0 5.8468966e-05
to O 0 7.3411764e-05
continue O 0 9.650445e-05
a O 0 0.00012371833
particular O 0 8.081652e-05
drug O 0 0.0014461693
for O 0 0.00013686984
more O 0 0.00031979723
than O 0 0.0002727453
one O 0 0.00047963523
year O 0 0.0008238303
. O 0 0.0016286

Since O 0 0.0014598484
it O 0 0.0012023343
takes O 0 0.00043767554
three O 0 0.00025301788
to O 0 0.00025169406
12 O 0 0.00013360105
months O 0 6.701513e-05
to O 0 7.8964666e-05
achieve O 0 7.3063755e-05
maximal O 0 0.00010855011
effects O 0 0.00016132629
, O 0 0.00017029843
those O 0 0.00018971905
patients O 0 0.00019873297
who O 0 0.0001587783
are O 0 6.229453e-05
unable O 0 5.5848748e-05
to O 0 6.9224865e-05
continue O 0 9.827533e-05
the O 0 0.0001257438
drug O 0 0.0018018039
receive O 0 0.00012526964
little O 0 0.00021337629
benefit O 0 0.00038432397
from O 0 0.00051644625
it O 0 0.0012860139
. O 0 0.0017978086

Patients O 0 0.0022746788
treated O 0 0.0015927826
with O 0 0.0012130134
alkylating B-Chemical 0 0.5802616
agents I-Chemical 0 0.0034884296
have O 0 0.00026068705
an O 0 0.00029499142
increased O 0 0.00041510497
risk O 0 0.0012252855
of O 0 0.00019028754
development O 0 0.00030505416
of O 0 0.00048044053
acute B-Disease 0 0.9970366
nonlymphocytic I-Disease 0 0.99998736
leukemia I-Disease 0 0.9999981
, O 0 0.0007655691
and O 0 0.0001465953
both O 0 0.0001228674
alkylating B-Chemical 0 0.4578601
agents I-Chemical 0 0.0020617633
and O 0 0.00042170935
azathioprine B-Chemical 0 0.99996936
are O 0 0.000123937
associated O 0 7.192951e-05
with O 0 9.7447504e-05
the O 0 8.6286185e-05
development O 0 0.0001960439
of O 0 0.00023432118
non B-Disease 0 0.00046681045
- I-Disease 0 0.0009568152
Hodgkin I-Disease 0 0.59823644
' I-Disease 0 0.0013465913
s I-Disease 0 0.0014669541
lymphoma I-Disease 0 0.96247834
. O 0 0.003151421

Cyclophosphamide B-Chemical 0 0.9957135
therapy O 0 0.004186707
increases O 0 0.0018032436
the O 0 0.0015701252
risk O 0 0.006156116
of O 0 0.00281265
carcinoma B-Disease 0 0.9868209
of I-Disease 0 0.002539038
the I-Disease 0 0.0024050337
bladder I-Disease 0 0.07342818
. O 0 0.0037773596

There O 0 0.0025672512
have O 0 0.0011329225
been O 0 0.0006165903
several O 0 0.00038658455
long O 0 0.00037749106
- O 0 0.0004160316
term O 0 0.0001429482
studies O 0 0.0001288693
of O 0 0.00014682893
patients O 0 0.00021214088
with O 0 0.00046097903
rheumatoid B-Disease 0 0.9999435
arthritis I-Disease 0 0.99995863
treated O 0 0.00071703416
with O 0 0.00067672157
azathioprine B-Chemical 0 0.9999825
and O 0 0.00050163164
cyclophosphamide B-Chemical 0 0.999572
and O 0 0.00017402403
the O 0 0.00010676237
incidence O 0 0.000212044
of O 0 0.00013161685
most O 0 0.00018998804
of O 0 0.00018998695
the O 0 0.00020774596
common O 0 0.00051423267
cancers B-Disease 0 0.74624586
is O 0 0.00058142684
not O 0 0.0006666286
increased O 0 0.0023910233
. O 0 0.0021461002

Data O 0 0.002107968
on O 0 0.0008545503
the O 0 0.0007690925
possible O 0 0.0005733365
increased O 0 0.000896495
risk O 0 0.0032377937
of O 0 0.0010391882
malignancy B-Disease 2 0.9991322
in O 0 0.0015748028
rheumatoid B-Disease 0 0.9999685
arthritis I-Disease 0 0.99996173
are O 0 0.00021904799
still O 0 0.00010078566
being O 0 0.00010122092
collected O 0 4.3900385e-05
, O 0 7.0957125e-05
and O 0 5.3977103e-05
until O 0 2.8133552e-05
further O 0 7.093777e-05
information O 0 6.6292574e-05
is O 0 7.659062e-05
available O 0 8.8705405e-05
, O 0 6.991509e-05
the O 0 5.133724e-05
use O 0 4.8271286e-05
of O 0 0.00011125316
immunosuppressive O 0 0.14802732
drugs O 0 0.029379042
, O 0 0.00013165122
particularly O 0 0.00015866813
alkylating B-Chemical 0 0.5621849
agents I-Chemical 0 0.0013261295
, O 0 0.00010153355
in O 0 4.8375477e-05
the O 0 5.146223e-05
treatment O 0 7.771139e-05
of O 0 0.00045226258
rheumatoid B-Disease 0 0.99996614
arthritis I-Disease 0 0.99995124
should O 0 6.611277e-05
be O 0 6.127017e-05
reserved O 0 8.825081e-05
for O 0 4.6247682e-05
patients O 0 0.00012095167
with O 0 0.00016444239
severe O 0 0.006287554
progressive O 0 0.2124045
disease O 0 0.34899366
or O 0 0.00034590255
life O 0 0.0006672464
- O 0 0.0011389592
threatening O 0 0.0039659003
complications O 0 0.102688044
. O 0 0.0023685542

Warfarin B-Chemical 0 0.99859494
- O 0 0.0074071144
induced O 0 0.0036810576
iliopsoas O 0 0.25587672
hemorrhage B-Disease 2 0.9986993
with O 0 0.0023042294
subsequent O 0 0.0022738944
femoral B-Disease 0 0.4925783
nerve I-Disease 0 0.68948734
palsy I-Disease 0 0.99983656
. O 0 0.008710384

We O 0 0.0014752812
present O 0 0.0009563554
the O 0 0.00082608365
case O 0 0.00059730007
of O 0 0.0006123468
a O 0 0.0005928317
28 O 0 0.00037368585
- O 0 0.00046643257
year O 0 0.00013710119
- O 0 0.00025401736
old O 0 0.00014266346
man O 0 0.00080788386
on O 0 7.828321e-05
chronic O 0 0.31756192
warfarin B-Chemical 1 0.9999113
therapy O 0 0.0002790523
who O 0 0.00014161174
sustained O 0 0.00015983554
a O 0 0.00014075231
minor O 0 0.0007348015
muscle B-Disease 0 0.24487302
tear I-Disease 0 0.9446339
and O 0 0.0001461696
developed O 0 0.00019476001
increasing O 0 0.00026460493
pain B-Disease 0 0.29182982
and O 0 0.00020579771
a O 0 0.00044124218
flexure O 0 0.62311184
contracture B-Disease 0 0.99611866
of O 0 0.0007168207
the O 0 0.0006862284
right O 0 0.004742624
hip O 0 0.58122027
. O 0 0.002828176

Surgical O 0 0.0030678206
exploration O 0 0.0017264753
revealed O 0 0.0007828526
an O 0 0.00094763475
iliopsoas O 0 0.038264498
hematoma B-Disease 0 0.98937386
and O 0 0.0006550636
femoral O 0 0.023332644
nerve B-Disease 0 0.635127
entrapment I-Disease 0 0.8251861
, O 0 0.00028284086
resulting O 0 0.0001638767
in O 0 0.00012908058
a O 0 0.00027305546
femoral B-Disease 0 0.12540072
nerve I-Disease 0 0.2538817
palsy I-Disease 0 0.99996996
and O 0 0.00053469586
partial B-Disease 0 0.0007711135
loss I-Disease 0 0.0014247923
of I-Disease 0 0.0010876339
quadriceps I-Disease 0 0.07094046
functions I-Disease 0 0.0016786905
. O 0 0.0020417296

Anticoagulant O 0 0.1953062
- O 0 0.0034878762
induced O 0 0.0017177091
femoral B-Disease 0 0.2092441
nerve I-Disease 0 0.44163278
palsy I-Disease 0 0.999941
represents O 0 0.00046689482
the O 0 0.00021530958
most O 0 0.00022740605
common O 0 0.00013815946
form O 0 0.000114306444
of O 0 0.00043178393
warfarin B-Chemical 1 0.99989367
- O 0 0.00057212106
induced O 0 0.00040863545
peripheral B-Disease 2 0.97900176
neuropathy I-Disease 2 0.9999987
; O 0 0.0006106281
it O 0 0.00013632851
is O 0 8.67592e-05
characterized O 0 0.00020168051
by O 0 0.00012494135
severe O 0 0.008920418
pain B-Disease 0 0.32747585
in O 0 8.060533e-05
the O 0 7.8129735e-05
inguinal O 0 0.00015160264
region O 0 5.6892935e-05
, O 0 6.556648e-05
varying O 0 7.901068e-05
degrees O 0 0.00047083228
of O 0 0.00013601118
motor B-Disease 0 0.00055468286
and I-Disease 0 0.00012698103
sensory I-Disease 0 0.0005071196
impairment I-Disease 0 0.09823989
, O 0 0.0002700012
and O 0 0.00033884228
flexure O 0 0.6369606
contracture B-Disease 0 0.9962282
of O 0 0.00067889364
the O 0 0.000550863
involved O 0 0.00074553106
extremity O 0 0.056942254
. O 0 0.0023473764

Pneumonitis O 0 0.8668923
with O 0 0.0029492613
pleural B-Disease 0 0.008812253
and I-Disease 0 0.0013529377
pericardial I-Disease 0 0.016193565
effusion I-Disease 0 0.091739275
and O 0 0.0026738143
neuropathy B-Disease 0 0.9998379
during O 0 0.0016474866
amiodarone B-Chemical 1 0.9998795
therapy O 0 0.00801451
. O 0 0.0032262083

A O 0 0.014053594
patient O 0 0.0017680133
with O 0 0.0015500948
sinuatrial B-Disease 0 0.58343697
disease I-Disease 0 0.8372716
and O 0 0.00039386124
implanted O 0 0.00033012562
pacemaker O 0 0.00058687804
was O 0 0.00013068218
treated O 0 0.0001639186
with O 0 0.00033537776
amiodarone B-Chemical 1 0.99995863
( O 0 0.00019256283
maximum O 0 7.506759e-05
dose O 0 0.0003954191
1000 O 0 0.0002963219
mg O 0 0.0020837102
, O 0 8.099266e-05
maintenance O 0 9.8783064e-05
dose O 0 0.0003117521
800 O 0 0.00042914887
mg O 0 0.0033253154
daily O 0 0.00015649664
) O 0 0.00011530793
for O 0 4.8184687e-05
10 O 0 6.416602e-05
months O 0 3.670956e-05
, O 0 8.84245e-05
for O 0 8.585046e-05
control O 0 0.00020338933
of O 0 0.0009270121
supraventricular B-Disease 0 0.999342
tachyarrhythmias I-Disease 0 0.99992275
. O 0 0.0039319047

He O 0 0.008089486
developed O 0 0.0059242356
pneumonitis B-Disease 0 0.9978259
, O 0 0.0026266787
pleural B-Disease 0 0.014960626
and I-Disease 0 0.0009425878
pericardial I-Disease 0 0.0304942
effusions I-Disease 0 0.12187469
, O 0 0.0006378654
and O 0 0.00040140218
a O 0 0.00052432687
predominantly O 0 0.00064079097
proximal B-Disease 0 0.005190821
motor I-Disease 0 0.81329226
neuropathy I-Disease 0 0.9999789
. O 0 0.006723992

Immediate O 0 0.0048957784
but O 0 0.0016093896
gradual O 0 0.0011555622
improvement O 0 0.00074325193
followed O 0 0.00045975338
withdrawal O 0 0.0043081376
of O 0 0.0014138711
amiodarone B-Chemical 1 0.9999032
and O 0 0.001017267
treatment O 0 0.0010834427
with O 0 0.0036941406
prednisolone B-Chemical 0 0.99972266
. O 0 0.004630441

Review O 0 0.00488643
of O 0 0.0015887853
this O 0 0.0010121786
and O 0 0.0006993558
previously O 0 0.0004310197
reported O 0 0.00039721598
cases O 0 0.00028486346
indicates O 0 0.00012053465
the O 0 0.00010393693
need O 0 6.733369e-05
for O 0 5.480417e-05
early O 0 0.00015437412
diagnosis O 0 0.00030714925
of O 0 0.00056291994
amiodarone B-Chemical 1 0.9999939
pneumonitis B-Disease 0 0.9999347
, O 0 0.00031703027
immediate O 0 0.00029626707
withdrawal O 0 0.013819927
of O 0 0.0005945071
amiodarone B-Chemical 1 0.9999808
, O 0 0.00019763433
and O 0 0.00010620633
prompt O 0 0.00035531627
but O 0 0.00013470846
continued O 0 0.00020732409
steroid B-Chemical 1 0.9434854
therapy O 0 0.00027936004
to O 0 0.00015999474
ensure O 0 0.00015525067
full O 0 0.000541789
recovery O 0 0.0021578653
. O 0 0.0019344321

Amiodarone B-Chemical 1 0.9988815
- O 0 0.01915954
induced O 0 0.0112405
sinoatrial B-Disease 0 0.3524932
block I-Disease 0 0.013291311
. O 0 0.011351856

We O 0 0.0013758275
observed O 0 0.0011172035
sinoatrial B-Disease 0 0.017843673
block I-Disease 0 0.0006481252
due O 0 0.0002661082
to O 0 0.0003661622
chronic O 0 0.56892514
amiodarone B-Chemical 1 0.99998486
administration O 0 0.0112919165
in O 0 0.00019532406
a O 0 0.00022087386
5 O 0 9.889805e-05
- O 0 0.00019597588
year O 0 6.866616e-05
- O 0 0.00015550239
old O 0 9.707569e-05
boy O 0 0.0002420172
with O 0 0.00018097306
primary B-Disease 0 0.013654787
cardiomyopathy I-Disease 0 0.9999976
, O 0 0.0010046996
Wolff B-Disease 0 0.23335366
- I-Disease 0 0.0011071133
Parkinson I-Disease 0 0.99869883
- I-Disease 0 0.00089845323
White I-Disease 0 0.0075839492
syndrome I-Disease 0 0.032551806
and O 0 0.0009193574
supraventricular B-Disease 0 0.99861383
tachycardia I-Disease 2 0.99959785
. O 0 0.0031729604

Reduction O 0 0.0039056563
in O 0 0.0011665558
the O 0 0.000885609
dosage O 0 0.008435905
of O 0 0.0015104507
amiodarone B-Chemical 1 0.9999225
resulted O 0 0.00040329833
in O 0 0.00016869651
the O 0 0.00012928619
disappearance O 0 0.0004094162
of O 0 0.00014914593
the O 0 0.00013412337
sinoatrial B-Disease 0 0.014242924
block I-Disease 0 0.00013997096
and O 0 0.000110128734
the O 0 0.00011133902
persistence O 0 0.00022402962
of O 0 0.00049177767
asymptomatic O 0 0.03064403
sinus B-Disease 0 0.47542134
bradycardia I-Disease 0 0.9996842
. O 0 0.0035268168

Desipramine B-Chemical 0 0.99983335
- O 0 0.009647282
induced O 0 0.0041770795
delirium B-Disease 0 0.99944156
at O 0 0.00083506235
" O 0 0.0011956294
subtherapeutic O 0 0.7221403
" O 0 0.0009720478
concentrations O 0 0.0014933662
: O 0 0.0009982279
a O 0 0.0012025601
case O 0 0.0015175166
report O 0 0.003741809
. O 0 0.003116291

An O 0 0.0031551416
elderly O 0 0.013530951
patient O 0 0.0009700338
treated O 0 0.0006756512
with O 0 0.0004441265
low O 0 0.0008077499
dose O 0 0.028362231
Desipramine B-Chemical 0 0.99999
developed O 0 0.0015904662
a O 0 0.0013007275
delirium B-Disease 0 0.99991965
while O 0 0.0002777292
her O 0 0.00032553947
plasma O 0 0.0018122473
level O 0 0.00013116981
was O 0 0.00017889775
in O 0 0.00015483658
the O 0 0.00026093994
" O 0 0.0006529618
subtherapeutic O 0 0.61042476
" O 0 0.001503554
range O 0 0.0015851334
. O 0 0.0021015843

Delirium B-Disease 2 0.9954904
, O 0 0.0030256507
which O 0 0.0013770465
may O 0 0.0006197642
be O 0 0.00041206094
induced O 0 0.0004352856
by O 0 0.0005647175
tricyclic O 0 0.99922633
drug O 0 0.028739935
therapy O 0 0.0002845603
in O 0 0.00012466169
the O 0 0.0001721226
elderly O 0 0.023382725
, O 0 0.00017949255
can O 0 8.328792e-05
be O 0 9.379016e-05
caused O 0 0.00015209739
by O 0 0.00029890134
tricyclics O 0 0.9909451
with O 0 0.00051739777
low O 0 0.0021842653
anticholinergic O 0 0.99873525
potency O 0 0.26150173
. O 0 0.0026302899

Therapeutic O 0 0.0050937347
ranges O 0 0.0015446933
for O 0 0.001115335
antidepressants B-Chemical 0 0.99901605
that O 0 0.00040724396
have O 0 0.00022506136
been O 0 0.00013278313
derived O 0 9.4467745e-05
from O 0 0.00010275359
general O 0 0.00013562925
adult O 0 0.00024020298
population O 0 0.00024863917
studies O 0 0.0001343644
may O 0 0.000101219375
not O 0 0.00012444922
be O 0 0.0001425279
appropriate O 0 0.00015733617
for O 0 0.00030901612
the O 0 0.00090137415
elderly O 0 0.074871376
. O 0 0.0023293777

Further O 0 0.002509036
studies O 0 0.0013582581
of O 0 0.0009993764
specifically O 0 0.0005772004
elderly O 0 0.02760187
patients O 0 0.0005773487
are O 0 0.00018459895
now O 0 0.0001291919
required O 0 6.5990695e-05
to O 0 9.2214075e-05
establish O 0 9.000807e-05
safer O 0 0.00016695958
and O 0 0.00012546068
more O 0 0.00016957315
appropriate O 0 0.00013228394
guidelines O 0 0.00026904812
for O 0 0.00034383783
drug O 0 0.009262262
therapy O 0 0.002435568
. O 0 0.0021253112

Indomethacin B-Chemical 0 0.9997646
- O 0 0.012758599
induced O 0 0.0056295786
renal B-Disease 0 0.99424523
insufficiency I-Disease 0 0.9986571
: O 0 0.004421058
recurrence O 0 0.06037872
on O 0 0.0018056802
rechallenge O 0 0.03982542
. O 0 0.0048717246

We O 0 0.0016212997
have O 0 0.001015554
reported O 0 0.0008535657
a O 0 0.0006803134
case O 0 0.000414993
of O 0 0.0007253267
acute O 0 0.84119815
oliguric O 0 0.9999492
renal B-Disease 0 0.9992212
failure I-Disease 0 0.83983
with O 0 0.0024599254
hyperkalemia B-Disease 2 0.99999046
in O 0 0.00016858893
a O 0 0.00015331223
patient O 0 0.00014087449
with O 0 0.0004965275
cirrhosis B-Disease 0 0.9999957
, O 0 0.0012018614
ascites B-Disease 0 0.99922645
, O 0 0.0005630021
and O 0 0.0011323257
cor B-Disease 0 0.9999726
pulmonale I-Disease 0 0.99999845
after O 0 0.0014664897
indomethacin B-Chemical 0 0.9999783
therapy O 0 0.01319042
. O 0 0.0024552445

Prompt O 0 0.0066491235
restoration O 0 0.0023017414
of O 0 0.0015929298
renal O 0 0.42809713
function O 0 0.0007138085
followed O 0 0.00035899284
drug O 0 0.023065334
withdrawal O 0 0.018962802
, O 0 0.00028028685
while O 0 0.00017756083
re O 0 0.00077837147
- O 0 0.0002697419
exposure O 0 0.00014502727
to O 0 8.133723e-05
a O 0 0.00012191611
single O 0 0.00010219904
dose O 0 0.00051725813
of O 0 0.0005595377
indomethacin B-Chemical 0 0.9999863
caused O 0 0.0011183268
recurrence O 0 0.2339549
of O 0 0.0015469202
acute O 0 0.9285747
reversible O 0 0.9612422
oliguria B-Disease 0 0.9998884
. O 0 0.0043916674

Our O 0 0.0025164834
case O 0 0.0014350803
supports O 0 0.0007691471
the O 0 0.00058758724
hypothesis O 0 0.0005258589
that O 0 0.0002564408
endogenous O 0 0.0007089441
renal O 0 0.99474734
prostaglandins B-Chemical 1 0.9999274
play O 0 0.00018479602
a O 0 0.00015700466
role O 0 5.2870182e-05
in O 0 6.3239626e-05
the O 0 6.631976e-05
maintenance O 0 0.00012334505
of O 0 0.0001799863
renal O 0 0.77497184
blood O 0 0.00536428
flow O 0 0.00063621363
when O 0 0.000105095816
circulating O 0 0.0010263635
plasma O 0 0.004067487
volume O 0 0.0012028104
is O 0 0.0008753738
diminished O 0 0.0029769284
. O 0 0.0022320417

Since O 0 0.0029025904
nonsteroidal O 0 0.99947995
anti O 0 0.026271798
- O 0 0.0035679569
inflammatory O 0 0.045466222
agents O 0 0.0017685604
interfere O 0 0.0001822882
with O 0 0.00020778143
this O 0 0.00017622967
compensatory O 0 0.00034878825
mechanism O 0 0.00016614156
and O 0 0.00013339406
may O 0 0.00010461737
cause O 0 0.00036997473
acute B-Disease 0 0.7228247
renal I-Disease 0 0.9974964
failure I-Disease 0 0.72317743
, O 0 0.00024256473
they O 0 8.01385e-05
should O 0 4.7272446e-05
be O 0 7.3024334e-05
used O 0 8.635641e-05
with O 0 0.0001827377
caution O 0 0.00022673143
in O 0 0.00030601164
such O 0 0.00051027344
patients O 0 0.0018216459
. O 0 0.0018328818

Patterns O 0 0.0075107794
of O 0 0.008207834
hepatic B-Disease 0 0.99675494
injury I-Disease 0 0.99035114
induced O 0 0.013542586
by O 0 0.01903369
methyldopa B-Chemical 0 0.99993813
. O 0 0.012824883

Twelve O 0 0.0045752195
patients O 0 0.002335618
with O 0 0.002188664
liver B-Disease 2 0.99564135
disease I-Disease 2 0.9524011
related O 0 0.0003680407
to O 0 0.00078996154
methyldopa B-Chemical 0 0.99998367
were O 0 0.0006322713
seen O 0 0.0003901517
between O 0 0.00033825875
1967 O 0 0.0017009728
and O 0 0.0012279507
1977 O 0 0.00516354
. O 0 0.0024472533

Illness O 0 0.0072041755
occurred O 0 0.0012720766
within O 0 0.0005089891
1 O 0 0.0007536831
- O 0 0.0010751386
- O 0 0.00061018823
9 O 0 0.0001691754
weeks O 0 6.4226995e-05
of O 0 0.00011740801
commencement O 0 9.437257e-05
of O 0 0.00014735924
therapy O 0 0.00017528266
in O 0 9.5725496e-05
9 O 0 7.813205e-05
patients O 0 0.00010531874
, O 0 7.077392e-05
the O 0 5.3863252e-05
remaining O 0 7.719334e-05
3 O 0 4.5845452e-05
patients O 0 6.98113e-05
having O 0 6.144454e-05
received O 0 3.9064656e-05
the O 0 5.8622558e-05
drug O 0 0.00084933423
for O 0 5.3529802e-05
13 O 0 7.126621e-05
months O 0 2.6610203e-05
, O 0 6.173049e-05
15 O 0 4.6249224e-05
months O 0 3.3250133e-05
and O 0 8.476722e-05
7 O 0 9.074423e-05
years O 0 0.00012853758
before O 0 0.00015248076
experiencing O 0 0.0019761983
symptoms O 0 0.019449694
. O 0 0.0023308164

Jaundice B-Disease 0 0.9171486
with O 0 0.003833585
tender O 0 0.0206342
hepatomegaly B-Disease 2 0.9992737
, O 0 0.00096060085
usually O 0 0.00041563954
preceded O 0 0.00029500888
by O 0 0.0002448243
symptoms O 0 0.0025502609
of O 0 0.0005866345
malaise O 0 0.99957556
, O 0 0.0011508989
anorexia B-Disease 0 0.9998487
, O 0 0.0014983817
nausea B-Disease 0 0.9999765
and O 0 0.0011686912
vomiting B-Disease 0 0.99975914
, O 0 0.00019116462
and O 0 8.1983795e-05
associated O 0 6.120139e-05
with O 0 0.00011448709
upper O 0 0.00048480794
abdominal B-Disease 0 0.023891507
pain I-Disease 0 0.5414637
, O 0 0.00023858697
was O 0 0.00017690175
an O 0 0.00024350783
invariable O 0 0.0016555768
finding O 0 0.0005740703
in O 0 0.0004070367
all O 0 0.00072805246
patients O 0 0.0019015588
. O 0 0.0018576301

Biochemical O 0 0.04325484
liver O 0 0.3178978
function O 0 0.0015040152
tests O 0 0.0018291109
indicated O 0 0.0010153683
hepatocellular O 0 0.9999919
necrosis B-Disease 2 0.99997914
and O 0 0.0005181736
correlated O 0 0.000117789736
with O 0 0.00019312513
histopathological O 0 0.005579103
evidence O 0 0.000101140635
of O 0 0.0003867882
hepatic B-Disease 0 0.9998534
injury I-Disease 0 0.99591464
, O 0 0.00025030607
the O 0 9.185398e-05
spectrum O 0 0.0001265839
of O 0 8.497553e-05
which O 0 8.6438544e-05
ranged O 0 7.87396e-05
from O 0 0.00012082751
fatty B-Disease 0 0.99928766
change I-Disease 0 0.00066864653
and O 0 0.0002608777
focal O 0 0.012237862
hepatocellular O 0 0.9999969
necrosis B-Disease 2 0.9999801
to O 0 0.0017136403
massive B-Disease 0 0.24133627
hepatic I-Disease 0 0.9988242
necrosis I-Disease 2 0.99970007
. O 0 0.0044343104

Most O 0 0.0036496094
patients O 0 0.0019609765
showed O 0 0.0010150984
moderate O 0 0.003098246
to O 0 0.00074680574
severe O 0 0.20149545
acute B-Disease 0 0.9998035
hepatitis I-Disease 2 0.9999993
or O 0 0.014162857
chronic B-Disease 0 0.99431735
active I-Disease 0 0.0412177
hepatitis I-Disease 2 0.99999607
with O 0 0.02576059
associated O 0 0.013928997
cholestasis B-Disease 2 0.99998164
. O 0 0.007152995

The O 0 0.0020580972
drug O 0 0.009658944
was O 0 0.001161165
withdrawn O 0 0.0008976343
on O 0 0.0002495864
presentation O 0 0.00039100455
to O 0 0.00024681998
hospital O 0 0.00040129412
in O 0 0.00018970348
11 O 0 0.00019564501
patients O 0 0.00023128801
, O 0 0.00019339417
with O 0 0.00022300988
rapid O 0 0.0006085484
clinical O 0 0.0009563896
improvement O 0 0.00067377294
in O 0 0.00076121994
9 O 0 0.0012042761
. O 0 0.001854877

One O 0 0.0024630432
patient O 0 0.0019057473
died O 0 0.0019546612
, O 0 0.0007531913
having O 0 0.00044696103
presented O 0 0.00029119677
in O 0 0.00036460307
hepatic B-Disease 0 0.9663489
failure I-Disease 0 0.46971714
, O 0 0.0003289303
and O 0 0.00014715956
another O 0 0.00014832123
, O 0 0.00013093637
who O 0 0.00014558608
had O 0 7.4758704e-05
been O 0 6.442206e-05
taking O 0 0.0004312184
methyldopa B-Chemical 0 0.99999404
for O 0 9.44836e-05
7 O 0 5.7778234e-05
years O 0 5.149139e-05
, O 0 6.0020622e-05
showed O 0 5.5649863e-05
slower O 0 0.0001047973
clinical O 0 0.00020701138
and O 0 9.33225e-05
biochemical O 0 0.00033378342
resolution O 0 0.0005767888
over O 0 6.554303e-05
a O 0 0.00016432359
period O 0 0.00010245702
of O 0 0.00031614112
several O 0 0.0004219462
months O 0 0.00054263556
. O 0 0.0014808456

The O 0 0.0013981235
remaining O 0 0.001194465
patient O 0 0.00076754316
in O 0 0.00040466624
the O 0 0.00033955163
series O 0 0.00056639075
developed O 0 0.0022753498
fulminant B-Disease 0 0.99998474
hepatitis I-Disease 2 0.9999993
when O 0 0.00041007655
the O 0 0.0002997632
drug O 0 0.024575006
was O 0 0.00021439798
accidentally O 0 0.00063283846
recommenced O 0 0.0006302387
1 O 0 6.560482e-05
year O 0 3.4119435e-05
after O 0 2.2816113e-05
a O 0 7.467534e-05
prior O 0 5.451073e-05
episode O 0 0.00039500184
of O 0 0.0011469764
methyldopa B-Chemical 0 0.9999943
- O 0 0.0069010467
induced O 0 0.008330655
hepatitis B-Disease 2 0.9999683
. O 0 0.0073878155

In O 0 0.0017309833
this O 0 0.001504856
latter O 0 0.0020625873
patient O 0 0.00097057037
, O 0 0.00060464686
and O 0 0.00036076026
in O 0 0.00025118535
2 O 0 0.00018292475
others O 0 0.00029985496
, O 0 0.00013570595
the O 0 8.430659e-05
causal O 0 0.00011219612
relationship O 0 4.2796622e-05
between O 0 0.000102161044
methyldopa B-Chemical 0 0.99999654
and O 0 0.0008487926
hepatic B-Disease 0 0.9999106
dysfunction I-Disease 0 0.9995467
was O 0 0.00025972794
proved O 0 0.00013863771
with O 0 8.5392574e-05
the O 0 8.57464e-05
recurrence O 0 0.014016611
of O 0 0.0005371374
hepatitis B-Disease 2 0.9999864
within O 0 6.102811e-05
2 O 0 7.0264665e-05
weeks O 0 3.4152996e-05
of O 0 0.00013849555
re O 0 0.0006983987
- O 0 0.00038873963
exposure O 0 0.00037095975
to O 0 0.00039362852
the O 0 0.0008598218
drug O 0 0.02875214
. O 0 0.0022587907

Suxamethonium B-Chemical 1 0.9690767
infusion O 0 0.011263131
rate O 0 0.0054078437
and O 0 0.0054941573
observed O 0 0.00791036
fasciculations B-Disease 0 0.9985649
. O 0 0.012430667

A O 0 0.049542613
dose O 0 0.027861053
- O 0 0.013341132
response O 0 0.009412928
study O 0 0.01288691
. O 0 0.012378699

Suxamethonium B-Chemical 1 0.9993591
chloride I-Chemical 0 0.9999138
( O 0 0.053487275
Sch B-Chemical 0 0.99995875
) O 0 0.0034245946
was O 0 0.0006285947
administered O 0 0.0004861926
i O 0 0.00073135196
. O 0 0.00017864411
v O 0 0.00073081563
. O 0 9.3542745e-05
to O 0 8.824105e-05
36 O 0 0.00010233985
adult O 0 0.00015299779
males O 0 0.00011779558
at O 0 3.9022212e-05
six O 0 3.5532696e-05
rates O 0 7.054395e-05
: O 0 9.769304e-05
0 O 0 6.388529e-05
. O 0 4.824588e-05
25 O 0 0.000116983254
mg O 0 0.0011434709
s O 0 0.00016317038
- O 0 0.00024202852
1 O 0 0.00010377828
to O 0 0.00011871323
20 O 0 0.00024358073
mg O 0 0.0026900375
s O 0 0.0007070464
- O 0 0.0015023568
1 O 0 0.0013050184
. O 0 0.0020191206

The O 0 0.0016872991
infusion O 0 0.0027311253
was O 0 0.0010715276
discontinued O 0 0.001356449
either O 0 0.00031893133
when O 0 0.00016612762
there O 0 0.00013480984
was O 0 0.00019619949
no O 0 0.00010890334
muscular O 0 0.008768317
response O 0 0.00013791688
to O 0 0.0001346087
tetanic B-Disease 0 0.8269645
stimulation O 0 9.414535e-05
of O 0 0.00014413557
the O 0 0.00015850163
ulnar O 0 0.085481286
nerve O 0 0.0040149814
or O 0 0.00016350958
when O 0 0.00022021566
Sch B-Chemical 0 0.9999347
120 O 0 0.00088723155
mg O 0 0.015416581
was O 0 0.001004422
exceeded O 0 0.00128648
. O 0 0.0019499124

Six O 0 0.002465593
additional O 0 0.0011354376
patients O 0 0.0011412052
received O 0 0.0005244174
a O 0 0.00061304925
30 O 0 0.00041141288
- O 0 0.00086154894
mg O 0 0.0058206213
i O 0 0.0011467038
. O 0 0.0004014688
v O 0 0.0017646082
. O 0 0.0006139489
bolus O 0 0.003630606
dose O 0 0.0061188797
. O 0 0.0030555963

Fasciculations B-Disease 0 0.11400924
in O 0 0.0013846897
six O 0 0.000514768
areas O 0 0.00048531077
of O 0 0.00040074936
the O 0 0.0002919
body O 0 0.000657985
were O 0 0.00019110412
scored O 0 0.00018834992
from O 0 0.00010517673
0 O 0 9.906994e-05
to O 0 9.165231e-05
3 O 0 8.79529e-05
and O 0 0.000119557524
summated O 0 0.000179453
as O 0 0.00021153351
a O 0 0.0004436769
total O 0 0.00080458407
fasciculation B-Disease 0 0.91172564
score O 0 0.0021376985
. O 0 0.0023811415

The O 0 0.0013067188
times O 0 0.00067620946
to O 0 0.0006235987
first O 0 0.0005606034
fasciculation B-Disease 0 0.8665077
, O 0 0.0013768132
twitch B-Disease 0 0.927345
suppression O 0 0.001469349
and O 0 0.0006884158
tetanus B-Disease 0 0.83638716
suppression O 0 0.0010709964
were O 0 0.00022942117
inversely O 0 0.0001417736
related O 0 0.000101656486
to O 0 0.00021162751
the O 0 0.00041552703
infusion O 0 0.0015819505
rates O 0 0.0015360842
. O 0 0.0020533097

Fasciculations B-Disease 0 0.1178119
in O 0 0.0013532637
the O 0 0.0007338165
six O 0 0.00032422927
areas O 0 0.0003490888
and O 0 0.0002559686
the O 0 0.00021143671
total O 0 0.00031557496
fasciculation B-Disease 0 0.8062179
score O 0 0.00021658349
were O 0 0.00013960013
related O 0 6.651813e-05
directly O 0 0.00012070694
to O 0 0.00015401904
the O 0 0.00024214691
rate O 0 0.00045771306
of O 0 0.0010189246
infusion O 0 0.0038996653
. O 0 0.0022042757

Total O 0 0.003224197
fasciculation B-Disease 0 0.55472255
scores O 0 0.00089563517
in O 0 0.00046818613
the O 0 0.0003388106
30 O 0 0.00025909673
- O 0 0.0004890365
mg O 0 0.0036355667
bolus O 0 0.0010456733
group O 0 0.00020034709
and O 0 0.000110504276
the O 0 9.8231765e-05
5 O 0 8.095305e-05
- O 0 0.00020229237
mg O 0 0.0018286809
s O 0 0.00015136345
- O 0 0.00020904088
1 O 0 6.807545e-05
and O 0 7.490334e-05
20 O 0 9.372355e-05
- O 0 0.0001964702
mg O 0 0.0014081602
s O 0 0.00015288155
- O 0 0.00022374722
1 O 0 9.649709e-05
infusion O 0 0.00023406885
groups O 0 0.0001425963
were O 0 0.00018402602
not O 0 0.00026991396
significantly O 0 0.0007179559
different O 0 0.00086439075
. O 0 0.0018743799

Treatment O 0 0.015442811
of O 0 0.014535538
psoriasis B-Disease 0 0.9973712
with O 0 0.043602485
azathioprine B-Chemical 0 0.999617
. O 0 0.018615032

Azathioprine B-Chemical 0 0.9987379
treatment O 0 0.0035824094
benefited O 0 0.005243279
19 O 0 0.0015616786
( O 0 0.000881237
66 O 0 0.00068294234
% O 0 0.00042091275
) O 0 0.000380901
out O 0 0.00018033983
of O 0 0.00033115293
29 O 0 0.0005918651
patients O 0 0.00068973965
suffering O 0 0.026787786
from O 0 0.0010438932
severe O 0 0.27142322
psoriasis B-Disease 0 0.99949825
. O 0 0.004460115

Haematological O 0 0.94642377
complications O 0 0.03472718
were O 0 0.001131047
not O 0 0.0006390876
troublesome O 0 0.0025892567
and O 0 0.0003980751
results O 0 0.0003175684
of O 0 0.00044153316
biochemical O 0 0.0019736362
liver O 0 0.4947963
function O 0 0.00086138473
tests O 0 0.001389645
remained O 0 0.0013805262
normal O 0 0.0034167822
. O 0 0.0022752718

Minimal O 0 0.01776108
cholestasis B-Disease 2 0.9998976
was O 0 0.0026082983
seen O 0 0.00073007843
in O 0 0.0004023111
two O 0 0.000241337
cases O 0 0.00036593465
and O 0 0.000399491
portal O 0 0.19334434
fibrosis B-Disease 2 0.99890995
of O 0 0.00082397985
a O 0 0.0007650961
reversible O 0 0.020727435
degree O 0 0.000956972
in O 0 0.00077070884
eight O 0 0.0010378199
. O 0 0.0019537867

Liver O 0 0.50412756
biopsies O 0 0.0025369278
should O 0 0.00046981455
be O 0 0.00034623974
undertaken O 0 0.00021475807
at O 0 0.00012377993
regular O 0 0.00013785611
intervals O 0 8.4270265e-05
if O 0 0.00013449272
azathioprine B-Chemical 0 0.9999026
therapy O 0 0.00039731537
is O 0 0.00011680702
continued O 0 9.1708265e-05
so O 0 6.784061e-05
that O 0 6.842978e-05
structural O 0 0.00052652805
liver B-Disease 2 0.9985775
damage I-Disease 2 0.9844602
may O 0 0.00017392913
be O 0 0.0001025677
detected O 0 7.470575e-05
at O 0 8.122276e-05
an O 0 0.00022595064
early O 0 0.00048175853
and O 0 0.00063227396
reversible O 0 0.055715922
stage O 0 0.0043848674
. O 0 0.0022880004

Angiosarcoma B-Disease 0 0.036384314
of I-Disease 0 0.0046513774
the I-Disease 0 0.003826639
liver I-Disease 0 0.46853256
associated O 0 0.004496352
with O 0 0.0112377135
diethylstilbestrol B-Chemical 0 0.99961495
. O 0 0.010404135

Angiosarcoma B-Disease 0 0.027120054
of I-Disease 0 0.002066464
the I-Disease 0 0.0013121712
liver I-Disease 0 0.26467228
occurred O 0 0.0005057809
in O 0 0.00031786255
a O 0 0.0003901275
76 O 0 0.0005404346
- O 0 0.00039121672
year O 0 0.00011389679
- O 0 0.00023774043
old O 0 0.00015459345
man O 0 0.0015711422
who O 0 0.00021445054
had O 0 9.015066e-05
been O 0 5.7602414e-05
treated O 0 0.000108286076
for O 0 5.920786e-05
a O 0 0.00014023493
well O 0 0.00010553599
- O 0 0.0003253046
differentiated O 0 0.0006514144
adenocarcinoma B-Disease 0 0.96215546
of I-Disease 0 0.00019823486
the I-Disease 0 0.00019376831
liver I-Disease 0 0.65714633
with O 0 0.0013109035
diethylstilbestrol B-Chemical 0 0.99989796
for O 0 0.00055569946
13 O 0 0.0008183756
years O 0 0.00087651314
. O 0 0.0014250387

Angiosarcoma B-Disease 0 0.04945218
was O 0 0.00271283
also O 0 0.0012837503
present O 0 0.00089976564
within O 0 0.00069885544
pulmonary O 0 0.041021813
and O 0 0.0030904145
renal O 0 0.9763238
arteries O 0 0.8053944
. O 0 0.005115008

The O 0 0.0015865368
possibility O 0 0.0009100049
that O 0 0.0006641437
the O 0 0.0009845449
intraarterial B-Disease 0 0.65065
lesions I-Disease 0 0.15269512
might O 0 0.00029425212
represent O 0 0.0002681628
independent O 0 0.0002506679
primary O 0 0.00082325464
tumors B-Disease 0 0.26705977
is O 0 0.0013456668
considered O 0 0.0015178263
. O 0 0.0024195483

Galanthamine B-Chemical 0 0.99942195
hydrobromide I-Chemical 0 0.99983823
, O 0 0.0024004367
a O 0 0.00085702684
longer O 0 0.00029933738
acting O 0 0.0008876569
anticholinesterase O 0 0.99956065
drug O 0 0.123236775
, O 0 0.0002780877
in O 0 0.00011402404
the O 0 9.938995e-05
treatment O 0 9.607519e-05
of O 0 0.00011966817
the O 0 0.0001032694
central O 0 0.00016837685
effects O 0 0.0002766238
of O 0 0.0017039021
scopolamine B-Chemical 1 0.99999547
( O 0 0.022862654
Hyoscine B-Chemical 0 0.99930024
) O 0 0.0046969657
. O 0 0.0024242015

Galanthamine B-Chemical 0 0.9993388
hydrobromide I-Chemical 0 0.9998233
, O 0 0.0028567745
an O 0 0.0019543066
anticholinesterase O 0 0.9993292
drug O 0 0.040922083
capable O 0 0.0002901111
of O 0 0.00047439348
penetrating O 0 0.1680598
the O 0 0.00022988406
blood O 0 0.004801194
- O 0 0.00039258218
brain O 0 0.0013359222
barrier O 0 0.0009266668
, O 0 0.0001342974
was O 0 8.5127605e-05
used O 0 5.1320938e-05
in O 0 5.884957e-05
a O 0 9.252907e-05
patient O 0 7.482374e-05
demonstrating O 0 5.795941e-05
central O 0 0.00010089222
effects O 0 0.00016117468
of O 0 0.0010009276
scopolamine B-Chemical 1 0.9999974
( O 0 0.04782318
hyoscine B-Chemical 0 0.99999106
) O 0 0.03807383
overdosage B-Disease 0 0.9998292
. O 0 0.0037841504

It O 0 0.0025772806
is O 0 0.0011992113
longer O 0 0.0005312544
acting O 0 0.0008755732
than O 0 0.00069667835
physostigmine B-Chemical 0 0.9999647
and O 0 0.0006330068
is O 0 0.0002317443
used O 0 0.00013621469
in O 0 0.0001583915
anaesthesia O 0 0.0013831358
to O 0 0.0001435102
reverse O 0 0.0007363783
the O 0 0.00023477135
non O 0 0.00046402393
- O 0 0.0008712523
depolarizing O 0 0.07100057
neuromuscular O 0 0.23878734
block O 0 0.0023969451
. O 0 0.0022294798

However O 0 0.0028856217
, O 0 0.001944211
studies O 0 0.00087908335
into O 0 0.00032464502
the O 0 0.000442494
dose O 0 0.0010107529
necessary O 0 0.00025910663
to O 0 0.00043411498
combating O 0 0.0031117273
scopolamine B-Chemical 1 0.99999547
intoxication O 0 0.9997876
are O 0 0.002438648
indicated O 0 0.0016912525
. O 0 0.0024061447

Comparison O 0 0.0013391823
of O 0 0.0011043008
the O 0 0.000644714
subjective O 0 0.0007308821
effects O 0 0.00045636375
and O 0 0.00040253164
plasma O 0 0.0026363211
concentrations O 0 0.0005947823
following O 0 0.00017044107
oral O 0 0.00735128
and O 0 0.00022282028
i O 0 0.00042671827
. O 0 0.00011020647
m O 0 0.00040642137
. O 0 0.000111225905
administration O 0 0.00069958507
of O 0 0.0012820935
flunitrazepam B-Chemical 0 0.99998367
in O 0 0.0014266254
volunteers O 0 0.0026036298
. O 0 0.001782477

Flunitrazepam B-Chemical 0 0.99941254
0 O 0 0.0025632721
. O 0 0.00092433096
5 O 0 0.000591361
, O 0 0.00059351884
1 O 0 0.00033064312
. O 0 0.00018557541
0 O 0 0.00017494739
or O 0 0.00014897961
2 O 0 0.00012444577
. O 0 8.0549544e-05
0 O 0 0.00010241806
mg O 0 0.00096217723
was O 0 0.00011022685
given O 0 5.2031795e-05
by O 0 8.244659e-05
the O 0 0.00010012681
oral O 0 0.0024015137
or O 0 0.00010716158
i O 0 0.0003073062
. O 0 7.221425e-05
m O 0 0.0002743304
. O 0 5.217245e-05
routes O 0 9.633786e-05
to O 0 6.664156e-05
groups O 0 8.385726e-05
of O 0 0.00014078425
volunteers O 0 0.00026385192
and O 0 0.00022926873
its O 0 0.00052819995
effects O 0 0.0007925769
compared O 0 0.0010052795
. O 0 0.0019922974

Plasma O 0 0.03371915
concentrations O 0 0.0030569404
of O 0 0.0011961682
the O 0 0.00074206566
drug O 0 0.0051919785
were O 0 0.00036365542
estimated O 0 0.00027070622
by O 0 0.00035223973
gas O 0 0.0794529
- O 0 0.0008375172
liquid O 0 0.005384527
chromatography O 0 0.052758455
, O 0 0.0002278353
in O 0 0.00014391131
a O 0 0.00022452466
smaller O 0 0.00024094361
number O 0 0.0002665752
of O 0 0.00050705957
the O 0 0.0007931677
subjects O 0 0.0018475289
. O 0 0.001967036

The O 0 0.0016275428
most O 0 0.0015873217
striking O 0 0.00092221884
effect O 0 0.00065195933
was O 0 0.00074020785
sedation O 0 0.018685903
which O 0 0.00032272373
increased O 0 0.00030100954
with O 0 0.00019437617
the O 0 0.00014775587
dose O 0 0.0007642654
, O 0 0.0001629005
2 O 0 8.7847286e-05
mg O 0 0.0008248192
producing O 0 0.00012871136
deep O 0 0.0004439635
sleep O 0 0.0016484979
although O 0 0.00010640511
the O 0 0.00014780083
subjects O 0 0.0002596737
could O 0 0.00023328017
still O 0 0.0004923175
be O 0 0.00082796434
aroused O 0 0.003792949
. O 0 0.0020548697

The O 0 0.0016329398
effects O 0 0.0015592796
of O 0 0.001456391
i O 0 0.0018197881
. O 0 0.00047455312
m O 0 0.0011726517
. O 0 0.00021139861
administration O 0 0.00060652377
were O 0 0.00018148556
apparent O 0 0.00017842281
earlier O 0 0.00017257451
and O 0 0.00013820834
sometimes O 0 0.0001953101
lasted O 0 5.9390575e-05
longer O 0 6.723379e-05
than O 0 9.994708e-05
those O 0 0.00025465485
following O 0 0.00032811315
oral O 0 0.021440716
administration O 0 0.009258289
. O 0 0.0024779213

Dizziness B-Disease 0 0.9852158
was O 0 0.0027225744
less O 0 0.0014533354
marked O 0 0.0016104417
than O 0 0.00076776126
sedation O 0 0.0332719
, O 0 0.00083547476
but O 0 0.00062984956
increased O 0 0.00095872104
with O 0 0.0010577389
the O 0 0.001423256
dose O 0 0.008005092
. O 0 0.003255363

There O 0 0.0031662772
was O 0 0.0028485397
pain B-Disease 0 0.09445136
on O 0 0.0005945315
i O 0 0.0012031868
. O 0 0.00033130607
m O 0 0.0008184326
. O 0 0.00015589017
injection O 0 0.0002478888
of O 0 0.00075388816
flunitrazepam B-Chemical 0 0.9999937
significantly O 0 0.0006048024
more O 0 0.00030521417
often O 0 0.00025569904
than O 0 0.00019036523
with O 0 0.0005667382
isotonic O 0 0.02344578
saline O 0 0.0067870934
. O 0 0.0020055464

Plasma O 0 0.03677001
concentrations O 0 0.0031898331
varied O 0 0.0010390617
with O 0 0.0008033453
dose O 0 0.0017926029
and O 0 0.00042903787
route O 0 0.00034769447
and O 0 0.00023167756
corresponded O 0 0.00017756372
qualitatively O 0 0.0003553666
with O 0 0.0004061003
the O 0 0.0005214019
subjective O 0 0.0014211917
effects O 0 0.002181344
. O 0 0.0027344432

The O 0 0.0022166902
drug O 0 0.0107812965
was O 0 0.0011845597
still O 0 0.00054985954
present O 0 0.00031974696
in O 0 0.0002825282
measurable O 0 0.0003395781
quantities O 0 0.00023068588
after O 0 8.337455e-05
24 O 0 0.00012425023
h O 0 0.00014950559
even O 0 0.00023451181
with O 0 0.00035397525
the O 0 0.0004822543
smallest O 0 0.0010246485
dose O 0 0.005819926
. O 0 0.0026167948

Possible O 0 0.035957377
teratogenicity O 0 0.99739754
of O 0 0.07337825
sulphasalazine B-Chemical 1 0.9995129
. O 0 0.026895544

Three O 0 0.0023117585
infants O 0 0.0018150564
, O 0 0.0010636355
born O 0 0.00079880795
of O 0 0.00041398942
two O 0 0.00018884949
mothers O 0 0.00032013372
with O 0 0.00034932717
inflammatory B-Disease 0 0.76554334
bowel I-Disease 0 0.75282717
disease I-Disease 0 0.8986337
who O 0 0.00026215633
received O 0 6.1044644e-05
treatment O 0 8.422631e-05
with O 0 0.000293169
sulphasalazine B-Chemical 1 0.9999664
throughout O 0 7.266672e-05
pregnancy O 0 0.0012334407
, O 0 0.0001523241
were O 0 0.000118996344
found O 0 0.000111792535
to O 0 0.00015350983
have O 0 0.00022928404
major O 0 0.0006748986
congenital B-Disease 0 0.77513474
anomalies I-Disease 0 0.93260443
. O 0 0.0034616399

In O 0 0.0015834174
the O 0 0.0012960093
singleton O 0 0.002306235
pregnancy O 0 0.0032787914
, O 0 0.00050379353
the O 0 0.00032670973
mother O 0 0.0017530399
had O 0 0.0018818509
ulcerative B-Disease 0 0.9999975
colitis I-Disease 0 0.99999833
, O 0 0.0010729475
and O 0 0.00021917668
the O 0 0.00014689109
infant O 0 0.0003635076
, O 0 0.00016530689
a O 0 0.00020197165
male O 0 0.00056859653
, O 0 0.00013331776
had O 0 0.0001368799
coarctation B-Disease 0 0.0789631
of I-Disease 0 0.00016361955
the I-Disease 0 0.0001676879
aorta I-Disease 0 0.0060417033
and O 0 0.00027118696
a O 0 0.00066563004
ventricular B-Disease 0 0.9642935
septal I-Disease 0 0.02187965
defect I-Disease 0 0.0064501003
. O 0 0.0022584307

In O 0 0.0023743843
the O 0 0.0022683376
twin O 0 0.0142563265
pregnancy O 0 0.007522618
, O 0 0.001200851
the O 0 0.0008450255
mother O 0 0.0026911856
had O 0 0.0016551598
Crohn B-Disease 0 0.9376458
' I-Disease 0 0.0024799765
s I-Disease 0 0.0023439243
disease I-Disease 0 0.12190726
. O 0 0.004217518

The O 0 0.0018400081
first O 0 0.0013825195
twin O 0 0.010180891
, O 0 0.0013267876
a O 0 0.0010854779
female O 0 0.0019474308
, O 0 0.00047129882
had O 0 0.00027657658
a O 0 0.00033519542
left O 0 0.00077380106
Potter B-Disease 0 0.0021215705
- I-Disease 0 0.0005401549
type I-Disease 0 0.00043272015
IIa I-Disease 0 0.49724913
polycystic I-Disease 0 0.99914193
kidney I-Disease 0 0.9038698
and O 0 0.00040694381
a O 0 0.00044290844
rudimentary B-Disease 0 0.0009979997
left I-Disease 0 0.0017556669
uterine I-Disease 0 0.012721774
cornu I-Disease 0 0.01250715
. O 0 0.0021704896

The O 0 0.001944916
second O 0 0.0019491388
twin O 0 0.011853595
, O 0 0.0013183658
a O 0 0.0010543516
male O 0 0.0019461021
, O 0 0.00042202882
had O 0 0.00021924438
some O 0 0.00016657983
features O 0 0.00017903496
of O 0 0.00023582576
Potter B-Disease 0 0.00097551174
' I-Disease 0 0.00022640177
s I-Disease 0 0.0001942826
facies I-Disease 0 0.06639542
, O 0 0.00045697278
hypoplastic B-Disease 0 0.982569
lungs I-Disease 0 0.044522725
, O 0 0.00028298484
absent B-Disease 0 0.00020420995
kidneys I-Disease 0 0.0054910034
and I-Disease 0 0.000350479
ureters I-Disease 0 0.00686276
, O 0 0.00066853594
and O 0 0.0014704604
talipes B-Disease 0 0.99927574
equinovarus I-Disease 0 0.9992748
. O 0 0.0046544294

Despite O 0 0.002145904
reports O 0 0.0017711382
to O 0 0.00094937807
the O 0 0.0007748355
contrary O 0 0.000878745
, O 0 0.00079538545
it O 0 0.0005036682
is O 0 0.00036441442
suggested O 0 0.0002895457
that O 0 0.00063673896
sulphasalazine B-Chemical 1 0.9999162
may O 0 0.0013860235
be O 0 0.0020048001
teratogenic O 0 0.9956567
. O 0 0.003972179

Thrombotic B-Disease 0 0.99903893
microangiopathy I-Disease 0 0.9999683
and O 0 0.007969501
renal B-Disease 0 0.96916896
failure I-Disease 0 0.30510044
associated O 0 0.0015150114
with O 0 0.0021469707
antineoplastic O 0 0.34430704
chemotherapy O 0 0.08524904
. O 0 0.0042093038

Five O 0 0.002890507
patients O 0 0.0019921502
with O 0 0.0019470026
carcinoma B-Disease 0 0.9932066
developed O 0 0.029091563
thrombotic B-Disease 2 0.9999926
microangiopathy I-Disease 2 0.9999994
( O 0 0.0027303358
characterized O 0 0.00084218953
by O 0 0.00034683704
renal B-Disease 0 0.99363315
insufficiency I-Disease 0 0.99972266
, O 0 0.0037687027
microangiopathic B-Disease 0 0.99998
hemolytic I-Disease 2 0.99999976
anemia I-Disease 2 0.99999976
, O 0 0.0018085936
and O 0 0.00024082442
usually O 0 0.0005192019
thrombocytopenia B-Disease 0 0.99989414
) O 0 0.00023142368
after O 0 2.808265e-05
treatment O 0 8.6446955e-05
with O 0 0.00027784283
cisplatin B-Chemical 0 0.9988576
, O 0 0.0008275458
bleomycin B-Chemical 0 0.9912248
, O 0 0.0005826867
and O 0 0.0004895635
a O 0 0.0014432747
vinca B-Chemical 0 0.9960886
alkaloid I-Chemical 0 0.9991653
. O 0 0.004072872

One O 0 0.0023208803
patient O 0 0.0021476797
had O 0 0.003155671
thrombotic B-Disease 0 0.99991906
thrombocytopenic I-Disease 0 0.99998844
purpura I-Disease 0 0.99998045
, O 0 0.0009306033
three O 0 0.0001450415
the O 0 0.0004378358
hemolytic B-Disease 0 0.9999541
- I-Disease 0 0.04095855
uremic I-Disease 0 0.9999894
syndrome I-Disease 0 0.81132776
, O 0 0.00024642874
and O 0 0.000113542956
one O 0 6.939606e-05
an O 0 0.00013998084
apparent O 0 0.0002687761
forme O 0 0.091137335
fruste O 0 0.91992664
of O 0 0.00039729773
one O 0 0.00024928624
of O 0 0.00060910865
these O 0 0.0015856007
disorders O 0 0.39218038
. O 0 0.0024144193

Histologic O 0 0.007892664
examination O 0 0.0012953319
of O 0 0.00093558274
the O 0 0.0007400512
renal O 0 0.53571516
tissue O 0 0.0016473391
showed O 0 0.0002539866
evidence O 0 0.0001650497
of O 0 0.00039482774
intravascular B-Disease 0 0.9532433
coagulation I-Disease 0 0.98989457
, O 0 0.00027799068
primarily O 0 0.00016228964
affecting O 0 0.00019780284
the O 0 0.00014583963
small O 0 0.00031484774
arteries O 0 0.08556161
, O 0 0.0005835087
arterioles O 0 0.053733345
, O 0 0.0007853411
and O 0 0.0010698375
glomeruli O 0 0.022310255
. O 0 0.0024085038

Because O 0 0.0012587719
each O 0 0.00079202425
patient O 0 0.0011197937
was O 0 0.0010270068
tumor B-Disease 0 0.17217481
- O 0 0.0009670587
free O 0 0.00038990873
or O 0 0.00018939932
had O 0 0.00015727169
only O 0 0.00014064042
a O 0 0.00016327371
small O 0 0.00017987684
tumor B-Disease 0 0.039594773
at O 0 6.0488346e-05
the O 0 7.1735856e-05
onset O 0 0.00010752024
of O 0 0.00011640716
this O 0 0.00020687426
syndrome O 0 0.0664348
, O 0 0.0002231915
the O 0 0.0005380002
thrombotic B-Disease 2 0.99999213
microangiopathy I-Disease 2 0.9999993
may O 0 0.0004380209
have O 0 0.00019534568
been O 0 0.00021467886
induced O 0 0.00048675443
by O 0 0.00094373256
chemotherapy O 0 0.012260023
. O 0 0.0021841126

Diagnosis O 0 0.0072679264
of O 0 0.0016971972
this O 0 0.0011729359
potentially O 0 0.0016316002
fatal O 0 0.72262704
complication O 0 0.047037367
may O 0 0.00028863974
be O 0 0.00018140528
delayed O 0 0.000498958
or O 0 0.00012254973
missed O 0 0.00019747515
if O 0 9.279274e-05
renal O 0 0.6495626
tissue O 0 0.0006324559
or O 0 6.562277e-05
the O 0 7.279808e-05
peripheral O 0 0.0008340779
blood O 0 0.0019656362
smear O 0 0.0005031494
is O 0 6.99822e-05
not O 0 5.2626125e-05
examined O 0 4.6440946e-05
, O 0 8.407128e-05
because O 0 6.745573e-05
renal B-Disease 0 0.88162935
failure I-Disease 0 0.12915652
may O 0 7.564376e-05
be O 0 5.0034574e-05
ascribed O 0 5.9586288e-05
to O 0 9.792081e-05
cisplatin B-Chemical 0 0.9996915
nephrotoxicity B-Disease 0 0.99999833
and O 0 0.00051640836
the O 0 0.00046943672
anemia B-Disease 0 0.9999678
and O 0 0.0012492322
thrombocytopenia B-Disease 0 0.999915
to O 0 0.00037289978
drug O 0 0.057337563
- O 0 0.00069447217
induced O 0 0.0007057041
bone B-Disease 0 0.74917406
marrow I-Disease 0 0.9981741
suppression I-Disease 0 0.88078946
. O 0 0.003944702

International O 0 0.00645327
mexiletine B-Chemical 0 0.9995326
and O 0 0.0030003577
placebo O 0 0.010676519
antiarrhythmic O 0 0.7301264
coronary O 0 0.26125002
trial O 0 0.0031468482
: O 0 0.003273485
I O 0 0.010795972
. O 0 0.0043581547

Report O 0 0.010344942
on O 0 0.0050018807
arrhythmia B-Disease 0 0.98180765
and O 0 0.006281193
other O 0 0.0054815933
findings O 0 0.011462938
. O 0 0.0090502165

Impact O 0 0.022984907
Research O 0 0.04325707
Group O 0 0.042991325
. O 0 0.027820254

The O 0 0.0017830736
antiarrhythmic O 0 0.18632954
effects O 0 0.00101795
of O 0 0.0007072547
the O 0 0.00040242003
sustained O 0 0.00069821405
release O 0 0.0008891214
form O 0 0.00020664914
of O 0 0.00068366656
mexiletine B-Chemical 0 0.9999912
( O 0 0.0012928869
Mexitil B-Chemical 0 0.6034263
- I-Chemical 0 0.00074745144
Perlongets I-Chemical 0 0.028666897
) O 0 0.00019979541
were O 0 6.98807e-05
evaluated O 0 4.990886e-05
in O 0 5.8446843e-05
a O 0 0.00011255992
double O 0 0.00021022598
- O 0 0.00026139585
blind O 0 0.003321484
placebo O 0 0.0006031578
trial O 0 0.000113777605
in O 0 9.6742726e-05
630 O 0 0.0032288653
patients O 0 0.00022103099
with O 0 0.00021970019
recent O 0 0.00037842136
documented O 0 0.0020304343
myocardial B-Disease 0 0.99968505
infarction I-Disease 2 0.9999646
. O 0 0.004779426

The O 0 0.0014822065
primary O 0 0.0011131751
response O 0 0.0008161663
variable O 0 0.00044420606
was O 0 0.00035900017
based O 0 0.00017769208
on O 0 0.00010825892
central O 0 0.00019813585
reading O 0 0.0006191101
of O 0 0.00011907694
24 O 0 4.8507925e-05
hour O 0 4.1242787e-05
ambulatory O 0 0.00010716076
electrocardiographic O 0 0.0044023674
recordings O 0 8.3676576e-05
and O 0 6.397417e-05
was O 0 5.943839e-05
defined O 0 3.6034315e-05
as O 0 4.1940282e-05
the O 0 4.744275e-05
occurrence O 0 8.203009e-05
of O 0 7.129673e-05
30 O 0 3.8674712e-05
or O 0 3.757215e-05
more O 0 6.725175e-05
single O 0 6.3592684e-05
premature O 0 0.0006593271
ventricular O 0 0.3647971
complexes O 0 0.00010443139
in O 0 3.9625287e-05
any O 0 2.7630282e-05
two O 0 2.0598949e-05
consecutive O 0 2.495709e-05
30 O 0 2.1621698e-05
minute O 0 2.4327439e-05
blocks O 0 3.0767325e-05
or O 0 3.487557e-05
one O 0 3.134396e-05
or O 0 3.8984945e-05
more O 0 7.30809e-05
runs O 0 8.418785e-05
of O 0 7.103416e-05
two O 0 3.678129e-05
or O 0 4.5771147e-05
more O 0 0.00010324674
premature O 0 0.0010243605
ventricular O 0 0.41515645
complexes O 0 0.00014570008
in O 0 6.815587e-05
the O 0 7.171369e-05
entire O 0 7.488221e-05
24 O 0 0.000110471294
hour O 0 0.00021679731
electrocardiographic O 0 0.009778593
recording O 0 0.0011401774
. O 0 0.0016259282

Large O 0 0.0044181747
differences O 0 0.0009922192
, O 0 0.0011404466
regarded O 0 0.0007834854
as O 0 0.00047311862
statistically O 0 0.0003506767
significant O 0 0.00022440394
, O 0 0.00018157819
between O 0 7.9699756e-05
the O 0 0.00023069778
mexiletine B-Chemical 0 0.99997973
and O 0 0.00031417247
placebo O 0 0.0013856462
groups O 0 8.010969e-05
were O 0 5.4349504e-05
noted O 0 3.3153312e-05
in O 0 3.7913178e-05
that O 0 2.9798339e-05
end O 0 2.6160566e-05
point O 0 3.8323946e-05
at O 0 3.602219e-05
months O 0 2.5649008e-05
1 O 0 4.6527213e-05
and O 0 6.702216e-05
4 O 0 6.0836363e-05
, O 0 9.509817e-05
but O 0 9.767302e-05
only O 0 0.00011390755
trends O 0 0.00012674271
were O 0 0.00014284778
observed O 0 0.00015010955
at O 0 0.00020466745
month O 0 0.00030641715
12 O 0 0.0006208154
. O 0 0.0014524242

These O 0 0.0018890925
differences O 0 0.00072816305
were O 0 0.0006548695
observed O 0 0.00037628133
even O 0 0.0003324635
though O 0 0.0002266268
the O 0 0.00025900488
serum O 0 0.21615867
mexiletine B-Chemical 0 0.9999896
levels O 0 0.0002893735
obtained O 0 0.0001389694
in O 0 7.9180994e-05
this O 0 9.8762626e-05
study O 0 0.000101402635
were O 0 6.4572254e-05
generally O 0 7.255544e-05
lower O 0 9.287365e-05
than O 0 4.377681e-05
those O 0 8.089539e-05
observed O 0 5.0828232e-05
in O 0 5.5346714e-05
studies O 0 6.257215e-05
that O 0 4.725136e-05
have O 0 5.458553e-05
used O 0 6.733389e-05
the O 0 0.000104966915
regular O 0 0.00016035579
form O 0 0.00019916757
of O 0 0.00046262535
the O 0 0.0008143834
drug O 0 0.025455091
. O 0 0.002151411

There O 0 0.002316865
were O 0 0.0013852227
more O 0 0.0013045426
deaths B-Disease 0 0.005919728
in O 0 0.00043952666
the O 0 0.0006767509
mexiletine B-Chemical 0 0.9999769
group O 0 0.001130848
( O 0 0.00037575045
7 O 0 0.000109010565
. O 0 7.388759e-05
6 O 0 6.253904e-05
% O 0 0.000105990024
) O 0 0.00012335292
than O 0 4.833131e-05
in O 0 6.193125e-05
the O 0 9.334003e-05
placebo O 0 0.00076934975
group O 0 0.0001755821
( O 0 0.00015777905
4 O 0 7.10545e-05
. O 0 5.843843e-05
8 O 0 7.6761135e-05
% O 0 0.00013547142
) O 0 0.00021779805
; O 0 0.00016514635
the O 0 0.00014465574
difference O 0 0.00012787899
was O 0 0.0002942381
not O 0 0.00038971924
statistically O 0 0.0008207232
significant O 0 0.0014563266
. O 0 0.0021265594

The O 0 0.0023560354
incidence O 0 0.0030794425
of O 0 0.0021235421
coronary O 0 0.075015046
events O 0 0.0033482173
was O 0 0.0010132696
similar O 0 0.00058969104
in O 0 0.0008981725
both O 0 0.0014884879
groups O 0 0.0022308114
. O 0 0.003095127

Previously O 0 0.00251588
recognized O 0 0.0019278958
side O 0 0.005934736
effects O 0 0.0010989113
, O 0 0.0008425186
particularly O 0 0.001112629
tremor B-Disease 0 0.9998117
and O 0 0.0010178293
gastrointestinal B-Disease 0 0.9958943
problems I-Disease 0 0.03118391
, O 0 0.00022533961
were O 0 0.0001009205
more O 0 0.00011154389
frequent O 0 0.00011465129
in O 0 7.737206e-05
the O 0 0.00018664156
mexiletine B-Chemical 0 0.9999672
group O 0 0.0003071217
than O 0 0.000114668896
in O 0 0.00018767032
the O 0 0.0003928379
placebo O 0 0.0031278864
group O 0 0.0014852498
. O 0 0.0018250168

Changes O 0 0.0025496618
in O 0 0.001604792
heart O 0 0.006954655
size O 0 0.0010528865
during O 0 0.000314632
long O 0 0.00044564877
- O 0 0.00072160637
term O 0 0.0006895737
timolol B-Chemical 0 0.99994457
treatment O 0 0.0010214604
after O 0 0.0007106301
myocardial B-Disease 0 0.9995179
infarction I-Disease 2 0.9999516
. O 0 0.006243235

The O 0 0.0015223301
effect O 0 0.0011325899
of O 0 0.0010978701
long O 0 0.0007239511
- O 0 0.00091774354
term O 0 0.0005848263
timolol B-Chemical 0 0.99997175
treatment O 0 0.0002970038
on O 0 9.372329e-05
heart O 0 0.0042061843
size O 0 0.00020843206
after O 0 6.915625e-05
myocardial B-Disease 0 0.99961805
infarction I-Disease 2 0.9999924
was O 0 0.00035536135
evaluated O 0 0.00011490225
by O 0 0.00021653289
X O 0 0.5779935
- O 0 0.00060911506
ray O 0 0.0657501
in O 0 0.00010329381
a O 0 0.00015525435
double O 0 0.00025098762
- O 0 0.00026665963
blind O 0 0.0015999357
study O 0 9.93763e-05
including O 0 6.0248e-05
241 O 0 0.0005517837
patients O 0 0.0001765107
( O 0 0.00020489082
placebo O 0 0.00083060877
126 O 0 0.0010031778
, O 0 0.00090005033
timolol B-Chemical 0 0.99993527
115 O 0 0.007306218
) O 0 0.0023998078
. O 0 0.0019839157

The O 0 0.0030848416
follow O 0 0.0023382395
- O 0 0.0031458775
up O 0 0.001790512
period O 0 0.001165219
was O 0 0.0019616757
12 O 0 0.0015760778
months O 0 0.0018675855
. O 0 0.0042400546

The O 0 0.0036797393
timolol B-Chemical 0 0.9998909
- O 0 0.0042531146
treated O 0 0.0012060024
patients O 0 0.0007184993
showed O 0 0.00030338237
a O 0 0.0003163823
small O 0 0.00027421117
but O 0 0.0001744119
significant O 0 0.00011350746
increase O 0 0.00010416623
in O 0 0.000101625665
heart O 0 0.0056569143
size O 0 0.00015513775
from O 0 5.7164358e-05
baseline O 0 5.806679e-05
in O 0 6.495875e-05
contrast O 0 0.00014503916
to O 0 0.00010925168
a O 0 0.00020972925
decrease O 0 0.00026495205
in O 0 0.00023345015
the O 0 0.00044941073
placebo O 0 0.0036291818
group O 0 0.001538632
. O 0 0.001842283

These O 0 0.0023226375
differences O 0 0.00091379485
may O 0 0.00079808745
be O 0 0.0006092712
caused O 0 0.0006881377
by O 0 0.0013199338
timolol B-Chemical 0 0.99998677
- O 0 0.0023832596
induced O 0 0.0007636895
bradycardia B-Disease 0 0.99702495
and O 0 0.00035219442
a O 0 0.00029289522
compensatory O 0 0.00045429773
increase O 0 0.0002310185
in O 0 0.00022908783
end O 0 0.00024632443
- O 0 0.0011230075
diastolic O 0 0.30916077
volume O 0 0.0035698356
. O 0 0.0022836654

The O 0 0.0041148057
timolol B-Chemical 0 0.99986875
- O 0 0.0030226102
related O 0 0.00035274753
increase O 0 0.00040303354
in O 0 0.0003298683
heart O 0 0.011713415
size O 0 0.00047621343
was O 0 0.00019453192
observed O 0 0.000107559004
only O 0 0.00013920241
in O 0 0.00012575965
patients O 0 0.00020837742
with O 0 0.00021654941
normal O 0 0.00054028415
and O 0 0.00045031004
borderline O 0 0.018804153
heart O 0 0.09541729
size O 0 0.0026999572
. O 0 0.0019958357

In O 0 0.0020781765
patients O 0 0.002406613
with O 0 0.002688751
cardiomegaly B-Disease 0 0.9991474
, O 0 0.00096406805
the O 0 0.00038286668
increase O 0 0.00031491826
in O 0 0.0002975616
heart O 0 0.012993994
size O 0 0.0005604706
was O 0 0.0003161028
similar O 0 0.00021699068
in O 0 0.0003996102
both O 0 0.0007866504
groups O 0 0.0013246778
. O 0 0.0019935623

After O 0 0.0016516596
re O 0 0.0076604974
- O 0 0.009412358
infarction B-Disease 2 0.9998324
, O 0 0.0016617086
heart O 0 0.03964975
size O 0 0.00063171645
increased O 0 0.0003552562
in O 0 0.00015156434
the O 0 0.00015769905
placebo O 0 0.0008470152
group O 0 0.0001692154
and O 0 0.00013380834
remained O 0 0.00020979086
unchanged O 0 0.00022739172
in O 0 0.00027309865
the O 0 0.00087024015
timolol B-Chemical 0 0.9999434
group O 0 0.0036806676
. O 0 0.0022289876

Vitamin B-Chemical 0 0.9999039
D3 I-Chemical 0 0.99975747
toxicity B-Disease 2 0.99808
in O 0 0.008951929
dairy O 0 0.08579474
cows O 0 0.016112873
. O 0 0.008045816

Large O 0 0.005274449
parenteral O 0 0.019628659
doses O 0 0.011053745
of O 0 0.0073403902
vitamin B-Chemical 0 0.99999213
D3 I-Chemical 0 0.9999844
( O 0 0.0012267726
15 O 0 0.00017822966
to O 0 0.00013772633
17 O 0 0.00017912171
. O 0 7.1738046e-05
5 O 0 6.8159636e-05
x O 0 0.0001821827
10 O 0 9.110631e-05
( O 0 0.00012613073
6 O 0 6.197415e-05
) O 0 0.00022861891
IU O 0 0.20098574
vitamin B-Chemical 0 0.9999964
D3 I-Chemical 0 0.99999404
) O 0 0.00062699354
were O 0 8.637896e-05
associated O 0 5.8914375e-05
with O 0 0.00012522677
prolonged O 0 0.0012716794
hypercalcemia B-Disease 0 0.9999956
, O 0 0.0047731744
hyperphosphatemia B-Disease 0 0.9999987
, O 0 0.00032690604
and O 0 9.311973e-05
large O 0 8.959018e-05
increases O 0 8.885085e-05
of O 0 0.0007705979
vitamin B-Chemical 0 0.9999982
D3 I-Chemical 0 0.99999416
and O 0 0.0002790776
its O 0 0.00033553704
metabolites O 0 0.17820656
in O 0 6.575011e-05
the O 0 7.48468e-05
blood O 0 0.00076794706
plasma O 0 0.0009903752
of O 0 0.00022468163
nonlactating O 0 0.0021939832
nonpregnant O 0 0.0010751591
and O 0 0.00030191665
pregnant O 0 0.0018924491
Jersey O 0 0.0026412557
cows O 0 0.002263775
. O 0 0.0016921187

Calcium B-Chemical 0 0.99766326
concentrations O 0 0.004752632
1 O 0 0.0008024992
day O 0 0.00035867456
postpartum O 0 0.00040664518
were O 0 0.00020450632
higher O 0 0.00018207383
in O 0 0.0001440372
cows O 0 0.00035695906
treated O 0 0.0002619672
with O 0 0.0009249097
vitamin B-Chemical 0 0.99999654
D3 I-Chemical 0 0.99998856
about O 0 0.00022652266
32 O 0 0.00012839609
days O 0 3.2848453e-05
prepartum O 0 0.00030679218
( O 0 0.000112351554
8 O 0 5.049921e-05
. O 0 3.7475602e-05
8 O 0 4.9605187e-05
mg O 0 0.00074596854
/ O 0 0.00028739474
100 O 0 0.00027552096
ml O 0 0.00038900302
) O 0 0.00013640655
than O 0 4.540791e-05
in O 0 6.131506e-05
control O 0 9.666333e-05
cows O 0 0.0003327381
( O 0 0.00015677592
5 O 0 7.888909e-05
. O 0 7.700322e-05
5 O 0 0.00012370759
mg O 0 0.0016169501
/ O 0 0.0010125495
100 O 0 0.0013765444
ml O 0 0.0027287207
) O 0 0.0025277378
. O 0 0.002357485

None O 0 0.0025970738
of O 0 0.001325083
the O 0 0.0008114861
cows O 0 0.0013367056
treated O 0 0.000786228
with O 0 0.002158911
vitamin B-Chemical 0 0.999995
D3 I-Chemical 0 0.9999901
showed O 0 0.0006179918
signs O 0 0.006161533
of O 0 0.0005400803
milk B-Disease 2 0.9555204
fever I-Disease 2 0.99981934
during O 0 7.0272225e-05
the O 0 9.913477e-05
peripartal O 0 0.0009268496
period O 0 4.6189238e-05
; O 0 9.972032e-05
however O 0 0.000105533174
, O 0 9.355969e-05
22 O 0 8.397497e-05
% O 0 5.6730456e-05
of O 0 6.0199123e-05
the O 0 5.4650325e-05
control O 0 7.19551e-05
cows O 0 0.00020514612
developed O 0 0.00014517062
clinical O 0 0.0003823282
signs O 0 0.0016527734
of O 0 0.00055716856
milk B-Disease 2 0.8833102
fever I-Disease 2 0.9995726
during O 0 0.00036450246
this O 0 0.0008155342
period O 0 0.00069009606
. O 0 0.0016036945

Signs O 0 0.15626378
of O 0 0.011214784
vitamin B-Chemical 0 0.99997795
D3 I-Chemical 0 0.99997973
toxicity B-Disease 2 0.9995809
were O 0 0.0005431191
not O 0 0.00017006509
observed O 0 0.000116558
in O 0 0.00013034864
nonlactating O 0 0.002069298
nonpregnant O 0 0.0013300768
cows O 0 0.00029155012
; O 0 0.00010917452
however O 0 0.00010679383
, O 0 0.00011275511
pregnant O 0 0.0005629639
cows O 0 0.00020696386
commonly O 0 8.3209496e-05
developed O 0 0.00015776687
severe O 0 0.0026008808
signs O 0 0.009727351
of O 0 0.002771515
vitamin B-Chemical 0 0.99999845
D3 I-Chemical 0 0.99999654
toxicity B-Disease 2 0.9996947
and O 0 0.00040372915
10 O 0 0.00020656954
of O 0 0.00036415932
17 O 0 0.00066011044
cows O 0 0.0015064707
died O 0 0.0024810866
. O 0 0.0019154486

There O 0 0.0040172585
was O 0 0.0031224699
widespread O 0 0.0031484687
metastatic O 0 0.3685679
calcification O 0 0.99031305
in O 0 0.0012412121
the O 0 0.0011195559
cows O 0 0.0022534507
that O 0 0.0013990678
died O 0 0.0056275083
. O 0 0.0037522041

Because O 0 0.0012444307
of O 0 0.0013023788
the O 0 0.0008687339
extreme O 0 0.0017628906
toxicity B-Disease 2 0.99620086
of O 0 0.014755458
vitamin B-Chemical 0 0.9999968
D3 I-Chemical 0 0.99998987
in O 0 0.0005151189
pregnant O 0 0.0035819563
Jersey O 0 0.0010502832
cows O 0 0.00020032302
and O 0 6.0233924e-05
the O 0 5.432028e-05
low O 0 0.00012954148
margin O 0 0.00032943304
of O 0 7.544371e-05
safety O 0 7.6466284e-05
between O 0 3.3402433e-05
doses O 0 0.0005456413
of O 0 0.0009180362
vitamin B-Chemical 0 0.99999845
D3 I-Chemical 0 0.99999356
that O 0 0.00012143982
prevent O 0 0.0002369222
milk B-Disease 2 0.9736279
fever I-Disease 2 0.999943
and O 0 0.00025378593
doses O 0 0.00070411194
that O 0 5.6094537e-05
induce O 0 9.49149e-05
milk B-Disease 2 0.9724975
fever I-Disease 2 0.99995124
, O 0 0.00020762993
we O 0 3.6726364e-05
concluded O 0 6.178079e-05
that O 0 0.00018992792
vitamin B-Chemical 0 0.99999774
D3 I-Chemical 0 0.9999939
cannot O 0 0.001273648
be O 0 7.110844e-05
used O 0 4.8599875e-05
practically O 0 0.00011896707
to O 0 7.613928e-05
prevent O 0 0.00019013885
milk B-Disease 2 0.86169434
fever I-Disease 2 0.9996517
when O 0 0.00017480615
injected O 0 0.00021925925
several O 0 0.00023308117
weeks O 0 0.00026475402
prepartum O 0 0.0023142046
. O 0 0.0016681999

Diseases B-Disease 0 0.006399499
of I-Disease 0 0.0033186215
peripheral I-Disease 0 0.008026688
nerves I-Disease 0 0.008300433
as O 0 0.0013368349
seen O 0 0.0011416335
in O 0 0.0011891202
the O 0 0.0018259396
Nigerian O 0 0.0089163715
African O 0 0.010255355
. O 0 0.0044216793

The O 0 0.0013541726
anatomical O 0 0.001270113
and O 0 0.0009243213
aetiological O 0 0.0021326898
diagnoses O 0 0.0011776888
of O 0 0.00062828977
peripheral B-Disease 0 0.06373238
nerve I-Disease 0 0.107622296
disease I-Disease 0 0.810069
excluding O 0 0.00039994178
its O 0 0.00027850346
primary O 0 0.00022245981
benign O 0 0.012440082
and O 0 0.00026557443
malignant O 0 0.49668878
disorders O 0 0.4039394
, O 0 0.00022272936
as O 0 0.00013193324
seen O 0 0.00016295891
in O 0 0.00025204563
358 O 0 0.003537089
Nigerians O 0 0.0039344467
are O 0 0.0006048434
presented O 0 0.0010903
. O 0 0.0018108669

There O 0 0.0033353926
is O 0 0.0021010144
a O 0 0.0019410904
male O 0 0.0031394302
preponderance O 0 0.0019162965
and O 0 0.00053774106
the O 0 0.0004129878
peak O 0 0.0006225378
incidence O 0 0.00097085244
is O 0 0.0004862123
in O 0 0.00046912496
the O 0 0.00074662355
fourth O 0 0.002083536
decade O 0 0.0024257975
. O 0 0.0024527656

Sensori B-Disease 0 0.011791548
- I-Disease 0 0.007911561
motor I-Disease 0 0.52877903
neuropathy I-Disease 0 0.99992585
was O 0 0.002074267
the O 0 0.00091246463
commonest O 0 0.003214543
presentation O 0 0.0016527071
( O 0 0.0016066845
50 O 0 0.0019170828
% O 0 0.0020505183
) O 0 0.0034430365
. O 0 0.0033522167

Guillain B-Disease 0 0.8848458
- I-Disease 0 0.007962907
Barr I-Disease 0 0.1569921
syndrome I-Disease 0 0.12979166
was O 0 0.0007701772
the O 0 0.00043544124
commonest O 0 0.0019878254
identifiable O 0 0.0016098974
cause O 0 0.0006259242
( O 0 0.00032712647
15 O 0 0.00011341787
. O 0 7.894366e-05
6 O 0 7.1064795e-05
% O 0 0.00013218509
) O 0 0.00018454932
, O 0 0.00012122763
accounting O 0 0.00015555207
for O 0 8.3090476e-05
half O 0 9.199204e-05
of O 0 0.00018067785
the O 0 0.00022208643
cases O 0 0.0004700946
with O 0 0.0010991164
motor B-Disease 0 0.7981167
neuropathy I-Disease 0 0.9999709
. O 0 0.005559188

Peripheral B-Disease 0 0.98002714
neuropathy I-Disease 0 0.99983144
due O 0 0.0011645905
to O 0 0.00097049784
nutritional B-Disease 0 0.4125005
deficiency I-Disease 0 0.9950976
of O 0 0.008953064
thiamine B-Chemical 0 0.99998987
and O 0 0.006455288
riboflavin B-Chemical 0 0.9999883
was O 0 0.0004622049
common O 0 0.00021223434
( O 0 0.00019168227
10 O 0 8.9736306e-05
. O 0 5.918703e-05
1 O 0 7.226144e-05
% O 0 9.836253e-05
) O 0 0.00012548832
and O 0 7.881263e-05
presented O 0 8.535724e-05
mainly O 0 0.00013686802
as O 0 0.00013232356
sensory O 0 0.00043739818
and O 0 0.00037102922
sensori B-Disease 0 0.010493699
- I-Disease 0 0.0025858025
motor I-Disease 0 0.74880624
neuropathy I-Disease 0 0.99996734
. O 0 0.0053528897

Diabetes B-Disease 0 0.9956524
mellitus I-Disease 0 0.9982961
was O 0 0.00341807
the O 0 0.0015131644
major O 0 0.0014721865
cause O 0 0.002537879
of O 0 0.0045817345
autonomic B-Disease 0 0.992562
neuropathy I-Disease 0 0.99994075
. O 0 0.009931812

Isoniazid B-Chemical 0 0.9987877
was O 0 0.0028823074
the O 0 0.0012967241
most O 0 0.0014078176
frequent O 0 0.0013493809
agent O 0 0.003244398
in O 0 0.0011845417
drug O 0 0.08859945
- O 0 0.004101941
induced O 0 0.0073568425
neuropathy B-Disease 0 0.99981827
. O 0 0.0067592906

Migraine B-Disease 0 0.99759907
( O 0 0.0039354167
20 O 0 0.0015093043
% O 0 0.0011509313
) O 0 0.00092650444
was O 0 0.0003977115
not O 0 0.00022808264
an O 0 0.0003089607
uncommon O 0 0.00061810133
cause O 0 0.00035617873
of O 0 0.0006109201
cranial B-Disease 0 0.9882004
neuropathy I-Disease 0 0.9999974
although O 0 0.0008158032
malignancies B-Disease 2 0.9838802
arising O 0 0.00010425546
from O 0 6.17438e-05
the O 0 7.642779e-05
reticuloendothelial O 0 0.08259738
system O 0 9.636027e-05
or O 0 4.791493e-05
related O 0 2.5669586e-05
structures O 0 5.686495e-05
of O 0 8.344868e-05
the O 0 9.865533e-05
head O 0 0.0008482723
and O 0 0.00020449208
neck O 0 0.0038987803
were O 0 0.00017850006
more O 0 0.00027650435
frequent O 0 0.00048396067
( O 0 0.0005652865
26 O 0 0.0007574052
% O 0 0.0009659426
) O 0 0.0019548242
. O 0 0.002118562

In O 0 0.0025869443
26 O 0 0.0024465825
. O 0 0.00088414876
5 O 0 0.0005685364
% O 0 0.0005433174
of O 0 0.0004499266
all O 0 0.00033198082
the O 0 0.00031187903
cases O 0 0.00038733528
, O 0 0.00030635725
the O 0 0.0002840228
aetiology O 0 0.0022107668
of O 0 0.00079123134
the O 0 0.0016005299
neuropathy B-Disease 0 0.9998958
was O 0 0.003612855
undetermined O 0 0.011758534
. O 0 0.0026199154

Heredofamilial O 0 0.2275729
and O 0 0.008246847
connective B-Disease 0 0.07050295
tissue I-Disease 0 0.018983878
disorders I-Disease 0 0.8556552
were O 0 0.006235985
rare O 0 0.014926529
. O 0 0.007233092

Some O 0 0.002703839
of O 0 0.0015857824
the O 0 0.00083723676
factors O 0 0.00063535565
related O 0 0.00021788735
to O 0 0.00023879178
the O 0 0.00023573921
clinical O 0 0.00051318255
presentation O 0 0.0003350392
and O 0 0.00027285403
pathogenesis O 0 0.000587639
of O 0 0.00047955906
the O 0 0.0008146678
neuropathies B-Disease 0 0.9994981
are O 0 0.0009255736
briefly O 0 0.0013649402
discussed O 0 0.0016999956
. O 0 0.0023794249

Reduction O 0 0.012075302
in O 0 0.008451019
caffeine B-Chemical 0 0.9992988
toxicity B-Disease 2 0.99882644
by O 0 0.056223772
acetaminophen B-Chemical 0 0.9999374
. O 0 0.015237361

A O 0 0.01776083
patient O 0 0.0022645374
who O 0 0.0018772957
allegedly O 0 0.0035819001
consumed O 0 0.0026725316
100 O 0 0.0012055902
tablets O 0 0.024123635
of O 0 0.00025112764
an O 0 0.00019163055
over O 0 7.089659e-05
- O 0 0.0002011867
the O 0 0.00010325708
- O 0 0.00021850878
counter O 0 0.0006469434
analgesic O 0 0.31546673
containing O 0 0.00035025843
sodium B-Chemical 0 0.99999595
acetylsalicylate I-Chemical 0 0.99999964
, O 0 0.0071686874
caffeine B-Chemical 0 0.999972
, O 0 0.0003874852
and O 0 0.00042604905
acetaminophen B-Chemical 0 0.9999975
displayed O 0 0.00017038046
no O 0 5.113613e-05
significant O 0 8.772256e-05
CNS O 0 0.0059385975
stimulation O 0 5.1504358e-05
despite O 0 4.665442e-05
the O 0 5.4013657e-05
presence O 0 6.25641e-05
of O 0 0.00011774718
175 O 0 0.00036480787
micrograms O 0 0.00088983914
of O 0 0.00041569595
caffeine B-Chemical 0 0.999172
per O 0 0.00017376304
mL O 0 0.0013318184
of O 0 0.0010219081
serum O 0 0.08855456
. O 0 0.0026142695

Because O 0 0.0031303153
salicylates O 0 0.99959165
have O 0 0.0011100767
been O 0 0.0004991169
reported O 0 0.00037679067
to O 0 0.0001819435
augment O 0 0.00013696673
the O 0 0.000144414
stimulatory O 0 0.0005046851
effects O 0 0.0002559444
of O 0 0.0006645116
caffeine B-Chemical 0 0.99989057
on O 0 0.000103198116
the O 0 0.00017756286
CNS O 0 0.06256297
, O 0 0.00015879043
attention O 0 0.00014941678
was O 0 7.345281e-05
focused O 0 3.71587e-05
on O 0 2.9788991e-05
the O 0 4.6760917e-05
possibility O 0 3.396358e-05
that O 0 3.6373352e-05
the O 0 5.7611975e-05
presence O 0 8.959608e-05
of O 0 0.00060241384
acetaminophen B-Chemical 0 0.9999982
( O 0 0.00039804363
52 O 0 0.00017960314
micrograms O 0 0.00093874725
/ O 0 0.0005626338
mL O 0 0.00074902584
) O 0 0.00023126842
reduced O 0 0.00026521742
the O 0 0.00031959213
CNS O 0 0.14802112
toxicity B-Disease 2 0.9970578
of O 0 0.007837469
caffeine B-Chemical 0 0.99973005
. O 0 0.0037204607

Studies O 0 0.0061346223
in O 0 0.0029601057
DBA O 0 0.9836659
/ O 0 0.015738957
2J O 0 0.3291125
mice O 0 0.00028839245
showed O 0 0.00023700847
that O 0 0.00015638057
: O 0 0.00025876076
1 O 0 0.00014234064
) O 0 0.00022468828
pretreatment O 0 0.0046073585
with O 0 0.0010659234
acetaminophen B-Chemical 0 0.9999981
( O 0 0.00058207917
100 O 0 0.00050023955
mg O 0 0.008938149
/ O 0 0.0005695625
kg O 0 0.00034164838
) O 0 0.00012079746
increased O 0 8.46454e-05
the O 0 5.129721e-05
interval O 0 3.6797603e-05
between O 0 2.2119211e-05
the O 0 4.7332538e-05
administration O 0 0.0003274419
of O 0 0.00036744063
caffeine B-Chemical 0 0.9999317
( O 0 0.00029385433
300 O 0 0.0002671739
to O 0 6.929369e-05
450 O 0 0.0015781891
mg O 0 0.0053986334
/ O 0 0.00044145592
kg O 0 0.00031960246
IP O 0 0.0013302153
) O 0 0.00013417221
and O 0 5.9022794e-05
the O 0 5.8591817e-05
onset O 0 0.00012675335
of O 0 0.00028993218
fatal O 0 0.9448794
convulsions B-Disease 0 0.9999726
by O 0 0.00025206388
a O 0 0.0001636272
factor O 0 0.00029786304
of O 0 0.000107891414
about O 0 7.666282e-05
two O 0 5.2522435e-05
; O 0 8.3015635e-05
and O 0 6.754887e-05
2 O 0 5.7050598e-05
) O 0 0.0001112224
pretreatment O 0 0.003267426
with O 0 0.0007128701
acetaminophen B-Chemical 0 0.99999833
( O 0 0.00035085293
75 O 0 0.00019649303
mg O 0 0.0030279963
/ O 0 0.00039581582
kg O 0 0.00027651724
) O 0 0.00011004685
reduced O 0 9.5350784e-05
the O 0 6.798029e-05
incidence O 0 0.00018807822
of O 0 0.00027503385
audiogenic O 0 0.9999596
seizures B-Disease 0 0.99997675
produced O 0 0.00014886602
in O 0 6.4433974e-05
the O 0 5.643396e-05
presence O 0 7.90691e-05
of O 0 0.00037457593
caffeine B-Chemical 0 0.99992204
( O 0 0.0003012978
12 O 0 5.5968812e-05
. O 0 4.8769944e-05
5 O 0 5.5043114e-05
to O 0 8.389789e-05
75 O 0 0.00027231136
mg O 0 0.0026648599
/ O 0 0.0012694418
kg O 0 0.0016376512
IP O 0 0.0067646676
) O 0 0.002566099
. O 0 0.002233951

The O 0 0.0016078233
frequency O 0 0.0014640528
of O 0 0.0012897999
sound O 0 0.002499173
- O 0 0.0017684189
induced O 0 0.0011999478
seizures B-Disease 0 0.9998135
after O 0 0.00014815174
12 O 0 0.000103806095
. O 0 7.076157e-05
5 O 0 5.9000286e-05
or O 0 6.56401e-05
25 O 0 0.00014226056
mg O 0 0.002051876
/ O 0 0.000631241
kg O 0 0.0010662007
caffeine B-Chemical 0 0.99946994
was O 0 0.00022515665
reduced O 0 0.00021971483
from O 0 0.00012347885
50 O 0 0.00024365926
to O 0 0.00017670738
5 O 0 0.00023882046
% O 0 0.00056365464
by O 0 0.0016884385
acetaminophen B-Chemical 0 0.99995065
. O 0 0.004157888

In O 0 0.0015749346
the O 0 0.0010913454
absence O 0 0.0006688814
of O 0 0.0020064265
caffeine B-Chemical 0 0.99990296
, O 0 0.010077203
acetaminophen B-Chemical 0 0.9999969
( O 0 0.00086634164
up O 0 0.0001824962
to O 0 0.000117927186
300 O 0 0.0004971526
mg O 0 0.0080072535
/ O 0 0.0006907046
kg O 0 0.00045403623
) O 0 0.00015375052
did O 0 7.557779e-05
not O 0 5.1632756e-05
modify O 0 5.2086896e-05
the O 0 0.00013358498
seizures B-Disease 0 0.99986386
induced O 0 0.0002631043
by O 0 0.00013916047
maximal O 0 0.000257128
electroshock O 0 0.999895
and O 0 0.00016670632
did O 0 8.424294e-05
not O 0 4.596777e-05
alter O 0 4.1231542e-05
the O 0 8.9098176e-05
convulsant O 0 0.994187
dose O 0 0.0014265886
of O 0 0.00027289044
pentylenetetrezol B-Chemical 0 0.29069352
in O 0 9.1354246e-05
mice O 0 5.8654263e-05
( O 0 0.00012066115
tests O 0 0.000144223
performed O 0 7.163032e-05
by O 0 0.000119959965
the O 0 0.0002475303
Anticonvulsant O 0 0.9973693
Screening O 0 0.0019492444
Project O 0 0.0035170803
of O 0 0.001317333
NINCDS O 0 0.464687
) O 0 0.0025608637
. O 0 0.0020309049

Acetaminophen B-Chemical 0 0.99989724
( O 0 0.0034215655
up O 0 0.0010142844
to O 0 0.00054912997
150 O 0 0.0008176056
micrograms O 0 0.0033048887
/ O 0 0.0016785044
mL O 0 0.001851357
) O 0 0.00036965497
did O 0 0.00017087717
not O 0 0.00012652487
retard O 0 0.0024423583
the O 0 0.00014197313
incorporation O 0 0.00036267063
of O 0 0.0002092303
radioactive O 0 0.006069908
adenosine B-Chemical 0 0.9921583
into O 0 0.00012558779
ATP B-Chemical 0 0.94917905
in O 0 0.00020730315
slices O 0 0.00071652385
of O 0 0.0004967405
rat O 0 0.0018244756
cerebral O 0 0.6600542
cortex O 0 0.06252976
. O 0 0.002501123

Thus O 0 0.0018863523
the O 0 0.0013639748
mechanism O 0 0.001185264
by O 0 0.0009988282
which O 0 0.0021165775
acetaminophen B-Chemical 0 0.99998844
antagonizes O 0 0.0017687625
the O 0 0.00036742436
actions O 0 0.0008094465
of O 0 0.00089782855
caffeine B-Chemical 0 0.9997123
in O 0 0.0005097193
the O 0 0.0005864031
CNS O 0 0.028558549
remains O 0 0.0009769176
unknown O 0 0.0029645814
. O 0 0.002368552

A O 0 0.025691086
double O 0 0.0036653867
- O 0 0.0027438186
blind O 0 0.0046017347
study O 0 0.0004698531
of O 0 0.00029328951
the O 0 0.00018397391
efficacy O 0 0.00021641565
and O 0 0.00014409791
safety O 0 0.0002260976
of O 0 0.00094217376
dothiepin B-Chemical 0 0.99999964
hydrochloride I-Chemical 0 0.9998542
in O 0 0.00022824756
the O 0 0.00015332655
treatment O 0 0.00018170962
of O 0 0.00038844955
major O 0 0.0010549453
depressive B-Disease 2 0.99985075
disorder I-Disease 0 0.98110515
. O 0 0.0028118775

In O 0 0.0021099842
a O 0 0.001975679
6 O 0 0.0008033239
- O 0 0.0010027603
week O 0 0.00028063127
double O 0 0.0005264455
- O 0 0.0005765914
blind O 0 0.0016212357
parallel O 0 0.00016793385
treatment O 0 0.0001344872
study O 0 0.00019308977
, O 0 0.0003864801
dothiepin B-Chemical 0 0.9999987
and O 0 0.0011974986
amitriptyline B-Chemical 0 0.999997
were O 0 0.00013867673
compared O 0 4.5595796e-05
to O 0 6.580149e-05
placebo O 0 0.0003400228
in O 0 7.530743e-05
the O 0 0.000105924955
treatment O 0 0.00017018511
of O 0 0.0004187238
33 O 0 0.0011532651
depressed B-Disease 2 0.8115727
outpatients O 0 0.007988426
. O 0 0.0018007339

Dothiepin B-Chemical 0 0.99838805
and O 0 0.0057659107
amitriptyline B-Chemical 0 0.9999721
were O 0 0.00081506965
equally O 0 0.00038619206
effective O 0 0.00017648967
in O 0 0.00015704762
alleviating O 0 0.00060351717
the O 0 0.00018478227
symptoms O 0 0.004687532
of O 0 0.001186823
depressive B-Disease 2 0.9999957
illness I-Disease 0 0.99595475
, O 0 0.0003911893
and O 0 0.0001698348
both O 0 0.0001528358
were O 0 0.00017687799
significantly O 0 0.00030043413
superior O 0 0.00064221
to O 0 0.000684503
placebo O 0 0.005385326
. O 0 0.0018972451

The O 0 0.0015736634
overall O 0 0.0015194598
incidence O 0 0.0016399277
of O 0 0.0009769948
side O 0 0.0035697066
effects O 0 0.00046273827
and O 0 0.00027323252
the O 0 0.0001695746
frequency O 0 0.0001720248
and O 0 0.00015002798
severity O 0 0.0003690182
of O 0 0.00040139933
blurred B-Disease 0 0.99207485
vision I-Disease 0 0.99864596
, O 0 0.00091870286
dry B-Disease 2 0.98792166
mouth I-Disease 2 0.95833564
, O 0 0.00023671763
and O 0 0.00023060982
drowsiness O 0 0.99946433
were O 0 0.00014564229
significantly O 0 0.00013464283
less O 0 0.0001438748
with O 0 0.00058794464
dothiepin B-Chemical 0 0.9999945
than O 0 0.0005330505
with O 0 0.0030316804
amitriptyline B-Chemical 0 0.9999722
. O 0 0.0032425928

Dothiepin B-Chemical 0 0.99374133
also O 0 0.0034662257
produced O 0 0.002624959
fewer O 0 0.0027400022
CNS O 0 0.03246545
and O 0 0.0037642547
cardiovascular O 0 0.7359109
effects O 0 0.0076083066
. O 0 0.0061833947

There O 0 0.0034774272
were O 0 0.0020238564
no O 0 0.0010543871
clinically O 0 0.0023126318
important O 0 0.00072408846
changes O 0 0.0013484245
in O 0 0.001256992
laboratory O 0 0.0026024848
parameters O 0 0.0031787055
. O 0 0.0039053482

Dothiepin B-Chemical 0 0.9976057
thus O 0 0.0028167241
was O 0 0.0011760466
found O 0 0.0004651042
to O 0 0.00029349033
be O 0 0.00020021132
an O 0 0.00021415608
effective O 0 0.0002377053
antidepressant B-Chemical 1 0.99947435
drug O 0 0.014963782
associated O 0 0.00011179904
with O 0 0.0001268138
fewer O 0 0.000111129215
side O 0 0.000972246
effects O 0 0.00017024779
than O 0 0.00020060611
amitriptyline B-Chemical 0 0.9999924
in O 0 0.00019365526
the O 0 0.00017452636
treatment O 0 0.00026975985
of O 0 0.00085365184
depressed B-Disease 2 0.9342463
outpatients O 0 0.013150434
. O 0 0.0018678665

Behavioral O 0 0.0052514183
effects O 0 0.0019248595
of O 0 0.0033197617
diazepam B-Chemical 0 0.99996877
and O 0 0.0044659562
propranolol B-Chemical 1 0.9999826
in O 0 0.00081584865
patients O 0 0.00091524655
with O 0 0.0013996662
panic B-Disease 0 0.9998871
disorder I-Disease 0 0.98910743
and O 0 0.0053954907
agoraphobia B-Disease 0 0.99994314
. O 0 0.004113004

The O 0 0.0013677978
effects O 0 0.0012960011
of O 0 0.0013451043
oral O 0 0.018935647
doses O 0 0.007343664
of O 0 0.002394176
diazepam B-Chemical 0 0.9999932
( O 0 0.00072082086
single O 0 0.00016926252
dose O 0 0.00042051426
of O 0 0.0001428505
10 O 0 9.6240256e-05
mg O 0 0.0014001582
and O 0 8.216937e-05
a O 0 8.37834e-05
median O 0 3.6294838e-05
dose O 0 0.00017542129
of O 0 8.362001e-05
30 O 0 5.583533e-05
mg O 0 0.0012731628
/ O 0 0.0001872435
day O 0 3.1569514e-05
for O 0 3.214724e-05
2 O 0 3.667219e-05
weeks O 0 2.1102458e-05
) O 0 9.249519e-05
and O 0 0.00015371402
propranolol B-Chemical 1 0.9999896
( O 0 0.00023393812
single O 0 7.5899035e-05
dose O 0 0.00020941773
of O 0 8.6510285e-05
80 O 0 0.00012692728
mg O 0 0.0013070113
and O 0 6.233601e-05
a O 0 6.527177e-05
median O 0 2.891094e-05
dose O 0 0.00014917777
of O 0 8.634612e-05
240 O 0 0.00021790314
mg O 0 0.002819781
/ O 0 0.00020749259
day O 0 3.1442723e-05
for O 0 3.1944805e-05
2 O 0 3.5234603e-05
weeks O 0 1.8111778e-05
) O 0 5.193111e-05
on O 0 2.3067649e-05
psychological O 0 0.000106457286
performance O 0 8.687494e-05
of O 0 9.240598e-05
patients O 0 0.00014100551
with O 0 0.00025799952
panic B-Disease 0 0.99994874
disorders I-Disease 0 0.735329
and O 0 0.00046288915
agoraphobia B-Disease 0 0.9999913
were O 0 0.000124216
investigated O 0 5.8595786e-05
in O 0 6.998781e-05
a O 0 0.00015002425
double O 0 0.00031635666
- O 0 0.00042212097
blind O 0 0.003313035
, O 0 0.00025430013
randomized O 0 0.0002958866
and O 0 0.00041939333
crossover O 0 0.003211576
design O 0 0.0014927171
. O 0 0.0017402834

Both O 0 0.0028762277
drugs O 0 0.011430106
impaired B-Disease 0 0.0022993255
immediate I-Disease 0 0.0011617126
free I-Disease 0 0.00087778515
recall I-Disease 0 0.0012633698
but O 0 0.00039402494
the O 0 0.00026895836
decrease O 0 0.0003677597
was O 0 0.00028868683
greater O 0 0.00033240806
for O 0 0.0006157646
diazepam B-Chemical 0 0.99997234
than O 0 0.0031128072
propranolol B-Chemical 1 0.9999527
. O 0 0.0046364074

Delayed B-Disease 0 0.010661581
free I-Disease 0 0.0028617105
recall I-Disease 0 0.002992722
was I-Disease 0 0.001023623
also I-Disease 0 0.0005903361
impaired I-Disease 0 0.0013104915
but O 0 0.00050145015
the O 0 0.00037415014
two O 0 0.00034093924
drugs O 0 0.0059925597
did O 0 0.0009005427
not O 0 0.0010496196
differ O 0 0.0015425092
. O 0 0.002426526

Patients O 0 0.0024706293
tapped O 0 0.0028265398
faster O 0 0.0009376402
after O 0 0.0005010902
propranolol B-Chemical 1 0.9999585
than O 0 0.0010601423
diazepam B-Chemical 0 0.99998415
and O 0 0.00039730873
they O 0 0.00014710541
were O 0 0.00014705562
more O 0 0.00024959946
sedated O 0 0.0019138812
after O 0 0.0002331872
diazepam B-Chemical 0 0.9999498
than O 0 0.0020680695
propranolol B-Chemical 1 0.9999447
. O 0 0.004020421

After O 0 0.0009992965
2 O 0 0.0009105488
weeks O 0 0.0003568223
of O 0 0.00057120004
treatment O 0 0.0005037959
, O 0 0.00047867105
patients O 0 0.0004141457
tested O 0 0.00022103457
5 O 0 0.00015463504
- O 0 0.00024139938
8 O 0 6.828481e-05
h O 0 5.103996e-05
after O 0 2.5885767e-05
the O 0 5.1084513e-05
last O 0 3.128528e-05
dose O 0 0.0002508838
of O 0 0.00018894856
medication O 0 0.0014459642
did O 0 0.00015251726
not O 0 0.000120688754
show O 0 0.00012554182
any O 0 0.0002058203
decrement O 0 0.0012149828
of O 0 0.0009846335
performance O 0 0.002244603
. O 0 0.002081857

These O 0 0.0025884963
results O 0 0.0017354977
are O 0 0.0010287674
similar O 0 0.00057264976
to O 0 0.000620987
those O 0 0.000807853
previously O 0 0.0006071583
found O 0 0.00062011345
in O 0 0.00087186525
healthy O 0 0.0042058453
subjects O 0 0.0029776585
. O 0 0.0028507838

Accumulation O 0 0.0054271333
of O 0 0.003101296
drugs O 0 0.020011216
was O 0 0.0014076311
not O 0 0.00075010094
reflected O 0 0.00081569585
in O 0 0.0009027137
prolonged O 0 0.0027951128
behavioral B-Disease 0 0.23995112
impairment I-Disease 0 0.98460233
. O 0 0.00551356

Comparison O 0 0.0016317307
of O 0 0.0016767563
i O 0 0.0019886524
. O 0 0.00063075457
v O 0 0.0024876853
. O 0 0.0005778133
glycopyrrolate B-Chemical 0 0.9999571
and O 0 0.0014813916
atropine B-Chemical 0 0.999964
in O 0 0.00022105883
the O 0 0.0001229961
prevention O 0 0.00018289841
of O 0 0.00026239138
bradycardia B-Disease 0 0.9939429
and O 0 0.00037091467
arrhythmias B-Disease 2 0.99876237
following O 0 9.203329e-05
repeated O 0 8.8788336e-05
doses O 0 0.00097044604
of O 0 0.00094495446
suxamethonium B-Chemical 0 0.99965847
in O 0 0.0011301327
children O 0 0.00252693
. O 0 0.001925541

The O 0 0.0012902595
effectiveness O 0 0.0008806343
of O 0 0.0009707855
administration O 0 0.0026010207
of O 0 0.0020696279
glycopyrrolate B-Chemical 0 0.99997604
5 O 0 0.00026226635
and O 0 0.00016080811
10 O 0 0.000113971444
micrograms O 0 0.00094703183
kg O 0 0.000506325
- O 0 0.00022662187
1 O 0 8.002861e-05
and O 0 0.00014841642
atropine B-Chemical 0 0.99988043
10 O 0 0.00010227956
and O 0 7.465825e-05
20 O 0 7.290493e-05
micrograms O 0 0.0006676096
kg O 0 0.00037783093
- O 0 0.0001856993
1 O 0 6.558123e-05
i O 0 0.00016661019
. O 0 5.533331e-05
v O 0 0.000300238
. O 0 3.5682304e-05
immediately O 0 2.9148301e-05
before O 0 1.9869962e-05
the O 0 4.1325857e-05
induction O 0 6.930955e-05
of O 0 0.0001385287
anaesthesia O 0 0.004131217
, O 0 8.9870504e-05
to O 0 5.6393827e-05
prevent O 0 0.00012192356
arrhythmia B-Disease 0 0.9967565
and O 0 0.00018757176
bradycardia B-Disease 0 0.928169
following O 0 4.8162634e-05
repeated O 0 4.4265744e-05
doses O 0 0.00048669844
of O 0 0.00044863558
suxamethonium B-Chemical 0 0.9997749
in O 0 0.00036302625
children O 0 0.0006990343
, O 0 0.00061614387
was O 0 0.0008825891
studied O 0 0.0015630056
. O 0 0.0019059596

A O 0 0.014792313
control O 0 0.001623855
group O 0 0.0013150828
was O 0 0.00061648514
included O 0 0.00027965102
for O 0 0.00019583858
comparison O 0 0.00018321295
with O 0 0.00020555925
the O 0 0.0001755985
lower O 0 0.0002777962
dose O 0 0.0007880977
range O 0 0.00037013172
of O 0 0.0014257316
glycopyrrolate B-Chemical 0 0.99997246
and O 0 0.008671213
atropine B-Chemical 0 0.9999037
. O 0 0.004431922

A O 0 0.013514146
frequency O 0 0.0018508699
of O 0 0.0017667464
bradycardia B-Disease 0 0.97412044
of O 0 0.0010895733
50 O 0 0.00086652004
% O 0 0.00033745784
was O 0 0.00019119545
noted O 0 8.400613e-05
in O 0 8.678999e-05
the O 0 8.8580564e-05
control O 0 0.000110996414
group O 0 0.00019056571
, O 0 0.00013237567
but O 0 0.00010499215
this O 0 0.0001181123
was O 0 0.00010201666
not O 0 6.826345e-05
significantly O 0 0.000103450846
different O 0 4.8741626e-05
from O 0 6.5423264e-05
the O 0 9.780937e-05
frequency O 0 0.00016413724
with O 0 0.00026625188
the O 0 0.00039157082
active O 0 0.0010994022
drugs O 0 0.04917557
. O 0 0.002276651

Bradycardia B-Disease 0 0.9921653
( O 0 0.002834157
defined O 0 0.0007395852
as O 0 0.00055664254
a O 0 0.00054030295
decrease O 0 0.00044055146
in O 0 0.00027700912
heart O 0 0.0071907775
rate O 0 0.00021747057
to O 0 0.000108059234
less O 0 0.00010989521
than O 0 6.668364e-05
50 O 0 0.00016068228
beat O 0 0.0003371112
min O 0 0.00018719725
- O 0 0.0002779276
1 O 0 9.967945e-05
) O 0 0.00015341575
was O 0 9.798534e-05
prevented O 0 0.000182714
when O 0 5.4469725e-05
the O 0 8.0284815e-05
larger O 0 0.00012339893
dose O 0 0.0003943218
of O 0 0.00020005123
either O 0 0.00022556187
active O 0 0.0005156109
drug O 0 0.0146032525
was O 0 0.000967963
used O 0 0.0011637128
. O 0 0.001958066

It O 0 0.0023514165
is O 0 0.0010806595
recommended O 0 0.00059302663
that O 0 0.00034767957
either O 0 0.00073686126
glycopyrrolate B-Chemical 0 0.999959
10 O 0 0.00038056268
micrograms O 0 0.003582906
kg O 0 0.0008595146
- O 0 0.00027886694
1 O 0 8.633714e-05
or O 0 0.00011867361
atropine B-Chemical 0 0.9998635
20 O 0 0.00016567313
micrograms O 0 0.001481173
kg O 0 0.00049360027
- O 0 0.0002050577
1 O 0 7.0253e-05
i O 0 0.00017902505
. O 0 6.126485e-05
v O 0 0.00035598932
. O 0 4.2964486e-05
should O 0 2.516055e-05
immediately O 0 3.4898727e-05
precede O 0 8.38093e-05
induction O 0 8.518721e-05
of O 0 0.00015768537
anaesthesia O 0 0.0044526393
, O 0 0.000120665514
in O 0 8.445223e-05
children O 0 0.00015991436
, O 0 8.9409594e-05
if O 0 4.689466e-05
the O 0 7.3035466e-05
repeated O 0 7.636789e-05
administration O 0 0.000823197
of O 0 0.0011574302
suxamethonium B-Chemical 0 0.99967325
is O 0 0.0012357468
anticipated O 0 0.0014123209
. O 0 0.0018928357

Veno B-Disease 0 0.0475957
- I-Disease 0 0.009592277
occlusive I-Disease 0 0.9936745
liver I-Disease 2 0.9981268
disease I-Disease 2 0.97663194
after O 0 0.00066077133
dacarbazine B-Chemical 0 0.9922679
therapy O 0 0.0031559905
( O 0 0.0032055518
DTIC B-Chemical 0 0.9996258
) O 0 0.0033757298
for O 0 0.0020738011
melanoma B-Disease 0 0.9898779
. O 0 0.0047067394

A O 0 0.016512698
case O 0 0.0018400854
of O 0 0.001862447
veno B-Disease 0 0.011007443
- I-Disease 0 0.0033579343
occlusive I-Disease 0 0.9895415
disease I-Disease 0 0.18124306
of I-Disease 0 0.00043371707
the I-Disease 0 0.00029112183
liver I-Disease 0 0.505653
with O 0 0.0004646668
fatal O 0 0.25569582
outcome O 0 0.0002035659
after O 0 8.4969695e-05
dacarbazine B-Chemical 0 0.98948973
( O 0 0.0014648812
DTIC B-Chemical 0 0.99989367
) O 0 0.00082829455
therapy O 0 0.00053616957
for O 0 0.00047398714
melanoma B-Disease 0 0.98071194
is O 0 0.0014700755
reported O 0 0.0021872472
. O 0 0.0022072103

There O 0 0.0034079347
was O 0 0.002549503
a O 0 0.0025967252
fulminant O 0 0.9778682
clinical O 0 0.0026220244
course O 0 0.0005075947
from O 0 0.00034160653
start O 0 0.00030077688
of O 0 0.00088202336
symptoms O 0 0.008597175
until O 0 0.0013586694
death B-Disease 0 0.95592207
. O 0 0.004067983

At O 0 0.0014481815
autopsy O 0 0.0073927054
the O 0 0.001766605
liver O 0 0.4348111
was O 0 0.0013213633
enlarged O 0 0.0033024035
and O 0 0.00065522594
firm O 0 0.0017385399
with O 0 0.00089817855
signs O 0 0.0071455617
of O 0 0.0029861701
venous B-Disease 0 0.98779386
congestion I-Disease 0 0.9915173
. O 0 0.004291854

Small O 0 0.009192855
- O 0 0.004352929
and O 0 0.0018010752
medium O 0 0.0034402756
- O 0 0.0020273535
sized O 0 0.0013451043
hepatic O 0 0.8806373
veins O 0 0.08122146
were O 0 0.0011992988
blocked O 0 0.0031045114
by O 0 0.00426106
thrombosis B-Disease 0 0.99932134
. O 0 0.0050947065

Eosinophilic O 0 0.051838927
infiltrations O 0 0.07342525
were O 0 0.0037836093
found O 0 0.0025838567
around O 0 0.0027934744
the O 0 0.004345533
vessels O 0 0.020947266
. O 0 0.00709952

Published O 0 0.010424836
cases O 0 0.0024464894
from O 0 0.0010894939
the O 0 0.0009703712
literature O 0 0.0012861682
are O 0 0.000769473
reviewed O 0 0.001031944
and O 0 0.00075529615
pertinent O 0 0.00087332854
features O 0 0.001597053
discussed O 0 0.0024825765
. O 0 0.0035228943

Maternal O 0 0.009319989
lithium B-Chemical 0 0.9986879
and O 0 0.002085569
neonatal O 0 0.0032866828
Ebstein B-Disease 0 0.07332196
' I-Disease 0 0.00073057786
s I-Disease 0 0.00050399883
anomaly I-Disease 0 0.005219772
: O 0 0.00044821855
evaluation O 0 0.00031702
with O 0 0.00051490037
cross O 0 0.0010607687
- O 0 0.0015080236
sectional O 0 0.00368231
echocardiography O 0 0.010114051
. O 0 0.0026855986

Cross O 0 0.011499529
- O 0 0.0035861998
sectional O 0 0.0035035636
echocardiography O 0 0.0036043753
was O 0 0.00053789094
used O 0 0.00025301523
to O 0 0.00019082736
evaluate O 0 0.00011480697
two O 0 0.00013834864
neonates O 0 0.0004329314
whose O 0 0.00042195828
mothers O 0 0.00067888456
ingested O 0 0.016616654
lithium B-Chemical 0 0.9997397
during O 0 0.00096630945
pregnancy O 0 0.018543284
. O 0 0.0024361021

In O 0 0.0023890792
one O 0 0.0016305641
infant O 0 0.0025535452
, O 0 0.0018027476
Ebstein B-Disease 0 0.030460259
' I-Disease 0 0.00092836266
s I-Disease 0 0.0006654561
anomaly I-Disease 0 0.0044032116
of O 0 0.0006646224
the O 0 0.0007674855
tricuspid O 0 0.06663943
valve O 0 0.0042178705
was O 0 0.0013631578
identified O 0 0.0016888259
. O 0 0.002571658

In O 0 0.0018160518
the O 0 0.0013223994
other O 0 0.00089130126
infant O 0 0.0013312713
cross O 0 0.0010082533
- O 0 0.0007749422
sectional O 0 0.0010779698
echocardiography O 0 0.0016071773
provided O 0 0.00023277404
reassurance O 0 0.00062961964
that O 0 0.00010229947
the O 0 0.00015189667
infant O 0 0.0003680578
did O 0 0.00023891432
not O 0 0.00023300228
have O 0 0.00033736392
Ebstein B-Disease 0 0.011754474
' I-Disease 0 0.00093707803
s I-Disease 0 0.0011562564
anomaly I-Disease 0 0.035409477
. O 0 0.0027589258

Cross O 0 0.0096604815
- O 0 0.0028319503
sectional O 0 0.00237426
echocardiographic O 0 0.0022338724
screening O 0 0.0005951965
of O 0 0.00037843382
newborns O 0 0.0005520799
exposed O 0 0.00020464131
to O 0 0.00022802396
lithium B-Chemical 0 0.99969566
during O 0 8.188324e-05
gestation O 0 0.00014294617
can O 0 4.9222082e-05
provide O 0 4.7802478e-05
highly O 0 6.274783e-05
accurate O 0 8.54271e-05
, O 0 8.601893e-05
noninvasive O 0 0.00015391276
assessment O 0 5.0462393e-05
of O 0 7.7728146e-05
the O 0 6.754083e-05
presence O 0 7.956126e-05
or O 0 8.364824e-05
absence O 0 0.000100954385
of O 0 0.00069155864
lithium B-Chemical 0 0.9999337
- O 0 0.0027628646
induced O 0 0.0023016583
cardiac B-Disease 0 0.9928497
malformations I-Disease 0 0.9997842
. O 0 0.0045998157

Effects O 0 0.0029161405
of O 0 0.0016624127
training O 0 0.00077031227
on O 0 0.00039239644
the O 0 0.00039821214
extent O 0 0.0003039585
of O 0 0.00056262524
experimental O 0 0.0015299451
myocardial B-Disease 0 0.9996551
infarction I-Disease 2 0.9999722
in O 0 0.002438733
aging O 0 0.13584179
rats O 0 0.0039990684
. O 0 0.002417206

The O 0 0.0014719764
effects O 0 0.0013156942
of O 0 0.0010868614
exercise O 0 0.0010000285
on O 0 0.00023078933
the O 0 0.00028040208
severity O 0 0.0006464416
of O 0 0.00070135284
isoproterenol B-Chemical 0 0.99990666
- O 0 0.001245077
induced O 0 0.0006539701
myocardial B-Disease 0 0.99991846
infarction I-Disease 2 0.9999944
were O 0 0.00028817644
studied O 0 0.00012817039
in O 0 8.411017e-05
female O 0 0.0003847835
albino O 0 0.00069746154
rats O 0 0.00010478171
of O 0 9.140112e-05
20 O 0 8.858647e-05
, O 0 0.000103476195
40 O 0 0.000107357744
, O 0 0.00012185743
60 O 0 0.00011687531
and O 0 0.00015384115
80 O 0 0.00027337426
weeks O 0 0.00016598622
of O 0 0.00068289356
age O 0 0.001474079
. O 0 0.0019303784

The O 0 0.0018836205
rats O 0 0.0019721882
were O 0 0.00087795994
trained O 0 0.00062949007
to O 0 0.00046479615
swim O 0 0.0030087281
for O 0 0.00023562732
a O 0 0.00030049228
specific O 0 0.00016394717
duration O 0 0.00014073351
and O 0 0.00027347176
for O 0 0.0002723594
a O 0 0.0006031647
particular O 0 0.00053468975
period O 0 0.0008235866
. O 0 0.0019516763

The O 0 0.0026708862
occurrence O 0 0.003557742
of O 0 0.004149072
infarcts B-Disease 0 0.9980616
were O 0 0.0022642834
confirmed O 0 0.0017405562
by O 0 0.0019802812
histological O 0 0.009322797
methods O 0 0.003592829
. O 0 0.0040814006

Elevations O 0 0.0134808635
in O 0 0.0014702422
the O 0 0.0013029831
serum O 0 0.26735097
GOT O 0 0.99960166
and O 0 0.0021279643
GPT O 0 0.9928953
were O 0 0.0003058008
maximum O 0 0.00015789886
in O 0 0.0001335259
the O 0 0.00017189937
sedentary O 0 0.000548867
- O 0 0.0003932465
isoproterenols B-Chemical 0 0.027230501
and O 0 0.0001528183
minimum O 0 0.00010770453
in O 0 0.00017103627
the O 0 0.00030529214
exercise O 0 0.0011291567
- O 0 0.0013826301
controls O 0 0.0022441917
. O 0 0.0021019403

These O 0 0.0020939
changes O 0 0.0014321874
in O 0 0.00077391794
the O 0 0.00074821006
serum O 0 0.08076994
transaminases O 0 0.99913126
were O 0 0.0005399635
associated O 0 0.00021904382
with O 0 0.0002358017
corresponding O 0 0.00018535614
depletions O 0 0.00499805
in O 0 0.00024845006
the O 0 0.00044387404
cardiac O 0 0.32347816
GOT O 0 0.9996007
and O 0 0.0054408954
GPT O 0 0.99724954
. O 0 0.003885709

However O 0 0.003359524
, O 0 0.0027052935
age O 0 0.0016131505
was O 0 0.00082155963
seen O 0 0.00040562384
to O 0 0.00025271313
interfere O 0 0.00017912989
with O 0 0.00024444668
the O 0 0.00019731365
responses O 0 0.00026946014
exhibited O 0 0.00031708163
by O 0 0.00029780794
the O 0 0.000348381
young O 0 0.0015618042
and O 0 0.0006025002
old O 0 0.0009480421
rats O 0 0.0020409846
. O 0 0.0019765752

Studies O 0 0.0046471255
dealing O 0 0.0022440294
with O 0 0.0030930454
myocardial B-Disease 0 0.99932015
infarction I-Disease 2 0.99994993
are O 0 0.001067511
more O 0 0.0007877508
informative O 0 0.0007924258
when O 0 0.00040752982
dealt O 0 0.0012854174
with O 0 0.0015869244
age O 0 0.002533718
. O 0 0.0026728078

Effect O 0 0.0029034654
of O 0 0.0035049587
polyethylene B-Chemical 0 0.9225239
glycol I-Chemical 0 0.97821414
400 I-Chemical 0 0.04379719
on O 0 0.0015716958
adriamycin B-Chemical 0 0.99954563
toxicity B-Disease 2 0.99888784
in O 0 0.003070072
mice O 0 0.0024741772
. O 0 0.0035110794

The O 0 0.00162974
effect O 0 0.0012341434
of O 0 0.0011806317
a O 0 0.0008981888
widely O 0 0.00039894527
used O 0 0.00036926402
organic O 0 0.88921463
solvent O 0 0.8695516
, O 0 0.00072450464
polyethylene B-Chemical 0 0.9795687
glycol I-Chemical 0 0.9913526
400 I-Chemical 0 0.052547574
( O 0 0.000462505
PEG B-Chemical 0 0.64939183
400 I-Chemical 0 0.0014055824
) O 0 0.0002284875
, O 0 9.175086e-05
on O 0 4.1575087e-05
the O 0 8.479502e-05
toxic O 0 0.017881919
action O 0 0.00016902063
of O 0 0.00014226597
an O 0 0.00020720079
acute O 0 0.15038265
or O 0 0.00015852053
chronic O 0 0.05013819
treatment O 0 0.00019057989
with O 0 0.00052058155
adriamycin B-Chemical 0 0.9998857
( O 0 0.0038323612
ADR B-Chemical 0 0.9999238
) O 0 0.0009478461
was O 0 0.0003751336
evaluated O 0 0.00033146088
in O 0 0.00056772056
mice O 0 0.00095799373
. O 0 0.001876356

PEG B-Chemical 0 0.5293501
400 I-Chemical 0 0.008241483
impressively O 0 0.007591561
decreased O 0 0.0019783154
both O 0 0.00089869247
acute O 0 0.23385067
high O 0 0.0019349738
- O 0 0.000988352
dose O 0 0.0014963911
and O 0 0.00039879885
chronic O 0 0.12488674
low O 0 0.0016683469
- O 0 0.0012032819
dose O 0 0.006412866
- O 0 0.0042041577
ADR B-Chemical 0 0.9998301
- O 0 0.0031970767
associated O 0 0.001687582
lethality O 0 0.7675561
. O 0 0.003387231

Light O 0 0.011345631
microscopic O 0 0.0030588622
analysis O 0 0.0010878392
showed O 0 0.0007226876
a O 0 0.0007474942
significant O 0 0.0005275146
protection O 0 0.001280112
against O 0 0.00082277076
ADR B-Chemical 0 0.999874
- O 0 0.0029916225
induced O 0 0.0015384576
cardiac B-Disease 0 0.6756489
morphological I-Disease 0 0.013844169
alterations I-Disease 0 0.04021263
. O 0 0.0029369756

Such O 0 0.0031997673
treatment O 0 0.0014883262
did O 0 0.0009723007
not O 0 0.00049945526
diminish O 0 0.000528812
the O 0 0.00072764466
ADR B-Chemical 0 0.99976116
antitumor O 0 0.26673734
activity O 0 0.00064460706
in O 0 0.0010670861
L1210 B-Disease 0 0.9999311
leukemia I-Disease 0 0.999992
and O 0 0.0028401117
in O 0 0.0016503123
Ehrlich B-Disease 0 0.9898544
ascites I-Disease 0 0.9995435
tumor I-Disease 0 0.99552554
. O 0 0.0040684487

Sublingual O 0 0.33632004
absorption O 0 0.22912934
of O 0 0.0016734112
the O 0 0.0012710522
quaternary B-Chemical 0 0.6527679
ammonium I-Chemical 0 0.9999244
antiarrhythmic O 0 0.997442
agent O 0 0.07512327
, O 0 0.0038876736
UM B-Chemical 0 0.90749305
- I-Chemical 0 0.005326909
272 I-Chemical 0 0.018539509
. O 0 0.0032720573

UM B-Chemical 0 0.8700484
- I-Chemical 0 0.0068637324
272 I-Chemical 0 0.013680292
( O 0 0.0035124675
N B-Chemical 0 0.96122867
, I-Chemical 0 0.0022009558
N I-Chemical 0 0.9858921
- I-Chemical 0 0.0018646705
dimethylpropranolol I-Chemical 0 0.033754244
) O 0 0.00055631524
, O 0 0.00020662154
a O 0 0.00021675516
quaternary O 0 0.016417101
antiarrhythmic O 0 0.8186634
agent O 0 0.0020740486
, O 0 0.00019853124
was O 0 0.00013288826
administered O 0 0.0002016711
sublingually O 0 0.40870684
to O 0 0.000119617725
dogs O 0 0.000271029
with O 0 0.00057445647
ouabain B-Chemical 1 0.99995255
- O 0 0.0017177793
induced O 0 0.0014336011
ventricular B-Disease 0 0.9990976
tachycardias I-Disease 0 0.9939448
. O 0 0.0027615172

Both O 0 0.0035511926
anti O 0 0.0072221234
- O 0 0.005087354
arrhythmic O 0 0.985479
efficacy O 0 0.0019964848
and O 0 0.0011616832
bioavailability O 0 0.8658566
were O 0 0.0006194418
compared O 0 0.0004011178
to O 0 0.0007938362
oral O 0 0.03811849
drug O 0 0.085476205
. O 0 0.0034236195

Sublingual O 0 0.7828945
UM B-Chemical 0 0.87593454
- I-Chemical 0 0.0033344654
272 I-Chemical 0 0.004075184
converted O 0 0.0013226854
ventricular B-Disease 2 0.9943772
tachycardia I-Disease 2 0.99926287
to O 0 0.0004889712
sinus O 0 0.0014369087
rhythm O 0 0.0013178174
in O 0 0.00039153828
all O 0 0.00054661086
5 O 0 0.0006877614
dogs O 0 0.0018957376
. O 0 0.00221743

The O 0 0.0015265581
area O 0 0.0011535777
under O 0 0.0005641354
the O 0 0.0005582524
plasma O 0 0.0022858416
concentration O 0 0.0005959123
time O 0 0.00013155134
curve O 0 0.00022215566
at O 0 7.568222e-05
90 O 0 9.946638e-05
min O 0 0.0001312096
was O 0 0.00012280744
4 O 0 7.183779e-05
- O 0 0.00011026418
12 O 0 2.9376517e-05
times O 0 2.3945604e-05
greater O 0 4.8050926e-05
than O 0 4.0220646e-05
for O 0 6.174733e-05
oral O 0 0.009327027
drug O 0 0.014599923
, O 0 0.00011626984
suggesting O 0 3.8747286e-05
the O 0 5.1473173e-05
existence O 0 5.7348425e-05
of O 0 0.00010111721
an O 0 0.00021360141
absorption O 0 0.6374634
- O 0 0.000277939
limiting O 0 0.00014932978
process O 0 7.267026e-05
in O 0 6.434482e-05
the O 0 8.944746e-05
intestine O 0 0.00080277596
, O 0 0.00010922284
and O 0 8.049611e-05
providing O 0 8.975129e-05
an O 0 0.000103157094
alternate O 0 0.000115857896
form O 0 0.000106225576
of O 0 0.00021614737
administration O 0 0.0009266412
for O 0 0.0004259995
quaternary O 0 0.06294309
drugs O 0 0.12998544
. O 0 0.0023121454

Early O 0 0.012148433
adjuvant O 0 0.032715194
adriamycin B-Chemical 0 0.9962132
in O 0 0.0059442837
superficial O 0 0.016763289
bladder B-Disease 0 0.43204504
carcinoma I-Disease 0 0.99538296
. O 0 0.00835197

A O 0 0.030056918
multicenter O 0 0.021289548
study O 0 0.0013737156
was O 0 0.00068151683
performed O 0 0.00035760365
in O 0 0.00031961346
110 O 0 0.0006055835
patients O 0 0.00034952472
with O 0 0.00032966083
superficial O 0 0.0009859584
transitional O 0 0.0028311966
cell O 0 0.0043245894
carcinoma B-Disease 0 0.9838727
of I-Disease 0 0.0012646519
the I-Disease 0 0.001334188
bladder I-Disease 0 0.051100392
. O 0 0.0024981033

Adriamycin B-Chemical 0 0.9978703
( O 0 0.0037946827
50 O 0 0.0021638824
mg O 0 0.018533552
/ O 0 0.0017713043
50 O 0 0.0007842945
ml O 0 0.0011383231
) O 0 0.00040585845
was O 0 0.00016684977
administered O 0 0.00013497371
intravesically O 0 0.00017389862
within O 0 3.1368214e-05
24 O 0 4.3183096e-05
h O 0 4.1552885e-05
after O 0 2.7508971e-05
transurethral O 0 0.00013877937
resection O 0 0.0004184395
of O 0 0.00028846998
TA O 0 0.58823115
- O 0 0.00076636614
T1 O 0 0.0064039063
( O 0 0.0009779056
O O 0 0.9819696
- O 0 0.0019890158
A O 0 0.01980392
) O 0 0.0024384453
bladder B-Disease 0 0.8259143
tumors I-Disease 0 0.993626
. O 0 0.003701702

Instillation O 0 0.026087299
was O 0 0.0013662102
repeated O 0 0.00040391504
twice O 0 0.00030519586
during O 0 0.00014166778
the O 0 0.00016256781
first O 0 0.00010296515
week O 0 8.3638435e-05
, O 0 0.000109244706
then O 0 6.549818e-05
weekly O 0 7.021449e-05
during O 0 3.806777e-05
the O 0 6.287451e-05
first O 0 5.3639054e-05
month O 0 6.020165e-05
and O 0 0.0001316363
afterwards O 0 0.0002588617
monthly O 0 0.00021852292
for O 0 0.00028899743
1 O 0 0.0005530016
year O 0 0.0007755499
. O 0 0.0016164421

The O 0 0.0023125273
tolerance O 0 0.015717188
was O 0 0.0012110953
evaluated O 0 0.0005243524
in O 0 0.00039020693
these O 0 0.00047922114
110 O 0 0.0007563975
patients O 0 0.00037938962
, O 0 0.0002353435
and O 0 0.00018704026
29 O 0 0.00027249733
patients O 0 0.00020107279
presented O 0 0.00017627288
with O 0 0.00033412658
local O 0 0.0007923239
side O 0 0.01043158
- O 0 0.0021031508
effects O 0 0.0023852116
. O 0 0.0027954343

In O 0 0.0016311498
24 O 0 0.000906805
of O 0 0.00087089126
these O 0 0.000800071
patients O 0 0.0008670386
chemical O 0 0.0046600793
cystitis B-Disease 0 0.99971074
was O 0 0.0009936889
severe O 0 0.0043056486
enough O 0 0.00027456248
for O 0 0.00013710026
them O 0 0.00030343767
to O 0 0.000176865
drop O 0 0.00072432205
out O 0 0.00025096824
of O 0 0.0005682219
the O 0 0.00085360877
study O 0 0.0017990017
. O 0 0.0020922148

No O 0 0.009300356
systemic O 0 0.2709015
side O 0 0.044636358
- O 0 0.0066293897
effects O 0 0.0042668018
were O 0 0.0043324237
observed O 0 0.0048838435
. O 0 0.0068521434

Recurrence O 0 0.0146525325
was O 0 0.0017125623
studied O 0 0.00086163427
in O 0 0.00044339508
82 O 0 0.0006121286
evaluable O 0 0.000594408
patients O 0 0.00022503773
after O 0 5.927668e-05
1 O 0 8.579333e-05
year O 0 5.51351e-05
of O 0 9.2968985e-05
follow O 0 6.493534e-05
- O 0 0.00014857642
up O 0 7.808579e-05
and O 0 7.626659e-05
in O 0 6.49564e-05
72 O 0 7.4182135e-05
patients O 0 9.886138e-05
followed O 0 5.7389785e-05
for O 0 7.0061324e-05
2 O 0 0.0001024969
- O 0 0.00019260342
3 O 0 8.859922e-05
years O 0 0.00010551485
( O 0 0.00017393893
mean O 0 0.00013015103
32 O 0 0.00045165216
months O 0 0.00036312867
) O 0 0.0015442226
. O 0 0.0019476969

Of O 0 0.0022769787
the O 0 0.0013630936
82 O 0 0.0016622879
patients O 0 0.00089660526
studied O 0 0.000491954
after O 0 0.00016513864
1 O 0 0.00024527358
year O 0 0.00018256997
, O 0 0.00027346134
23 O 0 0.00032178639
had O 0 0.00023982173
primary O 0 0.00036376878
and O 0 0.0005573962
59 O 0 0.0012358137
recurrent O 0 0.017245984
disease O 0 0.39076048
. O 0 0.003148316

Of O 0 0.001973376
the O 0 0.0011305775
82 O 0 0.0013925278
evaluable O 0 0.001353969
patients O 0 0.0006274257
, O 0 0.0003551224
50 O 0 0.00033905456
did O 0 0.0001861677
not O 0 0.00011503337
show O 0 8.9725014e-05
any O 0 0.000107664484
recurrence O 0 0.0025621157
after O 0 4.742335e-05
1 O 0 8.052435e-05
year O 0 6.0573027e-05
( O 0 0.00012425131
61 O 0 0.00015487336
% O 0 0.000118753764
) O 0 0.00015410174
, O 0 9.243462e-05
while O 0 7.184485e-05
32 O 0 9.4325886e-05
presented O 0 6.860555e-05
with O 0 0.000103243096
one O 0 7.567847e-05
or O 0 0.000114939736
more O 0 0.00033564563
recurrences O 0 0.0045352555
( O 0 0.00074527995
39 O 0 0.0009574138
% O 0 0.0010503759
) O 0 0.0020350998
. O 0 0.0021348277

Of O 0 0.0026706986
these O 0 0.0022273934
recurrences O 0 0.00605869
, O 0 0.0010772685
27 O 0 0.000858516
were O 0 0.0005146065
T1 O 0 0.0033192649
tumors B-Disease 0 0.05636702
while O 0 0.0002873413
five O 0 0.0001605942
progressed O 0 0.0004194347
to O 0 0.0002699155
more O 0 0.00056759175
highly O 0 0.0008042859
invasive O 0 0.0022801177
lesions O 0 0.02822209
. O 0 0.0027432821

In O 0 0.0018048562
patients O 0 0.0014150011
that O 0 0.0005328397
were O 0 0.0004733079
free O 0 0.0004633108
of O 0 0.00043639782
recurrence O 0 0.0041121067
during O 0 9.2764334e-05
the O 0 0.00011250616
first O 0 7.482481e-05
year O 0 7.967681e-05
, O 0 0.00011080447
80 O 0 0.00014312647
% O 0 0.00011475782
remained O 0 0.00019957112
tumor B-Disease 0 0.18842787
- O 0 0.00028959764
free O 0 0.00011947537
during O 0 4.4214183e-05
the O 0 9.237196e-05
2 O 0 9.476884e-05
- O 0 0.00017682502
to O 0 9.999322e-05
3 O 0 0.00011729769
- O 0 0.0002466262
year O 0 0.00012894403
follow O 0 0.0001743296
- O 0 0.00054707524
up O 0 0.000599239
period O 0 0.0006904328
. O 0 0.0017427134

Of O 0 0.0021564737
the O 0 0.0013235031
patients O 0 0.0012439828
developing O 0 0.001425277
one O 0 0.00027621895
or O 0 0.00021494715
more O 0 0.00030263106
recurrences O 0 0.0010207931
during O 0 6.428937e-05
the O 0 8.6771775e-05
first O 0 6.113634e-05
year O 0 6.8637084e-05
, O 0 9.6748445e-05
only O 0 9.785238e-05
50 O 0 0.00014863738
% O 0 8.4859654e-05
presented O 0 7.2675866e-05
with O 0 0.00012619593
further O 0 0.00022716355
recurrence O 0 0.0040417304
once O 0 0.00013540091
the O 0 0.0002424528
instillations O 0 0.000868551
were O 0 0.000720082
stopped O 0 0.002036712
. O 0 0.0019494095

The O 0 0.0016205513
beneficial O 0 0.0016772138
effect O 0 0.0009464947
of O 0 0.0017114312
Adriamycin B-Chemical 0 0.999488
appears O 0 0.000443954
obvious O 0 0.00026513627
and O 0 0.00020809745
might O 0 8.996756e-05
be O 0 8.122764e-05
related O 0 3.9443337e-05
to O 0 6.580099e-05
the O 0 0.00010094985
drug O 0 0.0021834853
itself O 0 0.00014661167
, O 0 0.000107686465
the O 0 7.451564e-05
early O 0 0.00012474396
and O 0 8.711087e-05
repeated O 0 6.619125e-05
instillations O 0 0.00028101413
after O 0 0.00012331975
TUR O 0 0.012263979
, O 0 0.00058072346
or O 0 0.0006553634
both O 0 0.001413673
. O 0 0.0020817637

D B-Chemical 0 0.9870351
- I-Chemical 0 0.09930098
penicillamine I-Chemical 1 0.9999323
- O 0 0.024434369
induced O 0 0.015913714
angiopathy B-Disease 0 0.99992514
in O 0 0.007654283
rats O 0 0.00957308
. O 0 0.0054858187

The O 0 0.0014514059
effect O 0 0.0010715806
of O 0 0.0010874246
high O 0 0.001555057
dose O 0 0.036177654
D B-Chemical 0 0.9975116
- I-Chemical 0 0.021656532
penicillamine I-Chemical 1 0.99999285
treatment O 0 0.0004656054
on O 0 0.00014225744
aortic O 0 0.07366382
permeability O 0 0.3802828
to O 0 0.00020334087
albumin O 0 0.83583677
and O 0 0.00020769247
on O 0 0.000106990854
the O 0 0.00021872953
ultrastructure O 0 0.00091274286
of O 0 0.0006478608
the O 0 0.0010203287
vessel O 0 0.017779106
. O 0 0.0024875447

Male O 0 0.015426277
Sprague O 0 0.066667035
- O 0 0.0031102842
Dawley O 0 0.005478628
rats O 0 0.00061946537
were O 0 0.00027567334
treated O 0 0.00035125436
with O 0 0.00062418915
D B-Chemical 0 0.992324
- I-Chemical 0 0.024071714
penicillamine I-Chemical 1 0.9999976
( O 0 0.008198628
D B-Chemical 1 0.99531376
- I-Chemical 1 0.0014856544
pen I-Chemical 1 0.016160868
) O 0 0.00032478804
500 O 0 0.00042886168
mg O 0 0.0034521946
/ O 0 0.0005297064
kg O 0 0.00036252404
/ O 0 0.0002844211
day O 0 8.629721e-05
for O 0 0.00011915087
10 O 0 0.00020903628
or O 0 0.00032113452
42 O 0 0.0006932093
days O 0 0.00061904284
. O 0 0.0016775826

Pair O 0 0.027329054
fed O 0 0.008510048
rats O 0 0.0064058206
served O 0 0.0063953344
as O 0 0.005149676
controls O 0 0.008959717
. O 0 0.008213693

Changes O 0 0.0022025313
in O 0 0.0014449806
aortic O 0 0.008626257
morphology O 0 0.0012979555
were O 0 0.00044430856
examined O 0 0.00024328643
by O 0 0.00035968778
light O 0 0.0012385878
- O 0 0.0006308026
and O 0 0.0003134658
transmission O 0 0.0004769603
- O 0 0.0008095784
electron O 0 0.003824266
microscopy O 0 0.0010581798
( O 0 0.0013095532
TEM O 0 0.010385246
) O 0 0.0030527203
. O 0 0.0026716662

In O 0 0.0017777602
addition O 0 0.0010329324
, O 0 0.0012037503
the O 0 0.00090495794
endothelial O 0 0.6811109
permeability O 0 0.65016097
and O 0 0.0003340419
the O 0 0.00018093507
penetration O 0 0.00043448238
through O 0 6.782586e-05
the O 0 9.4719675e-05
aortic O 0 0.0030567746
wall O 0 0.00036837152
of O 0 0.00017158217
albumin O 0 0.8834801
were O 0 0.00011803103
studied O 0 7.826477e-05
10 O 0 4.5384706e-05
minutes O 0 3.2700365e-05
, O 0 6.188964e-05
24 O 0 3.882644e-05
and O 0 4.8101632e-05
48 O 0 3.4156157e-05
hours O 0 2.4349489e-05
after O 0 2.4192166e-05
i O 0 0.00017145624
. O 0 6.0613478e-05
v O 0 0.000379617
. O 0 4.8936956e-05
injection O 0 7.634794e-05
of O 0 0.00011079421
human O 0 0.00021022555
serum O 0 0.090452716
131I O 0 0.99045616
- O 0 0.0016078601
albumin O 0 0.9865565
( O 0 0.0018547924
131I O 0 0.97309077
- O 0 0.0032645885
HSA O 0 0.9214267
) O 0 0.003940917
. O 0 0.0025133803

TEM O 0 0.013211851
revealed O 0 0.0018326873
extensive O 0 0.0016012402
elastolysis O 0 0.10320739
in O 0 0.00046001616
the O 0 0.00035084874
arterial O 0 0.009929638
wall O 0 0.0015340918
of O 0 0.00085901265
D B-Chemical 1 0.99127823
- I-Chemical 1 0.0019916992
pen I-Chemical 1 0.043176312
- O 0 0.00049799634
treated O 0 0.00027120556
rats O 0 0.00026270028
, O 0 0.0001315994
consistent O 0 9.792985e-05
with O 0 0.00014296253
an O 0 0.00019789003
inhibitory O 0 0.00060199766
effect O 0 0.00032844677
on O 0 0.00037578234
crosslink O 0 0.0049941926
formation O 0 0.0064950692
. O 0 0.0024530801

In O 0 0.0017103016
experimental O 0 0.0015590889
animals O 0 0.00073407666
excess O 0 0.0012735279
deposition O 0 0.0017479629
of O 0 0.00072784506
collagen O 0 0.088140935
and O 0 0.00041869844
glycoaminoglycans O 0 0.018519122
was O 0 0.00019041476
observed O 0 8.4814266e-05
in O 0 7.537109e-05
the O 0 8.839381e-05
subendothelial O 0 0.00049432775
and O 0 0.00010605331
medial O 0 0.00036804305
layer O 0 0.0002356055
of O 0 9.754188e-05
the O 0 0.00010120393
aortic O 0 0.011889752
wall O 0 0.0005429579
, O 0 0.000106088715
together O 0 7.8593024e-05
with O 0 0.00011849541
prominent O 0 0.0002586562
basal O 0 0.00030274704
membrane O 0 0.00048823535
substance O 0 0.047039524
around O 0 0.00029052512
aortic O 0 0.018315211
smooth O 0 0.0036543144
muscle O 0 0.0037576302
cells O 0 0.001833387
. O 0 0.0019048903

The O 0 0.0021925399
aorta O 0 0.029813575
/ O 0 0.0044644573
serum O 0 0.032991454
- O 0 0.0014846927
ratio O 0 0.0005791995
and O 0 0.00028003257
the O 0 0.00021576708
radioactive O 0 0.0009984047
build O 0 0.00038455983
- O 0 0.00029490425
up O 0 0.00010222359
24 O 0 5.845392e-05
and O 0 6.0985523e-05
48 O 0 3.811477e-05
hours O 0 2.4004044e-05
after O 0 2.0118678e-05
injection O 0 7.508628e-05
of O 0 0.00021149984
131I O 0 0.97549176
- O 0 0.00082783616
HSA O 0 0.9117786
was O 0 0.00015324513
reduced O 0 0.00014462156
in O 0 6.2061146e-05
animals O 0 4.9764243e-05
treated O 0 0.00013774485
with O 0 0.00031765318
D B-Chemical 1 0.98341537
- I-Chemical 1 0.00065909454
pen I-Chemical 1 0.0022654403
for O 0 5.686614e-05
42 O 0 7.78446e-05
days O 0 2.6286323e-05
, O 0 5.8037003e-05
indicating O 0 3.883629e-05
an O 0 7.623184e-05
impeded O 0 0.0001537747
transmural O 0 0.015781857
transport O 0 0.00024236912
of O 0 0.00011773988
tracer O 0 0.00044808042
which O 0 0.00011298705
may O 0 6.899335e-05
be O 0 7.1912305e-05
caused O 0 0.000103182174
by O 0 0.00012574693
a O 0 0.00021467065
steric O 0 0.0020080046
exclusion O 0 0.00036236283
effect O 0 0.00029403818
of O 0 0.0007823559
abundant O 0 0.0013015888
hyaluronate B-Chemical 0 0.9994117
. O 0 0.003519752

The O 0 0.0024894848
endothelial O 0 0.21138798
ultrastructure O 0 0.0058949655
was O 0 0.0011542647
unaffected O 0 0.0015386466
by O 0 0.0010857076
D B-Chemical 1 0.9867105
- I-Chemical 1 0.0022218334
pen I-Chemical 1 0.016312184
, O 0 0.00024722368
and O 0 0.00011852491
no O 0 5.2238618e-05
differences O 0 4.071643e-05
in O 0 9.217065e-05
aortic O 0 0.0574732
131I O 0 0.9583838
- O 0 0.00053693284
HSA O 0 0.79541135
radioactivity O 0 0.006829865
or O 0 9.950233e-05
aorta O 0 0.021631535
/ O 0 0.00049403147
serum O 0 0.014271902
- O 0 0.00022505535
ratio O 0 9.945728e-05
were O 0 4.6827674e-05
recorded O 0 3.2844597e-05
between O 0 2.249656e-05
experimental O 0 5.6378125e-05
and O 0 4.8317204e-05
control O 0 4.7414756e-05
groups O 0 4.1008614e-05
10 O 0 2.7385973e-05
minutes O 0 1.927431e-05
after O 0 1.9140887e-05
tracer O 0 0.00023612208
injection O 0 9.276752e-05
, O 0 7.640403e-05
indicating O 0 3.7044487e-05
that O 0 3.736281e-05
the O 0 7.980668e-05
permeability O 0 0.071787745
of O 0 0.00012118821
the O 0 0.0001117221
endothelial O 0 0.30310017
barrier O 0 0.00065885094
to O 0 0.00011713784
albumin O 0 0.86174816
remained O 0 0.00045943487
unaffected O 0 0.00079028343
by O 0 0.00069448346
D B-Chemical 1 0.9558543
- I-Chemical 1 0.0024970055
pen I-Chemical 1 0.022167461
treatment O 0 0.0018777979
. O 0 0.002185117

These O 0 0.0020328597
observations O 0 0.0013885775
support O 0 0.0006051456
the O 0 0.00049711566
hypothesis O 0 0.00043578443
that O 0 0.00018686788
treatment O 0 0.00022704336
with O 0 0.0002358658
high O 0 0.00045382397
doses O 0 0.0028730074
of O 0 0.0009428949
D B-Chemical 1 0.99656254
- I-Chemical 1 0.0015273686
pen I-Chemical 1 0.008263477
may O 0 8.2833205e-05
induce O 0 5.6292763e-05
a O 0 0.00015925776
fibroproliferative O 0 0.043336466
response O 0 0.000116193565
in O 0 8.882425e-05
rat O 0 0.00034530685
aorta O 0 0.022996023
, O 0 0.00011323502
possibly O 0 0.00013752133
by O 0 7.2508694e-05
an O 0 9.201828e-05
inhibitory O 0 0.0002656912
effect O 0 9.19219e-05
on O 0 6.539245e-05
the O 0 0.00013611082
cross O 0 0.00032863437
- O 0 0.00032401946
linking O 0 0.00021239872
of O 0 0.00058444095
collagen O 0 0.057677746
and O 0 0.0015631603
elastin O 0 0.14569888
. O 0 0.002568668

Effect O 0 0.0026414155
of O 0 0.0041114264
aspirin B-Chemical 0 0.9996885
on O 0 0.0017021568
N B-Chemical 0 0.9945016
- I-Chemical 0 0.0026943537
[ I-Chemical 0 0.0012511815
4 I-Chemical 0 0.00027036207
- I-Chemical 0 0.000481976
( I-Chemical 0 0.0003089943
5 I-Chemical 0 0.00018755638
- I-Chemical 0 0.00076280365
nitro I-Chemical 0 0.99943095
- I-Chemical 0 0.0010358321
2 I-Chemical 0 0.00021454603
- I-Chemical 0 0.0006386961
furyl I-Chemical 0 0.93233514
) I-Chemical 0 0.0006408735
- I-Chemical 0 0.0004302313
2 I-Chemical 0 0.00017194575
- I-Chemical 0 0.00074989686
thiazolyl I-Chemical 0 0.9990113
] I-Chemical 0 0.0018135727
- I-Chemical 0 0.00079055235
formamide I-Chemical 0 0.9516993
- O 0 0.0005713516
induced O 0 0.00023999054
epithelial O 0 0.004834551
proliferation O 0 0.11055327
in O 0 0.000110323694
the O 0 0.00013287406
urinary O 0 0.03764736
bladder O 0 0.030391525
and O 0 0.0005340068
forestomach O 0 0.77952355
of O 0 0.00076395815
the O 0 0.00085164676
rat O 0 0.003166837
. O 0 0.0018777463

The O 0 0.0025505072
co O 0 0.018320981
- O 0 0.002574997
administration O 0 0.0027448141
of O 0 0.0021735115
aspirin B-Chemical 0 0.99993384
with O 0 0.0053640367
N B-Chemical 0 0.9981824
- I-Chemical 0 0.0017298958
[ I-Chemical 0 0.00072937435
4 I-Chemical 0 0.00014949932
- I-Chemical 0 0.00029752782
( I-Chemical 0 0.00020339321
5 I-Chemical 0 0.00012899151
- I-Chemical 0 0.0005830995
nitro I-Chemical 0 0.9994549
- I-Chemical 0 0.0008705591
2 I-Chemical 0 0.00017961598
- I-Chemical 0 0.00055925077
furyl I-Chemical 0 0.9298275
) I-Chemical 0 0.0005759024
- I-Chemical 0 0.0003875934
2 I-Chemical 0 0.00015403844
- I-Chemical 0 0.00066935964
thiazolyl I-Chemical 0 0.99887556
] I-Chemical 0 0.0016063787
- I-Chemical 0 0.000757972
formamide I-Chemical 0 0.9774859
( O 0 0.0014878289
FANFT B-Chemical 0 0.99993384
) O 0 0.0003253924
to O 0 7.4992684e-05
rats O 0 0.00011117437
resulted O 0 6.7696616e-05
in O 0 6.476713e-05
a O 0 0.0001086223
reduced O 0 0.00020219402
incidence O 0 0.00042814703
of O 0 0.0006502749
FANFT B-Chemical 0 0.99996495
- O 0 0.00082381186
induced O 0 0.00042006673
bladder B-Disease 0 0.9504136
carcinomas I-Disease 0 0.98508716
but O 0 0.0002723934
a O 0 0.00027960146
concomitant O 0 0.00072353176
induction O 0 0.0006241963
of O 0 0.0025490157
forestomach B-Disease 0 0.99959797
tumors I-Disease 0 0.99851364
. O 0 0.0034334993

An O 0 0.0028063264
autoradiographic O 0 0.0027920813
study O 0 0.0010946492
was O 0 0.0005727665
performed O 0 0.00030852595
on O 0 0.00024211992
male O 0 0.0021388684
F O 0 0.12649904
- O 0 0.0006889796
344 O 0 0.0017678584
rats O 0 0.00020663434
fed O 0 0.00026958348
diet O 0 0.0019343956
containing O 0 0.00015844166
FANFT B-Chemical 0 0.9996426
at O 0 7.787037e-05
a O 0 0.000109562476
level O 0 6.0188733e-05
of O 0 0.00011422843
0 O 0 7.6328666e-05
. O 0 4.5378518e-05
2 O 0 4.9877748e-05
% O 0 6.3402425e-05
and O 0 7.356756e-05
/ O 0 0.00026517417
or O 0 0.00014733015
aspirin B-Chemical 0 0.99977607
at O 0 6.999956e-05
a O 0 0.000101387544
level O 0 5.564217e-05
of O 0 0.000106960564
0 O 0 6.9810296e-05
. O 0 3.9957198e-05
5 O 0 3.8394912e-05
% O 0 4.7919137e-05
to O 0 3.3483597e-05
evaluate O 0 2.3215842e-05
the O 0 4.7610087e-05
effect O 0 6.837982e-05
of O 0 0.0003434455
aspirin B-Chemical 0 0.9999306
on O 0 7.1922856e-05
the O 0 0.000108994784
increased O 0 0.00034633087
cell O 0 0.0027894645
proliferation O 0 0.42150065
induced O 0 0.0005197159
by O 0 0.0006947155
FANFT B-Chemical 0 0.99981624
in O 0 0.00042383908
the O 0 0.0006404671
forestomach O 0 0.8980387
and O 0 0.0015311693
bladder O 0 0.07244807
. O 0 0.0022525191

FANFT B-Chemical 0 0.99930775
- O 0 0.0070679937
induced O 0 0.0021370437
cell O 0 0.0057564573
proliferation O 0 0.18159635
in O 0 0.00037914285
the O 0 0.00031045475
bladder O 0 0.007611374
was O 0 0.00023591079
significantly O 0 0.00021382922
suppressed O 0 0.00034915138
by O 0 0.0005988412
aspirin B-Chemical 0 0.9999801
co O 0 0.33777305
- O 0 0.00054149213
administration O 0 0.0004161839
after O 0 4.1427422e-05
4 O 0 6.2169245e-05
weeks O 0 4.1529318e-05
but O 0 0.000111082176
not O 0 0.00013700356
after O 0 0.00013524966
12 O 0 0.00031187668
weeks O 0 0.0004631779
. O 0 0.001434516

In O 0 0.0024567773
the O 0 0.0027665722
forestomach O 0 0.8544061
, O 0 0.0012056981
and O 0 0.0005134169
also O 0 0.00030171548
in O 0 0.00024909712
the O 0 0.00033321427
liver O 0 0.8705092
, O 0 0.0013747416
aspirin B-Chemical 0 0.999949
did O 0 0.00030165192
not O 0 0.00012093875
affect O 0 8.588076e-05
the O 0 0.0003598051
FANFT B-Chemical 0 0.99987566
- O 0 0.00086187903
induced O 0 0.0003654158
increase O 0 0.000399361
in O 0 0.0004894485
labeling O 0 0.0012501928
index O 0 0.001879156
. O 0 0.0020190754

The O 0 0.0013396195
present O 0 0.0008428512
results O 0 0.0007695962
are O 0 0.00046116672
consistent O 0 0.00032051603
with O 0 0.00036432617
the O 0 0.00037214105
carcinogenicity O 0 0.9891137
experiment O 0 0.00013705413
suggesting O 0 5.607957e-05
that O 0 4.749024e-05
different O 0 4.3406126e-05
mechanisms O 0 8.1642705e-05
are O 0 6.0517017e-05
involved O 0 5.1067225e-05
in O 0 0.00016543857
FANFT B-Chemical 0 0.9999479
carcinogenesis B-Disease 0 0.9900267
in O 0 0.00010032713
the O 0 9.89725e-05
bladder O 0 0.011316875
and O 0 0.00022393971
forestomach O 0 0.9084924
, O 0 0.00012426646
and O 0 7.8578196e-05
that O 0 9.940208e-05
aspirin B-Chemical 0 0.99992526
' O 0 0.00018205059
s O 0 7.461519e-05
effect O 0 7.064965e-05
on O 0 8.66299e-05
FANFT B-Chemical 0 0.99982184
in O 0 0.00014677238
the O 0 0.00018970747
forestomach O 0 0.8694812
is O 0 0.00010255986
not O 0 6.0095714e-05
due O 0 4.353148e-05
to O 0 7.17152e-05
an O 0 0.00022412468
irritant O 0 0.83478665
effect O 0 0.0002385756
associated O 0 0.00027271357
with O 0 0.0005391673
increased O 0 0.0016910445
cell O 0 0.014065915
proliferation O 0 0.7561973
. O 0 0.0029987863

Also O 0 0.003921756
, O 0 0.0021966908
there O 0 0.0007220433
appears O 0 0.0005837568
to O 0 0.000452604
be O 0 0.00031728426
an O 0 0.00031414878
adaptation O 0 0.00031670398
by O 0 0.0002300562
the O 0 0.00019336633
rats O 0 0.00027951563
to O 0 0.00017450888
the O 0 0.00032113114
chronic O 0 0.09933318
ingestion O 0 0.39295983
of O 0 0.008547773
aspirin B-Chemical 0 0.99987614
. O 0 0.004034995

A O 0 0.023327596
case O 0 0.0044982308
of O 0 0.010559133
tardive B-Disease 0 0.999944
dyskinesia I-Disease 0 0.99996006
caused O 0 0.013532632
by O 0 0.012983164
metoclopramide B-Chemical 0 0.9998691
. O 0 0.008139547

Abnormal B-Disease 0 0.015123218
involuntary I-Disease 0 0.5264272
movements I-Disease 0 0.026686173
appeared O 0 0.0007509821
in O 0 0.0004222188
the O 0 0.000458764
mouth O 0 0.023417965
, O 0 0.0005174996
tongue O 0 0.006112475
, O 0 0.00037670703
neck O 0 0.004126517
and O 0 0.00022937194
abdomen O 0 0.0026042552
of O 0 0.00018126142
a O 0 0.00019948074
64 O 0 0.00022780319
- O 0 0.00021292671
year O 0 6.38407e-05
- O 0 0.00013873266
old O 0 7.961597e-05
male O 0 0.00019151838
patient O 0 4.9939143e-05
after O 0 1.8727122e-05
he O 0 5.0572613e-05
took O 0 7.943526e-05
metoclopramide B-Chemical 0 0.9999683
for O 0 0.00014524344
gastrointestinal B-Disease 0 0.998319
disorder I-Disease 0 0.9968893
in O 0 8.917169e-05
a O 0 9.308715e-05
regimen O 0 8.381346e-05
of O 0 6.833549e-05
30 O 0 4.767728e-05
mg O 0 0.00042987175
per O 0 2.5247871e-05
day O 0 3.7335663e-05
for O 0 5.4360964e-05
a O 0 0.00013626301
total O 0 0.00017266092
of O 0 0.00034059264
about O 0 0.00054266397
260 O 0 0.0069853775
days O 0 0.00071183854
. O 0 0.0016556917

The O 0 0.0032130112
symptoms O 0 0.012335658
exacerbated O 0 0.0053818584
to O 0 0.0014760245
a O 0 0.0015932347
maximum O 0 0.001218321
in O 0 0.0013899534
a O 0 0.0024729879
month O 0 0.0019203136
. O 0 0.003563806

When O 0 0.0014551779
the O 0 0.0024845873
metoclopramide B-Chemical 0 0.9999074
administration O 0 0.013330439
was O 0 0.00087403285
discontinued O 0 0.0015551508
, O 0 0.00031812754
the O 0 0.00025007612
abnormal B-Disease 0 0.029613342
movements I-Disease 0 0.0028366619
gradually O 0 0.0005730866
improved O 0 0.0006296638
to O 0 0.00035285848
a O 0 0.00069961045
considerable O 0 0.00081591203
extent O 0 0.0011807688
. O 0 0.0023020608

Attention O 0 0.0067545227
to O 0 0.0011587992
the O 0 0.0007540815
possible O 0 0.0005074254
induction O 0 0.00053205225
of O 0 0.00064080657
specific O 0 0.0009148185
tardive B-Disease 0 0.99999464
dyskinesia I-Disease 0 0.99999547
is O 0 0.00048913906
called O 0 0.00022698425
for O 0 0.00012591973
in O 0 0.00015951735
the O 0 0.00020585739
use O 0 0.00026705727
of O 0 0.00055467174
this O 0 0.001264163
drug O 0 0.04856991
. O 0 0.0025154662

Intra O 0 0.019729592
- O 0 0.0043576523
arterial O 0 0.085692614
BCNU B-Chemical 0 0.99940765
chemotherapy O 0 0.0085593825
for O 0 0.00042668675
treatment O 0 0.00049328664
of O 0 0.0010135203
malignant B-Disease 0 0.9884482
gliomas I-Disease 0 0.9992009
of O 0 0.0009603094
the O 0 0.00058565603
central O 0 0.0011207649
nervous O 0 0.021044953
system O 0 0.0023757513
. O 0 0.0024494706

Because O 0 0.0013525584
of O 0 0.0013827893
the O 0 0.00085778907
rapid O 0 0.00154552
systemic O 0 0.08737884
clearance O 0 0.017232906
of O 0 0.0017439962
BCNU B-Chemical 0 0.99990964
( O 0 0.000919368
1 B-Chemical 0 0.00020981167
, I-Chemical 0 0.00020407156
3 I-Chemical 0 0.00014205195
- I-Chemical 0 0.0004329124
bis I-Chemical 0 0.25903162
- I-Chemical 0 0.0006441336
( I-Chemical 0 0.00026712858
2 I-Chemical 0 0.00014281877
- I-Chemical 0 0.00044827562
chloroethyl I-Chemical 0 0.8631295
) I-Chemical 0 0.00051655783
- I-Chemical 0 0.00033374262
1 I-Chemical 0 0.00012402922
- I-Chemical 0 0.000362239
nitrosourea I-Chemical 0 0.9749747
) O 0 0.0003581183
, O 0 0.0001373955
intra O 0 0.00038256336
- O 0 0.00022753747
arterial O 0 0.0070163254
administration O 0 0.00034724132
should O 0 3.2339416e-05
provide O 0 3.9226336e-05
a O 0 6.292436e-05
substantial O 0 5.3259428e-05
advantage O 0 3.335767e-05
over O 0 3.351717e-05
intravenous O 0 0.00095181074
administration O 0 0.00034069963
for O 0 9.739492e-05
the O 0 0.00017457978
treatment O 0 0.00033631158
of O 0 0.0013698797
malignant B-Disease 0 0.9964888
gliomas I-Disease 0 0.9996166
. O 0 0.0041555986

Thirty O 0 0.0035156938
- O 0 0.0022039465
six O 0 0.00048678272
patients O 0 0.0006033654
were O 0 0.00033678196
treated O 0 0.00040140792
with O 0 0.00051042816
BCNU B-Chemical 0 0.999288
every O 0 6.99015e-05
6 O 0 6.368627e-05
to O 0 6.362173e-05
8 O 0 5.4782642e-05
weeks O 0 2.838645e-05
, O 0 6.1611405e-05
either O 0 5.6634894e-05
by O 0 7.463554e-05
transfemoral O 0 0.00013851008
catheterization O 0 0.0001224599
of O 0 4.7629565e-05
the O 0 3.8903945e-05
internal O 0 9.161701e-05
carotid O 0 0.033055995
or O 0 8.5753745e-05
vertebral O 0 0.044000823
artery O 0 0.0087886825
or O 0 5.9770056e-05
through O 0 3.784751e-05
a O 0 6.7146524e-05
fully O 0 6.985931e-05
implantable O 0 0.0003312025
intracarotid O 0 0.3032161
drug O 0 0.0013498296
delivery O 0 4.665793e-05
system O 0 6.8464964e-05
, O 0 6.230902e-05
beginning O 0 3.5235815e-05
with O 0 7.904806e-05
a O 0 0.0001145949
dose O 0 0.00032392217
of O 0 0.00018334245
200 O 0 0.0005618085
mg O 0 0.0074241157
/ O 0 0.0010375334
sq O 0 0.0017787032
m O 0 0.0010327386
body O 0 0.0012597488
surface O 0 0.0013045805
area O 0 0.0015846746
. O 0 0.0020408914

Twelve O 0 0.0037982785
patients O 0 0.0016836567
with O 0 0.0011833124
Grade O 0 0.016628727
III O 0 0.005672218
or O 0 0.00049905846
IV O 0 0.14078707
astrocytomas B-Disease 0 0.9978765
were O 0 0.00024960827
treated O 0 0.00016547342
after O 0 4.4898607e-05
partial O 0 0.00020206452
resection O 0 0.00044630488
of O 0 0.00015795232
the O 0 0.00017584767
tumor B-Disease 0 0.04552308
without O 0 0.00027034848
prior O 0 0.0002633985
radiation O 0 0.008420404
therapy O 0 0.0025944444
. O 0 0.001999927

After O 0 0.0009207122
two O 0 0.00073663384
to O 0 0.00054323376
seven O 0 0.000337695
cycles O 0 0.00022744204
of O 0 0.00037754938
chemotherapy O 0 0.0020304024
, O 0 0.00029380532
nine O 0 0.00018613611
patients O 0 0.00020602703
showed O 0 0.00011874584
a O 0 0.00015191476
decrease O 0 0.00016174355
in O 0 0.0001253074
tumor B-Disease 0 0.08674302
size O 0 0.00027102823
and O 0 0.00015304374
surrounding O 0 0.0002803521
edema B-Disease 0 0.9996629
on O 0 0.00015304054
contrast O 0 0.0004954249
- O 0 0.00055116636
enhanced O 0 0.00061148946
computerized O 0 0.002484444
tomography O 0 0.013924564
scans O 0 0.004171284
. O 0 0.0022966769

In O 0 0.0015078742
the O 0 0.0011079299
nine O 0 0.0008102973
responders O 0 0.0012623798
, O 0 0.00037370887
median O 0 0.00012694458
duration O 0 8.619696e-05
of O 0 0.00018626163
chemotherapy O 0 0.0007090404
response O 0 0.00011308374
from O 0 6.96282e-05
the O 0 6.28461e-05
time O 0 3.540308e-05
of O 0 8.2223996e-05
operation O 0 6.8547604e-05
was O 0 8.510918e-05
25 O 0 9.575161e-05
weeks O 0 3.4359953e-05
( O 0 9.563298e-05
range O 0 7.791872e-05
12 O 0 5.7453417e-05
to O 0 9.371667e-05
more O 0 0.00022610063
than O 0 0.00022970726
91 O 0 0.0008095469
weeks O 0 0.00037442578
) O 0 0.0015580412
. O 0 0.0019034041

The O 0 0.0013193242
median O 0 0.0006869765
duration O 0 0.0004219768
of O 0 0.0006550617
survival O 0 0.0017338679
in O 0 0.00027386445
the O 0 0.00019719571
12 O 0 0.00010462286
patients O 0 0.00017832196
was O 0 0.00012734723
54 O 0 0.00014524123
weeks O 0 3.7775895e-05
( O 0 9.2211965e-05
range O 0 6.787827e-05
21 O 0 6.346631e-05
to O 0 4.7720496e-05
more O 0 8.856375e-05
than O 0 5.7849582e-05
156 O 0 0.00022174363
weeks O 0 3.9580944e-05
) O 0 0.00013149416
, O 0 9.758383e-05
with O 0 0.00011320004
an O 0 0.00016300054
18 O 0 0.0001268813
- O 0 0.00020018288
month O 0 8.346141e-05
survival O 0 0.00056864176
rate O 0 0.00034215607
of O 0 0.0006416157
42 O 0 0.0010747182
% O 0 0.0014572914
. O 0 0.0019194504

Twenty O 0 0.0037987696
- O 0 0.0021479435
four O 0 0.0005051909
patients O 0 0.0006152561
with O 0 0.00050410425
recurrent O 0 0.003587686
Grade O 0 0.05383548
I O 0 0.0032152035
to O 0 0.00026384136
IV O 0 0.18831423
astrocytomas B-Disease 0 0.9990044
, O 0 0.00025301642
whose O 0 0.0002371561
resection O 0 0.00051052845
and O 0 9.2592614e-05
irradiation O 0 0.00063254486
therapy O 0 0.00018261524
had O 0 8.865314e-05
failed O 0 0.00010998421
, O 0 9.137951e-05
received O 0 4.6410445e-05
two O 0 3.5024626e-05
to O 0 4.4637978e-05
eight O 0 4.5987148e-05
courses O 0 8.3379164e-05
of O 0 0.00017906127
intra O 0 0.0008362911
- O 0 0.00089540746
arterial O 0 0.3132121
BCNU B-Chemical 0 0.99962723
therapy O 0 0.005063099
. O 0 0.0023645307

Seventeen O 0 0.004700511
of O 0 0.0015726426
these O 0 0.0010882762
had O 0 0.0005489881
a O 0 0.00042766976
response O 0 0.00028665725
or O 0 0.00019772064
were O 0 0.00015729477
stable O 0 0.0001349943
for O 0 7.3436975e-05
a O 0 0.00011451525
median O 0 5.077344e-05
of O 0 0.00010017055
20 O 0 8.835085e-05
weeks O 0 4.183447e-05
( O 0 0.000115037095
range O 0 9.450694e-05
6 O 0 6.7282475e-05
to O 0 9.874427e-05
more O 0 0.00023137075
than O 0 0.00022622291
66 O 0 0.0006214908
weeks O 0 0.00037869834
) O 0 0.0015891546
. O 0 0.001946443

The O 0 0.0018840053
catheterization O 0 0.0027465667
procedure O 0 0.0009205711
is O 0 0.0007024518
safe O 0 0.0007513042
, O 0 0.0004708812
with O 0 0.0003305089
no O 0 0.00019411984
immediate O 0 0.0005543523
complication O 0 0.0036658605
in O 0 0.00043015278
111 O 0 0.0014342032
infusions O 0 0.0022437691
of O 0 0.0024489139
BCNU B-Chemical 0 0.99919873
. O 0 0.0040847575

A O 0 0.022532208
delayed O 0 0.0064985193
complication O 0 0.01053748
in O 0 0.0007925482
nine O 0 0.00057075074
patients O 0 0.00054606335
has O 0 0.00023094009
been O 0 0.00022420121
unilateral O 0 0.0043482156
loss B-Disease 0 0.0036147782
of I-Disease 0 0.00081434916
vision I-Disease 0 0.909725
secondary O 0 0.0028824033
to O 0 0.0006880865
a O 0 0.0026714553
retinal B-Disease 0 0.9960478
vasculitis I-Disease 2 0.9997687
. O 0 0.0045478255

The O 0 0.0016101549
frequency O 0 0.0015060761
of O 0 0.0015386714
visual B-Disease 2 0.19190265
loss I-Disease 2 0.014940768
decreased O 0 0.0010463109
after O 0 0.00014359043
the O 0 0.00023228893
concentration O 0 0.00049000495
of O 0 0.0004583522
the O 0 0.000703387
ethanol B-Chemical 1 0.9995529
diluent O 0 0.3500567
was O 0 0.0023973305
lowered O 0 0.017298132
. O 0 0.002938712

Provocation O 0 0.024827149
of O 0 0.0040801917
postural O 0 0.94409555
hypotension B-Disease 0 0.9999031
by O 0 0.0105469655
nitroglycerin B-Chemical 0 0.99995077
in O 0 0.008086686
diabetic B-Disease 2 0.99993336
autonomic I-Disease 0 0.99898297
neuropathy I-Disease 0 0.99998116
? O 0 0.05364845

The O 0 0.0014760674
effect O 0 0.0012719417
of O 0 0.00242163
nitroglycerin B-Chemical 0 0.9998877
on O 0 0.00043797266
heart O 0 0.010366157
rate O 0 0.00028165252
and O 0 0.00019820046
systolic O 0 0.044017587
blood O 0 0.001811697
pressure O 0 0.0014180162
was O 0 9.70705e-05
compared O 0 4.003111e-05
in O 0 4.9442915e-05
5 O 0 4.050351e-05
normal O 0 0.00011885992
subjects O 0 9.303364e-05
, O 0 7.591113e-05
12 O 0 5.536065e-05
diabetic B-Disease 2 0.9926663
subjects O 0 0.00015735762
without O 0 0.0001487179
autonomic B-Disease 0 0.97437686
neuropathy I-Disease 0 0.9999956
, O 0 0.00040474877
and O 0 0.0001895491
5 O 0 0.0001724255
diabetic B-Disease 2 0.99609715
subjects O 0 0.0005676405
with O 0 0.0009853556
autonomic B-Disease 0 0.973584
neuropathy I-Disease 0 0.999966
. O 0 0.0043417388

The O 0 0.0015253105
magnitude O 0 0.0010524081
and O 0 0.0007243776
time O 0 0.00030152252
course O 0 0.00029481426
of O 0 0.00031982924
the O 0 0.00021459062
increase O 0 0.00018780654
in O 0 0.00016653491
heart O 0 0.0069439034
rate O 0 0.00015770401
and O 0 9.448639e-05
the O 0 6.702907e-05
decrease O 0 8.622089e-05
in O 0 6.273568e-05
systolic O 0 0.02278736
blood O 0 0.00090667495
pressure O 0 0.0008437535
after O 0 4.438152e-05
nitroglycerin B-Chemical 0 0.9999554
were O 0 6.82183e-05
similar O 0 2.5100251e-05
in O 0 3.1269057e-05
the O 0 3.9744456e-05
normal O 0 0.00013793845
and O 0 0.000121697754
diabetic B-Disease 2 0.99908173
subjects O 0 0.00017190479
without O 0 0.00013667005
autonomic B-Disease 0 0.9875596
neuropathy I-Disease 0 0.99999785
, O 0 0.0003695232
whereas O 0 0.00012377075
a O 0 0.00016440291
lesser O 0 0.00037363637
increase O 0 7.8791585e-05
in O 0 7.388562e-05
heart O 0 0.0054370104
rate O 0 9.591088e-05
and O 0 6.816256e-05
a O 0 7.500084e-05
greater O 0 6.2771345e-05
decrease O 0 8.72111e-05
in O 0 6.777658e-05
systolic O 0 0.034001827
blood O 0 0.0010481366
pressure O 0 0.00072594633
occurred O 0 7.1219605e-05
in O 0 8.627146e-05
the O 0 0.000205278
diabetic B-Disease 2 0.99879634
subjects O 0 0.00067178375
with O 0 0.0011013256
autonomic B-Disease 0 0.98104
neuropathy I-Disease 0 0.9999697
. O 0 0.0043837936

It O 0 0.0027992784
is O 0 0.0013419349
therefore O 0 0.0008024349
suggested O 0 0.00039893916
that O 0 0.00028192115
caution O 0 0.00025761314
should O 0 0.000119936165
be O 0 0.00014241243
exercised O 0 0.0002452039
when O 0 7.471972e-05
prescribing O 0 0.00067621976
vasodilator O 0 0.8629826
drugs O 0 0.035150785
in O 0 0.00032804903
diabetic B-Disease 2 0.99968815
patients O 0 0.00048585923
, O 0 0.00019524735
particularly O 0 0.00023689326
those O 0 0.00042729834
with O 0 0.0010907926
autonomic B-Disease 0 0.9811819
neuropathy I-Disease 0 0.99996924
. O 0 0.004711591

Blood O 0 0.012677376
pressure O 0 0.0060172128
response O 0 0.0012408384
to O 0 0.0009250759
chronic O 0 0.035942882
low O 0 0.0017280688
- O 0 0.0010881646
dose O 0 0.002480235
intrarenal O 0 0.9505253
noradrenaline B-Chemical 1 0.9998796
infusion O 0 0.0022038964
in O 0 0.00064367754
conscious O 0 0.0037543403
rats O 0 0.0023679389
. O 0 0.0020415587

Sodium B-Chemical 0 0.99986446
chloride I-Chemical 0 0.9999051
solution O 0 0.22688814
( O 0 0.0020530752
0 O 0 0.0005661238
. O 0 0.00026812777
9 O 0 0.00022688364
% O 0 0.00025940101
) O 0 0.0003135432
or O 0 0.0002453115
noradrenaline B-Chemical 1 0.999509
in O 0 0.00019670486
doses O 0 0.00081031397
of O 0 0.00018930272
4 O 0 7.972316e-05
, O 0 7.939489e-05
12 O 0 3.6143e-05
and O 0 5.5653683e-05
36 O 0 6.233101e-05
micrograms O 0 0.000374722
h O 0 9.005554e-05
- O 0 0.00019178097
1 O 0 7.76394e-05
kg O 0 0.00022105883
- O 0 0.00015135073
1 O 0 5.472693e-05
was O 0 5.6706336e-05
infused O 0 9.379016e-05
for O 0 3.325771e-05
five O 0 2.6270563e-05
consecutive O 0 3.6892754e-05
days O 0 2.4288609e-05
, O 0 6.178963e-05
either O 0 8.806217e-05
intrarenally O 0 0.14618257
( O 0 0.00016784773
by O 0 8.243298e-05
a O 0 0.00010599892
new O 0 0.00011071353
technique O 0 0.00015135363
) O 0 0.00014053479
or O 0 6.4959e-05
intravenously O 0 0.00010697128
into O 0 5.5566292e-05
rats O 0 0.00020498775
with O 0 0.00027284492
one O 0 0.00038100997
kidney O 0 0.31944516
removed O 0 0.0016307833
. O 0 0.0020029235

Intrarenal O 0 0.21610129
infusion O 0 0.004034225
of O 0 0.0026675276
noradrenaline B-Chemical 1 0.9997477
caused O 0 0.0031175106
hypertension B-Disease 2 0.9999207
at O 0 0.00036564615
doses O 0 0.0021927676
which O 0 0.00035639445
did O 0 0.00026075364
not O 0 0.00019220843
do O 0 0.00023170984
so O 0 0.00022968577
when O 0 0.00027492634
infused O 0 0.0014451591
intravenously O 0 0.001961823
. O 0 0.0021254942

Intrarenal O 0 0.10051844
compared O 0 0.0008746651
with O 0 0.00083168974
intravenous O 0 0.0044989507
infusion O 0 0.0010326038
of O 0 0.0007313817
noradrenaline B-Chemical 1 0.9997911
caused O 0 0.0002974938
higher O 0 0.00033046512
plasma O 0 0.09275336
noradrenaline B-Chemical 1 0.9999434
concentrations O 0 0.0007101203
and O 0 0.00011379594
a O 0 0.000108684864
shift O 0 0.0001259615
of O 0 8.615077e-05
the O 0 9.871179e-05
plasma O 0 0.0319342
noradrenaline B-Chemical 1 0.9999305
concentration O 0 0.00075504504
- O 0 0.00030369405
blood O 0 0.0009641278
pressure O 0 0.00084806175
effect O 0 0.0001002664
curve O 0 0.00023669099
towards O 0 0.00016932692
lower O 0 0.0005720949
plasma O 0 0.081957616
noradrenaline B-Chemical 1 0.9996125
levels O 0 0.0023653924
. O 0 0.002226141

These O 0 0.0018677304
results O 0 0.0010922088
suggest O 0 0.00045886677
that O 0 0.00065414276
hypertension B-Disease 2 0.9996817
after O 0 0.00022495196
chronic O 0 0.19237682
intrarenal O 0 0.9906218
noradrenaline B-Chemical 1 0.9999733
infusion O 0 0.0011131756
is O 0 0.00010354065
produced O 0 7.261969e-05
by O 0 7.472185e-05
relatively O 0 0.00010530378
higher O 0 8.894749e-05
levels O 0 8.041853e-05
of O 0 0.00017247334
circulating O 0 0.012610347
noradrenaline B-Chemical 1 0.9999261
and O 0 0.00018270896
by O 0 0.00011361857
triggering O 0 0.00013629731
of O 0 0.00016824895
an O 0 0.00023805731
additional O 0 0.00023977461
intrarenal O 0 0.44307244
pressor O 0 0.48300266
mechanism O 0 0.0019440433
. O 0 0.001958491

Characterization O 0 0.0032190217
of O 0 0.005076736
estrogen B-Chemical 1 0.9992285
- O 0 0.004280506
induced O 0 0.0022886533
adenohypophyseal B-Disease 0 0.9428292
tumors I-Disease 0 0.9788036
in O 0 0.0010228745
the O 0 0.0011680062
Fischer O 0 0.010318993
344 O 0 0.010368039
rat O 0 0.0040346193
. O 0 0.0025594751

Pituitary B-Disease 0 0.8033113
tumors I-Disease 0 0.94464755
were O 0 0.0013344492
induced O 0 0.0008382377
in O 0 0.00059979275
F344 O 0 0.14902055
female O 0 0.0012147957
rats O 0 0.00029587897
by O 0 0.00017282662
chronic O 0 0.012773605
treatment O 0 0.00022832154
with O 0 0.0007351282
diethylstilbestrol B-Chemical 0 0.9999856
( O 0 0.003120026
DES B-Chemical 0 0.999508
, O 0 0.00024848987
8 O 0 0.000103999875
- O 0 0.00018286302
10 O 0 0.00011143206
mg O 0 0.0016330968
) O 0 0.00027026443
implanted O 0 0.00025717483
subcutaneously O 0 0.00028866975
in O 0 0.00044060583
silastic O 0 0.003875873
capsules O 0 0.00539239
. O 0 0.001975855

Over O 0 0.0024060865
a O 0 0.0017609835
range O 0 0.0010295381
of O 0 0.00089162396
1 O 0 0.0005230358
- O 0 0.0005788804
150 O 0 0.0003190539
days O 0 0.000101280486
of O 0 0.0003586814
DES B-Chemical 0 0.99677485
treatment O 0 0.00024428777
, O 0 0.00014386972
pairs O 0 8.228801e-05
of O 0 0.000105452586
control O 0 0.00011928309
and O 0 0.0003076099
DES B-Chemical 0 0.99953914
- O 0 0.00042593267
treated O 0 0.00017689452
rats O 0 0.00014875675
were O 0 6.415048e-05
sacrificed O 0 4.4178447e-05
, O 0 8.098794e-05
and O 0 8.048797e-05
their O 0 0.00012565812
pituitaries O 0 0.001602626
dissociated O 0 0.00022971822
enzymatically O 0 0.0008492958
into O 0 9.58033e-05
single O 0 0.00031190016
- O 0 0.00080816366
cell O 0 0.0020962371
preparations O 0 0.0023054564
. O 0 0.0021171174

The O 0 0.0020919163
cell O 0 0.0036712042
populations O 0 0.0011735321
were O 0 0.00044859535
examined O 0 0.00019734207
regarding O 0 0.00013668934
total O 0 0.00022551308
cell O 0 0.00056473556
recovery O 0 0.0003059017
correlated O 0 9.189087e-05
with O 0 0.000174104
gland O 0 0.003635273
weight O 0 0.00076302676
, O 0 0.00013739511
intracellular O 0 0.000281364
prolactin O 0 0.9778953
( O 0 0.0008758473
PRL O 0 0.999881
) O 0 0.0002704098
content O 0 0.00013021372
and O 0 7.4555595e-05
subsequent O 0 7.586641e-05
release O 0 0.0002503142
in O 0 5.6297114e-05
primary O 0 7.7523095e-05
culture O 0 0.00014492482
, O 0 0.0001158263
immunocytochemical O 0 0.0005701059
PRL O 0 0.999819
staining O 0 0.000190004
, O 0 9.913061e-05
density O 0 0.00022099183
and O 0 9.7663615e-05
/ O 0 0.00021837944
or O 0 5.253516e-05
size O 0 9.422906e-05
alterations O 0 0.00014015312
via O 0 3.1831863e-05
separation O 0 9.5421645e-05
on O 0 4.3937365e-05
Ficoll O 0 0.10770013
- O 0 0.00052323006
Hypaque O 0 0.9596823
and O 0 0.00011692581
by O 0 7.523199e-05
unit O 0 6.408554e-05
gravity O 0 0.0006266661
sedimentation O 0 0.00077002164
, O 0 0.00012287864
and O 0 0.000106242194
cell O 0 0.0003640309
cycle O 0 0.00016093865
analysis O 0 9.033068e-05
, O 0 0.0001066541
after O 0 6.87575e-05
acriflavine B-Chemical 0 0.9942952
DNA O 0 0.03766052
staining O 0 0.00038642777
, O 0 0.00034217502
by O 0 0.00043032525
laser O 0 0.001970643
flow O 0 0.0030721857
cytometry O 0 0.0020223833
. O 0 0.0020817064

Total O 0 0.0029693816
cell O 0 0.0038867686
yields O 0 0.002202433
from O 0 0.0013050782
DES B-Chemical 0 0.99885523
- O 0 0.001416916
treated O 0 0.0006159152
pituitaries O 0 0.0060042385
increased O 0 0.00033629988
from O 0 0.00013302112
1 O 0 9.504759e-05
. O 0 4.800384e-05
3 O 0 3.798563e-05
times O 0 2.5556763e-05
control O 0 4.804314e-05
yields O 0 0.00011596533
at O 0 4.363472e-05
8 O 0 4.1146934e-05
days O 0 2.3525905e-05
of O 0 6.788655e-05
treatment O 0 7.947631e-05
to O 0 8.291026e-05
58 O 0 0.0001554843
. O 0 5.7157224e-05
9 O 0 6.0546976e-05
times O 0 4.8338814e-05
control O 0 0.00012023285
values O 0 0.00024331217
by O 0 0.0004121723
day O 0 0.000509364
150 O 0 0.0017338101
. O 0 0.0019549753

Intracellular O 0 0.009328199
PRL O 0 0.9968695
content O 0 0.0018739054
ranged O 0 0.00071973563
from O 0 0.0004317292
1 O 0 0.00031916797
. O 0 0.00017138613
9 O 0 0.00014739408
to O 0 0.00012722124
9 O 0 0.00011490894
. O 0 6.6982546e-05
4 O 0 5.1715644e-05
times O 0 3.4841e-05
control O 0 6.557692e-05
levels O 0 0.00010337896
, O 0 0.00016267062
and O 0 0.00028539464
PRL O 0 0.9998528
release O 0 0.0012042542
in O 0 9.726555e-05
vitro O 0 0.0001582345
was O 0 0.00010585367
significantly O 0 0.00011155634
and O 0 7.064965e-05
consistently O 0 6.782844e-05
higher O 0 8.842131e-05
than O 0 5.405859e-05
controls O 0 0.0001490616
, O 0 7.7274e-05
after O 0 2.8929308e-05
at O 0 5.3259326e-05
least O 0 8.027281e-05
8 O 0 0.00010963689
days O 0 0.00011405558
of O 0 0.0007125397
DES B-Chemical 0 0.9917812
exposure O 0 0.0035120372
. O 0 0.0025692496

Beyond O 0 0.0030951195
8 O 0 0.0011420634
days O 0 0.0005453588
of O 0 0.0012422932
DES B-Chemical 0 0.99310935
exposure O 0 0.0011368098
, O 0 0.00056391314
the O 0 0.0004934817
immunochemically O 0 0.629267
PRL O 0 0.999912
- O 0 0.0007946179
positive O 0 0.00020973264
proportion O 0 0.00013639028
of O 0 0.00017921087
cells O 0 0.00021212953
increased O 0 0.00020621846
to O 0 0.000104357016
over O 0 6.817927e-05
50 O 0 0.00022739086
% O 0 0.00019498578
of O 0 0.00027270577
the O 0 0.00037490283
total O 0 0.0007941949
population O 0 0.0024557656
. O 0 0.002130047

Increased O 0 0.003666533
density O 0 0.003035195
and O 0 0.0012577137
/ O 0 0.0016170887
or O 0 0.00042936337
size O 0 0.0006751961
and O 0 0.0006371302
PRL O 0 0.9994666
content O 0 0.0005066144
were O 0 0.00014359536
indicated O 0 7.00232e-05
for O 0 5.6141424e-05
the O 0 7.132523e-05
majority O 0 9.4863775e-05
of O 0 0.0001549299
the O 0 0.00027540853
PRL O 0 0.99983275
cell O 0 0.0016690594
population O 0 0.0003614253
in O 0 0.0001362139
both O 0 0.00016701261
types O 0 0.00016141417
of O 0 0.00044852955
separation O 0 0.0013693814
protocols O 0 0.001444841
. O 0 0.0018543211

All O 0 0.0018379233
these O 0 0.0016072532
effects O 0 0.001396002
of O 0 0.0023233148
DES B-Chemical 0 0.9967449
were O 0 0.00084016286
more O 0 0.0007748252
pronounced O 0 0.00097641966
among O 0 0.00079247187
previously O 0 0.0010043589
ovariectomized O 0 0.09221356
animals O 0 0.0017747434
. O 0 0.0025137798

The O 0 0.0015734334
data O 0 0.0013064991
extend O 0 0.000679793
the O 0 0.00054526725
findings O 0 0.0006989014
of O 0 0.00045974023
other O 0 0.00027439688
investigators O 0 0.0002625891
, O 0 0.00020494082
further O 0 0.00019652207
establishing O 0 0.00020395544
the O 0 0.00037635327
DES B-Chemical 0 0.99958867
- O 0 0.00060958025
induced O 0 0.0002790369
tumor B-Disease 0 0.29945242
as O 0 0.00014626495
a O 0 0.000155219
model O 0 0.000129053
for O 0 0.00010047678
study O 0 0.00022994872
of O 0 0.00056452997
PRL O 0 0.99924195
cellular O 0 0.0014766963
control O 0 0.00079290627
mechanisms O 0 0.0016300102
. O 0 0.0020039054

Age O 0 0.02163782
and O 0 0.007861993
renal O 0 0.728686
clearance O 0 0.1200746
of O 0 0.02737348
cimetidine B-Chemical 1 0.9998653
. O 0 0.0155130755

In O 0 0.0019564405
35 O 0 0.001763671
patients O 0 0.0014366016
( O 0 0.0009231982
ages O 0 0.00048038806
20 O 0 0.00023964251
to O 0 0.00016012936
86 O 0 0.0003035835
yr O 0 0.0001719138
) O 0 0.0002266644
receiving O 0 0.00051720964
cimetidine B-Chemical 1 0.99999106
therapeutically O 0 0.0017809725
two O 0 7.5229626e-05
serum O 0 0.0027243383
samples O 0 0.00010311805
and O 0 7.5733486e-05
all O 0 7.604509e-05
urine O 0 0.008800609
formed O 0 9.670759e-05
in O 0 4.7119964e-05
the O 0 5.0858245e-05
interim O 0 0.0002323215
were O 0 4.3779735e-05
collected O 0 2.3830129e-05
for O 0 3.166866e-05
analysis O 0 6.911181e-05
of O 0 0.0003331215
cimetidine B-Chemical 1 0.9999937
by O 0 0.00024787485
high O 0 0.00048069592
- O 0 0.0004414601
pressure O 0 0.003219993
liquid O 0 0.00418317
chromatography O 0 0.02713342
and O 0 0.0004805333
for O 0 0.00075904257
creatinine B-Chemical 1 0.9975715
. O 0 0.002972752

Cimetidine B-Chemical 0 0.9991392
clearance O 0 0.105171844
decreased O 0 0.0151006365
with O 0 0.010224658
age O 0 0.011653818
. O 0 0.010070218

The O 0 0.0017211286
extrapolated O 0 0.0015729323
6 O 0 0.0006775999
- O 0 0.0008795844
hr O 0 0.0005110547
serum O 0 0.003701234
concentration O 0 0.0009809537
of O 0 0.0012875408
cimetidine B-Chemical 1 0.9999908
per O 0 8.239347e-05
unit O 0 0.000100967285
dose O 0 0.00039428496
, O 0 0.00011666297
after O 0 5.6489098e-05
intravenous O 0 0.17367956
cimetidine B-Chemical 1 0.999995
, O 0 0.0003935107
increased O 0 0.00037282705
with O 0 0.00032884345
age O 0 0.00033775056
of O 0 0.0004708758
the O 0 0.0007401148
patients O 0 0.0020315873
. O 0 0.0018813411

The O 0 0.0015476128
ratio O 0 0.0019351193
of O 0 0.0025572022
cimetidine B-Chemical 1 0.99996996
clearance O 0 0.05469263
to O 0 0.0007416939
creatinine B-Chemical 1 0.9993237
clearance O 0 0.11447067
( O 0 0.0009538666
Rc O 0 0.35077178
) O 0 0.00025388395
averaged O 0 7.337236e-05
4 O 0 8.289824e-05
. O 0 6.787865e-05
8 O 0 8.92144e-05
+ O 0 0.00025672678
/ O 0 0.0005034829
- O 0 0.00031940572
2 O 0 0.000108320455
. O 0 7.680156e-05
0 O 0 0.000103251376
, O 0 0.00015141082
indicating O 0 0.00013353482
net O 0 0.00038804652
tubular O 0 0.06660822
secretion O 0 0.0058092424
for O 0 0.0019074631
cimetidine B-Chemical 1 0.9999566
. O 0 0.0039948006

Rc O 0 0.3137143
seemed O 0 0.0025096352
to O 0 0.0009630352
be O 0 0.0005202623
independent O 0 0.00024854863
of O 0 0.0004088318
age O 0 0.00032779734
and O 0 0.00019853863
decreased O 0 0.00034132434
with O 0 0.00018691296
increasing O 0 0.00020718062
serum O 0 0.021228343
concentration O 0 0.0010006513
of O 0 0.002442909
cimetidine B-Chemical 1 0.9999981
, O 0 0.00030577715
suggesting O 0 6.417238e-05
that O 0 8.448421e-05
secretion O 0 0.0011210297
of O 0 0.0014606395
cimetidine B-Chemical 1 0.9999927
is O 0 0.0007838618
a O 0 0.0009831688
saturable O 0 0.009385099
process O 0 0.001646218
. O 0 0.0019904173

There O 0 0.0027491932
was O 0 0.0017297445
only O 0 0.0009081816
one O 0 0.00047238095
case O 0 0.00048484607
of O 0 0.0010622755
dementia B-Disease 0 0.99975115
possibly O 0 0.0007642865
due O 0 0.00014253565
to O 0 0.00037605126
cimetidine B-Chemical 1 0.9999957
( O 0 0.00039802864
with O 0 0.00015202303
a O 0 0.00016886677
drug O 0 0.0018111917
level O 0 7.3216775e-05
of O 0 0.00013003183
1 O 0 7.422352e-05
. O 0 4.221419e-05
9 O 0 5.3463584e-05
microgram O 0 0.00085522234
/ O 0 0.00029491182
ml O 0 0.0002220915
6 O 0 3.4685618e-05
hr O 0 4.917067e-05
after O 0 2.152927e-05
a O 0 9.0192785e-05
dose O 0 0.0004749681
) O 0 0.00015015806
in O 0 5.7829227e-05
a O 0 8.932898e-05
group O 0 8.125358e-05
of O 0 7.990203e-05
13 O 0 6.974077e-05
patients O 0 8.176105e-05
without O 0 7.567139e-05
liver B-Disease 0 0.37154627
or I-Disease 0 0.0001578978
kidney I-Disease 0 0.9148527
disease I-Disease 0 0.5548566
who O 0 0.00044602234
had O 0 0.0003728008
cimetidine B-Chemical 1 0.99999297
levels O 0 0.00020264238
above O 0 0.00016476966
1 O 0 0.0001316013
. O 0 0.00011569009
25 O 0 0.00035438582
microgram O 0 0.0048665213
/ O 0 0.002524213
ml O 0 0.0036793477
. O 0 0.0021783237

Thus O 0 0.0029737286
, O 0 0.0031931384
high O 0 0.007725096
cimetidine B-Chemical 1 0.99996305
levels O 0 0.001837381
alone O 0 0.0011148284
do O 0 0.0008445683
not O 0 0.00079474744
always O 0 0.001484564
induce O 0 0.0020035428
dementia B-Disease 0 0.9993568
. O 0 0.005176068

Further O 0 0.0028171127
observations O 0 0.0017684139
on O 0 0.00076004706
the O 0 0.000905988
electrophysiologic O 0 0.003756873
effects O 0 0.001070645
of O 0 0.0020541982
oral O 0 0.65332824
amiodarone B-Chemical 1 0.99990976
therapy O 0 0.013466281
. O 0 0.0040338915

A O 0 0.020036317
case O 0 0.0016775588
is O 0 0.0009002544
presented O 0 0.00054163457
of O 0 0.00058724766
a O 0 0.00062168454
reversible O 0 0.017478252
intra B-Disease 0 0.0016944999
- I-Disease 0 0.0005041375
Hisian I-Disease 0 0.0009253231
block I-Disease 0 0.00011392168
occurring O 0 9.8577264e-05
under O 0 0.00010588567
amiodarone B-Chemical 1 0.9998933
treatment O 0 0.00013086523
for O 0 0.000105466774
atrial B-Disease 0 0.99409866
tachycardia I-Disease 2 0.99977106
in O 0 0.00014822748
a O 0 0.00016277365
patient O 0 0.00013086236
without O 0 0.00013958722
clear O 0 0.00024927483
intraventricular B-Disease 0 0.59989303
conduction I-Disease 0 0.015586441
abnormalities I-Disease 0 0.39700454
. O 0 0.0021774706

His O 0 0.006311263
bundle O 0 0.0031737206
recordings O 0 0.0010220167
showed O 0 0.00053565187
an O 0 0.00075354194
atrial B-Disease 0 0.9897086
tachycardia I-Disease 2 0.9997104
with O 0 0.00051914155
intermittent O 0 0.0008243953
exit O 0 0.0002676494
block O 0 0.00012211787
and O 0 0.000103767095
greatly O 0 0.00035889068
prolonged O 0 0.00035844228
BH O 0 0.028482875
and O 0 0.00014634167
HV O 0 0.002245267
intervals O 0 6.1551094e-05
( O 0 0.00012367386
40 O 0 0.00011375538
and O 0 0.00015773169
100 O 0 0.0005028709
msec O 0 0.0011296582
, O 0 0.00085987913
respectively O 0 0.0021225703
) O 0 0.0025036084
. O 0 0.0023081

Thirty O 0 0.0019541916
days O 0 0.0006065661
after O 0 0.00053398334
amiodarone B-Chemical 1 0.99978656
discontinuation O 0 0.20296873
, O 0 0.00060008495
His O 0 0.0008333572
bundle O 0 0.0006882865
electrograms O 0 0.0013322731
showed O 0 0.00018440367
atrial B-Disease 0 0.28169784
flutter I-Disease 0 0.45247644
without O 0 0.00017285482
intra O 0 0.00063798024
- O 0 0.00042492125
Hisian O 0 0.0013960327
or O 0 0.00030439615
infra O 0 0.0012514711
- O 0 0.0011866557
Hisian O 0 0.004533957
delay O 0 0.0021407278
. O 0 0.0021467635

Amiodarone B-Chemical 1 0.99927217
should O 0 0.001153581
be O 0 0.0006979649
used O 0 0.0003929789
with O 0 0.00036999446
caution O 0 0.00019639789
during O 0 9.963154e-05
long O 0 0.00015396705
- O 0 0.00023732464
term O 0 0.00012969105
oral O 0 0.003283033
therapy O 0 0.00019762943
in O 0 0.00010438638
patients O 0 0.00016176283
with O 0 0.00014085165
or O 0 0.00012335517
without O 0 0.00018081418
clear O 0 0.00029664527
intraventricular O 0 0.16975926
conduction O 0 0.008356411
defects O 0 0.006519907
. O 0 0.002149863

Development O 0 0.0061131464
of O 0 0.002931447
clear B-Disease 0 0.002701555
cell I-Disease 0 0.015042199
adenocarcinoma I-Disease 0 0.99877745
in O 0 0.0024858164
DES B-Chemical 0 0.9989483
- O 0 0.0017963748
exposed O 0 0.0008463592
offspring O 0 0.0028077078
under O 0 0.001021618
observation O 0 0.0020861605
. O 0 0.0028105325

Two O 0 0.0024992537
cases O 0 0.0018278994
of O 0 0.0014080678
clear B-Disease 0 0.0013345133
cell I-Disease 0 0.0072681224
adenocarcinoma I-Disease 0 0.9971464
of I-Disease 0 0.0005110762
the I-Disease 0 0.00025915136
vagina I-Disease 0 0.0006664751
detected O 0 8.496839e-05
at O 0 6.286966e-05
follow O 0 6.627954e-05
- O 0 0.0001574714
up O 0 9.199204e-05
in O 0 0.00010344246
young O 0 0.00061662524
women O 0 0.00028495255
exposed O 0 0.00011396948
in O 0 0.00014696256
utero O 0 0.0010550679
to O 0 0.0006201081
diethylstilbestrol B-Chemical 0 0.99987936
are O 0 0.0013621377
reported O 0 0.0019233413
. O 0 0.0019497899

One O 0 0.0028499379
patient O 0 0.0021416785
, O 0 0.0015319654
aged O 0 0.0012607889
23 O 0 0.00074485433
, O 0 0.00042815067
had O 0 0.00024321451
been O 0 0.00013425337
followed O 0 0.00010134783
for O 0 8.7421344e-05
2 O 0 9.159308e-05
years O 0 7.691465e-05
before O 0 6.2376035e-05
carcinoma B-Disease 0 0.95743066
was O 0 0.00024627562
diagnosed O 0 0.0005954195
; O 0 9.9293335e-05
the O 0 5.931201e-05
second O 0 7.086907e-05
patient O 0 0.00010406279
, O 0 0.00010799537
aged O 0 0.00015872275
22 O 0 0.00010229576
, O 0 8.594482e-05
had O 0 7.1039925e-05
been O 0 5.0929542e-05
seen O 0 5.5785677e-05
on O 0 3.917975e-05
a O 0 9.8079574e-05
regular O 0 8.956653e-05
basis O 0 0.000101727856
for O 0 0.000102736245
5 O 0 0.00014726415
years O 0 0.00021035108
, O 0 0.00038495046
8 O 0 0.00045003404
months O 0 0.00052200106
. O 0 0.0015187308

In O 0 0.0019000209
both O 0 0.0013351592
instances O 0 0.0006792386
, O 0 0.0009568936
suspicion O 0 0.0021752466
of O 0 0.00044224947
the O 0 0.00026525607
presence O 0 0.0002784512
of O 0 0.0007790861
carcinoma B-Disease 0 0.99667645
was O 0 0.0003796264
aroused O 0 0.00054217695
by O 0 0.00012899889
the O 0 0.00013289067
palpation O 0 0.0009033943
of O 0 0.00018115775
a O 0 0.00024448024
small O 0 0.00033228096
nodule O 0 0.018214015
in O 0 0.00035080512
the O 0 0.0005844076
vaginal O 0 0.0024286937
fornix O 0 0.043525655
. O 0 0.002205455

Hysterosalpingography O 0 0.005738767
was O 0 0.0013018064
performed O 0 0.0005738723
on O 0 0.00032433317
both O 0 0.00041055982
patients O 0 0.0005262257
and O 0 0.000327133
, O 0 0.0002767816
in O 0 0.0001669922
1 O 0 0.00012308151
instance O 0 0.000105392784
, O 0 0.00013184597
an O 0 0.0001627679
abnormal O 0 0.0014860193
x O 0 0.0008690013
- O 0 0.0006008856
ray O 0 0.0899341
film O 0 0.00071274344
was O 0 0.000128454
reflected O 0 7.774453e-05
by O 0 7.1765004e-05
the O 0 6.5684944e-05
gross O 0 0.00017619441
appearance O 0 0.00018828707
of O 0 0.00013111354
the O 0 0.00014365398
uterine O 0 0.001779074
cavity O 0 0.00036039896
found O 0 0.00015061478
in O 0 0.0001952388
the O 0 0.00033683845
surgical O 0 0.0007377909
specimen O 0 0.0012957951
. O 0 0.0017570817

Neurologic O 0 0.030672546
effects O 0 0.0017835151
of O 0 0.0019197123
subarachnoid O 0 0.95512044
administration O 0 0.0029771577
of O 0 0.0006623767
2 B-Chemical 0 0.00036808837
- I-Chemical 0 0.0012379957
chloroprocaine I-Chemical 0 0.99956495
- I-Chemical 0 0.0032404326
CE I-Chemical 0 0.9993123
, O 0 0.001193671
bupivacaine B-Chemical 1 0.99993837
, O 0 0.0004150769
and O 0 0.00025442016
low O 0 0.0006504761
pH O 0 0.0066617113
normal O 0 0.0011774545
saline O 0 0.0020990716
in O 0 0.0007689357
dogs O 0 0.002035589
. O 0 0.0019988453

The O 0 0.0015270138
purpose O 0 0.0011468099
of O 0 0.0009988253
this O 0 0.0007427785
study O 0 0.00058766955
was O 0 0.00030645196
to O 0 0.00014597054
evaluate O 0 8.35627e-05
the O 0 0.00017084541
neurologic O 0 0.30952427
consequences O 0 0.00025346066
of O 0 0.0002555582
deliberate O 0 0.0034153857
subarachnoid O 0 0.9647635
injection O 0 0.00014685918
of O 0 0.00011249586
large O 0 0.00010676461
volumes O 0 0.00016123478
of O 0 0.00015371593
2 B-Chemical 0 0.00014646744
- I-Chemical 0 0.0006953086
chloroprocaine I-Chemical 0 0.9990207
- I-Chemical 0 0.0020022867
CE I-Chemical 0 0.9885433
in O 0 0.000509671
experimental O 0 0.00093218824
animals O 0 0.0010734024
. O 0 0.0018466022

The O 0 0.0016895722
possible O 0 0.0011621088
role O 0 0.00067200017
of O 0 0.0010119014
low O 0 0.0018525019
pH O 0 0.012622406
as O 0 0.00035936042
well O 0 0.00019383132
as O 0 0.00015078923
total O 0 0.00015520376
volume O 0 0.00030738447
as O 0 0.00013052748
potential O 0 0.00016532425
factors O 0 0.00028282873
in O 0 0.00033078282
causing O 0 0.0026066417
neurotoxicity B-Disease 2 0.9998871
was O 0 0.0024726468
evaluated O 0 0.0015365967
. O 0 0.0021580071

The O 0 0.0017318437
65 O 0 0.001687296
dogs O 0 0.0010041158
in O 0 0.00042444415
the O 0 0.00031919632
study O 0 0.000297131
received O 0 0.00015595574
injections O 0 0.00020082908
in O 0 0.000109104585
the O 0 0.00015514929
subarachnoid O 0 0.7330923
space O 0 8.74768e-05
as O 0 6.8747526e-05
follows O 0 8.070455e-05
: O 0 9.413907e-05
6 O 0 3.570947e-05
to O 0 4.104864e-05
8 O 0 4.661608e-05
ml O 0 0.00016986688
of O 0 0.00025557552
bupivacaine B-Chemical 1 0.99995863
( O 0 0.0010909422
N O 0 0.976189
= O 0 0.0001992346
15 O 0 7.24818e-05
) O 0 0.00014221812
, O 0 0.00010602056
2 B-Chemical 0 9.543393e-05
- I-Chemical 0 0.00042394255
chloroprocaine I-Chemical 0 0.9990349
- I-Chemical 0 0.0016389005
CE I-Chemical 0 0.9991416
( O 0 0.00085921737
N O 0 0.96291584
= O 0 0.00020813954
20 O 0 0.00010851659
) O 0 0.00015292705
, O 0 0.00010590113
low O 0 0.00025000886
pH O 0 0.0033972953
normal O 0 0.00046779556
saline O 0 0.0011377145
( O 0 0.00023738142
pH O 0 0.0017137676
3 O 0 8.0458034e-05
. O 0 5.5787e-05
0 O 0 8.494531e-05
) O 0 0.00019909332
( O 0 0.0002903922
N O 0 0.76512426
= O 0 0.00022392221
20 O 0 0.00013425645
) O 0 0.00019134098
, O 0 0.00013004051
or O 0 0.0001197901
normal O 0 0.0004509668
saline O 0 0.00158326
( O 0 0.00082213833
N O 0 0.6770988
= O 0 0.0010119698
10 O 0 0.00089969794
) O 0 0.0021070845
. O 0 0.0022939579

Of O 0 0.0020676523
the O 0 0.0010877458
20 O 0 0.0006969652
animals O 0 0.00031088246
that O 0 0.00022343552
received O 0 0.00030269308
subarachnoid O 0 0.7750166
injection O 0 0.0002968229
of O 0 0.0002796553
2 B-Chemical 0 0.00019510518
- I-Chemical 0 0.0007567595
chloroprocaine I-Chemical 0 0.99938464
- I-Chemical 0 0.001718252
CE I-Chemical 0 0.9958891
seven O 0 0.00020006477
( O 0 0.00022612521
35 O 0 0.00017008213
% O 0 0.00022799829
) O 0 0.00040773436
developed O 0 0.0008780177
hind O 0 0.13361722
- O 0 0.002907986
limb O 0 0.46301612
paralysis B-Disease 0 0.9987232
. O 0 0.0042732228

None O 0 0.0027771085
of O 0 0.0013330944
the O 0 0.0006631302
animals O 0 0.0003325028
that O 0 0.0002531361
received O 0 0.00047400338
bupivacaine B-Chemical 1 0.999918
, O 0 0.00047704557
normal O 0 0.00063576264
saline O 0 0.0010077347
, O 0 0.0001215806
or O 0 7.5331845e-05
normal O 0 0.00022413752
saline O 0 0.00045376018
titrated O 0 0.0001598078
to O 0 8.813139e-05
a O 0 0.0002259877
pH O 0 0.0026193238
3 O 0 0.00011735674
. O 0 9.38773e-05
0 O 0 0.00016236982
developed O 0 0.00060883997
hind O 0 0.059207916
- O 0 0.002455949
limb O 0 0.3873679
paralysis B-Disease 0 0.9985885
. O 0 0.0041501475

Of O 0 0.0021975657
the O 0 0.0012238119
15 O 0 0.00079448544
spinal O 0 0.0017601168
cords O 0 0.0013429589
of O 0 0.00037549713
the O 0 0.00020248804
animals O 0 0.000109885994
that O 0 8.933827e-05
received O 0 0.00011567653
2 B-Chemical 0 0.00014199846
- I-Chemical 0 0.00065350713
chloroprocaine I-Chemical 0 0.99950004
- I-Chemical 0 0.0019173002
CE I-Chemical 0 0.9977374
, O 0 0.00022358086
13 O 0 0.00013167722
showed O 0 0.00016335094
subpial B-Disease 0 0.3808318
necrosis I-Disease 2 0.9999387
; O 0 0.00041023077
the O 0 0.00020387201
nerve O 0 0.0032223528
roots O 0 0.0020330518
and O 0 0.0005526468
subarachnoid O 0 0.95785046
vessels O 0 0.006471226
were O 0 0.0008357287
normal O 0 0.0022183342
. O 0 0.0018743889

The O 0 0.001962615
spinal O 0 0.0039485143
cords O 0 0.0024699077
of O 0 0.00066893373
the O 0 0.0003356525
animals O 0 0.00017594846
that O 0 0.00014893303
received O 0 0.00031022367
bupivacaine B-Chemical 1 0.9999261
, O 0 0.00039252872
low O 0 0.00063688494
pH O 0 0.013179203
normal O 0 0.00066652696
saline O 0 0.0015755001
( O 0 0.00027209133
pH O 0 0.0021452224
3 O 0 8.614881e-05
. O 0 5.76748e-05
0 O 0 8.155268e-05
) O 0 0.00014832278
, O 0 0.00010602511
or O 0 9.282724e-05
normal O 0 0.00030931557
saline O 0 0.0006299003
did O 0 0.0002061294
not O 0 0.00022089091
show O 0 0.0003329523
abnormal O 0 0.0035802345
findings O 0 0.0030348934
. O 0 0.0022865683

Procainamide B-Chemical 0 0.99844617
- O 0 0.014672786
induced O 0 0.009220907
polymorphous O 0 0.9145129
ventricular B-Disease 2 0.99907035
tachycardia I-Disease 2 0.99954516
. O 0 0.012637127

Seven O 0 0.0047658407
cases O 0 0.0025422254
of O 0 0.0033358668
procainamide B-Chemical 1 0.9998388
- O 0 0.0038537723
induced O 0 0.0018368758
polymorphous O 0 0.88144094
ventricular B-Disease 2 0.9996611
tachycardia I-Disease 2 0.999801
are O 0 0.0020390488
presented O 0 0.00207169
. O 0 0.0026578268

In O 0 0.0015407094
four O 0 0.0008326152
patients O 0 0.0010253565
, O 0 0.000822832
polymorphous O 0 0.23631683
ventricular B-Disease 2 0.99942386
tachycardia I-Disease 2 0.99980694
appeared O 0 0.00023848508
after O 0 5.3343905e-05
intravenous O 0 0.0014023307
administration O 0 0.00033943247
of O 0 0.0001225295
200 O 0 0.00019856666
to O 0 6.565413e-05
400 O 0 0.0002891038
mg O 0 0.0017846852
of O 0 0.00028676522
procainamide B-Chemical 1 0.9998925
for O 0 0.000108788554
the O 0 0.00012048339
treatment O 0 0.0001495341
of O 0 0.0003349022
sustained O 0 0.0029603394
ventricular B-Disease 2 0.99947566
tachycardia I-Disease 2 0.9998053
. O 0 0.0033575161

In O 0 0.0013790216
the O 0 0.0009295302
remaining O 0 0.0006842401
three O 0 0.00029347913
patients O 0 0.00063718995
, O 0 0.00071605836
procainamide B-Chemical 1 0.9999021
was O 0 0.00037725433
administered O 0 0.00021034025
orally O 0 0.00033952555
for O 0 7.450029e-05
treatment O 0 0.000107598185
of O 0 0.0002159564
chronic O 0 0.07757322
premature B-Disease 0 0.1751611
ventricular I-Disease 0 0.9684968
contractions I-Disease 0 0.49408484
or O 0 0.0006550302
atrial B-Disease 0 0.7751703
flutter I-Disease 0 0.83598495
. O 0 0.0019509576

These O 0 0.0028876965
patients O 0 0.0027779168
had O 0 0.0020979552
Q B-Disease 0 0.69116527
- I-Disease 0 0.0033482332
T I-Disease 0 0.4661838
prolongation I-Disease 0 0.004685779
and O 0 0.0008300723
recurrent O 0 0.049981896
syncope B-Disease 0 0.9994733
due O 0 0.00040903487
to O 0 0.0006630802
polymorphous O 0 0.8508464
ventricular B-Disease 2 0.999608
tachycardia I-Disease 2 0.9997923
. O 0 0.003998947

In O 0 0.0016779469
four O 0 0.0009341973
patients O 0 0.0011468787
, O 0 0.00074242183
the O 0 0.00067691226
arrhythmia B-Disease 0 0.99616647
was O 0 0.00051915104
rapidly O 0 0.00043169424
diagnosed O 0 0.00072736974
and O 0 0.00015587248
treated O 0 0.00020186248
with O 0 0.00018377212
disappearance O 0 0.0006270998
of O 0 0.00024626456
further O 0 0.00036213233
episodes O 0 0.0011996495
of O 0 0.00070729584
the O 0 0.0013672325
arrhythmia B-Disease 0 0.9983437
. O 0 0.0029951902

In O 0 0.0017881853
two O 0 0.0010853977
patients O 0 0.0012511004
, O 0 0.00080388517
the O 0 0.0007168101
arrhythmia B-Disease 0 0.99353844
degenerated O 0 0.0015451654
into O 0 0.00015553174
irreversible O 0 0.09291052
ventricular B-Disease 0 0.993737
fibrillation I-Disease 0 0.9999244
and O 0 0.0007002955
both O 0 0.0006585549
patients O 0 0.001474437
died O 0 0.003207556
. O 0 0.0021019124

In O 0 0.0017357687
the O 0 0.0014034149
seventh O 0 0.0022466723
patient O 0 0.00085141143
, O 0 0.00053645764
a O 0 0.0004316798
permanent O 0 0.001572257
ventricular O 0 0.73487383
pacemaker O 0 0.001531353
was O 0 0.00015112189
inserted O 0 6.5894106e-05
and O 0 8.3467545e-05
, O 0 8.1022394e-05
despite O 0 5.413474e-05
continuation O 0 0.00022953843
of O 0 0.0003076011
procainamide B-Chemical 1 0.9999573
therapy O 0 0.0005599623
, O 0 0.00032233476
polymorphous O 0 0.65986156
ventricular B-Disease 2 0.9996973
tachycardia I-Disease 2 0.9998548
did O 0 0.0009555589
not O 0 0.0007448397
reoccur O 0 0.0020845812
. O 0 0.0016591682

These O 0 0.0021728727
seven O 0 0.0010887308
cases O 0 0.0007968662
demonstrate O 0 0.00029585214
that O 0 0.0005014101
procainamide B-Chemical 1 0.9998654
can O 0 0.00027302266
produce O 0 0.00014018093
an O 0 0.00022704704
acquired O 0 0.00040700604
prolonged B-Disease 0 0.001184782
Q I-Disease 0 0.8582342
- I-Disease 0 0.0017792195
T I-Disease 0 0.7085828
syndrome I-Disease 0 0.14439602
with O 0 0.0012171795
polymorphous O 0 0.90603906
ventricular B-Disease 2 0.9996351
tachycardia I-Disease 2 0.9997906
. O 0 0.0036126787

Phenobarbitone B-Chemical 0 0.9998349
- O 0 0.007204192
induced O 0 0.001800595
enlargement B-Disease 0 0.015039683
of I-Disease 0 0.00079968374
the I-Disease 0 0.0005362554
liver I-Disease 0 0.45898116
in O 0 0.00025677594
the O 0 0.00019448686
rat O 0 0.0004363766
: O 0 0.00019550517
its O 0 0.00020425688
relationship O 0 9.416565e-05
to O 0 0.0003642428
carbon B-Chemical 0 0.9966594
tetrachloride I-Chemical 0 0.99999714
- O 0 0.032029875
induced O 0 0.012805556
cirrhosis B-Disease 0 0.99997437
. O 0 0.0052098813

The O 0 0.0017555833
yield O 0 0.0026401365
of O 0 0.0019902107
severe O 0 0.18744923
cirrhosis B-Disease 0 0.9999801
of I-Disease 0 0.0017044352
the I-Disease 0 0.0006353277
liver I-Disease 0 0.83464724
( O 0 0.0003481836
defined O 0 8.6771775e-05
as O 0 8.344008e-05
a O 0 0.00013422073
shrunken O 0 0.001558737
finely O 0 0.00025961432
nodular O 0 0.7757489
liver O 0 0.8439497
with O 0 0.0006745712
micronodular O 0 0.99860746
histology O 0 0.102684334
, O 0 0.00024140006
ascites B-Disease 0 0.9819536
greater O 0 9.48021e-05
than O 0 3.685351e-05
30 O 0 3.88297e-05
ml O 0 0.00017347268
, O 0 9.181502e-05
plasma O 0 0.0023483615
albumin O 0 0.89726627
less O 0 0.00013773853
than O 0 5.8705475e-05
2 O 0 5.4931315e-05
. O 0 3.5581186e-05
2 O 0 4.584327e-05
g O 0 0.00016700433
/ O 0 0.00032495154
dl O 0 0.0058397586
, O 0 0.00033600887
splenomegaly B-Disease 0 0.9984055
2 O 0 0.00014982668
- O 0 0.0001456359
3 O 0 3.4651133e-05
times O 0 2.4084986e-05
normal O 0 0.00010816492
, O 0 7.8294026e-05
and O 0 0.00010675544
testicular O 0 0.5763938
atrophy B-Disease 2 0.9979499
approximately O 0 0.00011795766
half O 0 4.4953194e-05
normal O 0 0.00014400273
weight O 0 0.0004013764
) O 0 8.797723e-05
after O 0 1.7135755e-05
12 O 0 2.6973466e-05
doses O 0 0.00026111663
of O 0 0.00025450872
carbon B-Chemical 0 0.9960581
tetrachloride I-Chemical 0 0.9999988
given O 0 9.855632e-05
intragastrically O 0 0.001982216
in O 0 7.4928066e-05
the O 0 0.00020500651
phenobarbitone B-Chemical 0 0.9999975
- O 0 0.0005836544
primed O 0 0.00014713363
rat O 0 0.0003102991
was O 0 8.706553e-05
increased O 0 0.00010212383
from O 0 5.6457644e-05
25 O 0 9.492459e-05
% O 0 6.3054635e-05
to O 0 4.7858128e-05
56 O 0 8.2825696e-05
% O 0 6.457496e-05
by O 0 5.8051508e-05
giving O 0 9.993299e-05
the O 0 5.1970994e-05
initial O 0 6.0512055e-05
" O 0 8.703664e-05
calibrating O 0 8.868612e-05
" O 0 0.00011374312
dose O 0 0.00044920342
of O 0 0.0003959902
carbon B-Chemical 0 0.9971161
tetrachloride I-Chemical 0 0.99999845
at O 0 0.00010015585
the O 0 7.464359e-05
peak O 0 0.00010044909
of O 0 0.00014602832
the O 0 0.00036339017
phenobarbitone B-Chemical 0 0.9999956
- O 0 0.0014089837
induced O 0 0.0005572089
enlargement B-Disease 0 0.042206075
of I-Disease 0 0.0010101896
the I-Disease 0 0.0013267106
liver I-Disease 0 0.9020916
. O 0 0.0028208792

At O 0 0.00091905217
this O 0 0.0012924055
point O 0 0.0007993733
it O 0 0.0006978924
was O 0 0.00042867704
assumed O 0 0.00023029957
that O 0 0.00022167682
the O 0 0.0007744624
cytochrome O 0 0.9999342
P450 O 0 0.9999939
/ O 0 0.25924987
CCl4 B-Chemical 0 0.9999975
toxic O 0 0.91663957
state O 0 0.00061189523
was O 0 0.00029114625
both O 0 0.00025620862
maximal O 0 0.00042605936
and O 0 0.0007587589
stable O 0 0.0016784214
. O 0 0.0020415266

The O 0 0.0013171635
optimal O 0 0.0007365513
rat O 0 0.0013666722
size O 0 0.000816542
to O 0 0.0004022382
begin O 0 0.0009882211
phenobarbitone B-Chemical 0 0.99998987
was O 0 0.0005834575
determined O 0 0.00017415451
as O 0 0.00013900611
100 O 0 0.00038393924
g O 0 0.0004275118
, O 0 0.00012111856
and O 0 8.128691e-05
this O 0 9.274513e-05
size O 0 0.00014046647
as O 0 6.7494984e-05
a O 0 0.000106295694
group O 0 0.0001004375
had O 0 5.2575157e-05
a O 0 5.4276166e-05
mean O 0 2.2017479e-05
maximum O 0 4.401017e-05
relative O 0 7.659998e-05
liver O 0 0.29138476
weight O 0 0.00099844
increase O 0 0.00011896095
47 O 0 0.00018150425
% O 0 7.221618e-05
greater O 0 6.7988396e-05
than O 0 5.724898e-05
normal O 0 0.00019869431
rats O 0 0.0001708094
of O 0 0.00017039555
the O 0 0.00019264255
same O 0 0.00022609846
body O 0 0.0017222236
weight O 0 0.004988727
. O 0 0.0021095432

The O 0 0.0012408444
optimal O 0 0.00060539757
time O 0 0.0004188442
for O 0 0.00032547925
the O 0 0.00030598944
initial O 0 0.00031791828
dose O 0 0.0019079272
of O 0 0.0014050564
carbon B-Chemical 0 0.9986526
tetrachloride I-Chemical 0 0.9999974
was O 0 0.000745616
after O 0 0.00011867248
14 O 0 0.00021515487
days O 0 0.00019886676
on O 0 0.0006829476
phenobarbitone B-Chemical 0 0.99990904
. O 0 0.0043629436

Triamterene B-Chemical 0 0.99766064
nephrolithiasis B-Disease 2 0.99952054
complicating O 0 0.69517976
dyazide B-Chemical 0 0.9380633
therapy O 0 0.020496307
. O 0 0.010604159

A O 0 0.015200372
case O 0 0.0018995272
of O 0 0.005242235
triamterene B-Chemical 0 0.9999976
nephrolithiasis B-Disease 2 0.99998426
is O 0 0.0014237562
reported O 0 0.00046710894
in O 0 0.00020657112
a O 0 0.00029513604
man O 0 0.0011417968
after O 0 4.8070084e-05
4 O 0 7.004896e-05
years O 0 8.395296e-05
of O 0 0.0003935752
hydrochlorothiazide B-Chemical 0 0.99999714
- I-Chemical 0 0.064347304
triamterene I-Chemical 0 0.99999905
therapy O 0 0.0088509265
for O 0 0.0020289936
hypertension B-Disease 2 0.99987566
. O 0 0.0036081276

The O 0 0.002286764
stone O 0 0.045152538
passed O 0 0.0017272021
spontaneously O 0 0.0021003676
and O 0 0.0006275692
was O 0 0.00039902664
found O 0 0.00019514836
to O 0 0.00015387974
contain O 0 0.00011691444
a O 0 0.0007444793
triamterene B-Chemical 0 0.9999981
metabolite O 0 0.9945791
admixed O 0 0.015757706
with O 0 0.004099593
uric B-Chemical 0 0.99998033
acid I-Chemical 0 0.999297
salts I-Chemical 0 0.99954695
. O 0 0.005626411

Factors O 0 0.007195685
affecting O 0 0.01019984
triamterene B-Chemical 0 0.9999937
nephrolithiasis B-Disease 2 0.9999542
are O 0 0.0012318041
discussed O 0 0.00049903564
and O 0 0.00045037738
2 O 0 0.00030340205
previously O 0 0.00035021448
reported O 0 0.00060542184
cases O 0 0.00092763855
are O 0 0.0010623717
reviewed O 0 0.0026051519
. O 0 0.002532089

Busulfan B-Chemical 0 0.9937137
- O 0 0.02530763
induced O 0 0.023916932
hemorrhagic B-Disease 2 0.9988581
cystitis I-Disease 0 0.99939597
. O 0 0.023663746

A O 0 0.018565943
case O 0 0.0023932185
of O 0 0.0024186315
a O 0 0.004226784
busulfan B-Chemical 0 0.9997048
- O 0 0.008172373
induced O 0 0.007388096
hemorrhage B-Disease 2 0.9999138
cystitis I-Disease 0 0.9998646
is O 0 0.0055533154
reported O 0 0.0045298245
. O 0 0.0034087335

Spontaneous O 0 0.008027965
resolution O 0 0.006804695
occurred O 0 0.0017777837
following O 0 0.0012369078
cessation O 0 0.0021356428
of O 0 0.0023582913
the O 0 0.0030308242
drug O 0 0.05922412
. O 0 0.0056065894

The O 0 0.0012964604
similarity O 0 0.00089179596
between O 0 0.00044354898
the O 0 0.00050829846
histologic O 0 0.002368827
appearances O 0 0.0011253984
of O 0 0.0009857434
busulfan B-Chemical 0 0.9999485
cystitis B-Disease 0 0.9999201
and O 0 0.0004582552
both O 0 0.00020766754
radiation O 0 0.009229885
and O 0 0.0004718495
cyclophosphamide B-Chemical 0 0.99986315
- O 0 0.001309204
induced O 0 0.00075388927
cystitis B-Disease 0 0.9997733
is O 0 0.000330645
discussed O 0 0.00018396969
and O 0 0.00023062323
the O 0 0.00029470134
world O 0 0.0008846059
literature O 0 0.0015888066
reviewed O 0 0.0024228964
. O 0 0.0020782026

In O 0 0.001750151
view O 0 0.0015288332
of O 0 0.0010334024
the O 0 0.00062659377
known O 0 0.0006308676
tendency O 0 0.0007270658
of O 0 0.0008353235
busulfan B-Chemical 0 0.99973017
to O 0 0.0002388519
induce O 0 0.00011831205
cellular O 0 0.00069160043
atypia O 0 0.056626484
and O 0 0.00037150277
carcinoma B-Disease 0 0.98798496
in O 0 0.000105802
other O 0 6.890807e-05
sites O 0 5.8058704e-05
, O 0 8.046325e-05
periodic O 0 0.00013779095
urinary O 0 0.015258948
cytology O 0 0.0004417169
is O 0 8.420279e-05
suggested O 0 5.797948e-05
in O 0 8.7196124e-05
patients O 0 0.00015498164
on O 0 0.00010209655
long O 0 0.0002637878
- O 0 0.00060217734
term O 0 0.0006565286
therapy O 0 0.0018724798
. O 0 0.0018840967

Variant O 0 0.10603137
ventricular B-Disease 2 0.9966271
tachycardia I-Disease 2 0.99936455
in O 0 0.021145994
desipramine B-Chemical 0 0.9999722
toxicity B-Disease 2 0.99912304
. O 0 0.012293367

We O 0 0.0019846286
report O 0 0.0020621223
a O 0 0.001329094
case O 0 0.0007422273
of O 0 0.0008621738
variant O 0 0.0023153608
ventricular B-Disease 2 0.9992405
tachycardia I-Disease 2 0.9998411
induced O 0 0.0034954487
by O 0 0.0062449686
desipramine B-Chemical 0 0.9999925
toxicity B-Disease 2 0.99953055
. O 0 0.005372787

Unusual O 0 0.004816689
features O 0 0.001459362
of O 0 0.0011402076
the O 0 0.0010186064
arrhythmia B-Disease 0 0.9923084
are O 0 0.0004040192
repetitive O 0 0.0002905437
group O 0 0.0003138629
beating O 0 0.0008691545
, O 0 0.00021720928
progressive O 0 0.004567156
shortening O 0 0.0013389487
of O 0 0.00024088527
the O 0 0.00033790147
R O 0 0.9890738
- O 0 0.0016303889
R O 0 0.9240962
interval O 0 0.00013642317
, O 0 0.00012724502
progressive O 0 0.0023236026
widening O 0 0.00023817037
of O 0 8.986331e-05
the O 0 7.771369e-05
QRS O 0 0.023843765
complex O 0 6.702165e-05
with O 0 9.243699e-05
eventual O 0 0.00042368396
failure O 0 0.013569448
of O 0 0.0002115323
intraventricular O 0 0.18142954
conduction O 0 0.00152362
, O 0 0.0001306833
and O 0 9.519988e-05
changes O 0 0.0001235957
in O 0 0.00010598477
direction O 0 0.0001948187
of O 0 0.00031807474
the O 0 0.00054663693
QRS O 0 0.15008733
axis O 0 0.003426997
. O 0 0.0021164624

Recognition O 0 0.0033483666
of O 0 0.0018125646
variant O 0 0.0031716486
ventricular B-Disease 2 0.9988423
tachycardia I-Disease 2 0.9997209
is O 0 0.00047942856
important O 0 0.0001331516
because O 0 0.00013715256
therapy O 0 0.0002251824
differs O 0 0.000104734754
from O 0 0.000121113815
that O 0 0.00015287951
of O 0 0.0005104919
classic O 0 0.016044624
ventricular B-Disease 2 0.999413
tachycardia I-Disease 2 0.99977416
. O 0 0.0037045695

Rebound O 0 0.38373068
hypertensive B-Disease 2 0.9976209
after O 0 0.002346202
sodium B-Chemical 1 0.9999194
nitroprusside I-Chemical 1 0.9999956
prevented O 0 0.1214113
by O 0 0.004998436
saralasin B-Chemical 0 0.99985814
in O 0 0.0028265128
rats O 0 0.004436877
. O 0 0.0031844098

The O 0 0.0015498728
role O 0 0.000884592
of O 0 0.0010868483
the O 0 0.001038104
renin O 0 0.967119
- O 0 0.0027151378
- O 0 0.00161952
angiotensin B-Chemical 1 0.9998609
system O 0 0.0002953905
in O 0 0.0001048017
the O 0 7.66814e-05
maintenance O 0 0.00010314913
of O 0 0.00010169906
blood O 0 0.0006540536
pressure O 0 0.0006707678
during O 0 5.9841517e-05
halothane B-Chemical 0 0.9998222
anesthesia O 0 0.062460303
and O 0 0.0006425749
sodium B-Chemical 1 0.9999932
nitroprusside I-Chemical 1 0.99999976
( O 0 0.022665055
SNP B-Chemical 1 0.99854004
) O 0 0.001047946
- O 0 0.0007333296
induced O 0 0.0009968446
hypotension B-Disease 0 0.9996784
was O 0 0.0017960671
evaluated O 0 0.0013737272
. O 0 0.0020592373

Control O 0 0.0028691974
rats O 0 0.0018521405
received O 0 0.0011743037
halothane B-Chemical 0 0.9996761
anesthesia O 0 0.14062968
( O 0 0.0007192858
1 O 0 0.00026944757
MAC O 0 0.02186452
) O 0 0.00027907122
for O 0 8.2458304e-05
one O 0 7.1823335e-05
hour O 0 7.477767e-05
, O 0 0.00010972725
followed O 0 8.17174e-05
by O 0 0.00019090051
SNP B-Chemical 1 0.96954805
infusion O 0 0.0005762217
, O 0 0.0001257456
40 O 0 0.00010287339
microgram O 0 0.0017511017
/ O 0 0.0004044364
kg O 0 0.00026015347
/ O 0 0.00021643794
min O 0 0.00010102005
, O 0 8.073949e-05
for O 0 4.721343e-05
30 O 0 5.5504002e-05
min O 0 0.0001046551
, O 0 0.00011649112
followed O 0 8.727591e-05
by O 0 0.00013327607
a O 0 0.00020395193
30 O 0 0.00016321598
- O 0 0.00037319865
min O 0 0.0004021393
recovery O 0 0.000997265
period O 0 0.00075537973
. O 0 0.001756707

A O 0 0.013767341
second O 0 0.0015487603
group O 0 0.0012475781
of O 0 0.00081341306
rats O 0 0.00078810035
was O 0 0.00035456478
treated O 0 0.00028956117
identically O 0 0.00015080751
and O 0 0.0001759612
, O 0 0.00014465602
in O 0 8.20035e-05
addition O 0 6.450381e-05
, O 0 0.000100552206
received O 0 5.2926836e-05
an O 0 9.154644e-05
infusion O 0 0.00023878767
of O 0 0.0003138046
saralasin B-Chemical 0 0.99997544
( O 0 0.00028603614
a O 0 0.00015599068
competitive O 0 0.0011447241
inhibitor O 0 0.000984053
of O 0 0.0008922427
angiotensin B-Chemical 1 0.9999932
II I-Chemical 1 0.64988077
) O 0 0.0003824222
throughout O 0 0.00010076136
the O 0 0.0002529161
experimental O 0 0.00059301866
period O 0 0.00061283604
. O 0 0.0015547652

In O 0 0.0016163329
each O 0 0.0008605414
group O 0 0.0014780231
, O 0 0.001457573
SNP B-Chemical 1 0.96711105
infusion O 0 0.0014179554
resulted O 0 0.00029003114
in O 0 0.00016610402
an O 0 0.00016232493
initial O 0 0.00011949734
decrease O 0 0.00017430053
in O 0 0.00011202913
blood O 0 0.00083869876
pressure O 0 0.00073283183
from O 0 7.680617e-05
86 O 0 0.00018134026
torr O 0 0.0011885138
and O 0 0.0001289337
83 O 0 0.0002996358
torr O 0 0.0030757617
, O 0 0.0002958767
respectively O 0 0.0005130921
, O 0 0.00037734117
to O 0 0.00039910068
48 O 0 0.0007170799
torr O 0 0.011575665
. O 0 0.002204018

During O 0 0.0011065092
the O 0 0.0018787116
SNP B-Chemical 1 0.93685657
infusion O 0 0.0018774469
the O 0 0.00040664946
control O 0 0.00026763638
animals O 0 0.00016387561
demonstrated O 0 0.0001454369
a O 0 0.00025255655
progressive O 0 0.0050604716
increase B-Disease 0 0.00016425217
in I-Disease 0 0.00011637876
blood I-Disease 0 0.0010255113
pressure I-Disease 0 0.000906913
to O 0 8.061501e-05
61 O 0 0.00017599191
torr O 0 0.0018878272
, O 0 0.00010941422
whereas O 0 9.684168e-05
the O 0 0.0002279709
saralasin B-Chemical 0 0.9999616
- O 0 0.0007011687
treated O 0 0.00033935512
animals O 0 0.00021608412
showed O 0 0.00036508654
no O 0 0.00047330992
change O 0 0.0013094209
. O 0 0.001958819

Following O 0 0.0019455486
discontinuation O 0 0.018187406
of O 0 0.0030445058
SNP B-Chemical 1 0.99030125
, O 0 0.0010204888
blood O 0 0.0031260697
pressure O 0 0.002161355
in O 0 0.00016284398
the O 0 0.00011699707
control O 0 0.00010616663
animals O 0 9.01639e-05
rebounded O 0 0.00049984874
to O 0 9.120575e-05
94 O 0 0.00023290147
torr O 0 0.0031776936
, O 0 0.000116600924
as O 0 6.294902e-05
compared O 0 4.5990262e-05
with O 0 9.901185e-05
78 O 0 0.00020979466
torr O 0 0.0013265376
in O 0 0.00013901977
the O 0 0.0003624561
saralasin B-Chemical 0 0.9999136
- O 0 0.001697693
treated O 0 0.0014890422
rats O 0 0.002506747
. O 0 0.0019444524

This O 0 0.0032162871
study O 0 0.0013752425
indicates O 0 0.0004889922
that O 0 0.00029056834
with O 0 0.00044328987
stable O 0 0.0008366967
halothane B-Chemical 0 0.99992025
anesthesia O 0 0.10595641
, O 0 0.00018762847
the O 0 8.580757e-05
partial O 0 0.00013557986
recovery O 0 0.0001697508
of O 0 0.00011601378
blood O 0 0.0008592095
pressure O 0 0.0008969136
during O 0 6.049273e-05
SNP B-Chemical 1 0.93044454
infusion O 0 0.0002941545
and O 0 7.58994e-05
the O 0 6.8613e-05
post O 0 6.3237574e-05
- O 0 0.00041423933
SNP B-Chemical 1 0.96842724
rebound O 0 0.007405867
of O 0 0.0002626121
blood O 0 0.0028548639
pressure O 0 0.001874289
can O 0 0.0001236214
be O 0 0.00016276015
completely O 0 0.00034783606
blocked O 0 0.0013670309
by O 0 0.0022693556
saralasin B-Chemical 0 0.99981004
. O 0 0.0035943673

This O 0 0.003152368
demonstrates O 0 0.0009503355
the O 0 0.00074111554
participation O 0 0.000679396
of O 0 0.0005416129
the O 0 0.0005466635
renin O 0 0.9765286
- O 0 0.0017714072
- O 0 0.0011399384
angiotensin B-Chemical 1 0.9998919
system O 0 0.00027283348
in O 0 0.00012781391
antagonizing O 0 0.0004512704
the O 0 0.0001323473
combined O 0 0.00032686052
hypotensive B-Disease 0 0.9618795
effects O 0 0.0005152907
of O 0 0.0016470491
halothane B-Chemical 0 0.99989367
and O 0 0.005550864
SNP B-Chemical 1 0.99320227
. O 0 0.0032368614

Clinical O 0 0.035929356
nephrotoxicity B-Disease 0 0.9997063
of O 0 0.017368658
tobramycin B-Chemical 0 0.99914443
and O 0 0.020477088
gentamicin B-Chemical 1 0.9985819
. O 0 0.013912482

A O 0 0.07919041
prospective O 0 0.042684246
study O 0 0.026398519
. O 0 0.024235828

Nearly O 0 0.006347839
3 O 0 0.0016505247
. O 0 0.00087719486
2 O 0 0.0006543934
million O 0 0.0007318879
people O 0 0.0006441194
in O 0 0.00035016143
this O 0 0.00044291944
country O 0 0.00061946124
receive O 0 0.00052124716
aminoglycoside B-Chemical 0 0.9322222
antibiotics O 0 0.14191891
annually O 0 0.00500729
. O 0 0.0030250612

Gentamicin B-Chemical 0 0.99942267
sulfate I-Chemical 0 0.9978174
and O 0 0.005819526
tobramycin B-Chemical 0 0.9999341
sulfate I-Chemical 0 0.9991555
continue O 0 0.00076607446
to O 0 0.0002866649
demonstrate O 0 0.00022471078
ototoxicity B-Disease 0 0.9999496
and O 0 0.002944828
nephrotoxicity B-Disease 0 0.9999949
in O 0 0.0005385382
both O 0 0.00033991842
animal O 0 0.000569184
and O 0 0.0005709521
clinical O 0 0.0018337466
studies O 0 0.0016127987
. O 0 0.0019736465

In O 0 0.0017182668
this O 0 0.0014699608
study O 0 0.0011267515
, O 0 0.0007079566
62 O 0 0.0005796706
patients O 0 0.00032083647
with O 0 0.00018457306
confirmed O 0 0.00012876539
initial O 0 0.0001155699
normal O 0 0.0004513756
renal O 0 0.6271725
function O 0 0.00019027069
and O 0 0.00010909273
treated O 0 0.0001430926
with O 0 0.000108171196
2 O 0 5.0693132e-05
to O 0 4.1482966e-05
5 O 0 4.4534692e-05
mg O 0 0.0008221117
/ O 0 0.0002520966
kg O 0 0.00017043667
/ O 0 0.00012721858
day O 0 3.1272753e-05
of O 0 0.00012528076
gentamicin B-Chemical 1 0.99993026
sulfate I-Chemical 0 0.9996075
or O 0 0.0007216669
tobramycin B-Chemical 0 0.9999907
sulfate I-Chemical 0 0.99936503
for O 0 0.00010221169
a O 0 9.0036054e-05
minimum O 0 3.47981e-05
of O 0 6.142011e-05
seven O 0 3.452457e-05
days O 0 1.7521514e-05
were O 0 3.2735246e-05
followed O 0 2.7444801e-05
up O 0 4.434991e-05
prospectively O 0 5.3609598e-05
for O 0 2.9071432e-05
the O 0 4.64471e-05
development O 0 0.00012479252
of O 0 0.00020855649
aminoglycoside B-Chemical 0 0.9875745
- O 0 0.00040211435
related O 0 5.9898153e-05
renal B-Disease 0 0.91971064
failure I-Disease 0 0.23526318
, O 0 0.00013756462
defined O 0 5.00487e-05
as O 0 5.0159502e-05
at O 0 3.9988878e-05
least O 0 5.75192e-05
a O 0 0.00013125714
one O 0 0.00010118897
- O 0 0.0002710135
third O 0 0.00025703904
reduction O 0 0.0007472457
in O 0 0.00061010977
renal O 0 0.8827756
function O 0 0.0027752249
. O 0 0.002204557

In O 0 0.0020663934
these O 0 0.0020433345
62 O 0 0.0019407525
patients O 0 0.0012513107
, O 0 0.0006963418
no O 0 0.00030628775
other O 0 0.00037986442
causes O 0 0.0006564391
for O 0 0.0005474143
renal B-Disease 0 0.9663391
failure I-Disease 0 0.49217856
could O 0 0.0009334872
be O 0 0.0009641562
identified O 0 0.0013933495
. O 0 0.0021643096

Five O 0 0.003341614
of O 0 0.0021879706
33 O 0 0.0018965093
( O 0 0.001060501
15 O 0 0.00042338518
% O 0 0.00044311958
) O 0 0.00039118947
of O 0 0.00026604938
the O 0 0.0003271015
tobramycin B-Chemical 0 0.99973243
- O 0 0.0011948097
treated O 0 0.00035965105
patients O 0 0.00023614008
and O 0 0.00011452705
16 O 0 8.698021e-05
of O 0 0.00012164101
29 O 0 0.00020654137
( O 0 0.00013855513
55 O 0 0.00010803173
. O 0 5.1471307e-05
2 O 0 5.9698905e-05
% O 0 8.3272906e-05
) O 0 0.00011008316
of O 0 0.00010835053
the O 0 0.00018546556
gentamicin B-Chemical 1 0.99899393
- O 0 0.0009956677
treated O 0 0.0005754022
patients O 0 0.00079458917
had O 0 0.00091873703
renal B-Disease 0 0.9759219
failure I-Disease 0 0.8130131
. O 0 0.0030535618

Thus O 0 0.0026095726
, O 0 0.0031141927
gentamicin B-Chemical 1 0.99630016
was O 0 0.0013496984
associated O 0 0.0005296847
with O 0 0.00082480465
renal B-Disease 0 0.9415772
failure I-Disease 0 0.21396178
more O 0 0.00038622244
than O 0 0.000101184436
three O 0 6.303925e-05
times O 0 7.8472905e-05
as O 0 0.0001630528
often O 0 0.0003406491
as O 0 0.0004864515
was O 0 0.0013284057
tobramycin B-Chemical 0 0.9988601
. O 0 0.003873841

Metabolic O 0 0.04680159
involvement O 0 0.011514838
in O 0 0.011884489
adriamycin B-Chemical 0 0.99899703
cardiotoxicity B-Disease 0 0.99982774
. O 0 0.02396814

The O 0 0.002455268
cardiotoxic B-Disease 0 0.9783992
effects O 0 0.0018491808
of O 0 0.002258822
adriamycin B-Chemical 0 0.9994824
were O 0 0.0006789875
studied O 0 0.0003612723
in O 0 0.00020740397
mammalian O 0 0.0003125401
myocardial O 0 0.9866001
cells O 0 0.0005972992
in O 0 0.0002506423
culture O 0 0.00047882
as O 0 0.00036539976
a O 0 0.00071390625
model O 0 0.0010820158
system O 0 0.001849224
. O 0 0.0022423347

Adriamycin B-Chemical 0 0.99796367
inhibited O 0 0.008204888
cell O 0 0.0067922603
growth O 0 0.0037817114
and O 0 0.00057257165
the O 0 0.00037530423
rhythmic O 0 0.00086998224
contractions O 0 0.0056090574
characteristic O 0 0.00040468827
of O 0 0.0007329841
myocardial O 0 0.99156415
cells O 0 0.0016431754
in O 0 0.0010452663
culture O 0 0.0027614143
. O 0 0.0025925692

A O 0 0.014981513
possible O 0 0.0016522069
involvement O 0 0.0015221881
of O 0 0.0011073131
energy O 0 0.0030659533
metabolism O 0 0.07993727
was O 0 0.00037297493
suggested O 0 0.00015290445
previously O 0 0.00016818575
, O 0 0.00015820887
and O 0 0.00010694619
in O 0 7.7464276e-05
this O 0 0.00010596699
study O 0 0.00011971942
the O 0 0.000117014024
adenylate O 0 0.035755012
energy O 0 0.00075762323
charge O 0 0.001957231
and O 0 0.00022354143
phosphorylcreatine B-Chemical 0 0.9214366
mole O 0 0.08027897
fraction O 0 0.0001316825
were O 0 7.961187e-05
determined O 0 7.083192e-05
in O 0 0.00010785047
the O 0 0.00029836295
adriamycin B-Chemical 0 0.99919146
- O 0 0.001974678
treated O 0 0.0017954465
cells O 0 0.002670114
. O 0 0.0023189888

The O 0 0.0029250998
adenylate O 0 0.07026805
energy O 0 0.005515323
charge O 0 0.007014159
was O 0 0.0008332484
found O 0 0.0003641024
to O 0 0.00027497407
be O 0 0.00024445273
significantly O 0 0.00034521584
decreased O 0 0.0005941412
, O 0 0.00029336082
while O 0 0.00022104365
the O 0 0.0003544902
phophorylcreatine B-Chemical 0 0.30850512
mole O 0 0.22413294
fraction O 0 0.0009250463
was O 0 0.0010273972
unchanged O 0 0.0015628701
. O 0 0.0019911001

Such O 0 0.0055480017
disparity O 0 0.002783457
suggests O 0 0.0014030829
an O 0 0.0023694343
inhibition O 0 0.0053031947
of O 0 0.010182255
creatine B-Chemical 1 0.9997224
phosphokinase O 0 0.9997216
. O 0 0.012761398

The O 0 0.0014719877
addition O 0 0.0008981982
of O 0 0.0013731106
1 O 0 0.00109219
mM O 0 0.09938785
adenosine B-Chemical 0 0.9918811
to O 0 0.00040158993
the O 0 0.00042923854
myocardial O 0 0.9956814
cell O 0 0.0023817648
cultures O 0 0.00028366802
markedly O 0 0.0005766618
increases O 0 0.00017777953
the O 0 0.00025793732
ATP B-Chemical 0 0.9936838
concentration O 0 0.00046768322
through O 0 9.086823e-05
a O 0 0.0001641956
pathway O 0 0.00015088762
reportedly O 0 0.0008119286
leading O 0 0.00032411152
to O 0 0.00021095785
a O 0 0.00048615114
compartmentalized O 0 0.00074954395
ATP B-Chemical 0 0.96165335
pool O 0 0.0029018428
. O 0 0.0023506337

In O 0 0.0020665673
the O 0 0.0026248817
adriamycin B-Chemical 0 0.9992599
- O 0 0.0039008805
treated O 0 0.0012037497
cells O 0 0.00073722686
, O 0 0.0002955759
the O 0 0.00015117176
addition O 0 0.00010898376
of O 0 0.00043220422
adenosine B-Chemical 0 0.994304
increased O 0 0.000525666
the O 0 0.00024335788
adenylate O 0 0.13567129
charge O 0 0.00392741
and O 0 0.00014738283
, O 0 0.000113325324
concomitant O 0 0.00023378669
with O 0 0.00011308417
this O 0 0.00014667668
inrcease O 0 0.0037157447
, O 0 0.000112141766
the O 0 7.888367e-05
cells O 0 0.00013242936
' O 0 0.00010649862
functional O 0 8.2923056e-05
integrity O 0 0.00012635282
, O 0 8.0771526e-05
in O 0 4.8372942e-05
terms O 0 4.0452986e-05
of O 0 7.310021e-05
percentage O 0 5.775653e-05
of O 0 0.00013161836
beating O 0 0.0006025441
cells O 0 0.00018943814
and O 0 0.00012660623
rate O 0 0.00017689855
of O 0 0.00037903426
contractions O 0 0.0224561
, O 0 0.00062742096
was O 0 0.0007535021
maintained O 0 0.0011774579
. O 0 0.0018154641

Age O 0 0.017767036
- O 0 0.0033610763
dependent O 0 0.00079306075
sensitivity O 0 0.002048012
of O 0 0.00096052635
the O 0 0.0006862423
rat O 0 0.0013445433
to O 0 0.0007633243
neurotoxic B-Disease 0 0.98538476
effects O 0 0.00223459
of O 0 0.0053069666
streptomycin B-Chemical 1 0.99967587
. O 0 0.007327317

Streptomycin B-Chemical 0 0.9946532
sulfate O 0 0.9726151
( O 0 0.0032208827
300 O 0 0.0032198844
mg O 0 0.027068296
/ O 0 0.0016479297
kg O 0 0.00090877275
s O 0 0.00032129805
. O 0 0.00018528754
c O 0 0.001160726
. O 0 0.00014019189
) O 0 0.00022294692
was O 0 0.0001085616
injected O 0 7.5440475e-05
for O 0 5.3845328e-05
various O 0 7.3410294e-05
periods O 0 4.6727175e-05
into O 0 3.7246227e-05
preweanling O 0 0.002434565
rats O 0 0.00015126477
and O 0 9.453038e-05
for O 0 8.029247e-05
3 O 0 9.496822e-05
weeks O 0 7.563994e-05
into O 0 0.00015353897
weanling O 0 0.0020278955
rats O 0 0.0018326516
. O 0 0.0018024704

Beginning O 0 0.0035128917
at O 0 0.0010790521
8 O 0 0.0006811912
days O 0 0.0003137899
of O 0 0.0005209392
age O 0 0.0004693244
, O 0 0.00033329945
body O 0 0.0006424515
movement O 0 0.0003794072
and O 0 0.00028701685
hearing O 0 0.8762656
were O 0 0.00021180557
examined O 0 8.387549e-05
for O 0 8.50562e-05
6 O 0 7.521441e-05
and O 0 0.000116694355
up O 0 0.000158214
to O 0 0.00018746
17 O 0 0.0003728432
weeks O 0 0.00022651188
, O 0 0.0008628527
respectively O 0 0.0024516582
. O 0 0.0023460302

Abnormal B-Disease 0 0.02077734
movements I-Disease 0 0.01239432
and O 0 0.0028179917
deafness B-Disease 0 0.99932694
occurred O 0 0.00067287753
only O 0 0.0004109582
in O 0 0.00021434342
rats O 0 0.00024685106
treated O 0 0.0001518241
during O 0 4.707146e-05
the O 0 8.398001e-05
preweaning O 0 0.0006413452
period O 0 3.905773e-05
; O 0 5.609828e-05
within O 0 1.6752769e-05
this O 0 4.398524e-05
period O 0 2.1930975e-05
the O 0 3.8278613e-05
greatest O 0 7.876176e-05
sensitivities O 0 0.0001317987
for O 0 4.799395e-05
these O 0 0.000117920215
abnormalities O 0 0.0015473777
occurred O 0 6.0858525e-05
from O 0 5.276094e-05
2 O 0 4.804328e-05
to O 0 5.086969e-05
11 O 0 8.179904e-05
- O 0 0.00012966532
17 O 0 8.171343e-05
and O 0 5.8267586e-05
5 O 0 3.8234946e-05
to O 0 4.034638e-05
11 O 0 4.761476e-05
days O 0 2.3072731e-05
of O 0 8.256374e-05
age O 0 0.00012521601
, O 0 0.00013124938
respectively O 0 0.00029350125
, O 0 9.697419e-05
indicating O 0 4.3625903e-05
that O 0 4.0949093e-05
the O 0 7.485194e-05
cochlea O 0 0.00059582375
is O 0 6.934479e-05
more O 0 8.390541e-05
sensitive O 0 6.422521e-05
to O 0 0.000108155014
streptomycin B-Chemical 1 0.999647
than O 0 9.977673e-05
the O 0 9.712151e-05
site O 0 9.448432e-05
( O 0 0.00017847047
vestibular O 0 0.0035914998
or O 0 0.00014815654
central O 0 0.00027400654
) O 0 0.00030926132
responsible O 0 0.00021820002
for O 0 0.0003574852
the O 0 0.0014130675
dyskinesias B-Disease 0 0.99959546
. O 0 0.003188463

Late O 0 0.03429655
, O 0 0.01354142
late O 0 0.02633879
doxorubicin B-Chemical 1 0.99771714
cardiotoxicity B-Disease 0 0.99974674
. O 0 0.028591683

Cardiac B-Disease 0 0.93476886
toxicity I-Disease 2 0.99906856
is O 0 0.001643637
a O 0 0.0009129168
major O 0 0.0005613958
complication O 0 0.0033062696
which O 0 0.0004091386
limits O 0 0.00049679424
the O 0 0.00021391547
use O 0 0.00021317495
of O 0 0.00055058696
adriamycin B-Chemical 0 0.998669
as O 0 0.00065842696
a O 0 0.0011734612
chemotherapeutic O 0 0.024684925
agent O 0 0.016103711
. O 0 0.0032842532

Cardiomyopathy B-Disease 0 0.9259909
is O 0 0.0018719318
frequent O 0 0.0009755084
when O 0 0.00030305545
the O 0 0.00027662748
total O 0 0.00025470924
dose O 0 0.00066309795
exceeds O 0 0.00016996426
600 O 0 0.0010373954
mg O 0 0.008926474
/ O 0 0.00059479446
m2 O 0 0.00084555877
and O 0 9.7468044e-05
occurs O 0 5.2597323e-05
within O 0 2.6949016e-05
one O 0 4.8413185e-05
to O 0 6.287379e-05
six O 0 5.5116918e-05
months O 0 4.9636517e-05
after O 0 7.676875e-05
cessation O 0 0.00041368246
of O 0 0.0008666476
therapy O 0 0.0023148046
. O 0 0.0020928942

A O 0 0.019264627
patient O 0 0.0019761992
is O 0 0.0010119998
reported O 0 0.00077858515
who O 0 0.00083173177
developed O 0 0.00096130907
progressive O 0 0.64823157
cardiomyopathy B-Disease 0 0.9999832
two O 0 0.00021943264
and O 0 0.00016081732
one O 0 9.220317e-05
- O 0 0.00016737959
half O 0 5.3464144e-05
years O 0 4.804149e-05
after O 0 2.621638e-05
receiving O 0 0.00014133344
580 O 0 0.0032205766
mg O 0 0.0049421177
/ O 0 0.0004445195
m2 O 0 0.0007270277
which O 0 0.00018283477
apparently O 0 0.00041477845
represents O 0 0.00022928404
late O 0 0.00082860235
, O 0 0.0008679131
late O 0 0.0063396725
cardiotoxicity B-Disease 0 0.99991405
. O 0 0.004190826

Attenuation O 0 0.008023376
of O 0 0.002317468
the O 0 0.002317601
lithium B-Chemical 0 0.9998307
- O 0 0.0056846724
induced O 0 0.0034169154
diabetes B-Disease 0 0.9998609
- I-Disease 0 0.015063866
insipidus I-Disease 0 0.9980952
- I-Disease 0 0.0011082444
like I-Disease 0 0.0003282677
syndrome I-Disease 0 0.07474329
by O 0 0.0011534205
amiloride B-Chemical 0 0.99990094
in O 0 0.0016578496
rats O 0 0.0030267986
. O 0 0.0021260413

The O 0 0.0014001629
effect O 0 0.0012105226
of O 0 0.0023700802
amiloride B-Chemical 0 0.99993277
on O 0 0.001196934
lithium B-Chemical 0 0.9999552
- O 0 0.0027218757
induced O 0 0.00086267677
polydipsia B-Disease 2 0.99996674
and O 0 0.0009575912
polyuria B-Disease 0 0.9986468
and O 0 0.00013855883
on O 0 4.501857e-05
the O 0 0.00011969258
lithium B-Chemical 0 0.9998049
concentration O 0 0.00043615556
in O 0 8.265449e-05
the O 0 9.69044e-05
plasma O 0 0.0027846193
, O 0 0.00014418064
brain O 0 0.0014080186
, O 0 0.00020968348
kidney O 0 0.67038053
, O 0 0.00025813855
thyroid O 0 0.27091488
and O 0 0.00016688145
red O 0 0.0019014267
blood O 0 0.0019397866
cells O 0 0.00017952627
was O 0 0.00010475753
investigated O 0 7.325239e-05
in O 0 0.00010153161
rats O 0 0.00023339741
, O 0 0.00021091945
chronically O 0 0.0009626573
treated O 0 0.0008144012
with O 0 0.0019209168
LiCl B-Chemical 0 0.99806255
. O 0 0.003603084

Amiloride B-Chemical 0 0.99955875
reduced O 0 0.0037747317
the O 0 0.0013038905
drinking O 0 0.019261362
and O 0 0.00062267185
urine O 0 0.022823585
volume O 0 0.00059141434
of O 0 0.00026153497
rats O 0 0.00024949215
in O 0 0.000119891345
an O 0 0.00025061314
acute O 0 0.15906191
( O 0 0.00026914332
6 O 0 5.638899e-05
or O 0 5.9217236e-05
12 O 0 4.6918547e-05
h O 0 7.891588e-05
) O 0 0.00017451987
and O 0 0.00015368516
a O 0 0.0004290679
subacute O 0 0.8936024
( O 0 0.0005381472
3 O 0 0.00021778145
days O 0 0.0002022642
) O 0 0.0007680261
experiment O 0 0.0009094662
. O 0 0.001973745

6 O 0 0.0014931614
h O 0 0.00088230317
after O 0 0.00033807545
the O 0 0.000505813
administration O 0 0.0016900371
of O 0 0.0017650275
amiloride B-Chemical 0 0.99998105
, O 0 0.0008569705
a O 0 0.00040077744
reduction O 0 0.0005935033
was O 0 0.0001619579
observed O 0 7.879339e-05
in O 0 8.1336155e-05
the O 0 0.00014902622
lithium B-Chemical 0 0.99975187
content O 0 0.0002672552
of O 0 0.00015924226
the O 0 0.00017381988
renal O 0 0.8968636
medulla O 0 0.083028995
but O 0 0.00018826479
not O 0 0.0001223132
in O 0 0.00014724478
the O 0 0.00023051354
other O 0 0.0004052036
organs O 0 0.0028487702
studied O 0 0.0017769588
. O 0 0.0019362754

At O 0 0.001106705
12 O 0 0.0010075226
h O 0 0.0010045987
, O 0 0.00093977194
all O 0 0.00055318896
the O 0 0.0004936751
tissues O 0 0.0007439208
showed O 0 0.00040998874
a O 0 0.00057344337
slight O 0 0.0010271756
increase O 0 0.0007218533
in O 0 0.001311566
lithium B-Chemical 0 0.99969316
levels O 0 0.004483232
. O 0 0.003304485

After O 0 0.0009804458
3 O 0 0.00082006335
days O 0 0.0003676635
of O 0 0.00053747644
combined O 0 0.0005854998
treatment O 0 0.0004398018
, O 0 0.00035186065
a O 0 0.0003111508
marked O 0 0.00048367385
elevation O 0 0.009073964
in O 0 0.0002052737
plasma O 0 0.0036690577
and O 0 0.0002362054
tissue O 0 0.0025222686
lithium B-Chemical 0 0.9998896
levels O 0 0.00035669474
accompanied O 0 0.00083229074
a O 0 0.00045147436
reduction O 0 0.0010244016
in O 0 0.0006185359
water O 0 0.03065056
intake O 0 0.3118728
. O 0 0.0023372765

In O 0 0.0017956739
all O 0 0.0011421698
the O 0 0.000709139
experiments O 0 0.00043665664
, O 0 0.00041409736
the O 0 0.00023507395
attenuation O 0 0.0004301593
of O 0 0.0003516053
the O 0 0.0005000493
lithium B-Chemical 0 0.9999671
- O 0 0.0026213783
induced O 0 0.0014709856
diabetes B-Disease 0 0.9999441
- I-Disease 0 0.009728462
insipidus I-Disease 0 0.9977986
- I-Disease 0 0.00046047836
like I-Disease 0 9.195767e-05
syndrome I-Disease 0 0.053790614
by O 0 0.00031995642
amiloride B-Chemical 0 0.99998736
was O 0 0.00028442979
accompanied O 0 0.0003719635
by O 0 9.367432e-05
a O 0 0.0001011992
reduction O 0 0.00016778019
of O 0 8.3613726e-05
the O 0 5.465345e-05
ratio O 0 8.077969e-05
between O 0 3.0226618e-05
the O 0 9.538071e-05
lithium B-Chemical 0 0.99981755
concentration O 0 0.0003850154
in O 0 7.678633e-05
the O 0 0.000105640305
renal O 0 0.8184586
medulla O 0 0.046675652
and O 0 0.000104912084
its O 0 0.00012278612
levels O 0 6.498397e-05
in O 0 5.673684e-05
the O 0 7.5340686e-05
blood O 0 0.0006475602
and O 0 0.00010663752
an O 0 0.00017432893
elevation O 0 0.003303678
in O 0 0.00021168988
the O 0 0.00040398055
plasma O 0 0.098978266
potassium B-Chemical 0 0.9998068
level O 0 0.0024538508
. O 0 0.0025216138

It O 0 0.002367432
is O 0 0.0010572543
concluded O 0 0.00058382243
that O 0 0.00056055904
acute O 0 0.8093642
amiloride B-Chemical 0 0.99998987
administration O 0 0.09149123
to O 0 0.00082061137
lithium B-Chemical 0 0.9999777
- O 0 0.0011351054
treated O 0 0.0002866638
patients O 0 0.00026812268
suffering O 0 0.021701448
from O 0 0.00014075941
polydipsia B-Disease 2 0.99995434
and O 0 0.00034091325
polyuria B-Disease 0 0.9964135
might O 0 5.0651575e-05
relieve O 0 0.00016769735
these O 0 8.733094e-05
patients O 0 9.4117706e-05
but O 0 7.900692e-05
prolonged O 0 0.0006503167
amiloride B-Chemical 0 0.9999944
supplementation O 0 0.8664564
would O 0 0.00011665173
result O 0 8.787377e-05
in O 0 0.00011751532
elevated O 0 0.007995737
lithium B-Chemical 0 0.99990845
levels O 0 0.0004220536
and O 0 0.0003357375
might O 0 0.00028690495
be O 0 0.0006252239
hazardous O 0 0.0042300546
. O 0 0.0018838977

Cardiovascular B-Disease 0 0.86993575
complications I-Disease 0 0.39315933
associated O 0 0.0021128182
with O 0 0.003180022
terbutaline B-Chemical 0 0.9996562
treatment O 0 0.002717773
for O 0 0.0021419625
preterm B-Disease 0 0.8561839
labor I-Disease 0 0.66204363
. O 0 0.00538457

Severe O 0 0.38481778
cardiovascular B-Disease 0 0.9966371
complications I-Disease 0 0.7672553
occurred O 0 0.00069964246
in O 0 0.00033091023
eight O 0 0.00016892314
of O 0 0.00026781022
160 O 0 0.0006568979
patients O 0 0.00031803045
treated O 0 0.00039629402
with O 0 0.0008405809
terbutaline B-Chemical 0 0.99982387
for O 0 0.0013280128
preterm B-Disease 0 0.9129316
labor I-Disease 0 0.67378986
. O 0 0.003298521

Associated O 0 0.008393985
corticosteroid O 0 0.9824327
therapy O 0 0.00300451
and O 0 0.0015800995
twin O 0 0.01063606
gestations O 0 0.0030672844
appear O 0 0.00072050426
to O 0 0.0006962628
be O 0 0.0009994764
predisposing O 0 0.004188679
factors O 0 0.0031706323
. O 0 0.0033695432

Potential O 0 0.0054984163
mechanisms O 0 0.0030820274
of O 0 0.0026155035
the O 0 0.0023445776
pathophysiology O 0 0.009366365
are O 0 0.0024370423
briefly O 0 0.0037072601
discussed O 0 0.004442749
. O 0 0.0055852146

Toxic B-Disease 0 0.9980703
hepatitis I-Disease 2 0.9999702
induced O 0 0.0054823495
by O 0 0.0021081402
antithyroid O 0 0.9863323
drugs O 0 0.1648015
: O 0 0.00047277758
four O 0 0.00012334764
cases O 0 0.00016354484
including O 0 7.7723846e-05
one O 0 8.54232e-05
with O 0 0.0001672657
cross O 0 0.0003379549
- O 0 0.00036887906
reactivity O 0 0.00066873356
between O 0 0.00034727744
carbimazole B-Chemical 0 0.99940825
and O 0 0.0029053711
benzylthiouracil B-Chemical 0 0.9714045
. O 0 0.0030237252

OBJECTIVE O 0 0.025721617
: O 0 0.0026176202
This O 0 0.0017193737
study O 0 0.00094511465
was O 0 0.00052163977
conducted O 0 0.00026971256
to O 0 0.00018641497
assess O 0 9.477796e-05
the O 0 0.0001562986
occurrence O 0 0.0002871217
of O 0 0.00044896477
hepatic B-Disease 0 0.9933484
adverse I-Disease 0 0.13163829
effects I-Disease 0 0.0008467916
encountered O 0 0.000537491
with O 0 0.0012629222
antithyroid O 0 0.9889515
drugs O 0 0.30104062
. O 0 0.00271388

METHODS O 0 0.0015914926
: O 0 0.0015058998
Retrospective O 0 0.002822672
review O 0 0.00086760806
of O 0 0.00045416044
medical O 0 0.00060712156
records O 0 0.00031875347
of O 0 0.00021388345
236 O 0 0.00063162675
patients O 0 0.00019645109
with O 0 0.00030035165
hyperthyroidism B-Disease 0 0.99993885
admitted O 0 0.00062677154
in O 0 8.453022e-05
our O 0 0.00014302523
department O 0 0.0002623066
( O 0 0.00015368134
in O 0 0.000100302845
- O 0 0.00019813319
or O 0 9.173992e-05
out O 0 0.000117386415
- O 0 0.00035641683
patients O 0 0.00034313183
) O 0 0.0003644146
from O 0 0.0002867294
1986 O 0 0.0013580342
to O 0 0.00072449807
1992 O 0 0.0027865944
. O 0 0.0018800249

RESULTS O 0 0.005014104
: O 0 0.0021735209
Four O 0 0.001215451
patients O 0 0.0012409176
( O 0 0.00089194474
1 O 0 0.0003791924
. O 0 0.00020976445
7 O 0 0.0001697032
% O 0 0.00022457262
) O 0 0.00023798537
were O 0 0.00012069474
identified O 0 0.00011138076
with O 0 0.0003604646
toxic B-Disease 0 0.99884146
hepatitis I-Disease 2 0.9999993
which O 0 0.002309929
could O 0 0.00017071106
reasonably O 0 0.00030314847
be O 0 9.3043825e-05
attributed O 0 7.2841416e-05
to O 0 9.8044315e-05
the O 0 0.00015716867
use O 0 0.00023767947
of O 0 0.00076980516
antithyroid O 0 0.9702709
agent O 0 0.021480044
. O 0 0.0029013902

Two O 0 0.0025102096
patients O 0 0.0022391747
had O 0 0.0015070891
a O 0 0.0041517224
cholestatic B-Disease 0 0.9999908
hepatitis I-Disease 2 0.9999938
induced O 0 0.021207899
by O 0 0.0055550877
carbimazole B-Chemical 0 0.999907
( O 0 0.013007517
N B-Chemical 0 0.99838185
omercazole I-Chemical 0 0.7299579
) O 0 0.005555278
. O 0 0.0032550246

Two O 0 0.0029329027
others O 0 0.0031014506
had O 0 0.0012712387
a O 0 0.0012162443
mixed O 0 0.002287811
( O 0 0.0031336006
cholestatic B-Disease 0 0.9999684
and O 0 0.0029343655
cytolytic O 0 0.69178087
) O 0 0.009817545
hepatitis B-Disease 2 0.999966
following O 0 0.006858823
carbimazole B-Chemical 0 0.9997136
. O 0 0.0052867197

One O 0 0.0021159484
of O 0 0.0014421028
the O 0 0.00082328444
latter O 0 0.0010447144
two O 0 0.00030892066
patients O 0 0.00038393046
further O 0 0.0003173381
experienced O 0 0.00031077547
a O 0 0.00048349798
cytolytic O 0 0.7362482
hepatitis B-Disease 2 0.9999937
which O 0 0.0010807232
appeared O 0 0.00025374696
after O 0 0.00010157122
Benzylthiouracil B-Chemical 0 0.102392636
( O 0 0.0006529892
Basd B-Chemical 0 0.03005961
ne I-Chemical 0 0.040370017
) O 0 0.0007348375
had O 0 0.00059036544
replaced O 0 0.0014755692
carbimazole B-Chemical 0 0.9990522
. O 0 0.003548811

Biological O 0 0.0063352105
features O 0 0.0020962716
of O 0 0.003420938
hepatitis B-Disease 2 0.99992406
disappeared O 0 0.0014284373
in O 0 0.00043841673
all O 0 0.0002712177
cases O 0 0.0001960768
after O 0 5.5004286e-05
cessation O 0 0.00014474103
of O 0 0.00014262591
the O 0 0.00014279957
incriminated O 0 0.0007247836
drug O 0 0.0107735945
, O 0 0.0001969434
while O 0 0.00018588743
biliary O 0 0.6252726
, O 0 0.00026948738
viral O 0 0.00067890174
and O 0 0.0003064116
immunological O 0 0.0017865524
searches O 0 0.00076715904
were O 0 0.0007677232
negative O 0 0.0018032987
. O 0 0.002121724

Only O 0 0.0032507712
2 O 0 0.0013492086
patients O 0 0.0010164087
of O 0 0.00073521823
our O 0 0.00077564747
retrospective O 0 0.0024703427
study O 0 0.00058501225
experienced O 0 0.0005942635
a O 0 0.0009191048
mild O 0 0.27961516
or O 0 0.0014781357
severe O 0 0.34107623
neutropenia B-Disease 0 0.9993718
. O 0 0.0052849473

CONCLUSION O 0 0.03967283
: O 0 0.007157788
Toxic B-Disease 0 0.99824643
hepatitis I-Disease 2 0.999987
is O 0 0.0015118747
a O 0 0.0006152387
potential O 0 0.00034750495
adverse O 0 0.008225129
effect O 0 0.00018622968
of O 0 0.00043221947
antithyroid O 0 0.98065627
drugs O 0 0.09354735
which O 0 0.00030296188
warrants O 0 0.00028848374
, O 0 0.00012124821
as O 0 7.049231e-05
for O 0 7.955747e-05
haematological O 0 0.9024457
disturbances O 0 0.07325848
, O 0 0.00015278523
a O 0 0.00014660187
pre O 0 0.00023059465
- O 0 0.00017750108
therapeutic O 0 0.00017319532
determination O 0 0.00029518103
and O 0 0.00010929035
a O 0 0.00013885932
careful O 0 0.00014019349
follow O 0 8.4906205e-05
- O 0 0.00021631457
up O 0 0.00015415245
of O 0 0.00024708323
relevant O 0 0.00028725064
biological O 0 0.0007908334
markers O 0 0.0029228313
. O 0 0.0021078095

Moreover O 0 0.004703872
, O 0 0.007273326
hepatotoxicity B-Disease 0 0.9999262
may O 0 0.0014154352
not O 0 0.00067056005
be O 0 0.0003998286
restricted O 0 0.00024611971
to O 0 0.0002705243
one O 0 0.000286975
class O 0 0.0006450747
of O 0 0.001325997
antithyroid O 0 0.97129804
agents O 0 0.023173776
. O 0 0.0036932318

Interactive O 0 0.0071682776
effects O 0 0.0018461784
of O 0 0.0013377097
variations O 0 0.0008380868
in O 0 0.0009497219
[ O 0 0.004815003
Na B-Chemical 1 0.99984884
] O 0 0.0030073866
o O 0 0.00376492
and O 0 0.0006721853
[ O 0 0.0029981534
Ca B-Chemical 1 0.99981993
] O 0 0.0015715731
o O 0 0.0015834243
on O 0 0.00022272236
rat O 0 0.0011221911
atrial O 0 0.2577206
spontaneous O 0 0.0042911055
frequency O 0 0.0019349183
. O 0 0.002201914

The O 0 0.0014743697
effects O 0 0.0012836808
of O 0 0.0009829515
varying O 0 0.00065613765
the O 0 0.00043233935
extracellular O 0 0.00068332325
concentrations O 0 0.0010119679
of O 0 0.0014266777
Na B-Chemical 1 0.9999634
and O 0 0.003038037
Ca B-Chemical 1 0.99996555
( O 0 0.0017540683
[ O 0 0.0037839005
Na B-Chemical 1 0.9999515
] O 0 0.0013564399
o O 0 0.002036116
and O 0 0.0002898462
[ O 0 0.0017615955
Ca B-Chemical 1 0.99993587
] O 0 0.0013127652
o O 0 0.0023679594
) O 0 0.00017972973
on O 0 4.371827e-05
both O 0 7.781817e-05
, O 0 8.545179e-05
the O 0 7.1510265e-05
spontaneous O 0 0.0004117986
beating O 0 0.000388186
and O 0 6.922579e-05
the O 0 5.747698e-05
negative O 0 0.00013154156
chronotropic O 0 0.4645227
action O 0 0.0002590259
of O 0 0.00069399516
verapamil B-Chemical 0 0.99999034
, O 0 0.00033410938
were O 0 0.00014522129
studied O 0 0.00014523872
in O 0 0.00012995709
the O 0 0.00020208953
isolated O 0 0.00035967235
rat O 0 0.001912421
atria O 0 0.03766338
. O 0 0.0018802001

Basal O 0 0.008087684
frequency O 0 0.0024658013
( O 0 0.0023295868
BF O 0 0.016370853
) O 0 0.0010515903
evaluated O 0 0.00035243723
by O 0 0.0003260327
surface O 0 0.0004998685
electrogram O 0 0.01125346
was O 0 0.00037487887
223 O 0 0.002181074
+ O 0 0.00046343933
/ O 0 0.00054250885
- O 0 0.0002441937
4 O 0 7.612425e-05
beats O 0 0.0005620442
/ O 0 0.00022458975
min O 0 0.00010439186
. O 0 4.89364e-05
in O 0 6.094425e-05
control O 0 0.00011202571
Krebs O 0 0.031190338
- O 0 0.0003246772
Ringer O 0 0.015324015
containing O 0 0.00012770743
137 O 0 0.0012018374
mM O 0 0.18651336
Na B-Chemical 1 0.9999217
and O 0 0.0003811616
1 O 0 0.00017603471
. O 0 0.00013527831
35 O 0 0.0003670179
mM O 0 0.08275122
Ca B-Chemical 1 0.99977964
( O 0 0.00624059
N O 0 0.9546158
) O 0 0.0044492055
. O 0 0.002990546

It O 0 0.0033529578
decreased O 0 0.0030875336
by O 0 0.0014749664
16 O 0 0.0010403007
+ O 0 0.0015841738
/ O 0 0.0018100041
- O 0 0.0008209097
3 O 0 0.00022132033
% O 0 0.00023571673
by O 0 0.0002461054
lowering O 0 0.009241248
[ O 0 0.0043480056
Na B-Chemical 1 0.99994373
] O 0 0.0014573344
o O 0 0.0013231332
to O 0 0.00014874256
78 O 0 0.00048676645
mM O 0 0.015123325
( O 0 0.00045815564
LNa O 0 0.2521701
) O 0 0.0003080034
, O 0 0.00015512417
23 O 0 0.00019667449
+ O 0 0.00028290393
/ O 0 0.00046282014
- O 0 0.00024355564
2 O 0 7.4282725e-05
% O 0 8.010969e-05
by O 0 8.496556e-05
lowering O 0 0.000934162
simultaneously O 0 0.00020094361
[ O 0 0.0017525109
Na B-Chemical 1 0.9999517
] O 0 0.0009216922
o O 0 0.0009350321
to O 0 0.000101769096
78 O 0 0.00033545404
mM O 0 0.0063294787
and O 0 0.00027120608
[ O 0 0.0016412756
Ca B-Chemical 1 0.9999275
] O 0 0.0009033521
o O 0 0.0009183686
to O 0 8.647935e-05
0 O 0 8.237845e-05
. O 0 7.181787e-05
675 O 0 0.0026541979
mM O 0 0.010137165
( O 0 0.00037623022
LNa O 0 0.28368345
+ O 0 0.00086910813
LCa O 0 0.978789
) O 0 0.0003048521
and O 0 0.00013223175
31 O 0 0.0001886213
+ O 0 0.00026037107
/ O 0 0.00041751572
- O 0 0.00021384718
5 O 0 6.381296e-05
% O 0 8.498736e-05
by O 0 0.000108277505
lowering O 0 0.0068546208
[ O 0 0.0028832268
Na B-Chemical 1 0.9999608
] O 0 0.0010227199
o O 0 0.0009828424
to O 0 9.796947e-05
78 O 0 0.00028552255
mM O 0 0.0021789344
plus O 0 9.761473e-05
increasing O 0 0.00031741106
[ O 0 0.0026981102
Ca B-Chemical 1 0.9999449
] O 0 0.0012669124
o O 0 0.0014131442
to O 0 0.00012540194
3 O 0 9.900194e-05
. O 0 8.765407e-05
6 O 0 0.00012861469
mM O 0 0.0028342728
( O 0 0.0008602225
LNa O 0 0.23448938
+ O 0 0.0031626008
HCa O 0 0.9525145
) O 0 0.0038767795
. O 0 0.0027647307

At O 0 0.0013630436
normal O 0 0.0044225142
[ O 0 0.010755788
Na B-Chemical 1 0.99969435
] O 0 0.0055856276
o O 0 0.0052223746
, O 0 0.0006302167
decrease O 0 0.00051834795
( O 0 0.00040178676
0 O 0 0.00018958595
. O 0 0.00015482285
675 O 0 0.0052132164
mM O 0 0.017558068
) O 0 0.0003582426
or O 0 0.00012478014
increase O 0 0.00015932975
( O 0 0.00020690623
3 O 0 8.065407e-05
. O 0 6.0922404e-05
6 O 0 7.155332e-05
mM O 0 0.0018288862
) O 0 0.00024645598
of O 0 0.00028418965
[ O 0 0.0020213253
Ca B-Chemical 1 0.99994564
] O 0 0.0012195725
o O 0 0.001343991
did O 0 0.00011592796
not O 0 6.98029e-05
modify O 0 7.927377e-05
BF O 0 0.010430882
; O 0 0.00011748854
a O 0 9.9122095e-05
reduction O 0 0.0001682281
of O 0 9.5922784e-05
ten O 0 4.3470372e-05
times O 0 3.411823e-05
( O 0 8.50352e-05
0 O 0 5.3522763e-05
. O 0 4.5800098e-05
135 O 0 0.00020364257
mM O 0 0.0014184187
of O 0 0.00017830513
normal O 0 0.0007609044
[ O 0 0.0019264742
Ca B-Chemical 1 0.9999422
] O 0 0.001140238
o O 0 0.0014445714
was O 0 0.00012259377
effective O 0 7.073479e-05
to O 0 8.142003e-05
reduce O 0 0.00010841698
BF O 0 0.0048409607
by O 0 0.00022507468
40 O 0 0.00029497093
+ O 0 0.0006653433
/ O 0 0.001346953
- O 0 0.0012062656
13 O 0 0.0010180513
% O 0 0.0015687085
. O 0 0.0021154417

All O 0 0.003106862
negative O 0 0.0038366858
chronotropic O 0 0.55655056
effects O 0 0.0036064277
were O 0 0.0033449125
BF O 0 0.035221074
- O 0 0.004566387
dependent O 0 0.002748134
. O 0 0.00539827

Dose O 0 0.01550236
- O 0 0.0030802072
dependent O 0 0.00083806884
bradycardia B-Disease 0 0.9641026
induced O 0 0.001524342
by O 0 0.0017404624
verapamil B-Chemical 0 0.99997354
was O 0 0.0013275455
potentiated O 0 0.02631212
by O 0 0.0009879735
LNa O 0 0.617145
, O 0 0.0013645217
LCa O 0 0.97098374
, O 0 0.001458123
and O 0 0.0020490598
HCa O 0 0.94663906
. O 0 0.003414153

Independent O 0 0.004355083
but O 0 0.001498179
not O 0 0.0007010294
additive O 0 0.001361606
effects O 0 0.000756502
of O 0 0.002138832
Na B-Chemical 1 0.99996173
and O 0 0.0033465214
Ca B-Chemical 1 0.9999505
are O 0 0.00028003365
shown O 0 9.9226694e-05
by O 0 9.458592e-05
decreases O 0 9.7456425e-05
in O 0 6.142233e-05
the O 0 6.1077495e-05
values O 0 8.094154e-05
of O 0 0.00019409781
[ O 0 0.0018638931
verapamil B-Chemical 0 0.99999046
] O 0 0.001195651
o O 0 0.0009121547
needed O 0 5.9092967e-05
to O 0 5.8538095e-05
reduce O 0 6.363393e-05
BF O 0 0.004529483
by O 0 8.407056e-05
30 O 0 5.9170896e-05
% O 0 0.00010930223
( O 0 0.0002837478
IC30 O 0 0.9998623
) O 0 0.0002797673
with O 0 8.532485e-05
the O 0 4.7807127e-05
following O 0 2.9819857e-05
order O 0 4.057259e-05
of O 0 8.315476e-05
inhibitory O 0 0.00045426245
potency O 0 0.02741248
: O 0 0.00032967905
LNa O 0 0.37596875
> O 0 0.0009209706
LCa O 0 0.9855344
> O 0 0.0013488219
HCa O 0 0.98418
> O 0 0.001616907
N O 0 0.91374457
, O 0 0.00025080942
resulting O 0 0.00033762856
LNa O 0 0.31801674
+ O 0 0.0012164199
HCa O 0 0.7821818
similar O 0 0.00046076905
to O 0 0.0009876488
LNa O 0 0.19354416
. O 0 0.0024562038

The O 0 0.0029339655
[ O 0 0.012253678
verapamil B-Chemical 0 0.99988437
] O 0 0.0051978235
o O 0 0.0026763524
that O 0 0.00033355816
arrested O 0 0.004231001
atrial O 0 0.65977395
beating O 0 0.0060027335
( O 0 0.0006935919
AC O 0 0.3267234
) O 0 0.0003459098
was O 0 0.00012541127
also O 0 9.391867e-05
potentiated O 0 0.0011170625
with O 0 0.00013116818
the O 0 8.495098e-05
order O 0 0.00010913579
LNa O 0 0.18788467
= O 0 0.0002818314
LNa O 0 0.116804466
+ O 0 0.0006488532
LCa O 0 0.9622002
= O 0 0.00041464783
LNa O 0 0.108214855
+ O 0 0.0008188873
HCa O 0 0.93221486
= O 0 0.0009016482
LCa O 0 0.9516353
> O 0 0.003348758
HCa O 0 0.9725271
= O 0 0.0033170446
N O 0 0.7364356
. O 0 0.003177663

The O 0 0.0014137593
results O 0 0.0010789508
indicate O 0 0.0004710246
that O 0 0.00039165927
rat O 0 0.0012641521
atrial O 0 0.34917334
spontaneous O 0 0.0028417544
beating O 0 0.0014821063
is O 0 0.00016642698
more O 0 0.00014418918
dependent O 0 6.3000545e-05
on O 0 0.00010469343
[ O 0 0.0014772962
Na B-Chemical 1 0.9999485
] O 0 0.0010860644
o O 0 0.0010058221
than O 0 7.507482e-05
on O 0 8.521671e-05
[ O 0 0.0011127319
Ca B-Chemical 1 0.9999181
] O 0 0.0009851463
o O 0 0.0010754496
in O 0 9.8336546e-05
a O 0 0.00013157644
range O 0 0.00010963762
of O 0 0.0001964108
+ O 0 0.00045154447
/ O 0 0.0007030643
- O 0 0.000376211
50 O 0 0.0002835001
% O 0 0.00021610926
of O 0 0.00030179718
their O 0 0.00050968915
normal O 0 0.001494466
concentration O 0 0.0028265882
. O 0 0.0023342317

Also O 0 0.0022682038
the O 0 0.00120291
enhancement O 0 0.0015512088
of O 0 0.001814317
verapamil B-Chemical 0 0.9999366
effects O 0 0.00077595795
on O 0 0.0002513425
atrial O 0 0.40797648
beating O 0 0.0016883758
was O 0 0.00019649696
more O 0 0.00016880785
pronounced O 0 0.00018727261
at O 0 0.00010318601
LNa O 0 0.021122355
than O 0 0.00010948497
at O 0 0.0001772758
LCa O 0 0.88185215
. O 0 0.00029618407
( O 0 0.00076625263
ABSTRACT O 0 0.003954506
TRUNCATED O 0 0.0036418352
AT O 0 0.0065380996
250 O 0 0.0035151092
WORDS O 0 0.007227
) O 0 0.0063490993

Pseudo O 0 0.22141759
- O 0 0.015608113
allergic B-Disease 0 0.9992588
reactions I-Disease 0 0.5272113
to O 0 0.0034566727
corticosteroids B-Chemical 1 0.99883705
: O 0 0.002963009
diagnosis O 0 0.0030072748
and O 0 0.0019052585
alternatives O 0 0.0027899288
. O 0 0.0035935817

Two O 0 0.0020125734
patients O 0 0.001604184
treated O 0 0.0012097636
with O 0 0.0012617884
parenteral O 0 0.583937
paramethasone B-Chemical 1 0.9999218
( O 0 0.0020543085
Triniol O 0 0.01438671
) O 0 0.00077740534
and O 0 0.0006469575
dexamethasone B-Chemical 0 0.99903727
( O 0 0.0016267434
Sedionbel O 0 0.009115691
) O 0 0.0012391417
are O 0 0.0009018428
described O 0 0.0013620988
. O 0 0.0022945756

A O 0 0.01009183
few O 0 0.0007465539
minutes O 0 0.00044359395
after O 0 0.00023736444
administration O 0 0.00081174675
of O 0 0.00038346578
the O 0 0.00030324908
drugs O 0 0.0100781005
, O 0 0.00021281204
they O 0 0.000121175384
presented O 0 0.0003456604
urticaria B-Disease 0 0.9999715
( O 0 0.0007356727
patients O 0 0.00029515964
1 O 0 0.000104626655
and O 0 0.00012079804
2 O 0 0.00012312496
) O 0 0.00026753533
and O 0 0.0003823562
conjunctivitis B-Disease 0 0.99454486
( O 0 0.001165982
patient O 0 0.00085519796
1 O 0 0.00087683136
) O 0 0.0019254863
. O 0 0.002116219

The O 0 0.0015460589
purpose O 0 0.0011870728
of O 0 0.0010855177
our O 0 0.00093878567
study O 0 0.0006751083
was O 0 0.00035352824
to O 0 0.00016541805
determine O 0 8.227907e-05
the O 0 0.00014173303
cause O 0 0.00019814791
of O 0 0.0001630304
the O 0 0.00013352107
patients O 0 0.00021877122
' O 0 0.00018129635
reactions O 0 0.00067208975
, O 0 0.00010724111
the O 0 7.537827e-05
immunological O 0 0.0004078325
mechanisms O 0 8.8481356e-05
involved O 0 4.436696e-05
and O 0 5.8956073e-05
whether O 0 3.1449803e-05
these O 0 0.00013126741
patients O 0 0.00015304769
would O 0 8.164162e-05
be O 0 7.197789e-05
able O 0 7.059335e-05
to O 0 0.00011984426
tolerate O 0 0.0003290379
any O 0 0.00024554407
kind O 0 0.000569994
of O 0 0.0016116473
corticoid O 0 0.9780995
. O 0 0.002739292

Clinical O 0 0.0059189694
examinations O 0 0.0021990864
and O 0 0.0012823206
skin O 0 0.004291426
, O 0 0.0008546098
oral O 0 0.004849366
and O 0 0.00040205268
parenteral O 0 0.0029039846
challenges O 0 0.00020250233
with O 0 0.00024991832
different O 0 0.00023396513
corticosteroids B-Chemical 1 0.9963381
and O 0 0.0008301728
ELISA O 0 0.42558932
tests O 0 0.0015262803
were O 0 0.00081952673
performed O 0 0.001174708
. O 0 0.0019661114

In O 0 0.0016048745
the O 0 0.001166144
two O 0 0.00066529954
patients O 0 0.00091024593
, O 0 0.00067776884
skin O 0 0.00308081
and O 0 0.0005461724
ELISA O 0 0.38913944
tests O 0 0.0009628742
with O 0 0.00075135706
paramethasone B-Chemical 1 0.999907
were O 0 0.00027336748
negative O 0 0.00024190464
, O 0 0.00016319916
as O 0 0.000103831924
was O 0 0.00012869785
the O 0 0.00015699987
prick O 0 0.0036884139
test O 0 0.00024190555
with O 0 0.00020317071
each O 0 0.00014320374
of O 0 0.0005675801
its O 0 0.0021843622
excipients O 0 0.900239
. O 0 0.0029330489

A O 0 0.019339269
single O 0 0.00235606
- O 0 0.0027487017
blind O 0 0.008232345
parenteral O 0 0.0076738084
challenge O 0 0.00032247277
with O 0 0.00040240545
Triniol O 0 0.0035886134
was O 0 0.00019322755
positive O 0 0.00013949994
in O 0 8.458618e-05
both O 0 8.570486e-05
patients O 0 9.4950105e-05
after O 0 2.467563e-05
the O 0 6.357098e-05
administration O 0 0.00028935226
of O 0 0.00013243416
1 O 0 7.710014e-05
ml O 0 0.00018769196
of O 0 0.00011114597
the O 0 0.00013188255
drug O 0 0.0033039043
, O 0 0.00020491779
and O 0 0.00019049068
negative O 0 0.00038546434
with O 0 0.0006579684
its O 0 0.0023062108
excipients O 0 0.90136296
. O 0 0.0028018248

We O 0 0.001457564
also O 0 0.0010317296
carried O 0 0.0007600558
out O 0 0.0005516039
oral O 0 0.004378294
and O 0 0.00045757694
parenteral O 0 0.0037183438
challenges O 0 0.00022060635
with O 0 0.00027463818
other O 0 0.0003312334
corticosteroids B-Chemical 1 0.99725276
and O 0 0.0003753369
found O 0 0.00030170972
intolerance O 0 0.06753775
to O 0 0.00034255392
some O 0 0.00054802146
of O 0 0.0011226829
them O 0 0.002866357
. O 0 0.0022052093

These O 0 0.0024156624
results O 0 0.0015787302
suggest O 0 0.0008043074
that O 0 0.0014232193
paramethasone B-Chemical 1 0.99965703
caused O 0 0.0051519577
pseudoallergic O 0 0.9726281
reactions O 0 0.016585883
in O 0 0.0012533858
our O 0 0.0022735232
patients O 0 0.0038520505
. O 0 0.0030492567

Corticosteroids O 0 0.3759916
different O 0 0.00123425
from O 0 0.0014104149
paramethasone B-Chemical 1 0.99939215
also O 0 0.00067796715
produced O 0 0.0006489646
hypersensitivity B-Disease 0 0.5770371
reactions O 0 0.0032230543
in O 0 0.000213869
these O 0 0.00031198398
patients O 0 0.00038384323
; O 0 0.00024105184
however O 0 0.00023209855
, O 0 0.00020661995
a O 0 0.00022445897
few O 0 0.00012925474
of O 0 0.0003522228
them O 0 0.00085152505
were O 0 0.000901756
tolerated O 0 0.0059394534
. O 0 0.0021150815

The O 0 0.0018749303
basic O 0 0.0015337674
mechanisms O 0 0.0013976097
of O 0 0.00130607
those O 0 0.0013091877
reactions O 0 0.0031392067
are O 0 0.0007910105
not O 0 0.0007664878
yet O 0 0.001305849
fully O 0 0.001706416
understood O 0 0.0046244916
. O 0 0.0033854556

To O 0 0.0023616059
our O 0 0.002500607
knowledge O 0 0.0023141548
, O 0 0.0011324831
this O 0 0.0006739162
is O 0 0.0003999115
the O 0 0.00025600204
first O 0 0.00017252105
report O 0 0.00039280718
of O 0 0.00040341122
a O 0 0.00068299775
pseudo O 0 0.011346957
- O 0 0.0026904806
allergy B-Disease 0 0.99420255
caused O 0 0.0028977892
by O 0 0.0052191406
paramethasone B-Chemical 1 0.9997156
. O 0 0.004872173

Study O 0 0.003264629
of O 0 0.0013301458
the O 0 0.00072473806
role O 0 0.00047823295
of O 0 0.0025758028
vitamin B-Chemical 0 0.9999933
B12 I-Chemical 0 0.99999857
and O 0 0.07862253
folinic B-Chemical 0 0.999997
acid I-Chemical 0 0.99985516
supplementation O 0 0.9742906
in O 0 0.0005623904
preventing O 0 0.0025732243
hematologic O 0 0.99985886
toxicity B-Disease 2 0.9999434
of O 0 0.02586355
zidovudine B-Chemical 1 0.9829285
. O 0 0.0029906898

A O 0 0.02340326
prospective O 0 0.004422044
, O 0 0.0012075163
randomized O 0 0.00074020925
study O 0 0.0004545061
was O 0 0.00026744994
conducted O 0 0.00014013173
to O 0 9.710373e-05
evaluate O 0 5.2960713e-05
the O 0 8.119023e-05
role O 0 7.065557e-05
of O 0 0.0008474114
vitamin B-Chemical 0 0.99999833
B12 I-Chemical 0 0.99999964
and O 0 0.044021897
folinic B-Chemical 0 0.99999845
acid I-Chemical 0 0.99987423
supplementation O 0 0.9613733
in O 0 0.0002496028
preventing O 0 0.00096509076
zidovudine B-Chemical 1 0.97818893
( O 0 0.0019320375
ZDV B-Chemical 0 0.9997695
) O 0 0.0008576967
- O 0 0.0006489649
induced O 0 0.0007597901
bone B-Disease 0 0.7410737
marrow I-Disease 0 0.9981358
suppression I-Disease 0 0.88842005
. O 0 0.0042119543

Seventy O 0 0.00537718
- O 0 0.0028302032
five O 0 0.00078421144
human B-Disease 0 0.003060852
immunodeficiency I-Disease 0 0.9991941
virus I-Disease 0 0.45105156
( I-Disease 0 0.002295506
HIV I-Disease 0 0.5606714
) I-Disease 0 0.00081491546
- I-Disease 0 0.0003560737
infected I-Disease 0 0.00011882921
patients O 0 0.00020322786
with O 0 0.00024194524
CD4 O 0 0.5726716
+ O 0 0.0006168996
cell O 0 0.0005698199
counts O 0 0.0001538438
< O 0 9.883848e-05
500 O 0 0.00020133177
/ O 0 0.0001851078
mm3 O 0 0.00013689685
were O 0 4.756348e-05
randomized O 0 4.4042074e-05
to O 0 2.9613013e-05
receive O 0 2.9714542e-05
either O 0 9.802863e-05
ZDV B-Chemical 0 0.9982058
( O 0 0.00016328617
500 O 0 0.00027148754
mg O 0 0.0029946521
daily O 0 0.00016400206
) O 0 0.00013462282
alone O 0 9.351331e-05
( O 0 0.0001473338
group O 0 0.00015517045
I O 0 0.001044337
, O 0 0.00011674622
n O 0 8.363429e-05
= O 0 9.849412e-05
38 O 0 9.465504e-05
) O 0 8.48251e-05
or O 0 3.99742e-05
in O 0 4.8035898e-05
combination O 0 0.00012783705
with O 0 0.0005979913
folinic B-Chemical 0 0.99999595
acid I-Chemical 0 0.99921703
( O 0 0.00035018742
15 O 0 6.219872e-05
mg O 0 0.0013421318
daily O 0 0.00012717006
) O 0 0.0001273839
and O 0 0.00013075222
intramascular O 0 0.7234311
vitamin B-Chemical 0 0.99999833
B12 I-Chemical 0 0.9999993
( O 0 0.00069882686
1000 O 0 0.00031832076
micrograms O 0 0.00066525454
monthly O 0 0.000121969264
) O 0 0.00020212618
( O 0 0.00018540349
group O 0 0.00023116807
II O 0 0.0016091419
, O 0 0.00035825116
n O 0 0.00036764052
= O 0 0.00067277555
37 O 0 0.0013314538
) O 0 0.0020088893
. O 0 0.0021273266

Finally O 0 0.0024083743
, O 0 0.0017745136
15 O 0 0.0007680459
patients O 0 0.0007166693
were O 0 0.00035071664
excluded O 0 0.00025547706
from O 0 0.00015466835
the O 0 0.00017022653
study O 0 0.00023967316
( O 0 0.0002919306
noncompliance O 0 0.012869477
14 O 0 0.00018782428
, O 0 0.00032040238
death B-Disease 0 0.9381014
1 O 0 0.00018963675
) O 0 0.00022792963
; O 0 0.00012287115
thus O 0 0.00011436325
, O 0 0.00010392543
60 O 0 8.5454565e-05
patients O 0 0.00012690065
( O 0 0.000116249874
31 O 0 9.99023e-05
in O 0 6.800869e-05
group O 0 0.00013364742
I O 0 0.0006483852
and O 0 0.000113316026
29 O 0 0.00017278279
in O 0 0.000107430154
group O 0 0.00023617384
II O 0 0.002147655
) O 0 0.0003715673
were O 0 0.00028146835
eligible O 0 0.00048702778
for O 0 0.0004662339
analysis O 0 0.0012408053
. O 0 0.001855943

No O 0 0.0039583165
significant O 0 0.0018265557
differences O 0 0.0008508008
between O 0 0.0007662314
groups O 0 0.0009957697
were O 0 0.0009986645
found O 0 0.0010670444
at O 0 0.0013967927
enrollment O 0 0.0043234527
. O 0 0.0039665857

During O 0 0.0009824085
the O 0 0.0012701373
study O 0 0.0015620698
, O 0 0.0033309145
vitamin B-Chemical 0 0.99998903
B12 I-Chemical 0 0.99999785
and O 0 0.013869542
folate B-Chemical 0 0.99990225
levels O 0 0.00036907027
were O 0 0.00015705735
significantly O 0 0.00013955381
higher O 0 0.000105787774
in O 0 8.226691e-05
group O 0 0.00016460681
II O 0 0.003683003
patients O 0 0.00023190917
; O 0 0.00012911137
however O 0 0.00011575123
, O 0 7.659091e-05
no O 0 3.2519405e-05
differences O 0 2.9754437e-05
in O 0 7.9236735e-05
hemoglobin O 0 0.6958581
, O 0 0.00023641402
hematocrit O 0 0.28746915
, O 0 0.0001117221
mean O 0 5.1809184e-05
corpuscular O 0 0.94842964
volume O 0 0.0006516904
, O 0 0.00015143247
and O 0 0.00013219746
white O 0 0.0019825196
- O 0 0.00034892344
cell O 0 0.0005329639
, O 0 0.00013856463
neutrophil O 0 0.009795853
and O 0 0.0001687676
platelet O 0 0.62366986
counts O 0 0.00014591057
were O 0 7.082719e-05
observed O 0 4.830122e-05
between O 0 3.8769613e-05
groups O 0 6.617382e-05
at O 0 5.678226e-05
3 O 0 8.497837e-05
, O 0 0.00014039174
6 O 0 0.000102492406
, O 0 0.00020306553
9 O 0 0.00020482244
and O 0 0.00032330636
12 O 0 0.00037367464
months O 0 0.0005318576
. O 0 0.0015534386

Severe O 0 0.5106831
hematologic O 0 0.9992217
toxicity B-Disease 2 0.9998543
( O 0 0.0036794425
neutrophil O 0 0.066217504
count O 0 0.001711964
< O 0 0.00034088528
1000 O 0 0.00045062407
/ O 0 0.0004098682
mm3 O 0 0.00032756678
and O 0 0.0001498324
/ O 0 0.0003451413
or O 0 0.00013826766
hemoglobin O 0 0.46521208
< O 0 0.0001464789
8 O 0 7.732914e-05
g O 0 0.00024797744
/ O 0 0.00038010045
dl O 0 0.0026309434
) O 0 0.00016656461
occurred O 0 6.3118765e-05
in O 0 6.18573e-05
4 O 0 4.795223e-05
patients O 0 7.2249866e-05
assigned O 0 5.0707495e-05
to O 0 7.337278e-05
group O 0 0.0001771048
I O 0 0.00083126675
and O 0 0.00015804482
7 O 0 0.00012205582
assigned O 0 0.00016968348
to O 0 0.00034909733
group O 0 0.0010658802
II O 0 0.00822835
. O 0 0.0023000084

There O 0 0.0026241501
was O 0 0.0015216273
no O 0 0.00056126685
correlation O 0 0.0005421031
between O 0 0.0009468906
vitamin B-Chemical 0 0.99998856
B12 I-Chemical 0 0.9999974
or O 0 0.0063344
folate B-Chemical 0 0.9998087
levels O 0 0.0008365836
and O 0 0.00069136417
development O 0 0.0016332539
of O 0 0.004031559
myelosuppression B-Disease 0 0.9998658
. O 0 0.0049844855

Vitamin B-Chemical 0 0.99997306
B12 I-Chemical 0 0.9999839
and O 0 0.059483085
folinic B-Chemical 0 0.9999883
acid I-Chemical 0 0.99976104
supplementation O 0 0.98948014
of O 0 0.009168467
ZDV B-Chemical 0 0.99991095
therapy O 0 0.00050954806
does O 0 0.000116552554
not O 0 8.48714e-05
seem O 0 7.6179946e-05
useful O 0 5.4884407e-05
in O 0 5.6471807e-05
preventing O 0 0.00010692457
or O 0 8.770365e-05
reducing O 0 0.00046287815
ZDV B-Chemical 0 0.9998983
- O 0 0.00064565596
induced O 0 0.00045800194
myelotoxicity B-Disease 0 0.9999863
in O 0 0.00012134606
the O 0 6.95487e-05
overall O 0 8.7451444e-05
treated O 0 0.00016825697
population O 0 0.00029331466
, O 0 0.0001140347
although O 0 6.6637556e-05
a O 0 0.000110623616
beneficial O 0 0.0001271925
effect O 0 8.456474e-05
in O 0 9.7396594e-05
certain O 0 0.00014022665
subgroups O 0 0.00020194857
of O 0 0.00025544176
patients O 0 0.00049701234
cannot O 0 0.0010273963
be O 0 0.0006046417
excluded O 0 0.00133074
. O 0 0.001746771

Safety O 0 0.012918526
and O 0 0.0055001373
side O 0 0.017109029
- O 0 0.005888494
effects O 0 0.0049230596
of O 0 0.014776054
alprazolam B-Chemical 0 0.99991596
. O 0 0.012826828

Controlled O 0 0.0054207644
study O 0 0.004345323
in O 0 0.0050628586
agoraphobia B-Disease 0 0.9997768
with O 0 0.023093974
panic B-Disease 0 0.9997178
disorder I-Disease 0 0.9940084
. O 0 0.0082138255

BACKGROUND O 0 0.008501948
: O 0 0.0020282392
The O 0 0.0007281191
widespread O 0 0.0008450964
use O 0 0.00057911477
of O 0 0.0012031541
benzodiazepines B-Chemical 1 0.99979323
has O 0 0.00034621992
led O 0 0.0003335811
to O 0 0.00021503304
increasing O 0 0.0002990239
recognition O 0 0.00035927616
of O 0 0.00056295935
their O 0 0.0008241926
unwanted O 0 0.007456577
effects O 0 0.0030834735
. O 0 0.0029460823

The O 0 0.001383466
efficacy O 0 0.0017387659
of O 0 0.0024709466
alprazolam B-Chemical 0 0.9999808
and O 0 0.0010651225
placebo O 0 0.0040160455
in O 0 0.0004726976
panic B-Disease 0 0.999905
disorder I-Disease 0 0.97860557
with O 0 0.0020488938
agoraphobia B-Disease 0 0.9999945
, O 0 0.00029038833
and O 0 0.00012000148
the O 0 0.00012638091
side O 0 0.0031210424
- O 0 0.00023998959
effect O 0 8.756677e-05
and O 0 0.00013180247
adverse O 0 0.004209534
effect O 0 0.000101862584
profiles O 0 0.000109135995
of O 0 0.00017345729
both O 0 0.00022979443
drug O 0 0.004627706
groups O 0 0.00038425744
were O 0 0.0005390394
measured O 0 0.00092028826
. O 0 0.0017533454

METHOD O 0 0.0056656054
: O 0 0.0019685924
In O 0 0.0008271265
London O 0 0.0023475438
and O 0 0.00068922585
Toronto O 0 0.0027837749
154 O 0 0.0010314044
patients O 0 0.0003298117
who O 0 0.00025158777
met O 0 0.00021829574
DSM O 0 0.0018804973
- O 0 0.00029067614
III O 0 0.0008949255
criteria O 0 0.00011432062
for O 0 0.000112937734
panic B-Disease 0 0.9998553
disorder I-Disease 0 0.8993567
with O 0 0.0006862146
agoraphobia B-Disease 0 0.99998534
were O 0 0.00019875949
randomised O 0 0.00023635814
to O 0 0.00030061122
alprazolam B-Chemical 0 0.99997866
or O 0 0.001096293
placebo O 0 0.0071717873
. O 0 0.0016955707

Subjects O 0 0.0026208726
in O 0 0.0011338411
each O 0 0.0006165715
drug O 0 0.0042949934
group O 0 0.0008342114
also O 0 0.00048397426
received O 0 0.0004190914
either O 0 0.0005621867
exposure O 0 0.0012480667
or O 0 0.0015606902
relaxation O 0 0.031937268
. O 0 0.0033506877

Treatment O 0 0.0054313256
was O 0 0.0015566598
from O 0 0.00064753985
weeks O 0 0.00028337282
0 O 0 0.00032809688
to O 0 0.0002626577
8 O 0 0.0002258649
and O 0 0.00023892411
was O 0 0.0002267325
then O 0 0.00017084948
tapered O 0 0.00033547293
from O 0 0.00020511229
weeks O 0 0.00016718355
8 O 0 0.00035124767
to O 0 0.0006385347
16 O 0 0.0014399468
. O 0 0.0022157624

RESULTS O 0 0.005497614
: O 0 0.0026185687
Mean O 0 0.0017341955
alprazolam B-Chemical 0 0.9998461
dose O 0 0.009376538
was O 0 0.0018859538
5 O 0 0.0013330583
mg O 0 0.012354386
daily O 0 0.004082362
. O 0 0.003936654

Compared O 0 0.0013738177
with O 0 0.0013595807
placebo O 0 0.0042642336
subjects O 0 0.0010246905
, O 0 0.001146811
alprazolam B-Chemical 0 0.99998975
patients O 0 0.00078380137
developed O 0 0.00034217892
more O 0 0.0003353997
adverse O 0 0.039558016
reactions O 0 0.0031103964
( O 0 0.0002717426
21 O 0 0.00013097958
% O 0 0.00012749473
v O 0 0.00047202848
. O 0 6.1510254e-05
0 O 0 6.975672e-05
% O 0 9.36485e-05
) O 0 0.00013121947
of O 0 0.00018594631
depression B-Disease 0 0.95320684
, O 0 0.00026794456
enuresis B-Disease 0 0.9590542
, O 0 0.00022681661
disinhibition O 0 0.39472657
and O 0 0.00032087835
aggression B-Disease 0 0.9787966
; O 0 0.00017220828
and O 0 8.973023e-05
more O 0 0.00017854535
side O 0 0.0036518308
- O 0 0.00023483964
effects O 0 0.00011959003
, O 0 0.00012717805
particularly O 0 0.00020469946
sedation O 0 0.085034475
, O 0 0.00033422565
irritability B-Disease 0 0.9990619
, O 0 0.0003517924
impaired B-Disease 0 0.040780503
memory I-Disease 0 0.9616473
, O 0 0.0006301561
weight B-Disease 0 0.0031866066
loss I-Disease 0 0.0047090584
and O 0 0.0031572988
ataxia B-Disease 0 0.9999101
. O 0 0.004569021

Side O 0 0.38876295
- O 0 0.0039472776
effects O 0 0.0013605788
tended O 0 0.00085206714
to O 0 0.00046653848
diminish O 0 0.00040900506
during O 0 0.00020767745
treatment O 0 0.00034659743
but O 0 0.00038126338
remained O 0 0.00048420732
significant O 0 0.0004100042
at O 0 0.0003859738
week O 0 0.00050580915
8 O 0 0.0010612346
. O 0 0.0019141037

Despite O 0 0.0029886258
this O 0 0.002749682
, O 0 0.0022667428
the O 0 0.0016249052
drop O 0 0.004414841
- O 0 0.0022543676
out O 0 0.0010327494
rate O 0 0.0017862319
was O 0 0.0025263366
low O 0 0.005305077
. O 0 0.00457485

CONCLUSIONS O 0 0.0230598
: O 0 0.005779262
Alprazolam B-Chemical 0 0.99986017
caused O 0 0.0023265046
side O 0 0.025967143
- O 0 0.0009773587
effects O 0 0.0003525033
and O 0 0.00031166297
adverse O 0 0.0065060356
effects O 0 0.00021236997
during O 0 8.5540414e-05
treatment O 0 0.0001606907
but O 0 0.0001691562
many O 0 0.00015026792
patients O 0 0.0003001607
were O 0 0.0002456504
willing O 0 0.00054007466
to O 0 0.00040229305
accept O 0 0.0009648476
these O 0 0.001826507
. O 0 0.0020598737

Crescentic O 0 0.7760435
fibrillary O 0 0.20882694
glomerulonephritis B-Disease 2 0.9997631
associated O 0 0.0014683754
with O 0 0.0012598345
intermittent O 0 0.00792937
rifampin B-Chemical 0 0.9997311
therapy O 0 0.0026517576
for O 0 0.0013818237
pulmonary B-Disease 0 0.98889273
tuberculosis I-Disease 0 0.9875159
. O 0 0.005023952

This O 0 0.0038760242
case O 0 0.0015743575
study O 0 0.00109582
reveals O 0 0.0006186474
an O 0 0.0005419752
unusual O 0 0.00055279443
finding O 0 0.00045769187
of O 0 0.0003181657
rapidly O 0 0.00056123023
proliferative O 0 0.5459688
crescentic O 0 0.99990547
glomerulonephritis B-Disease 2 0.9999957
in O 0 0.00026187953
a O 0 0.00015610228
patient O 0 9.4580064e-05
treated O 0 0.0001360388
with O 0 0.00027914677
rifampin B-Chemical 0 0.9999292
who O 0 0.00056137925
had O 0 0.00012313166
no O 0 6.764642e-05
other O 0 0.00012524599
identifiable O 0 0.00054983597
causes O 0 0.00037017057
for O 0 0.00028248513
developing O 0 0.0025104005
this O 0 0.0020113538
disease O 0 0.47468573
. O 0 0.0025637762

This O 0 0.0030691917
patient O 0 0.0014099213
underwent O 0 0.00069066946
a O 0 0.0005804335
10 O 0 0.00033805738
- O 0 0.00036193596
month O 0 8.7296394e-05
regimen O 0 0.00017242253
of O 0 0.0002789805
rifampin B-Chemical 0 0.99986434
and O 0 0.0008774984
isoniazid B-Chemical 1 0.99995995
for O 0 0.00026618107
pulmonary B-Disease 0 0.99212545
tuberculosis I-Disease 0 0.97060084
and O 0 0.00023333932
was O 0 0.00012107387
discovered O 0 0.000100024125
to O 0 5.4794713e-05
have O 0 4.7191737e-05
developed O 0 0.00013752973
signs O 0 0.0011879026
of O 0 0.00024812194
severe O 0 0.022863671
renal B-Disease 0 0.97449535
failure I-Disease 0 0.109433986
five O 0 7.242708e-05
weeks O 0 4.211857e-05
after O 0 5.5935998e-05
completion O 0 0.00015566232
of O 0 0.0006534972
therapy O 0 0.0019217307
. O 0 0.0019090334

Renal O 0 0.021223705
biopsy O 0 0.004038062
revealed O 0 0.0016439508
severe O 0 0.06666759
glomerulonephritis B-Disease 2 0.99993443
with O 0 0.002930044
crescents O 0 0.9482328
, O 0 0.0007019827
electron O 0 0.002589118
dense O 0 0.00045961625
fibrillar O 0 0.0038699317
deposits O 0 0.021873692
and O 0 0.0006859141
moderate O 0 0.056674358
lymphocytic O 0 0.9997118
interstitial O 0 0.8212787
infiltrate O 0 0.6901298
. O 0 0.0033409551

Other O 0 0.0038030993
possible O 0 0.0017878294
causes O 0 0.0017426262
of O 0 0.0014255511
rapidly O 0 0.0020788002
progressive O 0 0.5650074
glomerulonephritis B-Disease 2 0.9999584
were O 0 0.0015679693
investigated O 0 0.00078037346
and O 0 0.0012212844
ruled O 0 0.003605809
out O 0 0.001762356
. O 0 0.0028275049

This O 0 0.0037105512
report O 0 0.0021459176
documents O 0 0.001636786
the O 0 0.00062567904
unusual O 0 0.00067877915
occurrence O 0 0.000514478
of O 0 0.00039534745
rapidly O 0 0.000621758
progressive O 0 0.40767023
glomerulonephritis B-Disease 2 0.9999876
with O 0 0.0013292048
crescents O 0 0.94511455
and O 0 0.0004086615
fibrillar O 0 0.1354196
glomerulonephritis B-Disease 2 0.99998045
in O 0 0.00029202417
a O 0 0.00030740755
patient O 0 0.00030434853
treated O 0 0.00067976187
with O 0 0.0019236469
rifampin B-Chemical 0 0.9996599
. O 0 0.0036817084

Acute O 0 0.40411344
confusion B-Disease 0 0.40753812
induced O 0 0.0020863058
by O 0 0.0009759425
a O 0 0.00080717116
high O 0 0.0010111228
- O 0 0.0007935207
dose O 0 0.0010789047
infusion O 0 0.00068565074
of O 0 0.0003706427
5 B-Chemical 0 0.0002779814
- I-Chemical 0 0.0011348883
fluorouracil I-Chemical 0 0.9971922
and O 0 0.0041565946
folinic B-Chemical 0 0.99996746
acid I-Chemical 0 0.99895275
. O 0 0.0063420516

A O 0 0.0291052
61 O 0 0.004222343
- O 0 0.0025567668
year O 0 0.00072798517
- O 0 0.0009995564
old O 0 0.00050721987
man O 0 0.0021421106
was O 0 0.00024037983
treated O 0 0.0002022376
with O 0 0.00014883422
combination O 0 0.00020356978
chemotherapy O 0 0.001294034
incorporating O 0 0.00021224689
cisplatinum B-Chemical 0 0.99985003
, O 0 0.0009746751
etoposide B-Chemical 0 0.9997564
, O 0 0.0003399733
high O 0 0.0005097692
- O 0 0.00034941762
dose O 0 0.00058918045
5 B-Chemical 0 9.89473e-05
- I-Chemical 0 0.00046419265
fluorouracil I-Chemical 0 0.99653745
( O 0 0.00022411552
2 O 0 7.3049545e-05
, O 0 8.935905e-05
250 O 0 0.0001779734
mg O 0 0.0010421636
/ O 0 0.00031181393
m2 O 0 0.00067287526
/ O 0 0.00023036984
24 O 0 5.2651565e-05
hours O 0 4.8645692e-05
) O 0 0.00018121289
and O 0 0.00034891395
folinic B-Chemical 0 0.99997556
acid I-Chemical 0 0.99226016
for O 0 0.000494111
an O 0 0.0015696962
inoperable O 0 0.70969814
gastric B-Disease 0 0.99621755
adenocarcinoma I-Disease 0 0.9997038
. O 0 0.0034822887

He O 0 0.0056618755
developed O 0 0.0033715072
acute O 0 0.5572693
neurologic O 0 0.9766641
symptoms O 0 0.045603245
of O 0 0.0008532014
mental O 0 0.028391084
confusion B-Disease 0 0.68484885
, O 0 0.0006471373
disorientation B-Disease 0 0.99814844
and O 0 0.0007817292
irritability B-Disease 0 0.99962723
, O 0 0.00022760994
and O 0 9.645975e-05
then O 0 6.872301e-05
lapsed O 0 0.00026910432
into O 0 2.9767263e-05
a O 0 0.0001223202
deep O 0 0.0010178235
coma B-Disease 0 0.99761164
, O 0 0.00011135367
lasting O 0 4.8119065e-05
for O 0 3.3262153e-05
approximately O 0 5.387903e-05
40 O 0 4.5261953e-05
hours O 0 1.946071e-05
during O 0 1.8450966e-05
the O 0 3.679809e-05
first O 0 3.669339e-05
dose O 0 0.0003415984
( O 0 0.00012202521
day O 0 4.9698087e-05
2 O 0 6.42602e-05
) O 0 0.000110748166
of O 0 0.00011778929
5 B-Chemical 0 0.00011945247
- I-Chemical 0 0.0005633029
fluorouracil I-Chemical 0 0.99511284
and O 0 0.0019566186
folinic B-Chemical 0 0.9999784
acid I-Chemical 0 0.99908733
infusion O 0 0.07744659
. O 0 0.0029574807

This O 0 0.00458869
complication O 0 0.0088900905
reappeared O 0 0.0013876964
on O 0 0.0003373298
day O 0 0.00023674336
25 O 0 0.0002520514
during O 0 8.3865016e-05
the O 0 0.00011197562
second O 0 0.00011860891
dose O 0 0.0004395973
of O 0 0.00020095817
5 B-Chemical 0 0.00012685274
- I-Chemical 0 0.00054115365
fluorouracil I-Chemical 0 0.9983615
and O 0 0.0013404033
folinic B-Chemical 0 0.99999523
acid I-Chemical 0 0.9993831
, O 0 0.00049495243
which O 0 0.00024336555
were O 0 0.00013920746
then O 0 0.00011624256
the O 0 0.0002056467
only O 0 0.0004613756
drugs O 0 0.007468055
given O 0 0.0009359091
. O 0 0.0018563555

Because O 0 0.0043676686
folinic B-Chemical 0 0.9999199
acid I-Chemical 0 0.9985108
was O 0 0.0016860482
unlikely O 0 0.00038910186
to O 0 0.00028869204
be O 0 0.00018548024
associated O 0 0.0001309174
with O 0 0.0001677327
this O 0 0.00019676938
condition O 0 0.00057935127
, O 0 0.00045439304
neurotoxicity B-Disease 2 0.99987996
due O 0 0.00012208713
to O 0 0.00011956015
high O 0 0.0004054518
- O 0 0.0004005286
dose O 0 0.0007996952
5 B-Chemical 0 0.00020093097
- I-Chemical 0 0.0008602835
fluorouracil I-Chemical 0 0.9889776
was O 0 0.0007551329
highly O 0 0.00096833473
suspected O 0 0.00552108
. O 0 0.0022483233

The O 0 0.0019596564
pathogenesis O 0 0.0028412258
of O 0 0.0014475115
5 B-Chemical 0 0.00091220555
- I-Chemical 0 0.0030809299
fluorouracil I-Chemical 0 0.9996315
neurotoxicity B-Disease 2 0.9999293
may O 0 0.00042413655
be O 0 0.00016501697
due O 0 7.8497294e-05
to O 0 0.0001000808
a O 0 0.00024014802
Krebs O 0 0.049459707
cycle O 0 0.00033107717
blockade O 0 0.006042654
by O 0 0.0005310438
fluoroacetate B-Chemical 0 0.99998915
and O 0 0.003431482
fluorocitrate B-Chemical 0 0.9999926
, O 0 0.009495229
thiamine B-Chemical 0 0.99999213
deficiency O 0 0.98580235
, O 0 0.0011570443
or O 0 0.0014166583
dihydrouracil B-Chemical 0 0.9998374
dehydrogenase O 0 0.99800307
deficiency O 0 0.9769518
. O 0 0.0035205246

High O 0 0.009147082
- O 0 0.0036698892
dose O 0 0.0034273488
5 B-Chemical 0 0.00081498263
- I-Chemical 0 0.0020016695
fluorouracil I-Chemical 0 0.9983884
/ O 0 0.0353862
folinic B-Chemical 0 0.9999887
acid I-Chemical 0 0.9993431
infusion O 0 0.007890842
therapy O 0 0.00048659573
has O 0 0.00012858868
recently O 0 0.00011408756
become O 0 0.00014245439
a O 0 0.00021551026
popular O 0 0.0003620583
regimen O 0 0.00046190954
for O 0 0.00042690217
various O 0 0.0015806268
cancers B-Disease 0 0.89849424
. O 0 0.0028498755

It O 0 0.0027920203
is O 0 0.0012519908
necessary O 0 0.00052437314
that O 0 0.0004566871
both O 0 0.0005869397
oncologists O 0 0.0013252406
and O 0 0.0005476933
neurologists O 0 0.0014464159
be O 0 0.00027871784
fully O 0 0.00030275167
aware O 0 0.00031664272
of O 0 0.0005551285
this O 0 0.0009806952
unusual O 0 0.002959692
complication O 0 0.101111956
. O 0 0.0031111033

Effect O 0 0.0019920773
of O 0 0.0018907585
switching O 0 0.0032867768
carbamazepine B-Chemical 1 0.9999813
to O 0 0.0039230306
oxcarbazepine B-Chemical 0 0.99998975
on O 0 0.00046983652
the O 0 0.00056919834
plasma O 0 0.004136375
levels O 0 0.0010409356
of O 0 0.003191644
neuroleptics O 0 0.99923885
. O 0 0.0038427664

A O 0 0.06727292
case O 0 0.025275813
report O 0 0.033568196
. O 0 0.027648814

Carbamazepine B-Chemical 0 0.9998547
was O 0 0.0023872615
switched O 0 0.0011422896
to O 0 0.00051063596
its O 0 0.0007281624
10 O 0 0.00044892365
- O 0 0.0014114171
keto O 0 0.99966896
analogue O 0 0.42375964
oxcarbazepine B-Chemical 0 0.9999982
among O 0 0.00037743495
six O 0 6.407479e-05
difficult O 0 8.096014e-05
- O 0 0.00018454334
to O 0 8.208604e-05
- O 0 0.00022213934
treat O 0 0.00033405496
schizophrenic B-Disease 2 0.9998728
or O 0 0.00027869843
organic B-Disease 0 0.9998746
psychotic I-Disease 0 0.99999785
patients O 0 0.00052278064
using O 0 0.000117456846
concomitantly O 0 0.0052908817
haloperidol B-Chemical 1 0.99999714
, O 0 0.0030062704
chlorpromazine B-Chemical 0 0.99997973
or O 0 0.0045419876
clozapine B-Chemical 0 0.99996436
. O 0 0.0032951697

This O 0 0.0033697097
change O 0 0.0013588585
resulted O 0 0.0007689075
within O 0 0.00029727834
2 O 0 0.00040488504
- O 0 0.0004943475
4 O 0 0.00013793293
weeks O 0 6.3015206e-05
in O 0 9.5696196e-05
the O 0 0.00012408874
50 O 0 0.00027338965
- O 0 0.00029434724
200 O 0 0.0002769156
% O 0 0.000106761145
increase O 0 7.5275406e-05
in O 0 6.63309e-05
the O 0 8.229131e-05
plasma O 0 0.00072387134
levels O 0 9.352142e-05
of O 0 0.00014779026
these O 0 0.00035003625
neuroleptics O 0 0.99781275
and O 0 0.00017630735
the O 0 0.00017391951
appearance O 0 0.000659863
of O 0 0.0016773294
extrapyramidal B-Disease 0 0.99998224
symptoms I-Disease 0 0.9758588
. O 0 0.0033645525

None O 0 0.002993317
of O 0 0.0015663638
the O 0 0.00095450477
patients O 0 0.00088803336
showed O 0 0.0004456175
any O 0 0.00031809355
clinical O 0 0.00090015493
deteriotation O 0 0.0017273796
during O 0 0.00013173111
the O 0 0.00020714982
following O 0 0.00022412043
3 O 0 0.00034474273
- O 0 0.0007414758
6 O 0 0.0004914843
months O 0 0.000642068
. O 0 0.0018110676

The O 0 0.0014660408
results O 0 0.0011739157
of O 0 0.0009772982
this O 0 0.00068435486
case O 0 0.00044101677
report O 0 0.00043784207
support O 0 0.00015401111
the O 0 0.00013829536
idea O 0 0.00013920614
that O 0 6.6490094e-05
in O 0 8.2077575e-05
contrast O 0 0.00024951165
with O 0 0.00187105
carbamazepine B-Chemical 1 0.99999976
oxcarbazepine B-Chemical 0 0.9999995
does O 0 0.00018174428
not O 0 7.217123e-05
induce O 0 4.9164384e-05
the O 0 0.00014510998
hepatic O 0 0.98260486
microsomal O 0 0.99798054
enzyme O 0 0.008909721
systems O 0 0.000106943946
regulating O 0 5.296612e-05
the O 0 0.00012596654
inactivation O 0 0.0004668249
of O 0 0.001045261
antipsychotic O 0 0.99866855
drugs O 0 0.15544958
. O 0 0.0022138972

Time O 0 0.005146118
course O 0 0.0019255612
of O 0 0.0028988998
lipid O 0 0.9432833
peroxidation O 0 0.9999448
in O 0 0.0027106586
puromycin B-Chemical 0 0.93260163
aminonucleoside I-Chemical 0 0.9999244
- O 0 0.01828789
induced O 0 0.017133325
nephropathy B-Disease 2 0.9999734
. O 0 0.00828329

Reactive O 0 0.7209879
oxygen B-Chemical 1 0.98003274
species O 0 0.0018339221
have O 0 0.00049712986
been O 0 0.00027952733
implicated O 0 0.00016605335
in O 0 0.00016093881
the O 0 0.00016064412
pathogenesis O 0 0.00039100848
of O 0 0.0003507031
acute O 0 0.571828
puromycin B-Chemical 0 0.9727295
aminonucleoside I-Chemical 0 0.9999889
( O 0 0.012892867
PAN B-Chemical 0 0.99994457
) O 0 0.0014179115
- O 0 0.00061021326
induced O 0 0.00090289686
nephropathy B-Disease 2 0.9999969
, O 0 0.0007265124
with O 0 0.00077499216
antioxidants O 0 0.9992623
significantly O 0 0.00096922455
reducing O 0 0.0010330044
the O 0 0.002280962
proteinuria B-Disease 0 0.99995124
. O 0 0.0044345018

The O 0 0.0014064695
temporal O 0 0.0018655546
relationship O 0 0.00056177075
between O 0 0.0006780408
lipid O 0 0.91335005
peroxidation O 0 0.9999697
in O 0 0.000604516
the O 0 0.00044983806
kidney O 0 0.77830255
and O 0 0.0013060791
proteinuria B-Disease 0 0.9999815
was O 0 0.0007230375
examined O 0 0.00026564865
in O 0 0.00042329685
this O 0 0.00097610906
study O 0 0.0018225645
. O 0 0.0020860338

Rats O 0 0.0039772345
were O 0 0.001291671
treated O 0 0.0009730124
with O 0 0.0006107151
a O 0 0.00053029263
single O 0 0.00039920703
IV O 0 0.005965399
injection O 0 0.0002565601
of O 0 0.00035905943
puromycin B-Chemical 0 0.7161377
aminonucleoside I-Chemical 0 0.9999697
, O 0 0.0011376365
( O 0 0.0009883365
PAN B-Chemical 0 0.99973136
, O 0 0.0002746701
7 O 0 7.065921e-05
. O 0 4.465087e-05
5 O 0 5.1285468e-05
mg O 0 0.00083727867
/ O 0 0.0003374443
kg O 0 0.00027516918
) O 0 0.00011202357
and O 0 5.088488e-05
24 O 0 3.1888983e-05
hour O 0 3.591839e-05
urine O 0 0.0012023872
samples O 0 6.3502135e-05
were O 0 4.3830314e-05
obtained O 0 4.0073053e-05
prior O 0 2.4964113e-05
to O 0 4.4133227e-05
sacrifice O 0 0.0001049557
on O 0 3.2969307e-05
days O 0 3.0510637e-05
3 O 0 5.1202347e-05
, O 0 8.193269e-05
5 O 0 6.0889353e-05
, O 0 9.455301e-05
7 O 0 6.340363e-05
, O 0 9.8857134e-05
10 O 0 8.868494e-05
, O 0 0.00012635054
17 O 0 0.00015001466
, O 0 0.00013420217
27 O 0 0.00018678166
, O 0 0.00016204594
41 O 0 0.00031405926
( O 0 0.00039127097
N O 0 0.730247
= O 0 0.0003200321
5 O 0 0.0001580207
- O 0 0.0003217677
10 O 0 0.00022415974
per O 0 0.00021386084
group O 0 0.0008951498
) O 0 0.0020017074
. O 0 0.0022433398

The O 0 0.002828906
kidneys O 0 0.009694394
were O 0 0.0015538202
removed O 0 0.0010290337
, O 0 0.0012014289
flushed O 0 0.0018903984
with O 0 0.0012903614
ice O 0 0.012835923
cold O 0 0.16933657
TRIS O 0 0.99723464
buffer O 0 0.08433119
. O 0 0.0060292254

Kidney O 0 0.017123139
cortices O 0 0.017534347
from O 0 0.0012964975
each O 0 0.00065097713
animal O 0 0.001155956
were O 0 0.0008594929
used O 0 0.0007981718
to O 0 0.0010957834
prepare O 0 0.002218613
homogenates O 0 0.010191348
. O 0 0.0043878136

Tissue O 0 0.038197003
lipid O 0 0.97765404
peroxidation O 0 0.9999281
was O 0 0.0014275543
measured O 0 0.00039271376
in O 0 0.00026702898
whole O 0 0.00030408546
homogenates O 0 0.0008730303
as O 0 0.00015328341
well O 0 0.00010499314
as O 0 0.00010719981
in O 0 0.00013524039
lipid O 0 0.103594095
extracts O 0 0.00052478665
from O 0 0.0001959258
homogenates O 0 0.0021850918
as O 0 0.0011792441
thiobarbituric B-Chemical 0 0.99998343
acid I-Chemical 0 0.99918205
reactive O 0 0.6750002
substances O 0 0.6643804
. O 0 0.0028910006

Proteinuria B-Disease 2 0.99938774
was O 0 0.0026891564
evident O 0 0.0008012021
at O 0 0.00041054163
day O 0 0.0003114473
5 O 0 0.00025973166
, O 0 0.000291594
peaked O 0 0.00031715693
at O 0 0.00015869175
day O 0 0.0001548314
7 O 0 0.0001628589
and O 0 0.00023985784
persisted O 0 0.00027645397
to O 0 0.0004542406
day O 0 0.0006744632
27 O 0 0.0020808845
. O 0 0.0022020242

Lipid O 0 0.9972646
peroxidation O 0 0.9998747
in O 0 0.0020738759
homogenates O 0 0.0032253822
was O 0 0.00045340307
maximal O 0 0.00023956096
at O 0 0.00012994482
day O 0 0.000113079754
3 O 0 0.00010533852
and O 0 0.00013367445
declined O 0 0.00022371755
rapidly O 0 0.00021485864
to O 0 0.00015713197
control O 0 0.00022555413
levels O 0 0.00036921474
by O 0 0.0005707077
day O 0 0.0006022617
17 O 0 0.0016634086
. O 0 0.0019307495

This O 0 0.003815048
study O 0 0.0016541808
supports O 0 0.00071200344
the O 0 0.0005355022
role O 0 0.00033993312
of O 0 0.0009878281
lipid O 0 0.97325057
peroxidation O 0 0.9999814
in O 0 0.00039909058
mediating O 0 0.00018362638
the O 0 0.0008228825
proteinuric B-Disease 0 0.9999945
injury I-Disease 0 0.99946135
in O 0 0.013697554
PAN B-Chemical 0 0.9999243
nephropathy B-Disease 2 0.9999902
. O 0 0.0073013054

Composition O 0 0.0044515636
of O 0 0.0024511886
gall B-Disease 0 0.14813274
bladder I-Disease 0 0.059250187
stones I-Disease 0 0.9522106
associated O 0 0.0006971679
with O 0 0.0010398667
octreotide B-Chemical 0 0.9931852
: O 0 0.00056514965
response O 0 0.00040743075
to O 0 0.00065058767
oral O 0 0.42533416
ursodeoxycholic B-Chemical 0 0.99990654
acid I-Chemical 0 0.9956643
. O 0 0.005408521

Octreotide B-Chemical 0 0.99802786
, O 0 0.002457149
an O 0 0.0011167991
effective O 0 0.0005928351
treatment O 0 0.00058403506
for O 0 0.00052573375
acromegaly B-Disease 0 0.9824952
, O 0 0.00042706134
induces O 0 0.00024483388
gall B-Disease 0 0.40990552
bladder I-Disease 0 0.15131357
stones I-Disease 0 0.98293877
in O 0 0.00036469818
13 O 0 0.00032935484
- O 0 0.00043059853
60 O 0 0.0003006413
% O 0 0.0004600633
of O 0 0.0008965164
patients O 0 0.0021500457
. O 0 0.0021666677

Because O 0 0.001540912
knowledge O 0 0.0019992723
of O 0 0.0015231827
stone O 0 0.17433695
composition O 0 0.0013626243
is O 0 0.00033777714
essential O 0 0.00018540774
for O 0 0.00012619978
studies O 0 0.00015058751
of O 0 0.0001771494
their O 0 0.00021755935
pathogenesis O 0 0.0005165972
, O 0 0.0001830357
treatment O 0 0.00014732454
, O 0 0.00014147596
and O 0 0.00011942751
prevention O 0 0.00020520204
, O 0 0.00012253839
this O 0 0.000119395285
was O 0 9.9691424e-05
investigated O 0 5.845069e-05
by O 0 6.77727e-05
direct O 0 5.784594e-05
and O 0 7.237171e-05
indirect O 0 0.00014423125
methods O 0 7.288881e-05
in O 0 7.2198614e-05
14 O 0 0.0001132455
octreotide B-Chemical 0 0.95683044
treated O 0 0.0007938104
acromegalic B-Disease 0 0.9968657
patients O 0 0.0009253786
with O 0 0.0012185274
gall B-Disease 0 0.9567795
stones I-Disease 0 0.9987012
. O 0 0.0037264146

Chemical O 0 0.013712533
analysis O 0 0.001472111
of O 0 0.0014291207
gall B-Disease 0 0.54536754
stones I-Disease 0 0.9781887
retrieved O 0 0.00040598342
at O 0 0.00021733584
cholecystectomy O 0 0.008563094
from O 0 0.00010674262
two O 0 7.902259e-05
patients O 0 0.00015559228
, O 0 0.000112558955
showed O 0 7.815678e-05
that O 0 5.7849473e-05
they O 0 7.247821e-05
contained O 0 8.381058e-05
71 O 0 0.00026687098
% O 0 0.00015717077
and O 0 0.00019287322
87 O 0 0.0005778855
% O 0 0.0006161427
cholesterol B-Chemical 0 0.99857354
by O 0 0.0017463323
weight O 0 0.009737341
. O 0 0.0025781633

In O 0 0.001573169
the O 0 0.0010983654
remaining O 0 0.00082882197
12 O 0 0.00037440314
patients O 0 0.0004643544
, O 0 0.00026767617
localised O 0 0.00016920637
computed O 0 0.00017809954
tomography O 0 0.001172503
of O 0 0.00014383695
the O 0 0.00012476872
gall O 0 0.009959003
bladder O 0 0.0042264666
showed O 0 7.607186e-05
that O 0 3.9724342e-05
eight O 0 4.091588e-05
had O 0 7.291953e-05
stones O 0 0.12803683
with O 0 8.941957e-05
maximum O 0 5.5501834e-05
attenuation O 0 0.00015328443
scores O 0 6.259328e-05
of O 0 9.579014e-05
< O 0 7.3676514e-05
100 O 0 0.00015567894
Hounsfield O 0 0.0002553945
units O 0 8.0827005e-05
( O 0 9.960694e-05
values O 0 7.3108924e-05
of O 0 0.0001145455
< O 0 0.00011436554
100 O 0 0.00032935827
HU O 0 0.090871006
predict O 0 0.00023898267
cholesterol B-Chemical 0 0.9996828
rich O 0 0.002667992
, O 0 0.0011858748
dissolvable O 0 0.28146878
stones O 0 0.960203
) O 0 0.004509116
. O 0 0.0025348845

Gall O 0 0.025927648
bladder O 0 0.059994135
bile O 0 0.9658221
was O 0 0.0013999555
obtained O 0 0.00069757656
by O 0 0.0005864428
ultrasound O 0 0.0010935206
guided O 0 0.0003159748
, O 0 0.00046392722
fine O 0 0.0007866049
needle O 0 0.0007534875
puncture O 0 0.0009972278
from O 0 0.00044504655
six O 0 0.00056539476
patients O 0 0.00186318
. O 0 0.0022219445

All O 0 0.0014522327
six O 0 0.000757908
patients O 0 0.0009894797
had O 0 0.000764932
supersaturated O 0 0.7804721
bile O 0 0.99228823
( O 0 0.0005545426
mean O 0 0.00011454169
( O 0 0.00024471368
SEM O 0 0.0003867779
) O 0 0.00047359624
cholesterol B-Chemical 0 0.99947876
saturation O 0 0.0059564332
index O 0 0.00024617746
of O 0 0.00017695676
1 O 0 0.00010076799
. O 0 6.3108964e-05
19 O 0 0.00013146657
( O 0 0.00012102562
0 O 0 7.90734e-05
. O 0 7.4186166e-05
08 O 0 0.00076516607
) O 0 0.00020582284
( O 0 0.00014446305
range O 0 0.000104397535
1 O 0 9.073255e-05
. O 0 7.473711e-05
01 O 0 0.00037293797
- O 0 0.00019238814
1 O 0 7.651602e-05
. O 0 5.6404748e-05
53 O 0 0.00014529414
) O 0 0.00015247772
) O 0 0.00011628047
and O 0 6.449545e-05
all O 0 5.7987334e-05
had O 0 6.0162623e-05
abnormally O 0 0.00045771827
rapid O 0 0.001040111
cholesterol B-Chemical 0 0.9999454
microcrystal O 0 0.94662505
nucleation O 0 0.020732138
times O 0 6.183996e-05
( O 0 0.00011525076
< O 0 5.9802715e-05
4 O 0 3.6651563e-05
days O 0 2.6459587e-05
( O 0 8.259271e-05
range O 0 7.9827536e-05
1 O 0 8.543492e-05
- O 0 0.00017431033
4 O 0 7.8676334e-05
) O 0 0.00017611009
) O 0 0.00016736986
, O 0 0.00010901473
whilst O 0 0.00014513158
in O 0 7.979504e-05
four O 0 5.5822504e-05
, O 0 0.000105937375
the O 0 0.00014141716
bile O 0 0.9272183
contained O 0 0.00034460405
cholesterol B-Chemical 0 0.9998399
microcrystals O 0 0.6277048
immediately O 0 0.00037746478
after O 0 0.00029232333
sampling O 0 0.0008470768
. O 0 0.0016495379

Of O 0 0.0019464578
the O 0 0.0010048901
12 O 0 0.0004545715
patients O 0 0.0004892638
considered O 0 0.00023719388
for O 0 0.00026536282
oral O 0 0.17635849
ursodeoxycholic B-Chemical 0 0.99997663
acid I-Chemical 0 0.9991829
( O 0 0.035195425
UDCA B-Chemical 0 0.99999917
) O 0 0.0015784244
treatment O 0 0.00019844079
, O 0 0.0001265092
two O 0 5.5709123e-05
had O 0 7.487607e-05
a O 0 0.00011187048
blocked O 0 0.0003482598
cystic O 0 0.16557734
duct O 0 0.16460052
and O 0 0.000121161305
were O 0 6.698855e-05
not O 0 4.97856e-05
started O 0 7.436032e-05
on O 0 0.00011883839
UDCA B-Chemical 0 0.99999547
while O 0 0.00030773808
one O 0 0.00016133519
was O 0 0.00024125235
lost O 0 0.00030661764
to O 0 0.00033255666
follow O 0 0.00043704433
up O 0 0.001191845
. O 0 0.0018403359

After O 0 0.0009765303
one O 0 0.000894023
year O 0 0.0005915865
of O 0 0.0006234088
treatment O 0 0.00046032763
, O 0 0.00032039813
five O 0 0.00010627035
of O 0 0.00014853677
the O 0 0.00010690285
remaining O 0 0.00012852691
nine O 0 0.00010405921
patients O 0 0.00011841736
showed O 0 6.879108e-05
either O 0 7.249936e-05
partial O 0 0.0002138439
( O 0 0.00015921175
n O 0 8.504136e-05
= O 0 9.952728e-05
3 O 0 5.0851744e-05
) O 0 8.641572e-05
or O 0 4.972407e-05
complete O 0 7.878648e-05
( O 0 0.00012506102
n O 0 8.052957e-05
= O 0 0.00010226464
2 O 0 6.77209e-05
) O 0 0.00017162439
gall B-Disease 0 0.37007353
stone I-Disease 0 0.98488706
dissolution O 0 0.740142
, O 0 0.0002211086
suggesting O 0 7.564383e-05
that O 0 0.000108265725
their O 0 0.00036149973
stones O 0 0.7118685
were O 0 0.0015439742
cholesterol B-Chemical 0 0.9995415
rich O 0 0.010618618
. O 0 0.0027527874

This O 0 0.0037905984
corresponds O 0 0.0014452153
, O 0 0.001314374
by O 0 0.0008580237
actuarial O 0 0.008792613
( O 0 0.00083670876
life O 0 0.0004899117
table O 0 0.00029765035
) O 0 0.00034525074
analysis O 0 0.00016682225
, O 0 0.00015118156
to O 0 9.195328e-05
a O 0 0.00014812151
combined O 0 0.0002624194
gall B-Disease 0 0.8312568
stone I-Disease 0 0.9914027
dissolution O 0 0.6249999
rate O 0 0.0002131398
of O 0 0.00020563297
58 O 0 0.00023766588
. O 0 9.132864e-05
3 O 0 0.00011409442
( O 0 0.00021574773
15 O 0 0.00017640032
. O 0 0.00022964593
9 O 0 0.0004510195
% O 0 0.00097297254
) O 0 0.0021240192
. O 0 0.0024262776

In O 0 0.0019292276
conclusion O 0 0.0016119757
, O 0 0.002141927
octreotide B-Chemical 0 0.98883724
induced O 0 0.0017625163
gall B-Disease 0 0.9689031
stones I-Disease 0 0.99883395
are O 0 0.0004023276
generally O 0 0.0002447732
small O 0 0.00022686894
, O 0 0.00015072367
multiple O 0 0.00014867196
, O 0 0.00015993525
and O 0 0.0002475225
cholesterol B-Chemical 0 0.99987805
rich O 0 0.0009378546
although O 0 0.000118989316
, O 0 9.533769e-05
in O 0 5.4046224e-05
common O 0 6.4687505e-05
with O 0 9.6226395e-05
spontaneous O 0 0.001518404
gall B-Disease 0 0.9966979
stone I-Disease 0 0.9993773
disease I-Disease 0 0.9735477
, O 0 0.00013931649
at O 0 4.33416e-05
presentation O 0 9.556652e-05
some O 0 8.020647e-05
patients O 0 0.00011428158
will O 0 5.844634e-05
have O 0 5.3087733e-05
a O 0 0.00012054683
blocked O 0 0.00040592
cystic O 0 0.13384764
duct O 0 0.11566414
and O 0 0.00027991112
some O 0 0.00041866832
gall B-Disease 0 0.87686765
stones I-Disease 0 0.99832445
containing O 0 0.0027487017
calcium B-Chemical 0 0.9987342
. O 0 0.0035995287

Erythema B-Disease 0 0.97743165
multiforme I-Disease 0 0.99692446
and O 0 0.015271808
hypersensitivity B-Disease 0 0.9990103
myocarditis I-Disease 2 0.9999728
caused O 0 0.024586668
by O 0 0.0100240605
ampicillin B-Chemical 1 0.9984402
. O 0 0.008681787

OBJECTIVE O 0 0.027521832
: O 0 0.0025236367
To O 0 0.0010250497
report O 0 0.0012478182
a O 0 0.00089351455
case O 0 0.00062679994
of O 0 0.0014101731
erythema B-Disease 0 0.99866676
multiforme I-Disease 0 0.9943922
and O 0 0.003293867
hypersensitivity B-Disease 0 0.9996749
myocarditis I-Disease 2 0.99999404
caused O 0 0.012706188
by O 0 0.004797607
ampicillin B-Chemical 1 0.99887663
. O 0 0.0046992837

CASE O 0 0.0268014
SUMMARY O 0 0.0043810424
: O 0 0.0023053226
A O 0 0.0065710465
13 O 0 0.001008089
- O 0 0.0010087366
year O 0 0.00032871214
- O 0 0.0005304653
old O 0 0.00028302698
boy O 0 0.00053093623
was O 0 0.00020070694
treated O 0 0.00024771117
with O 0 0.0003657256
ampicillin B-Chemical 1 0.9969683
and O 0 0.0007733581
gentamicin B-Chemical 1 0.9982735
because O 0 0.00050708355
of O 0 0.0014365242
suspected O 0 0.036081694
septicemia B-Disease 0 0.9982718
. O 0 0.0041059516

Medications O 0 0.03575962
were O 0 0.0016192703
discontinued O 0 0.0023030469
when O 0 0.0008661444
erythema B-Disease 0 0.99207824
multiforme I-Disease 0 0.967767
and O 0 0.0016966066
congestive B-Disease 0 0.9990447
heart I-Disease 0 0.5300201
failure I-Disease 0 0.35388225
caused O 0 0.001451556
by O 0 0.0022497056
myocarditis B-Disease 2 0.999897
occurred O 0 0.004371216
. O 0 0.002817228

The O 0 0.0022886598
patient O 0 0.0022883269
was O 0 0.0017292998
treated O 0 0.0018823643
with O 0 0.0029121533
methylprednisolone B-Chemical 0 0.999311
and O 0 0.0027784954
gradually O 0 0.0038833732
improved O 0 0.006054459
. O 0 0.004068946

Macrophage O 0 0.20689736
- O 0 0.006030329
migration O 0 0.004842491
inhibition O 0 0.0045508873
( O 0 0.0029565317
MIF O 0 0.83100003
) O 0 0.0020001594
test O 0 0.0011428561
with O 0 0.0014850815
ampicillin B-Chemical 1 0.99610233
was O 0 0.0030786672
positive O 0 0.0038792347
. O 0 0.0035845542

DISCUSSION O 0 0.0032946935
: O 0 0.0014797864
After O 0 0.0004199252
most O 0 0.001066702
infections B-Disease 0 0.031961393
causing O 0 0.0043812753
erythema B-Disease 0 0.99928856
multiforme I-Disease 0 0.99426585
and O 0 0.0018400915
myocarditis B-Disease 2 0.99996805
were O 0 0.00061836
ruled O 0 0.00075850665
out O 0 0.0001235063
, O 0 0.00018554337
a O 0 0.0003000809
drug B-Disease 0 0.02040334
- I-Disease 0 0.000826679
induced I-Disease 0 0.0013336022
allergic I-Disease 2 0.9999423
reaction I-Disease 2 0.9603361
was O 0 0.0037946682
suspected O 0 0.01601726
. O 0 0.0026747861

Positive O 0 0.009468463
MIF O 0 0.57560754
test O 0 0.0020002984
for O 0 0.00078688835
ampicillin B-Chemical 1 0.99145925
showed O 0 0.00081083766
sensitization O 0 0.0036183852
of O 0 0.00046688455
the O 0 0.00031742037
patient O 0 0.00038683892
' O 0 0.000499027
s O 0 0.00053605536
lymphocytes O 0 0.050198592
to O 0 0.0016856904
ampicillin B-Chemical 1 0.99691916
. O 0 0.004519556

CONCLUSIONS O 0 0.03272446
: O 0 0.008244366
Hypersensitivity B-Disease 0 0.99823344
myocarditis I-Disease 2 0.99996936
is O 0 0.0021911291
a O 0 0.0012505583
rare O 0 0.0018735675
and O 0 0.0006232748
dangerous O 0 0.0021246397
manifestation O 0 0.003298319
of O 0 0.0018240944
allergy B-Disease 0 0.99674076
to O 0 0.0030963023
penicillins B-Chemical 0 0.99798894
. O 0 0.004759196

Clomipramine B-Chemical 0 0.9997626
- O 0 0.006662682
induced O 0 0.0022924389
sleep B-Disease 0 0.5539721
disturbance I-Disease 0 0.18444656
does O 0 0.00054818083
not O 0 0.00037032831
impair O 0 0.00037704853
its O 0 0.0013964868
prolactin O 0 0.96437675
- O 0 0.0024285687
releasing O 0 0.0028719774
action O 0 0.0032152417
. O 0 0.002919556

The O 0 0.0015120518
present O 0 0.0010397345
study O 0 0.0010385361
was O 0 0.0005887073
undertaken O 0 0.00030118035
to O 0 0.00017962113
examine O 0 8.268365e-05
the O 0 0.00011666454
role O 0 7.6858116e-05
of O 0 0.00024337506
sleep B-Disease 0 0.5582774
disturbance I-Disease 0 0.41083014
, O 0 0.00020909213
induced O 0 0.00018931174
by O 0 0.0003874935
clomipramine B-Chemical 0 0.99999726
administration O 0 0.0039233007
, O 0 0.00010673937
on O 0 3.259162e-05
the O 0 5.1195857e-05
secretory O 0 9.4432085e-05
rate O 0 7.7513345e-05
of O 0 0.0001938498
prolactin O 0 0.97556335
( O 0 0.0009436696
PRL O 0 0.99982625
) O 0 0.00030198024
in O 0 9.092508e-05
addition O 0 8.345648e-05
to O 0 0.00013785822
the O 0 0.00022684711
direct O 0 0.00040842313
drug O 0 0.00924952
effect O 0 0.0015327404
. O 0 0.0022768746

Two O 0 0.0018973608
groups O 0 0.0010670517
of O 0 0.0008449587
supine O 0 0.0010765673
subjects O 0 0.000501056
were O 0 0.0002467158
studied O 0 0.00021154077
under O 0 0.00014647764
placebo O 0 0.0011564306
- O 0 0.0002578955
controlled O 0 9.9398676e-05
conditions O 0 0.00012253558
, O 0 9.3304516e-05
one O 0 4.3093572e-05
during O 0 3.0623447e-05
the O 0 6.4104e-05
night O 0 0.00018835226
, O 0 9.1538765e-05
when O 0 6.114229e-05
sleeping O 0 0.0011188051
( O 0 0.0001573126
n O 0 8.629088e-05
= O 0 0.00010160639
7 O 0 5.172738e-05
) O 0 9.618089e-05
and O 0 6.1880906e-05
the O 0 6.072705e-05
other O 0 5.9778606e-05
at O 0 6.0715232e-05
daytime O 0 0.00046985556
, O 0 0.00012400736
when O 0 8.989844e-05
awake O 0 0.0004196115
( O 0 0.00032023294
n O 0 0.0002931237
= O 0 0.0005333303
6 O 0 0.0005069772
) O 0 0.0016166515
. O 0 0.0020103047

Each O 0 0.0010183175
subject O 0 0.0007928341
received O 0 0.0005596536
a O 0 0.0005540208
single O 0 0.00035882677
50 O 0 0.00048378058
mg O 0 0.0040235706
dose O 0 0.0011429627
of O 0 0.0007602992
clomipramine B-Chemical 0 0.99998975
given O 0 0.00017728137
orally O 0 0.00051963143
2 O 0 0.00013627316
hours O 0 0.0001095326
before O 0 0.00017776583
blood O 0 0.0021189859
collection O 0 0.0016620685
. O 0 0.0020655124

Plasma O 0 0.54860896
PRL O 0 0.9987633
concentrations O 0 0.00386198
were O 0 0.00069780054
analysed O 0 0.00034466537
at O 0 0.0001760473
10 O 0 0.0001655596
min O 0 0.00017626834
intervals O 0 9.531924e-05
and O 0 0.00013376524
underlying O 0 0.0002250989
secretory O 0 0.00030104196
rates O 0 0.0002052224
calculated O 0 0.00018732117
by O 0 0.00035657932
a O 0 0.00068656687
deconvolution O 0 0.002199279
procedure O 0 0.0016160974
. O 0 0.0022495484

For O 0 0.0010390775
both O 0 0.0009330218
experiments O 0 0.0005490143
the O 0 0.00059325784
drug O 0 0.013606314
intake O 0 0.07351147
led O 0 0.00033719023
to O 0 0.0001721308
significant O 0 0.00015223917
increases O 0 0.00017853359
in O 0 0.0003176102
PRL O 0 0.99989927
secretion O 0 0.0046137576
, O 0 0.00014872767
acting O 0 9.990668e-05
preferentially O 0 4.2220872e-05
on O 0 3.9833663e-05
tonic O 0 0.0016136412
secretion O 0 0.00042613817
as O 0 6.0471848e-05
pulse O 0 0.00011849247
amplitude O 0 0.00018662232
and O 0 8.164987e-05
frequency O 0 9.496641e-05
did O 0 9.981051e-05
not O 0 8.67357e-05
differ O 0 9.210563e-05
significantly O 0 0.00015031034
from O 0 0.00013728326
corresponding O 0 0.00022626152
control O 0 0.0005172414
values O 0 0.001249012
. O 0 0.0018796651

During O 0 0.00081267627
the O 0 0.0010718369
night O 0 0.0038092628
clomipramine B-Chemical 0 0.9999763
ingestion O 0 0.255815
altered O 0 0.0005243419
the O 0 0.00016777251
complete O 0 0.00014830045
sleep O 0 0.001262927
architecture O 0 0.00015911962
in O 0 6.945544e-05
that O 0 5.3843123e-05
it O 0 8.999743e-05
suppressed O 0 0.00022805049
REM O 0 0.9291851
sleep O 0 0.0030455913
and O 0 0.00010035106
the O 0 0.00010074041
sleep O 0 0.00084285357
cycles O 0 0.000108515866
and O 0 0.00023298408
induced O 0 0.0005240925
increased O 0 0.0018982928
wakefulness O 0 0.12728333
. O 0 0.0021320344

As O 0 0.0013883422
the O 0 0.0010427476
relative O 0 0.00071532786
increase O 0 0.00067952095
in O 0 0.00087134447
PRL O 0 0.9996247
secretion O 0 0.0029206139
expressed O 0 0.00014505867
as O 0 0.000120854245
a O 0 0.00012403254
percentage O 0 6.184102e-05
of O 0 8.548334e-05
the O 0 6.0951515e-05
mean O 0 3.393852e-05
did O 0 7.257801e-05
not O 0 5.9781734e-05
significantly O 0 0.00010502219
differ O 0 4.8308684e-05
between O 0 2.5368381e-05
the O 0 4.7235724e-05
night O 0 0.00012207177
and O 0 5.0833227e-05
day O 0 2.9345074e-05
time O 0 2.8037266e-05
studies O 0 7.1225106e-05
( O 0 0.00011186324
46 O 0 0.0001286711
+ O 0 0.00022308428
/ O 0 0.0004037132
- O 0 0.00023715406
19 O 0 0.00013627471
% O 0 9.300924e-05
vs O 0 9.7675445e-05
34 O 0 0.00012568268
+ O 0 0.00023022205
/ O 0 0.00041432044
- O 0 0.00023882274
10 O 0 9.618768e-05
% O 0 0.00013827583
) O 0 0.00019540603
, O 0 0.0001194348
it O 0 9.352293e-05
can O 0 4.9010097e-05
be O 0 4.4265154e-05
concluded O 0 3.353911e-05
that O 0 3.2435288e-05
the O 0 5.4960034e-05
observed O 0 7.923099e-05
sleep B-Disease 0 0.31618994
disturbance I-Disease 0 0.16808607
did O 0 0.00013916657
not O 0 7.569384e-05
interfere O 0 6.7201356e-05
with O 0 0.00014734983
the O 0 0.00019214724
drug O 0 0.0027051857
action O 0 0.00056898984
per O 0 0.0003328631
se O 0 0.0017121205
. O 0 0.0018521369

The O 0 0.0013999315
presence O 0 0.001133094
of O 0 0.0014078142
REM O 0 0.9182409
sleep O 0 0.02065642
was O 0 0.0004332251
shown O 0 0.00015703369
not O 0 0.0001316166
to O 0 0.00011226203
be O 0 9.240738e-05
a O 0 0.00010274791
determining O 0 6.1771774e-05
factor O 0 0.00022964198
either O 0 7.351538e-05
for O 0 5.0491075e-05
secretory O 0 0.00012410755
pulse O 0 0.00013000034
amplitude O 0 0.00020820284
and O 0 9.5174924e-05
frequency O 0 0.00012091396
, O 0 0.00011388779
as O 0 7.640367e-05
, O 0 7.963609e-05
for O 0 4.390244e-05
both O 0 6.4757995e-05
, O 0 6.3035826e-05
mean O 0 3.0810133e-05
nocturnal O 0 0.0005347719
values O 0 7.150713e-05
were O 0 6.048875e-05
similar O 0 4.412422e-05
with O 0 0.00010083171
and O 0 0.00012367846
without O 0 0.00018580239
prior O 0 0.00037700357
clomipramine B-Chemical 0 0.99997556
ingestion O 0 0.634428
. O 0 0.0026331064

Survey O 0 0.0044203717
of O 0 0.0034950366
complications O 0 0.015522808
of O 0 0.005506641
indocyanine B-Chemical 0 0.9996165
green I-Chemical 0 0.037694868
angiography O 0 0.15612371
in O 0 0.002960017
Japan O 0 0.012584374
. O 0 0.004840216

PURPOSE O 0 0.005620948
: O 0 0.0020130659
We O 0 0.0006709311
evaluated O 0 0.00056779577
the O 0 0.0005469111
safety O 0 0.00081516395
of O 0 0.0014591187
indocyanine B-Chemical 0 0.99983203
green I-Chemical 0 0.0045015416
for O 0 0.0004951289
use O 0 0.0006680647
in O 0 0.0011018863
fundus O 0 0.4380963
angiography O 0 0.1483415
. O 0 0.0031475376

METHODS O 0 0.0017264482
: O 0 0.0013325041
We O 0 0.0004994334
sent O 0 0.0005826939
a O 0 0.0004570965
questionnaire O 0 0.00027356148
concerning O 0 0.00020494024
complications O 0 0.0034096423
of O 0 0.00090287963
indocyanine B-Chemical 0 0.9999685
green I-Chemical 0 0.0035851882
to O 0 0.00012961317
32 O 0 0.00015756482
institutions O 0 0.00022397388
in O 0 0.00010310851
Japan O 0 0.0008196118
, O 0 0.000102452526
which O 0 9.042892e-05
were O 0 5.6183628e-05
selected O 0 4.147842e-05
on O 0 2.6737542e-05
the O 0 4.3596287e-05
basis O 0 5.30643e-05
of O 0 7.4407355e-05
the O 0 6.6385874e-05
client O 0 0.00010576267
list O 0 7.598421e-05
from O 0 6.254417e-05
the O 0 0.00012723556
Topcon O 0 0.027715106
Company O 0 0.0030702222
, O 0 0.00017906315
which O 0 0.00020970446
manufactures O 0 0.00041899976
the O 0 0.0005901789
indocyanine B-Chemical 0 0.99986315
green I-Chemical 0 0.055496976
fundus O 0 0.739436
camera O 0 0.0064756796
. O 0 0.002478801

RESULTS O 0 0.0052648988
: O 0 0.0023839818
Ophthalmologists O 0 0.002696529
at O 0 0.00046155148
15 O 0 0.00038048273
institutions O 0 0.0006398323
responded O 0 0.0004749151
, O 0 0.00027510728
reporting O 0 0.00024096039
a O 0 0.0001750844
total O 0 0.00012808693
of O 0 0.00016217193
3 O 0 9.3053415e-05
, O 0 0.00015276032
774 O 0 0.0036194287
indocyanine B-Chemical 0 0.9999347
green I-Chemical 0 0.0023446532
angiograms O 0 0.031377718
performed O 0 7.698472e-05
on O 0 5.465251e-05
2 O 0 8.3303574e-05
, O 0 0.00013127367
820 O 0 0.00076667627
patients O 0 0.00018164622
between O 0 0.00010297664
June O 0 0.00023834323
1984 O 0 0.0006731606
and O 0 0.00046766916
September O 0 0.0008341383
1992 O 0 0.0024744184
. O 0 0.0019052168

Before O 0 0.0027296878
angiography O 0 0.023862366
, O 0 0.0013840765
intradermal O 0 0.0017474606
or O 0 0.00060234434
intravenous O 0 0.16954035
indocyanine B-Chemical 0 0.999948
green I-Chemical 0 0.0074890577
testing O 0 0.00028197598
, O 0 0.00021916917
or O 0 0.00013656217
both O 0 0.00016285547
was O 0 0.00018429347
performed O 0 0.00015076638
at O 0 0.00016999521
13 O 0 0.0003327356
of O 0 0.00054417696
15 O 0 0.0006911929
institutions O 0 0.0025664258
. O 0 0.0021725914

For O 0 0.0011853414
three O 0 0.0008494917
patients O 0 0.0012284846
, O 0 0.0007298816
the O 0 0.0004475626
decision O 0 0.0007501616
was O 0 0.00036354293
made O 0 0.000199558
not O 0 0.00016333896
to O 0 0.00015916576
proceed O 0 0.0003192145
with O 0 0.00031796194
angiography O 0 0.0048947707
after O 0 0.0001585928
positive O 0 0.00069712
preangiographic O 0 0.0057668486
testing O 0 0.0015801153
. O 0 0.002167726

The O 0 0.0019551048
dosage O 0 0.010344425
of O 0 0.003216619
indocyanine B-Chemical 0 0.9998117
green I-Chemical 0 0.0037781724
used O 0 0.000309931
for O 0 0.00022799677
angiography O 0 0.0057455674
varied O 0 0.00016514005
from O 0 0.00011716723
25 O 0 0.00017511113
to O 0 0.00012349698
75 O 0 0.00031591844
mg O 0 0.0023858561
, O 0 0.0002921035
depending O 0 0.00024046969
upon O 0 0.00032373355
the O 0 0.0008122087
institution O 0 0.0021900483
. O 0 0.0021635878

There O 0 0.0026269823
were O 0 0.0015387902
13 O 0 0.000983597
cases O 0 0.00069349894
of O 0 0.0006807113
adverse O 0 0.031130498
reactions O 0 0.0043705995
( O 0 0.0005151542
0 O 0 0.0001830832
. O 0 0.00010607597
34 O 0 0.00017692454
% O 0 0.00016512841
) O 0 0.00019215165
, O 0 0.000101738224
ten O 0 5.0928233e-05
of O 0 8.815576e-05
which O 0 0.00011804712
were O 0 0.00011372164
mild O 0 0.024075408
reactions O 0 0.00077840046
such O 0 8.155976e-05
as O 0 0.00024902658
nausea B-Disease 0 0.9999728
, O 0 0.0011837533
exanthema B-Disease 0 0.99481
, O 0 0.00070807163
urtication B-Disease 0 0.9764998
, O 0 0.00058792334
itchiness B-Disease 0 0.92880356
, O 0 0.00018131814
and O 0 0.00012167304
urgency O 0 0.0007595403
to O 0 0.00015691067
defecate O 0 0.0016816003
, O 0 0.00018366928
and O 0 0.00018554248
did O 0 0.00026131212
not O 0 0.00030065418
require O 0 0.0003825276
treatment O 0 0.001180557
. O 0 0.0019135342

Also O 0 0.00247343
recorded O 0 0.0013186972
were O 0 0.0008002461
one O 0 0.00040452197
case O 0 0.00039566628
of O 0 0.00061561714
pain B-Disease 0 0.14358379
of O 0 0.00039295922
the O 0 0.00028603888
vein O 0 0.0046120933
, O 0 0.00019416798
which O 0 0.00014908136
required O 0 8.0416925e-05
treatment O 0 0.00018276612
, O 0 0.00023394571
and O 0 0.00023719296
two O 0 0.00023237908
cases O 0 0.0006920996
of O 0 0.0020067375
hypotension B-Disease 0 0.99955195
. O 0 0.0037246943

The O 0 0.0024435727
two O 0 0.0022038773
hypotensive B-Disease 0 0.89797735
patients O 0 0.002337729
required O 0 0.0009914369
treatment O 0 0.0018456929
for O 0 0.0025580805
shock B-Disease 0 0.92985904
. O 0 0.0068122596

CONCLUSIONS O 0 0.016936883
: O 0 0.0027885654
A O 0 0.004688564
comparison O 0 0.0005257747
of O 0 0.00045531915
frequency O 0 0.00033615145
of O 0 0.0003707257
adverse O 0 0.019436685
reactions O 0 0.0024429173
to O 0 0.00042972696
indocyanine B-Chemical 0 0.99997854
green I-Chemical 0 0.0045974734
with O 0 0.00015637699
the O 0 8.144947e-05
previously O 0 6.828806e-05
reported O 0 7.1923954e-05
frequency O 0 6.453218e-05
of O 0 7.3129144e-05
such O 0 4.702919e-05
reactions O 0 0.0006486232
to O 0 0.0001818332
fluorescein B-Chemical 0 0.99993336
sodium I-Chemical 0 0.9999709
indicated O 0 0.00016826259
that O 0 0.00020919222
indocyanine B-Chemical 0 0.999984
green I-Chemical 0 0.005947939
is O 0 0.00014269803
a O 0 0.00016514225
safe O 0 0.0002197846
as O 0 0.00021986908
fluorescein B-Chemical 0 0.8818193
for O 0 0.00027284466
use O 0 0.0004462505
in O 0 0.0008114081
angiography O 0 0.04520111
. O 0 0.0021900816

Angioedema B-Disease 0 0.996815
following O 0 0.0026378438
the O 0 0.002759153
intravenous O 0 0.023455337
administration O 0 0.01446269
of O 0 0.015010446
metoprolol B-Chemical 1 0.999949
. O 0 0.010568594

A O 0 0.021476077
72 O 0 0.002429611
- O 0 0.0024133802
year O 0 0.0007145607
- O 0 0.0009773932
old O 0 0.00049285934
woman O 0 0.00083193113
was O 0 0.00027679896
admitted O 0 0.00032357033
to O 0 0.00010664718
the O 0 0.00012163024
hospital O 0 0.00022731326
with O 0 0.00017312464
" O 0 0.00022925978
flash O 0 0.0064631226
" O 0 0.0004178659
pulmonary B-Disease 0 0.7478219
edema I-Disease 0 0.99994075
, O 0 0.00041916152
preceded O 0 0.0002892538
by O 0 0.0003625417
chest B-Disease 0 0.018198013
pain I-Disease 0 0.46399325
, O 0 0.0008643462
requiring O 0 0.0010572287
intubation O 0 0.003870549
. O 0 0.001843225

Her O 0 0.005842705
medical O 0 0.0033554235
history O 0 0.0013164913
included O 0 0.000560343
coronary B-Disease 0 0.06382544
artery I-Disease 0 0.11007709
disease I-Disease 0 0.08329651
with O 0 0.0004040425
previous O 0 0.0004656574
myocardial B-Disease 0 0.9995697
infarctions I-Disease 0 0.9997904
, O 0 0.0047955834
hypertension B-Disease 2 0.9999639
, O 0 0.001777309
and O 0 0.0024008479
diabetes B-Disease 0 0.9996941
mellitus I-Disease 0 0.999183
. O 0 0.00346189

A O 0 0.027491782
history O 0 0.004994288
of O 0 0.0050858194
angioedema B-Disease 0 0.9997789
secondary O 0 0.010226579
to O 0 0.0027930879
lisinopril B-Chemical 0 0.999964
therapy O 0 0.0055504036
was O 0 0.0021746175
elicited O 0 0.002602742
. O 0 0.0035843705

Current O 0 0.0076075247
medications O 0 0.009197109
did O 0 0.0011799876
not O 0 0.0006442343
include O 0 0.0007633831
angiotensin B-Chemical 1 0.9998958
- O 0 0.0028916204
converting O 0 0.017436104
enzyme O 0 0.028703276
inhibitors O 0 0.0041721878
or O 0 0.0012227865
beta O 0 0.9502859
- O 0 0.009747799
blockers O 0 0.9970778
. O 0 0.004281455

She O 0 0.004910275
had O 0 0.0022490614
no O 0 0.0012778608
previous O 0 0.002160518
beta O 0 0.81591356
- O 0 0.00422019
blocking O 0 0.004620336
drug O 0 0.10817455
exposure O 0 0.0074806055
. O 0 0.0051794522

During O 0 0.00090475276
the O 0 0.00086382707
first O 0 0.0004347834
day O 0 0.00036598404
of O 0 0.0005280685
hospitalization O 0 0.0012389903
( O 0 0.00043278307
while O 0 0.00024233079
intubated O 0 0.0006815357
) O 0 0.0003297372
, O 0 0.0002579619
intravenous O 0 0.1273572
metoprolol B-Chemical 1 0.99999547
was O 0 0.0003915286
given O 0 0.00013886039
, O 0 0.00026313995
resulting O 0 0.00039823074
in O 0 0.00078349136
severe O 0 0.33171073
angioedema B-Disease 0 0.99992573
. O 0 0.005055545

The O 0 0.0039043801
angioedema B-Disease 0 0.9990721
resolved O 0 0.0021582083
after O 0 0.00038354855
therapy O 0 0.00074818835
with O 0 0.0008210846
intravenous O 0 0.13759822
steroids B-Chemical 0 0.99895835
and O 0 0.009953236
diphenhydramine B-Chemical 0 0.9999927
hydrochloride O 0 0.9994479
. O 0 0.0051740496

Effect O 0 0.0046170657
of O 0 0.005807915
coniine B-Chemical 1 0.98103416
on O 0 0.0021373935
the O 0 0.0028012532
developing O 0 0.009643985
chick O 0 0.04133063
embryo O 0 0.019759623
. O 0 0.005732844

Coniine B-Chemical 0 0.937472
, O 0 0.0030877774
an O 0 0.0022937406
alkaloid O 0 0.9634982
from O 0 0.00189845
Conium O 0 0.999366
maculatum O 0 0.7691304
( O 0 0.0014755692
poison O 0 0.2442768
hemlock O 0 0.9908783
) O 0 0.0010811053
, O 0 0.00034033653
has O 0 0.00016412724
been O 0 0.00015131179
shown O 0 0.00015798183
to O 0 0.000259994
be O 0 0.0005470182
teratogenic O 0 0.9838982
in O 0 0.0015326716
livestock O 0 0.015486227
. O 0 0.0028501006

The O 0 0.0019375024
major O 0 0.0023571746
teratogenic O 0 0.98994654
outcome O 0 0.0022960256
is O 0 0.0017354137
arthrogryposis B-Disease 0 0.97798324
, O 0 0.000845094
presumably O 0 0.0007624501
due O 0 0.0003767311
to O 0 0.0009334752
nicotinic O 0 0.9994874
receptor O 0 0.28393403
blockade O 0 0.23029137
. O 0 0.0035771807

However O 0 0.00341995
, O 0 0.0038212985
coniine B-Chemical 1 0.9941549
has O 0 0.00072404905
failed O 0 0.00057661557
to O 0 0.00035048905
produce O 0 0.00034281003
arthrogryposis B-Disease 0 0.9596487
in O 0 0.0002693104
rats O 0 0.00029544515
or O 0 0.00011844208
mice O 0 9.488685e-05
and O 0 0.00016264904
is O 0 0.00018810871
only O 0 0.00030832956
weakly O 0 0.0009837451
teratogenic O 0 0.99430746
in O 0 0.0012792904
rabbits O 0 0.002812233
. O 0 0.0021297531

The O 0 0.0015487374
purpose O 0 0.0011686304
of O 0 0.0010216277
this O 0 0.0007685071
study O 0 0.000618806
was O 0 0.00033037848
to O 0 0.0001599981
evaluate O 0 8.8400644e-05
and O 0 0.00012649474
compare O 0 5.3557018e-05
the O 0 9.74896e-05
effects O 0 0.00017738756
of O 0 0.0005421408
coniine B-Chemical 1 0.9988869
and O 0 0.0010050088
nicotine B-Chemical 1 0.9986034
in O 0 0.0005051735
the O 0 0.00067222497
developing O 0 0.00538031
chick O 0 0.03902
. O 0 0.0025058303

Concentrations O 0 0.021456525
of O 0 0.003861775
coniine B-Chemical 1 0.99801445
and O 0 0.0031106863
nicotine B-Chemical 1 0.9996586
sulfate O 0 0.9852481
were O 0 0.00053249317
0 O 0 0.00023030903
. O 0 0.0001546707
015 O 0 0.0027071272
% O 0 0.0001939648
, O 0 0.00016558725
0 O 0 0.000122004036
. O 0 0.0001029956
03 O 0 0.00070436025
% O 0 0.00014570175
, O 0 0.00013036156
0 O 0 9.5498566e-05
. O 0 8.05878e-05
075 O 0 0.0012370446
% O 0 0.00014534764
, O 0 0.00012413785
0 O 0 8.338782e-05
. O 0 5.646928e-05
15 O 0 6.291362e-05
% O 0 9.9337565e-05
, O 0 0.00010562419
0 O 0 7.9805155e-05
. O 0 6.0735958e-05
75 O 0 0.0001443851
% O 0 0.000119901626
, O 0 0.00012408945
1 O 0 8.385821e-05
. O 0 5.694792e-05
5 O 0 6.39285e-05
% O 0 0.000104042934
, O 0 0.00011618061
3 O 0 7.6836055e-05
% O 0 0.0001078982
, O 0 0.00011402752
and O 0 0.0001059491
6 O 0 6.425377e-05
% O 0 0.00010350067
and O 0 0.00011432825
1 O 0 0.000107750755
% O 0 0.0001418009
, O 0 0.00016010617
5 O 0 0.00011680268
% O 0 0.00019304761
, O 0 0.00024443597
and O 0 0.00029621003
10 O 0 0.00038255498
% O 0 0.00069080206
, O 0 0.0012037462
respectively O 0 0.0030145838
. O 0 0.0026305628

Both O 0 0.0037454953
compounds O 0 0.081259795
caused O 0 0.0024385552
deformations B-Disease 0 0.030178245
and O 0 0.0015616734
lethality O 0 0.2906557
in O 0 0.00085989136
a O 0 0.0012105475
dose O 0 0.0043354314
- O 0 0.0016516864
dependent O 0 0.0008090487
manner O 0 0.0021758003
. O 0 0.0029237373

All O 0 0.0017191977
concentrations O 0 0.0026841036
of O 0 0.0026605558
nicotine B-Chemical 1 0.9995053
sulfate O 0 0.9889341
caused O 0 0.0012170497
some O 0 0.0006695861
lethality O 0 0.6803971
but O 0 0.00039477108
a O 0 0.00023251006
no O 0 7.818011e-05
effect O 0 0.00011404993
level O 0 0.0001357536
for O 0 0.00025130966
coniine B-Chemical 1 0.9990263
lethality O 0 0.84360695
was O 0 0.00064537546
0 O 0 0.00033769436
. O 0 0.00033791142
75 O 0 0.0010110977
% O 0 0.0013792678
. O 0 0.0019245353

The O 0 0.0021410945
deformations B-Disease 0 0.008706864
caused O 0 0.0014363887
by O 0 0.00090187765
both O 0 0.0009132213
coniine B-Chemical 1 0.9983286
and O 0 0.0014580213
nicotine B-Chemical 1 0.99975926
sulfate O 0 0.9856333
were O 0 0.00043122083
excessive B-Disease 0 0.0023331728
flexion I-Disease 0 0.12106233
or I-Disease 0 0.00017370706
extension I-Disease 0 0.00022350499
of I-Disease 0 0.00029537585
one I-Disease 0 0.0002678184
or I-Disease 0 0.00050291664
more I-Disease 0 0.0018340365
toes I-Disease 0 0.06924508
. O 0 0.0026625975

No O 0 0.0035057329
histopathological O 0 0.01167956
alterations O 0 0.0019616438
or O 0 0.00044781566
differences O 0 0.00018989026
in O 0 0.00023187159
bone O 0 0.0025750531
formation O 0 0.0007887054
were O 0 0.00015734624
seen O 0 9.455021e-05
in O 0 7.763517e-05
the O 0 0.00010778931
limbs O 0 0.005126401
or O 0 0.00013488764
toes O 0 0.006174698
of O 0 0.00012085724
any O 0 7.070377e-05
chicks O 0 0.00025106897
from O 0 5.6769375e-05
any O 0 6.264875e-05
group O 0 0.00013204488
; O 0 0.00011006302
however O 0 0.00011352337
, O 0 0.00010885621
extensive O 0 0.00018611834
cranial B-Disease 0 0.81533116
hemorrhage I-Disease 2 0.99998057
occurred O 0 0.00021698281
in O 0 0.00016628754
all O 0 0.00037734336
nicotine B-Chemical 1 0.99961674
sulfate O 0 0.9946308
- O 0 0.0026201322
treated O 0 0.0019139269
chicks O 0 0.0053163087
. O 0 0.0021553114

There O 0 0.0030637486
was O 0 0.0020837472
a O 0 0.0015555611
statistically O 0 0.0009811649
significant O 0 0.00080146355
( O 0 0.0013052138
P O 0 0.009795552
< O 0 0.00032385456
or O 0 0.00022479628
= O 0 0.0002733599
0 O 0 0.00014333829
. O 0 0.00010990758
01 O 0 0.0004204281
) O 0 0.00017661204
decrease O 0 0.00011764897
in O 0 8.528687e-05
movement O 0 0.00017108455
in O 0 0.00016223766
coniine B-Chemical 1 0.9954537
and O 0 0.00056638505
nicotine B-Chemical 1 0.9997545
sulfate O 0 0.9851291
treated O 0 0.0010038126
chicks O 0 0.0011737483
as O 0 0.0002971429
determined O 0 0.00042422512
by O 0 0.0009451732
ultrasound O 0 0.0056614242
. O 0 0.0022481903

Control O 0 0.0036291215
chicks O 0 0.0033072568
were O 0 0.0008358644
in O 0 0.00046911286
motion O 0 0.000667658
an O 0 0.00032158766
average O 0 0.00015728861
of O 0 0.00028213602
33 O 0 0.00031220957
. O 0 0.00010074051
67 O 0 0.0001887717
% O 0 9.694794e-05
of O 0 9.2069626e-05
the O 0 7.597493e-05
time O 0 5.0417173e-05
, O 0 0.00011934522
while O 0 0.00018133804
coniine B-Chemical 1 0.9985929
- O 0 0.0004734464
treated O 0 0.00019673468
chicks O 0 0.00039861456
were O 0 7.736594e-05
only O 0 7.936726e-05
moving O 0 0.0001343434
8 O 0 6.0328548e-05
. O 0 4.3379063e-05
95 O 0 8.823567e-05
% O 0 5.736188e-05
of O 0 7.502373e-05
a O 0 0.000104383296
5 O 0 5.882349e-05
- O 0 0.00011431942
min O 0 8.1268925e-05
interval O 0 6.5951695e-05
, O 0 8.1093356e-05
and O 0 7.169196e-05
no O 0 5.0966948e-05
movement O 0 0.0001599046
was O 0 0.00012672711
observed O 0 0.00011887942
for O 0 0.00025205716
nicotine B-Chemical 1 0.9994043
sulfate O 0 0.99106604
treated O 0 0.005142474
chicks O 0 0.008163287
. O 0 0.0022679898

In O 0 0.0017002368
summary O 0 0.0008001976
, O 0 0.0011691416
the O 0 0.0007774016
chick O 0 0.0043014027
embryo O 0 0.001431886
provides O 0 0.00021621023
a O 0 0.00026615112
reliable O 0 0.00017432478
and O 0 0.0001557217
simple O 0 0.0001987394
experimental O 0 0.00020817823
animal O 0 0.00026461453
model O 0 0.00031434384
of O 0 0.00089019956
coniine B-Chemical 1 0.99864215
- O 0 0.0031460777
induced O 0 0.0034956115
arthrogryposis B-Disease 0 0.99684155
. O 0 0.0035829078

Data O 0 0.0021475735
from O 0 0.0010696005
this O 0 0.00084370293
model O 0 0.0006092907
support O 0 0.0003312865
a O 0 0.00042670747
mechanism O 0 0.0003998478
involving O 0 0.000664522
nicotinic O 0 0.99983084
receptor O 0 0.087776996
blockade O 0 0.016933145
with O 0 0.00048825768
subsequent O 0 0.00046009492
decreased O 0 0.0015951685
fetal O 0 0.02343624
movement O 0 0.0037540726
. O 0 0.0024213316

Immediate O 0 0.0351413
allergic B-Disease 0 0.9983109
reactions I-Disease 0 0.7066246
to O 0 0.016518446
amoxicillin B-Chemical 0 0.9972813
. O 0 0.018220576

A O 0 0.014425497
large O 0 0.0019346568
group O 0 0.0011195355
of O 0 0.00076340575
patients O 0 0.00071001874
with O 0 0.0006593962
suspected O 0 0.013248791
allergic B-Disease 0 0.99994564
reactions I-Disease 0 0.829841
to O 0 0.0013288738
beta B-Chemical 0 0.9984023
- I-Chemical 0 0.005915518
lactam I-Chemical 0 0.9985292
antibiotics O 0 0.20320311
was O 0 0.001670339
evaluated O 0 0.0015420354
. O 0 0.002405613

A O 0 0.012688088
detailed O 0 0.0013534453
clinical O 0 0.0025732373
history O 0 0.0013792593
, O 0 0.00052568276
together O 0 0.00032027232
with O 0 0.00041925727
skin O 0 0.004103449
tests O 0 0.0009513348
, O 0 0.00054746703
RAST O 0 0.99774975
( O 0 0.00085210614
radioallergosorbent O 0 0.15432745
test O 0 0.00051229354
) O 0 0.0002819717
, O 0 0.000118747084
and O 0 8.368064e-05
controlled O 0 6.847365e-05
challenge O 0 7.2167095e-05
tests O 0 0.00026137417
, O 0 0.000104260434
was O 0 7.328425e-05
used O 0 4.075213e-05
to O 0 3.8359554e-05
establish O 0 3.2746455e-05
whether O 0 3.1278418e-05
patients O 0 0.00030275167
allergic B-Disease 0 0.9985145
to O 0 0.00043804492
beta B-Chemical 0 0.998965
- I-Chemical 0 0.00266347
lactam I-Chemical 0 0.99857605
antibiotics O 0 0.047919214
had O 0 0.00011529363
selective O 0 0.00033284884
immediate O 0 0.00034985843
allergic B-Disease 0 0.99655557
responses O 0 0.00027406163
to O 0 0.00020174049
amoxicillin B-Chemical 0 0.9996555
( O 0 0.001143868
AX B-Chemical 0 0.9967836
) O 0 0.00031063595
or O 0 0.00010001344
were O 0 0.00012601486
cross O 0 0.00025839487
- O 0 0.00032812724
reacting O 0 0.00131844
with O 0 0.0005298327
other O 0 0.001034445
penicillin B-Chemical 1 0.99979013
derivatives O 0 0.5733769
. O 0 0.003581412

Skin O 0 0.021809556
tests O 0 0.0027765792
were O 0 0.00083797105
performed O 0 0.00053987704
with O 0 0.0008151124
benzylpenicilloyl B-Chemical 0 0.22762017
- I-Chemical 0 0.0015907697
poly I-Chemical 0 0.011904219
- I-Chemical 0 0.0024944083
L I-Chemical 0 0.8449023
- I-Chemical 0 0.0017730513
lysine I-Chemical 0 0.2489785
( O 0 0.0016355988
BPO B-Chemical 0 0.99995434
- I-Chemical 0 0.005006155
PLL I-Chemical 0 0.99305785
) O 0 0.0009853932
, O 0 0.00045200146
benzylpenicilloate B-Chemical 0 0.986497
, O 0 0.00059540366
benzylpenicillin B-Chemical 0 0.998104
( O 0 0.0019813823
PG B-Chemical 0 0.9995602
) O 0 0.0008201954
, O 0 0.0005169814
ampicillin B-Chemical 1 0.99833554
( O 0 0.0024796792
AMP B-Chemical 1 0.99790585
) O 0 0.0016804775
, O 0 0.0011079531
and O 0 0.0018958009
AX B-Chemical 0 0.9627642
. O 0 0.00357037

RAST O 0 0.98882115
for O 0 0.006818134
BPO B-Chemical 0 0.9994054
- I-Chemical 0 0.016391682
PLL I-Chemical 0 0.9743799
and O 0 0.0060364427
AX B-Chemical 0 0.99651164
- O 0 0.00866505
PLL O 0 0.67694
was O 0 0.0039868136
done O 0 0.0036132915
. O 0 0.0046950085

When O 0 0.0014992338
both O 0 0.0015729668
skin O 0 0.0054223277
test O 0 0.0013240258
and O 0 0.0010027459
RAST O 0 0.99197406
for O 0 0.0006734806
BPO B-Chemical 0 0.9995468
were O 0 0.00040121016
negative O 0 0.00033638065
, O 0 0.00023396533
single O 0 0.0002015719
- O 0 0.00042884017
blind O 0 0.0069378926
, O 0 0.00019541553
placebo O 0 0.000951891
- O 0 0.00015744437
controlled O 0 5.9279842e-05
challenge O 0 5.989398e-05
tests O 0 0.00016333118
were O 0 6.682368e-05
done O 0 4.9615504e-05
to O 0 5.2364707e-05
ensure O 0 4.9432445e-05
tolerance O 0 0.004455538
of O 0 0.0006297352
PG B-Chemical 0 0.99712026
or O 0 0.0005027329
sensitivity O 0 0.0027912215
to O 0 0.0015559876
AX B-Chemical 0 0.98375446
. O 0 0.0031132733

A O 0 0.010857923
total O 0 0.0015995383
of O 0 0.0014791129
177 O 0 0.0034300697
patients O 0 0.00092334993
were O 0 0.00053653127
diagnosed O 0 0.001254138
as O 0 0.000627983
allergic B-Disease 0 0.9974784
to O 0 0.0017868425
beta B-Chemical 0 0.9977513
- I-Chemical 0 0.011319768
lactam I-Chemical 0 0.99851006
antibiotics O 0 0.52597547
. O 0 0.00411903

We O 0 0.0016148085
selected O 0 0.0012484418
the O 0 0.0010480827
54 O 0 0.0013124663
( O 0 0.00075712515
30 O 0 0.00032375546
. O 0 0.00021640369
5 O 0 0.00018805597
% O 0 0.0002559015
) O 0 0.0002908527
cases O 0 0.00019700291
of O 0 0.00024082787
immediate O 0 0.00090849574
AX B-Chemical 0 0.9982383
allergy B-Disease 0 0.9964675
with O 0 0.0008799423
good O 0 0.0015931877
tolerance O 0 0.13374056
of O 0 0.004571104
PG B-Chemical 0 0.99827206
. O 0 0.0038820787

Anaphylaxis B-Disease 0 0.94899255
was O 0 0.0024004516
seen O 0 0.0009379413
in O 0 0.0006153287
37 O 0 0.0009138218
patients O 0 0.00064828515
( O 0 0.00048774757
69 O 0 0.0003862149
% O 0 0.00028071424
) O 0 0.0003125389
, O 0 0.00017697836
the O 0 0.00013597551
other O 0 0.00014328951
17 O 0 0.00023014392
( O 0 0.00021345034
31 O 0 0.00021172137
% O 0 0.00019193851
) O 0 0.00034563258
having O 0 0.0007225898
urticaria B-Disease 0 0.99988985
and O 0 0.001346277
/ O 0 0.0037470846
or O 0 0.002480589
angioedema B-Disease 0 0.99985504
. O 0 0.0045258896

All O 0 0.0015908472
the O 0 0.0012427701
patients O 0 0.0011904099
were O 0 0.0007105491
skin O 0 0.0023951111
test O 0 0.00054335705
negative O 0 0.00043311258
to O 0 0.0004711178
BPO B-Chemical 0 0.99951184
; O 0 0.00046847918
49 O 0 0.00026359523
of O 0 0.0001875932
51 O 0 0.00024758224
( O 0 0.00018338439
96 O 0 0.00027464732
% O 0 0.00013635712
) O 0 0.00014807237
were O 0 7.501257e-05
also O 0 7.104528e-05
negative O 0 0.00014239532
to O 0 0.00014424171
MDM B-Disease 0 0.055493418
, O 0 0.00019366154
and O 0 0.00014050289
44 O 0 0.00017644475
of O 0 0.00018375811
46 O 0 0.00027667073
( O 0 0.00030346194
96 O 0 0.00057855697
% O 0 0.00046515232
) O 0 0.0008695306
to O 0 0.0012408851
PG B-Chemical 0 0.9915222
. O 0 0.0035883049

Skin O 0 0.027310353
tests O 0 0.004405717
with O 0 0.0025938423
AX B-Chemical 0 0.93495834
were O 0 0.0009971011
positive O 0 0.0007906865
in O 0 0.00061361457
34 O 0 0.00086274586
( O 0 0.00093838334
63 O 0 0.0011278898
% O 0 0.0011561821
) O 0 0.001982646
patients O 0 0.0029203834
. O 0 0.0031033987

RAST O 0 0.9845508
was O 0 0.0026860877
positive O 0 0.0014005357
for O 0 0.00093878043
AX B-Chemical 0 0.9517911
in O 0 0.0005516207
22 O 0 0.0005044347
patients O 0 0.00044251216
( O 0 0.00035545402
41 O 0 0.00036200133
% O 0 0.00022184938
) O 0 0.00025720455
and O 0 0.00018071491
to O 0 0.0002650339
BPO B-Chemical 0 0.99751115
in O 0 0.00031995002
just O 0 0.0003083169
5 O 0 0.00027939523
( O 0 0.00055890303
9 O 0 0.000549198
% O 0 0.0010829752
) O 0 0.0022733458
. O 0 0.0025241934

None O 0 0.0033361933
of O 0 0.0018007476
the O 0 0.0011846297
sera O 0 0.002809854
with O 0 0.0010661844
negative O 0 0.0019309702
RAST O 0 0.9946801
for O 0 0.0011343495
AX B-Chemical 0 0.98466533
were O 0 0.0010696938
positive O 0 0.0015073444
to O 0 0.0022999016
BPO B-Chemical 0 0.9977981
. O 0 0.0052230386

Challenge O 0 0.0047079995
tests O 0 0.0031587263
with O 0 0.0018789334
AX B-Chemical 0 0.9376695
were O 0 0.00054982863
performed O 0 0.00027324035
in O 0 0.00022663285
23 O 0 0.00030745333
subjects O 0 0.0002540377
( O 0 0.00022322216
43 O 0 0.00021219206
% O 0 0.0001402526
) O 0 0.0001342728
to O 0 5.5882418e-05
establish O 0 4.8171223e-05
the O 0 7.313834e-05
diagnosis O 0 0.00016171917
of O 0 0.00013509064
immediate O 0 0.0008293916
allergic B-Disease 2 0.9999745
reaction I-Disease 2 0.90481746
to O 0 0.0005898465
AX B-Chemical 0 0.9985864
, O 0 0.000206108
and O 0 9.9923265e-05
in O 0 7.230935e-05
15 O 0 6.00654e-05
cases O 0 0.00010703229
( O 0 0.00012084387
28 O 0 8.2213184e-05
% O 0 0.00010379144
) O 0 0.0001416574
both O 0 0.00012330766
skin O 0 0.0014205099
test O 0 0.00031890307
and O 0 0.00039896733
RAST O 0 0.9807757
for O 0 0.0006453146
AX B-Chemical 0 0.97572076
were O 0 0.0011990144
negative O 0 0.0022941246
. O 0 0.0023891113

PG B-Chemical 0 0.99236876
was O 0 0.005003552
well O 0 0.002653125
tolerated O 0 0.0074180546
by O 0 0.0024721387
all O 0 0.002401565
54 O 0 0.004285025
patients O 0 0.0050068814
. O 0 0.00471439

We O 0 0.0013496637
describe O 0 0.0008954884
the O 0 0.00076637825
largest O 0 0.0008220287
group O 0 0.00073396624
of O 0 0.0010829547
AX B-Chemical 0 0.99822813
- O 0 0.003809938
allergic B-Disease 0 0.99887294
patients O 0 0.001270931
who O 0 0.00060236815
have O 0 0.00027830066
tolerated O 0 0.015743166
PG B-Chemical 0 0.99818027
reported O 0 0.0013933225
so O 0 0.0010036726
far O 0 0.0017924408
. O 0 0.002196355

Diagnosis O 0 0.007838165
of O 0 0.0019434247
these O 0 0.0014715994
patients O 0 0.0010325694
can O 0 0.0003623257
be O 0 0.0002901841
achieved O 0 0.0003382971
only O 0 0.0002728899
if O 0 0.00018909994
specific O 0 0.0003527171
AX B-Chemical 0 0.98513734
- O 0 0.0009194026
related O 0 0.0002970137
reagents O 0 0.0039027373
are O 0 0.0010230835
employed O 0 0.0018983523
. O 0 0.0024497458

Further O 0 0.0027418272
studies O 0 0.0014919249
are O 0 0.0006782971
necessary O 0 0.00030166976
to O 0 0.0002705759
determine O 0 0.00013303965
the O 0 0.00019400845
exact O 0 0.00021362667
extent O 0 0.00011445293
of O 0 0.00018377564
this O 0 0.0001851528
problem O 0 0.00020415467
and O 0 0.00013961732
to O 0 0.000104572195
improve O 0 0.00010615003
the O 0 0.00016985863
efficacy O 0 0.0003359557
of O 0 0.000546227
diagnostic O 0 0.0011247408
methods O 0 0.0014972078
. O 0 0.0020331368

Reversal O 0 0.016770286
by O 0 0.0036218609
phenylephrine B-Chemical 0 0.9994443
of O 0 0.0011425943
the O 0 0.0004473404
beneficial O 0 0.0004113317
effects O 0 0.00029673238
of O 0 0.0005085095
intravenous O 0 0.32460707
nitroglycerin B-Chemical 0 0.99997616
in O 0 0.00042075204
patients O 0 0.0006018244
with O 0 0.0010330229
acute B-Disease 0 0.99406743
myocardial I-Disease 0 0.999923
infarction I-Disease 2 0.9999876
. O 0 0.0068243104

Nitroglycerin B-Chemical 0 0.99961495
has O 0 0.0016881477
been O 0 0.0006647386
shown O 0 0.0003542284
to O 0 0.0002859988
reduce O 0 0.00027867613
ST O 0 0.21476649
- O 0 0.00058045564
segment O 0 0.00031542036
elevation O 0 0.0034863616
during O 0 0.00013046502
acute B-Disease 0 0.98225135
myocardial I-Disease 0 0.999979
infarction I-Disease 2 0.9999989
, O 0 0.00051487837
an O 0 0.00018069301
effect O 0 0.00011400079
potentiated O 0 0.003412336
in O 0 0.00010788647
the O 0 0.00010588658
dog O 0 0.00027144433
by O 0 0.00011387063
agents O 0 0.00038222902
that O 0 0.00016665515
reverse O 0 0.050075978
nitroglycerin B-Chemical 0 0.999984
- O 0 0.004092124
induced O 0 0.0037443086
hypotension B-Disease 0 0.9997516
. O 0 0.003659325

Our O 0 0.0028298614
study O 0 0.0020785567
was O 0 0.0010674247
designed O 0 0.0006010087
to O 0 0.0003568818
determine O 0 0.00017154537
the O 0 0.0002442361
effects O 0 0.0003233116
of O 0 0.00054262776
combined O 0 0.002365803
nitroglycerin B-Chemical 0 0.999967
and O 0 0.0051243077
phenylephrine B-Chemical 0 0.9998745
therapy O 0 0.007367474
. O 0 0.00273343

Ten O 0 0.0027159837
patients O 0 0.0014118003
with O 0 0.0009803347
acute O 0 0.1009262
transmural O 0 0.587752
myocardial B-Disease 0 0.99966645
infarctions I-Disease 0 0.99917597
received O 0 0.00044414747
intravenous O 0 0.4726463
nitroglycerin B-Chemical 0 0.9999896
, O 0 0.00019390046
sufficient O 0 5.4083186e-05
to O 0 4.296387e-05
reduce O 0 3.1793817e-05
mean O 0 3.1453103e-05
arterial O 0 0.0017784279
pressure O 0 0.0007024853
from O 0 7.237723e-05
107 O 0 0.00020966407
+ O 0 0.00024624367
/ O 0 0.00038172398
- O 0 0.00017976864
6 O 0 4.3483516e-05
to O 0 5.707242e-05
85 O 0 0.00015959569
+ O 0 0.00023732665
/ O 0 0.0003837188
- O 0 0.00020462237
6 O 0 6.2503146e-05
mm O 0 0.00027946927
Hg O 0 0.67186576
( O 0 0.00043444574
P O 0 0.0023675852
less O 0 0.00012927619
than O 0 9.673146e-05
0 O 0 0.0001423759
. O 0 0.00016307394
001 O 0 0.0031675533
) O 0 0.00044273786
, O 0 0.00035298316
for O 0 0.00033763918
60 O 0 0.00064516143
minutes O 0 0.00082799816
. O 0 0.0019334917

Left O 0 0.01908368
ventricular O 0 0.48985317
filling O 0 0.0046336707
pressure O 0 0.004613087
decreased O 0 0.0010252978
from O 0 0.00037341804
19 O 0 0.00053335115
+ O 0 0.0006156901
/ O 0 0.00083775783
- O 0 0.0004170153
2 O 0 0.00012643466
to O 0 0.00011814047
11 O 0 0.00016890412
+ O 0 0.00032755433
/ O 0 0.00053966296
- O 0 0.00032066213
2 O 0 0.00013146206
mm O 0 0.00044270584
Hg O 0 0.673509
( O 0 0.00063138665
P O 0 0.0027198794
less O 0 0.00026199291
than O 0 0.00023822827
0 O 0 0.00040621124
. O 0 0.0005827409
001 O 0 0.008849096
) O 0 0.0026478572
. O 0 0.002578834

SigmaST O 0 0.024431948
, O 0 0.0020168608
the O 0 0.0008910465
sum O 0 0.0006500088
of O 0 0.00093201816
ST O 0 0.30473682
- O 0 0.0009975986
segment O 0 0.00052050763
elevations O 0 0.0040572775
in O 0 0.0001847435
16 O 0 0.00019383688
precordial O 0 0.16426365
leads O 0 0.00021210364
, O 0 0.0002411953
decreased O 0 0.0006453659
( O 0 0.00051546417
P O 0 0.0031362327
less O 0 0.00014168142
than O 0 0.000100415964
0 O 0 0.0001394748
. O 0 0.00014859627
02 O 0 0.0016838425
) O 0 0.0004708971
with O 0 0.0007138732
intravenous O 0 0.2135621
nitroglycerin B-Chemical 0 0.9998481
. O 0 0.003498037

Subsequent O 0 0.0019283061
addition O 0 0.0009604905
of O 0 0.0022993267
phenylephrine B-Chemical 0 0.99986446
infusion O 0 0.0049220626
, O 0 0.00047189763
sufficient O 0 0.00018204121
to O 0 0.00018856196
re O 0 0.0007409136
- O 0 0.00027812162
elevate O 0 0.00020752443
mean O 0 5.5412675e-05
arterial O 0 0.0025684335
pressure O 0 0.00093084626
to O 0 9.205822e-05
106 O 0 0.00016980033
+ O 0 0.00027100215
/ O 0 0.0004100935
- O 0 0.00020609365
4 O 0 6.904976e-05
mm O 0 0.0002599977
Hg O 0 0.7107762
( O 0 0.0003854583
P O 0 0.0025031012
less O 0 9.266416e-05
than O 0 6.046372e-05
0 O 0 7.9162426e-05
. O 0 7.210718e-05
001 O 0 0.0017038569
) O 0 0.00010850365
for O 0 3.8375434e-05
30 O 0 3.7429993e-05
minutes O 0 3.2126336e-05
, O 0 6.144319e-05
increased O 0 9.358307e-05
left O 0 0.0002599358
ventricular O 0 0.29073367
filling O 0 0.00069866766
pressure O 0 0.0009697579
to O 0 7.5481345e-05
17 O 0 0.00013467777
+ O 0 0.00020816433
/ O 0 0.0003513731
- O 0 0.00019405934
2 O 0 7.3256866e-05
mm O 0 0.00025957666
Hg O 0 0.73004735
( O 0 0.00037922763
P O 0 0.0024690856
less O 0 9.257372e-05
than O 0 6.183099e-05
0 O 0 8.367434e-05
. O 0 7.9815814e-05
05 O 0 0.0014214285
) O 0 0.00014927369
and O 0 8.2403676e-05
also O 0 8.7075314e-05
significantly O 0 0.00018399743
increased O 0 0.00044691583
sigmaST O 0 0.06414281
( O 0 0.0005444524
P O 0 0.0028016944
less O 0 0.00023733616
than O 0 0.00022126001
0 O 0 0.000386313
. O 0 0.0005662013
05 O 0 0.006394059
) O 0 0.002428145
. O 0 0.0024228906

Our O 0 0.001900741
results O 0 0.0011129937
suggest O 0 0.00038031864
that O 0 0.00030186222
addition O 0 0.0002748278
of O 0 0.0010542123
phenylephrine B-Chemical 0 0.9999609
to O 0 0.0015553448
nitroglycerin B-Chemical 0 0.9999877
is O 0 0.00026902044
not O 0 0.00011006637
beneficial O 0 0.00014926131
in O 0 8.022895e-05
the O 0 8.769195e-05
treatment O 0 0.00011152954
of O 0 0.00021781173
patients O 0 0.00045231436
with O 0 0.00096648576
acute B-Disease 0 0.995756
myocardial I-Disease 0 0.99993765
infarction I-Disease 2 0.9999894
. O 0 0.00659479

Acetazolamide B-Chemical 0 0.99979264
- O 0 0.0106437905
induced O 0 0.004686273
nephrolithiasis B-Disease 2 0.9997117
: O 0 0.0014803333
implications O 0 0.00053854747
for O 0 0.00045022502
treatment O 0 0.0007721633
of O 0 0.0020938346
neuromuscular B-Disease 0 0.9856046
disorders I-Disease 0 0.99486625
. O 0 0.0047138343

Carbonic O 0 0.993361
anhydrase O 0 0.99798906
inhibitors O 0 0.044122543
can O 0 0.0074119545
cause O 0 0.021442551
nephrolithiasis B-Disease 2 0.9994789
. O 0 0.0149721

We O 0 0.0015797678
studied O 0 0.0014157709
20 O 0 0.0009129368
patients O 0 0.00078659365
receiving O 0 0.00061456277
long O 0 0.00035607486
- O 0 0.0005433834
term O 0 0.00046708708
carbonic O 0 0.99941504
anhydrase O 0 0.9999052
inhibitor O 0 0.0065345946
treatment O 0 0.0003634466
for O 0 0.0002856993
periodic O 0 0.0021589797
paralysis B-Disease 0 0.9991617
and O 0 0.00661701
myotonia B-Disease 0 0.9996288
. O 0 0.0036950326

Three O 0 0.0029756932
patients O 0 0.0026868188
on O 0 0.0018200999
acetazolamide B-Chemical 0 0.9996855
( O 0 0.0026410096
15 O 0 0.00097347057
% O 0 0.0012964457
) O 0 0.0019512697
developed O 0 0.0038039123
renal B-Disease 0 0.9985141
calculi I-Disease 0 0.999156
. O 0 0.0082564

Extracorporeal O 0 0.0042663924
lithotripsy O 0 0.0029790944
successfully O 0 0.0009175237
removed O 0 0.0005186319
a O 0 0.00094179634
renal B-Disease 0 0.99793965
calculus I-Disease 0 0.99091107
in O 0 0.00029354295
one O 0 0.00012190705
patient O 0 0.00014112417
and O 0 0.00011513224
surgery O 0 0.00011926807
removed O 0 8.123623e-05
a O 0 0.00020802485
staghorn O 0 0.9159483
calculus B-Disease 0 0.6400824
in O 0 0.00026302304
another O 0 0.000331679
, O 0 0.00036043674
permitting O 0 0.00064598967
continued O 0 0.000705949
treatment O 0 0.0013372551
. O 0 0.0019741151

Renal O 0 0.020632807
function O 0 0.003682583
remained O 0 0.0033939611
normal O 0 0.0036733851
in O 0 0.00240689
all O 0 0.0031718474
patients O 0 0.005758387
. O 0 0.0054544196

Nephrolithiasis B-Disease 0 0.9898336
is O 0 0.0027834726
a O 0 0.0022630016
complication O 0 0.013497959
of O 0 0.003400324
acetazolamide B-Chemical 0 0.9999299
but O 0 0.0013909619
does O 0 0.0006574942
not O 0 0.00063624576
preclude O 0 0.0009911055
its O 0 0.002039047
use O 0 0.0021632665
. O 0 0.0028648803

Effects O 0 0.0036580525
of O 0 0.004150946
calcium B-Chemical 0 0.99800414
channel O 0 0.7911521
blockers O 0 0.99886835
on O 0 0.002626108
bupivacaine B-Chemical 1 0.99989545
- O 0 0.008485925
induced O 0 0.006236654
toxicity B-Disease 2 0.99817085
. O 0 0.00623501

The O 0 0.0015602629
purpose O 0 0.0011810772
of O 0 0.0010392657
this O 0 0.0007824312
study O 0 0.0006225283
was O 0 0.00032001227
to O 0 0.00014477054
investigate O 0 7.698486e-05
the O 0 0.00010081922
influence O 0 7.151633e-05
of O 0 0.00035854735
calcium B-Chemical 0 0.9995321
channel O 0 0.81222373
blockers O 0 0.9993774
on O 0 0.00054990523
bupivacaine B-Chemical 1 0.9999578
- O 0 0.0024359806
induced O 0 0.0018728158
acute O 0 0.96230155
toxicity B-Disease 2 0.9994174
. O 0 0.0044651125

For O 0 0.0009269556
each O 0 0.000558112
of O 0 0.0006434752
the O 0 0.00037671957
three O 0 0.000180748
tested O 0 0.00038627046
calcium B-Chemical 0 0.99891424
channel O 0 0.8332444
blockers O 0 0.9997819
( O 0 0.004859642
diltiazem B-Chemical 1 0.9999968
, O 0 0.0016621089
verapamil B-Chemical 0 0.99999225
and O 0 0.001511015
bepridil B-Chemical 1 0.9999927
) O 0 0.00042487646
6 O 0 4.7572055e-05
groups O 0 4.774817e-05
of O 0 5.7811303e-05
mice O 0 3.9490842e-05
were O 0 6.019637e-05
treated O 0 8.929993e-05
by O 0 6.36562e-05
two O 0 3.8902606e-05
different O 0 4.6961475e-05
doses O 0 0.0005604893
, O 0 0.00013338795
i O 0 0.0002708908
. O 0 5.6706172e-05
e O 0 0.000112772854
. O 0 4.2752767e-05
2 O 0 4.4665096e-05
and O 0 5.491665e-05
10 O 0 6.441131e-05
mg O 0 0.0011540349
/ O 0 0.00037978895
kg O 0 0.0003221738
/ O 0 0.00034557327
i O 0 0.00032022898
. O 0 7.996849e-05
p O 0 0.00010275673
. O 0 4.9093356e-05
, O 0 7.1256494e-05
or O 0 4.7373993e-05
an O 0 6.301341e-05
equal O 0 4.4861503e-05
volume O 0 0.00013207902
of O 0 9.995928e-05
saline O 0 0.0003147739
for O 0 3.672048e-05
the O 0 4.8911585e-05
control O 0 6.3886626e-05
group O 0 0.00011585193
( O 0 0.00011448098
n O 0 7.212341e-05
= O 0 9.2459464e-05
20 O 0 7.528552e-05
) O 0 0.00011922829
; O 0 6.818109e-05
15 O 0 3.321305e-05
minutes O 0 2.7537897e-05
later O 0 3.722055e-05
, O 0 6.687876e-05
all O 0 5.218882e-05
the O 0 5.1803105e-05
animals O 0 4.22601e-05
were O 0 4.7838734e-05
injected O 0 4.8263875e-05
with O 0 7.186267e-05
a O 0 8.911541e-05
single O 0 7.600297e-05
50 O 0 0.00016227047
mg O 0 0.0026111926
/ O 0 0.00048216418
kg O 0 0.00038361878
/ O 0 0.00041252645
i O 0 0.00038278496
. O 0 0.0001340336
p O 0 0.00021020952
. O 0 0.00018294062
dose O 0 0.0012348783
of O 0 0.0024408384
bupivacaine B-Chemical 1 0.99972826
. O 0 0.003722409

The O 0 0.0028863158
convulsant O 0 0.9927555
activity O 0 0.0015772111
, O 0 0.0008173602
the O 0 0.0003438385
time O 0 0.00016100772
of O 0 0.0002621553
latency O 0 0.0003721137
to O 0 0.00023169747
convulse O 0 0.085157655
and O 0 0.0002063957
the O 0 0.00018178276
mortality O 0 0.0013642885
rate O 0 0.00023214566
were O 0 0.00020161434
assessed O 0 0.0001779454
in O 0 0.00028672774
each O 0 0.00036137775
group O 0 0.0014089127
. O 0 0.0019548628

The O 0 0.0018328557
local O 0 0.002445612
anesthetic O 0 0.07255332
- O 0 0.0022028135
induced O 0 0.0009904739
mortality O 0 0.01134224
was O 0 0.00052795175
significantly O 0 0.0004046774
increased O 0 0.0003822374
by O 0 0.00021471833
the O 0 0.00017176518
three O 0 0.00012947271
different O 0 0.00034656387
calcium B-Chemical 0 0.997122
channel O 0 0.79244804
blockers O 0 0.99872005
. O 0 0.0039820033

The O 0 0.0022414923
convulsant O 0 0.9852764
activity O 0 0.0013433016
of O 0 0.0023236002
bupivacaine B-Chemical 1 0.9999232
was O 0 0.0006085766
not O 0 0.00019335914
significantly O 0 0.00023828645
modified O 0 0.00017839047
but O 0 0.00029193674
calcium B-Chemical 0 0.9995012
channel O 0 0.7912197
blockers O 0 0.99879384
decreased O 0 0.00044419145
the O 0 6.376526e-05
time O 0 2.6192365e-05
of O 0 5.675687e-05
latency O 0 9.1285096e-05
to O 0 5.405669e-05
obtain O 0 0.00011154549
bupivacaine B-Chemical 1 0.99996734
- O 0 0.00089274946
induced O 0 0.0006009853
convulsions B-Disease 0 0.99995744
; O 0 0.0003519685
this O 0 0.00017671159
effect O 0 0.0001588716
was O 0 0.00023845893
less O 0 0.0003012102
pronounced O 0 0.0009069947
with O 0 0.0026137226
bepridil B-Chemical 1 0.99988306
. O 0 0.0035737697

Epidural O 0 0.049740918
blood O 0 0.010311828
flow O 0 0.006139581
during O 0 0.0021795095
prostaglandin B-Chemical 1 0.9999658
E1 I-Chemical 1 0.9987208
or O 0 0.00620099
trimethaphan B-Chemical 0 0.99987185
induced O 0 0.033709764
hypotension B-Disease 0 0.9997464
. O 0 0.0073466883

To O 0 0.0016154636
evaluate O 0 0.0007825841
the O 0 0.00081160525
effect O 0 0.0008707622
of O 0 0.006233371
prostaglandin B-Chemical 1 0.999997
E1 I-Chemical 1 0.99990094
( O 0 0.069260664
PGE1 B-Chemical 0 0.99999726
) O 0 0.0019191671
or O 0 0.0004984898
trimethaphan B-Chemical 0 0.99997306
( O 0 0.0024505428
TMP B-Chemical 0 0.99996364
) O 0 0.0005660515
induced O 0 0.0003141569
hypotension B-Disease 0 0.9994967
on O 0 9.9726785e-05
epidural O 0 0.006878749
blood O 0 0.0019102778
flow O 0 0.0008853694
( O 0 0.00023057243
EBF O 0 0.008396695
) O 0 0.00012451319
during O 0 3.8370457e-05
spinal O 0 0.00038300816
surgery O 0 0.00017757218
, O 0 0.00015179603
EBF O 0 0.0086683035
was O 0 8.598433e-05
measured O 0 4.595883e-05
using O 0 4.080907e-05
the O 0 5.7112877e-05
heat O 0 0.0003244841
clearance O 0 0.0010126344
method O 0 0.00012825498
in O 0 5.2946274e-05
30 O 0 4.399032e-05
patients O 0 8.390125e-05
who O 0 0.00010346614
underwent O 0 9.376869e-05
postero O 0 0.0009926354
- O 0 0.00031304947
lateral O 0 0.0008566402
interbody O 0 0.05242738
fusion O 0 0.0006053287
under O 0 0.00069771684
isoflurane B-Chemical 1 0.99804854
anaesthesia O 0 0.14781049
. O 0 0.0025264807

An O 0 0.0023350162
initial O 0 0.001341432
dose O 0 0.002963409
of O 0 0.0009931395
0 O 0 0.00051842106
. O 0 0.00025813413
1 O 0 0.0002455675
microgram O 0 0.0024913314
. O 0 0.00019067986
kg O 0 0.00055662636
- O 0 0.00030535477
1 O 0 0.00010149714
. O 0 6.437821e-05
min O 0 0.00013258678
- O 0 0.00020891754
1 O 0 9.8629745e-05
of O 0 0.00038211537
PGE1 B-Chemical 0 0.9999943
( O 0 0.00040964008
15 O 0 9.025715e-05
patients O 0 0.0001668913
) O 0 0.00015718307
, O 0 8.690684e-05
or O 0 6.02476e-05
10 O 0 6.816711e-05
micrograms O 0 0.0005599652
. O 0 7.291126e-05
kg O 0 0.00027720965
- O 0 0.00017139233
1 O 0 5.9691047e-05
. O 0 4.019028e-05
min O 0 9.17254e-05
- O 0 0.00015022753
1 O 0 6.651597e-05
of O 0 0.00019370421
TMP B-Chemical 0 0.99989593
( O 0 0.00024733
15 O 0 6.66413e-05
patients O 0 0.00011963484
) O 0 0.00010597638
was O 0 5.4331576e-05
administered O 0 5.0824456e-05
intravenously O 0 5.3376014e-05
after O 0 1.9402336e-05
the O 0 6.451169e-05
dural O 0 0.033400152
opening O 0 0.0005962671
and O 0 7.376157e-05
the O 0 6.926892e-05
dose O 0 0.00036309886
was O 0 8.419998e-05
adjusted O 0 4.5295033e-05
to O 0 3.3560347e-05
maintain O 0 3.0130981e-05
the O 0 3.9186143e-05
mean O 0 3.3682187e-05
arterial O 0 0.0025775821
blood O 0 0.0015042216
pressure O 0 0.0025894344
( O 0 0.00033891413
MAP O 0 0.044547863
) O 0 0.00034655162
at O 0 0.00017793081
about O 0 0.0003934184
60 O 0 0.0007128739
mmHg O 0 0.0023099424
. O 0 0.0018382487

The O 0 0.0027721107
hypotensive B-Disease 0 0.9750865
drug O 0 0.04930102
was O 0 0.0012505084
discontinued O 0 0.0013417571
at O 0 0.00030058972
the O 0 0.00032353023
completion O 0 0.00026642883
of O 0 0.00057646557
the O 0 0.0007587669
operative O 0 0.0017399647
procedure O 0 0.0018436788
. O 0 0.0026394096

After O 0 0.0012051096
starting O 0 0.0026785783
PGE1 B-Chemical 0 0.9999536
or O 0 0.0043926304
TMP B-Chemical 0 0.999897
, O 0 0.001511386
MAP O 0 0.24969515
and O 0 0.0003060776
rate O 0 0.00025341503
pressure O 0 0.001832738
product O 0 0.0005028249
( O 0 0.00032777456
RPP O 0 0.38299537
) O 0 0.00023435941
decreased O 0 0.00020216394
significantly O 0 0.000116049836
compared O 0 4.6878657e-05
with O 0 0.00010696281
preinfusion O 0 0.008506612
values O 0 0.00016455956
( O 0 0.00030339079
P O 0 0.0038005982
< O 0 0.00010725542
0 O 0 8.3714884e-05
. O 0 7.09375e-05
01 O 0 0.00034842317
) O 0 0.00015817207
, O 0 9.141891e-05
and O 0 7.174434e-05
the O 0 6.8290545e-05
degree O 0 0.00012324877
of O 0 0.00025902144
hypotension B-Disease 0 0.9995912
due O 0 0.0001242108
to O 0 0.00031341947
PGE1 B-Chemical 0 0.9999938
remained O 0 0.00033193242
constant O 0 0.00012627323
until O 0 5.7141526e-05
60 O 0 9.92886e-05
min O 0 0.00015997796
after O 0 0.00014722918
its O 0 0.0010003349
discontinuation O 0 0.040132694
. O 0 0.0021812608

Heart O 0 0.0104164705
rate O 0 0.003565674
( O 0 0.0039019163
HR O 0 0.045591753
) O 0 0.0018865194
did O 0 0.0009870637
not O 0 0.0007271129
change O 0 0.0008958708
in O 0 0.0009839034
either O 0 0.0016347566
group O 0 0.0033118653
. O 0 0.003613341

EBFF O 0 0.049226336
did O 0 0.0017984416
not O 0 0.0007808721
change O 0 0.0006658765
during O 0 0.00055173005
PGE1 B-Chemical 0 0.99997973
infusion O 0 0.0027178947
whereas O 0 0.00027595705
in O 0 0.00017752039
the O 0 0.00031937982
TMP B-Chemical 0 0.9999423
group O 0 0.0007206841
, O 0 0.0003128925
EBF O 0 0.0325514
decreased O 0 0.00031491555
significantly O 0 0.0001280994
at O 0 4.2047814e-05
30 O 0 3.9386472e-05
and O 0 4.5097633e-05
60 O 0 4.0520237e-05
min O 0 4.3192653e-05
after O 0 1.7195329e-05
the O 0 3.8039205e-05
start O 0 3.690063e-05
of O 0 0.00024540012
TMP B-Chemical 0 0.99994576
( O 0 0.00044839276
preinfusion O 0 0.02183099
: O 0 0.00014189289
45 O 0 7.190551e-05
. O 0 4.964324e-05
9 O 0 6.7520035e-05
+ O 0 0.00018353538
/ O 0 0.00036408397
- O 0 0.0002309084
13 O 0 9.545431e-05
. O 0 4.888733e-05
9 O 0 5.9958387e-05
ml O 0 0.0002162259
/ O 0 0.00040804487
100g O 0 0.14693277
/ O 0 0.00027928044
min O 0 9.9726494e-05
. O 0 4.2762633e-05
30 O 0 4.232819e-05
min O 0 8.0766054e-05
: O 0 0.00010477292
32 O 0 0.00011133902
. O 0 5.6794877e-05
3 O 0 6.823131e-05
+ O 0 0.0001979568
/ O 0 0.00038928736
- O 0 0.00024024739
9 O 0 7.825656e-05
. O 0 5.0410104e-05
9 O 0 6.107277e-05
ml O 0 0.00018643451
/ O 0 0.00022694706
100 O 0 0.0002183628
g O 0 0.0002798615
/ O 0 0.0002833877
min O 0 0.00017759656
( O 0 0.0002997386
P O 0 0.0024062078
< O 0 0.00011519353
0 O 0 9.4516494e-05
. O 0 9.118331e-05
05 O 0 0.00124313
) O 0 0.00015391305
. O 0 4.986339e-05
60 O 0 6.173632e-05
min O 0 8.843235e-05
: O 0 0.00010451227
30 O 0 7.652332e-05
+ O 0 0.00023244425
/ O 0 0.00041954187
- O 0 0.00023816516
7 O 0 6.724431e-05
. O 0 5.1222025e-05
5 O 0 5.8236423e-05
ml O 0 0.00020587268
/ O 0 0.0002610952
100 O 0 0.0002645797
g O 0 0.00035204034
/ O 0 0.00038175797
min O 0 0.00026713597
( O 0 0.00047243087
P O 0 0.0025977509
< O 0 0.00031096666
0 O 0 0.00033126882
. O 0 0.00046598774
05 O 0 0.004871979
) O 0 0.0019063633
) O 0 0.0026942678
. O 0 0.0028140787

These O 0 0.0021071276
results O 0 0.0013319948
suggest O 0 0.00064858585
that O 0 0.0012256964
PGE1 B-Chemical 0 0.9999732
may O 0 0.00064454565
be O 0 0.0002715875
preferable O 0 0.00015666714
to O 0 0.00025539426
TMP B-Chemical 0 0.9997209
for O 0 0.00030565125
hypotensive B-Disease 0 0.9928086
anaesthesia O 0 0.0075542587
in O 0 0.00020574515
spinal O 0 0.00095607154
surgery O 0 0.00046793828
because O 0 0.00049610354
TMP B-Chemical 0 0.9996954
decreased O 0 0.020011147
EBF O 0 0.49051395
. O 0 0.0030639614

Dup B-Chemical 0 0.9983966
753 I-Chemical 0 0.7935948
prevents O 0 0.0019070356
the O 0 0.0010499626
development O 0 0.0013557243
of O 0 0.0015799843
puromycin B-Chemical 0 0.8478965
aminonucleoside I-Chemical 0 0.99991107
- O 0 0.015591981
induced O 0 0.010762034
nephrosis B-Disease 2 0.999889
. O 0 0.007909495

The O 0 0.0016350166
appearance O 0 0.002742997
of O 0 0.0036312516
nephrotic B-Disease 0 0.9999627
syndromes I-Disease 0 0.2732607
such O 0 0.00042962356
as O 0 0.0007642763
proteinuria B-Disease 0 0.9999912
, O 0 0.0052437047
hypoalbuminemia B-Disease 0 0.99998343
, O 0 0.0047733737
hypercholesterolemia B-Disease 0 0.99999297
and O 0 0.00024506391
increase O 0 0.00011211301
in O 0 0.00012194041
blood B-Chemical 0 0.21773566
nitrogen I-Chemical 0 0.99989676
urea I-Chemical 0 0.9999825
, O 0 0.0002712464
induced O 0 0.0001263873
in O 0 7.477917e-05
rats O 0 0.000105080086
by O 0 5.355309e-05
injection O 0 6.5130625e-05
of O 0 0.00012703214
puromycin B-Chemical 0 0.4829624
aminonucleoside I-Chemical 0 0.9999597
was O 0 0.00025631415
markedly O 0 0.00047140394
inhibited O 0 0.00025308225
by O 0 0.00012584096
oral O 0 0.008518831
administration O 0 0.0008344094
of O 0 0.00071050617
Dup B-Chemical 0 0.9999778
753 I-Chemical 0 0.99390113
( O 0 0.0010455811
losartan B-Chemical 1 0.9999933
) O 0 0.0003583143
, O 0 8.72889e-05
a O 0 9.71016e-05
novel O 0 0.0002430796
angiotensin B-Chemical 1 0.99999475
II I-Chemical 1 0.9097477
receptor O 0 0.19723585
antagonist O 0 0.8430397
, O 0 0.00013111728
at O 0 4.7157857e-05
a O 0 0.00010679638
dose O 0 0.0003223037
of O 0 0.00014065999
1 O 0 8.707392e-05
or O 0 8.984479e-05
2 O 0 0.00012640152
mg O 0 0.001594918
/ O 0 0.0007259054
kg O 0 0.0006536099
per O 0 0.0002578731
day O 0 0.0006508122
. O 0 0.0015101029

The O 0 0.0016213824
results O 0 0.0012698141
suggest O 0 0.00054338184
a O 0 0.00076274335
possible O 0 0.00043787732
involvement O 0 0.00051384507
of O 0 0.00037894593
the O 0 0.00037950446
renin O 0 0.9789524
- O 0 0.0020080924
angiotensin B-Chemical 1 0.9999244
system O 0 0.00024783306
in O 0 0.00010411321
the O 0 0.00010263029
development O 0 0.00023651817
of O 0 0.00040218586
puromycin B-Chemical 0 0.7825594
aminonucleoside I-Chemical 0 0.99995255
- O 0 0.007461604
induced O 0 0.0061155166
nephrosis B-Disease 2 0.99992275
. O 0 0.005243287

Neuroplasticity O 0 0.010509515
of O 0 0.0022398527
the O 0 0.0012226042
adult O 0 0.0011057473
primate O 0 0.00063920993
auditory O 0 0.0012073636
cortex O 0 0.003709092
following O 0 0.0009604078
cochlear O 0 0.018740712
hearing B-Disease 0 0.9920477
loss I-Disease 0 0.07781213
. O 0 0.004819886

Tonotopic O 0 0.008112559
organization O 0 0.0015093294
is O 0 0.00091815426
an O 0 0.0006589659
essential O 0 0.00039109998
feature O 0 0.00036528343
of O 0 0.0003218603
the O 0 0.0002072405
primary O 0 0.00023397939
auditory O 0 0.0006440397
area O 0 0.00043490692
( O 0 0.0007477008
A1 O 0 0.24926463
) O 0 0.0008939381
of O 0 0.00078279956
primate O 0 0.0012132238
cortex O 0 0.016635148
. O 0 0.0027844193

In O 0 0.0030256303
A1 O 0 0.07275049
of O 0 0.0012545593
macaque O 0 0.0004772773
monkeys O 0 0.00039014188
, O 0 0.00045042334
low O 0 0.0005174833
frequencies O 0 0.00035630082
are O 0 0.00021341046
represented O 0 0.00024365948
rostrolaterally O 0 0.0012647229
and O 0 0.00028101468
high O 0 0.0005298099
frequencies O 0 0.0005196758
are O 0 0.0005443103
represented O 0 0.0010104644
caudomedially O 0 0.0057810275
. O 0 0.0023305514

The O 0 0.0015906744
purpose O 0 0.0012108197
of O 0 0.0010729174
this O 0 0.0008225717
study O 0 0.00067775947
was O 0 0.00036760373
to O 0 0.00017636147
determine O 0 8.720628e-05
if O 0 0.00010175852
changes O 0 0.00016901981
occur O 0 9.474968e-05
in O 0 9.7168675e-05
this O 0 0.00014523679
tonotopic O 0 0.00056819397
organization O 0 0.00022631371
following O 0 0.0003241511
cochlear O 0 0.012113617
hearing B-Disease 0 0.99318224
loss I-Disease 0 0.07778779
. O 0 0.0033963586

Under O 0 0.004325019
anesthesia O 0 0.010361661
, O 0 0.0011147319
the O 0 0.0005143172
superior O 0 0.0006210314
temporal O 0 0.0011317746
gyrus O 0 0.13478915
of O 0 0.00039294743
adult O 0 0.000272502
macaque O 0 7.511665e-05
monkeys O 0 7.340414e-05
was O 0 0.00010154362
exposed O 0 9.623484e-05
, O 0 0.00010686951
and O 0 7.557354e-05
the O 0 6.7671375e-05
tonotopic O 0 0.0003216352
organization O 0 0.00010476792
of O 0 0.00026060155
A1 O 0 0.23266947
was O 0 0.00018464241
mapped O 0 0.00012506293
using O 0 0.00014376278
conventional O 0 0.00026415975
microelectrode O 0 0.0006616044
recording O 0 0.0006241115
techniques O 0 0.0012921175
. O 0 0.0018014747

Following O 0 0.0018993756
recovery O 0 0.0027801965
, O 0 0.0012121871
the O 0 0.00058666785
monkeys O 0 0.00036313906
were O 0 0.00035866327
selectively O 0 0.00043795627
deafened O 0 0.0043757716
for O 0 0.00022313365
high O 0 0.0005273359
frequencies O 0 0.0004667324
using O 0 0.0005091063
kanamycin B-Chemical 1 0.98347175
and O 0 0.006061471
furosemide B-Chemical 0 0.9999044
. O 0 0.0051276977

The O 0 0.0015810467
actual O 0 0.0012763074
frequencies O 0 0.0016332741
deafened O 0 0.010854319
were O 0 0.0005715733
determined O 0 0.0003285288
by O 0 0.0002869022
the O 0 0.00023779077
loss O 0 0.0006362385
of O 0 0.00047242214
tone O 0 0.02158415
- O 0 0.0006481295
burst O 0 0.0006040657
elicited O 0 0.0003783608
auditory O 0 0.001727901
brainstem O 0 0.0118607525
responses O 0 0.0023393387
. O 0 0.0024223663

Three O 0 0.003558256
months O 0 0.0016093288
after O 0 0.0015463296
deafening O 0 0.021043459
, O 0 0.0052528433
A1 O 0 0.32543486
was O 0 0.0053391065
remapped O 0 0.0072230934
. O 0 0.0066867447

Postmortem O 0 0.033811994
cytoarchitectural O 0 0.0048297537
features O 0 0.0014508179
identifying O 0 0.0015250028
A1 O 0 0.08846255
were O 0 0.0006526877
correlated O 0 0.00041541157
with O 0 0.0007096721
the O 0 0.000981705
electrophysiologic O 0 0.010225276
data O 0 0.0026788241
. O 0 0.0030999987

The O 0 0.0015520576
results O 0 0.0011952285
indicate O 0 0.0005120946
that O 0 0.00037671064
the O 0 0.00040533996
deprived O 0 0.0004826571
area O 0 0.00032721536
of O 0 0.00048609456
A1 O 0 0.23166479
undergoes O 0 0.00018904838
extensive O 0 0.00018946757
reorganization O 0 0.0002763122
and O 0 0.0001745252
becomes O 0 0.00016955812
responsive O 0 0.0001437067
to O 0 0.00025010997
intact O 0 0.0005776921
cochlear O 0 0.0053954367
frequencies O 0 0.0020793602
. O 0 0.002191401

The O 0 0.0016144718
region O 0 0.0011201672
of O 0 0.0010214205
cortex O 0 0.0025651532
that O 0 0.0003202601
represents O 0 0.00029343803
the O 0 0.00026672342
low O 0 0.000522027
frequencies O 0 0.00036408467
was O 0 0.00025444638
not O 0 0.00019948816
obviously O 0 0.0008722662
affected O 0 0.00042273165
by O 0 0.00039530906
the O 0 0.000581118
cochlear O 0 0.02496814
hearing B-Disease 0 0.9956529
loss I-Disease 0 0.10370121
. O 0 0.003617379

Sodium B-Chemical 0 0.99980134
bicarbonate I-Chemical 0 0.9996964
alleviates O 0 0.3808228
penile B-Disease 0 0.88048464
pain I-Disease 0 0.98847765
induced O 0 0.0014571047
by O 0 0.0010751642
intracavernous O 0 0.5936955
injections O 0 0.001267426
for O 0 0.0010374206
erectile B-Disease 0 0.94841874
dysfunction I-Disease 0 0.9452576
. O 0 0.003697301

In O 0 0.0016238977
an O 0 0.0013581197
attempt O 0 0.0009563759
to O 0 0.00041105377
determine O 0 0.0001726397
whether O 0 0.00018924009
penile B-Disease 0 0.15047838
pain I-Disease 0 0.96009463
associated O 0 0.00019607569
with O 0 0.00018610523
intracorporeal O 0 0.00023326438
injections O 0 0.00015250781
could O 0 5.83184e-05
be O 0 4.793052e-05
due O 0 3.113979e-05
to O 0 4.4432458e-05
the O 0 7.75935e-05
acidity O 0 0.34798986
of O 0 0.0001312937
the O 0 0.0001025627
medication O 0 0.0008336154
, O 0 6.218389e-05
we O 0 2.207637e-05
performed O 0 3.4545883e-05
a O 0 5.829104e-05
randomized O 0 5.5017765e-05
study O 0 4.0342456e-05
comparing O 0 1.9487807e-05
the O 0 3.804791e-05
incidence O 0 0.00010645191
of O 0 0.00013405534
penile B-Disease 0 0.17268717
pain I-Disease 0 0.8982223
following O 0 4.7518144e-05
intracorporeal O 0 0.000105509025
injections O 0 7.708014e-05
with O 0 5.876193e-05
or O 0 4.1133673e-05
without O 0 4.4971028e-05
the O 0 5.162852e-05
addition O 0 6.041876e-05
of O 0 0.00045450564
sodium B-Chemical 0 0.99990094
bicarbonate I-Chemical 0 0.99969935
to O 0 0.0003973513
the O 0 0.00045017482
intracorporeal O 0 0.001343975
medications O 0 0.009291783
. O 0 0.0016843299

A O 0 0.009528756
total O 0 0.0011957956
of O 0 0.00087245775
38 O 0 0.00062349316
consecutive O 0 0.00029399805
patients O 0 0.00032197603
who O 0 0.00022890398
presented O 0 0.000110552966
to O 0 9.3915536e-05
our O 0 0.00015652811
clinic O 0 0.00018470475
with O 0 0.00019702096
impotence B-Disease 0 0.4641837
received O 0 8.481913e-05
0 O 0 6.684319e-05
. O 0 4.120898e-05
2 O 0 4.918886e-05
ml O 0 0.00014172589
. O 0 3.6548037e-05
of O 0 6.442452e-05
a O 0 8.307693e-05
combination O 0 9.289216e-05
of O 0 0.00010590113
3 O 0 6.27108e-05
drugs O 0 0.0011411649
: O 0 9.4293064e-05
6 O 0 4.2371725e-05
mg O 0 0.0012207952
. O 0 8.765115e-05
papaverine B-Chemical 0 0.9996823
, O 0 0.0001371153
100 O 0 0.00021781774
micrograms O 0 0.0009476411
. O 0 9.780368e-05
phentolamine B-Chemical 0 0.99998057
and O 0 0.00013844813
10 O 0 7.838121e-05
micrograms O 0 0.0014772366
. O 0 0.00023240391
prostaglandin B-Chemical 1 0.99999774
E1 I-Chemical 1 0.9993426
with O 0 0.0005465884
( O 0 0.00035341046
pH O 0 0.0038897812
7 O 0 8.62088e-05
. O 0 7.703334e-05
05 O 0 0.0013935282
) O 0 0.00013741975
or O 0 6.863859e-05
without O 0 0.00010486916
( O 0 0.00022513303
pH O 0 0.0019355705
4 O 0 8.14873e-05
. O 0 5.4501477e-05
17 O 0 9.8733166e-05
) O 0 9.3441464e-05
the O 0 5.474776e-05
addition O 0 6.349064e-05
of O 0 0.00044710675
sodium B-Chemical 0 0.99993217
bicarbonate I-Chemical 0 0.99990606
( O 0 0.0008623932
0 O 0 0.00025631711
. O 0 0.00026017727
03 O 0 0.003659662
mEq O 0 0.2081904
. O 0 0.0008656208
) O 0 0.002227987
. O 0 0.0023259248

Of O 0 0.0020211614
the O 0 0.0011945036
19 O 0 0.0011598644
patients O 0 0.0008143213
without O 0 0.0008152623
sodium B-Chemical 0 0.9998393
bicarbonate I-Chemical 0 0.9997688
added O 0 0.00052725273
to O 0 0.00016606333
the O 0 0.00017146867
medication O 0 0.0012118194
11 O 0 0.00012836755
( O 0 0.00012665801
58 O 0 0.0001242076
% O 0 9.886025e-05
) O 0 0.00014661669
complained O 0 0.0006170007
of O 0 0.00020754126
penile B-Disease 0 0.2348797
pain I-Disease 0 0.9436034
due O 0 5.839965e-05
to O 0 5.8767815e-05
the O 0 8.8203866e-05
medication O 0 0.0009085572
, O 0 9.290447e-05
while O 0 6.639563e-05
only O 0 8.1457154e-05
1 O 0 5.213316e-05
of O 0 7.165519e-05
the O 0 8.36812e-05
19 O 0 0.00017458011
men O 0 0.00044900778
( O 0 0.00011516925
5 O 0 5.6610108e-05
% O 0 9.318813e-05
) O 0 0.00014593269
who O 0 0.00017663429
received O 0 0.00020995912
sodium B-Chemical 0 0.99973816
bicarbonate I-Chemical 0 0.9998235
complained O 0 0.13946865
of O 0 0.0022715223
penile B-Disease 0 0.7731628
pain I-Disease 0 0.99434716
. O 0 0.0030730108

From O 0 0.0017621876
these O 0 0.001384103
data O 0 0.0007413346
we O 0 0.00024827578
conclude O 0 0.00019001904
that O 0 0.00017585488
the O 0 0.0003102228
penile B-Disease 0 0.13437068
pain I-Disease 0 0.9189846
following O 0 0.00012322479
intracorporeal O 0 0.00025118463
injections O 0 0.00017267936
is O 0 8.1863334e-05
most O 0 0.00010144945
likely O 0 4.3315158e-05
due O 0 3.454875e-05
to O 0 4.7640784e-05
the O 0 8.261296e-05
acidity O 0 0.3441581
of O 0 0.00014650742
the O 0 0.00012492182
medication O 0 0.0014271179
, O 0 0.00011784017
which O 0 0.00011641105
can O 0 6.072241e-05
be O 0 6.387237e-05
overcome O 0 6.075027e-05
by O 0 0.00014917919
elevating O 0 0.0028496534
the O 0 0.00032369466
pH O 0 0.0046070917
to O 0 0.00038739154
a O 0 0.0008933647
neutral O 0 0.003860436
level O 0 0.0016488542
. O 0 0.002501637

The O 0 0.001652568
use O 0 0.001335542
and O 0 0.0013962254
toxicity B-Disease 2 0.97497094
of O 0 0.003558523
didanosine B-Chemical 0 0.99967694
( O 0 0.0033212344
ddI B-Chemical 0 0.99160284
) O 0 0.0005877149
in O 0 0.0002584555
HIV B-Disease 0 0.09550813
antibody I-Disease 0 0.0015073151
- I-Disease 0 0.00041666662
positive I-Disease 0 0.00023235736
individuals O 0 0.00034796773
intolerant O 0 0.0011256025
to O 0 0.0005742879
zidovudine B-Chemical 1 0.8934102
( O 0 0.0041918927
AZT B-Chemical 1 0.99795675
) O 0 0.010642415

One O 0 0.0024247295
hundred O 0 0.0015220143
and O 0 0.0009723175
fifty O 0 0.0008609302
- O 0 0.00065985764
one O 0 0.00020102371
patients O 0 0.00029247638
intolerant O 0 0.0005789823
to O 0 0.00025094117
zidovudine B-Chemical 1 0.8327121
( O 0 0.0008687331
AZT B-Chemical 1 0.99896026
) O 0 0.00043962453
received O 0 0.00020648428
didanosine B-Chemical 0 0.9977628
( O 0 0.00083787204
ddI B-Chemical 0 0.9686738
) O 0 0.00019637203
to O 0 6.374921e-05
a O 0 9.3290284e-05
maximum O 0 8.1288e-05
dose O 0 0.00035423413
of O 0 0.00015146712
12 O 0 7.2976436e-05
. O 0 7.655456e-05
5 O 0 0.00012024237
mg O 0 0.0016778007
/ O 0 0.0010154669
kg O 0 0.0011692318
/ O 0 0.0015571121
day O 0 0.00093296566
. O 0 0.0018418913

Patient O 0 0.0030657244
response O 0 0.0015468068
was O 0 0.0010224141
assessed O 0 0.00043274282
using O 0 0.00031035062
changes O 0 0.0003962857
in O 0 0.00035841373
CD4 O 0 0.33027676
+ O 0 0.0014767154
lymphocyte O 0 0.5650089
subset O 0 0.00055434246
count O 0 0.0012531147
, O 0 0.0005162947
HIV O 0 0.3401342
p24 O 0 0.42259106
antigen O 0 0.003326093
, O 0 0.00039249426
weight O 0 0.0013740388
, O 0 0.00034630924
and O 0 0.00030934036
quality O 0 0.00041626982
of O 0 0.0010051228
life O 0 0.002027398
. O 0 0.0021828783

Seventy O 0 0.0039595366
patients O 0 0.0016955005
developed O 0 0.0010500406
major O 0 0.00065447635
opportunistic B-Disease 0 0.004968342
infections I-Disease 0 0.1285809
whilst O 0 0.0007845359
on O 0 0.00017746858
therapy O 0 0.0004155528
; O 0 0.00024946124
this O 0 0.00021113755
was O 0 0.00021279887
the O 0 0.00021167009
first O 0 0.0003228459
AIDS B-Disease 2 0.9929402
diagnosis O 0 0.0024108593
in O 0 0.0010588423
17 O 0 0.0021344991
. O 0 0.002057911

Only O 0 0.0029461808
minor O 0 0.002484535
changes O 0 0.0011466001
in O 0 0.00081705564
CD4 O 0 0.38154003
+ O 0 0.0021580812
lymphocyte O 0 0.51343954
subset O 0 0.0005181182
count O 0 0.0006637371
were O 0 0.00016648331
observed O 0 0.000121055506
in O 0 0.00023632974
AIDS B-Disease 2 0.9985195
patients O 0 0.00050840434
, O 0 0.00015316931
although O 0 7.792161e-05
a O 0 0.000113772505
more O 0 0.00012392708
significant O 0 8.8561894e-05
rise O 0 0.00014118648
occurred O 0 8.6315405e-05
in O 0 9.907372e-05
those O 0 0.0001815529
with O 0 0.00022654688
earlier O 0 0.00039185444
stages O 0 0.0006376763
of O 0 0.0015629838
disease O 0 0.37639323
. O 0 0.002691668

Of O 0 0.0024529404
those O 0 0.0015791345
positive O 0 0.0009676255
for O 0 0.0005857426
p24 O 0 0.05902505
antigen O 0 0.0013068022
at O 0 0.0001662942
the O 0 0.00015003585
commencement O 0 0.000109522676
of O 0 0.00014108165
the O 0 0.00011521186
study O 0 0.00014636498
67 O 0 0.00019824924
% O 0 9.196555e-05
showed O 0 7.192423e-05
a O 0 0.00010099752
positive O 0 0.000106424704
response O 0 0.00010783155
, O 0 0.00011425326
and O 0 8.602369e-05
this O 0 0.00010706169
was O 0 9.282034e-05
most O 0 0.00010171699
likely O 0 4.665255e-05
in O 0 6.002955e-05
those O 0 0.00011095281
with O 0 0.00018118713
CD4 O 0 0.45567432
+ O 0 0.0009033212
lymphocyte O 0 0.40420803
subset O 0 0.00040452468
counts O 0 0.0003972156
above O 0 0.00052522135
100 O 0 0.0017021577
mm3 O 0 0.0032440266
. O 0 0.0021427537

A O 0 0.01578039
positive O 0 0.002453615
weight O 0 0.0038615328
response O 0 0.0014184951
was O 0 0.0011552128
seen O 0 0.0007611931
in O 0 0.0007148863
16 O 0 0.0008378161
% O 0 0.0010771463
of O 0 0.0017715599
patients O 0 0.0036830204
. O 0 0.003393813

Most O 0 0.0037864612
patients O 0 0.0018890691
showed O 0 0.00081684394
improvement O 0 0.00058758666
in O 0 0.00031131314
individual O 0 0.0002324808
parameters O 0 0.00027480893
and O 0 0.00023507868
global O 0 0.00028556582
score O 0 0.00025703167
of O 0 0.0004302143
quality O 0 0.00055322214
of O 0 0.0012691504
life O 0 0.0024501253
. O 0 0.0025525326

Adverse O 0 0.012324549
reactions O 0 0.0071277367
possibly O 0 0.0031939629
attributable O 0 0.0016387118
to O 0 0.0025159637
didanosine B-Chemical 0 0.99469733
were O 0 0.0034560845
common O 0 0.004308968
. O 0 0.004595918

The O 0 0.0018537352
most O 0 0.002057024
common O 0 0.0015911144
side O 0 0.012916606
- O 0 0.0015413844
effect O 0 0.0005878144
was O 0 0.0010936733
diarrhoea B-Disease 0 0.99340075
, O 0 0.00051784696
which O 0 0.00030113582
resulted O 0 0.00021104919
in O 0 0.00018279642
cessation O 0 0.0002971188
of O 0 0.0003572239
therapy O 0 0.0005877925
in O 0 0.0005399531
19 O 0 0.0012272344
individuals O 0 0.0018466708
. O 0 0.0020386563

Peripheral B-Disease 0 0.9772439
neuropathy I-Disease 0 0.9997625
occurred O 0 0.0020965321
in O 0 0.001039733
12 O 0 0.0006284701
patients O 0 0.0012643773
and O 0 0.0019523064
pancreatitis B-Disease 0 0.99983263
in O 0 0.0027911179
six O 0 0.0019482522
. O 0 0.0032340565

Thirteen O 0 0.0062748278
patients O 0 0.0026267772
developed O 0 0.0018392623
a O 0 0.0014985584
raised O 0 0.0018887834
serum O 0 0.09822849
amylase O 0 0.93553144
without O 0 0.0035937426
abdominal B-Disease 0 0.24081852
pain I-Disease 0 0.88312554
. O 0 0.00480212

Seven O 0 0.0036513747
patients O 0 0.0020035603
developed O 0 0.0023600615
glucose B-Disease 1 0.99765825
tolerance I-Disease 0 0.13596748
curves I-Disease 0 0.0009679225
characteristic O 0 0.00036868206
of O 0 0.00074191834
diabetes B-Disease 0 0.9991937
but O 0 0.0003129692
these O 0 0.00024985068
were O 0 0.00019109485
mild O 0 0.079917364
, O 0 0.00015208768
did O 0 9.709725e-05
not O 0 6.0840655e-05
require O 0 4.0852672e-05
treatment O 0 7.609893e-05
and O 0 9.205752e-05
returned O 0 0.00011500354
to O 0 0.00013234983
normal O 0 0.00044120094
on O 0 0.0002991765
ceasing O 0 0.005686711
didanosine B-Chemical 0 0.9943956
. O 0 0.0026468541

Immunohistochemical O 0 0.0040864726
studies O 0 0.001485776
with O 0 0.0010254385
antibodies O 0 0.0012203587
to O 0 0.0005618369
neurofilament O 0 0.120486066
proteins O 0 0.0005419899
on O 0 0.00026703818
axonal B-Disease 0 0.46247956
damage I-Disease 0 0.93251663
in O 0 0.00041109888
experimental O 0 0.0005866135
focal O 0 0.0022296177
lesions O 0 0.021952828
in O 0 0.0011442868
rat O 0 0.0040900214
. O 0 0.0023086416

Immunohistochemistry O 0 0.005917169
with O 0 0.0020341063
monoclonal O 0 0.0030785
antibodies O 0 0.0016089879
against O 0 0.0005876466
neurofilament O 0 0.6308683
( O 0 0.0016197884
NF O 0 0.8541364
) O 0 0.00046930963
proteins O 0 0.00017094384
of O 0 0.00016269606
middle O 0 0.0002661384
and O 0 0.00010492328
high O 0 0.00018184829
molecular O 0 0.0007354024
weight O 0 0.00075809186
class O 0 0.00024387098
, O 0 0.00026788196
NF O 0 0.9195683
- O 0 0.0011990638
M O 0 0.65182394
and O 0 0.00039388903
NF O 0 0.97444725
- O 0 0.0035625969
H O 0 0.99963
, O 0 0.00022136193
was O 0 0.00010778489
used O 0 6.138351e-05
to O 0 7.9838734e-05
study O 0 0.00021308148
axonal B-Disease 0 0.48501658
injury I-Disease 0 0.9455039
in O 0 0.0002066105
the O 0 0.0002329912
borderzone O 0 0.8191784
of O 0 0.00044258832
focal O 0 0.0018773046
lesions O 0 0.016345639
in O 0 0.0008435188
rats O 0 0.002146883
. O 0 0.0018259813

Focal O 0 0.010380386
injury B-Disease 0 0.086752675
in I-Disease 0 0.0011042278
the I-Disease 0 0.0007304528
cortex I-Disease 0 0.0039072908
was O 0 0.0004326851
produced O 0 0.00024096407
by O 0 0.00023626801
infusion O 0 0.00047901156
of O 0 0.0003780853
lactate B-Chemical 0 0.506351
at O 0 0.00026310555
acid O 0 0.8491272
pH O 0 0.030840985
or O 0 0.00033793994
by O 0 0.0004949383
stab O 0 0.04168866
caused O 0 0.0007392745
by O 0 0.0008556095
needle O 0 0.0017691125
insertion O 0 0.0017266629
. O 0 0.002098912

Infarcts B-Disease 0 0.34712985
in I-Disease 0 0.0034584075
substantia I-Disease 0 0.32235202
nigra I-Disease 0 0.30933136
pars I-Disease 0 0.011554891
reticulata I-Disease 0 0.07869374
were O 0 0.00049646496
evoked O 0 0.0010808237
by O 0 0.00051997433
prolonged O 0 0.0026885234
pilocarpine B-Chemical 1 0.99996185
- O 0 0.0030795655
induced O 0 0.0015628753
status B-Disease 0 0.0022745014
epilepticus I-Disease 0 0.9972572
. O 0 0.0034321505

Immunohistochemical O 0 0.0050118323
staining O 0 0.0017441292
for O 0 0.00088502356
NFs O 0 0.0026028238
showed O 0 0.00061089935
characteristic O 0 0.0005627496
terminal O 0 0.0009905805
clubs O 0 0.0007638522
of O 0 0.00046208812
axons O 0 0.00071046955
in O 0 0.0003857373
the O 0 0.0006930834
borderzone O 0 0.8906769
of O 0 0.0027173362
lesions O 0 0.08330286
. O 0 0.0031559393

Differences O 0 0.0013594461
in O 0 0.0009596143
the O 0 0.00067662937
labelling O 0 0.00063949026
pattern O 0 0.0002655504
occurred O 0 0.00021415892
with O 0 0.00022192235
different O 0 0.00011967877
antibodies O 0 0.0003361055
which O 0 0.00019225574
apparently O 0 0.00029842043
depended O 0 0.00010078662
on O 0 7.181828e-05
molecular O 0 0.0006255317
weight O 0 0.00067643303
class O 0 0.00028118998
of O 0 0.0003637726
NFs O 0 0.0020832187
and O 0 0.0005915194
phosphorylation O 0 0.0024517507
state O 0 0.002251648
. O 0 0.002148482

These O 0 0.0025212097
immunohistochemical O 0 0.002274537
changes O 0 0.0011984856
of O 0 0.0009919585
NFs O 0 0.0022790842
can O 0 0.00027553513
serve O 0 0.00026494675
as O 0 0.00019080388
a O 0 0.0002539246
marker O 0 0.00030978097
for O 0 0.00019161958
axonal B-Disease 0 0.47131866
damage I-Disease 0 0.9332877
in O 0 0.00027206796
various O 0 0.00030625914
experimental O 0 0.0007772827
traumatic B-Disease 0 0.9881274
or O 0 0.0033777452
ischemic O 0 0.9999443
lesions O 0 0.9888227
. O 0 0.003973744

Pharmacokinetic O 0 0.08531285
and O 0 0.0018617564
clinical O 0 0.0018712726
studies O 0 0.0007577431
in O 0 0.0005534746
patients O 0 0.00092242274
with O 0 0.0022261261
cimetidine B-Chemical 1 0.9999858
- O 0 0.003366886
associated O 0 0.0012889366
mental O 0 0.05247783
confusion B-Disease 0 0.7909455
. O 0 0.003620094

15 O 0 0.002860984
cases O 0 0.0028208983
of O 0 0.005080794
cimetidine B-Chemical 1 0.9999676
- O 0 0.004483208
associated O 0 0.0011735992
mental O 0 0.015144647
confusion B-Disease 0 0.3828165
have O 0 0.0010617949
been O 0 0.0012272011
reported O 0 0.0024538497
. O 0 0.0029001364

In O 0 0.0014634938
order O 0 0.00089029886
that O 0 0.0005952544
this O 0 0.000922937
syndrome O 0 0.028738536
might O 0 0.00021701718
be O 0 0.00016982754
investigated O 0 0.00011534752
changes O 0 0.00016091242
in O 0 0.00012874328
mental O 0 0.0015134268
status O 0 0.00020422028
( O 0 0.00044761677
M O 0 0.6487232
. O 0 0.00016304565
S O 0 0.6060625
. O 0 8.7466455e-05
) O 0 0.00012526201
were O 0 5.252324e-05
correlated O 0 3.6896974e-05
with O 0 8.710256e-05
serum O 0 0.004563247
concentrations O 0 0.0004653275
and O 0 0.00018513482
renal O 0 0.84358513
and O 0 0.00022275059
hepatic O 0 0.7852224
function O 0 0.0001199277
in O 0 5.950588e-05
36 O 0 5.963666e-05
patients O 0 7.694641e-05
, O 0 5.488671e-05
30 O 0 3.815474e-05
patients O 0 8.205482e-05
had O 0 7.102102e-05
no O 0 7.906239e-05
M O 0 0.519642
. O 0 0.00012267892
S O 0 0.34831786
. O 0 6.2204774e-05
change O 0 9.001905e-05
on O 0 0.00011994486
cimetidine B-Chemical 1 0.9999876
and O 0 0.0002498778
6 O 0 0.00010574391
had O 0 0.00019261867
moderate O 0 0.0013266046
to O 0 0.00053005334
severe O 0 0.011474415
changes O 0 0.0026238805
. O 0 0.0022475512

These O 0 0.002172058
6 O 0 0.0009795271
patients O 0 0.0009639366
had O 0 0.00054403563
both O 0 0.0005282845
renal B-Disease 0 0.74489313
and I-Disease 0 0.0012952731
liver I-Disease 0 0.99961686
dysfunction I-Disease 0 0.9998324
( O 0 0.0032040682
P O 0 0.019058138
less O 0 0.00013230716
than O 0 7.51097e-05
0 O 0 9.461641e-05
. O 0 8.646286e-05
05 O 0 0.0019067009
) O 0 0.00017295966
, O 0 9.0836e-05
as O 0 6.175369e-05
well O 0 6.54343e-05
as O 0 0.00018456849
cimetidine B-Chemical 1 0.9999957
trough O 0 0.25336912
- O 0 0.000328573
concentrations O 0 0.000229945
of O 0 0.0001252436
more O 0 0.00013906894
than O 0 6.0413575e-05
1 O 0 6.207523e-05
. O 0 4.28464e-05
25 O 0 0.00010745321
microgram O 0 0.0017594117
/ O 0 0.0005876687
ml O 0 0.0007736735
( O 0 0.00042873863
P O 0 0.002140848
less O 0 0.00022346429
than O 0 0.00021172523
0 O 0 0.0003739601
. O 0 0.0005528887
05 O 0 0.0061586136
) O 0 0.0023892564
. O 0 0.002395666

The O 0 0.0022022757
severity O 0 0.0037848642
of O 0 0.0030654725
M O 0 0.827395
. O 0 0.0009911649
S O 0 0.47953123
. O 0 0.00028149172
changes O 0 0.0003010865
increased O 0 0.0003523739
as O 0 0.00024329548
trough O 0 0.014901147
- O 0 0.0005556873
concentrations O 0 0.0007082232
rose O 0 0.0027435406
, O 0 0.0003395977
5 O 0 0.00021122255
patients O 0 0.0004899328
had O 0 0.0007537797
lumbar O 0 0.07984347
puncture O 0 0.0059813447
. O 0 0.0024852538

The O 0 0.002201668
cerebrospinal O 0 0.31366947
fluid O 0 0.0032305506
: O 0 0.0009858618
serum O 0 0.0044394345
ratio O 0 0.00079437526
of O 0 0.0014385771
cimetidine B-Chemical 1 0.9999945
concentrations O 0 0.0042798384
was O 0 0.00028697256
0 O 0 0.0001082585
. O 0 5.508754e-05
24 O 0 5.3858683e-05
: O 0 8.560129e-05
1 O 0 5.2330157e-05
and O 0 5.727432e-05
indicates O 0 5.42341e-05
that O 0 0.00011387964
cimetidine B-Chemical 1 0.999992
passes O 0 0.00031280215
the O 0 0.000112490496
blood O 0 0.0021892388
- O 0 0.00025350272
brain O 0 0.0009959751
barrier O 0 0.00080568274
; O 0 0.00010901785
it O 0 5.8007896e-05
also O 0 4.0610063e-05
raises O 0 2.45155e-05
the O 0 4.937959e-05
possibility O 0 4.92682e-05
that O 0 0.000107554086
M O 0 0.7645897
. O 0 0.00013619974
S O 0 0.49569723
. O 0 6.0898758e-05
changes O 0 8.605306e-05
are O 0 5.209693e-05
due O 0 3.5881996e-05
to O 0 6.567185e-05
blockade O 0 0.0025627958
of O 0 0.0011543098
histamine B-Chemical 1 0.99998164
H2 O 0 0.99986994
- O 0 0.0011340495
receptors O 0 0.0009016967
in O 0 0.00017865552
the O 0 0.00026154218
central O 0 0.0006660056
nervous O 0 0.013436021
system O 0 0.0018939106
. O 0 0.0020439217

Patients O 0 0.0021708058
likely O 0 0.00082461286
to O 0 0.00060047227
have O 0 0.00033975154
both O 0 0.00031601902
raised O 0 0.0005022914
trough O 0 0.027923334
- O 0 0.0006393629
concentrations O 0 0.00053693284
and O 0 0.0002638927
mental O 0 0.005858885
confusion B-Disease 0 0.24270388
are O 0 0.00015492208
those O 0 0.00015769919
with O 0 0.00016243145
both O 0 0.00023579047
severe O 0 0.011690909
renal B-Disease 0 0.9751194
and I-Disease 0 0.0028421043
hepatic I-Disease 0 0.9997129
dysfunction I-Disease 0 0.9993998
. O 0 0.004213511

They O 0 0.0037381346
should O 0 0.0010571027
be O 0 0.0008480116
closely O 0 0.00049376965
observed O 0 0.00046704922
and O 0 0.00046313237
should O 0 0.00023409475
be O 0 0.00028768997
given O 0 0.00024891572
reduced O 0 0.00092837954
doses O 0 0.007320578
of O 0 0.008382391
cimetidine B-Chemical 1 0.9999646
. O 0 0.0057167658

Prospective O 0 0.010340836
study O 0 0.001564208
of O 0 0.0009462567
the O 0 0.00056842854
long O 0 0.0004341129
- O 0 0.00046195777
term O 0 0.00016063554
effects O 0 0.00020672833
of O 0 0.00041136937
somatostatin O 0 0.73164386
analog O 0 0.0016321595
( O 0 0.00054241525
octreotide B-Chemical 0 0.9897119
) O 0 0.00023042235
on O 0 6.843278e-05
gallbladder O 0 0.008454033
function O 0 0.00019713408
and O 0 0.00033053817
gallstone B-Disease 0 0.9998468
formation O 0 0.0020788973
in O 0 0.00051701075
Chinese O 0 0.058333427
acromegalic B-Disease 0 0.9984542
patients O 0 0.003429382
. O 0 0.0019371317

This O 0 0.0030393114
article O 0 0.0014782299
reports O 0 0.0008680322
the O 0 0.00047446447
changes O 0 0.00042567638
in O 0 0.0002900397
gallbladder O 0 0.013129943
function O 0 0.00020958393
examined O 0 9.370166e-05
by O 0 0.00013916657
ultrasonography O 0 0.0012682261
in O 0 7.127478e-05
20 O 0 7.816147e-05
Chinese O 0 0.0007509971
patients O 0 0.00010241073
with O 0 8.612712e-05
active O 0 0.00017105715
acromegaly B-Disease 0 0.97094774
treated O 0 0.00015983952
with O 0 0.00010044363
sc O 0 0.00041995486
injection O 0 5.8809186e-05
of O 0 6.692164e-05
the O 0 8.266001e-05
somatostatin O 0 0.34140462
analog O 0 0.00082661747
octreotide B-Chemical 0 0.98275775
in O 0 8.7616885e-05
dosages O 0 0.002346088
of O 0 0.00013521462
300 O 0 0.00045392755
- O 0 0.00017847489
1500 O 0 0.00019550817
micrograms O 0 0.00048066778
/ O 0 0.00018112978
day O 0 3.1798914e-05
for O 0 3.194322e-05
a O 0 6.131887e-05
mean O 0 3.21249e-05
of O 0 9.1864495e-05
24 O 0 7.50381e-05
. O 0 7.082477e-05
2 O 0 0.000109972156
+ O 0 0.00032287792
/ O 0 0.0006795365
- O 0 0.0005484484
13 O 0 0.0003545602
. O 0 0.00029012826
9 O 0 0.0005076247
months O 0 0.00056337833
. O 0 0.001628476

During O 0 0.0009858599
treatment O 0 0.0013247158
with O 0 0.0018182591
octreotide B-Chemical 0 0.995452
, O 0 0.00088396424
17 O 0 0.0005137429
patients O 0 0.0003704233
developed O 0 0.0004092718
sludge O 0 0.011601648
, O 0 0.00024134529
10 O 0 0.000158018
had O 0 0.00033682756
gallstones B-Disease 0 0.9999156
, O 0 0.0003823741
and O 0 0.00022802134
1 O 0 0.00019673805
developed O 0 0.0008002575
acute B-Disease 0 0.9971642
cholecystitis I-Disease 0 0.99998796
requiring O 0 0.0051066168
surgery O 0 0.0034741273
. O 0 0.002035096

In O 0 0.0018409281
all O 0 0.0012272332
of O 0 0.0009792611
7 O 0 0.00046851448
patients O 0 0.00047292205
examined O 0 0.00023783903
acutely O 0 0.0018121179
, O 0 0.0004528808
gallbladder O 0 0.2529734
contractility O 0 0.6106899
was O 0 0.0002624159
inhibited O 0 0.00027393858
after O 0 7.308696e-05
a O 0 0.00024085472
single O 0 0.00026923008
100 O 0 0.0008564913
- O 0 0.000955006
micrograms O 0 0.004239221
injection O 0 0.0023006662
. O 0 0.002269375

In O 0 0.00203652
8 O 0 0.001302535
patients O 0 0.0010361257
followed O 0 0.00045904738
for O 0 0.00030409213
24 O 0 0.0002458552
weeks O 0 0.00015027968
, O 0 0.00037941008
gallbladder O 0 0.03063679
contractility O 0 0.31688544
remained O 0 0.0012712592
depressed B-Disease 2 0.5125694
throughout O 0 0.0005323232
therapy O 0 0.001961714
. O 0 0.0020836724

After O 0 0.0010698375
withdrawal O 0 0.0060251234
of O 0 0.0018092591
octreotide B-Chemical 0 0.9860145
in O 0 0.00043812094
10 O 0 0.00026102355
patients O 0 0.00032026437
without O 0 0.0003789866
gallstones B-Disease 0 0.99993575
, O 0 0.00034601628
8 O 0 9.9660436e-05
patients O 0 0.0001149485
assessed O 0 6.0030696e-05
had O 0 7.729213e-05
return O 0 0.00010621079
of O 0 0.00014540806
normal O 0 0.00046680536
gallbladder O 0 0.09940659
contractility O 0 0.11783147
within O 0 0.00016704843
1 O 0 0.00040594957
month O 0 0.00049713335
. O 0 0.0013011737

In O 0 0.0017126014
8 O 0 0.0009425275
of O 0 0.0007036016
the O 0 0.00042294676
remaining O 0 0.00037215627
10 O 0 0.0002559086
patients O 0 0.00030674273
who O 0 0.00031760658
developed O 0 0.00054538733
gallstones B-Disease 0 0.99990976
during O 0 8.355777e-05
treatment O 0 0.00012801918
, O 0 0.00014478188
gallbladder O 0 0.07993061
contractility O 0 0.13380936
normalized O 0 4.9451686e-05
in O 0 5.6188772e-05
5 O 0 4.330227e-05
patients O 0 8.3910374e-05
( O 0 7.611038e-05
3 O 0 3.425157e-05
of O 0 6.193125e-05
whom O 0 0.00012280837
has O 0 4.2390795e-05
disappearance O 0 0.00020129223
of O 0 8.765591e-05
their O 0 0.00011193196
stones O 0 0.1711835
within O 0 2.6546228e-05
3 O 0 3.8597704e-05
weeks O 0 2.2642425e-05
) O 0 8.7832705e-05
, O 0 6.894055e-05
and O 0 7.5136275e-05
remained O 0 0.00018471004
depressed B-Disease 2 0.5041146
in O 0 0.00010099858
3 O 0 6.373717e-05
( O 0 8.8446606e-05
2 O 0 4.7823727e-05
of O 0 8.4015024e-05
whom O 0 0.00019629118
had O 0 0.00015230826
stones O 0 0.14654022
present O 0 0.00016757745
at O 0 0.0001786574
6 O 0 0.0002360836
months O 0 0.0002980255
) O 0 0.0013612314
. O 0 0.0017763189

Our O 0 0.0020126177
results O 0 0.0012004679
suggest O 0 0.0004201831
that O 0 0.0003365897
the O 0 0.00034987225
suppression O 0 0.00055835966
of O 0 0.00058437476
gallbladder O 0 0.509414
contractility O 0 0.7166765
is O 0 0.0001879201
the O 0 0.00010846951
cause O 0 0.00012783594
of O 0 9.248919e-05
the O 0 6.3261345e-05
successive O 0 5.8117308e-05
formation O 0 0.00022813595
of O 0 0.00022850776
bile O 0 0.99506503
sludge O 0 0.33466163
, O 0 0.0006928764
gallstones B-Disease 0 0.9999758
, O 0 0.00032098027
and O 0 0.00029466
cholecystitis B-Disease 0 0.99990034
during O 0 0.00015353649
octreotide B-Chemical 0 0.9889404
therapy O 0 0.00042489005
in O 0 0.00035816644
Chinese O 0 0.034541894
acromegalic B-Disease 0 0.99824214
patients O 0 0.003313506
. O 0 0.001888088

It O 0 0.0027248727
is O 0 0.0013041575
therefore O 0 0.0007854485
very O 0 0.00063134846
important O 0 0.00020965868
to O 0 0.00020557121
follow O 0 0.00011711684
the O 0 0.00012580643
changes O 0 0.00015837413
of O 0 0.00020583304
gallbladder O 0 0.017783804
function O 0 0.00014442999
during O 0 5.7747064e-05
long O 0 0.00011431101
- O 0 0.00021794303
term O 0 0.00020582284
octreotide B-Chemical 0 0.968846
therapy O 0 0.00065061304
of O 0 0.0011540283
acromegalic B-Disease 0 0.9979346
patients O 0 0.0036501014
. O 0 0.0020321037

Increase O 0 0.01018129
of O 0 0.008310181
Parkinson B-Disease 0 0.99912816
disability I-Disease 0 0.88957524
after O 0 0.0033582633
fluoxetine B-Chemical 1 0.99986863
medication O 0 0.2954939
. O 0 0.0065808124

Depression B-Disease 2 0.9560551
is O 0 0.0028534632
a O 0 0.0018832218
major O 0 0.0012280837
clinical O 0 0.00205296
feature O 0 0.001326204
of O 0 0.0024210576
Parkinson B-Disease 0 0.99690056
' I-Disease 0 0.0035482072
s I-Disease 0 0.0029206057
disease I-Disease 0 0.11387315
. O 0 0.004748599

We O 0 0.00158348
report O 0 0.0015494751
the O 0 0.0007562638
increased O 0 0.0006807473
amount O 0 0.00026462437
of O 0 0.0005195086
motor B-Disease 0 0.092412814
disability I-Disease 0 0.6265604
in O 0 0.00016554508
four O 0 7.473026e-05
patients O 0 0.0001627434
with O 0 0.0002658721
idiopathic B-Disease 0 0.9104026
Parkinson I-Disease 0 0.99946207
' I-Disease 0 0.00031530252
s I-Disease 0 0.00016343321
disease I-Disease 0 0.002781274
after O 0 5.4686967e-05
exposure O 0 0.00019510256
to O 0 0.00022348005
the O 0 0.0007967736
antidepressant B-Chemical 1 0.9998385
fluoxetine B-Chemical 0 0.99995756
. O 0 0.0036536376

The O 0 0.0015259933
possibility O 0 0.0009231128
of O 0 0.0010316088
a O 0 0.00092520064
clinically O 0 0.002085619
relevant O 0 0.0005616115
dopamine B-Chemical 0 0.9997143
- O 0 0.0006957402
antagonistic O 0 0.00033826707
capacity O 0 0.00031624507
of O 0 0.0005693533
fluoxetine B-Chemical 1 0.99998534
in O 0 0.00056582823
Parkinson B-Disease 0 0.99876815
' I-Disease 0 0.00046548474
s I-Disease 0 0.0003176862
disease I-Disease 0 0.019238159
patients O 0 0.0005165403
must O 0 0.0002674423
be O 0 0.0005695899
considered O 0 0.00097102695
. O 0 0.0019005456

Sinus B-Disease 0 0.3248691
arrest I-Disease 0 0.3874934
associated O 0 0.002269745
with O 0 0.0020691426
continuous O 0 0.0017499934
- O 0 0.004471228
infusion O 0 0.02758357
cimetidine B-Chemical 1 0.99989367
. O 0 0.008143398

The O 0 0.0014048304
administration O 0 0.0022288794
of O 0 0.000982504
intermittent O 0 0.0020158764
intravenous O 0 0.014270823
infusions O 0 0.0024648493
of O 0 0.0016610854
cimetidine B-Chemical 1 0.9999924
is O 0 0.00043758398
infrequently O 0 0.00028928276
associated O 0 0.00016113964
with O 0 0.00023940821
the O 0 0.00028632343
development O 0 0.0008616339
of O 0 0.002188672
bradyarrhythmias B-Disease 0 0.9993411
. O 0 0.0032044183

A O 0 0.021685062
40 O 0 0.0028439816
- O 0 0.0023772933
year O 0 0.00068712514
- O 0 0.00094456197
old O 0 0.0005109943
man O 0 0.0039670565
with O 0 0.001046155
leukemia B-Disease 0 0.9999161
and O 0 0.00041595582
no O 0 0.000105331084
history O 0 0.00024711908
of O 0 0.0002086627
cardiac B-Disease 0 0.11314987
disease I-Disease 0 0.3079744
developed O 0 0.00036829984
recurrent O 0 0.0031138004
, O 0 9.257954e-05
brief O 0 6.296775e-05
episodes O 0 0.00020408968
of O 0 7.9779296e-05
apparent O 0 0.00013067533
sinus B-Disease 0 0.0359825
arrest I-Disease 0 0.585905
while O 0 0.00011427908
receiving O 0 0.00014875065
continuous O 0 7.740963e-05
- O 0 0.00027496938
infusion O 0 0.0015705558
cimetidine B-Chemical 1 0.99998415
50 O 0 0.0011796064
mg O 0 0.012981422
/ O 0 0.0017596806
hour O 0 0.0009372878
. O 0 0.0016565984

The O 0 0.002585622
arrhythmias B-Disease 2 0.99613535
were O 0 0.0009260177
temporally O 0 0.0005493928
related O 0 0.00020070196
to O 0 0.0005369211
cimetidine B-Chemical 1 0.9999902
administration O 0 0.009226318
, O 0 0.00028327262
disappeared O 0 0.00017157824
after O 0 8.249048e-05
dechallenge O 0 0.82830733
, O 0 0.00025152735
and O 0 0.00016743674
did O 0 0.00018496982
not O 0 0.00018749773
recur O 0 0.00071171846
during O 0 0.00040601188
ranitidine B-Chemical 1 0.9998956
treatment O 0 0.0024582574
. O 0 0.0022142765

This O 0 0.0038278208
is O 0 0.0014133594
the O 0 0.0007581446
first O 0 0.00042125472
reported O 0 0.0005185234
case O 0 0.00037459985
of O 0 0.0006067959
sinus B-Disease 0 0.090175934
arrest I-Disease 0 0.7065574
associated O 0 0.0003874665
with O 0 0.00044959158
continuous O 0 0.00040590874
- O 0 0.00145847
infusion O 0 0.013387645
cimetidine B-Chemical 1 0.9999424
. O 0 0.003946569

Phase O 0 0.0072482806
II O 0 0.008048686
trial O 0 0.0020002944
of O 0 0.002026465
vinorelbine B-Chemical 0 0.9869588
in O 0 0.0023742463
metastatic O 0 0.79253393
squamous B-Disease 0 0.99071664
cell I-Disease 0 0.1012179
esophageal I-Disease 0 0.9944652
carcinoma I-Disease 0 0.99960047
. O 0 0.0059674922

European O 0 0.004752894
Organization O 0 0.0018673276
for O 0 0.0011522757
Research O 0 0.0024767972
and O 0 0.0009226121
Treatment O 0 0.0015031226
of O 0 0.0013892666
Cancer B-Disease 0 0.19038363
Gastrointestinal O 0 0.027673537
Treat O 0 0.08605116
Cancer B-Disease 0 0.099439315
Cooperative O 0 0.00322295
Group O 0 0.004557643
. O 0 0.0027858114

PURPOSE O 0 0.0049384376
: O 0 0.0017283082
To O 0 0.00062552816
evaluate O 0 0.0003426441
the O 0 0.0003586985
response O 0 0.0003217321
rate O 0 0.00032888417
and O 0 0.00028709183
toxic O 0 0.021017797
effects O 0 0.00027897305
of O 0 0.00057951425
vinorelbine B-Chemical 0 0.9992155
( O 0 0.0010053704
VNB B-Chemical 0 0.9599638
) O 0 0.00029570778
administered O 0 0.00013740336
as O 0 9.3364506e-05
a O 0 0.0001429249
single O 0 0.00014581099
agent O 0 0.0007309424
in O 0 0.00038860049
metastatic O 0 0.64324087
squamous B-Disease 0 0.986948
cell I-Disease 0 0.05702338
esophageal I-Disease 0 0.9937238
carcinoma I-Disease 0 0.99973196
. O 0 0.0038648609

PATIENTS O 0 0.0019900592
AND O 0 0.0013073038
METHODS O 0 0.0006310254
: O 0 0.00071833195
Forty O 0 0.00070332905
- O 0 0.0005068405
six O 0 0.00014512299
eligible O 0 0.0002533227
patients O 0 0.00018959642
with O 0 0.00015749484
measurable O 0 0.00026209085
lesions O 0 0.0020951917
were O 0 0.00012383093
included O 0 8.192738e-05
and O 0 0.00011079855
were O 0 0.00011566164
stratified O 0 0.00011611526
according O 0 0.00011001946
to O 0 0.00024403309
previous O 0 0.00066574325
chemotherapy O 0 0.007958369
. O 0 0.0022161547

Thirty O 0 0.0024637885
patients O 0 0.001229455
without O 0 0.0004973111
prior O 0 0.0002660202
chemotherapy O 0 0.0014377924
and O 0 0.0002788571
16 O 0 0.00019376627
pretreated O 0 0.00069465296
with O 0 0.0005345858
cisplatin B-Chemical 0 0.9986576
- O 0 0.0005499455
based O 0 0.00014416086
chemotherapy O 0 0.0009984637
were O 0 0.00019332078
assessable O 0 0.0005086287
for O 0 0.00029468111
toxicity B-Disease 2 0.96460265
and O 0 0.0011827186
response O 0 0.0016985008
. O 0 0.002157922

VNB B-Chemical 0 0.88286334
was O 0 0.0020862652
administered O 0 0.0010968868
weekly O 0 0.0006312176
as O 0 0.00039580508
a O 0 0.00044883875
25 O 0 0.00048768276
- O 0 0.0005407154
mg O 0 0.003210541
/ O 0 0.0005869505
m2 O 0 0.00085515226
short O 0 0.00016657142
intravenous O 0 0.0031631629
( O 0 0.0003529828
i O 0 0.0005271751
. O 0 0.00024173819
v O 0 0.0013886647
. O 0 0.00047636352
) O 0 0.001327134
infusion O 0 0.0030894598
. O 0 0.0024286911

RESULTS O 0 0.0047412426
: O 0 0.0018520823
Six O 0 0.0008654023
of O 0 0.00067720254
30 O 0 0.00042496217
patients O 0 0.0005257983
( O 0 0.00039269245
20 O 0 0.00022173603
% O 0 0.00020828066
) O 0 0.00019010094
without O 0 8.326648e-05
prior O 0 5.755662e-05
chemotherapy O 0 0.0005262229
achieved O 0 0.00014588718
a O 0 0.00013502997
partial O 0 0.00020525118
response O 0 0.0001776345
( O 0 0.0003841077
PR O 0 0.23286733
) O 0 0.0003150201
( O 0 0.00018896621
95 O 0 0.00016235653
% O 0 0.00011083247
confidence O 0 0.00042494433
interval O 0 0.0001436989
[ O 0 0.00056944275
CI O 0 0.012671153
] O 0 0.00044419357
, O 0 0.00021451617
8 O 0 0.00016171193
% O 0 0.0002514271
to O 0 0.00031681306
39 O 0 0.00087902136
% O 0 0.0011041703
) O 0 0.0021890053
. O 0 0.0023309872

The O 0 0.0014766275
median O 0 0.0007872956
duration O 0 0.0004945921
of O 0 0.00071400177
response O 0 0.00062434055
was O 0 0.0005556801
21 O 0 0.00037140612
weeks O 0 0.00016782626
( O 0 0.0004087254
range O 0 0.00038390158
, O 0 0.0005480669
17 O 0 0.0006786641
to O 0 0.0006643048
28 O 0 0.001239368
) O 0 0.0025427432
. O 0 0.0027259793

One O 0 0.0023983263
of O 0 0.0018395757
16 O 0 0.0011702492
patients O 0 0.0010919871
( O 0 0.000700339
6 O 0 0.00022716982
% O 0 0.00027751745
) O 0 0.00025771142
with O 0 0.00013921967
prior O 0 7.67334e-05
chemotherapy O 0 0.00075512024
had O 0 0.00011304256
a O 0 0.000115910945
complete O 0 8.96348e-05
response O 0 0.00012621086
( O 0 0.0002354445
CR O 0 0.011660279
) O 0 0.00017260859
of O 0 0.000114766575
31 O 0 0.00011698069
weeks O 0 3.2449952e-05
' O 0 9.0973655e-05
duration O 0 5.295637e-05
( O 0 0.00017301243
95 O 0 0.00021248662
% O 0 0.00020360084
CI O 0 0.0026552265
, O 0 0.0001986161
0 O 0 0.00015960544
% O 0 0.00023008423
to O 0 0.00025987183
30 O 0 0.00042527867
% O 0 0.0010040365
) O 0 0.0021063597
. O 0 0.0023275698

The O 0 0.0014666364
overall O 0 0.0012339014
response O 0 0.00086350617
rate O 0 0.0007613722
( O 0 0.0006175325
World O 0 0.0004195807
Health O 0 0.000313748
Organization O 0 0.00032512262
[ O 0 0.00058486004
WHO O 0 0.0005550732
] O 0 0.00041064652
criteria O 0 0.00020435486
) O 0 0.0002254071
was O 0 0.0001269481
15 O 0 8.302996e-05
% O 0 0.00013356154
( O 0 0.00020966028
CR O 0 0.0047046198
, O 0 0.00018016467
2 O 0 0.000110093235
% O 0 0.00015502716
; O 0 0.00022381569
PR O 0 0.02347117
13 O 0 0.00018295144
% O 0 0.00017219302
; O 0 0.0001970651
95 O 0 0.0002514597
% O 0 0.00024285303
CI O 0 0.002908987
, O 0 0.00023195386
6 O 0 0.00014203392
% O 0 0.00026204687
to O 0 0.00033833596
29 O 0 0.0010125918
% O 0 0.0011765854
) O 0 0.0023067796
. O 0 0.0024457125

The O 0 0.001760003
median O 0 0.0011992279
dose O 0 0.0041134437
- O 0 0.0016983972
intensity O 0 0.00061000395
( O 0 0.0013097479
DI O 0 0.24233322
) O 0 0.00085253414
was O 0 0.00043660132
20 O 0 0.00043223987
mg O 0 0.0046310807
/ O 0 0.0017820725
m2 O 0 0.0037969402
/ O 0 0.002468597
wk O 0 0.0011678638
. O 0 0.002308826

VNB B-Chemical 0 0.9058739
was O 0 0.0023498412
well O 0 0.0009955941
tolerated O 0 0.00266646
and O 0 0.00047106214
zero O 0 0.00026325186
instances O 0 0.00017679873
of O 0 0.0004070864
WHO O 0 0.0009930846
grade O 0 0.004891617
4 O 0 0.000644792
nonhematologic O 0 0.99726033
toxicity B-Disease 2 0.99735093
occurred O 0 0.0033648994
. O 0 0.002804005

At O 0 0.00087385374
least O 0 0.00090784597
one O 0 0.0006175496
episode O 0 0.0010697234
of O 0 0.00075233076
grade O 0 0.0049423804
3 O 0 0.0002389102
or O 0 0.00021736092
4 O 0 0.00027413171
granulocytopenia B-Disease 0 0.9988813
was O 0 0.00046704613
seen O 0 0.00027551412
in O 0 0.00029359388
59 O 0 0.0005575909
% O 0 0.0005342224
of O 0 0.0010011336
patients O 0 0.002363415
. O 0 0.0022464264

A O 0 0.036617536
grade O 0 0.013679637
2 O 0 0.0010767401
or O 0 0.0006265025
3 O 0 0.0004285298
infection B-Disease 0 0.0013370513
occurred O 0 0.0002865149
in O 0 0.00023658111
16 O 0 0.0002147032
% O 0 0.00020846147
of O 0 0.00027765584
patients O 0 0.0004507244
, O 0 0.00035264564
but O 0 0.0003634095
no O 0 0.00039649982
toxic O 0 0.38582912
deaths B-Disease 0 0.26280522
occurred O 0 0.002280108
. O 0 0.002433958

Other O 0 0.004231596
side O 0 0.007567165
effects O 0 0.0016194499
were O 0 0.0010682334
rare O 0 0.0018839443
, O 0 0.00071548094
and O 0 0.0007269501
peripheral B-Disease 0 0.7326039
neurotoxicity I-Disease 2 0.99998844
has O 0 0.0005339595
been O 0 0.00027822374
minor O 0 0.00085916335
( O 0 0.00047434328
26 O 0 0.0004967258
% O 0 0.00056158955
grade O 0 0.004311592
1 O 0 0.0009812225
) O 0 0.0021123958
. O 0 0.002305261

CONCLUSION O 0 0.014107065
: O 0 0.0018603588
These O 0 0.0008525009
data O 0 0.0006706809
indicate O 0 0.00031100903
that O 0 0.0003910754
VNB B-Chemical 0 0.69877636
is O 0 0.0003892393
an O 0 0.00036131317
active O 0 0.00038809163
agent O 0 0.0014717072
in O 0 0.00061662967
metastatic O 0 0.6324598
esophageal B-Disease 0 0.8584373
squamous I-Disease 0 0.99873513
cell I-Disease 0 0.13745868
carcinoma I-Disease 0 0.9993148
. O 0 0.0038881719

Given O 0 0.0011819933
its O 0 0.0018113696
excellent O 0 0.0018701926
tolerance O 0 0.012612788
profile O 0 0.0007102238
and O 0 0.00051200355
low O 0 0.0013261295
toxicity B-Disease 2 0.99442106
, O 0 0.00039183145
further O 0 0.00025307434
evaluation O 0 0.00016850518
of O 0 0.00034901343
VNB B-Chemical 0 0.7305391
in O 0 0.0002803521
combination O 0 0.00056487933
therapy O 0 0.00084496837
is O 0 0.0008574001
warranted O 0 0.0012728767
. O 0 0.002148612

Evaluation O 0 0.0036235582
of O 0 0.002925496
adverse O 0 0.019481024
reactions O 0 0.0062161325
of O 0 0.0031250387
aponidine B-Chemical 0 0.6714737
hydrochloride I-Chemical 0 0.99952066
ophthalmic O 0 0.92228323
solution O 0 0.089981034
. O 0 0.0050264746

We O 0 0.0013993357
prospectively O 0 0.0012603897
evaluated O 0 0.00058292085
the O 0 0.0005440551
adverse O 0 0.00830061
reactions O 0 0.0028375108
of O 0 0.0014257159
apraclonidine B-Chemical 0 0.99998677
in O 0 0.00026937205
20 O 0 0.00014992287
normal O 0 0.000257823
volunteers O 0 0.0001870499
by O 0 0.00010740598
instilling O 0 0.00073324854
a O 0 0.00015317545
single O 0 0.0001135186
drop O 0 0.0004187486
of O 0 0.00018545247
1 O 0 0.00015325988
% O 0 0.00035999806
apraclonidine B-Chemical 0 0.9999368
in O 0 0.0004504663
their O 0 0.00077654014
right O 0 0.0046296744
eyes O 0 0.42737967
. O 0 0.0024967112

Examinations O 0 0.005911994
, O 0 0.0019930843
including O 0 0.0008149811
blood O 0 0.0033948373
pressure O 0 0.0040142913
, O 0 0.00051591144
pulse O 0 0.00048650763
rate O 0 0.00034962135
, O 0 0.00039256498
conjunctiva O 0 0.08186513
and O 0 0.00030338875
cornea O 0 0.10460872
, O 0 0.0002943085
intraocular O 0 0.80883855
pressure O 0 0.02080728
( O 0 0.000524267
IOP O 0 0.98742837
) O 0 0.0002997149
, O 0 0.00013835418
pupil O 0 0.0010559704
diameter O 0 0.000497835
, O 0 0.00012782487
basal O 0 0.00026086206
tear O 0 0.064861156
secretion O 0 0.0005281546
and O 0 0.00010434499
margin O 0 0.0006427027
reflex O 0 0.003476765
distance O 0 5.94833e-05
of O 0 6.975593e-05
both O 0 6.496483e-05
upper O 0 0.0001764666
and O 0 9.250119e-05
lower O 0 0.0002292823
eyelids O 0 0.14235045
, O 0 0.00010395478
were O 0 5.316991e-05
performed O 0 3.4398145e-05
prior O 0 2.4591905e-05
to O 0 4.7166537e-05
entry O 0 0.000116101975
and O 0 7.929123e-05
at O 0 5.935592e-05
1 O 0 8.4448846e-05
, O 0 0.00011173702
3 O 0 8.052619e-05
, O 0 0.00011880767
5 O 0 9.1622336e-05
and O 0 0.00014211766
7 O 0 0.00013732216
hours O 0 0.00016481742
after O 0 0.00029613887
instillation O 0 0.0026160656
. O 0 0.0022715859

The O 0 0.0023666227
ocular B-Disease 0 0.8997682
hypotensive I-Disease 0 0.99930334
effects O 0 0.0014618349
were O 0 0.00054861023
statistically O 0 0.0002986356
significant O 0 0.00022226159
for O 0 0.00032737636
apraclonidine B-Chemical 0 0.9999932
- O 0 0.0014428776
treated O 0 0.00047148168
eyes O 0 0.058318757
throughout O 0 3.528717e-05
the O 0 6.152457e-05
study O 0 8.005731e-05
and O 0 6.432715e-05
also O 0 6.2957246e-05
statistically O 0 6.9218266e-05
significant O 0 5.4001193e-05
for O 0 4.8247774e-05
contralateral O 0 0.00047017343
eyes O 0 0.03012333
from O 0 4.944546e-05
three O 0 2.5359092e-05
hours O 0 3.0473648e-05
after O 0 4.1137595e-05
topical O 0 0.049778003
administration O 0 0.0012423499
of O 0 0.0005846098
1 O 0 0.0005604404
% O 0 0.0016576477
apraclonidine B-Chemical 0 0.99988794
. O 0 0.0034767534

Decreases B-Disease 0 0.004824992
in I-Disease 0 0.0017142326
systolic I-Disease 0 0.04534778
blood I-Disease 0 0.006070268
pressure I-Disease 0 0.005476734
were O 0 0.0006805682
statistically O 0 0.00053657166
, O 0 0.0005459168
but O 0 0.0005191505
not O 0 0.0006060384
clinically O 0 0.0035444563
, O 0 0.001745054
significant O 0 0.0022636976
. O 0 0.0028743024

No O 0 0.0031178484
significant O 0 0.0013516161
changes O 0 0.00104282
in O 0 0.00071945577
diastolic O 0 0.17644767
blood O 0 0.0045344005
pressure O 0 0.0035041661
, O 0 0.0003760891
pulse O 0 0.0003959623
rate O 0 0.00030295784
and O 0 0.00036096046
basal O 0 0.00094983645
tear O 0 0.10072285
secretion O 0 0.0029920733
were O 0 0.001026129
noted O 0 0.0012371023
. O 0 0.0021356775

Conjunctival B-Disease 0 0.86018974
blanching I-Disease 0 0.98961055
and O 0 0.011007054
mydriasis B-Disease 0 0.9993923
were O 0 0.0049712756
commonly O 0 0.004487743
found O 0 0.004352334
. O 0 0.005504923

Upper O 0 0.03594857
lid O 0 0.040662464
retraction O 0 0.025766883
was O 0 0.007143614
frequently O 0 0.005876136
noted O 0 0.006206646
. O 0 0.008380216

While O 0 0.0017562772
the O 0 0.0013745936
elevations O 0 0.0050027305
of O 0 0.0007597727
the O 0 0.00045985047
upper O 0 0.0009207895
lid O 0 0.009455457
margin O 0 0.0013256838
in O 0 0.00014523859
most O 0 0.00021719001
subjects O 0 0.00016160065
were O 0 7.6430915e-05
not O 0 5.7322562e-05
more O 0 9.364761e-05
than O 0 5.021306e-05
2 O 0 5.4049113e-05
mm O 0 0.00011492198
and O 0 7.233266e-05
did O 0 8.448703e-05
not O 0 7.012422e-05
cause O 0 0.00013336136
noticeable O 0 0.00016643348
change O 0 8.148403e-05
in O 0 6.943829e-05
appearance O 0 0.00021117742
, O 0 8.1394726e-05
one O 0 3.8753198e-05
subject O 0 4.0143586e-05
suffered O 0 0.00029800928
from O 0 6.903672e-05
mechanical O 0 0.00032478868
entropion B-Disease 0 0.9994943
and O 0 0.0002228192
marked O 0 0.001119735
corneal B-Disease 0 0.9971499
abrasion I-Disease 0 0.8172223
3 O 0 9.533024e-05
hours O 0 4.9565846e-05
after O 0 5.5858283e-05
instillation O 0 0.0004021922
of O 0 0.0004927067
the O 0 0.0008202572
medication O 0 0.010196154
. O 0 0.0019191178

This O 0 0.005173648
may O 0 0.0020521104
well O 0 0.0013545866
be O 0 0.0010472643
a O 0 0.0011191528
particularly O 0 0.0010686682
notable O 0 0.0016815531
finding O 0 0.0020876117
in O 0 0.0016812579
Asian O 0 0.0145865735
people O 0 0.0052316827
. O 0 0.0036310717

Thiopentone B-Chemical 0 0.99818784
pretreatment O 0 0.08825199
for O 0 0.0025175356
propofol B-Chemical 1 0.9990109
injection O 0 0.003918068
pain B-Disease 0 0.4316078
in O 0 0.0014745243
ambulatory O 0 0.0029046957
patients O 0 0.0031810284
. O 0 0.003006323

This O 0 0.0034831727
study O 0 0.0018838618
investigated O 0 0.0014756887
propofol B-Chemical 1 0.9986815
injection O 0 0.0024543176
pain B-Disease 0 0.35994133
in O 0 0.0006840924
patients O 0 0.00093254354
undergoing O 0 0.0009984176
ambulatory O 0 0.0020348907
anaesthesia O 0 0.009770285
. O 0 0.0024030004

In O 0 0.0018649526
a O 0 0.0018179009
randomized O 0 0.001339681
, O 0 0.00091737945
double O 0 0.000960034
- O 0 0.0009714373
blind O 0 0.0037430031
trial O 0 0.00031904905
, O 0 0.0001613509
90 O 0 0.00011972045
women O 0 0.00019497648
were O 0 6.088755e-05
allocated O 0 3.6766774e-05
to O 0 4.090066e-05
receive O 0 3.2951582e-05
one O 0 3.347788e-05
of O 0 6.0490253e-05
three O 0 3.2298423e-05
treatments O 0 8.381729e-05
prior O 0 4.295039e-05
to O 0 8.5332824e-05
induction O 0 0.00019137599
of O 0 0.00045301422
anaesthesia O 0 0.013995108
with O 0 0.0022052764
propofol B-Chemical 1 0.9991155
. O 0 0.0028466575

Patients O 0 0.0022730755
in O 0 0.001426541
Group O 0 0.0051761167
C O 0 0.7630412
received O 0 0.0004525304
2 O 0 0.00027436574
ml O 0 0.00055212463
normal O 0 0.00044670244
saline O 0 0.00090577913
, O 0 0.00024286254
Group O 0 0.0012286094
L O 0 0.20453595
, O 0 0.00019052318
2 O 0 0.00010025044
ml O 0 0.00035596304
, O 0 0.00026410085
lidocaine B-Chemical 0 0.99953735
2 O 0 0.0001227339
% O 0 0.000101726786
( O 0 0.00010458546
40 O 0 9.3097806e-05
mg O 0 0.001523557
) O 0 0.00017466421
and O 0 0.00012629417
Group O 0 0.0010073268
T O 0 0.2754678
, O 0 0.00019033182
2 O 0 0.0001186528
ml O 0 0.0009692453
thiopentone B-Chemical 0 0.99995613
2 O 0 0.00019155839
. O 0 0.00010142604
5 O 0 0.00012625636
% O 0 0.00024972254
( O 0 0.00045404528
50 O 0 0.0009263755
mg O 0 0.012045332
) O 0 0.0028134019
. O 0 0.0024712218

Venous O 0 0.019662226
discomfort O 0 0.009149891
was O 0 0.0010424843
assessed O 0 0.00041265492
with O 0 0.0004000005
a O 0 0.0004539116
visual O 0 0.0045946613
analogue O 0 0.0021944665
scale O 0 0.00034832588
( O 0 0.00045439816
VAS O 0 0.0027469404
) O 0 0.00024689437
5 O 0 8.602287e-05
- O 0 0.00012998421
15 O 0 4.3702596e-05
sec O 0 4.8026646e-05
after O 0 2.5524514e-05
commencing O 0 0.00012178179
propofol B-Chemical 1 0.99609345
administration O 0 0.0005355288
using O 0 6.456006e-05
an O 0 0.00011509294
infusion O 0 0.00034496016
pump O 0 0.000799023
( O 0 0.000104765815
rate O 0 8.149445e-05
1000 O 0 0.00019167861
micrograms O 0 0.0006136198
. O 0 9.348228e-05
kg O 0 0.00034241506
- O 0 0.00027451775
1 O 0 0.00014282463
. O 0 0.00014335374
min O 0 0.00041236525
- O 0 0.0009604156
1 O 0 0.00085158093
) O 0 0.0019956385
. O 0 0.0022650075

Loss B-Disease 0 0.015184398
of I-Disease 0 0.004818633
consciousness I-Disease 0 0.4795543
occurred O 0 0.0021396668
in O 0 0.0016375576
60 O 0 0.0018041966
- O 0 0.002569757
90 O 0 0.0021580153
sec O 0 0.0030790796
. O 0 0.0044463635

Visual O 0 0.19200248
analogue O 0 0.0077763516
scores O 0 0.0012101579
( O 0 0.0009841032
mean O 0 0.00035205157
+ O 0 0.001048709
/ O 0 0.0015450979
- O 0 0.0010241234
SD O 0 0.003185683
) O 0 0.00026988873
during O 0 6.5615015e-05
induction O 0 0.00012811772
were O 0 0.00010942883
lower O 0 0.00013571398
in O 0 0.0001237489
Groups O 0 0.0016528734
L O 0 0.3246072
( O 0 0.00022879137
3 O 0 7.7186574e-05
. O 0 5.586371e-05
3 O 0 6.850069e-05
+ O 0 0.0002043948
/ O 0 0.00041340815
- O 0 0.00025808267
2 O 0 8.244226e-05
. O 0 5.5493263e-05
5 O 0 6.651204e-05
) O 0 0.00015270615
and O 0 0.00016950526
T O 0 0.29153106
( O 0 0.0002772831
4 O 0 9.0501744e-05
. O 0 6.544397e-05
1 O 0 8.79259e-05
+ O 0 0.00022874428
/ O 0 0.00044794334
- O 0 0.00027271904
2 O 0 8.411554e-05
. O 0 5.362079e-05
7 O 0 5.4589276e-05
) O 0 9.5604446e-05
than O 0 4.7670823e-05
in O 0 9.5479445e-05
Group O 0 0.0013853248
C O 0 0.94705063
( O 0 0.00026489442
5 O 0 8.2271385e-05
. O 0 6.1389015e-05
6 O 0 6.445585e-05
+ O 0 0.00022585242
/ O 0 0.00046747553
- O 0 0.0003172044
2 O 0 0.000121101926
. O 0 9.885582e-05
3 O 0 0.00014380446
) O 0 0.00037801542
; O 0 0.00051721284
P O 0 0.0036219778
= O 0 0.0006595954
0 O 0 0.0005800326
. O 0 0.00083773996
0031 O 0 0.007039192
. O 0 0.0027548147

The O 0 0.0017620047
incidence O 0 0.0022783123
of O 0 0.0015810437
venous O 0 0.18707079
discomfort O 0 0.007998324
was O 0 0.00044111896
lower O 0 0.00033451064
in O 0 0.00024805858
Group O 0 0.0018421025
L O 0 0.30400768
( O 0 0.0003480099
76 O 0 0.00028388336
. O 0 8.421675e-05
6 O 0 7.213262e-05
% O 0 0.00014409021
; O 0 0.000236444
P O 0 0.0022494597
< O 0 0.00012518522
0 O 0 9.942142e-05
. O 0 9.106401e-05
05 O 0 0.0011595424
) O 0 0.00013866046
than O 0 5.5232405e-05
in O 0 9.941735e-05
Group O 0 0.0012316891
C O 0 0.9402115
( O 0 0.0003085351
100 O 0 0.00040565326
% O 0 0.00017888103
) O 0 0.00019004078
but O 0 0.00010064583
not O 0 7.837359e-05
different O 0 7.490292e-05
from O 0 0.00015984225
Group O 0 0.0013347263
T O 0 0.16218974
( O 0 0.0007910543
90 O 0 0.0006839998
% O 0 0.0011159165
) O 0 0.002171281
. O 0 0.0023262491

The O 0 0.0020152414
VAS O 0 0.0058983336
scores O 0 0.00070088776
for O 0 0.00042357552
recall O 0 0.0009629344
of O 0 0.0007306067
pain B-Disease 0 0.19106336
in O 0 0.00018746448
the O 0 0.00013028426
recovery O 0 0.0002573029
room O 0 0.00017613727
were O 0 7.228846e-05
correlated O 0 4.3360407e-05
with O 0 7.675118e-05
the O 0 9.0566056e-05
VAS O 0 0.0007017918
scores O 0 5.7417594e-05
during O 0 3.925212e-05
induction O 0 0.000131387
( O 0 0.00021464465
r O 0 0.00021038318
= O 0 0.00015040582
0 O 0 0.000103059836
. O 0 0.00011771203
7045 O 0 0.0020192175
; O 0 0.0004595286
P O 0 0.002525536
< O 0 0.0003697538
0 O 0 0.00040914677
. O 0 0.00059077004
0001 O 0 0.005469347
) O 0 0.0025924093
. O 0 0.0026410245

Recovery O 0 0.005714823
room O 0 0.0020090002
discharge O 0 0.0011088791
times O 0 0.0003481197
were O 0 0.00035860465
similar O 0 0.00025617346
: O 0 0.0006845956
C O 0 0.8937384
( O 0 0.00052877015
75 O 0 0.0003668411
. O 0 0.00012019606
9 O 0 0.00013221182
+ O 0 0.0003100525
/ O 0 0.00054419664
- O 0 0.0003350702
19 O 0 0.00017502847
. O 0 6.257962e-05
4 O 0 6.1039e-05
min O 0 0.00012360892
) O 0 0.00022471955
; O 0 0.00022056112
L O 0 0.05733156
73 O 0 0.00031784162
. O 0 7.54345e-05
6 O 0 6.659912e-05
+ O 0 0.00021179931
/ O 0 0.00039609818
- O 0 0.00024379401
21 O 0 0.00010282366
. O 0 5.2737854e-05
6 O 0 4.862153e-05
min O 0 0.00012331716
) O 0 0.00025005822
; O 0 0.00026789497
T O 0 0.15095703
( O 0 0.0003511757
77 O 0 0.0004706317
. O 0 0.00011359472
1 O 0 0.00014736669
+ O 0 0.00036327823
/ O 0 0.000676848
- O 0 0.00050344644
18 O 0 0.00027116732
. O 0 0.00023798492
9 O 0 0.00041451774
min O 0 0.00096220156
) O 0 0.002260624
. O 0 0.0025077465

Assessing O 0 0.0026000685
their O 0 0.001770898
overall O 0 0.0014541376
satisfaction O 0 0.0019454937
, O 0 0.0010122784
89 O 0 0.0010947317
. O 0 0.00032161066
7 O 0 0.00026914745
% O 0 0.00036512467
would O 0 0.00039325008
choose O 0 0.0009189178
propofol B-Chemical 1 0.99830914
anaesthesia O 0 0.047299437
again O 0 0.0025049613
. O 0 0.0027153909

We O 0 0.0012667459
conclude O 0 0.0008206598
that O 0 0.00097419374
lidocaine B-Chemical 0 0.9993606
reduces O 0 0.0006036219
the O 0 0.00036712954
incidence O 0 0.00056576857
and O 0 0.00020740596
severity O 0 0.00042266032
of O 0 0.00038419483
propofol B-Chemical 1 0.9997125
injection O 0 0.00048391367
pain B-Disease 0 0.20035146
in O 0 0.000103569575
ambulatory O 0 0.0001997531
patients O 0 0.00019199413
whereas O 0 0.00030633097
thiopentone B-Chemical 0 0.999946
only O 0 0.0005416062
reduces O 0 0.0005524584
its O 0 0.001714825
severity O 0 0.004196025
. O 0 0.002123518

Persistent O 0 0.032846984
paralysis B-Disease 0 0.9814558
after O 0 0.00070434617
prolonged O 0 0.0013036483
use O 0 0.00063438964
of O 0 0.001105366
atracurium B-Chemical 0 0.99748224
in O 0 0.00058772444
the O 0 0.00052694924
absence O 0 0.00061833556
of O 0 0.0030276363
corticosteroids O 1 0.9988342
. O 0 0.004494585

Neuromuscular O 0 0.013612484
blocking O 0 0.0035621873
agents O 0 0.007621473
( O 0 0.0027153986
NMBAs O 0 0.7888512
) O 0 0.001186606
are O 0 0.0003315519
often O 0 0.00028883823
used O 0 0.00020397274
for O 0 0.00021239628
patients O 0 0.0004275071
requiring O 0 0.0004191094
prolonged O 0 0.0010698488
mechanical O 0 0.0016724324
ventilation O 0 0.0040195067
. O 0 0.0022073132

Reports O 0 0.003942267
of O 0 0.0021913345
persistent O 0 0.008070698
paralysis B-Disease 0 0.9907832
after O 0 0.0002349478
the O 0 0.00031611667
discontinuance O 0 0.0035867488
of O 0 0.00025507621
these O 0 0.0002701629
drugs O 0 0.003622646
have O 0 7.492363e-05
most O 0 0.00012187775
often O 0 9.8101555e-05
involved O 0 7.328531e-05
aminosteroid O 0 0.5918954
- O 0 0.0002402293
based O 0 8.3078194e-05
NMBAs O 0 0.1480019
such O 0 7.2794195e-05
as O 0 0.00016654428
vecuronium B-Chemical 0 0.9924219
bromide I-Chemical 0 0.9993864
, O 0 0.00025330632
especially O 0 0.0001333493
when O 0 7.673523e-05
used O 0 0.00012442298
in O 0 0.00020328755
conjunction O 0 0.0005428425
with O 0 0.0018291336
corticosteroids O 1 0.9985771
. O 0 0.003044183

Atracurium B-Chemical 0 0.9988568
besylate I-Chemical 0 0.99995136
, O 0 0.0025516355
a O 0 0.00095745316
short O 0 0.00044714933
- O 0 0.000779661
acting O 0 0.0008718785
benzylisoquinolinium B-Chemical 0 0.99852633
NMBA O 0 0.9977182
that O 0 0.00013089631
is O 0 9.9902965e-05
eliminated O 0 8.8032946e-05
independently O 0 5.554801e-05
of O 0 0.00014986384
renal O 0 0.74451786
or O 0 0.00018887957
hepatic O 0 0.9126877
function O 0 0.00024932547
, O 0 0.00012684803
has O 0 4.8462654e-05
also O 0 5.3197404e-05
been O 0 4.4906057e-05
associated O 0 5.9204645e-05
with O 0 0.00016233376
persistent O 0 0.011998835
paralysis B-Disease 0 0.99969554
, O 0 0.00039976853
but O 0 0.00019298194
only O 0 0.00017949786
when O 0 0.00014886659
used O 0 0.00034473912
with O 0 0.0016278746
corticosteroids O 1 0.9984456
. O 0 0.002959772

We O 0 0.0016540264
report O 0 0.0017288487
a O 0 0.0011247729
case O 0 0.0006901576
of O 0 0.0013566924
atracurium B-Chemical 0 0.9997156
- O 0 0.0014123854
related O 0 0.00019771348
paralysis B-Disease 0 0.9922018
persisting O 0 0.0003997628
for O 0 8.025061e-05
approximately O 0 0.00010854235
50 O 0 0.00012824252
hours O 0 4.0978393e-05
in O 0 6.513703e-05
a O 0 0.00012986168
patient O 0 0.00015404608
who O 0 0.0002305975
was O 0 0.00017716544
not O 0 0.00020168032
treated O 0 0.00071632146
with O 0 0.0021356724
corticosteroids O 1 0.99886394
. O 0 0.0031813022

A O 0 0.018921843
phase O 0 0.0046912134
I O 0 0.008422239
/ O 0 0.0026295984
II O 0 0.0039590686
study O 0 0.0005176767
of O 0 0.00056877075
paclitaxel B-Chemical 1 0.9835438
plus O 0 0.0005483251
cisplatin B-Chemical 0 0.9989128
as O 0 0.00026424314
first O 0 0.00013162814
- O 0 0.0003603079
line O 0 0.00023050189
therapy O 0 0.00019299996
for O 0 0.00013263483
head B-Disease 0 0.0015727362
and I-Disease 0 0.00052250695
neck I-Disease 0 0.095463
cancers I-Disease 0 0.9000564
: O 0 0.0009765378
preliminary O 0 0.001540633
results O 0 0.0017220957
. O 0 0.0022114706

Improved O 0 0.003937165
outcomes O 0 0.0016295663
among O 0 0.0010595775
patients O 0 0.00083022425
with O 0 0.00062881276
head B-Disease 0 0.002412633
and I-Disease 0 0.00063716323
neck I-Disease 0 0.023475673
carcinomas I-Disease 0 0.049629766
require O 0 0.00013110616
investigations O 0 0.00023569875
of O 0 0.00023964343
new O 0 0.00036170453
drugs O 0 0.0037948773
for O 0 0.00038960646
induction O 0 0.0011149687
therapy O 0 0.002766635
. O 0 0.002303654

Preliminary O 0 0.0029104853
results O 0 0.0012652869
of O 0 0.0009905116
an O 0 0.00081419473
Eastern O 0 0.0011241036
Cooperative O 0 0.0006126463
Oncology O 0 0.00043187742
Group O 0 0.000498192
study O 0 0.0001622697
of O 0 0.0001606083
single O 0 0.00016575766
- O 0 0.00032038227
agent O 0 0.0015847515
paclitaxel B-Chemical 1 0.99738497
( O 0 0.0013252741
Taxol B-Chemical 0 0.9998939
; O 0 0.0005373624
Bristol O 0 0.0050302343
- O 0 0.00045752805
Myers O 0 0.005820605
Squibb O 0 0.30539638
Company O 0 0.010732337
, O 0 0.00028567776
Princeton O 0 0.012191915
, O 0 0.00029904503
NJ O 0 0.047938686
) O 0 0.00022215907
reported O 0 0.00010163884
a O 0 0.0001083531
37 O 0 0.00013527831
% O 0 6.1660605e-05
response O 0 4.9606417e-05
rate O 0 6.469947e-05
in O 0 5.7780002e-05
patients O 0 9.8041695e-05
with O 0 0.00010656332
head B-Disease 0 0.0009931235
and I-Disease 0 0.00021817921
neck I-Disease 0 0.11625635
cancer I-Disease 0 0.9685316
, O 0 0.00015168794
and O 0 8.4031846e-05
the O 0 0.00011227284
paclitaxel B-Chemical 1 0.98887235
/ O 0 0.0038516808
cisplatin B-Chemical 0 0.99880683
combination O 0 0.0003485715
has O 0 6.6881825e-05
been O 0 4.682334e-05
used O 0 4.6337915e-05
successfully O 0 8.036871e-05
and O 0 7.507246e-05
has O 0 5.0239356e-05
significantly O 0 9.437536e-05
improved O 0 0.00012935203
median O 0 4.5647746e-05
response O 0 9.325418e-05
duration O 0 0.00010112927
in O 0 0.000437026
ovarian B-Disease 0 0.9946331
cancer I-Disease 0 0.9995316
patients O 0 0.008366256
. O 0 0.0021640223

We O 0 0.001591044
initiated O 0 0.0013135843
a O 0 0.0013508577
phase O 0 0.002016406
I O 0 0.0053702528
/ O 0 0.0016487294
II O 0 0.0033671886
trial O 0 0.00029050573
to O 0 0.00010262012
determine O 0 4.7672052e-05
the O 0 7.732508e-05
response O 0 9.9295234e-05
and O 0 0.00015437162
toxicity B-Disease 2 0.9530601
of O 0 0.00024931907
escalating O 0 0.048224784
paclitaxel B-Chemical 1 0.99747074
doses O 0 0.003366163
combined O 0 0.00016093298
with O 0 9.960532e-05
fixed O 0 7.1457034e-05
- O 0 0.00019343104
dose O 0 0.0010020785
cisplatin B-Chemical 0 0.99819475
with O 0 0.00072505506
granulocyte O 0 0.99881625
colony O 0 0.7522779
- O 0 0.0005310319
stimulating O 0 0.00019455512
factor O 0 0.00033619182
support O 0 5.997794e-05
in O 0 6.838712e-05
patients O 0 0.00011028259
with O 0 0.00010699412
untreated O 0 0.00024175247
locally O 0 0.00065277703
advanced O 0 0.0024673808
inoperable O 0 0.078721836
head B-Disease 0 0.006378963
and I-Disease 0 0.0013466707
neck I-Disease 0 0.31398934
carcinoma I-Disease 0 0.9977196
. O 0 0.0030824437

To O 0 0.0027417762
date O 0 0.0021710189
, O 0 0.0016388788
23 O 0 0.0013501754
men O 0 0.0016119204
with O 0 0.0004048042
a O 0 0.00034135266
median O 0 0.00014105743
age O 0 0.00019057625
of O 0 0.00018705988
50 O 0 0.00026379863
years O 0 0.000114324976
and O 0 0.000113779664
good O 0 0.00022351588
performance O 0 0.0002520322
status O 0 0.00018645106
have O 0 0.00019458013
entered O 0 0.0003965964
the O 0 0.0007012425
trial O 0 0.0016548564
. O 0 0.001858532

Primary O 0 0.004222642
tumor B-Disease 0 0.040278614
sites O 0 0.0010072581
were O 0 0.0009158659
oropharynx O 0 0.0098068435
, O 0 0.00048892136
10 O 0 0.00028635975
patients O 0 0.0004057838
; O 0 0.00037473737
hypopharynx O 0 0.0082809245
, O 0 0.00022219443
four O 0 0.00010392018
; O 0 0.00020825607
larynx O 0 0.0013981648
, O 0 0.00014963024
two O 0 8.127249e-05
; O 0 0.0001613626
oral O 0 0.002527149
cavity O 0 0.00035551097
, O 0 0.00011875241
three O 0 5.1147395e-05
; O 0 0.0001131981
unknown O 0 0.00014135527
primary O 0 0.00012528853
, O 0 0.00012229534
two O 0 7.094894e-05
; O 0 0.00012458373
and O 0 0.00012590531
nasal O 0 0.00047462102
cavity O 0 0.00041190398
and O 0 0.00030693258
parotid O 0 0.0037143675
gland O 0 0.007844665
, O 0 0.00054561923
one O 0 0.00046398918
each O 0 0.00064810785
. O 0 0.0017056292

Of O 0 0.0020431
20 O 0 0.0012855111
patients O 0 0.0010429675
evaluable O 0 0.0011572582
for O 0 0.0004888715
toxicity B-Disease 2 0.9784718
, O 0 0.0004914255
four O 0 0.00015914922
had O 0 0.00023276781
stage O 0 0.00059290824
III O 0 0.0022703197
and O 0 0.000278444
16 O 0 0.00029757066
had O 0 0.00044286955
stage O 0 0.0017982294
IV O 0 0.10733937
disease O 0 0.39429027
. O 0 0.003098499

Treatment O 0 0.005703738
, O 0 0.0015637067
given O 0 0.00044973433
every O 0 0.00019989585
21 O 0 0.00027345872
days O 0 0.00010427893
for O 0 0.000109428416
a O 0 0.0001558967
maximum O 0 0.000105569
of O 0 0.00012038899
three O 0 4.5569985e-05
cycles O 0 5.1956427e-05
, O 0 7.786391e-05
consisted O 0 6.249862e-05
of O 0 0.00018526989
paclitaxel B-Chemical 1 0.9807257
by O 0 0.00017926062
3 O 0 7.368256e-05
- O 0 0.00010501057
hour O 0 3.9286417e-05
infusion O 0 0.00010226766
followed O 0 3.5453526e-05
the O 0 3.7727506e-05
next O 0 2.3782768e-05
day O 0 3.352302e-05
by O 0 5.381115e-05
a O 0 7.524656e-05
fixed O 0 6.637708e-05
dose O 0 0.00040374417
of O 0 0.00038101143
cisplatin B-Chemical 0 0.99777126
( O 0 0.00056795654
75 O 0 0.0005917134
mg O 0 0.0073331604
/ O 0 0.00199116
m2 O 0 0.005801949
) O 0 0.0024210645
. O 0 0.0020553037

The O 0 0.0015827594
dose O 0 0.0027029004
levels O 0 0.00071056973
incorporate O 0 0.00037343
escalating O 0 0.012390931
paclitaxel B-Chemical 1 0.99726355
doses O 0 0.0142675005
, O 0 0.00031821424
and O 0 0.00018050428
intrapatient O 0 0.0014218063
escalations O 0 0.0029450185
within O 0 3.831167e-05
a O 0 0.00010591262
given O 0 6.3392145e-05
dose O 0 0.00036007818
level O 0 0.00012979249
are O 0 0.00018494618
permitted O 0 0.0004496336
if O 0 0.00044000708
toxicity B-Disease 2 0.97866344
permits O 0 0.0023618236
. O 0 0.002229464

At O 0 0.00086443144
the O 0 0.00096571166
time O 0 0.00048661476
of O 0 0.00064270233
this O 0 0.000590582
writing O 0 0.001938122
, O 0 0.00048992084
dose O 0 0.0010789076
level O 0 0.00020245327
4 O 0 0.00015767844
( O 0 0.00025413826
260 O 0 0.0017635444
, O 0 0.00020343142
270 O 0 0.00077255437
, O 0 0.00013578363
and O 0 0.00012462222
280 O 0 0.003250558
mg O 0 0.006738201
/ O 0 0.00057819864
m2 O 0 0.0015211521
) O 0 0.00020612529
is O 0 8.896828e-05
being O 0 0.00010998579
evaluated O 0 7.759602e-05
; O 0 0.00010286447
three O 0 4.918098e-05
patients O 0 0.00013696046
from O 0 0.000114316914
this O 0 0.00024214137
level O 0 0.00031971646
are O 0 0.0006623
evaluable O 0 0.0026219322
. O 0 0.0017677221

With O 0 0.003493863
paclitaxel B-Chemical 1 0.961929
doses O 0 0.0069706375
of O 0 0.0010230258
200 O 0 0.0015788536
mg O 0 0.020183703
/ O 0 0.0010736305
m2 O 0 0.0014941712
and O 0 0.0001978555
higher O 0 0.00023168464
, O 0 0.00032409822
granulocyte O 0 0.9888072
colony O 0 0.5110668
- O 0 0.00059788476
stimulating O 0 0.00025782446
factor O 0 0.0005021806
5 O 0 8.422816e-05
micrograms O 0 0.0007472026
/ O 0 0.0004570764
kg O 0 0.000346279
/ O 0 0.00031651414
d O 0 0.0001395296
is O 0 0.000100578
given O 0 8.069593e-05
( O 0 0.00017991252
days O 0 8.94832e-05
4 O 0 0.00016710866
through O 0 0.00026553217
12 O 0 0.00048906717
) O 0 0.0016522572
. O 0 0.0020348867

Of O 0 0.0023253341
18 O 0 0.0012323215
patients O 0 0.0009725929
evaluable O 0 0.000897542
for O 0 0.00027204954
response O 0 0.00035239695
, O 0 0.00035829755
seven O 0 0.00021135349
( O 0 0.0002863917
39 O 0 0.00025711453
% O 0 0.0001730824
) O 0 0.0001800256
achieved O 0 0.0001309832
a O 0 0.00012188763
complete O 0 9.176171e-05
response O 0 0.00010791508
and O 0 0.00012545481
six O 0 8.306552e-05
( O 0 0.00020852489
33 O 0 0.00024958115
% O 0 0.00022227537
) O 0 0.0003210436
achieved O 0 0.00037295755
a O 0 0.00060039555
partial O 0 0.001321924
response O 0 0.0016637009
. O 0 0.0022806558

Three O 0 0.0029554989
patients O 0 0.0024511814
had O 0 0.0012334243
no O 0 0.00069073035
change O 0 0.0009981495
and O 0 0.001353898
disease O 0 0.06657392
progressed O 0 0.0028743271
in O 0 0.0015757822
two O 0 0.0017710557
. O 0 0.0031142076

The O 0 0.0035264783
overall O 0 0.0037108366
response O 0 0.0035613629
rate O 0 0.004191923
is O 0 0.00425613
72 O 0 0.004698267
% O 0 0.0065032193
. O 0 0.007070932

Eleven O 0 0.00484678
responding O 0 0.0026902219
patients O 0 0.0015485989
had O 0 0.0007817731
subsequent O 0 0.00068956625
surgery O 0 0.0009889865
/ O 0 0.0016729156
radiotherapy O 0 0.0051512127
or O 0 0.0013133055
radical O 0 0.46413678
radiotherapy O 0 0.12656324
. O 0 0.0036168415

Two O 0 0.0021946025
pathologic O 0 0.0045938594
complete O 0 0.000865035
responses O 0 0.00074929866
were O 0 0.0004216145
observed O 0 0.0002726236
in O 0 0.00028256053
patients O 0 0.00044028673
who O 0 0.0004410609
had O 0 0.00029851432
achieved O 0 0.0005078207
clinical O 0 0.001214421
complete O 0 0.0009152417
responses O 0 0.0019697149
. O 0 0.002453812

Alopecia B-Disease 0 0.99328715
, O 0 0.008388121
paresthesias B-Disease 0 0.9973609
, O 0 0.0019659568
and O 0 0.0015916579
arthralgias B-Disease 0 0.99789643
/ O 0 0.02360046
myalgias B-Disease 0 0.9997484
have O 0 0.00025166167
occurred O 0 0.0001574064
frequently O 0 0.00014508287
, O 0 0.0001448534
but O 0 0.0001076611
with O 0 0.00010734208
one O 0 6.328354e-05
exception O 0 8.439411e-05
( O 0 0.00013649318
a O 0 0.00016637889
grade O 0 0.004988883
3 O 0 0.00019905914
myalgia B-Disease 2 0.9996644
) O 0 0.00040274026
they O 0 0.00011925296
have O 0 0.00012196659
been O 0 0.00019256651
grade O 0 0.002114904
1 O 0 0.00036196702
or O 0 0.0005526201
2 O 0 0.0009720878
. O 0 0.0016846011

No O 0 0.005289747
dose O 0 0.01066953
- O 0 0.00486491
limiting O 0 0.006026283
hematologic O 0 0.9991885
toxicity B-Disease 2 0.99976605
has O 0 0.0030616291
been O 0 0.0021810273
seen O 0 0.0028990486
. O 0 0.0036781663

Paclitaxel B-Chemical 0 0.99723095
/ O 0 0.025523156
cisplatin B-Chemical 0 0.9970715
is O 0 0.0009874117
an O 0 0.0005524937
effective O 0 0.00027287743
first O 0 0.000196505
- O 0 0.0004433866
line O 0 0.00025846882
regimen O 0 0.00022878397
for O 0 0.0001409726
locoregionally O 0 0.06685684
advanced O 0 0.0016069753
head B-Disease 0 0.0026719982
and I-Disease 0 0.0004225262
neck I-Disease 0 0.10246273
cancer I-Disease 0 0.9324008
and O 0 0.00038165628
continued O 0 0.00038137354
study O 0 0.0005709537
is O 0 0.00071078754
warranted O 0 0.0011108466
. O 0 0.001945978

Results O 0 0.0021418831
thus O 0 0.0017161275
far O 0 0.00090739527
suggest O 0 0.00033364943
no O 0 0.0003250879
dose O 0 0.0019707314
- O 0 0.0005962435
response O 0 0.00021550698
effect O 0 0.00019868654
for O 0 0.00023722238
paclitaxel B-Chemical 1 0.987497
doses O 0 0.0039198715
above O 0 0.00048070302
200 O 0 0.0016011641
mg O 0 0.02769682
/ O 0 0.0036120433
m2 O 0 0.008948051
. O 0 0.0024604776

Improvement O 0 0.0071463874
of O 0 0.0051138503
levodopa B-Chemical 0 0.9998447
- O 0 0.0049941856
induced O 0 0.0034113342
dyskinesia B-Disease 0 0.99997044
by O 0 0.0034352737
propranolol B-Chemical 1 0.99997926
in O 0 0.0023389428
Parkinson B-Disease 0 0.99874336
' I-Disease 0 0.0022551985
s I-Disease 0 0.001825305
disease I-Disease 0 0.089195415
. O 0 0.0034206486

Seven O 0 0.0042840852
patients O 0 0.002599382
suffering O 0 0.013101146
from O 0 0.0009838556
Parkinson B-Disease 0 0.9942707
' I-Disease 0 0.00081029546
s I-Disease 0 0.00051309256
disease I-Disease 0 0.11553285
( O 0 0.00093273906
PD B-Disease 0 0.9966324
) O 0 0.00037053545
with O 0 0.0002108722
severely O 0 0.013281534
disabling O 0 0.970666
dyskinesia B-Disease 0 0.9999956
received O 0 0.00016218539
low O 0 0.00037969882
- O 0 0.0003659043
dose O 0 0.0051161656
propranolol B-Chemical 1 0.9999933
as O 0 0.00016721513
an O 0 0.0001531512
adjunct O 0 0.00010867636
to O 0 9.328174e-05
the O 0 0.00014199223
currently O 0 0.00026952027
used O 0 0.00034813548
medical O 0 0.0018764846
treatment O 0 0.0013730839
. O 0 0.0019397091

There O 0 0.0029630454
was O 0 0.0018912716
a O 0 0.0012281254
significant O 0 0.0006467578
40 O 0 0.0005197714
% O 0 0.00035797662
improvement O 0 0.00027086496
in O 0 0.00020767012
the O 0 0.00041028476
dyskinesia B-Disease 0 0.9999579
score O 0 0.00022714036
without O 0 0.00019209668
increase O 0 0.00029707825
of O 0 0.0011569615
parkinsonian B-Disease 2 0.9998796
motor B-Disease 0 0.726987
disability I-Disease 0 0.95700824
. O 0 0.003119838

Ballistic O 0 0.009863836
and O 0 0.0055939183
choreic O 0 0.9993918
dyskinesia B-Disease 0 0.99995315
were O 0 0.0018816683
markedly O 0 0.0039966833
ameliorated O 0 0.29928342
, O 0 0.0019092127
whereas O 0 0.0026403063
dystonia B-Disease 2 0.99992335
was O 0 0.0031934709
not O 0 0.0022038124
. O 0 0.002916332

This O 0 0.0033119912
study O 0 0.0013510254
suggests O 0 0.00038675906
that O 0 0.00031657904
administration O 0 0.0010420682
of O 0 0.0004193853
low O 0 0.0006454487
doses O 0 0.002652285
of O 0 0.00079043297
beta O 0 0.9826528
- O 0 0.0021045702
blockers O 0 0.9943287
may O 0 0.00016250553
improve O 0 0.00022003517
levodopa B-Chemical 0 0.9999653
- O 0 0.0005222948
induced O 0 0.0002474793
ballistic O 0 0.0013394398
and O 0 0.0009510733
choreic O 0 0.9998727
dyskinesia B-Disease 0 0.9999865
in O 0 0.003385945
PD B-Disease 0 0.9975593
. O 0 0.002738887

Habitual O 0 0.014993465
use O 0 0.0019439342
of O 0 0.0034822691
acetaminophen B-Chemical 0 0.999977
as O 0 0.0010999469
a O 0 0.0008874853
risk O 0 0.0031943242
factor O 0 0.0012921164
for O 0 0.0003608844
chronic B-Disease 2 0.9267599
renal I-Disease 2 0.99768734
failure I-Disease 2 0.96711886
: O 0 0.0007311479
a O 0 0.00054075505
comparison O 0 0.00053003186
with O 0 0.0028298749
phenacetin B-Chemical 1 0.9999726
. O 0 0.0041594403

Six O 0 0.00258344
epidemiologic O 0 0.002148301
studies O 0 0.0008659571
in O 0 0.0004716507
the O 0 0.00037716355
United O 0 0.00045983845
States O 0 0.0005447896
and O 0 0.00022080098
Europe O 0 0.00028727093
indicate O 0 5.6399804e-05
that O 0 6.658324e-05
habitual O 0 0.0006383117
use O 0 0.00010915672
of O 0 0.0005818631
phenacetin B-Chemical 1 0.99999833
is O 0 0.0001746294
associated O 0 6.615439e-05
with O 0 7.4583535e-05
the O 0 5.5363074e-05
development O 0 0.00013618247
of O 0 0.0002218168
chronic B-Disease 2 0.88692683
renal I-Disease 2 0.996071
failure I-Disease 2 0.9045627
and O 0 0.0001488311
end B-Disease 0 5.27199e-05
- I-Disease 0 0.00021741046
stage I-Disease 0 0.0006337429
renal I-Disease 0 0.9997631
disease I-Disease 0 0.9990853
( O 0 0.0068370164
ESRD B-Disease 2 0.9999925
) O 0 0.00059526577
, O 0 0.00012678852
with O 0 0.00010742267
a O 0 0.00012515002
relative O 0 0.00010978575
risk O 0 0.0006588283
in O 0 0.00011923033
the O 0 0.00014473165
range O 0 0.00020652935
of O 0 0.0003657195
4 O 0 0.00035192457
to O 0 0.0006241112
19 O 0 0.001789597
. O 0 0.0018803559

As O 0 0.0017013671
a O 0 0.0015670948
result O 0 0.0007438669
of O 0 0.00071800407
these O 0 0.00059147266
and O 0 0.00036770466
other O 0 0.00026713038
studies O 0 0.0004094248
, O 0 0.0009982155
phenacetin B-Chemical 1 0.9999963
has O 0 0.00023821328
now O 0 0.00016184797
been O 0 0.0001030015
withdrawn O 0 0.0002169218
from O 0 0.0001101491
the O 0 0.00017505384
market O 0 0.00042211235
in O 0 0.00040623508
most O 0 0.0012092227
countries O 0 0.0022898775
. O 0 0.002198943

However O 0 0.0026206009
, O 0 0.0016667513
three O 0 0.00048969185
case O 0 0.00051232136
control O 0 0.0004100478
studies O 0 0.00037622682
, O 0 0.0002628461
one O 0 0.00010863296
each O 0 6.891543e-05
in O 0 0.00012335752
North O 0 0.00022609932
Carolina O 0 0.0007100063
, O 0 0.00016746692
northern O 0 0.0003839887
Maryland O 0 0.0010021926
, O 0 0.00012831921
and O 0 0.0001081576
West O 0 0.00015419773
Berlin O 0 0.0002775397
, O 0 0.00014242996
Germany O 0 0.00038206804
, O 0 9.637617e-05
showed O 0 5.8794714e-05
that O 0 4.868941e-05
habitual O 0 0.00056047726
use O 0 7.907053e-05
of O 0 0.000394848
acetaminophen B-Chemical 0 0.99999774
is O 0 0.00014198004
also O 0 6.2947154e-05
associated O 0 6.3462794e-05
with O 0 0.00019186035
chronic B-Disease 2 0.83225024
renal I-Disease 2 0.9965402
failure I-Disease 2 0.9814511
and O 0 0.0021066945
ESRD B-Disease 2 0.9999927
, O 0 0.00023587592
with O 0 0.00012452055
a O 0 0.000121371995
relative O 0 9.980747e-05
risk O 0 0.00061815133
in O 0 0.000106254156
the O 0 0.00012911038
range O 0 0.00018608572
of O 0 0.00033561783
2 O 0 0.00033494082
to O 0 0.00051819585
4 O 0 0.0008994159
. O 0 0.0016707971

These O 0 0.0019464717
studies O 0 0.0010522127
suggest O 0 0.00037519095
that O 0 0.00041517068
both O 0 0.0013223785
phenacetin B-Chemical 1 0.9999963
and O 0 0.0069591114
acetaminophen B-Chemical 0 0.99999666
may O 0 0.00022085616
contribute O 0 8.882874e-05
to O 0 7.2249524e-05
the O 0 8.421243e-05
burden O 0 0.00021323859
of O 0 0.00078385393
ESRD B-Disease 2 0.99998987
, O 0 0.00027824045
with O 0 0.00014190342
the O 0 0.00010605978
risk O 0 0.00056211627
of O 0 0.000118647375
the O 0 9.591217e-05
latter O 0 0.00030970803
being O 0 0.00018445414
somewhat O 0 0.00023826507
less O 0 0.00014603307
than O 0 0.000108781496
that O 0 0.00016933242
of O 0 0.0005196119
the O 0 0.0008601995
former O 0 0.0073686633
. O 0 0.002228977

This O 0 0.00354001
apparent O 0 0.0017822861
difference O 0 0.00069000927
in O 0 0.00072622625
risk O 0 0.002268031
may O 0 0.00031935057
not O 0 0.00023576643
be O 0 0.00016437155
due O 0 9.646913e-05
to O 0 0.000111626265
differences O 0 8.710904e-05
in O 0 0.0002141814
nephrotoxic B-Disease 2 0.99706703
potential O 0 0.00055411906
of O 0 0.00062073104
the O 0 0.00074209966
drugs O 0 0.033958763
themselves O 0 0.0035102956
. O 0 0.002334805

A O 0 0.017699966
lower O 0 0.0022376028
relative O 0 0.0011733465
risk O 0 0.0033633069
would O 0 0.00047004817
be O 0 0.00026215383
expected O 0 0.00019480292
for O 0 0.00030775717
acetaminophen B-Chemical 0 0.9999924
if O 0 0.00015659723
the O 0 0.00015505108
risk O 0 0.00070567545
of O 0 0.00013244388
both O 0 0.00011162923
drugs O 0 0.0029300104
in O 0 6.957549e-05
combination O 0 0.00011356093
with O 0 0.00012919238
other O 0 0.0001549834
analgesics O 0 0.31909207
was O 0 0.00011769532
higher O 0 0.000103123355
than O 0 6.751997e-05
the O 0 0.0001310283
risk O 0 0.0008242897
of O 0 0.00032818824
either O 0 0.00047071849
agent O 0 0.0035797036
alone O 0 0.0021023762
. O 0 0.002348651

Thus O 0 0.0032414615
, O 0 0.006208587
acetaminophen B-Chemical 0 0.9999654
has O 0 0.0009692001
been O 0 0.00035834848
used O 0 0.0002258087
both O 0 0.00021147363
as O 0 0.00015795622
a O 0 0.00018733832
single O 0 0.0001441834
agent O 0 0.0005224419
and O 0 0.00011961135
in O 0 8.160845e-05
combination O 0 0.00013474227
with O 0 0.00015291656
other O 0 0.00019433929
analgesics O 0 0.56372565
, O 0 0.0002693885
whereas O 0 0.0005926667
phenacetin B-Chemical 1 0.99999654
was O 0 0.0005694466
available O 0 0.00034451947
only O 0 0.00040718226
in O 0 0.00054501067
combinations O 0 0.0010568132
. O 0 0.001861333

The O 0 0.0014073811
possibility O 0 0.0008050765
that O 0 0.00061703654
habitual O 0 0.0026102753
use O 0 0.0005047943
of O 0 0.0013112806
acetaminophen B-Chemical 0 0.99999344
alone O 0 0.00055062317
increases O 0 0.00025104696
the O 0 0.00022842803
risk O 0 0.0032775172
of O 0 0.0013315001
ESRD B-Disease 2 0.99998784
has O 0 0.0001931977
not O 0 0.0001282084
been O 0 0.00010418332
clearly O 0 0.00012730059
demonstrated O 0 0.000195004
, O 0 0.000378565
but O 0 0.00051682664
cannot O 0 0.0016125329
be O 0 0.0010182521
dismissed O 0 0.0057473164
. O 0 0.0022645546

Acetaminophen B-Chemical 0 0.9995956
- O 0 0.042862546
induced O 0 0.031805556
hypotension B-Disease 0 0.99838245
. O 0 0.024555182

Through O 0 0.0026463226
30 O 0 0.0013083147
years O 0 0.0008611114
of O 0 0.0007286264
widespread O 0 0.0007206858
use O 0 0.00057316903
, O 0 0.001383423
acetaminophen B-Chemical 0 0.99999344
has O 0 0.00034769712
been O 0 0.0001477694
shown O 0 9.9519595e-05
to O 0 0.00010280691
be O 0 0.00010663691
a O 0 0.00017139838
remarkably O 0 0.00053688936
safe O 0 0.0004279022
medication O 0 0.0014535104
in O 0 0.00041393828
therapeutic O 0 0.0019084058
dosages O 0 0.06015459
. O 0 0.0025172634

The O 0 0.001904408
potential O 0 0.0019423189
for O 0 0.0020449571
acetaminophen B-Chemical 0 0.9999443
to O 0 0.0013667587
produce O 0 0.0011300005
cardiovascular B-Disease 0 0.9986546
toxicities I-Disease 2 0.9998203
is O 0 0.0026561955
very O 0 0.003068127
low O 0 0.0053323237
. O 0 0.0035058428

However O 0 0.003708105
, O 0 0.0062109004
acetaminophen B-Chemical 0 0.99996495
has O 0 0.00097079104
been O 0 0.00036298725
demonstrated O 0 0.0002161989
to O 0 0.00017148191
produce O 0 0.00015438134
symptoms O 0 0.0029999842
of O 0 0.0008381223
anaphylaxis B-Disease 2 0.9996562
, O 0 0.0006620324
including O 0 0.00038845214
hypotension B-Disease 0 0.9997178
, O 0 0.0007307014
in O 0 0.00046546393
sensitive O 0 0.00077944703
individuals O 0 0.0021448366
. O 0 0.0020804033

This O 0 0.0030222654
article O 0 0.0014830373
describes O 0 0.0010784053
two O 0 0.00046849845
critically B-Disease 0 0.0037978168
ill I-Disease 0 0.7910588
patients O 0 0.0005030557
in O 0 0.00017388783
whom O 0 0.0003325301
transient O 0 0.0011359819
episodes O 0 0.00091046793
of O 0 0.00048599773
hypotension B-Disease 0 0.99979526
reproducibly O 0 0.0016159451
developed O 0 0.0003375759
after O 0 0.00012620339
administration O 0 0.002189547
of O 0 0.0041020797
acetaminophen B-Chemical 0 0.99998033
. O 0 0.0042315274

Other O 0 0.005348535
symptoms O 0 0.015603725
of O 0 0.0056967144
allergic B-Disease 0 0.9996244
reactions I-Disease 0 0.588504
were O 0 0.0020583342
not O 0 0.0015672246
clinically O 0 0.006847408
detectable O 0 0.0034300894
. O 0 0.00413464

The O 0 0.003009283
hypotensive B-Disease 0 0.9649432
episodes O 0 0.007813434
were O 0 0.0015313916
severe O 0 0.0039855223
enough O 0 0.0009978324
to O 0 0.00073542737
require O 0 0.0008114978
vasopressor O 0 0.36864886
administration O 0 0.013894178
. O 0 0.0036756264

The O 0 0.0015800311
reports O 0 0.0012714124
illustrate O 0 0.0005930696
the O 0 0.0005323557
need O 0 0.0003242271
for O 0 0.00022840496
clinicians O 0 0.00040770543
to O 0 0.0001922616
consider O 0 0.00022227262
acetaminophen B-Chemical 0 0.99999094
in O 0 0.00041064652
patients O 0 0.0005161116
with O 0 0.00070704747
hypotension B-Disease 0 0.99952865
of O 0 0.0014003742
unknown O 0 0.0021596486
origin O 0 0.0020238564
. O 0 0.0020857172

Reduction O 0 0.005330493
of O 0 0.0035939473
heparan B-Chemical 0 0.9710109
sulphate I-Chemical 0 0.99928564
- O 0 0.004033246
associated O 0 0.0006286103
anionic O 0 0.068267636
sites O 0 0.00021733851
in O 0 0.00015720645
the O 0 0.00019340854
glomerular O 0 0.8685244
basement O 0 0.058884278
membrane O 0 0.00044799215
of O 0 0.00020510543
rats O 0 0.00034657147
with O 0 0.0007157871
streptozotocin B-Chemical 0 0.9999815
- O 0 0.004788866
induced O 0 0.011218306
diabetic B-Disease 2 0.99998903
nephropathy I-Disease 0 0.99999726
. O 0 0.0086901635

Heparan B-Chemical 0 0.49088803
sulphate I-Chemical 0 0.99643624
- O 0 0.004627293
associated O 0 0.0009743195
anionic O 0 0.0408968
sites O 0 0.0003189268
in O 0 0.00021465613
the O 0 0.00023481724
glomerular O 0 0.8661301
basement O 0 0.0853934
membrane O 0 0.0004922108
were O 0 0.00010821143
studied O 0 9.3019626e-05
in O 0 6.3498264e-05
rats O 0 9.68849e-05
8 O 0 3.636413e-05
months O 0 1.5268046e-05
after O 0 1.5631498e-05
induction O 0 7.2406365e-05
of O 0 0.00033986525
diabetes B-Disease 0 0.9997222
by O 0 0.0006692276
streptozotocin B-Chemical 0 0.99999225
and O 0 0.00024109022
in O 0 0.0001159859
age O 0 0.00017992021
- O 0 0.0003413455
adn O 0 0.015382572
sex O 0 0.00041987834
- O 0 0.00014745412
matched O 0 5.5192337e-05
control O 0 7.795172e-05
rats O 0 0.0001598386
, O 0 0.00012733083
employing O 0 0.0001418999
the O 0 0.00026026362
cationic O 0 0.0034302296
dye O 0 0.0647719
cuprolinic B-Chemical 0 0.69903755
blue I-Chemical 0 0.29974473
. O 0 0.0029589124

Morphometric O 0 0.008811334
analysis O 0 0.0013994798
at O 0 0.0006878833
the O 0 0.0007061966
ultrastructural O 0 0.001735982
level O 0 0.00047584862
was O 0 0.0004944441
performed O 0 0.00035803468
using O 0 0.0003941001
a O 0 0.0008131628
computerized O 0 0.0020249584
image O 0 0.00185149
processor O 0 0.0054881894
. O 0 0.0035039561

The O 0 0.0026741973
heparan B-Chemical 0 0.77076155
sulphate I-Chemical 0 0.9930421
specificity O 0 0.0035995184
of O 0 0.00093001954
the O 0 0.0006954438
cuprolinic B-Chemical 0 0.39267677
blue I-Chemical 0 0.0691221
staining O 0 0.00034215837
was O 0 0.00019459277
demonstrated O 0 0.00012759931
by O 0 0.00027151915
glycosaminoglycan B-Chemical 0 0.990594
- O 0 0.00078102626
degrading O 0 0.0009418516
enzymes O 0 0.0030297933
, O 0 0.00011258471
showing O 0 7.163961e-05
that O 0 4.9398805e-05
pretreatment O 0 0.0018679821
of O 0 0.000113807444
the O 0 7.067336e-05
sections O 0 8.533673e-05
with O 0 0.00016350475
heparitinase O 0 0.9217444
abolished O 0 0.0006710696
all O 0 0.00018230782
staining O 0 0.0001938537
, O 0 0.00018289182
whereas O 0 0.00024566607
chondroitinase O 0 0.37496796
ABC O 0 0.008793024
had O 0 0.000494727
no O 0 0.00048042636
effect O 0 0.0012867311
. O 0 0.0022255671

The O 0 0.0017422928
majority O 0 0.0014831963
of O 0 0.001596679
anionic O 0 0.059033573
sites O 0 0.0006450778
( O 0 0.00067287305
74 O 0 0.0005353188
% O 0 0.00030325024
in O 0 0.00032044487
diabetic B-Disease 2 0.9985441
and O 0 0.00027698322
81 O 0 0.00031339077
% O 0 0.00010512388
in O 0 6.946716e-05
control O 0 9.0117566e-05
rats O 0 0.00019768519
) O 0 0.00015365613
were O 0 7.328999e-05
found O 0 5.3147553e-05
within O 0 3.2845226e-05
the O 0 0.00011229629
lamina O 0 0.00052204786
rara O 0 0.014964514
externa O 0 0.060338777
of O 0 0.00051039946
the O 0 0.00065246783
glomerular O 0 0.9772265
basement O 0 0.34848225
membrane O 0 0.0052182022
. O 0 0.002260016

A O 0 0.025844552
minority O 0 0.0046003833
of O 0 0.0018455987
anionic O 0 0.040606007
sites O 0 0.00049398013
were O 0 0.00032224783
scattered O 0 0.00024968822
throughout O 0 7.701755e-05
the O 0 0.00013696568
lamina O 0 0.00039394756
densa O 0 0.0009807701
and O 0 0.00017060009
lamina O 0 0.00047662173
rara O 0 0.01109946
interna O 0 0.012819367
, O 0 0.0001740305
and O 0 0.00010373485
were O 0 8.226902e-05
significantly O 0 9.676358e-05
smaller O 0 7.910928e-05
than O 0 4.6127923e-05
those O 0 8.1274586e-05
in O 0 5.6789082e-05
the O 0 8.068115e-05
lamina O 0 0.00034710794
rara O 0 0.011569725
externa O 0 0.03145274
of O 0 0.00014696662
the O 0 0.00013182813
glomerular O 0 0.9459863
basement O 0 0.16674098
membrane O 0 0.0006899829
( O 0 0.00021932846
p O 0 0.00010485767
< O 0 7.5678036e-05
0 O 0 7.1032744e-05
. O 0 7.189776e-05
001 O 0 0.0013143253
and O 0 0.00013437965
p O 0 0.0001236794
< O 0 9.2663104e-05
0 O 0 8.2970204e-05
. O 0 7.562681e-05
01 O 0 0.00032018102
for O 0 0.00015340697
diabetic B-Disease 2 0.9940899
and O 0 0.00026775812
control O 0 0.00027125236
rats O 0 0.00065354013
, O 0 0.0007511266
respectively O 0 0.0019245901
) O 0 0.0023688741
. O 0 0.0022176735

Diabetic B-Disease 0 0.9986461
rats O 0 0.0029452732
progressively O 0 0.0014569929
developed O 0 0.0020355668
albuminuria B-Disease 2 0.99992025
reaching O 0 0.0014232817
40 O 0 0.00038720178
. O 0 0.00013928553
3 O 0 0.00011951512
( O 0 0.0001771536
32 O 0 0.00015948023
. O 0 8.0807506e-05
2 O 0 9.414337e-05
- O 0 0.00017573922
62 O 0 0.00013454826
. O 0 5.536841e-05
0 O 0 7.2311625e-05
) O 0 0.00014318516
mg O 0 0.0010393537
/ O 0 0.00023006168
24 O 0 4.5643912e-05
h O 0 3.8952316e-05
after O 0 2.1375588e-05
8 O 0 3.491231e-05
months O 0 1.823307e-05
in O 0 3.5053792e-05
contrast O 0 7.838981e-05
to O 0 5.239947e-05
the O 0 6.108553e-05
control O 0 7.0588365e-05
animals O 0 6.694474e-05
( O 0 0.00011670982
0 O 0 6.4274536e-05
. O 0 4.627989e-05
8 O 0 5.6278703e-05
( O 0 9.6145675e-05
0 O 0 6.546826e-05
. O 0 5.4082306e-05
2 O 0 7.271088e-05
- O 0 0.00014452172
0 O 0 7.358341e-05
. O 0 5.8732567e-05
9 O 0 8.104666e-05
) O 0 0.00017285152
mg O 0 0.0012742862
/ O 0 0.00036201908
24 O 0 0.000106152256
h O 0 0.00013911033
, O 0 0.0002600136
p O 0 0.00027623292
< O 0 0.00028721342
0 O 0 0.00034786557
. O 0 0.0005036581
002 O 0 0.005544869
) O 0 0.0025701213
. O 0 0.0025509414

At O 0 0.000874841
the O 0 0.0009676791
same O 0 0.0004558844
time O 0 0.00034581168
, O 0 0.00042366743
the O 0 0.000260245
number O 0 0.0002345617
of O 0 0.00044539795
heparan B-Chemical 0 0.97224987
sulphate I-Chemical 0 0.99970835
anionic O 0 0.7034651
sites O 0 0.00016088571
and O 0 0.00011202998
the O 0 8.666725e-05
total O 0 0.00013028774
anionic O 0 0.036729038
site O 0 0.0001093066
surface O 0 0.00022955574
( O 0 0.00013601157
number O 0 7.4126976e-05
of O 0 0.0001263802
anionic O 0 0.017741103
sites O 0 7.848623e-05
x O 0 0.00018794
mean O 0 4.8603488e-05
anionic O 0 0.010367266
site O 0 9.78828e-05
surface O 0 0.00022762317
) O 0 0.00015035766
in O 0 6.475775e-05
the O 0 8.708844e-05
lamina O 0 0.0003498786
rara O 0 0.010541965
externa O 0 0.029743947
of O 0 0.00014662494
the O 0 0.0001300033
glomerular O 0 0.94396096
basement O 0 0.1353446
membrane O 0 0.00046759853
was O 0 0.000116750234
reduced O 0 0.0001676593
by O 0 0.00012406874
19 O 0 0.00017275364
% O 0 0.00012478109
( O 0 0.00016753926
p O 0 0.00010783236
< O 0 8.110186e-05
0 O 0 7.468381e-05
. O 0 7.437778e-05
021 O 0 0.0016341156
) O 0 0.0001909635
and O 0 0.00011310596
by O 0 0.00013090405
26 O 0 0.00019449706
% O 0 0.0001782288
( O 0 0.0002522817
p O 0 0.00019697286
< O 0 0.00018377615
0 O 0 0.00020605454
. O 0 0.00027120116
02 O 0 0.0030303637
) O 0 0.0010668137
, O 0 0.0012768478
respectively O 0 0.0029646736
. O 0 0.0026982068

Number O 0 0.0038013763
and O 0 0.0014727488
total O 0 0.0011248806
anionic O 0 0.024529122
site O 0 0.00047689304
surface O 0 0.00052642816
in O 0 0.00020561964
the O 0 0.00015320568
remaining O 0 0.00015114696
part O 0 8.986501e-05
of O 0 0.0001442461
the O 0 0.00017390575
glomerular O 0 0.91084766
basement O 0 0.099076726
membrane O 0 0.000634356
( O 0 0.00024212338
lamina O 0 0.00038348074
densa O 0 0.0009603542
and O 0 0.00018554532
lamina O 0 0.00058355427
rara O 0 0.012131537
interna O 0 0.017326152
) O 0 0.0005140599
were O 0 0.00028595573
not O 0 0.00035699716
significantly O 0 0.0009316972
changed O 0 0.0015060576
. O 0 0.0021602726

We O 0 0.0013412896
conclude O 0 0.0008001739
that O 0 0.00073569274
in O 0 0.0015734688
streptozotocin B-Chemical 0 0.9999777
- O 0 0.0370703
diabetic B-Disease 2 0.9997292
rats O 0 0.00050691684
with O 0 0.00014572618
an O 0 0.00012089126
increased O 0 0.00019364306
urinary O 0 0.12780145
albumin O 0 0.9952923
excretion O 0 0.95424235
, O 0 0.00020096239
a O 0 0.00015508303
reduced O 0 0.00037715115
heparan B-Chemical 0 0.9773587
sulphate I-Chemical 0 0.9996025
charge O 0 0.050195422
barrier O 0 0.0023083284
/ O 0 0.00050507876
density O 0 0.0003083469
is O 0 9.682045e-05
found O 0 6.5623084e-05
at O 0 5.71685e-05
the O 0 0.00012360254
lamina O 0 0.00053875975
rara O 0 0.014634747
externa O 0 0.055616133
of O 0 0.000490555
the O 0 0.0006329317
glomerular O 0 0.9762463
basement O 0 0.34149688
membrane O 0 0.0051451093
. O 0 0.0022366259

Mediation O 0 0.017528927
of O 0 0.0023428204
enhanced O 0 0.0021250085
reflex O 0 0.14099999
vagal O 0 0.46452355
bradycardia B-Disease 0 0.998254
by O 0 0.0021930197
L B-Chemical 1 0.989335
- I-Chemical 1 0.005001077
dopa I-Chemical 1 0.99991894
via O 0 0.00036167624
central O 0 0.0009875534
dopamine B-Chemical 0 0.9986551
formation O 0 0.0024289503
in O 0 0.0009843132
dogs O 0 0.002347574
. O 0 0.0021383436

L B-Chemical 0 0.979183
- I-Chemical 0 0.017713526
Dopa I-Chemical 0 0.99857974
( O 0 0.00211177
5 O 0 0.00061094656
mg O 0 0.0057963347
/ O 0 0.0013020376
kg O 0 0.0008959869
i O 0 0.0006069671
. O 0 0.00017370474
v O 0 0.0008355901
. O 0 0.00012461486
) O 0 0.00020651144
decreased O 0 0.000259381
blood O 0 0.0011118111
pressure O 0 0.0011784773
and O 0 0.00011551769
heart O 0 0.0018698766
rate O 0 8.9915855e-05
after O 0 3.9451577e-05
extracerebral O 0 0.24566971
decarboxylase O 0 0.25096142
inhibition O 0 0.00062458514
with O 0 0.0004451885
MK B-Chemical 0 0.9927557
- I-Chemical 0 0.0008942368
486 I-Chemical 0 0.056380343
( O 0 0.00016244307
25 O 0 0.00013472376
mg O 0 0.0016505882
/ O 0 0.0003678537
kg O 0 0.00028588102
i O 0 0.00026238334
. O 0 8.5346335e-05
v O 0 0.00054784707
. O 0 0.0001083031
) O 0 0.00025697533
in O 0 0.00027864132
anesthetize O 0 0.05967222
MAO B-Chemical 0 0.9999931
- O 0 0.0032283005
inhibited O 0 0.0030163273
dogs O 0 0.0039032346
. O 0 0.002414695

In O 0 0.0016879627
addition O 0 0.0010461016
, O 0 0.0015783393
reflex O 0 0.136529
bradycardia B-Disease 0 0.9948685
caused O 0 0.0008189034
by O 0 0.00039314755
injected O 0 0.0004785948
norepinephrine B-Chemical 1 0.99968886
was O 0 0.00025658825
significantly O 0 0.00019017255
enhanced O 0 0.0002450153
by O 0 0.00037103138
L B-Chemical 1 0.9896422
- I-Chemical 1 0.007212393
dopa I-Chemical 1 0.99999046
, O 0 0.0009551443
DL B-Chemical 0 0.8893119
- I-Chemical 0 0.0007194449
Threo I-Chemical 0 0.013633357
- I-Chemical 0 0.00044075283
dihydroxyphenylserine I-Chemical 0 0.09825409
had O 0 9.012246e-05
no O 0 3.7670416e-05
effect O 0 5.6293567e-05
on O 0 5.35869e-05
blood O 0 0.0012904801
pressure O 0 0.002270689
, O 0 0.00018362375
heart O 0 0.003320051
rate O 0 0.00019255439
or O 0 0.000198371
reflex O 0 0.0072870455
responses O 0 0.000662074
to O 0 0.0011356032
norepinephrine B-Chemical 1 0.99878246
. O 0 0.0026411302

FLA B-Chemical 0 0.9171375
- I-Chemical 0 0.0053306404
63 I-Chemical 0 0.002201356
, O 0 0.0012473345
a O 0 0.001766585
dopamine B-Chemical 0 0.99976236
- O 0 0.0075600697
beta O 0 0.9874981
- O 0 0.011392688
oxidase O 0 0.99986327
inhibitor O 0 0.021307606
, O 0 0.00032872494
did O 0 0.00015658885
not O 0 8.5249536e-05
have O 0 5.349806e-05
any O 0 4.7519865e-05
effect O 0 5.530139e-05
on O 0 4.819641e-05
the O 0 0.00017930166
hypotension B-Disease 0 0.99984205
, O 0 0.0005279366
bradycardia B-Disease 0 0.9936287
or O 0 0.00024080649
reflex O 0 0.046964277
- O 0 0.00035055488
enhancing O 0 0.00021270028
effect O 0 0.00032339824
of O 0 0.0016041718
L B-Chemical 1 0.9881308
- I-Chemical 1 0.025381092
dopa I-Chemical 1 0.9998989
. O 0 0.0042420765

Pimozide B-Chemical 0 0.9997546
did O 0 0.00243951
not O 0 0.0007177674
affect O 0 0.00029967376
the O 0 0.00033958443
actions O 0 0.0007780645
of O 0 0.0010188078
L B-Chemical 1 0.9916583
- I-Chemical 1 0.0049689226
dopa I-Chemical 1 0.9999635
on O 0 0.0001520394
blood O 0 0.0019807506
pressure O 0 0.0017714368
and O 0 0.00016498897
heart O 0 0.005089297
rate O 0 0.00018601154
but O 0 0.00016701405
completely O 0 0.00022436243
blocked O 0 0.0004909697
the O 0 0.0003588425
enhancement O 0 0.0012280506
of O 0 0.0020146472
reflexes O 0 0.44032377
. O 0 0.0027082977

Removal O 0 0.004757683
of O 0 0.0016498803
the O 0 0.0011554455
carotid O 0 0.12024846
sinuses O 0 0.0035849428
caused O 0 0.0004681138
an O 0 0.00048069019
elevation O 0 0.016082859
blood O 0 0.0063010645
pressure O 0 0.0034441033
and O 0 0.00021093313
heart O 0 0.005281965
rate O 0 0.00016994253
and O 0 0.00013367049
abolished O 0 0.00024467567
the O 0 0.00016427065
negative O 0 0.00044500772
chronotropic O 0 0.66025925
effect O 0 0.0007135596
of O 0 0.0033189147
norepinephrine B-Chemical 1 0.9994294
. O 0 0.002839887

However O 0 0.0036770413
, O 0 0.0046217595
L B-Chemical 1 0.96823466
- I-Chemical 1 0.010258483
dopa I-Chemical 1 0.9998933
restored O 0 0.001581524
the O 0 0.00065052434
bradycardia B-Disease 0 0.9907231
caused O 0 0.0005872541
by O 0 0.00056481035
norepinephrine B-Chemical 1 0.9994542
in O 0 0.00014416716
addition O 0 8.8699824e-05
to O 0 0.0001294094
decreasing O 0 0.0003401588
blood O 0 0.0031929365
pressure O 0 0.004239622
and O 0 0.00067943026
heart O 0 0.03260411
rate O 0 0.0019273325
. O 0 0.002028362

5 B-Chemical 0 0.0035514678
- I-Chemical 0 0.0046274024
HTP I-Chemical 0 0.06348795
( O 0 0.0014858652
5 O 0 0.00056446326
mg O 0 0.00489062
/ O 0 0.0013144704
kg O 0 0.00093791675
i O 0 0.00064180436
. O 0 0.00018722616
v O 0 0.00088600407
. O 0 0.0001368941
) O 0 0.00023071648
decreased O 0 0.00029880423
blood O 0 0.0013327656
pressure O 0 0.0015074665
and O 0 0.00016126323
heart O 0 0.0032921687
rate O 0 0.00016109156
and O 0 0.00014285582
decreased O 0 0.00032431647
the O 0 0.0002930947
reflex O 0 0.13831912
bradycardia B-Disease 0 0.9976228
to O 0 0.0021574877
norepinephrine B-Chemical 1 0.9991968
. O 0 0.0026575522

It O 0 0.002976334
is O 0 0.0014625004
concluded O 0 0.0009167062
that O 0 0.0010548836
L B-Chemical 1 0.9729892
- I-Chemical 1 0.006725377
dopa I-Chemical 1 0.99991727
enhances O 0 0.00064838765
reflex O 0 0.2918201
bradycardia B-Disease 0 0.9928428
through O 0 0.0003221062
central O 0 0.00077789614
alpha O 0 0.4130376
- O 0 0.001956086
receptor O 0 0.008999885
stimulation O 0 0.0016331505
. O 0 0.0024828152

Furthermore O 0 0.0026730972
, O 0 0.0017773372
the O 0 0.00084198895
effects O 0 0.00074070884
are O 0 0.00041047976
mediated O 0 0.00022121634
through O 0 0.00028603588
dopamine B-Chemical 0 0.9981694
rather O 0 0.00021468068
than O 0 0.00023043466
norepinephrine B-Chemical 1 0.99869233
and O 0 0.00021131801
do O 0 0.00014159175
not O 0 0.00012271063
require O 0 0.00011762115
the O 0 0.00032123557
carotid O 0 0.101553895
sinus O 0 0.004468592
baroreceptors O 0 0.015170949
. O 0 0.0022220607

Microangiopathic B-Disease 0 0.98310316
hemolytic I-Disease 2 0.99995863
anemia I-Disease 2 0.99999034
complicating O 0 0.9816003
FK506 B-Chemical 0 0.9999788
( O 0 0.15323852
tacrolimus B-Chemical 0 0.99996626
) O 0 0.010289778
therapy O 0 0.0063845776
. O 0 0.0042944136

We O 0 0.0013203617
describe O 0 0.00093139545
3 O 0 0.0006952371
episodes O 0 0.0016154927
of O 0 0.0021446408
microangiopathic B-Disease 0 0.9999038
hemolytic I-Disease 2 0.99999905
anemia I-Disease 2 0.99999964
( O 0 0.41056818
MAHA B-Disease 2 0.9999676
) O 0 0.0010027045
in O 0 0.00016153995
2 O 0 0.000113185786
solid O 0 0.0008468965
organ O 0 0.0005086467
recipients O 0 0.000544767
under O 0 0.0003121685
FK506 B-Chemical 0 0.9999596
( O 0 0.006771454
tacrolimus B-Chemical 0 0.9999777
) O 0 0.003879583
therapy O 0 0.003077116
. O 0 0.0022828334

In O 0 0.0017356134
both O 0 0.0013305506
cases O 0 0.0011349142
, O 0 0.00080364465
discontinuation O 0 0.009952013
of O 0 0.0011072124
FK506 B-Chemical 0 0.99995816
and O 0 0.0004915331
treatment O 0 0.00021756059
with O 0 0.0002399077
plasma O 0 0.0043325634
exchange O 0 0.0003419891
, O 0 0.00011278544
fresh O 0 0.0002396464
frozen O 0 0.00041330757
plasma O 0 0.002831852
replacement O 0 0.0007334187
, O 0 0.00028037667
corticosteroids B-Chemical 1 0.9987288
, O 0 0.00088452536
aspirin B-Chemical 0 0.9999546
, O 0 0.00038576892
and O 0 0.00042753914
dipyridamole B-Chemical 0 0.99984205
led O 0 0.0005151326
to O 0 0.00039269435
resolution O 0 0.0073867384
of O 0 0.0041975877
MAHA B-Disease 2 0.9995832
. O 0 0.004139252

In O 0 0.0021024242
one O 0 0.0013732929
patient O 0 0.0014049921
, O 0 0.0011138072
reintroduction O 0 0.0014322052
of O 0 0.001521807
FK506 B-Chemical 0 0.99985397
led O 0 0.001412758
to O 0 0.0007137678
rapid O 0 0.002848843
recurrence O 0 0.20478055
of O 0 0.00660951
MAHA B-Disease 2 0.99950397
. O 0 0.00560584

FK506 B-Chemical 0 0.99967456
- O 0 0.01316595
associated O 0 0.003298093
MAHA B-Disease 2 0.9993375
is O 0 0.0012835058
probably O 0 0.0010866413
rare O 0 0.0018389664
but O 0 0.00048256468
physicians O 0 0.00052213774
must O 0 0.00013118533
be O 0 0.00019152588
aware O 0 0.0002494498
of O 0 0.0005037267
this O 0 0.0011069524
severe O 0 0.06980121
complication O 0 0.25526556
. O 0 0.0031820312

In O 0 0.0016728728
our O 0 0.001533596
experience O 0 0.0010403205
and O 0 0.00051885215
according O 0 0.0002239284
to O 0 0.00020601504
the O 0 0.00023210715
literature O 0 0.00052902073
, O 0 0.0005745156
FK506 B-Chemical 0 0.9999535
does O 0 0.00025026881
not O 0 0.00012439475
seem O 0 0.00010159399
to O 0 8.196198e-05
cross O 0 0.00021735283
- O 0 0.0002109496
react O 0 0.00022174319
with O 0 0.0006065551
cyclosporin B-Chemical 0 0.9999989
A I-Chemical 0 0.96572065
( O 0 0.002455226
CyA B-Chemical 0 0.99997973
) O 0 0.0005859893
, O 0 0.00016174247
an O 0 0.00022323856
immuno O 0 0.09539594
- O 0 0.00046325865
suppressive O 0 0.0010480807
drug O 0 0.011041824
already O 0 0.00026216934
known O 0 0.0004447355
to O 0 0.00048418515
induce O 0 0.0010494345
MAHA B-Disease 2 0.99934405
. O 0 0.0038283365

Effect O 0 0.0024172189
of O 0 0.001982201
some O 0 0.0015119346
anticancer O 0 0.053667676
drugs O 0 0.02163605
and O 0 0.0008598242
combined O 0 0.0011446074
chemotherapy O 0 0.00633772
on O 0 0.0013088706
renal B-Disease 0 0.9993918
toxicity I-Disease 2 0.99983764
. O 0 0.007528983

The O 0 0.0023940918
nephrotoxic B-Disease 2 0.9932429
action O 0 0.0023669254
of O 0 0.0013456553
anticancer O 0 0.17845538
drugs O 0 0.034594703
such O 0 0.000252339
as O 0 0.0003792067
nitrogranulogen B-Chemical 0 0.9926507
( O 0 0.00122569
NG B-Chemical 0 0.982495
) O 0 0.00058571884
, O 0 0.0004411017
methotrexate B-Chemical 0 0.99989367
( O 0 0.0023108886
MTX B-Chemical 1 0.9999734
) O 0 0.00059100264
, O 0 0.00016682177
5 B-Chemical 0 9.8141514e-05
- I-Chemical 0 0.00040296148
fluorouracil I-Chemical 0 0.9933385
( O 0 0.00022097264
5 B-Chemical 0 8.170961e-05
- I-Chemical 0 0.00024610633
FU I-Chemical 0 0.06054357
) O 0 0.00019721716
and O 0 0.00017960537
cyclophosphamide B-Chemical 0 0.99960333
( O 0 0.0013672429
CY B-Chemical 1 0.99991596
) O 0 0.00034393978
administered O 0 0.00011016066
alone O 0 7.956452e-05
or O 0 6.006213e-05
in O 0 7.054934e-05
combination O 0 0.00024272666
[ O 0 0.0015766766
MTX B-Chemical 1 0.9999553
+ O 0 0.00053573155
5 B-Chemical 0 9.44084e-05
- I-Chemical 0 0.00030131533
FU I-Chemical 0 0.15541257
+ O 0 0.00096142344
CY B-Chemical 1 0.99984694
( O 0 0.0010402898
CMF O 0 0.65719503
) O 0 0.0005058289
] O 0 0.0003631013
was O 0 0.00014120425
evaluated O 0 0.000107987544
in O 0 0.00014091589
experiments O 0 0.0001810122
on O 0 0.00029571966
Wistar O 0 0.002886899
rats O 0 0.0018934654
. O 0 0.0017713929

After O 0 0.0011274972
drug O 0 0.010561465
administration O 0 0.005103924
, O 0 0.0015483025
creatinine B-Chemical 1 0.99744475
concentrations O 0 0.0016040877
in O 0 0.00024755768
the O 0 0.00020622122
plasma O 0 0.001760923
and O 0 0.00014253442
in O 0 9.102355e-05
the O 0 0.00010597809
urine O 0 0.01033213
of O 0 0.00014724702
the O 0 0.00010571366
rats O 0 0.00017000998
were O 0 0.00010309209
determined O 0 0.000107136235
, O 0 0.00017364493
as O 0 0.00016821254
well O 0 0.00024673858
as O 0 0.00063671154
creatinine B-Chemical 1 0.9979976
clearance O 0 0.1368989
. O 0 0.0028202021

Histopathologic O 0 0.023226563
evaluation O 0 0.0027065831
of O 0 0.0024586641
the O 0 0.0021952083
kidneys O 0 0.014278617
was O 0 0.0024952674
also O 0 0.0022986422
performed O 0 0.003300458
. O 0 0.004643071

After O 0 0.0020789623
MTX B-Chemical 1 0.9993449
administration O 0 0.0071260054
a O 0 0.0012551311
significant O 0 0.000595931
increase O 0 0.00052823214
( O 0 0.0007086796
p O 0 0.00034409112
= O 0 0.00023827668
0 O 0 0.00012289341
. O 0 9.0484486e-05
0228 O 0 0.0004393317
) O 0 0.00014645586
in O 0 6.610703e-05
the O 0 9.344325e-05
plasma O 0 0.005695291
creatinine B-Chemical 1 0.9984882
concentration O 0 0.00066110113
and O 0 0.000150378
a O 0 0.00017442755
significant O 0 0.00014472695
( O 0 0.00022967679
p O 0 0.00013358511
= O 0 0.00011725172
0 O 0 7.45155e-05
. O 0 7.462957e-05
0001 O 0 0.00097641227
) O 0 0.00014595396
decrease O 0 0.00012650932
in O 0 0.00015951187
creatinine B-Chemical 1 0.99525106
clearance O 0 0.00941082
was O 0 0.0002885063
noted O 0 0.00017466856
compared O 0 0.00023534395
to O 0 0.00054411526
controls O 0 0.0020504023
. O 0 0.0019948466

After O 0 0.0009649374
the O 0 0.00125407
administration O 0 0.0027723825
of O 0 0.001896725
NG B-Chemical 0 0.96919435
, O 0 0.0007217198
5 B-Chemical 0 0.00029090763
- I-Chemical 0 0.000649645
FU I-Chemical 0 0.14023171
and O 0 0.00047310014
CY B-Chemical 1 0.99972385
neither O 0 0.00031411884
a O 0 0.0002668389
statistically O 0 0.00012327227
significant O 0 7.7146105e-05
increase O 0 8.325045e-05
in O 0 0.00012811602
creatinine B-Chemical 1 0.9982962
concentration O 0 0.00052868575
nor O 0 8.533168e-05
an O 0 9.517384e-05
increase O 0 8.0609716e-05
in O 0 0.0001225336
creatinine B-Chemical 1 0.99873775
clearance O 0 0.01683754
was O 0 0.00013221812
observed O 0 6.318489e-05
compared O 0 5.0673316e-05
to O 0 7.8589575e-05
the O 0 0.00013992704
group O 0 0.00030089475
receiving O 0 0.00057402626
no O 0 0.0006118081
cytostatics O 0 0.80931324
. O 0 0.0027142493

Following O 0 0.0019009598
polytherapy O 0 0.8368328
according O 0 0.00054411264
to O 0 0.00040614526
the O 0 0.00051981147
CMF O 0 0.81960684
regimen O 0 0.0017107356
, O 0 0.00033452373
a O 0 0.00028961748
statistically O 0 0.00018829857
significant O 0 0.00015369541
decrease O 0 0.00028368508
( O 0 0.0003326471
p O 0 0.0001662214
= O 0 0.00012821806
0 O 0 7.068704e-05
. O 0 5.816205e-05
0343 O 0 0.0004647085
) O 0 0.0001377636
in O 0 0.00010346644
creatinine B-Chemical 1 0.9950577
clearance O 0 0.012601528
was O 0 0.00016596881
found O 0 8.971175e-05
, O 0 0.00012731783
but O 0 0.00019297052
creatinine B-Chemical 1 0.99816114
concentration O 0 0.0006902032
did O 0 0.00018228925
not O 0 0.00012328356
increase O 0 0.00017827161
significantly O 0 0.0003259814
compared O 0 0.00024250342
to O 0 0.00053570647
controls O 0 0.0020462146
. O 0 0.0019026261

CY B-Chemical 1 0.99881387
caused O 0 0.011063048
hemorrhagic B-Disease 2 0.99965763
cystitis I-Disease 0 0.9997993
in O 0 0.0010459532
40 O 0 0.00049440644
% O 0 0.00027584605
of O 0 0.00026945348
rats O 0 0.00039081578
, O 0 0.00021408832
but O 0 0.00015985384
it O 0 0.00012766565
did O 0 0.000121117635
not O 0 9.144681e-05
cause O 0 0.0001617943
this O 0 0.00016819683
complication O 0 0.0017181032
when O 0 7.55113e-05
combined O 0 0.00019901244
with O 0 0.00024312155
5 B-Chemical 0 0.0002123222
- I-Chemical 0 0.0007766896
FU I-Chemical 0 0.11911226
and O 0 0.0021379162
MTX B-Chemical 1 0.99960834
. O 0 0.0035860464

Histologic O 0 0.008925576
changes O 0 0.0016919845
were O 0 0.00080191856
found O 0 0.00042544535
in O 0 0.0003277286
rat O 0 0.0005846031
kidneys O 0 0.0021871761
after O 0 7.544595e-05
administration O 0 0.000681297
of O 0 0.0008324216
MTX B-Chemical 1 0.9999815
, O 0 0.0014330646
CY B-Chemical 1 0.9999361
and O 0 0.0009555316
NG B-Chemical 0 0.9896371
, O 0 0.00019131873
while O 0 8.021511e-05
no O 0 4.1787975e-05
such O 0 4.539198e-05
change O 0 7.5483724e-05
was O 0 7.1908325e-05
observed O 0 4.3807046e-05
after O 0 2.4860881e-05
5 B-Chemical 0 5.3527558e-05
- I-Chemical 0 0.00018026229
FU I-Chemical 0 0.022005234
and O 0 0.00010310527
joint O 0 0.0013159387
administration O 0 0.00082247256
of O 0 0.0006968669
MTX B-Chemical 1 0.9999697
+ O 0 0.0007567068
5 B-Chemical 0 0.00014213135
- I-Chemical 0 0.0004738482
FU I-Chemical 0 0.15760683
+ O 0 0.0013469632
CY B-Chemical 1 0.9987556
compared O 0 0.00047248026
to O 0 0.0007587944
controls O 0 0.002467585
. O 0 0.002162322

Our O 0 0.0019865958
studies O 0 0.001237362
indicate O 0 0.00055277173
that O 0 0.0007799738
nephrotoxicity B-Disease 0 0.9999764
of O 0 0.022614365
MTX B-Chemical 1 0.9999777
+ O 0 0.0021883047
5 B-Chemical 0 0.00024113093
- I-Chemical 0 0.000614332
FU I-Chemical 0 0.21909146
+ O 0 0.0012397469
CY B-Chemical 1 0.99951553
administered O 0 0.00058055413
jointly O 0 0.0012887869
is O 0 0.00029160068
lower O 0 0.00038189907
than O 0 0.0002992592
in O 0 0.0006987399
monotherapy O 0 0.041106496
. O 0 0.0022052722

The O 0 0.0021946745
interpeduncular O 0 0.003906421
nucleus O 0 0.0009953097
regulates O 0 0.00043421309
nicotine B-Chemical 1 0.975156
' O 0 0.0010045915
s O 0 0.00052386505
effects O 0 0.00051432505
on O 0 0.0004118359
free O 0 0.0012125514
- O 0 0.0016774413
field O 0 0.0017377489
activity O 0 0.0022970943
. O 0 0.0033024945

Partial O 0 0.0049358327
lesions O 0 0.008661668
were O 0 0.0010882496
made O 0 0.0007443162
with O 0 0.0014608094
kainic B-Chemical 0 0.9998703
acid I-Chemical 0 0.954196
in O 0 0.00037218202
the O 0 0.00023613019
interpeduncular O 0 0.0007054183
nucleus O 0 0.0001243382
of O 0 0.00016264238
the O 0 0.00018799897
ventral O 0 0.000487584
midbrain O 0 0.007329558
of O 0 0.0007307912
the O 0 0.0009373574
rat O 0 0.0033128695
. O 0 0.0022113496

Compared O 0 0.0016929173
with O 0 0.0014829673
sham O 0 0.00091449346
- O 0 0.0012669849
operated O 0 0.0010501706
controls O 0 0.00075283827
, O 0 0.00046696467
lesions O 0 0.004930482
significantly O 0 0.0005558597
( O 0 0.0004292156
p O 0 0.00019285869
< O 0 0.00011615525
0 O 0 8.7157394e-05
. O 0 6.383048e-05
25 O 0 0.00013560092
) O 0 0.00015644814
blunted O 0 0.00055247836
the O 0 0.000105541025
early O 0 0.00019284654
( O 0 0.00014769996
< O 0 6.881751e-05
60 O 0 5.8849066e-05
min O 0 8.921601e-05
) O 0 0.00012244542
free O 0 0.00012563667
- O 0 0.0001827323
field O 0 0.00019963623
locomotor B-Disease 0 0.9476914
hypoactivity I-Disease 0 0.9999559
caused O 0 0.0004201775
by O 0 0.00038471824
nicotine B-Chemical 1 0.99956423
( O 0 0.00023974947
0 O 0 6.4526335e-05
. O 0 3.7259084e-05
5 O 0 4.6586258e-05
mg O 0 0.0010086221
kg O 0 0.00033771788
( O 0 0.00019644958
- O 0 0.00022367339
1 O 0 9.48087e-05
) O 0 0.00015716928
, O 0 0.000117025076
i O 0 0.00025463372
. O 0 8.082592e-05
m O 0 0.00038476387
. O 0 7.972636e-05
) O 0 0.00016305887
, O 0 9.754941e-05
enhanced O 0 0.00011720399
the O 0 8.737434e-05
later O 0 6.111646e-05
( O 0 0.00011436162
60 O 0 7.5471056e-05
- O 0 0.00011259159
120 O 0 6.79153e-05
min O 0 0.00013386221
) O 0 0.00037811126
nicotine B-Chemical 1 0.99797744
- O 0 0.00066517334
induced O 0 0.0006343101
hyperactivity B-Disease 2 0.999956
, O 0 0.00047204713
and O 0 0.0002812023
raised O 0 0.00052917656
spontaneous O 0 0.0028064034
nocturnal O 0 0.016129889
activity O 0 0.0014189902
. O 0 0.0019492222

Lesions O 0 0.011039108
reduced O 0 0.001969968
the O 0 0.00078246323
extent O 0 0.00044598934
of O 0 0.0005880517
immunohistological O 0 0.0020607833
staining O 0 0.0004401491
for O 0 0.0003751241
choline B-Chemical 1 0.9998416
acetyltransferase O 0 0.8296556
in O 0 0.00015408162
the O 0 0.00012321139
interpeduncular O 0 0.0005800331
nucleus O 0 0.00010082182
( O 0 0.00015790745
p O 0 0.00010175579
< O 0 7.9195874e-05
0 O 0 7.427812e-05
. O 0 7.4960364e-05
025 O 0 0.003319476
) O 0 0.00023485506
, O 0 0.00012772458
but O 0 0.00010440191
not O 0 9.4618124e-05
for O 0 0.00014414464
tyrosine B-Chemical 0 0.57711
hydroxylase O 0 0.98801965
in O 0 0.00022877306
the O 0 0.00024034042
surrounding O 0 0.00048015028
catecholaminergic O 0 0.059412975
A10 O 0 0.13369934
region O 0 0.0014973462
. O 0 0.0019369434

We O 0 0.0013333802
conclude O 0 0.0007211355
that O 0 0.00050961925
the O 0 0.0005425039
interpeduncular O 0 0.0013563809
nucleus O 0 0.00027490954
mediates O 0 0.00020061224
nicotinic O 0 0.9997416
depression B-Disease 0 0.98633784
of O 0 0.00041121116
locomotor O 0 0.029030932
activity O 0 0.00013529934
and O 0 0.00013984168
dampens O 0 0.00031049328
nicotinic O 0 0.9996402
arousal O 0 0.015391955
mechanisms O 0 0.00023949951
located O 0 0.00016532488
elsewhere O 0 0.0002585176
in O 0 0.00033021314
the O 0 0.0006934042
brain O 0 0.007062013
. O 0 0.0022212828

Lithium B-Chemical 0 0.9994875
- O 0 0.0056600156
associated O 0 0.0011166384
cognitive B-Disease 0 0.08568247
and I-Disease 0 0.00062795397
functional I-Disease 0 0.0005430935
deficits I-Disease 0 0.040635884
reduced O 0 0.00056152744
by O 0 0.00022370923
a O 0 0.00022370795
switch O 0 0.00021280615
to O 0 0.00039646085
divalproex B-Chemical 0 0.99996674
sodium I-Chemical 0 0.99979776
: O 0 0.0012996317
a O 0 0.0009774793
case O 0 0.0010689654
series O 0 0.0023645181
. O 0 0.0022673274

BACKGROUND O 0 0.013199559
: O 0 0.0051142536
Lithium B-Chemical 0 0.99926287
remains O 0 0.0009267304
a O 0 0.0007016122
first O 0 0.00030638414
- O 0 0.00065047294
line O 0 0.0003500062
treatment O 0 0.00018290208
for O 0 0.00012826869
the O 0 0.00022167873
acute O 0 0.04864904
and O 0 0.00029572728
maintenance O 0 0.00042778475
treatment O 0 0.00041502228
of O 0 0.0014937089
bipolar B-Disease 2 0.9993855
disorder I-Disease 0 0.98023623
. O 0 0.0027764565

Although O 0 0.0018517165
much O 0 0.0013999095
has O 0 0.0007190062
been O 0 0.00045263176
written O 0 0.0006022933
about O 0 0.0002463371
the O 0 0.00018454035
management O 0 0.0001700197
of O 0 0.0001554136
the O 0 0.000103777675
more O 0 0.00013564515
common O 0 0.00012356011
adverse O 0 0.004336914
effects O 0 0.00015722204
of O 0 0.00047769514
lithium B-Chemical 0 0.99996436
, O 0 0.00020642146
such O 0 6.4166816e-05
as O 0 0.00012686472
polyuria B-Disease 0 0.9983557
and O 0 0.00045754592
tremor B-Disease 0 0.9999064
, O 0 0.00014567327
more O 0 0.00013117107
subtle O 0 0.00038316593
lithium B-Chemical 0 0.9999356
side O 0 0.008473208
effects O 0 0.00012272605
such O 0 6.8387446e-05
as O 0 0.00014363657
cognitive B-Disease 2 0.9789396
deficits I-Disease 2 0.9848018
, O 0 0.0003848299
loss B-Disease 0 0.0038570233
of I-Disease 0 0.00045864287
creativity I-Disease 0 0.34231263
, O 0 0.0003350344
and O 0 0.00030036713
functional B-Disease 0 0.0014066951
impairments I-Disease 0 0.64655393
remain O 0 0.0011411529
understudied O 0 0.004032022
. O 0 0.0019748753

This O 0 0.002952148
report O 0 0.0015076129
summarizes O 0 0.00061206904
our O 0 0.0005614851
experience O 0 0.0004021157
in O 0 0.00021919383
switching O 0 0.00037394406
bipolar B-Disease 2 0.994041
patients O 0 0.00032929584
from O 0 0.0001635071
lithium B-Chemical 0 0.9998727
to O 0 0.00057946425
divalproex B-Chemical 0 0.999987
sodium I-Chemical 0 0.9998258
to O 0 0.00023220967
alleviate O 0 0.00037468452
such O 0 0.00020786426
cognitive B-Disease 0 0.091306075
and I-Disease 0 0.00071709836
functional I-Disease 0 0.003945362
impairments I-Disease 0 0.90656495
. O 0 0.0029774066

METHOD O 0 0.014845597
: O 0 0.0071440944
Open O 0 0.007386508
, O 0 0.0051801205
case O 0 0.0045622597
series O 0 0.0068924115
design O 0 0.009052517
. O 0 0.008565418

RESULTS O 0 0.004602998
: O 0 0.0016874679
We O 0 0.000585962
report O 0 0.00077559205
seven O 0 0.00037405727
cases O 0 0.0003616307
where O 0 0.0002227128
substitution O 0 0.0070361067
of O 0 0.0008906178
lithium B-Chemical 0 0.9999529
, O 0 0.0003230254
either O 0 0.0001147332
fully O 0 0.000104546176
or O 0 6.2487066e-05
partially O 0 0.00013650829
, O 0 0.00011920395
with O 0 0.00038030036
divalproex B-Chemical 0 0.9999882
sodium I-Chemical 0 0.9999161
was O 0 0.0002314707
extremely O 0 0.00030211385
helpful O 0 8.437752e-05
in O 0 5.5051198e-05
reducing O 0 8.1712176e-05
the O 0 0.000102705584
cognitive B-Disease 0 0.09581197
, I-Disease 0 0.00015500291
motivational I-Disease 0 0.00046340397
, I-Disease 0 0.00013319553
or I-Disease 0 9.5911615e-05
creative I-Disease 0 0.00076701824
deficits I-Disease 0 0.04387948
attributed O 0 0.00012783022
to O 0 0.00023806117
lithium B-Chemical 0 0.9997893
in O 0 0.00046730353
our O 0 0.0013871487
bipolar B-Disease 2 0.99824417
patients O 0 0.0036094582
. O 0 0.0018597073

CONCLUSION O 0 0.015477279
: O 0 0.0017068684
In O 0 0.0005191364
this O 0 0.00051211874
preliminary O 0 0.0007415309
report O 0 0.00086517516
, O 0 0.0011380049
divalproex B-Chemical 0 0.99998105
sodium I-Chemical 0 0.99991345
was O 0 0.00034591704
a O 0 0.0001464845
superior O 0 0.00013061937
alternative O 0 6.2452156e-05
to O 0 0.0001056123
lithium B-Chemical 0 0.999801
in O 0 0.00024248887
bipolar B-Disease 2 0.9981406
patients O 0 0.00032531357
experiencing O 0 0.0020027286
cognitive B-Disease 2 0.9928564
deficits I-Disease 2 0.98903954
, O 0 0.00046037545
loss B-Disease 0 0.004770783
of I-Disease 0 0.0006096465
creativity I-Disease 0 0.3811906
, O 0 0.00058636756
and O 0 0.000628651
functional B-Disease 0 0.0036009038
impairments I-Disease 0 0.8986729
. O 0 0.0030342215

Effect O 0 0.0026406592
of O 0 0.0040713516
nifedipine B-Chemical 1 0.9999149
on O 0 0.0011809096
renal O 0 0.741032
function O 0 0.0009589023
in O 0 0.0006538174
liver O 0 0.58700824
transplant O 0 0.0680091
recipients O 0 0.008077626
receiving O 0 0.01068881
tacrolimus B-Chemical 0 0.99993134
. O 0 0.004422143

The O 0 0.001433055
effect O 0 0.001228026
of O 0 0.0023710886
nifedipine B-Chemical 1 0.9999615
on O 0 0.00063166954
renal O 0 0.7682324
function O 0 0.00046680044
in O 0 0.000251228
liver O 0 0.48561394
transplant O 0 0.013663427
recipients O 0 0.00067340286
who O 0 0.00020806948
were O 0 0.000102205864
receiving O 0 0.00037528435
tacrolimus B-Chemical 0 0.99997616
was O 0 0.00020044224
evaluated O 0 9.352401e-05
between O 0 8.1642786e-05
January O 0 0.00014116617
1992 O 0 0.00047299505
and O 0 0.0003751361
January O 0 0.0005251772
1996 O 0 0.001954528
. O 0 0.001755479

Two O 0 0.0018085539
groups O 0 0.0010415353
of O 0 0.0008349001
patients O 0 0.0009095324
receiving O 0 0.001669999
tacrolimus B-Chemical 0 0.9999651
were O 0 0.00031365652
compared O 0 8.286599e-05
over O 0 4.46507e-05
a O 0 8.790227e-05
period O 0 3.8068203e-05
of O 0 9.290314e-05
1 O 0 6.5921515e-05
year O 0 4.2472908e-05
, O 0 5.764923e-05
one O 0 3.711015e-05
group O 0 7.2922594e-05
comprising O 0 9.46147e-05
hypertensive B-Disease 2 0.99829525
patients O 0 0.00018921842
who O 0 0.000119984434
were O 0 7.530513e-05
receiving O 0 0.00039397445
nifedipine B-Chemical 1 0.99999356
, O 0 0.00019344562
and O 0 8.682558e-05
the O 0 7.1311486e-05
other O 0 8.1319944e-05
comprising O 0 0.00017801835
nonhypertensive O 0 0.9852716
patients O 0 0.0004365476
not O 0 0.00038438258
receiving O 0 0.0034030084
nifedipine B-Chemical 1 0.99994206
. O 0 0.003276084

The O 0 0.001645867
time O 0 0.0009530049
from O 0 0.0009535708
transplant O 0 0.0033316305
to O 0 0.00069525064
baseline O 0 0.0006232597
was O 0 0.0006528934
similar O 0 0.00046679244
in O 0 0.0007954066
all O 0 0.0013522897
patients O 0 0.0030469408
. O 0 0.0030250957

Nifedipine B-Chemical 0 0.9996456
significantly O 0 0.0039350125
improved O 0 0.0032051348
kidney O 0 0.49103376
function O 0 0.00070329313
as O 0 0.0002840683
indicated O 0 0.00016261557
by O 0 0.00016807579
a O 0 0.00018937276
significant O 0 0.00014432769
lowering O 0 0.0016167853
of O 0 0.0003341323
serum O 0 0.19035128
creatinine B-Chemical 1 0.99935955
levels O 0 0.00034269848
at O 0 0.00016864215
6 O 0 0.00016862863
and O 0 0.00030607497
12 O 0 0.00034916037
months O 0 0.00049875164
. O 0 0.0014764012

The O 0 0.0014346254
observed O 0 0.00089249894
positive O 0 0.0006663828
impact O 0 0.0003343337
of O 0 0.0011233343
nifedipine B-Chemical 1 0.99998045
on O 0 0.00021654858
reducing O 0 0.00031354767
the O 0 0.00042903787
nephrotoxicity B-Disease 0 0.99999416
associated O 0 0.00037991317
with O 0 0.00090540084
tacrolimus B-Chemical 0 0.99999404
in O 0 0.00034244193
liver O 0 0.86102295
transplant O 0 0.035582263
recipients O 0 0.0005030243
should O 0 3.547625e-05
be O 0 4.0062165e-05
an O 0 4.934786e-05
important O 0 2.9553768e-05
factor O 0 0.00018931789
in O 0 6.363648e-05
selecting O 0 7.5762524e-05
an O 0 0.00014427405
agent O 0 0.00063300866
to O 0 0.00020685868
treat O 0 0.0016120633
hypertension B-Disease 2 0.99991465
in O 0 0.0006253148
this O 0 0.0010442048
population O 0 0.0024843817
. O 0 0.0018769152

Alpha O 0 0.04727661
and O 0 0.0049301023
beta O 0 0.96000344
coma B-Disease 0 0.9982407
in O 0 0.0019498641
drug O 0 0.20734327
intoxication O 0 0.998538
uncomplicated O 0 0.06823569
by O 0 0.003375714
cerebral B-Disease 0 0.9984314
hypoxia I-Disease 2 0.999258
. O 0 0.005940892

Four O 0 0.0023919994
patients O 0 0.0017665109
who O 0 0.0011486685
were O 0 0.0005265953
rendered O 0 0.000873525
comatose B-Disease 0 0.7381771
or O 0 0.0005249354
stuporous B-Disease 0 0.9902457
by O 0 0.00043295493
drug O 0 0.12623033
intoxication O 0 0.9987148
, O 0 0.000430404
but O 0 0.00023304118
who O 0 0.00028074312
were O 0 0.00017271939
not O 0 0.00023579183
hypoxic O 0 0.39463496
, O 0 0.00077299
are O 0 0.0007128092
described O 0 0.0010935111
. O 0 0.0018655246

Three O 0 0.0018461117
patients O 0 0.0012795366
received O 0 0.0005225968
high O 0 0.00072530383
doses O 0 0.002413889
of O 0 0.0015383784
chlormethiazole B-Chemical 0 0.99999726
for O 0 0.00082683255
alcohol B-Chemical 0 0.99993825
withdrawal B-Disease 0 0.9874622
symptoms I-Disease 0 0.7968857
, O 0 0.00025179895
and O 0 0.00013266935
one O 0 9.261981e-05
took O 0 0.00014565256
a O 0 0.0006856047
suicidal O 0 0.999482
overdose B-Disease 0 0.999948
of O 0 0.103552364
nitrazepam B-Chemical 0 0.99999547
. O 0 0.004828376

The O 0 0.0014481607
patient O 0 0.0017057671
with O 0 0.004700484
nitrazepam B-Chemical 0 0.9999987
overdose B-Disease 0 0.9999405
and O 0 0.00050470553
two O 0 0.00010873598
of O 0 0.00014701791
those O 0 0.00018981547
with O 0 0.0005582408
chlormethiazole B-Chemical 0 0.9999989
intoxication O 0 0.99956685
conformed O 0 0.0004041951
to O 0 5.3010684e-05
the O 0 4.950123e-05
criteria O 0 6.796933e-05
of O 0 0.00010606585
' O 0 0.00026096578
alpha O 0 0.8830188
coma B-Disease 0 0.99980897
' O 0 0.0003682679
, O 0 0.00013388225
showing O 0 0.000116011346
non O 0 0.00018424216
- O 0 0.00025300507
reactive O 0 0.0012261531
generalized O 0 0.00070656615
or O 0 0.00014282734
frontally O 0 0.012816695
predominant O 0 0.00026137117
alpha O 0 0.079889864
activity O 0 0.00033015778
in O 0 0.0004078065
the O 0 0.0008737259
EEG O 0 0.14627855
. O 0 0.0022419847

The O 0 0.0016142774
fourth O 0 0.0020769166
patient O 0 0.0011041989
who O 0 0.00092430273
was O 0 0.00048797595
unconscious O 0 0.0023362383
after O 0 0.00025466262
chlormethiazole B-Chemical 0 0.99999547
administration O 0 0.033026606
exhibite O 0 0.20421398
generalized O 0 0.0038508063
non O 0 0.0005532984
- O 0 0.0004625555
reactive O 0 0.0014292477
activity O 0 0.00019873638
in O 0 0.00020631799
the O 0 0.00034328885
slow O 0 0.0021563165
beta O 0 0.6111604
range O 0 0.0022387828
. O 0 0.0022471373

All O 0 0.0014842291
four O 0 0.00071972393
recovered O 0 0.0007160112
completely O 0 0.00084686984
without O 0 0.000859916
neurological B-Disease 0 0.9951249
sequelae I-Disease 0 0.3951978
following O 0 0.00033765304
the O 0 0.0004123517
withdrawal O 0 0.0040031765
of O 0 0.00066922186
the O 0 0.0007848985
offending O 0 0.007998812
agents O 0 0.008343452
. O 0 0.0029016465

The O 0 0.0014218726
similarities O 0 0.0008501937
between O 0 0.00044508008
the O 0 0.00042138988
effects O 0 0.00041332393
of O 0 0.00045212492
structural O 0 0.0006880734
lesions O 0 0.0049585947
and O 0 0.00032379592
pharmacological O 0 0.01618209
depression B-Disease 0 0.950352
of O 0 0.00029520865
the O 0 0.00020799253
brain O 0 0.0017236901
stem O 0 0.0040891687
reticular O 0 0.0018783244
formation O 0 0.0013548357
are O 0 0.00072660245
discussed O 0 0.0012377399
. O 0 0.00197446

It O 0 0.002881015
is O 0 0.0013271263
suggested O 0 0.0005843507
that O 0 0.00038389387
in O 0 0.0003561959
both O 0 0.00029496753
situations O 0 0.00029736504
disturbed O 0 0.0016941724
reticulo O 0 0.06083252
- O 0 0.00047991783
thalamic O 0 0.00075448543
interactions O 0 0.000157701
are O 0 9.0814945e-05
important O 0 6.2147206e-05
in O 0 0.0001263544
the O 0 0.00021502812
pathogenesis O 0 0.0008362464
of O 0 0.0014811701
alpha O 0 0.93566644
coma B-Disease 0 0.99960667
. O 0 0.0040494963

It O 0 0.0026182777
is O 0 0.0011373666
concluded O 0 0.0005395334
that O 0 0.00030554054
when O 0 0.00021094136
this O 0 0.0003198988
electroencephalographic O 0 0.017551664
and O 0 0.00021285893
behavioural O 0 0.00043546036
picture O 0 0.00020065259
is O 0 0.00010774573
seen O 0 8.960505e-05
in O 0 0.00011467666
drug O 0 0.056204468
intoxication O 0 0.9981401
, O 0 0.0002108718
in O 0 7.385674e-05
the O 0 6.3304185e-05
absence O 0 5.0904393e-05
of O 0 0.0001599209
significant O 0 0.0002816047
hypoxaemia B-Disease 0 0.9979824
, O 0 0.00032259268
a O 0 0.00028861855
favourable O 0 0.00045046562
outcome O 0 0.00032079488
may O 0 0.0003490527
be O 0 0.0005582189
anticipated O 0 0.0010739148
. O 0 0.0018255034

Magnetic O 0 0.02070916
resonance O 0 0.012374236
volumetry O 0 0.0054259542
of O 0 0.000979097
the O 0 0.00067677355
cerebellum O 0 0.0029122904
in O 0 0.00077295094
epileptic B-Disease 0 0.997216
patients O 0 0.0016320802
after O 0 0.00082809734
phenytoin B-Chemical 1 0.99997616
overdosages B-Disease 0 0.9976719
. O 0 0.0044364682

The O 0 0.0014935127
aim O 0 0.0013639318
of O 0 0.0010924018
this O 0 0.0007856955
study O 0 0.00060037844
was O 0 0.00029606634
to O 0 0.0001285051
evaluate O 0 6.1798586e-05
the O 0 7.8791585e-05
relationship O 0 4.791343e-05
between O 0 0.00010667201
phenytoin B-Chemical 1 0.9999951
medication O 0 0.02379602
and O 0 0.00031132263
cerebellar B-Disease 0 0.9933808
atrophy I-Disease 2 0.9999647
in O 0 0.00027826912
patients O 0 0.00031490598
who O 0 0.00028650503
had O 0 0.00024237097
experienced O 0 0.0006015819
clinical O 0 0.00411154
intoxication O 0 0.997767
. O 0 0.0031071422

Five O 0 0.0036275992
females O 0 0.0022488143
and O 0 0.0011074719
6 O 0 0.00057512213
males O 0 0.00087296165
, O 0 0.0004894543
21 O 0 0.0003787092
- O 0 0.00045114654
59 O 0 0.00027301325
years O 0 0.00012777465
of O 0 0.00016750558
age O 0 0.00017865127
, O 0 0.00013158748
were O 0 8.874415e-05
examined O 0 5.882377e-05
with O 0 0.0001244784
a O 0 0.00017278097
1 O 0 9.630883e-05
. O 0 6.3790205e-05
5 O 0 8.576756e-05
- O 0 0.0002940348
T O 0 0.057287894
whole O 0 0.00025844167
- O 0 0.00033251487
body O 0 0.00041929158
system O 0 0.00018519093
using O 0 0.00016587468
a O 0 0.000392934
circular O 0 0.0009769863
polarized O 0 0.0012544524
head O 0 0.007067197
coil O 0 0.0038082332
. O 0 0.0024334115

Conventional O 0 0.0044015525
spin O 0 0.0071195443
echo O 0 0.0033713852
images O 0 0.0011129046
were O 0 0.0006850408
acquired O 0 0.00078242074
in O 0 0.00049737585
the O 0 0.0006001902
sagittal O 0 0.0021586048
and O 0 0.0011854882
transverse O 0 0.0028318453
orientation O 0 0.002656898
. O 0 0.0035976886

In O 0 0.0018938765
addition O 0 0.001075217
, O 0 0.0010684838
we O 0 0.00034716405
performed O 0 0.00039019392
a O 0 0.0005034042
high O 0 0.0007181341
- O 0 0.0005899584
resolution O 0 0.0012803888
3D O 0 0.0006628831
gradient O 0 0.0004089647
echo O 0 0.001171659
, O 0 0.00027566176
T1 O 0 0.0018021178
- O 0 0.0002655686
weighted O 0 0.00012128682
sequences O 0 0.00013648212
at O 0 0.00012438264
a O 0 0.0003330529
1 O 0 0.000300805
- O 0 0.00062553294
mm O 0 0.0010341977
slice O 0 0.003301305
thickness O 0 0.010280176
. O 0 0.0027571565

The O 0 0.0017485246
images O 0 0.0016691356
were O 0 0.000981415
subsequently O 0 0.00069757225
processed O 0 0.00039517082
to O 0 0.00036943992
obtain O 0 0.00033681293
volumetric O 0 0.0011973126
data O 0 0.0007611267
for O 0 0.00073014665
the O 0 0.001548304
cerebellum O 0 0.014550647
. O 0 0.0036207903

Cerebellar O 0 0.025965387
volume O 0 0.0024425085
for O 0 0.0006218623
the O 0 0.00050020684
patient O 0 0.00042011554
group O 0 0.0003120248
ranged O 0 0.00018555098
between O 0 0.00011324776
67 O 0 0.00026856404
. O 0 9.566034e-05
66 O 0 0.00018036751
and O 0 0.00014502491
131 O 0 0.000383521
. O 0 0.00010663599
08 O 0 0.000755221
ml O 0 0.00038628667
( O 0 0.0002004801
mean O 0 0.0001072632
108 O 0 0.00037114896
. O 0 0.00024539942
9 O 0 0.0004670497
ml O 0 0.0017366797
) O 0 0.0023366562
. O 0 0.0024446005

In O 0 0.001451766
addition O 0 0.0007985507
3D O 0 0.001606004
gradient O 0 0.00094080315
echo O 0 0.0013735114
data O 0 0.00032759586
sets O 0 0.0001867455
from O 0 0.00012798878
10 O 0 0.00013471681
healthy O 0 0.00040658374
male O 0 0.00036527438
and O 0 0.00010445938
10 O 0 9.2881084e-05
healthy O 0 0.0004110675
female O 0 0.00045172794
age O 0 0.00014004917
- O 0 0.00015360457
matched O 0 7.4261545e-05
volunteers O 0 0.00014912502
were O 0 9.838682e-05
used O 0 0.0001058026
to O 0 0.00017040857
compare O 0 0.00020485643
cerebellar O 0 0.040160347
volumes O 0 0.0030712148
. O 0 0.0021534304

Using O 0 0.0015224245
linear O 0 0.0015327149
regression O 0 0.001305948
we O 0 0.00033095508
found O 0 0.00029350683
that O 0 0.00017163191
no O 0 0.00012262896
correlation O 0 0.000114131086
exists O 0 0.000106524814
between O 0 0.00010699361
seizure B-Disease 0 0.99376386
duration O 0 9.771437e-05
, O 0 0.00018130224
elevation O 0 0.006874262
of O 0 0.0011249096
phenytoin B-Chemical 1 0.9999958
serum O 0 0.29579917
levels O 0 0.000680903
and O 0 0.00084418856
cerebellar O 0 0.30227086
volume O 0 0.004590472
. O 0 0.002238759

However O 0 0.0024971196
, O 0 0.0016318363
multiple O 0 0.0008356005
regression O 0 0.0008359787
for O 0 0.0002574845
the O 0 0.00025787164
daily O 0 0.00038089702
dosage O 0 0.0029954438
, O 0 0.00015268635
duration O 0 5.950679e-05
of O 0 0.00033731922
phenytoin B-Chemical 1 0.99999404
treatment O 0 0.00027443215
and O 0 0.00017893052
cerebellar O 0 0.033987526
volume O 0 0.0003832867
revealed O 0 0.00014643687
a O 0 0.00020413479
correlation O 0 0.0001605406
of O 0 0.00041415673
these O 0 0.00084828
parameters O 0 0.0015291811
. O 0 0.0019443172

We O 0 0.0012250224
conclude O 0 0.0008686722
that O 0 0.001499405
phenytoin B-Chemical 1 0.9999937
overdosage B-Disease 0 0.9999646
does O 0 0.0005754462
not O 0 0.00020013785
necessarily O 0 0.00018075573
result O 0 0.00012072075
in O 0 0.00019284066
cerebellar B-Disease 0 0.9940561
atrophy I-Disease 2 0.9999814
and O 0 0.00034180985
it O 0 0.000115572766
is O 0 5.700307e-05
unlikely O 0 3.804998e-05
that O 0 9.737097e-05
phenytoin B-Chemical 1 0.99999714
medication O 0 0.012023245
was O 0 0.000104010396
the O 0 6.8464906e-05
only O 0 9.9288976e-05
cause O 0 0.00018598071
of O 0 0.0003938676
cerebellar B-Disease 0 0.9958853
atrophy I-Disease 2 0.9999466
in O 0 0.00043274157
the O 0 0.0003831192
remaining O 0 0.00077888864
patients O 0 0.0018141648
. O 0 0.0016966785

Quantitative O 0 0.0038272298
morphometric O 0 0.002543505
studies O 0 0.0009950375
of O 0 0.00076305185
the O 0 0.0005339318
cerebellum O 0 0.0016619096
provide O 0 0.00026178616
valuable O 0 0.00024403588
insights O 0 0.00023087404
into O 0 0.00012537363
the O 0 0.00030928553
pathogenesis O 0 0.0010498296
of O 0 0.001737108
cerebellar B-Disease 0 0.9934228
disorders I-Disease 0 0.99582386
. O 0 0.0042636553

Late O 0 0.009345144
recovery O 0 0.0032147465
of O 0 0.0020318795
renal O 0 0.48080546
function O 0 0.00097591145
in O 0 0.0005147616
a O 0 0.0006960113
woman O 0 0.0013574775
with O 0 0.000800579
the O 0 0.0019924492
hemolytic B-Disease 0 0.99997354
uremic I-Disease 0 0.99998164
syndrome I-Disease 0 0.99797374
. O 0 0.004884752

A O 0 0.020960541
case O 0 0.0019070503
is O 0 0.001124353
reported O 0 0.00078481995
of O 0 0.0008021269
the O 0 0.0014375268
hemolytic B-Disease 0 0.99998677
uremic I-Disease 0 0.99999535
syndrome I-Disease 0 0.9994642
( O 0 0.02216201
HUS B-Disease 0 0.9999871
) O 0 0.0009935322
in O 0 0.00026651702
a O 0 0.0005247399
woman O 0 0.0019251845
taking O 0 0.0026070669
oral B-Chemical 1 0.94273716
contraceptives I-Chemical 1 0.99954635
. O 0 0.0036568225

She O 0 0.0031928185
was O 0 0.0015192181
treated O 0 0.001174146
with O 0 0.0012946565
heparin B-Chemical 0 0.99622667
, O 0 0.00196783
dipyridamole B-Chemical 0 0.9999478
and O 0 0.0007925769
hemodialysis O 0 0.24898979
; O 0 0.00021462215
and O 0 8.50562e-05
after O 0 2.9066026e-05
more O 0 7.957096e-05
than O 0 3.867213e-05
three O 0 2.7055803e-05
months O 0 2.3175497e-05
, O 0 5.9309863e-05
her O 0 8.7891705e-05
urinary O 0 0.0032687369
output O 0 0.00011076274
rose O 0 0.0005956057
above O 0 8.527589e-05
500 O 0 0.00027345296
ml O 0 0.00031892344
; O 0 8.682053e-05
and O 0 5.3060605e-05
six O 0 2.6347036e-05
months O 0 1.694955e-05
after O 0 1.759133e-05
the O 0 5.5946297e-05
onset O 0 0.00014584504
of O 0 0.00033933957
anuria B-Disease 2 0.9899692
, O 0 0.0005209995
dialysis O 0 0.002898081
treatment O 0 0.0005279515
was O 0 0.00086877286
stopped O 0 0.0022114401
. O 0 0.0019941486

This O 0 0.003546343
case O 0 0.0012847087
emphasizes O 0 0.000817634
the O 0 0.0005580061
possibility O 0 0.00037572358
that O 0 0.0006477975
HUS B-Disease 0 0.99997616
in O 0 0.00062327157
adults O 0 0.00083880825
is O 0 0.00015330198
not O 0 0.00011864161
invariably O 0 0.0010575716
irreversible O 0 0.07905789
and O 0 0.00014360562
that O 0 7.252924e-05
, O 0 0.000109715125
despite O 0 8.35863e-05
prolonged O 0 0.0006515296
oliguria B-Disease 0 0.9997782
, O 0 0.00026490656
recovery O 0 0.00038208553
of O 0 0.000342864
renal O 0 0.7376509
function O 0 0.0005247396
can O 0 0.00034020824
be O 0 0.0005408263
obtained O 0 0.0011058294
. O 0 0.0017675909

Therefore O 0 0.0019111199
, O 0 0.0018063638
in O 0 0.00090920925
adult O 0 0.0011116788
patients O 0 0.00079750054
affected O 0 0.0006792402
by O 0 0.0010752047
HUS B-Disease 0 0.99998295
, O 0 0.0006191148
dialysis O 0 0.0014280403
should O 0 5.268095e-05
not O 0 6.558805e-05
be O 0 7.1155664e-05
discontinued O 0 0.00034585144
prematurely O 0 0.0011415597
; O 0 0.00014801987
moreover O 0 0.0004427843
, O 0 0.0001433562
bilateral O 0 0.0029806388
nephrectomy O 0 0.54226476
, O 0 0.00010020713
for O 0 4.132089e-05
treatment O 0 6.708635e-05
of O 0 0.00017049765
severe O 0 0.10719373
hypertension B-Disease 2 0.99999046
and O 0 0.005010109
microangiopathic B-Disease 0 0.99998367
hemolytic I-Disease 2 0.99999964
anemia I-Disease 2 0.99999964
, O 0 0.0017908409
should O 0 0.00015356093
be O 0 0.00020425748
performed O 0 0.00027515762
with O 0 0.000669124
caution O 0 0.0012373286
. O 0 0.0017436409

Morphological O 0 0.006543894
features O 0 0.0018739412
of O 0 0.0024092956
encephalopathy B-Disease 2 0.9993729
after O 0 0.00041149175
chronic O 0 0.055548858
administration O 0 0.0017632053
of O 0 0.0004398861
the O 0 0.0004993294
antiepileptic O 0 0.99733907
drug O 0 0.4960648
valproate B-Chemical 0 0.99994993
to O 0 0.0015196669
rats O 0 0.0029863536
. O 0 0.0021088626

A O 0 0.016314825
transmission O 0 0.0029969646
electron O 0 0.0062983064
microscopic O 0 0.0022930435
study O 0 0.000981977
of O 0 0.0009474688
capillaries O 0 0.003510796
in O 0 0.0007407985
the O 0 0.0011323165
cerebellar O 0 0.24265577
cortex O 0 0.0871723
. O 0 0.0038332501

Long O 0 0.007119662
- O 0 0.0024240466
term O 0 0.0008773891
intragastric O 0 0.040442362
application O 0 0.00042007517
of O 0 0.00031477632
the O 0 0.0003199561
antiepileptic O 0 0.9952597
drug O 0 0.5439232
sodium B-Chemical 0 0.99997544
valproate I-Chemical 0 0.99999654
( O 0 0.0020264199
Vupral O 0 0.4515637
" O 0 0.00044802015
Polfa O 0 0.509946
" O 0 0.00021792702
) O 0 0.00013718214
at O 0 4.8071277e-05
the O 0 7.135489e-05
effective O 0 8.438445e-05
dose O 0 0.0004119553
of O 0 0.0002972205
200 O 0 0.0010106306
mg O 0 0.015941892
/ O 0 0.0023082702
kg O 0 0.0023497627
b O 0 0.0029290998
. O 0 0.002116535

w O 0 0.0053914464
. O 0 0.0011428081
once O 0 0.00063297915
daily O 0 0.0006854979
to O 0 0.00035461155
rats O 0 0.00044818167
for O 0 0.0002012763
1 O 0 0.0002051422
, O 0 0.00021368879
3 O 0 0.00012395841
, O 0 0.00014757663
6 O 0 7.4839874e-05
, O 0 0.0001051314
9 O 0 6.5678556e-05
and O 0 6.346183e-05
12 O 0 3.7321923e-05
months O 0 2.9243052e-05
revealed O 0 0.00010698606
neurological B-Disease 0 0.9938567
disorders I-Disease 0 0.98635393
indicating O 0 0.00030057077
cerebellum B-Disease 0 0.70016026
damage I-Disease 0 0.98098695
( O 0 0.0011009806
" O 0 0.0017068832
valproate B-Chemical 0 0.9999839
encephalopathy B-Disease 2 0.9999566
" O 0 0.005446456
) O 0 0.0031573407
. O 0 0.0022384122

The O 0 0.0014464477
first O 0 0.0009019726
ultrastructural O 0 0.0022660217
changes O 0 0.0007319399
in O 0 0.00036158075
structural O 0 0.00041599968
elements O 0 0.00023919511
of O 0 0.00023318209
the O 0 0.00021650811
blood O 0 0.003271755
- O 0 0.0004879578
brain O 0 0.0019425026
- O 0 0.0004234187
barrier O 0 0.0009270943
( O 0 0.00037828073
BBB O 0 0.9679833
) O 0 0.00020161491
in O 0 6.99469e-05
the O 0 8.962445e-05
cerebellar O 0 0.01815747
cortex O 0 0.002473277
were O 0 0.000110659705
detectable O 0 7.950573e-05
after O 0 4.664098e-05
3 O 0 8.827168e-05
months O 0 7.2846975e-05
of O 0 0.00026915435
the O 0 0.0004931211
experiment O 0 0.00087649806
. O 0 0.0018080943

They O 0 0.0034905886
became O 0 0.0020969363
more O 0 0.0015087165
severe O 0 0.0034654255
in O 0 0.0004065962
the O 0 0.00024539075
later O 0 0.00011960178
months O 0 5.818475e-05
of O 0 0.000110833105
the O 0 9.685682e-05
experiment O 0 8.605438e-05
, O 0 0.00012081335
and O 0 9.9945566e-05
were O 0 9.1440794e-05
most O 0 0.00015883676
severe O 0 0.00062947656
after O 0 3.2683627e-05
12 O 0 3.8341233e-05
months O 0 2.6530612e-05
, O 0 6.153819e-05
located O 0 4.826995e-05
mainly O 0 8.5887295e-05
in O 0 8.104504e-05
the O 0 0.000116459574
molecular O 0 0.0008142817
layer O 0 0.0006617576
of O 0 0.0003973731
the O 0 0.0005823075
cerebellar O 0 0.2565445
cortex O 0 0.072236255
. O 0 0.002479152

Lesions O 0 0.013617741
of O 0 0.003298487
the O 0 0.0025671243
capillary O 0 0.030227361
included O 0 0.002763514
necrosis B-Disease 2 0.9961366
of O 0 0.007299851
endothelial O 0 0.9395152
cells O 0 0.008808956
. O 0 0.0052476283

Organelles O 0 0.006379441
of O 0 0.0019778914
these O 0 0.001494386
cells O 0 0.0012061725
, O 0 0.0005860916
in O 0 0.0002707901
particular O 0 0.00015348363
the O 0 0.00025778412
mitochondria O 0 0.0047391006
( O 0 0.0002684956
increased O 0 0.0002176021
number O 0 0.00012353327
and O 0 0.000116378644
size O 0 0.00019412464
, O 0 0.00013124889
distinct O 0 9.628605e-05
degeneration O 0 0.6762742
of O 0 0.00017307316
their O 0 0.00014492012
matrix O 0 0.00032788614
and O 0 0.00023898404
cristae O 0 0.1122242
) O 0 0.00032067313
and O 0 0.00021598277
Golgi O 0 0.00038961964
apparatus O 0 0.0003962043
were O 0 0.0006049945
altered O 0 0.0015399231
. O 0 0.0019093915

Reduced O 0 0.0046788855
size O 0 0.002267293
of O 0 0.0014785187
capillary O 0 0.022785183
lumen O 0 0.0010373015
and O 0 0.0004972488
occlusion O 0 0.010129937
were O 0 0.00027169936
caused O 0 0.00024960708
by O 0 0.00028363205
swollen O 0 0.0016145409
endothelial O 0 0.49683025
cells O 0 0.00039553863
which O 0 0.0002991183
had O 0 0.00034112783
luminal B-Chemical 0 0.01847938
protrusions O 0 0.0017669809
and O 0 0.0007959077
swollen O 0 0.004344679
microvilli O 0 0.008505989
. O 0 0.0021437246

Pressure O 0 0.010049304
on O 0 0.001523382
the O 0 0.0016929294
vessel O 0 0.0065362174
wall O 0 0.0036450687
was O 0 0.001175238
produced O 0 0.0009380445
by O 0 0.0013270632
enlarged O 0 0.009030127
perivascular O 0 0.053759173
astrocytic O 0 0.37939206
processes O 0 0.003997729
. O 0 0.0031396227

Fragments O 0 0.006942812
of O 0 0.0033535168
necrotic B-Disease 0 0.3799552
endothelial O 0 0.7092297
cells O 0 0.0011774931
were O 0 0.00034825035
in O 0 0.00020232168
the O 0 0.00022567161
vascular O 0 0.021079164
lumens O 0 0.0008513526
and O 0 0.00013779647
in O 0 9.998255e-05
these O 0 0.00014575037
there O 0 8.689134e-05
was O 0 0.00021276275
loosening O 0 0.010376723
and O 0 0.00026011077
breaking O 0 0.0008556409
of O 0 0.00042166127
tight O 0 0.00088157377
cellular O 0 0.0014645952
junctions O 0 0.0017684805
. O 0 0.0017116299

Damage O 0 0.015280144
to O 0 0.0029284465
the O 0 0.0029979083
vascular O 0 0.07430217
basement O 0 0.07902498
lamina O 0 0.0049539036
was O 0 0.002342962
also O 0 0.0022973348
observed O 0 0.003330557
. O 0 0.0048808507

Damage O 0 0.011450157
to O 0 0.0016790048
the O 0 0.0014620591
capillary O 0 0.041852467
was O 0 0.0010209788
accompanied O 0 0.001315084
by O 0 0.00058385415
marked O 0 0.0011373649
damage O 0 0.12865064
to O 0 0.00044581597
neuroglial O 0 0.15111454
cells O 0 0.00055889983
, O 0 0.00030020365
mainly O 0 0.00029783093
to O 0 0.00030898722
perivascular O 0 0.0034243537
processes O 0 0.00084804965
of O 0 0.0014361044
astrocytes O 0 0.04948371
. O 0 0.0025482324

The O 0 0.002863243
proliferation O 0 0.06726549
of O 0 0.0025780236
astrocytes O 0 0.043101054
( O 0 0.0017591452
Bergmann O 0 0.039596044
' O 0 0.000614262
s O 0 0.00032757493
in O 0 0.00022219146
particular O 0 0.00018846059
) O 0 0.0004412451
and O 0 0.0003266758
occasionally O 0 0.00072309264
of O 0 0.0009840422
oligodendrocytes O 0 0.35770062
was O 0 0.001641829
found O 0 0.0016733522
. O 0 0.0023900203

Alterations O 0 0.0031646008
in O 0 0.0011205578
the O 0 0.0007140896
structural O 0 0.0007391315
elements O 0 0.00043279375
of O 0 0.00043028957
the O 0 0.000484401
BBB O 0 0.9774071
coexisted O 0 0.0010726796
with O 0 0.00028337608
marked O 0 0.00045926718
lesions O 0 0.0023748542
of O 0 0.00019934861
neurons O 0 0.00024651006
of O 0 0.00016585112
the O 0 0.00017819858
cerebellum O 0 0.0038573346
( O 0 0.00047405215
Purkinje O 0 0.012296899
cells O 0 0.000603284
are O 0 0.0005152158
earliest O 0 0.0012099354
) O 0 0.0023286021
. O 0 0.0021779484

In O 0 0.0020490992
electron O 0 0.0039944025
micrographs O 0 0.00078176864
both O 0 0.0007291127
luminal B-Chemical 0 0.009623485
and O 0 0.0004858046
antiluminal O 0 0.0018518884
sides O 0 0.00069610495
of O 0 0.00027055782
the O 0 0.00029950353
BBB O 0 0.8725691
of O 0 0.00032615362
the O 0 0.00029327467
cerebellar O 0 0.06811508
cortex O 0 0.009088507
had O 0 0.00068939466
similar O 0 0.00073785137
lesions O 0 0.018100645
. O 0 0.0024735618

The O 0 0.0015524826
possible O 0 0.0010110388
influence O 0 0.00053920585
of O 0 0.000847766
the O 0 0.0010465703
hepatic B-Disease 0 0.99943703
damage I-Disease 0 0.9959573
, O 0 0.0010580895
mainly O 0 0.0013167749
hyperammonemia B-Disease 0 0.99997675
, O 0 0.00040775051
upon O 0 0.00010412273
the O 0 0.00015727601
development O 0 0.00045108784
of O 0 0.0015469041
valproate B-Chemical 0 0.9999901
encephalopathy B-Disease 2 0.9999609
is O 0 0.0027787397
discussed O 0 0.001956529
. O 0 0.002308121

Fatal O 0 0.16099443
intracranial B-Disease 0 0.99191743
bleeding I-Disease 0 0.99833506
associated O 0 0.0019671407
with O 0 0.001840914
prehospital O 0 0.003879995
use O 0 0.0015724038
of O 0 0.0037271492
epinephrine B-Chemical 0 0.99720484
. O 0 0.005497801

We O 0 0.0015297221
present O 0 0.0010258607
a O 0 0.0010992817
case O 0 0.00062271167
of O 0 0.0006886533
paramedic O 0 0.0018298388
misjudgment O 0 0.0063958257
in O 0 0.00018618653
the O 0 0.00014161553
execution O 0 0.00034574018
of O 0 0.00015694943
a O 0 0.00014235759
protocol O 0 0.00010233478
for O 0 4.9024777e-05
the O 0 7.281183e-05
treatment O 0 0.00011152518
of O 0 0.00049725967
allergic B-Disease 2 0.99996924
reaction I-Disease 2 0.819285
in O 0 0.0002638006
a O 0 0.00027477698
case O 0 0.00021890977
of O 0 0.00062120985
pulmonary B-Disease 0 0.90962005
edema I-Disease 0 0.999928
with O 0 0.017051375
wheezing B-Disease 0 0.9972209
. O 0 0.003305902

The O 0 0.00242837
sudden O 0 0.32765856
onset O 0 0.001998853
of O 0 0.0017352575
respiratory B-Disease 0 0.9020901
distress I-Disease 0 0.98871464
, O 0 0.0039518615
rash B-Disease 0 0.99899465
, O 0 0.00053073687
and O 0 0.0002252638
a O 0 0.00025095625
history O 0 0.0002599018
of O 0 0.00014997878
a O 0 0.0001605273
new O 0 0.00014805459
medicine O 0 0.00034201812
led O 0 0.00011527923
the O 0 9.006722e-05
two O 0 6.433494e-05
paramedics O 0 0.00014777645
on O 0 5.9463793e-05
the O 0 0.0001269522
scene O 0 0.00035011955
to O 0 0.00026546812
administer O 0 0.0009093566
subcutaneous O 0 0.009165529
epinephrine B-Chemical 0 0.9964611
. O 0 0.0026333542

Subsequently O 0 0.0045217834
, O 0 0.004817955
acute O 0 0.56208915
cardiac B-Disease 2 0.97833407
arrest I-Disease 2 0.9836795
and O 0 0.0053641633
fatal O 0 0.9893939
subarachnoid B-Disease 0 0.99949145
hemorrhage I-Disease 2 0.99974114
occurred O 0 0.0051780567
. O 0 0.003749207

Epinephrine B-Chemical 0 0.99848324
has O 0 0.0016487866
a O 0 0.0011596272
proven O 0 0.00070053217
role O 0 0.0002699742
in O 0 0.0003953207
cardiac B-Disease 2 0.7225801
arrest I-Disease 2 0.86061233
in O 0 0.0002931732
prehospital O 0 0.00097086636
care O 0 0.00020142047
; O 0 0.00015172991
however O 0 0.00013432199
, O 0 0.00010488748
use O 0 6.615742e-05
by O 0 7.669339e-05
paramedics O 0 0.00012382881
in O 0 5.655443e-05
patients O 0 0.00010392394
with O 0 0.00014744991
suspected O 0 0.0077823927
allergic B-Disease 2 0.9999784
reaction I-Disease 2 0.9363425
and O 0 0.001007729
severe O 0 0.36071923
hypertension B-Disease 2 0.9999639
should O 0 0.00018878936
be O 0 0.00023260585
viewed O 0 0.0003553612
with O 0 0.00069258985
caution O 0 0.001239944
. O 0 0.0017233749

Role O 0 0.002246803
of O 0 0.0015982289
activation O 0 0.0014850348
of O 0 0.003198986
bradykinin B-Chemical 1 0.9999515
B2 O 0 0.9992124
receptors O 0 0.006352265
in O 0 0.00023750796
disruption O 0 0.00021752057
of O 0 0.00022925957
the O 0 0.00022775865
blood O 0 0.00274296
- O 0 0.00056352414
brain O 0 0.0015903049
barrier O 0 0.0015311021
during O 0 0.000470177
acute O 0 0.8682644
hypertension B-Disease 2 0.9999095
. O 0 0.004237358

Cellular O 0 0.0064906916
mechanisms O 0 0.0017218235
which O 0 0.0010307541
account O 0 0.0004922928
for O 0 0.00028240486
disruption O 0 0.00035190026
the O 0 0.00032981296
blood O 0 0.0028776787
- O 0 0.0005820379
brain O 0 0.0012202521
barrier O 0 0.000921438
during O 0 0.0002049008
acute O 0 0.7415863
hypertension B-Disease 2 0.9999455
are O 0 0.0009037636
not O 0 0.00075499393
clear O 0 0.0012408941
. O 0 0.0019477626

The O 0 0.0015886026
goal O 0 0.0016479864
of O 0 0.0011570255
this O 0 0.00084106246
study O 0 0.000662376
was O 0 0.00034506642
to O 0 0.00015724993
determine O 0 7.446478e-05
the O 0 0.00010866362
role O 0 7.230935e-05
of O 0 0.00017627825
synthesis O 0 0.0010837803
/ O 0 0.0007746908
release O 0 0.0007176706
of O 0 0.00045508877
bradykinin B-Chemical 1 0.999913
to O 0 0.00013674566
activate O 0 6.4821565e-05
B2 O 0 0.97517765
receptors O 0 0.0009457875
in O 0 7.161256e-05
disruption O 0 9.135703e-05
of O 0 0.000116489784
the O 0 0.00013359085
blood O 0 0.0020388337
- O 0 0.00040202506
brain O 0 0.0012940562
barrier O 0 0.0012834996
during O 0 0.0003896858
acute O 0 0.8560292
hypertension B-Disease 2 0.9999143
. O 0 0.0038519804

Permeability O 0 0.023258962
of O 0 0.0017952422
the O 0 0.0011448213
blood O 0 0.0049118344
- O 0 0.0012402595
brain O 0 0.0018704872
barrier O 0 0.0012485874
was O 0 0.0002665935
quantitated O 0 0.00032369868
by O 0 0.00015168723
clearance O 0 0.001006194
of O 0 0.00021488342
fluorescent O 0 0.00066430616
- O 0 0.00023516723
labeled O 0 0.00011536181
dextran B-Chemical 1 0.88859415
before O 0 4.1250772e-05
and O 0 8.1166e-05
during O 0 7.506946e-05
phenylephrine B-Chemical 0 0.9999678
- O 0 0.00064398255
induced O 0 0.00034089177
acute O 0 0.94970804
hypertension B-Disease 2 0.9999908
in O 0 0.00017048171
rats O 0 0.0001557076
treated O 0 0.00011389266
with O 0 0.00011333797
vehicle O 0 0.00064719986
and O 0 0.0003337369
Hoe B-Chemical 0 0.9995976
- I-Chemical 0 0.000629936
140 I-Chemical 0 0.00038649555
( O 0 0.00024583453
0 O 0 0.00017403762
. O 0 0.00020500316
1 O 0 0.0004689135
microM O 0 0.032153353
) O 0 0.0031217278
. O 0 0.0025974112

Phenylephrine B-Chemical 0 0.99932635
infusion O 0 0.006001792
increased O 0 0.001964026
arterial O 0 0.04007958
pressure O 0 0.007064869
, O 0 0.0007043475
arteriolar O 0 0.8579803
diameter O 0 0.0011029614
and O 0 0.0002083804
clearance O 0 0.0011715484
of O 0 0.00028599196
fluorescent O 0 0.0013799333
dextran B-Chemical 1 0.98122966
by O 0 0.00028517816
a O 0 0.00024667836
similar O 0 0.00013136947
magnitude O 0 0.00021442212
in O 0 0.0003608593
both O 0 0.00073414313
groups O 0 0.0012411717
. O 0 0.0018594064

These O 0 0.002222268
findings O 0 0.0017508676
suggest O 0 0.00044038537
that O 0 0.00034914256
disruption O 0 0.00041405216
of O 0 0.00038770633
the O 0 0.0003125032
blood O 0 0.003775268
- O 0 0.00048301407
brain O 0 0.0010033777
barrier O 0 0.0006509002
during O 0 9.4583585e-05
acute O 0 0.7782635
hypertension B-Disease 2 0.9999833
is O 0 0.00018301512
not O 0 6.5595064e-05
related O 0 3.148125e-05
to O 0 5.4868022e-05
the O 0 8.58611e-05
synthesis O 0 0.000621556
/ O 0 0.0006053145
release O 0 0.0007362646
of O 0 0.000635716
bradykinin B-Chemical 1 0.9997874
to O 0 0.00044227848
activate O 0 0.00035870637
B2 O 0 0.97068226
receptors O 0 0.017728724
. O 0 0.0024002106

Risk O 0 0.008393544
factors O 0 0.004260041
of O 0 0.007070219
sensorineural B-Disease 2 0.99984944
hearing I-Disease 2 0.9989492
loss I-Disease 2 0.5017202
in O 0 0.0049703233
preterm O 0 0.91309285
infants O 0 0.058003604
. O 0 0.0054454384

Among O 0 0.0044083237
547 O 0 0.021270778
preterm O 0 0.24355426
infants O 0 0.0029318607
of O 0 0.00074446225
< O 0 0.0003732675
or O 0 0.00021742187
= O 0 0.00021966248
34 O 0 0.00012356411
weeks O 0 3.9583512e-05
gestation O 0 0.00010114228
born O 0 0.00013282697
between O 0 5.9385253e-05
1987 O 0 0.00035362062
and O 0 0.000117391006
1991 O 0 0.00017844784
, O 0 0.00011256475
8 O 0 7.3536554e-05
children O 0 0.00015285185
( O 0 0.0001446061
1 O 0 7.800533e-05
. O 0 5.718639e-05
46 O 0 0.00012268746
% O 0 0.00012794705
) O 0 0.0001950929
developed O 0 0.00028170485
severe O 0 0.003991537
progressive O 0 0.06973697
and O 0 0.00094389665
bilateral O 0 0.40957424
sensorineural B-Disease 2 0.9999889
hearing I-Disease 2 0.99986124
loss I-Disease 2 0.94417524
. O 0 0.004999973

Perinatal O 0 0.013974922
risk O 0 0.0059373924
factors O 0 0.0011457753
of O 0 0.00075763406
infants O 0 0.0006780356
with O 0 0.0006466758
hearing B-Disease 0 0.9713875
loss I-Disease 0 0.0027083093
were O 0 0.00018772026
compared O 0 6.6588575e-05
with O 0 0.00010346091
those O 0 9.973963e-05
of O 0 8.089315e-05
two O 0 3.9187824e-05
control O 0 5.5276138e-05
groups O 0 5.224868e-05
matched O 0 4.082028e-05
for O 0 4.510327e-05
gestation O 0 0.0001167322
and O 0 0.00011583227
birth O 0 0.00034231888
weight O 0 0.00082314166
and O 0 0.0003498069
for O 0 0.00045784874
perinatal O 0 0.03509861
complications O 0 0.19016609
. O 0 0.0025948712

Our O 0 0.0023355028
observations O 0 0.0017921362
demonstrated O 0 0.0008173547
an O 0 0.0007909336
association O 0 0.00039543136
of O 0 0.0009051631
hearing B-Disease 0 0.9732376
loss I-Disease 0 0.0043434743
with O 0 0.0006739413
a O 0 0.000573568
higher O 0 0.0005701396
incidence O 0 0.0012391441
of O 0 0.0013242099
perinatal O 0 0.11553023
complications O 0 0.33088997
. O 0 0.003083346

Ototoxicity B-Disease 0 0.9962115
appeared O 0 0.0018084368
closely O 0 0.0005705413
related O 0 0.00026109122
to O 0 0.00028321592
a O 0 0.00035047266
prolonged O 0 0.0004610041
administration O 0 0.0008214903
and O 0 0.00016605445
higher O 0 0.00014179888
total O 0 0.00013466697
dose O 0 0.00060701853
of O 0 0.00043537855
ototoxic B-Disease 0 0.99871445
drugs O 0 0.23714286
, O 0 0.00045648927
particularly O 0 0.0007113896
aminoglycosides B-Chemical 0 0.9701534
and O 0 0.0044634067
furosemide B-Chemical 0 0.9999182
. O 0 0.0039385096

Finally O 0 0.0023852137
, O 0 0.0015928327
we O 0 0.0004636116
strongly O 0 0.0005686006
recommend O 0 0.00030022796
to O 0 0.00022989941
prospectively O 0 0.00024609553
and O 0 0.00013159476
regularly O 0 9.2715956e-05
perform O 0 6.856428e-05
audiologic O 0 0.0007155958
assessment O 0 6.943789e-05
in O 0 8.641093e-05
sick O 0 0.00067620946
preterm O 0 0.0067695747
children O 0 0.00026728777
as O 0 0.00014991986
hearing B-Disease 0 0.9768687
loss I-Disease 0 0.0031546436
is O 0 0.00015457901
of O 0 0.00017498125
delayed O 0 0.0007858778
onset O 0 0.00023709484
and O 0 0.00013933814
in O 0 0.00013355774
most O 0 0.0003500853
cases O 0 0.0005350798
bilateral O 0 0.006347452
and O 0 0.001313443
severe O 0 0.046240747
. O 0 0.0025238285

Seizure B-Disease 2 0.9368172
resulting O 0 0.0058157947
from O 0 0.004674052
a O 0 0.012975992
venlafaxine B-Chemical 0 0.99979633
overdose B-Disease 0 0.9995753
. O 0 0.0139416745

OBJECTIVE O 0 0.0329206
: O 0 0.0038408649
To O 0 0.0018804201
report O 0 0.0025680228
a O 0 0.0023266023
case O 0 0.0022606472
of O 0 0.007338449
venlafaxine B-Chemical 0 0.9999275
overdose B-Disease 0 0.9998035
. O 0 0.009167383

CASE O 0 0.025760558
SUMMARY O 0 0.004089252
: O 0 0.0020764899
A O 0 0.0051574404
40 O 0 0.00095695746
- O 0 0.00095414417
year O 0 0.00029106578
- O 0 0.00044790917
old O 0 0.00022773584
woman O 0 0.0003888877
with O 0 0.0001915023
major B-Disease 2 0.0006961846
depression I-Disease 2 0.9987062
took O 0 0.00016952741
an O 0 0.00043528934
overdose B-Disease 0 0.99980706
of O 0 0.0013099848
venlafaxine B-Chemical 0 0.9999428
in O 0 0.0002957523
an O 0 0.00046567072
apparent O 0 0.0009090654
suicide O 0 0.53575045
attempt O 0 0.0030730288
. O 0 0.0023072688

After O 0 0.00096568867
the O 0 0.0012692962
ingestion O 0 0.007135238
of O 0 0.0010278554
26 O 0 0.0014548677
venlafaxine B-Chemical 0 0.9998876
50 O 0 0.0011944091
- O 0 0.000807753
mg O 0 0.028571846
tablets O 0 0.093747
, O 0 0.00025385633
the O 0 0.00017796474
patient O 0 0.00024307195
experienced O 0 0.00035335083
a O 0 0.0006026685
witnessed O 0 0.0027783026
generalized O 0 0.043757413
seizure B-Disease 0 0.9994431
. O 0 0.003988332

She O 0 0.0037438588
was O 0 0.0018229818
admitted O 0 0.0014630661
to O 0 0.0004711652
the O 0 0.00039304397
medical O 0 0.0006617242
intensive O 0 0.00021231611
care O 0 0.00019144444
unit O 0 0.00015561392
, O 0 0.00035248007
venlafaxine B-Chemical 0 0.9999156
was O 0 0.00035651913
discontinued O 0 0.0008914524
, O 0 0.00020717588
and O 0 0.00017580643
no O 0 0.00015449413
further O 0 0.00054127537
sequelae O 0 0.010542692
were O 0 0.0010688279
seen O 0 0.00148481
. O 0 0.002071227

DISCUSSION O 0 0.0035753793
: O 0 0.0018012449
To O 0 0.00083416136
our O 0 0.0011233643
knowledge O 0 0.0012010998
, O 0 0.0006072248
this O 0 0.00038669218
is O 0 0.00022905898
the O 0 0.0001476891
first O 0 9.377459e-05
reported O 0 0.00016544519
case O 0 0.00016263571
of O 0 0.00076326315
venlafaxine B-Chemical 0 0.9999913
overdose B-Disease 0 0.99992394
that O 0 0.00021971256
resulted O 0 0.00029463618
in O 0 0.00032371783
a O 0 0.0008720098
generalized O 0 0.025715062
seizure B-Disease 0 0.99940395
. O 0 0.0036555645

Based O 0 0.0029053795
on O 0 0.0010902553
nonoverdose O 0 0.009471378
pharmacokinetics O 0 0.18446703
and O 0 0.00066273654
pharmacodynamics O 0 0.10202766
of O 0 0.0007929138
venlafaxine B-Chemical 0 0.9999124
and O 0 0.00022587094
the O 0 0.00012121965
potential O 0 0.00013788295
risks O 0 0.0003834195
of O 0 0.00020285985
available O 0 0.00019524606
interventions O 0 0.00014605255
, O 0 0.0001910296
no O 0 0.00013678164
emergent O 0 0.00042140693
therapy O 0 0.0008261332
was O 0 0.0010321017
instituted O 0 0.002481403
. O 0 0.0021415406

CONCLUSIONS O 0 0.011264782
: O 0 0.0019788512
The O 0 0.0012242001
venlafaxine B-Chemical 0 0.99992204
overdose B-Disease 0 0.9998004
in O 0 0.00049587514
our O 0 0.00036164242
patient O 0 0.00021336773
resulted O 0 0.00014338818
in O 0 0.000114685296
a O 0 0.00014890362
single O 0 0.00011546482
episode O 0 0.0002697527
of O 0 0.00023489381
generalized O 0 0.005468253
seizure B-Disease 0 0.99953496
but O 0 0.00045816702
elicited O 0 0.0003313244
no O 0 0.00037695092
further O 0 0.0015221686
sequelae O 0 0.09683745
. O 0 0.0029019297

Combined O 0 0.0041332636
effects O 0 0.0018815465
of O 0 0.002258781
prolonged O 0 0.057029992
prostaglandin B-Chemical 1 0.99999547
E1 I-Chemical 1 0.9997689
- O 0 0.0043838904
induced O 0 0.0015816718
hypotension B-Disease 0 0.9998418
and O 0 0.0012578622
haemodilution B-Disease 0 0.9240505
on O 0 0.00042093234
human O 0 0.0013410711
hepatic O 0 0.9277726
function O 0 0.0032718424
. O 0 0.0026074424

Combined O 0 0.0037977702
effects O 0 0.001680772
of O 0 0.0019476495
prolonged O 0 0.04382652
prostaglandin B-Chemical 1 0.9999964
E1 I-Chemical 1 0.99988866
( O 0 0.10543268
PGE1 B-Chemical 0 0.9999974
) O 0 0.0036563256
- O 0 0.00071869727
induced O 0 0.0004661255
hypotension B-Disease 0 0.9998186
and O 0 0.00046695306
haemodilution B-Disease 0 0.8987086
on O 0 0.00011511753
hepatic O 0 0.7137964
function O 0 0.0001922143
were O 0 0.00011441899
studied O 0 0.00011203832
in O 0 9.686901e-05
30 O 0 0.00012172062
patients O 0 0.00033964484
undergoing O 0 0.0006849239
hip O 0 0.1500736
surgery O 0 0.0023054017
. O 0 0.0018639358

The O 0 0.0015365237
patients O 0 0.001282797
were O 0 0.00048725252
randomly O 0 0.00015043395
allocated O 0 0.00015054298
to O 0 0.00013265027
one O 0 0.00010087606
of O 0 0.00014546048
three O 0 6.9353715e-05
groups O 0 0.000120225624
; O 0 0.00011792369
those O 0 0.00010901847
in O 0 8.779435e-05
group O 0 0.00018690119
A O 0 0.0035905372
( O 0 0.0001867797
n O 0 9.410801e-05
= O 0 0.000103139784
10 O 0 6.2358966e-05
) O 0 9.1148184e-05
were O 0 4.152405e-05
subjected O 0 2.7760649e-05
to O 0 4.630969e-05
controlled O 0 0.00010559467
hypotension B-Disease 0 0.99917173
alone O 0 0.000191755
, O 0 0.00011890151
those O 0 0.00010442501
in O 0 7.207837e-05
group O 0 0.00017486702
B O 0 0.048507247
( O 0 0.0001720727
n O 0 8.104913e-05
= O 0 8.98771e-05
10 O 0 5.6748315e-05
) O 0 9.8764984e-05
to O 0 7.1574876e-05
haemodilution B-Disease 0 0.5564383
alone O 0 0.00013215232
and O 0 0.00010183171
those O 0 0.00012052017
in O 0 9.167609e-05
group O 0 0.0002962126
C O 0 0.9504651
( O 0 0.00026303812
n O 0 0.00011594433
= O 0 0.00013322296
10 O 0 9.2348e-05
) O 0 0.00015442152
to O 0 0.00010328474
both O 0 0.00019927506
controlled O 0 0.0004781548
hypotension B-Disease 0 0.9993249
and O 0 0.0024454286
haemodilution B-Disease 0 0.9799799
. O 0 0.0030345947

Haemodilution B-Disease 0 0.9268621
in O 0 0.0021039725
groups O 0 0.0015912744
B O 0 0.06648214
and O 0 0.0013697023
C O 0 0.960972
was O 0 0.00048992294
produced O 0 0.00024910356
by O 0 0.00023774359
withdrawing O 0 0.0013081952
approximately O 0 0.00017162274
1000 O 0 0.00033899557
mL O 0 0.00038975762
of O 0 0.00013567078
blood O 0 0.00095495925
and O 0 0.0001076378
replacing O 0 0.00016010493
it O 0 8.168554e-05
with O 0 7.0885835e-05
the O 0 4.5865352e-05
same O 0 2.5158992e-05
amount O 0 3.4345703e-05
of O 0 0.00015199606
dextran B-Chemical 1 0.99176496
solution O 0 0.008553506
, O 0 0.00015861397
and O 0 0.00010390621
final O 0 0.00020868839
haematocrit O 0 0.35672745
values O 0 0.00026293108
were O 0 0.00023775878
21 O 0 0.00028790702
or O 0 0.0003673676
22 O 0 0.00087707705
% O 0 0.001336766
. O 0 0.0018930275

Controlled O 0 0.004344261
hypotension B-Disease 0 0.99609226
in O 0 0.0014374363
groups O 0 0.0009920113
A O 0 0.00716692
and O 0 0.0009174354
C O 0 0.9638308
was O 0 0.00046679284
induced O 0 0.0004256084
with O 0 0.001306409
PGE1 B-Chemical 0 0.9999927
to O 0 0.00015661457
maintain O 0 7.0979324e-05
mean O 0 5.4575376e-05
arterial O 0 0.0024325703
blood O 0 0.0009959385
pressure O 0 0.00080882286
at O 0 0.00010817894
55 O 0 0.00021632407
mmHg O 0 0.00038805432
for O 0 0.0002563122
180 O 0 0.0007078737
min O 0 0.0012353067
. O 0 0.0018727017

Measurements O 0 0.002156244
included O 0 0.0014481292
arterial O 0 0.04823676
ketone O 0 0.9976178
body O 0 0.0043852795
ratio O 0 0.0013551298
( O 0 0.0013693012
AKBR O 0 0.9988236
, O 0 0.0012464902
aceto B-Chemical 0 0.99666804
- I-Chemical 0 0.0033985868
acetate I-Chemical 0 0.99742717
/ O 0 0.0022790374
3 B-Chemical 0 0.00023340854
- I-Chemical 0 0.00076088775
hydroxybutyrate I-Chemical 0 0.9994326
) O 0 0.00066117424
and O 0 0.00032338774
clinical O 0 0.001154554
hepatic O 0 0.696727
function O 0 0.0012292543
parameters O 0 0.0018387634
. O 0 0.0020620518

AKBR O 0 0.98722875
and O 0 0.0019305549
biological O 0 0.0014320401
hepatic O 0 0.5668987
function O 0 0.0008379814
tests O 0 0.00083987875
showed O 0 0.0002253869
no O 0 0.00010510554
change O 0 0.00012144908
throughout O 0 5.429977e-05
the O 0 9.101339e-05
time O 0 7.04784e-05
course O 0 0.00013516433
in O 0 0.00023058696
groups O 0 0.00042184425
A O 0 0.0044942903
and O 0 0.0015743109
B O 0 0.13514873
. O 0 0.0032502383

In O 0 0.0026047751
group O 0 0.004603339
C O 0 0.97378165
, O 0 0.0028329769
AKBR O 0 0.99775785
showed O 0 0.00063207594
a O 0 0.00044177272
significant O 0 0.00021602066
decrease O 0 0.00019401936
at O 0 8.5332504e-05
120 O 0 0.0001223349
min O 0 0.00017283141
( O 0 0.00021889391
- O 0 0.00021655727
40 O 0 0.000117467134
% O 0 0.00011697723
) O 0 0.00012428069
and O 0 6.569378e-05
at O 0 4.5246077e-05
180 O 0 9.4450006e-05
min O 0 0.00012254072
( O 0 0.00017342504
- O 0 0.00019989832
49 O 0 0.00014434326
% O 0 9.293698e-05
) O 0 8.4600055e-05
after O 0 1.9952544e-05
the O 0 4.057979e-05
start O 0 3.472504e-05
of O 0 0.00017774547
hypotension B-Disease 0 0.99925846
and O 0 0.00011508548
at O 0 4.4463235e-05
60 O 0 6.084971e-05
min O 0 9.427921e-05
( O 0 0.0001386454
- O 0 0.00015808598
32 O 0 0.000104914376
% O 0 8.0831705e-05
) O 0 7.5953925e-05
after O 0 1.9870644e-05
recovery O 0 0.00010912913
of O 0 0.0001442479
normotension O 0 0.73039997
, O 0 0.00017048593
and O 0 0.00036047524
SGOT O 0 0.99998844
, O 0 0.009413768
SGPT O 0 0.9999988
, O 0 0.0039694086
LDH O 0 0.9998702
and O 0 0.00032382895
total O 0 0.0004881925
bilirubin B-Chemical 1 0.9999485
showed O 0 0.00045380602
significant O 0 0.00029724318
increases O 0 0.00035470453
after O 0 0.00028603044
operation O 0 0.0009537262
. O 0 0.0016466522

The O 0 0.0014758614
results O 0 0.0010964349
suggest O 0 0.0004194611
that O 0 0.000367569
a O 0 0.0005214119
prolonged O 0 0.000549858
combination O 0 0.0003458661
of O 0 0.00022890748
more O 0 0.0001780642
than O 0 6.685517e-05
120 O 0 8.614141e-05
min O 0 0.00013476769
of O 0 0.0005964146
PGE1 B-Chemical 0 0.99999714
- O 0 0.0012696292
induced O 0 0.00049506756
hypotension B-Disease 0 0.9998785
and O 0 0.00041118235
moderate O 0 0.017480543
haemodilution B-Disease 0 0.9688784
would O 0 0.00031157146
cause O 0 0.00062811136
impairment B-Disease 0 0.1586328
of I-Disease 0 0.0015605593
hepatic I-Disease 0 0.97545695
function I-Disease 0 0.0031013798
. O 0 0.0021927094

Cardiovascular B-Disease 0 0.73247313
alterations I-Disease 0 0.014203191
in O 0 0.0017634545
rat O 0 0.0022676564
fetuses O 0 0.0021026924
exposed O 0 0.0010368753
to O 0 0.0016128677
calcium B-Chemical 0 0.9985267
channel O 0 0.9089304
blockers O 0 0.99880505
. O 0 0.0066049625

Preclinical O 0 0.024789589
toxicologic O 0 0.019726656
investigation O 0 0.0013012902
suggested O 0 0.00036751913
that O 0 0.0002469855
a O 0 0.00041651193
new O 0 0.00064782624
calcium B-Chemical 0 0.9994006
channel O 0 0.7798841
blocker O 0 0.99308336
, O 0 0.0005802477
Ro B-Chemical 0 0.71204245
40 I-Chemical 0 0.00031045772
- I-Chemical 0 0.00034216326
5967 I-Chemical 0 0.00043842677
, O 0 0.00012192937
induced O 0 0.0002090303
cardiovascular B-Disease 0 0.9883387
alterations I-Disease 0 0.027427116
in O 0 0.00014266795
rat O 0 0.00032027994
fetuses O 0 0.00031256038
exposed O 0 0.00012244939
to O 0 0.00013988369
this O 0 0.0003240816
agent O 0 0.0015319509
during O 0 0.000573354
organogenesis O 0 0.04265819
. O 0 0.002239502

The O 0 0.001516896
present O 0 0.0010423979
study O 0 0.0010354439
was O 0 0.0005722935
designed O 0 0.00033129126
to O 0 0.00019914344
investigate O 0 0.00010665389
the O 0 0.00015387959
hypothesis O 0 0.00021392955
that O 0 0.00018692848
calcium B-Chemical 0 0.99964166
channel O 0 0.82457995
blockers O 0 0.9986098
in O 0 0.0001682156
general O 0 0.0001440416
induce O 0 0.00015988373
cardiovascular B-Disease 0 0.9988545
malformations I-Disease 0 0.9998839
indicating O 0 0.00032826958
a O 0 0.0005222385
pharmacologic O 0 0.0022271983
class O 0 0.000959107
effect O 0 0.0013341409
. O 0 0.0021785174

We O 0 0.0014240599
studied O 0 0.0013151749
three O 0 0.0007002421
calcium B-Chemical 0 0.99625504
channel O 0 0.543606
blockers O 0 0.99643636
of O 0 0.00049827126
different O 0 0.00014296253
structure O 0 0.0002871099
, O 0 0.0005823419
nifedipine B-Chemical 1 0.999995
, O 0 0.0030009341
diltiazem B-Chemical 1 0.99999595
, O 0 0.0006607632
and O 0 0.0006531052
verapamil B-Chemical 0 0.999972
, O 0 0.0003988753
along O 0 0.00017320442
with O 0 0.0003451028
the O 0 0.00046802926
new O 0 0.0010887485
agent O 0 0.0059839194
. O 0 0.0026333628

Pregnant O 0 0.0061876127
rats O 0 0.0015500284
were O 0 0.0005661708
administered O 0 0.00038726028
one O 0 0.00018498447
of O 0 0.00026595322
these O 0 0.00052331336
calcium B-Chemical 0 0.9992926
channel O 0 0.65805584
blockers O 0 0.99430746
during O 0 5.8039273e-05
the O 0 5.95618e-05
period O 0 3.0514333e-05
of O 0 9.261327e-05
cardiac O 0 0.004644843
morphogenesis O 0 0.00044270666
and O 0 9.082396e-05
the O 0 8.289279e-05
offspring O 0 0.0003026766
examined O 0 4.6188008e-05
on O 0 4.3205586e-05
day O 0 5.747029e-05
20 O 0 0.00010375602
of O 0 0.00020203581
gestation O 0 0.0004545676
for O 0 0.00067773525
cardiovascular B-Disease 0 0.9985677
malformations I-Disease 0 0.99974376
. O 0 0.004858346

A O 0 0.017243909
low O 0 0.0029149207
incidence O 0 0.0023731568
of O 0 0.0021754378
cardiovascular B-Disease 0 0.999385
malformations I-Disease 0 0.9999144
was O 0 0.00070011703
observed O 0 0.00014688747
after O 0 4.8657614e-05
exposure O 0 0.00012820987
to O 0 6.210508e-05
each O 0 3.2125175e-05
of O 0 7.384294e-05
the O 0 7.23822e-05
four O 0 7.904022e-05
calcium B-Chemical 0 0.9988311
channel O 0 0.7933508
blockers O 0 0.9995097
, O 0 0.00026724805
but O 0 0.000119240896
this O 0 0.00013494078
incidence O 0 0.00029453394
was O 0 0.0001336933
statistically O 0 0.000107819105
significant O 0 0.00011069917
only O 0 0.00020226574
for O 0 0.000411229
verapamil B-Chemical 0 0.99996114
and O 0 0.009408464
nifedipine B-Chemical 1 0.99996734
. O 0 0.0042766286

All O 0 0.0015197275
four O 0 0.0008045393
agents O 0 0.001687084
were O 0 0.0004956954
associated O 0 0.0002944525
with O 0 0.0004273034
aortic O 0 0.07665326
arch O 0 0.37752643
branching O 0 0.0050276504
variants O 0 0.0005900768
, O 0 0.00021641154
although O 0 0.000121112316
significantly O 0 0.00018836034
increased O 0 0.00022233537
only O 0 0.00017353884
for O 0 0.00016380048
Ro B-Chemical 0 0.38562685
40 I-Chemical 0 0.0004972424
- I-Chemical 0 0.0007987501
5967 I-Chemical 0 0.001761156
and O 0 0.0015067891
verapamil B-Chemical 0 0.9997824
. O 0 0.0035765688

The O 0 0.002844267
site O 0 0.0022386634
of O 0 0.0024663366
common O 0 0.002462206
side O 0 0.008781474
effects O 0 0.003812188
of O 0 0.011665873
sumatriptan B-Chemical 0 0.9998367
. O 0 0.008848443

Atypical B-Disease 0 0.04003329
sensations I-Disease 0 0.054873288
following O 0 0.0006881441
the O 0 0.0005579322
use O 0 0.0003985891
of O 0 0.00059137796
subcutaneous O 0 0.0074663726
sumatriptan B-Chemical 0 0.999951
are O 0 0.00043949214
common O 0 0.0003745613
, O 0 0.00039468703
but O 0 0.00040290598
of O 0 0.0006636882
uncertain O 0 0.0012560663
origin O 0 0.0020377976
. O 0 0.0023620373

They O 0 0.003628373
are O 0 0.0014801937
almost O 0 0.0011563932
always O 0 0.0013331663
benign O 0 0.01862612
, O 0 0.0007809667
but O 0 0.00044855778
can O 0 0.00022819293
be O 0 0.00023642032
mistaken O 0 0.00061346136
for O 0 0.00015998133
a O 0 0.00035906202
serious O 0 0.00221928
adverse O 0 0.06443919
event O 0 0.0015794566
by O 0 0.00066594663
the O 0 0.00085580524
patient O 0 0.0017162028
. O 0 0.0020860732

Two O 0 0.00204067
patients O 0 0.0014985122
are O 0 0.00064705283
presented O 0 0.0005223555
with O 0 0.00093086663
tingling B-Disease 0 0.64376837
or I-Disease 0 0.0005414725
burning I-Disease 0 0.14148255
sensations I-Disease 0 0.0062686517
limited O 0 0.00021597452
to O 0 0.00016331264
areas O 0 0.00022236863
of O 0 0.00034120816
heat O 0 0.0016926473
exposure O 0 0.0015259644
or O 0 0.002348968
sunburn B-Disease 0 0.9991672
. O 0 0.004323518

In O 0 0.0021337646
these O 0 0.0021707749
individuals O 0 0.0019175556
, O 0 0.0012669015
side O 0 0.0037299534
effects O 0 0.000770636
are O 0 0.00046906635
most O 0 0.0005220803
likely O 0 0.00027569436
generated O 0 0.00031092367
superficially O 0 0.0008853028
in O 0 0.0006371195
the O 0 0.0012024236
skin O 0 0.013229543
. O 0 0.0029771153

Macula O 0 0.5647047
toxicity B-Disease 2 0.9751941
after O 0 0.007073812
intravitreal O 0 0.9913011
amikacin B-Chemical 0 0.99917114
. O 0 0.019866265

BACKGROUND O 0 0.0076738736
: O 0 0.0020271789
Although O 0 0.00091032323
intravitreal O 0 0.83368695
aminoglycosides B-Chemical 0 0.9485429
have O 0 0.0003205115
substantially O 0 0.0003342378
improved O 0 0.00047842338
visual O 0 0.0088752555
prognosis O 0 0.17902938
in O 0 0.00062899676
endophthalmitis B-Disease 0 0.9998559
, O 0 0.014936782
macular O 0 0.9999982
infarction B-Disease 2 0.99998784
may O 0 0.00034930152
impair O 0 0.00024084855
full O 0 0.00044278495
visual O 0 0.0076632346
recovery O 0 0.0035264746
. O 0 0.002164597

METHODS O 0 0.0016416617
: O 0 0.001247671
We O 0 0.00043025223
present O 0 0.00035178874
a O 0 0.00043812487
case O 0 0.00026551494
of O 0 0.00033784768
presumed O 0 0.0013304233
amikacin B-Chemical 0 0.9999559
retinal B-Disease 0 0.99995136
toxicity I-Disease 2 0.9999628
following O 0 0.00014782746
treatment O 0 0.0001367368
with O 0 0.00023160779
amikacin B-Chemical 0 0.9996141
and O 0 0.00044946728
vancomycin B-Chemical 0 0.9880586
for O 0 0.0003956348
alpha O 0 0.78894985
- O 0 0.004444715
haemolytic O 0 0.99886984
streptococcal B-Disease 0 0.999559
endophthalmitis I-Disease 0 0.9999579
. O 0 0.0070394585

RESULTS O 0 0.005525999
: O 0 0.0030507036
Endophthalmitis B-Disease 0 0.6487024
resolved O 0 0.0013272945
with O 0 0.0005631703
improvement O 0 0.00042242956
in O 0 0.00031871584
visual O 0 0.0116794165
acuity O 0 0.98615384
to O 0 0.00033694025
6 O 0 0.0001880983
/ O 0 0.0004567874
24 O 0 0.00019841241
at O 0 0.00023483225
three O 0 0.00034249172
months O 0 0.0006207819
. O 0 0.001748702

Fundus O 0 0.94023925
fluorescein B-Chemical 0 0.9865067
angiography O 0 0.25364745
confirmed O 0 0.0080687525
macular O 0 0.9998603
capillary O 0 0.7806539
closure O 0 0.02430777
and O 0 0.006582122
telangiectasis B-Disease 0 0.9985825
. O 0 0.006553331

CONCLUSIONS O 0 0.014353778
: O 0 0.0023770267
Currently O 0 0.0012005708
accepted O 0 0.0019996471
intravitreal O 0 0.7264887
antibiotic O 0 0.006109456
regimens O 0 0.0010338156
may O 0 0.00047689443
cause O 0 0.0020054565
retinal B-Disease 0 0.99968183
toxicity I-Disease 2 0.99995446
and O 0 0.1486141
macular O 0 0.99999106
ischaemia B-Disease 0 0.9999325
. O 0 0.0055503645

Treatment O 0 0.0058586164
strategies O 0 0.002374111
aimed O 0 0.0024573011
at O 0 0.0016319045
avoiding O 0 0.0046787434
retinal B-Disease 0 0.9986399
toxicity I-Disease 2 0.99969554
are O 0 0.004724217
discussed O 0 0.0040336926
. O 0 0.0045286166

The O 0 0.002187139
role O 0 0.0015882031
of O 0 0.003172342
nicotine B-Chemical 1 0.9976826
in O 0 0.002675641
smoking O 0 0.24731573
- O 0 0.0026709042
related O 0 0.0012293257
cardiovascular B-Disease 0 0.90831465
disease I-Disease 0 0.72519743
. O 0 0.004927666

Nicotine B-Chemical 0 0.99837506
activates O 0 0.001122096
the O 0 0.0012184631
sympathetic O 0 0.010398584
nervous O 0 0.011224687
system O 0 0.00058418623
and O 0 0.00037009522
in O 0 0.00025800173
this O 0 0.0003157495
way O 0 0.00029010526
could O 0 0.00027520064
contribute O 0 0.00037849878
to O 0 0.00087549473
cardiovascular B-Disease 0 0.9185533
disease I-Disease 0 0.73023957
. O 0 0.0035374002

Animal O 0 0.0059740515
studies O 0 0.0014735274
and O 0 0.0008739046
mechanistic O 0 0.00093716185
studies O 0 0.0004221878
indicate O 0 0.00018862633
that O 0 0.00027113702
nicotine B-Chemical 1 0.997529
could O 0 0.0001848115
play O 0 9.770432e-05
a O 0 0.00013293201
role O 0 6.2922256e-05
in O 0 0.00012123179
accelerating O 0 0.0034262286
atherosclerosis B-Disease 2 0.99997663
, O 0 0.00043184098
but O 0 0.00016044115
evidence O 0 9.1500886e-05
among O 0 0.0001293835
humans O 0 0.00021475829
is O 0 8.7710425e-05
too O 0 0.000107329506
inadequate O 0 0.00013368156
to O 0 0.0001017623
be O 0 0.00012150897
definitive O 0 0.00020035474
about O 0 0.00022314982
such O 0 0.00030475418
an O 0 0.00087204383
effect O 0 0.0013467654
. O 0 0.0022040913

Almost O 0 0.005344822
certainly O 0 0.0026259003
, O 0 0.0020429804
nicotine B-Chemical 1 0.990128
via O 0 0.0003361521
its O 0 0.00049427635
hemodynamic O 0 0.0016496275
effects O 0 0.00018918543
contributes O 0 0.00010994679
to O 0 0.00016580147
acute O 0 0.41165328
cardiovascular O 0 0.95182997
events O 0 0.004029147
, O 0 0.00016284212
although O 0 6.9287475e-05
current O 0 0.00013864103
evidence O 0 4.7896476e-05
suggests O 0 2.3378698e-05
that O 0 2.947108e-05
the O 0 4.7475478e-05
effects O 0 9.112803e-05
of O 0 0.00033476044
nicotine B-Chemical 1 0.99950206
are O 0 0.0001059973
much O 0 5.3454463e-05
less O 0 4.821911e-05
important O 0 2.6599395e-05
than O 0 3.6865324e-05
are O 0 4.9922477e-05
the O 0 7.724416e-05
prothrombotic O 0 0.1667162
effects O 0 0.0001371353
of O 0 0.00027341416
cigarette O 0 0.23972575
smoking O 0 0.06895127
or O 0 0.00013846808
the O 0 0.00016946421
effects O 0 0.00038987305
of O 0 0.0015390511
carbon B-Chemical 0 0.99558026
monoxide I-Chemical 0 0.99989223
. O 0 0.0039517567

Nicotine B-Chemical 0 0.9989818
does O 0 0.0030856146
not O 0 0.0017029891
appear O 0 0.0014023742
to O 0 0.0012875961
enhance O 0 0.0018329317
thrombosis B-Disease 0 0.9990392
among O 0 0.0045420565
humans O 0 0.007971936
. O 0 0.00438513

Clinical O 0 0.0054056128
studies O 0 0.0015071025
of O 0 0.0013335339
pipe O 0 0.007464058
smokers O 0 0.0032698154
and O 0 0.00034907882
people O 0 0.0003942348
using O 0 0.00025355158
transdermal O 0 0.9745283
nicotine B-Chemical 1 0.9983419
support O 0 0.00010970068
the O 0 9.136644e-05
idea O 0 0.000111078465
that O 0 7.4445044e-05
toxins O 0 0.0052478695
other O 0 0.00011739481
than O 0 0.000121411336
nicotine B-Chemical 1 0.99651504
are O 0 0.00011410781
the O 0 8.554531e-05
most O 0 0.00013977342
important O 0 8.447671e-05
causes O 0 0.0003560881
of O 0 0.0008122683
acute O 0 0.81018704
cardiovascular O 0 0.9866172
events O 0 0.03495813
. O 0 0.002462024

Finally O 0 0.0023469722
, O 0 0.0016803257
the O 0 0.00083543244
dose O 0 0.0015469401
response O 0 0.0004562855
for O 0 0.00032093926
cardiovascular O 0 0.44145238
events O 0 0.0018776674
of O 0 0.0007281995
nicotine B-Chemical 1 0.9991242
appears O 0 0.00013396333
to O 0 0.00010049795
be O 0 9.92004e-05
flat O 0 0.00036857923
, O 0 9.8289565e-05
suggesting O 0 4.0337298e-05
that O 0 5.1738432e-05
if O 0 9.442524e-05
nicotine B-Chemical 1 0.99761
is O 0 0.00012442714
involved O 0 6.072861e-05
, O 0 0.00011767624
adverse O 0 0.0034758584
effects O 0 0.00012019262
might O 0 6.0474733e-05
be O 0 7.5307e-05
seen O 0 8.1402955e-05
with O 0 0.00013896014
relatively O 0 0.00030228385
low O 0 0.0007004731
- O 0 0.00072565925
level O 0 0.00051761087
cigarette O 0 0.12491441
exposures O 0 0.008552555
. O 0 0.002454829

Iatrogenically O 0 0.08281554
induced O 0 0.0021648626
intractable O 0 0.028634004
atrioventricular B-Disease 0 0.7460805
reentrant I-Disease 0 0.24950622
tachycardia I-Disease 2 0.9977976
after O 0 0.0001967088
verapamil B-Chemical 0 0.999956
and O 0 0.00021391323
catheter O 0 0.00013899259
ablation O 0 9.2396804e-05
in O 0 6.347291e-05
a O 0 0.00010376018
patient O 0 0.00010865502
with O 0 0.00019590824
Wolff B-Disease 0 0.043853983
- I-Disease 0 0.0008398183
Parkinson I-Disease 0 0.9984964
- I-Disease 0 0.0008824351
White I-Disease 0 0.010110444
syndrome I-Disease 0 0.05817486
and O 0 0.0010190323
idiopathic B-Disease 0 0.998237
dilated I-Disease 0 0.99975866
cardiomyopathy I-Disease 0 0.9999937
. O 0 0.0056042937

In O 0 0.0015810642
a O 0 0.0015128743
patient O 0 0.001148743
with O 0 0.0021620863
WPW B-Disease 0 0.99993515
syndrome I-Disease 0 0.979412
and O 0 0.0015620973
idiopathic B-Disease 0 0.9993261
dilated I-Disease 0 0.99993813
cardiomyopathy I-Disease 0 0.9999995
, O 0 0.0008597361
intractable O 0 0.05615687
atrioventricular B-Disease 0 0.6618133
reentrant I-Disease 0 0.20692274
tachycardia I-Disease 2 0.9991842
( O 0 0.0010118493
AVRT B-Disease 0 0.9287406
) O 0 0.00069074286
was O 0 0.0006785796
iatrogenically O 0 0.026566261
induced O 0 0.0023358024
. O 0 0.0024339352

QRS O 0 0.28600213
without O 0 0.002833071
preexcitation O 0 0.94267803
, O 0 0.0010286185
caused O 0 0.00049823493
by O 0 0.00033597398
junctional O 0 0.00062876416
escape O 0 0.00051569316
beats O 0 0.0015286293
after O 0 8.561207e-05
verapamil B-Chemical 0 0.9999335
or O 0 0.00011852276
unidirectional O 0 0.00014524232
antegrade O 0 0.00020287724
block O 0 6.8904716e-05
of O 0 7.747728e-05
accessory O 0 7.473411e-05
pathway O 0 5.8119196e-05
after O 0 3.222963e-05
catheter O 0 0.00011927512
ablation O 0 0.00016385202
, O 0 0.00021744904
established O 0 0.00040223607
frequent O 0 0.0013735114
AVRT B-Disease 0 0.95976794
attack O 0 0.098515354
. O 0 0.0024545277

Epidemic O 0 0.0103457235
of O 0 0.0051201745
liver B-Disease 2 0.99748343
disease I-Disease 2 0.9906061
caused O 0 0.0019658268
by O 0 0.0012206208
hydrochlorofluorocarbons B-Chemical 0 0.8233513
used O 0 0.00048760677
as O 0 0.00062092894
ozone B-Chemical 0 0.9965365
- O 0 0.0021505225
sparing O 0 0.0055493857
substitutes O 0 0.0026943597
of O 0 0.002569625
chlorofluorocarbons B-Chemical 0 0.9546538
. O 0 0.0033594382

BACKGROUND O 0 0.011745529
: O 0 0.0041110306
Hydrochlorofluorocarbons B-Chemical 0 0.3053002
( O 0 0.0028515237
HCFCs B-Chemical 0 0.8547542
) O 0 0.0011311667
are O 0 0.00028541015
used O 0 0.00018518088
increasingly O 0 0.00024130318
in O 0 0.00018757908
industry O 0 0.0005323079
as O 0 0.00018315618
substitutes O 0 0.0004313277
for O 0 0.00023528517
ozone B-Chemical 0 0.99773467
- O 0 0.002060043
depleting O 0 0.01671297
chlorofluorocarbons B-Chemical 0 0.98986524
( O 0 0.0032381292
CFCs B-Chemical 0 0.91072035
) O 0 0.0038400732
. O 0 0.0024629158

Limited O 0 0.0082238605
studies O 0 0.0018502111
in O 0 0.0009603908
animals O 0 0.0005780009
indicate O 0 0.00044516748
potential O 0 0.0012963753
hepatotoxicity B-Disease 0 0.99996376
of O 0 0.0016876117
some O 0 0.0009129377
of O 0 0.0012405975
these O 0 0.0023835476
compounds O 0 0.41820556
. O 0 0.003617214

We O 0 0.0015360204
investigated O 0 0.00108371
an O 0 0.001138223
epidemic O 0 0.0015965193
of O 0 0.0015597364
liver B-Disease 2 0.999035
disease I-Disease 2 0.99084795
in O 0 0.00033172136
nine O 0 0.00019690752
industrial O 0 0.00091297843
workers O 0 0.00017482616
who O 0 0.00018393078
had O 0 7.990743e-05
had O 0 6.2928855e-05
repeated O 0 4.422093e-05
accidental O 0 0.004215504
exposure O 0 0.00016110309
to O 0 7.523264e-05
a O 0 0.00013081756
mixture O 0 0.00044586652
of O 0 0.00018217006
1 B-Chemical 0 9.596697e-05
, I-Chemical 0 0.000114650305
1 I-Chemical 0 0.000103635684
- I-Chemical 0 0.00038131516
dichloro I-Chemical 0 0.9613401
- I-Chemical 0 0.0004592536
2 I-Chemical 0 9.140495e-05
, I-Chemical 0 0.00010199001
2 I-Chemical 0 7.016596e-05
, I-Chemical 0 9.351384e-05
2 I-Chemical 0 7.912906e-05
- I-Chemical 0 0.0002033527
trifluoroethane I-Chemical 0 0.005390357
( O 0 0.00045224195
HCFC B-Chemical 0 0.999818
123 I-Chemical 0 0.07332185
) O 0 0.00026731734
and O 0 0.00012675492
1 B-Chemical 0 0.00012969773
- I-Chemical 0 0.00051416573
chloro I-Chemical 0 0.9981736
- I-Chemical 0 0.0006206911
1 I-Chemical 0 0.00012796925
, I-Chemical 0 0.00014152049
2 I-Chemical 0 0.00010096989
, I-Chemical 0 0.00013929908
2 I-Chemical 0 0.00011503468
, I-Chemical 0 0.00018080641
2 I-Chemical 0 0.00018965395
- I-Chemical 0 0.0006078638
tetrafluoroethane I-Chemical 0 0.45999756
( O 0 0.002172427
HCFC B-Chemical 0 0.9993425
124 I-Chemical 0 0.045813758
) O 0 0.0032564742
. O 0 0.002475261

All O 0 0.002613658
nine O 0 0.0019947884
exposed O 0 0.0016668593
workers O 0 0.0017683817
were O 0 0.0013809536
affected O 0 0.001515447
to O 0 0.001445267
various O 0 0.0027181013
degrees O 0 0.014704269
. O 0 0.005497811

Both O 0 0.0033260693
compounds O 0 0.1955337
are O 0 0.0018059475
metabolised O 0 0.26197022
in O 0 0.00041205544
the O 0 0.00024142675
same O 0 0.00012252822
way O 0 0.00018406112
as O 0 0.00018853751
1 B-Chemical 0 0.00020845114
- I-Chemical 0 0.0007362254
bromo I-Chemical 0 0.9977603
- I-Chemical 0 0.0009889021
1 I-Chemical 0 0.00021457428
- I-Chemical 0 0.0007692281
chloro I-Chemical 0 0.99893266
- I-Chemical 0 0.0006916855
2 I-Chemical 0 0.00011700599
, I-Chemical 0 0.00012282946
2 I-Chemical 0 8.1614366e-05
, I-Chemical 0 0.0001058252
2 I-Chemical 0 8.751485e-05
- I-Chemical 0 0.00022043791
trifluoroethane I-Chemical 0 0.0061908243
( O 0 0.0004484043
halothane B-Chemical 0 0.99989057
) O 0 0.00031556052
to O 0 8.5109015e-05
form O 0 0.00012263084
reactive O 0 0.020290786
trifluoroacetyl B-Chemical 0 0.99954
halide O 0 0.9804136
intermediates O 0 0.009648204
, O 0 0.00016874395
which O 0 0.00013998419
have O 0 7.4721065e-05
been O 0 7.615206e-05
implicated O 0 8.655171e-05
in O 0 0.00017510461
the O 0 0.0006115501
hepatotoxicity B-Disease 0 0.99998486
of O 0 0.021621635
halothane B-Chemical 0 0.9998518
. O 0 0.0040039825

We O 0 0.0017899121
aimed O 0 0.0020184473
to O 0 0.001211025
test O 0 0.0011693815
whether O 0 0.0005010451
HCFCs B-Chemical 0 0.8276868
123 I-Chemical 0 0.0044801557
and I-Chemical 0 0.000544109
124 I-Chemical 0 0.0008535388
can O 0 0.00024939844
result O 0 0.00035391113
in O 0 0.0006153996
serious O 0 0.022346647
liver B-Disease 2 0.9991911
disease I-Disease 2 0.9973456
. O 0 0.0048979307

METHODS O 0 0.0016652816
: O 0 0.001241556
For O 0 0.0003897932
one O 0 0.00046744547
severely O 0 0.0017830906
affected O 0 0.0005547283
worker O 0 0.0007108989
liver O 0 0.56613773
biopsy O 0 0.00090736424
and O 0 0.00016899369
immunohistochemical O 0 0.0003108893
stainings O 0 0.00020631128
for O 0 6.369805e-05
the O 0 9.1749025e-05
presence O 0 0.00014317014
of O 0 0.00049541786
trifluoroacetyl B-Chemical 0 0.9961862
protein O 0 0.0031578902
adducts O 0 0.7278838
were O 0 0.0010121973
done O 0 0.0011619306
. O 0 0.0018456216

The O 0 0.0018589363
serum O 0 0.007638132
of O 0 0.0012321537
six O 0 0.0004108591
affected O 0 0.00048583472
workers O 0 0.00033331336
and O 0 0.00021190877
five O 0 9.844585e-05
controls O 0 0.00023198129
was O 0 0.00012268407
tested O 0 8.5393636e-05
for O 0 8.4263665e-05
autoantibodies O 0 0.028009342
that O 0 8.385615e-05
react O 0 0.00023512686
with O 0 0.00017013354
human O 0 0.00043848486
liver O 0 0.993471
cytochrome O 0 0.9999758
- O 0 0.16556935
P450 O 0 0.99999833
2E1 O 0 0.9999989
( O 0 0.07707854
P450 O 0 0.9999974
2E1 O 0 0.99999714
) O 0 0.0009427529
and O 0 0.0003195604
P58 O 0 0.43918836
protein O 0 0.0014350653
disulphide O 0 0.9664106
isomerase O 0 0.6985447
isoform O 0 0.002582423
( O 0 0.0019908529
P58 O 0 0.61540383
) O 0 0.0032929776
. O 0 0.0024538296

FINDINGS O 0 0.0050125243
: O 0 0.001763388
The O 0 0.00077049586
liver O 0 0.07421545
biopsy O 0 0.001338129
sample O 0 0.000690445
showed O 0 0.0010275993
hepatocellular O 0 0.9999951
necrosis B-Disease 2 0.9999865
which O 0 0.0011146002
was O 0 0.00022809659
prominent O 0 0.00026506168
in O 0 0.0001373172
perivenular O 0 0.73881346
zone O 0 0.00037616366
three O 0 3.389835e-05
and O 0 5.9685924e-05
extended O 0 5.819512e-05
focally O 0 0.00025641362
from O 0 6.154288e-05
portal O 0 0.0017228196
tracts O 0 0.00011495398
to O 0 7.2365016e-05
portal O 0 0.0030745717
tracts O 0 0.00021573826
and O 0 0.00022677596
centrilobular O 0 0.942198
areas O 0 0.0005746949
( O 0 0.0007358844
bridging O 0 0.0042715287
necrosis B-Disease 2 0.99902666
) O 0 0.0051949243
. O 0 0.002529537

Trifluoroacetyl B-Chemical 0 0.91717917
- O 0 0.009461381
adducted O 0 0.015781257
proteins O 0 0.00226056
were O 0 0.0014828898
detected O 0 0.001186206
in O 0 0.0016985905
surviving O 0 0.00835521
hepatocytes O 0 0.17619637
. O 0 0.005303454

Autoantibodies O 0 0.02440645
against O 0 0.006604566
P450 O 0 0.9999722
2E1 O 0 0.999987
or O 0 0.0038212803
P58 O 0 0.8917245
, O 0 0.0005698152
previously O 0 0.00023390868
associated O 0 0.00020907537
with O 0 0.00094126805
halothane B-Disease 0 0.9999901
hepatitis I-Disease 2 0.99999774
, O 0 0.0011305882
were O 0 0.0001946091
detected O 0 9.543265e-05
in O 0 0.00010618608
the O 0 0.00016035946
serum O 0 0.0038607512
of O 0 0.0004812525
five O 0 0.00033043989
affected O 0 0.0009748515
workers O 0 0.0019508351
. O 0 0.0020827237

INTERPRETATION O 0 0.0071360697
: O 0 0.0018730742
Repeated O 0 0.001146557
exposure O 0 0.00083061855
of O 0 0.0006240276
human O 0 0.0005443985
beings O 0 0.0013504056
to O 0 0.00031200482
HCFCs B-Chemical 0 0.8681379
123 I-Chemical 0 0.002172339
and I-Chemical 0 0.00017617307
124 I-Chemical 0 0.00030197823
can O 0 6.0018734e-05
result O 0 7.5009426e-05
in O 0 0.000112846974
serious O 0 0.0043050135
liver B-Disease 0 0.9994925
injury I-Disease 0 0.9921787
in O 0 0.00025207785
a O 0 0.00023723501
large O 0 0.00019660061
proportion O 0 0.00015751088
of O 0 0.0002725826
the O 0 0.0003546508
exposed O 0 0.0007216105
population O 0 0.0024652362
. O 0 0.002054684

Although O 0 0.0014991809
the O 0 0.001186926
exact O 0 0.0010395943
mechanism O 0 0.00081066304
of O 0 0.0016902979
hepatotoxicity B-Disease 0 0.9999851
of O 0 0.0011163375
these O 0 0.0005790135
agents O 0 0.0013624018
is O 0 0.00016786694
not O 0 0.00011491079
known O 0 0.00017393545
, O 0 0.0001160587
the O 0 7.8938385e-05
results O 0 9.126108e-05
suggest O 0 5.3294283e-05
that O 0 0.00016315527
trifluoroacetyl B-Chemical 0 0.99750227
- O 0 0.001070186
altered O 0 0.00079209293
liver O 0 0.6949869
proteins O 0 0.0008844968
are O 0 0.000714622
involved O 0 0.000903334
. O 0 0.0017464004

In O 0 0.001895366
view O 0 0.0016427876
of O 0 0.0010717226
the O 0 0.00062369584
potentially O 0 0.0006047183
widespread O 0 0.0004786523
use O 0 0.00024705165
of O 0 0.00030829132
these O 0 0.0004790129
compounds O 0 0.23407637
, O 0 0.0003003468
there O 0 0.00011884303
is O 0 0.00017073679
an O 0 0.00023040565
urgent O 0 0.00033808302
need O 0 0.00020275776
to O 0 0.00026417512
develop O 0 0.0006103727
safer O 0 0.0011127092
alternatives O 0 0.0014023253
. O 0 0.0020442896

Bile B-Disease 0 0.98269534
duct I-Disease 0 0.53065014
hamartoma I-Disease 0 0.55545926
occurring O 0 0.0010358761
in O 0 0.00047418347
association O 0 0.00026464806
with O 0 0.00042176142
long O 0 0.00038965754
- O 0 0.00058038766
term O 0 0.0003973951
treatment O 0 0.00075335754
with O 0 0.0027846117
danazol B-Chemical 0 0.99939597
. O 0 0.0040720864

We O 0 0.0017960704
report O 0 0.001834894
a O 0 0.0011824972
case O 0 0.0006985005
of O 0 0.0010790696
bile B-Disease 0 0.99463093
duct I-Disease 0 0.8267155
hamartoma I-Disease 0 0.87350196
which O 0 0.0004087061
developed O 0 0.0002921194
in O 0 0.00012133958
a O 0 0.00017102697
patient O 0 0.000158841
who O 0 0.000198653
had O 0 0.00010971931
been O 0 8.212159e-05
on O 0 7.968152e-05
long O 0 0.00019966192
- O 0 0.00050699996
term O 0 0.0007479046
danazol B-Chemical 0 0.99925774
treatment O 0 0.0025224066
. O 0 0.0023402916

Such O 0 0.0039387224
patients O 0 0.0020734223
should O 0 0.00055520545
be O 0 0.0004474728
under O 0 0.0002689345
close O 0 0.00025874027
follow O 0 0.00020517701
- O 0 0.0004125743
up O 0 0.00022812746
, O 0 0.00023495677
preferably O 0 0.00025034376
with O 0 0.00022061919
periodic O 0 0.0003861595
ultrasound O 0 0.00090220076
examination O 0 0.00039235473
of O 0 0.0006577292
the O 0 0.0011946787
liver O 0 0.82427883
. O 0 0.0031445322

If O 0 0.0015144151
the O 0 0.0013726705
patient O 0 0.0011910223
develops O 0 0.0013990066
a O 0 0.0014744933
liver B-Disease 0 0.9954418
mass I-Disease 0 0.3044924
, O 0 0.0004029077
because O 0 0.00012476003
of O 0 0.00022159232
non O 0 0.00025954898
- O 0 0.00020964527
specific O 0 5.9952436e-05
clinical O 0 0.00019456941
features O 0 9.2139715e-05
and O 0 9.05045e-05
imaging O 0 0.0002098975
appearances O 0 0.0003384234
, O 0 0.00015069955
biopsy O 0 0.00027570385
may O 0 7.419848e-05
be O 0 6.9406975e-05
the O 0 7.614901e-05
only O 0 0.00010864932
way O 0 0.0001172496
to O 0 0.0001337484
achieve O 0 0.00019532107
a O 0 0.0005742074
definitive O 0 0.001095416
diagnosis O 0 0.002948832
. O 0 0.002076394

Endocrine O 0 0.024685174
screening O 0 0.0026413158
in O 0 0.001102663
1 O 0 0.000770974
, O 0 0.00084504
022 O 0 0.027415836
men O 0 0.0015747561
with O 0 0.00052370137
erectile B-Disease 0 0.8499743
dysfunction I-Disease 0 0.71801203
: O 0 0.00042182533
clinical O 0 0.00054201984
significance O 0 0.00021622758
and O 0 0.00028634476
cost O 0 0.00054121227
- O 0 0.00080026017
effective O 0 0.00069243176
strategy O 0 0.0018112452
. O 0 0.0023621584

PURPOSE O 0 0.0049817967
: O 0 0.0017476284
We O 0 0.0005721604
reviewed O 0 0.00073380815
the O 0 0.0003390174
results O 0 0.00030699407
of O 0 0.0004794128
serum O 0 0.23068836
testosterone B-Chemical 0 0.9999343
and O 0 0.00074854563
prolactin O 0 0.9570321
determination O 0 0.00073442934
in O 0 0.000113826114
1 O 0 8.475881e-05
, O 0 0.00011356635
022 O 0 0.010417532
patients O 0 0.00010009492
referred O 0 6.549923e-05
because O 0 3.6646004e-05
of O 0 0.00013618001
erectile B-Disease 0 0.87932444
dysfunction I-Disease 0 0.637437
and O 0 9.051313e-05
compared O 0 3.1643667e-05
the O 0 4.500767e-05
data O 0 6.369708e-05
with O 0 9.9795e-05
history O 0 0.00016499746
, O 0 6.681846e-05
results O 0 5.520092e-05
of O 0 8.461393e-05
physical O 0 0.00018102066
examination O 0 9.299311e-05
, O 0 7.196031e-05
other O 0 5.421502e-05
etiological O 0 0.00026962205
investigations O 0 0.000107931344
and O 0 5.715619e-05
effects O 0 6.980204e-05
of O 0 0.00013062036
endocrine O 0 0.023292476
therapy O 0 9.820376e-05
to O 0 4.6216068e-05
refine O 0 0.00018298687
the O 0 5.607957e-05
rules O 0 8.902878e-05
of O 0 0.0001109673
cost O 0 0.00016044374
- O 0 0.000174765
effective O 0 8.3600964e-05
endocrine O 0 0.013870416
screening O 0 0.00018835657
and O 0 9.498525e-05
to O 0 8.200749e-05
pinpoint O 0 0.00015735207
actual O 0 0.0001391626
responsibility O 0 0.00043342155
for O 0 0.0003641654
hormonal O 0 0.0077073225
abnormalities O 0 0.030408205
. O 0 0.0020910616

MATERIALS O 0 0.0028747017
AND O 0 0.0021676125
METHODS O 0 0.0013342744
: O 0 0.002506021
Testosterone B-Chemical 1 0.9965155
and O 0 0.0021910926
prolactin O 0 0.6047729
were O 0 0.0015223708
determined O 0 0.0014720773
by O 0 0.0029171421
radioimmunoassay O 0 0.43112448
. O 0 0.004776596

Every O 0 0.0018562794
patient O 0 0.0015503648
was O 0 0.0009882898
screened O 0 0.0008821397
for O 0 0.00054855406
testosterone B-Chemical 0 0.999566
and O 0 0.000691296
451 O 0 0.0041080033
were O 0 0.00016528656
screened O 0 0.00017878419
for O 0 8.982912e-05
prolactin O 0 0.33632535
on O 0 4.9844555e-05
the O 0 6.1008323e-05
basis O 0 7.0727976e-05
of O 0 0.00013014843
low B-Disease 0 0.0011266811
sexual I-Disease 0 0.015528603
desire I-Disease 0 0.05714432
, O 0 0.00051718025
gynecomastia B-Disease 0 0.9991937
or O 0 0.00044224528
testosterone B-Chemical 0 0.9998441
less O 0 0.00026839966
than O 0 0.0001334401
4 O 0 0.00015795608
ng O 0 0.00063224015
. O 0 0.0004172348
/ O 0 0.0019814407
ml O 0 0.0035937866
. O 0 0.0023325945

Determination O 0 0.0063092294
was O 0 0.0022676713
repeated O 0 0.0009962366
in O 0 0.0011039054
case O 0 0.0011083299
of O 0 0.0015478205
abnormal O 0 0.0050535756
first O 0 0.0015257115
results O 0 0.0033607443
. O 0 0.004347989

Prolactin O 0 0.96171236
results O 0 0.0016465158
were O 0 0.00077866565
compared O 0 0.00033222363
with O 0 0.00038402728
those O 0 0.00032680292
of O 0 0.00025679846
a O 0 0.0002364997
previous O 0 0.00016037705
personal O 0 0.0004982266
cohort O 0 0.0006611802
of O 0 0.00020040291
1 O 0 0.00011818689
, O 0 0.00015012755
340 O 0 0.0020099545
patients O 0 0.00020297708
with O 0 0.00025912194
erectile B-Disease 0 0.80635375
dysfunction I-Disease 0 0.5633019
and O 0 0.00042162032
systematic O 0 0.00080102764
prolactin O 0 0.9110548
determination O 0 0.0049145874
. O 0 0.0019573392

Main O 0 0.0050404253
clinical O 0 0.0025179486
criteria O 0 0.0009002686
tested O 0 0.00043262032
regarding O 0 0.00021986406
efficiency O 0 0.00036802734
in O 0 0.00030893658
hormone O 0 0.032012545
determination O 0 0.00077044294
were O 0 0.0002692013
low B-Disease 0 0.0012497475
sexual I-Disease 0 0.007029054
desire I-Disease 0 0.012373851
, O 0 0.0005304512
small O 0 0.0007099301
testes O 0 0.004826984
and O 0 0.002115927
gynecomastia B-Disease 0 0.99820983
. O 0 0.0031831462

Endocrine O 0 0.014394596
therapy O 0 0.001635427
consisted O 0 0.0008282432
of O 0 0.0016331349
testosterone B-Chemical 0 0.999907
heptylate I-Chemical 0 0.41018513
or O 0 0.0003443804
human O 0 0.00052300486
chorionic O 0 0.86594826
gonadotropin O 0 0.9908771
for O 0 0.0005103188
hypogonadism B-Disease 0 0.9998312
and O 0 0.0018592433
bromocriptine B-Chemical 0 0.99992096
for O 0 0.0026199676
hyperprolactinemia B-Disease 0 0.9999136
. O 0 0.003596011

RESULTS O 0 0.0073418496
: O 0 0.005455928
Testosterone B-Chemical 1 0.99936265
was O 0 0.0013428412
less O 0 0.00061169645
than O 0 0.00028791168
3 O 0 0.00022397516
ng O 0 0.00057964463
. O 0 0.0001857953
/ O 0 0.00056435785
ml O 0 0.00051076204
. O 0 9.3745635e-05
in O 0 0.00010388085
107 O 0 0.00023271277
patients O 0 0.00018047554
but O 0 0.00013833701
normal O 0 0.0002573095
in O 0 0.00014269844
40 O 0 0.00020236721
% O 0 0.0002462089
at O 0 0.00026236792
repeat O 0 0.00083171355
determination O 0 0.0026841133
. O 0 0.0020948288

The O 0 0.0016993192
prevalence O 0 0.0015194324
of O 0 0.0010423452
repeatedly O 0 0.00081924757
low O 0 0.0025118494
testosterone B-Chemical 0 0.9997985
increased O 0 0.0013374715
with O 0 0.00059962925
age O 0 0.00037604212
( O 0 0.0002373373
4 O 0 8.452128e-05
% O 0 9.0594214e-05
before O 0 4.3992666e-05
age O 0 0.0001134949
50 O 0 0.00016749295
years O 0 9.8709716e-05
and O 0 0.00011906081
9 O 0 0.00011977342
% O 0 0.00017473468
50 O 0 0.00031392128
years O 0 0.00027602367
or O 0 0.0004636706
older O 0 0.0028197756
) O 0 0.0024149306
. O 0 0.0022470998

Two O 0 0.005904975
pituitary B-Disease 0 0.92915165
tumors I-Disease 0 0.93658113
were O 0 0.0025329804
discovered O 0 0.00239011
after O 0 0.0015778503
testosterone B-Chemical 0 0.9985056
determination O 0 0.020809734
. O 0 0.005940528

Most O 0 0.0031539146
of O 0 0.0015074642
the O 0 0.0008505794
other O 0 0.00066744385
low O 0 0.0023677535
testosterone B-Chemical 0 0.99979264
levels O 0 0.0004895012
seemed O 0 0.0002833153
to O 0 0.00011675112
result O 0 0.000104717175
from O 0 0.00013179278
nonorganic O 0 0.96561193
hypothalamic B-Disease 0 0.43129373
dysfunction I-Disease 0 0.9800923
because O 0 5.820195e-05
of O 0 0.000102677695
normal O 0 0.00033423872
serum O 0 0.087654874
luteinizing O 0 0.961078
hormone O 0 0.2384444
and O 0 0.00017209502
prolactin O 0 0.7961926
and O 0 8.502806e-05
to O 0 4.893034e-05
have O 0 3.6676385e-05
only O 0 5.550358e-05
a O 0 7.146724e-05
small O 0 6.511045e-05
role O 0 3.366575e-05
in O 0 8.979358e-05
erectile B-Disease 0 0.8916586
dysfunction I-Disease 0 0.8522486
( O 0 0.00023580933
definite O 0 0.00042131054
improvement O 0 8.439434e-05
in O 0 4.881266e-05
only O 0 6.224744e-05
16 O 0 5.1919324e-05
of O 0 7.601739e-05
44 O 0 0.00012652752
[ O 0 0.0001590961
36 O 0 6.389223e-05
% O 0 8.019491e-05
] O 0 0.00013133878
after O 0 3.324766e-05
androgen O 0 0.9851313
therapy O 0 0.00016639697
, O 0 7.734322e-05
normal O 0 0.0001199468
morning O 0 0.00014090675
or O 0 5.7582754e-05
nocturnal O 0 0.0017064721
erections O 0 0.038523473
in O 0 6.630547e-05
30 O 0 5.366264e-05
% O 0 8.468844e-05
and O 0 0.00011928468
definite O 0 0.0010361543
vasculogenic O 0 0.44594932
contributions O 0 0.00039300646
in O 0 0.00039179742
42 O 0 0.00072368555
% O 0 0.00096255686
) O 0 0.0019182701
. O 0 0.0020241817

Determining O 0 0.0041646454
testosterone B-Chemical 0 0.99819046
only O 0 0.0013463128
in O 0 0.00059727015
cases O 0 0.0004819088
of O 0 0.00043953612
low B-Disease 0 0.0019960809
sexual I-Disease 0 0.008311108
desire I-Disease 0 0.007018618
or O 0 0.0001366982
abnormal O 0 0.000821202
physical O 0 0.00024681905
examination O 0 9.987544e-05
would O 0 6.501899e-05
have O 0 4.973891e-05
missed O 0 0.00010604856
40 O 0 7.334509e-05
% O 0 6.000964e-05
of O 0 6.657639e-05
the O 0 6.554553e-05
cases O 0 9.681195e-05
with O 0 0.00013440207
low O 0 0.0009307159
testosterone B-Chemical 0 0.9999269
, O 0 0.0002132837
including O 0 6.962143e-05
37 O 0 0.00017861396
% O 0 9.669329e-05
of O 0 0.0001229436
those O 0 0.00017909028
subsequently O 0 0.00023215696
improved O 0 0.0006211414
by O 0 0.0008132519
androgen O 0 0.997189
therapy O 0 0.0036002437
. O 0 0.0020554967

Prolactin O 0 0.95076305
exceeded O 0 0.0018850241
20 O 0 0.0011523049
ng O 0 0.0018453862
. O 0 0.00050064217
/ O 0 0.0011537062
ml O 0 0.00095703127
. O 0 0.0001823127
in O 0 0.00017684393
5 O 0 0.00015914027
men O 0 0.00052273605
and O 0 0.0001759176
was O 0 0.00020234367
normal O 0 0.0003371501
in O 0 0.00020188463
2 O 0 0.00021406912
at O 0 0.00027039484
repeat O 0 0.0008524533
determination O 0 0.0027030457
. O 0 0.0021992978

Only O 0 0.013699216
1 O 0 0.012761783
prolactinoma B-Disease 2 0.9941707
was O 0 0.013414363
discovered O 0 0.014588548
. O 0 0.012252443

These O 0 0.002218316
data O 0 0.0015970803
are O 0 0.00085736095
lower O 0 0.0007356118
than O 0 0.00030029638
those O 0 0.0003178104
we O 0 0.00010900039
found O 0 0.000116748786
during O 0 6.1032362e-05
the O 0 8.887271e-05
last O 0 4.551178e-05
2 O 0 7.6160555e-05
decades O 0 9.176337e-05
( O 0 0.00010264822
overall O 0 0.00011679187
prolactin O 0 0.47877
greater O 0 0.000111442365
than O 0 5.646615e-05
20 O 0 7.610241e-05
ng O 0 0.0002533249
. O 0 7.547797e-05
/ O 0 0.0003357436
ml O 0 0.00035928766
. O 0 5.824848e-05
in O 0 6.968252e-05
1 O 0 6.3974534e-05
. O 0 4.4124048e-05
86 O 0 0.00011180587
% O 0 7.669792e-05
of O 0 9.939488e-05
1 O 0 8.330215e-05
, O 0 0.00012798952
821 O 0 0.0015571009
patients O 0 0.00022831588
, O 0 0.0002488054
prolactinomas B-Disease 0 0.9943252
in O 0 0.00018318134
7 O 0 0.00012557198
, O 0 0.00020241083
0 O 0 0.00020189867
. O 0 0.00023767381
38 O 0 0.0006708902
% O 0 0.0009956198
) O 0 0.0020512335
. O 0 0.0022774423

Bromocriptine B-Chemical 0 0.9990232
was O 0 0.002787388
definitely O 0 0.0026076285
effective O 0 0.00056349696
in O 0 0.0004385668
cases O 0 0.00047183144
with O 0 0.00052271766
prolactin O 0 0.73985803
greater O 0 0.0003771522
than O 0 0.00022291548
35 O 0 0.0003521318
ng O 0 0.0010404156
. O 0 0.00058735994
/ O 0 0.0025120296
ml O 0 0.0042932867
. O 0 0.0027448167

( O 0 0.0041528526
8 O 0 0.0012615385
of O 0 0.0009460417
12 O 0 0.00038181897
compared O 0 0.0002650162
to O 0 0.00025718613
only O 0 0.00027129118
9 O 0 0.000164281
of O 0 0.000185479
22 O 0 0.00018823054
cases O 0 0.00015829004
with O 0 0.0002000701
prolactin O 0 0.567016
between O 0 8.3365005e-05
20 O 0 0.00011637798
and O 0 0.00012584492
35 O 0 0.00015782224
ng O 0 0.0004887405
. O 0 0.0002454205
/ O 0 0.0010882101
ml O 0 0.0016681809
. O 0 0.00079261843
) O 0 0.002204534
. O 0 0.002329229

Testosterone B-Chemical 1 0.99941146
was O 0 0.0030446243
low O 0 0.001834274
in O 0 0.0006361045
less O 0 0.0004811321
than O 0 0.0002507551
50 O 0 0.00040993464
% O 0 0.00023612163
of O 0 0.00023296608
cases O 0 0.00025730435
with O 0 0.00031960005
prolactin O 0 0.73159903
greater O 0 0.00025838922
than O 0 0.00016111736
35 O 0 0.00027078544
ng O 0 0.0008547307
. O 0 0.0004931977
/ O 0 0.0022399707
ml O 0 0.003925086
. O 0 0.0024944702

CONCLUSIONS O 0 0.014877935
: O 0 0.0026156898
Low O 0 0.0043626246
prevalences O 0 0.0013777588
and O 0 0.00047432838
effects O 0 0.00039647202
of O 0 0.0005119587
low O 0 0.0018140043
testosterone B-Chemical 0 0.99985313
and O 0 0.0004178221
high O 0 0.00076992693
prolactin O 0 0.9195716
in O 0 0.00034889486
erectile B-Disease 0 0.9042557
dysfunction I-Disease 0 0.7109557
cannot O 0 0.0009855322
justify O 0 0.0003831462
their O 0 0.0004404299
routine O 0 0.0006363301
determination O 0 0.0022406476
. O 0 0.0018027861

However O 0 0.0030102718
, O 0 0.002328601
cost O 0 0.0017448947
- O 0 0.0012490323
effective O 0 0.00039723486
screening O 0 0.00047822358
strategies O 0 0.00026594513
recommended O 0 0.00024014503
so O 0 0.00016307518
far O 0 0.00015632182
missed O 0 0.00019985446
40 O 0 0.000116622046
to O 0 8.009617e-05
50 O 0 0.00015619193
% O 0 9.9370045e-05
of O 0 0.00011751892
cases O 0 0.00014248429
improved O 0 0.00023013692
with O 0 0.00022674266
endocrine O 0 0.02292038
therapy O 0 0.00036267165
and O 0 0.00034461953
the O 0 0.00075266993
pituitary B-Disease 0 0.9925724
tumors I-Disease 0 0.9963355
. O 0 0.0032139919

We O 0 0.0016088547
now O 0 0.0012623293
advocate O 0 0.0009622639
that O 0 0.00037100803
before O 0 0.00021528908
age O 0 0.00036834288
50 O 0 0.00045963158
years O 0 0.00032052764
testosterone B-Chemical 0 0.99914515
be O 0 0.00015014446
determined O 0 8.962454e-05
only O 0 9.867677e-05
in O 0 7.8123405e-05
cases O 0 0.00010126059
of O 0 0.00013272188
low B-Disease 0 0.0010862988
sexual I-Disease 0 0.006845859
desire I-Disease 0 0.006419742
and O 0 0.0001090893
abnormal O 0 0.0007164427
physical O 0 0.00021658203
examination O 0 9.476577e-05
but O 0 7.0823546e-05
that O 0 5.0274964e-05
it O 0 8.422896e-05
be O 0 6.1708415e-05
measured O 0 6.547413e-05
in O 0 9.968667e-05
all O 0 0.00017993394
men O 0 0.0009858542
older O 0 0.00077261776
than O 0 0.0002917153
50 O 0 0.00095454336
years O 0 0.0009951541
. O 0 0.0015745868

Prolactin O 0 0.96741587
should O 0 0.0010495267
be O 0 0.0006894649
determined O 0 0.000414292
only O 0 0.00036741665
in O 0 0.00025751
cases O 0 0.0002703608
of O 0 0.00030137968
low B-Disease 0 0.001990385
sexual I-Disease 0 0.02324135
desire I-Disease 0 0.07588858
, O 0 0.00064216874
gynecomastia B-Disease 0 0.9984688
and O 0 0.00029333984
/ O 0 0.00068772526
or O 0 0.00024759545
testosterone B-Chemical 0 0.99964595
less O 0 0.00027154296
than O 0 0.0001438862
4 O 0 0.00017140688
ng O 0 0.00067177735
. O 0 0.00044402404
/ O 0 0.0020609
ml O 0 0.0037067
. O 0 0.0024184173

Extrapyramidal O 0 0.9890382
side O 0 0.011523705
effects O 0 0.0016308546
with O 0 0.0027275002
risperidone B-Chemical 0 0.9999708
and O 0 0.0031929763
haloperidol B-Chemical 1 0.99998975
at O 0 0.0005191089
comparable O 0 0.00069139025
D2 O 0 0.99628335
receptor O 0 0.02918018
occupancy O 0 0.0029464106
levels O 0 0.002108225
. O 0 0.0025838912

Risperidone B-Chemical 1 0.99968505
is O 0 0.0021281808
an O 0 0.0018696676
antipsychotic O 0 0.99648726
drug O 0 0.020775463
with O 0 0.00046427478
high O 0 0.0005197035
affinity O 0 0.00092279806
at O 0 0.00033991257
dopamine B-Chemical 0 0.99990666
D2 O 0 0.99938416
and O 0 0.00092776096
serotonin B-Chemical 0 0.9987231
5 I-Chemical 0 0.0004838124
- I-Chemical 0 0.0015388737
HT2 I-Chemical 0 0.96086866
receptors O 0 0.014478369
. O 0 0.0027695603

Previous O 0 0.0014613575
clinical O 0 0.0021664866
studies O 0 0.0007486563
have O 0 0.0003130256
proposed O 0 0.0002882671
that O 0 0.00035353715
risperidone B-Chemical 0 0.999967
' O 0 0.00038790706
s O 0 0.00015287806
pharmacologic O 0 0.00046127045
profile O 0 0.00010936665
may O 0 5.3653173e-05
produce O 0 4.040891e-05
improved O 0 0.00011591116
efficacy O 0 8.6467815e-05
for O 0 5.4685144e-05
negative O 0 0.0004840043
psychotic B-Disease 0 0.9999975
symptoms I-Disease 0 0.7396205
and O 0 0.00013056982
decreased O 0 0.0001922363
propensity O 0 0.00018124518
for O 0 0.00010329992
extrapyramidal O 0 0.99994445
side O 0 0.017875606
effects O 0 0.0002271774
; O 0 0.00015713676
features O 0 0.00012814949
shared O 0 0.00018938613
by O 0 0.00017277701
so O 0 0.00017982846
- O 0 0.00037750902
called O 0 0.0003348466
' O 0 0.0006402199
atypical O 0 0.0034373081
' O 0 0.0025053823
neuroleptics O 0 0.998757
. O 0 0.002701527

To O 0 0.0015343758
determine O 0 0.0006693007
if O 0 0.0006262243
routine O 0 0.0011428882
risperidone B-Chemical 0 0.99993825
treatment O 0 0.0005867632
is O 0 0.00023676771
associated O 0 0.00013988957
with O 0 0.00016173923
a O 0 0.0001475447
unique O 0 9.9804995e-05
degree O 0 0.00018687482
of O 0 0.0004753751
D2 O 0 0.99944705
receptor O 0 0.013346561
occupancy O 0 0.0002822786
and O 0 6.3979904e-05
pattern O 0 4.1742416e-05
of O 0 7.816684e-05
clinical O 0 0.00019466999
effects O 0 9.657516e-05
, O 0 8.115942e-05
we O 0 3.4598535e-05
used O 0 8.2561535e-05
[ O 0 0.00066900125
123I O 0 0.9965597
] O 0 0.0017245305
IBZM O 0 0.9999083
SPECT O 0 0.83568144
to O 0 7.526823e-05
determine O 0 4.8783386e-05
D2 O 0 0.96842784
occupancy O 0 0.00019670562
in O 0 5.167694e-05
subjects O 0 6.7220775e-05
treated O 0 6.602475e-05
with O 0 6.179216e-05
routine O 0 5.4284246e-05
clinical O 0 0.00016391891
doses O 0 0.00048342266
of O 0 0.0004227601
risperidone B-Chemical 0 0.9999913
( O 0 0.0002609643
n O 0 8.636661e-05
= O 0 9.217716e-05
12 O 0 4.8442653e-05
) O 0 0.00015589524
or O 0 0.00024200429
haloperidol B-Chemical 1 0.9999871
( O 0 0.00075510156
n O 0 0.00038166466
= O 0 0.00058745395
7 O 0 0.0005681103
) O 0 0.001636998
. O 0 0.001987218

Both O 0 0.004552023
risperidone B-Chemical 0 0.99987197
and O 0 0.0059672315
haloperidol B-Chemical 1 0.9999889
produced O 0 0.002850087
D2 O 0 0.9985152
occupancy O 0 0.00083950226
levels O 0 0.00017447495
between O 0 7.898643e-05
approximately O 0 0.00013563495
60 O 0 0.00012564372
and O 0 0.00012447448
90 O 0 0.00013986288
% O 0 0.00016289631
at O 0 0.0001480217
standard O 0 0.00034334793
clinical O 0 0.0018201311
doses O 0 0.006625276
. O 0 0.002550621

There O 0 0.0028932665
was O 0 0.0017459381
no O 0 0.0006402965
significant O 0 0.0005676064
difference O 0 0.00025608062
between O 0 0.00020139974
occupancy O 0 0.0004925917
levels O 0 0.00030413593
obtained O 0 0.0004709548
with O 0 0.0019186055
haloperidol B-Chemical 1 0.99999046
or O 0 0.007940833
risperidone B-Chemical 0 0.9999378
. O 0 0.003959249

Drug B-Disease 0 0.4266111
- I-Disease 0 0.005875434
induced I-Disease 0 0.0043298732
parkinsonism I-Disease 2 0.99992836
was O 0 0.0008971265
observed O 0 0.00024898504
in O 0 0.00018244816
subjects O 0 0.00022019468
treated O 0 0.00025347713
with O 0 0.0006088365
risperidone B-Chemical 0 0.99998903
( O 0 0.0003469908
42 O 0 0.00015235737
% O 0 0.000119680255
) O 0 0.0001824026
and O 0 0.00027544034
haloperidol B-Chemical 1 0.9999958
( O 0 0.00044491756
29 O 0 0.00026093944
% O 0 0.00013703322
) O 0 0.00016206417
and O 0 0.000105380124
was O 0 0.00011242916
observed O 0 8.647862e-05
at O 0 9.728994e-05
occupancy O 0 0.00036710151
levels O 0 0.0002965231
above O 0 0.0005112155
60 O 0 0.00078593893
% O 0 0.0013992345
. O 0 0.0019139233

Based O 0 0.0031188978
on O 0 0.0010106046
these O 0 0.0012460389
observations O 0 0.0011219122
, O 0 0.000764551
it O 0 0.0004282864
is O 0 0.00023519323
concluded O 0 0.00013727215
that O 0 0.000113183414
5 O 0 0.00012752878
- O 0 0.00038794754
HT2 O 0 0.9665709
blockade O 0 0.005128758
obtained O 0 0.0001634502
with O 0 0.0004076248
risperidone B-Chemical 0 0.9999869
at O 0 0.0001664192
D2 O 0 0.99360996
occupancy O 0 0.0002534868
rates O 0 6.703297e-05
of O 0 7.7880395e-05
60 O 0 6.553103e-05
% O 0 6.4255546e-05
and O 0 5.7719702e-05
above O 0 6.5252665e-05
does O 0 6.343968e-05
not O 0 6.71738e-05
appear O 0 7.217302e-05
to O 0 6.662504e-05
protect O 0 0.00011746032
against O 0 8.617411e-05
the O 0 0.00019528794
risk O 0 0.0016068652
for O 0 0.00048229934
extrapyramidal O 0 0.9998908
side O 0 0.11855745
effects O 0 0.003354617
. O 0 0.0026690857

Treatment O 0 0.0039865277
of O 0 0.0016042006
previously O 0 0.00092845154
treated O 0 0.0017667329
metastatic O 0 0.8116843
breast B-Disease 0 0.9992256
cancer I-Disease 0 0.99980634
by O 0 0.0010899783
mitoxantrone B-Chemical 1 0.99899787
and O 0 0.00024233865
48 O 0 8.628988e-05
- O 0 0.00010987425
hour O 0 3.5579626e-05
continuous O 0 3.7307367e-05
infusion O 0 0.000110729474
of O 0 8.95065e-05
high O 0 0.00021974626
- O 0 0.00022251075
dose O 0 0.0003743361
5 B-Chemical 0 7.218271e-05
- I-Chemical 0 0.0002173375
FU I-Chemical 0 0.052028745
and O 0 0.00024589832
leucovorin B-Chemical 0 0.999895
( O 0 0.000654361
MFL B-Chemical 0 0.91830283
) O 0 0.0002874572
: O 0 0.00013788596
low O 0 0.0001948512
palliative O 0 0.00016653571
benefit O 0 0.00012668641
and O 0 0.00014415756
high O 0 0.00038220207
treatment O 0 0.00039116226
- O 0 0.0008384351
related O 0 0.0005846683
toxicity B-Disease 2 0.9894845
. O 0 0.0029994964

For O 0 0.0013509026
previously O 0 0.0015050854
treated O 0 0.0023709666
advanced O 0 0.047994725
breast B-Disease 0 0.99901736
cancer I-Disease 0 0.9997422
, O 0 0.000924486
there O 0 0.0002103627
is O 0 0.00022338357
no O 0 0.000139357
standard O 0 0.00022831807
second O 0 0.0004549959
- O 0 0.001172575
line O 0 0.0015840493
therapy O 0 0.002717729
. O 0 0.0024790552

Combination O 0 0.01251489
chemotherapy O 0 0.009240986
with O 0 0.0023643172
mitoxantrone B-Chemical 1 0.99827635
, O 0 0.0011121142
high O 0 0.0011248796
- O 0 0.00081026956
dose O 0 0.001171683
5 B-Chemical 0 0.00020068664
- I-Chemical 0 0.00070660183
fluorouracil I-Chemical 0 0.9962081
( O 0 0.00030683636
5 B-Chemical 0 0.00010508148
- I-Chemical 0 0.00028945986
FU I-Chemical 0 0.055291433
) O 0 0.00021862236
and O 0 0.00021063085
leucovorin B-Chemical 0 0.9998561
( O 0 0.00067825086
MFL B-Chemical 0 0.99393445
regimen I-Chemical 0 0.0016572074
) O 0 0.00026205336
had O 0 0.00010585448
been O 0 7.546472e-05
reported O 0 0.00011025366
as O 0 8.838388e-05
an O 0 0.00014234605
effective O 0 0.00013393638
and O 0 0.00023733346
well O 0 0.0003373067
tolerated O 0 0.0038123745
regimen O 0 0.002093639
. O 0 0.0019426912

From O 0 0.0021636658
October O 0 0.0016847854
1993 O 0 0.0018756543
to O 0 0.0006104611
November O 0 0.0006032153
1995 O 0 0.0008621447
, O 0 0.00029045786
we O 0 0.0001060612
treated O 0 0.00023405257
13 O 0 0.0001522534
patients O 0 0.00014013855
with O 0 0.000116714386
previously O 0 0.00011794283
chemotherapy O 0 0.0017304808
- O 0 0.0003049399
treated O 0 0.00040089493
metastatic O 0 0.8426312
breast B-Disease 0 0.9996426
cancer I-Disease 0 0.9999169
by O 0 0.00069051713
mitoxantrone B-Chemical 1 0.99916434
, O 0 0.00016617404
12 O 0 4.7924532e-05
mg O 0 0.0013906446
/ O 0 0.0003145561
m2 O 0 0.0006249496
, O 0 7.128837e-05
on O 0 2.746588e-05
day O 0 2.9554725e-05
1 O 0 3.312904e-05
and O 0 3.6796126e-05
continuous O 0 3.4427616e-05
infusion O 0 0.00011270781
of O 0 9.050795e-05
5 B-Chemical 0 6.811351e-05
- I-Chemical 0 0.00021985732
FU I-Chemical 0 0.03662413
, O 0 0.00011457074
3000 O 0 0.00030860538
mg O 0 0.0019125782
/ O 0 0.00032575242
m2 O 0 0.00061758957
, O 0 8.636521e-05
together O 0 7.199093e-05
with O 0 0.00022783464
leucovorin B-Chemical 0 0.9998323
, O 0 0.0002202039
300 O 0 0.0005559548
mg O 0 0.006590939
/ O 0 0.0005288281
m2 O 0 0.00093110045
, O 0 0.000119634155
for O 0 6.390771e-05
48 O 0 7.053985e-05
h O 0 8.3316685e-05
from O 0 0.00011257571
day O 0 0.00015265257
1 O 0 0.0002851425
to O 0 0.0005003526
2 O 0 0.0009964363
. O 0 0.0017867865

Each O 0 0.0014891302
course O 0 0.0016344354
of O 0 0.0019930198
chemotherapy O 0 0.0052840775
was O 0 0.0012376981
given O 0 0.0006239423
every O 0 0.0005095309
4 O 0 0.0010553378
weeks O 0 0.00119392
. O 0 0.0030349626

Most O 0 0.0032607086
of O 0 0.0016856398
these O 0 0.0012712035
patients O 0 0.0009489706
had O 0 0.00044588352
more O 0 0.00041769922
than O 0 0.00021952805
two O 0 0.00023762939
metastatic O 0 0.015719607
sites O 0 0.00033930308
, O 0 0.00052248995
with O 0 0.000916684
lung O 0 0.3162786
metastasis O 0 0.99934405
predominant O 0 0.0051380508
. O 0 0.0029672184

Seven O 0 0.006880913
patients O 0 0.0040229154
had O 0 0.002429766
been O 0 0.0018989432
treated O 0 0.0033397088
with O 0 0.0059583853
anthracycline B-Chemical 0 0.99814034
. O 0 0.009167963

Seven O 0 0.003994814
patients O 0 0.0019418962
had O 0 0.00089377514
previously O 0 0.000551816
received O 0 0.00044127356
radiotherapy O 0 0.002481134
and O 0 0.0004512403
seven O 0 0.00034877795
had O 0 0.0004831907
received O 0 0.0006757411
hormone O 0 0.10231123
therapy O 0 0.003301705
. O 0 0.0025678473

Median O 0 0.0015869417
number O 0 0.0009393557
of O 0 0.0007397763
courses O 0 0.0005374721
of O 0 0.00077208044
MFL B-Chemical 0 0.9814463
regimen I-Chemical 0 0.0012736382
given O 0 0.00014212579
was O 0 0.00014939388
six O 0 5.5483586e-05
and O 0 7.3026145e-05
the O 0 6.373802e-05
median O 0 4.3817698e-05
cumulative O 0 0.00014042268
dose O 0 0.00049042946
of O 0 0.00038895427
mitoxantrone B-Chemical 1 0.99769324
was O 0 0.00037393693
68 O 0 0.00032246756
. O 0 0.00013832095
35 O 0 0.00031197956
mg O 0 0.0037772215
/ O 0 0.0022896237
m2 O 0 0.0063576307
. O 0 0.00225816

One O 0 0.0022073928
patient O 0 0.0014661764
had O 0 0.0007255777
complete O 0 0.00047875135
response O 0 0.00044641236
, O 0 0.00039935226
seven O 0 0.00020894024
had O 0 0.00021580345
stable O 0 0.00036497953
disease O 0 0.07865532
, O 0 0.00023165857
none O 0 0.00015294456
had O 0 0.00012628188
partial O 0 0.00021292147
response O 0 0.00017158412
and O 0 0.0002208271
five O 0 0.0002022781
had O 0 0.00061794405
progressive O 0 0.13116337
disease O 0 0.61855334
. O 0 0.0029577734

The O 0 0.0021028689
overall O 0 0.0020050749
objective O 0 0.0018558864
response O 0 0.0014839207
rate O 0 0.0016806825
was O 0 0.0015830896
7 O 0 0.0010359774
. O 0 0.001040492
6 O 0 0.0013491008
% O 0 0.0030554277
. O 0 0.0041127657

The O 0 0.0023105622
median O 0 0.0015294454
follow O 0 0.0013411031
- O 0 0.0020355494
up O 0 0.0012359151
period O 0 0.00084570266
was O 0 0.0015787648
14 O 0 0.0016436621
months O 0 0.001534414
. O 0 0.0035520887

Median O 0 0.007940203
survival O 0 0.017157843
was O 0 0.008193318
16 O 0 0.006953117
months O 0 0.0052739293
. O 0 0.009681265

Median O 0 0.004466913
progression O 0 0.01745591
- O 0 0.00515477
free O 0 0.003524629
survival O 0 0.008438897
was O 0 0.002942292
5 O 0 0.0020731904
months O 0 0.0019732623
. O 0 0.004271091

A O 0 0.012817534
complete O 0 0.0021081644
responder O 0 0.012172808
had O 0 0.0017808302
relapse O 0 0.26669204
- O 0 0.0017875246
free O 0 0.0010880402
survival O 0 0.002921275
up O 0 0.000846073
to O 0 0.00081785454
17 O 0 0.0014930065
months O 0 0.0009834977
. O 0 0.00236223

Major O 0 0.016991967
toxicities B-Disease 2 0.98580384
were O 0 0.014358124
cardiotoxicity B-Disease 0 0.9997452
and O 0 0.032048833
leukopenia B-Disease 0 0.99951625
. O 0 0.015015255

Eight O 0 0.0034945386
patients O 0 0.0018578352
were O 0 0.0008678065
dead O 0 0.0010542405
in O 0 0.00030345644
the O 0 0.00021596733
last O 0 0.000100996076
follow O 0 0.00013336811
- O 0 0.00030063468
up O 0 0.00017430884
; O 0 0.00016976196
two O 0 8.2829334e-05
of O 0 0.00017608238
them O 0 0.00034005792
died O 0 0.00045175894
of O 0 0.00035914363
treatment O 0 0.0004976808
- O 0 0.0010129575
related O 0 0.0006711572
toxicity B-Disease 2 0.990949
. O 0 0.0032440033

The O 0 0.0025082019
MFL B-Chemical 0 0.9201177
regimen I-Chemical 0 0.0033809363
achieves O 0 0.0009738573
little O 0 0.00058885536
palliative O 0 0.00062506634
benefit O 0 0.00037164963
and O 0 0.00029458673
induces O 0 0.00027605734
severe O 0 0.027314382
toxicity B-Disease 2 0.99495345
at O 0 0.0003647769
a O 0 0.0006807376
fairly O 0 0.0015587963
high O 0 0.001812891
rate O 0 0.0020174466
. O 0 0.0023192975

Administration O 0 0.0057674283
of O 0 0.0013690026
this O 0 0.0008671313
regimen O 0 0.0010669768
to O 0 0.0007734509
breast B-Disease 0 0.99577147
cancer I-Disease 0 0.99972934
patients O 0 0.0012014037
who O 0 0.00034202676
have O 0 7.7147946e-05
been O 0 6.6205896e-05
treated O 0 0.00013392731
by O 0 0.000117145435
chemotherapy O 0 0.0009160567
and O 0 0.00012197834
those O 0 0.00016167232
with O 0 0.00019057372
impaired B-Disease 0 0.0035589018
heart I-Disease 0 0.044172548
function I-Disease 0 0.00070145173
requires O 0 0.00026239236
careful O 0 0.00090197986
attention O 0 0.0018589736
. O 0 0.0018045763

Ticlopidine B-Chemical 0 0.99965656
- O 0 0.010363029
induced O 0 0.0071310643
aplastic B-Disease 0 0.99994445
anemia I-Disease 0 0.99999166
: O 0 0.0026462222
report O 0 0.0006845767
of O 0 0.00032929674
three O 0 0.00014267095
Chinese O 0 0.0019508962
patients O 0 0.00038952622
and O 0 0.0003145123
review O 0 0.00063836685
of O 0 0.00062648393
the O 0 0.0009071913
literature O 0 0.0027722875
. O 0 0.0023384579

In O 0 0.0016911823
this O 0 0.0014114442
study O 0 0.0010182987
, O 0 0.00056698837
three O 0 0.00021085348
Chinese O 0 0.0022090299
patients O 0 0.0004975785
with O 0 0.0010548594
ticlopidine B-Chemical 1 0.9999945
- O 0 0.0017399448
induced O 0 0.001409922
aplastic B-Disease 0 0.9999907
anemia I-Disease 0 0.99999833
were O 0 0.00065302587
reported O 0 0.00019252668
and O 0 0.00010901993
another O 0 0.00012293081
13 O 0 0.00011392591
patients O 0 0.0001324839
in O 0 0.00010971052
the O 0 0.00018692882
English O 0 0.0006940064
literature O 0 0.0007669178
were O 0 0.00080197846
reviewed O 0 0.0018899558
. O 0 0.0019200714

We O 0 0.0016590449
attempted O 0 0.0017013912
to O 0 0.000864541
find O 0 0.00057104457
underlying O 0 0.0006567116
similarities O 0 0.00032287886
, O 0 0.0003081579
evaluate O 0 0.0001189488
the O 0 0.00022653434
risk O 0 0.0013576818
factors O 0 0.0003378101
, O 0 0.00022858162
and O 0 0.00015281218
identify O 0 0.00011153199
appropriate O 0 0.00013051131
treatment O 0 0.0002557449
for O 0 0.00035427773
this O 0 0.0012725446
complication O 0 0.053536072
. O 0 0.002562311

All O 0 0.0019479962
but O 0 0.0013224303
one O 0 0.00057803304
of O 0 0.00060051685
the O 0 0.00041830234
patients O 0 0.00041123998
were O 0 0.00018163756
over O 0 7.5531745e-05
60 O 0 0.00012623373
years O 0 0.00010220274
old O 0 0.000118631644
, O 0 0.00012221049
and O 0 0.0001087788
the O 0 0.00011337872
6 O 0 8.813762e-05
who O 0 0.00021910043
died O 0 0.00036140237
were O 0 0.00023084036
all O 0 0.00031444753
older O 0 0.0011434947
than O 0 0.0005870859
65 O 0 0.001499295
. O 0 0.0017240478

Therefore O 0 0.002712518
, O 0 0.0029120564
old O 0 0.0018193049
age O 0 0.0012583884
may O 0 0.00065543206
be O 0 0.00058287836
a O 0 0.0008387355
risk O 0 0.002954733
factor O 0 0.0018638632
for O 0 0.00068517326
developing O 0 0.0037058808
this O 0 0.0026511622
complication O 0 0.13225
. O 0 0.0034102222

Agranulocytosis B-Disease 0 0.9985367
occurred O 0 0.0022063493
3 O 0 0.0009511957
- O 0 0.00087278034
20 O 0 0.00027968144
weeks O 0 8.758514e-05
after O 0 6.116509e-05
initiation O 0 0.00012380425
of O 0 0.0007030207
ticlopidine B-Chemical 1 0.99999
, O 0 0.00036432096
so O 0 0.00012138692
frequent O 0 0.00014812688
examination O 0 0.000109761575
of O 0 0.0001683279
white O 0 0.0011975556
cell O 0 0.000764222
count O 0 0.0005097694
during O 0 0.00016200409
treatment O 0 0.00043177776
is O 0 0.0007587225
recommended O 0 0.001419716
. O 0 0.0019536817

There O 0 0.0027757632
seemed O 0 0.002065721
to O 0 0.0009292163
be O 0 0.00052209565
no O 0 0.00022650973
direct O 0 0.00020426195
correlation O 0 0.00013279896
between O 0 9.0982336e-05
the O 0 0.00013659058
dose O 0 0.0005128867
or O 0 0.00010581088
duration O 0 5.8620826e-05
used O 0 9.2572656e-05
and O 0 0.00013739629
the O 0 0.00017568545
severity O 0 0.00060394016
of O 0 0.00075947226
bone B-Disease 0 0.6962793
marrow I-Disease 0 0.99790657
suppression I-Disease 0 0.884793
. O 0 0.0042568254

Treatment O 0 0.0060839946
for O 0 0.0030502977
ticlopidine B-Chemical 1 0.99995565
- O 0 0.0053690686
induced O 0 0.0038673955
aplastic B-Disease 0 0.99997365
anemia I-Disease 0 0.9999963
with O 0 0.013489669
colony O 0 0.69477814
- O 0 0.0010167544
stimulating O 0 0.0004422819
factors O 0 0.00038366832
seemed O 0 0.00039376025
to O 0 0.0002981588
have O 0 0.00034545403
little O 0 0.000676858
effect O 0 0.0015041528
. O 0 0.00250754

The O 0 0.0014824274
fact O 0 0.00074033055
that O 0 0.0004918869
5 O 0 0.00036318353
of O 0 0.00034841488
the O 0 0.0002345362
6 O 0 0.00012484966
patients O 0 0.00017677514
who O 0 0.00015607222
received O 0 8.096524e-05
concurrent O 0 0.00032555
calcium B-Chemical 0 0.99960464
channel O 0 0.8725632
blockers O 0 0.999684
died O 0 0.0013061122
, O 0 0.00012523012
should O 0 3.8813334e-05
alert O 0 0.00010966178
clinicians O 0 0.0001460183
to O 0 6.874445e-05
be O 0 7.092966e-05
more O 0 0.0001194175
cautious O 0 0.00020197607
when O 0 7.995255e-05
using O 0 0.00012306157
these O 0 0.00028089975
two O 0 0.0002917136
drugs O 0 0.0051050032
simultaneously O 0 0.0012970496
. O 0 0.0019509669

Upregulation O 0 0.0043817875
of O 0 0.0015361622
the O 0 0.0008388481
expression O 0 0.0007591046
of O 0 0.0010190197
vasopressin B-Chemical 1 0.99494714
gene O 0 0.00069784117
in O 0 0.00017395485
the O 0 0.00013922127
paraventricular O 0 0.00028652255
and O 0 0.00011494544
supraoptic O 0 0.0002321023
nuclei O 0 0.0001452444
of O 0 0.00015413627
the O 0 0.00030979424
lithium B-Chemical 0 0.99989235
- O 0 0.0022699027
induced O 0 0.0028018036
diabetes B-Disease 0 0.9998629
insipidus I-Disease 0 0.99954104
rat O 0 0.016230632
. O 0 0.0022594451

The O 0 0.0016983009
expression O 0 0.0016524979
of O 0 0.0019465839
arginine B-Chemical 0 0.5530902
vasopressin I-Chemical 1 0.9995227
( O 0 0.0037854505
AVP B-Chemical 0 0.9995035
) O 0 0.00069657085
gene O 0 0.000325273
in O 0 0.00013010288
the O 0 0.00013156037
paraventricular O 0 0.0003924318
( O 0 0.0002066452
PVN O 0 0.0009280974
) O 0 0.0001533229
and O 0 8.7220586e-05
supraoptic O 0 0.00021920554
nuclei O 0 0.0001597312
( O 0 0.00014707721
SON O 0 0.00094243506
) O 0 0.0001382235
was O 0 6.787037e-05
investigated O 0 4.6215053e-05
in O 0 5.7111894e-05
rats O 0 0.00013420498
with O 0 0.0002645633
lithium B-Chemical 0 0.99996006
( O 0 0.0016081847
Li B-Chemical 0 0.9873477
) O 0 0.00064245245
- O 0 0.00037918426
induced O 0 0.000363007
polyuria B-Disease 0 0.9989692
, O 0 0.0002725852
using O 0 0.0001184692
in O 0 0.00015459419
situ O 0 0.00050428975
hybridization O 0 0.0004960615
histochemistry O 0 0.0015106048
and O 0 0.0009637567
radioimmunoassay O 0 0.33946392
. O 0 0.002118562

The O 0 0.0022561005
male O 0 0.004551704
Wistar O 0 0.0040476704
rats O 0 0.0010171409
consuming O 0 0.0010149805
a O 0 0.0004550432
diet O 0 0.0017715024
that O 0 0.0001381443
contained O 0 0.00019764864
LiCl B-Chemical 0 0.997012
( O 0 0.00046014378
60 O 0 0.00021998984
mmol O 0 0.16669622
/ O 0 0.00082203146
kg O 0 0.00050333655
) O 0 0.00022296095
for O 0 0.000110633955
4 O 0 0.00013566844
weeks O 0 0.00012649474
developed O 0 0.00069629634
marked O 0 0.0034952792
polyuria B-Disease 0 0.9985103
. O 0 0.0036586712

The O 0 0.0039564483
Li B-Chemical 0 0.92537636
- O 0 0.0035864965
treated O 0 0.0013349054
rats O 0 0.000846356
produced O 0 0.00037069284
a O 0 0.00037481205
large O 0 0.00029036624
volume O 0 0.00039826718
of O 0 0.00035903067
hypotonic O 0 0.044149257
urine O 0 0.13459468
with O 0 0.00072760927
low O 0 0.0019203485
ionic O 0 0.38469225
concentrations O 0 0.008050453
. O 0 0.0029495668

Plasma O 0 0.5510109
sodium B-Chemical 0 0.99890625
concentrations O 0 0.00610475
were O 0 0.0008551963
found O 0 0.0003818681
to O 0 0.00026629886
be O 0 0.00021673099
slightly O 0 0.0003167182
increased O 0 0.00029497148
in O 0 0.00018034154
the O 0 0.0003224337
Li B-Chemical 0 0.96435946
- O 0 0.00060707115
treated O 0 0.00029794397
rats O 0 0.0002718315
compared O 0 0.00012279245
with O 0 0.000293426
those O 0 0.00052353163
in O 0 0.0006199792
controls O 0 0.002072402
. O 0 0.0019684087

Plasma O 0 0.030889498
concentration O 0 0.0035061282
of O 0 0.0024980654
AVP B-Chemical 0 0.997988
and O 0 0.00069709035
transcripts O 0 0.0005673495
of O 0 0.0006949906
AVP B-Chemical 0 0.998743
gene O 0 0.0004885214
in O 0 0.00012921223
the O 0 0.0001303781
PVN O 0 0.0011129682
and O 0 0.000132585
SON O 0 0.0008467557
were O 0 8.962531e-05
significantly O 0 0.000108133565
increased O 0 0.00014776742
in O 0 0.00010931317
the O 0 0.0002295262
Li B-Chemical 0 0.9418832
- O 0 0.00055715634
treated O 0 0.00034646544
rats O 0 0.00039296693
compared O 0 0.00023649137
with O 0 0.0007214719
controls O 0 0.0020796608
. O 0 0.0018803685

These O 0 0.0020073394
results O 0 0.0011964849
suggest O 0 0.00050595426
that O 0 0.0006429928
dehydration B-Disease 0 0.9511927
and O 0 0.00073687395
/ O 0 0.0009174957
or O 0 0.00015910294
the O 0 0.00012812299
activation O 0 0.00016584322
of O 0 0.00019481461
visceral O 0 0.0007195093
afferent O 0 0.0002043237
inputs O 0 0.00010915411
may O 0 4.876394e-05
contribute O 0 3.940341e-05
to O 0 4.243537e-05
the O 0 6.067344e-05
elevation O 0 0.0017448149
of O 0 0.00021898662
plasma O 0 0.055360895
AVP B-Chemical 0 0.9995142
and O 0 0.00010849062
the O 0 6.764756e-05
upregulation O 0 0.00014054016
of O 0 0.00027285118
AVP B-Chemical 0 0.999243
gene O 0 0.0002748215
expression O 0 0.00010240781
in O 0 6.0524348e-05
the O 0 7.727909e-05
PVN O 0 0.0006759079
and O 0 8.0781385e-05
the O 0 8.943594e-05
SON O 0 0.00071308244
of O 0 0.00017665364
the O 0 0.0003082546
Li B-Chemical 0 0.9441779
- O 0 0.0014121473
induced O 0 0.0023417417
diabetes B-Disease 0 0.9998554
insipidus I-Disease 0 0.99954164
rat O 0 0.016150076
. O 0 0.0022256603

Antinociceptive O 0 0.9743559
and O 0 0.0032047383
antiamnesic O 0 0.58679897
properties O 0 0.00084538147
of O 0 0.0008646724
the O 0 0.00080535584
presynaptic O 0 0.045640226
cholinergic O 0 0.7072983
amplifier O 0 0.028588321
PG B-Chemical 0 0.9989679
- I-Chemical 0 0.0054833894
9 I-Chemical 0 0.0023490053
. O 0 0.0029290998

The O 0 0.002358765
antinociceptive O 0 0.66794
effect O 0 0.0011793514
of O 0 0.0011801021
3 B-Chemical 0 0.00067460025
alpha I-Chemical 0 0.4633752
- I-Chemical 0 0.0018189498
tropyl I-Chemical 0 0.14478604
2 I-Chemical 0 0.00033442266
- I-Chemical 0 0.00053603854
( I-Chemical 0 0.00038055796
p I-Chemical 0 0.00028415766
- I-Chemical 0 0.00058881944
bromophenyl I-Chemical 0 0.95361763
) I-Chemical 0 0.0020815984
propionate I-Chemical 0 0.99974173
[ O 0 0.0016921768
( O 0 0.00033218344
+ O 0 0.00041798162
/ O 0 0.00076701347
- O 0 0.0005070412
) O 0 0.0004301462
- O 0 0.000872491
PG B-Chemical 0 0.99905294
- I-Chemical 0 0.00063616637
9 I-Chemical 0 0.00013897273
] O 0 0.0002668519
( O 0 0.0001283143
10 O 0 8.007578e-05
- O 0 0.00014300396
40 O 0 9.8528115e-05
mg O 0 0.0018647967
kg O 0 0.0003876631
- O 0 0.00019666324
1 O 0 7.045078e-05
s O 0 8.702518e-05
. O 0 6.988603e-05
c O 0 0.0005409376
. O 0 6.9444846e-05
; O 0 9.578329e-05
30 O 0 6.1137034e-05
- O 0 0.00012717272
60 O 0 8.16977e-05
mg O 0 0.0015962578
kg O 0 0.00041734643
- O 0 0.00024636858
1 O 0 9.956573e-05
p O 0 0.000103283775
. O 0 6.392368e-05
o O 0 0.0005869302
. O 0 7.597471e-05
; O 0 0.000110106674
10 O 0 7.711698e-05
- O 0 0.00013182384
30 O 0 6.270566e-05
mg O 0 0.0014515289
kg O 0 0.0003711398
- O 0 0.00020198223
1 O 0 7.605372e-05
i O 0 0.00019310415
. O 0 7.217061e-05
v O 0 0.0004822295
. O 0 7.5142365e-05
; O 0 0.000109733526
10 O 0 7.724917e-05
- O 0 0.00012750713
30 O 0 5.5102777e-05
micrograms O 0 0.0004751578
/ O 0 0.00032514
mouse O 0 0.00017393411
i O 0 0.00028696103
. O 0 7.540904e-05
c O 0 0.000695884
. O 0 7.809264e-05
v O 0 0.0006012657
. O 0 7.857369e-05
) O 0 0.00015041343
was O 0 8.239731e-05
examined O 0 4.7262714e-05
in O 0 6.351867e-05
mice O 0 5.353031e-05
, O 0 9.36602e-05
rats O 0 0.00012110481
and O 0 8.228063e-05
guinea O 0 0.00021328473
pigs O 0 5.895141e-05
by O 0 6.212107e-05
use O 0 4.9563954e-05
of O 0 7.986142e-05
the O 0 8.645627e-05
hot O 0 0.000706909
- O 0 0.0003081579
plate O 0 0.0012507354
, O 0 0.00022873774
abdominal O 0 0.005988777
- O 0 0.0005920961
constriction O 0 0.31171495
, O 0 0.0002969033
tail O 0 0.00044576178
- O 0 0.000610213
flick O 0 0.01824128
and O 0 0.0006108167
paw O 0 0.3120591
- O 0 0.0016054086
pressure O 0 0.0076627703
tests O 0 0.002885406
. O 0 0.0020817341

( O 0 0.007104241
+ O 0 0.0056723626
/ O 0 0.0058342796
- O 0 0.0034550629
) O 0 0.0024003065
- O 0 0.0032818252
PG B-Chemical 0 0.9984327
- I-Chemical 0 0.0018457816
9 I-Chemical 0 0.0005295295
antinociception O 0 0.99467033
peaked O 0 0.0004577966
15 O 0 0.00013593184
min O 0 0.00015941956
after O 0 8.342369e-05
injection O 0 0.0002665658
and O 0 0.00034345192
then O 0 0.00045278113
slowly O 0 0.0017956003
diminished O 0 0.0036664354
. O 0 0.0026753917

The O 0 0.0037315376
antinociception O 0 0.9974356
produced O 0 0.0019262213
by O 0 0.0013571278
( O 0 0.0012864873
+ O 0 0.0014006697
/ O 0 0.0020036458
- O 0 0.0011931327
) O 0 0.0008854808
- O 0 0.0015039989
PG B-Chemical 0 0.99910504
- I-Chemical 0 0.00072160154
9 I-Chemical 0 0.0001252251
was O 0 0.00011270996
prevented O 0 0.0002106678
by O 0 9.617832e-05
the O 0 0.00011735921
unselective O 0 0.5751288
muscarinic O 0 0.99973017
antagonist O 0 0.9967739
atropine B-Chemical 0 0.9999938
, O 0 0.00025755173
the O 0 0.00013715806
M1 O 0 0.30066094
- O 0 0.0002509058
selective O 0 0.0008953426
antagonists O 0 0.977811
pirenzepine B-Chemical 0 0.9999989
and O 0 0.0009843244
dicyclomine B-Chemical 0 0.99999547
and O 0 0.00017151478
the O 0 0.00027564287
acetylcholine B-Chemical 1 0.99998605
depletor O 0 0.9999851
hemicholinium B-Chemical 0 0.9999919
- I-Chemical 0 0.0008071889
3 I-Chemical 0 6.037798e-05
, O 0 6.3118525e-05
but O 0 5.021038e-05
not O 0 3.9823677e-05
by O 0 5.359273e-05
the O 0 0.000100602854
opioid O 0 0.99229455
antagonist O 0 0.98989606
naloxone B-Chemical 0 0.99999225
, O 0 0.00021226286
the O 0 0.00014998163
gamma B-Chemical 0 0.9256819
- I-Chemical 0 0.004415705
aminobutyric I-Chemical 0 0.9999466
acidB I-Chemical 0 0.9856096
antagonist O 0 0.9594544
3 B-Chemical 0 0.00013277022
- I-Chemical 0 0.00029254693
aminopropyl I-Chemical 0 0.3539399
- I-Chemical 0 0.0013045991
diethoxy I-Chemical 0 0.99836785
- I-Chemical 0 0.0023065752
methyl I-Chemical 0 0.99499243
- I-Chemical 0 0.0024775453
phosphinic I-Chemical 0 0.9972914
acid I-Chemical 0 0.96105224
, O 0 0.00026766575
the O 0 0.0002504579
H3 O 0 0.7179447
agonist O 0 0.9375292
R B-Chemical 0 0.99617934
- I-Chemical 0 0.00072815927
( I-Chemical 0 0.00030644317
alpha I-Chemical 0 0.47030056
) I-Chemical 0 0.00044993285
- I-Chemical 0 0.00047159896
methylhistamine I-Chemical 0 0.9853784
, O 0 0.00017218693
the O 0 0.00022337846
D2 O 0 0.9997403
antagonist O 0 0.9949832
quinpirole B-Chemical 0 0.99999356
, O 0 0.00019410838
the O 0 7.724644e-05
5 B-Chemical 0 5.6372428e-05
- I-Chemical 0 0.00016602421
hydroxytryptamine4 I-Chemical 0 0.005222766
antagonist O 0 0.7046987
2 B-Chemical 0 0.00015128942
- I-Chemical 0 0.0005040003
methoxy I-Chemical 0 0.99915326
- I-Chemical 0 0.0005976016
4 I-Chemical 0 9.7795295e-05
- I-Chemical 0 0.00028260687
amino I-Chemical 0 0.23863903
- I-Chemical 0 0.0004170483
5 I-Chemical 0 9.756801e-05
- I-Chemical 0 0.00035368075
chlorobenzoic I-Chemical 0 0.76999664
acid I-Chemical 0 0.9126519
2 I-Chemical 0 0.00018548961
- I-Chemical 0 0.0003245661
( I-Chemical 0 0.00029612985
diethylamino I-Chemical 0 0.98546106
) I-Chemical 0 0.001410795
ethyl I-Chemical 0 0.9999263
ester I-Chemical 0 0.9995796
hydrochloride O 0 0.99955565
, O 0 0.00023076752
the O 0 9.556224e-05
5 B-Chemical 0 6.875304e-05
- I-Chemical 0 0.00018747823
hydroxytryptamin1A I-Chemical 0 0.0019370081
antagonist O 0 0.5877003
1 B-Chemical 0 0.00013731614
- I-Chemical 0 0.00022367468
( I-Chemical 0 0.00014962682
2 I-Chemical 0 0.0001031324
- I-Chemical 0 0.0004079661
methoxyphenyl I-Chemical 0 0.9643223
) I-Chemical 0 0.00044265558
- I-Chemical 0 0.0002813141
4 I-Chemical 0 9.172593e-05
- I-Chemical 0 0.0002291241
[ I-Chemical 0 0.00024854863
4 I-Chemical 0 8.1716775e-05
- I-Chemical 0 0.00019041458
( I-Chemical 0 0.00014815429
2 I-Chemical 0 0.000103767685
- I-Chemical 0 0.00035900003
phthalimido I-Chemical 0 0.9561066
) I-Chemical 0 0.0011699003
butyl I-Chemical 0 0.9998466
] I-Chemical 0 0.012353915
piperazine I-Chemical 0 0.99995005
hydrobromide O 0 0.99983716
and O 0 0.0005272515
the O 0 0.0006694579
polyamines O 0 0.9972242
depletor O 0 0.99991524
reserpine B-Chemical 1 0.99996924
. O 0 0.0050097657

Based O 0 0.003223492
on O 0 0.0010681265
these O 0 0.001343202
data O 0 0.0010743323
, O 0 0.0008185998
it O 0 0.00048094435
can O 0 0.00022564277
be O 0 0.00018583749
postulated O 0 0.00019044145
that O 0 0.00015046608
( O 0 0.0003556655
+ O 0 0.0005328577
/ O 0 0.0010478362
- O 0 0.00066516316
) O 0 0.0005271663
- O 0 0.000996528
PG B-Chemical 0 0.9988794
- I-Chemical 0 0.0004668338
9 I-Chemical 0 8.988353e-05
exerted O 0 0.00015875652
an O 0 0.00024939034
antinociceptive O 0 0.8162808
effect O 0 0.00015823753
mediated O 0 9.608207e-05
by O 0 0.00015329993
a O 0 0.00022202966
central O 0 0.00034955406
potentiation O 0 0.18415028
of O 0 0.0013179892
cholinergic O 0 0.4707307
transmission O 0 0.00232976
. O 0 0.0020900688

( O 0 0.007145062
+ O 0 0.005722488
/ O 0 0.0059429393
- O 0 0.003529355
) O 0 0.0024737758
- O 0 0.0034485138
PG B-Chemical 0 0.9985863
- I-Chemical 0 0.0015422491
9 I-Chemical 0 0.00031100193
( O 0 0.0003096493
10 O 0 0.00017356184
- O 0 0.0002653368
40 O 0 0.00016864423
mg O 0 0.003033416
kg O 0 0.0005919752
- O 0 0.00028408645
1 O 0 0.00010108578
i O 0 0.00025570978
. O 0 8.8681896e-05
p O 0 0.00012218485
. O 0 6.69418e-05
) O 0 0.00014012305
was O 0 7.663395e-05
able O 0 5.206882e-05
to O 0 7.779725e-05
prevent O 0 0.00018552852
amnesia B-Disease 0 0.9993957
induced O 0 0.00044858083
by O 0 0.0006579414
scopolamine B-Chemical 1 0.99999857
( O 0 0.00049604307
1 O 0 9.317097e-05
mg O 0 0.002682748
kg O 0 0.00036124687
- O 0 0.00018111993
1 O 0 6.617913e-05
i O 0 0.00017929806
. O 0 6.157205e-05
p O 0 8.719471e-05
. O 0 5.175832e-05
) O 0 0.00014751952
and O 0 0.00023632028
dicyclomine B-Chemical 0 0.9999895
( O 0 0.00032327988
2 O 0 9.28469e-05
mg O 0 0.0020841763
kg O 0 0.0003964603
- O 0 0.00021572447
1 O 0 8.493567e-05
i O 0 0.00023017994
. O 0 8.792304e-05
p O 0 0.00013045756
. O 0 8.096856e-05
) O 0 0.00017301673
in O 0 0.000116044976
the O 0 0.00017198446
mouse O 0 0.00038017367
passive O 0 0.000612714
- O 0 0.0009799658
avoidance O 0 0.0022118818
test O 0 0.00217383
. O 0 0.0021991367

Affinity O 0 0.007170538
profiles O 0 0.0018146451
of O 0 0.0018494716
( O 0 0.0017608994
+ O 0 0.0018343385
/ O 0 0.002426502
- O 0 0.00146907
) O 0 0.0010499787
- O 0 0.00156747
PG B-Chemical 0 0.9984547
- I-Chemical 0 0.0006649268
9 I-Chemical 0 0.00013683487
for O 0 0.0001452055
muscarinic O 0 0.9923699
receptor O 0 0.042575635
subtypes O 0 0.0006859691
, O 0 0.000108509965
determined O 0 6.4396016e-05
by O 0 6.9562484e-05
functional O 0 7.971754e-05
studies O 0 8.959172e-05
( O 0 0.00012577848
rabbit O 0 0.0003109192
vas O 0 0.05503456
deferens O 0 0.0053591332
for O 0 7.291842e-05
M1 O 0 0.051547654
, O 0 0.000103158076
guinea O 0 0.00021312782
pig O 0 0.0001299867
atrium O 0 0.0031965475
for O 0 7.163168e-05
M2 O 0 0.076836176
, O 0 0.00011954999
guinea O 0 0.00027322263
pig O 0 0.00017352345
ileum O 0 0.033424474
for O 0 9.7047276e-05
M3 O 0 0.9433182
and O 0 0.0001067009
immature O 0 0.00037761306
guinea O 0 0.0002791561
pig O 0 0.00011835166
uterus O 0 0.00039391263
for O 0 5.2717434e-05
putative O 0 0.00015638758
M4 O 0 0.99724424
) O 0 0.00025528204
, O 0 8.6702305e-05
have O 0 4.2733125e-05
shown O 0 5.0446994e-05
an O 0 0.00020724148
M4 O 0 0.9959401
/ O 0 0.0012641413
M1 O 0 0.17919679
selectivity O 0 0.001522855
ratio O 0 0.00015257456
of O 0 0.0001082969
10 O 0 6.834866e-05
. O 0 3.8015816e-05
2 O 0 3.5201127e-05
that O 0 2.8744646e-05
might O 0 3.1186173e-05
be O 0 3.991131e-05
responsible O 0 3.7731315e-05
for O 0 4.4622695e-05
the O 0 0.00013808688
antinociception O 0 0.9990664
and O 0 0.00013499224
the O 0 0.00010900724
anti O 0 0.0015909229
- O 0 0.001103694
amnesic B-Disease 0 0.9999671
effect O 0 0.00019582159
induced O 0 0.00023459057
by O 0 0.00020151385
( O 0 0.00026829887
+ O 0 0.00039098147
/ O 0 0.00080280425
- O 0 0.00051928114
) O 0 0.0004399652
- O 0 0.00088831014
PG B-Chemical 0 0.9984124
- I-Chemical 0 0.00044543363
9 I-Chemical 0 9.5855205e-05
through O 0 7.572598e-05
an O 0 0.00017315835
increase O 0 0.00024891383
in O 0 0.0005759779
acetylcholine B-Chemical 1 0.99937844
extracellular O 0 0.0032209929
levels O 0 0.0020090702
. O 0 0.0023193152

In O 0 0.0018273314
the O 0 0.0018572499
antinociceptive O 0 0.8773299
and O 0 0.001530522
antiamnesic O 0 0.95150685
dose O 0 0.008207185
range O 0 0.00058944046
, O 0 0.00046283714
( O 0 0.00045421155
+ O 0 0.00060475204
/ O 0 0.0010935477
- O 0 0.00069471047
) O 0 0.0005565011
- O 0 0.0010812444
PG B-Chemical 0 0.99918467
- I-Chemical 0 0.0005499613
9 I-Chemical 0 9.019674e-05
did O 0 8.425138e-05
not O 0 6.124674e-05
impair O 0 6.1609935e-05
mouse O 0 0.00012352761
performance O 0 0.00014078399
evaluated O 0 8.780265e-05
by O 0 0.0001309596
the O 0 0.00020471936
rota O 0 0.013416705
- O 0 0.0006383631
rod O 0 0.0033901664
test O 0 0.0005648114
and O 0 0.0006190906
Animex O 0 0.0044417246
apparatus O 0 0.0015472856
. O 0 0.0019157314

The O 0 0.0017117439
effect O 0 0.0012805484
of O 0 0.0011916748
different O 0 0.00067613594
anaesthetic O 0 0.0052189124
agents O 0 0.002556277
in O 0 0.0008715268
hearing B-Disease 0 0.92994255
loss I-Disease 0 0.0045383153
following O 0 0.0010537845
spinal O 0 0.010216391
anaesthesia O 0 0.046036895
. O 0 0.0030603046

The O 0 0.0028748002
cause O 0 0.0034486542
of O 0 0.0030791075
hearing B-Disease 0 0.8850523
loss I-Disease 0 0.0047240113
after O 0 0.0008045175
spinal O 0 0.006084393
anaesthesia O 0 0.017560538
is O 0 0.002373576
unknown O 0 0.0046160705
. O 0 0.0038246324

Up O 0 0.015079383
until O 0 0.0011788752
now O 0 0.0010811373
, O 0 0.0007986938
the O 0 0.0004651889
only O 0 0.00047829427
factor O 0 0.0011987551
studied O 0 0.00042397485
has O 0 0.00014439254
been O 0 9.480798e-05
the O 0 8.993412e-05
effect O 0 8.592974e-05
of O 0 0.00012996317
the O 0 0.00010692518
diameter O 0 0.00033408904
of O 0 0.00013080411
the O 0 0.000119083066
spinal O 0 0.0005100293
needle O 0 0.00020688256
on O 0 8.3788516e-05
post O 0 0.00013896848
- O 0 0.00062140374
operative O 0 0.0022103568
sensorineural B-Disease 2 0.9999715
hearing I-Disease 2 0.99977225
loss I-Disease 2 0.91655105
. O 0 0.0049677296

The O 0 0.001549185
aim O 0 0.0014235243
of O 0 0.0011500228
this O 0 0.0008350791
study O 0 0.0006460364
was O 0 0.00033895776
to O 0 0.00017078205
describe O 0 0.00015737217
this O 0 0.00036153384
hearing B-Disease 0 0.9731005
loss I-Disease 0 0.0029360289
and O 0 0.00021895404
to O 0 0.000102821905
investigate O 0 6.0424463e-05
other O 0 0.00010069038
factors O 0 0.0001562673
influencing O 0 0.00010681186
the O 0 0.00021571644
degree O 0 0.0005258299
of O 0 0.0012741381
hearing B-Disease 0 0.99405754
loss I-Disease 0 0.099912405
. O 0 0.0034480758

Two O 0 0.002047247
groups O 0 0.001157912
of O 0 0.00082189083
22 O 0 0.00057263393
similar O 0 0.00024590205
patients O 0 0.00035672504
were O 0 0.00019614561
studied O 0 0.00018413011
: O 0 0.00015010024
one O 0 7.158688e-05
group O 0 0.00011250787
received O 0 6.7187255e-05
6 O 0 6.604667e-05
mL O 0 0.0012019312
prilocaine B-Chemical 0 0.99997103
2 O 0 0.00014568146
% O 0 0.00011931472
; O 0 0.00010090799
and O 0 7.31205e-05
the O 0 7.2075076e-05
other O 0 7.72816e-05
received O 0 8.816921e-05
3 O 0 0.000118852324
mL O 0 0.0012797278
bupivacaine B-Chemical 1 0.9996213
0 O 0 0.00040948042
. O 0 0.00032925562
5 O 0 0.00053667196
% O 0 0.0012928772
. O 0 0.0019424694

Patients O 0 0.002330211
given O 0 0.0014951697
prilocaine B-Chemical 0 0.9997806
were O 0 0.0007645655
more O 0 0.00044680166
likely O 0 0.00018537027
to O 0 0.00018282677
develop O 0 0.00037583985
hearing B-Disease 0 0.9686581
loss I-Disease 0 0.0039602686
( O 0 0.0002866944
10 O 0 8.1247075e-05
out O 0 5.6149507e-05
of O 0 0.00011061602
22 O 0 0.00013337421
) O 0 0.00011438647
than O 0 4.3744796e-05
those O 0 9.543993e-05
given O 0 9.181082e-05
bupivacaine B-Chemical 1 0.99988186
( O 0 0.00022273595
4 O 0 5.898588e-05
out O 0 5.664667e-05
of O 0 0.00014449336
22 O 0 0.00024761714
) O 0 0.00036934836
( O 0 0.0004734123
P O 0 0.0029995136
< O 0 0.0003685434
0 O 0 0.00041173285
. O 0 0.00060558406
05 O 0 0.0059874915
) O 0 0.002557431
. O 0 0.0025824464

The O 0 0.0016067943
average O 0 0.0013117878
hearing B-Disease 0 0.6461818
loss I-Disease 0 0.0026187468
for O 0 0.00050945656
speech O 0 0.004061422
frequencies O 0 0.0005174333
was O 0 0.00026796653
about O 0 0.00018245965
10 O 0 0.00016831137
dB O 0 0.000313748
after O 0 0.00015744136
prilocaine B-Chemical 0 0.99988663
and O 0 0.0004724762
15 O 0 0.00031535843
dB O 0 0.00080315856
after O 0 0.0006470176
bupivacaine B-Chemical 1 0.99933344
. O 0 0.0036122613

None O 0 0.0042578946
of O 0 0.0024972742
the O 0 0.0018393692
patients O 0 0.0024110063
complained O 0 0.006787906
of O 0 0.0022363428
subjective O 0 0.005737657
hearing B-Disease 0 0.98915976
loss I-Disease 0 0.07863204
. O 0 0.005871764

Long O 0 0.009566183
- O 0 0.0034182582
term O 0 0.0011751999
follow O 0 0.000755281
- O 0 0.0011001386
up O 0 0.00058379513
of O 0 0.0006582089
the O 0 0.00067361986
patients O 0 0.0010903198
was O 0 0.0009988273
not O 0 0.0010944642
possible O 0 0.0020907521
. O 0 0.0031543619

A O 0 0.04316005
transient O 0 0.03515981
neurological B-Disease 0 0.9976305
deficit I-Disease 0 0.7887191
following O 0 0.0006047633
intrathecal O 0 0.050973706
injection O 0 0.00046514944
of O 0 0.00035050279
1 O 0 0.00020843644
% O 0 0.000293426
hyperbaric O 0 0.1351561
bupivacaine B-Chemical 1 0.9997608
for O 0 0.00057111395
unilateral O 0 0.045763586
spinal O 0 0.011832335
anaesthesia O 0 0.045363873
. O 0 0.0024489579

We O 0 0.0013684677
describe O 0 0.0009612088
a O 0 0.0010298598
case O 0 0.00058990816
of O 0 0.00077107386
transient O 0 0.034304425
neurological B-Disease 0 0.99946815
deficit I-Disease 0 0.8638257
that O 0 0.00013421675
occurred O 0 9.180644e-05
after O 0 3.9719565e-05
unilateral O 0 0.0018993455
spinal O 0 0.0009282424
anaesthesia O 0 0.0025407507
with O 0 0.00010956917
8 O 0 5.93274e-05
mg O 0 0.00071157
of O 0 9.8301476e-05
1 O 0 6.4631764e-05
% O 0 9.575088e-05
hyperbaric O 0 0.12985791
bupivacaine B-Chemical 1 0.9999292
slowly O 0 0.00039973253
injected O 0 8.242168e-05
through O 0 6.3456864e-05
a O 0 0.00015262376
25 O 0 0.00022725343
- O 0 0.00031768257
gauge O 0 0.000324361
pencil O 0 0.0025792131
- O 0 0.0007688163
point O 0 0.0005426647
spinal O 0 0.0033192302
needle O 0 0.0030150313
. O 0 0.0022086464

The O 0 0.0016251936
surgery O 0 0.001527322
and O 0 0.0009059539
anaesthesia O 0 0.0028906555
were O 0 0.000367027
uneventful O 0 0.00031684776
, O 0 0.00025872423
but O 0 0.00016293218
3 O 0 7.406247e-05
days O 0 3.620523e-05
after O 0 3.464172e-05
surgery O 0 0.000108590386
, O 0 8.4042666e-05
the O 0 6.982275e-05
patient O 0 8.407393e-05
reported O 0 7.4659605e-05
an O 0 8.068454e-05
area O 0 7.5866184e-05
of O 0 0.00014796709
hypoaesthesia O 0 0.46072665
over O 0 5.6323363e-05
L3 O 0 0.0017220186
- O 0 0.0003054159
L4 O 0 0.00215951
dermatomes O 0 0.001843283
of O 0 0.00010973269
the O 0 0.000104364284
leg O 0 0.0007973812
which O 0 0.00012049661
had O 0 8.1962055e-05
been O 0 5.5235254e-05
operated O 0 0.0001458666
on O 0 4.551534e-05
( O 0 0.00012005208
loss B-Disease 0 0.0002881781
of I-Disease 0 0.00031679551
pinprick I-Disease 0 0.24581823
sensation I-Disease 0 0.11901515
) O 0 0.0004006487
without O 0 0.00023977713
reduction O 0 0.0009836917
in O 0 0.0007364109
muscular O 0 0.13964163
strength O 0 0.0030000752
. O 0 0.0022738911

Sensation O 0 0.019940708
in O 0 0.0015903444
this O 0 0.0010944094
area O 0 0.00078583485
returned O 0 0.00058595784
to O 0 0.00044290425
normal O 0 0.0006631315
over O 0 0.00023377645
the O 0 0.00040810398
following O 0 0.00048694582
2 O 0 0.00080340967
weeks O 0 0.00081916916
. O 0 0.0021887857

Prospective O 0 0.015016821
multicentre O 0 0.011150042
studies O 0 0.00095676776
with O 0 0.0006305255
a O 0 0.00052049075
large O 0 0.00042021772
population O 0 0.0004365395
and O 0 0.00018961054
a O 0 0.00019269141
long O 0 0.00012144515
follow O 0 7.927921e-05
- O 0 0.00017289272
up O 0 8.210114e-05
should O 0 3.967943e-05
be O 0 5.2372197e-05
performed O 0 4.9313137e-05
in O 0 5.3143904e-05
order O 0 5.614319e-05
to O 0 6.449151e-05
evaluate O 0 5.02155e-05
the O 0 0.00012216854
incidence O 0 0.00032355552
of O 0 0.00029072684
this O 0 0.00047640258
unusual O 0 0.0012650158
side O 0 0.010158902
effect O 0 0.0019790565
. O 0 0.0026547885

However O 0 0.0026708026
, O 0 0.0016275226
we O 0 0.0004498076
suggest O 0 0.00026519163
that O 0 0.00026478787
a O 0 0.00045204148
low O 0 0.0007099497
solution O 0 0.002502544
concentration O 0 0.00052714546
should O 0 7.163374e-05
be O 0 6.787619e-05
preferred O 0 4.9208757e-05
for O 0 5.4202716e-05
unilateral O 0 0.0014791412
spinal O 0 0.00071757927
anaesthesia O 0 0.001619855
with O 0 9.4702715e-05
a O 0 0.000121759615
hyperbaric O 0 0.046378713
anaesthetic O 0 0.0087618185
solution O 0 0.0017509843
( O 0 0.00014384175
if O 0 6.0870483e-05
pencil O 0 0.0012731845
- O 0 0.00018608075
point O 0 5.5758763e-05
needle O 0 0.000105603634
and O 0 6.38323e-05
slow O 0 0.00016815416
injection O 0 7.544012e-05
rate O 0 7.580125e-05
are O 0 6.0784343e-05
employed O 0 9.04322e-05
) O 0 0.00014747522
, O 0 7.222527e-05
in O 0 4.408241e-05
order O 0 3.9371374e-05
to O 0 3.8336806e-05
minimize O 0 3.275864e-05
the O 0 7.575934e-05
risk O 0 0.00046075982
of O 0 9.795788e-05
a O 0 8.519354e-05
localized O 0 3.2283024e-05
high O 0 0.000121855446
peak O 0 0.00014247913
anaesthetic O 0 0.0031346898
concentration O 0 0.00036148733
, O 0 0.00014392448
which O 0 0.00014027585
might O 0 8.6698084e-05
lead O 0 0.00084237463
to O 0 0.00020264178
a O 0 0.0006211139
transient O 0 0.051596865
neurological B-Disease 0 0.99948394
deficit I-Disease 0 0.990747
. O 0 0.003766523

Transient B-Disease 0 0.57303685
neurologic I-Disease 0 0.9285391
symptoms I-Disease 0 0.07768967
after O 0 0.00035594197
spinal O 0 0.0019534088
anesthesia O 0 0.007375088
: O 0 0.000349964
a O 0 0.00024861287
lower O 0 0.00026472454
incidence O 0 0.0004914892
with O 0 0.00076732703
prilocaine B-Chemical 0 0.99997973
and O 0 0.0015307945
bupivacaine B-Chemical 1 0.9998839
than O 0 0.00061121216
with O 0 0.0025849086
lidocaine B-Chemical 0 0.99949765
. O 0 0.0032441437

BACKGROUND O 0 0.008705572
: O 0 0.0020212173
Recent O 0 0.0008205527
evidence O 0 0.00044163608
suggests O 0 0.00021117761
that O 0 0.00025147005
transient B-Disease 0 0.06433911
neurologic I-Disease 0 0.99063206
symptoms I-Disease 0 0.70508313
( O 0 0.00090515026
TNSs B-Disease 0 0.2500434
) O 0 0.00022442108
frequently O 0 9.338606e-05
follow O 0 9.55812e-05
lidocaine B-Chemical 0 0.9980558
spinal O 0 0.0018221941
anesthesia O 0 0.005106868
but O 0 0.00024056579
are O 0 0.0002468619
infrequent O 0 0.0009251283
with O 0 0.0020500547
bupivacaine B-Chemical 1 0.99971384
. O 0 0.0031010336

However O 0 0.0026420574
, O 0 0.0017896412
identification O 0 0.0010432245
of O 0 0.00076929043
a O 0 0.00060180784
short O 0 0.00031914638
- O 0 0.00045589634
acting O 0 0.00023796016
local O 0 0.00026661562
anesthetic O 0 0.0047731013
to O 0 0.000109711145
substitute O 0 9.864629e-05
for O 0 0.00012639923
lidocaine B-Chemical 0 0.9983531
for O 0 0.000103357466
brief O 0 0.00013570208
surgical O 0 0.00017197135
procedures O 0 0.00015412938
remains O 0 0.00016732598
an O 0 0.0003702215
important O 0 0.00037677685
goal O 0 0.0017018691
. O 0 0.0021693923

Prilocaine B-Chemical 0 0.98822
is O 0 0.0022836155
an O 0 0.0018716664
amide O 0 0.41351604
local O 0 0.0011382782
anesthetic O 0 0.01981271
with O 0 0.000419351
a O 0 0.00028672256
duration O 0 0.00010155901
of O 0 0.00021396669
action O 0 0.00028741092
similar O 0 0.00016414789
to O 0 0.00024501182
that O 0 0.000405527
of O 0 0.0024526932
lidocaine B-Chemical 0 0.99953556
. O 0 0.0037336762

Accordingly O 0 0.002326401
, O 0 0.0016565928
the O 0 0.00080021244
present O 0 0.00052573095
, O 0 0.0006624897
prospective O 0 0.0012099833
double O 0 0.00058996823
- O 0 0.0005137704
blind O 0 0.0023200305
study O 0 0.00016927852
compares O 0 0.00022825146
prilocaine B-Chemical 0 0.99998295
with O 0 0.0009239532
lidocaine B-Chemical 0 0.9999449
and O 0 0.0005727002
bupivacaine B-Chemical 1 0.9999485
with O 0 0.00016186712
respect O 0 4.9204533e-05
to O 0 5.16798e-05
duration O 0 3.8575916e-05
of O 0 0.00011814227
action O 0 0.00021799187
and O 0 0.00022841431
relative O 0 0.00034198453
risk O 0 0.0035947878
of O 0 0.002104166
TNSs B-Disease 0 0.5747242
. O 0 0.0024517903

METHODS O 0 0.0014612991
: O 0 0.0012445315
Ninety O 0 0.0009955127
patients O 0 0.0006259063
classified O 0 0.00033146152
as O 0 0.00022087849
American O 0 0.00031933322
Society O 0 0.00015860263
of O 0 0.00011895017
Anesthesiologists O 0 8.017021e-05
physical O 0 0.00015152071
status O 0 9.771559e-05
I O 0 0.0006314378
or O 0 9.606494e-05
II O 0 0.0014233561
who O 0 0.00013096072
were O 0 4.9291415e-05
scheduled O 0 2.2454211e-05
for O 0 2.4368142e-05
short O 0 3.380869e-05
gynecologic O 0 0.00015402875
procedures O 0 4.123543e-05
under O 0 3.339514e-05
spinal O 0 0.00025455144
anesthesia O 0 0.00080418674
were O 0 3.4992005e-05
randomly O 0 1.2697997e-05
allocated O 0 2.0328993e-05
to O 0 2.9264756e-05
receive O 0 3.054342e-05
2 O 0 3.7309466e-05
. O 0 2.7552238e-05
5 O 0 3.3931236e-05
ml O 0 0.00013144063
2 O 0 5.6375437e-05
% O 0 0.00012076751
lidocaine B-Chemical 0 0.9981048
in O 0 0.00010311363
7 O 0 5.450158e-05
. O 0 3.949999e-05
5 O 0 4.7516238e-05
% O 0 0.00011227381
glucose B-Chemical 1 0.78437006
, O 0 0.00015626357
2 O 0 8.768676e-05
% O 0 0.00019279066
prilocaine B-Chemical 0 0.9999516
in O 0 0.00013372723
7 O 0 6.288566e-05
. O 0 4.4590237e-05
5 O 0 5.367027e-05
% O 0 0.00012703141
glucose B-Chemical 1 0.77956057
, O 0 0.00015495562
or O 0 8.807544e-05
0 O 0 8.098385e-05
. O 0 5.7476154e-05
5 O 0 7.538999e-05
% O 0 0.00021366577
bupivacaine B-Chemical 1 0.99926955
in O 0 0.00025695228
7 O 0 0.00018904929
. O 0 0.00020387239
5 O 0 0.00036453494
% O 0 0.0010907113
glucose B-Chemical 1 0.81483865
. O 0 0.0031201625

All O 0 0.0022648328
solutions O 0 0.0035975727
were O 0 0.0012553295
provided O 0 0.000925217
in O 0 0.00078828656
blinded O 0 0.0010986328
vials O 0 0.0016071469
by O 0 0.0009056562
the O 0 0.0011340821
hospital O 0 0.0029243212
pharmacy O 0 0.010567516
. O 0 0.0035270583

Details O 0 0.0017291204
of O 0 0.0018770081
spinal O 0 0.003827555
puncture O 0 0.0025214565
, O 0 0.0006364101
extension O 0 0.00040091082
and O 0 0.00027555902
regression O 0 0.0004325605
of O 0 0.00031818997
spinal O 0 0.0010842315
block O 0 0.00028203946
, O 0 0.00018854541
and O 0 0.000119017444
the O 0 9.253075e-05
times O 0 5.8171263e-05
to O 0 9.761082e-05
reach O 0 0.00013402531
discharge O 0 0.00033468133
criteria O 0 0.00042487768
were O 0 0.0005834792
noted O 0 0.0008890679
. O 0 0.0017338645

In O 0 0.0016079519
the O 0 0.001161781
evening O 0 0.0014875937
of O 0 0.00070701406
postoperative O 0 0.0008278912
day O 0 0.00021506299
1 O 0 0.00018647041
, O 0 0.00019115933
patients O 0 0.00018128564
were O 0 0.000107401174
evaluated O 0 8.387653e-05
for O 0 0.000103525934
TNSs B-Disease 0 0.053411644
by O 0 0.00012100185
a O 0 0.00014299004
physician O 0 0.0002705449
unaware O 0 0.00013507338
of O 0 0.00010570459
the O 0 9.849017e-05
drug O 0 0.0018897814
administered O 0 0.00013357136
and O 0 0.00010185501
the O 0 9.6801785e-05
details O 0 7.985068e-05
of O 0 0.00024720648
the O 0 0.0004266282
anesthetic O 0 0.013043675
procedure O 0 0.0013494426
. O 0 0.0018136796

RESULTS O 0 0.004218624
: O 0 0.0016854537
Nine O 0 0.001154764
of O 0 0.0005438964
30 O 0 0.0003159106
patients O 0 0.0004289397
receiving O 0 0.0007696652
lidocaine B-Chemical 0 0.99973506
experienced O 0 0.00093687896
TNSs B-Disease 0 0.36234373
, O 0 0.00016395954
1 O 0 6.288014e-05
of O 0 6.703367e-05
30 O 0 5.1591163e-05
patients O 0 0.00012508643
receiving O 0 0.0004981402
prilocaine B-Chemical 0 0.9999881
( O 0 0.00097094406
P O 0 0.0200728
= O 0 0.00014768292
0 O 0 7.532e-05
. O 0 6.670208e-05
03 O 0 0.00066548923
) O 0 0.00015722924
had O 0 9.3881776e-05
them O 0 0.00017487635
, O 0 0.000110060915
and O 0 8.791751e-05
none O 0 8.944507e-05
of O 0 0.00012105816
30 O 0 0.00010305974
patients O 0 0.00029491604
receiving O 0 0.001072123
bupivacaine B-Chemical 1 0.9997961
had O 0 0.0024341457
TNSs B-Disease 0 0.5002921
. O 0 0.0022845925

Times O 0 0.0032589827
to O 0 0.0015323346
ambulate O 0 0.0028533684
and O 0 0.00054667494
to O 0 0.00030110683
void O 0 0.00054340466
were O 0 0.00017065946
similar O 0 8.613558e-05
after O 0 8.4093335e-05
lidocaine B-Chemical 0 0.99961925
and O 0 0.0008445675
prilocaine B-Chemical 0 0.9999881
( O 0 0.00039903805
150 O 0 0.00020843127
vs O 0 9.832351e-05
. O 0 4.4244218e-05
165 O 0 0.00012292495
min O 0 7.479194e-05
and O 0 7.896271e-05
238 O 0 0.00032609986
vs O 0 8.59909e-05
. O 0 4.4579057e-05
253 O 0 0.00027970143
min O 0 9.518998e-05
, O 0 0.0001097755
respectively O 0 0.00024552183
) O 0 0.00013971067
but O 0 7.5268166e-05
prolonged O 0 0.00013031582
after O 0 5.5504377e-05
bupivacaine B-Chemical 1 0.99988747
( O 0 0.00024041148
200 O 0 0.00024091422
and O 0 0.00012485108
299 O 0 0.0012131041
min O 0 0.00017062415
, O 0 0.00021681325
respectively O 0 0.00055000396
; O 0 0.00046901993
P O 0 0.0031990984
< O 0 0.0003638872
0 O 0 0.0004023251
. O 0 0.0005909638
05 O 0 0.005874309
) O 0 0.002512045
. O 0 0.0025418554

CONCLUSIONS O 0 0.02190609
: O 0 0.0041540833
Prilocaine B-Chemical 0 0.9534827
may O 0 0.00069552433
be O 0 0.00035064717
preferable O 0 0.00020147121
to O 0 0.00029015422
lidocaine B-Chemical 0 0.99812704
for O 0 0.00012481085
short O 0 8.910811e-05
surgical O 0 0.00011270125
procedures O 0 7.9685466e-05
because O 0 5.6076464e-05
it O 0 9.24511e-05
has O 0 5.438559e-05
a O 0 8.086934e-05
similar O 0 4.107405e-05
duration O 0 3.760007e-05
of O 0 0.0001195003
action O 0 0.00023300273
but O 0 0.00022220587
a O 0 0.00035415092
lower O 0 0.00056381186
incidence O 0 0.0014128655
of O 0 0.0019797706
TNSs B-Disease 0 0.5614279
. O 0 0.0024982176

Suxamethonium B-Chemical 1 0.99411666
- O 0 0.006586205
induced O 0 0.003246212
cardiac B-Disease 2 0.94886315
arrest I-Disease 2 0.9754877
and O 0 0.0024729136
death B-Disease 0 0.9329255
following O 0 0.00047433242
5 O 0 0.0003895437
days O 0 0.0003237641
of O 0 0.0011292956
immobilization O 0 0.00564002
. O 0 0.0032274567

The O 0 0.0014164478
present O 0 0.0009619036
report O 0 0.0011318624
describes O 0 0.0008391624
a O 0 0.000585128
case O 0 0.00034111645
of O 0 0.0006282826
cardiac B-Disease 2 0.9348919
arrest I-Disease 2 0.9667231
and O 0 0.0004244304
subsequent O 0 0.00037920813
death B-Disease 0 0.97151
as O 0 0.00012849651
a O 0 0.000117276875
result O 0 7.362903e-05
of O 0 0.00020341261
hyperkalaemia B-Disease 0 0.9988619
following O 0 6.833445e-05
the O 0 7.5160635e-05
use O 0 7.4443764e-05
of O 0 0.000272247
suxamethonium B-Chemical 0 0.9997453
in O 0 0.00017252516
a O 0 0.00025784146
23 O 0 0.00031707677
- O 0 0.00035648886
year O 0 0.00018522468
- O 0 0.0005438016
old O 0 0.0006223191
Malawian O 0 0.0035568832
woman O 0 0.0045876796
. O 0 0.002141348

Five O 0 0.002244196
days O 0 0.00060319284
after O 0 0.00031003976
the O 0 0.00042440044
onset O 0 0.00047263922
of O 0 0.0003782149
the O 0 0.00031499067
symptoms O 0 0.0035346348
of O 0 0.0006397649
meningitis B-Disease 0 0.9617215
, O 0 0.00030603935
the O 0 0.00015945696
patient O 0 0.00019213076
aspirated O 0 0.00034220336
stomach O 0 0.0028168983
contents O 0 0.0007467979
and O 0 0.0003538951
needed O 0 0.0004405187
endotracheal O 0 0.0018860075
intubation O 0 0.0035491784
. O 0 0.0018202992

Forty O 0 0.0028704596
seconds O 0 0.00094925053
after O 0 0.00044368763
injection O 0 0.0008862667
of O 0 0.0017739646
suxamethonium B-Chemical 0 0.9997446
, O 0 0.0024161409
bradycardia B-Disease 0 0.99736744
and O 0 0.0021900004
cardiac B-Disease 2 0.9434333
arrest I-Disease 2 0.9712513
occurred O 0 0.0036237282
. O 0 0.0030859078

Attempts O 0 0.007223484
to O 0 0.0035279081
resuscitate O 0 0.007680295
the O 0 0.0020934131
patient O 0 0.0021752703
were O 0 0.0019414285
not O 0 0.0021773435
successful O 0 0.004134575
. O 0 0.005039608

The O 0 0.00207622
serum O 0 0.008854909
level O 0 0.0013337231
of O 0 0.003026895
potassium B-Chemical 0 0.999843
was O 0 0.0012164382
observed O 0 0.00040705223
to O 0 0.00032226904
be O 0 0.00029701146
8 O 0 0.00024544226
. O 0 0.00024149721
4 O 0 0.0004570172
mequiv O 0 0.519017
L O 0 0.42986652
- O 0 0.0030927162
1 O 0 0.001945239
. O 0 0.0026720094

Apart O 0 0.0024132803
from O 0 0.0011461349
the O 0 0.0008393767
reduction O 0 0.0010315478
in O 0 0.0003739398
the O 0 0.0002893219
patient O 0 0.0002805601
' O 0 0.00024367968
s O 0 0.00014412514
level O 0 9.996453e-05
of O 0 0.00023126599
consciousness O 0 0.29149434
, O 0 0.00018422952
there O 0 5.582069e-05
were O 0 7.176275e-05
no O 0 4.3220167e-05
signs O 0 0.0004889228
of O 0 0.00014612512
motor O 0 0.0013396618
neurone O 0 0.040395446
damage O 0 0.110049814
or O 0 8.3248546e-05
of O 0 9.741397e-05
any O 0 5.19536e-05
of O 0 8.088483e-05
the O 0 6.547482e-05
other O 0 6.261626e-05
known O 0 0.00011776751
predisposing O 0 0.00048805762
conditions O 0 0.0001183617
for O 0 0.000110857836
hyperkalaemia B-Disease 0 0.9970721
following O 0 0.0001493785
the O 0 0.00026089564
administration O 0 0.0020515958
of O 0 0.0027255318
suxamethonium B-Chemical 0 0.9996321
. O 0 0.0030598568

It O 0 0.0029085586
is O 0 0.0014585158
postulated O 0 0.0010525725
that O 0 0.000703149
her O 0 0.0022608475
death B-Disease 0 0.9769314
was O 0 0.0006670525
caused O 0 0.00044571052
by O 0 0.0005098817
hypersensitivity B-Disease 0 0.7449274
to O 0 0.00074517704
suxamethonium B-Chemical 0 0.999925
, O 0 0.00040775014
associated O 0 0.00019822315
with O 0 0.000324318
her O 0 0.00043167532
5 O 0 0.00025253824
- O 0 0.0006011239
day O 0 0.00045862625
immobilization O 0 0.0030799902
. O 0 0.0022085966

Acute O 0 0.9515693
hepatitis B-Disease 2 0.99994373
, O 0 0.1272066
autoimmune B-Disease 2 0.99992204
hemolytic I-Disease 2 0.9999975
anemia I-Disease 2 0.99999845
, O 0 0.012824281
and O 0 0.0020830343
erythroblastocytopenia B-Disease 0 0.3874653
induced O 0 0.0022283834
by O 0 0.003164771
ceftriaxone B-Chemical 0 0.99912196
. O 0 0.005098222

An O 0 0.0038137946
80 O 0 0.0036172902
- O 0 0.0029275208
yr O 0 0.0012029918
- O 0 0.0011786991
old O 0 0.00069712865
man O 0 0.0051016062
developed O 0 0.0023436698
acute O 0 0.99937123
hepatitis B-Disease 2 0.999998
shortly O 0 0.003157812
after O 0 0.00039658105
ingesting O 0 0.3841786
oral O 0 0.7493022
ceftriaxone B-Chemical 0 0.9995908
. O 0 0.004723581

Although O 0 0.0015383244
the O 0 0.0017597509
transaminases O 0 0.987748
gradually O 0 0.0011937584
returned O 0 0.00037293887
to O 0 0.00018301062
baseline O 0 0.00012360325
after O 0 5.6930596e-05
withholding O 0 0.00036292255
the O 0 0.00029994245
beta B-Chemical 0 0.99759704
lactam I-Chemical 0 0.9997447
antibiotic O 0 0.043445215
, O 0 0.00020330053
there O 0 6.0839324e-05
was O 0 9.3044895e-05
a O 0 9.003794e-05
gradual O 0 0.00010299687
increase O 0 7.7472476e-05
in O 0 0.000103849656
serum O 0 0.2130219
bilirubin B-Chemical 1 0.99998426
and O 0 0.00028755836
a O 0 0.00017795456
decrease O 0 0.0001581989
in O 0 0.0001288204
hemoglobin O 0 0.71187484
concentration O 0 0.0005538862
caused O 0 0.00025419588
by O 0 0.00029760442
an O 0 0.0016580706
autoimmune B-Disease 2 0.99995315
hemolytic I-Disease 2 0.99999857
anemia I-Disease 2 0.9999987
and O 0 0.06591906
erythroblastocytopenia B-Disease 0 0.92083853
. O 0 0.0030430427

These O 0 0.0047047627
responded O 0 0.0050088437
to O 0 0.003742029
systemic O 0 0.5809838
steroids B-Chemical 0 0.9973242
and O 0 0.009276468
immunoglobulins O 0 0.8904274
. O 0 0.008657034

Despite O 0 0.0018627439
the O 0 0.0013370833
widespread O 0 0.0010197656
use O 0 0.0005063745
of O 0 0.00046031098
these O 0 0.00043270594
agents O 0 0.00092601636
this O 0 0.00033314756
triad O 0 0.0018293983
of O 0 0.00035900122
side O 0 0.0040447013
effects O 0 0.0002357219
has O 0 0.000101147394
not O 0 9.8625795e-05
previously O 0 0.00010583873
been O 0 8.426818e-05
reported O 0 0.00012438193
in O 0 0.0001178003
connection O 0 0.00019560418
with O 0 0.0007771478
beta B-Chemical 0 0.99584806
lactam I-Chemical 0 0.99944896
antibiotics O 0 0.60198575
. O 0 0.0032623333

Thyroxine B-Chemical 0 0.99817586
abuse O 0 0.7962631
: O 0 0.0030553886
an O 0 0.001685769
unusual O 0 0.0017536426
case O 0 0.0012590946
of O 0 0.0026525373
thyrotoxicosis B-Disease 0 0.99904376
in O 0 0.0034171718
pregnancy O 0 0.04035178
. O 0 0.0039816815

Eating B-Disease 0 0.5344564
disorders I-Disease 0 0.82571673
and O 0 0.0013399222
the O 0 0.00065755146
associated O 0 0.00045435404
behavioural O 0 0.0011201105
problems O 0 0.0011111447
and O 0 0.0007388344
drug B-Disease 0 0.8111971
abuse I-Disease 0 0.9908618
are O 0 0.0009705368
uncommon O 0 0.00246177
in O 0 0.0012107147
pregnancy O 0 0.012330698
. O 0 0.002572299

When O 0 0.0015106364
they O 0 0.0011158787
do O 0 0.00081948296
occur O 0 0.00041273906
they O 0 0.00030530934
are O 0 0.00024811958
often O 0 0.00024475803
unrecognized O 0 0.00034125842
because O 0 0.000115579816
of O 0 0.0002674137
denial O 0 0.003615582
but O 0 0.00017170819
when O 0 7.1592e-05
significant O 0 9.7577125e-05
may O 0 7.786554e-05
pose O 0 0.000113378075
a O 0 0.00020964428
risk O 0 0.00079997914
to O 0 0.00012930232
both O 0 0.00018161349
the O 0 0.00026956393
mother O 0 0.0012149498
and O 0 0.00072095275
her O 0 0.001695628
fetus O 0 0.0064710607
. O 0 0.0024057638

This O 0 0.0036469153
case O 0 0.0013702686
illustrates O 0 0.0006612835
a O 0 0.00071662734
number O 0 0.00037669428
of O 0 0.00036782736
problems O 0 0.00048258997
that O 0 0.00013088333
may O 0 0.000111891284
be O 0 8.239928e-05
encountered O 0 8.441664e-05
in O 0 8.775034e-05
women O 0 0.0002687151
with O 0 0.00020623399
eating B-Disease 0 0.8827751
disorders I-Disease 0 0.9625358
in O 0 0.00015913633
pregnancy O 0 0.0015915213
, O 0 0.00010437613
including O 0 5.2265525e-05
prolonged O 0 0.00017358553
and O 0 0.00015432423
recurrent O 0 0.0046208184
metabolic O 0 0.6311529
disturbances O 0 0.87583506
and O 0 0.002136647
diuretic O 0 0.999746
abuse O 0 0.9585751
. O 0 0.002969022

In O 0 0.0016045597
particular O 0 0.000778033
it O 0 0.000715632
illustrates O 0 0.00033898538
the O 0 0.00039409296
derangements O 0 0.04856073
of O 0 0.00053489214
thyroid O 0 0.19739024
function O 0 0.00021902
seen O 0 0.00011048541
in O 0 9.713893e-05
pregnant O 0 0.0007340298
women O 0 0.000295348
with O 0 0.00019822975
eating B-Disease 0 0.8924466
disorders I-Disease 0 0.9706114
and O 0 0.0001991852
reminds O 0 0.0008987769
us O 0 0.00021738559
that O 0 4.7544203e-05
when O 0 4.2923857e-05
a O 0 0.00011359798
cause O 0 0.00015502065
for O 0 0.00012642452
thyrotoxicosis B-Disease 0 0.9991086
remains O 0 0.00016462158
obscure O 0 0.0007042368
, O 0 0.00044752288
thyroxine B-Chemical 1 0.99991727
abuse O 0 0.62756693
should O 0 0.0001535539
be O 0 0.0002190994
considered O 0 0.00028158916
and O 0 0.0006387818
explored O 0 0.0011019454
. O 0 0.002000562

Repeated O 0 0.0089848675
trimipramine B-Chemical 0 0.9999385
induces O 0 0.0038337163
dopamine B-Chemical 0 0.99988866
D2 O 0 0.99963236
/ O 0 0.03457739
D3 O 0 0.99971527
and O 0 0.0019054653
alpha1 O 0 0.9979469
- O 0 0.0034812482
adrenergic O 0 0.9428114
up O 0 0.0011704331
- O 0 0.0016449146
regulation O 0 0.0011384255
. O 0 0.0023398742

Trimipramine B-Chemical 0 0.99884367
( O 0 0.009409326
TRI B-Chemical 1 0.9941679
) O 0 0.0020992814
, O 0 0.0006225808
which O 0 0.00036589405
shows O 0 0.00014254542
a O 0 0.00027685915
clinical O 0 0.0011871656
antidepressant B-Chemical 1 0.999411
activity O 0 0.0002629694
, O 0 0.00018865852
is O 0 0.00010752997
chemically O 0 0.00044277526
related O 0 4.3119515e-05
to O 0 0.00015501207
imipramine B-Chemical 0 0.9999937
but O 0 0.00016268225
does O 0 5.532935e-05
not O 0 3.934469e-05
inhibit O 0 3.2716616e-05
the O 0 7.6797165e-05
reuptake O 0 0.72530836
of O 0 0.00024974893
noradrenaline B-Chemical 1 0.9998011
and O 0 0.00012773725
5 B-Chemical 0 7.5527634e-05
- I-Chemical 0 0.00027482203
hydroxytryptamine I-Chemical 0 0.6177229
, O 0 0.00014133977
nor O 0 8.6040105e-05
does O 0 9.361217e-05
it O 0 0.0001335301
induce O 0 0.00015188595
beta O 0 0.8466585
- O 0 0.0019637602
adrenergic O 0 0.95472485
down O 0 0.0013029532
- O 0 0.0012312977
regulation O 0 0.000822259
. O 0 0.0017482883

The O 0 0.0023224894
mechanism O 0 0.0022944773
of O 0 0.0023389226
its O 0 0.004319283
antidepressant B-Chemical 1 0.9985886
activity O 0 0.0022313583
is O 0 0.0020404835
still O 0 0.002431529
unknown O 0 0.0056367586
. O 0 0.0044579646

The O 0 0.0014921436
aim O 0 0.0013365854
of O 0 0.0010155567
the O 0 0.0005746734
present O 0 0.00036985695
study O 0 0.00044320978
was O 0 0.00025421506
to O 0 0.00013420933
find O 0 0.000107418375
out O 0 8.156784e-05
whether O 0 7.448786e-05
TRI B-Chemical 1 0.9602763
given O 0 7.707565e-05
repeatedly O 0 0.00010529364
was O 0 8.0269674e-05
able O 0 4.4105203e-05
to O 0 4.7399386e-05
induce O 0 3.5654994e-05
adaptive O 0 9.0599315e-05
changes O 0 8.515278e-05
in O 0 5.751218e-05
the O 0 8.7730594e-05
dopaminergic O 0 0.1852198
and O 0 0.0003325916
alpha1 O 0 0.99845874
- O 0 0.0010666645
adrenergic O 0 0.9166462
systems O 0 0.00015831829
, O 0 0.00013440655
demonstrated O 0 0.00010143426
by O 0 0.00016701724
us O 0 0.00041348653
previously O 0 0.0002615098
for O 0 0.00033778694
various O 0 0.0015566355
antidepressants B-Chemical 0 0.9995333
. O 0 0.0027636453

TRI B-Chemical 1 0.97352445
was O 0 0.0020861113
given O 0 0.0006851452
to O 0 0.000679003
male O 0 0.0017682741
Wistar O 0 0.001843197
rats O 0 0.00044218113
and O 0 0.0002803911
male O 0 0.00086667476
Albino O 0 0.0025576672
Swiss O 0 0.000544018
mice O 0 0.000105594365
perorally O 0 0.0006599633
twice O 0 0.00015141311
daily O 0 0.00025330632
for O 0 0.0002539997
14 O 0 0.00047890333
days O 0 0.00055571215
. O 0 0.001579285

In O 0 0.0017827309
the O 0 0.0016624619
acute O 0 0.072974786
experiment O 0 0.0012046718
TRI B-Chemical 1 0.99373144
( O 0 0.00071755704
given O 0 0.00019748701
i O 0 0.0006474152
. O 0 0.00016889237
p O 0 0.0001943128
. O 0 8.911686e-05
) O 0 0.00015134685
does O 0 7.1889124e-05
not O 0 7.091308e-05
antagonize O 0 0.00019399772
the O 0 0.00033869676
reserpine B-Chemical 1 0.9999964
hypothermia B-Disease 0 0.999938
in O 0 0.00017126834
mice O 0 5.8165882e-05
and O 0 7.414854e-05
does O 0 5.8546193e-05
not O 0 6.131267e-05
potentiate O 0 0.000104944105
the O 0 0.0001095723
5 B-Chemical 0 0.00011453415
- I-Chemical 0 0.00046734832
hydroxytryptophan I-Chemical 0 0.92368096
head O 0 0.5138129
twitches O 0 0.98338413
in O 0 0.0011148222
rats O 0 0.0023139787
. O 0 0.0018147142

TRI B-Chemical 1 0.94002193
given O 0 0.0010396051
repeatedly O 0 0.00076176267
to O 0 0.00043670388
rats O 0 0.00046628658
increases O 0 0.00026620846
the O 0 0.0003664641
locomotor O 0 0.98386556
hyperactivity B-Disease 2 0.99999404
induced O 0 0.00079386606
by O 0 0.00031575796
d B-Chemical 0 0.0010998243
- I-Chemical 0 0.0025020442
amphetamine I-Chemical 1 0.99999857
, O 0 0.0028421057
quinpirole B-Chemical 0 0.99998987
and O 0 0.00039564157
( O 0 0.0002996172
+ O 0 0.00037470812
) O 0 0.0002725545
- O 0 0.000255741
7 O 0 0.000101805694
- O 0 0.00050789333
hydroxy O 0 0.99981886
- O 0 0.0011710927
dipropyloaminotetralin O 0 0.025512554
( O 0 0.0012231107
dopamine B-Chemical 0 0.999894
D2 O 0 0.9993262
and O 0 0.0016144564
D3 O 0 0.9992606
effects O 0 0.0023032355
) O 0 0.0030618068
. O 0 0.0023237881

The O 0 0.003653766
stereotypies O 0 0.9967679
induced O 0 0.002514186
by O 0 0.0014214071
d B-Chemical 0 0.0028836955
- I-Chemical 0 0.0043972265
amphetamine I-Chemical 1 0.99999094
or O 0 0.0025921725
apomorphine B-Chemical 1 0.9999597
are O 0 0.00069336913
not O 0 0.00057863165
potentiated O 0 0.015572581
by O 0 0.003064872
TRI B-Chemical 1 0.98711085
. O 0 0.003604603

It O 0 0.0020821146
increases O 0 0.0010127637
the O 0 0.0006577681
behaviour O 0 0.0006111183
stimulation O 0 0.00033650786
evoked O 0 0.0019739245
by O 0 0.00085986604
phenylephrine B-Chemical 0 0.99995196
( O 0 0.00048066454
given O 0 0.000102210935
intraventricularly O 0 0.005067662
) O 0 0.00021751414
in O 0 8.174943e-05
rats O 0 0.00013214866
, O 0 7.614232e-05
evaluated O 0 4.6111072e-05
in O 0 4.698692e-05
the O 0 5.624431e-05
open O 0 0.00012667118
field O 0 0.00011087518
test O 0 0.00011143993
as O 0 5.2909123e-05
well O 0 4.4637425e-05
as O 0 5.091269e-05
the O 0 8.3483705e-05
aggressiveness B-Disease 2 0.49325842
evoked O 0 0.00179135
by O 0 0.0003579968
clonidine B-Chemical 0 0.9999702
in O 0 0.000118692406
mice O 0 5.5700515e-05
, O 0 7.8611396e-05
both O 0 6.45592e-05
these O 0 0.00010214214
effects O 0 0.00011842615
being O 0 0.00015940558
mediated O 0 8.89609e-05
by O 0 0.00022409693
an O 0 0.00083283737
alpha1 O 0 0.99811554
- O 0 0.0052297423
adrenergic O 0 0.9888677
receptor O 0 0.10427635
. O 0 0.002353224

It O 0 0.0027262059
may O 0 0.001192049
be O 0 0.00069013354
concluded O 0 0.00040305927
that O 0 0.00029386693
, O 0 0.0003497367
like O 0 0.00018076401
other O 0 0.00037333192
tricyclic O 0 0.9998933
antidepressants B-Chemical 0 0.99995923
studied O 0 0.00034004994
previously O 0 0.00013931343
, O 0 0.00019393262
TRI B-Chemical 1 0.9181016
given O 0 4.720438e-05
repeatedly O 0 5.6025685e-05
increases O 0 4.86857e-05
the O 0 4.5633817e-05
responsiveness O 0 6.7094225e-05
of O 0 0.00012206455
brain O 0 0.028546408
dopamine B-Chemical 0 0.999977
D2 O 0 0.9998423
and O 0 0.00058290694
D3 O 0 0.99991786
( O 0 0.00025987776
locomotor O 0 0.01302082
activity O 0 8.136725e-05
but O 0 9.441812e-05
not O 0 0.00012775637
stereotypy O 0 0.99779105
) O 0 0.0002749683
as O 0 7.858628e-05
well O 0 8.184678e-05
as O 0 0.0001930929
alpha1 O 0 0.9955244
- O 0 0.0015575814
adrenergic O 0 0.9667408
receptors O 0 0.0019988175
to O 0 0.0003874994
their O 0 0.0010393795
agonists O 0 0.21690723
. O 0 0.0022002985

A O 0 0.012236802
question O 0 0.0014055114
arises O 0 0.0006540879
whether O 0 0.00029992987
the O 0 0.0005623834
reuptake O 0 0.89000785
inhibition O 0 0.0009581718
is O 0 0.00021796027
of O 0 0.00018004618
any O 0 8.5238724e-05
importance O 0 5.6229608e-05
to O 0 6.43841e-05
the O 0 7.017105e-05
adaptive O 0 0.0001220968
changes O 0 0.00011988151
induced O 0 0.000118836346
by O 0 0.00011053209
repeated O 0 0.00011367447
antidepressants B-Chemical 0 0.99983454
, O 0 0.00018219314
suggested O 0 7.786747e-05
to O 0 9.17709e-05
be O 0 9.979567e-05
responsible O 0 0.00011335872
for O 0 0.00016821302
the O 0 0.00056451437
antidepressant B-Chemical 1 0.9979512
activity O 0 0.0018452036
. O 0 0.0021708948

Pethidine B-Chemical 0 0.9994325
- O 0 0.0055302167
associated O 0 0.0014493059
seizure B-Disease 0 0.9927377
in O 0 0.00061013916
a O 0 0.00056952727
healthy O 0 0.0013119077
adolescent O 0 0.0020882655
receiving O 0 0.0017714434
pethidine B-Chemical 0 0.9999455
for O 0 0.00069221365
postoperative B-Disease 0 0.09268457
pain I-Disease 0 0.97742724
control O 0 0.002375592
. O 0 0.0024975475

A O 0 0.02832539
healthy O 0 0.006444893
17 O 0 0.0019804395
- O 0 0.0014681357
year O 0 0.0004021663
- O 0 0.0005533242
old O 0 0.00024114197
male O 0 0.0003594312
received O 0 7.4438656e-05
standard O 0 7.343593e-05
intermittent O 0 0.0003305243
doses O 0 0.00082785037
of O 0 0.0005239897
pethidine B-Chemical 0 0.9999838
via O 0 7.92319e-05
a O 0 0.0001310353
patient O 0 0.00011561841
- O 0 0.00016535372
controlled O 0 0.00011154241
analgesia O 0 0.3991955
( O 0 0.0002628611
PCA O 0 0.10280861
) O 0 0.00025440633
pump O 0 0.00043113658
for O 0 8.554972e-05
management O 0 0.00018122721
of O 0 0.00042628063
postoperative B-Disease 0 0.028433623
pain I-Disease 0 0.9615547
control O 0 0.0019913418
. O 0 0.0021783642

Twenty O 0 0.004480321
- O 0 0.0025269613
three O 0 0.00057932694
h O 0 0.0007212819
postoperatively O 0 0.00064187654
he O 0 0.00062845246
developed O 0 0.0007401186
a O 0 0.0007545243
brief O 0 0.00081713597
self O 0 0.0028713332
- O 0 0.0022592107
limited O 0 0.0022797068
seizure B-Disease 0 0.99857557
. O 0 0.0047291433

Both O 0 0.0029989374
plasma O 0 0.1351468
pethidine B-Chemical 0 0.9999356
and O 0 0.0035044793
norpethidine B-Chemical 0 0.9997465
were O 0 0.0005593181
elevated O 0 0.00096670043
in O 0 0.00015966721
the O 0 0.00012872032
range O 0 0.00012538773
associated O 0 0.00011230144
with O 0 0.00019831918
clinical O 0 0.0006192095
manifestations O 0 0.0019341442
of O 0 0.0003869099
central O 0 0.0006688228
nervous O 0 0.016308833
system O 0 0.0015521228
excitation O 0 0.28972206
. O 0 0.0028040654

No O 0 0.005041435
other O 0 0.0028925526
risk O 0 0.0062060864
factors O 0 0.0022031835
for O 0 0.0017247127
CNS O 0 0.26083508
toxicity B-Disease 2 0.99533975
were O 0 0.0033355812
identified O 0 0.0030429603
. O 0 0.0038384246

This O 0 0.0033419412
method O 0 0.001898486
allowed O 0 0.0010859945
frequent O 0 0.0009943325
self O 0 0.0015201804
- O 0 0.0007815906
dosing O 0 0.00070583523
of O 0 0.0006552147
pethidine B-Chemical 0 0.9999503
at O 0 0.000106492116
short O 0 6.7202636e-05
time O 0 4.0896954e-05
intervals O 0 4.5908455e-05
and O 0 8.547274e-05
rapid O 0 0.0002694486
accumulation O 0 0.00051180716
of O 0 0.0015813495
pethidine B-Chemical 0 0.99996936
and O 0 0.0053501683
norpethidine B-Chemical 0 0.99961346
. O 0 0.003242078

The O 0 0.0016006327
routine O 0 0.0012062842
use O 0 0.00086936535
of O 0 0.0016405836
pethidine B-Chemical 0 0.9999057
via O 0 0.0005377426
PCA O 0 0.119188674
even O 0 0.00032474776
for O 0 0.00016846342
a O 0 0.00028861855
brief O 0 0.00034194253
postoperative O 0 0.0015247894
analgesia O 0 0.27965805
should O 0 0.000426446
be O 0 0.00079205295
reconsidered O 0 0.0013821088
. O 0 0.002061002

An O 0 0.003923206
unusual O 0 0.0036868649
toxic O 0 0.14925168
reaction O 0 0.007564637
to O 0 0.0011292837
axillary O 0 0.024101514
block O 0 0.0012650639
by O 0 0.0019866752
mepivacaine B-Chemical 0 0.9997769
with O 0 0.010860674
adrenaline B-Chemical 1 0.9996244
. O 0 0.0048407973

An O 0 0.0027781997
increase B-Disease 0 0.0014311832
in I-Disease 0 0.00097302545
blood I-Disease 0 0.0038437562
pressure I-Disease 0 0.0050619305
, O 0 0.0005274955
accompanied O 0 0.00072280667
by O 0 0.0004435741
atrial B-Disease 0 0.95449317
fibrillation I-Disease 0 0.99997437
, O 0 0.0007859411
agitation B-Disease 2 0.9792742
, O 0 0.00040069013
incomprehensible B-Disease 0 0.00839672
shouts I-Disease 0 0.110604905
and O 0 0.00016546225
loss B-Disease 0 0.0014796763
of I-Disease 0 0.0003091304
consciousness I-Disease 0 0.95305216
, O 0 0.00020407274
was O 0 9.160617e-05
observed O 0 4.858093e-05
in O 0 5.282599e-05
an O 0 0.0001247284
elderly O 0 0.026886815
, O 0 0.00017918662
ASA O 0 0.87199306
classification O 0 0.000110696215
group O 0 0.00013369457
II O 0 0.0018522489
, O 0 0.00013022589
cardiovascularly O 0 0.0443327
medicated O 0 0.12697697
male O 0 0.00038581563
, O 0 5.2761494e-05
12 O 0 1.8962435e-05
min O 0 2.9848794e-05
after O 0 1.2969499e-05
performance O 0 5.0801682e-05
of O 0 7.831323e-05
axillary O 0 0.0055192057
block O 0 9.925177e-05
with O 0 0.00023303319
mepivacaine B-Chemical 0 0.999938
850 O 0 0.0023835194
mg O 0 0.0042470302
containing O 0 0.00012975944
adrenaline B-Chemical 1 0.999736
0 O 0 9.296703e-05
. O 0 5.2982592e-05
225 O 0 0.00037286474
mg O 0 0.0012774604
, O 0 0.00013081655
for O 0 0.00010482148
correction O 0 0.00067860715
of O 0 0.0007106564
Dupuytren B-Disease 0 0.98014724
' I-Disease 0 0.001468426
s I-Disease 0 0.0016087497
contracture I-Disease 0 0.9918532
. O 0 0.0032538413

After O 0 0.0009418323
intravenous O 0 0.0060366034
administration O 0 0.002968498
of O 0 0.0026413323
labetalol B-Chemical 0 0.99999607
, O 0 0.008285178
metoprolol B-Chemical 1 0.999998
and O 0 0.002549042
midazolam B-Chemical 0 0.99998
the O 0 0.0002310502
patient O 0 0.00016028226
' O 0 0.00014522822
s O 0 0.00010891935
condition O 0 0.00022102868
improved O 0 0.00029037005
, O 0 0.00017737385
and O 0 0.00014899866
15 O 0 0.00012843257
min O 0 0.00024239084
later O 0 0.00027424673
he O 0 0.00072152977
woke O 0 0.001656555
up O 0 0.0014328121
. O 0 0.002106588

The O 0 0.0018692805
block O 0 0.0018236935
was O 0 0.0011590337
successful O 0 0.00075537286
and O 0 0.00064664066
surgery O 0 0.00061277626
was O 0 0.00035876498
conducted O 0 0.00024006332
as O 0 0.0002308331
scheduled O 0 0.00018435356
despite O 0 0.00031568302
persisting O 0 0.0018332946
atrial B-Disease 0 0.963074
fibrillation I-Disease 0 0.9997913
. O 0 0.0037932086

Postoperatively O 0 0.0059355744
, O 0 0.0022146609
the O 0 0.0012519216
patient O 0 0.0013727202
refused O 0 0.0033864665
DC O 0 0.035556734
cardioversion O 0 0.0057427953
and O 0 0.0010679037
was O 0 0.001319539
treated O 0 0.00266122
medically O 0 0.04946384
. O 0 0.003559883

Both O 0 0.0018557425
the O 0 0.0010047322
temporal O 0 0.0011841941
relationship O 0 0.00029741522
of O 0 0.0004653636
events O 0 0.00083368376
and O 0 0.00021929792
the O 0 0.00013546264
response O 0 0.00012512926
to O 0 9.2213806e-05
treatment O 0 8.6799424e-05
suggest O 0 3.2488253e-05
that O 0 4.4233588e-05
a O 0 0.00010098096
rapid O 0 0.00030674596
systemic O 0 0.17123494
absorption O 0 0.69024837
of O 0 0.0006331028
mepivacaine B-Chemical 0 0.9999782
with O 0 0.00093540363
adrenaline B-Chemical 1 0.9999368
and O 0 0.000148509
/ O 0 0.00022665749
or O 0 4.235637e-05
interaction O 0 3.814899e-05
of O 0 6.9620495e-05
these O 0 0.000112847716
drugs O 0 0.0016481235
with O 0 8.244273e-05
the O 0 6.491899e-05
patient O 0 8.44032e-05
' O 0 0.00010802288
s O 0 0.000118446376
cardiovascular O 0 0.22024919
medications O 0 0.0017297929
were O 0 0.00012793546
responsible O 0 0.0001185361
for O 0 0.00016777027
the O 0 0.00045605673
perioperative O 0 0.008840313
complications O 0 0.063277826
. O 0 0.002271653

Drug O 0 0.30072892
- O 0 0.0046315026
associated O 0 0.0015858308
acute O 0 0.2528769
- O 0 0.001959692
onset O 0 0.0011181905
vanishing B-Disease 0 0.067088716
bile I-Disease 0 0.9977024
duct I-Disease 0 0.88402444
and O 0 0.0008008769
Stevens B-Disease 0 0.012004336
- I-Disease 0 0.0010627633
Johnson I-Disease 0 0.00592277
syndromes I-Disease 0 0.0064752004
in O 0 0.00061758724
a O 0 0.001327294
child O 0 0.002511203
. O 0 0.0024682237

Acute O 0 0.12554763
vanishing B-Disease 0 0.15012169
bile I-Disease 0 0.9978794
duct I-Disease 0 0.982906
syndrome O 0 0.49809188
is O 0 0.00056588644
a O 0 0.00047839645
rare O 0 0.0009413429
but O 0 0.00024201511
established O 0 0.00022838426
cause O 0 0.00024600056
of O 0 0.00036011182
progressive O 0 0.74915075
cholestasis B-Disease 2 0.99999845
in O 0 0.00064625376
adults O 0 0.0008679826
, O 0 0.00013517903
is O 0 8.2032595e-05
most O 0 0.00013104455
often O 0 0.00014272197
drug O 0 0.0037642063
or O 0 0.00013394469
toxin O 0 0.006324938
related O 0 9.24391e-05
, O 0 0.00021864111
and O 0 0.00022989961
is O 0 0.00030156452
of O 0 0.00059376075
unknown O 0 0.0017455444
pathogenesis O 0 0.004001861
. O 0 0.002293489

It O 0 0.004491028
has O 0 0.0021714661
not O 0 0.0017459256
been O 0 0.001582012
reported O 0 0.0019398032
previously O 0 0.0019159921
in O 0 0.0024141094
children O 0 0.0053868946
. O 0 0.0048010116

Stevens B-Disease 0 0.034369513
- I-Disease 0 0.00663346
Johnson I-Disease 0 0.027778875
syndrome I-Disease 0 0.091606244
is O 0 0.00074100535
a O 0 0.0006013274
well O 0 0.00032748876
- O 0 0.00048544677
recognized O 0 0.00021852108
immune O 0 0.0020500664
complex O 0 0.00026599813
- O 0 0.00041380472
mediated O 0 0.00012509823
hypersensitivity B-Disease 0 0.5236557
reaction O 0 0.0035480456
that O 0 7.271053e-05
affects O 0 5.1898587e-05
all O 0 9.771121e-05
age O 0 0.000121149744
groups O 0 8.2347826e-05
, O 0 8.771904e-05
is O 0 8.750259e-05
drug O 0 0.002569362
or O 0 0.000106618005
infection B-Disease 0 0.0023503685
induced O 0 0.00024397028
, O 0 0.00019015804
and O 0 0.00014520744
has O 0 0.00011592729
classic O 0 0.0017631591
systemic O 0 0.23978303
, O 0 0.0005375468
mucosal O 0 0.020274414
, O 0 0.00056624797
and O 0 0.00080644013
dermatologic O 0 0.21173869
manifestations O 0 0.07609777
. O 0 0.0025293424

A O 0 0.016025206
previously O 0 0.001607374
healthy O 0 0.0028972598
child O 0 0.0011860302
who O 0 0.0009975577
developed O 0 0.0011412161
acute O 0 0.59752005
, O 0 0.00079971657
severe O 0 0.010981711
, O 0 0.00026161826
rapidly O 0 0.0002703054
progressive O 0 0.027424185
vanishing B-Disease 0 0.18771586
bile I-Disease 0 0.9991155
duct I-Disease 0 0.9643099
syndrome I-Disease 0 0.09537977
shortly O 0 0.00012573229
after O 0 4.421836e-05
Stevens B-Disease 0 0.0022061542
- I-Disease 0 0.0003609224
Johnson I-Disease 0 0.005891985
syndrome I-Disease 0 0.02095115
is O 0 0.000109387096
described O 0 8.372727e-05
; O 0 0.000114187475
this O 0 0.000117619464
was O 0 0.00013566237
temporally O 0 0.00021749796
associated O 0 0.00027894962
with O 0 0.0013029582
ibuprofen B-Chemical 0 0.9999087
use O 0 0.0024911892
. O 0 0.0021846343

Despite O 0 0.0017242662
therapy O 0 0.0020591433
with O 0 0.002727413
ursodeoxycholic B-Chemical 0 0.9999089
acid I-Chemical 0 0.9973423
, O 0 0.00380444
prednisone B-Chemical 1 0.9996283
, O 0 0.000469048
and O 0 0.00021914033
then O 0 0.0002588639
tacrolimus B-Chemical 0 0.99998856
, O 0 0.0008366107
her O 0 0.00490514
cholestatic B-Disease 0 0.99999964
disease I-Disease 0 0.99968195
was O 0 0.00069966546
unrelenting O 0 0.014574796
, O 0 0.000258742
with O 0 0.00067069335
cirrhosis B-Disease 0 0.999992
shown O 0 0.0002128098
by O 0 0.00019792755
biopsy O 0 0.00039469567
6 O 0 0.00010521574
months O 0 9.4377254e-05
after O 0 0.00018939191
presentation O 0 0.0011970185
. O 0 0.0018250133

This O 0 0.0037057276
case O 0 0.0017171808
documents O 0 0.0031459494
acute O 0 0.38535318
drug O 0 0.14569825
- O 0 0.00086945476
related O 0 0.00015503618
vanishing B-Disease 0 0.01894364
bile I-Disease 0 0.9978319
duct I-Disease 0 0.961575
syndrome I-Disease 0 0.13591093
in O 0 0.000109122695
the O 0 9.420463e-05
pediatric O 0 0.00026166186
age O 0 0.00010732295
group O 0 9.193987e-05
and O 0 6.2238774e-05
suggests O 0 3.326878e-05
shared O 0 0.00010041213
immune O 0 0.00075308327
mechanisms O 0 0.00010698228
in O 0 6.865018e-05
the O 0 8.00354e-05
pathogenesis O 0 0.00020554375
of O 0 0.00014309479
both O 0 0.00017922353
Stevens B-Disease 0 0.005142479
- I-Disease 0 0.0005149475
Johnson I-Disease 0 0.0044152895
syndrome I-Disease 0 0.017471226
and O 0 0.00041979653
vanishing B-Disease 0 0.06707966
bile I-Disease 0 0.99777967
duct I-Disease 0 0.98096406
syndrome I-Disease 0 0.6603093
. O 0 0.002565611

High O 0 0.0068249465
incidence O 0 0.0030182176
of O 0 0.0016101273
primary B-Disease 0 0.0034503606
pulmonary I-Disease 2 0.99820673
hypertension I-Disease 2 0.9999944
associated O 0 0.0016167423
with O 0 0.0025866597
appetite B-Chemical 1 0.9989666
suppressants I-Chemical 1 0.99945885
in O 0 0.0023885362
Belgium O 0 0.012566534
. O 0 0.0029695565

Primary B-Disease 0 0.0140799
pulmonary I-Disease 2 0.9974164
hypertension I-Disease 2 0.9999876
is O 0 0.0019683337
a O 0 0.0011346883
rare O 0 0.0021028083
, O 0 0.00057581626
progressive O 0 0.025148679
and O 0 0.0006317617
incurable O 0 0.15713751
disease O 0 0.56702995
, O 0 0.00029972574
which O 0 0.0002049166
has O 0 8.5853244e-05
been O 0 6.8198584e-05
associated O 0 7.741983e-05
with O 0 0.00013321775
the O 0 0.00018270686
intake O 0 0.027719028
of O 0 0.0009335632
appetite B-Chemical 0 0.9979417
suppressant I-Chemical 0 0.9984419
drugs O 0 0.6100559
. O 0 0.0026418425

The O 0 0.0014179244
importance O 0 0.0008063303
of O 0 0.0008884184
this O 0 0.0006219518
association O 0 0.00030064097
was O 0 0.00034059197
evaluated O 0 0.00019544087
in O 0 0.00019842054
Belgium O 0 0.00079196005
while O 0 0.0001411344
this O 0 0.00016746724
country O 0 0.00018250298
still O 0 0.00012379196
had O 0 0.000113152346
no O 0 6.984911e-05
restriction O 0 0.00022937894
on O 0 8.694174e-05
the O 0 0.00020761328
prescription O 0 0.0014643987
of O 0 0.0013294839
appetite B-Chemical 1 0.9983216
suppressants I-Chemical 1 0.9994123
. O 0 0.0035101317

Thirty O 0 0.0034497671
- O 0 0.0021135802
five O 0 0.00045901595
patients O 0 0.00055104215
with O 0 0.00041868468
primary B-Disease 0 0.0012695307
pulmonary I-Disease 2 0.99841845
hypertension I-Disease 2 0.99999833
and O 0 0.00045465643
85 O 0 0.00023045529
matched O 0 7.101879e-05
controls O 0 0.00011065739
were O 0 5.8338646e-05
recruited O 0 4.3901644e-05
over O 0 3.436251e-05
32 O 0 0.0001004806
months O 0 5.3758577e-05
( O 0 0.00020428454
1992 O 0 0.00052420795
- O 0 0.0005411805
1994 O 0 0.0010156769
) O 0 0.0007808053
in O 0 0.0008364338
Belgium O 0 0.0049847104
. O 0 0.0024818091

Exposure O 0 0.00661439
to O 0 0.0028017662
appetite B-Chemical 0 0.9916871
- I-Chemical 0 0.00787526
suppressants I-Chemical 0 0.9965365
was O 0 0.00064694916
assessed O 0 0.0001970467
on O 0 0.00011644292
the O 0 0.00015835042
basis O 0 0.00019178628
of O 0 0.00029964975
hospital O 0 0.00051719905
records O 0 0.0005563492
and O 0 0.0004870574
standardized O 0 0.0006946119
interview O 0 0.0012523285
. O 0 0.0020171066

Twenty O 0 0.003690908
- O 0 0.0019090272
three O 0 0.0003581069
of O 0 0.00047232397
the O 0 0.00033900992
patients O 0 0.00036333295
had O 0 0.0001814226
previously O 0 0.00013430636
taken O 0 0.00013275641
appetite B-Chemical 1 0.9955166
suppressants I-Chemical 1 0.9996136
, O 0 0.00034004755
mainly O 0 0.00036951722
fenfluramines B-Chemical 0 0.9634531
, O 0 0.0001439216
as O 0 6.0187187e-05
compared O 0 3.838825e-05
with O 0 7.257725e-05
only O 0 7.145308e-05
5 O 0 4.0643034e-05
of O 0 6.593158e-05
the O 0 7.3912255e-05
controls O 0 0.00018269781
( O 0 0.00013313763
66 O 0 0.00013455417
versus O 0 7.409793e-05
6 O 0 7.417612e-05
% O 0 0.00015217558
, O 0 0.00023482149
p O 0 0.00026199667
< O 0 0.00028032856
0 O 0 0.00035160218
. O 0 0.00053098274
0001 O 0 0.005297147
) O 0 0.0024114868
. O 0 0.0024628264

Five O 0 0.0034411815
patients O 0 0.0021261517
died O 0 0.0014510847
before O 0 0.00032719664
the O 0 0.00043445712
interview O 0 0.00040399074
, O 0 0.0004135551
all O 0 0.00029796927
of O 0 0.00042016187
them O 0 0.0006961899
had O 0 0.0005490261
taken O 0 0.0007446134
appetite B-Chemical 1 0.99486285
suppressants I-Chemical 1 0.9991301
. O 0 0.0042939736

In O 0 0.001797562
8 O 0 0.0011104901
patients O 0 0.0008872401
the O 0 0.0005217902
diagnosis O 0 0.00072585023
of O 0 0.00046314608
primary B-Disease 0 0.0019132547
pulmonary I-Disease 2 0.9994604
hypertension I-Disease 2 0.9999989
was O 0 0.0009607404
uncertain O 0 0.0003449094
, O 0 0.00019664859
5 O 0 9.8247976e-05
of O 0 0.0001755081
them O 0 0.00035309678
had O 0 0.0003282527
taken O 0 0.00050341233
appetite B-Chemical 1 0.99338806
suppressants I-Chemical 1 0.9991178
. O 0 0.0035798026

The O 0 0.0017167216
patients O 0 0.0018517791
who O 0 0.0012112799
had O 0 0.00047348882
been O 0 0.00023132817
exposed O 0 0.00024407405
to O 0 0.00034544
appetite B-Chemical 1 0.99822193
suppressants I-Chemical 1 0.99955374
tended O 0 0.00025035974
to O 0 9.130199e-05
be O 0 5.747643e-05
on O 0 3.092529e-05
average O 0 4.01352e-05
more O 0 0.00014226788
severely O 0 0.005574546
ill O 0 0.1526422
, O 0 0.000156864
and O 0 9.009652e-05
to O 0 6.248545e-05
have O 0 4.780617e-05
a O 0 7.898024e-05
shorter O 0 5.014549e-05
median O 0 3.994714e-05
delay O 0 9.995794e-05
between O 0 6.412357e-05
onset O 0 0.00023519504
of O 0 0.00043305152
symptoms O 0 0.0065878457
and O 0 0.0010147571
diagnosis O 0 0.0032459018
. O 0 0.0020293437

A O 0 0.01146597
policy O 0 0.0019121752
of O 0 0.0010688218
unrestricted O 0 0.0009945016
prescription O 0 0.0020692882
of O 0 0.0009917166
appetite B-Chemical 1 0.99828327
suppressants I-Chemical 1 0.9995036
may O 0 0.00033859993
lead O 0 0.0014893727
to O 0 0.00015693356
a O 0 0.00023290902
high O 0 0.00036597793
incidence O 0 0.00044701487
of O 0 0.00032626494
associated O 0 0.00042826578
primary B-Disease 0 0.005899771
pulmonary I-Disease 2 0.9994061
hypertension I-Disease 2 0.9999925
. O 0 0.006047912

Intake O 0 0.28241822
of O 0 0.0049524843
appetite B-Chemical 1 0.99579084
suppressants I-Chemical 1 0.9982065
may O 0 0.0010698589
accelerate O 0 0.00097470573
the O 0 0.0008278634
progression O 0 0.006662594
of O 0 0.0017126104
the O 0 0.0022925374
disease O 0 0.33123982
. O 0 0.00405117

Inappropriate O 0 0.0040322095
use O 0 0.0018978701
of O 0 0.0034540587
carbamazepine B-Chemical 1 0.9999726
and O 0 0.0057976595
vigabatrin B-Chemical 0 0.99993336
in O 0 0.0014190982
typical O 0 0.0015719846
absence B-Disease 0 0.005883547
seizures I-Disease 0 0.999933
. O 0 0.0078669535

Carbamazepine B-Chemical 0 0.9998405
and O 0 0.0102622025
vigabatrin B-Chemical 0 0.9998857
are O 0 0.0021903755
contraindicated O 0 0.0044693947
in O 0 0.0009732897
typical O 0 0.0014214164
absence B-Disease 0 0.0052954303
seizures I-Disease 0 0.9999182
. O 0 0.00829348

Of O 0 0.0020581607
18 O 0 0.0010056401
consecutive O 0 0.00059642486
referrals O 0 0.0009337038
of O 0 0.00040517905
children O 0 0.00038126358
with O 0 0.00021295149
resistant O 0 0.00019589516
typical O 0 0.0001913107
absences O 0 0.024629964
only O 0 0.0001698013
, O 0 0.000103538376
eight O 0 4.587318e-05
were O 0 6.391746e-05
erroneously O 0 0.00025724055
treated O 0 0.0001383448
with O 0 0.00034899876
carbamazepine B-Chemical 1 0.9999958
either O 0 0.00018614001
as O 0 0.00013479713
monotherapy O 0 0.0042743487
or O 0 0.00014197815
as O 0 0.00018587912
an O 0 0.00040896723
add O 0 0.0006243325
- O 0 0.0012120041
on O 0 0.0008901444
. O 0 0.0019853746

Vigabatrin B-Chemical 0 0.99939775
was O 0 0.0032328442
also O 0 0.0012034016
used O 0 0.00082451163
in O 0 0.0007102901
the O 0 0.00072313607
treatment O 0 0.0008751087
of O 0 0.0013620458
two O 0 0.0012665662
children O 0 0.003707982
. O 0 0.0035132186

Frequency O 0 0.0038870457
of O 0 0.0020635969
absences O 0 0.014627804
increased O 0 0.0009525056
in O 0 0.00033440642
four O 0 0.00015195113
children O 0 0.00028050633
treated O 0 0.00031489396
with O 0 0.0007535909
carbamazepine B-Chemical 1 0.9999963
and O 0 0.00022131126
two O 0 5.9983602e-05
of O 0 0.00010356583
these O 0 0.00017577088
developed O 0 0.0007897083
myoclonic B-Disease 2 0.99997795
jerks I-Disease 2 0.9999466
, O 0 0.00045638616
which O 0 0.00025561472
resolved O 0 0.00033742405
on O 0 0.00018271139
withdrawal O 0 0.013518483
of O 0 0.0038401862
carbamazepine B-Chemical 1 0.9999746
. O 0 0.003929201

Absences O 0 0.01979244
were O 0 0.0023171613
aggravated O 0 0.008527059
in O 0 0.000716944
both O 0 0.00053084065
cases O 0 0.00059135654
where O 0 0.00054918893
vigabatrin B-Chemical 0 0.999946
was O 0 0.00056768535
added O 0 0.00037012147
on O 0 0.00025041253
to O 0 0.00046616746
concurrent O 0 0.0013816928
treatment O 0 0.0020049184
. O 0 0.0025965082

Optimal O 0 0.0021650912
control O 0 0.0010841407
of O 0 0.0009004981
the O 0 0.0006444234
absences O 0 0.011925322
was O 0 0.0003714591
achieved O 0 0.00035123763
with O 0 0.0007674364
sodium B-Chemical 0 0.9999622
valproate I-Chemical 0 0.99999714
, O 0 0.011069602
lamotrigine B-Chemical 0 0.9999956
, O 0 0.0006448246
or O 0 0.0005324262
ethosuximide B-Chemical 0 0.9999875
alone O 0 0.00067819434
or O 0 0.000483076
in O 0 0.00070491835
combination O 0 0.0021030265
. O 0 0.0021760135

Choreoathetoid B-Disease 0 0.18862858
movements I-Disease 0 0.009506552
associated O 0 0.0019625588
with O 0 0.0018880861
rapid O 0 0.0030495957
adjustment O 0 0.0019398624
to O 0 0.0034528933
methadone B-Chemical 0 0.99712545
. O 0 0.006188953

Choreatiform B-Disease 0 0.059678826
hyperkinesias I-Disease 0 0.9839421
are O 0 0.0012777122
known O 0 0.0007800466
to O 0 0.0003691447
be O 0 0.0002782463
occasional O 0 0.00057486014
movement B-Disease 0 0.0015432466
abnormalities I-Disease 0 0.12387354
during O 0 0.00021771995
intoxications O 0 0.9962423
with O 0 0.0021223915
cocaine B-Chemical 1 0.99977225
but O 0 0.0012117852
not O 0 0.0014204977
opiates O 0 0.99294865
. O 0 0.0026508118

This O 0 0.0038861227
is O 0 0.0014948132
a O 0 0.0010500067
case O 0 0.0005764977
report O 0 0.00068014715
of O 0 0.0008320033
euphoria O 0 0.99873096
and O 0 0.001738342
choreoathetoid B-Disease 0 0.9999825
movements I-Disease 0 0.039234243
both O 0 0.00019952813
transiently O 0 0.00033000956
induced O 0 0.00014315704
by O 0 9.2814844e-05
rapid O 0 0.00018011402
adjustment O 0 4.8692476e-05
to O 0 4.468103e-05
the O 0 6.5404674e-05
selective O 0 0.00053333945
mu O 0 0.23534687
- O 0 0.0006574415
opioid O 0 0.98682237
receptor O 0 0.07169275
agonist O 0 0.8290811
methadone B-Chemical 0 0.9975701
in O 0 0.00010498814
an O 0 0.00015791378
inpatient O 0 0.00039869512
previously O 0 0.0003052686
abusing O 0 0.31356937
heroine B-Chemical 0 0.12979074
and O 0 0.0018919016
cocaine B-Chemical 1 0.99930847
. O 0 0.002758661

In O 0 0.003651666
addition O 0 0.0026643025
, O 0 0.0041690622
minor O 0 0.007501629
EEG O 0 0.274506
abnormalities O 0 0.048103068
occurred O 0 0.00619417
. O 0 0.0066185766

Possible O 0 0.01006729
underlying O 0 0.0072604194
neurobiological O 0 0.0137976995
phenomena O 0 0.00954343
are O 0 0.005838112
discussed O 0 0.0072843586
. O 0 0.008942438

Adverse O 0 0.014540041
effects O 0 0.0053165406
of O 0 0.005306609
the O 0 0.0056370203
atypical O 0 0.04180143
antipsychotics O 0 0.9977188
. O 0 0.010604049

Collaborative O 0 0.011334142
Working O 0 0.009752964
Group O 0 0.0073177437
on O 0 0.0029843964
Clinical O 0 0.009272516
Trial O 0 0.008957651
Evaluations O 0 0.006783192
. O 0 0.0076931277

Adverse O 0 0.010238155
effects O 0 0.0036686622
of O 0 0.004759742
antipsychotics O 0 0.9953408
often O 0 0.003785666
lead O 0 0.009253965
to O 0 0.0032524373
noncompliance O 0 0.23472857
. O 0 0.005707444

Thus O 0 0.0025268025
, O 0 0.0020480342
clinicians O 0 0.001364315
should O 0 0.000306677
address O 0 0.00019599157
patients O 0 0.0003784813
' O 0 0.0002755383
concerns O 0 0.00019504175
about O 0 0.00018209641
adverse O 0 0.00572131
effects O 0 0.00018523546
and O 0 0.00012184999
attempt O 0 0.00012691808
to O 0 7.042672e-05
choose O 0 0.00010042056
medications O 0 0.00056713703
that O 0 4.2702733e-05
will O 0 4.676703e-05
improve O 0 4.4688702e-05
their O 0 8.5762425e-05
patients O 0 0.00011061697
' O 0 9.7910255e-05
quality O 0 7.7614815e-05
of O 0 0.00014897791
life O 0 0.00020907278
as O 0 0.00016537138
well O 0 0.00020421366
as O 0 0.00034774872
overall O 0 0.0007825423
health O 0 0.003541672
. O 0 0.0022537776

The O 0 0.002047259
side O 0 0.0049546277
effect O 0 0.00083311705
profiles O 0 0.0005520867
of O 0 0.0005178087
the O 0 0.0004164016
atypical O 0 0.0035678716
antipsychotics O 0 0.99720806
are O 0 0.00022317875
more O 0 0.00020212212
advantageous O 0 0.00012503528
than O 0 0.00011082803
those O 0 0.00022603896
of O 0 0.00031743915
the O 0 0.00047165656
conventional O 0 0.0013943298
neuroleptics O 0 0.9986786
. O 0 0.0027056835

Conventional O 0 0.0036576216
agents O 0 0.0039060386
are O 0 0.0008057895
associated O 0 0.00043722728
with O 0 0.00043330446
unwanted O 0 0.0013315927
central O 0 0.00040579733
nervous O 0 0.004288277
system O 0 0.00017472701
effects O 0 0.00016903463
, O 0 0.00016965225
including O 0 0.00015993952
extrapyramidal B-Disease 0 0.99999547
symptoms I-Disease 0 0.97265327
( O 0 0.0014672511
EPS B-Disease 0 0.9995678
) O 0 0.0007315403
, O 0 0.0006451141
tardive B-Disease 0 0.99999654
dyskinesia I-Disease 0 0.9999981
, O 0 0.0005269749
sedation O 0 0.056494497
, O 0 9.883113e-05
and O 0 6.590435e-05
possible O 0 6.3800544e-05
impairment O 0 0.01091729
of O 0 0.00011931698
some O 0 9.429126e-05
cognitive O 0 0.038935035
measures O 0 4.4619417e-05
, O 0 7.949557e-05
as O 0 4.9829683e-05
well O 0 4.2733045e-05
as O 0 5.5635857e-05
cardiac O 0 0.0020057808
effects O 0 0.0001356061
, O 0 0.00028489195
orthostatic B-Disease 2 0.99994385
hypotension I-Disease 2 0.99999535
, O 0 0.0005920565
hepatic O 0 0.8839074
changes O 0 0.00024307496
, O 0 0.00021668615
anticholinergic O 0 0.9947515
side O 0 0.005421783
effects O 0 0.00030567602
, O 0 0.00047012052
sexual B-Disease 0 0.571222
dysfunction I-Disease 0 0.9969319
, O 0 0.00077405444
and O 0 0.0006159707
weight B-Disease 0 0.003582099
gain I-Disease 0 0.004230808
. O 0 0.0021638267

The O 0 0.0018597852
newer O 0 0.004191717
atypical O 0 0.003248609
agents O 0 0.002456401
have O 0 0.00037902014
a O 0 0.00045820852
lower O 0 0.0005354923
risk O 0 0.002869589
of O 0 0.0009475514
EPS B-Disease 0 0.9995782
, O 0 0.00039326976
but O 0 0.00015561585
are O 0 7.2888666e-05
associated O 0 5.2961423e-05
in O 0 5.1371226e-05
varying O 0 8.1658516e-05
degrees O 0 0.00062183326
with O 0 0.00021166807
sedation O 0 0.059104178
, O 0 0.00015505405
cardiovascular O 0 0.23174533
effects O 0 0.00017365189
, O 0 0.00020825607
anticholinergic O 0 0.9911458
effects O 0 0.00015837459
, O 0 0.000113676644
weight B-Disease 0 0.00060014904
gain I-Disease 0 0.00053184567
, O 0 0.00023324904
sexual B-Disease 0 0.4883862
dysfunction I-Disease 0 0.9980108
, O 0 0.0004098313
hepatic O 0 0.9181586
effects O 0 0.00022632084
, O 0 0.00016772645
lowered O 0 0.0049071237
seizure B-Disease 0 0.99904233
threshold O 0 0.0001584903
( O 0 0.0001810576
primarily O 0 0.000345016
clozapine B-Chemical 0 0.9999939
) O 0 0.00059690484
, O 0 0.0002513756
and O 0 0.0005450443
agranulocytosis B-Disease 0 0.9999778
( O 0 0.0074059158
clozapine B-Chemical 0 0.99997985
only O 0 0.0027103347
) O 0 0.0028917857
. O 0 0.0020950087

Since O 0 0.0013590907
the O 0 0.001410795
incidence O 0 0.001772616
and O 0 0.00074312615
severity O 0 0.0008964771
of O 0 0.00036450196
specific O 0 0.00019432671
adverse O 0 0.007834388
effects O 0 0.00025899327
differ O 0 0.00013045955
among O 0 0.00010153674
the O 0 8.352789e-05
various O 0 0.00016145679
atypicals O 0 0.3427049
, O 0 9.5032636e-05
the O 0 6.273179e-05
clinician O 0 0.00011252311
should O 0 2.3490416e-05
carefully O 0 2.2859933e-05
consider O 0 2.392264e-05
which O 0 9.559295e-05
side O 0 0.00085616246
effects O 0 0.000118882475
are O 0 7.6854885e-05
most O 0 0.000106282416
likely O 0 4.6475994e-05
to O 0 5.7959354e-05
lead O 0 0.00038350507
to O 0 5.265669e-05
the O 0 5.4536824e-05
individual O 0 5.6060533e-05
' O 0 9.5711344e-05
s O 0 8.354342e-05
dissatisfaction O 0 0.0005990403
and O 0 0.000112169044
noncompliance O 0 0.0018746547
before O 0 4.2073163e-05
choosing O 0 0.00011060378
an O 0 0.0002982586
antipsychotic O 0 0.97273344
for O 0 0.00022039926
a O 0 0.00046719998
particular O 0 0.0004449524
patient O 0 0.0013594545
. O 0 0.0017560882

A O 0 0.015601096
randomized O 0 0.0021632183
, O 0 0.0014206086
placebo O 0 0.0037955085
- O 0 0.0008466068
controlled O 0 0.00030916993
dose O 0 0.0011479948
- O 0 0.0003713665
comparison O 0 0.00011560098
trial O 0 0.00017783786
of O 0 0.00038425653
haloperidol B-Chemical 1 0.99999547
for O 0 0.00032998467
psychosis B-Disease 0 0.9994554
and O 0 0.00036498424
disruptive B-Disease 0 0.11715361
behaviors I-Disease 0 0.018215472
in O 0 0.00080244674
Alzheimer B-Disease 0 0.9999126
' I-Disease 0 0.0018769491
s I-Disease 0 0.0013547401
disease I-Disease 0 0.10259047
. O 0 0.0026490237

OBJECTIVE O 0 0.021697126
: O 0 0.0019385905
The O 0 0.00060846866
goal O 0 0.0007373108
of O 0 0.00056841143
this O 0 0.000447483
study O 0 0.00036869245
was O 0 0.00019639303
to O 0 9.5406445e-05
compare O 0 4.4671102e-05
the O 0 7.930908e-05
efficacy O 0 0.00013679
and O 0 0.00011929071
side O 0 0.0008104507
effects O 0 0.000103819344
of O 0 0.00011232543
two O 0 5.2918913e-05
doses O 0 0.0005638981
of O 0 0.00048232143
haloperidol B-Chemical 1 0.99999833
and O 0 0.00023268927
placebo O 0 0.0005732264
in O 0 4.2668173e-05
the O 0 4.649869e-05
treatment O 0 6.272372e-05
of O 0 0.00019181537
psychosis B-Disease 0 0.9991604
and O 0 0.00022544793
disruptive B-Disease 0 0.09181931
behaviors I-Disease 0 0.004865473
in O 0 0.00016252967
patients O 0 0.00034642263
with O 0 0.00074653525
Alzheimer B-Disease 0 0.9999182
' I-Disease 0 0.0017119575
s I-Disease 0 0.00125162
disease I-Disease 0 0.1023295
. O 0 0.0024898718

METHOD O 0 0.006412331
: O 0 0.0021832297
In O 0 0.0008044484
a O 0 0.0009341105
6 O 0 0.00040521787
- O 0 0.0005570548
week O 0 0.00015472826
random O 0 0.00029442497
- O 0 0.0004288091
assignment O 0 0.00037737846
, O 0 0.00023194987
double O 0 0.00037184797
- O 0 0.000453203
blind O 0 0.0063206386
, O 0 0.00018757282
placebo O 0 0.00086212374
- O 0 0.00015527866
controlled O 0 6.596062e-05
trial O 0 0.00010633624
( O 0 0.000107814376
phase O 0 0.00029965088
A O 0 0.011419722
) O 0 0.00035818643
, O 0 0.0004513106
haloperidol B-Chemical 1 0.9999974
, O 0 0.00032538123
2 O 0 9.625631e-05
- O 0 0.00014036335
3 O 0 5.1250074e-05
mg O 0 0.00066023314
/ O 0 0.00018289492
day O 0 4.067642e-05
( O 0 7.0924114e-05
standard O 0 5.1763458e-05
dose O 0 0.00043806626
) O 0 0.00021042168
, O 0 0.00013984955
and O 0 0.0003272278
haloperidol B-Chemical 1 0.999997
, O 0 0.0002565078
0 O 0 8.326481e-05
. O 0 4.8715647e-05
50 O 0 0.0001277331
- O 0 0.00014172548
0 O 0 5.507609e-05
. O 0 3.8969923e-05
75 O 0 0.000101041056
mg O 0 0.0008190302
/ O 0 0.00021605691
day O 0 5.1636747e-05
( O 0 0.00010590426
low O 0 0.00019026542
dose O 0 0.00086748577
) O 0 0.00025168518
, O 0 0.00011527649
were O 0 7.893606e-05
compared O 0 5.3430103e-05
in O 0 9.391778e-05
71 O 0 0.0002947092
outpatients O 0 0.0005834481
with O 0 0.0005969731
Alzheimer B-Disease 0 0.9998653
' I-Disease 0 0.0016294578
s I-Disease 0 0.0012865585
disease I-Disease 0 0.0876324
. O 0 0.0026038836

For O 0 0.0012302749
the O 0 0.0012359386
subsequent O 0 0.00088769326
6 O 0 0.00049416214
- O 0 0.00066337985
week O 0 0.0001898763
double O 0 0.00039001726
- O 0 0.00047739694
blind O 0 0.0025834288
crossover O 0 0.0017953508
phase O 0 0.0004208224
( O 0 0.00021762367
phase O 0 0.0005426268
B O 0 0.14867641
) O 0 0.000298929
, O 0 0.00012337058
patients O 0 0.00012642863
taking O 0 0.000119802666
standard O 0 6.6117376e-05
- O 0 0.00014387521
or O 0 6.0446942e-05
low O 0 0.0002370867
- O 0 0.00030856865
dose O 0 0.0060264408
haloperidol B-Chemical 1 0.99999785
were O 0 0.00012392271
switched O 0 8.8591376e-05
to O 0 5.6371675e-05
placebo O 0 0.0004259597
, O 0 6.375018e-05
and O 0 5.800364e-05
patients O 0 9.125098e-05
taking O 0 0.00011092763
placebo O 0 0.0002271447
were O 0 3.4223616e-05
randomly O 0 1.5099787e-05
assigned O 0 3.0212153e-05
to O 0 4.566651e-05
standard O 0 8.259303e-05
- O 0 0.00023183094
or O 0 0.0001701611
low O 0 0.00079942786
- O 0 0.0016351069
dose O 0 0.06132308
haloperidol B-Chemical 1 0.99998033
. O 0 0.0040954556

RESULTS O 0 0.0041400543
: O 0 0.0014023535
For O 0 0.00036320364
the O 0 0.00043408934
60 O 0 0.00038669384
patients O 0 0.0003572648
who O 0 0.00028340364
completed O 0 0.00015502537
phase O 0 0.0004595667
A O 0 0.003953142
, O 0 0.00015884553
standard O 0 0.00010999712
- O 0 0.00032929584
dose O 0 0.008552923
haloperidol B-Chemical 1 0.9999982
was O 0 0.0002594777
efficacious O 0 0.00011579727
and O 0 6.370734e-05
superior O 0 9.950404e-05
to O 0 4.479699e-05
both O 0 6.384716e-05
low O 0 0.00023041203
- O 0 0.00029691408
dose O 0 0.006457555
haloperidol B-Chemical 1 0.9999981
and O 0 0.00021412586
placebo O 0 0.0004195263
for O 0 3.4029654e-05
scores O 0 3.8339807e-05
on O 0 2.8921637e-05
the O 0 6.5754124e-05
Brief O 0 0.0002917381
Psychiatric O 0 0.0009611697
Rating O 0 0.0012246444
Scale O 0 0.0074245725
psychosis B-Disease 0 0.9974673
factor O 0 0.001227086
and O 0 0.00038657
on O 0 0.0004124185
psychomotor B-Disease 0 0.99107075
agitation I-Disease 2 0.99156547
. O 0 0.0030777727

Response O 0 0.0036291159
rates O 0 0.001147489
according O 0 0.00045395788
to O 0 0.00032254623
three O 0 0.0001494748
sets O 0 0.00018368471
of O 0 0.0001986549
criteria O 0 0.00017409703
were O 0 0.00010235976
greater O 0 8.916387e-05
with O 0 9.481169e-05
the O 0 7.625487e-05
standard O 0 8.107774e-05
dose O 0 0.00055919396
( O 0 0.00019581411
55 O 0 0.00014321425
% O 0 0.00011799196
- O 0 0.00016195049
60 O 0 7.993654e-05
% O 0 9.195372e-05
) O 0 0.00010156134
than O 0 4.0224637e-05
the O 0 6.631312e-05
low O 0 0.00020780499
dose O 0 0.000816267
( O 0 0.00021058487
25 O 0 0.00017556218
% O 0 0.00013593405
- O 0 0.00019079988
35 O 0 0.00010510202
% O 0 0.00012251407
) O 0 0.00016930515
and O 0 0.00015056539
placebo O 0 0.0008953426
( O 0 0.00027200367
25 O 0 0.00031890915
% O 0 0.00035549756
- O 0 0.00061167165
30 O 0 0.00044943986
% O 0 0.001023624
) O 0 0.0021029045
. O 0 0.0023067126

The O 0 0.001439515
advantage O 0 0.0008532395
of O 0 0.00091417367
standard O 0 0.00056997285
dose O 0 0.0013607995
over O 0 0.00026778824
low O 0 0.000806306
dose O 0 0.0019495282
was O 0 0.0005987355
replicated O 0 0.00052203
in O 0 0.00074160437
phase O 0 0.0035030607
B O 0 0.1750851
. O 0 0.0036650524

In O 0 0.0019951875
phase O 0 0.003917932
A O 0 0.02997297
, O 0 0.002877223
extrapyramidal B-Disease 0 0.9999745
signs I-Disease 0 0.79557973
tended O 0 0.0005087461
to O 0 0.00018768999
be O 0 0.000112509806
greater O 0 9.937394e-05
with O 0 9.9184595e-05
the O 0 7.2350034e-05
standard O 0 6.6909066e-05
dose O 0 0.0003016338
than O 0 5.2311498e-05
in O 0 5.8328245e-05
the O 0 6.0321185e-05
other O 0 5.4890377e-05
two O 0 4.206229e-05
conditions O 0 8.338615e-05
, O 0 7.495808e-05
primarily O 0 6.7072666e-05
because O 0 4.3821623e-05
of O 0 0.00010747114
a O 0 0.00017650498
subgroup O 0 0.0005339961
( O 0 0.00015292647
20 O 0 0.00010390592
% O 0 0.00013820584
) O 0 0.00021724883
who O 0 0.00025176175
developed O 0 0.0004076749
moderate O 0 0.0029420266
to O 0 0.00069268123
severe O 0 0.058410347
signs O 0 0.10107174
. O 0 0.0027732567

Low O 0 0.018998485
- O 0 0.004994691
dose O 0 0.051562898
haloperidol B-Chemical 1 0.9999862
did O 0 0.0011098048
not O 0 0.00032222722
differ O 0 0.00019514984
from O 0 0.00014649889
placebo O 0 0.00050271396
on O 0 7.885818e-05
any O 0 9.964523e-05
measure O 0 8.0505626e-05
of O 0 0.0002676208
efficacy O 0 0.00051406573
or O 0 0.00060162315
side O 0 0.0074178404
effects O 0 0.0028438545
. O 0 0.0029391448

CONCLUSIONS O 0 0.012289621
: O 0 0.0017066386
The O 0 0.0005498884
results O 0 0.0005185817
indicated O 0 0.000315356
a O 0 0.00037708698
favorable O 0 0.0005029941
therapeutic O 0 0.00038727545
profile O 0 0.00023860927
for O 0 0.00024155338
haloperidol B-Chemical 1 0.9999951
in O 0 0.00024593394
doses O 0 0.0011621774
of O 0 0.00021345115
2 O 0 0.00010639801
- O 0 0.00016982446
3 O 0 6.2403866e-05
mg O 0 0.0010200911
/ O 0 0.00025963358
day O 0 5.726738e-05
, O 0 9.294026e-05
although O 0 7.2659095e-05
a O 0 0.00015963725
subgroup O 0 0.0004464056
developed O 0 0.0003404423
moderate O 0 0.002602112
to O 0 0.000544535
severe O 0 0.41959664
extrapyramidal B-Disease 0 0.9999889
signs I-Disease 0 0.9875315
. O 0 0.0039599263

A O 0 0.011554511
starting O 0 0.0013472103
dose O 0 0.0030912638
of O 0 0.00102743
1 O 0 0.00058017904
mg O 0 0.0053934488
/ O 0 0.00081550464
day O 0 0.00017434821
with O 0 0.00025278592
gradual O 0 0.00041673853
, O 0 0.0004141528
upward O 0 0.001855882
dose O 0 0.002373664
titration O 0 0.0025787693
is O 0 0.0010697234
recommended O 0 0.0016973289
. O 0 0.0022129577

The O 0 0.0015399165
narrow O 0 0.0017697446
therapeutic O 0 0.0011687785
window O 0 0.00064561295
observed O 0 0.0004334255
with O 0 0.0012488455
haloperidol B-Chemical 1 0.99999344
may O 0 0.00024438163
also O 0 0.000119311524
apply O 0 6.468566e-05
to O 0 8.437093e-05
other O 0 0.00014731554
neuroleptics O 0 0.996988
used O 0 0.00012112872
in O 0 0.00021587448
Alzheimer B-Disease 0 0.9999535
' I-Disease 0 0.00035810823
s I-Disease 0 0.00019999211
disease I-Disease 0 0.019103706
patients O 0 0.00033797976
with O 0 0.0005002755
psychosis B-Disease 0 0.9984282
and O 0 0.0010417128
disruptive B-Disease 0 0.30304095
behaviors I-Disease 0 0.0810351
. O 0 0.0025569738

Effects O 0 0.0036499454
of O 0 0.007665816
acetylsalicylic B-Chemical 0 0.9999844
acid I-Chemical 0 0.99953496
, O 0 0.011599668
dipyridamole B-Chemical 0 0.99996257
, O 0 0.0011029629
and O 0 0.0007091211
hydrocortisone B-Chemical 0 0.9997049
on O 0 0.0004601024
epinephrine B-Chemical 0 0.99950933
- O 0 0.0016030602
induced O 0 0.0015410205
myocardial B-Disease 0 0.9999273
injury I-Disease 0 0.99756914
in O 0 0.0023361135
dogs O 0 0.0038007156
. O 0 0.0023484798

A O 0 0.012233367
reproducible O 0 0.0016529018
model O 0 0.0008805177
for O 0 0.0004311668
producing O 0 0.000647493
diffuse O 0 0.018009081
myocardial B-Disease 0 0.9999496
injury I-Disease 0 0.99906904
( O 0 0.00357334
epinephrine B-Chemical 0 0.99961996
infusion O 0 0.0024700721
) O 0 0.0002815505
has O 0 6.5277185e-05
been O 0 5.2913663e-05
developed O 0 9.4050956e-05
to O 0 5.5769502e-05
study O 0 7.6432734e-05
the O 0 7.186267e-05
cardioprotective O 0 0.040159293
effects O 0 0.0001156676
of O 0 0.0001475641
agents O 0 0.0004987369
or O 0 8.423932e-05
maneuvers O 0 0.00020489629
which O 0 9.321453e-05
might O 0 4.759152e-05
alter O 0 6.263537e-05
the O 0 0.00010433872
evolution O 0 0.00022041943
of O 0 0.00072203635
acute O 0 0.9931507
myocardial B-Disease 0 0.9999293
infarction I-Disease 2 0.9999888
. O 0 0.0065268856

Infusions O 0 0.04777631
of O 0 0.003970401
epinephrine B-Chemical 0 0.9980439
( O 0 0.001354611
4 O 0 0.0002778616
mug O 0 0.00025064495
per O 0 8.436207e-05
kilogram O 0 0.00023285905
per O 0 4.0873485e-05
minute O 0 5.4984357e-05
for O 0 4.9632632e-05
6 O 0 4.1951247e-05
hours O 0 4.0693645e-05
) O 0 0.00012410033
increased O 0 0.00024284054
radiocalcium B-Chemical 0 0.9973579
uptakes O 0 0.027019
into O 0 3.5069745e-05
intact O 0 8.126009e-05
myocardium O 0 0.007989469
and O 0 5.954357e-05
each O 0 2.2257302e-05
of O 0 5.15021e-05
its O 0 6.539394e-05
subcellular O 0 2.348876e-05
components O 0 3.0148141e-05
with O 0 5.958612e-05
the O 0 6.859286e-05
mitochondrial O 0 0.02693058
fraction O 0 8.49232e-05
showing O 0 5.86168e-05
the O 0 4.6570047e-05
most O 0 7.8313074e-05
consistent O 0 4.755536e-05
changes O 0 6.089382e-05
when O 0 2.79985e-05
compared O 0 3.1608834e-05
to O 0 5.4900782e-05
saline O 0 0.0005479787
- O 0 0.00013867937
infused O 0 0.00013707412
control O 0 6.190452e-05
animals O 0 5.764417e-05
( O 0 0.000103060825
4 O 0 5.2798037e-05
, O 0 9.717849e-05
957 O 0 0.0013352844
vs O 0 0.00010369914
. O 0 5.0669787e-05
827 O 0 0.00035205242
counts O 0 5.426183e-05
per O 0 2.1246617e-05
minute O 0 3.6131456e-05
per O 0 3.0208666e-05
gram O 0 0.00021582919
of O 0 0.00018723866
dried O 0 0.0014930022
tissue O 0 0.00096463395
or O 0 0.00041106966
fraction O 0 0.000973668
) O 0 0.0020692488
. O 0 0.0019326636

Myocardial O 0 0.18930809
concentrations O 0 0.003959745
of O 0 0.00242293
calcium B-Chemical 0 0.99681467
also O 0 0.00073118624
increased O 0 0.00089570956
significantly O 0 0.00066977576
( O 0 0.00034917568
12 O 0 9.371202e-05
. O 0 7.775839e-05
0 O 0 9.45751e-05
vs O 0 0.00011983055
. O 0 6.3578984e-05
5 O 0 6.0118065e-05
. O 0 5.103217e-05
0 O 0 7.2691815e-05
mg O 0 0.0005931151
. O 0 5.5086384e-05
per O 0 3.9311493e-05
100 O 0 0.00027348427
Gm O 0 0.08166215
. O 0 0.00012151246
of O 0 0.00036040737
fat O 0 0.8628976
- O 0 0.00078958296
free O 0 0.00077602005
dry O 0 0.06477245
weight O 0 0.008767531
) O 0 0.0030024836
. O 0 0.0023177976

Infusions O 0 0.052994918
of O 0 0.004591274
calcium B-Chemical 0 0.9994443
chloride I-Chemical 0 0.99977666
sufficient O 0 0.0005157831
to O 0 0.00027840605
raise O 0 0.00029764586
serum O 0 0.15104684
calcium B-Chemical 0 0.9996834
concentrations O 0 0.0049227257
2 O 0 0.00028066605
mEq O 0 0.32174096
. O 0 6.623677e-05
per O 0 3.7162845e-05
liter O 0 0.00031349566
failed O 0 0.00010847024
to O 0 0.000104994644
increase O 0 0.0002725376
calcium B-Chemical 0 0.99771297
influx O 0 0.07462242
into O 0 0.00018324738
the O 0 0.00067185797
myocardial O 0 0.99550986
cell O 0 0.017504897
. O 0 0.0027283872

Mitochondrial O 0 0.9266575
radiocalcium B-Chemical 0 0.99795365
uptakes O 0 0.18874228
were O 0 0.00072676444
significantly O 0 0.0004924565
decreased O 0 0.000478427
in O 0 0.00016298628
animals O 0 0.00010998537
pretreated O 0 0.0008338042
with O 0 0.001520072
acetylsalicylic B-Chemical 0 0.9999988
acid I-Chemical 0 0.9996954
or O 0 0.0009875895
dipyridamole B-Chemical 0 0.99998176
or O 0 0.00015069179
when O 0 9.769797e-05
hydrocortisone B-Chemical 0 0.9997538
was O 0 0.00013694217
added O 0 8.0360354e-05
to O 0 5.8868263e-05
the O 0 0.0001227346
epinephrine B-Chemical 0 0.9973001
infusion O 0 0.0008003989
( O 0 0.00016911975
2 O 0 7.427939e-05
, O 0 0.000119224984
682 O 0 0.0013678956
, O 0 0.00012062916
2 O 0 7.904595e-05
, O 0 0.00012995176
803 O 0 0.003021235
, O 0 0.00011811546
and O 0 9.278999e-05
3 O 0 6.3144114e-05
, O 0 9.0445996e-05
424 O 0 0.00033598582
counts O 0 6.138766e-05
per O 0 2.3398883e-05
minute O 0 3.901347e-05
per O 0 3.237762e-05
gram O 0 0.00022561243
of O 0 0.00019496943
dried O 0 0.0014069108
fraction O 0 0.0005168511
, O 0 0.0007866732
respectively O 0 0.0020163655
) O 0 0.0023060115
. O 0 0.0020962527

Myocardial O 0 0.77729243
calcium B-Chemical 0 0.99711347
concentrations O 0 0.00396867
also O 0 0.0008167661
were O 0 0.00059041544
decreased O 0 0.0009910789
( O 0 0.0005640258
11 O 0 0.00026201538
. O 0 0.00013006631
2 O 0 0.00013069785
, O 0 0.00015780808
8 O 0 0.00010126291
. O 0 7.485265e-05
3 O 0 7.752339e-05
, O 0 0.0001078262
and O 0 0.00010231127
8 O 0 7.369584e-05
. O 0 5.2155534e-05
9 O 0 6.497003e-05
mg O 0 0.00056622014
. O 0 4.3626023e-05
per O 0 2.8683306e-05
100 O 0 0.00020804051
Gm O 0 0.11086213
. O 0 6.636258e-05
of O 0 0.0001903821
fat O 0 0.91531277
- O 0 0.0002869561
free O 0 0.00017270191
dry O 0 0.030529296
weight O 0 0.0015608001
, O 0 0.00018373129
respectively O 0 0.00032323983
) O 0 0.00012341364
in O 0 4.6200425e-05
the O 0 4.6611367e-05
three O 0 2.9034638e-05
treatment O 0 7.379703e-05
groups O 0 8.701738e-05
, O 0 0.00010493269
being O 0 0.00014460583
significantly O 0 0.00018663977
decreased O 0 0.00034945077
only O 0 0.00022076334
in O 0 0.000203845
the O 0 0.000289122
last O 0 0.000272488
two O 0 0.0007253457
. O 0 0.0016733777

Evidence O 0 0.0039331084
of O 0 0.0022190032
microscopic O 0 0.0033457486
damage O 0 0.09232363
was O 0 0.0008421362
graded O 0 0.0008512922
as O 0 0.00032981264
less O 0 0.0003862405
severe O 0 0.0019115463
in O 0 0.000295046
the O 0 0.0003086701
three O 0 0.00026293733
treatment O 0 0.0008039212
groups O 0 0.0013685413
. O 0 0.002106141

Acetylsalicylic B-Chemical 0 0.9998543
acid I-Chemical 0 0.99848276
, O 0 0.01202682
dipyridamole B-Chemical 0 0.99992347
, O 0 0.001792586
and O 0 0.0010927115
hydrocortisone B-Chemical 0 0.9996327
all O 0 0.00038803913
appear O 0 0.00018091488
to O 0 0.00013144952
have O 0 0.00013525315
cardioprotective O 0 0.040731702
effects O 0 0.00028246304
when O 0 0.00017527297
tested O 0 0.00030202226
in O 0 0.000432025
this O 0 0.0009957189
model O 0 0.0020548834
. O 0 0.0023065119

Clinical O 0 0.005338524
and O 0 0.001613929
histopathologic O 0 0.004339429
examination O 0 0.00062981737
of O 0 0.0006499029
renal O 0 0.7137862
allografts O 0 0.09361463
treated O 0 0.0007302141
with O 0 0.0011788101
tacrolimus B-Chemical 0 0.99999356
( O 0 0.004702651
FK506 B-Chemical 0 0.99997354
) O 0 0.00077877217
for O 0 0.00018041651
at O 0 0.00019632468
least O 0 0.00031115348
one O 0 0.0005463647
year O 0 0.00091921684
. O 0 0.0017922097

BACKGROUND O 0 0.0078097936
: O 0 0.0018505789
We O 0 0.0006287846
clinically O 0 0.0015721718
and O 0 0.0006206411
pathologically O 0 0.011694608
analyzed O 0 0.00037673142
renal O 0 0.6676234
allografts O 0 0.032705143
from O 0 0.00013560792
1 O 0 8.78658e-05
9 O 0 7.481754e-05
renal O 0 0.067128934
transplant O 0 0.002703141
patients O 0 0.00017584146
treated O 0 0.00017814436
with O 0 0.00049905514
tacrolimus B-Chemical 0 0.99999475
( O 0 0.0032088018
FK506 B-Chemical 0 0.999979
) O 0 0.0006873443
for O 0 0.00016919717
more O 0 0.00038407985
than O 0 0.00031976038
1 O 0 0.0005531496
year O 0 0.0007666218
. O 0 0.0015949665

METHODS O 0 0.0017440593
: O 0 0.0016086502
Twenty O 0 0.0011878421
- O 0 0.00096529094
six O 0 0.00032104974
renal O 0 0.21704859
allograft O 0 0.4333712
biopsy O 0 0.0008518204
specimens O 0 0.00015139968
from O 0 8.8479e-05
1 O 0 7.911216e-05
9 O 0 7.8099336e-05
renal O 0 0.0504197
transplant O 0 0.0025434685
patients O 0 0.00020664795
who O 0 0.00015440224
underwent O 0 0.00010466148
transplantations O 0 0.0007587742
between O 0 9.8657205e-05
1991 O 0 0.0002990835
and O 0 0.00028129667
1993 O 0 0.0008759216
were O 0 0.0005598558
evaluated O 0 0.00088251964
. O 0 0.0017301766

Thirteen O 0 0.004300245
biopsies O 0 0.0016833969
were O 0 0.0005777208
performed O 0 0.00029891473
from O 0 0.00021497687
stable O 0 0.00025738752
functioning O 0 0.00041793325
renal O 0 0.6121683
allografts O 0 0.06402127
with O 0 0.00042719324
informed O 0 0.0023451373
consent O 0 0.009142365
( O 0 0.00024656975
nonepisode O 0 0.0010219334
biopsy O 0 0.0004452999
) O 0 0.00014074746
and O 0 6.416504e-05
the O 0 5.6811718e-05
other O 0 5.4547643e-05
13 O 0 5.880638e-05
were O 0 4.52623e-05
from O 0 4.5143155e-05
dysfunctional O 0 0.00029253465
renal O 0 0.6379873
allografts O 0 0.028867656
with O 0 0.0001420502
a O 0 0.00013185777
clinical O 0 0.00022173095
indication O 0 7.301855e-05
for O 0 0.00011194456
biopsy O 0 0.0006178292
( O 0 0.00045547757
episode O 0 0.0011770077
biopsy O 0 0.0024789374
) O 0 0.0019735536
. O 0 0.0018398436

RESULTS O 0 0.0041765287
: O 0 0.0014735176
The O 0 0.0005290706
main O 0 0.00060190074
pathologic O 0 0.004672078
diagnoses O 0 0.0013814099
( O 0 0.00042270168
some O 0 0.00020743108
overlap O 0 0.00017519713
) O 0 0.00028297352
were O 0 0.00019069585
acute O 0 0.14665546
rejection O 0 0.9818518
( O 0 0.001349147
AR O 0 0.8438902
; O 0 0.00023643204
n O 0 0.000110509965
= O 0 0.00011968813
4 O 0 6.385946e-05
) O 0 0.00013751374
, O 0 0.00013495854
chronic O 0 0.03083302
rejection O 0 0.9499832
( O 0 0.00062424236
CR O 0 0.045230888
; O 0 0.00015579759
n O 0 8.94188e-05
= O 0 0.00010538655
5 O 0 6.2205065e-05
) O 0 0.0001486035
, O 0 0.00015918503
AR O 0 0.33616495
+ O 0 0.0004862114
CR O 0 0.01744506
( O 0 0.00017769735
n O 0 9.028142e-05
= O 0 0.000103447586
4 O 0 5.7359695e-05
) O 0 0.00012287185
, O 0 0.00013371804
recurrent O 0 0.031054147
IgA B-Disease 0 0.99997914
nephropathy I-Disease 2 0.99999976
( O 0 0.0018001752
n O 0 0.00015786139
= O 0 0.00012382006
5 O 0 5.7671554e-05
) O 0 0.000111998575
, O 0 7.969458e-05
normal O 0 0.00016018921
findings O 0 0.0001902861
( O 0 0.00015393902
n O 0 9.2230075e-05
= O 0 0.00011646491
2 O 0 6.829015e-05
) O 0 0.00011617141
, O 0 7.708286e-05
minimal O 0 8.809173e-05
- O 0 0.00022804613
type O 0 0.00019833507
chronic O 0 0.68966454
FK506 B-Chemical 0 0.9999982
nephropathy B-Disease 2 0.9999995
( O 0 0.0014265656
n O 0 0.00014638578
= O 0 0.00012813631
9 O 0 7.165067e-05
) O 0 0.00013144739
, O 0 0.000106525826
and O 0 0.00015005429
mild O 0 0.10245308
- O 0 0.00061216595
type O 0 0.00076702115
FK506 B-Chemical 0 0.999992
nephropathy B-Disease 2 0.9999981
( O 0 0.0022732292
n O 0 0.000516852
= O 0 0.0007148566
11 O 0 0.00083842064
) O 0 0.0017251169
. O 0 0.0019953167

Of O 0 0.002537529
the O 0 0.0017025215
nonepisode O 0 0.0047934907
biopsies O 0 0.0015195061
, O 0 0.0006175255
7 O 0 0.00024074866
and O 0 0.00022426662
4 O 0 0.00014387823
biopsies O 0 0.00023213173
showed O 0 0.00013269493
minimal O 0 0.0001661246
- O 0 0.00034848895
type O 0 0.00019220843
and O 0 0.0002571096
mild O 0 0.2234453
- O 0 0.0007419848
type O 0 0.0005719722
chronic O 0 0.9052431
FK506 B-Chemical 0 0.9999949
nephropathy B-Disease 2 0.9999975
, O 0 0.010010319
respectively O 0 0.0065497127
. O 0 0.002424974

Chronic O 0 0.61026937
FK506 B-Chemical 0 0.9999386
nephropathy B-Disease 2 0.9999771
consisted O 0 0.0011714515
of O 0 0.00064070243
rough O 0 0.00062001596
and O 0 0.00035183132
foamy O 0 0.0019193013
tubular O 0 0.3110921
vacuolization O 0 0.1356778
( O 0 0.00028951344
5 O 0 8.774607e-05
biopsies O 0 0.00022906663
) O 0 0.00020257648
, O 0 0.000177696
arteriolopathy O 0 0.8659709
( O 0 0.00027570518
angiodegeneration O 0 0.00088706124
of O 0 0.000111084286
the O 0 0.00011811996
arteriolar O 0 0.93739444
wall O 0 0.0011412564
; O 0 0.0001224941
20 O 0 8.149772e-05
biopsies O 0 0.00017410467
) O 0 0.00013086922
, O 0 9.5841955e-05
focal B-Disease 0 0.0012604827
segmental I-Disease 0 0.3022455
glomerulosclerosis I-Disease 2 0.99999917
( O 0 0.0006732117
4 O 0 8.337407e-05
biopsies O 0 0.00016919409
) O 0 0.0001144574
and O 0 6.929435e-05
the O 0 8.332384e-05
striped O 0 0.0005346877
form O 0 0.00013880928
of O 0 0.00040533027
interstitial B-Disease 0 0.9180754
fibrosis I-Disease 2 0.9999602
( O 0 0.0017894778
11 O 0 0.00072720513
biopsies O 0 0.0015520664
) O 0 0.0018553485
. O 0 0.0018838932

The O 0 0.0019344544
serum O 0 0.05008361
creatinine B-Chemical 1 0.996579
levels O 0 0.00095864525
of O 0 0.00069108326
patients O 0 0.00048980716
in O 0 0.00020628552
the O 0 0.00025356148
mild O 0 0.22257693
- O 0 0.0006196508
type O 0 0.00033324608
chronic O 0 0.8261407
FK506 B-Chemical 0 0.99999857
nephropathy B-Disease 2 0.9999995
group O 0 0.0020110032
, O 0 0.00013460216
which O 0 8.8543646e-05
included O 0 4.7257534e-05
7 O 0 3.894734e-05
episode O 0 0.00013151624
biopsies O 0 0.00015321298
, O 0 7.807685e-05
were O 0 6.1996376e-05
statistically O 0 5.4228203e-05
higher O 0 6.0915023e-05
than O 0 3.723898e-05
those O 0 6.5813474e-05
in O 0 4.2050502e-05
the O 0 4.7834124e-05
minimum O 0 5.3978954e-05
- O 0 0.00019664185
type O 0 0.00018994692
chronic O 0 0.6149773
FK506 B-Chemical 0 0.9999958
- O 0 0.0989261
nephropathy B-Disease 2 0.999998
group O 0 0.002161604
( O 0 0.00075331406
P O 0 0.004850779
< O 0 0.00031278783
0 O 0 0.00034093406
. O 0 0.00049971533
001 O 0 0.007373294
) O 0 0.0023835194
. O 0 0.0023800342

CONCLUSIONS O 0 0.013160922
: O 0 0.0019872088
This O 0 0.0012190279
study O 0 0.0006002053
demonstrates O 0 0.00025553384
that O 0 0.00031771316
chronic O 0 0.746488
FK506 B-Chemical 0 0.99999654
nephropathy B-Disease 2 0.99999857
consists O 0 0.0002599085
primarily O 0 0.00019243306
of O 0 0.000304507
arteriolopathy O 0 0.98092985
manifesting O 0 0.036872033
as O 0 0.00014283853
insudative O 0 0.016511297
hyalinosis O 0 0.068048984
of O 0 0.00013098508
the O 0 0.00011856017
arteriolar O 0 0.9621994
wall O 0 0.0012964555
, O 0 0.00010879571
and O 0 6.514293e-05
suggests O 0 2.9961442e-05
that O 0 6.063318e-05
mild O 0 0.1703915
- O 0 0.00038700766
type O 0 0.00024069747
chronic O 0 0.8277713
FK506 B-Chemical 0 0.9999988
nephropathy B-Disease 2 0.9999995
is O 0 0.00043606074
a O 0 0.00019479069
condition O 0 0.0002203291
which O 0 0.00013297395
may O 0 9.1369664e-05
lead O 0 0.0006463862
to O 0 0.00015880147
deterioration O 0 0.008010848
of O 0 0.00078459125
renal O 0 0.9713092
allograft O 0 0.9548989
function O 0 0.0033133435
. O 0 0.0021684873

Different O 0 0.003365443
lobular O 0 0.16825354
distributions O 0 0.00068996026
of O 0 0.000716987
altered O 0 0.0007858022
hepatocyte O 0 0.1615107
tight O 0 0.0006193379
junctions O 0 0.00030716968
in O 0 0.00015821007
rat O 0 0.00032144453
models O 0 0.00024367665
of O 0 0.00046313036
intrahepatic B-Disease 0 0.7151562
and I-Disease 0 0.0030167084
extrahepatic I-Disease 0 0.9998671
cholestasis I-Disease 2 0.9999957
. O 0 0.010682756

Hepatocyte O 0 0.067863025
tight O 0 0.0027862196
junctions O 0 0.001757652
( O 0 0.0013844655
TJs O 0 0.0072993636
) O 0 0.0007111809
, O 0 0.00028539897
the O 0 0.00016805013
only O 0 0.00017442173
intercellular O 0 0.0002876091
barrier O 0 0.00040167168
between O 0 6.0258168e-05
the O 0 9.653612e-05
sinusoidal O 0 0.00081189454
and O 0 0.00013267505
the O 0 0.00015332362
canalicular O 0 0.18166266
spaces O 0 0.0002995424
, O 0 0.00016489146
play O 0 9.868553e-05
a O 0 0.00018206584
key O 0 0.0001544308
role O 0 0.00022024802
in O 0 0.000647746
bile O 0 0.9754895
formation O 0 0.013716597
. O 0 0.0027876878

Although O 0 0.0022854805
hepatocyte O 0 0.33858314
TJs O 0 0.018673792
are O 0 0.0007052725
impaired O 0 0.0015890062
in O 0 0.0010632819
cholestasis B-Disease 2 0.9999901
, O 0 0.0006914364
attempts O 0 0.00028095522
to O 0 8.402896e-05
localize O 0 2.698484e-05
the O 0 5.9626193e-05
precise O 0 5.9119116e-05
site O 0 7.089977e-05
of O 0 0.00021270878
hepatocyte O 0 0.9264114
TJ O 0 0.99870133
damage O 0 0.4094048
by O 0 0.0002889641
freeze O 0 0.004516952
- O 0 0.00070455304
fracture O 0 0.7351097
electron O 0 0.004774688
microscopy O 0 0.00032455838
have O 0 0.0001721088
produced O 0 0.00030170224
limited O 0 0.00058155437
information O 0 0.0011943631
. O 0 0.0019144253

Recently O 0 0.0032620493
, O 0 0.002628902
several O 0 0.001694839
TJ O 0 0.96679896
- O 0 0.001782293
associated O 0 0.00048564904
proteins O 0 0.0005660864
like O 0 0.0004965289
ZO O 0 0.9697855
- O 0 0.0009484089
1 O 0 0.00025079722
and O 0 0.0003196177
7H6 O 0 0.013168436
have O 0 0.0002848469
been O 0 0.0003104524
identified O 0 0.00046055389
and O 0 0.0009438584
characterized O 0 0.0031772223
. O 0 0.0025271752

Immunolocalization O 0 0.0045335786
of O 0 0.0034661172
7H6 O 0 0.03227215
appears O 0 0.0011858514
to O 0 0.0008702911
closely O 0 0.0007014878
correlate O 0 0.00090005895
with O 0 0.0020286718
paracellular O 0 0.07930163
permeability O 0 0.7222715
. O 0 0.004637354

We O 0 0.0014457302
used O 0 0.0010319066
rat O 0 0.0012681427
models O 0 0.00068212603
of O 0 0.0011434457
intrahepatic B-Disease 0 0.9996308
cholestasis I-Disease 2 0.9999994
by O 0 0.036750436
ethinyl B-Chemical 0 0.99999523
estradiol I-Chemical 0 0.99999034
( O 0 0.002356587
EE B-Chemical 0 0.9681533
) O 0 0.00022978632
treatment O 0 0.00010218354
and O 0 0.00021222056
extrahepatic B-Disease 0 0.9998938
cholestasis I-Disease 2 0.99999964
by O 0 0.0019245535
bile O 0 0.99905497
duct O 0 0.6059031
ligation O 0 0.0015359765
( O 0 0.0006903638
BDL O 0 0.9991517
) O 0 0.00029595825
to O 0 8.531768e-05
precisely O 0 7.803018e-05
determine O 0 6.4551255e-05
the O 0 0.00017921806
site O 0 0.0003185791
of O 0 0.0013557366
TJ O 0 0.9864739
damage O 0 0.7277812
. O 0 0.00322155

Alterations O 0 0.0036746035
in O 0 0.0018171456
hepatocyte O 0 0.22834972
TJs O 0 0.0115738865
were O 0 0.00052743417
assessed O 0 0.0002715792
by O 0 0.00031002855
double O 0 0.0004816054
- O 0 0.00044190304
immunolabeling O 0 0.0003510572
for O 0 0.00016502263
7H6 O 0 0.07822878
and O 0 0.00056506455
ZO O 0 0.95643336
- O 0 0.00056245684
1 O 0 0.00015244646
using O 0 0.00014457149
a O 0 0.00032060713
confocal O 0 0.0005118874
laser O 0 0.0015942378
scanning O 0 0.0013300241
microscope O 0 0.0021031327
. O 0 0.002359432

In O 0 0.0018598859
control O 0 0.0014491534
rats O 0 0.001547022
, O 0 0.0008301309
immunostaining O 0 0.0005583493
for O 0 0.00035712105
7H6 O 0 0.082525745
and O 0 0.00087652146
ZO O 0 0.9687856
- O 0 0.00060192484
1 O 0 0.00011831046
colocalized O 0 5.3958778e-05
to O 0 0.00011192128
outline O 0 0.00031631504
bile O 0 0.96553403
canaliculi O 0 0.08084497
in O 0 0.00039084748
a O 0 0.0006358184
continuous O 0 0.00062821736
fashion O 0 0.0021082067
. O 0 0.002035398

In O 0 0.0022945057
contrast O 0 0.0026176288
, O 0 0.0022721738
7H6 O 0 0.14892127
and O 0 0.002170087
ZO O 0 0.9846965
- O 0 0.0013728876
1 O 0 0.00028081544
immunostaining O 0 0.00026336533
was O 0 0.00019601399
more O 0 0.00021841815
discontinuous O 0 0.00028335984
, O 0 0.0002420569
outlining O 0 0.00035163917
the O 0 0.000470104
bile O 0 0.9761716
canaliculi O 0 0.20454109
after O 0 0.00087749003
BDL O 0 0.99797434
. O 0 0.0035967762

Immunostaining O 0 0.004128102
for O 0 0.0017746338
7H6 O 0 0.062415216
, O 0 0.0015225259
not O 0 0.001133974
ZO O 0 0.97805244
- O 0 0.0014587379
1 O 0 0.0002946345
, O 0 0.00025584048
decreased O 0 0.0003596305
and O 0 0.00016962396
predominantly O 0 0.0001289893
appeared O 0 0.00011458255
as O 0 7.438281e-05
discrete O 0 5.4761334e-05
signals O 0 5.6669633e-05
in O 0 7.367925e-05
the O 0 9.991126e-05
submembranous O 0 0.00041129527
cytoplasm O 0 0.000107635846
of O 0 0.00036408956
periportal O 0 0.6271444
hepatocytes O 0 0.06666068
after O 0 0.0006403111
BDL O 0 0.9976109
. O 0 0.0029705777

After O 0 0.0017135718
EE B-Chemical 0 0.73632044
treatment O 0 0.0013816224
, O 0 0.0008404251
changes O 0 0.0005249415
in O 0 0.00030123172
immunostaining O 0 0.00030889624
for O 0 0.00019983009
7H6 O 0 0.08869947
and O 0 0.00059746293
ZO O 0 0.98035115
- O 0 0.00051152875
1 O 0 8.8242145e-05
were O 0 6.325024e-05
similar O 0 3.942626e-05
to O 0 5.6440527e-05
those O 0 9.9877536e-05
seen O 0 8.057659e-05
in O 0 0.00011519814
periportal O 0 0.5574857
hepatocytes O 0 0.03841484
after O 0 9.3150644e-05
BDL O 0 0.99887854
, O 0 0.00024940036
but O 0 0.00013871507
distributed O 0 7.990104e-05
more O 0 0.00019055352
diffusely O 0 0.00023348977
throughout O 0 0.00019310249
the O 0 0.00079372263
lobule O 0 0.7552261
. O 0 0.0024424384

This O 0 0.0038979058
study O 0 0.0017680975
is O 0 0.00076985947
the O 0 0.0004255441
first O 0 0.00021705173
to O 0 0.00019774139
demonstrate O 0 0.000100165584
that O 0 0.00014444928
impairment O 0 0.032956757
of O 0 0.00044399782
hepatocyte O 0 0.8165103
TJs O 0 0.0141931735
occurs O 0 7.590222e-05
heterogenously O 0 0.000254702
in O 0 5.8233865e-05
the O 0 9.224635e-05
liver O 0 0.6924288
lobule O 0 0.96498966
after O 0 7.1783965e-05
BDL O 0 0.9983992
and O 0 0.00011751724
suggests O 0 3.863236e-05
that O 0 8.624637e-05
BDL O 0 0.99886876
and O 0 0.00030783197
EE B-Chemical 0 0.86162734
treatments O 0 0.00016176314
produce O 0 6.423667e-05
different O 0 9.685525e-05
lobular O 0 0.26844034
distributions O 0 0.00015149298
of O 0 0.00036457824
increased O 0 0.0012125942
paracellular O 0 0.12975204
permeability O 0 0.7374728
. O 0 0.0023786533

Memory O 0 0.07341832
facilitation O 0 0.005034083
and O 0 0.0010581592
stimulation O 0 0.0005062893
of O 0 0.000614233
endogenous O 0 0.0006489442
nerve O 0 0.009264047
growth O 0 0.0033145861
factor O 0 0.0015225969
synthesis O 0 0.0021025934
by O 0 0.0004144429
the O 0 0.0008598513
acetylcholine B-Chemical 1 0.9999231
releaser O 0 0.9967709
PG B-Chemical 0 0.9994779
- I-Chemical 0 0.003610851
9 I-Chemical 0 0.0015473475
. O 0 0.0020401732

The O 0 0.001751285
effects O 0 0.0020258606
of O 0 0.0036424303
PG B-Chemical 0 0.99905115
- I-Chemical 0 0.0029984985
9 I-Chemical 0 0.00060200284
( O 0 0.00082992436
3alpha B-Chemical 0 0.4703953
- I-Chemical 0 0.0015215912
tropyl I-Chemical 0 0.1150103
2 I-Chemical 0 0.0002663466
- I-Chemical 0 0.0004388972
( I-Chemical 0 0.00032039688
p I-Chemical 0 0.00024173311
- I-Chemical 0 0.00051429076
bromophenyl I-Chemical 0 0.9548414
) I-Chemical 0 0.0017827497
propionate I-Chemical 0 0.9996878
) O 0 0.00053209614
, O 0 0.00017201267
the O 0 0.00026836793
acetylcholine B-Chemical 1 0.99994004
releaser O 0 0.7802187
, O 0 0.00012753607
on O 0 4.8605714e-05
memory O 0 0.0074552996
processes O 0 0.00019164389
and O 0 0.00015706634
nerve O 0 0.0034547215
growth O 0 0.002672785
factor O 0 0.0026907797
( O 0 0.0012730962
NGF O 1 0.99930704
) O 0 0.0012714976
synthesis O 0 0.0024495448
were O 0 0.00085297134
evaluated O 0 0.0011154828
. O 0 0.0019443766

In O 0 0.0019677577
the O 0 0.001517859
mouse O 0 0.0014645604
passive O 0 0.0012911636
- O 0 0.001235376
avoidance O 0 0.0012752247
test O 0 0.000962163
, O 0 0.0009672647
PG B-Chemical 0 0.99944025
- I-Chemical 0 0.0010453316
9 I-Chemical 0 0.00017812161
( O 0 0.0001908381
10 O 0 0.000110815236
- O 0 0.00017411828
30 O 0 8.026615e-05
mg O 0 0.0013966077
/ O 0 0.00046500622
kg O 0 0.00036391776
, O 0 0.00014735713
i O 0 0.0003129107
. O 0 8.6955995e-05
p O 0 0.000115269664
. O 0 6.0537626e-05
) O 0 0.00012557677
, O 0 7.290201e-05
administered O 0 6.80763e-05
20 O 0 5.1233164e-05
min O 0 5.0654668e-05
before O 0 2.0058964e-05
the O 0 3.9883307e-05
training O 0 4.6382836e-05
session O 0 6.5350934e-05
, O 0 0.000111244044
prevented O 0 0.0010253271
amnesia B-Disease 0 0.9996792
induced O 0 0.00024466493
by O 0 8.643236e-05
both O 0 5.423886e-05
the O 0 4.8932485e-05
non O 0 7.914453e-05
selective O 0 0.00042798702
antimuscarinic O 0 0.97912186
drug O 0 0.35912108
scopolamine B-Chemical 1 0.999998
and O 0 0.00023564306
the O 0 0.00017251102
M1 O 0 0.34448928
- O 0 0.00040434118
selective O 0 0.001588516
antagonist O 0 0.9644179
S B-Chemical 0 0.9781532
- I-Chemical 0 0.0010671654
( I-Chemical 0 0.0005128376
- I-Chemical 0 0.0007052365
) I-Chemical 0 0.00074966246
- I-Chemical 0 0.00136395
ET I-Chemical 0 0.50824547
- I-Chemical 0 0.002372376
126 I-Chemical 0 0.0045918757
. O 0 0.0022369877

In O 0 0.0016144811
the O 0 0.0010351755
same O 0 0.00050108094
experimental O 0 0.00079294475
conditions O 0 0.00087847875
, O 0 0.001375885
PG B-Chemical 0 0.99934095
- I-Chemical 0 0.0014342839
9 I-Chemical 0 0.00024724912
( O 0 0.00025501056
5 O 0 0.00011368314
- O 0 0.00018593513
20 O 0 8.558096e-05
microg O 0 0.00015551217
per O 0 4.673408e-05
mouse O 0 0.0001552218
, O 0 0.00013904442
i O 0 0.0003005834
. O 0 8.7056564e-05
c O 0 0.0008301332
. O 0 8.895886e-05
v O 0 0.00069006084
. O 0 8.685879e-05
) O 0 0.00016292118
was O 0 8.511664e-05
also O 0 5.9215487e-05
able O 0 5.499453e-05
to O 0 7.85695e-05
prevent O 0 0.00015798004
antimuscarine O 0 0.075238846
- O 0 0.0005730014
induced O 0 0.0005137939
amnesia B-Disease 0 0.99974865
, O 0 0.00028701138
demonstrating O 0 0.00012339657
a O 0 0.00017139298
central O 0 0.00018096235
localization O 0 0.00012674271
of O 0 0.00039611597
the O 0 0.00060824055
activity O 0 0.0012580042
. O 0 0.0020000737

At O 0 0.00083771715
the O 0 0.0010357931
highest O 0 0.0009047924
effective O 0 0.0007325156
doses O 0 0.011338786
, O 0 0.00210127
PG B-Chemical 0 0.9996848
- I-Chemical 0 0.0013768839
9 I-Chemical 0 0.00016622253
did O 0 0.00013005911
not O 0 7.7183046e-05
produce O 0 5.6404424e-05
any O 0 7.549783e-05
collateral O 0 0.0067280023
symptoms O 0 0.0025682524
as O 0 9.1415415e-05
revealed O 0 7.897467e-05
by O 0 8.266678e-05
the O 0 0.000105368665
Irwin O 0 0.007998241
test O 0 0.00019343547
, O 0 0.00010125095
and O 0 8.118434e-05
it O 0 7.3382995e-05
did O 0 6.729549e-05
not O 0 4.7268662e-05
modify O 0 4.9198243e-05
spontaneous O 0 0.00048308706
motility O 0 0.0029444739
and O 0 0.00010041884
inspection O 0 0.00017074884
activity O 0 0.00010958275
, O 0 0.00014099113
as O 0 0.00010804112
revealed O 0 0.00013880715
by O 0 0.00020164493
the O 0 0.0003358411
hole O 0 0.02155418
- O 0 0.0013488091
board O 0 0.0021193267
test O 0 0.0018526218
. O 0 0.002051823

PG B-Chemical 0 0.99757737
- I-Chemical 0 0.0065452154
9 I-Chemical 0 0.0012905593
was O 0 0.0007889185
also O 0 0.0003975866
able O 0 0.0002789906
to O 0 0.0002455415
increase O 0 0.00021836862
the O 0 0.0001708604
amount O 0 0.0001226368
of O 0 0.0004880776
NGF O 1 0.9993923
secreted O 0 0.00028590884
in O 0 0.000151199
vitro O 0 0.0002743419
by O 0 0.00023318431
astrocytes O 0 0.0051188893
in O 0 0.00020431513
a O 0 0.00042394717
dose O 0 0.0019119487
- O 0 0.00087846955
dependent O 0 0.00046549362
manner O 0 0.0014511357
. O 0 0.0020603687

The O 0 0.0019159958
maximal O 0 0.0026543417
NGF O 1 0.9956529
contents O 0 0.0043655415
obtained O 0 0.0010268316
by O 0 0.0013643501
PG B-Chemical 0 0.9991025
- I-Chemical 0 0.0012863243
9 I-Chemical 0 0.000254838
were O 0 0.00021482892
17 O 0 0.0002447447
. O 0 0.00012897662
6 O 0 0.00013453029
- O 0 0.00033757463
fold O 0 0.00036538756
of O 0 0.0004202311
the O 0 0.0005304866
control O 0 0.00089770963
value O 0 0.0019301872
. O 0 0.002567758

During O 0 0.0013274489
culture O 0 0.00220105
, O 0 0.0011999639
no O 0 0.00047768783
morphological O 0 0.0013288516
changes O 0 0.0005464863
were O 0 0.00031490508
found O 0 0.00020362956
at O 0 0.00016490748
effective O 0 0.00027381303
concentrations O 0 0.001265781
of O 0 0.0025682184
PG B-Chemical 0 0.9990964
- I-Chemical 0 0.0046925293
9 I-Chemical 0 0.0019442803
. O 0 0.0024682342

The O 0 0.0017138557
current O 0 0.0020196978
work O 0 0.0009895047
indicates O 0 0.0004283452
the O 0 0.0003399759
ability O 0 0.00040659384
of O 0 0.0012689438
PG B-Chemical 0 0.9996973
- I-Chemical 0 0.0010721561
9 I-Chemical 0 0.00013476613
to O 0 8.239888e-05
induce O 0 6.343944e-05
beneficial O 0 0.00013581212
effects O 0 0.000113300914
on O 0 7.24534e-05
cognitive O 0 0.03293131
processes O 0 0.0001953917
and O 0 0.00010092675
stimulate O 0 6.0726703e-05
activity O 0 0.00015569794
of O 0 0.00058958854
NGF O 1 0.99941826
synthesis O 0 0.015277275
in O 0 0.0010358327
astroglial O 0 0.7468416
cells O 0 0.0033003842
. O 0 0.0023197567

Therefore O 0 0.00285761
, O 0 0.0052811503
PG B-Chemical 0 0.9979773
- I-Chemical 0 0.002932144
9 I-Chemical 0 0.0005275755
could O 0 0.0002775852
represent O 0 0.00020361444
a O 0 0.00025522217
potential O 0 0.00020664677
useful O 0 0.00018857347
drug O 0 0.001647893
able O 0 0.000118350195
to O 0 0.00011808325
improve O 0 0.00010751141
the O 0 0.00015037743
function O 0 0.00023821282
of O 0 0.00045208802
impaired O 0 0.002770291
cognitive O 0 0.41802236
processes O 0 0.003115226
. O 0 0.002274627

Mechanisms O 0 0.011493988
of O 0 0.008433328
FK B-Chemical 1 0.99951184
506 I-Chemical 1 0.9972487
- O 0 0.007928034
induced O 0 0.005303248
hypertension B-Disease 2 0.9998055
in O 0 0.0023851057
the O 0 0.00234241
rat O 0 0.006541291
. O 0 0.0037305732

- O 0 0.018540533
Tacrolimus B-Chemical 1 0.9995347
( O 0 0.017973397
FK B-Chemical 1 0.9997106
506 I-Chemical 1 0.99710566
) O 0 0.003012137
is O 0 0.00090123975
a O 0 0.0009698799
powerful O 0 0.001368233
, O 0 0.0009950148
widely O 0 0.000861262
used O 0 0.0014293179
immunosuppressant O 0 0.9098161
. O 0 0.004498034

The O 0 0.0018885118
clinical O 0 0.0026454371
utility O 0 0.0012981954
of O 0 0.002767485
FK B-Chemical 1 0.9997085
506 I-Chemical 1 0.9919104
is O 0 0.0011245067
complicated O 0 0.0014468526
by O 0 0.00081645715
substantial O 0 0.0023932355
hypertension B-Disease 2 0.9999198
and O 0 0.0128042605
nephrotoxicity B-Disease 0 0.99997294
. O 0 0.006753313

To O 0 0.0017565832
clarify O 0 0.00093688327
the O 0 0.000848664
mechanisms O 0 0.000982665
of O 0 0.0021850087
FK B-Chemical 1 0.999907
506 I-Chemical 1 0.99913687
- O 0 0.0036076717
induced O 0 0.0018995326
hypertension B-Disease 2 0.99997497
, O 0 0.00035236686
we O 0 6.407479e-05
studied O 0 0.00011691945
the O 0 0.000102376755
chronic O 0 0.007996342
effects O 0 0.00020936741
of O 0 0.0007595483
FK B-Chemical 1 0.99996054
506 I-Chemical 1 0.96436775
on O 0 5.718328e-05
the O 0 7.656347e-05
synthesis O 0 0.0004526931
of O 0 0.0004060748
endothelin O 0 0.99979323
- O 0 0.00063081644
1 O 0 0.00010483168
( O 0 0.00021281914
ET O 0 0.49454582
- O 0 0.0002968954
1 O 0 8.7328604e-05
) O 0 0.0001231522
, O 0 7.210545e-05
the O 0 5.9003545e-05
expression O 0 8.525945e-05
of O 0 0.00010333312
mRNA O 0 0.00018444464
of O 0 0.00025328094
ET O 0 0.80981463
- O 0 0.00027499505
1 O 0 7.1547925e-05
and O 0 0.00013827886
endothelin O 0 0.9984964
- O 0 0.0006231676
converting O 0 0.010987035
enzyme O 0 0.038085125
- O 0 0.0003954821
1 O 0 0.00011091313
( O 0 0.00022759734
ECE O 0 0.36582598
- O 0 0.0003590024
1 O 0 0.000101690224
) O 0 0.00014125921
, O 0 9.514625e-05
the O 0 0.000119515804
endothelial O 0 0.5846405
nitric B-Chemical 0 0.999335
oxide I-Chemical 0 0.9900143
synthase O 0 0.5678898
( O 0 0.0003759611
eNOS O 0 0.064791515
) O 0 0.00017887219
activity O 0 7.877205e-05
, O 0 8.80725e-05
and O 0 6.72161e-05
the O 0 6.3220396e-05
expression O 0 9.117496e-05
of O 0 0.00010943248
mRNA O 0 0.00018965322
of O 0 0.00022893542
eNOS O 0 0.1800081
and O 0 0.00038273094
C O 0 0.983333
- O 0 0.00051433337
type O 0 0.000319189
natriuretic O 0 0.88139534
peptide O 0 0.0007774012
( O 0 0.00060789654
CNP O 0 0.38976067
) O 0 0.0006076759
in O 0 0.00037558516
rat O 0 0.0014477139
blood O 0 0.0078036264
vessels O 0 0.012168153
. O 0 0.0022835722

In O 0 0.0017763189
addition O 0 0.0009951305
, O 0 0.0010139975
the O 0 0.00048921176
effect O 0 0.00033639476
of O 0 0.0003474195
the O 0 0.00022554642
specific O 0 0.00022384388
endothelin O 0 0.9987986
type O 0 0.00053310895
A O 0 0.057029463
receptor O 0 0.06558512
antagonist O 0 0.97023153
FR B-Chemical 0 0.99434644
139317 I-Chemical 0 0.99997175
on O 0 0.00033603338
FK B-Chemical 1 0.99994564
506 I-Chemical 1 0.99617755
- O 0 0.0010354617
induced O 0 0.000900923
hypertension B-Disease 2 0.9999392
in O 0 0.0005719973
rats O 0 0.0009318535
was O 0 0.0008229064
studied O 0 0.0013918796
. O 0 0.0017773429

FK B-Chemical 1 0.9972791
506 I-Chemical 1 0.9847862
, O 0 0.016067361
5 O 0 0.009960765
mg O 0 0.06455181
. O 0 0.014983525

kg O 0 0.050520368
- O 0 0.034667134
1 O 0 0.024128187
. O 0 0.027164735

d O 0 0.0049674227
- O 0 0.0030418467
1 O 0 0.0007969069
given O 0 0.00036255846
for O 0 0.00029882984
4 O 0 0.00022471034
weeks O 0 0.00011160583
, O 0 0.00021825705
elevated O 0 0.00070150284
blood O 0 0.0016182762
pressure O 0 0.0014756407
from O 0 0.0001392404
102 O 0 0.00047188994
+ O 0 0.00033050354
/ O 0 0.00046451626
- O 0 0.00023290991
13 O 0 9.185389e-05
to O 0 7.446321e-05
152 O 0 0.00023835278
+ O 0 0.00025320076
/ O 0 0.00036564053
- O 0 0.00017826603
15 O 0 6.146727e-05
mm O 0 0.0002094928
Hg O 0 0.2455864
and O 0 9.573554e-05
increased O 0 0.0001264478
the O 0 8.564024e-05
synthesis O 0 0.0005008598
of O 0 0.00033234814
ET O 0 0.8958726
- O 0 0.0003039443
1 O 0 5.898543e-05
and O 0 5.3663156e-05
the O 0 5.541611e-05
levels O 0 8.02363e-05
of O 0 0.000242841
ET O 0 0.82500005
- O 0 0.00030636543
1 O 0 6.622464e-05
mRNA O 0 9.406854e-05
in O 0 5.745725e-05
the O 0 9.08373e-05
mesenteric O 0 0.011654696
artery O 0 0.013846493
( O 0 0.00022627552
240 O 0 0.00026559646
% O 0 0.00017648107
and O 0 0.00022784248
230 O 0 0.0012039565
% O 0 0.00048180122
, O 0 0.000744723
respectively O 0 0.0019490346
) O 0 0.002477556
. O 0 0.0023355247

Little O 0 0.014726572
change O 0 0.0021112012
was O 0 0.0012902442
observed O 0 0.00061813375
in O 0 0.00048028876
the O 0 0.00044212636
expression O 0 0.0005910726
of O 0 0.001002212
ECE O 0 0.77125394
- O 0 0.0013712876
1 O 0 0.0004534778
mRNA O 0 0.0008945755
and O 0 0.0011835109
CNP O 0 0.39300618
mRNA O 0 0.0047885226
. O 0 0.003159602

FK B-Chemical 1 0.99899405
506 I-Chemical 1 0.98962307
decreased O 0 0.008161959
eNOS O 0 0.13408342
activity O 0 0.00063861744
and O 0 0.00038841917
the O 0 0.00025406943
levels O 0 0.00024502256
of O 0 0.0004265918
eNOS O 0 0.07212184
mRNA O 0 0.00033767422
in O 0 0.000121246245
the O 0 0.00015350178
aorta O 0 0.0129055325
( O 0 0.00023527666
48 O 0 0.00011590763
% O 0 0.00016837782
and O 0 0.00020852547
55 O 0 0.00035398686
% O 0 0.00044803857
, O 0 0.00076434546
respectively O 0 0.0020366732
) O 0 0.0026274545
. O 0 0.0024677801

The O 0 0.0017011611
administration O 0 0.00344373
of O 0 0.0023464074
FR B-Chemical 0 0.97966456
139317 I-Chemical 0 0.99990976
( O 0 0.0013429845
10 O 0 0.00038722044
mg O 0 0.0054777833
. O 0 0.000205621
kg O 0 0.0006217829
- O 0 0.00036221935
1 O 0 0.00013138387
. O 0 9.330647e-05
d O 0 0.00019581449
- O 0 0.00029288488
1 O 0 0.00015121645
) O 0 0.0003224906
prevented O 0 0.0020532743
FK B-Chemical 1 0.99993443
506 I-Chemical 1 0.9981775
- O 0 0.0021493786
induced O 0 0.0019744656
hypertension B-Disease 2 0.999913
in O 0 0.0016161328
rats O 0 0.0029466932
. O 0 0.0019968953

These O 0 0.001996612
results O 0 0.0012603296
indicate O 0 0.0006509645
that O 0 0.0009396167
FK B-Chemical 1 0.9997639
506 I-Chemical 1 0.98716563
may O 0 0.00038034946
increase O 0 0.0002845147
blood O 0 0.0020811202
pressure O 0 0.0016442928
not O 0 0.00011602672
only O 0 0.00013602817
by O 0 0.0001382732
increasing O 0 0.00031130688
ET O 0 0.8844171
- O 0 0.00042871083
1 O 0 9.72533e-05
production O 0 0.00015724917
but O 0 0.0001344945
also O 0 0.00013172156
by O 0 0.00020575065
decreasing O 0 0.0006480758
NO B-Chemical 0 0.99441916
synthesis O 0 0.003243098
in O 0 0.00054206065
the O 0 0.00094956305
vasculature O 0 0.036366016
. O 0 0.0022833373

